Comparison O
with O
alkaline I-GENE
phosphatases I-GENE
and O
5 I-GENE
- I-GENE
nucleotidase I-GENE

Pharmacologic O
aspects O
of O
neonatal O
hyperbilirubinemia O
. O

When O
CSF O
[ O
HCO3 O
-] O
is O
shown O
as O
a O
function O
of O
CSF O
PCO2 O
the O
data O
of O
K O
- O
depleted O
rats O
are O
no O
longer O
displaced O
when O
compared O
to O
controls O
but O
still O
have O
a O
significantly O
greater O
slope O
( O
1 O
. O
21 O
+/- O
0 O
. O
23 O
vs O
. O

Flurazepam O
thus O
appears O
to O
be O
an O
effective O
hypnotic O
drug O
with O
the O
optimum O
dose O
for O
use O
in O
general O
practice O
being O
15 O
mg O
at O
night O
. O

Beta O
blocking O
agents O
. O

When O
extracorporeal O
CO2 O
removal O
approximated O
CO2 O
production O
( O
VCO2 O
), O
alveolar O
ventilation O
almost O
ceased O
. O

Intravenous O
administration O
( O
25 O
mg O
/ O
kg O
) O
of O
carbonic I-GENE
anhydrase I-GENE
inhibitors O
( O
acetazolamide O
, O
methazolamide O
, O
dichlorphenamide O
, O
sulthiame O
) O
induced O
an O
early O
important O
rise O
of O
cortical O
p O
O2 O
, O
which O
is O
not O
dependent O
on O
increase O
of O
p O
O2 O
and O
p O
CO2 O
and O
decrease O
of O
pH O
in O
arterial O
blood O
. O

Teratological O
study O
of O
etoperidone O
in O
the O
rat O
and O
rabbit O
. O

Colorectal O
polyps O
should O
be O
removed O
endoscopically O
whenever O
possible O
. O

The O
variable O
HMG I-GENE
dosage O
regimen O
was O
found O
to O
offer O
no O
advantages O
when O
compared O
with O
our O
standard O
daily O
dosage O
regimen O
. O

When O
the O
CO2 O
content O
reached O
9 O
Vol O
% O
the O
animals O
became O
apathic O
and O
lost O
body O
weight O
. O

Serum I-GENE
gamma I-GENE
glutamyltransferase I-GENE
in O
the O
diagnosis O
of O
liver O
disease O
in O
cattle O
. O

By O
contrast O
, O
secretory I-GENE
HI I-GENE
antibodies I-GENE
were O
not O
demonstrated O
at O
the O
onset O
of O
illness O
in O
any O
of O
the O
patients O
, O
but O
their O
formation O
started O
early O
and O
the O
antibodies O
reached O
maximal O
levels O
about O
10 O
days O
after O
onset O
of O
illness O
. O

With O
the O
exception O
of O
virus O
assay O
and O
quantitation O
, O
these O
methods O
are O
simple O
and O
inexpensive O
enough O
to O
be O
done O
in O
typical O
shellfish O
microbiology O
laboratories O
. O

Characteristics O
of O
lipase I-GENE
activity O
. O

Takayasu O
' O
s O
disease O
: O
association O
with O
HLA I-GENE
- I-GENE
B5 I-GENE
. O

SGPT I-GENE
, O
SGOT I-GENE
, O
and O
alkaline I-GENE
phosphatase I-GENE
concentrations O
were O
essentially O
normal O
in O
all O
subjects O
. O

Gamma I-GENE
glutamyl I-GENE
transpeptidase I-GENE
( O
GGTP I-GENE
) O
activity O
in O
the O
seminal O
fluid O

Patients O
with O
Parkinson O
' O
s O
disease O
showed O
a O
relatively O
high O
incidence O
to O
psychoses O
during O
drug O
treatment O
( O
51 O
. O
47 O
%). O

Selective O
stimulation O
of O
central O
alpha I-GENE
- I-GENE
autoreceptors I-GENE
following O
treatment O
with O
alpha O
- O
methyldopa O
and O
FLA O
136 O
. O

Anti O
- O
anxiety O
action O
of O
diazepam O
after O
intra O
- O
amygdaloid O
application O
in O
the O
rat O
. O

Abstracts O
. O

Removal O
of O
thick O
, O
permanently O
altered O
mucoas O
is O
recommended O
even O
in O
the O
absence O
of O
squamous O
epithelium O
. O

An O
IgG I-GENE
monoclonal O
gammopathy O
was O
present O
in O
the O
serum O
of O
4 O
patients O
and O
Bence O
- O
Joanes O
proteinuria O
was O
found O
in O
1 O
patient O
. O

Studies O
on O
immunoglobulin I-GENE
E I-GENE
: O
the O
impact O
of O
a O
sojourn O
with O
Professor O
Dan O
H O
. O

Peroxydase I-GENE
reaction O
stains O
were O
negative O
, O
chloroacetate I-GENE
esterase I-GENE
were O
strongly O
positive O
. O

Ten O
out O
- O
patients O
with O
pustulosis O
palmaris O
et O
plantaris O
were O
examined O
with O
direct O
immunofluorescence O
( O
IF O
) O
technique O
for O
deposition O
of O
fibrinogen I-GENE
, O
fibrin I-GENE
or O
its O
degradation O
products O
( O
FR I-GENE
- I-GENE
antigen I-GENE
) O
in O
affected O
and O
unaffected O
skin O
, O
together O
with O
heparin O
- O
precipitable O
fraction O
( O
HPF O
), O
cryoglobulin I-GENE
and O
total O
plasma O
fibrinogen I-GENE
in O
the O
blood O
. O

Of O
600 O
mediastinoscopies O
carried O
out O
from O
1966 O
to O
1973 O
, O
479 O
were O
performed O
to O
assess O
the O
operability O
of O
a O
pulmonary O
carcinoma O
. O

A O
mixture O
of O
human I-GENE
albumin I-GENE
5 O
% O
and O
hydroxy O
- O
ethyl O
- O
starch O
was O
used O
as O
a O
solution O
for O
dilution O
. O

In O
the O
matched O
control O
group O
the O
acquisition O
- O
rate O
of O
both O
symptomatic O
and O
asymptomatic O
0acteriuria O
was O
over O
12 O
%, O
a O
figure O
similar O
to O
the O
percentage O
of O
women O
present O
in O
the O
practice O
population O
during O
one O
year O
with O
transient O
, O
symptomatic O
, O
and O
persistent O
A O
. O
B O
. O

Late O
complications O
of O
catheterisation O
for O
intravenous O
nutrition O
. O

Prenatal O
diagnosis O
of O
galactosaemia O
. O

Sings O
which O
are O
indicative O
of O
metaplastic O
erythropoiesis O
are O
absent O
. O

False O
positive O
amniotic I-GENE
fluid I-GENE
alpha I-GENE
fetoprotein I-GENE
levels O
resulting O
from O
contamination O
with O
fetal O
blood O
: O
results O
of O
an O
experiment O
. O

Serum O
- O
ferritin I-GENE
in O
diagnosis O
of O
haemochromatosis O
. O

In O
2 O
subjects O
the O
phytomitogen O
reactivity O
of O
the O
lymphocytes O
was O
improved O
after O
treatment O
. O

Patients O
at O
risk O
of O
hypothyroidism O
. O

Albumin I-GENE
and O
cyclic O
AMP O
levels O
in O
peritoneal O
fluids O
in O
the O
child O

Preface O
. O

Thirty O
- O
five O
strains O
of O
Legionnaires O
' O
disease O
bacteria O
were O
shown O
to O
belong O
in O
four O
distinct O
serologic O
groups O
on O
the O
basis O
of O
findings O
obtained O
with O
direct O
fluorescent O
antibody O
testing O
. O

On O
the O
other O
hand O
factor I-GENE
IX I-GENE
activity O
is O
decreased O
in O
coumarin O
treatment O
with O
factor I-GENE
IX I-GENE
antigen O
remaining O
normal O
. O

The O
concentration O
of O
alpha I-GENE
2 I-GENE
- I-GENE
macroglobulin I-GENE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
plasminogen I-GENE
, O
C3 I-GENE
- I-GENE
complement I-GENE
, O
fibrinogen I-GENE
degradation I-GENE
products I-GENE
( O
FDP I-GENE
) O
and O
fibrinolytic O
activity O
, O
were O
studied O
in O
the O
aqueous O
humour O
and O
serum O
from O
nine O
patients O
with O
Fuchs O
' O
endothelial O
dystrophy O
, O
17 O
patients O
with O
uncomplicated O
senile O
cataract O
and O
in O
the O
secondary O
aqueous O
from O
six O
cataract O
patients O
. O

Only O
17 O
% O
of O
all O
patients O
admitted O
it O
at O
all O
times O
. O

Prazosin O
alone O
was O
effective O
in O
volume O
responsive O
patients O
at O
a O
dose O
of O
5 O
+/- O
1 O
. O
0 O
mg O
daily O
. O

T4 O
and O
FT4I O
followed O
parallel O
courses O
in O
both O
groups O
; O
during O
the O
first O
45 O
days O
, O
however O
, O
the O
values O
were O
significantly O
lower O
in O
premature O
infants O
under O
34 O
weeks O
' O
EGA O
than O
in O
term O
infants O
( O
P O
less O
than O
0 O
. O
001 O
). O

A O
three O
- O
phased O
analysis O
of O
treatment O
plans O
for O
45 O
patients O
was O
undertaken O
. O

Aspirin O
intolerance O
: O
unaltered O
susceptibility O
of O
platelet I-GENE
cyclo I-GENE
- I-GENE
oxygenase I-GENE
to O
inhibition O
by O
aspirin O
in O
vitro O
. O

These O
results O
indicate O
that O
cynomolgus O
monkeys O
are O
either O
less O
sensitive O
or O
respond O
differently O
than O
rhesus O
monkeys O
to O
some O
of O
the O
pharmacological O
effects O
of O
norcocaine O
. O

59 O
cases O
of O
surgically O
resectable O
cancers O
( O
T1 O
, O
T2 O
, O
T3 O
, O
N0 O
, O
N1 O
) O
had O
a O
minimum O
followup O
of O
two O
years O
( O
average O
4 O
years O
+/- O
3 O
months O
). O

The O
effect O
of O
CBZ O
and O
DPH O
can O
be O
explained O
by O
interference O
with O
thyroid O
hormone O
binding O
to O
TBG I-GENE
combined O
with O
enzyme O
- O
induced O
increased O
metabolic O
clearance O
rate O
of O
thyroid O
hormones O
without O
homeostatic O
maintenance O
of O
premedication O
levels O
of O
FT4 O
and O
FT3 O
. O

The O
present O
research O
evaluated O
the O
possibility O
that O
polyethylene O
glycol O
400 O
( O
PEG O
400 O
) O
might O
be O
efficacious O
, O
toxic O
, O
or O
both O
. O

According O
to O
their O
functional O
properties O
the O
latter O
neurons O
were O
subdivided O
into O
: O
( O
a O
) O
neurons O
responding O
to O
stimuli O
near O
the O
eyes O
; O
( O
b O
) O
neurons O
triggered O
by O
complex O
visual O
stimuli O
; O
( O
c O
) O
neurons O
inhibited O
by O
visual O
stimuli O
. O

Pentobarbital O
( O
1 O
, O
3 O
, O
10 O
, O
and O
17 O
. O
5 O
mg O
/ O
kg O
) O
was O
also O
tested O
in O
combination O
with O
rate O
- O
decreasing O
doses O
of O
normeperidine O
( O
17 O
. O
5 O
mg O
/ O
kg O
), O
anileridine O
( O
10 O
mg O
/ O
kg O
), O
alphaprodine O
( O
10 O
mg O
/ O
kg O
), O
and O
fentanyl O
( O
0 O
. O
3 O
mg O
/ O
kg O
). O

Pb O
foil O
( O
0 O
. O
55 O
gcm O
- O
2 O
) O
provided O
the O
best O
overall O
improvement O
. O

An O
anatomical O
and O
histochemical O
study O
has O
been O
undertaken O
and O
as O
a O
result O
emphasis O
is O
given O
to O
recent O
hypotheses O
that O
suggest O
there O
are O
similarities O
with O
Type O
IV O
glycogen O
storage O
disease O
( O
Andersen O
' O
s O
disease O
) O
which O
, O
although O
clinically O
distinct O
, O
has O
the O
same O
enzyme O
defect O
. O

All O
groups O
were O
tested O
in O
a O
Hebb O
- O
Williams O
maze O
at O
100 O
approximately O
10 O
days O
of O
age O
. O

Erythromycin O
and O
clindamycin O
resistance O
in O
Corynebacterium O
diphtheriae O
from O
skin O
lesions O
. O

Imposed O
angular O
displacements O
of O
monkey O
' O
s O
wrist O
produce O
three O
major O
peaks O
of O
activity O
( O
terms O
M1 O
, O
M2 O
, O
and O
M3 O
peaks O
) O
in O
the O
averaged O
gross O
EMG O
activity O
ot O
the O
stretched O
muscles O
. O

Hemolytic O
disease O
of O
African O
newborn O
. O

In O
this O
animal O
, O
infected O
with O
what O
was O
judged O
previously O
to O
be O
the O
less O
virulent O
of O
the O
two O
T O
. O
cruzi O
stocks O
used O
(' O
strain O
7 O
'), O
there O
was O
severe O
myocarditis O
, O
with O
myofibre O
degeneration O
, O
and O
lesions O
of O
the O
oesophagus O
. O

The O
majority O
of O
MRF O
units O
were O
behaviorally O
incongruent O
; O
in O
the O
most O
frequently O
observed O
case O
, O
their O
activity O
failed O
to O
change O
reliably O
when O
behavior O
habituated O
. O

Variability O
within O
Down O
' O
s O
syndrome O
( O
trisomy O
- O
21 O
): O
empirically O
observed O
sex O
differences O
in O
IQs O
. O

VII O
. O

Several O
demographic O
indices O
of O
isolated O
populations O
in O
Uzbekistan O

2 O
.-- O
concepts O
of O
higher O
nervous O
function O
in O
the O
USSR O
. O

The O
maintenance O
of O
increased O
myocardial O
capillary O
density O
required O
a O
similar O
amount O
of O
exercise O
, O
and O
at O
least O
1 O
h O
of O
exercise O
once O
a O
week O
was O
necessary O
to O
maintain O
the O
enlargement O
of O
ECA O
. O
20 O

These O
observations O
have O
led O
us O
to O
conclude O
that O
an O
elevated O
VIII O
- O
ratio O
is O
a O
very O
sensitive O
indicator O
of O
intravascular O
coagulation O
. O

Eight O
hours O
after O
the O
administration O
of O
colchicine O
, O
the O
serum I-GENE
ceruloplasmin I-GENE
level O
began O
to O
rise O
again O
in O
female O
rats O
, O
but O
not O
in O
male O
rats O
. O

Radioimmunoassays O
of O
pregnenolone O
, O
progesterone O
, O
dehydroepiandrosterone O
( O
DHA O
) O
16 O
alpha O
- O
hydroxy O
- O
DHA O
, O
estriol O
, O
and O
cortisol O
were O
performed O
on O
a O
total O
of O
0 O
; O
1 O
ml O
; O
of O
fetal O
plasma O
, O
collected O
during O
the O
course O
of O
normal O
vaginal O
delivery O
. O

In O
only O
two O
patients O
were O
we O
able O
to O
demonstrate O
changes O
suggestive O
of O
pulmonary O
metastases O
any O
earlier O
with O
a O
99mTc O
- O
EHDP O
scan O
than O
with O
chest O
radiographs O
and O
one O
of O
these O
resolved O
spontaneously O
. O

The O
majority O
of O
tumors O
occurred O
in O
the O
nasal O
cavities O
, O
although O
significant O
incidences O
were O
also O
found O
in O
the O
larynx O
, O
trachea O
and O
stem O
bronchi O
. O

Prediction O
of O
the O
times O
of O
sandfly O
development O

Native O
human I-GENE
fibrinogen I-GENE
was O
brought O
to O
coagulation O
by O
adding O
thrombin I-GENE
. O

No O
post O
- O
operative O
haemorrhages O
from O
the O
prostheses O
were O
observed O
. O

The O
Southern O
technique O
allowed O
a O
further O
localization O
of O
the O
region O
of O
most O
extensive O
transcription O
to O
a O
1 O
. O
8 O
kb O
HindIII I-GENE
- O
EcoRI I-GENE
fragment O
. O

Accepting O
arbitrarily O
chosen O
limits O
of O
maximized O
errors O
of O
+/- O
10 O
%, O
it O
could O
be O
shown O
that O
the O
system O
did O
not O
work O
acceptably O
when O
the O
mean O
carbon O
dioxide O
concentration O
was O
below O
1 O
. O
5 O
vol O
.% O
within O
the O
fresh O
gas O
flow O
rates O
( O
2 O
. O
2 O
-- O
7 O
. O
7 O
1 O
min O
- O
1 O
) O
and O
the O
range O
of O
minute O
ventilation O
( O
4 O
-- O
10 O
1 O
min O
- O
1 O
) O
employed O
. O

SV O
increased O
less O
in O
SHR O
, O
mainly O
reflecting O
the O
reduced O
diastolic O
compliance O
of O
the O
hypertrophied O
SHR O
left O
ventricle O
and O
the O
consequent O
rightward O
shift O
of O
its O
Frank O
- O
Starling O
curve O
. O

The O
carcass O
of O
a O
great O
horned O
owl O
( O
Bubo O
virginianus O
), O
which O
had O
been O
found O
moribund O
in O
southern O
Ontario O
, O
was O
presented O
for O
necropsy O
. O

The O
inner O
ears O
were O
exposed O
by O
microdissection O
, O
and O
the O
vestibular O
sensory O
regions O
were O
either O
sectioned O
and O
studied O
with O
light O
or O
electron O
microscopy O
, O
or O
prepared O
and O
studied O
with O
the O
surface O
specimen O
technique O
. O

Patulin O
is O
extracted O
from O
apple O
butter O
samples O
with O
ethyl O
acetate O
and O
the O
extract O
is O
cleaned O
up O
on O
a O
silica O
gel O
column O
, O
using O
benzene O
- O
ethyl O
acetate O
( O
75 O
+ O
25 O
) O
as O
the O
eluant O
. O

Steroid O
glucuronides O
in O
amniotic O
fluid O
at O
term O
. O

The O
matrix O
surrounding O
the O
clusters O
either O
showed O
a O
normal O
morphology O
or O
a O
homogeneous O
appearance O
, O
within O
which O
faint O
cross O
striations O
but O
no O
distinctly O
fibrillar O
outlines O
could O
be O
identified O
. O

Riboflavin O
did O
not O
affect O
the O
percentage O
of O
aflatoxin O
- O
treated O
animals O
with O
abnormal O
urinary O
excretion O
patterns O
, O
but O
did O
increase O
the O
magnitude O
of O
the O
disturbances O
in O
elimination O
of O
kynurenic O
and O
xanthurenic O
acids O
. O

Polyglactin O
910 O
suture O
absorption O
and O
the O
role O
of O
cellular O
enzymes O
. O

The O
incidence O
of O
DNCB O
reactions O
was O
78 O
per O
cent O
for O
Stage O
I O
and O
II O
cancers O
( O
37 O
patinets O
), O
73 O
per O
cent O
for O
resectable O
Stage O
III O
cancer O
( O
22 O
patients O
), O
and O
66 O
per O
cent O
in O
patients O
with O
unresectable O
or O
inoperable O
Stage O
III O
cancer O
. O

Studies O
of O
lipoproteins O
should O
, O
however O
, O
be O
made O
in O
children O
from O
families O
known O
to O
have O
FH O
or O
early O
coronary O
heart O
disease O
. O

Sixteen O
other O
normal O
subjects O
with O
2 O
g O
of O
Metyrapone O
are O
best O
responses O
. O

EEG O
theta O
waves O
and O
psychological O
phenomena O
: O
a O
review O
and O
analysis O
. O

REM O
dream O
content O
was O
scored O
for O
categories O
suggesting O
the O
predominant O
influence O
of O
the O
left O
hemisphere O
, O
e O
. O
g O
., O
good O
ego O
functioning O
, O
verbalization O
, O
or O
the O
right O
hemisphere O
, O
e O
. O
g O
., O
music O
, O
spatial O
salience O
, O
bizarreness O
. O

Innervation O
of O
the O
ventral O
diaphragm O
of O
the O
locust O
( O
Locusta O
migratoria O
). O

Ectopic O
ACTH I-GENE
syndrome O
and O
medullary O
thyroid O
carcinoma O
. O

A O
striking O
finding O
in O
all O
of O
the O
studies O
was O
a O
positive O
correlation O
between O
PI O
ACTH I-GENE
and O
MSH I-GENE
contents O
. O

Chronic O
hypophosphatemia O
is O
the O
most O
common O
type O
of O
" O
resistant O
" O
rickets O
. O

There O
was O
no O
correlation O
between O
serum I-GENE
LH I-GENE
and O
chronological O
or O
bone O
age O
in O
this O
age O
group O
, O
which O
suggests O
that O
the O
correlation O
found O
is O
not O
due O
to O
age O
- O
related O
parallel O
phenomena O
. O

Molecular O
neurochemistry O
of O
addictive O
drugs O
. O

Efforts O
were O
made O
to O
determine O
the O
amount O
of O
time O
required O
for O
kidney O
lesions O
to O
develop O
and O
, O
if O
possible O
, O
to O
delineate O
the O
potential O
site O
of O
action O
of O
PBB O
. O

Effect O
of O
succimer O
on O
the O
intensity O
of O
tricarboxylic I-GENE
acid I-GENE
dehydrogenase I-GENE
reactions O
in O
the O
brain O
of O
rats O
poisoned O
with O
mercuric O
chloride O

Distribution O
and O
correlations O
of O
serum O
uric O
- O
acid O
in O
two O
French O
adult O
populations O
: O
13 O
, O
885 O
men O
and O
6 O
, O
861 O
women O

The O
incidence O
of O
hepatitis I-GENE
B I-GENE
antigen I-GENE
following O
transfusion O
was O
about O
2 O
. O
8 O
per O
cent O
. O

Technetium O
- O
99m O
stannous O
pyrophosphate O
myocardial O
scintigrams O
were O
obtained O
in O
138 O
clinically O
stable O
patients O
32 O
. O
7 O
+/- O
47 O
. O
3 O
weeks O
( O
range O
6 O
to O
260 O
) O
after O
acute O
myocardial O
infarction O
. O

A O
similar O
phenomenon O
has O
been O
reported O
in O
a O
few O
humans O
. O

The O
decline O
in O
the O
activity O
of O
cytochrome I-GENE
oxidase I-GENE
, O
peroxidase I-GENE
and O
in O
the O
lipid O
content O
of O
peripheral O
neutrophils O
was O
followed O
by O
a O
decrease O
in O
the O
phagocytic O
activity O
. O

Treatment O
of O
2 O
patients O
with O
pseudohypoparathyroidism O
type O
I O
with O
vitamin O
- O
D O
- O
3 O
and O
1 O
alpha O
- O
Hydroxycholecalciferol O
consecutively O
resulted O
in O
a O
nonuniform O
response O
with O
regard O
to O
the O
normalisation O
of O
serum O
- O
calcium O
. O

Workers O
with O
" O
sensitivity O
" O
to O
toluene O
diisocyanate O
( O
TDI O
) O
studied O
in O
depth O
in O
an O
attempt O
to O
determine O
mechanisms O
of O
bronchial O
hyperreactivity O
. O

Total O
VO2 O
was O
decreased O
in O
both O
groups O
during O
severe O
hypoxia O
but O
limb O
VO2 O
was O
maintained O
in O
the O
beta O
- O
block O
group O
. O
beta O
- O
Block O
prevented O
the O
fall O
in O
total O
and O
limb O
peripheral O
resistance O
seen O
in O
severe O
hypoxia O
but O
did O
not O
alter O
the O
consistently O
more O
efficient O
utilization O
of O
total O
O2 O
delivery O
shown O
by O
the O
limb O
in O
comparison O
to O
the O
whole O
body O
by O
higher O
O2 O
extraction O
ratios O
and O
lower O
venous O
O2 O
pressure O
. O
beta I-GENE
- I-GENE
Vasodilator I-GENE
receptors I-GENE
evidently O
played O
an O
active O
part O
in O
the O
vasodilatation O
seen O
during O
severe O
hypoxia O
. O

Phenobarbital O
- O
induced O
alterations O
in O
the O
metabolism O
of O
[ O
3H O
] O
vitamin O
D3 O
by O
the O
perfused O
rachitic O
rat O
liver O
in O
vitro O
. O

Modulation O
of O
25 I-GENE
- I-GENE
hydroxyvitamin I-GENE
D3 I-GENE
- I-GENE
24 I-GENE
- I-GENE
hydroxylase I-GENE
by O
aminophylline O
: O
a O
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
monooxygenase I-GENE
system O
. O

In O
both O
these O
respects O
, O
however O
, O
the O
DBP I-GENE
mRNA I-GENE
resembles O
the O
late O
messengers O
of O
SV40 O
and O
polyoma O
viruses O
. O

Effect O
of O
corticosteroid O
- O
containing O
antirheumatic O
combination O
drugs O
on O
endogenous O
ACTH I-GENE
and O
cortisol O
production O
. O

Serum I-GENE
ACTH I-GENE
did O
not O
respond O
to O
insulin I-GENE
and O
metyrapone O
. O

Anatomy O
of O
the O
RNA O
and O
gene O
products O
of O
MC29 O
and O
MH2 O
, O
two O
defective O
avian O
tumor O
viruses O
causing O
acute O
leukemia O
and O
carcinoma O
: O
evidence O
for O
a O
new O
class O
of O
transforming O
genes O
. O

Bertioga O
( O
Guama O
group O
) O
and O
Anhembi O
( O
Bunyamwera O
group O
), O
two O
new O
arboviruses O
isolated O
in O
Sao O
Paulo O
, O
Brazil O
. O

Gamma I-GENE
glutamyl I-GENE
transpeptidase I-GENE
activity O
was O
increased O
up O
to O
15 O
times O
above O
the O
upper O
normal O
limit O
in O
children O
, O
who O
received O
aminopyrine O
for O
two O
weeks O
or O
longer O
. O

XXI O
. O

A O
gas O
- O
liquid O
chromatographic O
method O
for O
the O
determination O
of O
p O
- O
chlorophenoxyisobutyric O
( O
CPIB O
) O
acid O
in O
blood O
plasma O
is O
described O
. O

Dopamine I-GENE
receptor I-GENE
blockade O
and O
the O
neuroleptics O
, O
a O
crystallographic O
study O
. O

V O
. O

A O
rapid O
fluorimetric O
procedure O
for O
the O
determination O
of O
the O
fungicide O
5 O
- O
fluorocytosine O
in O
serum O
is O
described O
. O

The O
' O
field O
of O
stress O
' O
of O
the O
supervisory O
nurse O

How O
do O
graduates O
of O
different O
types O
of O
programs O
perform O
on O
state O
boards O
? O

Similarly O
, O
maternal I-GENE
serum I-GENE
somatomedin I-GENE
A I-GENE
was O
significantly O
reduced O
in O
rats O
nursing O
large O
litters O
. O

The O
sequences O
following O
the O
X O
. O
borealis O
oocyte O
and O
somatic O
5S I-GENE
genes I-GENE
are O
identical O
in O
12 O
of O
the O
first O
14 O
residues O
and O
contain O
two O
or O
more O
T O
clusters O
, O
as O
does O
the O
corresponding O
region O
of O
X I-GENE
. I-GENE
laevis I-GENE
oocyte I-GENE
5S I-GENE
DNA I-GENE
. O

This O
mechanism O
is O
not O
due O
to O
the O
observed O
grain O
boundary O
precipitates O
. O

This O
report O
has O
reviewed O
some O
of O
the O
reasons O
for O
treatment O
failures O
and O
has O
presented O
a O
philosophy O
for O
their O
management O
. O

Diagnosis O
and O
treatment O
planning O
in O
Class O
II O
, O
division O
2 O

Because O
of O
serious O
infections O
( O
fever O
larger O
than O
or O
equal O
to O
101 O
degrees O
F O
. O
granulocytes O
less O
than O
1 O
, O
000 O
/ O
mm O
, O
3 O
and O
hospitalization O
) O
and O
1 O
drug O
death O
in O
the O
first O
4 O
patients O
, O
oral O
calcium O
leucovorin O
, O
20 O
to O
30 O
mg O
/ O
m2 O
orally O
, O
was O
given O
2 O
days O
after O
methotrexate O
in O
subsequent O
treatment O
cycles O
. O

It O
seems O
that O
the O
way O
in O
which O
drugs O
modify O
a O
patient O
' O
s O
serum O
chemistry O
may O
be O
used O
to O
assess O
the O
efficacy O
with O
which O
they O
control O
the O
inflammatory O
process O
. O

Here O
the O
conventional O
tests O
clearly O
pointed O
to O
the O
presence O
of O
retrocochlear O
disease O
. O

The O
end O
- O
stage O
or O
involutional O
phase O
of O
proliferative O
diabetic O
retinopathy O
may O
result O
in O
stabilization O
of O
vision O
for O
long O
periods O
of O
time O
. O

On O
the O
basis O
of O
serum I-GENE
alpha1AT I-GENE
quantitation O
, O
newborn O
infants O
may O
be O
separated O
into O
two O
groups O
, O
characterized O
respectively O
by O
concentrations O
above O
or O
below O
150 O
mg O
%. O

In O
patients O
who O
were O
not O
vented O
, O
there O
was O
overall O
significant O
depression O
of O
function O
( O
67 O
+/- O
5 O
% O
of O
control O
; O
range O
, O
91 O
-- O
45 O
%, O
p O
less O
than O
0 O
. O
01 O
). O

Changes O
in O
body O
weight O
and O
agonistic O
behavior O
were O
also O
recorded O
. O

The O
uterine O
response O
to O
prostaglandin O
E2 O
( O
PGE2 O
) O
and O
prostaglandin O
F2alpha O
( O
administered O
by O
intravenous O
and O
intrauterine O
routes O
) O
was O
evaluated O
during O
different O
phases O
of O
the O
menstrual O
cycle O
in O
five O
functionally O
infertile O
women O
. O

A O
total O
of O
26 O
BCG O
strains O
, O
out O
of O
them O
10 O
Czechoslovak O
strains O
( O
2 O
lyophilized O
cultures O
of O
BCG O
of O
different O
batch O
, O
6 O
strains O
isolated O
from O
abscesses O
of O
children O
after O
BCG O
- O
vaccination O
and O
2 O
strains O
from O
fatal O
cases O
after O
BCG O
- O
vaccination O
) O
and O
16 O
strains O
obtained O
from O
foreign O
laboratories O
, O
were O
used O
. O

High O
levels O
of O
serum O
calcitonin I-GENE
were O
found O
in O
patients O
with O
chronic O
renal O
failure O
. O

Detection O
of O
anti O
- O
lymphocyte O
antibodies O
using O
the O
immunoperoxidase I-GENE
antiglobulin I-GENE
technic O
. O

The O
response O
of O
serum I-GENE
GH I-GENE
to O
arginine O
infusion O
was O
normal O
, O
while O
that O
to O
insulin I-GENE
- O
induced O
hypoglycemia O
was O
poor O
. O

The O
mortality O
rate O
and O
histopathological O
features O
of O
Nocardia O
asteroides O
and O
Nocardia O
brasiliensis O
infections O
in O
congenitally O
athymic O
( O
nude O
) O
mice O
of O
ICR O
and O
C3H O
/ O
eB O
origins O
were O
quite O
different O
from O
what O
we O
found O
for O
Swiss O
white O
mice O
and O
other O
inbred O
mouse O
strains O
( O
namely O
, O
C57 O
/ O
BL O
/ O
6J O
, O
New O
Zealand O
Black O
, O
BALB O
/ O
c O
, O
CBA O
/ O
LAC O
, O
and O
C3H O
/ O
eB O
). O

Williams O
, O
2 O
August O
1977 O
. O

Use O
of O
radioactive O
isotopes O
in O
the O
chemistry O
of O
proteins O

( O
Emeritus O
) O
John O
Henri O
Roosegaarde O
Bisschop O

Disrupted O
vaccines O
and O
whole O
- O
virus O
vaccines O
containing O
type I-GENE
B I-GENE
antigen I-GENE
only O
did O
not O
cause O
significant O
reactivity O
. O

255 O
- O
61 O
. O

Antenatal O
diagnosis O
of O
haematological O
disorders O
--' O
1978 O
'. O

Hepatic O
oxygen O
supply O
and O
selected O
blood O
parameters O
were O
recorded O
in O
fasted O
male O
rates O
given O
20 O
-- O
30 O
mg O
/ O
kg O
Escherichia I-GENE
coli I-GENE
endotoxin I-GENE
intraperitoneally O
. O

Gonadal O
dysfunction O
in O
patients O
with O
ataxia O
telangiectasia O
. O

The O
maximum O
period O
of O
treatment O
was O
73 O
( O
oral O
), O
73 O
( O
intraperitoneal O
) O
or O
75 O
( O
dermal O
) O
weeks O
. O

A O
study O
of O
the O
comparative O
efficacy O
of O
diflucortolone O
valerate O
0 O
. O
3 O
% O
ointment O
and O
clobetasol O
propionate O
0 O
. O
05 O
% O
ointment O
. O

Most O
of O
the O
phenomena O
of O
azotaemic O
osteodystrophy O
are O
encountered O
in O
simple O
vitamin O
D O
deficiency O
; O
as O
in O
that O
condition O
, O
deficiency O
of O
1 O
, O
25 O
- O
dihydroxycholecalciferol O
may O
be O
of O
primary O
significance O
in O
causing O
secondary O
hyperparathyroidism O
in O
renal O
failure O
. O

Basal O
FSH I-GENE
and O
LH I-GENE
levels O
were O
significantly O
lower O
in O
addicts O
; O
after O
GnRH I-GENE
stimulation O
the O
addicts O
' O
FSH I-GENE
and O
LH I-GENE
values O
increased O
but O
not O
significantly O
compared O
to O
controls O
. O

Adriamycin O
: O
comparison O
of O
a O
5 O
- O
week O
schedule O
with O
a O
3 O
- O
week O
schedule O
in O
the O
treatment O
of O
breast O
cancer O
. O

Follow O
- O
up O
controls O
of O
luteinizing I-GENE
hormone I-GENE
( O
LH I-GENE
), O
follicle I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
), O
prolactin I-GENE
( O
HPRL I-GENE
), O
oestradiol O
( O
E2 O
), O
progesterone O
( O
P O
) O
and O
testosterone O
( O
T O
) O
in O
the O
catabolic O
and O
healing O
phase O
of O
burn O
disease O
. O

Renin I-GENE
studies O
performed O
in O
34 O
hypertensive O
patients O
and O
in O
a O
control O
group O
of O
11 O
recipients O
showed O
that O
elevation O
of O
plasma I-GENE
renin I-GENE
activity O
and O
of O
plasma O
aldosterone O
level O
is O
frequent O
but O
difficult O
to O
interpret O
, O
particularly O
when O
a O
renal O
artery O
stenosis O
is O
observed O
. O

A O
randomized O
clinical O
trial O
in O
sixty O
- O
two O
adult O
patients O
suffering O
from O
typhoid O
fever O
, O
proved O
by O
blood O
and O
marrow O
culture O
, O
showed O
that O
amoxycillin O
in O
a O
dosage O
schedule O
of O
1 O
g O
8 O
- O
hourly O
orally O
for O
fourteen O
days O
was O
better O
than O
chloramphenicol O
with O
regard O
to O
clinical O
and O
temperature O
response O
and O
in O
respect O
of O
carriers O
and O
relapse O
rates O
. O

202 O
- O
8 O
. O

Bone O
marrow O
transplantation O
- O
1979 O
. O

In O
this O
article O
, O
the O
clinical O
actions O
of O
the O
principal O
dopamine I-GENE
receptor I-GENE
stimulating O
agents O
( O
apomorphine O
and O
its O
derivatives O
; O
piribedil O
, O
rye O
- O
ergot O
derivatives O
) O
are O
discussed O
on O
the O
basis O
of O
their O
biochemical O
and O
pharmacological O
properties O
. O

The O
unilateral O
vestibular O
hypofunction O
. O

Thus O
, O
the O
inhibition O
of O
pepsin I-GENE
in O
human O
gastric O
juice O
does O
not O
appear O
to O
have O
a O
major O
influence O
on O
the O
healing O
of O
duodenal O
ulcer O
. O

The O
IDF O
standard O
method O
for O
the O
detection O
of O
penicillin O
in O
milk O
is O
not O
suitable O
for O
the O
detection O
of O
sulphonamide O
residues O
in O
milk O
. O

Capsular O
antigens O
of O
Staphylococcus O
aureus O

The O
course O
of O
endotoxin O
fever O
remained O
uninfluenced O
by O
ALS O
. O

2 O
new O
Algerian O
cases O

Seventy O
- O
one O
percent O
of O
patients O
treated O
with O
ticarcillin O
alone O
responded O
favorably O
. O

Accurate O
pathologic O
staging O
identifies O
patients O
who O
are O
potentially O
curable O
with O
radiotherapy O
. O

Inherent O
hematology O
of O
old O
age O

Neomycin O
is O
fairly O
effective O
against O
staphylococci O
, O
less O
effective O
against O
streptococci O
, O
and O
fairly O
effective O
against O
gram O
- O
negative O
intestinal O
organisms O
. O

It O
was O
concluded O
, O
that O
on O
a O
given O
section O
, O
75 O
, O
7 O
per O
cent O
of O
the O
trabeculae O
were O
in O
contact O
with O
vascular O
cavities O
. O

2 O
. O

Changes O
in O
tissue O
PCO2 O
were O
less O
dramatic O
and O
did O
not O
vary O
significantly O
from O
those O
recorded O
in O
venous O
blood O
. O

Ultrasonic O
evaluation O
of O
renal O
calculi O
. O

Recognition O
of O
emphysema O
was O
poor O
when O
radiographs O
of O
inadequate O
quality O
were O
included O
( O
anteroposterior O
films O
or O
films O
from O
patients O
with O
acute O
or O
chronic O
lung O
disease O
). O

Isolation O
of O
T O
. O
gambiense O
strains O
in O
Zaire O
and O
their O
adaptation O
to O
laboratory O
animals O

Pharmacokinetic O
profile O
of O
clonazepam O
in O
rhesus O
monkeys O
. O

Immunologic O
mechanisms O
in O
chronic O
brucellosis O
in O
humans O
. O

Intestinal O
adaptation O
( O
first O
of O
two O
parts O
). O

In O
patients O
who O
had O
received O
no O
previous O
drug O
treatment O
, O
log O
baseline O
plasma I-GENE
renin I-GENE
activity O
and O
change O
in O
mean O
blood O
pressure O
after O
SQ O
20881 O
correlated O
significantly O
( O
r O
= O
0 O
. O
651 O
, O
P O
less O
than O
0 O
. O
05 O
). O

These O
techniques O
have O
been O
used O
by O
many O
people O
for O
many O
years O
and O
no O
claim O
is O
being O
made O
for O
any O
innovation O
in O
this O
regard O
. O

40 O
patients O
with O
chronic O
osteomyelitis O
were O
treated O
per O
os O
with O
the O
bactericidal O
beta O
- O
lactam O
- O
antibiotic O
cephalexin O
during O
3 O
to O
60 O
weeks O
. O

A O
total O
of O
57 O
patients O
with O
Hodgkin O
' O
s O
disease O
limited O
to O
above O
the O
diaphragm O
( O
Stages O
I O
and O
II O
, O
A O
and O
B O
) O
were O
treated O
with O
radiation O
therapy O
alone O
at O
the O
University O
of O
Florida O
between O
1964 O
and O
1974 O
. O

Year O
one O
of O
the O
first O
general O
practitioner O
medical O
unit O
in O
the O
greater O
Glasgow O
area O
. O

This O
multiple O
- O
electrode O
array O
for O
round O
window O
cochlear O
implantation O
is O
a O
robust O
, O
reliable O
system O
for O
inserting O
20 O
mm O
along O
the O
scala O
tympani O
with O
a O
minimum O
of O
trauma O
and O
can O
provide O
for O
bipolar O
stimulation O
. O

As O
authorized O
by O
the O
World O
Health O
Organization O
29th O
Expert O
Committee O
on O
Biological O
Standardization O
, O
the O
preparation O
of O
human I-GENE
prolactin I-GENE
in O
ampoules O
coded O
75 O
/ O
504 O
has O
been O
established O
as O
the O
International O
Reference O
Preparation O
( O
IRP O
) O
of O
human I-GENE
prolactin I-GENE
for O
immunoassay O
. O

i O
. O

Biliary O
- O
enteric O
fistulas O

Plasma O
ion O
changes O
in O
venous O
blood O
incubated O
with O
beta I-GENE
receptor I-GENE
blockers O
and O
subjected O
to O
tonometry O
in O
vitro O
. O

Such O
marked O
differences O
are O
found O
occasionally O
in O
the O
literature O
: O
heterophile O
antibodies O
against O
bovine I-GENE
gammaglobulin I-GENE
are O
regarded O
as O
responsible O
for O
the O
interference O
in O
the O
Sephadex O
system O
of O
RIST O
. O

" O
Let O
the O
hundred O
flowers O
bloom O
". O

Various O
treatment O
modalities O
are O
reviewed O
in O
the O
context O
of O
the O
psychology O
as O
well O
as O
the O
physiology O
of O
severe O
intractable O
pain O
. O

Lethal O
Tachmalcor O
( O
4 O
-( O
3 O
'- O
diethylamino O
- O
2 O
'- O
hydroxypropyl O
)- O
ajmaline O
) O
poisoning O
in O
childhood O

Ophthalmosonographic O
evaluation O
of O
blood O
flow O
velocity O
in O
arteriocavernous O
fistula O

Serum O
ferritin I-GENE
concentration O
and O
bone O
marrow O
iron O
stores O
. O

The O
systolic O
pressure O
gradient O
( O
SPG O
) O
between O
the O
left O
ventricle O
( O
LV O
) O
and O
left O
atrium O
( O
LA O
) O
was O
obtained O
from O
high O
- O
fidelity O
pressure O
transducers O
. O

A O
prospective O
trail O
comparing O
hysterectomy O
, O
hysterectomy O
plus O
vaginal O
radium O
, O
and O
uterine O
radium O
plus O
hysterectomy O
in O
stage O
I O
endometrial O
carcinoma O
. O

On O
the O
basis O
of O
a O
patient O
' O
s O
report O
of O
one O
inaccurate O
Clinitemp O
, O
we O
undertook O
to O
investigate O
the O
accuracy O
of O
this O
thermometer O
. O

Cryoglobulinemia O
in O
Raynaud O
' O
s O
syndrome O

Data O
were O
processed O
with O
a O
semi O
- O
automatic O
computer O
program O
which O
develops O
an O
averaged O
- O
volume O
curve O
from O
an O
assigned O
LV O
region O
- O
of O
- O
interest O
. O

The O
preferential O
serum I-GENE
IgA I-GENE
response O
observed O
in O
the O
patient O
population O
suggests O
that O
bronchial O
associated O
lymphoid O
tissue O
in O
the O
diseased O
lung O
is O
an O
important O
source O
of O
circulating O
IgA I-GENE
. O

Ultimate O
strengthes O
seem O
to O
be O
reached O
for O
cast O
cobalt O
alloys O
, O
whereas O
titanium O
alloys O
, O
such O
as O
Ta O
6 O
V O
, O
present O
very O
high O
fatigue O
limit O
under O
corrosion O
. O

The O
effects O
of O
intracisternal O
injection O
( O
i O
. O
c O
. O
i O
.) O
of O
clonidine O
( O
1 O
microgram O
kg O
- O
1 O
) O
on O
blood O
pressure O
and O
heart O
rate O
were O
studied O
in O
conscious O
rabbits O
with O
an O
implanted O
catheter O
in O
the O
cisterna O
magna O
. O

Platelet O
number O
and O
life O
span O
were O
determined O
in O
the O
last O
trimester O
of O
pregnancy O
in O
22 O
women O
who O
were O
delivered O
of O
small O
- O
for O
- O
gestational O
age O
( O
SGA O
) O
infants O
and O
in O
21 O
women O
with O
infants O
having O
normal O
birth O
weights O
. O

Serial O
measurements O
of O
total O
serum O
IgE I-GENE
appears O
to O
be O
a O
useful O
index O
of O
disease O
activity O
in O
ABPA O
. O

In O
the O
8 O
patients O
the O
difference O
betweent O
he O
mean O
diastolic O
values O
of O
delta O
PU O
and O
delta O
PM O
was O
- O
0 O
. O
54 O
+/- O
1 O
. O
0 O
( O
SD O
) O
mmHg O
. O

A O
rise O
of O
hemoglobin I-GENE
concentration O
accompanied O
by O
an O
increase O
of O
the O
total O
iron O
in O
the O
blood O
serum O
of O
white O
mice O
was O
found O
under O
oxygen O
pressure O
of O
4 O
atm O
for O
an O
hour O
( O
preconvulsive O
state O
) O
and O
6 O
atm O
( O
convulsive O
state O
). O

Nernst O
-- O
Planck O
analog O
equations O
and O
stationary O
state O
membrane O
electric O
potentials O
. O

Effects O
of O
methylene O
chloride O
, O
trichloroethane O
, O
trichloroethylene O
, O
tetrachloroethylene O
and O
toluene O
on O
the O
development O
of O
chick O
embryos O
. O

Effect O
of O
intraventricular O
administration O
of O
streptolysin I-GENE
O I-GENE
on O
the O
electroencephalogram O
of O
rabbits O
. O

In O
this O
situation O
the O
convlusion O
threshold O
for O
the O
8 O
substances O
is O
as O
follows O
: O
pethidine O
20 O
mg O
. O
kg O
- O
1 O
I O
. O
V O
., O
piritramide O
30 O
, O
morphine O
180 O
, O
phenoperidine O
4 O
, O
R O
39 O
209 O
5 O
, O
fentanyl O
4 O
, O
sufentanil O
4 O
and O
R O
34 O
995 O
10 O
mg O
. O
kg O
- O
1 O
I O
. O
V O
. O

The O
biochemistry O
of O
amniotic O
fluid O
with O
poor O
fetal O
growth O
. O

Roentgenographically O
, O
the O
lesion O
was O
usually O
a O
well O
- O
defined O
and O
benign O
appearing O
one O
, O
either O
purely O
lytic O
( O
3 O
cases O
) O
or O
with O
central O
radiodensity O
( O
2 O
cases O
). O

Effects O
of O
chronic O
descending O
tractotomy O
on O
the O
response O
patterns O
of O
neurons O
in O
the O
trigeminal O
nuclei O
principalis O
and O
oralis O
. O

Efficacy O
of O
a O
three O
- O
versus O
a O
five O
- O
week O
alcohol O
treatment O
program O
. O

Resistance O
to O
the O
simulated O
physiologic O
environment O
was O
tested O
by O
measured O
retention O
of O
mechanical O
properties O
after O
immersion O
times O
in O
pseudo O
- O
extracellular O
fluid O
( O
PECF O
) O
at O
37 O
degrees O
C O
for O
as O
long O
as O
three O
years O
. O

Isolated O
calcaneal O
tuberculous O
osteomyelitis O
. O

It O
is O
concluded O
that O
opiate I-GENE
receptors I-GENE
bordering O
the O
fourth O
cerebral O
ventricle O
mediate O
the O
cardiovascular O
and O
hypnotic O
action O
of O
fentanyl O
. O

In O
case O
of O
a O
pathologically O
convoluted O
internal O
carotid O
the O
common O
carotid O
artery O
was O
resected O
with O
an O
end O
- O
to O
- O
end O
anastomosis O
. O

This O
expression O
assumes O
: O
( O
1 O
) O
a O
laminar O
flow O
regimen O
during O
expiration O
, O
and O
( O
2 O
) O
a O
constant O
CT O
value O
over O
the O
range O
of O
VT O
. O

These O
data O
confirm O
the O
existence O
of O
hyperlipemic O
abdominal O
crisis O
as O
a O
distinct O
entity O
and O
testify O
to O
the O
importance O
of O
recognizing O
this O
syndrome O
in O
order O
to O
avoid O
the O
occurrence O
of O
acute O
pancreatitis O
and O
the O
performance O
of O
unnecessary O
and O
potentially O
harmful O
surgery O
. O

In O
addition O
a O
significant O
Treatment O
X O
Strain O
interaction O
was O
due O
to O
the O
larger O
defecation O
numbers O
displayed O
by O
the O
taurine O
- O
injected O
MR O
rats O
relative O
to O
the O
saline O
- O
injected O
MR O
rats O
. O

Their O
conduction O
velocity O
ranged O
from O
0 O
. O
23 O
to O
0 O
. O
98 O
m O
/ O
sec O
( O
group O
C O
). O

The O
failures O
frequently O
were O
related O
to O
patient O
intolerance O
or O
poor O
mechanical O
fit O
and O
occurred O
in O
the O
first O
few O
days O
or O
first O
few O
months O
after O
insertion O
. O

The O
major O
urinary O
metabolites O
were O
3 O
-( O
3 O
- O
carboxyphenyl O
)- O
5 O
- O
hydroxymethyl O
- O
2 O
- O
oxazolidinone O
and O
a O
glucuronide O
of O
toloxatone O
. O

These O
characteristics O
indicated O
the O
pronounced O
activity O
of O
collagenous O
fiber O
synthesis O
and O
the O
matrix O
of O
the O
osteoid O
tissue O
. O

The O
ventilation O
did O
not O
increase O
when O
PACO2 O
was O
increased O
. O

Carbohydrate O
metabolism O
and O
the O
semen O
profile O
: O
glucose O
, O
insulin I-GENE
, O
and O
sperm O
studies O
. O

It O
has O
come O
out O
that O
CAEC O
is O
between O
CC O
and O
CIEC O
and O
that O
attacks O
of O
biliary O
fever O
and O
high O
levels O
of O
alkaline I-GENE
phosphatase I-GENE
and O
transaminases O
in O
the O
serum O
are O
the O
helpful O
findings O
for O
preoperative O
diagnosis O
. O

The O
sub O
- O
acute O
inhalation O
toxicity O
of O
furfural O
was O
studied O
in O
Syrian O
golden O
hamsters O
. O

Changes O
of O
thirtynine O
serum O
protein O
components O
following O
surgical O
stress O
. O

These O
differences O
are O
smaller O
than O
those O
described O
in O
standard O
textbooks O
. O

A O
study O
of O
the O
E O
. O
O O
. O
R O
. O
T O
. O
C O
. O

The O
present O
study O
examined O
the O
dependence O
of O
difference O
tone O
level O
[ O
L O
( O
f2 O
- O
f1 O
)] O
on O
the O
following O
parameters O
of O
the O
two O
- O
tone O
input O
: O
f1 O
, O
f2 O
/ O
f1 O
( O
f2 O
greater O
than O
f1 O
), O
L1 O
, O
L2 O
, O
and O
L1 O
= O
L2 O
. O

An O
intravenous O
preparation O
of O
doxycycline O
( O
DOTC O
, O
Vibramycin O
' O
Pfizer O
'), O
a O
long O
- O
lasting O
tetracycline O
, O
was O
administered O
mainly O
by O
drip O
infusion O
for O
a O
series O
of O
study O
in O
the O
pediatrics O
field O
, O
and O
the O
results O
were O
as O
follows O
: O
1 O
) O
DOTC O
( O
100 O
mg O
) O
was O
dissolved O
in O
a O
100 O
ml O
of O
glucose O
solution O
and O
2 O
-- O
3 O
mg O
/ O
kg O
was O
administered O
intravenously O
. O

5 O
) O
Before O
and O
ten O
days O
after O
DOTC O
infusion O
, O
laboratory O
tests O
for O
liver O
and O
renal O
functions O
and O
blood O
were O
performed O
. O

Structural O
characteristics O
of O
the O
erythrocyte O
membrane O
, O
peroxidation O
processes O
and O
antioxidant O
function O
in O
children O
with O
diffuse O
glomerulonephritis O

The O
enteric O
route O
is O
the O
principal O
mode O
of O
transmission O
for O
hepatitis O
A O
, O
but O
maximal O
levels O
of O
hepatitis O
A O
virus O
excretion O
occur O
before O
the O
onset O
of O
jaundice O
. O

All O
13 O
patients O
showed O
endoscopic O
evidence O
of O
oesophagitis O
, O
moderate O
in O
4 O
and O
severe O
in O
9 O
. O

Urinary O
excretion O
of O
oestrone O
, O
oestradiol O
- O
17 O
beta O
and O
oestriol O
in O
pregnancies O
complicated O
by O
steroid I-GENE
sulphatase I-GENE
deficiency O
. O

Both O
reduced O
spontaneous O
locomotor O
activity O
in O
mice O
, O
protected O
them O
from O
death O
from O
amphetamine O
induced O
toxicity O
, O
prolonged O
hexobarbitone O
sleeping O
time O
and O
caused O
a O
depletion O
of O
catecholamines O
from O
various O
organs O
of O
the O
rat O
. O

On O
the O
role O
of O
transferrin I-GENE
in O
the O
uptake O
of O
gallium O
by O
tumor O
cells O
. O

Irradiation O
of O
human O
blood O
platelets O
with O
UV O
- O
A O
in O
vitro O
impairs O
their O
ability O
to O
aggregate O
after O
challenge O
with O
collagen I-GENE
. O

With O
certain O
exceptions O
the O
method O
was O
considered O
suitable O
in O
the O
routine O
intravenous O
cholangiography O
. O

Following O
the O
satisfactory O
results O
and O
taking O
into O
account O
that O
the O
complications O
had O
reduced O
to O
a O
very O
low O
rate O
( O
in O
2 O
cases O
lead O
tip O
displacement O
and O
pouch O
haematoma O
occurred O
respectively O
), O
the O
Authors O
consider O
the O
adopted O
method O
an O
useful O
approach O
for O
PMK O
implantation O
particularly O
when O
the O
use O
of O
the O
vena O
cephalica O
is O
deemed O
impossible O
. O

When O
two O
determinations O
were O
performed O
on O
12 O
samples O
of O
plasma O
taken O
from O
normal O
adults O
in O
October O
, O
the O
values O
were O
22 O
. O
6 O
+/- O
4 O
. O
8 O
and O
21 O
. O
0 O
+/- O
3 O
. O
6 O
( O
mean O
+/- O
SD O
) O
ng O
/ O
ml O
, O
respectively O
. O

The O
six O
commonest O
causes O
of O
death O
varied O
in O
the O
three O
ethnic O
groups O
. O

Although O
Grice O
' O
s O
operation O
has O
been O
used O
all O
over O
the O
world O
, O
no O
systematic O
account O
of O
it O
has O
been O
found O
in O
the O
literature O
( O
including O
publications O
dealing O
with O
technique O
), O
which O
presents O
it O
in O
terms O
related O
to O
the O
basic O
" O
classical O
" O
principles O
on O
which O
the O
operation O
was O
conceived O
. O

( O
5 O
) O
No O
changes O
were O
observed O
in O
the O
gastric O
venous O
blood O
flow O
by O
continuous O
intravenous O
injection O
of O
cimetidine O
, O
but O
by O
rapid O
injection O
both O
the O
flow O
was O
augmented O
and O
the O
systemic O
blood O
pressure O
decreased O
transiently O
. O

Study O
on O
re O
- O
establishment O
of O
ovulation O
after O
termination O
of O
sex O
- O
steroidal O
treatment O
-- O
compared O
with O
re O
- O
appearance O
of O
ovulation O
after O
abortion O
and O
premature O
delivery O
. O

Pharmacokinetics O
of O
Carbamazepine O
in O
man O
: O
a O
review O
. O

Of O
the O
compounds O
tested O
, O
alpha O
-( O
3 O
- O
methyl O
- O
2 O
- O
quinoxalinyl O
)- O
N O
- O
methylnitrone O
1 O
, O
4 O
- O
dioxide O
( O
2 O
) O
was O
the O
most O
active O
agent O
in O
vivo O
against O
the O
gram O
- O
negative O
and O
the O
gram O
- O
positive O
organisms O
. O

Changes O
in O
ionic O
content O
of O
the O
mucous O
suggest O
that O
cholinergic O
mechanisms O
affect O
pressure O
in O
the O
excretory O
duct O
of O
the O
gland O
. O

Calves O
fed O
MCT O
- O
milk O
had O
significantly O
lower O
blood O
cholesterol O
than O
calves O
fed O
T O
- O
or O
SBO O
- O
milk O
. O

Delayed O
mortality O
of O
mice O
following O
inhalation O
of O
acute O
doses O
of O
CH2O O
, O
SO2Cl2 O
, O
and O
Br2 O
. O

Guinea O
pigs O
weighing O
300 O
approximately O
350 O
g O
were O
used O
. O

Under O
halothane O
anesthesia O
, O
the O
flow O
pneumocardiogram O
( O
PnCG O
) O
and O
its O
time O
derivative O
( O
acceleration O
pneumocardiogram O
or O
dPn O
/ O
dt O
) O
were O
transduced O
during O
apnea O
by O
a O
small O
high O
- O
gain O
pneumotachograph O
. O

Sensory O
kindling O
: O
implications O
for O
development O
of O
sensory O
prostheses O
. O

It O
is O
concluded O
that O
stereotypy O
can O
be O
evoked O
also O
in O
the O
case O
when O
the O
striatal O
dopaminergic O
tone O
is O
normal O
or O
even O
below O
normal O
: O
it O
is O
the O
equilibrium O
of O
the O
striatal O
cholinergic O
- O
dopaminergic O
systems O
which O
must O
be O
shifted O
towards O
dopamine O
, O
which O
is O
necessary O
for O
the O
development O
of O
this O
behavioral O
manifestation O
. O

None O
of O
the O
cystometrograms O
showed O
uninhibited O
detrusor O
contractions O
. O

In O
the O
duodenum O
a O
small O
part O
of O
the O
administered O
dose O
was O
transformed O
to O
3H O
- O
alpha O
- O
acetyldigoxin O
. O

Functional O
effects O
following O
subacute O
administration O
. O

Treatment O
of O
Graves O
' O
disease O
. O

Although O
it O
has O
been O
shown O
that O
it O
is O
possible O
to O
use O
orally O
administered O
testosterone O
to O
maintain O
se O
- O
T O
levels O
in O
the O
normal O
male O
range O
, O
the O
convenience O
to O
the O
patient O
must O
be O
balanced O
against O
the O
cost O
and O
possible O
side O
effects O
of O
the O
large O
doses O
required O
. O

Contrary O
to O
1 O
, O
8 O
- O
dihydroxy O
- O
9 O
- O
anthrone O
, O
1 O
, O
8 O
, O
9 O
- O
triacetoxyanthracene O
and O
1 O
, O
8 O
- O
diacetoxy O
- O
9 O
- O
anthrone O
are O
effective O
against O
psoriatic O
lesions O
without O
accompanying O
inflammations O
of O
the O
skin O
. O

Etiopathogenetic O
and O
therapeutic O
problems O
in O
acute O
orbital O
inflammation O

Nursing O
of O
patients O
with O
gynecological O
diseases O

We O
measured O
basal O
plasma O
prolactin I-GENE
concentrations O
( O
in O
samples O
obtained O
during O
the O
early O
follicular O
phase O
) O
in O
25 O
normal O
( O
control O
) O
women O
and O
in O
a O
similar O
group O
of O
40 O
patients O
with O
a O
long O
- O
standing O
history O
of O
infertility O
. O

Ovarian O
allotransplantation O
in O
human O
. O

Allergic O
reaction O
to O
Patent O
Blue O
Violet O
during O
lymphography O
. O

Screening O
of O
asthma O
patients O
by O
determination O
of O
IgE I-GENE
and O
by O
comprehension O
of O
spectrum O
of O
allergospecific I-GENE
IgE I-GENE
antibodies I-GENE

The O
induction O
of O
seizures O
in O
" O
Papio O
papio O
" O
following O
allylglycine O
alone O
or O
in O
combination O
with O
intermittent O
photic O
stimulation O

A O
highly O
significant O
correlation O
was O
found O
between O
the O
presence O
of O
fibrinolytic O
degradation O
products O
( O
FDP O
) O
and O
the O
incidence O
of O
nephropathy O
and O
renal O
insufficiency O
, O
as O
well O
as O
between O
the O
presence O
of O
fibrin I-GENE
monomers I-GENE
( O
Godal O
' O
s O
ethanol O
- O
gelification O
test O
) O
and O
the O
evolutive O
signs O
of O
the O
primary O
disease O
( O
fever O
, O
accelerated O
ESR O
). O

One O
- O
third O
of O
the O
men O
with O
azoospermia O
and O
with O
sperm O
density O
of O
less O
than O
10 O
million O
had O
marked O
FSH I-GENE
elevation O
and O
our O
experience O
confirms O
the O
work O
of O
others O
that O
this O
indicates O
a O
poor O
prognosis O
. O

In O
girls O
prolactin I-GENE
levels O
rise O
at O
stage O
2 O
, O
and O
are O
higher O
after O
menarche O
; O
in O
boys O
there O
is O
no O
change O
in O
prolactin I-GENE
levels O
. O

It O
was O
concluded O
that O
both O
of O
these O
surgical O
procedures O
were O
as O
effective O
as O
pinealectomy O
in O
reversing O
the O
pineal O
- O
induced O
alterations O
in O
the O
reproductive O
physiology O
of O
the O
blind O
- O
anosmic O
female O
rat O
. O

2 O
cases O
of O
toxic O
lymphomononucleosis O

Such O
an O
hemoglobin I-GENE
solution O
was O
shown O
to O
exhibit O
a O
high O
affinity O
for O
oxygen O
and O
a O
low O
Bohr O
effect O
( O
assessed O
from O
the O
delta O
log O
Po2 O
/ O
delta O
pH O
ratio O
). O

A O
one O
- O
week O
ulcer O
therapy O
with O
atropine O
and O
Vikalin O
( O
Roter O
) O
led O
to O
a O
significant O
( O
p O
less O
than O
0 O
. O
01 O
) O
reduction O
of O
the O
nocturnal O
proteolytic O
activity O
. O

In O
one O
patient O
with O
severe O
diarrhea O
the O
estriol O
concentration O
in O
serum O
was O
low O
until O
the O
intestinal O
function O
normalised O
and O
the O
estriol O
concentration O
went O
up O
exactly O
when O
the O
diarrhea O
stopped O
. O

Serum O
levels O
of O
IgG I-GENE
and O
IgM I-GENE
were O
also O
raised O
, O
but O
contrary O
to O
the O
findings O
of O
other O
observers O
IgA I-GENE
levels O
were O
normal O
. O

Experimental O
ischemic O
heart O
disease O
induced O
by O
thromboxane O
A2 O
in O
rabbits O
. O

Vitrectomy O
in O
ocular O
traumatology O

To O
study O
the O
sensitivity O
of O
some O
central O
brain O
structures O
to O
the O
action O
of O
an O
electromagnetic O
field O
of O
decimeter O
waves O
( O
EMF O
of O
DW O
) O
a O
dynamic O
investigation O
of O
single O
unit O
activity O
was O
undertaken O
. O

No O
systematic O
L O
- O
R O
differences O
were O
observed O
. O

A O
decrease O
of O
the O
lysozyme I-GENE
activity O
coincided O
with O
the O
clinical O
improvement O
of O
the O
bacterial O
meningitis O
. O

This O
implies O
that O
the O
groups O
do O
not O
just O
differ O
along O
one O
dimension O
, O
but O
along O
three O
dimensions O
. O

Deep O
tans O
were O
induced O
over O
the O
backs O
of O
volunteers O
with O
repeated O
exposure O
to O
longwave O
ultraviolet O
radiation O
( O
UV O
- O
A O
). O

1 O
The O
effects O
in O
normal O
subjects O
of O
a O
single O
oral O
dose O
of O
Motival O
( O
one O
tablet O
, O
containing O
fluphenazine O
0 O
. O
5 O
mg O
and O
nortriptyline O
10 O
mg O
) O
on O
the O
contingent O
negative O
variation O
( O
CNV O
), O
reaction O
time O
, O
heart O
rate O
, O
blood O
pressure O
and O
self O
- O
rating O
scales O
for O
alertness O
, O
anxiety O
, O
tension O
, O
detachment O
and O
depression O
were O
compared O
with O
those O
of O
diazepam O
( O
5 O
mg O
and O
7 O
. O
5 O
mg O
) O
and O
placebo O
or O
propranolol O
( O
60 O
mg O
). O

Stress O
effects O
on O
affiliation O
preferences O
among O
subjects O
possessing O
the O
type O
A O
coronary O
- O
prone O
behavior O
pattern O
. O

These O
show O
that O
the O
collagen I-GENE
in O
this O
tissue O
is O
modified O
compared O
with O
that O
in O
tendon O
. O

Smoking O
was O
regarded O
as O
the O
major O
contribution O
to O
pulmonary O
dysfunction O
. O

The O
malignity O
of O
nevoid O
lentigo O
. O

Elimination O
of O
bagassosis O
in O
Louisiana O
paper O
manufacturing O
plant O
workers O
. O

These O
responses O
were O
compared O
with O
others O
in O
the O
same O
subjects O
under O
the O
same O
conditions O
and O
it O
was O
concluded O
that O
the O
antihypertensive O
effect O
of O
labetalol O
is O
explained O
by O
concurrent O
blockade O
of O
alpha I-GENE
- I-GENE
and I-GENE
beta I-GENE
- I-GENE
adrenoceptors I-GENE
. O

Diuretics O
: O
basic O
clinical O
pharmacology O
and O
therapeutic O
use O
. O

Three O
patients O
with O
four O
renoureteral O
units O
have O
undergone O
single O
- O
stage O
reconstruction O
involving O
ureteroureterostomy O
and O
ipsilateral O
ureteroneocystostomy O
following O
temporary O
loop O
cutaneous O
ureterostomy O
. O

Evaluation O
of O
the O
Du O
Pont O
aca O
ammonia O
procedure O
. O

Internally O
oriented O
patients O
' O
scores O
on O
Rotter O
' O
s O
Internal O
- O
External O
Locus O
of O
Control O
Scale O
remained O
the O
same O
over O
treatment O
but O
those O
of O
externally O
oriented O
patients O
shifted O
toward O
greater O
internal O
control O
. O

Action O
of O
strontium O
- O
90 O
and O
metaphos O
on O
Cyprinus O
carpio O

Kodak O
XV O
- O
2 O
film O
is O
wrapped O
around O
a O
cylindrical O
water O
- O
filled O
phantom O
and O
the O
dose O
distribution O
is O
recorded O
. O

Diagnosis O
and O
differential O
diagnosis O

The O
multiple O
factors O
affecting O
plasma O
renin I-GENE
activity O
in O
essential O
hypertension O
. O

Cortisone O
induced O
bone O
changes O
and O
its O
response O
to O
lipid O
clearing O
agents O
. O

2 O
) O
The O
time O
- O
sharing O
principle O
was O
applied O
to O
gain O
high O
stability O
. O

When O
blood O
samples O
of O
patients O
with O
hyperbilirubinemia O
were O
analyzed O
, O
direct O
measurement O
of O
ZPP O
by O
this O
fluorimeter O
yielded O
significantly O
higher O
levels O
than O
did O
an O
alternate O
extraction O
method O
. O

Delayed O
hypersensitivity O
in O
man O
: O
effects O
of O
systemic O
anticoagulation O
. O

In O
three O
of O
the O
seven O
, O
inhalation O
of O
2 O
ml O
normal O
saline O
produced O
FEV1 O
falls O
of O
25 O
% O
to O
30 O
%, O
but O
these O
falls O
were O
not O
as O
great O
as O
each O
subject O
' O
s O
reactions O
to O
the O
test O
solutions O
. O

Experimental O
studies O
on O
virus O
excretion O
and O
non O
- O
arthropod O
transmission O
. O

Potency O
of O
enflurane O
in O
dogs O
: O
comparison O
with O
halothane O
and O
isoflurane O
. O

Prevention O
of O
acute O
paraquat O
toxicity O
in O
rats O
by O
superoxide I-GENE
dismutase I-GENE
. O

Measurement O
of O
magnesium O
absorption O
in O
man O
using O
stable O
26Mg O
as O
a O
tracer O
. O

Increased O
urinary O
riboflavin O
excretion O
resulting O
from O
boric O
acid O
ingestion O
. O

Radionuclide O
angiography O
and O
static O
whole O
body O
imaging O
performed O
with O
technetium O
- O
99m O
- O
labeled O
particulates O
can O
clearly O
demonstrate O
differential O
shunting O
in O
patients O
with O
patent O
ductus O
arteriosus O
( O
PDA O
) O
with O
Eisenmenger O
physiology O
. O

Looming O
detectors O
in O
the O
human O
visual O
pathway O
. O

Escherichia O
of O
a O
single O
sero O
- O
anzymatic O
type O
( O
06a6b O
: O
K13 O
: O
H1 O
) O
were O
isolated O
in O
a O
group O
affection O
. O

The O
method O
described O
may O
prove O
useful O
in O
studying O
the O
physiology O
of O
the O
nasal O
cycle O
. O

At O
the O
same O
time O
we O
obtained O
easily O
understandable O
EEG O
- O
information O
which O
has O
never O
previously O
been O
available O
to O
us O
. O

Analysis O
of O
liver O
biopsy O
specimens O
from O
patients O
with O
hepatitis O
showed O
a O
large O
variation O
in O
the O
mean O
iron O
content O
of O
the O
liver O
ferritin I-GENE
molecules O
. O

Female O
mice O
were O
significantly O
more O
resistant O
to O
infection O
than O
males O
. O

During O
the O
following O
9 O
1 O
/ O
2 O
years O
three O
sequential O
liver O
biopsies O
were O
performed O
. O

Angiotensin I-GENE
effect O
in O
the O
human O
kidney O
. O

Procion O
yellow O
dye O
was O
injected O
intracellularly O
into O
large O
auditory O
fibers O
of O
goldfish O
to O
investigate O
the O
relationship O
between O
the O
response O
type O
of O
these O
fibers O
and O
their O
site O
of O
termination O
in O
the O
saccular O
macula O
. O

Incidental O
findings O
in O
the O
epidermis O
and O
in O
the O
intraepidermal O
eccrine O
sweat O
duct O
units O
. O

Silicosis O
mortality O

These O
consisted O
of O
beading O
and O
strictures O
mainly O
of O
the O
intrahepatic O
biliary O
tree O
( O
IHB O
). O

Pentane O
and O
ethane O
, O
which O
arise O
during O
lipid O
peroxidation O
in O
vivo O
, O
were O
measured O
by O
gas O
chromatography O
in O
breath O
samples O
of O
rats O
fed O
for O
8 O
weeks O
a O
vitamin O
E O
- O
deficient O
diet O
to O
which O
had O
been O
added O
0 O
, O
11 O
, O
or O
40 O
IU O
vitamin O
E O
acetate O
per O
kg O
. O

Thromboplastic O
and O
fibrynolytic O
activity O
of O
the O
blood O
after O
administration O
of O
intralipid O
in O
men O
with O
history O
of O
myocardial O
infarction O
up O
to O
45 O
year O
of O
life O

The O
authors O
report O
the O
clinicopathologic O
findings O
in O
four O
cases O
of O
adult O
women O
with O
rhabdomyosarcomas O
that O
originated O
in O
the O
endometrium O
or O
cervix O
, O
or O
both O
. O

The O
effect O
of O
pure O
natural O
porcine I-GENE
secretin I-GENE
on O
endocrine O
and O
exocrine O
pancreatic O
secretion O
was O
studied O
in O
the O
totally O
isolated O
perfused O
porcine O
pancreas O
. O

Biometric O
analysis O
of O
intraocular O
lens O
power O
required O
to O
produce O
emmetropia O
: O
results O
of O
450 O
implants O
. O

Urine O
antibodies O
could O
not O
be O
demonstrated O
in O
any O
other O
cases O
. O

Althoug O
RBF O
tended O
to O
increase O
after O
the O
therapy O
, O
there O
was O
no O
statistically O
significant O
change O
in O
RBF O
, O
GFR O
and O
cardiac O
output O
. O

99mTc O
phytate O
, O
198Au O
colloid O
, O
and O
99mTc O
antimony O
sulfide O
have O
been O
used O
; O
the O
last O
appears O
to O
have O
been O
the O
most O
satisfactory O
. O

Six O
patients O
with O
glomerulonephritis O
in O
association O
with O
a O
ventriculovascular O
shunt O
were O
treated O
with O
three O
basic O
modes O
of O
therapy O
. O

The O
mass O
of O
UO2 O
in O
the O
extrapulmonary O
bronchi O
and O
first O
bifurcation O
decreased O
more O
slowly O
over O
0 O
-- O
8 O
d O
after O
inhalation O
than O
the O
corresponding O
mass O
on O
the O
trachea O
. O

Synovial O
cysts O
of O
the O
hip O
joint O

A O
suspected O
hypothalamic O
dysfunction O
and O
a O
slightly O
impaired O
pituitary O
function O
manifested O
as O
GH I-GENE
deficiency O
were O
their O
common O
endocrinological O
features O
. O

A O
sharp O
outbreak O
of O
influenza O
A O
occurred O
on O
the O
base O
during O
February O
that O
was O
due O
to O
an O
A O
/ O
Texas O
/ O
1 O
/ O
77 O
- O
like O
virus O
, O
a O
variant O
of O
the O
A O
/ O
Victoria O
/ O
3 O
/ O
75 O
prototpye O
. O

Because O
decreases O
in O
the O
disfluency O
rates O
of O
stutterers O
were O
observed O
during O
the O
presentation O
of O
all O
three O
stimulus O
words O
, O
the O
data O
failed O
to O
support O
the O
operant O
model O
. O

Effect O
of O
time O
and O
dose O
on O
alterations O
following O
inhalation O
of O
plutonium O
- O
239 O
dioxide O
aerosol O
in O
rat O
. O

In O
biopsies O
CK I-GENE
- I-GENE
MB I-GENE
fraction O
of O
total O
myocardial O
CPK I-GENE
was O
37 O
%, O
the O
total I-GENE
- I-GENE
CPK I-GENE
activity O
of O
human O
skeletal O
muscles O
still O
shows O
a O
5 O
% O
fraction O
of O
CK I-GENE
- I-GENE
MB I-GENE
. O

Value O
of O
determination O
of O
alkaline I-GENE
phosphatase I-GENE
isoenzymes I-GENE
for O
differential O
diagnosis O
of O
obstructive O
jaundice O
and O
biliary O
liver O
cirrhosis O

A O
one O
- O
way O
analysis O
of O
variance O
, O
performed O
separately O
for O
men O
and O
women O
for O
differences O
among O
the O
three O
phobic O
groups O
on O
field O
dependence O
, O
showed O
significance O
( O
rho O
less O
than O
. O
05 O
) O
for O
the O
females O
, O
with O
the O
famale O
agoraphobic O
being O
more O
field O
dependent O
than O
the O
female O
simple O
phobic O
groups O
, O
but O
not O
for O
the O
males O
. O

Several O
free O
2nd O
- O
generation O
schizonts O
, O
which O
varied O
in O
diameter O
from O
11 O
to O
21 O
. O
6 O
micrometer O
, O
were O
found O
on O
the O
epithelial O
surface O
of O
the O
cecum O
. O

The O
calculated O
pD2 O
values O
were O
8 O
. O
8 O
for O
E O
, O
8 O
. O
6 O
for O
DHE O
and O
6 O
. O
6 O
for O
M O
. O

Newcastle O
disease O
virus O
surveillance O
in O
Hong O
Kong O
on O
local O
and O
imported O
poultry O
. O

It O
was O
postulated O
that O
persistent O
challenge O
by O
M O
. O
leprae O
or O
its O
antigens O
to O
the O
IgA I-GENE
immunocytes O
of O
the O
intestinal O
epithelium O
might O
have O
induced O
tolerance O
leading O
to O
IgA I-GENE
deficiency O
and O
subsequent O
subtotal O
atrophy O
of O
the O
intestinal O
villi O
in O
the O
patients O
with O
lepromatous O
leprosy O
. O

Treatment O
of O
hypertension O
with O
a O
combination O
of O
the O
adrenergic I-GENE
beta I-GENE
receptor I-GENE
blockader O
, O
obsidan O
, O
and O
the O
vasodilator O
, O
apressin O

Orthop O
. O

Thyroid O
disease O
and O
pregnancy O
. O

Residues O
removed O
from O
transcripts O
by O
splicing O
were O
identified O
. O

To O
minimize O
reflux O
into O
the O
blind O
loop O
, O
a O
number O
of O
technical O
steps O
are O
considered O
indispensable O
: O
1 O
) O
fluted O
section O
of O
the O
jejunal O
stump O
; O
2 O
) O
isoperistaltic O
construction O
of O
the O
anastomosis O
and O
, O
particularly O
, O
3 O
) O
the O
creation O
of O
a O
single O
or O
double O
valve O
system O
upstream O
from O
the O
anastomosis O
by O
spiral O
introflexion O
of O
the O
mucosa O
using O
seroserous O
stitches O
parallel O
and O
perpendicular O
to O
the O
ileal O
lumen O
. O

At O
this O
stage O
, O
the O
eventual O
high O
mortality O
of O
acute O
ischemia O
is O
established O
whatever O
the O
urgency O
of O
the O
operation O
or O
the O
skill O
with O
which O
it O
is O
performed O
. O

Pathogens O
( O
Staphylococcus O
aureus O
or O
Gram O
- O
negative O
bacilli O
) O
were O
isolated O
from O
only O
one O
member O
of O
staff O
in O
small O
numbers O
and O
irregularly O
and O
rarely O
in O
large O
numbers O
from O
patients O
. O

The O
histochemistry O
and O
ultrastructure O
of O
calcified O
cerebellar O
deposits O
described O
by O
Tonge O
et O
al O
. O

A O
36 O
year O
- O
old O
woman O
was O
given O
Ergotamine O
Tartrate O
4 O
. O
5 O
mg O
p O
. O
d O
. O
during O
seven O
days O
, O
after O
an O
abortion O
( O
a O
still O
birth O
). O

Reaction O
times O
to O
tachistoscopically O
presented O
stimuli O
in O
diabetics O

Two O
out O
of O
five O
patients O
undergoing O
selective O
spinal O
arteriography O
developed O
transient O
neurological O
complications O
during O
the O
injection O
of O
Urografin O
310 O
M O
. O

The O
data O
indicate O
a O
three O
- O
phase O
reaction O
after O
B1 O
injection O
: O
Phase O
1 O
-- O
shortly O
after O
injection O
there O
is O
a O
drop O
of O
all O
parameters O
lasting O
for O
30 O
sec O
. O

Serum I-GENE
relaxin I-GENE
levels O
in O
prostaglandin O
E2 O
induced O
abortions O
. O

A O
-- O
A O
natural O
hydrostatic O
phenomenon O
, O
at O
the O
level O
of O
the O
ends O
of O
the O
plantar O
arcs O
, O
diffuses O
body O
weight O
, O
as O
PAIN O
plays O
the O
role O
of O
outsentry O
( O
fig O
.-- O
1 O
) O
( O
5 O
); O
B O
-- O
Plantar O
perforating O
ulceration O
( O
PPU O
) O
is O
caused O
by O
a O
combination O
of O
INSENSITIVITY O
and O
TRAUMATIS O
( O
1 O
); O
C O
-- O
The O
patient O
reposing O
, O
as O
body O
weight O
( O
traumatism O
) O
effects O
disappear O
, O
cicatrization O
process O
can O
be O
easily O
observed O
; O
D O
-- O
PNEUMATIC O
INSOLE O
, O
being O
elastic O
, O
diffuses O
localized O
compression O
at O
the O
ends O
of O
the O
plantar O
arcs O
, O
reduces O
attrition O
, O
makes O
easier O
blood O
circulation O
, O
as O
well O
as O
cure O
and O
prophylaxis O
of O
PPU O
( O
fig O
.-- O
6 O
) O
( O
3 O
). O

Effect O
of O
indoramin O
in O
small O
doses O
on O
the O
central O
vasomotor O
loci O
has O
been O
studied O
in O
chloralose O
anesthetized O
cats O
by O
localizing O
it O
to O
the O
central O
sites O
. O

As O
expected O
, O
the O
heparin O
did O
produce O
increased O
recalcification O
times O
and O
the O
development O
of O
occasional O
subcutaneous O
hematomas O
. O

Contingency O
contracting O
between O
clients O
and O
their O
parents O
/ O
caregivers O
was O
used O
to O
specify O
consequences O
for O
daily O
self O
- O
monitoring O
, O
reduced O
caloric O
intake O
, O
weight O
loss O
, O
and O
exercise O
. O

Dietetics O
of O
childhood O
- O
and O
juvenile O
diabetes O

The O
results O
of O
a O
quantitative O
study O
of O
vasculosyncytial O
membranes O
in O
123 O
placentas O
are O
presented O
. O

The O
micromethod O
uses O
microcuvettes O
and O
substitutes O
ferrozine O
for O
the O
bathophenanthroline O
chromogen O
of O
the O
ICSH O
. O

Platelet O
serotonin O
( O
5 O
- O
HT O
) O
and O
5 I-GENE
- I-GENE
HT I-GENE
releasing I-GENE
factor I-GENE
in O
plasma O
of O
migrainous O
patients O
. O

The O
overall O
incidence O
of O
SIDS O
was O
1 O
. O
43 O
per O
1 O
, O
000 O
live O
births O
. O

The O
vigilance O
task O
and O
the O
measurement O
of O
attentional O
deficits O
. O

The O
December O
armed O
revolt O
in O
Moscow O
and O
the O
paramedical O
personnel O

Significant O
increases O
in O
mean O
serum O
E2 O
concentration O
( O
100 O
to O
150 O
pg O
/ O
ml O
) O
were O
noted O
at O
6 O
and O
8 O
hours O
after O
administration O
on O
day O
1 O
and O
at O
8 O
hours O
on O
day O
4 O
. O

The O
motor O
unit O
viewed O
from O
above O
. O

Avian O
reproductive O
system O
: O
daily O
variations O
in O
responses O
to O
hormones O
. O

Biological O
properties O
of O
sumithion O
. O

Serological O
studies O
of O
antibodies O
to O
Epstein O
- O
Barr O
virus O
in O
infectious O
mononucleosis O

Carcinoembryonic I-GENE
antigen I-GENE
( O
CEA I-GENE
) O
procedures O
and O
clinical O
evaluation O
. O

We O
remain O
convinced O
that O
antilymphocyte I-GENE
globulin I-GENE
( O
ALG I-GENE
) O
is O
a O
potent O
immunosuppressive O
agent O
in O
humans O
. O

On O
the O
basis O
of O
a O
global O
assessment O
patients O
showed O
a O
highly O
significant O
preference O
for O
imipramine O
compared O
with O
placebo O
as O
adjunctive O
therapy O
. O

39 O
- O
47 O
. O

Patients O
were O
subclassified O
into O
age O
- O
matched O
groups O
of O
primary O
untreated O
cancer O
( O
21 O
), O
recurrent O
cancer O
( O
18 O
), O
and O
" O
cured O
" O
patients O
who O
had O
been O
free O
of O
disease O
for O
at O
least O
9 O
months O
( O
16 O
). O

Absorption O
varied O
between O
65 O
and O
95 O
per O
cent O
, O
with O
a O
mean O
absorption O
of O
80 O
per O
cent O
, O
in O
both O
pregnant O
and O
non O
- O
pregnant O
subjects O
. O

Bacteriostatic O
and O
bacteriacidal O
activity O
of O
hydroxy O
- O
9 O
ellipticine O
in O
vitro O

Advances O
in O
the O
management O
of O
gynecologic O
cancer O
-- O
radiation O
therapy O
. O

The O
clinico O
- O
pathological O
data O
from O
a O
patient O
with O
irreversible O
post O
- O
partum O
renal O
failure O
( O
IPRF O
) O
are O
presented O
. O

Personal O
satisfaction O
in O
nursing O
: O
an O
encounter O
with O
extremely O
hostile O
patients O

Dialyzable O
transfer I-GENE
factor I-GENE
. O

19 O
- O
32 O
. O

Rheumatoid I-GENE
factor I-GENE
and O
antinuclear O
antibody O
tests O
were O
frequently O
positive O
, O
and O
reactions O
to O
gold O
therapy O
were O
more O
frequent O
than O
in O
other O
rheumatoid O
populations O
. O

The O
effect O
of O
hydrostatic O
pressure O
on O
the O
swimming O
activity O
of O
three O
hyponeustonic O
crustacea O
, O
Anomalocera O
patersoni O
, O
Pontella O
mediterranea O
, O
Labidocera O
wollastoni O

This O
report O
presents O
an O
analysis O
of O
the O
vocal O
repertoire O
of O
howler O
monkeys O
( O
Alouatta O
palliata O
) O
observed O
during O
a O
field O
study O
in O
southwestern O
Panama O
. O

Up O
to O
now O
the O
number O
of O
patients O
examined O
is O
about O
300 O
, O
additionally O
6 O
persons O
who O
underwent O
binephrectomy O
. O

Deflunia O
was O
well O
tolerated O
by O
25 O
patients O
, O
very O
well O
tolerated O
by O
2 O
. O

III O
. O

A O
new O
instrument O
has O
been O
designed O
for O
freeze O
- O
fracturing O
of O
biological O
material O
in O
ultra O
high O
vacuum O
. O

Pancreatic O
and O
biliary O
secretion O
and O
gastric O
emptying O
rates O
of O
a O
liquid O
test O
meal O
( O
LTM O
) O
were O
determined O
in O
normal O
persons O
, O
in O
patients O
with O
subtotal O
gastrectomy O
with O
gastroduodenostomy O
( O
STG O
- O
BI O
) O
or O
with O
gastrojejunostomy O
( O
STG O
- O
BII O
), O
and O
in O
patients O
with O
truncal O
vagotomy O
and O
pyloroplasty O
( O
V O
& O
P O
). O

Abnormal O
calcium O
metabolism O
in O
normocalcaemic O
sarcoidosis O
. O

Also O
, O
except O
in O
one O
patient O
who O
developed O
gallstones O
following O
institution O
of O
colestipol O
, O
saturation O
of O
gallbladder O
bile O
with O
cholesterol O
was O
not O
markedly O
increased O
by O
this O
drug O
alone O
. O

A O
five O
- O
phase O
experiment O
was O
designed O
to O
investigate O
( O
a O
) O
whether O
contingent O
music O
- O
listening O
would O
act O
as O
a O
reinforcer O
to O
increase O
arithmetic O
performance O
of O
EMR O
children O
and O
( O
b O
) O
whether O
this O
contingent O
reinforcement O
would O
affect O
preference O
for O
that O
reinforcer O
. O

The O
responsiveness O
of O
visual O
cortex O
( O
VC O
) O
and O
superior O
colliculus O
( O
SC O
) O
was O
simultaneously O
compared O
following O
conditioning O
" O
ON O
" O
or O
" O
OFF O
" O
stimulation O
, O
in O
the O
rabbit O
. O

A O
diagnosis O
of O
MS O
was O
made O
based O
on O
subtle O
neurologic O
signs O
, O
spinal O
fluid O
gamma I-GENE
globulin I-GENE
elevations O
, O
and O
abnormalities O
in O
neuropsychological O
testing O
. O

If O
, O
however O
, O
the O
mean O
temperature O
rise O
was O
higher O
( O
0 O
. O
57 O
degrees O
C O
or O
0 O
. O
69 O
degrees O
C O
), O
such O
a O
selection O
practically O
resulted O
in O
the O
disappearance O
of O
' O
passable O
' O
qualifications O
in O
the O
triplet O
groups O
and O
a O
great O
predominance O
of O
' O
to O
be O
rejected O
' O
qualifications O
in O
the O
large O
groups O
. O

The O
elevated O
Viso O
V O
in O
the O
RDS O
group O
suggests O
an O
increase O
in O
small O
airway O
resistance O
secondary O
to O
the O
disease O
or O
to O
its O
therapy O
. O

The O
psychological O
tests O
consisted O
of O
a O
free O
- O
recall O
task O
, O
a O
test O
for O
visuomotor O
coordination O
and O
a O
recognition O
task O
. O

Selective O
bronchial O
intubation O
in O
the O
management O
of O
unilateral O
pulmonary O
interstitial O
emphysema O
. O

The O
background O
processes O
depending O
on O
the O
etiological O
factor O
and O
the O
character O
of O
lesion O
of O
the O
epithelium O
are O
divided O
into O
dyshormonal O
, O
inflammatory O
, O
and O
posttraumatic O
. O

The O
sense O
of O
self O
. O

Eleven O
strains O
of O
Fusarium O
poae O
and O
F O
. O
sporotrichioides O
from O
the O
U O
. O
S O
. O
S O
. O
R O
. O
and O
7 O
strains O
of O
these O
species O
and O
one O
of O
F O
. O
sporotrichioides O
var O
. O
tricinctum O
from O
U O
. O
S O
. O
A O
. O
and O
France O
have O
been O
compared O
as O
to O
their O
capacity O
to O
yield O
T I-GENE
- I-GENE
2 I-GENE
toxin I-GENE
. O

Current O
diagnostic O
uses O
of O
computerized O
tomography O
in O
clinical O
medicine O
. O

A O
follow O
- O
up O
study O
of O
22 O
patients O
with O
Ebstein O
' O
s O
anomaly O
has O
been O
performed O
. O

Deaths O
stopped O
11 O
hours O
after O
copper O
concentrations O
decreased O
below O
0 O
. O
2 O
ppm O
and O
signs O
of O
distress O
stopped O
in O
surviving O
pinfish O
by O
approximately O
6 O
hours O
after O
the O
last O
death O
. O

Recurrence O
of O
bladder O
tumors O
among O
the O
original O
9 O
cases O
has O
occurred O
only O
among O
the O
5 O
whose O
properdin I-GENE
levels O
remained O
below O
the O
median O
. O

Adaptation O
of O
taurocholate O
transport O
maximum O
to O
increased O
secretory O
load O
in O
the O
rat O
. O

Dangers O
in O
use O
of O
live O
- O
virus O
vaccines O
. O

Treatment O
with O
heparin O
, O
plasminogen I-GENE
activators O
and O
fibrinogenolytic O
agents O
was O
disappointing O
although O
renal O
function O
has O
stabilized O
in O
one O
patient O
on O
long O
term O
oral O
anticoagulant O
therapy O
. O

In O
diethyl O
ether O
solution O
the O
main O
peak O
is O
that O
of O
2 O
- O
benzylidenamio O
- O
1 O
- O
phenylpropane O
, O
which O
has O
a O
retention O
time O
of O
23 O
, O
2 O
minutes O
under O
the O
condition O
delineated O
. O

Amikacin O
was O
used O
in O
the O
treatment O
of O
56 O
serious O
gram O
- O
negative O
infections O
in O
54 O
patients O
of O
whom O
47 O
survived O
. O

The O
data O
normally O
available O
are O
insufficient O
and O
take O
no O
account O
of O
the O
direction O
of O
recirculation O
, O
which O
may O
be O
a O
determining O
factor O
. O

During O
activity O
III O
, O
one O
patient O
developed O
angina O
. O

Estimation O
of O
L O
- O
alanine O
in O
serum O
or O
plasma O
using O
the O
LKB O
reaction O
rate O
analyser O
. O

The O
acids O
were O
obtained O
by O
hydrolysis O
of O
the O
corresponding O
esters O
, O
and O
their O
anti O
- O
inflammatory O
activity O
was O
tested O
. O

Unrecognized O
amnionitis O
and O
prematurity O
: O
a O
preliminary O
report O
. O

Evaluation O
of O
the O
new O
Gravigard O
IUCD O
inserter O
. O

Bacterial O
meningitis O
secondary O
to O
abscess O
of O
the O
nasal O
septum O
. O

Serum I-GENE
amylase I-GENE
became O
markedly O
elevated O
( O
2 O
, O
624 O
CU O
/ O
100 O
ml O
), O
as O
did O
the O
serum O
FFA O
( O
29 O
. O
19 O
mEq O
/ O
liter O
). O

In O
the O
control O
preparation O
before O
weight O
was O
allowed O
to O
increase O
, O
isogravimetric O
capillary O
pressure O
( O
Pci O
) O
averaged O
8 O
mmHg O
lower O
than O
colloid O
osmotic O
pressure O
of O
the O
plasma O
( O
IIp O
). O

Infants O
who O
died O
in O
the O
first O
12 O
hours O
from O
' O
IVH O
only O
' O
had O
suffered O
severe O
birth O
asphyxia O
but O
in O
those O
who O
died O
later O
the O
main O
symptom O
was O
recurrent O
apnoea O
. O

The O
morphological O
effects O
of O
two O
snake O
venoms O
, O
N O
. O
naja O
and O
A O
. O
piscivorus O
, O
and O
of O
the O
Direct I-GENE
Lytic I-GENE
Factor I-GENE
and O
Phospholipase I-GENE
- I-GENE
A I-GENE
, O
compounds O
purified O
from O
N O
. O
naja O
crude O
venom O
, O
were O
investigated O
on O
lung O
and O
cremaster O
vessels O
of O
rats O
. O

Since O
GAGs O
are O
the O
components O
of O
cartilage O
matrix O
, O
the O
depletion O
of O
which O
is O
associated O
with O
osteoarthrosis O
, O
a O
method O
for O
measuring O
sulphated O
GAG O
synthesis O
in O
culture O
has O
been O
investigated O
. O

The O
length O
scales O
of O
the O
turbulence O
were O
also O
estimated O
: O
at O
a O
Reynolds O
number O
near O
4 O
, O
000 O
the O
macroscale O
is O
about O
1 O
. O
25 O
mm O
, O
the O
Taylor O
microscale O
is O
about O
0 O
. O
85 O
mm O
, O
and O
the O
Kolmogoroff O
scale O
is O
near O
0 O
. O
075 O
mm O
. O

Well O
- O
visualised O
arteriograms O
of O
the O
limbs O
can O
be O
obtained O
by O
xeroradiography O
after O
rapid O
manual O
injection O
of O
contrast O
- O
medium O
into O
an O
arm O
vein O
, O
as O
demonstrated O
in O
28 O
patients O
. O

No O
hypotension O
was O
noted O
in O
patients O
with O
toxemia O
and O
only O
2 O
ran O
a O
fever O
above O
37 O
. O
5 O
degrees O
C O
. O

The O
sera O
and O
nasal O
secretions O
of O
142 O
patients O
, O
who O
were O
positive O
in O
HD O
or O
mites O
skin O
test O
, O
were O
subjected O
to O
a O
radioallergosorbent O
test O
( O
RAST O
) O
for O
estimating O
the O
specific O
IgE I-GENE
antibody I-GENE
activity O
to O
mites O
. O

Wherever O
the O
site O
of O
the O
conditioning O
stimulation O
, O
these O
modifications O
disappeared O
after O
ischaemia O
of O
the O
leg O
. O

Diallylnitrosamine O
( O
DAN O
), O
one O
of O
the O
few O
nitrosamines O
tested O
thus O
far O
that O
has O
not O
induced O
neoplasms O
in O
rats O
, O
caused O
a O
high O
incidence O
of O
respiratory O
tract O
tumors O
in O
Syrian O
golden O
hamsters O
treated O
sc O
with O
single O
or O
weekly O
doses O
of O
the O
compound O
. O

Near O
term O
, O
under O
experimental O
conditions O
, O
maternal O
and O
fetal O
blood O
gases O
, O
pH O
, O
uterine O
and O
umbilical O
blood O
flows O
were O
measured O
or O
calculated O
. O

Haemodynamic O
responses O
to O
antagonism O
of O
bocurarine O
block O
with O
atropine O
- O
neostigmine O
mixture O
in O
children O
. O

The O
mechanism O
by O
which O
large O
molecules O
, O
such O
as O
the O
diphosphonate O
99mTc O
- O
labeled O
EHDP O
or O
99mTc O
- O
labeled O
pyrophosphate O
, O
pass O
through O
capillaries O
in O
bone O
is O
by O
passive O
diffusion O
. O

Twenty O
- O
nine O
days O
after O
injection O
of O
5 O
. O
8 O
mCi O
of O
Tc O
- O
99m O
, O
which O
gives O
28 O
rads O
to O
the O
testis O
, O
the O
number O
of O
sperm O
hads O
decreased O
to O
70 O
% O
of O
control O
. O

Self O
- O
emasculation O
is O
the O
end O
result O
of O
an O
unusual O
psychiatric O
disorder O
, O
which O
initially O
requires O
surgical O
treatment O
. O

Possibility O
of O
a O
TSH I-GENE
- O
Screening O
method O
for O
detection O
of O
hypothyroidism O
in O
the O
newborn O

Thus O
analysis O
indicated O
no O
reliable O
evidence O
that O
conscious O
presleep O
suggestions O
become O
incorporated O
into O
dream O
content O
. O

The O
prevalence O
of O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
( O
HBsAg I-GENE
) O
and O
anti I-GENE
- I-GENE
HBs I-GENE
was O
determined O
by O
a O
sensitive O
double O
- O
antibody O
radio O
- O
immunoassay O
technique O
in O
a O
series O
of O
patients O
with O
chronic O
liver O
diseases O
. O

It O
was O
concluded O
that O
patients O
with O
acute O
respiratory O
failure O
requiring O
artificial O
ventilation O
have O
two O
componenents O
of O
the O
pulmonary O
shunt O
, O
one O
parallel O
with O
and O
the O
other O
inversely O
related O
with O
the O
PAO2 O
. O

Decreased O
cardiac O
glycogen O
following O
phenformin O
injection O
in O
hyperglycemic O
, O
hyperinsulinemic O
anaesthetized O
rats O
. O

Biological O
evaluation O
of O
mibolerone O
in O
the O
female O
Beagle O
. O

Levels O
of O
both O
PGF O
and O
PGFM O
were O
significantly O
higher O
during O
early O
spontaneous O
labour O
, O
at O
a O
cervical O
dilatation O
of O
less O
than O
4 O
cm O
, O
than O
before O
the O
onset O
of O
labour O
. O

The O
most O
common O
cause O
of O
renal O
deterioration O
in O
the O
spinal O
cord O
injured O
patient O
is O
irreversible O
vesicoureteral O
reflux O
. O

Propranolol O
( O
Inderal O
) O
administered O
in O
a O
dose O
which O
blocks O
the O
beta O
- O
adrenergic O
apparatus O
of O
the O
heart O
prevents O
the O
development O
of O
the O
positive O
inotropic O
effect O
of O
therapeutic O
doses O
of O
strophanthin O
K O
on O
a O
hypodynamic O
left O
ventricular O
myocardium O
. O

Recent O
studies O
have O
shown O
the O
rat O
larynx O
to O
be O
an O
important O
organ O
in O
the O
evaluation O
of O
irritancy O
of O
inhaled O
materials O
. O

Scanning O
electron O
microscopic O
investigations O
on O
the O
formation O
of O
Reissner O
' O
s O
fiber O
in O
Rattus O
rattus O

Feeding O
behavior O
, O
circannual O
body O
weight O
and O
hibernation O
rhythms O
in O
European O
hamsters O
lesioned O
in O
the O
noradrenergic O
ascending O
bundles O

Role O
of O
the O
infectious O
- O
disease O
specialist O
of O
a O
polyclinic O
in O
reducing O
the O
incidence O
of O
communicable O
diseases O

These O
observed O
drug O
interactions O
, O
plus O
the O
known O
effect O
of O
probenecid O
to O
block O
secretion O
of O
PZA O
, O
have O
to O
be O
considered O
in O
evaluating O
the O
effect O
of O
the O
two O
drugs O
given O
together O
, O
compared O
to O
the O
effect O
of O
each O
drug O
given O
separately O
. O

Circulatory O
arrest O
in O
the O
operating O
room O
. O

At O
a O
systolic O
blood O
pressure O
( O
BP O
) O
of O
60 O
mmHg O
, O
C02 O
responsiveness O
was O
abolished O
, O
but O
was O
maintained O
at O
higher O
levels O
of O
BP O
. O

Iodine O
- O
123 O
was O
satisfactorily O
imaged O
only O
with O
the O
MEC O
and O
pinhole O
collimators O
, O
which O
in O
turn O
yielded O
MTF O
values O
comparable O
to O
those O
measured O
for O
99mTc O
. O

Petrous O
meningioma O
en O
plaque O
presenting O
as O
a O
right O
middle O
ear O
tumor O
. O

The O
difficulties O
to O
analyse O
prostaglandins O
( O
PG O
) O
by O
gas O
- O
liquid O
chromatography O
are O
mainly O
due O
to O
the O
lack O
of O
sensitivity O
of O
the O
gas O
- O
chromatograph O
itself O
( O
higher O
than O
200 O
ng O
) O
and O
to O
the O
poor O
resolution O
of O
the O
packed O
columns O
. O

On O
cessation O
of O
steroid O
therapy O
the O
patient O
was O
noted O
to O
have O
radiologic O
manifestations O
of O
hypertrophic O
osteoarthropathy O
( O
HOA O
) O
as O
well O
as O
clinical O
and O
laboratory O
features O
of O
rheumatoid O
arthritis O
( O
RA O
). O

The O
effect O
of O
food O
on O
procainamide O
absorption O
. O

After O
giving O
a O
survey O
on O
the O
situation O
of O
antibiotic O
resistance O
in O
the O
region O
of O
Northern O
Bavaria O
during O
1973 O
/ O
74 O
and O
comparing O
the O
activity O
of O
a O
sulfamethoxazole O
( O
SMZ O
) O
trimethoprim O
( O
TMP O
) O
combination O
to O
other O
commonly O
used O
antibiotics O
and O
chemotherapeutic O
agents O
, O
the O
results O
of O
tests O
with O
the O
new O
combination O
of O
N1 O
-( O
4 O
, O
5 O
- O
dimethyl O
- O
2 O
- O
oxazolyl O
)- O
sulfanilamide O
) O
( O
sulfamoxole O
) O
and O
2 O
, O
4 O
- O
diamino O
- O
5 O
-( O
3 O
, O
4 O
, O
5 O
- O
trimethoxy O
- O
benzyl O
)- O
pyrimidine O
( O
trimethoprim O
) O
at O
a O
ratio O
of O
5 O
: O
1 O
( O
CN O
3123 O
; O
Nevin O
, O
Supristol O
) O
are O
compared O
to O
those O
of O
tests O
with O
TMP O
/ O
SMZ O
. O

RESULTS O
: O
Total O
IgE I-GENE
levels O
showed O
a O
tendency O
to O
diminish O
. O

Does O
afferent O
loop O
syndrome O
exist O
?] O
It O
is O
the O
author O
' O
s O
opinion O
that O
diagnosis O
of O
the O
" O
adducent O
loop O
syndrome O
" O
is O
unlikely O
to O
be O
correct O
in O
patients O
subjected O
to O
Billroth O
- O
II O
gastrectomy O
. O

Letter O
: O
Is O
actinic O
( O
solar O
) O
damage O
the O
provoking O
cause O
of O
' O
post O
- O
inflammatory O
elastolysis O
and O
cutis O
laxa O
( O
PECL O
)'? O

These O
data O
suggest O
that O
spontaneous O
recovery O
of O
central O
respiratory O
function O
after O
intoxication O
with O
Soman O
or O
Sarin O
may O
not O
be O
related O
to O
the O
return O
of O
AChE I-GENE
activity O
. O

Batch O
cultures O
of O
S O
. O
mutans O
serotype O
a O
demonstrated O
no O
growth O
on O
MSB O
agar O
. O

Also O
, O
samples O
of O
serum O
were O
absorbed O
with O
the O
various O
solid O
- O
phase O
allergens O
and O
the O
reactivity O
of O
the O
remaining O
IgE I-GENE
antibodies I-GENE
was O
determined O
. O

Crisis O
of O
the O
therapeutic O
community O
in O
Great O
Britain O

Pregnant O
women O
at O
term O
had O
the O
lowest O
levels O
of O
antithrombin I-GENE
III I-GENE
. O

Hematology O
problem O
of O
the O
month O
: O
band O
or O
seg O
? O

It O
is O
possible O
that O
cyclic O
variations O
in O
heme O
turnover O
are O
related O
to O
changes O
in O
erythrocyte O
characteristics O
during O
the O
progesterone O
phase O
. O

Haemodilution O
in O
cardiopulmonary O
bypass O
using O
a O
gelatine O
derivative O
for O
priming O
. O

Extramedullary O
plasmacytoma O
of O
the O
parotid O
gland O

I O
. O

The O
recovered O
calves O
were O
tested O
for O
immunity O
to O
homologous O
severe O
challenge O
, O
50 O
or O
73 O
days O
after O
the O
first O
infection O
. O

The O
performance O
of O
three O
commonly O
used O
chemical O
cartridge O
respirators O
for O
SO2 O
was O
measured O
under O
working O
conditions O
in O
a O
copper O
smelter O
. O

The O
neuroleptic O
- O
induced O
increase O
in O
central O
DA O
turnover O
( O
an O
indicator O
for O
the O
degree O
of O
DA I-GENE
receptor I-GENE
blocking O
) O
was O
found O
to O
be O
positively O
correlated O
with O
the O
therapeutic O
effect O
of O
neuroleptics O
and O
the O
development O
of O
hypokinetic O
- O
rigid O
symptoms O
. O

Rainbow O
trout O
were O
obtained O
from O
a O
commercial O
trout O
farm O
, O
kept O
in O
running O
water O
and O
feeding O
in O
experimental O
pellets O
for O
4 O
to O
8 O
weeks O
. O

Stimulation O
of O
macrophage O
function O
by O
killed O
Bordetella O
pertussis O
cells O
did O
not O
show O
any O
beneficial O
effect O
as O
an O
increased O
susceptibility O
became O
apparent O
. O

Primary O
amenorrhoea O
in O
a O
phenotypically O
female O
individual O
with O
a O
karyotype O
46 O
, O
xy O
and O
bilateral O
gonadoblastoma O

Toward O
absolute O
methods O
in O
clinical O
chemistry O
: O
application O
of O
mass O
fragmentography O
to O
high O
- O
accuracy O
analyses O
. O

Application O
of O
the O
2 O
- O
deoxy O
- O
D O
- O
glucose O
method O
to O
the O
coupling O
of O
cerebral O
metabolism O
and O
blood O
flow O
. O

Serum O
gastrin I-GENE
levels O
did O
not O
change O
in O
either O
group O
; O
however O
, O
background O
serum O
gastrin I-GENE
concentrations O
were O
significantly O
greater O
for O
V O
& O
P O
patients O
than O
V O
& O
A O
patients O
throughout O
the O
study O
. O

Efferent O
projections O
of O
the O
ventral O
portion O
of O
the O
putamen O
to O
the O
frontal O
, O
parietal O
and O
temporal O
regions O
of O
the O
cat O
cerebral O
cortex O

Preflight O
, O
inflight O
, O
and O
postflight O
exercise O
response O
tests O
were O
conducted O
on O
the O
astronauts O
of O
the O
second O
Skylab O
mission O
( O
Skylab O
3 O
) O
as O
part O
of O
an O
evaluation O
of O
physiological O
adaptation O
to O
long O
- O
term O
weightlessness O
. O

Mean O
corpuscular I-GENE
hemoglobin I-GENE
concentrations O
remained O
normal O
for O
48 O
h O
and O
then O
decreased O
in O
both O
groups O
, O
the O
CO2 O
group O
showing O
the O
larger O
decrease O
. O

All O
Cu O
values O
obtained O
from O
the O
organs O
investigated O
had O
reached O
a O
saturation O
level O
at O
8 O
mug O
Cu O
/ O
g O
diet O
with O
the O
exception O
of O
the O
values O
for O
body O
Cu O
found O
in O
the O
dams O
that O
were O
killed O
on O
the O
day O
of O
delivery O
. O

The O
effect O
of O
calcitonin I-GENE
, O
a O
large O
amount O
of O
calcium O
given O
orally O
, O
pentagastrin O
and O
glucagon I-GENE
on O
plasma O
47Ca O
radioactivity O
curves O
in O
subjects O
pretreated O
with O
47Ca O
was O
examined O
. O

State O
of O
the O
body O
in O
disorders O
of O
diurnal O
physiological O
rhythms O
and O
long O
- O
term O
hypokinesia O

Oxygen O
tension O
of O
the O
small O
lymph O
vessels O
( O
PLO2 O
) O
of O
the O
rabbit O
hind O
limb O
was O
measured O
with O
both O
a O
flow O
- O
through O
micro O
chamber O
and O
a O
polarographic O
catheter O
- O
tip O
oxygen O
electrode O
to O
obtain O
experimental O
data O
on O
the O
source O
of O
oxygen O
in O
the O
lymph O
. O

The O
response O
of O
the O
plasma I-GENE
fibrinogen I-GENE
level O
to O
the O
subucutaneous O
injection O
of O
turpentine O
and O
to O
the O
intravenous O
injection O
of O
endotoxin O
was O
measured O
in O
normal O
rabbits O
and O
in O
rabbits O
made O
granulocytopenic O
and O
thrombocytopenic O
with O
busulfan O
. O

Constantly O
rectilinear O
pressure O
curves O
without O
uterine O
activities O
are O
interpreted O
as O
characteristic O
tocographic O
criteria O
of O
an O
advanced O
ectopic O
gravidity O
. O

Since O
myoglobin I-GENE
is O
co O
- O
extracted O
with O
the O
hemoglobin I-GENE
, O
the O
2 O
heme O
pigments O
are O
separated O
in O
one O
portion O
of O
the O
extract O
by O
precipitating O
the O
hemoglobin I-GENE
in O
an O
85 O
% O
( O
NH4 O
) O
2SO4 O
solution O
. O

Considering O
these O
sources O
of O
error O
some O
of O
the O
variability O
in O
the O
present O
investigation O
might O
be O
avoided O
by O
systematic O
instructions O
. O

E O
50 O
, O
843 O
( O
1994 O
)]. O

Six O
patients O
with O
the O
diagnosis O
of O
acute O
mania O
were O
treated O
with O
high O
doses O
of O
the O
beta O
- O
adrenergic O
blocking O
agent O
propranolol O
. O

Effect O
of O
trauma O
on O
plasma I-GENE
glucagon I-GENE
and O
insulin I-GENE
concentrations O
in O
sheep O
. O

With O
the O
help O
of O
a O
nomogram O
one O
can O
read O
off O
the O
refraction O
, O
when O
axis O
length O
and O
corneal O
curvature O
are O
known O
. O

This O
up O
- O
grading O
of O
the O
final O
score O
by O
the O
CA O
component O
is O
greater O
( O
3 O
- O
8 O
%) O
in O
the O
less O
able O
students O
with O
scores O
below O
the O
mean O
level O
. O

Compared O
to O
controls O
, O
both O
UB O
and O
OCS O
rats O
showed O
a O
small O
but O
significant O
post O
- O
operative O
reduction O
in O
the O
nocturnality O
of O
drinking O
. O

Effect O
of O
indomethacin O
on O
coronary O
circulation O
: O
effect O
on O
ECG O
tracing O

Dual O
innervation O
of O
fast O
fibers O
in O
trunk O
muscles O
of O
lamprey O
larvae O

The O
feed O
consumed O
which O
was O
lowered O
by O
25 O
% O
initially O
, O
did O
not O
alter O
later O
. O

Certain O
characteristics O
of O
eye O
changes O
in O
patients O
with O
pheochromocytoma O
including O
Sipple O
' O
s O
syndrome O

The O
color O
- O
word O
interference O
effect O
previously O
reported O
with O
normal O
populations O
when O
given O
the O
Stroop O
test O
was O
demonstrated O
for O
this O
retarded O
sample O
using O
a O
special O
format O
. O

It O
was O
found O
that O
under O
the O
selected O
conditions O
a O
linear O
dependence O
exists O
between O
the O
betaI O
% O
value O
and O
lgC O
within O
the O
range O
of O
0 O
. O
5 O
-- O
10 O
mug O
ruscogenin O
. O

The O
influence O
of O
adrenergic O
nerves O
of O
the O
response O
of O
blood O
vessels O
in O
the O
rabbit O
ear O
to O
2 I-GENE
-- I-GENE
phenylalanine I-GENE
- I-GENE
8 I-GENE
- I-GENE
lysine I-GENE
vasopressin I-GENE
( O
Octapressin I-GENE
). O

Potscoital O
test O

I O
. O

When O
a O
tumour O
is O
present O
nipple O
discharge O
is O
of O
little O
importance O
for O
the O
diagnosis O
and O
treatment O
. O

Studies O
of O
biochemical O
and O
morphological O
changes O
( O
between O
normal O
and O
treated O
animals O
) O
show O
that O
chrysotile O
induces O
an O
increase O
in O
the O
lung O
free O
cell O
population O
and O
pulmonary O
surfactant O
levels O
. O

Infrared O
measurements O
of O
temperature O
changes O
and O
estimates O
of O
the O
heating O
produced O
at O
the O
mical O
. O

Who O
says O
' O
National O
Health O
Dis O
- O
service O
'. O

Is O
criticism O
of O
patient O
care O
justified O
and O
does O
it O
have O
educational O
value O
? O
Patients O
' O
criticism O
contributes O
to O
improved O
patient O
care O

Critique O
of O
" O
Interactive O
Effects O
of O
Test O
Anxiety O
and O
Credit O
/ O
No O
Credit O
or O
A O
- O
F O
Grade O
Condition O
upon O
Short O
- O
term O
and O
Long O
- O
term O
Recall O
of O
Course O
Information O
. O

These O
studies O
have O
shown O
that O
the O
majority O
of O
tested O
staphylococci O
were O
resistant O
to O
penicillin O
G O
, O
erythromycin O
, O
and O
produced O
beta I-GENE
- I-GENE
lactamase I-GENE
. O

Since O
1968 O
, O
a O
steep O
decrease O
in O
the O
number O
of O
strains O
resistant O
to O
three O
or O
more O
antibiotics O
( O
multiple O
- O
resistant O
) O
and O
in O
strains O
of O
the O
83A O
complex O
was O
noticed O
. O

Improvement O
of O
nursing O
instruction O
to O
be O
given O
at O
the O
time O
of O
discharge O
from O
the O
ward O
for O
premature O
infants O

No O
difference O
in O
the O
clinical O
acceptability O
could O
be O
ascertained O
between O
the O
two O
groups O
. O

After O
90 O
d O
a O
subsurface O
, O
radiolucent O
caries O
- O
like O
lesion O
was O
observed O
in O
two O
specimens O
only O
. O

The O
contraceptive O
pattern O
of O
157 O
women O
was O
analysed O
and O
13 O
. O
8 O
percent O
were O
using O
inefficient O
methods O
. O

Plethysmographic O
technique O
and O
indirect O
blood O
pressure O
recordings O
were O
used O
. O

I O
. O

The O
second O
and O
third O
responded O
similarly O
to O
either O
a O
combined O
cyclophosphamide O
+ O
antilymphocyte I-GENE
globulin I-GENE
( O
ALG I-GENE
) O
treatment O
or O
to O
ALG I-GENE
administration O
preceded O
by O
a O
small O
dosage O
of O
cyclophosphamide O
, O
which O
had O
proved O
ineffective O
when O
administered O
alone O
. O

Evidence O
is O
presented O
that O
Leber O
' O
s O
military O
aneurysm O
retinitis O
is O
not O
a O
separate O
entity O
but O
a O
special O
form O
of O
Coats O
' O
disease O
. O

Fibrin I-GENE
cloaking O
along O
the O
catheter O
was O
found O
in O
20 O
patients O
studied O
by O
pull O
- O
out O
arteriography O
and O
was O
unassociated O
with O
clinical O
symptoms O
. O

The O
influence O
of O
a O
mobile O
pupil O
on O
the O
response O
in O
the O
DC O
- O
ERG O
is O
demonstrated O
. O

A O
newly O
synthesized O
anti O
- O
inflammatory O
agent O
, O
Y O
- O
8004 O
demonstrated O
a O
greater O
inhibition O
than O
did O
indomethacin O
( O
IM O
). O
on O
inflammatory O
response O
such O
as O
ultraviolet O
erythema O
in O
guinea O
pigs O
, O
carrageenin O
edema O
, O
evans O
blue O
and O
carrageenin O
- O
induced O
pleuritis O
and O
acetic O
acid O
- O
induced O
peritonitis O
in O
rats O
. O

As O
stands O
shifted O
in O
dominance O
from O
pine O
to O
fir O
with O
age O
, O
subalpine O
fir O
appeared O
to O
maintain O
gradually O
increasing O
rates O
of O
whole O
- O
forest O
productivity O
until O
stands O
were O
approximately O
400 O
years O
old O
. O

Alpha I-GENE
- I-GENE
1 I-GENE
antitrypsin I-GENE
and O
Indian O
childhood O
cirrhosis O
. O

Lymphocyte O
subpopulations O
, O
serum I-GENE
IgE I-GENE
and O
total O
eosinophil O
counts O
in O
patients O
with O
bronchial O
asthma O
. O

A O
range O
of O
normal O
ventricular O
measurements O
for O
the O
EMI O
scan O
is O
suggested O
. O

A O
comparison O
of O
physical O
and O
cytogenetic O
estimates O
of O
radiation O
dose O
in O
patients O
treated O
with O
iodine O
- O
131 O
for O
thyroid O
carcinoma O
. O

Technique O
for O
obtaining O
refined O
ceramics O
with O
dense O
mass O

Mean O
total O
lung O
capacity O
, O
functional O
residual O
capacity O
, O
and O
residual O
volume O
increased O
significantly O
, O
and O
the O
mean O
closing O
volume O
, O
the O
lung O
volume O
above O
residual O
volume O
at O
which O
phase O
IV O
begins O
, O
decreased O
significantly O
with O
11 O
cm O
H20 O
continuous O
positive O
airway O
pressure O
; O
differences O
at O
5 O
cm O
H20 O
were O
not O
significant O
. O

Current O
status O
of O
zinc O
deficiency O
in O
the O
pathogenesis O
of O
neurological O
, O
dermatological O
and O
musculoskeletal O
disorders O
. O

Calcium O
and O
phosphorus O
metabolism O
in O
chronic O
uremia O
. O

Modern O
studies O
, O
conducted O
with O
Delta O
- O
9 O
- O
THC O
, O
in O
healthy O
voluntaries O
, O
again O
suggest O
the O
comparison O
or O
even O
the O
identity O
of O
the O
modifications O
caused O
by O
cannabis O
with O
sleep O
and O
dream O
. O

The O
correcting O
action O
of O
tropatepine O
hydrochloride O
upon O
the O
extrapyramidal O
effects O
induced O
by O
neuroleptics O
has O
been O
studied O
in O
32 O
acute O
psychotic O
states O
. O

Epididymal O
growth O
was O
retarded O
in O
animals O
maintained O
solely O
on O
chickpea O
haulm O
and O
improved O
with O
supplementation O
. O

Two O
patients O
were O
treated O
with O
both O
regimens O
. O

Results O
obtained O
for O
chloramphenicol O
- O
containing O
preparations O
are O
presented O
, O
and O
both O
dissolution O
curves O
and O
cup O
- O
plate O
assays O
demonstrate O
that O
chloramphenicol O
has O
far O
superior O
release O
( O
and O
hence O
activity O
) O
from O
creams O
than O
from O
ophthalmic O
ointments O
. O

IgG I-GENE
levels O
of O
1 O
/ O
100 O
were O
present O
in O
only O
four O
out O
of O
ten O
samples O
obtained O
150 O
days O
after O
the O
clinical O
onset O
. O

Letter O
: O
Perspectives O
in O
bone O
marrow O
transplantation O
. O

Assessment O
of O
the O
carcinogenicity O
of O
non O
- O
nutritive O
sweetners O
II O
: O
Cyclamates O
and O
cyclohexylamine O
. O

The O
discordant O
behaviour O
in O
weakly O
infected O
mice O
was O
due O
to O
the O
occurrence O
in O
some O
animals O
of O
a O
second O
phase O
of O
more O
rapid O
increase O
of O
the O
parasitemia O
. O

Residual O
amphotericin O
B O
was O
detected O
in O
the O
feces O
of O
the O
mice O
only O
while O
they O
were O
receiving O
the O
0 O
. O
3 O
mg O
/ O
ml O
dose O
level O
. O

There O
was O
a O
slight O
increase O
in O
total O
transferrin I-GENE
2 O
hr O
after O
1 O
tablet O
and O
values O
remained O
high O
throughout O
the O
experiment O
. O

Following O
intravenous O
administration O
, O
the O
myocardial O
concentration O
of O
tracer O
thallium O
- O
201 O
, O
potassium O
- O
43 O
, O
and O
rubidium O
- O
81 O
were O
determined O
in O
mice O
; O
thallium O
was O
present O
in O
the O
greatest O
concentration O
in O
the O
myocardium O
( O
2 O
. O
08 O
% O
compared O
1 O
. O
25 O
% O
for O
potassium O
and O
1 O
. O
15 O
% O
for O
rubidium O
at O
10 O
minutes O
). O

Thromboplastin I-GENE
time O
, O
partial O
thromboplastin I-GENE
time O
, O
thrombin I-GENE
time O
, O
heat O
- O
dependent O
fibrin I-GENE
, O
clot O
retraction O
, O
and O
clotting I-GENE
factors I-GENE
II I-GENE
, I-GENE
V I-GENE
, I-GENE
VIII I-GENE
, I-GENE
IX I-GENE
, I-GENE
X I-GENE
, O
and O
the O
platelet O
count O
were O
determined O
. O

The O
data O
support O
the O
notion O
that O
suppression O
of O
images O
during O
binocular O
rivalry O
is O
independent O
in O
both O
eyes O
. O

Glycogen O
utilization O
was O
increased O
, O
but O
tissue O
levels O
of O
creatine O
phosphate O
, O
ATP O
, O
and O
lactate O
were O
similar O
to O
those O
in O
hearts O
receiving O
normal O
flow O
. O

The O
records O
from O
1948 O
through O
1967 O
of O
344 O
previously O
untreated O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
oropharynx O
, O
supraglottic O
larynx O
and O
hypopharynx O
who O
had O
clinically O
positive O
cervical O
lymph O
node O
metastases O
staged O
N1 O
, O
N2A O
, O
or O
N2B O
, O
and O
whose O
initial O
neck O
treatment O
consisted O
of O
external O
radiation O
therapy O
alone O
were O
reviewed O
. O

With O
0 O
. O
5 O
vol O
.-%, O
the O
corresponding O
values O
were O
345 O
mumol O
/ O
1 O
( O
5 O
. O
72 O
mg O
/ O
100 O
ml O
) O
and O
137 O
mumol O
/ O
1 O
( O
2 O
. O
25 O
mg O
/ O
100 O
ml O
) O
respectively O
. O

The O
authors O
describe O
the O
technique O
of O
transverse O
axial O
tomography O
of O
the O
spine O
and O
give O
a O
detailed O
description O
of O
the O
axial O
anatomy O
of O
the O
normal O
lumbar O
spine O
from O
L O
- O
4 O
to O
the O
sacrum O
. O

Owing O
to O
parental O
attitude O
, O
a O
low O
protein O
diet O
( O
1 O
- O
5 O
g O
/ O
kg O
) O
was O
introduced O
only O
late O
. O

In O
none O
of O
the O
44 O
type O
I O
attacks O
and O
29 O
type O
II O
attacks O
which O
were O
recorded O
did O
circulatory O
changes O
; O
the O
latter O
were O
different O
in O
the O
two O
groups O
. O

A O
clinically O
useful O
diagnostic O
method O
has O
been O
developed O
for O
detecting O
and O
quantitating O
periods O
of O
apnea O
in O
pediatric O
patients O
. O

The O
other O
hypoglycaemic O
patient O
showed O
an O
exaggerated O
insulin I-GENE
release O
in O
response O
to O
tolbutamide O
. O

Nerve O
stimulation O
( O
1 O
. O
5 O
- O
12 O
cycles O
/ O
s O
) O
produced O
frequency O
- O
dependent O
reductions O
in O
CBF O
, O
a O
decrease O
of O
50 O
percent O
occurring O
with O
the O
highest O
frequency O
. O

Effect O
of O
ingestion O
of O
Norbiogest O
during O
the O
quiescent O
period O
of O
the O
genital O
organs O

Risk O
of O
infection O
in O
the O
treatment O
of O
fractures O

Bulbar O
pouches O
were O
perfused O
with O
solutions O
of O
0 O
. O
9 O
% O
Na O
C1 O
, O
0 O
. O
1 O
N O
HC1 O
, O
40 O
% O
glucose O
, O
40 O
% O
NaC1 O
, O
and O
40 O
% O
peptone O
or O
with O
0 O
. O
1 O
% O
solutions O
of O
acetylcholine O
chloride O
. O

Liver O
microsomes O
of O
the O
shag O
showed O
smaller O
than O
8 O
% O
of O
the O
epoxide I-GENE
hydrase I-GENE
activity O
and O
smaller O
than O
14 O
% O
of O
the O
hydroxylating O
capacity O
of O
liver O
microsomes O
from O
the O
rat O
. O

Prolonged O
heavy O
work O
effected O
an O
increase O
of O
10 O
. O
3 O
plus O
or O
minus O
0 O
. O
9 O
mmHg O
in O
in O
vivo O
P50 O
( O
7 O
. O
30 O
PH O
- O
v O
, O
41 O
degrees O
C O
- O
v O
, O
and O
45 O
Pv O
- O
CO2 O
); O
due O
entirely O
to O
the O
additive O
effects O
of O
increased O
venous O
temperature O
and O
[ O
H O
+]. O

A O
clinical O
, O
serological O
and O
prognostic O
study O

The O
American O
Burkitt O
Lymphoma O
Registry O
: O
a O
progress O
report O
. O

Vitrectomy O
with O
an O
alternative O
instrument O
system O
. O

The O
metabolic O
clearance O
rate O
of O
progesterone O
was O
295 O
+/- O
49 O
( O
S O
. O
E O
.) O
1 O
/ O
day O
. O

This O
sequence O
is O
almost O
identical O
with O
that O
of O
human I-GENE
luteinizing I-GENE
hormone I-GENE
( O
Sairam O
, O
M O
. O

The O
mean O
plasma O
sodium O
concentration O
which O
was O
135 O
. O
95 O
(+/- O
SD O
4 O
. O
14 O
) O
mEq O
/ O
kg O
before O
diuretic O
treatment O
was O
significantly O
decreased O
during O
treatment O
to O
129 O
. O
19 O
(+/- O
SD O
2 O
. O
77 O
) O
mEq O
/ O
kg O
, O
P O
less O
than O
0 O
. O
001 O
. O

Editorial O
: O
Low O
- O
dose O
heparin O
and O
the O
prevention O
of O
venous O
thromboembolic O
disease O
. O

At O
the O
very O
high O
dose O
levels O
used O
, O
sodium O
saccharin O
and O
sodium O
cyclamate O
were O
weak O
solitary O
carcinogens O
producing O
4 O
/ O
253 O
and O
3 O
/ O
228 O
bladder O
tumours O
respectively O
, O
and O
the O
first O
of O
these O
tumours O
did O
not O
appear O
for O
more O
than O
80 O
weeks O
. O

Effects O
of O
perceptual O
salience O
on O
the O
matrix O
task O
performance O
of O
four O
- O
and O
six O
- O
year O
- O
old O
children O
. O

Glucose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
G I-GENE
- I-GENE
6 I-GENE
- I-GENE
PD I-GENE
) O
deficiency O
in O
the O
newborn O
. O

The O
eluting O
solvent O
was O
methanol O
- O
chloroform O
( O
10 O
+ O
90 O
) O
at O
a O
flow O
rate O
of O
2 O
. O
0 O
ml O
/ O
min O
. O

The O
bronchial O
epithelia O
of O
all O
smoke O
- O
exposed O
animals O
were O
hyperplastic O
, O
and O
their O
ultrastructure O
showed O
invaginations O
, O
tilt O
of O
nuclear O
axes O
, O
an O
increase O
in O
the O
number O
and O
size O
of O
lysosomes O
and O
multivesiculated O
bodies O
, O
and O
increased O
numbers O
of O
enlarged O
intramitochondrial O
granules O
. O

The O
routine O
administration O
of O
fat O
- O
soluble O
vitamins O
appears O
unnecessary O
but O
it O
is O
prudent O
to O
measure O
prothrombin I-GENE
time O
and O
serum O
vitamins O
A O
and O
E O
at O
intervals O
. O

Prostaglandins O
F O
( O
PGF O
) O
were O
measured O
in O
uterine O
vein O
, O
ovarian O
artery O
, O
and O
jugular O
vein O
plasma O
and O
in O
the O
endometrial O
tissues O
at O
various O
times O
during O
the O
bovine O
estrous O
cycle O
, O
and O
were O
compared O
to O
peripheral O
plasma O
progesterone O
levels O
. O

Before O
this O
date O
, O
the O
drug O
directly O
inhibits O
fetal O
weight O
gain O
, O
whereas O
the O
sensitivity O
of O
the O
placenta O
is O
only O
transient O
at O
day O
16 O
resulting O
in O
maximum O
weight O
decrease O
of O
this O
organ O
24 O
h O
later O
. O

Groups O
of O
ten O
dependent O
and O
ten O
saline O
mice O
were O
singly O
tested O
in O
both O
light O
and O
dark O
conditions O
in O
each O
of O
five O
covered O
cylinders O
( O
2 O
- O
23 O
in O
high O
). O

The O
effects O
initiated O
from O
the O
nucleus O
accumbens O
septi O
were O
most O
marked O
. O

The O
appearance O
of O
dyskinetic O
movement O
disorders O
in O
humans O
following O
the O
chronic O
use O
of O
levodopa O
or O
amphetamine O
may O
be O
a O
manifestation O
of O
similarly O
increased O
dopamine I-GENE
receptor I-GENE
site I-GENE
sensitivity O
within O
the O
striatum O
. O

Association O
with O
HL I-GENE
- I-GENE
A I-GENE
W I-GENE
- I-GENE
27 I-GENE
. O

Letter O
: O
Lactose O
tolerance O
tests O
as O
a O
predictor O
of O
milk O
tolerance O
. O

Retinoblastoma O
: O
a O
study O
of O
natural O
history O
and O
prognosis O
of O
268 O
cases O
. O

Like O
pineal O
melatonin O
, O
serum O
melatonin O
was O
high O
at O
mid O
- O
dark O
and O
low O
at O
mid O
- O
light O
. O

D O
. O

Atherosclerosis O

The O
authors O
concluded O
that O
ultrasonic O
Doppler O
- O
cardiography O
can O
be O
used O
for O
measuring O
the O
relative O
changes O
in O
the O
stroke O
volume O
. O

The O
attainment O
of O
sexual O
maturity O
in O
terms O
of O
secondary O
sexual O
characteristics O
, O
the O
production O
of O
spermatozoa O
in O
the O
male O
, O
and O
the O
cyclical O
female O
pattern O
with O
release O
of O
ova O
are O
end O
- O
points O
of O
the O
developmental O
process O
. O

However O
, O
a O
10 O
-- O
15 O
% O
lengthening O
of O
the O
partial O
thromboplastin I-GENE
time O
is O
evident O
after O
24 O
hours O
of O
storage O
. O

Caution O
should O
be O
exercised O
in O
the O
use O
of O
these O
dyes O
for O
lymphograms O
. O

This O
reveals O
a O
new O
test O
for O
short O
saphenous O
incompetence O
and O
shows O
that O
14 O
per O
cent O
of O
varices O
stem O
from O
a O
saphenopopliteal O
reflux O
. O

Three O
groups O
of O
patients O
who O
had O
undergone O
subtotal O
thyroidectomy O
for O
Graves O
' O
s O
disease O
, O
toxic O
multinodular O
goitre O
, O
or O
euthyroid O
multinodular O
goitre O
12 O
to O
15 O
years O
before O
and O
in O
whom O
a O
normal O
serum O
thyroxine O
( O
T O
- O
4 O
) O
level O
was O
found O
were O
each O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
a O
normal O
or O
a O
raised O
serum O
thyrotrophin I-GENE
concentration O
. O

Routine O
isotope O
cystography O
using O
99M O
Tc O
sulfur O
colloid O
for O
detection O
and O
follow O
- O
up O
of O
vesico O
- O
ureteral O
reflux O

Air O
ion O
action O
on O
bacteria O
. O

No O
evidence O
of O
either O
positive O
or O
negative O
chemography O
was O
found O
. O

The O
interpretation O
of O
antibiotic O
disc O
sensitivities O
. O

Following O
retransfusion O
, O
the O
affected O
epithelial O
lining O
appeared O
greatly O
distended O
over O
the O
oedematous O
lamina O
propria O
, O
with O
almost O
complete O
loss O
of O
structural O
detail O
. O

A O
study O
of O
chromosomes O
of O
lymphocytes O
from O
patients O
treated O
with O
hycanthone O
. O

Characteristics O
of O
anesthesia O
and O
resuscitation O
in O
emergency O
lung O
surgery O

Study O
of O
the O
physico O
- O
chemical O
state O
of O
plutonium O
- O
239 O
in O
a O
citrate O
solution O
- O
blood O
system O

Tobramycin O
60 O
mg O
did O
not O
show O
any O
remarkable O
effect O
, O
but O
dibecacin O
100 O
mg O
produced O
a O
slight O
potentiating O
effect O
on O
the O
action O
of O
d O
- O
tubocurarine O
. O

In O
about O
one O
third O
of O
the O
cases O
this O
operation O
results O
in O
tonal O
and O
vocal O
improvement O
for O
patients O
suffering O
from O
progressive O
perceptive O
deafness O
. O

The O
specific O
electrical O
resistance O
of O
the O
cerebrospinal O
fluid O
was O
measured O
by O
means O
of O
conductometry O
in O
14 O
cases O
of O
meningitis O
purulenta O
, O
17 O
cases O
of O
meningitis O
serosa O
, O
10 O
cases O
of O
encephalitis O
and O
in O
32 O
control O
subjects O
. O

2 O
- O
Chemical O
occlusion O
of O
vas O
is O
quite O
effective O
in O
producing O
a O
block O
in O
the O
vas O
deferens O
of O
dogs O
. O

Besides O
, O
we O
found O
in O
3 O
patients O
increased O
serum I-GENE
immunoglobulins I-GENE
, O
chiefly O
IgG I-GENE
, O
as O
first O
Russe O
, O
Busey O
and O
Barbeau O
demonstrated O
in O
a O
large O
French O
- O
Canadian O
family O
. O

We O
suggest O
that O
such O
occlusions O
occurred O
at O
the O
time O
of O
the O
infarction O
. O

Streptococcal O
preparation O
( O
OK O
- O
432 O
), O
a O
new O
type O
of O
anti O
- O
cancer O
agent O
, O
was O
given O
to O
the O
patients O
with O
advanced O
cancer O
in O
combination O
with O
Mitomycin O
- O
C O
, O
5 O
- O
FU O
and O
Cytosine O
arabinoside O
. O

Generally O
, O
a O
correlation O
was O
observed O
between O
highest O
concentrations O
of O
CSF I-GENE
immunoglobulins I-GENE
and O
degree O
of O
meningeal O
inflammatory O
response O
, O
even O
if O
this O
was O
a O
component O
of O
other O
neurological O
diseases O
. O

Maternal O
lactation O

Experimental O
cardiotoxicity O
of O
adriamycin O

Muscular O
pathology O

Demonstration O
of O
the O
agent O
was O
performed O
from O
the O
6th O
to O
the O
11th O
day O
p O
. O
i O
. O
by O
direct O
microscopic O
methods O
( O
Stamp O
and O
auramine O
staining O
, O
fluorescent O
antibody O
technique O
); O
the O
Coxiella O
content O
was O
determined O
by O
titration O
in O
embryonated O
hen O
' O
s O
eggs O
. O

The O
patients O
were O
divided O
into O
4 O
groups O
receiving O
NLA O
II O
with O
or O
without O
nalorphine O
, O
morphine O
or O
Micoren O
. O

The O
alterations O
of O
5 O
- O
HT O
and O
5 O
- O
HIAA O
levels O
in O
several O
regions O
of O
the O
brain O
under O
the O
conditions O
examined O
may O
indicate O
that O
IDPN O
' O
s O
neurotoxicity O
primarily O
affects O
5 O
- O
HT O
- O
containing O
neurones O
. O

( O
5 O
) O
An O
increase O
in O
leukocyte O
- O
counts O
occurred O
on O
the O
administration O
of O
serum O
obtained O
from O
rabbit O
during O
phase O
- O
2 O
. O

The O
results O
obtained O
tend O
to O
prove O
that O
the O
reticuloendothelial O
system O
mainly O
participated O
in O
beryllium O
retention O
. O

In O
both O
cases O
, O
at O
the O
end O
of O
exposure O
the O
same O
level O
of O
blood I-GENE
carboxyhemoglobin I-GENE
( O
COHb I-GENE
) O
( O
about O
50 O
%) O
was O
reached O
. O

The O
results O
indicate O
that O
increased O
pulmonary O
blood O
flow O
and O
decreased O
pulmonary O
vascular O
resistance O
with O
advancing O
gestation O
are O
due O
to O
an O
increase O
in O
the O
total O
number O
of O
vessels O
and O
increased O
vasomotor O
reactivity O
is O
related O
to O
an O
increase O
in O
the O
total O
amount O
of O
smooth O
muscle O
while O
the O
thickness O
of O
muscle O
in O
individual O
vessels O
remains O
constant O
. O

Reduction O
in O
dosage O
restored O
normal O
taste O
sense O
in O
all O
three O
, O
but O
in O
two O
the O
drug O
had O
to O
be O
discontinued O
because O
of O
persisting O
high O
transaminase O
levels O
. O

The O
calcium O
ratio O
( O
mean O
ratio O
of O
the O
predicted O
to O
measured O
TBCa O
) O
in O
men O
was O
1 O
. O
000 O
+/- O
7 O
. O
8 O
% O
and O
in O
women O
0 O
. O
996 O
+/- O
7 O
. O
1 O
%. O

A O
late O
diagnosis O
of O
retinoblastoma O
is O
an O
unquestionable O
fact O
that O
allows O
its O
growth O
and O
leads O
to O
a O
deterioration O
in O
the O
outlook O
. O

Total O
cholesterol O
was O
measured O
in O
amniotic O
fluids O
collected O
at O
different O
stages O
of O
gestation O
. O

Her O
serum O
FT3 O
concentration O
was O
, O
however O
, O
much O
higher O
than O
the O
ranges O
in O
normal O
pregnancy O
or O
in O
GTD O
patients O
without O
clinical O
hyperthyroidism O
. O

The O
authors O
found O
that O
except O
for O
fear O
and O
pugnacity O
all O
husband O
- O
wife O
trait O
correlations O
were O
positive O
, O
in O
contrast O
to O
Winch O
' O
s O
principle O
of O
type O
I O
complementarity O
. O

A O
note O
on O
the O
phase O
- O
plane O
technique O
representation O
of O
cardiac O
action O
potentials O
. O

3 O
activities O
of O
the O
factor I-GENE
II I-GENE
molecule O
in O
the O
newborn O
infant O
at O
term O

The O
concept O
of O
" O
structural O
identifiability O
" O
is O
employed O
in O
this O
analysis O
to O
determine O
which O
model O
parameters O
can O
be O
and O
which O
cannot O
be O
determined O
" O
uniquely O
" O
from O
given O
input O
- O
output O
data O
; O
a O
step O
- O
by O
- O
step O
procedure O
based O
on O
an O
extension O
of O
this O
concept O
is O
presented O
for O
adapting O
the O
overall O
approach O
to O
the O
experimental O
design O
problem O
. O

However O
, O
we O
did O
detect O
lot O
- O
to O
- O
lot O
variation O
and O
differences O
in O
performance O
between O
narrow O
bandpass O
and O
wide O
bandpass O
spectrophotometers O
. O

The O
cochlear O
compromise O
. O

A O
case O
observed O
in O
Saigon O

Hypertonic O
glucose O
administered O
intrajejunally O
in O
Heidenhain O
pouch O
dogs O
resulted O
in O
an O
equal O
inhibition O
of O
pentagastrin O
- O
induced O
acid O
secretion O
from O
the O
pouch O
and O
the O
main O
stomach O
, O
whereas O
hypertonic O
saline O
had O
no O
effect O
. O

Acquired O
factor I-GENE
VIII I-GENE
inhibitor O
in O
non O
- O
hemophilic O
patients O

Biohydrogenation O
of O
linoleic O
acid O
into O
octadecenoic O
acid O
was O
observed O
. O

The O
study O
of O
calcium O
metabolism O
in O
ten O
thalassaemic O
children O
comperatively O
with O
controls O
after O
oral O
administration O
of O
47Ca O
has O
shown O
diminished O
intestinal O
absorption O
. O

Chlamydial O
agents O
were O
isolated O
from O
the O
semen O
near O
the O
end O
of O
the O
chlamydemic O
phase O
. O

Because O
of O
the O
increased O
CPK I-GENE
activity O
found O
in O
normal O
newborns O
, O
screening O
for O
Duchenne O
- O
type O
muscular O
dystrophy O
should O
be O
postponed O
for O
a O
few O
weeks O
after O
delivery O
. O

In O
contrast O
, O
the O
insulin I-GENE
response O
had O
returned O
to O
the O
non O
- O
pregnant O
value O
by O
the O
second O
day O
of O
the O
puerperium O
. O

The O
authors O
report O
the O
results O
of O
a O
series O
of O
toxicological O
tests O
conducted O
on O
plastic O
materials O
( O
polyethylene O
) O
activated O
with O
tetraphenylbutadiene O
( O
TPB O
) O
an O
additive O
recently O
proposed O
as O
a O
sensitizer O
capable O
of O
photodegrading O
plastic O
materials O
. O

Mutational O
analysis O
of O
the O
major O
homology O
region O
of O
Mason O
- O
Pfizer O
monkey O
virus O
by O
use O
of O
saturation O
mutagenesis O
. O

One O
site O
, O
PAL I-GENE
, O
occurs O
within O
the O
10 O
bp O
sequence O
GGGGAGGAGG O
. O

Nuclear O
extracts O
prepared O
from O
both O
neural O
and O
non O
- O
neural O
cell O
lines O
, O
mouse O
brain O
, O
and O
mouse O
liver O
contain O
proteins O
that O
recognize O
and O
bind O
to O
the O
PROX O
and O
PAL O
sequences O
indicating O
that O
proteins O
which O
bind O
to O
these O
target O
sequences O
are O
widespread O
. O

To O
determine O
if O
the O
NF I-GENE
( I-GENE
H I-GENE
) I-GENE
promoter I-GENE
can O
be O
activated O
in O
a O
tissue O
specific O
manner O
during O
development O
transgenic O
mice O
containing O
the O
promoter O
region O
linked O
to O
a O
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter I-GENE
gene I-GENE
were O
generated O
. O

Here O
we O
describe O
and O
map O
two O
more O
new O
genes O
identified O
as O
allele O
- O
specific O
suppressors O
that O
compensate O
for O
carboxy O
- O
terminal O
truncation O
of O
PET122 I-GENE
. O

Previous O
studies O
have O
shown O
[ O
Hisanaga O
, O
S O
., O
Kusubata O
, O
M O
., O
Okumura O
, O
E O
. O
& O
Kishimoto O
, O
T O
. O

Treatment O
and O
staining O
of O
smears O
and O
sections O
for O
detection O
of O
microorganisms O

The O
apparent O
Kd O
of O
the O
MetRS I-GENE
/ I-GENE
CAU I-GENE
operator I-GENE
complex I-GENE
is O
one O
order O
magnitude O
higher O
than O
that O
of O
the O
ThrRS I-GENE
/ I-GENE
CGU I-GENE
operator I-GENE
complex I-GENE
. O

A O
significant O
direct O
relationship O
was O
observed O
between O
the O
percent O
area O
density O
of O
smooth O
muscle O
and O
the O
percent O
change O
in O
peak O
urinary O
flow O
rate O
. O

Rabbit I-GENE
skeletal I-GENE
muscle I-GENE
glycogenin I-GENE
. O

Characterization O
of O
the O
human I-GENE
gene I-GENE
encoding I-GENE
cytokeratin I-GENE
17 I-GENE
and O
its O
expression O
pattern O
. O

Animals O
that O
received O
DSP O
- O
4 O
were O
significantly O
retarded O
in O
motor O
recovery O
compared O
with O
the O
saline O
group O
. O

The O
prophylactic O
use O
of O
new O
medication O
for O
patients O
between O
the O
first O
and O
second O
cycle O
of O
chemotherapy O
, O
in O
agreement O
with O
the O
estimates O
calculated O
, O
does O
not O
save O
health O
care O
costs O
but O
may O
improve O
the O
quality O
of O
life O
in O
these O
patients O
and O
permit O
the O
continuation O
of O
a O
therapeutic O
schedule O
without O
interruption O
which O
may O
improve O
the O
life O
expectancy O
of O
the O
patient O
. O

AP O
was O
induced O
by O
intraductal O
infusion O
of O
two O
different O
concentrations O
of O
glycodeoxycholic O
acid O
( O
GDOC O
17 O
mmol O
and O
34 O
mmol O
). O

The O
isolation O
of O
this O
gene O
was O
based O
on O
the O
identification O
of O
the O
Y O
- O
231 O
cosmid O
that O
contains O
CpG O
rich O
sequences O
( O
HTF O
islands O
) O
in O
its O
human O
insert O
. O

Tissue I-GENE
plasminogen I-GENE
activator I-GENE
, O
its O
inhibitor O
and O
other O
parameters O
of O
fibrinolysis O
in O
blood O
of O
patients O
operated O
for O
mild O
hypertrophy O
of O
the O
prostate O

Gene O
constructs O
consisting O
of O
human I-GENE
growth I-GENE
hormone I-GENE
( O
hGH I-GENE
) O
gene O
driven O
by O
promoter O
/ O
regulatory O
sequence O
of O
mouse I-GENE
metallothionein I-GENE
( O
mMT I-GENE
), O
viral I-GENE
thymidine I-GENE
kinase I-GENE
( O
vTK I-GENE
), O
rat I-GENE
cholecystokinin I-GENE
( O
rCCK I-GENE
), O
or O
chicken I-GENE
beta I-GENE
- I-GENE
actin I-GENE
( O
cBA I-GENE
) O
gene O
were O
injected O
into O
the O
cytoplasm O
of O
fertilized O
medaka O
eggs O
via O
the O
micropyle O
. O

Serum O
gastrin I-GENE
and O
AFP I-GENE
levels O
had O
the O
same O
evolution O
and O
appear O
to O
have O
the O
same O
interest O
to O
follow O
the O
course O
of O
the O
disease O
. O

Prospects O
for O
controlled O
- O
delivery O
systems O
. O

The O
mean O
(+/- O
SD O
) O
PaO2 O
increased O
from O
80 O
. O
8 O
+/- O
26 O
. O
9 O
mmHg O
before O
to O
89 O
. O
8 O
+/- O
27 O
. O
3 O
mmHg O
after O
the O
infusion O
( O
P O
< O
0 O
. O
05 O
) O
and O
the O
PaCO2 O
decreased O
from O
42 O
. O
4 O
+/- O
8 O
. O
3 O
to O
39 O
. O
6 O
+/- O
7 O
. O
9 O
mmHg O
( O
P O
< O
0 O
. O
05 O
). O

Though O
hepatomegaly O
and O
mild O
elevation O
of O
enzymes O
can O
be O
observed O
in O
a O
significant O
proportion O
of O
patients O
, O
involvement O
of O
liver O
leading O
to O
acute O
hepatitis O
or O
liver O
cell O
necrosis O
is O
a O
relatively O
uncommon O
complication O
in O
P O
. O
falciparum O
malaria O
. O

For O
the O
first O
group O
, O
the O
maximal O
decrease O
in O
plasma O
potassium O
elicited O
by O
salbutamol O
was O
0 O
. O
80 O
+/- O
0 O
. O
19 O
, O
0 O
. O
48 O
+/- O
0 O
. O
22 O
, O
and O
0 O
. O
78 O
+/- O
0 O
. O
46 O
mmol O
/ O
l O
, O
and O
for O
the O
second O
group O
, O
maximal O
decrement O
was O
1 O
. O
31 O
+/- O
0 O
. O
37 O
, O
0 O
. O
70 O
+/- O
0 O
. O
24 O
, O
and O
0 O
. O
84 O
+/- O
0 O
. O
17 O
mmol O
/ O
l O
for O
the O
iv O
, O
po O
, O
and O
it O
routes O
, O
respectively O
. O

The O
two O
drugs O
increase O
the O
rate O
of O
early O
diastolic O
filling O
. O

A O
statistically O
significant O
improvement O
due O
to O
the O
administration O
of O
Bromergon O
was O
observed O
in O
symptoms O
associated O
with O
overreactiveness O
to O
normal O
prolactin I-GENE
levels O
, O
i O
. O
e O
. O
abdominal O
tension O
, O
edema O
, O
weight O
gain O
and O
breast O
tenderness O
. O

The O
magnitude O
of O
the O
early O
response O
was O
241 O
+/- O
51 O
% O
in O
A O
(% O
baseline O
RL O
; O
mean O
+/- O
SE O
), O
and O
significantly O
less O
in O
B O
( O
119 O
+/- O
7 O
%) O
and O
C O
( O
131 O
+/- O
16 O
%) O
( O
p O
< O
0 O
. O
01 O
). O

Most O
of O
the O
patients O
presented O
with O
Transient O
Ischemic O
Attacks O
( O
64 O
%) O
or O
Reversible O
Ischemic O
Neurologic O
Deficits O
( O
19 O
%). O

We O
cloned O
the O
third O
human O
gene O
for O
the O
LD78 I-GENE
, O
termed O
LD78 I-GENE
gamma I-GENE
and O
the O
sequence O
analysis O
showed O
that O
it O
is O
a O
5 O
'- O
truncated O
pseudogene O
. O

This O
analysis O
, O
together O
with O
a O
consideration O
of O
the O
SCBs O
found O
upstream O
of O
known O
SWI4 I-GENE
, I-GENE
6 I-GENE
- O
dependent O
genes O
, O
leads O
to O
the O
proposal O
of O
a O
revised O
consensus O
sequence O
for O
this O
important O
regulatory O
element O
. O

Mutational O
analysis O
of O
a O
DNA O
sequence O
involved O
in O
linking O
gene O
expression O
to O
the O
cell O
cycle O
. O

The O
natural O
history O
of O
these O
lesions O
, O
locoregional O
efficiency O
of O
the O
different O
treatments O
used O
, O
the O
part O
played O
by O
chemotherapy O
, O
survival O
, O
causes O
of O
death O
and O
therapeutic O
modalities O
used O
as O
a O
last O
measure O
, O
have O
been O
analysed O
. O

The O
method O
was O
adapted O
for O
the O
determination O
of O
nadolol O
racemate O
A O
by O
a O
change O
in O
mobile O
phase O
composition O
. O

In O
general O
, O
however O
, O
this O
study O
provided O
little O
evidence O
of O
any O
effect O
of O
supplementation O
to O
athletic O
performance O
for O
athletes O
consuming O
the O
dietary O
RDIs O
. O

In O
the O
absence O
of O
histological O
criteria O
, O
which O
it O
is O
difficult O
to O
demand O
in O
view O
of O
the O
variability O
of O
results O
and O
potential O
dangers O
of O
endomyocardial O
biopsy O
involving O
such O
thin O
and O
fragile O
ventricular O
walls O
, O
the O
diagnosis O
of O
ACRV O
is O
based O
upon O
the O
concomitant O
existence O
of O
: O
( O
1 O
) O
electrophysiological O
criteria O
: O
ventricular O
arrhythmias O
, O
in O
particular O
sustained O
monomorphous O
VT O
, O
with O
the O
particular O
feature O
of O
a O
very O
high O
degree O
of O
sensitivity O
to O
adrenergic O
stimulation O
( O
exercise O
), O
the O
existence O
of O
late O
potentials O
on O
the O
high O
amplification O
ECG O
, O
a O
highly O
specific O
sign O
, O
though O
unfortunately O
of O
poor O
sensitivity O
in O
localized O
froms O
, O
those O
which O
are O
most O
difficult O
to O
identify O
( O
2 O
); O
segmentary O
morphological O
and O
kinetic O
RV O
abnormalities O
, O
most O
often O
resulting O
in O
localized O
akinetic O
or O
dyskinetic O
parietal O
vaulting O
, O
with O
stasis O
" O
in O
situ O
". O

In O
7 O
of O
9 O
cases O
, O
the O
enhancer O
is O
fused O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
bearing I-GENE
sequences I-GENE
of O
chromosome O
8 O
. O

These O
components O
both O
had O
a O
median O
R2 O
of O
0 O
. O
84 O
, O
compared O
to O
median O
R2s O
ranging O
from O
0 O
. O
37 O
to O
0 O
. O
83 O
for O
five O
commonly O
used O
ad O
hoc O
EEG O
components O
. O

The O
obtained O
results O
were O
compared O
with O
control O
group O
( O
10 O
female O
volunteers O
). O

100 O
years O
of O
dentistry O
at O
the O
Friedrich O
Schiller O
University O
in O
Jena O

The O
target O
contained O
between O
positions O
- O
403 O
and O
- O
125 O
acts O
independently O
of O
orientation O
, O
in O
different O
cell O
types O
and O
species O
, O
and O
in O
the O
context O
of O
a O
heterologous O
promoter O
. O

66 O
: O
469 O
- O
479 O
, O
1992 O
). O

Synergistic O
transactivation O
of O
the O
BMRF1 I-GENE
promoter I-GENE
by O
the O
Z I-GENE
/ O
c I-GENE
- I-GENE
myb I-GENE
combination O
appears O
to O
involve O
direct O
binding O
by O
the O
Z I-GENE
protein I-GENE
but O
not O
the O
c I-GENE
- I-GENE
myb I-GENE
protein I-GENE
. O

The O
UCR O
core O
sequence O
, O
CGCCATTTT O
, O
binds O
a O
ubiquitous O
nuclear O
factor O
and O
mediates O
negative O
regulation O
of O
MuLV O
promoter O
activity O
. O

These O
studies O
show O
that O
UCRBP I-GENE
binds O
to O
various O
target O
motifs O
that O
are O
distinct O
from O
the O
UCR O
motif O
: O
the O
adeno I-GENE
- I-GENE
associated I-GENE
virus I-GENE
P5 I-GENE
promoter I-GENE
and O
elements O
in O
the O
immunoglobulin I-GENE
light I-GENE
- I-GENE
and I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
genes O
, O
as O
well O
as O
elements O
in O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Possibly O
, O
the O
scr1 I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
does O
not O
affect O
signal O
recognition O
or O
translational O
arrest O
but O
instead O
results O
in O
maintenance O
of O
translational O
arrest O
of O
AEP I-GENE
synthesis O
. O

The O
cellular O
sequences O
5 O
' O
to O
the O
viral O
integration O
site O
exhibited O
85 O
to O
97 O
% O
identity O
to O
several O
sequences O
belonging O
to O
the O
mouse I-GENE
L1 I-GENE
family I-GENE
of O
long O
interspersed O
repetitive O
sequences O
. O

Both O
Rep78 I-GENE
and O
Rep68 I-GENE
cut O
the O
terminal O
AAV O
sequence O
at O
the O
same O
site O
( O
nucleotide O
124 O
). O

Nucleotide O
sequence O
analysis O
revealed O
that O
TAR I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
very O
similar O
to O
the O
CREB2 I-GENE
protein I-GENE
. O

These O
results O
indicate O
that O
both O
N O
- O
and O
C O
- O
terminal O
mutations O
are O
required O
to O
inhibit O
transrepression O
by O
FBR I-GENE
protein I-GENE
and O
that O
multiple O
structural O
mutations O
accompanied O
by O
posttranslational O
protein O
modification O
alter O
gene O
regulation O
by O
FBR I-GENE
protein I-GENE
. O

The O
JS78 O
mutation O
changes O
Gln243 O
in O
gp0 O
. O
7 O
to O
an O
amber O
codon O
, O
which O
explains O
the O
production O
of O
the O
truncated O
, O
30 I-GENE
- I-GENE
kDa I-GENE
gp0 I-GENE
. I-GENE
7 I-GENE
- I-GENE
related I-GENE
polypeptide I-GENE
, O
and O
implicates O
the O
11 O
- O
kDa O
C O
- O
terminal O
domain O
in O
host O
transcription O
shut O
- O
off O
. O

A O
patient O
suffering O
from O
heparin O
- O
associated O
thrombocytopenia O
( O
HAT O
), O
recurrent O
arteriothromboses O
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin O
is O
described O
. O

The O
predicted O
receptor O
structure O
includes O
a O
cysteine O
- O
rich O
extracellular O
domain O
, O
a O
single O
hydrophobic O
transmembrane O
domain O
, O
and O
a O
predicted O
cytoplasmic I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
domain I-GENE
. O

Drosophila I-GENE
UbcD1 I-GENE
encodes O
a O
highly O
conserved O
ubiquitin I-GENE
- O
conjugating O
enzyme O
involved O
in O
selective O
protein O
degradation O
. O

Analysis O
of O
the O
entire O
16 O
. O
7 O
- O
kb O
mt O
genome O
determined O
that O
a O
MDP1 I-GENE
mediates O
cleavage O
of O
chick O
mtDNA O
in O
vitro O
at O
three O
H O
- O
and O
two O
L O
- O
strand O
sequence O
- O
specific O
target O
sites O
located O
within O
a O
90 O
- O
bp O
A O
+ O
T O
- O
rich O
genomic O
tract O
, O
theoretically O
capable O
of O
forming O
stable O
secondary O
structures O
, O
approximately O
200 O
bases O
upstream O
from O
the O
H O
- O
strand O
origin O
( O
OH O
) O
of O
replication O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
determine O
the O
feasibility O
of O
retrovirus O
mediated O
expression O
of O
rp47phox I-GENE
in O
the O
HL60 O
and O
U937 O
human O
hematopoietic O
cell O
lines O
, O
and O
in O
an O
Epstein O
- O
Barr O
virus O
transformed O
B O
- O
lymphocyte O
cell O
line O
( O
EBV O
- O
BCL O
) O
derived O
from O
a O
p47phox I-GENE
- O
deficient O
CGD O
patient O
. O

Comparison O
with O
the O
sequence O
databanks O
show O
that O
Tactile I-GENE
is O
a O
member O
of O
the O
immunoglobulin I-GENE
gene I-GENE
superfamily I-GENE
, O
with O
similarity O
to O
Drosophila I-GENE
amalgam I-GENE
, O
the O
melanoma I-GENE
Ag I-GENE
MUC I-GENE
- I-GENE
18 I-GENE
, O
members O
of O
the O
carcinoembryonic I-GENE
Ag I-GENE
family I-GENE
, O
the O
poliovirus I-GENE
receptor I-GENE
, O
and O
the O
neural I-GENE
cell I-GENE
adhesion I-GENE
molecule I-GENE
. O

A O
rather O
similar O
pattern O
of O
results O
was O
obtained O
with O
respect O
to O
LMP2B I-GENE
mRNA I-GENE
expression O
, O
such O
transcripts O
being O
detectable O
only O
in O
a O
subset O
of O
tumors O
, O
and O
then O
at O
apparently O
low O
levels O
. O

The O
phenotypes O
of O
the O
ICP0 I-GENE
nonsense O
mutants O
were O
intermediate O
between O
those O
of O
the O
wild O
- O
type O
virus O
and O
7134 O
in O
that O
the O
more O
ICP0 I-GENE
- I-GENE
coding I-GENE
sequence I-GENE
expressed O
by O
a O
given O
nonsense O
mutant O
, O
the O
more O
wild O
type O
- O
like O
was O
its O
phenotype O
. O

Analysis O
of O
nucleotide O
sequence O
of O
the O
rightmost O
43 O
kbp O
of O
herpesvirus O
saimiri O
( O
HVS O
) O
L O
- O
DNA O
: O
general O
conservation O
of O
genetic O
organization O
between O
HVS O
and O
Epstein O
- O
Barr O
virus O
. O

Treatment O
with O
MK O
- O
801 O
induced O
a O
burst O
suppression O
in O
the O
EEG O
and O
a O
transient O
drop O
( O
11 O
. O
4 O
+/- O
6 O
. O
5 O
mm O
Hg O
) O
in O
the O
mean O
arterial O
pressure O
. O

In O
contrast O
, O
gel O
mobility O
shift O
experiments O
have O
failed O
to O
reveal O
that O
HAP2 I-GENE
or O
HAP3 I-GENE
binds O
to O
domain O
1 O
or O
that O
hap3 I-GENE
mutations O
affect O
the O
complexes O
bound O
to O
it O
. O

Myogenic O
differentiation O
can O
be O
inhibited O
by O
the O
adenovirus O
E1a I-GENE
protein I-GENE
in O
the O
rat O
L6 O
muscle O
cell O
line O
. O

The O
experiment O
results O
showed O
: O
( O
i O
) O
not O
only O
1O2 O
, O
but O
also O
free O
radicals O
( O
O2 O
-. O
. O
OH O
and O
YHPD O
-.) O
can O
be O
formed O
by O
the O
aid O
of O
YHPD O
; O
and O
( O
ii O
) O
as O
to O
the O
ability O
of O
producing O
1O2 O
, O
YHPD O
less O
than O
BHPD O
, O
while O
for O
generating O
O2 O
-. O
and O
. O
OH O
, O
YHPD O
greater O
than O
BHPD O
. O

Two O
points O
are O
indicated O
: O
first O
, O
the O
photosensitized O
damage O
of O
YHPD O
is O
interrelated O
to O
not O
only O
1O2 O
, O
but O
also O
free O
radicals O
( O
O2 O
-. O
. O
OH O
and O
YHPD O
-.); O
second O
, O
although O
the O
photosensitized O
damage O
of O
YHPD O
is O
stronger O
than O
that O
of O
BHPD O
, O
yet O
the O
photosensitized O
damage O
is O
negatively O
correlated O
to O
the O
yield O
of O
1O2 O
but O
positively O
correlated O
to O
those O
of O
O2 O
-. O
and O
OH O
. O

Acad O
. O

Both O
in O
vitro O
- O
synthesized O
S2 I-GENE
protein I-GENE
and O
synthetic O
peptides O
corresponding O
to O
S2 I-GENE
are O
shown O
to O
react O
positively O
with O
sera O
obtained O
from O
EIAV O
- O
infected O
horses O
, O
providing O
the O
first O
direct O
evidence O
of O
expression O
of O
this O
protein O
in O
infected O
animals O
. O

Many O
canonical O
TATA O
sequences O
are O
present O
upstream O
from O
these O
VZV O
transcriptional O
start O
sites O
but O
, O
apparently O
, O
are O
not O
used O
. O

The O
ORF O
4 O
gene O
was O
minimally O
active O
, O
whereas O
the O
ORF O
62 O
gene O
gave O
twofold O
induction O
; O
both O
genes O
, O
acting O
together O
, O
gave O
fivefold O
induction O
. O

Interestingly O
, O
the O
IR5 I-GENE
ORF I-GENE
of O
EHV O
- O
1 O
possesses O
a O
sequence O
of O
13 O
amino O
acids O
( O
CAYWCCLGHAFAC O
) O
that O
is O
a O
perfect O
match O
to O
the O
consensus O
zinc O
finger O
motif O
( O
C O
- O
X2 O
- O
4 O
- O
C O
- O
X2 O
- O
15 O
- O
C O
/ O
H O
- O
X2 O
- O
4 O
- O
C O
/ O
H O
). O

The O
DNA O
sequence O
of O
the O
sulfate I-GENE
activation I-GENE
locus I-GENE
from O
Escherichia O
coli O
K O
- O
12 O
has O
been O
determined O
. O

The O
unphosphorylated O
form O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
is O
designated O
IIA O
, O
whereas O
the O
phosphorylated O
form O
is O
designated O
IIO O
. O

RNA I-GENE
polymerase I-GENE
IIA I-GENE
was O
recovered O
in O
transcriptionally O
active O
complexes O
in O
reactions O
in O
which O
the O
input O
enzyme O
was O
RNA I-GENE
polymerase I-GENE
IIA I-GENE
. O

Fructokinase I-GENE
activity O
is O
elevated O
up O
to O
twofold O
when O
Z O
. O
mobilis O
was O
grown O
on O
fructose O
instead O
of O
glucose O
, O
and O
there O
was O
a O
parallel O
increase O
in O
frk I-GENE
mRNA I-GENE
levels O
. O

Plasma O
membranes O
of O
cultured O
cells O
contain O
high O
affinity O
receptors O
for O
high I-GENE
density I-GENE
lipoprotein I-GENE
( O
HDL I-GENE
) O
that O
appear O
to O
mediate O
removal O
of O
excess O
intracellular O
cholesterol O
. O

After O
the O
first O
28 O
patients O
vincristine O
was O
replaced O
by O
teniposide O
( O
VM O
- O
26 O
) O
due O
to O
neurotoxicity O
. O

These O
results O
indicate O
that O
an O
internal O
short O
element O
located O
at O
the O
very O
5 O
' O
terminal O
of O
L1 I-GENE
sequence I-GENE
and O
the O
nuclear O
factor O
binding O
to O
the O
element O
play O
a O
crucial O
role O
in O
the O
transcription O
of O
human I-GENE
L1 I-GENE
. O

Tumor O
cells O
were O
focally O
immunoreactive O
for O
neuron I-GENE
- I-GENE
specific I-GENE
enolase I-GENE
, O
insulin I-GENE
, O
glucagon I-GENE
and O
VIP I-GENE
. O

A O
recombinant O
with O
a O
5 O
' O
end O
from O
src I-GENE
and O
a O
3 O
' O
end O
from O
ros I-GENE
, O
called O
SRC I-GENE
x O
ROS I-GENE
, O
transformed O
chicken O
embryo O
fibroblasts O
( O
CEF O
) O
to O
a O
spindle O
shape O
morphology O
, O
mimicking O
that O
of O
UR2 I-GENE
. O

ROS I-GENE
x O
SRC I-GENE
( O
R I-GENE
) O
contains O
a O
16 O
- O
amino O
- O
acid O
deletion O
that O
includes O
the O
3 O
' O
half O
of O
the O
transmembrane O
domain O
of O
ros I-GENE
. O

To O
define O
the O
number O
and O
nature O
of O
the O
E6 I-GENE
and O
E7 I-GENE
gene I-GENE
products O
expressed O
in O
BPV O
- O
1 O
- O
transformed O
cells O
, O
we O
performed O
immunoprecipitation O
experiments O
with O
antisera O
raised O
to O
bacterially O
expressed O
BPV I-GENE
- I-GENE
1 I-GENE
E6 I-GENE
and O
E7 I-GENE
fusion I-GENE
proteins I-GENE
. O

Transient O
transfection O
assays O
showed O
that O
site O
A O
is O
necessary O
and O
sufficient O
for O
RXR I-GENE
alpha I-GENE
- O
mediated O
transactivation O
of O
the O
apoAI I-GENE
gene I-GENE
basal I-GENE
promoter I-GENE
in O
human O
hepatoma O
HepG2 O
cells O
in O
the O
presence O
of O
RA O
and O
that O
this O
transactivation O
is O
abolished O
by O
increasing O
amounts O
of O
cotransfected O
ARP I-GENE
- I-GENE
1 I-GENE
. O

The O
enhancer O
region O
of O
Akv O
murine O
leukemia O
virus O
contains O
the O
sequence O
motif O
ACAGATGG O
. O

Two O
splice O
variants O
of O
ALF1 I-GENE
cDNA I-GENE
have O
been O
found O
, O
differing O
by O
a O
72 O
- O
bp O
insertion O
, O
coding O
for O
putative O
proteins O
of O
682 O
and O
706 O
amino O
acids O
. O

A O
third O
prominent O
component O
of O
apparent O
molecular O
mass O
16 O
kDa O
displayed O
several O
properties O
, O
including O
ability O
to O
bind O
45Ca2 O
+, O
that O
are O
characteristic O
of O
the O
regulatory O
( O
B O
) O
subunit O
of O
mammalian I-GENE
calcineurin I-GENE
and O
was O
recognized O
by O
an O
antiserum O
raised O
against O
bovine I-GENE
calcineurin I-GENE
. O

As O
was O
observed O
previously O
for O
MATa I-GENE
cna1 I-GENE
cna2 I-GENE
double O
mutants O
, O
MATa I-GENE
cnb1 I-GENE
mutants I-GENE
were O
defective O
in O
their O
ability O
to O
recover O
from O
alpha I-GENE
- I-GENE
factor I-GENE
- O
induced O
growth O
arrest O
. O

Antibodies O
against O
this O
purified O
protein O
localize O
RIM1 I-GENE
to O
mitochondria O
. O

METHODS O
: O
IgG I-GENE
antibodies I-GENE
vs O
HHV O
- O
6 O
( O
anti I-GENE
- I-GENE
HHV I-GENE
- I-GENE
6 I-GENE
- I-GENE
IgG I-GENE
) O
were O
determined O
by O
indirect O
immunofluorescence O
in O
100 O
IVDA O
( O
29 O
seronegative O
and O
71 O
seropositive O
for O
HIV O
- O
1 O
of O
which O
45 O
were O
in O
stage O
II O
and O
26 O
in O
IV O
- O
C1 O
of O
CDC O
) O
as O
well O
as O
in O
100 O
healthy O
subjects O
of O
a O
similar O
age O
( O
control O
group O
). O

A O
position O
- O
independent O
activation O
domain O
which O
contained O
conserved O
regions O
II O
and O
III O
was O
identified O
at O
the O
carboxyl O
terminus O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
protein I-GENE
( O
amino O
acids O
361 O
to O
458 O
). O

HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
sequences I-GENE
defined O
by O
conserved O
region O
IV O
also O
contributed O
to O
transactivation O
, O
but O
region O
IV O
activity O
required O
the O
participation O
of O
the O
region O
II O
- O
III O
domain O
. O

Possible O
roles O
of O
RAD5 I-GENE
putative O
ATPase I-GENE
/ O
DNA I-GENE
helicase I-GENE
activity O
in O
DNA O
repair O
and O
in O
the O
maintenance O
of O
wild O
- O
type O
rates O
of O
instability O
of O
simple O
repetitive O
sequences O
are O
discussed O
. O

Susceptibilities O
of O
540 O
anaerobic O
gram O
- O
negative O
bacilli O
to O
amoxicillin O
, O
amoxicillin O
- O
BRL O
42715 O
, O
amoxicillin O
- O
clavulanate O
, O
temafloxacin O
, O
and O
clindamycin O
. O

Nocodazole O
arrest O
of O
DU249 O
cells O
was O
exploited O
for O
the O
detection O
of O
an O
M O
- O
phase O
- O
activated O
MBP I-GENE
kinase I-GENE
that O
was O
resolved O
from O
p41 I-GENE
MAP I-GENE
kinase I-GENE
by O
phenyl O
- O
Superose O
chromatography O
. O

The O
hit1 I-GENE
- I-GENE
1 I-GENE
mutation O
caused O
a O
defect O
in O
synthesis O
of O
a O
74 I-GENE
- I-GENE
kD I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

The O
319 O
base O
pair O
region O
immediately O
upstream O
of O
the O
CAP O
site O
is O
characterized O
by O
the O
lack O
of O
a O
proximal O
TATA O
box O
and O
the O
presence O
of O
sequences O
similar O
to O
GC O
boxes O
, O
CACCC O
boxes O
, O
CCAAT O
boxes O
, O
activator I-GENE
protein I-GENE
2 I-GENE
( O
Ap I-GENE
- I-GENE
2 I-GENE
) O
sites O
, O
partial O
glucocorticoid O
response O
elements O
( O
GREs O
), O
and O
partial O
cyclic O
AMP O
response O
elements O
( O
CREs O
). O

Cloning O
and O
primary O
structure O
of O
neurocan O
, O
a O
developmentally O
regulated O
, O
aggregating O
chondroitin O
sulfate O
proteoglycan O
of O
brain O
. O

In O
rats O
anaesthetized O
with O
+- O
chloralose O
the O
changes O
in O
extracellular O
pH O
and O
K O
+ O
in O
spinal O
cord O
dorsal O
horn O
were O
studied O
using O
pH O
and O
K O
+ O
ion O
- O
selective O
electrodes O
. O

Replication O
of O
bovine O
papillomavirus O
- O
1 O
( O
BPV O
- O
1 O
) O
DNA O
requires O
two O
viral O
gene O
products O
, O
the O
E1 I-GENE
protein I-GENE
and O
the O
full I-GENE
- I-GENE
length I-GENE
E2 I-GENE
protein I-GENE
. O

Insertional O
inactivation O
of O
sms I-GENE
led O
to O
increased O
sensitivity O
to O
the O
alkylating O
agent O
methylmethane O
sulfonate O
, O
but O
not O
to O
a O
requirement O
for O
serine O
or O
other O
metabolites O
. O

These O
findings O
suggest O
that O
the O
MAP I-GENE
kinase I-GENE
activator I-GENE
/ O
MAP I-GENE
kinase I-GENE
system O
may O
be O
the O
downstream O
components O
of O
ras I-GENE
signal O
transduction O
pathways O
. O

NSCL I-GENE
- I-GENE
1 I-GENE
is O
expressed O
in O
a O
larger O
number O
of O
these O
cell O
lines O
. O

Labile O
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
appear O
to O
be O
essential O
for O
c I-GENE
- I-GENE
myc I-GENE
hyperexpression O
, O
since O
both O
LTR O
- O
enhanced O
transcription O
and O
the O
activities O
of O
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
are O
specifically O
decreased O
after O
inhibition O
of O
protein O
synthesis O
( O
A O
. O

Ruddell O
, O
M O
. O

A O
single O
MEF I-GENE
- I-GENE
2 I-GENE
site I-GENE
is O
a O
major O
positive O
regulatory O
element O
required O
for O
transcription O
of O
the O
muscle O
- O
specific O
subunit O
of O
the O
human I-GENE
phosphoglycerate I-GENE
mutase I-GENE
gene I-GENE
in O
skeletal O
and O
cardiac O
muscle O
cells O
. O

Truncation O
variants O
of O
peptides O
isolated O
from O
MHC I-GENE
class I-GENE
II I-GENE
molecules I-GENE
suggest O
sequence O
motifs O
. O

Although O
the O
E O
- O
box O
consensus O
is O
minimally O
defined O
as O
CANNTG O
, O
the O
adjacent O
nucleotides O
of O
functional O
E O
- O
boxes O
are O
variable O
for O
genes O
regulated O
by O
the O
bHLH I-GENE
proteins I-GENE
. O

Intermediate O
levels O
of O
gene O
activity O
were O
observed O
for O
TnI I-GENE
enhancers I-GENE
containing O
E O
- O
boxes O
derived O
from O
the O
MCK I-GENE
left I-GENE
E I-GENE
- I-GENE
box I-GENE
site I-GENE
or O
from O
the O
Ig I-GENE
kappa I-GENE
E2 I-GENE
E I-GENE
- I-GENE
box I-GENE
. O

T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
beta I-GENE
( O
TCR I-GENE
beta I-GENE
) O
gene O
rearrangements O
occur O
in O
a O
third O
of O
early O
B O
- O
cell O
acute O
lymphoblastic O
leukemias O
( O
ALLs O
). O

The O
CANNTG O
motifs O
were O
found O
to O
bind O
MyoD I-GENE
and O
myogenin I-GENE
fusion I-GENE
proteins I-GENE
and O
to O
interact O
with O
proteins O
in O
nuclear O
extracts O
from O
cultured O
myotubes O
. O

Peripheral O
polyneuropathy O
associated O
with O
multiple O
myeloma O
. O

We O
have O
cloned O
and O
sequenced O
COX12 I-GENE
, O
the O
nuclear O
gene O
for O
subunit I-GENE
VIb I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
. O

The O
structure O
of O
the O
calcineurin I-GENE
A I-GENE
gene I-GENE
was O
determined O
by O
comparison O
of O
the O
genomic O
and O
cDNA O
sequences O
. O

The O
basal O
promoter O
elements O
of O
murine I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
subunit I-GENE
IV I-GENE
gene I-GENE
consist O
of O
tandemly O
duplicated O
ets I-GENE
motifs O
that O
bind O
to O
GABP I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factors I-GENE
. O

Lastly O
, O
there O
are O
multiple O
instances O
in O
which O
short O
oligonucleotide O
direct O
repeats O
flank O
a O
region O
absent O
from O
either O
variola O
or O
vaccinia O
virus O
. O

Here O
we O
show O
that O
short O
synthetic O
peptides O
containing O
the O
pRB I-GENE
- I-GENE
binding I-GENE
sequences I-GENE
of O
E1A I-GENE
are O
sufficient O
for O
interaction O
with O
p107 I-GENE
, O
cyclin I-GENE
A I-GENE
, O
and O
p130 I-GENE
. O

These O
mutants O
grow O
normally O
in O
3T6 O
mouse O
fibroblast O
cells O
, O
and O
they O
do O
not O
complement O
the O
wild O
- O
type O
virus O
in O
coinfection O
experiments O
of O
C2 O
myoblasts O
. O

The O
MICs O
of O
this O
compound O
against O
90 O
% O
of O
these O
organisms O
, O
except O
for O
methicillin O
- O
resistant O
S O
. O
aureus O
, O
ranged O
from O
less O
than O
or O
equal O
to O
0 O
. O
006 O
to O
3 O
. O
13 O
micrograms O
/ O
ml O
. O

The O
minimal O
promoter O
of O
the O
RII I-GENE
beta I-GENE
gene I-GENE
was O
composed O
of O
two O
adjacent O
functional O
elements O
. O

Mapping O
the O
cAMP I-GENE
receptor I-GENE
protein I-GENE
contact I-GENE
site I-GENE
on O
the O
alpha O
subunit O
of O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

Here O
we O
show O
that O
epidermal I-GENE
growth I-GENE
factor I-GENE
or O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
stimulation O
of O
intact O
human O
or O
murine O
cells O
leads O
to O
phosphorylation O
of O
Nck I-GENE
protein I-GENE
on O
tyrosine O
, O
serine O
, O
and O
threonine O
residues O
. O

A O
major O
mechanism O
whereby O
steroid I-GENE
hydroxylase I-GENE
gene I-GENE
transcription O
is O
regulated O
in O
the O
adrenal O
cortex O
requires O
the O
pituitary O
peptide O
hormone O
, O
ACTH I-GENE
, O
which O
acts O
via O
cAMP O
. O

A O
combination O
of O
comparative O
sequence O
analysis O
and O
thermodynamic O
methods O
reveals O
the O
conservation O
of O
tertiary O
structure O
elements O
in O
the O
5 O
' O
untranslated O
region O
( O
UTR O
) O
of O
human O
enteroviruses O
and O
rhinoviruses O
. O

The O
- O
64 O
/- O
37 O
region O
interacted O
with O
purified O
Sp1 I-GENE
and O
an O
unidentified O
protein O
( O
s O
), O
proximal I-GENE
regulatory I-GENE
factor I-GENE
( I-GENE
s I-GENE
) I-GENE
I I-GENE
( O
PRF I-GENE
- I-GENE
I I-GENE
). O

Km O
and O
Vmax O
for O
two O
substrates O
, O
src I-GENE
- I-GENE
related I-GENE
peptide I-GENE
and O
poly O
( O
Glu O
, O
Tyr O
) O
( O
4 O
: O
1 O
), O
were O
2 O
. O
4 O
mM O
and O
2 O
. O
5 O
mumol O
min O
- O
1 O
mg O
- O
1 O
and O
0 O
. O
26 O
mM O
and O
1 O
. O
2 O
mumol O
min O
- O
1 O
mg O
- O
1 O
, O
respectively O
. O

This O
soluble O
form O
of O
the O
HGFr I-GENE
( O
sHGFr I-GENE
) O
bound O
HGF I-GENE
with O
an O
affinity O
similar O
to O
that O
of O
the O
authentic O
, O
membrane O
- O
associated O
receptor O
. O

Strategies O
for O
blood O
screening O
for O
the O
hepatitis O
C O
virus O
and O
for O
the O
human O
immunodeficiency O
virus O
in O
high O
risk O
groups O
. O

Also O
, O
the O
human I-GENE
glycoprotein I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
promoter I-GENE
was O
induced O
10 O
- O
fold O
by O
FSK I-GENE
in O
GH4 O
rat O
pituitary O
cells O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Comparison O
of O
data O
obtained O
with O
the O
results O
of O
chronic O
treatment O
with O
the O
opioid O
antagonist O
permits O
to O
conclude O
that O
the O
chronic O
blockade O
increases O
the O
fatiguability O
to O
a O
great O
extent O
than O
chronic O
activation O
of O
opioid O
system O
. O

Laboratory O
studies O
using O
Ca45 O
labeled O
teeth O
and O
biologically O
stained O
teeth O
confirmed O
that O
the O
dentifrice O
did O
not O
decalcify O
enamel O
or O
bleach O
teeth O
. O

Structure O
and O
expression O
of O
a O
gene O
from O
Arabidopsis O
thaliana O
encoding O
a O
protein O
related O
to O
SNF1 I-GENE
protein O
kinase O
. O

We O
have O
cloned O
and O
characterized O
a O
55 O
- O
kb O
region O
of O
DNA O
surrounding O
HRAS1 I-GENE
. O

The O
ORF1 O
protein O
was O
found O
to O
be O
highly O
homologous O
to O
the O
putative O
potexvirus I-GENE
RNA I-GENE
replicases I-GENE
; O
ORF2 O
, O
- O
3 O
, O
- O
5 O
and O
- O
6 O
proteins O
also O
have O
analogues O
among O
the O
potex O
- O
and O
/ O
or O
carlavirus O
- O
encoded O
proteins O
. O

A O
total O
of O
281 O
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
diagnosis O
and O
were O
examined O
using O
capnography O
, O
spirometry O
and O
blood O
- O
gas O
analysis O
. O

The O
relationships O
between O
the O
partial O
pressures O
of O
O2 O
and O
CO2 O
as O
well O
as O
between O
their O
gradients O
, O
become O
stronger O
with O
the O
increase O
of O
the O
ventilation O
- O
perfusion O
ratio O
. O

No O
significant O
correlations O
of O
peak O
VO2 O
were O
observed O
between O
the O
3 O
tests O
. O

An O
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
( O
rbp1 I-GENE
) O
from O
Drosophila O
melanogaster O
, O
encoding O
an O
RNA O
recognition O
motif O
and O
an O
Arg O
- O
Ser O
rich O
( O
RS O
) O
domain O
, O
has O
been O
characterized O
. O

Some O
research O
studies O
have O
related O
this O
kind O
of O
tumors O
with O
prolonged O
ingestion O
of O
H2 O
inhibitors O
and O
others O
antacid O
. O

A O
comparative O
study O
of O
the O
total O
protein O
profiles O
of O
wild O
- O
type O
S O
. O
entomophila O
UC9 O
and O
mutant O
UC21 O
revealed O
that O
the O
mutant O
lacked O
an O
approximately O
44 O
- O
kDa O
protein O
and O
overexpressed O
an O
approximately O
20 O
- O
kDa O
protein O
. O

Characterization O
of O
the O
regulon O
controlled O
by O
the O
leucine I-GENE
- I-GENE
responsive I-GENE
regulatory I-GENE
protein I-GENE
in O
Escherichia O
coli O
. O

Mapping O
of O
the O
mouse I-GENE
ornithine I-GENE
decarboxylase I-GENE
- I-GENE
related I-GENE
sequence I-GENE
family I-GENE
. O

This O
mutation O
also O
results O
in O
markedly O
decreased O
levels O
of O
CAD I-GENE
mRNA I-GENE
and O
protein O
in O
the O
mutant O
. O

The O
rationale O
for O
continuous O
dopaminergic O
stimulation O
in O
patients O
with O
Parkinson O
' O
s O
disease O
. O

Mutational O
studies O
revealed O
that O
it O
was O
the O
homeodomain I-GENE
binding I-GENE
site I-GENE
II I-GENE
sequence I-GENE
that O
was O
required O
for O
this O
regulation O
. O

Thus O
, O
the O
pol I-GENE
alpha I-GENE
- O
primase I-GENE
complex O
appears O
to O
act O
processively O
for O
only O
a O
short O
distance O
. O

Interestingly O
, O
the O
positions O
of O
these O
introns O
have O
been O
conserved O
in O
comparison O
with O
the O
genes O
of O
two O
other O
transglutaminase O
- O
like O
activities O
described O
in O
the O
literature O
, O
but O
the O
TGM1 I-GENE
gene I-GENE
is O
by O
far O
the O
smallest O
characterized O
to O
date O
because O
its O
introns O
are O
relatively O
smaller O
. O

In O
a O
retrospective O
analysis O
of O
data O
from O
35 O
cases O
with O
malignant O
lymphoma O
from O
a O
cohort O
of O
2017 O
HIV O
- O
infected O
patients O
, O
the O
stage O
of O
HIV O
- O
disease O
, O
the O
CD4 I-GENE
counts O
at O
the O
time O
of O
diagnosis O
, O
and O
the O
use O
of O
antineoplastic O
agents O
or O
radiotherapy O
were O
correlated O
with O
outcome O
. O

1 O
. O

Effects O
of O
dioxins O
on O
thyroid O
function O
in O
newborn O
babies O
. O

cDNA O
clones O
encoding O
Arabidopsis O
thaliana O
and O
Zea I-GENE
mays I-GENE
mitochondrial I-GENE
chaperonin I-GENE
HSP60 I-GENE
and O
gene O
expression O
during O
seed O
germination O
and O
heat O
shock O
. O

Amino O
acid O
sequence O
comparison O
revealed O
significant O
homology O
between O
the O
yeast I-GENE
and I-GENE
Escherichia I-GENE
coli I-GENE
gamma I-GENE
- I-GENE
glutamyl I-GENE
kinases I-GENE
throughout O
their O
lengths O
. O

The O
single O
site O
of O
glycosylation O
is O
located O
near O
the O
C O
- O
terminus O
in O
the O
N O
- O
glycosylation O
sequon O
- O
Asn O
- O
Cys O
- O
Ser O
- O
in O
which O
Cys O
forms O
part O
of O
a O
disulphide O
bridge O
. O

The O
pulmonary O
toxic O
events O
induced O
by O
acute O
nitrogen O
dioxide O
( O
NO O
) O
2 O
exposure O
were O
studied O
in O
the O
rat O
to O
develop O
an O
inhalation O
model O
to O
investigate O
therapeutic O
measures O
. O

The O
pulmonary O
effects O
observed O
, O
became O
more O
pronounced O
with O
increasing O
NO2 O
concentrations O
( O
0 O
, O
25 O
, O
75 O
, O
125 O
, O
175 O
or O
200 O
ppm O
, O
1 O
ppm O
NO2 O
= O
1 O
. O
88 O
mg O
m O
- O
3 O
NO2 O
) O
and O
exposure O
times O
( O
5 O
, O
10 O
, O
20 O
or O
30 O
min O
). O

Interaction O
of O
H I-GENE
- I-GENE
2Eb I-GENE
with O
an O
IAP I-GENE
retrotransposon I-GENE
in O
the O
A20 O
/ O
2J O
B O
cell O
lymphoma O
. O

Gestational O
trophoblastic O
diseases O
: O
recent O
advances O
in O
the O
understanding O
of O
cytogenetics O
, O
histopathology O
, O
and O
natural O
history O
. O

With O
the O
exception O
of O
mutants O
that O
remove O
the O
membrane O
anchor O
domain O
, O
all O
of O
the O
mutant O
glycoproteins O
retained O
the O
ability O
to O
cause O
fusion O
of O
CD4 I-GENE
- O
bearing O
cells O
. O

The O
subunit O
protein O
of O
curli I-GENE
was O
highly O
homologous O
at O
its O
amino O
terminus O
to O
SEF I-GENE
- I-GENE
17 I-GENE
, O
the O
subunit O
protein O
of O
thin O
, O
aggregative O
fimbriae O
of O
Salmonella O
enteritidis O
27655 O
strain O
3b O
, O
suggesting O
that O
these O
fibres O
form O
a O
novel O
class O
of O
surface O
organelles O
on O
enterobacteria O
. O

Substitution O
of O
the O
DR1 I-GENE
beta I-GENE
chain I-GENE
with O
H I-GENE
- I-GENE
2E I-GENE
beta I-GENE
k I-GENE
led O
to O
a O
dramatic O
loss O
of O
recognition O
; O
alpha O
chain O
substitution O
had O
a O
less O
marked O
effect O
. O

This O
negative O
regulatory O
pathway O
may O
be O
important O
for O
determining O
cell O
fate O
or O
maintaining O
an O
inducible O
state O
in O
the O
ventroposterior O
region O
of O
the O
embryo O
. O

The O
distal O
portion O
of O
the O
rat I-GENE
insulin I-GENE
I I-GENE
gene I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
DNA I-GENE
contains O
two O
sequence O
elements O
, O
the O
Far O
and O
FLAT O
elements O
, O
that O
can O
function O
in O
combination O
, O
but O
not O
separately O
, O
as O
a O
beta O
- O
cell O
- O
specific O
transcriptional O
enhancer O
. O

The O
deduced O
amino O
acid O
sequence O
exhibited O
98 O
% O
identity O
to O
the O
human O
cellular O
transglutaminase O
sequence O
. O

This O
computation O
is O
performed O
by O
a O
parallel O
network O
of O
locally O
connected O
neuron O
- O
like O
elements O
. O

Repeated O
efforts O
to O
isolate O
recombinant O
baculoviruses O
containing O
a O
wild O
- O
type O
kinase O
failed O
, O
whereas O
recombinants O
expressing O
a O
nonfunctional O
kinase O
with O
a O
catalytic O
domain O
II O
mutation O
were O
readily O
isolated O
. O

Finally O
, O
we O
determined O
that O
the O
P68 I-GENE
amino O
terminus O
was O
both O
necessary O
and O
sufficient O
for O
binding O
dsRNA O
as O
we O
were O
able O
to O
transfer O
dsRNA O
- O
binding O
properties O
to O
a O
reporter O
gene O
product O
previously O
unable O
to O
bind O
RNA O
. O

From O
August O
1989 O
to O
October O
1990 O
, O
83 O
pregnant O
Chinese O
women O
were O
the O
subjects O
for O
measuring O
the O
levels O
of O
plasma O
functional O
antithrombin I-GENE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
activity O
. O

Visual O
acuity O
may O
be O
decreased O
by O
transient O
changes O
in O
refractive O
error O
caused O
by O
sulfonamides O
, O
the O
antifungal O
agent O
metronidazole O
, O
thiazide O
diuretics O
, O
and O
carbonic I-GENE
anhydrase I-GENE
inhibitors O
. O

Currents O
aspects O
of O
H2 I-GENE
receptor I-GENE
antagonists O
in O
the O
treatment O
of O
ulcers O

In O
addition O
, O
a O
21 O
- O
mer O
subrepeat O
structure O
is O
also O
present O
in O
each O
unit O
. O

Sequencing O
revealed O
one O
large O
open O
reading O
frame O
encoding O
a O
39 O
- O
kDa O
protein O
. O

These O
sites O
are O
also O
potential O
keratan O
sulfate O
attachment O
sites O
. O

We O
propose O
that O
plasmids O
of O
the O
pLS1 O
family O
( O
pE194 O
, O
pADB201 O
, O
and O
pLB4 O
) O
share O
functional O
and O
structural O
characteristics O
for O
the O
regulation O
of O
their O
copy O
numbers O
. O

Perturbation O
of O
dNTP O
pools O
also O
affected O
the O
frameshift O
fidelity O
of O
the O
replicative O
yeast I-GENE
DNA I-GENE
polymerase I-GENE
alpha I-GENE
. O

Differential O
expression O
of O
the O
" O
B O
" O
subunit O
of O
the O
vacuolar I-GENE
H I-GENE
(+)- I-GENE
ATPase I-GENE
in O
bovine O
tissues O
. O

In O
addition O
, O
the O
hGCSFR I-GENE
gene I-GENE
was O
chromosomally O
localized O
by O
Southern O
blot O
analysis O
of O
its O
segregation O
pattern O
in O
a O
panel O
of O
rodent O
- O
human O
hybrid O
DNAs O
using O
the O
radiolabeled O
cDNA O
probe O
. O

We O
have O
isolated O
and O
characterised O
a O
differentially O
- O
regulated O
gene O
family O
in O
the O
protozoan O
parasite O
Leishmania O
major O
. O

At O
some O
sites O
, O
% O
T O
is O
greatly O
increased O
by O
Cl O
- O
concentrations O
up O
to O
1 O
M O
, O
while O
at O
other O
sites O
% O
T O
is O
reduced O
or O
unaffected O
by O
these O
conditions O
. O

Necrosis O
appears O
6 O
h O
after O
TA O
infusion O
, O
being O
5 O
. O
77 O
% O
in O
extent O
after O
12 O
h O
, O
14 O
. O
9 O
% O
after O
24 O
h O
and O
animals O
die O
with O
an O
area O
of O
29 O
. O
5 O
% O
necrosis O
. O

In O
summary O
, O
the O
segments O
of O
C3 I-GENE
represented O
by O
amino O
acid O
residues O
1082 O
- O
1118 O
, O
1117 O
- O
1155 O
, O
1234 O
- O
1294 O
and O
1312 O
- O
1404 O
accommodate O
C3 I-GENE
( I-GENE
D I-GENE
) I-GENE
epitopes I-GENE
that O
are O
expressed O
by O
erythrocyte O
- O
bound O
C3 I-GENE
fragments I-GENE
, O
but O
not O
by O
the O
corresponding O
fluid O
- O
phase O
fragment O
, O
whereas O
the O
segments O
spanning O
residues O
973 O
- O
1026 O
and O
1477 O
- O
1510 O
contain O
C3 I-GENE
( I-GENE
D I-GENE
) I-GENE
epitopes I-GENE
that O
are O
exposed O
exclusively O
in O
denatured O
C3 I-GENE
and O
therefore O
hidden O
in O
physiological O
fragments O
of O
the O
protein O
. O

These O
exons O
, O
further O
identified O
as O
exons O
9 O
, O
10 O
, O
and O
11 O
, O
together O
encode O
the O
37 O
amino O
acid O
residues O
present O
in O
alpha I-GENE
s1 I-GENE
- I-GENE
casein I-GENE
variant I-GENE
A I-GENE
but O
missing O
in O
variant O
F O
. O

We O
also O
report O
here O
the O
complete O
structural O
organization O
of O
the O
goat I-GENE
alpha I-GENE
s1 I-GENE
- I-GENE
casein I-GENE
transcription I-GENE
unit I-GENE
, O
deduced O
from O
polymerase O
chain O
reaction O
experiments O
. O

Homodimers O
of O
the O
three O
proteins O
specifically O
recognize O
the O
G O
- O
box O
motif O
, O
with O
GBF1 I-GENE
and O
GBF3 I-GENE
binding O
symmetrically O
to O
this O
palindromic O
sequence O
. O

Neither O
gene O
possesses O
a O
distinct O
transcriptional O
start O
site O
as O
shown O
by O
nuclease I-GENE
S1 I-GENE
analysis O
. O

The O
hydrophobicity O
plot O
of O
NHE I-GENE
- I-GENE
3 I-GENE
is O
very O
similar O
to O
that O
of O
NHE I-GENE
- I-GENE
1 I-GENE
and O
NHE I-GENE
- I-GENE
2 I-GENE
. O

The O
initial O
translation O
protein O
encoded O
by O
the O
cDNA O
is O
53 O
, O
932 O
kDa O
and O
possesses O
a O
hydrophilic O
amino O
acid O
composition O
with O
glutamic O
acid O
comprising O
22 O
% O
of O
the O
total O
amino O
acid O
residues O
. O

Each O
group O
received O
15 O
ml O
/ O
kg O
of O
either O
6 O
% O
pentafraction O
, O
6 O
% O
pentastarch O
, O
or O
plasma O
followed O
two O
hours O
later O
by O
1 O
. O
5 O
micrograms O
/ O
kg O
/ O
0 O
. O
5 O
hr O
E O
. O

Genetic O
and O
biochemical O
evidence O
suggests O
that O
v I-GENE
- I-GENE
Crk I-GENE
can O
induce O
transformation O
of O
chicken O
embryo O
fibroblasts O
by O
influencing O
the O
activity O
of O
cellular O
proteins O
involved O
in O
growth O
regulation O
. O

We O
have O
constructed O
, O
using O
synthetic O
DNA O
oligonucleotides O
, O
a O
U14 I-GENE
snRNA I-GENE
gene I-GENE
which O
has O
been O
positioned O
behind O
a O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
site I-GENE
and O
then O
inserted O
into O
a O
plasmid O
. O

Gene O
and O
pseudogene O
of O
the O
mouse O
cation O
- O
dependent O
mannose I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
receptor I-GENE
. O

The O
chick O
axon O
- O
associated O
surface O
glycoprotein O
neurofascin I-GENE
is O
implicated O
in O
axonal O
growth O
and O
fasciculation O
as O
revealed O
by O
antibody O
perturbation O
experiments O
. O

The O
carcinoma O
was O
restricted O
within O
the O
epithelium O
in O
one O
, O
the O
mucosal O
layer O
in O
five O
, O
and O
the O
submucosal O
layer O
in O
two O
. O

In O
addition O
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
gamma I-GENE
readily O
heterodimerize O
with O
each O
other O
as O
well O
as O
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
. O

In O
contrast O
, O
tobacco I-GENE
GS I-GENE
- I-GENE
2 I-GENE
is O
composed O
of O
subunits O
of O
identical O
size O
in O
all O
organs O
examined O
. O

Between O
acoR I-GENE
and O
acoXABC I-GENE
, O
two O
different O
types O
of O
sequences O
with O
dual O
rotational O
symmetry O
[ O
CAC O
-( O
N11 O
to O
N18 O
)- O
GTG O
and O
TGT O
-( O
N10 O
to O
N14 O
)- O
ACA O
] O
were O
found O
; O
these O
sequences O
are O
similar O
to O
NtrC I-GENE
and O
NifA I-GENE
upstream I-GENE
activator I-GENE
sequences I-GENE
, O
respectively O
. O

Although O
the O
effects O
of O
the O
calcium O
supplement O
or O
calcium O
antagonist O
alone O
were O
significant O
, O
such O
hypotensive O
responses O
were O
not O
optimal O
or O
predictable O
or O
clearly O
dose O
- O
dependent O
. O

C O
., O
Sun O
, O
J O
., O
Hsu O
, O
M O
.- O
Y O
., O
Vallejo O
- O
Ramirez O
, O
J O
., O
Inouye O
, O
S O
., O
and O
Inouye O
, O
M O
. O

Surprisingly O
, O
the O
full O
- O
deletion O
mutant O
showed O
a O
strong O
block O
in O
virus O
release O
, O
suggesting O
that O
NC I-GENE
is O
involved O
in O
virus O
assembly O
. O

Furthermore O
it O
was O
suggested O
that O
FK506 O
plasma O
levels O
were O
concerned O
with O
the O
appearance O
of O
side O
effect O
. O

Thirty O
percent O
of O
patients O
were O
tapered O
off O
all O
steroids O
, O
and O
the O
average O
steroid O
dose O
in O
the O
group O
who O
received O
steroids O
was O
8 O
. O
6 O
mg O
of O
prednisone O
per O
day O
. O

Thus O
, O
cibenzoline O
is O
an O
effective O
antiarrhythmic O
agent O
with O
a O
favourable O
pharmacokinetic O
profile O
that O
may O
be O
considered O
with O
other O
class O
I O
drugs O
in O
patients O
requiring O
therapy O
for O
high O
risk O
arrhythmias O
. O

T I-GENE
antigen I-GENE
contains O
four O
H O
- O
2Db O
- O
restricted O
cytotoxic O
T O
lymphocyte O
( O
CTL O
) O
recognition O
epitopes O
that O
are O
targets O
for O
CTL O
clones O
Y O
- O
1 O
, O
Y O
- O
2 O
, O
Y O
- O
3 O
, O
and O
Y O
- O
5 O
. O

The O
method O
requires O
a O
reversed O
- O
phase O
column O
and O
a O
paired O
- O
ion O
technique O
to O
separate O
docusate O
sodium O
from O
other O
components O
. O

Here O
we O
demonstrate O
that O
the O
protein O
product O
of O
the O
ref I-GENE
- I-GENE
1 I-GENE
gene I-GENE
stimulates O
the O
DNA O
binding O
activity O
of O
Fos I-GENE
- O
Jun I-GENE
heterodimers O
, O
Jun I-GENE
- O
Jun I-GENE
homodimers O
and O
Hela O
cell O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
as O
well O
as O
that O
of O
several O
other O
transcription O
factors O
including O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
, O
Myb I-GENE
and O
members O
of O
the O
ATF I-GENE
/ O
CREB I-GENE
family O
. O

The O
pulpal O
tissues O
of O
the O
permanent O
mandibular O
molars O
were O
amputated O
and O
then O
dressed O
with O
calcium O
hydrate O
. O

Northern O
blot O
analyses O
demonstrate O
that O
3 O
. O
9 O
- O
and O
5 O
- O
kilobase O
mRNAs O
corresponding O
to O
the O
cDNA O
were O
present O
in O
all O
tissues O
examined O
, O
suggesting O
that O
the O
protein O
it O
encodes O
performs O
a O
housekeeping O
function O
. O

The O
ARG I-GENE
SH2 I-GENE
domain I-GENE
exhibited O
relatively O
weak O
affinity O
for O
BCR I-GENE
and O
was O
determined O
to O
bind O
about O
10 O
- O
fold O
less O
strongly O
than O
the O
ABL I-GENE
SH2 I-GENE
domain I-GENE
. O

We O
analyzed O
an O
EBV O
B O
- O
cell O
clone O
, O
E29 O
. O
1 O
, O
derived O
from O
an O
11 O
week O
- O
old O
embryo O
, O
and O
secreting O
both O
IgM I-GENE
kappa I-GENE
and O
IgM I-GENE
lambda I-GENE
. O

Interestingly O
, O
this O
activation O
occurred O
only O
when O
the O
regions O
were O
cloned O
in O
the O
same O
relative O
orientation O
in O
which O
they O
exist O
on O
wild O
- O
type O
pCF10 O
. O

In O
rats O
, O
we O
examined O
the O
effect O
of O
an O
omentum O
wrapping O
on O
the O
vascularization O
of O
the O
trachea O
and O
on O
regeneration O
of O
the O
mucosal O
epithelium O
in O
the O
very O
early O
stage O
after O
free O
tracheal O
grafting O
. O

To O
study O
a O
possible O
functional O
role O
of O
this O
putative O
chicken O
ICS I-GENE
, O
an O
oligonucleotide O
spanning O
the O
upstream O
sequences O
of O
the O
BF I-GENE
- I-GENE
IV I-GENE
gene I-GENE
(- O
174 O
/- O
194 O
) O
was O
cloned O
singly O
or O
in O
multiple O
copies O
before O
the O
herpes O
TK I-GENE
promoter I-GENE
controlling O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
gene O
( O
pBLCAT2 I-GENE
). O

In O
general O
, O
two O
separate O
high O
- O
performance O
liquid O
chromatographic O
runs O
were O
performed O
, O
one O
for O
the O
gamma O
- O
aminobutyric O
acid O
determination O
and O
one O
for O
the O
determination O
of O
the O
monoamines O
. O

We O
report O
the O
successful O
use O
of O
electroconvulsive O
therapy O
for O
treatment O
of O
severe O
depression O
in O
a O
young O
man O
with O
adult O
GM2 O
gangliosidosis O
. O

Entry O
of O
yeast O
cells O
into O
the O
mitotic O
cell O
cycle O
( O
Start O
) O
involves O
a O
form O
of O
the O
CDC28 I-GENE
kinase I-GENE
that O
associates O
with O
G1 O
- O
specific O
cyclins I-GENE
encoded O
by O
CLN1 I-GENE
and O
CLN2 I-GENE
( O
ref O
. O

Through O
Southern O
blot O
analyses O
of O
DNA O
from O
backcross O
and O
cogenic O
mice O
, O
recombinant O
inbred O
strains O
, O
and O
somatic O
cell O
hybrids O
, O
the O
genetic O
loci O
that O
produce O
the O
cyclin I-GENE
B1 I-GENE
- I-GENE
related I-GENE
sequences I-GENE
( O
designated O
loci I-GENE
Cycb1 I-GENE
- I-GENE
rs1 I-GENE
to O
Cycb1 I-GENE
- I-GENE
rs9 I-GENE
) O
were O
mapped O
on O
mouse O
chromosomes O
5 O
, O
1 O
, O
17 O
, O
4 O
, O
14 O
, O
13 O
, O
7 O
, O
X O
, O
and O
8 O
, O
respectively O
. O

Again O
residue O
Glu O
- O
381 O
of O
beta O
was O
notably O
reduced O
and O
no O
missing O
residue O
from O
the O
epsilon O
peptide O
could O
be O
identified O
, O
but O
the O
peptide O
sequence O
limited O
the O
possible O
choices O
to O
Ser O
- O
106 O
, O
Ser O
- O
107 O
, O
or O
Ser O
- O
108 O
. O

Porcelain O
to O
dentin O
bond O
strength O
with O
a O
dentin O
adhesive O
. O

TBPf O
is O
defined O
as O
a O
quotient O
of O
the O
difference O
of O
the O
first O
and O
the O
second O
measurement O
: O
TBPf O
= O
( O
P1 O
- O
P2 O
)/( O
A1 O
- O
A2 O
). O

It O
was O
concluded O
that O
Scotchbond O
2 O
and O
Prisma O
Universal O
Bond O
2 O
are O
effective O
and O
are O
the O
dentine O
bonding O
agents O
of O
choice O
. O

From O
all O
clinically O
important O
yeasts O
species O
, O
a O
total O
of O
96 O
% O
were O
identified O
by O
ATB O
method O
according O
to O
conventional O
methods O
. O

The O
neurohypophysial O
vasopressin I-GENE
and O
oxytocin I-GENE
content O
was O
bioassayed O
by O
pressor O
effect O
following O
Dekanski O
or O
milk O
- O
ejection O
activity O
in O
vitro O
following O
van O
Dongen O
and O
Hays O
, O
respectively O
. O

Comments O
are O
given O
on O
the O
present O
status O
of O
regulations O
concerning O
water O
in O
swimming O
pools O
and O
baths O
-- O
1991 O
--( O
in O
connection O
with O
the O
KOK O
regulations O
-- O
1972 O
-- O
and O
the O
Federal O
German O
standard O
[ O
DIN O
] O
No O
. O

If O
no O
reply O
was O
received O
, O
telephone O
contact O
or O
home O
visits O
were O
made O
. O

The O
treatment O
group O
also O
showed O
in O
vivo O
T O
- O
cell O
activation O
with O
an O
initial O
lymphopenia O
followed O
by O
a O
rebound O
lymphocytosis O
and O
upregulation O
of O
the O
subset O
markers O
CD25 I-GENE
( O
interleukin I-GENE
2 I-GENE
receptor I-GENE
) O
and O
CD45RO I-GENE
( O
T O
- O
memory O
cells O
). O

Urease I-GENE
activity O
, O
judged O
as O
the O
amount O
of O
ammonia O
production O
from O
urea O
, O
could O
be O
measured O
at O
25 O
ng O
per O
tube O
( O
S O
/ O
N O
= O
1 O
. O
5 O
) O
with O
Jack I-GENE
bean I-GENE
meal I-GENE
urease I-GENE
. O

Consequently O
, O
significant O
differences O
between O
the O
measured O
and O
calculated O
methods O
were O
noted O
in O
oxygen O
uptake O
( O
213 O
+/- O
41 O
ml O
/ O
min O
vs O
193 O
+/- O
25 O
ml O
/ O
min O
, O
p O
< O
0 O
. O
001 O
), O
oxygen O
delivery O
( O
780 O
+/- O
297 O
ml O
/ O
min O
vs O
716 O
+/- O
296 O
ml O
/ O
min O
, O
p O
< O
0 O
. O
001 O
), O
and O
cardiac O
output O
( O
5 O
. O
8 O
+/- O
2 O
. O
2 O
L O
/ O
min O
vs O
5 O
. O
3 O
+/- O
1 O
. O
8 O
L O
/ O
min O
, O
p O
< O
0 O
. O
001 O
). O

Although O
a O
wide O
range O
of O
cognitive O
functions O
had O
been O
tested O
, O
all O
but O
one O
seizure O
occurred O
during O
assessment O
of O
memory O
performance O
. O

The O
experiments O
show O
that O
it O
is O
the O
micromilieu O
of O
the O
alveoli O
and O
the O
condition O
of O
the O
AM O
( O
certain O
physiological O
activation O
states O
, O
such O
as O
phagocytic O
activity O
) O
that O
essentially O
determine O
the O
degree O
of O
recovery O
. O

Negatively O
supercoiled O
plasmid O
pUC19 O
did O
not O
compete O
, O
whereas O
an O
otherwise O
identical O
plasmid O
pUC19 O
( O
CG O
), O
which O
contained O
a O
( O
dG O
- O
dC O
) O
7 O
segment O
in O
the O
Z O
- O
form O
was O
an O
excellent O
competitor O
. O

A O
cDNA O
library O
of O
tumour O
cells O
was O
screened O
with O
an O
interleukin I-GENE
2 I-GENE
gene O
- O
specific O
probe O
. O

Our O
experiments O
suggest O
that O
the O
SCL I-GENE
gene I-GENE
can O
be O
a O
target O
for O
the O
erythroid I-GENE
transcription I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
and O
that O
the O
SCL I-GENE
gene I-GENE
product I-GENE
serves O
as O
a O
positive O
regulator O
of O
erythroid O
differentiation O
. O

In O
contrast O
, O
the O
lumenal O
domains O
of O
Sec12p I-GENE
, O
Stl1p I-GENE
and O
Stl2p I-GENE
are O
very O
different O
in O
size O
and O
do O
not O
show O
any O
appreciable O
homology O
. O

Complexes O
containing O
wild O
- O
type O
and O
either O
his175 I-GENE
or I-GENE
his273 I-GENE
mutant I-GENE
p53 I-GENE
proteins I-GENE
are O
completely O
unable O
to O
bind O
to O
the O
RGC I-GENE
DNA I-GENE
sequence I-GENE
. O

These O
temperature O
- O
and O
cold O
- O
sensitive O
strains O
were O
used O
to O
prepare O
extracts O
deficient O
in O
BRF1 I-GENE
activity O
and O
were O
tested O
for O
transcriptional O
activity O
by O
RNA I-GENE
polymerases I-GENE
I I-GENE
, I-GENE
II I-GENE
, I-GENE
and I-GENE
III I-GENE
in O
vitro O
. O

These O
results O
lead O
us O
to O
hypothesize O
that O
a O
single O
multisubunit I-GENE
TFIID I-GENE
protein I-GENE
supports O
transcriptional O
stimulation O
by O
diverse O
activation O
domains O
and O
from O
a O
TATA O
- O
less O
promoter O
. O

The O
gene O
sequence O
also O
identified O
a O
340 O
- O
nucleotide O
RNA O
in O
total O
yeast O
RNA O
and O
in O
purified O
RNase I-GENE
MRP I-GENE
enzyme I-GENE
preparations O
. O

The O
RNase I-GENE
MRP I-GENE
RNA I-GENE
gene I-GENE
was O
deleted O
by O
insertional O
replacement O
and O
found O
to O
be O
essential O
for O
cellular O
viability O
, O
indicating O
a O
critical O
nuclear O
role O
for O
RNase I-GENE
MRP I-GENE
. O

Clone O
pSRc200 O
hybrid O
selected O
an O
mRNA O
that O
on O
cell O
- O
free O
translation O
produced O
a O
38 O
- O
kDa O
polypeptide O
. O

From O
these O
results O
, O
CBF I-GENE
- I-GENE
A I-GENE
is O
a O
novel O
CArG O
box O
-, O
ssDNA I-GENE
- I-GENE
and I-GENE
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
as O
well O
as O
a O
repressive O
transcriptional O
factor O
. O

Cleavage O
by O
the O
intron O
- O
encoded O
enzyme O
( O
I I-GENE
- I-GENE
CreI I-GENE
) O
occurs O
5 O
bp O
and O
1 O
bp O
3 O
' O
to O
the O
intron O
insertion O
site O
( O
in O
the O
3 O
'- O
exon O
) O
in O
the O
top O
(/) O
and O
bottom O
(,) O
strands O
, O
respectively O
, O
resulting O
in O
4 O
- O
nt O
single O
- O
stranded O
overhangs O
with O
3 O
'- O
OH O
termini O
. O

Surprisingly O
, O
the O
Xenopus I-GENE
U7 I-GENE
gene I-GENE
contains O
two O
adjacent O
octamer O
- O
binding O
motifs O
located O
only O
12 O
and O
24 O
bp O
upstream O
from O
the O
PSE I-GENE
, O
instead O
of O
the O
usual O
location O
around O
150 O
- O
200 O
bp O
upstream O
. O

The O
results O
support O
earlier O
reports O
that O
collagenase I-GENE
inhibitors O
are O
useful O
in O
controlling O
blister O
formation O
in O
recessive O
dystrophic O
epidermolysis O
bullosa O
. O

Mutational O
analysis O
of O
essential O
IncP O
alpha O
plasmid O
transfer O
genes O
traF I-GENE
and O
traG I-GENE
and O
involvement O
of O
traF I-GENE
in O
phage O
sensitivity O
. O

The O
promoter O
was O
stimulated O
8 O
- O
20 O
- O
fold O
by O
phorbol O
esters O
accounting O
for O
the O
previously O
observed O
transcriptional O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
beta I-GENE
. O

In O
humans O
, O
four O
AMP I-GENE
deaminase I-GENE
variants I-GENE
, O
termed O
M I-GENE
( O
muscle O
), O
L I-GENE
( O
liver O
), O
E1 I-GENE
, O
and O
E2 I-GENE
( O
erythrocyte O
) O
can O
be O
distinguished O
by O
a O
variety O
of O
biochemical O
and O
immunological O
criteria O
. O

Western O
blot O
analyses O
detect O
anti I-GENE
- I-GENE
E I-GENE
- O
specific O
immunoreactivity O
in O
affinity O
- O
purified O
extracts O
derived O
from O
the O
bacterial O
expression O
of O
a O
truncated I-GENE
AMPD3 I-GENE
cDNA I-GENE
. O

These O
results O
demonstrate O
that O
endogenous O
N O
- O
methylation O
of O
salsolinol O
into O
N O
- O
methylsalsolinol O
occurs O
in O
the O
brain O
in O
vivo O
. O

DR1 I-GENE
molecules I-GENE
purified O
from O
human O
lymphoblastoid O
cell O
lines O
could O
specifically O
bind O
to O
these O
peptide O
sequences O
expressed O
on O
the O
phage O
surface O
. O

This O
article O
describes O
the O
collaborative O
care O
of O
the O
woman O
participating O
in O
maternal O
blood O
donation O
for O
intrauterine O
transfusion O
. O

Chronic O
hepatitis O
B O
in O
adopted O
Romanian O
children O
. O

Behind O
the O
ATPase I-GENE
cluster I-GENE
, O
two O
open O
reading O
frames O
were O
detected O
that O
are O
not O
homologous O
to O
any O
known O
chloroplast O
gene O
. O

Therefore O
, O
recombinant O
human O
Ads O
that O
express O
noninfectious O
HIV O
or O
other O
microbial O
proteins O
are O
attractive O
vaccine O
candidates O
. O

Alignment O
of O
the O
selected O
sequences O
allowed O
us O
to O
predict O
a O
consensus O
sequence O
for O
binding O
of O
the O
individual O
homodimeric O
Rel I-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
and O
DNA O
- O
protein O
binding O
analysis O
of O
the O
selected O
DNA O
sequences O
revealed O
sequence O
specificity O
of O
the O
proteins O
. O

Using O
either O
a O
p50 I-GENE
- O
or O
p65 I-GENE
- I-GENE
selected I-GENE
kappa I-GENE
B I-GENE
motif I-GENE
, O
which O
displayed O
differential O
binding O
with O
respect O
to O
the O
other O
protein O
, O
little O
to O
no O
binding O
was O
observed O
with O
the O
heterodimeric I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
complex I-GENE
. O

However O
, O
a O
cosmid O
clone O
containing O
the O
entire O
mouse I-GENE
alpha I-GENE
1 I-GENE
( I-GENE
I I-GENE
) I-GENE
gene I-GENE
, O
including O
3 O
. O
7 O
kb O
of O
5 O
'- O
and O
4 O
kb O
of O
3 O
'- O
flanking O
DNA O
, O
was O
expressed O
at O
reduced O
levels O
in O
fibroblasts O
overexpressing O
oncogenic I-GENE
ras I-GENE
. O

To O
define O
transcriptional O
control O
elements O
responsible O
for O
muscle O
- O
specific O
expression O
of O
the O
human I-GENE
myoglobin I-GENE
gene I-GENE
, O
we O
performed O
mutational O
analysis O
of O
upstream O
sequences O
( O
nucleotide O
positions O
- O
373 O
to O
+ O
7 O
relative O
to O
the O
transcriptional O
start O
site O
) O
linked O
to O
a O
firefly I-GENE
luciferase I-GENE
gene I-GENE
. O

Sequencing O
analysis O
has O
shown O
that O
each O
rap1t I-GENE
allele I-GENE
contains O
a O
nonsense O
mutation O
within O
a O
discrete O
region O
between O
amino O
acids O
663 O
and O
684 O
. O

By O
screening O
a O
Y1 O
cell O
cDNA O
library O
with O
the O
DNA O
- O
binding O
region O
of O
the O
H I-GENE
- I-GENE
2RIIBP I-GENE
nuclear I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
, O
we O
isolated O
a O
cDNA O
that O
is O
selectively O
expressed O
in O
steroidogenic O
cells O
. O

Autopsy O
demonstrated O
good O
survival O
of O
the O
transplanted O
cells O
with O
good O
integration O
with O
the O
brain O
of O
the O
recipient O
and O
traces O
of O
positive O
immunocytochemical O
reaction O
for O
tyrosine I-GENE
hydroxylase I-GENE
. O

The O
technique O
of O
the O
TEE O
visualization O
of O
the O
proximal O
coronary O
arteries O
is O
described O
. O

The O
sequence O
of O
this O
region O
shows O
high O
G O
+ O
C O
content O
( O
62 O
%), O
which O
is O
particularly O
emphasized O
in O
the O
200 O
bp O
upstream O
from O
the O
mRNA O
start O
( O
80 O
% O
G O
+ O
C O
). O

In O
the O
eight O
patients O
with O
persistent O
generalized O
lymph O
- O
adenopathy O
( O
PGL O
) O
and O
nontender O
, O
nonenlarging O
nodes O
, O
pathologic O
analysis O
revealed O
lymphoid O
hyperplasia O
. O

PaO2 O
threshold O
was O
determined O
through O
an O
indwelling O
O2 O
sensor O
catheter O
. O

We O
found O
that O
both O
the O
E26 O
virus O
- O
encoded O
v I-GENE
- I-GENE
ets I-GENE
and O
the O
myeloid I-GENE
/ I-GENE
B I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
factor I-GENE
PU I-GENE
. I-GENE
1 I-GENE
bind O
efficiently O
to O
this O
site O
in O
vitro O
. O

By O
using O
lambda O
gt11 O
expression O
cloning O
with O
oligonucleotides O
corresponding O
to O
the O
human O
immunodeficiency O
virus O
1 O
TATA O
element O
, O
we O
report O
the O
identification O
of O
a O
cellular O
protein O
with O
a O
calculated O
molecular O
mass O
of O
123 O
kDa O
that O
we O
designate O
TATA I-GENE
element I-GENE
modulatory I-GENE
factor I-GENE
( O
TMF I-GENE
). O

Blood O
levels O
of O
melatonin O
, O
serotonin O
, O
cortisol O
, O
and O
prolactin I-GENE
in O
relation O
to O
the O
circadian O
rhythm O
of O
platelet O
serotonin O
uptake O
. O

We O
couldn O
' O
t O
detect O
any O
effect O
of O
n O
- O
3 O
FA O
supplementation O
on O
total O
cholesterol O
, O
HDL I-GENE
cholesterol I-GENE
, O
LDL I-GENE
cholesterol I-GENE
, O
apo I-GENE
A1 I-GENE
, O
Lp O
( O
a O
), O
HbA1C I-GENE
, O
glucose O
, O
fibrinogen I-GENE
, O
factor I-GENE
VIII I-GENE
, O
antithrombin I-GENE
III I-GENE
, O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
, O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
and O
von I-GENE
Willebrand I-GENE
factor I-GENE
concentration O
, O
on O
bleeding O
time O
or O
on O
systolic O
or O
diastolic O
blood O
pressure O
. O

In O
8 O
healthy O
volunteers O
there O
were O
no O
significant O
differences O
in O
AUC O
, O
peak O
plasma O
concentrations O
or O
time O
to O
peak O
concentration O
when O
OXC O
was O
administered O
either O
with O
or O
without O
ERY O
. O

Using O
5 O
ng O
/ O
mL O
as O
the O
cutoff O
, O
the O
sensitivity O
of O
CEA I-GENE
was O
68 O
%. O

Rolandic O
spikes O
and O
cognitive O
function O
. O

The O
effect O
of O
sodium O
18 O
beta O
- O
glycyrrhetate O
( O
SGA O
) O
on O
experimental O
arrhythmia O
was O
investigated O
. O

Thus O
, O
chronic O
hematocrit O
decrease O
induced O
by O
H O
or O
P O
resulted O
in O
a O
significant O
fall O
in O
blood O
pressure O
compared O
to O
control O
( O
201 O
+/- O
3 O
v O
175 O
+/- O
4 O
, O
167 O
+/- O
4 O
mm O
Hg O
, O
respectively O
; O
P O
< O
. O
05 O
). O

The O
effects O
of O
diltiazem O
were O
stereoselective O
, O
thus O
the O
potentiation O
induced O
by O
d O
- O
cis O
diltiazem O
was O
significantly O
greater O
in O
all O
cases O
than O
that O
induced O
by O
l O
- O
cis O
diltiazem O
, O
which O
suggests O
that O
calcium O
channel O
blockade O
plays O
a O
role O
in O
these O
interactions O
. O

Localization O
of O
the O
brachial O
plexus O
with O
the O
nerve O
stimulator O
is O
equally O
effective O
at O
the O
interscalene O
, O
supraclavicular O
, O
and O
axillary O
sites O
. O

Substitution O
of O
either O
Val33 O
( O
by O
Gly O
) O
or O
Gly28 O
( O
by O
Ser O
), O
two O
of O
the O
most O
conserved O
residues O
in O
all O
protein O
kinases O
, O
resulted O
in O
enzyme O
with O
marginally O
detectable O
activity O
. O

Significance O
of O
the O
biopsy O
site O
of O
the O
latissimus O
dorsi O
muscle O
for O
fiber O
typing O
. O

The O
TIMP I-GENE
(- O
59 O
/ O
- O
53 O
) O
AP1 I-GENE
site O
is O
a O
promiscuous O
motif O
that O
binds O
c I-GENE
- I-GENE
Fos I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
AP1 I-GENE
translated O
in O
vitro O
and O
is O
an O
effective O
competitor O
for O
binding O
of O
nuclear I-GENE
AP1 I-GENE
factors I-GENE
to O
the O
consensus O
TRE O
, O
but O
in O
addition O
it O
binds O
factors O
that O
do O
not O
associate O
with O
the O
consensus O
TRE O
. O

Involvement O
of O
AP1 I-GENE
and O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
regulation O
of O
murine I-GENE
tissue I-GENE
inhibitor I-GENE
of I-GENE
metalloproteinases I-GENE
- I-GENE
1 I-GENE
( O
TIMP I-GENE
- I-GENE
1 I-GENE
) O
transcription O
. O

Of O
the O
serum I-GENE
neutralizing I-GENE
( I-GENE
SN I-GENE
) I-GENE
antibody I-GENE
negative O
calves O
89 O
. O
7 O
% O
( O
26 O
/ O
29 O
) O
and O
92 O
. O
8 O
% O
( O
90 O
/ O
97 O
) O
developed O
SN I-GENE
antibody I-GENE
1 O
month O
after O
intranasal O
and O
intramuscular O
vaccination O
, O
respectively O
. O

Fractionation O
of O
crude O
nuclear O
extracts O
by O
heparin O
- O
agarose O
chromatography O
indicates O
that O
PCAT I-GENE
- I-GENE
1 I-GENE
is O
more O
prevalent O
in O
extracts O
prepared O
from O
salt O
- O
stressed O
leaf O
tissue O
. O

A O
controlled O
trial O
of O
recombinant I-GENE
human I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
after O
total O
body O
irradiation O
, O
high O
- O
dose O
chemotherapy O
, O
and O
autologous O
bone O
marrow O
transplantation O
for O
acute O
lymphoblastic O
leukemia O
or O
malignant O
lymphoma O
. O

These O
data O
demonstrate O
that O
DMVA O
does O
not O
cause O
more O
myocardial O
trauma O
than O
CPB O
when O
used O
to O
provide O
resuscitative O
circulatory O
support O
. O

The O
IgG I-GENE
subclass O
profile O
of O
untreated O
coeliac O
disease O
was O
found O
to O
be O
the O
same O
as O
in O
healthy O
controls O
( O
IgG1 I-GENE
approximately O
IgG2 I-GENE
> O
IgG3 I-GENE
> O
IgG4 I-GENE
), O
with O
only O
the O
magnitude O
of O
the O
individual O
subclass O
responses O
being O
increased O
in O
coeliac O
patients O
. O

Examination O
of O
ANCA I-GENE
is O
not O
only O
a O
significant O
contribution O
towards O
a O
more O
accurate O
diagnosis O
of O
renal O
vasculitis O
, O
but O
also O
an O
indicator O
of O
the O
activity O
of O
the O
disease O
and O
thus O
of O
the O
effectiveness O
of O
immunosuppressive O
treatment O
. O

On O
the O
other O
hand O
, O
total O
pinealectomy O
in O
these O
already O
sympathectomized O
blinded O
rabbits O
always O
resulted O
in O
a O
substantial O
deceleration O
of O
the O
rhythms O
( O
mean O
delta O
tau O
= O
+ O
0 O
. O
23 O
h O
). O

Cicatricial O
pemphigoid O
is O
an O
autoimmune O
systemic O
disease O
characterized O
by O
chronic O
conjunctival O
cicatrization O
. O

The O
effects O
of O
two O
levels O
of O
caffeine O
ingestion O
on O
excess O
postexercise O
oxygen O
consumption O
in O
untrained O
women O
. O

The O
distinguishing O
features O
involved O
eight O
amino O
acid O
changes O
, O
including O
a O
single O
lysine O
deletion O
relative O
to O
a O
primate O
consensus O
sequence O
in O
the O
first O
complementary O
- O
determing O
region O
of O
V1J1 I-GENE
. O

4 O
. O

The O
in O
vivo O
profile O
of O
ZFH I-GENE
- I-GENE
2 I-GENE
in O
the O
larval O
CNS O
shows O
intriguing O
overlap O
with O
DDC I-GENE
in O
specific O
serotonin O
and O
dopamine O
neurons O
. O

Unlike O
the O
introns O
of O
other O
duplicated O
ribosomal I-GENE
protein I-GENE
genes I-GENE
which O
are O
highly O
diverged O
, O
the O
duplicated O
S13 I-GENE
genes I-GENE
have O
two O
nearly O
identical O
DNA O
sequences O
of O
25 O
and O
31 O
bp O
in O
length O
within O
their O
introns O
. O

In O
a O
prospective O
, O
randomized O
clinical O
trial O
we O
compared O
the O
efficacy O
of O
subcutaneously O
( O
SC O
) O
administered O
( O
every O
8 O
h O
) O
calcium O
heparin O
to O
intravenous O
( O
IV O
) O
sodium O
heparin O
in O
the O
treatment O
of O
proximal O
deep O
- O
vein O
thrombosis O
( O
DVT O
). O

The O
highest O
prevalence O
of O
reported O
pet O
allergy O
, O
chronic O
cough O
, O
wheeze O
, O
attacks O
of O
shortness O
of O
breath O
with O
wheezing O
, O
and O
doctor O
- O
diagnosed O
asthma O
was O
found O
in O
children O
who O
had O
pets O
in O
the O
past O
but O
not O
anymore O
. O

Therefore O
, O
it O
would O
be O
advantageous O
to O
identify O
such O
persons O
and O
treat O
them O
preferentially O
. O

On O
the O
basis O
of O
these O
unique O
properties O
, O
the O
newly O
characterized O
hemagglutinin I-GENE
has O
been O
termed O
Limulus I-GENE
18K I-GENE
agglutination I-GENE
- I-GENE
aggregation I-GENE
factor I-GENE
( O
18K I-GENE
- I-GENE
LAF I-GENE
). O

The O
shift O
to O
the O
nonpermissive O
temperature O
is O
accompanied O
by O
the O
loss O
of O
guanyl O
nucleotide O
- O
dependent O
activity O
of O
adenylylcyclase I-GENE
in O
vitro O
. O

Clin O
. O

The O
data O
indicate O
that O
the O
minimal O
catalytic O
domain O
of O
Nmt1p I-GENE
is O
located O
between O
Ile59 O
--> O
Phe96 O
and O
Gly451 O
--> O
Leu455 O
. O

It O
corresponds O
to O
the O
complete O
mitochondrial O
presequence O
and O
the O
lipoyl O
- O
bearing O
domain O
that O
are O
encoded O
by O
exons O
I O
through O
IV O
of O
the O
functional O
E2 I-GENE
gene I-GENE
. O

Human O
neutrophil O
response O
to O
short O
- O
term O
exposure O
to O
F O
- O
75 O
cobalt O
- O
based O
alloy O
. O

Disruption O
of O
microtubules O
did O
not O
affect O
the O
fidelity O
or O
kinetics O
of O
vacuolar O
protein O
sorting O
, O
indicating O
that O
Vps1p I-GENE
function O
is O
not O
dependent O
on O
microtubules O
. O

A O
mutant O
form O
of O
Vps1p I-GENE
lacking O
the O
entire O
GTP O
- O
binding O
domain O
interfered O
with O
vacuolar O
protein O
sorting O
in O
wild O
- O
type O
cells O
. O

According O
to O
out O
field O
research O
, O
the O
tick O
fauna O
was O
very O
rich O
throughout O
that O
area O
, O
and O
it O
was O
permissible O
enough O
to O
determine O
ticks O
as O
the O
vectors O
, O
based O
on O
arising O
of O
anti I-GENE
- I-GENE
SF I-GENE
group I-GENE
rickettsiae I-GENE
( O
SFGR I-GENE
) O
antibody O
in O
mice O
inoculated O
with O
some O
tick O
emulsions O
, O
findings O
of O
rickettsiae O
reactive O
to O
patient O
sera O
or O
a O
species O
- O
specific O
monoclonal O
antibody O
to O
JSFR I-GENE
in O
the O
hemolymph O
cells O
of O
some O
ticks O
, O
and O
electron O
microscopical O
observations O
of O
SFGR I-GENE
in O
various O
internal O
organs O
including O
the O
salivary O
gland O
of O
ticks O
. O

The O
second O
method O
, O
the O
" O
macro O
" O
assay O
, O
has O
a O
sensitivity O
range O
of O
0 O
. O
03 O
- O
5 O
. O
0 O
micrograms O
phosphorus O
with O
100 O
- O
500 O
microliters O
HClO4 O
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
polyhedrin I-GENE
gene I-GENE
of O
Spodoptera O
exigua O
nuclear O
polyhedrosis O
virus O
. O

Validation O
of O
automated O
systems O
-- O
system O
definition O
. O

As O
a O
consequence O
of O
dark O
rearing O
, O
the O
numerical O
density O
of O
cortical O
neurons O
in O
area O
17 O
amounted O
to O
about O
double O
of O
the O
value O
observed O
in O
normally O
reared O
kittens O
and O
was O
also O
significantly O
higher O
in O
area O
18 O
. O

These O
results O
suggest O
that O
decreased O
class O
I O
enhancer O
activity O
in O
Ad12 O
- O
transformed O
cells O
may O
, O
at O
least O
in O
part O
, O
be O
due O
to O
the O
higher O
levels O
of O
an O
enhancer O
- O
specific O
factor O
, O
possibly O
acting O
as O
a O
repressor O
. O

A O
second O
domain O
, O
located O
in O
the O
C O
- O
terminal O
437 O
amino O
acids O
of O
IE1 I-GENE
, O
is O
required O
for O
inhibitory O
and O
DNA O
- O
binding O
activities O
. O

In O
order O
to O
investigate O
the O
blood O
compatibility O
of O
autogenous O
vein O
graft O
( O
AVG O
), O
changes O
in O
prostacyclin O
( O
PGI2 O
) O
production O
following O
harvesting O
and O
arterial O
implantation O
were O
studied O
experimentally O
. O

Subcutaneous O
administration O
of O
the O
somatostatin I-GENE
analogue O
, O
octreotide O
, O
100 O
micrograms O
thrice O
daily O
, O
resulted O
in O
a O
sustained O
improvement O
in O
diarrhoea O
and O
disappearance O
of O
faecal O
incontinence O
without O
reducing O
calcitonin I-GENE
levels O
. O

Anti I-GENE
- I-GENE
CRK I-GENE
antibodies I-GENE
detect O
a O
53kDa O
protein O
in O
extracts O
of O
C O
. O
fasciculata O
in O
agreement O
with O
the O
size O
predicted O
from O
the O
nucleotide O
sequence O
of O
the O
cloned O
gene O
. O

205 O
, O
285 O
- O
290 O
] O
and O
was O
subsequently O
cloned O
and O
sequenced O
[ O
J O
. O

Nonreplicating O
vaccinia O
vector O
efficiently O
expresses O
recombinant O
genes O
. O

Use O
of O
free O
- O
access O
minerals O
. O

Interferon I-GENE
type I-GENE
I I-GENE
in O
protective O
body O
reactions O
in O
an O
experimental O
Klebsiella O
infection O

No O
other O
changes O
in O
hematopoietic O
differentiation O
status O
were O
observed O
in O
association O
with O
Id I-GENE
- I-GENE
SCL I-GENE
expression O
. O

Respiratory O
interaction O
after O
spinal O
anesthesia O
and O
sedation O
with O
midazolam O
. O

For O
pressure O
greater O
than O
121 O
atm O
abs O
, O
an O
increased O
excitability O
of O
the O
tadpoles O
made O
it O
difficult O
to O
distinguish O
the O
righting O
reflex O
from O
involuntary O
movements O
. O

One O
air O
embolism O
occurred O
; O
this O
was O
the O
only O
filter O
- O
or O
retrieval O
- O
related O
complication O
. O

The O
5 O
' O
region O
of O
ADH5 I-GENE
contains O
consensus O
binding O
sites O
for O
the O
transcriptional O
regulatory O
proteins O
, O
Sp1 I-GENE
, O
AP2 I-GENE
, O
LF I-GENE
- I-GENE
A1 I-GENE
, O
NF I-GENE
- I-GENE
1 I-GENE
, O
NF I-GENE
- I-GENE
A2 I-GENE
, O
and O
NF I-GENE
- I-GENE
E1 I-GENE
. O

V O
. O

These O
data O
indicate O
that O
RNK I-GENE
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
is O
a O
serine I-GENE
protease I-GENE
with O
unique O
activity O
that O
is O
expressed O
in O
the O
granules O
of O
large O
granular O
lymphocytes O
. O

Purification O
and O
cloning O
of O
a O
novel O
serine I-GENE
protease I-GENE
, O
RNK I-GENE
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
, O
from O
the O
granules O
of O
a O
rat O
natural O
killer O
cell O
leukemia O
. O

We O
describe O
here O
17 O
dominant I-GENE
GCN2 I-GENE
mutations I-GENE
that O
lead O
to O
derepression O
of O
GCN4 I-GENE
expression O
in O
the O
absence O
of O
amino O
acid O
starvation O
. O

Administration O
of O
growth I-GENE
hormone I-GENE
leads O
to O
faster O
growth O
, O
but O
also O
faster O
bone O
maturation O
. O

Comparisons O
with O
the O
available O
amino O
acid O
residue O
( O
aa O
) O
sequence O
information O
from O
the O
complete O
CPMV I-GENE
RNA I-GENE
1 I-GENE
sequence I-GENE
and O
the O
partial O
sequence O
of O
red I-GENE
clover I-GENE
mottle I-GENE
virus I-GENE
RNA I-GENE
1 I-GENE
suggest O
that O
CPSMV I-GENE
RNA I-GENE
1 I-GENE
specifies O
the O
expected O
set O
of O
five O
mature O
proteins O
: O
32K I-GENE
proteinase I-GENE
cofactor I-GENE
, O
58K I-GENE
presumed I-GENE
helicase I-GENE
, O
VPg I-GENE
5 I-GENE
'- I-GENE
linked I-GENE
protein I-GENE
of O
the O
genomic O
RNAs O
, O
24K I-GENE
proteinase I-GENE
, O
and O
87K I-GENE
presumed I-GENE
polymerase I-GENE
, O
separated O
by O
four O
cleavage O
sites O
. O

Rice I-GENE
dwarf I-GENE
phytoreovirus I-GENE
segment I-GENE
S12 I-GENE
transcript I-GENE
is O
tricistronic O
in O
vitro O
. O

In O
addition O
, O
the O
utility O
of O
beta I-GENE
2 I-GENE
transferrin I-GENE
assay O
in O
the O
diagnosis O
of O
cerebrospinal O
fluid O
otorrhea O
is O
presented O
. O

Cold O
cardioplegia O
was O
administered O
at O
45 O
mm O
Hg O
every O
20 O
minutes O
for O
2 O
hours O
. O

The O
addition O
of O
diatrizoate O
to O
the O
IPRK O
led O
to O
a O
dose O
- O
dependent O
biphasic O
change O
in O
RPF O
and O
GFR O
characterized O
by O
an O
initial O
transient O
increase O
followed O
by O
a O
marked O
and O
sustained O
decrease O
. O

To O
prepare O
for O
analyses O
with O
the O
family O
variables O
, O
we O
next O
present O
descriptive O
data O
based O
on O
separate O
principal O
components O
analysis O
( O
PCA O
) O
and O
multidimensional O
scaling O
analysis O
( O
MDS O
) O
of O
14 O
self O
- O
reported O
health O
scores O
for O
husbands O
and O
for O
wives O
. O

The O
structural O
genes O
encoding O
glyceraldehyde I-GENE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
GAPDH I-GENE
), O
3 I-GENE
- I-GENE
phosphoglycerate I-GENE
kinase I-GENE
( O
PGK I-GENE
) O
and O
the O
N O
- O
terminal O
part O
of O
triosephosphate I-GENE
isomerase I-GENE
( O
TIM I-GENE
) O
from O
mesophilic O
Bacillus O
megaterium O
DSM319 O
have O
been O
cloned O
as O
a O
gene O
cluster O
( O
gap I-GENE
operon I-GENE
) O
by O
complementation O
of O
an O
Escherichia O
coli O
gap I-GENE
amber I-GENE
mutant I-GENE
. O

Pseudomonas I-GENE
aeruginosa I-GENE
exotoxin I-GENE
A I-GENE
: O
its O
role O
in O
retardation O
of O
wound O
healing O
: O
the O
1992 O
Lindberg O
Award O
. O

Laboratory O
studies O
showed O
that O
the O
direct O
fluorescent O
- O
antibody O
kits O
were O
the O
least O
sensitive O
in O
this O
case O
and O
did O
not O
detect O
fewer O
than O
10 O
( O
4 O
) O
elementary O
bodies O
per O
ml O
, O
while O
most O
ELISA O
kits O
detected O
between O
130 O
and O
600 O
elementary O
bodies O
per O
ml O
. O

To O
study O
the O
significance O
of O
these O
domains O
and O
the O
overall O
evolutionary O
conservation O
of O
the O
gene O
, O
the O
homolog O
from O
Drosophila O
melanogaster O
was O
isolated O
by O
low O
stringency O
hybridizations O
using O
two O
flanking O
probes O
of O
the O
human I-GENE
ERCC3 I-GENE
cDNA I-GENE
. O

Mono O
- O
ADP O
- O
ribosylation O
is O
a O
reversible O
modification O
of O
proteins O
, O
with O
NAD O
: O
arginine I-GENE
ADP I-GENE
- I-GENE
ribosyltransferases I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
31 I-GENE
) O
and O
ADP I-GENE
- I-GENE
ribosylarginine I-GENE
hydrolases I-GENE
( O
EC I-GENE
3 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
19 I-GENE
) O
catalyzing O
the O
opposing O
reactions O
in O
an O
ADP O
- O
ribosylation O
cycle O
. O

For O
this O
reason O
, O
the O
particle O
forming O
capacity O
of O
derivatives O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
group I-GENE
specific I-GENE
core I-GENE
antigen I-GENE
p55 I-GENE
gag I-GENE
was O
assayed O
and O
compared O
dependent O
on O
various O
expression O
systems O
: O
recombinant O
bacteria O
, O
vaccinia O
- O
and O
baculoviruses O
were O
established O
encoding O
the O
entire O
core I-GENE
protein I-GENE
p55 I-GENE
either O
in O
its O
authentic O
sequence O
or O
lacking O
the O
myristylation O
consensus O
signal O
. O

The O
tramtrack I-GENE
( O
ttk I-GENE
) O
gene O
of O
Drosophila O
encodes O
69 O
- O
kDa O
and O
88 O
- O
kDa O
proteins O
through O
alternative O
splicing O
of O
the O
primary O
ttk I-GENE
transcript I-GENE
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
hemofiltration O
: O
a O
four O
year O
follow O
up O
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
hemofiltration O
: O
a O
four O
year O
follow O
up O
. O

Adapromine O
was O
established O
to O
evoke O
a O
decrease O
of O
the O
amplitude O
of O
the O
dominant O
peak O
and O
dominant O
theta O
- O
activity O
in O
power O
spectra O
of O
the O
EEG O
in O
the O
cortex O
and O
hippocamp O
, O
with O
an O
increase O
of O
rapid O
wave O
activity O
in O
the O
beta O
2 O
range O
in O
the O
right O
cortex O
and O
hippocamp O
. O

These O
sequences O
were O
then O
used O
to O
clone O
the O
full O
- O
length O
genes O
from O
a O
yeast O
genomic O
library O
. O

GAL4 I-GENE
- O
VP16 I-GENE
- O
mediated O
antirepression O
required O
an O
auxiliary O
factor O
, O
denoted O
as O
a O
co O
- O
antirepressor O
, O
which O
was O
partially O
purified O
from O
Drosophila O
embryos O
. O

After O
28 O
days O
of O
haloperidol O
treatment O
, O
similar O
changes O
were O
observed O
for O
delta O
, O
together O
with O
an O
increase O
of O
alpha O
1 O
, O
and O
a O
decrease O
of O
fast O
beta O
. O

Four O
ruminally O
and O
duodenally O
cannulated O
Hampshire O
wethers O
were O
used O
in O
a O
4 O
x O
4 O
Latin O
square O
experiment O
to O
determine O
whether O
linoleoyl O
methionine O
and O
calcium O
linoleate O
would O
increase O
duodenal O
flow O
of O
unsaturated O
fatty O
acids O
( O
C18 O
: O
2 O
+ O
cis O
C18 O
: O
1 O
). O

Truncated I-GENE
ICSBP I-GENE
lacking O
the O
first O
33 O
amino O
- O
terminal O
amino O
acids O
fails O
to O
bind O
to O
the O
ICS I-GENE
, O
indicating O
that O
at O
least O
part O
of O
the O
DNA O
binding O
domain O
is O
located O
within O
the O
well O
conserved O
amino O
terminus O
. O

Therefore O
, O
ICSBP I-GENE
may O
be O
involved O
in O
maintaining O
submaximal O
transcriptional O
activity O
of O
IFN I-GENE
- O
inducible O
genes O
in O
hematopoietic O
cells O
. O

A O
case O
of O
chronic O
hepatitis O
C O
with O
primary O
hypothyroidism O
manifested O
during O
interferon I-GENE
treatment O

Dynamic O
decision O
making O
: O
human O
control O
of O
complex O
systems O
. O

A O
coiled I-GENE
- I-GENE
coil I-GENE
related I-GENE
protein I-GENE
specific O
for O
synapsed O
regions O
of O
meiotic O
prophase O
chromosomes O
. O

Comparable O
amounts O
of O
alpha I-GENE
5 I-GENE
beta I-GENE
1 I-GENE
integrin I-GENE
were O
isolated O
from O
these O
cells O
by O
chromatography O
of O
detergent O
extracts O
on O
a O
fibronectin I-GENE
cell O
- O
binding O
fragment O
affinity O
column O
and O
elution O
with O
EDTA O
. O

Abstracts O
. O

These O
results O
indicate O
a O
possible O
involvement O
of O
endogenous O
opioid O
peptides O
in O
the O
cardiac O
effects O
due O
to O
myocardial O
ischaemia O
and O
reperfusion O
, O
mediated O
by O
opiate I-GENE
receptors I-GENE
through O
opiate O
antagonism O
. O

From O
this O
library O
, O
LEU2 I-GENE
and O
HIS3 I-GENE
cDNAs O
were O
recovered O
at O
a O
frequency O
of O
about O
1 O
in O
10 O
( O
4 O
) O
and O
in O
12 O
out O
of O
13 O
cases O
these O
were O
expressed O
in O
a O
galactose O
- O
dependent O
manner O
. O

Among O
these O
, O
ACT1 I-GENE
was O
isolated O
four O
times O
, O
and O
NSR1 I-GENE
three O
times O
. O

Since O
CENP I-GENE
- I-GENE
B I-GENE
gene I-GENE
is O
conserved O
in O
mammalian O
species O
and O
CENP I-GENE
- I-GENE
B I-GENE
boxes I-GENE
are O
found O
also O
in O
mouse O
centromere O
satellite O
DNA O
( O
minor O
satellite O
), O
this O
sequence O
- O
specific O
DNA O
- O
protein O
interaction O
may O
be O
important O
for O
some O
kind O
of O
common O
centromere O
function O
. O

Interestingly O
, O
a O
portion O
of O
the O
tail O
domain O
( O
aa O
, O
1 O
, O
094 O
- O
1 O
, O
830 O
) O
shares O
58 O
% O
amino O
acid O
sequence O
identity O
with O
a O
723 O
- O
aa O
protein O
from O
mouse O
brain O
reported O
to O
be O
a O
glutamic I-GENE
acid I-GENE
decarboxylase I-GENE
. O

However O
, O
in O
the O
subgroup O
with O
normal O
Ht O
(< O
0 O
. O
45 O
l O
/ O
l O
; O
n O
= O
201 O
) O
there O
was O
a O
significant O
reduction O
( O
p O
< O
0 O
. O
05 O
) O
of O
the O
mortality O
after O
3 O
months O
( O
27 O
% O
and O
16 O
%, O
respectively O
) O
and O
an O
increase O
of O
independence O
at O
home O
( O
35 O
% O
and O
48 O
%, O
respectively O
) O
due O
to O
a O
reduction O
of O
the O
viscosity O
by O
means O
of O
haemodilution O
with O
albumin I-GENE
( O
a O
specific O
viscosity O
effect O
in O
the O
normovolaemic O
group O
). O

Distribution O
and O
changing O
morphological O
course O

The O
appropriate O
use O
and O
benefits O
of O
bile O
acid O
sequestrants O
, O
nicotinic O
acid O
, O
fibric O
acids O
, O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylglutaryl I-GENE
coenzyme I-GENE
A I-GENE
( I-GENE
HMG I-GENE
- I-GENE
CoA I-GENE
) I-GENE
reductase I-GENE
inhibitors O
, O
and O
probucol O
are O
individually O
discussed O
, O
whereas O
nonpharmacologic O
approaches O
used O
in O
conjunction O
with O
the O
drugs O
are O
recommended O
emphatically O
. O

This O
may O
result O
in O
more O
reabsorption O
and O
hence O
reduced O
renal O
clearance O
. O

The O
major O
pathological O
findings O
of O
the O
placenta O
were O
prematuration O
and O
hypoplasia O
. O

Green O
pepper O
significantly O
inhibited O
N O
- O
nitrosothiazolidine O
- O
carboxylic O
acid O
formation O
relative O
to O
ascorbic O
acid O
alone O
. O

A O
genomic O
clone O
, O
pTt21 O
, O
containing O
DNA O
apparently O
transcribed O
specifically O
in O
Trypanosoma O
cruzi O
trypomastigotes O
, O
was O
obtained O
by O
differentially O
screening O
a O
genomic O
library O
with O
trypomastigote O
and O
epimastigote O
cDNA O
. O

Brucellosis O
-- O
1990 O

Assay O
of O
urea O
by O
immobilized O
urease I-GENE
coupled O
to O
a O
differential O
pH O
- O
meter O
. O

RESULTS O
: O
In O
the O
AGA O
group O
, O
both O
fetal O
and O
maternal O
serum O
prolactin I-GENE
concentration O
increased O
significantly O
with O
gestation O
( O
P O
< O
0 O
. O
001 O
and O
P O
< O
0 O
. O
01 O
, O
respectively O
). O

One O
phage O
clone O
contains O
a O
junction O
between O
alpha O
satellite O
DNA O
and O
a O
novel O
low O
- O
copy O
repeated O
sequence O
. O

The O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
lactoferrin I-GENE
gene I-GENE
was O
isolated O
from O
a O
human O
placental O
genomic O
library O
. O

Therefore O
, O
the O
molecular O
mechanisms O
of O
the O
estrogen O
action O
that O
govern O
the O
lactoferrin I-GENE
gene I-GENE
expression O
differ O
between O
mouse O
and O
human O
. O

BiP670 I-GENE
retains O
basal O
and O
Ca2 O
+ O
ionophore O
A23187 O
- O
inducible O
activities O
. O

The O
CEM O
receives O
registration O
updates O
via O
an O
HL7 O
message O
and O
evaluates O
data O
dependencies O
in O
rules O
via O
an O
interface O
to O
the O
relational O
database O
. O

Magnetic O
resonance O
spectroscopy O
( O
MRS O
) O
and O
imaging O
( O
MRI O
) O
are O
now O
well O
established O
techniques O
for O
the O
study O
of O
cellular O
metabolism O
and O
gross O
structure O
of O
muscle O
. O

Simultaneously O
a O
greater O
NA O
was O
found O
with O
no O
change O
in O
plasma O
epinephrine O
response O
. O

We O
investigated O
the O
diagnostic O
value O
of O
a O
new O
in O
vitro O
test O
, O
Pharmacia O
CAP O
System O
( O
Pharmacia O
Diagnostics O
AB O
, O
Uppsala O
, O
Sweden O
), O
for O
the O
quantitative O
measurement O
of O
allergen I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
antibodies I-GENE
by O
comparison O
with O
RAST O
in O
2 O
groups O
of O
patients O
, O
71 O
atopic O
and O
48 O
non O
- O
atopic O
. O

Patients O
receiving O
VPA O
showed O
differences O
in O
attention O
, O
visuomotor O
performance O
, O
verbal O
span O
and O
sensory O
discrimination O
tasks O
at O
T1 O
, O
in O
visuomotor O
performance O
at O
T2 O
and O
in O
spatial O
span O
at O
T3 O
, O
whereas O
no O
differences O
were O
detected O
at O
T4 O
. O

We O
found O
that O
the O
gene O
segment O
containing O
the O
mu O
m O
poly O
( O
A O
) O
signals O
, O
along O
with O
536 O
bp O
of O
downstream O
flanking O
sequence O
, O
acted O
as O
a O
transcription O
terminator O
in O
both O
myeloma O
cells O
and O
L O
cell O
fibroblasts O
. O

As O
a O
part O
of O
a O
large O
examination O
, O
total O
and O
free O
serum O
cholesterol O
, O
total O
lipid O
and O
triglyceride O
levels O
were O
determined O
. O

Alena O
is O
a O
nurse O
in O
Prague O
-- O
she O
dreams O
of O
higher O
wages O
and O
a O
trip O
across O
the O
ocean O

Dopamine O
neurons O
in O
subjects O
that O
received O
6 O
- O
OHDA O
were O
protected O
by O
pre O
- O
treatment O
with O
GBR O
- O
12909 O
. O

DIBA O
was O
more O
sensitive O
and O
had O
a O
better O
negative O
predictive O
value O
and O
a O
lower O
false O
negative O
percentage O
than O
DFAT O
. O

Caries O
and O
parodontitis O
have O
been O
one O
of O
the O
most O
spread O
diseases O
of O
mankind O
. O

The O
results O
of O
this O
study O
demonstrate O
that O
strongyloidiasis O
was O
the O
cause O
of O
sudden O
death O
. O

A O
second O
large O
group O
of O
disorders O
in O
pregnancy O
is O
caused O
by O
effects O
of O
infections O
of O
the O
mother O
without O
pathogens O
being O
transmitted O
to O
the O
embryo O
or O
the O
placenta O
. O

Four O
short O
nucleotide O
sequences O
( O
boxes O
I O
to O
IV O
) O
contribute O
to O
the O
light O
responsiveness O
of O
the O
parsley I-GENE
chalcone I-GENE
synthase I-GENE
promoter I-GENE
. O

The O
case O
described O
is O
that O
of O
a O
72 O
- O
year O
- O
old O
man O
with O
ochronosis O
who O
suffered O
a O
hyperextension O
injury O
to O
his O
spine O
in O
a O
fall O
, O
resulting O
in O
a O
fracture O
through O
an O
ankylosed O
L2 O
- O
L3 O
disk O
space O
. O

The O
mean O
blood O
flow O
in O
the O
penile O
foreskin O
was O
estimated O
to O
be O
15 O
ml O
/ O
min O
/ O
100 O
g O
and O
it O
increased O
to O
150 O
- O
200 O
% O
after O
the O
induction O
of O
anesthesia O
, O
and O
then O
decreased O
to O
72 O
% O
at O
the O
tip O
of O
the O
created O
parameatal O
foreskin O
flap O
. O

ME1a1 I-GENE
, O
a O
16 O
- O
base O
- O
pair O
nuclear O
factor O
binding O
site O
residing O
between O
the O
c I-GENE
- I-GENE
MYC I-GENE
P1 I-GENE
and I-GENE
P2 I-GENE
transcription I-GENE
initiation I-GENE
sites I-GENE
, O
is O
required O
for O
P2 O
activity O
. O

The O
next O
twenty O
years O
of O
prevention O
in O
Indian O
country O
: O
visionary O
, O
complex O
, O
and O
practical O
. O

Exogenous O
LHRH I-GENE
is O
also O
known O
to O
facilitate O
mating O
behavior O
in O
several O
species O
. O

The O
first O
146 O
consecutive O
patients O
treated O
with O
EVL O
during O
the O
period O
from O
August O
, O
1986 O
to O
July O
, O
1989 O
are O
reported O
. O

Replacing O
the O
aspartic O
acid O
with O
a O
lysine O
but O
not O
with O
an O
alanine O
or O
valine O
residue O
allowed O
formation O
of O
disulfide O
- O
linked O
dimers O
. O

During O
V O
- O
A O
bypass O
, O
hemodynamics O
were O
stable O
. O

Greater O
rupture O
force O
was O
required O
in O
the O
adult O
pigs O
than O
in O
the O
young O
pigs O
. O

At O
rest O
AFF O
was O
significantly O
higher O
in O
UT O
( O
29 O
%) O
as O
compared O
to O
AT O
( O
25 O
%) O
and O
UEA O
( O
25 O
%). O

We O
investigated O
the O
smoking O
habits O
of O
relapsers O
1 O
year O
after O
quitting O
in O
a O
smoking O
cessation O
trial O
using O
nicotine O
or O
placebo O
patches O
. O

Exposure O
to O
hepatitis O
B O
virus O
in O
the O
general O
population O
of O
Hisayama O
, O
Japan O
: O
significance O
of O
isolated O
antibody O
to O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
in O
general O
population O
. O

Because O
of O
this O
latter O
phenomenon O
, O
we O
were O
able O
to O
identify O
a O
particular O
cysteine O
motif O
that O
was O
repeated O
multiple O
times O
in O
Dfurin2 I-GENE
but O
present O
only O
twice O
in O
mammalian I-GENE
furin I-GENE
. O

On O
the O
other O
hand O
, O
neither O
phosphate O
buffered O
saline O
injection O
into O
the O
ES O
nor O
primary O
KLH I-GENE
challenges O
of O
the O
ES O
were O
capable O
of O
elevating O
the O
threshold O
level O
and O
changing O
the O
latency O
. O

A O
newly O
developed O
broad O
- O
spectrum O
fluoroquinolone O
, O
levofloxacin O
( O
LVFX O
, O
DR O
- O
3355 O
), O
was O
evaluated O
in O
vitro O
and O
in O
vivo O
in O
comparison O
with O
ciprofloxacin O
( O
CPFX O
), O
ofloxacin O
( O
OFLX O
) O
and O
norfloxacin O
( O
NFLX O
). O

The O
mean O
serum O
creatinine O
levels O
were O
similar O
at O
one O
year O
( O
SPK O
1 O
. O
8 O
, O
KTA O
1 O
. O
9 O
mg O
/ O
d O
).( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Model O
predictions O
were O
in O
accord O
with O
the O
nine O
- O
year O
survival O
experience O
of O
women O
in O
the O
HIP O
trial O
, O
and O
, O
with O
the O
exception O
of O
women O
40 O
- O
44 O
years O
old O
, O
with O
HIP O
data O
on O
18 O
- O
year O
survival O
. O

High O
- O
resolution O
computed O
tomography O
in O
the O
diagnosis O
of O
miliary O
tuberculosis O
. O

Previously O
, O
we O
showed O
that O
SNF2 I-GENE
, O
SNF5 I-GENE
, O
and O
SNF6 I-GENE
function O
interdependently O
in O
transcriptional O
activation O
, O
possibly O
forming O
a O
heteromeric O
complex O
. O

We O
show O
that O
LexA I-GENE
- O
GAL4 I-GENE
and O
LexA I-GENE
- O
Bicoid I-GENE
fusion O
proteins O
are O
both O
dependent O
on O
SNF2 I-GENE
, O
SNF5 I-GENE
, O
and O
SNF6 I-GENE
for O
activation O
of O
target O
genes O
containing O
one O
or O
multiple O
lexA I-GENE
operators I-GENE
. O

George O
T O
. O

A O
lambda O
gt10 O
cDNA O
library O
was O
constructed O
from O
poly O
( O
A O
)+ O
RNA O
of O
young O
green O
leaves O
of O
spinach O
. O

NE I-GENE
and O
PR3 I-GENE
assist O
in O
the O
destruction O
of O
phagocytosed O
microorganisms O
, O
cleave O
the O
important O
connective I-GENE
- I-GENE
tissue I-GENE
protein I-GENE
elastin I-GENE
, O
and O
generate O
chemotactic O
activities O
by O
forming O
alpha I-GENE
1 I-GENE
- I-GENE
proteinase I-GENE
inhibitor I-GENE
complexes I-GENE
and O
elastin I-GENE
peptides I-GENE
. O

Selected O
topics O
in O
pediatric O
ultrasonography O
-- O
1992 O
. O

Methods O
included O
24 O
- O
hour O
dietary O
recall O
, O
menu O
weights O
, O
and O
recipe O
analysis O
. O

Factors O
associated O
with O
afterdrop O
included O
age O
, O
end O
- O
of O
- O
surgery O
temperature O
( O
both O
positively O
) O
and O
body O
mass O
( O
negatively O
). O

Both O
GH I-GENE
deficiency O
and O
impaired O
spinal O
growth O
may O
result O
in O
short O
stature O
, O
whereas O
the O
occurrence O
of O
early O
puberty O
in O
association O
with O
GH I-GENE
deficiency O
reduces O
the O
time O
available O
for O
GH I-GENE
therapy O
. O

By O
contrast O
, O
d I-GENE
( I-GENE
T2AG3T I-GENE
) I-GENE
and O
d I-GENE
( I-GENE
T2G4T I-GENE
) I-GENE
form O
only O
the O
G O
- O
quadruplex O
monomer O
structures O
independent O
of O
K O
cation O
concentration O
as O
reported O
previously O
[ O
Sen O
, O
D O
., O
& O
Gilbert O
, O
W O
. O

Differentiating O
among O
renal O
stones O
. O

IFI I-GENE
16 I-GENE
mRNA I-GENE
was O
found O
to O
be O
constitutively O
expressed O
in O
lymphoid O
cells O
and O
in O
cell O
lines O
of O
both O
the O
T O
and O
B O
lineages O
. O

Mitochondria O
- O
lytic O
action O
of O
warfarin O
in O
lymphocytes O
. O

Exon O
- O
intron O
junctions O
in O
the O
human O
and O
rat I-GENE
AdoMet I-GENE
decarboxylase I-GENE
genes I-GENE
were O
in O
identical O
positions O
except O
that O
exons O
6 O
and O
7 O
of O
the O
human O
gene O
formed O
a O
single O
exon O
in O
the O
rat O
gene O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
- O
induced O
gene O
expression O
: O
evidence O
for O
a O
selective O
effect O
of O
ouabain O
on O
activation O
of O
the O
ISGF3 I-GENE
transcription I-GENE
complex I-GENE
. O

The O
cDNA O
has O
an O
open O
reading O
frame O
of O
900 O
amino O
acids O
capable O
of O
encoding O
a O
97 O
- O
kDa O
protein O
. O

Moreover O
, O
LD50 O
in O
mice O
of O
RP O
- O
170 O
( O
4 O
. O
3 O
g O
/ O
kg O
on O
i O
. O
v O
.) O
was O
increased O
to O
5 O
. O
2 O
g O
/ O
kg O
by O
oral O
administration O
. O

Among O
the O
few O
proteins O
of O
the O
eukaryotic O
nucleolus O
that O
have O
been O
characterized O
, O
four O
proteins O
, O
nucleolin I-GENE
, O
fibrillarin I-GENE
, O
SSB1 I-GENE
and O
NSR1 I-GENE
, O
possess O
a O
common O
structural O
motif O
, O
the O
GAR O
domain O
, O
which O
is O
rich O
in O
glycine O
and O
arginine O
residues O
. O

Thus O
, O
this O
study O
provides O
evidence O
that O
a O
novel O
, O
ubiquitous O
factor O
( O
HF I-GENE
- I-GENE
1a I-GENE
) O
and O
a O
muscle O
factor O
( O
HF I-GENE
- I-GENE
1b I-GENE
/ O
MEF I-GENE
- I-GENE
2 I-GENE
) O
can O
form O
a O
novel O
, O
E O
- O
box O
- O
independent O
pathway O
for O
muscle O
- O
specific O
expression O
in O
ventricular O
cardiac O
muscle O
cells O
. O

Mutations O
in O
either O
gene O
block O
some O
crucial O
late O
step O
in O
assembly O
of O
F1 I-GENE
, O
causing O
the O
alpha O
and O
beta O
subunits O
to O
accumulate O
in O
mitochondria O
as O
inactive O
aggregates O
( O
Ackerman O
, O
S O
. O

Expense O
limits O
the O
use O
of O
hepatitis O
B O
vaccines O
, O
but O
low O
- O
dose O
intradermal O
immunization O
has O
been O
evaluated O
as O
a O
cost O
- O
saving O
strategy O
in O
numerous O
studies O
. O

Estrogen O
replacement O
therapy O
and O
risk O
of O
breast O
cancer O
: O
results O
of O
two O
meta O
- O
analyses O
. O

Switching O
FDC O
- O
P1 O
/ O
MAC O
cells O
from O
growth O
in O
M I-GENE
- I-GENE
CSF I-GENE
to O
GM I-GENE
- I-GENE
CSF I-GENE
caused O
the O
selective O
degradation O
of O
c I-GENE
- I-GENE
fms I-GENE
mRNA I-GENE
within O
6 O
h O
after O
factor O
switching O
. O

There O
was O
however O
, O
no O
significant O
difference O
in O
the O
prevalence O
of O
chronic O
respiratory O
symptoms O
between O
animal O
food O
workers O
with O
positive O
and O
negative O
skin O
tests O
to O
house O
dust O
or O
to O
fish O
flour O
or O
among O
those O
with O
increased O
or O
normal O
IgE I-GENE
( O
except O
for O
dyspnea O
). O

An O
unexpected O
finding O
was O
the O
presence O
at O
position O
- O
403 O
to O
- O
385 O
of O
a O
putative O
dioxin O
responsive O
element O
, O
a O
sequence O
found O
to O
be O
responsible O
for O
the O
induction O
of O
transcription O
of O
the O
cytochrome I-GENE
P450IA1 I-GENE
gene I-GENE
( O
CYPIA1 I-GENE
) O
and O
other O
genes O
involved O
in O
detoxification O
/ O
activation O
of O
polycyclic O
aromatic O
hydrocarbons O
. O

The O
gene O
encoding O
TRP I-GENE
- I-GENE
2 I-GENE
maps O
to O
mouse O
chromosome O
14 O
, O
in O
the O
region O
of O
the O
coat I-GENE
colour I-GENE
mutation I-GENE
slaty I-GENE
. O

Using O
bovine I-GENE
and I-GENE
murine I-GENE
c I-GENE
- I-GENE
myb I-GENE
clones O
, O
no O
change O
in O
the O
rate O
of O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
transcription O
or O
mRNA O
stability O
was O
detected O
during O
the O
cell O
cycle O
. O

A O
13 O
base O
- O
pair O
oligonucleotide O
spanning O
nucleotides O
+ O
80 O
to O
+ O
92 O
of O
the O
5 I-GENE
S I-GENE
RNA I-GENE
gene I-GENE
retained O
specific O
and O
high O
- O
affinity O
binding O
, O
although O
the O
latter O
was O
reduced O
sixfold O
relative O
to O
longer O
DNA O
fragments O
. O

Moreover O
, O
the O
reconstitution O
of O
eUSF I-GENE
and O
TFIID I-GENE
- O
depleted O
transcription O
complexes O
with O
purified O
protein O
fractions O
demonstrate O
that O
not O
only O
TFIID I-GENE
but O
also O
eUSF I-GENE
essentially O
participates O
in O
complex O
formation O
even O
on O
H5 I-GENE
promoter I-GENE
mutations O
lacking O
the O
TATA O
- O
box O
. O

A O
comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
T O
. O
thermophilus O
enzyme O
with O
that O
of O
the O
Escherichia O
coli O
enzyme O
showed O
( O
i O
) O
a O
37 O
% O
overall O
similarity O
; O
( O
ii O
) O
the O
conservation O
of O
the O
Ser O
residue O
, O
which O
is O
known O
to O
be O
phosphorylated O
in O
the O
E O
. O
coli O
enzyme O
, O
and O
of O
the O
surrounding O
sequence O
; O
and O
( O
iii O
) O
the O
presence O
of O
141 O
extra O
residues O
at O
the O
C O
terminus O
of O
the O
T O
. O
thermophilus O
enzyme O
. O

Radiolabelled O
palmitate O
was O
not O
incorporated O
into O
the O
mutated O
protein O
, O
showing O
that O
lipid O
modification O
occurs O
at O
the O
Cys O
- O
22 O
residue O
. O

17 O
volunteer O
deaf O
Ss O
were O
compared O
with O
18 O
volunteer O
hearing O
Ss O
on O
the O
Stanford O
Hypnotic O
Clinical O
Scale O
( O
SHCS O
) O
of O
Morgan O
and O
J O
. O

Mature I-GENE
tobacco I-GENE
L12 I-GENE
protein I-GENE
has O
44 O
% O
amino O
acid O
identity O
with O
ribosomal O
protein O
L7 I-GENE
/ O
L12 I-GENE
of O
Escherichia O
coli O
. O

Nuclear I-GENE
- I-GENE
encoded I-GENE
chloroplast I-GENE
ribosomal I-GENE
protein I-GENE
L12 I-GENE
of I-GENE
Nicotiana I-GENE
tabacum I-GENE
: O
characterization O
of O
mature O
protein O
and O
isolation O
and O
sequence O
analysis O
of O
cDNA O
clones O
encoding O
its O
cytoplasmic O
precursor O
. O

The O
gene O
encoding O
IFN I-GENE
- I-GENE
gamma I-GENE
was O
previously O
found O
to O
contain O
an O
intronic O
enhancer O
element O
that O
was O
not O
tissue O
- O
specific O
in O
its O
activity O
, O
despite O
the O
restricted O
expression O
of O
the O
intact O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
. O

Molecular O
cloning O
of O
the O
polypeptide O
component O
of O
the O
Rel I-GENE
- I-GENE
related I-GENE
human I-GENE
p75 I-GENE
nucleoprotein I-GENE
complex I-GENE
has O
revealed O
its O
identity O
with O
the O
65 O
- O
kDa O
( O
p65 I-GENE
) O
subunit O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
. O

Because O
single O
- O
chamber O
rate O
- O
adaptive O
atrial O
pacing O
leaves O
the O
patient O
exposed O
to O
the O
risk O
of O
future O
development O
of O
AV O
block O
and O
DDD O
pacing O
does O
not O
provide O
chronotropic O
support O
, O
it O
is O
likely O
that O
the O
new O
rate O
- O
adaptive O
dual O
- O
chamber O
( O
DDDR O
) O
devices O
will O
be O
used O
in O
a O
significant O
number O
of O
these O
patients O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

When O
transiently O
transfected O
into O
K562 O
cells O
, O
this O
Lg I-GENE
genomic O
clone O
is O
actively O
transcribed O
, O
suggesting O
that O
, O
although O
it O
possesses O
the O
characteristics O
of O
a O
processed O
pseudogene O
, O
it O
is O
likely O
to O
correspond O
to O
the O
gene O
encoding O
this O
new O
ferritin I-GENE
subunit I-GENE
. O

Of O
the O
drugs O
orally O
administered O
, O
WR O
- O
168643 O
was O
the O
best O
protector O
with O
a O
DMF O
of O
1 O
. O
51 O
. O

Characterization O
of O
these O
R O
subunits O
by O
their O
8 O
- O
azido O
- O
cAMP O
photoaffinity O
labeling O
and O
immunoreactivity O
, O
as O
well O
as O
by O
a O
phosphorylation O
- O
dependent O
mobility O
shift O
on O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- O
PAGE O
), O
indicated O
subunit O
sizes O
of O
RII I-GENE
beta I-GENE
( O
53 O
kDa O
) O
greater O
than O
RII I-GENE
alpha I-GENE
dephosphoform O
( O
51 O
kDa O
) O
greater O
than O
RI I-GENE
alpha I-GENE
( O
49 O
kDa O
). O

Comparison O
of O
the O
genomic O
DNA O
sequence O
with O
that O
of O
the O
four O
different O
mRNAs O
indicates O
that O
these O
transcripts O
are O
produced O
by O
alternative O
splicing O
of O
the O
murine O
pre O
- O
mRNA O
according O
to O
a O
cassette O
model O
. O

During O
the O
1980 O
' O
s O
, O
quantifications O
of O
immunoserological O
testings O
, O
especially O
C I-GENE
reactive I-GENE
protein I-GENE
, O
rheumatoid I-GENE
factor I-GENE
and O
antistreptolysin I-GENE
O I-GENE
, O
progressed O
rapidly O
. O

Within O
the O
human O
enhancer O
, O
these O
two O
sites O
are O
located O
within O
the O
previously O
defined O
DNase I-GENE
I I-GENE
footprints I-GENE
, O
NFAT I-GENE
- I-GENE
1 I-GENE
and O
NFIL I-GENE
- I-GENE
2B I-GENE
, O
respectively O
. O

The O
cardiac I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
- I-GENE
2 I-GENE
( O
MLC I-GENE
- I-GENE
2 I-GENE
) O
gene O
promoter O
contains O
several O
positive O
and O
negative O
cis O
- O
acting O
sequences O
that O
are O
involved O
in O
the O
regulation O
of O
its O
expression O
. O

Deletion O
mutagenesis O
demonstrated O
that O
these O
two O
elements O
are O
involved O
in O
the O
positive O
regulation O
of O
MLC I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription O
. O

Disruption O
mutations O
have O
been O
constructed O
in O
the O
SLK1 I-GENE
gene I-GENE
. O
slk1 I-GENE
null I-GENE
mutants I-GENE
cannot O
grow O
at O
37 O
degrees O
C O
, O
but O
many O
cells O
can O
grow O
at O
30 O
, O
24 O
, O
and O
17 O
degrees O
C O
. O

Molecular O
and O
genetic O
analysis O
of O
the O
yeast I-GENE
early I-GENE
meiotic I-GENE
recombination I-GENE
genes I-GENE
REC102 I-GENE
and O
REC107 I-GENE
/ O
MER2 I-GENE
. O

The O
p130 I-GENE
and O
p62 I-GENE
tyrosine O
- O
phosphorylated O
proteins O
that O
complexed O
v I-GENE
- I-GENE
Src I-GENE
SH2 I-GENE
in O
vitro O
also O
associated O
with O
v I-GENE
- I-GENE
Src I-GENE
in O
v I-GENE
- I-GENE
src I-GENE
- O
transformed O
Rat O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v I-GENE
- I-GENE
Src I-GENE
SH2 I-GENE
domain O
. O

Probable O
progressive O
multifocal O
leukoencephalopathy O
( O
PML O
) O
was O
diagnosed O
on O
the O
basis O
of O
clinical O
picture O
and O
magnetic O
resonance O
imaging O
in O
a O
63 O
- O
year O
- O
old O
man O
with O
a O
complete O
remission O
of O
a O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

These O
data O
support O
a O
possible O
biological O
significance O
of O
the O
frameshift O
to O
occur O
at O
this O
position O
of O
the O
large O
overlap O
by O
including O
the O
putative O
RNA O
template O
- O
binding O
site O
of O
the O
PLRV I-GENE
replicase I-GENE
in O
the O
ORF2a I-GENE
/ I-GENE
ORF2b I-GENE
transframe I-GENE
protein I-GENE
. O

Proprotein O
processing O
occurs O
intracellularly O
. O

A O
32P O
- O
labeled O
LAP I-GENE
DNA O
- O
binding O
and O
dimerization O
domain O
" O
zipper O
probe O
" O
was O
used O
to O
isolate O
a O
clone O
that O
encodes O
a O
new O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
homologous I-GENE
protein I-GENE
: O
CHOP I-GENE
- I-GENE
10 I-GENE
. O

Using O
a O
degenerate O
oligodeoxyribonucleotide O
( O
oligo O
) O
based O
on O
the O
N O
- O
terminal O
aa O
sequence O
, O
plus O
an O
internal O
oligo O
homologous O
to O
a O
conserved O
region O
within O
the O
portion O
of O
CYP1 I-GENE
and O
CYP2 I-GENE
that O
had O
been O
deleted O
in O
the O
genome O
, O
a O
CYP3 I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
fragment I-GENE
was O
generated O
by O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
using O
GL81 O
genomic O
DNA O
as O
a O
substrate O
. O

Stringent O
hybridization O
of O
EHS I-GENE
- I-GENE
1 I-GENE
back O
to O
primate O
genomic O
DNA O
indicates O
two O
distinct O
EHS I-GENE
- I-GENE
1 I-GENE
loci I-GENE
in O
normal O
human O
DNA O
, O
an O
identical O
band O
pattern O
in O
chimpanzee O
DNA O
, O
and O
a O
single O
locus O
in O
rhesus O
monkey O
DNA O
. O

The O
level O
of O
carboxyl I-GENE
- I-GENE
terminal I-GENE
parathyroid I-GENE
hormone I-GENE
in O
the O
patients O
with O
thyroid O
carcinoma O
was O
higher O
than O
that O
in O
the O
patients O
without O
thyroid O
carcinoma O
( O
P O
less O
than O
0 O
. O
05 O
). O

The O
Caenorhabditis I-GENE
elegans I-GENE
vitellogenin I-GENE
genes I-GENE
are O
subject O
to O
sex O
-, O
stage O
-, O
and O
tissue O
- O
specific O
regulation O
: O
they O
are O
expressed O
solely O
in O
the O
adult O
hermaphrodite O
intestine O
. O

The O
MET4 I-GENE
gene O
was O
cloned O
, O
and O
its O
sequence O
reveals O
that O
it O
encodes O
a O
protein O
related O
to O
the O
family O
of O
the O
bZIP I-GENE
transcriptional I-GENE
activators I-GENE
. O

The O
functions O
of O
isolated O
portions O
of O
the O
insulin I-GENE
, O
IAPP I-GENE
, O
and O
beta I-GENE
GK I-GENE
promoters I-GENE
were O
studied O
by O
using O
transient O
expression O
and O
DNA O
binding O
assays O
. O

It O
is O
believed O
that O
these O
domains O
are O
important O
for O
directing O
specific O
protein O
- O
protein O
interactions O
necessary O
for O
the O
proper O
functioning O
of O
Src I-GENE
. O

The O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
1 I-GENE
oncoprotein I-GENE
is O
a O
transcription O
activator O
that O
specifically O
binds O
to O
DNA O
. O

Previous O
transactivation O
experiments O
indicated O
that O
three O
amino O
acids O
residing O
in O
this O
region O
, O
Gly O
, O
Ser O
and O
Val O
, O
appear O
to O
be O
critical O
for O
target O
- O
site O
discrimination O
. O

GR63178A O
is O
a O
water O
- O
soluble O
analogue O
of O
mitoquidone O
, O
a O
pentacyclic O
pyrroloquinone O
. O

Marker O
rescue O
analysis O
has O
localized O
ts8 I-GENE
to O
a O
910 O
- O
bp O
internal O
segment O
of O
rpoB I-GENE
that O
encodes O
the O
Rif I-GENE
domain I-GENE
. O

This O
vector O
transfected O
into O
the O
yeast O
Saccharomyces O
cerevisiae O
directs O
expression O
of O
a O
secreted O
mature O
protein O
at O
levels O
up O
to O
200 O
mg O
of O
LAPP O
/ O
liter O
of O
culture O
medium O
. O

Competition O
analysis O
by O
gel O
mobility O
shift O
electrophoresis O
indicates O
that O
this O
DNA O
- O
protein O
interaction O
is O
novel O
and O
not O
related O
to O
many O
transcription O
factors O
previously O
reported O
. O

This O
DNA O
motif O
represents O
a O
novel O
protein O
- O
binding O
sequence O
. O

OBJECTIVE O
: O
The O
study O
was O
designed O
to O
investigate O
the O
frequency O
of O
alterations O
in O
serum O
creatinine O
in O
patients O
with O
psoriasis O
receiving O
5 O
mg O
/ O
kg O
/ O
day O
of O
cyclosporine O
. O

Intrapocket O
chemotherapy O
in O
adult O
periodontitis O
using O
a O
new O
controlled O
- O
release O
insert O
containing O
ofloxacin O
( O
PT O
- O
01 O
). O

Electromagnetic O
blood O
flow O
( O
BF O
) O
probe O
was O
applied O
on O
the O
left O
anterior O
descending O
artery O
( O
LAD O
). O

Hence O
temperature O
and O
virF I-GENE
are O
both O
required O
for O
the O
induction O
of O
the O
yop I-GENE
regulon I-GENE
. O

Problems O
remain O
to O
be O
resolved O
in O
the O
area O
of O
quantitative O
risk O
assessment O
. O

The O
recently O
developed O
gamma I-GENE
- I-GENE
interferon I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
assay O
system O
for O
the O
diagnosis O
of O
bovine O
tuberculosis O
in O
cattle O
has O
been O
accredited O
by O
the O
Standing O
Committee O
on O
Agriculture O
for O
use O
in O
Australia O
. O

Control O
Tmuscle O
was O
35 O
. O
8 O
+/- O
0 O
. O
7 O
degrees O
C O
, O
with O
control O
Wi O
, O
max O
being O
51 O
. O
6 O
( O
SD O
8 O
. O
7 O
) O
W O
. O
kg O
- O
1 O
. O

The O
Klebsiella I-GENE
aerogenes I-GENE
gene I-GENE
maoA I-GENE
, O
which O
is O
involved O
in O
the O
synthesis O
of O
monoamine I-GENE
oxidase I-GENE
, O
was O
induced O
by O
tyramine O
and O
the O
related O
compounds O
, O
subjected O
to O
catabolite O
and O
ammonium O
ion O
repression O
, O
and O
cloned O
. O

However O
, O
other O
regions O
of O
the O
plasmid O
are O
also O
efficiently O
repaired O
. O

Eight O
of O
14 O
infectious O
or O
inflammatory O
lesions O
could O
be O
detected O
in O
the O
early O
scan O
( O
4 O
- O
6 O
h O
p O
. O
i O
.). O

Thus O
, O
the O
human I-GENE
D1A I-GENE
gene I-GENE
belongs O
to O
the O
category O
of O
tissue O
- O
specific O
, O
regulated O
genes O
that O
have O
housekeeping O
- O
type O
promoters O
. O

Similar O
observations O
have O
been O
made O
previously O
for O
other O
genes O
. O

Preceptorship O
of O
CNS O
students O
: O
an O
exploratory O
study O
. O

To O
determine O
the O
genetic O
basis O
for O
the O
differences O
between O
the O
cardiac O
and O
brain I-GENE
AE3 I-GENE
variants I-GENE
, O
we O
isolated O
and O
characterized O
the O
rat O
gene O
. O

The O
1 O
. O
7 O
kb O
cloned O
fragment O
was O
sequenced O
and O
shown O
to O
contain O
the O
entire O
fliA I-GENE
gene I-GENE
. O

Institution O
of O
both O
intravenous O
and O
intracisternal O
administration O
of O
amphotericin O
B O
and O
possibly O
concomitant O
intravenous O
administration O
of O
dexamethasone O
may O
be O
warranted O
in O
situations O
in O
which O
the O
association O
of O
C O
. O
immitis O
with O
CNS O
vasculitis O
or O
encephalitis O
appears O
likely O
before O
serologic O
or O
cultural O
confirmation O
of O
C O
. O
immitis O
infection O
involving O
the O
CNS O
is O
available O
. O

Lac I-GENE
operators O
were O
introduced O
into O
several O
positions O
within O
the O
CAB I-GENE
promoter I-GENE
and O
operator O
- O
free O
plasmid O
was O
used O
as O
control O
. O

Overproduction O
, O
purification O
and O
characterization O
of O
M I-GENE
. I-GENE
HinfI I-GENE
methyltransferase I-GENE
and O
its O
deletion O
mutant O
. O

Various O
companies O
produce O
this O
type O
of O
lens O
. O

From O
March O
5 O
through O
October O
26 O
, O
1991 O
, O
eight O
persons O
were O
diagnosed O
with O
elevated O
blood O
lead O
levels O
( O
BLLs O
) O
at O
a O
local O
hospital O
and O
were O
reported O
to O
the O
notifiable O
disease O
surveillance O
system O
maintained O
by O
the O
Alabama O
Department O
of O
Public O
Health O
( O
ADPH O
). O

According O
to O
the O
changes O
of O
perfusion O
defects O
between O
Ex O
, O
RD O
and O
ReI O
images O
, O
they O
were O
classified O
into O
3 O
types O
: O
Type O
I O
; O
perfusion O
defect O
on O
the O
RD O
image O
was O
identical O
to O
ReI O
image O
( O
75 O
%) O
Type O
I O
was O
divided O
into O
2 O
subgroups O
whether O
perfusion O
defect O
at O
Ex O
was O
unchanged O
( O
Ia O
, O
42 O
%) O
or O
improved O
( O
Ib O
, O
33 O
%) O
on O
the O
RD O
image O
. O

Keck O
, O
C O
. O
J O
. O

Twenty O
- O
eight O
( O
7 O
. O
0 O
%) O
infants O
without O
periventricular O
hemorrhage O
were O
revealed O
as O
having O
spastic O
cerebral O
palsy O
by O
neurodevelopmental O
evaluation O
in O
later O
infancy O
. O

A O
possible O
mechanism O
is O
that O
elevated O
alveolar O
pressure O
and O
decreased O
cardiac O
output O
eliminate O
blood O
flow O
from O
corner O
vessels O
in O
nondependent O
high O
VA O
/ O
Q O
regions O
. O

Computer O
- O
aided O
" O
FRAME O
" O
analysis O
revealed O
four O
possible O
open O
reading O
frames O
( O
ORFs O
), O
three O
in O
one O
direction O
and O
one O
in O
the O
opposite O
direction O
. O

Domain O
II O
is O
highly O
homologous O
to O
the O
LDL I-GENE
receptor I-GENE
and O
contains O
four O
repeats O
with O
perfect O
conservation O
of O
all O
6 O
consecutive O
cysteines O
. O

In O
both O
cities O
, O
HTLV O
- O
I O
/ O
II O
prevalence O
increased O
significantly O
with O
age O
, O
and O
the O
New O
Orleans O
age O
- O
and O
sex O
- O
adjusted O
HTLV O
- O
I O
/ O
II O
prevalence O
was O
significantly O
higher O
than O
that O
of O
Baltimore O
( O
P O
less O
than O
. O
001 O
). O

Here O
, O
we O
present O
evidence O
for O
a O
model O
in O
which O
mRNA O
sequences O
up O
to O
around O
100 O
nucleotides O
downstream O
from O
the O
start O
codon O
of O
21K O
fold O
back O
and O
base O
- O
pair O
to O
the O
21K O
translation O
initiation O
region O
, O
thereby O
decreasing O
the O
translation O
initiation O
frequency O
. O

Hybridization O
data O
indicate O
that O
6F6 I-GENE
. I-GENE
2 I-GENE
corresponds O
to O
the O
previously O
characterized O
m6F6 I-GENE
cDNA I-GENE
clone I-GENE
and O
that O
6F6 I-GENE
. I-GENE
1 I-GENE
and O
6F6 I-GENE
. I-GENE
3 I-GENE
, O
but O
not O
6F6 I-GENE
. I-GENE
2 I-GENE
, O
are O
adjacent O
to O
alpha I-GENE
- I-GENE
type I-GENE
genes I-GENE
. O

The O
SEN1 I-GENE
gene I-GENE
corresponds O
to O
a O
6 O
, O
336 O
- O
bp O
open O
reading O
frame O
coding O
for O
a O
2 O
, O
112 O
- O
amino O
- O
acid O
protein O
( O
molecular O
mass O
, O
239 O
kDa O
). O

Protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
PTKs I-GENE
) O
are O
implicated O
in O
the O
control O
of O
cell O
growth O
by O
virtue O
of O
their O
frequent O
appearance O
as O
products O
of O
retroviral O
oncogenes O
, O
as O
intracellular O
signal O
transducers O
, O
and O
as O
growth I-GENE
factor I-GENE
receptors I-GENE
or O
components O
thereof O
. O

The O
IA4 I-GENE
mAb I-GENE
was O
identified O
among O
a O
series O
of O
antibodies O
raised O
in O
BALB O
/ O
c O
mice O
after O
immunization O
against O
a O
HLA I-GENE
class O
I O
- O
deficient O
, O
lymphokine O
- O
activated O
killer O
( O
LAK O
)- O
susceptible O
EBV O
- O
B O
lymphocyte O
line O
. O

In O
a O
randomized O
double O
- O
blind O
cross O
- O
over O
study O
, O
the O
subjects O
received O
theophylline O
5 O
mg O
. O
kg O
- O
1 O
per O
day O
with O
omeprazole O
20 O
mg O
per O
day O
or O
identical O
placebo O
during O
two O
periods O
, O
each O
of O
7 O
days O
, O
separated O
by O
a O
washout O
period O
of O
7 O
days O
. O

Primer O
extension O
and O
mung I-GENE
bean I-GENE
and I-GENE
S1 I-GENE
nuclease I-GENE
mapping O
indicated O
multiple O
transcription O
initiation O
sites O
and O
were O
consistent O
with O
Northern O
analyses O
. O

Two O
variant O
PRP I-GENE
- I-GENE
precursor I-GENE
alleles I-GENE
occur O
which O
slightly O
differ O
in O
the O
number O
of O
repeats O
in O
domain O
C O
. O

Unlike O
the O
typical O
enhancer O
element O
, O
this O
region O
functions O
in O
an O
orientation O
- O
dependent O
manner O
. O

In O
the O
last O
20 O
years O
, O
the O
therapeutic O
uses O
of O
botulinum I-GENE
toxin I-GENE
, O
a O
potent O
neurotoxin O
, O
have O
been O
investigated O
. O

Allagille O
' O
s O
syndrome O
associated O
with O
antenatal O
ascites O

Sensitivity O
and O
specificity O
was O
established O
for O
the O
Pharmacia O
CAP O
System O
and O
the O
DPC O
AlaSTAT O
System O
by O
comparison O
with O
results O
of O
the O
skin O
prick O
test O
. O

PSI I-GENE
- I-GENE
G I-GENE
and O
PSI I-GENE
- I-GENE
K I-GENE
probably O
have O
evolved O
from O
a O
gene O
duplication O
of O
an O
ancestral O
gene O
. O

At O
the O
C O
- O
terminus O
of O
the O
protein O
is O
a O
domain O
that O
contains O
sequences O
very O
similar O
to O
those O
found O
in O
the O
breakpoint O
cluster O
region O
gene O
product O
, O
n I-GENE
- I-GENE
chimerin I-GENE
, O
and O
rho I-GENE
GAP I-GENE
, O
all O
of O
which O
have O
been O
shown O
to O
possess O
intrinsic O
GAP I-GENE
activity O
on O
small I-GENE
GTPases I-GENE
. O

Site O
- O
directed O
mutagenesis O
revealed O
that O
two O
clusters O
of O
basic O
amino O
acids O
within O
a O
conserved O
basic O
region O
and O
two O
amphipathic O
helices O
within O
the O
adjacent O
HLH O
domain O
are O
essential O
for O
sequence O
- O
specific O
DNA O
binding O
and O
hetero O
- O
oligomerization O
, O
respectively O
. O

Dimerization O
of O
Myf I-GENE
- I-GENE
5 I-GENE
with O
the O
ubiquitously O
expressed O
bHLH O
protein O
E12 I-GENE
not O
only O
increases O
the O
affinity O
for O
DNA O
but O
also O
stimulates O
transactivation O
independently O
of O
DNA O
binding O
. O

The O
circadian O
rhythmicity O
of O
sleep O
was O
pronounced O
. O

SEA O
was O
recorded O
with O
bidirectional O
filters O
at O
25 O
- O
250 O
HZ O
and O
40 O
- O
250 O
Hz O
using O
Simson O
method O
. O

Neural O
- O
specific O
expression O
, O
genomic O
structure O
, O
and O
chromosomal O
localization O
of O
the O
gene O
encoding O
the O
zinc I-GENE
- I-GENE
finger I-GENE
transcription I-GENE
factor I-GENE
NGFI I-GENE
- I-GENE
C I-GENE
. O

An O
experiment O
examined O
the O
effects O
of O
treatment O
with O
gonadotrophin I-GENE
releasing I-GENE
hormone I-GENE
( O
100 O
micrograms O
GnRH I-GENE
injected O
24 O
h O
after O
progestagen O
sponge O
removal O
), O
season O
of O
treatment O
( O
autumn O
v O
. O
spring O
), O
the O
effect O
of O
supplementary O
feeding O
with O
lupin O
grain O
( O
in O
autumn O
only O
, O
from O
12 O
days O
before O
until O
8 O
days O
after O
sponge O
removal O
) O
on O
the O
time O
of O
ovulation O
in O
182 O
mature O
Merino O
ewes O
superovulated O
with O
a O
combination O
of O
400 O
I O
. O
U O
. O
pregnant I-GENE
mare I-GENE
serum I-GENE
gonadotrophin I-GENE
( O
PMSG I-GENE
) O
and O
12 O
mg O
follicle I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
- I-GENE
P I-GENE
). O

Drug O
- O
drug O
interactions O
are O
most O
likely O
to O
occur O
in O
patients O
receiving O
multiple O
medications O
and O
with O
drugs O
that O
have O
a O
narrow O
therapeutic O
window O
. O

The O
sequence O
data O
now O
permit O
a O
detailed O
interpretation O
of O
the O
X O
- O
ray O
crystallographic O
structure O
of O
the O
enzyme O
and O
the O
cloning O
and O
expression O
of O
the O
clostridial O
gene O
will O
facilitate O
site O
- O
directed O
mutagenesis O
. O

Total O
body O
irradiation O
was O
delivered O
according O
to O
a O
hyperfractionated O
scheme O
of O
12 O
fractions O
given O
three O
per O
day O
5 O
hr O
apart O
for O
4 O
days O
. O

A O
reduction O
in O
blood O
pressure O
was O
only O
observed O
at O
the O
end O
of O
the O
study O
, O
from O
142 O
+/- O
17 O
/ O
86 O
. O
6 O
+/- O
9 O
. O
1 O
to O
139 O
+/- O
13 O
/ O
82 O
. O
9 O
+/- O
8 O
. O
9 O
mmHg O
( O
P O
less O
than O
0 O
. O
05 O
for O
DBP O
). O

AgMNPV O
and O
Orgyia O
pseudotsugata O
MNPV O
( O
OpMNPV O
) O
are O
similar O
in O
terms O
of O
promoter O
structure O
and O
polyhedrin I-GENE
primary I-GENE
sequence I-GENE
, O
and O
the O
polyhedrin I-GENE
gene I-GENE
of O
both O
viruses O
is O
transcribed O
in O
the O
anti O
- O
clockwise O
direction O
in O
relation O
to O
their O
physical O
maps O
. O

A O
gene O
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
dnaA I-GENE
gene I-GENE
was O
isolated O
from O
Pseudomonas O
putida O
and O
its O
transcription O
was O
investigated O
in O
E O
. O
coli O
as O
well O
as O
in O
P O
. O
putida O
. O

STP1 I-GENE
is O
an O
unessential O
yeast O
gene O
involved O
in O
the O
removal O
of O
intervening O
sequences O
from O
some O
, O
but O
not O
all O
, O
families O
of O
intervening O
sequence O
- O
containing O
pre O
- O
tRNAs O
. O

Using O
these O
antibodies O
, O
we O
were O
able O
to O
define O
the O
conditions O
to O
completely O
solubilize O
the O
Cdc25 I-GENE
protein I-GENE
. O

GCR1 I-GENE
gene I-GENE
function O
is O
required O
for O
high O
- O
level O
glycolytic O
gene O
expression O
in O
Saccharomyces O
cerevisiae O
. O

The O
decay O
curves O
of O
chlorophyll O
fluorescence O
showed O
a O
superposition O
of O
three O
exponentially O
decaying O
components O
with O
time O
constants O
of O
T1 O
= O
100 O
- O
200 O
ps O
, O
T2 O
= O
300 O
- O
500 O
ps O
and O
T3 O
= O
2 O
. O
0 O
- O
3 O
. O
5 O
ns O
. O

After O
tilting O
, O
systolic O
blood O
pressure O
fell O
an O
average O
of O
17 O
% O
in O
patients O
who O
cramped O
infrequently O
( O
p O
= O
0 O
. O
0031 O
) O
but O
only O
10 O
% O
in O
frequently O
cramping O
patients O
. O

These O
results O
are O
consistent O
with O
the O
roles O
that O
CCK I-GENE
and O
trypsin I-GENE
inhibitors O
are O
believed O
to O
play O
in O
the O
negative O
feedback O
control O
of O
pancreatic O
exocrine O
function O
. O

Most O
apneic O
events O
occurred O
during O
Stages O
I O
and O
II O
, O
and O
REM O
, O
but O
this O
proportion O
was O
less O
during O
the O
gamma O
OH O
study O
( O
77 O
. O
9 O
+/- O
8 O
. O
9 O
%) O
than O
during O
the O
control O
studies O
( O
92 O
. O
3 O
+/- O
1 O
. O
9 O
and O
95 O
. O
9 O
+/- O
2 O
. O
2 O
%), O
apneas O
occurring O
even O
during O
SWS O
with O
gamma O
OH O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Eight O
rabbits O
were O
exposed O
to O
0 O
. O
7 O
+/- O
0 O
. O
4 O
mg O
/ O
m3 O
Co2 O
+ O
as O
CoCl2 O
and O
1 O
. O
2 O
+/- O
0 O
. O
7 O
mg O
/ O
m3 O
Cr3 O
+ O
as O
Cr O
( O
NO3 O
) O
3 O
( O
group O
Co O
+ O
Cr O
), O
eight O
to O
0 O
. O
6 O
+/- O
0 O
. O
5 O
mg O
/ O
m3 O
Co2 O
+ O
( O
group O
Co O
), O
and O
eight O
to O
filtered O
air O
( O
control O
group O
), O
for O
4 O
months O
, O
5 O
days O
/ O
week O
, O
and O
6 O
hr O
/ O
day O
. O

16 O
women O
were O
treated O
with O
methadone O
to O
prevent O
withdrawal O
symptoms O
. O

Disruption O
demonstrates O
that O
CDC14 I-GENE
is O
an O
essential O
gene O
. O

Coronary O
flow O
was O
reduced O
by O
10 O
% O
in O
the O
phosphocreatine O
and O
by O
18 O
% O
in O
the O
control O
group O
. O

The O
60A I-GENE
transcripts I-GENE
and O
protein O
are O
first O
detected O
at O
the O
onset O
of O
gastrulation O
, O
primarily O
in O
the O
mesoderm O
of O
the O
extending O
germ O
band O
. O

A O
724 O
- O
bp O
segment O
of O
the O
5 O
'- O
flanking O
region O
consisting O
of O
the O
proximal O
E O
- O
box O
flanked O
upstream O
by O
a O
mammalian O
- O
specific O
352 O
- O
bp O
region O
was O
sufficient O
for O
maximal O
transcriptional O
activation O
in O
postconfluent O
BC3H1 O
myoblasts O
. O

These O
results O
indicate O
that O
baculovirus O
- O
expressed O
TR I-GENE
mediates O
transcriptional O
activation O
and O
repression O
in O
a O
promoter O
- O
specific O
manner O
in O
vitro O
. O

Influence O
of O
neural O
regulation O
on O
anti O
- O
arrhythmic O
effects O
of O
GABA O
in O
rats O

Recent O
investigations O
have O
detailed O
a O
selective O
dye O
release O
technique O
in O
which O
a O
pulse O
of O
laser O
light O
induces O
the O
release O
of O
a O
fluorescent O
dye O
from O
temperature O
- O
sensitive O
liposomes O
circulating O
in O
the O
retinal O
vasculature O
. O

And O
the O
natural O
barriers O
? O

Three O
pyridoxine O
derivatives O
have O
been O
isolated O
from O
the O
fresh O
stem O
bark O
of O
Albizzia O
julibrissin O
DURAZZ O
.. O

The O
serum O
erythropoietin I-GENE
( O
EPO I-GENE
) O
concentrations O
of O
15 O
male O
triathletes O
( O
26 O
. O
3 O
U O
. O
ml O
- O
1 O
) O
were O
significantly O
lower O
than O
those O
of O
45 O
male O
distance O
runners O
( O
31 O
. O
6 O
U O
. O
ml O
- O
1 O
; O
P O
less O
than O
0 O
. O
05 O
). O

The O
coating O
materials O
were O
poloxamine O
904 O
, O
poloxamine O
908 O
, O
poloxamine O
1508 O
, O
poloxamer O
338 O
, O
and O
Brij O
35 O
. O

The O
eating O
and O
drinking O
patterns O
of O
pygmy O
goats O
fed O
ad O
lib O
and O
kept O
on O
a O
12 O
h O
light O
/ O
12 O
h O
dark O
cycle O
were O
recorded O
and O
analyzed O
. O

The O
present O
study O
highlights O
the O
improvement O
in O
sputum O
amoxycillin O
( O
amoxy O
) O
levels O
when O
a O
combination O
tablet O
, O
amoxy O
500 O
mg O
plus O
bromhexeine O
8 O
mg O
, O
is O
administered O
as O
compared O
to O
plain O
amoxy O
500 O
mg O
. O

His O
HC I-GENE
II I-GENE
activity O
and O
antigen O
levels O
were O
49 O
% O
and O
50 O
%, O
respectively O
, O
and O
his O
daughter O
also O
showed O
similar O
low O
levels O
. O

Argatroban O
may O
be O
more O
effective O
under O
low O
HC I-GENE
II I-GENE
conditions O
because O
of O
its O
potent O
inhibition O
of O
thrombin I-GENE
activity O
at O
sites O
of O
vascular O
wall O
damage O
. O

These O
results O
support O
the O
diagnostic O
validity O
of O
NFPD O
in O
CP O
/ O
NCA O
patients O
, O
because O
such O
patients O
had O
a O
family O
history O
of O
panic O
disorder O
similar O
to O
patients O
with O
a O
more O
classical O
panic O
disorder O
presentation O
. O

FDA O
regulations O
for O
growth O
factors O
and O
related O
products O
. O

Because O
the O
adrenergic O
nervous O
system O
influences O
cardiac O
arrhythmias O
and O
myocardial O
infarction O
can O
directly O
affect O
sympathetic O
innervation O
in O
the O
heart O
, O
we O
investigated O
the O
role O
of O
the O
sympathetic O
nervous O
system O
on O
reentry O
in O
the O
canine O
heart O
4 O
days O
after O
infarction O
. O

DESIGN O
: O
Serum O
aldosterone O
and O
plasma I-GENE
renin I-GENE
activity O
were O
measured O
supine O
prior O
to O
and O
60 O
, O
90 O
, O
120 O
minutes O
after O
oral O
captopril O
, O
25 O
mg O
. O

Furthermore O
, O
no O
transcripts O
of O
the O
same O
size O
and O
having O
the O
same O
developmental O
profile O
as O
those O
generated O
by O
the O
wild I-GENE
- I-GENE
type I-GENE
E10 I-GENE
fragment I-GENE
were O
identified O
by O
probes O
covering O
the O
remainder O
of O
the O
cloned O
region O
. O

Intravenous O
amine O
pressor O
tests O
in O
healthy O
volunteers O
. O

The O
mean O
minimum O
steady O
- O
state O
concentration O
after O
the O
oral O
regimen O
( O
23 O
micrograms O
. O
l O
- O
1 O
) O
was O
78 O
% O
of O
that O
after O
the O
intramuscular O
regime O
( O
29 O
micrograms O
. O
l O
- O
1 O
). O

In O
an O
ongoing O
study O
the O
performance O
of O
the O
SMSP O
is O
being O
compared O
with O
that O
of O
the O
Mini O
Speech O
Processor O
( O
MSP O
). O

Both O
parents O
are O
clinically O
normal O
and O
unrelated O
. O

These O
mutant O
proteins O
retained O
the O
ability O
to O
competitively O
inhibit O
kappa I-GENE
B I-GENE
- O
mediated O
transcriptional O
activation O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
but O
failed O
to O
efficiently O
transform O
chicken O
lymphoid O
cells O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
sequence O
- O
specific O
interaction O
of O
nuclear I-GENE
factor I-GENE
HiNF I-GENE
- I-GENE
D I-GENE
with O
this O
key O
proximal O
promoter O
element O
of O
the O
H4 I-GENE
- I-GENE
FO108 I-GENE
gene I-GENE
is O
cell O
cycle O
regulated O
in O
normal O
diploid O
cells O
( O
J O
. O

In O
conclusion O
, O
to O
study O
and O
overcome O
TI O
region O
- O
based O
expression O
problems O
it O
is O
worthwhile O
to O
start O
out O
with O
a O
versatile O
vector O
containing O
exhaustive O
mutations O
in O
the O
periShine O
- O
Dalgarno O
sequences O
; O
as O
a O
rule O
the O
coding O
MTI O
subregion O
can O
be O
kept O
unchanged O
. O

Four O
of O
these O
five O
subjects O
also O
performed O
mixed O
sequences O
under O
conditional O
control O
of O
the O
words O
( O
e O
. O
g O
., O
A1 O
---- O
B2 O
---- O
A3 O
---- O
B4 O
---- O
A5 O
and O
its O
reversal O
), O
verifying O
that O
the O
stimuli O
which O
occupied O
the O
same O
position O
in O
each O
sequence O
were O
members O
of O
the O
same O
class O
. O

UF O
- O
021 O
ophthalmic O
solution O
( O
0 O
. O
03 O
to O
0 O
. O
24 O
%), O
when O
topically O
applied O
to O
the O
eyes O
of O
rabbits O
, O
caused O
dose O
- O
dependent O
IOP O
reduction O
( O
2 O
. O
8 O
to O
5 O
. O
2 O
mmHg O
), O
without O
transient O
IOP O
rise O
. O

While O
blood O
pressure O
and O
noradrenergic O
activity O
, O
assessed O
as O
changes O
in O
the O
plasma O
levels O
and O
urinary O
excretion O
of O
norepinephrine O
, O
remained O
unaffected O
in O
the O
Pl O
group O
, O
a O
significant O
drop O
in O
the O
supine O
systolic O
and O
diastolic O
blood O
pressures O
, O
as O
well O
as O
in O
the O
resting O
venous O
norepinephrine O
level O
and O
in O
urinary O
norepinephrine O
excretion O
was O
found O
after O
the O
first O
month O
of O
dF O
administration O
. O

Wild O
- O
type O
protein O
bound O
azido O
- O
ATP O
well O
, O
but O
mutants O
with O
substitutions O
in O
the O
consensus O
amino O
acids O
were O
unable O
to O
bind O
azido O
- O
ATP O
. O

Therefore O
, O
with O
a O
biopsy O
from O
the O
stoma O
site O
there O
is O
a O
risk O
of O
missing O
early O
rejection O
. O

Whole O
blood O
serotonin O
levels O
were O
investigated O
in O
a O
control O
group O
( O
n O
= O
35 O
) O
and O
in O
a O
group O
of O
chronic O
renal O
failure O
patients O
( O
n O
= O
127 O
) O
on O
various O
treatment O
regimen O
i O
. O
e O
. O
conservative O
treatment O
( O
n O
= O
39 O
), O
maintenance O
haemodialysis O
( O
n O
= O
35 O
) O
and O
after O
renal O
transplantation O
( O
n O
= O
53 O
). O

Tissues O
and O
exudates O
contain O
sufficient O
thymidine O
for O
growth O
of O
anaerobic O
bacteria O
in O
the O
presence O
of O
inhibitory O
levels O
of O
trimethoprim O
- O
sulfamethoxazole O
. O

The O
homologies O
between O
RAD16 I-GENE
, O
RAD54 I-GENE
and O
SNF2 I-GENE
are O
also O
shared O
by O
several O
additional O
, O
recently O
isolated O
yeast O
and O
Drosophila O
genes O
. O

But O
the O
application O
solutions O
of O
instrument O
disinfectants O
should O
not O
be O
used O
longer O
than O
one O
day O
. O

In O
the O
Rett O
syndrome O
we O
, O
therefore O
, O
suspect O
there O
are O
disturbances O
in O
the O
brain O
stem O
functions O
especially O
in O
the O
ascending O
reticular O
activating O
system O
which O
is O
related O
to O
elevation O
of O
the O
conscious O
level O
. O

In O
a O
similar O
experiment O
, O
simultaneous O
nitrofurazone O
administration O
and O
S O
. O
enteritidis O
challenge O
resulted O
in O
no O
significant O
differences O
in O
S O
. O
enteritidis O
isolation O
frequency O
. O

In O
agreement O
with O
this O
southern O
blotting O
of O
mouse O
DNA O
with O
SmN I-GENE
probes O
reveals O
bands O
, O
additional O
to O
those O
derived O
from O
the O
pseudogene O
, O
which O
are O
characteristic O
of O
an O
intron O
- O
containing O
SmN I-GENE
gene I-GENE
. O

Two O
cDNAs O
encoding O
casein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
have O
been O
isolated O
from O
a O
yeast O
cDNA O
library O
and O
termed O
CKI1 I-GENE
and O
CKI2 I-GENE
. O

Incidence O
rate O
ranging O
between O
122 O
/ O
100 O
, O
000 O
/ O
year O
and O
190 O
/ O
100 O
, O
000 O
/ O
year O
were O
found O
( O
minimum O
, O
estimated O
and O
raw O
datasets O
). O

The O
observed O
sequence O
variation O
disrupts O
the O
first O
ORF O
in O
many O
Y I-GENE
' O
s O
while O
most O
of O
the O
second O
ORF O
including O
the O
putative O
helicase I-GENE
region I-GENE
is O
unaffected O
. O

The O
final O
screening O
yielded O
a O
clone O
containing O
a O
2 O
kilobase O
( O
kb O
) O
insert O
. O

Lesions O
were O
made O
by O
pressure O
injection O
of O
kainic O
acid O
into O
the O
SOC O
through O
a O
stereotaxically O
positioned O
glass O
micropipette O
. O

A O
38 O
- O
bp O
poly O
( O
dA O
- O
dT O
) O
region O
was O
found O
to O
be O
a O
positive O
regulator O
of O
Act1 I-GENE
promoter I-GENE
activity O
. O

We O
identified O
a O
protein O
, O
termed O
NFIL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
A I-GENE
( O
NF I-GENE
beta I-GENE
A I-GENE
), O
that O
binds O
to O
a O
highly O
conserved O
12 O
- O
bp O
DNA O
sequence O
(- O
49 O
to O
- O
38 O
) O
located O
upstream O
of O
the O
TATA O
box O
motif O
in O
both O
the O
human I-GENE
and I-GENE
murine I-GENE
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
genes I-GENE
. O

We O
tried O
amphotericin O
B O
( O
AmB O
), O
and O
remission O
of O
the O
tumor O
was O
obtained O
. O

Cutis O
aplasia O
. O

The O
DRF I-GENE
- I-GENE
2 I-GENE
nuclear I-GENE
protein I-GENE
has O
characteristics O
similar O
to O
those O
of O
the O
muscle O
- O
specific O
regulatory O
factor O
, O
MEF I-GENE
- I-GENE
2 I-GENE
( O
Buskin O
and O
Hauschka O
1989 O
; O
Gossett O
et O
al O
., O
1989 O
). O

From O
the O
15 O
- O
kb O
clone O
a O
4 I-GENE
- I-GENE
kb I-GENE
EcoRI I-GENE
fragment I-GENE
containing O
the O
first O
two O
exons O
and O
2 O
. O
6 O
kb O
of O
the O
5 O
' O
flanking O
region O
of O
the O
opn I-GENE
gene I-GENE
was O
sequenced O
, O
and O
the O
transcriptional O
start O
site O
determined O
by O
primer O
extension O
analysis O
and O
S1 I-GENE
nuclease I-GENE
mapping O
. O

Cardiovascular O
risk O
factors O
were O
measured O
by O
standardized O
techniques O
. O

Production O
costs O
included O
feed O
, O
non O
- O
feed O
operating O
, O
fixed O
, O
and O
replacement O
stock O
costs O
. O

We O
report O
a O
patient O
developing O
factor I-GENE
VII I-GENE
inhibitor I-GENE
possibly O
as O
a O
reaction O
to O
penicillin O
administration O
; O
it O
gave O
rise O
to O
fatal O
haemorrhage O
. O

This O
is O
in O
contrast O
with O
the O
classical O
' O
oxygen O
debt O
hypothesis O
', O
which O
states O
that O
the O
oxygen O
debt O
and O
lactate O
clearance O
are O
linked O
. O

Account O
was O
taken O
of O
noncellular O
and O
nonhuman O
elements O
in O
the O
smears O
; O
they O
included O
mucus O
, O
Charcot O
- O
Layden O
crystals O
, O
pollen O
grains O
, O
vegetal O
fragments O
and O
fungi O
. O

The O
results O
indicate O
that O
the O
carbon O
- O
perfused O
areas O
and O
MBF O
in O
the O
liver O
, O
renal O
cortex O
, O
spleen O
, O
and O
small O
intestinal O
serosa O
( O
only O
MBF O
) O
increased O
significantly O
5 O
h O
after O
CLP O
. O

In O
addition O
a O
greater O
proportion O
of O
women O
in O
the O
sweeping O
group O
had O
a O
cervical O
dilatation O
of O
4 O
cm O
or O
more O
at O
the O
first O
vaginal O
examination O
in O
the O
labour O
ward O
( O
16 O
/ O
33 O
( O
49 O
%) O
vs O
5 O
/ O
32 O
( O
16 O
%); O
OR O
4 O
. O
39 O
; O
95 O
% O
CI O
1 O
. O
56 O
to O
12 O
. O
32 O
; O
P O
= O
0 O
. O
005 O
). O

Lewis O
, O
N O
. O

A O
control O
group O
of O
nine O
women O
( O
age O
23 O
- O
40 O
years O
) O
on O
oral O
contraceptives O
( O
Nordette O
- O
28 O
) O
was O
also O
studied O
four O
times O
during O
a O
pill O
cycle O
. O

This O
accurate O
and O
rapid O
method O
makes O
the O
MLPA O
test O
logistically O
feasible O
for O
large O
- O
scale O
screening O
. O

The O
modalities O
for O
using O
reference O
values O
for O
individual O
subjects O
as O
well O
as O
for O
groups O
are O
then O
discussed O
and O
the O
main O
points O
of O
research O
which O
must O
be O
faced O
in O
the O
near O
future O
regarding O
reference O
values O
are O
highlighted O
. O

The O
clinical O
application O
of O
the O
antibody O
- O
targeted O
Phthalocyanine O
was O
performed O
in O
3 O
patients O
suffering O
from O
an O
advanced O
ovarian O
carcinoma O
( O
FIGO O
III O
). O

We O
found O
that O
lung O
cancer O
tissues O
of O
positive O
67Ga O
scan O
expressed O
TFR I-GENE
, O
but O
those O
of O
a O
negative O
scan O
did O
not O
. O

This O
open O
reading O
frame O
was O
confirmed O
the O
correct O
one O
by O
direct O
amino O
- O
terminal O
sequence O
analysis O
of O
the O
overproduced O
msgB I-GENE
gene I-GENE
product I-GENE
. O

In O
this O
study O
, O
we O
purified O
and O
characterized O
the O
recombinant I-GENE
furin I-GENE
from O
the O
conditioned O
medium O
of O
these O
cells O
. O

The O
virus O
encodes O
a O
40 O
- O
kDa O
protein O
, O
tax I-GENE
, O
that O
is O
important O
for O
the O
immortalization O
of O
T O
cells O
. O

However O
, O
butyrate O
was O
at O
least O
2 O
- O
fold O
more O
effective O
in O
stimulating O
CAT I-GENE
activity O
of O
fusion O
genes O
containing O
upstream O
sequences O
(- O
834 O
to O
- O
576 O
) O
than O
those O
containing O
proximal O
sequences O
(- O
456 O
to O
- O
172 O
), O
suggesting O
two O
regions O
in O
the O
PSG1 I-GENE
- I-GENE
I I-GENE
gene I-GENE
that O
mediate O
the O
butyrate O
response O
. O

An O
examination O
of O
the O
role O
of O
the O
carboxyl O
terminus O
in O
regulating O
NGFI I-GENE
- I-GENE
B I-GENE
transcriptional O
activity O
revealed O
that O
, O
in O
accordance O
with O
other O
nuclear O
receptors O
, O
mutants O
lacking O
portions O
of O
the O
carboxyl O
terminus O
had O
greatly O
decreased O
activity O
. O

Altogether O
these O
results O
indicate O
that O
the O
Syn I-GENE
5 I-GENE
locus I-GENE
segregates O
from O
the O
gene O
specifying O
gH I-GENE
, O
to O
a O
region O
encompassing O
portions O
of O
the O
TK I-GENE
and O
UL I-GENE
24 I-GENE
genes I-GENE
, O
and O
that O
the O
syn I-GENE
mutation I-GENE
does O
not O
affect O
the O
expression O
or O
activity O
of O
TK I-GENE
. O

Nucleoprotein O
( O
N O
) O
expressed O
by O
both O
recombinant O
vaccinia O
virus O
and O
TGEV O
had O
a O
relative O
molecular O
mass O
( O
Mr O
) O
of O
47 O
, O
000 O
and O
was O
susceptible O
to O
degradation O
at O
the O
C O
- O
terminus O
yielding O
discrete O
breakdown O
products O
. O

Recently O
, O
the O
3 I-GENE
. I-GENE
6 I-GENE
- I-GENE
kb I-GENE
full I-GENE
- I-GENE
length I-GENE
alpha I-GENE
- I-GENE
GalNAc I-GENE
cDNA I-GENE
sequence I-GENE
was O
isolated O
and O
found O
to O
have O
remarkable O
nucleotide O
and O
predicted O
amino O
acid O
homology O
( O
55 O
. O
8 O
and O
46 O
. O
9 O
%, O
respectively O
) O
with O
the O
human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
( O
alpha I-GENE
- I-GENE
Gal I-GENE
A I-GENE
) O
cDNA O
. O

Patients O
with O
an O
enzymatic O
activity O
below O
X O
-- O
1 O
manifested O
a O
decrease O
of O
the O
content O
of O
IgA I-GENE
, O
IgG I-GENE
, O
IgM I-GENE
, O
T O
and O
B O
lymphocytes O
, O
and O
of O
phagocytic O
activity O
of O
neutrophils O
as O
compared O
to O
patients O
exhibiting O
a O
high O
enzymatic O
activity O
. O

The O
reason O
that O
nitrous O
oxide O
does O
not O
produce O
hydroxyl O
radicals O
readily O
might O
be O
that O
the O
one O
- O
electron O
reduction O
proceeds O
through O
an O
N2O O
- O
intermediate O
which O
is O
energetically O
very O
unfavourable O
: O
EO O
( O
N2O O
/ O
N2O O
-) O
= O
- O
1 O
. O
1 O
V O
. O

All O
mutant I-GENE
JCV I-GENE
T I-GENE
antigens I-GENE
bound O
to O
JCV O
and O
SV40 O
origins O
of O
DNA O
replication O
. O

The O
relation O
between O
myocardial I-GENE
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
and O
left O
ventricular O
( O
LV O
) O
function O
was O
studied O
in O
10 O
patients O
, O
aged O
41 O
to O
61 O
years O
( O
average O
51 O
), O
with O
LV O
volume O
overload O
mainly O
due O
to O
chronic O
mitral O
regurgitation O
. O

Since O
each O
transcript O
appears O
to O
encode O
the O
same O
protein O
, O
this O
complexity O
may O
reflect O
the O
need O
for O
lineage O
- O
specific O
or O
differentiation O
- O
dependent O
control O
of O
expression O
. O

In O
patients O
with O
limited O
disease O
, O
the O
survival O
in O
the O
alternating O
arm O
was O
significantly O
superior O
to O
the O
survival O
in O
the O
CAV O
arm O
( O
P O
= O
. O
014 O
) O
or O
the O
survival O
in O
the O
PE O
arm O
( O
P O
= O
. O
023 O
). O

We O
identify O
the O
" O
M O
region O
" O
of O
the O
muscle I-GENE
- I-GENE
specific I-GENE
Xenopus I-GENE
cardiac I-GENE
actin I-GENE
gene I-GENE
promoter I-GENE
from O
- O
282 O
to O
- O
348 O
as O
necessary O
for O
the O
embryonic O
expression O
of O
a O
cardiac O
actin I-GENE
- O
beta I-GENE
- I-GENE
globin I-GENE
reporter O
gene O
injected O
into O
fertilized O
eggs O
. O

In O
addition O
to O
the O
previously O
identified O
and O
characterized O
attenuator I-GENE
1 I-GENE
situated O
93 O
nucleotides O
downstream O
from O
the O
major O
late O
transcription O
start O
site O
, O
a O
second O
attenuator O
, O
attenuator I-GENE
2 I-GENE
, O
situated O
55 O
nucleotides O
downstream O
from O
it O
, O
has O
been O
identified O
. O

EBNA I-GENE
- I-GENE
2 I-GENE
and O
the O
cis O
- O
acting O
CD23 I-GENE
element I-GENE
increased O
TK I-GENE
- O
promoted O
mRNA O
and O
did O
not O
alter O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
TK I-GENE
promoter I-GENE
transcription I-GENE
start I-GENE
site I-GENE
. O

These O
experiments O
delineate O
a O
186 O
- O
bp O
, O
EBNA I-GENE
- I-GENE
2 I-GENE
- O
responsive O
cell O
DNA O
fragment O
and O
provide O
firm O
evidence O
that O
EBNA I-GENE
- I-GENE
2 I-GENE
transactivates O
transcription O
of O
cell O
genes O
. O

Plasma O
vitamin O
E O
, O
total O
lipids O
and O
myeloperoxidase I-GENE
levels O
during O
spinal O
surgery O
. O

Transfecting O
the O
cloned O
bovine O
PBR I-GENE
/ O
IBP I-GENE
cDNA O
into O
COS O
- O
7 O
cells O
resulted O
in O
an O
11 O
- O
fold O
increase O
in O
the O
density O
of O
high O
affinity O
[ O
3H O
] O
PK O
11195 O
binding O
sites O
which O
had O
only O
low O
affinity O
for O
Ro5 O
- O
4864 O
. O

The O
initial O
phase O
of O
increased O
vascular O
permeability O
in O
the O
peritoneal O
cavity O
and O
LTB4 O
production O
was O
dose O
dependently O
inhibited O
by O
the O
5 O
- O
LO O
inhibitors O
phenidone O
, O
BW O
A4C O
, O
A63162 O
, O
and O
ICI O
207 O
968 O
but O
not O
by O
dexamethasone O
or O
colchicine O
. O

Discrepant O
results O
with O
a O
latex O
agglutination O
test O
in O
the O
assessment O
of O
cytomegalovirus O
antibody O
status O
of O
cardiac O
transplant O
donors O
. O

Each O
mRNA O
contained O
five O
or O
six O
internal O
uridine O
residues O
, O
which O
were O
transcribed O
using O
a O
mixture O
of O
UTP O
and O
thio O
- O
UTP O
. O

We O
have O
isolated O
and O
sequenced O
two O
overlapping O
cDNA O
fragments O
which O
could O
encode O
the O
complete O
amino O
acid O
sequence O
of O
rat I-GENE
testis I-GENE
fructose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
, I-GENE
2 I-GENE
- I-GENE
kinase I-GENE
: O
fructose I-GENE
- I-GENE
2 I-GENE
, I-GENE
6 I-GENE
- I-GENE
bisphosphatase I-GENE
. O

We O
have O
identified O
SWI5 I-GENE
' O
s O
nuclear O
localization O
signal O
( O
NLS O
) O
and O
show O
that O
it O
can O
confer O
cell O
cycle O
- O
dependent O
nuclear O
entry O
to O
a O
heterologous O
protein O
. O

In O
contrast O
to O
behavioral O
deviation O
( O
the O
avoidance O
conditioning O
lost O
), O
the O
haloperidol O
intrastriatal O
microinjections O
did O
not O
affect O
the O
DA O
synaptic O
level O
in O
rostral O
neostriatum O
. O

In O
similar O
transient O
transfection O
experiments O
in O
HeLa O
cells O
, O
overexpression O
of O
the O
wt I-GENE
human I-GENE
retinoblastoma I-GENE
susceptibility I-GENE
gene I-GENE
product I-GENE
, O
RB I-GENE
, O
was O
found O
to O
repress O
the O
serum O
- O
induced O
IL I-GENE
- I-GENE
6 I-GENE
(- O
225 O
to O
+ O
13 O
), O
c I-GENE
- I-GENE
fos I-GENE
(- O
711 O
to O
+ O
42 O
), O
and O
beta I-GENE
- I-GENE
actin I-GENE
(- O
3400 O
to O
+ O
912 O
) O
promoters O
but O
not O
the O
PRV O
- O
induced O
IL I-GENE
- I-GENE
6 I-GENE
(- O
110 O
to O
+ O
13 O
) O
or O
the O
serum O
- O
induced O
MHC I-GENE
(- O
528 O
to O
- O
38 O
) O
promoters O
. O

This O
repression O
was O
mediated O
through O
binding O
to O
the O
E2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
site I-GENE
immediately O
upstream O
of O
the O
P105 I-GENE
promoter O
TATA O
box O
and O
could O
be O
abrogated O
by O
preincubation O
of O
the O
HPV I-GENE
- I-GENE
18 I-GENE
P105 I-GENE
promoter I-GENE
template O
with O
the O
nuclear O
extract O
allowing O
the O
formation O
of O
the O
preinitiation O
complex O
. O

We O
did O
not O
detect O
p50 I-GENE
in O
association O
with O
native I-GENE
glucocorticoid I-GENE
receptor I-GENE
in O
L O
cells O
or O
with O
the O
overexpressed O
glucocorticoid I-GENE
receptor I-GENE
in O
Chinese O
hamster O
ovary O
cells O
. O

Two O
putative O
12 O
- O
O O
- O
tetradecanoyl O
- O
phorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
response O
elements O
, O
that O
might O
serve O
as O
binding O
sites O
for O
the O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
consensus O
sequence O
of O
a O
transforming I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
1 I-GENE
( O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
) O
inhibitory O
element O
were O
found O
in O
the O
promoter O
region O
. O

TPA O
and O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
did O
not O
markedly O
affect O
the O
activities O
of O
the O
72 O
- O
kDa O
enzyme O
. O

They O
were O
almost O
regularly O
excited O
by O
pressure O
to O
the O
ipsilateral O
cornea O
or O
to O
both O
corneas O
at O
a O
strength O
well O
above O
the O
human O
corneal O
pain O
threshold O
. O

Feed O
intake O
was O
not O
affected O
by O
dietary O
KCl O
or O
NaHCO3 O
supplementation O
, O
but O
average O
daily O
gain O
increased O
with O
increased O
K O
and O
tended O
to O
be O
reduced O
by O
dietary O
NaHCO3 O
. O

Extraction O
procedure O
for O
the O
measurement O
of O
butyltin O
compounds O
in O
biological O
tissues O
using O
toluene O
, O
HBr O
, O
and O
tropolone O
. O

In O
this O
study O
, O
we O
have O
cloned O
a O
region O
that O
complements O
the O
exoenzyme I-GENE
S I-GENE
- O
deficient O
phenotype O
of O
strain O
388 O
exs1 I-GENE
:: O
Tn1 I-GENE
, O
a O
chromosomal I-GENE
Tn1 I-GENE
insertional I-GENE
mutation I-GENE
. O

axl O
, O
a O
transforming O
gene O
isolated O
from O
primary O
human O
myeloid O
leukemia O
cells O
, O
encodes O
a O
novel O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Alignment O
of O
the O
amino O
acid O
sequences O
surrounding O
Tyr O
- O
766 O
with O
corresponding O
regions O
of O
other O
FGFRs I-GENE
revealed O
conserved O
tyrosine O
residues O
in O
all O
known O
members O
of O
the O
FGFR I-GENE
family I-GENE
. O

The O
single O
most O
important O
element O
, O
by O
linker O
- O
scanning O
analysis O
, O
is O
a O
10 O
- O
bp O
region O
that O
contains O
a O
CCAAT O
motif O
. O

Capnography O
curves O
of O
40 O
HVS O
patients O
, O
40 O
non O
- O
HVS O
patients O
with O
psycho O
- O
somatic O
complaints O
and O
26 O
healthy O
controls O
were O
analyzed O
. O

The O
transcription O
initiation O
site O
was O
determined O
to O
occur O
66 O
bp O
upstream O
of O
the O
initiating O
Met O
. O

All O
anti I-GENE
- I-GENE
I I-GENE
and O
anti I-GENE
- I-GENE
i I-GENE
CA I-GENE
were O
shown O
to O
express O
VH4 I-GENE
heavy I-GENE
chains I-GENE
, O
and O
14 O
of O
17 O
CA I-GENE
expressed O
a O
previously O
described O
VH4 I-GENE
second O
hypervariable O
region O
determinant O
, O
termed O
VH4 I-GENE
- I-GENE
HV2a I-GENE
. O

Intron O
K1 I-GENE
cox1 I-GENE
. I-GENE
2 I-GENE
is O
not O
found O
in O
S O
. O
cerevisiae O
and O
appears O
at O
an O
unique O
location O
in O
K O
. O
lactis O
. O

We O
have O
determined O
that O
the O
mutants O
define O
two O
complementation O
groups O
, O
designated O
cgs1 I-GENE
+ I-GENE
and O
cgs2 I-GENE
+ I-GENE
( O
continues O
to O
grow O
in O
stationary O
). O

However O
, O
alterations O
in O
electrostatic O
and O
hydrophobic O
interactions O
created O
by O
the O
three O
amino O
acid O
substitutions O
prevent O
the O
conformational O
change O
in O
the O
enzyme O
usually O
produced O
by O
calmodulin I-GENE
binding O
. O

The O
results O
of O
induced O
coexpression O
were O
also O
supported O
by O
rapid O
generation O
of O
FeLV O
recombinants O
when O
FeLV O
- O
C O
was O
used O
to O
infect O
the O
feline O
3201B O
cell O
line O
that O
constitutively O
expresses O
high O
levels O
of O
endogenous O
FeLV O
- O
specific O
mRNAs O
. O

Recombination O
between O
feline O
leukemia O
virus O
subgroup O
B O
or O
C O
and O
endogenous O
env I-GENE
elements O
alters O
the O
in O
vitro O
biological O
activities O
of O
the O
viruses O
. O

The O
nucleotide O
sequences O
at O
the O
5 O
' O
and O
3 O
' O
ends O
of O
these O
introns O
are O
characteristic O
of O
spliced O
transcripts O
from O
eukaryotic O
protein O
- O
encoding O
genes O
, O
with O
one O
significant O
difference O
; O
i O
. O
e O
., O
the O
5 O
' O
end O
of O
the O
LAT I-GENE
intron I-GENE
is O
GC O
instead O
of O
the O
consensus O
sequence O
GT O
. O

At O
1 O
, O
5 O
, O
and O
9 O
months O
after O
initial O
isolation O
of O
C O
. O
kutscheri O
from O
the O
oral O
cavity O
, O
hamsters O
were O
euthanatized O
, O
and O
attempts O
were O
made O
to O
culture O
C O
. O
kutscheri O
from O
13 O
additional O
sites O
. O

The O
strategy O
has O
been O
used O
to O
determine O
2 O
. O
6 O
kilobases O
of O
nucleotide O
sequence O
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
ADE I-GENE
1 I-GENE
locus I-GENE
. O

Two O
independent O
promoters O
as O
well O
as O
5 O
' O
untranslated O
regions O
regulate O
Dd I-GENE
ras I-GENE
expression O
in O
Dictyostelium O
. O

The O
results O
suggested O
that O
, O
depending O
upon O
the O
cell O
type O
, O
gene O
cotransfer O
using O
aminoglycoside O
resistance O
as O
a O
selectable O
marker O
may O
seriously O
perturb O
important O
cellular O
control O
mechanisms O
such O
as O
the O
PKC I-GENE
pathway O
leading O
to O
activation O
of O
gene O
expression O
. O

Transfer O
RNA O
genes O
from O
Dictyostelium O
discoideum O
are O
frequently O
associated O
with O
repetitive O
elements O
and O
contain O
consensus O
boxes O
in O
their O
5 O
' O
and O
3 O
'- O
flanking O
regions O
. O

Therefore O
, O
the O
strD I-GENE
and O
strE I-GENE
genes I-GENE
could O
serve O
as O
universal O
probes O
indicative O
of O
the O
presence O
of O
biosynthetic O
capacity O
for O
6 O
- O
deoxyhexose O
moieties O
. O

The O
two O
genes O
code O
for O
polypeptides I-GENE
of I-GENE
420 I-GENE
amino I-GENE
acids I-GENE
( I-GENE
M I-GENE
. I-GENE
HgiCI I-GENE
) I-GENE
and O
345 O
amino O
acids O
( O
R O
. O
HgiCI O
). O

Expression O
of O
the O
wt1 I-GENE
gene I-GENE
via O
transient O
transfection O
in O
COS O
- O
1 O
cells O
revealed O
a O
52 O
kDa O
protein O
which O
was O
immunoprecipitated O
by O
both O
the O
N O
- O
terminal O
- O
and O
C O
- O
terminal O
- O
specific O
antisera O
. O

The O
factor O
which O
binds O
to O
the O
TR I-GENE
promoter I-GENE
co O
- O
sedimented O
with O
SV40 O
chromosomes O
extracted O
late O
in O
infection O
. O

Temafloxacin O
400 O
mg O
b O
. O
i O
. O
d O
. O
administered O
orally O
for O
28 O
days O
represents O
a O
safe O
and O
effective O
treatment O
for O
chronic O
bacterial O
prostatitis O
. O

Its O
neuromuscular O
effects O
are O
similar O
to O
a O
single O
ED90 O
dose O
of O
vecuronium O
. O

The O
patient O
with O
a O
prolonged O
fever O
caused O
by O
dissecting O
aneurysm O
of O
the O
aorta O
in O
whom O
pleuropneumonia O
masked O
the O
real O
diseases O
has O
been O
presented O
. O

The O
resulting O
clone O
pKB11 I-GENE
, O
which O
has O
a O
1369 O
- O
base O
pair O
( O
bp O
) O
cDNA O
insert O
, O
overlapping O
pCAD142 I-GENE
by O
781 O
bp O
, O
was O
identified O
by O
hybridization O
methods O
and O
sequence O
analysis O
and O
found O
to O
contain O
the O
entire O
cDNA O
sequence O
for O
the O
amino O
end O
of O
the O
CAD I-GENE
polypeptide I-GENE
. O

This O
conclusion O
was O
confirmed O
by O
Northern O
blotting O
analysis O
of O
the O
5 O
'- O
flanking O
region O
of O
CAD I-GENE
gene I-GENE
. O

We O
report O
the O
isolation O
of O
genomic O
and O
cDNA O
clones O
of O
the O
light O
- O
independent O
Sn I-GENE
: I-GENE
bol3 I-GENE
allele I-GENE
. O

Histamine O
- O
2 O
blockade O
in O
psoriasis O

Its O
clearance O
has O
been O
found O
to O
be O
decreased O
( O
typically O
by O
around O
25 O
%, O
but O
often O
by O
far O
more O
) O
by O
erythromycin O
, O
troleandomycin O
( O
triacetyloleandomycin O
), O
roxithromycin O
, O
enoxacin O
, O
ciprofloxacin O
, O
pefloxacin O
, O
norfloxacin O
, O
ofloxacin O
, O
fluoroquinolone O
T O
- O
3262 O
, O
pipemidic O
acid O
, O
cimetidine O
, O
etintidine O
, O
propranolol O
, O
verapamil O
, O
diltiazem O
, O
nifedipine O
, O
furosemide O
( O
frusemide O
), O
at O
least O
some O
anovulent O
agents O
, O
viloxazine O
, O
allopurinol O
, O
ticlopidine O
, O
idrocilamide O
, O
thiabendazole O
, O
disulfiram O
, O
influenza O
- O
and O
BCG O
- O
vaccination O
, O
interferon I-GENE
, O
and O
caffeine O
( O
half O
- O
life O
increase O
). O

A O
third O
is O
a O
partial O
element O
terminating O
at O
a O
probable O
internal O
restriction O
site O
used O
for O
cloning O
. O

We O
enrolled O
253 O
HIV I-GENE
- I-GENE
antibody I-GENE
positive O
heroin O
addicts O
without O
HIV O
- O
related O
disease O
( O
n O
= O
81 O
) O
or O
with O
persistent O
generalized O
lymphadenopathy O
( O
n O
= O
172 O
) O
in O
a O
prospective O
study O
to O
evaluate O
clinical O
progression O
to O
AIDS O
related O
complex O
( O
ARC O
) O
or O
AIDS O
and O
to O
identify O
factors O
of O
possible O
prognostic O
relevance O
. O

No O
homology O
was O
found O
between O
RNA14 I-GENE
and O
RNA15 I-GENE
or O
between O
RNA14 I-GENE
and O
other O
proteins O
contained O
in O
data O
banks O
. O

Mutations O
in O
the O
yeast I-GENE
RNA14 I-GENE
and O
RNA15 I-GENE
genes I-GENE
result O
in O
an O
abnormal O
mRNA O
decay O
rate O
; O
sequence O
analysis O
reveals O
an O
RNA O
- O
binding O
domain O
in O
the O
RNA15 I-GENE
protein I-GENE
. O

Myocardial O
infarction O
in O
patients O
with O
previous O
bypass O
surgery O
. O

The O
most O
striking O
difference O
in O
the O
birch I-GENE
NAD I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
- I-GENE
NR I-GENE
sequence I-GENE
in O
comparison O
to O
NADH I-GENE
- I-GENE
NR I-GENE
sequences I-GENE
was O
found O
at O
the O
putative O
pyridine O
nucleotide O
binding O
site O
. O

A O
single O
amino O
acid O
difference O
in O
the O
C O
- O
terminal O
region O
influences O
dominant O
negative O
activity O
and O
receptor O
dimer O
formation O
. O

No O
such O
benefits O
were O
seen O
for O
children O
with O
CD4 I-GENE
+ I-GENE
counts O
below O
0 O
. O
2 O
x O
10 O
( O
9 O
) O
per O
liter O
at O
entry O
. O

Because O
the O
human I-GENE
Antp I-GENE
TATAA I-GENE
binding I-GENE
protein I-GENE
is O
expressed O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
we O
suggest O
that O
this O
homeobox I-GENE
gene I-GENE
has O
evolved O
a O
more O
general O
transcriptional O
regulatory O
function O
in O
higher O
eukaryotic O
cells O
. O

The O
95 O
% O
confidence O
values O
( O
2SD O
) O
for O
the O
change O
in O
Ros O
required O
to O
exclude O
natural O
variability O
were O
0 O
. O
39 O
, O
0 O
. O
50 O
and O
0 O
. O
53 O
cmH2O O
l O
- O
1 O
s O
, O
respectively O
. O

Among O
953 O
infants O
in O
22 O
neonatal O
care O
units O
studied O
, O
23 O
% O
( O
median O
value O
, O
range O
0 O
- O
78 O
) O
were O
found O
to O
be O
faecally O
colonized O
with O
one O
of O
21 O
distinct O
nosocomial O
strains O
of O
Escherichia O
coli O
, O
Klebsiella O
or O
Enterobacter O
spp O
. O

Biochemical O
studies O
revealed O
the O
expected O
loss O
of O
ChAT I-GENE
activity O
in O
the O
dorsal O
and O
ventral O
hippocampi O
of O
lesioned O
animals O
along O
with O
elevated O
levels O
of O
norepinephrine O
( O
NE O
) O
in O
the O
dorsal O
hippocampus O
of O
MS O
/ O
HSI O
animals O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
localization O
of O
this O
proteoglycan O
locus O
in O
the O
human O
genome O
and O
the O
availability O
of O
new O
RFLPs O
provide O
the O
tools O
for O
future O
studies O
of O
human O
diseases O
where O
the O
HSPG2 I-GENE
proteoglycan I-GENE
gene I-GENE
is O
suspected O
to O
be O
involved O
. O

After O
2 O
min O
of O
dobutamine O
injection O
, O
or O
after O
20 O
min O
of O
pimobendan O
injection O
, O
the O
myocardium O
was O
removed O
, O
and O
used O
for O
determination O
of O
the O
tissue O
levels O
of O
metabolites O
of O
energy O
and O
carbohydrate O
metabolism O
. O

During O
coronary O
stenosis O
, O
on O
the O
contrary O
, O
intracoronary O
procaterol O
at O
the O
same O
dose O
significantly O
deteriorated O
regional O
myocardial O
dysfunction O
without O
changing O
LCX O
flow O
, O
global O
hemodynamics O
and O
cardiac O
lactate O
metabolism O
. O

Here O
we O
present O
evidence O
that O
major I-GENE
IE I-GENE
proteins I-GENE
IE86 I-GENE
, O
IE72 I-GENE
, O
and O
IE55 I-GENE
are O
capable O
of O
trans O
- O
activating O
the O
HIV I-GENE
LTR I-GENE
in O
a O
T O
- O
cell O
line O
, O
HUT O
- O
78 O
. O

In O
a O
country O
where O
general O
HIV O
prevalence O
is O
low O
, O
the O
strategy O
is O
cost O
- O
effective O
for O
location O
and O
counselling O
of O
unknowingly O
seropositive O
individuals O
. O

The O
cis O
- O
acting O
element O
mediating O
glucocorticoid O
inducibility O
of O
the O
chicken I-GENE
glutamine I-GENE
synthetase I-GENE
gene I-GENE
has O
been O
identified O
. O

However O
, O
the O
increase O
in O
biliary O
excretion O
did O
not O
compensate O
for O
the O
reduced O
elimination O
of O
bretylium O
and O
hexylsalicylic O
acid O
via O
the O
kidney O
. O

Diagnostic O
value O
of O
cerebrospinal I-GENE
fluid I-GENE
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
in O
pediatric O
neurological O
diseases O
. O

Expression O
of O
six O
genes O
, O
ipaB I-GENE
, O
ipaC I-GENE
, O
invE I-GENE
, O
invG I-GENE
, O
invJ I-GENE
, O
and O
invK I-GENE
, O
was O
apparently O
regulated O
by O
the O
positive O
regulator O
virF I-GENE
. O

Inducible O
VT O
was O
suppressed O
entirely O
in O
one O
patient O
. O

Venkatesan O
, O
and O
D O
. O

The O
presence O
of O
the O
corresponding O
mature O
mRNA O
transcripts O
( O
3 O
. O
2 O
- O
3 O
. O
5 O
kilobase O
pairs O
( O
kb O
] O
in O
human O
fibroblasts O
was O
shown O
by O
Northern O
blot O
hybridization O
, O
S1 I-GENE
nuclease I-GENE
protection O
assay O
, O
and O
the O
polymerase O
chain O
reaction O
. O

Approximately O
50 O
% O
of O
the O
ribosomal O
DNA O
( O
rDNA O
) O
units O
of O
Drosophila O
melanogaster O
are O
inactivated O
by O
two O
different O
28 I-GENE
S I-GENE
RNA I-GENE
ribosomal I-GENE
gene I-GENE
insertions O
( O
type O
I O
and O
type O
II O
). O

Gap I-GENE
b3 I-GENE
consists O
of O
two O
polypeptide O
chains O
( O
Mr O
= O
110 O
, O
000 O
and O
30 O
, O
000 O
), O
which O
seem O
to O
be O
proteolytic O
cleavage O
products O
connected O
by O
disulfide O
bonds O
from O
a O
precursor O
protein O
. O

However O
, O
the O
rtFc I-GENE
gamma I-GENE
R I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
complementary O
to O
at O
least O
two O
different O
- O
sized O
mRNAs O
expressed O
by O
CRNK O
- O
16 O
cells O
, O
contrasting O
the O
single O
Fc I-GENE
gamma I-GENE
R I-GENE
- I-GENE
related I-GENE
mRNA I-GENE
species O
expressed O
by O
human O
and O
mouse O
natural O
killer O
cells O
. O

Both O
genes O
comprise O
three O
exons O
, O
two O
introns O
and O
an O
unusually O
long O
3 O
'- O
untranslated O
region O
( O
3 O
. O
2 O
kilobase O
pairs O
), O
specificying O
a O
mRNA O
of O
approximately O
4 O
. O
1 O
kilobases O
. O

Stable O
expression O
of O
the O
chimeric O
alpha I-GENE
i I-GENE
( I-GENE
54 I-GENE
)/ I-GENE
s I-GENE
polypeptide O
in O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
constitutively O
increased O
both O
cAMP O
synthesis O
and O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
activity O
. O

This O
exon O
, O
here O
named O
exon O
0 O
, O
contained O
the O
entire O
5 O
' O
untranslated O
region O
and O
the O
N O
- O
terminal O
signal O
sequence O
of O
the O
polypeptide O
. O

Treatment O
of O
human O
myeloid O
cell O
lines O
HL O
- O
60 O
and O
U937 O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
increased O
within O
2 O
h O
cellular O
levels O
of O
the O
RNA O
hybridizable O
to O
LD78 I-GENE
cDNA I-GENE
. O

A O
new O
, O
flexible O
fiberoptic O
ventriculoscope O
for O
observation O
of O
the O
ventricles O
and O
major O
cisterns O
is O
reported O
. O

Isopenicillin I-GENE
N I-GENE
isomerase I-GENE
( O
epimerase I-GENE
) O
has O
been O
purified O
from O
Streptomyces O
clavuligerus O
, O
and O
the O
amino O
acid O
sequence O
of O
the O
N O
- O
terminus O
has O
been O
determined O
. O

Serum O
IgG I-GENE
was O
initially O
elevated O
in O
6 O
patients O
. O

The O
patient O
initially O
attained O
complete O
remission O
( O
CR1 O
) O
with O
conventional O
chemotherapy O
and O
then O
relapsed O
14 O
months O
later O
. O

157 O
+/- O
16 O
mg O
/ O
dl O
; O
NS O
), O
glucose O
levels O
, O
and O
basal O
( O
17 O
+/- O
4 O
vs O
. O

Platelet O
aggregation O
and O
metabolic O
control O
are O
not O
affected O
by O
calcium O
antagonist O
treatment O
in O
type O
II O
diabetes O
mellitus O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
( O
int I-GENE
- I-GENE
1 I-GENE
) O
is O
a O
cellular O
oncogene O
often O
activated O
by O
insertion O
of O
proviral O
DNA O
of O
the O
mouse O
mammary O
tumor O
virus O
. O

Induction O
of O
Jurkat O
leukemic O
T O
cells O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
ionomycin O
did O
not O
affect O
the O
level O
of O
FKBP I-GENE
mRNA I-GENE
. O

GLUT5 I-GENE
mRNA I-GENE
is O
expressed O
at O
highest O
levels O
in O
small O
intestine O
and O
at O
much O
lower O
levels O
in O
kidney O
, O
skeletal O
muscle O
, O
and O
adipose O
tissue O
. O

e O
. O

We O
speculate O
that O
these O
tumors O
may O
represent O
congenital O
hamartomatous O
growths O
. O

Identification O
and O
characterization O
of O
the O
promoter O
for O
the O
cytotactin I-GENE
gene I-GENE
. O

Surprisingly O
, O
there O
is O
no O
sequence O
homology O
between O
this O
region O
of O
Ly I-GENE
- I-GENE
6E I-GENE
and O
the O
established O
consensus O
for O
the O
interferon I-GENE
- I-GENE
stimulated I-GENE
response I-GENE
element I-GENE
, O
which O
has O
been O
shown O
functionally O
important O
to O
all O
previously O
characterized O
alpha I-GENE
/ I-GENE
beta I-GENE
interferon I-GENE
- O
inducible O
promoters O
. O

Relatively O
large O
DNA O
rearrangements O
spanning O
the O
region O
with O
tandem O
direct O
repeats O
encoding O
the O
carboxy O
- O
terminal O
histone I-GENE
H1 I-GENE
- I-GENE
like I-GENE
structure O
of O
AlgP I-GENE
were O
detected O
in O
several O
strains O
upon O
conversion O
from O
the O
mucoid O
to O
the O
nonmucoid O
phenotype O
. O

( O
1988 O
) O
J O
. O

These O
results O
strongly O
suggested O
that O
similar O
, O
if O
not O
identical O
, O
the O
CArG I-GENE
box I-GENE
binding I-GENE
proteins I-GENE
interact O
with O
the O
functionally O
different O
promoter O
element O
in O
the O
VLC1 I-GENE
, O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
. O

Polyadenylation O
of O
B4 I-GENE
RNA I-GENE
, O
which O
occurs O
very O
early O
during O
maturation O
, O
is O
limited O
to O
150 O
residues O
, O
and O
it O
is O
this O
number O
that O
is O
required O
for O
polysomal O
recruitment O
. O

Co O
- O
existence O
of O
these O
regulatory O
elements O
with O
other O
elements O
, O
such O
as O
the O
AP I-GENE
- I-GENE
2 I-GENE
element I-GENE
or O
CCAAT O
box O
, O
was O
also O
found O
. O

Recently O
, O
studies O
of O
agents O
that O
disrupt O
collagen I-GENE
synthesis O
and O
deposition O
have O
yielded O
several O
new O
angiogenesis O
inhibitors O
. O

Since O
the O
5 O
'- O
flanking O
region O
of O
this O
gene O
is O
likely O
involved O
in O
hormonal O
regulation O
of O
its O
expression O
, O
we O
have O
isolated O
and O
partially O
characterized O
an O
avian O
fatty I-GENE
acid I-GENE
synthase I-GENE
gene O
. O

A O
new O
set O
of O
cDNA O
clones O
spanning O
approximately O
3 O
. O
2 O
kb O
was O
isolated O
from O
a O
lambda O
- O
ZAP O
goose O
liver O
cDNA O
library O
using O
the O
5 O
'- O
most O
exon O
- O
containing O
fragment O
of O
the O
5 O
'- O
most O
genomic O
DNA O
clone O
. O

Northern O
blotting O
analysis O
indicates O
that O
expression O
of O
the O
genes O
corresponding O
to O
these O
clones O
is O
confined O
to O
pollen O
tissue O
. O

Whereas O
cDNA O
hybridization O
to O
genomic O
DNA O
blots O
indicated O
a O
small O
subfamily O
of O
G0S19 I-GENE
genes I-GENE
, O
simple O
patterns O
of O
bands O
indicated O
that O
most O
cDNAs O
, O
including O
G0S30 I-GENE
cDNA I-GENE
, O
corresponded O
to O
single O
- O
copy O
genes O
. O

Lymphoproliferative O
disorders O
arising O
under O
immunosuppression O
with O
FK O
506 O
: O
initial O
observations O
in O
a O
large O
transplant O
population O
. O

The O
Drosophila I-GENE
suppressor I-GENE
of I-GENE
sable I-GENE
gene I-GENE
encodes O
a O
polypeptide O
with O
regions O
similar O
to O
those O
of O
RNA O
- O
binding O
proteins O
. O

2 O
: O
121 O
- O
133 O
, O
1988 O
). O

It O
is O
, O
however O
, O
extremely O
homologous O
to O
a O
third O
' O
non O
- O
classical O
' O
gene O
, O
HLA I-GENE
- I-GENE
5 I-GENE
. I-GENE
4 I-GENE
, O
and O
to O
the O
chimpanzee O
gene O
, O
Ch28 I-GENE
. O

Although O
the O
N13 O
- O
N20 O
interpeak O
interval O
remained O
stable O
because O
of O
the O
parallel O
shift O
of O
the O
2 O
peaks O
, O
the O
central O
conduction O
time O
measured O
from O
onset O
latencies O
of O
N11 O
and O
N20 O
significantly O
increased O
. O

Using O
avidin I-GENE
- I-GENE
biotin I-GENE
complex O
DNA O
binding O
assays O
, O
a O
series O
of O
overlapping O
alpha I-GENE
promoter I-GENE
DNA I-GENE
sequences I-GENE
between O
- O
170 O
to O
29 O
basepairs O
were O
tested O
, O
but O
each O
failed O
to O
bind O
GR I-GENE
, O
whereas O
a O
control O
GRE O
avidly O
bound O
receptor O
. O

Sequence O
determination O
of O
isolated O
peptides O
suggested O
that O
Asn120 O
is O
glycosylated O
, O
Asn65 O
and O
Asn109 O
glycosylated O
in O
some O
molecules O
but O
not O
in O
others O
, O
and O
Asn72 O
not O
glycosylated O
. O

The O
DNA O
sequence O
conferring O
AP I-GENE
- I-GENE
1 I-GENE
activity O
was O
located O
in O
the O
proximal O
promoter O
region O
. O

The O
murine I-GENE
mutation I-GENE
dominant I-GENE
white I-GENE
spotting I-GENE
( O
W I-GENE
) O
is O
in O
the O
proto O
- O
oncogene O
, O
c I-GENE
- I-GENE
kit I-GENE
. O

Isolation O
and O
characterization O
of O
the O
rat O
chromosomal O
gene O
for O
a O
polypeptide O
( O
pS1 I-GENE
) O
antigenically O
related O
to O
statin I-GENE
. O

The O
proteins O
differ O
in O
the O
presence O
or O
absence O
of O
a O
21 O
- O
amino O
- O
acid O
sequence O
located O
24 O
amino O
acids O
C O
terminal O
of O
the O
translational O
initiation O
codon O
. O

Our O
results O
also O
indicate O
the O
existence O
of O
sequences O
downstream O
of O
- O
0 O
. O
11 O
kb O
which O
can O
influence O
the O
pattern O
of O
tissue O
- O
specific O
expression O
of O
the O
HLA I-GENE
- I-GENE
B7 I-GENE
gene I-GENE
and O
the O
ability O
of O
this O
gene O
to O
respond O
to O
gamma I-GENE
interferon I-GENE
. O

The O
SH2 I-GENE
and O
SH3 I-GENE
domains I-GENE
of O
pp60src I-GENE
direct O
stable O
association O
with O
tyrosine O
phosphorylated O
proteins O
p130 I-GENE
and O
p110 I-GENE
. O

Chem O
. O

These O
clones O
overlapped O
and O
contained O
the O
structural O
gene O
encoding O
the O
complete O
C5 I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
and O
90 O
% O
of O
the O
beta O
- O
chain O
. O

The O
C5 I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
was O
encoded O
by O
49 O
kilobases O
containing O
26 O
exons O
; O
the O
beta O
- O
chain O
was O
encoded O
by O
29 O
kilobases O
containing O
16 O
exons O
. O

Heterozygous O
mutation O
in O
the O
G O
+ O
5 O
position O
of O
intron O
33 O
of O
the O
pro I-GENE
- I-GENE
alpha I-GENE
2 I-GENE
( I-GENE
I I-GENE
) I-GENE
gene I-GENE
( O
COL1A2 I-GENE
) O
that O
causes O
aberrant O
RNA O
splicing O
and O
lethal O
osteogenesis O
imperfecta O
. O

The O
nucleotide O
sequences O
of O
these O
genes O
differ O
at O
only O
nine O
positions O
, O
resulting O
in O
three O
amino O
acid O
differences O
. O

The O
protein O
predicted O
by O
the O
sequence O
of O
the O
human I-GENE
pim I-GENE
- I-GENE
1 I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
shares O
extensive O
homology O
with O
known O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinases I-GENE
, O
and O
yet O
the O
human I-GENE
Pim I-GENE
- I-GENE
1 I-GENE
enzyme I-GENE
has O
previously O
been O
reported O
to O
exhibit O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
both O
in O
vitro O
and O
in O
vivo O
. O

A O
full I-GENE
- I-GENE
length I-GENE
human I-GENE
pim I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
was O
subcloned O
into O
the O
bacterial O
vector O
pGEX O
- O
2T O
and O
the O
Pim I-GENE
- I-GENE
1 I-GENE
protein I-GENE
expressed O
as O
a O
fusion O
product O
with O
bacterial I-GENE
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

This O
report O
substantiates O
that O
at O
least O
two O
of O
the O
18 O
kDa O
hsps I-GENE
in O
maize O
are O
products O
of O
different O
but O
related O
genes O
. O

The O
10 O
kDa O
polypeptide O
was O
phosphorylated O
in O
vitro O
by O
incubating O
wheat O
etioplast O
membranes O
with O
[ O
gamma O
32P O
] O
ATP O
. O

Homology O
with O
the O
human O
protein O
is O
only O
34 O
% O
in O
the O
tandem O
repeat O
domain O
, O
mainly O
showing O
conservation O
of O
serines O
and O
threonines O
, O
presumed O
sites O
of O
O O
- O
linked O
carbohydrate O
attachment O
. O

In O
addition O
to O
targeting O
partially O
assembled O
Ti I-GENE
alpha I-GENE
- I-GENE
beta I-GENE
CD3 I-GENE
gamma I-GENE
delta I-GENE
epsilon I-GENE
TCR I-GENE
complexes I-GENE
to O
the O
cell O
surface O
, O
CD3 I-GENE
zeta I-GENE
appears O
to O
be O
essential O
for O
interleukin I-GENE
- I-GENE
2 I-GENE
production O
after O
TCR I-GENE
stimulation O
with O
antigen I-GENE
/ I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
. O

When O
desipramine O
was O
injected O
16 O
hrs O
after O
fluoxetine O
injection O
, O
brain O
levels O
of O
desipramine O
were O
no O
longer O
elevated O
. O

Opposite O
effects O
of O
CYP1 I-GENE
are O
observed O
in O
aerobic O
, O
heme O
- O
sufficient O
cells O
. O

A O
segmental O
analysis O
of O
the O
key O
regions O
of O
HLA I-GENE
- I-GENE
DR1 I-GENE
that O
control O
T O
cell O
allorecognition O
was O
performed O
by O
using O
a O
series O
of O
transfected O
cell O
lines O
expressing O
the O
products O
of O
recombinant O
DRB I-GENE
/ O
H I-GENE
- I-GENE
2Eb I-GENE
genes O
, O
paired O
with O
either O
DR I-GENE
alpha I-GENE
or O
H I-GENE
- I-GENE
2E I-GENE
alpha I-GENE
. O

We O
characterized O
cDNA O
clones O
specific O
for O
the O
extracellular O
matrix O
glycoprotein O
undulin I-GENE
. O

Finally O
, O
some O
point O
mutations O
in O
the O
Gag I-GENE
- O
Pol I-GENE
PR O
domain O
inhibited O
activation O
of O
RT I-GENE
in O
trans O
by O
a O
wild O
- O
type O
PR I-GENE
, O
suggesting O
that O
the O
correct O
conformation O
of O
the O
PR I-GENE
domain O
in O
Gag I-GENE
- O
Pol I-GENE
is O
prerequisite O
for O
activation O
of O
RT I-GENE
. O

The O
alpha I-GENE
inhibin I-GENE
promoter I-GENE
containing O
a O
mutated O
CRE O
was O
not O
regulated O
by O
forskolin O
in O
granulosa O
cells O
and O
did O
not O
bind O
the O
CREB I-GENE
protein I-GENE
. O

Regulation O
of O
the O
alpha I-GENE
inhibin I-GENE
gene I-GENE
by O
cyclic O
adenosine O
3 O
', O
5 O
'- O
monophosphate O
after O
transfection O
into O
rat O
granulosa O
cells O
. O

Comparison O
of O
the O
nucleotide O
sequences O
between O
the O
human O
and O
bovine O
DNA O
showed O
that O
the O
sequence O
similarity O
extended O
2400 O
bp O
downstream O
from O
the O
coding O
region O
. O

Cloning O
of O
a O
human O
cDNA O
encoding O
a O
CDC2 I-GENE
- I-GENE
related I-GENE
kinase I-GENE
by O
complementation O
of O
a O
budding I-GENE
yeast I-GENE
cdc28 I-GENE
mutation O
. O

In O
patients O
with O
osteomyelitis O
and O
joint O
empyema O
( O
n O
= O
48 O
) O
PMN I-GENE
elastase I-GENE
had O
a O
sensitivity O
of O
77 O
%, O
which O
was O
only O
exceeded O
by O
that O
of O
the O
unspecific O
erythrocyte O
sedimentation O
rate O
( O
sensitivity O
89 O
%). O

E O
., O
Hession O
, O
C O
., O
Goff O
, O
D O
., O
Griffiths O
, O
B O
., O
Tizard O
, O
R O
., O
Newman O
, O
B O
., O
Chi O
- O
Rosso O
, O
G O
., O
and O
Lobb O
, O
R O
., O
( O
1990 O
) O
Cell O
63 O
, O
1349 O
- O
1356 O
). O

The O
above O
results O
mean O
that O
the O
increase O
in O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
makes O
the O
prostate O
, O
which O
has O
been O
already O
hypertrophied O
, O
less O
elastic O
, O
inhibiting O
external O
urinary O
sphincter O
function O
. O

An O
approximately O
2 I-GENE
- I-GENE
kilobase I-GENE
B2 I-GENE
transcript I-GENE
was O
expressed O
in O
all O
alfalfa O
organs O
tested O
. O

These O
results O
indicate O
that O
the O
sulfhydryl O
group O
of O
certain O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
can O
potentiate O
their O
effect O
on O
the O
endogenous O
nitrovasodilator O
EDRF I-GENE
. O

Pharmacokinetics O
of O
FK O
506 O
in O
transplant O
patients O
. O

A O
second O
even O
more O
significant O
match O
to O
this O
E O
. O
coli O
region O
was O
found O
in O
the O
retroviral I-GENE
ribonuclease I-GENE
H I-GENE
( O
RNase I-GENE
H I-GENE
) O
domain O
, O
and O
corresponds O
precisely O
to O
a O
region O
that O
has O
been O
aligned O
by O
previous O
investigators O
with O
the O
E I-GENE
. I-GENE
coli I-GENE
RNase I-GENE
H I-GENE
, O
suggesting O
that O
Pol I-GENE
I I-GENE
helices O
O O
and O
P O
are O
homologous O
to O
helices O
A O
and O
D O
of O
the O
RNase I-GENE
H I-GENE
crystal O
structure O
, O
respectively O
. O

Analysis O
of O
the O
deduced O
amino O
acid O
sequence O
suggests O
that O
CHIP28 I-GENE
protein I-GENE
contains O
six O
bilayer O
- O
spanning O
domains O
, O
two O
exofacial O
potential O
N O
- O
glycosylation O
sites O
, O
and O
intracellular O
N O
and O
C O
termini O
. O

The O
qualitative O
concentrations O
of O
HCG I-GENE
had O
a O
sensitivity O
of O
37 O
. O
5 O
% O
and O
a O
specificity O
of O
100 O
%. O

The O
reduced O
rate O
of O
F O
absorption O
and O
slower O
rise O
in O
plasma O
F O
concentration O
accompanying O
delayed O
gastric O
emptying O
indicate O
that O
passage O
of O
F O
into O
the O
small O
intestine O
is O
the O
major O
factor O
in O
rapid O
F O
absorption O
. O

The O
activity O
of O
serum I-GENE
lipase I-GENE
and O
amylase I-GENE
distinctly O
increased O
at O
3 O
h O
and O
went O
up O
to O
the O
maximum O
at O
12 O
h O
after O
injection O
of O
Na O
- O
Tc O
. O

They O
were O
checked O
for O
anti I-GENE
- I-GENE
HCV I-GENE
( O
anti I-GENE
- I-GENE
C100 I-GENE
- I-GENE
3 I-GENE
) O
with O
HCV O
EIA O
kit O
( O
Abbott O
Lab O
., O
North O
Chicago O
, O
IL O
). O

Diltiazem O
resulted O
in O
a O
significant O
increase O
in O
epicardial O
diameter O
(+ O
10 O
%; O
p O
= O
0 O
. O
001 O
) O
and O
in O
coronary O
blood O
flow O
( O
CBF O
) O
(+ O
30 O
%; O
p O
= O
0 O
. O
0001 O
). O

The O
first O
transfusion O
resulted O
in O
a O
platelet O
increment O
to O
32 O
Gpt O
/ O
l O
( O
CCI O
11 O
). O

These O
risk O
factors O
can O
be O
divided O
into O
2 O
groups O
: O
local O
vessel O
wall O
- O
related O
factors O
, O
and O
local O
( O
focal O
action O
) O
systemic O
factors O
. O

Epidemiology O
and O
prevention O
of O
hospital O
infections O
in O
the O
Local O
Health O
Unit O
of O
Sassari O
: O
profile O
of O
bacterial O
resistance O
and O
antimicrobial O
agents O
of O
large O
usage O
. O

PRDII I-GENE
- I-GENE
BF1 I-GENE
- I-GENE
derived I-GENE
cDNAs I-GENE
did O
not O
result O
in O
stimulation O
of O
either O
basal O
or O
tat I-GENE
- O
induced O
activated O
gene O
expression O
. O

Vaccinia O
virus O
( O
VV O
) O
is O
a O
potent O
immunogen O
, O
but O
the O
nature O
of O
VV O
proteins O
involved O
in O
the O
activation O
of O
the O
immune O
response O
of O
the O
host O
is O
not O
yet O
known O
. O

Max I-GENE
: O
functional O
domains O
and O
interaction O
with O
c I-GENE
- I-GENE
Myc I-GENE
. O

86 O
: O
3199 O
- O
3203 O
) O
or O
G1 O
to O
S O
phase O
( O
Reilly O
, O
C O
. O

Substitutions O
introduced O
at O
bases O
surrounding O
the O
ICR2 I-GENE
motif I-GENE
yielded O
levels O
of O
pRNA O
replication O
that O
differed O
, O
depending O
on O
the O
maintenance O
of O
a O
putative O
5 O
' O
stem O
- O
loop O
structure O
in O
the O
positive O
strand O
of O
the O
viral O
genome O
. O

Zn O
( O
II O
) O
coordination O
domain O
mutants O
of O
T4 O
gene I-GENE
32 I-GENE
protein O
. O

Zn O
( O
II O
) O
coordination O
domain O
mutants O
of O
T4 I-GENE
gene I-GENE
32 I-GENE
protein I-GENE
. O

The O
tissue O
specificity O
of O
gene O
expression O
was O
identical O
to O
that O
described O
previously O
for O
the O
CaMV I-GENE
35S I-GENE
domain I-GENE
B I-GENE
enhancer I-GENE
element I-GENE
. O

The O
pathophysiology O
and O
clinical O
management O
of O
acute O
brain O
injury O
in O
infancy O
and O
childhood O
are O
presented O
using O
acute O
traumatic O
brain O
injury O
as O
a O
model O
. O

Transcripts O
from O
a O
second O
POU I-GENE
- I-GENE
domain I-GENE
gene I-GENE
, O
Oct I-GENE
- I-GENE
25 I-GENE
, O
were O
present O
at O
low O
levels O
in O
oocytes O
and O
early O
embryos O
and O
were O
dramatically O
upregulated O
during O
early O
gastrulation O
. O

In O
some O
early O
B O
cells O
and O
Abelson O
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
- O
cell O
lines O
, O
LT I-GENE
mRNA I-GENE
is O
constitutively O
expressed O
. O

The O
genome O
of O
Thogoto O
virus O
comprises O
six O
segments O
of O
single O
- O
stranded O
, O
negative O
sense O
RNA O
. O

These O
tumors O
were O
classified O
into O
three O
broad O
groups O
: O
I O
, O
cystadenoma O
; O
II O
, O
cystadenocarcinoma O
; O
and O
III O
, O
adenocarcinoma O
with O
mucin I-GENE
production O
or O
an O
associated O
cyst O
. O

Immunostaining O
of O
cells O
transfected O
with O
these O
constructs O
revealed O
that O
both O
the O
myristoylated O
and O
nonmyristoylated O
mutants O
were O
localized O
in O
nuclei O
, O
whereas O
wild I-GENE
- I-GENE
type I-GENE
PKC I-GENE
alpha I-GENE
was O
primarily O
cytoplasmic O
and O
perinuclear O
. O

We O
have O
partially O
sequenced O
the O
RAP74 I-GENE
protein I-GENE
from O
purified O
HeLa O
cells O
, O
cloned O
its O
complementary O
DNA O
and O
shown O
that O
its O
translation O
product O
can O
interact O
with O
RAP30 I-GENE
in O
vitro O
as O
well O
as O
in O
vivo O
. O

Effects O
of O
thromboxane I-GENE
synthetase I-GENE
inhibition O
on O
postburn O
mesenteric O
vascular O
resistance O
and O
the O
rate O
of O
bacterial O
translocation O
in O
a O
chronic O
porcine O
model O
. O

The O
primary O
pancreatic O
insult O
seemed O
to O
be O
unaffected O
by O
the O
treatment O
, O
because O
neither O
the O
rise O
in O
plasma I-GENE
lipase I-GENE
nor O
the O
development O
of O
ascites O
or O
the O
extension O
of O
the O
pancreatic O
necrosis O
were O
diminished O
. O

The O
size O
of O
the O
mutant O
molecule O
corresponds O
to O
the O
unprocessed O
cytoplasmic O
precursor O
( O
pre I-GENE
- I-GENE
super I-GENE
- I-GENE
pro I-GENE
- I-GENE
PrB I-GENE
), O
as O
detected O
in O
sec61 I-GENE
mutants I-GENE
, O
when O
translocation O
into O
the O
endoplasmic O
reticulum O
is O
blocked O
. O

Thus O
, O
the O
active O
- O
site O
mutation O
prevents O
the O
wild O
- O
type O
processing O
of O
the O
N O
- O
glycosylated O
73 O
- O
kDa O
precursor O
of O
PrB I-GENE
to O
the O
41 I-GENE
. I-GENE
5 I-GENE
kDa I-GENE
pro I-GENE
- I-GENE
PrB I-GENE
in O
the O
endoplasmic O
reticulum O
. O

The O
predicted O
amino O
acid O
sequence O
exhibited O
70 O
% O
identity O
to O
that O
of O
Bacillus I-GENE
stearothermophilus I-GENE
TyrTS I-GENE
and O
55 O
% O
identity O
to O
that O
of O
E I-GENE
. I-GENE
coli I-GENE
TyrTS I-GENE
, O
while O
identity O
to O
a O
second O
cryptic O
B I-GENE
. I-GENE
subtilis I-GENE
TyrTS I-GENE
gene I-GENE
, O
designated O
tyrZ I-GENE
, O
was O
only O
27 O
%. O

Heat O
- O
inducible O
CAT I-GENE
activity O
was O
detectable O
when O
additional O
sequences O
from O
the O
native O
promoter O
containing O
three O
CCAAT O
boxes O
and O
a O
single O
HSE O
were O
present O
in O
the O
constructions O
. O

SETTING O
-- O
Women O
, O
Infants O
, O
and O
Children O
clinics O
in O
Minneapolis O
, O
Minn O
. O

Testosterone O
, O
free O
testosterone O
, O
non I-GENE
- I-GENE
sex I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
- O
bound O
testosterone O
, O
and O
free O
androgen O
index O
: O
which O
testosterone O
measurement O
is O
most O
relevant O
to O
reproductive O
and O
sexual O
function O
in O
men O
with O
epilepsy O
? O

BACKGROUND O
: O
The O
effectiveness O
of O
monoamine I-GENE
oxidase I-GENE
inhibitors O
( O
MAOIs O
) O
in O
tricyclic O
resistant O
depression O
has O
received O
surprisingly O
little O
systematic O
study O
. O

The O
upstream O
delta O
- O
alpha O
breakpoint O
is O
flanked O
by O
the O
direct O
repeats O
of O
the O
acceptor O
splice O
site O
, O
whereas O
the O
down O
- O
stream O
alpha O
- O
delta O
breakpoint O
is O
located O
in O
the O
adjacent O
intron O
. O

Patients O
with O
moderate O
PDDAT O
were O
impaired O
on O
all O
serial O
positions O
for O
both O
spatial O
order O
and O
spatial O
recognition O
memory O
. O

Bone O
and O
bones O
. O

One O
patients O
had O
plasma I-GENE
C I-GENE
- I-GENE
peptide I-GENE
greater O
than O
3 O
pM O
and O
was O
therefore O
excluded O
from O
analysis O
. O

Complex O
repetitive O
discharges O
were O
observed O
in O
muscles O
of O
mdx O
mice O
but O
no O
complex O
repetitive O
discharges O
or O
other O
abnormalities O
were O
observed O
in O
muscles O
of O
normal O
control O
mice O
. O

Management O
often O
involves O
beta O
- O
and O
calcium O
channel O
blocking O
drugs O
or O
type O
IC O
antiarrhythmic O
drugs O
. O

To O
overcome O
this O
problem O
, O
we O
have O
overexpressed O
Kex2p I-GENE
using O
the O
baculovirus O
/ O
insect O
cell O
expression O
system O
. O

J O
. O

The O
major I-GENE
49 I-GENE
- I-GENE
kDa I-GENE
core I-GENE
protein I-GENE
in O
the O
liver O
HSPG I-GENE
preparation O
was O
found O
to O
be O
reactive O
to O
an O
antibody O
that O
specifically O
recognizes O
the O
cytoplasmic O
domain O
of O
fibroglycan I-GENE
. O

While O
no O
obvious O
transmembrane O
regions O
were O
identified O
, O
several O
short O
hydrophobic O
amino O
acid O
stretches O
were O
found O
to O
be O
localized O
in O
and O
around O
the O
Pro O
II O
region O
, O
and O
these O
may O
be O
responsible O
for O
attachment O
of O
precursors O
to O
membranes O
. O

Toxicity O
was O
mild O
, O
mainly O
consisting O
of O
emesis O
( O
81 O
% O
of O
the O
patients O
; O
66 O
% O
of O
the O
courses O
), O
leukopenia O
of O
World O
Health O
Organization O
( O
WHO O
) O
grade O
1 O
to O
2 O
( O
47 O
% O
of O
the O
patients O
; O
18 O
% O
of O
the O
courses O
), O
and O
thrombocytopenia O
( O
12 O
% O
of O
the O
patients O
; O
3 O
% O
of O
the O
courses O
). O

W O
. O
G O
. O

This O
study O
confirms O
, O
although O
individual O
reaction O
is O
remarkably O
different O
, O
transportation O
as O
a O
potent O
stressor O
for O
Beagle O
dogs O
. O

A O
mouse I-GENE
brain I-GENE
beta I-GENE
- I-GENE
spectrin I-GENE
of O
cDNA O
was O
identified O
within O
a O
lambda O
Gt11 O
expression O
library O
using O
an O
antibody O
which O
specifically O
binds O
with O
the O
235 I-GENE
kDa I-GENE
spectrin I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
. O

RESULTS O
: O
Plasma I-GENE
AVP I-GENE
responses O
to O
osmotic O
stimulation O
, O
and O
non O
- O
osmotic O
inhibition O
by O
drinking O
, O
were O
normal O
in O
patients O
with O
compulsive O
water O
drinking O
. O

The O
fragments O
of O
each O
region O
were O
amplified O
by O
polymerase O
chain O
reaction O
and O
analyzed O
by O
gel O
electrophoresis O
to O
detect O
single O
- O
strand O
conformation O
polymorphism O
. O

The O
csbA I-GENE
fusion I-GENE
was O
maximally O
expressed O
during O
early O
stationary O
phase O
in O
cells O
grown O
in O
Luria O
broth O
containing O
5 O
% O
glucose O
and O
0 O
. O
2 O
% O
glutamine O
. O

The O
constraints O
of O
primase I-GENE
recognition I-GENE
sequences I-GENE
, O
nucleotide O
substrate O
requirements O
, O
and O
the O
effects O
of O
additional O
proteins O
on O
oligoribonucleotide O
synthesis O
by O
the O
63 I-GENE
- I-GENE
kDa I-GENE
gene I-GENE
4 I-GENE
protein I-GENE
have O
been O
examined O
using O
templates O
of O
defined O
sequence O
. O

Thrombolytic O
therapy O
in O
spontaneous O
coronary O
artery O
dissection O
. O

A O
prospective O
trial O
was O
carried O
out O
in O
156 O
unselected O
patients O
( O
41 O
men O
, O
mean O
age O
67 O
. O
5 O
years O
, O
115 O
women O
, O
mean O
age O
71 O
. O
4 O
years O
) O
who O
had O
undergone O
total O
hip O
joint O
replacement O
because O
of O
degenerative O
or O
inflammatory O
arthritis O
or O
fracture O
of O
the O
neck O
of O
the O
femur O
. O

When O
both O
lesions O
were O
complete O
lateral O
hemisections O
in O
weanling O
operates O
, O
little O
behavioral O
recovery O
was O
observed O
, O
similar O
to O
complete O
spinal O
cord O
transection O
( O
N O
= O
3 O
). O

Human O
SRF I-GENE
- I-GENE
related I-GENE
proteins I-GENE
: O
DNA O
- O
binding O
properties O
and O
potential O
regulatory O
targets O
. O

We O
have O
isolated O
cDNAs O
for O
a O
gene O
coding O
for O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
from I-GENE
tomato I-GENE
( O
Lycopersicon O
esculentum O
, O
cv O
. O

Growth O
factor O
stimulation O
of O
cells O
causes O
the O
phosphorylation O
of O
the O
c I-GENE
- I-GENE
Myc I-GENE
transcriptional I-GENE
activation I-GENE
domain I-GENE
at O
Ser62 O
within O
a O
proline O
- O
rich O
region O
that O
is O
highly O
conserved O
among O
members O
of O
the O
Myc I-GENE
family I-GENE
( O
Alvarez O
, O
E O
., O
Northwood O
, O
I O
. O
C O
., O
Gonzalez O
, O
F O
. O

The O
authors O
evaluated O
the O
potential O
for O
thrombotic O
complications O
arising O
from O
implantation O
of O
a O
ventricular O
assist O
device O
( O
Sarns O
/ O
3M O
- O
VAD O
) O
in O
four O
calves O
. O

Cardiac O
output O
( O
CO O
) O
was O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
0005 O
) O
in O
the O
MBBF O
group O
. O

Amino O
acid O
residues O
147 O
- O
167 O
of O
the O
previously O
reported O
sequence O
are O
replaced O
by O
new O
residues O
147 O
to O
150 O
. O

Transcriptional O
activation O
by O
the O
HIV I-GENE
- I-GENE
1 I-GENE
Tat I-GENE
protein I-GENE
requires O
specific O
residues O
in O
the O
hexanucleotide O
loop O
and O
trinucleotide O
bulge O
of O
the O
TAR I-GENE
RNA O
stem O
- O
loop O
structure O
found O
in O
the O
5 O
'- O
untranslated O
leader O
of O
all O
viral O
transcripts O
. O

We O
obtained O
quantitative O
evidence O
on O
the O
coding O
of O
interaural O
time O
differences O
( O
ITDs O
) O
of O
click O
stimuli O
by O
40 O
single O
neurons O
in O
the O
auditory O
cortex O
of O
anesthetized O
albino O
rats O
. O

These O
results O
strongly O
suggest O
that O
locally O
- O
applied O
TTC O
in O
combination O
with O
FDBA O
enhances O
new O
bone O
formation O
in O
experimental O
alveolar O
bone O
defects O
. O

As O
an O
initial O
step O
towards O
the O
characterization O
of O
replicative O
DNA I-GENE
polymerases I-GENE
of I-GENE
trypanosomes I-GENE
, O
we O
have O
cloned O
, O
sequenced O
and O
examined O
the O
expression O
of O
the O
Trypanosoma O
( O
Trypanozoon O
) O
brucei O
brucei O
gene O
that O
encodes O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
catalytic I-GENE
core I-GENE
( O
pol I-GENE
alpha I-GENE
). O

In O
addition O
, O
there O
was O
a O
significant O
increase O
in O
postdexamethasone O
cortical O
concentrations O
with O
age O
( O
p O
less O
than O
0 O
. O
01 O
; O
r O
= O
0 O
. O
31 O
). O

Pulmonary O
hypertension O
, O
with O
or O
without O
coronary O
arterial O
narrowing O
, O
is O
the O
major O
condition O
leading O
to O
isolated O
atrial O
infarction O
. O

The O
volume O
fraction O
( O
Vv O
) O
and O
number O
/ O
mm2 O
( O
Na O
) O
of O
all O
capillaries O
( O
perfused O
and O
nonperfused O
) O
in O
a O
given O
area O
of O
brain O
were O
determined O
after O
staining O
for O
alkaline I-GENE
phosphatase I-GENE
. O

Airway O
pressure O
and O
air O
flow O
were O
measured O
at O
the O
endotracheal O
tube O
in O
13 O
children O
on O
a O
variety O
of O
ventilators O
. O

Appl O
. O

Issues O
of O
distribution O
of O
kinetic O
energy O
of O
traumatizing O
object O
in O
direct O
contact O
interaction O
with O
head O
during O
impact O
are O
discussed O
from O
position O
of O
biomechanics O
. O

CONCLUSION O
: O
Monitoring O
SpO2 O
at O
the O
nasal O
septum O
site O
is O
more O
reliable O
than O
monitoring O
it O
at O
the O
finger O
site O
in O
hypothermic O
patients O
. O

Diltiazem O
decreased O
the O
total O
body O
clearance O
from O
34 O
. O
0 O
+/- O
8 O
. O
0 O
to O
28 O
. O
6 O
+/- O
6 O
. O
1 O
mL O
/ O
min O
( O
P O
less O
than O
. O
01 O
), O
and O
prolonged O
the O
elimination O
half O
- O
life O
from O
12 O
. O
6 O
+/- O
3 O
. O
0 O
to O
14 O
. O
3 O
+/- O
2 O
. O
5 O
hours O
( O
P O
less O
than O
. O
01 O
) O
of O
antipyrine O
without O
any O
changes O
in O
volume O
of O
distribution O
. O

The O
granules O
grew O
as O
the O
melted O
material O
immersed O
into O
the O
void O
space O
among O
the O
adhered O
particles O
. O

Hence O
, O
the O
uPA I-GENE
promoter I-GENE
contains O
multiple O
weak O
cis O
- O
acting O
elements O
distributed O
over O
7 O
. O
0 O
kb O
5 O
' O
to O
the O
translation O
start O
site O
. O

Substituting O
a O
Ser O
for O
Gly69 O
or O
a O
Glu O
for O
Lys O
71 O
in O
the O
conserved O
TGEK I-GENE
tetrapeptide I-GENE
in O
finger O
II O
of O
TFIIIA I-GENE
resulted O
in O
the O
loss O
of O
DNA O
binding O
. O

P O
. O

In O
one O
, O
exploratory O
behavior O
( O
assessed O
by O
hole O
pokes O
) O
and O
locomotion O
were O
assessed O
during O
a O
10 O
- O
min O
test O
session O
. O

The O
model O
is O
able O
to O
anticipate O
why O
the O
effect O
of O
water O
fluoridation O
on O
caries O
prevalence O
is O
most O
pronounced O
when O
caries O
is O
diagnosed O
at O
cavity O
level O
. O

12 O
- O
O O
- O
Tetradecanoylphorbol O
13 O
- O
acetate O
was O
found O
to O
inhibit O
rapidly O
and O
potently O
the O
expression O
of O
mRNAs O
coding O
for O
the O
myogenic O
regulators O
CMD1 I-GENE
and O
myogenin I-GENE
. O

In O
Xenopus O
laevis O
, O
the O
gene O
encoding O
the O
elongation I-GENE
factor I-GENE
1 I-GENE
- I-GENE
alpha I-GENE
variant I-GENE
EF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
O I-GENE
, O
where O
O O
stands O
for O
oocyte O
, O
is O
expressed O
in O
oocytes O
and O
early O
embryos O
. O

These O
introns O
belong O
to O
the O
class O
of O
nuclear O
pre O
- O
mRNA O
introns O
and O
contain O
typical O
5 O
'- O
and O
3 O
'- O
consensus O
sequences O
, O
as O
well O
as O
unique O
features O
. O

The O
mRNA O
identified O
in O
both O
human O
and O
rat O
cells O
with O
the O
human I-GENE
clathrin I-GENE
clone O
revealed O
transcripts O
of O
approximately O
6 O
. O
5 O
kb O
, O
which O
is O
consistent O
with O
the O
predicted O
180 O
kDa O
molecular O
weight O
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
. O

In O
this O
report O
, O
almost O
6 O
kb O
of O
DNA O
sequence O
is O
presented O
, O
including O
1251 O
bp O
5 O
' O
to O
the O
gene O
, O
over O
4 O
kb O
of O
exon O
and O
exon O
- O
intron O
junctions O
, O
and O
583 O
bp O
3 O
' O
to O
the O
gene O
. O

An O
8 O
- O
h O
exposure O
to O
10 O
mg O
DMEA O
/ O
m3 O
corresponds O
to O
a O
postexposure O
plasma O
concentration O
and O
2 O
- O
h O
postexposure O
urinary O
excretion O
of O
4 O
. O
9 O
mumol O
/ O
l O
and O
75 O
mmol O
/ O
mol O
creatinine O
, O
respectively O
. O

Antibodies O
specific O
to O
rE12 I-GENE
and O
rNFIL I-GENE
- I-GENE
6 I-GENE
disrupt O
nucleoprotein O
complexes O
with O
these O
DNA O
- O
binding O
sites O
, O
confirming O
the O
interaction O
of O
native O
in O
vivo O
factors O
. O

A O
method O
is O
described O
for O
detecting O
targeted O
events O
at O
the O
mu I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
which O
relies O
on O
co O
- O
conversion O
( O
or O
co O
- O
exchange O
) O
of O
a O
point O
mutation O
with O
a O
selectable O
marker O
contained O
on O
a O
replacement O
vector O
. O

Allergenic O
activity O
of O
allergen O
extract O
Ambrosia O
elatior O
( O
AE O
) O
was O
tested O
in O
fifteen O
volunteers O
extremely O
sensitive O
to O
the O
allergen O
. O

This O
study O
was O
aimed O
at O
assessing O
whether O
c O
- O
DDP O
administration O
immediately O
before O
radiotherapy O
could O
increase O
frequency O
and O
duration O
of O
objective O
responses O
, O
as O
well O
as O
survival O
, O
in O
patients O
affected O
with O
locally O
advanced O
stages O
of O
squamous O
carcinomas O
of O
the O
head O
and O
neck O
. O

Two O
potential O
regulatory O
sequences O
for O
DNA O
binding O
proteins O
were O
found O
in O
the O
non O
- O
coding O
5 O
' O
region O
: O
a O
HAP2 I-GENE
/ O
HAP3 I-GENE
consensus O
recognition O
sequence O
at O
nucleotide O
- O
154 O
and O
a O
BAF1 I-GENE
consensus I-GENE
recognition I-GENE
sequence I-GENE
at O
nucleotide O
- O
136 O
. O

Marked O
thrombocytopenia O
, O
depletion O
of O
serum I-GENE
fibrinogen I-GENE
and O
prolonged O
prothrombin I-GENE
and O
activated O
partial O
thromboplastin I-GENE
time O
, O
were O
recorded O
at O
5 O
to O
10 O
and O
30 O
to O
40 O
minutes O
after O
intravenous O
envenomation O
. O

We O
exploit O
the O
properties O
of O
LexA I-GENE
fusion I-GENE
proteins I-GENE
to O
study O
the O
dimerization O
and O
DNA O
- O
contacting O
domains O
of O
cRel I-GENE
. O

Plasma O
lipid O
and O
lipoprotein O
profiles O
were O
compared O
in O
elderly O
female O
runners O
( O
RU O
: O
n O
= O
15 O
, O
aged O
66 O
+/- O
5 O
years O
, O
body O
fat O
20 O
+/- O
4 O
%, O
training O
distance O
35 O
+/- O
15 O
km O
week O
- O
1 O
, O
VO2max O
36 O
+/- O
4 O
ml O
kg O
- O
1 O
min O
- O
1 O
, O
mean O
+/- O
SD O
) O
and O
age O
- O
matched O
untrained O
women O
( O
UT O
: O
n O
= O
28 O
, O
66 O
+/- O
4 O
years O
, O
body O
fat O
26 O
+/- O
6 O
%, O
VO2max O
26 O
+/- O
3 O
ml O
kg O
- O
1 O
min O
- O
1 O
). O

Auditory O
threshold O
shifts O
, O
as O
measured O
by O
the O
auditory O
evoked O
brainstem O
response O
, O
were O
measured O
at O
2 O
, O
4 O
, O
8 O
, O
12 O
, O
16 O
, O
20 O
and O
24 O
kHz O
. O

Fundamental O
and O
clinical O
evaluation O
of O
equilibrium O
dialysis O
-- O
radioimmunoassay O
system O
for O
measurement O
of O
serum O
free O
thyroxine O

We O
conclude O
that O
TA O
caused O
a O
specific O
decrease O
in O
AGD O
on O
GD O
20 O
that O
was O
largely O
reversed O
by O
PCD O
23 O
. O

When O
examined O
as O
adults O
( O
8 O
weeks O
old O
), O
the O
external O
genitalia O
of O
TA O
- O
exposed O
offspring O
were O
normal O
. O

After O
PTCA O
, O
ejection O
fraction O
increased O
from O
54 O
+/- O
8 O
% O
to O
59 O
+/- O
8 O
% O
( O
p O
less O
than O
0 O
. O
05 O
) O
and O
regional O
function O
improved O
significantly O
( O
maximal O
standard O
deviation O
before O
PTCA O
: O
2 O
. O
8 O
+/- O
0 O
. O
8 O
; O
after O
PTCA O
: O
1 O
. O
9 O
+/- O
0 O
. O
9 O
- O
segments O
below O
the O
first O
standard O
deviation O
before O
PTCA O
: O
31 O
+/- O
16 O
; O
after O
PTCA O
: O
19 O
+/- O
17 O
). O

The O
alcoholic O
patient O
, O
his O
work O
and O
the O
subjectivity O
of O
the O
period O

These O
data O
suggest O
that O
the O
combined O
treatment O
with O
a O
thromboxane I-GENE
synthetase I-GENE
inhibitor O
and O
a O
thromboxane I-GENE
receptor I-GENE
antagonist O
provides O
a O
better O
protection O
against O
digoxin O
intoxication O
than O
with O
either O
agent O
alone O
. O

A O
330 O
- O
kb O
YAC O
, O
A148A7 O
, O
spanned O
from O
the O
HLA I-GENE
- O
DQA1 I-GENE
locus O
through O
the O
Y3 I-GENE
/ O
Ring I-GENE
4 I-GENE
locus O
and O
extended O
at O
least O
130 O
kb O
centromeric O
of O
YAC O
B1D12 O
. O

Interspecific O
backcross O
analysis O
using O
progeny O
derived O
from O
matings O
of O
( O
C57BL O
/ O
6J O
x O
Mus O
spretus O
) O
F1 O
x O
C57BL O
/ O
6J O
mice O
indicates O
that O
the O
thrombospondin I-GENE
gene I-GENE
is O
tightly O
linked O
to O
the O
Fshb I-GENE
, O
Actcl I-GENE
, O
Ltk I-GENE
, O
and O
B2M I-GENE
loci I-GENE
on O
murine O
chromosome O
2 O
. O

Adverse O
foetal O
outcome O
in O
specific O
IgM I-GENE
positive O
Chlamydia O
trachomatis O
infection O
in O
pregnancy O
. O

Using O
an O
image O
- O
processing O
computer O
, O
regional O
LV O
time O
- O
density O
curves O
were O
constructed O
for O
one O
cardiac O
cycle O
. O

In O
a O
second O
patient O
the O
VT O
became O
nonsustained O
. O

If O
delay O
has O
occurred O
between O
centrifugation O
and O
the O
measurement O
, O
causing O
substantial O
loss O
of O
CO2 O
, O
equilibration O
of O
the O
sample O
with O
a O
gas O
mixture O
corresponding O
to O
PCO2 O
= O
5 O
. O
3 O
kPa O
prior O
to O
the O
measurement O
is O
recommended O
. O

The O
possible O
mechanisms O
underlying O
differences O
in O
post O
- O
tetanic O
effects O
from O
muscle O
and O
cutaneous O
afferents O
in O
adults O
and O
neonates O
are O
discussed O
. O

We O
examined O
behavioral O
alterations O
in O
the O
brown O
cockroach O
, O
Periplaneta O
brunnea O
, O
infected O
with O
the O
acanthocephalan O
, O
Moniliformis O
moniliformis O
. O

First O
, O
the O
finding O
of O
a O
monomeric O
Alu I-GENE
family O
repeat O
at O
the O
junction O
between O
nonhomology O
block O
I O
and O
homology O
block O
Y O
of O
the O
alpha I-GENE
2 I-GENE
gene I-GENE
- I-GENE
containing I-GENE
unit I-GENE
in I-GENE
rhesus I-GENE
macaque I-GENE
suggests O
that O
the O
dimeric O
Alu I-GENE
family O
repeat O
, O
Alu I-GENE
3 I-GENE
, O
at O
the O
orthologous O
position O
in O
human O
was O
generated O
by O
insertion O
of O
a O
monomeric O
Alu I-GENE
family O
repeat O
into O
the O
3 O
' O
end O
of O
another O
preexisting O
Alu I-GENE
family O
repeat O
. O

The O
sequence O
of O
the O
repressor O
locus O
, O
c O
, O
of O
the O
Streptomyces O
temperate O
phage O
, O
phi O
C31 O
, O
was O
shown O
previously O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
74 O
kDa O
protein O
. O

The O
EPO I-GENE
levels O
were O
distinctly O
increased O
before O
transfusion O
; O
they O
did O
not O
significantly O
change O
just O
after O
transfusion O
, O
but O
subsequently O
decreased O
. O

This O
differential O
sensitivity O
to O
DB O
, O
as O
measured O
by O
a O
lower O
concentration O
of O
DB O
which O
caused O
loss O
of O
righting O
in O
LS O
, O
was O
accompanied O
by O
an O
equal O
rate O
of O
water O
- O
soluble O
barbiturate O
brain O
distribution O
and O
elimination O
in O
the O
two O
lines O
. O

The O
existence O
of O
threshold O
concentrations O
, O
above O
which O
certain O
phenomena O
may O
occur O
, O
strengthens O
the O
role O
of O
sentinels O
. O

However O
, O
it O
was O
synthesized O
at O
both O
temperatures O
after O
addition O
of O
A23187 O
. O

Felodipine O
did O
not O
alter O
the O
baseline O
FEV1 O
, O
but O
showed O
a O
small O
significant O
inhibitory O
effect O
upon O
histamine O
and O
AMP O
induced O
bronchoconstriction O
. O

Ten O
out O
of O
10 O
patients O
with O
progressive O
disease O
had O
mast O
cells O
greater O
than O
or O
equal O
to O
0 O
. O
5 O
%, O
hyaluronan O
greater O
than O
or O
equal O
to O
50 O
micrograms O
. O
l O
- O
1 O
and O
fibronectin I-GENE
greater O
than O
or O
equal O
to O
350 O
micrograms O
. O
l O
- O
1 O
compared O
to O
eight O
out O
of O
41 O
patients O
with O
stable O
or O
regressive O
disease O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Our O
mapping O
results O
did O
not O
suggest O
involvement O
of O
this O
gene O
in O
previously O
mapped O
genetic O
disorders O
or O
in O
known O
neoplasia O
- O
associated O
translocation O
breakpoints O
. O

Relatively O
little O
is O
known O
regarding O
the O
role O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
activity O
in O
male O
rat O
sexual O
behavior O
. O

These O
changes O
weren O
' O
t O
so O
significant O
in O
the O
group O
of O
obese O
children O
who O
didn O
' O
t O
lose O
weight O
. O

Arsenic O
contents O
in O
native O
copper O

In O
ten O
other O
experiments O
( O
5 O
experimental O
and O
5 O
control O
rats O
) O
99mTc O
- O
sulfur O
colloid O
was O
injected O
intravenously O
. O

Magnetotherapy O
of O
hepatitis O
A O
and O
B O
in O
children O

These O
results O
were O
superior O
to O
those O
in O
24 O
patients O
with O
conventional O
end O
- O
to O
- O
end O
sutures O
on O
clinical O
testing O
. O

Mutational O
analysis O
supports O
a O
role O
for O
multiple O
structural O
features O
in O
the O
C O
- O
terminal O
secretion O
signal O
of O
Escherichia I-GENE
coli I-GENE
haemolysin I-GENE
. O

Among O
blood O
donors O
in O
the O
Republic O
of O
Serbia O
, O
regardless O
the O
number O
of O
blood O
donations O
, O
the O
percentage O
of O
female O
donors O
is O
significantly O
lower O
compared O
to O
the O
percentage O
of O
male O
blood O
donors O
. O

Extramedullary O
relapse O
in O
childhood O
leukemia O
. O

Mycoplasma O
pneumoniae O
was O
isolated O
from O
the O
pleural O
fluid O
of O
this O
patient O
. O

RU486 O
and O
ONO O
802 O
in O
combination O
have O
been O
shown O
to O
be O
effective O
in O
early O
termination O
of O
pregnancy O
. O

The O
presence O
of O
local O
abnormalities O
in O
both O
patients O
can O
support O
the O
hypothesis O
that O
the O
cortex O
, O
especially O
of O
the O
temporal O
anterior O
lobe O
, O
is O
involved O
in O
the O
origin O
of O
the O
laughing O
seizures O
. O

In O
line O
with O
the O
small O
values O
for O
QS O
/ O
QC O
, O
our O
results O
further O
indicate O
that O
even O
large O
, O
well O
- O
perfused O
, O
occluded O
air O
spaces O
in O
the O
lung O
will O
hardly O
affect O
the O
recovered O
ventilation O
/ O
perfusion O
distribution O
obtained O
from O
inert O
gas O
data O
when O
CDCSF6 O
exceeds O
0 O
. O
1 O
ml O
. O
min O
- O
1 O
. O
mmHg O
- O
1 O
. O

Many O
cells O
were O
negative O
for O
endothelial O
- O
cell O
markers O
, O
and O
they O
reacted O
with O
a O
monoclonal O
antibody O
against O
muscle O
actin I-GENE
. O

CT O
abnormalities O
noted O
in O
term O
babies O
included O
hemorrhage O
( O
subarachnoid O
5 O
. O
8 O
%, O
intracerebral O
11 O
. O
6 O
%), O
hypodensity O
( O
mild O
23 O
. O
2 O
%, O
moderate O
11 O
. O
6 O
% O
severe O
5 O
. O
8 O
%); O
hypodensity O
with O
hemorrhage O
5 O
. O
8 O
% O
and O
cerebral O
atrophy O
5 O
. O
8 O
%. O

The O
effects O
of O
contrast O
media O
on O
coagulation I-GENE
factor I-GENE
XII I-GENE
. O

Pigs O
were O
switched O
from O
the O
growing O
to O
the O
finishing O
diet O
at O
57 O
and O
61 O
kg O
in O
Exp O
. O

In O
sixteen O
patients O
with O
moderate O
essential O
hypertension O
the O
effects O
of O
10 O
- O
day O
nifedipine O
treatment O
on O
serum O
uric O
acid O
and O
renal O
excretion O
of O
uric O
acid O
were O
evaluated O
. O

TPTA O
produced O
brain O
congestion O
, O
and O
hepatic O
and O
pulmonary O
petechial O
and O
generalized O
hemorrhages O
. O

Examples O
are O
using O
more O
subjects O
or O
an O
improved O
research O
design O
, O
developing O
consensus O
statements O
or O
using O
meta O
- O
analysis O
. O

A O
two O
phase O
slug O
flow O
tubular O
heat O
exchanger O
was O
used O
for O
the O
thermal O
inactivation O
of O
Listeria O
monocytogenes O
in O
natural O
infected O
milk O
from O
seven O
cows O
. O

So O
far O
15 O
children O
have O
been O
studied O
. O

Regional O
cerebral O
blood O
flow O
( O
rCBF O
) O
measurements O
and O
psychiatric O
ratings O
were O
performed O
on O
seven O
schizophrenic O
patients O
( O
mean O
age O
= O
41 O
. O
4 O
years O
) O
who O
had O
been O
examined O
18 O
years O
previously O
in O
a O
study O
that O
used O
similar O
psychiatric O
ratings O
and O
a O
comparable O
rCBF O
technique O
. O

In O
the O
present O
study O
, O
we O
identified O
a O
strong O
positive O
cis O
- O
regulatory O
element O
at O
- O
70 O
bp O
to O
- O
75 O
bp O
in O
the O
LpS1 I-GENE
beta I-GENE
promoter I-GENE
with O
the O
sequence O
( O
G O
) O
6 O
and O
a O
similar O
, O
more O
distal O
cis O
- O
element O
at O
- O
721 O
bp O
to O
- O
726 O
bp O
. O

The O
present O
study O
reports O
visual O
evoked O
potential O
responses O
to O
pattern O
reversal O
( O
VEP O
- O
P O
) O
in O
ten O
third O
trimester O
pregnant O
women O
and O
changes O
in O
latency O
of O
NPN O
complex O
when O
compared O
with O
these O
responses O
in O
the O
non O
pregnant O
state O
. O

No O
case O
of O
SMF O
demonstrated O
expansive O
tumorous O
growth O
. O

Different O
doses O
of O
15 O
- O
methyl O
- O
PGF2 O
alpha O
( O
0 O
. O
125 O
- O
10 O
mg O
) O
were O
used O
to O
induce O
luteolysis O
and O
oestrus O
in O
7 O
heifers O
with O
28 O
treatments O
on O
day O
8 O
- O
12 O
of O
the O
oestrous O
cycle O
. O

Review O
of O
the O
literature O
and O
report O
of O
a O
case O
of O
a O
dermoid O
cyst O
. O

Resolution O
of O
thermographic O
asymmetry O
and O
/ O
or O
decrease O
in O
Delta O
T O
was O
demonstrated O
in O
approximately O
81 O
% O
of O
the O
post O
- O
treatment O
population O
. O

In O
all O
instances O
the O
apparent O
alcohol O
responses O
were O
very O
small O
and O
never O
exceeded O
a O
reading O
of O
1 O
microgram O
/ O
100ml O
for O
breath O
samples O
more O
than O
10min O
post O
- O
exposure O
. O

Maize I-GENE
rbcS I-GENE
promoter I-GENE
activity O
depends O
on O
sequence O
elements O
not O
found O
in O
dicot I-GENE
rbcS I-GENE
promoters I-GENE
. O

Measurements O
were O
done O
with O
a O
commercial O
haematofluorometer O
Buchler O
ZF O
which O
was O
calibrated O
to O
the O
average O
haematocrit O
value O
of O
0 O
. O
42 O
. O

The O
relatively O
scanty O
number O
of O
examples O
, O
which O
could O
be O
justified O
by O
the O
variety O
and O
complexity O
of O
combined O
exposure O
, O
allows O
to O
conclude O
that O
life O
- O
style O
factors O
have O
considerable O
influence O
on O
interindividual O
differences O
in O
susceptibility O
to O
xenobiotics O
toxicity O
. O

The O
12S I-GENE
E1A I-GENE
product I-GENE
does O
not O
activate O
a O
TRE O
sequence O
, O
but O
cotransfection O
with O
c I-GENE
- I-GENE
jun I-GENE
circumvents O
this O
lack O
of O
stimulation O
. O

After O
treatment O
with O
tunicamycin O
, O
the O
transfectants O
secreted O
unglycosylated O
18 O
- O
kDa O
polypeptides O
which O
could O
also O
bind O
IgE I-GENE
. O

PAS1 I-GENE
, O
a O
yeast O
gene O
required O
for O
peroxisome O
biogenesis O
, O
encodes O
a O
member O
of O
a O
novel O
family O
of O
putative O
ATPases I-GENE
. O

The O
gene O
is O
1 O
, O
139 O
base O
pairs O
( O
bp O
) O
long O
, O
and O
, O
like O
other O
members O
of O
the O
SIG I-GENE
family I-GENE
, O
the O
beta I-GENE
TG I-GENE
gene I-GENE
is O
divided O
into O
3 O
exons O
. O

The O
pp90rsk I-GENE
- I-GENE
protein I-GENE
kinase I-GENE
activity O
( O
referred O
to O
as O
rsk I-GENE
- I-GENE
kinase I-GENE
) O
is O
also O
not O
related O
to O
cofactor O
- O
dependent O
signal O
transducing O
protein O
kinases O
such O
as O
the O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
, O
members O
of O
the O
protein I-GENE
kinase I-GENE
C I-GENE
family I-GENE
, O
or O
other O
Ca2 I-GENE
(+)- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Human I-GENE
GATA I-GENE
- I-GENE
3 I-GENE
: O
a O
lineage O
- O
restricted O
transcription O
factor O
that O
regulates O
the O
expression O
of O
the O
T I-GENE
cell I-GENE
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

Like O
many O
eukaryotic O
transcription O
factors O
, O
these O
proteins O
bind O
to O
DNA O
as O
dimers O
. O

Furthermore O
, O
the O
UvrA I-GENE
protein I-GENE
interacts O
with O
the O
UvrB I-GENE
protein I-GENE
to O
modulate O
its O
activities O
, O
both O
in O
solution O
and O
in O
association O
with O
DNA O
, O
where O
the O
UvrAB I-GENE
complex I-GENE
possesses O
a O
helicase I-GENE
activity O
. O

The O
ED30 O
values O
were O
2 O
. O
4 O
and O
2 O
. O
2 O
mg O
/ O
kg O
and O
similar O
to O
the O
respective O
values O
of O
nifedipine O
( O
ED O
30 O
: O
2 O
. O
4 O
, O
2 O
. O
1 O
mg O
/ O
kg O
). O

Southwestern O
blot O
analysis O
demonstrated O
that O
this O
phosphoprotein O
can O
bind O
the O
kappa I-GENE
B I-GENE
element I-GENE
directly O
and O
specifically O
. O

Thus O
, O
the O
positive O
effect O
of O
NS1 I-GENE
on O
the O
steady O
- O
state O
levels O
of O
P4 I-GENE
transcripts I-GENE
depends O
on O
the O
amplification O
of O
gene O
copy O
number O
and O
the O
integrity O
of O
the O
terminal O
repeats O
. O

The O
minus O
- O
end O
- O
directed O
microtubule O
motors O
, O
the O
dyneins I-GENE
, O
may O
also O
constitute O
a O
superfamily O
of O
force O
- O
generating O
proteins O
with O
distinct O
attachment O
domains O
. O

It O
is O
transparent O
, O
cheap O
to O
be O
made O
, O
and O
easy O
to O
empty O
and O
was O
tested O
in O
118 O
animals O
for O
two O
and O
four O
weeks O
. O

The O
incompatibility O
group O
W O
plasmid O
pSa O
suppresses O
Agrobacterium O
tumefaciens O
oncogenicity O
( O
J O
. O

Potential O
translational O
start O
signals O
are O
upstream O
of O
ORF1 O
and O
ORF2 O
. O

Imaging O
of O
D2 I-GENE
dopamine I-GENE
receptor I-GENE

The O
Thr161Val O
mutation O
causes O
a O
lethal O
phenotype O
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
, O
while O
replacement O
of O
Thr161 O
with O
glutamic O
acid O
, O
potentially O
mimicking O
phosphorylation O
, O
causes O
uncoordination O
of O
mitosis O
and O
multiple O
cytokinesis O
. O

The O
abundance O
of O
transcripts O
from O
several O
unrelated O
genes O
is O
decreased O
in O
cdc68 I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
cells O
after O
transfer O
to O
the O
restrictive O
temperature O
, O
while O
at O
least O
one O
transcript O
, O
from O
the O
HSP82 I-GENE
gene I-GENE
, O
persists O
in O
an O
aberrant O
fashion O
. O

Deregulation O
of O
their O
expression O
may O
contribute O
to O
malignant O
transformation O
associated O
with O
HTLV O
- O
1 O
infection O
. O

The O
murine I-GENE
Mov I-GENE
- I-GENE
34 I-GENE
gene I-GENE
: O
full O
- O
length O
cDNA O
and O
genomic O
organization O
. O

CREB I-GENE
was O
identified O
as O
one O
of O
the O
protein O
components O
in O
several O
of O
the O
gel O
shift O
complexes O
formed O
with O
the O
variant O
CRE O
. O

The O
spectrum O
of O
histologically O
diagnosed O
malignant O
neoplasms O
in O
Sabah O
, O
1983 O
- O
1988 O
. O

When O
transfected O
into O
Drosophila O
SL O
- O
2 O
cells O
, O
pCAT O
plasmid O
containing O
2 O
, O
090 O
bp O
of O
5 O
'- O
flanking O
region O
shows O
a O
3 O
. O
0 O
- O
to O
3 O
. O
5 O
- O
fold O
increase O
in O
chloramphenicol I-GENE
acetyltransferase I-GENE
activity O
after O
induction O
with O
retinoic O
acid O
and O
/ O
or O
8 O
- O
bromo O
- O
cAMP O
. O

Two O
alternatively O
spliced O
5 O
' O
UTRs O
, O
designated O
type O
I O
and O
type O
II O
, O
of O
222 O
and O
115 O
bp O
, O
respectively O
, O
were O
found O
associated O
with O
PFP I-GENE
. O

The O
N O
- O
terminus O
of O
another O
open O
reading O
frame O
was O
found O
3 O
' O
from O
nifA I-GENE
and O
tentatively O
identified O
as O
nifB I-GENE
by O
amino O
acid O
sequence O
comparison O
. O

The O
RNA O
genome O
of O
rabbit O
hemorrhagic O
disease O
virus O
( O
RHDV O
) O
was O
molecularly O
cloned O
. O

Therefore O
, O
we O
have O
developed O
a O
system O
to O
study O
nuclear O
targeting O
in O
plants O
and O
have O
established O
that O
the O
nuclear O
transport O
machinery O
is O
similar O
in O
monocots O
and O
dicots O
. O

A O
novel O
cDNA O
clone O
termed O
R2 O
was O
isolated O
by O
subtractive O
hybridization O
of O
a O
cDNA O
library O
of O
phytohemagglutinin I-GENE
( O
PHA I-GENE
)/ O
phorbol O
myristate O
acetate O
- O
stimulated O
Jurkat O
cells O
and O
by O
rescreening O
a O
cDNA O
library O
of O
PHA O
- O
stimulated O
peripheral O
blood O
lymphocytes O
. O

In O
conclusion O
, O
we O
observed O
a O
great O
regeneration O
ability O
following O
mechanical O
injury O
in O
the O
nasal O
mucosa O
. O

There O
occurred O
a O
linear O
relationship O
between O
the O
drop O
in O
glucose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphatase I-GENE
dehydrogenase I-GENE
activity O
and O
in O
vitamin O
E O
level O
, O
on O
one O
hand O
, O
and O
the O
duration O
of O
poisoning O
with O
sodium O
nitrite O
. O

A O
vector O
containing O
a O
transcriptionally O
inactive O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
gene I-GENE
was O
used O
to O
select O
promoter O
sequences O
from O
a O
pool O
of O
random O
genomic O
DNA O
fragments O
. O

Chagas O
' O
disease O
, O
visceral O
leishmaniasis O
, O
anti I-GENE
- I-GENE
nuclear I-GENE
factor I-GENE
, O
schistosomiasis O
, O
rheumatoid I-GENE
factor I-GENE
and O
normal O
controls O
. O

Previous O
analysis O
of O
the O
98 O
- O
bp O
sequence O
has O
delineated O
several O
protein O
- O
binding O
domains O
that O
are O
recognized O
by O
nuclear O
factors O
present O
in O
human O
brain O
cells O
. O

The O
second O
transcriptional O
unit O
, O
designated O
UL26 I-GENE
. I-GENE
5 I-GENE
, O
predicted O
to O
specify O
a O
protein O
of O
329 O
amino O
acids O
, O
encodes O
the O
family I-GENE
35 I-GENE
proteins I-GENE
; O
it O
is O
transcribed O
by O
an O
mRNA O
which O
initiates O
at O
approximately O
nucleotide O
+ O
1000 O
of O
the O
UL26 I-GENE
transcription O
initiation O
site O
and O
is O
translated O
from O
the O
methionine O
initiation O
codon O
located O
at O
position O
+ O
1099 O
of O
the O
UL26 I-GENE
transcriptional I-GENE
unit I-GENE
. O

The O
adeno I-GENE
- I-GENE
associated I-GENE
virus I-GENE
( I-GENE
AAV I-GENE
) I-GENE
rep I-GENE
gene I-GENE
encodes O
four O
proteins O
( O
Rep78 I-GENE
, O
Rep68 I-GENE
, O
Rep52 I-GENE
, O
and O
Rep40 I-GENE
) O
required O
for O
AAV O
DNA O
replication O
and O
AAV O
gene O
regulation O
. O

A O
larger O
region O
upstream O
of O
human I-GENE
CMV I-GENE
dbp I-GENE
also O
mediated O
replication O
in O
transient O
assays O
. O

It O
also O
contains O
a O
picornaviral I-GENE
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
domain I-GENE
and O
two O
papain I-GENE
- I-GENE
like I-GENE
protease I-GENE
domains I-GENE
. O

However O
, O
the O
relative O
positions O
of O
the O
VV O
genes O
( O
genus O
Orthopoxvirus O
) O
are O
different O
than O
those O
of O
the O
corresponding O
ORFs O
in O
SFV O
( O
genus O
Leporipoxvirus O
), O
indicating O
complex O
rearrangements O
of O
DNA O
in O
the O
genome O
of O
one O
or O
both O
of O
these O
viruses O
subsequent O
to O
their O
divergence O
from O
a O
common O
ancestor O
. O

This O
result O
suggests O
that O
phosphorylation O
of O
Thr O
14 O
and O
/ O
or O
Tyr O
15 O
inhibits O
p34cdc2 I-GENE
kinase I-GENE
activity O
, O
in O
line O
with O
the O
location O
of O
these O
residues O
within O
the O
putative O
ATP O
binding O
site O
of O
the O
kinase O
. O

In O
short O
- O
term O
cotransfections O
, O
a O
pFRTK I-GENE
- O
CAT I-GENE
target O
containing O
EBNA I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
from O
the O
EBV O
origin O
of O
plasmid O
replication O
, O
ori I-GENE
- I-GENE
P I-GENE
, O
was O
transactivated O
by O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
EBNA I-GENE
- I-GENE
1 I-GENE
construction I-GENE
( O
amino O
acids O
450 O
to O
641 O
) O
that O
also O
carried O
a O
c I-GENE
- I-GENE
myc I-GENE
nuclear I-GENE
localization I-GENE
signal I-GENE
. O

The O
findings O
are O
compatible O
with O
the O
idea O
that O
the O
genes O
encoding O
PDGF I-GENE
receptors I-GENE
in O
glioma O
cells O
are O
regulated O
in O
concert O
with O
other O
genes O
, O
the O
expression O
of O
which O
may O
reflect O
the O
developmental O
program O
of O
normal O
glia O
cell O
lineages O
. O

Suggestive O
evidence O
was O
obtained O
that O
cstA I-GENE
is O
involved O
in O
peptide O
utilization O
. O

This O
study O
tested O
the O
hypothesis O
that O
sodium O
channel O
blocking O
drugs O
selectively O
prolong O
the O
late O
potential O
, O
or O
terminal O
low O
amplitude O
signal O
, O
portion O
of O
the O
signal O
- O
averaged O
QRS O
complex O
and O
that O
prolongation O
of O
the O
late O
potential O
would O
correlate O
with O
slowing O
of O
ventricular O
tachycardia O
. O

Identification O
and O
nucleotide O
sequence O
of O
Rhizobium I-GENE
meliloti I-GENE
insertion I-GENE
sequence I-GENE
ISRm3 I-GENE
: O
similarity O
between O
the O
putative O
transposase I-GENE
encoded O
by O
ISRm3 I-GENE
and O
those O
encoded O
by O
Staphylococcus I-GENE
aureus I-GENE
IS256 I-GENE
and O
Thiobacillus I-GENE
ferrooxidans I-GENE
IST2 I-GENE
. O

To O
determine O
the O
relationship O
of O
these O
viruses O
, O
the O
complete O
DNA O
sequence O
of O
KV O
consisting O
of O
4754 O
bp O
was O
determined O
. O

Whereas O
a O
PR55 I-GENE
beta I-GENE
transcript I-GENE
of O
about O
2 O
. O
3 O
kb O
was O
detected O
at O
high O
levels O
in O
the O
neuroblastoma O
derived O
cell O
line O
LA O
- O
N O
- O
1 O
, O
the O
level O
of O
the O
mRNA O
was O
very O
low O
in O
the O
other O
human O
cell O
lines O
analyzed O
. O

Heterodimers O
of O
myogenin I-GENE
and O
E12 I-GENE
( O
or O
MyoD I-GENE
and O
E12 I-GENE
) O
specifically O
bound O
a O
restriction O
fragment O
extending O
from O
- O
200 O
to O
- O
103 O
relative O
to O
the O
start O
of O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
transcription O
. O

The O
effects O
of O
c I-GENE
- I-GENE
myc I-GENE
were O
further O
dissected O
by O
showing O
that O
c I-GENE
- I-GENE
myc I-GENE
can O
inhibit O
differentiation O
independently O
of O
Id I-GENE
, O
a O
negative O
regulator O
of O
muscle O
differentiation O
. O

Stable O
association O
of O
U2 I-GENE
snRNP I-GENE
with O
the O
branchpoint O
sequence O
of O
mammalian O
pre O
- O
mRNAs O
requires O
binding O
of O
a O
non O
- O
snRNP O
protein O
to O
the O
polypyrimidine O
tract O
. O

Naturally O
acquired O
antibodies O
were O
demonstrated O
in O
some O
rabbits O
kept O
on O
commercial O
farms O
. O

The O
Italian O
Lung O
Cancer O
Task O
Force O
( O
FONICAP O
). O

The O
promoter O
activity O
of O
the O
gene I-GENE
encoding I-GENE
Alzheimer I-GENE
beta I-GENE
- I-GENE
amyloid I-GENE
precursor I-GENE
protein I-GENE
( O
APP I-GENE
) O
is O
regulated O
by O
two O
blocks O
of O
upstream O
sequences O
. O

Biol O
. O

Nucleotide O
sequences O
between O
the O
env I-GENE
gene I-GENE
and O
the O
LTR I-GENE
of I-GENE
SFV I-GENE
- I-GENE
1 I-GENE
were O
determined O
. O

This O
element O
was O
used O
to O
screen O
an O
EMBL3 O
mouse O
genomic O
library O
. O

The O
MVV O
- O
value O
is O
under O
the O
predicted O
level O
in O
the O
case O
of O
67 O
- O
76 O
percent O
. O

The O
rad9 I-GENE
. I-GENE
192 I-GENE
DNA I-GENE
repair I-GENE
mutant I-GENE
from I-GENE
the I-GENE
fission I-GENE
yeast I-GENE
, I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
, O
is O
sensitive O
to O
both O
UV O
and O
ionising O
radiation O
. O

Review O
: O
deterioration O
of O
glucose O
tolerance O
with O
age O
: O
the O
role O
of O
insulin I-GENE
resistance O
. O

The O
5 O
' O
region O
shows O
strong O
sequence O
similarity O
to O
Escherichia O
coli O
consensus O
promoters O
and O
ribosome O
- O
binding O
sequences O
and O
allows O
high O
levels O
of O
expression O
in O
E O
. O
coli O
. O

Premature O
initiation O
of O
mitosis O
in O
yeast O
lacking O
RCC1 I-GENE
or O
an O
interacting O
GTPase I-GENE
. O

The O
method O
has O
been O
routinely O
used O
in O
our O
laboratory O
for O
1 O
year O
and O
has O
proven O
to O
be O
a O
reliable O
procedure O
for O
the O
biological O
control O
of O
occupational O
exposure O
to O
toluene O
and O
/ O
or O
xylene O
. O

The O
patient O
was O
a O
78 O
- O
year O
- O
old O
male O
in O
whom O
skin O
lesions O
preceded O
the O
diagnosis O
of O
myelofibrosis O
. O

Oculus O
- O
500 O
is O
a O
group O
of O
high O
resolution O
imaging O
boards O
for O
use O
with O
IBM O
- O
AT O
and O
compatible O
computers O
. O

The O
human O
cDNA O
was O
used O
to O
demonstrate O
that O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
could O
rapidly O
stimulate O
MARCKS I-GENE
gene I-GENE
transcription O
in O
the O
human O
promyelocytic O
leukemia O
cell O
line O
HL60 O
. O

After O
resection O
of O
the O
proximal O
fragment O
, O
all O
scaphoid O
contact O
area O
and O
pressure O
was O
born O
by O
the O
distal O
scaphoid O
fragment O
. O

Plate O
luting O
, O
a O
technique O
that O
uses O
polymethylmethacrylate O
( O
PMMA O
) O
interposed O
between O
the O
plate O
and O
the O
bone O
, O
as O
well O
as O
between O
the O
screw O
heads O
and O
the O
plate O
, O
to O
improve O
the O
stability O
of O
internal O
fixation O
was O
tested O
in O
vitro O
using O
20 O
paired O
equine O
third O
metacarpal O
bones O
with O
mid O
- O
diaphyseal O
osteotomies O
plated O
with O
six O
- O
hole O
broad O
ASIF O
compression O
plates O
. O

These O
features O
were O
considered O
consistent O
with O
a O
diagnosis O
of O
Rothmund O
- O
Thomson O
syndrome O
. O

Thyroid O
lymphoma O
and O
its O
management O
. O

The O
protein O
encoded O
by O
ORF113 I-GENE
contains O
a O
transmembrane O
domain O
. O

Space O
limitations O
prevent O
an O
exhaustive O
review O
of O
all O
biologic O
pharmaceuticals O
, O
such O
as O
tissue I-GENE
plasminogen I-GENE
activating I-GENE
substance I-GENE
, O
hormones O
( O
e O
. O
g O
., O
thyroid O
, O
insulin I-GENE
, O
growth I-GENE
hormone I-GENE
, O
erythropoietin I-GENE
), O
clotting O
factors O
, O
and O
blood O
products O
. O

Dd I-GENE
PK1 I-GENE
RNA I-GENE
decreases O
after O
6 O
h O
of O
starvation O
to O
re O
- O
accumulate O
once O
the O
cells O
have O
aggregated O
. O

The O
various O
forms O
of O
sickle O
cell O
disease O
share O
the O
common O
feature O
of O
an O
abnormal O
globin I-GENE
chain I-GENE
that O
, O
under O
certain O
conditions O
such O
as O
hypoxia O
, O
results O
in O
the O
sickling O
of O
red O
blood O
cells O
and O
obstruction O
of O
blood O
vessels O
. O

The O
primary O
structure O
of O
each O
of O
the O
three O
proteins O
has O
about O
70 O
% O
homology O
with O
that O
of O
mouse I-GENE
contrapsin I-GENE
, O
in O
contrast O
to O
43 O
- O
46 O
% O
homology O
with O
that O
of O
rat I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
protease I-GENE
inhibitor O
. O

Patterns O
of O
connections O
underlying O
cross O
- O
modality O
integration O
were O
studied O
by O
injecting O
distinguishable O
, O
retrograde O
tracers O
( O
Fluoro O
- O
Gold O
and O
diamidino O
yellow O
) O
in O
pairwise O
manner O
into O
different O
sensory O
representations O
( O
visual O
, O
somatosensory O
, O
and O
auditory O
) O
in O
the O
cerebral O
cortex O
of O
the O
rat O
. O

Young O
CD O
- O
1 O
mice O
, O
4 O
days O
old O
, O
exposed O
to O
0 O
. O
1 O
% O
nicotine O
sulfate O
on O
gestational O
days O
6 O
- O
20 O
were O
compared O
with O
untreated O
pups O
of O
the O
same O
age O
to O
determine O
its O
effect O
on O
the O
development O
of O
mandibular O
first O
molars O
. O

USF I-GENE
synthesized O
in O
an O
in O
vitro O
transcription O
and O
translation O
system O
also O
binds O
to O
the O
ADH I-GENE
promoter I-GENE
as O
well O
as O
to O
the O
MLP O
. O

The O
across O
- O
fiber O
pattern O
of O
the O
responses O
to O
hypotonic O
NaCl O
solutions O
correlated O
strongly O
to O
that O
elicited O
by O
distilled O
H2O O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Arterial O
radioactivity O
content O
after O
the O
intravenous O
administration O
of O
HMPAO O
in O
seven O
human O
subjects O
was O
analyzed O
. O

Linear O
regression O
analysis O
was O
performed O
and O
the O
following O
result O
was O
obtained O
: O
clearance O
( O
HMPAO O
) O
= O
0 O
. O
07 O
+ O
0 O
. O
43 O
. O
rCBF O
with O
a O
high O
significance O
( O
p O
less O
than O
0 O
. O
001 O
). O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
IN I-GENE
, O
expressed O
in O
Escherichia O
coli O
, O
was O
purified O
to O
near O
homogeneity O
. O

Thigh O
girth O
correlated O
positively O
with O
HDL I-GENE
and O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
mass O
, O
and O
with O
LDL I-GENE
particle O
size O
among O
women O
. O

Contributions O
from O
pairs O
of O
source O
and O
target O
volume O
elements O
are O
summed O
for O
the O
S O
values O
between O
the O
tumor O
and O
itself O
, O
between O
the O
remaining O
healthy O
host O
organ O
and O
itself O
, O
and O
between O
the O
tumor O
and O
the O
remaining O
healthy O
host O
organ O
, O
with O
the O
reciprocity O
theorem O
assumed O
for O
the O
last O
. O

Tests O
showed O
that O
an O
overall O
impression O
of O
the O
force O
applied O
could O
be O
obtained O
from O
a O
laboratory O
simulation O
, O
but O
that O
clearing O
cement O
and O
testing O
cement O
were O
not O
modelled O
by O
this O
method O
. O

The O
cDNA O
contained O
an O
open O
reading O
frame O
of O
1392 O
bp O
that O
predicted O
a O
protein O
of O
464 O
amino O
acids O
and O
a O
molecular O
mass O
of O
52 O
kDa O
; O
this O
protein O
has O
97 O
% O
identity O
to O
rat I-GENE
liver I-GENE
glucokinase I-GENE
. O

Analysis O
of O
viral O
mutants O
in O
vivo O
demonstrated O
that O
the O
NFIII I-GENE
/ O
OCT I-GENE
- I-GENE
1 I-GENE
binding O
site O
and O
a O
conserved O
ATF I-GENE
motif I-GENE
were O
important O
for O
efficient O
viral O
growth O
. O

Recovery O
of O
radiolabelled O
BA O
through O
urine O
( O
28 O
%) O
and O
faeces O
( O
22 O
%) O
up O
to O
96 O
hrs O
averaged O
50 O
%, O
whereas O
residual O
radioactivity O
in O
liver O
and O
testis O
experienced O
a O
recovery O
of O
29 O
% O
in O
scorbutic O
animals O
. O

Saccharomyces O
cerevisiae O
has O
been O
used O
widely O
both O
as O
a O
model O
system O
for O
unraveling O
the O
biochemical O
, O
genetic O
, O
and O
molecular O
details O
of O
gene O
expression O
and O
the O
secretion O
process O
, O
and O
as O
a O
host O
for O
the O
production O
of O
heterologous O
proteins O
of O
biotechnological O
interest O
. O

Paradoxically O
, O
however O
, O
the O
GH I-GENE
receptor I-GENE
cloned O
from O
liver O
exhibits O
no O
sequence O
similarity O
to O
receptors O
with O
known O
signal O
transduction O
mechanisms O
, O
including O
those O
exhibiting O
ligand O
- O
activated O
tyrosine I-GENE
kinase I-GENE
activity O
. O

This O
indicates O
that O
under O
certain O
experimental O
conditions O
cdc2 I-GENE
/ O
p58 I-GENE
and O
cdc2 I-GENE
/ O
p62 I-GENE
may O
express O
some O
differences O
in O
their O
catalytic O
activity O
. O

Mutation O
analysis O
implicated O
multiple O
segments O
of O
the O
5 O
' O
untranslated O
region O
as O
contributing O
to O
the O
inhibitory O
effect O
. O

Identification O
of O
Ets I-GENE
- O
and O
notch I-GENE
- O
related O
subunits O
in O
GA I-GENE
binding I-GENE
protein I-GENE
. O

The O
enzymatic O
response O
of O
neutrophils O
and O
monocytes O
was O
similar O
although O
the O
magnitude O
of O
the O
NADPH I-GENE
oxidase I-GENE
activity O
was O
significantly O
higher O
in O
neutrophils O
than O
in O
monocytes O
. O

In O
the O
ileum O
, O
enterotoxin O
increased O
the O
luminal O
disappearance O
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
peripheral O
blood O
appearance O
( O
P O
less O
than O
0 O
. O
001 O
) O
of O
chloroquine O
. O

Formalin O
activated O
both O
SNO O
NS O
and O
NnS O
neurones O
, O
but O
, O
when O
they O
responded O
, O
NS O
neurones O
( O
n O
= O
5 O
) O
showed O
only O
the O
first O
phase O
of O
activity O
while O
NnS O
neurones O
showed O
either O
one O
( O
n O
= O
13 O
) O
or O
two O
phases O
( O
n O
= O
6 O
). O

Uptake O
of O
ofloxacin O
by O
Escherichia O
coli O

It O
is O
concluded O
that O
attention O
to O
these O
issues O
can O
substantially O
improve O
the O
quality O
of O
research O
on O
AIDS O
related O
behaviors O
on O
Black O
communities O
. O

The O
effectiveness O
of O
alpha O
- O
mercapto O
- O
beta O
-( O
2 O
- O
furyl O
) O
acrylic O
acid O
( O
MFA O
) O
and O
N O
- O
benzyl O
- O
N O
- O
dithiocarboxy O
- O
D O
- O
glucamine O
( O
NaB O
), O
used O
in O
combination O
, O
in O
the O
mobilization O
and O
excretion O
of O
lead O
was O
investigated O
in O
rats O
. O

These O
results O
suggest O
that O
beta I-GENE
- I-GENE
1 I-GENE
may O
act O
as O
a O
tissue O
- O
specific O
, O
trans O
- O
acting O
regulator O
of O
the O
expression O
of O
the O
beta I-GENE
- I-GENE
zein I-GENE
gene I-GENE
in O
developing O
maize O
endosperm O
. O

This O
study O
examines O
the O
effects O
of O
hypovolemia O
on O
the O
extracellular O
ptO2 O
and O
ptH O
distributions O
at O
multiple O
tissue O
sites O
using O
a O
recently O
developed O
multipoint O
microelectrode O
, O
that O
provides O
simultaneous O
measurements O
of O
ptO2 O
and O
ptH O
. O

All O
members O
are O
also O
capable O
of O
activating O
in O
vivo O
transcription O
from O
promoters O
that O
contain O
a O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
domains O
involved O
in O
superactivation O
appear O
to O
be O
a O
subset O
of O
those O
necessary O
to O
achieve O
synergistic O
activation O
. O

Information O
on O
conserved O
noncoding O
sequences O
will O
help O
in O
studies O
on O
the O
regulation O
of O
the O
pro I-GENE
alpha I-GENE
1 I-GENE
( I-GENE
II I-GENE
) I-GENE
collagen I-GENE
gene I-GENE
. O

Chlamydia O
trachomatis O
and O
Chlamydia O
psittaci O
were O
not O
affected O
by O
methanol O
fixation O
. O

Although O
human O
infections O
with O
bacteraemia O
due O
to O
Pasteurella O
multocida O
are O
not O
uncommon O
, O
endocarditis O
associated O
with O
P O
. O
haemolytica O
is O
rare O
. O

For O
SMX O
at O
pH O
7 O
. O
0 O
, O
a O
1 O
: O
1 O
complex O
is O
formed O
, O
but O
at O
pH O
7 O
. O
5 O
HPCD O
has O
little O
effect O
on O
the O
solubility O
of O
the O
highly O
ionized O
SMX O
, O
presumably O
since O
only O
un O
- O
ionized O
molecules O
can O
form O
inclusion O
complexes O
with O
the O
HPCD O
. O

PO2 O
measurements O
using O
a O
double O
barrelled O
recess O
type O
microelectrodes O
were O
measured O
in O
the O
optic O
nerve O
head O
of O
miniature O
pigs O
in O
normoxia O
and O
hyperoxia O
. O

POU I-GENE
- O
specific O
and O
POU I-GENE
- O
homeo O
domains O
of O
Oct3 I-GENE
were O
produced O
in O
Echerichia O
coli O
for O
characterization O
of O
DNA O
binding O
to O
the O
octamer O
sequence O
. O

A O
deletion O
series O
of O
the O
5 O
' O
flanking O
region O
was O
created O
from O
position O
- O
1329 O
to O
- O
74 O
relative O
to O
the O
transcriptional O
initiation O
site O
and O
similarly O
examined O
in O
transgenic O
tobacco O
. O

The O
nucleotide O
( O
nt O
) O
sequences O
of O
the O
exons O
, O
exon O
/ O
intron O
boundaries O
and O
5 O
'- O
and O
3 O
'- O
untranslated O
regions O
were O
determined O
. O

Out O
of O
40 O
patients O
, O
who O
initially O
did O
not O
show O
eye O
complications O
due O
to O
leprosy O
, O
37 O
patients O
were O
essentially O
the O
same O
10 O
years O
later O
. O

Thus O
, O
two O
very O
different O
regulatory O
elements O
are O
used O
to O
mediate O
estrogen O
induction O
of O
related O
genes O
in O
chickens O
and O
amphibians O
. O

Toxicity O
was O
very O
mild O
with O
both O
regimens O
, O
although O
sedation O
was O
significantly O
higher O
in O
arm O
B O
( O
p O
less O
than O
0 O
. O
001 O
). O

Experimentally O
in O
green O
monkeys O
, O
Syrian O
hamsters O
and O
white O
mice O
the O
authors O
studied O
the O
pathogenic O
properties O
of O
a O
new O
virus O
Issyk O
- O
Kul O
. O

Increasing O
mean O
arterial O
pressure O
by O
phenylephrine O
infusion O
to O
levels O
much O
greater O
than O
produced O
by O
NMA O
and O
NNA O
caused O
only O
small O
reductions O
in O
cardiac O
output O
. O

J O
. O

Limits O
of O
energy O
turnover O
in O
relation O
to O
physical O
performance O
were O
addressed O
in O
terms O
of O
upper O
and O
lower O
limit O
, O
changes O
during O
a O
training O
programme O
and O
how O
to O
regulate O
energy O
balance O
at O
a O
changing O
energy O
turnover O
. O

With O
stepwise O
reductions O
in O
flow O
, O
the O
peak O
( O
S O
) O
and O
trough O
( O
D O
) O
points O
of O
the O
maximum O
shifted O
- O
frequency O
envelope O
fell O
in O
parallel O
in O
a O
linear O
fashion O
until O
D O
reached O
zero O
. O

The O
IE0 I-GENE
gene I-GENE
product O
also O
transactivated O
the O
IE1 I-GENE
promoter I-GENE
but O
did O
not O
affect O
expression O
from O
its O
own O
promoter O
. O

Moreover O
, O
promoters O
containing O
a O
TATA O
box O
in O
the O
absence O
of O
Sp1 I-GENE
sites I-GENE
or O
Sp1 I-GENE
sites I-GENE
in O
the O
absence O
of O
a O
TATA O
box O
were O
equally O
inducible O
in O
vitro O
, O
as O
was O
an O
RNA I-GENE
polymerase I-GENE
III I-GENE
promoter I-GENE
. O

Evaluation O
of O
left O
ventricular O
function O
using O
gated O
planar O
myocardial O
imaging O
with O
Tc O
- O
99m O
- O
MIBI O

Ivermectin O
uptake O
and O
distribution O
in O
the O
plasma O
and O
tissue O
of O
Sudanese O
and O
Mexican O
patients O
infected O
with O
Onchocerca O
volvulus O
. O

Bone O
marrow O
abnormalities O
in O
Hodgkin O
' O
s O
disease O
are O
reviewed O
and O
the O
current O
understanding O
of O
the O
pathological O
mechanisms O
leading O
to O
aplastic O
anemia O
is O
discussed O
. O

The O
smaller O
uptake O
rate O
and O
faster O
clearance O
rate O
resulted O
in O
the O
lower O
BCF O
for O
SWA O
killifish O
. O

The O
currently O
proposed O
extended O
arch O
repair O
should O
be O
reserved O
for O
the O
small O
group O
of O
infants O
with O
transverse O
aortic O
arch O
to O
ascending O
aorta O
diameter O
ratios O
( O
arch O
indices O
) O
of O
less O
than O
0 O
. O
25 O
. O

DNA O
hybridization O
analysis O
revealed O
that O
both O
pigmented O
and O
nonpigmented O
cells O
of O
Y O
. O
pestis O
possess O
a O
DNA O
locus O
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
fur I-GENE
gene I-GENE
. O

Increases O
in O
the O
perfusate O
PCO2 O
but O
not O
in O
the O
perfusate O
H O
+ O
were O
highly O
correlated O
with O
decreases O
in O
both O
myocardial O
contractility O
and O
oxygen O
consumption O
( O
r2 O
= O
. O
88 O
). O

Expression O
was O
cell O
cycle O
controlled O
, O
with O
steady O
- O
state O
RNA O
levels O
significantly O
higher O
in O
growth O
- O
arrested O
than O
in O
growth O
- O
stimulated O
cells O
. O

Determinants O
of O
recurrent O
ischaemia O
and O
revascularisation O
procedures O
after O
thrombolysis O
with O
recombinant O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
primary O
coronary O
occlusion O
. O

Therefore O
, O
the O
rbcL I-GENE
- O
rbcS I-GENE
locus O
seems O
to O
be O
barely O
expressed O
under O
a O
standard O
condition O
for O
photoautotrophic O
growth O
. O

Relationship O
between O
mitochondrial I-GENE
NADH I-GENE
- I-GENE
ubiquinone I-GENE
reductase I-GENE
and O
a O
bacterial I-GENE
NAD I-GENE
- I-GENE
reducing I-GENE
hydrogenase I-GENE
. O

Analysis O
of O
mRNA O
expression O
shows O
that O
AT I-GENE
- I-GENE
BP1 I-GENE
and O
AT I-GENE
- I-GENE
BP2 I-GENE
are O
expressed O
in O
all O
the O
tissues O
examined O
. O

We O
report O
two O
patients O
receiving O
maintenance O
valproate O
, O
one O
with O
resolving O
acute O
hepatitis O
C O
and O
the O
other O
with O
chronic O
persistent O
hepatitis O
C O
, O
with O
incidental O
microvesicular O
steatosis O
demonstrated O
on O
oil O
- O
red O
O O
stains O
. O

3 O
cases O

UDP I-GENE
- I-GENE
Gal I-GENE
: I-GENE
Gal I-GENE
beta I-GENE
1 I-GENE
---- I-GENE
4GlcNAc I-GENE
alpha I-GENE
1 I-GENE
---- I-GENE
3 I-GENE
- I-GENE
galactosyltransferase I-GENE
is O
a O
terminal I-GENE
glycosyltransferase I-GENE
that O
is O
widely O
expressed O
in O
a O
variety O
of O
mammalian O
species O
, O
with O
the O
notable O
exception O
of O
man O
, O
apes O
, O
and O
Old O
World O
monkeys O
. O

A O
synthetic O
oligonucleotide O
containing O
the O
SRE O
sequence O
from O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
promoter I-GENE
(- O
299 O
to O
- O
322 O
) O
was O
radioactively O
labeled O
, O
used O
as O
a O
probe O
for O
the O
mobility O
shift O
assay O
and O
Southwestern O
( O
DNA O
- O
protein O
) O
blotting O
, O
and O
also O
used O
for O
sequence O
- O
specific O
affinity O
chromatography O
. O

Sequence O
requirements O
for O
premature O
transcription O
arrest O
within O
the O
first O
intron O
of O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
. O

Infarct O
regional O
ejection O
fraction O
improved O
by O
10 O
. O
1 O
+/- O
2 O
. O
1 O
% O
between O
early O
and O
late O
studies O
when O
the O
infarct O
- O
related O
artery O
was O
patent O
and O
by O
4 O
. O
8 O
+/- O
1 O
. O
4 O
% O
if O
it O
was O
occluded O
( O
p O
= O
0 O
. O
048 O
); O
changes O
in O
global O
and O
noninfarct O
regional O
ejection O
fraction O
were O
similar O
irrespective O
of O
perfusion O
status O
. O

One O
of O
its O
lysine O
residues O
is O
modified O
by O
spermidine O
to O
form O
hypusine O
, O
a O
posttranslational O
modification O
unique O
to O
eIF I-GENE
- I-GENE
5A I-GENE
. O

The O
plasmid O
shuffle O
technique O
was O
used O
to O
replace O
the O
wild O
- O
type O
gene O
with O
the O
mutant O
form O
, O
resulting O
in O
failure O
of O
the O
yeast O
cells O
to O
grow O
. O

If O
this O
is O
the O
case O
, O
identification O
and O
characterization O
of O
transcripts O
from O
the O
Ig I-GENE
loci I-GENE
should O
permit O
a O
better O
understanding O
of O
the O
gene O
rearrangement O
process O
. O

Transcription O
of O
the O
metH I-GENE
gene I-GENE
in I-GENE
Salmonella I-GENE
typhimurium I-GENE
and I-GENE
Escherichia I-GENE
coli I-GENE
is O
positively O
regulated O
by O
the O
metR I-GENE
gene I-GENE
product I-GENE
, O
a O
DNA O
binding O
protein O
. O

Disruption O
of O
the O
chromosomal I-GENE
AAR1 I-GENE
gene I-GENE
in O
alpha O
and O
a O
/ O
alpha O
cells O
conferred O
the O
nonmating O
phenotype O
, O
and O
the O
a O
/ O
alpha O
diploids O
could O
not O
sporulate O
. O

The O
effect O
of O
ICRF O
- O
187 O
on O
the O
antitumor O
response O
induced O
by O
the O
combination O
of O
ADR O
and O
WBH O
was O
also O
investigated O
in O
order O
to O
assess O
alterations O
in O
the O
therapeutic O
index O
of O
this O
combined O
therapeutic O
modality O
treatment O
. O

The O
ORF O
was O
analyzed O
for O
secondary O
structural O
features O
, O
and O
the O
sequence O
data O
bases O
were O
searched O
for O
homologies O
. O

This O
study O
indicates O
that O
this O
dose O
- O
intense O
regimen O
can O
be O
safely O
administered O
, O
even O
with O
the O
use O
of O
purged O
marrow O
, O
with O
an O
acceptable O
toxicity O
profile O
. O

Mitomycin O
- O
C O
can O
cause O
severe O
necrosis O
and O
ulceration O
when O
extravasated O
inadvertently O
into O
skin O
and O
soft O
tissues O
following O
IV O
drug O
administration O
. O

In O
this O
study O
, O
we O
have O
cloned O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
nidogen I-GENE
gene I-GENE
. O

INTERVENTIONS O
: O
Patients O
received O
rt I-GENE
- I-GENE
PA I-GENE
, O
heparin O
, O
and O
aspirin O
. O

Consistent O
with O
the O
in O
vivo O
result O
, O
the O
pseudorevertant O
endonucleases O
in O
the O
crude O
cell O
extract O
display O
site O
- O
specific O
partial O
DNA O
cleavage O
activity O
. O

Additionally O
, O
I I-GENE
kappa I-GENE
B I-GENE
beta I-GENE
, O
but O
not O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
, O
also O
prevented O
the O
binding O
of O
Rel I-GENE
to O
the O
kappa I-GENE
B I-GENE
site I-GENE
. O

Sequence O
analysis O
reveals O
that O
the O
DNA O
binding O
domain O
of O
ILF I-GENE
has O
strong O
homology O
to O
the O
recently O
described O
fork I-GENE
head I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
found O
in O
the O
Drosophila I-GENE
homeotic I-GENE
protein I-GENE
fork I-GENE
head I-GENE
and O
a O
family O
of O
hepatocyte I-GENE
nuclear I-GENE
factors I-GENE
, O
HNF I-GENE
- I-GENE
3 I-GENE
. O

Lengthy O
and O
repeated O
hemodialyses O
were O
required O
to O
lower O
lithemia O
to O
nontoxic O
ranges O
. O

A O
single O
i O
. O
p O
. O
injection O
of O
d O
, O
l O
- O
baclofen O
10 O
mg O
/ O
kg O
both O
reduced O
noradrenaline O
( O
NA O
) O
biosynthesis O
in O
vivo O
( O
31 O
%) O
and O
the O
endogenous O
concentration O
of O
normetanephrine O
( O
NMN O
) O
( O
32 O
%) O
and O
increased O
NA O
levels O
( O
28 O
%). O

Fufang O
wuzi O
yanzong O
pills O
have O
strong O
leukogenic O
effect O
on O
cyclophosphamide O
induced O
leukopenia O
in O
mice O
. O

Mutations O
in O
the O
small O
subunit O
of O
ribulosebisphosphate I-GENE
carboxylase I-GENE
affect O
subunit O
binding O
and O
catalysis O
. O

The O
structural O
changes O
in O
intra O
- O
acinar O
artery O
manifested O
mainly O
by O
an O
increase O
in O
number O
of O
muscular O
artery O
resulting O
from O
muscularization O
of O
precursor O
cells O
( O
pericytes O
and O
intermediate O
cells O
) O
located O
within O
partially O
muscular O
and O
nonmuscular O
arterial O
wall O
to O
smooth O
muscle O
cell O
, O
and O
by O
the O
medial O
wall O
thickened O
due O
to O
hypertrophy O
and O
hyperplasia O
of O
smooth O
muscle O
cells O
as O
well O
as O
accumulation O
of O
a O
large O
amount O
of O
collagen I-GENE
, O
especially O
the O
type I-GENE
1 I-GENE
collagen I-GENE
. O

These O
results O
suggest O
that O
NZ O
- O
107 O
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
bronchial O
asthma O
by O
reducing O
late O
- O
phase O
airway O
responses O
and O
airway O
hyperreactivity O
. O

In O
study O
2 O
, O
the O
correlation O
coefficients O
between O
the O
ISO2 O
measurements O
obtained O
at O
the O
ulcer O
margin O
and O
at O
the O
adjacent O
normal O
mucosa O
, O
and O
delta O
ISO2 O
obtained O
by O
the O
experienced O
observer O
and O
one O
of O
the O
three O
learners O
were O
0 O
. O
94 O
, O
0 O
. O
97 O
, O
and O
0 O
. O
94 O
, O
respectively O
. O

Bronchial O
mucosa O
tattooing O
in O
persons O
exposed O
to O
different O
industrial O
aerosols O
did O
not O
depend O
on O
the O
forms O
of O
PC O
, O
DB O
and O
the O
diseases O
' O
stages O
. O

Anti I-GENE
- I-GENE
HBc I-GENE
production O
of O
PBMC O
was O
enhanced O
remarkably O
in O
this O
case O
. O

Sequence O
analysis O
of O
the O
sMtCK I-GENE
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
TATAA O
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

Sequence O
analysis O
of O
the O
sMtCK I-GENE
genomic I-GENE
upstream I-GENE
sequences I-GENE
reveals O
a O
typical O
TATAA O
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

The O
cDNA O
segment O
is O
flanked O
by O
the O
immunoglobulin I-GENE
gene I-GENE
recombination I-GENE
signal I-GENE
sequences I-GENE
so O
that O
the O
cDNA O
segment O
can O
invert O
and O
the O
human I-GENE
IL I-GENE
- I-GENE
2R I-GENE
L I-GENE
chain I-GENE
is O
subsequently O
expressed O
under O
the O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

Lipoprotein I-GENE
lipase I-GENE
( O
LPL I-GENE
), O
a O
key O
enzyme O
in O
normal O
lipoprotein O
metabolism O
, O
has O
a O
complex O
pattern O
of O
regulation O
and O
tissue O
- O
specific O
expression O
. O

Deletion O
of O
the O
proximal O
octanucleotide O
motif O
from O
the O
plasmid O
containing O
the O
- O
461 O
fragment O
of O
the O
LPL I-GENE
promoter I-GENE
, O
resulted O
in O
a O
79 O
and O
76 O
% O
decrease O
in O
the O
level O
of O
expression O
in O
transfected O
3T3 O
- O
L1 O
adipocytes O
and O
HepG2 O
hepatocytes O
, O
respectively O
. O

We O
examined O
the O
binding O
of O
purified O
T3 I-GENE
receptor I-GENE
alpha I-GENE
( O
T3R I-GENE
alpha I-GENE
), O
overexpressed O
in O
Escherichia O
coli O
, O
to O
wild O
- O
type O
and O
up O
and O
down O
mutations O
of O
the O
rGH I-GENE
T3RE I-GENE
to O
evaluate O
whether O
transcriptional O
potency O
correlates O
with O
changes O
in O
T3R I-GENE
binding O
. O

Comparison O
of O
the O
cDNA O
- O
predicted O
avian I-GENE
TnIcardiac I-GENE
amino I-GENE
acid I-GENE
sequences I-GENE
with O
known O
TnI I-GENE
sequences I-GENE
indicated O
1 O
) O
that O
the O
presence O
of O
an O
N O
- O
terminal O
extension O
sequence O
carrying O
a O
dual O
protein I-GENE
kinase I-GENE
A I-GENE
phosphorylation O
target O
site O
and O
an O
adjacent O
proline O
- O
rich O
segment O
is O
an O
ancient O
cardiac O
- O
specific O
feature O
of O
TnI I-GENE
which O
has O
been O
conserved O
since O
the O
bird O
/ O
mammal O
divergence O
, O
2 O
) O
that O
features O
of O
the O
near O
- O
N O
- O
terminal O
troponin I-GENE
C I-GENE
( O
TnC I-GENE
)- O
binding O
site O
sequence O
suggest O
isoform O
- O
specific O
adaptation O
of O
TnI I-GENE
and O
TnC I-GENE
, O
and O
3 O
) O
that O
the O
avian O
TnIcardiac I-GENE
internal O
actin I-GENE
/ I-GENE
TnC I-GENE
- I-GENE
binding I-GENE
, I-GENE
actomyosin I-GENE
- I-GENE
inhibitory I-GENE
, I-GENE
domain I-GENE
shows O
significant O
sequence O
divergence O
from O
mammalian I-GENE
TnIcardiac I-GENE
sequences I-GENE
, O
including O
the O
absence O
of O
a O
protein I-GENE
kinase I-GENE
C I-GENE
target O
site O
which O
is O
a O
cardiac O
- O
specific O
feature O
of O
TnI I-GENE
in O
mammals O
. O

Ventilatory O
management O
casebook O
. O

An O
ASSEMBLER O
routine O
for O
on O
- O
line O
graphic O
display O
and O
averaging O
of O
data O
acquired O
on O
a O
personal O
microcomputer O
. O

Expression O
of O
the O
mouse I-GENE
TSH I-GENE
beta I-GENE
gene I-GENE
, O
therefore O
, O
gives O
rise O
to O
multiple O
mRNAs O
, O
each O
with O
a O
unique O
5 O
'- O
untranslated O
region O
. O

Habituation O
of O
completely O
isolated O
neurons O
of O
the O
edible O
snail O
to O
electrical O
stimulation O
. O

It O
was O
found O
that O
the O
ROSP O
undergoes O
a O
number O
of O
fluctuations O
in O
the O
negative O
and O
positive O
directions O
with O
a O
gradually O
decreasing O
amplitude O
in O
the O
course O
of O
5 O
- O
25 O
days O
following O
the O
operation O
, O
after O
which O
relatively O
stable O
negative O
values O
of O
the O
ROSP O
are O
established O
on O
the O
average O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
dura O
mater O
, O
and O
positive O
values O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
pia O
mater O
. O

Blood O
flow O
velocity O
waveforms O
were O
recorded O
by O
pulsed O
Doppler O
examination O
of O
the O
fetal O
internal O
carotid O
and O
middle O
cerebral O
arteries O
using O
the O
established O
transabdominal O
route O
as O
well O
as O
a O
new O
transvaginal O
approach O
. O

Quantitative O
analysis O
of O
DNA O
using O
flow O
cytometry O
and O
immunocytochemical O
findings O
in O
16 O
cases O
of O
cardiac O
myxomas O

Sequence O
analysis O
revealed O
that O
in O
addition O
to O
the O
non O
- O
spliced O
variant O
, O
multiple O
mRNA O
species O
were O
generated O
by O
alternative O
splicing O
resulting O
in O
the O
exclusion O
of O
92 O
, O
166 O
, O
170 O
, O
174 O
and O
263 O
nucleotides O
( O
nt O
), O
respectively O
, O
from O
exon O
1 O
. O

Position O
22 O
is O
an O
isoleucine O
in O
the O
complete I-GENE
SsoL12 I-GENE
protein I-GENE
sequence I-GENE
, O
coded O
by O
an O
AUA O
codon O
. O

Symptoms O
due O
to O
the O
action O
of O
mastocyte O
mediators O
were O
observed O
. O

In O
the O
yeast O
Saccharomyces O
cerevisiae O
, O
copper O
levels O
exert O
some O
control O
over O
the O
level O
of O
SOD1 I-GENE
expression O
. O

Of O
these O
179 O
samples O
, O
Mobiluncus O
SP O
was O
observed O
in O
35 O
( O
19 O
. O
6 O
%) O
using O
Gram O
staining O
and O
in O
18 O
( O
10 O
. O
1 O
%) O
this O
microorganism O
was O
isolated O
in O
agar O
RLK O
and O
anaerobic O
atmosphere O
. O

Previous O
investigators O
have O
suggested O
that O
subretinal O
blood O
damages O
the O
retina O
in O
part O
because O
of O
its O
solid O
fibrin I-GENE
meshwork O
. O

Twenty O
- O
four O
hours O
later O
, O
the O
animals O
were O
randomized O
to O
subretinal O
treatment O
with O
2 O
. O
5 O
micrograms O
of O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
or O
a O
similar O
volume O
of O
physiologic O
saline O
. O

Neuro O
- O
otological O
examinations O
revealed O
spontaneous O
downbeat O
nystagmus O
, O
bilateral O
gaze O
nystagmus O
and O
rebound O
nystagmus O
. O

Since O
the O
morphology O
of O
the O
lesions O
can O
mimic O
that O
of O
other O
cutaneous O
disorders O
, O
Bowen O
' O
s O
disease O
is O
often O
not O
recognized O
initially O
. O

Equine O
amnion O
and O
live O
yeast O
cell O
derivative O
were O
evaluated O
as O
a O
biological O
dressing O
and O
as O
a O
topical O
wound O
medicament O
respectively O
, O
in O
the O
treatment O
of O
granulating O
wounds O
of O
the O
distal O
portion O
of O
the O
limbs O
of O
horses O
. O

To O
lower O
the O
current O
high O
incidence O
of O
NANB O
- O
induced O
PTH O
, O
in O
1986 O
, O
the O
American O
Association O
of O
Blood O
Banks O
( O
AABB O
) O
recommended O
testing O
for O
these O
PTH O
- O
associated O
" O
surrogate O
" O
markers O
on O
all O
donated O
units O
of O
blood O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
1 I-GENE
( O
IGF I-GENE
- I-GENE
1 I-GENE
) O
in O
burn O
patients O
. O

Fusion O
of O
ubiquitin I-GENE
to O
pADPRP I-GENE
increased O
the O
yield O
of O
pADPRP I-GENE
approximately O
10 O
- O
fold O
compared O
to O
that O
of O
the O
unfused O
enzyme O
. O

In O
group O
III O
, O
patients O
also O
received O
their O
own O
mediastinal O
drainage O
blood O
, O
shed O
for O
6 O
hours O
after O
operation O
, O
after O
concentration O
and O
washing O
in O
a O
MBRS O
. O

The O
suppression O
was O
also O
demonstrated O
in O
a O
transient O
expression O
assay O
in O
vivo O
using O
isolated O
barley O
endosperms O
. O

The O
effect O
of O
salmon I-GENE
calcitonin I-GENE
nasal O
spray O
in O
women O
with O
established O
osteoporosis O
has O
also O
been O
studied O
. O

Skeletal O
muscle O
metaboreceptor O
responses O
are O
impaired O
in O
heart O
failure O
. O

Skeletal O
muscle O
metaboreceptor O
exercise O
responses O
are O
attenuated O
in O
heart O
failure O
. O

Evaluation O
of O
antiepileptic O
drug O
effect O
on O
membrane O
fluidity O
. O

The O
examinations O
were O
performed O
on O
two O
groups O
of O
20 O
( O
using O
AmF O
/ O
SnF2 O
)-, O
resp O
. O

RNA O
gel O
retardation O
and O
competition O
analyses O
indicate O
that O
TRP I-GENE
- I-GENE
185 I-GENE
binding O
is O
strongly O
dependent O
on O
the O
TAR O
RNA O
loop O
sequences O
. O

The O
vaccine O
used O
was O
known O
to O
be O
immunogenic O
for O
older O
children O
and O
adults O
. O

Both O
groups O
then O
underwent O
hypnotic O
induction O
, O
and O
completed O
the O
test O
again O
( O
R2 O
). O

Applications O
of O
three O
- O
dimensional O
analysis O
to O
the O
auditory O
P300 O
. O

The O
construct O
was O
introduced O
into O
BW2001 O
( O
xth O
- O
11 O
, O
nfo O
- O
2 O
) O
strain O
cells O
of O
Escherichia O
coli O
. O

Recombinant I-GENE
human I-GENE
TFIID I-GENE
supported O
weak O
basal O
transcription O
in O
heat O
- O
treated O
nuclear O
extracts O
whereas O
a O
partially O
purified O
TFIID I-GENE
fraction O
from O
HeLa O
cells O
reconstituted O
a O
maximal O
level O
of O
transcription O
. O

Only O
after O
a O
pretreatment O
aimed O
at O
increasing O
its O
oxide O
surface O
layer O
was O
titanium O
powder O
found O
to O
accelerate O
the O
precipitation O
from O
solutions O
containing O
2 O
mmol O
/ O
L O
CaCl2 O
, O
2 O
mmol O
/ O
L O
KH2PO4 O
, O
50 O
mmol O
/ O
L O
Hepes O
, O
pH O
7 O
. O
2 O
, O
and O
to O
induce O
precipitation O
from O
metastable O
solutions O
containing O
1 O
. O
2 O
mmol O
/ O
L O
CaCl2 O
, O
1 O
. O
2 O
mmol O
/ O
L O
KH2PO4 O
, O
50 O
mmol O
/ O
L O
Hepes O
, O
pH O
7 O
. O
2 O
, O
at O
37 O
degrees O
C O
. O

We O
conclude O
that O
solidification O
could O
occur O
in O
all O
feeds O
containing O
casein I-GENE
and O
that O
alternative O
feeds O
should O
be O
considered O
in O
patients O
with O
increased O
gastric O
acidity O
. O

Neither O
model O
, O
as O
applied O
, O
provided O
a O
satisfactory O
account O
of O
the O
effects O
of O
the O
main O
variables O
of O
number O
of O
tones O
and O
amount O
of O
perturbation O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

This O
generalization O
of O
MFP O
involves O
defining O
an O
appropriate O
high O
- O
resolution O
cost O
function O
, O
parametrizing O
the O
search O
space O
of O
the O
environment O
and O
source O
, O
constructing O
solutions O
of O
the O
wave O
equation O
, O
and O
utilizing O
a O
nonlinear O
optimization O
method O
to O
search O
the O
parameter O
landscape O
for O
the O
global O
minimum O
of O
the O
cost O
function O
. O

Determination O
of O
an O
RNA O
structure O
involved O
in O
splicing O
inhibition O
of O
a O
muscle O
- O
specific O
exon O
. O

Endothelial O
cells O
stored O
with O
University O
of O
Wisconsin O
solution O
excluded O
trypan O
blue O
better O
( O
1 O
. O
0 O
% O
+/- O
0 O
. O
5 O
% O
cells O
stained O
, O
p O
less O
than O
0 O
. O
001 O
. O

The O
original O
technique O
was O
developed O
in O
the O
1960 O
' O
s O
to O
analyze O
the O
inner O
ear O
fluid O
as O
a O
diagnostic O
procedure O
( O
i O
. O
e O
., O
diagnostic O
labyrinthotomy O
) O
in O
acoustic O
neuroma O
suspects O
. O

The O
effect O
of O
diffusion O
limitation O
was O
quantified O
in O
terms O
of O
the O
ratio O
O2 O
uptake O
/ O
O2 O
requirement O
(= O
fraction O
of O
cross O
- O
sectional O
area O
supplied O
with O
O2 O
), O
assuming O
local O
O2 O
requirement O
per O
unit O
volume O
to O
be O
constant O
and O
independent O
of O
PO2 O
at O
PO2 O
greater O
than O
0 O
. O

( O
2 O
) O
Diffusion O
limitation O
in O
the O
heterogeneous O
model O
sets O
in O
at O
a O
lower O
O2 O
requirement O
value O
, O
and O
increases O
more O
gradually O
with O
increasing O
O2 O
requirement O
, O
than O
in O
the O
corresponding O
homogeneous O
models O
with O
the O
same O
average O
cylinder O
diameter O
. O

The O
antihypertensive O
effect O
of O
Estulic O
has O
been O
examined O
over O
a O
12 O
- O
month O
period O
in O
101 O
hypertensive O
patients O
. O

At O
the O
time O
of O
the O
seizure O
, O
the O
patient O
was O
asked O
to O
read O
a O
test O
phrase O
aloud O
until O
it O
was O
read O
correctly O
and O
clearly O
. O

Monitoring O
patients O
with O
acute O
leukemia O
for O
IL I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
levels O
throughout O
the O
clinical O
course O
of O
disease O
may O
help O
clarify O
the O
causes O
of O
febrile O
episodes O
. O

Echinococcus O
granulosus O
was O
diagnosed O
by O
fine O
- O
needle O
aspiration O
cytology O
of O
a O
lung O
cyst O
in O
a O
6 O
- O
yr O
- O
old O
white O
female O
in O
central O
Missouri O
. O

The O
sequence O
was O
determined O
of O
6493 O
nucleotides O
encompassing O
the O
bet I-GENE
genes I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
which O
encode O
the O
osmoregulatory O
choline O
- O
glycine O
betaine O
pathway O
. O

A O
7 O
- O
day O
treatment O
of O
amphotericin O
B O
( O
5 O
mg O
/ O
kg O
/ O
day O
i O
. O
p O
.) O
significantly O
reduced O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
measured O
as O
inuline O
clearance O
and O
creatinine O
clearance O
( O
0 O
. O
74 O
+/- O
0 O
. O
29 O
and O
0 O
. O
16 O
+/- O
0 O
. O
04 O
ml O
/ O
min O
, O
respectively O
) O
in O
comparison O
to O
vehicle O
- O
treated O
rats O
( O
2 O
. O
04 O
+/- O
0 O
. O
23 O
and O
1 O
. O
29 O
+/- O
0 O
. O
19 O
ml O
/ O
min O
, O
respectively O
). O

Evolution O
of O
lesions O
did O
not O
necessarily O
follow O
a O
regular O
progression O
through O
the O
later O
stages O
of O
the O
vitelliform O
classification O
. O

Confocal O
fluorescence O
microscopy O
in O
modern O
cell O
biology O
. O

Toluene O
is O
the O
chemical O
most O
frequently O
present O
in O
cases O
involving O
volatile O
solvents O
. O

Fortunately O
DDT O
-, O
HCH O
- O
and O
HCB O
- O
levels O
decreased O
in O
breast O
milk O
during O
the O
last O
years O
. O

A O
herpesvirus O
proteinase O
activity O
has O
been O
identified O
and O
partially O
characterized O
by O
using O
the O
cloned O
enzyme O
and O
substrate O
genes O
in O
transient O
transfection O
assays O
. O

Adult O
H O
, O
but O
not O
R O
, O
manifested O
the O
burrowing O
preference O
whenever O
offered O
the O
opportunity O
. O

The O
rear O
silver O
liquid O
chamber O
was O
threefold O
thick O
to O
17 O
MeV O
protons O
in O
water O
and O
it O
efficiently O
produced O
either O
13N O
by O
the O
16O O
( O
p O
, O
alpha O
) O
13N O
reaction O
or O
[ O
18F O
] O
fluoride O
ion O
by O
the O
18O O
( O
p O
, O
n O
) O
18F O
reaction O
. O

Heterogeneous O
electron O
transfer O
of O
cytochrome I-GENE
c I-GENE
facilitated O
by O
polypyrrole O
and O
methylene O
blue O
polypyrrole O
film O
modified O
electrodes O
. O

Selective O
activation O
of O
adrenaline O
secretion O
by O
the O
rat O
adrenal O
in O
neuroglycopenia O
detected O
via O
microdialysis O

Urine O
specimens O
containing O
either O
phencyclidine O
( O
PCP O
) O
or O
11 O
- O
nor O
- O
delta O
9 O
- O
tetrahydrocannabinol O
- O
9 O
- O
carboxylic O
acid O
( O
9 O
- O
THC O
- O
COOH O
) O
were O
adulterated O
with O
sodium O
chloride O
, O
bleach O
, O
vinegar O
, O
potassium O
hydroxide O
, O
liquid O
soap O
, O
2 O
- O
propanol O
, O
and O
ammonia O
. O

The O
1489 O
- O
base O
pair O
EFIA I-GENE
cDNA O
encodes O
a O
322 O
- O
amino O
acid O
protein O
which O
is O
nearly O
identical O
to O
two O
previously O
described O
human O
DNA O
binding O
proteins O
. O

Four O
putative O
positive O
cDNA O
clones O
were O
isolated O
, O
and O
the O
largest O
insert O
( O
pASB I-GENE
- I-GENE
1 I-GENE
) O
was O
sequenced O
in O
both O
orientations O
. O

Sci O
. O

Dose O
standardisation O
of O
botulinum I-GENE
toxin I-GENE
. O

The O
coding O
sequence O
for O
a O
260 O
- O
amino O
- O
acid O
residue O
polypeptide O
was O
interrupted O
by O
a O
single O
short O
intron O
of O
60 O
base O
pairs O
( O
bp O
), O
and O
about O
70 O
% O
of O
the O
deduced O
amino O
acid O
sequence O
of O
the O
Drosophila I-GENE
PCNA I-GENE
was O
identical O
to O
the O
rat O
and O
human I-GENE
PCNA I-GENE
polypeptides I-GENE
, O
with O
conserved O
unique O
repeats O
of O
leucine O
in O
the O
C O
- O
terminal O
region O
. O

Translational O
fusions O
of O
the O
aroF I-GENE
regulatory I-GENE
regions I-GENE
to O
lacZ I-GENE
were O
constructed O
and O
then O
introduced O
in O
single O
copy O
into O
the O
E O
. O
coli O
chromosome O
. O
beta I-GENE
- I-GENE
Galactosidase I-GENE
assays O
for O
tyrR O
- O
mediated O
regulation O
of O
aroF I-GENE
- O
lacZ I-GENE
expression O
revealed O
that O
the O
E I-GENE
. I-GENE
coli I-GENE
TyrR I-GENE
repressor I-GENE
apparently O
recognizes O
the O
operators O
of O
both O
organisms O
with O
about O
equal O
efficiency O
. O

Along O
with O
previously O
mapped O
genes O
including O
Ly I-GENE
- I-GENE
1 I-GENE
and O
CD20 I-GENE
, O
OSBP I-GENE
defines O
a O
new O
conserved O
syntenic O
group O
on O
the O
long O
arm O
of O
chromosome O
11 O
in O
the O
human O
and O
the O
proximal O
end O
of O
chromosome O
19 O
in O
the O
mouse O
. O

During O
exercise O
K O
+ O
is O
released O
from O
contracting O
muscle O
and O
plasma O
K O
+ O
concentration O
rises O
. O

Following O
treatment O
, O
serum O
estradiol O
levels O
were O
higher O
in O
groups O
E O
+ O
T O
and O
E O
than O
in O
group O
C O
. O

We O
conclude O
that O
the O
beta O
- O
adrenergic O
agonist O
, O
isoproterenol O
, O
has O
little O
influence O
on O
vascular O
capacitance O
or O
liver O
volume O
of O
dogs O
, O
unless O
the O
hepatic O
outflow O
resistance O
is O
elevated O
by O
agents O
such O
as O
histamine O
. O

DNA O
sequence O
and O
evolution O
of O
the O
CPS I-GENE
domain I-GENE
of O
the O
Syrian I-GENE
hamster I-GENE
multifunctional I-GENE
protein I-GENE
CAD I-GENE
. O

Here O
we O
show O
that O
these O
synthetic O
binding O
sites O
have O
a O
more O
restricted O
and O
specific O
ability O
to O
enhance O
transcription O
when O
assayed O
in O
transformed O
embryos O
. O

After O
base O
- O
line O
CBF O
was O
established O
, O
hexamethonium O
bromide O
( O
2 O
mg O
/ O
kg O
iv O
), O
ipratropium O
bromide O
( O
0 O
. O
5 O
microgram O
/ O
kg O
iv O
), O
indomethacin O
( O
2 O
mg O
/ O
kg O
iv O
), O
or O
intravenous O
0 O
. O
9 O
% O
saline O
was O
administered O
. O

A O
high O
- O
frequency O
restriction O
fragment O
length O
polymorphism O
was O
evident O
in O
the O
DNA O
from O
29 O
unrelated O
individuals O
using O
the O
enzyme O
BglII I-GENE
. O

The O
antilog O
transformation O
of O
pH O
did O
not O
improve O
the O
results O
. O

Telomeres O
prevent O
end O
- O
to O
- O
end O
fusions O
and O
exonucleolytic O
degradation O
, O
enable O
the O
end O
of O
the O
linear O
DNA O
molecule O
to O
replicate O
, O
and O
function O
in O
cell O
division O
. O

One O
of O
these O
is O
located O
in O
the O
5 O
'- O
untranslated O
region O
, O
and O
may O
encode O
regulatory O
sequences O
. O

The O
native O
enzyme O
purified O
from O
protease I-GENE
- I-GENE
B I-GENE
- O
deficient O
URA2 I-GENE
- O
transformed O
cells O
, O
was O
phosphorylated O
in O
vitro O
using O
catalytic O
subunits O
of O
pure O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

This O
study O
suggests O
that O
BSPMs O
are O
useful O
in O
the O
assessment O
of O
AMI O
in O
terms O
of O
diagnosis O
, O
location O
and O
extent O
of O
myocardial O
infarct O
. O

A O
bovine O
abomasum O
lambda O
gt11 O
cDNA O
library O
was O
screened O
with O
a O
monoclonal O
antibody O
raised O
against O
the O
rabbit I-GENE
H I-GENE
, I-GENE
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

Judicious O
use O
of O
laboratory O
testing O
, O
including O
monitoring O
of O
CD4 I-GENE
cell O
counts O
, O
is O
recommended O
. O

There O
is O
no O
TATA O
box O
appropriately O
spaced O
upstream O
from O
the O
transcription O
initiation O
site O
. O

Characterization O
of O
the O
5 O
' O
end O
of O
the O
growth O
- O
regulated O
Syrian I-GENE
hamster I-GENE
CAD I-GENE
gene I-GENE
. O

Early O
cirrhosis O
, O
an O
early O
modality O
of O
the O
evolution O
of O
acute O
hepatitis O
. O

Examination O
of O
immediate I-GENE
- I-GENE
early I-GENE
transcription I-GENE
factor I-GENE
expression O
during O
the O
MDI O
regimen O
revealed O
that O
RA O
mediated O
an O
elevated O
, O
prolonged O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
mRNA I-GENE
accompanied O
by O
diminished O
expression O
of O
c I-GENE
- I-GENE
Fos I-GENE
and O
Jun I-GENE
- I-GENE
B I-GENE
mRNAs I-GENE
. O

Although O
heart O
rate O
and O
diastolic O
pressure O
rose O
in O
some O
degree O
1 O
min O
after O
intubation O
, O
free O
and O
total O
CA O
concentrations O
did O
not O
increase O
during O
study O
period O
. O

Processing O
, O
secretion O
, O
and O
immunoreactivity O
of O
carboxy I-GENE
terminally I-GENE
truncated I-GENE
dengue I-GENE
- I-GENE
2 I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
expressed O
in O
insect O
cells O
by O
recombinant O
baculoviruses O
. O

Combined O
therapy O
with O
MK O
- O
801 O
and O
nimodipine O
for O
protection O
of O
ischemic O
brain O
damage O
. O

Initial O
screening O
of O
a O
rat O
liver O
cDNA O
library O
with O
an O
oligonucleotide O
probe O
derived O
from O
the O
rat O
SCP2 I-GENE
protein O
sequence O
revealed O
an O
825 O
- O
base O
pair O
cDNA O
clone O
coding O
for O
the O
complete O
SCP2 I-GENE
protein O
sequence O
. O

Cloning O
, O
expression O
, O
and O
nucleotide O
sequence O
of O
rat I-GENE
liver I-GENE
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
cDNAs I-GENE
. O

The O
addition O
of O
an O
equimolar O
complex O
of O
the O
fourth O
and O
seventh O
largest O
subunits O
, O
purified O
from O
pol I-GENE
II I-GENE
holoenzyme I-GENE
by O
ion O
- O
exchange O
chromatography O
in O
the O
presence O
of O
urea O
, O
restored O
promoter O
- O
directed O
initiation O
activity O
to O
pol I-GENE
II I-GENE
delta I-GENE
4 I-GENE
/ I-GENE
7 I-GENE
. O

We O
report O
here O
the O
identification O
of O
HSF I-GENE
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
. O

Induction O
requires O
the O
ACE1 I-GENE
gene I-GENE
product I-GENE
, O
which O
binds O
to O
specific O
sites O
in O
the O
promoter O
region O
of O
the O
CUP1 I-GENE
gene I-GENE
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic O
E6 I-GENE
motif I-GENE
detected O
a O
B O
- O
cell O
- O
specific O
complex O
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

Seven O
clones O
encoding O
interferon I-GENE
response I-GENE
element I-GENE
binding I-GENE
factors I-GENE
have O
been O
isolated O
from O
a O
mouse O
fibroblast O
lambda O
gt11 O
cDNA O
library O
by O
using O
a O
32P O
end O
- O
labeled O
tandem O
trimer O
of O
the O
mouse I-GENE
( I-GENE
2 I-GENE
'- I-GENE
5 I-GENE
') I-GENE
oligoadenylate I-GENE
synthetase I-GENE
gene I-GENE
interferon O
response O
element O
as O
a O
probe O
. O

The O
sequence O
of O
four O
clones O
was O
sufficient O
to O
construct O
a O
3018 I-GENE
- I-GENE
bp I-GENE
BAL I-GENE
cDNA I-GENE
structure O
. O

The O
application O
of O
these O
instruments O
allows O
occlusion O
of O
the O
ascending O
aorta O
traversed O
by O
the O
perfusion O
cannula O
inserted O
directly O
or O
through O
the O
apex O
of O
the O
heart O
as O
well O
as O
simultaneous O
left O
ventricular O
venting O
. O

Adenylosuccinate I-GENE
synthetase I-GENE
( O
IMP O
: O
L I-GENE
- I-GENE
aspartate I-GENE
ligase I-GENE
( O
GDP O
), O
EC I-GENE
6 I-GENE
. I-GENE
3 I-GENE
. I-GENE
4 I-GENE
. I-GENE
4 I-GENE
) O
plays O
an O
important O
role O
in O
purine O
biosynthesis O
catalyzing O
the O
GTP O
- O
dependent O
conversion O
of O
IMP O
to O
AMP O
. O

Immunophenotyping O
in O
four O
cases O
, O
demonstrated O
non O
- O
B O
, O
non O
- O
T O
cell O
origin O
in O
three O
and O
pre O
- O
B O
cell O
origin O
in O
one O
. O

DNA O
- O
protein O
UV O
cross O
- O
linking O
studies O
indicated O
that O
UHF I-GENE
- I-GENE
1 I-GENE
has O
an O
electrophoretic O
mobility O
on O
sodium O
dodecyl O
sulfate O
- O
acrylamide O
gels O
of O
approximately O
85 O
kDa O
and O
suggested O
that O
additional O
proteins O
, O
specific O
to O
each O
promoter O
, O
bind O
to O
each O
site O
. O

The O
results O
strengthen O
the O
conclusion O
that O
predominantly O
dynamic O
activity O
increases O
the O
G4 I-GENE
content O
of O
mature O
innervated O
fast O
muscles O
. O

The O
specific O
interaction O
between O
a O
defined O
structural O
element O
of O
the O
human O
immunodeficiency O
virus O
mRNA O
( O
RRE I-GENE
, O
the O
Rev I-GENE
response I-GENE
element I-GENE
) O
and O
the O
virus I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
Rev I-GENE
has O
been O
implicated O
in O
the O
regulation O
of O
the O
export O
of O
unspliced O
or O
singly O
spliced O
mRNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

We O
reviewed O
the O
records O
of O
151 O
patients O
with O
optic O
neuritis O
examined O
over O
an O
eight O
- O
year O
period O
. O

Cut O
- O
off O
levels O
that O
define O
abnormality O
are O
rather O
arbitrary O
and O
this O
decreases O
the O
specificity O
of O
the O
test O
in O
apparently O
healthy O
patients O
. O

Alanine I-GENE
aminotransferase I-GENE
in O
clinical O
practice O
. O

Nucleotide O
sequence O
analysis O
of O
the O
Pseudomonas I-GENE
putida I-GENE
PpG7 I-GENE
salicylate I-GENE
hydroxylase I-GENE
gene I-GENE
( O
nahG I-GENE
) O
and O
its O
3 O
'- O
flanking O
region O
. O

All O
six O
ARF I-GENE
cDNAs I-GENE
are O
more O
similar O
to O
each O
other O
than O
to O
other O
approximately O
20 I-GENE
- I-GENE
kDa I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

The O
long O
terminal O
repeat O
( O
LTR O
) O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
contains O
three O
binding O
sites O
for O
the O
transcriptional O
factor O
Sp1 I-GENE
. O

DNA O
from O
PCR O
was O
labeled O
and O
used O
to O
isolate O
several O
lambda O
gt11 O
cDNA O
clones O
, O
including O
one O
full O
- O
length O
one O
( O
Dd I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
). O

Radiation O
- O
induced O
changes O
in O
the O
area O
of O
alveoli O
and O
septa O
as O
well O
as O
collagen I-GENE
content O
were O
seen O
11 O
weeks O
after O
irradiation O
. O

The O
first O
follow O
- O
up O
was O
at O
a O
nearly O
constant O
interval O
of O
5 O
. O
1 O
years O
in O
Caerphilly O
and O
3 O
. O
2 O
years O
in O
Speedwell O
; O
251 O
major O
IHD O
events O
had O
occurred O
. O

A O
. O

Perilunar O
luxation O
-- O
an O
unusual O
injury O
demanding O
immediate O
and O
correct O
treatment O

Landsberg O
( O
La O
- O
O O
) O
and O
cv O
. O

In O
summary O
, O
at O
equianesthetic O
concentrations O
, O
desflurane O
and O
isoflurane O
produced O
similar O
hemodynamic O
effects O
; O
however O
, O
in O
the O
absence O
of O
drugs O
that O
inhibit O
autonomic O
reflexes O
, O
desflurane O
had O
less O
negative O
inotropic O
activity O
and O
produced O
less O
decrease O
in O
arterial O
pressure O
. O

We O
report O
here O
the O
isolation O
of O
a O
full O
- O
length O
cDNA O
clone O
coding O
for O
a O
hitherto O
undiscovered O
isoform O
of O
the O
bovine I-GENE
C I-GENE
- I-GENE
subunit I-GENE
. O

Isoform I-GENE
C I-GENE
beta I-GENE
2 I-GENE
, O
an O
unusual O
form O
of O
the O
bovine O
catalytic O
subunit O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

Salient O
applications O
of O
PB O
- O
PK O
modeling O
to O
toxicological O
problems O
are O
illustrated O
with O
examples O
. O

Patients O
with O
apparently O
minor O
CT O
abnormalities O
may O
have O
significant O
epidural O
disease O
. O

The O
cdr1 I-GENE
sequence I-GENE
includes O
an O
additional O
237 O
amino O
acids O
of O
the O
contiguous O
fragment O
and O
encodes O
a O
product O
of O
predicted O
Mr O
67 O
, O
000 O
. O

Armed O
with O
a O
clear O
understanding O
of O
the O
pathophysiologic O
pathways O
that O
may O
cause O
and O
/ O
or O
contribute O
to O
the O
development O
of O
unconjugated O
hyperbilirubinemia O
and O
the O
associated O
jaundice O
, O
the O
practitioner O
will O
be O
successful O
in O
helping O
the O
family O
understand O
their O
child O
' O
s O
illness O
. O

Displacement O
thresholds O
of O
peripheral O
sites O
in O
monocular O
human O
vision O
were O
obtained O
. O

The O
authors O
report O
a O
case O
in O
which O
stereotactic O
irrigation O
of O
a O
brain O
cyst O
was O
temporally O
associated O
with O
respiratory O
distress O
. O

ELISA O
was O
found O
to O
make O
a O
contribution O
to O
the O
diagnosis O
of O
tuberculosis O
similar O
to O
that O
of O
sputum O
smear O
. O

In O
this O
paper O
, O
we O
report O
a O
detailed O
study O
of O
the O
structure O
and O
the O
functional O
role O
of O
the O
MalT I-GENE
binding I-GENE
sites I-GENE
located O
in O
the O
adjacent O
and O
divergent O
pulAp I-GENE
and O
pulCp I-GENE
promoters I-GENE
. O

Despite O
the O
small O
number O
of O
patients O
, O
on O
the O
basis O
of O
this O
report O
, O
we O
can O
confirm O
that O
1 O
. O
5 O
MU O
/ O
day O
of O
alpha I-GENE
- I-GENE
IFN I-GENE
is O
an O
adequate O
treatment O
for O
patients O
with O
hairy O
cell O
leukemia O
. O

Paroxysmal O
fluctuations O
in O
observed O
parasitemia O
in O
Plasmodium O
falciparum O
malaria O
. O

No O
positive O
family O
history O
was O
obtained O
. O

Occupational O
asthma O
and O
rhinoconjunctivitis O
from O
inhalation O
of O
crystalline O
bovine I-GENE
serum I-GENE
albumin I-GENE
powder O
. O

A O
further O
subdivision O
of O
Category O
pN1 O
into O
pN1a O
( O
metastasis O
in O
single O
node O
) O
and O
pN1b O
( O
two O
or O
more O
nodes O
) O
is O
recommended O
. O

Amino O
acid O
sequence O
comparisons O
of O
the O
E74A I-GENE
protein I-GENE
reveal O
a O
highly O
conserved O
C O
- O
terminal O
region O
that O
is O
rich O
in O
basic O
amino O
acid O
residues O
and O
which O
has O
been O
proposed O
to O
possess O
sequence O
- O
specific O
DNA O
binding O
activity O
. O

We O
found O
that O
the O
relative O
strengths O
of O
the O
promoters O
were O
similar O
in O
different O
contexts O
. O

Grasso O
, O
and O
A O
. O

After O
6 O
months O
, O
definite O
improvement O
in O
strength O
occurred O
in O
4 O
of O
7 O
carnitine O
- O
treated O
patients O
and O
in O
none O
of O
7 O
controls O
. O

Age O
at O
POI O
and O
asymptote O
were O
achieved O
later O
for O
Line O
RBC2 O
than O
for O
Line O
F O
. O

To O
identify O
the O
DNA O
sequences O
that O
cis O
- O
regulate O
the O
expression O
of O
the O
rat I-GENE
liver I-GENE
pyruvate I-GENE
kinase I-GENE
( O
L I-GENE
- I-GENE
PK I-GENE
) O
genes O
, O
a O
series O
of O
constructs O
in O
which O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
genes I-GENE
is O
driven O
by O
various O
deleted O
fragments O
of O
the O
3200 O
base O
pairs O
( O
bp O
) O
upstream O
of O
the O
L I-GENE
- I-GENE
PK I-GENE
gene I-GENE
cap I-GENE
site I-GENE
have O
been O
assayed O
for O
transient O
expression O
after O
introduction O
into O
hepatoma O
HepG2 O
cells O
, O
rat O
hepatocytes O
in O
primary O
culture O
, O
fibroblast O
LTK O
- O
cells O
, O
myogenic O
C2C12 O
cells O
, O
and O
CHO O
cells O
. O

The O
disturbance O
of O
pulmonary O
gas O
exchange O
, O
as O
revealed O
by O
the O
high O
value O
of O
AaDO2 O
, O
existed O
without O
left O
ventricular O
dysfunction O
, O
and O
AaDO2 O
had O
no O
significant O
relationship O
with O
any O
of O
the O
hemodynamic O
parameters O
including O
the O
difference O
between O
plasma O
colloid O
osmotic O
pressure O
and O
PCW O
. O

A O
dose O
of O
3 O
and O
6 O
micrograms O
/ O
kg O
/ O
day O
GM I-GENE
- I-GENE
CSF I-GENE
reduces O
the O
severity O
of O
neutropenia O
and O
thrombocytopenia O
after O
carboplatin O
- O
cyclophosphamide O
chemotherapy O
, O
which O
may O
lead O
to O
more O
effective O
chemotherapy O
for O
ovarian O
cancer O
in O
the O
future O
. O

These O
differences O
involve O
specific O
hydrogen O
- O
bonding O
interactions O
between O
the O
protein O
and O
DNA O
, O
including O
guanine O
N7 O
sites O
in O
the O
major O
groove O
of O
DNA O
, O
and O
alterations O
in O
DNA O
phosphodiester O
conformation O
induced O
by O
protein O
binding O
. O

Biochemical O
analysis O
demonstrates O
that O
the O
BJ1 I-GENE
protein I-GENE
is O
associated O
with O
nucleosomes O
and O
is O
released O
from O
chromatin O
by O
agents O
which O
intercalate O
into O
DNA O
, O
as O
previously O
shown O
for O
the O
high I-GENE
mobility I-GENE
group I-GENE
proteins I-GENE
( O
HMGs I-GENE
). O

I O
propose O
that O
their O
gene O
products O
bind O
to O
the O
chromatin O
to O
establish O
or O
maintain O
a O
proper O
higher O
order O
structure O
as O
a O
prerequisite O
for O
a O
regulated O
gene O
expression O
. O

The O
C4BP I-GENE
alpha I-GENE
gene I-GENE
is O
organized O
as O
follows O
: O
the O
first O
exon O
codes O
for O
the O
first O
198 O
nucleotides O
of O
the O
5 O
' O
UTR O
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
Rev I-GENE
protein I-GENE
is O
a O
positive O
posttranscriptional O
regulator O
of O
viral O
structural O
gene O
expression O
and O
essential O
for O
virus O
replication O
. O

Once O
the O
proliferation O
of O
fibroblasts O
and O
collagen I-GENE
synthesis O
had O
led O
to O
an O
increase O
of O
mechanical O
strength O
, O
no O
negative O
effect O
on O
wound O
healing O
could O
be O
detected O
applying O
the O
same O
chemotherapeutic O
agents O
. O

The O
CDC7 I-GENE
gene I-GENE
has O
two O
in O
- O
frame O
AUG O
codons O
as O
possible O
translation O
start O
sites O
, O
which O
would O
produce O
58 O
- O
and O
56 O
- O
kDa O
proteins O
, O
respectively O
. O

During O
the O
years O
1980 O
- O
87 O
a O
total O
of O
287 O
persons O
received O
disability O
pensions O
in O
the O
municipality O
of O
Nordreisa O
in O
northern O
Norway O
. O

HeLa O
and O
Jurkat O
cell O
lines O
carrying O
the O
nef I-GENE
gene I-GENE
linked O
to O
the O
CMV O
promoter O
or O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
were O
isolated O
by O
coselection O
for O
neomycin O
resistance O
. O

Differences O
in O
the O
clinical O
presentation O
and O
the O
gross O
appearance O
of O
the O
two O
cases O
are O
described O
, O
and O
similarities O
in O
the O
microscopic O
features O
are O
discussed O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
The O
two O
groups O
were O
similar O
on O
entry O
into O
the O
study O
, O
including O
mean O
FEV1 O
measurements O
( O
0 O
. O
70 O
L O
atropine O
/ O
0 O
. O
60 O
L O
metaproterenol O
, O
P O
greater O
than O
. O
05 O
). O

Using O
an O
ELISA O
, O
we O
found O
that O
surfactant I-GENE
protein I-GENE
A I-GENE
( O
SP I-GENE
- I-GENE
A I-GENE
) O
was O
markedly O
elevated O
in O
the O
pneumonia O
patients O
. O

In O
view O
of O
the O
short O
t1 O
/ O
2 O
, O
we O
used O
three O
doses O
/ O
day O
. O

Temporal O
control O
of O
GUS I-GENE
expression O
was O
found O
to O
involve O
two O
negative O
regulatory O
sequences O
, O
NRS1 O
(- O
391 O
to O
- O
295 O
) O
and O
NRS2 O
(- O
518 O
to O
- O
418 O
), O
as O
well O
as O
the O
positive O
domain O
UAS1 O
. O

We O
purified O
a O
Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
( I-GENE
CaM I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
CaM I-GENE
kinase I-GENE
) O
from O
the O
yeast O
Saccharomyces O
cerevisiae O
with O
properties O
similar O
to O
mammalian I-GENE
type I-GENE
II I-GENE
CaM I-GENE
kinases I-GENE
. O

In O
most O
cases O
, O
DR4 I-GENE
- O
homozygous O
, O
DRB1 I-GENE
- O
heterozygous O
individuals O
could O
be O
genotyped O
with O
the O
panel O
of O
probes O
. O

Two O
patients O
had O
immediate O
adverse O
effects O
from O
NMF O
; O
one O
had O
a O
grand O
mal O
seizure O
and O
the O
other O
developed O
severe O
abdominal O
pain O
. O

The O
muscles O
from O
the O
ischemic O
group O
had O
significantly O
lower O
( O
P O
less O
than O
. O
05 O
) O
values O
for O
capillary O
density O
and O
capillary O
to O
fiber O
ratio O
and O
significantly O
higher O
intercapillary O
distance O
than O
those O
from O
the O
normal O
group O
. O

The O
prevalence O
of O
opportunistic O
infection O
among O
surviving O
AIDS O
patients O
and O
the O
probability O
of O
being O
in O
tumour O
response O
following O
cancer O
therapy O
conditional O
on O
being O
alive O
are O
two O
examples O
of O
such O
functions O
. O

Serum I-GENE
TNF I-GENE
concentrations O
were O
elevated O
at O
diagnosis O
and O
gradually O
decreased O
toward O
the O
reference O
limits O
by O
week O
16 O
. O

Genomic O
clones O
encompassing O
the O
human I-GENE
ETS1 I-GENE
gene I-GENE
were O
isolated O
and O
utilized O
to O
define O
its O
molecular O
organization O
. O

Polymerase O
chain O
reaction O
analysis O
of O
ETS1 I-GENE
cDNA I-GENE
identified O
several O
amplified O
products O
, O
indicating O
alternative O
splicing O
. O

Most O
of O
the O
expressed O
human I-GENE
E3 I-GENE
polypeptides I-GENE
( O
five O
bands O
) O
were O
found O
in O
the O
insoluble O
pellet O
while O
primarily O
full I-GENE
- I-GENE
length I-GENE
mature I-GENE
E3 I-GENE
was O
found O
in O
the O
soluble O
fraction O
. O

To O
test O
promotor O
function O
, O
chimeric O
genes O
were O
constructed O
linking O
fragments O
of O
chicken O
IGF I-GENE
- I-GENE
I I-GENE
5 O
'- O
flanking O
DNA O
to O
a O
promoterless O
reporter O
plasmid O
. O

The O
alpha I-GENE
4 I-GENE
gene I-GENE
5 O
' O
flanking O
region O
acted O
as O
a O
promoter O
in O
transfection O
assays O
. O

Characterization O
of O
the O
alpha I-GENE
4 I-GENE
integrin I-GENE
gene I-GENE
promoter I-GENE
. O

Only O
the O
3 O
. O
0 O
- O
kb O
transcript O
was O
detected O
in O
adult O
tissues O
, O
where O
its O
expression O
was O
restricted O
almost O
exclusively O
to O
the O
central O
nervous O
system O
. O

Two O
homologues O
of O
the O
rhombotin I-GENE
gene I-GENE
have O
now O
been O
isolated O
. O

Angina O
haemorrhagica O
bullosa O
causing O
respiratory O
obstruction O
postoperatively O
. O

We O
examined O
the O
effects O
of O
long O
- O
term O
perfusion O
with O
pyridoxalated O
hemoglobin I-GENE
polyoxyethylene O
conjugate O
( O
PHP O
) O
solution O
on O
cardiac O
function O
of O
isolated O
rat O
hearts O
. O

Conclusion O
: O
inlet O
type O
VSD O
and O
perimembranous O
type O
TOF O
have O
anatomic O
features O
in O
which O
the O
proximal O
His O
bundle O
tends O
to O
be O
jeopardized O
by O
suturing O
for O
VSD O
closure O
. O

The O
gcd2 I-GENE
- I-GENE
503 I-GENE
mutation O
also O
results O
in O
polysome O
runoff O
, O
accumulation O
of O
inactive O
80S I-GENE
ribosomal I-GENE
couples I-GENE
, O
and O
accumulation O
of O
at O
least O
one O
of O
the O
subunits O
of O
the O
general I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
( O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
) O
in O
43S I-GENE
- O
48S I-GENE
particles O
following O
a O
shift O
to O
the O
restrictive O
temperature O
. O

Eight O
patients O
with O
ARC O
and O
renal O
failure O
were O
recently O
evaluated O
. O

To O
measure O
the O
enhancer O
activity O
of O
DR60 I-GENE
, O
a O
reporter O
plasmid O
was O
constructed O
that O
contained O
DR60 I-GENE
cloned O
upstream O
of O
the O
reporter O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
delayed O
- O
early O
39K O
promoter O
. O

A O
single O
case O
of O
an O
adenocarcinoma O
, O
arising O
in O
a O
retroperitoneal O
enterogenous O
cyst O
and O
which O
presented O
as O
a O
left O
renal O
cyst O
, O
is O
reported O
. O

Using O
the O
polymerase O
chain O
reaction O
, O
we O
analyzed O
the O
U6 I-GENE
RNA I-GENE
genes I-GENE
of O
52 O
organisms O
. O

Both O
tear O
volume O
and O
tear O
flow O
were O
found O
to O
be O
significantly O
( O
P O
less O
than O
0 O
. O
001 O
) O
decreased O
up O
to O
6 O
h O
after O
instillation O
, O
reaching O
a O
minimum O
90 O
min O
after O
application O
( O
tear O
volume O
: O
- O
63 O
%; O
tear O
flow O
: O
- O
71 O
%). O

Hydrophobicity O
analysis O
indicated O
that O
the O
KlaA I-GENE
and O
KlaB I-GENE
polypeptides I-GENE
are O
likely O
to O
be O
soluble O
, O
whereas O
the O
KlaC I-GENE
polypeptide I-GENE
was O
predicted O
to O
have O
four O
potential O
membrane O
- O
spanning O
domains O
. O

To O
facilitate O
the O
availability O
of O
important O
new O
therapeutic O
agents O
, O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
in O
the O
mid O
- O
1970s O
began O
assigning O
therapeutic O
ratings O
to O
investigational O
new O
drugs O
and O
holding O
end O
- O
of O
- O
phase O
II O
conferences O
with O
drug O
sponsors O
. O

In O
contrast O
, O
similar O
rates O
of O
B O
. O
sphaericus O
products O
, O
ABG O
- O
6184 O
technical O
powder O
and O
BSP O
- O
2 O
flowable O
concentrate O
, O
produced O
no O
significant O
reduction O
. O

The O
remainder O
( O
18 O
. O
4 O
%) O
was O
with O
IgA I-GENE
nephropathy O
, O
which O
was O
histologically O
mild O
. O

Grossly O
, O
the O
experimental O
vulvitis O
was O
identical O
to O
the O
field O
condition O
, O
and O
bacteria O
indistinguishable O
from O
the O
inoculated O
strains O
were O
reisolated O
. O

3 O
. O

Furthermore O
, O
the O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
was O
difficult O
to O
obtain O
from O
dpb2 I-GENE
- I-GENE
1 I-GENE
mutant O
cells O
, O
suggesting O
that O
a O
stable O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
requires O
DPB2 I-GENE
and O
is O
essential O
for O
chromosomal O
replication O
. O

To O
determine O
whether O
mononuclear O
cell O
secretory O
products O
contribute O
to O
the O
changes O
in O
bone O
turnover O
that O
characterize O
the O
development O
of O
postmenopausal O
osteoporosis O
, O
we O
evaluated O
the O
effects O
of O
oophorectomy O
and O
subsequent O
estrogen O
replacement O
on O
the O
spontaneous O
secretion O
of O
interleukin I-GENE
1 I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
) O
and O
on O
the O
phytohemagglutinin I-GENE
A I-GENE
- O
induced O
secretion O
of O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
GM I-GENE
- I-GENE
CSF I-GENE
) O
from O
peripheral O
blood O
mononuclear O
cells O
. O

There O
were O
45 O
to O
56 O
nt O
differences O
between O
the O
virulent O
and O
avirulent O
groups O
while O
there O
were O
6 O
to O
14 O
nt O
differences O
among O
four O
avirulent O
strains O
. O

The O
standard O
principles O
of O
surgical O
management O
must O
be O
adhered O
to O
when O
using O
Sandostatin O
to O
treat O
patients O
with O
these O
disorders O
. O

Some O
of O
the O
PCR O
products O
contained O
mutations O
in O
ATG1 I-GENE
and O
/ O
or O
ATG2 I-GENE
. O

Hemorrhagic O
shock O
and O
bacterial O
translocation O
in O
a O
swine O
model O
. O

These O
data O
suggest O
that O
the O
levels O
of O
oxygen O
free O
radicals O
were O
increased O
in O
hepatocytes O
and O
mitochondria O
. O

The O
sequence O
of O
the O
pMxL1 O
plasmid O
containing O
the O
invertible O
region O
contains O
a O
perfect O
tandem O
repeat O
of O
19 O
bp O
in O
the O
orientation O
1 O
nonexpressed O
pilin I-GENE
gene I-GENE
at O
the O
middle O
of O
the O
recombination O
junction O
site O
. O

No O
evidence O
for O
the O
presence O
of O
introns O
within O
the O
acvA I-GENE
gene I-GENE
has O
been O
found O
. O

These O
observations O
, O
together O
with O
the O
occurrence O
of O
putative O
4 O
'- O
phosphopantetheine O
- O
attachment O
sites O
and O
a O
putative O
thioesterase I-GENE
site I-GENE
, O
are O
discussed O
with O
reference O
to O
the O
reaction O
sequence O
leading O
to O
production O
of O
the O
ACV I-GENE
tripeptide I-GENE
. O

Pargyline O
, O
a O
monoamine I-GENE
oxidase I-GENE
inhibitor O
, O
reduces O
peak O
3 O
transiently O
( O
max O
. O

When O
given O
the O
choice O
between O
an O
estrous O
female O
and O
a O
sexually O
active O
male O
in O
the O
AOF O
, O
flutamide O
females O
, O
as O
well O
as O
controls O
, O
preferred O
the O
male O
partner O
. O

Hypoxic O
ventilatory O
responses O
were O
- O
1 O
. O
99 O
+/- O
0 O
. O
37 O
L O
/ O
min O
/% O
SaO2 O
in O
the O
relatives O
and O
- O
1 O
. O
54 O
+/- O
0 O
. O
25 O
L O
/ O
min O
/% O
SaO2 O
in O
the O
control O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Very O
small O
deletions O
within O
the O
conserved O
region O
completely O
abolished O
transforming O
activity O
of O
dbl I-GENE
, O
while O
extensive O
deletion O
outside O
of O
this O
region O
had O
no O
effect O
. O

This O
computerized O
list O
was O
linked O
to O
the O
central O
files O
of O
the O
Massachusetts O
Cancer O
Registry O
and O
cases O
diagnosed O
between O
1982 O
and O
1988 O
were O
identified O
. O

We O
also O
present O
evidence O
for O
a O
negative O
regulatory O
element O
in O
the O
5 O
' O
flanking O
region O
of O
the O
Mlu I-GENE
I I-GENE
upstream I-GENE
activation I-GENE
sequence I-GENE
. O

A O
method O
for O
establishing O
stimulus O
control O
of O
ethanol O
responding O
was O
developed O
. O

Mechanism O
of O
activation O
of O
the O
vav I-GENE
protooncogene I-GENE
. O
vav I-GENE
is O
a O
human O
locus O
that O
appears O
to O
be O
specifically O
expressed O
in O
cells O
of O
hematopoietic O
origin O
regardless O
of O
their O
differentiation O
lineage O
. O

Endothelial O
cell O
seeding O
. O

Menetrier O
disease O
in O
a O
child O
. O

After O
hemodynamic O
stabilization O
, O
the O
goal O
of O
therapy O
is O
to O
diminish O
the O
chance O
that O
an O
ulcer O
will O
continue O
to O
bleed O
or O
will O
rebleed O
. O

Thirty O
seven O
patients O
( O
amitriptyline O
n O
= O
16 O
, O
moclobemide O
n O
= O
21 O
) O
completed O
the O
six O
week O
protocol O
, O
which O
was O
conducted O
under O
double O
blind O
conditions O
. O

The O
stimulus O
threshold O
for O
EER O
showed O
a O
less O
individual O
variation O
than O
amplitude O
. O

Analysis O
of O
electrically O
evoked O
response O
( O
EER O
) O
in O
relation O
to O
the O
central O
visual O
pathway O
of O
the O
cat O
( O
1 O
). O

Furthermore O
, O
plasma O
fibrinogen I-GENE
levels O
increased O
by O
a O
mean O
of O
17 O
. O
6 O
%, O
a O
potentially O
adverse O
effect O
of O
gemfibrozil O
that O
has O
not O
been O
previously O
reported O
. O

Gemfibrozil O
in O
hyperlipidaemic O
patients O
with O
peripheral O
arterial O
disease O
: O
some O
undiscovered O
actions O
. O

An O
RME1 I-GENE
- O
independent O
pathway O
for O
sporulation O
control O
in O
Saccharomyces O
cerevisiae O
acts O
through O
IME1 I-GENE
transcript I-GENE
accumulation O
. O

The O
role O
of O
pharmacological O
profiling O
in O
safety O
assessment O
. O

Its O
application O
in O
Madagascar O
: O
advantages O
and O
disadvantages O

In O
all O
cases O
, O
high O
- O
level O
expression O
of O
the O
truncated I-GENE
avian I-GENE
integrins I-GENE
was O
obtained O
. O

The O
authors O
evaluate O
the O
clinical O
efficacy O
of O
EMB O
AZS O
in O
recurrent O
ulcer O
after O
operation O
on O
the O
stomach O
caused O
by O
a O
high O
level O
of O
acid O
production O
and O
ulcerative O
gastroduodenal O
bleeding O
. O

In O
adulthood O
these O
rats O
were O
hyperactive O
and O
learned O
the O
active O
avoidance O
response O
later O
than O
the O
controls O
. O

To O
investigate O
the O
regulation O
of O
Spec I-GENE
gene I-GENE
activity O
, O
the O
region O
around O
the O
Spec1 I-GENE
transcriptional I-GENE
initiation I-GENE
site I-GENE
was O
analyzed O
for O
sites O
of O
protein O
- O
DNA O
interaction O
. O

Phosphopeptide O
mapping O
revealed O
the O
same O
autophosphorylation O
sites O
utilized O
by O
EGFR I-GENE
- I-GENE
IC I-GENE
as O
those O
identified O
in O
wild I-GENE
- I-GENE
type I-GENE
EGFR I-GENE
. O

The O
encoded O
sequence O
revealed O
a O
typical O
signal O
peptide O
, O
a O
predominantly O
hydrophilic O
707 O
amino O
acid O
residue O
domain O
with O
8 O
N O
- O
glycosylation O
sites O
, O
a O
transmembrane O
domain O
, O
and O
a O
C O
- O
terminal O
domain O
of O
52 O
amino O
acids O
. O

The O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
binding I-GENE
site I-GENE
was O
also O
required O
for O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
activity O
in O
transcriptionally O
active O
extracts O
from O
Jurkat O
but O
not O
HeLa O
cells O
, O
confirming O
that O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
a O
T I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
. O

A O
new O
semi O
- O
automatic O
method O
for O
quantifying O
regional O
cerebral O
uptake O
of O
99m O
technetium O
- O
hexamethylpropylene O
amine O
oxime O
( O
99mTc O
- O
HMPAO O
) O
was O
used O
to O
assess O
single O
photon O
emission O
tomograms O
from O
5 O
normal O
subjects O
, O
14 O
patients O
with O
Alzheimer O
' O
s O
disease O
, O
14 O
patients O
with O
dementia O
of O
frontal O
lobe O
type O
and O
4 O
patients O
with O
dementia O
with O
motor O
neurone O
disease O
. O

The O
results O
showed O
that O
fog O
, O
up O
to O
a O
level O
of O
base O
plus O
fog O
of O
0 O
. O
6 O
optical O
density O
units O
, O
had O
no O
influence O
on O
the O
diagnostic O
accuracy O
in O
the O
absence O
of O
any O
compensation O
. O

IdB O
1031 O
was O
first O
extracted O
by O
liquid O
- O
solid O
partition O
and O
the O
extracts O
were O
evaporated O
and O
analysed O
on O
a O
reversed O
- O
phase O
column O
under O
isocratic O
conditions O
, O
using O
either O
an O
electrochemical O
or O
a O
UV O
detector O
. O

In O
this O
model O
, O
eltoprazine O
has O
a O
very O
specific O
anti O
- O
aggressive O
( O
serenic O
) O
profile O
, O
inhibiting O
aggression O
while O
social O
interaction O
and O
exploration O
are O
not O
decreased O
but O
even O
enhanced O
; O
inactivity O
, O
a O
measure O
for O
sedation O
, O
is O
not O
affected O
. O

A O
new O
method O
for O
the O
in O
vitro O
transfer O
of O
delayed O
hypersensitivity O
by O
dialysed O
transfer I-GENE
factor I-GENE
. O

Effect O
of O
separate O
and O
combined O
effects O
of O
plutonium O
- O
239 O
, O
hexachlorobutadiene O
and O
tributyl O
phosphate O
on O
the O
thymus O
gland O
of O
rats O

Data O
collection O
was O
made O
with O
a O
query O
language O
, O
and O
data O
analysis O
performed O
with O
an O
interactive O
knowledge O
- O
based O
statistical O
tool O
, O
MAXITAB O
, O
employing O
a O
multivariate O
tabular O
analysis O
technique O
. O

ARPIA O
has O
been O
implemented O
by O
using O
a O
relational O
DBMS O
, O
very O
cheap O
and O
highly O
diffused O
on O
personal O
computers O
. O

Diuresis O
was O
induced O
by O
scheduled O
drinking O
of O
tea O
( O
150 O
ml O
/ O
h O
). O

Diagnostic O
value O
of O
adenosine I-GENE
deaminase I-GENE
activity O
in O
tuberculous O
effusions O
. O

Femoral O
strain O
adaptation O
after O
total O
hip O
replacement O
: O
a O
comparison O
of O
cemented O
and O
porous O
ingrowth O
components O
in O
canines O
. O

Immuno O
- O
cytochemistry O
, O
using O
antisera O
against O
Campylobacter O
jejuni O
, O
showed O
that O
the O
positive O
staining O
in O
altered O
epithelial O
cells O
were O
restricted O
to O
intracellular O
organisms O
having O
a O
structure O
resembling O
Campylobacter O
spp O
. O

Promoter O
activities O
were O
estimated O
using O
beta I-GENE
- I-GENE
glucuronidase I-GENE
and O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
reporter I-GENE
gene I-GENE
systems I-GENE
. O

The O
5 O
' O
regions O
of O
these O
two O
soybean I-GENE
actin I-GENE
genes I-GENE
contain O
many O
unusual O
features O
including O
( O
CT O
) O
repeats O
and O
long O
stretches O
of O
pyrimidine O
- O
rich O
DNA O
. O

All O
8 O
( O
100 O
%) O
patients O
with O
fulminant O
hepatic O
failure O
who O
received O
grafts O
survived O
, O
including O
3 O
who O
received O
ABO O
- O
incompatible O
grafts O
, O
though O
2 O
of O
these O
subsequently O
required O
retransplantation O
. O

No O
patient O
had O
a O
history O
of O
excess O
alcohol O
intake O
, O
or O
prolonged O
intake O
of O
hepatotoxic O
drugs O
and O
steroids O
, O
and O
were O
not O
obese O
or O
malnourished O
. O

An O
evolutionary O
comparison O
of O
amino O
acid O
sequences O
of O
34 O
HSP70 I-GENE
proteins I-GENE
from O
17 O
species O
suggests O
that O
BiP I-GENE
genes I-GENE
share O
a O
common O
ancestor O
, O
which O
diverged O
from O
other O
HSP70 I-GENE
genes I-GENE
near O
the O
time O
when O
eukaryotes O
first O
appeared O
. O

Spore O
inocula O
( O
approximately O
10 O
( O
6 O
)/ O
coupon O
) O
were O
dried O
onto O
0 O
. O
5 O
- O
in O
. O

However O
, O
overexpression O
of O
both O
the O
STE4 I-GENE
and O
STE18 I-GENE
proteins I-GENE
did O
not O
generate O
a O
stronger O
pheromone O
response O
than O
overexpression O
of O
STE4 I-GENE
in O
the O
presence O
of O
wild O
- O
type O
levels O
of O
STE18 I-GENE
. O

Reverse O
transcription O
- O
PCR O
was O
then O
used O
to O
clone O
from O
human O
poly O
( O
A O
)+ O
RNA O
the O
cDNA O
corresponding O
to O
the O
expressed O
homolog O
of O
psi I-GENE
ARF I-GENE
4 I-GENE
, O
referred O
to O
as O
human I-GENE
ARF I-GENE
4 I-GENE
. O

To O
evaluate O
the O
cost O
and O
benefits O
of O
screening O
tests O
for O
Chlamydia O
trachomatis O
in O
adolescent O
males O
, O
we O
developed O
a O
decision O
analysis O
model O
and O
compared O
the O
leukocyte I-GENE
esterase I-GENE
urine O
dipstick O
test O
with O
culture O
, O
with O
direct O
- O
smear O
fluorescent O
antibody O
( O
DFA O
), O
and O
with O
the O
option O
of O
no O
screening O
( O
no O
treatment O
). O

Sequencing O
the O
gene O
for O
an O
imipenem O
- O
cefoxitin O
- O
hydrolyzing O
enzyme O
( O
CfiA I-GENE
) O
from O
Bacteroides O
fragilis O
TAL2480 O
reveals O
strong O
similarity O
between O
CfiA I-GENE
and O
Bacillus I-GENE
cereus I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
II I-GENE
. O

The O
cloned O
HindIII I-GENE
fragment I-GENE
, O
which O
was O
shown O
by O
DNA O
sequence O
analysis O
to O
encode O
the O
N O
- O
terminal O
half O
of O
the O
B I-GENE
. I-GENE
subtilis I-GENE
IF2 I-GENE
protein I-GENE
and O
0 O
. O
2 O
kb O
of O
upstream O
flanking O
sequence O
, O
was O
utilized O
as O
a O
homologous O
probe O
to O
clone O
an O
overlapping O
2 I-GENE
. I-GENE
76 I-GENE
- I-GENE
kb I-GENE
ClaI I-GENE
chromosomal I-GENE
fragment I-GENE
containing O
the O
entire I-GENE
IF2 I-GENE
structural I-GENE
gene I-GENE
. O

The O
N O
- O
terminal O
115 O
amino O
acids O
correspond O
to O
a O
putative O
DNA O
- O
binding O
domain O
and O
show O
significant O
sequence O
similarity O
with O
other O
cloned O
IFN I-GENE
response I-GENE
factors I-GENE
( O
IRF I-GENE
- I-GENE
1 I-GENE
and O
IRF I-GENE
- I-GENE
2 I-GENE
). O

Maternal O
seizures O
had O
occurred O
during O
pregnancy O
in O
52 O
per O
cent O
. O

It O
encodes O
a O
protein O
with O
three O
zinc O
fingers O
similar O
to O
those O
of O
the O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
. O

Krox I-GENE
- I-GENE
24 I-GENE
is O
therefore O
a O
sequence O
- O
specific O
transcriptional O
activator O
. O

The O
interindividual O
variability O
of O
the O
parameters O
is O
taken O
into O
consideration O
by O
interactively O
determining O
the O
threshold O
levels O
. O

The O
patients O
were O
divided O
into O
3 O
subgroups O
: O
1 O
) O
13 O
N O
+ O
patients O
with O
multiple O
hot O
spots O
( O
greater O
than O
2 O
) O
( O
N O
+ O
IM O
); O
2 O
) O
24 O
N O
+ O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
+ O
IS O
); O
3 O
) O
12 O
N O
- O
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 O
) O
( O
N O
- O
IS O
). O

Inspired O
CO2 O
causing O
changes O
from O
hypo O
- O
to O
normocapnia O
has O
previously O
been O
shown O
to O
improve O
arterial O
O2 O
tension O
( O
PaO2 O
) O
and O
to O
reduce O
alveolar O
- O
arterial O
O2 O
difference O
. O

Expression O
, O
nucleotide O
sequence O
and O
mutational O
analysis O
of O
two O
open O
reading O
frames O
in O
the O
nif I-GENE
gene I-GENE
region I-GENE
of I-GENE
Anabaena I-GENE
sp I-GENE
. I-GENE
strain I-GENE
PCC7120 I-GENE
. O

Further O
, O
they O
are O
consistent O
with O
the O
suggestion O
that O
sites O
homologous O
to O
the O
CAR1 I-GENE
URS I-GENE
may O
be O
situated O
in O
the O
5 O
'- O
flanking O
regions O
of O
multiple O
unrelated O
yeast O
genes O
. O

Our O
results O
suggest O
that O
a O
sequence O
match O
between O
enhancers O
and O
certain O
promoter O
elements O
is O
critical O
. O

This O
Mr O
is O
similar O
to O
those O
of O
the O
purified I-GENE
smg I-GENE
p25A I-GENE
GDI I-GENE
estimated O
by O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
and O
sucrose O
density O
gradient O
ultracentrifugation O
, O
which O
are O
about O
54 O
, O
000 O
and O
65 O
, O
000 O
, O
respectively O
. O

Yeast O
mutants O
assigned O
to O
the O
pet I-GENE
complementation O
group O
G104 O
were O
found O
to O
lack O
alpha I-GENE
- I-GENE
ketoglutarate I-GENE
dehydrogenase I-GENE
activity O
as O
a O
result O
of O
mutations O
in O
the O
dihydrolipoyl I-GENE
transsuccinylase I-GENE
( O
KE2 I-GENE
) O
component O
of O
the O
complex O
. O

Critical O
residues O
required O
for O
repression O
are O
located O
within O
the O
C O
- O
terminal O
27 O
amino O
acids O
of O
c I-GENE
- I-GENE
Fos I-GENE
, O
since O
v I-GENE
- I-GENE
Fos I-GENE
and O
C O
- O
terminal O
truncations O
of O
c I-GENE
- I-GENE
Fos I-GENE
did O
not O
down O
regulate O
. O

We O
also O
discovered O
a O
V I-GENE
lambda I-GENE
pseudogene I-GENE
, O
called O
psi I-GENE
V I-GENE
lambda I-GENE
1 I-GENE
, O
3 O
kb O
upstream O
of O
the O
U266 I-GENE
lambda I-GENE
gene I-GENE
. O

In O
this O
paper O
, O
we O
have O
analyzed O
the O
structure O
of O
human O
gene O
for O
Gx I-GENE
alpha I-GENE
, O
which O
spans O
more O
than O
60 O
kilobases O
. O

A O
long O
follow O
- O
up O
study O
revealed O
that O
convalescent O
stage O
children O
still O
have O
the O
potency O
to O
have O
an O
immediate O
type O
hypersensitivity O
reaction O
on O
exposure O
to O
mite O
antigen O
, O
with O
a O
high O
titer O
of O
mite I-GENE
specific I-GENE
IgE I-GENE
in O
their O
sera O
, O
but O
they O
are O
free O
from O
asthmatic O
attacks O
because O
of O
the O
reduction O
in O
the O
amount O
of O
mite O
antigen O
in O
the O
body O
, O
as O
shown O
by O
the O
reduction O
in O
the O
amount O
of O
mite I-GENE
specific I-GENE
IgG I-GENE
. O

But O
no O
influence O
was O
observed O
at O
lower O
concentrations O
than O
1 O
/ O
4 O
MIC O
of O
AMK O
. O

Uses O
of O
orthoclone O
OKT3 I-GENE
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
nonfunction O
in O
kidney O
transplantation O
. O

Uses O
of O
orthoclone O
OKT3 O
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
nonfunction O
in O
kidney O
transplantation O
. O

Furthermore O
, O
we O
notice O
two O
potential O
consensus O
motifs O
which O
are O
also O
found O
in O
corresponding O
positions O
in O
the O
genes O
for O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
and O
the O
68 I-GENE
- I-GENE
kDa I-GENE
neurofilament I-GENE
protein I-GENE
. O

In O
addition O
, O
the O
- O
119 O
to O
- O
81 O
fragment O
of O
the O
CCK I-GENE
promoter I-GENE
contains O
a O
transcriptional O
enhancer O
that O
potentiates O
the O
transcription O
from O
the O
herpes O
simplex O
virus O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
in O
a O
position O
- O
and O
orientation O
- O
independent O
manner O
. O

Thirty O
minutes O
of O
supine O
restraint O
decreased O
DOPAC O
concentrations O
in O
the O
median O
eminence O
of O
female O
rats O
that O
were O
not O
exposed O
to O
ether O
, O
and O
brief O
exposure O
to O
ether O
enhanced O
this O
effect O
. O

Influence O
of O
metoprolol O
treatment O
on O
sympatho O
- O
adrenal O
activation O
of O
fibrinolysis O
. O

Five O
of O
10 O
scars O
studied O
decreased O
at O
least O
50 O
% O
in O
linear O
dimensions O
. O

Managing O
dysphagia O
in O
a O
chronic O
care O
setting O
: O
an O
introduction O
. O

Gel O
- O
mobility O
- O
shift O
assays O
confirmed O
that O
the O
Raji O
nuclear O
proteins O
that O
bound O
to O
W O
and O
V O
elements O
were O
competed O
with O
by O
an O
HLA I-GENE
- I-GENE
DRA I-GENE
X I-GENE
- I-GENE
box I-GENE
oligonucleotide I-GENE
. O

In O
Denmark O
only O
1 O
- O
3 O
cases O
of O
transfusion O
- O
associated O
hepatitis O
NANB O
( O
TAH O
- O
NANB O
) O
are O
registered O
annually O
or O
about O
1 O
case O
per O
100 O
, O
000 O
units O
transfused O
. O

The O
NF1 I-GENE
locus I-GENE
encodes O
a O
protein O
functionally O
related O
to O
mammalian I-GENE
GAP I-GENE
and O
yeast I-GENE
IRA I-GENE
proteins I-GENE
. O

Hence O
, O
the O
replacement O
of O
Phe O
- O
62 O
with O
Ser O
specifically O
affects O
a O
determinant O
on O
the O
lambda I-GENE
I I-GENE
light I-GENE
chain I-GENE
that O
is O
necessary O
for O
the O
intracellular O
transport O
of O
this O
molecule O
. O

A O
second O
isotype O
of O
Raja I-GENE
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
has O
been O
detected O
by O
screening O
a O
spleen O
cDNA O
library O
with O
homologous O
Raja I-GENE
VH I-GENE
- O
and O
CH1 I-GENE
- O
specific O
probes O
complementing O
the O
respective O
regions O
of O
the O
mu I-GENE
- I-GENE
like I-GENE
isotype I-GENE
. O

Petko O
, O
and O
S O
. O

Disruption O
of O
ARF2 I-GENE
causes O
no O
detectable O
phenotype O
. O

Human O
recombinant O
DNA O
- O
derived O
antihemophilic I-GENE
factor I-GENE
( O
factor I-GENE
VIII I-GENE
) O
in O
the O
treatment O
of O
hemophilia O
A O
. O
recombinant O
Factor I-GENE
VIII I-GENE
Study O
Group O
. O

Like O
other O
members O
of O
this O
family O
, O
the O
AP I-GENE
- I-GENE
4 I-GENE
HLH O
motif O
and O
the O
adjacent O
basic O
domain O
are O
necessary O
and O
sufficient O
to O
confer O
site O
- O
specific O
DNA O
binding O
. O

Furthermore O
, O
expression O
of O
the O
promoter O
in O
embryonic O
Drosophila O
melanogaster O
cells O
that O
lack O
MyoD1 I-GENE
and O
Sp1 I-GENE
is O
strictly O
dependent O
on O
all O
three O
sites O
remaining O
intact O
and O
on O
the O
presence O
of O
exogenously O
supplied O
Sp1 I-GENE
and O
MyoD1 I-GENE
. O

Effects O
of O
a O
selective O
monoamine I-GENE
oxidase I-GENE
( I-GENE
MAO I-GENE
)-- I-GENE
A I-GENE
inhibitor O
, O
clorgyline O
, O
a O
selective O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor O
, O
deprenyl O
, O
and O
a O
non O
- O
selective O
MAO I-GENE
inhibitor O
, O
nialamide O
, O
were O
investigated O
on O
footshock O
- O
induced O
aggression O
( O
FIA O
) O
in O
paired O
rats O
. O

To O
identify O
structural O
features O
of O
residues O
flanking O
the O
c O
- O
region O
that O
influence O
the O
fidelity O
and O
efficiency O
of O
signal O
peptidase O
cleavage O
as O
well O
as O
co O
- O
translational O
translocation O
, O
we O
introduced O
six O
amino O
acid O
substitutions O
into O
the O
COOH O
terminus O
of O
the O
hydrophobic O
core O
and O
seven O
substitutions O
at O
the O
NH2 O
terminus O
of O
the O
mature O
region O
( O
the O
+ O
1 O
position O
) O
of O
a O
model O
eukaryotic I-GENE
preprotein I-GENE
- I-GENE
human I-GENE
pre I-GENE
( I-GENE
delta I-GENE
pro I-GENE
) I-GENE
apoA I-GENE
- I-GENE
II I-GENE
. O

Additionally O
, O
although O
c I-GENE
- I-GENE
fos I-GENE
and O
egr I-GENE
- I-GENE
1 I-GENE
mRNAs I-GENE
are O
expressed O
at O
elevated O
levels O
in O
stimulated O
liver O
cells O
, O
fos I-GENE
- I-GENE
B I-GENE
, O
fra I-GENE
- I-GENE
1 I-GENE
, O
and O
egr I-GENE
- I-GENE
2 I-GENE
are O
not O
, O
which O
suggests O
that O
factors O
in O
addition O
to O
the O
serum I-GENE
response I-GENE
factor I-GENE
participate O
in O
the O
regulation O
of O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
. O

Of O
848 O
patients O
, O
819 O
cases O
with O
complete O
description O
of O
patient O
' O
s O
background O
were O
evaluable O
: O
Group O
A O
( O
surgery O
+ O
MMC O
+ O
5 O
- O
FU O
: O
chemotherapy O
) O
253 O
cases O
, O
group O
B O
( O
surgery O
+ O
MMC O
+ O
5 O
- O
FU O
+ O
OK O
- O
432 O
or O
PSK O
: O
immunochemotherapy O
) O
282 O
and O
group O
C O
( O
surgery O
alone O
) O
284 O
. O

The O
nuclear O
proteins O
encoded O
by O
the O
c I-GENE
- I-GENE
fos I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
protooncogenes I-GENE
are O
expressed O
during O
the O
proliferation O
period O
of O
osteoblast O
phenotype O
development O
. O

This O
model O
is O
further O
supported O
by O
binding O
of O
the O
Fos I-GENE
- O
Jun I-GENE
complex O
at O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
the O
type I-GENE
alpha I-GENE
I I-GENE
collagen I-GENE
promoter I-GENE
that O
is O
contiguous O
with O
, O
but O
not O
overlapping O
, O
the O
VDRE O
. O

PBSX I-GENE
is O
induced O
by O
agents O
which O
elicit O
the O
SOS O
response O
. O

A O
bacteriological O
relapse O
requiring O
treatment O
occurred O
by O
5 O
years O
in O
16 O
. O
8 O
% O
of O
113 O
R3 O
, O
5 O
. O
2 O
% O
of O
97 O
R5 O
, O
and O
20 O
. O
0 O
% O
of O
115 O
Z5 O
patients O
with O
organisms O
sensitive O
to O
streptomycin O
and O
isoniazid O
initially O
. O

In O
the O
controls O
, O
it O
was O
found O
that O
all O
right O
- O
handed O
and O
10 O
out O
of O
14 O
left O
- O
handed O
control O
subjects O
showed O
a O
right O
VHF O
( O
i O
. O
e O
., O
left O
hemisphere O
) O
advantage O
. O

Although O
no O
Rh I-GENE
- I-GENE
antibodies I-GENE
were O
demonstrable O
, O
a O
similar O
mechanism O
can O
be O
postulated O
for O
the O
Rh O
- O
system O
. O

The O
deduced O
amino O
acid O
sequence O
has O
the O
greatest O
homology O
( O
61 O
%) O
to O
the O
green I-GENE
alga I-GENE
Scenedemus I-GENE
obliquus I-GENE
plastocyanin I-GENE
. O

Higher O
fasting O
serum O
gastrin I-GENE
concentration O
( O
102 O
. O
0 O
+/- O
21 O
. O
1 O
vs O
63 O
. O
3 O
+/- O
8 O
. O
3 O
ng O
. O
l O
- O
1 O
), O
and O
greater O
postprandial O
gastrin I-GENE
release O
( O
AUC0 O
- O
120 O
: O
16690 O
+/- O
2648 O
vs O
10654 O
+/- O
1283 O
ng O
. O
l O
- O
1 O
min O
) O
were O
observed O
after O
VTP O
- O
HM O
than O
after O
VTP O
- O
Cas O
. O

The O
experimental O
group O
consisted O
of O
61 O
examinees O
class O
II O
/ O
2 O
orthodontic O
anomalies O
. O

This O
study O
was O
performed O
to O
clarify O
the O
location O
of O
a O
transesophageal O
echocardiographic O
( O
TEE O
) O
transducer O
when O
obtaining O
the O
short O
- O
axis O
view O
of O
the O
left O
ventricle O
( O
S O
- O
LV O
). O

Subjects O
were O
16 O
male O
chronic O
schizophrenics O
consisting O
of O
8 O
DST O
suppressors O
and O
8 O
nonsuppressors O
. O

From O
S3 O
( O
CBF O
: O
79 O
- O
60 O
%) O
to O
S5 O
( O
CBF O
: O
39 O
- O
0 O
%), O
% O
WTh O
, O
1 O
/ O
TPC O
and O
1 O
/ O
T O
were O
significantly O
decreased O
from O
those O
of O
the O
control O
levels O
( O
all O
p O
less O
than O
0 O
. O
01 O
). O

In O
this O
article O
we O
propose O
to O
find O
out O
the O
percentage O
of O
normal O
occlusion O
and O
the O
distribution O
of O
maloclusions O
, O
according O
to O
the O
anteroposterior O
relationship O
between O
the O
dental O
archs O
( O
following O
the O
ANGLE3 O
classification O
). O

In O
that O
case O
, O
the O
ratio O
of O
brush O
abrasion O
was O
0 O
. O
268 O
, O
compressive O
and O
transverse O
strength O
, O
124 O
. O
3 O
and O
86 O
. O
3 O
MPa O
respectively O
, O
hardness O
, O
43 O
. O
2 O
Hk O
, O
water O
absorption O
14 O
. O
2 O
micrograms O
/ O
mm3 O
and O
thermal O
expansion O
coefficient O
, O
47 O
. O
4 O
x O
10 O
(- O
6 O
)/ O
degrees O
C O
. O

9 O
, O
1498 O
- O
1506 O
). O

In O
a O
highly O
select O
group O
of O
stable O
hypertensive O
patients O
, O
we O
have O
assessed O
the O
strength O
of O
association O
between O
various O
blood O
pressure O
measurements O
( O
24 O
h O
average O
automated O
ambulatory O
blood O
pressure O
, O
4 O
h O
automated O
ambulatory O
morning O
average O
blood O
pressure O
, O
multiple O
office O
visit O
average O
blood O
pressure O
, O
and O
a O
single O
office O
visit O
average O
blood O
pressure O
) O
and O
various O
echocardiographic O
indices O
of O
hypertensive O
cardiac O
target O
organ O
damage O
( O
left O
atrial O
diameter O
, O
left O
ventricular O
end O
diastolic O
diameter O
, O
posterior O
wall O
thickness O
, O
combined O
wall O
thickness O
, O
relative O
wall O
thickness O
, O
left O
ventricular O
mass O
and O
mass O
index O
, O
and O
combined O
wall O
thickness O
/ O
left O
ventricular O
diastolic O
diameter O
ratio O
). O

We O
have O
previously O
identified O
, O
by O
screening O
a O
lambda O
gt11 O
expression O
library O
, O
murine I-GENE
protein I-GENE
mXBP I-GENE
, O
which O
binds O
to O
a O
sequence O
which O
overlaps O
the O
3 O
' O
end O
of O
the O
murine I-GENE
class I-GENE
II I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
A I-GENE
alpha I-GENE
gene I-GENE
X I-GENE
box I-GENE
, O
a O
conserved O
transcription O
element O
found O
upstream O
of O
all O
class O
II O
genes O
. O

The O
p36 I-GENE
gene I-GENE
is O
at O
least O
22 O
kb O
in O
length O
and O
has O
a O
coding O
sequence O
of O
approximately O
1 O
kb O
, O
representing O
only O
4 O
. O
5 O
% O
of O
the O
gene O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

This O
multimodality O
treatment O
for O
locally O
advanced O
gynecologic O
tumors O
appears O
feasible O
with O
modification O
, O
and O
continued O
work O
exploring O
this O
approach O
is O
encouraged O
. O

A O
contiguous O
and O
sequentially O
occupied O
secondary O
Fur I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
entC I-GENE
was O
protected O
at O
higher O
Fur I-GENE
concentrations O
, O
extending O
the O
protected O
region O
to O
+ O
49 O
, O
and O
sequestering O
the O
putative O
Shine O
- O
Dalgarno O
sequence O
. O

The O
major O
promoter O
responds O
strongly O
to O
virus O
- O
encoded O
trans O
activators O
EIA I-GENE
and O
EIV I-GENE
and O
contains O
four O
elements O
: O
a O
TAGA O
motif O
analogous O
to O
the O
TATA O
box O
, O
two O
EIIF I-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
, O
and O
an O
ATF I-GENE
/ O
CREB I-GENE
site O
. O

With O
the O
modified O
fingertip O
- O
to O
- O
floor O
( O
MFTF O
) O
method O
, O
patients O
stand O
on O
a O
stool O
and O
forward O
bend O
so O
that O
measurements O
can O
be O
taken O
on O
patients O
who O
are O
able O
to O
touch O
the O
floor O
or O
reach O
beyond O
the O
level O
of O
the O
floor O
. O

No O
significant O
differences O
could O
be O
seen O
in O
response O
rates O
according O
to O
the O
concentration O
of O
estrogen I-GENE
receptors I-GENE
or O
presence O
of O
progesteron I-GENE
receptors I-GENE
in O
this O
group O
of O
patients O
. O

Teicoplanin O
was O
given O
most O
often O
because O
of O
persistent O
fever O
or O
initial O
Gram O
- O
positive O
bacteraemia O
and O
only O
one O
- O
third O
of O
these O
cases O
responded O
. O

Luteinizing I-GENE
hormone I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
analog O
therapy O
of O
uterine O
fibroid O
: O
analysis O
of O
results O
obtained O
with O
buserelin O
administered O
intranasally O
and O
goserelin O
administered O
subcutaneously O
as O
a O
monthly O
depot O
. O

In O
Experiments O
1 O
and O
2 O
, O
infants O
, O
like O
adults O
, O
initially O
categorized O
novel O
objects O
on O
the O
basis O
of O
physical O
appearance O
, O
but O
only O
if O
trained O
with O
multiple O
exemplars O
, O
after O
delays O
of O
1 O
and O
7 O
days O
. O

The O
clinical O
picture O
of O
the O
disease O
was O
significantly O
different O
from O
anthropogenic O
cutaneous O
leishmaniasis O
caused O
by O
L O
. O
tropica O
but O
similar O
to O
cutaneous O
patterns O
caused O
by O
L O
. O
infantum O
which O
was O
a O
prevalent O
pattern O
in O
the O
southern O
France O
. O

Although O
there O
are O
no O
octamer O
elements O
in O
the O
adenovirus O
genome O
that O
are O
known O
to O
be O
important O
for O
transcription O
, O
there O
are O
octamer O
elements O
in O
the O
viral O
terminal O
repeat O
sequences O
. O

In O
comparison O
with O
the O
16 O
introns O
reported O
in O
AHA3 I-GENE
, O
AHA2 I-GENE
is O
missing O
one O
intron O
in O
the O
5 O
'- O
untranslated O
region O
and O
a O
second O
intron O
in O
the O
C O
- O
terminal O
coding O
region O
. O

Northern O
blot O
analysis O
indicates O
that O
AHA2 I-GENE
mRNA I-GENE
relative O
to O
total O
cellular O
RNA O
is O
expressed O
at O
significantly O
higher O
levels O
in O
root O
tissue O
as O
compared O
with O
shoot O
tissue O
. O

Impaction O
of O
gastrostomy O
tube O
in O
the O
abdominal O
wall O
. O

Both O
antidepressants O
elevated O
the O
pain O
threshold O
acutely O
, O
while O
pretreatment O
with O
pCPA O
largely O
blocked O
the O
analgesia O
. O

Sci O
. O

A O
needs O
assessment O
of O
these O
families O
was O
also O
done O
. O

TCR I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
gene I-GENE
expression O
may O
be O
regulated O
by O
a O
common O
set O
of O
T I-GENE
- I-GENE
cell I-GENE
nuclear I-GENE
proteins I-GENE
in O
that O
the O
T I-GENE
beta I-GENE
2 I-GENE
element I-GENE
binding O
a O
set O
of O
cyclic I-GENE
AMP I-GENE
response I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
also O
bound O
by O
the O
T I-GENE
alpha I-GENE
1 I-GENE
element I-GENE
of O
the O
human O
TCR I-GENE
alpha I-GENE
enhancer O
and O
the O
decamer O
element O
present O
in O
a O
large O
number O
of O
human O
and O
murine O
TCR I-GENE
beta I-GENE
promoters O
. O

The O
3 O
' O
stem O
- O
loop O
is O
highly O
divergent O
in O
structure O
among O
species O
and O
lies O
immediately O
upstream O
of O
the O
binding O
site O
for O
Sm I-GENE
proteins I-GENE
. O

The O
deleted O
nucleotide O
sequence O
corresponded O
to O
sequences O
that O
, O
by O
analogy O
to O
the O
organization O
of O
the O
type I-GENE
I I-GENE
collagen I-GENE
genes I-GENE
, O
should O
be O
precisely O
encoded O
by O
exon O
41 O
of O
the O
COL3A1 I-GENE
gene I-GENE
. O

These O
losses O
account O
for O
the O
resistance O
of O
EDS O
- O
IV O
collagen I-GENE
to O
cyanogen O
bromide O
and O
mammalian I-GENE
collagenase I-GENE
digestion O
. O

A O
4 O
. O
8 O
- O
kilobase O
BamHI I-GENE
- O
HindIII I-GENE
fragment O
encoding O
the O
entire I-GENE
Neurospora I-GENE
crassa I-GENE
CuZn I-GENE
superoxide I-GENE
dismutase I-GENE
gene I-GENE
( O
herein O
designated O
sod I-GENE
- I-GENE
1 I-GENE
) O
was O
isolated O
from O
a O
genomic O
library O
using O
two O
60 O
- O
base O
deoxyoligonucleotide O
probes O
corresponding O
to O
the O
published O
N O
. O
crassa O
amino O
acid O
sequence O
. O

Two O
other O
peptides O
, O
either O
partially O
or O
totally O
lacking O
the O
basic O
region O
, O
but O
containing O
the O
intact O
leucine O
zipper O
domain O
, O
readily O
form O
dimers O
but O
do O
not O
bind O
to O
the O
CRE O
. O

In O
contrast O
, O
the O
CRE O
of O
the O
human I-GENE
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
located O
at O
- O
60 O
was O
weakly O
induced O
by O
cAMP O
and O
E1a I-GENE
in O
both O
HeLa O
and O
PC12 O
cells O
. O

We O
have O
isolated O
and O
sequenced O
the O
gene O
encoding O
the O
human I-GENE
U1 I-GENE
- I-GENE
70K I-GENE
snRNP I-GENE
protein I-GENE
. O

Although O
popular O
this O
hypothesis O
is O
far O
from O
explaining O
all O
the O
clinical O
facts O
, O
namely O
that O
rigidity O
is O
equal O
in O
extensor O
and O
flexor O
, O
proximal O
and O
distal O
muscles O
. O

Using O
appropriate O
synthetic O
HSE O
oligonucleotides O
, O
three O
types O
of O
clones O
with O
potential O
HSE O
binding O
domains O
were O
isolated O
from O
a O
tomato O
lambda O
gt11 O
expression O
library O
by O
DNA O
- O
ligand O
screening O
. O

Fluid O
( O
AVLF O
) O
31 O
. O

The O
results O
supported O
the O
therapeutic O
principle O
of O
TCM O
: O
Treating O
patients O
according O
to O
their O
pathophysiological O
patterns O
. O

The O
nmr I-GENE
gene I-GENE
is O
the O
major O
negative O
regulatory O
gene O
in O
the O
nitrogen O
control O
circuit O
of O
Neurospora O
crassa O
, O
which O
, O
together O
with O
positive O
regulatory O
genes O
, O
governs O
the O
expression O
of O
multiple O
unlinked O
structural O
genes O
of O
the O
circuit O
. O

The O
4 O
days O
dexamethasone O
suppression O
test O
showed O
more O
than O
80 O
% O
suppression O
of O
dehydroepiandrosterone O
- O
sulphate O
and O
a O
variable O
( O
40 O
- O
60 O
%) O
reduction O
of O
testosterone O
and O
androstenedione O
levels O
. O

The O
ratio O
of O
P O
- O
31 O
NMR O
- O
S O
derived O
inorganic O
phosphates O
[ O
Pi O
] O
to O
phosphocreatine O
[ O
PCr O
] O
was O
significantly O
greater O
at O
rest O
in O
LVH O
baboons O
[ O
0 O
. O
53 O
+/- O
0 O
. O
06 O
versus O
controls O
= O
0 O
. O
41 O
+/- O
0 O
. O
17 O
; O
P O
less O
than O
0 O
. O
05 O
]. O

Cutaneous O
necrosis O
associated O
with O
protein I-GENE
S I-GENE
deficiency O
. O

Critical O
study O

Regional O
cerebral O
blood O
flow O
was O
measured O
using O
N O
- O
isopropyl O
- O
123I O
- O
iodoamphetamine O
with O
single O
- O
photon O
emission O
computed O
tomography O
( O
CT O
) O
in O
16 O
aged O
patients O
with O
noninsulin O
- O
dependent O
diabetes O
mellitus O
( O
NIDDM O
, O
average O
age O
72 O
. O
8 O
years O
, O
average O
fasting O
plasma O
glucose O
7 O
. O
7 O
mmol O
/ O
L O
), O
and O
12 O
nondiabetic O
subjects O
( O
71 O
. O
6 O
years O
, O
5 O
. O
3 O
mmol O
/ O
L O
). O

Mean O
ROI O
- O
A O
/ O
B O
ratio O
was O
49 O
. O
6 O
+/- O
1 O
. O
7 O
% O
in O
the O
diabetic O
group O
, O
significantly O
lower O
than O
the O
57 O
. O
9 O
+/- O
1 O
. O
6 O
% O
at O
the O
nondiabetic O
group O
( O
p O
less O
than O
0 O
. O
005 O
). O

These O
data O
strongly O
implicate O
the O
normal O
product O
of O
the O
int I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
which O
is O
related O
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
family I-GENE
, O
as O
a O
contributory O
factor O
in O
virally O
induced O
mammary O
tumors O
. O

This O
result O
indicates O
that O
separate O
complexes O
exist O
containing O
ankyrin I-GENE
and O
fodrin I-GENE
with O
either O
uvomorulin I-GENE
or O
Na I-GENE
+, I-GENE
K I-GENE
+- I-GENE
ATPase I-GENE
. O

These O
genes O
are O
expressed O
within O
a O
few O
hours O
of O
the O
initiation O
of O
development O
; O
their O
mRNAs O
accumulate O
to O
a O
peak O
at O
12 O
hr O
and O
persist O
until O
culmination O
. O

The O
PC2 I-GENE
protein I-GENE
also O
shows O
great O
similarity O
to O
the O
incomplete O
NH2 O
- O
terminal O
sequence O
of O
the O
human I-GENE
furin I-GENE
gene I-GENE
product I-GENE
, O
a O
putative O
membrane O
- O
inserted O
receptor O
- O
like O
molecule O
. O

Whether O
or O
not O
there O
are O
sequences O
conferring O
cAMP O
responsiveness O
which O
are O
common O
both O
to O
P I-GENE
- I-GENE
450scc I-GENE
and O
the O
other O
steroidogenic O
P I-GENE
- I-GENE
450 I-GENE
genes I-GENE
remains O
to O
be O
established O
. O

In O
this O
study O
, O
we O
used O
footprinting O
and O
gel O
mobility O
retardation O
assays O
to O
reveal O
that O
bacterially O
synthesized O
Zta I-GENE
fusion I-GENE
proteins I-GENE
bound O
directly O
to O
six O
TGTGCAA O
- O
like O
motifs O
within O
DSL I-GENE
. O

The O
zta I-GENE
transactivator I-GENE
involved O
in O
induction O
of O
lytic O
cycle O
gene O
expression O
in O
Epstein O
- O
Barr O
virus O
- O
infected O
lymphocytes O
binds O
to O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
ZRE I-GENE
sites I-GENE
in O
target O
promoter O
and O
enhancer O
regions O
. O

It O
is O
the O
human O
homolog O
of O
the O
mouse I-GENE
Mx I-GENE
protein I-GENE
involved O
in O
resistance O
to O
influenza O
virus O
. O

Fragments O
containing O
the O
21 O
- O
base O
- O
pair O
repeat O
region O
, O
the O
enhancer I-GENE
of I-GENE
simian I-GENE
virus I-GENE
40 I-GENE
or O
both O
strongly O
stimulated O
beta I-GENE
- I-GENE
galactosidase I-GENE
synthesis O
, O
and O
three O
fragments O
from O
the O
polyomavirus I-GENE
enhancer I-GENE
region I-GENE
stimulated O
moderate O
levels O
. O

The O
sites O
targeted O
for O
mutagenesis O
, O
residues O
60 O
, O
61 O
, O
and O
66 O
, O
are O
located O
within O
a O
putative O
helical O
loop O
structure O
which O
may O
be O
involved O
in O
substrate O
recognition O
by O
the O
enzyme O
. O

The O
possible O
benefits O
of O
LMW O
heparin O
( O
reduced O
frequency O
of O
bleeding O
, O
alleviation O
of O
hypertriglyceridemia O
) O
were O
not O
, O
however O
, O
apparent O
, O
possibly O
because O
of O
the O
short O
observation O
period O
and O
the O
low O
incidence O
of O
hemorrhagic O
complications O
in O
routine O
dialyses O
. O

The O
deduced O
amino O
acid O
sequence O
of O
destrin I-GENE
is O
165 O
residues O
long O
and O
is O
very O
similar O
( O
71 O
% O
identical O
) O
to O
that O
of O
cofilin I-GENE
, O
a O
widely O
distributed O
, O
pH O
- O
sensitive O
actin I-GENE
- O
modulating O
protein O
. O

Summers O
, O
Virology O
89 O
: O
517 O
- O
527 O
, O
1978 O
). O

With O
only O
purified O
T I-GENE
antigen I-GENE
in O
the O
presence O
of O
topoisomerase I-GENE
I I-GENE
to O
unwind O
purified O
DNA O
, O
ori O
- O
auxiliary O
sequences O
strongly O
facilitated O
T I-GENE
- I-GENE
antigen I-GENE
- O
dependent O
DNA O
conformational O
changes O
consistent O
with O
melting O
the O
first O
50 O
base O
pairs O
. O

A O
rabbit O
antiserum O
was O
raised O
against O
a O
synthetic O
peptide O
corresponding O
to O
a O
hydrophilic O
portion O
of O
the O
translated O
murine O
cDNA O
sequence O
. O

Conservation O
of O
function O
of O
Drosophila I-GENE
melanogaster I-GENE
abl I-GENE
and O
murine I-GENE
v I-GENE
- I-GENE
abl I-GENE
proteins I-GENE
in O
transformation O
of O
mammalian O
cells O
. O

In O
transient O
cotransfection O
assays O
using O
Chang O
liver O
cells O
( O
CCL O
13 O
), O
pM1 O
DNA O
exerts O
a O
6 O
- O
to O
10 O
- O
fold O
trans O
- O
activating O
effect O
on O
the O
expression O
of O
the O
pSV2CAT O
reporter O
plasmid O
. O

We O
have O
determined O
the O
nucleotide O
( O
nt O
) O
sequence O
of O
the O
7 I-GENE
. I-GENE
5 I-GENE
- I-GENE
kb I-GENE
COR I-GENE
segment I-GENE
that O
encompasses O
a O
cluster O
of O
six O
genes O
( O
CYC1 I-GENE
, O
UTR1 I-GENE
, O
UTR3 I-GENE
, O
OSM1 I-GENE
, O
tRNA I-GENE
( I-GENE
Gly I-GENE
) I-GENE
and O
RAD7 I-GENE
) O
located O
on O
chromosome O
X O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Specific O
binding O
of O
the O
protein O
factors O
to O
the O
sites O
, O
possibly O
to O
the O
three O
Mt O
sequences O
, O
may O
play O
an O
important O
role O
in O
the O
coordinate O
regulation O
of O
the O
transcription O
of O
nuclear O
genes O
encoding O
subunits O
responsible O
for O
mitochondrial O
oxidative O
phosphorylation O
. O

This O
points O
to O
a O
specific O
interference O
with O
HSV O
- O
induced O
DNA O
amplification O
. O

No O
recombination O
signal O
sequences O
have O
been O
found O
contiguous O
to O
the O
recombination O
point O
. O

The O
antinociceptive O
properties O
, O
as O
measured O
by O
the O
tail O
- O
flick O
and O
hot O
- O
plate O
tests O
, O
and O
the O
motor O
effects O
of O
an O
intrathecally O
- O
administered O
benzodiazepine O
agonist O
midazolam O
, O
alone O
, O
and O
in O
combination O
with O
morphine O
, O
was O
examined O
in O
rats O
. O

Constructs O
were O
made O
in O
which O
an O
AATAAA O
and O
the O
GT O
- O
rich O
region O
were O
separated O
by O
various O
distances O
ranging O
from O
7 O
to O
43 O
bp O
. O

To O
address O
this O
issue O
, O
the O
gene O
for O
factor I-GENE
Y I-GENE
has O
been O
cloned O
molecularly O
and O
its O
DNA O
sequence O
has O
been O
determined O
. O

We O
cloned O
and O
sequenced O
the O
cDNAs O
against O
genomic O
RNA O
and O
mRNA O
for O
phosphoprotein I-GENE
( I-GENE
P I-GENE
) I-GENE
of O
human O
parainfluenza O
type O
2 O
virus O
( O
PIV O
- O
2 O
). O
cDNA O
clone O
from O
genomic O
RNA O
was O
1439 O
nucleotides O
in O
length O
excluding O
poly O
( O
A O
) O
and O
was O
found O
to O
have O
two O
small O
open O
reading O
frames O
encoding O
proteins O
of O
233 O
and O
249 O
amino O
acids O
. O

We O
show O
that O
cytR I-GENE
expression O
is O
negatively O
controlled O
by O
the O
CytR I-GENE
protein I-GENE
and O
positively O
affected O
by O
the O
cAMP I-GENE
/ I-GENE
CAP I-GENE
complex I-GENE
. O

To O
identify O
these O
sites O
, O
the O
deduced O
amino O
acid O
sequence O
of O
the O
3T3 O
- O
L1 O
adipocyte I-GENE
insulin I-GENE
receptor I-GENE
of O
the O
mouse O
was O
determined O
. O

PAO O
blocks O
turnover O
of O
the O
phosphoryl O
group O
of O
pp15 I-GENE
, O
causing O
its O
accumulation O
, O
and O
thereby O
appears O
to O
interrupt O
signal O
transmission O
from O
the O
receptor O
to O
the O
glucose O
- O
transport O
system O
. O

It O
is O
likely O
that O
the O
sequence O
similarities O
reflect O
a O
common O
molecular O
architecture O
of O
the O
two O
heme O
binding O
sites O
and O
of O
a O
copper O
binding O
site O
in O
these O
enzymes O
. O

The O
cDNA O
sequence O
has O
an O
813 O
- O
bp O
open O
reading O
frame O
( O
ORF O
) O
whose O
predicted O
amino O
acid O
sequence O
is O
97 O
. O
6 O
% O
identical O
to O
the O
272 O
carboxy O
- O
terminal O
amino O
acids O
of O
the O
human I-GENE
ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

To O
characterize O
the O
O7 I-GENE
- I-GENE
LPS I-GENE
region I-GENE
, O
the O
recombinant O
cosmids O
pJHCV31 O
and O
pJHCV32 O
were O
mutagenized O
by O
transposon O
mutagenesis O
with O
Tn3HoHo1 I-GENE
, O
which O
carries O
a O
promoterless O
lac I-GENE
operon I-GENE
and O
can O
therefore O
generate O
lacZ I-GENE
transcriptional O
fusions O
with O
target O
DNA O
sequences O
. O

The O
sacT I-GENE
gene I-GENE
regulating O
the O
sacPA I-GENE
operon I-GENE
in I-GENE
Bacillus I-GENE
subtilis I-GENE
shares O
strong O
homology O
with O
transcriptional O
antiterminators O
. O

The O
TraD I-GENE
protein I-GENE
( I-GENE
83 I-GENE
, I-GENE
899 I-GENE
Da I-GENE
) I-GENE
contains O
three O
hydrophobic O
regions O
, O
of O
which O
two O
are O
located O
near O
the O
amino O
- O
terminal O
region O
. O

The O
protein O
product O
of O
orfD I-GENE
, O
which O
is O
probably O
a O
new O
tra I-GENE
gene I-GENE
( O
named O
traX I-GENE
), O
contains O
65 O
% O
hydrophobic O
amino O
acids O
, O
especially O
rich O
in O
alanine O
and O
leucine O
. O

Various O
mutant I-GENE
HN I-GENE
genes I-GENE
were O
constructed O
to O
examine O
the O
role O
of O
residues O
flanking O
the O
signal O
- O
anchor O
domain O
, O
including O
the O
cytoplasmic O
tail O
, O
on O
assembly O
and O
intracellular O
transport O
of O
the O
HN I-GENE
glycoprotein I-GENE
. O

Our O
studies O
extend O
these O
findings O
and O
show O
that O
the O
E2 I-GENE
transactivation I-GENE
gene I-GENE
is O
expressed O
from O
multiple O
promoters O
. O

Furthermore O
, O
analysis O
of O
the O
E2 I-GENE
proteins I-GENE
present O
in O
various O
cell O
lines O
harboring O
specific O
BPV O
- O
1 O
mutants O
, O
including O
the O
2558 O
acceptor O
mutant O
, O
proves O
that O
alternate O
modes O
of O
E2 I-GENE
expression O
exist O
. O

Disruption O
of O
the O
IRA2 I-GENE
gene I-GENE
resulted O
in O
( O
i O
) O
increased O
sensitivity O
to O
heat O
shock O
and O
nitrogen O
starvation O
, O
( O
ii O
) O
sporulation O
defects O
, O
and O
( O
iii O
) O
suppression O
of O
the O
lethality O
of O
the O
cdc25 I-GENE
mutant I-GENE
. O

This O
cohort O
of O
patients O
was O
selected O
on O
the O
basis O
of O
clinical O
stage O
. O

A O
gene O
in O
Drosophila O
melanogaster O
that O
maps O
cytologically O
to O
2C1 O
- O
3 O
on O
the O
distal O
portion O
of O
the O
X O
- O
chromosome O
encodes O
a O
member O
of O
the O
steroid I-GENE
/ I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

A O
portion O
of O
Region O
II O
also O
resembles O
part O
of O
the O
human O
c I-GENE
- I-GENE
jun I-GENE
oncoprotein O
' O
s O
leucine O
zipper O
, O
which O
in O
turn O
, O
has O
been O
demonstrated O
to O
be O
the O
heterodimerization O
site O
between O
the O
jun I-GENE
and O
fos I-GENE
oncoproteins I-GENE
. O

To O
determine O
whether O
vanadate O
could O
inhibit O
PEPCK I-GENE
gene I-GENE
transcription O
, O
a O
series O
of O
chimeric O
genes O
containing O
several O
deletions O
in O
the O
P I-GENE
- I-GENE
enolypyruvate I-GENE
carboxykinase I-GENE
promoter I-GENE
between O
- O
550 O
and O
- O
68 O
was O
linked O
to O
the O
structural O
genes O
for O
either O
amino I-GENE
- I-GENE
3 I-GENE
- I-GENE
glycosyl I-GENE
phosphotransferase I-GENE
( O
neo I-GENE
) O
or O
chloramphenicol I-GENE
acetyltransferase I-GENE
and O
introduced O
into O
hepatoma O
cells O
using O
three O
methods O
: O
( O
a O
) O
infection O
with O
a O
Moloney O
murine O
leukemia O
virus O
- O
based O
retrovirus O
, O
( O
b O
) O
transfection O
and O
stable O
selection O
for O
neo I-GENE
expression O
, O
or O
( O
c O
) O
transient O
expression O
of O
chloroamphenicol I-GENE
acetyltransferase I-GENE
. O

The O
diagnosis O
of O
miliary O
tuberculosis O
should O
be O
systematically O
considered O
in O
ARDS O
of O
unknown O
origin O
. O

In O
order O
to O
characterize O
the O
functional O
elements O
of O
the O
promoter O
that O
in O
some O
way O
must O
respond O
to O
these O
regulatory O
signals O
, O
a O
number O
of O
promoter O
mutations O
were O
constructed O
, O
including O
a O
set O
of O
linker O
- O
scanning O
mutations O
across O
the O
entire O
promoter O
region O
. O

A O
DNA O
motif O
related O
to O
the O
cAMP O
- O
responsive O
element O
and O
an O
exon I-GENE
- I-GENE
located I-GENE
activator I-GENE
protein I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
in O
the O
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
promoter I-GENE
cooperate O
in O
basal O
expression O
and O
convey O
activation O
by O
phorbol O
ester O
and O
cAMP O
. O

The O
26S I-GENE
rRNA I-GENE
binding I-GENE
ribosomal I-GENE
protein I-GENE
equivalent O
to O
bacterial I-GENE
protein I-GENE
L11 I-GENE
is O
encoded O
by O
unspliced O
duplicated O
genes O
in O
Saccharomyces O
cerevisiae O
. O

Five O
healthy O
male O
subjects O
inspired O
air O
for O
20 O
min O
and O
then O
5 O
% O
CO2 O
/ O
95 O
% O
O2 O
for O
30 O
min O
, O
of O
which O
the O
first O
10 O
min O
was O
used O
to O
achieve O
a O
steady O
- O
state O
end O
- O
tidal O
CO2 O
measurement O
. O

Significant O
correlations O
were O
obtained O
between O
changes O
in O
SSEP O
in O
response O
to O
AS O
and O
the O
presence O
of O
not O
deep O
residual O
- O
organic O
disturbances O
, O
so O
- O
called O
" O
ground O
" O
in O
psychogenic O
disorders O
. O

The O
transcripts O
were O
equally O
active O
with O
or O
without O
a O
5 O
' O
methylated O
capstructure O
as O
expected O
, O
since O
EMCV O
- O
RNA O
is O
one O
of O
the O
mRNAs O
capable O
of O
internal O
initiation O
. O

The O
E6 I-GENE
/ O
E7 I-GENE
promoter O
of O
all O
genital O
human O
papillomaviruses O
is O
responsible O
for O
expression O
of O
the O
viral O
transforming O
genes O
. O

A O
case O
of O
Goodpasture O
' O
s O
syndrome O
. O

Seventy O
- O
two O
of O
73 O
negative O
controls O
and O
all O
positive O
blocks O
as O
seen O
on O
soft O
tissue O
radiographs O
( O
STRs O
) O
were O
correctly O
coded O
( O
specificity O
98 O
. O
6 O
%, O
sensitivity O
100 O
%). O

No O
symptomatic O
abnormality O
has O
been O
noted O
in O
the O
neonatal O
period O
except O
periventricular O
calcifications O
. O

Immunohistochemical O
analysis O
of O
several O
rat O
organs O
also O
showed O
staining O
in O
epithelial O
cells O
. O

Both O
strains O
grew O
very O
poorly O
, O
or O
not O
at O
all O
, O
on O
nonfermentable O
carbon O
sources O
and O
exhibited O
, O
at O
most O
, O
only O
5 O
% O
of O
wild I-GENE
- I-GENE
type I-GENE
ubiquinol I-GENE
- I-GENE
cytochrome I-GENE
c I-GENE
oxidoreductase I-GENE
activity O
. O

Regulation O
of O
irgA I-GENE
by O
iron O
in O
V O
. O
cholerae O
occurs O
at O
the O
transcriptional O
level O
, O
and O
there O
is O
an O
interrupted O
dyad O
symmetric O
sequence O
in O
the O
vicinity O
of O
the O
promoter O
that O
is O
homologous O
to O
Fur I-GENE
binding I-GENE
sites I-GENE
of O
E O
. O
coli O
. O

Transcription O
of O
the O
first O
operon O
coding O
for O
m O
- O
xylene O
- O
degrading O
enzymes O
on O
the O
TOL O
plasmid O
of O
Pseudomonas O
putida O
is O
activated O
by O
the O
xylR I-GENE
gene I-GENE
product I-GENE
in O
the O
presence O
of O
m O
- O
xylene O
. O

The O
recombinant O
contains O
the O
normal O
beta I-GENE
A I-GENE
- I-GENE
globin I-GENE
gene I-GENE
, O
the O
mutant O
gene O
and O
Ylp O
vector O
sequences O
between O
the O
two O
copies O
. O

Some O
of O
the O
mutations O
obtained O
do O
not O
contain O
a O
copy O
of O
the O
Ulysses I-GENE
element I-GENE
at O
the O
mutant O
locus O
, O
suggesting O
that O
a O
different O
transposable O
element O
may O
be O
responsible O
for O
the O
mutation O
. O

Determination O
of O
diquat O
in O
biological O
materials O
by O
electron O
spin O
resonance O
spectroscopy O
. O

We O
show O
also O
that O
RA O
represses O
the O
transcriptional O
activity O
of O
a O
reporter O
gene O
containing O
a O
TPA O
responding O
AP1 I-GENE
binding I-GENE
site I-GENE
driving O
the O
HSV I-GENE
tk I-GENE
promoter I-GENE
. O

Moreover O
, O
radiolabeled O
EFI I-GENE
, O
NF I-GENE
- I-GENE
Y I-GENE
, O
or O
CBF I-GENE
DNAs I-GENE
give O
rise O
to O
identical O
gel O
retardation O
patterns O
in O
extracts O
from O
a O
variety O
of O
different O
cell O
types O
. O

Risk O
factors O
influencing O
lymph O
nodes O
metastasis O
in O
lung O
cancer O
with O
stage O
I O
, O
II O
or O
IIIA O

Multifunctional I-GENE
protein I-GENE
kinase I-GENE
( O
MFPK I-GENE
) O
phosphorylates O
ATP I-GENE
- I-GENE
citrate I-GENE
lyase I-GENE
on O
peptide I-GENE
B I-GENE
on O
two O
sites O
, O
BT O
and O
BS O
, O
on O
threonine O
and O
serine O
, O
respectively O
, O
inhibitor I-GENE
2 I-GENE
on O
a O
threonyl O
residue O
, O
and O
glycogen I-GENE
synthase I-GENE
at O
sites O
2 O
and O
3 O
. O

The O
characterized O
Y I-GENE
' I-GENE
repeated I-GENE
sequence I-GENE
families I-GENE
provide O
an O
experimental O
system O
in O
which O
repeated O
sequence O
interactions O
and O
subsequent O
evolution O
can O
be O
studied O
. O

The O
electrically O
induced O
motile O
responses O
were O
not O
suppressed O
in O
the O
presence O
of O
dinitrophenol O
or O
cytochalasin O
B O
. O

Unlike O
p59v I-GENE
- O
rel I-GENE
, O
which O
is O
a O
nuclear O
protein O
in O
CEF O
, O
indirect O
immunofluorescence O
showed O
that O
p68c I-GENE
- O
rel I-GENE
in O
JD214c O
- O
rel O
infected O
CEF O
is O
located O
exclusively O
in O
the O
cytoplasm O
of O
these O
cells O
, O
even O
though O
the O
sequence O
of O
p68c I-GENE
- O
rel I-GENE
showed O
that O
it O
contains O
a O
nuclear O
localizing O
sequence O
identical O
to O
the O
one O
previously O
identified O
in O
p59v I-GENE
- O
rel I-GENE
. O

Kinetic O
experiments O
revealed O
that O
within O
10 O
min O
this O
radiolabeled O
precursor O
protein O
was O
converted O
in O
HL O
- O
60 O
cells O
into O
an O
Mr O
approximately O
150 O
, O
000 O
chondroitin O
sulfate O
proteoglycan O
intermediate O
. O

Blood O
flow O
and O
velocity O
( O
measured O
using O
Doppler O
ultrasound O
) O
gradually O
decreased O
during O
diastole O
and O
ultimately O
reversed O
in O
direction O
as O
cotyledon O
resistance O
was O
increased O
up O
to O
14 O
fold O
. O

A O
total O
of O
112 O
patients O
received O
anistreplase O
and O
119 O
received O
heparin O
within O
a O
mean O
period O
of O
188 O
+/- O
62 O
min O
following O
the O
onset O
of O
symptoms O
. O

However O
, O
primary O
transcripts O
of O
a O
variant I-GENE
tRNA I-GENE
( I-GENE
Val I-GENE
)( I-GENE
UAC I-GENE
) I-GENE
gene I-GENE
are O
processing O
deficient O
under O
standard O
growth O
conditions O
( O
30 O
degrees O
C O
), O
due O
to O
a O
slightly O
altered O
5 O
' O
flanking O
region O
. O

The O
promoter O
activity O
was O
measured O
by O
a O
transient O
expression O
of O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
connected O
with O
various O
5 O
'- O
deletion O
mutants O
of O
the O
5 O
'- O
flanking O
region O
. O

Three O
of O
the O
short O
ORFs O
in O
the O
central O
region O
of O
BIV O
have O
been O
identified O
by O
location O
and O
structural O
similarity O
to O
the O
nonstructural O
/ O
regulatory O
genes O
( O
vif I-GENE
, O
tat I-GENE
, O
and O
rev I-GENE
) O
of O
other O
lentiviruses O
; O
we O
also O
discovered O
two O
unique O
ORFs O
, O
termed O
W O
and O
Y O
, O
which O
may O
serve O
as O
exons O
for O
novel O
genes O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
14DM I-GENE
gene I-GENE
, O
encoding O
cytochrome I-GENE
P450 I-GENE
lanosterol I-GENE
14 I-GENE
alpha I-GENE
- I-GENE
demethylase I-GENE
( O
14DM I-GENE
), O
was O
overexpressed O
in O
various O
S O
. O
cerevisiae O
strains O
under O
the O
control O
of O
three O
strong O
heterologous O
yeast O
transcription O
promoters O
( O
pADC1 I-GENE
, O
pGPD I-GENE
, O
pPHO5 I-GENE
) O
and O
under O
the O
control O
of O
its O
own O
promoter O
. O

Truncations O
composed O
of O
78 O
and O
64 O
amino O
acids O
were O
translocated O
across O
the O
endoplasmic O
reticulum O
membrane O
, O
and O
translocation O
was O
found O
to O
be O
strictly O
co O
- O
translational O
and O
SRP I-GENE
- O
dependent O
. O

Pulmonary O
vascular O
resistance O
was O
not O
altered O
, O
ejection O
fraction O
remained O
unchanged O
and O
isovolumic O
relaxation O
period O
was O
lengthened O
( O
119 O
+/- O
20 O
. O
1 O
to O
147 O
. O
39 O
+/- O
21 O
. O
15 O
, O
P O
less O
than O
0 O
. O
05 O
). O

The O
ANB1 I-GENE
locus I-GENE
of O
Saccharomyces O
cerevisiae O
encodes O
the O
protein I-GENE
synthesis I-GENE
initiation I-GENE
factor I-GENE
eIF I-GENE
- I-GENE
4D I-GENE
. O

The O
contribution O
that O
alternative O
splicing O
events O
in O
c I-GENE
- I-GENE
myb I-GENE
expression O
may O
make O
on O
c I-GENE
- I-GENE
myb I-GENE
function O
remains O
to O
be O
elucidated O
. O

Serum I-GENE
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
levels O
( O
beta I-GENE
- I-GENE
2 I-GENE
- I-GENE
M I-GENE
) O
were O
studied O
in O
150 O
drug O
addicts O
, O
50 O
of O
them O
asymptomatic O
carriers O
of O
anti I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
antibodies I-GENE
, O
50 O
symptomatic O
carriers O
with O
persistent O
generalized O
lymphadenopathy O
( O
P O
. O
G O
. O
L O
.) O
and O
50 O
serum O
negative O
patients O
who O
had O
been O
living O
in O
a O
closed O
community O
for O
at O
least O
2 O
years O
. O

This O
emancipation O
of O
the O
ability O
to O
copulate O
from O
hormonal O
influence O
makes O
female O
sexual O
motivation O
the O
primary O
regulator O
of O
mating O
in O
primates O
. O

No O
therapy O
exists O
for O
halting O
the O
progression O
of O
the O
disease O
with O
the O
possible O
exception O
of O
laser O
photocoagulation O
treatment O
used O
to O
ablate O
subretinal O
neovascular O
membranes O
in O
an O
attempt O
to O
avoid O
complications O
of O
subretinal O
hemorrhages O
. O

R O
. O

Specific O
hyperimmune I-GENE
globulins I-GENE
to O
pathogens O
such O
as O
Haemophilus O
influenzae O
and O
Streptococcus O
pneumoniae O
have O
also O
been O
studied O
. O

Therapeutic O
effects O
of O
cefpirome O
( O
HR O
810 O
) O
on O
experimental O
mixed O
infections O
with O
Enterococcus O
faecalis O
and O
Escherichia O
coli O
in O
mice O
. O

Regulation O
of O
yeast I-GENE
LEU2 I-GENE
. O

Homozygous O
individuals O
usually O
develop O
purpura O
fulminans O
as O
newborns O
; O
heterozygous O
protein I-GENE
C I-GENE
- O
deficient O
individuals O
are O
at O
increased O
risk O
for O
venous O
thrombosis O
and O
pulmonary O
embolism O
. O

Ischemic O
stroke O
due O
to O
protein I-GENE
C I-GENE
deficiency O
. O

TREB7 I-GENE
and O
TREB36 I-GENE
protected O
all O
three O
repeats O
of O
the O
21 O
bp O
, O
but O
TREB5 I-GENE
protected O
only O
the O
second O
repeat O
. O

These O
results O
suggest O
that O
5 O
KE O
X O
3 O
/ O
W O
may O
be O
the O
optimal O
regimen O
to O
augment O
the O
antitumor O
immunity O
of O
RNL O
. O

Analysis O
of O
various O
deletion O
mutants O
indicates O
that O
the O
sequence O
requirements O
for O
binding O
by O
QBP I-GENE
in O
vitro O
are O
indistinguishable O
from O
those O
necessary O
for O
Q O
activity O
in O
vivo O
, O
strongly O
suggesting O
that O
QBP I-GENE
is O
required O
for O
the O
function O
of O
this O
TATA O
- O
independent O
promoter O
. O

Since O
general I-GENE
regulatory I-GENE
factor I-GENE
I I-GENE
( O
GRFI I-GENE
)/ O
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
RAP1 I-GENE
)/ O
translation I-GENE
upstream I-GENE
factor I-GENE
( O
TUF I-GENE
) O
is O
believed O
to O
be O
an O
activator O
of O
MAT I-GENE
alpha I-GENE
expression O
, O
we O
examined O
whether O
PYK1 I-GENE
, O
which O
is O
known O
to O
be O
regulated O
by O
GRFI I-GENE
/ O
RAP1 I-GENE
/ O
TUF I-GENE
, O
is O
also O
affected O
by O
the O
gal11 I-GENE
mutation I-GENE
. O

Yeast I-GENE
Gal11 I-GENE
protein I-GENE
mediates O
the O
transcriptional O
activation O
signal O
of O
two O
different O
transacting O
factors O
, O
Gal4 I-GENE
and O
general I-GENE
regulatory I-GENE
factor I-GENE
I I-GENE
/ O
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
/ I-GENE
translation I-GENE
upstream I-GENE
factor I-GENE
. O

Deletion O
from O
either O
the O
N O
- O
or O
C O
- O
terminal O
ends O
of O
repA I-GENE
( O
28 O
and O
69 O
codons O
, O
respectively O
, O
out O
of O
the O
286 O
- O
codon O
open O
reading O
frame O
) O
affected O
the O
initiator O
but O
not O
the O
inhibitory O
activity O
. O

The O
two O
larger O
peptides O
, O
one O
containing O
amino O
acids O
1 O
- O
228 O
and O
the O
other O
containing O
amino O
acids O
85 O
- O
228 O
, O
formed O
dimers O
in O
solution O
and O
bound O
DNA O
specifically O
as O
a O
dimer O
. O

In O
vitro O
transcription O
extracts O
from O
ret1 I-GENE
- I-GENE
1 I-GENE
cells O
terminate O
less O
efficiently O
at O
weak O
transcription O
termination O
signals O
than O
those O
from O
RET1 I-GENE
cells O
, O
using O
a O
variety O
of O
tRNA O
templates O
. O

Guiding O
patients O
in O
the O
decision O
should O
involve O
a O
multidisciplinary O
team O
composed O
of O
a O
surgical O
oncologist O
, O
geneticist O
, O
pathologist O
, O
psychotherapist O
and O
plastic O
surgeon O
. O

IgG I-GENE
and O
IgM I-GENE
antibody O
activity O
was O
determined O
by O
adding O
a O
1 O
: O
100 O
dilution O
of O
serum O
to O
plates O
coated O
with O
A60 I-GENE
antigen I-GENE
. O

These O
factors O
belong O
to O
a O
set O
of O
genetically O
distinct O
molecules O
, O
including O
AP I-GENE
- I-GENE
4 I-GENE
and O
MLTF I-GENE
, O
that O
bind O
to O
the O
CACCTGTC O
motif O
or O
related O
sequences O
. O

Among O
known O
flea O
larvae O
, O
the O
genus O
Anomiopsyllus O
( O
Anomiopsyllinae O
, O
Anomiopsyllini O
) O
is O
as O
distinctive O
in O
larval O
form O
as O
are O
the O
adults O
. O

Here O
, O
we O
have O
used O
specific O
antibody O
to O
identify O
and O
characterize O
the O
SSN6 I-GENE
protein I-GENE
. O

These O
latter O
results O
showed O
that O
the O
ABFI I-GENE
protein I-GENE
, O
like O
the O
RAP1 I-GENE
protein I-GENE
, O
bound O
sequences O
required O
for O
positive O
as O
well O
as O
negative O
regulation O
of O
gene O
expression O
. O

Clinical O
nutrition O
of O
adult O
horses O
. O

The O
computer O
- O
programmed O
cytocentrifuge O
is O
currently O
most O
popular O
. O

RNase I-GENE
protection O
assays O
reveal O
that O
this O
gene O
, O
unr I-GENE
, O
is O
transcribed O
in O
the O
same O
direction O
as O
N I-GENE
- I-GENE
ras I-GENE
and O
that O
its O
3 O
' O
end O
is O
located O
just O
130 O
base O
pairs O
away O
from O
the O
point O
at O
which O
N I-GENE
- I-GENE
ras I-GENE
transcription O
begins O
. O

Isolation O
of O
a O
temperature O
- O
sensitive O
mutant O
with O
an O
altered O
tRNA I-GENE
nucleotidyltransferase I-GENE
and O
cloning O
of O
the O
gene I-GENE
encoding I-GENE
tRNA I-GENE
nucleotidyltransferase I-GENE
in I-GENE
the I-GENE
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

The O
juxtamembrane O
region O
of O
the O
insulin I-GENE
receptor I-GENE
( I-GENE
IR I-GENE
) I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
contains O
an O
unphosphorylated O
tyrosyl O
residue O
( O
Tyr960 O
) O
that O
is O
essential O
for O
insulin I-GENE
- O
stimulated O
tyrosyl O
phosphorylation O
of O
some O
endogenous O
substrates O
and O
certain O
biological O
responses O
( O
White O
, O
M O
. O
F O
., O
Livingston O
, O
J O
. O
N O
., O
Backer O
, O
J O
. O
M O
., O
Lauris O
, O
V O
., O
Dull O
, O
T O
. O
J O
., O
Ullrich O
, O
A O
., O
and O
Kahn O
, O
C O
. O
R O
. O

This O
gene O
joins O
the O
group O
of O
genes O
whose O
members O
are O
rapidly O
transcribed O
in O
response O
to O
insulin I-GENE
and O
other O
mitogens O
. O

The O
3 O
' O
region O
, O
GA2 I-GENE
, O
is O
necessary O
for O
maximal O
expression O
. O

1 O
, O
among O
which O
nine O
have O
been O
cloned O
and O
two O
( O
potentially O
functional O
) O
sequenced O
. O

Pups O
placed O
into O
the O
novel O
environment O
with O
their O
mothers O
exhibited O
an O
intermediate O
level O
of O
DA O
turnover O
. O

The O
efficacy O
and O
safety O
of O
a O
novel O
percutaneous O
anaesthetic O
preparation O
based O
on O
amethocaine O
has O
been O
investigated O
in O
the O
paediatric O
clinical O
environment O
. O

Homozygous O
protein I-GENE
C I-GENE
( O
PC I-GENE
) O
deficiency O
is O
reported O
in O
two O
siblings O
( O
girl O
and O
boy O
) O
who O
received O
their O
proper O
diagnoses O
at O
the O
ages O
of O
7 O
4 O
/ O
12 O
and O
1 O
3 O
/ O
12 O
years O
respectively O
. O

The O
grandfather O
and O
the O
granddaughter O
both O
had O
microtia O
and O
meatal O
atresia O
, O
whereas O
the O
daughter O
had O
a O
normal O
outer O
ear O
except O
for O
a O
narrow O
meatus O
and O
auricular O
appendages O
. O

Abnormal O
intrapulmonary O
shunting O
( O
IPS O
), O
which O
was O
proved O
in O
4 O
cases O
by O
whole O
- O
body O
radionuclide O
scanning O
with O
99mTc O
- O
MAA O
, O
is O
suggested O
as O
the O
major O
cause O
of O
cyanosis O
in O
liver O
cirrhosis O
. O

The O
urinary O
protein O
, O
serum O
albumin I-GENE
, O
BUN O
and O
SCr O
all O
had O
very O
significant O
improvement O
. O

More O
generally O
, O
Ets1 I-GENE
and O
Ets2 I-GENE
could O
regulate O
transcription O
of O
cellular O
genes O
. O

Within O
this O
sequence O
the O
MSAS I-GENE
gene I-GENE
was O
identified O
as O
a O
5322 O
- O
bp O
- O
long O
open O
reading O
frame O
coding O
for O
a O
protein O
of O
1774 O
amino O
acids O
and O
190 O
, O
731 O
Da O
molecular O
mass O
. O

Horseradish I-GENE
peroxidase I-GENE
as O
a O
permeability O
marker O
in O
injured O
rat O
caudal O
and O
iliac O
arteries O
. O

Standardized O
gastric O
wall O
specimens O
from O
the O
area O
of O
grossly O
healed O
ulcers O
were O
obtained O
, O
processed O
, O
and O
evaluated O
by O
light O
microscopy O
and O
by O
transmission O
electron O
microscopy O
. O

2 O
. O

The O
effects O
of O
coenzyme O
Q10 O
( O
CoQ O
) O
and O
captopril O
on O
functional O
capacity O
, O
hemodynamics O
and O
survival O
were O
studied O
in O
154 O
rats O
that O
recovered O
after O
experimental O
myocardial O
infarction O
. O

Evidence O
that O
therapeutic O
alterations O
of O
a O
circadian O
rhythm O
for O
gastric O
emptying O
response O
may O
be O
possible O
. O

The O
interrelation O
of O
the O
levels O
of O
glucocorticoids O
and O
insulin I-GENE
in O
the O
blood O
of O
irradiated O
animals O

This O
last O
includes O
tissue O
O2 O
transfer O
( O
Ft O
') O
and O
mitochondrial O
O2 O
utilization O
( O
Fm O
'). O

Foveating O
saccades O
, O
therefore O
, O
can O
be O
distinguished O
from O
other O
FEMs O
on O
the O
basis O
of O
speed O
. O

Incidence O
correlated O
with O
the O
grade O
of O
oral O
hygiene O
und O
periodontal O
disease O
. O

Our O
study O
shows O
that O
the O
area O
of O
Alcoy O
is O
a O
medium O
MS O
risk O
region O
according O
to O
the O
thesis O
of O
Kurzke O
, O
although O
high O
MS O
areas O
may O
be O
found O
, O
thus O
confirming O
that O
MS O
distribution O
in O
southern O
Europe O
is O
not O
uniform O
. O

On O
an O
antithrombin I-GENE
unit O
basis O
, O
CY O
216 O
and O
CY O
222 O
were O
equivalent O
and O
more O
potent O
than O
UH O
. O

Chick I-GENE
brain I-GENE
actin I-GENE
depolymerizing I-GENE
factor I-GENE
( O
ADF I-GENE
) O
is O
a O
19 O
- O
kDa O
protein O
that O
severs O
actin I-GENE
filaments I-GENE
and O
binds O
actin I-GENE
monomers I-GENE
. O

Initial O
experience O
with O
a O
serotonin O
agonist O
. O

Comprehensive O
care O
of O
the O
patient O
exposed O
to O
a O
human O
teratogen O
may O
also O
include O
discussion O
of O
prenatal O
diagnostic O
procedures O
and O
other O
pregnancy O
management O
options O
. O

Primer O
extension O
analysis O
and O
RNA O
sequencing O
demonstrates O
that O
the O
transcription O
start O
point O
of O
rat I-GENE
ODC I-GENE
mRNA I-GENE
is O
located O
303 O
nt O
upstream O
from O
the O
A O
residue O
in O
the O
start O
codon O
. O

For O
85Sr O
, O
larger O
- O
than O
- O
expected O
distribution O
coefficients O
were O
obtained O
in O
the O
desorption O
experiments O
, O
an O
indication O
of O
the O
irreversible O
formation O
of O
metal O
- O
oxyhydroxides O
during O
a O
slow O
reaction O
. O

Gene O
constructs O
possessing O
the O
complete I-GENE
tat I-GENE
, O
rev I-GENE
( O
tat I-GENE
+ I-GENE
rev O
+) O
and O
env I-GENE
genes I-GENE
were O
transiently O
expressed O
in O
COS O
- O
1 O
cells O
as O
precursor I-GENE
SU I-GENE
- I-GENE
TM I-GENE
( O
gp160 I-GENE
), O
SU I-GENE
. I-GENE
TM I-GENE
( O
gp120 I-GENE
x I-GENE
41 I-GENE
), O
and O
nucleolar I-GENE
rev I-GENE
protein I-GENE
. O

This O
growth O
arrest O
is O
partly O
suppressed O
on O
minimal O
medium O
or O
under O
conditions O
in O
which O
the O
cells O
are O
less O
dependent O
on O
mitochondrial O
metabolism O
. O

Patients O
with O
detectable O
serum O
TNF I-GENE
levels O
had O
significantly O
lower O
serum O
T3 O
concentrations O
compared O
to O
those O
with O
undetectable O
levels O
[ O
1 O
. O
072 O
+/- O
0 O
. O
588 O
vs O
. O

Giant O
pilomatrix O
carcinoma O
: O
report O
and O
review O
of O
the O
literature O
. O

Further O
studies O
of O
mandibular O
movement O
at O
initial O
tooth O
contact O
. O

Each O
parent O
interacted O
with O
their O
4 O
- O
or O
5 O
- O
year O
- O
old O
son O
or O
daughter O
in O
each O
of O
two O
conversations O
-- O
unstructured O
( O
social O
conversation O
) O
and O
structured O
( O
task O
activity O
). O

Droperidol O
- O
induced O
extrapyramidal O
symptoms O
in O
an O
adolescent O
following O
strabismus O
surgery O
. O

These O
results O
indicate O
that O
the O
cis O
- O
regulatory O
elements O
required O
for O
developmental O
control O
of O
the O
HaG3 I-GENE
- I-GENE
A I-GENE
helianthinin I-GENE
gene I-GENE
are O
located O
in O
a O
2 O
. O
4 O
kb O
upstream O
region O
of O
this O
gene O
. O

The O
induction O
by O
pseudorabies O
virus O
of O
an O
IL I-GENE
- I-GENE
6 I-GENE
construct I-GENE
containing O
the O
IL I-GENE
- I-GENE
6 I-GENE
TATA I-GENE
box I-GENE
and O
the O
RNA O
start O
site O
(" O
initiator O
" O
or O
Inr O
element O
) O
but O
not O
the O
MRE O
region O
was O
also O
repressed O
by O
Dex O
in O
the O
presence O
of O
wild I-GENE
- I-GENE
type I-GENE
GR I-GENE
. O

Some O
mutations O
affected O
Dhfr I-GENE
in O
a O
qualitative O
manner O
, O
such O
as O
by O
changing O
the O
startpoint O
of O
one O
of O
the O
major O
Dhfr I-GENE
transcripts I-GENE
or O
changing O
the O
relative O
abundance O
of O
the O
two O
major O
Dhfr I-GENE
transcripts I-GENE
. O

The O
glial O
cyst O
wall O
was O
lined O
in O
part O
by O
flattened O
or O
cuboidal O
epithelium O
. O

We O
conclude O
that O
class O
I O
cytologic O
smears O
with O
moderate O
to O
severe O
inflammation O
may O
be O
associated O
with O
findings O
of O
condylomata O
and O
cervical O
dysplasia O
. O

As O
in O
mammals O
, O
considerable O
nucleotide O
diversity O
was O
observed O
at O
the O
junctions O
of O
the O
variable O
, O
diversity O
, O
and O
joining O
elements O
in O
chicken I-GENE
TCR I-GENE
beta I-GENE
cDNAs I-GENE
. O

The O
protooncogene O
c I-GENE
- I-GENE
myb I-GENE
encodes O
a O
nuclear O
transcription O
factor O
that O
binds O
to O
DNA O
in O
a O
sequence O
- O
specific O
manner O
and O
transactivates O
transcription O
of O
several O
viral O
and O
cellular O
genes O
. O

Modification O
by O
this O
latter O
compound O
was O
so O
extensive O
that O
the O
amount O
of O
membrane O
- O
associated O
N O
- O
myristoylated O
protein O
was O
decreased O
. O

S6 I-GENE
kinase I-GENE
activation O
requires O
displacement O
of O
this O
inhibitory O
segment O
, O
which O
is O
proposed O
to O
occur O
consequent O
to O
its O
multiple O
phosphorylation O
. O

Rats O
with O
one O
olfactory O
bulb O
removed O
and O
the O
contralateral O
naris O
closed O
can O
detect O
odors O
. O

Expression O
of O
the O
human O
T I-GENE
cell I-GENE
receptor I-GENE
( I-GENE
TCR I-GENE
) I-GENE
alpha I-GENE
gene I-GENE
is O
regulated O
by O
a O
T O
cell O
- O
specific O
transcriptional O
enhancer O
that O
is O
located O
4 O
. O
5 O
kilobases O
( O
kb O
) O
3 O
' O
to O
the O
C I-GENE
alpha I-GENE
gene I-GENE
segment I-GENE
. O

The O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
was O
localized O
to O
a O
17 O
- O
base O
pair O
( O
bp O
) O
region O
from O
the O
3 O
' O
end O
of O
T I-GENE
alpha I-GENE
2 I-GENE
. O

Cerebral O
flow O
and O
resistance O
showed O
minor O
reductions O
with O
HD O
. O

Utilization O
of O
alternative O
polyadenylation O
signals O
was O
previously O
shown O
to O
generate O
two O
sialophorin I-GENE
mRNAs I-GENE
of I-GENE
1 I-GENE
. I-GENE
9 I-GENE
and I-GENE
4 I-GENE
. I-GENE
3 I-GENE
kb I-GENE
, O
which O
differ O
in O
the O
length O
of O
their O
3 O
' O
untranslated O
regions O
. O

Presidential O
address O
1990 O
-- O
coming O
in O
from O
the O
cold O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
encodes O
a O
40 O
- O
kDa O
nuclear O
protein O
, O
Tax I-GENE
, O
which O
stimulates O
transcription O
from O
three O
21 O
- O
base O
pair O
( O
bp O
) O
repeats O
in O
its O
U3 O
region O
. O

We O
have O
now O
identified O
, O
after O
21 O
serial O
undiluted O
passages O
of O
MHV O
, O
a O
small I-GENE
DI I-GENE
RNA I-GENE
, O
DIssF I-GENE
, O
which O
is O
efficiently O
packaged O
into O
virions O
. O

The O
Jenkins O
Activity O
Survey O
and O
the O
CPI O
- O
revised O
: O
further O
evidence O
of O
adaptive O
and O
maladaptive O
type O
A O
traits O
. O

There O
was O
evidence O
of O
attenuated O
regression O
slopes O
relating O
recalled O
to O
observed O
portion O
sizes O
for O
4 O
of O
the O
10 O
food O
groups O
; O
adjusted O
r2 O
values O
for O
the O
recalled O
portion O
sizes O
ranged O
from O
0 O
. O
02 O
to O
0 O
. O
94 O
. O

The O
result O
suggests O
that O
this O
non O
- O
invasive O
TTD O
method O
is O
easily O
available O
and O
useful O
in O
monitoring O
the O
intraoperative O
cardiac O
output O
. O

The O
TUP1 I-GENE
gene I-GENE
was O
isolated O
in O
a O
screen O
for O
genes O
that O
regulate O
mating O
type O
( O
V O
. O
L O
. O

The O
SUP44 I-GENE
suppressor I-GENE
mutation I-GENE
occurs O
near O
a O
region O
of O
the O
protein O
that O
corresponds O
to O
the O
known O
positions O
of O
alterations O
in O
E I-GENE
. I-GENE
coli I-GENE
S5 I-GENE
ram I-GENE
mutations I-GENE
. O

Interestingly O
, O
disruption O
of O
the O
VPS34 I-GENE
locus I-GENE
resulted O
in O
a O
temperature O
- O
sensitive O
growth O
defect O
, O
indicating O
that O
the O
VPS34 I-GENE
gene I-GENE
is O
essential O
for O
vegetative O
growth O
only O
at O
elevated O
growth O
temperatures O
. O

We O
describe O
a O
case O
of O
a O
perinephric O
abscess O
treated O
with O
amphotericin O
B O
and O
nephrectomy O
. O

This O
, O
together O
with O
the O
data O
obtained O
with O
haloperidol O
, O
suggests O
that O
a O
minimal O
increase O
in O
the O
firing O
rate O
of O
LC O
cells O
(+ O
140 O
%) O
is O
required O
before O
it O
could O
influence O
the O
turnover O
of O
NA O
, O
as O
measured O
by O
DOPAC O
changes O
. O

This O
interaction O
occurs O
over O
a O
wide O
range O
of O
both O
parameters O
; O
for O
charge O
density O
from O
at O
least O
10 O
to O
800 O
microC O
/ O
cm2 O
and O
, O
for O
charge O
per O
phase O
, O
from O
at O
least O
0 O
. O
05 O
to O
5 O
. O
0 O
microC O
per O
phase O
. O

Perceptions O
of O
illness O
intrusiveness O
were O
significantly O
higher O
when O
both O
muscle O
cramp O
and O
headache O
symptoms O
occurred O
during O
one O
or O
more O
assessment O
intervals O
as O
compared O
to O
when O
muscle O
cramps O
or O
headaches O
, O
only O
, O
occurred O
. O

Results O
have O
surprisingly O
revealed O
the O
presence O
of O
three O
U14 I-GENE
snRNA I-GENE
- I-GENE
homologous I-GENE
regions I-GENE
positioned O
within O
introns O
5 O
, O
6 O
, O
and O
8 O
of O
the O
mouse O
cognate O
hsc70 I-GENE
heat O
shock O
gene O
. O

65 O
- O
kilodalton O
protein O
phosphorylated O
by O
interleukin I-GENE
2 I-GENE
stimulation O
bears O
two O
putative O
actin I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
two O
calcium O
- O
binding O
sites O
. O

The O
highly O
restrained O
girls O
had O
a O
significantly O
higher O
EAT O
score O
than O
the O
low O
- O
restrained O
girls O
, O
and O
shared O
with O
their O
mothers O
a O
susceptibility O
to O
the O
disinhibitory O
effects O
of O
negative O
mood O
states O
on O
their O
eating O
behaviour O
. O

The O
Mauriceville O
and O
Varkud O
mitochondrial O
plasmids O
are O
closely O
related O
, O
closed O
- O
circular O
DNAs O
( O
3 O
. O
6 O
and O
3 O
. O
7 O
kb O
, O
respectively O
) O
that O
have O
characteristics O
of O
mtDNA O
introns O
and O
retroid O
elements O
. O

The O
circadian O
rhythm O
, O
however O
, O
was O
not O
affected O
and O
the O
difference O
between O
minimum O
( O
12 O
. O
00 O
h O
) O
and O
maximum O
( O
18 O
. O
50 O
h O
) O
serum O
concentrations O
was O
31 O
. O
3 O
%. O

Sequence O
and O
genetic O
organization O
of O
a O
Zymomonas O
mobilis O
gene O
cluster O
that O
encodes O
several O
enzymes O
of O
glucose O
metabolism O
. O

Most O
strains O
( O
95 O
%) O
of O
S O
. O
lugdunensis O
produced O
a O
delta I-GENE
hemolysin I-GENE
like O
that O
seen O
with O
nine O
other O
species O
of O
CNS O
. O

For O
this O
, O
cDNAs O
containing O
the O
60K O
, O
87K O
, O
110K O
and O
170K O
protein O
coding O
sequences O
were O
each O
provided O
with O
an O
ATG O
start O
codon O
and O
the O
cDNA O
containing O
the O
60K O
coding O
sequence O
with O
a O
TAA O
stop O
codon O
immediately O
downstream O
of O
the O
coding O
sequence O
. O

Finally O
, O
a O
complementary O
footprinting O
analysis O
of O
the O
upstream O
region O
of O
the O
constitutively O
expressed O
HSC82 I-GENE
gene I-GENE
reveals O
the O
presence O
of O
three O
discrete O
protein O
complexes O
. O

Pathophysiology O
of O
bone O
loss O
in O
castrated O
animals O
. O

Auditory O
- O
visual O
interaction O
in O
the O
generation O
of O
saccades O
in O
man O
. O

First O
, O
each O
lung O
was O
cut O
into O
slices O
, O
from O
which O
primary O
disectors O
were O
sampled O
systematically O
with O
a O
known O
sampling O
fraction O
. O

The O
upstream O
promoter O
is O
located O
within O
the O
coding O
sequence O
of O
a O
divergent O
gene O
expressing O
a O
protein O
of O
Mr O
39 O
kDa O
of O
unknown O
function O
. O

Assuming O
O2 O
consumption O
of O
the O
isolated O
skin O
to O
be O
same O
as O
in O
situ O
, O
calculations O
showed O
that O
when O
water O
PO2 O
was O
high O
( O
150 O
mm O
Hg O
), O
about O
40 O
% O
of O
total O
cutaneous O
O2 O
uptake O
was O
consumed O
by O
the O
skin O
. O

Experiments O
showed O
that O
temporary O
arrest O
of O
pulmonary O
circulation O
under O
conditions O
of O
extracorporeal O
circulation O
is O
attended O
by O
the O
development O
of O
ischemia O
of O
the O
respiratory O
pulmonary O
tissue O
. O

MCh O
infusion O
caused O
a O
concentration O
- O
dependent O
increase O
in O
airway O
resistance O
at O
constant O
QBA O
. O

Taste O
reactivity O
tests O
were O
used O
to O
examine O
the O
orofacial O
responses O
of O
alcohol O
preferring O
( O
P O
) O
rats O
and O
alcohol O
nonpreferring O
( O
NP O
) O
rats O
to O
the O
taste O
of O
alcohol O
. O

Plasma O
concentrations O
of O
atracurium O
and O
laudanosine O
were O
0 O
. O
73 O
- O
3 O
. O
11 O
micrograms O
ml O
- O
1 O
and O
0 O
. O
48 O
- O
8 O
. O
65 O
micrograms O
ml O
- O
1 O
, O
respectively O
; O
CSF O
concentration O
of O
laudanosine O
was O
70 O
- O
440 O
ng O
ml O
- O
1 O
. O

Plasma O
Al O
was O
obtained O
during O
each O
baseline O
and O
drug O
course O
. O

The O
survival O
in O
the O
case O
of O
these O
patients O
was O
studied O
five O
years O
later O
. O

The O
occurrence O
, O
maintenance O
and O
possible O
involvement O
of O
these O
repeated O
sequences O
, O
capable O
of O
forming O
stable O
secondary O
structures O
, O
are O
discussed O
in O
relation O
to O
their O
location O
in O
the O
region O
of O
control O
signals O
. O

IST I-GENE
is O
not O
the O
RNA O
target O
( O
TAR O
) O
for O
Tat I-GENE
trans O
- O
activation O
; O
however O
, O
because O
it O
relies O
entirely O
on O
cellular O
factors O
for O
activity O
, O
IST I-GENE
may O
serve O
to O
provide O
abundant O
RNA O
targets O
for O
Tat I-GENE
trans O
- O
activation O
without O
a O
requirement O
for O
full O
- O
length O
viral O
mRNA O
expression O
. O

Genotoxic O
activity O
of O
a O
tobacco O
- O
specific O
nitrosamine O
. O

The O
endodontal O
treatment O
need O
has O
been O
forming O
a O
clinical O
order O
of O
magnitude O
. O

1 O
(" O
long O
method O
") O
and O
the O
HML O
method O
. O

These O
results O
may O
suggest O
involvement O
of O
peripheral O
enkephalins O
in O
pain O
modulation O
in O
patients O
with O
episodic O
cluster O
headache O
. O

Effects O
of O
cisapride O
on O
upper O
- O
gastrointestinal O
motility O
and O
digestive O
hormones O

Common O
foot O
pathologies O
are O
heel O
pain O
, O
metatarsalgia O
, O
hammertoes O
and O
clawtoes O
, O
bunions O
, O
hallux O
rigidus O
, O
corns O
and O
calluses O
, O
nail O
pathologies O
, O
arthritis O
, O
and O
neuropathies O
. O

Liver O
dysfunction O
in O
the O
presence O
of O
different O
adverse O
reactions O
presented O
with O
a O
higher O
activity O
in O
the O
blood O
serum O
of O
indicator O
liver O
enzymes O
and O
its O
impaired O
protein O
- O
forming O
function O
. O

Coenzyme O
Q10 O
: O
blood O
levels O
and O
metabolic O
demand O
. O

The O
CT O
characteristics O
are O
discussed O
and O
the O
recent O
literature O
is O
reviewed O
. O

Unfortunately O
, O
these O
preservatives O
may O
also O
interfere O
with O
microbiological O
assays O
used O
to O
determine O
product O
sterility O
or O
bioburden O
levels O
. O

In O
26 O
patients O
with O
angina O
pectoris O
, O
the O
changes O
of O
LVEF O
, O
LVESV O
and O
PSP O
/ O
LVESV O
were O
more O
sensitive O
for O
the O
detection O
of O
exercise O
- O
induced O
ischemia O
than O
the O
appearance O
of O
chest O
pain O
and O
the O
changes O
of O
ECG O
. O

In O
both O
groups O
there O
were O
5 O
management O
failure O
of O
therapy O
, O
so O
that O
alternative O
medication O
or O
a O
cesarean O
section O
lead O
to O
delivery O
. O

Serum O
Fibrin I-GENE
Degradation I-GENE
Products I-GENE
( O
FDP I-GENE
) O
were O
determined O
in O
50 O
oral O
cancer O
patients O
and O
50 O
normal O
individuals O
prior O
to O
any O
kind O
of O
treatment O
. O

The O
uteroglobin I-GENE
promoter I-GENE
contains O
a O
noncanonical O
estrogen O
responsive O
element O
. O

Prostaglandin O
synthesis O
inhibitors O
have O
been O
shown O
to O
delay O
healing O
of O
bone O
and O
this O
has O
led O
to O
limitations O
on O
their O
use O
clinically O
in O
some O
situations O
. O

The O
inspiratory O
oxygen O
concentration O
needed O
( O
FiO2 O
) O
and O
the O
Horowitz O
quotient O
differed O
in O
a O
highly O
significant O
manner O
beginning O
on O
the O
1st O
day O
after O
trauma O
. O

The O
corn O
and O
mineral O
oil O
emulsions O
were O
almost O
as O
effective O
as O
milk O
but O
less O
effective O
than O
sucrose O
( O
0 O
. O
3M O
) O
in O
stimulating O
ingestion O
. O

Significance O
of O
thin O
glomerular O
basement O
membranes O
in O
hematuric O
children O
. O

Significance O
of O
cytokine O
production O
and O
adhesion O
molecules O
in O
malarial O
immunopathology O
. O

The O
former O
procedure O
is O
economical O
but O
complicated O
, O
whereas O
the O
latter O
is O
simple O
and O
labour O
- O
saving O
, O
but O
a O
special O
ultrafiltration O
tube O
is O
required O
. O

Simple O
method O
for O
determination O
of O
the O
cephalosporin O
DQ O
- O
2556 O
in O
biological O
fluids O
by O
high O
- O
performance O
liquid O
chromatography O
. O

Since O
one O
group O
of O
adolescents O
more O
difficult O
to O
influence O
are O
those O
whose O
parents O
smoke O
, O
parental O
involvement O
in O
smoking O
prevention O
may O
be O
a O
powerful O
enhancer O
. O

Further O
research O
is O
recommended O
to O
identify O
the O
coping O
styles O
associated O
with O
the O
high O
EE O
/ O
low O
EE O
research O
classification O
. O

Staining O
with O
IF O
MoAB O
alone O
of O
BAL O
fluid O
only O
seemed O
to O
be O
even O
more O
sensitive O
than O
silver O
methenamine O
staining O
of O
BAL O
, O
TBB O
and O
brushing O
material O
. O

Ultrastructural O
and O
morphometric O
study O
of O
the O
myeloid O
parenchyma O
cells O
of O
mice O
prior O
and O
after O
X O
- O
ray O
exposure O

Using O
an O
audiotape O
cassette O
and O
headphones O
the O
duration O
of O
the O
hallucinations O
decreased O
significantly O
. O

The O
mean O
change O
in O
HbA1 I-GENE
, O
adjusted O
for O
the O
initial O
value O
, O
was O
- O
0 O
. O
4 O
% O
in O
the O
experimental O
and O
+ O
0 O
. O
5 O
% O
in O
the O
control O
group O
( O
p O
less O
than O
0 O
. O
05 O
). O

Effect O
of O
biliary O
obstruction O
and O
cholangitis O
on O
serum I-GENE
SPan I-GENE
- I-GENE
1 I-GENE
level O

Very O
good O
accuracy O
( O
r O
greater O
than O
0 O
. O
9 O
) O
was O
found O
when O
except O
comparing O
H O
* O
2 O
with O
the O
other O
machine O
and O
the O
reference O
methods O
, O
except O
for O
MCHCH O
and O
basophil O
count O
. O

The O
second O
part O
of O
this O
paper O
shows O
some O
medical O
applications O
of O
these O
two O
aspects O
of O
NMR O
, O
with O
help O
of O
some O
examples O
, O
taken O
from O
the O
literature O
, O
according O
to O
what O
is O
concerned O
with O
endocrinology O
. O

Interlimb O
coordination O
during O
fictive O
locomotion O
in O
the O
thalamic O
cat O
. O

Antileukoproteinase I-GENE
( O
ALP I-GENE
) O
is O
a O
low O
mol O
wt O
mucosal O
secretory O
protein O
which O
, O
in O
human O
tissues O
, O
inhibits O
the O
activities O
of O
the O
neutral O
serine I-GENE
lysosomal I-GENE
proteinases I-GENE
elastase I-GENE
and O
cathepsin I-GENE
- I-GENE
G I-GENE
. O

By O
introducing O
a O
series O
of O
deletions O
in O
the O
vimentin I-GENE
promoter O
, O
we O
further O
restrict O
these O
sequences O
to O
30 O
base O
pairs O
, O
located O
between O
241 O
and O
210 O
base O
pairs O
upstream O
of O
the O
mRNA O
cap O
site O
. O

In O
particular O
, O
71 O
and O
69 O
% O
amino O
acid O
sequence O
similarities O
were O
identified O
with O
hsp70 I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
and I-GENE
Bacillus I-GENE
megaterium I-GENE
, O
respectively O
. O

No O
causal O
relations O
may O
be O
inferred O
from O
the O
correlation O
between O
the O
level O
of O
trapezius O
activity O
and O
complaints O
, O
though O
it O
indicates O
that O
individual O
, O
inexpedient O
muscle O
activity O
patterns O
may O
constitute O
an O
important O
risk O
factor O
for O
development O
of O
musculo O
- O
skeletal O
complaints O
. O

All O
89 O
participating O
household O
members O
were O
anti I-GENE
- I-GENE
HIV I-GENE
seronegative O
, O
and O
78 O
who O
were O
tested O
were O
serum I-GENE
p24 I-GENE
antigen I-GENE
negative O
. O

Analysis O
with O
additional O
anti O
- O
peptide O
antibodies O
specific O
for O
alpha I-GENE
, I-GENE
beta I-GENE
, I-GENE
or I-GENE
gamma I-GENE
PKC I-GENE
indicated O
that O
all O
three O
types O
of O
PKC I-GENE
are O
expressed O
in O
JK O
cells O
; O
however O
, O
JKPE O
cells O
lost O
a O
major O
approximately O
82 O
kDa O
immunoreactive O
cytosolic O
protein O
detectable O
with O
anti I-GENE
- I-GENE
PKC I-GENE
alpha I-GENE
antibody I-GENE
. O

To O
those O
of O
us O
who O
are O
not O
satisfied O
with O
the O
present O
outlook O
there O
is O
much O
to O
be O
investigated O
and O
much O
to O
be O
contributed O
. O

To O
determine O
the O
effects O
on O
the O
pulmonary O
barrier O
of O
several O
surface O
active O
agents O
, O
a O
series O
of O
metered O
dose O
inhalers O
( O
MDIs O
) O
was O
prepared O
and O
used O
to O
dose O
aerosolized O
surfactant O
to O
the O
airways O
of O
isolated O
perfused O
rat O
lungs O
. O

The O
beta O
chain O
contains O
five O
potential O
N O
- O
linked O
glycosylation O
sites O
, O
and O
endoglycosidase I-GENE
digestion O
suggested O
that O
the O
beta O
chain O
contained O
multiple O
complex O
carbohydrate O
side O
chains O
. O

The O
therapeutic O
protocole O
used O
at O
the O
Gustave O
Roussy O
Institute O
for O
invasive O
epithelioma O
of O
the O
uterine O
cervix O
rests O
, O
for O
limited O
forms O
( O
T1B O
- O
T2 O
proximal O
), O
on O
combined O
radiology O
and O
surgery O
. O

Thyrotropin I-GENE
- O
induced O
expression O
of O
a O
gene O
for O
a O
ribosomal I-GENE
protein I-GENE
related O
to O
the O
trk I-GENE
oncogene I-GENE
. O

The O
introns O
are O
1 O
. O
6 O
- O
1 O
. O
9 O
kbp O
long O
. O

After O
an O
initial O
titration O
period O
and O
adjustment O
of O
the O
therapeutic O
dose O
, O
the O
individual O
doses O
were O
from O
21 O
to O
500 O
micrograms O
/ O
24 O
hrs O
( O
mean O
160 O
micrograms O
/ O
24 O
hrs O
). O

In O
the O
first O
series O
of O
experiments O
, O
Sprague O
- O
Dawley O
male O
rats O
were O
implanted O
unilaterally O
with O
guide O
cannulas O
aimed O
at O
the O
lateral O
ventricle O
. O

Use O
of O
Selenastrum O
capricornutum O
and O
Microfeast O
as O
food O
for O
Daphnia O
pulex O
. O

The O
persistence O
of O
members O
of O
the O
prostigmatid O
families O
Tydeidae O
, O
Nanorchestidae O
and O
Tarsonemidae O
in O
the O
moisture O
- O
deficient O
90 O
%- O
concentration O
treatments O
supports O
previous O
evidence O
of O
adaptations O
to O
low O
- O
water O
- O
content O
habitats O
. O

To O
define O
the O
mechanism O
responsible O
for O
the O
loss O
of O
transcription O
elongation O
blockage O
and O
resulting O
c I-GENE
- I-GENE
myc I-GENE
deregulation O
in O
Burkitt O
' O
s O
lymphoma O
, O
we O
analyzed O
transcription O
patterns O
after O
transfer O
of O
normal O
and O
Burkitt O
' O
s O
lymphoma O
c I-GENE
- I-GENE
myc I-GENE
alleles O
into O
murine O
cells O
and O
Xenopus O
oocyte O
germinal O
vesicles O
. O

Erythrocyte O
protoporphyrin O
concentration O
increased O
significantly O
( O
P O
less O
than O
0 O
. O
05 O
) O
by O
14 O
days O
in O
dogs O
fed O
the O
basal O
diet O
, O
and O
remained O
significantly O
high O
relative O
to O
that O
in O
dogs O
of O
the O
other O
dietary O
groups O
for O
the O
remainder O
of O
the O
study O
. O

The O
coding O
sequences O
of O
the O
Crry I-GENE
gene I-GENE
encompass O
over O
25 O
kb O
of O
DNA O
, O
whereas O
the O
Crry I-GENE
- O
ps I-GENE
sequences O
are O
included O
within O
a O
single O
5 I-GENE
. I-GENE
6 I-GENE
- I-GENE
kb I-GENE
Eco I-GENE
- I-GENE
R1 I-GENE
fragment I-GENE
. O

The O
genomic O
and O
transcriptional O
complexity O
of O
the O
Crry I-GENE
and O
Crry I-GENE
- O
ps I-GENE
genes O
. O

From O
an O
RNK O
- O
16 O
lambda O
- O
gt11 O
library O
, O
we O
have O
isolated O
and O
sequenced O
a O
novel O
cDNA O
rat I-GENE
NK I-GENE
cell I-GENE
protease I-GENE
1 I-GENE
( O
RNKP I-GENE
- I-GENE
1 I-GENE
) O
that O
has O
characteristics O
unique O
to O
serine I-GENE
proteases I-GENE
. O

The O
induction O
of O
RNKP I-GENE
- I-GENE
1 I-GENE
expression O
in O
the O
Con I-GENE
A I-GENE
- O
cultured O
spleen O
cells O
is O
accompanied O
by O
increases O
in O
both O
NK O
and O
lymphokine O
- O
activated O
killer O
lymphocyte O
activities O
. O

The O
paper O
is O
concerned O
with O
the O
data O
on O
change O
in O
the O
blood O
level O
of O
ACTH I-GENE
, O
STH I-GENE
, O
TSH I-GENE
, O
cortisol O
, O
T3 O
, O
insulin I-GENE
, O
C I-GENE
- I-GENE
peptide I-GENE
during O
a O
25 O
- O
minute O
session O
of O
respiration O
using O
a O
gaseous O
hypoxic O
mixture O
with O
10 O
% O
oxygen O
( O
GHM O
- O
10 O
). O

The O
abscess O
was O
debrided O
and O
the O
septum O
was O
patched O
with O
a O
single O
layer O
of O
autologous O
pericardium O
. O

In O
18 O
% O
lymphography O
was O
clearly O
positive O
and O
CT O
negative O
. O

The O
present O
study O
examined O
the O
effect O
of O
intensity O
, O
rate O
, O
and O
polarity O
on O
the O
spectral O
content O
of O
ABRs O
of O
15 O
normal O
- O
hearing O
subjects O
. O

Similar O
memory O
impairments O
found O
in O
medial O
septal O
- O
vertical O
diagonal O
band O
of O
Broca O
and O
nucleus O
basalis O
lesioned O
rats O
: O
are O
memory O
defects O
induced O
by O
nucleus O
basalis O
lesions O
related O
to O
the O
degree O
of O
non O
- O
specific O
subcortical O
cell O
loss O
? O
The O
function O
of O
nucleus O
basalis O
( O
NB O
) O
and O
medial O
septal O
- O
vertical O
diagonal O
band O
of O
Broca O
( O
MS O
- O
VDBB O
) O
in O
a O
place O
navigation O
task O
requiring O
reference O
memory O
was O
investigated O
. O

Studies O
also O
have O
alluded O
to O
a O
relationship O
between O
the O
MSMR O
cyst O
and O
certain O
signs O
or O
symptoms O
of O
disease O
. O

The O
BAL O
- O
to O
- O
plasma O
specific O
activity O
of O
urea O
was O
about O
twice O
that O
of O
Na O
+, O
indicating O
that O
urea O
diffused O
into O
the O
ELF O
more O
rapidly O
than O
Na O
+ O
during O
the O
70 O
s O
that O
elapsed O
between O
the O
time O
the O
radioactive O
urea O
and O
Na O
+ O
were O
injected O
into O
the O
circulation O
and O
the O
time O
when O
lavage O
was O
complete O
. O

The O
kappa O
coefficient O
of O
agreement O
between O
the O
Patho O
Dx O
Kit O
and O
the O
standard O
method O
was O
0 O
. O
958 O
. O

Senior O
systems O
-- O
45 O
; O
Mental O
health O
and O
illness O
in O
old O
age O
-- O
3 O
. O

When O
normalized O
for O
imaging O
time O
, O
all O
parameters O
are O
significantly O
higher O
with O
RASE O
, O
with O
a O
C O
/ O
A O
per O
unit O
time O
that O
was O
338 O
% O
higher O
. O

Patients O
with O
acute O
myocardial O
infarction O
had O
higher O
plasma O
concentrations O
of O
neutrophil I-GENE
elastase I-GENE
and O
the O
non O
- O
peroxide O
diene O
conjugated O
isomer O
of O
linoleic O
acid O
than O
normal O
volunteers O
or O
patients O
with O
stable O
ischaemic O
heart O
disease O
. O

Determination O
of O
three O
- O
dimensional O
imaging O
properties O
of O
a O
light O
microscope O
system O
. O

The O
cis O
- O
acting O
element O
, O
identified O
as O
CACGTGACCCG O
, O
is O
located O
34 O
bp O
upstream O
from O
the O
transcription O
initiation O
site O
, O
and O
contains O
the O
core O
sequence O
of O
the O
upstream O
promoter O
sequence O
of O
Ad2MLP I-GENE
. O

The O
clinical O
relevance O
of O
these O
findings O
is O
strengthened O
by O
the O
observation O
that O
similar O
results O
were O
obtained O
when O
P O
. O
HCl O
was O
given O
by O
the O
intravenous O
route O
. O

TMBr I-GENE
- I-GENE
1 I-GENE
is O
identical O
to O
striated I-GENE
muscle I-GENE
alpha I-GENE
- I-GENE
tropomyosin I-GENE
from O
amino O
acids O
1 O
through O
258 O
but O
contains O
a O
novel O
COOH O
- O
terminal O
region O
from O
amino O
acids O
259 O
through O
281 O
. O

The O
procedure O
has O
been O
applied O
to O
three O
materials O
: O
particle O
board O
with O
carpet O
; O
gypsum O
board O
with O
wallpaper O
; O
and O
plywood O
with O
polyurethane O
lacquer O
, O
for O
which O
the O
steady O
- O
state O
emission O
factors O
( O
mg O
m O
- O
2 O
h O
- O
1 O
) O
of O
several O
compounds O
are O
given O
. O

Intron O
1 O
is O
6 O
. O
5 O
kb O
long O
, O
and O
the O
minimal O
sizes O
of O
introns O
2 O
and O
3 O
are O
estimated O
to O
be O
32 O
kb O
each O
. O

After O
4 O
h O
, O
lesions O
in O
the O
secretory O
part O
of O
the O
stomach O
were O
scored O
and O
mucosal O
prostaglandin O
E2 O
synthesis O
was O
determined O
by O
the O
ex O
vivo O
prostaglandin O
generation O
technique O
. O

Comparison O
of O
transmembrane O
and O
cytoplasmic O
domains O
to O
a O
third O
cell O
- O
surface O
proteoglycan O
, O
48K5 I-GENE
from O
human O
lung O
fibroblasts O
( O
Marynen O
, O
P O
., O
Zhang O
, O
J O
., O
Cassiman O
, O
J O
., O
Vanden O
Berghe O
, O
H O
., O
and O
David O
, O
C O
. O

Approximately O
65 O
% O
of O
the O
total O
cAMP I-GENE
- I-GENE
dependent I-GENE
phosphotransferase I-GENE
activity O
is O
recovered O
in O
particulate O
fractions O
of O
homogenates O
prepared O
from O
asynchronous O
populations O
of O
C O
. O
elegans O
. O

High O
levels O
of O
C I-GENE
subunits I-GENE
are O
observed O
in O
several O
subsequent O
larval O
and O
adult O
stages O
of O
development O
. O

A O
second O
, O
novel O
C O
subunit O
( O
CeCAT O
alpha O
', O
374 O
residues O
) O
has O
a O
unique O
56 O
- O
residue O
carboxyl O
- O
terminal O
region O
that O
is O
generated O
by O
the O
alternative O
splicing O
of O
the O
C I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
. O

The O
alternative O
exon O
introduces O
the O
novel O
carboxyl O
terminus O
and O
a O
new O
translation O
stop O
signal O
, O
while O
simultaneously O
converting O
the O
coding O
sequence O
for O
40 O
carboxyl O
- O
terminal O
residues O
in O
CeCAT I-GENE
alpha I-GENE
into O
3 O
'- O
untranslated O
nucleotides O
. O

French O
, O
M O
. O

Slowly O
adapting O
type O
I O
mechanoreceptor O
discharge O
as O
a O
function O
of O
dynamic O
force O
versus O
dynamic O
displacement O
of O
glabrous O
skin O
of O
raccoon O
and O
squirrel O
monkey O
hand O
. O

Methods O
used O
include O
Cobb O
angle O
and O
a O
segmental O
evaluation O
( O
T7 O
- O
T12 O
) O
of O
each O
of O
convex O
and O
concave O
rib O
- O
vertebra O
angles O
( O
RVAs O
), O
rib O
- O
vertebra O
angle O
differences O
( O
RVADs O
), O
vertebral O
rotation O
, O
tilt O
and O
displacement O
. O

Plasma O
lecithin I-GENE
/ I-GENE
cholesterol I-GENE
acyltransferase I-GENE
( O
LCAT I-GENE
) O
activity O
in O
multiple O
- O
organ O
donors O
: O
a O
predictor O
of O
allograft O
viability O
in O
clinical O
liver O
transplantation O
. O

Lars O
has O
AIDS O
-- O
a O
more O
dignified O
life O
with O
care O
at O
home O
. O

Axillary O
nodal O
status O
, O
tumour O
progesterone I-GENE
receptor I-GENE
status O
, O
and O
season O
of O
tumour O
detection O
significantly O
influenced O
survival O
in O
both O
older O
( O
greater O
than O
50 O
yrs O
) O
and O
younger O
( O
less O
than O
50 O
yrs O
) O
patients O
. O

The O
application O
of O
these O
microelectrodes O
to O
the O
measurement O
of O
rapid O
, O
transient O
changes O
in O
retinal O
[ O
K O
+] O
o O
is O
presented O
. O

Expression O
, O
cellular O
localization O
and O
in O
vitro O
transcription O
studies O
establish O
that O
cloned I-GENE
hUBF I-GENE
encodes O
a O
nucleolar O
factor O
that O
binds O
specifically O
to O
the O
upstream O
control O
element O
and O
core O
of O
the O
rRNA O
gene O
promoter O
to O
activate O
transcription O
in O
a O
binding O
site O
- O
dependent O
manner O
. O

Combining O
multiple O
laboratory O
studies O
may O
be O
of O
value O
in O
predetermining O
the O
eventual O
outcome O
in O
near O
- O
drowning O
. O

Accumulations O
of O
Tl O
+ O
1 O
( O
202Tl O
label O
) O
were O
6 O
times O
those O
for O
Ga O
or O
In O
in O
the O
brain O
and O
muscles O
, O
and O
. O
1 O
times O
in O
plasma O
. O

There O
was O
a O
gradual O
increase O
in O
the O
myocyte O
diameter O
according O
to O
age O
in O
the O
biopsy O
and O
autopsy O
specimens O
. O

Despite O
the O
absence O
of O
exercise O
- O
induced O
asthma O
( O
EIA O
) O
while O
breathing O
WH O
air O
, O
asthmatic O
patients O
still O
had O
significantly O
higher O
mean O
GH O
increments O
than O
normal O
subjects O
( O
9 O
. O
2 O
vs O
2 O
. O
3 O
ng O
/ O
ml O
, O
P O
less O
than O
0 O
. O
05 O
). O

The O
afferents O
' O
phase O
of O
response O
was O
unmodified O
by O
electrical O
EVS O
stimulation O
. O

Solving O
an O
age O
old O
problem O
. O

The O
distribution O
of O
their O
fibrinogen I-GENE
levels O
was O
Gaussian O
, O
but O
more O
wide O
- O
based O
than O
the O
distribution O
of O
our O
normal O
controls O
. O

In O
a O
stepwise O
logistic O
regression O
analysis O
of O
SPT O
and O
RAST O
data O
, O
the O
occurrence O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to I-GENE
P I-GENE
. I-GENE
orbiculare I-GENE
had O
the O
highest O
explanatory O
value O
for O
current O
eczema O
. O

The O
examination O
was O
focused O
on O
assessment O
of O
different O
types O
of O
drusen O
, O
on O
evaluation O
of O
the O
development O
and O
incidence O
of O
risk O
factors O
leading O
to O
complications O
and O
loss O
of O
central O
vision O
. O

They O
were O
then O
subjected O
to O
whole O
- O
body O
heat O
stress O
( O
water O
- O
perfused O
suits O
), O
and O
the O
3 O
minutes O
of O
LBNP O
was O
repeated O
. O

An O
NF1 I-GENE
- I-GENE
related I-GENE
vitellogenin I-GENE
activator I-GENE
element I-GENE
mediates O
transcription O
from O
the O
estrogen O
- O
regulated O
Xenopus I-GENE
laevis I-GENE
vitellogenin I-GENE
promoter I-GENE
. O

A O
poor O
correlation O
was O
also O
observed O
between O
PbB O
and O
ALAD I-GENE
activity O
of O
the O
stearate O
workers O
. O

At O
the O
carboxyl O
terminus O
, O
deletion O
as O
far O
as O
residue O
388 O
did O
not O
affect O
in O
vitro O
TRF I-GENE
. I-GENE
C I-GENE
assembly O
, O
although O
trans O
- O
activating O
activity O
was O
abolished O
. O

The O
effects O
of O
mean O
luminance O
were O
also O
measured O
and O
a O
general O
expression O
that O
would O
take O
them O
into O
account O
was O
derived O
. O

Effect O
of O
hyperglycemia O
on O
pain O
threshold O
in O
alloxan O
- O
diabetic O
rats O
. O

We O
have O
synthesized O
[ O
7 O
, O
7 O
- O
2H2 O
]- O
19 O
- O
OHA O
with O
high O
deuterium O
content O
and O
, O
together O
with O
[ O
7 O
, O
7 O
- O
2H2 O
] O
A O
and O
[ O
9 O
, O
11 O
- O
2H2 O
] O
estrone O
( O
E1 O
), O
have O
developed O
a O
quantitative O
assay O
of O
serum O
level O
19 O
- O
OHA O
, O
A O
, O
and O
E1 O
using O
the O
gas O
chromatography O
/ O
mass O
spectrometry O
- O
mass O
fragmentography O
method O
to O
monitor O
individual O
subjects O
throughout O
pregnancy O
. O

Sequence O
analysis O
of O
these O
genes O
and O
their O
surrounding O
sequences O
are O
presented O
and O
compared O
with O
other O
known O
tRNA O
genes O
from O
plant O
mitochondria O
. O

Experiments O
were O
performed O
in O
which O
brain O
- O
stem O
auditory O
- O
evoked O
responses O
( O
BAERs O
) O
were O
elicited O
by O
two O
types O
of O
pseudorandom O
pulse O
trains O
: O
maximum O
length O
sequences O
( O
MLS O
) O
and O
Legendre O
sequences O
( O
LGS O
). O

Since O
the O
UfAP I-GENE
and O
UTMP I-GENE
share O
many O
biosynthetic O
and O
structural O
features O
that O
include O
site O
of O
biosynthesis O
in O
the O
endometrium O
, O
P4 O
- O
responsiveness O
, O
the O
presence O
of O
the O
mannose O
6 O
- O
phosphate O
lysosomal O
recognition O
marker O
, O
and O
considerable O
sequence O
similarity O
, O
the O
UfAP I-GENE
and O
the O
UTMP I-GENE
may O
have O
homologous O
function O
which O
for O
both O
still O
remains O
obscure O
. O

Fifteen O
light O
for O
dates O
infants O
and O
their O
placentae O
were O
compared O
to O
15 O
well O
- O
grown O
infants O
and O
their O
placentae O
. O

Treating O
renal O
anaemia O
with O
recombinant O
human O
erythropoietin I-GENE
. O

The O
pseudolymphoma O
syndrome O
is O
a O
reversible O
reactive O
condition O
consisting O
of O
fever O
, O
lymphadenopathy O
and O
generalized O
rash O
. O

In O
the O
local O
geomagnetic O
field O
, O
the O
animals O
preferred O
the O
SE O
- O
sector O
. O

In O
the O
artificial O
lung O
, O
like O
in O
the O
natural O
lung O
and O
peripheral O
tissues O
, O
gas O
exchanges O
depend O
on O
several O
parameters O
: O
blood O
inlet O
conditions O
, O
blood O
flow O
rate O
, O
temperature O
, O
composition O
of O
the O
gas O
mixture O
used O
for O
ventilation O
, O
blood O
tissue O
perfusion O
, O
O2 O
consumption O
, O
etc O
. O

Mean O
(+/- O
SE O
) O
measurements O
of O
clearance O
( O
24 O
. O
5 O
+/- O
2 O
. O
06 O
v O
26 O
. O
5 O
+/- O
2 O
. O
05 O
mL O
/ O
min O
/ O
m2 O
), O
half O
- O
life O
( O
5 O
. O
7 O
+/- O
0 O
. O
5 O
v O
6 O
. O
4 O
+/- O
0 O
. O
5 O
hours O
), O
and O
volume O
of O
distribution O
( O
12 O
. O
4 O
+/- O
1 O
. O
1 O
v O
13 O
. O
7 O
+/- O
1 O
. O
6 O
L O
/ O
m2 O
) O
were O
not O
significantly O
different O
in O
patients O
with O
jaundice O
when O
compared O
with O
controls O
. O

Attitudes O
were O
found O
to O
be O
multidimensional O
, O
with O
similar O
dimensions O
being O
identified O
in O
both O
samples O
. O

We O
conclude O
that O
DNA O
ploidy O
is O
a O
major O
objective O
prognostic O
factor O
and O
therapeutic O
determinant O
for O
endometrial O
carcinoma O
. O

A O
semiautomatic O
digital O
system O
( O
Videoplan O
2 O
) O
was O
used O
. O

Environmental O
factors O
were O
more O
important O
in O
the O
older O
cohorts O
( O
perhaps O
because O
of O
less O
reliable O
recall O
). O

Dopamine O
SERS O
spectra O
from O
these O
electrodes O
are O
similar O
to O
those O
obtained O
at O
uncoated O
electrodes O
. O

These O
findings O
indicate O
that O
hypergastrinemia O
induced O
by O
surgical O
removal O
of O
acid O
- O
producing O
mucosa O
in O
the O
rat O
has O
the O
same O
effects O
on O
oxyntical O
mucosal I-GENE
HDC I-GENE
activity O
, O
histamine O
concentration O
and O
ECL O
cell O
density O
as O
hypergastrinemia O
induced O
by O
continuous O
gastrin I-GENE
infusion O
or O
by O
long O
- O
term O
treatment O
with O
effective O
antisecretagogues O
. O

Basing O
on O
experimental O
toxicity O
research O
it O
was O
established O
that O
, O
out O
of O
50 O
atmosphere O
metal O
corrosion O
inhibitors O
, O
some O
14 O
per O
cent O
were O
found O
extremely O
hazardous O
, O
42 O
per O
cent O
-- O
of O
high O
level O
hazardous O
, O
33 O
percent O
-- O
of O
moderate O
and O
11 O
per O
cent O
-- O
of O
low O
hazardous O
. O

The O
order O
of O
the O
helicase I-GENE
motif I-GENE
and O
the O
nsP3 I-GENE
homology I-GENE
region I-GENE
in O
the O
RUB O
genome O
is O
reversed O
with O
respect O
to O
the O
alphavirus O
genome O
indicating O
that O
a O
genetic O
rearrangement O
has O
occurred O
during O
the O
evolution O
of O
these O
viruses O
. O

The O
results O
suggest O
followings O
-- O
1 O
) O
both O
eosinophils O
and O
neutrophils O
participate O
in O
hypersecretion O
of O
type O
Ib O
in O
atopic O
cases O
, O
and O
only O
eosinophils O
in O
non O
- O
atopic O
cases O
. O

There O
were O
5 O
treatments O
: O
control O
( O
C O
); O
a O
wooden O
surround O
in O
one O
rear O
corner O
of O
the O
cage O
( O
S O
); O
a O
fiberglass O
rollaway O
hollow O
in O
one O
rear O
corner O
of O
the O
cage O
( O
H O
); O
a O
hollow O
and O
a O
surround O
( O
H O
/ O
S O
); O
a O
nest O
box O
attached O
to O
the O
back O
of O
the O
cage O
, O
containing O
a O
hollow O
( O
N O
). O

While O
no O
significant O
differences O
in O
the O
tensile O
responses O
or O
failure O
characteristics O
were O
noted O
for O
irradiated O
and O
nonirradiated O
grafts O
in O
the O
drip O
, O
in O
the O
bath O
environment O
the O
nonirradiated O
tissues O
had O
greater O
strength O
and O
modulus O
. O

The O
patient O
was O
treated O
with O
benzathine O
penicillin O
, O
2 O
, O
400 O
, O
000 O
U O
weekly O
for O
three O
weeks O
. O

A O
consensus O
binding O
site O
for O
the O
transcription O
factor O
SP1 I-GENE
was O
identified O
in O
intron O
As O
downstream O
of O
the O
proenkephalin I-GENE
germ I-GENE
cell I-GENE
cap I-GENE
site I-GENE
region I-GENE
. O

This O
proposed O
method O
is O
similar O
in O
principle O
to O
the O
sets O
technique O
but O
is O
shown O
to O
have O
much O
better O
expected O
time O
to O
alarm O
properties O
. O

The O
effects O
on O
reflex O
latencies O
but O
not O
on O
paCO2 O
or O
pHa O
were O
blocked O
by O
naloxone O
( O
2 O
mg O
/ O
kg O
), O
and O
were O
not O
present O
in O
morphine O
- O
tolerant O
animals O
. O

Of O
the O
remaining O
seven O
, O
five O
reacted O
either O
with O
immediate O
and O
strong O
symptoms O
or O
had O
spontaneously O
reduced O
gluten I-GENE
intake O
, O
or O
had O
an O
acquired O
IgA I-GENE
deficiency O
. O

Drug O
and O
personnel O
costs O
were O
reduced O
when O
batch O
manufacturing O
with O
40 O
- O
mL O
multidose O
vials O
was O
compared O
with O
extemporaneous O
compounding O
with O
unit O
- O
dose O
vials O
. O

Changes O
in O
prognosis O
of O
twin O
births O
over O
20 O
years O
. O

Dermal O
toxicity O
and O
carcinogenicity O
of O
4 O
- O
vinyl O
- O
1 O
- O
cyclohexene O
diepoxide O
in O
Fischer O
rats O
and O
B6C3F1 O
mice O
. O

Per O
kg O
FFM O
SMR O
was O
almost O
restored O
to O
baseline O
values O
for O
the O
EX O
group O
, O
whereas O
the O
non O
- O
exercising O
subjects O
still O
showed O
depressed O
values O
( O
EX O
3 O
. O
7 O
per O
cent O
and O
D O
+ O
DE O
15 O
. O
8 O
per O
cent O
lower O
than O
before O
treatment O
; O
P O
less O
than O
0 O
. O
05 O
). O

MK O
- O
927 O
: O
a O
topically O
active O
ocular O
hypotensive O
carbonic I-GENE
anhydrase I-GENE
inhibitor O
. O

PCR O
- O
derived O
fragments O
were O
used O
as O
probes O
for O
the O
isolation O
of O
the O
U3 I-GENE
snRNA I-GENE
genes I-GENE
from O
a O
genomic O
library O
of O
Arabidopsis O
. O

In O
addition O
serum I-GENE
IgE I-GENE
concentrations O
were O
not O
statistically O
different O
. O

The O
findings O
suggest O
that O
, O
although O
iodine O
deficiency O
is O
the O
most O
probable O
cause O
of O
goiter O
among O
immigrants O
of O
the O
1928 O
cohort O
, O
where O
the O
native O
population O
is O
concerned O
( O
both O
men O
and O
women O
), O
some O
other O
goitrogenic O
factor O
( O
s O
) O
must O
be O
involved O
. O

The O
transcriptional O
unit O
spans O
a O
chromosomal O
region O
of O
about O
55 O
kilobase O
pairs O
( O
kbp O
). O

100 O
of O
the O
patients O
who O
would O
have O
died O
survive O
. O

Co O
- O
administration O
of O
5FU O
, O
angiotensin I-GENE
II I-GENE
and O
microspheres O
via O
the O
hepatic O
artery O
may O
reduce O
drug O
exposure O
in O
the O
systemic O
compartment O
and O
therefore O
may O
increase O
the O
therapeutic O
ratio O
of O
5FU O
administration O
via O
the O
hepatic O
artery O
. O

The O
effects O
of O
tap O
( O
TW O
) O
or O
carbonated O
( O
CW O
) O
water O
on O
arterial O
pH O
, O
partial O
pressure O
of O
carbon O
dioxide O
( O
PCO2 O
) O
and O
plasma O
lactate O
were O
determined O
in O
heat O
- O
stressed O
broilers O
. O

Transient O
expression O
of O
human I-GENE
and I-GENE
chicken I-GENE
progesterone I-GENE
receptors I-GENE
does O
not O
support O
alternative O
translational O
initiation O
from O
a O
single O
mRNA O
as O
the O
mechanism O
generating O
two O
receptor O
isoforms O
. O

In O
contrast O
, O
2 O
, O
397 O
( O
74 O
%) O
had O
one O
or O
more O
risk O
factors O
( O
not O
low O
risk O
); O
of O
these O
, O
5 O
. O
3 O
% O
died O
in O
6 O
weeks O
( O
p O
less O
than O
0 O
. O
001 O
). O

The O
Community O
Adjustment O
Scale O
provided O
outcome O
data O
related O
to O
the O
subjects O
' O
degree O
of O
productivity O
, O
ability O
to O
maintain O
close O
relationships O
, O
and O
presence O
/ O
absence O
of O
symptomatology O
an O
average O
of O
32 O
years O
after O
initial O
admission O
. O

However O
, O
at O
18 O
months O
of O
age O
, O
significantly O
higher O
levels O
of O
IgG1 I-GENE
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
of O
IgG4 I-GENE
( O
P O
less O
than O
0 O
. O
01 O
) O
were O
found O
in O
infants O
with O
an O
elevated O
IgE I-GENE
( O
greater O
than O
or O
equal O
to O
8 O
. O
0 O
kU O
/ O
l O
) O
than O
in O
those O
with O
a O
lower O
level O
. O

The O
protein O
sequence O
contains O
seven O
potential O
N O
- O
linked O
glycosylation O
sites O
and O
a O
threonine O
/ O
serine O
- O
rich O
region O
which O
is O
a O
potential O
site O
for O
attachment O
of O
O O
- O
linked O
carbohydrate O
. O

Thus O
adaptation O
to O
continuous O
mild O
stress O
has O
a O
potent O
antiarrhythmic O
effect O
which O
occurs O
due O
to O
the O
increased O
vagal O
tone O
. O

The O
eluent O
from O
the O
column O
was O
mixed O
with O
the O
chemiluminescent O
solution O
containing O
lucigenin I-GENE
and O
Triton O
X O
- O
100 O
and O
a O
0 O
. O
28 O
M O
KOH O
solution O
by O
pumps O
and O
monitored O
by O
a O
chemiluminescence O
detector O
. O

On O
histologic O
examination O
the O
cuboidal O
epithelium O
of O
the O
mucous O
membrane O
was O
found O
to O
be O
changed O
into O
columnar O
epithelium O
, O
with O
uneven O
distribution O
of O
enlarged O
nuclei O
in O
the O
vacuolized O
cytoplasm O
. O

These O
results O
suggest O
an O
increased O
risk O
of O
developing O
cancer O
among O
polyp O
patients O
and O
the O
possibility O
of O
prophylactic O
effect O
of O
polypectomy O
against O
subsequent O
cancer O
. O

The O
same O
trend O
was O
noted O
between O
YG O
4 O
. O
5 O
heifers O
and O
YG O
5 O
. O
5 O
steers O
, O
indicating O
a O
sex O
- O
related O
deposition O
of O
seam O
fat O
in O
fed O
cattle O
. O

The O
nucleotide O
sequence O
consists O
of O
48 O
bp O
of O
5 O
'- O
end O
non O
- O
coding O
region O
, O
1695 O
bp O
of O
coding O
region O
and O
212 O
bp O
of O
3 O
'- O
end O
non O
- O
coding O
region O
including O
a O
20 O
bp O
poly O
( O
A O
) O
tail O
. O

Toxicities O
included O
: O
nausea O
/ O
vomiting O
( O
69 O
%), O
headache O
( O
25 O
%), O
chills O
( O
69 O
%), O
pain O
at O
tumor O
sites O
( O
63 O
%), O
hypotension O
( O
31 O
%), O
and O
hypertension O
( O
38 O
%). O

The O
results O
also O
showed O
that O
although O
oyster O
shell O
supplementation O
generally O
increased O
alkaline I-GENE
phosphatase I-GENE
activity O
, O
bone O
mineralization O
was O
relatively O
uninfluenced O
as O
judged O
by O
the O
low O
coefficients O
of O
variation O
( O
CV O
) O
of O
3 O
. O
14 O
- O
3 O
. O
51 O
% O
and O
3 O
. O
39 O
- O
4 O
. O
82 O
% O
for O
calcium O
and O
phosphorus O
content O
in O
the O
femur O
and O
tibia O
respectively O
. O

In O
6 O
of O
24 O
infants O
studied O
( O
27th O
- O
40th O
weeks O
of O
gestation O
), O
acquired O
and O
congenital O
structural O
anomalies O
of O
the O
airways O
were O
detected O
with O
an O
ultrathin O
flexible O
fiberscope O
( O
Olympus O
PF18 O
S O
, O
1 O
. O
8 O
mm O
). O

Fatal O
encephalitis O
in O
a O
patient O
with O
chronic O
graft O
- O
versus O
- O
host O
disease O
. O

Compared O
to O
its O
counterpart O
in O
the O
GPB I-GENE
gene I-GENE
, O
exon O
3 O
of O
the O
GPE I-GENE
gene I-GENE
contains O
several O
point O
mutations O
, O
an O
insertion O
of O
24 O
bp O
, O
and O
a O
stop O
codon O
which O
shortens O
the O
reading O
frame O
. O

Molecular O
cloning O
of O
a O
cDNA O
encoding O
rat I-GENE
NADH I-GENE
- I-GENE
cytochrome I-GENE
b5 I-GENE
reductase I-GENE
and O
the O
corresponding O
gene O
. O

The O
results O
corroborate O
the O
idea O
that O
the O
structure O
of O
relaxation O
curves O
contains O
information O
on O
the O
distance O
scale O
and O
on O
the O
architecture O
of O
the O
pore O
space O
, O
even O
if O
it O
is O
difficult O
to O
extract O
it O
without O
ambiguities O
. O

Serotonin I-GENE
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
binding O
on O
blood O
platelets O
as O
a O
state O
dependent O
marker O
in O
major O
affective O
disorder O
. O

Although O
% O
BF O
was O
correlated O
with O
all O
the O
BMIs O
( O
r O
= O
0 O
. O
60 O
- O
0 O
. O
82 O
), O
applying O
objective O
definitions O
of O
obesity O
based O
on O
BMIs O
or O
% O
BF O
by O
densitometry O
often O
produced O
conflicting O
results O
. O

The O
RF O
values O
correlated O
well O
with O
the O
angiographic O
semiquantitative O
scale O
of O
severity O
of O
aortal O
insufficiency O
( O
r O
= O
0 O
. O
805 O
; O
p O
less O
than O
0 O
. O
001 O
), O
although O
they O
enabled O
the O
authors O
only O
to O
make O
a O
partial O
differentiation O
of O
haemodynamically O
severe O
regurgitations O
and O
mild O
or O
insignificant O
ones O
. O

Promoter O
elements O
include O
an O
atypical O
TATA O
box O
( O
GTTA O
), O
one O
CCAAT O
box O
much O
further O
from O
the O
initiation O
site O
, O
three O
reverse O
compliments O
of O
CCAAT O
( O
ATTGG O
), O
and O
two O
pyrimidine O
- O
rich O
nucleotide O
stretches O
. O

The O
cloned O
genes O
were O
identified O
in O
genetic O
libraries O
by O
hybridization O
screening O
using O
four O
deoxyoligonucleotide O
probes O
which O
corresponded O
to O
the O
partial O
amino O
acid O
sequence O
of O
the O
purified O
enzyme O
. O

The O
pattern O
for O
catalytic O
zinc O
sites O
included O
two O
ligands O
close O
in O
sequence O
, O
a O
sequence O
- O
distant O
ligand O
, O
and O
a O
main O
- O
chain O
hydrogen O
bond O
joining O
two O
ligands O
. O

Results O
of O
the O
long O
- O
term O
observation O
and O
treatment O
of O
patients O
with O
arterial O
hypertension O

Eucaryotic O
transcription O
factors O
that O
stimulate O
RNA I-GENE
polymerase I-GENE
II I-GENE
by O
increasing O
the O
efficiency O
of O
elongation O
of O
specifically O
or O
randomly O
initiated O
RNA O
chains O
have O
been O
isolated O
and O
characterized O
. O

Sprague O
- O
Dawley O
newborn O
rats O
( O
n O
= O
85 O
) O
breathed O
100 O
% O
oxygen O
( O
O2 O
) O
or O
room O
air O
( O
RA O
) O
during O
the O
first O
8 O
days O
of O
life O
, O
and O
then O
RA O
. O

The O
Lm O
increased O
and O
the O
alveoli O
/ O
mm2 O
and O
elastic O
recoil O
pressure O
decreased O
. O

Comparison O
of O
propofol O
and O
thiopentone O
as O
anaesthetic O
agents O
for O
electroconvulsive O
therapy O
. O

In O
Experiment O
II O
, O
as O
performing O
moderate O
supine O
cycling O
( O
55 O
% O
VO2 O
max O
) O
for O
50 O
minutes O
under O
several O
LBNP O
conditions O
in O
5 O
sedentary O
women O
, O
there O
were O
correspondingly O
similar O
changing O
manners O
of O
the O
cardiovascular O
adjustments O
to O
each O
of O
the O
phases O
given O
in O
Experiment O
I O
. O

Commercially O
available O
formulations O
of O
2 O
. O
5 O
% O
and O
5 O
% O
lambdacyhalothrin O
can O
be O
diluted O
either O
with O
water O
for O
ULV O
cold O
aerosol O
space O
- O
spraying O
or O
with O
diesel O
/ O
kerosene O
for O
thermal O
fogging O
at O
recommended O
application O
rates O
of O
0 O
. O
5 O
- O
1 O
g O
ai O
/ O
ha O
for O
mosquito O
control O
and O
2 O
g O
ai O
/ O
ha O
for O
housefly O
control O
. O

Thus O
, O
this O
reading O
frame O
was O
concluded O
to O
encode O
the O
precursor O
of O
mitochondrial I-GENE
fumarase I-GENE
. O

Sequence O
analysis O
indicates O
that O
in O
addition O
to O
an O
ATA O
and O
GC O
box O
, O
this O
region O
contains O
domains O
that O
have O
been O
implicated O
in O
the O
regulation O
of O
other O
muscle O
- O
specific O
genes O
: O
a O
CArG O
box O
at O
- O
91 O
bp O
; O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
binding I-GENE
site I-GENE
homologies O
at O
- O
58 O
, O
- O
535 O
, O
and O
- O
583 O
bp O
; O
and O
a O
muscle O
- O
CAAT O
consensus O
sequence O
at O
- O
394 O
bp O
relative O
to O
the O
cap O
site O
. O

The O
trk I-GENE
- I-GENE
2h I-GENE
oncogene I-GENE
, O
isolated O
from O
the O
human O
breast O
carcinoma O
cell O
line O
MDA O
- O
MB O
231 O
by O
genomic O
DNA O
- O
transfection O
into O
NIH3T3 O
cells O
, O
consists O
of O
the O
trk I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
receptor I-GENE
kinase I-GENE
domain I-GENE
fused O
to O
a O
N O
- O
terminal O
41 O
amino O
acid O
activating O
sequence O
( O
Kozma O
, O
S O
. O
C O
., O
Redmond O
, O
S O
. O
M O
. O
S O
., O
Xiao O
- O
Chang O
, O
F O
., O
Saurer O
, O
S O
. O
M O
., O
Groner O
, O
B O
. O
and O
Hynes O
, O
N O
. O
E O
. O

Antibodies O
raised O
against O
a O
bacterially O
produced O
beta I-GENE
gal I-GENE
- O
trk I-GENE
receptor O
kinase O
fusion O
protein O
recognized O
a O
44 O
kd O
phosphoprotein O
phosphorylated O
on O
serine O
, O
threonine O
and O
tyrosine O
in O
extracts O
of O
trk I-GENE
- I-GENE
2h I-GENE
transformed O
NIH3T3 O
cells O
. O

Since O
very O
recent O
scanning O
- O
deletion O
analysis O
indicates O
that O
there O
is O
a O
critical O
region O
for O
activity O
near O
Cys O
- O
118 O
and O
that O
Cys O
- O
118 O
is O
necessary O
for O
maximal O
activity O
, O
we O
conclude O
that O
the O
Cys O
- O
118 O
residue O
is O
necessary O
for O
proper O
glycosylation O
and O
maximal O
biologic O
activity O
of O
GM I-GENE
- I-GENE
CSF I-GENE
. O

Molecular O
and O
functional O
characterization O
of O
the O
promoter O
of O
ETS2 I-GENE
, O
the O
human O
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
gene O
. O

Information O
about O
immunologic O
drug O
interactions O
is O
needed O
by O
pharmacists O
to O
make O
rational O
drug O
- O
use O
decisions O
. O

Branch O
occlusion O
of O
Heubner O
' O
s O
artery O
, O
or O
perforators O
from O
the O
proximal O
anterior O
or O
middle O
cerebral O
arteries O
were O
the O
posited O
mechanism O
of O
infarction O
. O

All O
ABFI I-GENE
- I-GENE
binding I-GENE
sites I-GENE
, O
regardless O
of O
origin O
, O
provided O
weak O
UAS O
function O
in O
vivo O
when O
examined O
in O
test O
plasmids O
. O

An O
examination O
of O
the O
properties O
of O
sequences O
surrounding O
ARS1 O
left O
open O
the O
possibility O
that O
ABFI I-GENE
enhances O
the O
initiation O
of O
DNA O
replication O
at O
ARS1 O
by O
transcriptional O
activation O
. O

Nonvascular O
ophthalmic O
and O
neurologic O
disorders O
that O
can O
be O
confused O
with O
amaurosis O
fugax O
are O
listed O
, O
and O
an O
algorithm O
for O
evaluation O
( O
which O
includes O
ophthalmic O
examination O
, O
laboratory O
studies O
, O
and O
noninvasive O
carotid O
artery O
studies O
) O
is O
given O
. O

Likewise O
, O
whether O
or O
not O
the O
hypotensive O
action O
of O
converting O
enzyme O
inhibitors O
is O
age O
- O
related O
is O
as O
yet O
unknown O
. O

Polyclonal O
antiserum O
generated O
to O
the O
fusion O
protein O
was O
capable O
of O
detecting O
42 O
- O
and O
46 O
- O
kilodalton O
polypeptides O
from O
virus O
particles O
; O
both O
polypeptides O
were O
also O
shown O
to O
contain O
HBsAg I-GENE
determinants I-GENE
. O

These O
characteristics O
of O
N22 O
/ O
P22 O
indicate O
that O
it O
is O
a O
localized O
synaptically O
dependent O
event O
conforming O
to O
a O
transverse O
dipole O
with O
dorsal O
negativity O
and O
a O
simultaneous O
anterior O
positivity O
. O

Role O
of O
superoxide I-GENE
dismutase I-GENE
in O
cellular O
oxidative O
processes O
and O
method O
of O
its O
determination O
in O
biological O
materials O

At O
maximum O
photosensitivity O
the O
inhibitory O
amino O
acids O
gamma O
- O
aminobutyric O
acid O
and O
taurine O
were O
lower O
, O
and O
those O
of O
asparagine O
( O
metabolite O
of O
the O
excitatory O
amino O
acid O
aspartate O
) O
were O
higher O
, O
than O
when O
the O
animals O
were O
not O
photosensitive O
. O

We O
evaluated O
the O
likelihood O
of O
tissues O
to O
be O
positive O
for O
carcinoembryonic I-GENE
antigen I-GENE
and O
the O
intensity O
of O
carcinoembryonic I-GENE
antigen I-GENE
staining O
in O
specimens O
of O
villous O
adenomas O
, O
mixed O
polypoid O
villous O
adenomas O
, O
polypoid O
adenomas O
, O
and O
diverticulitis O
using O
the O
peroxidase I-GENE
- O
antiperoxidase I-GENE
technique O
. O

The O
priming O
activity O
of O
DNA O
incised O
by O
either O
of O
the O
Drosophila O
enzymes O
can O
be O
enhanced O
, O
however O
, O
by O
an O
additional O
incubation O
with O
E I-GENE
. I-GENE
coli I-GENE
endonuclease I-GENE
IV I-GENE
, O
which O
is O
known O
to O
cleave O
depurinated O
DNA O
on O
the O
5 O
'- O
side O
of O
an O
apurinic O
site O
. O

A O
. O

Therefore O
, O
in O
conjunction O
with O
a O
positive O
pregnancy O
test O
and O
the O
patient O
' O
s O
clinical O
history O
, O
a O
severely O
depressed O
or O
absent O
serum O
PAPP I-GENE
- I-GENE
A I-GENE
level O
may O
aid O
in O
the O
diagnosis O
of O
extrauterine O
pregnancy O
. O

The O
levels O
of O
both O
MAP1 I-GENE
- I-GENE
specific I-GENE
and I-GENE
MAP2 I-GENE
- I-GENE
specific I-GENE
mRNAs I-GENE
decline O
in O
the O
postnatal O
developing O
brain O
; O
the O
level O
of O
MAP1 I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
also O
increases O
slightly O
in O
rat O
PC12 O
cells O
upon O
exposure O
to O
nerve I-GENE
growth I-GENE
factor I-GENE
. O

The O
cDNAs O
cross O
- O
hybridize O
with O
genomic O
sequences O
in O
rat O
, O
human O
, O
and O
chicken O
DNA O
, O
but O
not O
with O
DNA O
from O
frog O
, O
Drosophila O
, O
or O
sea O
urchin O
. O

Colorimetric O
method O
of O
determining O
glycerin O
in O
the O
blood O

Deletion O
analysis O
was O
carried O
out O
within O
a O
part O
of O
the O
5 O
'- O
flanking O
region O
showing O
homology O
to O
the O
upstream O
region O
of O
the O
yeast I-GENE
CYC1 I-GENE
gene I-GENE
. O

The O
N1 O
and O
P2 O
were O
comparable O
in O
amplitude O
and O
both O
had O
prolonged O
refractory O
periods O
. O

Tolerance O
to O
fenfluramine O
anorexia O
: O
fact O
or O
fiction O
? O
Recent O
findings O
in O
this O
laboratory O
with O
regard O
to O
tolerance O
to O
fenfluramine O
anorexia O
are O
reviewed O
with O
respect O
to O
generality O
of O
the O
behavioural O
phenomenon O
. O

In O
30 O
dogs O
the O
left O
limb O
( O
tail O
) O
of O
the O
pancreas O
was O
removed O
but O
left O
in O
the O
abdominal O
cavity O
after O
cessation O
of O
blood O
flow O
to O
produce O
warm O
ischemia O
for O
30 O
, O
60 O
, O
and O
120 O
min O
( O
10 O
dogs O
at O
each O
time O
point O
), O
and O
then O
was O
flushed O
with O
cold O
Ringers O
' O
lactate O
and O
transplanted O
to O
the O
iliac O
vessels O
. O

These O
results O
support O
the O
view O
that O
clonidine O
and O
6 O
- O
OHDA O
, O
but O
not O
alpha O
- O
MD O
, O
have O
central O
pressor O
actions O
in O
the O
rat O
that O
oppose O
their O
antihypertensive O
action O
. O

Furthermore O
, O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
sensitivity O
appears O
to O
be O
unaltered O
in O
BHT O
. O

We O
conclude O
that O
Hansel O
' O
s O
stain O
substantially O
improves O
the O
recognition O
of O
eosinophiluria O
as O
compared O
with O
Wright O
' O
s O
stain O
. O

These O
results O
suggest O
that O
the O
negative O
inotropic O
action O
of O
nicorandil O
is O
caused O
by O
inhibition O
of O
Ca O
influx O
and O
intracellular O
mobilization O
of O
Ca O
. O

The O
study O
included O
139 O
eyes O
with O
presumed O
ocular O
histoplasmosis O
syndrome O
( O
POHS O
) O
and O
age O
- O
related O
macular O
degeneration O
( O
AMD O
). O

Comparison O
of O
elastase I-GENE
- I-GENE
1 I-GENE
with O
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
- O
like O
immunoreactivity O
in O
the O
diagnosis O
of O
acute O
pancreatitis O
. O

A O
probe O
evoked O
potentials O
procedure O
was O
used O
to O
assess O
the O
relative O
engagement O
of O
both O
cerebral O
hemispheres O
during O
a O
language O
task O
in O
the O
following O
four O
groups O
of O
dextral O
adults O
: O
left O
hemisphere O
( O
LH O
)- O
damaged O
aphasics O
recovering O
from O
stroke O
, O
dysarthrics O
, O
right O
hemisphere O
( O
RH O
)- O
damaged O
nonaphasic O
patients O
, O
and O
normal O
control O
subjects O
. O

Mucolipidosis O
type O
IV O
: O
clinical O
spectrum O
and O
natural O
history O
. O

Two O
of O
the O
three O
groups O
were O
administered O
dauricine O
, O
as O
a O
new O
calcium O
channel O
blocker O
, O
and O
verapamil O
, O
as O
a O
generally O
recognized O
calcium O
channel O
blocker O
, O
respectively O
, O
from O
15 O
minutes O
pre O
- O
bypass O
to O
the O
end O
of O
the O
bypass O
procedure O
( O
a O
period O
of O
95 O
minutes O
). O

No O
reflow O
occurred O
in O
approximately O
30 O
percent O
of O
the O
muscle O
microvasculature O
upon O
reperfusion O
. O

Rarely O
, O
patients O
with O
locally O
advanced O
, O
uncontrollable O
, O
non O
- O
metastatic O
prostatic O
cancer O
enjoy O
prolonged O
survival O
. O

Lysozyme I-GENE
activity O
was O
evidently O
increased O
as O
well O
in O
undiluted O
as O
in O
diluted O
sera O
in O
all O
our O
tested O
patients O
. O

The O
first O
involved O
measurements O
of O
the O
steady O
state O
levels O
of O
mRNAs O
for O
subunit O
5 O
of O
cytochrome I-GENE
oxidase I-GENE
and O
the O
beta O
subunit O
of O
F1 I-GENE
ATPase I-GENE
in O
wild O
type O
and O
in O
a O
hem2 I-GENE
mutant I-GENE
. O

A O
5 I-GENE
. I-GENE
8S I-GENE
- I-GENE
like I-GENE
structure I-GENE
is O
present O
within O
the O
5 O
'- O
terminal O
region O
of O
all O
three O
fungal I-GENE
mitochondrial I-GENE
LSU I-GENE
rRNAs I-GENE
; O
in O
contrast O
, O
no O
4 I-GENE
. I-GENE
5S I-GENE
- I-GENE
like I-GENE
structure I-GENE
is O
evident O
at O
the O
3 O
' O
end O
of O
these O
molecules O
. O

ATP O
gamma O
S O
inhibition O
can O
be O
overcome O
by O
high O
concentrations O
of O
ATP O
, O
dATP O
, O
araATP O
, O
or O
ddATP O
. O

The O
recovery O
of O
labelled O
methoxydextrane O
is O
98 O
+/- O
7 O
%. O

ASL O
- O
8123 O
demonstrated O
weak O
competitive O
beta I-GENE
- I-GENE
adrenoreceptor I-GENE
blocking O
activity O
in O
isolated O
guinea O
pig O
right O
atria O
with O
a O
pA2 O
of O
3 O
. O
73 O
+/- O
0 O
. O
07 O
; O
no O
agonist O
- O
like O
activity O
was O
observed O
in O
this O
tissue O
at O
concentrations O
of O
ASL O
- O
8123 O
from O
3 O
X O
10 O
(- O
5 O
) O
to O
1 O
X O
10 O
(- O
2 O
) O
M O
. O

Enhancer O
and O
promoter O
elements O
directing O
activation O
and O
glucocorticoid O
repression O
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
in O
hepatocytes O
. O

We O
discuss O
the O
results O
in O
relation O
to O
previous O
systems O
for O
parcellating O
the O
posterior O
ectosylvian O
gyrus O
of O
the O
cat O
and O
consider O
the O
possibility O
that O
divisions O
of O
the O
feline O
posterior O
ectosylvian O
gyrus O
correspond O
directly O
to O
areas O
making O
up O
the O
superior O
temporal O
gyrus O
in O
primates O
. O

The O
gene O
is O
contained O
within O
a O
1 O
. O
8 O
- O
kilobase O
AccI I-GENE
- O
EcoRI I-GENE
restriction O
fragment O
mapping O
at O
map O
coordinates O
0 O
. O
136 O
to O
0 O
. O
148 O
in O
the O
UL O
region O
of O
the O
EHV O
- O
1 O
genome O
and O
is O
transcribed O
from O
right O
to O
left O
. O

The O
4 O
- O
AP O
( O
4 O
- O
20 O
mM O
) O
effect O
resulted O
in O
a O
decrease O
of O
the O
sensory O
activity O
, O
which O
was O
fully O
restored O
by O
TEA O
or O
Ba2 O
+. O

Hybridization O
of O
a O
probe O
from O
this O
region O
to O
electrophoretic O
blots O
of O
RNAs O
from O
different O
human O
tissues O
showed O
a O
predominant O
2 O
. O
8 O
- O
kilobase O
( O
kb O
) O
message O
accompanied O
by O
weaker O
bands O
4 O
. O
1 O
and O
2 O
. O
1 O
kb O
in O
size O
. O

Prognosis O
of O
asymptomatic O
multiple O
myeloma O
. O

A O
new O
method O
for O
the O
quantitative O
analysis O
of O
sleep O
spindles O
during O
continuous O
overnight O
EEG O
recordings O
. O

Svensson O
et O
al O
. O

Endogenous O
release O
of O
neuronal O
serotonin O
and O
5 O
- O
hydroxyindoleacetic O
acid O
in O
the O
caudate O
- O
putamen O
of O
the O
rat O
as O
revealed O
by O
intracerebral O
dialysis O
coupled O
to O
high O
- O
performance O
liquid O
chromatography O
with O
fluorimetric O
detection O
. O

In O
this O
report O
we O
describe O
for O
the O
first O
time O
the O
complete O
primary O
structure O
of O
type I-GENE
X I-GENE
collagen I-GENE
, O
based O
on O
cloning O
and O
sequencing O
of O
cDNA O
and O
genomic O
DNA O
. O

Viable O
flap O
areas O
were O
established O
following O
vascular O
pedicle O
ligation O
( O
both O
vessels O
or O
only O
artery O
or O
vein O
), O
on O
the O
third O
day O
after O
flap O
replantation O
in O
both O
island O
and O
free O
flaps O
. O

The O
size O
discrepancy O
is O
not O
due O
to O
glycosylation O
or O
phosphorylation O
of O
Ag35 I-GENE
but O
may O
result O
from O
a O
proline O
- O
rich O
sequence O
which O
occurs O
in O
this O
polypeptide O
. O

A O
9 O
. O
5 O
- O
kb O
KpnI I-GENE
- O
SalI I-GENE
fragment O
, O
where O
all O
the O
DNA O
changes O
associated O
with O
su I-GENE
( I-GENE
Hw I-GENE
) I-GENE
mutations I-GENE
were O
mapped O
, O
was O
able O
to O
rescue O
the O
su I-GENE
( I-GENE
Hw I-GENE
) I-GENE
mutant I-GENE
phenotype O
after O
P O
- O
element O
- O
mediated O
germ O
- O
line O
transformation O
. O

The O
corticosterone O
synthesis O
inhibitor O
metyrapone O
( O
75 O
mg O
/ O
kg O
i O
. O
p O
.) O
was O
given O
to O
attenuate O
the O
rise O
of O
corticosterone O
to O
a O
level O
typical O
of O
stressed O
males O
. O

The O
effects O
of O
L655 O
, O
240 O
, O
a O
selective O
thromboxane O
and O
prostaglandin O
endoperoxide O
antagonist O
, O
on O
ischemia O
- O
and O
reperfusion O
- O
induced O
cardiac O
arrhythmias O
. O

In O
10 O
pentobarbitalized O
dogs O
, O
plasma O
viscosity O
( O
Ep O
) O
was O
raised O
fourfold O
while O
apparent O
blood O
viscosity O
( O
Ea O
) O
increased O
about O
twofold O
by O
two O
steps O
of O
exchange O
transfusion O
of O
200 O
ml O
of O
plasma O
with O
plasma O
containing O
high O
molecular O
weight O
dextran O
( O
mol O
wt O
500 O
, O
000 O
, O
20 O
% O
wt O
/ O
vol O
). O

The O
small I-GENE
IGF I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
abundant O
in O
human O
amniotic O
fluid O
. O

Serum O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
levels O
showed O
a O
significantly O
weaker O
correlation O
with O
cancer O
volume O
( O
r O
equals O
0 O
. O
51 O
) O
and O
every O
other O
pathological O
parameter O
. O

The O
investigation O
was O
thereafter O
continued O
in O
an O
open O
fashion O
by O
administering O
a O
single O
10 O
mg O
dose O
of O
the O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor O
deprenyl O
to O
the O
same O
subjects O
. O

Their O
studies O
have O
revealed O
a O
considerable O
increase O
of O
CSF I-GENE
AP I-GENE
activity O
in O
purulent O
meningitides O
whereas O
in O
serous O
meningitides O
it O
grows O
negligibly O
. O

A O
cDNA O
encoding O
a O
new O
human O
lymphocyte O
cell O
surface O
molecule O
has O
been O
isolated O
and O
shown O
to O
identify O
a O
fourth O
member O
of O
a O
recently O
discovered O
family O
of O
adhesion O
proteins O
. O

Dopamine O
caused O
a O
prominent O
potassium O
efflux O
measured O
as O
86Rb O
+ O
efflux O
from O
control O
glands O
, O
but O
was O
without O
effect O
in O
denervated O
glands O
. O

Spontaneous O
sensitization O
to O
cross O
- O
reacting O
chemicals O
in O
a O
proportion O
of O
control O
animals O
is O
strongly O
suggested O
, O
somewhat O
akin O
to O
spontaneous O
sensitization O
in O
patients O
with O
anaphylactoid O
reactions O
to O
neuromuscular O
blockers O
on O
first O
exposure O
, O
and O
in O
whom O
IgE I-GENE
antibodies I-GENE
are O
detected O
. O

This O
approach O
was O
examined O
utilizing O
the O
fetal O
protein O
, O
HGB I-GENE
F I-GENE
. O

The O
investigation O
was O
apt O
at O
studying O
the O
relationship O
between O
urinary O
metabolites O
of O
serotonin O
and O
catecholamine O
( O
5 O
- O
HIAA O
and O
VMA O
), O
T O
- O
cells O
( O
OKT3 O
+), O
T O
- O
helper O
( O
OKT4 O
+), O
T O
- O
suppressor O
( O
OKT8 O
+) O
and O
B O
- O
cells O
( O
EAC O
- O
rosette O
forming O
cells O
) O
in O
normal O
( O
10 O
subjects O
, O
1 O
female O
, O
9 O
male O
, O
age O
21 O
+/- O
5 O
years O
) O
and O
stress O
administered O
subjects O
( O
20 O
subjects O
, O
3 O
female O
, O
17 O
male O
, O
age O
20 O
+/- O
4 O
years O
). O

The O
84 I-GENE
. I-GENE
1C I-GENE
mAb I-GENE
recognizes O
a O
site O
on O
IgE I-GENE
which O
is O
identical O
or O
very O
close O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
, O
and O
95 O
. O
3 O
recognizes O
a O
site O
on O
IgE I-GENE
which O
is O
related O
, O
but O
not O
identical O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
. O

Their O
hydropathic O
plots O
are O
very O
similar O
and O
both O
possess O
three O
hydrophobic O
segments O
that O
are O
likely O
alpha O
- O
helical O
transmembrane O
segments O
. O

Angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
enhance O
the O
antihypertensive O
efficacy O
of O
diuretics O
and O
blunt O
or O
prevent O
adverse O
metabolic O
effects O
. O

In O
addition O
to O
the O
significant O
reduction O
in O
blood O
pressure O
, O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
( O
ACE I-GENE
) O
inhibitor O
ramipril O
caused O
a O
significant O
regression O
of O
pathologic O
left O
ventricular O
hypertrophy O
demonstrated O
by O
magnetic O
resonance O
imaging O
and O
echocardiography O
. O

Endocrine O
cells O
were O
studied O
by O
means O
of O
Grimelius O
' O
silver O
staining O
and O
immunostaining O
for O
chromogranin I-GENE
, O
a O
general O
marker O
of O
endocrine O
cells O
. O

The O
ratio O
of O
radioactivity O
in O
tumour O
compared O
with O
normal O
tissue O
( O
T O
: O
N O
ratio O
) O
was O
determined O
after O
simultaneously O
injecting O
microspheres O
into O
the O
portal O
and O
arterial O
circulation O
of O
each O
animal O
. O

The O
mRNA O
was O
converted O
to O
cDNA O
and O
amplified O
by O
the O
polymerase O
chain O
reaction O
technique O
. O

Tissue O
necrosis O
was O
evaluated O
using O
triphenyltetrazolium O
staining O
and O
was O
related O
to O
two O
major O
baseline O
predictors O
of O
infarct O
size O
: O
anatomic O
risk O
zone O
size O
and O
coronary O
collateral O
flow O
. O

To O
study O
the O
retinal O
surface O
in O
the O
human O
eye O
in O
normal O
and O
diseased O
states O
we O
used O
laser O
scanning O
tomography O
. O

Previously O
, O
we O
reported O
the O
sequence O
of O
the O
gene I-GENE
encoding I-GENE
human I-GENE
K14 I-GENE
( O
D O
. O

A O
potential O
TATA O
box O
is O
located O
29 O
base O
pairs O
upstream O
of O
the O
first O
transcription O
initiation O
site O
. O

Cotransfection O
of O
either O
construct O
with O
plasmids O
encoding O
PKI I-GENE
( I-GENE
1 I-GENE
- I-GENE
31 I-GENE
) I-GENE
inhibits O
cAMP O
- O
stimulated O
but O
not O
basal O
- O
or O
phorbol O
ester O
- O
stimulated O
expression O
. O

Sequence O
analysis O
of O
the O
5 O
' O
flanking O
region O
revealed O
several O
GC O
boxes O
but O
no O
identifiable O
TATA O
box O
. O

The O
underlying O
cirrhosis O
was O
alcoholic O
in O
11 O
( O
53 O
. O
3 O
%), O
cryptogenic O
in O
5 O
( O
23 O
. O
8 O
%), O
and O
hepatitis O
B O
chronic O
infection O
related O
in O
5 O
( O
23 O
. O
8 O
%). O

Once O
P I-GENE
- I-GENE
450scc I-GENE
mRNA I-GENE
is O
induced O
as O
a O
consequence O
of O
the O
LH I-GENE
/ O
hCG I-GENE
surge O
it O
is O
constitutively O
maintained O
by O
luteinized O
cells O
in O
vivo O
( O
0 O
- O
4 O
days O
) O
and O
in O
vitro O
( O
0 O
- O
9 O
days O
) O
in O
the O
absence O
of O
gonadotropins I-GENE
, O
is O
susceptible O
to O
modulation O
by O
prolactin I-GENE
and O
is O
no O
longer O
regulated O
by O
cAMP O
. O

Similarly O
, O
a O
human O
but O
not O
a O
bovine I-GENE
alpha I-GENE
transgene I-GENE
was O
expressed O
in O
placenta O
in O
transgenic O
mice O
. O

A O
rapid O
staining O
technique O
for O
Leishmania O
parasites O
in O
splenic O
aspirate O
smears O
. O

NIK O
- O
244 O
suppressed O
coronary O
ligation O
- O
and O
digitalis O
- O
induced O
arrhythmias O
, O
and O
the O
minimum O
effective O
plasma O
concentrations O
for O
arrhythmias O
induced O
by O
24 O
- O
h O
and O
48 O
- O
h O
coronary O
ligation O
and O
digitalis O
were O
0 O
. O
41 O
+/- O
0 O
. O
10 O
( O
by O
1 O
mg O
/ O
kg O
i O
. O
v O
.), O
0 O
. O
70 O
+/- O
0 O
. O
13 O
( O
by O
1 O
mg O
/ O
kg O
i O
. O
v O
.), O
and O
0 O
. O
21 O
+/- O
0 O
. O
08 O
( O
by O
0 O
. O
5 O
mg O
/ O
kg O
i O
. O
v O
.) O
microgram O
/ O
ml O
, O
respectively O
( O
mean O
+/- O
SD O
of O
the O
mean O
, O
n O
= O
6 O
). O

In O
TNF I-GENE
- O
resistant O
T24 O
bladder O
carcinoma O
cells O
, O
TNF I-GENE
failed O
to O
alter O
EGF I-GENE
- I-GENE
R I-GENE
tyrosine I-GENE
protein I-GENE
kinase I-GENE
activity O
although O
both O
EGF I-GENE
and O
phorbol O
ester O
were O
shown O
to O
modulate O
the O
enzymatic O
activity O
of O
the O
receptor O
in O
these O
cells O
. O

Thus O
, O
phosphodiesterase O
inhibitors O
that O
produce O
an O
opiate O
quasi O
- O
withdrawal O
syndrome O
potentiate O
interoceptive O
stimuli O
and O
weight O
loss O
associated O
with O
the O
withdrawal O
syndrome O
precipitated O
by O
naltrexone O
in O
morphine O
- O
dependent O
rats O
. O

The O
diagnostic O
value O
of O
blood O
serum O
and O
urinary I-GENE
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
in O
exacerbations O
of O
chronic O
relapsing O
pancreatitis O
is O
discussed O
. O

On O
the O
basis O
of O
the O
mechanism O
of O
action O
, O
two O
groups O
of O
inodilators O
are O
distinguished O
, O
the O
phosphodiesterase O
inhibitors O
and O
the O
dopaminergic O
agents O
. O

Structural O
organization O
and O
expression O
of O
the O
mouse I-GENE
estrogen I-GENE
receptor I-GENE
. O

Intravenous O
gamma I-GENE
globulins I-GENE

Following O
chondroitinase I-GENE
AC I-GENE
and I-GENE
ABC I-GENE
digestion O
, O
staining O
reactions O
suggested O
that O
the O
highest O
levels O
of O
dermatan O
sulfate O
were O
in O
the O
diabetes O
resistant O
group O
( O
p O
less O
than O
0 O
. O
001 O
compared O
to O
diabetic O
, O
p O
less O
than O
0 O
. O
001 O
compared O
to O
diabetes O
prone O
) O
and O
the O
highest O
levels O
of O
chondroitin O
sulfates O
were O
in O
the O
diabetes O
prone O
group O
( O
p O
less O
than O
0 O
. O
001 O
). O

Myocardial O
perfusion O
was O
evaluated O
using O
the O
enhanced O
gray O
level O
after O
contrast O
injection O
, O
and O
the O
level O
was O
compared O
with O
the O
morphology O
and O
degree O
of O
collateral O
development O
. O

Once O
NGF I-GENE
administration O
is O
proven O
effective O
it O
will O
be O
possible O
to O
develop O
alternative O
ways O
of O
NGF I-GENE
administration O
. O

During O
the O
program O
' O
s O
use O
at O
the O
RSNA O
meeting O
, O
the O
program O
selected O
the O
correct O
diagnosis O
in O
the O
top O
five O
22 O
% O
of O
the O
time O
. O

Immunoglobulin I-GENE
light I-GENE
chain I-GENE
( O
IgL I-GENE
) O
diversity O
is O
generated O
in O
the O
chicken O
by O
recombination O
between O
the O
single O
functional O
variable O
( O
VL I-GENE
) O
and O
joining O
( O
JL I-GENE
) O
gene O
segments O
and O
subsequent O
somatic O
diversification O
of O
the O
rearranged O
VL I-GENE
region O
. O

The O
results O
were O
as O
follows O
: O
1 O
) O
Total O
integrated O
EMG O
activity O
of O
FB O
group O
was O
approximately O
equal O
in O
any O
occluded O
position O
, O
whereas O
that O
of O
CG O
and O
GF O
group O
varied O
from O
position O
to O
position O
. O

Muscle O
action O
potential O
and O
masticatory O
rhythm O
of O
anterior O
temporal O
and O
masseter O
muscles O
in O
children O
and O
adults O

In O
76 O
% O
of O
59 O
lead O
- O
toxic O
children O
, O
bone O
lead O
values O
measured O
by O
LXRF O
were O
equal O
to O
or O
greater O
than O
those O
measured O
in O
normal O
and O
industrially O
exposed O
adults O
. O

When O
considered O
with O
the O
known O
neurotoxic O
effects O
on O
children O
of O
" O
low O
levels O
" O
of O
exposure O
to O
lead O
, O
these O
results O
also O
suggest O
that O
either O
an O
excessively O
narrow O
margin O
of O
safety O
or O
insufficient O
safety O
is O
provided O
by O
present O
U O
. O
S O
. O
guidelines O
, O
which O
classify O
an O
elevated O
blood O
lead O
concentration O
as O
25 O
micrograms O
/ O
dl O
or O
greater O
. O

In O
resting O
3T3 O
cells O
, O
jun I-GENE
- I-GENE
D I-GENE
is O
expressed O
at O
a O
higher O
level O
compared O
to O
c I-GENE
- I-GENE
jun I-GENE
and O
jun I-GENE
- I-GENE
B I-GENE
, O
and O
its O
transcription O
is O
stimulated O
only O
slightly O
by O
serum O
growth O
factors O
. O

The O
thrombolytic O
effects O
of O
native O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
AK I-GENE
- I-GENE
124 I-GENE
) O
on O
experimental O
canine O
coronary O
thrombosis O
. O

O2 O
and O
CO2 O
in O
the O
tracheostomy O
tube O
were O
continuously O
monitored O
by O
mass O
spectrometry O
using O
a O
special O
sample O
- O
hold O
phase O
- O
locked O
sampling O
technique O
. O

Enzyme O
- O
linked O
immunosorbent O
assay O
for O
screening O
aflatoxin O
B1 O
in O
cottonseed O
products O
and O
mixed O
feed O
: O
collaborative O
study O
. O

However O
, O
experiments O
with O
S1 I-GENE
mapping O
of O
in O
vivo O
transcripts O
, O
gene O
disruptions O
in O
the O
alpha O
region O
, O
and O
a O
single O
- O
copy O
transcriptional O
fusion O
vector O
all O
suggested O
that O
these O
possible O
promoters O
were O
largely O
inactive O
during O
logarithmic O
growth O
, O
that O
the O
major O
promoter O
for O
the O
alpha O
operon O
lay O
upstream O
from O
the O
region O
cloned O
, O
and O
that O
the O
genes O
in O
the O
IF1 I-GENE
to O
L17 I-GENE
interval O
were O
cotranscribed O
. O

Functional O
rearranged O
antibody O
genes O
were O
detected O
with O
JH I-GENE
and O
VH I-GENE
heavy I-GENE
chain I-GENE
probes O
and O
with O
Jk I-GENE
and O
Vk I-GENE
light I-GENE
chain I-GENE
probes O
. O

Two O
specific O
DNA O
- O
protein O
complexes O
were O
identified O
in O
gel O
retardation O
assays O
using O
HeLa O
cell O
nuclear O
extracts O
and O
an O
oligonucleotide O
probe O
spanning O
the O
footprinted O
region O
. O

After O
transfection O
, O
specific O
TSH I-GENE
beta I-GENE
promoter I-GENE
activity O
was O
evident O
in O
both O
TRH I-GENE
- O
responsive O
pituitary O
- O
derived O
GH3 O
and O
primary O
pituitary O
cell O
cultures O
. O

In O
transformed O
E O
. O
coli O
, O
constitutive I-GENE
CAT I-GENE
expression O
is O
maintained O
when O
as O
little O
as O
0 O
. O
3 O
kilobase O
of O
DNA O
from O
the O
3 O
' O
end O
of O
the O
1 O
. O
6 O
- O
kilobase O
segment O
is O
inserted O
in O
the O
correct O
orientation O
in O
front O
of O
the O
CAT I-GENE
gene I-GENE
. O

Lowering O
of O
the O
renal O
blood O
flow O
alters O
the O
glomerular O
and O
tubular O
excretion O
processes O
. O

Tonometry O
of O
blood O
samples O
from O
patients O
may O
also O
be O
used O
in O
the O
determination O
of O
acid O
- O
base O
quantities O
and O
hemoglobin I-GENE
- O
oxygen O
affinity O
e O
. O
g O
. O
p50 O
. O

100 O
and O
14 O
p O
. O

Isolation O
of O
Weeksella O
virosa O
( O
formerly O
CDC O
group O
IIf O
) O
from O
a O
vaginal O
sample O
. O

Here O
, O
we O
alter O
the O
dimerization O
specificity O
of O
Fos I-GENE
by O
precisely O
replacing O
its O
leucine O
zipper O
with O
that O
from O
GCN4 I-GENE
. O

Growth O
of O
tracheal O
anastomoses O
in O
growing O
animals O

Fourth O
, O
sometime O
between O
4 O
and O
24 O
hours O
of O
recovery O
is O
necessary O
to O
reverse O
the O
effect O
of O
chronic O
hypoxia O
on O
cerebral O
blood O
flow O
. O

The O
ORF1 O
product O
was O
required O
for O
competence O
, O
while O
ORF2 O
, O
which O
was O
cotranscribed O
with O
ORF1 O
and O
encoded O
a O
predicted O
protein O
of O
126 O
amino O
acids O
, O
was O
not O
. O

Kindling O
of O
the O
primary O
visual O
cortex O
( O
VC O
) O
was O
compared O
with O
that O
of O
the O
amygdala O
in O
cats O
. O

Abundant O
infiltration O
of O
lymphocytes O
and O
plasma O
cells O
was O
also O
wide O
- O
spread O
beneath O
the O
carcinoma O
in O
situ O
, O
together O
with O
the O
lymphoid O
follicles O
. O

These O
case O
reports O
provide O
further O
evidence O
that O
LiCO3 O
can O
be O
a O
useful O
medication O
in O
the O
treatment O
of O
aggressive O
behavior O
and O
affective O
instability O
after O
brain O
injury O
, O
but O
that O
it O
has O
significant O
potential O
for O
neurotoxicity O
in O
this O
population O
, O
particularly O
when O
used O
in O
conjunction O
with O
neuroleptic O
agents O
. O

In O
all O
sessions O
under O
IFN I-GENE
, O
the O
latency O
of O
the O
P100 O
component O
of O
the O
VEP O
was O
shortened O
as O
compared O
to O
baseline O
conditions O
. O

Among O
100 O
cases O
of O
post O
- O
transfusion O
hepatitis O
, O
10 O
are O
due O
to O
the O
hepatitis O
B O
virus O
( O
despite O
systematic O
search O
for O
HBs I-GENE
Ag I-GENE
), O
89 O
are O
due O
to O
one O
of O
the O
non O
- O
A O
non O
- O
B O
viruses O
( O
not O
detectable O
by O
specific O
serological O
tests O
) O
and O
1 O
to O
several O
viruses O
, O
specially O
CMV O
. O

Recessive O
lethal O
mutations O
were O
isolated O
based O
upon O
failure O
to O
complement O
the O
recessive O
lethality O
of O
Df O
( O
3L O
) O
RR2 O
, O
a O
deletion O
of O
the O
DRE O
region O
that O
removes O
16 O
- O
18 O
polytene O
chromosome O
bands O
. O

Current O
status O
and O
future O
perspectives O

K O
. O

A O
215 O
- O
base O
- O
pair O
( O
bp O
) O
region O
of O
the O
mouse I-GENE
MOPC I-GENE
41 I-GENE
kappa I-GENE
light I-GENE
- I-GENE
chain I-GENE
immunoglobulin I-GENE
gene I-GENE
enhancer I-GENE
has O
been O
analyzed O
for O
specific O
binding O
of O
lymphoid O
and O
nonlymphoid O
nuclear O
factors O
. O

This O
paper O
presents O
the O
reasons O
why O
countries O
to O
which O
Chagas O
disease O
is O
endemic O
should O
carry O
out O
the O
relevant O
research O
themselves O
. O

The O
PETCO2 O
measurement O
during O
precordial O
compression O
predicted O
the O
success O
of O
defibrillation O
with O
return O
of O
spontaneous O
circulation O
. O

Gastric O
CO2 O
/ O
HCO3 O
was O
determined O
in O
absence O
of O
simultaneous O
inhibition O
of O
acid O
secretion O
by O
intra O
- O
and O
extragastric O
pCO2 O
/ O
pH O
measurements O
in O
23 O
persons O
and O
calculated O
using O
the O
equation O
of O
Henderson O
- O
Hasselbalch O
. O
pCO2 O
was O
measured O
with O
use O
of O
a O
new O
electrode O
. O

Follow O
- O
up O
study O
showed O
85 O
% O
of O
these O
patients O
with O
effectiveness O
. O

The O
other O
patients O
continued O
the O
trial O
with O
single O
daily O
doses O
of O
monotherapy O
. O

Neonatal O
Chagas O
disease O
: O
laboratory O
diagnosis O
during O
the O
first O
year O
of O
life O

Using O
mutated I-GENE
IL2R I-GENE
alpha I-GENE
promoter I-GENE
constructs I-GENE
in O
transient O
transfection O
and O
DNA O
binding O
assays O
, O
we O
now O
demonstrate O
that O
sequences O
located O
immediately O
upstream O
and O
downstream O
of O
the O
kappa I-GENE
B I-GENE
enhancer I-GENE
also O
contribute O
to O
the O
regulation O
of O
IL2R I-GENE
alpha I-GENE
gene I-GENE
expression O
. O

Palindromic O
rheumatism O

Inefficacy O
of O
phosphine O
fumigation O
against O
ticks O
. O

Forty O
patients O
, O
divided O
according O
to O
their O
initial O
total O
gastrointestinal O
transit O
times O
and O
presenting O
symptoms O
, O
were O
treated O
with O
cimetropium O
bromide O
50 O
mg O
t O
. O
d O
. O
s O
. O
or O
placebo O
for O
1 O
month O
according O
to O
a O
double O
- O
blind O
, O
parallel O
group O
design O
. O

An O
immunologically O
related O
protein O
was O
detected O
in O
ribosome O
and O
membrane O
fractions O
of O
mitochondria O
from O
Saccharomyces O
cerevisiae O
. O

Mapping O
of O
RNA O
- O
temperature I-GENE
- I-GENE
sensitive I-GENE
mutants I-GENE
of I-GENE
Sindbis I-GENE
virus I-GENE
: I-GENE
complementation I-GENE
group I-GENE
F I-GENE
mutants I-GENE
have O
lesions O
in O
nsP4 I-GENE
. O

The O
effect O
of O
the O
thromboxane I-GENE
A2 I-GENE
( I-GENE
TXA2 I-GENE
)/ I-GENE
prostaglandin I-GENE
endoperoxide I-GENE
receptor I-GENE
antagonist O
, O
SQ O
29 O
, O
548 O
on O
pacing O
- O
induced O
ischemia O
was O
determined O
in O
anesthetized O
open O
- O
chest O
dogs O
. O

According O
to O
the O
published O
sequence O
of O
the O
CHS1 I-GENE
gene I-GENE
, O
this O
fragment O
contains O
four O
repeats O
of O
a O
TGAAACA O
consensus O
sequence O
previously O
identified O
in O
the O
alpha I-GENE
- I-GENE
factor I-GENE
- O
inducible O
BAR1 I-GENE
promoter I-GENE
[ O
Kronstad O
, O
J O
. O

The O
recovery O
index O
( O
T25 O
- O
T75 O
) O
after O
the O
infusion O
stopped O
was O
similar O
in O
patients O
who O
received O
mivacurium O
and O
those O
who O
received O
suxamethonium O
. O

The O
sign O
of O
Leser O
- O
Trelat O
: O
does O
it O
exist O
? O
The O
sign O
of O
Leser O
- O
Trelat O
is O
usually O
regarded O
as O
a O
reliable O
cutaneous O
marker O
of O
internal O
malignancy O
. O

Xenopus I-GENE
homolog I-GENE
of I-GENE
the I-GENE
mos I-GENE
protooncogene I-GENE
transforms O
mammalian O
fibroblasts O
and O
induces O
maturation O
of O
Xenopus O
oocytes O
. O

Southern O
blot O
analyses O
demonstrated O
a O
low O
, O
if O
not O
single O
, O
copy O
number O
for O
this O
gene O
and O
conservation O
of O
this O
domain O
in O
other O
vertebrates O
. O

Three O
missense O
mutants O
in O
subunit O
a O
of O
the O
Escherichia I-GENE
coli I-GENE
F1F0 I-GENE
- I-GENE
ATPase I-GENE
were O
isolated O
and O
characterized O
after O
hydroxylamine O
mutagenesis O
of O
a O
plasmid O
carrying O
the O
uncB I-GENE
( I-GENE
subunit I-GENE
a I-GENE
) I-GENE
gene I-GENE
. O

Moreover O
, O
exons O
2a O
and O
2b O
share O
the O
same O
5 O
' O
sequence O
but O
differ O
from O
each O
other O
by O
the O
use O
of O
two O
distinct O
donor O
splice O
sites O
171 O
bp O
apart O
in O
the O
gene O
. O

S1 I-GENE
nuclease I-GENE
analysis O
of O
RNA O
prepared O
after O
transfection O
of O
these O
HIV O
constructs O
into O
HeLa O
cells O
infected O
with O
wild O
- O
type O
adenovirus O
indicated O
that O
the O
enhancer O
, O
SP1 I-GENE
, O
TATA O
, O
and O
a O
portion O
of O
the O
transactivation O
- O
responsive O
element O
were O
each O
required O
for O
complete O
E1A I-GENE
/ O
E1B I-GENE
- O
mediated O
activation O
of O
the O
HIV I-GENE
LTR I-GENE
. O

In O
supine O
position O
, O
plasma O
ANP I-GENE
levels O
ranged O
from O
12 O
pg O
/ O
ml O
to O
51 O
. O
5 O
pg O
/ O
ml O
, O
with O
an O
average O
level O
of O
35 O
. O
3 O
+/- O
11 O
. O
5 O
pg O
/ O
ml O
. O

The O
overall O
prevalence O
of O
HBV O
markers O
was O
higher O
among O
staff O
members O
than O
in O
the O
blood O
donors O
of O
our O
area O
. O

Quantitative O
predictions O
are O
confirmed O
for O
the O
positive O
responses O
, O
but O
not O
for O
the O
negatives O
, O
suggesting O
that O
the O
SSTS O
model O
is O
incorrect O
. O

Plasma O
concentrations O
of O
ANF I-GENE
( O
pANF I-GENE
), O
aldosterone O
( O
PAC O
) O
and O
renin I-GENE
( O
PRC I-GENE
) O
were O
measured O
daily O
, O
as O
were O
hemodynamic O
parameters O
. O

The O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
encodes O
a O
protein O
that O
transcriptionally O
activates O
viral I-GENE
early I-GENE
genes I-GENE
. O

Administration O
of O
dexamethasone O
was O
associated O
with O
progressive O
rises O
in O
plasma O
17 O
alpha O
OH O
progesterone O
, O
11 O
beta O
- O
desoxycortisol O
, O
DHEA O
sulphate O
, O
androstenedione O
and O
testosterone O
, O
together O
with O
increased O
urinary O
excretion O
of O
androsterone O
, O
11 O
beta O
OH O
androsterone O
, O
etiocholanolone O
, O
DHEA O
, O
and O
16 O
alpha O
OH O
DHEA O
. O

RNA O
transcripts O
that O
hybridize O
to O
the O
introduced O
foreign O
gene O
have O
been O
identified O
. O

In O
HeLa O
cells O
, O
it O
activated O
transcription O
from O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
linked O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
when O
located O
in O
inverted O
orientation O
upstream O
of O
the O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
or O
downstream O
of O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
coding I-GENE
sequence I-GENE
. O

At O
the O
basal O
unstimulated O
condition O
, O
Ren1d I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
sequence I-GENE
in O
the O
sense O
orientation O
inhibited O
basal O
CAT I-GENE
expression O
from O
the O
TK I-GENE
promoter I-GENE
of O
pUTKAT1 O
, O
whereas O
the O
same O
sequence O
in O
the O
antisense O
orientation O
did O
not O
. O

None O
were O
restricted O
from O
clinical O
duties O
, O
were O
given O
varicella I-GENE
- I-GENE
zoster I-GENE
immune I-GENE
globulin I-GENE
, O
or O
developed O
disease O
. O

In O
the O
formalin O
test O
, O
however O
, O
naloxone O
attenuated O
morphine O
analgesia O
at O
the O
lower O
doses O
( O
0 O
. O
1 O
and O
0 O
. O
3 O
mg O
/ O
kg O
) O
and O
potentiated O
morphine O
analgesia O
at O
the O
highest O
dose O
( O
10 O
mg O
/ O
kg O
). O

We O
have O
isolated O
cDNA O
clones O
from O
rat O
brain O
and O
human O
liver O
encoding O
a O
putative O
isoform O
of O
the O
Na I-GENE
, I-GENE
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

We O
have O
determined O
that O
several O
E1 I-GENE
mutants I-GENE
mapping O
in O
both O
the O
M O
and O
R O
regions O
and O
a O
single O
mutant O
of O
the O
upstream O
regulatory O
region O
have O
a O
higher O
transforming O
activity O
on O
mouse O
C127 O
cells O
than O
the O
wild O
- O
type O
genome O
does O
. O

UbiA I-GENE
is O
also O
unique O
among O
known O
polyubiquitin I-GENE
genes I-GENE
in O
containing O
four O
cis O
- O
spliced O
introns O
within O
its O
coding O
sequence O
. O

That O
of O
the O
T2 I-GENE
gene I-GENE
contains O
numerous O
potential O
sites O
for O
binding O
the O
mammalian I-GENE
transcription I-GENE
factor I-GENE
SP1 I-GENE
, O
but O
no O
TATA O
or O
CCAAT O
sequences O
are O
evident O
near O
to O
its O
5 O
' O
end O
, O
although O
these O
latter O
features O
are O
associated O
with O
the O
human I-GENE
T1 I-GENE
gene I-GENE
. O

Radiation O
therapy O
was O
effective O
in O
controlling O
symptomatic O
metastasis O
in O
all O
three O
patients O
. O

These O
results O
indicate O
that O
patients O
who O
undergo O
postoperative O
irradiation O
for O
low O
grade O
spinal O
astrocytomas O
and O
localized O
spinal O
ependymomas O
achieve O
excellent O
survival O
. O

The O
methylation O
of O
nuclear O
and O
chloroplast O
DNAs O
has O
been O
examined O
in O
relation O
to O
the O
known O
differential O
expression O
of O
C4 I-GENE
photosynthesis I-GENE
genes I-GENE
in O
the O
bundle O
sheath O
and O
mesophyll O
cells O
of O
etiolated O
, O
greening O
, O
and O
fully O
green O
maize O
leaves O
. O

S1 I-GENE
nuclease I-GENE
analysis O
of O
RNA O
from O
chemically O
induced O
B95 O
- O
8 O
cells O
and O
from O
Vero O
cells O
cotransfected O
with O
NotI I-GENE
repeat I-GENE
promoter I-GENE
- O
CAT I-GENE
and O
Z I-GENE
showed O
that O
Z I-GENE
transactivation O
increased O
the O
level O
of O
correctly O
initiated O
, O
stable O
RNA O
transcripts O
. O

We O
conclude O
that O
( O
a O
) O
the O
likelihood O
of O
detecting O
carcinoma O
or O
atypical O
hyperplasia O
exclusively O
in O
the O
adipose O
tissue O
component O
of O
grossly O
benign O
breast O
biopsies O
is O
extremely O
low O
, O
and O
( O
b O
) O
a O
possible O
cost O
- O
effective O
method O
of O
sampling O
grossly O
benign O
breast O
biopsies O
consists O
of O
initially O
submitting O
a O
maximum O
of O
10 O
blocks O
of O
fibrous O
parenchyma O
for O
each O
case O
, O
then O
examining O
the O
remaining O
tissue O
histologically O
only O
if O
carcinoma O
or O
atypical O
hyperplasia O
is O
found O
among O
these O
blocks O
. O

Analysis O
of O
the O
DNA O
from O
15 O
cases O
of O
sporadic O
and O
familial O
Wilms O
' O
tumor O
did O
not O
reveal O
any O
changes O
, O
indicating O
that O
the O
translocation O
breakpoint O
does O
not O
reside O
in O
this O
gene O
. O

We O
also O
provide O
evidence O
that O
neither O
the O
lambda I-GENE
O I-GENE
and O
P I-GENE
initiators I-GENE
nor O
the O
E I-GENE
. I-GENE
coli I-GENE
DnaJ I-GENE
and O
DnaK I-GENE
heat O
shock O
proteins O
play O
a O
direct O
role O
in O
the O
propagation O
of O
lambda O
replication O
forks O
in O
vitro O
. O

Synthetic O
oligonucleotides O
representing O
the O
19 O
bp O
repeat O
unit O
strongly O
reduced O
the O
activity O
of O
the O
IE1 I-GENE
/ I-GENE
2 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
in O
cotransfection O
assays O
after O
transient O
expression O
. O

Effects O
of O
nitrogen O
( O
PN2 O
: O
5 O
and O
14 O
MPa O
) O
and O
helium O
( O
PHe O
: O
13 O
and O
14 O
MPa O
) O
were O
also O
tested O
. O

The O
mustard I-GENE
chloroplast I-GENE
gene I-GENE
rps16 I-GENE
is O
split O
by O
an O
887 O
bp O
group O
II O
( O
or O
III O
) O
intron O
. O

Antibodies O
raised O
to O
the O
expressed O
NS3 I-GENE
by O
immunization O
of O
mice O
detected O
both O
NS3 I-GENE
and O
NS3A I-GENE
in O
BTV O
- O
10 O
- O
infected O
BHK O
cells O
but O
not O
in O
purified O
BTV O
- O
10 O
virus O
particles O
. O

Similarly O
, O
supraventricular O
tachycaydia O
following O
resuscitative O
efforts O
appeared O
to O
be O
associated O
with O
a O
negative O
outcome O
. O

The O
negative O
calcium O
balance O
with O
hyperparathyroidemia O
occurred O
after O
continuous O
oral O
administration O
of O
Cd O
and O
developed O
via O
increased O
urinary O
excretion O
of O
calcium O
. O

Clone O
4c O
( O
2681 O
bp O
) O
had O
a O
coding O
region O
identical O
to O
that O
of O
clone O
22c O
but O
it O
included O
a O
putative O
intron O
of O
959 O
bp O
. O

The O
application O
of O
ISH O
and O
IHC O
did O
not O
change O
significantly O
the O
routine O
histologic O
classification O
of O
pneumonias O
into O
CMV O
- O
IP O
and O
IIP O
. O

Validity O
of O
immunohistology O
and O
in O
situ O
hybridization O
in O
the O
differential O
diagnosis O
of O
cytomegalovirus O
pneumonia O
and O
idiopathic O
interstitial O
pneumonia O
after O
allogenic O
bone O
marrow O
transplantation O

The O
unique O
nature O
and O
arrangement O
of O
the O
ANT1 I-GENE
transcriptional I-GENE
control I-GENE
elements I-GENE
may O
account O
for O
this O
differential O
expression O
. O

A O
brief O
account O
of O
the O
1988 O
seminar O
in O
Shanghai O
on O
viral O
hepatitis O
A O

The O
Bacillus I-GENE
subtilis I-GENE
phage I-GENE
phi I-GENE
105 I-GENE
repressor I-GENE
, O
a O
lambda I-GENE
repressor I-GENE
- O
like O
transcriptional O
regulatory O
protein O
, O
was O
overproduced O
in O
Escherichia O
coli O
and O
purified O
to O
near O
homogeneity O
in O
order O
to O
examine O
its O
in O
vitro O
DNA O
- O
binding O
properties O
. O

In O
consequence O
, O
the O
gpI I-GENE
derived O
from O
cells O
infected O
with O
mO74 O
showed O
antigenic O
characteristics O
similar O
to O
those O
of O
gpI I-GENE
from O
VZV O
- O
infected O
cells O
as O
determined O
from O
the O
immunoprecipitation O
pattern O
, O
although O
the O
molecular O
weight O
of O
each O
polypeptide O
was O
different O
, O
and O
antibody O
produced O
in O
rabbits O
infected O
with O
recombinant O
virus O
had O
a O
high O
neutralizing O
activity O
, O
when O
the O
reaction O
was O
performed O
with O
complement O
. O

Erythrocytic O
stages O
of O
mammalian O
malarial O
parasites O
contain O
acristate O
mitochondria O
whose O
functions O
are O
not O
well O
understood O
. O

However O
, O
bilateral O
diffuse O
pulmonary O
infiltrations O
developed O
21 O
days O
later O
. O

Grossly O
, O
the O
incidence O
of O
a O
type O
IIc O
carcinoma O
was O
46 O
. O
5 O
% O
and O
that O
of O
a O
IIc O
+ O
III O
type O
was O
20 O
. O
5 O
%, O
respectively O
. O

Restriction O
maps O
of O
the O
cloned O
plasmids O
revealed O
that O
their O
chromosomal O
inserts O
consisted O
of O
overlapping O
fragments O
. O

VP5 I-GENE
, O
which O
encodes O
the O
major I-GENE
capsid I-GENE
protein I-GENE
, O
each O
fused O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
. O

Of O
202 O
initially O
seronegative O
caretakers O
( O
observed O
for O
an O
average O
of O
305 O
days O
per O
woman O
), O
19 O
seroconverted O
, O
for O
an O
annual O
seroconversion O
rate O
of O
11 O
percent O
. O

In O
contrast O
, O
a O
similar O
fragment O
lacking O
the O
38 O
- O
base O
- O
pair O
region O
had O
no O
such O
stabilizing O
effect O
. O

First O
, O
a O
pet54 I-GENE
:: O
LEU2 I-GENE
cytoductant O
bearing O
the O
' O
short O
' O
mitochondrial O
genome O
that O
lacks O
both O
COX1 I-GENE
introns I-GENE
aI5 I-GENE
alpha I-GENE
and O
aI5 I-GENE
beta I-GENE
is O
defective O
only O
in O
COX3 I-GENE
gene I-GENE
expression O
and O
not O
in O
COX1 I-GENE
mRNA I-GENE
splicing O
or O
mRNA O
translation O
. O

Insert2 O
contains O
repetitive O
non O
- O
Ig I-GENE
- O
related O
sequences O
and O
a O
small I-GENE
Ig I-GENE
- I-GENE
related I-GENE
sequence I-GENE
. O

Since O
considerable O
variations O
in O
length O
and O
primary O
sequence O
in O
the O
CDR3 I-GENE
( O
complementarity I-GENE
determining I-GENE
region I-GENE
) O
peptides O
of O
all O
the O
H I-GENE
- I-GENE
chains I-GENE
are O
evident O
, O
conservation O
of O
the O
D I-GENE
- I-GENE
region I-GENE
structure O
does O
not O
appear O
to O
be O
necessary O
for O
effective O
hapten O
binding O
. O

Tyrosine I-GENE
kinase I-GENE
oncogenes O
abrogate O
interleukin I-GENE
- I-GENE
3 I-GENE
dependence O
of O
murine O
myeloid O
cells O
through O
signaling O
pathways O
involving O
c I-GENE
- I-GENE
myc I-GENE
: O
conditional O
regulation O
of O
c I-GENE
- I-GENE
myc I-GENE
transcription O
by O
temperature O
- O
sensitive O
v I-GENE
- I-GENE
abl I-GENE
. O

This O
TC I-GENE
- I-GENE
II I-GENE
enhanson I-GENE
, O
which O
is O
identical O
to O
the O
kappa I-GENE
B I-GENE
motif I-GENE
from O
the O
kappa I-GENE
chain I-GENE
enhancer I-GENE
, O
was O
active O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
which O
contrasts O
with O
the O
previously O
reported O
lymphoid O
cell O
specificity O
of O
the O
kappa I-GENE
B I-GENE
motif I-GENE
. O

The O
DNA O
helix O
at O
the O
tandemly O
repeated O
, O
13mer O
sequence O
is O
thermodynamically O
unstable O
, O
as O
evidenced O
by O
hypersensitivity O
to O
single I-GENE
- I-GENE
strand I-GENE
- I-GENE
specific I-GENE
nuclease I-GENE
in O
a O
negatively O
supercoiled O
plasmid O
, O
and O
demonstrated O
by O
stable O
DNA O
unwinding O
seen O
after O
two O
- O
dimensional O
gel O
electrophoresis O
of O
topoisomers O
. O

There O
has O
been O
similar O
improvement O
in O
treating O
ampullary O
and O
periampullary O
cancer O
, O
gallbladder O
cancer O
, O
or O
extrahepatic O
bile O
duct O
cancer O
. O

Beta I-GENE
- I-GENE
endorphin I-GENE
, O
ACTH I-GENE
and O
cortisol O
secretion O
were O
measured O
in O
twelve O
healthy O
adult O
males O
after O
nasal O
spray O
administration O
200 O
IU O
salmon I-GENE
calcitonin I-GENE
. O

The O
data O
indicate O
that O
calcitonin I-GENE
induced O
a O
beta I-GENE
- I-GENE
endorphin I-GENE
increase O
independent O
of O
enhanced O
corticotrophin I-GENE
- O
cortisol O
release O
. O

The O
DNA O
sequences O
predict O
proteins O
for O
SRP54sc I-GENE
and O
SRP54sp I-GENE
that O
are O
47 O
% O
and O
52 O
% O
identical O
to O
SRP54mam I-GENE
, O
respectively O
. O

Other O
hemostatic O
values O
evaluated O
were O
activated O
partial O
thromboplastin I-GENE
times O
, O
prothrombin I-GENE
times O
, O
thrombin I-GENE
times O
, O
fibrinogen I-GENE
, O
platelet O
counts O
, O
and O
fibrin I-GENE
/ O
fibrinogen I-GENE
degradation O
products O
. O

Rare O
neurogenic O
tumor O
with O
metastasis O
to O
mouth O
, O
jaw O
and O
face O
regions O

We O
have O
designated O
the O
protein O
" I-GENE
cellular I-GENE
NBP I-GENE
" I-GENE
( O
CNBP I-GENE
). O

Responsiveness O
to O
beta O
- O
2 O
agonist O
therapy O
was O
retained O
with O
both O
agents O
( O
p O
less O
than O
0 O
. O
05 O
). O

Drug O
use O
in O
trauma O
victims O
. O

A O
critical O
heart O
rate O
and O
/ O
or O
appropriate O
sympathetic O
state O
was O
found O
to O
provoke O
all O
instances O
of O
reentrant O
or O
automatic O
atrial O
tachycardia O
and O
atypical O
junctional O
tachycardia O
. O

In O
contrast O
, O
the O
neu I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
did O
not O
show O
kinase O
activity O
or O
transforming O
properties O
when O
expressed O
at O
similar O
levels O
in O
NIH O
3T3 O
cells O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
65 O
- O
bp O
sequence O
contains O
the O
octameric O
cAMP O
- O
responsive O
enhancer O
( O
CRE O
) O
TGACGTCA O
( O
nucleotides O
- O
48 O
to O
- O
41 O
). O

Somatostatin I-GENE
gene I-GENE
expression O
in O
pancreatic O
islet O
cells O
is O
directed O
by O
cell O
- O
specific O
DNA O
control O
elements O
and O
DNA O
- O
binding O
proteins O
. O

In O
contrast O
, O
the O
full O
mu O
- O
opioid O
agonists O
fentanyl O
, O
morphine O
, O
I O
- O
methadone O
and O
levorphanol O
produced O
50 O
% O
fentanyl O
- O
appropriate O
responding O
at O
doses O
only O
1 O
. O
3 O
to O
10 O
. O
9 O
times O
smaller O
than O
those O
required O
to O
decrease O
response O
rates O
by O
50 O
%. O

After O
overtraining O
on O
the O
original O
discrimination O
, O
the O
controls O
showed O
the O
normal O
difficulty O
in O
learning O
the O
first O
reversal O
. O

Isolation O
and O
characterization O
of O
a O
cDNA O
encoding O
a O
putative O
cytokine O
which O
is O
induced O
by O
stimulation O
via O
the O
CD2 I-GENE
structure I-GENE
on O
human O
T O
lymphocytes O
. O

After O
termination O
of O
medication O
the O
animals O
were O
kindled O
electrically O
in O
the O
nucleus O
amygdala O
. O

Haploid O
cells O
of O
mating O
type O
A O
of O
the O
basidiomycetous O
yeast O
Rhodosporidium O
toruloides O
secrete O
a O
mating O
pheromone O
, O
rhodotorucine I-GENE
A I-GENE
, O
which O
is O
an O
undecapeptide O
containing O
S O
- O
farnesyl O
cysteine O
at O
its O
carboxy O
terminus O
. O

Tumour I-GENE
necrosis I-GENE
factor I-GENE
and O
adult O
respiratory O
distress O
syndrome O
. O

Monitoring O
of O
rheumatoid O
arthritis O
. O

The O
decrease O
in O
left O
ventricular O
( O
LV O
) O
stroke O
volume O
during O
positive O
end O
- O
expiratory O
pressure O
( O
PEEP O
) O
has O
been O
attributed O
to O
reduced O
LV O
filling O
and O
a O
decreased O
contractile O
state O
. O

An O
experiment O
on O
the O
return O
- O
of O
- O
fear O
( O
ROF O
) O
was O
carried O
out O
on O
40 O
snake O
- O
or O
spider O
- O
phobic O
subjects O
in O
order O
to O
determine O
whether O
an O
arousing O
event O
that O
occurs O
shortly O
before O
retest O
influences O
the O
magnitude O
of O
the O
ROF O
. O

Evolutionary O
conservation O
of O
homeodomain I-GENE
- O
binding O
sites O
and O
other O
sequences O
upstream O
and O
within O
the O
major O
transcription O
unit O
of O
the O
Drosophila I-GENE
segmentation I-GENE
gene I-GENE
engrailed I-GENE
. O

To O
assess O
the O
functional O
importance O
of O
these O
NBS O
in O
the O
overall O
drug O
resistance O
phenotype O
conferred O
by O
mdr1 I-GENE
, O
we O
introduced O
amino O
acid O
substitutions O
in O
the O
core O
consensus O
sequence O
for O
nucleotide O
binding O
, O
GXGKST O
. O

When O
the O
first O
twitch O
of O
TOF O
spontaneously O
recovered O
to O
10 O
% O
of O
control O
value O
, O
neostigmine O
was O
injected O
( O
40 O
micrograms O
/ O
kg O
in O
adults O
, O
30 O
micrograms O
/ O
kg O
in O
infants O
and O
children O
). O

No O
significant O
differences O
were O
found O
in O
relation O
to O
Type O
A O
behaviour O
and O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
blockade O
. O

Selection O
of O
the O
22 O
items O
of O
the O
Clinical O
Institute O
Withdrawal O
Assessment O
- O
Benzodiazepines O
( O
CIWA O
- O
B O
) O
was O
based O
on O
statistically O
significant O
differences O
between O
baseline O
and O
critical O
withdrawal O
periods O
in O
high O
- O
dose O
subjects O
and O
between O
symptoms O
associated O
with O
placebo O
and O
diazepam O
in O
low O
- O
dose O
subjects O
, O
using O
contingency O
tables O
and O
logistic O
regression O
analysis O
. O

Antihistamines O
in O
asthma O
. O

We O
have O
therefore O
evaluated O
the O
efficacy O
and O
safety O
of O
doxazosin O
, O
a O
new O
orally O
active O
selective O
alpha I-GENE
1 I-GENE
blocker O
, O
in O
patients O
with O
systemic O
hypertension O
with O
concomitant O
airflow O
limitation O
. O

Northern O
blot O
analysis O
revealed O
multiple O
oIGF I-GENE
- I-GENE
I I-GENE
transcripts I-GENE
in O
a O
broad O
band O
at O
800 O
- O
1 O
, O
100 O
nucleotides O
and O
other O
transcripts O
of O
higher O
molecular O
weight O
in O
liver O
. O

Materials O
science O
studies O
on O
the O
soldering O
of O
different O
orthodontic O
wires O

The O
latency O
time O
for O
the O
lactate O
concentration O
to O
reach O
the O
top O
values O
was O
reduced O
by O
aerobic O
training O
( O
T2 O
). O

In O
patients O
resistant O
to O
VAD O
, O
high O
- O
dose O
therapies O
with O
intravenous O
melphalan O
, O
a O
CBV O
combination O
( O
cyclophosphamide O
- O
BCNU O
- O
VP O
- O
16 O
) O
or O
an O
EDAP O
regimen O
( O
VP O
- O
16 O
- O
platinum O
) O
produced O
responses O
in O
about O
40 O
% O
of O
patients O
. O

The O
discussion O
focuses O
primarily O
on O
the O
newer O
drugs O
like O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
, O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockers O
, O
and O
calcium O
antagonists O
. O

The O
avian O
cellular O
homolog O
of O
the O
oncogene I-GENE
jun I-GENE
. O

A O
736 O
- O
bp O
sequence O
of O
the O
5 O
' O
flanking O
region O
adjacent O
to O
the O
cap O
site O
of O
the O
human I-GENE
AFP I-GENE
gene I-GENE
shows O
a O
61 O
% O
similarity O
with O
the O
corresponding O
region O
of O
the O
mouse I-GENE
AFP I-GENE
gene I-GENE
. O

High O
ATP O
/ O
GTP O
ratios O
promoted O
initiation O
of O
RNA O
primer O
synthesis O
at O
3 O
'- O
dCTTT O
sites O
, O
whereas O
low O
ATP O
/ O
GTP O
ratios O
promoted O
initiation O
at O
3 O
'- O
dCCC O
sites O
. O

After O
hepatitis O
B O
vaccine O
immunization O
, O
serum O
antibody O
response O
was O
of O
primary O
type O
in O
33 O
cases O
with O
anti I-GENE
- I-GENE
HBs I-GENE
less O
than O
2 O
. O
1 O
S O
/ O
N O
( O
S O
/ O
N O
Ratio O
Unit O
) O
at O
T0 O
, O
the O
anti I-GENE
- I-GENE
HBs I-GENE
positive O
rate O
was O
39 O
. O
4 O
%, O
84 O
. O
8 O
%, O
96 O
. O
7 O
% O
and O
96 O
. O
7 O
% O
in O
T1 O
, O
T2 O
, O
T0 O
and O
T12 O
respectively O
. O

The O
experimental O
design O
incorporated O
a O
multiple O
regression O
model O
, O
sequential O
treatments O
and O
a O
proportional O
end O
point O
( O
95 O
%) O
for O
protection O
time O
. O

Interspecific O
complementation O
tests O
showed O
that O
the O
P7 I-GENE
proteins I-GENE
are O
unable O
to O
complement O
P1 I-GENE
parA I-GENE
or O
parB I-GENE
mutants I-GENE
, O
and O
the O
P1 I-GENE
proteins I-GENE
fail O
to O
complement O
the O
P7 I-GENE
mutations I-GENE
. O

GN101 O
, O
YC819 O
- O
9 O
, O
and O
SB3 O
. O

Analysis O
of O
the O
inferred O
1 I-GENE
, I-GENE
859 I-GENE
- I-GENE
residue I-GENE
ama I-GENE
- I-GENE
1 I-GENE
product I-GENE
showed O
considerable O
identity O
with O
the O
largest O
subunit O
of O
RNAP I-GENE
II I-GENE
from O
other O
organisms O
, O
including O
the O
presence O
of O
a O
zinc O
finger O
motif O
near O
the O
amino O
terminus O
, O
and O
a O
carboxyl O
- O
terminal O
domain O
of O
42 O
tandemly O
reiterated O
heptamers O
with O
the O
consensus O
Tyr O
Ser O
Pro O
Thr O
Ser O
Pro O
Ser O
. O

Nodular O
involvement O
of O
the O
left O
lung O
and O
infiltration O
of O
the O
mucosa O
of O
the O
left O
lower O
lobe O
bronchus O
followed O
very O
gradually O
and O
a O
monoclonal O
gammopathy O
( O
IgA I-GENE
-- I-GENE
Type I-GENE
Kappa I-GENE
) O
was O
demonstrated O
. O

5 O
. O

None O
of O
the O
measured O
parameters O
( O
heart O
contents O
of O
neutral O
lipids O
, O
total O
phospholipids O
, O
phosphatidylcholine O
, O
phosphatidylethanolamine O
, O
diphosphatidylglycerol O
, O
sphingomyelin O
and O
fatty O
acid O
composition O
of O
each O
phospholipid O
class O
) O
appeared O
to O
be O
related O
with O
the O
grading O
of O
the O
lesions O
. O

Of O
165 O
women O
with O
non O
- O
malignant O
diagnoses O
26 O
( O
16 O
%) O
had O
CA I-GENE
125 I-GENE
levels O
in O
excess O
of O
35 O
U O
/ O
ml O
and O
8 O
( O
5 O
%) O
greater O
than O
65 O
U O
/ O
ml O
. O

We O
conclude O
that O
at O
steady O
state O
the O
timing O
of O
a O
light O
meal O
is O
unlikely O
to O
alter O
in O
any O
clinically O
important O
manner O
the O
pharmacokinetics O
of O
nifedipine O
released O
from O
' O
biphasic O
' O
tablets O
. O

The O
GALT O
- O
primed O
calves O
had O
increased O
serum O
IgG I-GENE
, O
lavage O
IgG I-GENE
and O
IgA I-GENE
and O
increased O
LNA I-GENE
titers O
in O
both O
lavage O
fluids O
and O
serum O
following O
the O
SC O
dose O
of O
killed O
bacteria O
. O

Recent O
investigations O
have O
shown O
that O
Grenz O
rays O
can O
suppress O
the O
allergic O
contact O
dermatitis O
reaction O
completely O
and O
that O
Langerhans O
cells O
, O
identified O
by O
OKT6 I-GENE
antibodies I-GENE
and O
electron O
microscopy O
, O
disappear O
from O
the O
epidermis O
at O
the O
same O
time O
. O

The O
elements O
responsible O
for O
glucocorticoid O
stimulation O
of O
ADH I-GENE
gene I-GENE
transcription O
appear O
to O
reside O
outside O
of O
this O
region O
. O

1 O
. O

The O
present O
studies O
compare O
the O
biochemical O
characteristics O
, O
Kanagawa O
hemolysin I-GENE
reactions O
, O
and O
plasmid O
profiles O
of O
13 O
patient O
and O
221 O
environmental O
isolates O
of O
the O
organism O
. O

High O
values O
of O
both O
retinol O
and O
beta O
- O
carotene O
were O
found O
in O
full O
fat O
cheeses O
and O
whipping O
cream O
: O
from O
179 O
. O
0 O
( O
cheese O
, O
Edam O
- O
type O
) O
to O
318 O
. O
7 O
micrograms O
/ O
100 O
g O
( O
whipping O
cream O
) O
and O
from O
86 O
. O
7 O
( O
cheese O
, O
Edam O
- O
type O
) O
to O
186 O
. O
5 O
micrograms O
/ O
100 O
g O
( O
whipping O
cream O
) O
for O
all O
- O
trans O
retinol O
and O
total O
beta O
- O
carotene O
, O
respectively O
. O

COGLAB O
includes O
measures O
of O
preattentional O
, O
attentional O
, O
conceptual O
, O
and O
psychomotor O
performance O
. O

These O
data O
locate O
the O
aniridia I-GENE
gene I-GENE
( O
AN2 I-GENE
) O
and O
a O
recurrent O
T I-GENE
- I-GENE
cell I-GENE
leukemia I-GENE
breakpoint I-GENE
( O
TCL2 I-GENE
) O
in O
the O
marker O
sequence O
, O
on O
opposite O
sides O
of O
MIC1 I-GENE
. O

A O
fine O
- O
structure O
deletion O
map O
of O
human O
chromosome O
11p O
: O
analysis O
of O
J1 O
series O
hybrids O
. O

With O
respect O
to O
effective O
diffusivity O
of O
platelets O
( O
De O
) O
and O
the O
surface O
reactivity O
constant O
( O
K O
), O
less O
significant O
differences O
were O
found O
among O
artificial O
materials O
. O

The O
two O
most O
recent O
patients O
( O
35 O
and O
132 O
days O
) O
received O
only O
oral O
dipyridamole O
( O
75 O
mg O
X O
3 O
/ O
day O
) O
and O
aspirin O
( O
80 O
mg O
/ O
day O
) O
after O
the O
early O
recovery O
period O
( O
four O
- O
six O
days O
), O
resulting O
in O
normal O
prothrombin I-GENE
and O
partial O
thromboplastin I-GENE
times O
. O

Middle O
- O
latency O
auditory O
evoked O
potentials O
( O
MAEPs O
) O
were O
recorded O
in O
controls O
and O
patients O
with O
focal O
lesions O
in O
dorsolateral O
prefrontal O
cortex O
. O

Most O
of O
them O
were O
situated O
at O
Sylvius O
fissure O
( O
13 O
cases O
). O

Intracellular O
activity O
studies O
indicated O
that O
, O
at O
ten O
times O
MBC O
, O
only O
penicillin O
had O
any O
significant O
activity O
against O
intracellular O
staphylococci O
, O
reducing O
survival O
by O
28 O
%. O

Specifically O
, O
they O
were O
performed O
to O
determine O
whether O
detection O
of O
envelope O
phase O
disparity O
was O
consistent O
with O
processing O
within O
a O
single O
channel O
in O
which O
the O
AM O
tones O
were O
simply O
added O
. O

Gel O
retardation O
assays O
combined O
with O
DNase I-GENE
I I-GENE
footprinting O
and O
diethyl O
pyrocarbonate O
interference O
showed O
that O
a O
nuclear O
factor O
from O
differentiated O
C2 O
myotubes O
and O
BC3H1 O
myocytes O
recognized O
a O
conserved O
A O
+ O
T O
- O
rich O
sequence O
within O
the O
peripheral O
activating O
region O
. O

Such O
transgenic O
plants O
should O
enable O
not O
only O
the O
mutational O
analysis O
of O
sequence O
elements O
within O
the O
replication O
origin O
region O
, O
but O
also O
the O
construction O
of O
a O
new O
generation O
of O
vectors O
for O
gene O
amplification O
in O
plants O
, O
based O
on O
a O
minimal O
virus O
replicon O
. O

Ventral O
rhinotomy O
is O
no O
more O
difficult O
than O
dorsal O
rhinotomy O
, O
has O
less O
patient O
morbidity O
and O
fewer O
postoperative O
complications O
, O
and O
is O
more O
cosmetically O
acceptable O
. O

Four O
full O
- O
thickness O
skin O
incisions O
were O
made O
in O
the O
back O
of O
10 O
female O
pigs O
that O
treated O
twice O
a O
day O
for O
14 O
days O
with O
2 O
ml O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
300 O
ng O
/ O
ml O
) O
or O
2 O
ml O
of O
Ringer O
' O
s O
lactate O
solution O
in O
a O
single O
- O
blind O
, O
randomized O
fashion O
. O

During O
challenge O
, O
rebiopsy O
was O
done O
when O
reticulin I-GENE
antibodies I-GENE
turned O
positive O
( O
mean O
0 O
. O
6 O
years O
, O
range O
0 O
. O
2 O
- O
2 O
. O
0 O
) O
or O
at O
the O
end O
of O
the O
two O
year O
study O
. O

The O
effect O
of O
iron O
intake O
on O
59Fe O
absorption O
throughout O
pregnancy O
, O
and O
on O
maternal O
and O
fetal O
Fe O
status O
towards O
the O
end O
of O
pregnancy O
, O
was O
investigated O
in O
rats O
. O

The O
deduced O
protein O
sequence O
is O
characterized O
by O
a O
putative O
16 O
- O
residue O
amino O
- O
terminal O
signal O
peptide O
that O
is O
cleaved O
, O
resulting O
in O
a O
239 O
- O
residue O
polypeptide O
. O

Analysis O
of O
the O
rate O
constants O
indicated O
that O
the O
isomerization O
rate O
k12 O
was O
approximately O
equal O
to O
the O
apparent O
degradation O
rate O
of O
the O
delta O
3 O
ester O
kdeg O
, O
and O
slower O
than O
the O
hydrolysis O
rate O
of O
the O
delta O
2 O
ester O
k24 O
. O

A O
protocol O
is O
elaborated O
for O
the O
preparation O
and O
characterization O
of O
a O
quality O
control O
material O
( O
QCM O
) O
containing O
intrinsic O
concentration O
of O
cadmium O
( O
Cd O
) O
( O
0 O
. O
8 O
microgram O
/ O
L O
) O
and O
lead O
( O
Pb O
) O
( O
13 O
. O
4 O
micrograms O
/ O
dL O
) O
from O
bovine O
blood O
and O
an O
elevated O
QCM O
containing O
Cd O
( O
5 O
. O
0 O
micrograms O
/ O
L O
), O
mercury O
( O
Hg O
) O
( O
11 O
. O
2 O
micrograms O
/ O
L O
), O
and O
Pb O
( O
34 O
. O
5 O
micrograms O
/ O
dL O
) O
from O
bovine O
blood O
spiked O
with O
aqueous O
spiking O
- O
solutions O
prepared O
with O
salts O
of O
Cd O
, O
Hg O
, O
and O
Pb O
. O

Reagent O
strips O
are O
frequently O
used O
in O
the O
practice O
of O
laboratory O
medicine O
as O
well O
as O
outside O
the O
professional O
laboratories O
. O

The O
lowest O
detectable O
concentration O
was O
1 O
. O
0 O
ng O
/ O
ml O
in O
the O
serum O
. O

Precipitating O
antibodies O
for O
Thermophilic O
actinomycetes O
and O
M O
. O
f O
. O
were O
negative O
. O

LON O
- O
72 O
( O
34 O
isolates O
), O
LON O
- O
73 O
( O
1 O
), O
LON O
- O
71 O
( O
2 O
) O
and O
LON O
- O
10 O
( O
2 O
) O
were O
found O
at O
altitudes O
around O
2000 O
m O
, O
3 O
of O
them O
in O
a O
single O
village O
. O

Animal O
experimental O
and O
clinical O
applications O
of O
plates O
, O
screws O
and O
spinal O
segmental O
replacement O
implants O
made O
of O
this O
composite O
material O
have O
shown O
good O
results O
so O
far O
. O

Significance O
of O
delta O
- O
aminolevulinic O
acid O
analysis O
in O
clinical O
tests O

No O
changes O
were O
evident O
in O
the O
FR O
- O
task O
performance O
of O
controls O
that O
received O
daily O
saline O
injections O
. O

The O
antigen I-GENE
- I-GENE
specific I-GENE
IgG4 I-GENE
antibody I-GENE
seems O
to O
be O
an O
index O
in O
evaluating O
immunotherapy O
objectively O
. O

Although O
the O
fertility O
decline O
in O
the O
black O
population O
in O
the O
Mississippi O
Delta O
between O
the O
late O
1870 O
' O
s O
and O
early O
1930 O
' O
s O
closely O
paralleled O
that O
of O
the O
national O
black O
population O
, O
it O
rose O
much O
more O
dramatically O
in O
the O
1940 O
' O
s O
and O
1950 O
' O
s O
to O
almost O
1880 O
levels O
. O

According O
to O
their O
staining O
affinity O
for O
anti I-GENE
- I-GENE
T I-GENE
antibodies I-GENE
, O
the O
glandular O
tissue O
cells O
were O
classified O
as O
T I-GENE
-, O
T I-GENE
+, O
T I-GENE
++, O
and O
T I-GENE
and O
the O
annual O
changes O
in O
the O
numbers O
of O
these O
cell O
populations O
, O
as O
well O
as O
in O
the O
volume O
occupied O
by O
the O
glandular O
tissue O
, O
were O
calculated O
. O

Ampicillin O
( O
AMP O
) O
alone O
or O
with O
an O
aminoglycoside O
( O
AMI O
) O
was O
the O
treatment O
in O
9 O
and O
16 O
cases O
, O
respectively O
. O

Alkoxymetgyl O
- O
3 O
, O
4 O
- O
dimethylpyridinium O
chlorides O
were O
synthetized O
by O
reacting O
3 O
, O
4 O
- O
dimethylpyridine O
with O
chloromethyl O
alkyl O
ethers O
, O
while O
1 O
- O
ethyloxymethyl O
- O
3 O
- O
alkylthiomethylimidazolium O
chlorides O
were O
obtained O
in O
reactions O
of O
1 O
- O
ethyloxymethylimidazol O
with O
chloromethyl O
alkyl O
sulfides O
. O

We O
investigated O
the O
incidence O
of O
congenital O
color O
deficiency O
among O
Koreans O
by O
the O
use O
of O
H O
- O
R O
- O
R O
pseudoisochromatic O
plates O
. O

Eighty O
patients O
presenting O
to O
HGGM O
with O
non O
- O
Hodgkin O
' O
s O
lymphomas O
between O
1962 O
and O
1986 O
, O
were O
reviewed O
. O

The O
relation O
between O
VE O
/ O
VO2 O
and O
Q O
/ O
VO2 O
showed O
a O
significant O
negative O
correlation O
( O
r O
= O
- O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
01 O
). O

The O
differential O
diagnosis O
of O
both O
affections O
is O
based O
on O
the O
clinical O
course O
, O
sialography O
and O
CT O
examination O
which O
along O
with O
modern O
ATB O
treatment O
significantly O
modify O
hitherto O
used O
surgical O
therapy O
. O

Retrograde O
filling O
consists O
in O
sealing O
endodontics O
system O
directly O
at O
the O
apical O
zone O
after O
surgical O
approach O
. O

Collaborative O
study O
of O
Japanese O
Pharmacopoeia O
Heparin O
Sodium O
Reference O
Standard O

Serological O
studies O
at O
the O
early O
relapse O
stage O
of O
this O
disease O
showed O
increased O
serum I-GENE
ANA I-GENE
, O
IgA I-GENE
and O
IgM I-GENE
level O
with O
normal O
IgG I-GENE
and O
decrease O
of O
C3 I-GENE
and O
C4 I-GENE
. O

The O
maximum O
stress O
due O
to O
the O
hygroscopic O
examination O
of O
the O
composite O
was O
0 O
. O
74 O
kg O
/ O
mm2 O
at O
equilibrium O
of O
the O
water O
absorbed O
of O
the O
composite O
. O

Ischemic O
heart O
disease O
evaluated O
by O
exercise O
stress O
thallium O
- O
201 O
myocardial O
scintigraphy O
: O
a O
comparison O
of O
SPECT O
and O
bull O
' O
s O
eye O
display O

Sequence O
analysis O
of O
the O
47 I-GENE
- I-GENE
kilodalton I-GENE
major I-GENE
integral I-GENE
membrane I-GENE
immunogen I-GENE
of I-GENE
Treponema I-GENE
pallidum I-GENE
. O

Potential O
consensus O
sequences O
for O
early O
and O
late O
regulatory O
elements O
were O
identified O
. O

An O
FP I-GENE
mutant I-GENE
, O
AcFP875 I-GENE
- I-GENE
2 I-GENE
, O
had O
a O
1 O
. O
6 O
- O
kbp O
insertion O
of O
S O
. O
frugiperda O
DNA O
near O
the O
5 O
' O
end O
of O
these O
transcripts O
which O
by O
S1 I-GENE
analysis O
were O
shown O
to O
initiate O
within O
the O
host O
cell O
sequence O
. O

Construction O
of O
a O
RIP1 I-GENE
deletion O
strain O
and O
isolation O
of O
temperature O
- O
sensitive O
mutants O
. O

These O
data O
suggest O
that O
hypocitraturia O
in O
type O
I O
renal O
tubular O
acidosis O
may O
be O
due O
to O
a O
defect O
in O
proximal O
tubule O
function O
. O

Concomitant O
chronic O
lymphocytic O
leukemia O
, O
acute O
myeloid O
leukemia O
, O
and O
thrombosis O
with O
protein I-GENE
C I-GENE
deficiency O
. O

Vivid O
visual O
hallucinations O
without O
other O
psychopathology O
have O
been O
reported O
for O
several O
hundred O
years O
. O

In O
the O
whole O
group O
, O
basal O
GH I-GENE
and O
somatomedin I-GENE
- I-GENE
C I-GENE
levels O
decreased O
from O
a O
mean O
(+/- O
standard O
error O
of O
the O
mean O
) O
of O
52 O
. O
3 O
+/- O
12 O
. O
7 O
to O
11 O
. O
1 O
+/- O
6 O
. O
3 O
ng O
/ O
ml O
and O
from O
7 O
. O
6 O
+/- O
0 O
. O
7 O
to O
2 O
. O
5 O
+/- O
0 O
. O
5 O
U O
/ O
ml O
, O
respectively O
. O

Application O
of O
different O
criteria O
of O
cure O
revealed O
that O
19 O
patients O
( O
66 O
%) O
had O
basal O
GH I-GENE
levels O
below O
5 O
ng O
/ O
ml O
, O
17 O
patients O
( O
59 O
%) O
had O
normal O
somatomedin I-GENE
- I-GENE
C I-GENE
values O
, O
16 O
patients O
( O
55 O
%) O
had O
complete O
GH I-GENE
suppression O
( O
less O
than O
1 O
ng O
/ O
ml O
) O
during O
OGTT O
, O
and O
13 O
patients O
( O
45 O
%) O
met O
the O
above O
- O
mentioned O
criteria O
with O
disappearance O
of O
the O
paradoxical O
GH I-GENE
response O
to O
TRH I-GENE
/ O
GnRH I-GENE
test O
. O

It O
suggests O
a O
sequence O
of O
surgical O
planning O
that O
can O
prevent O
them O
and O
also O
offers O
ways O
of O
dealing O
with O
the O
problems O
should O
they O
occur O
. O

In O
Rat O
- O
1a O
cells O
the O
expression O
of O
human I-GENE
c I-GENE
- I-GENE
jun I-GENE
mRNA I-GENE
was O
associated O
with O
the O
ability O
to O
clone O
in O
soft O
agarose O
and O
form O
tumors O
in O
nude O
mice O
. O

Furthermore O
, O
formation O
of O
foci O
of O
transformed O
RECs O
by O
the O
c I-GENE
- I-GENE
jun I-GENE
/ O
ras I-GENE
combination O
was O
augmented O
3 O
- O
fold O
by O
the O
tumor O
promoter O
phorbol O
12 O
- O
tetradecanoate O
13 O
- O
acetate O
. O

Platelet I-GENE
activating I-GENE
factor I-GENE
was O
given O
in O
six O
doses O
at O
15 O
minute O
intervals O
and O
airway O
response O
measured O
as O
change O
in O
partial O
expiratory O
flow O
at O
30 O
% O
of O
vital O
capacity O
( O
Vp30 O
). O

There O
was O
no O
significant O
correlation O
between O
baseline O
PC40 O
methacholine O
and O
the O
maximal O
fall O
in O
Vp30 O
after O
either O
the O
first O
( O
12 O
micrograms O
) O
or O
the O
second O
dose O
( O
24 O
micrograms O
) O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
. O

Both O
BG O
and O
IRI I-GENE
concentrations O
during O
the O
OGTT O
were O
the O
lowest O
in O
body O
builders O
, O
medium O
in O
controls O
, O
and O
the O
highest O
in O
obese O
men O
. O

Postcoital O
contraception O
: O
a O
family O
planning O
study O
. O

A O
0 O
. O
5 O
rating O
was O
intended O
to O
characterize O
subjects O
in O
whom O
mild O
cognitive O
impairment O
due O
to O
senile O
dementia O
of O
the O
Alzheimer O
type O
was O
suspected O
but O
was O
insufficient O
in O
degree O
to O
warrant O
a O
diagnosis O
of O
definite O
dementia O
. O

An O
implant O
may O
release O
a O
drug O
either O
by O
diffusion O
concurrent O
with O
dissolution O
of O
the O
polymeric O
implant O
material O
without O
depolymerization O
( O
Type O
A O
) O
or O
by O
bioerosion O
involving O
depolymerization O
( O
Type O
B O
). O

Although O
it O
is O
well O
known O
that O
calcium O
channel O
blockers O
can O
influence O
contraction O
of O
vascular O
smooth O
muscle O
, O
there O
is O
less O
knowledge O
on O
its O
effect O
on O
excitation O
contraction O
coupling O
in O
the O
endocrine O
glands O
and O
more O
specifically O
on O
insulin I-GENE
and O
glucagon I-GENE
release O
. O

Many O
studies O
have O
pointed O
out O
the O
possibility O
of O
" O
masked O
" O
organic O
factors O
in O
erectile O
impotence O
, O
detectable O
only O
by O
means O
of O
laboratory O
investigations O
: O
mild O
hypogonadism O
, O
hyperprolactinemia O
, O
occlusions O
selectively O
located O
at O
the O
site O
of O
the O
sexual O
arteries O
, O
venous O
incompetence O
, O
subclinical O
neuropathies O
. O

The O
site O
- O
specific O
DNA O
inversion O
system O
Cin I-GENE
encoded O
by O
the O
bacteriophage O
P1 O
consists O
of O
a O
recombinase I-GENE
, O
two O
inverted O
crossing O
- O
over O
sites O
and O
a O
recombinational O
enhancer O
. O

The O
terminator O
region O
supported O
termination O
of O
transcripts O
initiated O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
in O
vivo O
. O

US O
- O
Doppler O
has O
recently O
gained O
attention O
as O
a O
noninvasive O
method O
for O
the O
functional O
evaluation O
of O
arteriovenous O
fistulas O
( O
FAV O
). O

Doppler O
echo O
in O
evaluating O
arteriovenous O
fistulae O
for O
dialysis O

Improved O
cosmesis O
, O
extension O
of O
the O
scope O
of O
the O
problems O
that O
can O
be O
addressed O
with O
this O
repair O
( O
including O
treatment O
of O
a O
distal O
urethrocutaneous O
fistula O
) O
and O
the O
ease O
with O
which O
the O
Arap O
procedure O
can O
be O
performed O
are O
the O
advantages O
that O
this O
operation O
has O
over O
other O
1 O
- O
stage O
distal O
hypospadias O
repairs O
. O

Following O
the O
patients O
during O
a O
course O
of O
therapy O
with O
a O
selective O
vasodilator O
calcium O
antagonist O
, O
the O
beta O
- O
adrenergic O
reflex O
vasodilation O
became O
substantially O
attenuated O
but O
was O
preserved O
during O
a O
placebo O
course O
of O
therapy O
. O

The O
galactose I-GENE
transporter I-GENE
shows O
both O
sequence O
and O
structural O
homology O
with O
a O
superfamily O
of O
sugar I-GENE
transporters I-GENE
which O
includes O
the O
human I-GENE
HepG2 I-GENE
- I-GENE
erythrocyte I-GENE
and I-GENE
fetal I-GENE
muscle I-GENE
glucose I-GENE
transporters I-GENE
, O
the O
rat I-GENE
brain I-GENE
and I-GENE
liver I-GENE
glucose I-GENE
transporters I-GENE
, O
the O
Escherichia I-GENE
coli I-GENE
xylose I-GENE
and I-GENE
arabinose I-GENE
permeases I-GENE
, O
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
glucose I-GENE
, I-GENE
maltose I-GENE
, I-GENE
and I-GENE
galactose I-GENE
transporters I-GENE
. O

Of O
110 O
previously O
untreated O
patients O
who O
had O
entered O
the O
study O
of O
protocol O
TCL821 O
, O
96 O
were O
evaluable O
. O

There O
were O
3 O
/ O
32 O
( O
9 O
. O
4 O
per O
cent O
) O
adverse O
reactions O
( O
ADRs O
), O
and O
one O
case O
each O
of O
nausea O
, O
dizziness O
and O
increased O
menstrual O
flow O
. O

More O
mRNA O
corresponding O
to O
nagB I-GENE
and O
nagA I-GENE
is O
detected O
than O
that O
corresponding O
to O
the O
distal O
genes O
, O
nagC I-GENE
and O
nagD I-GENE
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
) O
is O
reported O
to O
cause O
a O
shock O
syndrome O
similar O
to O
that O
produced O
by O
endotoxin O
( O
LPS O
). O

The O
calcium O
requirement O
for O
hypothermic O
storage O
of O
the O
cardiac O
explant O
. O

The O
seventh O
cysteine O
residue O
of O
CTSE I-GENE
is O
located O
within O
the O
activation O
peptide O
region O
of O
the O
proenzyme O
. O

The O
p34 I-GENE
. I-GENE
8 I-GENE
gene I-GENE
has O
a O
strong O
codon O
usage O
bias O
which O
is O
strikingly O
different O
from O
that O
of O
the O
polyhedrin I-GENE
gene I-GENE
. O

Of O
the O
single O
- O
stranded O
DNA O
transformants O
, O
65 O
% O
resulted O
from O
replacement O
of O
the O
resident O
met2 I-GENE
mutation I-GENE
by O
the O
exogenous O
wild O
- O
type O
allele O
. O

The O
results O
strongly O
support O
the O
notion O
that O
the O
OBF1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
the O
OBF1 I-GENE
protein I-GENE
are O
important O
for O
normal O
ARS O
function O
as O
an O
origin O
of O
replication O
. O

On O
the O
basis O
of O
S1 I-GENE
nuclease I-GENE
protection O
analysis O
of O
RNA O
preparations O
from O
several O
mouse O
tissues O
, O
both O
dhfr I-GENE
and O
divergent O
genes O
showed O
similar O
levels O
of O
expression O
but O
did O
show O
some O
specificity O
in O
start O
site O
utilization O
. O

Four O
out O
of O
10 O
patients O
showed O
clinical O
improvement O
according O
to O
Ritchie O
- O
Index O
, O
pain O
score O
, O
ESR O
and O
CRP I-GENE
. O

62 O
: O
2491 O
- O
2499 O
, O
1987 O
). O

With O
both O
wild O
- O
type O
and O
the O
mutant O
enzymes O
, O
ATP O
activates O
both O
[ O
14C O
] O
Asp O
in O
equilibrium O
N O
- O
carbamyl O
- O
L O
- O
aspartate O
( O
C O
- O
Asp O
) O
and O
the O
[ O
32P O
] O
carbamyl O
phosphate O
( O
C O
- O
P O
) O
in O
equilibrium O
Pi O
exchanges O
. O

Survival O
rates O
for O
the O
original O
treatment O
group O
were O
84 O
. O
5 O
% O
and O
57 O
. O
6 O
% O
at O
12 O
and O
21 O
months O
, O
respectively O
; O
for O
the O
delayed O
treatment O
group O
, O
78 O
. O
8 O
% O
and O
64 O
. O
6 O
% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
and O
78 O
. O
8 O
% O
and O
47 O
. O
5 O
% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
for O
77 O
subjects O
with O
AIDS O
and O
93 O
. O
0 O
% O
and O
71 O
. O
8 O
%, O
respectively O
, O
for O
50 O
subjects O
with O
AIDS O
- O
related O
complex O
in O
the O
original O
treatment O
group O
. O

Mapping O
results O
suggested O
that O
the O
complementation O
group O
identified O
by O
these O
mutants O
is O
allelic O
to O
the O
ag I-GENE
alpha I-GENE
1 I-GENE
mutation O
identified O
previously O
. O

The O
products O
of O
genes O
ura10 I-GENE
and O
ura3 I-GENE
are O
proposed O
to O
participate O
in O
the O
channeling O
of O
orotidine O
monophosphate O
. O

After O
the O
application O
of O
RS O
86 O
, O
REM O
latency O
was O
shortened O
in O
all O
groups O
under O
investigation O
. O

Hybridization O
analysis O
showed O
that O
the O
size O
of O
the O
mRNA O
is O
about O
1 O
. O
4 O
kilobases O
. O

Agranulocytosis O
treatment O
with O
rhGM I-GENE
- I-GENE
CSF I-GENE

The O
R I-GENE
. I-GENE
meliloti I-GENE
nifH I-GENE
promoter I-GENE
but O
not O
the O
K I-GENE
. I-GENE
pneumoniae I-GENE
nifH I-GENE
promoter I-GENE
showed O
sigma I-GENE
54 I-GENE
- O
dependent O
methylation O
protection O
of O
guanine O
residues O
at O
- O
14 O
, O
- O
25 O
and O
- O
26 O
, O
the O
most O
conserved O
nucleotides O
characteristic O
of O
sigma I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
. O

Major O
clinical O
symptoms O
of O
the O
disease O
were O
defined O
in O
this O
group O
of O
patients O
. O

Recently O
, O
an O
alternatively O
spliced O
form O
of O
c I-GENE
- I-GENE
myb I-GENE
- I-GENE
encoded I-GENE
mRNA I-GENE
has O
been O
identified O
in O
murine O
cells O
containing O
either O
normal O
or O
rearranged O
c I-GENE
- I-GENE
myb I-GENE
genes I-GENE
. O

Routine O
clinical O
analysis O
revealed O
lower O
hematocrit O
and O
hemoglobin I-GENE
, O
and O
elevated O
BUN O
and O
alkaline I-GENE
phosphatase I-GENE
in O
the O
treated O
group O
. O

To O
assess O
the O
health O
significance O
of O
the O
early O
renal O
changes O
after O
chronic O
exposure O
to O
cadmium O
, O
23 O
workers O
removed O
from O
exposure O
because O
of O
the O
discovery O
of O
an O
increased O
urinary O
excretion O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
or O
retinol I-GENE
binding I-GENE
protein I-GENE
, O
or O
both O
, O
have O
been O
examined O
once O
a O
year O
for O
five O
years O
. O

In O
order O
to O
study O
the O
structural O
and O
functional O
organization O
of O
the O
eukaryotic O
nucleolus O
, O
we O
have O
started O
to O
isolate O
and O
characterize O
nucleolar O
components O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

A O
transcription O
factor O
exclusion O
assay O
was O
used O
to O
show O
that O
the O
PCF1 I-GENE
mutation I-GENE
affects O
two O
distinct O
stages O
in O
transcription O
: O
one O
prior O
to O
and O
one O
after O
stable O
complex O
formation O
; O
and O
that O
these O
effects O
are O
mediated O
by O
a O
component O
of O
the O
stable O
complex O
. O

Psychiatry O
and O
the O
skin O
. O

These O
adverse O
effects O
usually O
abate O
with O
time O
. O

The O
cytosolic O
glutathione I-GENE
S I-GENE
- I-GENE
transferases I-GENE
( O
GSTs I-GENE
, O
EC I-GENE
2 I-GENE
. I-GENE
5 I-GENE
. I-GENE
1 I-GENE
. I-GENE
18 I-GENE
) O
are O
a O
superfamily O
of O
dimeric O
isoenzymes O
which O
catalyze O
the O
conjugation O
of O
electrophilic O
substrates O
with O
glutathione O
. O

Furthermore O
, O
the O
3 O
'- O
untranslated O
regions O
of O
pmGT10 I-GENE
display O
a O
marked O
degree O
of O
homology O
to O
the O
3 O
' O
region O
of O
the O
rat I-GENE
Yb1 I-GENE
gene I-GENE
, O
while O
this O
region O
of O
pmGT2 I-GENE
displays O
marked O
homology O
to O
the O
corresponding O
region O
of O
the O
rat I-GENE
Yb2 I-GENE
gene I-GENE
. O

Model O
IV O
: O
primary O
abutments O
with O
the O
lateral O
incisor O
and O
the O
second O
molar O
as O
secondary O
abutments O
. O

The O
incidence O
of O
fetal O
breathing O
movements O
( O
06 O
. O
00 O
- O
10 O
. O
00 O
h O
) O
decreased O
with O
increasing O
gestational O
age O
while O
fetal O
arterial O
concentrations O
of O
plasma O
PGE O
increased O
significantly O
over O
the O
same O
period O
of O
gestation O
. O

During O
the O
first O
3 O
min O
of O
recovery O
, O
plasma O
potassium O
fell O
rapidly O
in O
spite O
of O
nearly O
unchanged O
blood O
acidosis O
and O
significantly O
decreasing O
bicarbonate O
concentration O
. O

The O
present O
data O
also O
suggest O
that O
when O
compared O
to O
the O
systemic O
vascular O
bed O
, O
the O
pulmonary O
vascular O
bed O
is O
less O
responsive O
to O
bolus O
administration O
of O
ET I-GENE
- I-GENE
1 I-GENE
. O

In O
comparison O
with O
normal O
pregnant O
women O
and O
normal O
non O
- O
pregnant O
women O
, O
women O
with O
PIH O
showed O
an O
increase O
in O
heart O
rate O
, O
suggesting O
an O
increased O
peripheral O
sympathetic O
tone O
, O
and O
an O
initial O
derangement O
in O
renal O
function O
as O
shown O
by O
the O
increase O
in O
serum O
uric O
acid O
and O
reduction O
in O
sodium O
excretion O
and O
total O
and O
fractional O
calcium O
excretion O
at O
any O
given O
level O
of O
sodium O
excretion O
. O

We O
have O
examined O
the O
role O
of O
two O
recombination O
- O
and O
repair O
- O
defective O
mutations O
, O
rad1 I-GENE
and O
rad52 I-GENE
, O
on O
direct O
repeat O
recombination O
in O
transcriptionally O
active O
and O
inactive O
sequences O
. O

The O
encoded O
protein O
has O
a O
leader O
sequence O
of O
27 O
amino O
acids O
. O

On O
the O
other O
hand O
, O
knowledge O
of O
the O
epidemiology O
of O
Parkinson O
' O
s O
disease O
is O
necessary O
in O
creating O
etiological O
hypotheses O
, O
since O
only O
hypotheses O
consistent O
with O
the O
epidemiological O
profile O
deserve O
careful O
testing O
. O

The O
stereoselectivity O
of O
drug O
action O
. O

Scotchbond O
2 O
showed O
the O
least O
dye O
penetration O
but O
not O
statistically O
less O
than O
the O
XR O
bond O
/ O
Silus O
Plus O
combination O
. O

A O
combination O
of O
cisplatin O
and O
5 O
- O
fluorouracil O
, O
both O
administered O
4 O
days O
continuously O
as O
infusion O
, O
was O
assessed O
in O
advanced O
head O
and O
neck O
cancer O
. O

Metformin O
plasma O
concentrations O
remained O
unchanged O
except O
for O
patients O
transferred O
from O
1 O
. O
5 O
to O
2 O
. O
0 O
g O
daily O
to O
850 O
mg O
twice O
daily O
; O
in O
these O
patients O
plasma O
concentrations O
increased O
from O
1 O
. O
83 O
+/- O
0 O
. O
87 O
to O
2 O
. O
50 O
+/- O
0 O
. O
89 O
micrograms O
/ O
l O
( O
p O
less O
than O
0 O
. O
01 O
). O

Diagnosis O
of O
primary O
sclerosing O
cholangitis O
in O
a O
blood O
donor O
with O
elevated O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
. O

When O
statistically O
analyzed O
in O
various O
subgroupings O
, O
the O
obtained O
average O
sedimentation O
coefficients O
and O
polydispersity O
profiles O
supported O
the O
following O
conclusions O
: O
( O
a O
) O
loss O
of O
proteoglycan O
aggregation O
and O
sedimentability O
is O
confirmed O
to O
be O
a O
primary O
sign O
of O
cartilage O
matrix O
degradation O
; O
( O
b O
) O
higher O
S O
values O
for O
proteoglycans O
of O
the O
high O
weight O
( O
HW O
)- O
bearing O
areas O
and O
lower O
values O
for O
those O
of O
the O
low O
weight O
( O
LW O
)- O
bearing O
areas O
were O
a O
typical O
finding O
in O
normal O
cartilage O
samples O
; O
( O
c O
) O
inversion O
of O
this O
pattern O
was O
indicative O
of O
matrix O
degradation O
, O
suggesting O
that O
the O
HW O
regions O
are O
more O
affected O
than O
the O
LW O
- O
bearing O
areas O
; O
( O
d O
) O
the O
average O
S O
value O
distribution O
across O
cartilage O
thickness O
tended O
to O
resemble O
the O
corresponding O
proteoglycan O
content O
versus O
distance O
from O
articular O
surface O
; O
and O
( O
e O
) O
the O
deepest O
cartilage O
layer O
had O
, O
in O
most O
cases O
, O
the O
smallest O
amount O
of O
aggregates O
while O
the O
highest O
average O
sedimentability O
was O
observed O
at O
the O
middle O
zone O
of O
the O
normal O
samples O
. O

A O
significant O
relationship O
existed O
during O
the O
evolution O
of O
the O
disease O
between O
CRS O
/ O
BW O
and O
gas O
exchange O
parameters O
( O
FIO2 O
and O
a O
/ O
AO2 O
ratio O
) O
( O
P O
less O
than O
0 O
. O
01 O
), O
but O
gas O
exchange O
improved O
earlier O
than O
lung O
mechanics O
. O

End O
points O
measured O
were O
perioperative O
( O
30 O
- O
day O
) O
myocardial O
infarction O
( O
MI O
) O
rate O
and O
death O
. O

The O
predicted O
molecular O
weight O
of O
the O
polyprotein O
encoded O
by O
ORF1 O
is O
33 O
kilodaltons O
( O
kDa O
). O

Thus O
RV O
O2 O
demand O
fell O
when O
RC O
O2 O
supply O
was O
reduced O
, O
although O
a O
flow O
reserve O
was O
available O
. O

An O
alternative O
method O
of O
UKM O
is O
proposed O
based O
on O
collecting O
a O
small O
fraction O
of O
spent O
dialysate O
flow O
for O
3 O
consecutive O
dialyses O
. O

Liquid O
chromatography O
with O
amperometric O
detection O
( O
LC O
/ O
AD O
) O
is O
used O
to O
determine O
fluazifop O
acid O
produced O
from O
the O
metabolism O
or O
base O
hydrolysis O
of O
fluazifop O
- O
butyl O
in O
soybeans O
and O
soybean O
oil O
. O

The O
dichloromethane O
is O
removed O
, O
mobile O
phase O
solvent O
is O
added O
, O
and O
aliquots O
are O
injected O
onto O
a O
PRP O
- O
1 O
liquid O
chromatographic O
column O
; O
fluazifop O
acid O
is O
separated O
from O
coextracted O
compounds O
and O
detected O
at O
an O
applied O
potential O
of O
+ O
1 O
. O
25 O
V O
, O
using O
an O
amperometric O
electrochemical O
detector O
in O
the O
oxidation O
mode O
. O

Primer O
extension O
experiments O
indicated O
that O
the O
transcription O
initiation O
site O
mapped O
to O
a O
position O
on O
gene I-GENE
IV I-GENE
that O
was O
analogous O
to O
that O
reported O
for O
the O
structurally O
similar O
P I-GENE
- I-GENE
450e I-GENE
gene I-GENE
. O

Significantly O
, O
the O
polymerase O
chain O
reaction O
results O
demonstrated O
that O
gene I-GENE
IV I-GENE
transcripts I-GENE
were O
associated O
with O
hepatic O
polysome O
fractions O
, O
indicating O
their O
active O
utilization O
in O
this O
tissue O
. O

Validation O
of O
the O
survey O
of O
work O
styles O
: O
a O
profile O
measure O
of O
the O
type O
A O
behaviour O
pattern O
. O

Only O
one O
ADR O
was O
related O
definitely O
to O
ciprofloxacin O
therapy O
. O

HIV O
infectiousness O
and O
the O
AIDS O
epidemic O
. O

From O
day O
30 O
after O
turnout O
, O
the O
PFB O
- O
group O
had O
significantly O
lower O
serum I-GENE
pepsinogen I-GENE
levels O
, O
which O
reflects O
the O
low O
degree O
of O
abomasal O
damage O
in O
these O
animals O
. O

The O
corresponding O
inhibition O
of O
acid I-GENE
phosphatase I-GENE
activity O
in O
control O
male O
and O
female O
guinea O
pigs O
was O
15 O
. O
91 O
% O
and O
20 O
. O
33 O
% O
respectively O
. O

Its O
clinical O
and O
histopathologic O
characteristics O
. O

Normocapnic O
( O
PACO2 O
= O
40 O
mm O
Hg O
) O
ventilatory O
drive O
increased O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
in O
six O
subjects O
( O
Type O
1 O
response O
) O
and O
decreased O
substantially O
in O
the O
others O
( O
Type O
2 O
response O
); O
with O
hypercapnia O
, O
the O
changes O
in O
drive O
were O
attenuated O
in O
both O
groups O
. O

Fundus O
changes O
in O
( O
type O
II O
) O
mesangiocapillary O
glomerulonephritis O
simulating O
drusen O
: O
a O
histopathological O
report O
. O

Chronic O
dose O
effects O
of O
methyl O
parathion O
on O
nuthatches O
: O
cholinesterase I-GENE
and O
ptilochronology O
. O

The O
titer O
of O
anti I-GENE
HSV I-GENE
type I-GENE
1 I-GENE
and O
anti I-GENE
HSV I-GENE
type I-GENE
2 I-GENE
antibodies I-GENE
in O
the O
mothers O
' O
and O
cord O
blood O
was O
determined O
and O
compared O
. O

Kidney O
weight O
and O
kidney O
- O
to O
- O
body O
weight O
ratio O
were O
significantly O
elevated O
at O
the O
highest O
dose O
level O
after O
10 O
weeks O
and O
at O
the O
two O
higher O
dose O
levels O
after O
15 O
weeks O
of O
exposure O
. O

Allelic O
variation O
in O
HLA I-GENE
- I-GENE
B I-GENE
and O
HLA I-GENE
- I-GENE
C I-GENE
sequences I-GENE
and O
the O
evolution O
of O
the O
HLA I-GENE
- I-GENE
B I-GENE
alleles I-GENE
. O

A O
method O
for O
determining O
optimal O
development O
conditions O
by O
summary O
oxygen O
consumption O

Men O
were O
more O
positive O
about O
their O
physical O
fitness O
than O
women O
. O

Handgrip O
dynamometry O
was O
also O
carried O
out O
in O
249 O
of O
the O
patients O
. O

In O
cerebrospinal O
fluid O
, O
an O
ADA I-GENE
catalytic O
concentration O
above O
0 O
. O
15 O
mu O
kat O
/ O
L O
strongly O
suggests O
tuberculous O
meningitis O
in O
patients O
older O
than O
7 O
years O
( O
sensitivity O
1 O
. O
00 O
, O
specificity O
0 O
. O
99 O
and O
efficiency O
0 O
. O
99 O
). O

NERVTRACK O
contains O
4000 O
anatomical O
data O
items O
arranged O
in O
a O
tree O
- O
like O
manner O
reflecting O
structural O
and O
functional O
relationships O
. O

Swim O
- O
over O
: O
an O
alternative O
method O
for O
harvesting O
motile O
spermatozoa O
. O

Perfusion O
washout O
: O
increasing O
a O
microvascular O
free O
flap O
tolerance O
to O
ischemia O
. O

Similarly O
, O
the O
sequence O
of O
the O
U2 I-GENE
RNA I-GENE
region I-GENE
shown O
to O
be O
involved O
in O
pre O
- O
mRNA O
branchpoint O
recognition O
in O
yeast O
, O
and O
exactly O
conserved O
in O
metazoan I-GENE
U2 I-GENE
RNAs I-GENE
, O
was O
totally O
divergent O
in O
trypanosomes O
. O

It O
is O
striking O
that O
the O
active O
CHO O
spacer O
promoter O
violated O
the O
otherwise O
universal O
rule O
that O
metazoan I-GENE
RNA I-GENE
polymerase I-GENE
I I-GENE
promoters I-GENE
all O
have O
a O
G O
residue O
at O
position O
- O
16 O
. O

A O
raised O
amplitude O
of O
the O
aggregation O
of O
plates O
and O
a O
decrease O
in O
the O
threshold O
of O
their O
sensitivity O
to O
ADP O
were O
established O
in O
the O
persons O
with O
types O
IIa O
and O
IIb O
HLP O
and O
in O
CHD O
without O
HLP O
. O

Significant O
intergroup O
differences O
are O
highlighted O
for O
both O
selected O
dentoskeletal O
and O
soft O
tissue O
profile O
variables O
. O

The O
author O
provides O
a O
rationale O
for O
an O
interactional O
view O
and O
presents O
a O
case O
in O
which O
post O
- O
surgical O
hiccups O
were O
successfully O
treated O
, O
using O
principles O
developed O
by O
the O
Mental O
Research O
Institute O
. O

The O
relative O
toxicity O
of O
nickel O
oxide O
( O
NiO O
), O
nickel O
sulfate O
hexahydrate O
( O
NiSO4 O
. O
6H2O O
), O
and O
nickel O
subsulfide O
( O
Ni3S2 O
) O
was O
studied O
in O
F344 O
/ O
N O
rats O
and O
B6C3F1 O
mice O
after O
inhalation O
exposure O
for O
6 O
hr O
/ O
day O
, O
5 O
days O
/ O
week O
, O
for O
13 O
weeks O
. O

Light O
microscopical O
and O
routine O
immunohistochemical O
studies O
of O
a O
cervical O
neoplasm O
in O
a O
32 O
year O
old O
woman O
initially O
suggested O
a O
histiocytic O
lymphoma O
, O
but O
histochemical O
staining O
for O
chloroacetate I-GENE
esterase I-GENE
established O
the O
correct O
diagnosis O
. O

From O
the O
National O
Institutes O
of O
Health O
. O

Molecular O
cloning O
and O
characterisation O
of O
the O
two O
homologous O
genes O
coding O
for O
nitrate I-GENE
reductase I-GENE
in I-GENE
tobacco I-GENE
. O

In O
the O
final O
model O
, O
grade O
( O
p O
= O
0 O
. O
0002 O
), O
peritoneal O
cytologic O
results O
( O
p O
= O
0 O
. O
0002 O
), O
progesterone I-GENE
receptor I-GENE
status O
( O
p O
= O
0 O
. O
004 O
), O
and O
age O
as O
a O
continuous O
variable O
( O
p O
= O
0 O
. O
008 O
) O
were O
most O
closely O
associated O
with O
disease O
- O
free O
survival O
. O

In O
contrast O
, O
despite O
external O
radiation O
therapy O
, O
brain O
metastases O
proved O
fatal O
. O

COUP I-GENE
transcription I-GENE
factor I-GENE
is O
a O
member O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

In O
Experiment O
2 O
, O
we O
again O
used O
classification O
, O
but O
the O
fixed O
standard O
75 O
was O
not O
at O
the O
center O
of O
the O
range O
of O
target O
numbers O
( O
20 O
, O
21 O
, O
... O

Cosmid O
clones O
containing O
both O
VNTR O
sequences O
were O
identified O
, O
and O
restriction O
mapping O
showed O
them O
to O
be O
less O
than O
15 O
kb O
apart O
. O

The O
oxygen O
uptake O
( O
VO2 O
), O
carbon O
dioxide O
output O
( O
VCO2 O
), O
respiratory O
rate O
( O
fR O
), O
minute O
ventilation O
( O
VE O
), O
alveolar O
ventilation O
( O
VA O
), O
alveolar O
oxygen O
pressure O
( O
PAO2 O
), O
and O
VE O
/ O
VO2 O
ratio O
were O
higher O
in O
the O
cows O
, O
while O
the O
tidal O
volume O
( O
VT O
) O
and O
physiological O
dead O
space O
( O
VD O
) O
were O
larger O
in O
the O
horses O
. O

Epithelial O
damage O
was O
not O
observed O
in O
any O
controls O
but O
was O
in O
all O
tissues O
exposed O
to O
SO2 O
. O

Among O
booked O
patients O
the O
maternal O
mortality O
rate O
was O
0 O
. O
32 O
and O
among O
unbooked O
patients O
11 O
. O
13 O
per O
1000 O
deliveries O
. O

The O
present O
study O
investigates O
whether O
prostaglandins O
" O
cytoprotect O
" O
the O
gastric O
mucosa O
against O
hemorrhage O
- O
induced O
stress O
ulceration O
by O
assessing O
the O
influence O
of O
16 O
, O
16 O
- O
dimethyl O
prostaglandin O
E2 O
( O
16 O
, O
16 O
- O
dm O
PGE2 O
) O
on O
gross O
and O
microscopic O
lesion O
formation O
, O
intramucosal O
tissue O
pH O
, O
H O
+ O
back O
- O
diffusion O
, O
and O
mucosal O
blood O
flow O
in O
rat O
gastric O
mucosa O
exposed O
to O
luminal O
acid O
( O
100 O
mM O
HCl O
) O
during O
hemorrhagic O
shock O
( O
13 O
ml O
/ O
kg O
for O
20 O
min O
). O

Transcripts O
characterized O
include O
( O
i O
) O
abundant O
monocistronic O
L11e I-GENE
and O
tricistronic O
L1e I-GENE
- O
L10e I-GENE
- O
L12e I-GENE
transcripts O
; O
( O
ii O
) O
less O
abundant O
bicistronic O
NAB I-GENE
- O
L11e I-GENE
and O
monocistronic O
NAB I-GENE
transcripts I-GENE
and O
( O
iii O
) O
a O
very O
rare O
ORF O
monocistronic O
transcript O
. O

Qualitatively O
, O
the O
results O
are O
similar O
for O
the O
two O
species O
: O
Both O
rhesus O
monkey O
and O
man O
have O
photopic O
and O
scotopic O
branches O
, O
which O
cross O
at O
approximately O
the O
same O
time O
in O
the O
dark O
and O
at O
approximately O
the O
same O
background O
luminance O
. O

Evidence O
from O
the O
structure O
of O
a O
number O
of O
cDNA O
clones O
, O
as O
well O
as O
S1 I-GENE
nuclease I-GENE
and O
primer O
extension O
studies O
supports O
the O
hypothesis O
that O
the O
PTHrP I-GENE
gene I-GENE
contains O
at O
least O
two O
mRNA O
transcription O
start O
points O
that O
define O
two O
putative O
regulatory O
domains O
. O

At O
each O
level O
of O
PaO2 O
we O
obtained O
simultaneous O
measures O
of O
arterial O
and O
venous O
blood O
gases O
, O
venous O
lactate O
concentration O
, O
and O
changes O
in O
the O
relative O
concentrations O
of O
inorganic O
phosphate O
, O
phosphocreatine O
, O
and O
ATP O
measured O
with O
31P O
magnetic O
resonance O
spectroscopy O
. O

The O
transcription O
initiation O
site O
was O
determined O
by O
S1 I-GENE
nuclease I-GENE
mapping O
. O

Endometrial O
biopsies O
and O
plasma O
oestradiol O
( O
E2 O
) O
and O
progesterone O
( O
P4 O
) O
levels O
in O
23 O
patients O
were O
evaluated O
during O
26 O
replacement O
therapy O
cycles O
for O
premature O
ovarian O
failure O
. O

The O
mobility O
of O
the O
upper O
and O
lower O
premolars O
under O
load O
was O
investigated O
in O
relation O
to O
the O
interproximal O
contact O
and O
occlusal O
facets O
. O

A O
larval I-GENE
albumin I-GENE
- I-GENE
like I-GENE
protein I-GENE
was O
not O
detectable O
by O
silver O
staining O
in O
serum O
of O
tadpoles O
before O
the O
beginning O
of O
metamorphosis O
at O
stage O
48 O
. O

Behaviorally O
, O
a O
pain O
- O
tolerant O
group O
( O
PT O
= O
29 O
Ss O
) O
tolerated O
the O
entire O
3 O
- O
min O
test O
( O
means O
= O
180 O
+/- O
0 O
sec O
), O
while O
a O
pain O
- O
sensitive O
group O
( O
PS O
= O
13 O
Ss O
) O
averaged O
only O
50 O
. O
31 O
+/- O
20 O
. O
81 O
sec O
of O
the O
cold O
- O
pressor O
test O
( O
t O
= O
16 O
. O
75 O
, O
P O
less O
than O
0 O
. O
0001 O
), O
replicating O
our O
earlier O
studies O
. O

This O
suggested O
that O
baboon I-GENE
liver I-GENE
class I-GENE
I I-GENE
ADH I-GENE
is O
of O
the O
same O
ancestral O
lineage O
as O
the O
human I-GENE
ADH I-GENE
- I-GENE
beta I-GENE
. O

Isolated O
proteinuria O
( O
i O
. O
e O
. O
without O
hematuria O
and O
/ O
or O
pyuria O
) O
is O
a O
frequent O
finding O
. O

Each O
individual O
shot O
25 O
bullets O
in O
about O
5 O
minutes O
, O
at O
an O
intensity O
level O
calculated O
at O
163 O
dB O
. O

Lithium O
delays O
the O
circadian O
rhythm O
of O
wheel O
- O
running O
in O
Syrian O
hamsters O
at O
plasma O
concentrations O
( O
0 O
. O
59 O
- O
0 O
. O
74 O
mM O
) O
that O
also O
cause O
toxic O
weight O
loss O
. O

Dynamic O
and O
static O
scintigrams O
, O
using O
99mtechnetium O
methylene O
diphosphonate O
, O
were O
obtained O
at O
zero O
, O
six O
, O
and O
12 O
weeks O
after O
fracture O
. O

On O
admission O
to O
our O
department O
in O
September O
, O
1987 O
, O
the O
patient O
was O
alert O
and O
had O
spastic O
paraparesis O
, O
the O
impairment O
of O
all O
sensory O
modalities O
below O
the O
level O
of O
Th O
10 O
and O
urinary O
disturbance O
. O

Prostaglandins O
and O
gallstones O

The O
nature O
of O
the O
process O
formed O
by O
the O
successive O
occurrences O
of O
this O
arrhythmia O
was O
studied O
in O
8 O
patients O
with O
a O
history O
of O
symptomatic O
paroxysmal O
AF O
. O

This O
would O
have O
had O
the O
effect O
of O
positioning O
the O
genes O
currently O
on O
the O
long O
arm O
adjacent O
to O
the O
centromeric O
heterochromatin O
, O
perhaps O
resulting O
in O
a O
" O
position O
effect O
" O
on O
transcription O
of O
these O
genes O
. O

Initial O
experience O
with O
a O
microprocessor O
controlled O
current O
based O
defibrillator O
. O

Obesity O
was O
strongly O
associated O
with O
the O
proportions O
of O
nonprotein O
- O
bound O
and O
albumin I-GENE
- O
bound O
estradiol O
, O
and O
inversely O
associated O
with O
sex I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
) O
levels O
and O
the O
proportion O
of O
SHBG I-GENE
- O
bound O
estradiol O
. O

Heterogeneous I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( I-GENE
hnRNP I-GENE
) I-GENE
core I-GENE
protein I-GENE
A1 I-GENE
is O
a O
major O
component O
of O
mammalian I-GENE
hnRNP I-GENE
40 I-GENE
S I-GENE
particles I-GENE
. O

Brain I-GENE
cholinesterase I-GENE
activity O
of O
nestling O
great O
egrets O
, O
snowy O
egrets O
and O
black O
- O
crowned O
night O
- O
herons O
. O
inhibition O
of O
brain I-GENE
cholinesterase I-GENE
( O
ChE I-GENE
) O
activity O
in O
birds O
is O
often O
used O
to O
diagnose O
exposure O
or O
death O
from O
organophosphorus O
or O
carbamate O
pesticides O
. O

The O
effect O
of O
zinc O
deficiency O
on O
trace O
metals O
in O
the O
liver O
, O
spleen O
, O
kidney O
, O
pancreas O
and O
duodenum O
was O
investigated O
in O
the O
control O
and O
zinc O
- O
deficient O
rats O
at O
17 O
days O
and O
20 O
days O
of O
pregnancy O
. O

Our O
findings O
support O
the O
view O
of O
a O
multifactorial O
genesis O
of O
the O
cardiac O
involvement O
in O
uremic O
patients O
. O

Heating O
cells O
to O
43 O
degrees O
C O
decreased O
the O
amount O
of O
newly O
synthesized O
rRNA O
to O
less O
than O
5 O
% O
of O
the O
control O
level O
and O
led O
to O
greater O
than O
95 O
% O
inhibition O
of O
transcription O
termination O
at O
a O
region O
355 O
to O
362 O
nucleotides O
downstream O
of O
the O
3 O
' O
end O
of O
28S I-GENE
rRNA I-GENE
, O
with O
readthrough O
continuing O
into O
the O
next O
transcription O
unit O
. O

Deletion O
analysis O
showed O
that O
the O
NF I-GENE
- I-GENE
4FA I-GENE
, O
NF I-GENE
- I-GENE
4FB I-GENE
, O
and O
AP I-GENE
- I-GENE
1 I-GENE
sequences O
are O
each O
necessary O
for O
full O
enhancer O
activity O
. O

Cord O
swelling O
was O
observed O
in O
2 O
patients O
who O
developed O
complete O
lesions O
. O

Reye O
' O
s O
syndrome O
: O
reports O
of O
7 O
cases O
in O
the O
period O
1982 O
- O
1987 O

When O
two O
- O
dimensional O
polyacrylamide O
gel O
electrophoretic O
patterns O
of O
[ O
35S O
] O
methionine O
- O
labeled O
proteins O
secreted O
from O
cells O
infected O
with O
parental O
and O
recombinant O
viruses O
were O
compared O
, O
a O
spot O
missing O
from O
the O
latter O
corresponded O
in O
molecular O
weigh O
and O
isoelectric O
point O
with O
that O
predicted O
from O
the O
N1L I-GENE
ORF I-GENE
. O

PULSE O
is O
used O
to O
set O
such O
NMR O
spectroscopic O
parameters O
as O
the O
delay O
and O
duration O
of O
rf O
transmit O
and O
receive O
gates O
, O
rf O
phase O
, O
sampling O
times O
, O
and O
such O
imaging O
parameters O
as O
rf O
pulse O
shape O
and O
gradient O
waveforms O
. O

Definite O
JPsA O
( O
24 O
patients O
) O
was O
defined O
as O
arthritis O
associated O
, O
but O
not O
necessarily O
coincident O
, O
with O
a O
typical O
psoriatic O
rash O
, O
or O
arthritis O
plus O
at O
least O
3 O
of O
4 O
minor O
criteria O
: O
dactylitis O
, O
nail O
pitting O
, O
psoriasis O
- O
like O
rash O
, O
or O
family O
history O
of O
psoriasis O
. O

Hence O
follows O
Kurti O
' O
s O
demand O
to O
mete O
out O
appropriate O
importance O
to O
the O
arguments O
. O

The O
author O
gives O
an O
account O
of O
antipsychotic O
, O
analgetic O
, O
myorelaxing O
and O
vasodilatating O
effects O
of O
some O
calcium O
antagonists O
, O
and O
their O
clinical O
application O
is O
discussed O
. O

A O
correlation O
coefficient O
was O
used O
for O
assessing O
the O
similarity O
of O
each O
map O
pattern O
with O
the O
normal O
mean O
IQRST O
map O
. O

A O
hospital O
- O
based O
study O
of O
the O
relationship O
between O
retained O
placenta O
and O
mastitis O
in O
dairy O
cows O
. O

This O
indicates O
that O
lipid O
peroxidation O
may O
be O
involved O
in O
the O
development O
of O
senile O
cataract O
and O
, O
as O
a O
direct O
consequence O
of O
retinal O
damage O
, O
also O
in O
the O
pathogenesis O
of O
cataract O
in O
diabetes O
and O
in O
severe O
myopia O
. O

The O
histological O
grading O
was O
certified O
in O
68 O
cases O
: O
12 O
G1 O
, O
39 O
G2 O
, O
17 O
G3 O
; O
extracapsular O
spread O
was O
found O
in O
20 O
/ O
54 O
cases O
( O
37 O
%). O

Asthma O
was O
significantly O
more O
often O
associated O
with O
ASA O
group O
( O
91 O
%) O
vs O
46 O
% O
at O
AT O
and O
in O
only O
16 O
% O
at O
INTR O
group O
. O

A O
value O
of O
1 O
. O
1 O
l O
/ O
kg O
was O
used O
for O
V O
in O
calculating O
all O
single O
sample O
estimates O
of O
clearance O
( O
CL O
), O
and O
a O
value O
of O
4 O
. O
3 O
l O
/ O
kg O
was O
used O
to O
calculate O
single O
sample O
estimates O
of O
clearance O
of O
plasma O
unbound O
drug O
( O
CLunb O
). O

The O
solitary O
kidney O
: O
a O
model O
of O
chronic O
hyperfiltration O
in O
humans O
. O

Halothane O
is O
metabolized O
by O
an O
oxidative O
pathway O
to O
stable O
, O
nonvolatile O
end O
products O
, O
trifluoroacetic O
acid O
( O
TFAA O
) O
and O
bromide O
( O
Br O
-), O
and O
by O
reductive O
pathways O
to O
Br O
- O
and O
inorganic O
fluoride O
( O
F O
-). O

The O
values O
were O
consistently O
lower O
( O
P O
less O
than O
0 O
. O
01 O
) O
during O
summer O
( O
3 O
. O
79 O
+/- O
0 O
. O
13 O
micrograms O
/ O
100 O
ml O
), O
as O
compared O
to O
winter O
( O
5 O
. O
06 O
+/- O
0 O
. O
27 O
). O

These O
results O
suggest O
that O
HAPE O
- O
S O
- O
S O
are O
prone O
to O
irregular O
nocturnal O
breathing O
patterns O
at O
high O
altitude O
, O
which O
is O
associated O
with O
the O
development O
of O
AMS O
, O
but O
it O
was O
not O
possible O
to O
determine O
whether O
these O
abnormal O
breathing O
patterns O
are O
a O
cause O
or O
an O
effect O
of O
AMS O
. O

Buflomedil O
( O
i O
. O
v O
.) O
induced O
a O
dose O
- O
dependent O
increase O
of O
cardiac O
output O
at O
0 O
. O
16 O
- O
0 O
. O
64 O
mg O
/ O
kg O
, O
biphasic O
changes O
at O
1 O
. O
28 O
and O
2 O
. O
56 O
mg O
/ O
kg O
and O
a O
marked O
decrease O
and O
subsequent O
slight O
increase O
at O
a O
large O
dose O
of O
5 O
. O
12 O
mg O
/ O
kg O
. O

It O
was O
possible O
to O
classify O
the O
animals O
into O
high O
and O
low O
responders O
according O
to O
the O
pattern O
of O
humoral O
immune O
response O
. O

Heart O
rate O
( O
HR O
), O
rectal O
temperature O
( O
Tre O
), O
blood O
pressure O
, O
temperature O
and O
relative O
humidity O
changes O
inside O
clothing O
were O
measured O
on O
18 O
professional O
firemen O
( O
mean O
age O
29 O
. O
4 O
+/- O
7 O
. O
4 O
yr O
, O
VO2 O
max O
41 O
. O
4 O
+ O
8 O
. O
8 O
ml O
kg O
- O
1 O
min O
- O
1 O
) O
wearing O
fire O
fighter O
' O
s O
uniforms O
( O
SU O
) O
or O
aluminized O
, O
fire O
resistant O
, O
impermeable O
clothing O
with O
self O
contained O
breathing O
apparatus O
( O
FE O
). O

The O
clinical O
tolerance O
and O
pharmacokinetics O
of O
FCE O
22101 O
( O
sodium O
( O
5R O
, O
6S O
)- O
6 O
-[( O
1R O
)- O
hydroxyethyl O
]- O
2 O
- O
carbamoyloxymethyl O
- O
2 O
- O
penem O
- O
3 O
- O
carboxylate O
), O
a O
new O
penem O
antibiotic O
, O
have O
been O
studied O
after O
giving O
a O
single O
i O
. O
v O
. O
dose O
of O
4 O
mg O
. O
kg O
- O
1 O
to O
ten O
healthy O
male O
volunteers O
. O

DNA O
blot O
hybridization O
suggests O
that O
the O
rat O
genome O
may O
contain O
more O
than O
one O
gene O
encoding O
PtdIns I-GENE
transfer I-GENE
protein I-GENE
. O

We O
use O
the O
term O
corticosteroid O
- O
dependent O
IA O
to O
refer O
to O
the O
serious O
problem O
of O
chronic O
IA O
requiring O
maintenance O
prednisone O
therapy O
. O

Another O
segment O
of O
CRL3 I-GENE
(- O
296 O
to O
- O
184 O
), O
also O
displaying O
enhancer O
function O
, O
contained O
tandem O
repeated O
sequences O
( O
DR O
- O
A1 O
and O
DR O
- O
A2 O
). O

1 O
-( O
1 O
- O
Naphthyl O
) O
piperazine O
( O
1 O
- O
NP O
) O
has O
been O
reported O
to O
have O
serotonin O
antagonist O
properties O
at O
the O
5 I-GENE
- I-GENE
HT2 I-GENE
subtype I-GENE
of O
receptor O
, O
and O
it O
has O
been O
suggested O
that O
it O
may O
have O
agonist O
actions O
at O
the O
5 I-GENE
- I-GENE
HT1 I-GENE
site I-GENE
. O

1 O
-( O
m O
- O
Chlorophenyl O
) O
piperazine O
( O
mCPP O
, O
0 O
. O
1 O
- O
3 O
. O
0 O
mg O
/ O
kg O
) O
and O
1 O
-( O
m O
- O
trifluoromethylphenyl O
) O
piperazine O
( O
TFMPP O
, O
0 O
. O
1 O
- O
3 O
. O
0 O
mg O
/ O
kg O
), O
both O
thought O
to O
act O
primarily O
at O
5 I-GENE
- I-GENE
HT1 I-GENE
sites I-GENE
, O
also O
decreased O
responding O
and O
this O
effect O
was O
blocked O
by O
methysergide O
and O
by O
1 O
- O
NP O
, O
but O
not O
by O
ketanserin O
. O

The O
characteristic O
feature O
of O
liver O
and O
spleen O
MP O
function O
in O
patients O
with O
VHA O
associated O
with O
HBsAg I-GENE
carriership O
consisted O
in O
the O
lack O
of O
the O
compensatory O
reaction O
on O
the O
part O
of O
spleen O
MP O
, O
which O
was O
likely O
to O
be O
connected O
with O
overstrain O
of O
long O
standing O
and O
depletion O
of O
the O
MP O
system O
due O
to O
permanent O
antigenic O
stimulation O
of O
HBsAg I-GENE
. O

Changes O
in O
xanthine I-GENE
oxidase I-GENE
activity O
in O
patients O
with O
circulatory O
failure O

A O
soap O
and O
water O
( O
1 O
: O
1 O
, O
v O
/ O
v O
) O
solution O
effectively O
decontaminated O
powdered O
stratum O
corneum O
. O

The O
cytoprotective O
and O
antiulcer O
activities O
of O
the O
antacid O
magaldrate O
( O
ES O
Riopan O
) O
as O
well O
as O
its O
effects O
on O
gastric O
mucosal O
blood O
flow O
and O
mucus O
secretions O
, O
were O
determined O
in O
the O
rat O
. O

The O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
preferentially O
infects O
CD4 I-GENE
+ I-GENE
T O
lymphocytes O
and O
may O
exist O
as O
a O
latent O
provirus O
within O
these O
cells O
for O
extended O
periods O
. O

Histiocytic O
panniculitis O
was O
observed O
in O
biopsy O
specimens O
with O
cytophagocytosis O
. O

We O
have O
utilized O
the O
human I-GENE
4F2 I-GENE
heavy I-GENE
chain I-GENE
( O
4F2HC I-GENE
) O
gene O
as O
a O
model O
system O
in O
studies O
designed O
to O
elucidate O
the O
molecular O
events O
involved O
in O
regulating O
inducible O
gene O
expression O
during O
normal O
human O
T O
- O
cell O
activation O
. O

A O
cDNA O
encoding O
the O
NF I-GENE
- I-GENE
4FB I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
has O
been O
cloned O
by O
screening O
a O
lambda O
gt11 O
cDNA O
library O
with O
a O
rabiolabelled O
oligonucleotide O
corresponding O
to O
the O
NF I-GENE
- I-GENE
4FB I-GENE
recognition I-GENE
sequence I-GENE
. O

Electrocardiographic O
right O
ventricular O
hypertrophy O
was O
seen O
in O
4 O
, O
and O
biventricular O
hypertrophy O
in O
5 O
patients O
. O

The O
two O
IL6 I-GENE
mRNA I-GENE
species O
are O
generated O
by O
alternative O
polyadenylation O
at O
sites O
separated O
by O
a O
distance O
of O
1 O
. O
2 O
kilobases O
. O

Sequencing O
analysis O
revealed O
that O
the O
0 O
. O
54 O
- O
and O
0 O
. O
4 O
- O
kb O
fragments O
are O
identical O
except O
for O
150 O
nucleotides O
missing O
at O
the O
5 O
' O
region O
of O
the O
0 O
. O
4 O
- O
kb O
fragment O
. O

The O
mature O
protein O
also O
contains O
a O
cysteine O
- O
rich O
, O
highly O
hydrophilic O
region O
homologous O
to O
the O
ovomucoid I-GENE
serine I-GENE
protease I-GENE
inhibitors I-GENE
( O
residues O
76 O
- O
132 O
). O

Oligosynaptic O
EPSP O
components O
were O
consistently O
modulated O
only O
in O
the O
superficial O
peroneal O
responses O
in O
flexor O
motoneurons O
, O
which O
exhibited O
enhanced O
amplitude O
during O
the O
flexion O
phase O
. O

Experiments O
on O
23 O
white O
rats O
and O
10 O
guinea O
pigs O
have O
shown O
that O
preliminarily O
indomethacin O
- O
induced O
inhibition O
of O
prostaglandins O
synthesis O
prevented O
development O
of O
pulmonary O
oedema O
, O
evoked O
by O
heterologous O
serum O
in O
rats O
and O
by O
vagotomy O
in O
guinea O
pigs O
. O

On O
the O
other O
hand O
, O
lack O
of O
conservation O
of O
the O
membrane O
attachment O
sequence O
arginine O
- O
glycine O
- O
aspartic O
acid O
argues O
against O
its O
functional O
importance O
in O
CgA I-GENE
. O

Third O
- O
and O
later O
- O
parity O
cows O
were O
randomly O
assigned O
after O
each O
parturition O
to O
Charolais O
and O
Red O
Poll O
bulls O
in O
multiple O
- O
sire O
pastures O
. O

Within O
each O
lobe O
, O
the O
PA O
dispersion O
was O
up O
to O
10 O
cmH2O O
at O
CFV O
of O
90 O
l O
/ O
min O
; O
when O
flow O
decreased O
, O
PA O
at O
all O
sites O
decreased O
, O
as O
did O
the O
intralobar O
dispersion O
. O

The O
system O
consisted O
of O
the O
intact O
canine O
heart O
connected O
to O
a O
microcomputer O
that O
operated O
as O
the O
modulated O
parasystolic O
pacemaker O
. O

In O
order O
to O
identify O
and O
classify O
the O
basic O
CT O
appearances O
of O
interstitial O
pneumonia O
, O
radiologic O
- O
pathologic O
correlative O
study O
was O
performed O
using O
inflated O
and O
fixed O
lungs O
from O
autopsy O
and O
surgery O
. O

The O
disease O
ran O
an O
atypical O
course O
; O
with O
early O
jaundice O
syndrome O
, O
severe O
enterorrhagia O
and O
late O
appearance O
of O
roseola O
. O

The O
transcription O
factor O
Sp1 I-GENE
bound O
to O
eight O
sites O
, O
as O
demonstrated O
by O
footprinting O
assays O
and O
gel O
shift O
analysis O
with O
purified O
Sp1 I-GENE
. O

The O
combination O
PIP O
64 O
micrograms O
- O
PEF O
4 O
micrograms O
prevents O
the O
frequent O
secondary O
regrowth O
seen O
after O
6 O
hours O
with O
the O
antibiotics O
used O
alone O
. O

With O
a O
sample O
of O
mothers O
of O
healthy O
infants O
, O
all O
three O
subscales O
of O
the O
revised O
instrument O
, O
WPL O
- O
R O
, O
had O
acceptable O
levels O
of O
internal O
consistency O
at O
7 O
, O
30 O
, O
and O
90 O
days O
postpartum O
, O
and O
stability O
across O
administrations O
. O

Since O
1948 O
, O
the O
use O
of O
saline O
- O
washed O
red O
cells O
( O
WRBCs O
) O
has O
been O
advocated O
to O
minimize O
hemolysis O
after O
transfusion O
to O
patients O
with O
PNH O
. O

In O
the O
group O
of O
asthmatics O
statistically O
significant O
correlation O
was O
found O
between O
PC20 O
PGF2 O
alpha O
and O
histamine O
values O
( O
r O
= O
0 O
. O
538 O
, O
p O
less O
than O
0 O
. O
05 O
). O

Acute O
experiments O
on O
nembutal O
- O
anesthetized O
cats O
( O
50 O
mg O
/ O
kg O
) O
were O
employed O
to O
investigate O
the O
effect O
of O
1 O
T O
pulsating O
magnetic O
field O
( O
PMF O
) O
on O
neuromuscular O
system O
of O
the O
leg O
. O

No O
significant O
differences O
were O
found O
between O
the O
TS O
and O
the O
PTS O
. O

The O
percentages O
of O
formed O
cysts O
and O
growth O
rates O
were O
monthly O
estimated O
and O
analyzed O
rhythmometrically O
by O
cosinor O
for O
5 O
clonal O
cultures O
of O
Scripsiella O
trochoidea O
Stein O
grown O
for O
2 O
years O
under O
laboratory O
conditions O
, O
rended O
as O
constant O
as O
possible O
from O
the O
view O
point O
of O
environmental O
temperature O
( O
24 O
+/- O
1 O
degree O
C O
), O
lighting O
( O
25 O
microEin O
m O
- O
2 O
s O
- O
1 O
), O
and O
artificial O
seawater O
. O

A O
genomic O
DNA O
clone O
encoding O
oryzacystatin I-GENE
( O
Oc I-GENE
), O
a O
cysteine I-GENE
proteinase I-GENE
inhibitor O
( O
cystatin I-GENE
) O
of O
rice O
, O
was O
isolated O
from O
a O
lambda O
EMBL3 O
phage O
library O
constructed O
with O
Sau3AI I-GENE
partial O
digests O
of O
rice O
chromosomal O
DNA O
, O
by O
screening O
with O
an O
oc I-GENE
cDNA I-GENE
as O
a O
probe O
. O

The O
use O
of O
an O
appropriate O
solution O
of O
methylene O
blue O
( O
0 O
. O
2 O
% O
in O
0 O
. O
9 O
M O
NaCl O
for O
15 O
min O
) O
permits O
the O
staining O
of O
premalignant O
areas O
and O
CIS O
, O
and O
their O
early O
diagnosis O
. O

Lower O
limits O
( O
to O
10 O
micrograms O
/ O
kg O
) O
were O
detectable O
, O
but O
with O
lower O
reliability O
( O
60 O
%). O

Instead O
, O
some O
small O
negative O
effects O
are O
observed O
, O
particularly O
involving O
effects O
of O
husbands O
' O
retirement O
on O
the O
marital O
satisfaction O
of O
employed O
wives O
. O

This O
in O
turn O
will O
further O
enhance O
the O
role O
of O
meta O
- O
analysis O
in O
helping O
clinicians O
and O
policy O
makers O
answer O
clinical O
questions O
. O

In O
one O
acromegalic O
patient O
visual O
improvement O
was O
obtained O
while O
the O
abnormal O
GH I-GENE
secretion O
remained O
unaltered O
. O

In O
contrast O
, O
the O
PPSF O
+ O
DBP O
side O
showed O
large O
amounts O
of O
bone O
formation O
, O
and O
bone O
almost O
covered O
the O
implant O
. O

The O
accuracies O
of O
presence O
or O
absence O
of O
neuroblastoma O
were O
compared O
between O
131I O
- O
MIBG O
imaging O
and O
several O
tumor O
markers O
. O

The O
congenital O
forms O
( O
7 O
cases O
) O
all O
occurred O
in O
female O
infants O
and O
involved O
the O
mucosa O
overlying O
either O
the O
anterior O
ridge O
of O
the O
maxilla O
or O
the O
mandible O
. O

Immunohistochemical O
studies O
revealed O
positive O
staining O
for O
S100 I-GENE
protein I-GENE
in O
all O
the O
granular O
cell O
tumors O
of O
the O
adult O
but O
in O
none O
of O
the O
congenital O
granular O
cell O
epulides O
. O

We O
also O
found O
that O
the O
same O
males O
, O
breeding O
in O
different O
years O
on O
the O
same O
territories O
, O
had O
significantly O
larger O
harems O
in O
the O
years O
they O
had O
familiar O
neighbors O
. O

Male I-GENE
- I-GENE
enhanced I-GENE
antigen I-GENE
gene I-GENE
is O
phylogenetically O
conserved O
and O
expressed O
at O
late O
stages O
of O
spermatogenesis O
. O

In O
rats O
bearing O
Walker O
- O
256 O
- O
carcinosarcoma O
4 O
- O
EPI O
was O
effective O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Pacing O
the O
Roux O
limb O
abolished O
the O
ectopic O
pacemakers O
, O
restored O
the O
slow O
emptying O
of O
liquids O
to O
the O
more O
rapid O
rate O
found O
in O
the O
Billroth O
dogs O
( O
t1 O
/ O
2 O
: O
paced O
Roux O
, O
72 O
+/- O
15 O
minutes O
; O
Billroth O
, O
43 O
+/- O
9 O
minutes O
; O
p O
greater O
than O
0 O
. O
05 O
) O
and O
did O
not O
change O
emptying O
of O
solids O
. O

The O
treatments O
were O
60 O
mg O
t O
. O
i O
. O
d O
. O
and O
120 O
mg O
t O
. O
i O
. O
d O
. O
during O
14 O
days O
' O
treatment O
, O
with O
the O
last O
dose O
pulsed O
with O
1 O
. O
85 O
MBq O
[ O
14C O
] O
diltiazem O
. O

The O
subepicardial O
lymphatic O
capillaries O
were O
ramified O
and O
anastomosed O
with O
each O
other O
to O
form O
a O
relatively O
dense O
network O
which O
extended O
over O
the O
entire O
surface O
of O
both O
ventricles O
. O

The O
examination O
must O
include O
T1 O
and O
T2 O
sequences O
and O
scans O
in O
three O
planes O
. O

A O
great O
deal O
of O
information O
is O
available O
on O
the O
morphology O
of O
the O
claustrum O
in O
various O
animal O
species O
, O
as O
well O
as O
on O
its O
neuronal O
distribution O
and O
relationships O
with O
the O
cerebral O
cortex O
and O
other O
nuclei O
. O

Low O
- O
grade O
glioma O
. O

In O
terms O
of O
sequence O
repetitions O
, O
seven O
tandemly O
repeated O
copies O
of O
the O
hexanucleotide O
ATTGTT O
and O
three O
flanking O
regions O
of O
dyad O
symmetry O
were O
detected O
, O
all O
in O
ORF O
T3C O
. O

The O
significance O
of O
these O
palindromic O
domains O
in O
this O
ORF O
is O
unclear O
but O
the O
coincidence O
of O
the O
end O
of O
one O
larger O
palindrome O
with O
the O
end O
of O
the O
translated O
protein O
sequence O
that O
has O
homology O
with O
the O
B O
chain O
of O
insulin I-GENE
suggests O
that O
the O
palindromes O
may O
divide O
the O
T2 I-GENE
protein I-GENE
into O
several O
functional O
units O
. O

During O
sub O
- O
maximal O
exercise O
, O
DCR O
in O
the O
UT O
dogs O
decreased O
from O
a O
resting O
value O
of O
4 O
. O
08 O
+/- O
0 O
. O
18 O
mm O
Hg O
X O
ml O
- O
1 O
X O
min O
- O
1 O
to O
1 O
. O
91 O
+/- O
0 O
. O
17 O
mm O
Hg O
X O
ml O
- O
1 O
X O
min O
- O
1 O
at O
a O
workload O
of O
6 O
. O
4 O
kph O
( O
speed O
)/ O
16 O
% O
( O
grade O
). O

7 O
. O

These O
data O
suggest O
that O
the O
G I-GENE
- I-GENE
protein I-GENE
gene I-GENE
family I-GENE
may O
be O
distributed O
over O
at O
least O
two O
human O
chromosomes O
. O

The O
major O
inserted O
DNA O
has O
no O
significant O
homology O
to O
published O
human O
nucleic O
acid O
sequences O
. O

In O
44 O
evaluable O
patients O
the O
response O
rate O
was O
50 O
%, O
with O
one O
complete O
response O
. O

We O
have O
also O
found O
that O
the O
in O
vitro O
interaction O
between O
the O
SV40 O
octamer O
motif O
and O
the O
lymphoid I-GENE
cell I-GENE
- I-GENE
specific I-GENE
protein I-GENE
oct I-GENE
- I-GENE
B2 I-GENE
was O
negatively O
modulated O
by O
a O
component O
present O
in O
the O
nuclear O
extracts O
from O
several O
lymphoid O
cell O
lines O
. O

Anoxia O
was O
introduced O
by O
perfusing O
the O
gill O
with O
water O
deprived O
of O
oxygen O
or O
by O
halting O
the O
water O
flow O
to O
the O
gill O
. O

Growth O
, O
4 O
- O
PA O
and O
14C O
turnover O
data O
indicated O
that O
WB O
contributed O
to O
B O
- O
6 O
intake O
of O
these O
rats O
. O

Thus O
, O
multiple O
myogenic O
factors O
that O
vary O
qualitatively O
and O
quantitatively O
may O
be O
responsible O
for O
the O
different O
and O
complex O
modulatory O
programs O
of O
actin I-GENE
gene I-GENE
expression O
observed O
during O
in O
vivo O
muscle O
differentiation O
. O

DNA O
sequence O
analysis O
revealed O
that O
these O
clones O
encode O
two O
distinct O
forms O
of O
translocase I-GENE
. O

The O
effect O
of O
acetazolamide O
( O
ACZ O
) O
on O
HCO3 O
- O
and O
Cl O
- O
activities O
in O
inner O
ear O
fluid O
was O
investigated O
by O
ion O
- O
selective O
microelectrode O
methods O
. O

RPA190 I-GENE
encodes O
a O
polypeptide O
chain O
of O
186 O
, O
270 O
daltons O
in O
a O
large O
uninterrupted O
reading O
frame O
. O

Both O
the O
intact I-GENE
A1 I-GENE
protein I-GENE
and O
its O
proteolytic O
fragment O
, O
the O
UP1 I-GENE
protein I-GENE
, O
can O
be O
cleaved O
by O
Staphylococcus I-GENE
aureus I-GENE
V I-GENE
- I-GENE
8 I-GENE
protease I-GENE
to O
produce O
two O
polypeptides O
of O
92 O
amino O
acids O
. O

Irmiere O
, O
and O
W O
. O

These O
offspring O
of O
the O
alpha I-GENE
- I-GENE
MSH I-GENE
treated O
mothers O
were O
less O
sensitive O
to O
pain O
and O
as O
adults O
showed O
a O
reduced O
analgesic O
response O
to O
morphine O
. O

Simian O
immunodeficiency O
virus O
( O
SIV O
) O
is O
a O
lentivirus O
with O
morphological O
and O
antigenic O
similarities O
to O
human O
immunodeficiency O
virus O
, O
the O
causative O
agent O
of O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
of O
humans O
. O

The O
lack O
of O
change O
in O
the O
ratio O
of O
the O
two O
spliced O
products O
expressed O
from O
either O
the O
normal O
or O
the O
5 I-GENE
'- I-GENE
rearranged I-GENE
myb I-GENE
further O
indicates O
that O
the O
insertion O
of O
the O
unique O
121 O
amino O
acids O
in O
the O
larger O
myb I-GENE
transcripts I-GENE
is O
not O
a O
consequence O
of O
tumor O
- O
specific O
activation O
of O
the O
mouse I-GENE
myb I-GENE
oncogene I-GENE
. O

The O
use O
of O
CRF I-GENE
- I-GENE
41 I-GENE
in O
the O
differential O
diagnosis O
of O
Cushing O
' O
s O
syndrome O
and O
obesity O
. O

We O
detected O
mos I-GENE
transcripts I-GENE
by O
Northern O
( O
RNA O
) O
analyses O
in O
RNA O
prepared O
from O
chicken O
and O
quail O
ovaries O
and O
testes O
. O

The O
predicted O
L I-GENE
mRNA I-GENE
was O
6398 O
nucleotides O
long O
and O
contained O
a O
single O
open O
reading O
frame O
corresponding O
to O
an O
L I-GENE
protein I-GENE
encompassing I-GENE
2109 I-GENE
amino I-GENE
acids I-GENE
with O
a O
MW O
of O
241 O
, O
546 O
. O

The O
results O
suggest O
that O
the O
organization O
of O
functional O
units O
of O
the O
72 O
- O
bp O
repeat O
required O
for O
transcriptional O
enhancement O
of O
the O
early O
promoter O
is O
different O
from O
that O
required O
for O
late O
promoter O
function O
. O

Variations O
in O
the O
5 O
' O
half O
of O
U3 O
were O
primarily O
due O
to O
insertions O
and O
deletions O
. O

An O
analysis O
of O
the O
steady O
state O
RNA O
levels O
in O
T O
- O
lymphoid O
cell O
lines O
showed O
that O
at O
least O
three O
different O
incomplete O
proviral O
transcripts O
and O
their O
spliced O
products O
made O
up O
the O
majority O
of O
expressed O
RD I-GENE
- I-GENE
114 I-GENE
mRNA I-GENE
, O
and O
further O
demonstrated O
that O
partially O
deleted O
proviral O
loci O
have O
the O
potential O
to O
be O
transcriptionally O
vigorous O
in O
certain O
feline O
cell O
types O
. O

Aplastic O
crisis O
in O
sickle O
cell O
disorders O
: O
bone O
marrow O
necrosis O
and O
human O
parvovirus O
infection O
. O

Either O
two O
or O
more O
different O
sequences O
can O
promote O
cleavage O
, O
or O
a O
single O
element O
exists O
which O
is O
long O
and O
diffuse O
. O

Low O
molecular O
weight O
heparins O
have O
stimulated O
much O
interest O
because O
of O
their O
supposedly O
more O
selective O
action O
on O
Xa I-GENE
factor I-GENE
. O

The O
bactericidal O
activity O
of O
six O
new O
rifamycin O
derivatives O
-- O
rifabutin O
( O
RBU O
), O
FCE O
22250 O
( O
F22 O
), O
rifapentine O
( O
RPE O
), O
CGP O
29861 O
( O
C29 O
), O
CGP O
7040 O
( O
C70 O
) O
and O
CGP O
27557 O
( O
C27 O
) O
and O
rifampicin O
( O
RMP O
)-- O
have O
been O
measured O
against O
log O
phase O
and O
, O
as O
a O
better O
test O
of O
sterilising O
activity O
, O
against O
stationary O
phase O
cultures O
of O
Mycobacterium O
tuberculosis O
, O
H37Rv O
. O

Mo O
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
moribund O
at O
3 O
to O
13 O
months O
postinoculation O
, O
whereas O
delta O
Mo O
+ O
SV O
M O
- O
MuLV O
- O
inoculated O
animals O
became O
moribund O
at O
6 O
to O
24 O
months O
postinoculation O
. O

Sodium O
dodecyl O
sulphate O
- O
induced O
cleavage O
by O
eukaryotic I-GENE
topoisomerase I-GENE
I I-GENE
is O
known O
to O
yield O
enzyme O
covalently O
attached O
to O
the O
3 O
' O
cut O
end O
of O
the O
DNA O
. O

Amino O
acid O
sequence O
of O
one O
human O
liver O
clone O
( O
HL O
- O
14 O
) O
was O
identical O
to O
the O
rabbit I-GENE
skeletal I-GENE
muscle I-GENE
phosphatase I-GENE
2A I-GENE
cDNA I-GENE
( O
with O
97 O
% O
nucleotide O
identity O
). O

Herpes O
virus O
infection O
was O
characterized O
by O
inversion O
of O
the O
T4 O
/ O
T8 O
ratio O
below O
1 O
. O
0 O
( O
sensitivity O
90 O
%, O
specificity O
88 O
%), O
caused O
by O
proliferation O
of O
the O
T8 O
subpopulation O
, O
which O
-- O
compared O
with O
the O
findings O
in O
patients O
with O
rejection O
crises O
-- O
was O
significantly O
raised O
( O
P O
less O
than O
0 O
. O
001 O
). O

RVEF O
and O
LVEF O
both O
increased O
by O
about O
14 O
% O
( O
p O
less O
than O
0 O
. O
05 O
and O
p O
less O
than O
0 O
. O
01 O
). O

The O
levels O
of O
NPY I-GENE
- O
ir O
in O
the O
rat O
vas O
deferens O
were O
not O
affected O
by O
either O
surgical O
or O
pharmacological O
treatment O
. O

Quantitative O
assays O
in O
which O
the O
activity O
of O
the O
synthetic I-GENE
alpha I-GENE
s I-GENE
- I-GENE
1 I-GENE
was O
compared O
to O
that O
of O
native O
purified O
human I-GENE
erythrocyte I-GENE
type I-GENE
- I-GENE
1 I-GENE
Gs I-GENE
, O
indicated O
that O
the O
two O
products O
are O
equipotent O
within O
a O
2 O
- O
fold O
margin O
of O
error O
. O

In O
these O
cells O
, O
E2 I-GENE
proteins I-GENE
had O
little O
or O
no O
stimulatory O
effect O
on O
the O
transcriptional O
activity O
of O
the O
HPV I-GENE
- I-GENE
11 I-GENE
enhancer I-GENE
- O
SV40 I-GENE
promoter I-GENE
. O

The O
mechanism O
by O
which O
E2 I-GENE
- I-GENE
C I-GENE
represses O
E2 I-GENE
- I-GENE
dependent I-GENE
enhancer I-GENE
activity O
most O
likely O
involves O
competition O
with O
E2 I-GENE
for O
binding O
to O
a O
common O
transcriptional O
regulatory O
site O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Accurate O
evaluation O
of O
the O
treatment O
results O
in O
unresectable O
lung O
cancer O
patients O
must O
take O
the O
strong O
prognostic O
factors O
into O
account O
. O

( O
anti I-GENE
- I-GENE
IIa I-GENE
) O
and O
Holmer O
et O
al O
. O

Introduction O
of O
v I-GENE
- I-GENE
fms I-GENE
into O
a O
CSF I-GENE
- I-GENE
1 I-GENE
dependent O
murine O
macrophage O
cell O
line O
induced O
factor O
independence O
and O
tumorigenicity O
by O
a O
nonautocrine O
mechanism O
. O

Chronic O
E O
- O
B O
virus O
infection O
terminated O
in O
malignant O
lymphoma O
: O
a O
case O
report O

The O
primary O
structure O
and O
cotranscription O
of O
the O
petCA I-GENE
genes I-GENE
encoding O
the O
Rieske I-GENE
- I-GENE
FeS I-GENE
( O
nuclear I-GENE
encoded I-GENE
in I-GENE
plants I-GENE
) O
and O
apocytochrome I-GENE
f I-GENE
proteins I-GENE
has O
been O
described O
previously O
( O
Kallas O
, O
T O
., O
Spiller O
, O
S O
., O
and O
Malkin O
, O
R O
. O

The O
Nostoc O
petBD I-GENE
genes I-GENE
are O
not O
closely O
linked O
to O
the O
psbB I-GENE
gene I-GENE
( O
encoding O
the O
51 O
- O
kDa O
photosystem I-GENE
II I-GENE
polypeptide I-GENE
) O
and O
do O
not O
contain O
introns O
as O
do O
the O
closely O
related O
chloroplast O
genes O
. O

RNA O
blot O
hybridizations O
identified O
an O
1 O
. O
8 O
- O
kb O
mRNA O
common O
to O
cytochrome I-GENE
b6 I-GENE
and O
subunit O
IV O
, O
and O
an O
intensely O
hybridizing O
0 O
. O
8 O
- O
kb O
mRNA O
specific O
to O
the O
subunit O
IV O
gene O
probe O
. O

Whereas O
the O
muscle O
isoform O
consists O
of O
997 O
amino O
acids O
and O
terminates O
with O
the O
sequence O
Ala O
- O
Ile O
- O
Leu O
- O
Glu O
, O
the O
second O
isoform O
is O
1043 O
amino O
acids O
in O
length O
due O
to O
the O
replacement O
of O
these O
last O
4 O
amino O
acids O
with O
a O
50 O
- O
amino O
acid O
sequence O
that O
contains O
a O
potential O
transmembrane O
domain O
followed O
by O
a O
consensus O
sequence O
for O
an O
N O
- O
linked O
glycosylation O
site O
. O

Substitution O
of O
a O
threonine O
residue O
by O
an O
alanine O
residue O
at O
position O
- O
2 O
( O
P2 O
) O
of O
this O
cleavage O
site O
abolished O
cleavage O
, O
whereas O
substitution O
of O
a O
tyrosine O
residue O
by O
a O
phenylalanine O
residue O
at O
amino O
acid O
position O
- O
1 O
( O
P1 O
) O
of O
the O
cleavage O
site O
did O
not O
influence O
processing O
. O

All O
of O
the O
indigo O
- O
producing O
bacteria O
had O
an O
indoxyl I-GENE
phosphatase I-GENE
with O
a O
pI O
of O
6 O
. O
4 O
. O

The O
number O
of O
polymerases O
active O
in O
vitro O
at O
the O
E O
strand O
promoter O
was O
similar O
to O
the O
number O
of O
polymerases O
at O
the O
L O
strand O
promoter O
. O

A O
family O
of O
RNA O
molecules O
in O
the O
2 O
. O
0 O
- O
2 O
. O
2 O
- O
kilobase O
range O
identified O
with O
a O
probe O
from O
this O
gene O
was O
overexpressed O
in O
the O
resistant O
cells O
. O

A O
highly O
hydrophobic O
sequence O
located O
near O
the O
carboxyl O
- O
terminal O
extremity O
of O
the O
molecule O
most O
likely O
constitutes O
the O
anchor O
to O
the O
plasma O
membrane O
. O

The O
SV40 I-GENE
enhancer I-GENE
augmented O
replication O
1 O
. O
5 O
- O
10 O
fold O
. O

One O
of O
these O
, O
the O
origin O
core O
, O
is O
required O
only O
for O
DNA O
replication O
. O

Induction O
of O
proto I-GENE
- I-GENE
oncogene I-GENE
fos I-GENE
transcription O
through O
the O
adenylate I-GENE
cyclase I-GENE
pathway O
: O
characterization O
of O
a O
cAMP O
- O
responsive O
element O
. O

A O
17 O
- O
mer O
oligodeoxynucleotide O
, O
corresponding O
to O
a O
region O
of O
the O
VtHb I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
was O
used O
as O
a O
hybridization O
probe O
to O
screen O
a O
Vitreoscilla O
genomic O
library O
constructed O
in O
broad O
- O
host O
- O
range O
cosmid O
vector O
pVK102 O
. O

( O
total O
soluble O
solids O
) O
and O
organoleptic O
characteristics O
under O
the O
influence O
of O
different O
treatments O
. O

Causes O
of O
death O
found O
in O
an O
epidemiological O
study O
of O
native O
chickens O
in O
Thai O
villages O
. O

The O
progression O
of O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
to O
chronic O
diseases O
, O
and O
the O
transformation O
to O
hepatocellular O
carcinoma O

Elevated O
IOP O
developed O
in O
35 O
patients O
( O
44 O
eyes O
) O
during O
the O
study O
. O

Use O
of O
serum O
thyroglobulin I-GENE
determination O
in O
the O
follow O
- O
up O
of O
differentiated O
carcinomas O
of O
the O
thyroid O

Poor O
response O
when O
laboratory O
recommended O
range O
for O
serum O
lithium O
is O
changed O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
nebulized O
ipratropium O
in O
patients O
with O
acute O
asthma O
in O
order O
to O
determine O
whether O
it O
augments O
the O
bronchodilator O
effect O
of O
a O
beta O
agonist O
drug O
. O

Further O
analysis O
of O
this O
DNA O
fragment O
showed O
that O
four O
genes O
are O
present O
encoding O
proteins O
of O
16 O
, O
18 O
. O
5 O
, O
21 O
and O
89 O
kDal O
. O

Hantaan O
virus O
. O

Changes O
in O
dopamine I-GENE
receptor I-GENE
sensitivity O
in O
humans O
after O
heavy O
alcohol O
intake O
. O

No O
significant O
differences O
between O
the O
two O
treatment O
groups O
were O
found O
, O
but O
rapid O
responders O
had O
a O
smaller O
mean O
initial O
platelet I-GENE
- I-GENE
associated I-GENE
IgG I-GENE
index O
which O
returned O
more O
rapidly O
and O
more O
permanently O
to O
normal O
than O
that O
of O
slow O
responders O
. O

Replacement I-GENE
variant I-GENE
histone I-GENE
genes I-GENE
contain O
intervening O
sequences O
. O

Double O
- O
blind O
randomised O
trial O
of O
intravenous O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
versus O
placebo O
in O
acute O
myocardial O
infarction O
. O

The O
C O
- O
terminal O
domains O
( O
CTDs O
) O
of O
the O
RPase I-GENE
beta I-GENE
subunit I-GENE
and O
DNA I-GENE
primase I-GENE
( O
dnaG I-GENE
protein I-GENE
) O
were O
not O
only O
strongly O
homologous O
to O
each O
other O
but O
also O
considerably O
homologous O
to O
the O
RPase I-GENE
alpha I-GENE
, O
suggesting O
that O
an O
alpha O
subunit O
- O
like O
enzyme O
must O
have O
been O
commonly O
ancestral O
to O
core I-GENE
enzyme I-GENE
subunits I-GENE
and O
primase I-GENE
. O

However O
, O
vancomycin O
and O
fosfomycin O
, O
which O
revealed O
suboptimal O
in O
vitro O
bactericidal O
activity O
, O
proved O
as O
efficacious O
as O
penicillin O
G O
and O
imipenem O
in O
an O
experimental O
mode O
of O
murine O
gas O
gangrene O
. O

Fentanyl O
, O
a O
prototypic O
mu I-GENE
- I-GENE
opiate I-GENE
receptor I-GENE
agonist O
, O
has O
been O
previously O
shown O
to O
produce O
a O
syndrome O
characterized O
by O
marked O
analgesia O
and O
locomotor O
stimulation O
as O
well O
as O
tachycardia O
, O
tachypnoea O
and O
behavioural O
arousal O
. O

Intravesical O
chemotherapy O
. O

Bisoprolol O
was O
found O
to O
be O
an O
effective O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
the O
pA2 O
values O
determined O
against O
isoprenaline O
in O
guinea O
pig O
atria O
and O
tracheal O
muscle O
being O
7 O
. O
45 O
and O
6 O
. O
41 O
, O
respectively O
. O

Output O
of O
99mTcO O
- O
4 O
by O
the O
parotid O
gland O
closely O
mimicked O
fluctuations O
in O
parotid O
saliva O
flow O
rate O
. O

The O
Hagen O
- O
Poiseuille O
equation O
is O
used O
to O
assess O
the O
effects O
of O
attached O
parasites O
in O
the O
foregut O
of O
Leishmania O
- O
infected O
sandflies O
on O
blood O
flow O
. O

Moreover O
, O
in O
rats O
allowed O
to O
choose O
in O
a O
T O
- O
maze O
between O
immediate O
- O
but O
- O
small O
vs O
. O
delayed O
- O
but O
- O
large O
reward O
, O
BZP O
significantly O
decreased O
the O
frequency O
with O
which O
the O
delayed O
reward O
was O
chosen O
, O
with O
5 O
- O
HT O
uptake O
blockers O
producing O
opposite O
effects O
. O

An O
endometrial O
luteal O
phase O
deficiency O
was O
detected O
in O
15 O
( O
30 O
%) O
of O
aborting O
patients O
. O

Prenatal O
exposure O
to O
the O
fungicide O
dinocap O
causes O
behavioral O
torticollis O
, O
ballooning O
and O
cleft O
palate O
in O
mice O
, O
but O
not O
rats O
or O
hamsters O
. O

Reperfusion O
with O
normal O
blood O
in O
the O
beating O
, O
working O
hearts O
caused O
extensive O
structural O
damage O
, O
reduced O
reflow O
, O
and O
failed O
to O
restore O
contractility O
in O
any O
instance O
(- O
27 O
% O
systolic O
shortening O
, O
p O
less O
than O
0 O
. O
05 O
). O

The O
sensitivity O
of O
the O
vas O
deferens O
to O
adrenaline O
was O
also O
reduced O
in O
scorbutic O
guinea O
pigs O
, O
thus O
decreasing O
their O
fertility O
rate O
. O

In O
metabolic O
acidosis O
there O
was O
a O
marked O
stimulation O
when O
clamped O
at O
- O
10 O
to O
- O
100 O
mV O
. O

On O
Days O
1 O
and O
14 O
, O
most O
young O
and O
elderly O
subjects O
exhibited O
monoexponential O
decline O
in O
bevantolol O
plasma O
concentrations O
after O
absorption O
phase O
. O

Mature O
and O
old O
B6AF1 O
and O
B6D2F1 O
mice O
were O
given O
acidified O
tap O
water O
or O
promethazine O
HCl O
( O
a O
phenothiazine O
with O
H1 I-GENE
receptor I-GENE
blocking O
activity O
), O
chlorpheniramine O
( O
an O
H1 I-GENE
blocker O
) O
or O
trifluoperazine O
( O
a O
phenothiazine O
with O
no O
H1 I-GENE
blocking O
activity O
) O
in O
their O
drinking O
water O
, O
and O
the O
effects O
of O
these O
agents O
on O
bone O
mineral O
content O
were O
assessed O
by O
intermittently O
measuring O
the O
24 O
- O
h O
whole O
body O
retention O
of O
Tc O
99m O
methylene O
diphosphonate O
( O
Tc O
99m O
MDP O
, O
an O
indicator O
of O
bone O
metabolism O
) O
and O
at O
the O
end O
of O
the O
studies O
by O
determining O
ash O
weights O
of O
femur O
, O
ilium O
and O
sacrum O
. O

Present O
results O
reveal O
a O
frequency O
- O
dependent O
inhibition O
of O
ganglionic O
transmission O
by O
diltiazem O
, O
and O
suggest O
that O
diltiazem O
may O
depress O
excessive O
sympathetic O
activity O
without O
affecting O
normal O
ganglionic O
transmission O
. O

Studies O
were O
performed O
on O
several O
superficial O
veins O
from O
the O
rabbit O
face O
to O
examine O
the O
relationship O
between O
beta I-GENE
adrenoceptor I-GENE
subtype I-GENE
distribution O
, O
intrinsic O
myogenic O
tone O
and O
sympathetic O
nerve O
innervation O
. O

Effects O
of O
a O
new O
antihypertensive O
agent O
, O
SGB O
- O
1534 O
, O
on O
rat O
platelet O
aggregation O
. O

Since O
the O
stability O
of O
TF1 I-GENE
resides O
in O
its O
primary O
structure O
, O
we O
cloned O
a O
gene O
coding O
for O
TF1 I-GENE
, O
and O
the O
primary O
structure O
of O
the O
beta O
subunit O
was O
deduced O
from O
the O
nucleotide O
sequence O
of O
the O
gene O
to O
compare O
the O
sequence O
with O
those O
of O
beta O
' O
s O
of O
three O
major O
categories O
of O
F1 I-GENE
' O
s O
; O
prokaryotic O
membranes O
, O
chloroplasts O
, O
and O
mitochondria O
. O

Body O
temperature O
and O
overall O
conductance O
in O
the O
cold O
appear O
to O
be O
more O
variable O
in O
P O
. O
s O
. O
campbelli O
than O
in O
nominative O
sp O
. O

Two O
polyadenylation O
sites O
were O
used O
, O
one O
at O
the O
end O
of O
the O
early I-GENE
( I-GENE
E I-GENE
) I-GENE
region I-GENE
of O
the O
viral O
DNA O
, O
the O
other O
at O
the O
end O
of O
the O
late I-GENE
( I-GENE
L I-GENE
) I-GENE
region I-GENE
. O

A O
drug O
with O
ISA O
" O
down O
regulates O
" O
beta I-GENE
receptors I-GENE
; O
thus O
, O
when O
the O
drug O
is O
withdrawn O
there O
is O
no O
post O
- O
beta O
- O
blocking O
drug O
hypersensitivity O
in O
contrast O
to O
agents O
without O
ISA O
. O

Six O
patients O
with O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
( O
HTLV O
- O
I O
)- O
associated O
myelopathy O
( O
HAM O
) O
were O
studied O
by O
electrophysiologic O
methods O
. O

Terazosin O
, O
a O
structural O
analog O
of O
prazosin O
, O
also O
inhibits O
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
and O
is O
recommended O
as O
once O
or O
twice O
- O
daily O
therapy O
. O

Testing O
blood O
donors O
for O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
: O
irrational O
, O
perhaps O
, O
but O
inescapable O
. O

Most O
patients O
with O
high O
blood O
pressure O
( O
BP O
) O
can O
be O
managed O
by O
using O
one O
of O
4 O
classes O
of O
compounds O
: O
a O
diuretic O
, O
beta O
blocker O
, O
converting O
enzyme O
inhibitor O
or O
calcium O
antagonist O
. O

In O
a O
randomised O
double O
- O
blind O
study O
, O
46 O
first O
episode O
schizophrenics O
were O
given O
pimozide O
or O
flupenthixol O
for O
up O
to O
5 O
weeks O
; O
the O
mean O
daily O
dose O
at O
the O
end O
was O
18 O
. O
8 O
mg O
pimozide O
and O
20 O
mg O
flupenthixol O
. O

Somatostatin I-GENE
- O
producing O
endocrine O
pancreatic O
tumor O
in O
Recklinghausen O
' O
s O
neurofibromatosis O
. O

Direct O
and O
inverted O
repeat O
elements O
of O
10 O
, O
11 O
, O
16 O
, O
19 O
, O
and O
22 O
nucleotides O
( O
nt O
) O
flank O
the O
promoter O
site O
. O

We O
have O
been O
able O
to O
map O
specific O
DNA O
fragments O
at O
the O
bases O
of O
chromatin O
loops O
with O
the O
help O
of O
a O
novel O
extraction O
procedure O
by O
using O
lithium O
- O
3 O
', O
5 O
'- O
diiodosalicylate O
. O

Seventy O
- O
one O
supplementary O
doses O
of O
vecuronium O
were O
used O
for O
muscle O
relaxation O
during O
a O
22 O
- O
h O
- O
long O
NLA O
II O
anaesthesia O
. O

Finally O
, O
the O
recovery O
indexes O
represented O
by O
the O
times O
required O
for O
T1 O
/ O
T0 O
and O
T4 O
/ O
T1 O
to O
rise O
from O
25 O
% O
to O
75 O
% O
respectively O
were O
studied O
. O

Transformed O
bacterial O
colonies O
were O
screened O
for O
recombinant O
plasmids O
containing O
cDNA O
coding O
for O
BiP I-GENE
by O
hybrid O
- O
selected O
mRNA O
translation O
. O

DPA O
attenuated O
the O
increase O
of O
the O
intensity O
of O
the O
ischemic O
and O
pressure O
pain O
components O
with O
increasing O
ischemia O
duration O
, O
but O
only O
the O
effect O
on O
the O
pressure O
pain O
component O
was O
significant O
. O

Topical O
1 O
percent O
isoproterenol O
in O
the O
presence O
of O
the O
phosphodiesterase O
inhibitor O
theophylline O
was O
tested O
for O
its O
ability O
to O
stimulate O
the O
rate O
of O
aqueous O
humor O
flow O
through O
the O
anterior O
chamber O
of O
the O
normal O
and O
the O
partially O
adrenergically O
denervated O
human O
eye O
( O
Horner O
' O
s O
syndrome O
). O

Hyperthyroidism O
is O
one O
of O
the O
numerous O
causes O
of O
infertility O
and O
recurrent O
abortion O
. O

A O
strong O
correlation O
exists O
between O
the O
numbers O
of O
CFU O
- O
GM O
transfused O
and O
the O
rate O
of O
granulocytes O
and O
platelets O
recovery O
. O

We O
propose O
that O
the O
technique O
of O
low O
- O
frequency O
kindling O
is O
a O
useful O
experimental O
model O
in O
assessing O
the O
effects O
of O
antipsychotic O
or O
antiepileptic O
drugs O
on O
the O
excitability O
of O
the O
limbic O
regions O
. O

Oestrogen O
implant O
overdose O
. O

Three O
sequence O
elements O
are O
shown O
to O
be O
required O
for O
accurate O
and O
efficient O
transcription O
termination O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
( O
pol I-GENE
I I-GENE
) O
assayed O
both O
in O
a O
cell O
- O
free O
transcription O
system O
and O
in O
vivo O
after O
transfection O
of O
rDNA O
minigene O
constructs O
into O
3T6 O
cells O
. O

The O
biosynthesis O
and O
stability O
of O
the O
three O
mutant O
proteins O
were O
similar O
to O
those O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
erbB I-GENE
protein I-GENE
, O
and O
all O
three O
retained O
the O
ability O
to O
transform O
chicken O
embryo O
fibroblasts O
. O

Codon O
usage O
in O
C O
. O
reinhardtii O
mitochondria O
is O
highly O
biased O
, O
with O
eight O
codons O
entirely O
absent O
from O
all O
protein O
- O
coding O
genes O
; O
however O
, O
even O
though O
codon O
usage O
is O
restricted O
, O
it O
appears O
that O
C O
. O
reinhardtii O
mtDNA O
cannot O
encode O
the O
minimum O
number O
of O
tRNAs O
needed O
to O
support O
mitochondrial O
protein O
synthesis O
. O

A O
new O
physiopathological O
treatment O
of O
HBV O
- O
related O
polyarteritis O
inspired O
by O
advances O
in O
the O
treatment O
of O
chronic O
active O
hepatitis O
B O
was O
tested O
in O
7 O
patients O
. O

Like O
scrotal O
testes O
, O
undescended O
testes O
were O
hypointense O
to O
fat O
on O
sequences O
with O
a O
short O
repetition O
time O
( O
TR O
) O
and O
echo O
time O
( O
TE O
) O
in O
all O
cases O
, O
and O
hyperintense O
or O
isointense O
to O
fat O
on O
long O
TR O
/ O
TE O
sequences O
in O
all O
but O
two O
cases O
. O

The O
subunit I-GENE
- I-GENE
a I-GENE
gene I-GENE
is O
preceded O
by O
a O
gene O
coding O
for O
a O
small O
hydrophobic O
protein O
, O
as O
has O
been O
observed O
previously O
in O
the O
atp I-GENE
operons I-GENE
in O
E O
. O
coli O
, O
bacterium O
PS3 O
and O
cyanobacteria O
. O

Here O
, O
we O
describe O
the O
isolation O
of O
bovine I-GENE
and I-GENE
rat I-GENE
GHF I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
clones O
. O

To O
explore O
the O
functional O
properties O
of O
the O
protein O
encoded O
by O
neu I-GENE
, O
we O
created O
a O
fusion O
gene O
that O
joins O
the O
cytoplasmic O
domain O
of O
neu I-GENE
to O
the O
extracellular O
portion O
of O
an O
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
. O

The O
East O
African O
dik O
- O
dik O
antelope O
represents O
a O
miniature O
model O
ruminant O
for O
comparative O
studies O
. O

By O
sequence O
comparison O
, O
42 O
blocks O
of O
homology O
are O
defined O
in O
the O
5 O
'- O
terminal O
region O
, O
of O
which O
36 O
appear O
in O
the O
CpG O
island O
and O
contain O
numerous O
conserved O
CpG O
dinucleotides O
. O

Among O
unusual O
features O
, O
we O
report O
numerous O
large O
G O
+ O
C O
- O
rich O
conserved O
sequences O
located O
in O
the O
first O
intron O
. O

In O
the O
first O
group O
, O
0 O
. O
02 O
% O
Prazosin O
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
was O
administered O
intravenously O
for O
1 O
. O
5 O
hours O
before O
the O
application O
of O
Oxy O
- O
Hb O
or O
PGF2 O
alpha O
. O

Efficacy O
and O
field O
evaluation O
of O
Bacillus O
thuringiensis O
( O
H O
- O
14 O
) O
and O
B O
. O
sphaericus O
against O
floodwater O
mosquitoes O
in O
California O
. O

2 O
cases O
of O
type O
II O
tyrosinosis O
( O
Richner O
- O
Hanhart O
syndrome O
) O

This O
loss O
was O
independent O
of O
drug O
concentration O
and O
a O
correction O
factor O
was O
employed O
to O
calculate O
the O
true O
free O
diazepam O
concentration O
. O

Effects O
of O
a O
perfluorochemical O
blood O
substitute O
on O
diazepam O
binding O
by O
human I-GENE
albumin I-GENE
. O

A O
second O
promoter O
activity O
was O
identified O
in O
the O
region O
between O
the O
two O
major O
transcriptional O
start O
sites O
. O

A O
decamer O
sequence O
, O
5 O
'- O
CGA O
- O
CCCCUCC O
- O
3 O
', O
complementary O
to O
a O
conserved O
sequence O
adjacent O
to O
the O
enzymatic O
cleavage O
site O
on O
the O
mitochondrial O
RNA O
substrate O
, O
is O
present O
in O
the O
RNAase I-GENE
MRP I-GENE
RNA I-GENE
. O

Effects O
of O
aging O
and O
beta O
- O
adrenergic O
- O
blockade O
on O
standing O
- O
induced O
QT O
/ O
QS2 O
changes O
. O

A O
patient O
with O
an O
infected O
wound O
or O
one O
on O
a O
primary O
area O
( O
hands O
, O
feet O
, O
face O
, O
or O
perineum O
) O
may O
have O
to O
be O
hospitalized O
to O
ensure O
proper O
care O
. O

Pharmacology O
studies O
with O
potassium O
chloride O
and O
acetylcholine O
suggest O
that O
raveron O
acts O
as O
a O
calcium O
antagonist O
by O
blocking O
the O
influx O
of O
extracellular O
calcium O
. O

Computer O
analysis O
included O
digital O
averaging O
, O
followed O
by O
digital O
filtering O
in O
different O
frequency O
bands O
in O
order O
to O
determine O
the O
frequency O
range O
corresponding O
to O
notches O
and O
slurs O
. O

On O
admission O
to O
the O
ICU O
, O
117 O
patients O
( O
61 O
percent O
) O
had O
hypomagnesemia O
( O
serum O
Mg O
less O
than O
1 O
. O
5 O
mEq O
/ O
dl O
), O
66 O
patients O
( O
34 O
percent O
) O
had O
normomagnesemia O
( O
1 O
. O
5 O
to O
2 O
. O
0 O
mEq O
/ O
dl O
), O
and O
ten O
patients O
( O
5 O
percent O
) O
had O
hypermagnesemia O
( O
greater O
than O
2 O
. O
0 O
mEq O
/ O
dl O
). O

The O
risk O
factors O
studied O
were O
male O
sex O
, O
hypertension O
, O
diabetes O
mellitus O
, O
hypercholesterolemia O
, O
cigarette O
smoking O
, O
sedentary O
life O
- O
style O
, O
and O
family O
history O
. O

Neither O
verapamil O
nor O
nifedipine O
changed O
collateral O
myocardial O
blood O
flow O
from O
0 O
. O
10 O
+/- O
0 O
. O
02 O
in O
the O
subendocardium O
and O
0 O
. O
17 O
+/- O
0 O
. O
03 O
ml O
/ O
min O
/ O
g O
in O
the O
subepicardium O
. O

There O
were O
35 O
boys O
and O
15 O
girls O
, O
with O
a O
mean O
age O
of O
five O
and O
a O
half O
years O
. O

Controlled O
versus O
uncontrolled O
reperfusion O
of O
ischemic O
myocardium O
after O
experimental O
coronary O
artery O
occlusion O
was O
studied O
to O
determine O
the O
effect O
on O
regional O
ventricular O
wall O
motion O
and O
associated O
biochemical O
alterations O
. O

Cardiac O
disease O
was O
not O
detected O
with O
M O
- O
mode O
, O
2 O
- O
dimensional O
real O
- O
time O
or O
pulsed O
- O
wave O
Doppler O
echocardiography O
. O

Hemodynamic O
assessment O
was O
obtained O
before O
and O
following O
administration O
of O
digoxin O
10 O
micrograms O
/ O
kg O
IV O
or O
dopamine O
, O
5 O
to O
12 O
micrograms O
/ O
kg O
/ O
min O
IV O
. O

We O
also O
examined O
the O
relationship O
between O
the O
side O
of O
sinusitis O
and O
the O
cleft O
side O
in O
patients O
with O
unilateral O
cleft O
palate O
. O

We O
conclude O
that O
at O
these O
low O
levels O
studied O
, O
aluminum O
accumulates O
in O
intestinal O
tissue O
, O
and O
that O
this O
accumulation O
is O
enhanced O
by O
citrate O
ligand O
. O

Thus O
, O
the O
effects O
of O
father O
absence O
under O
routine O
conditions O
in O
relatively O
healthy O
samples O
may O
exert O
no O
significant O
effects O
independent O
of O
intervening O
family O
stressors O
or O
maternal O
psychopathology O
. O

Recently O
, O
an O
electrical O
- O
mechanical O
analog O
model O
of O
heat O
flow O
within O
the O
brain O
has O
been O
developed O
from O
which O
an O
expression O
for O
CBF O
has O
been O
derived O
: O
CBF O
= O
Cb O
/( O
tau O
rho O
c O
) O
where O
tau O
is O
the O
thermal O
decay O
constant O
, O
rho O
is O
the O
density O
of O
blood O
, O
and O
c O
is O
its O
specific O
heat O
. O

All O
of O
the O
newly O
acquired O
proviruses O
identified O
in O
mosaic O
founder O
SWR O
/ O
J O
- O
RF O
/ O
J O
mice O
that O
could O
be O
transmitted O
through O
the O
germ O
line O
were O
also O
present O
in O
somatic O
tissues O
, O
demonstrating O
that O
viral O
integration O
occurred O
before O
the O
germ O
line O
was O
set O
aside O
from O
the O
somatic O
lineages O
. O

Molecular O
cloning O
of O
the O
cDNA O
for O
the O
human I-GENE
U2 I-GENE
snRNA I-GENE
- I-GENE
specific I-GENE
A I-GENE
' I-GENE
protein I-GENE
. O

For O
the O
present O
work O
we O
used O
water O
saturated O
with O
a O
50 O
/ O
50 O
mixture O
of O
H2 O
and O
O2 O
gases O
, O
for O
which O
the O
heat O
defect O
is O
calculated O
to O
be O
- O
2 O
. O
1 O
%. O

Successful O
use O
of O
transureteroureterostomy O
to O
salvage O
ureterosigmoidostomy O
after O
anastomotic O
failure O
. O

During O
flexion O
whiplash O
, O
the O
torque O
at O
the O
occipital O
condyle O
reverses O
its O
direction O
at O
about O
25 O
ms O
after O
impact O
. O

The O
data O
indicates O
the O
presence O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
serotonergic I-GENE
receptors I-GENE
in O
the O
bronchial O
artery O
of O
these O
species O
. O

Oxfendazole O
, O
which O
was O
active O
for O
the O
shortest O
time O
( O
about O
65 O
days O
) O
from O
the O
start O
of O
grazing O
( O
May O
1 O
), O
produced O
a O
78 O
. O
1 O
per O
cent O
reduction O
in O
Ostertagia O
species O
and O
an O
84 O
. O
4 O
per O
cent O
reduction O
in O
D O
viviparus O
. O

By O
adapting O
a O
method O
for O
DNA O
- O
footprinting O
using O
impure O
extracts O
of O
ner I-GENE
overproducing O
cells O
, O
we O
were O
able O
to O
determine O
that O
the O
ner I-GENE
- I-GENE
binding I-GENE
sites I-GENE
are O
located O
between O
nucleotides O
1026 O
and O
1058 O
from O
the O
Mu O
left O
end O
. O

We O
have O
identified O
and O
characterized O
the O
structure O
of O
the O
Spec1 I-GENE
gene I-GENE
in O
the O
sea O
urchin O
Strongylocentrotus O
purpuratus O
. O

Platelet O
function O
and O
platelet O
- O
polymorphonuclear O
- O
neutrophil O
interaction O
in O
patients O
with O
deficient O
platelet I-GENE
lipoxygenase I-GENE
activity O
. O

Spontaneous O
degradation O
of O
atracurium O
in O
plasma O
is O
the O
major O
route O
of O
elimination O
in O
man O
and O
contributes O
to O
a O
short O
elimination O
half O
- O
life O
( O
approximatively O
20 O
min O
). O

Transformed O
cell O
lines O
expressing O
solely O
E1a I-GENE
or O
E1a I-GENE
and O
E1b I-GENE
gene I-GENE
products I-GENE
derived O
from O
these O
viruses O
display O
enhanced O
anchorage O
- O
independent O
growth O
at O
37 O
degrees O
C O
versus O
32 O
degrees O
C O
and O
display O
a O
cytoskeletal O
architecture O
resembling O
untransformed O
fibroblastic O
CREF O
cells O
. O

Partial O
N O
- O
terminal O
amino O
acid O
sequence O
analysis O
showed O
that O
the O
43K I-GENE
and I-GENE
42K I-GENE
T I-GENE
antigens I-GENE
contain O
methionine O
at O
residues O
1 O
and O
5 O
, O
as O
predicted O
from O
the O
DNA O
sequence O
, O
whereas O
no O
methionine O
was O
released O
from O
the O
39K I-GENE
T I-GENE
antigen I-GENE
during O
the O
first O
six O
cycles O
of O
Edman O
degradation O
. O

Group O
A O
was O
treated O
with O
three O
or O
four O
doses O
of O
hepatitis I-GENE
B I-GENE
immune I-GENE
globulin I-GENE
( O
HBIG I-GENE
) O
in O
one O
of O
three O
different O
schedules O
. O

In O
the O
former O
instance O
, O
in O
addition O
to O
serum O
calcium O
and O
phosphorous O
ion O
concentrations O
, O
tissue O
pH O
, O
blood O
supply O
, O
hormones O
, O
i O
. O
e O
., O
vitamin O
D O
, O
vitamin O
A O
, O
and O
various O
enzymes O
( O
e O
. O
g O
., O
alkaline I-GENE
phosphatase I-GENE
and O
pyrophosphatase I-GENE
) O
may O
all O
play O
significant O
, O
ancillary O
, O
time O
- O
dependent O
, O
but O
as O
yet O
undetermined O
roles O
. O

Penicillinase I-GENE
production O
in O
Staphylococcus O
aureus O
strains O
of O
clinical O
importance O
. O

Thus O
, O
quantitative O
analysis O
of O
thallium O
- O
201 O
uptake O
and O
washout O
provided O
objective O
evidence O
for O
improved O
myocardial O
perfusion O
after O
coronary O
angioplasty O
. O

This O
study O
reports O
the O
effects O
of O
a O
preparation O
with O
50 O
micrograms O
ethinyl O
estradiol O
and O
2 O
mg O
cyproterone O
acetate O
on O
gonadotropins I-GENE
, O
prolactin I-GENE
, O
testosterone O
, O
sex I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
), O
androstenedione O
, O
and O
calculated O
free O
testosterone O
index O
before O
and O
after O
six O
months O
of O
treatment O
. O

Functional O
flow O
was O
evaluated O
using O
laser O
Doppler O
flowmetry O
( O
LDF O
), O
for O
which O
the O
output O
signal O
, O
blood O
cell O
flux O
( O
BCF O
), O
is O
expressed O
in O
terms O
of O
volts O
. O

In O
nine O
patients O
with O
renal O
failure O
routine O
haemodialysis O
was O
accompanied O
by O
a O
30 O
per O
cent O
reduction O
in O
plasma O
ANP I-GENE
concentration O
. O

To O
investigate O
the O
effects O
of O
isotretinoin O
on O
HDL I-GENE
, O
we O
measured O
HDL I-GENE
- I-GENE
C I-GENE
, O
HDL I-GENE
phospholipids O
( O
HDL I-GENE
- I-GENE
PL I-GENE
), O
apoprotein I-GENE
A1 I-GENE
( O
apo I-GENE
A I-GENE
- I-GENE
1 I-GENE
), O
and O
HDL I-GENE
- I-GENE
C I-GENE
subfractions O
( O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
HDL3 I-GENE
- I-GENE
C I-GENE
) O
in O
24 O
healthy O
, O
male O
patients O
receiving O
a O
16 O
- O
week O
course O
of O
isotretinoin O
( O
1 O
. O
0 O
mg O
/ O
kg O
/ O
day O
) O
for O
treatment O
of O
severe O
acne O
vulgaris O
. O

The O
clinical O
picture O
and O
laboratory O
parameters O
were O
consistent O
with O
a O
serum O
sickness O
reaction O
. O

Our O
data O
, O
however O
, O
did O
not O
suggest O
the O
existence O
of O
a O
conversion O
factor O
for O
LDF O
signal O
to O
absolute O
flow O
values O
from O
experiment O
to O
experiment O
. O

Preventive O
effect O
of O
ONO O
- O
3708 O
on O
thrombosis O
and O
vasospasms O
in O
vitro O
and O
in O
vivo O
. O

The O
frequency O
of O
PPNG O
strains O
increased O
from O
1 O
. O
7 O
% O
in O
1981 O
to O
6 O
. O
7 O
% O
in O
1985 O
. O

Monospecific O
antibodies O
, O
eluted O
from O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
fusion O
protein O
of O
either O
clone O
reacted O
with O
the O
U1 I-GENE
snRNP I-GENE
- O
specific O
A I-GENE
antigen I-GENE
. O

Quantitative O
analysis O
of O
the O
coronary O
stenosis O
was O
assessed O
before O
and O
after O
PTCA O
, O
and O
the O
dilatation O
resulted O
in O
an O
increase O
in O
minimal O
luminal O
cross O
- O
sectional O
area O
from O
1 O
. O
1 O
+/- O
0 O
. O
8 O
to O
2 O
. O
7 O
+/- O
1 O
. O
2 O
mm2 O
. O

The O
pathogenesis O
of O
Limited O
Joint O
Mobility O
( O
LJM O
) O
in O
diabetes O
is O
unknown O
, O
but O
the O
abnormality O
is O
said O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
microangiopathy O
. O

In O
a O
previous O
study O
( O
Brandl O
, O
C O
. O

The O
experimental O
end O
points O
were O
the O
time O
required O
for O
treated O
tumors O
to O
reach O
3 O
times O
their O
treatment O
size O
, O
the O
survival O
of O
stem O
cells O
in O
the O
duodenal O
crypts O
, O
and O
the O
breathing O
rate O
measured O
early O
( O
19 O
- O
23 O
weeks O
) O
and O
late O
( O
41 O
- O
46 O
weeks O
) O
after O
treatment O
. O

Schedule O
2 O
, O
in O
which O
2 O
. O
4 O
mg O
/ O
kg O
c O
- O
DDP O
was O
administered O
immediately O
before O
X O
- O
ray O
on O
5 O
consecutive O
days O
produced O
the O
highest O
degree O
of O
enhancement O
of O
radiation O
effect O
( O
expressed O
as O
dose O
- O
effect O
factor O
); O
and O
the O
next O
greatest O
enhancement O
was O
produced O
by O
12 O
mg O
/ O
kg O
c O
- O
DDP O
administered O
24 O
h O
before O
the O
start O
of O
fractionated O
daily O
radiotherapy O
. O

The O
cpc I-GENE
- I-GENE
1 I-GENE
- I-GENE
encoded I-GENE
transcript I-GENE
contains O
three O
open O
reading O
frames O
, O
two O
of O
which O
are O
located O
in O
the O
720 O
- O
nucleotide O
leader O
segment O
preceding O
the O
cpc I-GENE
- I-GENE
1 I-GENE
coding I-GENE
region I-GENE
. O

The O
seco O
- O
steroid O
hormone O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
is O
known O
to O
induce O
the O
expression O
of O
a O
calcium O
binding O
protein O
termed O
calbindin I-GENE
- I-GENE
D28K I-GENE
in O
a O
variety O
of O
target O
tissues O
. O

In O
addition O
, O
the O
calbindin I-GENE
- I-GENE
D28K I-GENE
promoter I-GENE
is O
composed O
of O
a O
variety O
of O
simple O
repeated O
sequences O
, O
some O
of O
which O
are O
components O
of O
putative O
regulatory O
signals O
. O

The O
HOI O
induced O
a O
nearly O
fourfold O
increase O
in O
ANF I-GENE
in O
the O
elderly O
, O
whereas O
that O
for O
the O
young O
was O
threefold O
. O

To O
assess O
the O
ability O
of O
the O
atria O
to O
maintain O
elevated O
plasma O
concentrations O
of O
atrial I-GENE
natriuretic I-GENE
peptide I-GENE
( O
ANP I-GENE
), O
the O
temporal O
changes O
in O
plasma I-GENE
ANP I-GENE
concentrations O
were O
studied O
in O
seven O
chloralose O
- O
anaesthetized O
dogs O
during O
4 O
h O
of O
sustained O
rapid O
cardiac O
pacing O
. O

Ig I-GENE
D I-GENE
- O
JH I-GENE
recombinations O
may O
precede O
TcR I-GENE
gene I-GENE
recombination O
in O
these O
early O
T O
cell O
lines O
, O
and O
some O
but O
not O
all O
express O
sterile O
Cmu I-GENE
transcripts I-GENE
. O

The O
RAD18 I-GENE
gene I-GENE
open I-GENE
reading I-GENE
frame I-GENE
encodes O
a O
protein O
of O
487 O
amino O
acids O
, O
with O
a O
calculated O
molecular O
weight O
of O
55 O
, O
512 O
. O

Atomic O
absorption O
spectrophotometry O
applied O
to O
bacterially O
expressed O
E1A I-GENE
proteins I-GENE
revealed O
that O
the O
289 O
- O
amino O
acid O
protein O
binds O
one O
zinc O
ion O
, O
whereas O
the O
243 O
- O
amino O
acid O
protein O
binds O
no O
zinc O
. O

Most O
patients O
preferred O
tablets O
to O
injection O
both O
on O
day O
1 O
( O
313 O
v O
200 O
) O
and O
at O
follow O
up O
( O
373 O
v O
104 O
). O

Plots O
of O
RV O
, O
LV O
+ O
S O
and O
2A O
weight O
vs O
real O
hematocrit O
showed O
sharp O
upward O
inflections O
at O
real O
hematocrit O
65 O
%, O
suggesting O
a O
possible O
role O
of O
increased O
viscosity O
in O
CO O
cardiomegaly O
at O
the O
higher O
hematocrit O
. O

The O
absorbable O
perisplenic O
mesh O
is O
an O
important O
improvement O
, O
and O
in O
some O
cases O
it O
may O
replace O
other O
techniques O
for O
arresting O
splenic O
bleeding O
. O

A O
rare O
chronic O
course O
of O
Budd O
- O
Chiari O
syndrome O
associated O
with O
thrombosis O
of O
the O
portal O
vein O
was O
observed O
in O
a O
30 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
postmyocarditic O
cardiosclerosis O
. O

After O
one O
accommodation O
night O
, O
sleep O
EEG O
recordings O
were O
performed O
during O
three O
consecutive O
nights O
in O
ten O
drug O
- O
free O
inpatients O
presenting O
generalized O
anxiety O
disorder O
( O
GAD O
) O
with O
significant O
depression O
, O
compared O
with O
a O
age O
- O
and O
sex O
- O
matched O
group O
of O
patients O
with O
GAD O
and O
a O
group O
of O
primary O
major O
depressive O
disorder O
( O
MDD O
) O
patients O
. O

Oligonucleotide O
mutagenesis O
of O
these O
binding O
domains O
indicated O
their O
importance O
in O
the O
transcriptional O
regulation O
of O
the O
E3 I-GENE
promoter I-GENE
in O
yeast O
cells O
. O

The O
concentration O
of O
PGI2 O
on O
the O
newly O
- O
formed O
luminal O
surface O
remained O
low O
. O

Organ O
transplantation O
in O
Denmark O
. O

Effects O
of O
single O
and O
combined O
maltose O
tetrapalmitate O
immunotherapy O
, O
cyclophosphamide O
chemotherapy O
and O
radiotherapy O
on O
ethyl O
carbamate O
accelerated O
primary O
lung O
cancer O
in O
A O
/ O
J O
mice O
. O

D O
. O

A O
114 O
- O
base O
pair O
sequence O
of O
predominantly O
repeating O
purine O
- O
pyrimidine O
nucleotides O
separates O
these O
two O
d O
( O
AC O
) O
repeats O
. O

Phase O
II O
study O
of O
VP O
- O
16 O
( O
capsule O
) O
in O
solid O
tumors O
. O

When O
the O
coding O
segments O
, O
including O
both O
framework O
and O
complementarity O
- O
determining O
regions O
, O
of O
these O
genes O
and O
the O
murine O
probe O
sequences O
are O
compared O
by O
metric O
analysis O
, O
it O
is O
apparent O
that O
the O
caiman O
genes O
are O
only O
slightly O
more O
related O
to O
each O
other O
than O
to O
the O
mammalian O
sequence O
, O
consistent O
with O
significant O
preservation O
of O
nucleotide O
sequence O
over O
an O
extended O
period O
of O
phylogenetic O
time O
. O

Evidence O
for O
a O
role O
of O
endogenous I-GENE
corticotropin I-GENE
- I-GENE
releasing I-GENE
factor I-GENE
in O
cold O
, O
ether O
, O
immobilization O
, O
and O
traumatic O
stress O
. O

An O
unusual O
feature O
of O
these O
replicative O
genes O
is O
that O
the O
smaller O
mRNA O
begins O
within O
a O
long O
open O
reading O
frame O
of O
the O
larger O
mRNA O
. O

Different O
sequence O
elements O
of O
both O
the O
retroviral O
vectors O
and O
the O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
recombined O
during O
genesis O
of O
highly O
oncogenic O
retroviruses O
CMII O
, O
MC29 O
, O
or O
MH2 O
. O

81 O
milk O
samples O
collected O
from O
35 O
donors O
3 O
days O
to O
7 O
months O
after O
delivery O
were O
examined O
for O
the O
occurrence O
of O
cytomegalovirus O
( O
CMV O
). O

Subcloning O
of O
DNA O
fragments O
from O
the O
8 O
. O
5 O
- O
kilobase O
( O
kb O
) O
insert O
of O
pAVO4 O
defined O
a O
4 O
- O
kb O
DNA O
fragment O
which O
contained O
the O
functional I-GENE
FBP I-GENE
+ I-GENE
gene I-GENE
and O
its O
regulatory O
region O
. O

Three O
cases O
of O
primary O
signet O
- O
ring O
cell O
carcinoma O
of O
the O
rectum O
are O
described O
. O

The O
data O
obtained O
up O
to O
now O
only O
suggest O
the O
future O
potentiality O
of O
Bestatin O
treatment O
for O
these O
types O
of O
malignancy O
. O

These O
data O
suggest O
that O
dopaminergic O
regulation O
of O
adrenal O
zona O
glomerulosa O
corticosteroid O
and O
renal I-GENE
renin I-GENE
secretion O
is O
absent O
in O
patients O
with O
high O
spinal O
cord O
transections O
, O
suggesting O
that O
intact O
neural O
pathways O
from O
the O
central O
nervous O
system O
are O
necessary O
for O
metoclopramide O
stimulation O
of O
aldosterone O
and O
renin I-GENE
secretion O
in O
men O
. O

In O
the O
absence O
of O
enhancer O
sequences O
, O
the O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
can O
not O
stimulate O
CATase I-GENE
synthesis O
. O

These O
IgG I-GENE
antibodies I-GENE
in O
the O
babies O
diminished O
rapidly O
after O
delivery O
, O
and O
were O
detectable O
only O
in O
3 O
cases O
at O
2 O
, O
3 O
, O
and O
5 O
months O
of O
ages O
out O
of O
38 O
babies O
up O
to O
21 O
months O
. O

Fine O
analysis O
at O
the O
nucleotide O
level O
of O
the O
early O
events O
in O
the O
digestion O
with O
nuclease I-GENE
S1 I-GENE
shows O
that O
the O
enzyme O
attacks O
preferentially O
the O
sequence O
( O
G O
- O
A O
) O
12 O
on O
the O
message O
complementary O
strand O
. O

Those O
dosages O
that O
inhibited O
mean O
NTE I-GENE
activity O
in O
spinal O
cord O
greater O
than O
or O
equal O
to O
72 O
% O
and O
brain O
greater O
than O
or O
equal O
to O
66 O
% O
of O
control O
values O
within O
44 O
hr O
postexposure O
produced O
marked O
spinal O
cord O
pathology O
14 O
days O
postexposure O
in O
greater O
than O
or O
equal O
to O
90 O
% O
of O
similarly O
dosed O
animals O
. O

FK O
33 O
- O
824 O
, O
a O
methionine O
- O
enkephalin I-GENE
analogue O
, O
suppressed O
plasma O
ACTH I-GENE
to O
85 O
% O
of O
basal O
level O
, O
while O
bromocriptine O
( O
CB O
- O
154 O
) O
caused O
no O
significant O
change O
. O

A O
v I-GENE
- I-GENE
erbB I-GENE
- I-GENE
related I-GENE
protooncogene I-GENE
, O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
, O
is O
distinct O
from O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
1 I-GENE
/ O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
receptor I-GENE
gene O
and O
is O
amplified O
in O
a O
human O
salivary O
gland O
adenocarcinoma O
. O

The O
sequence O
analysis O
of O
both O
products O
of O
individual O
phi O
80 O
site O
- O
specific O
recombination O
events O
in O
vivo O
shows O
that O
recombination O
with O
a O
secondary O
attachment O
( O
att O
) O
site O
generates O
several O
different O
novel O
joints O
at O
the O
mismatched O
position O
: O
one O
recombination O
event O
resulted O
in O
a O
single O
base O
- O
pair O
deletion O
and O
two O
other O
recombination O
events O
resulted O
in O
two O
different O
single O
base O
- O
pair O
substitutions O
. O

This O
L I-GENE
- I-GENE
myc I-GENE
sequence I-GENE
is O
amplified O
10 O
- O
20 O
- O
fold O
in O
four O
SCLC O
cell O
line O
DNAs O
and O
in O
one O
SCLC O
tumour O
specimen O
taken O
directly O
from O
a O
patient O
. O

Temperature O
- O
shift O
experiments O
using O
synchronously O
grown O
cells O
of O
a O
delta I-GENE
top1 I-GENE
top2 I-GENE
temperature I-GENE
- I-GENE
sensitive I-GENE
( I-GENE
ts I-GENE
) I-GENE
double I-GENE
mutant I-GENE
and O
its O
isogenic O
top2 I-GENE
ts O
strain O
show O
that O
, O
whereas O
mitotic O
blocks O
can O
prevent O
killing O
of O
the O
top2 I-GENE
ts I-GENE
mutant I-GENE
at O
a O
nonpermissive O
temperature O
, O
the O
same O
treatments O
are O
ineffective O
in O
preventing O
cell O
death O
of O
the O
delta I-GENE
top1 I-GENE
top2 I-GENE
ts I-GENE
double I-GENE
mutant I-GENE
. O

The O
homology O
to O
v I-GENE
- I-GENE
mil I-GENE
starts O
within O
the O
coding O
sequence O
of O
exon O
1 O
and O
ends O
within O
the O
3 O
' O
untranslated O
region O
of O
exon O
11 O
, O
12 O
nucleotides O
downstream O
from O
the O
nonsense O
codon O
terminating O
the O
large O
open O
reading O
frame O
shared O
between O
c I-GENE
- I-GENE
mil I-GENE
and O
v I-GENE
- I-GENE
mil I-GENE
. O

Examination O
of O
the O
sequence O
of O
the O
Punta I-GENE
Toro I-GENE
M I-GENE
gene I-GENE
product I-GENE
reveals O
the O
presence O
of O
multiple O
hydrophobic O
sequences O
including O
a O
19 O
- O
amino O
acid O
, O
carboxy O
- O
proximal O
, O
hydrophobic O
region O
( O
G2 O
). O

Six O
( O
four O
FAP O
; O
two O
primary O
amyloidosis O
) O
also O
had O
diffusely O
positive O
myocardial O
uptakes O
, O
but O
the O
intensity O
was O
less O
than O
that O
of O
the O
sternum O
. O

The O
intensity O
of O
myocardial O
uptake O
of O
Tc O
- O
99m O
- O
PYP O
in O
patients O
with O
echocardiographic O
left O
ventricular O
hypertrophy O
and O
/ O
or O
highly O
refractile O
myocardial O
echoes O
, O
so O
- O
called O
granular O
sparkling O
appearance O
( O
GS O
) O
was O
slightly O
greater O
than O
that O
in O
patients O
with O
neither O
myocardial O
hypertrophy O
nor O
GS O
. O

The O
210 O
kDa O
precursor O
is O
converted O
slowly O
( O
t O
1 O
/ O
2 O
= O
2 O
h O
) O
by O
proteolytic O
processing O
into O
a O
125 O
kDa O
( O
alpha O
') O
and O
83 O
kDa O
( O
beta O
') O
species O
. O

Alveolar O
lymphocytes O
were O
surprisingly O
increased O
in O
most O
patients O
with O
AIDS O
( O
mean O
26 O
. O
1 O
+/- O
21 O
. O
9 O
%; O
range O
1 O
- O
76 O
%) O
and O
CGL O
( O
mean O
26 O
. O
6 O
+/- O
22 O
. O
6 O
%; O
range O
3 O
- O
76 O
%) O
with O
criteria O
of O
activation O
contrasting O
with O
the O
blood O
lymphopenia O
. O

We O
have O
determined O
that O
these O
nicks O
occur O
in O
both O
the O
wild O
- O
type O
and O
the O
mutant O
sites O
. O

The O
sequence O
was O
determined O
for O
a O
4024 O
- O
base O
pair O
( O
bp O
) O
segment O
that O
extends O
from O
149 O
bp O
5 O
' O
to O
the O
cap O
site O
of O
alpha I-GENE
1 I-GENE
to O
207 O
bp O
3 O
' O
to O
psi I-GENE
alpha I-GENE
. O

Its O
predicted O
amino O
acid O
sequence O
shows O
extensive O
homology O
to O
those O
of O
Drosophila I-GENE
hsp70 I-GENE
, O
trout I-GENE
hsp70 I-GENE
, O
Xenopus I-GENE
hsp70 I-GENE
, O
yeast I-GENE
hsp70 I-GENE
, O
and O
some O
homology O
to O
the O
heat I-GENE
- I-GENE
inducible I-GENE
dnaK I-GENE
gene I-GENE
product I-GENE
of O
Escherichia O
coli O
. O

When O
phosphorylation O
of O
exogenous O
peptide O
substrates O
was O
measured O
as O
a O
function O
of O
receptor O
self O
- O
phosphorylation O
, O
tyrosine I-GENE
kinase I-GENE
activity O
was O
found O
to O
be O
enhanced O
two O
to O
threefold O
at O
1 O
- O
2 O
mol O
of O
phosphate O
per O
mol O
of O
receptor O
. O

At O
temperatures O
permissive O
for O
transformation O
, O
6m2 O
cells O
contain O
P58gag I-GENE
produced O
from O
the O
4 O
. O
0 O
- O
kilobase O
( O
kb O
) O
viral O
RNA O
genome O
and O
P85gag I-GENE
- O
mos I-GENE
translated O
from O
a O
3 O
. O
5 O
- O
kb O
spliced O
mRNA O
. O

The O
pet56 I-GENE
and O
his3 I-GENE
genes I-GENE
are O
transcribed O
divergently O
from O
initiation O
sites O
that O
are O
separated O
by O
only O
192 O
bp O
. O

Multistep O
transformation O
by O
defined O
fragments O
of O
herpes O
simplex O
virus O
type O
2 O
DNA O
: O
oncogenic O
region O
and O
its O
gene O
product O
. O

It O
is O
concluded O
that O
in O
patients O
with O
first O
- O
attack O
genital O
herpes O
, O
the O
type O
of O
HSV O
is O
the O
most O
important O
determinant O
of O
subsequent O
recurrences O
and O
that O
intravenous O
acyclovir O
has O
little O
effect O
on O
subsequent O
recurrences O
. O

Comparison O
of O
sequences O
of O
ovine O
and O
bovine O
, O
rat O
and O
guinea I-GENE
- I-GENE
pig I-GENE
alpha I-GENE
s1 I-GENE
- I-GENE
casein I-GENE
mRNAs I-GENE
has O
revealed O
a O
greater O
homology O
in O
the O
3 O
' O
and O
especially O
5 O
' O
non O
coding O
regions O
. O

One O
group O
( O
n O
= O
9 O
) O
was O
premedicated O
with O
midazolam O
, O
0 O
. O
1 O
mg O
kg O
- O
1 O
, O
and O
atropine O
0 O
. O
2 O
- O
0 O
. O
4 O
mg O
i O
. O
m O
. O

Comparison O
with O
a O
recently O
described O
c I-GENE
- I-GENE
sis I-GENE
cDNA I-GENE
clone I-GENE
( O
Collins O
et O
al O
., O
Nature O
316 O
, O
748 O
- O
750 O
( O
1985 O
)) O
revealed O
that O
the O
1 O
. O
9 O
kbp O
DNA O
region O
contained O
a O
large O
5 I-GENE
' I-GENE
c I-GENE
- I-GENE
sis I-GENE
exon I-GENE
of O
at O
least O
1050 O
bp O
. O

It O
was O
also O
suggested O
that O
the O
biological O
activities O
of O
5 O
- O
FU O
, O
ADM O
and O
MMC O
in O
FAMLIP O
were O
stable O
in O
FULIP O
, O
ADRLIP O
and O
MMCLIP O
. O

Surprisingly O
, O
a O
C O
to O
G O
transversion O
at O
the O
first O
residue O
of O
the O
CAT I-GENE
pentanucleotide I-GENE
, O
which O
severely O
impairs O
the O
activity O
of O
both O
promoters O
, O
appears O
to O
increase O
affinity O
of O
the O
CAT I-GENE
binding I-GENE
protein I-GENE
. O

The O
nucleotide O
sequence O
of O
3874 O
bp O
of O
cloned O
R O
. O
sphaeroides O
chromosomal O
DNA O
, O
including O
the O
three O
structural O
genes O
fbcF I-GENE
, O
fbcB I-GENE
and O
fbcC I-GENE
has O
been O
determined O
. O

The O
N O
- O
terminal O
sequence O
of O
one O
hydrophilic O
peptide O
of O
the O
FeS I-GENE
protein I-GENE
has O
been O
also O
obtained O
confirming O
the O
fbcF I-GENE
reading O
frame O
. O

The O
5 O
' O
and O
3 O
' O
untranslated O
sequences O
contain O
characteristic O
sequences O
that O
are O
involved O
in O
the O
initiation O
and O
termination O
of O
transcription O
, O
including O
two O
possible O
promoters O
, O
one O
of O
which O
may O
contain O
two O
overlapping O
- O
10 O
sequences O
. O

Unlike O
P135gag I-GENE
- O
myb I-GENE
- O
ets I-GENE
and O
the O
Mr O
75 O
, O
000 O
translation O
product O
of O
c I-GENE
- I-GENE
myb I-GENE
( O
P75c I-GENE
- I-GENE
myb I-GENE
), O
which O
are O
nuclear O
proteins O
, O
P54c I-GENE
- I-GENE
ets I-GENE
was O
found O
to O
be O
predominantly O
cytoplasmic O
. O

The O
Dox I-GENE
- I-GENE
A2 I-GENE
locus I-GENE
is O
within O
3 O
. O
4 O
to O
4 O
. O
4 O
kb O
of O
the O
Df I-GENE
( I-GENE
2L I-GENE
) I-GENE
OD15 I-GENE
breakpoint I-GENE
, O
placing O
four O
of O
the O
vital O
loci O
within O
a O
maximum O
of O
15 O
. O
5 O
kb O
. O

The O
C O
- O
terminal O
end O
of O
this O
polypeptide O
harbors O
three O
types O
of O
repeated O
sequences O
. O

Further O
outbreaks O
of O
ocular O
disease O
in O
farmed O
red O
deer O
calves O
caused O
by O
HVC O
- O
1 O
were O
investigated O
. O

From O
our O
ultrastructural O
and O
biochemical O
studies O
, O
it O
is O
evident O
that O
Type O
II O
pneumocytes O
are O
an O
early O
target O
of O
radiation O
and O
the O
release O
of O
surfactant O
into O
the O
alveolus O
shortly O
after O
exposure O
persists O
for O
days O
and O
weeks O
. O

Thirty O
of O
the O
clones O
contained O
a O
complete O
340 O
base O
- O
pair O
dimer O
unit O
of O
the O
repeat O
. O

Two O
copies O
of O
the O
72 O
- O
bp O
repeat O
provided O
efficient O
activation O
of O
gene O
expression O
. O

The O
open O
reading O
frames O
of O
rbsD I-GENE
, O
rbsA I-GENE
, O
and O
rbsC I-GENE
encode O
proteins O
of O
139 O
, O
501 O
, O
and O
321 O
amino O
acid O
residues O
, O
respectively O
. O

In O
order O
to O
study O
the O
influence O
of O
iron O
overload O
on O
the O
polymorphonuclear O
leucocyte O
( O
PMN O
) O
metabolism O
of O
patients O
on O
chronic O
hemodialysis O
, O
generation O
of O
superoxide O
anion O
( O
O2 O
-) O
by O
PMN O
in O
whole O
blood O
was O
compared O
in O
two O
groups O
of O
hemodialyzed O
patients O
: O
group O
A O
consisted O
of O
twenty O
- O
one O
individuals O
with O
serum O
ferritin I-GENE
levels O
above O
1000 O
ng O
/ O
ml O
and O
group O
B O
of O
nineteen O
individuals O
with O
serum O
ferritin I-GENE
levels O
below O
1000 O
ng O
/ O
ml O
. O

Cattaneo O
, O
and O
J O
. O

Human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
: O
nucleotide O
sequence O
of O
a O
cDNA O
clone O
encoding O
the O
mature O
enzyme O
. O

Diazepam O
( O
3 O
mg O
/ O
kg O
) O
generalized O
to O
Ro O
11 O
- O
6896 O
whereas O
the O
structurally O
related O
Ro O
5 O
- O
4864 O
( O
3 O
mg O
/ O
kg O
and O
30 O
mg O
/ O
kg O
) O
did O
not O
. O

The O
amino O
acid O
sequence O
was O
determined O
to O
be O
residues O
716 O
- O
724 O
and O
hence O
lysine O
residue O
721 O
is O
located O
within O
the O
ATP O
- O
binding O
site O
. O

Osteocalcin I-GENE
( O
and O
urinary O
hydroxyproline O
) O
were O
not O
elevated O
in O
isolated O
hyperphosphatasaemia O
, O
indicating O
that O
mechanisms O
other O
than O
increased O
bone O
turnover O
may O
account O
for O
the O
markedly O
elevated O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
in O
these O
subjects O
. O

Analysis O
of O
glucocorticoid O
unresponsive O
cell O
variants O
using O
a O
mouse I-GENE
glucocorticoid I-GENE
receptor I-GENE
complementary O
DNA O
clone O
. O

Among O
the O
v I-GENE
- I-GENE
myc I-GENE
codons O
, O
the O
first O
5 O
are O
derived O
from O
the O
noncoding O
5 O
' O
terminus O
of O
the O
second O
c I-GENE
- I-GENE
myc I-GENE
exon O
, O
and O
412 O
codons O
correspond O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
coding O
region O
. O

A O
recombinant O
vector O
, O
p410 O
+, O
was O
constructed O
which O
carried O
the O
BamHI I-GENE
- I-GENE
K I-GENE
fragment I-GENE
( O
nucleotides O
107565 O
to O
112625 O
of O
the O
B95 O
- O
8 O
strain O
, O
encoding O
the O
EBV O
- O
associated O
nuclear O
antigen O
EBNA I-GENE
- I-GENE
1 I-GENE
), O
the O
cis O
- O
acting O
sequence O
from O
the O
BamHI I-GENE
- I-GENE
C I-GENE
fragment I-GENE
, O
and O
a O
dominant O
selectable O
marker O
gene O
encoding O
G O
- O
418 O
resistance O
in O
animal O
cells O
. O

13 O
men O
with O
a O
history O
of O
recurrent O
genital O
herpes O
simplex O
virus O
type O
2 O
( O
HSV O
- O
2 O
) O
infection O
were O
followed O
daily O
for O
4 O
weeks O
with O
samples O
taken O
from O
the O
urethra O
for O
virus O
isolation O
. O

Next O
, O
with O
carcinoma O
presenting O
a O
leather O
bottle O
( O
linitis O
plastica O
type O
) O
of O
the O
stomach O
itself O
, O
the O
II O
c O
portion O
of O
the O
stomach O
consisted O
of O
fundic O
glands O
( O
undifferentiated O
carcinoma O
) O
shall O
become O
the O
primary O
focus O
supporting O
Nakamura O
' O
s O
theory O
. O

During O
the O
biosynthesis O
of O
all O
three O
mutant O
polypeptides O
, O
the O
signal O
peptide O
is O
efficiently O
and O
accurately O
cleaved O
from O
the O
nascent O
protein O
, O
even O
though O
in O
mutants O
X2 O
and O
X3 O
the O
cleavage O
site O
itself O
has O
been O
altered O
. O

The O
hexanucleotide O
5 O
'- O
TGTCCT O
- O
3 O
', O
thought O
to O
be O
important O
for O
GRE O
activity O
, O
not O
only O
was O
found O
in O
this O
sequence O
and O
in O
the O
5 O
'- O
flanking O
region O
, O
but O
also O
was O
present O
twice O
in O
the O
3 O
' O
end O
of O
the O
gene O
that O
did O
not O
show O
specific O
receptor O
binding O
. O

Five O
patients O
developed O
metastatic O
spread O
, O
and O
all O
of O
them O
died O
of O
tumor O
. O

The O
smallest O
of O
the O
mini O
- O
Mu O
elements O
is O
only O
7 O
. O
9 O
kilobase O
pairs O
long O
, O
allowing O
the O
cloning O
of O
DNA O
fragments O
of O
up O
to O
31 O
. O
1 O
kilobase O
pairs O
, O
and O
the O
largest O
of O
them O
is O
21 O
. O
7 O
kilobase O
pairs O
, O
requiring O
that O
clones O
carry O
insertions O
of O
less O
than O
17 O
. O
3 O
kilobase O
pairs O
. O

The O
52 O
- O
protein O
subunit O
of O
T4 I-GENE
DNA I-GENE
topoisomerase I-GENE
is O
homologous O
to O
the O
gyrA I-GENE
- I-GENE
protein I-GENE
of O
gyrase I-GENE
. O

There O
were O
no O
interfering O
peaks O
in O
the O
quantitation O
of O
sulbactam O
. O

The O
latent O
periods O
from O
the O
antral O
exclusion O
to O
the O
occurrence O
of O
anastomotic O
ulcers O
after O
a O
subtotal O
gastrectomy O
with O
Billroth O
' O
s O
type O
II O
reconstruction O
varied O
from O
a O
few O
days O
to O
19 O
years O
, O
with O
an O
average O
of O
2 O
. O
8 O
years O
. O

The O
nucleosomal O
arrays O
detected O
by O
MPE O
X O
Fe O
( O
II O
) O
were O
characterized O
by O
a O
considerable O
loss O
of O
detail O
and O
significantly O
enhanced O
accessibility O
, O
the O
extent O
of O
which O
probably O
reflected O
the O
relative O
transcription O
rate O
of O
each O
gene O
. O

Translation O
of O
specific O
cellular O
genes O
from O
the O
chimeric O
viral O
- O
cellular O
transcripts O
seems O
to O
be O
unlikely O
. O

The O
molecular O
weight O
of O
in O
vivo O
- O
labeled O
proteins O
was O
increased O
relative O
to O
that O
of O
in O
vitro O
- O
translated O
proteins O
, O
indicating O
that O
a O
posttranslational O
modification O
had O
occurred O
. O

Insertion O
of O
4 O
bp O
reduced O
SV40 I-GENE
early I-GENE
promoter I-GENE
- O
dependent O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
expression O
by O
six O
- O
to O
eightfold O
. O

In O
the O
DNAs O
of O
all O
Ph1 O
- O
positive O
chronic O
myelocytic O
leukemia O
patients O
studied O
to O
date O
, O
a O
breakpoint O
on O
chromosome O
22 O
( O
the O
Ph1 O
chromosome O
) O
can O
be O
demonstrated O
with O
a O
probe O
from O
the O
bcr I-GENE
( O
breakpoint I-GENE
cluster I-GENE
region I-GENE
). O

Nuclease O
footprinting O
revealed O
that O
purified O
glucocorticoid I-GENE
receptor I-GENE
bound O
at O
multiple O
discrete O
sites O
within O
and O
at O
the O
borders O
of O
the O
tandemly O
repeated O
sequence O
motif O
that O
defines O
Sa I-GENE
. O

The O
96 O
- O
bp O
insert O
contained O
a O
termination O
signal O
which O
caused O
the O
premature O
termination O
of O
the O
protein O
, O
leading O
to O
the O
generation O
of O
a O
p53 I-GENE
product I-GENE
9 O
amino O
acids O
shorter O
than O
usual O
. O

All O
tumors O
proved O
histologically O
to O
be O
neuroendocrine O
in O
origin O
. O

The O
coding O
region O
of O
2385 O
nucleotides O
corresponds O
to O
a O
polypeptide O
chain O
of O
795 O
amino O
acids O
, O
giving O
a O
molecular O
weight O
of O
91 O
, O
555 O
for O
the O
hsp108 I-GENE
protein I-GENE
. O

Transcriptional O
control O
signals O
of O
a O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
late I-GENE
( I-GENE
gamma I-GENE
2 I-GENE
) I-GENE
gene I-GENE
lie O
within O
bases O
- O
34 O
to O
+ O
124 O
relative O
to O
the O
5 O
' O
terminus O
of O
the O
mRNA O
. O

A O
noncatalytic O
domain O
conserved O
among O
cytoplasmic I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
modifies O
the O
kinase O
function O
and O
transforming O
activity O
of O
Fujinami I-GENE
sarcoma I-GENE
virus I-GENE
P130gag I-GENE
- O
fps I-GENE
. O

Gluzman O
, O
EMBO O
J O
. O

A O
single O
exon O
encodes O
the O
carboxyl O
- O
terminal O
26 O
amino O
acids O
of O
the O
ssd I-GENE
chain I-GENE
and O
the O
3 O
' O
untranslated O
region O
of O
its O
mRNA O
, O
ending O
with O
a O
poly O
( O
A O
)- O
addition O
site O
. O

The O
5 O
'- O
nontranslated O
sequences O
and O
parts O
of O
the O
coding O
sequences O
of O
various O
yeast O
genes O
have O
been O
cloned O
into O
representative O
lacZ I-GENE
fusion O
vectors O
. O

Two O
activities O
of O
the O
D I-GENE
protein I-GENE
of O
the O
miniF O
plasmid O
have O
been O
found O
. O

SPECT O
examination O
of O
the O
TMJ O
using O
99m O
Tc O
- O
MDP O
was O
performed O
in O
43 O
patients O
with O
arthrographically O
proven O
anterior O
dislocation O
of O
the O
disc O
and O
in O
30 O
normals O
. O

Plasma I-GENE
renin I-GENE
activity O
rose O
and O
the O
plasma O
aldosterone O
level O
fell O
after O
taking O
lisinopril O
. O

Two O
mutants O
, O
each O
representative O
of O
a O
separate O
pet I-GENE
complementation O
group O
, O
have O
been O
analyzed O
. O

The O
second O
group O
of O
homologous O
elements O
is O
present O
in O
the O
upstream O
region O
of O
both O
genes O
. O

A O
centromere O
in O
S O
. O
cerevisiae O
consists O
of O
a O
region O
of O
DNA O
, O
approximately O
150 O
bp O
in O
length O
, O
containing O
three O
important O
sequence O
elements O
, O
which O
are O
folded O
with O
proteins O
into O
a O
specific O
conformation O
in O
the O
chromatin O
( O
the O
yeast O
kinetochore O
). O

Constitutive O
function O
of O
a O
positively O
regulated O
promoter O
reveals O
new O
sequences O
essential O
for O
activity O
. O

Two O
separate O
NF1 I-GENE
- I-GENE
binding I-GENE
loci I-GENE
were O
also O
found O
in O
the O
equivalent O
IE68 I-GENE
gene I-GENE
of O
HCMV O
( O
Towne O
) O
DNA O
, O
but O
in O
this O
case O
the O
DNA O
sequence O
and O
competition O
filter O
binding O
experiments O
indicated O
a O
maximum O
of O
only O
four O
to O
five O
consensus O
binding O
sites O
encompassing O
the O
promoter O
- O
enhancer O
region O
. O

The O
previously O
described O
four O
sets O
of O
13 O
- O
to O
18 O
- O
base O
- O
pair O
interspersed O
repeat O
elements O
between O
- O
55 O
and O
- O
580 O
provide O
most O
of O
the O
high O
basal O
transcriptional O
strength O
, O
whereas O
the O
arrangement O
of O
further O
upstream O
tandemly O
repeated O
NF1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
may O
contribute O
significantly O
to O
the O
expanded O
biological O
host O
range O
for O
expression O
of O
SCMV I-GENE
IE94 I-GENE
compared O
with O
HCMV I-GENE
IE68 I-GENE
. O

We O
inserted O
genes O
or O
gene O
segments O
, O
that O
code O
for O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
, O
the O
bacterial O
gene O
conferring O
resistance O
against O
hygromycin O
, O
and O
the O
ORF O
E7 I-GENE
of O
the O
human O
papillomavirus O
type O
18 O
into O
these O
vectors O
. O

By O
contrast O
, O
their O
basal O
adrenal O
androgen O
levels O
were O
significantly O
decreased O
compared O
to O
those O
in O
normal O
subjects O
on O
both O
the O
day O
on O
and O
the O
day O
off O
prednisone O
( O
P O
less O
than O
0 O
. O
05 O
). O

Active O
lambda I-GENE
and I-GENE
kappa I-GENE
antibody I-GENE
gene I-GENE
rearrangement O
in O
Abelson O
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
cell O
lines O
. O

Identification O
of O
p40x O
- O
responsive O
regulatory O
sequences O
within O
the O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
long O
terminal O
repeat O
. O

During O
pentobarbital O
anesthesia O
, O
the O
basal O
VO2 O
was O
5 O
. O
26 O
ml O
/ O
kg O
/ O
min O
and O
was O
increased O
by O
epinephrine O
in O
a O
dose O
dependent O
manner O
at O
plasma O
concentrations O
between O
3 O
. O
9 O
ng O
/ O
ml O
( O
VO2 O
= O
5 O
. O
68 O
ml O
/ O
kg O
/ O
min O
) O
and O
36 O
. O
5 O
ng O
/ O
ml O
( O
VO2 O
= O
6 O
. O
47 O
ml O
/ O
kg O
/ O
min O
). O

Influence O
of O
cyclo I-GENE
- I-GENE
oxygenase I-GENE
inhibition O
and O
of O
leukotriene I-GENE
receptor I-GENE
blockade O
on O
pulmonary O
vascular O
pressure O
/ O
cardiac O
index O
relationships O
in O
hyperoxic O
and O
in O
hypoxic O
dogs O
. O

Oligonucleotide O
- O
directed O
mutagenesis O
was O
used O
to O
create O
an O
NdeI I-GENE
restriction I-GENE
site I-GENE
at O
the O
natural O
ATG O
of O
the O
yeast O
R O
. O

ACTH I-GENE
release O
is O
transiently O
suppressed O
in O
some O
children O
after O
exogenous O
ACTH I-GENE
treatment O
. O

We O
previously O
showed O
that O
the O
upstream O
promoter O
element O
of O
the O
yeast I-GENE
RP39A I-GENE
gene I-GENE
consists O
of O
these O
identical O
sequence O
motifs O
. O

These O
data O
suggest O
that O
mammalian O
erythroid O
alpha I-GENE
- I-GENE
spectrin I-GENE
evolved O
by O
duplication O
and O
rapid O
divergence O
from O
an O
ancestral O
alpha I-GENE
- I-GENE
fodrin I-GENE
- I-GENE
like I-GENE
gene I-GENE
. O

Northern O
analyses O
of O
RNAs O
from O
mouse O
tissues O
and O
cell O
lines O
indicated O
that O
p11 I-GENE
mRNA I-GENE
levels O
vary O
widely O
. O

One O
group O
of O
six O
cDNA O
clones O
was O
derived O
from O
a O
2 O
. O
9 O
- O
kilobase O
early O
transcript O
encoded O
by O
the O
IR2 O
repeat O
element O
and O
showed O
restriction O
site O
polymorphism O
for O
the O
enzyme I-GENE
SmaI I-GENE
. O

Combined O
immunochemotherapy O
with O
cyclophosphamide O
plus O
BCG O
gave O
a O
better O
enhancement O
of O
the O
antitumor O
effect O
of O
the O
cytostatic O
than O
that O
of O
the O
combination O
of O
methotrexate O
plus O
BCG O
and O
cyclophosphamide O
plus O
levamisole O
. O

Morphine O
produced O
a O
dose O
- O
dependent O
bradycardia O
followed O
by O
tachycardia O
. O

The O
PSS I-GENE
gene I-GENE
was O
subcloned O
into O
a O
1 O
. O
1 O
- O
kb O
fragment O
of O
the O
yeast O
DNA O
on O
the O
YEp13 O
vector O
. O

Indeed O
, O
A O
- O
MuLV O
pseudotyped O
with O
some O
viruses O
, O
such O
as O
the O
Moloney O
MuLV O
, O
has O
been O
shown O
to O
be O
highly O
lymphogenic O
, O
whereas O
A O
- O
MuLV O
pseudotyped O
with O
other O
viruses O
, O
such O
as O
the O
BALB O
/ O
c O
endogenous O
N O
- O
tropic O
MuLV O
, O
has O
been O
shown O
to O
be O
devoid O
of O
lymphogenic O
potential O
( O
N O
. O

The O
presence O
of O
circulating O
platelet O
aggregates O
and O
elevated O
levels O
of O
fibrinopeptide I-GENE
A I-GENE
( O
a O
cleavage O
product O
of O
fibrin I-GENE
) O
suggests O
that O
platelet O
activation O
and O
fibrin I-GENE
deposition O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
disorder O
. O

The O
gene O
is O
essential O
for O
yeast O
vegetative O
growth O
. O

4 O
. O

In O
general O
, O
the O
values O
obtained O
by O
the O
two O
methods O
were O
in O
agreement O
for O
each O
species O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
and O
followed O
the O
order O
: O
wild O
type O
greater O
than O
Glu24 O
---- O
Gly O
greater O
than O
Asp27 O
---- O
Gly O
much O
greater O
than O
Pro7 O
---- O
Thr O
greater O
than O
Tyr29 O
---- O
Gly O
greater O
than O
Leu47 O
---- O
His O
. O

It O
is O
concluded O
that O
suppression O
of O
elevated O
prolactin I-GENE
levels O
in O
progressive O
metastatic O
breast O
cancer O
patients O
is O
not O
effective O
in O
restoring O
tumor O
sensitivity O
to O
chemotherapy O
. O

We O
report O
a O
prevalence O
study O
of O
the O
best O
visual O
acuity O
in O
the O
affected O
eye O
of O
100 O
selected O
patients O
with O
herpetic O
keratitis O
seen O
during O
a O
two O
- O
year O
period O
. O

We O
also O
found O
an O
eIF I-GENE
- I-GENE
4A I-GENE
intronless O
retroposon O
which O
, O
when O
compared O
to O
the O
cDNA O
, O
contains O
a O
single O
nucleotide O
difference O
. O

Bacteriologic O
culture O
of O
pancreatic O
tissue O
was O
positive O
in O
6 O
/ O
8 O
IB O
and O
3 O
/ O
17 O
NIB O
rats O
( O
p O
less O
than O
0 O
. O
01 O
). O

These O
similarities O
suggest O
that O
these O
E2 I-GENE
proteins I-GENE
are O
structurally O
and O
evolutionarily O
related O
. O

After O
infection O
of O
293 O
cells O
( O
which O
provide O
complementary O
E1a I-GENE
- O
E1b I-GENE
functions O
), O
both O
viruses O
directed O
equal O
amounts O
of O
P I-GENE
/ I-GENE
C I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcription O
. O

This O
observation O
cannot O
be O
explained O
by O
the O
scanning O
model O
for O
ribosomal O
initiation O
and O
suggests O
that O
ribosomes O
may O
be O
binding O
directly O
at O
an O
internal O
mRNA O
site O
at O
or O
near O
the O
initiator O
AUG O
codon O
for O
the O
C I-GENE
protein I-GENE
. O

In O
view O
of O
these O
results O
, O
simultaneous O
pancreas O
- O
kidney O
transplantation O
appears O
to O
be O
the O
treatment O
of O
choice O
for O
Type O
I O
diabetic O
patients O
. O

This O
makes O
these O
compounds O
attractive O
as O
vehicles O
for O
these O
and O
other O
gases O
in O
- O
vivo O
and O
in O
- O
vitro O
. O

DNA O
sequencing O
of O
the O
DPM1 I-GENE
gene I-GENE
revealed O
an O
open O
reading O
frame O
of O
801 O
bases O
. O

The O
relationship O
between O
primary O
malignant O
lymphoma O
of O
the O
thyroid O
and O
chronic O
thyroiditis O
is O
discussed O
. O

Administration O
of O
anticoagulants O
, O
i O
. O
e O
., O
heparin O
, O
prostaglandin O
E1 O
and O
ticlopidine O
seems O
to O
be O
effective O
in O
alleviating O
symptoms O
and O
might O
prevent O
further O
deterioration O
. O

Mutational O
analysis O
of O
the O
L1 I-GENE
binding I-GENE
site I-GENE
of O
23S I-GENE
rRNA I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
. O

Animals O
may O
be O
immunized O
by O
oral O
vaccination O
, O
but O
natural O
mechanisms O
that O
also O
can O
terminate O
outbreaks O
are O
discussed O
. O

Prostacyclin O
formation O
, O
reflected O
by O
the O
excretion O
rate O
of O
its O
stable O
metabolite O
6 O
- O
keto O
- O
prostaglandin O
F1 O
alpha O
, O
was O
measured O
by O
means O
of O
radioimmunoassay O
in O
4 O
- O
hour O
urine O
specimens O
obtained O
during O
a O
smoking O
- O
free O
period O
and O
after O
participants O
had O
inhaled O
smoke O
from O
four O
high O
- O
nicotine O
cigarettes O
. O

However O
, O
excretion O
of O
6 O
- O
keto O
- O
prostaglandin O
F1 O
alpha O
was O
further O
reduced O
in O
the O
smokers O
who O
used O
oral O
contraceptives O
( O
133 O
+/- O
20 O
to O
86 O
+/- O
9 O
ng O
/ O
gm O
of O
creatinine O
, O
p O
less O
than O
0 O
. O
05 O
). O

The O
in O
vitro O
activity O
of O
mecillinam O
and O
amoxicillin O
/ O
clavulanic O
acid O
against O
Escherichia O
coli O
strains O
producing O
beta I-GENE
- I-GENE
lactamases I-GENE
of O
the O
TEM I-GENE
- I-GENE
1 I-GENE
, O
Oxa I-GENE
- I-GENE
1 I-GENE
and O
chromosomal O
type O
were O
studied O
using O
the O
broth O
and O
agar O
dilution O
technique O
. O

GCN4 I-GENE
encodes O
a O
transcriptional O
activator O
of O
amino O
acid O
biosynthetic O
genes O
in O
Saccharomyces O
cerevisiae O
. O

These O
results O
imply O
that O
the O
GCN3 I-GENE
product I-GENE
can O
promote O
either O
repression O
or O
activation O
of O
GCN4 I-GENE
expression O
depending O
on O
amino O
acid O
availability O
. O

The O
efficacy O
of O
these O
immunosuppressive O
drugs O
is O
clinical O
proven O
. O

The O
amino O
acid O
sequence O
of O
the O
S O
. O
aureus O
peptide O
carrying O
the O
phosphoryl O
group O
was O
found O
to O
be O
Gln O
- O
Val O
- O
Val O
- O
Ser O
- O
Thr O
- O
Phe O
- O
Met O
- O
Gly O
- O
Asn O
- O
Gly O
- O
Leu O
- O
Ala O
- O
Ile O
- O
Pro O
- O
His O
- O
Gly O
- O
Thr O
- O
Asp O
- O
Asp O
. O

These O
mutations O
alter O
two O
regions O
of O
GAL4 I-GENE
protein I-GENE
: O
the O
DNA O
binding O
domain O
, O
and O
the O
transcription O
activation O
domain O
. O

The O
results O
indicated O
that O
two O
genes O
( O
citA I-GENE
and O
citB I-GENE
) O
have O
separate O
promoters O
, O
and O
the O
location O
of O
the O
promoter O
for O
the O
citB I-GENE
gene I-GENE
in O
the O
Tn3411 I-GENE
nucleotide O
sequence O
was O
different O
from O
that O
in O
pMS185 O
. O

The O
rci I-GENE
gene I-GENE
was O
fused O
with O
lacZ I-GENE
and O
its O
gene O
product O
was O
identified O
by O
Western O
blot O
analysis O
. O

Structure O
and O
regulation O
of O
a O
nuclear O
gene O
in O
Saccharomyces O
cerevisiae O
that O
specifies O
MRP13 I-GENE
, O
a O
protein O
of O
the O
small O
subunit O
of O
the O
mitochondrial O
ribosome O
. O

After O
a O
survey O
of O
the O
anatomical O
and O
physiological O
basis O
of O
operative O
treatment O
of O
behaviour O
disorders O
by O
stereotactic O
lesions O
in O
the O
amygdala O
and O
the O
posterior O
medial O
hypothalamus O
the O
author O
describes O
his O
own O
experiences O
with O
603 O
operations O
for O
control O
of O
conservatively O
untreatable O
aggressiveness O
. O

Histological O
examination O
revealed O
a O
small O
simple O
renal O
cyst O
associated O
with O
renal O
cell O
carcinoma O
. O

Although O
large O
epidemiologic O
studies O
are O
best O
able O
to O
identify O
the O
relative O
contributions O
of O
specific O
risk O
factors O
while O
controlling O
for O
other O
risk O
factors O
, O
new O
studies O
need O
to O
focus O
on O
important O
unresolved O
questions O
. O

Thus O
, O
prostacyclin O
enhanced O
the O
autoregulative O
property O
of O
the O
inner O
ear O
vessels O
. O

The O
method O
is O
accurate O
, O
with O
good O
precision O
and O
adequate O
sensitivity O
. O

Factors O
influencing O
the O
bond O
strength O
between O
glass O
polyalkenoate O
( O
ionomer O
) O
cements O
and O
dentine O
. O

The O
amino O
acid O
sequences O
of O
the O
yeast O
and O
mammalian O
mitochondrial O
targeting O
sequences O
are O
similar O
but O
less O
related O
than O
the O
mature O
polypeptides O
. O

Van O
der O
Ende O
, O
R O
. O

During O
insulin I-GENE
infusion O
, O
a O
20 O
% O
dextrose O
solution O
was O
infused O
by O
a O
Biostator O
in O
order O
to O
maintain O
the O
patient O
' O
s O
glycemia O
at O
90 O
mg O
/ O
dl O
. O

Amounts O
of O
glucose O
infused O
during O
the O
last O
20 O
min O
of O
each O
2 O
hour O
insulin I-GENE
infusion O
were O
( O
at O
1 O
and O
10 O
m O
/ O
kg O
/ O
min O
respectively O
): O
before O
treatment O
( O
K O
+ O
= O
2 O
. O
7 O
mmol O
/ O
l O
): O
2 O
. O
4 O
and O
8 O
. O
4 O
mg O
/ O
kg O
/ O
min O
; O
after O
spironolactone O
( O
K O
+ O
= O
3 O
. O
9 O
mmol O
/ O
l O
): O
3 O
. O
3 O
and O
15 O
. O
4 O
mg O
/ O
kg O
/ O
min O
; O
after O
indomethacine O
( O
K O
+ O
= O
3 O
. O
7 O
mmol O
/ O
l O
): O
5 O
and O
19 O
mg O
/ O
kg O
/ O
min O
after O
stopping O
drugs O
( O
K O
+ O
= O
2 O
. O
9 O
mmol O
/ O
l O
): O
2 O
. O
5 O
and O
5 O
. O
3 O
mg O
/ O
kg O
/ O
min O
. O

Mycobacterium O
avium O
- O
intracellulare O
complex O
infections O
in O
the O
acquired O
immunodeficiency O
syndrome O
. O

Recurrence O
of O
oxalate O
deposition O
in O
a O
renal O
transplant O
during O
ciclosporin O
A O
therapy O
. O

The O
bile O
acid O
sequestrants O
( O
cholestyramine O
and O
colestipol O
), O
nicotinic O
acid O
, O
fenofibrate O
and O
inhibitors O
of O
hydroxymethylglutaryl I-GENE
coenzyme I-GENE
A I-GENE
( I-GENE
HMG I-GENE
CoA I-GENE
) I-GENE
reductase I-GENE
( O
e O
. O
g O
. O
lovastatin O
or O
simvastatin O
) O
are O
the O
most O
effective O
drugs O
for O
use O
in O
patients O
with O
primary O
hypercholesterolaemia O
; O
these O
agents O
reduce O
plasma O
concentrations O
of O
total O
and O
LDL I-GENE
- I-GENE
cholesterol I-GENE
by O
15 O
to O
45 O
%. O

Finally O
, O
the O
pathophysiological O
aspects O
of O
urinary O
acidification O
are O
discussed O
, O
focusing O
on O
renal O
tubular O
acidosis O
models O
( O
induced O
by O
maleate O
and O
amphotericin O
B O
treatment O
) O
and O
their O
cellular O
mechanisms O
, O
as O
well O
as O
the O
role O
of O
adrenal O
steroids O
in O
urinary O
acidification O
. O

Analysis O
in O
3 O
groups O
of O
patients O
suffering O
from O
simple O
acute O
and O
pernicious O
malarial O
flare O
- O
ups O

Statement O
on O
the O
development O
of O
guidelines O
for O
the O
prevention O
of O
AIDS O
transmission O
in O
the O
workplace O
. O

Modifications O
of O
the O
involuntary O
postcontraction O
in O
diseased O
people O
. O

Cocaine O
- O
treated O
rats O
acquired O
a O
preference O
for O
cocaine O
- O
associated O
contextual O
stimuli O
( O
CS O
) O
relative O
to O
saline O
- O
injected O
control O
rats O
. O

Under O
these O
schedules O
, O
a O
reinforced O
response O
run O
consisted O
of O
responding O
between O
eight O
and O
12 O
times O
on O
one O
response O
key O
( O
work O
key O
) O
and O
then O
responding O
once O
on O
a O
second O
response O
key O
( O
reinforced O
key O
). O

Intravenous O
glucose O
tolerance O
tests O
were O
performed O
before O
operation O
, O
before O
starting O
CyA O
and O
after O
3 O
weeks O
. O

The O
effects O
of O
glutaraldehyde O
on O
dimensions O
and O
ultrastructure O
of O
microvascular O
beds O
in O
rat O
mesentery O
were O
studied O
in O
two O
kinds O
of O
experiment O
, O
administering O
the O
fixative O
by O
intra O
- O
arterial O
perfusion O
at O
a O
pressure O
of O
80 O
mm O
Hg O
and O
by O
superfusion O
of O
the O
exteriorized O
mesenteric O
membrane O
. O

This O
gave O
rise O
to O
RNA O
molecules O
with O
3 O
'- O
untranslated O
regions O
of O
roughly O
375 O
, O
655 O
, O
and O
945 O
base O
pairs O
. O

Also O
, O
the O
BALB I-GENE
/ I-GENE
c I-GENE
gene I-GENE
contains O
a O
single O
substitution O
in O
a O
conserved O
octamer O
sequence O
approximately O
equal O
to O
100 O
nucleotides O
upstream O
of O
the O
coding O
region O
, O
which O
could O
affect O
its O
expression O
. O

Clinical O
findings O
were O
: O
height O
183 O
cm O
, O
weight O
62 O
kg O
, O
increased O
length O
of O
lower O
limbs O
, O
P2 O
- O
A2 O
pilosity O
and O
micropenis O
. O

Our O
data O
suggest O
that O
it O
may O
be O
possible O
to O
individualize O
hCG I-GENE
administration O
at O
midcycle O
by O
determining O
the O
number O
of O
follicles O
greater O
than O
1 O
cm O
by O
ultrasound O
on O
cycle O
day O
12 O
or O
13 O
and O
giving O
hCG I-GENE
when O
serum O
E2 O
levels O
reach O
1100 O
to O
1200 O
pmol O
/ O
l O
per O
follicle O
. O

The O
8 O
patients O
receiving O
Ir192 O
implant O
in O
addition O
to O
external O
radiation O
showed O
improved O
( O
p O
= O
0 O
. O
06 O
) O
survival O
compared O
to O
the O
9 O
receiving O
external O
only O
: O
median O
15 O
months O
( O
range O
1 O
. O
5 O
- O
34 O
+ O
months O
) O
versus O
7 O
months O
( O
range O
2 O
. O
5 O
- O
21 O
months O
). O

Within O
Stage O
IA O
, O
141 O
patients O
had O
well O
differentiated O
tumor O
( O
G1 O
), O
20 O
had O
moderately O
well O
differentiated O
tumor O
( O
G2 O
), O
and O
12 O
patients O
had O
poorly O
differentiated O
( O
G3 O
). O

Mechanism O
of O
the O
t O
( O
14 O
; O
18 O
) O
chromosomal O
translocation O
: O
structural O
analysis O
of O
both O
derivative O
14 O
and O
18 O
reciprocal O
partners O
. O

After O
age O
30 O
, O
mean O
hemoglobin I-GENE
levels O
for O
men O
gradually O
declined O
, O
while O
those O
in O
women O
rose O
, O
so O
that O
the O
sex O
difference O
diminished O
after O
60 O
years O
of O
age O
. O

Ritanserin O
is O
a O
new O
substance O
with O
highly O
selective O
blocking O
activity O
on O
S2 I-GENE
receptors I-GENE
for O
5 O
- O
HT O
in O
the O
central O
nervous O
system O
. O

Ethylene O
glycol O
and O
diethylene O
glycol O
were O
each O
administered O
once O
weekly O
subcutaneously O
to O
groups O
of O
100 O
female O
NMRI O
mice O
at O
3 O
dosages O
( O
30 O
; O
10 O
und O
3 O
mg O
single O
dose O
per O
mouse O
). O

Research O
on O
ethylene O
glycol O
and O
diethylene O
glycol O
for O
carcinogenic O
effects O

The O
results O
suggest O
that O
the O
greater O
estrogenic O
influence O
associated O
with O
the O
ethinyl O
estradiol O
- O
containing O
OC O
resulted O
in O
inhibition O
of O
coronary O
artery O
atherosclerosis O
despite O
a O
pronounced O
progestin O
- O
induced O
lowering O
of O
plasma O
HDL I-GENE
cholesterol I-GENE
concentration O
and O
, O
further O
, O
that O
hormonal O
balance O
may O
have O
a O
marked O
influence O
on O
the O
relationship O
between O
plasma O
lipids O
and O
atherogenesis O
. O

During O
BH O
the O
ventilator O
was O
disconnected O
and O
a O
bias O
flow O
of O
50 O
% O
O2 O
at O
4 O
- O
5 O
l O
/ O
min O
was O
delivered O
through O
the O
side O
ports O
of O
a O
small O
catheter O
whose O
tip O
was O
positioned O
1 O
cm O
cephalad O
of O
the O
carina O
. O

Comparison O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
removal O
using O
the O
same O
polysulphone O
membrane O
for O
haemodialysis O
and O
haemofiltration O
shows O
that O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
is O
more O
effectively O
removed O
by O
convection O
than O
by O
diffusion O
when O
both O
treatment O
modes O
are O
matched O
for O
blood O
flow O
and O
urea O
clearance O
. O

40 O
. O
3 O
+/- O
10 O
. O
1 O
mg O
/ O
l O
( O
SD O
) O
vs O
31 O
. O
2 O
+/- O
8 O
. O
0 O
, O
P O
less O
than O
0 O
. O
01 O
). O
beta I-GENE
2m I-GENE
was O
not O
significantly O
higher O
in O
patients O
with O
bone O
cysts O
( O
37 O
. O
7 O
+/- O
11 O
. O
4 O
mg O
/ O
l O
vs O
37 O
. O
0 O
+/- O
10 O
. O
0 O
), O
but O
median O
duration O
of O
dialysis O
was O
significantly O
( O
P O
less O
than O
0 O
. O
01 O
) O
longer O
in O
patients O
with O
bone O
cysts O
( O
90 O
vs O
57 O
months O
). O
beta I-GENE
2m I-GENE
was O
lower O
in O
patients O
maintained O
on O
dialysis O
for O
less O
than O
1 O
year O
and O
whose O
residual O
urine O
volume O
was O
greater O
than O
0 O
. O
1 O
litre O
per O
day O
. O

The O
mean O
percentage O
of O
linoleic O
acid O
in O
the O
triglycerides O
of O
the O
subcutaneous O
adipose O
tissue O
( O
PLASAT O
) O
of O
these O
subjects O
was O
substantially O
higher O
than O
that O
in O
a O
similar O
group O
examined O
in O
1975 O
- O
1976 O
. O

In O
overdoses O
up O
to O
2 O
g O
fluvoxamine O
no O
lasting O
toxic O
effects O
were O
observed O
. O

It O
is O
concluded O
that O
the O
plasma I-GENE
prolactin I-GENE
response O
to O
12 O
. O
5 O
micrograms O
i O
. O
v O
. O

No O
effect O
was O
found O
on O
grooming O
behavior O
. O

The O
remaining O
six O
patients O
had O
slightly O
decreased O
( O
n O
= O
3 O
) O
or O
normal O
( O
n O
= O
3 O
) O
seminal O
parameters O
. O

In O
addition O
, O
a O
wild O
- O
type O
strain O
containing O
a O
temperature I-GENE
- I-GENE
sensitive I-GENE
threonyl I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
mutation I-GENE
showed O
increased O
thr I-GENE
operon I-GENE
expression O
at O
the O
non O
- O
permissive O
temperature O
, O
whereas O
none O
of O
the O
mutants O
showed O
any O
change O
. O

Significant O
treatment O
- O
related O
problems O
appeared O
during O
the O
second O
decade O
in O
5 O
patients O
, O
including O
one O
chest O
wall O
sarcoma O
; O
all O
of O
these O
patients O
had O
received O
at O
least O
60 O
Gy O
to O
breast O
and O
regional O
nodal O
areas O
. O

Clinical O
and O
biological O
correlates O
of O
panic O
states O
. O

Effects O
of O
long O
- O
term O
parenteral O
nutrition O
on O
gastrin I-GENE
release O
in O
dogs O
. O

The O
mean O
weight O
and O
height O
velocities O
were O
148 O
% O
and O
122 O
% O
of O
the O
standard O
, O
respectively O
. O

Of O
7 O
patients O
treated O
with O
cyclophosphamide O
, O
hexamethylmelamine O
, O
adriamycin O
and O
cisplatin O
( O
CHAP O
- O
5 O
), O
6 O
had O
measurable O
disease O
, O
of O
whom O
5 O
yielded O
a O
response O
( O
2 O
complete O
responses O
for O
19 O
+ O
and O
40 O
months O
and O
3 O
partial O
responses O
for O
4 O
, O
7 O
and O
8 O
months O
). O

Isolation O
and O
characterization O
of O
a O
vinculin I-GENE
cDNA I-GENE
from I-GENE
chick I-GENE
- I-GENE
embryo I-GENE
fibroblasts I-GENE
. O

A O
complementary O
study O
, O
showing O
a O
good O
agreement O
between O
surface O
and O
oesophageal O
EMGd O
seems O
to O
confirm O
that O
surface O
EMGd O
is O
a O
useful O
and O
promising O
tool O
for O
clinical O
investigation O
. O

No O
differences O
in O
fixation O
quality O
were O
observed O
between O
cochleas O
fixed O
by O
intravascular O
perfusion O
and O
cochleas O
fixed O
by O
intralabyrinthine O
perfusion O
. O

The O
DNA O
sequence O
encodes O
a O
protein O
of O
1520 O
amino O
acids O
with O
sequence O
homology O
to O
the O
human I-GENE
c I-GENE
- I-GENE
abl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
, O
beginning O
at O
the O
amino O
terminus O
and O
extending O
656 O
amino O
acids O
through O
the O
region O
essential O
for O
tyrosine I-GENE
kinase I-GENE
activity O
. O

The O
requirement O
of O
different O
essential O
fatty O
acids O
in O
patients O
with O
total O
parenteral O
nutrition O
after O
heavy O
injury O
is O
of O
special O
interest O
with O
respect O
to O
the O
development O
and O
prognosis O
of O
shock O
, O
sepsis O
or O
adult O
respiratory O
distress O
syndrome O
. O

In O
64 O
% O
a O
small O
cardiac O
vein O
does O
not O
exist O
, O
but O
its O
origin O
, O
the O
right O
marginal O
vein O
, O
joins O
the O
system O
of O
anterior O
cardiac O
veins O
. O

The O
Drosophila I-GENE
melanogaster I-GENE
Gart I-GENE
gene I-GENE
encodes O
three O
enzymatic O
activities O
in O
the O
pathway O
for O
purine O
de O
novo O
synthesis O
. O

The O
role O
of O
neuroplasticity O
in O
the O
response O
to O
drugs O
. O

Biol O
. O

The O
results O
of O
these O
experiments O
indicate O
that O
at O
least O
two O
upstream O
activator O
sequences O
( O
UAS O
) O
mediate O
maximum O
induction O
by O
galactose O
. O

Reversal O
of O
the O
increase O
in O
apomorphine O
- O
induced O
stereotypy O
and O
aggression O
in O
REM O
sleep O
deprived O
rats O
by O
dopamine O
agonist O
pretreatments O
. O

The O
heart O
rate O
, O
respiratory O
rate O
, O
arterial O
O2 O
and O
systemic O
vascular O
resistance O
were O
not O
significantly O
altered O
. O

Human I-GENE
rIL I-GENE
- I-GENE
3 I-GENE
expressed O
in O
COS7 O
cells O
has O
multipotential O
CSF I-GENE
activity O
in O
semisolid O
cultures O
of O
bone O
marrow O
cells O
, O
and O
selectively O
induced O
the O
proliferation O
of O
My O
- O
10 O
+ O
marrow O
or O
cord O
blood O
cells O
in O
liquid O
cultures O
. O

In O
14 O
patients O
whose O
PaCO2 O
was O
greater O
than O
or O
equal O
to O
39 O
torr O
( O
range O
39 O
to O
58 O
torr O
) O
and O
clinical O
asthma O
score O
was O
6 O
or O
greater O
, O
PaCO2 O
decreased O
a O
mean O
of O
11 O
. O
7 O
torr O
during O
a O
mean O
of O
8 O
. O
1 O
hours O
. O

A O
randomized O
, O
prospective O
study O
was O
conducted O
to O
compare O
ovarian O
stimulation O
with O
human I-GENE
menopausal I-GENE
gonadotropin I-GENE
( O
hMG I-GENE
) O
and O
human I-GENE
follicle I-GENE
- I-GENE
stimulating I-GENE
hormone I-GENE
( O
hFSH I-GENE
) O
in O
an O
in O
vitro O
fertilization O
and O
embryo O
transfer O
( O
IVF O
- O
ET O
) O
program O
. O

Our O
findings O
suggest O
that O
the O
mtr I-GENE
product I-GENE
causes O
both O
transcription O
attenuation O
and O
inhibition O
of O
translation O
of O
trpE I-GENE
mRNA I-GENE
. O

Apropos O
of O
a O
case O

A O
prostaglandin O
analogue O
given O
in O
early O
pregnancy O
and O
human I-GENE
chorionic I-GENE
gonadotropin I-GENE
given O
near O
the O
end O
of O
the O
ensuing O
follicular O
phase O
were O
used O
for O
controlling O
the O
reproductive O
cycle O
, O
timing O
oocyte O
collection O
, O
and O
synchronizing O
the O
cycles O
of O
oocyte O
donors O
and O
embryo O
recipients O
. O

The O
nucleolin I-GENE
gene I-GENE
extends O
over O
9000 O
base O
- O
pairs O
and O
is O
split O
into O
14 O
exons O
that O
encode O
the O
706 O
amino O
acid O
residues O
of O
the O
protein O
. O

Although O
L O
- O
threo O
- O
dihydroxyphenylserine O
( O
DOPS O
), O
an O
artificial O
norepinephrine O
( O
NE O
) O
precursor O
, O
did O
not O
change O
immobility O
in O
intact O
mice O
, O
DOPS O
significantly O
reduced O
immobility O
in O
mice O
pretreated O
with O
the O
selective O
NE O
neurotoxin O
DSP4 O
. O

Substantial O
amounts O
of O
liposomal O
ampicillin O
were O
recovered O
from O
isolated O
Kupffer O
cells O
, O
the O
target O
cells O
of O
L O
. O
monocytogenes O
after O
intravenous O
inoculation O
. O

This O
suggested O
that O
delta O
6 O
and O
delta O
5 O
desaturation O
activities O
are O
normal O
in O
these O
conditions O
with O
this O
C18 O
: O
2w6 O
supply O
. O

The O
genetic O
basis O
for O
the O
expression O
of O
a O
latent O
VH I-GENE
allotype I-GENE
in O
the O
rabbit O
was O
investigated O
. O

Here O
we O
report O
the O
complete O
6 O
- O
kilobase O
cDNA O
sequence O
coding O
for O
a O
chain O
of O
1775 O
amino O
acids O
, O
as O
well O
as O
the O
genomic O
structure O
. O

HDL I-GENE
- I-GENE
cholesterol I-GENE
(+ O
6 O
%, O
P O
less O
than O
. O
01 O
) O
and O
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
(+ O
6 O
%, O
P O
less O
than O
. O
01 O
) O
concentrations O
increased O
significantly O
only O
in O
the O
young O
. O

The O
Euglena I-GENE
ribosomal I-GENE
protein I-GENE
gene I-GENE
cluster I-GENE
resembles O
the O
S I-GENE
- I-GENE
10 I-GENE
ribosomal I-GENE
protein I-GENE
operon I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
in O
gene O
organization O
and O
follows O
the O
exact O
linear O
order O
of O
the O
analogous O
genes O
in O
the O
tobacco O
and O
liverwort O
chloroplast O
genomes O
. O

The O
distribution O
of O
the O
sites O
of O
recombinational O
resolution O
is O
inversely O
correlated O
with O
that O
of O
the O
gradient O
of O
sequence O
divergence O
, O
with O
only O
approximately O
7 O
% O
of O
the O
X O
recombinants O
resolved O
within O
the O
3 O
' O
third O
of O
the O
X O
blocks O
where O
two O
diverged O
Alu I-GENE
family O
repeats O
reside O
. O

The O
nucleotide O
sequence O
of O
the O
region O
upstream O
from O
M I-GENE
. I-GENE
voltae I-GENE
ORFtrpA I-GENE
was O
determined O
and O
revealed O
the O
presence O
of O
an O
ORF O
of O
1227 O
nucleotides O
( O
ORFtrpB I-GENE
) O
encoding O
a O
409 O
amino O
acid O
polypeptide O
of O
mol O
. O
wt O
. O

Potentiation O
of O
the O
thrombolytic O
efficacy O
of O
single I-GENE
- I-GENE
chain I-GENE
urokinase I-GENE
( O
Pro I-GENE
- I-GENE
urokinase I-GENE
) O
by O
heparin O
. O

Of O
49 O
receptors O
which O
fired O
in O
phase O
with O
ventilation O
, O
13 O
behaved O
like O
mammalian O
rapidly O
adapting O
pulmonary O
stretch O
receptors O
, O
19 O
like O
mammalian O
slowly O
adapting O
pulmonary O
stretch O
receptors O
( O
PSR O
), O
and O
17 O
like O
avian O
intrapulmonary O
CO2 O
- O
sensitive O
chemoreceptors O
( O
IPC O
). O

Symptomatic O
hyperventilators O
had O
a O
larger O
number O
of O
sighs O
and O
abnormally O
wide O
fluctuations O
in O
baseline O
for O
inspiratory O
time O
, O
expiratory O
time O
, O
and O
PETCO2 O
. O

In O
the O
IA O
task O
, O
post O
- O
training O
intraperitoneal O
injections O
of O
picrotoxin O
and O
bicuculline O
induced O
a O
dose O
- O
dependent O
enhancement O
of O
retention O
measured O
24 O
h O
after O
the O
training O
, O
while O
retention O
was O
not O
affected O
by O
bicuculline O
methiodide O
( O
a O
GABA I-GENE
receptor I-GENE
antagonist O
that O
does O
not O
readily O
cross O
the O
blood O
- O
brain O
barrier O
). O

Clinical O
research O
of O
non O
- O
A O
, O
non O
- O
B O
post O
- O
transfusion O
hepatitis O

It O
is O
suggested O
that O
the O
use O
of O
endogenous O
creatinine O
clearance O
to O
estimate O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
requires O
caution O
and O
the O
recognition O
of O
the O
limitations O
of O
the O
method O
, O
and O
that O
simpler O
techniques O
( O
serum O
creatinine O
or O
estimated O
endogenous O
creatinine O
clearance O
) O
are O
preferable O
in O
routine O
practice O
. O

The O
protein O
mixtures O
of O
sesame O
flour O
and O
soybean O
flour O
were O
well O
accepted O
. O

The O
5 O
' O
end O
of O
the O
coding O
region O
was O
located O
precisely O
by O
comparing O
the O
deduced O
amino O
acid O
sequence O
to O
the O
actual O
N O
- O
terminal O
amino O
acid O
sequence O
of O
IHF I-GENE
. O

A O
protein O
footprint O
also O
was O
identified O
for O
a O
GC O
box O
element O
at O
nucleotides O
- O
59 O
to O
- O
45 O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
IGFII I-GENE
) O
is O
a O
mitogenic O
polypeptide O
, O
the O
mRNAs O
of O
which O
are O
present O
in O
multiple O
forms O
, O
despite O
derivation O
from O
a O
single O
gene O
. O

The O
central O
visual O
fields O
of O
2165 O
normal O
and O
106 O
glaucoma O
eyes O
were O
measured O
using O
a O
threshold O
related O
suprathreshold O
strategy O
. O

The O
variability O
is O
most O
likely O
a O
result O
of O
alternative O
splicing O
of O
exons O
from O
the O
primary O
elastin I-GENE
transcripts I-GENE
. O

This O
led O
to O
the O
conclusion O
that O
the O
metatarsal O
artery O
should O
be O
used O
for O
toe O
MP O
joint O
grafts O
, O
while O
the O
unilateral O
proper O
digital O
artery O
is O
suitable O
for O
toe O
PIP O
joint O
grafts O
, O
together O
with O
concomitant O
or O
dorsal O
cutaneous O
vein O
. O

Effect O
of O
chronic O
undernutrition O
on O
susceptibility O
to O
cold O
stress O
in O
young O
adult O
and O
aged O
rats O
. O

This O
effect O
and O
the O
fact O
that O
all O
three O
doses O
were O
toxic O
to O
the O
dams O
dictated O
that O
a O
second O
experiment O
be O
carried O
out O
at O
lower O
doses O
. O

The O
CHARGE O
association O
is O
a O
collection O
of O
multisystem O
congenital O
anomalies O
including O
choanal O
atresia O
. O

Esophageal O
brush O
cytological O
screening O
was O
undertaken O
and O
blood O
concentrations O
of O
micronutrients O
( O
vitamin O
A O
, O
E O
, O
B12 O
, O
folic O
acid O
and O
methionine O
) O
determined O
from O
adults O
at O
risk O
for O
esophageal O
carcinoma O
( O
EC O
) O
in O
Transkei O
and O
Ciskei O
, O
Southern O
Africa O
. O

Aviators O
from O
the O
Light O
Attack O
Wing O
, O
Pacific O
were O
surveyed O
and O
the O
results O
were O
categorized O
by O
aircraft O
type O
. O

Evaluation O
of O
human O
and O
bovine O
modified O
- O
hemoglobin I-GENE
solution O
as O
oxygen O
- O
carrying O
fluid O
for O
blood O
volume O
replacement O
. O

Delayed O
gallbladder O
visualization O
and O
reduction O
in O
ejection O
fraction O
were O
sensitive O
but O
nonspecific O
indicators O
of O
biliary O
disease O
. O

26 O
micrograms O
PAF I-GENE
or O
placebo O
was O
sprayed O
into O
each O
nasal O
cavity O
8 O
h O
and O
1 O
h O
before O
a O
nasal O
allergen O
challenge O
. O

Sci O
. O

Chem O
. O

Sequential O
MR O
examinations O
of O
the O
nasal O
cavity O
and O
paranasal O
sinuses O
were O
performed O
within O
a O
6 O
- O
8 O
h O
period O
in O
five O
normal O
volunteers O
. O

Comparison O
was O
made O
with O
other O
neuroradiological O
imaging O
modalities O
including O
CT O
, O
myelography O
, O
CT O
ventriculography O
, O
and O
CT O
myelocisternography O
. O

The O
feed O
given O
to O
young O
broiler O
chickens O
was O
contaminated O
artificially O
with O
Salmonella O
kedougou O
, O
a O
serotype O
associated O
with O
both O
subclinical O
infections O
in O
commercially O
reared O
chickens O
and O
food O
poisoning O
in O
humans O
. O

A O
poor O
correlation O
was O
found O
between O
a O
mildly O
- O
atypical O
( O
inflammatory O
) O
cytological O
result O
( O
class O
2 O
) O
and O
a O
benign O
histological O
diagnosis O
: O
48 O
% O
of O
class O
- O
2 O
smears O
were O
diagnosed O
histologically O
as O
dysplasia O
or O
worse O
. O

Factors O
involved O
in O
specific O
transcription O
by O
mammalian O
RNA I-GENE
polymerase I-GENE
II I-GENE
: O
purification O
, O
genetic O
specificity O
, O
and O
TATA O
box O
- O
promoter O
interactions O
of O
TFIID I-GENE
. O

Change O
in O
plasma I-GENE
cystyl I-GENE
aminopeptidase I-GENE
( O
oxytocinase I-GENE
) O
between O
30 O
- O
34 O
weeks O
' O
gestation O
as O
a O
predictor O
of O
pregnancy O
- O
induced O
hypertension O
. O

You O
make O
the O
diagnosis O
. O

The O
test O
for O
alpha I-GENE
- I-GENE
naphthyl I-GENE
esterase I-GENE
and O
quantitation O
of O
macrophages O
( O
absolute O
number O
) O
per O
infiltration O
area O
unit O
adjacent O
to O
the O
abscess O
suggest O
a O
direct O
correlation O
between O
the O
absolute O
number O
of O
macrophages O
and O
the O
width O
of O
the O
capsule O
. O

Determined O
as O
migration O
differentials O
, O
chemotactic O
and O
chemokinetic O
responsiveness O
tended O
to O
be O
higher O
in O
the O
neutropenic O
group O
. O

The O
deduced O
96 O
- O
residue O
amino O
acid O
coding O
sequence O
of O
the O
murine O
HMG I-GENE
- I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
cDNA O
is O
very O
similar O
to O
the O
reported O
amino O
acid O
sequence O
of O
human O
HMG I-GENE
- I-GENE
I I-GENE
, O
except O
that O
it O
lacks O
11 O
internal O
amino O
acids O
reported O
in O
the O
human O
protein O
. O

Interpersonal O
style O
differences O
among O
drug O
abusers O
were O
explored O
using O
Ryan O
' O
s O
( O
1977 O
) O
typological O
system O
of O
FIRO O
- O
B O
interpretation O
. O

Statement O
of O
the O
American O
Academy O
of O
Implant O
Dentistry O
. O

Sera O
from O
euthyroid O
post O
- O
menopausal O
or O
pregnant O
women O
yielded O
TSH I-GENE
levels O
within O
the O
normal O
range O
. O

No O
UOxase I-GENE
mRNA I-GENE
was O
detected O
in O
11 O
nonhepatic O
tissues O
of O
rat O
, O
suggesting O
tissue O
specificity O
of O
expression O
of O
this O
UOxase I-GENE
gene I-GENE
. O

The O
platelet O
adhesion O
rate O
on O
these O
layers O
were O
tested O
concerning O
the O
valuation O
of O
the O
haemocompatibility O
of O
the O
basic O
- O
polymers O
polyurethane O
( O
PUR O
), O
polyvinylchloride O
( O
PVC O
), O
and O
polystyrene O
( O
PS O
) O
in O
two O
different O
worked O
test O
chambers O
. O

Conservative O
treatment O
of O
bladder O
carcinoma O
by O
partial O
cystectomy O
and O
interstitial O
iridium O
192 O
. O

In O
a O
112 O
- O
d O
feedlot O
trial O
, O
105 O
heifers O
were O
assigned O
to O
light O
, O
medium O
and O
heavy O
weight O
blocks O
on O
five O
treatments O
: O
dietary O
MGA O
(. O
5 O
mg O
. O
hd O
- O
1 O
. O
d O
- O
1 O
), O
control O
( O
no O
MGA O
) O
or O
DEPO O
- O
MGA O
on O
d O
1 O
at O
. O
5 O
, O
1 O
. O
0 O
or O
1 O
. O
5 O
ml O
/ O
hd O
( O
30 O
, O
60 O
or O
90 O
mg O
MGA O
/ O
hd O
, O
respectively O
). O

Existence O
and O
uniqueness O
of O
solutions O
of O
the O
appropriate O
boundary O
value O
problems O
are O
established O
, O
in O
the O
case O
of O
small O
permeability O
coefficients O
and O
transport O
rates O
, O
or O
large O
diffusion O
coefficients O
and O
small O
resistance O
to O
flow O
constants O
. O

There O
were O
gene O
clusters O
encoding O
photosynthesis O
components O
such O
as O
the O
psbB I-GENE
- O
psbH I-GENE
- O
petB I-GENE
- O
petD I-GENE
and O
the O
psbE O
- O
psbF O
clusters O
. O

The O
results O
presented O
suggest O
that O
TIQ O
reduces O
the O
turnover O
rate O
of O
the O
nigrostriatal O
dopamine O
neurons O
after O
repeated O
administration O
for O
a O
long O
period O
in O
mice O
. O

The O
partial O
sequence O
of O
the O
62 I-GENE
- I-GENE
kDa I-GENE
nuclear I-GENE
pore I-GENE
glycoprotein I-GENE
shows O
little O
similarity O
to O
other O
characterized O
proteins O
and O
elucidates O
structural O
features O
of O
a O
member O
of O
the O
family O
of O
nuclear I-GENE
pore I-GENE
glycoproteins I-GENE
. O

Seventy O
- O
two O
hours O
after O
administration O
of O
vitamin O
K1 O
, O
plasma O
concentrations O
of O
the O
vitamin O
were O
not O
different O
from O
normal O
. O

The O
glomerular O
filtration O
rate O
did O
not O
change O
but O
lithium O
clearance O
fell O
by O
30 O
%. O

During O
a O
28 O
- O
week O
promotion O
bioassay O
, O
groups O
of O
30 O
male O
CD O
- O
1 O
mice O
were O
treated O
once O
with O
50 O
microliter O
of O
either O
DMBA O
( O
1 O
. O
0 O
mg O
/ O
ml O
) O
or O
acetone O
, O
rested O
for O
2 O
weeks O
, O
and O
then O
treated O
twice O
per O
week O
with O
test O
material O
for O
the O
remaining O
25 O
weeks O
. O

The O
pathogenesis O
of O
Dupuytren O
' O
s O
contracture O

An O
ELISA O
procedure O
was O
developed O
for O
monitoring O
the O
specific O
IgE I-GENE
response O
in O
dogs O
to O
Dirofilaria O
immitis O
infection O
. O

Fifty O
min O
after O
release O
from O
stress O
, O
increases O
in O
plasma O
corticosterone O
levels O
induced O
by O
stress O
recovered O
in O
the O
biting O
group O
but O
remained O
high O
in O
the O
non O
- O
biting O
group O
. O

The O
only O
isolate O
of O
Aeromonas O
hydrophila O
produced O
cytotoxic O
enterotoxin O
and O
was O
invasive O
. O

An O
11 O
- O
month O
- O
old O
girl O
suffering O
from O
Dandy O
- O
Walker O
malformation O
( O
DWM O
) O
associated O
with O
tetralogy O
of O
Fallot O
( O
TOF O
) O
is O
presented O
. O

The O
incidence O
of O
early O
neonatal O
convulsions O
for O
inborn O
babies O
was O
3 O
. O
0 O
/ O
1000 O
live O
births O
. O

The O
median O
survival O
is O
not O
reached O
with O
a O
median O
follow O
- O
up O
time O
of O
9 O
. O
6 O
years O
. O

Critical O
evaluation O
of O
various O
methods O
of O
determining O
markers O
of O
fetal O
maturity O
in O
amniotic O
fluid O

Of O
the O
43 O
infants O
with O
a O
( O
probable O
) O
loss O
18 O
were O
examined O
again O
at O
3 O
months O
corrected O
age O
. O

Variety O
of O
cows O
and O
sires O
according O
to O
types O
of O
dermatoglyphics O
( O
patterns O
) O
of O
the O
nose O
- O
labial O
mirror O
of O
cattle O

Although O
not O
consistently O
identified O
in O
all O
samples O
, O
secondary O
Academic O
, O
Personal O
Responsibility O
, O
and O
Community O
/ O
Vocational O
dimensions O
were O
also O
identified O
. O

Recovery O
was O
characterized O
by O
rapid O
improvement O
such O
that O
all O
measured O
parameters O
normalized O
by O
1 O
week O
, O
except O
for O
cross O
- O
sectional O
cardiac O
area O
which O
remained O
dilated O
up O
to O
4 O
weeks O
( O
14 O
+/- O
3 O
cm2 O
, O
p O
less O
than O
0 O
. O
05 O
versus O
control O
).( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Not O
even O
extensive O
pancreatic O
resection O
could O
prevent O
pancreatic O
remnant O
infection O
. O

It O
has O
been O
calculated O
that O
600 O
, O
000 O
new O
cases O
of O
lung O
cancer O
occur O
worldwide O
every O
year O
, O
most O
of O
them O
due O
to O
smoking O
. O

Neuromyelitis O
optica O
( O
Devic O
' O
s O
syndrome O
): O
not O
always O
multiple O
sclerosis O
. O

Effect O
of O
the O
methods O
of O
cutaneous O
administration O
of O
methyl O
isobutyl O
ketone O
on O
its O
toxicity O

Incorporation O
of O
0 O
. O
1 O
or O
0 O
. O
2 O
M O
sodium O
dihydrogen O
phosphate O
in O
the O
sugar O
solutions O
resulted O
in O
a O
decrease O
in O
the O
shelf O
- O
life O
of O
diltiazem O
. O

None O
had O
a O
past O
history O
of O
opportunistic O
infections O
; O
neither O
did O
any O
have O
lymphopenia O
. O

Increasing O
the O
phosphorus O
content O
of O
the O
diet O
improved O
the O
reabsorption O
of O
calcium O
and O
magnesium O
. O

Post O
- O
transcriptional O
regulation O
of O
ribosomal I-GENE
protein I-GENE
gene I-GENE
expression O
during O
development O
in O
Dictyostelium O
discoideum O
. O

The O
temporal O
and O
static O
plasma O
concentration O
- O
effect O
relationships O
were O
evaluated O
by O
pharmacodynamic O
modeling O
and O
linear O
regression O
. O

The O
increase O
in O
amplitudes O
of O
the O
b O
- O
wave O
during O
the O
adaptation O
period O
was O
more O
prominent O
in O
lead O
- O
exposed O
subjects O
than O
in O
controls O
. O

Possible O
factors O
for O
the O
development O
of O
psychotic O
symptomatology O
during O
group O
activities O
and O
the O
role O
of O
group O
dynamics O
acting O
as O
stress O
factors O
precipitating O
functional O
psychoses O
, O
especially O
bipolar O
manifestations O
, O
are O
discussed O
. O

Baseline O
measurements O
of O
forced O
expiratory O
volume O
in O
1 O
s O
( O
FEV1 O
), O
specific O
airway O
conductance O
( O
SGaw O
) O
and O
the O
provocative O
dose O
of O
carbachol O
causing O
a O
35 O
% O
reduction O
in O
SGaw O
( O
PD35 O
), O
and O
a O
20 O
% O
reduction O
in O
FEV1 O
( O
PD20 O
) O
were O
established O
on O
entry O
while O
each O
subject O
was O
still O
smoking O
. O

Many O
children O
with O
BGC O
are O
delayed O
in O
their O
development O
, O
but O
calcifications O
are O
not O
directly O
related O
to O
specific O
forms O
of O
neurologic O
dysfunction O
. O

R O
- O
wave O
voltage O
in O
the O
right O
precordial O
leads O
in O
anthracycline O
cardiomyopathy O
: O
a O
clinical O
study O
. O

The O
results O
indicate O
that O
the O
pooling O
requirements O
are O
task O
dependent O
. O

These O
results O
indicate O
that O
CSFHU I-GENE
can O
increase O
neutrophil O
counts O
by O
increasing O
the O
number O
and O
maturity O
of O
the O
marrow O
neutrophil O
precursors O
in O
some O
types O
of O
childhood O
chronic O
neutropenia O
. O

The O
purposes O
of O
this O
study O
were O
1 O
) O
to O
examine O
the O
effect O
of O
high O
intensity O
, O
low O
frequency O
transcutaneous O
electrical O
nerve O
stimulation O
at O
auricular O
acupuncture O
points O
on O
experimental O
pain O
threshold O
measured O
at O
the O
wrist O
and O
2 O
) O
to O
determine O
the O
changes O
in O
effect O
over O
time O
. O

In O
the O
infected O
neonates O
serum O
alpha I-GENE
- I-GENE
amylase I-GENE
value O
, O
as O
determined O
by O
the O
blue O
starch O
method O
, O
was O
only O
40 O
% O
that O
of O
healthy O
controls O
; O
the O
mean O
value O
of O
175 O
. O
1 O
+/- O
64 O
. O
9 O
IU O
/ O
l O
for O
healthy O
neonates O
was O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
0010 O
) O
than O
the O
value O
of O
82 O
. O
8 O
+/- O
44 O
. O
4 O
IU O
/ O
l O
for O
the O
infected O
neonates O
. O

Records O
of O
31 O
children O
with O
AIDS O
or O
AIDS O
- O
related O
complex O
admitted O
to O
the O
pediatric O
intensive O
care O
unit O
for O
acute O
respiratory O
failure O
throughout O
a O
46 O
- O
month O
period O
were O
reviewed O
. O

Fourteen O
patients O
were O
in O
the O
multifocal O
disease O
group O
; O
13 O
were O
detected O
by O
SPECT O
and O
10 O
by O
TCT O
. O

SPECT O
is O
an O
important O
aid O
in O
the O
diagnosis O
of O
AIDS O
dementia O
complex O
and O
contributes O
to O
the O
understanding O
of O
the O
pathophysiological O
mechanisms O
of O
this O
disorder O
. O

We O
were O
interested O
in O
studying O
the O
relationship O
between O
the O
circadian O
rhythm O
in O
body O
temperature O
and O
24 O
- O
h O
variations O
in O
plasma O
concentrations O
of O
iron O
, O
zinc O
, O
circulating O
leukocyte O
counts O
, O
and O
plasma O
interleukin I-GENE
1 I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
activity O
. O

The O
murine I-GENE
MHC I-GENE
class I-GENE
I I-GENE
genes I-GENE
, O
H I-GENE
- I-GENE
2Dq I-GENE
and O
H I-GENE
- I-GENE
2Lq I-GENE
, O
are O
strikingly O
homologous O
to O
each O
other O
, O
H I-GENE
- I-GENE
2Ld I-GENE
, O
and O
two O
genes O
reported O
to O
encode O
tumor O
- O
specific O
antigens O
. O

The O
active O
derivatives O
of O
the O
present O
series O
were O
also O
tested O
for O
their O
analgesic O
activity O
against O
aconitine O
- O
induced O
writhing O
in O
albino O
mice O
and O
ulcerogenic O
activity O
in O
albino O
rats O
. O

In O
untreated O
mice O
, O
bactericidal O
activity O
of O
peritoneal O
macrophages O
decreased O
from O
one O
day O
to O
3 O
days O
after O
ip O
injection O
of O
killed O
L O
. O
monocytogenes O
. O

Among O
a O
population O
of O
18 O
, O
175 O
children O
below O
7 O
years O
of O
age O
in O
medium O
sized O
towns O
and O
rural O
areas O
in O
south O
- O
western O
Germany O
552 O
( O
3 O
. O
03 O
%) O
cases O
of O
croup O
were O
registered O
during O
a O
12 O
months O
period O
in O
1984 O
- O
85 O
by O
their O
physicians O
. O

We O
concluded O
that O
Ga O
- O
fbg O
scintigraphy O
is O
a O
very O
simple O
method O
and O
sufficiently O
useful O
for O
detecting O
active O
left O
ventricular O
thrombi O
and O
for O
monitoring O
the O
effect O
of O
anticoagulant O
therapy O
. O

In O
vitro O
assessment O
of O
the O
biocompatibility O
of O
dental O
materials O
-- O
the O
millipore O
filter O
method O
. O

Hypomagnesemia O
was O
due O
to O
magnesium O
wasting O
by O
the O
kidney O
. O

Dentalplaque O
was O
controlled O
by O
the O
oral O
higienic O
index O
of O
the O
whole O
dentition O
daily O
, O
after O
staining O
with O
1 O
per O
cent O
alkaline O
fuxin O
. O

GRFI I-GENE
bound O
to O
sequences O
at O
the O
negative O
regulatory O
elements O
( O
silencers O
) O
of O
the O
silent I-GENE
mating I-GENE
type I-GENE
loci I-GENE
HML I-GENE
E I-GENE
and O
HMR I-GENE
E I-GENE
and O
to O
the O
upstream O
activating O
sequence O
( O
UAS O
) O
required O
for O
transcription O
of O
the O
MAT I-GENE
alpha I-GENE
genes I-GENE
. O

The O
effects O
of O
these O
mutations O
on O
RNA I-GENE
polymerase I-GENE
II I-GENE
activity O
were O
assayed O
by O
measuring O
the O
ability O
of O
mutant O
genes O
to O
confer O
alpha I-GENE
- I-GENE
amanitin I-GENE
resistance O
after O
transfection O
of O
susceptible O
rodent O
cells O
. O

We O
report O
the O
use O
of O
a O
new O
technetium O
- O
99m O
- O
albumin I-GENE
colloid O
white O
blood O
cell O
( O
TAC O
- O
WBC O
) O
scan O
in O
the O
evaluation O
of O
appendicitis O
. O

In O
one O
of O
these O
tumors O
the O
observed O
rearrangement O
was O
not O
due O
to O
the O
insertion O
of O
an O
intact O
MoMuLV O
provirus O
. O

The O
indications O
for O
its O
use O
include O
every O
primary O
and O
secondary O
rhinoplasty O
candidate O
unless O
tip O
grafts O
are O
going O
to O
be O
under O
tension O
or O
if O
the O
deformity O
is O
minor O
. O

The O
SSB I-GENE
- O
poly O
( O
dT O
) O
affinity O
is O
too O
high O
to O
measure O
in O
buffers O
containing O
even O
5 O
M O
NaCl O
; O
however O
, O
in O
1 O
. O
8 O
- O
2 O
. O
5 O
M O
NaBr O
, O
we O
measure O
alpha O
log O
Kobsd O
/ O
alpha O
log O
[ O
NaBr O
] O
= O
- O
5 O
. O
7 O
+/- O
0 O
. O
7 O
, O
with O
a O
lower O
value O
of O
omega O
T O
/ O
O O
= O
130 O
+/- O
70 O
. O

Mutations O
at O
the O
suf12 I-GENE
locus I-GENE
were O
isolated O
in O
Saccharomyces O
cerevisiae O
as O
extragenic O
suppressors O
of O
+ O
1 O
frameshift O
mutations O
in O
glycine O
( O
GGX O
) O
and O
proline O
( O
CCX O
) O
codons O
, O
as O
well O
as O
UGA O
and O
UAG O
nonsense O
mutations O
. O

The O
behavior O
of O
suf12 I-GENE
- I-GENE
null I-GENE
/ I-GENE
SUF12 I-GENE
+ I-GENE
heterozygotes I-GENE
indicates O
that O
suf12 I-GENE
is O
co O
- O
dominantly O
expressed O
and O
suggests O
that O
suf12 I-GENE
allele O
- O
specific O
suppression O
may O
result O
from O
functionally O
distinct O
mutant O
proteins O
rather O
than O
variation O
in O
residual O
wild I-GENE
- I-GENE
type I-GENE
SUF12 I-GENE
+ I-GENE
activity O
. O

Antituberculosis O
agents O
. O

The O
putative O
immunity O
protein O
was O
detected O
among O
the O
[ O
35S O
] O
methionine O
- O
labelled O
proteins O
produced O
by O
minicells O
carrying O
cni I-GENE
cloned O
under O
lac I-GENE
promoter I-GENE
control O
, O
and O
when O
the O
gene O
was O
subcloned O
into O
expression O
vectors O
under O
the O
control O
of O
a O
bacteriophage O
T7 O
promoter O
. O

Antibodies O
made O
against O
fusion O
protein O
produced O
by O
the O
DP1A I-GENE
clone O
reacted O
specifically O
with O
DP I-GENE
- I-GENE
I I-GENE
and I-GENE
- I-GENE
II I-GENE
on O
immunoblots O
. O

Finally O
, O
over O
a O
similar O
range O
of O
QO2 O
, O
oxygen O
extraction O
was O
greater O
in O
patients O
with O
ARDS O
compared O
to O
patients O
with O
non O
- O
ARDS O
respiratory O
failure O
( O
r O
= O
- O
0 O
. O
67 O
and O
slope O
= O
- O
0 O
. O
62 O
vs O
r O
= O
- O
0 O
. O
45 O
and O
slope O
= O
- O
0 O
. O
35 O
; O
p O
less O
than O
0 O
. O
05 O
). O

Stable O
patients O
have O
mucous O
hypersecretion O
and O
little O
evidence O
of O
acute O
inflammation O
. O

Hyperprolactinaemia O
, O
moderate O
hypogonadism O
, O
infraclinical O
neuropathies O
, O
arterial O
stenoses O
and O
moderate O
venous O
leakages O
seem O
to O
play O
a O
partial O
role O
of O
organic O
starter O
or O
cofactor O
, O
the O
sexual O
consequences O
of O
which O
are O
amplified O
by O
psychological O
factors O
, O
partly O
secondary O
to O
the O
initial O
sexual O
failures O
. O

Yang O
and O
H O
. O

Secretory O
function O
of O
the O
prostate O
gland O
. O

Chronic O
endotoxemia O
appears O
to O
be O
associated O
with O
an O
elevated O
pulmonary O
microvascular O
permeability O
and O
a O
tendency O
toward O
a O
hyperdynamic O
circulation O
but O
with O
an O
appreciable O
degree O
of O
refractoriness O
associated O
with O
regional O
hemodynamics O
and O
eicosanoid O
biosynthesis O
. O

In O
contrast O
, O
we O
observed O
high O
concentrations O
in O
29 O
of O
75 O
patients O
with O
tumors O
of O
the O
central O
nervous O
system O
, O
especially O
in O
meningioma O
( O
6 O
/ O
9 O
), O
glioblastoma O
( O
9 O
/ O
23 O
), O
and O
neurinoma O
( O
5 O
/ O
5 O
). O

Diet O
and O
atopic O
eczema O
. O

Time O
delay O
effects O
on O
the O
tensile O
bond O
strength O
developed O
by O
the O
Silicoater O
. O

The O
future O
of O
research O
with O
interferon I-GENE
may O
be O
divided O
into O
three O
areas O
: O
Efforts O
must O
be O
made O
to O
determine O
how O
best O
to O
translate O
the O
in O
vitro O
synergy O
into O
clinically O
meaningful O
terms O
; O
in O
order O
to O
exploit O
the O
fullest O
potential O
of O
IFN I-GENE
, O
research O
is O
moving O
toward O
using O
this O
agent O
earlier O
in O
disease O
either O
as O
an O
adjuvant O
after O
tumor O
debulking O
or O
after O
initial O
diagnosis O
; O
the O
medical O
community O
must O
rethink O
the O
natural O
history O
of O
some O
diseases O
, O
because O
the O
fullest O
potential O
of O
the O
biologic O
agents O
will O
most O
likely O
manifest O
itself O
when O
these O
agents O
are O
used O
together O
. O

Minor O
differences O
were O
noted O
with O
latamoxef O
producing O
mild O
persistant O
elevation O
of O
prothrombin I-GENE
time O
( O
0 O
. O
7 O
second O
) O
associated O
with O
depression O
of O
factor I-GENE
II I-GENE
and O
factor I-GENE
VII I-GENE
. O

Six O
healthy O
male O
subjects O
received O
single O
oral O
doses O
of O
regular O
release O
( O
RR O
) O
quinidine O
sulfate O
, O
sustained O
release O
( O
SR O
) O
quinidine O
bisulfate O
and O
the O
same O
dose O
of O
the O
SR O
product O
with O
food O
( O
SR O
- O
F O
). O

This O
report O
expands O
on O
previous O
work O
with O
interferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
( I-GENE
Intron I-GENE
A I-GENE
; I-GENE
Schering I-GENE
- I-GENE
Plough I-GENE
) I-GENE
in O
the O
treatment O
of O
hairy O
cell O
leukemia O
( O
HCL O
). O

Oxygen O
delivery O
and O
base O
excess O
decreased O
significantly O
and O
four O
pigs O
died O
. O

Clinical O
chemistry O
. O

Revascularization O
after O
anterior O
maxillary O
and O
mandibular O
osteotomy O

Static O
orthoses O
for O
the O
management O
of O
microstomia O
. O

The O
intrapancreatic O
spread O
of O
the O
carcinoma O
correlated O
with O
portal O
invasion O
of O
carcinoma O
, O
hardness O
of O
the O
body O
and O
tail O
, O
obstruction O
of O
main O
pancreatic O
duct O
and O
irregular O
pancreaticogram O
. O

Lysosomal O
enzymes O
that O
degrade O
cartilage O
are O
released O
. O

Contrary O
to O
the O
observation O
made O
with O
other O
S O
. O
pombe O
genes O
transcribed O
in O
the O
budding O
yeast O
, O
the O
heterologous O
actin I-GENE
gene I-GENE
transcript I-GENE
is O
initiated O
39 O
nucleotides O
upstream O
of O
the O
initiation O
start O
site O
used O
in O
the O
homologous O
yeast O
. O

A O
multicentre O
study O
involving O
9 O
Italian O
institutions O
was O
carried O
out O
to O
compare O
the O
efficacy O
and O
safety O
of O
ranitidine O
150 O
mg O
b O
. O
i O
. O
d O
. O
and O
ranitidine O
300 O
mg O
nocte O
in O
the O
treatment O
of O
reflux O
oesophagitis O
. O

Monotherapy O
with O
ceftazidime O
was O
clinically O
and O
bacteriologically O
as O
effective O
as O
a O
combination O
therapy O
with O
cefazolin O
and O
tobramycin O
. O

The O
N3 O
wave O
of O
the O
SSEP O
' O
s O
, O
which O
has O
been O
found O
to O
correlate O
best O
with O
neurological O
recovery O
, O
returned O
to O
65 O
% O
+/- O
48 O
% O
of O
the O
preischemia O
amplitude O
in O
the O
insulin I-GENE
- O
treated O
animals O
, O
compared O
to O
40 O
% O
+/- O
34 O
% O
in O
the O
fasted O
group O
and O
26 O
% O
+/- O
24 O
% O
in O
the O
control O
animals O
. O

Proctoscopy O
and O
roentgenographic O
studies O
may O
be O
an O
important O
part O
of O
evaluation O
, O
especially O
in O
patients O
who O
present O
with O
perianal O
suppuration O
, O
masses O
, O
or O
anal O
fissures O
. O

In O
the O
control O
group O
the O
histological O
picture O
resembled O
osteoarthritis O
. O

In O
contrast O
to O
this O
mRNA O
, O
90 O
% O
of O
alpha I-GENE
and I-GENE
beta I-GENE
actin I-GENE
mRNAs I-GENE
were O
translated O
in O
both O
myoblasts O
and O
myotubes O
. O

Plasma I-GENE
renin I-GENE
activity O
does O
not O
predict O
the O
antihypertensive O
efficacy O
of O
chlorthalidone O
. O

Cephradine O
250 O
mg O
at O
night O
for O
12 O
months O
was O
given O
as O
a O
prophylactic O
measure O
to O
33 O
female O
patients O
of O
mean O
age O
41 O
. O
6 O
years O
, O
who O
had O
a O
history O
in O
the O
preceding O
12 O
months O
of O
between O
three O
and O
24 O
( O
median O
= O
7 O
) O
episodes O
of O
frequency O
and O
/ O
or O
dysuria O
. O

If O
this O
is O
unavailable O
, O
then O
Supramid O
has O
a O
proven O
record O
for O
good O
tissue O
compatibility O
and O
resistance O
to O
infection O
. O

The O
size O
of O
the O
group O
allocated O
to O
the O
good O
compliance O
category O
by O
the O
use O
of O
the O
digoxin O
marker O
was O
equivalent O
in O
size O
to O
a O
group O
of O
patients O
who O
had O
returned O
less O
than O
15 O
% O
of O
their O
prescribed O
dose O
or O
reported O
a O
deviation O
of O
less O
than O
6 O
% O
from O
their O
prescription O
. O

Bullous O
keratopathy O
was O
usually O
aphakic O
in O
origin O
in O
1982 O
, O
but O
after O
1983 O
pseudophakic O
bullous O
keratopathy O
( O
PBK O
) O
was O
the O
most O
common O
cause O
of O
bullous O
keratopathy O
. O

The O
ultrastructural O
findings O
, O
as O
well O
as O
the O
urinary O
C I-GENE
- I-GENE
peptide I-GENE
excretion O
, O
confirmed O
that O
the O
glycemic O
effects O
should O
not O
be O
thought O
to O
be O
due O
to O
a O
direct O
action O
of O
the O
drugs O
used O
on O
the O
endocrine O
pancreas O
. O

The O
activity O
of O
the O
EGF I-GENE
receptor I-GENE
promoter I-GENE
can O
be O
modulated O
by O
E1A I-GENE
protein I-GENE
and O
receptor O
RNA O
levels O
increased O
by O
stimulation O
with O
phorbol O
ester O
or O
fetal O
calf O
serum O
. O

In O
vitro O
antimalarial O
activity O
of O
neem O
( O
Azadirachta O
indica O
A O
. O

" O
In O
vitro O
" O
study O
of O
dentin O
adhesion O
to O
adhesives O
made O
from O
urethane O
molecules O
with O
free O
groups O
of O
isocyanate O

By O
Felix O
Lagrange O
, O
1918 O
. O

There O
is O
a O
cysteine O
clustering O
region O
in O
an O
N O
- O
terminal O
region O
of O
the O
c I-GENE
- I-GENE
raf I-GENE
(- I-GENE
1 I-GENE
) I-GENE
product I-GENE
deduced O
from O
the O
nucleotide O
sequence O
, O
and O
this O
cysteine O
clustering O
region O
was O
found O
to O
be O
highly O
homologous O
to O
that O
present O
in O
an O
N O
- O
terminal O
region O
of O
protein I-GENE
kinase I-GENE
C I-GENE
, O
although O
, O
in O
the O
latter O
cysteine O
clusters O
are O
present O
in O
duplicate O
. O

Hand O
- O
held O
, O
continuous O
- O
wave O
Doppler O
probes O
, O
coupled O
with O
sound O
spectral O
analysis O
, O
can O
successfully O
predict O
carotid O
artery O
stenosis O
. O

The O
German O
Society O
of O
Pediatric O
Oncology O
in O
1981 O
initiated O
the O
Cooperative O
Ewing O
' O
s O
Sarcoma O
Study O
( O
CESS O
81 O
) O
using O
a O
four O
- O
drug O
combination O
of O
chemotherapy O
prior O
to O
definitive O
local O
control O
with O
surgery O
and O
/ O
or O
radiation O
. O

The O
program O
has O
been O
written O
in O
a O
generic O
BASIC O
in O
order O
to O
make O
the O
procedure O
user O
- O
friendly O
. O

Since O
high O
levels O
of O
immunoglobulin I-GENE
G I-GENE
were O
demonstrated O
against O
the O
surface O
of O
the O
NVS O
after O
immunization O
, O
passive O
transfer O
experiments O
were O
initiated O
. O

A O
study O
was O
conducted O
of O
a O
human O
male O
who O
had O
inhaled O
a O
mixture O
of O
241Am O
and O
Pu O
. O

An O
analytic O
method O
for O
comparative O
parameter O
weighting O
in O
magnetic O
resonance O
( O
MR O
) O
imaging O
has O
been O
developed O
using O
the O
concept O
of O
" O
fractional O
sensitivity O
." O
This O
new O
approach O
results O
in O
easily O
calculated O
indexes O
for O
T1 O
, O
T2 O
, O
and O
hydrogen O
weighting O
. O

Fifty O
- O
four O
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
presentation O
; O
seven O
asymptomatic O
volunteers O
, O
20 O
patients O
with O
duodenal O
- O
gastric O
reflux O
gastropathy O
( O
DRG O
), O
16 O
patients O
with O
recurrent O
ulcers O
of O
the O
duodenal O
bulb O
( O
RUD O
), O
and O
11 O
patients O
with O
Moynihan O
' O
s O
disease O
. O

No O
previous O
studies O
have O
determined O
the O
pharmaco O
- O
dynamics O
of O
intravenous O
procainamide O
when O
administered O
in O
a O
dose O
of O
15 O
mg O
/ O
kg O
and O
at O
a O
rate O
of O
50 O
mg O
/ O
min O
, O
as O
is O
common O
practice O
during O
electropharmacologic O
testing O
. O

High O
concentrations O
of O
tumor O
- O
associated O
trypsin I-GENE
inhibitor O
in O
hemodialyzed O
patients O
. O

In O
the O
chicken O
liver O
, O
levels O
of O
chicken I-GENE
MT I-GENE
mRNA I-GENE
were O
rapidly O
induced O
by O
metals O
( O
Cd2 O
+, O
Zn2 O
+, O
Cu2 O
+), O
glucocorticoids O
and O
lipopolysaccharide O
. O

With O
histology O
and O
Evans O
blue O
injections O
, O
blood O
- O
brain O
barrier O
alterations O
were O
seen O
as O
early O
as O
4 O
days O
after O
a O
dose O
of O
50 O
Gy O
. O

Dosimetric O
estimates O
for O
these O
organs O
were O
2 O
. O
3 O
+/- O
1 O
. O
1 O
and O
2 O
. O
3 O
+/- O
1 O
. O
4 O
rad O
(. O
02 O
+/- O
. O
01 O
Gy O
), O
respectively O
, O
with O
a O
whole O
- O
body O
estimate O
of O
0 O
. O
28 O
rad O
(. O
003 O
Gy O
). O

A O
significant O
association O
between O
a O
family O
history O
and O
a O
higher O
urinary O
pH O
was O
observed O
among O
the O
female O
calcium O
stone O
patients O
. O

New O
technologies O
in O
diagnosis O
and O
classification O
of O
malignancy O
. O

Thus O
the O
present O
data O
also O
suggest O
that O
BP O
and O
HR O
measurements O
are O
influenced O
not O
only O
by O
state O
- O
dependent O
factors O
but O
also O
by O
at O
least O
three O
different O
factors O
that O
are O
each O
independent O
of O
the O
state O
: O
one O
leads O
to O
BP O
and O
HR O
values O
that O
are O
influenced O
by O
the O
cycle O
the O
animal O
is O
in O
and O
the O
other O
two O
influence O
, O
respectively O
, O
the O
ranking O
of O
the O
individual O
' O
s O
BP O
and O
HR O
levels O
within O
the O
population O
. O

The O
correlation O
between O
PaCO2 O
and O
PtcO2 O
in O
RDS O
was O
insufficient O
to O
make O
clinical O
judgement O
. O

Since O
1967 O
at O
the O
times O
of O
their O
biennial O
ABCC O
/ O
RERF O
radiological O
examinations O
, O
all O
Adult O
Health O
Study O
( O
AHS O
) O
subjects O
have O
been O
interviewed O
to O
determine O
the O
exposures O
to O
medical O
x O
- O
rays O
they O
experienced O
in O
institutions O
other O
than O
RERF O
in O
order O
to O
estimate O
the O
numbers O
of O
examinations O
and O
corresponding O
doses O
which O
they O
received O
. O

The O
epidermal I-GENE
growth I-GENE
factor I-GENE
( I-GENE
EGF I-GENE
) I-GENE
receptor I-GENE
, O
which O
exhibits O
intrinsic O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
, O
undergoes O
a O
rapid O
, O
intramolecular O
self O
- O
phosphorylation O
reaction O
following O
EGF I-GENE
activation O
. O

One O
millimolar O
ouabain O
completely O
inhibited O
net O
HCO3 O
- O
secretion O
. O

There O
are O
regions O
with O
long O
runs O
of O
up O
to O
45 O
% O
C O
or O
35 O
% O
G O
residues O
. O

The O
same O
rhythmic O
structure O
enables O
a O
prediction O
to O
be O
made O
concerning O
when O
vowels O
of O
stressed O
syllables O
will O
be O
auditorily O
perceived O
. O

Vocal O
cord O
abduction O
rehabilitation O
by O
nervous O
selective O
anastomosis O
. O

UK O
' O
s O
biotechnology O
lacking O
specialists O
. O

A O
case O
of O
AIDS O
- O
related O
complex O
( O
ARC O
/ O
LAS O
) O
in O
a O
health O
worker O

Distant O
spread O
was O
found O
in O
46 O
patients O
( O
34 O
%), O
42 O
of O
whom O
had O
serum O
Tg I-GENE
greater O
than O
10 O
micrograms O
/ O
l O
. O

The O
glomerular O
filtration O
rate O
and O
effective O
renal O
plasma O
flow O
were O
determined O
by O
a O
standard O
clearance O
method O
, O
employing O
continuous O
infusion O
of O
inulin O
and O
para O
- O
aminohippuric O
acid O
. O

After O
the O
meal O
containing O
potato O
, O
plasma O
glucose O
levels O
rose O
sharply O
, O
peaked O
at O
30 O
- O
45 O
min O
and O
fell O
below O
initial O
levels O
2 O
to O
3 O
h O
later O
. O

The O
relations O
among O
various O
negative O
emotional O
and O
behavioral O
characteristics O
( O
e O
. O
g O
., O
aggression O
, O
anxiety O
, O
undercompliance O
, O
depressive O
mood O
) O
and O
adjustment O
were O
examined O
through O
use O
of O
data O
from O
the O
31 O
- O
year O
- O
old O
New O
York O
Longitudinal O
Study O
. O

To O
evaluate O
the O
effect O
of O
altitude O
on O
adolescent O
growth O
and O
development O
, O
three O
groups O
of O
healthy O
, O
well O
- O
nourished O
youth O
of O
similar O
socioeconomic O
status O
and O
ethnic O
grouping O
who O
resided O
at O
sea O
level O
( O
n O
= O
1262 O
subjects O
), O
mid O
- O
altitude O
( O
n O
= O
1743 O
subjects O
), O
and O
high O
altitude O
( O
n O
= O
1137 O
subjects O
) O
were O
studied O
. O

Because O
the O
CAP O
measures O
variables O
predictive O
of O
abusive O
behavior O
, O
a O
substantial O
relationship O
was O
expected O
between O
the O
CAP O
and O
the O
MHI O
Loss O
of O
Behavioral O
/ O
Emotional O
Control O
scale O
. O

We O
have O
improved O
our O
system O
for O
nuclear O
contour O
digitization O
and O
determined O
its O
theoretical O
limitations O
by O
digitizing O
standardized O
objects O
. O

Such O
a O
change O
may O
involve O
increased O
mammary O
utilization O
of O
pre O
- O
formed O
long O
- O
chain O
fatty O
acid O
and O
increased O
metabolism O
of O
glucose O
via O
glycolysis O
. O

The O
skin O
site O
, O
6 O
- O
cm O
- O
distal O
and O
- O
proximal O
subcutaneous O
segments O
of O
the O
catheter O
, O
exudates O
, O
and O
blood O
were O
cultured O
. O

Because O
of O
its O
great O
reliability O
, O
conventional O
arteriography O
occupies O
a O
place O
of O
choice O
among O
the O
medical O
imaging O
techniques O
. O

Rapid O
detection O
of O
radioisotopically O
contaminated O
test O
serum O
before O
radioassay O
of O
vitamin O
B12 O
. O

The O
former O
group O
did O
excrete O
less O
dry O
fecal O
material O
compared O
to O
both O
other O
groups O
. O

Electronic O
data O
processing O
( O
EDP O
) O
latex O
immunoassay O
using O
anti I-GENE
- I-GENE
human I-GENE
seminal I-GENE
acid I-GENE
phosphatase I-GENE
( O
anti I-GENE
- I-GENE
HSAP I-GENE
) O
immune O
serum O
was O
applied O
for O
the O
species O
and O
organ O
identification O
of O
human O
seminal O
stains O
. O

Vimentin I-GENE
positivity O
was O
noted O
in O
the O
undifferentiated O
and O
fibroblastic O
components O
. O

The O
maximum O
deflections O
of O
phase O
IV O
for O
Ar O
and O
N2 O
from O
extrapolated O
phase O
III O
slopes O
were O
smaller O
in O
the O
prone O
position O
, O
suggesting O
more O
uniform O
tracer O
gas O
concentrations O
across O
the O
lungs O
. O

Recent O
developments O
in O
drugs O
antagonistic O
to O
factors O
causing O
peptic O
ulcer O
-- O
clinical O
efficacy O
and O
problems O
; O
gastrin I-GENE
receptor I-GENE
blockaders O

The O
spermicide O
nonoxynol O
- O
9 O
is O
a O
member O
of O
a O
homologous O
series O
of O
alkylphenol O
- O
ethoxylates O
( O
polyethoxyethanols O
) O
of O
general O
formula O
C9H19 O
- O
C6H6 O
- O
O O
-( O
CH2CH2O O
) O
n O
- O
1 O
CH2CH2OH O
. O

Static O
magnetic O
fields O
affect O
the O
diffusion O
of O
biological O
particles O
in O
solutions O
through O
the O
Lorentz O
force O
and O
Maxwell O
stress O
. O

Psychological O
disturbance O
was O
greater O
in O
the O
high O
life O
stress O
group O
as O
indicated O
by O
significant O
elevations O
on O
the O
global O
severity O
index O
of O
the O
Symptom O
Checklist O
- O
90 O
and O
elevations O
on O
somatization O
, O
obsessive O
compulsive O
, O
interpersonal O
sensitivity O
, O
depression O
, O
anxiety O
and O
psychoticism O
subscales O
. O

Chronic O
administration O
of O
sodium O
cyanate O
decreases O
O2 O
extraction O
ratio O
in O
dogs O
. O

Nucleotide O
sequencing O
indicates O
that O
this O
E1 I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
1821 O
base O
pairs O
( O
bp O
) O
in O
length O
with O
an O
open O
reading O
frame O
of O
1365 O
bp O
and O
a O
3 O
'- O
untranslated O
region O
of O
356 O
bp O
. O

SPA O
from O
PAG O
sites O
was O
associated O
with O
aversion O
. O

In O
contrast O
, O
the O
MAN O
showed O
a O
unimodal O
, O
skewed O
distribution O
, O
with O
a O
range O
from O
approximately O
1 O
to O
14 O
micron O
and O
a O
maximum O
at O
3 O
- O
4 O
micron O
. O

Abnormal O
technetium O
Tc O
99m O
medronate O
scans O
in O
patients O
with O
previously O
undiagnosed O
polyarthralgias O
suggested O
inflammatory O
arthropathy O
and O
influenced O
management O
decisions O
with O
favorable O
therapeutic O
outcomes O
. O

Practical O
interest O
of O
such O
studies O
is O
limited O
since O
the O
pharmacokinetic O
parameters O
are O
systematically O
evaluated O
in O
man O
during O
phase O
I O
trials O
. O

The O
artery O
cuff O
was O
slightly O
superior O
to O
the O
fat O
wrap O
, O
particularly O
in O
having O
fewer O
adhesions O
and O
a O
better O
histological O
picture O
. O

Lithium O
- O
carbonate O
action O
during O
radiation O
therapy O
has O
been O
studied O
, O
valuing O
the O
positive O
effect O
on O
leukopoiesis O
and O
the O
consequent O
better O
clinical O
conditions O
of O
the O
patients O
in O
course O
of O
treatment O
. O

Of O
the O
53 O
units O
tested O
during O
sinusoidal O
motion O
at O
0 O
. O
05 O
Hz O
( O
9 O
. O
1 O
cm O
/ O
s O
), O
1 O
( O
1 O
. O
9 O
%) O
was O
responsive O
to O
the O
otolith O
input O
only O
, O
13 O
( O
24 O
. O
5 O
%) O
were O
influenced O
by O
the O
visual O
input O
only O
and O
23 O
( O
43 O
. O
4 O
%) O
responded O
to O
both O
modalities O
. O

Depending O
on O
the O
location O
and O
size O
of O
the O
mass O
, O
a O
wide O
range O
of O
clinical O
presentations O
is O
associated O
with O
the O
lesion O
. O

The O
development O
and O
distribution O
of O
Trypanosoma O
congolense O
, O
T O
vivax O
and O
T O
brucei O
in O
the O
skin O
of O
goats O
was O
examined O
after O
the O
animals O
were O
bitten O
by O
infected O
Glossina O
morsitans O
centralis O
. O

Electroglottography O
is O
a O
useful O
, O
non O
- O
invasive O
technique O
that O
can O
assist O
in O
the O
assessment O
of O
vocal O
fold O
dysfunction O
. O

Statistical O
analysis O
of O
the O
degrees O
of O
secondary O
spinal O
cord O
compression O
was O
performed O
in O
group O
- O
1 O
dogs O
by O
measuring O
and O
comparing O
ratios O
of O
the O
vertical O
to O
the O
horizontal O
diameters O
of O
the O
transverse O
spinal O
cord O
sections O
from O
locations O
within O
( O
T12 O
to O
L1 O
) O
and O
out O
of O
( O
T11 O
, O
T11 O
- O
12 O
, O
L1 O
- O
2 O
, O
and O
L2 O
) O
the O
region O
of O
surgical O
intervention O
. O

The O
pharmacological O
effects O
of O
the O
novel O
compound O
WEB O
1881 O
FU O
( O
4 O
- O
amino O
- O
methyl O
- O
1 O
- O
benzyl O
- O
pyrrolidine O
- O
2 O
- O
one O
- O
fumarate O
) O
were O
investigated O
. O

Histopathological O
examination O
revealed O
dose O
- O
related O
proliferation O
of O
type O
II O
pneumocytes O
in O
dams O
and O
proliferation O
of O
interstitial O
cells O
and O
delayed O
septal O
/ O
capillary O
development O
in O
neonates O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

So O
far O
no O
problems O
with O
multiply O
resistant O
strains O
have O
developed O
. O

During O
the O
observation O
period O
of O
0 O
. O
4 O
- O
30 O
weeks O
, O
cardiac O
white O
spots O
on O
the O
right O
ventricle O
of O
BALB O
/ O
c O
mice O
were O
first O
detected O
at O
three O
weeks O
( O
6 O
of O
20 O
mice O
; O
30 O
%), O
and O
the O
maximal O
incidence O
of O
cardiac O
white O
spots O
was O
obtained O
at O
nine O
weeks O
( O
39 O
of O
44 O
mice O
; O
88 O
%). O

The O
state O
of O
the O
liver O
in O
generalized O
forms O
of O
meningococcal O
infection O

Increasing O
the O
RH O
beyond O
32 O
% O
resulted O
in O
solvation O
of O
the O
peroxy O
radical O
, O
sterically O
hindering O
the O
radical O
from O
entering O
the O
propagation O
transition O
state O
. O

The O
effects O
produced O
by O
oral O
administration O
of O
500 O
mg O
/ O
kg O
p O
- O
xylene O
or O
toluene O
lasted O
at O
least O
8 O
hr O
, O
while O
the O
effect O
of O
inhaled O
p O
- O
xylene O
dissipated O
within O
75 O
min O
of O
removal O
from O
the O
exposure O
. O

PATIENTS O
and O
METHODS O
: O
Thallium O
- O
201 O
myocardial O
scintigraphy O
was O
performed O
at O
rest O
and O
after O
0 O
. O
56 O
mg O
/ O
kg O
intravenous O
dipyridamole O
during O
four O
minutes O
in O
16 O
patients O
with O
sarcoidosis O
. O

Thin O
melanomas O
can O
metastasize O
and O
be O
lethal O
. O

The O
TA O
muscle O
was O
fatigued O
by O
four O
forms O
of O
repeated O
isometric O
contractions O
: O
( O
1 O
) O
maximal O
voluntary O
contractions O
( O
MVC O
), O
( O
2 O
) O
MVC O
with O
circulation O
occluded O
, O
( O
3 O
) O
electrically O
evoked O
contractions O
with O
20 O
Hz O
supramaximal O
voltage O
stimulation O
and O
( O
4 O
) O
electrically O
evoked O
contractions O
with O
circulation O
occluded O
. O

The O
actuarial O
local O
control O
rates O
at O
10 O
years O
for O
the O
three O
treatment O
groups O
were O
as O
follows O
: O
subtotal O
excision O
alone O
, O
18 O
%; O
subtotal O
excision O
plus O
postoperative O
radiation O
therapy O
, O
82 O
%; O
and O
total O
excision O
alone O
, O
77 O
%. O

The O
effects O
of O
anabolic O
implants O
on O
rate O
, O
composition O
and O
energetic O
efficiency O
of O
growth O
were O
determined O
in O
steers O
fed O
diets O
varying O
in O
forage O
and O
grain O
content O
. O

Prolonged O
suspension O
induced O
a O
significant O
change O
in O
the O
geometric O
configuration O
of O
the O
femur O
middiaphysis O
by O
increasing O
the O
minimum O
diameter O
( O
12 O
%) O
without O
any O
significant O
alterations O
in O
cortical O
area O
, O
density O
, O
mineral O
, O
and O
collagen I-GENE
concentrations O
. O

Which O
cineangiographically O
assessed O
anatomic O
variable O
correlates O
best O
with O
functional O
measurements O
of O
stenosis O
severity O
? O
A O
comparison O
of O
quantitative O
analysis O
of O
the O
coronary O
cineangiogram O
with O
measured O
coronary O
flow O
reserve O
and O
exercise O
/ O
redistribution O
thallium O
- O
201 O
scintigraphy O
. O

Water O
content O
and O
equilibrium O
water O
partition O
in O
immature O
cartilage O
. O

Thyroid O
function O
tests O
were O
performed O
on O
300 O
admissions O
, O
leaving O
707 O
untested O
. O

Data O
on O
the O
line O
spread O
function O
( O
LSF O
) O
were O
obtained O
from O
the O
image O
of O
a O
0 O
. O
2 O
mm O
wide O
slit O
between O
tungsten O
blocks O
that O
were O
positioned O
at O
the O
isocentre O
in O
front O
of O
a O
polystyrene O
phantom O
. O

Primary O
infection O
is O
usually O
managed O
conservatively O
. O

Papers O
of O
the O
Society O
for O
Clinical O
Vascular O
Surgery O
. O

Ischemic O
heart O
disease O
, O
age O
of O
more O
than O
75 O
years O
, O
and O
the O
fact O
that O
the O
patient O
was O
a O
woman O
were O
independent O
predictors O
of O
poor O
cardiac O
function O
. O

Prognosis O
in O
Bowen O
' O
s O
disease O
localized O
to O
the O
ano O
- O
genital O
region O
. O

Taken O
together O
, O
the O
results O
suggest O
that O
chlorphentermine O
may O
be O
capable O
of O
producing O
dual O
stimulus O
effects O
in O
animals O
. O

Liquid O
chromatographic O
method O
for O
determination O
of O
citreoviridin O
in O
corn O
and O
rice O
. O

These O
findings O
indicate O
that O
autophosphorylation O
of O
Thr286 O
( O
alpha O
subunit O
) O
and O
Thr287 O
( O
beta O
subunit O
) O
is O
responsible O
for O
transition O
of O
CaM I-GENE
- I-GENE
kinase I-GENE
II I-GENE
to O
the O
Ca2 O
+- O
independent O
form O
. O

This O
rapid O
and O
extensive O
penetration O
of O
intrathecally O
administered O
chemotherapy O
may O
offer O
insight O
into O
the O
myelopathy O
observed O
with O
these O
treatments O
. O

The O
interaction O
of O
radiation O
and O
hyperthermia O
was O
systematically O
studied O
in O
the O
Dunning O
R3327G O
prostatic O
adenocarcinoma O
, O
the O
preeminent O
animal O
model O
for O
human O
prostatic O
cancer O
. O

Pregnant O
rats O
were O
exposed O
to O
one O
of O
the O
following O
: O
( O
1 O
) O
10 O
% O
O2 O
in O
N2 O
or O
100 O
% O
O2 O
for O
2 O
days O
beginning O
at O
day O
7 O
, O
11 O
, O
14 O
, O
or O
18 O
of O
pregnancy O
; O
( O
2 O
) O
10 O
% O
O2 O
in O
N2 O
or O
100 O
% O
O2 O
for O
10 O
h O
/ O
day O
beginning O
at O
day O
7 O
; O
or O
( O
3 O
) O
14 O
- O
11 O
% O
O2 O
in O
N2 O
continuously O
beginning O
at O
day O
14 O
till O
day O
21 O
when O
they O
were O
sacrificed O
. O

The O
incidence O
of O
cryptosporidiosis O
in O
young O
children O
was O
determined O
by O
staining O
of O
faecal O
specimens O
with O
a O
modified O
Kinyoun O
stain O
. O

Seven O
patients O
( O
8 O
. O
3 O
percent O
) O
had O
latent O
hypothyroidism O
only O
discovered O
by O
hormonal O
determinations O
. O

Addition O
of O
sucralfate O
or O
De O
- O
Nol O
resulted O
in O
increments O
of O
gastric O
HCO3 O
secretion O
, O
reaching O
about O
45 O
% O
and O
59 O
%, O
respectively O
, O
of O
the O
maximal O
HCO3 O
response O
to O
16 O
, O
16 O
- O
dimethyl O
PGE2 O
( O
dmPGE2 O
). O

Moreover O
, O
unlike O
control O
rats O
operated O
animals O
did O
not O
show O
aversion O
to O
the O
highest O
concentrations O
of O
saccharin O
solutions O
. O

In O
Salmo O
gairdneri O
, O
no O
specialized O
system O
of O
portal O
vessels O
appears O
to O
exist O
between O
the O
pineal O
organ O
and O
other O
portions O
of O
the O
brain O
. O

The O
4 O
degrees O
stimuli O
were O
found O
to O
elicit O
scalp O
distributions O
for O
the O
pattern O
reversal O
P100 O
and O
the O
pattern O
onset O
C1 O
consistent O
with O
striate O
and O
extrastriate O
visual O
cortical O
origins O
respectively O
. O

Nuclear I-GENE
factor I-GENE
III I-GENE
( O
NFIII I-GENE
) O
is O
a O
protein O
from O
HeLa O
cells O
that O
stimulates O
the O
initiation O
of O
adenovirus O
type O
2 O
( O
Ad2 O
) O
DNA O
replication O
by O
binding O
to O
a O
specific O
nucleotide O
sequence O
in O
the O
origin O
, O
adjacent O
to O
the O
nuclear I-GENE
factor I-GENE
I I-GENE
recognition I-GENE
site I-GENE
. O

A O
Golgi O
study O
of O
the O
sixth O
layer O
of O
the O
cerebral O
cortex O
. O

We O
conclude O
that O
cephalothin O
clearance O
of O
S O
. O
aureus O
from O
a O
site O
accessible O
to O
phagocytes O
was O
delayed O
when O
compared O
to O
a O
phagocyte O
- O
inaccessible O
site O
. O

The O
findings O
are O
discussed O
in O
the O
context O
of O
known O
properties O
of O
cortical O
- O
bar O
detectors O
. O

Mean O
rCBF O
increased O
in O
some O
patients O
4 O
- O
8 O
weeks O
after O
surgery O
on O
the O
ipsilateral O
side O
. O

Quantitative O
computed O
tomography O
for O
measuring O
vertebral O
bone O
mineral O
content O
offers O
high O
sensitivity O
and O
reproducibility O
. O

The O
structure O
of O
the O
enhancer O
was O
also O
probed O
by O
inserting O
a O
pair O
of O
complementary O
synthetic O
oligodeoxynucleotides O
which O
represented O
the O
region O
between O
nt O
positions O
- O
235 O
and O
- O
215 O
into O
a O
truncated O
template O
which O
lacked O
the O
enhancer O
. O

Kf O
, O
c O
and O
CT O
( O
referenced O
to O
the O
initial O
lung O
mass O
) O
decreased O
linearly O
with O
reductions O
in O
lung O
mass O
% O
delta O
Kf O
, O
c O
= O
1 O
. O
26 O
- O
0 O
. O
98 O
% O
mass O
removed O
( O
r O
= O
0 O
. O
90 O
, O
P O
less O
than O
0 O
. O
01 O
) O
and O
% O
delta O
CT O
= O
- O
3 O
. O
99 O
- O
0 O
. O
98 O
% O
mass O
removed O
( O
r O
= O
0 O
. O
82 O
, O
P O
less O
than O
0 O
. O
01 O
) O
relationships O
that O
were O
not O
altered O
by O
blocker O
pretreatment O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Two O
scintigraphic O
methods O
, O
resting O
dipyridamole O
and O
exercise O
thallium O
- O
201 O
myocardial O
perfusion O
imaging O
, O
to O
detect O
and O
localize O
coronary O
artery O
stenosis O
were O
compared O
in O
32 O
patients O
suffering O
from O
coronary O
artery O
disease O
. O

From O
these O
results O
, O
it O
is O
concluded O
that O
EDLF O
has O
clear O
vasoconstrictor O
properties O
which O
are O
not O
due O
to O
adrenergic O
or O
calcium O
entry O
mechanisms O
and O
that O
there O
are O
differences O
in O
the O
vasoconstrictor O
effects O
of O
EDLFs O
with O
respect O
to O
different O
vascular O
beds O
. O

Research O
was O
carried O
out O
on O
the O
rheumatoid I-GENE
factors I-GENE
in O
the O
serum O
of O
917 O
patients O
by O
means O
of O
two O
tests O
( O
one O
using O
polystyrene O
and O
one O
with O
erythrocytes O
) O
and O
the O
results O
obtained O
were O
compared O
using O
a O
method O
of O
reference O
. O

A O
low O
aspirin I-GENE
esterase I-GENE
activity O
may O
be O
a O
contributory O
factor O
in O
precipitating O
these O
aspirin O
sensitive O
reactions O
. O

In O
both O
experiments O
, O
average O
daily O
gain O
and O
gain O
- O
to O
- O
feed O
ratio O
were O
similar O
for O
TR O
and O
CR O
. O

Overall O
least O
- O
squares O
means O
for O
uncooked O
and O
cooked O
longissimus O
muscle O
and O
subcutaneous O
fat O
were O
63 O
. O
32 O
, O
80 O
. O
27 O
and O
98 O
. O
90 O
mg O
of O
cholesterol O
/ O
100 O
g O
of O
tissue O
, O
respectively O
. O

The O
role O
of O
supercritical O
fluid O
chromatography O
( O
SFC O
) O
as O
a O
viable O
technique O
for O
analyzing O
agricultural O
products O
has O
been O
investigated O
using O
packed O
and O
capillary O
column O
methodology O
. O

Nitrofurazone O
significantly O
reduced O
the O
rise O
in O
LH I-GENE
induced O
by O
LHRH I-GENE
. O

Ovarian O
tumors O
in O
pregnancy O
. O

Ultrastructural O
study O
of O
polyarteritis O

X2 O
test O
, O
with O
Yates O
correction O
if O
need O
, O
was O
used O
as O
statistical O
. O
method O
. O

After O
a O
baseline O
study O
, O
WPW O
syndrome O
was O
simulated O
by O
stimulation O
at O
seven O
different O
sites O
around O
the O
base O
of O
the O
ventricles O
, O
and O
RNV O
' O
s O
were O
obtained O
. O

Man O
and O
insect O
, O
past O
, O
present O
, O
future O

All O
patients O
had O
the O
CA I-GENE
125 I-GENE
assay O
performed O
within O
one O
week O
before O
their O
second O
- O
look O
operation O
. O

Allergy O
and O
Tourette O
' O
s O
syndrome O
. O

The O
criterion O
was O
reached O
after O
two O
sessions O
and O
generalization O
to O
a O
variety O
of O
pills O
and O
capsules O
occurred O
. O

Clinical O
method O
for O
the O
treatment O
of O
Class O
II O
occlusal O
anomalies O
with O
open O
bite O

Enoxacin O
appears O
to O
be O
well O
suited O
for O
the O
treatment O
of O
complicated O
UTI O
. O

Mean O
fluorosis O
scores O
, O
however O
, O
were O
similar O
. O

Autonomic O
dysfunctions O
were O
restricted O
to O
tonic O
pupils O
. O

An O
industry O
- O
wide O
retrospective O
cohort O
mortality O
study O
was O
conducted O
on O
6 O
, O
152 O
chemical O
workers O
( O
2 O
, O
460 O
exposed O
and O
3 O
, O
692 O
nonexposed O
) O
engaged O
in O
chloromethyl O
ether O
manufacture O
at O
7 O
major O
U O
. O
S O
. O
companies O
between O
1948 O
and O
1980 O
. O

The O
diagnosis O
of O
amyloidosis O
was O
determined O
from O
a O
labial O
salivary O
gland O
biopsy O
. O

Hair O
and O
blood O
samples O
were O
taken O
before O
vitamin O
C O
or O
placebo O
supplementation O
was O
started O
and O
at O
monthly O
intervals O
thereafter O
for O
three O
months O
. O

In O
treated O
herds O
, O
cows O
more O
than O
40 O
d O
postpartum O
with O
a O
corpus O
luteum O
received O
prostaglandin O
F2 O
alpha O
. O

On O
the O
other O
hand O
, O
if O
the O
measured O
angle O
ANB O
is O
smaller O
than O
the O
calculated O
angle O
, O
the O
skeletal O
relation O
is O
Class O
III O
. O

Emergency O
treatment O
of O
facial O
and O
maxillary O
/ O
mandibular O
injuries O

In O
14 O
cases O
, O
isolates O
were O
biotyped O
yielding O
eight O
with O
biotype O
II O
, O
four O
with O
biotype O
III O
, O
and O
one O
each O
with O
biotypes O
IV O
and O
V O
. O

A O
total O
of O
117 O
EVS O
treatments O
were O
performed O
on O
34 O
patients O
. O

Most O
of O
the O
prepeptide O
portion O
of O
the O
precursor O
polypeptide O
is O
encoded O
by O
the O
next O
three O
exons O
, O
and O
the O
mature O
form O
of O
IL I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
encoded O
by O
the O
remaining O
three O
exons O
. O

A O
stochastic O
version O
of O
Kernell O
' O
s O
( O
1968 O
, O
1972 O
) O
model O
with O
cumulative O
afterhyperpolarization O
( O
AHP O
) O
was O
simulated O
. O

In O
a O
previous O
interim O
report O
we O
noted O
more O
prompt O
resolution O
of O
dermatomal O
signs O
and O
symptoms O
with O
acyclovir O
treatment O
. O

The O
detectability O
of O
the O
defects O
in O
RCA O
or O
LAD O
region O
was O
80 O
% O
in O
single O
- O
position O
scans O
in O
stress O
studies O
. O

Pharmacologic O
properties O
of O
serotonergic O
agents O
and O
antidepressant O
drugs O
. O

This O
brief O
hypercapnic O
challenge O
induced O
a O
rapid O
increase O
in O
CBF O
in O
the O
absence O
of O
any O
change O
in O
MABP O
. O

These O
data O
should O
be O
useful O
in O
developing O
reagents O
for O
heterozygote O
detection O
and O
prenatal O
diagnosis O
of O
11 I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
deficiency O
, O
the O
second O
most O
frequent O
cause O
of O
congenital O
adrenal O
hyperplasia O
. O

Osteocalcin I-GENE
( O
serum I-GENE
bone I-GENE
- I-GENE
Gla I-GENE
protein I-GENE
, O
sBGP I-GENE
), O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
sAP I-GENE
) O
and O
urinary O
hydroxyproline O
/ O
creatinine O
ratio O
( O
uOH O
- O
Prol O
/ O
creatinine O
) O
have O
been O
measured O
in O
21 O
patients O
with O
primary O
hyperparathyroidism O
( O
PHPT O
) O
and O
in O
nine O
patients O
with O
hypercalcaemia O
of O
malignancy O
( O
HM O
). O

Multivariate O
logistic O
regression O
analysis O
indicated O
that O
seropositivity O
was O
strongly O
associated O
with O
the O
prevalence O
of O
hepatitis O
B O
in O
an O
employee O
' O
s O
country O
of O
birth O
and O
with O
age O
. O

Hexsyn O
is O
the O
Goodyear O
Tire O
and O
Rubber O
Company O
tradename O
for O
a O
polyolefin O
rubber O
synthesized O
from O
1 O
- O
hexene O
with O
3 O
- O
5 O
% O
methylhexadiene O
as O
the O
source O
of O
residual O
double O
bonds O
for O
vulcanization O
. O

Chimeric O
phage O
- O
plasmid O
expression O
vectors O
were O
constructed O
from O
pUC18 O
/ O
19 O
plasmids O
by O
cloning O
a O
single O
- O
stranded O
DNA O
( O
ssDNA O
) O
origin O
of O
replication O
from O
bacteriophage O
f1 O
and O
inserting O
a O
bacteriophage O
T7 O
promoter O
within O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
gene I-GENE
. O

By O
order O
of O
decreasing O
rate O
, O
finger O
flexors O
, O
jaw O
, O
crossed O
adductors O
, O
and O
triceps O
reflexes O
were O
less O
frequently O
elicited O
in O
both O
groups O
. O

Natl O
. O

Neither O
ethanol O
nor O
estrogen O
has O
been O
shown O
to O
cause O
UROD I-GENE
- O
deficiency O
in O
animals O
. O

Although O
not O
common O
, O
the O
disorder O
is O
the O
most O
frequently O
diagnosed O
disturbance O
of O
porphyrin O
metabolism O
in O
many O
countries O
, O
and O
further O
insight O
into O
its O
unusual O
pathogenesis O
may O
clarify O
the O
hepatotoxic O
effects O
of O
the O
4 O
etiologic O
agents O
. O

Five O
out O
of O
eight O
consecutive O
cases O
with O
initial O
symptoms O
of O
a O
' O
midline O
granuloma O
' O
were O
identified O
as O
malignant O
histiocytosis O
( O
histiocytic O
sarcoma O
) O
which O
within O
5 O
months O
to O
4 O
years O
led O
to O
generalization O
and O
death O
. O

All O
patients O
then O
received O
suxamethonium O
1 O
. O
5 O
mg O
kg O
- O
1 O
i O
. O
v O
. O

The O
highest O
postoperative O
CK I-GENE
- I-GENE
MB I-GENE
level O
was O
less O
after O
BC O
( O
BC O
, O
31 O
+/- O
17 O
U O
/ O
L O
; O
CC O
, O
56 O
+/- O
13 O
U O
/ O
L O
; O
p O
less O
than O
0 O
. O
05 O
). O

No O
relevant O
changes O
in O
heart O
rate O
, O
body O
weight O
, O
and O
plasma O
levels O
of O
renin I-GENE
activity O
and O
aldosterone O
concentration O
were O
observed O
. O

High O
trough O
serum O
TOB O
concentrations O
were O
associated O
with O
death O
and O
very O
low O
levels O
with O
recovery O
. O

State O
- O
approved O
schools O
of O
nursing O
R O
. O
N O
. O

In O
a O
maxicell O
system O
a O
protein O
with O
an O
approximate O
molecular O
weight O
of O
36 O
, O
000 O
was O
synthesized O
. O

This O
means O
that O
the O
loss O
of O
recessives O
must O
be O
calculated O
by O
using O
a O
hypergeometric O
and O
not O
a O
binomial O
model O
as O
Fisher O
did O
. O

The O
incidence O
of O
second O
malignant O
neoplasms O
was O
lower O
( O
1 O
. O
3 O
%) O
in O
the O
group O
treated O
with O
5 O
- O
fluorouracil O
, O
doxorubicin O
, O
and O
cyclophosphamide O
than O
in O
the O
historical O
control O
group O
( O
4 O
. O
8 O
%). O

Ovulation O
was O
induced O
in O
8 O
( O
56 O
. O
7 O
%) O
patients O
who O
conceived O
. O

In O
previous O
work O
( O
E O
. O

The O
small O
size O
and O
placement O
of O
the O
mutagenesis O
marker O
( O
the O
supF I-GENE
suppressor I-GENE
tRNA I-GENE
gene I-GENE
from I-GENE
Escherichia I-GENE
coli I-GENE
) O
within O
the O
vector O
substantially O
reduced O
the O
frequency O
of O
spontaneous O
mutations O
normally O
observed O
after O
transfection O
of O
mammalian O
cells O
with O
plasmid O
DNA O
; O
hence O
, O
UV O
- O
induced O
mutations O
were O
easily O
identified O
above O
the O
spontaneous O
background O
. O

W O
. O

Tetrad O
analysis O
and O
mitotic O
recombination O
experiments O
localized O
the O
PEP4 I-GENE
gene I-GENE
proximal O
to O
GAL4 I-GENE
on O
chromosome O
XVI O
. O

Based O
on O
our O
observations O
, O
we O
propose O
a O
model O
whereby O
inactive O
precursor O
molecules O
produced O
from O
the O
PEP4 I-GENE
gene I-GENE
self O
- O
activate O
within O
the O
yeast O
vacuole O
and O
subsequently O
activate O
other O
vacuolar I-GENE
hydrolases I-GENE
. O

The O
poly O
( O
A O
) O
segment O
of O
the O
RNA O
was O
selectively O
cross O
- O
linked O
to O
the O
72 O
, O
000 O
- O
molecular O
- O
weight O
protein O
( O
72K O
protein O
). O

In O
vitro O
translation O
of O
RNA O
synthesized O
from O
the O
cloned O
cDNAs O
predicts O
that O
P0 I-GENE
transcripts I-GENE
are O
translated O
into O
a O
novel O
12 O
. O
5 O
- O
kilodalton O
protein O
corresponding O
to O
the O
first O
open O
reading O
frame O
. O

The O
N O
- O
terminal O
amino O
acid O
sequence O
of O
Mop I-GENE
has O
sequence O
homology O
with O
DNA O
binding O
proteins O
. O

Several O
new O
techniques O
are O
available O
for O
monitoring O
control O
of O
diabetes O
. O

Ciprofloxacin O
: O
an O
overview O
of O
adverse O
experiences O
. O

Possible O
pathogenetic O
mechanisms O
of O
hemopoietic O
changes O
in O
response O
to O
space O
flight O
effects O
are O
described O
. O

The O
rho I-GENE
genes I-GENE
comprise O
an O
evolutionarily O
conserved O
family O
with O
significant O
homology O
to O
the O
ras I-GENE
oncogene I-GENE
family I-GENE
. O

Also O
, O
component O
I O
significantly O
correlated O
with O
fasting O
insulin I-GENE
and O
VO2 O
max O
for O
both O
sexes O
and O
with O
basal O
metabolism O
and O
HDL I-GENE
- I-GENE
cholesterol I-GENE
for O
females O
and O
males O
, O
respectively O
. O

The O
glucose O
areas O
following O
the O
ingestion O
of O
the O
foods O
were O
: O
Study O
1 O
: O
glucose O
11 O
. O
7 O
, O
orange O
juice O
7 O
. O
3 O
, O
sucrose O
5 O
. O
2 O
, O
glucose O
+ O
fructose O
6 O
. O
3 O
, O
and O
fructose O
0 O
. O
7 O
mmol O
X O
h O
/ O
l O
; O
Study O
2 O
: O
glucose O
14 O
. O
6 O
, O
orange O
juice O
7 O
. O
3 O
, O
apples O
5 O
. O
5 O
, O
and O
apple O
juice O
4 O
. O
7 O
mmol O
X O
h O
/ O
l O
; O
Study O
3 O
: O
glucose O
12 O
. O
6 O
, O
ice O
cream O
8 O
. O
1 O
, O
milk O
3 O
. O
7 O
, O
and O
lactose O
4 O
. O
1 O
mmol O
X O
h O
/ O
l O
. O

The O
serum I-GENE
insulin I-GENE
response O
cannot O
. O

SCL O
prolonged O
promptly O
after O
verapamil O
, O
and O
sinus O
arrest O
developed O
in O
two O
of O
10 O
group O
2 O
and O
two O
of O
five O
group O
3 O
animals O
. O

Development O
of O
a O
yeast O
system O
to O
assay O
mutational O
specificity O
. O

Postglucose O
serum I-GENE
insulin I-GENE
levels O
showed O
no O
significant O
correlations O
with O
systolic O
or O
diastolic O
blood O
pressure O
levels O
in O
men O
, O
but O
in O
female O
diabetic O
and O
non O
- O
diabetic O
subjects O
significant O
correlations O
were O
found O
in O
particular O
with O
systolic O
blood O
pressure O
level O
. O

We O
used O
oligonucleotide O
- O
directed O
mutagenesis O
to O
alter O
a O
site O
in O
MucA I-GENE
homologous O
to O
the O
Ala O
- O
Gly O
cleavage O
site O
of O
LexA I-GENE
. O

The O
latter O
was O
determined O
as O
follows O
: O
Type O
I O
- O
solid O
tumor O
tissue O
without O
significant O
peripheral O
isolated O
tumor O
cells O
; O
Type O
II O
- O
solid O
tumor O
tissue O
associated O
with O
peripheral O
isolated O
tumor O
cells O
; O
Type O
III O
- O
isolated O
tumor O
cells O
only O
. O

The O
pharmacology O
of O
carnitine O
. O

Acute O
inhalation O
toxicity O
of O
T O
- O
2 O
mycotoxin O
in O
mice O
. O

The O
present O
investigation O
sought O
to O
identify O
the O
principal O
dimensions O
of O
the O
Framingham O
Type O
A O
scale O
( O
FTAS O
) O
and O
then O
to O
examine O
their O
physiological O
and O
psychological O
correlates O
. O

A O
preliminary O
study O
on O
pyogenic O
arthritis O
. O

Legionella O
, O
microbial O
ecology O
, O
and O
inconspicuous O
consumption O
. O

Lymphatics O
in O
the O
aorta O
of O
rats O
treated O
with O
a O
soy O
- O
bean O
oil O
extract O
( O
lipofundin O
). O

As O
a O
last O
resort O
, O
it O
may O
be O
possible O
to O
maintain O
a O
patient O
on O
dialysis O
in O
reasonable O
health O
with O
a O
DiaTAP O
button O
graft O
complex O
infected O
with O
Staphylococcus O
epidermidis O
and O
intermittent O
positive O
blood O
cultures O
using O
long O
term O
vancomycin O
therapy O
. O

For O
signal O
durations O
less O
than O
10 O
ms O
, O
however O
, O
the O
SoNo O
and O
S O
pi O
No O
threshold O
functions O
converged O
and O
the O
masking O
- O
level O
difference O
decreased O
. O

The O
spleen O
rate O
of O
about O
600 O
villagers O
of O
RK O
I O
examined O
was O
54 O
. O
3 O
% O
and O
the O
parasite O
rate O
13 O
. O
2 O
% O
before O
the O
drug O
intervention O
. O

Multiple O
dosing O
four O
times O
daily O
for O
7 O
days O
of O
indoprofen O
200 O
mg O
, O
a O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
with O
a O
short O
half O
- O
life O
( O
t1 O
/ O
2 O
), O
revealed O
drug O
accumulation O
in O
eight O
elderly O
subjects O
. O

In O
10 O
patients O
with O
subacute O
cardiac O
tamponade O
, O
pulmonary O
wedge O
pressure O
( O
PWP O
), O
RAP O
, O
and O
IPP O
were O
measured O
along O
with O
indexes O
of O
systolic O
function O
. O

Encompassing O
tamponade O
and O
pericardiocentesis O
data O
, O
left O
ventricular O
stroke O
work O
index O
showed O
positive O
correlation O
with O
TMFP1 O
( O
r O
= O
. O
59 O
) O
and O
TMFP2 O
( O
r O
= O
. O
52 O
) O
but O
not O
with O
TMFP3 O
. O

Rabbits O
developed O
profound O
hypocalcemia O
, O
with O
levels O
falling O
from O
15 O
. O
5 O
+/- O
0 O
. O
2 O
to O
7 O
. O
6 O
+/- O
0 O
. O
4 O
mg O
/ O
dl O
under O
the O
influence O
of O
TSST I-GENE
- I-GENE
1 I-GENE
. O

Reward O
value O
of O
prosodic O
features O
of O
language O
for O
autistic O
, O
mentally O
retarded O
, O
and O
normal O
children O
. O

Similarly O
, O
actuarial O
interpretations O
for O
the O
second O
protocols O
were O
not O
more O
frequently O
selected O
by O
therapists O
as O
more O
valid O
, O
regardless O
of O
treatment O
condition O
and O
elevation O
of O
the O
F O
and O
F O
- O
K O
indices O
on O
the O
first O
MMPI O
profile O
. O

Due O
to O
its O
relatively O
soluble O
chemical O
form O
, O
90Sr O
was O
rapidly O
translocated O
from O
lung O
to O
bone O
where O
a O
substantial O
portion O
was O
retained O
for O
a O
long O
period O
of O
time O
. O

The O
study O
disclosed O
generalized O
atrophy O
and O
diffuse O
symmetric O
white O
matter O
hypodensities O
. O

The O
diagnosis O
of O
metachromatic O
leukodystrophy O
( O
MLD O
) O
was O
confirmed O
by O
the O
finding O
of O
low O
arylsulfatase I-GENE
A I-GENE
( O
ASA I-GENE
) O
levels O
in O
cultured O
fibroblasts O
in O
both O
sisters O
. O

Artificial O
ventilation O
was O
conducted O
using O
a O
tidal O
volume O
of O
10 O
ml O
X O
kg O
- O
1 O
and O
a O
rate O
of O
10 O
to O
12 O
c O
X O
min O
- O
1 O
. O

Significantly O
lower O
heart O
rate O
reactivity O
and O
significantly O
less O
pronounced O
left O
temporal O
artery O
pulse O
amplitude O
responses O
were O
found O
in O
non O
- O
medicated O
TH O
subjects O
than O
in O
controls O
. O

An O
epidemiological O
survey O
of O
rheumatic O
valve O
disease O
and O
rheumatic O
fever O
in O
primary O
and O
secondary O
school O
students O
in O
Jiangxi O
Province O

Drugs O
that O
are O
transformed O
via O
phase O
II O
reactions O
usually O
do O
not O
require O
dosage O
adjustment O
. O

A O
study O
of O
human O
genes O
coding O
for O
U4 I-GENE
small I-GENE
nuclear I-GENE
RNA I-GENE
is O
presented O
. O

Using O
the O
balloon O
- O
gas O
procedure O
with O
a O
single O
gas O
injection O
, O
a O
bubble O
was O
obtained O
that O
was O
large O
enough O
to O
tamponade O
a O
giant O
tear O
without O
prior O
drainage O
of O
subretinal O
fluid O
or O
vitrectomy O
. O

Heat O
- O
labile O
- O
like O
enterotoxin O
( O
LT I-GENE
) O
was O
produced O
by O
26 O
of O
42 O
stool O
isolates O
( O
62 O
%), O
while O
only O
1 O
of O
the O
42 O
isolates O
( O
2 O
%) O
produced O
enterotoxinlike O
activity O
in O
suckling O
mice O
; O
65 O
% O
of O
the O
cytotoxin O
- O
producing O
strains O
also O
produced O
an O
LT I-GENE
- I-GENE
like I-GENE
material O
. O

Development O
of O
a O
provisional O
information O
- O
retrieval O
descriptor O
language O
for O
" O
Roentgenology O
and O
Medical O
Radiology O
" O
for O
use O
in O
the O
Medinform O
system O

Persistent O
acantholytic O
dermatosis O
with O
increased O
light O
sensitivity O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
disease O
activity O
and O
/ O
or O
efficacy O
of O
calcium O
antagonist O
treatment O
. O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
disease O
activity O
and O
/ O
or O
efficacy O
of O
calcium O
antagonist O
treatment O
. O

Dorsal O
foot O
TcpO2 O
was O
measured O
by O
using O
oxygen O
- O
sensing O
electrodes O
with O
surface O
temperatures O
of O
42 O
degrees O
C O
and O
45 O
degrees O
C O
; O
in O
theory O
, O
changes O
in O
sympathetic O
activity O
should O
affect O
vasomotor O
tone O
and O
TcpO2 O
in O
skin O
beneath O
an O
electrode O
at O
42 O
degrees O
C O
( O
submaximal O
vasodilation O
), O
but O
not O
at O
45 O
degrees O
C O
( O
maximal O
vasodilation O
). O

In O
subjects O
( O
n O
= O
5 O
) O
with O
quadriplegia O
and O
reduced O
sympathetic O
tone O
secondary O
to O
cervical O
cord O
trauma O
, O
TcpO2 O
at O
42 O
degrees O
C O
and O
vasodilation O
index O
were O
increased O
( O
45 O
. O
0 O
mmHg O
and O
0 O
. O
61 O
); O
TcpO2 O
at O
45 O
degrees O
C O
did O
not O
change O
. O

The O
nucleotide O
sequences O
of O
the O
human I-GENE
and I-GENE
murine I-GENE
ornithine I-GENE
decarboxylase I-GENE
mRNAs I-GENE
share O
an O
85 O
% O
homology O
, O
even O
in O
their O
3 O
'- O
noncoding O
regions O
. O

The O
absolute O
concentrations O
of O
alpha I-GENE
2 I-GENE
- I-GENE
plasmin I-GENE
inhibitor O
, O
alpha I-GENE
2 I-GENE
- I-GENE
macroglobulin I-GENE
, O
and O
antithrombin I-GENE
III I-GENE
increased O
with O
exercise O
( O
all O
P O
less O
than O
0 O
. O
005 O
), O
but O
when O
concentrations O
were O
corrected O
for O
acute O
shifts O
of O
plasma O
water O
during O
exercise O
, O
the O
quantity O
of O
these O
inhibitors O
actually O
decreased O
( O
all O
P O
less O
than O
0 O
. O
005 O
). O

The O
other O
model O
was O
a O
continuous O
exponential O
plus O
constant O
of O
the O
form O
La O
- O
= O
a O
+ O
b O
[ O
exp O
( O
cVO2 O
)]. O

Cell O
. O

Timing O
of O
symptoms O
and O
oocyst O
excretion O
in O
human O
cryptosporidiosis O
. O

After O
dopamine O
infusion O
in O
women O
with O
polycystic O
ovary O
syndrome O
and O
in O
matched O
controls O
, O
steady O
state O
levels O
of O
plasma O
dopamine O
, O
norepinephrine O
, O
and O
the O
ratio O
of O
dopamine O
/ O
norepinephrine O
were O
similar O
in O
the O
two O
groups O
. O

Diagnostic O
importance O
of O
determining O
the O
complement O
constituents O
in O
children O
with O
autoimmune O
thyroiditis O

In O
the O
normal O
, O
basal O
( O
unstimulated O
) O
condition O
there O
were O
no O
significant O
correlations O
( O
p O
greater O
than O
0 O
. O
05 O
) O
between O
the O
systolic O
blood O
pressure O
and O
dopamine O
( O
r O
= O
0 O
. O
09 O
), O
norepinephrine O
( O
r O
= O
0 O
. O
26 O
), O
or O
epinephrine O
( O
r O
= O
0 O
. O
27 O
), O
nor O
were O
there O
significant O
correlations O
between O
melatonin O
and O
dopamine O
( O
r O
= O
- O
0 O
. O
01 O
), O
norepinephrine O
( O
r O
= O
- O
0 O
. O
26 O
), O
or O
growth I-GENE
hormone I-GENE
( O
r O
= O
0 O
. O
17 O
). O

The O
4 O
patients O
with O
carboxyhemoglobin I-GENE
levels O
in O
excess O
of O
10 O
% O
may O
represent O
occult O
carbon O
monoxide O
poisoning O
in O
this O
population O
. O

All O
these O
processes O
were O
fully O
developed O
during O
the O
last O
month O
of O
pregnancy O
, O
offering O
the O
same O
picture O
as O
the O
controls O
. O

Hypoglycemic O
action O
of O
" O
he O
xiang O
zhuang O
qi O
gong O
" O
and O
its O
mechanism O
on O
diabetes O
mellitus O

In O
cases O
of O
1 O
degrees O
HPT O
, O
the O
plasma O
1 O
, O
25 O
-( O
OH O
) O
2D O
level O
rose O
significantly O
in O
all O
cases O
( O
P O
less O
than O
0 O
. O
05 O
), O
although O
the O
pattern O
of O
the O
increase O
was O
not O
uniform O
. O

This O
region O
of O
60 O
amino O
acids O
may O
be O
involved O
in O
coiled O
- O
coil O
interactions O
similar O
to O
those O
that O
facilitate O
the O
filament O
formation O
in O
the O
rod O
region O
. O

This O
approach O
enables O
the O
sources O
of O
error O
in O
the O
calculation O
of O
nutrient O
utilization O
to O
be O
readily O
identified O
, O
and O
their O
effect O
on O
precision O
to O
be O
assessed O
in O
different O
nutritional O
and O
metabolic O
states O
. O

The O
effect O
of O
dietary O
zinc O
deficiency O
on O
the O
mossy O
fiber O
zinc O
content O
of O
the O
rat O
hippocampus O
. O

Weaned O
rats O
were O
fed O
a O
normal O
diet O
or O
a O
low O
- O
protein O
, O
low O
- O
energy O
diet O
, O
and O
injected O
with O
saline O
or O
thyroxine O
( O
5 O
micrograms O
/ O
100 O
g O
BW O
) O
for O
22 O
days O
. O

It O
is O
largely O
predicted O
by O
lupus O
anticoagulant O
( O
estimated O
by O
activated O
partial O
thromboplastin I-GENE
time O
) O
and O
/ O
or O
antibody O
to O
cardiolipin O
. O

The O
effects O
of O
several O
opioid O
agonists O
and O
the O
opioid O
antagonist O
naloxone O
were O
examined O
in O
rats O
responding O
under O
a O
fixed O
- O
consecutive O
- O
number O
( O
FCN O
) O
schedule O
. O

The O
rate O
- O
decreasing O
effects O
of O
morphine O
and O
U50488 O
were O
reversed O
completely O
by O
a O
0 O
. O
01 O
and O
1 O
. O
0 O
mg O
/ O
kg O
dose O
of O
naloxone O
, O
respectively O
. O

Data O
from O
119 O
men O
and O
40 O
women O
undergoing O
coronary O
angiography O
provide O
an O
opportunity O
to O
compare O
these O
associations O
in O
relation O
to O
a O
direct O
and O
continuous O
measure O
of O
atherosclerosis O
while O
controlling O
for O
age O
, O
sex O
, O
income O
, O
hypertension O
, O
serum O
cholesterol O
, O
smoking O
, O
angina O
, O
diabetes O
, O
family O
history O
of O
heart O
disease O
, O
Type O
A O
behavior O
pattern O
, O
and O
hostility O
. O

An O
intralobar O
change O
in O
temperature O
above O
or O
below O
36 O
degrees O
C O
decreases O
only O
the O
lobar O
bronchial O
blood O
flow O
and O
does O
not O
influence O
blood O
flow O
to O
other O
nearby O
tissues O
including O
those O
vascularized O
by O
the O
bronchial O
circulation O
. O

Convulsive O
status O
epilepticus O
after O
infusion O
of O
cisplatin O

The O
presence O
in O
such O
patients O
of O
antibodies O
to O
adrenaline O
and O
noradrenaline O
is O
indicative O
of O
considerable O
disruption O
of O
catecholamine O
biotransformation O
. O

The O
following O
markers O
were O
looked O
for O
in O
the O
serum O
, O
skin O
and O
liver O
of O
all O
patients O
with O
chronic O
hepatitis O
: O
HBV O
( O
HBs I-GENE
Ag I-GENE
and O
HBe I-GENE
Ag I-GENE
, O
anti I-GENE
- I-GENE
HBs I-GENE
, O
anti I-GENE
- I-GENE
HBe I-GENE
and O
anti I-GENE
- I-GENE
HBc I-GENE
in O
the O
serum O
, O
HBs I-GENE
and I-GENE
HBc I-GENE
Ag I-GENE
in O
the O
liver O
); O
non I-GENE
- I-GENE
A I-GENE
non I-GENE
- I-GENE
B I-GENE
( O
non I-GENE
- I-GENE
A I-GENE
, I-GENE
non I-GENE
- I-GENE
B I-GENE
Ag I-GENE
and I-GENE
antibody I-GENE
, O
anti I-GENE
non I-GENE
- I-GENE
A I-GENE
non I-GENE
- I-GENE
Bc I-GENE
in O
the O
serum O
, O
non I-GENE
- I-GENE
A I-GENE
, I-GENE
non I-GENE
- I-GENE
Bc I-GENE
Ag I-GENE
in O
the O
liver O
). O

Groups O
of O
male O
and O
female O
Fischer O
344 O
rats O
, O
B6C3F1 O
mice O
, O
and O
Hartley O
guinea O
pigs O
were O
exposed O
once O
for O
6 O
hr O
to O
mean O
concentrations O
of O
10 O
. O
5 O
, O
5 O
. O
4 O
, O
2 O
. O
4 O
, O
1 O
. O
0 O
, O
or O
0 O
( O
control O
) O
ppm O
of O
methyl O
isocyanate O
( O
MIC O
) O
vapor O
. O

Radionuclide O
study O
and O
endomyocardial O
biopsy O
revealed O
remarkable O
degeneration O
of O
myocardium O
. O

Immobilization O
of O
the O
fracture O
in O
a O
collar O
and O
cuff O
sling O
was O
as O
effective O
as O
more O
elaborate O
methods O
. O

Comparison O
of O
patients O
receiving O
phenytoin O
and O
those O
who O
were O
not O
showed O
significantly O
lower O
serum O
folate O
in O
the O
sub O
- O
group O
receiving O
phenytoin O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
sub O
- O
groups O
with O
respect O
to O
vitamin O
B12 O
or O
behaviour O
problem O
rating O
. O

Effects O
of O
a O
low O
- O
energy O
laser O
beam O
on O
the O
cells O
of O
the O
newt O
embryo O

Typical O
and O
atypical O
clinical O
features O
of O
this O
lacrimal O
sac O
cyst O
are O
emphasized O
. O

The O
role O
of O
saliva O
in O
sour O
taste O
perception O
was O
investigated O
in O
a O
series O
of O
4 O
experiments O
. O

Samples O
from O
1415 O
neurological O
patients O
were O
used O
to O
study O
the O
diagnostic O
value O
of O
acid I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
glycoprotein I-GENE
in O
the O
lumbar O
cerebrospinal O
fluid O
. O

Separate O
experiments O
measured O
AIB O
and O
86RbCl O
uptake O
in O
36B O
- O
10 O
cells O
in O
vitro O
1 O
and O
2 O
days O
following O
20 O
Gy O
irradiation O
to O
assess O
whether O
this O
radiation O
dose O
reduced O
the O
capacity O
of O
tumor O
cells O
to O
trap O
AIB O
or O
Rb O
+. O

For O
patients O
with O
recurrent O
or O
metastatic O
disease O
, O
the O
data O
suggest O
that O
I O
- O
131 O
MIBG O
scintigraphy O
is O
the O
examination O
of O
choice O
. O

W O
. O

Comparison O
of O
the O
amino O
acid O
sequence O
of O
the O
M I-GENE
RNA I-GENE
product I-GENE
of I-GENE
Uukuniemi I-GENE
virus I-GENE
with O
that O
of O
Punta O
Toro O
and O
Rift O
Valley O
fever O
viruses O
showed O
in O
both O
cases O
a O
weak O
homology O
that O
was O
more O
pronounced O
for O
the O
proteins O
located O
at O
the O
COOH O
- O
terminal O
end O
of O
the O
precursor O
. O

Cyclosporine O
treatment O
for O
intractable O
polymyositis O
. O

In O
addition O
, O
on O
the O
Cohler O
' O
s O
maternal O
scale O
, O
Korean O
mothers O
were O
found O
to O
view O
their O
infants O
as O
more O
passive O
and O
dependent O
than O
American O
mothers O
did O
( O
P O
less O
than O
0 O
. O
00 O
). O

A O
preoperative O
teaching O
booklet O
for O
pediatric O
patients O
. O

Hyperthyroidism O

We O
conclude O
that O
for O
mono O
- O
intronic O
precursors O
in O
which O
there O
is O
only O
one O
choice O
of O
splice O
sites O
, O
most O
of O
the O
exon O
sequences O
are O
not O
mechanistically O
involved O
in O
the O
splicing O
process O
. O

UVA O
- O
induced O
melanocytic O
lesions O
. O

Ex O
vivo O
MAO I-GENE
inhibition O
data O
indicated O
DPGPEA O
to O
be O
an O
inhibitor O
of O
MAO I-GENE
- I-GENE
B I-GENE
, O
although O
the O
effect O
was O
much O
weaker O
than O
seen O
with O
tranylcypromine O
or O
pargyline O
. O

Thus O
in O
this O
region O
of O
the O
vessel O
pyridinoline O
represents O
the O
major O
stabilising O
crosslink O
of O
collagen I-GENE
. O

A O
careful O
, O
radiolabelled O
tissue O
- O
distribution O
study O
is O
warranted O
to O
elucidate O
the O
complicated O
metabolic O
fate O
of O
perhexiline O
. O

Systemic O
lupus O
erythematosus O
was O
diagnosed O
. O

In O
the O
evening O
, O
the O
amplitude O
of O
the O
responses O
to O
both O
O2 O
and O
CO2 O
increased O
but O
the O
increase O
in O
CO2 O
sensitivity O
was O
proportionally O
more O
important O
. O

The O
statistical O
significance O
of O
the O
prognosis O
factors O
was O
studied O
by O
uni O
- O
and O
multivariative O
methods O
, O
according O
to O
the O
model O
of O
Cox O
, O
with O
the O
help O
of O
an O
IMB O
computer O
. O

These O
changes O
at O
the O
site O
of O
injection O
consist O
of O
a O
focal O
abnormality O
characterized O
by O
a O
slight O
increase O
in O
signal O
intensity O
on O
T1 O
weighted O
images O
and O
markedly O
increased O
signal O
intensity O
on O
T2 O
weighted O
images O
. O

These O
results O
suggest O
that O
less O
antidopaminergic O
activity O
of O
RHAL O
in O
this O
neuroleptic O
test O
might O
be O
explained O
by O
the O
lesser O
conversion O
of O
RHAL O
to O
HAL O
. O

The O
purpose O
of O
this O
study O
is O
twofold O
: O
( O
1 O
) O
to O
present O
a O
parallel O
form O
of O
the O
Gudjonsson O
Suggestibility O
Scale O
( O
GSS O
, O
Form O
1 O
); O
( O
2 O
) O
to O
study O
test O
- O
retest O
reliabilities O
of O
interrogative O
suggestibility O
. O

Organisms O
were O
recovered O
from O
the O
conjunctiva O
for O
several O
weeks O
, O
and O
persistent O
genital O
and O
gastrointestinal O
infection O
also O
resulted O
from O
the O
ocular O
infection O
in O
some O
cats O
. O

In O
vivo O
epiluminescence O
microscopy O
of O
pigmented O
skin O
lesions O
. O

These O
equilibrium O
solutions O
are O
then O
shown O
to O
arise O
from O
the O
vertices O
of O
a O
particular O
convex O
polyhedron O
. O

The O
average O
deviations O
in O
the O
X O
- O
ray O
counts O
of O
the O
constant O
elements O
from O
the O
series O
means O
were O
used O
to O
correct O
the O
recorded O
count O
of O
the O
variable O
element O
in O
each O
block O
. O

Statistically O
significant O
effects O
were O
noted O
at O
doses O
which O
did O
not O
appear O
to O
be O
maternally O
toxic O
. O

Low O
MAO I-GENE
subjects O
showed O
a O
pattern O
of O
higher O
scores O
in O
KSP O
Impulsiveness O
, O
EPQ O
Neuroticism O
, O
and O
KSP O
Somatic O
Anxiety O
and O
Irritability O
and O
lower O
scores O
in O
KSP O
Socialization O
, O
in O
line O
with O
personality O
profiles O
found O
in O
alcoholics O
, O
psychopaths O
, O
and O
suicide O
attempters O
who O
also O
tend O
to O
have O
low O
platelet O
MAO I-GENE
activity O
. O

To O
evaluate O
the O
relative O
accuracy O
of O
continuous O
wave O
( O
CW O
) O
and O
high O
pulse O
repetition O
frequency O
( O
HPRF O
) O
Doppler O
for O
estimating O
aortic O
transvalvular O
pressure O
gradients O
, O
Doppler O
examinations O
with O
both O
devices O
were O
obtained O
in O
87 O
consecutive O
patients O
with O
aortic O
valve O
disease O
. O

In O
group O
I O
, O
Paw O
, O
delta O
V O
, O
PaO2 O
, O
Vinj O
and O
VT O
significantly O
decreased O
whereas O
operating O
pressure O
and O
E O
significantly O
increased O
when O
the O
internal O
diameter O
of O
the O
injector O
cannula O
was O
reduced O
. O

In O
calves O
receiving O
milk O
- O
substitute O
diets O
containing O
80 O
- O
260 O
g O
DM O
/ O
kg O
, O
milk O
intakes O
were O
reduced O
by O
up O
to O
30 O
% O
on O
the O
1st O
day O
that O
calves O
were O
fed O
once O
daily O
instead O
of O
twice O
daily O
. O

Today O
there O
is O
no O
doubt O
that O
elevated O
plasma O
cholesterol O
levels O
should O
be O
lowered O
first O
by O
dietary O
modification O
even O
in O
early O
childhood O
, O
beginning O
at O
the O
age O
of O
two O
years O
. O

The O
number O
of O
fecal O
pellets O
ingested O
peaked O
at O
5 O
to O
6 O
weeks O
old O
( O
13 O
pellets O
/ O
day O
) O
and O
gradually O
decreased O
, O
thereafter O
( O
2 O
. O
1 O
pellets O
at O
78 O
weeks O
old O
, O
1 O
. O
5 O
pellets O
at O
104 O
weeks O
old O
). O

These O
results O
suggest O
that O
N O
- O
nitroso O
compounds O
can O
be O
formed O
in O
vivo O
in O
the O
infected O
bladder O
, O
which O
could O
explain O
the O
association O
between O
urinary O
- O
tract O
infections O
and O
increased O
risk O
for O
bladder O
cancer O
. O

Epithelial O
nerve O
fiber O
defects O
included O
absence O
or O
distorted O
architecture O
of O
the O
basal O
epithelial O
plexus O
and O
intra O
- O
epithelial O
terminals O
. O

The O
histologic O
grade O
for O
the O
same O
anatomic O
site O
varied O
among O
hearts O
and O
among O
different O
anatomic O
sites O
in O
the O
same O
heart O
. O

Serum O
levels O
of O
albumin I-GENE
, O
globulin I-GENE
, O
and O
coagulation I-GENE
protein I-GENE
activity O
were O
measured O
preshock O
, O
postshock O
, O
and O
daily O
for O
3 O
days O
; O
skin O
lymph O
levels O
were O
measured O
on O
Day O
3 O
. O

For O
colostral O
milk O
there O
was O
a O
significant O
correlation O
of O
vitamin O
K1 O
to O
cholesterol O
( O
r O
= O
0 O
. O
62 O
) O
but O
not O
to O
total O
lipid O
or O
phospholipid O
suggesting O
a O
role O
for O
cholesterol O
in O
the O
secretion O
of O
vitamin O
K1 O
into O
colostral O
milk O
. O

Endurance O
training O
resulted O
in O
an O
increase O
of O
stiffness O
associated O
with O
a O
decrease O
of O
type O
II O
fibers O
. O

A O
rate O
- O
decreasing O
dose O
of O
physostigmine O
, O
an O
acetylcholinesterase I-GENE
inhibitor O
, O
was O
studied O
in O
combination O
with O
the O
range O
of O
atropine O
doses O
. O

References O
for O
occupational O
fitness O
of O
adolescents O
with O
diseases O
of O
the O
respiratory O
tract O
and O
lungs O

Salzburg O
, O
9 O
- O
12 O
September O
1987 O
. O

Two O
new O
glucosidase I-GENE
inhibitors O
( O
BAY O
m O
1099 O
and O
BAY O
o O
1248 O
) O
were O
studied O
in O
volunteers O
and O
type O
II O
diabetics O
under O
various O
conditions O
. O

The O
models O
accurately O
localized O
the O
common O
boundaries O
between O
the O
PBB O
and O
CN O
. O

Two O
of O
these O
six O
cases O
showed O
mucosal O
spread O
without O
stromal O
invasion O
( O
type O
A O
); O
the O
remaining O
four O
cases O
presented O
a O
direct O
extension O
( O
type O
B O
) O
from O
muscle O
- O
invasive O
carcinomas O
of O
the O
bladder O
. O

However O
, O
conversions O
of O
12 O
mm O
or O
more O
from O
a O
documented O
negative O
result O
indicated O
spread O
of O
infection O
. O

The O
maximum O
amplitude O
of O
evoked O
responses O
in O
the O
cervical O
sympathetic O
trunk O
was O
obtained O
when O
the O
T2 O
white O
ramus O
was O
stimulated O
and O
decreased O
gradually O
when O
followed O
by O
the O
stimulation O
of O
T1 O
, O
T3 O
, O
T4 O
and O
T5 O
white O
rami O
. O

It O
is O
concluded O
that O
contact O
allergy O
to O
K O
- O
CG O
is O
common O
. O

The O
effect O
of O
a O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
pindolol O
, O
on O
uterine O
smooth O
muscle O
in O
term O
pregnant O
women O
was O
studied O
in O
vitro O
and O
in O
vivo O
( O
in O
hypertensive O
women O
). O

The O
less O
- O
polar O
mycolic O
acid O
- O
containing O
Rhodococcus O
species O
showed O
chromatographic O
patterns O
that O
partially O
overlapped O
( O
in O
elution O
times O
) O
the O
patterns O
of O
Nocardia O
asteroides O
, O
N O
. O
otitidiscaviarum O
, O
and O
N O
. O
brasiliensis O
, O
but O
the O
larger O
number O
of O
peaks O
in O
the O
last O
species O
made O
separation O
between O
the O
genera O
possible O
. O

The O
development O
of O
a O
data O
base O
is O
described O
which O
can O
be O
used O
as O
common O
reference O
for O
ECG O
computer O
programs O
analyzing O
12 O
or O
15 O
simultaneously O
recorded O
leads O
. O

Blood I-GENE
serum I-GENE
erythropoietin I-GENE
level O
and O
basic O
hematological O
indices O
during O
the O
adaptation O
of O
healthy O
newborn O
infants O

49 O
, O
XXXXY O
chromosome O
anomaly O
: O
an O
unusual O
variant O
of O
Klinefelter O
' O
s O
syndrome O
. O

Contraction O
of O
the O
tracheal O
muscle O
and O
the O
activity O
of O
stretch O
receptors O
in O
the O
trachea O

The O
selenium O
level O
and O
glutathione I-GENE
peroxidase I-GENE
activity O
in O
the O
blood O
, O
liver O
, O
and O
stomach O
mucosa O
were O
significantly O
higher O
in O
the O
high O
- O
selenium O
diet O
group O
than O
in O
the O
low O
- O
selenium O
diet O
group O
. O

Oxygen O
delivery O
and O
consumption O
and O
P50 O
in O
patients O
with O
acute O
myocardial O
infarction O
. O

Infants O
of O
this O
sample O
had O
monocular O
PL O
visual O
acuities O
similar O
to O
those O
established O
by O
McDonald O
et O
al O
. O
in O
a O
laboratory O
setting O
. O

These O
results O
indicate O
that O
the O
effect O
of O
the O
isomers O
of O
pentobarbital O
and O
secobarbital O
on O
mult O
FR30 O
FI600 O
responding O
and O
on O
suppressed O
responding O
are O
qualitatively O
similar O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
number O
of O
crystalline O
deposits O
is O
less O
in O
the O
advanced O
atrophic O
areas O
of O
the O
RPE O
- O
choriocapillaris O
complex O
. O

All O
33 O
subjects O
were O
given O
psychometric O
instruments O
for O
measuring O
various O
components O
of O
anger O
and O
anxiety O
: O
Spielberger O
' O
s O
State O
- O
Trait O
Personality O
Inventory O
, O
the O
Anger O
Expression O
Scale O
, O
and O
the O
State O
Anger O
Reaction O
Scale O
. O

It O
was O
found O
that O
the O
primary O
visual O
cortex O
of O
the O
rat O
is O
asymmetrical O
in O
volume O
, O
and O
that O
the O
asymmetry O
reflects O
side O
differences O
in O
the O
number O
of O
neurons O
. O

The O
subjects O
received O
a O
single O
500 O
mg O
dose O
of O
acetaminophen O
i O
. O
v O
. O
and O
concentrations O
in O
plasma O
were O
measured O
for O
360 O
minutes O
and O
in O
urine O
for O
24 O
h O
in O
order O
to O
estimate O
the O
production O
of O
metabolites O
. O

Mean O
weighted O
skin O
temperature O
( O
Tsk O
) O
was O
lower O
( O
P O
less O
than O
0 O
. O
01 O
) O
following O
acclimation O
than O
before O
, O
and O
acclimation O
resulted O
in O
a O
larger O
( O
P O
less O
than O
0 O
. O
02 O
) O
Tre O
- O
to O
- O
Tsk O
gradient O
. O

Indium O
- O
111 O
leukocyte O
imaging O
in O
patients O
with O
rheumatoid O
arthritis O
. O

The O
effect O
of O
L O
- O
methionine O
supplementation O
on O
the O
utilization O
of O
a O
soy O
protein O
isolate O
( O
SPI O
) O
was O
evaluated O
by O
short O
- O
term O
nitrogen O
balance O
studies O
in O
young O
women O
. O

Primary O
invasive O
Haemophilus O
influenzae O
type O
b O
disease O
: O
a O
population O
- O
based O
assessment O
of O
risk O
factors O
. O

Overall O
, O
lesions O
infiltrating O
the O
deep O
lamina O
propria O
do O
not O
exhibit O
a O
reduced O
frequency O
of O
occurrence O
compared O
to O
lesions O
infiltrating O
the O
skeletal O
muscle O
; O
however O
, O
carcinomas O
affecting O
other O
oral O
sites O
showed O
a O
reduced O
frequency O
of O
deeply O
infiltrating O
lesions O
in O
comparison O
to O
more O
superficial O
lesions O
. O

Factors O
that O
showed O
significant O
correlation O
to O
elevated O
CIC O
' O
s O
in O
the O
highly O
elevated O
portion O
of O
our O
CIC O
population O
were O
poor O
NIH O
score O
, O
increased O
patient O
age O
, O
low O
peak O
expiratory O
flow O
rate O
, O
and O
elevated O
total O
serum I-GENE
IgG I-GENE
. O

Induction O
of O
both O
potential O
transcripts O
follows O
heat O
shock O
in O
vivo O
. O

New O
and O
successful O
steps O
have O
been O
made O
in O
immunodiagnostics O
, O
immunotherapy O
, O
and O
immunoprophylaxis O
of O
immunologically O
conditioned O
infertility O
. O

Amikacin O
was O
the O
most O
stable O
and O
tobramycin O
was O
the O
least O
stable O
aminoglycoside O
under O
the O
conditions O
tested O
. O

This O
may O
explain O
in O
part O
a O
secular O
trend O
towards O
reduced O
birthweight O
for O
gestation O
in O
preterm O
infants O
. O

Estimated O
nucleic O
acid O
N O
absorption O
is O
7 O
- O
8 O
% O
of O
N O
intake O
. O

Adhesion O
, O
phagocytosis O
, O
chemotactic O
and O
random O
migration O
, O
nitroblue O
tetrazolium O
dye O
reduction O
of O
peritoneal O
exudate O
neutrophils O
and O
macrophages O
, O
fibrinogen I-GENE
level O
, O
gelation O
of O
soluble O
fibrin I-GENE
and O
serial O
dilution O
protamine O
sulfate O
test O
were O
investigated O
in O
115 O
New O
Zealand O
white O
rabbits O
with O
experimentally O
induced O
Shwartzman O
phenomenon O
in O
the O
colon O
, O
and O
in O
control O
animals O
. O

Nickel O
is O
the O
most O
common O
cause O
of O
allergic O
contact O
dermatitis O
in O
Singapore O
, O
resulting O
in O
positive O
reactions O
in O
patch O
tests O
between O
7 O
and O
14 O
%. O

The O
FFA O
levels O
were O
not O
affected O
( O
P O
greater O
than O
. O
1 O
) O
by O
meal O
interval O
. O

He O
visited O
our O
hospital O
and O
left O
solitary O
renal O
cyst O
was O
suspected O
. O

However O
, O
further O
analyses O
of O
the O
data O
indicate O
that O
increasing O
VO2 O
AT O
( O
r O
= O
- O
0 O
. O
63 O
, O
P O
less O
than O
0 O
. O
05 O
) O
rather O
than O
VO2max O
( O
r O
= O
- O
0 O
. O
15 O
) O
could O
result O
in O
improving O
the O
10 O
, O
000 O
m O
race O
performance O
to O
a O
larger O
extent O
, O
and O
that O
the O
absolute O
amount O
of O
change O
( O
delta O
) O
in O
the O
10 O
, O
000 O
m O
run O
time O
is O
best O
accounted O
for O
by O
a O
combination O
of O
delta O
VO2 O
AT O
and O
delta O
5 O
, O
000 O
m O
run O
time O
. O

A O
significant O
herd O
X O
period O
interaction O
existed O
for O
liver O
TG O
and O
serum O
dextran O
precipitable O
cholesterol O
concentrations O
. O

Liver O
TG O
and O
serum O
NEFA O
concentrations O
were O
positively O
correlated O
. O

The O
results O
show O
that O
nerve O
and O
roots O
differ O
considerably O
both O
in O
the O
force O
they O
sustain O
before O
failure O
and O
in O
the O
other O
biomechanics O
they O
exhibit O
. O

When O
the O
coronary O
sinus O
pressure O
reached O
15 O
torr O
, O
there O
was O
a O
significant O
decrease O
in O
cardiac O
index O
( O
3 O
. O
60 O
+/- O
0 O
. O
5 O
to O
2 O
. O
70 O
+/- O
0 O
. O
6 O
L O
/ O
min O
/ O
m2 O
, O
p O
less O
than O
0 O
. O
001 O
), O
coronary O
blood O
flow O
( O
13 O
. O
7 O
+/- O
3 O
. O
1 O
to O
7 O
. O
0 O
+/- O
2 O
. O
1 O
ml O
/ O
min O
, O
p O
less O
than O
0 O
. O
001 O
), O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
1 O
, O
567 O
+/- O
275 O
to O
1 O
, O
331 O
+/- O
314 O
, O
p O
less O
than O
0 O
. O
05 O
), O
and O
an O
increase O
in O
coronary O
arteriovenous O
difference O
( O
62 O
. O
8 O
% O
+/- O
9 O
. O
3 O
% O
to O
70 O
. O
5 O
% O
+/- O
5 O
. O
4 O
% O
saturation O
, O
p O
less O
than O
0 O
. O
03 O
). O

Calcifications O
in O
the O
thoracic O
aorta O
at O
the O
level O
of O
the O
11th O
and O
the O
12th O
thoracic O
vertebrae O
in O
592 O
men O
and O
333 O
women O
were O
studied O
using O
computed O
tomography O
. O

In O
a O
series O
of O
402 O
consecutive O
autopsies O
, O
parietal O
pleural O
plaques O
( O
PP O
) O
were O
found O
in O
68 O
individuals O
above O
40 O
years O
of O
age O
. O

Approximately O
60 O
% O
of O
cell O
bodies O
of O
primary O
neurons O
innervating O
the O
intra O
and O
perioral O
structures O
through O
the O
inferior O
alveolar O
, O
lingual O
, O
mental O
, O
and O
buccal O
nerves O
were O
in O
the O
range O
between O
300 O
and O
600 O
micron O
2 O
in O
cross O
- O
sectional O
area O
: O
mean O
+/- O
SD O
509 O
+/- O
243 O
micron O
2 O
, O
420 O
+/- O
181 O
micron O
2 O
, O
469 O
+/- O
200 O
micron O
2 O
, O
and O
444 O
+/- O
186 O
micron O
2 O
, O
respectively O
. O

Pharmacological O
action O
of O
eptazocine O
( O
l O
- O
1 O
, O
4 O
- O
dimethyl O
- O
10 O
- O
hydroxy O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
- O
hexahydro O
- O
1 O
, O
6 O
- O
methano O
- O
1H O
- O
4 O
- O
benz O
azonine O
). O

On O
transition O
from O
high O
to O
low O
voltage O
there O
was O
a O
significant O
fall O
in O
arterial O
pressure O
( O
7 O
%) O
and O
an O
increase O
in O
flow O
( O
19 O
- O
38 O
%) O
to O
areas O
of O
the O
brain O
corresponding O
to O
the O
arborization O
of O
the O
reticular O
formation O
, O
i O
. O
e O
. O
excluding O
the O
cerebrum O
and O
cerebellum O
. O

Findings O
of O
positive O
potentials O
showed O
that O
N1 O
originated O
in O
the O
area O
of O
ventral O
gray O
matter O
through O
the O
ventro O
- O
lateral O
column O
and O
N2 O
through O
the O
dorsal O
column O
. O

One O
hundred O
and O
four O
( O
14 O
per O
cent O
) O
second O
primary O
tumours O
were O
reported O
. O

Failures O
of O
colorimetric O
additivity O
under O
these O
experimental O
conditions O
are O
discussed O
. O

There O
have O
been O
five O
problems O
( O
extravasation O
2 O
, O
suspected O
sepsis O
1 O
, O
and O
hematoma O
2 O
) O
during O
a O
total O
of O
2 O
, O
927 O
days O
of O
exposure O
. O

It O
is O
suggested O
that O
these O
results O
may O
raise O
the O
interesting O
possibility O
of O
providing O
a O
means O
of O
identifying O
greater O
or O
lesser O
susceptibility O
to O
the O
coronary O
effects O
of O
Type O
A O
behavior O
. O

Two O
studies O
assessed O
two O
types O
of O
reliability O
of O
the O
student O
Jenkins O
Activity O
Survey O
( O
JAS O
; O
a O
questionnaire O
measure O
of O
Type O
A O
behavior O
). O

Splenectomized O
patients O
are O
predisposed O
toward O
developing O
overwhelming O
bacterial O
infections O
. O

When O
phencyclidine O
was O
administered O
alone O
, O
overall O
response O
rate O
decreased O
and O
percent O
errors O
increased O
with O
increasing O
doses O
. O

Possibilities O
and O
outlook O
for O
wrist O
joint O
endoprosthesis O

Study O
of O
the O
energy O
metabolism O
of O
the O
sensomotor O
cortex O
and O
hippocampus O
by O
the O
( O
14C O
) O
2 O
- O
deoxyglucose O
method O
during O
the O
development O
of O
dissociated O
states O

Malignant O
lymphoma O
is O
very O
heterogeneous O
in O
terms O
of O
its O
biological O
behavior O
. O

Further O
investigations O
are O
necessary O
to O
elucidate O
the O
biochemical O
and O
physiological O
properties O
of O
DLIS O
. O

Among O
them O
, O
26 O
cases O
were O
benign O
and O
34 O
malignant O
. O

Of O
the O
cases O
with O
PLD O
, O
50 O
% O
had O
associated O
renal O
cysts O
and O
10 O
% O
of O
the O
cases O
with O
APCD O
had O
associated O
liver O
cysts O
. O

Fast O
goal O
- O
directed O
voluntary O
movements O
of O
the O
human O
upper O
extremity O
are O
known O
to O
be O
associated O
with O
three O
distinct O
bursts O
of O
EMG O
activity O
in O
antagonistic O
muscles O
. O

The O
combination O
of O
F1 O
and O
F2 O
which O
was O
the O
best O
predictor O
of O
CHD O
in O
this O
population O
( O
G1 O
) O
might O
be O
interpreted O
as O
reflecting O
trunk O
adiposity O
mainly O
abdominal O
. O

Renal O
clearance O
fell O
from O
19 O
. O
0 O
+/- O
4 O
. O
9 O
ml O
/ O
min O
/ O
1 O
. O
73 O
m2 O
( O
group O
I O
) O
to O
1 O
. O
0 O
+/- O
0 O
. O
4 O
ml O
/ O
min O
/ O
1 O
. O
73 O
m2 O
( O
group O
IV O
). O

The O
relations O
between O
type O
A O
behavior O
, O
clinically O
relevant O
behavior O
, O
academic O
achievement O
, O
and O
IQ O
in O
children O
. O

The O
rats O
were O
used O
for O
the O
study O
of O
the O
effects O
of O
sepsis O
on O
the O
utilization O
of O
exogenous O
fat O
emulsion O
. O

She O
also O
had O
slight O
weakness O
of O
the O
upper O
extremities O
. O

Results O
of O
electron O
therapy O
of O
tumors O
in O
different O
sites O

The O
mechanism O
of O
action O
is O
explored O
in O
some O
detail O
, O
specifically O
as O
it O
relates O
to O
reticuloendothelial O
system O
( O
RES O
) O
Fc I-GENE
receptor I-GENE
blockade O
and O
suppression O
of O
antiplatelet O
antibody O
synthesis O
. O

Incidences O
of O
nonfatal O
stroke O
, O
myocardial O
infarction O
, O
angina O
pectoris O
und O
left O
ventricular O
hypertrophy O
could O
also O
be O
lowered O
. O

High O
radial O
r O
values O
with O
small O
standard O
deviations O
were O
observed O
in O
normal O
LV O
( O
0 O
. O
972 O
+/- O
0 O
. O
016 O
) O
and O
in O
non O
- O
MI O
regions O
( O
0 O
. O
964 O
+/- O
0 O
. O
018 O
), O
indicating O
temporally O
homogeneous O
radial O
shortening O
. O

These O
results O
indicate O
that O
during O
pregnancy O
there O
are O
increases O
in O
bone O
formation O
rates O
contributing O
to O
the O
increases O
in O
skeletal O
mass O
. O

We O
analyzed O
data O
from O
56 O
patients O
with O
Systemic O
Lupus O
Erythematosus O
( O
SLE O
) O
in O
whom O
renal O
biopsies O
were O
done O
systematically O
. O

The O
possibility O
of O
a O
hereditary O
disorder O
leading O
to O
a O
minor O
defect O
in O
elastic O
fibre O
structure O
which O
could O
be O
responsible O
for O
the O
spontaneous O
lesions O
is O
discussed O
. O

Prevention O
by O
a O
heparin O
- O
antithrombin I-GENE
III I-GENE
combination O

N O
- O
Substituted O
trimethylsilylcarbamates O
were O
tested O
as O
derivatizing O
reagents O
for O
gas O
chromatographic O
analysis O
. O

MICs O
of O
four O
antifungal O
agents O
( O
5 O
- O
fluorocytosine O
, O
miconazole O
, O
ketoconazole O
, O
and O
amphotericin O
B O
) O
for O
84 O
clinical O
isolates O
of O
various O
Candida O
species O
were O
then O
determined O
with O
both O
media O
in O
agar O
dilution O
and O
microtiter O
broth O
dilution O
systems O
. O

There O
were O
18 O
patients O
with O
Group O
II O
( O
a O
) O
tumors O
; O
although O
tumor O
biopsy O
was O
attempted O
on O
eight O
of O
these O
, O
pathological O
diagnosis O
at O
the O
time O
of O
surgery O
was O
made O
in O
only O
one O
case O
. O

Evidence O
that O
opiate O
addiction O
is O
in O
part O
an O
immune O
response O
. O

Parasitological O
post O
- O
mortem O
examination O
of O
all O
seropositive O
animals O
showed O
five O
and O
seven O
false O
- O
positive O
animals O
when O
E I-GENE
/ I-GENE
S I-GENE
and I-GENE
CWE I-GENE
antigens I-GENE
were O
used O
, O
respectively O
. O

Glucocorticoid O
induced O
hypertension O
has O
been O
regarded O
as O
independent O
of O
sodium O
( O
Na O
), O
in O
contrast O
to O
mineralocorticoid O
induced O
hypertension O
, O
which O
is O
Na O
+- O
dependent O
. O

Seventeen O
of O
them O
were O
on O
treatment O
with O
systemic O
steroids O
. O

Examples O
of O
its O
use O
in O
the O
intensive O
therapy O
unit O
are O
described O
. O

The O
growing O
drug O
problem O
is O
also O
reflected O
in O
the O
increasing O
number O
of O
cases O
of O
hepatitis O
B O
and O
of O
drug O
- O
related O
deaths O
. O

Only O
seven O
patients O
, O
five O
of O
whom O
have O
metastatic O
disease O
, O
survive O
more O
than O
10 O
years O
after O
first O
presentation O
; O
nine O
patients O
, O
one O
of O
whom O
has O
secondaries O
, O
survive O
for O
5 O
years O
or O
less O
. O

Although O
differences O
were O
not O
significant O
, O
infants O
in O
the O
experimental O
group O
had O
more O
changes O
in O
the O
intermittent O
mandatory O
ventilation O
( O
IMV O
) O
settings O
during O
transport O
, O
and O
more O
such O
infants O
arrived O
at O
the O
receiving O
hospital O
with O
acceptable O
pH O
and O
PCO2 O
values O
. O

Repetitive O
sequences O
are O
present O
in O
at O
least O
three O
introns O
of O
the O
cytochrome I-GENE
P I-GENE
- I-GENE
450PBc2 I-GENE
gene I-GENE
, O
but O
not O
in O
exons O
or O
the O
5 O
'- O
flanking O
region O
. O

A O
large O
increase O
of O
serum O
ketones O
occurred O
under O
all O
conditions O
, O
and O
the O
exercise O
respiratory O
quotient O
suggested O
some O
increase O
of O
fat O
utilization O
, O
WW O
( O
0 O
. O
85 O
) O
through O
CW O
( O
0 O
. O
84 O
) O
to O
CC O
( O
0 O
. O
83 O
). O

This O
lack O
of O
correlation O
may O
be O
due O
to O
variations O
in O
the O
metabolic O
activity O
of O
the O
endometriotic O
implants O
present O
at O
different O
stages O
of O
the O
disease O
. O

Respiratory O
adaptation O
to O
chronic O
hypoxia O
in O
newborn O
rats O
. O

Compound O
1 O
is O
either O
21 O
- O
O O
- O
angeloyl O
, O
22 O
- O
O O
- O
tigloyl O
R1 O
- O
barrigenol O
, O
or O
21 O
- O
O O
- O
tigloyl O
, O
22 O
- O
O O
- O
angeloyl O
R1 O
- O
barrigenol O
. O

Human O
and O
Chinese I-GENE
hamster I-GENE
S14 I-GENE
protein I-GENE
sequences I-GENE
deduced O
from O
the O
cDNAs O
are O
identical O
. O

RPS14 I-GENE
introns O
3 O
and O
4 O
both O
contain O
Alu I-GENE
sequences O
. O

One O
of O
the O
most O
relevant O
aspects O
in O
achieving O
the O
consistent O
survival O
of O
an O
animal O
undergoing O
the O
experimental O
implantation O
of O
a O
total O
artificial O
heart O
is O
obviously O
related O
to O
the O
correct O
anatomic O
placement O
of O
prosthetic O
ventricles O
inside O
the O
chest O
. O

An O
exaggerated O
tissue O
response O
adjacent O
to O
the O
cyanoacrylate O
site O
suggested O
a O
potential O
toxic O
chemical O
or O
thermal O
reaction O
, O
or O
both O
, O
to O
the O
tissue O
adhesive O
, O
but O
there O
was O
no O
evidence O
of O
any O
distant O
ocular O
effects O
. O

These O
findings O
suggest O
that O
there O
may O
be O
a O
relationship O
between O
the O
pathogenesis O
of O
MAL O
, O
narcolepsy O
, O
and O
OSA O
. O

Among O
82 O
superficial O
lesions O
34 O
were O
classified O
as O
showing O
CR O
and O
another O
23 O
as O
showing O
PR O
, O
with O
a O
response O
rate O
of O
69 O
. O
5 O
%. O

Under O
the O
same O
hematocrit O
and O
flow O
conditions O
, O
the O
rate O
of O
oxygen O
saturation O
decrease O
was O
significantly O
higher O
for O
the O
sickle O
cells O
than O
for O
normal O
cells O
. O

While O
the O
examiner O
observed O
the O
interior O
of O
the O
eye O
with O
indirect O
ophthalmoscopy O
, O
the O
point O
source O
of O
light O
from O
the O
fiberoptic O
light O
pipe O
was O
moved O
along O
the O
margins O
of O
the O
episcleral O
plaque O
. O

These O
fusion O
proteins O
also O
allowed O
the O
localization O
of O
the O
transcriptional O
activation O
and O
DNA O
binding O
domains O
of O
the O
ToxR I-GENE
protein I-GENE
to O
its O
cytoplasmically O
located O
N O
- O
terminal O
portion O
. O

From O
life O
- O
table O
analyses O
of O
these O
patients O
, O
we O
estimated O
that O
the O
incidence O
of O
secondary O
chondrosarcoma O
in O
patients O
who O
have O
Ollier O
disease O
is O
about O
25 O
per O
cent O
at O
the O
age O
of O
forty O
years O
, O
and O
that O
malignant O
degeneration O
is O
almost O
a O
certainty O
in O
patients O
who O
have O
Maffucci O
syndrome O
. O

The O
lethal O
toxicity O
of O
inorganic O
( O
HgCl2 O
) O
and O
organic O
( O
CH3HgCl O
) O
mercury O
chloride O
was O
compared O
for O
Coturnix O
( O
Japanese O
quail O
, O
Coturnix O
japonica O
) O
of O
different O
ages O
from O
hatch O
through O
adulthood O
by O
single O
- O
dose O
acute O
oral O
and O
intramuscular O
injections O
and O
by O
a O
5 O
- O
d O
dietary O
trial O
. O

Since O
the O
integrated O
13h00 O
- O
16h00 O
plasma O
cortisol O
estimation O
is O
cheaper O
and O
simpler O
than O
the O
mean O
13h00 O
- O
16h00 O
plasma O
cortisol O
estimation O
, O
we O
recommend O
it O
as O
an O
adjunct O
in O
the O
diagnosis O
of O
Cushing O
' O
s O
syndrome O
. O

Most O
of O
the O
patients O
had O
locally O
advanced O
lesions O
( O
63 O
T3 O
- O
4 O
: O
91 O
. O
5 O
%) O
according O
to O
the O
adopted O
TNM O
system O
( O
Lederman O
- O
Gadeberg O
, O
Sisson O
- O
Jesse O
). O

The O
risk O
for O
these O
complications O
is O
increased O
by O
the O
following O
factors O
: O
multiple O
gestation O
, O
the O
combination O
of O
magnesium O
sulfate O
and O
beta O
- O
adrenergic O
agonist O
, O
and O
the O
use O
of O
adrenocortico O
- O
steroids O
to O
hasten O
fetal O
pulmonary O
maturity O
. O

Chlorambucil O
and O
interferon I-GENE
for O
low O
grade O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Selenium O
(. O
1 O
ppm O
) O
and O
E O
( O
50 O
IU O
/ O
kg O
) O
supplementation O
of O
the O
diet O
of O
the O
sow O
increased O
plasma O
tocopherol O
and O
Se O
concentrations O
, O
but O
did O
not O
increase O
plasma I-GENE
glutathione I-GENE
peroxidase I-GENE
( O
GSH I-GENE
- I-GENE
Px I-GENE
) O
activity O
. O

Framingham O
Type O
A O
behavior O
was O
positively O
associated O
with O
diastolic O
blood O
pressure O
( O
r O
= O
0 O
. O
17 O
, O
p O
less O
than O
0 O
. O
05 O
) O
among O
the O
women O
. O

The O
in O
vitro O
antibacterial O
potency O
is O
greatest O
when O
the O
1 O
- O
substituent O
is O
2 O
, O
4 O
- O
difluorophenyl O
and O
the O
7 O
- O
substituent O
is O
a O
3 O
- O
amino O
- O
1 O
- O
pyrrolidinyl O
group O
. O

The O
M I-GENE
reading I-GENE
frame I-GENE
differed O
from O
the O
reported O
sequence O
by O
a O
single O
nucleotide O
corresponding O
to O
a O
conservative O
lysine O
to O
arginine O
amino O
acid O
substitution O
near O
the O
carboxy O
- O
terminus O
conserved O
among O
the O
M I-GENE
proteins I-GENE
of O
paramyxoviruses O
. O

An O
ion O
chromatographic O
method O
was O
used O
to O
determine O
Br O
ion O
in O
the O
urine O
of O
Greyhounds O
. O

II O
. O

Laryngographic O
changes O
following O
endotracheal O
intubation O
in O
adults O
. O

Intensification O
of O
human O
myocardial O
contractile O
activity O
as O
affected O
by O
blood O
serum O

Autotransplantation O
of O
a O
vein O
segment O
with O
valve O
in O
the O
treatment O
of O
deep O
vein O
valvular O
insufficiency O
of O
the O
lower O
extremity O

The O
relationships O
among O
four O
descriptors O
of O
lactate O
increase O
: O
lactate O
threshold O
( O
LT O
) O
( O
the O
VO2 O
at O
which O
blood O
lactate O
concentration O
begins O
to O
increase O
above O
the O
resting O
level O
during O
an O
incremental O
exercise O
test O
), O
LT1 O
( O
the O
VO2 O
at O
which O
blood O
lactate O
increases O
1 O
mM O
above O
the O
resting O
level O
), O
LT2 O
( O
the O
VO2 O
at O
which O
blood O
lactate O
concentration O
reaches O
a O
fixed O
value O
of O
2 O
mM O
), O
onset O
of O
blood O
lactate O
accumulation O
( O
OBLA O
; O
the O
VO2 O
at O
which O
blood O
lactate O
reaches O
a O
concentration O
of O
4 O
mM O
), O
were O
compared O
with O
aerobic O
capacity O
( O
VO2max O
) O
and O
12 O
min O
running O
performance O
in O
19 O
untrained O
female O
students O
. O

This O
is O
based O
on O
partitioning O
an O
underlying O
multivariate O
normal O
distribution O
. O

The O
observation O
of O
late O
effects O
after O
irradiations O
or O
after O
space O
flights O
show O
the O
difficulties O
encountered O
in O
assessing O
radiative O
risks O
during O
long O
duration O
space O
flights O
. O

Practical O
use O
and O
interpretation O
of O
viral O
hepatitis O
B O
markers O
and O
hepatic O
biopsy O
in O
HBs I-GENE
Ag I-GENE
carriers O
and O
at O
the O
chronic O
hepatitis O
stage O

The O
1 O
, O
2 O
, O
3 O
and O
4 O
year O
survival O
rates O
were O
94 O
%, O
84 O
%, O
76 O
% O
and O
63 O
%, O
respectively O
. O

Inhibition O
of O
histalog O
- O
stimulated O
gastric O
secretion O
by O
40 O
749 O
RP O
, O
a O
new O
long O
- O
acting O
gastric O
antisecretory O
agent O
. O

Five O
- O
year O
prospective O
study O
of O
peripheral O
white O
blood O
cells O
in O
infectious O
mononucleosis O
. O

Northern O
blotting O
with O
a O
unique O
17 O
- O
mer O
oligonucleotide O
demonstrated O
the O
absence O
of O
the O
mutant O
sequence O
in O
the O
mRNA O
from O
which O
the O
cDNA O
library O
giving O
rise O
to O
the O
mutant O
cDNA O
was O
constructed O
. O

Novel O
multigene O
families O
encoding O
highly O
repetitive O
peptide O
sequences O
. O

Chemotherapy O
of O
metastasizing O
breast O
cancer O

In O
recent O
years O
, O
successful O
physiological O
models O
have O
been O
developed O
for O
a O
variety O
of O
volatile O
and O
nonvolatile O
chemicals O
, O
and O
their O
ability O
to O
perform O
the O
extrapolations O
needed O
in O
risk O
assessment O
has O
been O
demonstrated O
. O

Linear O
extrapolation O
is O
used O
below O
the O
experimental O
data O
range O
to O
establish O
an O
upper O
bound O
on O
carcinogenic O
risk O
at O
low O
doses O
. O

Hisako O
Minowa O
who O
has O
worked O
as O
a O
psychiatric O
counsellor O
in O
industry O
for O
the O
past O
20 O
years O

Deletion O
mapping O
studies O
revealed O
that O
the O
upstream O
DNA O
sequences O
up O
to O
- O
86 O
were O
sufficient O
for O
the O
optimal O
basal O
level O
transcription O
in O
HeLa O
cells O
and O
also O
for O
the O
EIA I-GENE
- O
induced O
transcription O
. O

Incorporation O
of O
the O
polyene O
antibiotic O
amphotericin O
B O
( O
AMB O
) O
in O
liposomes O
results O
in O
a O
marked O
reduction O
in O
drug O
toxicity O
with O
no O
loss O
of O
antifungal O
potency O
. O

Eleven O
healthy O
, O
normotensive O
males O
undergoing O
routine O
restorative O
dental O
care O
were O
evaluated O
during O
treatment O
for O
possible O
hemodynamic O
alterations O
in O
response O
to O
potential O
sympathetic O
nervous O
system O
stimulation O
. O

Serum I-GENE
IgM I-GENE
and O
IgE I-GENE
concentrations O
, O
allergen I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
scores O
, O
and O
the O
tumor O
E2R I-GENE
status O
were O
combined O
to O
construct O
a O
three O
- O
level O
risk O
classification O
that O
was O
more O
prognostic O
than O
any O
of O
the O
individual O
components O
. O

The O
M O
- O
3 O
subtype O
was O
an O
adverse O
prognostic O
factor O
. O

Within O
the O
Strep O
. O
mutans O
group O
there O
was O
a O
highly O
- O
significant O
difference O
between O
Strep O
. O
mutans O
/ O
Strep O
. O
cricetus O
( O
p O
less O
than O
0 O
. O
01 O
) O
with O
respect O
to O
mean O
clump O
size O
. O

These O
results O
indicate O
that O
T O
. O
C O
., O
LDL I-GENE
- I-GENE
C I-GENE
., O
HDL I-GENE
- I-GENE
C I-GENE
., O
HDL2 I-GENE
- I-GENE
C I-GENE
., O
apo I-GENE
B I-GENE
, O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
/ I-GENE
B I-GENE
ratio O
and O
apo I-GENE
A I-GENE
- I-GENE
II I-GENE
/ I-GENE
B I-GENE
ratio O
are O
predictive O
risk O
factors O
of O
the O
coronary O
heart O
disease O
. O

It O
is O
concluded O
that O
the O
unique O
suppository O
formulation O
of O
CZX O
- O
S O
is O
useful O
in O
the O
treatment O
of O
infections O
in O
children O
with O
heavy O
psychophysiologic O
disorders O
and O
in O
children O
who O
cannot O
take O
oral O
drugs O
because O
of O
severe O
vomiting O
. O

In O
addition O
, O
marked O
hypertension O
accompanied O
this O
disorder O
and O
all O
abnormalities O
, O
including O
the O
hypertension O
, O
responded O
to O
1 I-GENE
- I-GENE
desamino I-GENE
- I-GENE
8 I-GENE
- I-GENE
D I-GENE
- I-GENE
arginine I-GENE
vasopressin I-GENE
therapy O
. O

Single O
photon O
emission O
computerized O
tomography O
( O
SPECT O
), O
by O
providing O
three O
- O
dimensional O
representation O
of O
myocardial O
Tl O
- O
201 O
, O
offers O
promise O
for O
improved O
localization O
of O
CAD O
. O

Computer O
assisted O
mapping O
in O
quantitative O
analysis O
of O
cerebral O
positron O
emission O
tomograms O
. O

In O
19 O
patients O
vagotomy O
not O
only O
curbed O
the O
bleeding O
but O
provided O
definitive O
therapy O
( O
Visick O
I O
- O
II O
); O
4 O
patients O
died O
( O
mortality O
rate O
16 O
%). O

Documentation O
of O
a O
successful O
intrauterine O
fertilization O
with O
delivery O
of O
a O
term O
baby O
supports O
the O
theoretical O
feasibility O
of O
the O
EP O
; O
however O
, O
anovulation O
incurred O
by O
our O
procedure O
appears O
to O
be O
the O
major O
drawback O
. O

MRI O
disclosed O
one O
or O
more O
of O
the O
following O
abnormalities O
in O
24 O
( O
63 O
%) O
of O
38 O
treated O
kidneys O
: O
( O
1 O
) O
loss O
of O
corticomedullary O
differentiation O
, O
( O
2 O
) O
perirenal O
fluid O
, O
( O
3 O
) O
subcapsular O
hematoma O
, O
( O
4 O
) O
hemorrhage O
into O
a O
renal O
cyst O
, O
and O
( O
5 O
) O
unexplained O
abnormalities O
. O

The O
results O
obtained O
are O
similar O
to O
those O
described O
with O
the O
previous O
Cremophor O
formulation O
although O
greater O
variability O
in O
induction O
and O
recovery O
times O
was O
noted O
with O
the O
emulsion O
formulation O
. O

The O
percentage O
RFR O
reduction O
at O
the O
end O
of O
CPB O
showed O
significant O
correlation O
with O
1 O
) O
CPB O
duration O
( O
r O
= O
0 O
. O
49 O
), O
2 O
) O
oxygen O
flow O
rate O
index O
( O
OFRI O
), O
i O
. O
e O
. O
flow O
/ O
min O
in O
the O
bubble O
oxygenator O
/ O
m2 O
bsa O
( O
r O
= O
0 O
. O
38 O
), O
and O
3 O
) O
blood O
flow O
rate O
index O
( O
BFRI O
), O
i O
. O
e O
. O
average O
volume O
of O
blood O
pumped O
through O
the O
heart O
- O
lung O
machine O
/ O
min O
CPB O
time O
/ O
m2 O
bsa O
( O
r O
= O
0 O
. O
51 O
). O

Diagnosis O
of O
unilateral O
renal O
artery O
lesions O
after O
captopril O
administration O
. O

A O
yeast O
DNA O
fragment O
carrying O
the O
gene I-GENE
CP I-GENE
A1 I-GENE
encoding O
the O
small O
subunit O
of O
the O
arginine O
pathway O
carbamoyl I-GENE
- I-GENE
phosphate I-GENE
synthetase I-GENE
has O
been O
sequenced O
. O

A O
retrospective O
study O
of O
banked O
sera O
from O
19 O
cats O
with O
the O
eosinophilic O
granuloma O
complex O
revealed O
that O
68 O
% O
of O
affected O
cats O
had O
circulating O
antibodies O
to O
components O
of O
normal O
cat O
epithelium O
. O

In O
memory O
of O
Magdelaine O
Comtesse O

The O
H2 I-GENE
receptor I-GENE
antagonists O
and O
sucralfate O
cost O
about O
the O
same O
and O
have O
few O
side O
effects O
. O

These O
results O
suggest O
that O
indoramin O
may O
have O
Class O
III O
antiarrhythmic O
activity O
. O

A O
high O
efficacy O
of O
the O
combined O
use O
of O
nontoxic O
doses O
of O
two O
pharmaceuticals O
: O
cystamine O
( O
50 O
mg O
/ O
kg O
) O
and O
mexamine O
( O
25 O
mg O
/ O
kg O
) O
under O
the O
conditions O
of O
short O
- O
term O
exogenous O
hypoxia O
( O
7 O
. O
5 O
% O
O2 O
) O
was O
found O
in O
( O
CBA O
X O
C57Bl O
) O
F1 O
mice O
. O

The O
Mean O
was O
74 O
, O
3 O
+/- O
53 O
, O
6 O
micrograms O
J O
/ O
g O
Cr O
, O
the O
Median O
61 O
micrograms O
J O
/ O
g O
Cr O
. O

In O
the O
region O
Walgau O
with O
mixed O
industrial O
- O
rural O
population O
an O
iodine O
deficiency O
I O
was O
found O
in O
81 O
% O
and O
an O
iodine O
deficiency O
II O
in O
45 O
%. O

The O
structural O
gene O
for O
hydrogenase I-GENE
encodes O
a O
protein O
product O
of O
molecular O
mass O
45820 O
Da O
. O

Pancreaticoduodenal O
lymph O
node O
enlargement O
, O
regardless O
of O
cause O
, O
has O
been O
a O
source O
of O
imaging O
confusion O
because O
of O
its O
propensity O
to O
mimic O
pancreatic O
malignancy O
yet O
not O
cause O
biliary O
obstruction O
. O

Interference O
with O
rheumatoid I-GENE
factor I-GENE
was O
only O
observed O
in O
the O
ELISA O
enzygnost O
if O
sera O
were O
not O
pretreated O
with O
latex O
adsorbents O
. O

All O
patients O
had O
elevated O
levels O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to O
the O
crude O
soybean O
extract O
; O
binding O
values O
ranged O
from O
2 O
. O
3 O
to O
28 O
. O
1 O
times O
that O
of O
a O
negative O
control O
serum O
. O

New O
techniques O
for O
the O
mass O
spectrometry O
of O
natural O
products O
. O

Dual O
radionuclide O
subtraction O
imaging O
of O
the O
spleen O
using O
67Ga O
citrate O
and O
99mTc O
is O
useful O
in O
further O
delineating O
lesions O
that O
are O
identified O
on O
either O
a O
routine O
radiogallium O
survey O
or O
on O
a O
conventional O
sulfur O
colloid O
liver O
- O
spleen O
image O
. O

Such O
studied O
acquired O
with O
low O
energy O
or O
medium O
energy O
collimation O
and O
a O
window O
centered O
on O
the O
159 O
keV O
123I O
photopeak O
contain O
appreciable O
septal O
breakthrough O
signals O
originating O
from O
Compton O
scatter O
of O
high O
energy O
photons O
primarily O
from O
124I O
. O

Nursing O
education O
-- O
the O
computer O
obligation O
. O

Shear O
bond O
strength O
of O
a O
composite O
resin O
to O
an O
etched O
glass O
ionomer O
. O

An O
additional O
advantage O
is O
that O
the O
resin O
can O
be O
removed O
and O
the O
immunoperoxidase I-GENE
technique O
carried O
out O
on O
thin O
sections O
. O

Such O
a O
concept O
is O
crucial O
to O
our O
understanding O
of O
the O
pathology O
of O
ageing O
in O
general O
. O

We O
consider O
that O
DIL O
- O
CP O
is O
a O
safe O
and O
excellent O
CP O
in O
CABG O
surgery O
and O
we O
are O
now O
utilizing O
this O
CP O
in O
all O
patients O
requiring O
CABG O
surgery O
. O

We O
have O
earlier O
evolved O
an O
experimental O
model O
by O
means O
of O
which O
changes O
identical O
to O
the O
microembolism O
syndrome O
can O
be O
induced O
from O
a O
reproducible O
musculo O
- O
skeletal O
trauma O
in O
pigs O
observed O
under O
long O
- O
term O
anesthesia O
under O
standardized O
conditions O
. O

Although O
no O
statistical O
significance O
was O
achieved O
, O
it O
is O
remarkable O
that O
there O
was O
a O
clear O
trend O
for O
the O
superiority O
of O
Galphimia O
D6 O
while O
the O
Galphimia O
dilution O
10 O
(- O
6 O
) O
was O
about O
equally O
effective O
compared O
with O
placebo O
. O

The O
volume O
of O
blood O
to O
the O
flap O
ranges O
from O
1 O
to O
2 O
ml O
/ O
min O
, O
collateral O
circulation O
to O
the O
flap O
exists O
, O
but O
is O
negligible O
, O
and O
there O
is O
little O
change O
in O
the O
capillary O
blood O
flow O
as O
the O
flap O
ages O
. O

With O
aging O
, O
many O
aspects O
of O
immune O
function O
change O
. O

Oral O
candidiasis O

In O
addition O
, O
the O
gcd1 I-GENE
- I-GENE
101 I-GENE
mutation I-GENE
suppressed O
the O
low O
translational O
efficiency O
of O
GCN4 I-GENE
- O
lacZ I-GENE
mRNA O
observed O
in O
gcn2 I-GENE
- I-GENE
and O
gcn3 I-GENE
- I-GENE
cells O
. O

This O
suggests O
that O
alaproclate O
acutely O
increases O
the O
responsiveness O
of O
postsynaptic O
muscarinic I-GENE
and I-GENE
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
. O

The O
concentrations O
of O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
and O
apo I-GENE
A I-GENE
- I-GENE
II I-GENE
of O
abstainers O
decreased O
significantly O
compared O
with O
the O
corresponding O
changes O
in O
controls O
. O

The O
distribution O
of O
patients O
was O
as O
follows O
: O
group O
1 O
-- O
complex O
gamma O
- O
therapy O
( O
55 O
cases O
), O
group O
2 O
-- O
complex O
gamma O
- O
therapy O
plus O
iliac O
lymphadenectomy O
( O
50 O
cases O
) O
and O
group O
3 O
-- O
complex O
radiation O
treatment O
with O
megavolt O
bremsstrahlung O
beam O
from O
the O
luc O
type O
installation O
and O
iliac O
lymphadenectomy O
( O
50 O
cases O
). O

The O
availability O
of O
cryoprecipitate O
and O
DDAVP O
offers O
an O
alternative O
and O
effective O
treatment O
for O
the O
temporary O
reversal O
of O
uremic O
bleeding O
in O
patients O
who O
require O
urgent O
invasive O
procedures O
. O

Thrombophlebitis O
and O
pulmonary O
embolism O
in O
congenital O
factor I-GENE
XII I-GENE
deficiency O

Biopsies O
of O
the O
jejunal O
mucosa O
have O
shown O
abnormal O
enzyme O
activity O
or O
deficiencies O
in O
transport O
mechanisms O
. O

Laboratory O
pyrolyses O
have O
indeed O
shown O
that O
PCBs O
give O
significant O
yields O
of O
PCDFs O
, O
and O
chlorobenzenes O
give O
both O
PCDFs O
and O
PCDDs O
. O

A O
significant O
degree O
of O
homology O
was O
also O
found O
among O
these O
genes O
and O
the O
Mtase I-GENE
gene I-GENE
of O
related O
phage O
SPR O
, O
which O
codes O
for O
an O
enzyme O
with O
different O
modification O
specificity O
. O

Thyrotropin I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
- O
induced O
contraction O
of O
urethral O
and O
vaginal O
muscle O
. O

In O
a O
blind O
controlled O
trial O
, O
15 O
patients O
with O
COCM O
( O
NYHA O
II O
- O
III O
) O
with O
sinus O
rhythm O
and O
a O
left O
ventricular O
ejection O
fraction O
( O
LV O
- O
EF O
) O
of O
34 O
. O
5 O
+/- O
2 O
. O
6 O
% O
received O
consecutively O
D O
( O
0 O
. O
25 O
- O
0 O
. O
5 O
mg O
/ O
d O
), O
placebo O
( O
PLAC O
), O
P O
( O
slow O
releases O
= O
SR O
) O
( O
80 O
mg O
/ O
d O
SR O
) O
and O
both O
drugs O
combined O
in O
respective O
doses O
. O

Mild O
orbital O
discomfort O
occurred O
in O
some O
patients O
. O

The O
sample O
is O
deproteinized O
and O
after O
centrifugation O
valproic O
acid O
in O
the O
supernatant O
is O
measured O
in O
the O
free O
form O
by O
direct O
injection O
into O
the O
gas O
chromatograph O
. O

Changes O
in O
muscarinic I-GENE
acetylcholine I-GENE
receptors I-GENE
in O
guinea O
- O
pig O
lung O
: O
effects O
of O
aging O
, O
inhalation O
of O
an O
allergen O
, O
administration O
of O
drugs O
, O
and O
vagotomy O
. O

In O
the O
absence O
of O
other O
stabilizers O
, O
increased O
sucrose O
can O
provide O
increased O
thermoresistance O
to O
the O
virus O
in O
2 O
. O
5 O
% O
albumin I-GENE
. O

The O
overall O
prevalence O
of O
psoriasis O
was O
4 O
. O
79 O
% O
in O
men O
and O
4 O
. O
85 O
% O
in O
women O
. O

Greek O
classicism O
in O
living O
structure O
? O
Some O
deductive O
pathways O
in O
animal O
morphology O
. O

The O
possible O
origin O
and O
role O
of O
CSF I-GENE
prolactin I-GENE
are O
discussed O
. O

Three O
chromosomal I-GENE
crsA I-GENE
mutations I-GENE
, O
crsA1 I-GENE
, O
crsA4 I-GENE
, O
and O
crsA47 I-GENE
, O
were O
transferred O
by O
the O
" O
gene O
conversion O
" O
process O
to O
B O
. O
subtilis O
plasmid O
pRPD11 O
, O
which O
consists O
of O
the O
entire O
wild I-GENE
- I-GENE
type I-GENE
rpoD I-GENE
coding I-GENE
sequence I-GENE
, O
encoding O
the O
major I-GENE
sigma I-GENE
43 I-GENE
factor I-GENE
of I-GENE
B I-GENE
. I-GENE
subtilis I-GENE
RNA I-GENE
polymerase I-GENE
, O
and O
pUB110 O
. O

Selective O
effect O
of O
pulmonary O
oedema O
on O
prostaglandin O
E2 O
pharmacokinetics O
in O
rat O
lung O
. O

This O
article O
will O
briefly O
review O
the O
published O
data O
on O
the O
morphology O
, O
function O
, O
and O
biochemistry O
of O
the O
normal O
renal O
medulla O
and O
the O
pathology O
associated O
with O
RPN O
, O
together O
with O
the O
secondary O
changes O
which O
give O
rise O
to O
cortical O
degeneration O
or O
epithelial O
carcinoma O
. O

The O
data O
indicate O
that O
the O
five O
different O
( O
and O
partially O
overlapping O
) O
sry I-GENE
messenger I-GENE
RNAs I-GENE
detectable O
in O
early O
embryos O
are O
initiated O
at O
three O
separate O
sites O
, O
each O
directly O
upstream O
from O
one O
of O
the O
three O
protein O
- O
coding O
regions O
, O
designated O
( O
in O
5 O
' O
to O
3 O
' O
order O
) O
beta O
, O
alpha O
and O
delta O
. O

Chronic O
thyroiditis O
as O
a O
risk O
factor O
of O
B O
- O
cell O
lymphoma O
in O
the O
thyroid O
gland O
. O

Plasma I-GENE
secretin I-GENE
levels O
also O
augmented O
after O
the O
administration O
of O
ethanol O
solutions O
, O
with O
a O
delay O
of O
about O
one O
hour O
after O
the O
onset O
of O
acid O
secretion O
. O

Spectrophotometric O
microanalysis O
of O
ethylenediaminotetracetic O
acid O
in O
pharmaceutical O
preparations O

A O
comparison O
among O
the O
5 O
' O
flanking O
regions O
encompassing O
the O
presumptive O
HS I-GENE
promoter I-GENE
of O
the O
soybean I-GENE
HS I-GENE
- I-GENE
protein I-GENE
genes I-GENE
demonstrated O
this O
region O
to O
be O
extremely O
homologous O
. O

Results O
of O
this O
study O
indicate O
that O
GLC O
of O
short O
chain O
fatty O
acids O
produced O
on O
agar O
medium O
by O
anaerobes O
, O
combined O
with O
simple O
tests O
such O
as O
Gram O
' O
s O
stain O
and O
colonial O
morphology O
, O
may O
allow O
fir O
direct O
presumptive O
genus O
identification O
from O
an O
initial O
pure O
agar O
culture O
. O

Using O
this O
method O
, O
we O
measured O
absorption O
of O
low O
doses O
of O
vitamin O
A O
, O
which O
may O
provide O
a O
more O
physiological O
approach O
to O
assessment O
of O
fat O
malabsorption O
. O

Fulminant O
hepatitis O
A O
in O
chronic O
HBV O
carrier O
. O

Tissue O
pressure O
, O
rCBF O
, O
and O
water O
content O
were O
measured O
from O
gray O
matter O
in O
the O
central O
core O
and O
the O
peripheral O
margin O
of O
the O
MCA O
territory O
over O
6 O
h O
after O
MCAO O
. O

During O
this O
time O
, O
the O
patients O
all O
had O
the O
characteristic O
plasma O
thyroid O
hormone O
changes O
associated O
with O
amiodarone O
therapy O
, O
i O
. O
e O
. O
increased O
T4 O
, O
free O
T4 O
, O
and O
rT3 O
and O
decreased O
T3 O
, O
while O
remaining O
clinically O
euthyroid O
. O

Drug O
and O
nutrient O
interactions O
. O

In O
each O
compartment O
O2 O
is O
removed O
by O
the O
tissues O
as O
a O
chemical O
reaction O
takes O
place O
between O
O2 O
and O
oxyhemoglobin I-GENE
( O
HbO2 I-GENE
). O

To O
evaluate O
the O
effects O
of O
propranolol O
on O
myocardial O
metabolism O
after O
coronary O
reperfusion O
, O
serial O
measurements O
of O
myocardial I-GENE
creatine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
and O
calcium O
( O
Ca O
) O
contents O
and O
CK I-GENE
and O
lactic O
acid O
( O
LA O
) O
concentrations O
in O
coronary O
sinus O
blood O
were O
carried O
out O
in O
33 O
open O
- O
chest O
dogs O
. O

Dissolution O
of O
the O
Pt O
- O
30 O
% O
Ir O
microelectrode O
tip O
was O
observed O
by O
scanning O
electron O
microscopy O
at O
charge O
densities O
as O
low O
as O
200 O
microC O
/ O
cm2 O
X O
ph O
( O
1 O
A O
/ O
cm2 O
), O
whereas O
erosion O
of O
activated O
iridium O
microelectrodes O
occurred O
only O
at O
the O
highest O
charge O
and O
current O
densities O
( O
3200 O
microC O
/ O
cm2 O
X O
ph O
, O
16 O
A O
/ O
cm2 O
). O

Cortisol O
excretion O
, O
appeared O
to O
be O
markedly O
affected O
by O
the O
season O
although O
other O
factors O
such O
as O
social O
and O
environmental O
stress O
cannot O
be O
discounted O
. O

Two O
studies O
on O
the O
relationship O
between O
taking O
a O
commercial O
coaching O
course O
and O
performance O
on O
the O
Medical O
College O
Admission O
Test O
( O
MCAT O
) O
are O
reported O
. O

A O
total O
of O
90 O
patients O
were O
randomly O
allocated O
either O
to O
an O
MY O
- O
1 O
treated O
or O
an O
untreated O
group O
. O

Below O
50 O
% O
decrease O
of O
PaO2 O
, O
NADH O
was O
reduced O
largely O
. O

Angiography O
was O
performed O
following O
the O
rCBF O
study O
and O
the O
degree O
of O
vasospasm O
was O
measured O
on O
the O
angiograms O
. O

The O
results O
from O
the O
first O
five O
years O
of O
follow O
up O
in O
1972 O
showed O
a O
4 O
. O
7 O
- O
fold O
excess O
mortality O
for O
ischaemic O
and O
other O
heart O
diseases O
( O
ICD O
A83 O
- O
A84 O
) O
compared O
with O
a O
comparable O
reference O
cohort O
of O
paper O
mill O
workers O
. O

The O
financial O
impact O
of O
childhood O
asthma O
has O
not O
been O
assessed O
since O
Vance O
and O
Taylor O
reported O
their O
data O
in O
Annals O
of O
Allergy O
13 O
years O
ago O
. O

Hypersplenism O

Electrical O
activity O
was O
evaluated O
by O
monitoring O
the O
general O
electrocorticogram O
( O
ECoG O
) O
as O
well O
as O
local O
DC O
steady O
potential O
( O
two O
sites O
). O

The O
topography O
and O
trajectories O
of O
the O
commissural O
fibers O
of O
the O
superior O
temporal O
region O
( O
STR O
) O
are O
studied O
using O
the O
autoradiographic O
technique O
. O

The O
diabetic O
state O
was O
characterized O
by O
mild O
insulin I-GENE
deficiency O
, O
plasma O
levels O
being O
73 O
% O
of O
controls O
, O
and O
mild O
hyperglycemia O
, O
with O
nonfasting O
plasma O
glucose O
levels O
of O
1 O
. O
5 O
times O
normal O
. O

The O
primary O
CT O
findings O
were O
misinterpreted O
as O
a O
brain O
infarct O
or O
possibly O
a O
tumour O
. O

No O
consistent O
correlation O
between O
blood O
pressure O
change O
and O
SCR O
- O
change O
was O
seen O
. O

Shoulder O
forearm O
support O
for O
the O
subluxed O
shoulder O
. O

Piroxicam O
produced O
a O
lower O
incidence O
of O
gastric O
ulcers O
than O
equivalent O
doses O
of O
indomethacin O
. O

These O
findings O
suggest O
that O
both O
in O
the O
early O
stages O
( O
0T O
, O
0N O
) O
and O
in O
more O
severe O
stages O
of O
VWF O
( O
stages O
1 O
- O
2 O
) O
cold O
induced O
hyperreactivity O
in O
the O
digital O
vessels O
and O
Raynaud O
' O
s O
syndrome O
are O
vascular O
disorders O
of O
functional O
origin O
occurring O
without O
any O
prethrombotic O
alterations O
. O

In O
MCCP O
functions O
of O
the O
source O
emission O
, O
surface O
reflection O
, O
photoacceptor O
sensitivity O
are O
approximated O
by O
the O
normal O
distribution O
curves O
. O

However O
, O
kidneys O
perfused O
for O
72 O
hr O
demonstrated O
more O
similar O
renal O
functions O
when O
tested O
by O
either O
IMPK O
or O
IBPK O
. O

To O
assess O
the O
effects O
of O
alveolar O
hypoxia O
and O
angiotensin I-GENE
II I-GENE
infusion O
on O
distribution O
of O
blood O
flow O
to O
the O
lung O
we O
performed O
perfusion O
lung O
scans O
on O
anesthetized O
mechanically O
ventilated O
lambs O
. O

A O
flow O
rate O
of O
at O
least O
5 O
mL O
/ O
h O
is O
required O
through O
the O
receptor O
( O
volume O
, O
0 O
. O
4 O
mL O
) O
for O
accurate O
results O
. O

We O
have O
now O
located O
the O
5 O
' O
ends O
of O
the O
two O
remaining O
late O
mRNAs O
. O

The O
efficacy O
of O
quantitative O
and O
qualitative O
chloride O
titrators O
in O
the O
estimation O
of O
human O
salt O
intake O
. O

Doctor O
Berglund O
warns O
members O
of O
union O
pitfalls O
. O

Acute O
appearance O
of O
hemiparesis O
or O
hemiplegia O
with O
initial O
marked O
spasticity O
was O
observed O
in O
8 O
stroke O
patients O
. O

Recurrent O
acute O
rhinosinusitis O
was O
common O
in O
both O
groups O
of O
patients O
, O
but O
the O
development O
of O
chronic O
rhinosinusitis O
was O
only O
found O
in O
patients O
with O
CVID O
, O
indicating O
the O
more O
severe O
nature O
of O
this O
condition O
compared O
with O
selective O
IgA I-GENE
deficiency O
. O

These O
data O
suggest O
that O
AP I-GENE
- I-GENE
A I-GENE
may O
be O
potentially O
useful O
in O
the O
management O
of O
heart O
failure O
. O

The O
various O
muscles O
of O
the O
pelvic O
floor O
region O
could O
be O
reflexly O
activated O
either O
individually O
or O
as O
a O
mass O
unit O
depending O
on O
the O
intensity O
of O
stimulation O
. O

It O
has O
been O
reported O
that O
rat O
blood O
chloroform O
levels O
were O
significantly O
decreased O
after O
treatment O
with O
ClO2 O
. O

The O
frequency O
of O
lactase I-GENE
phenotypes I-GENE
in O
Aymara O
children O
. O

Activities O
of O
hepatic O
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
- O
dependent O
metabolizing O
enzymes O
such O
as O
aminopyrine I-GENE
- I-GENE
and I-GENE
TMO I-GENE
N I-GENE
- I-GENE
demethylase I-GENE
and O
aniline I-GENE
hydroxylase I-GENE
activity O
were O
decreased O
by O
pretreatment O
of O
rats O
with O
cimetidine O
, O
whereas O
in O
the O
rats O
pretreated O
with O
ranitidine O
, O
these O
enzyme O
activities O
were O
not O
changed O
. O

Doxorubicin O
, O
dacarbazine O
, O
vincristine O
, O
and O
cyclophosphamide O
in O
the O
treatment O
of O
advanced O
gastrointestinal O
leiomyosarcoma O
. O

The O
effect O
of O
the O
opiate O
antagonist O
naloxone O
was O
evaluated O
in O
11 O
unselected O
patients O
with O
cerebral O
ischemia O
. O

Electrochemical O
detection O
of O
depressed O
circulating O
levels O
of O
vitamin O
K1 O
in O
osteoporosis O
. O

In O
the O
present O
experiments O
, O
we O
investigate O
the O
role O
played O
by O
the O
temporal O
pattern O
of O
neural O
activity O
during O
the O
ontogeny O
of O
frequency O
tuning O
in O
the O
mouse O
central O
auditory O
system O
. O

Ultrastructure O
of O
the O
tumor O
in O
1 O
patient O
in O
whom O
transurethral O
resection O
was O
performed O
2 O
weeks O
after O
alum O
irrigation O
revealed O
well O
preserved O
nuclear O
chromatin O
, O
thus O
, O
suggesting O
that O
whatever O
changes O
occur O
after O
alum O
irrigation O
are O
short O
- O
lived O
. O

The O
generally O
adopted O
criteria O
enabling O
to O
classify O
the O
examined O
persons O
into O
the O
following O
3 O
groups O
have O
been O
used O
: O
( O
a O
) O
diseased O
of O
BEN O
; O
( O
b O
) O
suspect O
to O
be O
diseased O
of O
BEN O
, O
and O
( O
c O
) O
individuals O
without O
signs O
of O
a O
renal O
disease O
. O

For O
this O
purpose O
, O
a O
simple O
respiration O
- O
control O
device O
has O
been O
developed O
that O
enables O
the O
patient O
to O
monitor O
breath O
- O
holding O
during O
successive O
scans O
. O

The O
POEMS O
syndrome O
( O
Polyneuropathy O
, O
Organomegaly O
, O
Endocrinopathy O
, O
Monoclonal O
component O
, O
Skin O
). O

During O
a O
disease O
remission O
there O
was O
an O
increase O
in O
GAG O
secretion O
with O
urine O
, O
linked O
with O
hyperheparinuria O
( O
13 O
. O
1 O
- O
fold O
, O
P O
less O
than O
0 O
. O
001 O
). O

In O
metastasis O
- O
free O
patients O
, O
the O
best O
results O
were O
obtained O
with O
tumor O
diameters O
under O
2 O
cm O
regardless O
of O
their O
localization O
in O
lung O
tissue O
and O
with O
2 O
-- O
4 O
. O
9 O
cm O
tumors O
embedded O
in O
lung O
parenchyma O
. O

Two O
siblings O
with O
hemolytic O
anemia O
caused O
by O
triosephosphate I-GENE
isomerase I-GENE
deficiency O
developed O
a O
progressive O
neurological O
syndrome O
featuring O
dystonic O
movements O
, O
tremor O
, O
pyramidal O
tract O
signs O
, O
and O
evidence O
of O
spinal O
motor O
neuron O
involvement O
. O

One O
extract O
with O
the O
lowest O
PCA O
content O
was O
non O
- O
carcinogenic O
. O

In O
the O
10 O
patients O
with O
a O
more O
severe O
degree O
of O
steatorrhea O
the O
decrease O
in O
fat O
loss O
approached O
20 O
% O
and O
a O
close O
relationship O
was O
found O
( O
r O
= O
0 O
. O
84 O
, O
p O
less O
than O
0 O
. O
01 O
) O
between O
the O
extent O
of O
the O
fatty O
acid O
loss O
on O
placebo O
and O
the O
decrease O
of O
this O
loss O
on O
taurine O
. O

Aortic O
diameters O
in O
infants O
and O
young O
children O
: O
normative O
angiographic O
data O
. O

The O
present O
investigation O
has O
revealed O
that O
the O
distribution O
of O
the O
main O
fatty O
acids O
in O
Leptospira O
phospholipids O
is O
similar O
to O
their O
distribution O
in O
Leptospira O
neutral O
lipids O
with O
the O
exception O
of O
unsaturated O
fatty O
acid O
with O
14 O
carbon O
atoms O
, O
occurring O
mainly O
in O
phospholipids O
. O

Since O
1970 O
the O
frequency O
of O
potassium O
- O
induced O
ulceration O
has O
been O
low O
-- O
3 O
cases O
per O
100 O
000 O
patient O
- O
years O
of O
slow O
- O
release O
tablet O
use O
. O

Hydrocortisone O
caused O
lymphopenia O
and O
inhibited O
the O
blastogenic O
response O
of O
peripheral O
blood O
lymphocytes O
to O
phytohemagglutinin I-GENE
and O
concanavalin I-GENE
A I-GENE
mitogens O
. O

To O
test O
the O
feasibility O
of O
using O
liposomes O
to O
deliver O
therapeutic O
agents O
to O
the O
lungs O
, O
the O
effect O
of O
liposome O
- O
encapsulated O
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
or O
catalase I-GENE
on O
pulmonary O
oxygen O
toxicity O
was O
studied O
in O
rats O
. O

Marrow O
cell O
necrosis O
in O
anorexia O
nervosa O
and O
involuntary O
starvation O
. O

For O
comparison O
conventional O
heparin O
was O
used O
during O
18 O
dialyses O
in O
the O
same O
patients O
. O

Chenodeoxycholic O
acid O
( O
cheno O
) O
and O
ursodeoxycholic O
acid O
( O
urso O
) O
dissolve O
cholesterol O
gallstones O
in O
man O
. O

Sensory O
evoked O
field O
potentials O
were O
recorded O
from O
the O
mesencephalic O
reticular O
formation O
( O
MRF O
), O
central O
gray O
( O
CG O
) O
and O
somatosensory O
cortex O
( O
SCX O
), O
following O
incremental O
doses O
of O
halothane O
in O
freely O
- O
moving O
rats O
. O

Ultrastructure O
of O
the O
heart O
muscle O
in O
experimental O
myocardial O
infarct O
following O
physical O
training O

Pharmacological O
desympathization O
leads O
to O
the O
development O
of O
hyper O
- O
reactivity O
of O
the O
true O
pacemakers O
to O
noradrenaline O
and O
dopamine O
and O
triggers O
off O
changes O
in O
the O
regulation O
of O
the O
electric O
activity O
of O
these O
cells O
by O
catecholamines O
. O

OODG O
is O
a O
diagnostic O
method O
permitting O
assessment O
of O
ocular O
pulse O
curves O
and O
objective O
determination O
of O
blood O
pressures O
in O
the O
ophthalmic O
circulatory O
system O
( O
retinal O
and O
ciliary O
arterial O
blood O
pressures O
) O
simultaneously O
for O
both O
eyes O
, O
without O
dilatation O
of O
the O
pupils O
. O

Viral O
infections O
have O
long O
been O
suspected O
to O
be O
causative O
agents O
in O
a O
number O
of O
inner O
ear O
dysfunctions O
. O

55 O
+/- O
11 O
%), O
all O
other O
parameters O
showed O
a O
significant O
increase O
: O
RS O
index O
5 O
. O
4 O
+/- O
1 O
. O
4 O
mVolt O
to O
6 O
. O
0 O
+/- O
1 O
. O
7 O
mVolt O
( O
p O
less O
than O
0 O
. O
01 O
); O
EDD O
6 O
. O
3 O
+/- O
0 O
. O
7 O
to O
6 O
. O
8 O
+/- O
0 O
. O
9 O
cm O
( O
p O
less O
than O
0 O
. O
001 O
); O
HV O
1017 O
+/- O
151 O
ml O
to O
1099 O
+/- O
261 O
ml O
( O
p O
less O
than O
0 O
. O
01 O
); O
EDV O
371 O
+/- O
131 O
ml O
to O
441 O
+/- O
175 O
ml O
( O
p O
less O
than O
0 O
. O
001 O
); O
RBV O
117 O
+/- O
57 O
ml O
to O
151 O
+/- O
77 O
ml O
( O
p O
less O
than O
0 O
. O
001 O
). O

Retrospective O
analyses O
of O
this O
death O
revealed O
a O
significant O
decrease O
of O
the O
left O
ventricular O
( O
LV O
) O
end O
- O
diastolic O
volume O
index O
( O
EDVI O
) O
of O
21 O
ml O
/ O
m2 O
( O
36 O
% O
of O
normal O
). O

In O
group O
I O
adults O
both O
of O
these O
variables O
increased O
. O

Polysorbate O
80 O
did O
not O
have O
a O
direct O
stimulant O
or O
relaxant O
effect O
on O
either O
guinea O
pig O
ileum O
or O
rat O
uterus O
, O
however O
, O
it O
antagonised O
the O
contractions O
induced O
by O
acetylcholine O
, O
histamine O
, O
barium O
, O
5 O
- O
hydroxytryptamine O
and O
carbachol O
in O
a O
dose O
- O
dependent O
manner O
. O

Individual O
alcohol O
reaction O
profiles O
. O

Vitiligo O
in O
diabetes O
mellitus O
. O

The O
pharmacokinetics O
of O
each O
tetracycline O
in O
serum O
and O
dermal O
, O
suction O
blister O
fluid O
were O
determined O
after O
oral O
doses O
of O
300 O
mg O
lymecycline O
or O
100 O
mg O
doxycycline O
on O
the O
3rd O
day O
. O

A O
high O
degree O
of O
correlation O
in O
the O
sense O
of O
the O
classic O
conception O
of O
brain O
localization O
of O
neuropsychological O
syndromes O
was O
found O
. O

Either O
a O
UV O
detector O
set O
at O
268 O
nm O
or O
an O
electrochemical O
( O
EC O
) O
detector O
set O
at O
a O
potential O
of O
+ O
0 O
. O
9 O
V O
( O
versus O
Ag O
/ O
AgCl O
/ O
3 O
M O
NaCl O
) O
was O
used O
to O
monitor O
the O
drug O
. O

35 O
patients O
with O
acute O
arterial O
occlusions O
[ O
27 O
] O
and O
graft O
thromboses O
[ O
8 O
], O
responsible O
for O
severe O
and O
recent O
ischemia O
, O
were O
treated O
by O
fibrinolytic O
therapy O
( O
Urokinase I-GENE
: O
1 O
000 O
units O
/ O
kg O
/ O
hour O
, O
and O
Lys O
Plasminogen I-GENE
). O

The O
mean O
transfer O
ratios O
of O
the O
drug O
into O
the O
genital O
tissues O
to O
the O
concentration O
in O
the O
uterine O
arterial O
blood O
were O
such O
that O
the O
transfer O
ratio O
into O
the O
portio O
vaginalis O
was O
the O
highest O
, O
followed O
by O
the O
uterine O
cervix O
and O
the O
myometrium O
, O
and O
that O
into O
the O
oviduct O
was O
the O
lowest O
with O
about O
1 O
/ O
2 O
that O
into O
the O
portio O
vaginalis O
. O

We O
conclude O
that O
androgenic O
hormones O
reduce O
HDL I-GENE
- I-GENE
cholesterol I-GENE
concentrations O
and O
the O
HDL2 I-GENE
- I-GENE
cholesterol I-GENE
subfraction O
, O
possibly O
by O
enhancing O
hepatic I-GENE
triglyceride I-GENE
lipase I-GENE
activity O
. O

Because O
of O
its O
wide O
spectrum O
of O
activity O
particularly O
against O
ampicillin O
resistant O
strains O
of O
H O
. O
influenzae O
and O
because O
of O
its O
good O
tolerance O
Cefaclor O
is O
very O
useful O
in O
treatment O
of O
respiratory O
tract O
infections O
in O
children O
. O

Lower O
extremity O
weight O
bearing O
under O
various O
standing O
conditions O
in O
independently O
ambulatory O
patients O
with O
hemiparesis O
. O

Shape O
factor O
correlated O
well O
with O
hemodynamic O
data O
for O
RV O
/ O
LV O
systolic O
pressure O
ratios O
( O
r O
= O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
001 O
) O
for O
normalized O
interventricular O
pressure O
differences O
( O
r O
= O
- O
0 O
. O
95 O
, O
p O
less O
than O
0 O
. O
001 O
). O

The O
effective O
and O
low O
toxic O
dose O
schedules O
of O
KW O
- O
2083 O
should O
be O
investigated O
further O
. O

Furthermore O
, O
the O
initial O
plasma O
retinol O
level O
in O
conjunction O
with O
RBP I-GENE
was O
found O
to O
be O
even O
lower O
in O
12 O
patients O
( O
35 O
. O
1 O
micrograms O
dl O
- O
1 O
, O
3 O
. O
7 O
mg O
dl O
- O
1 O
) O
who O
subsequently O
had O
cancer O
recurrence O
than O
in O
those O
who O
remained O
free O
of O
apparent O
cancer O
( O
44 O
. O
5 O
micrograms O
dl O
- O
1 O
, O
4 O
. O
6 O
mg O
dl O
- O
1 O
). O

The O
results O
indicate O
that O
: O
1 O
) O
the O
initial O
response O
to O
tethering O
varies O
according O
to O
previous O
penning O
and O
handling O
experience O
, O
2 O
) O
although O
the O
circadian O
rhythm O
of O
cortisol O
was O
either O
altered O
or O
disrupted O
during O
estrus O
, O
such O
disruptions O
were O
not O
influenced O
by O
type O
of O
penning O
and O
3 O
) O
tether O
stalls O
may O
chronically O
increase O
cortisol O
concentrations O
in O
gilts O
. O

This O
laser O
provided O
sufficient O
power O
in O
an O
amniotic O
fluid O
medium O
to O
occlude O
placental O
vessels O
as O
large O
as O
7 O
mm O
in O
diameter O
within O
6 O
seconds O
at O
a O
power O
density O
of O
2000 O
W O
/ O
cm2 O
. O

On O
d O
112 O
, O
progesterone O
was O
higher O
( O
P O
less O
than O
. O
05 O
) O
in O
hysterectomized O
heifers O
than O
in O
other O
treatment O
groups O
. O

Male O
Japanese O
quail O
were O
chronically O
exposed O
to O
5000 O
ppm O
manganese O
( O
Mn O
) O
as O
particulate O
manganese O
oxide O
( O
Mn3O4 O
) O
in O
their O
diet O
from O
hatching O
to O
75 O
days O
of O
age O
. O

This O
study O
indicated O
that O
the O
Japanese O
quail O
was O
less O
sensitive O
to O
particulate O
Mn3O4 O
exposure O
than O
rodents O
treated O
comparably O
. O

Plasma O
and O
bladder O
platinum O
concentration O
were O
measured O
following O
intravesical O
DDP O
, O
and O
also O
histopathological O
examination O
, O
urinalysis O
, O
complete O
blood O
count O
and O
blood O
chemistry O
were O
performed O
in O
order O
to O
know O
the O
toxicity O
of O
intravesical O
DDP O
. O

Scintigraphic O
visualisation O
of O
Walker O
carcinoma O
- O
256 O
in O
Sprague O
- O
Dawley O
rats O
by O
means O
of O
99mTc O
- O
labelled O
monocytes O
. O

These O
results O
were O
compared O
with O
those O
obtained O
in O
- O
D O
mothers O
and O
pups O
, O
after O
giving O
the O
mothers O
an O
oral O
supplement O
( O
10 O
i O
. O
u O
. O
vitamin O
D3 O
/ O
day O
) O
during O
the O
period O
of O
lactation O
( O
20 O
days O
). O

Rabbit O
eyes O
were O
removed O
and O
held O
in O
temperature O
- O
regulated O
chambers O
and O
irrigated O
with O
saline O
. O

Before O
birth O
, O
there O
were O
a O
few O
perivascular O
adrenergic O
nerves O
and O
correspondingly O
low O
ovarian O
NE O
levels O
. O

Monitoring O
changes O
in O
the O
heart O
rate O
of O
the O
premature O
fetus O
during O
tocolysis O
with O
the O
beta O
- O
adrenomimetics O
partusisten O
and O
Pre O
- O
par O

Since O
September O
1980 O
to O
June O
1983 O
we O
have O
treated O
32 O
patients O
with O
ovarian O
cancer O
. O

The O
results O
suggest O
that O
the O
calcium O
antagonist O
, O
diltiazem O
, O
may O
modify O
the O
effects O
of O
isoflurane O
on O
myocardial O
function O
. O

Supraventricular O
arrhythmias O
-- O
digoxin O
and O
quinidine O
revisited O
. O

Visidex O
I O
is O
unsuitable O
for O
storage O
and O
re O
- O
reading O
. O

Treatment O
with O
oxyphenylbutazone O
and O
hydrocortisone O
failed O
to O
inhibit O
the O
raised O
serum I-GENE
CPN I-GENE
levels O
. O

40 O
, O
000 O
). O

The O
Cox O
proportional O
hazards O
model O
was O
applied O
to O
the O
data O
in O
order O
to O
determine O
the O
prognostic O
factors O
for O
long O
- O
term O
survival O
. O

This O
suggests O
that O
mechanisms O
other O
than O
an O
excessive O
increase O
in O
myocardial O
oxygen O
demand O
may O
be O
responsible O
for O
the O
many O
episodes O
occurring O
outside O
the O
hospital O
. O

Duration O
of O
remission O
in O
advanced O
gastric O
cancer O
patients O
responding O
to O
sequential O
dose O
of O
MTX O
and O
5 O
- O
FU O

These O
data O
showed O
: O
that O
progesterone O
secretion O
is O
pulsatile O
throughout O
the O
human O
luteal O
phase O
, O
with O
maximum O
frequency O
in O
the O
mid O
- O
luteal O
phase O
; O
that O
during O
the O
mid O
- O
luteal O
phase O
most O
subjects O
had O
progesterone O
levels O
both O
above O
and O
below O
currently O
accepted O
ovulatory O
thresholds O
; O
the O
use O
of O
a O
single O
measurement O
of O
progesterone O
in O
the O
mid O
- O
luteal O
phase O
is O
not O
always O
a O
reliable O
indicator O
of O
ovulation O
; O
a O
threshold O
greater O
than O
20 O
nmol O
/ O
l O
may O
yield O
an O
unacceptable O
number O
of O
false O
negative O
results O
. O

The O
fast O
real O
- O
time O
digital O
processing O
of O
the O
N2 O
and O
flow O
signals O
incorporated O
filtering O
, O
delay O
compensation O
, O
and O
corrections O
for O
the O
effects O
of O
changes O
in O
gas O
composition O
and O
temperature O
. O

This O
slope O
tended O
to O
be O
higher O
( O
approximately O
1 O
. O
6 O
dB O
/ O
dB O
) O
for O
L1 O
= O
L2 O
greater O
than O
80 O
dB O
. O

Histamine O
reactivity O
was O
significantly O
reduced O
after O
the O
nifedipine O
aerosol O
, O
the O
geometric O
mean O
provocative O
concentration O
causing O
a O
35 O
% O
fall O
in O
specific O
airway O
conductance O
, O
rising O
from O
5 O
. O
0 O
to O
10 O
. O
9 O
mg O
/ O
ml O
of O
histamine O
( O
p O
less O
than O
0 O
. O
05 O
). O

Pharmacologic O
doses O
of O
vitamin O
B6 O
administered O
to O
lactating O
women O
have O
been O
reported O
to O
suppress O
plasma I-GENE
prolactin I-GENE
. O

There O
was O
a O
significant O
but O
similar O
elevation O
of O
mean O
O2 O
uptake O
during O
40 O
min O
postexercise O
by O
13 O
. O
6 O
% O
in O
both O
the O
fasted O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
fed O
state O
( O
p O
less O
than O
0 O
. O
001 O
). O

National O
Institutes O
of O
Health O
Consensus O
Development O
Conference O
Statement O
. O

In O
controls O
, O
most O
of O
the O
output O
from O
the O
conduit O
occurred O
during O
type O
I O
activity O
( O
73 O
+/- O
14 O
%). O

Greater O
attenuation O
of O
the O
N1 O
- O
P2 O
and O
baseline O
- O
P2 O
amplitude O
of O
the O
probe O
EPs O
was O
observed O
when O
the O
probe O
stimulus O
was O
presented O
to O
the O
right O
ear O
and O
the O
verbal O
material O
presented O
to O
the O
left O
ear O
than O
when O
the O
opposite O
stimulation O
arrangement O
was O
used O
. O

Twenty O
- O
five O
patients O
( O
80 O
, O
6 O
%) O
with O
mixed O
neoplasms O
were O
operated O
on O
by O
total O
conservative O
parotidectomy O
( O
T O
. O
C O
. O
P O
.), O
3 O
( O
9 O
, O
7 O
%) O
by O
S O
. O
P O
. O
and O
3 O
( O
9 O
, O
7 O
%) O
by O
En O
. O

The O
comparisons O
revealed O
that O
female O
homicide O
- O
suicide O
perpetrators O
were O
more O
likely O
than O
female O
homicide O
- O
suicide O
victims O
to O
live O
in O
mobile O
homes O
, O
kill O
their O
lover O
or O
ex O
- O
lover O
, O
have O
their O
crime O
accidentally O
discovered O
, O
leave O
a O
suicide O
note O
, O
kill O
on O
a O
weekend O
, O
and O
be O
depressed O
, O
but O
are O
less O
likely O
than O
female O
homicide O
- O
suicide O
victims O
to O
live O
with O
a O
spouse O
. O

Germ O
- O
free O
rabbits O
given O
mouse O
CRF O
- O
flora O
showed O
values O
quite O
different O
from O
control O
animals O
for O
most O
parameters O
, O
indicating O
unsuitability O
of O
mouse O
CRF O
flora O
to O
' O
normalize O
' O
rabbits O
. O

The O
weak O
relationships O
between O
F O
and O
Zn O
to O
Mg O
clearly O
have O
no O
significant O
effect O
on O
the O
contents O
of O
these O
elements O
in O
bone O
. O

L3 O
- O
L4 O
compressive O
load O
was O
calculated O
using O
a O
model O
of O
the O
anatomy O
of O
the O
trunk O
musculoskeletal O
system O
. O

Diagnosis O
: O
progressive O
multifocal O
leukoencephalopathy O
. O

Component O
P100 O
was O
associated O
with O
a O
frontal O
negativity O
of O
similar O
latency O
favoring O
the O
hypothesis O
of O
a O
dipolar O
occipital O
generator O
. O

Although O
no O
differences O
were O
noted O
in O
the O
decrease O
in O
platelet O
counts O
between O
the O
two O
groups O
, O
fibrinogen I-GENE
levels O
and O
alpha I-GENE
2 I-GENE
- I-GENE
antiplasmin I-GENE
levels O
declined O
less O
drastically O
in O
the O
antithrombin I-GENE
- O
treated O
group O
. O

Failure O
of O
stapedius O
reflexometry O
in O
the O
diagnosis O
of O
myasthenia O
gravis O
. O

Factors O
influencing O
semen O
characteristics O
in O
young O
boars O
reared O
in O
a O
subtropical O
environment O
were O
studied O
. O

[ O
14C O
]- O
beta O
- O
phenethylamine O
, O
its O
distribution O
after O
administration O
by O
various O
routes O
to O
cats O
, O
and O
the O
effects O
of O
monoamine I-GENE
oxidase I-GENE
inhibitors O
. O

All O
runners O
drank O
a O
total O
of O
1 O
. O
4 O
L O
of O
water O
during O
the O
race O
. O

The O
rates O
of O
total O
energy O
use O
( O
mean O
+/- O
SD O
= O
39 O
. O
3 O
+/- O
1 O
. O
2 O
vs O
35 O
. O
7 O
+/- O
1 O
. O
3 O
kJ O
X O
min O
- O
1 O
; O
P O
less O
than O
0 O
. O
05 O
) O
were O
significantly O
higher O
at O
- O
10 O
degrees O
C O
than O
at O
22 O
degrees O
C O
. O

Clinical O
aspects O
and O
therapy O

Following O
seven O
days O
' O
incubation O
both O
at O
20 O
degrees O
C O
and O
28 O
degrees O
C O
, O
Ae O
. O
vexans O
nip O
. O
was O
capable O
of O
transmitting O
the O
virus O
. O

Blood O
eosinophils O
in O
patients O
with O
Taenia O
saginata O
taeniasis O
. O

The O
imino O
proton O
of O
T3 O
in O
the O
O6meG O
. O
T O
12 O
- O
mer O
and O
G3 O
in O
the O
O6meG O
. O
N O
12 O
- O
mer O
helix O
, O
which O
are O
associated O
with O
the O
modification O
site O
, O
resonate O
at O
unusually O
high O
field O
( O
8 O
. O
5 O
to O
9 O
. O
0 O
ppm O
) O
compared O
to O
imino O
protons O
in O
Watson O
- O
Crick O
base O
pairs O
( O
12 O
. O
5 O
to O
14 O
. O
5 O
ppm O
). O

The O
recommendation O
is O
made O
that O
specific O
sub O
- O
groups O
of O
attempters O
need O
to O
be O
identified O
and O
may O
warrant O
specialized O
intervention O
strategies O
. O

There O
was O
no O
correlation O
between O
secretor O
status O
and O
clinical O
status O
, O
spirometry O
measurements O
, O
salivary I-GENE
and I-GENE
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
tract O
colonization O
with O
P O
. O
aeruginosa O
and O
S O
. O
aureus O
. O

There O
was O
no O
correlation O
between O
secretor O
status O
and O
clinical O
status O
, O
spirometry O
measurements O
, O
salivary O
and O
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
tract O
colonization O
with O
P O
. O
aeruginosa O
and O
S O
. O
aureus O
. O

Gains O
increased O
3 O
. O
5 O
% O
( O
P O
less O
than O
. O
10 O
) O
and O
feed O
conversion O
improved O
5 O
. O
9 O
% O
( O
P O
less O
than O
. O
07 O
) O
in O
steers O
fed O
. O
28 O
% O
AS O
- O
VFA O
compared O
with O
gain O
and O
feed O
conversion O
of O
the O
control O
steers O
. O

Postnatal O
volumetric O
development O
of O
the O
prefrontal O
cortex O
in O
the O
rat O
. O

Daily O
and O
seasonal O
rhythmicity O
in O
the O
methylation O
of O
pineal O
indolic O
compounds O
in O
adult O
male O
golden O
hamsters O
, O
kept O
under O
natural O
conditions O
. O

The O
transit O
time O
was O
significantly O
shortened O
. O

Among O
the O
patients O
grades O
1 O
- O
2 O
- O
3 O
, O
81 O
% O
had O
a O
good O
out O
come O
without O
any O
neurological O
abnormality O
, O
among O
the O
patients O
graded O
4 O
- O
5 O
, O
only O
27 O
% O
had O
a O
fair O
out O
come O
. O

Activity O
of O
acid I-GENE
hydrolases I-GENE
of O
peripheral O
blood O
leukocytes O
in O
focal O
and O
segmental O
pneumonia O
in O
children O

Comparative O
studies O
of O
the O
antithrombin I-GENE
III I-GENE
level O
and O
plasminogen I-GENE
activator I-GENE
activity O
in O
patients O
with O
thrombophlebitis O

We O
also O
observed O
that O
the O
predictive O
ability O
of O
the O
selected O
attitudes O
and O
orientations O
increased O
considerably O
from O
1975 O
to O
1982 O
. O

Relations O
between O
cellular O
electrical O
activity O
and O
cardiac O
mechanical O
activity O
in O
man O
, O
the O
dog O
and O
the O
rabbit O

Treatment O
of O
Paget O
' O
s O
disease O
. O

Improvement O
of O
the O
CRT O
display O
of O
an O
averager O
. O

Is O
desensitization O
' O
for O
ragweed O
hay O
fever O
immunologically O
specific O
? O

Renal O
excretion O
of O
sulphadimidine O
in O
normal O
and O
uraemic O
subjects O
. O

Experiences O
with O
the O
clinical O
and O
experimental O
use O
of O
Urat O
- O
I O
lithotriptor O
. O

Formation O
of O
hyphae O
and O
chlamydospores O
by O
Cryptococcus O
laurentii O
. O

Evaluation O
of O
thyroid O
function O
. O

The O
effect O
of O
a O
tissue O
emulsion O
, O
vitamin O
A O
and O
nonspecific O
gamma I-GENE
- I-GENE
globulin I-GENE
on O
the O
blood O
clearance O
in O
rabbits O

HL I-GENE
- I-GENE
A I-GENE
antibodies I-GENE
in O
polytransfused O
patients O

Demonstration O
of O
fine O
structure O
of O
the O
guinea O
pig O
organ O
of O
Corti O
after O
electron O
microscopic O
silver O
staining O

Histamine O
metabolism O
in O
hemorrhagic O
- O
hypotensive O
shock O

They O
also O
discuss O
the O
existing O
nomenclature O
. O

Relaxation O
of O
catch O
in O
a O
molluscan O
smooth O
muscle O
. O

Studies O
on O
alcoholic O
liver O
injury O
. O

Hypothalamic O
control O
of O
coronary O
circulation O
in O
the O
dog O
. O

Evidence O
for O
two O
distinctive O
clinical O
, O
epidemiological O
, O
and O
immunological O
types O
of O
infection O
. O

Ultraviolet O
light O
- O
induced O
kinin I-GENE
formation O
in O
human O
skin O
. O

Poliomyelitis O
from O
a O
vaccine O
. O

To O
the O
problem O
of O
the O
stimulation O
of O
the O
growth O
of O
transplantable O
tumors O
of O
animals O
previously O
treated O
with O
antineoplastic O
antibiotics O

Assessment O
of O
nutrient O
media O
in O
the O
diagnosis O
of O
diptheria O

Aluminium O
resin O
for O
the O
treatment O
of O
the O
hyperkalamia O
of O
renal O
failure O
. O

Value O
of O
the O
EMG O
in O
the O
diagnosis O
of O
a O
cardiomyopathy O
associated O
with O
a O
myotonic O
myopathy O
. O

D O
. O

Prevention O
of O
maternal O
Rh O
sensitization O
: O
anti I-GENE
- I-GENE
Rh I-GENE
immune I-GENE
globulin I-GENE
. O

Serotonin O
levels O
in O
infant O
hypothyroidism O
. O

Cerebrospinal O
fluid O
transferrin I-GENE
II I-GENE
studies O
in O
ischemic O
disorders O
of O
the O
central O
nervous O
system O
. O

High O
dosages O
of O
D O
- O
penicillamine O
in O
pulmonary O
fibroses O

Inverse O
relation O
between O
serum O
IgG I-GENE
concentration O
and O
glucose O
and O
xylose O
absorption O
in O
Zambian O
African O
adults O
. O

Disorders O
of O
platelet O
function O
in O
chronic O
myeloid O
leukemias O

The O
effect O
of O
anticonvulsants O
on O
sodium I-GENE
- I-GENE
potassium I-GENE
- I-GENE
activated I-GENE
ATPase I-GENE
, O
sodium O
, O
and O
potassim O
in O
cortex O
. O

Effect O
of O
immune O
lymphocytes O
and O
of O
rabbit I-GENE
- I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
( O
RAMLG I-GENE
) O
on O
infected O
macrophages O
exposed O
to O
increased O
incubation O
temperature O
in O
vitro O
. O

Estral O
cycle O
in O
white O
rats O
in O
the O
low O
and O
high O
mountains O
of O
Kirghizia O

Lactation O
of O
baboons O
fed O
a O
low O
protein O
maintenance O
diet O
. O

Studies O
on O
the O
organic O
matrix O
of O
human O
ear O
ossicles O

A O
medical O
- O
geographical O
review O

Age O
and O
sex O
structure O
of O
the O
natural O
population O
of O
Ornithodoros O
tatarovski O
Ol O
. O

Sensitization O
to O
hyperlactatemia O
induced O
by O
phenformin O
after O
subtotal O
ablation O
of O
the O
pancreas O
. O

Vitamin O
D3 O
and O
calcium O
absorption O
in O
the O
chick O
. O

The O
incidence O
of O
tumours O
in O
young O
chickens O
. O

Laboratory O
aspects O
with O
particular O
reference O
to O
chemotherapy O
and O
control O
. O

Their O
effect O
on O
the O
guinea O
pig O
vas O
deferens O
. O

Androgens O
and O
growth O
. O

Effect O
of O
variations O
in O
time O
interval O
between O
treatment O
with O
BCG O
and O
quartz O
dust O
on O
translocation O
of O
quartz O
dust O
from O
the O
lungs O
to O
their O
regional O
lymph O
nodes O
. O

Therapeutic O
action O
of O
a O
new O
antibiotic O
- O
corticoid O
association O
used O
for O
instillations O
in O
otology O

Clinico O
- O
physiological O
experiment O

Enzyme O
histochemical O
findings O
in O
the O
ultimobranchial O
body O
of O
the O
horse O

Familial O
glutathione I-GENE
reductase I-GENE
deficiency O
and O
disorder O
of O
glutathione O
synthesis O
in O
the O
erythrocyte O

Studies O
on O
swine O
enteroviruses O
. O

Serodiagnosis O
of O
ectromelia O
in O
laboratory O
mice O

Ultrasound O
effect O
on O
the O
cytochrome I-GENE
oxidase I-GENE
activity O

Metastasis O
of O
colon O
carcinoma O
to O
the O
lip O
. O

Genesis O
of O
foam O
cells O
: O
study O
in O
rats O
after O
administration O
of O
Cloforex O
. O

Pre I-GENE
- I-GENE
beta I-GENE
- I-GENE
1 I-GENE
lipoprotein I-GENE
and O
early O
detection O
of O
risk O
factors O
for O
coronary O
heart O
disease O
. O

Conditions O
influencing O
inhibitors O
of O
the O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
). O

Absence O
of O
action O
potentials O
in O
frog O
slow O
muscle O
fibres O
paralysed O
by O
botulinum I-GENE
toxin I-GENE
. O

An O
automated O
method O
for O
the O
quantitative O
analysis O
of O
the O
polyamines O
putrescine O
, O
spermidine O
and O
spermine O
in O
cerebrospinal O
fluid O
( O
CSF O
) O
was O
used O
to O
analyze O
CSF O
samples O
from O
37 O
patients O
with O
central O
nervous O
system O
( O
CNS O
) O
tumors O
and O
from O
13 O
patients O
without O
tumors O
. O

I O
. O

Disulfiram O
and O
the O
drug O
- O
induced O
effects O
on O
motility O
. O

Particles O
resembling O
microbodies O
in O
normal O
and O
neoplastic O
perianal O
glands O
of O
dogs O
. O

Natural O
and O
induced O
malarias O
in O
western O
hemisphere O
monkeys O
. O

A O
study O
in O
vivo O
of O
adrenergic I-GENE
receptors I-GENE
in O
the O
rectum O
and O
in O
the O
internal O
and O
sphincter O
of O
the O
cat O
. O

Intracranial O
arachnoid O
cyst O
of O
the O
middle O
fossa O
demonstrated O
by O
positive O
99mTc O
brainscintigraphy O
. O

Effects O
of O
estrogen O
and O
glucocorticoids O
on O
the O
adrenal O
development O
of O
the O
fetus O
. O

Copper O
and O
ceruloplasmin I-GENE
content O
in O
pregnant O
women O
and O
in O
women O
with O
certain O
gynecological O
diseases O

Effect O
of O
noise O
on O
CO O
- O
induced O
increases O
of O
LAP I-GENE
and O
GPT I-GENE
activity O
in O
the O
plasma O
of O
rats O

Kinetics O
of O
calcium O
metabolism O
. O

On O
the O
transport O
of O
mucus O
and O
its O
rheologic O
simulants O
in O
ciliated O
systems O
. O

A O
hydrodynamic O
description O
of O
the O
osmotic O
reflection O
coefficient O
with O
application O
to O
the O
pore O
theory O
of O
transcapillary O
exchange O
. O

Pathology O
of O
neuritis O
caudae O
equinae O
in O
the O
horse O

Abnormal O
characteristics O
and O
verticillation O
in O
Platynothrus O
peltifer O

Selected O
topics O
in O
laboratory O
animal O
medicine O
. O

Problems O
common O
to O
pediatrics O
and O
anesthesiology O

Clinical O
course O
and O
nursing O
care O
of O
patients O
with O
decubitus O
ulcer O
-- O
use O
of O
pillows O
stuffed O
with O
buckwheat O
chaff O

On O
parents O

From O
the O
Icelandic O
Red O
Cross O
activities O

Effects O
of O
alcoholism O
on O
the O
family O

Treatment O
and O
care O
of O
adult O
diabetes O
mellitus O
without O
coma O

Re O
- O
examining O
methylbenzene O
( O
toluene O
) O
as O
a O
treatment O
for O
Ancylostomum O
caninum O
. O

Junctions O
between O
cells O
of O
the O
human O
enamel O
organ O
. O

Electrocardiograms O
of O
the O
month O
. O

Composites O
as O
restoration O
materials O

Hodgkin O
' O
s O
disease O
. O

Value O
of O
Normotest O
and O
antithrombin I-GENE
3 I-GENE
in O
the O
assessment O
of O
liver O
function O
. O

Glutathione I-GENE
peroxidase I-GENE
in O
human O
red O
cells O
in O
health O
and O
disease O
. O

Histopathologic O
response O
of O
gingival O
tissues O
to O
hemodent O
and O
aluminum O
chloride O
solutions O
as O
tissue O
displacement O
materials O
. O

Changes O
following O
periodontal O
surgery O
. O

Intracellular O
pH O
, O
H O
ion O
flux O
and O
H O
ion O
permeability O
coefficient O
in O
bullfrog O
toe O
muscle O
. O

Teratological O
studies O
on O
SF O
- O
837 O
. O

Directives O
concerning O
medical O
care O

Proceedings O
: O
Reversible O
complete O
heart O
block O
following O
surgery O
of O
congenital O
heart O
defects O

Method O
of O
synthesis O
of O
the O
rheumatoid I-GENE
factor I-GENE
in O
clinico O
- O
immunological O
studies O

Variations O
of O
the O
timing O
of O
deflections O
in O
the O
His O
bundle O
recordings O
. O

Extracellular O
fibril O
formation O
by O
neuroglial O
cells O
at O
the O
vitreoretinal O
junction O
of O
the O
human O
eye O
. O

Blood O
platelets O
, O
coagulation O
factors O
and O
morphologic O
organ O
changes O
following O
scalding O
shock O
in O
rhesus O
monkeys O

Cell O
viability O
and O
lysosomal I-GENE
enzymes I-GENE

State O
- O
approved O
schools O
of O
nursing O
-- O
R O
. O
N O
., O
1972 O
. O

Further O
investigation O
on O
the O
chemotactic O
influence O
of O
thymic I-GENE
hormone I-GENE
on O
lymphocytes O

1 O
, O
3 O
- O
bis O
( O
2 O
- O
chloroethyl O
)- O
1 O
- O
nitrosourea O
( O
bcnu O
) O
and O
other O
nitrosoureas O
in O
cancer O
treatment O
: O
a O
review O
. O

Pneumothorax O
following O
lung O
abscess O
in O
the O
renal O
transplant O
patient O
. O

Taxonomically O
significant O
colour O
changes O
in O
Brevibacterium O
linens O
probably O
associated O
with O
a O
carotenoid O
- O
like O
pigment O
. O

Temporal O
relationships O
and O
the O
development O
phase O
affected O
. O

A O
short O
history O
of O
dermatology O
in O
Lagos O
, O
Nigeria O
. O

Local O
graft O
irradiation O
as O
an O
adjunct O
to O
pharmacologic O
immunosuppression O
. O

Letter O
: O
Salmonella O
detection O

Role O
of O
biocenosis O
in O
the O
manifestation O
of O
Shigella O
virulence O

The O
effect O
of O
antilymphocyte O
sera O
on O
formation O
of O
transplantation O
and O
anti O
- O
infection O
immunity O
in O
mice O

60th O
birthday O
of O
colonel O
prof O
. O
e O
. O
cerny O
m O
. O
d O
. O

Morphology O
of O
bacteriophages O
of O
Klebsiella O
bacilli O
. O

Cortical O
afferents O
to O
the O
entorhinal O
cortex O
of O
the O
Rhesus O
monkey O
. O

Mechanism O
of O
immunogenesis O
in O
vaccination O
with O
streptomycin O
- O
dependent O
mutants O
of O
salmonellae O
and O
shigellae O
. O

Resistance O
pattern O
of O
Mycobacterium O
tuberculosis O
( O
H O
37 O
Rv O
) O
to O
a O
new O
antibiotic O
, O
lividomycin O

Pulmonary O
arterial O
pressure O
and O
structure O
in O
the O
patas O
monkey O
after O
prolonged O
administration O
of O
aminorex O
fumarate O
. O

Effect O
of O
triftazin O
and O
aminazin O
on O
hippocampal O
bioelectric O
activity O

Sex O
ratio O
at O
birth O
. O

Pathological O
processes O
in O
the O
cervix O
uteri O

Benign O
intramural O
tumors O
of O
the O
esophagus O

General O
formulae O
for O
estimating O
heritability O
in O
a O
population O
with O
related O
parents O
. O

Measurement O
of O
open O
- O
loop O
responses O
to O
electrical O
stimulation O
in O
olfactory O
bulb O
of O
cat O
. O

Glucose O
disappearance O
rate O
and O
changes O
in O
plasma O
nutrients O
after O
intravenouly O
injected O
glucose O
in O
normoglycaemic O
and O
hypoglycaemic O
underweight O
newborns O
. O

Normal O
values O
for O
the O
peripheral O
blood O
and O
bone O
marrow O
of O
the O
grey O
( O
Armenian O
) O
hamster O

The O
relationship O
of O
human O
umbilical O
arterial O
and O
venous O
plasma O
levels O
of O
corticosteroids O
to O
gestational O
age O
. O

Antibiotic O
effect O
of O
the O
mud O
from O
heviz O

Sulfuric O
acid O
concentration O
in O
the O
catalyzed O
breathalyzer O
ampules O
. O

Role O
of O
histoclinical O
studies O
in O
the O
prophylaxis O
of O
spontaneous O
abortions O

Range O
behavior O
of O
Hereford O
, O
Hereford O
x O
Holstein O
and O
Holstein O
non O
- O
lactating O
heifers O
. O

Chemical O
constituents O
of O
the O
gentianaceae O
V O
: O
tetraoxygenated O
xanthones O
of O
Swertia O
chirata O
Buch O
.- O
Ham O
. O

Methyl O
mercury O
intoxication O
in O
rat O
kidneys O
. O

Microdetermination O
of O
adrenocortical O
steroids O
by O
double O
isotope O
method O
. O

Compensative O
justice O
and O
moral O
investment O
among O
Japanese O
, O
Chinese O
, O
and O
Koreans O
. O

Effects O
of O
cortisone O
, O
starvation O
, O
and O
rickets O
on O
oxidative O
enzyme O
activities O
of O
epiphyseal O
cartilage O
from O
rats O
. O

Metal O
coordination O
compounds O
of O
thiabendazole O
. O

Estimation O
of O
renin I-GENE
secretion O
rate O
and O
renal O
plasma O
flow O
from O
peripheral O
and O
renal I-GENE
vein I-GENE
renin I-GENE
levels O
. O

Disability O
insurance O
under O
social O
security O
. O

Choice O
of O
vessel O
. O

Suppression O
of O
food O
intake O
in O
the O
rat O
by O
tung O
oil O
. O

Studies O
of O
lipoprotein I-GENE
- I-GENE
X I-GENE
( O
LP I-GENE
- I-GENE
X I-GENE
) O
and O
bile O
acids O
in O
familial O
LCAT I-GENE
deficiency O
. O

Pneumothorax O
complicated O
by O
chronic O
steroid O
treatment O
. O

Polycythemia O
- O
1973 O
. O

Manifest O
anxiety O
of O
Vietnam O
returnees O
and O
undergraduates O
. O

Familial O
juvenile O
nephronophthisis O

Early O
heparin O
therapy O
in O
60 O
children O
with O
acute O
meningococcemia O
. O

9 O
, O
11 O
- O
Seco O
steroids O
derived O
from O
estradiol O
3 O
- O
methyl O
ether O
. O

Psychological O
examinations O
in O
patients O
with O
chronic O
kidney O
insufficiency O

Possibilities O
of O
needleless O
administration O
of O
various O
substances O
to O
animals O

Change O
in O
the O
makeup O
of O
the O
blood O
following O
a O
short O
- O
term O
local O
action O
of O
a O
permanent O
magnetic O
field O
on O
the O
human O
body O

Observations O
on O
the O
flight O
activities O
of O
Chrysops O
caecutiens O
L O
. O

Combination O
of O
3 O
multiple O
primary O
malignant O
and O
benign O
tumors O
of O
the O
breasts O
and O
uterus O

Analysis O
of O
clearance O
curve O
of O
rose O
bengal O
- O
I O
- O
131 O

Proceedings O
: O
Barrels O
and O
somatotopy O
in O
S O
I O
neocortex O
of O
the O
brush O
- O
tailed O
possum O
. O

Antivitamin O
K O
agents O

Canine O
reproduction O
: O
effects O
of O
a O
single O
injection O
of O
medroxyprogesterone O
acetate O
on O
the O
reproductive O
organs O
of O
the O
bitch O
. O

3 O
. O

Hypoglycemic O
and O
antidiabetic O
properties O

Hematopoietic O
system O
in O
streptococcal O
allergy O
. O

Letter O
: O
Aryl I-GENE
hydrocarbon I-GENE
hydroxylase I-GENE
and O
smoking O
. O

Evaluation O
of O
1 O
, O
10 O
- O
phenanthroline O
as O
a O
reagent O
for O
sialic O
acid O
determinations O
. O

Delta O
- O
aminolevulinic O
acid O
in O
physiological O
conditions O
and O
some O
diseases O
in O
children O

Nonteratogenicity O
in O
rats O
of O
blighted O
potatoes O
and O
compounds O
contained O
in O
them O
. O

VII O
. O

Isolation O
of O
tha O
avian O
reticuloendothelial O
virus O
( O
strain O
T O
). O

Observations O
on O
saccules O
of O
rats O
exposed O
to O
long O
- O
term O
hypergravity O
. O

Effect O
of O
a O
high O
- O
intensity O
SHF O
field O
on O
the O
blood O
coagulation O
system O

The O
levels O
of O
galactosyltransferase I-GENE
activity O
in O
sera O
from O
normal O
children O
and O
patients O
with O
cystic O
fibrosis O
. O

Lack O
of O
effect O
of O
the O
appetite O
stimulant O
pizotifen O
( O
BC O
105 O
) O
on O
the O
absorption O
of O
isonicotinylhydrazine O
. O

Relationship O
between O
gross O
lesions O
and O
Escherichia O
coli O
serotypes O
in O
chronic O
respiratory O
disease O
( O
CRD O
) O
of O
poultry O
. O

Plastic O
solution O
of O
elbow O
joint O
ankylosis O
with O
a O
decorticated O
cylindrical O
flap O

Effects O
of O
ionizing O
radiation O
in O
the O
human O
oral O
cavity O
and O
oropharynx O
: O
results O
of O
a O
survey O
. O

The O
Twentieth O
Anniversary O
of O
the O
Pomeranian O
Medical O
Academy O
. O

Immunelectrophoretic O
pattern O
of O
Wassermann O
reagin O
and O
comparison O
of O
the O
appearance O
time O
between O
RPCF I-GENE
and O
FTA I-GENE
antibodies I-GENE

Motile O
nocardoid O
Actinomycetales O
. O

Electrocardiographic O
QRS O
complexes O
and O
vectorcardiographic O
QRS O
loop O

Study O
of O
antinuclear O
autoantibodies O
by O
immunofluorescence O
technic O
in O
collagen I-GENE
diseases O

Cardiac O
preservation O
. O

Labial O
bar O
. O

Yusuf O
Dawood O
Docrat O
L O
. O
R O
. O
C O
. O
P O
. O

Dr O
. O

The O
metabolism O
and O
pharmacology O
of O
5 O
- O
fluorouracil O
. O

Spleen O
weight O
in O
rats O
during O
tumour O
growth O
and O
in O
homograft O
rejection O
. O

Isolation O
of O
Proteus O
vulgaris O
MC O
- O
63 O
from O
carcinoma O
63 O
and O
its O
antitumor O
effect O
on O
Crocker O
sarcoma O
180 O
and O
Ehrlich O
carcinoma O
. O

Human O
synovial O
fluid O
: O
detection O
of O
a O
new O
component O
. O

Effects O
of O
temperature O
and O
moulting O
cycle O
on O
melanin O
synthesis O
in O
the O
newt O
, O
Triturus O
cristatus O
. O

Some O
reflexions O
apropos O
of O
a O
personal O
statistical O
study O
of O
513 O
arterial O
embolisms O

LA O
- O
3848 O
- O
MS O
. O

Immunochemical O
studies O
with O
filarial O
antigens O
. O

Morphological O
and O
functional O
alterations O
noted O
after O
baboon O
renal O
allotransplantation O
. O

Heterogeneity O
of O
human I-GENE
serum I-GENE
albumin I-GENE
. O

Analysis O
of O
corticosteroids O
. O

Reactivities O
to O
horse I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
. O

Plasma I-GENE
histaminase I-GENE
in O
patients O
of O
bronchial O
asthma O
and O
the O
effect O
of O
prednisolone O
administration O
on O
it O
. O

A O
comparative O
study O
of O
the O
cortical O
end O
of O
the O
auditory O
analyzer O
during O
postnatal O
ontogenesis O
in O
lower O
monkeys O
and O
man O

The O
effect O
of O
osmotic O
flow O
on O
the O
distribution O
of O
horseradish I-GENE
peroxidase I-GENE
within O
the O
intercellular O
spaces O
of O
toad O
bladder O
epithelium O
. O

Immunogenicity O
of O
various O
mycobacteria O
and O
the O
corresponding O
levels O
of O
cross O
- O
protection O
developed O
between O
species O
. O

Ten O
- O
year O
experience O
with O
one O
- O
stage O
proctocolectomy O
and O
anal O
ileostomy O
. O

Nitrogen O
- O
hydrogen O
tautomerism O
in O
porphyrins O
and O
chlorins O
. O

Factors O
affecting O
the O
inhibition O
of O
phagocytosis O
by O
chlorpromazine O
. O

Photopic O
spectral O
sensitivity O
determined O
electroretinographically O
for O
the O
pigeon O
eye O
. O

Angiography O
of O
aneurysmal O
bone O
cyst O
. O

Cholinesterase I-GENE

Sodium O
restriction O
in O
cardiac O
failure O
. O

Clinical O
and O
angiographic O
examinations O
in O
occlusion O
disease O
of O
the O
great O
intestinal O
arteries O

Serum O
lipid O
changes O
during O
pregnancy O
due O
to O
oral O
calcium O
administration O

Successful O
treatment O
of O
candidiasis O
with O
transfer I-GENE
factor I-GENE
. O

A O
possible O
role O
for O
the O
mixed O
function O
oxidase I-GENE
enzyme O
system O
in O
the O
requirement O
for O
selenium O
in O
the O
rat O
. O

Periodic O
breathing O
and O
apnea O
in O
preterm O
infants O
. O

Working O
session O
report O
: O
in O
vivo O
- O
in O
vitro O
screening O
. O

Clinicopathologic O
studies O
in O
feminizing O
tumors O
of O
the O
ovary O
. O

On O
the O
constituents O
of O
Dryopteris O
polylepis O

Relation O
between O
mixing O
ratio O
of O
raw O
materials O
and O
composition O
of O
products O
in O
the O
synthesis O
of O
aluminosilicates O

Influence O
of O
diet O
on O
urinary O
VMA O
excretion O
. O

Oscilloscope O
triggering O
circuit O
for O
recording O
long O
transients O
at O
fast O
sweep O
speeds O
. O

Derivatives O
of O
boswellic O
acids O
. O

The O
status O
of O
education O
and O
training O
programs O
in O
speech O
pathology O
and O
audiology O
-- O
1971 O
- O
72 O
. O

Coronary O
arteries O
-- O
old O
and O
new O
. O

Antiviral O
agents O
. O

Separation O
of O
ninhydrin O
- O
positive O
compounds O
in O
urine O
by O
the O
combined O
methods O
of O
medium O
- O
tension O
intophoresis O
and O
partition O
chromatography O

Conservative O
treatment O
of O
central O
nervous O
system O
injuries O

Spasmus O
nutans O
: O
a O
syndrome O
of O
auto O
- O
arousal O
. O

6 O
. O

1st O
data O
on O
the O
immunosuppressive O
therapy O
of O
scleroderma O

Slowed O
lysosomal I-GENE
enzyme I-GENE
release O
and O
its O
normalization O
by O
drugs O
in O
adjuvant O
- O
induced O
polyarthritis O
. O

Treatment O
of O
ovarian O
neoplasms O

Experimental O
pancreatitis O
in O
pigs O
. O

Bacterial O
metabolism O
of O
4 O
- O
chlorophenoxyacetate O
. O

Dynamics O
of O
hospital O
stay O
in O
peptic O
ulcer O
patients O

I O
. O

Surgical O
treatment O
of O
pathologic O
scars O
of O
myocardial O
infarct O

The O
interaction O
of O
caffeine O
, O
theophylline O
and O
theobromine O
with O
monoamine I-GENE
oxidase I-GENE
inhibitors O
. O

Effect O
of O
phenformin O
on O
gluconeogenesis O
in O
perfused O
rat O
liver O
. O

New O
alkaloids O
from O
bark O
of O
Erythrophleum O
ivorense O
. O

A O
case O
of O
M O
hemoglobinosis O

Radiosensitive O
nature O
of O
paravascular O
infiltrate O
- O
producing O
potential O
of O
parental O
spleen O
cells O
. O

Sinusoidal O
oscillations O
of O
a O
gas O
dilution O
indicator O

The O
value O
of O
different O
sources O
of O
nitrogen O
in O
diets O
for O
the O
early O
- O
weaned O
calf O
. O

1 O
. O

Abdominal O
tumors O
in O
childhood O
. O

Results O
of O
the O
official O
inspection O
of O
the O
commercial O
anti O
- O
inflammatory O
enzyme O
preparations O
containing O
chymotrypsin I-GENE
and O
trypsin I-GENE
by O
means O
of O
modified O
NF O
13 O
methods O

Studies O
on O
the O
hereditary O
nature O
of O
sole O
prints O
-- O
with O
special O
reference O
to O
interdigital O
and O
triradii O

The O
problem O
of O
disablement O
due O
to O
pulmonary O
tuberculosis O
, O
on O
the O
basis O
of O
an O
analysis O
of O
the O
history O
of O
395 O
cases O
as O
observed O
in O
Gdansk O
in O
the O
years O
1946 O
- O
1965 O

Cleidocranial O
dysostosis O

Proposals O
on O
authorization O
; O
by O
a O
group O
of O
nurses O
from O
psychiatric O
hospitals O

Successive O
abdominal O
scintillation O
with O
131 O
- O
I O
- O
tagged O
BSP O
-- O
description O
of O
the O
thyroid O
gland O
, O
kidney O
and O
spleen O
( O
comparison O
with O
131 O
- O
I O
- O
RB O
) O

Pneumonia O
in O
children O

Osteosarcoma O
caused O
by O
3 O
, O
4 O
- O
benzopyrene O

The O
content O
of O
glucosamine O
and O
galactosamine O
in O
tartar O

Relapse O
of O
leukemia O
after O
prolonged O
remission O
. O

Influence O
of O
cigarette O
smoking O
on O
some O
blood O
coagulation O
tests O
. O

The O
non O
- O
role O
of O
fluoride O
in O
the O
control O
of O
plasma O
calcium O
in O
the O
parathyroidectomized O
rat O
. O

Second O
report O
of O
the O
Norwegian O
Cancer O
Society O
. O

Modification O
of O
the O
growth O
of O
Tetrahymena O
by O
compounds O
which O
affect O
the O
adrenergic O
mechanism O
. O

SAM O
- O
TR O
- O
68 O
- O
54 O
. O

A O
brief O
discussion O
of O
color O
deficiencies O
. O

BIM O
130 O
. O

Problems O
in O
the O
determination O
of O
the O
antigenic O
content O
of O
influenza O
vaccines O
. O

Aedes O
aegypti O
( O
L O
.) O
and O
Aedes O
albopictus O
( O
Skuse O
) O
in O
Singapore O
City O
. O

Homograft O
response O
and O
hemagglutinin I-GENE
production O
by O
sensitized O
thymectomized O
irradiated O
adult O
mice O
. O

Comparative O
study O
on O
acute O
oral O
overload O
using O
tolbutamide O
and O
tolazamide O
in O
normal O
and O
diabetic O
subjects O
. O

Mycotoxins O
in O
feeds O
and O
foods O
. O

Factors O
influencing O
in O
vitro O
skin I-GENE
permeability I-GENE
factor I-GENE
production O
by O
Vibrio O
cholerae O
. O

Spinal O
cord O
representation O
of O
the O
micturition O
reflex O
. O

Biological O
action O
and O
kinetics O
of O
the O
elimination O
of O
tritium O
oxide O
in O
dogs O

Auto O
- O
and O
isotopy O
of O
the O
conjunctiva O

IX O
. O

Pitfalls O
in O
the O
use O
of O
chromosome O
aberration O
analysis O
for O
biological O
radiation O
dosimetry O
. O

Renin I-GENE
secretion O
in O
essential O
and O
accelerated O
hypertension O
. O

The O
need O
for O
including O
forensic O
medical O
expertise O
in O
the O
list O
of O
urgent O
criminal O
investigative O
actions O

Histopathology O
and O
pathogenesis O
of O
exanthematous O
viroses O

CNS O
effects O
of O
local O
anesthetics O
only O
partially O
dependent O
on O
biogenic O
amine O
mechanisms O
. O

Diethylene O
benzene O

Midge O
control O
in O
flood O
channels O
. O

The O
effects O
of O
taloximine O
and O
aminophylline O
on O
isolated O
human O
smooth O
muscle O
. O

The O
exploratory O
behaviour O
in O
normal O
and O
aggressive O
mice O
. O

Genitography O
in O
intersexual O
states O
. O

Tolerance O
test O
of O
HB O
419 O
in O
animal O
experiments O

The O
role O
of O
ascorbic O
acid O
in O
the O
prevention O
of O
bladder O
tumor O
formation O
. O

The O
" O
28 O
percent O
" O
Venturi O
mask O
in O
obstructive O
airway O
disease O
. O

3 O
'- O
Methyl O
, O
8 O
- O
methyl O
, O
and O
8 O
- O
phenyl O
derivatives O
of O
5 O
, O
9 O
- O
dimethyl O
- O
6 O
, O
7 O
- O
benzomorphans O
. O

Antidromic O
invasion O
of O
impulses O
and O
recurrent O
collateral O
inhibition O
in O
pyramidal O
tract O
neurones O
. O

The O
distribution O
of O
body O
fluids O
following O
hemorrhage O
and O
resuscitation O
in O
combat O
casualties O
. O

Once O
more O
Hong O
Kong O
influenza O
in O
the O
Netherlands O

Early O
disagnosis O
of O
cancer O
-- O
50 O
per O
cent O
of O
all O
patients O
could O
be O
cured O

Difficulties O
bound O
to O
measuring O
of O
sputum O
viscosity O

Lipid O
concentration O
and O
lipase I-GENE
activity O
in O
the O
epiphysis O
of O
adrenalectomized O
rats O
consuming O
food O
with O
different O
sodium O
content O

Behavior O
of O
aspartate I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
6 I-GENE
. I-GENE
1 I-GENE
. I-GENE
1 I-GENE
) O
and O
alanine I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. I-GENE
6 I-GENE
. I-GENE
1 I-GENE
. I-GENE
2 I-GENE
) O
in O
rat O
serum O
during O
the O
course O
of O
acute O
radiation O
syndrome O
following O
whole O
body O
X O
- O
irradiation O

Diminished O
forearm O
arteriolar O
dilator O
capacity O
produced O
by O
mineralocorticoid O
- O
induced O
salt O
retention O
in O
man O
. O

Studies O
on O
the O
pathogenicity O
of O
ECHO O
9 O
( O
HILL O
) O
virus O
and O
its O
mutants O
for O
suckling O
mice O

Counter O
- O
current O
heat O
exchange O
in O
the O
respiratory O
passages O
: O
effect O
on O
water O
and O
heat O
balance O
. O

Calibration O
and O
a O
correction O
of O
blood O
O2 O
content O
measured O
by O
Po2 O
and O
CO O
saturation O
. O

Mae O
West O
and O
the O
doctor O
shortage O
. O

Elimination O
of O
gamma O
- O
irradiation O
induced O
oxidation O
in O
aqueous O
drug O
preparations O

The O
absolute O
configuration O
at O
C O
- O
2 O
in O
monocrotalic O
acid O
. O

Teratogenic O
effects O
of O
actinomycin O
D O
in O
rats O

The O
plasma I-GENE
growth I-GENE
hormone I-GENE
concentration O
of O
the O
foetal O
lamb O
. O

Bimodal O
cochlear O
response O
curves O
in O
rodents O
. O

A O
new O
hemagglutination O
test O
for O
the O
on O
- O
slide O
assay O
of O
rheumatoid I-GENE
factor I-GENE

CO2 O
assimilation O
by O
chloroplasts O
illuminated O
on O
filter O
paper O
. O

The O
biology O
of O
Hyostrongylus O
ruidus O
. O

Foreign O
profiles O
in O
air O
pollution O
control O
activities O
. O

Effects O
of O
chronic O
metaraminol O
treatment O
on O
the O
sympathetic O
activity O
of O
intact O
and O
adrenal O
demedullated O
rats O
kept O
in O
warm O
or O
cold O
environments O
. O

The O
association O
of O
clopamide O
and O
hydergine O
( O
Brinedine O
) O
in O
the O
treatment O
of O
the O
vasculo O
- O
renal O
syndromes O
of O
pregnancy O

The O
effect O
of O
low O
dosage O
radiation O
on O
metabolism O
and O
function O
of O
the O
rat O
kidney O
damaged O
by O
ischemia O

Leukemia O
in O
twins O
: O
world O
- O
wide O
review O
of O
clinical O
cases O
. O

Preliminary O
report O
. O

Quantitation O
of O
exocrine I-GENE
IgA I-GENE
in O
human O
serum O
in O
health O
and O
disease O
. O

Gastrointestinal O
manifestations O
of O
systemic O
sclerosis O

Iodine O
metabolism O
in O
chronic O
thyroiditis O
. O

Total O
body O
water O
, O
rhodanide O
space O
and O
I I-GENE
- I-GENE
131 I-GENE
- I-GENE
albumin I-GENE
space O
under O
the O
acute O
effect O
of O
furosemide O

V O
. O

18F O
and O
85Sr O
scintimetry O
in O
the O
study O
of O
primary O
arthropathies O
. O

Propagation O
and O
hormone O
production O
by O
human O
normal O
and O
malignant O
trophoblast O
in O
rats O
. O

Health O
: O
an O
integrative O
reticulum O
. O

Sensitive O
fluorometric O
method O
of O
determining O
SH O
- O
and O
S O
- O
S O
- O
groups O
when O
jointly O
present O

Morphogenesis O
of O
the O
trochanter O
produced O
by O
femoral O
regeneration O
in O
the O
phasmid O
Carausius O
morosus O
Br O

Behavioral O
and O
electrographic O
expression O
of O
natural O
sleep O
and O
wakefulness O
in O
reptiles O

Sensitivities O
of O
thromboplastins I-GENE
to O
factor I-GENE
VII I-GENE
deficiency O
. O

3 O
. O

Central O
venous O
catheter O
used O
for O
recording O
intracardiac O
electrocardiogram O
. O

Two O
Lab O
8 O
computer O
programmes O
for O
use O
in O
the O
study O
of O
the O
isometric O
and O
isotonic O
contractile O
characteristics O
of O
skeletal O
muscle O
. O

Open O
head O
- O
brain O
injuries O

The O
modification O
of O
P32 O
uptake O
into O
the O
Jensen O
sarcoma O
in O
vitro O
by O
adding O
of O
peroxide O
to O
the O
nutritive O
medium O

Students O
, O
parents O
, O
teachers O
and O
hearing O
disorders O

Changing O
and O
predicting O
doses O
of O
Cs137 O
irradiation O

Positive O
shifts O
of O
basal O
skin O
potentials O
during O
human O
sleep O
. O

Evaluating O
dietary O
department O
management O
. O

5 O
-( O
Dimethylaminopropyl O
)- O
19 O
, O
11 O
- O
dihydro O
- O
5H O
- O
benzo O
[ O
2 O
, O
3 O
] O
pyrido O
[ O
6 O
, O
7 O
- O
b O
] O
azepine O
. O

Osteogenesis O
imperfecta O

Investigation O
on O
the O
exchange O
of O
Ca45 O
in O
intact O
and O
burned O
rats O
by O
the O
kinetic O
analysis O
method O

Effect O
of O
thrombotic O
and O
antithrombotic O
drugs O
on O
the O
surface O
charge O
characteristics O
of O
canine O
blood O
vessels O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Measurements O
of O
activity O
with O
the O
radioprotective O
chamber O
VA O
- O
K O
- O
254 O
of O
the O
osimeter O
VA O
- O
J18 O

3 O
-( O
N O
- O
Alkyl O
- O
N O
- O
2 O
- O
chloroethylaminomethyl O
)- O
5 O
- O
or O
7 O
- O
halogenobenzo O
[ O
b O
] O
thiophen O
hydrochlorides O
. O

Nephrectomy O
applied O
to O
cattle O

Evaluation O
of O
automatic O
blood O
cell O
counters O
. O

Determination O
of O
transaminases O
with O
an O
autoanalyzer O

Sterols O
in O
pollen O
. O

Dermoid O
cyst O
in O
a O
free O
skin O
flap O
as O
the O
complication O
after O
treatment O
of O
recurring O
hernia O

Histological O
observations O
on O
the O
decidua O
in O
the O
second O
half O
of O
pregnancy O

Endocardial O
fibro O
- O
elastosis O
, O
mitral O
incompetence O
, O
and O
coarctation O
of O
abdominal O
aorta O
. O

Studies O
on O
the O
method O
of O
size O
reduction O
of O
medicinal O
compounds O
. O

Children O
with O
defective O
vision O

Identification O
and O
estimation O
of O
monosaccharides O
and O
disaccharides O
in O
urine O
by O
gas O
- O
liquid O
chromatography O
. O

Steroids O
in O
germfree O
and O
conventional O
rats O
. O

The O
effects O
of O
loading O
the O
respiratory O
pumps O
on O
the O
oxygen O
consumption O
of O
Callionymus O
lyra O
. O

Trials O
of O
sevine O
activity O
against O
mosquito O
larvae O

The O
significance O
of O
structural O
integrity O
of O
lymphoid O
tissue O
for O
antibody O
production O
in O
culture O
in O
vivo O

The O
effect O
of O
a O
constant O
magnetic O
field O
on O
the O
phagocytic O
activity O
of O
Paramecia O

Studies O
carried O
out O
with O
the O
Glossina O
morsitans O
colony O
of O
Lisbon O
. O

Relations O
between O
adrenergic O
mechanisms O
and O
analgesic O
effects O

Transformations O
in O
the O
morphine O
series O
. O

Dissociative O
anesthetics O
2 O
-( O
o O
- O
chlorophenyl O
)- O
2 O
- O
methyl O
- O
amino O
cyclohexane O
HCL O
( O
CI O
- O
581 O
) O

Estrus O
and O
copulative O
abilities O
of O
androgen O
- O
sterilized O
rats O

The O
bearing O
of O
season O
and O
sequence O
of O
calving O
on O
frequency O
of O
male O
, O
female O
and O
total O
calvings O
in O
Hariana O
cows O
. O

Hemodynamics O
changes O
in O
man O
during O
flight O

Caries O
prevention O
in O
the O
dental O
office O
. O

I O
. O

Clinical O
applications O
of O
inhibition O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
with O
propranolol O
. O

Automatic O
view O
box O
. O

Measurement O
of O
gastric O
acid O
secretion O
by O
conductivity O
. O

Effect O
of O
castration O
on O
pituitary I-GENE
and I-GENE
serum I-GENE
LH I-GENE
and O
FSH I-GENE
in O
testosterone O
- O
sterilized O
rats O
. O

The O
significance O
of O
the O
phenolphthalein I-GENE
sulphatase I-GENE
test O
for O
the O
differentiation O
and O
identification O
of O
Nocardia O
species O
. O

Relationship O
of O
mast O
cells O
to O
sarcoidosis O
granuloma O
of O
the O
skin O

Long O
- O
term O
effects O
of O
clofibrate O
( O
Atromid O
- O
S O
) O
on O
serum O
lipids O
in O
man O
. O

Phosphate I-GENE
glucose I-GENE
dehydrogenase I-GENE
deficiency O
causing O
hyperbilirubinemia O
in O
the O
newborn O

Evidence O
forthe O
electroosmosis O
theory O
of O
transport O
in O
the O
phloem O
. O

Effects O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockade O
on O
airway O
conductance O
and O
lung O
volume O
in O
normal O
and O
asthmatic O
subjects O
. O

Effect O
of O
heparin O
on O
the O
inactivation O
of O
serum I-GENE
lipoprotein I-GENE
lipase I-GENE
by O
the O
liver O
in O
unanesthetized O
dogs O
. O

Experimental O
chlorpromazine O
cataracts O
. O

I O
. O

Specialist O
in O
family O
practice O
-- O
prototype O
of O
a O
doctor O
. O

The O
possibility O
of O
selective O
chemotherapy O
of O
progressive O
recurring O
ovarian O
carcinoma O
with O
the O
aid O
of O
cytodiagnosis O
and O
incorporation O
of O
tagged O
idoxuridine O

Variation O
in O
the O
temporal O
- O
spatial O
distribution O
of O
228Ra O
and O
224Ra O
in O
the O
RES O
and O
marrow O
- O
free O
skeleton O
after O
incorporation O
of O
colloidal O
ThO2 O

Oxidative O
degradation O
of O
adrenaline O
solutions O
: O
study O
of O
the O
intermediate O
stages O
and O
their O
analytic O
value O
for O
the O
control O
of O
this O
solute O

Absorption O
of O
electrolytes O
from O
the O
colon O
in O
cases O
of O
ulcerative O
colitis O
and O
in O
control O
subjects O
. O

Ion O
injection O
. O

Polyvinyl O
alcohol O
as O
a O
solution O
mediator O

Mining O
the O
diagnostic O
iron O
ore O
. O

The O
structure O
of O
digiprogenin O
. O

The O
need O
in O
the O
small O
hospital O
. O

I O
. O

On O
the O
character O
of O
changes O
in O
the O
enzyme O
activity O
in O
the O
brain O
tissue O
during O
reflex O
epilepsy O

A O
malignant O
true O
teratoma O
of O
liver O
in O
childhood O
. O

Methoxyflurane O
and O
renal O
function O

Histochemistry O
and O
electron O
microscopy O
of O
acute O
liver O
lesions O
induced O
by O
Aflatoxin O
B1 O
in O
ducklings O
. O

Functional O
disorders O
of O
the O
ureter O
following O
gynecologic O
surgery O

Study O
of O
the O
alterations O
of O
intestinal O
absorption O
, O
by O
means O
of O
I O
- O
131 O
- O
triolein O
, O
in O
the O
whole O
body O
irradiated O
rat O

Chemical O
histologic O
and O
immunologic O
responses O
in O
rats O
to O
CC1 O
- O
4 O
by O
different O
routes O
of O
administration O
. O

Clinical O
trials O
with O
1 O
, O
3 O
- O
bis O
( O
2 O
- O
chloroethyl O
)- O
1 O
- O
nitrosourea O
, O
NSC O
- O
409962 O
. O

Hydroxypropyl O
methacrylate O
, O
a O
new O
water O
- O
miscible O
embedding O
medium O
for O
electron O
microscopy O
. O

Statistics O
of O
the O
past O
5 O
years O

On O
the O
diagnosis O
of O
bovine O
leucosis O
and O
its O
control O
in O
southern O
Lower O
Saxony O

Experience O
with O
the O
restoration O
of O
agglutination O
properties O
of O
non O
- O
agglutinating O
dysenterial O
cultures O
with O
the O
use O
of O
Rzhaninov O
' O
s O
method O

Study O
on O
micromelias O
in O
the O
mouse O
fetus O
caused O
by O
x O
- O
radiation O
, O
hypoxia O
, O
trypan O
blue O
injection O
of O
hypervitaminosis O
- O
A O
upon O
mother O
animals O
during O
pregnancy O
. O

Human O
antitetanus O
serum O
: O
an O
unused O
wealth O

( O
3 O
). O

Studies O
on O
the O
intracutaneous O
infection O
of O
rabbits O
by O
Staphylococcus O
aureus O
. O

On O
catabolism O
of O
aminoketones O
in O
climacteric O
age O

The O
effect O
of O
feeding O
patterns O
on O
fat O
deposition O
in O
mice O
. O

Naphthalene O
and O
paradichlorobenzene O
in O
clinical O
toxicology O

IV O
. O

Studies O
on O
powdered O
preparations O
. O

A O
case O
report O
with O
angiographic O
follow O
- O
up O
study O
. O

Interactions O
between O
adrenergics O
, O
adrenolytics O
and O
monoamine I-GENE
oxidase I-GENE
inhibitors O

Further O
studies O
on O
a O
" O
new O
" O
human O
isoprecipitin I-GENE
system O
( O
Australia O
antigen O
). O

Pigmentary O
rhythms O
as O
indicators O
of O
neurosecretion O
. O

Story O
of O
a O
hospital O
that O
filmed O
its O
employee O
orientation O
program O
. O

When O
the O
cervical O
Pap O
smear O
is O
positive O
. O

I O
. O

The O
3 O
- O
hour O
test O
iodine O
( O
I O
- O
132 O
) O
uptake O
by O
the O
thyroid O
in O
children O
with O
growth O
deficiency O

Persistence O
of O
toxaphene O
in O
treated O
lakes O
. O

Studies O
on O
Coxsackie O
B O
Type O
5 O
virus O
infections O
. O

Value O
of O
the O
method O
of O
passive O
hemagglutination O
with O
polysaccharide O
C O
in O
detecting O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
as O
compared O
to O
precipitation O
in O
capillaries O
and O
slide O
latex O
test O
with O
anti I-GENE
- I-GENE
CRP I-GENE
serum O

Adrenergic O
nerve O
function O
, O
noradrenaline O
level O
and O
noradrenaline O
uptake O
in O
cat O
nictitating O
membrane O
after O
reserpine O
treatment O
. O

Concussion O
of O
the O
spinal O
cord O

Study O
on O
the O
evagination O
of O
Cysticercus O
pisiformis O
. O

Antimicrobial O
substance O
isolated O
from O
an O
acorn O
extract O
. O

The O
pathogenicity O
of O
Achromobacter O
puntatum O
for O
cold O
blooded O
and O
warm O
blooded O
animals O

Consanguinity O
and O
migration O
in O
the O
marriages O
of O
the O
region O
of O
Nunoa O
, O
Santiago O
, O
1850 O
- O
1960 O

On O
the O
amount O
and O
significance O
of O
the O
effective O
glucose O
level O
in O
tumors O
. O

Studies O
of O
lipogenesis O
by O
labelled O
precursors O
in O
the O
pregnant O
rat O
. O

Pharmacodynamic O
studies O
on O
the O
cardiovascular O
system O
of O
spontaneously O
hypertensive O
rats O
. O

Nuclear O
spin O
of O
249Bk O
from O
the O
hyperfine O
structure O
in O
its O
emission O
spectrum O
. O

Further O
observations O
on O
resorption O
in O
guinea O
pigs O
following O
injections O
of O
trypan O
blue O
. O

Derivatives O
of O
fluorene O
. O

Note O
on O
Slot O
' O
s O
method O
for O
the O
specific O
determination O
of O
creatinine O
. O

Retention O
behavior O
of O
steroids O
in O
gas O
chromatography O
with O
a O
series O
of O
combination O
columns O
. O

Compensatory O
renal O
hypertrophy O
in O
parabiotic O
rats O
. O

( O
3 O
). O

XXI O
. O

In O
vitro O
evaluation O
of O
the O
mucolytic O
action O
of O
urea O
. O

Electrophoretic O
characteriaztion O
of O
virus O
- O
induced O
interferon I-GENE
of O
the O
blood O
and O
urine O
in O
rabbits O

Iron O
and O
folate O
deficiency O
in O
pregnancy O

Symposium O
on O
presenile O
spongy O
encephalopathies O
. O

Twenty O
- O
two O
of O
the O
24 O
patients O
had O
a O
rise O
in O
the O
total O
serum O
amylase I-GENE
following O
ERCP O
. O

The O
immuno O
- O
purified O
mRNA O
in O
the O
polysome O
complex O
was O
used O
to O
prepare O
cDNA O
with O
which O
to O
probe O
a O
D O
. O
melanogaster O
genomic O
library O
. O

Elevated O
maternal I-GENE
alpha I-GENE
fetoproteins I-GENE
and O
oligoamnios O
: O
fetal O
prognosis O

Also O
discussed O
is O
the O
possibility O
of O
a O
combined O
genetic O
and O
environmental O
etiology O
. O

Courses O
were O
repeated O
monthly O
upon O
recovery O
of O
myelosuppression O
. O

Stimulation O
with O
MCh O
produced O
a O
Ca O
- O
dependent O
transient O
elevation O
of O
cGMP O
level O
from O
10 O
to O
80 O
fmol O
/ O
gland O
, O
peaking O
at O
1 O
- O
2 O
min O
but O
returning O
to O
the O
basal O
level O
by O
5 O
min O
. O

Two O
hundred O
forty O
- O
three O
patients O
have O
received O
WR O
- O
2721 O
in O
Phase O
I O
- O
II O
studies O
. O

The O
PEPCK I-GENE
promoter O
fragment O
was O
introduced O
either O
in O
the O
proper O
orientation O
for O
transcription O
of O
the O
TK I-GENE
gene I-GENE
or O
in O
the O
opposite O
orientation O
. O

Many O
mammary O
tumors O
induced O
by O
mouse O
mammary O
tumor O
virus O
( O
MMTV O
) O
contain O
a O
provirus O
in O
the O
same O
region O
of O
the O
host O
- O
cell O
genome O
, O
leading O
to O
expression O
of O
a O
putative O
cellular O
oncogene O
called O
int I-GENE
- I-GENE
1 I-GENE
. O

In O
these O
cases O
, O
asbestos O
or O
erionite O
- O
tissue O
burden O
followed O
by O
fibrosis O
was O
frequently O
observed O
. O

Hepatitis O
B O
virus O
and O
hepatoma O
. O

Eight O
recombinant O
DNA O
clones O
of O
endogenous O
murine O
leukemia O
virus O
( O
MuLV O
)- O
related O
DNA O
sequences O
have O
been O
isolated O
from O
a O
lambdaphage O
genomic O
library O
of O
Balb O
/ O
c O
mouse O
DNA O
. O

USA O
80 O
, O
3618 O
- O
3622 O
) O
The O
two O
proteins O
show O
36 O
% O
identities O
in O
their O
amino O
acid O
sequence O
, O
in O
an O
alignment O
requiring O
six O
gaps O
. O

The O
envelope O
glycoproteins O
of O
Rous O
sarcoma O
virus O
( O
RSV O
), O
gp85 I-GENE
and O
gp37 I-GENE
, O
are O
anchored O
in O
the O
membrane O
by O
a O
27 O
- O
amino O
acid O
, O
hydrophobic O
domain O
that O
lies O
adjacent O
to O
a O
22 O
- O
amino O
acid O
, O
cytoplasmic O
domain O
at O
the O
carboxy O
terminus O
of O
gp37 I-GENE
. O

The O
drug O
was O
given O
in O
a O
daily O
oral O
dose O
of O
0 O
. O
5 O
g O
/ O
m2 O
, O
3 O
. O
5 O
h O
prior O
to O
each O
radiation O
treatment O
. O

Histogenetic O
aspects O
of O
mesoblastic O
nephroma O
. O

Effect O
of O
acute O
and O
chronic O
psychogenic O
stress O
on O
corticoadrenal O
and O
pituitary I-GENE
- I-GENE
thyroid I-GENE
hormones I-GENE
in O
male O
rats O
. O

Mature O
mRNA O
for O
cytosolic I-GENE
phosphoenolpyruvate I-GENE
carboxykinase I-GENE
of I-GENE
the I-GENE
chicken I-GENE
is O
2 O
. O
8 O
kilobases O
in O
length O
, O
similar O
to O
that O
previously O
noted O
for O
mRNA O
coding O
for O
the O
same O
enzyme O
in O
the O
rat O
. O

Upstream O
activation O
sites O
of O
the O
CYC1 I-GENE
gene I-GENE
of O
Saccharomyces O
cerevisiae O
are O
active O
when O
inverted O
but O
not O
when O
placed O
downstream O
of O
the O
" O
TATA O
box O
". O

An O
intact O
5 O
. O
7 O
- O
kb O
provirus O
of O
the O
avian O
erythroblastosis O
virus O
E26 O
has O
been O
molecularly O
cloned O
for O
comparisons O
with O
avian O
myeloblastosis O
virus O
( O
AMV O
) O
and O
other O
avian O
tumor O
viruses O
. O

It O
is O
concluded O
that O
haloperidol O
selectively O
reduced O
the O
animal O
' O
s O
capacity O
to O
' O
programme O
non O
- O
stimulus O
directed O
motor O
behaviour O
'. O

Neither O
side O
effect O
nor O
abnormal O
laboratory O
findings O
due O
to O
this O
drug O
were O
observed O
. O

The O
results O
presented O
in O
this O
report O
suggest O
that O
the O
SV40 O
G O
- O
C O
- O
rich O
sequences O
can O
function O
as O
independent O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcriptional O
- O
control O
elements O
. O

Construction O
of O
human O
cell O
lines O
which O
contain O
and O
express O
the O
adenovirus O
DNA O
binding O
protein O
gene O
by O
cotransformation O
with O
the O
HSV I-GENE
- I-GENE
1 I-GENE
tk I-GENE
gene I-GENE
. O

Diagnosis O
and O
treatment O
of O
insulin I-GENE
- O
secreting O
tumours O
. O

Theories O
proffered O
to O
account O
for O
the O
modality O
shift O
effect O
are O
critically O
evaluated O
. O

The O
effects O
of O
cardioselective O
beta O
- O
1 O
adrenergic O
agonist O
, O
1 O
-( O
4 O
- O
hydroxyphenoxy O
)- O
isopropylamino O
- O
2 O
- O
propanol O
), O
i O
. O
e O
., O
prenalterol O
, O
were O
examined O
on O
direct O
and O
continuous O
measurements O
of O
left O
ventricular O
( O
LV O
) O
pressure O
, O
diameter O
, O
dP O
/ O
dt O
, O
velocity O
of O
shortening O
, O
arterial O
pressure O
, O
iliac O
blood O
flow O
and O
heart O
rate O
in O
10 O
conscious O
dogs O
. O

Endorphins I-GENE
at O
the O
approach O
of O
death O
. O

Trial O
treatment O
of O
schizophrenia O
with O
des I-GENE
- I-GENE
Tyr I-GENE
- I-GENE
gamma I-GENE
- I-GENE
endorphin I-GENE

Cardiac O
taurine O
levels O
and O
sarcolemmal O
calcium O
binding O
activity O
in O
furazolidone O
- O
induced O
cardiomyopathy O
. O

Separation O
of O
malaria O
- O
infected O
erythrocytes O
from O
whole O
blood O
: O
use O
of O
a O
selective O
high O
- O
gradient O
magnetic O
separation O
technique O
. O

The O
roll O
- O
over O
test O
to O
predict O
toxemia O
in O
pregnancy O
. O

Can O
thyroglobulin I-GENE
assay O
really O
supplant O
radioiodine O
scans O
in O
patients O
with O
differentiated O
thyroid O
cancer O
? O

3 O
Significant O
reductions O
in O
lying O
mean O
arterial O
blood O
pressure O
were O
observed O
with O
daily O
doses O
of O
200 O
mg O
(- O
9 O
%), O
400 O
mg O
(- O
10 O
%) O
and O
800 O
mg O
(- O
14 O
%), O
and O
were O
associated O
with O
significant O
decreases O
in O
heart O
rate O
and O
plasma I-GENE
renin I-GENE
activity O
. O

Isolation O
of O
Aeromonas O
from O
faeces O
. O

Plasma O
and O
erthrocyte O
lipid O
profile O
and O
lipoprotein I-GENE
lipase I-GENE
activity O
in O
postheparin O
plasma O
on O
vasectomized O
rabbits O
were O
studied O
and O
also O
the O
incidence O
of O
atherosclerosis O
in O
different O
arterial O
beds O
. O

( O
iii O
) O
The O
mRNA O
is O
not O
efficiently O
polyadenylated O
at O
sequences O
in O
the O
3 O
' O
end O
of O
the O
DHFR I-GENE
cDNA I-GENE
but O
rather O
uses O
polyadenylation O
signals O
downstream O
from O
the O
DHFR I-GENE
cDNA I-GENE
. O

At O
both O
water O
temperatures O
, O
VO2 O
increased O
linearly O
with O
increasing O
swimming O
velocity O
. O

Propranolol O
also O
effectively O
controlled O
her O
familial O
tremor O
. O

Brief O
report O
. O

The O
distribution O
phase O
is O
followed O
by O
an O
elimination O
phase O
with O
a O
much O
longer O
half O
- O
life O
( O
mean O
value O
375 O
min O
) O
and O
a O
volume O
of O
distribution O
of O
approximately O
200 O
- O
400 O
l O
. O

Hybrid O
- O
selection O
experiments O
against O
total O
PB O
- O
inducible O
RNA O
were O
performed O
with O
plasmid O
DNA O
derived O
from O
clones O
enriched O
in O
PB O
- O
inducible O
information O
. O

Risk O
of O
HTLV O
infection O
in O
patients O
on O
haemodialysis O
. O

In O
vitro O
metabolism O
of O
progesterone O
by O
the O
human O
undescended O
testis O
. O

Two O
patients O
withdrew O
from O
therapy O
, O
one O
for O
personal O
reasons O
and O
one O
because O
a O
paraspinal O
mass O
developed O
. O

All O
patients O
received O
VCR O
1 O
. O
0 O
mg O
/ O
m2 O
weekly O
for O
6 O
weeks O
with O
dose O
modification O
for O
neurotoxicity O
. O

Glutamic O
acid O
in O
a O
dose O
of O
1 O
/ O
100 O
of O
the O
LD50 O
was O
injected O
in O
the O
form O
of O
sodium O
salt O
into O
male O
and O
female O
Wistar O
rats O
for O
7 O
days O
after O
8 O
- O
and O
12 O
- O
day O
injections O
of O
dexazone O
. O

Serum O
ascorbic O
acid O
had O
an O
inverse O
and O
the O
strongest O
association O
with O
systolic O
blood O
pressure O
among O
the O
risk O
factors O
including O
blood O
pressure O
, O
total O
cholesterol O
, O
triglyceride O
, O
gamma I-GENE
- I-GENE
GTP I-GENE
and O
obesity O
. O

Plasma I-GENE
secretin I-GENE
, O
pancreozymin I-GENE
, O
and O
somatostatin I-GENE
- I-GENE
like I-GENE
hormone I-GENE
in O
chronic O
renal O
failure O
patients O
. O

Effect O
of O
bromazepam O
on O
growth I-GENE
hormone I-GENE
and O
prolactin I-GENE
secretion O
in O
normal O
subjects O
. O

In O
several O
cases O
of O
definite O
SjS O
, O
labial O
salivary O
gland O
examinations O
after O
more O
than O
a O
one O
year O
interval O
were O
performed O
on O
two O
occasions O
, O
and O
the O
clinical O
and O
histopathological O
changes O
were O
investigated O
. O

All O
radiologists O
using O
the O
machine O
found O
that O
the O
reporting O
terminal O
was O
simple O
to O
operate O
, O
but O
found O
that O
reporting O
abnormalities O
caused O
an O
increased O
effort O
and O
took O
a O
longer O
time O
. O

Thalamotomy O
aiming O
at O
the O
CM O
- O
Pf O
complex O
and O
using O
stereotactic O
gamma O
irradiation O
has O
been O
performed O
in O
a O
series O
of O
52 O
patients O
with O
severe O
pain O
due O
to O
malignancy O
. O

2 O
Silastic O
capsules O
, O
each O
containing O
22 O
- O
23 O
mg O
of O
ethinyl O
estradiol O
, O
were O
inserted O
subcutaneously O
in O
5 O
men O
with O
benign O
prostatic O
hypertrophy O
. O

When O
used O
subcutaneously O
or O
intravenously O
in O
maximum O
tolerated O
doses O
the O
antibiotic O
inhibited O
the O
development O
of O
lymphadenosis O
NK O
/ O
Li O
by O
90 O
and O
70 O
per O
cent O
respectively O
. O

Effect O
of O
2 O
-( O
p O
- O
chlorophenyl O
) O
cyclopropylamine O
on O
5 O
- O
hydroxyindole O
concentration O
and O
monoamine I-GENE
oxidase I-GENE
activity O
in O
rat O
brain O
. O

Then O
, O
pure O
pancreatic O
juice O
was O
infused O
into O
the O
duodenum O
. O

An O
experiment O
was O
carried O
on O
133 O
grown O
up O
fowls O
and O
broilers O
from O
4 O
industrial O
farms O
, O
vaccinated O
with O
spray O
lento O
and O
mesogenic O
vaccines O
for O
straining O
the O
immunity O
against O
pseodopest O
through O
RIHA O
and O
provoking O
pseudoplague O
with O
a O
pathogenic O
virus O
. O

( O
2 O
) O
The O
inappropriateness O
of O
adaptive O
segmentation O
for O
the O
isolation O
of O
spikes O
and O
sharp O
waves O
, O
which O
had O
been O
anticipated O
in O
view O
of O
the O
short O
duration O
of O
such O
transients O
in O
relation O
to O
the O
length O
of O
the O
window O
( O
1 O
. O
2 O
sec O
) O
used O
for O
the O
autocorrelation O
functions O
employed O
in O
the O
segmentation O
algorithm O
, O
was O
confirmed O
. O

The O
ability O
of O
chronic O
UM O
- O
272 O
( O
dimethylpropranolol O
) O
treatment O
to O
prevent O
the O
induction O
of O
reentrant O
ventricular O
tachyarrhythmias O
was O
assessed O
in O
the O
conscious O
dog O
subjected O
to O
serial O
programmed O
electrical O
stimulation O
on O
days O
3 O
-- O
5 O
after O
myocardial O
infarction O
. O

The O
effect O
of O
echothiophate O
on O
the O
biphasic O
response O
of O
rabbit O
ocular O
pressure O
to O
dipivefrin O
. O

In O
most O
cases O
of O
acute O
transmural O
infarction O
, O
the O
reciprocal O
ST O
segment O
depressions O
observed O
in O
contralateral O
leads O
are O
less O
marked O
than O
the O
primary O
ST O
segment O
elevations O
. O

Bacillus O
cereus O
cross O
- O
infection O
in O
a O
maternity O
- O
unit O
. O

We O
have O
followed O
37 O
phenytoin O
- O
treated O
patients O
with O
reduced O
serum I-GENE
IgA I-GENE
concentrations O
for O
2 O
- O
7 O
years O
. O

In O
the O
latter O
category O
particular O
emphasis O
is O
being O
placed O
on O
new O
anthracycline O
analogues O
of O
doxorubicin O
and O
analogues O
of O
cisplatinum O
diammine O
dichloride O
. O

Unusual O
course O
of O
plasmocytosis O
. O

Late O
mRNA O
selected O
by O
a O
cDNA O
homologous O
to O
the O
HindIII I-GENE
- I-GENE
P I-GENE
/ O
EcoRI I-GENE
- I-GENE
B I-GENE
region O
of O
the O
AcNPV O
map O
directed O
the O
synthesis O
of O
31K O
and O
30K O
proteins O
which O
comigrated O
with O
the O
31K O
and O
30K O
proteins O
translated O
from O
RNA O
selected O
by O
the O
HindIII I-GENE
- I-GENE
A I-GENE
/ O
EcoRI I-GENE
- I-GENE
C I-GENE
/ O
SstI I-GENE
- I-GENE
G I-GENE
cDNA O
. O

Intraoperatively O
the O
complement I-GENE
factor I-GENE
C3c I-GENE
decreased O
by O
20 O
%, O
while O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
showed O
postoperatively O
an O
increase O
by O
30 O
%. O

A O
polypeptide O
chain O
of O
34 O
residues O
of O
the O
deduced O
yeast O
amino O
acid O
sequence O
closely O
resembles O
a O
peptide O
sequence O
at O
the O
ADP O
binding O
site O
of O
bovine I-GENE
muscle I-GENE
pyruvate I-GENE
kinase I-GENE
. O

The O
P165 O
component O
, O
however O
, O
could O
be O
differentiated O
from O
the O
two O
later O
components O
since O
it O
increased O
in O
amplitude O
with O
increased O
task O
demands O
while O
the O
N2 O
and O
P3 O
amplitudes O
remained O
constant O
. O

Differential O
drawing O
size O
associated O
with O
unilateral O
brain O
damage O
. O

The O
intracoronary O
administration O
of O
both O
drugs O
markedly O
reduced O
the O
incidence O
of O
VF O
induced O
by O
the O
release O
of O
a O
40 O
- O
min O
coronary O
artery O
occlusion O
. O

These O
fusions O
are O
contained O
on O
plasmids O
which O
have O
both O
yeast O
and O
E O
. O
coli O
replication O
origins O
and O
selectable O
markers O
and O
, O
therefore O
, O
can O
be O
used O
to O
transform O
either O
yeast O
or O
E O
. O
coli O
cells O
. O

Therefore O
, O
it O
was O
concluded O
that O
thrombotic O
tendency O
certainly O
existed O
in O
patients O
with O
MS O
compared O
to O
those O
with O
non O
RHD O
and O
that O
it O
was O
one O
of O
the O
causes O
of O
the O
significantly O
high O
incidence O
of O
thromboembolism O
in O
comparison O
with O
non O
RHD O
. O

Toxicity O
was O
significant O
in O
selected O
cases O
; O
three O
patients O
developed O
WBC O
counts O
less O
than O
1 O
, O
000 O
/ O
mm3 O
and O
one O
of O
these O
patients O
died O
with O
sepsis O
. O

Subdural O
electrodes O
may O
yield O
larger O
VEP O
amplitudes O
than O
skull O
or O
scalp O
electrodes O
. O

Products O
of O
immune O
cells O
such O
as O
transfer I-GENE
factor I-GENE
and O
lymphokines O
form O
the O
third O
and O
possibly O
most O
important O
group O
of O
immune O
- O
stimulating O
agents O
. O

Use O
of O
the O
immunofluorescence O
method O
for O
identification O
of O
enteroviruses O
in O
cell O
cultures O

This O
fraction O
is O
resistant O
to O
digestions O
by O
DNase I-GENE
I I-GENE
and O
RNase I-GENE
T1 I-GENE
and O
disappears O
completely O
upon O
alkali O
hydrolysis O
. O

The O
construction O
of O
a O
small O
library O
of O
mouse O
repetitive O
DNA O
has O
been O
previously O
reported O
( O
Pietras O
et O
al O
., O
Nucleic O
Acids O
Res O
. O

No O
direct O
repeats O
flank O
the O
pseudogene O
in O
the O
U2 I-GENE
/ I-GENE
4 I-GENE
locus I-GENE
. O

The O
direct O
effects O
of O
transmitter O
release O
were O
( O
a O
) O
an O
early O
fall O
in O
MAP O
followed O
by O
a O
late O
pressor O
effect O
; O
and O
( O
b O
) O
an O
early O
bradycardia O
followed O
by O
a O
late O
tachycardia O
. O

At O
Cabras O
( O
Oristano O
), O
a O
town O
characterized O
by O
a O
high O
incidence O
of O
thalassaemia O
and O
G6PD I-GENE
deficiency O
less O
than O
half O
the O
people O
between O
18 O
and O
35 O
have O
a O
fair O
knowledge O
of O
genetic O
diseases O
and O
of O
their O
prevention O
. O

The O
number O
of O
elements O
and O
their O
sizes O
relative O
to O
the O
configuration O
were O
varied O
in O
a O
series O
of O
five O
experiments O
. O

In O
addition O
, O
the O
overall O
chance O
that O
a O
patient O
would O
undergo O
ET O
was O
greater O
in O
a O
cycle O
in O
which O
more O
than O
one O
follicle O
20 O
mm O
or O
larger O
was O
developing O
than O
in O
a O
cycle O
in O
which O
a O
single O
large O
follicle O
was O
developing O
. O

Experience O
with O
the O
tensor O
fasciae O
latae O
free O
flap O
. O

Five O
of O
the O
patients O
with O
increased O
L O
- O
L O
size O
had O
a O
normal O
A O
- O
P O
diameter O
. O

Immunochemotherapy O
with O
schizophyllan O
( O
SPG O
) O
combined O
with O
chemotherapeutic O
agents O
was O
evaluated O
in O
two O
syngeneic O
tumor O
- O
C3H O
/ O
He O
mouse O
systems O
. O

However O
, O
when O
combined O
with O
mitomycin O
C O
given O
with O
1 O
to O
5 O
- O
days O
interval O
, O
the O
concurrent O
administration O
of O
SPG O
prolonged O
significantly O
the O
life O
- O
span O
of O
the O
tumor O
- O
bearing O
mice O
. O

Data O
are O
presented O
hinting O
that O
the O
15 O
beta O
- O
hydroxy O
-, O
metabolite O
of O
CPA O
may O
actually O
be O
the O
biologically O
active O
agent O
. O

The O
abluminal O
surface O
is O
often O
almost O
entirely O
encircled O
by O
a O
thick O
layer O
of O
fibrillary O
connective O
tissue O
. O

In O
contrast O
, O
in O
LL O
patients O
during O
ENL O
the O
ConA I-GENE
- O
induced O
suppressor O
response O
was O
markedly O
reduced O
. O

Functional O
characterization O
of O
a O
fraction O
identified O
by O
its O
activity O
in O
a O
second O
template O
rescue O
assay O
. O

It O
has O
been O
established O
that O
preoperative O
irradiation O
in O
the O
form O
of O
the O
fractionation O
of O
a O
single O
focal O
dose O
of O
6 O
Gy O
every O
other O
day O
, O
the O
summary O
dose O
of O
24 O
Gy O
within O
8 O
- O
10 O
days O
followed O
by O
surgery O
1 O
- O
3 O
days O
after O
irradiation O
does O
not O
either O
complicate O
its O
performance O
or O
the O
course O
of O
the O
postoperative O
period O
, O
and O
by O
the O
short O
- O
and O
long O
- O
term O
results O
it O
is O
no O
worse O
than O
the O
routine O
dose O
fractionation O
. O

Fibrin I-GENE
gels O
and O
their O
possible O
implication O
for O
surface O
hemorheology O
in O
health O
and O
disease O
. O

Hepatitis O
- O
B O
vaccination O
in O
the O
elderly O
. O

Radiogallium O
imaging O
is O
thus O
of O
limited O
use O
in O
evaluation O
of O
suspected O
giant O
cell O
tumors O
of O
bone O
. O

The O
customary O
coupling O
reagent O
sulfanilic O
acid O
has O
been O
replaced O
by O
1 O
, O
3 O
- O
dimethylbarbituric O
acid O
; O
CNCl O
is O
produced O
in O
the O
flow O
through O
system O
directly O
from O
KCN O
and O
chloramine O
T O
. O

Ventricular O
volume O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
LVH O
shifted O
upward O
, O
whereas O
the O
normalized O
wall O
muscle O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
LVH O
showed O
a O
smaller O
slope O
. O

Synthesis O
of O
(+)- O
lysergic O
acid O
diethylamide O
tartrate O

Weight O
loss O
reduces O
arterial O
pressure O
by O
a O
decrease O
in O
intravascular O
volume O
and O
cardiac O
output O
associated O
with O
a O
fall O
in O
sympathetic O
activity O
. O

The O
effect O
of O
treatment O
may O
thus O
be O
divided O
into O
two O
main O
phases O
-- O
an O
initial O
phase O
with O
a O
reduction O
in O
LV O
mass O
and O
a O
reduction O
in O
cardiac O
output O
and O
no O
change O
in O
total O
peripheral O
resistance O
-- O
and O
a O
second O
phase O
with O
a O
constant O
LV O
mass O
but O
an O
increase O
in O
cardiac O
output O
to O
the O
pretreatment O
level O
again O
and O
a O
concomitant O
decrease O
in O
total O
peripheral O
resistance O
. O

This O
study O
was O
undertaken O
to O
assess O
the O
effects O
of O
hypothermia O
and O
chemical O
cardioplegia O
on O
the O
functional O
recovery O
of O
hypertrophied O
non O
- O
failing O
rat O
hearts O
subjected O
to O
an O
extended O
period O
of O
global O
ischaemia O
. O

Oxygen O
profiles O
calculated O
for O
the O
Krogh O
model O
with O
excentric O
diffusion O
were O
similar O
to O
those O
derived O
for O
the O
two O
models O
of O
concentric O
diffusion O
. O

Cultivation O
technics O
for O
Codonopsis O
pilosula O

Radioimmunoassay O
of O
serum O
creatine I-GENE
kinase I-GENE
B I-GENE
isoenzyme I-GENE
in O
the O
diagnosis O
of O
acute O
myocardial O
infarction O
. O

Selective O
macrophage O
inhibition O
abolishes O
warfarin O
- O
induced O
reduction O
of O
metastasis O
. O

Restriction O
enzyme O
and O
heteroduplex O
analyses O
confirmed O
that O
sequences O
unique O
to O
FeSV O
( O
src I-GENE
sequences I-GENE
) O
are O
located O
at O
the O
center O
of O
the O
FeSV O
genome O
and O
are O
approximately O
1 O
. O
5 O
kilobase O
pairs O
in O
length O
. O

Among O
six O
different O
library O
isolates O
containing O
6 I-GENE
. I-GENE
5 I-GENE
- I-GENE
to I-GENE
7 I-GENE
- I-GENE
kb I-GENE
IAP I-GENE
units I-GENE
, O
some O
restriction O
sites O
were O
highly O
conserved O
whereas O
others O
varied O
in O
both O
occurrence O
and O
position O
. O

Catecholamines O
and O
aversive O
learning O
: O
a O
review O
. O

A O
haemolytic O
enterotoxigenic O
strain O
of O
E O
. O
coli O
( O
O149 O
: O
K88 O
: O
H10 O
) O
was O
regularly O
recovered O
from O
piglets O
with O
PWD O
while O
rotavirus O
was O
demonstrated O
on O
a O
number O
of O
occasions O
. O

The O
antibody O
titer O
of O
202 O
chickens O
to O
SA O
- O
11 O
rotavirus O
was O
determined O
by O
enzyme O
- O
linked O
immunosorbent O
blocking O
assay O
. O

Poly O
( O
dT O
) O
and O
denatured O
calf O
thymus O
DNA O
were O
more O
effective O
than O
were O
other O
polynucleotides O
tested O
in O
promoting O
accumulation O
of O
19 O
HDP O
*; O
( O
dT O
) O
8 O
was O
as O
effective O
as O
were O
longer O
molecules O
of O
( O
dT O
) O
n O
, O
but O
( O
dT O
) O
4 O
and O
( O
dT O
) O
6 O
were O
much O
less O
effective O
, O
indicating O
that O
the O
binding O
site O
involved O
in O
19 O
HDP I-GENE
* I-GENE
accumulation O
covered O
between O
6 O
and O
8 O
residues O
of O
( O
dT O
) O
n O
. O

A O
double O
- O
blind O
trial O
of O
half O
- O
strength O
Polybactrin O
Soluble O
GU O
bladder O
irrigation O
in O
cystoscopy O
. O

Thus O
it O
appears O
that O
insertion O
of O
a O
transposable O
element O
near O
the O
5 O
' O
terminus O
of O
the O
structural O
gene O
can O
produce O
constitutive O
expression O
of O
a O
normally O
glucose O
- O
repressed O
enzyme O
. O

Five O
experiments O
examined O
the O
influence O
of O
opiate O
antagonists O
on O
both O
the O
short O
- O
term O
analgesic O
reaction O
resulting O
30 O
min O
after O
exposure O
to O
inescapable O
shock O
and O
the O
long O
- O
term O
analgesic O
reaction O
resulting O
after O
reexposure O
to O
shock O
24 O
hr O
after O
inescapable O
shock O
exposure O
. O

Experiment O
3 O
showed O
that O
the O
long O
- O
term O
analgesic O
reaction O
could O
also O
be O
reduced O
by O
administration O
of O
naltrexone O
prior O
to O
reexposure O
to O
shock O
. O

During O
the O
period O
from O
May O
to O
August O
, O
1978 O
, O
an O
epidemic O
of O
hand O
, O
foot O
and O
mouth O
disease O
( O
HFMD O
) O
occurred O
in O
Gifu O
prefecture O
. O

A O
22K O
polypeptide O
was O
detected O
as O
a O
translation O
product O
of O
late O
RNA O
that O
hybridized O
to O
this O
DNA O
fragment O
. O

Replicating O
simian O
virus O
40 O
( O
SV40 O
) O
chromosomes O
were O
found O
to O
be O
similar O
to O
other O
eukaryotic O
chromosomes O
in O
that O
the O
rate O
and O
extent O
of O
micrococcal I-GENE
nuclease I-GENE
( O
MNase I-GENE
) O
digestion O
were O
greater O
with O
replicating O
than O
with O
nonreplicating O
mature O
SV40 O
chromatin O
. O

A O
hypothesis O
. O

We O
have O
investigated O
the O
requirements O
of O
the O
CH I-GENE
gene I-GENE
switch O
by O
characterizing O
two O
rearranged I-GENE
gamma I-GENE
2b I-GENE
genes I-GENE
from O
a O
gamma I-GENE
2b I-GENE
producing O
mouse O
myeloma O
( O
MPC O
- O
11 O
). O

Physiology O
and O
Physiopathology O

The O
genome O
of O
avian O
erythroblastosis O
virus O
contains O
two O
independently O
expressed O
genetic O
loci O
( O
v I-GENE
- I-GENE
erbA I-GENE
and O
v I-GENE
- I-GENE
erbB I-GENE
) O
whose O
activities O
are O
probably O
responsible O
for O
oncogenesis O
by O
the O
virus O
. O

Because O
RNase I-GENE
III I-GENE
host I-GENE
mutants I-GENE
are O
defective O
in O
sib I-GENE
regulation O
, O
processing O
of O
the O
PL I-GENE
mRNA I-GENE
at O
sib I-GENE
by O
this O
endoribonuclease O
may O
cause O
int I-GENE
mRNA I-GENE
decay O
and O
decrease O
int I-GENE
synthesis O
. O

At O
least O
one O
clone O
, O
lambda O
HHG O
41 O
, O
contains O
, O
in O
addition O
to O
the O
histone I-GENE
genes I-GENE
, O
a O
region O
that O
hybridizes O
with O
a O
cytoplasmic O
RNA O
approximately O
330 O
nucleotides O
in O
length O
. O

Both O
neural O
and O
hormonal O
pathways O
and O
both O
opiate O
and O
nonopiate O
substances O
play O
roles O
in O
the O
complex O
modulation O
of O
pain O
transmission O
. O

Restoration O
of O
impaired O
immune O
functions O
in O
aging O
animals O
. O

Postoperative O
serum O
ACTH I-GENE
levels O
were O
normal O
. O

WR O
- O
2721 O
( O
S O
- O
2 O
-( O
3 O
aminopropylamino O
) O
ethylphosphorothioic O
acid O
) O
has O
been O
investigated O
for O
its O
ability O
to O
protect O
gut O
, O
lung O
, O
and O
testis O
, O
as O
well O
as O
fibrosarcoma O
( O
FSa O
) O
tumor O
nodules O
, O
in O
the O
lungs O
of O
mice O
from O
gamma O
- O
radiation O
injury O
. O

In O
fact O
, O
families O
of O
polypeptides O
were O
produced O
by O
initiation O
of O
translation O
at O
AUG O
codons O
within O
sequences O
coding O
for O
VP1 I-GENE
and O
T I-GENE
, O
presumably O
as O
a O
result O
of O
transcription O
initiation O
events O
that O
generated O
5 O
' O
ends O
immediately O
upstream O
from O
these O
AUGs O
. O

In O
addition O
, O
TRP1 I-GENE
RI O
Circle O
DNA O
is O
organized O
into O
nucleosomes O
whose O
size O
and O
spacing O
are O
indistinguishable O
from O
that O
of O
bulk O
yeast O
chromatin O
. O

The O
frequency O
of O
previous O
transfusion O
in O
chronic O
hepatitis O
, O
cirrhosis O
and O
hepatocellular O
carcinoma O
of O
type O
NANB O
was O
42 O
. O
8 O
, O
37 O
. O
1 O
and O
15 O
. O
1 O
%, O
respectively O
, O
whereas O
the O
incidence O
of O
early O
posttransfusion O
hepatitis O
was O
8 O
. O
5 O
, O
8 O
. O
6 O
and O
7 O
. O
5 O
%, O
respectively O
. O
in O
chronic O
liver O
diseases O
with O
a O
history O
of O
jaundice O
and O
/ O
or O
hepatitis O
, O
previous O
transfusions O
are O
more O
frequently O
associated O
with O
type O
NANB O
than O
with O
type O
B O
disease O
. O

Of O
115 O
hepatitis O
B O
patients O
seen O
at O
12 O
months O
, O
6 O
% O
had O
chronic O
hepatitis O
Bs O
antigenaemia O
, O
60 O
% O
had O
developed O
anti I-GENE
- I-GENE
HBs I-GENE
antibodies I-GENE
, O
and O
7 O
. O
3 O
% O
still O
had O
abnormal O
liver O
function O
. O

Survey O
on O
antibody O
against O
egg O
drop O
syndrome O
- O
1976 O
virus O
among O
chicken O
flocks O
in O
Japan O
. O

In O
49 O
patients O
in O
whom O
gated O
equilibrium O
ventriculography O
and O
cardiac O
catheterization O
were O
performed O
within O
a O
6 O
day O
interval O
, O
total O
and O
fractional O
portions O
of O
global O
and O
regional O
right O
ventricular O
ejection O
fraction O
( O
RVEF O
) O
were O
correlated O
with O
pulmonary O
arterial O
systolic O
pressure O
. O

74 O
, O
193 O
- O
197 O
). O

The O
combination O
of O
MISO O
and O
WR O
- O
2721 O
gave O
an O
intermediate O
response O
compared O
with O
either O
drug O
used O
alone O
, O
resulting O
in O
some O
sensitization O
with O
single O
doses O
and O
an O
overall O
protection O
with O
repeated O
small O
doses O
. O

Two O
mutations O
that O
affect O
larval I-GENE
cuticle I-GENE
protein I-GENE
gene I-GENE
expression O
in O
the O
2 O
/ O
3 O
variant O
Drosophila O
melanogaster O
strain O
were O
investigated O
. O

The O
ensembles O
are O
considered O
to O
be O
one O
of O
the O
forms O
of O
activity O
of O
the O
structured O
morphofunctional O
cortical O
units O
, O
i O
. O
e O
. O
the O
columns O
. O

The O
strong O
conservation O
of O
the O
inverted O
terminal O
repeat O
sequence O
may O
reflect O
a O
common O
integration O
mechanism O
for O
VL30 I-GENE
elements I-GENE
and O
MuLV O
proviruses O
. O

A O
cDNA O
cloning O
vector O
that O
permits O
expression O
of O
cDNA O
inserts O
in O
mammalian O
cells O
. O

Hybridization O
of O
plasmid O
- O
transformed O
Escherichia O
coli O
RR1 O
colonies O
with O
32P O
- O
labeled O
viral O
genome O
RNAs O
demonstrated O
the O
presence O
of O
DNA O
clones O
representative O
of O
each O
of O
the O
10 O
reovirus O
RNAs O
and O
10 O
of O
the O
11 O
constituent O
segments O
of O
the O
rotavirus O
genome O
. O

Another O
sequence O
, O
GGGXGGAG O
, O
which O
is O
repeated O
several O
times O
in O
many O
polyomaviruses O
and O
adenoviruses O
, O
and O
which O
is O
thought O
to O
play O
a O
role O
in O
DNA O
replication O
and O
/ O
or O
transcription O
, O
is O
not O
found O
in O
the O
JCV O
sequence O
presented O
. O

In O
conclusion O
, O
these O
studies O
indicate O
that O
LiCl O
( O
1 O
) O
decreases O
histamine O
- O
stimulated O
gastric O
acid O
secretion O
, O
and O
( O
2 O
) O
diminishes O
bile O
- O
induced O
disruption O
of O
the O
gastric O
mucosal O
barrier O
in O
the O
canine O
Heidenhain O
pouch O
. O

Lung O
density O
increased O
in O
quartz O
- O
exposed O
, O
but O
not O
in O
volcanic O
- O
ash O
- O
exposed O
animals O
. O

The O
hepatitis I-GENE
A I-GENE
virus I-GENE
antibody I-GENE
( O
anti I-GENE
- I-GENE
HAV I-GENE
) O
in O
chronic O
diffuse O
liver O
diseases O

The O
junctions O
between O
viral O
and O
cellular O
sequences O
were O
determined O
by O
DNA O
sequence O
analysis O
to O
be O
517 O
nucleotides O
into O
the O
p30 I-GENE
sequence I-GENE
and O
1 O
, O
920 O
nucleotides O
into O
the O
polymerase O
sequence O
. O

Naloxone O
( O
2 O
mg O
/ O
kg O
bolus O
+ O
2 O
mg O
X O
kg O
- O
1 O
X O
h O
- O
1 O
) O
was O
given O
with O
one O
of O
the O
two O
doses O
of O
the O
lipopolysaccharide O
. O

Gel O
route O
preparation O
of O
low O
fusing O
dental O
porcelain O
frit O
. O

I O
. O

Viral O
RNA O
, O
molecularly O
cloned O
proviral O
DNA O
, O
and O
virus O
- O
specific O
protein O
of O
avian O
retrovirus O
MH2 O
were O
analyzed O
. O

Intracellular O
recordings O
were O
performed O
on O
the O
optic O
tectum O
of O
the O
carp O
in O
vitro O
. O

Molecular O
structure O
and O
evolutionary O
origin O
of O
human I-GENE
cardiac I-GENE
muscle I-GENE
actin I-GENE
gene I-GENE
. O

The O
mutants O
were O
obtained O
by O
substitution O
into O
a O
molecular O
clone O
of O
M O
- O
MuLV O
DNA O
by O
DNA O
from O
two O
acutely O
transforming O
viruses O
, O
Ableson O
MuLV O
( O
Ab O
- O
MuLV O
) O
and O
Moloney O
murine O
sarcoma O
virus O
( O
M O
- O
MSV O
). O

Plasmids O
for O
the O
cloning O
and O
expression O
of O
full O
- O
length O
double O
- O
stranded O
cDNAs O
under O
control O
of O
the O
SV40 I-GENE
early I-GENE
or O
late I-GENE
gene I-GENE
promoter O
. O

Supplementing O
a O
soybean O
protein O
and O
sucrose O
- O
based O
diet O
with O
levels O
of O
2 O
. O
2 O
, O
11 O
, O
and O
55 O
ppm O
of O
the O
antibiotic O
, O
from O
the O
two O
sources O
each O
with O
two O
different O
purities O
, O
improved O
weight O
gain O
of O
chicks O
an O
average O
of O
23 O
% O
and O
improved O
feed O
efficiency O
an O
average O
of O
13 O
% O
at O
the O
higher O
levels O
( O
all O
P O
less O
than O
. O
01 O
). O

The O
dnaQ I-GENE
- O
lacZ I-GENE
and O
the O
rnh I-GENE
- O
lacZ I-GENE
fused O
genes O
were O
constructed O
and O
hybrid O
proteins O
with O
beta I-GENE
- I-GENE
galactosidase I-GENE
activity O
were O
produced O
. O

Overall O
prevalences O
of O
antibody O
were O
70 O
per O
cent O
in O
cattle O
, O
67 O
per O
cent O
in O
sheep O
and O
76 O
per O
cent O
in O
goats O
as O
assessed O
by O
an O
immunodiffusion O
test O
. O

Expression O
of O
herpes O
simplex O
virus O
beta O
and O
gamma O
genes O
integrated O
in O
mammalian O
cells O
and O
their O
induction O
by O
an O
alpha O
gene O
product O
. O

The O
splice O
acceptor O
site O
is O
ca O
. O

This O
is O
consistent O
with O
a O
model O
proposing O
that O
SSV O
was O
generated O
by O
recombination O
between O
proviral O
DNA O
of O
a O
simian O
sarcoma O
associated O
virus O
and O
proto I-GENE
- I-GENE
sis I-GENE
and O
that O
introns O
were O
spliced O
out O
subsequently O
from O
a O
fused O
viral I-GENE
- I-GENE
sis I-GENE
messenger I-GENE
RNA I-GENE
. O

We O
conclude O
that O
, O
with O
autonomic O
nervous O
system O
activity O
intact O
, O
carotid O
chemoreceptor O
reflex O
activation O
can O
elicit O
an O
absolute O
reflexly O
mediated O
reduction O
in O
coronary O
blood O
flow O
in O
the O
normal O
, O
conscious O
dog O
, O
despite O
an O
increase O
in O
arterial O
pressure O
. O

Female O
subjects O
, O
including O
both O
normal O
subjects O
and O
idiopathic O
calcium O
stone O
- O
formers O
, O
have O
higher O
urinary O
cyclic O
AMP O
levels O
than O
their O
male O
counterparts O
, O
and O
this O
difference O
is O
significant O
when O
urinary O
cyclic O
AMP O
is O
expressed O
in O
the O
units O
mumol O
/ O
g O
of O
creatinine O
. O

We O
conclude O
that O
the O
' O
morning O
dip O
' O
observed O
in O
asthmatic O
patients O
cannot O
simply O
be O
explained O
by O
changes O
in O
cell O
receptor O
number O
or O
affinity O
, O
as O
our O
results O
suggest O
that O
both O
groups O
have O
intact O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
function O
. O

The O
effect O
of O
desipramine O
probably O
represents O
inhibition O
of O
neuronal O
uptake O
and O
that O
of O
amitriptyline O
and O
mianserin O
blockade O
of O
neuronal O
uptake O
and O
prejunctional O
alpha I-GENE
2 I-GENE
- I-GENE
adrenoreceptors I-GENE
. O

We O
conclude O
that O
the O
gp54 I-GENE
structural I-GENE
gene I-GENE
is O
required O
for O
initiation O
or O
amplification O
of O
the O
splenic O
erythroblast O
hyperplasia O
which O
characterizes O
the O
preleukemic O
phase O
of O
Rauscher O
disease O
. O

Surgical O
treatment O
of O
pulmonary O
metastases O
. O

A O
promoter O
sequence O
( O
Goldberg O
- O
Hogness O
or O
TATA O
box O
) O
is O
situated O
28 O
base O
pairs O
upstream O
from O
the O
point O
of O
initiation O
of O
transcription O
which O
was O
found O
by O
S1 I-GENE
nuclease I-GENE
mapping O
and O
by O
oligonucleotide O
- O
primed O
reverse O
transcription O
of O
rat I-GENE
PTH I-GENE
mRNA I-GENE
. O

Each O
of O
these O
spliced O
mRNAs O
has O
an O
untranslated O
leader O
sequence O
of O
249 O
bases O
and O
a O
single O
intron O
of O
approximately O
540 O
bases O
which O
are O
contained O
entirely O
within O
TRs O
/ O
IRs O
sequences O
. O

The O
expression O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
was O
detected O
within O
1 O
h O
after O
infection O
of O
cells O
with O
recombinant O
virus O
, O
reflecting O
the O
early O
nature O
of O
the O
promoters O
used O
. O

NPT I-GENE
II I-GENE
synthesis O
, O
measured O
by O
agar O
plate O
assays O
of O
kanamycin O
resistance O
and O
by O
immunoprecipitation O
of O
the O
NPT I-GENE
II I-GENE
protein I-GENE
, O
was O
repressed O
in O
the O
presence O
of O
cysteine O
and O
derepressed O
in O
its O
absence O
. O

A O
computed O
tomographic O
scan O
obtained O
after O
EOE O
- O
13 O
infusion O
accurately O
showed O
the O
perfusion O
pattern O
of O
the O
implanted O
catheter O
. O

The O
primary O
structure O
of O
the O
GAL7 I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
region I-GENE
has O
many O
features O
common O
to O
those O
of O
multicellular O
eukaryotic O
genes O
. O

The O
12 I-GENE
, I-GENE
000 I-GENE
MW I-GENE
( I-GENE
12K I-GENE
) I-GENE
IE I-GENE
polypeptide I-GENE
encoded O
by O
IEmRNA I-GENE
- I-GENE
5 I-GENE
is O
translated O
from O
an O
88 O
codon O
open O
reading O
frame O
, O
leaving O
a O
1200 O
base O
3 O
' O
non O
- O
translated O
region O
. O

The O
greatest O
difference O
between O
the O
Ad7 I-GENE
and I-GENE
Ad5 I-GENE
DBPs I-GENE
is O
the O
absence O
, O
in O
the O
Ad7 O
protein O
, O
of O
12 O
amino O
acids O
located O
between O
the O
two O
functional O
domains O
in O
the O
Ad5 O
protein O
( O
amino O
acids O
151 O
- O
162 O
). O

No O
significant O
correlation O
was O
found O
between O
LVM O
or O
wall O
thickness O
and O
body O
surface O
area O
, O
age O
, O
blood O
pressure O
, O
heart O
rate O
, O
cardiac O
output O
, O
total O
peripheral O
resistance O
and O
left O
ventricular O
systolic O
wall O
stress O
, O
whereas O
CD25 O
was O
correlated O
with O
urinary O
catecholamines O
only O
in O
hypertensive O
patients O
( O
r O
= O
0 O
. O
606 O
, O
p O
less O
than O
0 O
. O
001 O
). O

Furthermore O
, O
no O
Shine O
- O
Dalgarno O
sequences O
are O
present O
upstream O
of O
the O
presumed O
translational O
start O
codons O
. O

The O
gene I-GENE
cat I-GENE
- I-GENE
86 I-GENE
, O
specifying O
chloramphenicol I-GENE
- I-GENE
inducible I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
, O
is O
located O
on O
the O
1 O
. O
1 O
- O
kilobase O
cloned O
DNA O
. O

The O
myeloproliferative O
sarcoma O
virus O
( O
MPSV O
) O
was O
derived O
by O
passage O
of O
Moloney O
sarcoma O
virus O
( O
Mo O
- O
MuSV O
) O
in O
adult O
mice O
. O

The O
same O
- O
sized O
EBNA I-GENE
protein I-GENE
( I-GENE
approximately I-GENE
78 I-GENE
, I-GENE
000 I-GENE
) I-GENE
was O
made O
after O
transfection O
with O
BamHI I-GENE
- I-GENE
K I-GENE
( I-GENE
5 I-GENE
. I-GENE
2 I-GENE
kilobase I-GENE
pairs I-GENE
[ I-GENE
kbp I-GENE
]) I-GENE
or O
the O
I1f O
subfragment O
( O
2 O
. O
9 O
kbp O
). O

They O
generated O
ca O
. O

Here O
we O
have O
determined O
the O
nucleotide O
sequence O
of O
3 O
. O
5 O
kb O
from O
the O
3 O
' O
end O
of O
delta I-GENE
gag I-GENE
to O
the O
3 O
' O
end O
of O
molecularly O
cloned O
proviral O
MH2 O
DNA O
, O
in O
order O
to O
elucidate O
the O
genetic O
structure O
of O
the O
virus O
and O
to O
compare O
it O
with O
other O
mht I-GENE
- O
and O
myc I-GENE
- O
containing O
oncogenic O
viruses O
as O
well O
as O
with O
the O
chicken I-GENE
proto I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

USA O
80 O
, O
802 O
- O
806 O
] O
was O
used O
to O
isolate O
a O
genomic O
clone O
lambda O
PGK I-GENE
- I-GENE
1 I-GENE
containing O
a O
portion O
of O
an O
autosomal O
locus O
for O
phosphoglycerate I-GENE
kinase I-GENE
( O
PGK I-GENE
). O

A O
. O

188 O
patients O
received O
cimetidine O
400 O
mg O
q O
. O
i O
. O
d O
. O
intravenously O
and O
1 O
, O
000 O
mg O
daily O
orally O
in O
divided O
doses O
. O

An O
immunologic O
test O
using O
stomach O
and O
tumor O
antigens O
for O
screening O
of O
those O
at O
high O
risk O
for O
stomach O
cancer O
is O
suggested O
. O

Thirty O
isolates O
of O
Haemophilus O
influenzae O
type O
b O
were O
obtained O
during O
an O
outbreak O
of O
invasive O
H O
. O
influenzae O
type O
b O
disease O
and O
were O
classified O
by O
the O
electrophoretic O
profile O
of O
their O
lipopolysaccharide O
( O
LPS O
). O

Tiaprofenic O
acid O
overdose O
. O

Frog O
type O
I O
( O
Ft O
I O
) O
and O
frog O
type O
II O
( O
Ft O
II O
) O
slowly O
adapting O
( O
SA O
) O
units O
produced O
spikes O
only O
at O
the O
indentation O
phase O
, O
and O
the O
threshold O
response O
phase O
( O
TRP O
), O
i O
. O
e O
.. O
the O
phase O
of O
the O
first O
spike O
was O
for O
ca O
. O

Frog O
type O
I O
( O
Ft O
I O
) O
and O
frog O
type O
II O
( O
Ft O
II O
) O
slowly O
adapting O
( O
SA O
) O
units O
produced O
spikes O
only O
at O
the O
indentation O
phase O
, O
and O
the O
threshold O
response O
phase O
( O
TRP O
), O
i O
. O
e O
.. O
the O
phase O
of O
the O
first O
spike O
was O
for O
ca O
. O

DMCM O
also O
permits O
extension O
of O
the O
possibilities O
of O
obtaining O
and O
transplanting O
donor O
organs O
. O

Grimelius O
stain O
was O
positive O
, O
Masson O
Fontana O
stain O
negative O
. O

Blood O
glucose O
and O
plasma O
insulin I-GENE
were O
measured O
at O
zero O
time O
and O
then O
at O
15 O
, O
30 O
, O
60 O
, O
90 O
and O
120 O
min O
after O
ingestion O
of O
25 O
g O
glucose O
, O
fructose O
or O
lactose O
, O
or O
30 O
g O
honey O
, O
50 O
g O
white O
bread O
, O
125 O
g O
white O
rice O
or O
potatoes O
, O
150 O
g O
apples O
or O
260 O
g O
carrots O
. O

Clinical O
use O
of O
absorbable O
polyglycolic O
acid O
suture O
in O
Blalock O
- O
Taussig O
' O
s O
operation O

Among O
these O
are O
: O
( O
1 O
) O
Is O
there O
sufficient O
understanding O
of O
family O
pathophysiology O
, O
of O
the O
sensitivity O
and O
specificity O
of O
diagnostic O
techniques O
and O
of O
the O
safety O
and O
efficacy O
of O
therapeutic O
modalities O
to O
make O
true O
family O
health O
care O
possible O
? O
( O
2 O
) O
If O
this O
type O
of O
care O
is O
possible O
, O
how O
are O
the O
needs O
of O
the O
family O
and O
its O
individual O
members O
met O
, O
or O
value O
judgements O
made O
about O
their O
relative O
importance O
? O
and O
( O
3 O
) O
What O
are O
the O
consequences O
for O
the O
health O
care O
delivery O
system O
of O
this O
type O
of O
care O
? O
An O
extensive O
literature O
review O
is O
used O
in O
an O
attempt O
to O
answer O
these O
queries O
, O
from O
which O
questions O
for O
further O
study O
are O
posed O
. O

In O
patients O
in O
group O
A O
(" O
normal O
" O
CI O
), O
the O
CI O
, O
heart O
rate O
and O
the O
mean O
circumferential O
fiber O
shortening O
velocity O
( O
mVCF O
) O
were O
normal O
, O
but O
the O
TPR O
was O
increased O
significantly O
. O

Immunologically O
reactive O
insulin I-GENE
levels O
were O
determined O
in O
freely O
- O
moving O
normal O
rats O
offered O
three O
different O
test O
- O
meals O
. O

These O
results O
indicate O
that O
both O
naturally O
acquired O
and O
passive O
( O
modified O
immune I-GENE
serum I-GENE
globulin I-GENE
) O
antibodies O
to O
type I-GENE
III I-GENE
group I-GENE
B I-GENE
Streptococcus I-GENE
antigen I-GENE
are O
partially O
protective O
against O
intra O
- O
amniotic O
infection O
. O

In O
the O
posthospital O
phase O
of O
AMI O
, O
as O
well O
as O
in O
CCHD O
, O
the O
occurrence O
of O
high O
- O
grade O
VPBs O
usually O
indicates O
more O
advanced O
degrees O
of O
both O
coronary O
and O
left O
ventricular O
disease O
as O
well O
as O
the O
possibility O
of O
cardiac O
and O
/ O
or O
sudden O
death O
. O

Sweet O
oranges O
, O
mandarin O
, O
grapefruit O
, O
lemon O
, O
and O
lime O
are O
generally O
used O
for O
processing O
. O

The O
genes O
at O
each O
locus O
are O
divergently O
transcribed O
and O
the O
coding O
sequences O
are O
separated O
by O
646 O
base O
- O
pairs O
at O
one O
locus O
and O
676 O
base O
- O
pairs O
at O
the O
other O
. O

The O
enzymic O
hydrolysis O
of O
urea O
produces O
ammonia O
which O
causes O
a O
vivid O
yellow O
to O
purple O
colour O
change O
in O
the O
pH O
indicator O
. O

The O
clinical O
efficacy O
rates O
evaluated O
in O
151 O
cases O
( O
KS O
- O
R1 O
group O
in O
77 O
cases O
, O
oral O
group O
in O
74 O
cases O
) O
on O
standard O
criteria O
of O
committee O
members O
were O
88 O
. O
3 O
% O
for O
the O
KS O
- O
R1 O
group O
and O
86 O
. O
5 O
% O
for O
the O
oral O
group O
, O
respectively O
. O

Side O
effect O
including O
subjective O
and O
objective O
symptoms O
were O
strictly O
evaluated O
in O
163 O
cases O
( O
KS O
- O
R1 O
group O
in O
83 O
cases O
, O
oral O
group O
in O
80 O
cases O
), O
but O
the O
incidence O
rate O
which O
was O
22 O
. O
9 O
% O
for O
the O
KS O
- O
R1 O
group O
and O
23 O
. O
8 O
% O
for O
the O
oral O
group O
showed O
no O
significant O
difference O
. O

Plasma O
renin I-GENE
activity O
did O
not O
change O
in O
response O
to O
head O
- O
up O
tilt O
or O
isoprenaline O
infusion O
in O
the O
patients O
. O

Martin O
Luther O
and O
his O
physicians O
. O

Enhancement O
of O
the O
immune O
response O
by O
aspecific O
action O
of O
vaccine O
additives O
in O
the O
aerogenic O
immunization O
of O
swine O
against O
swine O
plague O

Induced O
gamma O
- O
ray O
spectroscopy O

Bepridil O
, O
a O
calcium O
antagonist O
with O
a O
half O
- O
life O
of O
approximately O
42 O
hours O
, O
was O
compared O
with O
placebo O
in O
a O
double O
- O
blind O
, O
randomized O
, O
crossover O
trial O
. O

Analysis O
of O
proteins O
synthesized O
by O
plasmids O
containing O
deleted O
forms O
of O
the O
trfA I-GENE
region I-GENE
indicates O
that O
the O
A2 I-GENE
protein I-GENE
is O
the O
essential O
trfA I-GENE
- I-GENE
encoded I-GENE
replication I-GENE
protein I-GENE
of O
plasmid O
RK2 O
. O

Effects O
of O
negative O
pleural O
pressure O
on O
left O
ventricular O
hemodynamics O
. O

Resting O
plasma O
norepinephrine O
( O
NE O
) O
and O
epinephrine O
( O
E O
) O
levels O
were O
lower O
during O
active O
therapy O
than O
2 O
wk O
after O
withdrawal O
( O
guanfacine O
and O
control O
: O
plasma O
NE O
, O
0 O
. O
27 O
+/- O
0 O
. O
03 O
/ O
0 O
. O
64 O
+/- O
0 O
. O
13 O
ng O
/ O
ml O
; O
plasma O
E O
, O
0 O
. O
09 O
+/- O
0 O
. O
02 O
/ O
0 O
. O
17 O
+/- O
0 O
. O
05 O
ng O
/ O
ml O
). O

Renal O
response O
to O
captopril O
in O
severe O
heart O
failure O
: O
role O
of O
furosemide O
in O
natriuresis O
and O
reversal O
of O
hyponatremia O
. O

Lauciello O
describes O
a O
technique O
for O
the O
placement O
of O
functionally O
generated O
amalgam O
stops O
as O
restorations O
within O
mandibular O
acrylic O
teeth O
. O

Eleven O
biopsy O
specimens O
( O
five O
papules O
and O
six O
dusky O
or O
crusted O
lesions O
) O
from O
four O
patients O
with O
pityriasis O
lichenoides O
et O
varioliformis O
acuta O
( O
PLEVA O
) O
were O
studied O
by O
direct O
immunofluorescence O
and O
immunoperoxidase I-GENE
technics O
. O

These O
data O
suggest O
that O
a O
major O
part O
of O
the O
reduction O
in O
food O
intake O
in O
hyperphagic O
rats O
eating O
a O
quinine O
- O
adulterated O
diet O
is O
due O
to O
postingestional O
events O
. O

The O
aspirate O
from O
a O
parathyroid O
cyst O
was O
watery O
clear O
and O
contained O
high O
amount O
of O
parathyroid I-GENE
hormone I-GENE
. O

EGV O
had O
no O
detectable O
effect O
on O
PP I-GENE
secretion O
under O
basal O
or O
stimulated O
conditions O
. O

The O
numerous O
tests O
demonstrate O
that O
the O
HDL O
- O
2M O
can O
be O
extensively O
and O
successfully O
used O
for O
therapy O
of O
insulin I-GENE
- O
dependent O
diabetes O
mellitus O
in O
clinical O
practice O
. O

Lung O
prostacyclin O
production O
may O
be O
related O
to O
flow O
. O

For O
the O
first O
30 O
min O
following O
insulin I-GENE
administration O
, O
the O
rate O
of O
change O
in O
glucose O
levels O
was O
significantly O
less O
among O
the O
patients O
with O
major O
depressive O
disorder O
than O
among O
either O
the O
patients O
with O
dysthymic O
disorder O
or O
the O
normal O
control O
subjects O
. O

Management O
of O
hypertension O
in O
the O
elderly O
. O

Climatic O
treatment O
of O
children O
with O
respiratory O
allergy O

Transplantation O
of O
kidneys O
of O
juvenile O
donors O
in O
adult O
recipients O
. O

Ten O
patients O
with O
advanced O
, O
diffuse O
Hodgkin O
' O
s O
and O
non O
- O
Hodgkin O
' O
s O
lymphomas O
responding O
poorly O
to O
the O
most O
widely O
employed O
primary O
chemotherapy O
regimens O
were O
treated O
with O
a O
high O
- O
dose O
chemotherapy O
( O
HDC O
) O
followed O
by O
rescue O
with O
non O
- O
frozen O
autologous O
bone O
marrow O
infusion O
( O
ABMT O
). O

Effect O
of O
proteolytic O
enzymes O
and O
polypeptides O
on O
the O
antacid O
activity O
of O
almagate O
and O
other O
antacids O
. O

Results O
of O
a O
controlled O
study O

Hydrallazine O
also O
caused O
a O
slight O
increase O
in O
plasma I-GENE
renin I-GENE
activity O
and O
urinary O
excretion O
of O
noradrenaline O
. O

Urease I-GENE
activity O
of O
97 O
% O
of O
these O
organisms O
became O
evident O
within O
30 O
min O
. O

After O
description O
of O
his O
short O
life O
and O
an O
explanation O
of O
the O
light O
conductor O
Bozzini O
' O
s O
merit O
is O
emphasized O
, O
by O
his O
invention O
as O
first O
physician O
to O
have O
made O
accessible O
to O
medicine O
endoscopic O
diagnostic O
possibilities O
. O

The O
effect O
of O
lithium O
on O
the O
osmoregulation O
of O
arginine I-GENE
vasopressin I-GENE
secretion O
. O

The O
susceptibility O
of O
the O
PPNG O
strains O
to O
clinically O
relevant O
antibiotics O
varied O
with O
the O
plasmid O
pattern O
; O
this O
stresses O
the O
necessity O
of O
permanent O
surveillance O
of O
gonococcal O
infections O
and O
of O
regular O
evaluation O
of O
the O
recommendations O
for O
antimicrobial O
treatment O
. O

Antithrombin I-GENE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
is O
a O
plasma O
protein O
which O
acts O
as O
the O
principal O
inhibitor O
of O
thrombin I-GENE
and O
is O
a O
major O
modulator O
of O
intravascular O
coagulation O
. O

Eighteen O
patients O
were O
untreated O
, O
and O
8 O
had O
been O
given O
previous O
treatment O
with O
depot O
testosterone O
100 O
mg O
intramuscularly O
every O
2 O
- O
3 O
weeks O
for O
an O
average O
duration O
of O
4 O
. O
7 O
years O
. O

195mPt O
- O
labeled O
cisplatin O
was O
administered O
iv O
and O
ip O
to O
control O
mice O
and O
to O
mice O
bearing O
Sarcoma O
180 O
. O

New O
beta O
- O
blocking O
drugs O
have O
been O
introduced O
which O
may O
prove O
beneficial O
in O
certain O
clinical O
situations O
since O
they O
exert O
more O
selective O
blockade O
of O
the O
cardiac I-GENE
receptors I-GENE
( O
beta1 I-GENE
) O
as O
opposed O
to O
smooth I-GENE
muscle I-GENE
receptors I-GENE
( O
beta2 I-GENE
). O

If O
facilities O
for O
measurements O
of O
O2 O
consumption O
and O
hence O
metabolic O
rate O
are O
available O
, O
these O
should O
be O
utilized O
. O

This O
generally O
means O
an O
energy O
intake O
of O
1 O
. O
4 O
to O
1 O
. O
6 O
times O
the O
energy O
expenditure O
, O
with O
a O
N O
intake O
of O
250 O
to O
400 O
mg O
/ O
kg O
/ O
day O
. O

In O
the O
37 O
patients O
without O
lung O
disease O
respiratory O
muscle O
weakness O
was O
accompanied O
by O
significant O
decreases O
in O
vital O
capacity O
, O
total O
lung O
capacity O
, O
and O
maximum O
voluntary O
ventilation O
; O
by O
significant O
increases O
in O
residual O
volume O
and O
arterial O
carbon O
dioxide O
tension O
( O
PaCO2 O
); O
and O
greater O
likelihood O
of O
dependence O
on O
ventilators O
, O
atelectasis O
, O
and O
pneumonia O
. O

Commun O
. O

The O
statistical O
analysis O
of O
data O
of O
TRH I-GENE
test O
on O
a O
sample O
of O
57 O
healthy O
volunteers O
has O
permitted O
an O
evaluation O
of O
the O
upper O
limits O
of O
the O
normal O
thyrotropin I-GENE
response O
; O
the O
secretory O
area O
( O
As O
) O
was O
shown O
to O
be O
more O
discriminating O
. O

Total O
cumulative O
doses O
of O
doxorubicin O
ranged O
from O
145 O
to O
625 O
mg O
./ O
m O
. O
2 O
. O

Movement O
programming O
depends O
on O
understanding O
of O
behavioral O
requirements O
. O

Following O
20 O
min O
of O
steady O
state O
anaesthesia O
during O
which O
measurements O
of O
IOP O
, O
arterial O
pressure O
, O
heart O
rate O
, O
FIO2 O
, O
FE O
' O
CO2 O
and O
CVP O
were O
recorded O
, O
one O
group O
of O
patients O
received O
atracurium O
0 O
. O
45 O
mg O
kg O
- O
1 O
and O
the O
other O
pancuronium O
0 O
. O
1 O
mg O
kg O
- O
1 O
. O

Transitory O
subclinical O
and O
permanent O
hypothyroidism O
in O
the O
course O
of O
subacute O
thyroiditis O
( O
de O
Quervain O
). O

Gonadotropin I-GENE
levels O
in O
mothers O
who O
have O
had O
two O
sets O
of O
DZ O
twins O
. O

Freezing O
of O
plasma O
to O
obtain O
better O
yield O
of O
factor I-GENE
VIII I-GENE
: O
C O
. O

These O
children O
were O
grouped O
into O
four O
diagnostic O
categories O
: O
1 O
) O
idiopathic O
GH I-GENE
deficiency O
( O
n O
= O
10 O
); O
2 O
) O
organic O
hypopituitarism O
( O
n O
= O
7 O
); O
3 O
) O
intrauterine O
growth O
retardation O
( O
n O
= O
5 O
); O
and O
4 O
) O
constitutional O
delay O
of O
growth O
and O
/ O
or O
familial O
short O
stature O
( O
n O
= O
18 O
), O
by O
standard O
clinical O
criteria O
and O
physiological O
and O
pharmacological O
tests O
of O
GH I-GENE
reserve O
. O

Each O
patient O
had O
measurable O
LH I-GENE
and O
FSH I-GENE
levels O
, O
with O
pulsed O
nocturnal O
secretion O
, O
and O
pubertal O
LH I-GENE
and O
FSH I-GENE
responses O
to O
LRH I-GENE
. O

These O
changes O
were O
the O
result O
of O
a O
decrease O
in O
afterload O
: O
mean O
aortic O
pressure O
fell O
from O
85 O
+/- O
11 O
. O
8 O
to O
68 O
+/- O
19 O
. O
6 O
mmHg O
( O
p O
less O
than O
0 O
. O
01 O
) O
and O
systemic O
arterial O
resistance O
fell O
from O
2 O
886 O
+/- O
745 O
to O
2 O
010 O
+/- O
610 O
dynes O
/ O
cm O
- O
5 O
/ O
sec O
/ O
m O
- O
2 O
( O
p O
less O
than O
0 O
. O
01 O
). O

Cimetidine O
800 O
mg O
given O
at O
night O
is O
as O
effective O
as O
400 O
mg O
twice O
daily O
; O
the O
single O
dose O
regimen O
may O
improve O
patient O
compliance O
, O
thus O
facilitating O
treatment O
. O

Ceftazidime O
shows O
promise O
as O
single O
- O
agent O
therapy O
for O
serious O
gram O
- O
negative O
bacillary O
infections O
. O

Regional O
CBF O
was O
determined O
by O
clearance O
of O
xenon O
133 O
in O
67 O
patients O
undergoing O
coronary O
bypass O
grafting O
procedures O
. O

Our O
results O
indicate O
that O
serum I-GENE
BGP I-GENE
is O
a O
valuable O
measurement O
of O
bone O
metabolism O
. O

The O
management O
of O
the O
" O
chronic O
" O
patient O
. O

Study O
of O
bacterial O
motility O
and O
rate O
of O
movement O
using O
a O
closed O
circuit O
television O

Finding O
of O
Rhodnius O
prolixus O
Stal O
, O
1859 O
, O
in O
babassu O
palm O
trees O

Each O
causative O
organism O
has O
a O
species O
- O
specific O
preference O
and O
requirement O
for O
temperature O
, O
salinity O
, O
pH O
, O
the O
basic O
nutrients O
, O
and O
growth O
factors O
, O
and O
the O
toxin O
formation O
is O
affected O
by O
these O
environmental O
factors O
. O

It O
is O
concluded O
that O
axillo O
- O
axillary O
by O
- O
pass O
is O
a O
simple O
solution O
for O
a O
complex O
haemodynamic O
, O
clinical O
and O
therapeutic O
problem O
. O

Deformities O
of O
the O
tip O
of O
the O
olecranon O
and O
of O
the O
coronoid O
process O
are O
also O
described O
( O
De O
Palma O
1956 O
, O
Jordan O
1958 O
, O
Ahlberg O
1965 O
, O
Weseloh O
1973 O
). O

There O
was O
significant O
correlation O
of O
LVM O
/ O
M2 O
and O
PWVn O
for O
pre O
- O
AVR O
and O
post O
AVR O
studies O
. O

Statokinesimetric O
recording O
in O
Huntington O
choreas O

The O
development O
and O
histostructural O
organization O
of O
intrahepatic O
biliary O
ducts O
were O
studied O
on O
a O
human O
embryofetal O
material O
6 O
to O
32 O
weeks O
old O
. O

It O
has O
been O
shown O
in O
an O
animal O
experiment O
that O
alterations O
of O
the O
renal O
vasculature O
and O
parenchyma O
after O
hemostasis O
performed O
by O
Infrared O
- O
Contact O
- O
Coagulation O
are O
best O
shown O
by O
intravital O
magnification O
angiography O
( O
magnification O
factor O
2 O
. O
22 O
). O

Cardiovascular O
and O
adrenal O
medullo O
- O
sympathetic O
reactions O
to O
acute O
tobacco O
poisoning O

Intravenous O
injections O
of O
SG O
- O
75 O
( O
0 O
. O
03 O
- O
1 O
mg O
/ O
kg O
) O
decreased O
systemic O
blood O
pressure O
( O
SBP O
) O
and O
increased O
peripheral O
( O
coronary O
, O
renal O
, O
mesenteric O
and O
femoral O
) O
blood O
flow O
( O
PBF O
) O
dose O
- O
dependently O
. O

In O
doses O
of O
0 O
. O
03 O
- O
0 O
. O
3 O
mg O
/ O
kg O
i O
. O
v O
., O
SG O
- O
75 O
did O
not O
significantly O
affect O
pulse O
pressure O
, O
heart O
rate O
, O
aortic O
blood O
flow O
, O
left O
ventricular O
pressure O
( O
LVP O
) O
and O
LVdP O
/ O
dt O
max O
. O

Resting O
VE O
in O
the O
luteal O
phase O
was O
7 O
. O
8 O
% O
greater O
than O
that O
in O
the O
follicular O
phase O
. O

Exposure O
of O
endothelium O
to O
pulsatile O
shear O
stresses O
that O
followed O
a O
tape O
recording O
of O
physiological O
flow O
waveforms O
( O
electromagnetic O
flowmeter O
) O
did O
not O
cause O
gross O
injury O
or O
denudation O
even O
when O
peak O
shear O
exceeded O
1500 O
dyne O
/ O
cm2 O
. O

Modern O
cancer O
therapy O
has O
included O
surgery O
, O
radiotherapy O
, O
chemotherapy O
, O
and O
most O
recently O
, O
immunotherapy O
and O
hyperthermia O
. O

There O
was O
a O
close O
correlation O
between O
plasma O
clearance O
of O
NT O
by O
10 O
- O
hydroxylation O
and O
the O
D O
metabolic O
ratio O
( O
D O
/ O
4 O
- O
OH O
- O
D O
in O
urine O
) O
in O
the O
Ghanaians O
( O
rs O
= O
- O
0 O
. O
95 O
; O
P O
less O
than O
0 O
. O
01 O
) O
and O
Swedes O
( O
rs O
= O
- O
0 O
. O
84 O
; O
P O
less O
than O
0 O
. O
01 O
). O

The O
response O
properties O
of O
cat O
horizontal O
canal O
afferents O
( O
N O
= O
81 O
) O
were O
characterized O
by O
three O
parameters O
: O
their O
long O
time O
constants O
( O
tau O
), O
low O
frequency O
gain O
constants O
( O
G1 O
), O
and O
middle O
frequency O
gain O
constants O
( O
Gm O
). O

Endothelium O
of O
the O
central O
ear O
artery O
of O
an O
anesthetized O
rabbit O
is O
damaged O
by O
placing O
artery O
forceps O
on O
the O
ear O
directly O
over O
the O
vessel O
. O

Despite O
supraphysiologic O
E2 O
concentrations O
, O
however O
, O
cervical O
mucus O
scores O
were O
significantly O
reduced O
in O
the O
CC O
- O
treated O
group O
( O
P O
less O
than O
0 O
. O
01 O
). O

Stimulation O
of O
the O
caudate O
nucleus O
' O
dophamine O
- O
reactive O
system O
in O
dogs O
by O
means O
of O
administration O
of O
dophamine O
( O
60 O
micrograms O
) O
and O
phenamine O
led O
to O
deterioration O
of O
conditioned O
and O
unconditioned O
components O
of O
feeding O
behaviour O
. O

Value O
of O
urine O
glucose O
tests O
in O
the O
management O
of O
type O
II O
diabetes O
mellitus O
. O

This O
experiment O
was O
conducted O
to O
determine O
if O
the O
sex O
or O
actual O
egg O
production O
was O
the O
important O
factor O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Hydrocortisone O
seems O
to O
be O
unable O
to O
hinder O
the O
postdenervation O
changes O
in O
the O
muscle O
membrane O
whereas O
high O
doses O
of O
the O
hormone O
are O
able O
to O
induce O
changes O
in O
the O
muscle O
membrane O
. O

Significant O
clinical O
differences O
between O
the O
patients O
treated O
with O
and O
without O
AMB O
were O
longer O
survival O
time O
following O
diagnosis O
of O
illness O
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
more O
frequent O
cranial O
nerve O
signs O
in O
the O
treated O
patients O
( O
P O
= O
0 O
. O
089 O
). O

A O
pharmacokinetic O
study O
of O
apalcillin O
was O
performed O
in O
12 O
patients O
in O
an O
intensive O
- O
care O
unit O
. O

Catch O
- O
up O
growth O
was O
observed O
only O
for O
a O
12 O
- O
month O
period O
in O
4 O
children O
with O
a O
bone O
age O
of O
7 O
to O
8 O
years O
. O

Thrombocyte O
function O
was O
impaired O
in O
all O
patients O
, O
characterized O
by O
a O
diminished O
platelet O
shape O
change O
. O

The O
findings O
demonstrate O
that O
AMPH O
administration O
induces O
a O
significant O
increase O
in O
the O
height O
of O
a O
major O
electroactive O
peak O
in O
the O
caudate O
nucleus O
of O
pigtail O
monkeys O
, O
and O
further O
that O
such O
amphetamine O
- O
induced O
increases O
can O
be O
manipulated O
by O
altering O
the O
affective O
and O
/ O
or O
emotional O
state O
of O
the O
animal O
. O

In O
two O
experiments O
, O
neonatal O
female O
BALB O
/ O
cCrgl O
or O
BALB O
/ O
cfC3HCrgl O
mice O
were O
given O
subcutaneous O
injections O
of O
5 O
micrograms O
17 O
beta O
- O
estradiol O
or O
sesame O
oil O
for O
the O
first O
3 O
days O
of O
life O
and O
were O
ovariectomized O
at O
60 O
days O
of O
age O
, O
at O
which O
time O
vaginal O
concretions O
( O
Experiments O
I O
and O
II O
) O
or O
silica O
( O
Experiment O
II O
) O
were O
implanted O
intravaginally O
. O

For O
228 O
of O
425 O
deaths O
( O
54 O
%) O
occurring O
among O
26 O
100 O
people O
of O
known O
age O
in O
the O
Malumfashi O
area O
of O
northern O
Nigeria O
, O
data O
were O
collected O
on O
symptoms O
present O
prior O
to O
death O
. O

Salivary O
estradiol O
17 O
beta O
( O
E2 O
- O
17 O
beta O
) O
and O
progesterone O
( O
P O
) O
were O
determined O
by O
using O
radioimmunoassay O
techniques O
in O
30 O
pregnant O
females O
in O
the O
first O
, O
second O
and O
third O
trimesters O
as O
well O
as O
in O
10 O
non O
- O
pregnant O
controls O
during O
the O
luteal O
phase O
of O
the O
menstrual O
cycle O
. O

Other O
than O
d O
7 O
, O
there O
was O
no O
significant O
effect O
on O
the O
number O
of O
implants O
. O

Variable O
FHR O
decelerations O
or O
bradycardias O
were O
encountered O
on O
95 O
nonstress O
tests O
( O
18 O
. O
8 O
%) O
in O
80 O
( O
33 O
. O
5 O
%) O
postdate O
patients O
. O

The O
response O
chain O
in O
each O
component O
was O
maintained O
by O
food O
presentation O
under O
a O
fixed O
- O
ratio O
schedule O
. O

The O
results O
imply O
that O
kindling O
does O
not O
produce O
its O
facilitating O
effect O
on O
acquisition O
of O
HPC O
SS O
by O
removing O
a O
disruptive O
effect O
of O
the O
stimulation O
. O

The O
persistent O
fetal O
dispersion O
of O
nodal O
and O
Hiss O
bundle O
fragments O
within O
the O
ventricular O
septum O
is O
proposed O
as O
a O
possible O
explanation O
. O

According O
to O
the O
biochemical O
tests O
, O
high O
activity O
( O
over O
200 O
U O
/ O
l O
) O
of O
alkaline I-GENE
phosphatase I-GENE
was O
recorded O
exclusively O
in O
patients O
with O
the O
lymphogranulomatosis O
- O
induced O
liver O
damage O
. O

Changes O
of O
plasma O
cortisol O
level O
in O
late O
asthmatic O
responses O

Significant O
alterations O
in O
the O
vasectomized O
rats O
from O
sham O
rats O
included O
: O
testicular O
and O
epididymal O
hypertrophy O
, O
formation O
of O
pathologic O
vas O
deferens O
granulomas O
, O
decreased O
total O
serum O
protein O
, O
lowered O
alpha I-GENE
- I-GENE
globulin I-GENE
levels O
as O
shown O
by O
serum O
electrophoresis O
, O
and O
increased O
sperm O
agglutinin I-GENE
antibody O
titers O
. O

SFP O
was O
significantly O
elevated O
in O
Hn O
( O
s O
). O

The O
average O
birth O
mass O
of O
these O
newborns O
was O
3491 O
. O
9 O
+/- O
2 O
SD O
780 O
. O
5 O
g O
and O
that O
in O
the O
control O
group O
3 O
, O
767 O
. O
5 O
+/- O
2 O
SD O
824 O
. O
2 O
g O
( O
P O
less O
than O
0 O
. O
05 O
). O

This O
machine O
drift O
, O
which O
was O
not O
associated O
with O
a O
rise O
in O
water O
phantom O
temperature O
and O
did O
not O
consistently O
correlate O
with O
estimated O
x O
- O
ray O
tube O
heat O
, O
could O
result O
in O
a O
significant O
overestimation O
of O
regional O
cerebral O
blood O
flow O
( O
rCBF O
) O
for O
a O
xenon O
/ O
CT O
rCBF O
protocol O
involving O
5 O
- O
7 O
sequential O
scans O
obtained O
at O
1 O
- O
min O
interscan O
intervals O
. O

Other O
uncertainties O
in O
the O
dosimetry O
at O
Y O
- O
12 O
and O
Vinca O
are O
unaltered O
. O

E2 O
treatments O
elevated O
hen O
plasma O
TG O
7 O
. O
2X O
, O
PL O
5 O
. O
1X O
, O
and O
C O
7 O
. O
2X O
; O
and O
pullet O
plasma O
TG O
6 O
. O
8X O
, O
PL O
3 O
. O
7X O
, O
and O
C O
2 O
. O
5X O
. O

By O
contrast O
, O
kidneys O
from O
rats O
with O
chronic O
metabolic O
acidosis O
produced O
significantly O
more O
NH3 O
than O
both O
these O
groups O
( O
2 O
. O
73 O
+/- O
0 O
. O
29 O
mumol O
X O
min O
- O
1 O
X O
g O
- O
1 O
). O

Serodiagnosis O
of O
trypanosomiasis O
in O
dromedary O
camels O
using O
a O
card O
agglutination O
test O
set O
( O
Testryp O
CATT O
). O

Adenyl I-GENE
cyclase I-GENE
activity O
of O
gastric O
mucosa O
in O
patients O
with O
duodenal O
ulcer O
before O
and O
after O
treatment O

Proteinuria O
-- O
selected O
physiopathological O
and O
clinical O
problems O

However O
, O
subcutaneously O
administered O
pneumococci O
gave O
a O
lower O
mortality O
than O
pneumococci O
given O
intravenously O
or O
intraperitoneally O
. O

Reaction O
of O
human O
organism O
to O
exercise O
. O

HA O
resulted O
in O
decreased O
( O
p O
less O
than O
0 O
. O
05 O
) O
Tre O
( O
0 O
. O
4 O
degrees O
C O
) O
and O
HR O
( O
17 O
b O
X O
min O
- O
1 O
), O
and O
increased O
( O
p O
less O
than O
0 O
. O
05 O
) O
Msw O
( O
16 O
g O
X O
m O
- O
2 O
X O
h O
- O
1 O
) O
during O
the O
saline O
experiments O
. O

The O
results O
obtained O
were O
as O
follows O
: O
The O
mitral O
valve O
orifice O
area O
( O
MVA O
) O
was O
significantly O
smaller O
in O
patients O
with O
type O
III O
of O
the O
LVIT O
flow O
velocity O
pattern O
than O
in O
patients O
with O
type O
I O
( O
p O
less O
than O
0 O
. O
001 O
). O

Scientific O
cooperation O
of O
CMEA O
member O
countries O
has O
been O
carried O
out O
since O
1974 O
under O
the O
sponsorship O
of O
the O
Cancer O
Research O
Institute O
, O
Slovak O
Academy O
of O
Sciences O
( O
Czechoslovakia O
) O
within O
the O
framework O
of O
CMEA O
. O

This O
compares O
favorably O
to O
results O
of O
similarly O
sized O
melanomas O
treated O
by O
enucleation O
. O

A O
new O
variant O
of O
the O
EMG O
- O
BFB O
method O
( O
multichannel O
) O
is O
offered O
which O
has O
made O
it O
possible O
to O
use O
the O
method O
not O
only O
for O
training O
weakened O
muscles O
and O
reducing O
spasticity O
in O
their O
antagonists O
but O
also O
for O
improving O
motor O
coordination O
. O

Lymphocytes O
from O
all O
3 O
species O
yielded O
maximum O
responses O
with O
a O
48 O
- O
hour O
prelabel O
and O
12 O
- O
to O
- O
16 O
hour O
postlabel O
incubation O
period O
at O
41 O
C O
and O
1 O
: O
20 O
blood O
dilution O
. O

However O
, O
there O
was O
a O
difference O
in O
the O
quality O
of O
immunity O
: O
fever O
and O
body O
weight O
loss O
were O
seen O
in O
hamsters O
vaccinated O
with O
the O
killed O
- O
toxoplasma O
vaccine O
after O
they O
were O
challenge O
exposed O
with O
T O
- O
1 O
strain O
, O
whereas O
these O
changes O
were O
rarely O
seen O
in O
hamsters O
given O
the O
live O
- O
toxoplasma O
vaccine O
and O
then O
challenge O
exposed O
with O
RH O
strain O
. O

Alternating O
proline O
/ O
alanine O
sequence O
of O
beta I-GENE
B1 I-GENE
subunit I-GENE
originates O
from O
a O
repetitive O
DNA O
sequence O
. O

The O
segmental O
and O
regional O
projections O
of O
the O
sciatic O
, O
tibial O
and O
common O
peroneal O
nerves O
to O
the O
substantia O
gelatinosa O
of O
the O
spinal O
cord O
in O
rats O
-- O
an O
experimental O
study O
by O
means O
of O
an O
acid I-GENE
phosphatase I-GENE
( O
ACP I-GENE
) O
method O
. O

Removal O
of O
lipid O
fractions O
of O
plant O
extractions O
with O
hexane O
is O
recommended O
to O
avoid O
damage O
to O
the O
HPLC O
column O
. O

In O
the O
Arithmetic O
subtest O
one O
of O
the O
items O
would O
not O
meet O
the O
difficulty O
grading O
shown O
while O
the O
last O
two O
items O
offer O
very O
little O
possibility O
of O
success O
for O
all O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

The O
toxicological O
evaluation O
of O
chlorofluorocarbon O
22 O
( O
CFC O
22 O
). O

All O
patients O
were O
evaluable O
for O
toxicity O
and O
9 O
for O
response O
. O

Methods O
of O
clinical O
and O
experimental O
algesimetry O
are O
described O
that O
have O
been O
used O
to O
evaluate O
effects O
of O
peripherally O
and O
centrally O
acting O
analgesics O
. O

The O
present O
paper O
elucidates O
the O
existing O
discrepancies O
, O
and O
offers O
a O
consistent O
terminology O
incorporating O
also O
such O
terms O
as O
" O
additivity O
", O
" O
potentiation O
", O
and O
" O
simple O
similarity O
". O

We O
propose O
that O
the O
ambiguous O
discrimination O
required O
a O
greater O
time O
for O
simulus O
evaluation O
and O
that O
this O
was O
reflected O
in O
the O
delayed O
P3 O
latencies O
. O

Ammonia O
concentration O
dropped O
significantly O
in O
all O
treatments O
, O
a O
finding O
which O
suggests O
a O
protective O
effect O
on O
protein O
nitrogen O
degradation O
to O
non O
- O
protein O
nitrogen O
( O
NH3 O
). O

In O
this O
respect O
C I-GENE
reactive I-GENE
protein I-GENE
concentrations O
are O
superior O
to O
white O
cell O
count O
, O
erythrocyte O
sedimentation O
rate O
, O
and O
temperature O
and O
the O
concentrations O
of O
antiproteases O
. O

Human I-GENE
thyroid I-GENE
stimulator I-GENE
( O
HTS I-GENE
) O
in O
thyroid O
diseases O

We O
conclude O
that O
administration O
of O
the O
calcium O
antagonist O
Verapamil O
is O
of O
no O
additional O
value O
in O
tocolytic O
treatment O
with O
beta O
- O
mimetics O
. O

Brainstem O
auditory O
evoked O
responses O
( O
BAERs O
) O
and O
quantitative O
saccadic O
eye O
movement O
studies O
provide O
information O
on O
the O
integrity O
of O
pathways O
traversing O
the O
brainstem O
. O

Effects O
of O
ketamine O
on O
the O
circulatory O
functions O
and O
body O
tissue O
oxygenation O
in O
dogs O
under O
normal O
and O
hypovolemic O
conditions O
. O

The O
salient O
clinical O
features O
, O
the O
problems O
of O
management O
and O
the O
modern O
approaches O
to O
the O
reconstruction O
of O
facial O
deformities O
seen O
in O
this O
disease O
are O
described O
. O

Besides O
, O
it O
was O
considered O
that O
the O
NPF O
was O
a O
useful O
tool O
for O
activation O
of O
velopharyngeal O
activity O
by O
way O
of O
visual O
feed O
- O
back O
control O
. O

To O
evaluate O
the O
comparative O
safety O
of O
U O
- O
P O
and O
D O
& O
E O
, O
we O
analyzed O
2 O
, O
805 O
U O
- O
P O
and O
9 O
, O
572 O
D O
& O
E O
abortions O
at O
13 O
to O
24 O
menstrual O
weeks O
' O
gestation O
. O

Three O
radiologists O
without O
knowledge O
of O
patients O
' O
data O
and O
treatment O
analyzed O
30 O
angiograms O
with O
and O
30 O
examinations O
without O
PGF O
. O

In O
a O
man O
with O
myelomonocytic O
leukemia O
, O
the O
association O
of O
increased O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
activity O
in O
serum O
and O
the O
presence O
of O
typical O
bone O
lesions O
on O
roentgenography O
suggested O
the O
existence O
of O
disseminated O
prostatic O
carcinoma O
. O

The O
rational O
for O
the O
prophylactic O
treatment O
, O
the O
therapy O
of O
the O
meningopathy O
and O
AIL O
- O
AIEOP O
protocols O
are O
exposed O
. O

An O
experimental O
long O
- O
term O
study O
. O

No O
anisotropism O
was O
recorded O
in O
a O
tetrahydrofuran O
solution O
. O

Hepatitis O
B O
vaccine O

The O
calculated O
values O
of O
lambda O
tb O
at O
37 O
degrees O
C O
and O
50 O
per O
cent O
haematocrit O
were O
0 O
. O
650 O
for O
the O
pulp O
, O
0 O
. O
674 O
for O
the O
tongue O
, O
0 O
. O
828 O
for O
the O
submandibular O
gland O
and O
0 O
. O
881 O
for O
the O
gingiva O
of O
the O
dog O
. O
lambda O
cp O
increased O
and O
lambda O
tp O
decreased O
as O
the O
temperature O
was O
reduced O
from O
37 O
to O
4 O
degrees O
C O
. O

As O
pleural O
thickening O
is O
seen O
commonly O
in O
asbestosis O
and O
may O
influence O
lung O
volumes O
and O
the O
ratio O
of O
transfer I-GENE
factor I-GENE
to O
effective O
alveolar O
volume O
, O
the O
results O
of O
these O
measurements O
were O
compared O
only O
in O
the O
cases O
showing O
absent O
or O
minimal O
pleural O
thickening O
. O

The O
invasive O
pattern O
of O
squamous O
cell O
carcinoma O
in O
the O
mandibular O
gingiva O

Azygos O
vein O
abutting O
the O
posterior O
wall O
of O
the O
right O
main O
and O
upper O
lobe O
bronchi O
: O
a O
normal O
CT O
variant O
. O

However O
, O
the O
history O
of O
acute O
severe O
complications O
from O
otitis O
media O
revealed O
a O
higher O
frequency O
in O
those O
individuals O
with O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
deficiency O
as O
compared O
to O
normals O
. O

The O
Sarns O
51F O
cavoatrial O
cannula O
decompressed O
the O
venous O
system O
as O
efficiently O
as O
the O
double O
caval O
cannulas O
. O

All O
other O
changes O
at O
the O
3 O
-, O
5 O
-, O
and O
6 O
- O
positions O
, O
as O
well O
as O
the O
replacement O
of O
the O
phenyl O
group O
at O
position O
2 O
, O
caused O
a O
marked O
decrease O
of O
activity O
. O

Three O
experiments O
contrasted O
the O
effects O
of O
6 O
- O
hydroxydopamine O
- O
induced O
lesions O
of O
the O
ventral O
noradrenergic O
and O
dorsal O
noradrenergic O
projections O
, O
predominantly O
to O
hypothalamus O
and O
cortex O
, O
respectively O
, O
upon O
body O
weight O
changes O
and O
food O
- O
related O
behaviour O
in O
the O
rat O
. O

Limb O
allografts O
in O
rats O
immunosuppressed O
with O
cyclosporin O
A O
. O

The O
method O
involved O
deproteinizing O
samples O
with O
two O
volumes O
of O
acetonitrile O
followed O
by O
injection O
of O
5 O
microliters O
of O
deproteinized O
supernatant O
onto O
a O
C18 O
reversed O
- O
phase O
column O
. O

Refractory O
periods O
of O
the O
AV O
junction O
were O
altered O
in O
a O
comparable O
fashion O
to O
conduction O
through O
the O
AV O
node O
. O

This O
paper O
brings O
together O
data O
, O
obtained O
from O
a O
variety O
of O
sources O
, O
on O
the O
extent O
of O
prescription O
and O
use O
of O
psychotropic O
drugs O
in O
the O
late O
1960s O
and O
early O
1970s O
. O

Sixteen O
patients O
were O
studied O
within O
24 O
hours O
of O
resuscitation O
and O
all O
showed O
depressed O
right O
ventricular O
ejection O
( O
RVEF O
) O
and O
/ O
or O
an O
increased O
end O
- O
diastolic O
volume O
( O
RVEDVI O
). O

During O
a O
single O
LAD O
occlusion O
lasting O
35 O
minutes O
( O
series O
I O
, O
n O
= O
10 O
) O
9 O
microns O
TMs O
were O
infused O
immediately O
and O
30 O
minutes O
after O
ligation O
, O
15 O
microns O
TMs O
being O
infused O
after O
15 O
- O
20 O
minutes O
. O

The O
population O
of O
between O
75 O
, O
000 O
and O
100 O
, O
000 O
was O
largely O
unstable O
, O
and O
cost O
per O
capita O
was O
$ O
0 O
. O
95 O
to O
$ O
1 O
. O
21 O
. O

Female O
Wistar O
rats O
were O
fed O
a O
liquid O
diet O
, O
Sustacal O
, O
which O
contained O
ethanol O
( O
40 O
% O
of O
calories O
) O
or O
isocaloric O
sucrose O
. O

HL O
02 O
type O
oculomotor O
stimulator O
. O

Four O
patients O
( O
group O
1 O
) O
had O
type O
I O
basement O
membrane O
nephropathy O
, O
characterized O
by O
marked O
thickening O
and O
lamellation O
of O
the O
basement O
membrane O
in O
a O
pattern O
resembling O
that O
of O
Alport O
' O
s O
syndrome O
. O

Brain O
pH O
following O
3 O
h O
of O
cerebral O
focal O
ischemia O
changed O
from O
a O
normal O
value O
of O
7 O
. O
0 O
to O
6 O
. O
5 O
and O
6 O
. O
2 O
in O
animals O
studied O
under O
barbiturate O
and O
halothane O
anesthesia O
, O
respectively O
. O

Our O
results O
demonstrate O
the O
importance O
of O
phosphate O
and O
calcium O
in O
influencing O
the O
secretion O
of O
PTH I-GENE
and O
CT I-GENE
in O
uremia O
. O

Thin O
- O
layer O
chromatographic O
methods O
were O
up O
- O
dated O
for O
pharmacokinetic O
studies O
of O
imipramine O
in O
plasma O
and O
urine O
. O

Introductory O
remarks O
. O

Increasing O
the O
cut O
- O
off O
point O
to O
3 O
positive O
responses O
decreased O
the O
sensitivity O
to O
81 O
% O
and O
increased O
the O
specificity O
to O
94 O
%. O

After O
clofelin O
administration O
the O
autoregulation O
borders O
shifted O
to O
the O
right O
i O
. O
e O
. O
towards O
higher O
AP O
levels O
. O

This O
phenomenon O
may O
be O
regarded O
as O
a O
variant O
of O
selective O
individual O
cell O
death O
, O
currently O
referred O
to O
as O
apoptosis O
, O
which O
has O
not O
been O
previously O
reported O
in O
a O
case O
of O
embryonal O
rhabdomyosarcoma O
. O

Combination O
of O
a O
Shwachman O
syndrome O
and O
a O
complex O
granulocyte O
function O
disorder O
in O
a O
girl O

A O
combined O
series O
of O
patients O
experienced O
a O
TOL O
after O
two O
or O
more O
previous O
cesarean O
deliveries O
; O
the O
rate O
of O
vaginal O
delivery O
was O
66 O
%, O
and O
there O
was O
virtually O
no O
morbidity O
. O

Nursing O
home O
discharges O
in O
clinical O
practice O
. O

Trial O
3 O
broiler O
chickens O
were O
maintained O
on O
control O
feed O
until O
they O
reached O
3 O
weeks O
of O
age O
at O
which O
time O
they O
were O
taken O
off O
of O
feed O
for O
2 O
. O
5 O
hr O
and O
then O
placed O
on O
either O
control O
feed O
or O
feed O
containing O
4 O
. O
0 O
ppm O
ochratoxin O
A O
, O
and O
heart O
rate O
and O
blood O
pressure O
were O
measured O
every O
half O
hour O
through O
7 O
hr O
. O

The O
carcinogen O
bioassay O
therefore O
is O
a O
very O
important O
component O
of O
the O
battery O
of O
toxicological O
tests O
used O
in O
hazard O
evaluation O
. O

Harmful O
effects O
in O
animals O
and O
man O
may O
result O
from O
both O
deficient O
or O
excessive O
amounts O
of O
intake O
. O

Angionephroscintigraphy O
in O
the O
diagnosis O
of O
diseases O
of O
the O
kidney O

The O
analysis O
of O
the O
structure O
of O
the O
sleep O
period O
as O
a O
whole O
reveals O
that O
with O
increasing O
of O
the O
age O
the O
delta O
- O
wave O
stage O
( O
DS O
) O
of O
the O
QS O
( O
determined O
by O
defined O
polygraphic O
parameters O
) O
increases O
, O
while O
the O
paradoxical O
phase O
of O
sleep O
( O
PS O
) O
decreases O
, O
this O
change O
being O
more O
pronounced O
during O
the O
first O
six O
months O
than O
during O
the O
second O
ones O
of O
the O
first O
year O
of O
the O
life O
. O

[ O
82Br O
] O
MISO O
was O
prepared O
by O
irradiating O
samples O
of O
Br O
- O
MISO O
in O
a O
SLOWPOKE O
reactor O
for O
2 O
h O
at O
a O
thermal O
neutron O
flux O
of O
10 O
( O
12 O
) O
n O
cm O
- O
2 O
s O
- O
1 O
. O

While O
these O
findings O
may O
reflect O
the O
sensitivity O
of O
a O
thick O
myocardial O
wall O
to O
ischaemia O
during O
surgery O
, O
the O
postoperative O
recovery O
was O
not O
related O
to O
the O
serum I-GENE
CK I-GENE
- I-GENE
MB I-GENE
level O
. O

Morphofunctional O
status O
of O
the O
formed O
elements O
of O
the O
blood O
in O
rats O
subjected O
to O
different O
variants O
of O
combined O
and O
isolated O
exposure O
to O
BR O
- O
1 O
benzene O

Using O
a O
MOS O
- O
Hypersil O
reversed O
- O
phase O
column O
with O
a O
phosphate O
buffer O
-- O
acetonitrile O
mobile O
phase O
, O
baseline O
separation O
of O
antipyrine O
, O
its O
metabolites O
3 O
- O
hydroxymethylantipyrine O
, O
norantipyrine O
and O
4 O
- O
hydroxyantipyrine O
, O
and O
the O
internal O
standard O
, O
phenacetin O
, O
was O
achieved O
within O
6 O
min O
. O

The O
liver O
in O
the O
severely O
ill O

In O
a O
randomized O
study O
on O
150 O
patients O
( O
ASA O
1 O
) O
undergoing O
induction O
of O
anaesthesia O
, O
the O
effects O
of O
Fentanyl O
( O
0 O
. O
1 O
mg O
), O
the O
combination O
of O
Fentanyl O
( O
0 O
. O
1 O
mg O
) O
and O
Droperidol O
( O
5 O
mg O
) O
( O
Innovar O
, O
Thalamonal O
) O
and O
Atropine O
( O
0 O
. O
01 O
mg O
/ O
kg O
b O
. O
w O
.) O
alone O
on O
cardiocirculatory O
parameters O
were O
studied O
. O

These O
results O
confirming O
the O
high O
validity O
of O
NOM O
inhibiting O
test O
in O
the O
diagnosis O
of O
tumoural O
hyperprolactinemic O
states O
, O
reveal O
contradictory O
responses O
to O
CD O
/ O
LD O
, O
LD O
and O
DOM O
, O
with O
sustain O
the O
existence O
of O
2 O
sub O
- O
group O
of O
Prolactinomas O
: O
with O
or O
without O
a O
maintained O
DA O
central O
tonus O
supporting O
the O
possibility O
of O
different O
etiopathogenetical O
factors O
in O
inducing O
a O
tumoural O
hyperprolactinemic O
states O
. O

Serum O
lipids O
and O
lipoproteins O
of O
29 O
insulin I-GENE
dependent O
diabetic O
children O
have O
been O
determined O
and O
related O
to O
the O
metabolic O
status O
of O
the O
patients O
. O

Low O
NA O
and O
A O
may O
participate O
in O
lowering O
the O
plasma I-GENE
renin I-GENE
activity O
which O
in O
PA O
in O
suppressed O
, O
sometimes O
disproportionately O
to O
the O
actual O
body O
sodium O
content O
. O

Amikacin O
concentrations O
in O
serum O
and O
blister O
fluid O
in O
healthy O
volunteers O
and O
in O
patients O
with O
renal O
impairment O
. O

The O
subgroup O
innervating O
the O
medial O
rectus O
lies O
exclusively O
along O
the O
medial O
face O
of O
the O
oculomotor O
nucleus O
, O
with O
no O
aberrant O
neurons O
in O
the O
medial O
longitudinal O
fasciculus O
, O
as O
have O
been O
found O
in O
other O
mammals O
. O

Hepatitis O
B O
vaccination O
strategy O
for O
health O
- O
care O
workers O
in O
a O
country O
of O
intermediate O
hepatitis O
B O
endemicity O
. O

An O
intravenous O
drip O
infusion O
of O
AMK O
in O
adequate O
dosage O
would O
be O
beneficial O
to O
use O
against O
some O
infectious O
diseases O
of O
otorhinolaryngologic O
field O
. O

Out O
of O
these O
families O
74 O
, O
3 O
% O
planned O
next O
pregnancy O
( O
table O
IX O
), O
57 O
, O
6 O
% O
wanted O
to O
have O
prenatal O
diagnosis O
( O
table O
VI O
). O

The O
authors O
have O
tested O
the O
interference O
of O
the O
hemoglobin I-GENE
by O
two O
routine O
methods O
( O
Berthelot O
classic O
and O
Berthelot O
modified O
) O
for O
the O
determination O
of O
plasmatic O
urea O
. O

Parkinsonian O
patients O
had O
a O
significantly O
lower O
prevalence O
of O
alcohol O
use O
. O

These O
cells O
averaged O
17 O
microns O
in O
diameter O
and O
reproduced O
by O
fission O
, O
forming O
clusters O
of O
two O
or O
four O
daughter O
cells O
. O

Female O
but O
not O
male O
mortalities O
were O
significantly O
higher O
for O
cake O
- O
fed O
rats O
than O
for O
those O
fed O
diet O
41B O
. O

Urinary I-GENE
N I-GENE
- I-GENE
acetylglucosaminidase I-GENE
activity O
per O
mg O
creatinine O
did O
not O
differ O
significantly O
between O
groups O
. O

The O
associations O
between O
sex I-GENE
- I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
capacity O
( O
SHBG I-GENE
), O
age O
, O
body O
mass O
index O
( O
BMI O
), O
and O
physical O
fitness O
have O
been O
studied O
in O
34 O
men O
and O
36 O
women O
. O

Dipetalonema O
( O
Alafilaria O
) O
hydrochoerus O
subgen O
. O
et O
sp O
. O
n O
. O

After O
1 O
. O
5 O
years O
of O
such O
photoperiodic O
control O
, O
all O
ewes O
were O
blinded O
by O
bilateral O
orbital O
enucleation O
. O

The O
concentrations O
of O
C4 I-GENE
and O
C1 I-GENE
- I-GENE
INH I-GENE
increased O
with O
advancing O
stage O
of O
disease O
and O
were O
above O
normal O
mean O
values O
in O
all O
stages O
. O

Less O
antibacterial O
activity O
was O
shown O
toward O
the O
Gram O
- O
negative O
bacilli O
, O
i O
. O
e O
., O
Pseudomonas O
, O
Klebsiella O
- O
Enterobacter O
, O
Shigella O
, O
Escherichia O
coli O
, O
Serratia O
marcescens O
and O
Proteus O
. O

The O
mucosal O
defence O
capacity O
against O
proteolytic O
leukocyte O
enzymes O
. O

The O
apparatus O
consists O
of O
an O
Am O
- O
241 O
exciting O
source O
( O
300 O
mCi O
) O
and O
pure O
Ge O
detector O
( O
50 O
mm2 O
X O
5 O
mm O
) O
for O
measuring O
K O
alpha O
fluorescent O
x O
- O
rays O
( O
28 O
. O
3 O
and O
28 O
. O
6 O
KeV O
) O
emitted O
from O
exited O
iodine O
. O

Ultrastructural O
studies O
of O
retinopathy O
of O
premature O
infants O

The O
range O
of O
serum O
concentrations O
, O
mean O
values O
, O
median O
values O
, O
and O
standard O
deviations O
for O
each O
analyte O
are O
reported O
for O
males O
and O
females O
and O
for O
three O
age O
groups O
( O
25 O
- O
44 O
, O
45 O
- O
59 O
, O
60 O
- O
70 O
). O

The O
effects O
of O
antithrombotic O
drugs O
in O
patients O
with O
left O
ventricular O
thrombi O
: O
assessment O
with O
indium O
- O
111 O
platelet O
imaging O
and O
two O
- O
dimensional O
echocardiography O
. O

A O
stable O
interface O
depends O
on O
overall O
stress O
and O
microstress O
distribution O
on O
the O
bone O
, O
particularly O
trabecular O
bone O
. O

Plasma O
NE O
was O
also O
low O
in O
the O
anephric O
group O
( O
289 O
mg O
/ O
liter O
+/- O
126 O
( O
1 O
SD O
) O
vs O
612 O
+/- O
189 O
, O
P O
= O
0 O
. O
033 O
, O
resting O
).( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

10 O
long O
- O
term O
hemodialysis O
patients O
had O
immediate O
and O
redistribution O
thallium O
- O
201 O
myocardial O
imaging O
performed O
after O
a O
course O
of O
hemodialysis O
. O

The O
Prolactin I-GENE
levels O
were O
within O
the O
physiological O
norms O
; O
the O
responses O
to O
TRH I-GENE
were O
normal O
, O
and O
elevated O
only O
in O
a O
few O
cases O
. O

Despite O
total O
tumor O
resection O
, O
multiple O
intraperitoneal O
tumor O
nodules O
of O
varying O
sizes O
were O
found O
and O
resected O
six O
months O
and O
one O
year O
later O
. O

Private O
hospital O
accreditation O
. O

Antithrombin I-GENE
III I-GENE
in O
hip O
surgery O

In O
14 O
of O
21 O
infant O
hearts O
( O
66 O
%) O
with O
aortic O
arch O
interruption O
between O
the O
left O
common O
carotid O
and O
left O
subclavian O
arteries O
( O
type O
B O
of O
Celoria O
and O
Patton O
), O
the O
right O
subclavian O
artery O
( O
SA O
) O
arose O
anomalously O
. O

We O
suggest O
that O
sensitivity O
to O
photoperiod O
in O
pallid O
bats O
, O
as O
in O
several O
other O
mammals O
, O
is O
mediated O
by O
the O
pineal O
gland O
. O

Absorption O
was O
rapid O
, O
with O
a O
mean O
time O
to O
peak O
of O
39 O
min O
. O

Additionally O
, O
observations O
that O
patients O
with O
mitral O
versus O
aortic O
regurgitation O
respond O
differently O
to O
valve O
replacement O
suggest O
that O
differences O
exist O
preoperatively O
between O
these O
two O
types O
of O
volume O
overload O
. O

A O
case O
of O
manifest O
latent O
nystagmus O
of O
late O
onset O
in O
a O
13 O
- O
year O
- O
old O
girl O
is O
reported O
. O

Within O
the O
compartment O
or O
dimension O
of O
severity O
of O
depression O
a O
subscale O
of O
the O
Hamilton O
Depression O
Scale O
( O
or O
the O
Melancholia O
Scale O
) O
was O
shown O
to O
have O
reached O
an O
instrumental O
perfection O
, O
e O
. O
g O
. O
as O
an O
outcome O
measure O
of O
antidepressant O
treatment O
. O

Significant O
immunoglobulinuria O
developed O
prior O
to O
the O
development O
of O
azotemia O
, O
significantly O
decreased O
creatinine O
clearance O
, O
significant O
proteinuria O
( O
greater O
than O
or O
equal O
to O
3 O
+ O
dipstick O
or O
greater O
than O
or O
equal O
to O
5 O
gm O
per O
24 O
- O
hour O
urine O
collection O
), O
or O
oliguria O
. O

A O
total O
number O
of O
1628 O
cases O
were O
collected O
from O
135 O
medical O
institutions O
. O

Epileptiform O
activity O
recorded O
from O
superficial O
laminae O
bordering O
layer O
4 O
, O
and O
into O
which O
layer O
4 O
' O
s O
primary O
projections O
terminate O
, O
is O
suppressed O
preferentially O
by O
phenytoin O
. O

The O
AD O
components O
were O
markedly O
more O
dependent O
on O
the O
affective O
state O
of O
the O
rat O
then O
was O
the O
V1 O
component O
. O

Is O
nisoldipine O
capable O
of O
reducing O
left O
ventricular O
preload O
? O
In O
ten O
anesthetized O
pigs O
, O
nisoldipine O
( O
2 O
- O
4 O
micrograms O
X O
kg O
- O
1 O
X O
min O
- O
1 O
), O
a O
calcium O
channel O
blocker O
structurally O
related O
to O
nifedipine O
, O
reduced O
left O
ventricular O
systolic O
pressure O
( O
40 O
%) O
and O
systemic O
vascular O
resistance O
( O
35 O
%), O
whereas O
maxLVdP O
/ O
dt O
decreased O
by O
20 O
% O
and O
cardiac O
output O
was O
unchanged O
. O

Monkeys O
were O
evaluated O
before O
and O
after O
unilateral O
and O
serial O
bilateral O
removal O
of O
superior O
temporal O
cortex O
. O

HBB O
concentration O
in O
the O
fetuses O
indicated O
little O
, O
if O
any O
accumulation O
. O

All O
samples O
exhibited O
a O
decline O
in O
ethanol O
concentration O
, O
with O
most O
losses O
falling O
within O
the O
expected O
20 O
to O
40 O
mg O
% O
range O
. O

Plasma I-GENE
lactoferrin I-GENE
and O
the O
blood O
count O
of O
polynuclear O
neutrophils O

The O
importance O
of O
selective O
renal O
vein O
phlebography O
in O
the O
evaluation O
of O
unexplained O
hematuria O
and O
filing O
defects O
in O
the O
excretory O
urogram O
is O
illustrated O
. O

Pilot O
study O
of O
blood O
coagulation O
in O
gout O
patients O
. O

The O
statistical O
analysis O
consist O
of O
the O
F O
test O
followed O
by O
Snedecor O
' O
s O
contrast O
test O
. O

The O
pyramidal O
tract O
and O
Mesencephalic O
Reticular O
Formation O
( O
MRF O
) O
were O
stimulated O
before O
and O
after O
the O
transection O
. O

Further O
, O
the O
reduction O
in O
5 O
- O
hydroxytryptophan O
( O
5 O
- O
HTP O
) O
accumulation O
by O
LSD O
showed O
regional O
differences O
in O
inhibition O
by O
methiothepin O
( O
hypothalamus O
greater O
than O
cortex O
greater O
than O
striatum O
) O
which O
paralleled O
the O
autoreceptor O
antagonist O
activity O
of O
methiothepin O
in O
vitro O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Effects O
of O
methiothepin O
and O
lysergic O
acid O
diethylamide O
on O
serotonin O
release O
in O
vitro O
and O
serotonin O
synthesis O
in O
vivo O
: O
possible O
relation O
to O
serotonin I-GENE
autoreceptor I-GENE
function O
. O

In O
a O
recent O
measles O
epidemic O
in O
El O
Paso O
, O
TX O
, O
120 O
, O
000 O
records O
were O
screened O
using O
these O
criteria O
, O
and O
as O
a O
result O
13 O
, O
000 O
students O
were O
vaccinated O
. O

No O
patient O
with O
bradyarrhythmia O
- O
related O
SCD O
had O
manifest O
atrioventricular O
block O
or O
bundle O
branch O
block O
. O

The O
measurement O
of O
the O
areas O
of O
fibrin I-GENE
, O
of O
tissue O
and O
fibrinolysis O
, O
at O
the O
above O
mentioned O
times O
, O
has O
been O
effected O
at O
standard O
magnification O
( O
15 O
X O
) O
by O
an O
image O
analyser O
( O
Videoplan O
) O
scale O
1 O
: O
8 O
. O

Diclofenac O
sodium O
- O
chlormezanone O
poisoning O
. O

Postprandial O
plasma I-GENE
enteroglucagon I-GENE
concentration O
after O
90 O
minutes O
in O
untreated O
patients O
correlated O
positively O
to O
the O
faecal O
fat O
excretion O
( O
r O
= O
0 O
. O
58 O
, O
p O
less O
than O
0 O
. O
02 O
). O

Blood O
pressure O
in O
children O
. O

In O
this O
study O
the O
splenectomized O
captive O
born O
cynomolgus O
appeared O
to O
be O
capable O
of O
supplementing O
rhesus O
as O
an O
antimalarial O
drug O
testing O
model O
. O

The O
results O
showed O
that O
the O
sensitivity O
of O
the O
3 O
given O
guinea O
pig O
strains O
was O
comparable O
. O

Adult O
Amblyomma O
lepidum O
ticks O
fed O
as O
nymphs O
on O
this O
goat O
transmitted O
heartwater O
to O
a O
Friesian O
( O
Bos O
taurus O
) O
calf O
. O

Twenty O
- O
one O
percent O
of O
these O
patients O
had O
neurologic O
disease O
that O
appeared O
to O
be O
responsible O
for O
the O
tinnitus O
. O

Morphine O
injected O
into O
the O
lateral O
ventricle O
of O
the O
rat O
produced O
unilateral O
analgesia O
in O
the O
formalin O
test O
, O
which O
involves O
continuous O
, O
moderate O
pain O
. O

The O
maps O
of O
Case O
2 O
showed O
that O
a O
maximum O
first O
appeared O
on O
the O
upper O
right O
back O
and O
then O
moved O
down O
the O
right O
side O
of O
the O
posterior O
thorax O
. O

Urinary O
urate O
excretion O
, O
urate O
clearance O
, O
and O
fractional O
excretion O
of O
urate O
all O
increased O
significantly O
during O
water O
immersion O
, O
and O
decreased O
in O
the O
hour O
following O
water O
immersion O
. O

Mutations O
in O
seven O
other O
lts I-GENE
genes I-GENE
do O
not O
result O
in O
the O
mak I-GENE
- I-GENE
phenotype I-GENE
. O

Twenty O
- O
eight O
were O
excluded O
as O
gallstones O
were O
not O
proved O
: O
of O
the O
remainder O
, O
21 O
patients O
received O
glucagon I-GENE
and O
22 O
placebo O
. O

4 O
Five O
patients O
died O
within O
one O
month O
of O
captopril O
and O
five O
between O
four O
and O
seven O
months O
, O
three O
of O
whom O
had O
improved O
to O
class O
IIM O
and O
one O
to O
IIS O
before O
death O
. O

Bullous O
angiolymphoid O
hyperplasia O
with O
eosinophilia O

Regions O
of O
the O
translated O
open O
reading O
frames O
of O
cobA I-GENE
and O
the O
third O
intron O
of O
the O
cob I-GENE
gene I-GENE
in I-GENE
yeast I-GENE
show O
high O
amino O
acid O
homology O
. O

Multiresistant O
strains O
isolated O
from O
humans O
in O
enteral O
toxico O
- O
infections O
kill O
orally O
infected O
mice O
more O
frequently O
than O
strains O
isolated O
in O
hospital O
infections O
. O

Single O
tooth O
replacement O
with O
the O
aid O
of O
the O
ITI O
( O
International O
Team O
fur O
Implantologie O
) O
type O
F O
hollow O
- O
cylinder O
implant O

The O
13 O
, O
14 O
- O
dihydro O
- O
15 O
- O
keto O
- O
metabolites O
of O
PGE2 O
and O
PGF2 O
alpha O
had O
no O
statistically O
significant O
antiarrhythmic O
effect O
. O

Nucleotide O
sequence O
of O
DNA O
controlling O
expression O
of O
genes O
for O
maltosaccharide O
utilization O
in O
Streptococcus O
pneumoniae O
. O

The O
hypertension O
with O
elevated O
PRA O
, O
however O
, O
was O
resistant O
to O
the O
angiotensin I-GENE
II I-GENE
( O
AII I-GENE
) O
analog O
[ O
Sar1 O
, O
Ile8 O
] O
ALL O
. O

Colorimetric O
determination O
of O
urinary O
iron O
, O
chelated O
with O
deferoxamine O
B O
, O
using O
a O
single O
reagent O

Measurements O
of O
perfusion O
also O
showed O
significantly O
higher O
values O
under O
active O
therapy O
. O

Volume O
of O
distribution O
of O
total O
DMDZ O
( O
range O
, O
1 O
. O
33 O
to O
6 O
. O
30 O
l O
/ O
kg O
) O
and O
of O
unbound O
DMDZ O
after O
correction O
for O
protein O
binding O
( O
range O
, O
43 O
to O
243 O
l O
/ O
kg O
) O
was O
larger O
in O
women O
than O
in O
men O
of O
all O
ages O
, O
and O
in O
the O
elderly O
as O
opposed O
to O
the O
young O
. O

Effects O
of O
dopamine O
and O
of O
a O
dopaminergic O
blocker O
, O
haloperidol O
, O
on O
the O
responses O
of O
carotid O
body O
chemoreceptors O
to O
hypoxia O
and O
hypercapnia O
were O
investigated O
in O
16 O
anesthetized O
cats O
. O

HLA I-GENE
- I-GENE
A I-GENE
and I-GENE
B I-GENE
phenotypes O
of O
105 O
patients O
suffering O
from O
malignant O
melanomas O
were O
determined O
, O
with O
special O
regard O
for O
metastatic O
form O
or O
relapse O
. O

Trypanosoma O
cruzi O
. O

The O
subjects O
of O
the O
study O
were O
10 O
normal O
subjects O
and O
64 O
patients O
with O
gastroduodenal O
disease O
. O

1 O
. O

This O
study O
represents O
the O
first O
published O
long O
- O
term O
follow O
- O
up O
regarding O
this O
mode O
of O
treatment O
in O
patients O
with O
alveolar O
hypoventilation O
. O

The O
alterations O
in O
differentiation O
of O
osteoprogenitor O
cells O
, O
together O
with O
the O
failure O
of O
mineralization O
, O
resulted O
in O
significantly O
lower O
rates O
of O
bone O
formation O
( O
as O
measured O
by O
fluorochrome O
labeling O
) O
in O
the O
magnesium O
- O
deficient O
rats O
. O

A O
convenient O
measure O
of O
this O
impairment O
may O
be O
obtained O
using O
the O
ratio O
of O
urine O
volume O
( O
V O
) O
divided O
by O
lithium O
clearance O
( O
CLi O
). O

Nitrogen O
balance O
was O
compared O
, O
and O
metabolic O
complications O
were O
monitored O
by O
evaluating O
BUN O
, O
serum O
creatinine O
, O
creatinine O
clearance O
, O
serum O
CO2 O
, O
SGOT I-GENE
, O
SGPT I-GENE
, O
serum I-GENE
LDH I-GENE
, O
and O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
. O

Production O
of O
C I-GENE
mu I-GENE
RNAs I-GENE
, O
unlike O
mu I-GENE
mRNAs I-GENE
, O
does O
not O
require O
recombination O
with O
the O
joining I-GENE
region I-GENE
( O
JH I-GENE
) O
locus O
. O

The O
1 O
. O
9 O
- O
kb O
C I-GENE
mu I-GENE
RNA O
contains O
the O
3 O
' O
sequence O
characteristic O
of O
secreted O
mu I-GENE
chain I-GENE
, O
whereas O
the O
longer O
species O
bear O
that O
of O
membrane O
- O
bound O
mu I-GENE
chin O
. O

Transcripts O
of O
the O
immunoglobulin I-GENE
C I-GENE
mu I-GENE
gene I-GENE
vary O
in O
structure O
and O
splicing O
during O
lymphoid O
development O
. O

Non O
- O
complement O
- O
dependent O
sperm O
- O
immobilizing O
activity O
was O
also O
detected O
in O
the O
cervical O
mucus O
of O
several O
patients O
. O

The O
role O
of O
DNA O
rearrangement O
and O
alternative O
RNA O
processing O
in O
the O
expression O
of O
immunoglobulin I-GENE
delta I-GENE
genes I-GENE
. O

Although O
the O
mechanism O
of O
action O
of O
ICRF O
- O
159 O
and O
187 O
has O
not O
been O
clearly O
defined O
, O
it O
is O
evident O
from O
both O
preclinical O
and O
early O
clinical O
studies O
that O
these O
compounds O
are O
of O
interest O
. O

All O
62 O
isolates O
were O
resistant O
to O
lincomycin O
, O
colistin O
, O
nystatin O
, O
amphotericin O
B O
, O
trimethoprim O
lactate O
, O
polymyxin O
B O
, O
and O
anisomycin O
. O

The O
evaluation O
of O
amniotic O
fluid O
delta O
OD450 O
is O
considered O
to O
be O
the O
cornerstone O
of O
clinical O
management O
. O

Host O
lipids O
in O
tuberculous O
infection O
. O

There O
is O
now O
a O
significative O
difference O
between O
age O
group O
1 O
- O
5 O
and O
the O
others O
( O
p O
Less O
Than O
0 O
, O
02 O
). O

The O
sympathetic O
neuroeffector O
influence O
on O
the O
myocardium O
with O
ATCI O
depends O
to O
a O
large O
measure O
on O
the O
intensity O
of O
the O
neurotransmitter O
biosynthesis O
and O
function O
of O
cardiomyocyte O
adrenoreceptors O
. O

Lens I-GENE
aldose I-GENE
reductase I-GENE
in O
diabetic O
and O
galactosemic O
cataracts O
. O

Fenfluramine O
( O
in O
doses O
ranging O
from O
0 O
. O
0625 O
- O
4 O
. O
0 O
mg O
/ O
kg O
/ O
infusion O
) O
did O
not O
maintain O
self O
- O
administration O
behavior O
at O
or O
above O
the O
minimum O
requirement O
( O
FR O
30 O
). O

In O
the O
course O
of O
Hepatitis I-GENE
A I-GENE
HBs I-GENE
- I-GENE
and I-GENE
HBe I-GENE
- I-GENE
antigen I-GENE
as O
well O
as O
HBc I-GENE
( I-GENE
IgM I-GENE
and I-GENE
IgG I-GENE
)-, I-GENE
HBs I-GENE
- I-GENE
and I-GENE
HBe I-GENE
- I-GENE
antibodies I-GENE
can O
be O
detected O
. O

The O
effect O
of O
the O
fatty I-GENE
acid I-GENE
cyclo I-GENE
- I-GENE
oxygenase I-GENE
inhibitor O
indomethacin O
on O
cerebral O
blood O
flow O
( O
CBF O
) O
and O
the O
metabolic O
rate O
for O
oxygen O
( O
CMRO2 O
) O
was O
studied O
in O
paralyzed O
and O
artificially O
ventilated O
rats O
. O

The O
rat O
incisor O
is O
an O
excellent O
model O
system O
in O
which O
to O
study O
amelgenesis O
. O

The O
already O
elevated O
prolactin I-GENE
levels O
in O
nursing O
women O
were O
not O
influenced O
by O
chronic O
oestradiol O
administration O
. O

Factor I-GENE
VIII I-GENE
procoagulant O
activity O
, O
antigen O
concentration O
and O
von I-GENE
Willebrand I-GENE
activity O
as O
ristocetin I-GENE
cofactor I-GENE
were O
determined O
several O
times O
in O
10 O
patients O
with O
DIC O
. O

Morphine O
- O
dependent O
and O
control O
rats O
in O
an O
oral O
free O
- O
choice O
protocol O
were O
treated O
with O
gamma O
- O
vinyl O
GABA O
( O
GVG O
), O
60 O
, O
120 O
and O
240 O
mg O
/ O
kg O
IP O
, O
for O
3 O
days O
over O
three O
successive O
periods O
. O

Significance O
of O
the O
pulmonary O
gas O
exchange O
reaction O
to O
physical O
loading O
in O
evaluating O
the O
effectiveness O
of O
mitral O
commissurotomy O

Thyreoliberin I-GENE
VUFB O
in O
thyroid O
gammagraphy O

In O
silicosis O
, O
significant O
relationships O
between O
patients O
and O
sons O
were O
not O
seen O
with O
respect O
to O
arterial O
blood O
gas O
determinations O
and O
ventilatory O
responses O
except O
for O
Paco2 O
of O
patients O
and O
hypercapnic O
ventilatory O
responses O
of O
sons O
. O

For O
steers O
the O
urinary O
N O
values O
were O
403 O
and O
295 O
mg O
/ O
kg O
W0 O
. O
75 O
at O
200 O
and O
350 O
kg O
live O
weight O
respectively O
and O
total O
N O
excretion O
including O
faecal O
N O
was O
408 O
and O
320 O
mg O
/ O
kg O
W0 O
. O
75 O
. O

Advances O
in O
hemophilia O
treatment O
: O
a O
hepatitis O
- O
safe O
factor I-GENE
VIII I-GENE
concentrate O

This O
study O
was O
designed O
to O
assess O
and O
compare O
the O
ability O
of O
three O
different O
forms O
of O
DSG O
to O
block O
EIB O
. O

Comparison O
of O
three O
different O
preparations O
of O
disodium O
cromoglycate O
in O
the O
prevention O
of O
exercise O
- O
induced O
bronchospasm O
: O
a O
double O
- O
blind O
study O
. O

LCBF O
in O
normal O
and O
hypoxic O
puppies O
was O
correlated O
with O
local O
cerebral O
glucose O
utilization O
( O
LCGU O
) O
obtained O
under O
the O
same O
experimental O
conditions O
( O
Duffy O
et O
al O
, O
1982 O
). O

Phagocytosis O
of O
tubercle O
bacilli O
by O
macrophages O
. O

Detection O
of O
hemophilia O
A O
carriers O
. O

The O
stability O
of O
isoniazid O
solutions O
increases O
markedly O
with O
increasing O
NTA O
or O
EDTA O
concentration O
up O
to O
1 O
mmol O
/ O
l O
. O

Bile O
bilirubin O
did O
not O
rise O
within O
12 O
h O
after O
haem O
infusion O
a O
finding O
which O
warrants O
further O
investigation O
. O

Autoimmune O
manipulation O
aids O
juvenile O
diabetes O
management O
. O

Other O
properties O
of O
Hg O
- O
and O
Cd O
- O
spores O
were O
similar O
to O
those O
of O
control O
spores O
. O

The O
decrease O
in O
HDL I-GENE
- I-GENE
cholesterol I-GENE
with O
increasing O
VLDL I-GENE
- I-GENE
triglycerides I-GENE
was O
relatively O
much O
larger O
than O
the O
concomitant O
decrease O
in O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
. O

Apo I-GENE
A I-GENE
- I-GENE
I I-GENE
level O
was O
unrelated O
to O
age O
, O
but O
increased O
with O
ethanol O
consumption O
and O
decreased O
with O
adiposity O
. O

TEMTU O
and O
DPTU O
were O
the O
most O
potent O
teratogens O
. O

The O
osmotic O
diuretic O
mannitol O
was O
administered O
to O
21 O
patients O
. O

Of O
270 O
patients O
with O
well O
- O
defined O
drug O
reactions O
, O
190 O
( O
70 O
per O
cent O
) O
gave O
a O
positive O
response O
to O
the O
mast O
cell O
test O
. O

Selenium O
, O
as O
a O
constituent O
of O
glutathione I-GENE
peroxidase I-GENE
, O
plays O
a O
role O
in O
the O
antioxidant O
defense O
systems O
of O
the O
body O
, O
but O
other O
metabolic O
roles O
for O
selenium O
may O
yet O
be O
discovered O
. O

Diagnostic O
value O
of O
serum I-GENE
myoglobin I-GENE
in O
cases O
of O
neuromuscular O
disease O

At O
43 O
% O
blood O
pressure O
reduction O
, O
PCO2 O
fell O
by O
0 O
. O
53 O
kPa O
, O
a O
decrease O
which O
could O
not O
explain O
the O
observed O
CBF O
fall O
of O
27 O
%. O

During O
the O
last O
6 O
months O
of O
the O
study O
a O
striking O
change O
in O
epidemiology O
concerning O
hepatitis O
A O
was O
seen O
, O
apparently O
caused O
by O
a O
steep O
increase O
in O
the O
incidence O
of O
this O
type O
of O
hepatitis O
among O
drug O
addicts O
. O

Asthmatic O
patients O
showed O
greater O
responses O
of O
both O
parameters O
to O
adrenaline O
than O
controls O
indicating O
that O
long O
- O
term O
corticosteroid O
treatment O
enhances O
the O
acute O
responses O
of O
plasminogen I-GENE
activator I-GENE
and O
clotting I-GENE
factor I-GENE
VIII I-GENE
to O
adrenaline O
infusion O
. O

Sulphur O
amino O
acids O
( O
g O
/ O
16 O
g O
N O
) O
were O
higher O
in O
the O
isolates O
than O
in O
the O
flours O
. O

Time O
shifts O
increase O
growth I-GENE
hormone I-GENE
release O
. O

It O
then O
merged O
with O
right O
ventricular O
wavefronts O
ending O
along O
the O
right O
ventricular O
anterior O
atrioventricular O
groove O
and O
outflow O
tract O
. O

Many O
of O
these O
landfill O
operations O
were O
undertaken O
in O
the O
early O
1950s O
and O
1960s O
, O
when O
knowledge O
regarding O
the O
safe O
and O
prolonged O
containment O
of O
the O
waste O
buried O
was O
nonexistent O
or O
minimal O
at O
best O
. O

Vesicles O
could O
be O
induced O
only O
with O
multiple O
exposures O
to O
UVA O
. O

The O
level O
of O
contamination O
in O
the O
wound O
can O
be O
determined O
with O
the O
rapid O
biopsy O
fixation O
technique O
. O

Self O
- O
heating O
after O
deep O
hypothermia O
( O
20 O
degrees O
C O
) O
causes O
a O
considerable O
increase O
in O
the O
brain O
tissues O
glutaminase I-GENE
activity O
at O
all O
studied O
incubation O
temperatures O
( O
37 O
, O
30 O
, O
20 O
and O
10 O
degrees O
C O
) O
as O
compared O
to O
control O
rats O
and O
rats O
under O
hypothermia O
. O

Similar O
observations O
were O
made O
with O
unilateral O
pneumothorax O
of O
15 O
cmH2O O
for O
30 O
min O
. O

According O
to O
Sugiura O
' O
s O
classification O
, O
they O
consisted O
of O
Type O
Ia O
in O
63 O
%, O
Type O
Ib O
in O
11 O
%, O
Type O
II O
in O
11 O
%, O
and O
Type O
III O
in O
16 O
%. O

This O
study O
was O
undertaken O
to O
define O
the O
mechanism O
for O
the O
respiratory O
inhibition O
observed O
during O
high O
- O
frequency O
oscillatory O
ventilation O
( O
HFOV O
). O

Determination O
of O
20 O
alpha O
- O
hydroxy O
- O
9 O
beta O
, O
10 O
alpha O
- O
pregna O
- O
4 O
, O
6 O
- O
dien O
- O
3 O
- O
one O
in O
plasma O
by O
selected O
ion O
monitoring O
. O

A O
case O
of O
a O
dense O
epidermoid O
cyst O
of O
the O
suprasellar O
cistern O
is O
presented O
. O

Copper O
treatments O
were O
assigned O
to O
simulate O
the O
different O
levels O
of O
copper O
intake O
that O
might O
result O
from O
differences O
in O
daily O
feed O
intake O
similar O
to O
the O
practice O
followed O
with O
commercial O
industry O
. O

Fibromuscular O
intimal O
thickening O
was O
seen O
in O
the O
ascending O
and O
thoracic O
aorta O
of O
the O
swine O
fed O
62 O
, O
500 O
IU O
of O
vitamin O
D3 O
/ O
kg O
of O
diet O
for O
three O
months O
duration O
; O
and O
after O
3 O
months O
of O
vitamin O
D3 O
withdrawal O
, O
atherosclerotic O
lesions O
were O
found O
. O

Because O
of O
a O
rapid O
development O
of O
the O
connective O
tissue O
scars O
, O
however O
, O
at O
the O
place O
of O
the O
destroyed O
glandular O
parenchyma O
areas O
, O
there O
is O
no O
normalization O
of O
the O
organ O
' O
s O
structure O
and O
function O
by O
the O
42d O
day O
. O

Histological O
signs O
of O
the O
flare O
- O
up O
reaction O
were O
already O
present O
at O
6 O
hr O
after O
i O
. O
v O
. O
challenge O
and O
lasted O
for O
at O
least O
4 O
days O
. O

Significant O
GMBF O
reductions O
occurred O
in O
early O
shock O
in O
both O
treatment O
groups O
. O

Of O
254 O
children O
with O
neuroblastoma O
treated O
at O
St O
. O

Penicillin O
- O
G O
degradation O
products O
inhibit O
in O
vitro O
granulopoiesis O
. O

Plasma O
fibrinogen I-GENE
was O
measured O
by O
the O
turbidimetric O
method O
in O
timol O
turbidimetric O
units O
. O

Five O
patients O
with O
type O
III O
musculoskeletal O
infection O
from O
nongonococcal O
Neisseria O
species O
were O
examined O
during O
a O
13 O
- O
month O
period O
. O

Distal O
tubular O
acidification O
and O
the O
threshold O
for O
proximal O
tubular O
bicarbonate O
reabsorption O
were O
normal O
, O
as O
was O
urine O
concentrating O
capacity O
. O

Detection O
of O
exercise O
- O
induced O
asynergy O
by O
M O
- O
mode O
echocardiography O
. O

The O
Tullio O
phenomenon O
, O
fistula O
test O
, O
and O
Hennebert O
' O
s O
sign O
: O
clinical O
significance O
. O

These O
results O
indicate O
that O
significant O
pulmonary O
metabolism O
of O
5 O
- O
HT O
followed O
by O
efflux O
of O
5 O
- O
HIAA O
into O
venous O
output O
occurs O
during O
single O
- O
pass O
circulation O
. O

Disturbances O
of O
placental O
maturation O
, O
2 O
. O

On O
the O
basis O
of O
histopathological O
findings O
, O
the O
origin O
of O
amyloid O
appeared O
to O
be O
closely O
related O
to O
the O
fibroblasts O
. O

Both O
groups O
were O
subjected O
to O
tests O
of O
delayed O
hypersensitivity O
with O
Candidin I-GENE
, O
Trycophytin I-GENE
and O
Tuberculin I-GENE
. O

Serum O
lactate I-GENE
dehydrogenase I-GENE
and O
haptoglobin I-GENE
levels O
were O
normal O
, O
and O
total O
bilirubin O
was O
only O
slightly O
elevated O
. O

Low O
- O
dose O
D O
( O
0 O
. O
4 O
- O
0 O
. O
8 O
mg O
) O
and O
DB O
( O
1 O
. O
0 O
- O
5 O
. O
0 O
mg O
) O
did O
not O
significantly O
alter O
any O
parameter O
from O
control O
. O

Efficacy O
of O
cervical O
spine O
immobilization O
methods O
. O

Leads O
from O
the O
MMWR O
. O

The O
presence O
of O
visna O
- O
maedi O
in O
Italy O
is O
reported O
for O
the O
first O
time O
. O

High O
levels O
of O
IC O
coincided O
with O
relative O
hypocomplementemia O
. O

Circulating O
platelets O
may O
be O
activated O
by O
exposed O
triple O
- O
helical O
collagen I-GENE
in O
atherosclerotic O
lesions O
in O
Mg O
- O
deficient O
ruminants O
. O

Acute O
type O
A O
hepatitis O
in O
three O
patients O
with O
chronic O
HBV O
infection O
. O

Pathogenetic O
relationships O
between O
renal O
tubular O
acidosis O
and O
sodium O
metabolism O
alterations O
in O
liver O
cirrhosis O
. O

5 O
microU O
/ O
l O
thyrotropin I-GENE
: O
75 O
% O
( O
1974 O
), O
45 O
% O
( O
1977 O
) O
and O
20 O
% O
( O
1980 O
). O

Echosismography O
enables O
to O
improve O
the O
diagnosis O
when O
compared O
with O
classical O
sonography O
in O
about O
20 O
% O
of O
cases O
. O

Relationships O
with O
the O
acquired O
immune O
deficiency O
syndrome O
. O

The O
prevalence O
of O
CPAF O
was O
similar O
in O
type O
1 O
and O
type O
2 O
diabetes O
, O
was O
greater O
in O
women O
than O
in O
men O
, O
and O
was O
significantly O
greater O
after O
repeated O
administrations O
than O
after O
one O
single O
administration O
of O
chlorpropamide O
. O

A O
reassessment O
of O
the O
prevalence O
data O
was O
carried O
out O
in O
the O
southern O
province O
of O
Uusimaa O
and O
in O
the O
western O
province O
of O
Vaasa O
, O
the O
prevalence O
day O
being O
January O
1 O
, O
1979 O
. O

The O
results O
confirm O
and O
extend O
previous O
work O
by O
other O
researchers O
. O

In O
the O
ultramarathon O
runner O
the O
testosterone O
levels O
sharply O
rose O
at O
the O
beginning O
of O
the O
training O
session O
( O
from O
the O
7 O
, O
20 O
ng O
/ O
ml O
to O
11 O
, O
50 O
ng O
/ O
ml O
after O
20 O
' O
training O
), O
and O
subsequently O
decrease O
after O
3 O
hours O
( O
9 O
, O
20 O
ng O
/ O
ml O
) O
and O
at O
the O
end O
of O
the O
6 O
hours O
training O
( O
4 O
, O
60 O
ng O
/ O
ml O
). O

In O
patients O
with O
complete O
or O
partial O
remission O
of O
the O
tumor O
, O
the O
neopterine O
excretion O
dropped O
to O
normal O
values O
. O

In O
visible O
tumours O
the O
best O
results O
were O
obtained O
with O
FB O
( O
85 O
%) O
while O
TBN O
was O
positive O
in O
65 O
%. O

Total O
PGE O
levels O
in O
synovial O
fluid O
remained O
significantly O
depressed O
in O
the O
patient O
group O
for O
24 O
hours O
after O
the O
400 O
- O
mg O
test O
dose O
of O
tolmetin O
on O
day O
8 O
. O

Normal O
rates O
of O
weight O
gain O
were O
seen O
once O
absorbed O
energy O
intakes O
reached O
100 O
- O
110 O
% O
of O
requirements O
. O

Its O
vasodilatory O
, O
anti O
- O
vasopressor O
, O
and O
platelet O
stabilizing O
effects O
could O
be O
expected O
to O
counteract O
the O
placental O
ischemia O
, O
hypertension O
and O
excessive O
coagulation O
that O
are O
seen O
in O
pre O
- O
eclampsia O
. O

Behcet O
' O
s O
syndrome O

Survival O
of O
111 O
Indium O
- O
labelled O
autologous O
platelets O
was O
studied O
in O
2 O
patients O
after O
correction O
of O
platelet O
count O
and O
was O
still O
found O
shortened O
. O

The O
effect O
of O
emotional O
- O
painful O
stress O
( O
EPS O
) O
on O
myocardial O
extensibility O
and O
contractility O
was O
studied O
on O
an O
isolated O
rat O
atrium O
. O

Terbutaline O
; O
a O
beta2 O
- O
adrenergic O
agonist O
, O
and O
aminophyllin O
, O
a O
phosphodiesterase O
inhibitor O
, O
were O
given O
separately O
, O
or O
in O
combination O
, O
to O
rabbit O
fetuses O
on O
the O
28th O
day O
of O
gestation O
. O

When O
O2 O
therapy O
was O
controlled O
for O
, O
the O
association O
between O
RBT O
and O
RLF O
did O
not O
achieve O
statistical O
significance O
( O
P O
= O
. O
07 O
). O

This O
two O
- O
helix O
motif O
is O
thought O
to O
be O
involved O
in O
specific O
DNA O
sequence O
recognition O
by O
CAP I-GENE
. O

The O
hyperacute O
phase O
of O
posterolateral O
myocardial O
infarction O
. O

Statistics O
for O
nurse O
managers O
-- O
3 O
. O

The O
infection O
rate O
was O
five O
times O
greater O
in O
patients O
with O
Hickman O
catheters O
than O
in O
those O
with O
Broviac O
catheters O
( O
p O
= O
0 O
. O
01 O
). O

After O
a O
year O
of O
planning O
in O
the O
Laboratory O
Assistants O
' O
School O
in O
Stockholm O
: O
new O
education O
for O
laboratory O
assistants O
is O
now O
arranged O

The O
electrocardiogram O
. O

Setting O
takes O
place O
through O
complex O
formation O
of O
( O
NH4Mg O
PO4 O
. O
6H2O O
) O
n O
, O
excess O
reactants O
, O
and O
water O
. O

The O
Authors O
have O
proposed O
to O
develop O
this O
research O
employing O
a O
preparation O
containing O
exclusively O
a O
cortisonic O
, O
the O
desametazone O
, O
in O
order O
to O
evaluate O
the O
alterations O
of O
the O
dentinogenesis O
to O
be O
attributed O
to O
such O
component O
. O

Secretory I-GENE
IgA I-GENE
and O
serum I-GENE
immunoglobulins I-GENE
as O
indices O
of O
the O
local O
immunity O
of O
the O
intestinal O
mucosa O
in O
acute O
leukemias O

Serum I-GENE
IgE I-GENE
levels O
in O
Tauranga O
children O
. O

Use O
of O
prostaglandin O
F2 O
alpha O
( O
PGF2 O
alpha O
) O
in O
cattle O
breeding O
. O

Thus O
it O
appears O
that O
the O
management O
of O
blood O
, O
including O
washing O
is O
of O
great O
importance O
. O

Range O
, O
variations O
and O
neoplastic O
potential O
. O

The O
scores O
are O
dependent O
in O
part O
on O
the O
reliability O
of O
faculty O
evaluations O
. O

Study O
on O
distribution O
of O
metal O
in O
the O
teeth O
treated O
by O
iontophoresis O
with O
transparent O
specimens O

Whereas O
creatine I-GENE
kinase I-GENE
activity O
declined O
exponentially O
from O
a O
single O
peak O
, O
myoglobin I-GENE
appeared O
in O
multiple O
episodes O
inadequately O
represented O
by O
a O
single O
peak O
value O
and O
having O
no O
clear O
clinical O
correlation O
. O

Utero O
- O
placental O
blood O
flow O
and O
the O
effect O
of O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
stimulating O
drugs O
. O

Development O
of O
basophilic O
leukemia O
with O
trisomy O
8 O
and O
atypical O
erythroblastosis O
in O
a O
patient O
with O
a O
history O
of O
aplastic O
anemia O
22 O
years O
earlier O

The O
arginyl O
peptide O
bonds O
that O
are O
cleaved O
in O
the O
conversion O
of O
human I-GENE
factor I-GENE
IX I-GENE
to O
factor I-GENE
IXa I-GENE
by O
factor I-GENE
XIa I-GENE
were O
identified O
as O
Arg145 O
- O
Ala146 O
and O
Arg180 O
- O
Val181 O
. O

Alveolar O
growth O
, O
contemporary O
with O
dental O
eruption O
, O
is O
sufficient O
to O
compensate O
possible O
hypotrophy O
of O
maxillary O
bone O
bases O
. O

Fluorometric O
methods O
can O
also O
provide O
information O
about O
porphyrin O
binding O
sites O
that O
is O
useful O
in O
understanding O
porphyrin O
transport O
and O
clearance O
. O

Renal O
and O
extrarenal O
arterial O
fibromuscular O
hyperplasia O
with O
hypertension O
. O

The O
monoexponential O
rate O
of O
clearance O
of O
tracer O
-- O
obtained O
from O
the O
portion O
of O
the O
residue O
- O
detection O
curve O
reflecting O
metabolism O
of O
fatty O
acid O
incorporated O
into O
neutral O
lipids O
-- O
correlated O
directly O
with O
induced O
changes O
in O
tension O
- O
time O
index O
after O
injections O
into O
the O
left O
atrium O
( O
r O
= O
0 O
. O
96 O
, O
n O
= O
12 O
), O
right O
atrium O
( O
r O
= O
0 O
. O
86 O
, O
n O
= O
14 O
), O
and O
ear O
vein O
( O
r O
= O
0 O
. O
93 O
, O
n O
= O
14 O
). O

Both O
examinations O
are O
sensitive O
indicators O
of O
CNS O
abnormalities O
associated O
with O
bacterial O
meningeal O
infections O
and O
are O
important O
determinants O
of O
the O
therapy O
and O
ultimate O
prognosis O
of O
such O
complications O
. O

Specific O
IgE I-GENE
levels O
decreased O
slightly O
, O
but O
always O
remained O
within O
the O
pathological O
range O
. O

Similar O
clinical O
evaluation O
of O
an O
obligate O
carrier O
revealed O
no O
ocular O
abnormalities O
. O

Correlation O
between O
intraocular O
involvement O
and O
systemic O
outcome O
was O
poor O
. O

A O
case O
of O
anterior O
cleavage O
syndrome O
in O
a O
27 O
- O
year O
- O
old O
female O
patient O
is O
described O
. O

The O
daily O
administration O
of O
betamethasone O
for O
three O
weeks O
markedly O
reduced O
the O
absorption O
of O
calcium O
and O
phosphate O
as O
well O
as O
the O
growth O
rate O
. O

Endorphins I-GENE
and O
legal O
issues O
. O

At O
necropsy O
28 O
days O
post O
- O
inoculation O
, O
F344 O
rats O
had O
no O
gross O
lung O
lesions O
, O
even O
those O
given O
the O
maximum O
dose O
of O
1 O
. O
4 O
X O
10 O
( O
9 O
) O
colony O
- O
forming O
units O
of O
M O
. O
pulmonis O
. O

Aneurysmectomy O
and O
the O
performance O
of O
CABG O
were O
not O
significantly O
associated O
with O
postoperative O
ECG O
changes O
, O
but O
more O
bypass O
grafts O
per O
patient O
grafted O
appeared O
in O
the O
group O
with O
postoperative O
ECG O
changes O
, O
suggesting O
that O
coronary O
artery O
disease O
may O
be O
more O
severe O
in O
that O
group O
. O

REV O
I O
: O
All O
vessels O
up O
to O
50 O
% O
stenosed O
have O
a O
patent O
graft O
. O

Complete O
sequences O
were O
obtained O
for O
the O
three O
large O
thrombic O
peptides O
, O
and O
these O
were O
aligned O
by O
using O
peptides O
from O
the O
V8 I-GENE
protease I-GENE
digest O
. O

The O
extraction O
measurements O
were O
used O
to O
test O
for O
extracerebral O
contamination O
of O
venous O
outflow O
. O

Contractile O
responses O
to O
norepinephrine O
, O
serotonin O
and O
potassium O
( O
K O
+) O
and O
relaxant O
responses O
to O
isoproterenol O
and O
papaverine O
were O
studied O
in O
vitro O
with O
spirally O
cut O
thoracic O
aortic O
strips O
from O
aortic O
coarcted O
hypertensive O
rats O
( O
AHR O
) O
2 O
, O
6 O
, O
14 O
and O
28 O
days O
postoperatively O
and O
compared O
to O
time O
- O
matched O
, O
sham O
- O
operated O
normotensive O
controls O
. O

On O
line O
calculation O
of O
steroid O
concentrations O
by O
radioimmunoassay O

Detection O
of O
congenital O
hypothyroidism O
in O
26 O
, O
282 O
newborn O
infants O

In O
rubella O
patients O
with O
serologic O
confirmation O
by O
HI O
, O
the O
IF O
test O
detected O
significant O
rises O
in O
219 O
( O
99 O
. O
1 O
%) O
of O
221 O
patients O
and O
the O
PHA I-GENE
test O
detected O
antibody O
conversion O
in O
68 O
( O
93 O
%) O
of O
73 O
patients O
. O

The O
results O
indicate O
that O
folate O
compounds O
decrease O
formate O
accumulation O
after O
methanol O
by O
stimulating O
formate O
oxidation O
or O
utilization O
and O
suggest O
a O
possible O
use O
for O
folates O
in O
the O
treatment O
of O
certain O
cases O
of O
human O
methanol O
poisoning O
. O

The O
effect O
of O
sodium O
saccharin O
in O
the O
diet O
on O
caecal O
microflora O
. O

The O
residue O
functions O
, O
R O
( O
t O
), O
for O
C O
- O
11 O
CPZ O
and O
In O
- O
113m O
transferrin I-GENE
were O
plotted O
against O
time O
for O
selected O
areas O
of O
interest O
, O
and O
the O
CPZ O
area O
- O
weighted O
extraction O
, O
E O
( O
t O
), O
was O
computed O
for O
the O
same O
areas O
every O
250 O
msec O
using O
the O
formula O
: O
E O
( O
t O
) O
= O
[ O
RT O
( O
t O
) O
- O
RR O
( O
t O
)]/[ O
1 O
- O
RR O
( O
t O
)], O
where O
RT O
and O
RR O
are O
the O
normalized O
residue O
functions O
for O
CPZ O
and O
transferrin I-GENE
, O
respectively O
. O

Synchronous O
extracts O
showed O
no O
significant O
migration O
inhibition O
in O
allogeneic O
assays O
. O

Ten O
days O
of O
cefadroxil O
therapy O
was O
used O
to O
treat O
44 O
children O
with O
urinary O
tract O
infection O
and O
CRP I-GENE
values O
greater O
than O
or O
equal O
to O
28 O
microgram O
/ O
ml O
( O
CRP I-GENE
- O
positive O
group O
). O

Both O
resting O
blood O
flow O
( O
RBF O
) O
and O
maximal O
blood O
flow O
( O
NBF O
) O
were O
studied O
by O
Xenon O
133 O
clearance O
. O

Plasma I-GENE
renin I-GENE
concentration O
is O
significantly O
higher O
in O
the O
subcapsular O
venous O
outflow O
, O
which O
drains O
the O
superficial O
cortex O
, O
than O
in O
the O
deep O
venous O
outflow O
, O
which O
drains O
the O
inner O
half O
of O
the O
cortex O
and O
medulla O
of O
the O
cat O
kidney O
. O

After O
acclimation O
, O
resting O
supine O
and O
sitting O
DPB O
decreased O
( O
P O
less O
than O
0 O
. O
05 O
) O
by O
6 O
and O
9 O
mmHg O
, O
respectively O
. O

In O
the O
diabetics O
, O
Ca2 O
+ O
infusions O
induced O
a O
rise O
of O
plasma O
Ca2 O
+ O
up O
to O
3 O
. O
2 O
+/- O
0 O
. O
1 O
mmol O
/ O
1 O
and O
a O
fall O
of O
circulating O
glucagon I-GENE
(- O
26 O
. O
4 O
+/- O
5 O
. O
7 O
%; O
p O
less O
than O
0 O
. O
001 O
) O
and O
glucose O
(- O
23 O
. O
3 O
+/- O
3 O
. O
6 O
%; O
p O
less O
than O
0 O
. O
05 O
). O

Fifty O
- O
eight O
RMI O
' O
s O
occurred O
in O
the O
placebo O
group O
as O
compared O
to O
only O
twenty O
in O
the O
AC O
group O
( O
p O
less O
than O
0 O
. O
01 O
). O

The O
" O
cracked O
- O
tooth O
" O
syndrome O
. O

The O
foregoing O
results O
show O
that O
CXD O
has O
high O
efficacy O
and O
safety O
and O
it O
can O
be O
said O
that O
it O
is O
a O
drug O
required O
in O
the O
pediatric O
field O
. O

Based O
on O
peptide O
map O
similarities O
, O
partial O
amino O
- O
terminal O
sequence O
data O
, O
and O
common O
genetic O
origin O
, O
it O
is O
suggested O
that O
p60 I-GENE
and O
p62 I-GENE
have O
identical O
amino O
acid O
sequences O
carboxy O
- O
terminal O
to O
the O
p60 I-GENE
initiator O
methionine O
( O
residue O
21 O
of O
p62 I-GENE
). O

All O
patients O
in O
the O
control O
group O
showed O
a O
significant O
improvement O
in O
their O
PEFR O
while O
only O
3 O
patients O
in O
the O
treated O
group O
showed O
an O
improvement O
. O

Facts O
on O
the O
Economic O
Recovery O
Tax O
Act O
of O
1981 O
for O
speech O
- O
language O
pathologists O
and O
audiologists O
. O

From O
Pap O
to O
ApUp O
. O

The O
relationship O
between O
the O
rare O
complications O
mentioned O
above O
and O
the O
pathophysiology O
of O
Bartter O
' O
s O
syndrome O
is O
still O
obscure O
. O

Using O
an O
opsonophagocytic O
bacterial O
assay O
and O
a O
suckling O
rat O
model O
of O
GBS O
sepsis O
, O
we O
analyzed O
a O
modified O
human I-GENE
immunoglobulin I-GENE
for O
opsonic O
and O
protective O
antibody O
. O

Glomerular O
lesions O
in O
renal O
allografts O
. O

Commonly O
observed O
systemic O
toxic O
effects O
( O
bone O
marrow O
, O
gastrointestinal O
tract O
, O
and O
heart O
) O
were O
not O
seen O
in O
this O
study O
. O

2 O
. O

When O
vascular O
pressure O
( O
Pvas O
) O
was O
raised O
abruptly O
from O
- O
5 O
to O
+ O
25 O
cmH2O O
by O
air O
inflation O
for O
60 O
min O
, O
Px O
( O
f O
) O
became O
abruptly O
less O
negative O
, O
then O
remained O
stable O
. O

( O
1980 O
): O
Science O
210 O
, O
77 O
- O
72 O
) O
that O
stimulating O
the O
crossed O
olivocochlear O
bundle O
( O
COCB O
) O
can O
change O
the O
magnitude O
of O
the O
distortion O
product O
( O
f2 O
- O
f1 O
) O
in O
the O
ear O
- O
canal O
sound O
pressure O
. O

Rats O
underwent O
either O
a O
90 O
- O
95 O
% O
JIB O
or O
a O
sham O
operation O
. O

When O
the O
l O
- O
methadone O
- O
sensitive O
, O
opioid I-GENE
receptor I-GENE
is O
blocked O
by O
naloxone O
or O
tolerance O
has O
developed O
, O
than O
l O
- O
methadone O
can O
produce O
behavioral O
effects O
by O
a O
nonopioid O
mechanism O
. O

Microwave O
hyperthermia O
- O
induced O
blood O
- O
brain O
barrier O
alterations O
. O

Large O
and O
small O
medullary O
lesions O
inhibited O
the O
occurrence O
of O
target O
fibres O
in O
the O
tenotomized O
muscles O
, O
the O
smallest O
one O
being O
neurolysis O
of O
the O
dorsal O
roots O
. O

Diagnosis O
of O
phenylalanine I-GENE
hydroxylase I-GENE
deficiency O
( O
phenylketonuria O
). O

In O
10 O
control O
sheep O
mean O
plasma O
TXB2 O
concentration O
increased O
from O
0 O
. O
39 O
ng O
/ O
ml O
prebypass O
to O
about O
1 O
. O
1 O
ng O
/ O
ml O
at O
8 O
and O
16 O
min O
of O
bypass O
. O

The O
respiratory O
rate O
was O
13 O
+/- O
1 O
breaths O
/ O
min O
with O
52 O
+/- O
4 O
% O
of O
the O
respiratory O
cycle O
spent O
in O
inspiration O
; O
end O
- O
tidal O
CO2 O
pressure O
increased O
by O
3 O
. O
3 O
+/- O
1 O
. O
0 O
Torr O
during O
runs O
at O
SIP O
. O

There O
was O
no O
further O
increase O
in O
oxygen O
consumption O
when O
these O
subjects O
breathed O
with O
inspiratory O
pressures O
above O
SIP O
. O

We O
compared O
the O
volume O
of O
the O
pulmonary O
extravascular O
, O
extracellular O
water O
space O
using O
sodium O
and O
sucrose O
indicators O
in O
8 O
normal O
and O
11 O
edematous O
rabbit O
lungs O
by O
steady O
- O
state O
techniques O
. O

Investigated O
the O
reliability O
, O
validity O
and O
dimensionality O
of O
scores O
obtained O
by O
acute O
psychiatric O
inpatients O
( O
N O
= O
120 O
) O
on O
the O
Michigan O
Alcoholism O
Screening O
Test O
adapted O
to O
assess O
lifetime O
and O
current O
symptomatology O
. O

A O
simple O
method O
for O
measuring O
urinary O
iron O
following O
the O
administration O
of O
desferrioxamine O
( O
DF O
) O
is O
described O
. O

During O
conventional O
hemofiltration O
using O
substitution O
fluid O
with O
a O
Na O
+ O
concentration O
of O
140 O
mEq O
/ O
L O
, O
a O
decrease O
in O
extracellular O
fluid O
volume O
was O
noted O
whereas O
the O
intracellular O
fluid O
volume O
was O
unaltered O
. O

The O
uncomplicated O
cases O
of O
typhoid O
fever O
were O
found O
to O
have O
an O
intact O
CMIR O
as O
compared O
to O
the O
complicated O
cases O
. O

Transvenous O
serial O
xeroradiography O
. O

Recommendations O
to O
deal O
with O
these O
and O
related O
issues O
are O
presented O
. O

Use O
of O
subcutaneous O
deferoxamine O
in O
a O
child O
with O
hemochromatosis O
associated O
with O
congenital O
dyserythropoietic O
anemia O
, O
type O
I O
. O

There O
was O
a O
significant O
correlation O
between O
tubular O
diameter O
and O
spg O
( O
r O
= O
0 O
. O
68 O
, O
P O
less O
than O
0 O
. O
001 O
) O
suggesting O
that O
tubular O
diameter O
measurements O
in O
histological O
sections O
could O
be O
used O
to O
predict O
sperm O
production O
. O

The O
differential O
investigation O
of O
lipoproteins O
, O
however O
, O
showed O
that O
the O
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
( O
HDL I-GENE
) O
fractions O
are O
absolutely O
or O
relatively O
decreased O
with O
respect O
to O
low I-GENE
- I-GENE
density I-GENE
lipoproteins I-GENE
( O
LDL I-GENE
) O
in O
cerebral O
infarcts O
and O
in O
transient O
ischaemic O
attacks O
. O

Although O
noninhibitory O
fluid O
had O
higher O
mean O
concentrations O
of O
phosphorus O
and O
zinc O
, O
these O
differences O
did O
not O
hold O
after O
meconium O
- O
stained O
samples O
were O
excluded O
. O

Selenium O
status O
of O
thoroughbreds O
in O
the O
United O
Kingdom O
. O

During O
an O
8 O
- O
wk O
follow O
- O
up O
, O
parasites O
reappeared O
in O
10 O
patients O
, O
5 O
after O
each O
drug O
, O
between O
1 O
and O
7 O
wk O
after O
treatment O
. O

Preparation O
of O
a O
stable O
phospholipid O
reagent O
for O
coagulation O
assays O
. O

A O
note O
on O
some O
consequences O
of O
UV O
vision O
in O
birds O
. O

Before O
turnout O
, O
a O
morantel O
sustained O
release O
bolus O
( O
MSRB O
) O
was O
administered O
to O
each O
animal O
in O
the O
" O
treated O
" O
category O
. O

In O
a O
longitudinal O
study O
, O
14 O
low O
- O
risk O
fetuses O
were O
studied O
at O
2 O
- O
week O
intervals O
from O
32 O
weeks O
of O
gestation O
onward O
. O

Further O
, O
intracerebroventricular O
injections O
of O
KA O
resulted O
in O
the O
substantial O
loss O
of O
pyramidal O
cells O
in O
the O
whole O
CA3 O
field O
of O
the O
hippocampus O
. O

Seventeen O
of O
the O
35 O
patients O
were O
randomly O
chosen O
to O
receive O
a O
training O
program O
( O
lasting O
approximately O
1 O
month O
) O
designed O
to O
establish O
a O
systematic O
strategy O
of O
organizing O
complex O
visual O
material O
. O

The O
duration O
and O
the O
amplitude O
of O
the O
negative O
potential O
were O
greatest O
for O
completely O
regenerating O
ears O
with O
overgrowth O
, O
smaller O
for O
partially O
regenerating O
ears O
, O
and O
smallest O
for O
the O
nonregenerating O
ears O
. O

Samples O
obtained O
from O
normal O
volunteers O
and O
from O
the O
great O
majority O
of O
the O
patients O
, O
excluding O
those O
with O
asthma O
, O
had O
no O
effect O
on O
ciliary O
beating O
. O

These O
results O
suggested O
the O
possibility O
that O
the O
fetus O
played O
some O
role O
in O
the O
production O
of O
E3 O
- O
16 O
- O
G O
in O
early O
pregnancy O
. O

In O
this O
way O
it O
is O
possible O
to O
simulate O
the O
growth O
function O
of O
the O
embryofetal O
curve O
of O
the O
length O
' O
increase O
of O
man O
and O
the O
curve O
of O
the O
mass O
' O
increase O
of O
rat O
. O

The O
highest O
doses O
were O
found O
for O
drivers O
who O
transported O
large O
numbers O
of O
99Mo O
generators O
. O

The O
steepness O
of O
the O
standard O
O2 O
dissociation O
curve O
becomes O
greater O
during O
the O
training O
period O
( O
increase O
in O
Hill O
' O
s O
n O
from O
2 O
. O
68 O
+/- O
0 O
. O
10 O
to O
2 O
. O
96 O
+/- O
0 O
. O
15 O
). O

Conjugated O
and O
unconjugated O
phenylacetic O
acid O
and O
m O
- O
and O
p O
- O
hydroxyphenylacetic O
acid O
have O
been O
determined O
in O
the O
plasma O
of O
normal O
, O
healthy O
subjects O
after O
fasting O
, O
consumption O
of O
a O
meal O
and O
ingestion O
of O
deuterium O
labelled O
amine O
precursors O
, O
by O
high O
- O
resolution O
gas O
chromatography O
-- O
high O
resolution O
mass O
spectrometry O
with O
selected O
ion O
monitoring O
of O
their O
trifluoroethyl O
- O
pentafluoropropionyl O
derivatives O
. O

In O
concept O
II O
62 O
patients O
were O
treated O
with O
selective O
vagotomy O
and O
pyloroplasty O
. O

They O
consisted O
of O
behavioural O
disorders O
, O
tetraparesis O
, O
incontinence O
and O
oculomotor O
paralysis O
. O

CSF O
adenosine I-GENE
deaminase I-GENE
activity O
( O
ADA O
) O
was O
measured O
at O
the O
same O
time O
. O

Histamine O
reactivity O
had O
returned O
to O
normal O
in O
half O
the O
workers O
who O
had O
left O
their O
original O
factories O
, O
but O
in O
only O
one O
worker O
who O
had O
moved O
within O
her O
original O
factory O
. O

It O
was O
also O
found O
that O
there O
is O
no O
significant O
difference O
between O
the O
prevalence O
of O
nasal O
carriage O
of O
S O
. O
aureus O
amongst O
the O
hospital O
staff O
and O
the O
patients O
. O

Ficat O
and O
Bizou O
' O
s O
condylar O
depth O
index O
and O
the O
condylar O
- O
joint O
surface O
angle O
of O
Brattstrom O
are O
recommended O
as O
especially O
suitable O
methods O
of O
measurement O
. O

There O
were O
no O
significant O
differences O
in O
EF O
between O
the O
two O
studies O
, O
both O
at O
rest O
( O
56 O
. O
0 O
+/- O
13 O
. O
8 O
% O
vs O
58 O
. O
2 O
+/- O
11 O
. O
7 O
%, O
p O
= O
NS O
) O
and O
with O
exercise O
( O
51 O
. O
1 O
+/- O
17 O
. O
6 O
% O
vs O
54 O
. O
3 O
+/- O
17 O
. O
6 O
%, O
p O
= O
NS O
) O
and O
a O
highly O
significant O
correlation O
was O
shown O
between O
the O
two O
groups O
of O
values O
( O
rest O
r O
= O
0 O
. O
90 O
, O
exercise O
r O
= O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
001 O
). O

After O
MOPP O
therapy O
, O
complete O
remission O
of O
Hodgkin O
' O
s O
disease O
was O
accompanied O
by O
normalization O
of O
the O
glucocerebrosidase I-GENE
level O
and O
disappearance O
of O
Gaucher O
' O
s O
cells O
. O

Specifically O
, O
by O
the O
type O
of O
adjuvant O
therapy O
, O
the O
median O
disease O
- O
free O
interval O
and O
survival O
from O
stage O
IVA O
for O
23 O
patients O
receiving O
Corynebacterium O
parvum O
were O
6 O
. O
9 O
and O
19 O
months O
; O
for O
39 O
patients O
receiving O
BCG O
, O
eight O
months O
and O
26 O
months O
; O
for O
24 O
patients O
receiving O
BCG O
+ O
DTIC O
, O
eight O
and O
17 O
. O
4 O
months O
; O
and O
for O
all O
51 O
DTIC O
treated O
patients O
6 O
. O
3 O
and O
17 O
. O
8 O
months O
, O
respectively O
. O

The O
COP O
- O
PAWP O
gradient O
was O
markedly O
decreased O
in O
both O
shock O
and O
non O
- O
shock O
patients O
with O
pulmonary O
edema O
. O

Re O
: O
A O
modified O
method O
for O
the O
in O
vivo O
labeling O
of O
red O
blood O
cells O
with O
Tc O
- O
99m O
. O

A O
limited O
study O
in O
a O
glassware O
factory O
( O
As2O3 O
exposure O
) O
involving O
the O
measurement O
of O
total O
airborne O
arsenic O
, O
the O
determination O
of O
urinary O
arsenic O
, O
and O
the O
evaluation O
of O
hand O
and O
mouth O
contamination O
by O
arsenic O
before O
and O
after O
the O
workshift O
suggests O
that O
the O
high O
urinary O
arsenic O
levels O
( O
300 O
microgram O
/ O
g O
creatinine O
) O
are O
likely O
to O
be O
more O
related O
to O
an O
increased O
oral O
intake O
from O
contaminated O
hands O
than O
to O
an O
increased O
absorption O
from O
the O
lungs O
. O

Parasitological O
and O
pathological O
findings O
in O
capuchin O
monkeys O
infected O
with O
Schistosoma O
japonicum O
or O
Schistosoma O
mansoni O
. O

The O
pia O
mater O
at O
the O
site O
of O
the O
entry O
of O
blood O
vessels O
into O
the O
central O
nervous O
system O
. O

Experimental O
reproduction O
of O
malignant O
catarrhal O
fever O
in O
Bali O
cattle O

1 O
A O
colonic O
delivery O
system O
is O
described O
to O
deliver O
orally O
ingested O
drugs O
to O
the O
colon O
and O
release O
them O
at O
that O
site O
by O
coating O
with O
an O
acrylic O
based O
resin O
( O
Eudragit O
S O
). O

Administration O
of O
the O
dopamine O
agonist O
bromocriptine O
( O
2 O
. O
5 O
mg O
three O
times O
a O
day O
for O
4 O
days O
) O
suppressed O
( O
P O
less O
than O
0 O
. O
01 O
) O
mean O
24 O
- O
h O
plasma O
18 O
- O
OHB O
levels O
from O
21 O
. O
9 O
+/- O
2 O
. O
0 O
to O
14 O
. O
8 O
+/- O
1 O
. O
4 O
ng O
/ O
dl O
. O

Restarting O
time O
was O
not O
affected O
by O
magnesium O
cardioplegia O
. O

The O
most O
common O
types O
of O
malformations O
were O
eye O
defects O
and O
open O
coeloms O
. O

Repair O
of O
a O
cosmetic O
defect O
of O
the O
lower O
leg O
with O
a O
myocutaneous O
free O
flap O
. O

According O
to O
the O
literature O
, O
second O
malignant O
epithelial O
tumours O
are O
, O
in O
contrast O
to O
mesenchymal O
tumours O
such O
as O
osteosarcoma O
, O
very O
rare O
in O
retinoblastoma O
survivors O
. O

In O
Malmo O
, O
Sweden O
, O
17 O
, O
181 O
school O
children O
born O
in O
the O
years O
1961 O
- O
1965 O
were O
screened O
for O
scoliosis O
once O
a O
year O
between O
the O
ages O
of O
7 O
and O
16 O
years O
, O
during O
1971 O
- O
1980 O
. O

In O
the O
past O
, O
immunology O
in O
Singapore O
was O
mainly O
confined O
to O
serology O
for O
the O
diagnosis O
of O
certain O
infectious O
diseases O
. O

Intra O
- O
articular O
dislocation O
of O
the O
patella O
. O

This O
study O
demonstrates O
secretion O
of O
bicarbonate O
by O
the O
human O
stomach O
in O
vivo O
at O
a O
rate O
equivalent O
to O
10 O
-- O
20 O
% O
of O
basal O
acid O
secretion O
. O

Histological O
evaluation O
revealed O
a O
more O
than O
twofold O
increase O
in O
the O
number O
of O
interepithelial O
mononuclear O
cells O
( O
p O
less O
than O
0 O
. O
005 O
), O
while O
the O
number O
of O
epithelial O
cells O
/ O
100 O
microns O
of O
villous O
mucosa O
and O
the O
mean O
height O
of O
the O
epithelial O
cells O
were O
comparable O
in O
both O
groups O
. O

Cramps O
in O
extrapyramidal O
disorders O
. O

A O
suspected O
new O
storage O
disease O
in O
cattle O
. O

For O
various O
dog O
vessels O
in O
vivo O
, O
Q O
/ O
Dk O
ranged O
from O
0 O
. O
15 O
to O
47 O
X O
10 O
( O
5 O
) O
Torr O
/ O
cm2 O
. O

The O
tetraphasic O
action O
of O
lidocaine O
on O
CNS O
electrical O
activity O
and O
behavior O
in O
cats O
. O

Modification O
of O
enteral O
resorption O
by O
cytostatic O
therapy O

Asymptomatic O
bacteriospermia O
and O
fertility O

Triumph O
of O
Leninist O
national O
policy O

The O
favourable O
effect O
of O
thymic O
shielding O
was O
also O
reflected O
in O
a O
significant O
increase O
of O
LD50 O
/ O
30 O
, O
and O
the O
dose O
reduction O
factor O
was O
equal O
to O
2 O
. O

The O
application O
of O
ultrafiltration O
to O
sample O
preparation O
in O
the O
detection O
and O
quantification O
of O
ethylene O
glycol O
in O
plasma O
by O
gas O
chromatography O
is O
described O
. O

Mastocytosis O
. O

A O
new O
Onchocerca O
species O
, O
a O
parasite O
of O
domestic O
cattle O
, O
in O
Senegal O

It O
was O
suggested O
that O
the O
absence O
of O
pronounced O
differences O
between O
conditions O
may O
have O
been O
due O
to O
the O
complexity O
of O
the O
task O
or O
the O
type O
of O
prompts O
employed O
. O

A O
limiting O
factor O
were O
disturbances O
in O
the O
system O
of O
energy O
transport O
( O
creatine O
phosphate O
, O
creatine I-GENE
phosphokinase I-GENE
) O
and O
of O
the O
calcium O
pump O
( O
Ca I-GENE
++- I-GENE
ATPase I-GENE
of O
the O
sarcoplasmic O
reticulum O
, O
SPR O
), O
which O
evidently O
led O
to O
a O
decrease O
of O
the O
inotropic O
properties O
of O
the O
myocardium O
at O
70 O
% O
restriction O
of O
coronary O
blood O
flow O
. O

In O
vitro O
penetration O
tests O
of O
human O
sperm O
into O
cervical O
mucus O
were O
introduced O
in O
order O
to O
study O
the O
interaction O
between O
sperm O
and O
cervical O
mucus O
. O

Vibrio O
fluvialis O
( O
group O
F O
vibrio O
) O
in O
Maharashtra O
. O

Serum I-GENE
creatine I-GENE
kinase I-GENE
( O
SCK I-GENE
) O
was O
measured O
in O
ten O
subjects O
in O
the O
laboratory O
before O
and O
after O
the O
performance O
of O
bicycle O
ergometry O
and O
a O
lifting O
task O
. O

Organisms O
were O
not O
observed O
in O
the O
5 O
bobcats O
trapped O
in O
2 O
other O
counties O
. O

The O
cause O
of O
death O
is O
often O
quite O
apparent O
from O
the O
pathological O
and O
toxicological O
findings O
; O
however O
, O
the O
manner O
of O
death O
often O
gives O
the O
examining O
official O
some O
difficulty O
. O

The O
average O
annual O
cost O
per O
head O
of O
population O
was O
US O
+ O
0 O
X O
46 O
. O

It O
is O
postulated O
that O
altered O
blood O
flow O
, O
mediated O
through O
the O
well O
- O
known O
prostaglandin I-GENE
synthetase I-GENE
inhibitory O
effects O
of O
ibuprofen O
, O
resulted O
in O
tubular O
necrosis O
. O

Either O
20 O
mg O
mitomycin O
/ O
20 O
ml O
distilled O
water O
or O
40 O
mg O
/ O
40 O
ml O
distilled O
water O
was O
locally O
instilled O
into O
the O
bladder O
with O
a O
catheter O
after O
emptying O
it O
and O
was O
left O
for O
about O
25 O
- O
l20 O
min O
. O

Both O
groups O
rejected O
pops O
with O
added O
SOA O
, O
decreasing O
mouthing O
times O
as O
SOA O
concentration O
increased O
. O

The O
mean O
extracted O
concentration O
of O
flucloxacillin O
obtained O
at O
operation O
was O
12 O
. O
9 O
micrograms O
/ O
ml O
( O
SD O
5 O
. O
25 O
) O
in O
synovial O
fluid O
; O
2 O
. O
9 O
micrograms O
/ O
g O
( O
SD O
3 O
. O
59 O
) O
in O
synovium O
; O
2 O
. O
0 O
micrograms O
/ O
g O
( O
SD O
1 O
. O
48 O
) O
in O
cancellous O
bone O
and O
1 O
. O
3 O
micrograms O
/ O
g O
( O
SD O
1 O
. O
25 O
) O
in O
cortical O
bone O
. O

A O
preliminary O
study O
of O
vincristine O
, O
methotrexate O
, O
and O
prednisolone O
( O
VM O
* O
P O
) O
combination O
chemotherapy O
for O
advanced O
adult O
non O
- O
Hodgkin O
' O
s O
lymphoma O

Lacrimal O
secretion O
in O
hyperthyroidism O

Re O
- O
examination O
of O
the O
ED01 O
study O
. O

Based O
on O
213 O
determinations O
, O
the O
control O
mean O
serum I-GENE
CPK I-GENE
activity O
was O
262 O
+/- O
113 O
I O
. O
U O
./ O
liter O
. O

A O
further O
study O
on O
plasminogen I-GENE
activator I-GENE
release O
by O
vasoactive O
agents O
in O
the O
isolated O
perfused O
dog O
leg O
. O

CDDP O
is O
active O
as O
a O
single O
agent O
in O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Treatment O
of O
meat O
muscle O
800 O
V O
for O
45 O
s O
reduced O
weeping O
but O
increased O
slightly O
the O
rate O
of O
autoxidation O
of O
lipids O
. O

The O
hormonal O
response O
to O
a O
standardized O
bicycle O
exercise O
test O
was O
studied O
in O
11 O
male O
cadets O
exposed O
to O
a O
course O
of O
107 O
h O
of O
continuous O
activity O
with O
less O
than O
2 O
h O
sleep O
. O

At O
an O
ambient O
temperature O
of O
25 O
degrees O
C O
, O
the O
responses O
to O
spinal O
cooling O
are O
reduced O
during O
the O
dark O
phase O
. O

A O
method O
for O
determining O
cumulative O
behavioral O
toxicity O
after O
chronic O
oral O
administration O
of O
l O
- O
alpha O
- O
acetylmethadol O
to O
female O
rats O
. O

After O
successful O
subtotal O
parathyroidectomy O
, O
evident O
by O
the O
decrease O
of O
serum O
iPTH I-GENE
levels O
, O
both O
the O
CL O
of O
group O
2 O
PMNs O
and O
the O
ability O
of O
group O
2 O
sera O
to O
induce O
augmented O
CL O
in O
normal O
PMNs O
decreased O
( O
p O
< O
0 O
. O
025 O
). O

TCZ O
provides O
quick O
, O
inexpensive O
, O
noninvasive O
indication O
of O
tissue O
necrosis O
, O
moderate O
- O
to O
- O
severe O
intracranial O
hemorrhage O
, O
and O
delayed O
brain O
maturation O
. O

The O
number O
of O
muricidal O
rats O
increased O
with O
increase O
in O
the O
duration O
of O
Cd O
administration O
in O
association O
with O
greater O
accumulation O
of O
Cd O
in O
the O
olfactory O
bulb O
than O
in O
any O
other O
region O
of O
the O
brain O
. O

This O
test O
should O
provide O
another O
practical O
means O
to O
study O
leprosy O
. O

The O
preferences O
were O
for O
intact O
vis O
- O
a O
- O
vis O
castrated O
males O
, O
though O
injections O
of O
TP O
restored O
the O
castrates O
' O
attractiveness O
to O
the O
females O
. O

Each O
trial O
consisted O
of O
light O
and O
buzzer O
for O
five O
seconds O
as O
conditioned O
stimuli O
and O
electric O
shock O
for O
five O
seconds O
as O
an O
unconditioned O
stimulus O
. O

Ulcer O
appeared O
on O
the O
angulus O
of O
the O
stomach O
at O
the O
28th O
week O
and O
resulted O
in O
ulcer O
scar O
at O
the O
42nd O
week O
. O

Family O
visits O
and O
involvement O
in O
treatment O
of O
patients O
at O
a O
state O
hospital O
. O

A O
transparent O
overlay O
for O
assessing O
amplitude O
of O
ECG O
wave O
forms O
. O

Adverse O
reaction O
of O
the O
apparently O
healthy O
partner O
in O
response O
to O
improvement O
in O
the O
overtly O
dysfunctional O
partner O
. O

Brain O
scan O
with O
99mTc O
- O
labelled O
macroaggregated I-GENE
albumin I-GENE
( O
MAA I-GENE
brain O
scan O
) O
and O
computed O
tomography O
studies O
( O
CT O
) O
were O
performed O
on O
78 O
patients O
with O
intracranial O
diseases O
. O

Inhibition O
of O
Fusarium O
moniliforme O
var O
. O
subglutinans O
, O
the O
causal O
agent O
of O
pine O
pitch O
canker O
, O
by O
the O
soil O
bacterium O
Arthrobacter O
sp O
. O

The O
five O
- O
drug O
combination O
of O
fluorouracil O
imidazole O
carboxamide O
dimethyl O
triazeno O
, O
vincristine O
, O
bis O
- O
chloroethyl O
nitrosourea O
, O
and O
prednisone O
( O
FIVB O
+ O
P O
) O
was O
given O
to O
120 O
women O
with O
metastatic O
breast O
cancer O
. O

A O
method O
is O
described O
for O
the O
simultaneous O
determination O
of O
1 O
, O
alpha O
- O
acetylmethadol O
( O
LAAM O
) O
and O
five O
active O
metabolites O
-- O
noracetylmethadol O
, O
dinoracetylmethadol O
, O
methadol O
, O
normethadol O
, O
and O
dinormethadol O
-- O
in O
biofluids O
by O
high O
- O
performance O
liquid O
chromatography O
using O
a O
normal O
- O
phase O
column O
and O
a O
UV O
detector O
at O
218 O
nm O
. O

Results O
of O
the O
recognition O
task O
revealed O
significant O
effects O
of O
consonant O
voicing O
, O
position O
and O
vowel O
context O
on O
syllable O
recognition O
. O

Visual O
response O
properties O
of O
neurons O
in O
four O
extrastriate O
visual O
areas O
of O
the O
owl O
monkey O
( O
Aotus O
trivirgatus O
): O
a O
quantitative O
comparison O
of O
medial O
, O
dorsomedial O
, O
dorsolateral O
, O
and O
middle O
temporal O
areas O
. O

A O
unified O
approach O
to O
the O
standardization O
of O
allergens O
. O

Clinical O
and O
anatomical O
considerations O

A O
dose O
- O
dependent O
fall O
in O
GABA O
content O
was O
observed O
; O
GABA O
decrease O
was O
evident O
15 O
min O
after O
the O
administration O
, O
reached O
its O
nadir O
at O
60 O
min O
and O
disappeared O
at O
120 O
minutes O
. O

Theory O
and O
applications O
of O
pulse O
dosing O
: O
a O
summary O
of O
the O
symposium O
. O

These O
results O
show O
that O
the O
neonate O
differs O
from O
the O
adult O
in O
respect O
of O
both O
the O
nature O
of O
effects O
of O
the O
drug O
and O
sensitivity O
to O
it O
. O

To O
evaluate O
the O
gas O
chromatographic O
electron O
capture O
detection O
method O
described O
earlier O
, O
23 O
plasma O
samples O
have O
been O
analysed O
by O
both O
techniques O
. O

The O
hemodynamics O
of O
isoproterenol O
- O
induced O
cardiac O
failure O
in O
the O
rat O
. O

Several O
authors O
have O
recently O
reported O
interference O
in O
theophylline O
analysis O
by O
paraxanthine O
( O
1 O
, O
7 O
- O
dimethylxanthine O
), O
an O
important O
metabolite O
of O
caffeine O
. O

Multi O
drug O
regimens O
like O
C O
- O
MOPP O
, O
CHOP O
and O
BACOP O
led O
to O
high O
remission O
rates O
and O
in O
some O
cases O
probably O
also O
to O
a O
cure O
of O
the O
disease O
. O

For O
monocytes O
, O
as O
measured O
on O
the O
Hematrak O
, O
it O
was O
13 O
. O
4 O
%. O

Morphological O
features O
of O
Jat O
dentition O
. O

Clinical O
accuracy O
of O
updated O
version O
of O
the O
Phadebas O
RAST O
test O
. O

Five O
control O
subjects O
with O
COPD O
, O
who O
performed O
the O
same O
sequence O
of O
tests O
without O
breathing O
30 O
% O
O2 O
, O
showed O
no O
change O
in O
flow O
rates O
or O
density O
dependence O
. O

Following O
extended O
recovery O
hippocampal O
EEG O
was O
normal O
despite O
extensive O
cellular O
loss O
in O
areas O
CA3 O
and O
CA4 O
. O

Evoked O
potential O
and O
single O
unit O
responses O
to O
olfactory O
nerve O
volleys O
in O
the O
isolated O
turtle O
olfactory O
bulb O
. O

While O
all O
deletions O
within O
the O
sequence O
coding O
for O
the O
mature O
tRNA O
led O
to O
inactivity O
of O
the O
mutated O
genes O
, O
substitution O
of O
the O
central O
portion O
by O
concatenated I-GENE
Hind I-GENE
III I-GENE
linkers I-GENE
produced O
gene O
units O
active O
in O
transcription O
. O

Cross O
reactivity O
in O
theophylline O
RIA O
kit O
decreased O
. O

Strontium O
- O
90 O
was O
inject O
i O
. O
v O
. O
into O
pregnant O
rats O
on O
day O
18 O
post O
conception O
( O
p O
. O
c O
.). O

Recording O
of O
the O
digital O
sphygmic O
activity O
in O
the O
lower O
extremities O
with O
the O
photoplethysmographic O
and O
strain O
- O
gauge O
methods O
. O

Eight O
hr O
of O
acidosis O
caused O
a O
significant O
( O
P O
less O
than O
0 O
. O
01 O
) O
decrease O
in O
P50 O
in O
vitro O
which O
fell O
from O
29 O
. O
0 O
to O
24 O
. O
4 O
torr O
. O

Catheter O
transit O
slows O
the O
response O
to O
a O
step O
increase O
in O
concentration O
by O
about O
0 O
. O
13 O
s O
( O
from O
10 O
per O
cent O
- O
90 O
per O
cent O
) O
and O
prolongs O
the O
transit O
time O
through O
the O
catheter O
for O
a O
volatile O
anesthetic O
by O
about O
0 O
. O
04 O
s O
more O
than O
N2 O
. O

These O
women O
should O
not O
be O
given O
the O
current O
estrogen O
PPI O
, O
which O
was O
designed O
to O
warn O
women O
of O
the O
risks O
of O
long O
- O
term O
estrogen O
use O
; O
a O
PPI O
should O
be O
written O
specifically O
for O
patients O
receiving O
short O
courses O
. O

The O
oral O
temperature O
rose O
and O
the O
serum I-GENE
creatine I-GENE
kinase I-GENE
levels O
fell O
only O
in O
those O
patients O
who O
were O
actively O
warmed O
. O

Determination O
of O
aortic O
distensibility O
and O
its O
variations O
in O
arterial O
hypertension O
. O

We O
studied O
the O
role O
of O
prostaglandins O
in O
acid O
- O
induced O
esophagitis O
and O
the O
associated O
LES O
hypotension O
by O
simultaneous O
treatment O
of O
some O
animals O
with O
indomethacin O
( O
150 O
micrograms O
/ O
kg O
intravenous O
), O
a O
specific O
inhibitor O
of O
prostaglandin O
synthesis O
, O
either O
during O
production O
of O
esophagitis O
or O
during O
recovery O
. O

Since O
only O
58 O
% O
of O
our O
sample O
could O
be O
adequately O
classified O
with O
one O
diagnosis O
, O
we O
expect O
that O
the O
ASDC O
nosology O
will O
need O
to O
evolve O
further O
. O

A O
surgical O
technique O
for O
correcting O
this O
problem O
is O
described O
. O

Effects O
of O
prostaglandin O
inhibitors O
on O
the O
onset O
of O
proteinuria O
and O
stroke O
in O
stroke O
- O
prone O
spontaneously O
hypertensive O
rats O
. O

In O
this O
study O
, O
the O
general O
clinical O
criteria O
for O
inhalation O
injury O
-- O
presence O
of O
facial O
or O
oropharyngeal O
burns O
, O
carboxyhemoglobin I-GENE
levels O
, O
carbonaceous O
sputum O
, O
or O
closed O
space O
injury O
-- O
did O
not O
differentiate O
patients O
with O
airway O
injury O
only O
from O
those O
with O
parenchymal O
injury O
. O

Survival O
was O
calculated O
both O
from O
the O
date O
of O
onset O
and O
from O
the O
date O
of O
diagnosis O
. O

Methisergide O
( O
0 O
. O
5 O
mg O
/ O
kg O
, O
i O
. O
p O
.), O
a O
blocker O
of O
serotonin I-GENE
receptors I-GENE
, O
prevented O
the O
development O
of O
the O
antinociceptive O
effect O
of O
serotonin O
. O

The O
plasma O
half O
- O
life O
of O
slow O
disposition O
phase O
t1 O
/ O
2 O
beta O
, O
increases O
from O
0 O
. O
26 O
hour O
in O
rabbits O
with O
normal O
renal O
function O
to O
5 O
. O
41 O
hours O
in O
rabbits O
with O
severe O
renal O
impairment O
. O

Effects O
of O
early O
monocular O
deprivation O
on O
development O
of O
cortico O
- O
geniculate O
projections O
in O
the O
cat O
. O

Corticosteroid O
therapy O
is O
known O
to O
be O
hazardous O
in O
patients O
with O
occult O
infection O
but O
the O
mechanism O
by O
which O
the O
host O
parasite O
relationship O
is O
altered O
by O
steroids O
is O
not O
known O
. O
We O
have O
used O
an O
intestinal O
protozoal O
parasite O
, O
Giardia O
muris O
, O
to O
examine O
the O
effects O
of O
corticosteroids O
on O
the O
number O
of O
parasites O
in O
the O
intestine O
in O
the O
course O
of O
a O
primary O
infection O
. O

Static O
lung O
function O
in O
puppies O
after O
pneumonectomy O
. O

With O
Sair O
and O
So2 O
, O
mean O
vital O
capacity O
was O
reduced O
by O
44 O
% O
from O
control O
. O

Bilateral O
Charnley O
arthroplasty O
as O
a O
single O
procedure O
. O

Of O
the O
117 O
patients O
( O
out O
of O
the O
136 O
) O
with O
serologic O
evidence O
of O
chronic O
thyroiditis O
who O
could O
be O
studied O
, O
eight O
( O
7 O
%) O
had O
hyperthyroidism O
and O
45 O
( O
38 O
%) O
were O
hypothyroid O
. O

The O
relationship O
between O
estrogenic O
properties O
of O
Tamoxifen O
and O
breast O
cancer O
management O
is O
discussed O
. O

The O
new O
semi O
- O
synthetic O
oral O
cephalosporin O
, O
CGP O
9 O
, O
000 O
, O
has O
been O
evaluated O
in O
a O
large O
number O
of O
hospitalized O
patients O
with O
urinary O
infections O
. O

A O
fluoroimmunoassay O
for O
the O
determination O
of O
serum O
of O
plasma O
levels O
of O
propranolol O
was O
developed O
using O
antibodies O
to O
propranolol O
coupled O
to O
magnetizable O
solid O
- O
phase O
particles O
and O
fluorescein O
- O
labeled O
propranolol O
as O
tracer O
. O

The O
syncytial O
microvillous O
projections O
seemed O
to O
be O
more O
numerous O
and O
longer O
in O
CNF O
, O
otherwise O
the O
structure O
of O
the O
trophoblastic O
layer O
of O
the O
villi O
and O
the O
lining O
of O
the O
subtrophoblastic O
vessels O
were O
identical O
in O
CNF O
and O
controls O
. O

When O
pollen O
allergen O
from O
three O
grass O
species O
were O
used O
, O
The O
RAST O
- O
test O
results O
did O
not O
differ O
from O
duplicate O
values O
either O
. O

DMI O
and O
2 O
- O
OH O
- O
DMI O
concentrations O
were O
determined O
in O
a O
similar O
group O
of O
61 O
DMI O
- O
treated O
patients O
. O

It O
has O
been O
shown O
in O
experiments O
in O
vitro O
that O
the O
hepatotrophic O
organic O
anions O
, O
the O
radiographic O
contrast O
agent O
( O
RCA O
) O
bilignost O
used O
in O
cholecystography O
and O
Bengal O
pink O
, O
have O
an O
affinity O
, O
unlike O
the O
urographic O
RCA O
triombrin O
and O
renotrophic O
dye O
indigo O
- O
carmine O
, O
for O
the O
plasmatic O
membranes O
( O
PM O
) O
of O
liver O
cells O
. O

33 O
out O
of O
90 O
neurons O
of O
the O
cat O
medial O
geniculate O
body O
revealed O
the O
selectivity O
of O
their O
afterdischarges O
to O
movement O
of O
sound O
when O
velocity O
of O
the O
movement O
changed O
from O
30 O
to O
180 O
deg O
/ O
s O
. O

In O
controls O
, O
only O
modest O
differences O
were O
observed O
. O

Assay O
of O
serum I-GENE
immunoreactive I-GENE
trypsin I-GENE
in O
dried O
blood O
spots O
and O
the O
early O
detection O
of O
cystic O
fibrosis O
. O

Similar O
waves O
were O
seen O
on O
cross O
- O
correlating O
a O
motor O
unit O
with O
an O
electronic O
oscillator O
, O
confirming O
that O
their O
occurrence O
does O
not O
necessarily O
demonstrate O
the O
existence O
of O
active O
neural O
interactions O
. O

Leukocyte O
enzyme O
activity O
and O
blood O
lymphocyte O
blast O
transformation O
in O
chronic O
bronchitis O

Current O
status O
of O
chemotherapy O
for O
Hodgkin O
' O
s O
disease O

In O
literature O
, O
the O
HBE O
has O
been O
displayed O
by O
application O
of O
the O
averaging O
method O
. O

Forty O
- O
five O
cases O
were O
surgically O
by O
direct O
approach O
to O
the O
tumour O
, O
while O
two O
cases O
were O
treated O
only O
with O
a O
shunt O
. O

In O
Group O
V O
, O
the O
salvaged O
tissue O
was O
primarily O
subepicardial O
with O
virtually O
no O
lateral O
zone O
of O
salvaged O
tissue O
( O
ratio O
of O
salvaged O
subepicardium O
to O
salvaged O
subendocardium O
14 O
. O
8 O
+/- O
1 O
. O
9 O
to O
1 O
). O

Progressive O
100 O
- O
mmHg O
stepwise O
decreases O
in O
superfusate O
oxygen O
partial O
pressure O
( O
PO2 O
) O
from O
control O
( O
95 O
% O
O2 O
aeration O
, O
PO2 O
, O
620 O
- O
650 O
mmHg O
) O
were O
produced O
, O
and O
subsequent O
changes O
in O
isometric O
active O
and O
resting O
tension O
were O
measured O
. O

The O
known O
B1 O
- O
deficiency O
reaches O
excessive O
high O
values O
with O
light O
exercise O
. O

Based O
on O
AUC O
infinity O
analyses O
, O
the O
pharmacokinetics O
of O
buflomedil O
were O
found O
to O
be O
linear O
within O
the O
dose O
ranges O
studied O
( O
50 O
to O
200 O
mg O
for O
i O
. O
v O
. O
injection O
and O
150 O
to O
450 O
mg O
for O
oral O
administration O
). O

Gastrin I-GENE
secretion O
during O
food O
stimulation O
in O
digestive O
system O
diseases O

Fibrinogen I-GENE
determination O
using O
the O
KZM O
- O
1 O
meter O

Over O
a O
period O
of O
15 O
days O
16 O
% O
of O
the O
dose O
administered O
was O
excreted O
with O
faeces O
and O
0 O
. O
9 O
% O
in O
the O
urine O
. O

Delayed O
or O
paradoxically O
emptying O
regions O
of O
the O
left O
ventricle O
were O
detected O
by O
a O
relatively O
new O
nuclear O
technique O
-- O
phase O
imaging O
. O

Responses O
to O
brainstem O
of O
nuclei O
medialis O
dorsalis O
, O
lateralis O
posterior O
were O
of O
considerably O
longer O
latency O
. O

Nineteen O
patients O
with O
non O
- O
visualized O
gallbladder O
with O
OCG O
subsequently O
had O
Tc O
- O
99m O
- O
PyG O
cholescintigraphy O
performed O
. O

One O
was O
allowed O
fresh O
drinking O
water O
ad O
libitum O
whilst O
the O
other O
received O
Aludrox O
in O
their O
drinking O
water O
. O

Anamnestic O
data O
were O
obtained O
from O
case O
history O
, O
smoking O
habits O
were O
not O
known O
in O
collective O
A O
and O
C O
. O

The O
determination O
of O
physical O
performance O
capacity O
was O
based O
on O
W170 O
, O
W85 O
% O
and O
on O
predicted O
VO2 O
max O
measured O
with O
continuously O
increasing O
work O
load O
on O
a O
bicycle O
ergometer O
. O

Determination O
of O
lead O
in O
blood O
. O

Effect O
of O
indomethacin O
and O
prostaglandin O
F2 O
alpha O
on O
parturition O
in O
swine O
. O

LD50 O
values O
of O
terms O
of O
KP O
were O
84 O
mg O
/ O
kg O
in O
male O
rats O
and O
122 O
mg O
/ O
kg O
in O
female O
rats O
when O
KP O
- O
CMC O
was O
administered O
intrarectally O
, O
and O
117 O
mg O
/ O
kg O
in O
male O
and O
92 O
mg O
/ O
kg O
in O
female O
when O
KP O
- O
T10 O
was O
administered O
intrarectally O
., O
while O
peroral O
administration O
of O
KP O
- O
CMC O
showed O
LD50 O
values O
of O
68 O
mg O
/ O
kg O
in O
males O
and O
78 O
mg O
/ O
kg O
in O
females O
in O
terms O
of O
KP O
. O

Autotransfusion O
was O
performed O
as O
follows O
: O
Heparin O
- O
ACD O
- O
B O
- O
Heparin O
- O
DPD O
- O
Heparin O
- O
ACD O
- O
B O
etc O
. O

Electron O
microscopic O
picture O
of O
the O
cerebral O
cortex O
in O
rats O
cooled O
to O
22 O
degrees O
C O

Generally O
the O
differences O
between O
short O
gut O
and O
sham O
operation O
animals O
disappeared O
when O
the O
data O
were O
normalised O
for O
mucosal O
weight O
. O

A O
simplified O
thin O
- O
layer O
chromatographic O
determination O
of O
hippuric O
acid O
and O
methylhippuric O
acids O
. O

The O
architecture O
of O
microvasculature O
in O
these O
two O
regions O
was O
also O
examined O
by O
scanning O
electron O
microscopy O
, O
using O
the O
resin O
casting O
method O
. O

MSMS O
Council O
hears O
new O
public O
health O
director O
. O

Chordoma O
of O
the O
spinal O
cord O
in O
a O
F344 O
rat O
. O

Micro O
high O
- O
performance O
liquid O
chromatographic O
system O
with O
micro O
precolumn O
and O
dual O
electrochemical O
detector O
for O
direct O
injection O
analysis O
of O
catecholamines O
in O
body O
fluids O
. O

Thirty O
- O
one O
age O
- O
matched O
, O
conscious O
, O
virgin O
, O
male O
Sprague O
- O
Dawley O
rats O
and O
spontaneously O
hypertensive O
rats O
( O
SHRs O
) O
were O
individually O
injected O
with O
a O
single O
subcutaneous O
dose O
of O
85 O
mg O
/ O
kg O
dl O
- O
isoproterenol O
to O
determine O
the O
degree O
and O
time O
course O
of O
drug O
- O
induced O
cardiac O
failure O
and O
functional O
recovery O
. O

A O
narrow O
zone O
of O
myelin O
- O
axonal O
dissociation O
was O
also O
observed O
. O

The O
IgA I-GENE
deficiency O
is O
combined O
with O
the O
IgE I-GENE
one O
. O

In O
PB O
mice O
, O
there O
was O
only O
a O
small O
deficit O
in O
the O
number O
of O
the O
hippocampal O
pyramidal O
neurons O
compared O
to O
controls O
( O
15 O
%, O
p O
less O
than O
0 O
. O
01 O
), O
and O
no O
deficit O
in O
the O
granule O
cells O
. O

Nutritional O
cataracts O
in O
timber O
wolves O
. O

Prevention O
of O
transfusion O
reactions O
by O
the O
use O
of O
saline O
washed O
red O
blood O
cells O
. O

The O
geometric O
mean O
hemagglutination O
- O
inhibition O
antibody O
titers O
( O
GMT O
) O
of O
non O
- O
immunized O
, O
once O
- O
immunized O
, O
and O
twice O
- O
immunized O
chickens O
were O
compared O
at O
2 O
- O
week O
intervals O
following O
primary O
immunization O
, O
secondary O
immunization O
, O
and O
challenge O
. O

The O
quantitative O
determination O
of O
HBSAG I-GENE
-- O
a O
valuable O
aid O
in O
evaluating O
the O
infectiousness O
of O
hepatitis O
B O
virus O
carriers O

2 O
. O
numerous O
narrow O
shunt O
vessels O
departing O
continuously O
from O
the O
primary O
arteries O
to O
feed O
a O
secondary O
arterial O
system O
which O
parallels O
the O
primary O
one O
. O

Urological O
complications O
are O
frequent O
during O
and O
after O
the O
treatment O
of O
gynecological O
malignancy O
. O

Arachnoid O
cyst O
. O

100 O
more O
than O
in O
the O
summer O
coat O
). O

Hypotension O
was O
produced O
by O
head O
up O
tilt O
. O

Therefore O
the O
procedure O
of O
Lich O
- O
Gregoir O
is O
not O
to O
be O
recommended O
in O
adults O
. O

Mucoepidermoid O
and O
acinous O
cell O
carcinomas O
of O
salivary O
tissues O
. O

Twenty O
patients O
aged O
45 O
or O
older O
with O
the O
diagnosis O
of O
endogenous O
depression O
were O
evaluated O
in O
terms O
of O
safety O
and O
efficacy O
in O
their O
response O
to O
multiple O
monitored O
electroconvulsive O
therapy O
( O
MMECT O
) O
versus O
single O
electroconvulsive O
therapy O
( O
SECT O
). O

Two O
new O
artifacts O
in O
automated O
coagulation O
testing O
. O

This O
relatively O
simple O
and O
easily O
performed O
technique O
of O
measuring O
deep O
muscle O
temperature O
appears O
to O
be O
a O
useful O
adjunct O
in O
choosing O
the O
amputation O
level O
. O

Longitudinal O
force O
- O
length O
relationships O
of O
guinea O
pig O
ureter O
were O
studied O
in O
vitro O
in O
animals O
3 O
weeks O
, O
3 O
months O
, O
and O
3 O
years O
of O
age O
. O

Tests O
of O
the O
method O
indicate O
( O
1 O
) O
the O
Mossbauer O
source O
can O
be O
placed O
on O
the O
basilar O
membrane O
without O
altering O
the O
signal O
- O
transmission O
properties O
of O
the O
cochlea O
, O
and O
( O
2 O
) O
the O
source O
adheres O
to O
the O
basilar O
membrane O
. O

Angiographic O
work O
- O
up O
in O
a O
patient O
with O
late O
vaginal O
metastasis O
from O
a O
renal O
carcinoma O
. O

The O
authors O
conclude O
that O
nonspecificity O
of O
low O
platelet I-GENE
MAO I-GENE
as O
a O
possible O
correlate O
of O
bipolar O
affective O
disorder O
, O
as O
well O
as O
schizophrenia O
, O
increases O
the O
burden O
of O
proof O
necessary O
before O
findings O
of O
low O
platelet I-GENE
MAO I-GENE
can O
be O
accepted O
as O
primary O
. O

Ecthyma O
, O
a O
known O
disease O
, O
of O
which O
little O
is O
known O

Estrogen O
replacement O
, O
either O
as O
17 O
beta O
- O
estradiol O
or O
beta O
- O
estradiol O
- O
3 O
- O
benzoate O
via O
subcutaneous O
Silastic O
capsules O
, O
was O
associated O
with O
elevated O
rates O
of O
heat O
production O
and O
dry O
heat O
loss O
relative O
to O
untreated O
ovariectomized O
controls O
. O

The O
following O
aspects O
were O
assessed O
: O
( O
1 O
) O
The O
effect O
on O
the O
cardiovascular O
system O
in O
terms O
of O
brachial O
arterial O
pressure O
, O
pulse O
rate O
, O
and O
oxygen O
consumption O
( O
VO2 O
) O
during O
exercise O
in O
5 O
health O
volunteers O
; O
( O
2 O
) O
emg O
activity O
of O
the O
tibialis O
anterior O
and O
gastrocnemius O
muscles O
during O
exercise O
in O
the O
same O
5 O
volunteers O
; O
and O
( O
3 O
) O
postexercise O
ankle O
pressure O
changes O
in O
10 O
subjects O
with O
angiographically O
proven O
occlusive O
arterial O
diseases O
of O
the O
lower O
extremities O
. O

Changes O
in O
immunologic O
reactivity O
in O
subjects O
receiving O
transfer I-GENE
factor I-GENE
could O
not O
be O
distinguished O
from O
those O
in O
subjects O
receiving O
placebo O
. O

It O
was O
argued O
that O
this O
arose O
from O
the O
possibility O
that O
the O
nature O
of O
blue O
collar O
jobs O
was O
physical O
, O
and O
that O
loss O
of O
myocardial O
tissue O
might O
be O
expected O
to O
more O
markedly O
interfere O
with O
their O
work O
efficiency O
( O
on O
returning O
to O
work O
) O
than O
it O
would O
the O
efficiency O
of O
the O
more O
sedentary O
jobs O
of O
white O
collar O
workers O
. O

Importance O
of O
determining O
the O
blood O
sulfhydryl O
groups O
in O
fractures O
of O
the O
long O
tubular O
bones O
complicated O
by O
infection O

The O
results O
revealed O
increased O
blood O
lead O
level O
associated O
with O
decreased O
blood I-GENE
haemoglobin I-GENE
and O
increased O
urinary O
excretion O
of O
delta O
amino O
levulinic O
acid O
. O

Following O
iv O
injection O
of O
0 O
. O
5 O
g O
galactose O
per O
kg O
body O
weight O
, O
together O
with O
2 O
mu O
Ci O
generally O
14C O
- O
labelled O
galactose O
, O
14CO2 O
is O
collected O
in O
regular O
intervals O
during O
one O
hour O
. O

Specific O
clotting O
factor O
assays O
showed O
an O
isolated O
deficiency O
of O
factor I-GENE
X I-GENE
ranging O
from O
7 O
to O
12 O
per O
cent O
on O
three O
determinations O
. O

Charcoal O
- O
facilitated O
dialysis O
. O

Blood O
variables O
measured O
at O
eight O
intervals O
before O
, O
during O
, O
and O
after O
operation O
were O
as O
follows O
: O
seven O
plasma O
proteins O
, O
free O
hemoglobin I-GENE
, O
formed O
elements O
, O
and O
clotting O
functions O
. O

Retinal O
changes O
in O
pigmentary O
retinopathy O
in O
children O

As O
a O
result O
, O
beta O
- O
apo O
- O
8 O
'- O
carotenoic O
acid O
ethyl O
ester O
( O
apo O
- O
EE O
) O
was O
used O
as O
a O
reference O
standard O
in O
Experiments O
4 O
to O
6 O
. O

The O
ability O
of O
sodium O
phenobarbital O
( O
60 O
mg O
/ O
kg O
) O
and O
sodium O
barbital O
( O
80 O
mg O
/ O
kg O
) O
to O
produce O
a O
taste O
aversion O
in O
23 O
hr O
fluid O
deprived O
rats O
was O
examined O
using O
a O
discrimination O
or O
two O
bottle O
taste O
aversion O
task O
( O
0 O
. O
125 O
% O
sodium O
saccharin O
solution O
or O
water O
). O

It O
appears O
that O
the O
pulmonary O
gas O
exchange O
parenchyma O
of O
these O
smallest O
mammals O
is O
well O
suited O
to O
supply O
the O
organism O
with O
the O
comparatively O
high O
levels O
of O
O2 O
required O
by O
the O
high O
metabolic O
rates O
, O
exhibiting O
a O
structural O
adaptation O
of O
the O
lung O
to O
higher O
VO2 O
. O

Underestimations O
by O
as O
much O
as O
35 O
% O
may O
occur O
due O
to O
the O
problems O
in O
the O
existing O
methodologies O
. O

Chemotherapy O
was O
administered O
without O
altering O
the O
course O
of O
the O
disorder O
. O

Drug O
inhibition O
of O
whole O
blood O
aspirin I-GENE
esterase I-GENE
. O

However O
, O
at O
lower O
temperature O
the O
positive O
staircase O
was O
not O
clear O
and O
rather O
negative O
staircase O
appeared O
( O
1 O
-- O
3 O
Hz O
). O

Visual O
averaged O
evoked O
responses O
and O
platelet I-GENE
monoamine I-GENE
oxidase I-GENE
in O
patients O
suffering O
from O
alcoholism O
. O

At O
the O
end O
of O
the O
experiment O
the O
urinary O
porphyrin O
excretion O
and O
the O
porphyrin O
content O
in O
lijver O
and O
skin O
were O
diminished O
in O
HCB O
- O
CQ O
- O
treated O
animals O
by O
about O
50 O
% O
compared O
to O
the O
HCB O
controls O
. O

Six O
hours O
after O
the O
last O
administration O
, O
uterus O
of O
Gf O
and O
Cv O
mice O
were O
weight O
337 O
. O
6 O
mg O
% O
and O
423 O
. O
5 O
mg O
% O
respectively O
, O
the O
difference O
was O
statistically O
significant O
( O
p O
less O
than O
0 O
. O
01 O
). O

Although O
stone O
- O
formers O
were O
not O
found O
to O
display O
any O
features O
of O
magnesium O
metabolism O
that O
were O
different O
from O
those O
in O
the O
control O
group O
, O
their O
lower O
urinary O
excretion O
of O
magnesium O
in O
relation O
to O
calcium O
may O
be O
a O
factor O
in O
their O
increased O
stone O
- O
forming O
propensity O
. O

Analysis O
of O
an O
autopsy O
population O
. O

A O
16 O
- O
year O
follow O
- O
up O
study O
of O
69 O
paraplegics O
with O
complete O
lesions O
from O
T1 O
- O
L3 O
is O
presented O
. O

Autoradiographic O
localisation O
of O
its O
cellular O
distribution O
in O
the O
kidney O
. O

Hippocampal O
stimulation O
overlapping O
conditioned O
stimulus O
preexposure O
produced O
attenuation O
of O
latent O
inhibition O
, O
as O
did O
stimulation O
presented O
during O
conditioning O
after O
preexposure O
. O

The O
centromedial O
amygdala O
and O
gastric O
pathology O
in O
rats O
. O

Cataract O
extraction O
in O
primary O
glaucoma O

Number O
and O
size O
of O
the O
myelin O
structures O
in O
the O
pneumocytes O
typ O
II O
increased O
simultaneously O
. O

In O
the O
intact O
animal O
, O
postextrasystolic O
potentiation O
depended O
on O
the O
basic O
pacing O
interval O
, O
t0 O
, O
and O
the O
timing O
of O
the O
extrasystole O
, O
t1 O
: O
when O
t0 O
was O
held O
constant O
and O
t1 O
was O
increased O
, O
potentiation O
decreased O
; O
when O
t1 O
was O
held O
constant O
and O
t0 O
was O
increased O
, O
potentiation O
increased O
. O

In O
spite O
of O
this O
and O
other O
complications O
of O
corticosteroids O
, O
she O
made O
a O
full O
recovery O
from O
the O
fungal O
infection O
following O
treatment O
with O
amphotericin O
B O
and O
surgical O
excision O
of O
the O
lung O
abscess O
. O

Implications O
of O
this O
observation O
for O
pediatrics O
are O
discussed O
. O

For O
the O
study O
of O
the O
transition O
of O
long O
to O
short O
waves O
( O
deep O
- O
water O
waves O
) O
a O
closed O
- O
form O
solution O
is O
advantageous O
; O
this O
can O
, O
however O
, O
only O
be O
obtained O
at O
the O
cost O
of O
further O
simplification O
. O

Treatment O
of O
suppurative O
peritonitis O

We O
report O
a O
case O
of O
pheochromocytoma O
manifesting O
during O
the O
third O
trimester O
of O
pregnancy O
. O

Fasting O
plasma O
and O
lipoprotein O
lipid O
concentrations O
, O
adipose I-GENE
tissue I-GENE
lipoprotein I-GENE
lipase I-GENE
activity O
, O
anthropometric O
data O
, O
alcohol O
consumption O
, O
smoking O
habits O
, O
weekly O
mileage O
run O
and O
performance O
on O
a O
bicycle O
ergometer O
were O
recorded O
before O
and O
after O
the O
training O
period O
. O

The O
C18 O
: O
1 O
: O
C10 O
value O
is O
a O
convenient O
measure O
of O
these O
changes O
and O
can O
be O
determined O
more O
rapidly O
than O
determining O
all O
the O
lower O
fatty O
acids O
. O

A O
progressive O
growth O
of O
blood O
erythrocyte O
membrane O
injury O
has O
been O
demonstrated O
after O
rats O
were O
exposed O
to O
gamma O
- O
irradiaton O
at O
a O
dose O
of O
100 O
to O
500 O
Gy O
. O

Within O
the O
3 O
' O
terminal O
50 O
nucleotides O
, O
the O
mouse I-GENE
mt I-GENE
12S I-GENE
rRNA I-GENE
contains O
a O
potential O
10 O
bp O
hairpin O
structure O
and O
a O
sequence O
of O
15 O
consecutive O
nucleotides O
common O
to O
the O
RNA O
of O
the O
small O
ribosomal O
subunit O
in O
all O
systems O
, O
but O
does O
not O
contain O
the O
mRNA O
binding O
site O
( O
ACCUCC O
) O
found O
in O
E O
. O
coli O
and O
corn O
chloroplast O
rRNAs O
. O

Microscopic O
anatomy O
and O
cell O
population O
dynamics O
. O

Thirty O
cadaver O
brains O
were O
examined O
under O
X O
6 O
to O
16 O
magnification O
in O
order O
to O
define O
the O
microsurgical O
anatomy O
of O
the O
pineal O
region O
, O
particularly O
the O
relationship O
of O
the O
pineal O
body O
, O
posterior O
cerebral O
artery O
, O
superior O
cerebellar O
artery O
, O
vein O
of O
Galen O
, O
basal O
vein O
of O
Rosenthal O
, O
internal O
cerebral O
vein O
, O
straight O
sinus O
, O
bridging O
vein O
, O
the O
size O
of O
the O
tentorial O
notch O
, O
and O
the O
third O
and O
the O
fourth O
cranial O
nerves O
. O

Serum O
antibody O
titre O
was O
not O
significantly O
associated O
with O
the O
recurrence O
rate O
or O
the O
duration O
of O
infection O
. O

We O
propose O
that O
refeeding O
may O
be O
an O
important O
mechanism O
for O
activation O
of O
certain O
viral O
infections O
previously O
suppressed O
by O
famine O
. O

One O
hundred O
twenty O
units O
of O
deglycerolized O
red O
blood O
cells O
, O
some O
with O
glycerol O
added O
so O
as O
to O
exceed O
an O
acceptable O
1 O
% O
glycerol O
content O
, O
had O
measurements O
made O
of O
the O
post O
- O
wash O
supernatant O
fluid O
by O
refractive O
index O
and O
osmometry O
. O

The O
symptoms O
and O
objective O
findings O
were O
caused O
by O
a O
malignant O
lymphoma O
, O
and O
the O
diagnosis O
was O
established O
from O
a O
drill O
biopsy O
. O

Our O
study O
differs O
from O
previous O
studies O
in O
that O
it O
is O
limited O
to O
one O
diagnostic O
entity O
, O
yet O
at O
the O
same O
time O
evaluates O
a O
broad O
range O
of O
social O
and O
work O
- O
related O
factors O
in O
disability O
. O

It O
is O
suggested O
that O
a O
raised O
hydroxykynurenine O
/ O
hydroxyanthranilic O
acid O
ratio O
does O
not O
necessarily O
indicate O
vitamin O
B6 O
deficiency O
but O
may O
represent O
a O
nonspecific O
response O
of O
tryptophan O
metabolism O
to O
stress O
. O

All O
control O
persons O
had O
a O
normal O
reaction O
to O
DNFB O
. O

In O
a O
control O
group O
both O
common O
carotid O
arteries O
( O
CCA O
) O
were O
ligated O
. O

At O
pH O
6 O
. O
9 O
, O
the O
same O
lidocaine O
concentrations O
significantly O
reduced O
resting O
potential O
( O
3 O
- O
10 O
%), O
action O
potential O
amplitude O
( O
3 O
- O
8 O
%) O
and O
Vmax O
( O
14 O
- O
22 O
%). O

Simultaneous O
right O
and O
left O
adrenal O
and O
peripheral O
blood O
samples O
were O
collected O
for O
determination O
of O
oestrone O
( O
E1 O
) O
and O
oestradiol O
( O
E2 O
). O

Arm O
function O
tests O
. O

All O
lambs O
with O
B O
breeding O
had O
significantly O
higher O
Hb I-GENE
levels O
at O
the O
end O
of O
the O
experiment O
than O
did O
NB O
lambs O
. O
b O
and O
S O
x O
B O
lambs O
had O
higher O
( O
P O
< O
. O
05 O
) O
Hb I-GENE
levels O
than O
the O
D O
x O
B O
lambs O
, O
and O
B O
lambs O
had O
the O
highest O
( O
P O
< O
. O
05 O
) O
mean O
corpuscular O
hemoglobin I-GENE
concentrations O
. O

The O
same O
response O
occurs O
whether O
acrylamide O
is O
given O
immediately O
after O
nerve O
ligation O
or O
1 O
week O
later O
. O

The O
operation O
recommended O
is O
excision O
of O
3 O
mm O
of O
central O
slip O
followed O
by O
end O
- O
to O
- O
end O
repair O
of O
the O
tendon O
. O

In O
the O
unclipped O
group O
arterial O
pressure O
decreased O
50 O
mmHg O
to O
normal O
by O
24 O
h O
and O
was O
associated O
with O
increased O
diuresis O
and O
a O
small O
decrease O
in O
blood O
volume O
( O
9 O
. O
8 O
%). O

Marked O
sedative O
activity O
was O
observed O
with O
9 O
- O
methoxy O
- O
5 O
- O
phenylpyrrolo O
[ O
2 O
, O
1 O
- O
d O
][ O
1 O
, O
5 O
] O
benzothiazepin O
- O
6 O
, O
6 O
- O
dioxide O
( O
NF19 O
) O
and O
9 O
- O
chloro O
- O
5 O
- O
p O
- O
nitrophenylpyrrolo O
[ O
2 O
, O
1 O
- O
d O
][ O
1 O
, O
5 O
] O
benzothiazepin O
- O
6 O
, O
6 O
- O
dioxide O
( O
NF20 O
). O

In O
patients O
, O
the O
effect O
of O
CCK I-GENE
- O
PZ I-GENE
on O
the O
movement O
of O
the O
terminal O
part O
of O
the O
bile O
duct O
was O
measured O
with O
a O
pressure O
sensor O
using O
a O
duodenofiberscope O
. O

In O
11 O
patients O
with O
Horton O
' O
s O
headache O
morphological O
investigations O
( O
differential O
white O
blood O
cell O
count O
), O
cytoenzymatic O
determinations O
( O
alkaline I-GENE
and I-GENE
acid I-GENE
phosphatase I-GENE
, O
non I-GENE
- I-GENE
specific I-GENE
esterase I-GENE
) O
and O
cytoimmunological O
tests O
( O
IgM I-GENE
and O
IgG I-GENE
binding O
) O
were O
carried O
out O
on O
capillary O
blood O
neutrophils O
obtained O
from O
the O
area O
of O
pain O
, O
non O
- O
painful O
area O
of O
the O
skin O
on O
the O
head O
on O
the O
contralateral O
side O
, O
and O
from O
the O
finger O
. O

As O
high O
- O
speed O
, O
volumetric O
imaging O
, O
computed O
tomographic O
scan O
machines O
such O
as O
the O
Dynamic O
Spatial O
Reconstructor O
become O
available O
with O
higher O
density O
resolution O
, O
perhaps O
a O
single O
injection O
of O
contrast O
agent O
into O
the O
right O
atrium O
or O
even O
a O
peripheral O
vein O
may O
be O
adequate O
to O
obtain O
all O
these O
measurements O
. O

The O
ESEG O
' O
s O
are O
a O
direct O
result O
of O
the O
NEXT O
study O
. O

The O
potentially O
SLE O
- O
inducing O
drugs O
are O
reviewed O
. O

A O
third O
series O
of O
mice O
were O
given O
a O
single O
injection O
of O
5 O
- O
OH O
- O
DA O
, O
sacrificed O
, O
and O
prepared O
for O
ultrastructural O
study O
. O

Fourteen O
different O
species O
( O
eight O
Platyhelmintha O
, O
one O
Nematoda O
and O
five O
Crustacea O
) O
have O
been O
inventorized O
. O

No O
symptoms O
other O
than O
hot O
flush O
showed O
such O
significant O
correlation O
with O
plasma O
epinephrine O
or O
norepinephrine O
levels O
. O

The O
mean O
values O
of O
the O
concentrations O
of O
the O
components O
due O
to O
tobacco O
smoke O
are O
: O
CO O
= O
1 O
. O
1 O
ppm O
, O
NO O
= O
32 O
ppb O
, O
NO2 O
= O
24 O
ppb O
, O
nicotine O
= O
0 O
. O
9 O
micrograms O
/ O
m3 O
, O
particulate O
matter O
= O
133 O
micrograms O
/ O
m3 O
. O

The O
average O
backscatter O
coefficient O
was O
six O
time O
larger O
in O
regions O
of O
infarct O
studied O
8 O
-- O
10 O
weeks O
after O
occlusion O
than O
that O
in O
regions O
of O
infarct O
studied O
5 O
-- O
6 O
weeks O
after O
occlusion O
. O

At O
4 O
wk O
however O
, O
tumor O
relapse O
was O
noted O
in O
6 O
of O
7 O
group O
4 O
responders O
, O
10 O
of O
12 O
in O
group O
5 O
, O
13 O
of O
16 O
in O
group O
7 O
, O
but O
only O
4 O
of O
19 O
group O
8 O
responders O
( O
p O
less O
than O
. O
001 O
group O
8 O
versus O
4 O
, O
5 O
, O
7 O
). O

Early O
infection O
was O
detected O
in O
one O
of O
50 O
control O
women O
who O
gave O
birth O
to O
a O
healthy O
infant O
. O

Pentachlorophenol O
accelerates O
the O
onset O
of O
HCB O
porphyria O
, O
in O
other O
words O
it O
increases O
the O
total O
urinary O
porphyrin O
excretion O
and O
causes O
an O
earlier O
disturbance O
of O
the O
porphyrin O
pattern O
. O

Family O
planning O
continues O
to O
play O
a O
minor O
role O
, O
and O
only O
25 O
. O
3 O
per O
cent O
of O
all O
patients O
reviewed O
took O
to O
oral O
contraceptives O
for O
shorter O
or O
longer O
periods O
of O
time O
. O
- O
The O
percentages O
of O
primiparae O
and O
secundiparae O
in O
all O
births O
as O
well O
as O
the O
high O
percentage O
of O
multigravidity O
are O
parameters O
by O
which O
the O
approach O
to O
reproduction O
differs O
substantively O
from O
behaviour O
patterns O
in O
Europe O
. O

The O
term O
osteomesopycnosis O
is O
proposed O
for O
a O
sclerosing O
bone O
disease O
with O
dominant O
inheritance O
that O
has O
been O
discovered O
in O
five O
members O
of O
four O
different O
families O
. O

The O
87K O
protein O
, O
together O
with O
proteins O
of O
105 O
, O
000 O
and O
75 O
, O
000 O
daltons O
, O
are O
translated O
from O
leftward O
transcribed O
( O
1 O
- O
strand O
) O
messenger O
RNAs O
that O
are O
complementary O
to O
the O
viral O
genome O
between O
positions O
11 O
. O
2 O
and O
31 O
. O
5 O
. O

The O
identification O
of O
viable O
myocardium O
with O
both O
99mTc O
- O
tetrofosmin O
and O
201Tl O
can O
be O
greatly O
enhanced O
to O
a O
similar O
degree O
if O
the O
severity O
of O
reduction O
in O
activity O
within O
nonreversible O
defects O
is O
considered O
. O

The O
temporal O
component O
lacked O
a O
mandibular O
fossa O
as O
well O
as O
articular O
eminence O
. O

EUK O
- O
8 O
is O
a O
novel O
, O
synthetic O
, O
low O
- O
molecular O
- O
weight O
salen O
- O
manganese O
complex O
that O
exhibits O
both O
superoxide I-GENE
dismutase I-GENE
and O
catalase I-GENE
activities O
in O
vitro O
. O

The O
protein I-GENE
ELT I-GENE
- I-GENE
1 I-GENE
, O
encoded O
by O
a O
single O
- O
copy O
gene O
homologous O
to O
the O
GATA I-GENE
family I-GENE
of I-GENE
vertebrate I-GENE
transcription I-GENE
factors I-GENE
, O
is O
potentially O
capable O
of O
interacting O
with O
this O
element O
. O

However O
, O
in O
contrast O
with O
previous O
in O
vitro O
cell O
- O
free O
integration O
studies O
, O
alteration O
of O
the O
highly O
conserved O
CA O
dinucleotide O
resulted O
in O
a O
mutant O
which O
still O
retained O
40 O
% O
of O
wild O
- O
type O
integration O
activity O
. O

The O
resulting O
R I-GENE
protein I-GENE
terminates O
five O
codons O
downstream O
of O
the O
frameshift O
site O
at O
the O
V I-GENE
protein I-GENE
stop O
codon O
. O

These O
results O
demonstrate O
that O
although O
PI2 O
and O
PI3 O
viruses O
belong O
to O
the O
same O
parainfluenza O
virus O
genus O
, O
these O
viruses O
show O
marked O
differences O
with O
respect O
to O
functional O
requirements O
for O
the O
cytoplasmic O
tail O
of O
the O
F I-GENE
glycoprotein I-GENE
. O

By O
site O
- O
specific O
mutagenesis O
, O
we O
also O
show O
that O
individual O
ICP27 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
amino I-GENE
acid I-GENE
residues I-GENE
that O
are O
positionally O
conserved O
in O
ICP27 I-GENE
homologs I-GENE
in O
other O
herpesviruses O
( O
D O
- O
357 O
, O
E O
- O
358 O
, O
H O
- O
479 O
, O
C O
- O
400 O
, O
C O
- O
483 O
, O
and O
C O
- O
488 O
) O
are O
critical O
for O
trans O
- O
regulatory O
activity O
. O

Magnetic O
resonance O
imaging O
( O
MRI O
) O
has O
enabled O
us O
to O
see O
the O
spinal O
intramedullary O
pathology O
as O
differences O
in O
signal O
intensity O
. O

Patients O
with O
psychotropic O
drugs O
showed O
significantly O
higher O
PRL I-GENE
levels O
. O

The O
Laser O
Scanning O
Ophthalmoscope O
enables O
a O
fundus O
- O
based O
examination O
and O
therefore O
allows O
exact O
comparison O
between O
morphologic O
appearance O
and O
corresponding O
function O
. O

Malaria O
, O
anaemia O
, O
and O
HIV O
- O
1 O
transmission O
in O
central O
Africa O
. O

BSE O
and O
farmworkers O
. O

In O
addition O
, O
two O
- O
dimensional O
nuclear O
magnetic O
resonance O
studies O
with O
F17A O
, O
K13Q O
, O
F15Y O
and O
F27Y O
revealed O
that O
the O
mutants O
have O
the O
same O
overall O
structure O
as O
the O
wild I-GENE
- I-GENE
type I-GENE
CspB I-GENE
protein I-GENE
. O

Considerably O
high O
levels O
of O
IgE I-GENE
antibodies I-GENE
was O
also O
established O
while O
other O
pollens O
did O
not O
show O
such O
correspondence O
. O

Peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPARs I-GENE
) O
and O
retinoid I-GENE
X I-GENE
receptors I-GENE
( O
RXRs I-GENE
) O
are O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
that O
are O
activated O
by O
fatty O
acids O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
respectively O
. O

This O
is O
particularly O
intriguing O
because O
SKUT O
- O
1B O
- O
20 O
cells O
lack O
the O
transcription O
factor O
Pit I-GENE
- I-GENE
1 I-GENE
. O

The O
number O
of O
lactotropes O
, O
somatotropes O
, O
thyrotropes O
, O
and O
gonadotropes O
was O
not O
altered O
compared O
with O
controls O
, O
indicating O
that O
in O
the O
adult O
pituitary O
, O
POMC I-GENE
products I-GENE
are O
not O
required O
to O
maintain O
the O
distribution O
of O
cell O
types O
. O

Some O
strains O
of O
A O
. O
parasiticus O
produced O
all O
four O
aflatoxins O
B1 O
B2 O
G1 O
G2 O
, O
while O
the O
other O
ones O
produced O
AF O
B1 O
+ O
G1 O
only O
, O
with O
concentrations O
of O
aflatoxins O
from O
0 O
. O
1 O
to O
450 O
mg O
/ O
kg O
. O

We O
have O
isolated O
a O
new O
, O
larger O
rat I-GENE
B I-GENE
- I-GENE
myc I-GENE
genomic I-GENE
clone I-GENE
. O

In O
addition O
to O
the O
nine O
and O
51 O
terminal O
amino O
acid O
forms O
already O
known O
, O
we O
identified O
a O
third O
with O
43 O
terminal O
amino O
acids O
predicted O
to O
encode O
a O
novel O
RET I-GENE
protein I-GENE
isoform I-GENE
. O

Both O
classes O
of O
MHBst I-GENE
proteins I-GENE
were O
found O
to O
form O
dimers O
; O
an O
which O
is O
involved O
in O
mediating O
the O
dimerization O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
the O
PERE I-GENE
formed O
three O
major O
complexes O
( O
P1 O
, O
P2 O
and O
P3 O
) O
with O
proteins O
in O
nuclear O
extracts O
from O
HeLa O
or O
293 O
cells O
. O

She O
had O
been O
receiving O
MTX O
7 O
. O
5 O
mg O
/ O
week O
for O
2 O
. O
5 O
months O
because O
of O
her O
vasculitis O
symptoms O
. O

Analysis O
of O
the O
sequence O
identified O
four O
open O
reading O
frames O
( O
ORFs O
) O
which O
are O
designated O
UL1 I-GENE
, O
UL2 I-GENE
, O
UL3 I-GENE
, O
and O
UL3 I-GENE
. I-GENE
5 I-GENE
based O
on O
their O
homology O
with O
proteins O
of O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
), O
pseudorabies O
virus O
( O
PRV O
), O
equine O
herpesvirus O
- O
1 O
, O
and O
varicella O
- O
zoster O
virus O
. O

These O
HPV16 O
E6 I-GENE
/ O
E7 I-GENE
cDNAs O
were O
cloned O
under O
the O
SV40 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
and O
the O
MMTV I-GENE
LTR I-GENE
to O
examine O
the O
activities O
of O
ras I-GENE
- O
collaborative O
transformation O
and O
induction O
of O
cellular O
DNA O
synthesis O
, O
both O
of O
which O
depend O
on O
the O
E7 I-GENE
gene I-GENE
product O
. O

Correlation O
coefficients O
between O
the O
reference O
methods O
and O
NIT O
were O
> O
or O
= O
0 O
. O
95 O
for O
water O
, O
fat O
, O
crude O
protein O
and O
connective O
- O
tissue O
- O
protein O
frei O
meat O
protein O
, O
and O
> O
or O
= O
0 O
. O
86 O
for O
connective O
- O
tissue O
- O
protein O
. O

The O
translation O
products O
of O
both O
clones O
are O
highly O
homologous O
to O
APS1 I-GENE
( O
66 O
and O
86 O
% O
identity O
, O
respectively O
) O
over O
their O
entire O
lengths O
, O
including O
amino O
terminal O
sequences O
resembling O
transit O
peptides O
for O
plastid O
localization O
. O

The O
serum O
levels O
of O
IgE I-GENE
, O
and O
asIgE I-GENE
and O
IgG I-GENE
- I-GENE
4 I-GENE
against O
14 O
common O
food O
allergens O
were O
determined O
. O

Two O
experiments O
investigating O
the O
effects O
of O
short O
- O
term O
spaceflight O
on O
cancellous O
bone O
turnover O
were O
carried O
out O
: O
Physiological O
Systems O
Experiment O
- O
1 O
( O
PSE O
- O
1 O
) O
( O
a O
4 O
- O
d O
orbital O
spaceflight O
) O
and O
PSE O
- O
2 O
( O
a O
10 O
- O
d O
flight O
). O

That O
sequence O
strongly O
promoted O
the O
transcription O
of O
the O
promotorless O
chloramphenicol I-GENE
acetyltranferase I-GENE
( O
CAT I-GENE
) O
gene O
in O
cells O
of O
pancreatic O
origin O
( O
AR O
- O
42J O
) O
but O
not O
in O
cells O
of O
non O
- O
pancreatic O
origin O
( O
Rat O
2 O
and O
IEC O
6 O
). O

Functional O
analysis O
of O
aryl I-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
translocator I-GENE
interactions O
with O
aryl I-GENE
hydrocarbon I-GENE
receptor I-GENE
in O
the O
yeast O
two O
- O
hybrid O
system O
. O

Histopathologic O
observations O
showed O
that O
both O
somatostatin I-GENE
and O
triamcinolone O
acetonide O
reduced O
the O
inflammatory O
signs O
in O
the O
joint O
structures O
, O
although O
triamcinolone O
acetonide O
appeared O
to O
be O
more O
effective O
. O

An O
approach O
to O
a O
biomathematical O
model O
of O
lymphocytopoiesis O
. O

The O
influenza O
virus O
NS1 I-GENE
protein O
is O
a O
unique O
posttranscriptional O
regulator O
that O
has O
two O
activities O
: O
inhibition O
of O
the O
nuclear O
export O
of O
poly O
A O
- O
containing O
mRNAs O
and O
inhibition O
of O
pre O
- O
mRNA O
splicing O
. O

These O
are O
two O
regions O
of O
known O
conserved O
synteny O
, O
providing O
further O
evidence O
that O
the O
human I-GENE
STEP I-GENE
is O
a O
true O
homolog O
of O
the O
murine I-GENE
STEP I-GENE
gene I-GENE
. O

Molecular O
cloning O
of O
the O
human O
homolog O
of O
a O
striatum I-GENE
- I-GENE
enriched I-GENE
phosphatase I-GENE
( I-GENE
STEP I-GENE
) I-GENE
gene I-GENE
and O
chromosomal O
mapping O
of O
the O
human O
and O
murine O
loci O
. O

Carbonic I-GENE
anhydrase I-GENE
V I-GENE
( O
CA I-GENE
V I-GENE
) O
is O
expressed O
in O
mitochondrial O
matrix O
in O
liver O
and O
several O
other O
tissues O
. O

Vitamin O
D3 O
plus O
nicotine O
treatment O
produced O
parallel O
increases O
in O
cardiac O
mass O
and O
elastic O
modulus O
, O
with O
a O
significant O
correlation O
between O
the O
two O
. O

The O
latter O
domain O
appears O
to O
be O
involved O
in O
targeting O
Num1p I-GENE
to O
the O
mother O
cell O
cortex O
. O

This O
finding O
is O
consistent O
with O
the O
notion O
that O
the O
dsRNA O
binding O
domains O
may O
be O
composed O
of O
two O
separate O
functional O
subdomains O
. O

Preferential O
heterodimeric O
parallel O
coiled O
- O
coil O
formation O
by O
synthetic I-GENE
Max I-GENE
and O
c I-GENE
- I-GENE
Myc I-GENE
leucine I-GENE
zippers I-GENE
: O
a O
description O
of O
putative O
electrostatic O
interactions O
responsible O
for O
the O
specificity O
of O
heterodimerization O
. O

Comparison O
to O
other O
coxI I-GENE
genes I-GENE
revealed O
a O
966 O
- O
bp O
group O
I O
intron O
, O
which O
, O
based O
on O
homology O
with O
the O
related O
yeast I-GENE
coxI I-GENE
intron I-GENE
aI4 I-GENE
, O
potentially O
encodes O
a O
279 O
- O
amino O
- O
acid O
site O
- O
specific O
DNA I-GENE
endonuclease I-GENE
. O

We O
studied O
the O
GR I-GENE
in O
DMS O
- O
79 O
cells O
derived O
from O
a O
human O
ACTH I-GENE
- O
secreting O
small O
cell O
lung O
cancer O
. O

This O
study O
analyzed O
whether O
the O
localization O
of O
an O
accessory O
pathway O
could O
be O
predicted O
by O
using O
the O
polarity O
of O
the O
QRS O
complex O
during O
sinus O
rhythm O
on O
the O
surface O
ECG O
, O
instead O
of O
the O
delta O
wave O
polarity O
as O
used O
in O
many O
reports O
. O

The O
promoter O
mutation O
is O
complemented O
in O
trans O
by O
E1A I-GENE
products O
of O
the O
heterologous O
helper O
adenovirus O
type O
5 O
( O
Ad5 O
). O

Thus O
, O
as O
expected O
, O
trans O
- O
splicing O
depends O
on O
the O
integrity O
of O
U2 I-GENE
, O
U4 I-GENE
, O
and O
U6 I-GENE
snRNAs I-GENE
. O

Treatment O
of O
PCC4 O
. O
aza1R O
cells O
with O
an O
RAR I-GENE
- O
selective O
agonist O
also O
repressed O
the O
expression O
of O
EC I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
while O
treatment O
with O
an O
RXR I-GENE
- O
selective O
agonist O
reduced O
EC I-GENE
- I-GENE
1 I-GENE
expression O
slightly O
. O

In O
the O
absence O
of O
E1A243 I-GENE
, O
YY1 I-GENE
represses O
CRE O
- O
dependent O
transcription O
of O
c I-GENE
- I-GENE
fos I-GENE
by O
physically O
interacting O
with O
ATF I-GENE
/ O
CREB I-GENE
proteins O
bound O
to O
the O
- O
67 O
CRE O
. O

Shift O
- O
down O
experiments O
indicated O
that O
the O
10 O
( O
4 O
)- O
to O
10 O
( O
5 O
)- O
fold O
reduction O
in O
virus O
yield O
at O
the O
nonpermissive O
temperature O
was O
due O
to O
the O
disfunction O
of O
alpha I-GENE
TIF I-GENE
late O
in O
infection O
, O
presumably O
in O
virion O
maturation O
. O

These O
results O
demonstrate O
that O
tip I-GENE
acts O
at O
an O
early O
stage O
of O
the O
T O
- O
cell O
signal O
transduction O
cascade O
by O
associating O
with O
Lck I-GENE
and O
downregulating O
Lck O
- O
mediated O
activation O
. O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
Vpr I-GENE
is O
a O
virion O
- O
associated O
, O
regulatory O
protein O
that O
is O
required O
for O
efficient O
viral O
replication O
in O
monocytes O
/ O
macrophages O
. O

Here O
we O
examine O
the O
potential O
for O
VP16 I-GENE
protein O
- O
protein O
interactions O
specific O
to O
virus O
- O
infected O
cells O
and O
show O
that O
VP16 I-GENE
copurifies O
in O
a O
highly O
enriched O
fraction O
with O
a O
single O
major O
polypeptide O
which O
we O
identify O
as O
the O
virus O
- O
encoded O
structural O
protein O
VP22 I-GENE
. O

Thus O
, O
transcriptional O
regulation O
, O
splicing O
, O
kinase O
interaction O
sites O
, O
and O
tyrosine O
phosphorylation O
of O
the O
LMP2A I-GENE
homologs I-GENE
have O
been O
conserved O
despite O
significant O
sequences O
heterogeneity O
in O
the O
preterminal O
repeat O
regions O
of O
these O
human O
and O
nonhuman O
primate O
EBVs O
. O

Results O
of O
the O
ECAT O
Angina O
Pectoris O
Study O
Group O
. O

Therefore O
, O
a O
prospective O
Phase O
II O
trial O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
cryosurgery O
following O
radiation O
therapy O
in O
men O
with O
local O
recurrence O
. O

These O
motifs O
include O
a O
Chi O
motif O
and O
a O
Chi O
- O
like O
element O
previously O
found O
in O
the O
recombination O
hotspot O
region O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
and O
close O
to O
chromosomal O
breakpoints O
in O
T O
- O
ALL O
lines O
. O

Common O
history O
and O
prospects O
in O
surgical O
gynecology O
of O
the O
Charite O
and O
the O
Vienna O
University O
Clinic O

In O
contrast O
with O
the O
previously O
reported O
HMGR1 I-GENE
mRNA I-GENE
( O
HMGR1S I-GENE
mRNA I-GENE
), O
which O
is O
detected O
at O
high O
levels O
in O
all O
tissues O
of O
the O
plant O
, O
HMGR1L I-GENE
mRNA I-GENE
is O
present O
at O
relatively O
low O
levels O
and O
its O
expression O
is O
restricted O
mostly O
to O
seedlings O
, O
roots O
and O
inflorescences O
. O

However O
, O
the O
requirement O
of O
rev3 I-GENE
for O
the O
production O
of O
G O
. O
C O
--> O
T O
. O
A O
transversions O
by O
the O
rad18 I-GENE
mutator I-GENE
, O
which O
induces O
only O
these O
substitutions O
, O
was O
similar O
to O
that O
for O
rad6 I-GENE
- O
mediated O
G O
. O
C O
--> O
T O
. O
A O
transversion O
. O

The O
second O
mutation O
present O
in O
the O
original O
mutant O
proved O
to O
be O
an O
allele O
of O
a O
known O
gene O
, O
PBS2 I-GENE
, O
which O
encodes O
a O
putative O
protein O
kinase O
that O
functions O
in O
the O
high O
osmolarity O
stress O
pathway O
. O

In O
adult O
tissues O
, O
it O
was O
less O
restricted O
, O
indicating O
that O
RAFTK I-GENE
expression O
is O
developmentally O
up O
- O
regulated O
. O

As O
hGM I-GENE
- I-GENE
CSF I-GENE
receptor I-GENE
( O
hGMR I-GENE
) O
does O
not O
contain O
a O
consensus O
sequence O
for O
binding O
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
hGMR I-GENE
must O
use O
a O
distinct O
mechanism O
for O
its O
association O
with O
and O
activation O
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

J O
. O

The O
identity O
between O
hnRNPs I-GENE
H I-GENE
and O
H I-GENE
' I-GENE
is O
96 O
%, O
between O
H I-GENE
and O
F I-GENE
78 O
%, O
and O
between O
H I-GENE
' I-GENE
and O
F I-GENE
75 O
%, O
respectively O
. O

TPBF I-GENE
has O
two O
potential O
coiled O
- O
coil O
regions O
, O
a O
basic O
region O
, O
a O
proline O
- O
rich O
region O
, O
a O
histidine O
- O
rich O
N O
terminus O
, O
and O
a O
nuclear O
targeting O
sequence O
. O

In O
the O
present O
study O
, O
we O
transiently O
expressed O
in O
primary O
cultures O
of O
rat O
hepatocytes O
plasmids O
consisting O
of O
CYP3A1 I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
sequences I-GENE
fused O
to O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
plasmid O
. O

We O
show O
that O
stimulation O
of O
resting O
splenic O
B O
cells O
with O
CD40L I-GENE
- O
expressing O
Sf9 O
cells O
induces O
germ O
- O
line O
gamma O
1 O
and O
epsilon O
transcripts O
independently O
of O
cytokines O
. O

To O
confirm O
the O
GapIII I-GENE
protein I-GENE
activity O
, O
constructs O
containing O
different O
GapIII I-GENE
- O
GRD I-GENE
domains O
were O
transformed O
into O
iral I-GENE
mutant O
yeast O
to O
determine O
their O
relative O
ability O
to O
replace O
IRA1 I-GENE
functionally O
. O

At O
the O
time O
of O
the O
13 O
latest O
BPVs O
, O
age O
ranged O
from O
three O
days O
to O
13 O
. O
1 O
years O
( O
mean O
5 O
. O
7 O
+/- O
SD O
4 O
. O
8 O
years O
). O

A O
tobacco O
homologue O
( O
trolC I-GENE
) O
of O
the O
rolC I-GENE
gene I-GENE
of I-GENE
the I-GENE
Agrobacterium I-GENE
rhizogenes I-GENE
Ri I-GENE
- I-GENE
plasmid I-GENE
was O
cloned O
and O
sequenced O
from O
Nicotiana O
tabacum O
L O
. O
cv O
. O

High O
ADR1 I-GENE
gene I-GENE
dosage O
increased O
the O
transcription O
of O
genes O
encoding O
peroxisomal O
proteins O
as O
compared O
to O
one O
copy O
of O
the O
ADR1 I-GENE
gene I-GENE
. O

A O
water O
- O
vapour O
giga O
- O
maser O
in O
the O
active O
galaxy O
TXFS2226 O
- O
184 O
. O

Of O
the O
three O
known O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
inhibitors O
, O
Ig I-GENE
/ I-GENE
EBP I-GENE
, O
LIP I-GENE
and O
CHOP I-GENE
- I-GENE
10 I-GENE
, O
only O
Ig I-GENE
/ I-GENE
EBP I-GENE
is O
ubiquitously O
expressed O
. O

The O
effects O
of O
a O
1 O
- O
or O
24 O
- O
hour O
pretreatment O
regimen O
with O
monophosphoryl O
lipid O
A O
( O
MLA O
, O
35 O
micrograms O
/ O
kg O
i O
. O
v O
.) O
on O
myocardial O
stunning O
produced O
by O
repetitive O
coronary O
occlusions O
were O
studied O
in O
barbital O
- O
anesthetized O
dogs O
. O

These O
incisors O
were O
studied O
by O
scanning O
electron O
microscopy O
- O
energy O
dispersive O
spectroscopy O
analysis O
( O
SEM O
- O
EDS O
) O
and O
light O
microscopy O
to O
examine O
the O
calciotraumatic O
lines O
of O
strontium O
in O
the O
rat O
incisor O
labial O
dentin O
. O

A O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
PDGF I-GENE
- I-GENE
R I-GENE
) O
phosphopeptide O
containing O
Tyr O
- O
857 O
does O
not O
bind O
appreciably O
to O
the O
Src I-GENE
SH2 I-GENE
domain I-GENE
, O
suggesting O
it O
is O
not O
the O
PDGF I-GENE
- I-GENE
R I-GENE
binding O
site O
for O
Src I-GENE
as O
previously O
reported O
. O

We O
have O
also O
tested O
Src I-GENE
SH2 I-GENE
mutants O
for O
their O
binding O
properties O
and O
have O
interpreted O
our O
results O
in O
light O
of O
the O
recent O
crystal O
structure O
solution O
for O
the O
Src I-GENE
SH2 I-GENE
domain O
. O

These O
observations O
link O
actin I-GENE
plaque O
assembly O
to O
increased O
cell O
substrate O
adhesion O
. O

The O
early O
lethality O
of O
the O
left O
- O
sided O
resectio O
was O
0 O
% O
and O
the O
postoperative O
survival O
-- O
5 O
- O
10 O
months O
. O

There O
are O
two O
immunogenic O
sites O
on O
the O
type O
A O
influenza O
A O
/ O
Japan O
/ O
57 O
( O
H2N2 O
) O
hemagglutinin I-GENE
( O
HA I-GENE
) O
that O
can O
be O
recognized O
by O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
), O
H I-GENE
- I-GENE
2Kd I-GENE
- O
restricted O
cytolytic O
T O
lymphocytes O
( O
CTLs O
). O

This O
enhancer O
activates O
both O
the O
K19 I-GENE
and O
TK I-GENE
basal I-GENE
promoters I-GENE
in O
HeLa O
cells O
. O

Mechanism O
of O
enhancement O
of O
DNA O
expression O
consequent O
to O
cointernalization O
of O
a O
replication O
- O
deficient O
adenovirus O
and O
unmodified O
plasmid O
DNA O
. O

Interestingly O
, O
one O
IRF I-GENE
binding I-GENE
site I-GENE
was O
found O
within O
the O
IRF I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
, O
and O
expression O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
gene I-GENE
was O
affected O
by O
both O
transient O
and O
stable O
IRF I-GENE
- I-GENE
1 I-GENE
expression O
. O

Therefore O
, O
we O
studied O
ninety O
coagulopathic O
patients O
with O
the O
aim O
of O
determining O
the O
prevalence O
of O
hepatitis I-GENE
C I-GENE
virus I-GENE
( I-GENE
HCV I-GENE
) I-GENE
antibodies I-GENE
using O
the O
ELISA O
and O
RIBA O
methods O
. O

The O
highest O
decrease O
in O
mutagenic O
activity O
was O
observed O
when O
enzymatic O
bleaching O
was O
used O
together O
with O
chlorine O
. O

Hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
was O
detected O
in O
2 O
patients O
, O
with O
negative O
hepatitis I-GENE
C I-GENE
virus I-GENE
antibody I-GENE
. O

There O
was O
also O
a O
highly O
significant O
correlation O
between O
total O
selenium O
intake O
and O
liver O
selenium O
concentration O
( O
r O
= O
0 O
. O
99 O
, O
p O
< O
0 O
. O
01 O
) O
after O
1 O
mo O
of O
treatment O
, O
but O
this O
time O
liver O
selenium O
did O
not O
change O
with O
time O
, O
and O
the O
correlation O
remained O
highly O
significant O
throughout O
the O
investigation O
. O

Antibodies O
affinity O
- O
purified O
using O
the O
bacterially O
expressed O
recombinant O
protein O
recognized O
the O
56K I-GENE
autoantigen I-GENE
in O
a O
HeLa O
cell O
extract O
. O
cDNA O
sequencing O
revealed O
that O
the O
56K I-GENE
cDNA I-GENE
shares O
a O
high O
degree O
of O
homology O
in O
both O
nucleotide O
( O
87 O
%) O
and O
amino O
acid O
sequence O
( O
92 O
. O
5 O
%) O
with O
bovine I-GENE
annexin I-GENE
XI I-GENE
, O
indicating O
that O
the O
56K I-GENE
cDNA I-GENE
encodes O
the O
human I-GENE
homologue I-GENE
of I-GENE
annexin I-GENE
XI I-GENE
, O
a O
member O
of O
the O
Ca I-GENE
( I-GENE
2 I-GENE
+)- I-GENE
dependent I-GENE
phospholipid I-GENE
binding I-GENE
protein I-GENE
family I-GENE
. O

The O
avidin I-GENE
- I-GENE
biotin I-GENE
complex I-GENE
peroxidase I-GENE
( O
ABC I-GENE
- I-GENE
P I-GENE
) O
method O
was O
used O
to O
detect O
Mycobacterium O
bovis O
, O
and O
the O
results O
were O
compared O
with O
those O
obtained O
by O
the O
Ziehl O
- O
Neelsen O
( O
ZN O
) O
technique O
. O

Its O
role O
in O
these O
processes O
suggests O
that O
the O
function O
of O
c I-GENE
- I-GENE
Myb I-GENE
may O
be O
important O
early O
in O
the O
establishment O
of O
the O
hematopoietic O
lineage O
. O

The O
transforming O
gene O
of O
the O
avian I-GENE
sarcoma I-GENE
virus I-GENE
CT10 I-GENE
encodes O
a O
fusion O
protein O
( O
p47gag I-GENE
- O
crk I-GENE
or O
v I-GENE
- I-GENE
Crk I-GENE
) O
containing O
viral I-GENE
Gag I-GENE
sequences I-GENE
fused O
to O
cellular O
sequences O
consisting O
primarily O
of O
Src I-GENE
homology I-GENE
regions I-GENE
2 I-GENE
and I-GENE
3 I-GENE
( O
SH2 I-GENE
and O
SH3 I-GENE
sequences I-GENE
). O

This O
specific O
methylation O
pattern O
caused O
inactivation O
of O
the O
HSV I-GENE
tk I-GENE
gene I-GENE
, O
while O
methylation O
of O
the O
cytosine O
residues O
within O
the O
nucleotide O
sequence O
from O
+ O
811 O
to O
+ O
1309 O
had O
no O
effect O
on O
HSV I-GENE
tk I-GENE
gene I-GENE
activity O
. O

CONCLUSION O
: O
This O
study O
documents O
that O
regression O
of O
choroidal O
neovascularization O
that O
occurred O
with O
alpha I-GENE
interferon I-GENE
treatment O
was O
minimal O
. O

Long O
- O
range O
mapping O
of O
the O
11q23 O
region O
involved O
in O
chromosome O
aberrations O
in O
human O
tumors O
by O
pulsed O
- O
field O
gel O
electrophoresis O
with O
a O
yeast O
artificial O
chromosome O
. O

GTRE O
, O
TRE O
, O
and O
CRE O
oligonucleotides O
all O
compete O
more O
efficiently O
for O
protein O
binding O
to O
their O
labeled O
congeners O
than O
for O
protein O
binding O
to O
either O
of O
the O
other O
labeled O
oligonucleotides O
, O
suggesting O
that O
the O
GTRE O
, O
TRE O
, O
and O
CRE O
oligonucleotides O
, O
suggesting O
that O
the O
GTRE O
, O
TRE O
, O
and O
CRE O
oligonucleotides O
each O
bind O
unique O
as O
well O
as O
common O
proteins O
, O
likely O
to O
be O
members O
of O
the O
Jun I-GENE
/ O
Fos I-GENE
and O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
/ O
activating I-GENE
transcription I-GENE
factors I-GENE
( O
CREB I-GENE
/ O
ATF I-GENE
) O
families O
of O
transcription O
factors O
, O
in O
chromaffin O
cells O
. O

One O
patient O
only O
had O
any O
test O
abnormalities O
. O

One O
antibody O
, O
mAb1C2 I-GENE
, O
and O
a O
synthetic O
peptide O
comprising O
its O
epitope O
selectively O
inhibited O
in O
vitro O
transcription O
from O
TATA O
- O
containing O
, O
but O
not O
from O
TATA O
- O
less O
promoters O
, O
irrespective O
of O
whether O
they O
were O
transcribed O
by O
Pol I-GENE
II I-GENE
or O
Pol I-GENE
III I-GENE
. O

The O
lymph O
nodes O
from O
two O
of O
the O
patients O
with O
rheumatoid O
arthritis O
contained O
numerous O
sarcoid O
like O
granulomata O
, O
further O
indicating O
a O
possible O
association O
between O
sarcoidosis O
and O
rheumatoid O
arthritis O
. O

HCV O
infection O
acquired O
during O
or O
after O
BMT O
caused O
only O
mild O
acute O
hepatitis O
C O
, O
which O
progressed O
to O
chronic O
hepatitis O
C O
in O
one O
patient O
surviving O
10 O
years O
after O
BMT O
. O

Hepatitis O
C O
virus O
infection O
is O
a O
risk O
factor O
for O
liver O
failure O
from O
veno O
- O
occlusive O
disease O
after O
bone O
marrow O
transplantation O
. O

High O
plasma O
concentrations O
of O
soluble O
E I-GENE
- I-GENE
selectin I-GENE
were O
closely O
associated O
with O
multiple O
- O
organ O
dysfunction O
and O
death O
. O

These O
human O
IFN I-GENE
- I-GENE
beta I-GENE
- O
transformed O
cell O
populations O
have O
acquired O
a O
low O
, O
constitutive O
production O
of O
human I-GENE
IFN I-GENE
, O
while O
replicating O
at O
a O
rate O
similar O
to O
that O
of O
untransformed O
cells O
and O
of O
cells O
transformed O
with O
the O
control O
vector O
carrying O
a O
human I-GENE
IFN I-GENE
- I-GENE
beta I-GENE
sequence I-GENE
encoding O
an O
inactive O
, O
mutated O
protein O
. O

Improvement O
of O
the O
polypyrimidine O
tract O
also O
increased O
the O
splicing O
efficiency O
, O
but O
to O
a O
degree O
slightly O
less O
than O
that O
obtained O
with O
the O
branchpoint O
mutation O
. O

Liver O
transplantation O
in O
one O
patient O
resolved O
metabolic O
complications O
but O
did O
not O
improve O
PMN O
count O
or O
the O
infectious O
status O
, O
while O
neutropenia O
was O
corrected O
by O
G I-GENE
- I-GENE
CSF I-GENE
. O

Joys O
and O
F O
. O

Activation O
of O
the O
SH2 I-GENE
- I-GENE
containing I-GENE
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
SH I-GENE
- I-GENE
PTP2 I-GENE
, O
by O
phosphotyrosine O
- O
containing O
peptides O
derived O
from O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
. O

Tyrosine O
phosphorylation O
of O
cellular O
proteins O
is O
the O
earliest O
identifiable O
event O
following O
T I-GENE
- I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
TCR I-GENE
) O
stimulation O
and O
is O
essential O
for O
activating O
downstream O
signaling O
machinery O
. O

The O
interferon I-GENE
- O
induced O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
is O
considered O
to O
play O
an O
important O
role O
in O
the O
cellular O
defense O
against O
viral O
infection O
and O
, O
in O
addition O
, O
has O
been O
suggested O
to O
be O
a O
tumor O
suppressor O
gene O
because O
of O
its O
growth O
- O
suppressive O
properties O
. O

Moreover O
, O
Lck I-GENE
was O
reversibly O
co O
- O
immunoprecipitated O
with O
p95Vav I-GENE
, O
and O
the O
stoichiometry O
of O
binding O
increased O
in O
anti I-GENE
- I-GENE
CD3 I-GENE
- O
treated O
Jurkat O
cells O
. O

In O
contrast O
, O
injection O
of O
a O
plasmid O
encoding O
simian I-GENE
virus I-GENE
40 I-GENE
small I-GENE
t I-GENE
antigen I-GENE
, O
which O
interacts O
with O
PP2A I-GENE
to O
inhibit O
its O
activity O
towards O
several O
phosphoprotein O
substrates O
, O
had O
no O
effect O
on O
the O
phosphorylation O
state O
of O
CREB I-GENE
in O
stimulated O
or O
unstimulated O
NIH O
3T3 O
cells O
. O

Several O
Src I-GENE
SH3 I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
were O
phosphorylated O
in O
Src I-GENE
- O
transformed O
cells O
. O

We O
also O
examined O
the O
effect O
of O
proteolytic O
processing O
in O
the O
MVE O
nonstructural O
polyprotein O
segment O
mediated O
by O
the O
viral I-GENE
proteinase I-GENE
NS3 I-GENE
on O
antigen O
processing O
and O
presentation O
of O
the O
MVE O
H O
- O
2Kk O
- O
restricted O
T O
cell O
determinant O
. O

A O
full I-GENE
- I-GENE
length I-GENE
PRL I-GENE
receptor I-GENE
( O
PRLR I-GENE
) O
complementary O
DNA O
from O
pigeons O
was O
obtained O
by O
screening O
pigeon O
crop O
sac O
libraries O
and O
by O
reverse O
transcription O
coupled O
with O
polymerase O
chain O
reaction O
. O

After O
7 O
days O
, O
a O
spontaneous O
regression O
of O
the O
morphologic O
alterations O
caused O
by O
caerulein O
- O
induced O
acute O
pancreatitis O
occurs O
; O
however O
, O
recovery O
of O
the O
secretory O
function O
of O
the O
pancreas O
was O
only O
reached O
after O
this O
period O
of O
time O
when O
L O
- O
364 O
, O
718 O
was O
administered O
therapeutically O
( O
0 O
. O
1 O
mg O
/ O
kg O
/ O
day O
). O

We O
observed O
that O
dephosphorylation O
severely O
inhibits O
the O
DNA O
- O
binding O
ability O
of O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
delta I-GENE
and O
its O
transactivating O
potential O
increases O
in O
the O
presence O
of O
cellular O
phosphatase O
inhibitors O
, O
such O
as O
okadaic O
acid O
and O
sodium O
orthovanadate O
. O

Two O
promoters O
were O
identified O
by O
S1 I-GENE
nuclease I-GENE
mapping O
: O
P1 O
, O
which O
lies O
about O
72 O
bp O
upstream O
from O
the O
structural O
gene O
; O
and O
P2 O
, O
which O
lies O
about O
35 O
bp O
upstream O
. O

Interleukin I-GENE
- I-GENE
8 I-GENE
( O
IL I-GENE
- I-GENE
8 I-GENE
) O
is O
a O
potent O
inflammatory O
mediator O
that O
belongs O
to O
the O
family O
of O
C I-GENE
- I-GENE
X I-GENE
- I-GENE
C I-GENE
chemokines I-GENE
. O

On O
the O
other O
hand O
, O
cells O
containing O
a O
PTP1C I-GENE
in O
which O
the O
catalytic O
site O
had O
been O
inactivated O
through O
mutagenesis O
, O
stably O
phosphorylated O
the O
phosphatase O
. O

We O
recently O
found O
that O
the O
p72syk I-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
is O
physically O
associated O
with O
the O
TCR I-GENE
/ O
CD3 I-GENE
complex O
and O
is O
rapidly O
tyrosine O
phosphorylated O
and O
activated O
by O
receptor O
triggering O
also O
in O
T O
cells O
lacking O
p56lck I-GENE
. O

The O
transforming O
protein O
of O
Rous O
sarcoma O
virus O
, O
pp60v I-GENE
- I-GENE
src I-GENE
, O
and O
its O
normal O
cellular O
homolog O
, O
pp60c I-GENE
- I-GENE
src I-GENE
, O
differ O
not O
only O
in O
oncogenic O
potential O
but O
also O
in O
their O
subcellular O
localization O
and O
cytoskeletal O
binding O
ability O
. O
pp60v I-GENE
- I-GENE
src I-GENE
has O
been O
shown O
to O
stably O
associate O
with O
a O
detergent O
- O
insoluble O
cytoskeletal O
matrix O
, O
whereas O
pp60c I-GENE
- I-GENE
src I-GENE
does O
not O
. O

Organization O
of O
the O
bovine O
gene O
encoding O
the O
endothelial I-GENE
nitric I-GENE
oxide I-GENE
synthase I-GENE
. O

We O
determined O
whether O
regional O
myocardial O
work O
efficiency O
( O
segment O
work O
/ O
regional O
O2 O
consumption O
) O
would O
be O
elevated O
by O
surgically O
- O
augmented O
inflow O
. O

In O
female O
Sl I-GENE
( I-GENE
pan I-GENE
)/ I-GENE
Sl I-GENE
( I-GENE
pan I-GENE
) I-GENE
mice O
, O
ovarian O
follicle O
development O
is O
arrested O
at O
the O
one O
layered O
cuboidal O
stage O
as O
a O
result O
of O
reduced O
KL I-GENE
expression O
in O
follicle O
cells O
, O
indicating O
a O
role O
for O
c I-GENE
- I-GENE
kit I-GENE
in O
oocyte O
growth O
. O

Anti I-GENE
- I-GENE
NPROSP I-GENE
- I-GENE
C I-GENE
also O
exclusively O
detected O
time O
- O
dependent O
appearances O
of O
5 I-GENE
- I-GENE
10 I-GENE
- I-GENE
kDa I-GENE
proSP I-GENE
- I-GENE
C I-GENE
forms O
in O
lamellar O
bodies O
and O
homogenates O
. O

In O
the O
B6 O
- O
derived O
Db I-GENE
mutant I-GENE
B6 I-GENE
. I-GENE
CH I-GENE
- I-GENE
2bm13 I-GENE
( I-GENE
bm13 I-GENE
) I-GENE
strain O
, O
part O
of O
the O
class I-GENE
I I-GENE
Db I-GENE
antigen I-GENE
- I-GENE
presenting I-GENE
groove I-GENE
is O
shaped O
by O
a O
class I-GENE
I I-GENE
Kb I-GENE
- I-GENE
encoded I-GENE
sequence I-GENE
. O

Three O
mutants O
( O
pms1 I-GENE
, O
pms2 I-GENE
and O
pms3 I-GENE
) O
isolated O
earlier O
from O
MW104 O
- O
1B O
were O
shown O
to O
correct O
in O
vitro O
constructed O
plasmids O
with O
defined O
DNA O
mismatches O
( O
G O
/ O
T O
, O
A O
/ O
C O
, O
G O
/ O
G O
, O
etc O
.) O
poorly O
( O
Kramer O
et O
al O
., O
1989a O
). O

Our O
findings O
confirm O
the O
high O
frequency O
of O
proximal O
nerve O
lesions O
in O
early O
GBS O
and O
CIDP O
, O
not O
all O
of O
which O
are O
associated O
with O
distal O
motor O
conduction O
abnormalities O
, O
and O
suggest O
that O
assessment O
of O
multiple O
F O
wave O
parameters O
, O
in O
particular O
chronodispersion O
, O
mean O
latency O
and O
mean O
amplitude O
( O
in O
addition O
to O
absence O
and O
minimum O
latency O
), O
increases O
the O
yield O
of O
F O
wave O
studies O
. O

Hematopoietic I-GENE
growth I-GENE
factors I-GENE
are O
being O
used O
to O
accelerate O
the O
recovery O
of O
myelopoiesis O
following O
high O
- O
dose O
chemotherapy O
in O
cancer O
patients O
. O

Effects O
of O
alterations O
of O
primer O
- O
binding O
site O
sequences O
on O
human O
immunodeficiency O
virus O
type O
1 O
replication O
. O

Presentation O
of O
a O
horse I-GENE
cytochrome I-GENE
c I-GENE
peptide I-GENE
by O
multiple O
H I-GENE
- I-GENE
2b I-GENE
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
) O
molecules O
to O
C57BL O
/ O
6 O
- O
and O
bm1 O
- O
derived O
cytotoxic O
T O
lymphocytes O
: O
presence O
of O
a O
single O
MHC I-GENE
anchor I-GENE
residue I-GENE
may O
confer O
efficient O
peptide O
- O
specific O
CTL O
recognition O
. O

A O
particularly O
striking O
HpaII I-GENE
tiny O
fragment O
island O
, O
extending O
over O
nearly O
2 O
, O
000 O
base O
pairs O
, O
surrounds O
the O
USF2 I-GENE
translation I-GENE
initiation I-GENE
site I-GENE
. O

Diagnosis O
of O
prostatic O
carcinoma O
: O
the O
yield O
of O
serum I-GENE
prostate I-GENE
specific I-GENE
antigen I-GENE
, O
digital O
rectal O
examination O
and O
transrectal O
ultrasonography O
. O

Increased O
granulocyte I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
G I-GENE
- I-GENE
CSF I-GENE
) O
levels O
in O
neonates O
with O
perinatal O
complications O
. O

The O
results O
revealed O
a O
hierarchy O
of O
ligand O
affinities O
that O
mirrored O
their O
adhesive O
activity O
( O
rsVCAM I-GENE
- I-GENE
1 I-GENE
> O
fibronectin I-GENE
variants I-GENE
containing O
CS1 I-GENE
>> O
other O
fibronectin I-GENE
variants I-GENE
). O

When O
expressed O
in O
and O
purified O
from O
Escherichia O
coli O
, O
both O
full I-GENE
- I-GENE
length I-GENE
Fpr3 I-GENE
and O
its O
isolated O
COOH O
- O
terminal O
domain O
exhibit O
readily O
detectable O
PPIase I-GENE
activity O
. O

Dilutions O
of O
H I-GENE
- I-GENE
2b I-GENE
or I-GENE
H I-GENE
- I-GENE
2d I-GENE
NP I-GENE
peptides I-GENE
indicated O
that O
3 O
- O
4 O
logs O
less O
H I-GENE
- I-GENE
2b I-GENE
NP I-GENE
peptide I-GENE
was O
required O
to O
sensitize O
syngeneic O
target O
cells O
for O
CTL O
- O
specific O
lysis O
, O
suggesting O
that O
the O
differing O
affinities O
of O
H O
- O
2b O
and O
H O
- O
2d O
major I-GENE
histocompatibility I-GENE
complex I-GENE
molecules I-GENE
for O
their O
peptides O
likely O
account O
for O
the O
total O
removal O
of O
NP O
CTL O
in O
the O
H O
- O
2b O
mice O
but O
only O
partial O
removal O
in O
H O
- O
2d O
mice O
made O
to O
express O
thymic O
NP O
. O

However O
, O
expression O
of O
sigma I-GENE
3 I-GENE
from O
S4 I-GENE
( O
3 I-GENE
' I-GENE
UTR I-GENE
/ I-GENE
S1 I-GENE
), O
which O
included O
the O
PKR I-GENE
activator I-GENE
sequence I-GENE
from O
S1 I-GENE
within O
the O
3 I-GENE
'- I-GENE
UTR I-GENE
of I-GENE
S4 I-GENE
, O
was O
comparable O
to O
that O
from O
wild I-GENE
- I-GENE
type I-GENE
S4 I-GENE
. O

Microvessels O
were O
counted O
in O
a O
x200 O
field O
( O
0 O
. O
754 O
mm2 O
) O
in O
the O
area O
of O
maximal O
angiogenesis O
. O

Although O
both O
transfected O
cell O
lines O
contain O
FGF I-GENE
- I-GENE
1 I-GENE
cell I-GENE
surface I-GENE
receptors I-GENE
as O
judged O
by O
crosslinking O
studies O
, O
the O
wild O
- O
type O
transfectants O
are O
refractory O
to O
exogenous O
FGF I-GENE
- I-GENE
1 I-GENE
, O
whereas O
the O
mutant O
transfectants O
respond O
normally O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Recent O
studies O
have O
demonstrated O
that O
the O
activated O
GH I-GENE
receptor I-GENE
can O
stimulate O
Stat1 I-GENE
, O
a O
cytoplasmic O
transcription O
factor O
that O
becomes O
tyrosine O
phosphorylated O
and O
translocates O
to O
the O
nucleus O
, O
where O
it O
can O
interact O
with O
specific O
DNA O
sequences O
to O
modulate O
gene O
expression O
. O

In O
viral O
infections O
, O
G I-GENE
- I-GENE
CSF I-GENE
was O
correlated O
with O
mononuclear O
cells O
( O
rs O
= O
0 O
. O
41 O
, O
P O
< O
0 O
. O
05 O
), O
white O
blood O
cell O
counts O
( O
rs O
= O
0 O
. O
56 O
, O
P O
< O
0 O
. O
01 O
), O
neutrophils O
( O
rs O
= O
0 O
. O
41 O
, O
P O
< O
0 O
. O
05 O
) O
and O
CRP I-GENE
( O
rs O
= O
0 O
. O
47 O
, O
P O
< O
0 O
. O
05 O
). O

Minor O
initiation O
sites O
were O
found O
at O
positions O
- O
128 O
, O
- O
111 O
, O
- O
91 O
, O
and O
- O
74 O
. O

Phosphoamino O
acid O
analysis O
of O
radiolabeled O
ASGPR I-GENE
subunits I-GENE
identified O
Ser O
( O
P O
) O
as O
the O
predominant O
( O
approximately O
95 O
%) O
and O
Thr O
( O
P O
) O
as O
a O
minor O
( O
approximately O
5 O
%) O
phosphoamino O
acid O
in O
each O
polypeptide O
and O
confirmed O
the O
presence O
of O
Tyr O
( O
P O
) O
( O
approximately O
1 O
%) O
in O
RHL1 I-GENE
. O

To O
further O
define O
the O
structural O
requirements O
for O
ZAP I-GENE
- I-GENE
70 I-GENE
interaction O
with O
the O
TCR I-GENE
, O
we O
developed O
a O
binding O
assay O
using O
immobilized O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
proteins I-GENE
containing O
the O
NH2 O
- O
and O
/ O
or O
COOH I-GENE
- I-GENE
terminal I-GENE
SH2 I-GENE
domains I-GENE
of O
ZAP I-GENE
- I-GENE
70 I-GENE
, O
and O
soluble O
synthetic O
peptides O
with O
the O
sequence O
of O
the O
cytoplasmic O
region O
of O
the O
TCR I-GENE
zeta I-GENE
chain I-GENE
( O
TCR I-GENE
zeta I-GENE
cyt I-GENE
) O
or O
individual O
TCR I-GENE
zeta I-GENE
and O
CD3 I-GENE
epsilon I-GENE
TAM I-GENE
motifs I-GENE
. O

All O
four O
doubly O
tyrosine O
phosphorylated O
TAM O
peptides O
cross O
- O
compete O
with O
each O
other O
for O
binding O
to O
the O
tandem O
SH2 I-GENE
domains I-GENE
of O
ZAP I-GENE
- I-GENE
70 I-GENE
. O

The O
three O
- O
dimensional O
structure O
of O
RT I-GENE
shows O
that O
it O
is O
a O
strikingly O
asymmetric O
heterodimer O
consisting O
of O
two O
differently O
folded O
subunits O
( O
molecular O
weights O
66 O
kDa O
and O
51 O
kDa O
) O
with O
identical O
amino O
- O
terminal O
amino O
acid O
sequences O
( O
residues O
1 O
- O
428 O
). O

Pharmacological O
and O
pharmacokinetic O
characteristics O
of O
the O
non O
- O
ionic O
monomeric O
X O
- O
ray O
contrast O
agent O
iopromide O
( O
Ultravist O
, O
CAS O
73334 O
- O
07 O
- O
3 O
) O
were O
evaluated O
in O
preclinical O
studies O
. O

All O
subsequent O
patients O
were O
treated O
at O
the O
maximal O
tolerated O
dose O
of O
EDXR O
( O
35 O
mg O
/ O
m2 O
/ O
day O
). O

The O
median O
post O
- O
treatment O
, O
pre O
- O
operative O
serum I-GENE
PSA I-GENE
was O
0 O
. O
4 O
ng O
/ O
ml O
. O

Addition O
of O
soluble O
recombinant I-GENE
human I-GENE
SLF I-GENE
to O
SI4 O
- O
h220 O
cultures O
enhanced O
reduction O
of O
cell O
- O
surface O
c I-GENE
- I-GENE
kit I-GENE
expression O
and O
its O
protein O
degradation O
. O

Membrane O
- O
bound O
Steel I-GENE
factor I-GENE
induces O
more O
persistent O
tyrosine I-GENE
kinase I-GENE
activation O
and O
longer O
life O
span O
of O
c I-GENE
- I-GENE
kit I-GENE
gene O
- O
encoded O
protein O
than O
its O
soluble O
form O
. O

Analysis O
of O
the O
sequences O
with O
the O
BLAST O
and O
GRAIL O
programs O
provided O
additional O
independent O
evidence O
that O
15 O
of O
these O
17 O
clones O
contain O
coding O
sequences O
and O
that O
nine O
other O
clones O
are O
likely O
to O
contain O
sequences O
coding O
for O
portions O
of O
new O
genes O
. O

Patients O
with O
more O
than O
250 O
PVC O
/ O
24 O
hours O
were O
selected O
for O
distribution O
of O
PVC O
and O
CI O
evaluation O
. O

Horvath O
, O
I O
. O

Cell O
lines O
derived O
from O
the O
tumors O
were O
examined O
by O
fluorescent O
in O
situ O
hybridization O
for O
the O
status O
of O
the O
transferred O
human O
chromosome O
and O
by O
PCR O
for O
marker O
loss O
. O

The O
amino O
acid O
sequences O
of O
the O
predicted O
RfbA I-GENE
and O
RfbB I-GENE
homologs I-GENE
showed O
identities O
of O
75 O
. O
7 O
% O
( O
87 O
. O
9 O
% O
total O
similarity O
) O
and O
78 O
. O
0 O
% O
( O
86 O
. O
5 O
% O
total O
similarity O
), O
respectively O
. O

However O
, O
multiple O
alanine O
substitutions O
or O
proline O
( O
helix O
- O
destabilizing O
) O
substitutions O
disrupted O
both O
oligomerization O
and O
transport O
of O
GP64 I-GENE
EFP I-GENE
. O

The O
FinO I-GENE
protein I-GENE
of O
IncF O
plasmids O
binds O
FinP I-GENE
antisense I-GENE
RNA I-GENE
and O
its O
target O
, O
traJ I-GENE
mRNA I-GENE
, O
and O
promotes O
duplex O
formation O
. O

In O
this O
paper O
we O
report O
that O
ligand O
binding O
induced O
tyrosine O
phosphorylation O
in O
BaF3 O
cells O
engineered O
to O
express O
the O
murine I-GENE
Mpl I-GENE
receptor I-GENE
( O
BaF3 O
/ O
mMpl I-GENE
). O

A O
chicken I-GENE
paxillin I-GENE
cDNA I-GENE
was O
also O
cloned O
and O
is O
predicted O
to O
encode O
a O
protein O
approximately O
90 O
% O
identical O
to O
human I-GENE
paxil I-GENE
- I-GENE
lin I-GENE
. O

We O
linked O
a O
4 O
. O
1 O
- O
kilobase O
pair O
HindIII I-GENE
DNA I-GENE
fragment I-GENE
from O
the O
region O
upstream O
of O
the O
human I-GENE
AP I-GENE
endonuclease I-GENE
gene I-GENE
( O
APE I-GENE
) O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
. O

The O
overexpressed O
His6 I-GENE
- I-GENE
tagged I-GENE
GrsA I-GENE
derivatives I-GENE
were O
affinity O
- O
purified O
, O
and O
the O
catalytic O
properties O
of O
the O
deletion O
mutants O
were O
examined O
by O
biochemical O
studies O
including O
ATP O
- O
dependent O
amino O
acid O
activation O
, O
carboxyl O
thioester O
formation O
, O
and O
the O
ability O
to O
racemize O
the O
covalently O
bound O
phenylalanine O
from O
L O
- O
to O
the O
D O
- O
isomer O
. O

CD7 I-GENE
+/ O
CD3 I-GENE
- O
T O
- O
cell O
precursors O
exhibit O
V I-GENE
delta I-GENE
2D I-GENE
delta I-GENE
3 I-GENE
rearrangements I-GENE
. O

HVH2 I-GENE
mRNA I-GENE
showed O
an O
expression O
pattern O
distinct O
from O
CL100 I-GENE
( O
human I-GENE
homologue I-GENE
of I-GENE
mouse I-GENE
MKP1 I-GENE
) O
and O
PAC1 I-GENE
, O
two O
previously O
identified O
MAP I-GENE
kinase I-GENE
phosphatases I-GENE
. O

These O
data O
suggest O
that O
these O
sequences O
located O
immediately O
3 O
' O
to O
the O
breakpoint O
of O
the O
HPFH I-GENE
- I-GENE
3 I-GENE
deletion I-GENE
, O
exhibit O
both O
the O
structure O
and O
the O
function O
of O
an O
enhancer O
, O
and O
can O
modify O
the O
developmental O
specificity O
of O
the O
fetal I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
genes I-GENE
, O
resulting O
in O
their O
continued O
expression O
during O
adult O
life O
. O

In O
vivo O
association O
between O
Shb I-GENE
- O
SH3 I-GENE
domain O
proteins O
v I-GENE
- I-GENE
Src I-GENE
and O
Eps8 I-GENE
was O
detected O
by O
coimmunoprecipitation O
. O

Our O
results O
indicate O
that O
interaction O
between O
Jak2 I-GENE
and O
PRLR I-GENE
requires O
a O
proline O
- O
rich O
sequence O
in O
the O
membrane O
proximal O
region O
of O
the O
receptor O
, O
which O
is O
conserved O
among O
the O
different O
members O
of O
the O
cytokine I-GENE
receptor I-GENE
superfamily I-GENE
. O

Transcription O
of O
the O
vascular I-GENE
cell I-GENE
adhesion I-GENE
molecule I-GENE
1 I-GENE
( O
VCAM I-GENE
- I-GENE
1 I-GENE
) O
gene O
in O
endothelial O
cells O
is O
induced O
by O
lipopolysaccharide O
and O
the O
inflammatory O
cytokines I-GENE
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
). O

Experiments O
with O
recombinant O
proteins O
showed O
that O
p50 I-GENE
/ O
p65 I-GENE
and O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
cooperatively O
facilitated O
the O
binding O
of O
IRF I-GENE
- I-GENE
1 I-GENE
to O
the O
VCAM1 I-GENE
IRF I-GENE
binding I-GENE
site I-GENE
and O
that O
IRF I-GENE
- I-GENE
1 I-GENE
physically O
interacted O
with O
p50 I-GENE
and O
with O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
protein I-GENE
. O

Based O
on O
these O
results O
the O
minimal O
control O
element O
( O
AX O
470 O
) O
specifying O
the O
anterior O
boundary O
of O
Hox I-GENE
expression O
was O
designated O
as O
Hoxa I-GENE
- I-GENE
7 I-GENE
enhancer I-GENE
. O

In O
this O
report O
we O
describe O
the O
isolation O
of O
a O
Fab I-GENE
fragment I-GENE
( O
Fab I-GENE
A8 I-GENE
) O
showing O
a O
high O
relative O
affinity O
for O
the O
receptor O
( O
0 O
. O
5 O
nM O
). O

MBP I-GENE
- O
Rep68 I-GENE
delta I-GENE
- O
mediated O
DNA O
- O
RNA O
helicase O
activity O
required O
ATP O
hydrolysis O
and O
the O
presence O
of O
Mg2 O
+ O
ions O
and O
was O
inhibited O
by O
high O
ionic O
strength O
. O

To O
identify O
critical O
regions O
mediating O
growth O
signal O
transduction O
by O
hG I-GENE
- I-GENE
CSFR I-GENE
, O
deletions O
or O
site O
- O
directed O
amino O
acid O
substitutions O
were O
introduced O
into O
the O
cytoplasmic O
domain O
of O
hG I-GENE
- I-GENE
CSFR I-GENE
, O
and O
the O
mutant O
cDNAs O
were O
transfected O
into O
the O
murine I-GENE
interleukin I-GENE
- I-GENE
3 I-GENE
( O
IL I-GENE
- I-GENE
3 I-GENE
)- O
dependent O
Ba O
/ O
F3 O
and O
FDCP O
cell O
lines O
. O

When O
combined O
with O
independent O
activating O
mutations O
in O
the O
c I-GENE
- I-GENE
abl I-GENE
kinase I-GENE
domain I-GENE
or O
NH2 O
- O
terminus O
, O
the O
G128R I-GENE
mutation O
blocked O
transformation O
by O
the O
double O
mutant O
, O
suggesting O
that O
the O
G128R I-GENE
mutant I-GENE
was O
unable O
to O
transform O
cells O
for O
trivial O
reasons O
. O

Both O
mutations O
completely O
abolished O
binding O
of O
the O
Abl I-GENE
SH3 I-GENE
domain O
to O
proline O
- O
rich O
target O
proteins O
in O
a O
filter O
- O
binding O
assay O
. O

Changes O
induced O
in O
the O
gills O
of O
milkfish O
( O
Chanos O
chanos O
Forsskal O
) O
fingerlings O
after O
acute O
exposure O
to O
nifurpirinol O
( O
Furanace O
; O
P O
- O
7138 O
). O

Retreatment O
of O
these O
2 O
dogs O
resulted O
in O
a O
similar O
, O
but O
blunted O
, O
response O
to O
human I-GENE
immunoglobulin I-GENE
. O

The O
levels O
of O
NSE I-GENE
and O
MBP I-GENE
in O
the O
IJVB O
were O
compared O
to O
those O
in O
the O
PVB O
. O

As O
expected O
, O
the O
insulin I-GENE
effect O
to O
increase O
ras I-GENE
GTP I-GENE
formation O
and O
MAP I-GENE
kinase I-GENE
activity O
was O
negligible O
in O
A O
/ O
K1018 O
cells O
but O
normal O
, O
or O
supernormal O
, O
in O
Y O
/ O
F2 O
cells O
. O

Morphologic O
variables O
included O
cancer O
volume O
, O
histologic O
grade O
, O
capsular O
penetration O
, O
seminal O
vesicle O
invasion O
, O
and O
lymph O
node O
metastasis O
. O

Sequence O
analysis O
of O
these O
regions O
showed O
a O
CAAT O
box O
upstream O
of O
exon O
1a O
and O
high O
G O
- O
C O
content O
regions O
within O
both O
P1 O
and O
P2 O
. O

The O
fusion O
proteins O
were O
tested O
by O
ELISA O
for O
reactivity O
with O
a O
panel O
of O
human I-GENE
anti I-GENE
- I-GENE
La I-GENE
sera I-GENE
in O
order O
to O
define O
the O
nature O
of O
the O
epitopes O
. O

GCD10 I-GENE
was O
first O
identified O
genetically O
as O
a O
translational O
repressor O
of O
GCN4 I-GENE
. O

GCD10 I-GENE
binds O
RNA O
in O
vitro O
and O
we O
present O
strong O
biochemical O
evidence O
that O
it O
is O
identical O
to O
the O
RNA O
- O
binding O
subunit O
of O
yeast I-GENE
initiation I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
eIF I-GENE
- I-GENE
3 I-GENE
). O
eIF I-GENE
- I-GENE
3 I-GENE
is O
a O
multisubunit O
complex O
that O
stimulates O
translation O
initiation O
in O
vitro O
at O
several O
different O
steps O
. O

Sources O
of O
noise O
in O
these O
signals O
were O
evaluated O
in O
preparations O
stained O
with O
the O
potentiometric O
probe O
RH O
- O
414 O
. O

1993 O
. O

A O
transformation O
- O
competent O
mutant O
, O
like O
the O
wild I-GENE
- I-GENE
type I-GENE
E5 I-GENE
protein I-GENE
, O
bound O
the O
receptor O
and O
induced O
receptor O
tyrosine O
phosphorylation O
and O
down O
- O
regulation O
. O

We O
conclude O
that O
cAMP O
, O
acting O
through O
PKA I-GENE
, O
is O
an O
essential O
regulator O
of O
basal O
CFTR I-GENE
gene I-GENE
expression O
and O
may O
mediate O
an O
induction O
of O
CFTR I-GENE
in O
responsive O
cell O
types O
. O

Appropriate O
restriction O
sites O
allow O
one O
to O
insert O
virtually O
any O
desired O
cDNA O
fragment O
directly O
behind O
the O
epitope O
- O
specific O
sequence O
and O
before O
a O
long O
poly O
( O
A O
) O
tail O
. O

Both O
PPC O
- O
1 O
and O
ALVA O
- O
31 O
cells O
display O
tumorigenesis O
and O
invasiveness O
in O
nude O
mice O
, O
whereas O
LNCap O
cells O
exhibit O
a O
less O
malignant O
phenotype O
, O
suggesting O
a O
correlation O
between O
CD44 I-GENE
variant I-GENE
( O
CD44v I-GENE
) O
expression O
and O
aggressive O
prostate O
tumor O
behavior O
. O

The O
gene O
product O
of O
cotS I-GENE
was O
confirmed O
to O
be O
identical O
to O
Cot40 I-GENE
- I-GENE
2 I-GENE
by O
SDS O
- O
PAGE O
and O
immunoblotting O
from O
Escherichia O
coli O
transformed O
with O
a O
plasmid O
containing O
the O
cotS I-GENE
region I-GENE
. O

Two O
such O
genes O
, O
designated O
hsiggll150 I-GENE
and O
hsiggll295 I-GENE
, O
were O
cloned O
and O
sequenced O
from O
genomic O
DNA O
. O

A O
retrospective O
epidemiological O
study O
is O
reported O
concerning O
burn O
injuries O
in O
775 O
children O
hospitalized O
at O
the O
unit O
of O
burn O
care O
of O
Casablanca O
between O
1985 O
and O
1993 O
. O

Our O
results O
suggest O
that O
protein O
binding O
to O
the O
E2F I-GENE
- I-GENE
like I-GENE
sequences I-GENE
may O
act O
to O
reduce O
expression O
. O

The O
RAD6 I-GENE
/ O
UBC2 I-GENE
gene O
from O
Saccharomyces O
cerevisiae O
encodes O
a O
ubiquitin I-GENE
- I-GENE
conjugating I-GENE
enzyme I-GENE
involved O
in O
DNA O
repair O
, O
induced O
mutagenesis O
, O
and O
sporulation O
. O

Echocardiography O
revealed O
right O
ventricular O
diastolic O
collapse O
( O
RVDC O
) O
without O
physical O
signs O
of O
cardiac O
tamponade O
. O

In O
on O
- O
going O
screening O
programmes O
, O
the O
Haemoccult O
test O
consists O
of O
six O
slides O
and O
a O
test O
is O
considered O
positive O
if O
at O
least O
one O
slide O
is O
coloured O
. O

We O
showed O
previously O
that O
a O
fusion O
protein O
( O
GAL4 I-GENE
- O
p40 I-GENE
) O
containing O
the O
DNA O
- O
binding O
domain O
of O
GAL4 I-GENE
and O
sequences O
of O
chicken I-GENE
l I-GENE
kappa I-GENE
B I-GENE
- I-GENE
alpha I-GENE
( O
p40 I-GENE
) O
inhibits O
growth O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

We O
have O
demonstrated O
previously O
that O
two O
binding O
sites O
in O
the O
- I-GENE
184 I-GENE
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
are O
recognized O
by O
widely O
distributed O
factors O
and O
that O
there O
is O
also O
a O
critical O
autoregulatory O
site O
, O
we O
identified O
a O
binding O
site O
for O
a O
cell O
- O
specific O
factor O
, O
LF I-GENE
- I-GENE
H3 I-GENE
beta I-GENE
, O
that O
may O
function O
in O
restricting O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
gene I-GENE
expression O
to O
hepatocytes O
. O

In O
4 O
spinalized O
cats O
, O
the O
effects O
of O
afferent O
inputs O
from O
hindlimb O
cutaneous O
nerves O
( O
sural O
cutaneous O
nerve O
: O
Sur O
) O
on O
mono O
- O
and O
poly O
- O
synaptic O
reflex O
recorded O
from O
tail O
muscle O
motoneurons O
were O
studied O
before O
and O
after O
spinal O
lesioning O
at O
S2 O
- O
3 O
level O
. O

The O
flow O
rate O
of O
phosphate O
buffered O
saline O
through O
dermis O
was O
measured O
as O
a O
function O
of O
applied O
pressure O
. O

However O
, O
parallax O
measurements O
showed O
that O
at O
150K O
, O
collapse O
of O
Epon O
sections O
does O
not O
take O
place O
. O

Although O
within O
normal O
limits O
, O
latency O
was O
high O
. O

The O
outcome O
of O
the O
optimization O
of O
the O
seven O
- O
field O
plan O
prompted O
an O
investigation O
into O
the O
best O
results O
that O
could O
be O
achieved O
by O
an O
" O
ideal O
" O
conformal O
radiotherapy O
technique O
. O

Specific O
requirements O
for O
branched O
- O
chain O
amino O
acids O
, O
glutamine O
, O
and O
arginine O
are O
evaluated O
. O

The O
pea I-GENE
rps10 I-GENE
intron I-GENE
is O
homologous O
to O
introns O
in O
rrn26 I-GENE
and O
cox3 I-GENE
in O
the O
Marchantia O
mitochondrial O
genome O
, O
while O
the O
Marchantia I-GENE
rps10 I-GENE
gene I-GENE
lacks O
an O
intron O
. O

The O
optimal O
care O
of O
CHF O
patient O
includes O
the O
recognition O
and O
management O
of O
these O
electrolyte O
disturbances O
. O

Serum O
magnesium O
in O
79 O
patients O
of O
gynecologic O
neoplasms O
treated O
with O
cisplatin O
and O
their O
controls O
was O
measured O
. O

METHODS O
: O
rHb1 I-GENE
. I-GENE
1 I-GENE
or O
human I-GENE
serum I-GENE
albumin I-GENE
was O
administered O
intravenously O
to O
fasting O
male O
volunteers O
. O

Alanine I-GENE
aminotransferase I-GENE
( O
ALT I-GENE
) O
levels O
had O
been O
elevated O
for O
six O
months O
in O
all O
patients O
and O
hepatitis O
B O
viral O
infection O
was O
replicative O
. O

In O
this O
study O
we O
have O
investigated O
the O
role O
of O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
initiating O
the O
adipogenic O
program O
by O
overexpressing O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
multipotential O
NIH O
- O
3T3 O
fibroblasts O
. O

XYL1 I-GENE
was O
isolated O
as O
a O
highly O
expressed O
fusion O
clone O
from O
a O
' I-GENE
lacZ I-GENE
translational O
fusion O
library O
. O

Various O
transcripts O
are O
generated O
from O
the O
VCSA1 I-GENE
gene I-GENE
by O
alternative O
splicing O
and O
poly O
( O
A O
) O
processing O
in O
the O
rat O
submandibular O
gland O
. O

However O
, O
division O
of O
the O
chest O
wall O
muscles O
, O
usually O
with O
diathermy O
, O
contributes O
to O
prolonged O
pain O
and O
morbidity O
. O

Closure O
of O
an O
open O
high O
below O
- O
knee O
guillotine O
amputation O
wound O
using O
a O
skin O
- O
stretching O
device O
. O

Our O
study O
was O
addressed O
to O
the O
synthesis O
of O
some O
derivatives O
of O
this O
sequence O
in O
order O
to O
obtain O
both O
peptide O
substrates O
suitable O
for O
the O
detection O
of O
the O
Src I-GENE
- O
like O
tyrosine I-GENE
kinase I-GENE
activity O
and O
active O
site O
- O
directed O
inhibitors O
specific O
for O
this O
class O
of O
enzymes O
. O

Citrate I-GENE
synthase I-GENE
activity O
was O
increased O
in O
the O
medial O
head O
( O
81 O
%, O
P O
< O
0 O
. O
001 O
) O
and O
the O
red O
long O
head O
( O
88 O
%, O
P O
< O
0 O
. O
001 O
) O
of O
the O
triceps O
brachii O
muscle O
in O
R O
rats O
but O
not O
in O
the O
white O
long O
head O
( O
25 O
%, O
P O
= O
0 O
. O
06 O
). O

The O
expression O
of O
the O
putative O
operon O
bglPH I-GENE
of O
Bacillus O
subtilis O
was O
studied O
by O
using O
bglP O
'- O
lacZ I-GENE
transcriptional O
fusions O
. O

Although O
eight O
contiguous O
genes O
necessary O
for O
urease I-GENE
activity O
have O
been O
cloned O
and O
sequenced O
, O
the O
transcriptional O
organization O
and O
regulation O
of O
specific O
genes O
within O
the O
Proteus I-GENE
gene I-GENE
cluster I-GENE
has O
not O
been O
investigated O
in O
detail O
. O

The O
hypBFCDE I-GENE
operon I-GENE
from O
Rhizobium O
leguminosarum O
biovar O
viciae O
is O
expressed O
from O
an O
Fnr I-GENE
- I-GENE
type I-GENE
promoter I-GENE
that O
escapes O
mutagenesis O
of O
the O
fnrN I-GENE
gene I-GENE
. O

We O
demonstrate O
that O
a O
VT O
+ O
peptide O
was O
specifically O
phosphorylated O
by O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
in O
vitro O
, O
but O
not O
by O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
). O

R O
. O

15 O
, O
2500 O
- O
2508 O
; O
O O
' O
Neill O
, O
T O
. O

Control O
experiments O
showed O
that O
each O
fusion O
protein O
had O
a O
high O
affinity O
binding O
site O
for O
estradiol O
- O
17 O
beta O
and O
could O
transactivate O
an O
ERE O
- O
LacZ I-GENE
reporter O
gene O
in O
yeast O
similar O
to O
the O
wild I-GENE
type I-GENE
ER I-GENE
. O

Although O
Micrococcus I-GENE
luteus I-GENE
UV I-GENE
endonuclease I-GENE
has O
been O
reported O
to O
be O
an O
18 O
- O
kDa O
enzyme O
with O
possible O
homology O
to O
the O
16 I-GENE
- I-GENE
kDa I-GENE
endonuclease I-GENE
V I-GENE
from I-GENE
bacteriophage I-GENE
T4 I-GENE
( O
Gordon O
, O
L O
. O

Several O
different O
oncogenes O
and O
growth O
factors O
promote O
G1 O
phase O
progression O
. O

Cyclin I-GENE
D1 I-GENE
promoter I-GENE
activity O
was O
stimulated O
by O
overexpression O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
p41MAPK I-GENE
) O
or O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
2 I-GENE
through O
the O
proximal O
22 O
base O
pairs O
. O

Indeed O
, O
ERM I-GENE
and O
c I-GENE
- I-GENE
Jun I-GENE
synergistically O
activated O
the O
EBS O
- O
CRE O
without O
making O
an O
apparent O
ternary O
complex O
. O

A O
mutant O
( O
residues O
1 O
- O
332 O
) O
showed O
complete O
Ca2 O
+/ O
CaM I-GENE
- O
dependent O
activity O
. O

In O
addition O
, O
the O
R206S I-GENE
HSF I-GENE
substitution O
exhibits O
constitutive O
transcriptional O
activation O
from O
a O
consensus O
HSE O
( O
HSE2 O
). O

The O
two O
bases O
immediately O
flanking O
the O
5 O
' O
end O
of O
the O
element O
proved O
to O
be O
very O
important O
to O
its O
function O
as O
a O
UAS O
element O
as O
did O
the O
two O
bases O
immediately O
3 O
' O
of O
the O
bHLH O
core O
motif O
. O

These O
results O
indicate O
that O
the O
PCNA I-GENE
gene I-GENE
is O
a O
likely O
target O
gene O
of O
E2F I-GENE
. O

Differential O
sensitivity O
of O
the O
MMPI O
- O
2 O
depression O
scales O
and O
subscales O
. O

After O
recovery O
, O
a O
hypertonic O
saline O
challenge O
was O
performed O
. O

The O
range O
of O
eosinophils O
was O
22 O
- O
56 O
% O
of O
the O
number O
of O
peripheral O
white O
blood O
cells O
( O
mean O
nadir O
33 O
%). O

Comparisons O
of O
rrnB I-GENE
P1 I-GENE
- O
lacZ I-GENE
expression O
at O
different O
ppGpp O
levels O
is O
interpreted O
for O
the O
rpoD I-GENE
( I-GENE
P504L I-GENE
) I-GENE
mutant I-GENE
as O
resulting O
from O
a O
hypersensitivity O
to O
ppGpp O
. O

These O
intron O
chimeras O
show O
that O
peripheral O
sequences O
and O
the O
elements O
that O
define O
the O
splice O
sites O
are O
adequate O
for O
self O
- O
splicing O
activity O
but O
that O
the O
central O
portions O
containing O
the O
catalytic O
cores O
of O
ai4 I-GENE
and O
bi4 I-GENE
are O
deficient O
; O
these O
cores O
are O
the O
likely O
targets O
of O
the O
splicing O
proteins O
. O

Here O
we O
demonstrate O
genetically O
that O
plus O
- O
strand O
DNA O
synthesis O
of O
the O
yeast I-GENE
Ty1 I-GENE
element I-GENE
is O
initiated O
at O
two O
sites O
located O
at O
the O
5 O
' O
boundary O
of O
the O
3 O
' O
long O
terminal O
repeat O
( O
PPT1 I-GENE
) O
and O
near O
the O
middle O
of O
the O
pol I-GENE
gene I-GENE
in O
the O
integrase I-GENE
coding I-GENE
sequence I-GENE
( O
PPT2 I-GENE
). O

Characterization O
of O
the O
3 O
' O
ends O
of O
the O
plus O
- O
strand O
DNA O
fragments O
reveals O
( O
1 O
) O
that O
the O
upstream O
fragment O
is O
elongated O
beyond O
PPT2 I-GENE
creating O
a O
plus O
- O
strand O
overlap O
and O
( O
2 O
) O
that O
the O
majority O
of O
plus O
- O
strand O
strong O
- O
stop O
DNA O
fragments O
bear O
a O
copy O
of O
the O
minus O
- O
strand O
primer O
binding O
site O
in O
agreement O
with O
the O
accepted O
model O
of O
retroviral O
genomic O
RNA O
reverse O
transcription O
. O

The O
patients O
undergoing O
VTLB O
had O
significantly O
shorter O
operative O
times O
( O
VTLB O
, O
100 O
. O
2 O
+/- O
27 O
. O
2 O
min O
. O
vs O
OLB O
, O
119 O
. O
8 O
+/- O
42 O
. O
6 O
min O
; O
p O
< O
0 O
. O
01 O
) O
and O
less O
blood O
loss O
( O
VTLB O
, O
4 O
. O
7 O
+/- O
14 O
. O
6 O
ml O
vs O
OLB O
, O
65 O
. O
7 O
+/- O
77 O
. O
0 O
ml O
; O
p O
< O
0 O
. O
001 O
). O

By O
150 O
minutes O
after O
Cr2O3 O
inhalation O
, O
FEV1 O
. O
0 O
had O
decreased O
by O
32 O
%. O

This O
combined O
intravenous O
anaesthetic O
regimen O
gave O
good O
anaesthesia O
and O
analgesia O
to O
pigs O
for O
up O
to O
2 O
h O
as O
monitored O
by O
clinical O
signs O
. O

Twenty O
food O
products O
were O
contaminated O
with O
V O
. O
cholerae O
O1 O
, O
Ogawa O
, O
toxigenic O
and O
not O
toxigenic O
strains O
: O
yoghurt O
, O
cream O
cheese O
, O
apricot O
marmelade O
, O
hip O
rose O
marmelade O
, O
mayonnaise O
, O
italian O
pasta O
for O
" O
empanadas O
", O
" O
dulce O
de O
leche O
", O
meat O
sausage O
, O
meat O
and O
spinach O
ravioli O
, O
margarine O
, O
milk O
dessert O
( O
made O
with O
cocoa O
, O
milk O
confiture O
, O
starch O
and O
additives O
), O
lettuce O
, O
tuna O
fish O
, O
ricotta O
and O
sterilized O
milk O
. O

It O
is O
impossible O
to O
define O
only O
one O
clinical O
outline O
because O
both O
symptomatic O
and O
asymptomatic O
infected O
NB O
may O
be O
found O
with O
gestational O
age O
at O
term O
and O
pre O
- O
term O
and O
when O
born O
with O
a O
weight O
above O
or O
below O
2000 O
g O
. O

The O
expression O
of O
the O
pilin I-GENE
gene I-GENE
, O
tcpA I-GENE
, O
is O
dependent O
upon O
ToxR I-GENE
and O
upon O
ToxT I-GENE
. O

The O
chloramphenicol I-GENE
- I-GENE
resistance I-GENE
transposon I-GENE
Tn4451 I-GENE
undergoes O
precise O
conjugative O
deletion O
from O
its O
parent O
plasmid O
plP401 O
in O
Clostridium O
perfringens O
and O
precise O
spontaneous O
excision O
from O
multicopy O
plasmids O
in O
Escherichia O
coli O
. O

Ras I-GENE
p21Val I-GENE
inhibits O
myogenesis O
without O
altering O
the O
DNA O
binding O
or O
transcriptional O
activities O
of O
the O
myogenic I-GENE
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
. O

In O
cells O
limited O
for O
His O
, O
increased O
expression O
of O
arg I-GENE
- I-GENE
2 I-GENE
and O
cpc I-GENE
- I-GENE
1 I-GENE
, O
and O
decreased O
expression O
of O
cox I-GENE
- I-GENE
5 I-GENE
, O
also O
had O
translational O
and O
transcriptional O
components O
. O

The O
peptide O
sequences O
reveal O
that O
the O
factor O
consists O
of O
GABP I-GENE
alpha I-GENE
and O
GABP I-GENE
beta I-GENE
1 I-GENE
with O
Ets I-GENE
and O
Notch I-GENE
motifs I-GENE
, O
respectively O
. O

Immunofluorescence O
microscopy O
and O
cell O
fractionation O
analyses O
showed O
that O
the O
110 O
- O
kDa O
protein O
was O
exclusively O
nuclear O
, O
whereas O
the O
150 O
- O
kDa O
protein O
was O
present O
in O
both O
the O
cytoplasm O
and O
nucleus O
of O
human O
cells O
. O

Expression O
and O
regulation O
by O
interferon I-GENE
of O
a O
double I-GENE
- I-GENE
stranded I-GENE
- I-GENE
RNA I-GENE
- I-GENE
specific I-GENE
adenosine I-GENE
deaminase I-GENE
from O
human O
cells O
: O
evidence O
for O
two O
forms O
of O
the O
deaminase O
. O

T O
- O
cell O
hybridomas O
, O
thymocytes O
, O
and O
T O
cells O
can O
be O
induced O
to O
undergo O
apoptotic O
cell O
death O
by O
activation O
through O
the O
T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
. O

Deletions O
were O
examined O
in O
the O
LYS2 I-GENE
gene I-GENE
, O
using O
a O
set O
of O
31 O
- O
to O
156 O
- O
bp O
inserts O
that O
included O
inserts O
with O
no O
apparent O
potential O
for O
secondary O
structure O
as O
well O
as O
two O
quasipalindromes O
. O

Overexpression O
of O
SCS1 I-GENE
could O
not O
complement O
an O
HSP60 I-GENE
- I-GENE
null I-GENE
allele I-GENE
, O
indicating O
that O
suppression O
was O
not O
due O
to O
the O
bypassing O
of O
Hsp60 I-GENE
activity O
. O

The O
DNA O
binding O
domain O
of O
NirA I-GENE
was O
expressed O
as O
a O
fusion O
protein O
with O
the O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
of O
Schistosoma O
japonicum O
. O

The O
kinase O
is O
essential O
in O
vivo O
for O
normal O
phosphorylation O
of O
the O
CTD O
and O
for O
normal O
growth O
and O
differentiation O
. O

A O
general O
model O
for O
ARE O
- O
mediated O
mRNA O
degradation O
involving O
a O
potential O
role O
for O
certain O
heterogeneous O
nuclear O
ribonucleoproteins O
and O
ARE I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
is O
proposed O
. O

Finally O
, O
we O
demonstrate O
that O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
can O
also O
active O
the O
GM I-GENE
- I-GENE
CSF I-GENE
receptor I-GENE
alpha I-GENE
promoter O
in O
nonmyeloid O
cells O
. O

Endocytosis O
and O
vacuolar O
degradation O
of O
the O
plasma O
membrane O
- O
localized O
Pdr5 I-GENE
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
multidrug I-GENE
transporter I-GENE
in O
Saccharomyces O
cerevisiae O
. O

Individual O
mutations O
in O
motifs O
III O
, O
IV O
, O
and O
V O
had O
distinctive O
effects O
on O
the O
affinity O
of O
enzyme O
for O
GTP O
, O
the O
rate O
of O
covalent O
catalysis O
( O
EpG O
formation O
), O
or O
the O
transfer O
of O
GMP O
from O
enzyme O
to O
RNA O
. O

Mutational O
analysis O
of O
mRNA I-GENE
capping I-GENE
enzyme I-GENE
identifies O
amino O
acids O
involved O
in O
GTP O
binding O
, O
enzyme O
- O
guanylate O
formation O
, O
and O
GMP O
transfer O
to O
RNA O
. O

Disruption O
of O
the O
HOG1 I-GENE
and O
PBS2 I-GENE
genes I-GENE
leads O
to O
a O
dramatic O
decrease O
of O
the O
HSP12 I-GENE
inducibility O
in O
osmostressed O
cells O
, O
whereas O
overproduction O
of O
Hog1 I-GENE
produces O
a O
fivefold O
increase O
in O
wild O
- O
type O
induced O
levels O
upon O
a O
shift O
to O
a O
high O
salt O
concentration O
. O

Deletion O
or O
inactivation O
of O
CRY1 I-GENE
leads O
to O
5 O
- O
to O
10 O
- O
fold O
- O
increased O
levels O
of O
CRY2 I-GENE
mRNA I-GENE
. O

( O
1986 O
) O
method O
of O
separation O
of O
Cryptosporidium O
spp O
. O
oocysts O
from O
feces O
by O
using O
a O
percoll O
discontinuous O
density O
gradient O
appeared O
a O
method O
of O
choice O
for O
obtaining O
large O
numbers O
of O
oocysts O
of O
C O
. O
parvum O
free O
of O
fecal O
contamination O
. O

Staphylococcal I-GENE
enterotoxin I-GENE
A I-GENE
involvement O
in O
the O
illness O
of O
a O
20 O
- O
month O
- O
old O
burn O
patient O
. O

METHODS O
: O
We O
obtained O
maximal O
inspiratory O
and O
expiratory O
flow O
- O
volume O
curves O
in O
41 O
unselected O
patients O
with O
essential O
tremor O
( O
14 O
males O
, O
27 O
females O
, O
age O
61 O
. O
7 O
+/- O
2 O
. O
14 O
years O
). O

Our O
findings O
also O
provide O
the O
basis O
for O
the O
development O
of O
assays O
to O
screen O
for O
the O
ligands O
to O
testis I-GENE
receptor I-GENE
2 I-GENE
and O
hERR1 I-GENE
. O

Four O
p53 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
peptides I-GENE
bind O
natural O
p53 I-GENE
- I-GENE
response I-GENE
elements I-GENE
and O
bend O
the O
DNA O
. O

The O
Stat5b I-GENE
mRNA I-GENE
has O
a O
size O
of O
5 O
. O
6 O
kb O
and O
encodes O
a O
protein O
of O
786 O
amino O
acids O
. O

The O
hydropathy O
plot O
revealed O
a O
rather O
hydrophilic O
N O
- O
terminal O
region O
and O
the O
absence O
of O
a O
hydrophobic O
signal O
peptide O
. O

These O
results O
suggest O
that O
G I-GENE
beta I-GENE
gamma I-GENE
- O
stimulated O
Shc I-GENE
phosphorylation O
represents O
an O
early O
step O
in O
the O
pathway O
leading O
to O
p21ras I-GENE
activation O
, O
similar O
to O
the O
mechanism O
utilized O
by O
growth I-GENE
factor I-GENE
tyrosine I-GENE
kinase I-GENE
receptors I-GENE
. O

This O
report O
focused O
on O
the O
relationship O
between O
Type O
A O
behavior O
and O
eight O
basic O
emotion O
dimensions O
. O

All O
carcasses O
resulted O
in O
contamination O
with O
aerobic O
mesophilic O
bacteria O
in O
the O
range O
from O
6 O
x O
10 O
( O
3 O
) O
to O
1 O
. O
2 O
x O
10 O
( O
6 O
) O
CFU O
/ O
ml O
liquid O
washed O
, O
and O
94 O
% O
them O
with O
sporulate O
bacteria O
, O
the O
threshold O
being O
under O
100 O
CFU O
/ O
ml O
( O
Figure O
1 O
). O

As O
for O
31 O
stage O
I O
- O
II O
lung O
cancer O
patients O
, O
CR O
has O
been O
observed O
in O
82 O
. O
8 O
% O
of O
them O
and O
PR O
in O
13 O
. O
8 O
%; O
the O
response O
was O
always O
assessed O
with O
chest O
radiography O
, O
CT O
, O
FBS O
, O
cytology O
and O
/ O
or O
histology O
. O

Pediatric O
medical O
emergencies O
in O
a O
regional O
hospital O
: O
appropriate O
locale O
? O

Protein O
electrophoresis O
showed O
decreased O
albumin I-GENE
levels O
in O
both O
groups O
, O
with O
lower O
values O
in O
G2 O
. O

METHODS O
: O
All O
these O
30 O
non O
- O
responders O
received O
an O
extra O
dose O
of O
the O
same O
vaccine O
2 O
months O
after O
primary O
immunization O
and O
a O
booster O
dose O
with O
a O
yeast O
- O
derived O
vaccine O
6 O
years O
later O
. O

An O
abnormally O
high O
percentage O
of O
hypertensive O
patients O
( O
approximately O
30 O
%) O
undergoing O
cardiac O
catheterization O
because O
of O
anginal O
pain O
and O
/ O
or O
exercise O
- O
induced O
ST O
- O
segment O
depressions O
has O
angiographically O
normal O
coronary O
arteries O
. O

Negative O
- O
staining O
, O
refractile O
mycobacteria O
in O
Romanowsky O
- O
stained O
smears O
. O

Mibefradil O
( O
Ro O
40 O
- O
5967 O
) O
is O
a O
novel O
calcium O
antagonist O
from O
a O
new O
chemical O
class O
and O
is O
the O
first O
that O
selectively O
blocks O
the O
T O
- O
type O
calcium O
channel O
. O

However O
, O
2 O
minimum O
alveolar O
concentration O
anesthesia O
did O
significantly O
decrease O
the O
calculated O
VE O
at O
a O
PCO2 O
of O
60 O
mmHg O
( O
from O
7 O
. O
4 O
+/- O
1 O
. O
2 O
to O
4 O
. O
0 O
+/- O
0 O
. O
6 O
l O
. O
min O
- O
1 O
), O
indicating O
a O
rightward O
shift O
in O
the O
response O
relationship O
. O

cDNA O
encoding O
a O
functional O
feline I-GENE
liver I-GENE
/ I-GENE
bone I-GENE
/ I-GENE
kidney I-GENE
- I-GENE
type I-GENE
alkaline I-GENE
phosphatase I-GENE
. O

Protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
), O
a O
widely O
- O
distributed O
enzyme O
implicated O
in O
the O
regulation O
of O
many O
physiological O
processes O
, O
consists O
of O
a O
family O
of O
at O
least O
twelve O
isoenzymes O
which O
differ O
in O
tissue O
distribution O
, O
subcellular O
localization O
, O
regulatory O
properties O
, O
etc O
. O

This O
work O
, O
therefore O
, O
also O
emphasizes O
the O
importance O
of O
careful O
choice O
of O
oligonucleotide O
and O
cDNA O
probes O
to O
study O
PKC I-GENE
zeta I-GENE
mRNA I-GENE
. O

This O
action O
is O
dependent O
on O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
bound O
to O
the O
E1 I-GENE
element O
. O

The O
debate O
over O
electives O
-- O
1899 O
. O

Polypeptide O
growth O
factors O
and O
cytokines O
mediate O
their O
biochemical O
functions O
through O
their O
responsive O
receptors O
. O

However O
, O
a O
strongly O
increased O
frequency O
of O
CpG O
dinucleotides O
was O
found O
. O

Here O
we O
focused O
on O
the O
role O
of O
the O
5 O
' O
proximal O
regulatory O
cassette O
(- O
190 O
; O
+ O
53 O
bp O
) O
of O
the O
rat I-GENE
enkephalin I-GENE
( O
rENK I-GENE
) O
gene O
in O
the O
developmental O
regulation O
of O
the O
enkephalin I-GENE
phenotype O
. O

Unexpectedly O
, O
all O
ENK I-GENE
- I-GENE
specific I-GENE
motifs I-GENE
formed O
specific O
and O
highly O
abundant O
protein O
- O
DNA O
complexes O
when O
nuclear O
extracts O
from O
the O
human O
tumor O
cell O
line O
( O
HeLa O
), O
which O
does O
not O
express O
ENK I-GENE
, O
were O
used O
. O

Infant O
aged O
3 O
. O
5 O
years O
presents O
persistence O
of O
primordial O
vitreous O
body O
with O
crystalline O
dislocation O
in O
the O
camera O
aquosa O
and O
secondary O
buphthalmos O
of O
the O
left O
eye O
and O
microphthalmos O
with O
dislocation O
of O
the O
crystalline O
in O
the O
vitreous O
body O
of O
the O
right O
eye O
. O

During O
the O
dose O
- O
finding O
, O
two O
patients O
were O
temporarily O
withdrawn O
from O
medication O
and O
one O
patient O
was O
excluded O
because O
of O
elevated O
levels O
of O
liver O
enzymes O
. O

In O
comparison O
of O
cDNA O
and O
genomic O
sequences O
four O
RNA O
editing O
events O
were O
found O
in O
both O
atp9 I-GENE
genes I-GENE
. O

MZF I-GENE
- I-GENE
1 I-GENE
represses O
CAT I-GENE
reporter I-GENE
gene I-GENE
expression O
via O
GAL4 I-GENE
binding I-GENE
sites I-GENE
in O
the O
nonhematopoietic O
cell O
lines O
NIH O
3T3 O
and O
293 O
. O

As O
with O
the O
heterologous O
DNA O
binding O
domain O
, O
MZF I-GENE
- I-GENE
1 I-GENE
represses O
reporter O
gene O
expression O
in O
nonhematopoietic O
cell O
lines O
and O
activates O
expression O
in O
hematopoietic O
cell O
lines O
. O

Analyses O
of O
hGMR I-GENE
beta I-GENE
subunit I-GENE
mutants I-GENE
revealed O
two O
cytoplasmic O
regions O
involved O
in O
activation O
of O
the O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
, O
one O
is O
essential O
and O
the O
other O
is O
dispensable O
but O
enhances O
the O
activity O
. O

Similarly O
, O
we O
observed O
synthetic O
phenotypes O
between O
mutations O
in O
MIF2 I-GENE
and O
trans O
- O
acting O
mutations O
in O
three O
known O
yeast O
centromere O
protein O
genes O
- O
CEP1 I-GENE
/ O
CBF1 I-GENE
/ O
CPF1 I-GENE
, O
NDC10 I-GENE
/ O
CBF2 I-GENE
, O
and O
CEP3 I-GENE
/ O
CBF3B I-GENE
. O

Taken O
together O
, O
these O
data O
suggest O
that O
the O
Mif2 I-GENE
protein I-GENE
interacts O
with O
Cep1p I-GENE
at O
the O
centromere O
and O
that O
the O
yeast O
centromere O
indeed O
exists O
as O
a O
higher O
order O
protein O
- O
DNA O
complex O
. O

To O
accomplish O
this O
, O
actin I-GENE
cables O
and O
patches O
are O
redistributed O
during O
the O
cell O
cycle O
to O
direct O
secretory O
components O
to O
appropriate O
sites O
for O
cell O
growth O
. O

The O
effects O
of O
Codonopsis O
pilosula O
oral O
liquor O
( O
CPOL O
) O
on O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
( O
PAI I-GENE
) O
in O
the O
plasma O
of O
25 O
patients O
of O
coronary O
heart O
disease O
with O
blood O
stasis O
were O
studied O
. O

Estimated O
daily O
intakes O
( O
EDIs O
) O
per O
person O
were O
0 O
. O
56 O
microgram O
for O
total O
HCH O
, O
0 O
. O
20 O
microgram O
for O
gamma O
- O
HCH O
, O
0 O
. O
09 O
microgram O
for O
dieldrin O
, O
1 O
. O
42 O
micrograms O
for O
total O
DDT O
, O
and O
0 O
. O
15 O
microgram O
for O
HCB O
. O

Imaging O
features O
of O
splenic O
epidermoid O
cyst O
with O
pathologic O
correlation O
. O

In O
two O
further O
cases O
( O
one O
type O
I O
and O
one O
type O
III O
SMA O
), O
de O
novo O
deletions O
of O
only O
one O
copy O
of O
Ag1 I-GENE
- I-GENE
CA I-GENE
and O
C212 I-GENE
were O
found O
. O

With O
each O
of O
the O
three O
pairs O
of O
isolates O
( O
case O
and O
suspicious O
case O
), O
identical O
IS6110 O
banding O
patterns O
were O
found O
suggesting O
identical O
MTB O
strains O
. O

HRES O
has O
been O
found O
to O
be O
clinically O
useful O
in O
assessing O
histologic O
damage O
following O
pneumatic O
dilatation O
and O
in O
localizing O
the O
LES O
during O
the O
administration O
of O
intrasphincter O
botulinum I-GENE
toxin I-GENE
injection O
in O
the O
treatment O
of O
achalasia O
. O

These O
early O
structural O
processes O
are O
assumed O
to O
be O
subserved O
by O
the O
anterior O
parts O
of O
the O
left O
hemisphere O
, O
as O
event O
- O
related O
brain O
potentials O
show O
this O
area O
to O
be O
maximally O
activated O
when O
phrase O
structure O
violations O
are O
processed O
and O
as O
circumscribed O
lesions O
in O
this O
area O
lead O
to O
an O
impairment O
of O
the O
on O
- O
line O
structural O
assignment O
. O

In O
men O
with O
BMI O
< O
30 O
, O
the O
OR O
was O
1 O
. O
83 O
for O
postprandial O
TG O
( O
P O
= O
. O
041 O
) O
and O
2 O
. O
77 O
for O
postprandial O
RP O
( O
P O
= O
. O
032 O
) O
in O
models O
that O
included O
fasting O
TG O
, O
LDL I-GENE
- I-GENE
C I-GENE
, O
and O
hypertension O
. O

SL1 I-GENE
trans O
- O
splicing O
specified O
by O
AU O
- O
rich O
synthetic O
RNA O
inserted O
at O
the O
5 O
' O
end O
of O
Caenorhabditis O
elegans O
pre O
- O
mRNA O
. O

A O
pyrazolo O
- O
quinoline O
compound O
, O
6 O
- O
methoxy O
- O
4 O
-[ O
2 O
-[( O
2 O
- O
hydroxyethoxyl O
)- O
ethyl O
] O
amino O
]- O
3 O
- O
methyl O
- O
1M O
- O
pyrazo O
lo O
[ O
3 O
, O
4 O
- O
b O
] O
quinoline O
( O
SCH O
51344 O
), O
was O
identified O
based O
on O
its O
ability O
to O
derepress O
human O
smooth O
muscle O
alpha I-GENE
- I-GENE
actin I-GENE
promoter I-GENE
activity O
in O
ras I-GENE
- O
transformed O
cells O
. O

On O
the O
basis O
of O
these O
relations O
, O
a O
risk O
factor O
- O
selection O
scale O
( O
RFSS O
) O
( O
range O
, O
0 O
to O
10 O
) O
was O
developed O
by O
computing O
appropriate O
weights O
for O
each O
risk O
factor O
. O

The O
Caenorhabditis I-GENE
elegans I-GENE
death I-GENE
susceptibility I-GENE
gene I-GENE
, O
ced I-GENE
- I-GENE
3 I-GENE
, O
has O
a O
number O
of O
homologs O
in O
vertebrate O
species O
, O
including O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( I-GENE
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
)- I-GENE
converting I-GENE
enzyme I-GENE
( O
ICE I-GENE
), O
Ich I-GENE
- I-GENE
1long I-GENE
, O
and O
CPP32 I-GENE
. O

Repression O
of O
glucocorticoid I-GENE
receptor I-GENE
- O
mediated O
transcriptional O
activation O
by O
unliganded O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
is O
TR I-GENE
isoform O
- O
specific O
. O

The O
results O
indicate O
considerable O
flexibility O
in O
the O
spacing O
between O
DH I-GENE
regulatory O
sites O
. O

Obstruction O
of O
the O
ERF I-GENE
repressor I-GENE
function O
by O
the O
transactivating O
members O
of O
the O
ets I-GENE
family I-GENE
of O
genes O
( O
i O
. O
e O
. O
gag I-GENE
- O
myb I-GENE
- O
ets I-GENE
) O
may O
be O
essential O
for O
the O
control O
of O
genes O
involved O
in O
cell O
proliferation O
and O
may O
also O
underlie O
their O
tumorigenic O
effects O
. O

Overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
also O
induces O
apoptosis O
in O
an O
LCL O
. O

We O
show O
that O
c I-GENE
- I-GENE
Fos I-GENE
( O
the O
c I-GENE
- I-GENE
fos I-GENE
protooncogene I-GENE
product I-GENE
), O
which O
is O
an O
intrinsically O
unstable O
nuclear O
protein O
, O
is O
metabolically O
highly O
stabilized O
, O
and O
greatly O
enhances O
the O
transforming O
efficiency O
of O
NIH O
3T3 O
cells O
, O
by O
Mos I-GENE
. O

Cloning O
, O
sequencing O
and O
expression O
of O
the O
3 I-GENE
- I-GENE
phosphoglycerate I-GENE
kinase I-GENE
gene I-GENE
of O
Pyrococcus O
woesei O
in O
Escherichia O
coli O
and O
characterization O
of O
the O
protein O
. O

These O
observations O
lead O
to O
the O
proposal O
that O
the O
RNAP I-GENE
II I-GENE
CTD I-GENE
might O
be O
an O
in O
vivo O
target O
for O
the O
activated O
p42mapk I-GENE
and O
p44mapk I-GENE
MAP I-GENE
kinases I-GENE
. O

We O
also O
isolated O
two O
alternatively O
spliced O
forms O
of O
human I-GENE
CD6 I-GENE
cDNA I-GENE
lacking O
sequences O
encoding O
membrane O
- O
proximal O
regions O
of O
the O
cytoplasmic O
domain O
which O
maintain O
the O
same O
reading O
frame O
as O
CD6 I-GENE
- O
PB1 I-GENE
. O

We O
sought O
to O
determine O
whether O
such O
differences O
in O
polyadenylation O
affect O
the O
steady O
- O
state O
levels O
of O
DHFR I-GENE
and O
mRNAs O
expressed O
from O
either O
allele O
and O
, O
in O
a O
more O
general O
sense O
, O
to O
ask O
whether O
differences O
in O
3 O
' O
end O
RNA O
processing O
in O
a O
gene O
containing O
multiple O
poly O
( O
A O
) O
sites O
affects O
the O
final O
level O
of O
gene O
expression O
. O

We O
have O
isolated O
a O
Drosophila O
melanogaster O
( O
Dm O
) O
cDNA O
encoding O
a O
polypeptide O
that O
has O
extensive O
sequence O
similarity O
to O
the O
mammalian I-GENE
MAPKAPK I-GENE
- I-GENE
2 I-GENE
. O

A O
2 I-GENE
. I-GENE
4 I-GENE
- I-GENE
kb I-GENE
MAPKAPK I-GENE
- I-GENE
2 I-GENE
message I-GENE
is O
expressed O
throughout O
development O
, O
while O
two O
shorter O
transcripts O
of O
2 O
. O
3 O
and O
1 O
. O
8 O
kb O
appear O
to O
be O
specifically O
expressed O
in O
the O
germline O
. O

The O
finding O
that O
the O
chimeric I-GENE
TdT I-GENE
:: O
Pol I-GENE
beta I-GENE
protein I-GENE
possessed O
significant O
template O
- O
dependent O
polymerase O
activity O
suggests O
that O
aa O
1 O
- O
60 O
of O
Pol I-GENE
beta I-GENE
are O
involved O
in O
template O
utilization O
during O
the O
polymerization O
reaction O
, O
as O
suggested O
by O
the O
previous O
finding O
that O
the O
8 O
- O
kDa O
N O
- O
terminal O
domain O
of O
Pol I-GENE
beta I-GENE
possesses O
ssDNA O
- O
binding O
activity O
[ O
Kumar O
et O
al O
., O
J O
. O

The O
average O
values O
were O
199 O
and O
424 O
revertants O
/ O
g O
for O
the O
hamburgers O
and O
hot O
dogs O
, O
respectively O
. O

Cholangiography O
was O
performed O
in O
all O
cases O
and O
classified O
by O
a O
scoring O
system O
specifically O
developed O
for O
pediatric O
patients O
. O

The O
integrity O
of O
the O
cDNA O
sequence O
was O
confirmed O
by O
analysis O
of O
several O
overlapping O
genomic O
clones O
that O
span O
the O
GAR1 I-GENE
gene I-GENE
. O

In O
Trial O
1 O
, O
eight O
sows O
were O
allowed O
to O
farrow O
naturally O
( O
d O
114 O
, O
NF O
sows O
) O
and O
eight O
sows O
were O
induced O
to O
farrow O
( O
IF O
sows O
) O
prematurely O
by O
injection O
of O
prostaglandin O
F2 O
alpha O
on O
d O
112 O
of O
gestation O
. O

End O
- O
tidal O
PO2 O
and O
the O
ratio O
of O
minute O
ventilation O
to O
oxygen O
consumption O
( O
VE O
/ O
VO2 O
) O
were O
lower O
while O
PETCO2 O
was O
higher O
for O
Hyp O
( O
P O
< O
or O
= O
0 O
. O
01 O
). O

These O
results O
suggested O
that O
NfxB I-GENE
negatively O
autoregulates O
the O
expression O
of O
nfxB I-GENE
itself O
. O

A511 O
is O
a O
broad O
- O
host O
- O
range O
, O
virulent O
myovirus O
for O
Listeria O
monocytogenes O
. O

The O
mechanism O
of O
peroxisome O
proliferation O
is O
poorly O
understood O
. O

If O
NCR O
- O
sensitive O
gene O
expression O
occurs O
exclusively O
by O
this O
pathway O
, O
as O
has O
been O
thought O
to O
be O
the O
case O
, O
then O
the O
NCR O
sensitivity O
of O
a O
gene O
' O
s O
expression O
should O
be O
abolished O
by O
a O
ure2 I-GENE
delta I-GENE
mutation I-GENE
. O

The O
single O
- O
stranded O
DNA O
Pur I-GENE
alpha I-GENE
recognition I-GENE
element I-GENE
disrupts O
these O
complexes O
. O

Association O
of O
human I-GENE
Pur I-GENE
alpha I-GENE
with O
the O
retinoblastoma I-GENE
protein I-GENE
, O
Rb I-GENE
, O
regulates O
binding O
to O
the O
single O
- O
stranded O
DNA O
Pur I-GENE
alpha I-GENE
recognition I-GENE
element I-GENE
. O

The O
insulin I-GENE
- O
induced O
DNA O
- O
binding O
complex O
was O
identified O
as O
the O
p50 I-GENE
/ O
p65 I-GENE
heterodimer O
. O

Using O
varying O
conditions O
, O
three O
distinct O
complexes O
were O
shown O
to O
interact O
specifically O
with O
the O
NIP I-GENE
region I-GENE
, O
although O
only O
one O
correlates O
with O
repressor O
activity O
. O

Exchange O
of O
the O
LPL I-GENE
and O
HL I-GENE
lids O
resulted O
in O
a O
reversal O
of O
the O
phospholipase I-GENE
/ O
neutral O
lipase I-GENE
ratio O
, O
establishing O
the O
important O
role O
of O
this O
region O
in O
mediating O
substrate O
specificity O
. O

The O
interferon I-GENE
- O
inducible O
protein I-GENE
kinase I-GENE
PKR I-GENE
modulates O
the O
transcriptional O
activation O
of O
immunoglobulin I-GENE
kappa I-GENE
gene I-GENE
. O

Truncated O
forms O
of O
a O
novel O
yeast O
protein O
suppress O
the O
lethality O
of O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
deficiency O
by O
interacting O
with O
the O
beta O
subunit O
. O

Another O
common O
mutation O
involved O
amino O
acids O
that O
are O
thought O
to O
make O
specific O
contacts O
with O
DNA O
. O

Phorbol O
esters O
stimulated O
phosphorylation O
of O
CSK I-GENE
35H I-GENE
proteins I-GENE
, O
thus O
emphasizing O
that O
sequences O
isolated O
according O
to O
PKC I-GENE
binding O
activity O
in O
vitro O
are O
also O
PKC I-GENE
substrates O
in O
vivo O
. O

Levels O
of O
TSG I-GENE
- I-GENE
14 I-GENE
protein I-GENE
( O
also O
termed O
PTX I-GENE
- I-GENE
3 I-GENE
) O
become O
elevated O
in O
the O
serum O
of O
mice O
and O
humans O
after O
injection O
with O
bacterial O
lipopolysaccharide O
, O
but O
in O
contrast O
to O
conventional O
acute O
phase O
proteins O
, O
the O
bulk O
of O
TSG I-GENE
- I-GENE
14 I-GENE
synthesis O
in O
the O
intact O
organism O
occurs O
outside O
the O
liver O
. O

The O
mouse I-GENE
beta I-GENE
2 I-GENE
- I-GENE
syntrophin I-GENE
gene I-GENE
( O
> O
33 O
kilobases O
) O
contains O
seven O
exons O
, O
all O
of O
which O
have O
homologues O
at O
the O
corresponding O
position O
in O
the O
alpha I-GENE
1 I-GENE
- I-GENE
syntrophin I-GENE
gene I-GENE
. O

Altogether O
our O
data O
indicate O
that O
PEDF I-GENE
belongs O
to O
the O
subgroup O
of O
noninhibitory O
serpins I-GENE
and O
that O
its O
N O
- O
terminal O
region O
confers O
a O
neurite O
- O
promoting O
activity O
to O
the O
protein O
. O

We O
report O
here O
the O
cloning O
of O
the O
murine O
p44 I-GENE
MAP I-GENE
kinase I-GENE
( O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
1 I-GENE
) O
gene O
, O
the O
determination O
of O
its O
intron O
/ O
exon O
boundaries O
, O
and O
the O
characterization O
of O
its O
promoter O
. O

It O
contains O
three O
putative O
TATA O
boxes O
far O
upstream O
of O
the O
main O
start O
sites O
region O
, O
one O
AP I-GENE
- I-GENE
1 I-GENE
box I-GENE
, O
one O
AP I-GENE
- I-GENE
2 I-GENE
box I-GENE
, O
one O
Malt I-GENE
box I-GENE
, O
one O
GAGA O
box O
, O
one O
half O
serum O
- O
responsive O
element O
, O
and O
putative O
binding O
sites O
for O
Sp1 I-GENE
( O
five O
), O
GC I-GENE
- I-GENE
rich I-GENE
binding I-GENE
factor I-GENE
( O
five O
), O
CTF I-GENE
- I-GENE
NF1 I-GENE
( O
one O
), O
Myb I-GENE
( O
one O
), O
p53 I-GENE
( O
two O
), O
Ets I-GENE
- I-GENE
1 I-GENE
( O
one O
), O
NF I-GENE
- I-GENE
IL6 I-GENE
( O
two O
), O
MyoD I-GENE
( O
two O
), O
Zeste I-GENE
( O
one O
), O
and O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
5 I-GENE
( O
one O
). O

One O
of O
these O
is O
surrounded O
by O
an O
adenine O
- O
uridine O
rich O
region O
that O
can O
form O
an O
11 O
- O
base O
pair O
stem O
structure O
. O

We O
conclude O
that O
this O
new O
measurement O
technique O
provides O
an O
easy O
and O
accurate O
P0 O
. O
1 O
measurement O
using O
standard O
respiratory O
equipment O
when O
tested O
in O
a O
lung O
model O
. O

Effects O
of O
verapamil O
and O
propranolol O
on O
early O
afterdepolarizations O
and O
ventricular O
arrhythmias O
induced O
by O
epinephrine O
in O
congenital O
long O
QT O
syndrome O
. O

Deletion O
of O
the O
NF I-GENE
- I-GENE
IL6 I-GENE
beta I-GENE
leucine I-GENE
zipper I-GENE
domain I-GENE
also O
greatly O
diminished O
the O
interaction O
between O
these O
two O
proteins O
. O

After O
cells O
were O
stably O
transfected O
with O
CIITA I-GENE
, O
endogenous O
MHC I-GENE
class I-GENE
II I-GENE
genes I-GENE
were O
constitutively O
expressed O
, O
and O
MHC I-GENE
class I-GENE
II I-GENE
promoters I-GENE
, O
delivered O
by O
transfection O
, O
were O
actively O
transcribed O
in O
CIITA I-GENE
- O
expressing O
cells O
. O

Two O
domains O
of O
EBNA2 I-GENE
defined O
by O
deletion O
of O
amino O
acids O
247 O
- O
337 O
and O
437 O
- O
476 O
were O
found O
to O
be O
important O
for O
the O
activation O
of O
both O
promoters O
, O
while O
two O
different O
domains O
corresponding O
to O
residues O
4 O
- O
18 O
and O
118 O
- O
198 O
were O
required O
solely O
for O
the O
LMP1 I-GENE
promoter I-GENE
. O

The O
peak O
velocities O
of O
the O
atrial O
systolic O
waves O
of O
the O
transmitral O
and O
pulmonary O
venous O
flow O
velocities O
( O
A O
and O
PVA O
, O
respectively O
) O
and O
first O
systolic O
wave O
( O
PVS1 O
) O
of O
pulmonary O
venous O
flow O
, O
durations O
of O
both O
atrial O
systolic O
waves O
, O
and O
amplitude O
of O
interatrial O
septal O
motion O
during O
atrial O
systole O
increased O
significantly O
ten O
days O
after O
cardioversion O
compared O
with O
those O
measured O
within O
a O
day O
of O
cardioversion O
in O
all O
patients O
except O
the O
5 O
patients O
with O
dilated O
cardiomyopathy O
. O

Additionally O
, O
the O
enzyme O
shows O
activity O
towards O
triglycerides O
such O
as O
olive O
oil O
and O
tributyrin O
and O
towards O
egg O
- O
yolk O
emulsions O
. O

The O
nucleotide O
sequence O
directly O
upstream O
of O
fimA I-GENE
contains O
two O
open O
reading O
frames O
, O
ORF5 O
and O
ORF1 O
, O
whose O
deduced O
protein O
products O
are O
homologous O
to O
members O
of O
a O
superfamily O
of O
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
membrane I-GENE
transport I-GENE
proteins I-GENE
, O
including O
both O
prokaryotic O
and O
eukaryotic O
uptake O
and O
export O
systems O
. O

The O
ORF3 O
probe O
also O
hybridized O
to O
a O
540 O
bp O
transcript O
consistent O
with O
the O
size O
of O
ORF3 O
alone O
and O
supportive O
of O
the O
mutagenesis O
data O
of O
non O
- O
linkage O
. O

These O
results O
suggest O
that O
low O
concentrations O
of O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
may O
be O
useful O
for O
nonsurgical O
treatment O
of O
human O
vitreous O
hemorrhage O
. O

We O
conclude O
that O
pancreatic O
polypeptide O
and O
motilin I-GENE
responses O
to O
a O
meal O
are O
different O
in O
encopretic O
children O
than O
in O
children O
in O
the O
control O
group O
. O

Here O
we O
report O
the O
cloning O
, O
expression O
, O
and O
biochemical O
characterization O
of O
the O
32 O
- O
kDa O
subunit O
of O
human O
( O
h O
) O
TFIID I-GENE
, O
termed O
hTAFII32 I-GENE
. O

Hemolytic O
jaundice O
due O
to O
G6PD I-GENE
deficiency O
causing O
kernicterus O
in O
a O
female O
newborn O
. O

Two O
transcripts O
of O
1 O
. O
6 O
kb O
and O
5 O
. O
8 O
kb O
are O
5 O
' O
coterminal O
and O
may O
both O
encode O
the O
novel O
glycoprotein I-GENE
gene I-GENE
EUS4 I-GENE
. O

Mean O
growth O
changes O
in O
this O
Class O
II O
sample O
were O
comparable O
to O
those O
previously O
reported O
for O
male O
subjects O
with O
Class O
I O
malocclusions O
over O
the O
same O
age O
period O
, O
suggesting O
a O
similarity O
in O
postpubertal O
development O
between O
these O
two O
groups O
. O

However O
, O
the O
few O
studies O
that O
address O
antimicrobial O
prophylaxis O
in O
bone O
marrow O
transplantation O
have O
not O
always O
shown O
a O
survival O
benefit O
. O

The O
fracture O
groups O
were O
significantly O
older O
and O
had O
more O
years O
since O
menopause O
than O
the O
control O
groups O
. O

In O
addition O
, O
we O
found O
differences O
in O
the O
binding O
of O
nuclear O
factors O
from O
shoots O
versus O
from O
roots O
, O
in O
agreement O
with O
the O
different O
activities O
of O
the O
promoter O
in O
these O
two O
organs O
. O

The O
prevalence O
and O
incidence O
of O
human O
immunodeficiency O
virus O
types O
1 O
and O
2 O
( O
HIV O
- O
1 O
, O
HIV O
- O
2 O
), O
human O
T O
- O
lymphotropic O
virus O
types O
I O
and O
II O
( O
HTLV O
- O
I O
/ O
II O
), O
and O
syphilitic O
infections O
and O
the O
association O
between O
these O
infections O
were O
determined O
in O
a O
cohort O
of O
police O
officers O
in O
Guinea O
- O
Bissau O
. O

By O
in O
vitro O
immunoprecipitations O
and O
gel O
shift O
assays O
, O
we O
identified O
two O
classes O
of O
high O
affinity O
Engrailed I-GENE
- I-GENE
binding I-GENE
sites I-GENE
upstream O
of O
each O
of O
the O
two O
polyhomeotic O
transcription O
units O
. O

Subjects O
with O
a O
short O
postexposure O
time O
and O
a O
dioxin O
burden O
> O
0 O
. O
6 O
pg O
/ O
m3 O
had O
a O
significantly O
higher O
risk O
of O
hypoergy O
than O
unexposed O
subjects O
( O
hypoergy O
I O
: O
OR O
= O
9 O
. O
51 O
, O
95 O
% O
CI O
= O
1 O
. O
96 O
- O
42 O
. O
02 O
; O
hypoergy O
II O
: O
OR O
= O
2 O
. O
92 O
, O
95 O
% O
CI O
= O
1 O
. O
14 O
- O
7 O
. O
5 O
). O

Analysis O
of O
this O
sequence O
combined O
with O
that O
previously O
reported O
for O
the O
5 O
'- O
flanking O
region O
directly O
proximal O
to O
the O
start O
of O
transcription O
revealed O
several O
putative O
regulatory O
sequences O
. O

We O
now O
show O
that O
the O
BAT1 I-GENE
translation I-GENE
product I-GENE
is O
the O
homolog O
of O
the O
rat I-GENE
p47 I-GENE
nuclear I-GENE
protein I-GENE
, O
the O
WM6 I-GENE
Drosophila I-GENE
gene I-GENE
product I-GENE
, O
and O
probably O
also O
Ce08102 I-GENE
of O
Caenorhabditis O
elegans O
, O
all O
members O
of O
the O
DEAD I-GENE
protein I-GENE
family I-GENE
of O
ATP I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
helicases I-GENE
. O

By O
using O
lacZ I-GENE
fusions I-GENE
, O
it O
was O
possible O
to O
localize O
the O
DNA O
sequences O
required O
to O
mediate O
nitrate O
repression O
to O
the O
pfl I-GENE
promoter I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
. O

In O
this O
report O
, O
we O
describe O
the O
characterization O
of O
two O
early O
class I-GENE
II I-GENE
flagellar I-GENE
genes I-GENE
contained O
in O
the O
orfX O
- O
fliP I-GENE
locus O
. O

Vestibular O
adaptation O
exercises O
and O
recovery O
: O
acute O
stage O
after O
acoustic O
neuroma O
resection O
. O

The O
experimental O
design O
represents O
a O
2 O
x O
3 O
factorial O
arrangement O
of O
treatments O
with O
three O
dietary O
levels O
of O
incorporation O
of O
RSB O
( O
0 O
, O
50 O
, O
and O
100 O
%), O
and O
chickens O
either O
infected O
or O
uninfected O
. O

A O
cDNA O
clone O
corresponding O
to O
the O
putative O
GA I-GENE
20 I-GENE
- O
oxidase I-GENE
genomic O
sequence O
was O
constructed O
with O
the O
reverse O
transcription O
- O
PCR O
method O
, O
and O
the O
identity O
of O
the O
cDNA O
clone O
was O
confirmed O
by O
analyzing O
the O
capability O
of O
the O
fusion O
protein O
expressed O
in O
Escherichia O
coli O
to O
convert O
GA53 I-GENE
to O
GA44 I-GENE
and O
GA19 I-GENE
to O
GA20 I-GENE
. O

There O
were O
no O
significant O
changes O
in O
either O
the O
fatty O
acid O
composition O
of O
biliary O
lecithin O
or O
in O
the O
bile O
acid O
composition O
of O
bile O
. O

Total O
cholesterol O
was O
also O
reduced O
at O
week O
12 O
by O
17 O
. O
0 O
% O
( O
20 O
mg O
/ O
day O
) O
and O
15 O
. O
7 O
% O
( O
20 O
- O
30 O
mg O
/ O
day O
), O
and O
at O
week O
52 O
by O
20 O
. O
4 O
% O
(< O
or O
= O
20 O
mg O
/ O
day O
) O
and O
19 O
. O
2 O
% O
(> O
or O
= O
30 O
mg O
/ O
day O
). O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
PEBP2 I-GENE
in O
the O
GM I-GENE
- I-GENE
CSF I-GENE
promoter I-GENE
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
PEBP2 I-GENE
isoforms I-GENE
in O
regulating O
the O
levels O
of O
the O
promoter O
activity O
. O

Benefits O
of O
obtaining O
board O
certification O
in O
pharmacotherapy O
. O

Piperacillin O
- O
tazobactam O
can O
be O
used O
for O
the O
treatment O
of O
infections O
caused O
by O
gram O
- O
negative O
, O
gram O
- O
positive O
, O
aerobic O
, O
and O
anaerobic O
bacteria O
. O

Basal O
plasma O
renin I-GENE
activity O
( O
PRA O
) O
was O
slightly O
raised O
prior O
to O
training O
( O
P O
< O
0 O
. O
07 O
) O
compared O
to O
the O
controls O
and O
post O
- O
training O
. O

This O
apparently O
anomalous O
structure O
/ O
activity O
relationship O
raises O
important O
issues O
for O
understanding O
the O
evolution O
of O
regulatory O
peptides O
and O
the O
mechanisms O
that O
control O
their O
expression O
. O

The O
structural O
gene O
encoding O
the O
novel O
lantibiotic O
epilancin I-GENE
K7 I-GENE
from O
Staphylococcus O
epidermidis O
K7 O
was O
cloned O
and O
its O
nucleotide O
sequence O
was O
determined O
. O

This O
paper O
summarises O
the O
experimental O
evidence O
upon O
which O
the O
clinical O
trials O
of O
aldose I-GENE
reductase I-GENE
inhibitors O
in O
diabetic O
patients O
have O
been O
initiated O
and O
the O
results O
of O
published O
drug O
trials O
in O
these O
patients O
. O

The O
spectrum O
of O
phenotypes O
caused O
by O
these O
mutations O
was O
strikingly O
different O
than O
mutations O
in O
the O
adaptor O
for O
the O
VP16 I-GENE
activation I-GENE
domain I-GENE
. O

Increase O
in O
urinary O
calcium O
and O
oxalate O
after O
fructose O
infusion O
. O

The O
5 O
' O
flanking O
region O
is O
highly O
GC O
rich O
, O
with O
multiple O
CpG O
doublets O
, O
and O
contains O
multiple O
binding O
sites O
for O
Sp1 I-GENE
. O

To O
discern O
whether O
these O
disorders O
of O
GnRH I-GENE
deficiency O
are O
associated O
with O
altered O
melatonin O
secretion O
profiles O
, O
we O
compared O
untreated O
young O
males O
IGD O
( O
n O
= O
7 O
) O
and O
DP O
( O
n O
= O
7 O
) O
to O
normal O
pubertal O
male O
controls O
( O
n O
= O
6 O
). O

Increased O
blood O
pressure O
during O
CyA O
treatment O
was O
independent O
of O
circulating O
ET I-GENE
- I-GENE
1 I-GENE
levels O
. O

Analysis O
of O
several O
Tat I-GENE
mutants I-GENE
indicated O
that O
both O
the O
cysteine O
- O
rich O
and O
the O
core O
domains O
of O
this O
transactivator O
are O
necessary O
and O
sufficient O
to O
activate O
transcription O
when O
TBP I-GENE
is O
overexpressed O
. O

In O
addition O
, O
depletion O
of O
Oct I-GENE
- I-GENE
1 I-GENE
from O
the O
nuclear O
extract O
by O
using O
Oct I-GENE
- I-GENE
1 I-GENE
- O
specific O
antiserum O
or O
a O
sequence O
- O
specific O
DNA O
affinity O
resin O
decreased O
in O
vitro O
transcription O
from O
the O
wild O
- O
type O
MMTV O
promoter O
to O
a O
level O
identical O
to O
that O
obtained O
from O
a O
promoter O
in O
which O
all O
three O
octamer O
- O
related O
sequences O
were O
mutated O
. O

Transactivation O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
by O
T3R I-GENE
alpha I-GENE
and O
several O
receptor O
mutants O
revealed O
that O
the O
50 O
- O
amino O
- O
acid O
N O
- O
terminal O
A O
/ O
B O
region O
of O
T3R I-GENE
alpha I-GENE
, O
known O
to O
interact O
with O
the O
basal I-GENE
transcription I-GENE
factor I-GENE
TFIIB I-GENE
, O
is O
critical O
for O
activation O
of O
both O
Tat I-GENE
- O
dependent O
and O
Tat I-GENE
- O
independent O
responsive O
sequences O
of O
the O
LTR O
. O

M O
. O
M O
. O
C O
. O
was O
used O
for O
2 O
. O
5 O
minutes O
in O
44 O
cases O
( O
20 O
HR O
patients O
, O
24 O
LR O
patients O
), O
and O
for O
5 O
minutes O
in O
66 O
cases O
( O
46 O
HR O
patients O
, O
20 O
LR O
patients O
). O

Finally O
, O
we O
show O
that O
complexes O
similar O
to O
the O
C25 I-GENE
, O
C30 I-GENE
and O
C35 I-GENE
complexes I-GENE
are O
formed O
by O
rat O
cortex O
nuclear O
extracts O
and O
the O
SAA O
element O
in O
EMSA O
experiments O
, O
suggesting O
the O
relevance O
of O
our O
in O
vitro O
observations O
to O
the O
in O
vivo O
functioning O
of O
the O
rat I-GENE
APP I-GENE
promoter I-GENE
. O

Oncological O
, O
clinical O
and O
psychological O
aspects O
are O
evaluated O
according O
to O
experience O
accumulated O
in O
recent O
years O
, O
with O
immediate O
and O
delayed O
reconstruction O
, O
carried O
out O
in O
the O
most O
diverse O
specialized O
centers O
. O

The O
analysis O
of O
the O
prevalence O
values O
shows O
clearly O
that O
the O
global O
MS O
- O
frequency O
is O
closer O
related O
to O
the O
geomagnetic O
than O
to O
the O
geographic O
latitude O
. O

Diltiazem O
caused O
significant O
decrease O
in O
the O
ventricular O
response O
without O
conversion O
to O
sinus O
rhythm O
. O

Subhuman O
primates O
appear O
to O
be O
more O
sensitive O
to O
reproductive O
and O
other O
adverse O
effects O
of O
PCBs O
than O
humans O
. O

When O
excluding O
children O
with O
ocular O
and O
cerebral O
pathology O
, O
32 O
matched O
pairs O
of O
premature O
and O
control O
children O
remained O
. O

The O
cryptococcal I-GENE
antigen I-GENE
test O
was O
positive O
at O
1 O
: O
125 O
by O
latex O
agglutination O
. O

Functional O
analysis O
of O
DNase I-GENE
- I-GENE
I I-GENE
hypersensitive O
sites O
at O
the O
mouse I-GENE
porphobilinogen I-GENE
deaminase I-GENE
gene I-GENE
locus I-GENE
. O

These O
transcripts O
have O
a O
unique O
5 O
' O
untranslated O
region O
and O
NH2 O
- O
terminal O
sequence O
and O
encode O
a O
predicted O
protein O
of O
121 O
kD O
. O

Both O
mu I-GENE
and I-GENE
gamma I-GENE
2b I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
cause O
this O
feedback O
inhibition O
of O
heavy O
chain O
gene O
rearrangement O
. O

Purified O
CarP I-GENE
binds O
in O
vitro O
to O
the O
carAB I-GENE
control I-GENE
region I-GENE
and O
protects O
against O
DNase I-GENE
I I-GENE
two O
approximately O
25 O
bp O
long O
stretches O
, O
one O
of O
which O
is O
located O
just O
downstream O
of O
the O
GATC O
sequence O
. O

They O
include O
genes O
encoding O
three O
subunits O
of O
the O
cytochrome I-GENE
oxidase I-GENE
( O
cox1 I-GENE
to I-GENE
3 I-GENE
), O
apocytochrome I-GENE
b I-GENE
( O
cob I-GENE
), O
seven O
subunits O
of O
the O
NADH I-GENE
dehydrogenase I-GENE
complex I-GENE
( O
nad1 I-GENE
to I-GENE
6 I-GENE
, O
nad4L I-GENE
), O
two O
ATPase I-GENE
subunits O
( O
atp6 I-GENE
and O
atp9 I-GENE
), O
three O
ribosomal O
RNAs O
( O
rrn5 I-GENE
, O
srn I-GENE
and O
lrn I-GENE
), O
23 O
tRNAs O
and O
four O
ribosomal O
proteins O
( O
rps3 I-GENE
, O
rps11 I-GENE
, O
rps12 I-GENE
and O
rpl16 I-GENE
). O

From O
day O
10 O
, O
a O
significant O
increase O
in O
platelet O
count O
was O
observed O
in O
eight O
of O
the O
ten O
patients O
treated O
with O
heparin O
( O
p O
< O
0 O
. O
05 O
), O
with O
return O
to O
the O
initial O
value O
after O
heparin O
cessation O
in O
six O
of O
the O
responders O
. O

These O
" O
nucleocapsid O
- O
like O
" O
structures O
were O
readily O
purified O
by O
density O
gradient O
centrifugation O
. O

The O
Babcock O
Surgical O
Clinic O
. O

Resources O
for O
helping O
patients O
to O
quit O
smoking O
. O

The O
PEBP2 I-GENE
alpha I-GENE
proteins I-GENE
contain O
a O
128 O
- O
amino O
- O
acid O
( O
aa O
) O
region O
highly O
homologous O
to O
the O
Drosophila I-GENE
melanogaster I-GENE
segmentation I-GENE
gene I-GENE
runt I-GENE
. O

In O
human O
proliferative O
cells O
, O
the O
NADP O
- O
dependent O
ME I-GENE
activity O
is O
poorly O
expressed O
and O
barely O
inducible O
by O
thyroid O
hormones O
. O

Based O
on O
previous O
mapping O
of O
the O
G I-GENE
beta I-GENE
gamma I-GENE
binding I-GENE
region I-GENE
of O
beta I-GENE
ARK I-GENE
, O
and O
conserved O
residues O
within O
the O
PH I-GENE
domain I-GENE
, O
we O
have O
constructed O
a O
series O
of O
mutants O
in O
the O
carboxyl O
terminus O
of O
beta I-GENE
ARK I-GENE
in O
order O
to O
determine O
important O
residues O
involved O
in O
G I-GENE
beta I-GENE
gamma I-GENE
and O
PIP2 O
binding O
. O

Histopathological O
features O
of O
relapsed O
leprosy O
. O

To O
dissect O
these O
mechanisms O
, O
wild O
- O
type O
and O
mutant I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
were O
studied O
in O
an O
in O
vitro O
system O
with O
purified O
plasma O
membranes O
from O
v I-GENE
- I-GENE
Ras I-GENE
- O
and O
v I-GENE
- I-GENE
Src I-GENE
- O
transformed O
cells O
( O
transformed O
membranes O
). O

In O
CV O
- O
1 O
cells O
, O
cotransfection O
of O
the O
retinoid I-GENE
and I-GENE
estrogen I-GENE
receptors I-GENE
led O
to O
mutual O
inhibition O
of O
the O
other O
' O
s O
activity O
, O
while O
an O
RA O
- O
dependent O
inhibition O
of O
ER I-GENE
activity O
was O
observed O
in O
breast O
cancer O
cells O
. O

One O
of O
these O
factors O
, O
HRF I-GENE
- I-GENE
1 I-GENE
, O
recognizes O
a O
cis O
element O
consisting O
of O
an O
inverted O
palindromic O
motif O
. O

Regulation O
of O
Gax I-GENE
homeobox I-GENE
gene I-GENE
transcription O
by O
a O
combination O
of O
positive O
factors O
including O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
factor I-GENE
2 I-GENE
. O

The O
carboxyl O
- O
terminal O
transactivation O
domain O
of O
heat I-GENE
shock I-GENE
factor I-GENE
1 I-GENE
is O
negatively O
regulated O
and O
stress O
responsive O
. O

D O
. O

It O
was O
proposed O
that O
the O
synthetase O
- O
related O
sequences O
of O
GCN2 I-GENE
stimulate O
the O
activity O
of O
the O
kinase O
by O
interacting O
directly O
with O
uncharged O
tRNA O
that O
accumulates O
during O
amino O
acid O
limitation O
. O

However O
, O
unlike O
Bcl I-GENE
- I-GENE
2 I-GENE
and O
the O
E1B I-GENE
19K I-GENE
proteins I-GENE
, O
which O
completely O
block O
apoptosis O
but O
not O
p53 I-GENE
- O
dependent O
growth O
arrest O
, O
H I-GENE
- I-GENE
ras I-GENE
expression O
permitted O
DNA O
synthesis O
and O
cell O
proliferation O
in O
the O
presence O
of O
high O
levels O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
. O

To O
compare O
the O
PAX3 I-GENE
and O
putative O
PAX3 I-GENE
- O
FKHR I-GENE
transactivation O
domains O
, O
we O
fused O
C O
- O
terminal O
test O
fragments O
to O
the O
heterologous O
GAL4 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
tested O
activation O
of O
a O
reporter O
gene O
co O
- O
transfected O
into O
four O
cell O
types O
. O

All O
subjects O
were O
submitted O
to O
ECG O
and O
arterial O
blood O
pressure O
determination O
and O
were O
assayed O
for O
TSH I-GENE
, O
thyroid O
hormone O
, O
PRL I-GENE
, O
glucose O
, O
creatinine O
, O
nitrogen O
, O
glutamine I-GENE
transaminase I-GENE
, O
cholesterol O
and O
triglycerides O
plasma O
levels O
before O
therapy O
( O
T0 O
), O
after O
30 O
treatment O
days O
( O
T30 O
) O
and O
after O
a O
15 O
days O
washout O
( O
T45 O
). O

Acute O
decrease O
in O
body O
temperature O
( O
TB O
) O
lowered O
PaCO2 O
( O
32 O
. O
5 O
to O
14 O
. O
5 O
mmHg O
) O
and O
[ O
HCO3 O
-] O
a O
( O
24 O
. O
20 O
mEq O
/ O
L O
to O
17 O
. O
56 O
mEq O
/ O
L O
), O
increased O
pHa O
( O
7 O
. O
481 O
to O
7 O
. O
608 O
) O
and O
diminished O
the O
[ O
OH O
-]/[ O
H O
+] O
ratio O
, O
but O
had O
no O
significant O
effect O
on O
[ O
SID O
] O
or O
[ O
Atot O
], O
although O
both O
total O
phosphorus O
[ O
PT O
] O
and O
inorganic O
phosphate O
[ O
Pi O
] O
increased O
. O

Hepatitis O
B O
vaccine O
: O
still O
has O
its O
problems O
. O

Basal O
promoter O
activity O
is O
enhanced O
by O
a O
functional O
M1 O
domain O
in O
LHR I-GENE
- O
expressing O
mouse O
Leydig O
tumor O
cells O
( O
MLTC O
) O
but O
not O
in O
non O
- O
expressing O
CHO O
cells O
. O

The O
RAT3 I-GENE
gene I-GENE
encodes O
an O
1157 O
- O
amino O
acid O
protein O
without O
similarity O
to O
other O
known O
proteins O
. O

For O
Al O
, O
the O
exposure O
to O
1 O
. O
36 O
mg O
/ O
m3 O
during O
the O
shift O
corresponded O
to O
a O
urinary O
concentration O
at O
the O
end O
of O
the O
shift O
of O
200 O
microgram O
/ O
g O
creatinine O
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
), O
a O
proinflammatory O
cytokine O
, O
inhibits O
cAMP O
- O
stimulated O
testosterone O
production O
in O
mouse O
Leydig O
cells O
. O

The O
Drosophila I-GENE
insulin I-GENE
receptor I-GENE
homolog I-GENE
: O
a O
gene O
essential O
for O
embryonic O
development O
encodes O
two O
receptor O
isoforms O
with O
different O
signaling O
potential O
. O

We O
show O
here O
that O
RA O
and O
E1A I-GENE
induce O
phosphorylation O
of O
the O
E1A I-GENE
- I-GENE
associated I-GENE
300 I-GENE
kDa I-GENE
protein I-GENE
( O
p300 I-GENE
) O
during O
the O
differentiation O
of O
F9 O
cells O
. O

The O
double O
- O
stranded O
RNA O
binding O
domain O
( O
dsRBD O
) O
is O
an O
approximately O
65 O
amino O
acid O
motif O
that O
is O
found O
in O
a O
variety O
of O
proteins O
that O
interact O
with O
double O
- O
stranded O
( O
ds O
) O
RNA O
, O
such O
as O
Escherichia O
coli O
RNase I-GENE
III I-GENE
and O
the O
dsRNA I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
PKR I-GENE
. O

CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
isoforms I-GENE
beta I-GENE
and I-GENE
delta I-GENE
are O
expressed O
in O
mammary O
epithelial O
cells O
and O
bind O
to O
multiple O
sites O
in O
the O
beta I-GENE
- I-GENE
casein I-GENE
gene I-GENE
promoter I-GENE
. O

SCA I-GENE
was O
resistant O
to O
inhibitors O
of O
serine O
, O
aspartyl O
, O
and O
metalloproteases I-GENE
, O
but O
it O
was O
sensitive O
to O
N O
- O
ethylmaleimide O
. O

Mutational O
analysis O
of O
potential O
activating O
phosphorylation O
sites O
found O
in O
NIMA I-GENE
, O
NIM I-GENE
- I-GENE
1 I-GENE
, O
and O
related O
protein O
kinases O
was O
performed O
on O
NIMA I-GENE
. O

However O
, O
a O
similar O
mutation O
of O
a O
leucine O
residue O
to O
arginine O
at O
position O
422 O
showed O
no O
alteration O
of O
heterodimerization O
, O
DNA O
binding O
, O
or O
transcriptional O
activation O
. O

Expression O
of O
the O
CYP11A1 I-GENE
gene I-GENE
is O
increased O
by O
hormones O
, O
such O
as O
adrenocorticotropin I-GENE
and O
luteinizing I-GENE
hormone I-GENE
, O
as O
well O
as O
by O
a O
number O
of O
growth O
factors O
, O
suggesting O
that O
its O
promoter O
may O
contain O
regulatory O
elements O
that O
respond O
to O
multiple O
signal O
transduction O
pathways O
. O

NH2 O
- O
and O
COOH O
- O
terminal O
deletion O
analysis O
revealed O
that O
both O
the O
PH I-GENE
and O
putative O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
domains I-GENE
are O
required O
, O
but O
the O
zinc O
butterfly O
is O
dispensable O
, O
for O
transformation O
. O

We O
have O
found O
that O
the O
expression O
of O
GTPase I-GENE
- O
deficient O
mutants O
of O
alpha I-GENE
12 I-GENE
( O
alpha I-GENE
12Q229L I-GENE
) O
or O
alpha I-GENE
13 I-GENE
( O
alpha I-GENE
13Q226L I-GENE
) O
leads O
to O
robust O
activation O
of O
the O
Jun I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ O
SAPK I-GENE
) O
pathway O
. O

The O
objective O
of O
our O
study O
was O
to O
evaluate O
the O
age O
, O
sex O
, O
clinical O
conditions O
, O
family O
history O
, O
site O
, O
catheter O
association O
, O
means O
of O
radiologic O
evaluation O
, O
development O
of O
pulmonary O
involvement O
, O
prevalence O
of O
antithrombin I-GENE
III I-GENE
, O
protein I-GENE
C I-GENE
and O
protein I-GENE
S I-GENE
deficiencies O
, O
and O
lupus O
anticoagulants O
in O
children O
who O
suffered O
a O
thrombotic O
event O
. O

Harel O
, O
E O
. O
M O
. O

Radiotherapy O
and O
early O
orchiectomy O
in O
stage O
D1 O
prostatic O
carcinoma O

Structural O
organization O
and O
developmental O
expression O
pattern O
of O
the O
mouse I-GENE
WD I-GENE
- I-GENE
repeat I-GENE
gene I-GENE
DMR I-GENE
- I-GENE
N9 I-GENE
immediately O
upstream O
of O
the O
myotonic I-GENE
dystrophy I-GENE
locus I-GENE
. O

The O
ARX2 O
procedure O
models O
the O
recorded O
signal O
as O
the O
sum O
of O
three O
signals O
: O
( O
a O
) O
the O
background O
EEG O
activity O
, O
modelled O
as O
an O
autoregressive O
process O
driven O
by O
a O
white O
noise O
; O
( O
b O
) O
a O
filtered O
version O
of O
a O
reference O
signal O
carrying O
the O
average O
information O
contained O
in O
each O
sweep O
; O
( O
c O
) O
a O
signal O
due O
to O
the O
ocular O
artefact O
propagation O
. O

The O
expression O
of O
the O
gene O
encoding O
the O
enzyme O
( O
CYP19 I-GENE
) O
is O
regulated O
, O
in O
part O
, O
by O
tissue O
- O
specific O
promoters O
through O
the O
use O
of O
alternative O
- O
splicing O
mechanisms O
. O

Using O
mutagenesis O
, O
we O
have O
identified O
two O
mutations O
of O
the O
second O
actin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
that O
can O
also O
suppress O
the O
act1 I-GENE
mutations O
of O
interest O
. O

CIITA I-GENE
mRNA I-GENE
is O
normally O
inducible O
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
class O
II O
non O
- O
inducible O
, O
RB O
- O
defective O
lines O
, O
and O
in O
one O
line O
, O
re O
- O
expression O
of O
RB I-GENE
has O
no O
effect O
on O
CIITA I-GENE
mRNA I-GENE
induction O
levels O
. O

The O
normal O
cell O
cycle O
is O
regulated O
by O
several O
molecules O
, O
such O
as O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
pRb I-GENE
, O
the O
G1 I-GENE
cyclins I-GENE
, O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
and O
their O
inhibitors O
. O

Consistent O
with O
the O
protein O
expression O
data O
, O
V I-GENE
beta I-GENE
8 I-GENE
. I-GENE
3 I-GENE
gene I-GENE
transcripts I-GENE
were O
found O
only O
in O
the O
transgenic O
lines O
with O
the O
wild O
- O
type O
promoter O
. O

These O
results O
are O
very O
useful O
for O
deciding O
on O
the O
doses O
of O
hormones O
and O
the O
expected O
serum O
estradiol O
level O
in O
HRT O
for O
Japanese O
women O
. O

Comparison O
of O
1 O
. O
5 O
Tesla O
and O
0 O
. O
35 O
Tesla O
field O
strength O
magnetic O
resonance O
imaging O
scans O
in O
the O
morphometric O
evaluation O
of O
the O
lumbar O
intervertebral O
foramina O
. O

One O
month O
after O
the O
DTaP O
booster O
vaccination O
, O
both O
groups O
had O
6 O
- O
to O
40 O
- O
fold O
increases O
in O
serum O
antibody O
concentrations O
to O
all O
antigens O
tested O
; O
the O
concentrations O
against O
the O
three O
pertussis I-GENE
antigens I-GENE
were O
higher O
in O
the O
DTaP O
- O
primed O
children O
( O
p O
< O
0 O
. O
05 O
). O

Interestingly O
, O
this O
amino O
- O
terminal O
determinant O
appears O
not O
to O
reside O
in O
the O
HSV O
- O
alpha I-GENE
TIF I-GENE
, O
which O
displays O
no O
independent O
amino O
- O
terminal O
activity O
. O

We O
also O
show O
that O
in O
fusions O
with O
the O
DNA O
binding O
domain O
of O
GAL4 I-GENE
, O
full O
activity O
requires O
the O
entire O
BHV I-GENE
- I-GENE
alpha I-GENE
TIF I-GENE
, O
although O
both O
amino O
and O
carboxyl O
termini O
display O
some O
activity O
on O
their O
own O
. O

To O
investigate O
the O
potential O
role O
of O
SP1 I-GENE
, O
we O
examined O
nuclear O
extracts O
from O
HCMV O
- O
infected O
cells O
. O

Here O
we O
show O
that O
messenger O
RNAs O
encoding O
trans O
- O
sialidases O
containing O
the O
repeats O
are O
not O
present O
in O
epimastigotes O
but O
are O
abundant O
in O
trypomastigotes O
. O

From O
May O
1985 O
to O
May O
1989 O
, O
126 O
necropsies O
were O
performed O
at O
the O
Sao O
Paulo O
City O
Morgue O
on O
cadavers O
of O
individuals O
AIDS O
victims O
whose O
unnatural O
deaths O
had O
prompted O
police O
investigations O
. O

A O
model O
with O
age O
and O
weight O
described O
the O
best O
fit O
for O
TBBMD O
, O
whereas O
age O
, O
weight O
, O
and O
height O
described O
the O
best O
fit O
for O
total O
body O
TBBMC O
. O

As O
retinoic O
acid O
and O
thyroid O
hormone O
are O
frequently O
involved O
in O
developmental O
regulatory O
processes O
, O
it O
is O
possible O
that O
this O
element O
may O
be O
important O
in O
the O
process O
of O
islet O
cell O
differentiation O
. O

The O
C O
- O
terminal O
peptide O
sequences O
of O
the O
human I-GENE
lymphocyte I-GENE
- I-GENE
specific I-GENE
high I-GENE
mobility I-GENE
group I-GENE
( I-GENE
HMG I-GENE
)- I-GENE
box I-GENE
transcription I-GENE
factor I-GENE
TCF I-GENE
- I-GENE
1 I-GENE
are O
determined O
by O
alternative O
splice O
mechanisms O
affecting O
the O
exons O
VIII O
to O
X O
. O

Thromboxane O
B2 O
increased O
( O
97 O
+/- O
105 O
versus O
40 O
+/- O
26 O
pg O
/ O
ml O
) O
and O
was O
significantly O
higher O
during O
heparin O
free O
hemodialysis O
than O
during O
hemodialysis O
with O
heparin O
( O
p O
= O
0 O
. O
01 O
, O
Wilcoxon O
matched O
pairs O
signed O
rank O
test O
). O

A O
new O
vector O
, O
pHBK280 O
, O
was O
designed O
to O
facilitate O
this O
analysis O
. O

To O
explore O
the O
mechanism O
of O
RSK I-GENE
activation O
, O
a O
cloned O
human O
RSK I-GENE
cDNA O
( O
RSK3 I-GENE
) O
was O
used O
to O
generate O
and O
characterize O
several O
site O
- O
directed O
RSK I-GENE
mutants I-GENE
; O
K91A O
( O
N O
- O
Lys O
, O
NH2 O
- O
terminal O
ATP O
- O
binding O
mutant O
), O
K444A O
( O
C O
- O
Lys O
, O
COOH O
- O
terminal O
ATP O
- O
binding O
mutant O
), O
N O
/ O
C O
- O
Lys O
( O
double O
ATP O
- O
binding O
mutant O
) O
T570A O
( O
C O
- O
Thr O
, O
mutant O
of O
the O
putative O
MAPK I-GENE
phosphorylation O
site O
in O
subdomain O
VIII O
of O
the O
C O
- O
domain O
), O
S218A O
( O
N O
- O
Ser O
, O
mutant O
of O
the O
corresponding O
NH2 O
- O
terminal O
residue O
). O

In O
contrast O
, O
both O
C O
- O
Lys O
and O
C O
- O
Thr O
retained O
high O
levels O
of O
kinase O
activity O
and O
were O
capable O
of O
responding O
to O
stimulation O
. O

Conversely O
, O
treatment O
of O
human I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
alpha I-GENE
- O
overexpressing O
cells O
with O
phenylarsine O
oxide O
led O
to O
a O
loss O
of O
the O
constitutive O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
activity O
. O

A O
TATA O
- O
less O
promoter O
containing O
binding O
sites O
for O
ubiquitous O
transcription O
factors O
mediates O
cell O
type O
- O
specific O
regulation O
of O
the O
gene O
for O
transcription I-GENE
enhancer I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TEF I-GENE
- I-GENE
1 I-GENE
). O

Since O
electrical O
stimulation O
of O
neurones O
may O
activate O
not O
only O
cell O
bodies O
but O
also O
neuronal O
fibres O
, O
this O
study O
aimed O
to O
test O
a O
selectively O
cholinergic O
neurochemical O
stimulation O
of O
the O
rat O
substantia O
innominata O
( O
SI O
) O
by O
the O
local O
microinjection O
of O
carbachol O
; O
the O
effects O
of O
this O
acetylcholine O
agonist O
were O
compared O
with O
glutamate O
. O

Here O
we O
describe O
an O
in O
vitro O
assay O
where O
the O
NS3 I-GENE
- I-GENE
4A I-GENE
polyprotein I-GENE
, O
NS3 I-GENE
, O
the O
serine O
proteinase O
domain O
( O
the O
N O
- O
terminal O
181 O
residues O
of O
NS3 O
), O
and O
the O
NS4A I-GENE
cofactor I-GENE
were O
produced O
by O
cell O
- O
free O
translation O
and O
tested O
for O
trans O
- O
processing O
of O
radiolabeled O
substrates O
. O

In O
contrast O
, O
over O
- O
expression O
of O
RAR I-GENE
beta I-GENE
only O
poorly O
restored O
differentiation O
, O
although O
it O
could O
replace O
RAR I-GENE
gamma I-GENE
for O
the O
activation O
of O
target O
genes O
. O

We O
purified O
both O
proteins O
from O
human O
platelet O
membranes O
using O
DEAE O
- O
Sepharose O
chromatography O
followed O
by O
mAb I-GENE
F11 I-GENE
affinity O
chromatography O
. O

The O
homeobox I-GENE
gene I-GENE
ATK1 I-GENE
of O
Arabidopsis O
thaliana O
is O
expressed O
in O
the O
shoot O
apex O
of O
the O
seedling O
and O
in O
flowers O
and O
inflorescence O
stems O
of O
mature O
plants O
. O

The O
most O
likely O
explanation O
for O
this O
is O
that O
gold O
principally O
accumulates O
in O
the O
Kupffer O
cells O
and O
renal O
cortex O
and O
these O
cells O
do O
not O
express O
Type I-GENE
I I-GENE
deiodinase I-GENE
. O

These O
results O
suggest O
that O
different O
models O
of O
intestinal O
ischemia O
have O
different O
cytokine O
profiles O
and O
that O
the O
early O
TNF I-GENE
response O
associated O
with O
SMA O
occlusion O
model O
is O
primarily O
due O
to O
the O
laparotomy O
. O

Our O
evidence O
derives O
from O
three O
principal O
observations O
: O
1 O
) O
a O
transfection O
construct O
containing O
only O
122 O
nucleotides O
( O
nt O
) O
of O
promoter O
1 O
and O
328 O
nt O
of O
the O
5 O
'- O
UTR O
retained O
full O
PGE2 O
- O
stimulated O
reporter O
expression O
; O
2 O
) O
maximal O
PGE2 O
- O
driven O
reporter O
expression O
required O
the O
presence O
of O
nt O
196 O
to O
328 O
of O
exon O
1 O
when O
tested O
within O
the O
context O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
; O
3 O
) O
cotransfection O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
- O
luciferase I-GENE
- O
reporter O
constructs O
with O
a O
plasmid O
encoding O
the O
alpha O
- O
isoform O
of O
the O
catalytic O
subunit O
of O
murine I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
produced O
results O
comparable O
to O
those O
seen O
with O
PGE2 O
treatment O
, O
whereas O
cotransfection O
with O
a O
plasmid O
encoding O
a O
mutant O
regulatory O
subunit O
of O
PKA I-GENE
that O
cannot O
bind O
cAMP O
blocked O
PGE2 O
- O
induced O
reporter O
expression O
. O

The O
changes O
after O
treatment O
were O
observed O
chiefly O
by O
electromyography O
while O
sensory O
and O
motor O
improvement O
were O
also O
recorded O
as O
auxiliary O
indicators O
. O

Band O
- O
shift O
assays O
and O
DNase I-GENE
I I-GENE
footprinting O
experiments O
using O
purified O
42 O
kDa O
repressor O
isoform O
confirmed O
that O
CIRs I-GENE
5 I-GENE
and I-GENE
6 I-GENE
were O
indeed O
the O
targets O
for O
binding O
of O
this O
protein O
. O

The O
5 O
'- O
terminus O
of O
the O
p I-GENE
- I-GENE
gvpF I-GENE
- I-GENE
M I-GENE
mRNA I-GENE
was O
located O
169 O
nucleotides O
upstream O
of O
p I-GENE
- I-GENE
gvpF I-GENE
within O
p I-GENE
- I-GENE
gvpE I-GENE
. O

Retransformation O
of O
uvsH77 I-GENE
mutants I-GENE
with O
the O
rescued O
cosmids O
from O
the O
MMS O
- O
resistant O
transformants O
resulted O
in O
restoration O
of O
both O
UV O
and O
MMS O
resistance O
to O
wild O
- O
type O
levels O
. O

Furthermore O
, O
this O
element O
confers O
p53 I-GENE
induction O
to O
the O
otherwise O
nonresponsive O
adenovirus O
major O
late O
promoter O
. O

In O
flies O
, O
the O
dShc I-GENE
protein I-GENE
physically O
associates O
with O
the O
activated O
Drosophila I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
homolog I-GENE
( O
DER I-GENE
) O
and O
is O
inducibly O
phosphorylated O
on O
tyrosine O
by O
DER I-GENE
. O

A O
potential O
binding O
site O
for O
the O
dShc I-GENE
PTB O
domain O
is O
located O
at O
Tyr O
- O
1228 O
of O
DER I-GENE
. O

A O
Drosophila I-GENE
shc I-GENE
gene I-GENE
product I-GENE
is O
implicated O
in O
signaling O
by O
the O
DER I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

This O
inhibition O
can O
be O
overcome O
by O
mutating O
either O
the O
exon O
' O
s O
5 O
' O
or O
3 O
' O
splice O
site O
to O
make O
it O
correspond O
more O
closely O
to O
the O
relevant O
consensus O
sequence O
. O

Biochemical O
analysis O
shows O
that O
Ssm1p I-GENE
is O
a O
structural O
protein O
that O
forms O
part O
of O
the O
largest O
60S I-GENE
ribosomal I-GENE
subunit I-GENE
, O
which O
does O
not O
exist O
in O
a O
pool O
of O
free O
proteins O
. O

In O
wild O
- O
type O
cells O
, O
SSM1b I-GENE
transcripts I-GENE
accumulate O
to O
twice O
the O
level O
of O
SSM1a I-GENE
transcripts I-GENE
, O
suggesting O
that O
SSM1b I-GENE
is O
responsible O
for O
the O
majority O
of O
the O
Ssm1p I-GENE
pool O
. O

Northern O
blot O
analysis O
revealed O
the O
expression O
of O
LIMK I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
predominantly O
in O
the O
brain O
and O
the O
expression O
of O
LIMK I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
in O
various O
tissues O
in O
the O
rat O
. O

However O
, O
the O
relative O
binding O
affinity O
for O
the O
motifs O
is O
different O
. O

On O
the O
basis O
of O
this O
anatomic O
concept O
, O
the O
brachioplasty O
procedure O
was O
modified O
to O
provide O
secure O
anchoring O
of O
the O
arm O
flap O
to O
the O
axillary O
fascia O
along O
with O
strong O
superficial O
fascial O
system O
repair O
of O
incisions O
, O
reducing O
the O
risk O
of O
widening O
or O
migration O
of O
scars O
and O
unnatural O
contours O
. O

Furthermore O
, O
microinjection O
of O
dominant O
negative O
forms O
of O
Rac I-GENE
and O
Cdc42 I-GENE
or O
of O
the O
Rho I-GENE
inhibitor O
C3 I-GENE
transferase I-GENE
blocked O
serum O
- O
induced O
DNA O
synthesis O
. O

INF I-GENE
- I-GENE
alpha I-GENE
therapy O
has O
been O
a O
major O
development O
in O
the O
treatment O
of O
CML O
. O

A O
series O
of O
amino O
terminal O
deletion O
mutants O
( O
d10 O
, O
d20 O
, O
d27 O
, O
d31 O
, O
d40 O
, O
d44 O
, O
and O
d73 O
) O
were O
compared O
for O
processing O
, O
cell O
surface O
expression O
, O
and O
maintenance O
of O
their O
biological O
attributes O
by O
recombinant O
expression O
of O
mutant O
genes O
using O
a O
plasmid O
vector O
( O
pcDL O
- O
SR O
alpha O
- O
296 O
) O
in O
CV O
- O
1 O
and O
HeLa O
cells O
. O

Intrathecal O
acetyl I-GENE
cholinesterase I-GENE
inhibitors O
produce O
analgesia O
that O
is O
synergistic O
with O
morphine O
and O
clonidine O
in O
rats O
. O

After O
determining O
isoflurane O
MAC O
in O
triplicate O
, O
birds O
were O
given O
a O
mu O
- O
opioid O
agonist O
( O
morphine O
, O
n O
= O
9 O
) O
or O
a O
kappa O
- O
opioid O
agonist O
( O
U50488H O
, O
n O
= O
9 O
). O

Max I-GENE
was O
constantly O
transcribed O
at O
a O
relatively O
low O
level O
during O
cell O
cycle O
progression O
. O

The O
yeast O
enzyme O
was O
6 O
- O
fold O
slower O
than O
the O
mammalian O
enzymes O
, O
which O
made O
it O
amenable O
to O
pre O
- O
steady O
- O
state O
stopped O
- O
flow O
spectroscopic O
kinetic O
analysis O
at O
30 O
degrees O
C O
and O
pH O
6 O
. O
0 O
. O

Key O
areas O
of O
the O
selection O
process O
including O
medical O
and O
surgical O
alternatives O
to O
transplantation O
, O
the O
composition O
of O
the O
transplant O
work O
- O
up O
, O
specific O
inclusion O
criteria O
as O
well O
as O
specific O
psychosocial O
factors O
and O
specific O
disease O
etiologies O
and O
co O
- O
morbidities O
that O
might O
represent O
contraindications O
were O
extensively O
reviewed O
. O

The O
transport O
of O
a O
genetically O
engineered O
chimeric O
transmembrane O
protein O
connected O
to O
this O
ER O
leader O
sequence O
was O
as O
efficient O
as O
that O
of O
the O
original O
protein O
from O
which O
the O
ER O
sequence O
has O
been O
derived O
. O

In O
both O
shoots O
and O
roots O
, O
GT I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
undetectable O
in O
meristematic O
tissue O
but O
becomes O
expressed O
at O
later O
stages O
of O
cellular O
development O
, O
consistent O
with O
a O
role O
in O
contributing O
to O
the O
pattern O
of O
phytochrome I-GENE
A I-GENE
gene I-GENE
expression O
. O

A O
polymorphic O
bipartite O
motif O
signals O
nuclear O
targeting O
of O
early O
auxin O
- O
inducible O
proteins O
related O
to O
PS O
- O
IAA4 O
from O
pea O
( O
Pisum O
sativum O
). O

Comparative O
DNA O
sequence O
analysis O
showed O
the O
Genethon O
microsatellite I-GENE
D19S596 I-GENE
lies O
2 O
. O
2 O
kb O
downstream O
of O
the O
coding O
region O
of O
FUT1 I-GENE
, O
indicating O
that O
the O
cluster O
comprising O
the O
closely O
linked O
FUT1 I-GENE
and O
FUT2 I-GENE
genes I-GENE
is O
located O
4 O
cM O
distal O
to O
D19S412 I-GENE
( O
lod O
score O
13 O
. O
7 O
) O
and O
9 O
cM O
proximal O
to O
D19S571 I-GENE
( O
lod O
score O
11 O
. O
7 O
). O

We O
conclude O
that O
transcription O
activation O
by O
LEF I-GENE
- I-GENE
1 I-GENE
in O
vitro O
is O
a O
chromatin O
- O
dependent O
process O
that O
requires O
a O
functional O
trans O
- O
activation O
domain O
in O
addition O
to O
the O
HMG I-GENE
domain I-GENE
. O

TH I-GENE
- O
SH3 I-GENE
binding O
in O
vitro O
is O
abolished O
by O
specific O
, O
single O
amino O
acid O
substitutions O
within O
the O
Btk I-GENE
TH I-GENE
domain I-GENE
or O
the O
Fyn I-GENE
SH3 I-GENE
domain I-GENE
. O

These O
results O
indicate O
that O
K I-GENE
- I-GENE
glypican I-GENE
is O
a O
novel O
GPI I-GENE
- I-GENE
anchored I-GENE
HSPG I-GENE
involved O
in O
embryonic O
development O
. O

Protein I-GENE
S I-GENE
levels O
were O
virtually O
undetectable O
at O
the O
time O
of O
admission O
and O
failed O
to O
respond O
to O
infusions O
of O
fresh O
frozen O
plasma O
, O
despite O
correction O
of O
other O
procoagulant O
and O
anticoagulant O
factors O
. O

The O
plant O
hormone O
auxin O
transcriptionally O
activates O
early I-GENE
genes I-GENE
. O

The O
test O
was O
not O
performed O
in O
3923 O
patients O
because O
of O
contraindications O
. O

The O
ubiquitous O
transcription O
factor O
Oct I-GENE
- I-GENE
1 I-GENE
forms O
complexes O
with O
an O
octamer O
motif O
present O
within O
FPIV O
by O
gel O
shift O
analysis O
with O
liver O
and O
kidney O
extracts O
, O
making O
Oct I-GENE
- I-GENE
1 I-GENE
an O
intriguing O
candidate O
for O
partnership O
in O
androgen O
regulation O
. O

A O
new O
non O
- O
LTR O
retrotransposon O
provides O
evidence O
for O
multiple O
distinct O
site O
- O
specific O
elements O
in O
Crithidia O
fasciculata O
miniexon O
arrays O
. O

We O
used O
deletion O
analysis O
and O
transfection O
assays O
with O
reporter O
gene O
constructs O
to O
examine O
the O
transcription O
control O
elements O
in O
the O
5 O
' O
flanking O
region O
of O
the O
human I-GENE
EpoR I-GENE
gene I-GENE
. O

The O
CVA16 I-GENE
. I-GENE
4 I-GENE
proteolipid I-GENE
transcript I-GENE
is O
the O
most O
prevalent O
of O
the O
two O
proteolipid O
messages O
in O
expanding O
ovules O
harvested O
10 O
d O
post O
- O
anthesis O
. O

Incubation O
of O
the O
purified O
fusion O
proteins O
with O
[ O
gamma O
- O
32P O
] O
ATP O
in O
an O
in O
vitro O
assay O
showed O
that O
both O
proteins O
were O
capable O
of O
autophosphorylation O
. O

The O
character O
of O
specific O
immune O
response O
in O
101 O
immunized O
children O
and O
in O
12 O
adults O
belonging O
to O
a O
high O
risk O
group O
with O
respect O
to O
VHB O
. O

After O
nadolol O
, O
heart O
rate O
decreased O
(- O
22 O
+/- O
8 O
%), O
and O
so O
did O
PBV O
and O
PBF O
( O
8 O
. O
8 O
+/- O
3 O
. O
4 O
vs O
. O

The O
synthetic O
DNA O
sequence O
was O
constructed O
to O
achieve O
efficient O
base O
pairing O
with O
Escherichia I-GENE
coli I-GENE
16S I-GENE
ribosomal I-GENE
RNA I-GENE
, O
avoidance O
of O
internal O
secondary O
structure O
, O
and O
optimal O
codon O
usage O
for O
high O
- O
level O
protein O
expression O
in O
accord O
with O
the O
known O
preferences O
in O
E O
. O
coli O
. O

Adrenergic O
system O
activation O
, O
indicated O
by O
metanephrine O
/ O
epinephrine O
ratio O
, O
increased O
with O
time O
in O
losing O
males O
, O
except O
that O
after O
one O
month O
of O
cohabitation O
, O
turnover O
returned O
to O
levels O
that O
equaled O
those O
of O
control O
animals O
. O

Transabdominal O
repair O
of O
type O
IV O
thoraco O
- O
abdominal O
aortic O
aneurysms O
. O

A O
. O

Transcription O
factors O
containing O
a O
basic O
helix O
- O
loop O
- O
helix O
( O
bHLH O
) O
motif O
regulate O
the O
expression O
of O
tissue O
- O
specific O
genes O
in O
a O
number O
of O
mammalian O
and O
insect O
systems O
. O

Primer O
extension O
and O
cDNA O
cloning O
were O
used O
to O
isolate O
the O
complete O
5 O
' O
end O
of O
the O
Nramp1 I-GENE
mRNA I-GENE
. O

Primer O
extension O
and O
S1 I-GENE
nuclease I-GENE
mapping O
experiments O
were O
used O
to O
locate O
the O
transcription O
initiation O
site O
of O
Nramp1 I-GENE
and O
revealed O
the O
presence O
of O
one O
major O
and O
several O
minor O
initiation O
sites O
. O

EsaR I-GENE
can O
repress O
its O
own O
expression O
but O
seems O
not O
to O
regulate O
the O
expression O
of O
esaI I-GENE
. O

Sequence O
analysis O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
CD69 I-GENE
gene I-GENE
revealed O
the O
presence O
of O
a O
potential O
TATA O
element O
30 O
base O
pairs O
upstream O
of O
the O
major O
transcription O
initiation O
site O
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription O
factors O
( O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
, O
Egr I-GENE
- I-GENE
1 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
), O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
plasmin I-GENE
- I-GENE
derived I-GENE
D I-GENE
( I-GENE
approximately I-GENE
105 I-GENE
- I-GENE
kDa I-GENE
) I-GENE
product I-GENE
, O
however O
, O
could O
be O
cross O
- O
linked O
into O
DD O
dimers O
. O

All O
clinical O
isolates O
were O
concomitantly O
tested O
by O
disk O
diffusion O
and O
agar O
dilution O
procedures O
as O
outlined O
by O
the O
National O
Committee O
for O
Clinical O
Laboratory O
Standards O
. O

IgE I-GENE
levels O
showed O
higher O
values O
compared O
to O
normal O
individuals O
and O
IgE I-GENE
levels O
were O
higher O
in O
children O
groups O
than O
in O
adults O
regardless O
of O
the O
intensity O
of O
infection O
. O

Tissue O
- O
specific O
expression O
of O
the O
tmy I-GENE
- I-GENE
1 I-GENE
gene I-GENE
was O
determined O
by O
microinjection O
of O
a O
promoter I-GENE
/ I-GENE
lacZ I-GENE
fusion I-GENE
gene I-GENE
and O
with O
immunohistochemistry O
by O
using O
affinity O
- O
purified O
tissue I-GENE
- I-GENE
specific I-GENE
anti I-GENE
- I-GENE
tropomyosins I-GENE
. O

The O
nucleotide O
sequence O
of O
the O
chloroplast O
( O
cp O
) O
DNA O
from O
maize O
( O
Zea O
mays O
) O
has O
been O
completed O
. O

Investigation O
of O
the O
control O
of O
coronavirus O
subgenomic O
mRNA O
transcription O
by O
using O
T7 O
- O
generated O
negative O
- O
sense O
RNA O
transcripts O
. O

Initiation O
of O
translation O
of O
the O
human O
hepatitis O
C O
virus O
( O
HCV O
) O
RNA O
genome O
occurs O
by O
internal O
ribosome O
entry O
into O
the O
5 O
' O
noncoding O
region O
( O
5 O
' O
NCR O
) O
in O
a O
cap O
- O
independent O
manner O
. O

Mean O
longitudinal O
extension O
of O
the O
epidural O
lesion O
was O
2 O
. O
6 O
vertebral O
segments O
. O

The O
association O
of O
p255 I-GENE
with O
splicing O
complexes O
is O
suggested O
by O
the O
finding O
that O
mAb I-GENE
CC3 I-GENE
can O
inhibit O
in O
vitro O
splicing O
and O
immunoprecipitate O
pre O
- O
messenger O
RNA O
and O
splicing O
products O
. O

L O
- O
735 O
, O
524 O
free O
base O
or O
sulfate O
salt O
was O
administered O
orally O
as O
suspension O
, O
solution O
or O
in O
solid O
dosage O
forms O
to O
fasted O
or O
fed O
Beagle O
dogs O
. O

Doppler O
ultrasound O
studies O
of O
long O
- O
term O
follow O
- O
up O
of O
children O
with O
hemolytic O
- O
uremic O
syndrome O

Thus O
, O
endemic O
cumlations O
of O
hepatitis O
A O
diseases O
are O
possible O
. O

( O
1991 O
). O

The O
properties O
of O
the O
phi O
29 O
SSB I-GENE
- I-GENE
ssDNA I-GENE
complex O
are O
described O
. O

This O
shows O
that O
the O
characteristically O
diffuse O
banding O
pattern O
of O
plant O
nuclear O
proteins O
interacting O
with O
the O
G O
- O
box O
is O
also O
observed O
in O
a O
binding O
assay O
using O
only O
one O
recombinant I-GENE
GBF I-GENE
. O

We O
studied O
120 O
male O
and O
42 O
female O
patients O
with O
early O
CAD O
who O
were O
unrelated O
to O
each O
other O
but O
were O
from O
families O
in O
which O
at O
least O
one O
other O
sibling O
had O
early O
CAD O
. O

The O
physical O
linkage O
of O
the O
FHR2 I-GENE
and O
the O
factor I-GENE
H I-GENE
genes I-GENE
provides O
additional O
evidence O
for O
a O
close O
relatedness O
of O
complement I-GENE
factor I-GENE
H I-GENE
and O
the O
factor I-GENE
H I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Genomic O
structure O
and O
chromosomal O
location O
of O
the O
mouse I-GENE
pre I-GENE
- I-GENE
T I-GENE
- I-GENE
cell I-GENE
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

The O
third O
domain O
had O
the O
motif O
of O
a O
cAMP O
response O
element O
( O
CRE O
). O

The O
tyrosine O
- O
phosphorylated O
state O
of O
CAK I-GENE
beta I-GENE
was O
not O
reduced O
on O
trypsinization O
, O
nor O
enhanced O
in O
response O
to O
plating O
3Y1 O
cells O
onto O
fibronectin I-GENE
. O

Our O
results O
suggest O
that O
while O
many O
muscle O
gene O
E O
- O
boxes O
are O
capable O
of O
binding O
the O
previously O
characterized O
spectrum O
of O
MDF I-GENE
/ I-GENE
bH I-GENE
- I-GENE
L I-GENE
- I-GENE
H I-GENE
heterodimers I-GENE
in O
vitro O
, O
MCK I-GENE
- I-GENE
L I-GENE
type O
E O
- O
boxes O
probably O
bind O
qualitatively O
different O
factors O
in O
vivo O
. O

A O
single O
- O
case O
experimental O
ABAB O
multiple O
baseline O
design O
was O
employed O
to O
test O
for O
treatment O
effectiveness O
. O

These O
clones O
were O
found O
to O
share O
a O
common O
domain O
encoded O
by O
p O
( O
CA O
) O
n O
repeats O
; O
a O
simple O
sequence O
length O
polymorphism O
( O
SSLP O
). O

In O
one O
glioblastoma O
cell O
line O
, O
a O
Shc I-GENE
- O
associated O
p190 I-GENE
was O
identified O
as O
the O
activated O
PDGFR I-GENE
. O

We O
conclude O
that O
, O
in O
comparison O
to O
reports O
from O
other O
regions O
, O
Scandinavian O
renal O
transplant O
recipients O
are O
at O
high O
risk O
of O
dying O
of O
IHD O
. O

Veterinary O
certification O
for O
livestock O
export O
. O

The O
serum O
concentration O
of O
iP O
before O
dialysis O
( O
HD O
) O
was O
on O
average O
3 O
. O
06 O
(+/- O
0 O
. O
81 O
) O
mmol O
/ O
l O
and O
D O
was O
on O
average O
55 O
. O
6 O
(+/- O
10 O
. O
0 O
) O
mmol O
. O

A O
significant O
correlation O
between O
a O
number O
of O
functional O
parameters O
of O
gastric O
secretion O
, O
incretion O
and O
histological O
changes O
of O
gastric O
mucosa O
was O
found O
in O
patients O
with O
chronic O
gastritis O
. O

The O
TAF O
factor O
appears O
to O
be O
particularly O
significant O
in O
OCD O
. O

Diffuse O
white O
matter O
injury O
can O
be O
attributed O
to O
radiation O
and O
associated O
with O
neurological O
deficits O
, O
but O
leukoencephalopathy O
is O
rarely O
observed O
in O
the O
absence O
of O
chemotherapy O
. O

RNase I-GENE
protection O
analyses O
indicate O
that O
either O
61 I-GENE
- I-GENE
kDa I-GENE
CaM I-GENE
PDE I-GENE
mRNA I-GENE
or O
structurally O
related O
transcripts O
encoding O
different O
CaM I-GENE
PDE I-GENE
isoforms I-GENE
are O
expressed O
in O
a O
tissue O
- O
specific O
manner O
. O

Little O
or O
no O
protection O
was O
detected O
using O
adrenal O
cortex O
, O
adrenal O
medulla O
, O
liver O
, O
kidney O
cortex O
, O
spleen O
, O
or O
T O
- O
lymphocyte O
total O
RNA O
. O

The O
PDGFR I-GENE
mutants I-GENE
that O
failed O
to O
associate O
with O
PLC I-GENE
gamma I-GENE
were O
not O
able O
to O
mediate O
the O
PDGF I-GENE
- O
dependent O
production O
of O
inositol O
phosphates O
. O

We O
found O
a O
direct O
correlation O
between O
the O
levels O
of O
transcription O
of O
the O
acc I-GENE
genes I-GENE
and O
the O
rate O
of O
cellular O
growth O
. O

The O
hybridizing O
clone O
of O
V O
. O
vulnificus O
chromosomal O
DNA O
complemented O
a O
V I-GENE
. I-GENE
cholerae I-GENE
fur I-GENE
mutant I-GENE
. O

We O
generated O
transformed O
B O
lymphoblast O
cell O
lines O
from O
controls O
, O
from O
four O
patients O
with O
p47 I-GENE
- O
phox I-GENE
- O
deficient O
chronic O
granulomatous O
disease O
, O
and O
from O
three O
parents O
. O

The O
ectopic O
expression O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
in O
hybrid O
cells O
under O
a O
constitutive O
promoter O
is O
sufficient O
for O
transcriptional O
activation O
of O
an O
octamer O
- O
dependent O
promoter O
. O

RNase I-GENE
protection O
and O
primer O
extension O
assays O
confirmed O
that O
the O
5 O
' O
non O
- O
coding O
exon O
is O
included O
in O
the O
DDT1 O
aFGF I-GENE
mRNA I-GENE
and O
that O
a O
major O
transcription O
start O
site O
is O
approximately O
136 O
bp O
upstream O
of O
the O
5 O
' O
non O
- O
coding O
splice O
junction O
of O
this O
exon O
. O

These O
results O
suggest O
that O
FK O
506 O
is O
a O
useful O
immunosuppressive O
agent O
in O
kidney O
transplantation O
. O

The O
roles O
of O
phorbol O
esters O
and O
cyclic O
AMP O
in O
mediating O
the O
GnRH I-GENE
response O
were O
also O
investigated O
. O

RT O
- O
PCR O
using O
1 O
. O
D O
- O
specific O
primers O
showed O
that O
kidney O
, O
brain O
and O
prostate O
do O
not O
express O
1 O
. O
D O
mRNA O
even O
though O
kidney O
and O
brain O
are O
the O
most O
abundant O
source O
for O
aFGF I-GENE
protein I-GENE
. O

Molecular O
cloning O
and O
characterization O
of O
two O
genes I-GENE
encoding I-GENE
gp138 I-GENE
, O
a O
cell O
surface O
glycoprotein O
involved O
in O
the O
sexual O
cell O
fusion O
of O
Dictyostelium O
discoideum O
. O

Two O
- O
dimensional O
phosphotryptic O
analyses O
indicate O
that O
phosphorylation O
on O
Ser O
- O
12 O
and O
Ser O
- O
48 O
in O
unstimulated O
cells O
is O
associated O
with O
the O
ability O
of O
overexpressed O
pp60c I-GENE
- I-GENE
src I-GENE
to O
potentiate O
beta O
- O
adrenergic O
signalling O
. O

Piroximone O
is O
a O
new O
phosphodiesterase I-GENE
III I-GENE
inhibitor O
that O
combines O
inotropic O
and O
vasodilator O
properties O
. O

Cytogenetic O
studies O
were O
performed O
in O
lymphocytes O
from O
hospital O
workers O
exposed O
to O
low O
doses O
of O
radiation O
( O
1 O
. O
6 O
- O
42 O
. O
71 O
mSv O
). O

To O
study O
the O
origin O
of O
different O
fMLF I-GENE
- I-GENE
R I-GENE
transcripts I-GENE
, O
the O
genetic O
linkage O
of O
chemotactic O
receptor O
genes O
, O
and O
the O
regulation O
of O
fMLF I-GENE
- I-GENE
R I-GENE
gene I-GENE
expression O
, O
we O
determined O
the O
copy O
number O
, O
chromosomal O
location O
, O
structural O
organization O
, O
and O
5 O
'- O
flanking O
sequence O
of O
the O
human I-GENE
fMLF I-GENE
- I-GENE
R I-GENE
gene I-GENE
. O

The O
first O
exon O
encodes O
66 O
bp O
of O
the O
5 O
'- O
untranslated O
sequence O
, O
while O
exon O
2 O
encodes O
the O
coding O
and O
3 O
'- O
untranslated O
sequences O
. O

The O
genomic O
structure O
of O
four O
members O
of O
the O
SRC I-GENE
- I-GENE
family I-GENE
revealed O
nearly O
identical O
exon O
/ O
intron O
boundaries O
within O
the O
catalytic O
domain O
of O
this O
family O
. O

Since O
we O
have O
observed O
effects O
of O
growth O
factors O
and O
cAMP O
as O
well O
as O
estradiol O
( O
E2 O
) O
on O
regulation O
of O
expression O
of O
some O
genes O
stimulated O
by O
the O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
), O
we O
have O
undertaken O
studies O
to O
examine O
directly O
whether O
activators O
of O
protein O
kinases O
can O
modulate O
transcriptional O
activity O
of O
the O
ER I-GENE
. O

Using O
the O
polymerase O
chain O
reaction O
, O
Whipple O
- O
specific O
DNA O
fragments O
of O
284 O
base O
pairs O
from O
the O
genome O
of O
the O
Whipple O
bacterium O
( O
Tropheryma O
whippelii O
) O
were O
demonstrated O
. O

RNA I-GENE
polymerase I-GENE
bound O
to O
the O
+ O
10A O
promoter O
partially O
protects O
a O
20 O
base O
- O
pair O
sequence O
from O
DNase I-GENE
I I-GENE
digestion O
upstream O
of O
the O
start O
site O
. O

Salivary O
sodium O
, O
calcium O
, O
and O
magnesium O
concentrations O
were O
significantly O
higher O
in O
the O
SLE O
patients O
with O
systemic O
lupus O
erythematosus O
, O
whereas O
potassium O
and O
total O
protein O
concentrations O
and O
amylase I-GENE
activity O
did O
not O
differ O
significantly O
from O
the O
controls O
. O

Chem O
. O

Recombinant O
plasmid O
pFV100 O
was O
subsequently O
isolated O
by O
its O
ability O
to O
complement O
B O
- O
band O
expression O
in O
ge6 I-GENE
. O

We O
here O
demonstrate O
that O
a O
temperature O
- O
sensitive O
fission O
yeast O
mutant O
which O
has O
a O
mutation O
in O
a O
homologous O
gene O
, O
and O
two O
of O
three O
additional O
( O
mtr1 I-GENE
/ O
prp20 I-GENE
/ O
srm1 I-GENE
) O
mutants O
accumulate O
nuclear O
poly O
( O
A O
)+ O
RNA O
at O
37 O
degrees O
C O
. O

Since O
RCC1p I-GENE
acts O
as O
GNRP I-GENE
for O
Ran I-GENE
, O
a O
small I-GENE
nuclear I-GENE
GTPase I-GENE
of O
the O
ras I-GENE
superfamily I-GENE
, O
we O
have O
identified O
two O
homologs O
of O
Ran I-GENE
in O
S O
. O
cerevisiae O
( O
CNR1 I-GENE
and O
CNR2 I-GENE
). O

The O
immunosuppressant O
FK506 O
inhibits O
amino O
acid O
import O
in O
Saccharomyces O
cerevisiae O
. O

Prostate I-GENE
specific I-GENE
antigen I-GENE
shows O
the O
metastatic O
cases O
better O
[ O
correction O
of O
worse O
] O
than O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
. O

Protein O
phosphorylation O
appears O
to O
play O
a O
critical O
role O
in O
uPA I-GENE
gene I-GENE
expression O
in O
these O
cells O
; O
protein I-GENE
kinase I-GENE
C I-GENE
- O
activating O
phorbol O
esters O
cooperate O
with O
pp60v I-GENE
- I-GENE
src I-GENE
to O
synergistically O
increase O
uPA I-GENE
mRNA I-GENE
, O
whereas O
cyclic I-GENE
AMP I-GENE
( I-GENE
cAMP I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
- O
activating O
agents O
( O
e O
. O
g O
., O
8 O
- O
bromo O
cAMP O
) O
repress O
uPA I-GENE
mRNA I-GENE
levels O
. O

Of O
these O
carriers O
149 O
were O
diagnosed O
to O
be O
asymptomatic O
clinically O
, O
biochemically O
and O
echographically O
. O

This O
300 O
bp O
5 O
'- O
upstream O
sequence O
of O
K3 I-GENE
keratin I-GENE
gene I-GENE
, O
which O
can O
function O
in O
vitro O
as O
a O
keratinocyte O
- O
specific O
promoter O
, O
contains O
two O
clusters O
of O
partially O
overlapping O
motifs O
, O
one O
with O
an O
NFkB I-GENE
consensus O
sequence O
and O
another O
with O
a O
GC O
box O
. O

Identification O
of O
mutations O
in O
the O
coding O
sequence O
of O
the O
proto I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
kit I-GENE
in O
a O
human O
mast O
cell O
leukemia O
cell O
line O
causing O
ligand O
- O
independent O
activation O
of O
c I-GENE
- I-GENE
kit I-GENE
product I-GENE
. O

BACKGROUND O
: O
Delineation O
of O
the O
morphologic O
aspects O
of O
age O
- O
related O
macular O
degeneration O
( O
ARMD O
) O
is O
helpful O
in O
correlation O
with O
the O
clinical O
features O
and O
may O
contribute O
to O
understanding O
the O
pathogenesis O
. O

An O
abundant O
1 O
. O
1 O
- O
kb O
virion O
- O
sense O
polyadenylated O
RNA O
and O
four O
complementary O
- O
sense O
polyadenylated O
RNAs O
of O
1 O
. O
7 O
, O
1 O
. O
5 O
, O
1 O
. O
3 O
, O
and O
0 O
. O
7 O
kb O
have O
been O
identified O
by O
northern O
blot O
hybridization O
, O
confirming O
the O
bidirectional O
transcription O
strategy O
implied O
by O
the O
arrangement O
of O
ORFs O
. O

Risk O
factors O
associated O
with O
a O
high O
seroprevalence O
of O
hepatitis O
C O
virus O
infection O
in O
Egyptian O
blood O
donors O
. O

Here O
the O
cloning O
and O
molecular O
analysis O
of O
the O
Zm I-GENE
- I-GENE
ERabp1 I-GENE
, O
Zm I-GENE
- I-GENE
ERabp4 I-GENE
, O
and O
Zm I-GENE
- I-GENE
ERabp5 I-GENE
genes I-GENE
is O
presented O
. O

This O
agent O
, O
isolated O
from O
the O
fungus O
Streptomyces O
tsukubaensis O
, O
has O
a O
mechanism O
of O
action O
similar O
to O
that O
of O
cyclosporine O
. O

DNase I-GENE
I I-GENE
footprinting O
of O
the O
proximal O
promoter O
revealed O
four O
regions O
of O
protection O
. O

Finally O
, O
the O
stability O
of O
the O
nucleotide O
binding O
function O
of O
the O
two O
proteins O
is O
similar O
as O
assessed O
by O
sensitivity O
to O
urea O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
IGF I-GENE
- I-GENE
BP I-GENE
- I-GENE
2 I-GENE
) O
transcription O
in O
rat O
liver O
varies O
with O
developmental O
age O
and O
fasting O
. O

The O
presence O
of O
the O
RV O
5 O
'(+) O
SL O
sequence O
had O
the O
primary O
enhancing O
effect O
on O
translation O
. O

By O
contrast O
, O
all O
proteins O
initiated O
with O
a O
methionine O
placed O
one O
residue O
upstream O
of O
the O
natural O
N O
terminus O
of O
PR I-GENE
failed O
to O
show O
specific O
proteolysis O
. O

Reverse I-GENE
transcriptase I-GENE
and O
protease O
activities O
of O
avian O
leukosis O
virus O
Gag I-GENE
- O
Pol I-GENE
fusion O
proteins O
expressed O
in O
insect O
cells O
. O

In O
addition O
, O
an O
mck1 I-GENE
mds1 I-GENE
mrk1 I-GENE
triple O
disruptant O
was O
viable O
. O

However O
, O
there O
were O
some O
properties O
of O
Rak I-GENE
that O
are O
distinct O
from O
Src I-GENE
- I-GENE
like I-GENE
kinases I-GENE
: O
( O
a O
) O
expression O
of O
Rak I-GENE
was O
predominantly O
in O
epithelial O
- O
derived O
cell O
lines O
and O
tissues O
, O
especially O
normal O
liver O
and O
kidney O
, O
and O
cell O
lines O
of O
breast O
and O
colon O
origin O
; O
( O
b O
) O
Rak I-GENE
does O
not O
harbor O
the O
NH2 O
- O
terminal O
glycine O
essential O
for O
myristylation O
and O
membrane O
localization O
; O
and O
( O
c O
) O
Rak I-GENE
possesses O
a O
putative O
bipartite O
nuclear O
localization O
signal O
in O
the O
SH2 I-GENE
domain I-GENE
, O
and O
subcellular O
fractionation O
studies O
revealed O
that O
p54rak I-GENE
resides O
predominantly O
in O
the O
nucleus O
. O

PATIENTS O
AND O
METHODS O
: O
We O
report O
our O
experience O
with O
seven O
children O
with O
active O
small O
bowel O
Crohn O
' O
s O
disease O
given O
a O
casein I-GENE
- O
based O
, O
polymeric O
feed O
rich O
in O
TGF I-GENE
- I-GENE
beta I-GENE
2 I-GENE
( O
Specific O
Polymeric O
Diet O
; O
Nestle O
- O
Clintec O
; O
Vevey O
, O
Switzerland O
) O
as O
complete O
nutrition O
for O
8 O
weeks O
. O

The O
leader O
sequence O
of O
the O
isolated O
cDNA O
clone O
contains O
several O
small O
open O
reading O
frames O
upstream O
of O
the O
initiation O
codon O
of O
the O
largest O
open O
reading O
frame O
coding O
for O
the O
homeodomain I-GENE
protein I-GENE
. O

A O
small O
amount O
of O
HSP81 I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
was O
detected O
only O
in O
roots O
. O

Cell O
adhesion O
and O
migration O
assays O
demonstrate O
that O
alpha I-GENE
6 I-GENE
beta I-GENE
1 I-GENE
is O
the O
major O
laminin I-GENE
receptor I-GENE
in O
undifferentiated O
F9 O
cells O
as O
well O
as O
F9 O
- O
derived O
PE O
cells O
. O

No O
local O
destruction O
by O
tumor O
or O
infection O
could O
be O
demonstrated O
apart O
from O
HIV O
infection O
. O

Among O
the O
mixed O
race O
persons O
one O
Chukcha O
- O
Eskimo O
had O
AS O
, O
one O
Eskimo O
- O
Russian O
had O
psoriatic O
arthritis O
( O
PsA O
). O

Our O
data O
complement O
other O
studies O
of O
circumpolar O
populations O
and O
reinforce O
the O
reported O
high O
prevalences O
of O
SPA O
and O
HLA I-GENE
- I-GENE
B27 I-GENE
among O
those O
populations O
. O

Clinical O
studies O
SY5555 O
was O
administered O
to O
45 O
patients O
with O
various O
infectious O
diseases O
( O
2 O
with O
acute O
pharyngitis O
, O
8 O
with O
acute O
tonsillitis O
, O
4 O
with O
lacunar O
tonsillitis O
, O
3 O
each O
with O
acute O
bronchitis O
, O
pneumonia O
and O
pertussis O
, O
7 O
with O
scarlet O
fever O
, O
3 O
with O
impetigo O
contagiosa O
, O
6 O
with O
acute O
urinary O
tract O
infections O
, O
2 O
with O
balanoposthitis O
and O
1 O
each O
with O
cervical O
lymphadenitis O
, O
S O
. O
S O
. O
S O
. O
S O
., O
vulvitis O
and O
acute O
colitis O
) O
at O
daily O
doses O
between O
3 O
. O
4 O
- O
10 O
mg O
/ O
kg O
, O
t O
. O
i O
. O
d O
., O
for O
3 O
- O
14 O
days O
. O

Although O
most O
SH2 I-GENE
- O
pTyr I-GENE
interactions O
occur O
between O
two O
different O
types O
of O
molecules O
, O
some O
appear O
to O
involve O
only O
a O
single O
molecular O
type O
. O

RESULTS O
: O
Closure O
time O
of O
fistulas O
in O
patients O
receiving O
TPN O
+ O
somatostatin I-GENE
was O
significantly O
shorter O
( O
13 O
. O
86 O
+/- O
1 O
. O
84 O
versus O
20 O
. O
4 O
+/- O
2 O
. O
89 O
days O
) O
than O
in O
those O
receiving O
TPN O
alone O
. O

Experimental O
adhesion O
prophylaxis O
with O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
. O

Scratching O
during O
sleep O
in O
children O
with O
atopic O
dermatitis O
is O
associated O
with O
increased O
VO2 O
. O

To O
determine O
which O
sequences O
in O
the O
rat I-GENE
P450c17 I-GENE
promoter I-GENE
may O
be O
responsible O
for O
basal O
and O
cAMP O
- O
stimulated O
gene O
transcription O
, O
deletion O
constructs O
containing O
between O
- O
1 O
, O
560 O
and O
- O
53 O
base O
pairs O
of O
5 O
'- O
flanking O
DNA O
from O
the O
rat I-GENE
P450c17 I-GENE
gene I-GENE
were O
ligated O
to O
plasmids O
expressing O
the O
reporter O
gene O
luciferase I-GENE
and O
transfected O
into O
two O
mouse O
cell O
lines O
, O
adrenal O
Y O
- O
1 O
cells O
, O
and O
testicular O
Leydig O
MA O
- O
10 O
cells O
. O

Within O
- O
subject O
BP O
differences O
between O
fish O
oil O
and O
corn O
oil O
treatment O
were O
similar O
for O
Dinamap O
( O
3 O
. O
2 O
+/- O
1 O
. O
8 O
/ O
2 O
. O
5 O
+/- O
1 O
. O
0 O
mm O
Hg O
) O
and O
for O
24 O
- O
h O
ABP O
( O
2 O
. O
5 O
+/- O
1 O
. O
0 O
/ O
2 O
. O
3 O
+/- O
0 O
. O
8 O
mm O
Hg O
), O
but O
were O
more O
significant O
with O
the O
latter O
. O

We O
have O
cloned O
and O
sequenced O
the O
mouse I-GENE
NMO1 I-GENE
cDNA I-GENE
, O
which O
encodes O
the O
NAD I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
: I-GENE
menadione I-GENE
oxidoreductase I-GENE
[ O
also O
called O
NAD I-GENE
( I-GENE
P I-GENE
) I-GENE
H I-GENE
:( I-GENE
quinone I-GENE
acceptor I-GENE
) I-GENE
oxidoreductase I-GENE
; O
quinone I-GENE
reductase I-GENE
; O
azo I-GENE
dye I-GENE
reductase I-GENE
; O
DT I-GENE
diaphorase I-GENE
; O
EC I-GENE
1 I-GENE
. I-GENE
6 I-GENE
. I-GENE
99 I-GENE
. I-GENE
2 I-GENE
]. O

Escherichia O
coli O
JRG582 O
is O
an O
ampD I-GENE
ampE I-GENE
deletion O
derivative O
of O
strain O
HfrH O
and O
accordingly O
it O
is O
derepressed O
for O
expression O
of O
the O
cloned O
inducible O
beta I-GENE
- I-GENE
lactamase I-GENE
gene I-GENE
of O
Citrobacter O
freundii O
, O
carried O
on O
plasmid O
pNU305 O
. O

Such O
a O
mechanism O
may O
allow O
acceleration O
of O
degenerative O
joint O
conditions O
, O
and O
may O
account O
for O
the O
increased O
prevalence O
of O
such O
conditions O
seen O
with O
HMS O
subjects O
. O

Solitary O
thyroid O
nodule O
. O

Male O
contraception O
: O
ideas O
for O
the O
future O
. O

While O
daily O
food O
intake O
was O
almost O
constant O
regardless O
of O
the O
dietary O
protein O
level O
, O
water O
intake O
and O
urine O
volume O
increased O
with O
increasing O
the O
dietary O
protein O
. O

We O
propose O
that O
Mad I-GENE
and O
Medea I-GENE
encode O
rate O
- O
limiting O
components O
integral O
to O
dpp I-GENE
pathways O
throughout O
development O
. O

Transcriptional O
regulation O
of O
the O
vacuolar I-GENE
H I-GENE
(+)- I-GENE
ATPase I-GENE
B2 I-GENE
subunit I-GENE
gene I-GENE
in O
differentiating O
THP O
- O
1 O
cells O
. O

However O
, O
the O
inability O
to O
export O
RNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
was O
not O
limited O
to O
a O
particular O
phase O
of O
the O
cell O
division O
cycle O
. O

An O
E O
box O
element O
is O
required O
for O
the O
expression O
of O
the O
ad4bp I-GENE
gene I-GENE
, O
a O
mammalian I-GENE
homologue I-GENE
of I-GENE
ftz I-GENE
- I-GENE
f1 I-GENE
gene I-GENE
, O
which O
is O
essential O
for O
adrenal O
and O
gonadal O
development O
. O

Inhibition O
assays O
performed O
with O
over O
30 O
different O
natural O
and O
synthetic O
sialylated O
and O
/ O
or O
sulfated O
compounds O
are O
utilized O
to O
define O
in O
greater O
detail O
specific O
structural O
features O
involved O
in O
oligosaccharide O
- O
protein O
binding O
. O

The O
amino O
acid O
sequence O
of O
the O
protein O
in O
the O
region O
of O
the O
specificity O
pocket O
is O
similar O
to O
that O
of O
S I-GENE
. I-GENE
griseus I-GENE
proteases I-GENE
A I-GENE
, I-GENE
B I-GENE
, I-GENE
and I-GENE
C I-GENE
. O

Mutations O
in O
the O
VPS45 I-GENE
gene I-GENE
, O
a O
SEC1 I-GENE
homologue O
, O
result O
in O
vacuolar O
protein O
sorting O
defects O
and O
accumulation O
of O
membrane O
vesicles O
. O

In O
293 O
cells O
, O
expression O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
inhibitor O
, O
I I-GENE
kappa I-GENE
B I-GENE
- I-GENE
alpha I-GENE
, O
reduced O
the O
stimulatory O
activity O
of O
LMP I-GENE
. O

This O
experimental O
design O
was O
used O
to O
determine O
the O
effect O
of O
displacement O
of O
the O
alpha I-GENE
4 I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
on O
the O
repression O
of O
alpha I-GENE
4 I-GENE
gene I-GENE
transcription O
by O
ICP4 I-GENE
. O

Immediate O
- O
early O
transcription O
from O
the O
channel O
catfish O
virus O
genome O
: O
characterization O
of O
two O
immediate I-GENE
- I-GENE
early I-GENE
transcripts I-GENE
. O

The O
GRE O
at O
nucleotide O
7640 O
is O
a O
composite O
GRE O
( O
cGRE O
) O
containing O
an O
overlapping O
activator I-GENE
protein I-GENE
- I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
motif O
for O
the O
c I-GENE
- I-GENE
jun I-GENE
homodimer I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
/ O
c I-GENE
- I-GENE
fos I-GENE
heterodimer O
. O

In O
contrast O
to O
some O
results O
previously O
published O
for O
a O
very O
close O
sequence O
variant O
( O
see O
ref O
. O

Transcriptional O
activation O
by O
thyroid O
hormone O
( O
T3 O
) O
requires O
interactions O
between O
the O
T3 I-GENE
receptor I-GENE
( O
TR I-GENE
) O
and O
T3 O
response O
elements O
( O
TREs O
) O
composed O
of O
two O
copies O
of O
sequences O
related O
to O
AGGTCA O
. O

A O
multivariate O
analysis O
of O
risk O
factors O
for O
relapse O
examined O
age O
, O
WBC O
at O
diagnosis O
, O
blast O
count O
at O
diagnosis O
, O
percentage O
of O
marrow O
blasts O
, O
FAB I-GENE
subtype O
, O
the O
number O
of O
remission O
induction O
courses O
to O
achieve O
a O
remission O
, O
maintenance O
therapy O
, O
consolidation O
therapy O
, O
marrow O
cell O
dose O
, O
donor O
- O
recipient O
sex O
, O
GVHD O
prophylaxis O
regimen O
and O
isolation O
and O
decontamination O
in O
laminar O
airflow O
rooms O
. O

Carnitine I-GENE
palmitoyltransferase I-GENE
( I-GENE
CPT I-GENE
) I-GENE
II I-GENE
deficiency O
is O
the O
most O
common O
inherited O
disorder O
of O
lipid O
metabolism O
affecting O
skeletal O
muscle O
. O

We O
show O
that O
these O
three O
gain O
- O
of O
- O
function O
mutants O
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
sex O
determination O
signal O
, O
with O
SxlM4 I-GENE
being O
the O
strongest O
and O
SxlM1 I-GENE
the O
weakest O
. O

We O
show O
that O
these O
three O
gain O
- O
of O
- O
function O
mutants O
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
sex O
determination O
signal O
, O
with O
SxlM4 I-GENE
being O
the O
strongest O
and O
SxlM1 I-GENE
the O
weakest O
. O

Binding O
of O
meAda I-GENE
is O
necessary O
to O
activate O
transcription O
of O
the O
adaptive O
response O
genes O
; O
accordingly O
, O
in O
vitro O
transcription O
of O
aidB I-GENE
is O
dependent O
on O
the O
presence O
of O
meAda I-GENE
. O

No O
significant O
differences O
were O
identified O
between O
groups O
for O
pH O
, O
PaCO2 O
, O
intracranial O
pressure O
, O
heart O
rate O
, O
brain O
temperature O
, O
or O
glucose O
levels O
. O

Blood O
pressure O
also O
was O
increased O
by O
lidocaine O
( O
6 O
mg O
kg O
- O
1 O
). O

Anesthesiologists O
often O
use O
more O
than O
one O
drug O
in O
a O
patient O
to O
achieve O
a O
target O
response O
, O
such O
as O
a O
desired O
blood O
pressure O
. O

We O
suggest O
that O
this O
gene O
cluster O
codes O
for O
( O
parts O
of O
) O
a O
multisubunit I-GENE
cytochrome I-GENE
c I-GENE
haem I-GENE
lyase I-GENE
. O

In O
this O
paper O
, O
a O
comparison O
between O
the O
number O
and O
shape O
of O
corneal O
endothelial O
cells O
has O
been O
performed O
in O
25 O
patients O
before O
and O
6 O
months O
after O
PRK O
. O

Standard O
reference O
sources O
indicate O
that O
an O
able O
- O
bodied O
11 O
- O
year O
- O
old O
child O
of O
comparable O
height O
requires O
1 O
, O
493 O
kcal O
/ O
d O
for O
support O
of O
basal O
metabolic O
functions O
. O

Weak O
allergenicity O
of O
recombinant I-GENE
hirudin I-GENE
CGP I-GENE
39393 I-GENE
( O
REVASC O
) O
in O
immunocompetent O
volunteers O
. O

In O
contrast O
to O
the O
myoD I-GENE
promoter I-GENE
, O
the O
myoD I-GENE
enhancer I-GENE
shows O
striking O
conservation O
between O
humans O
and O
mice O
both O
in O
its O
sequence O
and O
its O
distal O
position O
. O

However O
, O
a O
clear O
difference O
exists O
between O
myoblasts O
and O
10T1 O
/ O
2 O
cells O
( O
and O
other O
non O
- O
muscle O
cell O
types O
) O
in O
the O
chromatin O
structure O
of O
the O
chromosomal O
myoD I-GENE
core I-GENE
enhancer I-GENE
, O
suggesting O
that O
the O
myoD I-GENE
enhancer I-GENE
is O
repressed O
by O
epigenetic O
mechanisms O
in O
10T1 O
/ O
2 O
cells O
. O

Using O
Ki I-GENE
- I-GENE
ras I-GENE
- O
transformed O
3T3 O
cells O
as O
a O
model O
system O
, O
we O
show O
that O
both O
RA O
and O
the O
' O
dissociating O
' O
retinoids O
inhibit O
anchorage O
- O
independent O
cell O
proliferation O
, O
suggesting O
that O
retinoid O
- O
induced O
growth O
inhibition O
may O
be O
related O
to O
AP1 I-GENE
transrepression O
. O

The O
Oct I-GENE
and O
HMG2 I-GENE
proteins I-GENE
also O
interact O
in O
vivo O
. O

Atopic O
dermatitis O
is O
an O
" O
itch O
which O
rashes O
and O
not O
a O
rash O
which O
itches O
" O
and O
therefore O
, O
any O
patient O
treatment O
program O
should O
address O
the O
multiplicity O
of O
potential O
trigger O
factors O
that O
provoke O
this O
itching O
. O

Primer O
extension O
experiments O
showed O
that O
there O
are O
two O
transcription O
initiation O
sites O
16 O
bp O
apart O
in O
the O
mouse I-GENE
type I-GENE
2 I-GENE
receptor I-GENE
gene I-GENE
. O

The O
beta O
subunit O
of O
the O
Fc I-GENE
epsilon I-GENE
R1 I-GENE
is O
a O
33 O
- O
kDa O
tyrosine O
phosphoprotein O
, O
but O
the O
p33 I-GENE
Grb2 I-GENE
- I-GENE
binding I-GENE
protein I-GENE
described O
in O
the O
present O
report O
is O
not O
the O
Fc I-GENE
epsilon I-GENE
R1 I-GENE
beta I-GENE
chain I-GENE
and O
its O
identity O
is O
unknown O
. O

To O
study O
the O
mechanisms O
as O
well O
as O
magnitude O
of O
the O
transmembrane O
transfer O
of O
bacterial O
products O
from O
the O
dialysate O
, O
we O
developed O
a O
computerized O
in O
vitro O
dialysis O
model O
which O
provides O
continuous O
pressure O
recording O
from O
the O
arterial O
, O
venous O
, O
dialysate O
inflow O
and O
outflow O
ports O
. O

After O
24 O
hour O
incubation O
, O
total O
cell O
- O
associated O
IL I-GENE
- I-GENE
1Ra I-GENE
and O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
were O
measured O
by O
specific O
radioimmunoassay O
. O

Each O
dietary O
treatment O
was O
fed O
to O
six O
pen O
replicates O
of O
five O
chicks O
per O
pen O
for O
21 O
d O
. O

1972 O
. O

In O
contrast O
, O
recent O
evidence O
suggests O
that O
children O
with O
sickle I-GENE
- I-GENE
hemoglobin I-GENE
C I-GENE
disease O
do O
not O
develop O
functional O
asplenia O
before O
3 O
to O
4 O
years O
of O
age O
and O
thus O
may O
not O
benefit O
from O
penicillin O
prophylaxis O
. O

Deletion O
analysis O
indicates O
that O
TBP I-GENE
and O
hTAFII18 I-GENE
bind O
to O
distinct O
domains O
of O
hTAFII28 I-GENE
. O
hTAFII18 I-GENE
also O
interacts O
with O
TBP I-GENE
, O
but O
it O
interacts O
more O
strongly O
with O
hTAFII28 I-GENE
and O
hTAFII30 I-GENE
. O

The O
NarX I-GENE
and O
NarQ I-GENE
proteins I-GENE
with O
amino O
acid O
substitutions O
at O
the O
first O
conserved O
histidine O
position O
were O
also O
unable O
to O
dephosphorylate O
NarL I-GENE
- O
phosphate O
in O
vitro O
. O

Vascular O
endothelial O
cells O
undergo O
profound O
changes O
upon O
cellular O
activation O
including O
expression O
of O
a O
spectrum O
of O
cell O
activation O
- O
associated O
genes O
. O

Because O
ATF I-GENE
- I-GENE
1 I-GENE
and O
CREM I-GENE
are O
known O
to O
bind O
to O
cAMP O
response O
elements O
( O
CRE O
), O
this O
functional O
sequence O
was O
named O
the O
kappa O
E3 O
'- O
CRE O
. O

The O
Ng I-GENE
/ I-GENE
RC3 I-GENE
and O
PKC I-GENE
- I-GENE
gamma I-GENE
genes I-GENE
have O
a O
similar O
expression O
pattern O
in O
the O
brain O
during O
development O
. O

Structure O
and O
regulation O
of O
the O
gene O
encoding O
the O
neuron O
- O
specific O
protein I-GENE
kinase I-GENE
C I-GENE
substrate O
neurogranin I-GENE
( O
RC3 I-GENE
protein I-GENE
). O

The O
amino O
acid O
sequences O
of O
the O
known O
largest O
subunits O
of O
DdRPs I-GENE
from O
different O
species O
contain O
highly O
conserved O
regions O
. O

The O
TTG I-GENE
- I-GENE
2 I-GENE
gene I-GENE
has O
been O
identified O
at O
the O
site O
of O
chromosomal O
translocations O
in O
acute O
T O
- O
cell O
leukemia O
' O
s O
( O
T O
- O
ALL O
). O

In O
vitro O
studies O
with O
blood O
cells O
incubated O
with O
acetate O
or O
bicarbonate O
ions O
in O
concentrations O
, O
which O
are O
observed O
in O
vivo O
during O
hemodialysis O
, O
suggest O
that O
probably O
these O
ions O
do O
not O
directly O
affect O
superoxide O
anions O
generation O
, O
erythrocyte O
SOD I-GENE
- I-GENE
1 I-GENE
and O
catalase I-GENE
activities O
and O
erythrocyte O
membrane O
lipid O
peroxidation O
. O

Short O
therapy O
with O
omeprazole O
20 O
mg O
/ O
b O
. O
i O
. O
d O
., O
clarithromycin O
500 O
mg O
/ O
b O
. O
i O
. O
d O
., O
and O
CBS O
120 O
mg O
/ O
q O
. O
i O
. O
d O
. O
is O
a O
safe O
, O
well O
tolerated O
combination O
that O
achieves O
a O
80 O
. O
6 O
% O
eradication O
rate O
of O
H O
. O
pylori O
and O
duodenal O
ulcer O
healing O
rates O
as O
good O
as O
those O
achieved O
by O
omeprazole O
20 O
mg O
/ O
d O
when O
given O
for O
4 O
wk O
. O

The O
concentration O
of O
mite O
allergen O
was O
very O
low O
( O
mean O
0 O
. O
18 O
micrograms O
Der O
p O
milligrams O
sieved O
house O
dust O
), O
whereas O
that O
of O
cat O
allergen O
was O
high O
in O
homes O
with O
a O
cat O
( O
80 O
. O
8 O
micrograms O
Fel O
d O
milligrams O
) O
but O
also O
in O
homes O
with O
no O
cat O
( O
3 O
. O
2 O
micrograms O
Fel O
d O
milligrams O
). O

CONCLUSIONS O
: O
A O
comparison O
of O
the O
LysU I-GENE
crystal O
structure O
with O
the O
structures O
of O
seryl I-GENE
- I-GENE
and I-GENE
aspartyl I-GENE
- I-GENE
tRNA I-GENE
synthetases I-GENE
enables O
a O
conserved O
core O
to O
be O
identified O
. O

Whole O
bowel O
irrigation O
is O
a O
recently O
described O
technique O
to O
enhance O
the O
passage O
of O
drugs O
already O
beyond O
the O
pylorus O
. O

The O
MPS1 I-GENE
open I-GENE
reading I-GENE
frame I-GENE
has O
been O
fused O
to O
those O
that O
encode O
the O
LexA I-GENE
protein I-GENE
or O
the O
GST I-GENE
protein I-GENE
and O
both O
of O
these O
constructs O
function O
in O
yeast O
. O

As O
in O
Tb O
, O
U6 I-GENE
is O
a O
single O
- O
copy O
gene O
and O
two O
tRNA O
genes O
, O
tRNAGln I-GENE
and O
tRNAIle I-GENE
, O
are O
found O
upstream O
to O
the O
gene O
. O

Hematopoietic I-GENE
growth I-GENE
factors I-GENE
have O
already O
had O
an O
enormous O
impact O
on O
transfusion O
practice O
by O
eliminating O
or O
reducing O
the O
need O
for O
red O
blood O
cell O
transfusions O
in O
a O
variety O
of O
anemic O
states O
characterized O
by O
an O
absolute O
or O
relative O
decrease O
in O
erythropoietin I-GENE
. O

However O
, O
the O
mouse O
has O
previously O
been O
shown O
to O
possess O
only O
three O
forms O
of O
ADH I-GENE
. O

During O
IC O
breaths O
and O
following O
EC O
and O
VC O
breaths O
at O
rest O
, O
end O
- O
tidal O
CO2 O
pressure O
( O
PET O
, O
CO2 O
) O
fell O
by O
7 O
. O
5 O
, O
8 O
. O
5 O
and O
9 O
. O
5 O
mmHg O
, O
respectively O
. O

2 O
. O

Phylogenetic O
analyses O
of O
19 O
amino O
acid O
sequences O
of O
6 O
related O
protein O
types O
indicate O
that O
actin I-GENE
- O
associated O
proteins O
related O
to O
gelsolin I-GENE
are O
monophyletic O
to O
a O
common O
ancestor O
and O
include O
flightless I-GENE
proteins I-GENE
. O

No O
homologs O
of O
other O
members O
of O
the O
Surfeit I-GENE
gene I-GENE
cluster I-GENE
were O
detected O
in O
close O
proximity O
to O
the O
D O
. O
melanogaster O
Surf I-GENE
- I-GENE
3 I-GENE
/ O
rpL7a I-GENE
gene O
. O

Moreover O
, O
we O
found O
that O
cyclin I-GENE
E I-GENE
, O
in O
contrast O
to O
cyclin I-GENE
D1 I-GENE
, O
was O
required O
for O
the O
G1 O
/ O
S O
transition O
even O
in O
cells O
lacking O
retinoblastoma I-GENE
protein I-GENE
function O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
SGC1 I-GENE
gene I-GENE
product I-GENE
includes O
a O
region O
with O
substantial O
similarity O
to O
the O
basic O
- O
helix O
- O
loop O
- O
helix O
domain O
of O
the O
Myc I-GENE
family I-GENE
of O
DNA O
- O
binding O
proteins O
. O

By O
creating O
Pax I-GENE
- I-GENE
6 I-GENE
- O
BSAP I-GENE
fusion O
proteins O
, O
we O
were O
able O
to O
identify O
a O
short O
amino O
acid O
stretch O
in O
the O
N O
- O
terminal O
part O
of O
the O
paired I-GENE
domain O
which O
is O
responsible O
for O
these O
differences O
in O
DNA O
- O
binding O
specificity O
. O

To O
establish O
a O
possible O
association O
between O
familial O
dysfibrinogenemia O
and O
thrombophilia O
, O
data O
on O
cases O
with O
both O
affections O
were O
collected O
in O
a O
study O
within O
the O
framework O
of O
the O
SSC O
Subcommittee O
on O
Fibrinogen I-GENE
of O
the O
International O
Society O
on O
Thrombosis O
and O
Haemostasis O
. O

Conjugated O
estrogens O
shorten O
bleeding O
time O
in O
uraemia O
: O
a O
possible O
role O
of O
serotonin O
? O

These O
six O
districts O
have O
an O
area O
of O
34 O
, O
000 O
km2 O
and O
hold O
a O
population O
of O
30 O
million O
. O

According O
to O
symptoms O
, O
signs O
, O
imaging O
features O
, O
operation O
findings O
, O
the O
original O
places O
and O
the O
expansive O
directions O
of O
the O
tumor O
, O
they O
were O
divided O
into O
four O
clinical O
types O
: O
sellar O
, O
clival O
, O
occipito O
- O
temporal O
and O
extent O
. O

Two O
mammalian O
enzymes O
, O
the O
haem I-GENE
- I-GENE
controlled I-GENE
repressor I-GENE
( O
HCR I-GENE
) O
and O
the O
double I-GENE
- I-GENE
stranded I-GENE
RNA I-GENE
- I-GENE
activated I-GENE
inhibitor I-GENE
( O
dsI I-GENE
), O
phosphorylate O
Ser O
- O
51 O
of O
the O
alpha O
subunit O
, O
thereby O
inhibiting O
the O
exchange O
of O
bound O
nucleotides O
on O
, O
and O
thus O
the O
recycling O
of O
, O
eIF I-GENE
- I-GENE
2 I-GENE
. O

A O
triple O
Ser O
--> O
Ala O
mutant O
form O
of O
yeast O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
was O
found O
to O
be O
no O
longer O
phosphorylated O
by O
either O
of O
the O
yeast O
( O
or O
mammalian O
) O
casein I-GENE
kinase I-GENE
activities O
in O
vitro O
. O

The O
cases O
included O
35 O
de O
novo O
diffuse O
aggressive O
lymphomas O
( O
DAL O
; O
19 O
large O
- O
cell O
, O
4 O
mixed O
- O
cell O
, O
and O
12 O
large O
- O
cell O
immunoblastic O
), O
52 O
transformed O
aggressive O
lymphomas O
derived O
from O
follicular O
lymphomas O
( O
TFL O
), O
42 O
indolent O
follicular O
lymphomas O
( O
FL O
), O
14 O
mantle O
cell O
lymphomas O
( O
MCL O
), O
and O
27 O
small O
noncleaved O
cell O
lymphomas O
( O
SNCL O
). O

Icterus O
and O
beta O
- O
thalassemia O
in O
Congolese O
children O
in O
Brazzaville O

Female O
patients O
with O
breast O
cancer O
diagnosed O
between O
1982 O
and O
1991 O
at O
Roswell O
Park O
Cancer O
Institute O
( O
RPCI O
) O
in O
Buffalo O
, O
New O
York O
, O
who O
provided O
information O
on O
their O
cigarette O
smoking O
history O
at O
the O
time O
of O
their O
diagnosis O
were O
included O
. O

Upon O
analysis O
of O
the O
tissue O
distribution O
of O
AAMP I-GENE
, O
it O
was O
found O
to O
be O
expressed O
strongly O
in O
endothelial O
cells O
, O
cytotrophoblasts O
, O
and O
poorly O
differentiated O
colon O
adenocarcinoma O
cells O
found O
in O
lymphatics O
. O

Data O
from O
the O
V O
- O
HeFT O
II O
show O
that O
at O
2 O
- O
year O
follow O
- O
up O
, O
a O
progressive O
rise O
of O
plasma O
norepinephrine O
was O
observed O
in O
both O
treatment O
arms O
, O
suggesting O
that O
disease O
progresses O
despite O
treatment O
with O
either O
an O
angiotensin I-GENE
- I-GENE
converting I-GENE
enzyme I-GENE
inhibitor O
, O
enalapril O
, O
or O
vasodilator O
therapy O
with O
hydralazine O
/ O
isosorbide O
dinitrate O
. O

Binding O
activity O
in O
rat O
liver O
nuclear O
extracts O
includes O
these O
orphan O
receptors O
as O
judged O
from O
electromobility O
supershift O
experiments O
and O
from O
results O
obtained O
with O
expressed O
receptors O
, O
although O
the O
element O
in O
CYP2C11 I-GENE
did O
not O
bind O
HNF I-GENE
- I-GENE
4 I-GENE
. O

Transcript O
analysis O
reveals O
that O
lethal O
B I-GENE
block I-GENE
substitutions O
reduce O
U6 I-GENE
RNA I-GENE
synthesis O
at O
least O
10 O
- O
fold O
in O
vivo O
and O
20 O
- O
fold O
in O
vitro O
. O

Analysis O
of O
Bcl I-GENE
- I-GENE
2 I-GENE
/ O
Bcl I-GENE
- I-GENE
2 I-GENE
homodimerization O
using O
both O
in O
vitro O
binding O
assays O
as O
well O
as O
a O
yeast O
two O
- O
hybrid O
method O
provided O
evidence O
in O
support O
of O
a O
head O
- O
to O
- O
tail O
model O
for O
Bcl I-GENE
- I-GENE
2 I-GENE
/ O
Bcl I-GENE
- I-GENE
2 I-GENE
homodimerization O
and O
revealed O
that O
sequences O
within O
the O
NH2 O
- O
terminal O
A O
domain O
interact O
with O
a O
structure O
that O
requires O
the O
presence O
of O
both O
the O
carboxyl O
B O
and O
C O
domains O
in O
combination O
. O

The O
protein O
is O
composed O
of O
a O
central O
alpha O
- O
helical O
portion O
with O
globular O
domains O
at O
both O
NH2 O
and O
COOH O
termini O
, O
and O
the O
epitope O
to O
the O
monoclonal O
antibody O
resides O
in O
the O
central O
alpha O
- O
helical O
stalk O
. O

Radioligand O
binding O
was O
indistinguishable O
for O
both O
transiently O
expressed O
constructs O
. O

Diagnosis O
of O
FHCS O
has O
been O
weighed O
upon O
laparoscopic O
findings O
. O

Human I-GENE
papillomavirus I-GENE
type I-GENE
31b I-GENE
late I-GENE
gene I-GENE
expression O
is O
regulated O
through O
protein I-GENE
kinase I-GENE
C I-GENE
- O
mediated O
changes O
in O
RNA O
processing O
. O

Interestingly O
, O
virions O
also O
contained O
smaller O
proteins O
that O
reacted O
with O
antibodies O
specific O
for O
the O
accessory O
proteins O
as O
well O
as O
SN I-GENE
and O
CAT I-GENE
fusion I-GENE
partners O
. O

Studies O
using O
an O
inhibitor O
or O
a O
mutant I-GENE
Lb I-GENE
proteinase I-GENE
indicated O
that O
stimulation O
of O
IRES O
- O
driven O
translation O
is O
mediated O
via O
proteolysis O
of O
some O
cellular O
component O
( O
s O
). O

Restriction O
mapping O
analysis O
localized O
this O
cDNA O
to O
the O
HHV I-GENE
- I-GENE
6A I-GENE
( I-GENE
U1102 I-GENE
) I-GENE
genomic I-GENE
BamHI I-GENE
G I-GENE
fragment I-GENE
, O
at O
the O
right O
end O
of O
the O
unique O
long O
segment O
of O
the O
genome O
and O
to O
the O
SalI I-GENE
L I-GENE
and O
SalI I-GENE
O I-GENE
fragments I-GENE
within O
the O
left O
and O
right O
terminal O
direct O
repeat O
regions O
, O
respectively O
. O

For O
replication O
reporter O
constructs O
where O
E1 I-GENE
and O
E2 I-GENE
are O
supplied O
in O
trans O
by O
the O
respective O
expression O
vectors O
, O
distance O
between O
the O
half O
sites O
seems O
to O
play O
a O
major O
role O
, O
yet O
the O
phasing O
relationships O
are O
measurable O
. O

As O
it O
had O
been O
previously O
reported O
that O
the O
18 O
- O
bp O
palindrome O
contains O
sufficient O
nucleotide O
sequence O
information O
for O
E1 I-GENE
binding O
, O
we O
speculate O
that O
a O
minimal O
E1 I-GENE
recognition O
motif O
is O
presented O
in O
each O
half O
site O
. O

METHODS O
: O
Out O
of O
171 O
patients O
receiving O
anticoagulation O
between O
July O
1992 O
and O
December O
1993 O
, O
83 O
patients O
with O
hemispheric O
embolisms O
received O
heparin O
within O
72 O
hours O
from O
onset O
( O
activated O
partial O
thromboplastin I-GENE
time O
[ O
aPTT O
] O
1 O
. O
5 O
times O
control O
value O
). O

In O
the O
commercially O
available O
intravenous O
formulation O
of O
Cyclosporin O
A O
( O
Sandimmun O
), O
polyoxyethylated O
castor O
oil O
( O
Cremophor O
EL O
) O
is O
used O
as O
a O
solubilizing O
agent O
. O

Lung O
function O
tests O
( O
EFR O
) O
were O
performed O
on O
these O
patients O
for O
a O
period O
of O
19 O
. O
2 O
+/- O
3 O
. O
4 O
months O
. O

Sequence O
comparisons O
of O
prokaryotic I-GENE
RCR I-GENE
initiators I-GENE
has O
revealed O
a O
set O
of O
three O
common O
motifs O
, O
two O
of O
which O
, O
a O
putative O
metal O
coordination O
site O
and O
a O
downstream O
active O
- O
site O
tyrosine O
motif O
, O
could O
be O
tentatively O
identified O
in O
parvoviral I-GENE
replicator I-GENE
proteins I-GENE
. O

The O
mean O
marginal O
discrepancy O
of O
provisional O
restorations O
was O
compared O
for O
restorations O
fabricated O
from O
stone O
, O
low O
- O
viscosity O
poly O
( O
vinyl O
siloxane O
), O
and O
medium O
- O
viscosity O
poly O
( O
vinyl O
siloxane O
). O

The O
characterized O
Aplysia I-GENE
Afurin2 I-GENE
is O
a O
candidate O
PC I-GENE
that O
may O
play O
an O
important O
role O
in O
the O
processing O
of O
egg I-GENE
- I-GENE
laying I-GENE
hormone I-GENE
( O
ELH I-GENE
)- O
related O
precursors O
in O
the O
secretory O
cells O
of O
the O
atrial O
gland O
. O

Rats O
treated O
with O
8 O
- O
OH O
- O
DPAT O
were O
not O
impaired O
in O
their O
ability O
to O
learn O
a O
visual O
discrimination O
in O
a O
water O
maze O
. O

The O
term O
endovascular O
papillary O
haemangioma O
is O
suggested O
. O

In O
addition O
, O
two O
internal O
promoters O
, O
PmiaA I-GENE
and O
P1hfq I-GENE
were O
identified O
and O
mapped O
to O
201 O
and O
837 O
nucleotides O
upstream O
from O
the O
respective O
translation O
start O
sites O
. O

These O
results O
indicate O
that O
mutL I-GENE
, O
miaA I-GENE
, O
and O
hfq I-GENE
expression O
could O
be O
regulated O
by O
multiple O
mechanisms O
, O
including O
degree O
of O
cotranscription O
from O
upstream O
genes O
, O
modulation O
of O
internal O
promoter O
strength O
, O
and O
by O
RNase I-GENE
E I-GENE
activity O
. O

Coronary O
T1 O
and O
T2 O
weighted O
images O
were O
obtained O
. O

The O
2 O
kb O
of O
5 O
'- O
flanking O
region O
and O
the O
1 O
. O
1 O
kb O
of O
the O
entire O
sGTH I-GENE
alpha I-GENE
subunit I-GENE
coding O
region O
were O
sequenced O
from O
the O
genomic O
clone O
, O
sGTH I-GENE
alpha I-GENE
- I-GENE
G1 I-GENE
. O

Functional O
analysis O
of O
the O
sGTH I-GENE
alpha I-GENE
subunit I-GENE
promoter I-GENE
by O
the O
transient O
transfection O
of O
several O
sGTH I-GENE
alpha I-GENE
/ O
CAT I-GENE
chimeric O
plasmids O
into O
rainbow O
trout O
pituitary O
cells O
suggests O
that O
its O
pituitary O
- O
specific O
expression O
is O
GSE I-GENE
- O
dependent O
. O

Indium O
- O
111 O
OncoScint O
CR O
/ O
OV O
and O
F O
- O
18 O
FDG O
in O
colorectal O
and O
ovarian O
carcinoma O
recurrences O
. O

His O
carnitine I-GENE
palmitoyltransferase I-GENE
( I-GENE
CPT I-GENE
) I-GENE
I I-GENE
and I-GENE
II I-GENE
activities O
were O
0 O
. O
06 O
and O
0 O
. O
12 O
nmol O
/ O
min O
/ O
mg O
protein O
, O
as O
compared O
with O
a O
mean O
value O
of O
0 O
. O
22 O
+/- O
0 O
. O
14 O
and O
0 O
. O
27 O
+/- O
0 O
. O
07 O
nmol O
/ O
min O
/ O
mg O
protein O
, O
respectively O
, O
in O
control O
subjects O
. O

The O
Myc I-GENE
LZ I-GENE
was O
found O
to O
prevent O
homodimeric O
interactions O
, O
thus O
explaining O
Myc I-GENE
inability O
to O
homodimerize O
efficiently O
. O

Staphylococcus O
aureus O
and O
CNS O
showed O
high O
or O
moderate O
resistance O
rates O
to O
methicillin O
( O
DMPPC O
). O

Thus O
, O
VF O
resistant O
to O
defibrillation O
is O
not O
necessarily O
associated O
with O
both O
toxic O
plasma O
drug O
level O
and O
remarkably O
decreased O
conduction O
. O

The O
smallest O
active I-GENE
FecR I-GENE
derivative I-GENE
contained O
59 O
amino O
acid O
residues O
as O
compared O
to O
the O
317 O
residues O
of O
wild I-GENE
- I-GENE
type I-GENE
FecR I-GENE
. O

The O
gene O
pairs O
psbB I-GENE
- O
psbT I-GENE
and O
psbH I-GENE
- O
psbN I-GENE
are O
cotranscribed O
from O
opposite O
strands O
. O

Hybridization O
signals O
were O
also O
detected O
with O
total O
DNAs O
of O
Rhizobium O
leguminosarum O
bv O
. O
phaseoli O
, O
Rhodobacter O
capsulatus O
and O
Escherichia O
coli O
, O
but O
not O
those O
of O
Xanthomonas O
campestris O
pv O
. O
campestris O
and O
Pseudomonas O
putida O
. O

The O
predicted O
amino O
acid O
sequence O
contains O
regions O
identical O
to O
the O
sequences O
of O
peptides O
derived O
from O
bovine I-GENE
liver I-GENE
eIF I-GENE
- I-GENE
2B I-GENE
alpha I-GENE
subunit I-GENE
. O

Expression O
of O
this O
cDNA O
in O
vitro O
yields O
a O
peptide O
which O
comigrates O
with O
natural I-GENE
eIF I-GENE
- I-GENE
2B I-GENE
alpha I-GENE
in O
SDS O
/ O
polyacrylamide O
gels O
. O

When O
RNA O
encoding O
the O
tail O
domain O
of O
desmoglein I-GENE
was O
coinjected O
with O
plakoglobin I-GENE
RNA I-GENE
, O
both O
the O
dorsalizing O
effect O
and O
nuclear O
accumulation O
of O
plakoglobin I-GENE
were O
suppressed O
. O

Six O
of O
them O
, O
NUC1 I-GENE
, O
PRP21 I-GENE
( O
also O
called O
SPP91 I-GENE
), O
CDC6 I-GENE
, O
CRY2 I-GENE
, O
the O
gene O
encoding O
the O
ribosomal I-GENE
protein I-GENE
S24 I-GENE
and O
the O
gene O
coding O
for O
a O
hypothetical O
protein O
of O
599 O
amino O
acids O
, O
have O
been O
sequenced O
previously O
. O

Intrastriatal O
grafts O
of O
nigral O
and O
adrenal O
tissues O
have O
been O
found O
to O
be O
effective O
in O
alleviating O
many O
of O
the O
simple O
motor O
and O
sensorimotor O
deficits O
associated O
with O
lesions O
of O
the O
nigrostriatal O
dopamine O
system O
. O

OBJECTIVE O
: O
To O
determine O
the O
impact O
of O
the O
introduction O
of O
clarithromycin O
and O
azithromycin O
on O
the O
treatment O
and O
survival O
of O
patients O
with O
AIDS O
and O
disseminated O
Mycobacterium O
avium O
complex O
( O
DMAC O
). O

Thereafter O
, O
the O
aggregation O
rose O
to O
the O
initial O
100 O
% O
value O
4 O
h O
after O
drug O
application O
and O
remained O
at O
this O
level O
during O
the O
observation O
period O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Growth O
curves O
indicated O
that O
proliferation O
of O
clone O
CA9 O
in O
the O
presence O
of O
10 O
% O
serum O
was O
reduced O
by O
60 O
% O
compared O
with O
clone O
ME10 O
. O

The O
protein O
coding O
region O
, O
1 O
, O
696 O
bps O
long O
, O
is O
divided O
by O
an O
intron O
into O
two O
exons O
. O

The O
UAS O
of O
the O
AAC2 I-GENE
gene I-GENE
contains O
at O
least O
two O
distinct O
motifs O
for O
DNA O
- O
binding O
transcriptional O
activators O
, O
including O
one O
which O
is O
identical O
with O
the O
core O
HAP2 I-GENE
/ I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
binding I-GENE
motif I-GENE
, O
and O
a O
second O
one O
with O
the O
ABF1 I-GENE
consensus I-GENE
binding I-GENE
sequence I-GENE
. O

The O
emerging O
complexity O
of O
the O
5 O
' O
regulatory O
region O
of O
the O
GH I-GENE
receptor I-GENE
gene I-GENE
was O
emphasised O
by O
the O
observation O
that O
probes O
derived O
from O
exon O
1B O
and O
the O
distal O
3 O
' O
intron O
boundary O
do O
not O
hybridise O
with O
previously O
cloned O
genomic O
sequences O
that O
span O
the O
liver O
- O
specific O
P1 O
promoter O
and O
exon O
2 O
. O

A O
polymorphic O
dinucleotide O
( O
GT O
/ O
CA O
) O
n O
repeat O
contained O
in O
the O
NHE5 O
cosmid O
was O
identified O
and O
developed O
into O
a O
microsatellite O
PCR O
marker O
. O

The O
proteins O
are O
more O
than O
90 O
% O
identical O
to O
each O
other O
within O
the O
protein O
kinase O
domain O
but O
only O
51 O
- O
59 O
% O
identical O
to O
other O
casein I-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
within O
this O
region O
. O

We O
used O
two O
approaches O
to O
ascertain O
whether O
CDP I-GENE
/ O
cut I-GENE
serves O
as O
a O
repressor O
of O
gp91 I-GENE
- O
phox I-GENE
gene O
expression O
. O

Serum O
induction O
of O
a O
MEF2 I-GENE
reporter I-GENE
gene I-GENE
was O
not O
observed O
in O
a O
line O
of O
NIH O
3T3 O
cells O
which O
contain O
low O
MEF2 I-GENE
site I-GENE
binding O
activity O
. O

Despite O
the O
activation O
of O
these O
intracellular O
signaling O
molecules O
, O
PDGF I-GENE
beta I-GENE
receptor I-GENE
activation O
elicited O
no O
detectable O
effect O
on O
cell O
proliferation O
or O
differentiation O
. O

UAS1 O
is O
the O
binding O
site O
for O
the O
transcriptional O
regulator O
Adr1p I-GENE
. O

In O
the O
context O
of O
the O
ADH2 I-GENE
upstream I-GENE
regulatory I-GENE
region I-GENE
, O
including O
UAS1 O
, O
working O
in O
concert O
with O
the O
ADH2 I-GENE
basal I-GENE
promoter I-GENE
elements I-GENE
, O
UAS2 O
- O
dependent O
gene O
activation O
was O
dependent O
on O
orientation O
, O
copy O
number O
, O
and O
helix O
phase O
. O

Induction O
in O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
correlates O
with O
a O
concomitant O
GH I-GENE
trans O
- O
activation O
of O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
described O
previously O
. O

Inactivation O
of O
MAP I-GENE
kinases I-GENE
occurs O
via O
a O
specific O
phosphatase O
, O
MKP I-GENE
- I-GENE
1 I-GENE
. O

Short O
- O
course O
amphotericin O
B O
therapy O
for O
candidemia O
in O
pediatric O
patients O
. O

Furthermore O
, O
45Ca O
- O
binding O
assays O
revealed O
that O
CCaMK I-GENE
directly O
binds O
Ca2 O
+. O

Since O
AP I-GENE
- I-GENE
1 I-GENE
is O
an O
important O
mediator O
of O
tumor O
promoter O
action O
, O
these O
findings O
may O
explain O
the O
anti O
- O
tumor O
- O
promoting O
activity O
of O
phenolic O
antioxidants O
. O

The O
second O
complex O
, O
when O
purified O
, O
contained O
four O
protein O
components O
including O
the O
36 O
- O
kDa O
protein O
. O

The O
protein O
expressed O
from O
the O
cloned O
cDNA O
is O
secreted O
into O
the O
culture O
medium O
and O
yields O
of O
up O
to O
40 O
mg O
per O
litre O
have O
been O
obtained O
. O

The O
study O
was O
repeated O
after O
administration O
of O
oral O
amiodarone O
, O
50 O
mg O
/ O
kg O
/ O
day O
for O
2 O
days O
in O
8 O
divided O
doses O
( O
mean O
dose O
6 O
. O
9 O
+/- O
0 O
. O
4 O
g O
). O

Plasmids O
pAMS12 O
, O
pAMS13 O
and O
pAMS14 O
were O
transformed O
into O
a O
laboratory O
strain O
of O
Saccharomyces O
cerevisiae O
, O
whereas O
pAMS15 O
was O
stably O
introduced O
into O
two O
commercial O
wine O
yeast O
strains O
. O

The O
maximum O
induction O
of O
ACC I-GENE
- I-GENE
oxidase I-GENE
transcripts I-GENE
occurred O
at O
about O
6 O
h O
after O
excision O
, O
while O
the O
maximum O
enzyme O
activity O
was O
observed O
at O
24 O
h O
. O

Within O
their O
polypeptide O
chain O
, O
they O
all O
contain O
those O
conserved O
features O
that O
define O
a O
plant O
CDPK I-GENE
; O
kinase O
catalytic O
sequences O
are O
linked O
to O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
regulatory I-GENE
domain I-GENE
through O
a O
junction O
region O
. O

Repair O
of O
this O
insertion O
by O
homologous O
recombination O
restores O
the O
activity O
of O
the O
hprt I-GENE
locus I-GENE
, O
thus O
confirming O
the O
site O
of O
mutation O
. O

The O
timing O
of O
fla I-GENE
gene I-GENE
expression O
in O
the O
cell O
cycle O
is O
determined O
by O
specialized O
forms O
of O
RNA I-GENE
polymerase I-GENE
and O
the O
appearance O
and O
/ O
or O
activation O
of O
regulatory O
proteins O
. O

Primer O
extension O
experiments O
revealed O
a O
strong O
transcription O
initiation O
site O
102 O
bp O
upstream O
of O
the O
translational O
start O
site O
. O

Polypeptides O
of O
the O
same O
apparent O
sizes O
are O
detected O
in O
spores O
of O
a O
cotE I-GENE
null O
mutant O
, O
on O
which O
basis O
we O
infer O
that O
the O
products O
of O
the O
cotJ I-GENE
operon I-GENE
are O
required O
for O
the O
normal O
formation O
of O
the O
inner O
layers O
of O
the O
coat O
or O
are O
themselves O
structural O
components O
of O
the O
coat O
. O

Based O
on O
the O
estimated O
values O
of O
divergence O
of O
apobec1 I-GENE
sequences I-GENE
in O
terms O
of O
the O
numbers O
of O
synonymous O
and O
non O
- O
synonymous O
suhstitutions O
per O
site O
, O
we O
found O
that O
apobec1 I-GENE
is O
a O
fairly O
rapidly O
evolving O
protein O
. O

EEA1 I-GENE
is O
a O
conserved O
alpha O
- O
helical O
peripheral O
membrane O
protein O
flanked O
by O
cysteine O
" O
fingers O
" O
and O
contains O
a O
calmodulin I-GENE
- I-GENE
binding I-GENE
IQ I-GENE
motif I-GENE
. O

Nucleotide O
sequences O
of O
the O
clones O
revealed O
that O
one O
clone O
, O
cap3 I-GENE
, O
contained O
an O
open O
reading O
frame O
( O
ORF O
) O
that O
would O
code O
for O
a O
26 O
- O
amino O
acid O
, O
cysteine O
- O
rich O
peptide O
with O
significant O
homology O
to O
Neurospora I-GENE
crassa I-GENE
copper I-GENE
metallothionein I-GENE
. O

Sensing O
with O
chemically O
and O
biologically O
modified O
carbon O
electrodes O
. O

Elevation O
of O
the O
tissues O
of O
the O
face O
is O
essentially O
vertical O
and O
acts O
on O
the O
forehead O
, O
temporal O
region O
, O
gaze O
and O
cheekbones O
. O

This O
region O
binds O
two O
ubiquitous O
nuclear O
factors O
, O
USF I-GENE
/ O
MLTF I-GENE
and O
the O
CAAT I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
factor I-GENE
/ O
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
CTF I-GENE
/ O
NF1 I-GENE
). O

The O
potential O
impact O
of O
using O
a O
rapid O
diagnostic O
test O
( O
Strep O
A O
OIA O
) O
on O
detection O
and O
treatment O
of O
group O
A O
beta O
- O
hemolytic O
streptococcal O
( O
GABHS O
) O
pharyngitis O
in O
a O
large O
- O
volume O
pediatric O
and O
adolescent O
clinic O
was O
examined O
. O

The O
bHLH I-GENE
proteins I-GENE
function O
as O
potent O
transcriptional O
activators O
of O
tissue O
- O
specific O
genes O
by O
forming O
heterodimers O
between O
ubiquitous O
and O
cell O
- O
restricted O
family O
members O
. O

YAC O
and O
cosmid O
contigs O
spanning O
the O
BRCA1 I-GENE
region I-GENE
were O
used O
to O
select O
cDNA O
clones O
from O
pools O
of O
cDNAs O
derived O
from O
human O
placenta O
, O
HeLa O
cells O
, O
activated O
T O
cells O
, O
and O
fetal O
head O
. O

The O
other O
two O
clones O
, O
Ash I-GENE
- I-GENE
m I-GENE
and I-GENE
- I-GENE
s I-GENE
, O
had O
nucleotide O
sequences O
identical O
with O
Ash I-GENE
- I-GENE
l I-GENE
cDNA O
in O
the O
amino O
- O
terminal O
region O
. O

This O
study O
assesses O
the O
feasibility O
and O
toxicity O
of O
adoptive O
immunotherapy O
with O
tumor O
infiltrating O
lymphocytes O
and O
recombinant I-GENE
interleukin I-GENE
- I-GENE
2 I-GENE
in O
29 O
patients O
who O
underwent O
resection O
for O
stage O
III O
non O
- O
small O
- O
cell O
lung O
cancer O
. O

MATERIAL O
AND O
METHODS O
: O
Of O
the O
17 O
men O
and O
17 O
women O
, O
who O
were O
21 O
to O
80 O
years O
of O
age O
, O
27 O
had O
hereditary O
motor O
and O
sensory O
neuropathy O
type O
I O
and O
7 O
had O
acquired O
demyelinating O
polyneuropathy O
. O

The O
present O
study O
describes O
the O
cell O
volume O
dynamics O
in O
intact O
rat O
hearts O
, O
during O
ischemia O
and O
after O
reperfusion O
. O

In O
contrast O
, O
COUP I-GENE
- I-GENE
TF I-GENE
alone O
had O
no O
effect O
on O
repCRS2 O
- O
dependent O
reporter O
gene O
activity O
. O

DNA O
sequencing O
and O
Southern O
blot O
analyses O
established O
that O
the O
cDNA O
clones O
are O
derived O
from O
two O
different O
genes O
. O

Muscle I-GENE
GSH I-GENE
- I-GENE
Px I-GENE
activity O
after O
prolonged O
exercise O
, O
training O
, O
and O
selenium O
supplementation O
. O

Mutation O
of O
the O
Sp1 I-GENE
element I-GENE
, O
which O
abolishes O
Sp1 I-GENE
binding O
, O
results O
in O
a O
6 O
- O
10 O
- O
fold O
reduction O
in O
reporter O
activity O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
is O
overexpressed O
in O
a O
variety O
of O
tumor O
types O
and O
appears O
to O
play O
an O
important O
role O
in O
the O
abnormal O
growth O
of O
a O
number O
of O
cell O
types O
. O

We O
found O
that O
PML I-GENE
was O
expressed O
at O
a O
lower O
level O
in O
S O
, O
G2 O
, O
and O
M O
phases O
and O
at O
a O
significantly O
higher O
level O
in O
G1 O
phase O
. O

Schooling O
is O
found O
to O
be O
related O
to O
good O
health O
even O
after O
controlling O
for O
differences O
in O
observable O
health O
inputs O
. O

With O
this O
bisected O
diastolic O
driving O
, O
the O
abnormal O
echo O
disappeared O
completely O
. O

It O
acts O
on O
Cdks I-GENE
in O
the O
G1 O
and O
S O
phases O
of O
the O
cell O
cycle O
, O
and O
also O
binds O
to O
proliferating I-GENE
cell I-GENE
nuclear I-GENE
antigen I-GENE
( O
PCNA I-GENE
), O
blocking O
DNA O
replication O
in O
vitro O
. O

Two O
major O
and O
one O
minor O
transcription O
initiation O
sites O
were O
assigned O
to O
positions O
+ O
1 O
and O
+ O
24 O
and O
position O
+ O
14 O
, O
respectively O
, O
by O
a O
combination O
of O
ribonuclease O
protection O
, O
primer O
extension O
, O
and O
5 O
' O
RACE O
analyses O
. O

The O
roxithromycin O
doses O
that O
were O
chosen O
for O
these O
studies O
were O
less O
than O
achievable O
blood O
levels O
. O

We O
demonstrate O
here O
that O
the O
- O
DEDDDL O
sequence O
stabilizes O
GDP O
binding O
to O
Ran I-GENE
, O
and O
that O
the O
domain O
is O
required O
for O
high O
affinity O
interaction O
with O
a O
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
HTF9A I-GENE
/ O
RanBP1 I-GENE
. O

Further O
, O
the O
ORFs O
of O
components O
3 O
and O
5 O
potentially O
encoded O
proteins O
of O
about O
20 O
kDa O
, O
the O
size O
of O
the O
BBTV I-GENE
coat I-GENE
protein I-GENE
. O

Serial O
followup O
strength O
data O
for O
2 O
patients O
were O
compared O
to O
change O
in O
creatinine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
levels O
. O

CodY I-GENE
does O
not O
have O
any O
homologues O
in O
the O
data O
- O
bases O
. O

OBJECTIVE O
: O
To O
investigate O
the O
incidence O
and O
presentation O
of O
acute O
pernicious O
or O
fulminating O
beriberi O
in O
a O
general O
district O
hospital O
. O

Unlike O
most O
other O
small I-GENE
G I-GENE
proteins I-GENE
which O
are O
expressed O
ubiquitously O
, O
TTF I-GENE
was O
transcribed O
only O
in O
hemopoietic O
cells O
as O
a O
2 O
. O
2 O
kb O
transcript O
. O

An O
explanation O
explored O
for O
this O
lack O
of O
gene O
expression O
was O
that O
increased O
levels O
of O
RAR I-GENE
alpha I-GENE
or O
PML I-GENE
might O
suppress O
APL O
cell O
growth O
. O

Transfection O
of O
non O
- O
deleted O
expression O
vector O
into O
NIH3T3 O
cells O
results O
in O
acquisition O
of O
focus O
- O
forming O
activity O
while O
a O
deleted O
form O
of O
expression O
vector O
fails O
to O
show O
this O
activity O
even O
in O
the O
presence O
of O
basic I-GENE
FGF I-GENE
. O

Cytosolic O
extracts O
from O
a O
variety O
of O
mammalian O
cell O
lines O
( O
monkey O
Cos7 O
, O
several O
mouse O
fibrosarcomas O
and O
human O
HeLa O
S3 O
) O
demonstrated O
similar O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
dependent O
RNA O
- O
protein O
band O
shifts O
as O
cell O
extract O
from O
BALB O
/ O
c O
3T3 O
mouse O
fibroblasts O
. O

All O
ribosomal I-GENE
protein I-GENE
( O
rp I-GENE
) O
gene O
promoters O
from O
Saccharomyces O
cerevisiae O
studied O
so O
far O
contain O
either O
( O
usually O
two O
) O
binding O
sites O
for O
the O
global O
gene O
regulator O
Rap1p I-GENE
or O
one O
binding O
site O
for O
another O
global O
factor O
, O
Abf1p I-GENE
. O

The O
provisional O
reports O
are O
based O
mainly O
upon O
macroscopic O
findings O
, O
whereas O
the O
final O
reports O
include O
the O
information O
provided O
by O
supplementary O
investigations O
such O
as O
microscopy O
, O
histochemistry O
, O
more O
rarely O
electron O
microscopy O
, O
immunohistochemistry O
and O
/ O
or O
microbiology O
. O

Circulating O
thrombomodulin I-GENE
: O
current O
knowledge O
and O
future O
prospects O

CPT O
- O
11 O
was O
administered O
as O
a O
30 O
- O
minute O
i O
. O
v O
. O
infusion O
at O
a O
dose O
of O
350 O
mg O
/ O
m2 O
diluted O
in O
250 O
ml O
normal O
saline O
every O
3 O
weeks O
. O

CONCLUSION O
: O
The O
MTD O
for O
CPT O
- O
11 O
administered O
in O
a O
3 O
consecutive O
- O
days O
- O
every O
- O
3 O
weeks O
schedule O
in O
this O
patient O
population O
is O
115 O
mg O
/ O
m2 O
/ O
day O
. O

A O
73 O
bp O
fragment O
( O
X1 O
region O
) O
of O
the O
PRB I-GENE
- I-GENE
1b I-GENE
promoter I-GENE
, O
located O
between O
positions O
- O
213 O
and O
- O
141 O
, O
was O
sufficient O
to O
confer O
ethylene O
responsiveness O
to O
the O
reporter O
gene O
. O

To O
assess O
the O
function O
( O
s O
) O
of O
E74 I-GENE
during O
metamorphosis O
, O
we O
have O
isolated O
and O
characterized O
recessive O
loss O
- O
of O
- O
function O
mutations O
specific O
to O
each O
transcription O
unit O
. O

Although O
the O
extracellular O
domain O
of O
the O
TSH I-GENE
- I-GENE
R I-GENE
is O
sufficient O
for O
high O
affinity O
binding O
of O
TSH I-GENE
, O
we O
conclude O
that O
the O
hyt O
mutation O
in O
the O
fourth O
transmembrane O
domain O
eliminates O
TSH I-GENE
binding O
. O

Lipiodol O
was O
covalently O
conjugated O
with O
EDTB O
. O

Moreover O
, O
Western O
blots O
demonstrated O
at O
least O
six O
types O
of O
Ypt I-GENE
in O
both O
Cr O
and O
Vc O
, O
suggesting O
that O
these O
Ypt I-GENE
are O
used O
for O
household O
functions O
responsible O
for O
vesicle O
transport O
rather O
than O
for O
cellular O
differentiation O
. O

The O
absence O
of O
other O
regions O
of O
hybridization O
suggests O
that O
there O
are O
no O
closely O
related O
sequences O
( O
e O
. O
g O
., O
reverse O
transcribed O
pseudogenes O
) O
scattered O
throughout O
the O
genome O
and O
that O
if O
there O
are O
closely O
related O
genes O
, O
they O
must O
be O
clustered O
near O
GSTT2 I-GENE
. O

However O
, O
the O
lens O
dose O
( O
3 O
. O
6 O
Gy O
/ O
25 O
fractions O
) O
was O
higher O
compared O
to O
the O
other O
techniques O
. O

Antibodies O
to O
the O
human I-GENE
PTS1R I-GENE
recognize O
this O
protein O
in O
human O
, O
monkey O
, O
rat O
, O
and O
hamster O
cells O
. O

There O
is O
a O
national O
effort O
to O
begin O
to O
ask O
all O
female O
patients O
about O
family O
violence O
. O

GnRH I-GENE
treatment O
was O
found O
to O
increase O
the O
phosphorylation O
of O
tyrosine O
residues O
of O
MAPK I-GENE
and O
to O
increase O
MAPK I-GENE
activity O
, O
as O
determined O
by O
an O
immune O
complex O
kinase O
assay O
. O

Molecular O
cloning O
of O
an O
amphibian I-GENE
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
- I-GENE
like I-GENE
cDNA I-GENE
and O
involvement O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
insulin I-GENE
- O
induced O
Xenopus O
oocyte O
maturation O
. O

We O
report O
here O
that O
in O
cultured O
Jurkat O
T O
cells O
, O
Cbl I-GENE
is O
coprecipitated O
with O
antibody O
against O
the O
adapter I-GENE
protein I-GENE
Grb2 I-GENE
. O

The O
effect O
of O
these O
cell O
cycle O
regulators O
is O
not O
specific O
to O
the O
rap1s I-GENE
or O
hmr I-GENE
delta I-GENE
A I-GENE
mutation I-GENE
, O
since O
swi6 I-GENE
, O
swi4 I-GENE
, O
and O
clb5 I-GENE
mutations I-GENE
also O
suppress O
mutations O
in O
SIR1 I-GENE
, O
another O
gene O
implicated O
in O
the O
establishment O
of O
silencing O
. O

ICP4 I-GENE
has O
been O
shown O
to O
form O
tripartite O
complexes O
cooperatively O
with O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
and O
TFIIB I-GENE
on O
DNA O
containing O
an O
ICP4 I-GENE
binding I-GENE
site I-GENE
and O
a O
TATA O
box O
( O
C O
. O

Otte O
, O
Mol O
. O

Characterization O
of O
fus1 I-GENE
of O
Schizosaccharomyces O
pombe O
: O
a O
developmentally O
controlled O
function O
needed O
for O
conjugation O
. O

SRY I-GENE
- I-GENE
related I-GENE
cDNA I-GENE
encoding O
a O
protein O
with O
a O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
( O
HMG I-GENE
) O
box O
and O
a O
leucine O
zipper O
motif O
, O
which O
was O
designated O
SOX I-GENE
- I-GENE
LZ I-GENE
, O
was O
isolated O
from O
a O
rainbow O
trout O
testis O
cDNA O
library O
. O

Scalp O
flaps O
can O
be O
expanded O
just O
to O
the O
point O
of O
becoming O
noticeable O
over O
4 O
to O
6 O
weeks O
followed O
by O
scalp O
flap O
transposition O
and O
easy O
closure O
of O
the O
donor O
site O
. O

In O
the O
Center O
for O
Human O
Genetics O
in O
Leuven O
, O
predictive O
DNA O
- O
testing O
for O
Huntington O
' O
s O
disease O
is O
available O
as O
a O
clinical O
service O
since O
November O
1987 O
, O
initially O
by O
DNA O
- O
linkage O
and O
since O
mid O
1993 O
by O
direct O
mutation O
analysis O
. O

Risks O
of O
chronicity O
following O
acute O
hepatitis O
B O
virus O
infection O
: O
a O
review O
. O

Examination O
of O
neurohumoral O
factors O
revealed O
a O
hyperactive O
sympathetic O
nervous O
system O
and O
an O
increase O
in O
plasma O
renin I-GENE
activity O
. O

We O
compared O
the O
inhibitory O
effect O
of O
naturally O
occurring O
mutant I-GENE
hTR I-GENE
beta I-GENE
1 I-GENE
, O
artificially O
created O
hTR I-GENE
alpha I-GENE
1 I-GENE
mutants I-GENE
, O
c I-GENE
- I-GENE
erbA I-GENE
alpha I-GENE
2 I-GENE
and O
the O
human I-GENE
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
( O
hPPAR I-GENE
) O
on O
three O
prototypic O
T3 O
- O
response O
elements O
( O
TREs O
), O
TRE O
- O
PAL O
, O
DR O
+ O
4 O
and O
TRE O
- O
LAP O
. O

The O
amino O
- O
terminal O
DNA O
- O
binding O
domain O
of O
Pip I-GENE
exhibits O
a O
high O
degree O
of O
homology O
to O
the O
DNA O
- O
binding O
domains O
of O
members O
of O
the O
interferon I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family O
, O
which O
includes O
IRF I-GENE
- I-GENE
1 I-GENE
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
ICSBP I-GENE
, O
and O
ISGF3 I-GENE
gamma I-GENE
. O

An O
outbreak O
of O
hepatitis O
A O
among O
homosexual O
men O
in O
Amsterdam O
, O
1991 O
- O
1993 O
. O

The O
RAP74 I-GENE
subunit I-GENE
of O
TFIIF I-GENE
alone O
contained O
the O
stimulatory O
activity O
and O
the O
minimal O
region O
sufficient O
for O
stimulation O
corresponds O
to O
COOH O
- O
terminal O
residues O
358 O
- O
517 O
. O

We O
have O
generated O
various O
base O
substitutions O
and O
internal O
deletions O
in O
and O
around O
DRE O
( O
nucleotide O
positions O
- O
93 O
to O
- O
100 O
with O
respect O
to O
the O
transcription O
initiation O
site O
) O
of O
the O
PCNA I-GENE
gene I-GENE
in O
vitro O
and O
subsequently O
examined O
their O
effects O
on O
the O
binding O
to O
DREF I-GENE
( O
DRE I-GENE
- I-GENE
binding I-GENE
factor I-GENE
) O
and O
PCNA I-GENE
gene I-GENE
promote O
activity O
in O
cultured O
Drosophila O
Kc O
cells O
as O
well O
as O
in O
living O
flies O
. O

The O
hsp70 I-GENE
gene I-GENE
family I-GENE
of O
Neurospora O
crassa O
: O
cloning O
, O
sequence O
analysis O
, O
expression O
, O
and O
genetic O
mapping O
of O
the O
major O
stress O
- O
inducible O
member O
. O

The O
deduced O
amino O
acid O
sequences O
of O
each O
of O
the O
W3A1 I-GENE
ETF I-GENE
subunits I-GENE
exhibit O
only O
approximately O
30 O
% O
identity O
with O
the O
corresponding O
subunits O
of O
the O
ETF I-GENE
from O
human O
, O
rat O
, O
and O
Paracoccus O
denitrificans O
, O
which O
as O
a O
group O
are O
greater O
than O
50 O
% O
identical O
. O

A O
secondary O
phosphorylation O
of O
CREB341 I-GENE
at O
Ser129 O
is O
required O
for O
the O
cAMP O
- O
mediated O
control O
of O
gene O
expression O
. O

A O
role O
for O
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
in O
the O
control O
of O
gene O
expression O
. O

This O
last O
region O
contains O
two O
sites O
that O
bind O
Ets I-GENE
- I-GENE
related I-GENE
proteins I-GENE
present O
in O
liver O
nuclear O
extracts O
as O
well O
as O
recombinant I-GENE
purified I-GENE
Ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

Other O
assays O
also O
distinguished O
the O
processive O
replication O
of O
pNeo O
. O
Myc O
- O
2 O
. O
4 O
from O
the O
dispersive O
labeling O
of O
control O
plasmids O
. O

Reconstitution O
of O
complexes O
containing O
p62 I-GENE
and O
the O
src I-GENE
family I-GENE
kinase I-GENE
p59fyn I-GENE
in O
HeLa O
cells O
demonstrated O
that O
complex O
formation O
resulted O
in O
tyrosine O
phosphorylation O
of O
p62 I-GENE
and O
was O
mediated O
by O
both O
the O
SH3 I-GENE
and O
SH2 I-GENE
domains I-GENE
of O
p59fyn I-GENE
. O

Therefore O
, O
it O
is O
hoped O
that O
by O
defining O
the O
transcriptional O
control O
of O
the O
L7 I-GENE
gene I-GENE
insights O
into O
the O
mechanisms O
that O
control O
functional O
fate O
and O
organization O
in O
the O
nervous O
system O
can O
be O
gained O
. O

In O
contrast O
, O
a O
Maf I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
Nrl I-GENE
, O
completely O
mimicked O
c I-GENE
- I-GENE
Maf I-GENE
actions O
. O

The O
27 O
- O
base O
element O
interacts O
with O
a O
PDGF I-GENE
- O
activated O
serine O
/ O
threonine O
phosphoprotein O
that O
is O
detected O
only O
within O
the O
nucleus O
of O
PDGF O
- O
treated O
3T3 O
cells O
. O

By O
contrast O
, O
deletion O
of O
this O
Ras I-GENE
- I-GENE
binding I-GENE
site I-GENE
did O
not O
diminish O
activation O
of O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
Src I-GENE
, O
implying O
that O
Src I-GENE
and O
Ras I-GENE
can O
activate O
Raf I-GENE
- I-GENE
1 I-GENE
through O
independent O
mechanisms O
. O

In O
studies O
of O
many O
different O
phenotypically O
distinct O
cells O
, O
the O
CRE O
of O
the O
somatostatin I-GENE
gene I-GENE
promoter I-GENE
is O
a O
prototype O
of O
a O
highly O
cAMP O
- O
responsive O
element O
regulated O
by O
CREB I-GENE
. O

The O
first O
gene O
, O
NSR1 I-GENE
, O
a O
previously O
identified O
gene O
, O
encodes O
a O
protein O
involved O
in O
ribosomal O
RNA O
maturation O
and O
possibly O
in O
transport O
of O
proteins O
into O
the O
nucleus O
. O

Characterization O
of O
the O
promoter O
for O
the O
human I-GENE
85 I-GENE
kDa I-GENE
cytosolic I-GENE
phospholipase I-GENE
A2 I-GENE
gene I-GENE
. O

This O
paper O
describes O
the O
advantages O
and O
limitations O
of O
the O
main O
study O
approaches O
used O
. O

Comparative O
study O
of O
the O
differential O
white O
blood O
cell O
count O
using O
three O
automated O
analyzers O
: O
Coulter O
STKS O
, O
Sysmex O
NE O
8000 O
and O
Technicon O
H O
- O
1 O
. O

Characterization O
of O
FIII I-GENE
/ O
YY1 I-GENE
, O
a O
Xenopus I-GENE
laevis I-GENE
conserved I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
binding O
to O
the O
first O
exon O
of O
L1 I-GENE
and O
L14 I-GENE
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Further O
studies O
established O
that O
the O
Ep I-GENE
- O
induced O
increase O
in O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
could O
be O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
inhibitor O
genistein O
and O
the O
protein I-GENE
kinase I-GENE
C I-GENE
inhibitor O
Compound O
3 O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

This O
structure O
of O
cucumisin I-GENE
suggests O
that O
it O
is O
probably O
synthesized O
as O
an O
inactive O
precursor O
. O

Molecular O
dissection O
of O
the O
multimeric O
CD3 I-GENE
- O
TCR I-GENE
complex O
revealed O
that O
at O
least O
two O
associated O
polypeptides O
, O
CD3 I-GENE
zeta I-GENE
and O
CD3 I-GENE
epsilon I-GENE
, O
autonomously O
couple O
antigenic O
recognition O
event O
to O
early O
and O
late O
events O
of O
the O
intracytoplasmic O
activation O
cascade O
. O

Protein I-GENE
cHMGI I-GENE
binds O
preferentially O
to O
AT O
- O
rich O
DNA O
with O
a O
half O
- O
saturation O
value O
of O
1 O
. O
1 O
nM O
. O

This O
study O
investigated O
the O
degree O
to O
which O
racial O
identity O
influences O
Mexican O
- O
Americans O
' O
performance O
on O
the O
L O
, O
K O
, O
and O
MF O
scales O
of O
the O
MMPI O
- O
2 O
. O

Both O
can O
be O
elevated O
on O
a O
single O
vascular O
pedicle O
based O
on O
the O
superficial O
temporal O
artery O
, O
the O
double O
- O
layered O
temporal O
fascia O
flap O
. O

To O
do O
this O
, O
segments O
of O
DNA O
from O
the O
5 O
' O
flank O
of O
the O
initiation O
sites O
for O
germline O
epsilon O
RNA O
were O
ligated O
to O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
and O
transfected O
into O
two O
mouse O
B O
cell O
lines O
, O
one O
of O
which O
can O
be O
induced O
to O
switch O
to O
IgE I-GENE
. O

The O
negative O
predictive O
value O
is O
92 O
%, O
vs O
80 O
% O
for O
the O
NCEP O
I O
. O

Oncogenic O
capacity O
of O
the O
E2F1 I-GENE
gene I-GENE
. O

In O
some O
of O
the O
cases O
of O
solitary O
lesion O
, O
serum I-GENE
TSH I-GENE
levels O
, O
serum I-GENE
thyroglobulin I-GENE
values O
, O
and O
131I O
protein O
bounded O
iodine O
( O
131I O
- O
PBI O
) O
were O
measured O
, O
but O
there O
were O
no O
significant O
differences O
between O
successful O
and O
unsuccessful O
therapy O
. O

Endo16 I-GENE
transcripts I-GENE
are O
confined O
to O
the O
definitive O
vegetal O
plate O
in O
blastula O
stage O
embryos O
; O
at O
gastrula O
stage O
this O
gene O
is O
expressed O
throughout O
the O
archenteron O
, O
but O
later O
only O
in O
the O
midgut O
. O

A O
unique O
leucine O
- O
proline O
repeat O
element O
found O
N O
- O
terminal O
to O
the O
DNA O
- O
binding O
domain O
of O
EmBP I-GENE
- I-GENE
1 I-GENE
does O
not O
appear O
to O
play O
a O
role O
in O
DNA O
- O
binding O
or O
dimerization O
. O

Another O
full O
ORF O
was O
found O
on O
the O
opposite O
strand O
downstream O
from O
the O
nspC I-GENE
gene I-GENE
. O

The O
U14 I-GENE
genes I-GENE
of O
mouse O
as O
well O
as O
rat O
, O
hamster O
, O
human O
, O
Xenopus O
and O
trout O
are O
encoded O
within O
introns O
of O
the O
constitutively O
expressed O
70 I-GENE
- I-GENE
kDa I-GENE
- I-GENE
cognate I-GENE
- I-GENE
heat I-GENE
- I-GENE
shock I-GENE
protein I-GENE
gene I-GENE
( O
hsc70 I-GENE
). O

Two O
related O
cDNAs O
were O
isolated O
that O
encode O
proteins O
that O
recognize O
the O
XMyoDa I-GENE
TATA I-GENE
motif I-GENE
. O

Deletion O
of O
both O
prfA I-GENE
and O
ponA I-GENE
resulted O
in O
extremely O
slow O
growth O
and O
a O
reduction O
in O
sporulation O
efficiency O
. O

Inclusion O
in O
this O
family O
of O
proteins O
suggests O
that O
FliQ I-GENE
and O
FliR I-GENE
may O
participate O
in O
an O
export O
pathway O
required O
for O
flagellum O
assembly O
. O

In O
broken O
L O
- O
cell O
membranes O
expressing O
wild O
type O
or O
mutant I-GENE
M6P I-GENE
/ I-GENE
IGF I-GENE
II I-GENE
receptors I-GENE
, O
30 O
nM O
IGF I-GENE
II I-GENE
also O
failed O
to O
affect O
the O
pertussis I-GENE
toxin I-GENE
substrate O
activity O
. O

Chem O
. O

For O
the O
first O
time O
we O
describe O
deletion O
and O
point O
mutations O
within O
the O
plasma I-GENE
membrane I-GENE
family I-GENE
of I-GENE
guanylyl I-GENE
cyclase I-GENE
receptors I-GENE
that O
result O
in O
the O
formation O
of O
effective O
dominant O
negative O
proteins O
. O

Increase O
in O
blood O
NEFA O
was O
further O
augmented O
by O
fat O
plus O
AA O
supplementation O
, O
but O
no O
changes O
in O
concentrations O
of O
Lys O
or O
Met O
in O
blood O
were O
found O
. O

Virol O
. O

Coronary O
vasoconstriction O
caused O
by O
endothelin I-GENE
- I-GENE
1 I-GENE
is O
enhanced O
by O
ischemia O
- O
reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

Comparison O
of O
the O
deduced O
amino I-GENE
acid I-GENE
sequence I-GENE
of I-GENE
gamma I-GENE
- I-GENE
kafirin I-GENE
with O
the O
published O
sequences I-GENE
of I-GENE
gamma I-GENE
- I-GENE
prolamins I-GENE
of I-GENE
maize I-GENE
, I-GENE
and I-GENE
Coix I-GENE
revealed O
highly O
conserved O
domains O
. O

Atcys1 I-GENE
, O
Athyp1 I-GENE
, O
AKin10 I-GENE
and O
the O
ORF O
are O
very O
close O
to O
each O
other O
and O
organized O
in O
the O
same O
polarity O
; O
hence O
, O
the O
intergenic O
regions O
probably O
contain O
, O
within O
less O
than O
0 O
. O
5 O
kb O
, O
all O
the O
regulatory O
elements O
necessary O
to O
govern O
initiation O
and O
termination O
of O
transcription O
. O

Southern O
blot O
hybridization O
experiments O
suggest O
the O
presence O
of O
one O
copy O
of O
Atcys1 I-GENE
, O
Athyp1 I-GENE
and O
AKin10 I-GENE
per O
haploid O
genome O
, O
and O
Northern O
blot O
analysis O
demonstrates O
that O
the O
three O
genes O
are O
differentially O
expressed O
in O
roots O
, O
shoots O
and O
leaves O
. O

These O
results O
suggest O
that O
HAC1 I-GENE
may O
also O
be O
one O
of O
the O
meiotic O
genes O
. O

We O
characterized O
three O
Arabidopsis O
thaliana O
cDNA O
clones O
that O
could O
rescue O
the O
sterile O
phenotype O
of O
the O
Schizosaccharomyces I-GENE
pombe I-GENE
pde1 I-GENE
mutant I-GENE
, O
which O
is O
defective O
in O
cAMP I-GENE
phosphodiesterase I-GENE
. O

Furthermore O
, O
the O
identification O
of O
a O
Dr1 I-GENE
- I-GENE
like I-GENE
protein I-GENE
in O
A O
. O
thaliana O
strongly O
argues O
for O
the O
ubiquity O
of O
this O
protein O
among O
eukaryotic O
genera O
and O
for O
a O
conserved O
mechanism O
to O
regulate O
transcription O
initiation O
that O
involves O
Dr1 I-GENE
. O

Similarly O
approximately O
300 O
bp O
of O
sequence O
downstream O
of O
the O
translation O
terminator O
TGA O
of O
the O
beta I-GENE
- I-GENE
tubulin I-GENE
2 I-GENE
( O
BTU2 I-GENE
) O
gene O
could O
substitute O
for O
the O
3 O
' O
region O
of O
the O
H4 I-GENE
- I-GENE
I I-GENE
gene I-GENE
. O

These O
data O
demonstrate O
that O
the O
STR I-GENE
family I-GENE
of O
genes O
is O
represented O
in O
a O
nematode O
whose O
ancestor O
appeared O
well O
before O
the O
branching O
that O
gave O
rise O
to O
the O
Arthropoda O
and O
Chordata O
. O

The O
pre O
- O
and O
postoperative O
haemoglobin I-GENE
concentrations O
in O
the O
autologous O
group O
were O
lower O
by O
15 O
and O
10 O
g O
/ O
L O
, O
respectively O
, O
after O
primary O
THR O
and O
by O
10 O
g O
/ O
L O
in O
both O
instances O
after O
revision O
THR O
. O

The O
introduction O
of O
an O
acidic O
residue O
at O
the O
second O
site O
was O
essential O
for O
suppression O
of O
the O
Asn O
- O
285 O
mutation O
because O
Lys O
- O
220 O
and O
Gln O
- O
220 O
second O
- O
site O
mutants O
of O
the O
Asn O
- O
285 O
mutant O
showed O
very O
low O
tetracycline O
resistance O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
, O
the O
cytokine O
that O
participates O
in O
the O
autocrine O
growth O
control O
of O
hairy O
cell O
leukemia O
has O
strong O
bone O
resorptive O
properties O
. O

( O
iv O
) O
Although O
UCRBP I-GENE
has O
been O
previously O
shown O
to O
act O
as O
a O
transcriptional O
repressor O
, O
we O
show O
here O
that O
UCRBP I-GENE
can O
also O
act O
as O
a O
positive O
transactivator O
of O
a O
reporter O
driven O
by O
UCR O
elements O
when O
used O
in O
co O
- O
transfection O
assays O
. O

The O
sequence O
of O
monkey I-GENE
opsin I-GENE
closely O
resembles O
the O
human O
sequence O
at O
the O
nucleotide O
and O
the O
amino O
acid O
levels O
, O
with O
the O
latter O
having O
only O
7 O
differences O
out O
of O
348 O
residues O
. O

One O
complex O
appears O
to O
be O
ubiquitous O
but O
enriched O
in O
lymphoid O
cells O
and O
represents O
the O
binding O
of O
a O
potentially O
novel O
factor O
with O
an O
apparent O
molecular O
mass O
of O
approximately O
50 O
kDa O
. O

Chem O
. O

Conversely O
, O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
by O
RAR I-GENE
: O
RXR I-GENE
heterodimers I-GENE
was O
completely O
abolished O
by O
EAR I-GENE
- I-GENE
3 I-GENE
/ O
COUP I-GENE
- I-GENE
TFI I-GENE
and O
by O
ARP I-GENE
- I-GENE
1 I-GENE
/ O
COUP I-GENE
- I-GENE
TFII I-GENE
. O

These O
results O
demonstrate O
that O
EKLF I-GENE
provides O
a O
crucial O
transactivation O
function O
for O
globin I-GENE
expression O
and O
further O
reinforce O
the O
idea O
that O
EKLF I-GENE
is O
an O
important O
regulator O
of O
CACCC O
element O
- O
directed O
transcription O
in O
erythroid O
cells O
. O

Using O
a O
battery O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
mutants I-GENE
, O
we O
show O
that O
( O
i O
) O
a O
dimer O
binds O
a O
single O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
molecule I-GENE
, O
( O
ii O
) O
the O
acidic O
C O
- O
terminal O
region O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
is O
not O
required O
for O
protein O
- O
protein O
binding O
and O
does O
not O
mask O
the O
nuclear O
localization O
signal O
of O
the O
dimer O
, O
( O
iii O
) O
the O
same O
C O
- O
terminal O
region O
is O
required O
for O
inhibition O
of O
DNA O
binding O
, O
and O
( O
iv O
) O
this O
inhibition O
may O
be O
accomplished O
by O
direct O
interaction O
between O
the O
PEST O
- O
like O
region O
and O
the O
DNA O
- O
binding O
region O
of O
one O
of O
the O
subunits O
of O
the O
dimer O
. O

The O
negative O
regulatory O
activity O
of O
the O
N O
- O
terminal O
domain O
was O
antagonized O
by O
a O
C O
- O
terminal O
segment O
of O
Pho81p I-GENE
supplied O
in O
trans O
. O

At O
different O
times O
of O
the O
surgical O
procedures O
( O
thorax O
opening O
and O
closure O
, O
period O
of O
cardiopulmonary O
bypass O
) O
67 O
to O
100 O
% O
of O
the O
patients O
in O
group O
1 O
had O
vancomycin O
concentrations O
in O
the O
studied O
tissues O
above O
the O
MIC O
90 O
for O
Staphylococcus O
aureus O
( O
1 O
microgram O
/ O
g O
) O
and O
Staphylococcus O
epidermidis O
( O
2 O
micrograms O
/ O
g O
). O

On O
- O
line O
angioscopic O
images O
of O
tissue O
flaps O
floating O
in O
the O
lumen O
, O
recent O
or O
structured O
thrombi O
, O
artery O
wall O
dissections O
, O
plaque O
ruptures O
, O
deep O
fissurations O
and O
sub O
- O
intimal O
haemorrhages O
demonstrate O
, O
in O
live O
colour O
, O
the O
pathophysiological O
mechanisms O
of O
coronary O
artery O
stenosis O
. O

The O
enhanced O
cysteine O
formation O
in O
a O
pCSK4F O
plant O
responding O
to O
sulfite O
was O
also O
observed O
in O
leaf O
discs O
. O

Each O
type O
was O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
whether O
the O
body O
and O
tail O
of O
the O
pancreas O
showed O
intense O
fatty O
replacement O
( O
type O
a O
= O
negative O
for O
intense O
fatty O
replacement O
, O
type O
b O
= O
positive O
for O
intense O
fatty O
replacement O
). O

Between O
the O
subgroups O
of O
dementia O
disorders O
there O
were O
no O
significant O
differences O
in O
basal O
cortisol O
levels O
. O

A O
new O
hypothesis O
on O
mechanisms O
for O
inhibiting O
catalytic O
subunits O
by O
gamma O
- O
subunits O
and O
activation O
of O
a O
holoenzyme O
by O
transducin I-GENE

Basal O
components O
of O
the O
transcription O
apparatus O
( O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
contain O
activation O
domains O
: O
is O
the O
repetitive O
C O
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
a O
" O
portable O
enhancer O
domain O
"? O
Regions O
rich O
in O
serine O
, O
threonine O
, O
and O
proline O
residues O
can O
be O
found O
in O
transcriptional O
activation O
domains O
, O
as O
well O
as O
in O
the O
N O
- O
terminal O
parts O
of O
mammalian I-GENE
TATA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
where O
they O
are O
interrupted O
by O
polyglutamine O
stretches O
. O

Mutagenesis O
of O
IM1 I-GENE
enhances O
the O
ability O
of O
c I-GENE
- I-GENE
Fos I-GENE
to O
activate O
an O
AP1 I-GENE
bearing I-GENE
promoter I-GENE
. O

Binding O
of O
SSP I-GENE
to O
the O
stage I-GENE
selector I-GENE
element I-GENE
( O
SSE I-GENE
) O
in O
the O
proximal O
gamma I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
is O
integral O
to O
the O
competitive O
silencing O
of O
a O
linked O
beta I-GENE
- I-GENE
promoter I-GENE
in O
embryonic O
/ O
fetal O
stage O
erythroleukemia O
( O
K562 O
) O
cells O
. O

This O
failure O
to O
execute O
regulated O
G1 O
/ O
S O
arrest O
is O
correlated O
with O
enhanced O
thermosensitivity O
of O
colony O
- O
forming O
ability O
. O

Mutations O
that O
alter O
photoreceptor O
cell O
structure O
and O
development O
were O
isolated O
that O
fail O
to O
complement O
these O
deletions O
. O

It O
is O
possible O
that O
the O
telomeres O
of O
the O
two O
nuclei O
have O
different O
functions O
. O

The O
marker O
orders O
from O
the O
genetic O
and O
RH O
maps O
were O
consistent O
. O

Integrated O
mapping O
analysis O
of O
the O
Werner O
syndrome O
region O
of O
chromosome O
8 O
. O

The O
region O
between O
DXS52 I-GENE
and O
Factor I-GENE
VIII I-GENE
gene I-GENE
in O
the O
human O
Xq28 O
chromosomal O
band O
contains O
a O
G O
+ O
C O
- O
rich O
isochore O
to O
which O
many O
genes O
have O
been O
mapped O
. O

Haplotype O
mapping O
and O
sequence O
analysis O
of O
the O
mouse O
Nramp I-GENE
gene I-GENE
predict O
susceptibility O
to O
infection O
with O
intracellular O
parasites O
. O

This O
utilization O
of O
an O
intronic O
polyadenylation O
site O
without O
alternative O
exon O
usage O
is O
comparable O
to O
the O
mechanism O
whereby O
both O
secreted O
and O
membrane O
- O
bound O
forms O
of O
the O
immunoglobulin I-GENE
mu I-GENE
heavy I-GENE
chain I-GENE
are O
made O
from O
a O
single O
genetic O
locus O
. O

To O
further O
our O
knowledge O
about O
the O
systemic O
humoral O
immune O
system O
response O
to O
weak O
hapten O
- O
syngeneic O
or O
allogeneic O
protein O
conjugates O
( O
corrosion O
and O
wear O
products O
of O
metallic O
orthopedic O
devices O
), O
a O
sensitive O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
method O
for O
testing O
for O
antibody O
( O
humoral O
immunity O
) O
to O
metals O
was O
developed O
. O

In O
contrast O
, O
peak O
filling O
rate O
( O
PFR O
), O
normalized O
to O
end O
diastolic O
volume O
( O
EDV O
), O
or O
stroke O
volume O
( O
SV O
), O
or O
expressed O
as O
the O
ratio O
of O
PFR O
- O
to O
- O
PER O
was O
reduced O
( O
p O
< O
0 O
. O
01 O
), O
time O
to O
PFR O
( O
TPFR O
) O
was O
prolonged O
( O
p O
< O
0 O
. O
01 O
), O
and O
echocardiographic O
left O
ventricular O
mass O
index O
was O
higher O
( O
p O
< O
0 O
. O
001 O
) O
in O
patients O
with O
acromegaly O
compared O
to O
normals O
. O

A O
genetic O
complementation O
system O
was O
developed O
in O
which O
tobacco I-GENE
etch I-GENE
virus I-GENE
( I-GENE
TEV I-GENE
) I-GENE
polymerase I-GENE
( O
NIb I-GENE
)- O
expressing O
transgenic O
plants O
or O
protoplasts O
were O
inoculated O
with O
NIb I-GENE
- O
defective O
TEV I-GENE
mutants I-GENE
. O

Nucleotide O
sequence O
and O
transcriptional O
analysis O
of O
the O
DNA I-GENE
polymerase I-GENE
gene I-GENE
of I-GENE
Bombyx I-GENE
mori I-GENE
nuclear I-GENE
polyhedrosis I-GENE
virus I-GENE
. O

Comparison O
of O
the O
genomes O
of O
PMTV O
, O
BNYVV O
, O
and O
SBWMV O
shows O
that O
furoviruses O
exhibit O
considerable O
heterogeneity O
in O
genome O
organization O
. O

The O
drug O
sensitivity O
was O
100 O
% O
for O
vancomycin O
( O
VCM O
), O
30 O
% O
for O
imipenam O
( O
IMP O
), O
31 O
% O
for O
minomycin O
( O
MINO O
), O
31 O
% O
for O
amikacin O
( O
AMK O
), O
and O
7 O
% O
for O
fosfomycin O
( O
FOM O
). O

Deglycosylation O
with O
endoglycosidase I-GENE
H I-GENE
showed O
that O
the O
mutant O
receptors O
had O
mainly O
high O
- O
mannose O
oligosaccharide O
chains O
. O

Dietary O
supplement O
with O
fish O
oil O
and O
related O
n O
- O
3 O
EFAs O
has O
been O
used O
to O
study O
their O
antihypertensive O
property O
in O
animals O
and O
humans O
with O
borderline O
and O
essential O
hypertension O
. O

The O
HSD3B1 I-GENE
and O
HSD3B2 I-GENE
genes I-GENE
encoding O
the O
types I-GENE
I I-GENE
and I-GENE
II I-GENE
3 I-GENE
beta I-GENE
- I-GENE
HSD I-GENE
isoenzymes I-GENE
, O
respectively O
, O
have O
been O
previously O
assigned O
by O
in O
situ O
hybridization O
to O
the O
chromosome O
1p13 O
. O
1 O
region O
. O

Therefore O
the O
prevalences O
of O
total O
diabetes O
and O
GDM O
were O
1 O
. O
19 O
% O
and O
0 O
. O
56 O
%, O
respectively O
. O

Insulin I-GENE
- O
stimulated O
glucose O
transport O
in O
adipocytes O
is O
mediated O
by O
the O
insulin I-GENE
receptor I-GENE
. O

After O
selection O
and O
conversion O
to O
adipocytes O
, O
the O
level O
of O
EGFR I-GENE
expression O
was O
retained O
in O
infectant O
adipocytes O
( O
150 O
, O
000 O
and O
250 O
, O
000 O
/ O
cell O
, O
respectively O
), O
but O
not O
in O
the O
parental O
3T3 O
- O
L1 O
adipocytes O
(< O
5000 O
/ O
cell O
). O

Intron O
- O
exon O
structure O
of O
the O
porcine I-GENE
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
. O

Fraction O
2 O
contains O
1 O
, O
25 O
( O
OH O
) O
2 O
- O
vitamin O
D3 O
, O
vitamin O
D3 O
, O
25 O
( O
OH O
)- O
vitamin O
D3 O
and O
1 O
, O
24 O
, O
25 O
( O
OH O
) O
3 O
- O
vitamin O
D3 O
. O

The O
kallistatin I-GENE
gene I-GENE
was O
localized O
by O
in O
situ O
hybridization O
to O
human O
chromosome O
14q31 O
- O
q32 O
. O
1 O
, O
close O
to O
the O
serpin I-GENE
genes I-GENE
encoding O
alpha I-GENE
1 I-GENE
- I-GENE
antichymotrypsin I-GENE
, O
protein I-GENE
C I-GENE
inhibitor I-GENE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
and O
corticosteroid I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
. O

The O
locus O
encoding O
the O
XD I-GENE
gene I-GENE
( O
designated O
Xd I-GENE
) O
was O
mapped O
to O
the O
distal O
part O
of O
mouse O
chromosome O
17 O
by O
haplotype O
analysis O
of O
114 O
interspecific O
backcross O
mice O
. O

Some O
studies O
of O
exercise O
have O
associated O
beta I-GENE
- I-GENE
endorphin I-GENE
release O
with O
increased O
exertion O
levels O
, O
but O
other O
evidence O
suggests O
that O
acidosis O
may O
stimulate O
the O
release O
of O
beta I-GENE
- I-GENE
endorphin I-GENE
. O

An O
interatrial O
communication O
mitigates O
the O
impairment O
of O
LV O
function O
after O
an O
acute O
and O
sustained O
drop O
of O
intrathoracic O
pressure O
. O

Self O
or O
foreign O
cellular O
proteins O
provide O
peptides O
for O
presentation O
by O
major I-GENE
histocompatibility I-GENE
complex I-GENE
( I-GENE
MHC I-GENE
) I-GENE
class I-GENE
I I-GENE
molecules I-GENE
on O
the O
surface O
of O
antigen O
presenting O
cells O
( O
APC O
). O

The O
characteristics O
of O
the O
VirD1 I-GENE
/ O
VirD2 I-GENE
- O
mediated O
cleavage O
reaction O
strongly O
resemble O
those O
observed O
with O
relaxosomes O
of O
IncP O
plasmids O
involved O
in O
initiation O
of O
transfer O
DNA O
replication O
during O
bacterial O
conjugation O
. O

Isoelectric O
focusing O
of O
tryptic O
peptides O
generated O
from O
MHC I-GENE
- I-GENE
B I-GENE
phosphorylated O
with O
cdc2 I-GENE
kinase I-GENE
revealed O
one O
major O
phosphopeptide O
that O
was O
purified O
by O
reverse O
- O
phase O
high O
performance O
liquid O
chromatography O
and O
sequenced O
. O

The O
deduced O
protein O
sequence O
was O
88 O
% O
homologous O
to O
that O
of O
hNUC I-GENE
I I-GENE
, O
isolated O
from O
human O
osteosarcoma O
cells O
. O

However O
, O
cotransfection O
studies O
indicate O
that O
RVR I-GENE
does O
not O
activate O
transcription O
when O
this O
hormone O
response O
element O
is O
linked O
to O
a O
reporter O
gene O
but O
rather O
acts O
as O
a O
potent O
competitive O
repressor O
of O
ROR I-GENE
alpha I-GENE
function O
. O

A O
comparison O
of O
the O
Flavobacterium O
glycosylasparaginase I-GENE
with O
a O
mammalian O
glycosylasparaginase I-GENE
revealed O
30 O
% O
structural O
identity O
and O
60 O
% O
overall O
similarity O
between O
the O
prokaryotic O
and O
eukaryotic O
forms O
of O
the O
enzyme O
. O

Dissociation O
and O
complexation O
of O
the O
fluoroquinolone O
antimicrobials O
-- O
an O
update O
. O

Superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
activity O
decreased O
significantly O
in O
sperm O
subjected O
to O
direct O
electric O
current O
in O
comparison O
to O
the O
control O
or O
the O
sample O
incubated O
with O
electrolyzed O
medium O
. O

These O
studies O
indicate O
that O
in O
vitro O
and O
in O
vivo O
electrical O
stimulation O
generate O
reactive O
oxygen O
species O
and O
affect O
SOD I-GENE
activity O
, O
which O
in O
part O
are O
responsible O
for O
decreased O
sperm O
motion O
and O
viability O
. O

Molecular O
cloning O
and O
sequencing O
of O
a O
cDNA O
encoding O
SR I-GENE
beta I-GENE
revealed O
that O
SR I-GENE
beta I-GENE
is O
a O
transmembrane O
protein O
and O
, O
like O
SR I-GENE
alpha I-GENE
and O
SRP54 I-GENE
, O
is O
a O
member O
of O
the O
GTPase I-GENE
superfamily I-GENE
. O

To O
understand O
the O
function O
of O
receptor I-GENE
- I-GENE
linked I-GENE
tyrosine I-GENE
phosphatases I-GENE
in O
neural O
development O
, O
we O
sought O
to O
identify O
LAR I-GENE
isoforms I-GENE
preferentially O
expressed O
in O
the O
nervous O
system O
and O
cellular O
processes O
regulating O
LAR I-GENE
alternative O
splicing O
. O

Sex O
selection O
via O
albumin I-GENE
columns O
: O
20 O
years O
of O
results O
. O

135 O
students O
had O
a O
count O
of O
less O
than O
50 O
eggs O
/ O
10 O
ml O
. O
urine O
and O
56 O
had O
more O
than O
50 O
eggs O
/ O
10ml O
. O

They O
also O
reported O
that O
E I-GENE
mu I-GENE
pim I-GENE
- I-GENE
1 I-GENE
transgenic O
mice O
show O
greatly O
accelerated O
lymphoma O
development O
when O
infected O
with O
wild O
- O
type O
M O
- O
MuLV O
at O
birth O
. O

Comparison O
of O
human I-GENE
and I-GENE
murine I-GENE
blk I-GENE
sequences I-GENE
indicated O
that O
they O
share O
86 O
% O
amino O
acid O
identity O
, O
the O
most O
conserved O
region O
being O
the O
catalytic O
domain O
( O
93 O
% O
identity O
). O

Chrispeels O
[ O
1993 O
] O
EMBO O
J O
12 O
: O
2241 O
- O
2247 O
). O

The O
mRNAs O
of O
the O
GRF I-GENE
genes I-GENE
are O
encoded O
by O
six O
exons O
interrupted O
by O
five O
introns O
. O

The O
effect O
of O
ethanol O
on O
human O
sensorimotor O
reactivity O
was O
assessed O
by O
examining O
the O
acoustic O
startle O
response O
. O

Digitalis O
glycosides O
or O
beta I-GENE
- I-GENE
receptor I-GENE
antagonists O
are O
not O
helpful O
in O
the O
therapy O
of O
this O
form O
of O
atrial O
fibrillation O
whereas O
class O
I O
antiarrhythmic O
drugs O
have O
been O
shown O
to O
be O
more O
effective O
. O

Atrial O
fibrillation O
and O
the O
autonomic O
nervous O
system O

VIII O
in O
doses O
2 O
- O
3 O
times O
higher O
than O
usually O
used O
in O
haemophiliacs O
without O
inhibitor O
were O
successful O
. O

A O
reduction O
of O
the O
aspartate I-GENE
aminotransferase I-GENE
activity O
was O
observed O
from O
800 O
mg O
/ O
kg O
b O
. O
w O
./ O
d O
onwards O
. O

Thus O
, O
these O
studies O
indicate O
that O
the O
104 O
- O
kDa O
isoform O
is O
required O
for O
normal O
proliferation O
of O
female O
germline O
cells O
and O
perhaps O
for O
oocyte O
differentiation O
. O

Physical O
analysis O
maps O
SAL6 I-GENE
to O
chromosome O
XVI O
between O
TPK2 I-GENE
and O
spt14 I-GENE
. O

The O
newly O
devised O
DCT O
method O
yields O
reliable O
data O
in O
measuring O
TBF O
. O

Removal O
of O
PDMP O
from O
the O
cell O
medium O
resulted O
in O
reversal O
of O
the O
cell O
cycle O
changes O
, O
with O
cells O
re O
- O
entering O
the O
S O
phase O
. O

Rho I-GENE
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
inhibitor I-GENE
, O
Rho I-GENE
GDI I-GENE
, O
comigrated O
with O
Rac2 I-GENE
and O
RhoA I-GENE
, O
but O
not O
Rac1 I-GENE
. O

A O
major O
task O
for O
sports O
scientists O
may O
be O
to O
verify O
empirically O
the O
nature O
of O
an O
integrated O
model O
of O
the O
sport O
performer O
. O

Schnell O
, O
J O
. O

Encapsidation O
of O
poliovirus O
replicons O
encoding O
the O
complete O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
gag I-GENE
gene I-GENE
by O
using O
a O
complementation O
system O
which O
provides O
the O
P1 I-GENE
capsid I-GENE
protein I-GENE
in O
trans O
. O

Removal O
of O
the O
GST I-GENE
domain I-GENE
from O
GST I-GENE
- O
Tax I-GENE
by O
thrombin I-GENE
restores O
Tax I-GENE
' O
s O
ability O
to O
assemble O
a O
ternary O
Tax I-GENE
- O
CREB I-GENE
- O
21 O
- O
bp O
- O
repeat O
complex O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
requirement O
of O
PilE I-GENE
in O
pilus O
biogenesis O
was O
confirmed O
by O
demonstrating O
that O
chromosomal I-GENE
pilE I-GENE
insertion I-GENE
mutants I-GENE
were O
pilus O
- O
and O
twitching O
- O
motility O
deficient O
. O

The O
pilE I-GENE
gene I-GENE
product I-GENE
of I-GENE
Pseudomonas I-GENE
aeruginosa I-GENE
, O
required O
for O
pilus O
biogenesis O
, O
shares O
amino O
acid O
sequence O
identity O
with O
the O
N O
- O
termini O
of O
type I-GENE
4 I-GENE
prepilin I-GENE
proteins I-GENE
. O

Because O
of O
the O
functional O
conservation O
of O
cell O
cycle O
control O
elements O
, O
the O
expression O
of O
a O
vertebrate I-GENE
wee1 I-GENE
or O
mik1 I-GENE
homolog I-GENE
would O
be O
expected O
to O
rescue O
such O
lethal O
mutations O
in O
yeast O
. O

The O
expression O
of O
this O
clone O
in O
a O
wee1 I-GENE
/ O
mik1 I-GENE
- O
deficient O
mutant O
causes O
an O
elongated O
cell O
phenotype O
under O
non O
- O
permissive O
growth O
conditions O
. O

These O
data O
indicate O
that O
phosphorylation O
of O
M I-GENE
protein I-GENE
at O
the O
major O
in O
vivo O
sites O
is O
not O
essential O
for O
virus O
assembly O
. O

Near O
a O
third O
( O
31 O
. O
6 O
%) O
of O
Insulin I-GENE
Dependent O
and O
a O
third O
( O
33 O
. O
41 O
%) O
for O
Non O
Insulin I-GENE
Dependent O
were O
of O
D O
, O
F O
, O
H O
White O
' O
s O
Class O
. O

The O
activity O
of O
6 O
- O
fluoroquinolones O
and O
their O
nonfluorinated O
derivatives O
is O
compared O
in O
general O
. O

As O
the O
half O
- O
life O
of O
the O
compound O
did O
never O
exceed O
8 O
- O
9 O
h O
, O
the O
data O
do O
not O
support O
any O
change O
of O
pidotimod O
administration O
schedule O
( O
every O
24 O
- O
12 O
h O
). O

The O
MAP I-GENE
kinase I-GENE
cascade O
is O
highly O
conserved O
in O
all O
eukaryotes O
and O
involved O
in O
numerous O
cellular O
responses O
. O

A O
comparative O
study O
by O
holographic O
interferometry O
of O
ten O
porcine O
bioprosthetic O
valves O
( O
seven O
Carpentier O
- O
Edwards O
SAV O
, O
two O
BioImplant O
and O
one O
Valcor O
) O
with O
five O
human O
aortic O
valves O
before O
and O
after O
glutaraldehyde O
treatment O
is O
presented O
. O

No O
serious O
side O
effects O
were O
observed O
. O

This O
region O
constitutes O
the O
DNA O
- O
binding O
domain O
with O
basic O
- O
helix O
- O
loop O
- O
helix O
and O
leucine O
- O
zipper O
motifs O
, O
features O
common O
to O
the O
myc I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Specific O
binding O
was O
not O
observed O
with O
either O
the O
orthologous O
rat O
or O
mouse O
fragments O
using O
human O
or O
rodent O
extracts O
. O

The O
mean O
jitter O
and O
the O
fiber O
density O
did O
not O
change O
significantly O
from O
day O
0 O
( O
30 O
. O
1 O
+/- O
3 O
. O
6 O
microseconds O
; O
1 O
. O
4 O
+/- O
0 O
. O
07 O
) O
to O
day O
30 O
( O
34 O
. O
5 O
+/- O
2 O
. O
7 O
microseconds O
; O
1 O
. O
6 O
+/- O
0 O
. O
13 O
). O

Lack O
of O
cyclin I-GENE
D I-GENE
- O
Cdk I-GENE
complexes O
in O
Rb I-GENE
- O
negative O
cells O
correlates O
with O
high O
levels O
of O
p16INK4 I-GENE
/ O
MTS1 I-GENE
tumour O
suppressor O
gene O
product O
. O

Recombinant I-GENE
human I-GENE
serum I-GENE
albumin I-GENE
( O
rHSA I-GENE
) O
produced O
by O
cultured O
fermentation O
has O
been O
prepared O
in O
the O
form O
of O
microcapsules O
nominally O
3 O
- O
5 O
microns O
in O
diameter O
and O
radiolabelled O
with O
technetium O
- O
99m O
following O
reduction O
with O
stannous O
chloride O
. O

We O
have O
measured O
the O
release O
of O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
and O
tumour I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
) O
by O
unstimulated O
monocytes O
and O
monocytes O
stimulated O
with O
lipopolysaccharide O
( O
LPS O
) O
isolated O
from O
the O
peripheral O
blood O
of O
two O
patients O
with O
acute O
poststreptococcal O
glomerulonephritis O
( O
AGN O
) O
and O
16 O
healthy O
controls O
. O

Such O
an O
intervention O
may O
be O
of O
considerable O
use O
for O
the O
treatment O
of O
angiogenesis O
- O
dependent O
diseases O
involving O
FGF I-GENE
- I-GENE
2 I-GENE
. O

We O
have O
attempted O
to O
clone O
two O
recessive O
extragenic O
suppressors O
of O
such O
ts O
mutants O
( O
sdp1 I-GENE
for O
mutation I-GENE
pol3 I-GENE
- I-GENE
14 I-GENE
and O
sdp5 I-GENE
- I-GENE
1 I-GENE
for O
mutation I-GENE
pol3 I-GENE
- I-GENE
11 I-GENE
) O
by O
transforming O
thermoresistant O
haploid O
strains O
pol3 I-GENE
- I-GENE
14 I-GENE
sdp1 I-GENE
and O
pol3 I-GENE
- I-GENE
11 I-GENE
sdp5 I-GENE
- I-GENE
1 I-GENE
with O
wild O
- O
type O
genomic O
libraries O
in O
singlecopy O
or O
multicopy O
vectors O
. O

UV O
cross O
- O
linking O
experiments O
show O
that O
TEP I-GENE
has O
an O
apparent O
molecular O
mass O
of O
approximately O
65 O
kDa O
. O

In O
acute O
- O
phase O
livers O
, O
we O
observed O
a O
dramatic O
reduction O
in O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
expression O
which O
correlates O
with O
a O
decrease O
in O
the O
expression O
of O
its O
target O
gene O
, O
the O
TTR I-GENE
gene I-GENE
. O

Alternatively O
, O
loss O
- O
of O
- O
function O
alleles O
of O
genes O
that O
inhibit O
cAPK I-GENE
lead O
to O
the O
inability O
to O
undergo O
sexual O
differentiation O
. O

One O
member O
of O
this O
family O
, O
RFX1 I-GENE
, O
is O
a O
transcription O
factor O
for O
a O
variety O
of O
viral O
and O
cellular O
genes O
. O

This O
mutant O
was O
identified O
by O
screening O
with O
a O
TGF I-GENE
- I-GENE
beta I-GENE
- O
inducible O
vector O
a O
series O
of O
mink O
lung O
epithelial O
cell O
clones O
that O
have O
normal O
TGF I-GENE
- I-GENE
beta I-GENE
binding O
activity O
but O
have O
lost O
antiproliferative O
and O
transcriptional O
responses O
to O
TGF I-GENE
- I-GENE
beta I-GENE
. O

Cloning O
by O
complementation O
and O
subsequent O
physical O
and O
genetic O
analysis O
revealed O
that O
it O
maps O
to O
RAF1 I-GENE
. O

In O
the O
presence O
of O
inositol O
and O
choline O
( O
repressing O
), O
the O
product O
of O
the O
OPI1 I-GENE
gene I-GENE
represses O
transcription O
dictated O
by O
the O
UASINO O
element O
. O

By O
treating O
monkey O
COS O
cells O
with O
oligonucleotides O
linked O
to O
psoralen O
, O
we O
have O
generated O
targeted O
mutations O
in O
a O
simian O
virus O
40 O
( O
SV40 O
) O
vector O
contained O
within O
the O
cells O
via O
intracellular O
triple O
helix O
formation O
. O

The O
interleukin I-GENE
2 I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
( O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
) O
gene O
is O
rapidly O
and O
potently O
induced O
in O
T O
cells O
in O
response O
to O
mitogenic O
stimuli O
. O

The O
Wilms I-GENE
' I-GENE
tumour I-GENE
suppressor I-GENE
protein I-GENE
( O
WT1 I-GENE
) O
is O
a O
putative O
transcriptional O
regulatory O
protein O
with O
four O
zinc O
fingers O
, O
the O
last O
three O
of O
which O
have O
extensive O
sequence O
homology O
to O
the O
early I-GENE
growth I-GENE
response I-GENE
- I-GENE
1 I-GENE
( O
EGR I-GENE
- I-GENE
1 I-GENE
) O
protein O
. O

OBJECTIVES O
: O
1 O
) O
to O
determine O
serum I-GENE
ACE I-GENE
activity O
in O
patients O
with O
COPD O
treated O
with O
and O
without O
continuous O
ambulatory O
oxygen O
therapy O
( O
CAOT O
); O
2 O
) O
to O
verify O
whether O
there O
is O
a O
correlation O
between O
ACE I-GENE
and O
any O
hematological O
, O
spirometric O
or O
gasometric O
parameter O
. O

In O
order O
to O
infer O
shape O
from O
contour O
, O
the O
human O
visual O
system O
must O
selectively O
integrate O
fragments O
projecting O
from O
a O
common O
object O
while O
keeping O
fragments O
from O
different O
objects O
separate O
. O

Among O
9 O
group O
I O
patients O
with O
a O
positive O
result O
on O
head O
- O
up O
tilt O
- O
table O
testing O
and O
no O
evidence O
of O
structural O
heart O
disease O
( O
mean O
follow O
- O
up O
4 O
. O
3 O
years O
), O
7 O
are O
without O
further O
episodes O
of O
syncope O
; O
3 O
have O
discontinued O
medication O
and O
5 O
have O
resumed O
at O
least O
limited O
exercise O
. O

Constructs O
designed O
and O
expressed O
were O
E2L1 O
( O
1 O
- O
98 O
), O
E2L1 O
. O
H1 O
( O
1 O
- O
128 O
), O
E2L2 O
( O
120 O
- O
233 O
), O
E2H1 O
. O
L2 O
( O
98 O
- O
233 O
), O
and O
E2L1 O
. O
H1 O
. O
L2 O
( O
1 O
- O
233 O
), O
where O
numbers O
in O
parentheses O
give O
the O
amino O
acid O
sequence O
for O
the O
portions O
of O
the O
E2 I-GENE
component O
incorporated O
into O
a O
construct O
. O

Thus O
, O
we O
have O
produced O
lipoyl O
domain O
constructs O
that O
can O
be O
employed O
in O
sorting O
the O
specific O
roles O
of O
E2L1 I-GENE
and O
E2L2 I-GENE
in O
facilitating O
catalytic O
and O
regulatory O
processes O
. O

METHODS O
: O
Ten O
influenza O
A O
( O
H3N2 O
) O
viruses O
isolated O
during O
the O
outbreaks O
were O
examined O
for O
resistance O
to O
amantadine O
and O
rimantadine O
by O
means O
of O
an O
enzyme O
immunoassay O
and O
by O
sequencing O
of O
the O
viral O
nucleic O
acid O
that O
encodes O
the O
transmembrane O
domain O
of O
the O
M2 I-GENE
protein I-GENE
. O

The O
first O
contains O
ATF I-GENE
/ O
CRE O
and O
TBP I-GENE
/ O
TATA O
sequence O
motifs O
within O
an O
87 O
- O
bp O
region O
. O

Gene O
expression O
occurs O
in O
a O
circadian O
rhythm O
and O
induced O
by O
light O
in O
leaves O
of O
dark O
- O
adapted O
plants O
. O

Our O
results O
suggested O
that O
the O
hexamer O
and O
the O
octamer O
motifs O
may O
play O
important O
role O
( O
s O
) O
in O
regulation O
of O
replication O
- O
dependent O
but O
not O
of O
replication O
- O
independent O
expression O
of O
the O
wheat I-GENE
histone I-GENE
H3 I-GENE
gene I-GENE
. O

The O
tissue O
- O
specific O
expression O
of O
DP I-GENE
family I-GENE
members I-GENE
suggests O
that O
the O
combination O
of O
DP I-GENE
/ O
E2F I-GENE
heterodimers O
that O
constitute O
DRTF1 I-GENE
/ O
E2F I-GENE
is O
influenced O
by O
the O
phenotype O
of O
the O
cell O
. O

Similarly O
, O
in O
mammalian O
cells O
PBP74 I-GENE
is O
synthesized O
as O
a O
pre O
- O
protein O
that O
requires O
membrane O
potential O
- O
dependent O
import O
into O
mitochondria O
for O
its O
maturation O
. O

In O
a O
second O
experiment O
involving O
an O
18 O
- O
h O
lung O
clearance O
assay O
, O
we O
used O
the O
mAb I-GENE
3 I-GENE
. I-GENE
2 I-GENE
. I-GENE
3 I-GENE
to O
deplete O
rats O
of O
LGL O
/ O
NK O
cells O
with O
the O
following O
rationale O
: O
if O
LGL O
/ O
NK O
cells O
are O
necessary O
to O
mediate O
an O
event O
, O
then O
in O
their O
absence O
, O
that O
event O
should O
not O
occur O
. O

Treatment O
of O
recurrent O
FSGS O
has O
included O
high O
- O
dose O
steroids O
, O
high O
- O
dose O
cyclosporine O
( O
CSA O
), O
plasmapheresis O
, O
and O
ACE I-GENE
inhibitors O
with O
mixed O
results O
. O

Our O
results O
concluded O
that O
1 O
) O
the O
two O
inhibin I-GENE
/ O
activin I-GENE
beta O
B O
- O
subunit O
mRNAs O
were O
transcribed O
from O
different O
initiation O
sites O
; O
2 O
) O
both O
promoters O
may O
be O
controlled O
by O
up O
- O
stream O
negative O
regulatory O
elements O
; O
and O
3 O
) O
neither O
of O
these O
promoters O
is O
responsive O
to O
cAMP O
and O
/ O
or O
phorbol O
esters O
under O
the O
conditions O
employed O
. O

Promoter O
region O
of O
the O
transcriptional O
unit O
for O
human I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
chimaerin I-GENE
, O
a O
neuron I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
p21rac I-GENE
. O
alpha I-GENE
1 I-GENE
- I-GENE
chimaerin I-GENE
is O
a O
neuron I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
p21rac I-GENE
, O
a O
protein O
involved O
in O
morphological O
events O
. O

Upstream O
from O
the O
transcription O
start O
point O
( O
tsp O
), O
a O
nucleotide O
sequence O
highly O
homologous O
to O
the O
consensus I-GENE
sequence I-GENE
motif I-GENE
for I-GENE
the I-GENE
sigma I-GENE
35 I-GENE
- I-GENE
recognized I-GENE
promoters I-GENE
was O
found O
. O

In O
this O
paper O
, O
an O
analysis O
of O
the O
dynamics O
in O
the O
closing O
phase O
of O
the O
occluder O
of O
a O
mechanical O
monoleaflet O
heart O
valve O
prosthesis O
is O
presented O
. O

During O
ISO O
+ O
AT O
infusion O
, O
abdominal O
fat O
blood O
flow O
was O
still O
significantly O
increased O
as O
compared O
with O
control O
values O
in O
lean O
and O
obese O
subjects O
. O

When O
expressed O
per O
kilogram O
body O
weight O
, O
mean O
GIT O
increased O
in O
the O
dF O
group O
from O
0 O
. O
14 O
% O
to O
0 O
. O
16 O
% O
above O
RMR O
, O
with O
a O
significant O
decrease O
from O
0 O
. O
15 O
% O
to O
0 O
. O
13 O
% O
in O
the O
P O
group O
. O

In O
nucleus O
ventralis O
anterior O
thalami O
- O
nucleus O
ventralis O
lateralis O
thalami O
neurons O
with O
an O
inhibitory O
input O
from O
nucleus O
entopeduncularis O
, O
a O
shortening O
of O
inhibition O
from O
17 O
. O
5 O
+/- O
3 O
. O
6 O
to O
9 O
. O
1 O
+/- O
1 O
. O
8 O
ms O
( O
P O
< O
0 O
. O
05 O
) O
under O
the O
haloperidol O
influence O
was O
evident O
. O

However O
, O
inclusion O
of O
the O
neighboring O
CGGAAR O
motifs O
from O
the O
ICP4 I-GENE
promoter I-GENE
, O
which O
bind O
factors O
GABP I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
, O
results O
in O
a O
strong O
synergistic O
activation O
. O

The O
first O
open O
reading O
frame O
of O
the O
blueberry O
scorch O
carlavirus O
( O
BBScV O
) O
genome O
encodes O
a O
putative O
replication O
- O
associated O
protein O
of O
223 O
kDa O
( O
p223 I-GENE
). O

From O
sequence O
alignments O
with O
phylogenetically O
related O
viruses O
, O
including O
tymoviruses O
, O
we O
predicted O
that O
p223 I-GENE
contained O
a O
papain I-GENE
- I-GENE
like I-GENE
proteinase I-GENE
domain I-GENE
with O
a O
putative O
catalytic O
cysteine994 O
and O
histidine1075 O
. O

This O
finding O
represents O
both O
a O
potentially O
important O
mechanism O
by O
which O
HPV O
gene O
expression O
can O
be O
regulated O
and O
an O
interesting O
model O
for O
the O
study O
of O
transcriptional O
cooperativity O
. O

Using O
this O
method O
, O
VLPs O
were O
obtained O
in O
quantities O
sufficient O
for O
further O
characterization O
. O

Analysis O
of O
the O
sequence O
upstream O
of O
this O
initiation O
codon O
reveals O
the O
presence O
of O
a O
promotor O
sequence O
. O

SUP46 I-GENE
is O
implicated O
in O
translation O
fidelity O
and O
encodes O
the O
ribosomal I-GENE
protein I-GENE
S13 I-GENE
. O

To O
explore O
the O
functional O
relationship O
between O
c I-GENE
- I-GENE
fos I-GENE
and O
Rb I-GENE
, O
a O
eukaryotic O
expression O
plasmid O
was O
constructed O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
under O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
complex O
. O

The O
high O
degree O
of O
sequence O
identity O
( O
96 O
%) O
between O
hydrolase I-GENE
B I-GENE
and I-GENE
C I-GENE
, O
particularly O
in O
the O
3 O
' O
untranslated O
region O
, O
suggests O
that O
the O
genes O
encoding O
these O
two O
carboxylesterases I-GENE
evolved O
by O
duplication O
and O
divergence O
of O
a O
common O
ancestral O
gene O
. O

The O
regions O
of O
the O
tooth O
fracture O
are O
determined O
. O

Secondary O
pancreatic O
involvement O
of O
mycosis O
fungoides O
detected O
by O
a O
clinically O
palpable O
mass O
. O

The O
NR2 O
hybrid O
is O
a O
powerful O
tool O
for O
the O
mapping O
of O
new O
probes O
of O
this O
region O
, O
as O
well O
as O
for O
obtaining O
new O
informative O
probes O
specific O
for O
the O
deletion O
by O
subtractive O
cloning O
of O
the O
region O
. O

TDEYA O
at O
doses O
of O
200 O
to O
500 O
mg O
/ O
kg O
significantly O
suppressed O
xanthine I-GENE
oxidase I-GENE
( O
XO I-GENE
) O
activity O
in O
the O
stomach O
tissue O
following O
its O
oral O
administration O
. O

Like O
humans O
, O
the O
PITSLRE I-GENE
PK I-GENE
genes I-GENE
in I-GENE
chickens I-GENE
must O
be O
closely O
linked O
, O
based O
on O
fluorescent O
in O
situ O
hybridization O
( O
FISH O
) O
localization O
of O
these O
genes O
to O
a O
single O
chicken O
microchromosome O
. O

Here O
, O
we O
report O
the O
characterization O
of O
an O
alternatively O
processed O
form O
of O
AFAP I-GENE
- I-GENE
110 I-GENE
that O
encodes O
an O
additional O
258 O
base O
pair O
( O
bp O
) O
of O
open O
reading O
frame O
. O

Expression O
of O
class I-GENE
IV I-GENE
ADH I-GENE
mRNA I-GENE
was O
detected O
in O
human O
stomach O
but O
not O
liver O
. O

In O
ICE I-GENE
gamma I-GENE
, O
most O
of O
the O
propeptide O
( O
amino O
acids O
20 O
- O
112 O
) O
is O
deleted O
, O
which O
suggests O
that O
it O
may O
function O
as O
a O
catalyst O
for O
ICE I-GENE
autoprocessing O
in O
vivo O
. O

Endocytosis O
and O
lysosomal O
targeting O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptors I-GENE
are O
mediated O
by O
distinct O
sequences O
independent O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
. O

It O
is O
now O
recognized O
that O
essentially O
all O
eukaryotic O
and O
prokaryotic O
genes O
whose O
5 O
'- O
flanking O
regions O
are O
known O
and O
that O
encode O
barbiturate O
- O
inducible O
proteins O
contain O
the O
Barbie O
box O
element O
. O

Mutation O
of O
the O
P450BM I-GENE
- I-GENE
3 I-GENE
Barbie I-GENE
box I-GENE
significantly O
increased O
the O
expression O
of O
both O
P450BM I-GENE
- I-GENE
3 I-GENE
and O
Bm3P1 I-GENE
( O
another O
small O
gene O
located O
upstream O
of O
the O
P450BM I-GENE
- I-GENE
3 I-GENE
gene I-GENE
that O
encodes O
a O
second O
putative O
regulatory O
protein O
) O
in O
response O
to O
pentobarbital O
induction O
but O
left O
the O
basal O
levels O
unaffected O
. O

The O
p97 I-GENE
- O
depleted O
nuclei O
remained O
largely O
competent O
for O
nuclear O
protein O
import O
. O

A O
potential O
outcome O
of O
these O
biochemical O
effects O
may O
include O
the O
limited O
responsiveness O
of O
infected O
T O
cells O
to O
antigenic O
stimulation O
observed O
during O
HIV O
- O
1 O
infection O
. O

The O
full O
protocol O
was O
completed O
by O
33 O
patients O
( O
45 O
% O
of O
original O
cohort O
). O

In O
addition O
, O
we O
found O
that O
cell O
- O
specific O
suppression O
of O
RA O
- O
stimulated O
zif268 I-GENE
gene I-GENE
expression O
can O
be O
attributed O
to O
a O
29 O
base O
pair O
nucleotide O
sequence O
, O
located O
downstream O
of O
the O
RA O
- O
responsive O
region O
in O
the O
zif268 I-GENE
gene I-GENE
. O

We O
show O
that O
CBF I-GENE
- I-GENE
A I-GENE
and O
CBF I-GENE
- I-GENE
C I-GENE
interact O
with O
each O
other O
to O
form O
a O
CBF I-GENE
- I-GENE
A I-GENE
- O
CBF I-GENE
- I-GENE
C I-GENE
complex O
and O
that O
CBF I-GENE
- I-GENE
B I-GENE
does O
not O
interact O
with O
CBF I-GENE
- I-GENE
A I-GENE
or O
CBF I-GENE
- I-GENE
C I-GENE
individually O
but O
that O
it O
associates O
with O
the O
CBF I-GENE
- I-GENE
A I-GENE
- O
CBF I-GENE
- I-GENE
C I-GENE
complex O
. O

In O
the O
first O
, O
homologous O
sequences O
were O
deleted O
from O
a O
mouse O
enhancer O
, O
resulting O
in O
a O
tissue O
- O
specific O
loss O
of O
activity O
when O
assayed O
in O
transgenic O
mice O
. O

OKT3 I-GENE
prophylaxis O
improves O
long O
- O
term O
renal O
graft O
survival O
in O
high O
- O
risk O
patients O
as O
compared O
to O
cyclosporine O
: O
combined O
results O
from O
the O
prospective O
, O
randomized O
Belgian O
and O
US O
studies O
. O

The O
major O
PKC I-GENE
beta I-GENE
transcription O
initiation O
site O
was O
identified O
by O
primer O
extension O
and O
S1 I-GENE
nuclease I-GENE
protection O
. O

In O
the O
course O
of O
a O
study O
of O
low O
dose O
X O
- O
rays O
effects O
, O
we O
found O
that O
male O
ICR O
white O
Swiss O
mice O
showed O
remarkable O
suppression O
of O
mounting O
behavior O
after O
whole O
body O
irradiation O
by O
5 O
to O
15 O
cGy O
X O
- O
rays O
. O

A O
quantitative O
analysis O
of O
the O
diffraction O
intensity O
as O
function O
of O
the O
accumulated O
electron O
dose O
suggests O
the O
possibility O
of O
recording O
up O
to O
250 O
diffraction O
patterns O
with O
3 O
. O
5 O
A O
resolution O
from O
a O
single O
crotoxin O
complex O
crystal O
128 O
A O
thick O
. O

Supplementary O
Phase O
Contraste O
RSE O
(" O
Rapid O
Sequential O
Excitation O
") O
sequences O
were O
carried O
out O
in O
29 O
patients O
. O

In O
yeast O
, O
the O
products O
of O
the O
UPF1 I-GENE
and O
UPF3 I-GENE
genes I-GENE
are O
required O
for O
this O
decay O
pathway O
, O
and O
in O
this O
report O
we O
focus O
on O
the O
identification O
and O
characterization O
of O
additional O
factors O
required O
for O
rapid O
decay O
of O
nonsense O
- O
containing O
mRNAs O
. O

Mutations O
in O
UPF1 I-GENE
lead O
to O
the O
selective O
stabilization O
of O
mRNAs O
containing O
early O
nonsense O
mutations O
without O
affecting O
the O
decay O
rates O
of O
most O
other O
mRNAs O
. O

A O
DNA O
fragment O
encoding O
the O
DNA O
- O
binding O
domain O
( O
amino O
acids O
1 O
- O
60 O
) O
of O
the O
Escherichia I-GENE
coli I-GENE
fru I-GENE
transcriptional I-GENE
regulator I-GENE
was O
cloned O
into O
the O
pGEX O
- O
KT O
vector O
and O
expressed O
in O
frame O
with O
the O
fused O
gene O
encoding O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
. O

Using O
gel O
retardation O
assays O
with O
HepG2 O
nuclear O
extract O
, O
we O
demonstrated O
the O
presence O
of O
a O
specific O
protein O
which O
bound O
to O
the O
NRE O
fragment O
. O

0 O
. O
61 O
+/- O
0 O
. O
04 O
). O

Several O
nuclear O
factors O
that O
interact O
with O
sequences O
in O
the O
5 O
' O
flanking O
region O
of O
the O
mouse I-GENE
tyrosinase I-GENE
gene I-GENE
were O
identified O
using O
band O
shift O
and O
methylation O
interference O
assays O
. O

With O
a O
population O
of O
853 O
million O
there O
should O
be O
51 O
, O
204 O
patients O
with O
hemophilia O
A O
in O
India O
assuming O
a O
prevalence O
of O
6 O
/ O
100 O
, O
000 O
population O
. O

When O
combined O
with O
serum O
ferritin I-GENE
and O
hemoglobin I-GENE
determinations O
, O
the O
serum O
transferrin I-GENE
receptor I-GENE
assay O
is O
a O
valuable O
addition O
in O
epidemiologic O
surveys O
because O
it O
provides O
a O
quantitative O
measure O
of O
functional O
iron O
deficiency O
and O
it O
distinguishes O
true O
IDA O
from O
the O
anemia O
of O
chronic O
disease O
. O

Twenty O
- O
two O
consecutive O
patients O
with O
ischaemic O
ulcers O
had O
tcPO2 O
measured O
and O
the O
ankle O
/ O
brachial O
( O
ABI O
) O
and O
toe O
/ O
brachial O
( O
TBI O
) O
indices O
calculated O
. O

TcPO2 O
measurement O
appears O
to O
be O
a O
reliable O
technique O
that O
can O
influence O
ischaemic O
ulcer O
management O
. O

Since O
1990 O
the O
University O
Hospital O
of O
Tromso O
has O
provided O
local O
hospitals O
in O
northern O
Norway O
with O
a O
remote O
frozen O
section O
service O
and O
with O
access O
to O
video O
conferences O
for O
the O
review O
of O
microscopic O
findings O
and O
for O
the O
discussion O
of O
major O
diagnostic O
issues O
. O

Current O
status O
of O
telepathology O
. O

Expression O
of O
h6 O
. O
1 O
in O
COS O
- O
1 O
cells O
led O
to O
the O
production O
of O
a O
typical O
type I-GENE
IV I-GENE
PDE I-GENE
activity O
in O
that O
cAMP O
, O
but O
not O
cGMP O
, O
served O
as O
substrate O
and O
its O
activity O
was O
insensitive O
to O
either O
Ca2 O
+/ O
CaM I-GENE
or O
cGMP O
but O
was O
inhibited O
by O
low O
concentrations O
of O
rolipram O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

PMEK1 I-GENE
displays O
96 O
and O
80 O
% O
identity O
respectively O
with O
the O
tobacco I-GENE
NTF3 I-GENE
and O
Arabidopsis I-GENE
ATMPK1 I-GENE
kinases I-GENE
, O
and O
only O
50 O
% O
to O
the O
more O
distantly O
related O
plant O
MAP O
kinase O
MsERK1 I-GENE
from O
alfalfa O
. O

Translation O
of O
the O
coding O
segment O
, O
which O
was O
designated O
MsPRP2 I-GENE
, O
suggested O
it O
encodes O
a O
chimeric O
40 O
, O
569 O
Da O
cell O
wall O
protein O
with O
an O
amino O
- O
terminal O
signal O
sequence O
, O
a O
repetitive O
proline O
- O
rich O
sequence O
, O
and O
a O
cysteine O
- O
rich O
carboxyl O
- O
terminal O
sequence O
homologous O
to O
nonspecific O
lipid O
transfer O
proteins O
. O

The O
presence O
of O
type O
I O
hypersensitivity O
in O
a O
subgroup O
of O
aspergillomas O
suggests O
an O
immunoallergic O
component O
to O
this O
disease O
which O
could O
contribute O
to O
a O
chronic O
inflammatory O
response O
to O
Aspergillus O
in O
some O
aspergillomas O
. O

This O
concept O
is O
supported O
by O
the O
identification O
of O
RH I-GENE
- I-GENE
like I-GENE
genes I-GENE
in O
non O
human O
primates O
. O

With O
steady O
illumination O
, O
outer O
retinal O
( O
photoreceptor O
) O
QO2 O
decreased O
to O
1 O
. O
4 O
+/- O
0 O
. O
9 O
ml O
O2 O
/( O
100 O
g O
. O
min O
), O
but O
inner O
retinal O
QO2 O
remained O
unchanged O
at O
3 O
. O
7 O
+/- O
1 O
. O
5 O
ml O
O2 O
/( O
100 O
g O
. O
min O
) O
( O
5 O
cats O
). O

We O
have O
screened O
the O
mouse O
cDNA O
library O
of O
an O
MIN6 O
cell O
line O
, O
derived O
from O
pancreatic O
beta O
cells O
, O
for O
its O
novel O
isoform O
and O
have O
identified O
a O
cDNA O
encoding O
a O
593 O
- O
amino O
acid O
protein O
having O
63 O
, O
53 O
, O
and O
30 O
% O
identity O
with O
munc I-GENE
- I-GENE
18 I-GENE
/ I-GENE
n I-GENE
- I-GENE
Sec1 I-GENE
/ I-GENE
rbSec1 I-GENE
, O
Caenorhabditis I-GENE
elegans I-GENE
unc18 I-GENE
, O
and O
Saccharomyces I-GENE
cerevisiae I-GENE
Sec1p I-GENE
, O
respectively O
. O

The O
catenins I-GENE
bind O
to O
APC I-GENE
and O
E I-GENE
- I-GENE
cadherin I-GENE
in O
a O
similar O
fashion O
, O
but O
APC I-GENE
and O
E I-GENE
- I-GENE
cadherin I-GENE
do O
not O
associate O
with O
each O
other O
either O
in O
the O
presence O
or O
absence O
of O
catenins I-GENE
. O

However O
, O
addition O
of O
core I-GENE
DNA I-GENE
polymerase I-GENE
III I-GENE
to O
preinitiation O
complex O
, O
fully O
reconstituting O
holoenzyme O
resulted O
in O
replacement O
of O
gamma O
by O
alpha O
at O
the O
primer O
terminus O
. O

The O
PSD2 I-GENE
gene I-GENE
was O
heterologously O
expressed O
by O
infection O
of O
Sf O
- O
9 O
insect O
cells O
with O
recombinant O
baculovirus O
, O
resulting O
in O
a O
10 O
- O
fold O
increase O
in O
PSD I-GENE
activity O
. O

Computerized O
detection O
of O
abnormal O
asymmetry O
in O
digital O
chest O
radiographs O
. O

These O
results O
suggest O
that O
gluconeogenic O
genes O
are O
derepressed O
upon O
binding O
of O
Cat8p I-GENE
, O
whose O
synthesis O
depends O
on O
the O
release O
of O
Cat4p I-GENE
( O
Mig1p I-GENE
) O
from O
the O
CAT8 I-GENE
promoter I-GENE
. O

Like O
Epo I-GENE
, O
HNF I-GENE
- I-GENE
4 I-GENE
is O
expressed O
in O
kidney O
, O
liver O
, O
and O
Hep3B O
cells O
but O
not O
in O
HeLa O
cells O
. O

Moreover O
, O
the O
hypoxia O
- O
induced O
expression O
of O
the O
endogenous O
Epo I-GENE
gene I-GENE
was O
significantly O
inhibited O
in O
Hep3B O
cells O
stably O
transfected O
with O
HNF I-GENE
- I-GENE
4 I-GENE
delta I-GENE
C I-GENE
. O

These O
observations O
indicate O
that O
there O
are O
multiple O
mechanisms O
by O
which O
an O
individual O
transcript O
can O
be O
degraded O
following O
deadenylation O
. O

Small I-GENE
Maf I-GENE
proteins I-GENE
heterodimerize O
with O
Fos I-GENE
and O
may O
act O
as O
competitive O
repressors O
of O
the O
NF I-GENE
- I-GENE
E2 I-GENE
transcription I-GENE
factor I-GENE
. O

We O
show O
here O
that O
the O
binding O
of O
C1F I-GENE
in O
vitro O
is O
sensitive O
to O
the O
concentration O
of O
calcium O
ions O
. O

Survival O
after O
development O
of O
symptomatic O
infection O
( O
P O
- O
2 O
) O
did O
not O
differ O
by O
transmission O
mode O
. O

Both O
factors O
demonstrated O
significant O
correlations O
with O
rCBF O
in O
the O
medial O
prefrontal O
cortex O
and O
frontal O
polar O
cortex O
while O
for O
each O
factor O
there O
were O
also O
unique O
patterns O
of O
correlations O
with O
posterior O
brain O
regions O
. O

These O
data O
suggest O
that O
the O
function O
of O
the O
DS2 I-GENE
may O
be O
the O
protection O
of O
the O
nuclear O
DNA O
from O
desiccation O
. O

Glomerular O
hemodynamics O
during O
abortion O
induced O
by O
RU O
486 O
and O
sepsis O
in O
rats O
. O

The O
aim O
of O
this O
retrospective O
study O
was O
to O
demonstrate O
that O
in O
certain O
cases O
of O
expulsive O
choroidal O
hemorrhage O
( O
ECH O
) O
anatomical O
success O
and O
useful O
vision O
can O
be O
obtained O
with O
repeated O
vitreoretinal O
surgery O
. O

The O
function O
of O
the O
C O
- O
terminal O
tail O
in O
telomere O
maintenance O
is O
not O
mediated O
through O
the O
RAP1 I-GENE
interacting I-GENE
factor I-GENE
RIF1 I-GENE
: O
rap1 I-GENE
alleles I-GENE
defective O
in O
both O
the O
C O
- O
terminal O
tail O
and O
RIF1 I-GENE
interaction I-GENE
domains I-GENE
have O
additive O
effects O
on O
telomere O
length O
. O

The O
resulting O
integrated O
physical O
, O
genetic O
, O
and O
cytogenetic O
map O
constitutes O
a O
resource O
for O
the O
characterization O
of O
genes O
that O
may O
be O
involved O
in O
the O
WAGR O
syndrome O
. O

The O
contribution O
of O
skin O
flow O
to O
the O
changes O
in O
760 O
- O
800 O
nm O
absorption O
was O
investigated O
by O
simultaneous O
measurement O
of O
skin O
flow O
by O
laser O
flow O
Doppler O
and O
NIR O
recordings O
during O
hot O
water O
immersion O
. O

Proteins O
immunoprecipitated O
from O
lysates O
of O
control O
- O
and O
VEGF I-GENE
- O
stimulated O
BAEC O
with O
antisera O
to O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
( O
PLC I-GENE
- I-GENE
gamma I-GENE
) O
were O
fractionated O
by O
SDS O
- O
polyacrylamide O
gel O
electrophoresis O
and O
transferred O
to O
Immobilon O
- O
P O
. O

Alternatively O
processed O
isoforms O
of O
cellular I-GENE
nucleic I-GENE
acid I-GENE
- I-GENE
binding I-GENE
protein I-GENE
interact O
with O
a O
suppressor O
region O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
. O

Involvement O
of O
early I-GENE
growth I-GENE
response I-GENE
factor I-GENE
Egr I-GENE
- I-GENE
1 I-GENE
in O
apolipoprotein I-GENE
AI I-GENE
gene I-GENE
transcription O
. O

The O
wild O
- O
type O
and O
altered O
forms O
of O
the O
F I-GENE
protein I-GENE
were O
expressed O
in O
BHK O
- O
21 O
and O
HeLa O
T4 O
cells O
by O
use O
of O
the O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
- I-GENE
encoding I-GENE
T7 I-GENE
polymerase I-GENE
system O
. O

Erythrocyte I-GENE
delta I-GENE
- I-GENE
aminolevulinic I-GENE
acid I-GENE
dehydratase I-GENE
( O
ALAD I-GENE
) O
activity O
, O
erythrocyte O
zinc O
protoporphyrin O
( O
ZPP O
)/ O
heme O
ratio O
, O
and O
urinary O
coproporphyrin O
( O
UC O
) O
concentration O
have O
been O
employed O
as O
biological O
indicators O
of O
moderate O
- O
to O
high O
- O
level O
lead O
exposure O
, O
corresponding O
to O
blood O
levels O
in O
excess O
of O
50 O
micrograms O
/ O
dl O
, O
in O
human O
subjects O
. O

The O
relative O
risk O
of O
graft O
loss O
after O
conversion O
to O
azathioprine O
compared O
with O
graft O
loss O
after O
conversion O
to O
azathioprine O
compared O
with O
cyclosporin O
maintenance O
was O
0 O
. O
71 O
( O
0 O
. O
37 O
- O
1 O
. O
38 O
) O
and O
the O
relative O
risk O
of O
patient O
death O
was O
0 O
. O
57 O
( O
0 O
. O
23 O
- O
1 O
. O
41 O
). O

Three O
classes O
of O
test O
objects O
were O
considered O
: O
( O
1 O
) O
a O
multicompartment O
test O
object O
for O
31P O
MRS O
measurements O
performed O
with O
slice O
- O
selective O
sequences O
; O
( O
2 O
) O
a O
two O
- O
compartment O
test O
object O
for O
volume O
- O
selection O
1H O
MRS O
; O
and O
( O
3 O
) O
two O
- O
compartment O
test O
objects O
for O
assessing O
the O
performance O
of O
experimental O
systems O
using O
ISIS O
as O
volume O
localization O
sequence O
in O
31P O
MRS O
. O

The O
" O
tobacco O
issue O
". O

Pregnancy O
screening O
by O
uterine O
artery O
Doppler O
velocimetry O
-- O
which O
criterion O
performs O
best O
? O
OBJECTIVE O
: O
To O
test O
whether O
repeating O
Doppler O
studies O
of O
the O
uteroplacental O
circulation O
late O
in O
gestation O
will O
improve O
the O
test O
' O
s O
power O
for O
predicting O
pregnancy O
- O
induced O
hypertension O
and O
fetal O
growth O
restriction O
( O
FGR O
), O
and O
whether O
analysis O
based O
on O
a O
combination O
of O
quantitative O
and O
qualitative O
assessments O
of O
the O
uterine O
arterial O
waveforms O
will O
yield O
better O
results O
than O
analysis O
based O
on O
either O
alone O
. O

The O
effect O
of O
the O
Ca O
entry O
blocker O
nitrendipine O
, O
the O
antioxidant O
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
), O
and O
a O
combination O
of O
nitrendipine O
and O
superoxide I-GENE
dismutase I-GENE
on O
postischemic O
renal O
function O
was O
studied O
in O
four O
groups O
( O
n O
= O
24 O
) O
of O
rats O
. O

PURPOSE O
: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
bony O
anchorage O
of O
a O
new O
implant O
( O
orderly O
wired O
surface O
effect O
with O
alloy O
Ti O
Al O
Va O
and O
ordered O
pores O
of O
488 O
mu O
). O

To O
determine O
whether O
food O
and O
/ O
or O
water O
in O
the O
gastrointestinal O
tract O
affects O
restitution O
of O
blood O
volume O
and O
plasma O
protein O
after O
hemorrhage O
, O
fed O
and O
24 O
- O
h O
- O
fasted O
awake O
rats O
received O
a O
20 O
ml O
. O
kg O
- O
1 O
x O
3 O
min O
- O
1 O
hemorrhage O
, O
and O
restitution O
of O
blood O
volume O
was O
measured O
by O
Evans O
blue O
dye O
and O
dilution O
of O
hematocrit O
. O

Cooperative O
dimerization O
of O
paired I-GENE
class O
homeo O
domains O
on O
DNA O
. O

We O
took O
advantage O
of O
the O
high O
degree O
of O
aa O
sequence O
homology O
between O
DAHPSs I-GENE
from O
several O
species O
to O
isolate O
ARO3 I-GENE
homologues I-GENE
from O
the O
pathogenic O
yeast O
Candida O
albicans O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
BOX O
DNA O
enhances O
transcription O
from O
the O
thymidine I-GENE
kinase I-GENE
( O
TK I-GENE
) O
promoter O
in O
various O
EC O
cells O
. O

Deletion O
analyses O
of O
the O
construct O
revealed O
that O
the O
transcription O
of O
BOXF1 I-GENE
gene I-GENE
is O
regulated O
by O
BOX O
DNA O
, O
preferentially O
in O
undifferentiated O
EC O
cells O
versus O
differentiated O
cells O
. O

Analysis O
of O
disassociation O
rates O
indicates O
that O
the O
Grf10 I-GENE
- O
Swi5 I-GENE
- O
DNA O
complex O
has O
a O
longer O
half O
- O
life O
than O
protein O
- O
DNA O
complexes O
that O
contain O
only O
Swi5 I-GENE
or O
Grf10 I-GENE
. O

The O
presence O
of O
an O
unusual O
transcript O
possessing O
IVS2C I-GENE
beta I-GENE
1 I-GENE
at O
the O
5 O
' O
terminus O
suggests O
that O
cleavage O
of O
its O
splice O
acceptor O
is O
inefficient O
or O
negatively O
regulated O
. O

The O
mutant O
allele O
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
tubulin I-GENE
gene I-GENE
was O
designated O
tua1 I-GENE
- I-GENE
1 I-GENE
. O

During O
chronic O
treatment O
, O
when O
plasma O
concentrations O
fluctuated O
between O
23 O
. O
5 O
ng O
. O
ml O
- O
1 O
at O
8 O
h O
and O
14 O
ng O
. O
ml O
- O
1 O
at O
24 O
h O
post O
- O
dosing O
, O
ST O
segment O
depression O
at O
an O
individually O
comparable O
workload O
was O
significantly O
decreased O
by O
28 O
% O
compared O
with O
placebo O
( O
P O
< O
0 O
. O
005 O
) O
at O
both O
points O
in O
time O
. O

Results O
from O
in O
vitro O
transcription O
- O
translation O
analysis O
and O
maxicell O
experiments O
suggested O
that O
the O
447 O
- O
bp O
ORF O
was O
the O
one O
being O
actively O
expressed O
. O

Preliminary O
experiments O
demonstrated O
that O
it O
was O
possible O
to O
produce O
fasD I-GENE
mutants I-GENE
, O
whose O
products O
remain O
functional O
for O
fimbrial O
export O
and O
assembly O
. O

Evoked O
electromyographic O
response O
to O
indirect O
supramaximal O
stimulation O
at O
1 O
Hz O
was O
monitored O
in O
ten O
adult O
goats O
under O
thiopentone O
- O
halothane O
anaesthesia O
. O

313 O
, O
98 O
- O
102 O
). O

Group O
6 O
was O
given O
physostigmine O
, O
0 O
. O
1 O
mg O
/ O
kg O
i O
. O
v O
., O
known O
to O
inhibit O
cholinesterase I-GENE
degradation O
, O
5 O
min O
before O
bupivacaine O
administration O
, O
and O
Group O
7 O
received O
a O
combination O
of O
physostigmine O
pretreatment O
and O
electrical O
vagal O
stimulation O
. O

To O
examine O
the O
possibility O
that O
LNNB O
performance O
of O
the O
schizophrenic O
groups O
may O
have O
been O
related O
to O
neuroleptic O
medication O
, O
analyses O
were O
completed O
on O
the O
relationship O
between O
medication O
levels O
and O
LNNB O
scores O
. O

ISIS O
5 O
possibilities O
. O

The O
use O
of O
specific O
antibodies O
allowed O
the O
identification O
of O
at O
least O
RAR I-GENE
beta I-GENE
in O
some O
of O
the O
DNA O
- O
protein O
complexes O
, O
although O
the O
four O
sequences O
bind O
single O
RARs I-GENE
transfected O
in O
COS O
cells O
much O
less O
efficiently O
, O
or O
not O
at O
all O
, O
when O
compared O
to O
a O
canonical O
RAR I-GENE
responsive I-GENE
element I-GENE
. O

The O
present O
treatment O
strategy O
in O
progressive O
disorders O
is O
mainly O
based O
on O
the O
complementary O
effect O
of O
intensive O
radiochemotherapy O
, O
autologous O
stem O
- O
cell O
transplantation O
and O
the O
rational O
use O
of O
cytokines O
, O
mostly O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
. O

Our O
study O
cohorts O
consisted O
of O
15 O
patients O
who O
received O
SC O
rIL I-GENE
- I-GENE
2 I-GENE
at O
doses O
of O
4 O
. O
8 O
- O
14 O
. O
4 O
million O
IU O
/ O
m2 O
/ O
day O
on O
5 O
days O
per O
week O
for O
a O
total O
of O
8 O
weeks O
, O
20 O
patients O
who O
received O
rIFN I-GENE
- I-GENE
alpha I-GENE
2b I-GENE
at O
3 O
. O
0 O
- O
6 O
. O
0 O
million O
U O
/ O
m2 O
/ O
day O
thrice O
weekly O
for O
a O
total O
of O
6 O
weeks O
, O
and O
72 O
patients O
who O
were O
given O
SC O
rIFN I-GENE
- I-GENE
alpha I-GENE
2b I-GENE
at O
6 O
. O
0 O
million O
U O
/ O
m2 O
/ O
day O
thrice O
weekly O
plus O
SC O
rIL I-GENE
- I-GENE
2 I-GENE
at O
14 O
. O
4 O
- O
18 O
. O
0 O
million O
IU O
/ O
m2 O
/ O
day O
on O
days O
1 O
and O
2 O
, O
followed O
by O
4 O
. O
8 O
million O
IU O
/ O
m2 O
/ O
day O
, O
5 O
days O
per O
week O
for O
6 O
consecutive O
weeks O
. O

Analysis O
of O
a O
set O
of O
deletion O
constructs O
in O
transient O
transfection O
assays O
measuring O
heterologous O
reporter O
gene O
( O
luciferase I-GENE
) O
activity O
demonstrated O
that O
the O
182 O
- O
bp O
5 O
'- O
flanking O
region O
provides O
full O
promoter O
activity O
in O
IL I-GENE
- I-GENE
2 I-GENE
- O
stimulated O
L2 O
cells O
. O

At O
the O
MTD O
( O
8 O
mg O
/ O
m2 O
/ O
day O
), O
the O
dose O
- O
limiting O
toxicity O
of O
this O
agent O
is O
myelosuppression O
. O

Mitogen O
- O
induced O
lymphocyte O
proliferation O
was O
diminished O
. O

A O
decanucleotide O
promoter O
sequence O
homologous O
to O
those O
found O
in O
humans O
and O
mice O
was O
located O
in O
the O
5 O
' O
untranslated O
region O
of O
one O
horse O
gene O
. O

Some O
of O
these O
targets O
were O
reported O
to O
code O
for O
molecules O
involved O
in O
cell O
- O
cell O
interactions O
, O
whereas O
no O
relationship O
has O
yet O
been O
demonstrated O
between O
Hox I-GENE
genes I-GENE
and O
other O
transcription O
factors O
involved O
in O
determining O
and O
/ O
or O
maintaining O
tissue O
specificity O
. O

Northern O
analysis O
of O
RNA O
samples O
isolated O
from O
ammonium O
- O
grown O
cultures O
of O
the O
ntcA I-GENE
mutant I-GENE
showed O
reduced O
amounts O
of O
glnA I-GENE
message I-GENE
and O
the O
absence O
of O
a O
1 O
. O
7 O
- O
kb O
transcript O
. O

HER2 I-GENE
overexpressing O
cells O
showed O
a O
single O
prominent O
DNase I-GENE
I I-GENE
hypersensitive O
site O
near O
a O
conserved O
and O
hitherto O
unrecognized O
ets I-GENE
response O
element O
( O
GAGGAA O
), O
located O
38 O
bases O
down O
- O
stream O
from O
the O
CAAT O
box O
and O
directly O
5 O
' O
of O
the O
TATA O
box O
in O
the O
human I-GENE
HER2 I-GENE
promoter I-GENE
. O

Gel O
- O
shift O
assays O
with O
nuclear O
extracts O
and O
oligonucleotide O
sequences O
spanning O
the O
0 O
. O
125 O
- O
kb O
promoter O
region O
detected O
an O
ETS I-GENE
- O
immunoreactive O
complex O
, O
present O
most O
abundantly O
in O
cells O
overexpressing O
HER2 I-GENE
, O
whose O
high O
- O
affinity O
binding O
depended O
on O
the O
GAGGAA O
response O
element O
. O

Comparison O
of O
cDNA O
sequences O
revealed O
that O
the O
two O
mRNA O
species O
arise O
as O
a O
result O
of O
alternate O
use O
of O
poly O
( O
A O
)- O
addition O
sites O
. O

The O
gene O
for O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
was O
isolated O
from O
mouse O
genomic O
DNA O
and O
characterized O
. O

High O
- O
frequency O
electrical O
stimulation O
in O
the O
hippocampus O
leads O
to O
an O
increase O
in O
synaptic O
efficacy O
that O
lasts O
for O
many O
hours O
. O

Similar O
to O
the O
mouse O
gene O
, O
the O
5 O
' O
flanking O
region O
of O
human I-GENE
CD79 I-GENE
alpha I-GENE
lacks O
a O
TATA O
box O
; O
however O
, O
unlike O
mouse I-GENE
CD79 I-GENE
alpha I-GENE
, O
a O
classical O
octamer O
motif O
could O
not O
be O
identified O
in O
the O
human O
gene O
. O

Detailed O
molecular O
organization O
of O
the O
coding O
and O
upstream O
regulatory O
regions O
of O
the O
murine O
homeodomain I-GENE
- I-GENE
containing I-GENE
gene I-GENE
, O
Msx I-GENE
- I-GENE
1 I-GENE
, O
is O
reported O
. O

We O
report O
here O
the O
cloning O
of O
the O
human I-GENE
goosecoid I-GENE
gene I-GENE
( O
GSC I-GENE
) O
from O
a O
genomic O
library O
and O
the O
sequence O
of O
its O
encoded O
protein O
. O

In O
order O
to O
define O
potential O
candidate O
genes O
for O
inherited O
disorders O
characterized O
by O
aberrant O
gene O
expression O
, O
we O
utilized O
Kruppel I-GENE
- I-GENE
related I-GENE
sequences I-GENE
to O
isolate O
zinc O
finger O
- O
containing O
cDNAs O
. O

This O
virus O
is O
not O
merely O
a O
South O
African O
strain O
of O
passion O
fruit O
woodiness O
virus O
( O
PWV O
): O
the O
deduced O
CP I-GENE
sequence I-GENE
is O
only O
distantly O
related O
to O
CPs I-GENE
of O
other O
sequenced O
strains O
of O
PWV O
, O
although O
it O
is O
part O
of O
a O
distinct O
subgroup O
of O
potyviruses O
related O
to O
PWV O
. O

The O
ratio O
of O
the O
activity O
of O
arogenate I-GENE
dehydrogenase I-GENE
to O
that O
of O
prephenate I-GENE
dehydrogenase I-GENE
( O
approximately O
3 O
: O
1 O
) O
remained O
constant O
throughout O
purification O
, O
and O
the O
two O
activities O
were O
therefore O
inseparable O
. O

The O
isolated O
POT1 I-GENE
clones O
hybridized O
to O
a O
1 O
. O
4 O
kb O
RNA O
species O
, O
which O
was O
induced O
approximately O
30 O
- O
fold O
when O
oleate O
was O
the O
carbon O
source O
. O

The O
Y O
. O
lipolytica O
genomic O
POT1 I-GENE
gene O
was O
disrupted O
by O
replacing O
120 O
bp O
of O
its O
coding O
sequence O
with O
2 O
. O
7 O
kbp O
of O
DNA O
including O
the O
Y O
. O
lipolytica O
LEU2 I-GENE
gene I-GENE
. O

A O
leucine O
zipper O
domain O
of O
the O
suppressor I-GENE
of I-GENE
Hairy I-GENE
- I-GENE
wing I-GENE
protein I-GENE
mediates O
its O
repressive O
effect O
on O
enhancer O
function O
. O

It O
is O
concluded O
that O
CT O
should O
be O
routinely O
employed O
in O
patients O
with O
N1 O
- O
N3 O
neck O
disease O
to O
determine O
the O
proper O
electron O
- O
energy O
prescription O
. O

The O
predicted O
DNA O
- O
binding O
, O
zinc I-GENE
finger I-GENE
domain I-GENE
protein I-GENE
sequence O
was O
strictly O
conserved O
. O

60 O
patients O
were O
entered O
into O
a O
randomised O
study O
comparing O
vindesine O
( O
3 O
mg O
/ O
m2 O
/ O
week O
) O
plus O
interferon I-GENE
- I-GENE
alpha I-GENE
2b I-GENE
( O
6 O
U O
/ O
m2 O
3 O
times O
per O
week O
) O
to O
vindesine O
alone O
or O
to O
interferon I-GENE
alone O
for O
the O
treatment O
of O
metastatic O
malignant O
melanoma O
. O

The O
novel O
Notch I-GENE
homologue I-GENE
mouse I-GENE
Notch I-GENE
3 I-GENE
lacks O
specific O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
repeats I-GENE
and O
is O
expressed O
in O
proliferating O
neuroepithelium O
. O

BACKGROUND O
: O
We O
conducted O
a O
phase O
I O
study O
with O
MDL O
73 O
, O
147EF O
, O
a O
new O
5 I-GENE
hydroxytryptamine I-GENE
3 I-GENE
( I-GENE
5 I-GENE
- I-GENE
HT3 I-GENE
) I-GENE
receptor I-GENE
antagonist O
, O
in O
25 O
patients O
requiring O
emetogenic O
chemotherapy O
. O

In O
the O
presence O
of O
the O
in O
vivo O
reducing O
system O
( O
thioredoxin I-GENE
, O
thioredoxin I-GENE
reductase I-GENE
, O
and O
NADPH O
), O
however O
, O
each O
of O
these O
mutants O
catalyzed O
the O
formation O
of O
only O
0 O
. O
6 O
- O
0 O
. O
8 O
dCTPs O
per O
mole O
of O
enzyme O
. O

These O
genetic O
alterations O
do O
not O
affect O
synthesis O
of O
the O
major O
c I-GENE
- I-GENE
myc I-GENE
protein I-GENE
, O
p64 I-GENE
, O
which O
is O
initiated O
from O
the O
first O
AUG O
codon O
in O
exon O
2 O
. O

In O
addition O
, O
both O
the O
exon O
1 O
- O
and O
exon O
2 O
- O
initiated O
forms O
of O
the O
c I-GENE
- I-GENE
Myc I-GENE
protein I-GENE
stimulated O
transcription O
of O
a O
Myc I-GENE
/ O
Max I-GENE
- O
responsive O
reporter O
construct O
to O
a O
similar O
level O
. O

Biological O
activities O
of O
hematopoietic I-GENE
growth I-GENE
factors I-GENE
that O
lead O
to O
future O
clinical O
application O
. O

Expression O
is O
exclusively O
limited O
to O
the O
CNS O
at O
this O
and O
later O
stages O
. O

Immunoreactive O
AR I-GENE
content O
in O
transfected O
COS O
- O
1 O
cells O
was O
not O
influenced O
by O
exposure O
to O
8 O
- O
Br O
- O
cAMP O
. O

Disruption O
of O
any O
one O
of O
the O
four O
genes O
encoding O
the O
newly O
identified O
SRP I-GENE
proteins I-GENE
results O
in O
slow O
cell O
growth O
and O
inefficient O
protein O
translocation O
across O
the O
ER O
membrane O
. O

Genetic O
alterations O
in O
elements O
of O
normal O
signal O
transduction O
mechanisms O
are O
known O
to O
be O
oncogenic O
events O
often O
resulting O
in O
aberrant O
activation O
of O
programs O
of O
gene O
transcription O
. O

The O
expression O
pattern O
of O
GL2 I-GENE
, O
as O
demonstrated O
by O
in O
situ O
hybridization O
, O
indicated O
that O
the O
gene O
is O
expressed O
in O
trichome O
progenitor O
cells O
and O
at O
stages O
associated O
with O
trichome O
development O
. O

NOT4 I-GENE
interacts O
with O
NOT1 I-GENE
and O
NOT3 I-GENE
in O
the O
two O
- O
hybrid O
assay O
, O
and O
overexpression O
of O
NOT3 I-GENE
or O
NOT4 I-GENE
suppresses O
not1 I-GENE
and O
not2 I-GENE
mutations O
. O

Binding O
site O
selection O
using O
in O
vitro O
- O
synthesized O
proteins O
reveals O
that O
the O
ROR I-GENE
alpha I-GENE
1 I-GENE
and O
ROR I-GENE
alpha I-GENE
2 I-GENE
isoforms I-GENE
bind O
DNA O
as O
monomers O
to O
hormone O
response O
elements O
composed O
of O
a O
6 O
- O
bp O
AT O
- O
rich O
sequence O
preceding O
a O
half O
- O
site O
core O
motif O
PuGGTCA O
( O
RORE I-GENE
). O

The O
p73pct1 I-GENE
/ O
p85cdc10 I-GENE
complex O
binds O
both O
in O
vitro O
and O
in O
vivo O
to O
MCB I-GENE
but O
not O
SCB I-GENE
or O
E2F I-GENE
sites I-GENE
. O

We O
show O
that O
the O
en I-GENE
stripes O
expand O
anteriorly O
in O
slp I-GENE
mutant O
embryos O
and O
that O
slp I-GENE
activity O
is O
an O
absolute O
requirement O
for O
maintenance O
of O
wg I-GENE
expression O
at O
the O
same O
time O
that O
wg I-GENE
transcription O
is O
dependent O
on O
hh I-GENE
. O

The O
DNA O
sequence O
adjacent O
to O
the O
lacZ I-GENE
gene I-GENE
has O
been O
determined O
for O
91 O
vegetative O
fusion O
genes O
whose O
products O
have O
been O
localized O
and O
for O
43 O
meiotically O
induced O
fusions O
. O

CMV O
hyperimmunoglobulin I-GENE
treatment O
( O
Cytotect O
, O
Biotest O
) O
was O
started O
( O
2 O
ml O
/ O
kg O
bw O
on O
day O
1 O
and O
3 O
, O
and O
1 O
ml O
/ O
kg O
on O
days O
5 O
, O
7 O
and O
9 O
), O
which O
led O
to O
the O
eradication O
of O
the O
residual O
infiltrate O
and O
CMV O
- O
DNA O
in O
the O
myocardium O
. O

Internal O
biliary O
drainage O
, O
unlike O
external O
drainage O
, O
does O
not O
suppress O
the O
regeneration O
of O
cholestatic O
rat O
liver O
after O
partial O
hepatectomy O
. O

ORF O
2 O
potentially O
encoded O
a O
hydrophobic O
protein O
of O
29 O
, O
705 O
Da O
with O
six O
potential O
membrane O
- O
spanning O
regions O
. O

In O
eight O
groups O
of O
subjects O
operating O
various O
hand O
- O
held O
vibrating O
tools O
and O
aged O
from O
30 O
to O
59 O
years O
, O
the O
prevalence O
rates O
of O
vibration O
- O
induced O
white O
finger O
( O
VWF O
) O
and O
numbness O
, O
pain O
, O
or O
stiffness O
in O
the O
upper O
and O
lower O
extremities O
were O
investigated O
. O

DNA O
sequence O
analysis O
showed O
that O
the O
gene O
was O
525 O
bp O
long O
and O
encoded O
a O
175 O
- O
amino O
- O
acid O
protein O
with O
a O
molecular O
weight O
of O
19 O
, O
094 O
containing O
a O
21 O
- O
residue O
typical O
lipoprotein O
signal O
peptide O
and O
consensus O
prolipoprotein O
processing O
site O
. O

DNA O
sequence O
and O
functions O
of O
the O
actVI I-GENE
region I-GENE
of O
the O
actinorhodin O
biosynthetic O
gene O
cluster O
of O
Streptomyces O
coelicolor O
A3 O
( O
2 O
). O

( O
1992 O
) O
Genomics O
12 O
, O
58 O
- O
62 O
). O

A O
comparison O
of O
the O
predicted O
polypeptide O
sequence O
of O
the O
Drosophila O
protein O
with O
the O
equivalent O
subunits O
from O
mouse O
and O
yeast O
suggests O
that O
they O
are O
closely O
related O
and O
defines O
three O
conserved O
regions O
which O
are O
likely O
to O
be O
important O
for O
enzyme O
activity O
. O

Plasmids O
were O
constructed O
with O
the O
mouse O
promoter O
region O
linked O
to O
the O
reporter I-GENE
gene I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
), O
and O
transiently O
and O
stably O
transfected O
in O
the O
INS O
- O
1 O
cells O
. O

Cytoplasmic I-GENE
dynein I-GENE
is O
a O
multisubunit O
, O
microtubule O
- O
dependent O
mechanochemical O
enzyme O
that O
has O
been O
proposed O
to O
function O
in O
a O
variety O
of O
intracellular O
movements O
, O
including O
minus O
- O
end O
- O
directed O
transport O
of O
organelles O
. O

Identification O
of O
the O
plakoglobin I-GENE
- O
binding O
domain O
in O
desmoglein I-GENE
and O
its O
role O
in O
plaque O
assembly O
and O
intermediate O
filament O
anchorage O
. O

PATIENTS O
AND O
METHODS O
: O
One O
hundred O
eighty O
- O
four O
chemotherapy O
- O
naive O
patients O
receiving O
high O
- O
dose O
cisplatin O
( O
81 O
to O
120 O
mg O
/ O
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
granisetron O
doses O
( O
5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms O
/ O
kg O
) O
administered O
before O
chemotherapy O
. O

Nine O
new O
naphthalene O
related O
compounds O
( O
I O
, O
IV O
, O
V O
, O
VII O
- O
XII O
) O
together O
with O
four O
known O
compounds O
( O
II O
, O
III O
, O
VI O
, O
XIII O
) O
were O
isolated O
from O
the O
root O
bark O
of O
Oroxylum O
indicum O
Vent O
. O

Specifically O
, O
this O
study O
determined O
the O
influence O
of O
: O
( O
1 O
) O
an O
awareness O
strategy O
, O
( O
2 O
) O
a O
non O
- O
awareness O
strategy O
, O
( O
3 O
) O
a O
Five O
- O
Step O
Approach O
strategy O
and O
( O
4 O
) O
a O
control O
condition O
. O

Mutually O
exclusive O
interaction O
of O
the O
adenovirus I-GENE
E4 I-GENE
- I-GENE
6 I-GENE
/ I-GENE
7 I-GENE
protein I-GENE
and O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
with O
internal O
domains O
of O
E2F I-GENE
- I-GENE
1 I-GENE
and O
DP I-GENE
- I-GENE
1 I-GENE
. O

As O
shown O
previously O
, O
EBNA2 I-GENE
transactivates O
the O
promoters O
of O
the O
viral I-GENE
latent I-GENE
membrane I-GENE
proteins I-GENE
. O

We O
previously O
showed O
that O
v I-GENE
- I-GENE
Rel I-GENE
, O
the O
oncoprotein O
of O
the O
avian O
retrovirus O
Rev O
- O
T O
, O
can O
increase O
expression O
from O
promoters O
containing O
binding O
sites O
for O
the O
cellular O
transcription O
factor O
Sp1 I-GENE
in O
chicken O
embryo O
fibroblasts O
( O
S O
. O

Previous O
studies O
have O
demonstrated O
that O
the O
TATA O
element O
is O
critical O
for O
basal O
and O
Tat I-GENE
- O
induced O
HIV O
- O
1 O
gene O
expression O
. O

A O
comparison O
of O
the O
nucleotide O
sequence O
of O
the O
p54 I-GENE
gene I-GENE
carried O
by O
two O
virulent O
ASFV O
strains O
( O
E70 O
and O
E75 O
) O
with O
that O
obtained O
from O
virus O
Ba71V O
showed O
100 O
% O
similarity O
. O

The O
p55 I-GENE
mRNA I-GENE
is O
undetectable O
in O
non O
- O
EBV O
- O
infected O
B O
- O
and O
T O
- O
cell O
lines O
or O
in O
a O
myelomonocytic O
cell O
line O
( O
U937 O
). O

A O
simple O
registration O
as O
an O
incentive O
for O
improvement O

The O
transverse O
magnetization O
decays O
mentioned O
above O
exhibited O
two O
components O
, O
a O
T2 O
fast O
( O
T2f O
) O
and O
a O
T2 O
slow O
( O
T2s O
) O
component O
. O

RESULTS O
: O
The O
diagnostic O
quality O
of O
FDG O
images O
was O
at O
least O
as O
good O
as O
that O
of O
their O
Tl O
- O
201 O
counterparts O
, O
with O
less O
liver O
background O
in O
all O
but O
one O
FDG O
study O
. O

The O
coordinated O
expression O
of O
CD4 I-GENE
and O
CD8 I-GENE
during O
T O
- O
cell O
development O
is O
tightly O
coupled O
with O
the O
maturation O
state O
of O
the O
T O
cell O
. O

Expression O
of O
a O
dominant I-GENE
- I-GENE
negative I-GENE
ras I-GENE
gene I-GENE
also O
blocks O
TIS10 I-GENE
/ O
PGS2 I-GENE
induction O
by O
v I-GENE
- I-GENE
src I-GENE
. O

The O
dying O
tTG I-GENE
- O
transfected O
cells O
exhibit O
both O
cytoplasmic O
and O
nuclear O
changes O
characteristic O
of O
cells O
undergoing O
apoptosis O
. O

Using O
an O
RNase I-GENE
H I-GENE
- O
mediated O
mapping O
technique O
, O
we O
show O
that O
the O
64 O
- O
kDa O
subunit O
of O
CstF I-GENE
can O
be O
photo O
cross O
- O
linked O
to O
pre O
- O
mRNAs O
at O
U O
- O
rich O
regions O
located O
downstream O
of O
the O
cleavage O
site O
of O
the O
simian O
virus O
40 O
late O
and O
adenovirus I-GENE
L3 I-GENE
pre I-GENE
- I-GENE
mRNAs I-GENE
. O

The O
protein O
encoded O
is O
114 O
kDa O
and O
contains O
eight O
zinc O
finger O
motifs O
, O
seven O
of O
which O
are O
present O
in O
two O
clusters O
at O
opposite O
ends O
of O
the O
molecule O
. O

Tissue O
- O
specific O
expression O
of O
the O
diazepam I-GENE
- I-GENE
binding I-GENE
inhibitor I-GENE
in O
Drosophila O
melanogaster O
: O
cloning O
, O
structure O
, O
and O
localization O
of O
the O
gene O
. O

Using O
a O
v I-GENE
- I-GENE
erbA I-GENE
probe O
, O
we O
obtained O
a O
cDNA O
which O
encodes O
a O
novel O
445 O
- O
amino O
- O
acid O
protein O
, O
RLD I-GENE
- I-GENE
1 I-GENE
, O
that O
contains O
the O
characteristic O
domains O
of O
nuclear O
receptors O
. O

Only O
two O
of O
the O
isoforms O
possess O
the O
N O
- O
terminal O
zinc O
finger O
domain O
that O
is O
necessary O
and O
sufficient O
for O
TdT I-GENE
promoter I-GENE
binding O
. O

This O
study O
provides O
direct O
evidence O
that O
USF I-GENE
, O
a O
member O
of O
the O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
family I-GENE
, O
binds O
to O
MLE1 I-GENE
, O
HF I-GENE
- I-GENE
1a I-GENE
, O
and O
PRE I-GENE
B I-GENE
sites I-GENE
and O
suggests O
that O
it O
is O
a O
component O
of O
protein O
complexes O
that O
may O
coordinately O
control O
the O
expression O
of O
MLC I-GENE
- I-GENE
2v I-GENE
and O
alpha I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
genes I-GENE
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
I O
Tax I-GENE
activation O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ O
Rel I-GENE
involves O
phosphorylation O
and O
degradation O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
and O
RelA O
( O
p65 O
)- O
mediated O
induction O
of O
the O
c I-GENE
- I-GENE
rel I-GENE
gene I-GENE
. O

Activation O
of O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
expression O
by O
a O
kinase O
- O
deficient O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

Because O
endogenous O
HSF I-GENE
DNA O
- O
binding O
activity O
is O
low O
and O
anti I-GENE
- I-GENE
hHSF1 I-GENE
antibody I-GENE
does O
not O
recognize O
Xenopus I-GENE
HSF I-GENE
, O
we O
employed O
this O
system O
for O
mapping O
regions O
in O
hHSF1 I-GENE
that O
are O
required O
for O
the O
maintenance O
of O
the O
monomeric O
state O
. O

Enhancers O
containing O
disrupted O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
were O
tested O
in O
transient O
expression O
assays O
in O
the O
murine O
T O
- O
cell O
line O
EL4 O
. O
E1 O
; O
alterations O
in O
the O
LVb O
element O
affected O
constitutive O
enhancer O
activity O
, O
while O
mutation O
of O
either O
the O
LVb O
or O
LVc O
element O
disrupted O
phorbol O
ester O
- O
induced O
enhancer O
activity O
. O

The O
predominant O
binding O
activity O
was O
not O
Ets I-GENE
- I-GENE
1 I-GENE
but O
rather O
two O
independent O
DNA O
- O
protein O
complexes O
that O
comigrated O
in O
mobility O
shift O
assays O
. O

These O
RZR I-GENE
subtypes O
represent O
members O
of O
a O
new O
family O
of O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
that O
most O
likely O
regulate O
specific O
gene O
expression O
. O

Interestingly O
, O
these O
response O
elements O
display O
dramatically O
reduced O
affinity O
for O
retinoic I-GENE
acid I-GENE
receptor I-GENE
- O
retinoid I-GENE
- I-GENE
X I-GENE
receptor I-GENE
heterodimers O
. O

Treatment O
with O
amphotericin O
B O
and O
flucytosine O
led O
to O
improvement O
of O
the O
symptoms O
but O
did O
not O
eradicate O
the O
micro O
- O
organisms O
from O
the O
cerebrospinal O
fluid O
( O
CSF O
). O

The O
unexpected O
presence O
of O
the O
tRNA I-GENE
( I-GENE
trp I-GENE
)( I-GENE
CCA I-GENE
)- I-GENE
gene I-GENE
transcript I-GENE
in I-GENE
mitochondria I-GENE
is O
also O
reported O
. O

The O
parameters O
of O
nonspecific O
humoral O
immunity O
-- O
serum I-GENE
immunoglobulins I-GENE
and O
immune O
complexes O
-- O
were O
evaluated O
in O
irradiated O
group O
of O
patients O
with O
uterine O
cervix O
carcinoma O
( O
Stages O
IIB O
and O
IIIB O
), O
during O
one O
year O
follow O
up O
. O

Mutation O
of O
KRKR O
to O
NGER O
retains O
MO15 I-GENE
in O
the O
cytoplasmic O
compartment O
, O
whilst O
the O
wild O
- O
type O
protein O
is O
detected O
exclusively O
in O
the O
nucleus O
. O

To O
confirm O
the O
binding O
of O
protein O
to O
these O
sites O
in O
cells O
, O
we O
carried O
out O
an O
in O
vivo O
genomic O
footprinting O
analysis O
of O
this O
portion O
of O
the O
TGF I-GENE
alpha I-GENE
promoter I-GENE
in O
normal O
and O
transformed O
rat O
liver O
epithelial O
cell O
lines O
that O
express O
the O
endogenous O
gene O
at O
varying O
levels O
. O

Strikingly O
, O
this O
subdomain O
is O
also O
present O
in O
the O
otherwise O
unrelated O
N O
- O
terminal O
activating O
region O
of O
p58c I-GENE
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
and O
was O
thus O
named O
BEC I-GENE
for O
Ets I-GENE
- I-GENE
1 I-GENE
- I-GENE
beta I-GENE
/ O
Ets I-GENE
- I-GENE
2 I-GENE
- I-GENE
Conserved I-GENE
sequence I-GENE
. O

This O
work O
unravels O
a O
new O
model O
for O
the O
ets I-GENE
- I-GENE
1 I-GENE
/ O
ets I-GENE
- I-GENE
2 I-GENE
gene I-GENE
' O
s O
evolution O
, O
based O
for O
the O
first O
time O
on O
both O
structural O
and O
functional O
evidences O
. O

The O
v I-GENE
- I-GENE
ets I-GENE
oncogene I-GENE
of O
the O
avian O
retrovirus O
E26 O
differs O
from O
its O
cellular O
progenitor O
p68c I-GENE
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
by O
two O
amino O
acid O
substitutions O
( O
alanine O
285 O
and O
isoleucine O
445 O
in O
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
both O
substituted O
by O
valine O
in O
v I-GENE
- I-GENE
ets I-GENE
, O
mutations O
A O
and O
B O
respectively O
) O
and O
its O
carboxy O
- O
terminal O
end O
( O
mutation O
C O
). O

Consequently O
functional O
mRNAs O
can O
be O
produced O
by O
endogenous I-GENE
RNA I-GENE
polymerase I-GENE
I O
. O

The O
individual O
subunits O
of O
Ku I-GENE
have O
been O
difficult O
to O
isolate O
from O
human O
cells O
without O
denaturation O
and O
attempts O
to O
produce O
functional I-GENE
recombinant I-GENE
Ku I-GENE
have O
been O
largely O
unsuccessful O
. O

Using O
this O
method O
, O
we O
were O
able O
to O
select O
strong O
enhancer O
- O
type O
activation O
domains O
from O
the O
immediate I-GENE
early I-GENE
regions I-GENE
of O
two O
herpesviruses O
, O
namely O
pseudorabies O
virus O
and O
bovine O
herpesvirus O
1 O
. O

Remarkably O
, O
U21 I-GENE
contains O
a O
long O
stretch O
( O
13 O
nt O
.) O
of O
complementarity O
to O
a O
highly O
conserved O
sequence O
in O
28S I-GENE
rRNA I-GENE
. O

A O
genetic O
system O
was O
devised O
to O
select O
for O
pi I-GENE
protein I-GENE
mutants I-GENE
which O
discriminate O
between O
IR O
and O
DR O
( O
York O
et O
al O
., O
Gene O
( O
Amst O
.) O
116 O
, O
7 O
- O
12 O
, O
1992 O
; O
York O
and O
Filutowicz O
, O
J O
. O

Univariate O
statistical O
analysis O
based O
on O
Kaplan O
- O
Meier O
- O
estimates O
and O
Log O
- O
Rank O
- O
Test O
showed O
the O
following O
prognostically O
beneficial O
factors O
: O
Limited O
disease O
stage O
( O
p O
= O
0 O
. O
009 O
), O
NSE I-GENE
serum O
level O
less O
than O
25 O
micrograms O
/ O
l O
( O
p O
= O
0 O
. O
016 O
), O
serum O
alkaline I-GENE
phosphatase I-GENE
less O
than O
200 O
U O
/ O
l O
( O
p O
= O
0 O
. O
035 O
), O
normal O
serum O
albumin I-GENE
( O
p O
= O
0 O
. O
003 O
) O
and O
activity O
index O
of O
minimum O
of O
70 O
( O
p O
< O
0 O
. O
001 O
). O

These O
results O
provide O
evidence O
of O
a O
bypass O
of O
p53 I-GENE
- O
induced O
Waf1 I-GENE
/ O
Cip1 I-GENE
- O
mediated O
cell O
cycle O
regulatory O
pathways O
by O
a O
member O
of O
the O
myb I-GENE
oncogene I-GENE
family I-GENE
. O

HBx I-GENE
strongly O
elevates O
levels O
of O
GTP O
- O
bound O
Ras I-GENE
, O
activated O
and O
phosphorylated O
Raf I-GENE
, O
and O
tyrosine O
- O
phosphorylated O
and O
activated O
MAP I-GENE
kinase I-GENE
. O

Role O
of O
c I-GENE
- I-GENE
myc I-GENE
in O
simian I-GENE
virus I-GENE
40 I-GENE
large I-GENE
tumor I-GENE
antigen I-GENE
- O
induced O
DNA O
synthesis O
in O
quiescent O
3T3 O
- O
L1 O
mouse O
fibroblasts O
. O

All O
groups O
were O
challenged O
subsequently O
with O
naloxone O
( O
0 O
. O
4 O
mg O
/ O
kg O
) O
in O
the O
distinctive O
environment O
and O
then O
observed O
for O
signs O
of O
opiate O
withdrawal O
. O

Laser O
therapy O
of O
penile O
carcinoma O

A O
15 O
. O
1 O
kb O
fragment O
of O
the O
yeast O
genome O
was O
allocated O
to O
the O
centromeric O
region O
of O
chromosome O
XIV O
by O
genetic O
mapping O
. O

A O
third O
one O
is O
homologous O
in O
half O
of O
its O
length O
to O
the O
prokaryotic I-GENE
hydantoinase I-GENE
HyuA I-GENE
and O
in O
the O
other O
half O
to O
hydatoinase I-GENE
HyuB I-GENE
. O

It O
was O
shown O
that O
estradiol O
concentrations O
obtained O
after O
estradiol O
valerate O
and O
micronized O
estradiol O
ingestion O
were O
dependent O
on O
the O
patient O
' O
s O
age O
as O
well O
as O
on O
the O
constitutional O
type O
. O

There O
were O
9 O
patients O
in O
NYHA O
class O
III O
and O
8 O
in O
class O
IV O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Constipation O
is O
not O
a O
risk O
factor O
for O
hemorrhoids O
: O
a O
case O
- O
control O
study O
of O
potential O
etiological O
agents O
. O

Of O
419 O
persons O
surveyed O
, O
207 O
( O
49 O
. O
4 O
%) O
were O
antigen O
- O
positive O
with O
the O
Og4C3 I-GENE
assay O
. O

TG O
- O
day O
and O
TG O
- O
night O
were O
19 O
. O
4 O
+/- O
6 O
. O
1 O
%, O
26 O
. O
6 O
+/- O
5 O
. O
3 O
%, O
( O
750 O
mm3 O
< O
T O
. O

Vibrio O
cholerae O
O139 O
in O
Calcutta O
. O

Ten O
volunteers O
were O
tested O
at O
18 O
, O
000 O
ft O
( O
5 O
, O
486 O
m O
), O
and O
through O
12 O
, O
000 O
, O
8 O
, O
000 O
, O
and O
5 O
, O
000 O
ft O
( O
3 O
, O
657 O
, O
2 O
, O
438 O
, O
and O
1 O
, O
524 O
m O
) O
with O
directional O
sounds O
recorded O
via O
a O
dummy O
head O
microphone O
and O
presented O
binaurally O
. O

Upon O
differentiation O
with O
retinoic O
acid O
( O
RA O
), O
transcription O
of O
the O
Rex I-GENE
- I-GENE
1 I-GENE
gene I-GENE
decreases O
rapidly O
. O

Sequence O
analysis O
of O
the O
zebrafish I-GENE
egr1 I-GENE
coding I-GENE
region I-GENE
revealed O
a O
high O
level O
of O
homology O
to O
the O
mouse O
, O
rat O
, O
and O
human I-GENE
Egr1 I-GENE
genes I-GENE
with O
the O
notable O
exception O
of O
a O
polymorphic O
, O
triplet O
nucleotide O
repeat O
sequence O
in O
the O
region O
coding O
for O
the O
amino O
terminus O
of O
the O
Egr1 I-GENE
protein I-GENE
. O

The O
fibrinogen I-GENE
, O
serum O
proteins O
, O
sodium O
heparin O
and O
membrane O
contributed O
to O
Cm O
by O
20 O
%, O
14 O
%, O
2 O
% O
and O
64 O
%, O
respectively O
. O

In O
these O
vectors O
the O
chimeric I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
( O
chLTR I-GENE
) O
drives O
the O
expression O
of O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
that O
is O
followed O
by O
an O
internal O
SV40 I-GENE
virus I-GENE
early I-GENE
region I-GENE
promoter I-GENE
linked O
to O
the O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
( O
NEO I-GENE
) O
gene O
. O

Optima O
) O
genomic O
library O
by O
hybridizing O
with O
elicitor O
- O
induced O
stilbene I-GENE
synthase I-GENE
cDNA I-GENE
as O
a O
probe O
. O

A O
total O
of O
125 O
acute O
leukemia O
adult O
patients O
were O
autografted O
with O
bone O
marrow O
( O
BM O
) O
purged O
by O
mafosfamide O
( O
ASTA O
Z O
) O
during O
the O
period O
of O
January O
1983 O
to O
January O
1993 O
. O

The O
pretransplant O
regimen O
consisted O
of O
cyclophosphamide O
( O
120 O
mg O
/ O
kg O
) O
and O
total O
body O
irradiation O
. O

The O
site O
- O
directed O
mutation O
of O
the O
kappa I-GENE
B I-GENE
motif I-GENE
in O
IL I-GENE
- I-GENE
6 I-GENE
/ O
CAT I-GENE
plasmid O
resulted O
in O
the O
complete O
abrogation O
of O
IL I-GENE
- I-GENE
6 I-GENE
promoter I-GENE
activity O
in O
these O
cells O
. O

Curiously O
, O
testololactone O
was O
earlier O
and O
more O
widely O
used O
than O
aminoglutethimide O
in O
treating O
advanced O
breast O
carcinoma O
. O

Use O
of O
the O
vena O
cava O
to O
extend O
the O
right O
renal O
vein O
for O
cadaver O
transplantation O
is O
controversial O
. O

Enhanced O
hepatic O
portal O
blood O
flow O
induced O
by O
prostaglandin O
E1 O
following O
liver O
transplantation O
in O
pigs O
. O

One O
gene O
appears O
ubiquitously O
expressed O
while O
the O
other O
is O
prominently O
expressed O
in O
muscle O
. O

For O
HeLa O
, O
293 O
, O
U937 O
, O
and O
A549 O
cells O
, O
participation O
of O
E2F I-GENE
- I-GENE
1 I-GENE
, O
DP I-GENE
- I-GENE
1 I-GENE
, O
cyclin I-GENE
A I-GENE
, O
and O
RB I-GENE
was O
involved O
in O
formation O
of O
some O
complexes O
only O
, O
assuming O
participation O
of O
factors O
different O
from O
E2F I-GENE
- I-GENE
1 I-GENE
or O
DP I-GENE
- I-GENE
1 I-GENE
in O
others O
. O

E1A I-GENE
autoactivation O
mediated O
by O
these O
sites O
was O
about O
twofold O
compared O
with O
a O
ninefold O
activation O
described O
for O
the O
complete O
E1A I-GENE
promoter I-GENE
. O

Cestode O
invasion O
in O
irradiated O
host O
organism O
increases O
the O
negative O
effect O
of O
ionizing O
radiation O
on O
the O
hamster O
immune O
system O
. O

During O
heat O
exposure O
, O
chicks O
that O
had O
been O
subjected O
to O
early O
60 O
% O
restriction O
with O
non O
- O
metyrapone O
- O
treated O
food O
had O
lower O
H O
/ O
L O
ratios O
and O
improved O
resistance O
to O
marble O
spleen O
disease O
infection O
. O

Analyses O
of O
additional O
tumors O
induced O
in O
mice O
from O
two O
reciprocal O
crosses O
, O
A O
/ O
J O
x O
C3H O
/ O
HeJ O
F1 O
( O
hereafter O
called O
AC3F1 O
) O
and O
C3H O
/ O
HeJ O
x O
A O
/ O
J O
F1 O
( O
hereafter O
called O
C3AF1 O
), O
provided O
evidence O
for O
the O
inactivation O
of O
one O
allele O
of O
the O
putative O
chromosome O
4 O
tumor O
suppressor O
gene O
by O
parental O
imprinting O
. O

ERV1 I-GENE
is O
involved O
in O
the O
cell O
- O
division O
cycle O
and O
the O
maintenance O
of O
mitochondrial O
genomes O
in O
Saccharomyces O
cerevisiae O
. O

Lesion O
diameters O
of O
greater O
than O
20 O
mm O
and O
the O
large O
sessile O
- O
type O
configurations O
were O
factors O
that O
were O
associated O
with O
incomplete O
removal O
. O

Routinely O
collected O
, O
processed O
and O
stored O
breast O
cancer O
tissue O
blocks O
recovered O
from O
the O
archives O
of O
the O
Pathology O
laboratory O
in O
Dar O
es O
Salaam O
after O
storage O
of O
up O
to O
3 O
years O
were O
analysed O
by O
a O
flow O
cytometry O
for O
DNA O
ploidy O
and O
S O
- O
phase O
fraction O
. O

Cbf3 I-GENE
contains O
three O
proteins O
, O
Cbf3a I-GENE
, O
Cbf3b I-GENE
and O
Cbf3c I-GENE
. O

Such O
an O
interaction O
could O
be O
detected O
using O
a O
GST I-GENE
- O
POU I-GENE
fusion O
protein O
bound O
to O
glutathione O
- O
agarose O
beads O
. O

These O
mutations O
are O
localized O
in O
the O
same O
region O
where O
the O
HSV I-GENE
transactivator I-GENE
VP16 I-GENE
binds O
, O
but O
did O
not O
coincide O
with O
the O
VP16 I-GENE
contacts O
. O

In O
general O
, O
the O
filtration O
rate O
in O
relevant O
areas O
appears O
to O
be O
an O
integrative O
and O
easily O
determined O
parameter O
, O
reflecting O
hormonal O
and O
neurogenic O
vascular O
as O
well O
as O
local O
interstitial O
control O
of O
the O
Starling O
forces O
. O

Notably O
, O
these O
residues O
are O
located O
in O
different O
domains O
. O

However O
, O
rapamycin O
inhibited O
proliferation O
of O
Ba O
/ O
F3 O
- O
EpoRgp55 O
but O
not O
of O
MEL O
cells O
despite O
inhibition O
of O
p70 I-GENE
S6 I-GENE
kinase I-GENE
activity O
in O
both O
cells O
. O

Intraventricular O
injection O
of O
( O
2S O
, O
1 O
' O
R O
, O
2 O
' O
R O
, O
3 O
' O
R O
)- O
2 O
-( O
2 O
, O
3 O
- O
dicarboxycyclopropyl O
) O
glycine O
( O
DCG O
- O
IV O
), O
a O
potent O
agonist O
for O
metabotropic O
glutamate I-GENE
receptors I-GENE
, O
to O
rats O
retarded O
dose O
- O
dependently O
the O
recovery O
from O
halothane O
anesthesia O
at O
a O
dose O
range O
from O
30 O
to O
300 O
pmol O
/ O
rat O
. O

The O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
HNF I-GENE
- I-GENE
3 I-GENE
)/ O
forkhead I-GENE
( O
fkh I-GENE
) O
proteins O
consist O
of O
an O
extensive O
family O
of O
tissue O
- O
specific O
and O
developmental O
gene O
regulators O
which O
share O
homology O
within O
the O
winged O
helix O
DNA O
binding O
motif O
. O

Homozygous O
null O
embryos O
also O
displayed O
abnormalities O
in O
heart O
development O
, O
consistent O
with O
the O
conclusion O
that O
Tek I-GENE
is O
necessary O
for O
endocardial O
/ O
myocardial O
interactions O
during O
development O
. O

Interestingly O
, O
dTFIIA I-GENE
- I-GENE
L I-GENE
/ I-GENE
S I-GENE
is O
also O
able O
to O
significantly O
enhance O
transcriptional O
activation O
by O
upstream O
transcription O
factors O
including O
Sp1 I-GENE
, O
VP16 I-GENE
, O
and O
NTF I-GENE
- I-GENE
1 I-GENE
. O

A O
strong O
trithorax I-GENE
binding I-GENE
site I-GENE
was O
found O
at O
the O
cytological O
location O
of O
the O
fork I-GENE
head I-GENE
gene I-GENE
, O
a O
region O
- O
specific O
homeotic I-GENE
gene I-GENE
not O
located O
within O
a O
homeotic I-GENE
complex I-GENE
. O

In O
particular O
, O
changes O
in O
intracellular O
Ca2 O
+ O
have O
the O
potential O
to O
either O
inhibit O
or O
augment O
the O
ability O
of O
cAMP O
to O
stimulate O
transcription O
, O
depending O
on O
the O
presence O
of O
specific O
forms O
of O
Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Antibodies O
directed O
against O
the O
SNM1 I-GENE
protein I-GENE
immunoprecipitated O
RNase I-GENE
MRP I-GENE
RNA I-GENE
from O
whole O
- O
cell O
extracts O
without O
precipitating O
the O
structurally O
and O
functionally O
related O
RNase I-GENE
P I-GENE
RNA I-GENE
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
[ O
Potter O
et O
al O
., O
Arch O
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter O
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence O
- O
specific O
manner O
[ O
Potter O
et O
al O
., O
Arch O
. O

Our O
results O
show O
that O
the O
ORF O
of O
hAMPK I-GENE
encodes O
552 O
amino O
acids O
( O
aa O
) O
( O
62 O
. O
250 O
kDa O
) O
and O
is O
highly O
conserved O
with O
rAMPK I-GENE
with O
identities O
of O
97 O
. O
3 O
and O
90 O
% O
at O
the O
aa O
and O
nt O
levels O
, O
respectively O
. O

In O
human O
brain O
, O
contactin I-GENE
was O
first O
identified O
by O
amino O
terminal O
and O
peptide O
sequencing O
of O
the O
lentil I-GENE
- I-GENE
lectin I-GENE
- I-GENE
binding I-GENE
glycoprotein I-GENE
Gp135 I-GENE
. O

The O
centromeric O
YAC O
contig O
, O
which O
consists O
of O
23 O
overlapping O
YACs O
and O
orders O
19 O
sequence O
- O
tagged O
sites O
( O
STSs O
), O
covers O
a O
minimum O
of O
2 O
. O
2 O
Mb O
and O
spans O
the O
Ewing O
sarcoma O
breakpoint O
. O
c I-GENE
- I-GENE
ets I-GENE
1 I-GENE
and O
Fli I-GENE
- I-GENE
1 I-GENE
, O
two O
members O
of O
the O
ets I-GENE
family I-GENE
, O
have O
been O
linked O
within O
400 O
kb O
of O
intervening O
DNA O
within O
this O
contig O
, O
which O
also O
comprises O
a O
polymorphic O
microsatellite O
, O
D11S912 I-GENE
( O
CA O
) O
n O
, O
which O
we O
have O
localized O
within O
the O
Fli I-GENE
- I-GENE
1 I-GENE
gene I-GENE
. O

A O
cDNA O
for O
a O
newly O
discovered O
pseudogene O
, O
closely O
related O
to O
the O
mouse I-GENE
mast I-GENE
cell I-GENE
chymases I-GENE
was O
isolated O
by O
polymerase O
chain O
reaction O
amplification O
from O
a O
mouse O
connective O
tissue O
- O
like O
mast O
cell O
line O
. O

IFI16 I-GENE
consists O
of O
ten O
exons O
and O
nine O
intervening O
introns O
spanning O
at O
least O
28 O
kilobases O
( O
kb O
) O
of O
DNA O
. O

Courses O
were O
repeated O
every O
four O
weeks O
. O

Peter O
Elfer O
explores O
the O
implications O
of O
the O
ruling O
. O

Other O
adverse O
events O
with O
incidences O
significantly O
higher O
than O
with O
placebo O
were O
dizziness O
, O
constipation O
, O
sweating O
, O
nervousness O
, O
and O
abnormal O
ejaculation O
. O

Homology O
was O
also O
detected O
between O
the O
putative O
transit O
peptide O
sequence O
of O
cysteine I-GENE
synthase I-GENE
C I-GENE
and O
other O
mitochondrion O
- O
targeting O
leader O
sequences O
. O

Furthermore O
, O
our O
data O
also O
show O
that O
, O
in O
addition O
to O
TEF I-GENE
- I-GENE
1 I-GENE
, O
another O
HF I-GENE
- I-GENE
1a I-GENE
- I-GENE
related I-GENE
factor I-GENE
may O
be O
recognized O
by O
the O
alpha I-GENE
- I-GENE
MHC I-GENE
gene I-GENE
EM O
element O
. O

Rat I-GENE
kidney I-GENE
carboxylesterase I-GENE
. O

Recombinant I-GENE
I I-GENE
- I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
inhibited O
kappa I-GENE
B I-GENE
motif I-GENE
binding O
by O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B1 I-GENE
, O
RelA I-GENE
, O
and O
c I-GENE
- I-GENE
Rel I-GENE
as O
indicated O
by O
studies O
using O
UV O
radiation O
- O
induced O
covalent O
cross O
- O
linking O
to O
a O
bromodeoxyuridine O
- O
substituted O
kappa I-GENE
B I-GENE
oligonucleotide I-GENE
. O

The O
physical O
and O
chemical O
stability O
of O
a O
combination O
of O
drugs O
commonly O
administered O
into O
the O
epidural O
or O
intrathecal O
space O
for O
the O
treatment O
of O
chronic O
pain O
was O
investigated O
. O

Therefore O
, O
mechanisms O
that O
control O
activation O
of O
the O
MAP I-GENE
kinase I-GENE
cascade O
temporally O
and O
spatially O
may O
be O
important O
for O
specification O
of O
cellular O
responses O
. O

A O
candidate O
gene O
for O
Bcg I-GENE
, O
designated O
natural I-GENE
resistance I-GENE
- I-GENE
associated I-GENE
macrophage I-GENE
protein I-GENE
( O
Nramp I-GENE
), O
has O
been O
isolated O
and O
shown O
to O
encode O
a O
novel O
macrophage O
- O
specific O
membrane O
protein O
, O
which O
is O
altered O
in O
susceptible O
animals O
. O

This O
motif O
is O
similar O
to O
but O
distinct O
from O
the O
LIM I-GENE
domain I-GENE
and O
the O
RING I-GENE
finger I-GENE
family I-GENE
, O
and O
is O
reminiscent O
of O
known O
metal O
- O
binding O
regions O
. O

The O
P131 O
ORF O
is O
followed O
in O
- O
frame O
by O
a O
second O
ORF O
which O
is O
probably O
expressed O
by O
partial O
readthrough O
of O
the O
UGA O
termination O
codon O
of O
the O
P131 O
ORF O
to O
produce O
a O
polypeptide O
of O
M O
( O
r O
) O
191044 O
( O
P191 O
). O

One O
hundred O
fifty O
patients O
were O
reviewed O
at O
1 O
year O
after O
arthroplasty O
. O

Elementary O
visual O
hallucinations O
in O
migraine O
and O
epilepsy O
. O

The O
influence O
of O
patient O
- O
related O
factors O
on O
inter O
- O
observer O
variability O
in O
the O
evaluation O
of O
neurological O
signs O
was O
investigated O
. O

Segments O
with O
more O
reduced O
BMIPP O
uptake O
than O
MIBI O
uptake O
( O
mismatching O
) O
showed O
either O
normal O
wall O
motion O
or O
demonstrated O
inotropic O
reserve O
during O
dobutamine O
stimulation O
. O

The O
defined O
length O
of O
the O
mRNA O
, O
1 O
, O
838 O
nucleotides O
, O
was O
in O
agreement O
with O
that O
of O
a O
1 O
. O
9 O
- O
kb O
RNA O
expressed O
throughout O
the O
replication O
cycle O
, O
starting O
at O
the O
early O
stages O
of O
infection O
. O

Infect O
. O

Transient O
transfections O
of O
a O
construct O
expressing O
the O
RNA O
transcript O
defined O
by O
clone O
B1 O
. O
1 O
into O
D17 O
cells O
led O
to O
the O
expression O
of O
an O
Env I-GENE
/ O
Mlvi I-GENE
- I-GENE
4 I-GENE
fusion O
protein O
with O
an O
apparent O
molecular O
mass O
of O
33 O
kDa O
. O

Roizman O
, O
J O
. O

Articles O
addressing O
valvular O
heart O
disease O
or O
heart O
failure O
secondary O
to O
acute O
myocardial O
infarction O
or O
Chagas O
' O
disease O
were O
excluded O
. O

The O
present O
data O
also O
indicate O
that O
patients O
with O
TGBM O
nephropathy O
often O
have O
concomitant O
IgA I-GENE
nephropathy O
and O
mesangial O
proliferative O
glomerulonephritis O
. O

All O
nuclear O
receptors O
have O
several O
well O
- O
characterized O
structural O
domains O
, O
including O
a O
conserved O
DNA O
- O
binding O
domain O
, O
and O
a O
ligand O
binding O
domain O
at O
the O
carboxyl O
terminus O
of O
the O
receptor O
. O

The O
sample O
includes O
all O
the O
HIV O
- O
infected O
- O
patients O
continuously O
referred O
to O
the O
Outpatient O
Service O
of O
the O
Infectious O
Diseases O
dept O
. O
of O
Bologna O
' O
s O
" O
Ospedale O
Maggiore O
" O
General O
Hospital O
during O
some O
five O
days O
( O
19 O
- O
23rd O
, O
July O
1993 O
). O

Using O
in O
organello O
footprint O
analysis O
, O
we O
demonstrate O
that O
within O
human O
placental O
mitochondria O
there O
is O
a O
high O
level O
of O
protein O
- O
DNA O
binding O
at O
regularly O
phased O
intervals O
throughout O
a O
500 O
- O
bp O
region O
encompassing O
the O
D O
- O
loop O
DNA O
origins O
and O
two O
promoter O
regions O
. O

The O
Nur77 I-GENE
protein I-GENE
can O
act O
as O
a O
potent O
transcription O
activator O
and O
may O
function O
to O
regulate O
the O
expression O
of O
downstream O
genes O
in O
response O
to O
extracellular O
stimuli O
. O

One O
class O
of O
plasmids O
contained O
tRNA I-GENE
( I-GENE
His I-GENE
) I-GENE
genes I-GENE
and O
conferred O
efficient O
suppression O
only O
when O
cells O
were O
starved O
for O
histidine O
; O
these O
plasmids O
suppressed O
a O
gcn2 I-GENE
deletion O
much O
less O
efficiently O
than O
they O
suppressed O
gcn2 I-GENE
- I-GENE
507 I-GENE
. O

Thus O
, O
the O
presence O
of O
the O
Cln2 I-GENE
PEST I-GENE
domain I-GENE
was O
sufficient O
to O
destabilize O
a O
heterologous O
protein O
. O

Electrophoretic O
mobility O
shift O
assays O
with O
each O
of O
these O
sequences O
demonstrated O
complexes O
with O
mobilities O
identical O
to O
those O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
from O
the O
kappa I-GENE
light I-GENE
- I-GENE
chain I-GENE
gene I-GENE
. O

Although O
a O
carboxyl O
- O
terminal O
HSF I-GENE
transcriptional O
activation O
domain O
is O
critical O
for O
the O
activation O
of O
CUP1 I-GENE
transcription O
in O
response O
to O
both O
heat O
shock O
stress O
and O
glucose O
starvation O
, O
this O
region O
is O
dispensable O
for O
transient O
heat O
shock O
activation O
of O
at O
least O
two O
genes O
encoding O
members O
of O
the O
S O
. O
cerevisiae O
hsp70 I-GENE
family I-GENE
. O

We O
have O
recently O
detected O
high O
levels O
of O
CKB I-GENE
mRNA I-GENE
in O
HeLa O
cells O
and O
, O
in O
this O
study O
, O
have O
tested O
whether O
this O
may O
be O
due O
to O
the O
extremely O
low O
amounts O
of O
p53 I-GENE
protein I-GENE
present O
in O
HeLa O
cells O
. O

Distal O
lower O
motor O
neuron O
syndrome O
with O
high O
- O
titer O
serum I-GENE
IgM I-GENE
anti I-GENE
- I-GENE
GM1 I-GENE
antibodies I-GENE
: O
improvement O
following O
immunotherapy O
with O
monthly O
plasma O
exchange O
and O
intravenous O
cyclophosphamide O
. O

Regulators O
responsible O
for O
the O
pervasive O
, O
nonsex O
- O
specific O
alternative O
pre O
- O
mRNA O
splicing O
characteristic O
of O
metazoans O
are O
almost O
entirely O
unknown O
or O
uncertain O
. O

A O
normal O
systemic O
response O
was O
obtained O
after O
IF O
, O
indicating O
that O
rhG I-GENE
- I-GENE
CSF I-GENE
retains O
activity O
in O
the O
solid O
state O
. O

A O
full O
- O
length O
cDNA O
clone O
isolated O
from O
a O
rat O
lung O
library O
was O
predicted O
to O
encode O
a O
55 O
- O
kDa O
protein O
containing O
at O
its O
amino O
terminus O
a O
targeting O
domain O
that O
binds O
to O
the O
ANP I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
- I-GENE
like I-GENE
domain I-GENE
and O
containing O
at O
its O
carboxyl O
terminus O
a O
putative O
protein I-GENE
- I-GENE
serine I-GENE
phosphatase I-GENE
domain O
. O

A O
high O
- O
resolution O
restriction O
map O
of O
over O
200 O
kb O
of O
contiguous O
DNA O
containing O
N I-GENE
- I-GENE
myc I-GENE
has O
been O
generated O
by O
subcloning O
YACs O
into O
cosmids O
. O

PAI I-GENE
- I-GENE
1 I-GENE
levels O
increased O
significantly O
in O
patients O
who O
received O
iohexol O
but O
not O
in O
those O
who O
received O
ioxaglate O
. O

In O
the O
present O
article O
, O
the O
causes O
of O
death O
or O
ill O
- O
being O
as O
found O
in O
10 O
consecutive O
carcinogenicity O
studies O
-- O
5 O
studies O
with O
2400 O
OFA O
( O
Sprague O
- O
Dawley O
- O
derived O
) O
and O
Wistar O
rats O
and O
5 O
studies O
with O
2400 O
OF1 O
and O
NMRI O
mice O
-- O
were O
re O
- O
examined O
. O

Determination O
of O
potassium O
iodide O
in O
Polish O
edible O
salt O

The O
recovery O
value O
of O
systolic O
pressure O
was O
higher O
than O
diastolic O
pressure O
and O
pulse O
pressure O
increased O
. O

The O
importance O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
as O
a O
cause O
of O
chronic O
liver O
disease O
has O
become O
clear O
with O
the O
introduction O
of O
serologic O
detection O
methods O
. O

Human O
adenovirus O
type O
41 O
contains O
two O
fibers O
. O

Outflow O
obstruction O
of O
pancreatic O
juice O
, O
i O
. O
e O
., O
" O
relative O
stenosis O
of O
the O
minor O
papilla O
," O
was O
considered O
to O
be O
present O
in O
the O
patients O
with O
type O
II O
papilla O
, O
and O
, O
therefore O
, O
the O
patients O
with O
type O
II O
papilla O
might O
suffer O
from O
acute O
pancreatitis O
resulting O
from O
poor O
drainage O
of O
pancreatic O
juice O
and O
excessive O
pressure O
in O
the O
dorsal O
duct O
. O

Sequencing O
of O
the O
TP53 I-GENE
transcripts I-GENE
from O
exons O
2 O
to O
10 O
, O
however O
, O
did O
not O
reveal O
mutations O
of O
the O
remaining O
allele O
in O
any O
of O
these O
tumors O
. O

An O
unusual O
complication O
in O
an O
unsuitable O
patient O
. O

In O
the O
ISO O
group O
, O
at O
pre O
- O
DEX O
, O
CBF O
increased O
from O
86 O
+/- O
8 O
to O
166 O
+/- O
19 O
mL O
. O
min O
- O
1 O
. O
100 O
g O
- O
1 O
in O
response O
to O
hypercapnia O
( O
PCO2 O
approximately O
90 O
mmHg O
).( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

All O
other O
ejaculate O
parameters O
( O
density O
, O
motility O
, O
swelling O
test O
, O
penetration O
test O
) O
remained O
unchanged O
, O
and O
there O
was O
only O
one O
post O
- O
therapeutic O
pregnancy O
. O

KRN2391 O
and O
cromakalim O
produced O
a O
dose O
- O
dependent O
increase O
in O
aortic O
and O
coronary O
blood O
flow O
. O

In O
H4IIE O
rat O
hepatoma O
cells O
, O
glucocorticoids O
, O
retinoic O
acid O
and O
cyclic O
AMP O
( O
cAMP O
) O
increase O
PEPCK I-GENE
gene I-GENE
transcription O
whereas O
insulin I-GENE
and O
phorbol O
esters O
have O
the O
opposite O
effect O
. O

Acta O
572 O
, O
113 O
- O
120 O
]. O

Basal O
plasma O
AVP I-GENE
levels O
and O
AVP I-GENE
release O
after O
postural O
change O
were O
assessed O
, O
and O
plasma O
NPY I-GENE
levels O
were O
measured O
in O
the O
same O
samples O
. O

A O
stretch O
of O
16 O
nucleotides O
just O
upstream O
of O
the O
IL I-GENE
- I-GENE
4RE I-GENE
contributed O
to O
IL I-GENE
- I-GENE
4 I-GENE
inducibility O
and O
formed O
nucleoprotein O
complexes O
with O
constitutive O
factors O
. O

Our O
previous O
study O
suggested O
that O
pertussis I-GENE
toxin I-GENE
( O
IAP I-GENE
)- O
sensitive O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
s I-GENE
) I-GENE
( O
G I-GENE
- I-GENE
protein I-GENE
) O
is O
involved O
in O
the O
process O
of O
differentiation O
by O
hormones O
/ O
IBMX O
, O
accompanied O
by O
c I-GENE
- I-GENE
fos I-GENE
induction O
. O

ATX I-GENE
, O
like O
PC I-GENE
- I-GENE
1 I-GENE
, O
was O
found O
to O
hydrolyze O
the O
type I-GENE
I I-GENE
phosphodiesterase I-GENE
substrate O
p O
- O
nitrophenyl O
thymidine O
- O
5 O
'- O
monophosphate O
. O

The O
effect O
of O
site O
- O
specific O
mutations O
in O
the O
mouse I-GENE
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( I-GENE
PDGF I-GENE
) I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
on O
activation O
of O
the O
Na I-GENE
+/ I-GENE
H I-GENE
+ I-GENE
exchanger I-GENE
was O
examined O
in O
normal O
murine O
mammary O
gland O
epithelial O
( O
NMuMG O
) O
and O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
. O

Sequence O
analysis O
revealed O
: O
1 O
) O
a O
kinase O
catalytic O
domain O
most O
characteristic O
of O
serine I-GENE
/ I-GENE
threonine I-GENE
kinases I-GENE
but O
hybrid O
between O
members O
of O
the O
family O
of O
microtubule I-GENE
- I-GENE
associated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
kinases I-GENE
and O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
family I-GENE
; O
2 O
) O
two O
putative O
alpha O
- O
helical O
leucine O
zipper O
motifs O
separated O
by O
a O
25 O
- O
amino O
acid O
charged O
intermediate O
segment O
but O
lacking O
an O
NH2 O
- O
terminal O
basic O
domain O
; O
and O
3 O
) O
COOH O
- O
terminal O
and O
NH2 O
- O
terminal O
proline O
- O
rich O
domains O
suggestive O
of O
src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
) O
domain O
binding O
regions O
. O

Type O
2 O
genomes O
containing O
this O
sequence O
presumably O
more O
closely O
reflect O
the O
structure O
of O
the O
infectious O
, O
replication O
- O
competent O
retrovirus O
ancestors O
of O
the O
HERV O
- O
K O
family O
than O
do O
type O
1 O
genomes O
that O
lack O
the O
sequence O
. O

However O
, O
when O
domain O
I O
and O
domain O
II O
were O
linked O
on O
the O
same O
plasmid O
, O
high O
levels O
of O
replication O
were O
observed O
. O

Point O
mutations O
that O
suppressed O
the O
in O
vitro O
binding O
of O
NF I-GENE
- I-GENE
Y I-GENE
to O
the O
internal O
palindromic O
arm O
reduced O
the O
activity O
of O
the O
resident O
P4 O
promoter O
, O
while O
those O
preventing O
complex O
formation O
with O
USF I-GENE
did O
not O
, O
as O
determined O
by O
transient O
expression O
assays O
using O
the O
luciferase I-GENE
reporter O
gene O
. O

Surprisingly O
, O
Northern O
( O
RNA O
) O
blot O
analysis O
and O
reverse I-GENE
transcriptase I-GENE
- O
PCRs O
performed O
after O
transfection O
of O
COS O
- O
7 O
or O
HeLa O
cells O
with O
these O
viral O
RNAs O
revealed O
that O
Y88S I-GENE
and O
Y88L I-GENE
RNAs I-GENE
replicated O
at O
only O
very O
low O
levels O
. O

Surprisingly O
, O
nuclear O
forms O
of O
IE110 I-GENE
were O
found O
to O
move O
a O
cytoplasmic O
form O
of O
IE175 I-GENE
into O
nuclear O
punctate O
structures O
, O
and O
a O
cytoplasmic O
form O
of O
IE110 I-GENE
was O
able O
to O
retain O
nuclear O
forms O
of O
IE175 I-GENE
in O
cytoplasmic O
punctate O
structures O
. O

Transcription O
of O
the O
gene O
for O
ivanolysin I-GENE
O I-GENE
and O
expression O
of O
other O
genes O
of O
the O
virulence I-GENE
gene I-GENE
cluster I-GENE
in I-GENE
L I-GENE
. I-GENE
ivanovii I-GENE
were O
dependent O
on O
PrfA I-GENE
. O

Moreover O
, O
by O
complementation O
of O
the O
WA I-GENE
fyuA I-GENE
mutant I-GENE
by O
the O
cloned O
fyuA I-GENE
gene I-GENE
, O
yersiniabactin O
uptake O
and O
mouse O
virulence O
were O
restored O
. O

The O
ICBF O
in O
the O
ischaemic O
cortex O
revealed O
a O
graded O
reduction O
from O
the O
ischaemic O
centre O
to O
the O
surrounding O
tissues O
. O

The O
treatment O
of O
hydronephrosis O
in O
children O

The O
inflation O
hub O
of O
the O
probe O
is O
recreated O
by O
modifying O
a O
standard O
USCI O
Tuohy O
- O
Borst O
Y O
adaptor O
and O
attaching O
this O
to O
the O
transected O
probe O
hypotube O
. O

The O
other O
element O
bound O
RBP I-GENE
- I-GENE
J I-GENE
kappa I-GENE
with O
low O
affinity O
. O

The O
basal O
promoter O
strength O
of O
constructs O
that O
contained O
deletions O
in O
the O
U5 I-GENE
region I-GENE
of O
the O
LTR O
was O
analyzed O
by O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
assays O
following O
transfection O
of O
HeLa O
cells O
or O
Jurkat O
T O
- O
cells O
in O
the O
presence O
or O
absence O
of O
viral O
transactivator O
tax I-GENE
protein O
. O

In O
reviewing O
a O
number O
of O
the O
most O
intensely O
studied O
environmentally O
inducible O
promoters O
it O
becomes O
clear O
that O
the O
presence O
of O
two O
cis O
- O
acting O
elements O
are O
critical O
for O
promoter O
activity O
, O
one O
of O
which O
is O
the O
G O
- O
box O
( O
CCACGTGG O
). O

Recently O
, O
a O
protein O
designated O
GF14 I-GENE
has O
been O
isolated O
that O
is O
associated O
with O
the O
GBF I-GENE
protein I-GENE
complex I-GENE
. O

New O
diagnostic O
strategies O
for O
lupus O
anticoagulants O
and O
antiphospholipid O
antibodies O
. O

Moreover O
, O
the O
ability O
to O
selectivity O
arrest O
elongation O
by O
polIII I-GENE
at O
defined O
positions O
within O
the O
tRNA O
gene O
transcription O
unit O
has O
permitted O
the O
identification O
of O
discrete O
functional O
properties O
of O
paused O
mammalian I-GENE
polIII I-GENE
ternary I-GENE
complexes I-GENE
. O

Propafenone O
is O
well O
tolerated O
in O
the O
majority O
of O
young O
patients O
. O

Mutational O
analysis O
of O
yeast I-GENE
CEG1 I-GENE
demonstrated O
that O
four O
of O
the O
five O
conserved O
motifs O
are O
essential O
for O
capping I-GENE
enzyme I-GENE
function O
in O
vivo O
. O

2 O
patients O
( O
11 O
%) O
had O
significant O
morbidity O
502 O
and O
529 O
days O
respectively O
after O
transplantation O
. O

A O
recent O
index O
( O
Fluorosis O
Risk O
Index O
) O
developed O
by O
Pendrys O
( O
1990 O
) O
is O
also O
included O
in O
this O
review O
. O

Alternative O
splicing O
of O
the O
cytoplasmic O
tail O
appears O
to O
generate O
multiple O
PECAM I-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
that O
may O
regulate O
phosphorylation O
, O
cytoskeletal O
association O
, O
and O
affinity O
modulation O
of O
the O
mature O
protein O
. O

Transfer O
also O
correlated O
inversely O
with O
gastric O
juice O
pH O
( O
r O
= O
- O
0 O
. O
619 O
, O
P O
< O
0 O
. O
02 O
). O

This O
technique O
has O
a O
sensitivity O
and O
a O
specificity O
of O
almost O
100 O
%, O
and O
is O
currently O
the O
best O
way O
to O
diagnose O
nodal O
involvement O
, O
apart O
from O
laparotomy O
. O

The O
data O
show O
conclusively O
that O
phosphorylation O
of O
His O
- O
304 O
is O
not O
essential O
for O
any O
of O
the O
known O
functions O
of O
A I-GENE
. I-GENE
vinelandii I-GENE
NifL I-GENE
. O

The O
role O
of O
HIV I-GENE
tat I-GENE
, O
which O
is O
the O
main O
enhancing O
factor O
for O
viral I-GENE
LTR I-GENE
, O
in O
the O
regulation O
of O
IL I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription O
has O
been O
studied O
following O
transient O
expression O
of O
the O
tat I-GENE
gene I-GENE
in O
phorbol O
ester O
and O
calcium O
ionophore O
- O
activated O
Jurkat O
cells O
transfected O
with O
IL I-GENE
- I-GENE
2 I-GENE
promoter O
- O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter O
constructs O
. O

Splice O
variations O
in O
genes O
coding O
for O
the O
transmembrane I-GENE
FGF I-GENE
receptor I-GENE
( O
FGFR I-GENE
) O
result O
in O
isoforms O
that O
vary O
in O
the O
ectodomain O
, O
intracellular O
juxtamembrane O
domain O
, O
and O
the O
intracellular O
kinase O
domain O
. O

If O
this O
is O
present O
, O
such O
patients O
should O
be O
closely O
monitored O
, O
and O
any O
atypical O
lesions O
biopsied O
. O

Cumulated O
maximum O
lod O
scores O
between O
FRDA I-GENE
and O
D9S5 I-GENE
and O
between O
FRDA I-GENE
and O
D9S15 I-GENE
are O
above O
36 O
and O
61 O
, O
respectively O
, O
at O
a O
recombination O
fraction O
of O
0 O
, O
indicating O
that O
recombination O
events O
needed O
to O
orient O
the O
search O
of O
the O
gene O
are O
very O
difficult O
to O
identify O
and O
ascertain O
. O

A O
receptor I-GENE
- I-GENE
like I-GENE
protein I-GENE
kinase I-GENE
, O
OsPK10 I-GENE
, O
has O
been O
cloned O
from O
rice O
( O
Oryza O
sativa O
). O

A O
sequence O
representing O
about O
50 O
% O
of O
the O
expected O
complete O
sequence O
was O
obtained O
by O
translation O
of O
the O
two O
open O
reading O
frames O
present O
on O
a O
1 O
. O
6 O
kb O
DNA O
genomic O
fragment O
. O

Goodpasture O
' O
s O
- O
like O
syndrome O
and O
effect O
of O
extracorporeal O
membrane O
oxygenator O
support O
. O

A O
cDNA O
clone O
pCZ1 O
, O
with O
a O
1 O
. O
1 O
kb O
insert O
, O
was O
isolated O
from O
a O
NaCl O
- O
adapted O
tobacco O
cell O
cDNA O
library O
that O
encodes O
an O
apparently O
full O
- O
length O
29 O
kDa O
protein O
( O
251 O
amino O
acids O
) O
with O
a O
calculated O
pI O
of O
5 O
. O
7 O
. O

METHODS O
-- O
16 O
volunteered O
for O
spirometry O
with O
methacholine O
provocation O
test O
including O
a O
test O
for O
small O
airways O
function O
by O
volume O
of O
trapped O
gas O
( O
VTG O
). O

Relationship O
of O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
CTD O
kinase O
TFIIH I-GENE
/ O
TFIIK I-GENE
. O

The O
git1 I-GENE
, O
git3 I-GENE
, O
git5 I-GENE
, O
git7 I-GENE
, O
git8 I-GENE
and O
git10 I-GENE
genes I-GENE
act O
upstream O
of O
adenylate I-GENE
cyclase I-GENE
, O
presumably O
encoding O
an O
adenylate I-GENE
cyclase I-GENE
activation O
pathway O
. O

These O
same O
regions O
showed O
remarkable O
homology O
to O
two O
invertebrate O
proteins O
, O
CNC I-GENE
and O
skin I-GENE
- I-GENE
1 I-GENE
, O
postulated O
to O
regulate O
embryonic O
development O
in O
Drosophila O
melanogaster O
and O
Caenorhabditis O
elegans O
, O
respectively O
. O

DNA O
sequence O
analysis O
has O
confirmed O
that O
this O
mutation O
affects O
the O
C O
- O
terminal O
region O
of O
the O
alpha O
subunit O
, O
changing O
a O
leucine O
residue O
at O
position O
290 O
to O
a O
histidine O
( O
rpoAL290H I-GENE
). O

CONCLUSIONS O
: O
These O
findings O
indicate O
a O
physical O
barrier O
of O
oesophageal O
surfactant O
which O
could O
offer O
some O
degree O
of O
protection O
against O
gastro O
- O
oesophageal O
reflux O
but O
one O
which O
is O
particularly O
prone O
to O
attack O
by O
bile O
. O

Differential O
screening O
of O
mitochondrial O
cDNA O
libraries O
from O
male O
- O
fertile O
and O
cytoplasmic O
male O
- O
sterile O
sugar O
- O
beet O
reveals O
genome O
rearrangements O
at O
atp6 I-GENE
and O
atpA I-GENE
loci I-GENE
. O

The O
effects O
of O
social O
isolation O
on O
morphine O
- O
induced O
locomotor O
activity O
were O
compared O
in O
: O
( O
i O
) O
animals O
with O
an O
intact O
hypothalamo O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
; O
( O
ii O
) O
animals O
in O
which O
stress O
- O
induced O
corticosterone O
secretion O
was O
blocked O
by O
adrenalectomy O
. O

Using O
this O
reporter O
gene O
system O
, O
we O
previously O
showed O
that O
EPO I-GENE
- O
induced O
activation O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
can O
be O
detected O
rapidly O
and O
sensitively O
as O
an O
elevation O
of O
cellular I-GENE
luciferase I-GENE
activity O
. O

I O
hypothesize O
that O
white I-GENE
gene I-GENE
expression O
from O
P I-GENE
[ I-GENE
en I-GENE
] I-GENE
is O
repressed O
by O
the O
formation O
of O
a O
protein O
complex O
which O
is O
initiated O
at O
the O
engrailed I-GENE
PS I-GENE
sites I-GENE
and O
also O
requires O
interactions O
with O
flanking O
genomic O
DNA O
. O

SPP41 I-GENE
was O
cloned O
and O
sequenced O
and O
found O
to O
be O
essential O
. O
spp43 I-GENE
is O
allelic O
to O
the O
previously O
identified O
suppressor I-GENE
srn1 I-GENE
, O
which O
encodes O
a O
negative O
regulator O
of O
gene O
expression O
. O

Standard O
curve O
correlation O
coefficients O
of O
0 O
. O
995 O
or O
greater O
were O
obtained O
during O
validation O
experiments O
and O
analysis O
of O
study O
samples O
. O

To O
see O
if O
a O
pulse O
oximeter O
can O
monitor O
the O
fetus O
during O
labour O
we O
recruited O
100 O
Caucasian O
women O
in O
normal O
uncomplicated O
labour O
. O

There O
was O
no O
difference O
in O
plasma O
concentrations O
of O
PGI2 O
( O
figure O
4 O
) O
and O
TxA2 O
in O
patients O
with O
normal O
blood O
pressure O
, O
mild O
preeclampsia O
and O
hypotension O
, O
whereas O
in O
severe O
preeclampsia O
, O
the O
plasma O
concentration O
of O
PGI2 O
was O
significantly O
lower O
( O
p O
< O
0 O
. O
001 O
) O
and O
of O
TxA2 O
significantly O
higher O
( O
p O
< O
0 O
. O
001 O
). O

A O
causal O
analysis O
of O
secondary O
variables O
showed O
that O
the O
formation O
of O
FB O
memories O
was O
primarily O
associated O
with O
the O
level O
of O
importance O
attached O
to O
the O
event O
and O
level O
of O
affective O
response O
to O
the O
news O
. O

Deletion O
studies O
identified O
a O
distal O
response O
element O
that O
is O
responsible O
for O
the O
cytokine O
response O
and O
has O
properties O
of O
an O
inducible O
transcriptional O
enhancer O
. O

The O
IPL1 I-GENE
gene I-GENE
is O
required O
for O
high O
- O
fidelity O
chromosome O
segregation O
in O
the O
budding O
yeast O
Saccharomyces O
cerevisiae O
. O

2 O
. O

No O
drop O
in O
oxygen O
saturation O
( O
SaO2 O
) O
or O
visual O
evidence O
of O
transient O
electroencephalographic O
( O
EEG O
) O
arousals O
can O
be O
found O
at O
repeat O
polysomnography O
. O

The O
complete O
gene O
organization O
was O
obtained O
by O
combining O
the O
results O
of O
the O
sequence O
of O
these O
clones O
and O
those O
of O
the O
characterization O
of O
polymerase O
chain O
reaction O
- O
amplified O
genomic O
segments O
. O

INO2 I-GENE
, O
a O
regulatory O
gene O
in O
yeast O
phospholipid O
biosynthesis O
, O
affects O
nuclear O
segregation O
and O
bud O
pattern O
formation O
. O

The O
pentafluorobenzyl O
derivative O
of O
clonidine O
yields O
an O
intense O
ion O
fragment O
at O
m O
/ O
z O
354 O
, O
and O
the O
lower O
limit O
of O
detection O
is O
0 O
. O
025 O
ng O
/ O
ml O
for O
a O
1 O
- O
ml O
plasma O
sample O
. O

Mammalian I-GENE
ABPs I-GENE
and O
SHBGs I-GENE
bind O
sex O
steroids O
with O
high O
affinity O
, O
but O
some O
binding O
properties O
differ O
among O
species O
. O

Src I-GENE
homology I-GENE
( O
SH I-GENE
) O
domain O
dependent O
protein O
- O
protein O
interactions O
are O
important O
to O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
signal O
transduction O
. O

Sample O
treatment O
was O
optimized O
in O
order O
to O
achieve O
a O
complete O
extraction O
of O
labetalol O
diastereoisomers O
and O
to O
avoid O
racemization O
during O
extraction O
. O

Under O
resting O
conditions O
, O
activity O
levels O
of O
cardiac O
vagal O
and O
sympathetic O
outflows O
are O
not O
related O
across O
young O
, O
healthy O
human O
subjects O
and O
peripheral O
interaction O
is O
not O
manifest O
between O
the O
autonomic O
divisions O
. O

Both O
proprioceptive O
and O
electroreceptive O
units O
showed O
a O
progression O
of O
receptive O
fields O
from O
anterior O
to O
posterior O
body O
in O
the O
rostral O
to O
caudal O
direction O
along O
the O
length O
of O
DGR O
. O

In O
control O
patients O
, O
baseline O
images O
presented O
Type O
I O
in O
25 O
, O
Type O
II O
in O
7 O
, O
and O
the O
Type O
III O
& O
IV O
in O
0 O
, O
and O
the O
Type O
after O
loading O
was O
the O
same O
as O
the O
Type O
at O
baseline O
. O

A O
more O
complete O
analysis O
of O
dose O
response O
, O
time O
and O
mode O
of O
Ga O
administration O
( O
preinjury O
or O
postinjury O
), O
and O
availability O
of O
Ga O
across O
the O
blood O
- O
brain O
barrier O
is O
needed O
to O
further O
evaluate O
the O
efficacy O
of O
this O
compound O
. O

The O
presence O
of O
regulatory O
sequences O
for O
the O
binding O
of O
transcription O
factors O
such O
as O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
and O
AP I-GENE
- I-GENE
2 I-GENE
, O
whose O
activation O
is O
associated O
with O
the O
immediate O
response O
of O
the O
cell O
to O
an O
injury O
, O
may O
be O
an O
indication O
of O
the O
important O
role O
which O
HO I-GENE
- I-GENE
1 I-GENE
may O
play O
in O
defense O
mechanisms O
against O
tissue O
injury O
. O

Granisetron O
, O
but O
not O
saline O
, O
abolished O
vomiting O
and O
nausea O
when O
given O
as O
intervention O
after O
this O
combined O
emetic O
regimen O
. O

The O
femoroarterial O
coronary O
sinus O
difference O
in O
lactate O
turned O
negative O
, O
and O
pH O
, O
PCO2 O
and O
potassium O
differences O
increased O
in O
group O
2 O
during O
pacing O
. O

This O
was O
obtained O
with O
the O
thermal O
neutron O
fluency O
2 O
. O
0 O
x O
10 O
( O
10 O
) O
n O
/ O
cm2 O
. O

Endotoxemia O
induced O
by O
gram O
- O
negative O
bacteria O
leads O
to O
endotoxic O
shock O
pathogenetically O
stemming O
from O
the O
integral O
component O
of O
the O
bacterial O
wall O
-- O
lipid O
A O
. O

The O
study O
made O
to O
define O
the O
ability O
of O
lipid I-GENE
A I-GENE
monoclonal I-GENE
antibodies I-GENE
to O
correct O
hemodynamic O
disturbances O
due O
to O
endotoxemia O
in O
dog O
experiments O
showed O
the O
efficacy O
of O
the O
antibodies O
administration O
. O

A O
randomised O
, O
controlled O
trial O
was O
undertaken O
in O
40 O
patients O
with O
active O
Crohn O
' O
s O
disease O
to O
evaluate O
clinical O
and O
nutritional O
outcomes O
after O
an O
amino O
acid O
based O
diet O
containing O
3 O
% O
fat O
was O
given O
by O
a O
feeding O
tube O
compared O
with O
a O
peptide O
based O
diet O
containing O
33 O
% O
fat O
. O

This O
sequenced O
region O
of O
the O
V O
beta O
locus O
contains O
an O
average O
number O
of O
repetitive O
DNA O
elements O
( O
21 O
Alu I-GENE
, O
three O
L1 I-GENE
, O
three O
MER O
, O
and O
three O
retrovirus O
- O
related O
elements O
. O

The O
sequenced O
genomic O
region O
thus O
accounts O
for O
essentially O
all O
of O
the O
longest O
known O
transcript O
( O
4 O
. O
5 O
kb O
), O
although O
the O
precise O
ends O
of O
this O
transcript O
have O
not O
been O
defined O
. O

The O
pexB I-GENE
upstream I-GENE
region I-GENE
contained O
245 O
nucleotides O
within O
which O
sequences O
approximating O
the O
consensus O
for O
cyclic I-GENE
AMP I-GENE
receptor I-GENE
protein I-GENE
and O
integration I-GENE
host I-GENE
factor I-GENE
binding O
sites O
were O
discernible O
. O

The O
fepA I-GENE
- O
entD I-GENE
and O
fes I-GENE
- O
entF I-GENE
operons O
in O
the O
enterobactin O
synthesis O
and O
transport O
system O
are O
divergently O
transcribed O
from O
overlapping O
promoters O
, O
and O
both O
are O
inhibited O
by O
the O
Fur I-GENE
repressor I-GENE
protein I-GENE
under O
iron O
- O
replete O
conditions O
. O

Sequence O
analysis O
of O
a O
6 O
. O
3 O
- O
kbp O
genomic O
EcoRI I-GENE
- O
fragment O
of O
Alcaligenes O
eutrophus O
, O
which O
was O
recently O
identified O
by O
using O
a O
dihydrolipoamide I-GENE
dehydrogenase I-GENE
- O
specific O
DNA O
probe O
( O
A O
. O

Using O
a O
previously O
published O
two O
- O
frequency O
( O
AC O
excitation O
) O
three O
- O
electrode O
method O
, O
the O
admittance O
locus O
plot O
( O
ALP O
) O
in O
the O
low O
- O
frequency O
region O
(< O
1000 O
Hz O
) O
has O
been O
shown O
to O
be O
very O
well O
approximated O
by O
a O
straight O
line O
and O
can O
be O
described O
with O
frequency O
- O
independent O
parameters O
; O
phase O
angle O
alpha O
pi O
/ O
2 O
, O
conductance O
at O
extrapolated O
zero O
frequency O
G0 O
= O
1 O
/ O
R0 O
, O
and O
ion O
relaxation O
time O
tau O
. O

Intraoperative O
measurement O
of O
activated O
partial O
thromboplastin I-GENE
time O
and O
prothrombin I-GENE
time O
with O
a O
new O
compact O
monitor O
. O

In O
addition O
, O
we O
sought O
to O
test O
the O
hypothesis O
that O
, O
when O
equal O
volumes O
are O
administered O
intrathecally O
, O
significant O
differences O
exist O
in O
the O
potential O
to O
three O
commonly O
used O
anesthetic O
solutions O
to O
induce O
sensory O
impairment O
. O

In O
an O
in O
vitro O
study O
, O
10 O
/ O
0 O
nylon O
was O
found O
to O
require O
a O
significantly O
lower O
laser O
energy O
density O
to O
produce O
suture O
lysis O
following O
a O
single O
shot O
than O
either O
10 O
/ O
0 O
Dacron O
or O
10 O
/ O
0 O
prolene O
. O

The O
proteins O
encoded O
downstream O
of O
rpoN I-GENE
are O
known O
to O
negatively O
regulate O
sigma I-GENE
54 I-GENE
activity O
. O

We O
report O
here O
that O
microinjection O
of O
an O
anti I-GENE
- I-GENE
CBP I-GENE
antiserum I-GENE
into O
fibroblasts O
can O
inhibit O
transcription O
from O
a O
cAMP O
responsive O
promoter O
. O

These O
results O
demonstrate O
that O
a O
class O
of O
proline O
- O
rich O
activator O
proteins O
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
possess O
a O
common O
structural O
and O
functional O
component O
which O
can O
interact O
with O
the O
same O
target O
in O
the O
general O
transcription O
machinery O
. O

Cloning O
of O
higher I-GENE
plant I-GENE
omega I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
desaturases I-GENE
. O

65 O
, O
3829 O
- O
3838 O
, O
1991 O
), O
a O
truncated O
form O
of O
the O
IE I-GENE
polypeptide I-GENE
lacking O
IE I-GENE
amino I-GENE
acid I-GENE
residues I-GENE
1 I-GENE
- I-GENE
322 I-GENE
( O
and O
, O
therefore O
lacks O
the O
deduced O
transcriptional O
activation O
domain O
), O
fails O
to O
transactivate O
the O
EHV I-GENE
- I-GENE
1 I-GENE
tk I-GENE
promoter I-GENE
, O
but O
retains O
the O
ability O
to O
down O
- O
regulate O
the O
EHV I-GENE
- I-GENE
1 I-GENE
IE I-GENE
promoter I-GENE
. O

However O
, O
by O
an O
NS35 I-GENE
- I-GENE
specific I-GENE
RNA I-GENE
capture O
assay O
, O
the O
multimers O
were O
shown O
to O
possess O
the O
RNA O
- O
binding O
activity O
previously O
demonstrated O
for O
NS35 I-GENE
. O

CONCLUSION O
: O
Human O
preterm O
birth O
is O
associated O
with O
significantly O
lower O
progesterone O
/ O
17 O
beta O
- O
estradiol O
ratios O
than O
those O
of O
women O
with O
preterm O
labor O
delivered O
at O
term O
. O

Ketamine O
in O
the O
treatment O
of O
bronchospasm O
during O
mechanical O
ventilation O
. O

In O
conclusion O
, O
the O
disposition O
of O
venlafaxine O
and O
O O
- O
desmethylvenlafaxine O
is O
markedly O
altered O
in O
renal O
disease O
; O
therefore O
dosage O
adjustment O
is O
warranted O
for O
patients O
with O
creatinine O
clearance O
values O
below O
30 O
ml O
/ O
min O
. O

The O
availability O
of O
sequence O
from O
multiple O
species O
has O
permitted O
us O
to O
determine O
that O
the O
UBE O
site O
has O
close O
similarity O
to O
motifs O
that O
bind O
members O
of O
the O
NF I-GENE
- I-GENE
1 I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
. O

The O
incidence O
of O
HSV O
- O
2 O
positive O
subjects O
( O
HSV I-GENE
- I-GENE
2 I-GENE
/ I-GENE
HSV I-GENE
- I-GENE
1 I-GENE
antibody I-GENE
ratio O
> O
or O
= O
1 O
) O
was O
low O
in O
the O
Jewish O
Israeli O
population O
, O
compared O
to O
other O
demographic O
areas O
. O

The O
mechanism O
whereby O
zeta I-GENE
PKC I-GENE
regulates O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
most O
probably O
involves O
the O
activation O
of O
a O
putative O
I I-GENE
kappa I-GENE
B I-GENE
kinase I-GENE
of O
molecular O
mass O
approximately O
50 O
kDa O
, O
which O
phosphorylates O
and O
inactivates O
I I-GENE
kappa I-GENE
B I-GENE
. O

Stable O
expression O
of O
truncated I-GENE
inositol I-GENE
1 I-GENE
, I-GENE
4 I-GENE
, I-GENE
5 I-GENE
- I-GENE
trisphosphate I-GENE
receptor I-GENE
subunits I-GENE
in O
3T3 O
fibroblasts O
. O

The O
molecular O
basis O
for O
commitment O
of O
progenitors O
to O
the O
eosinophil O
lineage O
and O
mechanisms O
by O
which O
eosinophil O
- O
specific O
genes O
are O
expressed O
and O
regulated O
during O
differentiation O
is O
unknown O
. O

We O
report O
the O
identification O
and O
characterization O
of O
myr I-GENE
4 I-GENE
( O
myosin I-GENE
from I-GENE
rat I-GENE
), O
the O
first O
mammalian I-GENE
myosin I-GENE
I I-GENE
that O
is O
not O
closely O
related O
to O
brush O
border O
myosin I-GENE
I I-GENE
. O

M O
., O
and O
D O
. O

In O
addition O
, O
computer O
analysis O
suggests O
that O
sequences O
similar O
to O
the O
A O
stem O
element O
are O
present O
within O
the O
three O
AAV I-GENE
promoter I-GENE
regions O
. O

At O
least O
some O
of O
the O
difference O
in O
stability O
of O
the O
two O
kinds O
of O
complexes O
was O
due O
to O
the O
fact O
that O
the O
dissociation O
rate O
of O
the O
A O
stem O
substrate O
from O
the O
protein O
- O
DNA O
complexes O
was O
approximately O
fourfold O
faster O
than O
that O
of O
the O
complete O
TR I-GENE
. O

Processing O
of O
the O
NS3 O
'- O
5B I-GENE
polyprotein O
was O
complex O
and O
occurred O
rapidly O
. O

However O
, O
each O
promoter O
activated O
by O
IEP86 I-GENE
was O
synergistically O
affected O
by O
the O
addition O
of O
IEP72 I-GENE
. O

32Pi O
labeling O
or O
isoelectric O
focusing O
analysis O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
from O
conditional O
casein I-GENE
kinase I-GENE
II I-GENE
mutants I-GENE
indicated O
that O
phosphorylation O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
is O
abolished O
or O
dephosphorylated O
forms O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
are O
detected O
when O
these O
strains O
are O
grown O
at O
the O
restrictive O
growth O
conditions O
. O

Thus O
, O
YMIP I-GENE
is O
a O
functional O
homolog O
of O
RMIP I-GENE
and O
represents O
a O
new O
component O
of O
the O
yeast O
mitochondrial O
import O
machinery O
. O

The O
R2 O
region O
within O
the O
class O
I O
enhancer O
acts O
as O
a O
negative O
element O
in O
Ad12 O
- O
transformed O
cells O
and O
exhibits O
a O
stronger O
binding O
activity O
than O
is O
observed O
in O
nontumorigenic O
Ad5 O
- O
transformed O
cells O
, O
which O
are O
not O
reduced O
in O
class O
I O
expression O
. O

PURPOSE O
: O
To O
evaluate O
the O
kinetics O
of O
erythropoietin I-GENE
( O
EPO I-GENE
) O
production O
and O
address O
the O
pathogenesis O
of O
anemia O
of O
prematurity O
, O
we O
measured O
EPO I-GENE
levels O
in O
infants O
during O
the O
first O
year O
of O
life O
. O

The O
nerve I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
gene I-GENE
( O
NGFB I-GENE
) O
belongs O
to O
a O
conserved O
syntenic O
group O
on O
human O
chromosome O
1 O
and O
mouse O
Chromosome O
3 O
. O

Furthermore O
, O
an O
upstream O
element O
, O
collagen O
element O
I O
(- O
370 O
/- O
344 O
), O
which O
shares O
homology O
with O
the O
LAP I-GENE
binding O
cis O
- O
element O
of O
the O
albumin I-GENE
promoter I-GENE
( O
9 O
of O
13 O
bp O
) O
is O
described O
. O

Number O
and O
size O
of O
silver O
- O
stained O
nucleoli O
( O
Ag O
- O
NOR O
clusters O
) O
in O
canine O
seminomas O
: O
correlation O
with O
histological O
features O
and O
tumour O
behaviour O
. O

We O
speculate O
that O
mast O
cell O
degranulation O
may O
be O
involved O
in O
the O
pathogenesis O
of O
necrobiosis O
by O
altering O
fibroblast O
enzyme O
activity O
and O
/ O
or O
producing O
prolonged O
inflammatory O
reactions O
. O

Molecular O
cloning O
of O
a O
cysteine I-GENE
synthase I-GENE
cDNA I-GENE
from O
Citrullus O
vulgaris O
( O
watermelon O
) O
by O
genetic O
complementation O
in O
an O
Escherichia O
coli O
Cys O
- O
auxotroph O
. O

In O
earlier O
studies O
we O
identified O
several O
regulatory O
elements O
that O
control O
transcriptional O
activation O
and O
aerobic O
repression O
of O
one O
of O
these O
genes O
, O
COX5b I-GENE
. O

Although O
elevated O
serum O
levels O
of O
antibodies O
to O
the O
nicotinic I-GENE
acetylcholine I-GENE
receptor I-GENE
( O
nAChR I-GENE
) O
have O
been O
reported O
in O
neuroleptic O
treated O
patients O
with O
tardive O
dyskinesia O
, O
such O
antibodies O
have O
not O
been O
determined O
in O
comparable O
nondyskinetic O
patients O
. O

The O
tumor O
suppressor O
and O
transcriptional O
factor O
p53 I-GENE
is O
a O
phosphorylated O
protein O
. O

This O
DNA O
containing O
promoter O
activity O
has O
been O
sequenced O
in O
its O
entirety O
and O
found O
to O
contain O
multiple O
putative O
regulatory O
sites O
. O

However O
, O
Southern O
blot O
and O
karyotype O
analyses O
did O
not O
reveal O
any O
significant O
changes O
in O
copy O
number O
or O
gross O
rearrangements O
of O
the O
p53 I-GENE
gene I-GENE
in O
any O
of O
the O
p53 I-GENE
- I-GENE
cell O
lines O
. O

HupI I-GENE
showed O
strong O
identity O
to O
rubredoxin I-GENE
and O
rubredoxin I-GENE
- I-GENE
like I-GENE
proteins I-GENE
from O
many O
other O
bacteria O
. O

The O
PCr O
resynthesis O
rate O
( O
P O
< O
0 O
. O
01 O
) O
and O
the O
effective O
maximal O
rate O
of O
mitochondrial O
ATP O
synthesis O
( O
P O
< O
0 O
. O
05 O
) O
also O
improved O
. O

An O
examination O
was O
performed O
in O
15 O
patients O
who O
had O
developed O
pronounced O
osteomalacia O
following O
gastric O
resection O
. O

However O
, O
regional O
MVO2 O
increased O
to O
about O
the O
same O
extent O
in O
the O
CFX O
( O
from O
6 O
. O
0 O
+/- O
0 O
. O
7 O
to O
12 O
. O
4 O
+/- O
0 O
. O
9 O
ml O
O2 O
. O
min O
- O
1 O
times O
100 O
g O
- O
1 O
) O
and O
the O
LAD O
region O
( O
from O
7 O
. O
0 O
+/- O
0 O
. O
6 O
to O
14 O
. O
5 O
+/- O
1 O
. O
3 O
ml O
O2 O
. O
min O
- O
1 O
times O
100 O
g O
- O
1 O
). O

IGF I-GENE
I I-GENE
and O
insulin I-GENE
receptors I-GENE
are O
homologous O
proteins O
that O
function O
in O
distinct O
physiological O
pathways O
. O

Immunodepression O
was O
combined O
with O
the O
increase O
of O
glucocorticoid O
activity O
of O
adrenal O
cortex O
, O
while O
no O
significant O
changes O
in O
thyroid O
hormones O
were O
registered O
. O

Tryptic O
cleavage O
and O
peptide O
sequence O
analysis O
demonstrated O
that O
the O
98 O
- O
kD O
protein O
is O
identical O
to O
a O
recently O
cloned O
protein O
, O
special I-GENE
A I-GENE
- I-GENE
T I-GENE
- I-GENE
rich I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
SATB1 I-GENE
), O
that O
binds O
selectively O
to O
nuclear O
matrix O
/ O
scaffold O
- O
associated O
regions O
of O
DNA O
( O
MARs O
/ O
SARs O
). O

Aberrant O
protein O
phosphorylation O
at O
tyrosine O
is O
responsible O
for O
the O
growth O
- O
inhibitory O
action O
of O
pp60v I-GENE
- I-GENE
src I-GENE
expressed O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Acute O
pancreatitis O
: O
a O
multisystem O
disease O
. O

Alginate O
biosynthesis O
is O
controlled O
by O
a O
complex O
regulatory O
mechanism O
. O

The O
sequence O
upstream O
of O
the O
rhlA I-GENE
promoter I-GENE
contains O
two O
inverted O
repeats O
which O
define O
putative O
binding O
sites O
for O
the O
RhlR I-GENE
regulator I-GENE
. O

We O
have O
examined O
by O
in O
vitro O
footprinting O
a O
region O
located O
downstream O
of O
the O
human O
immunodeficiency O
virus O
, O
type O
1 O
( O
HIV O
- O
1 O
) O
promoter O
found O
to O
be O
hypersensitive O
to O
DNase I-GENE
I I-GENE
digestion O
in O
vivo O
. O

Heparin O
had O
no O
effect O
on O
rAC I-GENE
- I-GENE
st I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
phosphatase I-GENE
activity O
, O
while O
the O
B O
subunit O
- O
containing O
forms O
were O
stimulated O
2 O
- O
3 O
- O
fold O
. O

The O
relative O
abundance O
of O
each O
alternatively O
spliced O
mRNA O
was O
determined O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
in O
various O
human O
tissues O
and O
cell O
lines O
. O

BACKGROUND O
AND O
DESIGN O
: O
Fifty O
- O
nine O
melanocytic O
nevi O
with O
eccentric O
foci O
of O
hyperpigmentation O
(" O
small O
dark O
dots O
") O
that O
measured O
primarily O
1 O
to O
2 O
mm O
in O
diameter O
were O
prospectively O
examined O
to O
determine O
the O
histologic O
correlates O
of O
the O
dark O
dots O
. O

The O
retention O
index O
of O
201Tl O
SPECT O
is O
a O
useful O
indicator O
of O
metastatic O
potential O
, O
thereby O
facilitating O
the O
prediction O
of O
prognosis O
, O
and O
provides O
insight O
into O
the O
relationship O
between O
201Tl O
uptake O
and O
malignancy O
. O

The O
central O
globular O
domain O
is O
highly O
similar O
to O
those O
regions O
from O
other O
H1 I-GENE
molecules I-GENE
, O
and O
the O
carboxyl O
- O
terminal O
domain O
contains O
a O
repeating O
hexapeptide O
motif O
, O
variants O
of O
which O
are O
conserved O
among O
H1 I-GENE
molecules I-GENE
. O

The O
location O
and O
approximate O
length O
of O
the O
intron O
are O
conserved O
in O
both O
the O
tomato O
and O
Arabidopsis O
genes O
, O
with O
the O
intron O
separating O
the O
' O
nose O
' O
region O
( O
encoded O
by O
exon O
1 O
) O
from O
the O
central O
globular O
domain O
( O
exon O
2 O
). O

The O
topology O
and O
chain O
folding O
of O
the O
beta O
subunits O
in O
the O
artifactual O
beta O
60 O
capsid O
are O
similar O
to O
the O
native I-GENE
alpha I-GENE
3 I-GENE
beta I-GENE
60 I-GENE
enzyme I-GENE
. O

A O
single O
NMSC O
was O
present O
in O
69 O
. O
4 O
%, O
two O
in O
16 O
%, O
three O
in O
6 O
. O
4 O
%, O
four O
in O
3 O
. O
5 O
%, O
five O
to O
nine O
in O
4 O
. O
2 O
%, O
and O
0 O
. O
5 O
% O
had O
ten O
or O
more O
. O

A O
constitutive O
mutant O
form O
with O
a O
single O
substitution O
( O
V88A O
) O
in O
the O
amino O
- O
terminal O
( O
response O
regulator O
) O
region O
was O
used O
. O

Comparisons O
of O
the O
four O
operon O
control O
regions O
studied O
indicate O
that O
the O
NarL I-GENE
heptamers I-GENE
are O
arranged O
with O
diverse O
orientations O
and O
spacing O
. O

Direct O
binding O
and O
competition O
assays O
using O
30 O
- O
mer O
oligonucleotide O
probes O
representing O
the O
individual O
CBF1 I-GENE
binding I-GENE
sites I-GENE
indicated O
that O
CBF1 I-GENE
bound O
less O
efficiently O
to O
the O
CD23 I-GENE
promoter I-GENE
and O
the O
EBV I-GENE
LMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sites I-GENE
than O
to O
the O
Cp I-GENE
site I-GENE
. O

We O
have O
found O
a O
satisfactory O
reproducibility O
in O
vitro O
( O
T1 O
: O
1 O
. O
9 O
%; O
T2 O
: O
6 O
. O
2 O
%), O
while O
the O
reproducibility O
was O
less O
satisfactory O
in O
vivo O
( O
T1 O
: O
16 O
. O
4 O
%; O
T2 O
: O
13 O
. O
4 O
%). O

The O
two O
ParA I-GENE
proteins I-GENE
that O
are O
produced O
as O
a O
result O
of O
independent O
translation O
initiation O
at O
two O
different O
start O
codons O
within O
the O
same O
open O
reading O
frame O
were O
overexpressed O
in O
Escherichia O
coli O
and O
partially O
purified O
. O

To O
get O
further O
insights O
into O
the O
molecular O
mechanisms O
that O
control O
tal I-GENE
- I-GENE
1 I-GENE
expression O
, O
we O
have O
isolated O
5 O
' O
sequences O
of O
the O
murine O
gene O
and O
compared O
them O
to O
their O
human O
counterparts O
. O

CONCLUSION O
: O
Sonographic O
angiography O
has O
a O
possible O
role O
in O
the O
detection O
of O
small O
nodules O
in O
patients O
with O
CRF O
. O

Each O
expressed O
domain O
, O
as O
well O
as O
FKBP I-GENE
- I-GENE
33 I-GENE
itself O
, O
possesses O
peptidyl I-GENE
- I-GENE
prolyl I-GENE
cis I-GENE
- I-GENE
trans I-GENE
isomerase I-GENE
activity O
, O
though O
with O
much O
lower O
specific O
activities O
than O
FKBP I-GENE
- I-GENE
12 I-GENE
. O

The O
first O
85 O
nt O
upstream O
of O
the O
transcription O
initiation O
site O
of O
the O
mouse I-GENE
desmin I-GENE
gene I-GENE
, O
which O
contain O
an O
E O
box O
( O
E1 O
), O
the O
binding O
site O
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
myogenic I-GENE
regulators I-GENE
, O
are O
sufficient O
to O
confer O
low O
level O
muscle O
- O
specific O
expression O
. O

The O
acfD I-GENE
gene I-GENE
encompasses O
254 O
nt O
that O
are O
predicted O
to O
encode O
an O
88 O
- O
amino O
- O
acid O
( O
aa O
) O
protein O
. O

We O
find O
that O
beta I-GENE
II I-GENE
PKC I-GENE
phosphorylates O
nuclear I-GENE
envelope I-GENE
lamin I-GENE
B I-GENE
at O
10 O
- O
20 O
times O
the O
rate O
of O
alpha I-GENE
PKC I-GENE
, O
whereas O
both O
kinases O
phosphorylate O
soluble I-GENE
lamin I-GENE
B I-GENE
at O
similar O
rates O
. O

Regulation O
of O
parathyroid I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
PTHrP I-GENE
) O
gene O
expression O
. O

These O
results O
demonstrate O
that O
a O
diverse O
set O
of O
carboxyl O
- O
terminal O
sequence O
motifs O
and O
posttranslational O
modifications O
lead O
to O
functional O
Ras I-GENE
proteins I-GENE
in O
yeast O
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Abl I-GENE
activates O
c I-GENE
- I-GENE
myc I-GENE
transcription O
indirectly O
with O
no O
requirement O
for O
DNA O
binding O
by O
c I-GENE
- I-GENE
Abl I-GENE
. O

Long O
- O
latency O
: O
locked O
units O
responded O
to O
shocks O
with O
little O
jitter O
and O
long O
latency O
( O
4 O
- O
11 O
ms O
). O

The O
highly O
conserved O
ninth O
heptad O
, O
which O
is O
involved O
in O
heterodimerization O
, O
appears O
to O
participate O
in O
the O
receptor O
- O
inhibitor O
interaction O
, O
suggesting O
that O
the O
inhibitor O
is O
a O
related O
member O
of O
the O
receptor O
gene O
family O
. O

Here O
we O
show O
that O
for O
expression O
of O
snRNA O
genes O
in O
maize O
, O
a O
monocotyledonous O
plant O
, O
the O
USE O
and O
TATA O
elements O
are O
essential O
, O
but O
not O
sufficient O
, O
for O
transcription O
. O

Extensive O
DNA O
rearrangement O
occurs O
during O
the O
development O
of O
the O
somatic O
macronucleus O
from O
the O
germ O
line O
micronucleus O
in O
ciliated O
protozoans O
. O

An O
in O
vitro O
binding O
site O
selection O
procedure O
was O
used O
to O
determine O
DNA O
sequences O
preferentially O
bound O
by O
wild I-GENE
- I-GENE
type I-GENE
HLF I-GENE
and O
chimeric O
E2A I-GENE
- O
HLF I-GENE
proteins O
isolated O
from O
various O
t O
( O
17 O
; O
19 O
)- O
bearing O
leukemias O
. O

The O
Oct I-GENE
- I-GENE
2 I-GENE
glutamine O
- O
rich O
and O
proline O
- O
rich O
activation O
domains O
can O
synergize O
with O
each O
other O
or O
duplicates O
of O
themselves O
to O
activate O
transcription O
. O

Binding O
of O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( O
snRNP O
) O
to O
the O
pre O
- O
mRNA O
is O
an O
early O
and O
important O
step O
in O
spliceosome O
assembly O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Dbf8p I-GENE
plays O
an O
essential O
role O
in O
chromosome O
segregation O
. O

Ariga O
, O
Biochem O
. O

Our O
results O
indicate O
that O
the O
KRAB I-GENE
domain I-GENE
present O
in O
the O
non O
- O
finger O
region O
of O
many O
ZFP I-GENE
genes I-GENE
quenches O
transcription O
possibly O
due O
to O
specific O
protein O
- O
protein O
interactions O
between O
the O
KRAB I-GENE
- I-GENE
A I-GENE
domain I-GENE
and O
components O
of O
the O
proximal O
transcriptional O
apparatus O
. O

Marine O
oils O
and O
cardiovascular O
reactivity O
. O

The O
diagnostic O
significance O
of O
creatine I-GENE
phosphokinase I-GENE
antibodies O
in O
the O
cardiac O
muscle O
in O
non O
- O
coronarogenic O
myocardial O
diseases O

According O
to O
the O
results O
of O
assays O
obtained O
with O
the O
use O
of O
assay O
systems O
ORTHO O
ELISA O
and O
ABBOTT O
HCV O
EIA O
( O
USA O
), O
the O
detection O
rate O
of O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
C100 I-GENE
- I-GENE
3 I-GENE
among O
primary O
blood O
donors O
in O
Moscow O
was O
1 O
. O
37 O
% O
and O
was O
not O
different O
from O
that O
among O
HBsAg I-GENE
carriers O
( O
1 O
. O
8 O
%) O
and O
among O
donors O
with O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
C100 I-GENE
- I-GENE
3 I-GENE
in O
the O
blood O
( O
1 O
. O
6 O
%) O
( O
p O
< O
0 O
. O
01 O
). O

We O
examined O
the O
hypothesis O
that O
the O
coronary O
vasomotor O
responses O
to O
etomidate O
( O
ETO O
), O
propofol O
( O
PRO O
), O
and O
sodium O
thiopental O
( O
STP O
) O
are O
mediated O
through O
contrasting O
effects O
on O
the O
resting O
nitric O
oxide O
( O
NO O
)- O
dependent O
vasodilator O
tone O
that O
opposes O
adrenergic O
vasoconstrictor O
activity O
in O
the O
intact O
dog O
. O

Significant O
alterations O
in O
CBC O
results O
and O
serum I-GENE
CRP I-GENE
concentration O
, O
compared O
with O
baseline O
values O
, O
were O
lacking O
in O
dogs O
of O
the O
control O
group O
. O

These O
alternative O
splice O
variants O
were O
detected O
in O
RNA O
isolated O
from O
several O
sources O
, O
including O
primary O
leptomeningeal O
tissue O
and O
an O
established O
line O
of O
leptomeningeal O
cells O
( O
LMC O
). O

Roux O
- O
en O
- O
Y O
gastroenterostomy O
severely O
disturbs O
emptying O
of O
the O
gallbladder O
. O

Surface O
- O
coil O
experiments O
on O
phantoms O
and O
on O
human O
calf O
muscles O
in O
vivo O
are O
presented O
. O

Large O
interpatient O
variation O
in O
peak O
PCZ O
plasma O
levels O
( O
91 O
- O
3215 O
ng O
/ O
ml O
) O
was O
seen O
, O
with O
the O
plasma O
half O
- O
life O
( O
t1 O
/ O
2 O
alpha O
) O
being O
approximately O
57 O
min O
in O
patients O
given O
135 O
- O
180 O
mg O
/ O
m2 O
PCZ O
. O

The O
maximal O
effect O
was O
seen O
at O
100 O
ng O
/ O
ml O
EGF I-GENE
, O
with O
a O
time O
lag O
of O
about O
5 O
h O
. O

KAR1 I-GENE
encodes O
an O
essential O
component O
of O
the O
yeast O
spindle O
pole O
body O
( O
SPB O
) O
that O
is O
required O
for O
karyogamy O
and O
SPB O
duplication O
. O

CDC31 I-GENE
is O
required O
for O
SPB O
duplication O
and O
encodes O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
that O
is O
most O
closely O
related O
to O
caltractin I-GENE
/ O
centrin I-GENE
, O
a O
protein O
associated O
with O
the O
Chlamydomonas O
basal O
body O
. O

During O
transcript O
elongation O
, O
the O
sizes O
of O
the O
DNA O
footprint O
and O
the O
single O
- O
stranded O
transcription O
bubble O
vary O
markedly O
among O
transcription O
complexes O
halted O
at O
different O
template O
positions O
. O

The O
newly O
recognised O
skeletogenital O
syndrome O
. O

All O
our O
patients O
had O
polyps O
, O
23 O
( O
54 O
%) O
had O
asthma O
, O
12 O
( O
27 O
%) O
had O
aspirin O
sensitivity O
, O
20 O
( O
65 O
%) O
had O
eosinophilia O
, O
and O
9 O
( O
69 O
%) O
had O
increased O
total O
IgE I-GENE
levels O
. O

Ras I-GENE
- I-GENE
and I-GENE
ultra I-GENE
- I-GENE
violet I-GENE
- I-GENE
responsive I-GENE
protein I-GENE
kinases I-GENE
that O
phosphorylate O
c I-GENE
- I-GENE
Jun I-GENE
on O
serine O
residues O
at O
positions O
63 O
and O
73 O
and O
stimulate O
its O
transcriptional O
activity O
have O
been O
identified O
. O

A O
short O
sequence O
surrounding O
the O
major O
JNK I-GENE
phosphorylation O
site O
of O
c I-GENE
- I-GENE
Jun I-GENE
is O
conserved O
in O
c I-GENE
- I-GENE
Fos I-GENE
and O
is O
part O
of O
its O
activation O
domain O
, O
suggesting O
that O
c I-GENE
- I-GENE
Fos I-GENE
may O
be O
similarly O
regulated O
. O

c I-GENE
- I-GENE
Fos I-GENE
transcriptional O
activity O
stimulated O
by O
H I-GENE
- I-GENE
Ras I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
distinct O
from O
JNK I-GENE
and O
ERK I-GENE
. O

A O
new O
generation O
of O
information O
retrieval O
tools O
for O
biologists O
: O
the O
example O
of O
the O
ExPASy O
WWW O
server O
. O

Essential O
features O
of O
this O
model O
are O
bending O
of O
the O
DNA O
double O
helix O
and O
contact O
of O
operator O
sites O
with O
repressor O
domains O
bearing O
sequence O
homologies O
with O
the O
helix O
- O
turn O
- O
helix O
( O
HTH O
) O
motifs O
of O
other O
DNA O
- O
binding O
proteins O
. O

The O
partial O
ORF O
was O
found O
to O
be O
identical O
to O
the O
C O
terminus O
of O
HrpJ2 I-GENE
. O

The O
partial O
ORF O
was O
found O
to O
be O
identical O
to O
the O
C O
terminus O
of O
HrpJ2 I-GENE
. O

The O
binding O
of O
transcription O
factor O
AP I-GENE
- I-GENE
1 I-GENE
and O
vitamin I-GENE
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
to O
the O
composite O
AP I-GENE
- I-GENE
1 I-GENE
plus I-GENE
vitamin I-GENE
- I-GENE
D I-GENE
- I-GENE
responsive I-GENE
promoter I-GENE
region O
( O
AP I-GENE
- I-GENE
1 I-GENE
+ I-GENE
VDRE I-GENE
) O
of O
the O
human I-GENE
osteocalcin I-GENE
gene I-GENE
was O
characterized O
in O
osteocalcin I-GENE
- O
producing O
( O
MG O
- O
63 O
) O
and O
non O
- O
producing O
( O
U2 O
- O
Os O
, O
SaOs O
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

Rapid O
detection O
of O
this O
mutation O
is O
achieved O
by O
restriction O
digestion O
of O
PCR O
- O
amplified O
genomic O
DNA O
; O
a O
mismatch O
primer O
combined O
with O
the O
point O
mutation O
creates O
a O
Tru9I I-GENE
restriction I-GENE
site I-GENE
. O

Wild I-GENE
type I-GENE
and I-GENE
mutant I-GENE
Epo I-GENE
cDNAs I-GENE
were O
transiently O
expressed O
at O
high O
levels O
in O
COS1 O
and O
COS7 O
cells O
. O

OBJECTIVE O
-- O
To O
assess O
the O
risk O
of O
hepatitis O
A O
in O
international O
travelers O
and O
to O
recommend O
preventive O
measures O
. O

The O
bactericidal O
effect O
of O
disinfectants O
against O
biofilm O
cells O
was O
found O
to O
be O
considerably O
enhanced O
by O
increasing O
the O
concentrations O
of O
the O
disinfectants O
. O

Expression O
of O
ME31B I-GENE
cDNA I-GENE
in O
S O
. O
pombe O
suppresses O
the O
ste13 I-GENE
mutation O
. O

Use O
of O
Medi O
- O
Jector O
EZ O
dermojet O
for O
anesthesia O
in O
minor O
surgery O

2 O
. O

The O
immune O
response O
of O
past O
- O
infection O
of O
cytomegalovirus O
in O
the O
patients O
of O
RTID O
is O
rather O
remarkable O
. O

Acupuncture O
effect O
on O
deep O
receptors O
was O
not O
limited O
to O
one O
point O
but O
within O
a O
certain O
area O
, O
namely O
distant O
effect O
existed O
. O

Reduced O
NK O
activity O
correlates O
with O
active O
disease O
in O
HIV O
- O
patients O
with O
multidrug O
- O
resistant O
pulmonary O
tuberculosis O
. O

Smoking O
history O
and O
awake O
oxygen O
saturation O
( O
SaO2 O
) O
was O
recorded O
in O
all O
of O
them O
. O

( O
LH I-GENE
P O
< O
0 O
. O
05 O
, O
LH I-GENE
/ O
FSH I-GENE
P O
< O
0 O
. O
01 O
). O

The O
relative O
R O
- O
and O
L O
- O
brain O
weights O
were O
found O
to O
be O
inversely O
related O
to O
the O
relative O
R O
- O
L O
brain O
weight O
only O
in O
the O
RH O
female O
cats O
with O
R O
- O
L O
brain O
weight O
smaller O
than O
zero O
( O
testosterone O
in O
males O
, O
estrogen O
in O
females O
). O

This O
mode O
of O
ternary O
complex O
formation O
is O
in O
contrast O
to O
the O
one O
seen O
in O
the O
promoter O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
protooncogene I-GENE
, O
where O
formation O
of O
the O
ternary O
complex O
is O
dependent O
on O
the O
prior O
assembly O
of O
the O
serum I-GENE
response I-GENE
factor I-GENE
- I-GENE
DNA I-GENE
binary I-GENE
complex I-GENE
. O

The O
LTR O
- O
binding O
activities O
of O
VBP I-GENE
, O
a1 I-GENE
/ I-GENE
EBP I-GENE
, O
and O
B I-GENE
- I-GENE
cell I-GENE
nuclear I-GENE
extract I-GENE
protein I-GENE
were O
compared O
and O
mapped O
by O
gel O
shift O
, O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
methylation O
interference O
assays O
. O

These O
results O
suggest O
that O
leader O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
complementary O
sequences O
. O

These O
results O
suggest O
that O
leader O
- O
mRNA O
fusion O
in O
coronavirus O
transcription O
does O
not O
require O
direct O
RNA O
- O
RNA O
interaction O
between O
complementary O
sequences O
. O

Vaccinia O
virus O
- O
expressed O
, O
purified O
full I-GENE
- I-GENE
length I-GENE
HPV I-GENE
- I-GENE
16 I-GENE
and I-GENE
BPV I-GENE
- I-GENE
1 I-GENE
E2 I-GENE
proteins I-GENE
bound O
a O
consensus O
E2 I-GENE
site I-GENE
with O
high O
specific O
affinities O
( O
Kd O
= O
approximately O
10 O
(- O
9 O
) O
M O
) O
and O
stimulated O
in O
vitro O
transcription O
up O
to O
six O
- O
to O
eightfold O
. O

This O
alternatively O
spliced O
transcript O
contained O
an O
open O
reading O
frame O
extending O
from O
the O
upstream O
J O
alpha O
11 O
- O
2 O
region O
to O
82 O
nucleotides O
downstream O
of O
the O
beginning O
of O
the O
TCR I-GENE
C I-GENE
alpha I-GENE
region I-GENE
, O
and O
potentially O
encoded O
a O
36 O
amino O
acid O
polypeptide O
. O

In O
HeLa O
x O
fibroblast O
cell O
hybrids O
its O
expression O
correlates O
with O
tumorigenicity O
. O

Demographic O
characteristics O
and O
risk O
factor O
data O
for O
76 O
, O
672 O
clients O
were O
studied O
to O
characterize O
the O
distribution O
of O
infection O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
and O
the O
use O
of O
counseling O
and O
testing O
facilities O
in O
Houston O
, O
Tex O
. O

Results O
indicate O
that O
KNM O
- O
LU O
335 O
differs O
from O
both O
human O
and O
chimpanzee O
M1s O
in O
relative O
distances O
( O
measured O
in O
three O
dimensions O
) O
between O
crown O
fissure O
termini O
. O

We O
describe O
49 O
cases O
with O
papillary O
tumor O
< O
1 O
cm O
. O

Comparison O
with O
the O
bovine O
gene O
showed O
that O
the O
5 O
'- O
flanking O
region O
of O
the O
hATP1 I-GENE
gene I-GENE
has O
an O
unconserved O
guanine O
- O
cytosine O
( O
GC O
) O
rich O
region O
, O
including O
several O
binding O
motifs O
of O
transcriptional O
factors O
, O
such O
as O
Sp1 I-GENE
, O
AP I-GENE
- I-GENE
2 I-GENE
, O
and O
GCF I-GENE
. O

Structure O
, O
promoter O
analysis O
and O
chromosomal O
assignment O
of O
the O
human I-GENE
APEX I-GENE
gene I-GENE
. O

The O
polyubiquitin I-GENE
gene I-GENE
was O
transcribed O
throughout O
the O
Volvox O
life O
cycle O
with O
peaks O
in O
the O
1 O
. O
6 O
- O
kb O
mRNA O
levels O
during O
pre O
- O
cleavage O
, O
cleavage O
, O
and O
post O
- O
inversion O
. O

Thus O
, O
in O
stress O
- O
induced O
arrhythmic O
disease O
as O
well O
as O
in O
ischemic O
heart O
disease O
, O
the O
main O
pathogenetic O
links O
are O
outside O
the O
heart O
, O
but O
they O
differ O
from O
those O
observed O
in O
ischemia O
. O

Here O
, O
we O
present O
genetic O
evidence O
in O
Saccharomyces O
cerevisiae O
for O
a O
functional O
interaction O
between O
the O
DEAH I-GENE
protein I-GENE
Prp16 I-GENE
, O
and O
the O
U6 I-GENE
and O
U2 I-GENE
spliceosomal I-GENE
snRNAs I-GENE
. O

The O
consensus O
gene O
order O
deduced O
by O
combining O
data O
from O
both O
crosses O
is O
D2Mit1 I-GENE
-( O
Dbh I-GENE
, O
Notch1 I-GENE
)-( O
Col5a1 I-GENE
, O
Rxra I-GENE
)- O
Spna2 I-GENE
- O
Ab I-GENE
l I-GENE
-( O
Ak1 I-GENE
, O
Fpgs I-GENE
)- O
( O
Grp78 I-GENE
, O
Pbx3 I-GENE
)-( O
Epb7 I-GENE
. I-GENE
2 I-GENE
, I-GENE
Hc I-GENE
, I-GENE
Gsn I-GENE
)- O
Acra I-GENE
. O

The O
high O
level O
of O
transformation O
- O
associated O
deletions O
in O
the O
human O
YACs O
was O
reduced O
over O
10 O
- O
fold O
when O
the O
host O
was O
a O
recombination O
- O
deficient O
strain O
deleted O
for O
the O
RAD52 I-GENE
gene I-GENE
. O

In O
addition O
, O
the O
megabase O
region O
surrounding O
the O
dagA I-GENE
locus I-GENE
was O
mapped O
. O

These O
mutants O
had O
deletions O
of O
the O
extreme O
amino O
- O
terminal O
residues O
as O
far O
as O
amino O
acid O
residue O
30 O
. O

SECONDARY O
OUTCOME O
MEASURE O
-- O
Double O
- O
blind O
caffeine O
- O
withdrawal O
evaluation O
. O

Elimination O
of O
natural O
antibodies O
in O
discordant O
xenografts O

An O
8 O
- O
bp O
sequence O
( O
ATTTCAAA O
) O
within O
the O
protected O
region O
shares O
significant O
homology O
with O
promoter O
sequences O
required O
for O
ethylene O
responsiveness O
from O
the O
tomato O
fruit O
- O
ripening O
E4 I-GENE
gene I-GENE
. O

We O
present O
evidence O
that O
DNA I-GENE
polymerase I-GENE
delta I-GENE
of I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
, O
an O
enzyme O
that O
is O
essential O
for O
viability O
and O
chromosomal O
replication O
, O
is O
also O
required O
for O
base O
excision O
repair O
of O
exogenous O
DNA O
methylation O
damage O
. O

We O
have O
identified O
two O
Marek O
' O
s O
Disease O
Virus O
( O
MDV O
) O
genes O
within O
the O
EcoRI I-GENE
- I-GENE
B I-GENE
fragment I-GENE
of O
MDV O
- O
GA O
genomic O
DNA O
. O

Cowpox O
virus O
contains O
two O
copies O
of O
an O
early I-GENE
gene I-GENE
encoding O
a O
soluble O
secreted O
form O
of O
the O
type I-GENE
II I-GENE
TNF I-GENE
receptor I-GENE
. O

To O
determine O
whether O
P35 I-GENE
could O
activate O
the O
39k O
promoter O
in O
the O
absence O
of O
IE1 I-GENE
, O
the O
p35 I-GENE
open O
reading O
frame O
was O
cloned O
under O
the O
control O
of O
the O
ie1 I-GENE
promoter I-GENE
. O

Mutagenesis O
of O
each O
NRF I-GENE
- I-GENE
1 I-GENE
motif I-GENE
in O
the O
ALAS I-GENE
promoter I-GENE
gave O
substantially O
lowered O
levels O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
expression O
, O
whereas O
mutagenesis O
of O
both O
NRF I-GENE
- I-GENE
1 I-GENE
motifs I-GENE
resulted O
in O
the O
almost O
complete O
loss O
of O
expression O
. O

DNase I-GENE
I I-GENE
footprinting O
analysis O
indicated O
that O
DREF I-GENE
binds O
to O
the O
24 O
- O
bp O
DRE O
region O
of O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
in O
which O
8 O
- O
bp O
palindromic O
sequences O
are O
centered O
. O

Novel O
8 O
- O
base O
pair O
sequence O
( O
Drosophila O
DNA O
replication O
- O
related O
element O
) O
and O
specific O
binding O
factor O
involved O
in O
the O
expression O
of O
Drosophila O
genes O
for O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
and O
proliferating I-GENE
cell I-GENE
nuclear I-GENE
antigen I-GENE
. O

In O
addition O
, O
a O
microsatellite O
repeat O
polymorphism O
with O
a O
heterozygosity O
of O
71 O
% O
at O
the O
RET I-GENE
locus I-GENE
and O
a O
restriction O
fragment O
length O
polymorphism O
with O
a O
heterozygosity O
of O
42 O
% O
detected O
by O
a O
lambda O
clone O
from O
the O
D10S94 I-GENE
locus I-GENE
have O
been O
developed O
for O
high O
- O
resolution O
genetic O
linkage O
mapping O
and O
predictive O
diagnostic O
testing O
. O

However O
, O
tyrA I-GENE
can O
be O
expressed O
efficiently O
from O
an O
internal O
promoter O
which O
appears O
to O
lie O
within O
the O
3 O
' O
portion O
of O
aroF I-GENE
. O

Within O
the O
span O
of O
attenuator O
region O
encoding O
the O
three O
stem O
- O
loop O
structures O
of O
mRNA O
secondary O
configuration O
, O
hot O
spots O
of O
base O
- O
residue O
divergence O
were O
localized O
to O
looped O
- O
out O
regions O
. O

Most O
, O
however O
, O
would O
tell O
the O
spouse O
the O
full O
truth O
about O
both O
diagnosis O
and O
prognosis O
. O

Previous O
studies O
showed O
that O
mutations O
in O
the O
6K O
protein O
led O
to O
the O
slow O
release O
of O
aberrant O
, O
multi O
- O
cored O
infectious O
virions O
. O

Metabolism O
of O
calcium O
and O
vitamin O
D3 O
in O
patients O
with O
acute O
tubulointerstitial O
nephritis O
: O
a O
study O
of O
41 O
patients O
with O
nephropathia O
epidemica O
. O

Furthermore O
, O
this O
study O
demonstrates O
that O
reduced O
inotropy O
with O
timolol O
helped O
uniform O
local O
contraction O
as O
estimated O
by O
the O
increased O
LONG O
/ O
CIRC O
ratio O
, O
a O
transition O
that O
could O
improve O
contraction O
efficacy O
. O

Effects O
of O
moderate O
hypercapnia O
on O
hypothermia O
induced O
by O
cold O
He O
- O
O2 O
in O
rats O
. O

The O
RFLP O
patterns O
of O
the O
isolates O
from O
six O
of O
these O
patients O
remained O
essentially O
unchanged O
( O
two O
strains O
showed O
one O
additional O
band O
) O
despite O
the O
development O
of O
drug O
resistance O
. O

We O
recommend O
that O
ovarian O
stimulation O
is O
done O
only O
if O
there O
is O
a O
valid O
indication O
after O
proper O
assessment O
of O
the O
ovaries O
, O
and O
that O
women O
who O
have O
had O
ovarian O
stimulation O
are O
followed O
for O
longer O
than O
at O
present O
. O

A23187 O
did O
not O
induce O
any O
modifications O
of O
the O
endolymphatic O
potential O
, O
the O
ampullar O
direct O
current O
or O
the O
frequency O
of O
the O
evoked O
afferent O
spikes O
. O

Activation O
of O
the O
aboral O
ectoderm I-GENE
- I-GENE
specific I-GENE
Spec2a I-GENE
gene I-GENE
in O
blastula O
- O
stage O
sea O
urchin O
embryos O
requires O
an O
upstream O
regulatory O
region O
that O
is O
part O
of O
a O
repetitive O
sequence O
element O
( O
RSR O
) O
associated O
with O
all O
Spec1 I-GENE
/ O
Spec2 I-GENE
genes O
. O

A O
transcript O
of O
about O
2 O
kb O
is O
expected O
for O
each O
PPO I-GENE
. O

Mutations O
in O
a O
region O
located O
15 O
to O
30 O
bp O
downstream O
from O
the O
major O
transcription O
start O
site O
that O
shows O
good O
homology O
to O
a O
sequence O
in O
the O
first O
exon O
of O
c I-GENE
- I-GENE
fos I-GENE
implicated O
as O
a O
negative O
regulatory O
element O
resulted O
in O
a O
significant O
increase O
in O
basal O
gene O
expression O
but O
did O
not O
affect O
regulation O
. O

Salazopyrine O
desensitization O

During O
exercise O
, O
the O
Pes O
- O
Ves O
relation O
was O
shifted O
toward O
the O
left O
and O
the O
slope O
[ O
end O
- O
systolic O
elastance O
( O
Ees O
)] O
increased O
from O
7 O
. O
7 O
+/- O
2 O
. O
8 O
to O
12 O
. O
7 O
+/- O
4 O
. O
2 O
( O
SD O
) O
mmHg O
/ O
ml O
( O
P O
< O
0 O
. O
05 O
). O

We O
show O
that O
HRI I-GENE
and O
dsRNA I-GENE
- I-GENE
PK I-GENE
phosphorylate O
yeast I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
in O
vitro O
and O
in O
vivo O
and O
functionally O
substitute O
for O
GCN2 I-GENE
protein I-GENE
to O
stimulate O
GCN4 I-GENE
translation O
in O
yeast O
. O

Double O
- O
staining O
confirmed O
that O
there O
were O
separate O
populations O
of O
CD68 I-GENE
- O
positive O
macrophages O
and O
XIIIa I-GENE
- O
positive O
dendrocytes O
. O

Interestingly O
, O
in O
the O
adult O
, O
transgene O
expression O
patterns O
within O
the O
cerebellum O
in O
two O
lines O
appeared O
to O
mark O
distinct O
anterior O
- O
posterior O
compartments O
. O

Southern O
analysis O
on O
genomic O
DNA O
isolated O
from O
tissues O
and O
cell O
lines O
from O
several O
mouse O
strains O
using O
mCD22 I-GENE
cDNA I-GENE
demonstrated O
that O
the O
Cd22 I-GENE
locus I-GENE
encoding O
mCD22 I-GENE
is O
a O
single O
copy O
gene O
of O
< O
or O
= O
30 O
kb O
. O

The O
concentrations O
of O
plasma O
ACTH I-GENE
and O
cortisol O
increased O
by O
40 O
% O
and O
60 O
% O
after O
MPTP O
treatment O
, O
respectively O
. O

Instead O
, O
the O
results O
support O
the O
idea O
that O
Pc I-GENE
group I-GENE
products I-GENE
provide O
stable O
memory O
or O
imprinting O
of O
boundaries O
which O
are O
initially O
specified O
by O
gap O
and O
pair O
- O
rule O
regulators O
. O

To O
investigate O
the O
regulation O
of O
expression O
of O
the O
human I-GENE
mdr1 I-GENE
gene I-GENE
, O
the O
response O
of O
the O
mdr1 I-GENE
promoter I-GENE
to O
signals O
involved O
in O
cell O
proliferation O
was O
examined O
. O

The O
tyrosine I-GENE
hydroxylase I-GENE
gene I-GENE
( O
TH I-GENE
) O
contains O
a O
single O
copy O
of O
a O
consensus O
CRE O
at O
- O
45 O
to O
- O
38 O
base O
pair O
( O
bp O
) O
upstream O
of O
the O
transcription O
initiation O
site O
. O

Tobacco O
mosaic O
virus O
- O
infected O
tobacco O
( O
Nicotiana O
tabacum O
var O
. O

Through O
a O
stretch O
of O
56 O
amino O
acids O
, O
constituting O
the O
MADS I-GENE
domain I-GENE
, O
the O
two O
proteins O
are O
identical O
except O
for O
two O
conservative O
amino O
acid O
substitutions O
. O

Isolation O
and O
characterization O
of O
SRF I-GENE
accessory I-GENE
proteins I-GENE
. O

These O
data O
suggest O
that O
: O
( O
a O
) O
proSRIF I-GENE
cleavage O
is O
initiated O
in O
the O
TGN O
, O
and O
( O
b O
) O
this O
reaction O
requires O
an O
acidic O
pH O
which O
is O
facilitated O
by O
a O
Golgi I-GENE
- I-GENE
associated I-GENE
vacuolar I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
. O

Fenoldopam O
, O
a O
dopamine I-GENE
receptor I-GENE
agonist O
, O
has O
been O
shown O
, O
in O
animal O
experiments O
, O
to O
improve O
renal O
perfusion O
. O

Clinical O
aspects O
of O
early O
increase O
in O
serum O
gamma I-GENE
- I-GENE
glutamyl I-GENE
transferase I-GENE
in O
cerebral O
infarction O
. O

In O
the O
3 O
' O
flanking O
region O
of O
the O
27 I-GENE
kDa I-GENE
zein I-GENE
gene I-GENE
, O
several O
AATAAA O
- O
like O
sequences O
and O
a O
sequence O
resembling O
the O
mammalian O
GT O
- O
rich O
sequence O
are O
present O
around O
the O
polyadenylation O
sites O
. O

The O
indoor O
radon O
concentration O
in O
the O
summer O
( O
1990 O
) O
period O
ranged O
between O
8 O
and O
81 O
Bq O
m O
- O
3 O
, O
while O
in O
the O
winter O
( O
1989 O
- O
1990 O
) O
it O
ranged O
between O
20 O
and O
143 O
Bq O
m O
- O
3 O
for O
the O
first O
year O
of O
measurements O
or O
between O
8 O
and O
92 O
Bq O
m O
- O
3 O
in O
the O
summer O
( O
1991 O
) O
period O
and O
between O
12 O
and O
119 O
Bq O
m O
- O
3 O
in O
the O
winter O
( O
1990 O
- O
1991 O
) O
for O
the O
second O
year O
of O
measurements O
. O

The O
results O
indicate O
that O
hrpRS I-GENE
and O
hrpL I-GENE
are O
part O
of O
a O
regulatory O
cascade O
in O
which O
HrpR I-GENE
and O
HrpS I-GENE
activate O
expression O
of O
hrpL I-GENE
and O
HrpL I-GENE
, O
a O
putative O
sigma I-GENE
factor I-GENE
, O
induces O
expression O
of O
HrpL I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
. O

DtxR I-GENE
is O
an O
iron O
- O
dependent O
sequence O
- O
specific O
DNA O
- O
binding O
protein O
that O
binds O
to O
the O
tox I-GENE
operator I-GENE
, O
an O
inverted O
- O
repeat O
nucleotide O
sequence O
located O
upstream O
from O
the O
diphtheria I-GENE
toxin I-GENE
gene I-GENE
. O

Vasopressin I-GENE
( O
AVP I-GENE
), O
the O
antidiuretic O
hormone O
, O
is O
a O
cyclic O
nonapeptide O
that O
acts O
through O
binding O
to O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
specific I-GENE
membrane I-GENE
receptors I-GENE
pharmacologically O
divided O
into O
three O
subtypes O
( O
V1a I-GENE
, O
V1b I-GENE
, O
and O
V2 I-GENE
) O
linked O
to O
distinct O
second O
messengers O
. O

These O
results O
confirmed O
that O
cleavage O
of O
the O
leader O
peptide O
is O
the O
last O
step O
in O
nisin I-GENE
maturation O
and O
is O
necessary O
to O
generate O
a O
biologically O
active O
peptide O
. O

When O
the O
promoter O
region O
was O
linked O
with O
a O
heterologous O
reporter O
gene O
, O
we O
found O
that O
the O
promoter O
region O
is O
inducible O
by O
both O
interferons I-GENE
( O
interferon I-GENE
- I-GENE
alpha I-GENE
and I-GENE
- I-GENE
gamma I-GENE
) O
and O
interferon I-GENE
regulatory I-GENE
factor I-GENE
1 I-GENE
. O

Anti I-GENE
- I-GENE
B I-GENE
. I-GENE
burgdorferi I-GENE
, O
anti I-GENE
- I-GENE
B I-GENE
. I-GENE
turicatae I-GENE
and O
anti I-GENE
- I-GENE
B I-GENE
. I-GENE
parkeri I-GENE
antibodies I-GENE
, O
tested O
by O
the O
indirect O
immunofluorescent O
assay O
( O
IFA O
), O
were O
detected O
in O
10 O
. O
8 O
, O
16 O
. O
1 O
and O
8 O
. O
2 O
% O
of O
the O
serum O
samples O
tested O
, O
and O
confirmed O
by O
IFA O
- O
ABS O
in O
1 O
. O
3 O
, O
1 O
. O
3 O
and O
1 O
. O
0 O
%, O
respectively O
. O

The O
approach O
derives O
from O
a O
recently O
described O
strategy O
for O
making O
recombinants O
from O
five O
overlapping O
EBV O
cosmid O
- O
cloned O
DNAs O
( O
B O
. O

Evaluation O
of O
desmopressin O
for O
dental O
extractions O
in O
patients O
with O
hemostatic O
disorders O
. O

Comparative O
analysis O
with O
an O
antiandrogen O
niftolid O
and O
synthetic I-GENE
GnRH I-GENE
was O
carried O
out O
in O
22 O
normal O
subjects O
, O
14 O
patients O
with O
primary O
and O
20 O
ones O
with O
secondary O
hypogonadism O
, O
and O
in O
5 O
patients O
with O
clinical O
signs O
of O
gonadal O
insufficiency O
and O
obscure O
diagnosis O
in O
order O
to O
elucidate O
the O
pituitary I-GENE
gonadotropin I-GENE
reserves O
. O

All O
other O
normal O
and O
transformed O
lymphoid O
and O
nonlymphoid O
cell O
lines O
and O
normal O
tissues O
were O
negative O
for O
PANG I-GENE
expression O
except O
for O
the O
brain O
, O
wherein O
unique O
4 O
. O
0 O
- O
and O
6 O
. O
1 O
- O
kb O
transcripts O
were O
detected O
. O

The O
cis O
- O
acting O
regulatory O
properties O
of O
an O
872 O
bp O
promoter O
fragment O
of O
a O
B O
. O
napus O
oleosin I-GENE
gene I-GENE
were O
examined O
by O
analysis O
of O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
expression O
in O
transgenic O
tobacco O
plants O
containing O
an O
oleosin I-GENE
promoter I-GENE
- O
GUS I-GENE
transcriptional O
fusion O
. O

This O
indicates O
that O
the O
mechanism O
by O
which O
CX O
blocks O
rapid O
degradation O
of O
tubulin I-GENE
mRNA I-GENE
in O
vivo O
is O
not O
simply O
by O
preventing O
its O
translation O
and O
suggests O
the O
involvement O
of O
an O
altered O
trans O
- O
factor O
. O

L O
., O
Greer O
, O
J O
. O
& O
Carter O
, O
G O
. O

Increasing O
the O
extracellular O
calcium O
concentration O
enhanced O
detrusor O
contractility O
in O
a O
dose O
- O
dependent O
manner O
in O
both O
control O
and O
obstructed O
bladders O
. O

Structural O
organization O
of O
the O
gene O
encoding O
the O
human I-GENE
lipocalin I-GENE
tear I-GENE
prealbumin I-GENE
and O
synthesis O
of O
the O
recombinant O
protein O
in O
Escherichia O
coli O
. O

The O
sequence O
has O
a O
1092 O
- O
bp O
open O
reading O
frame O
encoding O
a O
protein O
of O
364 O
amino O
acids O
. O

Western O
blotting O
( O
immunoblotting O
) O
with O
an O
antiserum O
to O
a O
partial O
SOD I-GENE
expressed O
in O
Escherichia O
coli O
revealed O
two O
proteins O
with O
estimated O
molecular O
masses O
of O
19 O
and O
29 O
kDa O
. O

The O
gene O
organization O
of O
CRSV I-GENE
RNA I-GENE
- I-GENE
1 I-GENE
is O
similar O
to O
those O
of O
red O
clover O
necrotic O
mosaic O
( O
RCNMV O
) O
and O
sweet O
clover O
necrotic O
mosaic O
( O
SCNMV O
) O
dianthoviruses O
with O
the O
exception O
that O
CRSV I-GENE
RNA I-GENE
- I-GENE
1 I-GENE
contains O
the O
additional O
3 O
'- O
terminal O
ORF O
. O

Members O
of O
the O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
2 I-GENE
( O
MEF2 I-GENE
) O
family O
of O
transcription O
factors O
bind O
a O
conserved O
A O
/ O
T O
- O
rich O
sequence O
in O
the O
control O
regions O
of O
numerous O
muscle O
- O
specific O
genes O
. O

We O
have O
previously O
shown O
that O
LBP I-GENE
- I-GENE
1 I-GENE
represses O
HIV O
- O
1 O
transcription O
by O
inhibiting O
the O
binding O
of O
TFIID I-GENE
to O
the O
TATA O
box O
. O

These O
results O
illustrate O
an O
important O
role O
for O
La I-GENE
in O
RNA O
production O
by O
demonstrating O
its O
ability O
to O
clear O
the O
termination O
sites O
of O
class O
III O
templates O
, O
thereby O
promoting O
efficient O
use O
of O
transcription O
complexes O
by O
pol I-GENE
III I-GENE
. O

The O
films O
were O
analyzed O
using O
a O
scanning O
helium O
- O
neon O
laser O
densitometer O
with O
a O
small O
aperture O
of O
5 O
- O
10 O
microns O
. O

The O
GafChromic O
method O
has O
proven O
to O
be O
an O
accurate O
and O
rapid O
method O
of O
analysis O
and O
could O
be O
easily O
incorporated O
into O
a O
quality O
assurance O
program O
. O

Viral O
genomic O
RNA O
for O
these O
reactions O
was O
obtained O
directly O
from O
fecal O
specimens O
of O
infected O
infant O
rats O
. O

GATA I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
was O
present O
in O
equivalent O
levels O
in O
both O
erythroid O
cell O
lines O
, O
but O
at O
a O
low O
level O
in O
FDC O
- O
P1 O
cells O
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
) O
is O
one O
of O
several O
autocrine O
/ O
paracrine O
factors O
known O
to O
exert O
potent O
inhibitory O
effects O
on O
bone O
. O

We O
have O
investigated O
the O
role O
of O
cellular I-GENE
p21ras I-GENE
protein I-GENE
in O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
signaling O
pathways O
. O

The O
lack O
of O
the O
C2 I-GENE
domain O
of O
the O
Ca I-GENE
( I-GENE
2 I-GENE
+)- I-GENE
dependent I-GENE
PKCs I-GENE
and O
the O
presence O
of O
a O
unique O
NH2 O
- O
terminal O
sequence O
with O
a O
potential O
signal O
peptide O
and O
a O
transmembrane O
domain O
suggest O
that O
PKC I-GENE
mu I-GENE
is O
a O
novel O
member O
of O
the O
subgroup O
of O
atypical O
PKCs I-GENE
. O

Moreover O
, O
we O
observed O
that O
the O
function O
of O
T3R I-GENE
- O
RXR I-GENE
heterodimers O
on O
response O
elements O
composed O
of O
two O
half O
- O
sites O
in O
a O
directly O
repeated O
orientation O
spaced O
by O
4 O
nucleotides O
is O
determined O
in O
major O
parts O
by O
the O
5 O
'- O
flanking O
sequence O
of O
the O
upstream O
half O
- O
site O
. O

However O
, O
three O
Hm1 I-GENE
mutants I-GENE
that O
were O
moderately O
deficient O
in O
stimulating O
PI O
turnover O
displayed O
normal O
sequestration O
, O
suggesting O
distinct O
mechanisms O
. O

Furthermore O
, O
in O
vitro O
decay O
reaction O
mixtures O
supplemented O
with O
the O
20 O
- O
nt O
sense O
RNA O
transcript O
resulted O
in O
stabilization O
of O
R2 I-GENE
message I-GENE
. O

Deletion O
analyses O
of O
the O
pCD41 I-GENE
ORF I-GENE
- I-GENE
A I-GENE
and O
the O
use O
of O
promoter O
constructs O
further O
mapped O
an O
internal O
functional O
promoter O
within O
the O
pCD41 I-GENE
sequence I-GENE
that O
can O
direct O
the O
synthesis O
of O
the O
trans O
- O
activating O
protein O
. O

Seven O
of O
these O
had O
counterparts O
in O
the O
US O
of O
herpes O
simplex O
type O
1 O
( O
HSV O
- O
1 O
), O
pseudorabies O
virus O
( O
PRV O
), O
and O
equine O
herpesvirus O
type O
1 O
( O
EHV O
- O
1 O
). O

The O
inferred O
amino O
acid O
sequence O
of O
the O
cyanobacterial I-GENE
HemB I-GENE
protein I-GENE
indicates O
a O
significant O
difference O
in O
the O
metal O
cofactor O
requirement O
from O
the O
higher O
- O
plant O
enzymes O
, O
which O
was O
confirmed O
by O
overexpression O
and O
biochemical O
analysis O
. O

METHODS O
AND O
RESULTS O
: O
In O
25 O
open O
- O
chest O
, O
anesthetized O
dogs O
, O
progressive O
circumflex O
artery O
stenosis O
led O
to O
a O
concordant O
decrease O
of O
circumflex O
artery O
resting O
and O
hyperemic O
flow O
, O
coronary O
flow O
reserve O
, O
and O
inverse O
angiographic O
mean O
transit O
time O
Tmicro O
- O
1 O
( O
P O
< O
. O
01 O
). O

However O
, O
a O
correlation O
was O
observed O
between O
SF O
levels O
of O
IL I-GENE
- I-GENE
8 I-GENE
with O
those O
of O
lactate O
, O
LDH I-GENE
, O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
and O
glucose O
. O

Sodium O
- O
taurocholate O
- O
induced O
acute O
necrotizing O
pancreatitis O
does O
not O
affect O
jejunal O
oxygenation O
in O
pigs O
. O

Although O
inactive O
in O
cells O
under O
normal O
conditions O
, O
the O
CHOP I-GENE
gene I-GENE
is O
markedly O
induced O
by O
a O
variety O
of O
cellular O
stresses O
, O
including O
nutrient O
deprivation O
and O
metabolic O
perturbations O
. O

The O
ipiO I-GENE
genes I-GENE
code O
for O
two O
almost O
identical O
152 O
- O
aa O
proteins O
which O
do O
not O
have O
any O
homology O
with O
sequences O
present O
in O
data O
libraries O
. O

Sterol O
analysis O
of O
the O
disrupted O
mutant O
demonstrated O
the O
accumulation O
of O
ignosterol O
, O
indicating O
a O
loss O
of O
Erg24p I-GENE
activity O
. O

The O
previously O
described O
enhanced O
translation O
of O
spinach O
L12 I-GENE
mRNA I-GENE
from O
its O
two O
tandem O
AUG O
codons O
and O
the O
two O
functional O
rpl12 I-GENE
genes I-GENE
in O
Arabidopsis O
probably O
provide O
two O
mechanisms O
for O
generating O
the O
four O
copies O
of O
L12 I-GENE
/ I-GENE
chloroplast I-GENE
ribosome I-GENE
, O
qualitatively O
different O
from O
those O
attempted O
in O
eubacteria O
. O

In O
these O
experiments O
we O
begin O
to O
study O
the O
potential O
functions O
of O
the O
alpha I-GENE
7 I-GENE
cytoplasmic I-GENE
domain I-GENE
by O
analyzing O
homologies O
between O
the O
rat O
and O
human O
sequences O
, O
by O
immunologic O
studies O
using O
an O
anti O
- O
cytoplasmic O
domain O
antiserum O
, O
and O
by O
identifying O
two O
alternate O
forms O
. O

The O
alpha O
7A O
form O
RNA O
contains O
an O
additional O
113 O
nucleotides O
compared O
to O
the O
B O
form O
, O
and O
a O
common O
coding O
region O
in O
the O
A O
and O
B O
form O
RNAs O
is O
used O
in O
alternate O
reading O
frames O
. O

In O
order O
to O
evaluate O
the O
function O
of O
the O
hypothalamic O
- O
pituitary O
- O
thyroid O
( O
HPT O
)- O
axis O
in O
unipolar O
depression O
, O
the O
authors O
measured O
basal O
0800h O
plasma O
levels O
of O
free O
thyroxine O
( O
FT4 O
), O
free O
triiodothyronine O
( O
FT3 O
), O
and O
thyroid I-GENE
stimulating I-GENE
hormone I-GENE
( O
TSH I-GENE
) O
by O
means O
of O
the O
new O
, O
ultrasensitive O
assays O
( O
TSH O
- O
IRMA O
) O
in O
69 O
healthy O
controls O
, O
62 O
minor O
, O
101 O
simple O
major O
, O
and O
57 O
melancholic O
depressed O
subjects O
. O

CRS I-GENE
function O
in O
a O
5 O
' O
LTR O
- O
linked O
gene O
expression O
assay O
correlates O
with O
the O
ability O
of O
both O
p60CRS I-GENE
and O
p40CRS I-GENE
to O
interact O
with O
5 O
' O
LTR O
RNA O
in O
vitro O
. O

Serial O
levels O
of O
troponin I-GENE
T I-GENE
and O
the O
activity O
of O
CK I-GENE
- I-GENE
MB I-GENE
were O
measured O
6 O
, O
12 O
, O
24 O
and O
48 O
h O
after O
aortic O
unclamping O
. O

Regionalization O
of O
drug O
delivery O
is O
a O
potential O
method O
to O
avoid O
this O
problem O
. O

The O
epidemic O
occurred O
in O
a O
group O
of O
26 O
community O
members O
( O
23 O
men O
and O
3 O
women O
, O
mean O
age O
, O
28 O
. O
9 O
-- O
3 O
years O
) O
living O
and O
working O
together O
, O
who O
underwent O
acute O
and O
convalescent O
serologic O
tests O
for O
Mycoplasma O
pneumoniae O
, O
Legionella O
pneumophila O
, O
cytomegalovirus O
, O
adenovirus O
, O
Coxiella O
burnetii O
, O
and O
Chlamydia O
pneumoniae O
. O

MEK I-GENE
itself O
is O
activated O
via O
serine O
phosphorylation O
by O
upstream I-GENE
activator I-GENE
kinases I-GENE
, O
including O
c I-GENE
- I-GENE
raf I-GENE
, O
mos I-GENE
and O
MEK I-GENE
kinase I-GENE
. O

Genomic O
DNA O
clones O
containing O
the O
T I-GENE
- I-GENE
cell I-GENE
- I-GENE
specific I-GENE
human I-GENE
MAL I-GENE
gene I-GENE
were O
isolated O
. O

Members O
of O
SVA I-GENE
are O
also O
present O
in O
the O
complement I-GENE
C2 I-GENE
gene I-GENE
located O
about O
20 O
kilobases O
upstream O
of O
RP1 I-GENE
in O
the O
HLA I-GENE
and O
in O
the O
cytochrome I-GENE
CYP1A1 I-GENE
gene I-GENE
. O

Expression O
of O
the O
dibasic O
proprotein O
processing O
enzyme O
furin I-GENE
is O
directed O
by O
multiple O
promoters O
. O

European O
Community O
Huntington O
' O
s O
Disease O
Collaborative O
Study O
Group O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
and O
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
gene I-GENE
promoters I-GENE
contain O
YY1 I-GENE
binding I-GENE
sites I-GENE
thought O
to O
act O
either O
as O
positive O
or O
negative O
cis O
- O
acting O
elements O
. O

MSSP I-GENE
- I-GENE
1 I-GENE
produced O
in O
E O
. O
coli O
as O
a O
fusion O
protein O
with O
GST I-GENE
specifically O
interacted O
with O
single O
- O
stranded O
TCTTAT O
( O
plus O
myc I-GENE
( O
H O
- O
P O
) O
21 O
) O
and O
ACT O
- O
ATT O
( O
in O
minus O
myc I-GENE
( O
H O
- O
P O
) O
21 O
), O
the O
consensus O
of O
which O
can O
be O
referred O
to O
as O
A O
/ O
TCTA O
/ O
TA O
/ O
TT O
. O

Within O
12 O
hours O
after O
MR O
tomography O
the O
patients O
were O
surgically O
explored O
, O
biopsied O
and O
if O
necessary O
orchiectomised O
. O

Certain O
spt10 I-GENE
spontaneous O
alleles O
are O
good O
suppressors O
but O
have O
a O
normal O
growth O
rate O
, O
suggesting O
that O
the O
SPT10 I-GENE
protein I-GENE
may O
have O
two O
distinct O
functions O
. O

Varieties O
of O
envious O
experience O
. O

The O
results O
show O
that O
both O
the O
amino O
and O
carboxy O
termini O
of O
the O
NS1 I-GENE
protein I-GENE
molecule I-GENE
and O
the O
cysteines O
at O
residues O
337 O
and O
340 O
are O
essential O
for O
tubule O
formation O
. O

The O
3 O
' O
UTR O
has O
several O
stable O
hairpins O
that O
are O
flanked O
by O
single O
- O
stranded O
( O
A O
/ O
U O
) O
UGC O
sequences O
. O

Moreover O
, O
the O
major O
site O
of O
transcriptional O
initiation O
, O
which O
was O
localized O
by O
primer O
extension O
250 O
bp O
upstream O
of O
the O
5 O
' O
end O
of O
the O
Ets I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
clone I-GENE
, O
was O
shown O
to O
be O
identical O
in O
normal O
cells O
and O
tumors O
carrying O
a O
provirus O
in O
the O
Tpl I-GENE
- I-GENE
1 I-GENE
locus I-GENE
. O

Specifically O
, O
by O
oligonucleotide O
- O
directed O
site O
- O
specific O
mutagenesis O
, O
we O
demonstrate O
that O
of O
10 O
cysteine O
residues O
in O
the O
ORF4 O
polypeptide O
, O
only O
C O
- O
421 O
and O
C O
- O
426 O
are O
essential O
for O
transactivator O
function O
and O
suggest O
that O
these O
cysteine O
residues O
may O
participate O
in O
critical O
protein O
- O
protein O
interactions O
rather O
than O
protein O
- O
nucleic O
acid O
interactions O
to O
mediate O
ORF4 O
inducibility O
. O

In O
Rat O
1a O
cells O
, O
m1R I-GENE
stimulation O
of O
phospholipase I-GENE
C I-GENE
beta I-GENE
and O
the O
marked O
rise O
in O
intracellular O
calcium O
stimulated O
cyclic O
AMP O
( O
cAMP O
) O
synthesis O
, O
resulting O
in O
the O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
. O

The O
mutations O
did O
not O
affect O
the O
repression O
of O
CPA1 I-GENE
by O
arginine O
. O

A O
segment O
of O
mRNA O
encoding O
the O
leader O
peptide O
of O
the O
CPA1 I-GENE
gene I-GENE
confers O
repression O
by O
arginine O
on O
a O
heterologous O
yeast O
gene O
transcript O
. O

To O
search O
for O
genes O
that O
interact O
with O
the O
SLK1 I-GENE
- O
SLT2 I-GENE
pathway O
, O
a O
synthetic O
lethal O
suppression O
screen O
was O
carried O
out O
. O

Genetic O
and O
phenotypic O
analysis O
indicates O
that O
NHP6A I-GENE
and O
NHP6B I-GENE
function O
downstream O
of O
SLT2 I-GENE
. O

In O
this O
report O
, O
we O
present O
two O
lines O
of O
evidence O
that O
all O
ribosomes O
which O
synthesize O
GCN4 I-GENE
have O
previously O
translated O
uORF1 O
, O
resumed O
scanning O
, O
and O
reinitiated O
at O
the O
GCN4 I-GENE
start O
site O
. O

Identical O
components O
of O
yeast O
transcription I-GENE
factor I-GENE
IIIB I-GENE
are O
required O
and O
sufficient O
for O
transcription O
of O
TATA O
box O
- O
containing O
and O
TATA O
- O
less O
genes O
. O

Concordantly O
, O
it O
was O
shown O
that O
the O
dnHLH I-GENE
protein I-GENE
Id1 I-GENE
inhibits O
differentiation O
of O
muscle O
and O
myeloid O
cells O
in O
vitro O
. O

RNP1 I-GENE
, O
a O
new O
ribonucleoprotein O
gene O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

Crohn O
' O
s O
disease O
in O
prolonged O
remission O
: O
should O
one O
augment O
protein O
- O
calorie O
intake O
as O
compared O
to O
healthy O
subjects O
?] O
The O
aim O
of O
our O
two O
year O
prospective O
study O
was O
to O
evaluate O
whether O
adult O
Crohn O
' O
s O
disease O
patients O
in O
prolonged O
remission O
( O
CDAI O
< O
150 O
), O
in O
order O
to O
maintain O
their O
body O
weight O
as O
close O
as O
possible O
to O
the O
ideal O
one O
, O
need O
a O
protein O
- O
calorie O
intake O
higher O
than O
the O
predicted O
one O
and O
that O
of O
healthy O
controls O
. O

To O
achieve O
complete O
dissection O
of O
the O
anterior O
vitreous O
, O
we O
remove O
even O
a O
clear O
lens O
during O
the O
first O
surgical O
intervention O
in O
selected O
cases O
. O

Restoration O
of O
opponens O
function O
with O
transplantation O
of O
free O
composites O
dorsal O
pedal O
skin O
flap O
containing O
m O
. O
extensor O
hallucis O
brevis O

Neither O
ethanol O
regimen O
impaired O
spontaneous O
alternation O
, O
but O
the O
4 O
g O
ethanol O
. O
kg O
- O
1 O
x O
day O
- O
1 O
regimen O
increased O
the O
percent O
completed O
trials O
. O

The O
mean O
(+/- O
sd O
) O
intra O
- O
vesicular O
pressure O
( O
IVP O
) O
and O
maximal O
urethral O
closure O
pressures O
( O
MUCP O
) O
were O
10 O
. O
3 O
(+/- O
1 O
. O
7 O
) O
and O
129 O
. O
8 O
(+/- O
19 O
. O
6 O
) O
cmH2O O
, O
respectively O
, O
and O
the O
ratio O
between O
MUCP O
and O
IVP O
was O
13 O
. O
2 O
(+/- O
2 O
. O
5 O
). O

Several O
highly O
conserved O
regions O
were O
identified O
at O
the O
near O
N O
terminus O
, O
middle O
and O
C O
terminus O
. O

Thioredoxin I-GENE
( O
TR I-GENE
) O
is O
a O
small O
ubiquitous O
dithiol I-GENE
- I-GENE
reductase I-GENE
enzyme I-GENE
first O
identified O
in O
bacteria O
and O
plants O
. O

The O
mutation O
within O
the O
asgB480 I-GENE
allele I-GENE
was O
identified O
as O
an O
A O
- O
to O
- O
G O
transition O
that O
results O
in O
a O
threonine O
- O
to O
- O
alanine O
substitution O
in O
the O
predicted O
protein O
product O
. O

The O
cysteine O
- O
rich O
region O
of O
raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
contains O
zinc O
, O
translocates O
to O
liposomes O
, O
and O
is O
adjacent O
to O
a O
segment O
that O
binds O
GTP I-GENE
- I-GENE
ras I-GENE
. O

Kinetic O
coupling O
and O
requirement O
for O
ATP O
hydrolysis O
. O

ATP O
by O
itself O
also O
reduced O
polypeptide O
binding O
to O
Ssb1 I-GENE
/ I-GENE
2p I-GENE
to O
a O
level O
that O
was O
intermediate O
between O
that O
observed O
for O
the O
Ssa I-GENE
Hsp70 I-GENE
proteins I-GENE
tested O
and O
BiP I-GENE
and O
DnaK I-GENE
. O

Digestion O
of O
NF I-GENE
- I-GENE
IL6 I-GENE
with O
endoprotease I-GENE
Asp I-GENE
- I-GENE
N I-GENE
produced O
a O
domain O
smaller O
than O
the O
TCD I-GENE
( O
NF I-GENE
- I-GENE
IL6 I-GENE
bZIP I-GENE
domains I-GENE
( O
NFBD I-GENE
) O
( O
272 O
- O
345 O
)), O
a O
domain O
identified O
either O
in O
the O
absence O
or O
the O
presence O
of O
DNA O
. O

Signaling O
by O
tyrosine I-GENE
kinases I-GENE
involves O
direct O
associations O
between O
proteins O
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domains O
and O
sites O
of O
tyrosine O
phosphorylation O
. O

Rather O
, O
complete O
skipping O
of O
exon O
V O
and O
subsequent O
joining O
of O
exon O
IV O
to O
exon O
VI O
caused O
a O
shift O
in O
the O
open O
reading O
frame O
, O
which O
remodeled O
GPHe I-GENE
( I-GENE
P2 I-GENE
) I-GENE
with O
an O
elongated O
new O
hydrophobic O
sequence O
for O
membrane O
anchoring O
. O

The O
responses O
of O
the O
" O
stress O
hormones O
" O
cortisol O
, O
11 O
- O
deoxycortisol O
, O
ACTH I-GENE
, O
vasopressin I-GENE
( O
AVP I-GENE
), O
and O
corticotropin I-GENE
releasing I-GENE
factor I-GENE
( O
CRF I-GENE
) O
were O
studied O
in O
6 O
normal O
males O
in O
response O
to O
acute O
cortisol O
deficiency O
induced O
by O
the O
11 I-GENE
- I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
inhibitor O
, O
metyrapone O
. O

Structure O
and O
expression O
of O
the O
alternative O
sigma I-GENE
factor I-GENE
, O
RpoN I-GENE
, O
in O
Rhodobacter O
capsulatus O
; O
physiological O
relevance O
of O
an O
autoactivated O
nifU2 I-GENE
- O
rpoN I-GENE
superoperon O
. O

Thus O
our O
observations O
establish O
a O
functional O
link O
between O
the O
PKC I-GENE
and O
retinoid O
pathways O
, O
which O
are O
generally O
considered O
to O
have O
antagonistic O
activities O
on O
differentiation O
processes O
. O

The O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
CSFs I-GENE
) O
principally O
involved O
in O
the O
production O
of O
neutrophils O
and O
monocytes O
are O
granulocyte I-GENE
CSF I-GENE
, O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
CSF I-GENE
, O
macrophage I-GENE
CSF I-GENE
, O
and O
interleukin I-GENE
3 I-GENE
( O
sometimes O
called O
multi I-GENE
- I-GENE
CSF I-GENE
). O

The O
degree O
of O
lung O
destruction O
, O
reflected O
by O
interstitial O
hemorrhage O
was O
assessed O
by O
measuring O
hemoglobin I-GENE
content O
in O
the O
fluid O
of O
the O
lavaged O
lungs O
. O

Expression O
plasmids O
harboring O
full O
- O
length O
or O
kinase O
domain O
of O
PKC I-GENE
alpha I-GENE
and O
PKC I-GENE
delta I-GENE
( O
PKC I-GENE
alpha I-GENE
K I-GENE
and O
PKC I-GENE
delta I-GENE
K I-GENE
) O
were O
constructed O
. O

These O
results O
indicate O
that O
both O
PKC I-GENE
alpha I-GENE
( O
calcium O
dependent O
) O
and O
PKC I-GENE
delta I-GENE
( O
calcium O
independent O
) O
may O
mediate O
the O
transcription O
of O
TPA O
- O
inducible O
genes O
through O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
non O
- O
AP I-GENE
- I-GENE
1 I-GENE
sequences O
. O

With O
a O
cutoff O
level O
for O
TSST I-GENE
- I-GENE
1 I-GENE
of O
less O
than O
100 O
pg O
/ O
ml O
, O
28 O
samples O
obtained O
from O
12 O
patients O
were O
positive O
for O
TSST I-GENE
- I-GENE
1 I-GENE
. O

Insertion O
of O
short O
oligonucleotides O
encoding O
the O
basic O
amino O
acid O
motifs O
726 O
- O
GRKRKSP O
- O
732 O
from O
IE175 I-GENE
and O
500 O
- O
VRPRKRR O
- O
506 O
from O
IE110 I-GENE
into O
deleted O
cytoplasmic O
forms O
of O
the O
two O
proteins O
restored O
the O
karyophilic O
phenotype O
and O
confirmed O
that O
these O
motifs O
are O
both O
necessary O
and O
sufficient O
for O
proper O
nuclear O
localization O
. O

Mapping O
of O
intracellular O
localization O
domains O
and O
evidence O
for O
colocalization O
interactions O
between O
the O
IE110 I-GENE
and O
IE175 I-GENE
nuclear O
transactivator O
proteins O
of O
herpes O
simplex O
virus O
. O

The O
revertant O
TATA O
boxes O
accelerated O
the O
kinetics O
of O
HIV O
replication O
when O
present O
in O
the O
context O
of O
an O
LTR O
containing O
a O
Sp1 I-GENE
mutation O
( O
deletion O
or O
site O
specific O
); O
no O
effect O
was O
observed O
on O
the O
infectivity O
of O
wild O
- O
type O
HIV O
. O

Panlobular O
emphysema O

Since O
the O
ETS I-GENE
domain I-GENE
, O
which O
is O
localized O
in O
the O
carboxy O
terminal O
region O
of O
the O
encoded O
protein O
, O
is O
95 O
% O
and O
96 O
% O
identical O
to O
that O
of O
PEA3 I-GENE
and O
ER81 I-GENE
, O
respectively O
, O
we O
named O
this O
new O
member O
' I-GENE
Ets I-GENE
Related I-GENE
Molecule I-GENE
PEA3 I-GENE
- I-GENE
like I-GENE
' I-GENE
( O
ERM I-GENE
). O

Gel O
shift O
analysis O
indicates O
that O
the O
full I-GENE
- I-GENE
length I-GENE
ERM I-GENE
protein I-GENE
is O
able O
to O
bind O
specifically O
to O
an O
oligonucleotide O
containing O
the O
consensus O
nucleotide O
core O
sequence O
GGAA O
recognized O
by O
the O
Ets I-GENE
proteins O
. O

Effects O
of O
estradiol O
on O
worm O
burden O
and O
peripheral O
leukocytes O
in O
Parastrongylus O
malaysiensis O
- O
infected O
rats O
. O

Dotarizine O
produced O
arterial O
dilation O
in O
both O
systemic O
and O
pulmonary O
circulation O
: O
the O
total O
peripheral O
resistance O
dropped O
, O
and O
femoral O
artery O
flow O
rose O
; O
aortic O
and O
pulmonary O
artery O
mean O
and O
diastolic O
pressures O
declined O
, O
and O
systolic O
pressures O
remained O
almost O
stable O
. O

These O
issues O
include O
the O
use O
of O
LMWHs O
in O
patients O
with O
arterial O
thrombosis O
or O
myocardial O
infarction O
( O
e O
. O
g O
. O
in O
conjunction O
with O
thrombolytic O
treatment O
), O
and O
in O
patients O
with O
pulmonary O
embolism O
. O

The O
usefulness O
of O
the O
lambda O
PG15 O
and O
the O
lambda O
AD5 O
cloning O
vectors O
was O
demonstrated O
by O
constructing O
large O
Neurospora O
crassa O
cDNA O
libraries O
. O

Endoscopic O
transthoracic O
sympathectomy O
as O
adjuvant O
treatment O
for O
critical O
upper O
- O
limb O
ischaemia O
. O

Sequence O
comparisons O
have O
shown O
that O
Aps1p I-GENE
is O
more O
similar O
to O
the O
sigma O
subunit O
of O
the O
Golgi O
- O
localized O
mammalian O
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
than O
Aps2p I-GENE
, O
which O
is O
more O
related O
to O
the O
plasma O
membrane O
AP I-GENE
- I-GENE
2 I-GENE
sigma I-GENE
subunit O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
APS1 I-GENE
gene I-GENE
encodes O
a O
homolog O
of O
the O
small O
subunit O
of O
the O
mammalian I-GENE
clathrin I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
: O
evidence O
for O
functional O
interaction O
with O
clathrin I-GENE
at O
the O
Golgi O
complex O
. O

These O
results O
are O
the O
first O
to O
demonstrate O
the O
structural O
organization O
of O
a O
vertebrate O
gene O
encoding O
an O
integral O
membrane O
protein O
of O
the O
nuclear O
envelope O
that O
may O
be O
a O
member O
of O
a O
family O
of O
polypeptides O
conserved O
in O
evolution O
. O

Biochemical O
characterization O
of O
valosin I-GENE
- I-GENE
containing I-GENE
protein I-GENE
, O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
substrate O
in O
hematopoietic O
cells O
. O

The O
presence O
of O
the O
foreign O
gene O
was O
confirmed O
by O
Southern O
analysis O
. O

All O
patients O
with O
deterioriation O
in O
mental O
status O
showed O
a O
marked O
increase O
in O
liver O
enzymes O
( O
aspartate I-GENE
and I-GENE
alanine I-GENE
aminotransaminases I-GENE
) O
and O
severe O
coagulopathy O
. O

Functional O
postnatal O
development O
of O
the O
rat O
primary O
visual O
cortex O
and O
the O
role O
of O
visual O
experience O
: O
dark O
rearing O
and O
monocular O
deprivation O
. O

Eleven O
patients O
tested O
positive O
for O
the O
hepatitis I-GENE
B I-GENE
surface I-GENE
antigen I-GENE
( O
HBsAg I-GENE
). O

The O
xylose I-GENE
isomerase I-GENE
- I-GENE
encoding I-GENE
gene I-GENE
( O
xylA I-GENE
) O
of O
Clostridium O
thermosaccharolyticum O
: O
cloning O
, O
sequencing O
and O
phylogeny O
of O
XylA I-GENE
enzymes I-GENE
. O

Two O
phosphopeptides O
, O
identified O
as O
RS O
-[ O
32P O
] O
SGASGLLTSEHHSR O
and O
S O
-[ O
32P O
] O
SGASGLLTSEHHSR O
, O
were O
obtained O
after O
stoichiometric O
phosphorylation O
and O
trypsinization O
of O
the O
peptide O
. O

Mitochondrial I-GENE
Mas70p I-GENE
signal I-GENE
anchor I-GENE
sequence I-GENE
. O

Altogether O
, O
these O
data O
suggest O
that O
Ypt51p I-GENE
, O
Ypt52p I-GENE
, O
and O
Ypt53p I-GENE
are O
required O
for O
transport O
in O
the O
endocytic O
pathway O
and O
for O
correct O
sorting O
of O
vacuolar I-GENE
hydrolases I-GENE
suggesting O
a O
possible O
intersection O
of O
the O
endocytic O
with O
the O
vacuolar O
sorting O
pathway O
. O

All O
of O
the O
basal O
TPN O
solutions O
were O
isonitrogenous O
and O
identical O
in O
nutrient O
composition O
, O
except O
for O
the O
difference O
in O
energy O
level O
, O
which O
was O
adjusted O
with O
glucose O
. O

Surprisingly O
, O
TFIIIC I-GENE
alpha I-GENE
has O
no O
homology O
to O
any O
of O
the O
yeast I-GENE
TFIIIC I-GENE
subunits I-GENE
already O
cloned O
, O
suggesting O
a O
significant O
degree O
of O
evolutionary O
divergence O
for O
RNA I-GENE
polymerase I-GENE
III I-GENE
factors I-GENE
. O

Transactivation O
domain O
is O
located O
downstream O
of O
the O
128 I-GENE
- I-GENE
amino I-GENE
- I-GENE
acid I-GENE
runt I-GENE
homology I-GENE
region I-GENE
, O
referred O
to O
as O
the O
Runt I-GENE
domain I-GENE
. O

We O
estimate O
that O
the O
protease O
activity O
is O
at O
least O
35 O
- O
fold O
greater O
in O
mature O
B O
cells O
than O
in O
pre O
- O
B O
cells O
. O

The O
ligand O
for O
RXR I-GENE
, O
9 O
- O
cis O
retinoic O
acid O
, O
has O
the O
opposite O
effect O
of O
destabilizing O
the O
heterodimeric O
- O
DNA O
complex O
. O

Cerebral125 I-GENE
albumin I-GENE
was O
increased O
to O
similar O
proportions O
in O
those O
groups O
submitted O
to O
hyperosmolality O
. O

Retrogradely O
labelled O
neurons O
significantly O
prevailed O
in O
the O
ipsilateral O
substantia O
nigra O
pars O
compacta O
. O

Response O
to O
treatment O
was O
better O
in O
patients O
with O
less O
pretreatment O
( O
one O
- O
two O
prior O
treatments O
) O
than O
in O
heavily O
pretreated O
ones O
( O
more O
than O
three O
) O
and O
this O
relation O
was O
found O
to O
be O
statistically O
significant O
( O
p O
< O
0 O
. O
05 O
). O

Therefore O
, O
the O
amino O
- O
terminal O
sequence O
of O
the O
purified O
carA I-GENE
product I-GENE
is O
identical O
to O
that O
derived O
from O
the O
nucleotide O
sequence O
in O
both O
organisms O
, O
P O
. O
stutzeri O
having O
four O
additional O
amino O
acids O
. O

Aneurysmal O
bone O
cyst O
of O
the O
jaws O
: O
analysis O
of O
11 O
cases O
. O

Location O
and O
orientation O
of O
an O
activating O
region O
in O
the O
Escherichia O
coli O
transcription O
factor O
, O
FNR I-GENE
. O

Moxidectin O
( O
at O
3 O
times O
the O
therapeutic O
dose O
) O
did O
not O
have O
deleterious O
effects O
on O
cow O
reproductive O
performance O
as O
examined O
( O
eg O
, O
at O
folliculogenesis O
, O
ovulation O
, O
and O
the O
early O
embryonic O
phase O
of O
development O
). O

Northern O
- O
blot O
analysis O
of O
mRNA O
from O
Avicel O
- O
grown O
N O
. O
patriciarum O
showed O
that O
xynB I-GENE
hybridized O
to O
a O
3 O
. O
4 O
kb O
mRNA O
species O
. O

The O
variable O
regions O
of O
vertebrate O
striated O
TnT I-GENE
isoforms I-GENE
reflect O
the O
subsequent O
addition O
and O
modification O
of O
genomic O
sequences O
to O
give O
rise O
to O
members O
of O
the O
TnT I-GENE
multigene I-GENE
family I-GENE
. O

The O
class I-GENE
II I-GENE
Escherichia I-GENE
coli I-GENE
alanine I-GENE
tRNA I-GENE
synthetase I-GENE
aminoacylates I-GENE
RNA I-GENE
miniduplexes I-GENE
, O
which O
reconstruct O
the O
acceptor O
end O
of O
alanine I-GENE
tRNA I-GENE
with O
the O
critical O
G3 O
: O
U70 O
base O
pair O
. O

Simple O
reaction O
time O
( O
RT O
) O
to O
a O
peripheral O
visual O
target O
( O
S2 O
) O
is O
shortened O
when O
a O
non O
- O
informative O
cue O
( O
S1 O
) O
is O
flashed O
at O
the O
S2 O
location O
100 O
- O
150 O
ms O
before O
target O
onset O
( O
early O
facilitation O
). O

A O
second O
study O
group O
, O
with O
intact O
cardiac O
innervation O
, O
consisted O
of O
19 O
patients O
with O
stable O
angina O
pectoris O
class O
I O
to O
III O
. O

These O
viruses O
depend O
on O
the O
host O
cell O
machinery O
for O
their O
existence O
, O
and O
interference O
with O
these O
processes O
typically O
interferes O
with O
other O
important O
host O
physiology O
. O

Treatment O
was O
well O
- O
tolerated O
. O

A O
concentration O
of O
12 O
. O
5 O
ppm O
SO2 O
induced O
a O
decrease O
from O
baseline O
values O
of O
approximately O
80 O
% O
in O
mean O
MCA O
and O
of O
roughly O
70 O
% O
in O
mean O
CBF O
. O

We O
have O
used O
these O
modified O
assay O
conditions O
to O
extend O
studies O
on O
the O
transposition O
pathway O
. O

Renal O
cell O
carcinoma O
in O
children O
: O
a O
single O
institution O
' O
s O
experience O
. O

The O
data O
suggest O
that O
ICP10 I-GENE
constitutively O
increases O
ras I-GENE
activity O
, O
and O
its O
TM O
segment O
plays O
a O
critical O
role O
in O
transformation O
- O
related O
signaling O
pathways O
. O

Thus O
, O
we O
have O
separated O
the O
signal O
function O
from O
the O
anchor O
function O
of O
the O
6 O
. O
7K O
SA O
domain O
. O

Five O
concensus O
poly O
A O
addition O
sites O
are O
located O
in O
the O
350 O
base O
pairs O
immediately O
following O
the O
protein I-GENE
IX I-GENE
coding O
region O
. O

Factors O
associated O
with O
intrafamilial O
transmission O
of O
hepatitis O
B O
virus O
infection O
in O
Korea O
. O

Exposure O
to O
higher O
TPA O
concentrations O
decreased O
the O
content O
of O
these O
transcripts O
. O

Northern O
analysis O
, O
to O
search O
for O
a O
pcbAB I-GENE
transcript I-GENE
, O
showed O
no O
distinct O
transcript O
and O
indicated O
severely O
degraded O
mRNA O
. O

Our O
results O
indicate O
that O
the O
minimal O
requirements O
for O
induction O
of O
PEPCK I-GENE
by O
PKA I-GENE
and O
inhibition O
by O
insulin I-GENE
include O
: O
1 O
) O
the O
CREB I-GENE
activation I-GENE
domain I-GENE
, O
2 O
) O
the O
PEPCK I-GENE
TATA I-GENE
sequence I-GENE
, O
and O
3 O
) O
insulin I-GENE
- O
responsive O
hepatoma O
cells O
. O

The O
high O
degree O
of O
conservation O
between O
NQO2 I-GENE
and O
NQO1 I-GENE
gene I-GENE
organization O
and O
sequence O
confirmed O
that O
NQO2 I-GENE
gene I-GENE
encodes O
for O
a O
second O
member O
of O
the O
NQO I-GENE
gene I-GENE
family I-GENE
in O
human O
. O

The O
efficacy O
of O
a O
Propionibacterium O
acnes O
product O
for O
treatment O
of O
coliform O
mastitis O
was O
evaluated O
following O
intramammary O
infusion O
of O
Escherichia O
coli O
. O

The O
human I-GENE
eps15 I-GENE
gene I-GENE
, O
encoding O
a O
tyrosine I-GENE
kinase I-GENE
substrate O
, O
is O
conserved O
in O
evolution O
and O
maps O
to O
1p31 O
- O
p32 O
. O

The O
gene O
encoding O
the O
105 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
( I-GENE
p105 I-GENE
) I-GENE
precursor I-GENE
of O
the O
p50 I-GENE
subunit I-GENE
of O
transcription O
factor O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
also O
encodes O
a O
p70 I-GENE
I I-GENE
kappa I-GENE
B I-GENE
protein I-GENE
, O
I I-GENE
kappa I-GENE
B I-GENE
gamma I-GENE
, O
which O
is O
identical O
to O
the O
C O
- O
terminal O
607 O
amino O
acids O
of O
p105 I-GENE
. O

Alternative O
splicing O
of O
RNA O
transcripts O
encoded O
by O
the O
murine O
p105 I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
gene O
generates O
I I-GENE
kappa I-GENE
B I-GENE
gamma I-GENE
isoforms I-GENE
with O
different O
inhibitory O
activities O
. O

Topical O
L O
- O
NNA O
attenuated O
the O
hypercapnic O
increase O
of O
CoBF O
by O
52 O
+/- O
6 O
% O
and O
CeBF O
by O
29 O
+/- O
5 O
% O
after O
45 O
- O
min O
exposure O
. O

The O
experiment O
included O
6 O
male O
and O
4 O
female O
healthy O
subjects O
who O
, O
during O
a O
24 O
- O
hour O
stay O
in O
the O
respiration O
chambers O
, O
performed O
, O
in O
the O
morning O
and O
afternoon O
, O
15 O
min O
cycling O
with O
the O
total O
work O
of O
6 O
, O
750 O
kg O
m O
. O

These O
rearrangements O
result O
in O
the O
formation O
of O
chimeric O
genes O
showing O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
ret I-GENE
fused O
with O
the O
5 O
' O
end O
sequences O
of O
different O
genes O
. O

Frequent O
loss O
of O
heterozygosity O
( O
LOH O
) O
of O
> O
30 O
% O
of O
the O
informative O
cases O
was O
observed O
on O
chromosomes O
3p O
( O
41 O
. O
1 O
%), O
5q O
( O
52 O
. O
6 O
%), O
6p O
( O
30 O
. O
4 O
%), O
8p O
( O
33 O
. O
3 O
%), O
9p O
( O
35 O
. O
7 O
%), O
9q O
( O
30 O
. O
8 O
%), O
11p O
( O
32 O
. O
4 O
%), O
13q O
( O
52 O
. O
7 O
%), O
17p O
( O
55 O
. O
2 O
%), O
17q O
( O
33 O
. O
3 O
%), O
18q O
( O
45 O
. O
7 O
%), O
and O
19q O
( O
30 O
. O
4 O
%). O

A O
single O
amino O
acid O
change O
in O
the O
CPY I-GENE
vacuolar I-GENE
sorting I-GENE
signal I-GENE
prevents O
this O
interaction O
. O

Glutamyl I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
and O
prolyl I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
belong O
to O
different O
classes O
of O
aminoacyl I-GENE
- I-GENE
tRNA I-GENE
synthetases I-GENE
that O
are O
thought O
to O
have O
evolved O
along O
independent O
evolutionary O
pathways O
. O

Using O
the O
sequence O
data O
obtained O
from O
the O
human O
TCRAC I-GENE
/ O
TCRDC I-GENE
region O
, O
we O
have O
extended O
a O
polymerase O
chain O
reaction O
- O
based O
assay O
to O
test O
for O
the O
expression O
of O
the O
individual O
TCRAJ I-GENE
gene I-GENE
segments I-GENE
. O

This O
analysis O
revealed O
an O
intact O
gene O
( O
arg4 I-GENE
) O
showing O
a O
high O
degree O
of O
homology O
with O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
CPA2 I-GENE
gene I-GENE
encoding O
the O
large O
subunit O
of O
carbamoyl I-GENE
- I-GENE
phosphate I-GENE
synthetase I-GENE
( O
CPS I-GENE
- I-GENE
A I-GENE
). O

Restriction O
analysis O
and O
Southern O
hybridization O
revealed O
the O
presence O
of O
Tn5422 I-GENE
in O
all O
the O
plasmid O
- O
mediated O
cadmium O
- O
resistant O
L O
. O
monocytogenes O
strains O
tested O
but O
not O
in O
strains O
encoding O
cadmium O
resistance O
on O
the O
chromosome O
. O

The O
baroreflex O
latency O
( O
from O
the O
ECG O
R O
- O
wave O
to O
the O
integrated O
MSNA O
burst O
peak O
) O
was O
constant O
at O
approximately O
1 O
. O
20 O
s O
during O
sleep O
, O
suggesting O
that O
pulse O
- O
synchronicity O
was O
maintained O
. O

DESIGN O
-- O
A O
randomised O
study O
was O
conducted O
in O
all O
women O
aged O
50 O
- O
70 O
years O
who O
were O
eligible O
for O
breast O
cancer O
screening O
and O
living O
in O
the O
city O
of O
Utrecht O
. O

Identification O
of O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
in O
the O
Marek O
' O
s O
disease O
virus O
long O
internal O
repeat O
region O
which O
encodes O
a O
unique O
14 O
- O
kilodalton O
polypeptide O
. O

We O
have O
used O
a O
full O
- O
length O
cDNA O
clone O
of O
a O
mouse O
hepatitis O
virus O
strain O
A59 O
defective O
interfering O
( O
DI O
) O
RNA O
, O
pMIDI I-GENE
- I-GENE
C I-GENE
, O
and O
cassette O
mutagenesis O
to O
study O
the O
mechanism O
of O
coronavirus O
subgenomic O
mRNA O
synthesis O
. O

To O
study O
the O
structure O
- O
function O
of O
the O
gene I-GENE
5 I-GENE
product I-GENE
, O
wild O
- O
type O
and O
mutant O
forms O
of O
NS53 I-GENE
were O
produced O
by O
using O
a O
recombinant O
baculovirus O
expression O
system O
and O
a O
recombinant O
vaccinia O
virus O
/ O
T7 O
( O
vTF7 O
- O
3 O
) O
expression O
system O
. O

Gel O
electrophoresis O
and O
Western O
immunoblot O
analyses O
of O
intracellular O
fractions O
derived O
from O
infected O
cells O
revealed O
that O
large O
amounts O
of O
NS53 I-GENE
were O
present O
in O
the O
cytosol O
and O
in O
association O
with O
the O
cytoskeletal O
matrix O
. O

The O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
2 I-GENE
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
6 O
near O
the O
HLA I-GENE
locus I-GENE
. O

The O
mature O
AP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
is O
spliced O
from O
7 O
exons O
distributed O
over O
a O
region O
of O
18 O
kb O
genomic O
DNA O
. O

San O
Martin O
' O
s O
psychological O
traits O
coupled O
to O
his O
work O
with O
masonic O
lodges O
that O
allowed O
him O
to O
display O
his O
abilities O
as O
strategist O
and O
political O
ruler O
. O

The O
participants O
were O
homosexual O
men O
in O
hepatitis O
B O
vaccine O
trials O
in O
Amsterdam O
( O
n O
= O
74 O
), O
New O
York O
City O
( O
n O
= O
120 O
), O
and O
San O
Francisco O
( O
n O
= O
168 O
). O

The O
7 O
- O
day O
treatment O
resulted O
in O
a O
decrease O
in O
mitochondrial O
uptake O
of O
Rh123 O
and O
an O
increase O
in O
NAO O
uptake O
. O

Thrombotic O
thrombocytopenic O
purpura O
in O
systemic O
lupus O
erythematosus O
. O

Comparison O
with O
the O
crystal O
structure O
of O
Desulfovibrio O
gigas O
, O
Dg O
, O
Fd I-GENE
( O
Kissinger O
et O
al O
., O
1991 O
) O
reveals O
a O
very O
similar O
folding O
topology O
, O
although O
several O
secondary O
structural O
elements O
are O
extended O
in O
Pf O
relative O
to O
Dg O
Fd I-GENE
. O

CONCLUSIONS O
: O
Serum I-GENE
prolactin I-GENE
concentrations O
show O
age O
related O
variations O
in O
presumably O
fertile O
men O
. O

Eight O
highly O
trained O
male O
kayakers O
were O
studied O
to O
determine O
the O
relationship O
between O
critical O
power O
( O
CP O
) O
and O
the O
onset O
of O
blood O
lactate O
accumulation O
( O
OBLA O
). O

As O
in O
S O
. O
cerevisiae O
, O
the O
sequence O
of O
rhp51 I-GENE
+ I-GENE
showed O
two O
MluI I-GENE
cell I-GENE
- I-GENE
cycle I-GENE
boxes I-GENE
and O
a O
putative O
DNA O
damage O
- O
responsive O
element O
in O
its O
upstream O
region O
. O

Women O
' O
s O
opportunities O
for O
paid O
work O
outside O
the O
home O
are O
constrained O
by O
their O
role O
as O
primary O
carer O
within O
the O
family O
, O
writes O
Trudy O
Wynne O
. O

A O
partial O
cDNA O
sequence O
indicated O
that O
the O
T I-GENE
lymphocyte I-GENE
early I-GENE
- I-GENE
activation I-GENE
gene I-GENE
( O
Tea I-GENE
) O
encodes O
a O
protein O
related O
to O
the O
dual O
- O
function O
ecotropic I-GENE
retrovirus I-GENE
receptor I-GENE
/ O
cationic I-GENE
amino I-GENE
acid I-GENE
transporter I-GENE
( O
ecoR I-GENE
/ O
CAT1 I-GENE
), O
and O
RNA O
blots O
suggested O
highest O
Tea I-GENE
expression O
in O
T O
lymphocytes O
and O
liver O
( O
MacLeod O
, O
C O
. O
L O
., O
Finley O
, O
K O
., O
Kakuda O
, O
D O
. O

Furthermore O
, O
unlike O
the O
case O
for O
HIS3 I-GENE
where O
only O
a O
limited O
subset O
of O
TATA O
- O
like O
sequences O
can O
activate O
transcription O
in O
conjunction O
with O
GCN4p I-GENE
, O
many O
divergent O
TATA O
- O
like O
sequences O
allowed O
GCN4p I-GENE
activation O
of O
TRP3 I-GENE
. O

Bacterially O
expressed O
protein O
, O
as O
well O
as O
the O
in O
vitro O
reticulocyte O
lysate O
translation O
product O
, O
comigrated O
with O
the O
purified O
37 O
- O
kDa O
protein O
on O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gels O
. O

In O
addition O
, O
this O
kinase O
is O
well O
conserved O
evolutionarily O
, O
ubiquitously O
expressed O
, O
and O
its O
genes O
map O
to O
a O
position O
on O
human O
chromosome O
1 O
frequently O
deleted O
in O
the O
late O
stages O
of O
tumorigenesis O
. O

Deletion O
analysis O
of O
the O
ICL1 I-GENE
promoter I-GENE
led O
to O
the O
identification O
of O
an O
upstream O
activating O
sequence O
element O
, O
UASICL1 O
( O
5 O
' O
CATTCATCCG O
3 O
'), O
necessary O
and O
sufficient O
for O
conferring O
carbon O
source O
- O
dependent O
regulation O
on O
a O
heterologous O
reporter O
gene O
. O

Interestingly O
, O
the O
interaction O
of O
ZAP I-GENE
- I-GENE
70 I-GENE
with O
the O
motif O
was O
dependent O
on O
the O
presence O
of O
both O
ZAP I-GENE
- I-GENE
70 I-GENE
SH2 I-GENE
domains I-GENE
and O
both O
of O
the O
tyrosine O
residues O
in O
the O
motif O
, O
suggesting O
that O
ZAP I-GENE
- I-GENE
70 I-GENE
interacts O
with O
two O
phosphotyrosine O
residues O
and O
that O
the O
binding O
of O
the O
two O
SH2 I-GENE
domains I-GENE
is O
cooperative O
. O

PRL I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
dephosphorylate O
phosphotyrosine O
substrates O
, O
and O
mutation O
of O
the O
active O
- O
site O
cysteine O
residue O
abolishes O
this O
activity O
. O

In O
Mv1Lu O
lung O
epithelial O
cells O
, O
ActR I-GENE
- I-GENE
IB I-GENE
and O
T I-GENE
beta I-GENE
R I-GENE
- I-GENE
I I-GENE
signal O
a O
common O
set O
of O
growth O
- O
inhibitory O
and O
transcriptional O
responses O
in O
association O
with O
their O
corresponding O
ligands O
and O
type I-GENE
II I-GENE
receptors I-GENE
. O

50 O
kDa O
and O
130 O
- O
170 O
kDa O
were O
detected O
. O

H O
- O
7 O
, O
which O
specifically O
, O
although O
weakly O
, O
inhibited O
PKC I-GENE
activation O
, O
had O
no O
effect O
on O
tyrosine O
phosphorylation O
and O
PtdIns O
( O
3 O
, O
4 O
) O
P2 O
production O
. O

The O
effects O
of O
systemic O
glucose O
concentration O
on O
brain O
metabolism O
following O
repeated O
brain O
ischemia O
. O

This O
strategy O
was O
used O
to O
place O
both O
the O
Tn903 I-GENE
neo I-GENE
gene I-GENE
and O
the O
Rhodosporidium I-GENE
toruloides I-GENE
phenylalanine I-GENE
ammonia I-GENE
lyase I-GENE
( O
PAL I-GENE
)- O
encoding O
gene O
under O
the O
transcriptional O
control O
of O
pPGK I-GENE
:: O
REP2 I-GENE
. O

In O
the O
case O
of O
congenital O
protein I-GENE
C I-GENE
deficiency O
, O
vitamin O
K O
antagonists O
must O
be O
started O
cautiously O
due O
to O
the O
risk O
of O
skin O
necrosis O
. O

A O
- O
69 O
- O
year O
- O
old O
patient O
with O
postoperative O
small O
- O
bowel O
obstruction O
underwent O
laparotomy O
three O
times O
. O

On O
physical O
examination O
a O
mild O
symmetrical O
polyarthritis O
of O
small O
and O
large O
joints O
was O
seen O
. O

In O
addition O
, O
we O
observe O
that O
the O
hUBF I-GENE
- I-GENE
promoter I-GENE
interaction O
is O
highly O
sensitive O
to O
the O
antagonistic O
effects O
of O
cisplatin O
- O
DNA O
adducts O
. O

We O
conclude O
that O
the O
SIMV O
is O
useful O
in O
weaning O
neonates O
from O
the O
ventilator O
. O

VP O
- O
16 O
, O
ifosfamide O
and O
cisplatin O
( O
VIP O
) O
for O
extensive O
small O
cell O
lung O
cancer O
. O

A O
total O
of O
7 O
( O
4 O
males O
and O
3 O
females O
) O
patients O
were O
included O
in O
this O
retrospective O
study O
to O
determine O
the O
sensitivity O
of O
radioimmunoscintigraphy O
with O
I O
- O
131 O
labeled O
anti I-GENE
CEA I-GENE
/ O
CA I-GENE
19 I-GENE
- I-GENE
9 I-GENE
monoclonal O
antibodies O
. O

Simultaneous O
, O
bilateral O
and O
permanent O
ventilation O
with O
a O
diaphragm O
pacing O
in O
childhood O
: O
the O
implantation O
technique O
and O
indications O

A O
genomic O
clone O
for O
the O
cyc07 I-GENE
gene I-GENE
, O
which O
is O
expressed O
specifically O
at O
the O
S O
phase O
during O
the O
cell O
cycle O
in O
synchronous O
cultures O
of O
periwinkle O
( O
Catharanthus O
roseus O
) O
cells O
, O
was O
isolated O
. O

CONCLUSIONS O
: O
Translocation O
of O
bacteria O
or O
endotoxin O
from O
the O
gastrointestinal O
tract O
into O
the O
bloodstream O
has O
been O
noted O
in O
animal O
experiments O
; O
however O
, O
translocation O
was O
not O
detected O
in O
our O
patients O
with O
hemorrhagic O
shock O
. O

The O
pyrR I-GENE
and O
pyrP I-GENE
genes I-GENE
encoded O
polypeptides O
with O
calculated O
molecular O
masses O
of O
19 O
. O
9 O
and O
45 O
. O
2 O
kDa O
, O
respectively O
. O

Southern O
blotting O
analysis O
implied O
the O
occurrence O
of O
multiple O
COXVb I-GENE
genes I-GENE
in O
the O
rat O
genome O
. O

Acylation O
with O
the O
palmitate O
analog O
was O
prevented O
when O
Gly O
- O
2 O
was O
mutated O
to O
alanine O
, O
implying O
that O
N O
- O
myristylation O
is O
required O
for O
palmitylation O
, O
and O
when O
either O
Cys O
- O
3 O
or O
Cys O
- O
6 O
was O
mutated O
to O
serine O
. O

Subunit O
composition O
and O
domain O
structure O
of O
the O
Spo0A I-GENE
sporulation I-GENE
transcription I-GENE
factor I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
. O

Electrophoretic O
mobility O
shift O
analysis O
indicates O
that O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
, O
as O
well O
as O
other O
related O
members O
of O
this O
family O
, O
bind O
specifically O
to O
the O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
site O
in O
the O
IL I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
. O

BYV O
, O
citrus O
tristeza O
virus O
( O
CTV O
), O
beet O
yellow O
stunt O
virus O
( O
BYSV O
) O
and O
carnation O
necrotic O
fleck O
virus O
templates O
produced O
1 O
kb O
amplification O
products O
, O
which O
were O
shown O
by O
sequencing O
to O
represent O
fragments O
of O
the O
respective O
HSP70 I-GENE
genes I-GENE
. O

To O
identify O
the O
precise O
location O
of O
the O
phosphorylation O
site O
on O
the O
64 O
- O
kDa O
protein O
, O
a O
step O
- O
by O
- O
step O
mutagenesis O
procedures O
was O
followed O
. O

The O
p53 I-GENE
tumor I-GENE
suppressor I-GENE
gene I-GENE
product I-GENE
, O
a O
sequence O
- O
specific O
DNA O
- O
binding O
protein O
, O
has O
been O
shown O
to O
act O
as O
a O
transcriptional O
activator O
and O
repressor O
both O
in O
vitro O
and O
in O
vivo O
. O

Mutational O
analysis O
of O
chromosomal O
segment O
64AB O
, O
a O
region O
containing O
the O
glutamic I-GENE
acid I-GENE
decarboxylase I-GENE
gene I-GENE
. O

Rearrangements O
of O
the O
NFKB2 I-GENE
gene I-GENE
are O
associated O
with O
lymphoid O
malignancies O
, O
but O
the O
functional O
significance O
of O
these O
alterations O
is O
not O
known O
. O

Cloning O
and O
sequencing O
of O
the O
corresponding O
cDNAs O
indicates O
that O
, O
via O
alternative O
splicing O
, O
the O
rearranged O
gene O
codes O
for O
two O
proteins O
of O
84 O
and O
85 O
kD O
( O
p84 I-GENE
/ I-GENE
85 I-GENE
) O
which O
retain O
the O
DNA O
- O
binding O
rel I-GENE
domain I-GENE
and O
the O
first O
five O
ankyrin I-GENE
repeats O
, O
but O
have O
lost O
their O
carboxy O
- O
terminus O
including O
the O
seventh O
ankyrin I-GENE
repeat O
. O

Transient O
co O
- O
transfection O
assays O
involving O
NFKB2 I-GENE
expression O
vectors O
and O
kappa I-GENE
B I-GENE
- O
driven O
reporter O
plasmids O
indicate O
that O
NFKB2 I-GENE
p85 I-GENE
has O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
NFKB2 I-GENE
p52 I-GENE
. O

Also O
, O
HR21ap I-GENE
as O
well O
as O
HR21Xap I-GENE
are O
specific O
in O
their O
inhibition O
of O
Sp1 I-GENE
binding O
. O

Intravenous O
antibiotic O
therapy O
in O
cystic O
fibrosis O
: O
in O
hospital O
or O
at O
home O
? O

Open O
reading O
frames O
in O
a O
4556 O
nucleotide O
sequence O
within O
MDV I-GENE
- I-GENE
1 I-GENE
BamHI I-GENE
- I-GENE
D I-GENE
DNA I-GENE
fragment I-GENE
: O
evidence O
for O
splicing O
of O
mRNA O
from O
a O
new O
viral O
glycoprotein O
gene O
. O

The O
ns2 I-GENE
gene I-GENE
comprises O
an O
open O
reading O
frame O
( O
ORF O
) O
encoding O
a O
putative O
nonstructural O
( O
ns O
) O
protein O
of O
279 O
amino O
acids O
with O
a O
predicted O
molecular O
mass O
of O
32 O
- O
kDa O
. O

Co O
- O
transfection O
of O
a O
tat I-GENE
expressing O
plasmid O
with O
these O
viruses O
containing O
the O
tat I-GENE
ORF I-GENE
mutations O
resulted O
in O
higher O
levels O
of O
virus O
production O
demonstrating O
that O
the O
effects O
of O
both O
mutants O
are O
tat I-GENE
specific O
. O

Analysis O
of O
the O
gag I-GENE
and O
rev I-GENE
proteins I-GENE
in O
the O
transfected O
cells O
demonstrated O
that O
these O
proteins O
were O
not O
detectable O
in O
cells O
transfected O
with O
the O
tat I-GENE
mutants I-GENE
but O
could O
be O
readily O
detected O
when O
the O
mutations O
were O
complemented O
in O
trans O
with O
a O
tat I-GENE
expression O
vector O
. O

The O
hydrophobicity O
profile O
of O
the O
methyltransferase O
reveals O
the O
presence O
of O
at O
least O
five O
potential O
transmembrane O
domains O
. O

Measurement O
of O
SaO2 O
at O
moderate O
altitude O
can O
be O
helpful O
in O
the O
care O
of O
both O
healthy O
and O
ill O
newborns O
or O
infants O
. O

To O
determine O
whether O
the O
excess O
prevalence O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
in O
US O
black O
and O
Hispanic O
homosexual O
men O
relative O
to O
white O
men O
can O
be O
explained O
by O
differences O
in O
sociodemographic O
factors O
, O
history O
of O
sexually O
transmitted O
diseases O
, O
or O
sexual O
and O
drug O
- O
use O
behaviors O
, O
the O
authors O
conducted O
a O
cross O
- O
sectional O
analysis O
of O
baseline O
HIV O
- O
1 O
seroprevalence O
and O
HIV O
- O
1 O
risk O
factors O
among O
4 O
, O
475 O
non O
- O
Hispanic O
white O
, O
234 O
Hispanic O
white O
, O
and O
194 O
black O
homosexual O
men O
from O
four O
centers O
in O
the O
United O
States O
( O
Baltimore O
/ O
Washington O
, O
DC O
, O
Pittsburgh O
, O
Chicago O
, O
and O
Los O
Angeles O
). O

The O
patients O
in O
one O
group O
had O
intrauterine O
catheters O
inserted O
and O
oxytocin I-GENE
was O
titrated O
to O
achieve O
the O
75th O
percentile O
of O
uterine O
activity O
observed O
in O
spontaneous O
normal O
labour O
according O
to O
parity O
. O

Continued O
development O
of O
the O
rat O
conditioning O
paradigm O
is O
especially O
warranted O
because O
of O
the O
ability O
to O
record O
sympathetic O
nerve O
activity O
in O
intact O
, O
awake O
subjects O
and O
the O
large O
number O
of O
readily O
available O
genetic O
strains O
, O
which O
model O
human O
pathological O
states O
. O

The O
ultrastructure O
of O
retinal O
vessels O
was O
examined O
in O
three O
eyes O
from O
diabetic O
patients O
and O
two O
eyes O
from O
control O
subjects O
. O

The O
regulatory O
region O
also O
has O
a O
sequence O
similar O
to O
the O
binding O
site O
for O
a O
liver O
- O
specific O
transcription O
factor O
, O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
HNF I-GENE
- I-GENE
1 I-GENE
), O
at O
positions O
- O
120 O
to O
- O
132 O
. O

Thus O
, O
we O
have O
identified O
a O
GRE O
sufficient O
to O
account O
for O
full O
glucocorticoid O
inducibility O
and O
an O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
close O
to O
the O
promoter O
that O
are O
major O
determinants O
of O
transcriptional O
control O
of O
the O
Xenopus I-GENE
fibrinogen I-GENE
B I-GENE
beta I-GENE
subunit I-GENE
gene I-GENE
in O
cells O
from O
normal O
liver O
tissue O
. O

Acad O
. O

The O
PRB I-GENE
- I-GENE
1b I-GENE
gene I-GENE
encodes O
for O
a O
basic O
- O
type O
component O
of O
the O
pathogenesis O
- O
related O
PR I-GENE
- I-GENE
1 I-GENE
protein I-GENE
family I-GENE
. O

Replacement O
of O
the O
CRE O
with O
a O
second O
copy O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
results O
in O
a O
level O
of O
transcriptional O
activity O
comparable O
with O
that O
of O
the O
wild O
- O
type O
sequence O
, O
but O
replacement O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
with O
a O
CRE O
abolishes O
activity O
. O

The O
T I-GENE
- I-GENE
cyt I-GENE
promoter I-GENE
, O
although O
of O
bacterial O
origin O
is O
active O
in O
planta O
and O
the O
30 I-GENE
bp I-GENE
cyt I-GENE
- I-GENE
1 I-GENE
element I-GENE
is O
located O
within O
a O
region O
that O
is O
essential O
for O
T I-GENE
- I-GENE
cyt I-GENE
promotor I-GENE
activity O
in O
leaf O
, O
stem O
and O
root O
cells O
of O
tobacco O
plants O
. O

Reviewing O
manuscripts O
: O
developing O
an O
efficient O
system O
. O

We O
suggest O
that O
CT O
scan O
be O
preferable O
in O
diagnosis O
of O
tumors O
in O
that O
area O
. O

SIN O
- O
1 O
had O
no O
influence O
on O
either O
the O
ischemic O
parameters O
in O
the O
surface O
electrocardiogram O
( O
ECG O
) O
or O
the O
intracoronary O
ECG O
. O

Effect O
of O
aging O
on O
respiratory O
skeletal O
muscles O
. O

Two O
BASIC O
computer O
programs O
using O
logit O
transformation O
for O
the O
analysis O
of O
S O
- O
shaped O
curves O
are O
presented O
. O

The O
yeast I-GENE
SSS1 I-GENE
gene I-GENE
is O
essential O
for O
secretory O
protein O
translocation O
and O
encodes O
a O
conserved O
protein O
of O
the O
endoplasmic O
reticulum O
. O

The O
lengths O
of O
the O
complete O
polypeptide O
chain O
of O
the O
recombinant O
enzyme O
and O
its O
transit O
peptide O
are O
388 O
and O
53 O
residues O
, O
respectively O
. O

The O
absence O
of O
H4PteGlun O
bound O
to O
the O
T I-GENE
protein I-GENE
in O
our O
experimental O
conditions O
demonstrates O
that O
H4PteGlun O
is O
not O
covalently O
linked O
to O
the O
T I-GENE
protein I-GENE
. O

TATA O
and O
CCAAT O
boxes O
are O
located O
34 O
- O
bp O
and O
68 O
- O
bp O
, O
respectively O
, O
upstream O
of O
the O
transcription O
start O
site O
, O
the O
5 O
'- O
untranslated O
leader O
is O
78 O
nucleotides O
long O
, O
and O
the O
intronless O
gene O
has O
at O
least O
two O
different O
polyadenylation O
sites O
. O

GGS1 I-GENE
is O
the O
same O
gene O
as O
TPS1 I-GENE
which O
was O
identified O
as O
encoding O
a O
subunit O
of O
the O
trehalose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
synthase I-GENE
/ I-GENE
phosphatase I-GENE
complex I-GENE
and O
it O
is O
allelic O
to O
the O
fdp1 I-GENE
, O
byp1 I-GENE
, O
glc6 I-GENE
and O
cif1 O
mutations O
. O

We O
also O
compared O
the O
sequence O
with O
the O
partly O
homologous O
products O
of O
the O
S O
. O
cerevisiae O
genes O
TPS2 I-GENE
and O
TSL1 I-GENE
which O
code O
for O
the O
larger O
subunits O
of O
the O
trehalose I-GENE
synthase I-GENE
complex I-GENE
and O
with O
a O
TSL1 I-GENE
homologue I-GENE
, O
TPS3 I-GENE
, O
of O
unknown O
function O
. O

Stroop O
interference O
: O
aging O
effects O
assessed O
with O
the O
Stroop O
Color O
- O
Word O
Test O
. O

Stimulation O
of O
[ O
3H O
] O
PA O
production O
upon O
CD3 I-GENE
cross O
- O
linking O
was O
77 O
% O
lower O
in O
permeabilized O
CD45 I-GENE
- I-GENE
cells O
than O
in O
CD45 I-GENE
+ I-GENE
cells O
, O
consistent O
with O
the O
reduced O
activity O
of O
p59fyn I-GENE
in O
CD45 I-GENE
- I-GENE
cells O
. O

CONCLUSION O
: O
The O
study O
demonstrates O
that O
transvaginal O
ultrasonography O
has O
an O
efficiency O
of O
88 O
% O
in O
differentiating O
endometriomas O
from O
other O
ovarian O
masses O
with O
a O
specificity O
of O
90 O
%. O

Genomic O
Southern O
blot O
analysis O
of O
rat I-GENE
EFIA I-GENE
( O
gene O
encoding O
enhancer I-GENE
factor I-GENE
I I-GENE
subunit I-GENE
A I-GENE
) O
reveals O
a O
complex O
band O
pattern O
when O
cDNA O
subfragment O
probes O
are O
used O
. O

The O
effect O
of O
ibopamine O
and O
furosemide O
in O
130 O
patients O
with O
NYHA O
Class O
I O
and O
II O
heart O
failure O
were O
studied O
in O
a O
parallel O
, O
double O
- O
blind O
, O
randomized O
placebo O
- O
controlled O
multi O
- O
centre O
trial O
. O

The O
nit I-GENE
- I-GENE
3 I-GENE
gene I-GENE
of I-GENE
the I-GENE
filamentous I-GENE
fungus I-GENE
Neurospora I-GENE
crassa I-GENE
encodes O
nitrate I-GENE
reductase I-GENE
, O
the O
enzyme O
which O
catalyzes O
the O
first O
step O
in O
nitrate O
assimilation O
. O

Unfolding O
can O
be O
described O
by O
a O
two O
- O
state O
process O
since O
a O
ratio O
of O
delta O
Hcalorimetric O
to O
delta O
Hvan O
' O
t O
Hoff O
equals O
0 O
. O
96 O
. O

A O
Dictyostelium O
transformant O
overexpressing O
DdPTPa I-GENE
does O
not O
develop O
normally O
. O

This O
motif O
has O
been O
shown O
to O
mediate O
protein O
interactions O
in O
the O
case O
of O
ankyrin I-GENE
as O
well O
as O
several O
other O
repeat O
- O
bearing O
proteins O
. O

[ I-GENE
Ala85 I-GENE
] I-GENE
Dk I-GENE
( I-GENE
69 I-GENE
- I-GENE
85 I-GENE
) I-GENE
retains O
full O
biological O
activity O
. O

We O
postulate O
that O
CaM I-GENE
binding O
by O
HIV I-GENE
envelope I-GENE
proteins I-GENE
is O
likely O
to O
exert O
diverse O
modulatory O
effects O
, O
and O
the O
mechanism O
for O
HIV O
- O
induced O
cytotoxicity O
may O
involve O
, O
in O
part O
, O
inhibition O
of O
CaM I-GENE
- O
regulated O
cellular O
functions O
. O

There O
was O
no O
apparent O
effect O
of O
growth O
temperature O
on O
the O
steady O
- O
state O
levels O
of O
fad7 I-GENE
mRNA I-GENE
in O
wild O
type O
plants O
. O

The O
major O
myosin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
skeletal I-GENE
muscle I-GENE
MyBP I-GENE
- I-GENE
C I-GENE
( O
C I-GENE
protein I-GENE
) O
resides O
in O
the O
COOH O
- O
terminal O
, O
immunoglobulin I-GENE
C2 I-GENE
motif I-GENE
. O

A O
second O
important O
molecule O
in O
TCR I-GENE
signal O
transduction O
is O
the O
guanine I-GENE
nucleotide I-GENE
binding I-GENE
protein I-GENE
, O
p21ras I-GENE
, O
which O
is O
coupled O
to O
the O
TCR I-GENE
by O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
dependent O
mechanism O
. O

Our O
results O
indicate O
that O
periseizure O
lipid O
accumulation O
is O
related O
to O
cortical O
oxygenation O
. O

We O
conclude O
that O
the O
QLMI O
questionnaire O
has O
good O
potential O
as O
an O
instrument O
for O
assessing O
QL O
in O
post O
- O
AMI O
patients O
and O
that O
it O
can O
be O
successfully O
self O
- O
administered O
. O

Most O
smokers O
would O
prefer O
to O
quit O
smoking O
on O
their O
own O
. O

The O
inhibitory O
response O
to O
taps O
is O
essentially O
a O
protective O
reflex O
which O
probably O
serves O
to O
reduce O
the O
activity O
of O
the O
jaw O
- O
closing O
muscles O
when O
one O
bites O
unexpectedly O
on O
hard O
objects O
. O

The O
action O
of O
nef I-GENE
was O
specific O
to O
the O
LTR O
, O
as O
expression O
of O
nef I-GENE
had O
no O
effect O
on O
the O
activity O
of O
the O
simian O
virus O
40 O
, O
c I-GENE
- I-GENE
fms I-GENE
, O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
, O
or O
type I-GENE
5 I-GENE
acid I-GENE
phosphatase I-GENE
promoter I-GENE
. O
trans O
- O
activating O
activity O
was O
also O
manifested O
by O
a O
frameshift O
mutant O
expressing O
only O
the O
first O
35 O
amino O
acids O
of O
the O
protein O
. O

The O
product O
of O
the O
vpr I-GENE
open I-GENE
reading I-GENE
frame I-GENE
of I-GENE
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
is O
a O
15 O
- O
kDa O
, O
arginine O
- O
rich O
protein O
that O
is O
present O
in O
virions O
in O
molar O
quantities O
equivalent O
to O
that O
of O
Gag I-GENE
. O

The O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
- I-GENE
expressed I-GENE
mutant I-GENE
P1 I-GENE
polyproteins I-GENE
were O
analyzed O
for O
proteolytic O
processing O
defects O
in O
cells O
coinfected O
with O
a O
recombinant O
vaccinia O
virus O
( O
VVP3 O
) O
that O
expresses O
the O
poliovirus I-GENE
3CD I-GENE
protease I-GENE
and O
for O
processing O
and O
assembly O
defects O
by O
using O
a O
trans O
complementation O
system O
in O
which O
P1 I-GENE
- O
expressing O
recombinant O
vaccinia O
viruses O
provide O
capsid I-GENE
precursor I-GENE
to O
a O
defective O
poliovirus O
genome O
that O
does O
not O
express O
functional O
capsid I-GENE
proteins I-GENE
( O
D O
. O

In O
contrast O
, O
capsid I-GENE
proteins I-GENE
derived O
from O
the O
P1 I-GENE
precursor I-GENE
with O
a O
valine O
substitution O
at O
the O
amino O
terminus O
of O
VP1 I-GENE
( O
VP1 I-GENE
- I-GENE
G001V I-GENE
) O
assembled O
empty O
capsid O
particles O
but O
were O
deficient O
in O
assembling O
RNA O
- O
containing O
virions O
. O

RESULTS O
: O
In O
an O
18 O
moth O
period O
and O
out O
of O
a O
total O
of O
284 O
positive O
blood O
cultures O
( O
154 O
significant O
isolations O
) O
14 O
episodes O
of O
bacteremia O
by O
M O
. O
tuberculosis O
were O
studied O
in O
12 O
prison O
patients O
coinfected O
by O
the O
human O
immunodeficiency O
virus O
with O
associated O
severe O
immunosuppression O
( O
mean O
of O
CD4 I-GENE
= O
0 O
. O
068 O
x O
10 O
( O
9 O
)/ O
l O
). O

Acid O
instilled O
on O
the O
larynx O
of O
maturing O
rabbits O
resulted O
in O
significant O
obstructive O
, O
central O
, O
and O
mixed O
apnea O
. O

By O
using O
total O
- O
protein O
extracts O
from O
mycelia O
grown O
under O
penicillin O
producing O
conditions O
we O
have O
detected O
a O
DNA O
- O
binding O
activity O
that O
specifically O
shifts O
a O
promoter O
fragment O
located O
between O
- O
654 O
and O
- O
455 O
( O
relative O
to O
IPNS I-GENE
tsp I-GENE
). O

A O
series O
of O
5 O
'- O
deletions O
revealed O
that O
the O
fragment O
- O
218 O
to O
+ O
4 O
from O
the O
TSS O
had O
the O
highest O
promoter O
activity O
, O
nearly O
1000 O
- O
fold O
greater O
than O
the O
promoterless O
chloramphenicol I-GENE
acetyltransferase I-GENE
construct I-GENE
. O

The O
lemdr1 I-GENE
gene I-GENE
was O
cloned O
in O
the O
expression O
vector O
pALTNEO O
and O
transfected O
into O
wild O
- O
type O
L O
. O
enriettii O
and O
the O
resulting O
transfected O
cells O
were O
resistant O
to O
vinblastine O
but O
at O
lower O
levels O
than O
in O
the O
selected O
mutant O
cells O
. O

The O
bioavailability O
of O
etodolac O
from O
capsules O
exposed O
to O
stressed O
conditions O
was O
compared O
in O
both O
dogs O
and O
humans O
to O
capsules O
stored O
at O
RT O
conditions O
. O

Similar O
synergistic O
activation O
was O
observed O
in O
the O
IL I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
, O
which O
also O
contains O
both O
NF I-GENE
- I-GENE
IL6 I-GENE
and O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
binding I-GENE
sites I-GENE
. O

Notice O
of O
retraction O
. O

No O
homology O
was O
found O
between O
the O
36K O
protein O
and O
known O
structures O
of O
proteins O
. O

We O
report O
an O
odd O
case O
of O
marked O
enlargement O
of O
suprapineal O
recess O
in O
a O
patient O
with O
triventricular O
hydrocephalus O
. O

As O
regards O
lipid O
metabolism O
, O
the O
mean O
values O
for O
total O
triglycerides O
, O
cholesterol O
, O
LDL I-GENE
- I-GENE
cholesterol I-GENE
and O
HDL I-GENE
- I-GENE
cholesterol I-GENE
seen O
at O
the O
end O
of O
five O
years O
of O
Norplant O
- O
2 O
rod O
use O
and O
six O
months O
postremoval O
were O
similar O
to O
the O
preinsertion O
mean O
. O

At O
a O
PaCO2 O
of O
40 O
mmHg O
, O
baseline O
brain O
pHi O
measured O
7 O
. O
03 O
+/- O
0 O
. O
04 O
, O
while O
regional O
cortical O
blood O
flow O
was O
47 O
. O
0 O
+/- O
4 O
. O
3 O
ml O
. O
100 O
g O
- O
1 O
. O
min O
- O
1 O
. O

CPAP O
reduced O
isotime O
( O
defined O
as O
the O
last O
common O
minute O
of O
exercise O
) O
VO2 O
and O
dyspnea O
in O
those O
patients O
with O
more O
severe O
lung O
disease O
, O
but O
these O
values O
tended O
to O
increase O
slightly O
in O
the O
patients O
with O
only O
mild O
lung O
disease O
. O

Effects O
of O
diltiazem O
on O
netilmicin O
- O
induced O
nephrotoxicity O
in O
rabbits O
. O

Four O
forms O
of O
salmonellosis O
were O
recognised O
in O
feedlots O
and O
during O
transport O
by O
sea O
: O
septicaemic O
, O
and O
acute O
, O
subacute O
and O
chronic O
enteric O
. O

About O
20 O
% O
of O
single O
- O
stranded O
DNA O
binding O
was O
observed O
in O
the O
presence O
of O
MgdTDP O
, O
but O
none O
was O
detectable O
in O
the O
absence O
of O
nucleotides O
. O

To O
our O
knowledge O
this O
is O
the O
first O
case O
in O
which O
a O
probable O
association O
between O
cholelithiasis O
and O
Wildervanck O
' O
s O
syndrome O
has O
been O
recorded O
. O

Both O
4 O
, O
8 O
- O
DiMeIQx O
and O
A O
alpha O
C O
were O
found O
at O
< O
1 O
p O
. O
p O
. O
b O
. O

Three O
cysteine O
and O
four O
tryptophan O
residues O
, O
previously O
identified O
as O
conserved O
amongst O
nitrous I-GENE
- I-GENE
oxide I-GENE
reductases I-GENE
, O
are O
found O
in O
the O
Paracoccus O
enzyme O
. O

Recombinant I-GENE
Leishmania I-GENE
surface I-GENE
glycoprotein I-GENE
GP63 I-GENE
is O
secreted O
in O
the O
baculovirus O
expression O
system O
as O
a O
latent O
metalloproteinase I-GENE
. O

Delineating O
the O
molecular O
basis O
for O
agonist O
- O
induced O
destabilization O
of O
mRNA O
of O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
linked I-GENE
receptors I-GENE
that O
contributes O
to O
receptor O
down O
- O
regulation O
is O
fundamental O
to O
our O
understanding O
of O
long O
- O
term O
regulation O
of O
receptors O
by O
agonist O
. O

Addition O
of O
phalloidin O
- O
stabilized O
F I-GENE
- I-GENE
actin I-GENE
nuclei O
and O
phalloidin O
restored O
L266D O
actin I-GENE
' O
s O
ability O
to O
polymerize O
at O
4 O
degrees O
C O
. O

These O
cells O
produce O
a O
low O
level O
of O
IL I-GENE
- I-GENE
5 I-GENE
when O
stimulated O
with O
PMA O
alone O
; O
however O
, O
N6 O
, O
O2 O
- O
dibutyryl O
cAMP O
( O
Bt2cAMP O
), O
in O
combination O
with O
PMA O
, O
augmented O
by O
more O
than O
tenfold O
the O
IL I-GENE
- I-GENE
5 I-GENE
production O
at O
the O
mRNA O
and O
the O
protein O
levels O
. O

Hu I-GENE
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
expression O
in O
a O
small O
number O
of O
human O
T O
cell O
tumor O
lines O
did O
not O
correlate O
with O
any O
particular O
phenotype O
or O
stage O
of O
development O
. O

Partial O
engorgement O
was O
higher O
in O
the O
treatments O
. O

Northern O
( O
RNA O
) O
analysis O
demonstrated O
expression O
of O
human O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
all O
tissues O
and O
cell O
lines O
tested O
. O

These O
results O
demonstrate O
the O
existence O
of O
different O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
isoforms I-GENE
and O
define O
a O
family O
of O
genes O
encoding O
distinct O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic I-GENE
subunits I-GENE
that O
can O
associate O
with O
p85 I-GENE
. O

In O
addition O
to O
the O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
domain I-GENE
, O
p56lck I-GENE
possesses O
Src I-GENE
homology I-GENE
2 I-GENE
and I-GENE
3 I-GENE
( O
SH2 I-GENE
and O
SH3 I-GENE
) O
domains O
as O
well O
as O
a O
unique O
N O
- O
terminal O
region O
. O

Strains O
bearing O
the O
drs2 I-GENE
mutation I-GENE
process O
the O
20S I-GENE
precursor I-GENE
of O
the O
mature I-GENE
18S I-GENE
rRNA I-GENE
slowly O
and O
are O
deficient O
in O
40S I-GENE
ribosomal I-GENE
subunits I-GENE
. O

Hepatitis O
B O
and O
liver O
transplantation O
. O

One O
complex O
most O
likely O
contained O
Sp1 I-GENE
, O
and O
another O
complex O
showed O
S O
- O
phase O
- O
specific O
binding O
, O
suggesting O
a O
direct O
role O
in O
the O
cell O
- O
cycle O
- O
dependent O
R1 I-GENE
gene I-GENE
expression O
. O

These O
combined O
observations O
define O
a O
promoter O
and O
an O
enhancer O
for O
the O
chicken I-GENE
L I-GENE
- I-GENE
CAM I-GENE
gene I-GENE
. O

The O
rate O
of O
enzymic O
stimulation O
induced O
by O
a O
given O
nitrate O
correlates O
closely O
with O
the O
rate O
of O
measured O
NO O
production O
from O
the O
nitrate O
molecule O
. O

Clipping O
resulted O
in O
a O
serious O
mislocalization O
of O
the O
position O
of O
the O
peak O
of O
the O
epicortical O
potential O
field O
. O

The O
duration O
of O
diabetes O
mellitus O
in O
these O
patients O
was O
from O
5 O
months O
to O
6 O
years O
, O
and O
in O
all O
patients O
this O
was O
the O
first O
myocardial O
infarction O
. O

The O
247 O
- O
kDa O
complex O
appears O
to O
contain O
two O
distinct O
protein O
- O
DNA O
complexes O
of O
approximately O
232 O
and O
256 O
kDa O
and O
represents O
two O
proteins O
covalently O
cross O
- O
linked O
to O
a O
single O
DRE O
oligonucleotide O
, O
while O
the O
97 O
, O
105 O
, O
and O
115 O
- O
kDa O
complexes O
represent O
single O
protein O
- O
DRE O
cross O
- O
links O
. O

The O
promoter O
and O
upstream O
region O
of O
the O
Brassica I-GENE
napus I-GENE
2S I-GENE
storage I-GENE
protein I-GENE
napA I-GENE
gene I-GENE
were O
studied O
to O
identify O
cis O
- O
acting O
sequences O
involved O
in O
developmental O
seed O
- O
specific O
expression O
. O

However O
, O
limited O
comparisons O
reveal O
domains O
in O
the O
NH2 O
and O
COOH O
termini O
that O
have O
a O
high O
degree O
of O
similarity O
suggesting O
functional O
conservation O
. O

Rinit O
reflects O
the O
Newtonian O
resistances O
and O
Rdiff O
represents O
the O
viscoelastic O
/ O
inhomogeneous O
pressure O
dissipations O
in O
the O
system O
. O

We O
have O
explored O
the O
mechanism O
of O
action O
of O
the O
fibronectin I-GENE
splicing I-GENE
enhancer I-GENE
and O
found O
that O
the O
SE O
element O
is O
required O
for O
efficient O
assembly O
of O
early O
splicing O
complexes O
, O
allowing O
a O
more O
efficient O
interaction O
of O
the O
U2 I-GENE
snRNP I-GENE
with O
branch O
site O
sequences O
. O

Inspection O
of O
enhancer O
mutants O
suggests O
that O
trans O
- O
activation O
by O
hLEF I-GENE
/ O
GAL4 I-GENE
is O
especially O
dependent O
on O
TCF I-GENE
- I-GENE
2 I-GENE
, O
a O
distinct O
T O
- O
cell O
- O
enriched O
protein O
that O
binds O
to O
sequences O
flanking O
the O
hLEF I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
enhancer O
. O

We O
conclude O
that O
sequences O
outside O
of O
the O
hLEF I-GENE
HMG I-GENE
box I-GENE
mediate O
cell O
- O
and O
context O
- O
specific O
activation O
of O
the O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
and O
may O
facilitate O
interactions O
between O
hLEF I-GENE
and O
other O
T O
- O
cell O
- O
specific O
factors O
recruited O
to O
the O
enhancer O
. O

A O
cAMP O
response O
element O
( O
CRE O
) O
consensus O
signal O
was O
identified O
in O
the O
5 O
'- O
noncoding O
region O
. O
cAMP O
regulates O
the O
expression O
of O
Kv1 I-GENE
. I-GENE
5 I-GENE
gene I-GENE
in O
a O
cell O
- O
specific O
manner O
. O

A O
number O
of O
serological O
tests O
measuring O
the O
presence O
of O
Helicobacter O
pylori O
- O
specific O
serum O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
are O
now O
commercially O
available O
. O

Using O
a O
series O
of O
mutant I-GENE
T I-GENE
antigens I-GENE
expressed O
by O
recombinant O
baculoviruses O
in O
Sf9 O
cells O
, O
we O
find O
that O
the O
origin O
unwinding O
activities O
of O
both O
TS677 O
--> O
A O
and O
TS677 O
, O
679 O
--> O
A O
are O
inhibited O
by O
the O
T I-GENE
- I-GENE
antigen I-GENE
kinase I-GENE
, O
as O
is O
wild I-GENE
- I-GENE
type I-GENE
T I-GENE
antigen I-GENE
. O

The O
degree O
of O
hypoperfusion O
was O
slightly O
related O
to O
decrease O
in O
FEV1 O
. O
0 O
%, O
V25 O
and O
PaO2 O
and O
increase O
in O
circulating O
blood O
volume O
and O
peripheral O
red O
blood O
cell O
counts O
. O

Two O
patients O
were O
treated O
successfully O
with O
a O
combination O
of O
metronidazole O
( O
a O
tissue O
amoebicide O
) O
and O
diloxanide O
( O
a O
lumenal O
amoebicide O
). O

We O
have O
identified O
in O
the O
5 O
' O
untranslated O
region O
of O
the O
Drosophila I-GENE
copia I-GENE
retrotransposon I-GENE
, O
3 O
' O
to O
the O
left O
LTR O
, O
a O
sequence O
for O
transcriptional O
regulation O
by O
homeoproteins O
. O

In O
the O
present O
study O
, O
lesions O
of O
the O
OPT O
complex O
( O
the O
thalamic O
source O
of O
afferents O
to O
IHA O
and O
HD O
) O
were O
found O
to O
have O
no O
effect O
on O
color O
- O
reversal O
learning O
performance O
. O

The O
fourth O
dose O
produced O
favorable O
results O
( O
66 O
. O
7 O
%) O
in O
individuals O
with O
HB I-GENE
antibodies I-GENE
between O
10 O
and O
100 O
IU O
/ O
ml O
and O
unfavorable O
ones O
( O
3 O
. O
8 O
%) O
where O
the O
HB I-GENE
antibodies I-GENE
were O
below O
10 O
IU O
/ O
ml O
. O

CONCLUSIONS O
: O
In O
our O
patients O
and O
within O
the O
range O
of O
treatment O
variables O
studied O
, O
age O
, O
Karnofsky O
index O
, O
and O
graft O
- O
versus O
- O
host O
disease O
are O
the O
most O
important O
factors O
related O
with O
early O
mortality O
. O

Nucleotide O
sequence O
analysis O
of O
the O
HA I-GENE
gene I-GENE
in O
these O
two O
mutants O
confirmed O
the O
HA I-GENE
- I-GENE
phenotype O
. O

This O
intron O
occupies O
a O
conserved O
position O
corresponding O
to O
that O
of O
intron O
1 O
in O
the O
transit O
peptide O
region O
of O
chloroplast I-GENE
GAPDH I-GENE
genes I-GENE
( O
GapA I-GENE
and O
GapB I-GENE
) O
of O
higher O
plants O
. O

The O
drug O
- O
resistant O
cell O
lines O
P388 O
/ O
ADR O
/ O
3 O
and O
P388 O
/ O
ADR O
/ O
7 O
express O
a O
shortened O
topo I-GENE
II I-GENE
alpha I-GENE
mRNA I-GENE
transcript I-GENE
in O
addition O
to O
the O
native O
transcript O
present O
in O
the O
drug O
- O
sensitive O
P388 O
/ O
4 O
cell O
line O
. O

Using O
a O
3 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
strategy O
, O
we O
have O
cloned O
cDNAs O
representing O
the O
3 O
'- O
termini O
of O
both O
the O
native O
and O
mutant O
transcripts O
from O
both O
P388 O
/ O
ADR O
/ O
3 O
and O
P388 O
/ O
ADR O
/ O
7 O
cells O
. O

The O
phi I-GENE
AP3 I-GENE
factor I-GENE
is O
a O
nuclear O
phosphoprotein O
; O
the O
extent O
of O
its O
phosphorylation O
is O
regulated O
during O
the O
cell O
cycle O
. O

Similarly O
, O
the O
N O
- O
terminal O
cytoplasmic O
domain O
of O
the O
latent I-GENE
membrane I-GENE
protein I-GENE
2A I-GENE
( O
LMP2A I-GENE
) O
of O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
contains O
a O
single O
copy O
of O
the O
Tyr O
- O
X O
- O
X O
- O
Leu O
/ O
Ile O
- O
containing O
motif O
which O
could O
play O
a O
critical O
role O
in O
B O
cell O
transformation O
. O

The O
functional O
homology O
of O
Cwg2 I-GENE
with O
Cdc43 I-GENE
, O
which O
has O
been O
implicated O
in O
the O
control O
of O
cell O
polarity O
, O
suggests O
a O
link O
between O
two O
morphogenetic O
events O
such O
as O
establishment O
of O
cell O
polarity O
and O
cell O
wall O
biosynthesis O
. O

Molecular O
cloning O
of O
a O
P I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
gene I-GENE
from O
the O
cyanobacterium O
Synechocystis O
sp O
. O

The O
cloning O
of O
PTR2 I-GENE
represents O
the O
first O
example O
of O
the O
molecular O
genetic O
characterization O
of O
a O
eucaryotic O
peptide O
transport O
gene O
. O

By O
using O
the O
full O
- O
length O
cytoplasmic O
domain O
and O
mutants O
with O
progressive O
carboxy O
- O
terminal O
deletions O
, O
internal O
deletions O
, O
or O
point O
mutations O
, O
we O
identified O
the O
first O
150 O
amino O
acid O
residues O
of O
LIFR I-GENE
as O
the O
minimal O
region O
necessary O
for O
signaling O
. O

To O
examine O
the O
biochemical O
basis O
of O
the O
end O
joining O
, O
nuclear O
extracts O
were O
prepared O
from O
a O
wide O
variety O
of O
mammalian O
cell O
lines O
and O
tested O
for O
their O
ability O
to O
join O
test O
plasmid O
substrates O
. O

These O
data O
indicate O
that O
the O
largest O
subunit O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
TFIIB I-GENE
are O
important O
determinants O
of O
transcription O
start O
site O
selection O
in O
S O
. O
cerevisiae O
and O
suggest O
that O
this O
function O
might O
be O
conferred O
by O
interaction O
between O
these O
two O
proteins O
. O

Recombinant O
expression O
of O
a O
chimeric O
EGFR I-GENE
/ O
ErbB I-GENE
- I-GENE
3 I-GENE
receptor I-GENE
in O
NIH O
3T3 O
fibroblasts O
allowed O
us O
to O
investigate O
cytoplasmic O
events O
associated O
with O
ErbB I-GENE
- I-GENE
3 I-GENE
signal O
transduction O
upon O
ligand O
activation O
. O

Oligonucleotide O
competitors O
were O
used O
to O
evaluate O
the O
accessibility O
of O
the O
TATA O
- O
binding O
site O
in O
TIF I-GENE
- I-GENE
IB I-GENE
, O
TFIID I-GENE
, O
and O
TFIIIB I-GENE
. O

The O
227 O
- O
to O
- O
239 O
region O
blocked O
ADR1 I-GENE
activity O
independently O
of O
the O
TAD I-GENE
present O
on O
ADR1 I-GENE
, O
ADR1 I-GENE
DNA O
binding O
, O
and O
specific O
ADH2 I-GENE
promoter I-GENE
sequences I-GENE
. O

Analysis O
of O
strains O
harboring O
an O
mds1 I-GENE
null I-GENE
mutation I-GENE
demonstrates O
that O
MDS1 I-GENE
is O
not O
essential O
during O
normal O
vegetative O
growth O
but O
appears O
to O
be O
required O
for O
meiosis O
. O

TGF I-GENE
beta I-GENE
1 I-GENE
expression O
is O
largely O
governed O
by O
three O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
located O
in O
two O
different O
promoters O
of O
this O
gene O
. O

Val O
--> O
Ala O
mutations O
selectively O
alter O
helix O
- O
helix O
packing O
in O
the O
transmembrane O
segment O
of O
phage I-GENE
M13 I-GENE
coat I-GENE
protein I-GENE
. O

Strategic O
change O
in O
the O
NHS O
. O

A O
much O
less O
expensive O
solution O
than O
UW O
, O
containing O
only O
K O
(+)- O
lactobionate O
, O
KH2PO4 O
, O
MgSO4 O
and O
raffinose O
, O
can O
be O
used O
successfully O
for O
preservation O
of O
rat O
hepatocytes O
for O
24 O
hr O
for O
drug O
transport O
studies O
. O

Repeated O
administration O
of O
GRg2 O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
significantly O
improved O
the O
CYP O
- O
induced O
recognitional O
deficits O
by O
increasing O
the O
CYP O
- O
decreased O
rate O
from O
55 O
. O
8 O
+/- O
9 O
. O
6 O
to O
80 O
. O
8 O
+/- O
4 O
. O
2 O
in O
d O
3 O
learning O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
5 O
. O
6 O
, O
p O
< O
0 O
. O
05 O
), O
from O
53 O
. O
4 O
+/- O
8 O
. O
4 O
to O
60 O
. O
0 O
+/- O
8 O
. O
2 O
in O
48 O
h O
memory O
acquisition O
( O
F O
( O
1 O
, O
14 O
) O
= O
7 O
. O
5 O
, O
p O
< O
0 O
. O
05 O
) O
and O
from O
55 O
. O
0 O
+/- O
5 O
. O
5 O
to O
88 O
. O
3 O
+/- O
2 O
. O
5 O
in O
24 O
h O
memory O
retention O
( O
F O
( O
1 O
, O
12 O
) O
27 O
. O
5 O
, O
p O
< O
0 O
. O
01 O
) O
as O
well O
as O
from O
60 O
. O
0 O
+/- O
6 O
. O
8 O
to O
85 O
. O
6 O
+/- O
6 O
. O
9 O
in O
48 O
h O
memory O
retrieval O
( O
F O
( O
1 O
, O
12 O
) O
= O
5 O
. O
2 O
, O
p O
< O
0 O
. O
05 O
), O
respectively O
. O

Human I-GENE
bcl3 I-GENE
protein I-GENE
specifically O
displaces O
( I-GENE
p50 I-GENE
) I-GENE
2 I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
. O

The O
therapeutic O
action O
of O
cyclosporin O
A O
( O
Sandimmun O
): O
its O
application O
in O
rheumatoid O
arthritis O
. O

In O
vitro O
translation O
experiments O
show O
that O
human O
cDNA O
derived O
RNA O
translates O
into O
a O
protein O
with O
a O
mobility O
of O
44 O
- O
46 O
kD O
on O
SDS O
polyacrylamide O
gels O
. O

After O
peripheral O
administration O
of O
both O
CRF I-GENE
and O
TRH I-GENE
, O
ACTH I-GENE
levels O
were O
significantly O
higher O
on O
the O
tumor O
side O
in O
all O
patients O
. O

Pentazocine O
analgesia O
: O
is O
there O
a O
niche O
for O
Talwin O
Nx O
? O
Pentazocine O
can O
be O
a O
useful O
analgesic O
agent O
for O
the O
management O
of O
acute O
dental O
pain O
. O

A O
sequence O
homology O
analysis O
between O
human I-GENE
nm23 I-GENE
- I-GENE
H1 I-GENE
and O
the O
homolog O
gene O
of O
the O
rat O
( O
NDP I-GENE
- I-GENE
K I-GENE
beta I-GENE
) O
shows O
that O
exon O
- O
intron O
boundaries O
are O
well O
conserved O
between O
these O
two O
species O
. O

A O
favourable O
response O
was O
achieved O
with O
a O
combination O
of O
amphotericin O
B O
and O
cotrimoxazole O
. O

Response O
durations O
were O
short O
. O

RESULTS O
: O
At O
the O
beginning O
of O
the O
QA O
/ O
QI O
process O
, O
monitoring O
of O
blood O
administration O
practices O
revealed O
that O
a O
variance O
from O
institutional O
blood O
administration O
policy O
occurred O
during O
50 O
percent O
of O
blood O
and O
component O
transfusions O
. O

In O
addition O
, O
REP21 O
plants O
were O
resistant O
to O
an O
unusually O
broad O
range O
of O
tobamoviruses O
including O
tomato O
mosaic O
virus O
, O
tobacco O
mild O
green O
mosaic O
virus O
, O
TMV O
- O
U5 O
, O
green O
tomato O
atypical O
mosaic O
virus O
, O
and O
ribgrass O
mosaic O
virus O
. O

Drug O
effect O
, O
measured O
as O
postural O
sway O
, O
was O
also O
similar O
in O
the O
patients O
with O
cirrhosis O
and O
control O
subjects O
; O
therefore O
the O
ratio O
of O
effect O
area O
under O
the O
curve O
to O
concentration O
area O
under O
the O
curve O
, O
a O
measure O
of O
sensitivity O
, O
did O
not O
differ O
significantly O
between O
the O
patients O
with O
cirrhosis O
and O
the O
control O
subjects O
. O

We O
present O
evidence O
that O
YY1 I-GENE
, O
a O
ubiquitously O
expressed O
DNA O
- O
binding O
protein O
, O
regulates O
the O
activity O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
primarily O
through O
an O
effect O
on O
DNA O
structure O
. O

In O
a O
retrospective O
analysis O
of O
first O
- O
time O
total O
colonoscopies O
in O
685 O
patients O
, O
we O
investigated O
the O
relationship O
between O
hyperplastic O
and O
adenomatous O
polyps O
. O

The O
rate O
of O
decrement O
in O
DPOAE O
amplitude O
over O
a O
prescribed O
time O
period O
was O
utilized O
as O
a O
measure O
of O
susceptibility O
to O
the O
acoustic O
trauma O
. O

Effect O
of O
single O
base O
substitutions O
at O
glycine O
- O
870 O
codon O
of O
gramicidin I-GENE
S I-GENE
synthetase I-GENE
2 I-GENE
gene I-GENE
on O
proline O
activation O
. O

The O
predicted O
Pay4p I-GENE
sequence I-GENE
contains O
two O
putative O
ATP O
- O
binding O
domains O
and O
shows O
structural O
relationships O
to O
other O
potential O
ATP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
involved O
in O
biological O
processes O
as O
diverse O
as O
peroxisome O
biogenesis O
, O
vesicle O
- O
mediated O
protein O
transport O
, O
cell O
cycle O
control O
, O
and O
transcriptional O
regulation O
. O

The O
results O
show O
that O
the O
structure O
of O
the O
decorin I-GENE
gene I-GENE
promoter I-GENE
is O
different O
from O
that O
of O
any O
other O
proteoglycan O
promoter O
characterized O
so O
far O
and O
indicate O
that O
the O
pur O
/ O
pyr O
segment O
plays O
a O
role O
in O
the O
regulation O
of O
gene O
transcription O
. O

The O
kinase O
inhibitor O
staurosporine O
( O
1 O
microM O
) O
blocks O
LPA O
- O
induced O
, O
but O
not O
epidermal O
growth O
factor O
- O
induced O
, O
activation O
of O
p21ras I-GENE
and O
MAP I-GENE
kinase I-GENE
, O
consistent O
with O
an O
intermediate O
protein O
kinase O
linking O
the O
LPA I-GENE
receptor I-GENE
to O
p21ras I-GENE
activation O
. O

267 O
, O
4870 O
- O
4877 O
)) O
indicates O
an O
overall O
identity O
of O
58 O
and O
56 O
%, O
respectively O
, O
with O
a O
91 O
and O
92 O
% O
identity O
in O
the O
highly O
conserved O
transmembrane O
and O
cytoplasmic O
domains O
. O

S O
., O
K O
. O

The O
survival O
rate O
at O
forty O
months O
in O
15 O
patients O
with O
N2 O
disease O
who O
underwent O
R2b O
operation O
was O
51 O
%. O

Mothers O
with O
severe O
anatomical O
abnormalities O
, O
who O
are O
HIV O
positive O
, O
have O
active O
TB O
or O
whose O
children O
have O
inherited O
mono O
- O
or O
disaccharide O
intolerances O
should O
not O
breastfeed O
. O

G O
. O

The O
psaD I-GENE
, O
psaF I-GENE
, O
psaH I-GENE
, O
and O
psaL I-GENE
products I-GENE
have O
two O
isoforms O
each O
that O
are O
distinguished O
by O
different O
mobilities O
in O
polyacrylamide O
gel O
electrophoresis O
, O
and O
the O
psaE I-GENE
product I-GENE
has O
four O
isoforms O
. O

When O
Hy O
- O
Vac O
SPF O
type O
V O
embryos O
were O
exposed O
to O
either O
0 O
. O
20 O
ml O
50 O
% O
ethanol O
in O
CRS O
or O
to O
0 O
. O
20 O
ml O
CRS O
( O
controls O
), O
ethanol O
- O
treated O
embryos O
showed O
a O
VSD O
incidence O
of O
34 O
. O
1 O
% O
compared O
with O
a O
3 O
. O
6 O
% O
incidence O
in O
the O
controls O
( O
P O
= O
0 O
. O
0017 O
). O

Peripheral O
vitreochorioretinal O
dystrophies O
in O
myopia O
patients O

In O
our O
studies O
, O
we O
utilized O
HIV O
- O
1 O
HXB2 I-GENE
and O
HIV O
- O
1 O
Z2Z6 I-GENE
core I-GENE
enhancers I-GENE
because O
the O
Z2Z6 I-GENE
strain O
has O
a O
single O
point O
mutation O
flanking O
the O
right O
ETS I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
secondary O
, O
but O
not O
the O
primary O
, O
antibody O
responses O
of O
male O
C57Bl O
/ O
6 O
mice O
were O
higher O
among O
mice O
housed O
alone O
compared O
to O
mice O
housed O
in O
groups O
; O
differences O
were O
observed O
for O
both O
IgM I-GENE
and O
IgG I-GENE
anti I-GENE
- I-GENE
KLH I-GENE
antibodies I-GENE
. O

However O
, O
a O
surprisingly O
high O
degree O
of O
conservation O
of O
intron O
sequences O
was O
observed O
between O
both O
species O
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
may O
possibly O
potentiate O
metastasis O
of O
cardiac O
myxoma O
. O

Other O
parameters O
of O
iron O
metabolism O
, O
including O
ferritin I-GENE
, O
were O
not O
found O
to O
contribute O
to O
the O
risk O
. O

Responses O
to O
the O
Plowright O
Rinderpest O
vaccine O
by O
43 O
calves O
and O
70 O
adult O
cattle O
in O
Uganda O
in O
1990 O
, O
through O
the O
production O
of O
IgG I-GENE
antibodies I-GENE
, O
were O
monitored O
for O
4 O
weeks O
using O
the O
ELISA O
assay O
. O

Because O
of O
the O
small O
number O
of O
visceral O
angiography O
procedures O
performed O
( O
38 O
), O
no O
definitive O
conclusions O
could O
be O
drawn O
as O
to O
the O
differences O
between O
ionic O
and O
nonionic O
agents O
regarding O
grade O
- O
2 O
and O
grade O
- O
3 O
adverse O
events O
. O

Tumours O
of O
the O
cavum O
oris O
and O
oropharynx O
of O
T1 O
- O
stage O
are O
possible O
only O
in O
1 O
of O
3 O
cases O
. O

Thomas O
' O
Hospital O
solution O
( O
with O
95 O
% O
O2 O
: O
5 O
% O
CO2 O
) O
can O
meet O
the O
metabolic O
demand O
of O
the O
ischaemic O
myocardium O
and O
thus O
increase O
the O
safe O
duration O
of O
cardiac O
arrest O
. O

Plasma O
, O
LDL I-GENE
and O
liver O
cholesterol O
concentrations O
were O
higher O
in O
the O
hyperlipidemic O
control O
than O
the O
nonhyperlipidemic O
control O
and O
lower O
in O
the O
groups O
fed O
diets O
containing O
pectin I-GENE
or O
prune O
fiber O
than O
in O
the O
hyperlipidemic O
control O
group O
. O

The O
Stryker O
frame O
modification O
to O
the O
standard O
Dornier O
HM3 O
lithotriptor O
allows O
for O
improved O
visualization O
and O
easier O
localization O
of O
distal O
ureteral O
calculi O
compared O
to O
the O
standard O
gantry O
. O

Glomerular O
mesangial O
cells O
expressed O
an O
abundant O
1 O
. O
1 O
kb O
mRNA O
transcript O
for O
Id1 I-GENE
, O
but O
in O
contrast O
to O
other O
cell O
types O
Id1 I-GENE
mRNA I-GENE
was O
expressed O
in O
both O
randomly O
cycling O
cells O
and O
in O
serum O
- O
deprived O
, O
quiescent O
cultures O
. O

Routine O
psychometric O
screening O
of O
IHD O
patients O
may O
provide O
a O
cost O
- O
effective O
means O
of O
alerting O
cardiologists O
and O
internists O
to O
the O
relatively O
high O
levels O
of O
distress O
among O
their O
patients O
. O

A O
single O
1 O
. O
8 O
- O
kb O
transcript O
mRNA O
was O
detected O
by O
Northern O
( O
RNA O
) O
blot O
analysis O
, O
and O
its O
5 O
' O
end O
maps O
to O
a O
position O
51 O
bp O
upstream O
from O
the O
site O
of O
initiation O
of O
protein O
synthesis O
. O

Employing O
this O
sequence O
information O
from O
c11 O
/ O
1 O
, O
the O
c11 O
/ O
1 O
- O
specific O
cDNA O
was O
generated O
from O
poly O
( O
A O
)+ O
RNA O
of O
bovine O
PMNLs O
by O
reverse O
transcription O
and O
a O
combination O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
methods O
. O

The O
sequence O
similarity O
has O
suggested O
that O
SCG10 I-GENE
and O
stathmin I-GENE
have O
been O
derived O
from O
structurally O
and O
evolutionarily O
related O
genes O
. O

These O
data O
are O
consistent O
with O
the O
idea O
that O
the O
neuron I-GENE
- I-GENE
specific I-GENE
SCG10 I-GENE
gene I-GENE
evolved O
by O
duplication O
and O
modification O
of O
the O
more O
broadly O
expressed O
stathmin I-GENE
/ O
Lap18 I-GENE
gene O
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
mouse I-GENE
HO I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
identical O
to O
that O
of O
p32 I-GENE
, O
initially O
identified O
as O
a O
stress O
- O
induced O
protein O
in O
mouse O
BALBc O
/ O
3T3 O
cells O
. O

We O
found O
that O
T3 O
( O
10 O
(- O
8 O
) O
M O
) O
selectively O
stimulates O
transcription O
from O
rGH I-GENE
- O
TRE O
- O
and O
TREpal O
-, O
but O
not O
ME O
- O
TRE O
- O
and O
F2 O
- O
TRE O
-, O
containing O
templates O
in O
which O
these O
TREs O
are O
linked O
in O
front O
of O
the O
rGH I-GENE
minimal I-GENE
promoter I-GENE
containing O
only O
the O
TATA I-GENE
box I-GENE
binding I-GENE
protein I-GENE
, O
but O
not O
any O
other O
proximal O
binding O
protein O
, O
sequence O
. O

Using O
a O
polymerase O
chain O
reaction O
- O
based O
approach O
, O
we O
cloned O
a O
150 O
- O
base O
pair O
fragment O
of O
a O
new O
sialymotif O
from O
human O
placenta O
mRNA O
, O
which O
was O
then O
used O
as O
a O
probe O
to O
clone O
the O
complete O
coding O
sequence O
of O
the O
corresponding O
gene O
from O
a O
cDNA O
library O
. O

The O
structural O
analysis O
also O
demonstrated O
that O
the O
heterogeneity O
of O
the O
HDC I-GENE
mRNA I-GENE
is O
caused O
by O
an O
insertion O
of O
the O
seventh O
intron O
sequence O
and O
alternative O
use O
of O
the O
splicing O
acceptor O
site O
at O
the O
12th O
exon O
. O

A O
complementary O
DNA O
was O
isolated O
from O
Caenorhabditis O
elegans O
that O
encoded O
a O
polypeptide O
of O
1438 O
amino O
acid O
residues O
, O
CeGAP I-GENE
, O
which O
contains O
a O
domain O
with O
sequence O
similarity O
to O
the O
COOH I-GENE
- I-GENE
terminal I-GENE
segment I-GENE
( I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
region I-GENE
) I-GENE
of O
Bcr I-GENE
and O
other O
known O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
of O
the O
Rho I-GENE
subfamily I-GENE
. O

Additional O
exonuclease I-GENE
III I-GENE
protection O
was O
observed O
beyond O
the O
core O
region O
on O
both O
the O
5 O
' O
and O
3 O
' O
sides O
, O
suggesting O
that O
E1 I-GENE
interacted O
with O
more O
distal O
sequences O
as O
well O
. O

Repression O
is O
alleviated O
when O
the O
two O
( O
for O
E2 I-GENE
) O
or O
three O
( O
for O
E2 I-GENE
- I-GENE
C I-GENE
) O
promoter O
- O
proximal O
copies O
of O
E2 I-GENE
- O
RS O
are O
mutated O
. O

A O
mutant O
in O
the O
AAV O
terminal O
resolution O
site O
( O
trs O
) O
was O
defective O
for O
DNA O
replication O
in O
the O
in O
vitro O
assay O
. O

The O
results O
indicate O
that O
rep I-GENE
strongly O
enhances O
the O
function O
of O
negative O
regulatory O
elements O
of O
the O
LTR O
. O

However O
, O
artificially O
ventilated O
rats O
, O
pretreated O
with O
MK O
- O
801 O
, O
were O
more O
sensitive O
( O
lethal O
cocaine O
dose O
, O
76 O
. O
6 O
+/- O
8 O
. O
0 O
mg O
/ O
kg O
, O
n O
= O
5 O
) O
than O
vehicle O
pretreated O
rats O
( O
129 O
. O
4 O
+/- O
15 O
. O
8 O
mg O
/ O
kg O
, O
n O
= O
6 O
), O
indicating O
that O
MK O
- O
801 O
may O
increase O
both O
the O
respiratory O
and O
the O
cardiac O
toxicity O
of O
cocaine O
in O
urethane O
anesthetized O
rats O
. O

The O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
gene I-GENE
product I-GENE
, O
which O
belongs O
to O
the O
POU I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
, O
is O
a O
good O
candidate O
for O
regulating O
initial O
differentiation O
decisions O
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
show O
that O
the O
RAREoct I-GENE
contributes O
to O
the O
transcriptional O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
in O
P19 O
cells O
and O
, O
most O
interestingly O
, O
mediates O
the O
RA O
- O
induced O
repression O
in O
RA O
- O
differentiated O
EC O
cells O
. O

176 O
: O
787 O
- O
792 O
, O
1992 O
; O
M O
. O

Furthermore O
, O
the O
negative O
transcriptional O
effect O
of O
COUP I-GENE
- I-GENE
TFs I-GENE
is O
dominant O
over O
the O
activating O
effect O
of O
the O
Oct4 I-GENE
embryonic I-GENE
stem I-GENE
cell I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
. O

Analysis O
of O
mig I-GENE
/ O
CAT I-GENE
chimeric O
constructs O
transiently O
transfected O
into O
the O
RAW O
264 O
. O
7 O
mouse O
monocytic O
cell O
line O
revealed O
a O
unique O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
gamma I-GENE
RE I-GENE
- I-GENE
1 I-GENE
). O

When O
expressed O
alone O
in O
test O
cells O
, O
Atr I-GENE
- I-GENE
I I-GENE
is O
unable O
to O
bind O
TGF I-GENE
- I-GENE
beta I-GENE
, O
activin I-GENE
, O
or O
bone I-GENE
morphogenetic I-GENE
protein I-GENE
2 I-GENE
. O

Therefore O
, O
Mxi1 I-GENE
and O
Mad I-GENE
might O
antagonize O
Myc I-GENE
function O
and O
are O
candidate O
tumor O
suppressor O
genes O
. O

To O
our O
knowledge O
, O
type O
IV O
renal O
tubular O
acidosis O
has O
not O
been O
reported O
previously O
in O
association O
with O
Alport O
' O
s O
syndrome O
in O
an O
adult O
patient O
. O

A O
cDNA O
clone O
was O
isolated O
from O
a O
chicken O
embryo O
cDNA O
library O
employing O
a O
PCR O
- O
generated O
radiolabeled O
probe O
specific O
for O
the O
U3 I-GENE
region I-GENE
of O
the O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
LTR I-GENE
. O

Two O
basic O
patterns O
of O
locomotor O
behavior O
and O
corresponding O
torso O
morphology O
exist O
among O
extant O
anthropoids O
. O

Animal O
age O
and O
sex O
had O
no O
significant O
effects O
on O
CSF O
composition O
, O
but O
serum O
IgG I-GENE
concentration O
increased O
with O
age O
. O

Fast O
continuous O
expansion O
. O

A O
randomized O
, O
multicenter O
study O
comparing O
the O
efficacy O
and O
tolerability O
of O
tropisetron O
, O
a O
new O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
, O
with O
a O
metoclopramide O
- O
containing O
antiemetic O
cocktail O
in O
the O
prevention O
of O
cisplatin O
- O
induced O
emesis O
. O

Each O
repeat O
consists O
of O
12 O
nt O
, O
coding O
for O
the O
reiterated O
sequence O
, O
K O
/ O
NPAG O
. O

ENV I-GENE
also O
was O
secreted O
from O
P O
. O
pastoris O
using O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
alpha I-GENE
- I-GENE
factor I-GENE
prepro I-GENE
secretion I-GENE
leader I-GENE
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
invertase I-GENE
signal I-GENE
sequence I-GENE
. O

BACKGROUND O
: O
To O
determine O
the O
predictors O
of O
desipramine O
- O
refractory O
depression O
, O
the O
authors O
examined O
the O
outcome O
in O
patients O
with O
major O
depression O
who O
were O
admitted O
to O
a O
general O
hospital O
and O
treated O
with O
desipramine O
adjusted O
to O
an O
adequate O
blood O
level O
. O

Analysis O
of O
the O
intact O
hGH I-GENE
gene I-GENE
or O
hGH I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
DNA I-GENE
( I-GENE
5 I-GENE
'- I-GENE
FR I-GENE
) I-GENE
coupled O
to O
the O
hGh I-GENE
cDNA I-GENE
or O
chloramphenicol I-GENE
acetyltransferase I-GENE
or O
luciferase I-GENE
genes I-GENE
, O
indicated O
that O
cAMP O
primarily O
stimulated O
hGH I-GENE
promoter I-GENE
activity O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
SAP I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
showed O
that O
mature I-GENE
SAP I-GENE
- I-GENE
1 I-GENE
consisted O
of O
1093 O
amino O
acids O
and O
a O
transmembrane I-GENE
- I-GENE
type I-GENE
PTP I-GENE
, O
which O
possessed O
a O
single O
PTP I-GENE
- I-GENE
conserved I-GENE
domain I-GENE
in O
the O
cytoplasmic O
region O
. O

The O
following O
evidence O
indicates O
that O
the O
69 O
- O
kD O
protein O
is O
a O
common O
, O
rather O
than O
a O
U1 I-GENE
- O
specific O
, O
protein O
, O
possibly O
associating O
with O
the O
snRNP O
core O
particles O
by O
protein O
- O
protein O
interaction O
. O

Several O
features O
of O
10 O
. O
24 O
. O
6 O
cells O
suggest O
that O
the O
mutation O
disrupts O
normal O
intracellular O
formation O
of O
peptide I-GENE
/ I-GENE
DR I-GENE
complexes I-GENE
. O

This O
distribution O
parallels O
that O
of O
the O
neurotransmitters O
glutamate O
and O
aspartate O
; O
however O
, O
neither O
of O
these O
excitatory O
amino O
acids O
is O
a O
substrate O
for O
transport O
. O

The O
Harleco O
apparatus O
is O
a O
simple O
, O
useful O
, O
cost O
- O
effective O
adjunct O
to O
the O
diagnosis O
and O
treatment O
of O
this O
life O
- O
threatening O
condition O
. O

Co O
- O
transfection O
of O
expression O
vectors O
for O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
trans O
- O
activated O
the O
rat I-GENE
uncoupling I-GENE
protein I-GENE
gene I-GENE
promoter I-GENE
due O
to O
sequences O
in O
the O
5 O
' O
proximal O
region O
. O

It O
was O
not O
possible O
to O
study O
the O
basis O
for O
tissue O
- O
specific O
expression O
of O
this O
gene O
, O
because O
the O
beta I-GENE
3 I-GENE
gene I-GENE
promoter I-GENE
had O
not O
been O
isolated O
previously O
. O

Isolation O
and O
characterization O
of O
a O
TATA O
- O
less O
promoter O
for O
the O
human I-GENE
beta I-GENE
3 I-GENE
integrin I-GENE
gene I-GENE
. O

Subretinal O
fluid O
was O
punctured O
on O
the O
poorer O
eye O
in O
19 O
eyes O
( O
52 O
. O
7 O
%) O
and O
on O
the O
better O
eye O
in O
7 O
eyes O
( O
19 O
. O
4 O
%). O

These O
data O
indicate O
that O
activation O
of O
these O
enzymes O
is O
not O
sufficient O
for O
the O
acute O
stimulation O
of O
glucose O
transport O
. O

The O
inserted O
region O
, O
which O
represents O
an O
intron O
in O
brain O
and O
muscle O
, O
is O
expressed O
in O
the O
tumor O
cell O
lines O
either O
as O
a O
" O
readthrough O
" O
form O
or O
with O
78 O
residues O
deleted O
from O
its O
5 O
' O
end O
. O

Concordance O
of O
IBDQ O
scores O
was O
tested O
in O
280 O
stable O
subjects O
. O

Regression O
line O
slopes O
of O
IBDQ O
scores O
were O
significantly O
different O
in O
patients O
who O
deteriorated O
from O
those O
who O
remained O
stable O
([ O
b O
] O
< O
0 O
. O
15 O
; O
P O
< O
0 O
. O
0001 O
). O

Praziquantel O
and O
Albendazole O
were O
found O
effective O
in O
the O
treatment O
of O
neurocysticercosis O
, O
but O
because O
of O
serious O
side O
effects O
encountered O
in O
some O
cases O
, O
the O
drugs O
should O
be O
used O
cautiously O
in O
selected O
cases O
only O
. O

Inhibition O
of O
erythromycin O
synthesis O
by O
disruption O
of O
malonyl I-GENE
- I-GENE
coenzyme I-GENE
A I-GENE
decarboxylase I-GENE
gene I-GENE
eryM I-GENE
in O
Saccharopolyspora O
erythraea O
. O

This O
region O
is O
required O
for O
activation O
of O
DNA O
binding O
of O
MyoD I-GENE
and O
E12 I-GENE
homodimers I-GENE
and O
E12 I-GENE
/ O
MyoD I-GENE
heterodimers O
. O

Transcriptional O
analysis O
of O
a O
series O
of O
deletion O
mutants O
of O
the O
gene O
in O
the O
nuclear O
extracts O
prepared O
from O
the O
middle O
silk O
gland O
of O
2 O
- O
day O
- O
old O
fifth O
instar O
larvae O
revealed O
the O
presence O
of O
multiple O
cis O
- O
regulatory O
elements O
located O
both O
upstream O
and O
downstream O
of O
the O
initiation O
site O
. O

One O
of O
these O
elements O
, O
the O
homeodomain I-GENE
- I-GENE
binding I-GENE
element I-GENE
, O
was O
identified O
to O
mediate O
negative O
regulation O
. O

Site O
- O
directed O
mutagenesis O
of O
the O
traI I-GENE
structural I-GENE
gene I-GENE
and O
application O
of O
purified O
mutant O
TraI I-GENE
proteins I-GENE
for O
in O
vitro O
assays O
served O
to O
evaluate O
the O
functional O
importance O
of O
conserved O
amino O
acid O
residues O
. O

Concerted O
action O
of O
three O
distinct O
domains O
in O
the O
DNA O
cleaving O
- O
joining O
reaction O
catalyzed O
by O
relaxase I-GENE
( O
TraI I-GENE
) O
of O
conjugative O
plasmid O
RP4 O
. O

The O
COOH O
- O
terminal O
46 O
codons O
of O
slyD I-GENE
encode O
a O
remarkable O
histidine O
- O
rich O
peptide O
sequence O
which O
is O
at O
least O
partly O
dispensable O
for O
slyD I-GENE
function O
in O
E I-GENE
- O
mediated O
lysis O
. O

Monospecific O
antibodies O
raised O
against O
rat I-GENE
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
1A1 I-GENE
recognized O
a O
protein O
in O
the O
hepatic O
microsomes O
of O
the O
double O
- O
crested O
cormorant O
, O
and O
also O
in O
those O
of O
the O
great O
blue O
heron O
( O
Ardea O
herodias O
), O
using O
immunoblotting O
. O

We O
studied O
GSH O
- O
Px O
enzyme O
activity O
in O
serum O
after O
acute O
myocardial O
infarction O
( O
AMI O
) O
and O
unstable O
angina O
pectoris O
( O
UAP O
). O

The O
HGF I-GENE
- O
induced O
cell O
motility O
was O
mimicked O
by O
12 O
- O
0 O
- O
tetradecanoyl O
- O
phorbol O
- O
13 O
- O
acetate O
, O
a O
protein I-GENE
kinase I-GENE
C I-GENE
- O
activating O
phorbol O
ester O
, O
but O
not O
by O
Ca2 O
+ O
ionophore O
. O

In O
addition O
, O
lexical O
priming O
was O
examined O
by O
presenting O
an O
identity O
prime O
earlier O
in O
the O
text O
. O

METHODS O
: O
Forty O
- O
nine O
cases O
with O
intrahepatic O
multiple O
nodules O
of O
HCC O
, O
by O
gross O
examination O
, O
among O
184 O
consecutive O
resected O
HCCs O
were O
examined O
clinicopathologically O
. O

In O
the O
present O
report O
, O
66 O
hemochromatosis O
families O
yielding O
151 O
hemochromatosis O
chromosomes O
and O
182 O
normal O
chromosomes O
were O
RFLP O
- O
typed O
with O
a O
battery O
of O
probes O
, O
including O
two O
newly O
derived O
polymorphic O
markers O
from O
the O
6 O
. O
7 O
and O
HLA I-GENE
- I-GENE
F I-GENE
loci I-GENE
located O
150 O
and O
250 O
kb O
telomeric O
to O
HLA I-GENE
- I-GENE
A I-GENE
, O
respectively O
. O

Pneumothorax O
during O
laparoscopic O
dissection O
of O
the O
diaphragmatic O
hiatus O
. O

Different O
cortical O
malformations O
were O
produced O
in O
rats O
by O
a O
single O
dose O
of O
X O
- O
rays O
( O
200 O
cGy O
) O
given O
on O
different O
days O
during O
gestation O
. O

T2 O
cancers O
should O
not O
be O
excluded O
from O
the O
benefit O
of O
preoperative O
irradiation O
. O

IFN I-GENE
alpha I-GENE
and O
IFN I-GENE
gamma I-GENE
inducibility O
is O
mediated O
by O
a O
single O
element O
: O
a O
high O
affinity O
, O
nearly O
palindromic O
version O
of O
the O
IFN I-GENE
gamma I-GENE
activation I-GENE
site I-GENE
( O
GAS I-GENE
). O

Mutations O
in O
the O
nuclear I-GENE
gene I-GENE
CBP1 I-GENE
of I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
result O
in O
degradation O
of O
mitochondrially I-GENE
encoded I-GENE
cytochrome I-GENE
b I-GENE
( O
cob I-GENE
) O
RNA O
; O
thus O
, O
the O
cells O
are O
unable O
to O
respire O
. O

Twenty O
- O
three O
sequence O
- O
tagged O
sites O
( O
STSs O
) O
were O
mapped O
within O
the O
contig O
, O
a O
density O
of O
approximately O
1 O
per O
200 O
kb O
. O

In O
this O
paper O
, O
we O
demonstrate O
that O
binding O
of O
the O
GA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
GABP I-GENE
) O
to O
ets I-GENE
sequence I-GENE
motifs I-GENE
within O
each O
repeated O
unit O
is O
required O
for O
transcriptional O
activation O
of O
the O
COXIV I-GENE
promoter I-GENE
. O

To O
gain O
further O
insight O
into O
the O
pathogenesis O
of O
the O
adult O
respiratory O
distress O
syndrome O
( O
ARDS O
), O
the O
authors O
studied O
possible O
relationships O
among O
the O
activation O
status O
of O
circulating O
polymorphonuclear O
neutrophils O
( O
PMN O
), O
cytokine O
levels O
, O
and O
the O
severity O
of O
lung O
injury O
in O
31 O
patients O
: O
15 O
with O
ARDS O
, O
9 O
with O
severe O
pneumonia O
uncomplicated O
by O
ARDS O
, O
and O
7 O
mechanically O
ventilated O
patients O
with O
neither O
ARDS O
nor O
pneumonia O
. O

Amiodarone O
, O
seldom O
used O
as O
first O
- O
line O
treatment O
, O
appears O
to O
be O
the O
most O
effective O
drug O
. O

These O
results O
demonstrate O
that O
dopamine I-GENE
receptor I-GENE
stimulation O
by O
different O
dopamine O
agonists O
produces O
a O
different O
pattern O
of O
effects O
on O
the O
characteristics O
of O
the O
reaction O
time O
response O
. O

Two O
experiments O
were O
conducted O
to O
study O
the O
vacuous O
jaw O
movements O
induced O
in O
rats O
by O
acute O
administration O
of O
the O
monoamine O
- O
depleting O
agent O
reserpine O
. O

Depletion O
of O
dopamine O
in O
the O
nucleus O
accumbens O
led O
to O
a O
dramatic O
shift O
in O
behavior O
in O
which O
there O
was O
a O
significant O
decrease O
in O
lever O
pressing O
but O
a O
significant O
increase O
in O
consumption O
of O
lab O
chow O
. O

We O
have O
investigated O
the O
influence O
of O
NaFe3 O
+ O
EDTA O
, O
and O
of O
increasing O
dietary O
levels O
of O
Na2EDTA O
, O
on O
Zn O
, O
Cu O
and O
Ca O
metabolism O
in O
rats O
fed O
on O
Zn O
- O
sufficient O
and O
Zn O
- O
deficient O
soya O
- O
bean O
- O
isolate O
- O
based O
diets O
. O

Recovery O
of O
carbimazole O
- O
induced O
agranulocytosis O
following O
recombinant I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
rhGM I-GENE
- I-GENE
CSF I-GENE
) O
administration O
. O

Thus O
, O
the O
system O
can O
be O
used O
to O
detect O
and O
study O
dynamic O
perfusion O
changes O
from O
the O
brain O
surface O
with O
minimal O
tissue O
damage O
. O

The O
neglect O
of O
Richards O
' O
s O
theory O
demonstrates O
the O
range O
of O
factors O
, O
other O
than O
the O
strictly O
scientific O
, O
which O
can O
be O
important O
in O
determining O
the O
influence O
or O
otherwise O
of O
a O
psychological O
theory O
. O

The O
positive O
- O
acting O
global O
sulfur O
regulatory O
protein O
, O
CYS3 I-GENE
, O
of O
Neurospora O
crassa O
turns O
on O
the O
expression O
of O
a O
family O
of O
unlinked O
structural O
genes O
that O
encode O
enzymes O
of O
sulfur O
catabolism O
. O

Analysis O
of O
the O
upstream O
untranslated O
region O
of O
CHL15 I-GENE
revealed O
the O
presence O
of O
the O
hexamer O
element O
, O
ACGCGT O
( O
an O
MluI I-GENE
restriction I-GENE
site I-GENE
) O
controlling O
both O
the O
periodic O
expression O
and O
coordinate O
regulation O
of O
the O
DNA O
synthesis O
genes O
in O
budding O
yeast O
. O

The O
C O
- O
terminal O
region O
of O
the O
150 O
- O
kDa O
protein O
contains O
an O
NTP O
- O
binding O
helicase I-GENE
motif I-GENE
and O
the O
readthrough O
region O
, O
an O
RNA I-GENE
polymerase I-GENE
motif I-GENE
, O
indicating O
that O
these O
two O
overlapping O
proteins O
may O
form O
an O
RNA O
replication O
complex O
similar O
to O
those O
of O
tobamo O
- O
and O
tobraviruses O
. O

The O
5 O
' O
ends O
of O
F3R I-GENE
late O
transcripts O
were O
located O
to O
an O
A O
within O
the O
sequence O
5 O
'- O
TAAAG O
, O
41 O
nt O
downstream O
from O
the O
early O
promoter O
and O
17 O
nt O
upstream O
from O
the O
initiation O
codon O
. O

On O
T2 O
weighted O
images O
, O
low O
intensity O
areas O
in O
the O
thalamus O
, O
the O
striatum O
, O
the O
anterior O
limb O
of O
the O
internal O
capsule O
, O
the O
tegmentum O
of O
midbrain O
, O
high O
intensity O
areas O
in O
middle O
cerebellar O
peduncle O
, O
the O
posterior O
limb O
of O
the O
internal O
capsule O
, O
the O
lateral O
part O
of O
the O
cerebral O
peduncle O
, O
and O
the O
cerebral O
white O
matter O
were O
noted O
. O

Using O
the O
rap1t I-GENE
alleles I-GENE
to O
generate O
wild O
- O
type O
cells O
differing O
only O
in O
telomere O
tract O
lengths O
, O
we O
also O
show O
that O
telomere O
position O
effects O
are O
highly O
sensitive O
to O
changes O
in O
the O
size O
( O
or O
structure O
) O
of O
the O
telomeric O
tract O
. O

Pronounced O
microangiopathy O
characterized O
by O
avascular O
fields O
, O
enlarged O
and O
tortuous O
capillaries O
and O
increased O
transcapillary O
diffusion O
of O
sodium O
fluorescein O
, O
was O
clearly O
demonstrable O
in O
the O
area O
of O
the O
nodules O
. O

Epigenetic O
switching O
of O
transcriptional O
states O
: O
cis O
- O
and O
trans O
- O
acting O
factors O
affecting O
establishment O
of O
silencing O
at O
the O
HMR I-GENE
locus I-GENE
in O
Saccharomyces O
cerevisiae O
. O

NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
p65 I-GENE
, O
p50 I-GENE
, O
and O
Rel I-GENE
functionally O
synergize O
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
, O
and O
C I-GENE
/ I-GENE
EBP I-GENE
delta I-GENE
. O

It O
could O
be O
detected O
exclusively O
in O
the O
culture O
medium O
of O
cDNA O
- O
transfected O
COS O
cells O
. O

The O
first O
group O
of O
sequential O
BMB O
showed O
a O
significant O
progress O
to O
myelofibrosis O
in O
so O
- O
called O
" O
Chronic O
Megakaryocytic O
- O
Granulocytic O
Myelosis O
"-- O
CMGM O
-, O
which O
corresponds O
to O
Agnogenic O
Myeloid O
Metaplasia O
- O
AMM O
- O
in O
72 O
. O
4 O
% O
( O
21 O
/ O
29 O
patients O
), O
as O
well O
as O
in O
CML O
with O
megakaryocytic O
increase O
- O
CML O
. O
MI O
- O
in O
39 O
. O
2 O
% O
( O
20 O
/ O
51 O
). O

The O
two O
methods O
identify O
the O
same O
patients O
only O
if O
micturitional O
pressures O
are O
normal O
( O
40 O
to O
60 O
cmH2O O
) O
to O
high O
( O
over O
60 O
cmH2O O
) O
and O
the O
Sussett O
formula O
is O
used O
with O
a O
higher O
( O
95th O
centile O
) O
cutoff O
. O

There O
was O
no O
clear O
correlation O
between O
the O
MFA O
and O
the O
severity O
of O
the O
UTS O
phenotype O
. O

Chicken O
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
/ O
sterol I-GENE
carrier I-GENE
protein I-GENE
x I-GENE
: O
cDNA O
cloning O
reveals O
evolutionary O
conservation O
of O
structure O
and O
regulated O
expression O
. O

The O
plasmatic I-GENE
albumin I-GENE
concentration O
( O
3 O
. O
5 O
- O
4 O
. O
5 O
g O
/ O
dl O
) O
represents O
about O
60 O
% O
of O
the O
total O
plasma O
protein O
. O

These O
lesions O
were O
asymptomatic O
, O
but O
both O
were O
characterized O
clinically O
by O
central O
ulceration O
. O

A O
single O
five O
minute O
period O
of O
rapid O
atrial O
pacing O
fails O
to O
limit O
infarct O
size O
in O
the O
in O
situ O
rabbit O
heart O
. O

Neither O
RD19 I-GENE
nor O
RD21 I-GENE
mRNA I-GENE
synthesis O
was O
responsive O
to O
cold O
or O
to O
heat O
stress O
. O

Previous O
studies O
indicated O
that O
the O
20S I-GENE
proteasome I-GENE
is O
a O
catalytic O
core O
of O
the O
26S I-GENE
proteolytic I-GENE
complex I-GENE
that O
possesses O
a O
latent O
multicatalytic O
proteinase O
activity O
and O
catalyzes O
an O
ATP O
- O
dependent O
, O
selective O
breakdown O
of O
proteins O
ligated O
to O
ubiquitin I-GENE
. O

The O
O2 O
deficit O
was O
not O
related O
to O
blood O
lactate O
during O
submaximal O
exercise O
, O
muscle O
enzyme O
activity O
( O
citrate I-GENE
synthase I-GENE
, O
3 I-GENE
- I-GENE
hydroxyacyl I-GENE
- I-GENE
CoA I-GENE
- I-GENE
dehydrogenase I-GENE
, O
lactate I-GENE
dehydrogenase I-GENE
), O
number O
of O
muscle O
capillaries O
, O
% O
ST O
fibres O
or O
muscle O
buffer O
capacity O
. O

The O
sequence O
of O
the O
putative O
RBP1 I-GENE
protein I-GENE
contains O
two O
copies O
of O
an O
RNA O
recognition O
motif O
, O
two O
glutamine O
stretches O
, O
an O
asparagine O
- O
rich O
region O
, O
a O
methionine O
- O
rich O
region O
, O
and O
two O
long O
potential O
alpha O
- O
helixes O
. O

One O
defective O
RNA O
with O
a O
large O
deletion O
in O
the O
p70 I-GENE
coding I-GENE
region I-GENE
was O
able O
to O
replicate O
efficiently O
, O
both O
when O
inoculated O
with O
the O
helper O
genome O
and O
when O
inoculated O
with O
a O
second O
complementing O
defective O
RNA O
that O
supplied O
a O
wild I-GENE
- I-GENE
type I-GENE
p70 I-GENE
. O

Release O
of O
this O
selective O
pressure O
, O
however O
, O
gave O
way O
to O
homologous O
resolution O
of O
the O
cointegrate O
structures O
. O

Complete O
nucleotide O
sequence O
of O
the O
bacteriophage I-GENE
K1F I-GENE
tail I-GENE
gene I-GENE
encoding O
endo I-GENE
- I-GENE
N I-GENE
- I-GENE
acylneuraminidase I-GENE
( O
endo I-GENE
- I-GENE
N I-GENE
) O
and O
comparison O
to O
an O
endo I-GENE
- I-GENE
N I-GENE
homolog I-GENE
in O
bacteriophage O
PK1E O
. O

Binding O
of O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
was O
partially O
inhibited O
. O

Morphometrical O
quantification O
of O
brain O
edema O
related O
to O
experimental O
multiple O
micro O
- O
infarcts O
in O
mice O
: O
assessment O
of O
neurotropin I-GENE
effect O
. O

One O
member O
of O
this O
multigene O
family O
, O
GATA I-GENE
- I-GENE
3 I-GENE
, O
is O
most O
abundantly O
expressed O
in O
T O
lymphocytes O
, O
a O
cellular O
target O
for O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
and O
replication O
. O

Indeed O
, O
significant O
level O
of O
CAT I-GENE
activity O
was O
observed O
in O
human O
lung O
adenocarcinoma O
( O
A549 O
- O
1 O
) O
cells O
which O
had O
been O
incubated O
with O
a O
complex O
of O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
, O
pT7 I-GENE
- I-GENE
EMC I-GENE
- I-GENE
CAT I-GENE
DNA I-GENE
and O
DC O
- O
chol O
cationic O
liposomes O
. O

Pneumoscrotum O
is O
a O
rare O
condition O
that O
receives O
little O
discussion O
in O
standard O
texts O
of O
urology O
. O

The O
first O
gene O
codes O
for O
a O
protein O
containing O
11 O
cystein O
residues O
in O
an O
arrangement O
typical O
for O
Fe I-GENE
/ I-GENE
S I-GENE
proteins I-GENE
. O

Triton O
- O
disrupted O
cells O
retained O
capacity O
for O
activation O
of O
the O
pathway O
by O
both O
peptide O
growth O
factors O
and O
by O
addition O
of O
GTP O
- O
loaded O
p21 I-GENE
rasVal12 I-GENE
. O

To O
begin O
to O
examine O
the O
mechanism O
controlling O
expression O
of O
this O
gene O
during O
the O
cell O
- O
cycle O
, O
a O
mouse I-GENE
B I-GENE
- I-GENE
myb I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
sequence I-GENE
was O
isolated O
from O
a O
cosmid O
library O
and O
shown O
to O
promote O
efficiently O
the O
transcription O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
when O
transfected O
into O
NIH3T3 O
fibroblasts O
. O

The O
influence O
of O
a O
high O
ionic O
strength O
on O
the O
resolution O
was O
clearly O
shown O
. O

The O
number O
of O
bacteria O
in O
the O
lung O
, O
peripheral O
white O
blood O
cell O
and O
BAL O
fluid O
cell O
also O
decreased O
by O
the O
administration O
of O
FN I-GENE
. O

In O
mice O
, O
three O
major O
families O
of O
L1 O
elements O
, O
termed O
" O
A O
," O
" O
F O
," O
and O
" O
V O
," O
have O
been O
defined O
on O
the O
basis O
of O
the O
sequence O
found O
at O
the O
5 O
' O
terminus O
. O

TFEC I-GENE
, O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
, O
forms O
heterodimers O
with O
TFE3 I-GENE
and O
inhibits O
TFE3 I-GENE
- O
dependent O
transcription O
activation O
. O

The O
equivalent O
of O
the O
third O
ligand O
, O
H O
- O
87 O
, O
is O
T O
- O
47 O
in O
the O
PSTAIRE O
sequence O
motif O
. O

Similar O
results O
were O
seen O
on O
Western O
blots O
of O
Autographa O
californica O
MNPV O
( O
AcMNPV O
)- O
infected O
Spodoptera O
frugiperda O
cells O
. O

In O
infected O
mammalian O
cells O
, O
the O
ARV I-GENE
G I-GENE
and O
GNS I-GENE
genes I-GENE
are O
transcribed O
primarily O
as O
a O
polycistronic O
mRNA O
which O
appears O
to O
extend O
from O
the O
consensus O
sequence O
( O
AACAG O
) O
at O
the O
start O
of O
the O
G I-GENE
gene I-GENE
to O
the O
next O
recognized O
polyadenylation O
signal O
( O
CATG O
[ O
A O
] O
7 O
) O
located O
697 O
nucleotides O
downstream O
of O
the O
GNS I-GENE
protein I-GENE
termination O
codon O
. O

Molecular O
cloning O
and O
expression O
of O
RPE65 I-GENE
, O
a O
novel O
retinal O
pigment O
epithelium O
- O
specific O
microsomal O
protein O
that O
is O
post O
- O
transcriptionally O
regulated O
in O
vitro O
. O

The O
mean O
power O
( O
in O
mu O
W O
) O
required O
to O
produce O
the O
observed O
flow O
rate O
was O
estimated O
at O
each O
outflow O
pressure O
as O
the O
product O
of O
the O
flow O
rate O
and O
the O
pressure O
across O
the O
lymphatic O
vessel O
. O

Although O
antisperm O
antibodies O
are O
associated O
with O
infertility O
, O
many O
hospital O
laboratories O
do O
not O
test O
for O
these O
antibodies O
. O

PPD I-GENE
- O
specific O
IgG I-GENE
subclass O
responses O
were O
evident O
to O
all O
four O
IgG I-GENE
subclasses O
. O

Anterior O
body O
pattern O
in O
Drosophila O
is O
specified O
by O
the O
graded O
distribution O
of O
the O
bicoid I-GENE
protein I-GENE
( O
bcd I-GENE
), O
which O
activates O
subordinate O
genes O
in O
distinct O
anterior O
domains O
. O

GAP I-GENE
- I-GENE
N I-GENE
bound O
constitutively O
to O
p190 I-GENE
in O
both O
serum O
- O
deprived O
and O
growth O
factor O
- O
stimulated O
cells O
. O

The O
peptide O
sequence O
contains O
a O
region O
of O
80 O
amino O
acids O
that O
shows O
similarity O
to O
bcl I-GENE
- I-GENE
2 I-GENE
and O
to O
the O
recently O
described O
bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
gene I-GENE
, O
MCL1 I-GENE
. O

The O
phosphorylation O
efficiency O
is O
improved O
by O
increasing O
the O
number O
of O
N O
- O
terminal O
arginine O
residues O
and O
by O
moving O
the O
arginyl O
cluster O
one O
residue O
further O
away O
from O
the O
serine O
, O
the O
nonapeptide O
( O
Arg O
) O
4 O
- O
Ala O
- O
Ala O
- O
Ser O
- O
Val O
- O
Ala O
being O
the O
best O
substrate O
among O
all O
the O
short O
peptides O
tested O
( O
Km O
= O
15 O
microM O
). O

Botulinum I-GENE
toxin I-GENE
: O
preferred O
treatment O
for O
hemifacial O
spasm O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
GAL1 I-GENE
and O
GAL10 I-GENE
genes I-GENE
are O
controlled O
in O
response O
to O
the O
availability O
of O
galactose O
and O
glucose O
by O
multiple O
activating O
and O
repressing O
proteins O
bound O
at O
adjacent O
or O
overlapping O
sites O
in O
UASG O
. O

Surprisingly O
, O
the O
results O
of O
several O
experiments O
suggest O
that O
the O
TSF I-GENE
genes I-GENE
encode O
global O
regulatory O
factors O
. O
tsf1 I-GENE
to O
tsf6 I-GENE
mutations O
derepressed O
expression O
from O
yeast O
CYC I-GENE
- O
GAL I-GENE
hybrid O
promoters O
( O
fused O
to O
lacZ I-GENE
) O
that O
harbor O
a O
variety O
of O
operator O
sequences O
, O
and O
caused O
pleiotropic O
defects O
in O
cell O
growth O
, O
mating O
, O
and O
sporulation O
. O

Sex O
of O
calf O
( O
variate O
2 O
) O
was O
associated O
most O
closely O
with O
width O
of O
muzzle O
and O
head O
. O

Sequence O
comparison O
indicates O
that O
exons O
5 O
'/ O
L O
and O
L O
/ O
N O
in O
PSG12 I-GENE
and O
PSG12 I-GENE
psi I-GENE
are O
99 O
% O
identical O
, O
except O
that O
the O
L O
/ O
N O
exon O
in O
the O
PSG12 I-GENE
psi I-GENE
gene I-GENE
contains O
a O
stop O
codon O
. O

The O
mechanisms O
that O
govern O
the O
activation O
or O
suppression O
of O
the O
CD8 I-GENE
gene I-GENE
are O
likely O
to O
be O
central O
to O
the O
T O
cell O
development O
program O
. O

We O
suggest O
that O
the O
ER O
lumenal O
variable O
domain O
of O
gp19K I-GENE
has O
a O
specific O
tertiary O
structure O
that O
is O
important O
for O
binding O
to O
the O
polymorphic O
alpha O
1 O
and O
alpha O
2 O
domains O
of O
class I-GENE
I I-GENE
heavy I-GENE
( I-GENE
alpha I-GENE
) I-GENE
chains I-GENE
. O

We O
recently O
found O
that O
17 O
beta O
- O
estradiol O
( O
E2 O
) O
not O
only O
suppresses O
bone O
resorption O
but O
also O
stimulates O
bone O
formation O
in O
the O
cancellous O
bone O
of O
female O
rats O
. O

Recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
epoetin I-GENE
) O
is O
approved O
to O
be O
administered O
by O
the O
intravenous O
( O
i O
. O
v O
.) O
or O
subcutaneous O
( O
SC O
) O
route O
. O

Single O
- O
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
with O
99mTc O
- O
hexamethylpropyleneamine O
oxime O
( O
HMPAO O
) O
was O
used O
to O
investigate O
changes O
in O
cerebral O
blood O
flow O
in O
seven O
patients O
with O
cortical O
visual O
impairment O
. O

The O
rCBF O
ratio O
was O
mainly O
reduced O
in O
frontal O
lobes O
( O
65 O
%). O

METHODS O
: O
Twenty O
- O
two O
patients O
were O
grouped O
according O
to O
their O
etiology O
based O
on O
the O
study O
of O
antiadrenal O
antibodies O
at O
diagnosis O
of O
the O
disease O
: O
7 O
were O
positive O
( O
autoimmune O
etiology O
or O
EAA O
), O
11 O
were O
negative O
( O
tuberculous O
etiology O
or O
EAT O
) O
and O
in O
four O
serologic O
study O
was O
not O
available O
( O
undetermined O
etiology O
or O
EAI O
). O

2 O
- O
AP O
induced O
marked O
, O
steady O
rises O
in O
mRNA O
accumulation O
from O
both O
transfected O
and O
chromosomally O
integrated O
HIV O
- O
1 O
constructs O
but O
no O
increases O
from O
an O
endogenous O
gene O
encoding O
gamma I-GENE
- I-GENE
actin I-GENE
or O
glucose I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
. O

The O
UV O
induction O
of O
c I-GENE
- I-GENE
jun I-GENE
is O
mediated O
by O
two O
UV O
response O
elements O
consisting O
of O
AP I-GENE
- I-GENE
1 I-GENE
- I-GENE
like I-GENE
sequences I-GENE
within O
its O
5 O
' O
control O
region O
. O

Protein I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
PTPs I-GENE
), O
together O
with O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
PTKs I-GENE
), O
are O
involved O
in O
the O
regulation O
of O
cell O
activation O
, O
growth O
, O
and O
differentiation O
. O

ST O
elevation O
occurs O
in O
5 O
patients O
( O
55 O
. O
5 O
%) O
of O
subgroup O
A O
and O
in O
no O
patient O
of O
the O
subgroup O
B O
. O

Furthermore O
, O
a O
p21X I-GENE
protein I-GENE
lacking O
the O
N O
- O
terminus O
of O
Rex1 I-GENE
was O
expressed O
at O
high O
levels O
; O
our O
data O
indicate O
that O
p21X I-GENE
is O
translated O
from O
the O
1 O
. O
6 O
- O
kb O
mRNA O
which O
is O
derived O
primarily O
from O
deleted O
proviruses O
. O

HTLV O
- O
1 O
gene O
expression O
by O
defective O
proviruses O
in O
an O
infected O
T O
- O
cell O
line O
. O

Thus O
, O
it O
was O
confirmed O
that O
the O
sodium O
lauryl O
sulfate O
method O
of O
estimating O
hemoglobin I-GENE
concentration O
is O
an O
appropriate O
alternative O
to O
the O
cyanmethemoglobin I-GENE
method O
and O
avoids O
the O
generation O
of O
toxic O
wastes O
. O

A O
comparison O
of O
the O
predicted O
amino O
acid O
sequences O
of O
the O
two O
human I-GENE
PKC I-GENE
- I-GENE
delta I-GENE
clones O
with O
the O
rat O
and O
mouse O
homologues O
indicated O
a O
greater O
degree O
of O
sequence O
divergence O
( O
89 O
- O
90 O
% O
homology O
) O
compared O
to O
the O
high O
degree O
of O
sequence O
conservation O
observed O
with O
other O
human I-GENE
PKC I-GENE
family I-GENE
members I-GENE
and O
their O
mammalian O
counterparts O
. O

XII O
. O

When O
comparing O
the O
barley I-GENE
PSI I-GENE
- I-GENE
K I-GENE
and O
PSI I-GENE
- I-GENE
G I-GENE
with O
the O
reported O
PSI I-GENE
- I-GENE
K I-GENE
sequence I-GENE
from I-GENE
Synechococcus I-GENE
vulcanus I-GENE
, O
the O
degree O
of O
similarity O
is O
equal O
, O
suggesting O
that O
an O
ancestral O
gene O
has O
been O
duplicated O
in O
a O
chloroplast O
progenitor O
but O
not O
in O
a O
cyanobacterial O
. O

On O
the O
other O
hand O
, O
the O
structures O
of O
the O
b O
- O
Zip O
domain O
are O
well O
conserved O
among O
these O
Maf I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Under O
these O
conditions O
, O
transfections O
with O
cDNAs O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
p50 I-GENE
and O
serum I-GENE
response I-GENE
factor I-GENE
( O
SRF I-GENE
) O
produced O
a O
factor O
( O
s O
) O
that O
mediated O
Tax I-GENE
binding O
to O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
and O
the O
CArG O
box O
respectively O
. O

We O
show O
here O
that O
v I-GENE
- I-GENE
Rel I-GENE
specifically O
increased O
expression O
from O
a O
reporter O
plasmid O
containing O
multiple O
Sp1 I-GENE
binding I-GENE
sites I-GENE
approximately O
sixfold O
in O
chicken O
embryo O
fibroblasts O
( O
CEFs O
), O
even O
though O
v I-GENE
- I-GENE
Rel I-GENE
did O
not O
bind O
directly O
to O
these O
sites O
. O
v I-GENE
- I-GENE
Rel I-GENE
also O
increased O
expression O
from O
a O
reporter O
plasmid O
containing O
a O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
( O
LTR O
) O
in O
which O
the O
kappa I-GENE
B I-GENE
binding I-GENE
sites I-GENE
were O
mutated O
but O
which O
still O
contained O
intact O
Sp1 I-GENE
binding I-GENE
sites I-GENE
. O

The O
simultaneous O
recording O
of O
electrical O
activity O
from O
the O
surface O
electrocardiogram O
, O
right O
ventricular O
apex O
, O
His O
bundle O
, O
high O
right O
atrium O
, O
coronary O
sinus O
, O
with O
or O
without O
a O
roving O
mapping O
catheter O
, O
enables O
us O
to O
precisely O
map O
the O
electrical O
activation O
sequence O
in O
the O
heart O
. O

CONCLUSION O
: O
This O
retrospective O
analysis O
does O
not O
confirm O
the O
efficacy O
of O
one O
course O
of O
simultaneous O
Mitomycin O
- O
C O
and O
5 O
- O
fluorouracil O
, O
at O
least O
in O
association O
with O
full O
- O
dose O
radiotherapy O
incorporating O
Iridium O
- O
192 O
boost O
. O

Despite O
the O
existence O
of O
30 O
cysteine O
residues O
, O
carboxymethylation O
prevented O
the O
formation O
of O
most O
if O
not O
all O
disulfide O
bonds O
that O
otherwise O
occurred O
when O
the O
cells O
were O
sonicated O
. O

Cerebro O
- O
oculo O
- O
facioskeletal O
syndrome O
( O
Pena O
- O
Shokeir O
syndrome O
II O
) O

Most O
importantly O
, O
the O
addition O
of O
purified O
17S I-GENE
U2 I-GENE
snRNPs I-GENE
, O
but O
not O
of O
12S I-GENE
U2 I-GENE
snRNPs I-GENE
, O
to O
HeLa O
splicing O
extracts O
in O
which O
the O
endogeneous I-GENE
U2 I-GENE
snRNPs I-GENE
have O
been O
functionally O
neutralized O
with O
anti I-GENE
- I-GENE
PRP9 I-GENE
antibodies I-GENE
fully O
restores O
the O
mRNA O
- O
splicing O
activity O
of O
the O
extracts O
. O

Differences O
in O
profiles O
of O
viscosity O
variables O
between O
subgroups O
of O
EAD O
in O
RA O
patients O
were O
observed O
. O

These O
contain O
a O
single O
1977 O
- O
bp O
exon O
that O
encodes O
900 O
bp O
of O
the O
5 O
' O
and O
3 O
' O
untranslated O
sequences O
in O
addition O
to O
a O
1077 O
- O
bp O
open O
reading O
frame O
identical O
to O
that O
found O
in O
vascular I-GENE
smooth I-GENE
muscle I-GENE
cell I-GENE
AT1a I-GENE
receptor I-GENE
cDNAs I-GENE
. O

Deletion O
of O
a O
53 O
- O
bp O
early O
promoter O
region O
containing O
the O
transcription O
start O
site O
and O
a O
putative O
TATA O
box O
completely O
abolishes O
the O
ability O
of O
upstream O
elements O
to O
drive O
transcription O
of O
the O
luciferase I-GENE
cDNA I-GENE
. O

One O
chimpanzee O
reliably O
selected O
the O
larger O
numeral O
4 O
during O
testing O
with O
a O
nonadjacent O
pair O
( O
2 O
- O
4 O
), O
and O
2 O
chimps O
showed O
no O
preference O
. O

Dissipation O
of O
claudication O
pain O
after O
walking O
: O
implications O
for O
endurance O
training O
. O

Alternative O
transcript O
of O
the O
nonselective O
- O
type O
endothelin I-GENE
receptor I-GENE
from O
rat O
brain O
. O

The O
Functional O
Independence O
Measure O
: O
a O
comparative O
study O
of O
clinician O
and O
self O
ratings O
. O

Polymyxin O
B O
was O
given O
intravenously O
for O
1 O
week O
postburn O
in O
doses O
designed O
to O
neutralize O
circulating O
endotoxemia O
. O

SvO2 O
can O
be O
determined O
in O
vitro O
and O
in O
vivo O
. O

The O
transverse O
relaxation O
time O
( O
T2 O
) O
and O
apparent O
diffusion O
coefficient O
of O
water O
were O
determined O
. O

The O
Drosophila O
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene O
: O
clathrin I-GENE
function O
is O
essential O
in O
a O
multicellular O
organism O
. O

The O
binding O
specificity O
of O
this O
protein O
was O
compared O
to O
that O
of O
human I-GENE
E2F I-GENE
using O
a O
number O
of O
mutant I-GENE
E2F I-GENE
sites I-GENE
as O
competitors O
. O

To O
analyze O
the O
VH O
regions O
of O
polyreactive O
antibodies O
, O
with O
particular O
attention O
at O
their O
somatically O
mutated O
status O
, O
we O
generated O
five O
IgG I-GENE
( O
three O
IgG1 I-GENE
and O
two O
IgG3 I-GENE
) O
mAb O
( O
using O
B O
cells O
from O
a O
healthy O
subject O
, O
a O
patient O
with O
insulin I-GENE
- O
dependent O
diabetes O
mellitus O
and O
a O
patient O
with O
SLE O
), O
which O
bound O
with O
various O
efficiencies O
a O
number O
of O
different O
self O
and O
foreign O
Ag O
. O

It O
is O
possible O
that O
the O
patch O
determines O
the O
proper O
conformation O
of O
the O
site O
and O
thereby O
contributes O
to O
recognition O
indirectly O
. O

These O
findings O
suggest O
a O
functional O
cross O
- O
talk O
between O
RB I-GENE
protein I-GENE
and O
p21ras I-GENE
, O
which O
balances O
the O
cell O
phenotype O
between O
normal O
and O
transformed O
states O
. O

The O
7 O
- O
kb O
mRNA O
differs O
by O
alternative O
splicing O
such O
that O
it O
encodes O
a O
protein O
with O
a O
distinct O
amino O
terminus O
. O

Kinetics O
of O
the O
inhibition O
indicated O
that O
this O
polymerase O
domain O
can O
inhibit O
viral O
replication O
only O
during O
the O
preinitiation O
stage O
. O

The O
other O
transmembrane O
regions O
as O
well O
as O
the O
nucleoplasmic O
domain O
are O
not O
required O
for O
sorting O
. O

3 O
. O

McCann O
III O
, O
F O
. O

These O
cell O
lines O
, O
selected O
for O
the O
ability O
to O
support O
the O
replication O
of O
a O
temperature O
- O
sensitive O
VP5 I-GENE
mutant I-GENE
, O
were O
used O
to O
isolate O
VP5 I-GENE
and O
VP23 I-GENE
null O
mutants O
. O

The O
E1 I-GENE
nuclear I-GENE
transport I-GENE
motif I-GENE
is O
highly O
conserved O
in O
the O
animal O
and O
human O
papillomaviruses O
and O
is O
encoded O
in O
a O
similar O
region O
in O
the O
related O
E1 I-GENE
genes I-GENE
. O

The O
E1 I-GENE
replication I-GENE
protein I-GENE
of O
bovine O
papillomavirus O
type O
1 O
contains O
an O
extended O
nuclear O
localization O
signal O
that O
includes O
a O
p34cdc2 I-GENE
phosphorylation O
site O
. O

In O
order O
to O
investigate O
to O
what O
extent O
this O
interaction O
might O
contribute O
to O
tumor O
induction O
by O
the O
virus O
, O
we O
have O
introduced O
two O
different O
point O
mutations O
within O
the O
putative O
pRb I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
of O
large I-GENE
T I-GENE
antigen I-GENE
, O
and O
as O
a O
preliminary O
to O
in O
vivo O
experiments O
we O
have O
studied O
their O
effects O
in O
vitro O
on O
some O
biological O
activities O
relevant O
to O
tumor O
induction O
. O

We O
conclude O
that O
the O
conservation O
of O
nucleotides O
154 O
to O
156 O
is O
likely O
to O
be O
a O
consequence O
of O
their O
role O
as O
a O
sequence O
- O
specific O
recognition O
element O
for O
the O
SRP54 I-GENE
protein I-GENE
. O

A O
region O
of O
the O
deduced O
protein O
shares O
extensive O
homology O
with O
a O
catalytic O
region O
of O
Raf I-GENE
kinases I-GENE
, O
a O
feature O
shared O
only O
with O
TFIIE I-GENE
among O
transcription O
factors O
. O

The O
low O
molecular O
mass O
polypeptide O
complex O
is O
assumed O
to O
be O
involved O
in O
antigen O
presentation O
, O
generating O
peptides O
from O
cytosolic O
protein O
antigens O
, O
which O
are O
subsequently O
presented O
to O
cytotoxic O
T O
- O
lymphocytes O
on O
the O
cell O
surface O
. O

Secondary O
cleavage O
of O
RT I-GENE
at O
Trp O
- O
595 O
- O
Tyr O
- O
596 O
of O
Pol I-GENE
yields O
a O
truncated O
form O
lacking O
the O
C I-GENE
- I-GENE
terminal I-GENE
RNase I-GENE
H I-GENE
domain I-GENE
. O

The O
C O
- O
terminal O
approximately O
50 O
amino O
acids O
of O
Bel I-GENE
- I-GENE
1 I-GENE
are O
shown O
to O
be O
essential O
for O
Bel I-GENE
- I-GENE
1 I-GENE
activity O
but O
can O
be O
effectively O
substituted O
by O
the O
C O
- O
terminal O
activation O
domain O
of O
VP16 I-GENE
. O

Since O
the O
- O
172 O
/- O
148 O
element O
also O
conferred O
estrogen O
and O
thyroid O
hormone O
responsiveness O
, O
it O
can O
be O
considered O
a O
composite O
hormone O
response O
element O
. O

Optimal O
activation O
of O
T O
cells O
requires O
at O
least O
two O
signals O
. O

Together O
with O
a O
considerably O
shortened O
and O
interrupted O
aromatic O
aa O
stretch O
in O
this O
region O
, O
these O
differences O
are O
discussed O
in O
terms O
of O
the O
peculiar O
affinity O
of O
cyanobacterial I-GENE
cytochrome I-GENE
oxidases I-GENE
for O
acidic O
c I-GENE
- I-GENE
type I-GENE
cytochromes I-GENE
. O

All O
four O
of O
the O
genes O
have O
a O
similar O
structure O
, O
with O
the O
receptor O
protein O
encoded O
in O
a O
single O
exon O
. O

Identity O
of O
GABP I-GENE
with O
NRF I-GENE
- I-GENE
2 I-GENE
, O
a O
multisubunit O
activator O
of O
cytochrome I-GENE
oxidase I-GENE
expression O
, O
reveals O
a O
cellular O
role O
for O
an O
ETS I-GENE
domain I-GENE
activator O
of O
viral O
promoters O
. O

In O
the O
present O
study O
, O
beta O
- O
funaltrexamine O
( O
beta O
- O
FNA O
) O
and O
naltrindole O
( O
NTI O
) O
( O
nonequilibrium O
mu O
- O
and O
delta O
- O
antagonist O
, O
respectively O
) O
were O
used O
to O
precipitate O
withdrawal O
in O
butorphanol O
- O
dependent O
rats O
. O

The O
intracellular O
basic I-GENE
region I-GENE
/ I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
( I-GENE
bHLH I-GENE
) I-GENE
dioxin I-GENE
receptor I-GENE
mediates O
signal O
transduction O
by O
dioxin O
( O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
) O
and O
functions O
as O
a O
ligand O
- O
activated O
DNA O
binding O
protein O
directly O
interacting O
with O
target O
genes O
by O
binding O
to O
dioxin O
response O
elements O
. O

The O
alpha I-GENE
2A I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
( O
alpha I-GENE
2AAR I-GENE
) O
is O
coupled O
to O
a O
variety O
of O
effectors O
via O
pertussis I-GENE
toxin I-GENE
- O
sensitive O
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

A O
sequence O
comparison O
reveals O
two O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
consensus O
sequences O
, O
basic O
DNA O
binding O
region O
and O
leucine O
zippers O
1 O
and O
2 O
( O
bZIP1 O
and O
bZIP2 O
), O
within O
this O
region O
. O

One O
of O
these O
genes O
, O
REC114 I-GENE
, O
is O
described O
here O
, O
and O
the O
data O
confirm O
that O
REC114 I-GENE
is O
a O
meiosis O
- O
specific O
recombination O
gene O
with O
no O
detectable O
function O
in O
mitosis O
. O

The O
transactivation O
function O
of O
EBNA2 I-GENE
was O
also O
observed O
in O
the O
HeLa O
epithelial O
cell O
line O
, O
which O
suggests O
that O
EBV O
and O
HIV O
- O
1 O
infection O
of O
non O
- O
B O
cells O
may O
result O
in O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activation O
. O

Mutation O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
sites I-GENE
in O
the O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
and O
gag I-GENE
enhancers I-GENE
. O

Nuclear I-GENE
protein I-GENE
phosphatase I-GENE
2A I-GENE
dephosphorylates O
protein I-GENE
kinase I-GENE
A I-GENE
- O
phosphorylated O
CREB I-GENE
and O
regulates O
CREB I-GENE
transcriptional O
stimulation O
. O

We O
show O
that O
IL I-GENE
- I-GENE
6 I-GENE
activates O
JRE I-GENE
- I-GENE
IL6 I-GENE
through O
an O
H7 O
- O
sensitive O
pathway O
that O
does O
not O
involve O
protein I-GENE
kinase I-GENE
C I-GENE
, O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
Ca I-GENE
( I-GENE
2 I-GENE
+)- I-GENE
or I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
Ras I-GENE
, O
Raf I-GENE
- I-GENE
1 I-GENE
, O
or O
NF I-GENE
- I-GENE
IL6 I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
). O

Mutation O
of O
the O
presumptive O
phosphorylated O
tyrosine O
and O
threonine O
residues O
of O
Mpk1p I-GENE
individually O
to O
phenylalanine O
and O
alanine O
, O
respectively O
, O
severely O
impaired O
Mpk1p I-GENE
function O
. O

Growth O
factor O
stimulation O
rapidly O
induces O
a O
reversible O
change O
in O
the O
electrophoretic O
mobility O
of O
the O
ternary O
complex O
, O
accompanied O
by O
increased O
phosphorylation O
of O
the O
Elk I-GENE
- I-GENE
1 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
region I-GENE
and O
by O
the O
activation O
of O
a O
42 I-GENE
kd I-GENE
cellular I-GENE
Elk I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

In O
contrast O
to O
the O
situation O
in O
mammalian O
cells O
, O
prolonged O
exposure O
of O
the O
agonist O
( O
24 O
h O
) O
does O
not O
result O
in O
down O
regulation O
of O
the O
remaining O
70 O
% O
of O
the O
receptors O
. O

This O
stimulatory O
effect O
could O
also O
be O
elicited O
by O
c I-GENE
- I-GENE
Jun I-GENE
, O
which O
interacts O
with O
topo I-GENE
II I-GENE
, O
but O
not O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
which O
does O
not O
bind O
topo I-GENE
II I-GENE
in O
our O
in O
vitro O
assay O
. O

The O
regulation O
of O
Myf I-GENE
- I-GENE
5 I-GENE
and O
MyoD I-GENE
function O
by O
a O
cAMP O
- O
dependent O
pathway O
may O
partly O
explain O
how O
external O
signals O
generated O
by O
serum O
and O
certain O
peptide O
growth O
factors O
can O
be O
transduced O
to O
the O
nucleus O
and O
inhibit O
dominant O
- O
acting O
factors O
that O
are O
responsible O
for O
myoblast O
differentiation O
. O

16 O
, O
99 O
- O
104 O
). O

We O
have O
previously O
reported O
that O
high O
level O
human I-GENE
desmin I-GENE
expression O
depends O
on O
a O
280 O
- O
base O
pair O
muscle O
- O
specific O
enhancer O
which O
can O
function O
not O
only O
in O
myotubes O
, O
but O
can O
also O
activate O
gene O
expression O
in O
myoblasts O
. O

After O
surgery O
, O
patients O
self O
administered O
one O
of O
three O
possible O
postsurgical O
medications O
, O
which O
included O
placebo O
, O
codeine O
60 O
mg O
, O
and O
ibuprofen O
400 O
mg O
, O
when O
their O
pain O
reached O
a O
moderate O
or O
severe O
intensity O
. O

Replacement O
of O
the O
wild O
- O
type O
5 O
'- O
regulatory O
region O
with O
either O
of O
the O
mutants O
' O
cis O
- O
acting O
regulatory O
element O
resulted O
in O
the O
anaerobic O
expression O
of O
active I-GENE
Mn I-GENE
- I-GENE
superoxide I-GENE
dismutase I-GENE
. O

The O
orf61 I-GENE
gene I-GENE
product I-GENE
, O
when O
expressed O
from O
an O
exogenous O
promoter O
, O
inhibited O
int I-GENE
- O
mediated O
integration O
at O
the O
chromosomal I-GENE
attB I-GENE
site I-GENE
. O

Expression O
in O
established O
LCLs O
, O
occurring O
irrespective O
of O
virus O
producer O
status O
, O
was O
not O
a O
consequence O
of O
continued O
in O
vitro O
passage O
; O
thus O
, O
appropriately O
spliced O
BamHI I-GENE
- I-GENE
A I-GENE
transcripts I-GENE
could O
be O
amplified O
from O
normal O
B O
cells O
within O
1 O
day O
of O
their O
experimental O
infection O
in O
vitro O
, O
along O
with O
BamHI I-GENE
- I-GENE
C I-GENE
/ I-GENE
W I-GENE
promoter O
- O
initiated O
but O
not O
BamHI I-GENE
- I-GENE
F I-GENE
promoter I-GENE
- I-GENE
initiated I-GENE
mRNAs I-GENE
. O

Analysis O
by O
cell O
surface O
immunofluorescence O
showed O
that O
the O
UL28 I-GENE
gene I-GENE
is O
not O
required O
for O
expression O
of O
viral O
glycoproteins O
on O
the O
surface O
of O
infected O
cells O
. O

Furthermore O
, O
a O
mutant O
receptor O
( O
Y977F O
/ O
Y989F O
[ O
PLC I-GENE
gamma I-GENE
- O
binding O
sites O
]) O
could O
fully O
activate O
Ras I-GENE
, O
and O
the O
direct O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
calcium O
mobilization O
had O
almost O
no O
effect O
on O
the O
GDP O
/ O
GTP O
state O
of O
Ras I-GENE
in O
this O
cell O
line O
. O

Estrogen O
treatment O
in O
high O
doses O
is O
effective O
in O
reducing O
adult O
stature O
in O
constitutionally O
tall O
girls O
. O

Mutations O
at O
the O
extreme O
C O
- O
terminus O
of O
EIAV I-GENE
Tat I-GENE
impaired O
both O
RNA O
binding O
and O
activation O
domain O
functions O
, O
suggesting O
effects O
on O
secondary O
or O
tertiary O
structure O
. O

This O
observation O
suggests O
that O
the O
methyl O
- O
directed O
repair O
system O
utilizes O
the O
proximal O
d O
( O
GATC O
) O
sequence O
to O
direct O
correction O
. O

Uracil I-GENE
DNA I-GENE
glycosylase I-GENE
catalyzes O
the O
initial O
step O
in O
the O
repair O
pathway O
that O
removes O
potentially O
mutagenic O
uracil O
from O
duplex O
DNA O
. O

Current O
clinical O
trials O
should O
answer O
the O
question O
of O
which O
of O
the O
therapeutic O
options O
impairs O
quality O
of O
life O
less O
. O

Lithium O
phthalocyanine O
( O
LiPc O
) O
is O
a O
prototype O
of O
another O
generation O
of O
synthetic O
, O
metallic O
- O
organic O
, O
paramagnetic O
crystallites O
that O
appear O
very O
useful O
for O
in O
vitro O
and O
in O
vivo O
electron O
paramagnetic O
resonance O
oximetry O
. O

In O
this O
report O
, O
we O
focus O
on O
the O
genetics O
of O
the O
region O
of O
the O
17 I-GENE
hep I-GENE
syn I-GENE
gB I-GENE
gene I-GENE
that O
conferred O
both O
the O
syncytial O
and O
pathogenic O
phenotypes O
to O
17 O
syn O
+. O

Recipients O
with O
acute O
leukaemia O
in O
first O
remission O
or O
chronic O
myeloid O
leukaemia O
in O
first O
chronic O
phase O
were O
analysed O
as O
good O
risk O
, O
and O
those O
beyond O
these O
stages O
, O
as O
poor O
risk O
patients O
. O

Elledge O
, O
P O
. O

Drugs O
suppressed O
> O
or O
= O
75 O
% O
of O
the O
total O
premature O
ventricular O
contractions O
in O
all O
patients O
who O
had O
both O
use O
- O
dependent O
QRS O
prolongation O
and O
reverse O
use O
- O
dependent O
QT O
prolongation O
, O
in O
79 O
% O
of O
patients O
with O
use O
- O
dependent O
QRS O
prolongation O
alone O
, O
in O
70 O
% O
with O
reverse O
use O
- O
dependent O
QT O
prolongation O
alone O
, O
and O
in O
11 O
% O
with O
neither O
use O
- O
dependent O
QRS O
prolongation O
nor O
reverse O
use O
- O
dependent O
QT O
prolongation O
. O

Losses O
during O
the O
complete O
procedure O
are O
corrected O
for O
using O
radioactive O
estrogen O
conjugates O
during O
the O
first O
steps O
and O
later O
by O
adding O
deuterated O
internal O
standards O
of O
all O
compounds O
measured O
( O
matairesinol O
, O
enterodiol O
, O
enterolactone O
, O
daidzein O
, O
O O
- O
desmethylangolensin O
, O
equol O
, O
and O
genistein O
). O

IE2 I-GENE
- O
IE2 I-GENE
interactions O
were O
mapped O
to O
a O
domain O
containing O
a O
putative O
helix O
- O
turn O
- O
helix O
motif O
located O
near O
the O
C O
terminus O
of O
IE2 I-GENE
, O
between O
amino O
acids O
456 O
and O
539 O
. O

The O
Sp1 I-GENE
region I-GENE
, O
however O
, O
is O
converted O
to O
a O
functionally O
strong O
TRE O
by O
the O
viral I-GENE
tat I-GENE
factor I-GENE
. O

Precipitation O
using O
GST I-GENE
fusion I-GENE
proteins I-GENE
containing O
Fyn I-GENE
SH2 I-GENE
, O
SH3 I-GENE
, O
and O
SH2 I-GENE
/ O
SH3 I-GENE
domains O
revealed O
that O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
bound O
principally O
to O
the O
SH3 I-GENE
domain I-GENE
of O
Fyn I-GENE
. O

A O
sheep O
testicular O
cDNA O
library O
constructed O
in O
pcDNA1 O
vector O
was O
screened O
with O
a O
probe O
generated O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
corresponding O
to O
a O
1 O
. O
6 O
kb O
fragment O
of O
the O
rat I-GENE
luteinizing I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
. O

Two O
putative O
Rev I-GENE
proteins I-GENE
with O
apparent O
molecular O
masses O
of O
18 O
and O
16 O
kDa O
were O
expressed O
by O
p2 I-GENE
/ I-GENE
2 I-GENE
and O
p176 I-GENE
, O
while O
p20 I-GENE
expressed O
only O
a O
16 O
- O
kDa O
species O
. O

Three O
group O
1 O
patients O
developed O
CMV O
disease O
; O
1 O
group O
2 O
patient O
developed O
CMV O
hepatitis O
. O

The O
ability O
of O
spt2 I-GENE
mutations I-GENE
to O
suppress O
the O
transcriptional O
interference O
caused O
by O
the O
delta I-GENE
promoter I-GENE
insertion I-GENE
his I-GENE
- I-GENE
4 I-GENE
- I-GENE
912 I-GENE
delta I-GENE
correlates O
with O
an O
increase O
in O
wild I-GENE
- I-GENE
type I-GENE
HIS4 I-GENE
mRNA I-GENE
levels O
. O

Nuclear O
localization O
and O
protein O
sequence O
similarities O
suggested O
that O
the O
SPT2 I-GENE
/ O
SIN1 I-GENE
protein O
may O
be O
related O
to O
the O
nonhistone I-GENE
chromosomal I-GENE
protein I-GENE
HMG1 I-GENE
. O

The O
conserved O
ninth O
C O
- O
terminal O
heptad O
in O
thyroid O
hormone O
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
mediates O
diverse O
responses O
by O
affecting O
heterodimer O
but O
not O
homodimer O
formation O
. O

Genetic O
interactions O
between O
BCK2 I-GENE
and O
other O
pathway O
components O
suggested O
that O
BCK2 I-GENE
functions O
on O
a O
common O
pathway O
branch O
with O
PPZ1 I-GENE
and O
PPZ2 I-GENE
. O

Steroidogenic I-GENE
factor I-GENE
1 I-GENE
, O
an O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
, O
regulates O
the O
expression O
of O
the O
rat I-GENE
aromatase I-GENE
gene I-GENE
in O
gonadal O
tissues O
. O

To O
study O
the O
functional O
differences O
between O
cutaneous O
HPV5 O
and O
HPV8 O
E7s I-GENE
and O
genital I-GENE
HPV16 I-GENE
E7 I-GENE
, O
we O
cloned O
each O
of O
the O
E7 I-GENE
open O
reading O
frames O
and O
tested O
their O
immortalizing O
and O
transforming O
activities O
, O
the O
binding O
ability O
of O
their O
products O
with O
retinoblastoma I-GENE
protein I-GENE
( O
RB I-GENE
) O
and O
their O
complementation O
activity O
of O
a O
RB I-GENE
- I-GENE
nonbinding I-GENE
adenovirus I-GENE
E1A I-GENE
mutant I-GENE
. O

The O
rhaB I-GENE
transcription I-GENE
start I-GENE
site I-GENE
was O
mapped O
to O
- O
24 O
relative O
to O
the O
start O
of O
translation O
. O

Several O
lines O
of O
evidence O
demonstrate O
that O
this O
growth O
inhibition O
requires O
active O
PKA I-GENE
subunits I-GENE
and O
cAMP O
: O
( O
i O
) O
this O
phenotype O
is O
dependent O
on O
cAMP O
since O
it O
is O
not O
seen O
in O
a O
strain O
lacking O
adenylyl I-GENE
cyclase I-GENE
activity O
, O
but O
the O
growth O
rate O
of O
these O
transformants O
is O
slower O
when O
exogenous O
cAMP O
is O
added O
; O
( O
ii O
) O
normal O
growth O
occurs O
when O
wild O
- O
type O
RI I-GENE
cDNA O
is O
replaced O
by O
a O
mutant I-GENE
RI I-GENE
cDNA I-GENE
encoding O
a O
RI I-GENE
protein I-GENE
with O
reduced O
cAMP O
binding O
; O
and O
( O
iii O
) O
the O
growth O
- O
inhibited O
phenotype O
of O
the O
transformed O
BL21 O
( O
DE3 O
) O
cells O
requires O
soluble O
, O
active O
C I-GENE
alpha I-GENE
protein I-GENE
. O

Liu O
, O
B O
. O

BCR I-GENE
- O
ABL I-GENE
and O
v I-GENE
- I-GENE
abl I-GENE
oncogenes I-GENE
induce O
distinct O
patterns O
of O
thymic O
lymphoma O
involving O
different O
lymphocyte O
subsets O
. O

These O
experiments O
confirm O
that O
the O
6 O
- O
S O
liganded O
form O
of O
the O
receptor O
identified O
in O
nuclear O
extracts O
of O
cells O
treated O
with O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
( O
TCDD O
) O
contains O
the O
Ah I-GENE
receptor I-GENE
protein I-GENE
and O
ARNT I-GENE
but O
not O
the O
90 I-GENE
- I-GENE
kDa I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 O
. O
74 O
+/- O
0 O
. O
87 O
to O
3 O
. O
78 O
+/- O
0 O
. O
78 O
mmol O
/ O
l O
after O
8 O
weeks O
on O
simvastatin O
( O
P O
< O
0 O
. O
001 O
), O
and O
apo I-GENE
B I-GENE
fell O
from O
142 O
+/- O
31 O
to O
112 O
+/- O
22 O
mg O
/ O
dl O
( O
P O
< O
0 O
. O
001 O
). O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 O
. O
74 O
+/- O
0 O
. O
87 O
to O
3 O
. O
78 O
+/- O
0 O
. O
78 O
mmol O
/ O
l O
after O
8 O
weeks O
on O
simvastatin O
( O
P O
< O
0 O
. O
001 O
), O
and O
apo I-GENE
B I-GENE
fell O
from O
142 O
+/- O
31 O
to O
112 O
+/- O
22 O
mg O
/ O
dl O
( O
P O
< O
0 O
. O
001 O
). O

This O
negative O
element O
may O
, O
at O
least O
in O
part O
, O
be O
responsible O
for O
the O
cell O
type O
- O
specific O
expression O
of O
the O
DGK I-GENE
gene I-GENE
. O

Regulated O
activity O
of O
the O
distal O
promoter O
- O
like O
element O
of O
the O
human I-GENE
corticotropin I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
gene I-GENE
and O
secondary O
structural O
features O
of O
its O
corresponding O
transcripts O
. O

A O
new O
bioencapsulation O
technology O
for O
microbial O
inoculants O
. O

We O
linked O
hypersensitivity O
site O
2 O
( O
HS2 O
) O
from O
the O
locus O
control O
region O
( O
LCR O
) O
to O
a O
A I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
gene O
( O
A O
gamma O
*) O
mutationally O
marked O
to O
allow O
its O
transcript O
to O
be O
distinguished O
from O
endogenous O
gamma I-GENE
- I-GENE
globin I-GENE
mRNA O
. O

INTERVENTIONS O
-- O
Patients O
allocated O
to O
treatment O
with O
levodopa I-GENE
/ I-GENE
dopa I-GENE
decarboxylase I-GENE
inhibitor O
alone O
( O
arm O
1 O
), O
levodopa I-GENE
/ I-GENE
decarboxylase I-GENE
inhibitor O
/ O
selegiline O
in O
combination O
( O
arm O
2 O
), O
or O
bromocriptine O
( O
arm O
3 O
). O

It O
contains O
three O
putative O
binding O
sites O
for O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
as O
well O
as O
several O
short O
sequences O
that O
are O
similar O
to O
known O
cis O
- O
acting O
enhancers O
or O
binding O
sites O
for O
transcription O
factors O
. O

French O
bean O
contains O
a O
small O
family O
of O
genes I-GENE
encoding I-GENE
PAL I-GENE
and O
two O
of O
these O
genes O
, O
PAL2 I-GENE
and O
PAL3 I-GENE
, O
have O
been O
shown O
to O
be O
differentially O
expressed O
at O
the O
mRNA O
level O
in O
bean O
tissues O
. O

Plasma O
thromboxane O
B2 O
levels O
in O
the O
older O
group O
were O
about O
double O
those O
in O
younger O
piglets O
. O

By O
stepwise O
linear O
multiple O
regression O
analysis O
, O
ionized O
magnesium O
was O
significantly O
related O
to O
cyclosporin O
trough O
level O
and O
total O
cholesterol O
but O
not O
to O
serum O
creatinine O
, O
time O
after O
transplant O
or O
the O
dose O
of O
cyclosporin O
. O

The O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
IGF I-GENE
- I-GENE
II I-GENE
) O
gene O
contains O
four O
promoters O
( O
P1 O
, O
P2 O
, O
P3 O
and O
P4 O
). O

Moreover O
, O
in O
transient O
transfection O
assays O
, O
PU I-GENE
. I-GENE
1 I-GENE
alone O
activated O
reporter O
constructs O
containing O
the O
JB O
cis O
- O
element O
, O
and O
the O
activation O
was O
shown O
to O
be O
dependent O
on O
a O
glutamine O
- O
rich O
sequence O
in O
the O
amino O
- O
terminal O
portion O
of O
PU I-GENE
. I-GENE
1 I-GENE
. O

Army O
veterans O
given O
yellow O
fever O
vaccine O
contaminated O
with O
hepatitis O
B O
virus O
in O
1942 O
and O
controls O
and O
( O
b O
) O
a O
case O
- O
control O
study O
comparing O
veterans O
with O
hepatocellular O
carcinoma O
in O
Veterans O
Affairs O
hospitals O
with O
matched O
controls O
with O
respect O
to O
receipt O
of O
contaminated O
vaccine O
in O
1942 O
. O

They O
were O
found O
to O
be O
seropositive O
for O
antibodies O
to O
hepatitis O
C O
virus O
by O
second O
- O
generation O
testing O
( O
RIBA O
2 O
, O
Ortho O
Diagnostic O
Systems O
Inc O
, O
Westwood O
, O
MA O
). O

Defects O
of O
fibrillin I-GENE
( O
FBN1 I-GENE
), O
a O
glycoprotein O
component O
of O
the O
extracellular O
microfibril O
, O
cause O
Marfan O
syndrome O
. O

When O
introduced O
into O
recJ I-GENE
+ I-GENE
strains O
, O
srjA I-GENE
mutations O
conferred O
hyperrecombinational O
and O
hyper I-GENE
- I-GENE
UVr I-GENE
phenotypes O
. O

Distinguishing O
roles O
of O
the O
membrane O
- O
cytoskeleton O
and O
cadherin I-GENE
mediated O
cell O
- O
cell O
adhesion O
in O
generating O
different O
Na I-GENE
+, I-GENE
K I-GENE
(+)- I-GENE
ATPase I-GENE
distributions O
in O
polarized O
epithelia O
. O

Neonatal O
lupus O
erythematosus O
is O
most O
often O
associated O
with O
autoantibodies O
against O
Ro I-GENE
and O
La I-GENE
antigens O
. O

Genetic O
abnormalities O
that O
could O
lead O
to O
mutagenesis O
include O
chromosomal O
abnormalities O
and O
single O
- O
gene O
mutations O
. O

Hops O
, O
and O
L O
. O

Continued O
absorption O
of O
amino O
acids O
by O
the O
NBB O
carrier O
( O
for O
neutral O
amino O
acids O
), O
the O
Y O
+ O
system O
( O
for O
dibasic O
amino O
acids O
), O
and O
the O
PHE O
carrier O
were O
operative O
even O
during O
the O
actively O
purging O
stage O
of O
watery O
diarrhoea O
due O
to O
cholera O
. O

1 O
) O
CFDN O
, O
AMPC O
and O
MNZ O
showed O
a O
potent O
antimicrobial O
activity O
against O
H O
. O
pylori O
, O
and O
especially O
, O
AMPC O
showed O
a O
marked O
bactericidal O
activity O
in O
a O
short O
time O
. O

Creutzfeldt O
- O
Jakob O
disease O
and O
lyophilised O
dura O
mater O
grafts O
: O
report O
of O
two O
cases O
. O

A O
high O
mean O
intensity O
of O
CLTPA O
( O
standardized O
multivariate O
regression O
coefficient O
beta O
- O
0 O
. O
059 O
, O
p O
= O
0 O
. O
020 O
) O
and O
a O
high O
maximal O
oxygen O
uptake O
( O
beta O
- O
0 O
. O
163 O
, O
p O
< O
0 O
. O
001 O
) O
were O
associated O
with O
reduced O
plasma I-GENE
fibrinogen I-GENE
when O
adjusting O
for O
the O
strongest O
covariates O
. O

What O
young O
people O
think O
and O
do O
when O
the O
option O
for O
cystic O
fibrosis O
carrier O
testing O
is O
available O
. O

A O
patient O
matches O
a O
PIC O
patient O
if O
both O
have O
the O
same O
mechanism O
of O
injury O
, O
the O
same O
coding O
of O
Revised O
Trauma O
Score O
variables O
( O
Glascow O
Coma O
Scale O
score O
, O
systolic O
blood O
pressure O
, O
respiratory O
rate O
), O
the O
same O
coded O
age O
per O
A O
Severity O
Characterization O
of O
Trauma O
) O
( O
ASCOT O
), O
and O
if O
they O
differ O
by O
no O
more O
than O
0 O
. O
5 O
for O
A O
, O
B O
, O
and O
C O
( O
the O
ASCOT O
components O
for O
serious O
injuries O
). O

Skin O
and O
bowel O
TPO2 O
varied O
with O
DO2 O
and O
each O
other O
( O
P O
< O
0 O
. O
05 O
). O

A O
region O
approximately O
100 O
bp O
upstream O
from O
the O
transcription O
start O
point O
of O
virB I-GENE
was O
identified O
as O
being O
necessary O
for O
full O
activation O
of O
this O
promoter O
by O
VirF I-GENE
. O

We O
have O
isolated O
a O
cosmid O
containing O
DNA O
that O
corresponds O
to O
the O
site O
of O
transposon O
insertion O
in O
257DH4 O
and O
have O
localized O
Tn5 I-GENE
on O
an O
8 I-GENE
. I-GENE
0 I-GENE
kb I-GENE
EcoRI I-GENE
fragment I-GENE
. O

The O
scr I-GENE
regulon I-GENE
of O
pUR400 O
and O
the O
chromosomally I-GENE
encoded I-GENE
scr I-GENE
regulon I-GENE
of I-GENE
Klebsiella I-GENE
pneumoniae I-GENE
KAY2026 I-GENE
are O
both O
negatively O
controlled O
by O
a O
specific O
repressor O
( O
ScrR I-GENE
). O

Although O
the O
molecular O
mechanisms O
involved O
in O
this O
regulation O
are O
currently O
being O
elucidated O
, O
very O
little O
is O
known O
about O
the O
trans O
- O
acting O
factors O
that O
allow O
expression O
of O
the O
nitrate I-GENE
and I-GENE
nitrite I-GENE
reductase I-GENE
genes I-GENE
which O
code O
for O
the O
first O
enzymes O
in O
the O
pathway O
. O

The O
Ntl1 I-GENE
gene I-GENE
is O
present O
as O
a O
unique O
copy O
in O
the O
diploid O
N O
. O
plumbaginifolia O
species O
. O

Transient O
transfection O
experiments O
revealed O
that O
Pax I-GENE
- I-GENE
8 I-GENE
isoforms I-GENE
a I-GENE
and I-GENE
b I-GENE
, O
but O
not O
c O
and O
d O
, O
strongly O
stimulate O
transcription O
from O
a O
promoter O
containing O
six O
copies O
of O
a O
paired I-GENE
- I-GENE
domain I-GENE
recognition I-GENE
sequence I-GENE
. O

The O
amino O
- O
terminal O
third O
of O
the O
protein O
contains O
a O
high I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
motif I-GENE
characteristic O
of O
DNA O
- O
binding O
proteins O
. O

We O
have O
examined O
the O
ability O
of O
various O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
subunits I-GENE
to O
bind O
to O
, O
and O
activate O
transcription O
from O
, O
the O
IL I-GENE
- I-GENE
8 I-GENE
promoter I-GENE
. O

When O
multiple O
copies O
of O
the O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
were O
linked O
to O
an O
enhancerless O
simian I-GENE
virus I-GENE
40 I-GENE
promoter I-GENE
, O
this O
element O
was O
able O
to O
mediate O
phorbol O
ester O
- O
or O
lipopolysaccharide O
- O
inducible O
gene O
expression O
. O

We O
found O
that O
the O
3 O
'- O
end O
- O
adjacent O
sequence O
CA O
( O
N O
) O
3 O
- O
10AGTNNAA O
, O
conserved O
in O
plant O
Pol I-GENE
II I-GENE
- O
specific O
U I-GENE
snRNA I-GENE
genes I-GENE
, O
is O
essential O
for O
the O
3 O
'- O
end O
formation O
of O
U2 I-GENE
transcripts I-GENE
and O
, O
similar O
to O
the O
vertebrate O
3 O
' O
box O
, O
is O
highly O
tolerant O
to O
mutation O
. O

These O
results O
indicate O
that O
Rb I-GENE
protein I-GENE
is O
interacting O
with O
some O
component O
( O
s O
) O
of O
the O
cell O
cycle O
- O
regulatory O
machinery O
during O
G2 O
phase O
. O

MDBP I-GENE
from O
HeLa O
and O
Raji O
cells O
formed O
DNA O
- O
protein O
complexes O
with O
X O
- O
box O
oligonucleotides O
that O
coelectrophoresed O
with O
those O
containing O
standard O
MDBP I-GENE
sites I-GENE
. O

Transgenic O
mice O
harboring O
the O
rat O
TnI I-GENE
- O
CAT I-GENE
fusion O
gene O
expressed O
the O
reporter O
specifically O
in O
the O
skeletal O
muscle O
. O

METHODS O
: O
Fifty O
- O
one O
healthy O
eyes O
, O
169 O
ocular O
hypertensive O
eyes O
with O
normal O
visual O
fields O
, O
and O
132 O
glaucomatous O
eyes O
with O
early O
visual O
field O
defects O
were O
evaluated O
with O
qualitative O
and O
quantitative O
measures O
of O
structural O
damage O
to O
the O
optic O
nerve O
and O
nerve O
fiber O
layer O
. O

Consistent O
with O
the O
hypothesis O
that O
it O
acts O
as O
transcriptional O
regulator O
, O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
protein I-GENE
binds O
DNA O
and O
activates O
transcription O
of O
several O
promoters O
. O

The O
ADP I-GENE
- I-GENE
ribosylation I-GENE
factor I-GENE
( O
ARF I-GENE
) O
family O
is O
one O
of O
four O
subfamilies O
of O
the O
RAS I-GENE
superfamily I-GENE
of O
low I-GENE
molecular I-GENE
weight I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
G I-GENE
proteins I-GENE
). O

The O
E1 I-GENE
gene I-GENE
is O
located O
within O
the O
first O
intron O
of O
the O
gene O
for O
RCC1 I-GENE
, O
a O
protein O
that O
regulates O
onset O
of O
mitosis O
. O

Genomic O
Southern O
blot O
analysis O
and O
chromosome O
mapping O
showed O
that O
GPRK6 I-GENE
hybridizes O
to O
two O
closely O
related O
genes O
located O
on O
chromosomes O
5 O
and O
13 O
and O
are O
, O
therefore O
, O
distinct O
from O
the O
GPRK I-GENE
located O
near O
the O
Huntington I-GENE
disease I-GENE
locus I-GENE
on O
chromosome O
4 O
. O

Metabolic O
labeling O
studies O
in O
S O
. O
cerevisiae O
and O
co O
- O
expression O
of O
nmt72p I-GENE
with O
several O
protein O
substrates O
of O
Nmt1p I-GENE
in O
Escherichia O
coli O
indicate O
that O
the O
Leu99 O
--> O
Pro O
substitution O
causes O
a O
reduction O
in O
the O
acylation O
of O
some O
but O
not O
all O
protein O
substrates O
. O

These O
CTD I-GENE
kinases I-GENE
, O
designated O
CTDK1 I-GENE
and O
CTDK2 I-GENE
, O
are O
fractionated O
by O
chromatography O
on O
Mono O
Q O
. O

Instead O
, O
mRNA O
of O
2 O
. O
0 O
and O
2 O
. O
8 O
kb O
are O
detected O
in O
varying O
abundance O
. O

Previously O
, O
we O
identified O
a O
51 O
- O
bp O
promoter O
fragment O
, O
oligo31 O
/ O
32 O
, O
which O
conferred O
heat O
shock O
inducibility O
on O
the O
heterologous O
CYC1 I-GENE
- O
lacZ I-GENE
reporter O
gene O
in O
S O
. O
cerevisiae O
( O
N O
. O

The O
sequence O
of O
the O
HIR1 I-GENE
gene I-GENE
predicts O
an O
88 O
- O
kDa O
protein O
with O
three O
repeats O
of O
a O
motif O
found O
in O
the O
G I-GENE
beta I-GENE
subunit I-GENE
of O
retinal I-GENE
transducin I-GENE
and O
in O
a O
yeast O
transcriptional O
repressor O
, O
Tup1 I-GENE
. O

All O
of O
these O
data O
suggest O
that O
replication O
of O
UV O
- O
damaged O
templates O
occurs O
in O
vitro O
as O
it O
does O
in O
vivo O
and O
that O
this O
replication O
results O
in O
mutation O
fixation O
. O

To O
identify O
factors O
that O
may O
modify O
the O
heterosexual O
transmission O
of O
human O
T O
cell O
leukemia O
/ O
lymphoma O
virus O
type O
I O
( O
HTLV O
- O
I O
), O
534 O
married O
couples O
enrolled O
in O
the O
Miyazaki O
Cohort O
Study O
between O
November O
1984 O
and O
April O
1989 O
were O
studied O
: O
95 O
husband O
HTLV O
- O
I O
- O
seropositive O
( O
H O
+)/ O
wife O
seropositive O
( O
W O
+), O
33 O
H O
+/ O
W O
-, O
64 O
H O
-/ O
W O
+, O
and O
342 O
H O
-/ O
W O
-. O

Biol O
. O

To O
characterize O
the O
expression O
of O
this O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
we O
have O
isolated O
the O
corresponding O
genomic O
clone O
. O

L O
., O
Stange O
, O
G O
., O
Markovich O
, O
D O
., O
Biber O
, O
J O
., O
Testar O
, O
X O
., O
Zorzano O
, O
A O
., O
Palacin O
, O
M O
., O
and O
Murer O
, O
H O
. O

The O
nucleotide O
sequence O
of O
the O
gene O
predicts O
a O
polypeptide O
of O
215 O
amino O
acids O
( O
25 O
. O
2 O
kDa O
) O
with O
two O
putative O
membrane O
- O
spanning O
domains O
. O

SAECG O
, O
echocardiography O
and O
thallium O
- O
201 O
imaging O
were O
performed O
before O
and O
1 O
month O
after O
attempted O
angioplasty O
. O

They O
were O
called O
PACE4 I-GENE
and O
PC4 I-GENE
. O

265 O
, O
1102 O
- O
1110 O
). O

Both O
fusion O
proteins O
form O
stable O
specific O
complexes O
with O
a O
short O
DNA O
duplex O
harboring O
the O
CTGT O
( O
at O
) O
4ACAG O
consensus O
sequence O
of O
the O
LexA I-GENE
repressor I-GENE
. O

Ten O
selenocysteine O
residues O
( O
deduced O
) O
are O
present O
. O

CONCLUSIONS O
: O
Free O
protein I-GENE
S I-GENE
deficiency O
is O
common O
among O
hospitalized O
patients O
, O
even O
in O
the O
absence O
of O
a O
recognized O
predisposing O
condition O
. O

During O
the O
past O
decade O
, O
different O
types O
of O
endogenous O
retroviral O
sequences O
have O
been O
defined O
in O
the O
human O
genome O
usually O
by O
low O
stringency O
hybridization O
employing O
DNA O
probes O
of O
evolutionary O
conserved O
animal O
retrovirus O
genes O
. O

As O
the O
components O
of O
these O
complexes O
, O
at O
least O
five O
TRBPs I-GENE
( O
p30 I-GENE
, O
p37 I-GENE
, O
p46 I-GENE
, O
p50 I-GENE
, O
and O
p56 I-GENE
) O
showing O
specific O
binding O
to O
the O
TAR O
RNA O
were O
detected O
in O
the O
uv O
cross O
- O
linking O
assay O
. O

The O
obvious O
functional O
necessity O
for O
editing O
in O
kinetoplastid O
mitochondria O
is O
the O
formation O
of O
translatable O
mRNAs O
. O

The O
use O
of O
this O
model O
for O
investigating O
pathophysiologically O
significant O
issues O
in O
denervating O
diseases O
is O
illustrated O
with O
five O
different O
sets O
of O
parameters O
. O

An O
extensive O
inverted O
repeat O
is O
present O
3 O
' O
of O
rpeA I-GENE
; O
inverted O
repeats O
are O
found O
downstream O
of O
all O
PE I-GENE
operons I-GENE
sequenced O
to O
date O
, O
although O
the O
sequence O
is O
not O
conserved O
. O

We O
describe O
a O
novel O
cytoplasmic I-GENE
tyrosine I-GENE
kinase I-GENE
, O
termed O
BPK I-GENE
( O
B I-GENE
cell I-GENE
progenitor I-GENE
kinase I-GENE
), O
which O
is O
expressed O
in O
all O
stages O
of O
the O
B O
lineage O
and O
in O
myeloid O
cells O
. O

Large O
differences O
between O
the O
groups O
were O
not O
observed O
in O
HA I-GENE
- I-GENE
synthesizing I-GENE
enzyme I-GENE
activity O
, O
but O
degradative O
enzyme O
activity O
was O
much O
higher O
in O
aspirin O
- O
induced O
asthma O
- O
related O
polyps O
than O
in O
other O
types O
of O
nasal O
polyps O
tested O
. O

In O
the O
multivariate O
analysis O
, O
six O
variables O
were O
independently O
correlated O
with O
survival O
: O
blood O
urea O
nitrogen O
level O
, O
serum I-GENE
aspartate I-GENE
aminotransferase I-GENE
level O
, O
community O
- O
acquired O
vs O
. O
hospital O
- O
acquired O
peritonitis O
, O
age O
, O
Child O
- O
Pugh O
score O
and O
ileus O
. O

Localization O
of O
the O
intronless O
gene O
coding O
for O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
CLP I-GENE
to O
human O
chromosome O
10p13 O
- O
ter O
. O

In O
wandering O
stage O
larvae O
, O
the O
OBP I-GENE
transcript I-GENE
appeared O
to O
be O
at O
least O
250 O
- O
fold O
less O
abundant O
than O
ribosomal O
RNA O
. O

One O
such O
mutant O
also O
affects O
the O
overlapping O
- O
10 O
hexamer O
of O
PR O
and O
results O
in O
reduced O
occupancy O
by O
both O
MerR I-GENE
and O
RNA I-GENE
polymerase I-GENE
, O
likely O
as O
a O
result O
of O
inefficient O
transcriptional O
initiation O
of O
merR I-GENE
mRNA I-GENE
. O

However O
, O
L I-GENE
- I-GENE
plastin I-GENE
has O
been O
found O
in O
many O
types O
of O
malignant O
human O
cells O
of O
non O
- O
hemopoietic O
origin O
suggesting O
that O
its O
expression O
is O
induced O
accompanying O
tumorigenesis O
in O
solid O
tissues O
. O

Finally O
, O
we O
present O
evidence O
that O
fimbrin I-GENE
is O
a O
third O
distinct O
plastin I-GENE
isoform I-GENE
which O
is O
specifically O
expressed O
at O
high O
levels O
in O
the O
small O
intestine O
. O

This O
promoter O
could O
direct O
the O
constitutive O
expression O
of O
the O
reporter O
beta I-GENE
- I-GENE
galactosidase I-GENE
at O
high O
frequency O
in O
transfected O
colonies O
of O
transformed O
cells O
that O
express O
L I-GENE
- I-GENE
plastin I-GENE
constitutively O
; O
by O
contrast O
, O
this O
promoter O
was O
virtually O
inactive O
in O
transfected O
colonies O
of O
normal O
fibroblasts O
and O
it O
exhibited O
a O
low O
frequency O
of O
constitutive O
activation O
in O
transfected O
colonies O
of O
in O
vitro O
SV40 O
- O
transformed O
fibroblasts O
which O
did O
not O
exhibit O
L I-GENE
- I-GENE
plastin I-GENE
expression O
. O

The O
half O
- O
life O
of O
the O
serum O
- O
induced O
CBP I-GENE
/ O
tk I-GENE
binding O
activity O
was O
estimated O
to O
be O
less O
than O
1 O
h O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
DNase I-GENE
I I-GENE
footprint O
extended O
5 O
' O
in O
the O
silencer O
region O
to O
include O
an O
inverted O
repeat O
of O
a O
six O
- O
nucleotide O
motif O
( O
epsilon O
- O
267 O
to O
- O
278 O
bp O
) O
which O
shares O
5 O
of O
6 O
bases O
with O
the O
GATA I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
. O

Furthermore O
, O
competitor O
containing O
the O
YY1 I-GENE
consensus I-GENE
sequence I-GENE
competed O
for O
protein I-GENE
B I-GENE
binding O
, O
whereas O
competitor O
containing O
a O
perfect O
yeast I-GENE
ABF I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
did O
not O
.( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
gene O
includes O
three O
exons O
and O
two O
introns O
within O
1 O
. O
6 O
kilobases O
of O
DNA O
, O
and O
the O
entire O
open O
reading O
frame O
for O
glycoprotein I-GENE
IX I-GENE
is O
included O
within O
the O
third O
exon O
. O

Rhizobium O
meliloti O
large O
plasmid O
pRmeGR4b O
carries O
the O
nodulation O
competitiveness O
locus O
nfe I-GENE
responsible O
for O
the O
nodulation O
efficiency O
and O
competitive O
ability O
of O
strain O
GR4 O
on O
alfalfa O
roots O
. O

Further O
, O
the O
ability O
of O
recombinant O
beta O
and O
/ O
or O
gamma O
chains O
to O
function O
in O
defined O
biochemical O
assays O
of O
beta O
gamma O
activity O
was O
assessed O
for O
membrane O
extracts O
and O
supernatant O
fractions O
from O
infected O
Sf9 O
cells O
. O

This O
report O
describes O
the O
identification O
of O
a O
gene O
of O
related O
function O
, O
SMD1 I-GENE
, O
located O
immediately O
3 O
' O
to O
PRP38 I-GENE
. O

These O
data O
establish O
Smd1p I-GENE
as O
a O
required O
component O
of O
the O
cellular O
splicing O
apparatus O
and O
a O
factor O
in O
snRNA O
maturation O
and O
stability O
. O

This O
study O
compared O
the O
gross O
and O
fine O
motor O
performance O
of O
14 O
traumatically O
brain O
- O
injured O
children O
( O
five O
to O
15 O
years O
old O
, O
with O
loss O
of O
consciousness O
for O
at O
least O
24 O
hours O
) O
to O
14 O
normal O
children O
group O
matched O
for O
age O
and O
sex O
. O

We O
compared O
the O
parameters O
pleural I-GENE
adenosine I-GENE
deaminase I-GENE
( O
PADA I-GENE
, O
determined O
in O
405 O
patients O
), O
the O
PADA I-GENE
/ O
serum I-GENE
ADA I-GENE
ratio O
( O
P I-GENE
/ O
SADA I-GENE
; O
276 O
cases O
), O
pleural I-GENE
lysozyme I-GENE
( O
PLYS I-GENE
, O
276 O
cases O
), O
the O
PLYS I-GENE
/ O
serum I-GENE
LYS I-GENE
ratio O
( O
P I-GENE
/ O
SLYS I-GENE
; O
276 O
cases O
), O
and O
pleural I-GENE
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
, O
145 O
cases O
) O
regarding O
their O
ability O
to O
differentiate O
tuberculous O
pleural O
effusions O
from O
others O
. O

These O
exons O
were O
identified O
by O
cloning O
and O
sequencing O
cDNAs O
obtained O
by O
polymerase O
chain O
reaction O
amplification O
of O
a O
fibroblast O
cDNA O
library O
. O

Deletion O
of O
the O
apeA I-GENE
gene I-GENE
, O
either O
with O
or O
without O
deletion O
of O
other O
proteinases O
( O
protease I-GENE
IV I-GENE
and O
aminopeptidase I-GENE
N I-GENE
), O
did O
not O
have O
any O
effect O
on O
cell O
growth O
in O
the O
various O
media O
tested O
. O

In O
Experiment O
2 O
scopolamine O
hydrobromide O
, O
0 O
. O
5 O
and O
1 O
. O
0 O
mg O
/ O
kg O
i O
. O
p O
., O
was O
administered O
1 O
h O
before O
each O
electrical O
stimulation O
until O
each O
rat O
showed O
the O
stage O
- O
3 O
seizure O
. O

PNT O
, O
ADD O
and O
BSS O
in O
the O
initial O
stage O
of O
kindling O
, O
kindling O
rate O
for O
the O
stage O
- O
3 O
and O
- O
5 O
seizures O
, O
seizure O
parameters O
at O
the O
first O
stage O
- O
3 O
and O
- O
5 O
were O
recorded O
and O
compared O
to O
the O
values O
of O
saline O
- O
treated O
, O
control O
group O
. O

CONCLUSIONS O
. O

There O
was O
a O
positive O
correlation O
between O
pyridinium O
cross O
- O
link O
excretion O
and O
thyroid O
hormone O
concentrations O
. O

Mutations O
truncating O
as O
many O
as O
143 O
C O
- O
terminal O
residues O
from O
the O
transcriptional O
activator O
encoded O
by O
the O
areA I-GENE
gene I-GENE
, O
mediating O
nitrogen O
metabolite O
repression O
in O
Aspergillus O
nidulans O
, O
do O
not O
significantly O
reduce O
the O
ability O
of O
the O
areA I-GENE
product I-GENE
to O
activate O
expression O
of O
most O
genes O
under O
areA I-GENE
control O
. O

Naval O
personnel O
who O
exceed O
standards O
for O
% O
BF O
can O
be O
separated O
from O
active O
duty O
. O

Weak O
promoter O
activity O
was O
observed O
for O
the O
promoter O
of O
the O
C1 I-GENE
and O
C2 I-GENE
ORFs O
( O
C1 I-GENE
- O
C2 I-GENE
gene O
) O
and O
for O
the O
promoter O
of O
the O
V1 I-GENE
ORF I-GENE
. O

The O
activity O
of O
the O
coat I-GENE
protein I-GENE
promoter I-GENE
of O
chloris O
striate O
mosaic O
virus O
is O
enhanced O
by O
its O
own O
and O
C1 I-GENE
- O
C2 I-GENE
gene O
products O
. O

The O
amino O
acid O
sequence O
alignment O
of O
TC I-GENE
II I-GENE
with O
that O
of O
other O
Cbl I-GENE
binding I-GENE
proteins I-GENE
( O
rat I-GENE
intrinsic I-GENE
factor I-GENE
, O
human I-GENE
transcobalamin I-GENE
I I-GENE
and O
porcine I-GENE
haptocorrin I-GENE
) O
revealed O
only O
33 O
% O
overall O
homology O
. O

This O
short O
communication O
compares O
a O
novel O
fluorimetric O
microplate O
enzyme O
immunoassay O
( O
FEIA O
) O
with O
a O
commercial O
time O
- O
resolved O
fluoroimmunoassay O
for O
the O
determination O
of O
thyrotropin I-GENE
in O
dried O
blood O
spots O
. O

The O
evaluation O
was O
performed O
using O
a O
retrospective O
study O
design O
with O
newborn O
blood O
samples O
from O
three O
screening O
centres O
. O

A O
region O
in O
the O
C O
- O
terminus O
of O
adenovirus I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
E1a I-GENE
protein I-GENE
is O
required O
for O
association O
with O
a O
cellular O
phosphoprotein O
and O
important O
for O
the O
negative O
modulation O
of O
T24 O
- O
ras I-GENE
mediated O
transformation O
, O
tumorigenesis O
and O
metastasis O
. O

These O
studies O
demonstrate O
that O
both O
G I-GENE
alpha I-GENE
i I-GENE
genes I-GENE
are O
dynamically O
regulated O
in O
LLC O
- O
PK1 O
cells O
by O
both O
growth O
, O
differentiation O
, O
and O
hormone O
signals O
. O

Constructs O
containing O
the O
full I-GENE
- I-GENE
length I-GENE
PfCPK I-GENE
cDNA I-GENE
have O
been O
expressed O
in O
Escherichia O
coli O
at O
a O
high O
level O
to O
generate O
a O
60 O
- O
kDa O
recombinant O
protein O
. O

When O
ligated O
to O
the O
proIL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
cap I-GENE
site I-GENE
- I-GENE
proximal I-GENE
region I-GENE
( O
located O
between O
- O
131 O
to O
+ O
12 O
), O
both O
the O
proIL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
the O
simian I-GENE
virus I-GENE
40 I-GENE
enhancer I-GENE
elements I-GENE
functioned O
more O
efficiently O
in O
monocytes O
than O
in O
HeLa O
cells O
, O
which O
are O
not O
normally O
competent O
for O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
expression O
. O

Therefore O
, O
PC I-GENE
- I-GENE
PLC I-GENE
is O
a O
component O
of O
a O
signal O
transduction O
pathway O
leading O
to O
transcription O
of O
c I-GENE
- I-GENE
fos I-GENE
and O
junB I-GENE
that O
collaborates O
with O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
independent O
of O
PKC I-GENE
- I-GENE
delta I-GENE
and O
Ras I-GENE
activation O
. O

In O
mitogen O
- O
stimulated O
splenocytes O
, O
Gfi I-GENE
- I-GENE
1 I-GENE
expression O
begins O
to O
rise O
at O
12 O
h O
after O
stimulation O
and O
reaches O
very O
high O
levels O
after O
50 O
h O
, O
suggesting O
that O
it O
may O
be O
functionally O
involved O
in O
events O
occurring O
after O
the O
interaction O
of O
IL I-GENE
- I-GENE
2 I-GENE
with O
its O
receptor O
, O
perhaps O
during O
the O
transition O
from O
the O
G1 O
to O
the O
S O
phase O
of O
the O
cell O
cycle O
. O

We O
have O
isolated O
and O
characterized O
the O
GCD6 I-GENE
and O
GCD7 I-GENE
genes I-GENE
and O
shown O
that O
their O
products O
are O
required O
to O
repress O
GCN4 I-GENE
translation O
under O
nonstarvation O
conditions O
. O

The O
plateau O
MO2 O
value O
was O
that O
predicted O
by O
allometric O
relation O
. O

While O
the O
latter O
corresponded O
to O
a O
protein O
of O
824 O
amino O
acids O
, O
an O
upstream O
open O
reading O
frame O
( O
uORF O
) O
within O
the O
5 O
' O
leader O
could O
potentially O
encode O
a O
54 O
amino O
acid O
peptide O
. O

The O
SCH9 I-GENE
protein I-GENE
kinase I-GENE
mRNA I-GENE
contains O
a O
long O
5 O
' O
leader O
with O
a O
small O
open O
reading O
frame O
. O

In O
contrast O
to O
T O
cells O
, O
in O
fibroblasts O
PILOT I-GENE
gene I-GENE
expression O
requires O
only O
one O
signal O
( O
PMA O
) O
and O
is O
not O
affected O
by O
CyA O
. O

Histochemical O
localization O
of O
GUS I-GENE
revealed O
promoter O
function O
in O
leaf O
epidermis O
, O
mesophyll O
and O
vascular O
bundles O
, O
in O
the O
cortex O
and O
vascular O
cylinder O
of O
the O
root O
. O

In O
order O
to O
investigate O
how O
these O
expression O
patterns O
are O
established O
, O
we O
fused O
promoter O
regions O
of O
an O
acidic O
and O
a O
basic O
glucanase I-GENE
gene I-GENE
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
reporter O
gene O
and O
examined O
expression O
of O
these O
constructs O
in O
transgenic O
tobacco O
plants O
. O

Southern O
blot O
analysis O
using O
probes O
from O
the O
3 O
' O
portions O
of O
the O
genomic O
and O
B I-GENE
. I-GENE
napus I-GENE
MA I-GENE
and O
MB I-GENE
cDNA I-GENE
clones O
showed O
that O
MA I-GENE
type I-GENE
myrosinases I-GENE
are O
encoded O
by O
approximately O
4 O
genes O
, O
while O
MB I-GENE
type I-GENE
myrosinases I-GENE
are O
encoded O
by O
more O
than O
10 O
genes O
in O
B O
. O
napus O
. O

Sudomoina O
, O
A O
. O

Zinc O
fingers O
( O
Zf O
) O
are O
a O
common O
structural O
motif O
found O
in O
many O
nucleic O
acid O
- O
binding O
proteins O
. O

The O
deduced O
bovine O
EFIA I-GENE
# I-GENE
1 I-GENE
amino O
acid O
( O
aa O
) O
sequence O
is O
98 O
% O
identical O
to O
rat O
EFIA I-GENE
and O
100 O
% O
identical O
to O
human O
EFIA I-GENE
/ O
DbpB I-GENE
/ O
YB I-GENE
- I-GENE
1 I-GENE
family O
member O
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
B I-GENE
( O
DbpB I-GENE
). O

Effect O
of O
tracheal O
insufflation O
of O
deferoxamine O
on O
acute O
ozone O
toxicity O
in O
rats O
. O

Localization O
of O
the O
insertion O
locus O
in O
the O
yeast O
genome O
and O
complementation O
studies O
with O
the O
temperature O
- O
sensitive O
mutant O
indicate O
that O
the O
two O
mutations O
are O
allelic O
. O

Replacement O
of O
the O
spacer O
sequence O
between O
the O
two O
ARMs O
with O
a O
shorter O
stretch O
of O
sequence O
also O
reduced O
RNA O
binding O
in O
vitro O
. O

Type O
II O
could O
be O
divided O
further O
into O
two O
forms O
( O
IIA O
and O
IIB O
) O
that O
may O
represent O
two O
underscribed O
species O
or O
developmental O
stages O
of O
the O
same O
species O
. O

Second O
, O
the O
transcription I-GENE
factor I-GENE
Gal I-GENE
- I-GENE
ER I-GENE
was O
rendered O
more O
potent O
and O
less O
susceptible O
to O
cell O
type O
- O
specific O
variation O
by O
fusing O
the O
strong O
activating O
domain O
of O
the O
herpesvirus I-GENE
protein I-GENE
VP16 I-GENE
onto O
its O
C O
terminus O
. O

The O
exogenous O
fos I-GENE
gene I-GENE
was O
rapidly O
induced O
to O
maximal O
levels O
within O
1 O
- O
2 O
hr O
of O
estrogen O
addition O
. O

Elimination O
of O
Haemophilus O
influenzae O
type O
b O
meningitis O
after O
introduction O
of O
vaccination O

Endosonography O
accurately O
assessed O
tumor O
extension O
in O
two O
T2 O
tumors O
, O
14 O
T3 O
tumors O
, O
and O
seven O
T4 O
tumors O
. O

In O
the O
present O
study O
we O
demonstrated O
a O
unique O
mechanism O
of O
action O
of O
8 O
- O
Cl O
- O
cAMP O
in O
the O
regulation O
of O
these O
kinase O
isozymes O
in O
HL O
- O
60 O
human O
promyelocytic O
leukemia O
cells O
. O

Analysis O
of O
cell O
cycle O
regulation O
in O
the O
budding O
yeast O
Saccharomyces O
cerevisiae O
has O
shown O
that O
a O
central O
regulatory O
protein O
kinase O
, O
Cdc28 I-GENE
, O
undergoes O
changes O
in O
activity O
through O
the O
cell O
cycle O
by O
associating O
with O
distinct O
groups O
of O
cyclins I-GENE
that O
accumulate O
at O
different O
times O
. O

Overlapping O
clones O
representing O
full O
- O
length O
cDNAs O
for O
MMI I-GENE
alpha I-GENE
were O
obtained O
from O
mouse O
brain O
. O

The O
method O
involves O
preliminary O
isolation O
of O
oxiracetam O
and O
internal O
standard O
from O
plasma O
by O
solid O
- O
phase O
extraction O
prior O
to O
the O
formation O
of O
their O
n O
- O
propyl O
carbamate O
derivatives O
. O

There O
are O
, O
however O
, O
several O
differences O
between O
the O
two O
new O
ars O
sequences O
. O

Pathways O
linking O
the O
olfactory O
bulbs O
with O
the O
medial O
preoptic O
anterior O
hypothalamus O
are O
important O
for O
intermale O
aggression O
in O
mice O
. O

Pokeweed I-GENE
mitogen I-GENE
( O
PWM I-GENE
) O
or O
anti I-GENE
- I-GENE
CD3 I-GENE
significantly O
increases O
c I-GENE
- I-GENE
jun I-GENE
messenger I-GENE
RNA I-GENE
( I-GENE
mRNA I-GENE
) I-GENE
levels O
in O
T O
cells O
. O

Following O
seizure O
induction O
, O
MABP O
increased O
to O
105 O
mm O
Hg O
and O
brain O
pHi O
fell O
to O
6 O
. O
79 O
+/- O
0 O
. O
03 O
within O
15 O
min O
and O
remained O
at O
this O
level O
for O
1 O
h O
( O
P O
< O
0 O
. O
001 O
). O

In O
contrast O
, O
rats O
receiving O
U74500A O
( O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
infusion O
commencing O
30 O
min O
prior O
to O
revascularisation O
) O
exhibited O
enhanced O
GMBF O
throughout O
reperfusion O
[ O
PI O
10 O
min O
: O
3 O
. O
26 O
( O
2 O
. O
56 O
- O
3 O
. O
63 O
); O
120 O
min O
: O
2 O
. O
03 O
( O
1 O
. O
73 O
- O
2 O
. O
25 O
); O
240 O
min O
: O
2 O
. O
13 O
( O
1 O
. O
75 O
- O
2 O
. O
44 O
), O
p O
< O
0 O
. O
01 O
vs O
. O
controls O
and O
normals O
] O
with O
complete O
muscle O
salvage O
[ O
GMV O
100 O
% O
in O
all O
reperfused O
muscles O
, O
p O
< O
0 O
. O
01 O
vs O
. O
controls O
, O
not O
significant O
( O
NS O
) O
vs O
. O
normals O
and O
6 O
h O
ischaemia O
].( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Sequencing O
of O
a O
1 O
. O
3 O
- O
kilobase O
fragment O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
TSG6 I-GENE
gene I-GENE
identified O
TATA O
- O
like O
and O
CAAT O
sequences O
near O
the O
transcription O
start O
site O
. O

The O
region O
that O
imparts O
inducibility O
by O
IL I-GENE
- I-GENE
1 I-GENE
or O
TNF I-GENE
( O
positions O
- O
165 O
to O
- O
58 O
) O
contains O
potential O
binding O
sites O
for O
IRF I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
, O
and O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
. O

Ig I-GENE
- I-GENE
alpha I-GENE
and O
Ig I-GENE
- I-GENE
beta I-GENE
contain O
extended O
cytoplasmic O
structure O
( O
61 O
and O
48 O
amino O
acids O
, O
respectively O
) O
and O
associate O
with O
cytoplasmic O
effectors O
indicating O
that O
they O
are O
directly O
involved O
in O
signal O
transduction O
. O

Sterile O
mutants O
of O
Saccharomyces O
cerevisiae O
were O
isolated O
from O
alpha O
* O
cells O
having O
the O
a I-GENE
/ I-GENE
alpha I-GENE
aar1 I-GENE
- I-GENE
6 I-GENE
genotype O
( O
exhibiting O
alpha O
mating O
ability O
and O
weak O
a O
mating O
ability O
as O
a O
result O
of O
a O
defect O
in O
a1 I-GENE
- I-GENE
alpha I-GENE
2 I-GENE
repression O
). O

We O
studied O
the O
functional O
interaction O
between O
human O
embryonic O
zeta I-GENE
2 I-GENE
globin I-GENE
promoter O
and O
the O
alpha I-GENE
globin I-GENE
regulatory I-GENE
element I-GENE
( O
HS I-GENE
- I-GENE
40 I-GENE
) O
located O
40 O
kb O
upstream O
of O
the O
zeta I-GENE
2 I-GENE
globin I-GENE
gene I-GENE
. O

It O
was O
shown O
by O
transient O
expression O
assay O
that O
HS I-GENE
- I-GENE
40 I-GENE
behaved O
as O
an O
authentic O
enhancer O
for O
high O
- O
level O
zeta I-GENE
2 I-GENE
globin I-GENE
promoter I-GENE
activity O
in O
K562 O
cells O
, O
an O
erythroid O
cell O
line O
of O
embryonic O
and O
/ O
or O
fetal O
origin O
. O

Initial O
results O
indicate O
that O
this O
23S I-GENE
pre I-GENE
- I-GENE
rRNA I-GENE
is O
the O
same O
as O
the O
species O
detected O
on O
depletion O
of O
the O
small I-GENE
nucleolar I-GENE
RNA I-GENE
- I-GENE
associated I-GENE
proteins I-GENE
NOP1 I-GENE
and O
GAR1 I-GENE
and O
in O
an O
snr10 I-GENE
mutant I-GENE
strain O
. O

Breitbart O
, O
L O
. O

This O
study O
evaluates O
the O
feasibility O
of O
indirect O
mesenteric O
lymphangiography O
as O
a O
colonoscopic O
technique O
in O
a O
canine O
model O
. O

OBJECTIVE O
: O
Our O
purpose O
was O
to O
determine O
the O
simultaneous O
concentrations O
of O
serum O
cotinine O
in O
both O
fetal O
and O
maternal O
blood O
. O

Internal O
amino O
acid O
sequence O
has O
now O
been O
obtained O
from O
this O
protein O
which O
shares O
50 O
- O
100 O
% O
sequence O
identity O
with O
sequences O
encoded O
by O
mammalian I-GENE
G I-GENE
alpha I-GENE
11 I-GENE
and O
G I-GENE
alpha I-GENE
q I-GENE
cDNAs I-GENE
. O

Estradiol O
is O
known O
to O
induce O
expression O
of O
certain O
proto O
- O
oncogenes O
, O
and O
this O
led O
us O
to O
examine O
potential O
regulatory O
regions O
of O
the O
cellular I-GENE
c I-GENE
- I-GENE
fos I-GENE
oncogene I-GENE
. O

Air O
lead O
was O
not O
a O
significant O
explanatory O
variable O
. O

We O
now O
show O
that O
regulation O
of O
flaN I-GENE
transcription O
in O
vivo O
depends O
on O
a O
sigma I-GENE
54 I-GENE
promoter I-GENE
and O
two O
ftr O
elements O
located O
downstream O
of O
the O
transcription O
start O
site O
at O
+ O
86 O
( O
ftr2 O
) O
and O
+ O
120 O
( O
ftr3 O
). O

5 O
micrograms O
/ O
l O
was O
detected O
in O
urine O
from O
some O
non O
- O
occupationally O
exposed O
persons O
. O

Fibular O
dimelia O
with O
deficiency O
of O
the O
tibia O
. O

This O
prospective O
study O
compared O
the O
measured O
energy O
expenditures O
of O
30 O
patients O
using O
indirect O
calorimetry O
with O
their O
predicted O
basal O
energy O
expenditure O
according O
to O
the O
Harris O
- O
Benedict O
equation O
, O
or O
their O
calculated O
energy O
expenditure O
derived O
from O
basal O
energy O
expenditure O
times O
, O
an O
activity O
factor O
, O
and O
a O
stress O
factor O
. O

However O
, O
after O
repeated O
infections O
, O
hypobiotic O
larvae O
were O
numerous O
. O

This O
was O
performed O
in O
a O
double O
blinded O
, O
randomized O
, O
placebo O
- O
controlled O
study O
. O

Group O
I O
consisted O
of O
six O
noncholestatic O
patients O
; O
group O
II O
consisted O
of O
nine O
mildly O
cholestatic O
patients O
with O
mild O
hepatic O
impairment O
( O
conjugated O
bilirubin O
, O
47 O
mumol O
liter O
- O
1 O
; O
alkaline I-GENE
phosphatase I-GENE
, O
280 O
IU O
liter O
- O
1 O
; O
gamma I-GENE
- I-GENE
glutamyltranspeptidase I-GENE
, O
190 O
IU O
liter O
- O
1 O
); O
group O
III O
consisted O
of O
six O
benign O
intrahepatic O
cholestatic O
patients O
with O
high O
isolated O
conjugated O
hyperbilirubinemia O
( O
98 O
. O
1 O
mumol O
liter O
- O
1 O
). O

There O
was O
either O
no O
change O
or O
an O
improvement O
in O
renographic O
findings O
( O
t1 O
/ O
2 O
time O
and O
/ O
or O
split O
function O
) O
in O
40 O
patients O
( O
93 O
%). O

We O
discuss O
the O
need O
to O
use O
animals O
older O
than O
3 O
months O
for O
the O
study O
of O
' O
adult O
' O
regeneration O
phenomena O
since O
3 O
- O
month O
- O
old O
rats O
may O
be O
somewhat O
immature O
. O

Nuclear I-GENE
beta I-GENE
II I-GENE
PKC I-GENE
, O
like O
p34cdc2 I-GENE
kinase I-GENE
, O
may O
function O
to O
regulate O
nuclear O
lamina O
structural O
stability O
during O
cell O
cycle O
. O

In O
situ O
copper O
- O
phenanthroline O
footprinting O
of O
individual O
gel O
shift O
assembly O
intermediates O
shows O
that O
on O
the O
302 O
- O
nucleotide O
G4oric O
, O
the O
first O
two O
SSB I-GENE
tetramers I-GENE
assemble O
at O
random O
, O
but O
the O
addition O
of O
more O
SSB I-GENE
tetramers I-GENE
results O
in O
formation O
of O
a O
unique O
structure O
. O

Effects O
of O
intramammary O
endotoxin O
infusion O
on O
milking O
- O
induced O
oxytocin I-GENE
release O
. O

Finger I-GENE
associated I-GENE
box I-GENE
- I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
( O
FAX I-GENE
- I-GENE
ZFPs I-GENE
) O
constitute O
a O
subfamily O
of O
the O
many O
C2H2 I-GENE
type I-GENE
ZFPs I-GENE
in O
Xenopus O
laevis O
. O

Further O
evidence O
for O
a O
clustered O
organization O
of O
FAX I-GENE
- O
ZFP I-GENE
transcription O
units O
is O
provided O
by O
Southern O
blot O
analysis O
of O
large O
genomic O
restriction O
fragments O
separated O
by O
transverse O
field O
gel O
electrophoresis O
, O
and O
by O
in O
situ O
hybridization O
on O
intact O
chromosomes O
. O

A O
rat O
cDNA O
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
has O
been O
isolated O
and O
expressed O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
active O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

Mutational O
analyses O
have O
demonstrated O
the O
importance O
of O
sequences O
within O
the O
327 O
bp O
segment O
that O
contain O
a O
putative O
cyclic I-GENE
AMP I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
binding O
site O
for O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
and O
PMA O
responsiveness O
and O
putative O
PU I-GENE
- I-GENE
1 I-GENE
and O
Sp1 I-GENE
binding I-GENE
sites I-GENE
for O
basal O
promoter O
activity O
. O

( O
1992 O
) O
J O
. O

In O
F42A O
- O
stimulated O
internalization O
assays O
on O
forskolin O
- O
induced O
YT O
- O
1 O
cells O
, O
the O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
chain I-GENE
is O
consistently O
endocytosed O
together O
with O
the O
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
subunit I-GENE
indicating O
that O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
is O
stably O
associated O
with O
the O
F42A I-GENE
- I-GENE
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
complex I-GENE
even O
though O
the O
alpha O
- O
subunit O
contributes O
little O
if O
any O
affinity O
to O
the O
F42A O
binding O
reaction O
. O

The O
microcirculatory O
dynamics O
of O
prostaglandin O
E1 O
and O
/ O
or O
nicardipine O
and O
their O
different O
reactions O
in O
the O
hyper O
- O
and O
hypodynamic O
state O
of O
septic O
shock O
in O
a O
rat O
model O

We O
obtained O
the O
prevalence O
of O
IgG I-GENE
antibodies I-GENE
against O
Trypanosoma O
cruzi O
among O
1076 O
blood O
donors O
at O
the O
Instituto O
Nacional O
de O
Cardiologia O
" O
Ignacio O
Chavez O
" O
in O
Mexico O
City O
. O

Examination O
of O
the O
immediate O
sequence O
5 O
' O
to O
the O
mRNA O
start O
site O
reveals O
no O
TATA O
box O
and O
multiple O
known O
enhancer O
sequences O
. O

The O
short O
- O
term O
synthesis O
and O
infant O
- O
regulated O
removal O
of O
milk O
in O
lactating O
women O
. O

Pseudosubstrate O
( O
19 O
- O
36 O
), O
derived O
from O
the O
C O
- O
terminus O
of O
Ca I-GENE
- I-GENE
dependent I-GENE
PKC I-GENE
isotypes I-GENE
, O
inhibited O
beta I-GENE
- I-GENE
PKC I-GENE
but O
not O
nPKC I-GENE
activity O
using O
either O
Histone I-GENE
IIIS I-GENE
or O
peptide O
( O
19 O
- O
31 O
) O
as O
substrate O
. O

Based O
on O
these O
results O
, O
a O
new O
model O
for O
the O
regulation O
of O
nif I-GENE
/ O
fix I-GENE
gene O
expression O
in O
A O
. O
caulinodans O
is O
proposed O
. O

Nitric O
oxide O
inhalation O
selectively O
reduces O
pulmonary O
hypertension O
in O
porcine O
endotoxin O
shock O
and O
improves O
arterial O
oxygenation O
and O
pH O
with O
a O
marked O
attenuation O
of O
sympathetic O
activation O
. O

B O
cell O
- O
specific O
mb I-GENE
- I-GENE
1 I-GENE
and O
B29 I-GENE
genes I-GENE
encode O
the O
alpha O
/ O
beta O
components O
of O
the O
BCR I-GENE
- I-GENE
associated I-GENE
complex I-GENE
in O
mature O
sIgM I-GENE
+ I-GENE
B O
cells O
. O

Bipolarity O
in O
Jungian O
type O
theory O
and O
the O
Myers O
- O
Briggs O
Type O
Indicator O
. O

A O
variety O
of O
nuclear O
ribonucleoproteins O
are O
believed O
to O
associate O
directly O
with O
nascent O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcripts I-GENE
and O
remain O
associated O
during O
subsequent O
nuclear O
RNA O
processing O
reactions O
, O
including O
pre O
- O
mRNA O
polyadenylation O
and O
splicing O
as O
well O
as O
nucleocytoplasmic O
mRNA O
transport O
. O

Mutations O
at O
three O
sites O
have O
larger O
effects O
in O
muscle O
than O
nonmuscle O
cells O
; O
an O
A O
/ O
T O
- O
rich O
site O
mutation O
has O
a O
pronounced O
effect O
in O
both O
striated O
muscle O
types O
, O
mutations O
at O
the O
MEF1 I-GENE
( I-GENE
Right I-GENE
E I-GENE
- I-GENE
box I-GENE
) I-GENE
site I-GENE
are O
relatively O
specific O
to O
expression O
in O
skeletal O
muscle O
, O
and O
mutations O
at O
the O
CArG O
site O
are O
relatively O
specific O
to O
expression O
in O
cardiac O
muscle O
. O

Transient O
transfection O
analysis O
with O
these O
mutations O
revealed O
that O
only O
a O
10 O
- O
bp O
region O
, O
containing O
precisely O
the O
Ets I-GENE
and O
proximal O
LyF I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
, O
was O
needed O
for O
D O
' O
activity O
. O

However O
, O
despite O
its O
relationship O
to O
the O
TR I-GENE
, O
Rev I-GENE
- O
Erb I-GENE
bound O
poorly O
to O
TR I-GENE
binding I-GENE
sites I-GENE
. O

We O
report O
here O
that O
a O
25 O
- O
bp O
promoter O
element O
previously O
shown O
to O
be O
important O
for O
the O
G1 O
- O
S O
activation O
of O
the O
human I-GENE
thymidine I-GENE
kinase I-GENE
( O
htk I-GENE
) O
promoter O
in O
growth O
- O
stimulated O
cells O
is O
a O
cellular O
target O
of O
cyclin I-GENE
A I-GENE
and O
the O
p33cdk2 I-GENE
complexes I-GENE
. O

These O
protective O
influences O
were O
observed O
throughout O
the O
range O
of O
filling O
pressures O
measured O
, O
from O
0 O
to O
30 O
mmHg O
. O

DNase I-GENE
I I-GENE
footprinting O
with O
rat O
liver O
nuclear O
extracts O
identified O
7 O
major O
protein O
- O
binding O
domains O
termed O
P1 O
through O
P7 O
in O
a O
796 O
base O
pair O
DNA O
fragment O
( O
base O
pairs O
- O
763 O
to O
+ O
33 O
). O

This O
may O
account O
, O
at O
least O
in O
part O
, O
for O
the O
ability O
of O
excess O
wt I-GENE
p53 I-GENE
to O
inhibit O
cell O
proliferation O
and O
to O
interfere O
with O
neoplastic O
processes O
. O

Neither O
clone O
encoded O
the O
cognate O
endonuclease O
. O

Northern O
blot O
analysis O
of O
total O
cellular O
RNA O
indicated O
that O
xylP I-GENE
encodes O
a O
1 O
. O
3 O
- O
kb O
transcript O
which O
is O
induced O
by O
xylan O
. O

The O
nifJ I-GENE
and O
nifH I-GENE
promoters I-GENE
of I-GENE
Klebsiella I-GENE
pneumoniae I-GENE
are O
divergently O
transcribed O
sigma I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
that O
are O
positively O
activated O
by O
the O
NifA I-GENE
protein I-GENE
. O

These O
data O
show O
that O
PTH I-GENE
and O
cAMP O
can O
repress O
collagen I-GENE
promoter I-GENE
activity O
in O
calvariae O
from O
transgenic O
mice O
, O
suggesting O
that O
the O
alpha I-GENE
1 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
promoter I-GENE
may O
contain O
cis O
elements O
down O
- O
stream O
of O
- O
2 O
. O
3 O
kilobases O
that O
mediate O
PTH I-GENE
and O
cAMP O
repression O
of O
collagen I-GENE
gene I-GENE
expression O
in O
bone O
. O

Both O
inhaled O
and O
superfused O
isoflurane O
dilated O
the O
baseline O
vein O
diameter O
before O
stimulation O
. O

Prevalence O
of O
rheumatoid O
arthritis O
and O
rheumatoid I-GENE
factor I-GENE
in O
women O
: O
evidence O
for O
a O
secular O
decline O
. O

Although O
olfactory O
associative O
conditioning O
in O
newborn O
rats O
produces O
marked O
structural O
and O
functional O
changes O
in O
the O
olfactory O
bulb O
, O
recent O
evidence O
suggests O
that O
extrabulbar O
circuits O
must O
be O
involved O
in O
storing O
these O
early O
memories O
. O

The O
fission I-GENE
yeast I-GENE
dsk1 I-GENE
+ I-GENE
gene I-GENE
, O
a O
multicopy O
suppressor O
for O
cold O
- O
sensitive O
dis1 I-GENE
mutants I-GENE
, O
encodes O
a O
novel O
61 O
- O
kd O
protein O
kinase O
. O

Closure O
of O
the O
patent O
ductus O
arteriosus O
with O
a O
Ligaclip O
through O
a O
minithoracotomy O
. O

Sequence O
comparison O
between O
the O
translated O
ORF O
and O
a O
protein O
database O
reveal O
between O
26 O
. O
5 O
and O
23 O
. O
4 O
% O
aa O
sequence O
homology O
to O
bacterial I-GENE
transmembrane I-GENE
( I-GENE
TM I-GENE
) I-GENE
proteins I-GENE
including O
those O
mediating O
chloramphenicol O
( O
Cm O
) O
and O
tetracycline O
( O
Tc O
) O
resistance O
and O
an O
arabinose O
- O
proton O
symport O
protein O
. O

The O
yeast O
gene O
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
, O
designated O
TIF5 I-GENE
, O
has O
been O
isolated O
and O
expressed O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
active O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

The O
strategies O
by O
which O
hepatitis O
B O
and O
hepatitis O
D O
can O
be O
diminished O
and O
eventually O
eliminated O
are O
: O
immunization O
, O
measures O
to O
prevent O
exposure O
to O
infective O
blood O
or O
blood O
derivatives O
and O
education O
( O
in O
particular O
awareness O
that O
hepatitis O
B O
is O
a O
sexually O
transmitted O
disease O
). O

Xylose O
- O
and O
arabinose O
- O
containing O
polymers O
were O
better O
digested O
than O
was O
cellulose O
for O
both O
breads O
. O

The O
technical O
construction O
of O
the O
mouth O
protectors O
is O
illustrated O
, O
as O
is O
the O
need O
for O
instrumentation O
and O
its O
costs O
and O
the O
materials O
required O
to O
manufacture O
these O
mouth O
protectors O
. O

The O
alpha O
- O
subunit O
by O
itself O
binds O
to O
telomeric O
DNA O
. O

We O
conclude O
that O
the O
alpha O
- O
subunit O
of O
the O
telomere I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
like O
many O
transcription O
factors O
, O
has O
separable O
DNA O
- O
binding O
and O
protein O
- O
protein O
interaction O
domains O
. O

Three O
patients O
had O
well O
-, O
6 O
patients O
had O
moderately O
-, O
and O
5 O
patients O
had O
poorly O
- O
differentiated O
adenocarcinoma O
of O
the O
prostate O
. O

Spontaneous O
burst O
firing O
in O
cat O
primary O
auditory O
cortex O
: O
age O
and O
depth O
dependence O
and O
its O
effect O
on O
neural O
interaction O
measures O
. O

By O
applying O
the O
potentiometric O
method O
, O
in O
aqueous O
medium O
of O
ionic O
strength O
mu O
= O
0 O
. O
2 O
, O
the O
stability O
constants O
, O
log O
beta O
1 O
= O
4 O
. O
42 O
and O
log O
beta O
2 O
= O
8 O
. O
57 O
were O
obtained O
. O

Cryopreservation O
straws O
filled O
with O
media O
plus O
additive O
are O
emersed O
below O
the O
surface O
of O
an O
unprocessed O
donor O
ejaculate O
. O

The O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
can O
potentially O
encode O
26 O
- O
and O
22 O
- O
kDa O
proteins O
that O
differ O
only O
in O
their O
carboxyl O
tails O
because O
of O
an O
alternative O
splicing O
mechanism O
. O

The O
active O
open O
reading O
frame O
in O
the O
clone O
maps O
at O
27 O
min O
on O
the O
E O
. O
coli O
chromosome O
and O
is O
identical O
in O
sequence O
to O
a O
wild O
type O
counterpart O
. O

Subsequent O
cloning O
and O
nucleotide O
sequence O
analysis O
of O
the O
S I-GENE
. I-GENE
pombe I-GENE
adenylate I-GENE
kinase I-GENE
gene I-GENE
, O
adk1 I-GENE
, O
revealed O
a O
coding O
region O
of O
660 O
nucleotides O
. O

Calcification O
of O
a O
cariogenic O
Streptococcus O
and O
of O
Corynebacterium O
( O
Bacterionema O
) O
matruchotii O
. O

As O
a O
result O
of O
alternative O
splicing O
, O
the O
BGP I-GENE
gene I-GENE
is O
transcribed O
into O
at O
least O
seven O
distinct O
mRNA O
species O
. O

A O
comparison O
of O
the O
promoters O
for O
muMIP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
muMIP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
reveals O
a O
conserved O
CK O
- O
1 O
element O
, O
but O
transient O
expression O
studies O
in O
RAW O
264 O
. O
7 O
macrophages O
with O
proximal O
fragments O
of O
either O
the O
muMIP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
or O
the O
muMIP I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
5 I-GENE
' I-GENE
promoter I-GENE
fused O
to O
a O
human I-GENE
growth I-GENE
hormone I-GENE
reporter I-GENE
gene I-GENE
link O
LPS O
- O
inducibility O
in O
both O
to O
promoter O
segments O
near O
to O
, O
but O
not O
identical O
with O
, O
the O
consensus O
CK O
- O
1 O
sequence O
. O

However O
, O
essential O
contrast O
differences O
existing O
between O
the O
FSE O
sequences O
and O
their O
routine O
asymmetric O
dual O
SE O
counterpart O
can O
be O
identified O
. O

Sequence O
analysis O
and O
identification O
of O
two O
hyp I-GENE
regulatory I-GENE
mutants I-GENE
. O

The O
gene O
encoding O
the O
receptor O
for O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
), O
the O
c I-GENE
- I-GENE
fms I-GENE
protooncogene I-GENE
, O
is O
selectively O
expressed O
in O
immature O
and O
mature O
mononuclear O
phagocytes O
and O
trophoblasts O
. O

The O
level O
of O
the O
SUP4A53T61 I-GENE
transcript I-GENE
was O
threefold O
higher O
in O
the O
tap1 I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
than O
in O
the O
wild O
type O
. O

This O
sequence O
similarity O
raises O
the O
possibility O
that O
GCN1 I-GENE
interacts O
with O
ribosomes O
or O
tRNA O
molecules O
and O
functions O
in O
conjunction O
with O
GCN2 I-GENE
in O
monitoring O
uncharged O
tRNA O
levels O
during O
the O
process O
of O
translation O
elongation O
. O

NF I-GENE
- I-GENE
HB I-GENE
( O
BSAP I-GENE
) O
is O
a O
repressor O
of O
the O
murine I-GENE
immunoglobulin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
3 I-GENE
' I-GENE
alpha I-GENE
enhancer I-GENE
at O
early O
stages O
of O
B O
- O
cell O
differentiation O
. O

Since O
the O
regulation O
of O
SWI4 I-GENE
is O
required O
for O
normal O
cell O
cycle O
progression O
, O
we O
have O
characterized O
cis O
- O
and O
trans O
- O
acting O
regulators O
of O
SWI4 I-GENE
transcription O
. O

It O
also O
suggests O
that O
there O
is O
another O
pathway O
which O
can O
activate O
SWI4 I-GENE
transcription O
in O
the O
absence O
of O
SWI6 I-GENE
. O

Multiple O
SWI6 I-GENE
- O
dependent O
cis O
- O
acting O
elements O
control O
SWI4 I-GENE
transcription O
through O
the O
cell O
cycle O
. O

In O
conclusion O
, O
changes O
in O
carotid O
sinus O
stimulation O
alters O
blood O
flow O
to O
the O
hindlimb O
through O
changes O
in O
both O
Pcrit O
and O
Ra O
. O

Multizone O
PRK O
has O
been O
suggested O
to O
increase O
the O
predictability O
of O
higher O
myopic O
corrections O
. O

In O
17 O
patients O
with O
deletions O
, O
the O
parental O
origin O
of O
deletion O
was O
determined O
. O

The O
COL7A1 I-GENE
gene I-GENE
, O
which O
encodes O
type I-GENE
VII I-GENE
collagen I-GENE
, O
has O
been O
implicated O
as O
a O
candidate O
gene O
for O
dominantly O
and O
recessively O
inherited O
forms O
of O
dystrophic O
epidermolysis O
bullosa O
. O

However O
, O
study O
of O
the O
productive O
gamma O
gene O
showed O
that O
the O
skipped O
variable O
exon O
was O
bounded O
by O
normal O
splicing O
signals O
and O
that O
the O
adjacent O
intron O
organization O
was O
not O
altered O
. O

We O
conclude O
that O
grade O
III O
BGCT O
can O
be O
treated O
by O
modified O
intralesional O
excision O
provided O
the O
articular O
surfaces O
and O
part O
of O
the O
metaphysis O
are O
intact O
. O

Second O
, O
nitrate O
induction O
of O
aeg I-GENE
- I-GENE
46 I-GENE
. I-GENE
5 I-GENE
operon I-GENE
expression O
is O
substantially O
enhanced O
in O
narL I-GENE
null O
strains O
( O
M O
. O
H O
. O

This O
new O
knowledge O
has O
contributed O
to O
the O
development O
of O
a O
successful O
immunoprophylactic O
strategy O
for O
eliminating O
Hib O
disease O
. O

The O
HMG I-GENE
CoA I-GENE
reductase I-GENE
inhibitors O
are O
the O
most O
effective O
cholesterol O
- O
lowering O
agents O
currently O
available O
. O

The O
etiology O
, O
pathology O
, O
brain O
CT O
scan O
features O
, O
clinical O
manifestations O
and O
treatment O
of O
these O
accidents O
were O
discussed O
. O

Drosophila O
230 O
- O
kD O
TFIID I-GENE
subunit O
, O
a O
functional O
homolog O
of O
the O
human O
cell O
cycle O
gene O
product O
, O
negatively O
regulates O
DNA O
binding O
of O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
of I-GENE
TFIID I-GENE
. O

One O
enigmatic O
aspect O
of O
GATA I-GENE
factor I-GENE
expression O
is O
that O
several O
GATA I-GENE
proteins I-GENE
, O
which O
ostensibly O
share O
the O
same O
DNA O
- O
binding O
site O
specificity O
, O
are O
coexpressed O
in O
erythroid O
cells O
. O

Pit I-GENE
- I-GENE
1 I-GENE
is O
a O
tissue O
- O
specific O
POU I-GENE
domain I-GENE
factor I-GENE
obligatory O
for O
the O
appearance O
of O
three O
cell O
phenotypes O
in O
the O
anterior O
pituitary O
gland O
. O

Maximum O
number O
of O
strains O
( O
39 O
. O
1 O
%) O
were O
resistant O
in O
S O
. O
bareilly O
serotype O
, O
followed O
by O
S O
. O
typhimurium O
( O
21 O
. O
7 O
%) O
and O
least O
in O
S O
. O
typhi O
( O
17 O
. O
4 O
%). O

Biol O
. O

Characterization O
and O
hormonal O
regulation O
of O
the O
promoter O
of O
the O
rat I-GENE
prostaglandin I-GENE
endoperoxide I-GENE
synthase I-GENE
2 I-GENE
gene I-GENE
in O
granulosa O
cells O
. O

The O
retention O
of O
75SeHCAT O
was O
low O
. O

Patient O
characteristics O
associated O
with O
deep O
wounds O
as O
well O
as O
patient O
and O
wound O
characteristics O
predictive O
of O
the O
extent O
of O
healing O
and O
time O
required O
for O
healing O
were O
identified O
. O

Members O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
of O
basic I-GENE
- I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bZip I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
form O
heterodimers O
and O
bind O
to O
the O
CAAT O
box O
and O
other O
sequence O
- O
related O
enhancer O
motifs O
. O

In O
mammalian O
cells O
, O
phosphorylation O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
inhibits O
the O
activity O
of O
eIF I-GENE
- I-GENE
2B I-GENE
, O
the O
GDP I-GENE
- I-GENE
GTP I-GENE
exchange I-GENE
factor I-GENE
for O
eIF I-GENE
- I-GENE
2 I-GENE
. O

In O
conclusion O
, O
these O
observations O
demonstrated O
that O
stratification O
of O
acute O
MI O
patients O
by O
plasma O
ANF I-GENE
level O
is O
a O
useful O
non O
- O
invasive O
method O
for O
predicting O
prognosis O
and O
for O
identifying O
individuals O
at O
high O
risk O
of O
cardiac O
death O
. O

Analysis O
of O
the O
binding O
of O
Lrp I-GENE
to O
a O
set O
of O
circularly O
permuted O
DNA O
fragments O
from O
this O
region O
indicates O
that O
Lrp I-GENE
induces O
DNA O
bending O
. O

Yeast O
mutants O
lacking O
a O
functional O
NOP1 I-GENE
gene I-GENE
can O
be O
complemented O
by O
human I-GENE
fibrillarin I-GENE
but O
are O
temperature O
sensitive O
for O
growth O
and O
impaired O
in O
pre O
- O
rRNA O
processing O
. O

The O
patients O
were O
divided O
into O
ischaemia O
and O
non O
- O
ischaemia O
groups O
on O
the O
basis O
of O
the O
change O
in O
lactate O
extraction O
ratio O
during O
balloon O
inflation O
. O

Seven O
out O
of O
34 O
patients O
died O
, O
giving O
a O
mortality O
rate O
of O
21 O
%. O

A O
36 O
- O
kDa O
protein O
that O
was O
localized O
to O
the O
membrane O
fraction O
was O
detected O
in O
minicells O
containing O
plasmids O
with O
the O
ftsN I-GENE
gene I-GENE
, O
confirming O
that O
FtsN I-GENE
was O
a O
membrane O
protein O
. O

SSG1 I-GENE
, O
a O
gene O
encoding O
a O
sporulation I-GENE
- I-GENE
specific I-GENE
1 I-GENE
, I-GENE
3 I-GENE
- I-GENE
beta I-GENE
- I-GENE
glucanase I-GENE
in O
Saccharomyces O
cerevisiae O
. O

Expression O
of O
this O
protein O
in O
E O
. O
coli O
demonstrated O
that O
tyrosine O
was O
incorporated O
during O
suppression O
and O
that O
yeast I-GENE
cytoplasmic I-GENE
TyrRS I-GENE
activity O
was O
produced O
. O

The O
first O
involved O
complementation O
of O
a O
nonphotosynthetic O
mutant O
of O
Chlamydomonas O
, O
CC O
- O
2341 O
( O
ac O
- O
u O
- O
g O
- O
2 O
. O
3 O
), O
which O
has O
a O
frameshift O
mutation O
in O
the O
psaB I-GENE
gene I-GENE
, O
and O
selection O
of O
photosynthetic O
transformants O
on O
minimal O
medium O
. O

Against O
200 O
strains O
of O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
isolated O
from O
1990 O
to O
1991 O
, O
minimum O
inhibitory O
concentrations O
( O
MICs O
) O
of O
a O
total O
of O
15 O
antibacterial O
agents O
including O
arbekacin O
( O
ABK O
) O
were O
determined O
. O

It O
is O
reported O
that O
, O
at O
present O
, O
most O
of O
the O
MRSAs O
spreading O
in O
Japan O
are O
acceleratedly O
acquiring O
resistance O
to O
many O
drugs O
, O
and O
especially O
, O
they O
are O
developing O
high O
resistance O
against O
beta O
- O
lactams O
. O

Beg2 I-GENE
and O
Beg1 I-GENE
are O
regulated O
differently O
which O
may O
indicate O
variation O
in O
storage O
or O
utilization O
properties O
among O
the O
barley I-GENE
globulins I-GENE
. O

Here O
, O
we O
have O
more O
closely O
investigated O
transactivation O
of O
the O
human I-GENE
HSP70 I-GENE
promoter I-GENE
by O
Myb I-GENE
proteins I-GENE
. O

We O
have O
found O
out O
that O
one O
- O
year O
- O
old O
carps O
are O
extremely O
sensitive O
to O
ichthiomycin O
in O
concentrations O
between O
25 O
- O
125 O
micrograms O
/ O
dm3 O
. O

RESULTS O
: O
Statistically O
significant O
differences O
were O
obtained O
between O
group O
I O
and O
II O
concerning O
the O
number O
of O
patients O
in O
whom O
induced O
atrial O
fibrillation O
with O
conduction O
by O
the O
accessory O
pathway O
and O
RR O
< O
or O
= O
250 O
msec O
was O
found O
( O
0 O
vs O
6 O
, O
p O
= O
0 O
. O
0045 O
). O

We O
studied O
the O
effect O
of O
skinfold O
thickness O
on O
the O
correlation O
between O
serum O
total O
bilirubin O
level O
and O
transcutaneous O
bilirubin O
( O
TcB O
) O
readings O
. O

Both O
immunophilins I-GENE
may O
have O
important O
roles O
in O
receptor O
assembly O
and O
may O
represent O
a O
new O
category O
of O
ligand O
- O
and O
calcium O
- O
dependent O
modulators O
of O
protein O
function O
. O

The O
GTPase I-GENE
activity O
of O
CDC42Ce I-GENE
is O
moderately O
stimulated O
by O
human I-GENE
n I-GENE
- I-GENE
chimaerin I-GENE
, O
a O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
the O
related O
p21 I-GENE
rac1 I-GENE
. O

Tl O
- O
201 O
uptake O
ratio O
of O
the O
right O
ventricle O
, O
which O
represents O
the O
ratio O
of O
total O
counts O
of O
the O
right O
ventricle O
to O
counts O
of O
the O
administered O
dose O
of O
Tl O
- O
201 O
, O
was O
higher O
in O
COPD O
, O
especially O
in O
pulmonary O
emphysema O
and O
B O
type O
COPD O
by O
Burrows O
classification O
than O
in O
controls O
. O

A O
second O
hydrophobic O
domain O
, O
bordered O
by O
two O
hydrophilic O
regions O
strongly O
suggests O
a O
transmembrane O
region O
. O

This O
gene O
spans O
23 O
kb O
and O
is O
composed O
of O
five O
exons O
and O
four O
introns O
. O

The O
remaining O
RAD I-GENE
+ I-GENE
cells O
progressed O
to O
form O
microcolonies O
(< O
30 O
cells O
) O
containing O
aberrantly O
shaped O
inviable O
cells O
. O

The O
11 O
; O
22 O
chromosomal O
translocation O
specifically O
linked O
to O
Ewing O
sarcoma O
and O
primitive O
neuroectodermal O
tumor O
results O
in O
a O
chimeric O
molecule O
fusing O
the O
amino O
- O
terminal O
- O
encoding O
portion O
of O
the O
EWS I-GENE
gene I-GENE
to O
the O
carboxyl O
- O
terminal O
DNA O
- O
binding O
domain O
encoded O
by O
the O
FLI1 I-GENE
gene I-GENE
. O

These O
findings O
suggest O
that O
a O
range O
of O
microenvironmental O
conditions O
exist O
within O
purified O
water O
systems O
, O
leading O
to O
variable O
populations O
of O
bacteria O
. O

X O
- O
linked O
liver O
glycogenosis O
: O
localization O
and O
isolation O
of O
a O
candidate O
gene O
. O

This O
conclusion O
is O
based O
on O
the O
observations O
of O
the O
immunologic O
changes O
that O
characterize O
the O
acute O
stages O
of O
illness O
as O
well O
as O
on O
the O
demonstrated O
association O
with O
toxin O
- O
producing O
bacteria O
in O
the O
pharynx O
and O
gastrointestinal O
tract O
. O

Measurement O
of O
anti I-GENE
- I-GENE
HCV I-GENE
IgM I-GENE
antibodies I-GENE
with O
an O
experimental O
kit O

Embryo O
coculture O
system O
may O
contribute O
to O
understand O
the O
mechanisms O
underlying O
the O
decrease O
of O
fertility O
with O
aging O
. O

These O
cell O
lines O
displayed O
methylation O
of O
the O
CpG O
island O
surrounding O
the O
first O
exon O
of O
p16INK4A I-GENE
and O
expressed O
abundant O
levels O
of O
a O
nontranslated O
mRNA O
containing O
an O
alternative O
first O
exon O
( O
E1 O
beta O
), O
as O
did O
all O
other O
cell O
lines O
in O
which O
the O
p16INK4A I-GENE
locus I-GENE
was O
not O
deleted O
. O

An O
immunoperoxidase I-GENE
reaction O
, O
PAP I-GENE
method O
, O
with O
the O
antiserum O
of O
Factor I-GENE
VIII I-GENE
as O
the O
primary O
antibody O
, O
was O
carried O
out O
in O
the O
endometrial O
biopsies O
to O
detect O
the O
Factor I-GENE
VIII I-GENE
activity O
in O
the O
endometrial O
endothelium O
before O
and O
after O
insertion O
of O
LNG O
- O
IUD O
- O
20 O
. O

Umweltchem O
. O

Egd1p I-GENE
is O
homologous O
to O
human I-GENE
BTF3b I-GENE
, O
recently O
identified O
as O
the O
beta O
subunit O
of O
the O
heterodimeric I-GENE
nascent I-GENE
- I-GENE
polypeptide I-GENE
- I-GENE
associated I-GENE
complex I-GENE
( O
NAC I-GENE
) O
involved O
in O
ensuring O
signal O
- O
sequence O
- O
specific O
protein O
sorting O
and O
translocation O
[ O
Wiedmann O
et O
al O
., O
Nature O
370 O
( O
1994 O
) O
434 O
- O
440 O
]. O

Purified O
PLB I-GENE
showed O
optimal O
lyase I-GENE
activity O
at O
pH O
10 O
. O
0 O
. O

The O
5 O
' O
flanking O
regions O
of O
both O
pelA I-GENE
and O
pelB I-GENE
were O
translationally O
fused O
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
gene I-GENE
and O
introduced O
into O
F O
. O
solani O
f O
. O
sp O
. O
pisi O
, O
and O
beta I-GENE
- I-GENE
glucuronidase I-GENE
activities O
of O
the O
transformants O
were O
measured O
. O

When O
nifA I-GENE
mRNA I-GENE
5 O
' O
start O
points O
were O
mapped O
by O
primer O
extension O
, O
both O
a O
minor O
upstream O
transcript O
( O
s O
) O
starting O
45 O
bp O
distal O
to O
the O
anaerobox O
and O
a O
major O
downstream O
transcript O
starting O
10 O
bp O
distal O
to O
the O
sigma I-GENE
54 I-GENE
box O
were O
observed O
. O

We O
failed O
to O
find O
these O
data O
to O
be O
useful O
in O
predicting O
the O
time O
of O
onset O
of O
initial O
seizures O
after O
acute O
ischemic O
stroke O
and O
recurrence O
. O

The O
human I-GENE
papillomavirus I-GENE
type I-GENE
16 I-GENE
E7 I-GENE
protein I-GENE
complements O
adenovirus I-GENE
type I-GENE
5 I-GENE
E1A I-GENE
amino O
- O
terminus O
- O
dependent O
transactivation O
of O
adenovirus I-GENE
type I-GENE
5 I-GENE
early I-GENE
genes I-GENE
and O
increases O
ATF I-GENE
and O
Oct I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activity O
. O

A O
chaotropic O
detergent O
, O
0 O
. O
1 O
% O
Nonidet O
P O
- O
40 O
, O
also O
abolished O
the O
interaction O
, O
further O
supporting O
the O
hydrophobic O
nature O
of O
the O
interaction O
. O

Contrary O
to O
expectations O
, O
we O
find O
a O
relatively O
high O
level O
of O
variation O
in O
the O
stripe I-GENE
2 I-GENE
enhancer O
region O
, O
including O
point O
substitutions O
and O
insertion O
/ O
deletions O
in O
binding O
sites O
, O
and O
a O
comparable O
level O
of O
variation O
in O
the O
other O
noncoding O
regions O
. O

Degradation O
of O
the O
soybean I-GENE
ribulose I-GENE
- I-GENE
1 I-GENE
, I-GENE
5 I-GENE
- I-GENE
bisphosphate I-GENE
carboxylase I-GENE
small I-GENE
- I-GENE
subunit I-GENE
mRNA I-GENE
, O
SRS4 I-GENE
, O
initiates O
with O
endonucleolytic O
cleavage O
. O

Cloning O
and O
sequencing O
revealed O
that O
dMax I-GENE
contains O
a O
deletion O
spanning O
the O
basic O
region O
and O
helix O
1 O
and O
the O
loop O
of O
the O
helix O
- O
loop O
- O
helix O
region O
, O
presumably O
as O
a O
result O
of O
alternative O
splicing O
of O
max I-GENE
RNA I-GENE
. O

I O
report O
here O
that O
induction O
of O
HSP82 I-GENE
is O
regulated O
by O
the O
early O
meiotic O
IME1 I-GENE
- O
IME2 I-GENE
transcriptional O
cascade O
. O

The O
domain O
structure O
of O
bovine I-GENE
LTBP I-GENE
- I-GENE
2 I-GENE
is O
very O
similar O
to O
that O
of O
the O
human I-GENE
LTBP I-GENE
- I-GENE
2 I-GENE
, O
containing O
20 O
examples O
of O
6 O
- O
cysteine O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
, O
16 O
of O
which O
have O
the O
consensus O
sequence O
for O
calcium O
binding O
, O
together O
with O
4 O
examples O
of O
8 O
- O
cysteine O
motifs O
characteristic O
of O
fibrillins I-GENE
and O
LTBP I-GENE
- I-GENE
1 I-GENE
. O

Similarly O
, O
expression O
of O
a O
transiently O
transfected O
wild I-GENE
- I-GENE
type I-GENE
prothymosin I-GENE
alpha I-GENE
gene I-GENE
as O
the O
reporter O
was O
not O
affected O
by O
a O
repertoire O
of O
myc I-GENE
- I-GENE
derived I-GENE
genes I-GENE
, O
including O
myc I-GENE
itself O
and O
dominant O
or O
recessive O
negative O
myc I-GENE
mutants I-GENE
. O

Differential O
regulation O
of O
the O
alpha I-GENE
/ I-GENE
beta I-GENE
interferon I-GENE
- O
stimulated O
Jak I-GENE
/ O
Stat I-GENE
pathway O
by O
the O
SH2 I-GENE
domain O
- O
containing O
tyrosine I-GENE
phosphatase I-GENE
SHPTP1 I-GENE
. O

We O
now O
report O
the O
isolation O
and O
expression O
of O
cDNAs O
encoding O
PTF I-GENE
gamma I-GENE
and O
PTF I-GENE
delta I-GENE
, O
as O
well O
as O
functional O
studies O
with O
cognate O
antibodies O
that O
recognize O
the O
native O
PTF I-GENE
complex I-GENE
in O
HeLa O
extracts O
. O

Results O
from O
the O
mechanism O
study O
have O
revealed O
that O
YY1 I-GENE
is O
able O
to O
inhibit O
transactivation O
mediated O
by O
either O
AP1 I-GENE
or O
the O
Sp1 I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
and O
YY1 I-GENE
suppressive O
activity O
is O
DNA O
binding O
dependent O
. O

The O
skp1 I-GENE
+ I-GENE
gene I-GENE
is O
not O
essential O
. O

The O
TEA1 I-GENE
( O
Ty I-GENE
enhancer I-GENE
activator I-GENE
) O
gene O
sequence O
predicts O
a O
protein O
of O
86 O
. O
9 O
kDa O
whose O
N O
terminus O
contains O
a O
zinc O
cluster O
and O
dimerization O
motif O
typical O
of O
the O
Gal4 I-GENE
- I-GENE
type I-GENE
family I-GENE
of O
DNA O
- O
binding O
proteins O
. O

Refugees O
living O
in O
Lund O
and O
repatriated O
to O
Chile O
considered O
their O
health O
as O
bad O
in O
a O
higher O
proportion O
than O
their O
Swedish O
counterparts O
, O
with O
an O
odds O
ratio O
of O
3 O
. O
48 O
( O
2 O
. O
03 O
- O
5 O
. O
66 O
) O
and O
4 O
. O
78 O
( O
2 O
. O
1 O
- O
10 O
. O
25 O
) O
respectively O
. O

This O
study O
underlines O
the O
importance O
of O
terminal O
SC5b I-GENE
- I-GENE
9 I-GENE
complement I-GENE
complex I-GENE
as O
a O
suitable O
marker O
in O
the O
evaluation O
of O
complement O
activation O
during O
cardiopulmonary O
bypass O
. O

Videonystagmoscopy O
has O
been O
used O
to O
subjectively O
observe O
the O
responses O
of O
the O
vestibular O
system O
in O
a O
population O
of O
patients O
with O
vestibular O
deficits O
. O

The O
MCA O
and O
UA O
PI O
values O
showed O
the O
greatest O
deviation O
for O
any O
single O
- O
vessel O
parameter O
. O

Striking O
sequence O
similarities O
( O
57 O
and O
53 O
%) O
were O
observed O
with O
yeast O
mitochondrial O
proteins O
, O
SMF1 I-GENE
and O
SMF2 I-GENE
, O
especially O
within O
putative O
functional O
domains O
: O
exon O
6 O
encoding O
the O
second O
transmembrane O
spanning O
domain O
, O
site O
of O
the O
murine I-GENE
susceptibility I-GENE
mutation O
; O
and O
exon O
11 O
encoding O
a O
conserved O
transport O
motif O
. O

Stems O
contain O
distinctly O
less O
P I-GENE
protein I-GENE
mRNA I-GENE
and O
the O
relative O
level O
in O
roots O
is O
very O
low O
but O
still O
clearly O
detectable O
. O

The O
B I-GENE
. I-GENE
germanica I-GENE
cyclophilin I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
shares O
83 O
% O
identity O
with O
the O
cytosolic I-GENE
cyclophilin I-GENE
isoform I-GENE
from I-GENE
Drosophila I-GENE
melanogaster I-GENE
( O
Cyp I-GENE
- I-GENE
1 I-GENE
). O

Furthermore O
, O
we O
have O
identified O
a O
soluble O
form O
of O
ERp57 I-GENE
/ O
GRP58 I-GENE
by O
Western O
blotting O
and O
biosynthetic O
labeling O
. O

The O
minimal O
region O
of O
overlap O
of O
Langer O
- O
Giedion O
syndrome O
deletions O
, O
previously O
identified O
by O
analysis O
of O
15 O
patients O
, O
was O
placed O
on O
the O
map O
by O
analysis O
of O
2 O
patients O
whose O
deletions O
define O
the O
endpoints O
. O

Consistent O
with O
the O
hepatic O
and O
epidermal O
expression O
of O
histidase I-GENE
, O
this O
finding O
suggests O
that O
histidase I-GENE
transcription O
may O
be O
regulated O
by O
these O
factors O
. O

Comparison O
of O
promoters O
repressed O
by O
c I-GENE
- I-GENE
myc I-GENE
reveals O
a O
weak O
consensus O
sequence O
of O
the O
initiator O
( O
Inr O
) O
element O
: O
TCA O
(+ O
1 O
) O
YYYNY O
. O

The O
human I-GENE
gp39 I-GENE
promoter I-GENE
. O

Transfection O
analyses O
indicate O
that O
mutation O
of O
any O
one O
of O
these O
TGACCT O
motifs O
or O
truncation O
of O
the O
entire O
HD I-GENE
PPRE O
into O
a O
separate O
DR1 O
and O
DR2 O
element O
significantly O
reduced O
the O
transcriptional O
response O
of O
HD I-GENE
PPRE O
to O
peroxisome O
proliferators O
. O

The O
site O
of O
autophosphorylation O
is O
Tyr397 O
which O
corresponds O
to O
the O
consensus O
autophosphorylation O
site O
of O
other O
Src I-GENE
family I-GENE
tyrosine I-GENE
kinases I-GENE
. O

This O
protein O
- O
protein O
interaction O
does O
not O
require O
the O
simultaneous O
binding O
of O
Oct I-GENE
proteins I-GENE
to O
DNA O
, O
and O
high O
resolution O
footprinting O
of O
the O
Oct I-GENE
- I-GENE
DNA I-GENE
interaction O
reveals O
that O
binding O
of O
BOB I-GENE
. I-GENE
1 I-GENE
/ O
OBF I-GENE
. I-GENE
1 I-GENE
to O
Oct1 I-GENE
or O
Oct2 I-GENE
does O
not O
alter O
the O
interaction O
with O
DNA O
. O

Together O
, O
our O
data O
suggest O
that O
the O
TR2 I-GENE
orphan I-GENE
receptor I-GENE
may O
be O
a O
master O
regulator O
in O
modulating O
the O
activation O
of O
two O
key O
HREs O
, O
RARE O
beta O
and O
CRBPIIp O
, O
involved O
in O
the O
retinoic O
acid O
signal O
transduction O
pathway O
. O

Using O
a O
series O
of O
mutant O
proteins O
, O
we O
have O
characterized O
domains O
responsible O
for O
activation O
or O
repression O
. O

Unlike O
ARF I-GENE
, O
the O
ARP I-GENE
immunoreactivity O
was O
detected O
in O
plasma O
membranes O
but O
not O
in O
cytosol O
of O
fractionated O
3T3 O
- O
L1 O
cells O
. O

It O
is O
considered O
that O
the O
recurrent O
annular O
erythema O
is O
a O
specific O
skin O
manifestation O
of O
SjS O
with O
anti I-GENE
SS I-GENE
- I-GENE
A I-GENE
/ O
SS I-GENE
- I-GENE
B I-GENE
antibodies I-GENE
. O

Competition O
needs O
to O
be O
better O
studied O
, O
since O
in O
Central O
America O
and O
Caribean O
islands O
this O
kind O
of O
study O
has O
favored O
the O
biological O
control O
of O
planorbid O
species O
. O

In O
this O
paper O
we O
describe O
properties O
of O
the O
cdc10 I-GENE
- O
C4 O
mutant O
of O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
. O

TIEG I-GENE
expression O
in O
hFOB O
cells O
was O
highly O
induced O
by O
TGF I-GENE
- I-GENE
beta I-GENE
and O
bone I-GENE
morphogenetic I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
BMP I-GENE
- I-GENE
2 I-GENE
), O
with O
a O
moderate O
induction O
by O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
), O
but O
no O
induction O
by O
other O
growth O
factors O
/ O
cytokines O
was O
observed O
. O

An O
infectious O
origin O
should O
always O
be O
excluded O
since O
specific O
etiologic O
therapy O
may O
be O
implemented O
. O

The O
predicted O
protein O
products O
of O
ORFs I-GENE
N2417 I-GENE
and O
N2403 I-GENE
present O
similarities O
with O
domains O
from O
proteins O
of O
other O
organisms O
: O
the O
Candida O
maltosa O
cycloheximide I-GENE
- I-GENE
resistance I-GENE
protein I-GENE
, O
the O
human O
interleukin I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
( O
ILF I-GENE
- I-GENE
2 I-GENE
). O

In O
particular O
, O
the O
highly O
expressed O
ADH1 I-GENE
gene I-GENE
is O
represented O
in O
this O
database O
by O
no O
less O
than O
20 O
EST O
sequences O
. O

Five O
families O
of O
Ashkenazi O
Jewish O
descent O
carried O
the O
185delAG O
mutation O
and O
shared O
the O
same O
haplotype O
at O
eight O
polymorphic O
markers O
spanning O
approximately O
850 O
kb O
at O
BRCA1 I-GENE
. O

The O
subjects O
from O
the O
two O
regions O
with O
a O
higher O
pollution O
level O
had O
lower O
FVC O
and O
FEV1 O
values O
than O
those O
from O
the O
Viskovo O
region O
. O

PTP I-GENE
- I-GENE
S3 I-GENE
differs O
from O
PTP I-GENE
- I-GENE
S4 I-GENE
in O
having O
a O
deletion O
of O
19 O
amino O
acids O
corresponding O
to O
exon O
E1 O
. O

All O
three O
NR I-GENE
isoforms I-GENE
are O
expressed O
in O
cv O
. O

All O
three O
NR I-GENE
isoforms O
are O
expressed O
in O
cv O
. O

The O
Arabidopsis I-GENE
FAD7 I-GENE
gene I-GENE
encodes O
a O
chloroplast I-GENE
omega I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
desaturase I-GENE
that O
catalyzes O
the O
desaturation O
of O
lipid O
- O
linked O
dienoic O
fatty O
acids O
( O
18 O
: O
2 O
and O
16 O
: O
2 O
). O

When O
differentiated O
G0 O
- O
arrested O
leaf O
cells O
were O
induced O
to O
resume O
cell O
division O
by O
treatment O
with O
plant O
hormones O
, O
cycMs4 I-GENE
transcription O
was O
induced O
before O
the O
onset O
of O
DNA O
synthesis O
. O

A O
survey O
is O
given O
of O
the O
pharmacological O
backgrounds O
that O
are O
relevant O
for O
the O
drug O
treatment O
of O
essential O
hypertension O
in O
the O
elderly O
. O

Protein O
kinases O
play O
pivotal O
roles O
in O
the O
control O
of O
many O
cellular O
processes O
. O

Interestingly O
, O
internal O
and O
5 O
' O
deletions O
revealed O
tha O
the O
distal O
promoter O
was O
not O
required O
for O
full O
transcriptional O
activity O
and O
that O
the O
first O
631 O
base O
pairs O
of O
WNT I-GENE
- I-GENE
5A I-GENE
harbored O
the O
strongest O
promoter O
activity O
. O

The O
protein O
kinase O
domains O
of O
LIMK1 I-GENE
and O
LIMK2 I-GENE
are O
unique O
in O
that O
they O
contain O
an O
unusual O
sequence O
motif O
Asp O
- O
Leu O
- O
Asn O
- O
Ser O
- O
His O
- O
Asn O
in O
subdomain O
VIB O
and O
a O
highly O
basic O
insert O
between O
subdomains O
VII O
and O
VIII O
. O

A O
human O
recombinant O
cDNA O
clone O
that O
encoded O
253 O
amino O
acids O
residues O
of O
a O
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
( O
THZif I-GENE
- I-GENE
1 I-GENE
) O
was O
cloned O
by O
screening O
a O
cDNA O
library O
prepared O
from O
human O
promyelocytic O
leukemia O
HL60 O
cells O
with O
synthetic O
oligodeoxynucleotide O
probes O
that O
corresponded O
to O
the O
amino O
acid O
sequences O
of O
tryptic O
peptides O
derived O
from O
the O
DNA O
- O
binding O
protein O
specific O
for O
the O
nuclease I-GENE
- I-GENE
hypersensitive I-GENE
element I-GENE
( O
NHE I-GENE
) O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

Erythrocyte O
AA O
in O
FO O
+ O
EPO I-GENE
- O
supplemented O
infants O
remained O
low O
and O
below O
breast O
- O
and O
placebo O
formula O
- O
fed O
levels O
. O

Taking O
into O
consideration O
weight O
and O
seasonal O
changes O
in O
bone O
mass O
, O
total O
( O
TBBMC O
) O
and O
regional O
body O
bone O
mineral O
content O
were O
measured O
in O
38 O
women O
treated O
with O
GnRH I-GENE
agonists O
for O
6 O
months O
for O
endometriosis O
or O
leiomyomata O
. O

The O
encoded O
polypeptide O
is O
similar O
in O
sequence O
to O
the O
ABA I-GENE
- I-GENE
1 I-GENE
allergen I-GENE
of I-GENE
Ascaris I-GENE
, O
the O
gp15 I-GENE
/ I-GENE
400 I-GENE
' I-GENE
ladder I-GENE
' I-GENE
protein I-GENE
of I-GENE
Brugia I-GENE
malayi I-GENE
, I-GENE
Brugia I-GENE
pahangi I-GENE
and I-GENE
Wuchereria I-GENE
bancrofti I-GENE
, O
and O
a O
15 I-GENE
- I-GENE
kDa I-GENE
antigen I-GENE
of I-GENE
Dirofilaria I-GENE
immitis I-GENE
. O

Certain O
transcript O
patterns O
in O
Epifagus O
plastids O
are O
highly O
complex O
and O
similar O
to O
those O
of O
tobacco O
operons O
. O

Spontaneous O
recovery O
occurs O
within O
30 O
min O
to O
2 O
hrs O
. O

DAF I-GENE
is O
a O
70 O
kD O
glycoprotein O
containing O
complement O
regulatory O
short O
consensus O
repeats O
( O
SCRs O
); O
its O
gene O
is O
located O
in O
the O
regulation I-GENE
of I-GENE
complement I-GENE
activation I-GENE
( O
RCA I-GENE
) O
gene O
cluster O
on O
chromosome O
1 O
and O
is O
about O
40 O
kb O
in O
size O
. O

The O
XS2 I-GENE
gene I-GENE
down O
- O
regulates O
but O
does O
not O
abolish O
expression O
of O
LU I-GENE
genes I-GENE
and O
does O
not O
affect O
expression O
of O
CD44 I-GENE
. O

Diabetes O
care O
: O
a O
guideline O
to O
the O
facilities O
needed O
to O
support O
internationally O
endorsed O
standards O
. O

There O
is O
no O
TATA O
box O
around O
the O
transcriptional O
start O
points O
( O
tsp O
), O
as O
determined O
by O
primer O
extension O
analysis O
. O

According O
to O
the O
investigation O
, O
the O
recent O
burst O
of O
pseudoterranovosis O
in O
this O
area O
can O
be O
attributed O
to O
the O
increased O
presence O
of O
sea O
lions O
, O
which O
proliferate O
in O
the O
Arctic O
region O
, O
then O
migrate O
to O
the O
northern O
Japan O
Sea O
and O
eat O
the O
intermediate O
host O
fish O
. O

In O
summary O
, O
the O
efficacies O
of O
adjuvant O
carboplatin O
and O
of O
abdominal O
radiotherapy O
seem O
to O
be O
identical O
. O

To O
identify O
some O
of O
the O
genes O
expressed O
in O
LPS O
- O
activated O
coelomocytes O
, O
we O
sequenced O
randomly O
chosen O
clones O
from O
a O
directionally O
constructed O
cDNA O
library O
to O
produce O
a O
set O
of O
expressed O
sequence O
tags O
( O
ESTs O
). O

Characterization O
of O
an O
EcR I-GENE
/ O
USP I-GENE
heterodimer O
target O
site O
that O
mediates O
ecdysone O
responsiveness O
of O
the O
Drosophila I-GENE
Lsp I-GENE
- I-GENE
2 I-GENE
gene I-GENE
. O

Thus O
, O
SPECT O
was O
not O
as O
sensitive O
as O
PET O
in O
this O
activation O
task O
. O

Transcriptional O
activation O
of O
the O
chicken I-GENE
lysozyme I-GENE
gene I-GENE
by O
NF I-GENE
- I-GENE
kappa I-GENE
Bp65 I-GENE
( O
RelA I-GENE
) O
and O
c I-GENE
- I-GENE
Rel I-GENE
, O
but O
not O
by O
NF I-GENE
- I-GENE
kappa I-GENE
Bp50 I-GENE
. O

The O
results O
indicate O
that O
the O
bradycardic O
agents O
alinidine O
and O
zatebradine O
do O
not O
exert O
antiarrhythmic O
efficacy O
against O
SVT O
induced O
during O
subacute O
myocardial O
infarction O
in O
conscious O
dogs O
. O

In O
vivo O
, O
selective O
activation O
of O
SAPKs I-GENE
stimulates O
formation O
of O
the O
ternary O
complex O
containing O
Elk I-GENE
- I-GENE
1 I-GENE
, O
serum I-GENE
response I-GENE
factor I-GENE
and O
the O
serum O
response O
element O
, O
and O
enhances O
Elk I-GENE
- I-GENE
1 I-GENE
- O
dependent O
transcription O
. O

An O
epidemic O
of O
hepatitis O
B O
virus O
infection O
among O
intravenous O
drug O
users O
in O
Iceland O
. O

The O
gene O
was O
uniquely O
mapped O
with O
odds O
> O
1 O
, O
000 O
: O
1 O
on O
chromosome O
3p O
in O
Centre O
d O
' O
Etude O
du O
Polymorphisme O
Humain O
pedigrees O
. O

Three O
of O
these O
subunits O
are O
also O
homologous O
to O
the O
dimeric O
POR I-GENE
from O
a O
mesophilic O
archaeon O
, O
Halobacterium O
halobium O
( O
21 O
% O
identity O
). O

The O
transposon O
- O
inactivated O
gene O
, O
designated O
pilP I-GENE
, O
is O
525 O
bp O
long O
, O
potentially O
encoding O
a O
19 O
. O
1 O
- O
kDa O
protein O
precursor O
that O
contains O
a O
typical O
membrane O
lipoprotein O
leader O
sequence O
. O

Cheung O
and O
S O
. O

Upstream O
of O
the O
dra I-GENE
gene I-GENE
an O
open O
reading O
frame O
of O
313 O
amino O
acids O
was O
identified O
. O

Sucrose O
- O
specific O
regulation O
of O
scrB I-GENE
was O
also O
lost O
upon O
deletion O
of O
4 O
bp O
of O
a O
palindromic O
sequence O
( O
OB O
) O
covering O
positions O
+ O
6 O
to O
+ O
21 O
downstream O
of O
the O
scrB I-GENE
transcriptional O
start O
site O
. O

In O
E O
. O
coli O
, O
CheW I-GENE
mediates O
the O
physical O
coupling O
of O
the O
receptors O
to O
the O
kinase O
CheA I-GENE
. O

The O
promoter O
of O
the O
first O
gene O
, O
epiF I-GENE
, O
responded O
to O
the O
activator I-GENE
protein I-GENE
EpiQ I-GENE
and O
contained O
a O
palindromic O
sequence O
similar O
to O
the O
EpiQ I-GENE
binding I-GENE
site I-GENE
of O
the O
epiA I-GENE
promoter I-GENE
, O
which O
is O
also O
activated O
by O
EpiQ I-GENE
. O

CXC O
chemokines O
bind O
to O
unique O
sets O
of O
selectivity O
determinants O
that O
can O
function O
independently O
and O
are O
broadly O
distributed O
on O
multiple O
domains O
of O
human O
interleukin I-GENE
- I-GENE
8 I-GENE
receptor I-GENE
B I-GENE
. O

Oligodeoxynucleotides O
antisense O
to O
the O
predicted O
translation O
initiation O
regions O
of O
ICP4 I-GENE
and O
pp38 I-GENE
mRNAs I-GENE
inhibited O
proliferation O
of O
MSB1 O
cells O
but O
not O
MDCC O
- O
CU91 O
( O
CU91 O
) O
reticuloendotheliosis O
virus O
- O
transformed O
cells O
. O

Retroviral O
replication O
requires O
that O
a O
portion O
of O
the O
primary O
transcripts O
generated O
from O
proviral O
DNA O
be O
spliced O
to O
serve O
as O
mRNA O
for O
the O
envelope I-GENE
protein I-GENE
and O
in O
Rous O
sarcoma O
virus O
as O
src I-GENE
mRNA I-GENE
. O

In O
this O
case O
the O
degree O
of O
promoter O
methylation O
, O
which O
could O
extend O
beyond O
the O
T O
- O
DNA O
borders O
, O
was O
not O
correlated O
with O
the O
reduction O
in O
steady O
- O
state O
poly O
( O
A O
)+ O
mRNA O
levels O
, O
the O
silenced O
state O
was O
transmitted O
through O
meiosis O
and O
reactivation O
lasted O
several O
generations O
. O

Thus O
, O
the O
consensus O
sequences O
for O
phosphatase O
regulation O
are O
5 O
'- O
GCACGTGGG O
- O
3 O
' O
and O
5 O
'- O
GCACGTTTT O
- O
3 O
' O
which O
differ O
from O
the O
binding O
sequences O
for O
the O
Cpflp I-GENE
protein O
required O
for O
transcription O
of O
the O
genes O
in O
methionine O
biosynthesis O
and O
for O
centromere O
function O
. O

Here O
we O
report O
that O
the O
proline O
- O
rich O
region O
of O
CAP I-GENE
is O
recognized O
by O
the O
SH3 I-GENE
domains I-GENE
of O
several O
proteins O
, O
including O
the O
yeast I-GENE
actin I-GENE
- I-GENE
associated I-GENE
protein I-GENE
Abp1p I-GENE
. O

We O
have O
identified O
and O
characterized O
a O
vitamin O
D O
response O
element O
( O
VDRE O
) O
in O
the O
promoter O
of O
c I-GENE
- I-GENE
fos I-GENE
. O

In O
addition O
to O
protein O
binding O
at O
sequences O
known O
to O
be O
involved O
in O
the O
regulation O
of O
transcription O
, O
genomic O
footprinting O
of O
the O
entire O
promoter O
region O
also O
showed O
that O
a O
protein O
factor O
is O
constitutively O
bound O
to O
the O
first O
intron O
of O
the O
rep3 I-GENE
gene I-GENE
. O

Differentiation O
was O
not O
observed O
after O
cellular O
expression O
of O
GTPase I-GENE
- O
deficient O
forms O
of O
alpha I-GENE
i2 I-GENE
or O
alpha I-GENE
0 I-GENE
, O
indicating O
selectivity O
for O
the O
Gq I-GENE
family I-GENE
of O
G I-GENE
proteins I-GENE
. O

Consistent O
with O
a O
possible O
role O
in O
transcription O
, O
Paf1p I-GENE
is O
localized O
to O
the O
nucleus O
. O

By O
comparing O
the O
abundances O
of O
many O
yeast O
transcripts O
in O
isogenic O
wild O
- O
type O
and O
paf1 I-GENE
mutant I-GENE
strains O
, O
we O
have O
identified O
genes O
whose O
expression O
is O
affected O
by O
PAF1 I-GENE
. O

Paf1p I-GENE
may O
therefore O
be O
required O
for O
both O
positive O
and O
negative O
regulation O
of O
subsets O
of O
yeast O
genes O
. O

Using O
a O
high O
- O
copy O
suppression O
strategy O
, O
we O
have O
identified O
a O
yeast O
gene O
( O
UBS1 I-GENE
) O
whose O
elevated O
expression O
suppresses O
the O
conditional O
cell O
cycle O
defects O
associated O
with O
cdc34 I-GENE
mutations O
. O

Molecular O
characterization O
of O
malignant O
melanoma O
of O
soft O
parts O
or O
soft O
tissue O
clear O
cell O
sarcoma O
which O
shares O
t O
( O
12 O
; O
22 O
) O
chromosome O
translocation O
revealed O
fusion O
of O
EWS I-GENE
with O
a O
transcriptional O
factor O
gene I-GENE
ATF I-GENE
- I-GENE
1 I-GENE
. O

Clones O
that O
expressed O
DBD O
exhibited O
a O
dominant O
negative O
phenotype O
and O
did O
not O
elicit O
antiviral O
activity O
against O
vesicular O
stomatitis O
virus O
( O
VSV O
) O
infection O
upon O
IFN I-GENE
treatment O
. O

Abp1 I-GENE
preferentially O
binds O
to O
multiple O
sites O
in O
ARS I-GENE
3002 I-GENE
and O
to O
the O
DNA O
polymer O
poly O
[ O
d O
( O
A O
. O
T O
)]. O

Identification O
, O
purification O
, O
and O
molecular O
cloning O
of O
autonomously I-GENE
replicating I-GENE
sequence I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
from I-GENE
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
. O

A O
short O
open O
reading O
frame O
( O
ORF2 O
), O
of O
unknown O
function O
, O
is O
present O
in O
all O
FIV O
isolates O
. O

The O
patient O
was O
homozygous O
for O
the O
underlying O
mutation O
, O
which O
was O
found O
to O
be O
a O
G O
--> O
T O
transversion O
within O
the O
acceptor O
splice O
site O
between O
intron O
e O
and O
exon O
6 O
, O
abolishing O
normal O
RNA O
splicing O
. O

These O
regions O
overlap O
with O
the O
HIT I-GENE
protein I-GENE
similarity I-GENE
regions I-GENE
. O

We O
tested O
10 O
rats O
with O
electrophysiologically O
guided O
, O
ibotenic O
acid O
lesions O
of O
the O
PBN O
( O
PBNx O
) O
to O
determine O
whether O
they O
could O
acquire O
a O
LiCl O
- O
induced O
CTA O
to O
l O
- O
alanine O
( O
0 O
. O
3 O
M O
) O
or O
demonstrate O
a O
sodium O
appetite O
following O
furosemide O
treatment O
and O
overnight O
access O
to O
sodium O
deficient O
chow O
. O

Liposomal O
Amphotericin O
- O
B O
failed O
in O
6 O
/ O
7 O
patients O
with O
culture O
- O
proven O
mycosis O
who O
died O
from O
infection O
with O
Aspergillus O
( O
n O
= O
2 O
) O
and O
Candida O
( O
n O
= O
4 O
), O
respectively O
. O

Mg2 O
+ O
and O
Mn2 O
+ O
compete O
for O
binding O
sites O
, O
with O
the O
former O
having O
lower O
affinity O
. O

Magnetic O
storm O
indicators O
could O
be O
used O
in O
medicine O
, O
in O
geophysics O
and O
for O
special O
purposes O
. O

Transgenic O
tobacco O
plants O
( O
ppa I-GENE
- I-GENE
1 I-GENE
) O
constitutively O
expressing O
Escherichia I-GENE
coli I-GENE
pyrophosphatase I-GENE
behind O
the O
35S I-GENE
CaMV I-GENE
promoter I-GENE
accumulate O
high O
levels O
of O
soluble O
sugars O
in O
their O
leaves O
[ O
27 O
]. O

Human I-GENE
LAF I-GENE
- I-GENE
4 I-GENE
readily O
hybridized O
with O
genes O
in O
mouse O
and O
chicken O
, O
thus O
showing O
that O
this O
gene O
family O
has O
been O
highly O
conserved O
during O
vertebrate O
evolution O
. O

Hb I-GENE
levels O
remained O
adequate O
( O
Hb I-GENE
= O
10 O
. O
68 O
+/- O
0 O
. O
77 O
g O
/ O
dl O
) O
after O
14 O
. O
6 O
+/- O
7 O
. O
64 O
months O
. O

CBT O
is O
discussed O
in O
comparison O
with O
the O
Wisconsin O
Card O
Sorting O
Test O
as O
a O
potential O
cognitive O
activation O
task O
for O
functional O
neuroimaging O
of O
the O
frontal O
lobes O
. O

These O
data O
indicate O
that O
although O
218leu O
retains O
normal O
transactivation O
activity O
on O
a O
p53 I-GENE
promoter I-GENE
in O
yeast O
at O
physiological O
temperatures O
, O
it O
is O
not O
capable O
of O
normal O
p53 I-GENE
function O
in O
the O
presence O
of O
a O
248trp I-GENE
allele I-GENE
in O
SNU O
- O
C5 O
cells O
. O

Cycles O
were O
repeated O
every O
3 O
weeks O
. O

Neither O
class O
II O
nor O
IV O
infections O
precluded O
transplantation O
. O

Although O
a O
great O
deal O
is O
understood O
about O
how O
bHLH I-GENE
factors I-GENE
activate O
gene O
transcription O
via O
E O
- O
box O
DNA O
consensus O
sequences O
, O
studies O
of O
bHLH I-GENE
factor I-GENE
function O
in O
higher O
eukaryotes O
often O
have O
been O
hindered O
by O
the O
presence O
of O
multiple O
family O
members O
. O

Mobility O
and O
supershift O
assays O
demonstrated O
that O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
( O
USF I-GENE
) O
and O
Sp1 I-GENE
bind O
to O
the O
former O
elements O
and O
competition O
experiments O
confirmed O
that O
CREB I-GENE
/ O
ATF I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
bind O
to O
the O
CRE O
/ O
TRE O
element O
. O

Upstream O
of O
- O
37 O
, O
the O
5 O
' O
untranslated O
sequences O
of O
the O
isolates O
differ O
in O
both O
length O
and O
sequence O
. O

In O
these O
cases O
, O
greatly O
increased O
human I-GENE
chorionic I-GENE
gonadotropin I-GENE
( O
hCG I-GENE
) O
levels O
and O
suppressed O
TSH I-GENE
levels O
suggest O
that O
hCG I-GENE
has O
thyrotropic O
activity O
. O

High O
fibrinogen I-GENE
levels O
could O
thus O
be O
a O
risk O
for O
perioperative O
thrombosis O
. O

Strontium O
chloride O
Sr O
89 O
is O
costly O
, O
but O
preliminary O
analysis O
indicates O
that O
it O
may O
reduce O
management O
expenditures O
overall O
.( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

We O
propose O
that O
epigenetic O
features O
of O
tissue O
- O
specific O
control O
and O
of O
the O
control O
of O
allelic O
expression O
are O
intricately O
linked O
. O

This O
study O
determined O
the O
arthritogenic O
potential O
of O
silicone O
gel O
by O
either O
mixing O
it O
with O
bovine I-GENE
collagen I-GENE
II I-GENE
( O
BII I-GENE
) O
or O
by O
injecting O
silicone O
gel O
alone O
in O
DA O
rats O
. O

SBF I-GENE
binds O
to O
the O
promoter O
prior O
to O
the O
activation O
of O
transcription O
in O
late O
G1 O
, O
suggesting O
that O
Cln I-GENE
/ O
Cdc28 I-GENE
kinase O
regulates O
the O
ability O
of O
previously O
bound O
SBF I-GENE
to O
activate O
transcription O
. O

However O
, O
it O
remains O
an O
open O
question O
whether O
vertebrate I-GENE
Hox I-GENE
genes I-GENE
expressed O
under O
the O
control O
of O
Drosophila O
regulatory O
sequences O
can O
substitute O
the O
function O
of O
Drosophila I-GENE
Hox I-GENE
genes I-GENE
. O

This O
approach O
places O
gHoxb I-GENE
- I-GENE
1 I-GENE
into O
the O
normal O
embryonic O
spatiotemporal O
context O
in O
which O
lab O
acts O
. O

This O
5 O
' O
splice O
site O
sequence O
was O
required O
for O
enhanced O
polyadenylation O
and O
was O
recognized O
by O
both O
U1 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoproteins I-GENE
( O
snRNPs O
) O
and O
alternative I-GENE
splicing I-GENE
factor I-GENE
/ O
splicing I-GENE
factor I-GENE
2 I-GENE
( O
ASF I-GENE
/ O
SF2 I-GENE
). O

This O
analysis O
revealed O
that O
SAP I-GENE
145 I-GENE
, O
together O
with O
four O
other O
SF3a I-GENE
/ O
SF3b I-GENE
subunits O
, O
UV O
cross O
- O
links O
to O
pre O
- O
mRNA O
in O
a O
20 O
- O
nucleotide O
region O
upstream O
of O
the O
BPS O
. O

We O
propose O
that O
CTS1 I-GENE
and I-GENE
CTS2 I-GENE
of I-GENE
Ci I-GENE
are O
members O
of O
two O
distinct O
classes O
of O
fungal I-GENE
chitinases I-GENE
, O
an O
observation O
not O
previously O
reported O
for O
a O
single O
fungus O
. O

Although O
the O
consumption O
of O
myoglobin I-GENE
- O
bound O
O2 O
( O
MbO2 O
) O
stores O
in O
seal O
muscles O
has O
been O
demonstrated O
in O
seal O
muscles O
during O
laboratory O
simulations O
of O
diving O
, O
this O
may O
not O
be O
a O
feature O
of O
normal O
field O
diving O
in O
which O
measurements O
of O
heart O
rate O
and O
lactate O
production O
show O
marked O
differences O
from O
the O
profound O
diving O
response O
induced O
by O
forced O
immersion O
. O

The O
human I-GENE
purH I-GENE
cDNA I-GENE
is O
1776 O
base O
pairs O
in O
length O
encoding O
for O
a O
591 O
- O
amino O
acid O
polypeptic O
( O
Mr O
= O
64 O
, O
425 O
). O

The O
Saccharomyces O
cerevisiae O
spindle O
pole O
body O
duplication O
gene I-GENE
MPS1 I-GENE
is O
part O
of O
a O
mitotic O
checkpoint O
. O

In O
our O
opinion O
, O
the O
SM O
- O
CMA O
system O
is O
, O
despite O
some O
shortcomings O
in O
its O
user O
- O
interface O
, O
a O
useful O
and O
versatile O
instrument O
for O
examination O
of O
human O
semen O
samples O
, O
with O
desirable O
features O
. O

The O
purpose O
of O
the O
study O
reported O
here O
was O
to O
investigate O
whether O
differences O
in O
T1 O
and O
T2 O
between O
tumors O
are O
mainly O
a O
consequence O
of O
differences O
in O
the O
fractional O
volume O
of O
the O
extracellular O
compartment O
. O

A O
mutant I-GENE
areA I-GENE
product I-GENE
truncated O
immediately O
after O
the O
last O
residue O
of O
the O
highly O
conserved O
GATA I-GENE
( I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
) I-GENE
domain I-GENE
retains O
partial O
function O
. O

Oligonucleotides O
, O
designed O
on O
the O
basis O
of O
conserved O
flanking O
amino O
acid O
sequence O
segments O
within O
the O
catalytic O
domain O
of O
eukaryotic I-GENE
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
proteins O
, O
were O
used O
as O
primers O
for O
polymerase O
chain O
reactions O
to O
amplify O
a O
427 O
- O
bp O
chromosomal O
DNA O
fragment O
from O
the O
filamentous O
fungus O
Trichoderma O
reesei O
. O

Disruption O
of O
RB I-GENE
/ O
E2F I-GENE
- I-GENE
1 I-GENE
interaction O
by O
single O
point O
mutations O
in O
E2F I-GENE
- I-GENE
1 I-GENE
enhances O
S O
- O
phase O
entry O
and O
apoptosis O
. O

Apparent O
loss O
of O
differentiation O
markers O
characterizes O
advanced O
malignant O
neoplasms O
. O

This O
region O
contains O
a O
motif O
with O
partial O
identity O
with O
the O
binding O
site O
for O
the O
ubiquitous O
transcription O
factor O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
( O
USF I-GENE
), O
which O
binds O
to O
the O
human I-GENE
insulin I-GENE
promoter I-GENE
. O

The O
method O
has O
been O
satisfactorily O
applied O
to O
the O
determination O
of O
paracetamol O
in O
pharmaceutical O
formulations O
and O
biological O
fluids O
. O

These O
primers O
yielded O
a O
PCR O
product O
of O
a O
characteristic O
length O
within O
most O
Xanthomonas O
species O
and O
pathovars O
tested O
. O

The O
Clb5 I-GENE
kinase I-GENE
, O
which O
promotes O
S O
phase O
, O
remains O
active O
during O
the O
G2 O
- O
phase O
arrest O
of O
cells O
of O
the O
parental O
strain O
, O
but O
its O
activity O
declines O
rapidly O
in O
sim I-GENE
mutants I-GENE
. O

The O
C O
/ O
D O
ratio O
was O
equal O
to O
or O
over O
0 O
. O
6 O
in O
9 O
cases O
( O
16 O
eyes O
), O
and O
the O
values O
were O
inconsistent O
between O
both O
eyes O
in O
55 O
% O
of O
the O
patients O
. O

Rad6 I-GENE
mutants I-GENE
display O
a O
remarkably O
pleiotropic O
phenotype O
, O
implicating O
the O
protein O
in O
DNA O
damage O
- O
induced O
mutagenesis O
, O
postreplication O
repair O
, O
repression O
of O
retrotransposition O
, O
and O
sporulation O
. O

RNase I-GENE
protection O
assays O
revealed O
a O
correlation O
between O
the O
levels O
of O
dorsal O
and O
ventral O
skin O
expression O
with O
pigmentation O
/ O
phaeomelanin O
phenotypes O
. O

Molecular O
cloning O
, O
expression O
pattern O
, O
and O
chromosomal O
localization O
of O
human O
CDKN2D I-GENE
/ O
INK4d I-GENE
, O
an O
inhibitor O
of O
cyclin I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

Overproduction O
of O
HrcA I-GENE
protein I-GENE
from O
a O
second O
copy O
of O
hrcA I-GENE
derived O
from O
a O
plasmid O
( O
phrcA I-GENE
+) O
in O
B O
. O
subtilis O
wild O
- O
type O
and O
delta O
hrcA I-GENE
strains O
prevented O
heat O
shock O
induction O
of O
the O
dnaK I-GENE
and O
groE I-GENE
operons I-GENE
at O
the O
level O
of O
transcription O
almost O
completely O
and O
strongly O
reduced O
the O
amounts O
of O
mRNA O
at O
a O
low O
temperature O
as O
well O
. O

We O
report O
the O
molecular O
cloning O
and O
functional O
characterization O
of O
USF2 I-GENE
isoforms I-GENE
, O
corresponding O
to O
a O
44 O
- O
kDa O
subunit O
, O
USF2a I-GENE
, O
and O
a O
new O
38 O
- O
kDa O
subunit O
, O
USF2b I-GENE
, O
generated O
by O
differential O
splicing O
. O

The O
preferential O
heterodimerization O
of O
USF I-GENE
subunits I-GENE
was O
reproduced O
ex O
vivo O
, O
while O
the O
in O
vitro O
association O
of O
cotranslated O
subunits O
, O
or O
recombinant I-GENE
USF I-GENE
proteins I-GENE
, O
appeared O
to O
be O
random O
. O

Activated O
PKR I-GENE
may O
exist O
as O
a O
dimer O
and O
phosphorylates O
the O
eukaryotic I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
alpha I-GENE
subunit I-GENE
( O
cIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
) O
to O
inhibit O
polypeptide O
chain O
initiation O
. O

GRP78 I-GENE
, O
a O
molecular O
chaperone O
expressed O
in O
the O
endoplasmic O
reticulum O
, O
is O
a O
" O
glucose O
- O
regulated O
protein O
" O
induced O
by O
stress O
responses O
that O
deplete O
glucose O
or O
intracisternal O
calcium O
or O
otherwise O
disrupt O
glycoprotein O
trafficking O
. O

The O
IL I-GENE
- I-GENE
8 I-GENE
receptor I-GENE
is O
a O
seven O
- O
transmembrane O
spanning O
receptor O
coupled O
to O
specific O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
including O
Gi I-GENE
and O
G16 I-GENE
. O

In O
a O
second O
series O
of O
experiments O
, O
the O
efficacy O
of O
PDC O
/ O
HDC O
Ac O
was O
evaluated O
in O
both O
single O
and O
multiple O
dose O
regiments O
. O

To O
elucidate O
the O
functional O
significance O
of O
Fyn I-GENE
in O
the O
expression O
of O
viral O
promoters O
, O
we O
transfected O
a O
Fyn I-GENE
- O
expression O
vector O
together O
with O
a O
reporter O
plasmid O
containing O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
driven O
by O
HIV I-GENE
LTR I-GENE
into O
a O
human O
T O
cell O
line O
, O
Jurkat O
. O

We O
conducted O
a O
prospective O
, O
randomized O
controlled O
trial O
of O
metoprolol O
, O
a O
selective O
beta O
- O
blocker O
for O
prevention O
of O
gastrointestinal O
bleeding O
from O
portal O
hypertension O
in O
29 O
non O
- O
selected O
patients O
with O
liver O
disease O
and O
previous O
gastrointestinal O
bleeding O
. O

A O
genetic O
and O
molecular O
analysis O
of O
non O
- O
inducible O
qutA I-GENE
mutants I-GENE
showed O
that O
all O
23 O
mutations O
analysed O
map O
within O
the O
N O
- O
terminal O
half O
of O
the O
encoded O
QUTA I-GENE
protein I-GENE
. O

These O
studies O
indicate O
that O
the O
acidimetric O
test O
was O
less O
sensitive O
than O
the O
chromogenic O
cephalosporin O
substrates O
and O
that O
nitrocefin O
and O
S1 O
could O
be O
used O
to O
screen O
for O
beta I-GENE
- I-GENE
lactamase I-GENE
production O
in O
these O
tested O
species O
. O

Suppressors O
of O
defective O
silencing O
in O
yeast O
: O
effects O
on O
transcriptional O
repression O
at O
the O
HMR I-GENE
locus I-GENE
, O
cell O
growth O
and O
telomere O
structure O
. O

Although O
ANP I-GENE
induced O
systemic O
capillary O
filtration O
, O
in O
the O
calf O
, O
filtration O
was O
reduced O
with O
ANP I-GENE
. O

Recent O
literature O
has O
suggested O
that O
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
can O
also O
be O
used O
as O
a O
clinical O
marker O
for O
perilymph O
. O

With O
current O
methodology O
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
does O
not O
appear O
to O
be O
a O
reliable O
clinical O
marker O
for O
perilymph O
in O
the O
operative O
setting O
. O

The O
hIGF I-GENE
- I-GENE
I I-GENE
gene I-GENE
has O
two O
promoters O
, O
P1 O
and O
P2 O
. O

Gel O
mobility O
shift O
assays O
indicated O
that O
at O
least O
four O
nuclear O
proteins O
with O
distinct O
biochemical O
and O
binding O
properties O
possess O
the O
ability O
to O
bind O
the O
3 O
beta O
I O
- O
A O
element O
to O
produce O
four O
DNA O
- O
protein O
complexes O
( O
R1 O
to O
R4 O
). O

Sixty O
- O
five O
patients O
( O
aged O
between O
3 O
years O
5 O
months O
and O
60 O
years O
) O
suffering O
from O
medically O
resistant O
temporal O
lobe O
epilepsy O
( O
TLE O
) O
were O
operated O
on O
over O
a O
period O
of O
33 O
months O
in O
Bethel O
Epilepsy O
Center O
. O

Significant O
correlations O
existed O
between O
FEV1 O
and O
the O
corresponding O
values O
of O
Raw O
, O
MEF50 O
and O
MEF25 O
, O
although O
there O
were O
considerable O
individual O
differences O
between O
test O
results O
. O

( O
1989 O
), O
which O
is O
identical O
to O
the O
SSC1 I-GENE
gene I-GENE
( O
Smith O
et O
al O
., O
1988 O
). O

This O
region O
also O
contains O
a O
gene O
specifying O
a O
Leu I-GENE
- I-GENE
tRNA I-GENE
precursor I-GENE
and O
a O
remnant O
of O
a O
tau O
element O
. O

Occupational O
exposure O
to O
hepatitis O
B O
virus O
and O
human O
immunodeficiency O
virus O
: O
a O
comparative O
risk O
analysis O
. O

Hybrid O
female O
mice O
( O
C57BL O
x O
CBA O
) O
were O
paired O
with O
breeder O
males O
( O
CD O
- O
1 O
) O
and O
LNG O
pellets O
were O
implanted O
on O
day O
0 O
, O
the O
day O
on O
which O
copulation O
plugs O
were O
found O
, O
or O
on O
day O
2 O
or O
day O
3 O
in O
the O
postcoital O
period O
. O

This O
gene O
encodes O
a O
putative O
transcription O
factor O
with O
regions O
of O
homology O
to O
several O
other O
proteins O
including O
the O
zinc O
fingers O
and O
other O
domains O
of O
the O
Drosophila I-GENE
trithorax I-GENE
gene I-GENE
product I-GENE
, O
and O
the O
" O
AT O
- O
hook O
" O
DNA O
- O
binding O
motif O
of O
high I-GENE
mobility I-GENE
group I-GENE
proteins I-GENE
. O

Using O
reference O
probes O
as O
internal O
standards O
, O
we O
show O
that O
the O
ost I-GENE
transcription I-GENE
unit I-GENE
is O
located O
within O
the O
cytogenetic O
band O
interval O
89A1 O
, O
2 O
on O
the O
right O
arm O
of O
the O
third O
chromosome O
, O
and O
that O
it O
exerts O
diagnostic O
segmentation O
gene O
expression O
patterns O
in O
the O
embryo O
. O

The O
purified O
recombinant O
enzyme O
catalyzed O
specific O
phosphoryl O
transfer O
from O
ATP O
to O
UMP O
and O
CMP O
. O

Studies O
on O
the O
life O
cycle O
of O
Haplorchis O
pumilio O
( O
Looss O
, O
1896 O
) O
Looss O
, O
1899 O
with O
morphological O
redescription O
of O
larval O
and O
adult O
stages O
. O

Regressing O
microaneurysms O
in O
5 O
cases O
of O
hepatitis O
B O
virus O
related O
polyarteritis O
nodosa O
. O

During O
the O
following O
pregnancy O
ultrasonographic O
studies O
of O
the O
male O
fetus O
in O
the O
16th O
week O
of O
gestation O
revealed O
severe O
micrognathia O
, O
short O
and O
wide O
thumbs O
, O
and O
big O
toes O
, O
and O
bowed O
tibiae O
. O

Despite O
an O
overall O
survival O
rate O
of O
43 O
%, O
survival O
to O
discharge O
varied O
greatly O
( O
0 O
to O
100 O
%) O
among O
the O
24 O
diagnostic O
groups O
: O
tumor O
lysis O
syndrome O
and O
systemic O
lupus O
erythematosus O
( O
3 O
/ O
3 O
patients O
each O
, O
100 O
%), O
hemolytic O
uremic O
syndrome O
( O
8 O
/ O
9 O
patients O
, O
89 O
%). O

One O
hundred O
units O
/ O
kg O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
rhEPO I-GENE
) O
was O
given O
subcutaneously O
3 O
times O
a O
week O
for O
3 O
weeks O
. O

A O
3 O
- O
week O
regimen O
of O
erythropoietin I-GENE
may O
help O
prevent O
the O
donor O
' O
s O
need O
to O
receive O
allogeneic O
blood O
transfusion O
, O
when O
the O
initial O
Hb I-GENE
levels O
were O
below O
130 O
milligrams O
. O

In O
these O
constructs O
, O
GUS I-GENE
expression O
was O
driven O
by O
promoter O
regions O
derived O
from O
the O
Arabidopsis I-GENE
alcohol I-GENE
dehydrogenase I-GENE
( O
Adh1 I-GENE
), O
maize I-GENE
ubiquitin I-GENE
( O
Ubi1 I-GENE
), O
rice I-GENE
actin I-GENE
( O
Act1 I-GENE
) O
and O
CaMV I-GENE
35S I-GENE
genes I-GENE
. O

Its O
organization O
and O
regulation O
indicate O
that O
the O
S I-GENE
. I-GENE
pombe I-GENE
URA1 I-GENE
gene I-GENE
product I-GENE
appears O
very O
similar O
to O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
URA2 I-GENE
gene I-GENE
product I-GENE
. O

The O
mean O
body O
mass O
index O
( O
BMI O
) O
was O
31 O
. O
8 O
+/- O
6 O
. O
3 O
kg O
/ O
m2 O
and O
28 O
. O
5 O
+/- O
6 O
. O
3 O
kg O
/ O
m2 O
in O
women O
and O
men O
, O
respectively O
. O

These O
findings O
demonstrate O
that O
haemodialysis O
patients O
with O
chronic O
hepatitis O
C O
respond O
well O
to O
interferon I-GENE
treatment O
and O
that O
a O
long O
- O
term O
response O
is O
achieved O
in O
a O
high O
proportion O
of O
patients O
. O

Synthetic O
enantiomers O
of O
drugs O

Polysome O
analysis O
further O
indicated O
that O
these O
germ I-GENE
cell I-GENE
- I-GENE
specific I-GENE
Sp1 I-GENE
mRNAs I-GENE
are O
translated O
, O
albeit O
with O
a O
lower O
efficiency O
than O
the O
somatic O
transcript O
. O

In O
nondiabetics O
the O
response O
of O
tcPO2 O
but O
not O
of O
LDF O
was O
influenced O
by O
the O
values O
at O
rest O
. O

This O
study O
proposes O
an O
estimator O
for O
such O
global O
synchronizing O
effects O
upon O
unit O
- O
pair O
correlations O
based O
on O
local O
field O
potentials O
( O
LFPs O
). O

The O
assembly O
of O
sequence O
ready O
, O
high O
- O
resolution O
physical O
maps O
and O
construction O
of O
minimally O
overlapping O
contigs O
for O
the O
human O
as O
well O
as O
model O
genomes O
requires O
accurate O
determination O
of O
the O
extent O
of O
overlap O
between O
adjacent O
clones O
as O
well O
as O
their O
relative O
orientation O
. O

( O
ii O
) O
opening O
of O
KATP O
attenuates O
, O
inhibition O
of O
the O
channel O
exacerbates O
functional O
consequences O
of O
coronary O
occlusion O
, O
and O
( O
iii O
) O
KATP O
opening O
attenuates O
reperfusion O
- O
induced O
VF O
, O
but O
it O
triggers O
ischemia O
- O
induced O
VF O
. O

The O
DNA O
sequences O
upstream O
of O
these O
termini O
exhibit O
homology O
to O
plant O
mitochondrial O
- O
processing O
sites O
, O
therefore O
the O
proximal O
5 O
' O
ends O
are O
most O
probably O
generated O
by O
RNA O
processing O
. O

Curing O
shrinkage O
and O
volumetric O
changes O
of O
resin O
- O
modified O
glass O
ionomer O
restorative O
materials O
. O

Here O
we O
present O
genetic O
evidence O
suggesting O
that O
PP2A I-GENE
functions O
downstream O
of O
Ras1 I-GENE
in O
the O
Sevenless I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
( O
RTK I-GENE
) O
signal O
transduction O
pathway O
that O
specifies O
R7 O
photoreceptor O
cell O
fate O
in O
the O
developing O
Drosophila O
eye O
. O

QBMDs O
for O
a O
5 O
% O
change O
in O
response O
( O
QBMD05 O
) O
were O
6 O
- O
fold O
lower O
, O
on O
average O
, O
than O
the O
corresponding O
NOAEL O
. O

Effects O
of O
repeated O
exposures O
of O
hydrogen O
sulphide O
on O
rat O
hippocampal O
EEG O
. O

The O
gene O
encodes O
an O
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
, O
ABC I-GENE
transporter I-GENE
. O

The O
T O
- O
box O
motif O
is O
present O
in O
a O
family O
of O
genes O
whose O
structural O
features O
and O
expression O
patterns O
support O
their O
involvement O
in O
developmental O
gene O
regulation O
. O

Molecular O
analysis O
of O
a O
novel O
schizosaccharomyces O
pombe O
gene O
containing O
two O
RNP O
consensus O
- O
sequence O
RNA O
- O
binding O
domains O
. O

Do O
overall O
treatment O
time O
, O
field O
size O
, O
and O
treatment O
energy O
influence O
local O
control O
of O
T1 O
- O
T2 O
squamous O
cell O
carcinomas O
of O
the O
glottic O
larynx O
? O
PURPOSE O
: O
To O
evaluate O
treatment O
and O
patient O
related O
prognostic O
factors O
that O
may O
influence O
local O
control O
in O
the O
treatment O
of O
T1 O
- O
T2 O
squamous O
cell O
carcinoma O
of O
the O
glottic O
larynx O
. O

In O
contrast O
to O
the O
signaling O
triggered O
by O
surface O
Ig I-GENE
engagement O
in O
B O
lymphocytes O
, O
CD38 I-GENE
ligation O
did O
not O
appear O
to O
induce O
tyrosine O
phosphorylation O
of O
the O
src I-GENE
- I-GENE
like I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
lyn I-GENE
, O
fyn I-GENE
, O
and O
btk I-GENE
, O
or O
of O
vav I-GENE
- I-GENE
and I-GENE
ras I-GENE
- I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
nor O
did O
it O
induce O
detectable O
changes O
in O
cytosolic O
CA2 O
+ O
concentrations O
. O

Mutations O
in O
the O
alpha I-GENE
- I-GENE
amanitin I-GENE
conserved O
domain O
of O
the O
largest O
subunit O
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
affect O
pausing O
, O
RNA O
cleavage O
and O
transcriptional O
transitions O
. O

The O
evidence O
presented O
here O
suggests O
that O
the O
p40 I-GENE
complex I-GENE
is O
a O
ribonucleoprotein O
complex O
containing O
L1Hs I-GENE
RNA I-GENE
( I-GENE
s I-GENE
) I-GENE
and O
that O
protein O
- O
protein O
interactions O
in O
which O
alpha O
- O
helix O
structures O
participate O
, O
for O
example O
coiled O
- O
coils O
, O
may O
occur O
in O
the O
complex O
. O

Our O
data O
suggest O
that O
trans O
- O
activation O
from O
the O
prothymosin I-GENE
intron I-GENE
enhancer I-GENE
is O
a O
faithful O
reflection O
of O
the O
transforming O
properties O
of O
the O
Myc I-GENE
protein I-GENE
. O

Pseudomembranous O
conjunctivitis O
following O
bone O
marrow O
transplantation O
: O
immunopathological O
and O
ultrastructural O
study O
of O
one O
case O
. O

In O
view O
of O
the O
presence O
of O
SECIS O
elements O
in O
the O
open O
reading O
frames O
( O
ORFs O
) O
of O
bacterial I-GENE
selenoproteins I-GENE
, O
we O
examine O
the O
effects O
in O
the O
type I-GENE
1 I-GENE
deiodinase I-GENE
of O
extending O
the O
ORF O
into O
the O
SECIS O
element O
, O
and O
find O
that O
this O
dramatically O
inhibits O
SECIS O
function O
. O

The O
5 O
' O
external O
transcribed O
spacer O
( O
ETS O
) O
region O
of O
the O
pre O
- O
rRNA O
in O
Saccharomyces O
cerevisiae O
contains O
a O
sequence O
with O
10 O
bp O
of O
perfect O
complementarity O
to O
the O
U3 I-GENE
snoRNA I-GENE
. O

These O
animals O
were O
viable O
and O
fertile O
. O

This O
spindle O
defect O
of O
pds1 I-GENE
mutants I-GENE
results O
from O
a O
temperature O
- O
sensitive O
step O
that O
occurs O
around O
the O
G1 O
/ O
S O
boundary O
about O
the O
time O
of O
spindle O
assembly O
. O

These O
data O
suggest O
that O
RPF I-GENE
- I-GENE
1 I-GENE
is O
likely O
to O
be O
involved O
in O
early O
steps O
in O
the O
differentiation O
of O
amacrine O
and O
ganglion O
cells O
. O

In O
the O
point O
mutant O
we O
observed O
normal O
repair O
of O
endonuclease I-GENE
III I-GENE
site I-GENE
( O
i O
. O
e O
. O
as O
wild O
type O
), O
but O
no O
removal O
of O
CPDs O
at O
the O
MAT I-GENE
alpha I-GENE
and O
HML I-GENE
alpha I-GENE
loci I-GENE
. O

However O
, O
for O
the O
evaluable O
cases O
, O
the O
performances O
of O
the O
CD3500 O
and O
the O
STKS O
were O
broadly O
similar O
and O
generally O
correlated O
well O
with O
the O
manual O
reference O
procedure O
. O

Carboxy O
- O
terminal O
Spc110p I-GENE
truncations O
lacking O
the O
calmodulin I-GENE
binding O
site O
can O
support O
growth O
and O
are O
also O
phosphorylated O
in O
a O
cell O
cycle O
- O
specific O
manner O
. O

Both O
EWS I-GENE
- O
FLI I-GENE
- I-GENE
1 I-GENE
and O
FLI I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
function O
as O
transcription O
factors O
that O
bind O
specifically O
to O
ets I-GENE
sequences O
( O
the O
ets I-GENE
boxes O
) O
present O
in O
promoter O
elements O
. O

In O
electromobility O
shift O
assays O
, O
EWS I-GENE
- O
FLI I-GENE
- I-GENE
1 I-GENE
binding O
to O
the O
SRE O
is O
detectable O
in O
the O
absence O
of O
SRF I-GENE
whereas O
the O
binding O
of O
FLI I-GENE
- I-GENE
1 I-GENE
is O
not O
, O
suggesting O
that O
the O
interaction O
with O
DNA O
is O
the O
step O
which O
limits O
ternary O
complex O
formation O
by O
FLI I-GENE
- I-GENE
1 I-GENE
. O

Additional O
studies O
with O
new O
and O
reprocessed O
regenerated O
cellulose O
dialyzers O
comparing O
450 O
and O
220 O
mL O
/ O
min O
blood O
flow O
rates O
at O
10 O
minutes O
showed O
no O
change O
in O
BTG O
. O

DNA O
methylation O
, O
especially O
of O
either O
one O
or O
both O
of O
the O
deoxyadenosines O
at O
the O
two O
GATC O
motifs O
( O
one O
in O
the O
first O
exon O
and O
the O
other O
in O
the O
first O
intron O
of O
the O
rice O
CatA I-GENE
gene I-GENE
), O
appeared O
to O
be O
responsible O
for O
the O
CatA I-GENE
promoter I-GENE
activity O
identified O
in O
the O
transient O
assay O
. O

The O
viral I-GENE
LTR I-GENE
was O
used O
as O
the O
promoter O
. O

Overlapping O
cDNA O
clones O
were O
isolated O
and O
sequenced O
. O

In O
conclusion O
, O
IgM I-GENE
class O
CIC O
is O
the O
predominant O
CIC O
in O
acute O
hepatitis O
A O
and O
correlated O
with O
disease O
activity O
. O

Epitope O
mapping O
revealed O
that O
these O
three O
clones O
appear O
to O
recognize O
an O
identical O
epitope O
domain O
present O
on O
the O
C O
- O
terminal O
RNP O
motif O
of O
the O
U1A I-GENE
protein I-GENE
. O

Variables O
evaluated O
were O
number O
of O
weekly O
anginal O
events O
, O
data O
from O
ergometric O
exercise O
testing O
with O
simultaneous O
electrocardiographic O
registration O
, O
semiquantitative O
evaluation O
of O
Tc O
- O
99m O
2 O
- O
methoxy O
isobutyl O
isonitrile O
( O
MIBI O
) O
scans O
and O
rheologic O
variables O
. O

As O
the O
length O
of O
the O
fatty O
acid O
decreased O
, O
the O
binding O
affinity O
was O
reduced O
; O
myristic O
acid O
( O
14 O
: O
0 O
) O
bound O
with O
a O
K O
( O
d O
) O
of O
1409 O
+/- O
423 O
nM O
, O
but O
medium O
- O
chain O
( O
decanoic O
acid O
, O
10 O
: O
0 O
) O
and O
short O
- O
chain O
( O
octanoic O
acid O
, O
8 O
: O
0 O
) O
lipids O
were O
not O
bound O
at O
all O
. O

The O
membrane O
- O
distal O
cytoplasmic O
region O
of O
human I-GENE
granulocyte I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
receptor I-GENE
is O
required O
for O
STAT3 I-GENE
but O
not O
STAT1 I-GENE
homodimer I-GENE
formation O
. O

However O
, O
whether O
or O
not O
nonsense O
codon O
recognition O
within O
TPI I-GENE
transcripts I-GENE
takes O
place O
prior O
to O
or O
after O
splicing O
remained O
unresolved O
. O

Although O
some O
residues O
are O
found O
reactive O
toward O
dimethylsulphate O
and O
kethoxal O
in O
regions O
predicted O
to O
be O
unpaired O
by O
the O
phylogenetic O
secondary O
structure O
model O
of O
4 I-GENE
. I-GENE
5S I-GENE
RNA I-GENE
, O
generally O
the O
reactivity O
is O
low O
, O
and O
some O
residues O
in O
internal O
loops O
are O
not O
reactive O
at O
all O
. O

Ongoing O
and O
future O
investigations O
may O
better O
define O
the O
optimal O
approach O
for O
local O
control O
, O
the O
optimal O
duration O
of O
maintenance O
chemotherapy O
, O
and O
the O
possible O
role O
of O
biologic O
response O
modifiers O
and O
growth O
factors O
in O
further O
improving O
the O
outcome O
for O
patients O
with O
this O
disease O
. O

SUMMARY O
OF O
REVIEW O
: O
We O
discuss O
the O
criteria O
that O
make O
such O
studies O
comparable O
, O
drawing O
on O
the O
experiences O
of O
recent O
studies O
performed O
around O
the O
world O
. O

Forty O
- O
five O
patients O
with O
pleural O
lesions O
identified O
on O
CT O
scans O
were O
subsequently O
examined O
by O
MR O
imaging O
at O
0 O
. O
5 O
T O
. O

Left O
atrial O
volumes O
were O
greater O
in O
old O
compared O
with O
young O
subjects O
( O
maximal O
: O
31 O
+/- O
10 O
cm3 O
/ O
m2 O
vs O
24 O
+/- O
8 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
02 O
; O
at O
onset O
of O
atrial O
systole O
: O
23 O
+/- O
8 O
cm3 O
/ O
m2 O
vs O
15 O
+/- O
5 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
0002 O
; O
minimal O
: O
13 O
+/- O
5 O
cm3 O
/ O
m2 O
vs O
9 O
+/- O
4 O
cm3 O
/ O
m2 O
, O
p O
= O
0 O
. O
001 O
). O

RESULTS O
: O
Basal O
plasma I-GENE
IGF I-GENE
- I-GENE
I I-GENE
levels O
as O
well O
as O
body O
mass O
index O
( O
BMI O
) O
were O
lower O
in O
amenorrheic O
patients O
than O
in O
healthy O
controls O
. O

We O
observed O
abundant O
levels O
of O
Rev I-GENE
- O
erbA I-GENE
alpha I-GENE
mRNA O
in O
dividing O
C2C12 O
myoblasts O
, O
which O
were O
suppressed O
when O
the O
cells O
differentiated O
into O
postmitotic O
multinucleated O
myotubes O
. O

We O
then O
demonstrated O
that O
1 O
) O
GAL4 I-GENE
- O
REV I-GENE
- O
erbA I-GENE
alpha I-GENE
chimeras O
that O
contain O
the O
' O
AB O
' O
region O
and O
lack O
the O
' O
E O
' O
region O
activated O
transcription O
of O
GAL4 I-GENE
response I-GENE
elements I-GENE
in O
the O
presence O
of O
8 O
- O
Br O
- O
cAMP O
and O
2 O
) O
the O
ligand O
- O
binding O
domain O
( O
LBD O
) O
contains O
an O
active O
transcriptional O
silencer O
. O

The O
alpha O
T3 O
- O
1 O
cell O
line O
, O
a O
GnRH I-GENE
- O
responsive O
gonadotroph O
cell O
line O
developed O
by O
targeted O
oncogenesis O
in O
transgenic O
mice O
, O
was O
used O
to O
study O
regulation O
of O
the O
glycoprotein I-GENE
hormone I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
by O
activin I-GENE
. O

Cotransfection O
with O
the O
ie1 I-GENE
gene I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
the O
amount O
of O
the O
two O
enzymes O
expressed O
in O
the O
transfected O
cells O
. O

As O
expected O
, O
glycosylation O
of O
Env I-GENE
produced O
from O
mutants O
was O
affected O
but O
, O
irrespective O
of O
the O
glycosylation O
phenotype O
, O
( O
i O
) O
similar O
quantities O
of O
Env I-GENE
were O
synthesized O
, O
( O
ii O
) O
the O
immunoreactivity O
of O
V3 I-GENE
was O
similar O
, O
( O
iii O
) O
gp160 I-GENE
was O
efficiently O
cleaved O
into O
gp120 I-GENE
and O
gp41 I-GENE
, O
( O
vi O
) O
Env I-GENE
was O
exposed O
at O
the O
cell O
membrane O
, O
( O
v O
) O
secreted O
gp120 I-GENE
bound O
CD4 I-GENE
, O
and O
( O
vi O
) O
membrane O
gp41 I-GENE
was O
able O
to O
induce O
membrane O
fusion O
with O
CD4 I-GENE
+ I-GENE
cells O
. O

Effects O
of O
posteroventral O
pallidotomy O
on O
Parkinson O
' O
s O
disease O
. O

On O
the O
trail O
of O
Dr O
. O

However O
, O
only O
complete I-GENE
DnaJ I-GENE
can O
cooperate O
with O
DnaK I-GENE
and O
a O
third O
protein O
, O
GrpE I-GENE
, O
in O
refolding O
denatured I-GENE
firefly I-GENE
luciferase I-GENE
. O

The O
two O
different O
phosphoforms O
of O
STAT5 I-GENE
have O
identical O
in O
vitro O
DNA O
binding O
specificity O
and O
reactivity O
with O
tyrosine O
phosphopeptides O
, O
but O
differ O
in O
their O
cellular O
localization O
. O

TNF I-GENE
Treatment O
of O
cell O
activated O
the O
p38 I-GENE
MAP I-GENE
kinase I-GENE
pathway O
, O
as O
revealed O
by O
increased O
phosphorylation O
of O
p38 I-GENE
MAP I-GENE
kinase I-GENE
itself O
, O
activation O
of O
the O
substrate O
protein O
MAPKAP I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
, O
and O
culminating O
in O
the O
phosphorylation O
of O
the O
heat I-GENE
shock I-GENE
protein I-GENE
27 I-GENE
( O
hsp27 I-GENE
). O

We O
have O
isolated O
a O
novel O
protein O
from O
Drosophila O
nuclear O
extracts O
which O
binds O
specifically O
to O
a O
site O
in O
this O
second O
region O
. O

However O
, O
while O
the O
sequence O
similarity O
between O
the O
membrane O
exons O
of O
avian I-GENE
mIgY I-GENE
and O
mammalian I-GENE
mIgG I-GENE
and I-GENE
IgE I-GENE
is O
striking O
, O
the O
overall O
similarity O
with O
Xenopus I-GENE
mIgY I-GENE
is O
very O
low O
. O

Control O
of O
transcription O
of O
the O
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
an O
important O
determinant O
of O
receptor O
expression O
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility O
shift O
assays O
indicate O
that O
PBP I-GENE
binds O
to O
the O
half O
- O
site O
of O
each O
palindrome O
with O
the O
core O
recognition O
sequence O
TGGGAG O
. O

These O
results O
demonstrate O
that O
sequences O
in O
the O
SH2 I-GENE
/ O
SH3 I-GENE
/ O
SH2 I-GENE
region O
of O
p120 I-GENE
GAP I-GENE
are O
required O
for O
full O
catalytic O
activity O
toward O
Ras I-GENE
. O

The O
novel O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
FLT3 I-GENE
ligand I-GENE
( O
FL I-GENE
) O
is O
the O
cognate O
ligand O
for O
the O
FLT3 I-GENE
, O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
( O
R I-GENE
), O
also O
referred O
to O
as O
FLK I-GENE
- I-GENE
2 I-GENE
and O
STK I-GENE
- I-GENE
1 I-GENE
. O

In O
contrast O
to O
the O
selective O
expression O
of O
the O
receptor O
, O
FL I-GENE
expression O
was O
detected O
in O
90 O
- O
100 O
% O
of O
the O
various O
cell O
types O
of O
leukemia O
cell O
lines O
from O
all O
hematopoietic O
cell O
lineages O
. O

Further O
analysis O
of O
this O
domain O
by O
in O
vitro O
mutagenesis O
pointed O
to O
a O
core O
of O
hydrophobic O
and O
acidic O
residues O
as O
critical O
for O
the O
activity O
. O

Analysis O
of O
RAR I-GENE
alpha I-GENE
mutants I-GENE
in O
transfection O
studies O
reveals O
that O
the O
DNA O
binding O
domain O
is O
sufficient O
for O
inhibition O
of O
BZLF1 I-GENE
activity O
. O

We O
measured O
serum I-GENE
hepatocyte I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
in O
patients O
with O
acute O
myocardial O
infarction O
, O
angina O
pectoris O
, O
and O
other O
heart O
diseases O
. O

The O
neural O
mechanism O
of O
parkinsonian O
motor O
symptoms O
, O
i O
. O
e O
., O
rigidity O
, O
tremor O
and O
akinesia O
, O
which O
are O
the O
result O
of O
nigrostriatal O
dopamine O
deficiency O
, O
is O
interpreted O
from O
long O
- O
term O
observations O
on O
the O
effect O
of O
surgical O
and O
pharmacological O
treatment O
of O
the O
disease O
in O
relation O
to O
the O
neuropathological O
findings O
within O
the O
substantia O
nigra O
zona O
compacta O
( O
SNc O
). O

Protein O
splicing O
: O
evidence O
for O
an O
N O
- O
O O
acyl O
rearrangement O
as O
the O
initial O
step O
in O
the O
splicing O
process O
. O

In O
agreement O
with O
these O
data O
, O
western O
blot O
experiments O
using O
an O
antibody O
directed O
against O
the O
carboxy O
- O
terminal O
portion O
of O
the O
mouse O
c I-GENE
- I-GENE
kit I-GENE
protein I-GENE
showed O
that O
a O
polypeptide O
, O
of O
the O
size O
predicted O
by O
the O
open O
reading O
frame O
of O
the O
spermatid I-GENE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
kit I-GENE
cDNA I-GENE
, O
accumulates O
in O
the O
latest O
stages O
of O
spermatogenesis O
and O
in O
epididymal O
spermatozoa O
. O

It O
is O
shown O
that O
the O
( O
G O
+ O
C O
)- O
rich O
element O
of O
the O
aldolase I-GENE
C I-GENE
promoter I-GENE
directs O
transcription O
in O
neuronal O
as O
well O
as O
in O
nonneuronal O
cells O
. O

LY290181 O
appears O
to O
inhibit O
uPA I-GENE
promoter I-GENE
activation O
by O
blocking O
phorbol O
ester O
- O
stimulated O
binding O
of O
nuclear O
proteins O
to O
the O
uPA I-GENE
PEA3 I-GENE
/ O
12 O
- O
0 O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
responsive O
element O
( O
TRE O
). O

Treatment O
of O
keratinocytes O
expressing O
a O
normal O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
EGFR I-GENE
) O
with O
TGFalpha I-GENE
or O
epidermal I-GENE
growth I-GENE
factor I-GENE
for O
5 O
min O
induced O
PKCdelta I-GENE
tyrosine O
phosphorylation O
. O

Only O
one O
of O
these O
bands O
was O
supershifted O
by O
antibody O
to O
p50 I-GENE
, O
whereas O
antibodies O
to O
p65 I-GENE
or O
other O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
had O
no O
effect O
. O

We O
isolated O
a O
complementary O
DNA O
( O
cDNA O
) O
clone O
from O
an O
RL95 O
- O
2 O
expression O
library O
that O
encodes O
the O
C1 I-GENE
site I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Biol O
. O

In O
addition O
, O
anti I-GENE
- I-GENE
phosphotyrosine I-GENE
antibodies I-GENE
immunoprecipitated O
80K I-GENE
- I-GENE
H I-GENE
from O
cell O
lysates O
of O
FGF I-GENE
- O
stimulated O
but O
not O
from O
control O
fibroblasts O
. O

The O
novel O
protein O
kinases O
, O
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
JNKs I-GENE
)/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
, O
are O
also O
activated O
by O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
IL I-GENE
- I-GENE
1 I-GENE
, O
and O
CD28 I-GENE
costimulation O
. O

Thus O
, O
hGRbeta I-GENE
potentially O
functions O
as O
a O
dominant O
negative O
inhibitor O
of O
hGRalpha I-GENE
activity O
. O

Gas6 I-GENE
contains O
an O
NH2 O
- O
terminal O
Gla O
domain O
followed O
by O
four O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
and O
tandem O
globular O
( O
G O
) O
domains O
. O

Both O
P5CDh I-GENE
cDNA I-GENE
clones O
detect O
a O
single O
3 O
. O
2 O
- O
kb O
transcript O
on O
Northern O
blots O
of O
multiple O
human O
tissues O
, O
indicating O
the O
long O
cDNA O
containing O
the O
3 O
'- O
untranslated O
intron O
represents O
the O
predominant O
transcript O
. O

Polymerization O
of O
neurofilament I-GENE
L I-GENE
protein I-GENE
in O
vitro O
was O
inhibited O
by O
phosphorylation O
of O
neurofilament I-GENE
L I-GENE
protein I-GENE
by O
PKN I-GENE
. O

The O
protein O
folds O
correctly O
with O
two O
disulfide O
bonds O
and O
a O
free O
thiol O
group O
at O
Cys25 O
. O

We O
and O
others O
have O
demonstrated O
that O
the O
c I-GENE
- I-GENE
cbl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
is O
one O
of O
the O
earliest O
targets O
of O
tyrosine O
phosphorylation O
upon O
T I-GENE
cell I-GENE
receptor I-GENE
stimulation O
. O

A O
substantial O
fraction O
of O
Cbl I-GENE
was O
constitutively O
associated O
with O
Grb2 I-GENE
and O
this O
interaction O
was O
mediated O
by O
Grb2 I-GENE
SH3 I-GENE
domains O
. O

An O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sequence I-GENE
is O
essential O
for O
regulation O
of O
the O
human I-GENE
alpha2 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
( O
COL1A2 I-GENE
) O
promoter O
activity O
by O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
. O

No O
significant O
differences O
existed O
between O
the O
two O
age O
groups O
in O
baseline O
characteristics O
, O
including O
treatment O
protocol O
, O
performance O
status O
, O
and O
serum I-GENE
lactate I-GENE
dehydrogenase I-GENE
( O
LDH I-GENE
) O
level O
. O

Only O
two O
patients O
( O
0 O
. O
3 O
%) O
had O
a O
CA I-GENE
125 I-GENE
response O
at O
the O
time O
of O
clinical O
progression O
. O

The O
men O
self O
- O
selected O
a O
prescribed O
diet O
at O
home O
emphasizing O
saturated O
fat O
as O
the O
visible O
fat O
for O
1 O
week O
. O

Conversely O
, O
when O
VDR I-GENE
is O
overexpressed O
, O
vitamin O
D3 O
attenuates O
9 O
- O
cis O
RA O
induction O
from O
an O
RXR I-GENE
- O
responsive O
element O
. O

These O
results O
illuminate O
a O
hitherto O
unanticipated O
function O
of O
U6 I-GENE
RNA I-GENE
: O
the O
modulation O
of O
a O
phosphorylation O
- O
dephosphorylation O
cycle O
of O
C1 I-GENE
hnRNP I-GENE
protein I-GENE
that O
influences O
the O
binding O
affinity O
of O
this O
protein O
for O
pre O
- O
mRNA O
. O

Inclusion O
of O
the O
extended O
N O
terminus O
into O
the O
originally O
reported O
protein O
resulted O
in O
a O
striking O
similarity O
to O
the O
lymphoid I-GENE
factor I-GENE
Lef I-GENE
- I-GENE
1 I-GENE
. O

Truncated O
mammalian I-GENE
Notch1 I-GENE
activates O
CBF1 I-GENE
/ O
RBPJk I-GENE
- O
repressed O
genes O
by O
a O
mechanism O
resembling O
that O
of O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
EBNA2 I-GENE
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
using O
purified O
glucocorticoid I-GENE
receptor I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
( O
DBD O
) O
demonstrated O
that O
both O
GRE I-GENE
- I-GENE
2 I-GENE
and I-GENE
- I-GENE
3 I-GENE
motifs I-GENE
interact O
with O
DBD O
and O
oligonucleotide O
competition O
experiments O
established O
that O
these O
have O
different O
affinities O
for O
DBD O
. O

The O
large O
subfamily O
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
( O
RTKs I-GENE
) O
for O
which O
EPH I-GENE
is O
the O
prototype O
have O
likely O
roles O
in O
intercellular O
communication O
during O
normal O
mammalian O
development O
, O
but O
the O
biochemical O
signalling O
pathways O
utilised O
by O
this O
family O
are O
poorly O
characterised O
. O

The O
17 O
- O
kDa O
protein O
is O
required O
for O
the O
systemic O
infection O
of O
plants O
. O

We O
present O
here O
a O
detailed O
genomic O
sequencing O
analysis O
of O
the O
cytosine O
methylation O
patterns O
of O
the O
transposase I-GENE
binding O
sites O
within O
both O
Ac I-GENE
ends O
in O
the O
wx I-GENE
- I-GENE
m9 I-GENE
:: O
Ac I-GENE
allele I-GENE
, O
where O
Ac I-GENE
is O
inserted O
into O
the O
tenth O
exon O
of O
the O
Waxy I-GENE
gene I-GENE
. O

Krox I-GENE
- I-GENE
20 I-GENE
, O
a O
zinc I-GENE
finger I-GENE
gene I-GENE
, O
has O
a O
highly O
conserved O
pattern O
of O
expression O
in O
r3 O
and O
r5 O
and O
is O
functionally O
required O
for O
their O
maintenance O
in O
mouse O
embryos O
. O

Pituitary O
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
regulates O
prolactin I-GENE
promoter I-GENE
activity O
via O
a O
protein I-GENE
kinase I-GENE
A I-GENE
- O
mediated O
pathway O
that O
is O
independent O
of O
the O
transcriptional O
pathway O
employed O
by O
thyrotropin I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
. O

Clones O
33F O
and O
34B O
encoded O
identical O
aromatase I-GENE
proteins I-GENE
of O
503 O
amino O
acids O
, O
but O
differed O
in O
size O
due O
to O
alternative O
polyadenylation O
signal O
usage O
for O
the O
corresponding O
mRNAs O
. O

In O
sorted O
bone O
marrow O
cells O
expression O
of O
both O
VpreB I-GENE
genes I-GENE
was O
detected O
in O
pro O
- O
B O
/ O
pre O
- O
BI O
and O
large O
pre O
- O
BII O
cells O
, O
while O
the O
RNA O
steady O
state O
levels O
were O
at O
least O
100 O
- O
fold O
lower O
in O
small O
pre O
- O
BII O
and O
immature O
/ O
mature O
B O
cells O
. O

We O
have O
cloned O
and O
sequenced O
a O
3574 O
- O
bp O
Bacillus O
subtilis O
( O
Bs O
) O
DNA O
fragment O
located O
between O
the O
nrdA I-GENE
and O
citB I-GENE
genes I-GENE
at O
about O
169 O
degrees O
on O
the O
chromosome O
. O

Aeromonas O
salmonicida O
possesses O
two O
genes O
encoding O
homologs O
of O
the O
major I-GENE
outer I-GENE
membrane I-GENE
protein I-GENE
, O
OmpA I-GENE
. O

Expression O
of O
Msp I-GENE
was O
toxic O
to O
E O
. O
coli O
when O
the O
entire O
msp I-GENE
gene I-GENE
was O
present O
. O

In O
agreement O
with O
previous O
in O
vitro O
data O
, O
we O
have O
shown O
that O
UmuD I-GENE
and O
UmuD I-GENE
' I-GENE
are O
able O
to O
form O
both O
homodimers O
( O
UmuD I-GENE
- O
UmuD I-GENE
and O
UmuD O
'- O
UmuD O
') O
and O
a O
heterodimer O
( O
UmuD I-GENE
- O
UmuD O
'). O

Lyn I-GENE
kinase I-GENE
immunoprecipitated O
from O
lysates O
of O
irradiated O
BCP O
as O
well O
as O
a O
full O
- O
length O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- O
Lyn I-GENE
fusion O
protein O
- O
phosphorylated O
recombinant I-GENE
human I-GENE
p34cdc2 I-GENE
on O
tyrosine O
15 O
. O

Mutations O
within O
conserved O
region O
2 O
( O
CR2 O
) O
of O
E1A I-GENE
that O
inhibit O
the O
binding O
of O
E1A I-GENE
to O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
( O
pRb I-GENE
) O
further O
enhanced O
the O
stimulation O
of O
transcription O
from O
the O
PEPCK I-GENE
promoter I-GENE
by O
2 O
3 O
- O
fold O
compared O
with O
wild I-GENE
type I-GENE
E1A I-GENE
. O

Using O
autoantibodies O
from O
a O
Sjogren O
' O
s O
syndrome O
patient O
, O
we O
have O
previously O
identified O
a O
230 O
- O
kDa O
peripheral O
membrane O
protein O
associated O
with O
the O
cytosolic O
face O
of O
the O
trans O
- O
Golgi O
( O
Kooy O
, O
J O
., O
Toh O
, O
B O
. O

Apart O
from O
two O
proline O
- O
rich O
regions O
( O
amino O
acids O
1 O
- O
117 O
and O
239 O
- O
270 O
), O
p230 I-GENE
contains O
a O
very O
high O
frequency O
of O
heptad O
repeats O
, O
characteristic O
of O
alpha O
- O
helices O
that O
form O
dimeric O
coiled O
- O
coil O
structures O
. O
p230 I-GENE
also O
includes O
the O
sequence O
ESLALEELEL O
( O
amino O
acids O
538 O
- O
546 O
), O
a O
motif O
found O
in O
the O
granin I-GENE
family I-GENE
of O
acidic O
proteins O
present O
in O
secretory O
granules O
of O
neuroendocrine O
cells O
. O

Binding O
specificity O
and O
modulation O
of O
the O
ApoA I-GENE
- I-GENE
I I-GENE
promoter I-GENE
activity O
by O
homo O
- O
and O
heterodimers O
of O
nuclear O
receptors O
. O

They O
were O
found O
to O
stimulate O
at O
nanomolar O
concentrations O
the O
turnover O
of O
biosynthetically O
labeled O
ceramide O
, O
glucosylceramide O
, O
and O
lactosylceramide O
. O

There O
is O
growing O
evidence O
that O
mammalian I-GENE
AMP I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
AMPK I-GENE
) O
plays O
a O
role O
in O
protecting O
cells O
from O
stresses O
that O
cause O
ATP O
depletion O
by O
switching O
off O
ATP O
- O
consuming O
biosynthetic O
pathways O
. O

Sterol O
- O
mediated O
suppression O
of O
cleavage O
of O
SREBP I-GENE
- I-GENE
1 I-GENE
was O
found O
to O
be O
dependent O
on O
the O
extreme O
COOH O
- O
terminal O
region O
( O
residue O
1034 O
to O
the O
COOH O
terminus O
), O
which O
exists O
in O
two O
forms O
as O
a O
result O
of O
alternative O
splicing O
. O

Am O
. O

EMSA O
competition O
experiments O
showed O
that O
mutations O
within O
the O
direct O
repeats O
failed O
to O
compete O
for O
binding O
of O
the O
nuclear O
proteins O
to O
labeled O
wild O
type O
oligonucleotide O
. O

Transcription O
from O
the O
promoter O
containing O
the O
mutated O
direct O
repeats O
was O
increased O
greatly O
, O
consistent O
with O
the O
conclusion O
that O
these O
motifs O
functions O
in O
vivo O
to O
repress O
GPT I-GENE
gene I-GENE
expression O
. O

However O
, O
a O
> O
10 O
- O
fold O
increase O
in O
ERK3 I-GENE
activity O
in O
each O
PKC I-GENE
beta I-GENE
transfectant O
was O
shown O
by O
immunoprecipitation O
with O
anti I-GENE
- I-GENE
ERK3 I-GENE
monoclonal I-GENE
antibody I-GENE
followed O
by O
either O
immune O
complex O
kinase O
assay O
or O
by O
in O
gel O
kinase O
assay O
. O

Sequence O
analysis O
of O
this O
100 O
- O
bp O
Col2a1 I-GENE
enhancer I-GENE
revealed O
several O
sequence O
motifs O
similar O
to O
motifs O
present O
within O
the O
regulatory O
region O
of O
the O
link I-GENE
protein I-GENE
gene I-GENE
, O
another O
cartilage O
gene O
. O

Retinoid O
- O
dependent O
activation O
of O
the O
tissue I-GENE
transglutaminase I-GENE
promoter I-GENE
depends O
on O
both O
a O
proximal O
regulatory O
region O
containing O
sequences O
highly O
conserved O
between O
the O
human O
and O
the O
mouse I-GENE
tissue I-GENE
transglutaminase I-GENE
promoters I-GENE
and O
a O
distal O
region O
that O
includes O
a O
30 O
- O
base O
pair O
retinoid O
response O
element O
( O
mTGRRE1 O
). O
mTGRRE1 O
contains O
three O
hexanucleotide O
half O
- O
sites O
( O
two O
canonical O
and O
one O
non O
- O
canonical O
) O
in O
a O
DR7 I-GENE
/ O
DR5 I-GENE
motif O
that O
bind O
both O
RAR I-GENE
* O
RXR I-GENE
heterodimers O
and O
RXR I-GENE
homodimers I-GENE
. O

Significantly O
, O
pPKR I-GENE
is O
capable O
of O
specifically O
phosphorylating O
Ser51 O
in O
a O
synthetic I-GENE
eIF I-GENE
- I-GENE
2alpha I-GENE
peptide I-GENE
, O
a O
key O
characteristic O
of O
the O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase I-GENE
family I-GENE
. O

Vertebrate I-GENE
synapsins I-GENE
constitute O
a O
family O
of O
synaptic O
proteins O
that O
participate O
in O
the O
regulation O
of O
neurotransmitter O
release O
. O

Electrophoretic O
mobility O
shift O
assays O
using O
crude O
extracts O
from O
FREJ4 O
cells O
revealed O
the O
binding O
of O
a O
member O
( O
s O
) O
of O
the O
Ets I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
to O
the O
P4 I-GENE
EBS I-GENE
, O
as O
well O
as O
the O
interaction O
of O
two O
members O
of O
the O
Sp1 I-GENE
family I-GENE
, O
Sp1 I-GENE
and O
Sp3 I-GENE
, O
with O
the O
adjacent O
GC O
box O
. O

ZEBRA I-GENE
and O
cellular O
AP I-GENE
- I-GENE
1 I-GENE
bZip I-GENE
activators I-GENE
, O
such O
as O
c I-GENE
- I-GENE
Fos I-GENE
, O
have O
homologous O
DNA O
- O
binding O
domains O
, O
and O
their O
DNA O
- O
binding O
specificities O
overlap O
. O

This O
result O
suggested O
that O
mutant O
I299 O
has O
diminished O
cap O
- O
binding O
activity O
. O

UV O
cross O
- O
linking O
experiments O
demonstrated O
that O
HSV O
infection O
caused O
enhanced O
binding O
of O
protein O
factors O
, O
including O
the O
64 I-GENE
- I-GENE
kDa I-GENE
component I-GENE
of I-GENE
cleavage I-GENE
stimulation I-GENE
factor I-GENE
( O
CstF I-GENE
), O
to O
poly O
( O
A O
) O
site O
RNAs O
from O
virus O
genes O
of O
all O
temporal O
classes O
and O
that O
this O
enhanced O
binding O
required O
expression O
of O
IE63 I-GENE
. O

CM I-GENE
- I-GENE
ACO3 I-GENE
is O
expressed O
in O
flowers O
and O
is O
not O
induced O
by O
any O
of O
the O
stimuli O
tested O
. O

We O
show O
here O
that O
these O
Jun I-GENE
/ O
eb1 I-GENE
chimeras O
are O
potent O
transactivators O
of O
AP1 I-GENE
sites I-GENE
and O
that O
they O
can O
cooperate O
with O
c I-GENE
- I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
to O
induce O
foci O
. O

In O
synchronized O
HeLa O
cells O
, O
expression O
of O
luciferase I-GENE
activity O
was O
induced O
at O
the O
beginning O
of O
DNA O
synthesis O
and O
was O
dependent O
on O
the O
presence O
of O
an O
E2F I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
H2A I-GENE
. I-GENE
1 I-GENE
promoter I-GENE
. O

Utilizing O
transient O
transfection O
studies O
in O
HepG2 O
cells O
, O
we O
have O
shown O
that O
deletion O
of O
the O
factor I-GENE
VIII I-GENE
promoter I-GENE
sequences I-GENE
distal O
to O
nucleotide O
- O
44 O
results O
in O
a O
significant O
but O
small O
increase O
in O
promoter O
activity O
. O

We O
constructed O
a O
yeast O
reporter O
strain O
containing O
the O
lacZ I-GENE
gene I-GENE
under O
the O
control O
of O
the O
CYC1 I-GENE
promoter I-GENE
associated O
with O
three O
copies O
of O
TRE I-GENE
- I-GENE
1 I-GENE
. O

If O
hnRNP I-GENE
K I-GENE
is O
a O
transcription O
factor O
, O
then O
interactions O
with O
the O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcription O
apparatus O
are O
predicted O
. O

A O
developmentally O
regulated O
4 O
. O
6 O
kb O
mRNA O
is O
recognized O
on O
Northern O
blots O
of O
oocyte O
RNA O
using O
the O
X O
. O
laevis O
cDNA O
. O

Sequence O
conservation O
is O
greatest O
for O
residues O
located O
near O
the O
active O
centers O
of O
the O
exo I-GENE
and O
pol I-GENE
domains I-GENE
of O
the O
E I-GENE
. I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
structure O
. O

Despite O
the O
favourable O
natural O
history O
of O
acute O
BI O
, O
mild O
, O
moderate O
, O
and O
severe O
posttraumatic O
changes O
were O
shown O
to O
appear O
as O
cicatricial O
- O
adhesive O
and O
atrophic O
processes O
, O
intracerebral O
cysts O
, O
porencephaly O
, O
which O
result O
in O
posttraumatic O
epilepsy O
, O
hydrocephalus O
, O
etc O
. O

These O
findings O
suggest O
that O
the O
increase O
in O
V O
O2 O
may O
have O
been O
a O
consequence O
of O
the O
increase O
in O
Q O
O2 O
rather O
than O
a O
response O
to O
the O
procedure O
itself O
. O

Several O
cytokines O
exhibit O
a O
high O
degree O
of O
temporal O
regulation O
as O
well O
as O
somnogenic O
potency O
( O
e O
. O
g O
., O
interleukin I-GENE
- I-GENE
1 I-GENE
[ O
IL I-GENE
- I-GENE
1 I-GENE
], O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
[ O
TNF I-GENE
- I-GENE
alpha I-GENE
]). O

As O
pH O
and O
Hb I-GENE
can O
also O
affect O
mixed O
venous O
CO2 O
content O
, O
the O
effect O
on O
Q O
was O
also O
assessed O
. O

No O
difference O
in O
elastin I-GENE
peptide I-GENE
concentration O
was O
observed O
between O
emphysematous O
patients O
and O
control O
subjects O
( O
mean O
+/- O
SD O
= O
2 O
. O
39 O
+/- O
1 O
. O
18 O
micrograms O
/ O
ml O
in O
patients O
versus O
2 O
. O
55 O
+/- O
1 O
. O
34 O
micrograms O
/ O
ml O
in O
policemen O
and O
2 O
. O
59 O
+/- O
1 O
. O
20 O
micrograms O
/ O
ml O
in O
coal O
miners O
). O

Identification O
of O
this O
region O
as O
the O
E I-GENE
. I-GENE
coli I-GENE
tmk I-GENE
gene I-GENE
was O
confirmed O
by O
functional O
complementation O
of O
a O
yeast I-GENE
dTMP I-GENE
kinase I-GENE
temperature O
- O
sensitive O
mutant O
and O
by O
in O
vitro O
enzyme O
assay O
of O
the O
thymidylate I-GENE
kinase I-GENE
activity O
in O
cell O
extracts O
of O
E O
. O
coli O
by O
use O
of O
tmk I-GENE
- O
overproducing O
plasmids O
. O

The O
structural O
gene O
for O
copper I-GENE
- I-GENE
and I-GENE
topa I-GENE
quinone I-GENE
- I-GENE
containing I-GENE
monoamine I-GENE
oxidase I-GENE
( O
maoA I-GENE
) O
and O
an O
unknown O
amine I-GENE
oxidase I-GENE
gene I-GENE
have O
been O
located O
at O
30 O
. O
9 O
min O
on O
the O
Escherichia O
coli O
chromosome O
. O

This O
interaction O
is O
mediated O
by O
the O
SH2 I-GENE
domain I-GENE
of O
Crk I-GENE
and O
can O
be O
inhibited O
with O
a O
phosphopeptide O
containing O
the O
Crk I-GENE
- O
SH2 I-GENE
binding O
motif O
. O

Consistent O
with O
ErbB I-GENE
- I-GENE
2 I-GENE
being O
a O
shared O
receptor O
subunit O
, O
its O
tyrosine O
phosphorylation O
was O
increased O
by O
both O
heterologous O
ligands O
and O
it O
mediated O
a O
trans O
- O
inhibitory O
effect O
of O
NDF I-GENE
on O
EGF I-GENE
binding O
. O

Identification O
of O
a O
consensus O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
phosphorylation I-GENE
site I-GENE
unique O
to O
the O
nuclear O
form O
of O
human I-GENE
deoxyuridine I-GENE
triphosphate I-GENE
nucleotidohydrolase I-GENE
. O

The O
cDNA O
corresponding O
to O
the O
FPS1 I-GENE
gene I-GENE
was O
isolated O
by O
functional O
complementation O
of O
a O
mutant O
yeast O
strain O
defective O
in O
FPS I-GENE
activity O
( O
Delourme O
, O
D O
., O
Lacroute O
, O
F O
., O
and O
Karst O
, O
F O
. O

The O
isolated O
plasmin I-GENE
fragments O
of O
VEGF I-GENE
were O
compared O
with O
respect O
to O
heparin O
binding O
, O
interaction O
with O
soluble O
VEGF I-GENE
receptors I-GENE
, O
and O
ability O
to O
promote O
endothelial O
cell O
mitogenesis O
. O

VDR I-GENE
/ O
RXR I-GENE
bound O
well O
to O
the O
VDREs O
and O
to O
DR4 O
and O
DR5 O
using O
the O
electrophoretic O
mobility O
shift O
assay O
. O

The O
members O
of O
the O
Myb I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
are O
defined O
by O
homology O
in O
the O
DNA O
- O
binding O
domain O
; O
all O
bind O
the O
Myb I-GENE
- I-GENE
binding I-GENE
site I-GENE
( O
MBS I-GENE
) O
sequence O
( O
YG O
( O
A O
/ O
G O
) O
C O
( O
A O
/ O
C O
/ O
G O
) O
GTT O
( O
G O
/ O
A O
)). O

In O
contrast O
, O
when O
the O
isoform O
containing O
the O
C O
epsilon4 O
domain O
joined O
directly O
to O
the O
M2 O
exon O
( O
IgE I-GENE
grande I-GENE
) O
is O
expressed O
in O
the O
J558L O
cell O
line O
, O
it O
is O
degraded O
intracellularly O
, O
suggesting O
a O
cell O
line O
- O
dependent O
regulation O
of O
secretion O
. O

Human I-GENE
cytomegalovirus I-GENE
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 I-GENE
tethers O
a O
transcriptional O
repression O
domain O
to O
p53 I-GENE
. O

The O
specificity O
of O
action O
of O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
members I-GENE
may O
be O
derived O
from O
the O
characteristics O
of O
each O
factor O
, O
including O
the O
expression O
profiles O
, O
the O
DNA O
binding O
affinities O
, O
the O
cofactors O
, O
and O
so O
on O
, O
in O
addition O
to O
the O
DNA O
binding O
specificities O
. O

The O
antibodies O
inhibited O
specifically O
the O
transcription O
of O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
promoter O
in O
vitro O
. O

Immunocytochemical O
analysis O
demonstrated O
the O
presence O
of O
DREF I-GENE
polypeptide I-GENE
in O
nuclei O
after O
the O
eighth O
nuclear O
division O
cycle O
, O
suggesting O
that O
nuclear O
accumulation O
of O
DREF I-GENE
is O
important O
for O
the O
coordinate O
zygotic O
expression O
of O
DNA O
replication O
- O
related O
genes O
carrying O
DRE O
sequences O
. O

A O
DNA O
fragment O
carrying O
1 O
, O
100 O
nucleotides O
derived O
from O
the O
5 O
'- O
flanking O
region O
of O
the O
UGT1A1 I-GENE
gene I-GENE
was O
enough O
for O
MC O
induction O
. O

This O
result O
supports O
the O
argument O
that O
the O
beta O
' O
subunit O
plays O
an O
essential O
role O
in O
determining O
the O
progress O
of O
transcription O
elongation O
. O

Two O
XPG I-GENE
regions I-GENE
with O
putative O
NLS O
[ O
amino O
acid O
( O
AA O
) O
coordinates O
: O
NLS O
- O
B O
( O
AA O
1057 O
- O
1074 O
) O
and O
NLS O
- O
C O
( O
AA O
1171 O
- O
1185 O
)] O
were O
each O
shown O
to O
independently O
localize O
the O
beta I-GENE
- I-GENE
gal I-GENE
extensively O
(> O
80 O
%) O
to O
the O
nucleus O
of O
HeLa O
cells O
. O

The O
lacS I-GENE
gene I-GENE
was O
cloned O
in O
an O
E O
. O
coli O
- O
Streptococcus O
shuttle O
vector O
and O
was O
expressed O
both O
in O
a O
lacS I-GENE
deletion O
derivative O
of O
S O
. O
thermophilus O
and O
in O
a O
pNZ63 O
- O
cured O
strain O
, O
L O
. O
lactis O
NZ6091 O
. O

The O
genome O
of O
all O
retroviruses O
consists O
of O
two O
identical O
RNAs O
noncovalently O
linked O
near O
their O
5 O
' O
end O
. O

The O
extraction O
recovery O
of O
Amphotericin O
B O
from O
the O
cerebrospinal O
fluid O
is O
higher O
than O
90 O
% O
over O
the O
entire O
linear O
range O
. O

HuEpo I-GENE
- I-GENE
R I-GENE
Ab I-GENE
inhibited O
Epo I-GENE
- O
induced O
parental O
UT O
- O
7 O
cell O
growth O
, O
but O
not O
that O
of O
cells O
of O
clone O
12 O
, O
suggesting O
that O
the O
muEpo I-GENE
- I-GENE
R I-GENE
is O
able O
to O
induce O
human O
UT O
- O
7 O
cell O
proliferation O
. O

The O
frequency O
of O
integrations O
that O
led O
to O
transcription O
of O
the O
lacZ I-GENE
gene I-GENE
was O
estimated O
to O
be O
0 O
. O
5 O
% O
of O
all O
integrations O
, O
of O
which O
14 O
% O
were O
downregulated O
on O
differentiation O
of O
32D O
cells O
towards O
neutrophils O
. O

The O
sequence O
and O
isolated O
cDNAs O
will O
provide O
useful O
reagents O
for O
studying O
the O
expression O
of O
Brca1 I-GENE
in O
the O
mouse O
, O
and O
for O
testing O
the O
importance O
of O
the O
evolutionarily O
conserved O
domains O
. O

A O
study O
was O
performed O
to O
compare O
the O
ONLINE O
and O
EMIT O
II O
immunoassays O
with O
gas O
chromatographic O
/ O
mass O
spectrometric O
( O
GC O
/ O
MS O
) O
analysis O
of O
methaqualone O
metabolites O
on O
urine O
using O
samples O
obtained O
from O
a O
clinical O
study O
. O

Interaction O
of O
the O
Fur I-GENE
repressor I-GENE
with O
a O
150 O
- O
bp O
fragment O
encompassing O
the O
pvdS I-GENE
promoter I-GENE
was O
demonstrated O
in O
vivo O
by O
the O
Fur I-GENE
titration O
assay O
and O
confirmed O
in O
vitro O
by O
gel O
retardation O
experiments O
with O
a O
partially O
purified O
Fur I-GENE
preparation O
. O

This O
protein O
encoded O
by O
this O
cDNA O
, O
which O
we O
have O
termed O
p150TSP I-GENE
( O
for O
TPR O
- O
containing O
, O
SH2 I-GENE
- I-GENE
binding I-GENE
phosphoprotein I-GENE
), O
is O
located O
predominantly O
in O
the O
nucleus O
and O
is O
highly O
conserved O
in O
evolution O
. O

Both O
mutant O
receptors O
were O
expressed O
on O
the O
cell O
surface O
and O
bound O
insulin I-GENE
normally O
, O
but O
showed O
markedly O
impaired O
autophosphorylation O
in O
response O
to O
insulin I-GENE
. O

EMBO O
J O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
thrombin I-GENE
- O
stimulated O
vascular O
smooth O
muscle O
proliferation O
is O
delayed O
and O
requires O
the O
de O
novo O
expression O
of O
one O
or O
more O
autocrine O
mitogens O
. O

Transcription O
from O
adenovirus I-GENE
E2 I-GENE
- I-GENE
early I-GENE
promoter I-GENE
is O
controlled O
by O
a O
unique O
array O
of O
four O
cis O
- O
acting O
elements O
which O
include O
an O
atypical O
TBP I-GENE
site I-GENE
, O
two O
E2F I-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
relative O
to O
each O
other O
, O
and O
an O
ATF I-GENE
site I-GENE
. O

Furthermore O
, O
we O
showed O
that O
the O
IL I-GENE
- I-GENE
6 I-GENE
/ O
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
gamma I-GENE
) O
response O
element O
in O
the O
IRF I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
( O
IR I-GENE
/ O
IRF I-GENE
- I-GENE
1 I-GENE
), O
which O
contains O
a O
Stat I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
an O
adjacent O
CRE O
- O
like O
site O
, O
also O
makes O
IL I-GENE
- I-GENE
6 I-GENE
- O
induced O
binding O
complexes O
similar O
to O
JRE O
- O
IL6 I-GENE
- O
BCs O
. O

A O
second O
peptide O
( O
amino O
acids O
58 O
- O
77 O
) O
also O
antagonized O
p21 I-GENE
- O
activity O
, O
but O
this O
peptide O
did O
not O
affect O
the O
ability O
of O
p21 I-GENE
to O
interact O
with O
cyclin I-GENE
E I-GENE
/ O
Cdk2 I-GENE
. O

A O
p21 I-GENE
peptide I-GENE
spanning O
amino O
acids O
139 O
- O
164 O
was O
found O
to O
bind O
PCNA I-GENE
in O
a O
filter O
binding O
assay O
and O
this O
peptide O
suppressed O
recombinant O
p21 I-GENE
- O
PCNA I-GENE
interaction O
. O

Results O
were O
supported O
by O
the O
agar O
diffusion O
method O
for O
Y O
. O
enterocolitica O
, O
whereas O
inhibition O
activity O
was O
not O
found O
for O
A O
. O
hydrophila O
. O

OND O
8 O
mg O
tid O
days O
2 O
- O
3 O
, O
and O
8 O
mg O
tid O
prn O
days O
4 O
- O
5 O
and O
prednisolone O
75 O
- O
100 O
mg O
qds O
days O
2 O
- O
5 O
and O
2 O
) O
MCP O
30 O
mg O
/ O
metylprednisolone O
80 O
mg O
i O
. O
v O
. O
before O
CT O
and O
MCP O
20 O
mg O
p O
. O
r O
. O
after O
4 O
and O
8 O
h O
respectively O
. O

The O
dynamic O
properties O
of O
this O
protein O
fragment O
were O
measured O
and O
analyzed O
using O
both O
isotropic O
and O
anisotropic O
models O
of O
molecular O
motion O
. O

Adduction O
of O
the O
human I-GENE
N I-GENE
- I-GENE
ras I-GENE
codon I-GENE
61 I-GENE
sequence I-GENE
with O
(-)-( O
7S O
, O
8R O
, O
9R O
, O
10S O
)- O
7 O
, O
8 O
- O
dihydroxy O
- O
9 O
, O
10 O
- O
epoxy O
- O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
tetrahydrobenzo O
[ O
a O
] O
pyrene O
: O
structural O
refinement O
of O
the O
intercalated O
SRSR O
( O
61 O
, O
2 O
) O
(-)-( O
7S O
, O
8R O
, O
9S O
, O
10R O
)- O
N6 O
-[ O
10 O
-( O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
tetrahydrobenzo O
[ O
a O
] O
pyrenyl O
)]- O
2 O
'- O
deoxyadenosyl O
adduct O
from O
1H O
NMR O
. O

Isolation O
by O
PCR O
of O
a O
cDNA O
clone O
from O
pea O
petals O
with O
similarity O
to O
petunia O
and O
wheat I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

This O
fragment O
can O
bind O
several O
trans O
- O
acting O
factors O
in O
vitro O
, O
including O
GATA I-GENE
- I-GENE
1 I-GENE
and O
members O
of O
the O
Ets I-GENE
family I-GENE
. O

Exposure O
of O
peripheral O
blood O
T O
cells O
from O
young O
subjects O
to O
PHA I-GENE
or O
cross O
- O
linked O
anti I-GENE
- I-GENE
CD3 I-GENE
monoclonal I-GENE
antibodies I-GENE
stimulated O
rapid O
increases O
in O
MAPK I-GENE
and O
MEK I-GENE
enzymatic O
activity O
. O

These O
different O
observations O
exclude O
a O
heterozygosity O
of O
the O
A O
--> O
G O
mutation O
at O
codon O
beta O
77 O
, O
as O
well O
as O
a O
deletion O
comparable O
to O
that O
of O
Hbs I-GENE
Lepore I-GENE
or I-GENE
Kenya I-GENE
, O
or O
a O
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
duplication O
, O
and O
point O
to O
a O
nontraditional O
inheritance O
of O
Hb I-GENE
Costa I-GENE
Rica I-GENE
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory O
elements O
that O
control O
expression O
of O
a O
gene O
encoding O
a O
B7 I-GENE
costimulatory I-GENE
molecule I-GENE
. O

DNA I-GENE
- I-GENE
STAT I-GENE
complexes I-GENE
were O
detected O
in O
all O
Bcr I-GENE
/ O
Abl I-GENE
- O
transformed O
cell O
lines O
and O
they O
were O
supershifted O
by O
antibodies O
against O
STAT1 I-GENE
and O
STAT5 I-GENE
. O

When O
overexpressed O
in O
an O
appropriate O
cell O
line O
, O
TAN I-GENE
- I-GENE
1C I-GENE
prevented O
kappa I-GENE
B I-GENE
- O
dependent O
transactivation O
in O
transient O
reporter O
gene O
assays O
in O
a O
fashion O
similar O
to O
the O
structurally O
related O
protein O
, O
Bcl I-GENE
- I-GENE
3 I-GENE
. O

T O
cell O
leukemia O
- O
associated O
human O
Notch I-GENE
/ O
translocation O
- O
associated O
Notch I-GENE
homologue O
has O
I I-GENE
kappa I-GENE
B I-GENE
- O
like O
activity O
and O
physically O
interacts O
with O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B I-GENE
proteins O
in O
T O
cells O
. O

Polyprotein O
processing O
in O
Southampton O
virus O
: O
identification O
of O
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
cleavage O
sites O
by O
in O
vitro O
mutagenesis O
. O

The O
humanized I-GENE
LL2 I-GENE
( O
hLL2 I-GENE
), O
lacking O
light I-GENE
chain I-GENE
variable I-GENE
region I-GENE
glycosylation O
, O
exhibited O
immunoreactivities O
that O
were O
comparable O
to O
that O
of O
chimeric I-GENE
LL2 I-GENE
( O
cLL2 I-GENE
), O
which O
was O
shown O
previously O
to O
have O
antigen O
- O
binding O
properties O
similar O
to O
its O
murine O
counterpart O
, O
suggesting O
that O
the O
VK O
- O
appended O
oligosaccharides O
found O
in O
mLL2 I-GENE
are O
not O
necessary O
for O
antigen O
binding O
. O

An O
apparent O
N O
- O
terminal O
transit O
peptide O
in O
the O
coding O
region O
and O
a O
3 O
' O
poly O
( O
A O
) O
tail O
exist O
in O
the O
cDNA O
clone O
indicated O
that O
this O
chloroplast O
protein O
as O
nuclear O
encoded O
. O

Deletion O
analysis O
of O
rOC I-GENE
promoter I-GENE
- O
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs O
demonstrates O
that O
an O
AML I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
within O
the O
proximal O
promoter O
(- O
138 O
to O
- O
130 O
nt O
) O
contributes O
to O
75 O
% O
of O
the O
level O
of O
osteocalcin I-GENE
gene I-GENE
expression O
. O

Thus O
, O
a O
critical O
question O
is O
how O
HOX I-GENE
proteins I-GENE
select O
the O
correct O
sets O
of O
target O
genes O
in O
vivo O
. O

RAS2val19 I-GENE
, O
a O
dominant O
activated O
form O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
Ras2 I-GENE
, O
stimulates O
both O
filamentous O
growth O
and O
expression O
of O
a O
transcriptional O
reporter O
FG I-GENE
( O
TyA I-GENE
):: O
lacZ I-GENE
but O
does O
not O
induce O
the O
mating I-GENE
pathway I-GENE
reporter I-GENE
FUS1 I-GENE
:: O
lacZ I-GENE
. O

Moreover O
, O
the O
Rho I-GENE
family I-GENE
protein I-GENE
Cdc42 I-GENE
, O
a O
conserved O
morphogenetic I-GENE
G I-GENE
protein I-GENE
, O
is O
also O
a O
potent O
regulator O
of O
filamentous O
growth O
and O
FG I-GENE
( O
TyA I-GENE
):: O
lacZ I-GENE
expression O
in O
S O
. O
cerevisiae O
. O

Each O
immunoprecipitate O
contained O
a O
complex O
of O
N1 I-GENE
( I-GENE
deltaEC I-GENE
) I-GENE
and O
CBF1 I-GENE
. O

This O
region O
includes O
verA I-GENE
, O
a O
structural O
gene O
previously O
shown O
to O
be O
required O
for O
ST O
biosynthesis O
, O
and O
24 O
additional O
closely O
spaced O
transcripts O
ranging O
in O
size O
from O
0 O
. O
6 O
to O
7 O
. O
2 O
kb O
that O
are O
coordinately O
induced O
only O
under O
ST O
- O
producing O
conditions O
. O

Subcellular O
localizations O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
CBFbeta I-GENE
and O
the O
CBFbeta I-GENE
- O
SMMHC I-GENE
fusion O
protein O
were O
determined O
by O
immunofluorescence O
of O
NIH O
3T3 O
cells O
that O
overexpress O
wild O
- O
type O
or O
fusion O
protein O
. O

Menstrual O
- O
cycle O
phase O
did O
not O
significantly O
affect O
personality O
variables O
in O
either O
group O
. O

We O
report O
the O
isolation O
of O
human O
cDNAs O
homologous O
to O
the O
Drosophila I-GENE
dishevelled I-GENE
( O
dsh I-GENE
) O
segment O
- O
polarity O
gene O
. O

Escherichia O
coli O
BL21 O
( O
DE3 O
) O
plysS O
, O
harbouring O
a O
recombinant O
plasmid O
containing O
the O
catalase I-GENE
- O
peroxidase I-GENE
gene O
, O
produced O
a O
large O
amount O
of O
proteins O
that O
co O
- O
migrated O
on O
SDS O
/ O
PAGE O
with O
the O
native O
enzyme O
. O

Ca2 O
+ O
decreased O
Zn2 O
+ O
binding O
in O
S100 I-GENE
beta I-GENE
but O
it O
did O
not O
influence O
binding O
to O
MRP14 I-GENE
, O
suggesting O
that O
the O
Zn2 O
+ O
binding O
site O
was O
distinct O
from O
and O
independent O
of O
the O
two O
Ca2 O
+ O
binding O
domains O
. O

Cdk2 I-GENE
formed O
a O
complex O
with O
cyclin I-GENE
D1 I-GENE
in O
this O
system O
. O

The O
Cdk2 I-GENE
- O
cyclin I-GENE
- I-GENE
D1 I-GENE
complex O
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 I-GENE
histone I-GENE
, O
pRB I-GENE
, O
SV40 I-GENE
large I-GENE
T I-GENE
antigen I-GENE
, O
p53 I-GENE
, O
E2F I-GENE
- I-GENE
1 I-GENE
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 I-GENE
- O
cyclin I-GENE
- I-GENE
E I-GENE
and O
Cdk2 I-GENE
- O
cyclin I-GENE
- I-GENE
A I-GENE
phosphorylated O
these O
proteins O
. O

Cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
( O
Cdk2 I-GENE
) O
forms O
an O
inactive O
complex O
with O
cyclin I-GENE
D1 I-GENE
since O
Cdk2 I-GENE
associated O
with O
cyclin I-GENE
D1 I-GENE
is O
not O
phosphorylated O
by O
Cdk7 I-GENE
- O
cyclin I-GENE
- I-GENE
H I-GENE
. O

Two O
overlapping O
clones O
contained O
the O
complete O
Adh I-GENE
- I-GENE
2 I-GENE
gene I-GENE
composed O
of O
nine O
exons O
in O
a O
12 O
- O
kb O
region O
, O
with O
the O
placement O
of O
introns O
matching O
that O
observed O
in O
other O
mammalian I-GENE
ADH I-GENE
genes I-GENE
. O

Ligation O
of O
CD40 I-GENE
rescues O
Ramos O
- O
Burkitt O
lymphoma O
B O
cells O
from O
calcium O
ionophore O
- O
and O
antigen O
receptor O
- O
triggered O
apoptosis O
by O
inhibiting O
activation O
of O
the O
cysteine I-GENE
protease I-GENE
CPP32 I-GENE
/ O
Yama I-GENE
and O
cleavage O
of O
its O
substrate O
PARP I-GENE
. O

Large I-GENE
T I-GENE
antigen I-GENE
was O
coimmunoprecipitated O
by O
antibodies O
to O
epitope O
- O
tagged O
TBP I-GENE
, O
endogenous O
TBP I-GENE
, O
hTAF I-GENE
( I-GENE
II I-GENE
) I-GENE
100 I-GENE
, O
hTAF I-GENE
( I-GENE
II I-GENE
) I-GENE
130 I-GENE
, O
and O
hTAF I-GENE
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
, O
under O
conditions O
where O
holo I-GENE
- I-GENE
TFIID I-GENE
would O
be O
precipitated O
. O

Northern O
blot O
hybridization O
demonstrated O
that O
HEP I-GENE
- O
COP I-GENE
was O
expressed O
in O
a O
wide O
range O
of O
human O
adult O
and O
fetal O
tissues O
. O

A O
human O
cytoplasmic O
signaling O
protein O
has O
been O
cloned O
that O
possesses O
the O
same O
structural O
arrangement O
of O
SH3 I-GENE
- O
SH2 I-GENE
- O
SH3 I-GENE
domains O
as O
Grb2 I-GENE
. O

A O
direct O
role O
for O
sterol I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
protein I-GENE
in O
activation O
of O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylglutaryl I-GENE
coenzyme I-GENE
A I-GENE
reductase I-GENE
gene I-GENE
. O

E3 I-GENE
/ I-GENE
19K I-GENE
resides O
in O
the O
endoplasmic O
reticulum O
where O
it O
binds O
to O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
, O
thereby O
preventing O
their O
transport O
to O
the O
cell O
surface O
. O

When O
the O
PHT O
and O
CSA O
groups O
were O
compared O
, O
Hyp O
levels O
were O
significantly O
higher O
in O
the O
PHT O
- O
GO O
+ O
group O
than O
in O
the O
CSA O
- O
GO O
+ O
group O
. O

Among O
the O
LE6 I-GENE
deletions O
, O
only O
one O
had O
a O
reduced O
transformation O
efficiency O
, O
while O
seven O
transformed O
cells O
at O
least O
as O
efficiently O
as O
wild I-GENE
- I-GENE
type I-GENE
LE6 I-GENE
. O

ORF I-GENE
E8 I-GENE
colinear O
with O
ORF I-GENE
E6 I-GENE
, O
which O
could O
generate O
a O
50 O
- O
amino O
- O
acid O
protein O
with O
a O
hydrophobic O
segment O
, O
did O
not O
transform O
cells O
when O
cloned O
into O
the O
pZipNeo O
vector O
. O

Cloning O
of O
individual O
ZI O
domains O
upstream O
of O
a O
minimal O
promoter O
demonstrated O
that O
the O
ZIA O
, O
ZIC O
, O
and O
ZID O
domains O
, O
but O
not O
the O
ZIB O
domain O
, O
are O
TPA O
responsive O
. O

Clb2 I-GENE
/ O
Cdc28 I-GENE
kinase O
is O
not O
required O
for O
the O
repression O
of O
MCB I-GENE
- I-GENE
binding I-GENE
factor I-GENE
transcriptional O
activity O
in O
G2 O
and O
M O
phase O
. O

The O
carboxy O
terminus O
of O
Mbp1 I-GENE
is O
sufficient O
for O
interaction O
with O
Swi6 I-GENE
, O
and O
the O
carboxy O
terminus O
of O
Swi6 I-GENE
is O
required O
for O
interaction O
with O
Mbp1 I-GENE
. O

Multiple O
single O
- O
stranded O
cis O
elements O
are O
associated O
with O
activated O
chromatin O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
in O
vivo O
. O

A O
new O
UASH O
consensus O
sequence O
derived O
from O
this O
mutational O
analysis O
closely O
matches O
a O
consensus O
Abf1 I-GENE
binding I-GENE
site I-GENE
. O

We O
have O
isolated O
and O
analyzed O
human I-GENE
CTCF I-GENE
cDNA I-GENE
clones O
and O
show O
here O
that O
the O
ubiquitously O
expressed O
11 I-GENE
- I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
factor I-GENE
CTCF I-GENE
is O
an O
exceptionally O
highly O
conserved O
protein O
displaying O
93 O
% O
identity O
between O
avian O
and O
human O
amino O
acid O
sequences O
. O

Mutational O
analysis O
of O
the O
P2 I-GENE
- I-GENE
proximal I-GENE
CTCF I-GENE
binding I-GENE
site I-GENE
and O
transient O
- O
cotransfection O
experiments O
demonstrate O
that O
CTCF I-GENE
is O
a O
transcriptional O
repressor O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

A O
chromosome I-GENE
transmission I-GENE
fidelity I-GENE
( O
ctf I-GENE
) O
mutant O
, O
s138 O
, O
of O
Saccharomyces O
cerevisiae O
was O
identified O
by O
its O
centromere O
( O
CEN O
) O
transcriptional O
readthrough O
phenotype O
, O
suggesting O
perturbed O
kinetochore O
integrity O
in O
vivo O
. O

The O
growth O
defect O
of O
a O
reg1 I-GENE
reg2 I-GENE
double I-GENE
mutant I-GENE
is O
alleviated O
by O
a O
loss O
- O
of O
- O
function O
mutation O
in O
the O
SNF1 I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
kinase I-GENE
. O

Sp1 I-GENE
binds O
two O
sites O
in O
the O
CD11c I-GENE
promoter I-GENE
in O
vivo O
specifically O
in O
myeloid O
cells O
and O
cooperates O
with O
AP1 I-GENE
to O
activate O
transcription O
. O

Expression O
of O
the O
phenylalanine I-GENE
hydroxylase I-GENE
gene I-GENE
in O
livers O
and O
kidneys O
of O
rodents O
is O
activated O
at O
birth O
and O
is O
induced O
by O
glucocorticoids O
and O
cyclic O
AMP O
in O
the O
liver O
. O

We O
found O
that O
120 O
bp O
of O
the O
enhancer O
' O
s O
transcriptional O
core O
becomes O
DNase I-GENE
I I-GENE
hypersensitive O
early O
in O
B O
- O
cell O
development O
. O

A O
developmentally O
modulated O
chromatin O
structure O
at O
the O
mouse I-GENE
immunoglobulin I-GENE
kappa I-GENE
3 I-GENE
' I-GENE
enhancer I-GENE
. O

We O
report O
here O
the O
identification O
of O
a O
cDNA O
that O
encodes O
a O
new O
member O
of O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
GAP I-GENE
) O
family O
of O
GTPase I-GENE
regulators O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
regulation O
of O
the O
synthesis O
of O
the O
c I-GENE
- I-GENE
mos I-GENE
oncogene I-GENE
product I-GENE
, O
which O
is O
necessary O
for O
the O
activation O
of O
Cdc2 I-GENE
. O

The O
heterogeneity O
of O
bovine I-GENE
IgG2 I-GENE
-- I-GENE
VIII I-GENE
. O

The O
ability O
of O
BCL I-GENE
- I-GENE
6 I-GENE
to O
function O
as O
a O
transcriptional O
repressor O
may O
contribute O
to O
its O
ability O
to O
transform O
B O
lymphocytes O
in O
diffuse O
large O
cell O
lymphoma O
. O

Positioning O
this O
uORF O
, O
together O
with O
its O
accompanying O
Kozak O
sequences O
, O
between O
a O
heterologous O
promoter O
from O
SV40 O
and O
a O
CAT I-GENE
reporter I-GENE
gene I-GENE
resulted O
in O
marked O
inhibition O
of O
CAT I-GENE
protein I-GENE
production O
without O
a O
decrease O
in O
CAT I-GENE
mRNA I-GENE
. O

A O
secondary O
spread O
of O
an O
imported O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
strain O
( O
MRSA O
) O
to O
two O
other O
patients O
occurred O
within O
a O
Danish O
surgical O
ward O
in O
spite O
of O
isolation O
of O
a O
multitraumatized O
index O
- O
patient O
immediately O
after O
arrival O
from O
a O
hospital O
in O
the O
Mediterranean O
area O
. O

Mesial O
temporal O
sclerosis O
was O
characterized O
by O
severe O
neuronal O
loss O
accompanied O
by O
gliosis O
occurring O
in O
the O
CA1 O
/ O
prosubiculum O
( O
27 O
patients O
, O
100 O
%), O
focally O
in O
the O
dentate O
gyrus O
( O
12 O
patients O
, O
44 O
%), O
and O
in O
the O
CA4 O
region O
( O
11 O
patients O
, O
41 O
%). O

Mesial O
temporal O
sclerosis O
. O

More O
specific O
adverse O
events O
, O
also O
frequently O
considered O
as O
dose O
- O
limiting O
toxicities O
, O
include O
hypotension O
with O
IL I-GENE
- I-GENE
1 I-GENE
, O
severe O
headache O
or O
skin O
rash O
with O
IL I-GENE
- I-GENE
3 I-GENE
, O
and O
nasal O
congestion O
and O
gastroduodenal O
lesions O
with O
IL I-GENE
- I-GENE
4 I-GENE
. O

Therefore O
, O
magnetic O
resonance O
imaging O
was O
used O
to O
determine O
liver O
volume O
in O
pediatric O
and O
adolescent O
patients O
, O
in O
whom O
systemic O
clearance O
of O
three O
model O
substrates O
[ O
lorazepam O
( O
0 O
. O
03 O
mg O
/ O
kg O
), O
antipyrine O
( O
10 O
mg O
/ O
kg O
), O
and O
indocyanine O
green O
( O
ICG O
; O
0 O
. O
5 O
mg O
/ O
kg O
)] O
was O
also O
determined O
. O

A O
mutational O
analysis O
has O
resolved O
a O
region O
of O
seven O
amino O
acids O
( O
amino O
acids O
26 O
- O
32 O
) O
in O
the O
N O
- O
terminus O
of O
Bob1 I-GENE
that O
are O
important O
for O
contacting O
the O
DNA I-GENE
binding I-GENE
POU I-GENE
domain I-GENE
of O
Oct I-GENE
- I-GENE
1 I-GENE
or O
Oct I-GENE
- I-GENE
2 I-GENE
. O

Heme I-GENE
oxygenase I-GENE
1 I-GENE
is O
an O
essential O
enzyme O
in O
heme O
catabolism O
that O
cleaves O
heme O
to O
form O
biliverdin O
, O
iron O
, O
and O
carbon O
monoxide O
. O

An O
inactive O
analog O
of O
wortmannin O
, O
WM12 O
, O
did O
not O
affect O
TCR I-GENE
/ O
CD3 I-GENE
- O
induced O
Erk2 I-GENE
activation O
, O
and O
wortmannin O
had O
no O
effect O
on O
the O
activity O
of O
Erk2 I-GENE
when O
added O
directly O
to O
the O
in O
vitro O
assays O
. O

155 O
aa O
, O
shares O
78 O
% O
identity O
with O
the O
analogous O
region O
of O
Xenopus O
laevis O
FGF3 I-GENE
and O
72 O
% O
identity O
with O
the O
product O
of O
the O
more O
distantly O
related O
human O
gene O
. O

The O
transcription O
start O
point O
of O
the O
proximal O
promoter O
aligns O
to O
that O
of O
mouse O
promoter O
P3 O
and O
lies O
within O
a O
conserved O
region O
of O
sequence O
. O

Defects O
in O
the O
Schizosaccharomyces O
pombe O
( O
Sp O
) O
cell O
cycle O
- O
controlling O
genes O
prevent O
the O
cell O
cycle O
progression O
. O

To O
determine O
the O
signal I-GENE
recognition I-GENE
particle I-GENE
( O
SRP I-GENE
)- O
SRP I-GENE
receptor I-GENE
( O
Srb I-GENE
) O
system O
in O
Bacillus O
subtilis O
( O
Bs O
), O
we O
cloned O
the O
Bs I-GENE
srb I-GENE
gene I-GENE
, O
which O
encodes O
a O
homologue O
of O
the O
mammalian I-GENE
SRP I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
[ O
Oguro O
et O
al O
., O
DNA O
Res O
. O

A O
novel O
gene O
designated O
cmr I-GENE
, O
which O
mapped O
to O
18 O
. O
8 O
min O
of O
the O
Escherichia O
coli O
K O
- O
12 O
genome O
, O
was O
shown O
to O
mediate O
resistance O
to O
chloramphenicol O
when O
it O
was O
expressed O
from O
a O
multicopy O
vector O
. O

In O
addition O
, O
5 O
' O
deletions O
removing O
all O
but O
34 O
bp O
upstream O
of O
the O
transcription O
start O
point O
retained O
greater O
than O
90 O
% O
promoter O
activity O
, O
suggesting O
that O
the O
- O
35 O
hexamer O
was O
not O
essential O
for O
promoter O
activity O
. O

The O
DNA O
sequence O
immediately O
upstream O
from O
the O
- O
10 O
hexamer O
contained O
the O
TGn O
motif O
described O
as O
an O
extended O
- O
10 O
region O
in O
prokaryotic O
promoters O
. O

An O
apparent O
ufo I-GENE
mRNA I-GENE
overexpression O
was O
not O
found O
in O
any O
of O
the O
positive O
leukemia O
cell O
lines O
, O
but O
was O
identified O
in O
the O
drug O
- O
resistant O
subclones O
of O
the O
cervix O
carcinoma O
cell O
line O
HeLa O
. O

We O
conclude O
from O
these O
studies O
that O
CKII I-GENE
may O
act O
as O
a O
positive O
regulator O
of O
myogenesis O
by O
preventing O
E I-GENE
protein I-GENE
homodimers I-GENE
from O
binding O
to O
muscle O
gene O
regulatory O
elements O
. O

The O
role O
of O
negative O
regulators O
such O
as O
NCE3 I-GENE
, O
as O
well O
as O
the O
previously O
described O
SIN5 I-GENE
gene I-GENE
, O
in O
determining O
the O
promoter O
specificity O
of O
homologous O
activators O
is O
discussed O
. O

Transcriptional O
regulators O
utilizing O
the O
POU I-GENE
domain I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
motif I-GENE
have O
been O
shown O
to O
form O
multi O
- O
protein O
complexes O
dependent O
on O
the O
POU I-GENE
domain I-GENE
itself O
and O
its O
flexible O
recognition O
of O
various O
octamer O
sequence O
elements O
. O

We O
found O
strand O
selective O
repair O
in O
DNA O
fragments O
within O
two O
active O
genes O
, O
DHFR I-GENE
and O
an O
unknown O
gene O
adjacent O
to O
DHFR I-GENE
. O

MATERIALS O
AND O
METHODS O
: O
Coronal O
3D O
GRE O
imaging O
was O
used O
to O
study O
the O
volar O
, O
middle O
, O
and O
dorsal O
portions O
of O
the O
SLL O
in O
14 O
patients O
with O
an O
arthroscopically O
normal O
SLL O
and O
in O
five O
cadaveric O
wrists O
that O
had O
a O
normal O
SLL O
proved O
with O
dissection O
. O

In O
an O
effort O
to O
contribute O
to O
the O
transcript O
map O
of O
human O
chromosome O
21 O
and O
the O
understanding O
of O
the O
pathophysiology O
of O
trisomy O
21 O
, O
we O
have O
used O
exon O
trapping O
to O
identify O
fragments O
of O
chromosome O
21 O
genes O
. O

Reproducing O
populations O
of O
this O
aphid O
were O
first O
detected O
in O
Puerto O
Rico O
in O
April O
1992 O
. O

The O
model O
captures O
the O
essence O
of O
predator O
- O
prey O
dynamics O
to O
provide O
reasonable O
predictions O
of O
population O
patterns O
. O

At O
cuticular O
positions O
exhibiting O
the O
Brd I-GENE
bristle I-GENE
loss I-GENE
phenotype I-GENE
, O
we O
have O
found O
that O
the O
progeny O
of O
the O
multiplied O
SOPs O
develop O
aberrantly O
, O
in O
that O
neurons O
and O
thecogen O
( O
sheath O
) O
cells O
appear O
but O
not O
trichogen O
( O
shaft O
) O
and O
tormogen O
( O
socket O
) O
cells O
. O

Transcriptional O
blockade O
was O
reversed O
by O
co O
- O
transfections O
of O
a O
wild I-GENE
- I-GENE
type I-GENE
SRF I-GENE
expression O
vector O
, O
but O
was O
not O
rescued O
by O
the O
expression O
of O
other O
myogenic O
factors O
, O
such O
as O
MyoD I-GENE
and O
Mef I-GENE
- I-GENE
2C I-GENE
. O

The O
mMIWC1 I-GENE
promoter I-GENE
was O
identified O
and O
contained O
TATA O
, O
CAAT O
, O
GATA O
, O
and O
AP I-GENE
- I-GENE
2 I-GENE
elements I-GENE
; O
primer O
extension O
revealed O
mMIWC I-GENE
transcription O
initiation O
at O
621 O
bp O
upstream O
from O
the O
mMIWC1 I-GENE
translational O
initiation O
site O
. O

Human I-GENE
MN I-GENE
/ I-GENE
CA9 I-GENE
gene I-GENE
, O
a O
novel O
member O
of O
the O
carbonic I-GENE
anhydrase I-GENE
family I-GENE
: O
structure O
and O
exon O
to O
protein O
domain O
relationships O
. O

The O
exon O
- O
intron O
distribution O
of O
Cdebp I-GENE
appears O
strikingly O
similar O
to O
that O
of O
the O
App I-GENE
gene I-GENE
in O
the O
regions O
encoding O
the O
conserved O
domains O
, O
with O
a O
divergent O
structure O
in O
the O
other O
parts O
. O

DNA O
sequence O
analysis O
reveals O
that O
the O
gene O
encodes O
a O
protein O
highly O
homologous O
to O
rat I-GENE
CRP1 I-GENE
. O

The O
gene O
was O
expressed O
as O
an O
approximately O
1 O
. O
5 O
- O
kb O
mRNA O
in O
most O
nonlymphoid O
human O
cells O
/ O
tissues O
including O
prostate O
, O
lung O
, O
liver O
, O
and O
colon O
. O

Both O
of O
these O
domains O
have O
striking O
sequence O
homology O
with O
human O
SIM I-GENE
and O
Drosophila O
SIM I-GENE
proteins O
. O

Promoter O
activity O
was O
high O
in O
cell O
lines O
that O
expressed O
high O
levels O
of O
endogenous O
D3 I-GENE
mRNA I-GENE
, O
as O
indicated O
by O
Northern O
blot O
analyses O
, O
and O
was O
significantly O
reduced O
when O
the O
promoter O
was O
truncated O
to O
- O
122 O
bp O
. O

We O
have O
obtained O
the O
human I-GENE
EP4 I-GENE
receptor I-GENE
gene I-GENE
sequence I-GENE
and O
determined O
its O
structure O
relative O
to O
EP4R I-GENE
cDNA I-GENE
synthesized O
from O
peripheral O
blood O
lymphocytes O
. O

Some O
users O
will O
willingly O
comply O
with O
management O
measures O
, O
other O
users O
will O
comply O
in O
response O
to O
education O
, O
but O
there O
will O
be O
another O
group O
who O
will O
only O
respond O
to O
enforcement O
activities O
. O

Three O
separate O
activation O
subdomains O
, O
and O
one O
negative O
- O
acting O
region O
, O
which O
function O
in O
yeast O
were O
located O
in O
the O
carboxyl O
- O
terminal O
region O
of O
NIT4 I-GENE
. O

The O
front O
( O
F O
) O
interaction O
occurs O
ahead O
of O
the O
growing O
end O
of O
RNA O
. O

Collectively O
, O
these O
data O
indicate O
that O
HIP I-GENE
is O
a O
membrane O
- O
associated O
HP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
expressed O
on O
the O
surface O
of O
normal O
human O
uterine O
epithelia O
and O
uterine O
epithelial O
cell O
lines O
. O

The O
corresponding O
gene O
was O
identified O
in O
the O
GenBankTM O
data O
base O
by O
sequence O
alignment O
and O
termed O
RPS30A I-GENE
. O

The O
location O
of O
multiple O
GRK2 I-GENE
and O
GRK5 I-GENE
phosphoacceptor I-GENE
sites I-GENE
at O
the O
extreme O
carboxyl O
terminus O
of O
the O
beta2AR I-GENE
is O
highly O
reminiscent O
of O
GRK1 I-GENE
- O
mediated O
phosphorylation O
of O
rhodopsin I-GENE
. O

This O
regulation O
could O
not O
be O
appreciably O
modified O
by O
enhanced O
expression O
of O
STAT I-GENE
proteins I-GENE
. O

Receptors O
for O
interleukin I-GENE
( I-GENE
IL I-GENE
)- I-GENE
10 I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
- I-GENE
type I-GENE
cytokines I-GENE
use O
similar O
signaling O
mechanisms O
for O
inducing O
transcription O
through O
IL I-GENE
- I-GENE
6 I-GENE
response O
elements O
. O

Specifically O
, O
the O
deduced O
FR I-GENE
- I-GENE
19 I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
has O
approximately89 O
, O
77 O
, O
and O
68 O
% O
overall O
identity O
to O
chicken I-GENE
TEF I-GENE
- I-GENE
1A I-GENE
, O
mouse I-GENE
TEF I-GENE
- I-GENE
1 I-GENE
, O
and O
mouse I-GENE
embryonic I-GENE
TEA I-GENE
domain I-GENE
- I-GENE
containing I-GENE
factor I-GENE
, O
respectively O
. O

This O
phenomenon O
did O
not O
require O
DNA O
binding O
by O
the O
" O
interfering O
" O
receptor O
but O
required O
it O
to O
be O
hormone O
- O
bound O
, O
indicating O
that O
a O
transcriptionally O
active O
form O
of O
the O
interfering O
receptor O
is O
essential O
for O
the O
interfering O
effect O
. O

The O
receptor I-GENE
for I-GENE
hyaluronan I-GENE
mediated I-GENE
motility I-GENE
( I-GENE
RHAMM I-GENE
) I-GENE
gene I-GENE
expression O
is O
markedly O
elevated O
in O
fibrosarcomas O
exposed O
to O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
). O

Oncogenic I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
activates O
p70 I-GENE
S6 I-GENE
kinase I-GENE
via O
a O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- O
independent O
pathway O
. O

Hydropathy O
analysis O
of O
KCC1 I-GENE
indicates O
structural O
homology O
to O
NKCC I-GENE
, O
including O
12 O
transmembrane O
domains O
, O
a O
large O
extracellular O
loop O
with O
potential O
N O
- O
linked O
glycosylation O
sites O
, O
and O
cytoplasmic O
N O
- O
and O
C O
- O
terminal O
regions O
. O

A O
cis O
- O
acting O
DNA O
element O
located O
between O
TATA O
box O
and O
transcription O
initiation O
site O
is O
critical O
in O
response O
to O
regulatory O
sequences O
in O
human O
angiotensinogen I-GENE
gene I-GENE
. O

This O
protein O
with O
a O
hydrophobic O
amino O
terminus O
appears O
to O
be O
a O
secreted O
protein O
. O

The O
promoter O
of O
the O
rat I-GENE
PGS I-GENE
- I-GENE
2 I-GENE
gene I-GENE
contains O
a O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
consensus I-GENE
site I-GENE
( I-GENE
CAAT I-GENE
box I-GENE
) I-GENE
which O
can O
confer O
hormone O
inducibility O
to O
a O
PGS I-GENE
- I-GENE
2 I-GENE
. O
CAT I-GENE
reporter O
gene O
, O
as O
well O
as O
a O
putative O
E O
- O
box O
region O
. O

Notably O
, O
SRF I-GENE
has O
been O
found O
to O
be O
a O
key O
regulator O
of O
members O
of O
a O
class O
of O
cellular O
response O
genes O
termed O
immediate I-GENE
- I-GENE
early I-GENE
genes I-GENE
( O
IEGs I-GENE
), O
many O
of O
which O
are O
believed O
to O
be O
involved O
in O
regulating O
cell O
growth O
and O
differentiation O
. O

The O
final O
sigma54 I-GENE
- I-GENE
dependent I-GENE
DmpR I-GENE
activator I-GENE
regulates O
transcription O
of O
the O
dmp I-GENE
operon I-GENE
that O
encodes O
the O
enzymes O
for O
catabolism O
of O
( O
methyl O
) O
phenols O
. O

In O
this O
study O
, O
we O
have O
cloned O
the O
human I-GENE
DSG3 I-GENE
gene I-GENE
and O
examined O
the O
transcriptional O
regulation O
of O
its O
expression O
. O

Clinical O
evaluation O
of O
the O
Allergan O
Humphrey O
500 O
autorefractor O
and O
the O
Nidek O
AR O
- O
1000 O
autorefractor O
. O

None O
of O
the O
five O
proprotein O
processing O
proteases O
tested O
were O
capable O
of O
cleaving O
human I-GENE
pro I-GENE
- I-GENE
LPH I-GENE
, O
strongly O
suggesting O
that O
they O
are O
not O
involved O
in O
the O
maturation O
of O
this O
enzyme O
. O

These O
changes O
may O
be O
the O
result O
of O
, O
on O
the O
one O
hand O
, O
an O
increased O
sensitivity O
of O
the O
neuromuscular O
transmission O
and O
/ O
or O
decreased O
muscle O
contractility O
and O
, O
on O
the O
other O
hand O
, O
the O
result O
of O
a O
reduced O
plasma O
clearance O
during O
hypothermia O
. O

SETTING O
-- O
Delhi O
, O
urban O
India O
, O
1985 O
- O
6 O
. O

By O
using O
interleukin I-GENE
- I-GENE
3 I-GENE
- O
dependent O
cells O
that O
ectopically O
express O
the O
three O
ErbB I-GENE
proteins I-GENE
or O
their O
combinations O
, O
we O
found O
that O
ErbB I-GENE
- I-GENE
3 I-GENE
is O
devoid O
of O
any O
biological O
activity O
but O
both O
ErbB I-GENE
- I-GENE
1 I-GENE
and O
ErbB I-GENE
- I-GENE
2 I-GENE
can O
reconstitute O
its O
extremely O
potent O
mitogenic O
activity O
. O

ZIOS O
was O
significantly O
more O
sensitive O
than O
all O
subsequent O
methods O
, O
and O
Ptc O
, O
O2 O
was O
significantly O
more O
sensitive O
than O
FEV1 O
. O

Selective O
translation O
initiation O
by O
ribosome O
jumping O
in O
adenovirus O
- O
infected O
and O
heat O
- O
shocked O
cells O
. O

Furthermore O
, O
we O
have O
identified O
a O
43 O
- O
bp O
region O
of O
the O
24p3 I-GENE
promoter I-GENE
required O
for O
the O
Dex O
responsiveness O
. O

These O
findings O
suggest O
that O
direct O
cDNA O
mapping O
using O
fluorescence O
in O
situ O
hybridization O
provides O
an O
accurate O
and O
rapid O
approach O
to O
the O
definition O
of O
a O
transcribed O
map O
of O
the O
human O
genome O
. O

YAC O
and O
cosmid O
contigs O
spanning O
the O
Batten I-GENE
disease I-GENE
( O
CLN3 I-GENE
) O
region O
at O
16p12 O
. O
1 O
- O
p11 O
. O
2 O
. O

Isolation O
of O
a O
near O
full O
- O
length O
cDNA O
from O
a O
human O
fetal O
brain O
cDNA O
library O
revealed O
a O
protein I-GENE
serine I-GENE
- I-GENE
threonine I-GENE
phosphatase I-GENE
with O
a O
tetratricopeptide O
motif O
, O
almost O
identical O
to O
human I-GENE
PPP5C I-GENE
( O
PP5 I-GENE
) O
and O
highly O
homologous O
to O
rat I-GENE
PPT I-GENE
. O

Ly I-GENE
- I-GENE
49 I-GENE
is O
a O
family I-GENE
type I-GENE
II I-GENE
transmembrane I-GENE
proteins I-GENE
encoded O
by O
a O
gene O
cluster O
on O
murine O
chromosome O
6 O
. O

The O
Dox I-GENE
- I-GENE
A2 I-GENE
ORF I-GENE
driven O
by O
the O
TDH3 I-GENE
promoter I-GENE
complemented O
the O
phenotype O
of O
a O
strain O
deleted O
for O
sun2 I-GENE
. O

The O
introduction O
of O
hARF4 I-GENE
to O
the O
cells O
maintained O
the O
balance O
between O
cytosolic O
and O
membrane O
- O
associated O
Sec7p I-GENE
pools O
. O

Our O
data O
demonstrate O
directly O
that O
Rpm1r I-GENE
is O
transcribed O
with O
its O
substrates O
, O
tRNA I-GENE
met I-GENE
f I-GENE
and O
tRNAPro I-GENE
, O
from O
a O
promoter O
located O
upstream O
of O
the O
tRNA I-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
suggest O
that O
a O
portion O
also O
originates O
from O
a O
second O
promoter O
, O
located O
between O
the O
tRNA I-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
RPM1 I-GENE
. O

Furthermore O
, O
strains O
with O
mutant I-GENE
RPM1 I-GENE
genes I-GENE
also O
accumulate O
precursor I-GENE
Rpm1r I-GENE
, O
suggesting O
that O
mutations O
in O
either O
gene O
can O
lead O
to O
similar O
biogenesis O
defects O
. O

Vacuolar O
membrane O
vesicles O
from O
hum1 I-GENE
mutants I-GENE
lack O
all O
Ca2 O
+/ O
H O
+ O
antiport O
activity O
, O
demonstrating O
that O
Hum1p I-GENE
catalyzes O
the O
exchange O
of O
Ca2 O
+ O
for O
H O
+ O
across O
the O
yeast O
vacuolar O
membrane O
. O

Detailed O
mutagenesis O
of O
the O
element O
' O
s O
rare O
- O
codon O
/ O
AU O
- O
rich O
sequence O
boundary O
revealed O
that O
the O
destabilizing O
activity O
of O
the O
MATalpha1 I-GENE
IE I-GENE
is O
observed O
when O
the O
terminal O
codon O
of O
the O
element O
' O
s O
rare O
- O
codon O
interval O
is O
translated O
. O

FTF I-GENE
is O
also O
abundantly O
expressed O
in O
the O
pancreas O
and O
may O
exert O
differentiation O
functions O
in O
endodermal O
sublineages O
, O
similar O
to O
SF I-GENE
- I-GENE
1 I-GENE
in O
steroidogenic O
tissues O
. O

Merlie O
, O
Cold O
Spring O
Harbor O
Symp O
. O

Substantial O
evidence O
supports O
a O
critical O
role O
for O
the O
activation O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
/ O
MEK I-GENE
/ O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
in O
oncogenic O
Ras I-GENE
- O
mediated O
transformation O
. O

Stylohyoid O
chain O
ossification O
: O
choice O
of O
the O
surgical O
approach O
. O

The O
incidence O
of O
cardiac O
death O
( O
one O
per O
group O
), O
Q O
wave O
MI O
( O
propofol O
, O
n O
= O
7 O
; O
midazolam O
, O
n O
= O
3 O
; O
P O
= O
0 O
. O
27 O
), O
or O
non O
Q O
wave O
MI O
( O
propofol O
, O
n O
= O
16 O
; O
midazolam O
, O
n O
= O
18 O
; O
P O
= O
0 O
. O
81 O
) O
did O
not O
differ O
between O
treatment O
groups O
. O

63 O
. O
3 O
micromol O
/ O
1 O
, O
p O
< O
0 O
. O
01 O
) O
and O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
extrapolated O
to O
infinity O
AUC O
9 O
( O
0 O
- O
infinity O
)( O
518 O
. O
7 O
vs O
. O

Cluster O
formation O
of O
E I-GENE
- I-GENE
cadherin I-GENE
on O
the O
cell O
surface O
is O
believed O
to O
be O
of O
major O
importance O
for O
cell O
- O
cell O
adhesion O
. O

DNA I-GENE
polymerase I-GENE
E I-GENE
, O
DNA I-GENE
ligase I-GENE
III I-GENE
and O
a O
DNA O
structure O
- O
specific O
endonuclease O
co O
- O
purify O
with O
the O
five O
polypeptide O
complex O
. O

By O
using O
reporter O
gene O
constructs O
, O
it O
is O
shown O
that O
upstream O
sequences O
of O
the O
P1 O
promoter O
contain O
several O
regions O
that O
modulate O
the O
expression O
either O
positively O
or O
negatively O
. O

The O
factor O
structure O
of O
" O
schizotypal O
' O
traits O
: O
a O
large O
replication O
study O
. O

Interestingly O
, O
however O
, O
it O
is O
homologous O
to O
several O
expressed O
sequence O
tags O
( O
EST O
) O
of O
unknown O
function O
from O
Caenorhabditis O
elegans O
, O
Oryza O
sativa O
and O
Homo O
sapiens O
. O

RESULTS O
: O
The O
bilinear O
model O
provided O
a O
significantly O
better O
fit O
to O
the O
acuity O
outcome O
data O
. O

Outcome O
of O
severe O
congenital O
hypothyroidism O
. O

Mean O
increase O
of O
milk O
protein O
yield O
was O
46 O
g O
/ O
d O
with O
Met O
plus O
Lys O
, O
and O
mean O
increase O
of O
true O
protein O
content O
was O
1 O
. O
1 O
g O
/ O
kg O
of O
milk O
. O

Nonreturn O
rates O
can O
be O
used O
to O
derive O
more O
elementary O
biological O
measures O
for O
reproductive O
efficiency O
, O
such O
as O
conception O
rate O
and O
calving O
rate O
, O
which O
separately O
might O
be O
more O
reliable O
than O
nonreturn O
rate O
itself O
to O
evaluate O
the O
fertility O
of O
a O
bull O
or O
the O
performance O
of O
an O
AI O
technician O
. O

However O
, O
if O
EMPD O
involves O
the O
glans O
penis O
or O
perianal O
area O
, O
a O
search O
for O
internal O
malignancy O
is O
still O
warranted O
. O

The O
mean O
values O
of O
protease O
activity O
were O
significantly O
higher O
in O
the O
test O
groups O
than O
in O
the O
control O
group O
at O
baseline O
. O

Each O
half O
molecule O
contains O
four O
disulfide O
linkages O
and O
four O
cis O
peptides O
. O

Only O
fully O
processed O
Pra I-GENE
( O
N0 O
and O
Nb O
) O
and O
ICP35 I-GENE
( O
ICP35 I-GENE
e I-GENE
, I-GENE
f I-GENE
) O
are O
present O
in O
B O
capsids O
, O
which O
are O
believed O
to O
be O
precursors O
of O
mature O
virions O
. O

A O
chimeric O
VP16 I-GENE
- O
Tat I-GENE
construct O
containing O
the O
leucine O
mutations O
showed O
no O
increased O
AP I-GENE
- I-GENE
1 I-GENE
responsiveness O
in O
comparison O
with O
that O
of O
the O
VP16 I-GENE
activation I-GENE
domain I-GENE
alone O
. O

However O
, O
one O
3 O
' O
splice O
site O
, O
located O
at O
nucleotide O
( O
nt O
) O
3225 O
, O
is O
used O
for O
the O
processing O
of O
most O
BPV O
- O
1 O
pre O
- O
mRNAs O
in O
BPV O
- O
1 O
- O
transformed O
C127 O
cells O
and O
at O
early O
to O
intermediate O
times O
in O
productively O
infected O
warts O
. O

Here O
, O
the O
cloning O
and O
characterization O
of O
S I-GENE
- I-GENE
RNase I-GENE
genes I-GENE
from O
two O
species O
of O
Rosaceae O
, O
apple O
( O
Malus O
x O
domestica O
) O
and O
Japanese O
pear O
( O
Pyrus O
serotina O
) O
is O
described O
and O
these O
sequences O
are O
compared O
with O
those O
of O
other O
T2 I-GENE
- I-GENE
type I-GENE
RNases I-GENE
. O

A O
phylogenetic O
tree O
of O
members O
of O
the O
T2 I-GENE
/ I-GENE
S I-GENE
- I-GENE
RNase I-GENE
superfamily I-GENE
in O
plants O
was O
obtained O
. O

In O
a O
Hoosier O
Oncology O
Group O
randomized O
study O
involving O
extensive O
- O
disease O
SCLC O
patients O
, O
VIP O
was O
superior O
to O
etoposide O
/ O
cisplatin O
with O
regard O
to O
median O
time O
to O
progression O
( O
6 O
. O
6 O
v O
5 O
. O
8 O
months O
), O
median O
survival O
times O
( O
9 O
. O
1 O
v O
7 O
. O
3 O
months O
), O
and O
2 O
- O
and O
3 O
- O
year O
survival O
rates O
( O
13 O
% O
v O
5 O
% O
and O
5 O
% O
v O
0 O
%, O
respectively O
). O

It O
was O
shown O
that O
administration O
of O
immunomodulator O
neurotropin I-GENE
( O
NSP I-GENE
) O
results O
in O
more O
steady O
consolidation O
and O
retention O
of O
feeding O
and O
avoidance O
behavior O
, O
and O
some O
neurophysiological O
mechanisms O
of O
that O
phenomena O
were O
revealed O
. O

Sestamibi O
scintigraphy O
, O
performed O
in O
70 O
patients O
, O
was O
less O
sensitive O
than O
ultrasonography O
( O
80 O
%). O

Atopic O
allergy O
and O
other O
hypersensitivities O
. O

Despite O
significant O
lethality O
and O
cardiovascular O
dysfunction O
, O
in O
the O
septic O
group O
on O
Days O
1 O
and O
2 O
, O
septic O
versus O
control O
animals O
had O
no O
significant O
differences O
in O
mean O
metabolic O
cart O
measured O
( O
Vo2DIR O
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
9 O
versus O
12 O
. O
4 O
, O
p O
= O
0 O
. O
81 O
; O
Day O
2 O
: O
14 O
. O
2 O
versus O
13 O
. O
5 O
, O
p O
= O
0 O
. O
72 O
, O
respectively O
) O
and O
intravascular O
catheter O
calculated O
( O
Vo2INDIR O
, O
ml O
/ O
kg O
/ O
min O
; O
Day O
1 O
: O
11 O
. O
2 O
versus O
11 O
. O
2 O
, O
p O
= O
0 O
. O
99 O
; O
Day O
2 O
: O
12 O
. O
8 O
versus O
15 O
. O
4 O
, O
p O
= O
0 O
. O
49 O
, O
respectively O
). O

After O
6 O
h O
of O
reperfusion O
, O
PO2 O
/ O
FlO2 O
ratio O
was O
significantly O
better O
after O
Combined O
Therapy O
( O
372 O
+/- O
52 O
mm O
Hg O
) O
than O
in O
the O
Recipient O
Instilled O
( O
117 O
+/- O
47 O
mm O
Hg O
) O
and O
Control O
groups O
( O
87 O
+/- O
26 O
mm O
Hg O
), O
with O
intermediate O
values O
in O
Donor O
Aerosol O
dogs O
( O
232 O
+/- O
64 O
mm O
Hg O
). O

The O
euglobulin I-GENE
clot O
lysis O
time O
was O
slightly O
longer O
in O
the O
smokers O
than O
in O
the O
non O
- O
smokers O
in O
all O
three O
experimental O
situations O
, O
but O
the O
differences O
were O
not O
significant O
. O

HS O
inducibility O
required O
the O
HSE O
which O
was O
bound O
by O
HS I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HSF I-GENE
- I-GENE
1 I-GENE
) O
present O
in O
extracts O
prepared O
from O
cells O
exposed O
to O
HS O
. O

Although O
the O
DSK2 I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
alters O
a O
conserved O
residue O
in O
the O
Dsk2p I-GENE
ubiquitin I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
we O
detect O
no O
differences O
in O
Dsk2p I-GENE
or O
Cdc31p I-GENE
stability O
. O

Although O
IL I-GENE
- I-GENE
2 I-GENE
and O
IFN I-GENE
- I-GENE
alpha I-GENE
activated O
STAT1 I-GENE
alpha I-GENE
and O
STAT5 I-GENE
, O
IL I-GENE
- I-GENE
2 I-GENE
predominantly O
activated O
STAT5 I-GENE
, O
while O
IFN I-GENE
- I-GENE
alpha I-GENE
predominantly O
activated O
STAT1 I-GENE
alpha I-GENE
. O

Consistent O
with O
this O
interpretation O
, O
recombinant I-GENE
CREB I-GENE
and O
activating I-GENE
transcription I-GENE
factor I-GENE
proteins I-GENE
bound O
the O
junB I-GENE
CRE O
- O
like O
site O
, O
but O
did O
not O
interact O
with O
a O
mutant O
CRE O
- O
like O
site O
. O

Collectively O
, O
these O
results O
suggest O
that O
components O
of O
the O
protein I-GENE
kinase I-GENE
A I-GENE
signaling O
pathway O
are O
recruited O
by O
mIg I-GENE
to O
induce O
junB I-GENE
transcription O
. O

One O
complex O
containing O
a O
70 O
D O
protein O
was O
found O
to O
be O
associated O
specifically O
with O
transcriptionally O
active O
leukemia O
cells O
. O

Our O
results O
confirm O
the O
participation O
of O
intron O
1 O
in O
transcriptional O
regulation O
of O
the O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
( O
in O
mouse O
and O
human O
) O
and O
implicate O
multiple O
and O
complex O
regulatory O
mechanisms O
of O
activation O
during O
myelomonocytic O
differentiation O
and O
leukemic O
cell O
growth O
control O
. O

Immunofluorescence O
microscopy O
revealed O
extensive O
deposition O
of O
such O
extracellular O
matrices O
as O
type I-GENE
IV I-GENE
collagen I-GENE
and O
laminin I-GENE
in O
the O
vascular O
wall O
. O

OBJECTIVE O
: O
To O
compare O
pregnancy O
complications O
in O
women O
having O
genetic O
amniocentesis O
at O
11 O
- O
14 O
weeks O
versus O
those O
undergoing O
amniocentesis O
at O
16 O
- O
19 O
weeks O
' O
gestation O
. O

Three O
ORFs O
( O
9765orfR002 O
, O
9765orfR011 O
and O
9765orfR013 O
) O
were O
found O
to O
be O
homologous O
with O
Schizosaccharomyces O
pombe O
polyadenylate I-GENE
binding I-GENE
protein I-GENE
, O
Escherichia O
coli O
hypothetical O
38 O
. O
1 O
- O
kDa O
protein O
in O
the O
BCR I-GENE
5 O
' O
region O
, O
and O
transcription O
regulatory O
protein O
Swi3 I-GENE
, O
respectively O
. O

Two O
new O
flavone O
glucosides O
, O
nevadensin O
5 O
- O
O O
- O
beta O
- O
D O
- O
glucoside O
and O
nevadensin O
5 O
- O
O O
- O
beta O
- O
D O
- O
glucosyl O
( O
1 O
--> O
6 O
) O
beta O
- O
D O
- O
glucoside O
, O
have O
been O
isolated O
from O
the O
aerial O
parts O
of O
Lysionotus O
pauciflorus O
. O

Recently O
, O
our O
laboratory O
developed O
a O
screen O
that O
identified O
five O
multicopy O
suppressors O
that O
can O
rescue O
lethal O
strains O
of O
clathrin I-GENE
heavy O
chain O
- O
deficient O
yeast O
( O
Chc I-GENE
- O
scd1 I-GENE
- I-GENE
i I-GENE
) O
to O
viability O
. O

Reproductive O
period O
affects O
water O
intake O
in O
heat O
- O
stressed O
dehydrated O
goats O
. O

The O
logistic O
regression O
analysis O
of O
the O
manual O
method O
( O
percentage O
normal O
morphology O
) O
and O
IVOS O
indicated O
that O
both O
were O
predictors O
of O
fertilization O
. O

METHODS O
: O
Rats O
received O
continuous O
intragastric O
infusion O
of O
elemental O
diet O
or O
with O
supplementation O
of O
oatbase O
, O
Lactobacillus O
reuteri O
R2LC O
, O
and O
Lactobacillus O
plantarum O
DSM O
9843 O
, O
with O
and O
without O
fermentation O
, O
from O
the O
beginning O
of O
the O
study O
. O

However O
, O
D8 I-GENE
binding O
was O
observed O
by O
nuclease O
protection O
with O
lactotroph I-GENE
- I-GENE
as I-GENE
well I-GENE
as I-GENE
somatotroph I-GENE
- I-GENE
like I-GENE
cell I-GENE
nuclear I-GENE
protein I-GENE
. O

Limited O
role O
for O
PCR O
- O
based O
diagnosis O
of O
Whipple O
' O
s O
disease O
from O
peripheral O
blood O
mononuclear O
cells O
. O

The O
ability O
of O
A20 I-GENE
to O
block O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
was O
mapped O
to O
its O
C O
- O
terminal O
zinc O
finger O
domain O
. O

The O
Pro O
- O
258 O
--> O
Leu O
( O
P258L O
) O
mutation O
caused O
constitutive O
receptor O
signaling O
that O
was O
equivalent O
to O
about O
45 O
% O
of O
the O
maximum O
level O
observed O
in O
wild O
- O
type O
cells O
stimulated O
with O
alpha I-GENE
- I-GENE
factor I-GENE
. O

By O
using O
a O
DNA O
sequence O
selected O
for O
its O
ability O
to O
bind O
recombinant I-GENE
BCL I-GENE
- I-GENE
6 I-GENE
in O
vitro O
, O
we O
show O
here O
that O
BCL I-GENE
- I-GENE
6 I-GENE
is O
present O
in O
DNA O
- O
binding O
complexes O
in O
nuclear O
extracts O
from O
various O
B O
- O
cell O
lines O
. O

The O
predictive O
value O
of O
a O
positive O
flag O
was O
77 O
. O
7 O
%. O

CONCLUSIONS O
: O
Our O
findings O
suggest O
that O
pre O
- O
treatment O
with O
coenzyme O
Q10 O
may O
play O
a O
protective O
role O
during O
routine O
vascular O
procedures O
requiring O
abdominal O
aortic O
cross O
clamping O
by O
attenuating O
the O
degree O
of O
peroxidative O
damage O
. O

Because O
chromosome O
X O
is O
frequently O
involved O
in O
structural O
alterations O
in O
neoplastic O
Syrian O
hamster O
cells O
transformed O
by O
chemical O
carcinogens O
and O
oncogenic O
viruses O
, O
the O
localization O
of O
the O
cph I-GENE
locus I-GENE
on O
this O
chromosome O
supports O
the O
notion O
that O
the O
cph I-GENE
oncogene I-GENE
plays O
a O
role O
in O
the O
malignant O
conversion O
of O
chemically O
transformed O
hamster O
fibroblasts O
. O

In O
a O
screen O
for O
genes O
with O
oncogenic O
potential O
expressed O
by O
the O
murine O
B6SUtA1 O
myeloid O
progenitor O
cell O
line O
, O
we O
isolated O
a O
2 O
. O

Gap1 O
( O
IP4BP O
), O
one O
of O
a O
member O
of O
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
, O
has O
been O
identified O
as O
a O
specific O
inositol I-GENE
1 I-GENE
, I-GENE
3 I-GENE
, I-GENE
4 I-GENE
, I-GENE
5 I-GENE
- I-GENE
tetrakisphosphate I-GENE
( I-GENE
IP4 I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
( O
Cullen O
, O
P O
. O

We O
previously O
described O
the O
purification O
of O
an O
83 I-GENE
- I-GENE
kDa I-GENE
phosphatidic I-GENE
acid I-GENE
phosphatase I-GENE
( O
PAP I-GENE
) O
from O
the O
porcine O
thymus O
membranes O
( O
Kanoh O
, O
H O
., O
Imai O
, O
S O
.- O
i O
., O
Yamada O
, O
K O
. O
and O
Sakane O
, O
F O
.( O
1992 O
) O
J O
. O

The O
mechanism O
involves O
Gbetagamma I-GENE
subunit O
- O
mediated O
increases O
in O
tyrosine O
phosphorylation O
of O
the O
Shc I-GENE
adapter I-GENE
protein I-GENE
, O
Shc I-GENE
* O
Grb2 I-GENE
complex O
formation O
, O
and O
recruitment O
of O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
activity O
. O

A O
cDNA O
encoding O
the O
amino O
- O
terminal O
17 O
% O
of O
apoB I-GENE
( O
apoB17 I-GENE
) O
was O
fused O
to O
a O
cDNA O
coding O
for O
the O
last O
37 O
amino O
acids O
of O
decay I-GENE
- I-GENE
accelerating I-GENE
factor I-GENE
( O
DAF I-GENE
), O
which O
contains O
the O
signal O
for O
glycosylphosphatidylinositol O
anchor O
attachment O
. O

Next O
, O
we O
stably O
overexpressed O
wild I-GENE
- I-GENE
type I-GENE
Shc I-GENE
or O
Y317F I-GENE
mutant I-GENE
Shc I-GENE
into O
HIRc O
cells O
. O

The O
small I-GENE
GTPase I-GENE
Rho I-GENE
is O
implicated O
in O
physiological O
functions O
associated O
with O
actin I-GENE
- O
myosin I-GENE
filaments O
such O
as O
cytokinesis O
, O
cell O
motility O
, O
and O
smooth O
muscle O
contraction O
. O

Conversely O
, O
activation O
of O
this O
signaling O
pathway O
by O
expression O
of O
a O
constitutively O
active O
MKK1 I-GENE
mutant I-GENE
dramatically O
increased O
cyclin I-GENE
D1 I-GENE
promoter O
activity O
and O
cyclin I-GENE
D1 I-GENE
protein I-GENE
expression O
, O
in O
a O
growth O
factor O
- O
independent O
manner O
. O

Furthermore O
, O
upstream O
insertion O
of O
the O
GSTP1 I-GENE
silencer I-GENE
element I-GENE
failed O
to O
inhibit O
activity O
of O
a O
heterologous O
promoter O
in O
MCF7 O
cells O
. O

In O
order O
to O
delineate O
structural O
motifs O
regulating O
substrate O
affinity O
and O
recognition O
for O
the O
human I-GENE
dopamine I-GENE
transporter I-GENE
( O
DAT I-GENE
), O
we O
assessed O
[ O
3H O
] O
dopamine O
uptake O
kinetics O
and O
[ O
3H O
] O
CFT O
binding O
characteristics O
of O
COS O
- O
7 O
cells O
transiently O
expressing O
mutant I-GENE
DATs I-GENE
in O
which O
the O
COOH O
terminus O
was O
truncated O
or O
substituted O
. O

An O
expression O
library O
was O
constructed O
by O
inserting O
5 O
' O
portion O
- O
enriched O
cDNAs O
from O
phytohemagglutinin I-GENE
- O
stimulated O
peripheral O
blood O
mononuclear O
cells O
into O
upstream O
of O
signal I-GENE
sequence I-GENE
- I-GENE
deleted I-GENE
CD4 I-GENE
cDNA I-GENE
in O
an O
Epstein O
- O
Barr O
virus O
shuttle O
vector O
. O

Radiolabeled O
recombinant I-GENE
TARC I-GENE
specifically O
bound O
to O
T O
cell O
lines O
and O
peripheral O
T O
cells O
but O
not O
to O
monocytes O
or O
granulocytes O
. O

The O
cis O
- O
acting O
elements O
that O
control O
promoter O
activity O
include O
binding O
sites O
for O
transcription O
factors O
Sp1 I-GENE
and O
alphaCbf I-GENE
, O
a O
60 I-GENE
- I-GENE
kDa I-GENE
CCAAT I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Therefore O
, O
we O
have O
identified O
a O
cis O
- O
acting O
element O
, O
the O
E1 O
E O
- O
box O
, O
located O
in O
the O
GAP I-GENE
- I-GENE
43 I-GENE
promoter O
region O
that O
modulates O
either O
positively O
or O
negatively O
the O
expression O
of O
the O
GAP I-GENE
- I-GENE
43 I-GENE
gene I-GENE
depending O
on O
which O
E I-GENE
- I-GENE
box I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
occupy O
this O
site O
. O

Collectively O
, O
our O
findings O
demonstrate O
that O
SF I-GENE
- I-GENE
1 I-GENE
plays O
a O
key O
role O
in O
controlling O
the O
basal O
and O
cAMP O
- O
stimulated O
expression O
of O
the O
StAR I-GENE
gene I-GENE
. O

There O
was O
a O
general O
broadening O
of O
proton O
resonances O
for O
a O
three O
- O
nucleotide O
segment O
centered O
about O
the O
lesion O
site O
which O
resulted O
in O
a O
tentative O
assignment O
for O
the O
sugar O
protons O
of O
the O
C7 O
residue O
in O
the O
spectrum O
of O
the O
adduct O
duplex O
. O

Using O
one O
of O
the O
six O
fragments O
( O
CPK3 I-GENE
- I-GENE
8 I-GENE
), O
we O
isolated O
a O
2022 I-GENE
bp I-GENE
cDNA I-GENE
( I-GENE
VrCDPK I-GENE
- I-GENE
1 I-GENE
) I-GENE
from O
a O
Vigna O
radiata O
lambda O
gt11 O
library O
. O

However O
, O
in O
TF O
- O
1 O
cells O
grown O
on O
GM I-GENE
- I-GENE
CSF I-GENE
before O
starvation O
, O
CREB I-GENE
phosphorylation O
was O
observed O
10 O
minutes O
after O
PIXY321 I-GENE
stimulation O
. O

Workplace O
violence O
-- O
nurses O
at O
risk O
. O

RESULTS O
: O
The O
LV O
maximum O
brightness O
and O
area O
under O
the O
curve O
showed O
significant O
negative O
correlations O
( O
p O
= O
< O
0 O
. O
004 O
) O
with O
the O
FIO2 O
, O
while O
the O
minimum O
brightness O
showed O
a O
significant O
positive O
correlation O
( O
p O
= O
< O
0 O
. O
002 O
). O

The O
results O
also O
imply O
that O
the O
absence O
of O
perforin I-GENE
expression O
in O
non O
- O
cytotoxic O
cells O
may O
be O
due O
to O
the O
suppression O
of O
the O
induction O
of O
the O
killer O
- O
cell O
- O
specific O
trans O
- O
acting O
factor O
NF I-GENE
- I-GENE
P2 I-GENE
. O

We O
identify O
considerable O
spatio O
- O
temporal O
similarities O
between O
reported O
expression O
patterns O
of O
Ypr10 I-GENE
genes I-GENE
and O
ribonuclease O
genes O
, O
which O
, O
together O
with O
the O
significant O
sequence O
similarity O
to O
the O
ginseng I-GENE
ribonuclease I-GENE
, O
support O
the O
hypothesis O
of O
a O
ribonuclease O
function O
for O
PR I-GENE
- I-GENE
10 I-GENE
proteins I-GENE
and O
allow O
the O
prediction O
of O
possible O
biological O
roles O
. O

The O
expression O
of O
ERV3 I-GENE
env I-GENE
mRNA I-GENE
was O
found O
to O
be O
differentiation O
- O
associated O
, O
with O
high O
expression O
detected O
in O
the O
late O
stages O
of O
monocytic O
development O
. O

Initial O
estimates O
indicate O
that O
27 O
, O
193 O
people O
are O
either O
in O
receipt O
of O
or O
in O
need O
of O
mental O
handicap O
services O
. O

It O
is O
exclusively O
observed O
in O
smooth O
muscle O
cells O
by O
Northern O
blotting O
and O
immunohistochemical O
analysis O
and O
therefore O
designated O
" I-GENE
smoothelin I-GENE
." I-GENE
A O
human O
smooth O
muscle O
cDNA O
library O
was O
screened O
with O
the O
monoclonal I-GENE
antibody I-GENE
R4A I-GENE
, O
and O
a O
full O
- O
size O
cDNA O
of O
the O
protein O
was O
selected O
. O

Using O
immunogold O
electron O
microscopy O
, O
we O
found O
that O
p58 I-GENE
/ O
p45 I-GENE
and O
p54 I-GENE
are O
localized O
on O
both O
sides O
of O
the O
nuclear O
pore O
complex O
, O
like O
p62 I-GENE
. O

Concurrent O
with O
ligand O
- O
dependent O
uptake O
, O
we O
now O
show O
that O
the O
receptor O
undergoes O
ligand O
- O
induced O
ubiquitination O
, O
suggesting O
that O
receptor O
ubiquitination O
may O
function O
in O
the O
ligand O
- O
dependent O
endocytosis O
of O
the O
a I-GENE
- I-GENE
factor I-GENE
receptor I-GENE
as O
well O
as O
in O
its O
constitutive O
endocytosis O
. O

Transcription O
initiation O
sites O
of O
the O
rat O
II I-GENE
beta I-GENE
-, I-GENE
III I-GENE
beta I-GENE
, I-GENE
and I-GENE
O I-GENE
beta I-GENE
- I-GENE
globin I-GENE
genes O
were O
determined O
to O
be O
52 O
base O
pairs O
( O
bp O
) O
5 O
'- O
upstream O
of O
the O
translation O
initiation O
codon O
( O
ATG O
), O
in O
each O
gene O
by O
primer O
extension O
analysis O
. O

Aggravating O
process O
induced O
by O
indomethacin O
on O
chronic O
gastric O
lesion O
in O
rat O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
protein I-GENE
2 I-GENE
( O
EBNA2 I-GENE
) O
binds O
to O
a O
component O
of O
the O
human O
SNF I-GENE
- O
SWI I-GENE
complex O
, O
hSNF5 I-GENE
/ O
Ini1 I-GENE
. O

Our O
studies O
also O
excluded O
the O
possibility O
that O
the O
phosphorylation O
of O
Ser O
- O
2 O
, O
Ser O
- O
123 O
, O
or O
Ser O
- O
210 O
, O
had O
roles O
in O
the O
trans O
- O
suppression O
activity O
of O
the O
large I-GENE
HDAg I-GENE
, O
in O
the O
assembly O
of O
empty O
virus I-GENE
- I-GENE
like I-GENE
HDAg I-GENE
particle I-GENE
, O
and O
in O
the O
nuclear O
transport O
of O
HDAgs I-GENE
. O

Homologous O
recombination O
between O
the O
Autographa O
californica O
nuclear O
polyhedrosis O
virus O
( O
AcNPV O
) O
genome O
and O
a O
0 O
. O
6 O
- O
kbp O
- O
long O
DNA O
fragment O
derived O
from O
the O
putative O
DNA I-GENE
helicase I-GENE
gene I-GENE
of I-GENE
Bombyx I-GENE
mori I-GENE
nuclear I-GENE
polyhedrosis I-GENE
virus I-GENE
generates O
eh2 O
- O
AcNPV O
, O
an O
expanded O
- O
host O
- O
range O
AcNPV O
mutant O
( O
S O
. O

The O
data O
further O
indicate O
that O
the O
IL I-GENE
- I-GENE
7R I-GENE
alpha I-GENE
chains I-GENE
are O
directly O
involved O
in O
the O
activation O
of O
JAKs I-GENE
and O
STATs I-GENE
and O
have O
a O
major O
role O
in O
proliferative O
signaling O
in O
precursor O
B O
cells O
. O

Furthermore O
, O
the O
potency O
of O
Dacarbacine O
in O
the O
treatment O
of O
carcinoid O
tumors O
seems O
to O
be O
underestimated O
up O
to O
now O
. O

5 O
) O
We O
' O
ve O
noticed O
that O
the O
mean O
value O
of O
the O
cost O
for O
episode O
of O
pnx O
s O
. O
in O
class O
A O
was O
more O
than O
15 O
% O
compared O
to O
class O
B O
and O
the O
cost O
for O
patient O
in O
class O
A O
was O
nearly O
double O
than O
in O
class O
B O
. O

We O
have O
been O
studying O
the O
interaction O
of O
the O
oncogenic O
human O
polyomavirus O
BK O
( O
BKV O
) O
with O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
to O
understand O
the O
biology O
of O
this O
virus O
as O
well O
as O
to O
understand O
the O
basic O
mechanisms O
of O
p53 I-GENE
transactivation O
. O

Site O
S O
- O
II O
also O
spans O
a O
23 O
bp O
sequence O
containing O
two O
tandem O
consensus O
binding O
sites O
with O
three O
base O
pair O
mismatches O
in O
each O
and O
a O
one O
base O
pair O
deletion O
. O

Cbl I-GENE
constitutively O
interacts O
with O
the O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
, O
with O
a O
preference O
for O
the O
amino O
- O
terminal O
domain O
, O
and O
is O
in O
this O
way O
recruited O
to O
Shc I-GENE
upon O
BCR I-GENE
stimulation O
. O

Activation O
mediated O
by O
Cat8p I-GENE
was O
no O
longer O
detectable O
in O
a O
cat1 I-GENE
mutant I-GENE
. O

Treatment O
is O
instituted O
with O
prednisone O
and O
cyclophosphamide O
. O

Unaided O
attempts O
to O
quit O
smoking O
are O
generally O
unsuccessful O
. O

Laboratory O
evaluation O
was O
normal O
, O
and O
neuroimaging O
failed O
to O
confirm O
obstruction O
of O
venous O
or O
lymphatic O
drainage O
. O

Microcomputer O
management O
of O
chronic O
hepatitis O
B O
virus O
asymptomatic O
patients O

While O
fusion O
to O
the O
N O
- O
terminus O
required O
a O
linker O
to O
become O
surface O
accessible O
, O
both O
fusion O
to O
the O
N O
- O
terminus O
and O
to O
the O
C O
- O
terminus O
was O
compatible O
with O
particle O
assembly O
and O
preserved O
the O
native O
antigenicity O
and O
immunogenicity O
of O
HBcAg I-GENE
. O

The O
standard O
dosage O
of O
anti I-GENE
- I-GENE
D I-GENE
currently O
given O
at O
all O
gestational O
ages O
is O
1 O
ampoule O
containing O
125 O
micrograms O
of O
anti I-GENE
- I-GENE
D I-GENE
. O

We O
report O
here O
the O
molecular O
cloning O
of O
a O
putative O
adhesive O
molecule O
from O
P O
. O
falciparum O
that O
shares O
both O
sequence O
and O
structural O
similarities O
with O
a O
sporozoite O
surface O
molecule O
from O
Plasmodium O
termed O
the O
thrombospondin I-GENE
- I-GENE
related I-GENE
anonymous I-GENE
protein I-GENE
( O
TRAP I-GENE
) O
and O
, O
to O
a O
lesser O
extent O
, O
with O
the O
circumsporozoite I-GENE
( I-GENE
CS I-GENE
) I-GENE
protein I-GENE
. O

There O
are O
no O
introns O
within O
the O
gene O
, O
which O
contains O
a O
9360 O
- O
bp O
open O
reading O
frame O
and O
encodes O
a O
377 O
- O
kDa O
protein O
. O

METHODS O
: O
DSF O
was O
instilled O
in O
one O
eye O
chosen O
at O
random O
and O
CF O
in O
the O
fellow O
eye O
of O
13 O
normal O
subjects O
and O
in O
13 O
patients O
with O
KCS O
. O

The O
experience O
of O
the O
lateral O
rhinotomy O
approach O
in O
transsphenoidal O
surgery O
of O
acromegaly O
has O
been O
favourable O
. O

CONCLUSION O
: O
The O
results O
demonstrate O
that O
at O
the O
site O
of O
lumbar O
disc O
herniation O
, O
inflammatory O
cytokines O
such O
as O
interleukin I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
are O
produced O
, O
which O
increases O
prostaglandin O
E2 O
production O
. O

The O
predominant O
sensitizing O
allergens O
in O
Swedish O
asthmatic O
children O
are O
furred O
pet O
animals O
. O

Our O
results O
demonstrate O
that O
distinct O
cytoplasmic O
domains O
of O
these O
cytokine O
receptors O
elicit O
convergent O
signaling O
pathways O
and O
provide O
evidence O
that O
beta I-GENE
c I-GENE
and O
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
function O
as O
a O
complete O
signal O
transducer O
. O

In O
addition O
, O
they O
display O
common O
features O
that O
make O
them O
strikingly O
related O
to O
snoRNA I-GENE
U14 I-GENE
. O

U24 I-GENE
has O
two O
separate O
12 O
nt O
long O
complementarities O
to O
a O
highly O
conserved O
tract O
of O
28S I-GENE
rRNA I-GENE
. O

This O
complex O
interacts O
at O
the O
GTPase I-GENE
domain I-GENE
in O
the O
large O
subunit O
rRNA O
, O
overlapping O
the O
binding O
site O
of O
the O
protein I-GENE
L11 I-GENE
- I-GENE
like I-GENE
eukaryotic I-GENE
counterpart I-GENE
( O
Saccharomyces I-GENE
cerevisiae I-GENE
protein I-GENE
L15 I-GENE
and O
mammalian I-GENE
protein I-GENE
L12 I-GENE
). O

Chromatin O
repression O
of O
these O
replacement O
genes O
would O
be O
avoided O
, O
consistent O
with O
the O
high O
, O
constitutive O
expression O
of O
replacement O
H3 I-GENE
histone I-GENE
genes I-GENE
in O
plants O
. O

This O
transition O
is O
regulated O
positively O
by O
G1 I-GENE
- I-GENE
specific I-GENE
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
cdks I-GENE
) O
and O
negatively O
by O
the O
product O
of O
the O
retinoblastoma I-GENE
tumour I-GENE
suppressor I-GENE
gene I-GENE
, O
pRb I-GENE
. O

Possible O
relationship O
between O
hyperinsulinemia O
and O
glomerular O
hypertrophy O
in O
nephrosclerosis O
. O

Blood O
GSH I-GENE
- I-GENE
Px I-GENE
activity O
was O
measured O
with O
a O
spectrophotometer O
, O
using O
a O
modification O
of O
a O
previously O
described O
assay O
. O

The O
concentrations O
of O
vitamin O
A O
precursors O
and O
vitamin O
E O
in O
the O
hay O
were O
below O
currently O
recommended O
dietary O
levels O
for O
llamas O
, O
and O
alfalfa O
hay O
appears O
to O
provide O
an O
unreliable O
source O
of O
vitamins O
A O
and O
E O
in O
this O
species O
. O

Eight O
cats O
infected O
with O
H O
. O
pylori O
were O
used O
in O
the O
study O
. O

However O
, O
as O
determined O
by O
PCR O
with O
primers O
specific O
for O
the O
26 O
- O
kDa O
product O
, O
the O
majority O
of O
cats O
at O
2 O
and O
4 O
weeks O
p O
. O
t O
. O
had O
gastric O
fluid O
samples O
which O
were O
positive O
for O
H O
. O
pylori O
and O
three O
of O
three O
cats O
at O
2 O
weeks O
p O
. O
t O
. O
had O
dental O
plaque O
which O
was O
positive O
for O
H O
. O
pylori O
. O

To O
derive O
quantitative O
concentration O
changes O
from O
measurements O
of O
light O
attenuation O
, O
the O
optical O
path O
length O
must O
be O
known O
. O

STUDY O
DESIGN O
. O

Following O
the O
injection O
of O
PGF2 O
alpha O
, O
heifers O
were O
observed O
visually O
for O
signs O
of O
estrus O
at O
0730 O
and O
1630 O
( O
45 O
min O
each O
). O

Differential O
activation O
of O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
, O
Jun I-GENE
kinase I-GENE
and O
Janus I-GENE
kinase I-GENE
- O
Stat I-GENE
pathways O
by O
oncostatin I-GENE
M I-GENE
and O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
in O
AIDS O
- O
derived O
Kaposi O
' O
s O
sarcoma O
cells O
. O

There O
is O
general O
agreement O
that O
the O
hepatitis O
C O
virus O
is O
efficiently O
transmitted O
parenterally O
, O
while O
data O
on O
viral O
transmission O
from O
mothers O
to O
babies O
or O
by O
sexual O
or O
non O
- O
sexual O
household O
contact O
are O
conflicting O
. O

Ten O
weeks O
after O
reconstruction O
, O
the O
regenerating O
nerves O
already O
resembled O
normal O
nerves O
. O

The O
distribution O
and O
organization O
of O
projections O
from O
the O
spinal O
cervical O
enlargement O
to O
subnucleus O
reticularis O
dorsalis O
( O
SRD O
) O
and O
the O
neighbouring O
Cuneate O
nucleus O
( O
Cu O
) O
area O
was O
studied O
in O
the O
rat O
by O
using O
microinjections O
of O
Phaseolus I-GENE
vulgaris I-GENE
leucoagglutinin I-GENE
( O
PHA I-GENE
- I-GENE
L I-GENE
) O
into O
different O
laminae O
around O
the O
C7 O
level O
. O

The O
levels O
of O
fibrinogen I-GENE
as O
well O
as O
antithrombin I-GENE
III I-GENE
( O
ATIII I-GENE
) O
and O
heparin I-GENE
cofactor I-GENE
II I-GENE
( O
HCII I-GENE
) O
activities O
were O
steadily O
increased O
in O
loop O
- O
bearing O
animals O
. O

Amplification O
and O
overexpression O
of O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
21MT O
- O
2 O
and O
21MT O
- O
1 O
human O
breast O
carcinoma O
cells O
results O
in O
progressively O
elevated O
levels O
of O
constitutively O
tyrosine I-GENE
- I-GENE
phosphorylated I-GENE
p185erbB I-GENE
- I-GENE
2 I-GENE
and O
is O
associated O
with O
progressive O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( O
IGF I-GENE
) O
and O
combined O
IGF I-GENE
/ O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
) O
independence O
in O
culture O
. O

Facioscapulohumeral O
muscular O
dystrophy O
( O
FSHD O
) O
is O
an O
autosomal O
dominant O
, O
neuromuscular O
disorder O
characterized O
by O
progressive O
weakness O
of O
muscles O
in O
the O
face O
, O
shoulder O
and O
upper O
arm O
. O

The O
mature O
chromosome O
4 O
FRG1 I-GENE
transcript I-GENE
is O
1042 O
bp O
in O
length O
and O
contains O
nine O
exons O
which O
encode O
a O
putative O
protein O
of O
258 O
amino O
acid O
residues O
. O

Patients O
who O
have O
undergone O
thyroidectomy O
for O
thyroid O
carcinoma O
are O
frequently O
subjected O
to O
periods O
of O
induced O
severe O
hypothyroidism O
in O
preparation O
for O
131I O
whole O
body O
scanning O
and O
measurement O
of O
serum O
TG I-GENE
. O

Full O
thyroid O
function O
testing O
was O
performed O
on O
600 O
randomly O
selected O
samples O
with O
normal O
TSH I-GENE
values O
and O
also O
on O
subjects O
with O
abnormal O
TSH I-GENE
levels O
. O

In O
a O
third O
experiment O
, O
crossover O
AM O
between O
dissimilar O
textures O
was O
investigated O
, O
and O
it O
was O
found O
that O
the O
more O
salient O
textures O
carried O
the O
AM O
. O

The O
relative O
tumor O
FDG O
- O
uptake O
( O
Q O
- O
MRGlu O
) O
( O
tumor O
/ O
contralateral O
cortex O
) O
of O
all O
meningiomas O
was O
calculated O
with O
0 O
. O
73 O
+/- O
0 O
. O
37 O
( O
0 O
. O
24 O
- O
1 O
. O
79 O
). O

Zatebradine O
weakly O
depressed O
the O
ectopic O
ventricular O
rate O
but O
not O
the O
arrhythmic O
ratio O
of O
the O
ventricular O
arrhythmias O
induced O
by O
two O
- O
stage O
coronary O
ligation O
24 O
h O
after O
the O
ligation O
in O
conscious O
dogs O
. O

Catha O
edulis O
, O
a O
plant O
that O
has O
amphetamine O
effects O
. O

The O
predicted O
protein O
, O
Seb1p I-GENE
, O
consists O
of O
82 O
amino O
acids O
and O
contains O
one O
potential O
membrane O
- O
spanning O
region O
at O
the O
C O
- O
terminus O
but O
no O
N O
- O
terminal O
signal O
sequence O
. O

The O
SEB1 I-GENE
homologue O
thus O
isolated O
, O
SEB2 I-GENE
, O
encodes O
a O
protein O
53 O
% O
identical O
to O
Seb1p I-GENE
. O

Nonetheless O
, O
that O
ventricular O
afferents O
, O
in O
certain O
special O
settings O
, O
are O
able O
to O
induce O
e O
. O
g O
. O
generalised O
vasodilation O
and O
hypotension O
cannot O
be O
excluded O
. O

Large O
ones O
were O
similar O
in O
size O
to O
the O
main O
lobe O
and O
small O
ones O
were O
approximately O
1 O
/ O
4 O
of O
the O
length O
of O
the O
main O
lobe O
. O

Fragments O
and O
analogs O
of O
the O
hormone O
ACTH I-GENE
were O
previously O
shown O
to O
have O
beneficial O
effect O
on O
the O
outcome O
of O
head O
injury O
, O
while O
elevated O
levels O
of O
corticosterone O
( O
CS O
) O
exacerbate O
it O
. O

The O
most O
frequent O
causes O
of O
the O
meningitis O
was O
the O
external O
ventricular O
drainage O
( O
14 O
. O
8 O
%), O
post O
- O
neurosurgical O
( O
0 O
. O
8 O
%) O
and O
head O
injury O
( O
0 O
. O
0007 O
%). O

Fifty O
- O
one O
patients O
with O
primary O
refractory O
or O
relapsed O
malignant O
lymphoma O
( O
47 O
non O
- O
Hodgkin O
' O
s O
lymphoma O
and O
four O
Hodgkin O
' O
s O
disease O
) O
were O
treated O
with O
a O
new O
chemotherapeutic O
regimen O
( O
cisplatinum O
, O
methyl O
GAG O
, O
bleomocyin O
, O
methyl O
prednisolon O
). O

With O
the O
increasing O
use O
of O
ACE I-GENE
inhibitors O
, O
the O
incidence O
of O
rare O
adverse O
effects O
such O
as O
potentially O
lethal O
pancreatitis O
is O
likely O
to O
increase O
. O

In O
3 O
treatments O
the O
diet O
was O
supplemented O
with O
0 O
, O
100 O
and O
150 O
mg O
probiotic O
/ O
kg O
food O
. O

Low O
- O
dose O
aspirin O
and O
recurrent O
miscarriage O
. O

Protein O
films O
are O
distinctly O
different O
in O
mechanical O
profiles O
from O
those O
films O
made O
of O
other O
materials O
. O

Furthermore O
, O
cpxA I-GENE
* I-GENE
mutations O
suppress O
the O
toxicity O
conferred O
by O
the O
LamB I-GENE
- O
LacZ I-GENE
hybrid O
protein O
, O
which O
exerts O
its O
effects O
in O
the O
cytoplasm O
, O
sequestered O
from O
DegP I-GENE
. O

The O
PI3K_68D I-GENE
cDNA I-GENE
encodes O
a O
protein O
of O
210 O
kDa O
, O
which O
lacks O
sequences O
implicated O
in O
linking O
p110 I-GENE
PI I-GENE
3 I-GENE
- I-GENE
kinases I-GENE
to O
p85 I-GENE
adaptor I-GENE
proteins I-GENE
, O
but O
contains O
an O
amino O
- O
terminal O
proline O
- O
rich O
sequence O
, O
which O
could O
bind O
to O
SH3 I-GENE
domains I-GENE
, O
and O
a O
carboxy O
- O
terminal O
C2 I-GENE
domain O
. O

In O
vitro O
interaction O
studies O
, O
using O
proteins O
fused O
to O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
, O
showed O
that O
RBP I-GENE
- I-GENE
J I-GENE
kappa I-GENE
and O
Su I-GENE
( I-GENE
H I-GENE
) I-GENE
bind O
directly O
to O
the O
RAM23 I-GENE
regions I-GENE
of O
mouse I-GENE
Notch1 I-GENE
and O
Drosophila I-GENE
Notch I-GENE
, O
respectively O
. O

AIMS O
/ O
METHODS O
: O
Reticuloendothelial O
system O
function O
, O
as O
assessed O
by O
clearance O
of O
radiolabelled O
bacteria O
, O
was O
evaluated O
in O
acute O
liver O
injury O
induced O
by O
D O
- O
galactosamine O
in O
rats O
, O
and O
compared O
with O
that O
after O
70 O
% O
liver O
resection O
model O
. O

Our O
laboratory O
and O
others O
have O
shown O
alternative O
splicing O
of O
up O
to O
ten O
exons O
at O
a O
discrete O
extracellular O
site O
to O
be O
primarily O
responsible O
for O
the O
generation O
of O
CD44 I-GENE
variant I-GENE
( O
CD44v I-GENE
) O
isoforms O
. O

Study O
groups O
were O
control O
, O
and O
those O
treated O
with O
the O
alpha1 I-GENE
- I-GENE
adrenoceptor I-GENE
- I-GENE
subtype I-GENE
blockers O
WB4101 O
( O
0 O
. O
5 O
mg O
/ O
kg O
i O
. O
v O
.) O
or O
chloroethylclonidine O
( O
1 O
. O
9 O
mg O
/ O
kg O
i O
. O
v O
.). O

This O
caused O
severe O
cortical O
damage O
and O
neuronal O
loss O
in O
hippocampus O
subfields O
CA1 O
, O
CA3 O
, O
and O
hilus O
. O

The O
occurrence O
of O
multiple O
malignancy O
was O
studied O
in O
674 O
patients O
with O
hematologic O
malignancies O
who O
were O
admitted O
to O
this O
department O
during O
the O
past O
10 O
years O
. O

The O
upTRE O
binds O
more O
T3R I-GENE
homodimers I-GENE
and O
less O
T3R I-GENE
- O
RXR I-GENE
heterodimers O
than O
the O
dnTRE O
, O
and O
T3 O
more O
readily O
facilitates O
heterodimer O
binding O
to O
the O
dn O
- O
than O
to O
the O
upTRE O
. O

Transcriptional O
control O
of O
a O
nuclear O
gene O
encoding O
a O
mitochondrial O
fatty O
acid O
oxidation O
enzyme O
in O
transgenic O
mice O
: O
role O
for O
nuclear O
receptors O
in O
cardiac O
and O
brown O
adipose O
expression O
. O

Hoeben O
, O
F O
. O
J O
. O

Twelve O
genomic O
fragments O
containing O
novel O
response O
elements O
are O
described O
, O
and O
the O
transcription O
unit O
associated O
with O
one O
of O
them O
, O
NN I-GENE
- I-GENE
84AG I-GENE
, O
was O
characterized O
in O
detail O
. O

Moreover O
, O
glucan I-GENE
synthase I-GENE
activity O
, O
which O
is O
activated O
by O
Rho1p I-GENE
, O
was O
significantly O
reduced O
in O
the O
deltabem4 I-GENE
mutant I-GENE
. O

In O
gel O
retardation O
assays O
, O
an O
RCS O
cell O
- O
specific O
protein O
and O
another O
closely O
related O
protein O
expressed O
only O
in O
RCS O
cells O
and O
primary O
chondrocytes O
bound O
to O
a O
10 O
- O
bp O
sequence O
within O
the O
18 O
- O
mer O
. O

Two O
classes O
of O
Xanthomonas O
pathogens O
evading O
Bs2 O
host O
resistance O
and O
displaying O
reduced O
fitness O
were O
found O
to O
be O
specifically O
mutated O
in O
avrBs2 I-GENE
. O

Members O
of O
the O
Ras I-GENE
subfamily I-GENE
of O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
have O
been O
shown O
to O
be O
promiscuous O
towards O
a O
variety O
of O
putative O
effector O
molecules O
such O
as O
the O
protein I-GENE
kinase I-GENE
c I-GENE
- I-GENE
Raf I-GENE
and O
the O
Ral I-GENE
- I-GENE
specific I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
Ral I-GENE
- I-GENE
GEF I-GENE
). O

Thus O
, O
the O
characterization O
of O
the O
promoter O
region O
should O
help O
to O
define O
regulatory O
elements O
that O
control O
neuron O
- O
specific O
and O
developmental O
expression O
of O
the O
MAP1B I-GENE
gene I-GENE
. O

The O
cDNA O
encoded O
a O
mature O
protein O
of O
240 O
amino O
acids O
, O
including O
a O
29 O
- O
amino O
acid O
signal O
sequence O
. O

Mutants O
lacking O
the O
3 O
' O
stem O
- O
loop O
exhibited O
a O
75 O
% O
reduction O
in O
the O
level O
of O
psaB I-GENE
mRNA O
. O

The O
deduced O
amino O
acid O
sequence O
was O
highly O
conserved O
across O
the O
wide O
range O
of O
eukaryotes O
( O
vertebrates O
, O
invertebrates O
, O
fungi O
, O
plants O
and O
protozoa O
) O
in O
which O
this O
gene O
has O
now O
been O
identified O
. O

Biol O
. O

Semidominant O
mutations O
in O
the O
yeast I-GENE
Rad51 I-GENE
protein I-GENE
and O
their O
relationships O
with O
the O
Srs2 I-GENE
helicase I-GENE
. O

Alterations O
of O
the O
5q23 O
- O
q31 O
interval O
are O
frequently O
observed O
in O
myelodysplasia O
and O
myeloid O
leukemia O
. O

Previous O
studies O
have O
suggested O
that O
the O
616 O
amino O
acid O
, O
70 I-GENE
- I-GENE
kDa I-GENE
subunit I-GENE
of I-GENE
RPA I-GENE
( O
RPA I-GENE
70 I-GENE
) O
is O
composed O
of O
multiple O
structural O
/ O
functional O
domains O
. O

Neurons O
were O
held O
at O
- O
67 O
mV O
to O
equate O
voltage O
- O
dependent O
effects O
. O

This O
site O
acts O
as O
a O
negative O
element O
when O
transferred O
to O
the O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
, O
but O
does O
not O
confer O
inducibility O
. O

The O
extent O
of O
the O
fbpA O
operator O
sequence O
( O
42 O
bp O
), O
as O
defined O
by O
our O
footprinting O
analysis O
, O
would O
suggest O
the O
binding O
of O
two O
Fur I-GENE
repressor I-GENE
dimers I-GENE
. O

The O
structural O
similarity O
between O
Vav I-GENE
and O
other O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
for O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
together O
with O
the O
recent O
identification O
of O
biochemical O
routes O
specific O
for O
members O
of O
the O
Ras I-GENE
and O
Rho I-GENE
family I-GENE
of O
GTPases I-GENE
, O
prompted O
us O
to O
explore O
whether O
MAPK I-GENE
or O
JNK I-GENE
are O
downstream O
components O
of O
the O
Vav I-GENE
signaling O
pathways O
. O

CONCLUSION O
: O
Twice O
daily O
treatment O
with O
inhaled O
fluticasone O
propionate O
50 O
micrograms O
or O
100 O
micrograms O
was O
significantly O
more O
effective O
than O
theophylline O
in O
the O
treatment O
of O
mild O
- O
to O
- O
moderate O
asthma O
. O

Our O
results O
support O
a O
model O
where O
both O
E2F I-GENE
- O
and O
CDE O
- O
mediated O
repression O
, O
acting O
at O
different O
stages O
in O
the O
cell O
cycle O
, O
are O
dependent O
on O
promoter O
- O
specific O
CHR O
elements O
. O

The O
cDNA O
clone O
was O
used O
as O
a O
homologous O
probe O
to O
isolate O
a O
truncated O
genomic O
clone O
encoding O
H2A1 I-GENE
. O

Comparison O
of O
the O
deduced O
amino O
acid O
sequences O
with O
protein O
sequences O
of O
T O
. O
pyriformis O
H2As I-GENE
showed O
only O
two O
and O
three O
differences O
respectively O
, O
in O
a O
total O
of O
137 O
amino O
acids O
for O
H2A1 I-GENE
, O
and O
132 O
amino O
acids O
for O
H2A2 I-GENE
, O
indicating O
the O
two O
genes O
arose O
before O
the O
divergence O
of O
these O
two O
species O
. O

Cognitive O
visual O
dysfunction O
in O
a O
child O
with O
cerebral O
damage O
. O

Interaction O
was O
apparently O
determined O
by O
the O
N O
- O
terminal O
splice O
region O
of O
RPDE I-GENE
- I-GENE
6 I-GENE
, O
as O
the O
PDE4A I-GENE
splice O
variant O
RPDE I-GENE
- I-GENE
39 I-GENE
, O
which O
differs O
from O
RPDE I-GENE
- I-GENE
6 I-GENE
at O
the O
extreme O
N O
- O
terminus O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
; O
met26RD1 I-GENE
( O
where O
RD1 I-GENE
is O
rat I-GENE
' I-GENE
dunc I-GENE
- I-GENE
like I-GENE
' I-GENE
PDE I-GENE
), O
which O
has O
the O
N O
- O
terminal O
splice O
region O
deleted O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
, O
and O
the O
association O
of O
RPDE I-GENE
- I-GENE
6 I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
- O
SH3 I-GENE
was O
blocked O
by O
a O
fusion O
protein O
formed O
from O
the O
N O
- O
terminal O
splice O
region O
. O

Potentially O
load O
- O
insensitive O
measures O
of O
ventricular O
performance O
were O
therefore O
evaluated O
in O
10 O
open O
- O
and O
closed O
- O
chested O
, O
anesthetized O
rabbits O
. O

Large O
strain O
differences O
were O
found O
for O
all O
variables O
recorded O
, O
i O
. O
e O
., O
the O
proportion O
of O
attacking O
males O
, O
the O
time O
spent O
in O
the O
brightly O
lit O
box O
, O
and O
the O
number O
of O
transitions O
between O
the O
lit O
and O
the O
dark O
boxes O
. O

The O
effect O
of O
ligustrazine O
hydrochloride O
( O
LTH O
) O
on O
depressing O
pulmonary O
artery O
hypertension O
has O
been O
proved O
in O
recent O
studies O
. O

It O
is O
the O
oxidation O
peak O
of O
this O
product O
, O
arising O
in O
acidic O
media O
at O
0 O
. O
42 O
V O
, O
which O
was O
analysed O
using O
DPV O
, O
again O
following O
the O
accumulation O
of O
clenbuterol O
at O
the O
Nafion O
- O
modified O
CPE O
. O

Phenylephrine O
is O
a O
pure O
alpha I-GENE
- I-GENE
1 I-GENE
adrenoreceptor I-GENE
agonist O
known O
to O
produce O
marked O
systemic O
vasoconstriction O
and O
associated O
hypertension O
with O
occasional O
profound O
reflex O
bradycardia O
. O

The O
expression O
of O
the O
first O
two O
genes O
located O
in O
this O
unit O
( O
c I-GENE
- I-GENE
gvpD I-GENE
and O
c I-GENE
- I-GENE
gvpE I-GENE
) O
was O
also O
monitored O
by O
Western O
blot O
( O
immunoblot O
) O
analyses O
using O
antisera O
raised O
against O
these O
proteins O
synthesized O
in O
Escherichia O
coli O
. O

One O
unit O
encodes O
traA I-GENE
, O
traF I-GENE
, O
and O
traB I-GENE
, O
while O
the O
second O
encodes O
traC I-GENE
, O
traD I-GENE
, O
and O
traG I-GENE
. O

A O
. O

In O
an O
effort O
to O
isolate O
genes O
with O
down O
- O
regulated O
expression O
at O
the O
mRNA O
level O
during O
oncogenic O
transformation O
of O
human O
mammary O
epithelial O
cells O
( O
MECs O
), O
we O
performed O
subtractive O
hybridization O
between O
normal O
MEC O
strain O
76N O
and O
its O
radiation O
- O
transformed O
tumorigenic O
derivative O
76R O
- O
30 O
. O

CASE O
REPORT O
: O
Referred O
because O
of O
a O
right O
corneal O
perforation O
with O
cellular O
reaction O
in O
anterior O
chamber O
, O
a O
patient O
was O
sutured O
and O
treated O
with O
a O
single O
intravitreal O
injection O
of O
0 O
. O
2 O
ml O
( O
1 O
mg O
) O
Amikacin O
and O
0 O
. O
2 O
ml O
( O
1 O
mg O
) O
Vancomycin O
. O

In O
the O
same O
period O
we O
pointed O
out O
an O
increase O
of O
hematocrit O
( O
from O
29 O
% O
to O
35 O
%) O
and O
of O
the O
Hb I-GENE
( O
from O
9 O
. O
3 O
to O
11 O
. O
2 O
g O
/ O
dl O
). O

The O
P I-GENE
- I-GENE
wr I-GENE
and O
P I-GENE
- I-GENE
rr I-GENE
cDNA I-GENE
sequences I-GENE
are O
very O
similar O
in O
their O
5 O
' O
regions O
. O

Because O
the O
hcf109 I-GENE
locus I-GENE
was O
mapped O
at O
a O
distance O
< O
0 O
. O
1 O
centimorgans O
from O
the O
phytochrome I-GENE
C I-GENE
gene I-GENE
, O
its O
molecular O
characterization O
by O
positional O
cloning O
is O
possible O
. O

The O
human I-GENE
MSH I-GENE
- I-GENE
2 I-GENE
gene I-GENE
product I-GENE
is O
a O
member O
of O
a O
highly O
conserved O
family O
of O
proteins O
which O
are O
involved O
in O
post O
- O
replication O
mismatch O
repair O
. O
hMSH I-GENE
- I-GENE
2 I-GENE
is O
homologous O
to O
Escherichia O
coli O
( O
E O
. O
coli O
) O
MutS I-GENE
and O
Sacchromyces I-GENE
cerevisiae I-GENE
MSH I-GENE
- I-GENE
1 I-GENE
and O
MSH I-GENE
- I-GENE
2 I-GENE
proteins I-GENE
, O
which O
recognise O
heteroduplex O
DNA O
at O
the O
sites O
of O
all O
single O
base O
mismatches O
and O
deletions O
or O
insertions O
up O
to O
4 O
base O
pairs O
. O
hMSH I-GENE
- I-GENE
2 I-GENE
is O
one O
of O
the O
hereditary I-GENE
non I-GENE
- I-GENE
polyposis I-GENE
colorectal I-GENE
cancer I-GENE
( I-GENE
HNPCC I-GENE
) I-GENE
tumor I-GENE
suppressor I-GENE
genes I-GENE
, O
and O
maps O
to O
human O
chromosome O
2p16 O
. O

We O
have O
recently O
shown O
that O
the O
tissue O
- O
specific O
expression O
of O
the O
RAR I-GENE
beta I-GENE
2 I-GENE
gene I-GENE
in I-GENE
mouse I-GENE
embryos I-GENE
is O
regulated O
at O
the O
translational O
level O
by O
short O
upstream O
open O
reading O
frames O
( O
uORFs O
) O
In O
the O
5 O
'- O
untranslated O
region O
( O
Zimmer O
, O
A O
., O
A O
. O
M O
. O

We O
have O
previously O
isolated O
a O
cDNA O
for O
a O
transcription O
factor O
referred O
to O
as O
Zfhep I-GENE
( O
zinc I-GENE
finger I-GENE
homeodomain I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
containing O
two O
separate O
zinc O
finger O
domains O
, O
ZD1 I-GENE
and O
ZD2 I-GENE
, O
each O
of O
which O
binds O
DNA O
, O
and O
a O
homeodomain O
. O

The O
structure O
of O
these O
genes O
suggests O
a O
common O
ancestor O
for O
all O
viperid I-GENE
PLA2 I-GENE
genes I-GENE
. O

Increased O
PTHRP I-GENE
production O
by O
a O
tyrosine I-GENE
kinase I-GENE
oncogene I-GENE
, O
Tpr I-GENE
- I-GENE
Met I-GENE
: O
role O
of O
the O
Ras I-GENE
signaling O
pathway O
. O

Subsequent O
to O
their O
secretion O
, O
the O
IGF I-GENE
- I-GENE
II I-GENE
in O
xz97 O
and O
G11 O
cells O
accumulated O
in O
the O
conditioned O
medium O
mostly O
as O
two O
partially O
processed O
species O
with O
appMr O
, O
of O
17K O
and O
14K O
, O
respectively O
. O

Paradoxically O
, O
coexpression O
of O
the O
transcriptionally O
inactive O
, O
amino O
- O
terminally O
deleted O
IDX I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
proteins I-GENE
, O
either O
with O
the O
wild I-GENE
- I-GENE
type I-GENE
IDX I-GENE
- I-GENE
1 I-GENE
or O
with O
themselves O
, O
results O
in O
a O
marked O
enhancement O
of O
transactivation O
of O
the O
transcriptional O
TAAT I-GENE
- I-GENE
1 I-GENE
element I-GENE
reporter I-GENE
. O

All O
patients O
had O
abnormal O
von I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
fragmentation O
as O
reflected O
by O
decreased O
high O
molecular O
weight O
and O
increased O
low O
molecular O
weight O
vWF I-GENE
multimers I-GENE
in O
the O
circulation O
. O

In O
an O
attempt O
to O
investigate O
whether O
the O
intergenic O
region O
between O
the O
oleosin I-GENE
and O
a O
second O
open O
reading O
frame O
( O
ORFII O
) O
in O
Brassica O
napus O
( O
L O
.) O
is O
a O
divergent O
promoter O
, O
and O
also O
to O
characterize O
the O
ORFII I-GENE
, O
cDNA I-GENE
clones I-GENE
homologous I-GENE
to I-GENE
ORFII I-GENE
were O
isolated O
from O
a O
leaf O
cDNA O
library O
. O

The O
ORFII I-GENE
gene I-GENE
product I-GENE
is O
targeted O
to O
the O
chloroplast O
, O
which O
is O
consistent O
with O
previous O
data O
indicating O
the O
presence O
of O
PMSR I-GENE
activity O
in O
the O
chloroplast O
. O

Characterization O
of O
LRP I-GENE
, O
a O
leucine I-GENE
- I-GENE
rich I-GENE
repeat I-GENE
( I-GENE
LRR I-GENE
) I-GENE
protein I-GENE
from I-GENE
tomato I-GENE
plants I-GENE
that O
is O
processed O
during O
pathogenesis O
. O

To O
test O
whether O
Sp1 I-GENE
and O
zif268 I-GENE
/ O
egr I-GENE
- I-GENE
1 I-GENE
interact O
with O
this O
motif O
, O
gel O
retardation O
assays O
were O
performed O
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
clinical O
characteristics O
, O
treatment O
and O
outcome O
of O
310 O
patients O
with O
hydatidiform O
mole O
. O

Stably O
transfected O
human O
kidney O
293 O
cells O
expressing O
the O
wild I-GENE
type I-GENE
rat I-GENE
LH I-GENE
/ I-GENE
CG I-GENE
receptor I-GENE
( O
rLHR I-GENE
) O
or O
receptors O
with O
C O
- O
terminal O
tails O
truncated O
at O
residues O
653 O
, O
631 O
, O
or O
628 O
( O
designated O
rLHR I-GENE
- I-GENE
t653 I-GENE
, O
rLHR I-GENE
- I-GENE
t631 I-GENE
, O
and O
rLHR I-GENE
- I-GENE
t628 I-GENE
) O
were O
used O
to O
probe O
the O
importance O
of O
this O
region O
on O
the O
regulation O
of O
hormonal O
responsiveness O
. O

Are O
low O
P300 O
amplitudes O
a O
marker O
for O
schizophrenia O
. O

Sleep O
was O
determined O
again O
for O
an O
additional O
3 O
days O
and O
6 O
hours O
. O

The O
patients O
are O
two O
healthy O
adult O
males O
. O

Chloroplast I-GENE
mutator I-GENE
( O
chm I-GENE
) O
of O
Arabidopsis O
is O
a O
recessive O
nuclear O
mutation O
that O
causes O
green O
and O
white O
variegation O
in O
leaves O
and O
is O
inherited O
in O
a O
non O
- O
Mendelian O
fashion O
. O

Indoor O
concentrations O
were O
only O
weakly O
correlated O
with O
outdoor O
concentrations O
, O
however O
, O
and O
personal O
exposures O
were O
even O
more O
poorly O
correlated O
with O
outdoor O
concentrations O
. O

A O
neuropsychological O
test O
battery O
was O
used O
that O
contained O
the O
Wisconsin O
card O
sorting O
test O
, O
Street O
completion O
test O
, O
Stroop O
test O
, O
a O
dichotic O
memory O
listening O
test O
, O
and O
a O
facial O
recognition O
test O
. O

We O
present O
this O
case O
because O
of O
the O
rarity O
of O
left O
ventricular O
involvement O
associated O
with O
ARVD O
. O

In O
a O
randomized O
single O
- O
blind O
3 O
x O
3 O
Latin O
- O
square O
study O
with O
corrections O
for O
any O
carryover O
effects O
, O
27 O
males O
and O
30 O
females O
consumed O
supplements O
containing O
glucose O
or O
resistant O
starch O
( O
RS O
) O
from O
raw O
high O
- O
amylose O
cornstarch O
( O
RS2 O
) O
or O
from O
retrograded O
high O
- O
amylose O
cornstarch O
( O
RS3 O
). O

The O
5 O
' O
flanking O
region O
of O
the O
mouse I-GENE
Met I-GENE
- I-GENE
ase I-GENE
- I-GENE
1 I-GENE
gene I-GENE
also O
shares O
considerable O
regions O
of O
identity O
with O
the O
5 O
' O
flanking O
region O
of O
the O
rat I-GENE
Met I-GENE
- I-GENE
ase I-GENE
- I-GENE
1 I-GENE
gene I-GENE
. O

The O
[ O
18F O
] O
FMISO O
TMRR O
is O
a O
simple O
and O
clinically O
useful O
index O
for O
detecting O
tumour O
hypoxia O
in O
NPC O
. O

Improved O
methods O
have O
been O
developed O
for O
maintaining O
and O
breeding O
the O
neotropical O
short O
- O
tailed O
fruit O
bat O
, O
Carollia O
perspicillata O
, O
in O
an O
easily O
- O
reproduced O
, O
laboratory O
setting O
. O

In O
addition O
, O
the O
time O
to O
engraftment O
was O
significantly O
shorter O
in O
the O
amifostine O
arm O
in O
both O
cohorts O
. O

Also O
like O
the O
thrombin I-GENE
receptor I-GENE
, O
PAR2 I-GENE
can O
be O
activated O
by O
the O
hexapeptide O
corresponding O
to O
its O
tethered O
ligand O
sequence O
independent O
of O
receptor O
cleavage O
. O

We O
conclude O
that O
CPET O
is O
a O
useful O
investigation O
in O
the O
management O
of O
patients O
with O
cardiopulmonary O
disease O
and O
complements O
the O
various O
other O
investigations O
offered O
by O
a O
pulmonary O
function O
laboratory O
. O

Using O
fluorescence O
in O
situ O
hybridization O
, O
we O
mapped O
the O
chromosome O
- O
17 O
breakpoint O
in O
a O
patient O
with O
acampomelic O
CMPD O
and O
sex O
reversal O
, O
who O
carries O
a O
de O
novo O
constitutional O
t O
( O
12 O
; O
17 O
) O
translocation O
, O
between O
two O
known O
cosmid O
markers O
in O
the O
17q24 O
- O
q25 O
region O
. O

This O
is O
concluded O
from O
the O
isolation O
of O
cDNAs O
from O
spinach O
( O
Spinacia O
oleracea O
) O
and O
barley O
( O
Hordeum O
vulgare O
cv O
. O

The O
data O
presented O
in O
this O
work O
indicate O
that O
thi1 I-GENE
may O
also O
be O
involved O
in O
DNA O
damage O
tolerance O
in O
plant O
cells O
. O

In O
the O
rat I-GENE
rnu I-GENE
allele I-GENE
described O
here O
, O
a O
nonsense O
mutation O
in O
exon O
8 O
of O
the O
whn I-GENE
gene I-GENE
was O
identified O
. O

Such O
an O
increase O
in O
the O
steady O
- O
state O
testicular I-GENE
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
apparently O
is O
not O
the O
result O
of O
an O
up O
- O
regulation O
by O
germ O
cells O
because O
germ O
cells O
cocultured O
with O
Sertoli O
cells O
failed O
to O
elicit O
an O
increase O
in O
the O
Sertoli O
cell O
steady O
- O
state O
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
. O

Control O
intact O
rats O
were O
age O
- O
matched O
to O
the O
different O
treated O
groups O
. O

DESIGN O
: O
A O
cross O
- O
sectional O
study O
. O

In O
the O
SPK O
and O
PTA O
category O
, O
anti O
- O
T O
- O
cell O
therapy O
significantly O
lowered O
the O
risk O
of O
graft O
loss O
. O

We O
have O
identified O
a O
strong O
Tas I-GENE
- I-GENE
responsive I-GENE
element I-GENE
, O
designated O
TRE I-GENE
( O
GP I-GENE
), O
near O
the O
3 O
' O
end O
of O
the O
gag I-GENE
gene I-GENE
and O
preceding O
the O
pol I-GENE
gene I-GENE
of O
SFV O
- O
1 O
. O

Although O
the O
binding O
of O
IE2 I-GENE
86 I-GENE
to O
nonphosphorylated O
full I-GENE
- I-GENE
length I-GENE
CREB I-GENE
or O
deltaCREB I-GENE
is O
minimal O
, O
IE2 I-GENE
86 I-GENE
does O
form O
complexes O
with O
p300 I-GENE
and O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
), O
which O
in O
turn O
bind O
to O
CREB I-GENE
and O
can O
serve O
as O
adaptor O
proteins O
for O
CREB I-GENE
function O
. O

A O
transgenic O
complementation O
assay O
was O
used O
to O
test O
whether O
NIa I-GENE
supplied O
in O
trans O
could O
rescue O
amplification O
- O
defective O
viral O
genomes O
encoding O
altered O
NIa I-GENE
proteins I-GENE
. O

On O
the O
basis O
of O
its O
bZIP O
structural O
homology O
, O
meq I-GENE
is O
perhaps O
the O
only O
member O
of O
the O
jun I-GENE
- O
fos I-GENE
gene O
family O
completely O
viral O
in O
origin O
. O

The O
rCBF O
and O
vasomotion O
were O
recorded O
by O
laser O
- O
doppler O
fluxmetry O
. O

Although O
basal O
vessels O
may O
constrict O
distal O
parenchymal O
vessels O
tend O
to O
dilate O
after O
SAH O
. O

The O
triple O
combination O
of O
nizatidine O
, O
clarithromycin O
, O
and O
bismuth O
subcitrate O
resulted O
in O
an O
ulcer O
healing O
rate O
of O
98 O
% O
and O
an O
H O
. O
pylori O
eradication O
rate O
of O
90 O
%. O

Several O
lines O
of O
evidence O
presented O
here O
suggest O
that O
PKC I-GENE
- I-GENE
zeta I-GENE
plays O
a O
role O
in O
alpha I-GENE
2 I-GENE
integrin I-GENE
gene I-GENE
expression O
. O

Plasma O
thrombomodulin I-GENE
: O
a O
marker O
for O
microvascular O
complications O
in O
diabetes O
mellitus O
. O

Update O
: O
diphtheria O
epidemic O
in O
the O
newly O
independent O
states O
of O
the O
former O
USSR O
, O
January O
1995 O
- O
March O
1996 O
. O

The O
characterization O
of O
the O
promoter O
region O
indicated O
that O
three O
distinct O
regulatory O
elements O
corresponding O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
( O
or O
TRE O
), O
a O
PRDII I-GENE
/ O
kappaB I-GENE
domain O
, O
and O
a O
CAAT O
box O
are O
involved O
in O
the O
activation O
by O
pp60 I-GENE
( I-GENE
v I-GENE
-) I-GENE
src I-GENE
. O

Serine O
528 O
is O
phosphorylated O
in O
vivo O
in O
several O
cell O
lines O
, O
and O
substitution O
of O
serine O
528 O
to O
alanine O
( O
S528A O
) O
resulted O
in O
an O
increased O
ability O
of O
Myb I-GENE
to O
transactivate O
a O
synthetic O
promoter O
containing O
five O
copies O
of O
the O
mim I-GENE
- I-GENE
1A I-GENE
Myb I-GENE
- O
responsive O
element O
and O
a O
minimal O
herpes I-GENE
tk I-GENE
promoter I-GENE
. O

The O
DNA O
binding O
and O
multimerization O
activities O
of O
c I-GENE
- I-GENE
Myb I-GENE
appear O
to O
be O
unaffected O
by O
the O
S528A O
substitution O
, O
suggesting O
that O
phosphorylation O
of O
serine O
528 O
may O
mediate O
its O
effect O
on O
the O
transcription O
transactivating O
activity O
of O
c I-GENE
- I-GENE
Myb I-GENE
by O
regulating O
interactions O
with O
other O
proteins O
. O

The O
amount O
of O
these O
factors O
was O
reduced O
in O
GEO O
cells O
in O
which O
the O
u I-GENE
- I-GENE
PAR I-GENE
gene I-GENE
is O
only O
weakly O
transcriptionally O
activated O
. O

PIP2 O
, O
when O
incorporated O
into O
phosphatidylcholine O
carrier O
vesicles O
, O
binds O
tightly O
to O
the O
guanine O
nucleotide O
- O
depleted O
form O
of O
Cdc42Hs I-GENE
and O
weakly O
to O
the O
GDP O
- O
bound O
form O
of O
the O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
but O
does O
not O
bind O
to O
GTP O
- O
bound O
Cdc42Hs I-GENE
, O
similar O
to O
what O
was O
observed O
for O
the O
Dbl I-GENE
oncoprotein I-GENE
. O

Purified O
spleen O
GAP I-GENE
accelerated O
hydrolysis O
of O
GTP O
bound O
to O
recombinant I-GENE
ARF1 I-GENE
, O
ARF3 I-GENE
, O
ARF5 I-GENE
, O
and O
ARF6 I-GENE
; O
no O
effect O
of O
NH2 O
- O
terminal O
myristoylation O
was O
observed O
. O

Biol O
. O

A O
novel O
phosphotyrosine O
- O
binding O
domain O
in O
the O
N O
- O
terminal O
transforming O
region O
of O
Cbl I-GENE
interacts O
directly O
and O
selectively O
with O
ZAP I-GENE
- I-GENE
70 I-GENE
in O
T O
cells O
. O

Cys O
- O
757 O
within O
the O
( O
Fe4S4 O
)- O
siroheme O
- O
binding O
domain O
was O
essential O
for O
native O
enzyme O
activity O
. O

Its O
transcription O
has O
been O
shown O
to O
be O
induced O
40 O
- O
50 O
- O
fold O
in O
response O
to O
oxygen O
or O
heme O
deficiency O
, O
in O
part O
through O
relief O
of O
repression O
exerted O
by O
Rox1p I-GENE
and O
in O
part O
by O
activation O
mediated O
by O
an O
upstream O
activation O
sequence O
( O
UAS O
). O

Altogether O
, O
our O
results O
indicate O
that O
the O
transcriptional O
activity O
of O
Cut I-GENE
proteins I-GENE
is O
modulated O
by O
PKC I-GENE
. O

Lck I-GENE
has O
been O
postulated O
to O
dimerize O
through O
the O
SH2 I-GENE
and O
SH3 I-GENE
domains I-GENE
. O

Furthermore O
, O
freezing O
in O
the O
presence O
of O
bovine I-GENE
lactalbumin I-GENE
resulted O
in O
a O
good O
maintenance O
of O
the O
cellular O
viability O
and O
of O
the O
CCCD O
heterogeneity O
in O
respect O
to O
fresh O
cells O
. O

Myelomatous O
pleural O
effusion O
as O
presentation O
form O
of O
multiple O
myeloma O

Five O
- O
year O
survivals O
amounted O
to O
100 O
%, O
86 O
. O
2 O
%, O
59 O
. O
4 O
%, O
29 O
. O
8 O
%, O
and O
20 O
% O
for O
stages O
I O
, O
II O
, O
III O
, O
IVA O
and O
IVB O
respectively O
. O

The O
presence O
of O
unidentified O
macroscopic O
or O
microscopic O
clusters O
of O
neoplastic O
cells O
, O
lying O
around O
, O
more O
or O
less O
close O
to O
, O
the O
line O
of O
insertion O
of O
lesion O
, O
could O
render O
any O
attempt O
to O
gain O
a O
" O
radical O
" O
excision O
useless O
. O

The O
partial O
categories O
of O
the O
SIP O
that O
were O
more O
affected O
were O
work O
, O
recreation O
and O
pastimes O
, O
home O
management O
, O
and O
sleep O
and O
rest O
. O

Northern O
blot O
analysis O
, O
using O
the O
Ltp4 I-GENE
- O
specific O
probe O
, O
indicated O
that O
Xanthomonas O
campestris O
pv O
. O
translucens O
induced O
an O
increase O
over O
basal O
levels O
of O
Ltp4 I-GENE
mRNA I-GENE
, O
while O
Pseudomonas O
syringae O
pv O
. O
japonica O
caused O
a O
decrease O
. O

Targeted O
disruption O
of O
the O
OGG1 I-GENE
gene I-GENE
in O
yeast O
revealed O
a O
second O
OG I-GENE
glycosylase I-GENE
/ I-GENE
lyase I-GENE
protein I-GENE
, O
tentatively O
named O
Ogg2 I-GENE
, O
which O
differs O
from O
Ogg1 I-GENE
in O
that O
it O
preferentially O
acts O
on O
OG O
: O
G O
. O

Furthermore O
, O
the O
use O
of O
zero O
- O
loss O
filtering O
in O
combination O
with O
exit O
wavefront O
reconstruction O
is O
considerably O
more O
effective O
at O
removing O
the O
effects O
of O
multiple O
elastic O
and O
inelastic O
scattering O
and O
microscope O
objective O
lens O
aberrations O
than O
either O
technique O
by O
itself O
. O

Transcripts O
for O
both O
ODV I-GENE
- I-GENE
E18 I-GENE
and O
ODV I-GENE
- I-GENE
EC27 I-GENE
initiate O
from O
conserved O
TAAG O
motifs O
, O
and O
transcripts O
are O
detected O
from O
16 O
through O
72 O
hr O
p O
. O
i O
. O

In O
order O
to O
determine O
which O
sequences O
in O
the O
GATA I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
are O
crucial O
for O
activation O
by O
the O
ME26 I-GENE
viral I-GENE
protein I-GENE
, O
we O
made O
deletions O
of O
the O
promoter O
, O
cloned O
them O
into O
a O
luciferase I-GENE
expression O
vector O
and O
tested O
their O
activity O
in O
mouse O
fibroblasts O
, O
which O
do O
not O
express O
GATA I-GENE
- I-GENE
1 I-GENE
. O

Sequence O
analysis O
of O
the O
isolated O
genomic O
clone O
revealed O
that O
the O
DNA O
binding O
domain O
of O
this O
orphan O
receptor O
is O
most O
homologous O
to O
the O
human I-GENE
TR2 I-GENE
receptor I-GENE
. O

Genomic O
DNA O
hybridization O
suggests O
that O
SpSHR2 I-GENE
is O
a O
single O
- O
copy O
gene O
in O
the O
S O
. O
purpuratus O
genome O
. O

A O
3 O
- O
yr O
retrospective O
review O
is O
effective O
and O
detects O
94 O
% O
of O
the O
undercalls O
. O

Isolation O
and O
identification O
of O
genes O
activating O
UAS2 I-GENE
- I-GENE
dependent I-GENE
ADH2 I-GENE
expression O
in O
Saccharomyces O
cerevisiae O
. O

METHODS O
AND O
RESULTS O
: O
A O
64 O
- O
year O
- O
old O
woman O
with O
confirmed O
AV O
nodal O
reentrant O
tachycardia O
underwent O
a O
successful O
" O
slow O
pathway O
" O
AV O
modification O
with O
a O
single O
radiofrequency O
application O
. O

Patients O
with O
low O
probability O
of O
having O
aluminum O
overload O
( O
serum O
iron O
levels O
< O
40 O
micrograms O
/ O
L O
and O
DAI O
< O
150 O
micrograms O
/ O
L O
) O
had O
significantly O
higher O
values O
of O
serum O
iron O
, O
iron O
transferrin I-GENE
saturation O
, O
and O
serum I-GENE
ferritin I-GENE
levels O
compared O
with O
those O
patients O
with O
a O
high O
probability O
of O
having O
aluminum O
overload O
( O
serum O
aluminum O
levels O
> O
40 O
micrograms O
/ O
L O
and O
DAI O
> O
150 O
micrograms O
/ O
L O
). O

Although O
the O
RAD23 I-GENE
equivalents O
are O
well O
conserved O
during O
evolution O
, O
the O
mammalian O
genes O
did O
not O
express O
the O
UV O
- O
inducible O
phenotype O
of O
their O
yeast O
counterpart O
. O

Ha I-GENE
- I-GENE
RasV12 I-GENE
and O
activated O
proteins O
in O
both O
the O
extra I-GENE
- I-GENE
cellular I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
and O
the O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
) O
or O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
cascades O
independently O
stimulated O
PEA3 I-GENE
- O
mediated O
gene O
expression O
. O

Sequence O
analysis O
of O
reverse O
transcribed O
, O
amplified O
cDNA O
generated O
from O
total O
RNA O
isolated O
from O
transfected O
cells O
demonstrated O
the O
presence O
of O
abnormally O
spliced O
products O
containing O
13 O
and O
78 O
additional O
bases O
as O
well O
as O
the O
accumulation O
of O
unspliced O
mRNA O
. O

Its O
hydropathy O
profile O
predicts O
seven O
transmembrane O
spans O
and O
a O
hydrophilic O
amino O
terminus O
of O
approximately O
100 O
residues O
, O
and O
it O
suggests O
the O
presence O
of O
an O
amphiphilic O
alpha O
- O
helix O
( O
L O
- O
61 O
to O
F O
- O
97 O
) O
in O
close O
proximity O
to O
the O
first O
strongly O
hydrophobic O
segment O
of O
ProW I-GENE
. O

A O
1 O
. O
5 O
- O
kb O
HindIII I-GENE
genomic O
fragment O
carrying O
the O
vspA I-GENE
gene O
from O
M O
. O
bovis O
PG45 O
was O
cloned O
and O
sequenced O
. O

Carbon O
catabolite O
repression O
of O
the O
gnt I-GENE
operon I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
is O
mediated O
by O
the O
catabolite O
control O
protein O
CcpA I-GENE
and O
by O
HPr I-GENE
, O
a O
phosphocarrier O
protein O
of O
the O
phosphotransferase O
system O
. O

Melatonin O
and O
seasonality O
: O
filling O
the O
gap O
. O

A O
subsequent O
screen O
for O
the O
loss O
of O
the O
positively O
selectable O
target O
locus O
marker O
detects O
the O
desired O
replacement O
at O
modest O
frequency O
(> O
2 O
%). O

Here O
we O
demonstrate O
that O
another O
cellular O
protein O
linked O
to O
BCR I-GENE
/ O
ABL I-GENE
through O
the O
CRKL I-GENE
- O
SH2 I-GENE
domain O
is O
p130 I-GENE
( O
CAS I-GENE
). O
p130 I-GENE
( O
CAS I-GENE
) O
was O
found O
to O
be O
tyrosine O
phosphorylated O
and O
associated O
with O
CRKL I-GENE
in O
BCR I-GENE
/ O
ABL I-GENE
expressing O
cell O
lines O
and O
in O
samples O
obtained O
from O
CML O
and O
ALL O
patients O
, O
but O
not O
in O
samples O
from O
controls O
. O

There O
are O
four O
polyglutamine O
motifs O
interspersed O
with O
histidine O
- O
rich O
regions O
. O

The O
effects O
of O
procedural O
variations O
on O
lateralized O
Stroop O
effects O
. O

In O
a O
third O
experiment O
, O
a O
Chessmaster O
gradually O
increases O
the O
number O
of O
boards O
he O
can O
reproduce O
with O
higher O
than O
70 O
% O
average O
accuracy O
to O
nine O
, O
replacing O
as O
many O
as O
160 O
pieces O
correctly O
. O

PCNA I-GENE
mRNA I-GENE
has O
a O
3 O
' O
UTR O
antisense O
to O
yellow O
crescent O
RNA O
and O
is O
localized O
in O
ascidian O
eggs O
and O
embryos O
. O

A O
1 O
. O
8 O
- O
kb O
cDNA O
clone O
( O
designed O
hKID I-GENE
, O
gene I-GENE
symbol I-GENE
AQP2L I-GENE
) O
with O
homology O
to O
the O
aquaporins I-GENE
was O
isolated O
from O
a O
human O
kidney O
cDNA O
library O
. O

PCR O
/ O
Southern O
blot O
analysis O
of O
human O
kidney O
cDNA O
using O
primers O
flanking O
the O
hKID I-GENE
coding I-GENE
sequence I-GENE
revealed O
expression O
of O
a O
full O
- O
length O
mRNA O
and O
short O
transcripts O
with O
partial O
exon O
1 O
and O
partial O
exon O
4 O
deletions O
. O

The O
high O
sequence O
homology O
, O
similar O
genomic O
structure O
, O
and O
identical O
chromosomal O
loci O
of O
hKID I-GENE
, O
MIP I-GENE
, O
and O
AQP I-GENE
- I-GENE
2 I-GENE
suggest O
a O
MIP I-GENE
family I-GENE
gene I-GENE
cluster I-GENE
at O
chromosome O
locus O
12q13 O
. O

The O
third O
ORF O
generates O
a O
transcript O
of O
1 O
. O
6 O
kb O
and O
encodes O
a O
protein O
of O
382 O
residues O
including O
a O
perfect O
match O
to O
the O
consensus O
sequence O
of O
a O
C2H2 O
zinc O
finger O
domain O
; O
it O
shares O
a O
strong O
homology O
with O
yeast I-GENE
Mig1p I-GENE
and O
Cre I-GENE
- I-GENE
A I-GENE
from I-GENE
Aspergillus I-GENE
, I-GENE
Emericella I-GENE
and I-GENE
E I-GENE
. I-GENE
coli I-GENE
. O

Adding O
phytase I-GENE
and O
nP O
improved O
the O
orderliness O
of O
development O
, O
mineralization O
and O
arrangement O
of O
cartilage O
and O
bone O
cells O
, O
and O
alleviated O
the O
effects O
of O
P O
deficiency O
on O
the O
histological O
and O
gross O
structure O
of O
the O
tibias O
. O

The O
importance O
of O
temporal O
factors O
on O
the O
presence O
and O
severity O
of O
ethanol O
withdrawal O
signs O
in O
the O
rat O
was O
quantified O
using O
rating O
scale O
, O
tremor O
, O
and O
acoustic O
startle O
paradigms O
. O

Data O
supported O
the O
brevity O
of O
the O
WISC O
- O
III O
short O
form O
and O
the O
criterion O
- O
related O
validity O
of O
both O
the O
K O
- O
FAST O
and O
and O
Kaufman O
Short O
Neuropsychological O
Assessment O
Procedure O
( O
K O
- O
SNAP O
). O

Quantitative O
analysis O
of O
plasmid O
loss O
rates O
in O
cdc28 I-GENE
- I-GENE
1N I-GENE
strains O
carrying O
plasmids O
with O
multiple O
replication O
origins O
suggests O
that O
a O
defect O
in O
initiating O
DNA O
replication O
probably O
causes O
this O
plasmid O
loss O
phenotype O
. O

Thus O
, O
the O
multidomained O
ROK I-GENE
alpha I-GENE
appears O
to O
be O
involved O
in O
reorganization O
of O
the O
cytoskeleton O
, O
with O
the O
N O
and O
C O
termini O
acting O
as O
positive O
and O
negative O
regulators O
, O
respectively O
, O
of O
the O
kinase O
domain O
whose O
activity O
is O
crucial O
for O
formation O
of O
stress O
fibers O
and O
focal O
adhesion O
complexes O
. O

These O
findings O
and O
the O
differential O
tissue O
distribution O
of O
p54 I-GENE
suggest O
that O
this O
novel O
SR I-GENE
protein I-GENE
may O
participate O
in O
regulation O
of O
alternative O
splicing O
in O
a O
tissue O
- O
and O
substrate O
- O
dependent O
manner O
. O

The O
elevation O
of O
cyclic O
AMP O
( O
cAMP O
) O
levels O
in O
the O
cell O
downregulates O
the O
activity O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

An O
interaction O
screen O
with O
the O
repression O
domain O
of O
the O
orphan I-GENE
receptor I-GENE
RevErb I-GENE
identified O
N I-GENE
- I-GENE
CoR I-GENE
, O
the O
corepressor O
for O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
and O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
). O

These O
results O
indicate O
that O
inhibition O
of O
Jun I-GENE
kinase I-GENE
activation O
was O
sufficient O
to O
inhibit O
Ras I-GENE
transformation O
even O
in O
the O
presence O
of O
activated O
Erk I-GENE
- I-GENE
2 I-GENE
. O

Our O
analysis O
suggests O
that O
Upf1p I-GENE
is O
a O
multifunctional O
protein O
with O
separable O
activities O
that O
can O
affect O
mRNA O
turnover O
and O
nonsense O
suppression O
. O

Identification O
of O
Ste4 I-GENE
as O
a O
potential O
regulator O
of O
Byr2 I-GENE
in O
the O
sexual O
response O
pathway O
of O
Schizosaccharomyces O
pombe O
. O

Two O
closely O
related O
variants O
of O
Stat5 I-GENE
, O
Stat5a I-GENE
and O
Stat5b I-GENE
, O
are O
encoded O
by O
distinct O
genes O
. O

Mutations O
in O
three O
loci O
( O
SIC1 I-GENE
, O
SWI5 I-GENE
, O
and O
RIC3 I-GENE
) O
were O
identified O
. O

The O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
functions O
downstream O
of O
Rats I-GENE
in O
a O
signal O
transduction O
cascade O
which O
transmits O
mitogenic O
stimuli O
from O
the O
plasma O
membrane O
to O
the O
nucleus O
. O

Platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
- O
dependent O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
is O
regulated O
by O
receptor O
binding O
of O
SH2 I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing I-GENE
proteins I-GENE
which O
influence O
Ras I-GENE
activity O
. O

In O
transient O
cotransfections O
E1A I-GENE
could O
induce O
the O
activity O
of O
the O
p53 I-GENE
promoter I-GENE
to O
a O
high O
level O
; O
12S I-GENE
E1A I-GENE
was O
threefold O
as O
efficient O
as O
13S I-GENE
E1A I-GENE
in O
this O
activity O
, O
and O
YY1 I-GENE
bound O
to O
the O
composite O
element O
was O
shown O
to O
mediate O
55 O
% O
of O
this O
induction O
. O

The O
retinoid I-GENE
Z I-GENE
receptor I-GENE
beta I-GENE
( O
RZR I-GENE
beta I-GENE
), O
an O
orphan O
receptor O
, O
is O
a O
member O
of O
the O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
)/ O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
subfamily O
of O
nuclear O
receptors O
. O

DNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
DNA I-GENE
- I-GENE
PK I-GENE
) O
consists O
of O
a O
heterodimeric O
protein O
( O
Ku I-GENE
) O
and O
a O
large O
catalytic O
subunit O
( O
DNA I-GENE
- I-GENE
PKcs I-GENE
). O

Almost O
complete O
sequence O
identity O
was O
found O
between O
the O
3 O
' O
end O
of O
the O
DXS6673E I-GENE
gene I-GENE
and O
two O
expressed O
sequence O
tags O
( O
ESTs O
) O
and O
between O
the O
5 O
' O
end O
of O
the O
DXS6673E I-GENE
gene I-GENE
and O
a O
third O
EST O
. O

Sequencing O
of O
the O
16p O
11 O
. O
1 O
/ O
Xq28 O
duplication O
breakpoints O
has O
revealed O
the O
presence O
of O
repetitive O
immunoglobulin I-GENE
- I-GENE
like I-GENE
CAGGG I-GENE
pentamer I-GENE
sequences I-GENE
at O
or O
near O
the O
paralogy O
boundaries O
. O

However O
, O
in O
a O
multivariate O
analysis O
considering O
age O
, O
gender O
, O
and O
a O
previous O
history O
of O
cardiovascular O
diseases O
, O
female O
gender O
was O
not O
independently O
associated O
with O
death O
. O

Moreover O
, O
following O
a O
single O
intravenous O
injection O
of O
the O
bicistronic O
vector O
complexed O
to O
cationic O
liposomes O
into O
recipient O
mice O
, O
delivery O
of O
MDR1 I-GENE
and O
GC I-GENE
cDNAs I-GENE
was O
achieved O
in O
all O
the O
organs O
we O
tested O
. O

The O
limits O
of O
agreement O
between O
DBS O
and O
TOF O
responses O
were O
so O
wide O
that O
they O
cannot O
be O
used O
interchangeably O
. O

The O
harpin I-GENE
- O
encoding O
hrpZ I-GENE
gene I-GENE
is O
located O
in O
an O
operon O
that O
also O
encodes O
Hrp I-GENE
secretion I-GENE
pathway I-GENE
components I-GENE
and O
is O
part O
of O
the O
functional O
cluster O
of O
hrp I-GENE
genes I-GENE
carried O
on O
cosmid O
pHIR11 O
that O
enables O
saprophytic O
bacteria O
like O
Escherichia O
coli O
and O
Pseudomonas O
fluorescens O
to O
elicit O
the O
HR O
in O
tobacco O
leaves O
. O

Despite O
the O
presence O
of O
one O
additional O
ribonucleotide I-GENE
reductase I-GENE
, O
the O
nrdAB I-GENE
- I-GENE
encoded I-GENE
enzyme I-GENE
is O
essential O
to O
the O
aerobic O
growth O
of O
the O
cell O
because O
nrdAB I-GENE
- I-GENE
defective I-GENE
mutants I-GENE
of O
both O
species O
are O
not O
viable O
in O
the O
presence O
of O
oxygen O
. O

Altogether O
, O
the O
results O
demonstrate O
that O
the O
two O
isoforms O
elicit O
similar O
responses O
in O
vivo O
despite O
differences O
in O
their O
regulation O
. O

Motivational O
factors O
focusing O
on O
attitudes O
, O
perceived O
susceptibility O
to O
pregnancy O
, O
and O
normative O
factors O
were O
also O
relevant O
. O

High O
- O
resolution O
structure O
of O
the O
diphtheria I-GENE
toxin I-GENE
repressor I-GENE
complexed O
with O
cobalt O
and O
manganese O
reveals O
an O
SH3 I-GENE
- I-GENE
like I-GENE
third O
domain O
and O
suggests O
a O
possible O
role O
of O
phosphate O
as O
co O
- O
corepressor O
. O

Titration O
of O
the O
human O
and O
porcine O
proteins O
with O
2 O
- O
nitro O
- O
5 O
- O
thiosulfabenzoate O
indicates O
that O
membrane I-GENE
dipeptidase I-GENE
additionally O
possesses O
two O
intrachain O
disulfide O
bonds O
. O

FEV1 O
did O
not O
fall O
significantly O
in O
patients O
without O
acute O
or O
chronic O
GVHD O
and O
recovered O
earlier O
than O
in O
patients O
without O
posttransplant O
pulmonary O
infection O
. O

Administration O
of O
adrenaline O
resulted O
in O
a O
large O
overestimation O
of O
the O
SaO2 O
in O
6 O
of O
the O
7 O
measurements O
. O

Therapy O
with O
dietary O
modification O
and O
triglyceride O
lowering O
drugs O
resulted O
in O
resolution O
of O
symptoms O
and O
parotid O
swelling O
in O
one O
patient O
. O

Chernoff O
, O
submitted O
for O
publication O
). O

We O
have O
cloned O
a O
novel O
protein O
kinase O
, O
termed O
hematopoietic I-GENE
progenitor I-GENE
kinase I-GENE
1 I-GENE
( O
HPK1 I-GENE
), O
that O
is O
expressed O
predominantly O
in O
hematopoietic O
cells O
, O
including O
early O
progenitor O
cells O
. O

Human O
ESP1 I-GENE
/ O
CRP2 I-GENE
protein O
has O
two O
LIM I-GENE
domains O
, O
and O
each O
shares O
35 O
. O
1 O
% O
and O
77 O
or O
79 O
% O
identical O
residues O
with O
human I-GENE
cysteine I-GENE
- I-GENE
rich I-GENE
protein I-GENE
( O
CRP I-GENE
) O
and O
rat I-GENE
CRIP I-GENE
, O
respectively O
. O

The O
fragments O
are O
separated O
and O
directly O
sized O
by O
agarose O
gel O
electrophoresis O
. O

Several O
of O
the O
exon O
boundaries O
correspond O
to O
the O
boundaries O
of O
functional O
domains O
in O
the O
p55 I-GENE
protein I-GENE
. O

Linkage O
studies O
have O
shown O
locus O
heterogeneity O
with O
one O
TSC I-GENE
gene I-GENE
mapped O
to O
chromosome O
9q34 O
and O
a O
second O
to O
16p13 O
. O
3 O
. O

The O
cytogenetic O
expression O
of O
the O
folate O
sensitive O
fragile O
site O
, O
FRAXE I-GENE
, O
is O
due O
to O
the O
expansion O
of O
a O
GCC O
repeat O
in O
proximal O
Xq28 O
of O
the O
human O
X O
chromosome O
and O
is O
associated O
with O
a O
mild O
form O
of O
mental O
handicap O
. O

DNA O
sequence O
analysis O
of O
a O
3213 O
bp O
BamHI I-GENE
- O
ClaI I-GENE
fragment O
revealed O
that O
three O
open O
reading O
frames O
( O
ORFs O
) O
were O
encoded O
in O
the O
same O
orientation O
. O

The O
initial O
inpatient O
experience O
for O
individuals O
with O
HIV O
- O
related O
TB O
may O
be O
pivotal O
to O
the O
acceptance O
of O
and O
participation O
in O
ongoing O
TB O
care O
. O

Tristetraprolin I-GENE
( O
TTP I-GENE
) O
is O
the O
prototype O
of O
a O
group O
of O
potential O
transcription O
factors O
that O
contain O
two O
or O
more O
unusual O
CCCH O
zinc O
fingers O
. O

This O
element O
, O
termed O
CREsp O
- O
a O
( O
TGACCTCA O
), O
differs O
by O
one O
nucleotide O
from O
a O
palindromic O
CRE O
( O
CREpal O
, O
TGACGTCA O
), O
which O
is O
known O
to O
bind O
CREB I-GENE
as O
a O
homodimer O
. O

Analysis O
of O
human O
genomic O
DNA O
reveals O
an O
intronless O
sequence O
with O
strong O
homology O
to O
human I-GENE
G I-GENE
alpha I-GENE
q I-GENE
cDNA I-GENE
. O

The O
complete O
exon O
- O
intron O
structure O
of O
the O
156 I-GENE
- I-GENE
kb I-GENE
human I-GENE
gene I-GENE
NFKB1 I-GENE
, O
which O
encodes O
the O
p105 I-GENE
and O
p50 I-GENE
proteins I-GENE
of O
transcription O
factors O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
and O
I I-GENE
kappa I-GENE
B I-GENE
- I-GENE
gamma I-GENE
: O
implications O
for O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- O
mediated O
signal O
transduction O
. O

An O
inverted O
Alu I-GENE
repeat O
element O
, O
flanked O
by O
nonamer O
direct O
repeats O
, O
was O
identified O
within O
the O
region O
- O
913 O
/- O
620 O
, O
relative O
to O
the O
cap O
site O
. O

The O
ewes O
were O
returned O
to O
normoxia O
, O
and O
monitoring O
was O
continued O
for O
1 O
h O
. O

Feline O
leukemia O
viruses O
( O
FeLVs O
), O
which O
are O
replication O
- O
competent O
oncoretroviruses O
of O
the O
domestic O
cat O
species O
, O
are O
contagiously O
transmitted O
in O
natural O
environments O
. O

Comparison O
of O
the O
amino O
acid O
sequences O
of O
the O
RPO1 I-GENE
polypeptides I-GENE
of I-GENE
IIV6 I-GENE
, I-GENE
LCDV I-GENE
, I-GENE
and I-GENE
MCV I-GENE
- I-GENE
1 I-GENE
with O
the O
corresponding O
prokaryotic O
, O
eukaryotic O
, O
and O
viral O
proteins O
revealed O
differences O
in O
amino O
acid O
similarity O
and O
phylogenetic O
relationships O
. O

The O
RPO1 I-GENE
of O
LCDV O
shows O
the O
highest O
similarity O
to O
the O
RPO1 I-GENE
of O
IIV6 O
and O
significant O
lower O
similarity O
to O
the O
eukaryotic I-GENE
polymerases I-GENE
II I-GENE
and I-GENE
III I-GENE
as O
well O
as O
to O
the O
archaebacteral O
subunit O
. O

The O
use O
of O
primary O
GE O
cells O
thus O
provides O
a O
convenient O
in O
vitro O
system O
for O
further O
study O
of O
the O
endocrine O
, O
paracrine O
, O
and O
autocrine O
factors O
regulating O
endometrial O
gene O
expression O
during O
pregnancy O
. O

We O
performed O
dipole O
estimation O
of O
spikes O
and O
SEP O
components O
in O
identical O
patients O
. O

Both O
verapamil O
and O
propranolol O
can O
exhibit O
additive O
effects O
with O
adenosine O
in O
prolonging O
AV O
nodal O
conduction O
time O
; O
however O
, O
only O
verapamil O
can O
reduce O
the O
dose O
of O
adenosine O
required O
to O
produce O
AV O
nodal O
block O
. O

Proximal O
CBD O
was O
inversely O
correlated O
with O
bone I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
r O
= O
- O
0 O
. O
71 O
, O
p O
< O
0 O
. O
01 O
) O
and O
intact O
PTH I-GENE
( O
r O
= O
- O
0 O
. O
59 O
, O
p O
< O
0 O
. O
05 O
). O

In O
addition O
, O
a O
comparison O
of O
the O
hCHLR I-GENE
gene I-GENE
sequences I-GENE
with O
available O
databases O
indicates O
that O
a O
large O
portion O
of O
these O
genes O
, O
including O
exons O
encoding O
two O
functional O
domains O
of O
the O
carboxyl O
- O
terminal O
region O
of O
these O
proteins O
, O
has O
been O
duplicated O
as O
part O
of O
a O
larger O
human O
telomeric O
repeat O
sequence O
found O
on O
many O
human O
chromosomes O
. O

We O
show O
here O
that O
the O
LIM I-GENE
domain I-GENE
homeobox I-GENE
protein I-GENE
isl I-GENE
- I-GENE
1 I-GENE
activates O
the O
rat I-GENE
amylin I-GENE
promoter I-GENE
in O
both O
fibroblast O
and O
islet O
cell O
lines O
. O

Although O
isl I-GENE
- I-GENE
1 I-GENE
binds O
to O
both O
the O
insulin I-GENE
and O
amylin I-GENE
gene I-GENE
promoter I-GENE
elements I-GENE
in O
vitro O
, O
these O
sequences O
display O
marked O
differences O
in O
their O
relative O
transcriptional O
properties O
when O
ligated O
adjacent O
to O
a O
heterologous O
promoter O
and O
transfected O
into O
InR1 O
- O
G9 O
islet O
cells O
. O

It O
is O
likely O
that O
other O
pathways O
involve O
alternate O
signal O
transduction O
events O
( O
e O
. O
g O
., O
calcium O
mobilization O
) O
and O
promoter O
response O
elements O
( O
e O
. O
g O
., O
SRE O
). O

The O
CD4 I-GENE
count O
at O
which O
remission O
occurs O
may O
reflect O
severe O
immunodeficiency O
such O
that O
risk O
for O
AIDS O
- O
related O
infection O
is O
high O
. O

Although O
diagnostic O
laparoscopy O
is O
still O
considered O
the O
standard O
reference O
in O
the O
diagnosis O
of O
ectopic O
pregnancy O
( O
EP O
), O
use O
of O
high O
- O
resolution O
endovaginal O
sonography O
, O
in O
conjunction O
with O
qualitative O
serum O
assays O
of O
the O
beta O
subunit O
of O
human I-GENE
chorionic I-GENE
gonadotropin I-GENE
( O
beta I-GENE
- I-GENE
hCG I-GENE
), O
allows O
detection O
of O
earlier O
and O
smaller O
EPs O
. O

Bifunctionality O
of O
the O
AcMNPV I-GENE
homologous I-GENE
region I-GENE
sequence I-GENE
( O
hr1 I-GENE
): O
enhancer O
and O
ori O
functions O
have O
different O
sequence O
requirements O
. O

RVR I-GENE
' O
loss O
of O
function O
' O
studies O
by O
constitutive O
over O
- O
expression O
of O
a O
dominant O
negative O
RVR I-GENE
delta I-GENE
E I-GENE
resulted O
in O
increased O
levels O
of O
p21Cip1 I-GENE
/ O
Waf1 I-GENE
and O
myogenin I-GENE
mRNAs I-GENE
after O
serum O
withdrawal O
. O

Neither O
CES1 I-GENE
nor O
CES4 I-GENE
is O
essential O
for O
cell O
growth O
, O
and O
a O
double O
deletion O
mutant O
is O
viable O
. O

These O
two O
repeat O
motifs O
are O
organized O
in O
an O
extremely O
well O
- O
ordered O
pattern O
in O
each O
domain O
, O
which O
suggests O
that O
SbHRGP3 I-GENE
belongs O
to O
a O
new O
group O
of O
proteins O
having O
the O
repeat O
motifs O
of O
two O
distinct O
groups O
of O
dicot I-GENE
extensins I-GENE
. O

Their O
use O
established O
that O
the O
BrAAP O
activity O
catalyzed O
both O
a O
postproline O
and O
a O
postglutamate O
cleavage O
and O
therefore O
has O
a O
broader O
specificity O
than O
previously O
recognized O
. O

To O
explore O
the O
functional O
significance O
of O
these O
subdomains O
in O
PRL I-GENE
binding O
and O
signal O
transduction O
, O
deletion O
mutants O
of O
S1 O
or O
/ O
and O
S2 O
subdomains O
were O
constructed O
. O

A O
stable O
heterologous O
cell O
line O
containing O
the O
mouse I-GENE
TRH I-GENE
receptor I-GENE
was O
constructed O
by O
transfection O
of O
nonexcitable O
293 O
cells O
, O
which O
lack O
L O
channel O
activity O
. O

To O
understand O
further O
the O
expression O
and O
regulation O
of O
the O
V1aR I-GENE
, O
we O
now O
describe O
the O
genomic O
characteristics O
, O
tissue O
expression O
, O
chromosomal O
localization O
, O
and O
regional O
mapping O
of O
the O
human I-GENE
V1aR I-GENE
gene I-GENE
, O
AVPR1A I-GENE
. O

The O
final O
predicted O
structure O
has O
an O
overall O
backbone O
deviation O
of O
0 O
. O
7 O
A O
from O
that O
of O
ras I-GENE
- O
p21 I-GENE
. O

Genomic O
organization O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
catenin I-GENE
gene I-GENE
( O
CTNNB1 I-GENE
). O

Furthermore O
, O
although O
the O
regional O
distribution O
of O
lean O
tissue O
mass O
in O
the O
trunk O
and O
legs O
remained O
fairly O
constant O
at O
different O
pubertal O
stages O
, O
the O
regional O
distribution O
of O
fat O
was O
altered O
significantly O
, O
becoming O
more O
central O
and O
less O
peripheral O
. O

Thus O
, O
the O
predicted O
CD30v I-GENE
protein I-GENE
retains O
most O
of O
the O
cytoplasmic O
region O
, O
but O
lacks O
the O
extracellular O
and O
transmembrane O
domains O
. O

Constitutive O
phosphorylation O
of O
the O
CD30v I-GENE
protein I-GENE
was O
demonstrated O
by O
in O
vitro O
labeling O
with O
[ O
32P O
]. O

17 O
. O
5 O
% O
of O
cycles O
). O

We O
report O
here O
the O
discovery O
of O
a O
new O
actin I-GENE
- I-GENE
related I-GENE
gene I-GENE
in O
this O
organism O
, O
which O
we O
have O
named O
ACT4 I-GENE
. O

Two O
of O
the O
ORFs O
are O
completely O
internal O
to O
longer O
ones O
and O
a O
third O
is O
partially O
embedded O
in O
G2850 I-GENE
. O

MVR O
typing O
of O
rare O
- O
length O
alleles O
indicates O
that O
they O
are O
comprised O
of O
disorganized O
sequences O
, O
although O
they O
usually O
bear O
a O
resemblance O
to O
one O
of O
the O
common O
alleles O
at O
the O
5 O
'- O
most O
end O
. O

Plasmid O
pAL618 O
contains O
the O
genetic O
determinants O
for O
H2 O
uptake O
( O
hup I-GENE
) O
from O
Rhizobium O
leguminosarum O
bv O
. O
viciae O
, O
including O
a O
cluster O
of O
17 O
genes O
named O
hupSLCDEFGHIJK I-GENE
- I-GENE
hypABFCDE I-GENE
. O

Two O
classes O
of O
inactive O
receptors O
were O
identified O
: O
one O
in O
which O
both O
transcriptional O
activation O
and O
dimerization O
were O
compromised O
and O
a O
second O
in O
which O
only O
transcriptional O
activation O
was O
abolished O
. O

Here O
we O
localize O
a O
transferable O
40 O
- O
amino O
acid O
region O
within O
the O
LBDs I-GENE
of O
RXR I-GENE
, O
RAR I-GENE
, O
TR I-GENE
, O
and O
chicken I-GENE
ovalbumin I-GENE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
that O
is O
critical O
for O
determining O
identity O
in O
the O
heterodimeric O
interaction O
and O
for O
high O
- O
affinity O
DNA O
binding O
. O

OKA O
and O
calyculin O
A O
do O
not O
decrease O
OCFRE I-GENE
DNA O
- O
protein O
interactions O
, O
suggesting O
that O
important O
protein O
- O
protein O
interactions O
are O
phosphatase O
regulated O
. O

An O
open O
- O
label O
, O
placebo O
- O
controlled O
, O
randomized O
, O
two O
- O
way O
crossover O
study O
was O
performed O
in O
12 O
healthy O
volunteers O
( O
between O
20 O
and O
44 O
years O
of O
age O
) O
to O
assess O
the O
effect O
of O
orlistat O
, O
a O
gastrointestinal I-GENE
lipase I-GENE
inhibitor O
that O
reduces O
dietary O
fat O
absorption O
and O
is O
being O
developed O
for O
weight O
control O
in O
obesity O
, O
on O
the O
absorption O
of O
vitamins O
A O
and O
E O
. O

Tilmicosin O
is O
a O
novel O
macrolide O
antibiotic O
developed O
for O
exclusive O
use O
in O
veterinary O
medicine O
. O

Effect O
of O
nitrous O
oxide O
( O
N2O O
) O
on O
the O
somatosympathetic O
A O
- O
and O
C O
- O
reflexes O
was O
investigated O
using O
artificially O
ventilated O
rats O
anesthetized O
with O
alpha O
- O
chloralose O
and O
urethane O
. O

Restriction O
enzyme O
mapping O
and O
Southern O
analysis O
indicated O
further O
that O
the O
human I-GENE
MZF I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
a O
single O
- O
copy O
gene O
. O

In O
the O
absence O
of O
Swi4 I-GENE
and O
Swi6 I-GENE
cell O
viability O
is O
lost O
, O
but O
can O
be O
regained O
by O
ectopic O
expression O
of O
the O
G1 I-GENE
cyclin I-GENE
encoding I-GENE
genes I-GENE
, O
CLN1 I-GENE
or O
CLN2 I-GENE
. O

The O
detection O
ratio O
peaked O
at O
ages O
30 O
to O
34 O
and O
decreased O
heavily O
during O
the O
next O
15 O
years O
of O
age O
. O

How O
many O
embryos O
to O
transfer O
in O
patients O
undergoing O
IVF O
? O

IMPLICATIONS O
: O
Given O
the O
small O
size O
of O
this O
study O
and O
the O
inconsistency O
of O
results O
among O
the O
few O
prospective O
studies O
of O
ovarian O
cancer O
conducted O
to O
test O
these O
associations O
, O
replications O
of O
these O
findings O
are O
highly O
desirable O
. O

The O
nonconsensus O
TATA O
box O
in O
promoter O
B O
plays O
a O
more O
important O
role O
in O
promoter O
activity O
than O
the O
TATA O
box O
in O
promoter O
A O
. O

These O
properties O
indicate O
that O
Gle1 I-GENE
is O
an O
RNA O
- O
export O
factor O
and O
that O
Rev I-GENE
may O
mediate O
viral O
RNA O
export O
by O
mimicking O
the O
function O
of O
Gle1 I-GENE
. O

Demispan O
is O
a O
reliable O
and O
reproducible O
measure O
of O
stature O
in O
the O
elderly O
. O

Two O
techniques O
based O
on O
assay O
coefficients O
of O
variation O
were O
employed O
to O
characterize O
a O
normal O
circadian O
pattern O
of O
cortisol O
. O

We O
have O
performed O
toeprinting O
analyses O
on O
repA I-GENE
mRNA I-GENE
of O
plasmid O
R1 O
, O
both O
free O
and O
in O
duplex O
with O
the O
antisense O
RNA O
, O
CopA I-GENE
. O

Previous O
work O
showed O
that O
repA I-GENE
( O
initiator O
protein O
) O
expression O
requires O
tap I-GENE
( O
leader O
peptide O
) O
translation O
. O

A O
system O
is O
described O
in O
which O
the O
volume O
flow O
rate O
of O
blood O
in O
a O
vessel O
is O
determined O
using O
transverse O
colour O
Doppler O
ultrasound O
imaging O
. O

The O
enzyme O
activities O
studied O
are O
important O
elements O
in O
the O
pathophysiology O
of O
dental O
caries O
and O
may O
even O
be O
addressed O
as O
virulence O
factors O
. O

Tonsillectomy O
is O
an O
effective O
means O
of O
prophylaxis O
for O
upper O
respiratory O
infection O
in O
habitual O
angina O
patients O
. O

In O
lean O
mice O
, O
the O
fat O
/ O
water O
intensity O
ratio O
was O
about O
1 O
: O
4 O
, O
about O
half O
that O
in O
normal O
mice O
. O

Pharmacokinetic O
parameters O
were O
similar O
to O
values O
given O
in O
the O
literature O
for O
intravenous O
( O
IV O
) O
or O
intraarterial O
( O
IA O
) O
bolus O
MMC O
injections O
( O
Tmax O
= O
7 O
. O
0 O
min O
following O
the O
beginning O
of O
MMC O
infusion O
, O
Vss O
= O
0 O
. O
57 O
1 O
/ O
kg O
, O
C1 O
= O
8 O
. O
9 O
ml O
/ O
min O
. O
kg O
, O
T1 O
/ O
2 O
alpha O
= O
8 O
. O
3 O
min O
, O
T1 O
/ O
2 O
beta O
= O
58 O
. O
6 O
min O
). O

In O
this O
study O
, O
we O
identified O
four O
distinct O
E2F I-GENE
complexes I-GENE
present O
in O
aged O
and O
senescent O
normal O
, O
human O
diploid O
fibroblasts O
. O

This O
paper O
gives O
an O
overview O
of O
the O
global O
pattern O
of O
casualties O
in O
earthquakes O
which O
occurred O
during O
the O
30 O
- O
month O
period O
from O
1 O
September O
1993 O
to O
29 O
February O
1996 O
. O

If O
we O
apply O
the O
finding O
of O
non O
- O
visualization O
of O
the O
GB O
at O
4 O
h O
post O
injection O
as O
the O
criterion O
for O
the O
diagnosis O
of O
AC O
, O
the O
diagnostic O
accuracy O
was O
only O
40 O
. O
7 O
% O
( O
11 O
/ O
27 O
). O

These O
results O
were O
corroborated O
in O
a O
subsequent O
study O
in O
which O
30 O
hypogonadal O
men O
were O
supplemented O
with O
SLT O
5 O
mg O
three O
times O
daily O
for O
6 O
months O
. O

Alternative O
processing O
of O
the O
tryptophanyl I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
mRNA I-GENE
from O
interferon I-GENE
- O
treated O
human O
cells O
. O

Evidence O
for O
the O
promoting O
role O
of O
the O
intra I-GENE
- I-GENE
uterine I-GENE
kinin I-GENE
release O
in O
the O
development O
of O
late O
hypertonic O
saline O
- O
induced O
abortion O
. O

This O
GAP I-GENE
activity O
was O
observed O
in O
3T3 O
- O
L1 O
adipocyte O
lysates O
, O
and O
was O
able O
to O
accelerate O
the O
hydrolysis O
of O
the O
[ O
alpha O
- O
32P O
] O
GTP O
bound O
to O
GST I-GENE
- O
Rab4 I-GENE
into O
[ O
alpha O
- O
32P O
] O
GDP O
. O

CONCLUSION O
: O
During O
chronic O
treatment O
, O
the O
haemodynamic O
response O
to O
oral O
cilazapril O
was O
attenuated O
, O
indicating O
that O
continued O
clinical O
improvement O
in O
patients O
with O
CHF O
on O
CLZ O
is O
independent O
of O
to O
its O
acute O
haemodynamic O
effects O
. O

We O
conclude O
that O
, O
in O
AIDS O
patients O
with O
cryptococcosis O
, O
tolerance O
to O
ILd O
- O
AmB O
was O
acceptable O
when O
the O
daily O
dosage O
did O
not O
exceed O
1 O
mg O
/ O
kg O
, O
but O
the O
higher O
1 O
. O
5 O
mg O
/ O
kg O
daily O
dosage O
was O
associated O
with O
an O
unacceptable O
rate O
of O
nephrotoxicity O
. O

Moreover O
, O
the O
second O
RCC1 I-GENE
- I-GENE
like I-GENE
motif I-GENE
located O
at O
the O
amino O
- O
terminus O
of O
p619 I-GENE
stimulates O
guanine O
nucleotide O
exchange O
on O
ARF1 I-GENE
and O
on O
members O
of O
the O
related O
Rab I-GENE
proteins I-GENE
, O
but O
not O
on O
other O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
such O
as O
Ran I-GENE
or O
R I-GENE
- I-GENE
Ras2 I-GENE
/ O
TC21 I-GENE
. O

The O
reconstituted O
RNA I-GENE
polymerases I-GENE
containing O
the O
mutant O
alpha O
subunits O
were O
examined O
for O
their O
response O
to O
transcription O
activation O
by O
cAMP I-GENE
- I-GENE
CRP I-GENE
and O
the O
rrnBP1 I-GENE
UP I-GENE
element I-GENE
. O

Transcription O
factor O
recognition O
surface O
on O
the O
RNA I-GENE
polymerase I-GENE
alpha I-GENE
subunit I-GENE
is O
involved O
in O
contact O
with O
the O
DNA O
enhancer O
element O
. O

Consistent O
with O
this O
similarity O
, O
the O
cdc28 I-GENE
- O
P8 O
mutant O
accumulates O
unspliced O
precursors O
at O
the O
restrictive O
temperature O
. O

A O
decrease O
of O
erythrocyte O
Mn O
with O
age O
, O
expressed O
in O
nmol O
/ O
L O
, O
was O
noted O
( O
p O
< O
0 O
. O
02 O
). O

Cloning O
and O
sequence O
analyses O
revealed O
a O
second O
cDNA O
with O
a O
95 O
- O
nt O
deletion O
in O
the O
region O
coding O
for O
the O
putative O
second O
intracellular O
loop O
and O
the O
fourth O
transmembrane O
domain O
of O
the O
5 I-GENE
- I-GENE
HT2C I-GENE
- I-GENE
R I-GENE
. O

Expression O
of O
thymidine I-GENE
kinase I-GENE
gene I-GENE
in O
normal O
human O
diploid O
cells O
is O
both O
cell O
cycle O
- O
and O
age O
- O
dependent O
and O
appears O
to O
be O
transcriptionally O
regulated O
. O

The O
minimum O
inhibitory O
concentrations O
( O
MICs O
) O
of O
ketoconazole O
, O
miconazole O
, O
itraconazole O
, O
fluconazole O
, O
and O
amphotericin O
B O
were O
significantly O
influenced O
by O
the O
inoculum O
size O
, O
regardless O
of O
the O
techniques O
used O
. O

These O
bacteria O
produce O
and O
export O
proteins O
capable O
of O
specific O
interactions O
with O
key O
mammalian O
cell O
regulatory O
molecules O
in O
order O
to O
derail O
the O
normal O
functions O
of O
the O
cells O
. O

The O
elevations O
achieved O
by O
LDEE O
given O
s O
. O
c O
. O
were O
higher O
than O
those O
achieved O
after O
i O
. O
p O
. O
administration O
and O
lasted O
for O
longer O
periods O
. O

Thus O
, O
although O
p28 I-GENE
may O
play O
only O
a O
limited O
role O
during O
the O
early O
embryonic O
cleavages O
, O
it O
may O
function O
later O
in O
development O
to O
establish O
a O
somatic O
type O
of O
cell O
cycle O
. O

The O
main O
aim O
of O
the O
contribution O
, O
which O
opens O
an O
arena O
for O
discussion O
on O
the O
Rivista O
dell O
' O
Infermiere O
is O
to O
critically O
appraise O
published O
research O
works O
focusing O
both O
on O
strengths O
and O
novelty O
and O
weaknesses O
in O
the O
hypothesis O
formulation O
, O
methods O
and O
instruments O
used O
, O
discussion O
of O
results O
. O

Moreover O
, O
it O
also O
discusses O
the O
effects O
of O
antihypertensive O
drugs O
currently O
regarded O
as O
first O
- O
choice O
agents O
, O
i O
. O
e O
. O
calcium O
antagonists O
and O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
, O
on O
intrarenal O
hemodynamics O
. O

Many O
human O
viruses O
are O
able O
to O
develop O
suitable O
strategies O
for O
modifying O
apoptosis O
in O
virus O
- O
infected O
cells O
and O
in O
virus O
- O
primed O
T O
cells O
. O

It O
is O
suggested O
that O
the O
observed O
clinical O
phenomena O
in O
response O
to O
morphine O
can O
be O
explained O
by O
differences O
in O
expression O
and O
sensitivity O
of O
some O
opioid I-GENE
receptor I-GENE
subtypes O
in O
migraine O
. O

Previous O
studies O
demonstrated O
that O
the O
flavin I-GENE
- I-GENE
containing I-GENE
monooxygenases I-GENE
( O
FMO I-GENE
) O
are O
expressed O
in O
a O
tissue O
- O
specific O
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
the O
C O
- O
terminal O
24 O
amino O
acids O
are O
sufficient O
for O
NodO I-GENE
secretion O
although O
the O
region O
adjacent O
to O
this O
domain O
appears O
to O
affect O
secretion O
efficiency O
. O

Thus O
, O
despite O
the O
potential O
for O
common O
regulatory O
mechanisms O
, O
the O
available O
evidence O
indicates O
that O
the O
Mtx I-GENE
minimal I-GENE
promoter I-GENE
does O
not O
significantly O
affect O
Thbs3 I-GENE
gene I-GENE
expression O
. O

MSSP I-GENE
proteins I-GENE
have O
been O
identified O
by O
their O
binding O
to O
an O
upstream O
element O
of O
c I-GENE
- I-GENE
myc I-GENE
. O

Gene I-GENE
1 I-GENE
has O
been O
completely O
sequenced O
. O

B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
BCR I-GENE
)- O
induced O
apoptosis O
in O
the O
WEHI O
- O
231 O
B O
lymphoma O
cell O
line O
can O
be O
prevented O
by O
engaging O
CD40 I-GENE
. O

Both O
alleles O
are O
functionally O
expressed O
and O
are O
distributed O
within O
CD4 I-GENE
+/ O
CD8 I-GENE
+ O
T O
cell O
subsets O
. O

The O
model O
also O
predicts O
that O
blood O
flow O
shunt O
fraction O
( O
Qs O
/ O
QT O
) O
is O
directly O
related O
to O
the O
oxygen O
sine O
- O
wave O
amplitude O
perturbations O
transmitted O
to O
end O
- O
expired O
air O
and O
arterial O
and O
mixed O
- O
venous O
blood O
through O
two O
simple O
equations O
. O

The O
deduced O
amino O
acid O
sequence O
of O
LvUSF2 I-GENE
is O
nearly O
identical O
to O
LvUSF1 I-GENE
except O
at O
the O
amino O
end O
, O
where O
they O
are O
sharply O
divergent O
. O

ECM O
disruption O
in O
Lytechinus O
embryos O
caused O
a O
relative O
drop O
in O
USF I-GENE
RNA I-GENE
accumulation O
levels O
to O
approximately O
60 O
% O
of O
control O
embryos O
, O
while O
LpS1 I-GENE
RNA I-GENE
accumulation O
levels O
dropped O
to O
less O
than O
5 O
%. O

Five O
of O
these O
eight O
patients O
in O
group O
II O
also O
received O
8 O
- O
in O
- O
1 O
chemotherapy O
. O

Sixty O
days O
after O
the O
intervention O
, O
twitch O
and O
tetanic O
tensions O
remained O
dependent O
upon O
the O
extracellular O
Ca2 O
+ O
concentration O
([ O
Ca O
] O
o O
) O
both O
in O
groups O
A O
and O
B O
. O

Discrimination O
between O
HIV O
- O
1 O
and O
HIV O
- O
2 O
showed O
evidence O
for O
the O
presence O
of O
HIV O
- O
1 O
only O
. O

However O
, O
an O
intrinsic O
DNA O
- O
binding O
subunit O
for O
HiNF I-GENE
- I-GENE
D I-GENE
was O
not O
identified O
. O

The O
HiNF I-GENE
- I-GENE
D I-GENE
( O
CDP I-GENE
/ O
cut I-GENE
) O
complex O
with O
the O
H4 I-GENE
promoter I-GENE
is O
immunoreactive O
with O
antibodies O
against O
CDP I-GENE
/ O
cut I-GENE
and O
pRB I-GENE
but O
not O
p107 I-GENE
, O
whereas O
the O
CDP I-GENE
/ O
cut I-GENE
complex O
with O
a O
nonhistone O
promoter O
( O
gp91 I-GENE
- O
phox I-GENE
) O
reacts O
only O
with O
CDP I-GENE
and O
p107 I-GENE
antibodies O
. O

Recently O
, O
a O
distantly O
related O
UmuC I-GENE
- I-GENE
homolog I-GENE
, O
DinB I-GENE
, O
has O
also O
been O
identified O
in O
E O
. O
coli O
. O

To O
study O
the O
regulation O
of O
mdr2 I-GENE
expression O
, O
the O
promoter O
of O
the O
mdr2 I-GENE
gene I-GENE
has O
been O
isolated O
from O
a O
murine O
vinblastine O
- O
resistant O
cell O
line O
, O
J7 O
. O
V2 O
- O
1 O
, O
and O
characterized O
. O

The O
amplification O
was O
achieved O
using O
two O
primers O
which O
correspond O
to O
TRH I-GENE
progenitor I-GENE
sequence I-GENE
( O
Lys O
/ O
Arg O
- O
Arg O
- O
Gln O
- O
His O
- O
Pro O
- O
Gly O
- O
Lys O
/ O
Arg O
- O
Arg O
). O

The O
intranodal O
mesothelial O
cells O
occupied O
the O
sinusoids O
of O
the O
lymph O
nodes O
and O
were O
initially O
suspected O
of O
being O
metastatic O
from O
the O
ovarian O
tumor O
in O
each O
case O
. O

The O
gene I-GENE
ccpA I-GENE
encoding O
the O
catabolite I-GENE
control I-GENE
protein I-GENE
CcpA I-GENE
of O
Staphylococcus O
xylosus O
has O
been O
cloned O
and O
characterized O
. O

An O
InlC I-GENE
deletion I-GENE
mutant I-GENE
shows O
reduced O
virulence O
when O
tested O
in O
an O
intravenous O
mouse O
model O
, O
but O
intracellular O
replication O
of O
the O
mutant O
in O
Caco O
- O
2 O
and O
J774 O
cells O
appears O
to O
be O
comparable O
with O
that O
of O
the O
wild O
- O
type O
strain O
. O

Thus O
, O
the O
N I-GENE
- O
Nus I-GENE
complex O
may O
be O
affected O
through O
contacts O
with O
the O
CTD O
of O
the O
alpha O
subunit O
of O
RNA I-GENE
polymerase I-GENE
, O
as O
is O
a O
group O
of O
regulatory O
proteins O
that O
influences O
initiation O
of O
transcription O
. O

Administration O
of O
RIFA O
at O
200 O
mg O
/ O
kg O
/ O
day O
in O
combination O
with O
ATO O
at O
100 O
mg O
/ O
kg O
/ O
day O
resulted O
in O
a O
marked O
prolongation O
of O
survival O
compared O
with O
that O
for O
mice O
that O
received O
ATO O
or O
RIFA O
alone O
. O

Eight O
- O
four O
ACOAs O
were O
tested O
in O
order O
to O
examine O
the O
fit O
of O
the O
model O
to O
the O
data O
by O
path O
analysis O
with O
LISREL O
VII O
. O

Two O
of O
seven O
initiation O
sites O
were O
flanked O
by O
a O
sequence O
homologous O
to O
the O
consensus O
promoter O
motif O
that O
includes O
the O
CRTA O
motif O
( O
where O
R O
is O
A O
or O
G O
) O
of O
the O
rice O
mitochondrion O
. O

Selection O
using O
SC O
EPD O
was O
more O
effective O
than O
phenotypic O
selection O
in O
reducing O
age O
at O
puberty O
in O
daughters O
. O

Using O
anchored O
PCR O
, O
a O
VL I-GENE
element I-GENE
rearranged O
to O
CL2 I-GENE
was O
isolated O
. O

Sodium O
polystyrene O
sulfonate O
treatment O
for O
lithium O
toxicity O
: O
effects O
on O
serum O
potassium O
concentrations O
. O

The O
mammalian I-GENE
homeodomain I-GENE
proteins I-GENE
encoded O
by O
Hox I-GENE
genes I-GENE
play O
an O
important O
role O
in O
embryonic O
development O
by O
providing O
positional O
queues O
which O
define O
developmental O
identities O
along O
the O
anteroposterior O
axis O
of O
developing O
organisms O
. O

Interferon I-GENE
stimulated I-GENE
gene I-GENE
factor I-GENE
3 I-GENE
( O
ISGF3 I-GENE
) O
is O
a O
trimeric O
transcription O
factor O
activated O
on O
treatment O
of O
cells O
with O
interferon I-GENE
- I-GENE
alpha I-GENE
and I-GENE
beta I-GENE
( O
type I-GENE
I I-GENE
IFNs I-GENE
). O

The O
TYAC O
/ O
P1 O
resource O
, O
derivative O
STSs O
, O
and O
polymorphisms O
constitute O
an O
enabling O
resource O
to O
further O
studies O
of O
telomere O
structure O
and O
function O
and O
a O
means O
for O
physical O
and O
genetic O
map O
integration O
and O
closure O
. O

Confirmatory O
statistics O
included O
item O
2 O
of O
the O
Clinical O
Global O
Impression O
( O
CGI O
), O
the O
total O
score O
of O
the O
Sandoz O
Clinical O
Assessment O
Geriatric O
( O
SCAG O
) O
scale O
, O
the O
subscale O
' O
need O
for O
help O
' O
of O
the O
nurse O
' O
s O
rating O
of O
geriatric O
patients O
( O
Beurteilungsskala O
fur O
geriatrische O
Patienten O
; O
BGP O
) O
and O
the O
total O
score O
of O
the O
Short O
Cognitive O
Performance O
Test O
( O
Syndrom O
- O
Kurztest O
; O
SKT O
). O

Three O
mutants O
were O
isolated O
from O
the O
widely O
used O
strain O
, O
PAO1 O
. O

As O
extensively O
examined O
with O
the O
myogenin I-GENE
promoter I-GENE
, O
presence O
of O
one O
or O
multiple O
copies O
of O
Me I-GENE
in O
the O
vectors O
elevated O
the O
expression O
activity O
in O
myotubes O
by O
4 O
. O
5 O
- O
to O
19 O
- O
fold O
over O
those O
without O
Me I-GENE
, O
but O
not O
significantly O
in O
myoblasts O
. O

We O
conclude O
that O
common O
upstream O
signals O
cause O
activation O
of O
Ras I-GENE
and O
TC21 I-GENE
, O
but O
activated O
TC21 I-GENE
controls O
cell O
growth O
via O
distinct O
Raf I-GENE
- O
independent O
downstream O
signaling O
pathways O
. O

Fission I-GENE
yeast I-GENE
mal2 I-GENE
+ I-GENE
is O
required O
for O
chromosome O
segregation O
. O

Selection O
was O
based O
on O
expression O
of O
an O
integrated O
DNA O
fragment O
containing O
the O
con I-GENE
- I-GENE
10 I-GENE
promoter I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
followed O
by O
the O
initial O
segment O
of O
the O
con I-GENE
- I-GENE
10 I-GENE
open I-GENE
reading I-GENE
frame I-GENE
fused O
in O
frame O
with O
the O
bacterial I-GENE
hygromycin I-GENE
B I-GENE
phosphotransferase I-GENE
structural I-GENE
gene I-GENE
( O
con10 I-GENE
'-' I-GENE
hph I-GENE
). O

Mutations O
at O
two O
neighboring O
sites O
, O
serine O
242 O
and O
threonine O
255 O
, O
exacerbated O
the O
effect O
. O

IRF I-GENE
- I-GENE
1 I-GENE
acts O
as O
a O
transcriptional O
activator O
, O
while O
IRF I-GENE
- I-GENE
2 I-GENE
acts O
as O
a O
repressor O
. O

In O
contrast O
, O
cotransfection O
of O
TFIIB I-GENE
and O
IRF I-GENE
- I-GENE
1 I-GENE
into O
NIH O
3T3 O
cells O
resulted O
in O
a O
dose O
- O
dependent O
repression O
of O
promoter O
activation O
which O
occurred O
in O
a O
TATA O
- O
dependent O
manner O
. O

The O
requirement O
of O
Tyr O
- O
19 O
dephosphorylation O
for O
spindle O
assembly O
is O
also O
observed O
under O
conditions O
in O
which O
spindle O
formation O
is O
independent O
of O
mitosis O
, O
suggesting O
that O
the O
involvement O
of O
Cdc28 I-GENE
/ O
Clb I-GENE
kinase O
in O
SPB O
separation O
is O
direct O
. O

A O
subset O
of O
these O
DMP1 I-GENE
recognition I-GENE
sequences I-GENE
containing O
a O
GGA O
trinucleotide O
core O
can O
also O
function O
as O
Ets I-GENE
- I-GENE
responsive I-GENE
elements I-GENE
. O

In O
both O
settings O
, O
it O
can O
be O
phosphorylated O
by O
cyclin I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
suggesting O
that O
its O
transcriptional O
activity O
may O
normally O
be O
regulated O
through O
such O
mechanisms O
. O

Expression O
of O
the O
proapoptotic I-GENE
protein I-GENE
Bax I-GENE
under O
the O
control O
of O
a O
GAL10 I-GENE
promoter I-GENE
in O
Saccharomyces O
cerevisiae O
resulted O
in O
galactose O
- O
inducible O
cell O
death O
. O

This O
technique O
was O
employed O
in O
12 O
patients O
with O
a O
unicameral O
bone O
cyst O
. O

Enterococcus O
faecium O
strains O
with O
vanA O
- O
mediated O
glycopeptide O
resistance O
were O
isolated O
by O
enrichment O
culture O
from O
the O
intestines O
and O
feces O
of O
several O
animal O
species O
, O
mainly O
horses O
and O
dogs O
( O
8 O
% O
positive O
), O
chickens O
( O
7 O
% O
positive O
), O
and O
pigs O
( O
6 O
% O
positive O
). O

The O
amino O
- O
terminal O
region O
of O
E1A I-GENE
binds O
several O
high O
molecular O
weight O
proteins O
and O
inhibits O
the O
transcriptional O
coactivator O
function O
of O
p300 I-GENE
and O
the O
homologous O
cAMP I-GENE
response I-GENE
element I-GENE
( I-GENE
CRE I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
. O

Transient O
transfection O
assays O
using O
reporter O
gene O
constructs O
containing O
various O
lengths O
of O
the O
5 I-GENE
' I-GENE
mdr1b I-GENE
sequences I-GENE
revealed O
that O
the O
sequence O
located O
between O
- O
247 O
to O
- O
126 O
bp O
was O
important O
for O
the O
expression O
of O
the O
reporter O
gene O
in O
many O
different O
cell O
lines O
. O

We O
show O
that O
the O
5 O
' O
UTR O
characteristic O
of O
testis I-GENE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
mos I-GENE
mRNA I-GENE
strongly O
represses O
translation O
relative O
to O
the O
translation O
of O
transcripts O
that O
contain O
a O
5 O
' O
UTR O
derived O
from O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
, O
and O
this O
is O
mainly O
due O
to O
the O
four O
uORFs O
. O

To O
address O
the O
biological O
effect O
of O
specific O
isoform O
expression O
, O
NIH3T3 O
cells O
were O
transfected O
with O
a O
eukaryotic O
expression O
vector O
containing O
cDNA O
for O
FGF8a I-GENE
, O
FGF8b I-GENE
, O
or O
FGF8e I-GENE
. O

These O
findings O
suggest O
that O
the O
F O
- O
wave O
may O
be O
elicited O
in O
motoneuron O
of O
different O
depolarization O
threshold O
but O
primarily O
in O
larger O
and O
faster O
nerve O
fibers O
, O
with O
a O
lower O
threshold O
of O
depolarization O
. O

In O
addition O
, O
carp I-GENE
JAK1 I-GENE
shows O
higher O
sequence O
homology O
to O
mammalian I-GENE
JAK1 I-GENE
in O
both O
the O
kinase O
- O
like O
( O
JH2 I-GENE
) O
and O
kinase O
( O
JH1 I-GENE
) O
domains O
( O
approximately O
70 O
% O
identity O
). O

When O
this O
DNA O
fragment O
was O
placed O
upstream O
of O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
and O
transfected O
into O
a O
carp O
CF O
cell O
line O
, O
it O
could O
drive O
the O
synthesis O
of O
CAT I-GENE
enzyme I-GENE
16 O
times O
more O
efficiently O
than O
the O
promoterless O
pCAT I-GENE
- I-GENE
Basic I-GENE
. O

Molecular O
cloning O
of O
Elk I-GENE
- I-GENE
3 I-GENE
, O
a O
new O
member O
of O
the O
Ets I-GENE
family I-GENE
expressed O
during O
mouse O
embryogenesis O
and O
analysis O
of O
its O
transcriptional O
repression O
activity O
. O

We O
report O
an O
example O
of O
an O
MDV O
- O
transformed O
T O
- O
lymphoblastoid O
cell O
line O
( O
T9 O
) O
expressing O
high O
levels O
of O
a O
truncated I-GENE
C I-GENE
- I-GENE
MYB I-GENE
protein I-GENE
as O
a O
result O
of O
RAV O
integration O
within O
one O
c I-GENE
- I-GENE
myb I-GENE
allele I-GENE
. O

Frozen O
/ O
thawed O
extensor O
digitorum O
longus O
muscle O
tendon O
units O
had O
significantly O
lower O
values O
for O
load O
to O
failure O
( O
p O
< O
0 O
. O
01 O
), O
energy O
absorbed O
to O
failure O
( O
p O
< O
0 O
. O
01 O
), O
and O
strain O
at O
failure O
( O
p O
< O
0 O
. O
01 O
), O
and O
they O
tended O
to O
fail O
at O
a O
different O
anatomic O
location O
( O
p O
< O
0 O
. O
01 O
) O
( O
broadly O
at O
the O
fascia O
- O
muscle O
interface O
as O
compared O
with O
horizontally O
at O
the O
musculotendinous O
junction O
) O
than O
fresh O
units O
. O

Northern O
analysis O
of O
the O
3 I-GENE
. I-GENE
1 I-GENE
- I-GENE
kb I-GENE
PWP2H I-GENE
cDNA I-GENE
revealed O
that O
a O
3 O
. O
3 O
- O
kb O
major O
transcript O
is O
ubiquitously O
expressed O
in O
human O
adult O
tissues O
. O

Forty O
- O
eight O
10 O
- O
12 O
- O
week O
- O
old O
male O
Sprague O
- O
Dawley O
rats O
were O
randomized O
to O
receive O
, O
daily O
for O
28 O
days O
: O
( O
1 O
) O
CsA O
vehicle O
p O
. O
o O
. O
plus O
FB O
vehicle O
sc O
; O
( O
2 O
) O
CsA O
( O
15 O
mg O
/ O
kg O
) O
p O
. O
o O
. O
plus O
FB O
vehicle O
sc O
, O
( O
3 O
) O
CsA O
vehicle O
p O
. O
o O
. O
plus O
FB O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
sc O
; O
and O
( O
4 O
) O
CsA O
( O
15 O
mg O
/ O
kg O
) O
p O
. O
o O
. O
plus O
FB O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
sc O
. O

CsA O
alone O
resulted O
in O
elevated O
bone O
turnover O
. O

Individuals O
attending O
the O
GUM O
Department O
in O
the O
Royal O
Infirmary O
of O
Edinburgh O
between O
1990 O
and O
1994 O
with O
the O
diagnosis O
of O
HIV O
infection O
, O
genital O
warts O
, O
genital O
herpes O
, O
non O
- O
specific O
genital O
infection O
( O
NSGI O
), O
gonorrhoea O
and O
syphilis O
were O
included O
in O
the O
study O
. O

Oncogenic O
activation O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
the O
human I-GENE
trk I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
by O
fusion O
to O
a O
cell O
adhesion O
molecule O
. O

Northern O
blotting O
showed O
that O
MDMX I-GENE
, O
like O
MDM2 I-GENE
, O
is O
expressed O
in O
all O
tissues O
tested O
, O
and O
that O
several O
mRNAs O
for O
MDMX I-GENE
can O
be O
detected O
. O

Physiol O
. O

The O
nucleotide O
sequence O
of O
22 O
, O
846 O
bp O
of O
the O
left O
arm O
of O
chromosome O
IV O
is O
described O
. O

They O
suggest O
that O
decreased O
steady O
- O
state O
levels O
of O
IME1 I-GENE
and O
IME2 I-GENE
mRNA I-GENE
were O
not O
merely O
the O
result O
of O
non O
- O
specific O
adverse O
affects O
on O
nucleic O
acid O
metabolism O
caused O
by O
the O
yvh1 I-GENE
disruption O
. O

Natural O
FL I-GENE
protein I-GENE
has O
been O
purified O
from O
a O
stromal O
cell O
line O
and O
shown O
to O
be O
a O
65 O
kD O
nondisulfide O
- O
linked O
homodimeric O
glycoprotein O
comprised O
of O
30 O
kD O
subunits O
, O
each O
containing O
12 O
kD O
of O
N O
- O
and O
O O
- O
linked O
sugars O
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
the O
influence O
of O
HHCA O
and O
other O
serological O
factors O
upon O
the O
development O
of O
VGS O
. O

Spliced O
exons O
of O
adenovirus O
late O
RNAs O
colocalize O
with O
snRNP O
in O
a O
specific O
nuclear O
domain O
. O

Using O
Spurr O
' O
s O
resin O
as O
a O
mounting O
medium O
, O
we O
could O
observe O
thick O
specimens O
with O
oil O
immersion O
objective O
lens O
without O
the O
use O
of O
coverslips O
, O
then O
avoid O
air O
bubbles O
near O
the O
specimen O
. O

The O
present O
study O
investigated O
dose O
dependence O
and O
time O
course O
effects O
of O
the O
benzodiazepine O
( O
BDZ O
) O
partial O
inverse O
agonist O
, O
RO19 O
- O
4603 O
( O
0 O
. O
005 O
- O
0 O
. O
30 O
mg O
/ O
kg O
) O
alone O
, O
and O
in O
combination O
with O
the O
BDZ I-GENE
receptor I-GENE
antagonists O
flumazenil O
, O
ZK O
93426 O
, O
and O
CGS O
8216 O
( O
20 O
mg O
/ O
kg O
) O
in O
selectively O
bred O
alcohol O
- O
preferring O
( O
P O
) O
rats O
provided O
a O
two O
- O
bottle O
choice O
test O
between O
ethanol O
( O
EtOH O
) O
( O
10 O
% O
v O
/ O
v O
), O
and O
a O
palatable O
saccharin O
( O
0 O
. O
0125 O
% O
g O
/ O
v O
) O
solution O
. O

Beyond O
the O
Tower O
of O
Babel O
: O
a O
nomenclature O
for O
suicidology O
. O

Infection O
with O
Neisseria O
meningitidis O
group O
B O
has O
been O
difficult O
to O
detect O
, O
partly O
because O
this O
bacterial O
group O
' O
s O
polysaccharide O
is O
a O
weak O
immunogen O
. O

RNase I-GENE
protection O
analysis O
of O
two O
rRNA O
fragments O
whose O
genes O
are O
adjacent O
provided O
evidence O
for O
a O
polycistronic O
transcript O
containing O
sequences O
from O
both O
, O
as O
well O
as O
separate O
small O
RNAs O
. O

Rss1p I-GENE
encodes O
a O
novel O
essential O
protein O
of O
538 O
amino O
acids O
, O
which O
contains O
an O
extended O
predicted O
coiled O
- O
coil O
domain O
and O
is O
located O
both O
at O
nuclear O
pore O
complexes O
( O
NPCs O
) O
and O
in O
the O
cytoplasm O
. O

To O
map O
this O
regulatory O
serine O
phosphorylation O
site O
we O
developed O
a O
baculovirus O
- O
mediated O
expression O
system O
for O
wild I-GENE
- I-GENE
type I-GENE
annexin I-GENE
II I-GENE
and O
for O
a O
series O
of O
annexin I-GENE
II I-GENE
mutants I-GENE
which O
contained O
substitutions O
in O
one O
or O
more O
serine O
residues O
present O
in O
the O
N O
- O
terminal O
domain O
. O

The O
PAI I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
one O
of O
the O
most O
TNF I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
known O
and O
is O
also O
highly O
induced O
by O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
and O
the O
phosphatase O
inhibitor O
, O
okadaic O
acid O
, O
in O
both O
HT O
- O
1080 O
fibrosarcoma O
and O
U O
- O
937 O
histiocytic O
cells O
. O

220 O
, O
263 O
- O
273 O
). O

These O
two O
contigs O
contain O
a O
total O
of O
163 O
open O
reading O
frames O
( O
ORFs O
) O
in O
26 O
- O
29 O
putative O
operons O
; O
56 O
ORFs O
could O
be O
identified O
with O
reasonable O
certainty O
. O

T O
., O
Patel O
, O
S O
. O

Growth O
factors O
induce O
the O
expression O
of O
the O
immediate I-GENE
early I-GENE
gene I-GENE
products I-GENE
MAP I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
( O
MKP I-GENE
- I-GENE
1 I-GENE
), O
c I-GENE
- I-GENE
Fos I-GENE
and O
c I-GENE
- I-GENE
Jun I-GENE
. O

The O
up O
- O
regulation O
of O
E I-GENE
- I-GENE
selectin I-GENE
, O
one O
of O
the O
adhesion O
molecules O
on O
the O
endothelium O
, O
is O
an O
important O
event O
in O
the O
mediation O
of O
the O
inflammatory O
response O
. O

The O
NIT2 I-GENE
protein I-GENE
is O
localised O
in O
nuclei O
and O
could O
not O
be O
detected O
in O
the O
cytoplasmic O
fraction O
of O
cells O
subjected O
to O
nitrogen O
derepression O
or O
nitrogen O
repression O
, O
indicating O
that O
the O
nuclear O
import O
of O
NIT2 I-GENE
is O
not O
regulated O
. O

In O
spite O
of O
much O
effort O
, O
no O
one O
has O
succeeded O
in O
isolating O
and O
characterizing O
the O
enzyme O
( O
s O
) O
responsible O
for O
synthesis O
of O
cellulose O
, O
the O
major O
cell O
wall O
polymer O
of O
plants O
. O

Vascular O
responses O
to O
reactive O
hyperemia O
( O
with O
flow O
increase O
leading O
to O
endothelium O
- O
dependent O
dilation O
) O
and O
to O
sublingual O
glyceryl O
trinitrate O
( O
GTN O
; O
endothelium O
- O
independent O
dilation O
) O
were O
recorded O
. O

During O
this O
period O
, O
administration O
of O
additional O
exogenous I-GENE
PRL I-GENE
did O
not O
stimulate O
further O
activation O
( O
binding O
) O
of O
the O
Stat I-GENE
factors I-GENE
. O

Intraperitoneal O
administration O
of O
L O
- O
5 O
- O
hydroxytryptophan O
( O
L O
- O
5 O
- O
HTP O
) O
at O
doses O
of O
25 O
to O
100 O
mg O
/ O
kg O
dramatically O
increase O
defecation O
in O
mice O
. O

In O
the O
VA O
- O
SMV O
mode O
, O
the O
connection O
was O
made O
with O
valved O
conduits O
from O
the O
LV O
apex O
( O
inflow O
) O
to O
the O
ascending O
aorta O
( O
outflow O
) O
( O
n O
= O
11 O
) O
or O
to O
the O
DAo O
( O
n O
= O
12 O
). O

The O
evidence O
in O
support O
of O
this O
was O
derived O
from O
the O
fact O
that O
the O
affinity O
or O
interaction O
between O
the O
two O
subunits O
was O
impaired O
as O
indicated O
by O
the O
first O
order O
rate O
constant O
of O
hCG I-GENE
alpha I-GENE
1 I-GENE
beta I-GENE
( O
km O
= O
4 O
. O
1 O
x O
10 O
(- O
2 O
) O
min O
- O
1 O
) O
at O
pH O
3 O
. O
0 O
at O
23 O
degrees O
C O
which O
is O
one O
order O
of O
magnitude O
greater O
relative O
to O
rehCG I-GENE
( O
kw O
= O
4 O
. O
6 O
x O
10 O
(- O
3 O
) O
min O
- O
1 O
). O

Factor O
V O
Leiden O
is O
a O
genetic O
disorder O
associated O
with O
an O
increased O
risk O
of O
venous O
thrombosis O
. O

This O
is O
the O
first O
determination O
of O
the O
complete O
secondary O
structure O
of O
an O
RNA O
spliced O
in O
a O
spliceosome O
. O

The O
majority O
of O
the O
cases O
with O
0 O
- O
I O
or O
0 O
- O
III O
components O
were O
sm O
. O
cancer O
. O

These O
patients O
appear O
to O
have O
slightly O
better O
pulmonary O
function O
and O
nutritional O
status O
; O
yet O
, O
they O
seem O
to O
have O
a O
higher O
degree O
of O
health O
care O
utilization O
. O

This O
observation O
calls O
for O
careful O
monitoring O
of O
calcium O
and O
alkaline I-GENE
phosphatase I-GENE
values O
and O
possible O
adjustments O
of O
vitamin O
D O
intake O
when O
fortifiers O
are O
used O
for O
extended O
periods O
. O

We O
have O
found O
that O
PEA2 I-GENE
is O
also O
required O
for O
the O
bipolar O
budding O
pattern O
and O
that O
it O
encodes O
a O
novel O
protein O
with O
a O
predicted O
coiled O
- O
coil O
domain O
. O

Signaling O
from O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
Cdc42 I-GENE
to O
the O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
. O

Percent O
identities O
of O
the O
mouse I-GENE
PP2 I-GENE
to O
mouse I-GENE
Y1 I-GENE
, O
mouse O
Y4 I-GENE
/ O
PP1 I-GENE
and O
human I-GENE
Y2 I-GENE
receptors I-GENE
are O
53 O
, O
42 O
, O
and O
31 O
, O
respectively O
. O

Correlating O
with O
the O
previous O
observation O
that O
CBF I-GENE
binding O
to O
the O
78C1 O
site O
is O
enhanced O
by O
EGTA O
and O
EDTA O
, O
these O
divalent O
cation O
chelators O
specifically O
stimulate O
78C1 O
- O
directed O
transcription O
. O

The O
human O
gene O
fragment O
ligated O
to O
the O
minimal O
rat O
liver O
glucokinase I-GENE
promoter O
was O
shown O
to O
work O
as O
an O
enhancer O
in O
the O
hepatocyte O
transfection O
system O
. O

To O
test O
the O
role O
of O
ML O
in O
human O
reproductive O
axis O
, O
128 O
healthy O
children O
, O
68 O
boys O
and O
60 O
girls O
, O
were O
studied O
. O

However O
, O
the O
truncated O
deer I-GENE
receptor I-GENE
lacks O
the O
most O
C O
- O
terminal O
tyrosine O
residue O
in O
the O
intracellular O
domain O
which O
is O
believed O
to O
be O
essential O
for O
activation O
of O
the O
beta I-GENE
- I-GENE
casein I-GENE
promoter I-GENE
. O

This O
report O
provides O
further O
evidence O
for O
the O
riMLF O
in O
the O
control O
of O
downgaze O
, O
and O
a O
synkinesis O
is O
postulated O
for O
the O
development O
of O
the O
convergence O
retraction O
nystagmus O
. O

Rifabutin O
has O
substantial O
efficacy O
when O
combined O
with O
other O
agents O
. O

Ninety O
- O
four O
percent O
of O
the O
EPs O
were O
tubal O
, O
and O
90 O
% O
of O
the O
tubes O
exhibited O
some O
pathologic O
changes O
, O
including O
chronic O
salpingitis O
( O
49 O
. O
5 O
%) O
and O
follicular O
salpingitis O
( O
10 O
%), O
among O
others O
. O

The O
assessment O
using O
7 O
H O
9 O
liquid O
medium O
by O
the O
former O
author O
demonstrated O
the O
potent O
activities O
of O
both O
CS O
- O
940 O
* O
and O
sparfloxacin O
( O
SPFX O
), O
followed O
by O
AM O
- O
1155 O
*, O
ciprofloxacin O
( O
CPFX O
), O
levofloxacin O
( O
LVFX O
), O
OPC O
- O
17116 O
*, O
NM O
- O
394 O
* O
in O
sequence O
. O

The O
STE20 I-GENE
gene I-GENE
, O
encoding O
a O
protein O
kinase O
required O
for O
pheromone O
signal O
transduction O
, O
has O
recently O
been O
identified O
in O
a O
genetic O
screen O
for O
high O
- O
gene O
- O
dosage O
suppressors O
of O
a O
partly O
defective O
G I-GENE
beta I-GENE
mutation O
. O

This O
enzyme O
is O
designated O
( I-GENE
1 I-GENE
--> I-GENE
4 I-GENE
)- I-GENE
beta I-GENE
- I-GENE
xylan I-GENE
endohydrolase I-GENE
isoenzyme I-GENE
X I-GENE
- I-GENE
I I-GENE
. O

Magnetic O
resonance O
imaging O
in O
coccidioidal O
arthritis O
. O

Moloney O
murine O
leukemia O
virus O
( O
MMLV O
)- O
derived O
pUCMoTiN O
- O
based O
retroviral O
vectors O
were O
engineered O
to O
allow O
constitutive O
and O
Tat I-GENE
( O
trans I-GENE
- I-GENE
activator I-GENE
of I-GENE
transcription I-GENE
)- O
inducible O
expression O
of O
five O
hammerhead O
ribozymes O
targeted O
against O
highly O
conserved O
sequences O
within O
the O
group I-GENE
antigen I-GENE
( O
Gag I-GENE
), O
protease I-GENE
( O
Pro I-GENE
), O
reverse I-GENE
transcriptase I-GENE
( O
RT I-GENE
), O
tat I-GENE
, O
and O
envelope I-GENE
( O
Env I-GENE
) O
coding O
regions O
of O
human O
immunodeficiency O
virus O
type O
- O
1 O
( O
HIV O
- O
1 O
) O
RNA O
. O

REM O
sleep O
deprivation O
was O
performed O
using O
the O
platform O
technique O
. O

The O
same O
ligands O
also O
exhibit O
a O
similar O
inhibitory O
effect O
on O
PDGF I-GENE
- I-GENE
BB I-GENE
- O
dependent O
[ O
3H O
] O
thymidine O
incorporation O
in O
PAE O
cells O
expressing O
the O
PDGF I-GENE
beta I-GENE
- I-GENE
receptors I-GENE
. O

We O
analyzed O
serial O
biopsy O
specimens O
from O
eight O
patients O
with O
FL O
for O
secondary O
alterations O
of O
the O
rearranged I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
the O
breakpoint O
and O
open O
reading O
frame O
( O
ORF O
) O
regions O
. O

In O
all O
eight O
cases O
, O
neither O
FL O
nor O
DLL O
cells O
showed O
alterations O
of O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
sequences I-GENE
in O
the O
breakpoint O
region O
, O
suggesting O
high O
conservation O
of O
the O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
during O
both O
t O
( O
14 O
; O
18 O
) O
translocation O
and O
morphologic O
transformation O
of O
the O
FL O
cells O
. O

BACKGROUND O
: O
The O
Bazett O
- O
corrected O
QT O
( O
QTc O
) O
interval O
during O
exercise O
has O
been O
used O
as O
a O
marker O
for O
ischemic O
disease O
, O
arrhythmogenic O
substrate O
and O
the O
long O
QT O
syndrome O
. O

An O
essential O
role O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
c I-GENE
- I-GENE
Fos I-GENE
in O
basal O
and O
PMA O
- O
stimulated O
transcription O
of O
the O
PAI I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
demonstrated O
by O
our O
finding O
that O
antisense O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
oligodeoxynucleotides O
both O
strongly O
reduced O
basal O
and O
PMA O
- O
stimulated O
PAI I-GENE
- I-GENE
1 I-GENE
synthesis O
. O

Leukemia I-GENE
- I-GENE
inhibitory I-GENE
factor I-GENE
( O
LIF I-GENE
) O
is O
a O
neuropoietin I-GENE
able O
to O
regulate O
the O
differentiation O
and O
the O
survival O
of O
many O
cell O
types O
, O
which O
include O
some O
neuronal O
populations O
. O

To O
analyze O
the O
mechanism O
of O
fos I-GENE
/ O
jun I-GENE
activation O
by O
TCDD O
we O
have O
used O
electrophoretic O
mobility O
shift O
and O
transient O
expression O
assays O
of O
reporter O
gene O
constructs O
containing O
response O
elements O
for O
12 O
- O
O O
- O
tetradecanoyl O
- O
phorbol O
- O
13 O
- O
acetate O
( O
TRE O
), O
serum O
( O
SRE O
), O
cAMP O
( O
CRE O
), O
and O
aromatic O
hydrocarbons O
( O
AhRE O
) O
from O
the O
fos I-GENE
and O
jun I-GENE
genes I-GENE
fused O
to O
the O
firefly I-GENE
luciferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
SV40 I-GENE
minimal I-GENE
promoter I-GENE
. O

The O
optimal O
sequence O
for O
interaction O
with O
mu I-GENE
2 I-GENE
and O
with O
AP I-GENE
- I-GENE
2 I-GENE
has O
tyrosine O
as O
an O
anchor O
and O
prefers O
arginine O
at O
position O
Y O
+ O
2 O
and O
leucine O
at O
position O
Y O
+ O
3 O
. O

STK I-GENE
/ O
RON I-GENE
- O
expressing O
Ba O
/ O
F3 O
pro O
- O
B O
cells O
( O
BaF O
/ O
STK I-GENE
) O
exhibited O
MSP I-GENE
- O
dependent O
growth O
, O
whereas O
STK I-GENE
/ O
RON I-GENE
- O
expressing O
mouse O
erythroleukaemia O
cells O
( O
MEL O
/ O
STK I-GENE
) O
displayed O
MSP I-GENE
- O
induced O
apoptosis O
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
showed O
that O
OxyR I-GENE
- I-GENE
C199S I-GENE
protected O
Pmom I-GENE
from O
- O
104 O
to O
- O
46 O
on O
the O
top O
strand O
and O
produced O
a O
protection O
pattern O
characteristic O
of O
reduced I-GENE
wild I-GENE
- I-GENE
type I-GENE
OxyR I-GENE
. O

Kss1 I-GENE
binds O
specifically O
to O
a O
GST I-GENE
- O
Dig1 I-GENE
fusion O
in O
the O
absence O
of O
any O
other O
yeast O
protein O
. O

In O
contrast O
, O
dig1 I-GENE
dig2 I-GENE
cells O
constitutively O
invade O
agar O
medium O
, O
whereas O
a O
dig1 I-GENE
dig2 I-GENE
ste12 I-GENE
triple O
mutant O
does O
not O
, O
indicating O
that O
Dig1 I-GENE
and O
Dig2 I-GENE
share O
a O
role O
in O
negatively O
regulating O
the O
invasive O
growth O
pathway O
. O

Paracrine O
activation O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
promoter I-GENE
by O
the O
viral I-GENE
Tat I-GENE
protein I-GENE
is O
mechanistically O
similar O
to O
trans O
- O
activation O
within O
a O
cell O
. O

Comparison O
of O
the O
sequences O
of O
the O
xFxFG O
repeat O
regions O
of O
p62 I-GENE
and O
Nsplp I-GENE
indicated O
that O
NTF2 I-GENE
was O
probably O
interacting O
with O
the O
phenylalanine O
- O
containing O
core O
of O
these O
repeats O
and O
not O
the O
intervening O
hydrophilic O
linkers O
. O

This O
is O
the O
first O
report O
of O
the O
successful O
resection O
of O
a O
MFH O
originating O
in O
the O
renal O
capsular O
tissue O
and O
extending O
into O
the O
inferior O
vena O
cava O
. O

Transient O
expression O
of O
VSF I-GENE
- I-GENE
1 I-GENE
in O
protoplasts O
stimulated O
vs I-GENE
- I-GENE
1 I-GENE
dependent O
activation O
of O
the O
- I-GENE
76 I-GENE
/ I-GENE
grp1 I-GENE
. I-GENE
8 I-GENE
minimal I-GENE
promoter I-GENE
. O

Keeping O
in O
mind O
the O
limited O
range O
of O
age O
and O
dosages O
, O
advantages O
and O
disadvantages O
of O
the O
drug O
are O
discussed O
, O
comparing O
the O
experimental O
results O
with O
those O
derived O
from O
the O
literature O
. O

Blood O
sampling O
procedures O
were O
videotaped O
. O

Analysis O
of O
one O
cDNA O
revealed O
an O
unusual O
splicing O
event O
involving O
EZH1 I-GENE
and O
a O
tandemly O
linked O
gene O
GPR2 I-GENE
and O
suggests O
a O
potential O
mechanism O
for O
modifying O
the O
EZH1 I-GENE
protein I-GENE
in O
the O
conserved O
C O
- O
terminal O
domain O
. O

A O
given O
standard O
input O
function O
and O
a O
given O
value O
of O
distribution O
volume O
( O
Vd O
) O
used O
for O
the O
rCBF O
measurement O
of O
this O
method O
were O
calculated O
from O
the O
dynamic O
study O
by O
six O
normal O
volunteers O
. O

They O
lack O
a O
predicted O
single O
stranded O
( O
ss O
) O
DNA O
binding O
motif O
that O
is O
unique O
the O
large O
terminase I-GENE
proteins I-GENE
in O
T4 I-GENE
gp17 I-GENE
, O
and O
that O
has O
been O
implicated O
in O
recognizing O
ssDNA O
regions O
in O
replicating O
and O
recombining O
T4DNA O
destined O
to O
be O
packaged O
. O

It O
can O
be O
concluded O
that O
in O
normotensive O
subjects O
, O
uric O
acid O
and O
xanthine I-GENE
oxidase I-GENE
have O
significant O
association O
with O
blood O
pressure O
and O
thus O
are O
one O
of O
the O
many O
factors O
which O
are O
involved O
in O
the O
cause O
or O
effect O
of O
hypertension O
. O

Immunoblotting O
of O
expressed O
recombinant O
proteins O
with O
the O
monoclonal I-GENE
08L I-GENE
antibody I-GENE
localized O
the O
08L I-GENE
epitope O
to O
the O
carboxyl O
end O
of O
the O
protein O
. O

We O
infer O
that O
the O
dominant O
negative O
inhibition O
results O
from O
both O
direct O
proteolysis O
of O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
tetramer I-GENE
by O
the O
fusion O
subunit O
and O
detour O
of O
the O
tetramer O
to O
the O
lysosome O
. O

The O
current O
study O
defines O
the O
vinculin I-GENE
- O
and O
FAK I-GENE
- I-GENE
interaction I-GENE
domains I-GENE
on O
paxillin I-GENE
and O
identifies O
the O
principal O
paxillin I-GENE
focal O
adhesion O
targeting O
motif O
. O

These O
data O
demonstrate O
the O
presence O
of O
a O
single O
binding O
site O
for O
vinculin I-GENE
, O
and O
at O
least O
two O
binding O
sites O
for O
FAK I-GENE
that O
are O
separated O
by O
an O
intervening O
stretch O
of O
100 O
amino O
acids O
. O

These O
data O
demonstrate O
that O
paxillin I-GENE
localizes O
to O
focal O
adhesions O
independent O
of O
interactions O
with O
vinculin I-GENE
and O
/ O
or O
FAK I-GENE
, O
and O
represents O
the O
first O
definitive O
demonstration O
of O
LIM I-GENE
domains I-GENE
functioning O
as O
a O
primary O
determinant O
of O
protein O
subcellular O
localization O
to O
focal O
adhesions O
. O

A O
single O
protease O
- O
resistant O
structure O
formed O
by O
the O
entirety O
of O
both O
PDZ I-GENE
repeats I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
PDZ1 I-GENE
- I-GENE
2 I-GENE
) O
contains O
the O
protein I-GENE
4 I-GENE
. I-GENE
1 I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

Several O
agents O
have O
been O
tried O
for O
treatment O
, O
often O
limited O
by O
toxic O
side O
effects O
. O

Jerseys O
had O
higher O
hepatic O
Cu O
concentrations O
than O
did O
Holsteins O
on O
d O
60 O
( O
346 O
vs O
. O

RUSH I-GENE
- I-GENE
1 I-GENE
beta I-GENE
is O
a O
95 O
- O
kDa O
truncated O
version O
of O
RUSH I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
that O
results O
from O
alternative O
splicing O
of O
a O
57 O
- O
bp O
exon O
as O
confirmed O
by O
genomic O
cloning O
. O

These O
results O
are O
consistent O
with O
the O
well O
established O
polarity O
of O
RXR I-GENE
heterodimer O
binding O
to O
bipartite O
hormone O
response O
elements O
, O
with O
the O
VDR I-GENE
recognizing O
the O
3 O
'- O
half O
- O
element O
. O

PPAR I-GENE
gamma I-GENE
mRNA I-GENE
levels O
were O
reduced O
by O
95 O
% O
with O
3 O
nM O
TNF I-GENE
alpha I-GENE
treatment O
for O
24 O
h O
. O

Exons O
III O
to O
VIII O
, O
which O
cover O
the O
coding O
region O
and O
the O
3 O
' O
untranslated O
region O
, O
are O
almost O
identical O
in O
all O
types O
of O
PST I-GENE
or O
AST I-GENE
cDNAs I-GENE
. O

Growth O
factor O
allows O
effective O
dose O
- O
intensive O
regimen O
in O
advanced O
breast O
cancer O
patients O
. O

Recombinant I-GENE
erythropoietin I-GENE
( O
r I-GENE
- I-GENE
HuEPO I-GENE
) O
in O
the O
treatment O
of O
anemia O
in O
multiple O
myeloma O

In O
1993 O
and O
1994 O
and O
infection O
with O
body O
lice O
was O
registered O
41 O
times O
in O
31 O
patients O
at O
the O
clinic O
for O
homeless O
of O
the O
Community O
Health O
Service O
of O
Utrecht O
. O

Ki I-GENE
- I-GENE
ras I-GENE
and O
p53 I-GENE
mutations I-GENE
in O
pancreatic O
ductal O
adenocarcinoma O
. O

Epidemiological O
data O
are O
quite O
controversial O
but O
sudden O
death O
occurring O
during O
sporting O
activity O
is O
probably O
not O
a O
rare O
occurrence O
. O

However O
, O
the O
ratio O
M O
/ O
Pc O
provides O
a O
useful O
index O
that O
seems O
to O
be O
independent O
of O
the O
metabolic O
demand O
. O

Rat I-GENE
liver I-GENE
catalase I-GENE
is O
sorted O
to O
peroxisomes O
by O
its O
C O
- O
terminal O
tripeptide O
Ala O
- O
Asn O
- O
Leu O
, O
not O
by O
the O
internal O
Ser O
- O
Lys O
- O
Leu O
motif O
. O

The O
mobility O
shift O
assay O
of O
the O
65 O
bp O
(- O
318 O
/ O
- O
254 O
) O
fragment O
with O
nuclear O
extract O
from O
the O
dark O
- O
adapted O
sample O
showed O
an O
additional O
band O
, O
not O
seen O
with O
the O
light O
- O
grown O
sample O
. O

These O
data O
provide O
strong O
evidence O
that O
E2F I-GENE
or O
an O
E2F I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
is O
involved O
in O
the O
regulation O
of O
nonmuscle I-GENE
myosin I-GENE
expression O
. O

When O
the O
E1A I-GENE
N I-GENE
- I-GENE
terminus I-GENE
is O
used O
as O
a O
competitor O
in O
squelshing O
experiments O
it O
abolishes O
CBP I-GENE
- O
induced O
activation O
of O
E2F1 I-GENE
/ O
DP1 I-GENE
, O
whereas O
an O
E1A I-GENE
mutant I-GENE
lacking O
CBP I-GENE
binding O
ability O
fails O
to O
do O
so O
. O

Small O
Maf I-GENE
proteins I-GENE
interact O
with O
the O
human O
transcription O
factor O
TCF11 I-GENE
/ O
Nrf1 I-GENE
/ O
LCR I-GENE
- I-GENE
F1 I-GENE
. O

On O
the O
third O
occasion O
water O
( O
W O
) O
was O
ingested O
throughout O
the O
run O
. O

The O
effect O
of O
maternal O
ingestion O
of O
the O
reduced O
energy O
sweetener O
erythritol O
was O
investigated O
in O
KBL O
: O
JW O
strain O
pregnant O
rabbits O
. O

Moreover O
, O
the O
same O
mutations O
alter O
the O
structure O
of O
junB I-GENE
5 O
' O
flanking O
DNA O
within O
chromatin O
. O

The O
nm23 I-GENE
- I-GENE
H1 I-GENE
/ O
nm23 I-GENE
- I-GENE
H2 I-GENE
gene O
transcriptional O
activity O
ratio O
varied O
depending O
on O
the O
cell O
line O
. O

CONCLUSION O
: O
Intravenous O
diazepam O
administration O
before O
EGD O
produces O
a O
significant O
fall O
in O
SpO2 O
during O
the O
procedure O
, O
and O
so O
should O
be O
avoided O
; O
continuous O
monitoring O
of O
SpO2 O
should O
be O
done O
during O
EGD O
. O

The O
nucleotide O
sequence O
alignment O
between O
mouse O
and O
human I-GENE
CA I-GENE
IV I-GENE
shows O
69 O
% O
identity O
in O
the O
coding O
region O
and O
all O
of O
the O
exon O
- O
intron O
boundaries O
are O
conserved O
, O
as O
are O
the O
sizes O
of O
the O
introns O
. O

Discordance O
on O
the O
cost O
dimension O
correlated O
negatively O
with O
G I-GENE
Hb I-GENE
, O
suggesting O
better O
glycemic O
control O
with O
greater O
disagreement O
. O

DATA O
SOURCES O
: O
Epidemiologic O
studies O
, O
research O
studies O
, O
review O
articles O
, O
and O
government O
reports O
pertaining O
to O
epidemiology O
of O
lung O
cancer O
. O

RESULTS O
: O
The O
age O
distribution O
was O
28 O
to O
83 O
years O
old O
( O
mean O
was O
54 O
. O
1 O
years O
). O

Histological O
changes O
, O
including O
cortical O
cell O
involution O
and O
hemorrhage O
occurring O
during O
the O
neonatal O
period O
, O
would O
seem O
to O
have O
crucial O
relevance O
to O
the O
remodeling O
of O
the O
adrenal O
vasculature O
. O

Furthermore O
, O
co O
- O
expression O
of O
both O
p46 I-GENE
and O
p54 I-GENE
subunits I-GENE
markedly O
altered O
the O
subcellular O
distribution O
of O
p46 I-GENE
; O
co O
- O
expressed O
p46 I-GENE
was O
transported O
into O
the O
nucleus O
as O
efficiently O
as O
p54 I-GENE
. O

The O
results O
suggest O
that O
, O
although O
both O
the O
N O
- O
and O
C O
- O
terminal O
regions O
of O
talin I-GENE
bind O
actin I-GENE
, O
the O
properties O
of O
these O
two O
regions O
of O
the O
protein O
are O
distinct O
. O

Merr O
.) O
embryo O
library O
. O

The O
accumulation O
of O
both O
LHA4 I-GENE
and O
LHA2 I-GENE
mRNAs I-GENE
is O
induced O
by O
the O
addition O
of O
exogenous O
sugars O
and O
this O
induction O
appears O
to O
be O
dependent O
on O
sugar O
uptake O
and O
metabolism O
, O
because O
mannitol O
and O
3 O
- O
O O
- O
methylglucose O
do O
not O
stimulate O
mRNA O
accumulation O
. O

Using O
the O
yeast O
one O
- O
hybrid O
screen O
with O
integrated O
NRE O
and O
flanking O
DNA O
as O
bait O
, O
the O
predominant O
clone O
obtained O
was O
bovine I-GENE
Nrl I-GENE
. O

As O
the O
rate O
of O
protein O
synthesis O
decreases O
during O
late O
embryogenesis O
, O
levels O
of O
SEC I-GENE
- I-GENE
1 I-GENE
and O
its O
cognate O
mRNA O
decline O
precipitously O
. O

These O
findings O
suggest O
that O
fodrin I-GENE
proteolysis O
in O
vivo O
may O
reflect O
the O
activity O
of O
multiple O
ICE I-GENE
/ O
Ced I-GENE
- I-GENE
3 I-GENE
proteases O
whose O
partial O
sensitivity O
to O
DEVD O
- O
CHO O
reflects O
a O
limited O
contribution O
from O
CPP32 I-GENE
, O
or O
an O
ICE I-GENE
/ O
Ced I-GENE
- I-GENE
3 I-GENE
protease O
less O
sensitive O
than O
CPP32 I-GENE
to O
DEVD O
- O
CHO O
inhibition O
. O

In O
3Y1 O
and O
3Y1 O
v I-GENE
- I-GENE
crk I-GENE
- O
transformed O
fibroblasts O
, O
almost O
all O
of O
the O
total O
PTP1B I-GENE
and O
about O
40 O
% O
of O
total O
p130 I-GENE
( O
Cas I-GENE
) O
co O
- O
sediment O
with O
membranes O
composed O
primarily O
of O
endoplasmic O
reticulum O
. O

Replacing O
residues O
405 O
- O
419 O
on O
delta419 O
with O
the O
conserved O
AF O
- O
2 O
domain O
from O
the O
vitamin I-GENE
D3 I-GENE
receptor I-GENE
or O
the O
estrogen I-GENE
receptor I-GENE
results O
in O
a O
receptor O
with O
wild O
- O
type O
or O
low O
transcriptional O
activity O
, O
respectively O
. O

Recurrent O
G O
- O
to O
- O
A O
substitution O
in O
a O
single O
codon O
of O
SREBP I-GENE
cleavage I-GENE
- I-GENE
activating I-GENE
protein I-GENE
causes O
sterol O
resistance O
in O
three O
mutant O
Chinese O
hamster O
ovary O
cell O
lines O
. O

The O
Escherichia I-GENE
coli I-GENE
tet I-GENE
- I-GENE
repressor I-GENE
( O
TetR I-GENE
) O
operator O
system O
was O
used O
to O
develop O
a O
variation O
of O
the O
yeast O
two O
- O
hybrid O
assay O
in O
which O
disruptions O
of O
protein O
- O
protein O
interactions O
can O
be O
identified O
by O
a O
positive O
selection O
. O

Recent O
studies O
have O
suggested O
that O
SHP I-GENE
- I-GENE
1 I-GENE
regulates O
the O
function O
of O
Jak I-GENE
family O
tyrosine I-GENE
kinases I-GENE
, O
as O
shown O
by O
its O
constitutive O
association O
with O
the O
Tyk2 I-GENE
kinase I-GENE
and O
the O
hyperphosphorylation O
of O
Jak I-GENE
kinases I-GENE
in O
the O
motheaten O
cells O
that O
lack O
functional O
SHP I-GENE
- I-GENE
1 I-GENE
. O

Administration O
of O
a O
second O
dose O
of O
vaccine O
during O
the O
outbreak O
was O
not O
protective O
. O

But O
, O
as O
Theriault O
explains O
, O
improvements O
in O
assessing O
exposure O
have O
not O
yet O
translated O
into O
clear O
and O
consistent O
findings O
. O

Biol O
. O

Structural O
basis O
for O
activation O
of O
human I-GENE
lymphocyte I-GENE
kinase I-GENE
Lck I-GENE
upon O
tyrosine O
phosphorylation O
. O

Evolutive O
morphology O
of O
the O
olfactory O
bulb O
in O
man O
and O
certain O
non O
- O
human O
mammals O

From O
these O
results O
, O
we O
concluded O
that O
this O
ORF O
is O
the O
FRDS I-GENE
gene I-GENE
. O

FK506 O
is O
10 O
- O
to O
100 O
- O
fold O
more O
potent O
than O
cyclosporin O
A O
in O
preventing O
organ O
rejection O
and O
in O
toxicity O
. O

These O
results O
suggest O
that O
Rho1p I-GENE
regulates O
cytoskeletal O
reorganization O
at O
least O
through O
Bni1p I-GENE
and O
Pkc1p I-GENE
. O

The O
ERH I-GENE
expression O
profile O
is O
similar O
, O
to O
that O
of O
An3 I-GENE
, O
which O
localizes O
to O
the O
animal O
hemisphere O
of O
oocytes O
and O
is O
abundantly O
expressed O
in O
the O
embryo O
. O

Waves O
N1 O
, O
P3 O
and O
CNV O
were O
recorded O
during O
a O
CNV O
paradigm O
in O
a O
simple O
reaction O
time O
task O
with O
a O
constant O
interstimulus O
interval O
( O
ISI O
) O
of O
1 O
sec O
. O

Therefore O
, O
both O
the O
Chilean O
and O
the O
Japanese O
samples O
collected O
in O
high O
- O
risk O
areas O
showed O
higher O
mutagenic O
rates O
than O
the O
Japanese O
ones O
in O
a O
low O
- O
risk O
area O
, O
with O
a O
statistical O
significance O
( O
p O
< O
0 O
. O
001 O
), O
chi O
- O
square O
test O
). O

Regulation O
of O
ASN1 I-GENE
and O
ASN2 I-GENE
expression O
was O
studied O
using O
lacZ I-GENE
fusions I-GENE
and O
both O
genes O
were O
found O
to O
be O
several O
times O
less O
expressed O
in O
the O
absence O
of O
the O
transcription O
activator O
Gcn4p I-GENE
. O

Several O
particular O
features O
of O
this O
polypeptide O
fragment O
from O
the O
hamster I-GENE
lysyl I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
suggest O
that O
it O
is O
implicated O
in O
the O
assembly O
of O
that O
enzyme O
within O
the O
multisynthetase O
complex O
. O

He O
is O
well O
, O
five O
years O
after O
relapse O
. O

Comparison O
of O
the O
proportion O
of O
nonsynonymous O
( O
pN O
) O
and O
synonymous O
( O
pS O
) O
substitutions O
occurring O
per O
site O
within O
tamarin I-GENE
variable I-GENE
region I-GENE
genes I-GENE
demonstrated O
a O
reduction O
in O
pN O
in O
the O
framework O
regions O
compared O
with O
pN O
in O
the O
presumed O
MHC I-GENE
contact I-GENE
regions I-GENE
( O
CDR1 I-GENE
and O
CDR2 I-GENE
). O

The O
effects O
of O
oral O
vanadyl O
sulfate O
( O
VOSO4 O
) O
( O
0 O
. O
5 O
mg O
/ O
kg O
/ O
day O
) O
on O
anthropometry O
, O
body O
composition O
, O
and O
performance O
were O
investigated O
in O
a O
12 O
- O
week O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
involving O
weight O
- O
training O
volunteers O
. O

Later O
in O
development O
, O
Tbx6 I-GENE
expression O
is O
restricted O
to O
presomitic O
, O
paraxial O
mesoderm O
and O
to O
the O
tail O
bud O
, O
which O
replaces O
the O
streak O
as O
the O
source O
of O
mesoderm O
. O

Disruption O
of O
re O
- O
replication O
control O
by O
overexpression O
of O
human I-GENE
ORC1 I-GENE
in O
fission O
yeast O
. O

Our O
results O
demonstrate O
that O
the O
promoter O
and O
enhancer O
regions O
identified O
here O
are O
essential O
for O
maintaining O
the O
efficient O
promoter O
activity O
of O
the O
human I-GENE
activin I-GENE
betaA I-GENE
subunit I-GENE
gene I-GENE
. O

Recombinant O
, O
bacterially O
expressed O
PIP5KIalpha I-GENE
possessed O
PIP5K I-GENE
activity O
and O
was O
immunoreactive O
with O
erythroid I-GENE
PIP5KI I-GENE
antibodies I-GENE
. O

Human I-GENE
acid I-GENE
ceramidase I-GENE
(( O
AC O
) O
N O
- O
acylsphingosine O
amidohydrolase O
, O
EC I-GENE
3 I-GENE
. I-GENE
5 I-GENE
. O

The O
0 O
. O
22 O
- O
kb O
NheI I-GENE
/ O
BglII I-GENE
promoter O
exhibited O
PMA O
inducibility O
in O
myeloid O
cells O
and O
contained O
a O
PMA O
- O
responsive O
element O
recognized O
by O
Sp1 I-GENE
and O
EGR I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
. O

Northern O
( O
RNA O
) O
blot O
analyses O
indicated O
that O
the O
cdh I-GENE
genes I-GENE
encoding O
the O
five O
subunits O
and O
an O
open O
reading O
frame O
( O
ORF1 O
) O
with O
unknown O
function O
are O
cotranscribed O
during O
growth O
on O
acetate O
. O

Two O
classes O
of O
mutations O
were O
obtained O
: O
( O
i O
) O
those O
that O
altered O
the O
coding O
region O
of O
HOL1 I-GENE
, O
conferring O
the O
ability O
to O
take O
up O
histidinol O
; O
and O
( O
ii O
) O
cis O
- O
acting O
mutations O
( O
selected O
in O
a O
mutant O
HOL1 I-GENE
- I-GENE
1 I-GENE
background O
) O
that O
increased O
expression O
of O
the O
Hol1 I-GENE
protein I-GENE
. O

Damage O
to O
the O
BBB O
was O
judged O
by O
extravasation O
of O
Evans O
Blue O
( O
EB O
) O
dye O
, O
which O
was O
administered O
either O
2 O
, O
3 O
, O
24 O
or O
48 O
h O
after O
onset O
of O
MCAo O
. O

Lipid O
hydroperoxide O
levels O
in O
plasma O
and O
LDL I-GENE
remained O
unchanged O
throughout O
the O
study O
. O

When O
the O
degree O
of O
exercise O
was O
maximal O
, O
mPAP O
was O
maintained O
, O
SVI O
decreased O
, O
HR O
was O
unchanged O
, O
and O
CO O
and O
VO2 O
decreased O
. O

We O
report O
a O
case O
of O
vasculitis O
( O
cutaneous O
and O
neurologic O
) O
which O
led O
to O
the O
discovery O
of O
a O
selective O
immunodeficit O
towards O
EBV O
, O
similar O
to O
Purtilo O
' O
s O
syndrome O
. O

To O
elucidate O
whether O
potential O
endocrine O
changes O
resulted O
from O
acute O
hypoxaemia O
alone O
, O
the O
underlying O
disease O
, O
or O
unspecific O
influences O
connected O
with O
the O
ICU O
setting O
, O
all O
measurements O
were O
compared O
to O
those O
of O
a O
completely O
healthy O
reference O
group O
( O
REF O
) O
with O
comparable O
acute O
experimental O
hypoxaemia O
. O

There O
were O
no O
significant O
differences O
in O
graft O
survival O
between O
groups O
with O
early O
graft O
function O
( O
EGF O
) O
and O
DGF O
, O
either O
in O
first O
transplantations O
or O
retransplantations O
. O

These O
results O
suggested O
that O
the O
GG O
motifs O
contributed O
to O
the O
cell O
- O
specific O
transcription O
of O
the O
human I-GENE
insulin I-GENE
gene I-GENE
in O
association O
with O
the O
binding O
of O
the O
sequence O
- O
specific O
nuclear O
factor O
. O

Abnormal O
urinary O
coproporphyrin O
levels O
in O
patients O
infected O
by O
hepatitis O
C O
virus O
with O
or O
without O
human O
immunodeficiency O
virus O
. O

The O
determination O
of O
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
antibodies O
by O
one O
of O
several O
laboratory O
tests O
, O
by O
skin O
- O
prick O
tests O
or O
by O
appropriate O
challenge O
procedures O
is O
useful O
either O
to O
identify O
atopic O
individuals O
or O
as O
outcome O
predictors O
in O
wheezy O
children O
. O

Thrombosis O
of O
the O
renal O
vein O
may O
be O
dramatic O
and O
include O
renal O
failure O
. O

Filter O
and O
cytocentrifuge O
preparations O
of O
the O
urine O
were O
studied O
and O
all O
cases O
displayed O
numerous O
scattered O
aggregates O
or O
single O
tumor O
cells O
in O
an O
inflammatory O
background O
. O

327 O
and O
736 O
protocols O
of O
postmortem O
examinations O
from O
Moscow O
hospitals O
N O
31 O
and O
57 O
, O
respectively O
, O
were O
evaluated O
statistically O
. O

The O
promoter O
segment O
was O
inactive O
when O
introduced O
into O
the O
rat O
glioma O
cell O
line O
C6B4 O
, O
the O
rat O
submandibular O
cell O
line O
RSMT O
- O
A5 O
, O
and O
the O
rat O
pancreatic O
beta O
cell O
line O
RIN O
- O
5AH O
, O
all O
of O
which O
do O
not O
express O
the O
endogenous O
alpha2c I-GENE
- I-GENE
AR I-GENE
gene I-GENE
. O

The O
sequencing O
of O
the O
conditional O
lethal O
mutation O
ts O
- O
A13 O
, O
localized O
in O
the O
nrdE I-GENE
cistron I-GENE
, O
and O
the O
lethality O
of O
insertional O
mutations O
targeted O
in O
the O
internal O
region O
of O
nrdE I-GENE
and O
nrdF I-GENE
, O
demonstrated O
the O
essential O
role O
of O
this O
locus O
. O

The O
microdensitometric O
scores O
and O
their O
side O
- O
to O
- O
side O
differences O
in O
patients O
correlated O
negatively O
with O
the O
serum O
25 O
- O
OHD O
concentration O
and O
positively O
with O
the O
degree O
of O
paralysis O
. O

These O
data O
do O
not O
support O
the O
use O
of O
LDD O
to O
reduce O
risk O
of O
progression O
to O
MSOF O
in O
sepsis O
. O

This O
correlated O
with O
reduced O
levels O
of O
secreted O
hepatitis I-GENE
B I-GENE
e I-GENE
antigen I-GENE
and O
increased O
intracellular O
levels O
of O
core I-GENE
and O
Pol I-GENE
proteins I-GENE
and O
replicative O
HBV O
DNA O
intermediates O
. O

In O
contrast O
, O
extracts O
of O
the O
mutant O
virions O
catalyze O
the O
wild O
- O
type O
level O
of O
transcription O
from O
an O
exogenous O
template O
containing O
an O
early O
promoter O
. O

The O
SCMV I-GENE
SNE I-GENE
sites I-GENE
contain O
potential O
overlapping O
core O
recognition O
binding O
motifs O
for O
SRF I-GENE
, O
Rel I-GENE
/ O
NFkappaB I-GENE
, O
ETS I-GENE
, O
and O
YY1 I-GENE
class I-GENE
transcription I-GENE
factors I-GENE
but O
fail O
to O
respond O
to O
either O
serum O
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
. O

Upon O
serum O
withdrawal O
at O
the O
permissive O
temperature O
, O
p53 I-GENE
- O
mediated O
apoptosis O
was O
induced O
in O
50 O
to O
60 O
% O
of O
the O
cells O
. O

To O
circumvent O
this O
problem O
, O
a O
simple O
two O
- O
step O
strategy O
was O
devised O
by O
which O
essential O
cis O
- O
acting O
sites O
like O
the O
a O
sequence O
can O
be O
readily O
deleted O
from O
their O
natural O
loci O
in O
large O
viral O
DNA O
genomes O
. O

On O
the O
basis O
of O
serological O
studies O
, O
the O
highly O
conserved O
A O
domain O
of O
HspA I-GENE
was O
found O
to O
be O
the O
immunodominant O
domain O
. O

In O
Group O
IV O
dogs O
that O
received O
alpha I-GENE
- I-GENE
MSH I-GENE
only O
during O
reperfusion O
, O
BAEPs O
were O
increased O
approximately O
10 O
to O
14 O
% O
more O
than O
in O
Group O
II O
during O
the O
late O
reperfusion O
period O
. O

The O
Fas I-GENE
receptor I-GENE
mediates O
a O
signalling O
cascade O
resulting O
in O
programmed O
cell O
death O
( O
apoptosis O
) O
within O
hours O
of O
receptor O
cross O
- O
linking O
. O

Fas I-GENE
has O
been O
shown O
to O
require O
ICE I-GENE
( O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
- I-GENE
converting I-GENE
enzyme I-GENE
) O
family O
proteases O
to O
induce O
apoptosis O
from O
studies O
utilizing O
the O
cowpox O
ICE I-GENE
inhibitor I-GENE
protein I-GENE
CrmA I-GENE
, O
the O
synthetic O
tetrapeptide O
ICE I-GENE
inhibitor O
YVAD I-GENE
- I-GENE
CMK I-GENE
, O
and O
the O
tripeptide O
pan O
- O
ICE I-GENE
inhibitor O
Z I-GENE
- I-GENE
VAD I-GENE
- I-GENE
FMK I-GENE
. O

The O
imprinted O
expression O
of O
the O
endogenous O
gene O
can O
be O
recapitulated O
in O
mice O
by O
using O
a O
14 O
- O
kb O
transgene O
encompassing O
4 O
kb O
of O
5 O
'- O
flanking O
sequence O
, O
8 O
kb O
of O
3 O
'- O
flanking O
sequence O
, O
which O
includes O
the O
two O
endoderm O
- O
specific O
enhancers O
, O
and O
an O
internally O
deleted O
structural O
gene O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
hGCN5 I-GENE
is O
also O
an O
HAT I-GENE
and O
has O
the O
same O
substrate O
specificity O
as O
yGCN5 I-GENE
. O

The O
effect O
of O
six O
arginine O
mutations O
of O
oxidative O
phosphorylation O
and O
AAC I-GENE
expression O
. O

Complementary O
DNAs O
encompassing O
the O
coat I-GENE
protein I-GENE
coding O
and O
adjacent O
regions O
of O
Agropyron O
mosaic O
virus O
( O
AgMV O
) O
and O
Hordeum O
mosaic O
virus O
( O
HoMV O
) O
were O
cloned O
and O
sequenced O
. O

In O
some O
cases O
, O
factor O
- O
induced O
Rac I-GENE
activation O
results O
in O
Rho I-GENE
activation O
, O
and O
factor O
- O
induced O
Cdc42 I-GENE
activation O
leads O
to O
Rac I-GENE
activation O
, O
as O
determined O
by O
specific O
morphological O
changes O
. O

Several O
cDNAs O
corresponding O
to O
the O
human I-GENE
PWP2 I-GENE
gene I-GENE
were O
identified O
and O
partially O
sequenced O
. O

Isolation O
and O
genomic O
structure O
of O
a O
human O
homolog O
of O
the O
yeast I-GENE
periodic I-GENE
tryptophan I-GENE
protein I-GENE
2 I-GENE
( O
PWP2 I-GENE
) O
gene O
mapping O
to O
21q22 O
. O
3 O
. O

Patterns O
defined O
by O
combinations O
of O
normal O
and O
abnormal O
laboratory O
results O
had O
decreased O
the O
likelihood O
of O
PEM O
from O
an O
all O
- O
2 O
to O
all O
- O
0 O
pattern O
. O

To O
examine O
whether O
thiamine O
( O
vitamin O
B1 O
) O
deficiency O
is O
associated O
with O
recurrent O
aphthous O
stomatitis O
, O
we O
studied O
vitamin O
B1 O
levels O
in O
70 O
patients O
with O
recurrent O
aphthous O
stomatitis O
and O
in O
50 O
members O
of O
a O
control O
group O
. O

Liver O
injuries O

By O
screening O
a O
cDNA O
library O
with O
a O
probe O
derived O
from O
sequences O
downstream O
of O
the O
p53p2 I-GENE
start O
site O
, O
we O
have O
cloned O
and O
characterized O
a O
cDNA O
that O
represents O
a O
mRNA O
that O
appears O
to O
have O
been O
initiated O
from O
the O
p53p2 I-GENE
promoter I-GENE
. O

However O
, O
we O
did O
not O
observe O
a O
correlation O
between O
serum O
and O
seminal I-GENE
plasma I-GENE
PSA I-GENE
levels O
. O

The O
implications O
for O
estimates O
of O
cortical O
magnification O
and O
possible O
differences O
in O
the O
specializations O
of O
foveal O
and O
peripheral O
vision O
are O
discussed O
. O

G I-GENE
- I-GENE
CSF I-GENE
activates O
multiple O
signaling O
molecules O
, O
including O
the O
JAK1 I-GENE
and O
JAK2 I-GENE
kinases I-GENE
and O
the O
STAT I-GENE
transcription O
factors O
. O

Mutants O
lacking O
any O
tyrosine O
residues O
in O
the O
cytoplasmic O
domain O
maintain O
their O
ability O
to O
activate O
STAT5 I-GENE
and O
STAT1 I-GENE
but O
cannot O
activate O
STAT3 I-GENE
, O
implying O
that O
STAT5 I-GENE
and O
STAT1 I-GENE
activation O
does O
not O
require O
receptor O
tyrosine O
phosphorylation O
. O

The O
RI I-GENE
alpha I-GENE
gene I-GENE
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
introns O
, O
giving O
the O
gene O
a O
total O
length O
of O
at O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
RI I-GENE
alpha I-GENE
pseudogene I-GENE
with O
a O
5 O
'- O
noncoding O
region O
different O
from O
the O
previously O
reported O
RI I-GENE
alpha I-GENE
complementary I-GENE
RNA I-GENE
indicated O
that O
the O
RI I-GENE
alpha I-GENE
gene I-GENE
may O
have O
multiple O
leader O
exons O
giving O
rise O
to O
alternately O
spliced O
messenger O
RNAs O
( O
mRNAs O
). O

This O
establishes O
Rad3 I-GENE
/ O
Mec1 I-GENE
as O
the O
only O
conserved O
protein O
which O
is O
required O
for O
all O
the O
DNA O
structure O
checkpoints O
in O
both O
yeast O
model O
systems O
. O

In O
addition O
, O
double O
mutants O
with O
either O
dim1 I-GENE
- I-GENE
delta I-GENE
or O
dim2 I-GENE
- I-GENE
1 I-GENE
and O
the O
endocytosis O
mutants I-GENE
end4 I-GENE
- I-GENE
1 I-GENE
or O
act1 I-GENE
- I-GENE
1 I-GENE
displayed O
synthetic O
growth O
defects O
, O
indicating O
that O
the O
DIM I-GENE
gene I-GENE
products I-GENE
function O
in O
a O
common O
or O
parallel O
endocytic O
pathway O
. O

The O
identification O
of O
the O
hepatitis O
C O
virus O
as O
the O
major O
cause O
of O
liver O
disease O
both O
in O
dialysis O
patients O
and O
in O
transplant O
patients O
has O
focused O
attention O
on O
the O
epidemiology O
and O
the O
impact O
of O
continuing O
infection O
in O
these O
patient O
groups O
. O

Stable O
transfection O
of O
the O
BL O
cell O
line O
Raji O
with O
constructs O
containing O
core O
promoter O
mutations O
confirmed O
that O
the O
proximal O
Sp1 I-GENE
site I-GENE
and O
the O
TATA O
box O
are O
essential O
for O
the O
activation O
of O
promoter O
P1 O
by O
the O
Ig I-GENE
kappa I-GENE
enhancers I-GENE
. O

Such O
multisensory O
interactions O
can O
be O
significant O
for O
behavior O
. O

The O
P13 O
and O
N22 O
of O
ppSEPs O
had O
phase O
reversal O
relationship O
with O
the O
P2 O
and O
N2 O
recorded O
from O
the O
PES O
, O
respectively O
. O

The O
cDNA O
of O
cpm7 I-GENE
encodes O
a O
closely O
related O
protein O
of O
36 O
. O
8 O
kDa O
. O

Finally O
, O
the O
C O
- O
terminal O
region O
of O
ENBP1 I-GENE
shows O
strong O
homology O
to O
a O
protein O
from O
rat O
that O
is O
specifically O
expressed O
in O
testis O
tissue O
. O

The O
conservation O
of O
both O
the O
G O
- O
box O
and O
H O
- O
box O
in O
different O
CHS I-GENE
promoters I-GENE
emphasizes O
their O
importance O
as O
regulatory O
motifs O
. O

Mortality O
on O
the O
last O
ranch O
was O
particularly O
severe O
among O
certain O
segregated O
groups O
of O
turkeys O
that O
included O
toms O
, O
heavier O
birds O
, O
and O
birds O
undergoing O
a O
stressful O
event O
such O
as O
artificial O
insemination O
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
85 O
- O
90 O
kDa O
protein O
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
85 O
- O
90 O
kDa O
protein O
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

Just O
before O
inserting O
on O
the O
anterior O
margin O
and O
apex O
of O
the O
iliac O
crest O
it O
widens O
, O
assuming O
the O
aspect O
of O
a O
small O
cone O
. O

The O
first O
identification O
of O
the O
active O
37LRP I-GENE
/ O
p40 I-GENE
gene O
presented O
in O
this O
study O
is O
a O
critical O
step O
toward O
the O
isolation O
of O
the O
corresponding O
human O
gene O
and O
the O
understanding O
of O
the O
molecular O
mechanisms O
involved O
in O
the O
up O
- O
regulation O
of O
its O
expression O
during O
tumor O
invasion O
and O
metastasis O
. O

The O
promoter O
region O
( O
P1 O
) O
corresponding O
to O
the O
main O
group O
of O
transcription O
initiation O
sites O
is O
devoid O
of O
TATA O
and O
CAAT O
boxes O
but O
has O
putative O
binding O
sites O
for O
the O
transcription I-GENE
factor I-GENE
SP1 I-GENE
and O
is O
embedded O
in O
a O
large O
G O
+ O
C O
- O
rich O
domain O
of O
a O
CpG O
island O
, O
features O
shared O
by O
the O
promoters O
of O
constitutively O
expressed O
housekeeping O
genes O
. O

The O
STAT I-GENE
- I-GENE
1 I-GENE
signaling O
pathway O
provides O
at O
least O
one O
mechanism O
for O
activation O
of O
the O
CAEV I-GENE
LTR I-GENE
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
monocytes O
. O

Reperfusion O
caused O
a O
transient O
reduction O
in O
lactate O
production O
and O
a O
significant O
increase O
in O
LDH I-GENE
release O
. O

To O
evaluate O
the O
hepatic O
regenerative O
response O
in O
patients O
with O
alcoholic O
liver O
disease O
, O
sera O
from O
263 O
patients O
with O
severe O
alcoholic O
hepatitis O
and O
/ O
or O
cirrhosis O
were O
analyzed O
for O
hepatocyte I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
and O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
( O
AFP I-GENE
). O

Children O
born O
from O
chronic O
alcoholic O
mothers O
have O
shown O
behavioral O
teratogenic O
effects O
more O
frequently O
than O
morphological O
malformations O
. O

INTERVENTION O
( O
S O
): O
Twenty O
- O
six O
hemostasis O
parameters O
evaluated O
repeatedly O
in O
patients O
undergoing O
IVF O
- O
ET O
. O

Here O
we O
report O
that O
expression O
of O
the O
I I-GENE
- I-GENE
POU I-GENE
/ O
tI I-GENE
- I-GENE
POU I-GENE
message O
is O
maximal O
late O
in O
the O
embryonic O
phase O
of O
Drosophila O
development O
, O
and O
I I-GENE
- I-GENE
POU I-GENE
is O
the O
preferred O
splice O
variant O
. O

Unlike O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
, O
the O
delta I-GENE
proAE I-GENE
mutant I-GENE
cDNA I-GENE
can O
be O
stably O
expressed O
in O
tumor O
derived O
cell O
lines O
with O
few O
immediate O
detrimental O
effects O
. O

The O
patient O
' O
s O
role O
, O
organized O
by O
the O
prerequisites O
of O
expressive O
freedom O
, O
is O
counter O
posed O
with O
the O
psychoanalyst O
' O
s O
, O
which O
is O
structured O
to O
empower O
listening O
and O
understanding O
. O

The O
most O
common O
risk O
factor O
reported O
for O
both O
recent O
and O
all O
other O
hepatitis O
C O
cases O
was O
a O
history O
of O
injecting O
drug O
use O
, O
although O
the O
proportion O
of O
cases O
with O
that O
history O
was O
different O
in O
NT O
from O
ACT O
and O
Queensland O
. O

Silencing O
can O
be O
restored O
by O
creation O
of O
a O
telomere O
at O
13 O
kb O
from O
the O
reporter O
construct O
, O
or O
by O
insertion O
of O
340 O
bp O
of O
yeast O
telomeric O
repeat O
sequence O
at O
this O
site O
without O
chromosomal O
truncation O
. O

In O
contrast O
with O
previous O
two O
- O
pool O
models O
, O
provisions O
were O
made O
for O
folate O
turnover O
by O
urinary O
folate O
excretion O
( O
as O
measured O
here O
) O
and O
by O
fecal O
excretion O
and O
catabolic O
processes O
. O

When O
voltage O
- O
operated O
Ca2 O
+ O
channels O
( O
VOC O
) O
were O
blocked O
by O
nifedipine O
, O
midazolam O
, O
in O
concentrations O
more O
than O
1 O
microM O
, O
attenuated O
both O
phasic O
and O
tonic O
responses O
. O

Several O
artifacts O
occurred O
that O
interfered O
with O
visualization O
of O
the O
diaphragm O
. O

Although O
p48 I-GENE
gene I-GENE
induction O
is O
dependent O
on O
STAT1 I-GENE
and O
JAK1 I-GENE
, O
activated O
STAT1 I-GENE
does O
not O
bind O
to O
GATE I-GENE
. O

The O
syndrome O
of O
resistance O
to O
thyroid O
hormone O
is O
characterized O
by O
elevated O
serum O
free O
thyroid O
hormones O
, O
failure O
to O
suppress O
pituitary I-GENE
thyrotropin I-GENE
secretion O
, O
and O
variable O
peripheral O
refractoriness O
to O
hormone O
action O
. O

Finally O
, O
nonphotosynthetic O
mutants O
, O
including O
the O
tscA I-GENE
- I-GENE
lacking I-GENE
photosystem I-GENE
I I-GENE
mutant I-GENE
, O
H13 O
, O
did O
not O
show O
evidence O
of O
light O
- O
stimulated O
RNA O
processing O
. O

The O
progression O
of O
acute O
bronchitis O
is O
associated O
with O
elevated O
blood O
concentrations O
of O
acute O
- O
phase O
proteins O
, O
KKS I-GENE
activation O
in O
the O
blood O
and O
high O
serotonin O
and O
lactic O
acid O
content O
in O
the O
humor O
condensated O
from O
the O
exhaled O
air O
. O

Because O
of O
the O
potential O
implications O
of O
these O
findings O
in O
human O
physiology O
, O
we O
cloned O
the O
hPACAP I-GENE
- I-GENE
R I-GENE
gene I-GENE
. O

Differential O
signaling O
and O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
activation O
by O
four O
splice O
variants O
of O
the O
human I-GENE
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
receptor I-GENE
( O
hPACAP I-GENE
- I-GENE
R I-GENE
). O

During O
skeletal O
muscle O
development O
, O
different O
types O
of O
muscle O
fibers O
are O
generated O
, O
which O
express O
different O
combinations O
of O
muscle O
- O
specific O
gene O
products O
. O

We O
discuss O
these O
results O
with O
respect O
to O
the O
transcriptional O
induction O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
gene I-GENE
in O
respiratory O
epithelium O
during O
embryogenesis O
. O

BACKGROUND O
: O
Mitosis O
is O
regulated O
by O
MPF I-GENE
( O
maturation I-GENE
promoting I-GENE
factor I-GENE
), O
the O
active O
form O
of O
Cdc2 I-GENE
/ I-GENE
28 I-GENE
- O
cyclin I-GENE
B I-GENE
complexes O
. O

Ectopic O
expression O
of O
Apo I-GENE
- I-GENE
3 I-GENE
in O
HEK293 O
or O
HeLa O
cells O
induced O
marked O
apoptosis O
. O

An O
N O
- O
terminal O
arm O
from O
each O
subunit O
wraps O
around O
the O
dinucleotide O
- O
binding O
domain O
of O
an O
adjacent O
subunit O
, O
covering O
the O
adenine O
ring O
of O
NADP O
. O

Similarity O
is O
most O
striking O
in O
the O
zinc O
knuckle O
region O
, O
a O
region O
characteristic O
of O
gag I-GENE
genes I-GENE
of O
most O
replication O
- O
competent O
retroelements O
. O

D O
. O
melanogaster O
HeT I-GENE
- I-GENE
A I-GENE
coding O
sequences O
have O
a O
polymorphic O
region O
with O
insertions O
/ O
deletions O
of O
1 O
- O
31 O
codons O
and O
many O
nucleotide O
changes O
. O

Eukaryotic I-GENE
initiation I-GENE
factor I-GENE
3 I-GENE
( O
eIF3 I-GENE
) O
is O
a O
large O
multisubunit O
complex O
that O
stabilizes O
the O
ternary O
complex O
, O
eIF2 I-GENE
x O
GTP O
x O
tRNA I-GENE
( I-GENE
Met I-GENE
) I-GENE
i I-GENE
and O
promotes O
mRNA O
binding O
to O
the O
40 I-GENE
S I-GENE
ribosomal I-GENE
subunit I-GENE
. O
eIF3 I-GENE
also O
functions O
as O
a O
ribosome O
subunit O
anti O
- O
association O
factor O
. O

Our O
data O
, O
combined O
with O
those O
of O
Hershey O
and O
co O
- O
workers O
, O
suggest O
that O
mammalian I-GENE
eIF3 I-GENE
is O
composed O
of O
at O
least O
10 O
subunits O
: O
p170 I-GENE
, O
p116 I-GENE
( O
hPrt1 I-GENE
), O
p110 I-GENE
, O
p66 I-GENE
, O
p48 I-GENE
, O
p47 I-GENE
, O
p44 I-GENE
, O
p40 I-GENE
, O
p36 I-GENE
, O
and O
p35 I-GENE
. O

Identification O
of O
a O
cis O
- O
acting O
element O
in O
the O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
gene I-GENE
promoter I-GENE
responsive O
to O
activation O
by O
retroviral O
sequences O
. O

The O
results O
demonstrate O
that O
( O
i O
) O
no O
intact O
capsids O
were O
assembled O
when O
the O
full O
- O
length O
or O
a O
truncated O
( O
missing O
the O
C O
- O
terminal O
65 O
amino O
acids O
) O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
was O
tested O
; O
( O
ii O
) O
when O
the O
C O
- O
terminal O
65 O
amino O
acids O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
were O
replaced O
with O
the O
C O
- O
terminal O
25 O
amino O
acids O
of O
the O
UL26 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
, O
intact O
capsids O
were O
made O
and O
direct O
interaction O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
with O
VP5 I-GENE
was O
detected O
; O
( O
iii O
) O
assembly O
of O
intact O
capsids O
was O
demonstrated O
when O
the O
sequence O
of O
the O
last O
12 O
amino O
acids O
of O
the O
UL80 I-GENE
. I-GENE
5 I-GENE
protein I-GENE
was O
changed O
from O
RRIFVA O
ALNKLE O
to O
RRIFVAAMMKLE O
; O
( O
iv O
) O
self O
- O
interaction O
of O
the O
scaffold O
proteins O
is O
mediated O
by O
sequences O
N O
terminal O
to O
the O
maturation O
cleavage O
site O
; O
and O
( O
v O
) O
the O
UL26 I-GENE
. I-GENE
5 I-GENE
and O
UL80 I-GENE
. I-GENE
5 I-GENE
proteins I-GENE
will O
not O
coassemble O
into O
scaffold O
structures O
. O

Fourth O
, O
the O
3 O
'- O
region O
splice O
junctions O
of O
the O
MSRs I-GENE
during O
latent O
and O
productive O
infection O
were O
determined O
by O
sequencing O
RNA O
- O
PCR O
products O
generated O
with O
primers O
that O
flank O
the O
3 O
' O
splice O
region O
. O

( O
ii O
) O
ICP27 I-GENE
binds O
preferentially O
to O
less O
modified O
forms O
of O
ICP4 I-GENE
, O
a O
protein O
that O
is O
extensively O
modified O
posttranslationally O
. O

Lack O
of O
sufficient O
data O
on O
vibration O
measurements O
and O
employment O
durations O
add O
to O
the O
uncertainty O
, O
as O
do O
variations O
in O
tool O
conditions O
( O
grinder O
wheels O
, O
etc O
) O
and O
inherent O
difficulties O
in O
measurement O
. O

C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
V I-GENE
> O
A O
selectively O
binds O
only O
the O
subset O
of O
C I-GENE
/ I-GENE
EBP I-GENE
sites I-GENE
that O
are O
also O
DBP I-GENE
sites I-GENE
, O
both O
as O
oligonucleotides O
and O
within O
the O
natural O
contexts O
of O
the O
albumin I-GENE
and O
cholesterol I-GENE
hydroxylase I-GENE
promoters I-GENE
. O

Specific O
IgG I-GENE
, O
specific O
IgE I-GENE
and O
total O
IgE I-GENE
immunoglobulins I-GENE
against O
Toxocara I-GENE
canis I-GENE
excretory I-GENE
/ I-GENE
secretory I-GENE
antigens I-GENE
( O
TES I-GENE
) O
were O
detected O
by O
using O
ELISA O
technique O
. O

SUMMARY O
BACKGROUND O
DATA O
: O
Melanoma O
care O
has O
not O
changed O
significantly O
in O
the O
last O
20 O
years O
, O
and O
the O
controversy O
of O
elective O
lymph O
node O
dissections O
in O
this O
disease O
continues O
to O
be O
discussed O
. O

The O
differences O
among O
subgenera O
of O
the O
genus O
Dermacentor O
are O
more O
significant O
. O

Mutating O
the O
E O
- O
box O
in O
the O
context O
of O
the O
3 O
'- O
flanking O
region O
confirmed O
that O
it O
contributes O
to O
the O
enhancement O
of O
transcriptional O
activity O
of O
the O
alpha1 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
gene I-GENE
promoter I-GENE
. O

Expression O
of O
neuronal O
traits O
in O
pancreatic O
beta O
cells O
. O

We O
propose O
that O
Mnt I-GENE
: O
Max I-GENE
: O
Sin3 I-GENE
complexes O
normally O
function O
to O
restrict O
Myc I-GENE
: O
Max I-GENE
activities O
associated O
with O
cell O
proliferation O
. O

Its O
transcription O
product O
, O
a O
1 O
. O
3 O
kb O
mRNA O
, O
is O
polyadenylated O
at O
a O
site O
containing O
consensus O
eukaryotic O
polyadenylation O
signals O
and O
mapping O
87 O
bp O
downstream O
of O
the O
translation O
termination O
codon O
for O
CG30 I-GENE
. O

Phenotypic O
changes O
induced O
by O
wild I-GENE
type I-GENE
and I-GENE
variant I-GENE
c I-GENE
- I-GENE
src I-GENE
genes I-GENE
carrying O
C O
- O
terminal O
sequence O
alterations O
. O

The O
resurgence O
of O
drug O
- O
resistant O
malaria O
makes O
urgent O
the O
evaluation O
of O
new O
antimalarial O
agents O
. O

In O
the O
p51 I-GENE
subunit I-GENE
, O
the O
Cys181 O
side O
- O
chain O
is O
oriented O
in O
a O
similar O
direction O
to O
the O
Tyr181 O
side O
- O
chain O
in O
the O
wild O
- O
type O
complex O
. O

The O
relatively O
high O
level O
transcription O
from O
this O
gene O
shows O
that O
the O
polymorphic O
chromosome O
ends O
of O
P O
. O
falciparum O
, O
which O
have O
been O
proposed O
to O
be O
transcriptionally O
silent O
, O
can O
be O
active O
expression O
sites O
for O
var I-GENE
genes I-GENE
. O

NUP145 I-GENE
was O
previously O
identified O
by O
using O
a O
genetic O
synthetic O
lethal O
screen O
( O
E O
. O

Prevalence O
of O
sleep O
- O
disordered O
breathing O
( O
SDB O
) O
is O
reported O
to O
increase O
in O
menopausal O
women O
. O

In O
all O
cases O
the O
antigenemia O
was O
transient O
and O
cleared O
by O
28th O
day O
post O
- O
vaccination O
. O

A O
total O
of O
1459 O
men O
aged O
48 O
to O
84 O
years O
, O
who O
were O
diagnosed O
for O
the O
first O
time O
by O
physicians O
as O
having O
BPH O
in O
1994 O
and O
who O
had O
not O
received O
treatment O
, O
participated O
in O
the O
study O
. O

BCL I-GENE
- I-GENE
2 I-GENE
, O
an O
inhibitor O
of O
apoptosis O
in O
a O
wide O
variety O
of O
cell O
types O
, O
has O
been O
reported O
to O
prevent O
oxidative O
stress O
- O
induced O
cell O
death O
. O

In O
vitro O
translation O
of O
the O
mTRF1 I-GENE
cDNA I-GENE
resulted O
in O
a O
56 O
kDa O
protein O
that O
binds O
to O
TTAGGG O
repeat O
arrays O
. O
mTRF1 I-GENE
displayed O
the O
same O
sequence O
specificity O
as O
hTRF1 I-GENE
, O
preferring O
arrays O
of O
TTAGGG O
repeats O
as O
a O
binding O
substrate O
over O
TTAGGC O
and O
TTGGGG O
repeats O
. O

The O
ubiquitously O
expressed O
E12 I-GENE
bHLH I-GENE
protein I-GENE
dimerizes O
with O
numerous O
cell O
- O
specific O
bHLH I-GENE
factors I-GENE
. O

The O
E O
- O
box O
sequence O
in O
the O
SE2 I-GENE
fragment I-GENE
of O
the O
transferrin I-GENE
promoter I-GENE
was O
CATCTG O
and O
was O
similar O
in O
gel O
shifts O
to O
the O
consensus O
E O
- O
box O
elements O
( O
CANNTG O
) O
previously O
characterized O
. O

A O
5 O
. O
3 O
- O
kb O
DNA O
fragment O
, O
which O
included O
the O
entire O
structural O
porin I-GENE
gene I-GENE
( O
named O
porCa I-GENE
) O
and O
its O
flanking O
regions O
, O
was O
identified O
. O

Full I-GENE
- I-GENE
length I-GENE
AT I-GENE
- I-GENE
PHH1 I-GENE
, O
and O
both O
AT I-GENE
- I-GENE
PHH1 I-GENE
and O
AT I-GENE
- I-GENE
PHH1 I-GENE
delta I-GENE
C I-GENE
- I-GENE
513 I-GENE
( O
truncated O
to O
be O
approximately O
the O
size O
of O
microbial I-GENE
photolyase I-GENE
genes I-GENE
) O
cDNAs O
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast O
and O
Escherichia O
coli O
mutants O
hypersensitive O
to O
ultraviolet O
light O
. O

The O
human I-GENE
p100 I-GENE
protein I-GENE
was O
recently O
identified O
as O
a O
coactivator O
of O
the O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
. O

However O
, O
five O
new O
mutation O
sites O
( O
S61 I-GENE
, O
SL1 I-GENE
, O
S29 I-GENE
, O
SL11 I-GENE
, O
SL196 I-GENE
and O
SL126 I-GENE
) O
are O
unique O
to O
the O
nrdB I-GENE
intron O
and O
disrupt O
self O
- O
splicing O
. O

This O
report O
presents O
the O
isolation O
and O
characterization O
of O
the O
5 O
'- O
flanking O
region O
( O
1 O
. O
2 O
kb O
) O
and O
exon O
1 O
of O
the O
human I-GENE
RII I-GENE
alpha I-GENE
gene I-GENE
. O

A O
cohort O
of O
Swedish O
children O
was O
monitored O
from O
6 O
months O
to O
11 O
years O
of O
age O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
reproducibility O
of O
a O
number O
of O
simplified O
clearance O
methods O
using O
chromium O
- O
51 O
ethylenediamine O
tetraacetic O
acid O
( O
51Cr O
- O
EDTA O
) O
and O
to O
compare O
these O
with O
the O
multiple O
blood O
sample O
technique O
. O

The O
primary O
structure O
of O
a O
2671 O
bp O
DNA O
fragment O
between O
the O
pla I-GENE
gene I-GENE
( O
encoding O
plasminogen I-GENE
activator I-GENE
) O
and O
the O
origin O
of O
replication O
of O
the O
wild O
- O
type O
Yersinia O
pestis O
plasmid O
pYP358 O
was O
determined O
. O

Serotonin O
concentration O
in O
the O
blood O
of O
patients O
with O
hemorrhagic O
fever O
with O
renal O
syndrome O

MAIN O
OUTCOME O
MEASURES O
: O
Associations O
of O
factor O
analysis O
- O
derived O
syndromes O
with O
risk O
factors O
for O
chemical O
interactions O
that O
inhibit O
butyrylcholinesterase I-GENE
and O
neuropathy O
target O
esterase I-GENE
. O

CONCLUSION O
: O
Some O
Gulf O
War O
veterans O
may O
have O
delayed O
, O
chronic O
neurotoxic O
syndromes O
from O
wartime O
exposure O
to O
combinations O
of O
chemicals O
that O
inhibit O
butyrylcholinesterase I-GENE
and O
neuropathy I-GENE
target I-GENE
esterase I-GENE
. O

Control O
examination O
was O
performed O
at O
the O
end O
of O
each O
period O
. O

No O
correlation O
between O
the O
age O
of O
the O
horses O
and O
the O
antibody O
level O
could O
be O
found O
. O

The O
GHR I-GENE
mRNA I-GENE
: O
GHBP I-GENE
mRNA I-GENE
ratio O
was O
1 O
. O
1 O
+/- O
0 O
. O
12 O
and O
remained O
unchanged O
during O
differentiation O
. O

The O
results O
demonstrate O
( O
i O
) O
that O
the O
selenocysteine O
- O
specific O
UGA O
codon O
is O
readily O
suppressed O
under O
conditions O
where O
the O
homologous I-GENE
SelB I-GENE
protein I-GENE
is O
absent O
and O
( O
ii O
) O
that O
apart O
from O
the O
specificity O
of O
the O
SelB I-GENE
- I-GENE
mRNA I-GENE
interaction O
, O
a O
structural O
compatibility O
of O
the O
quaternary O
complex O
with O
the O
ribosome O
is O
required O
. O

One O
linker O
- O
peptide O
insertion O
in O
the O
RsaA I-GENE
C I-GENE
terminus I-GENE
( I-GENE
amino I-GENE
acid I-GENE
784 I-GENE
) I-GENE
had O
no O
effect O
on O
S O
- O
layer O
biogenesis O
, O
while O
another O
( O
amino O
acid O
907 O
) O
disrupted O
secretion O
of O
the O
protein O
, O
suggesting O
that O
RsaA I-GENE
possesses O
a O
secretion O
signal O
lying O
C O
terminal O
to O
amino O
acid O
784 O
, O
near O
or O
including O
amino O
acid O
907 O
. O

To O
characterize O
the O
gene O
products O
, O
the O
cvaA I-GENE
gene I-GENE
was O
subcloned O
and O
expressed O
under O
the O
control O
of O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
. O

PrpB I-GENE
showed O
homology O
to O
carboxyphosphonoenolpyruvate I-GENE
phosphonomutase I-GENE
of I-GENE
Streptomyces I-GENE
hygroscopicus I-GENE
and O
to O
its O
homolog O
in O
the O
carnation O
Dianthus O
caryophyllus O
; O
PrpC I-GENE
was O
homologous O
to O
both O
archaeal I-GENE
and I-GENE
bacterial I-GENE
citrate I-GENE
synthases I-GENE
; O
PrpD I-GENE
showed O
homology O
to O
yeast O
and O
Bacillus O
subtilis O
proteins O
of O
unknown O
function O
; O
PrpE I-GENE
showed O
homology O
to O
acetyl I-GENE
coenzyme I-GENE
A I-GENE
synthetases I-GENE
. O

MAIN O
OUTCOME O
MEASURES O
: O
Systemic O
and O
pulmonary O
hemodynamics O
, O
arterial O
blood O
gas O
determination O
, O
bronchoalveolar O
lavage O
protein O
and O
neutrophil O
content O
, O
neutrophil O
oxidant O
burst O
, O
lung I-GENE
myeloperoxidase I-GENE
content O
, O
and O
scanning O
electron O
micrographic O
studies O
. O

We O
have O
isolated O
a O
cDNA O
encoding O
human I-GENE
MEKK3 I-GENE
. O

To O
investigate O
the O
mechanisms O
involved O
in O
the O
transcriptional O
control O
of O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
) O
gene O
expression O
, O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
RXRgamma2 I-GENE
isoform I-GENE
was O
characterized O
. O

JNK I-GENE
and O
p38 I-GENE
are O
constitutively O
present O
in O
the O
nucleus O
, O
and O
DNA O
- O
bound O
c I-GENE
- I-GENE
JUN I-GENE
and O
ATF I-GENE
- I-GENE
2 I-GENE
are O
stably O
contacted O
by O
JNK I-GENE
and O
p38 I-GENE
, O
respectively O
. O

The O
effects O
of O
dominant O
interfering O
forms O
of O
the O
JNK I-GENE
/ O
p38 I-GENE
signaling O
pathway O
demonstrate O
that O
activation O
of O
these O
kinases O
is O
critical O
for O
cytokine O
- O
induced O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
expression O
. O

Sp1 I-GENE
binds O
the O
CTC O
repeat O
with O
an O
affinity O
, O
KD O
= O
0 O
. O
37 O
nM O
, O
at O
least O
as O
high O
as O
the O
consensus O
GC O
box O
. O

Identification O
of O
the O
region O
in O
actin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
binds O
to O
the O
cytoplasmic O
domain O
of O
glycoprotein I-GENE
IBalpha I-GENE
. O

Mutant O
enzyme O
forms O
were O
prepared O
to O
eliminate O
the O
initial O
autoprocessing O
site O
and O
thus O
form O
an O
active O
single O
- O
chain O
protein O
for O
structure O
- O
function O
studies O
. O

The O
primer O
is O
generated O
by O
a O
cleavage O
that O
occurs O
between O
bases O
11 O
and O
12 O
of O
the O
Tf1 I-GENE
mRNA I-GENE
. O

Similarly O
, O
we O
examined O
whether O
the O
ELK1 I-GENE
, O
SAP1a I-GENE
, O
FLI1 I-GENE
, O
EWS I-GENE
- O
FLI1 I-GENE
, O
ETS1 I-GENE
, O
ETS2 I-GENE
, O
PEA3 I-GENE
and O
PU I-GENE
. I-GENE
1 I-GENE
proteins I-GENE
can O
form O
ternary O
complexes O
with O
SRF I-GENE
on O
the O
Egr1 I-GENE
SREI I-GENE
and I-GENE
II I-GENE
. O

This O
R O
- O
domain O
may O
modulate O
the O
interaction O
with O
SRF I-GENE
, O
providing O
a O
mechanism O
that O
would O
be O
unique O
to O
FLI1 I-GENE
and O
EWS I-GENE
- O
FLI1 I-GENE
, O
thus O
implicating O
a O
novel O
function O
for O
these O
ETS I-GENE
transcription I-GENE
factors I-GENE
in O
the O
regulation O
of O
the O
Egr1 I-GENE
gene I-GENE
. O

The O
total O
number O
of O
specimens O
was O
131 O
with O
78 O
nonsmokers O
and O
53 O
smokers O
. O

The O
murine O
chromosomal O
locations O
of O
the O
five O
NMDA I-GENE
receptor I-GENE
channel I-GENE
subunits I-GENE
, O
the O
epsilon I-GENE
1 I-GENE
( O
Grin2a I-GENE
), O
epsilon I-GENE
2 I-GENE
( O
Grin2b I-GENE
), O
epsilon I-GENE
3 I-GENE
( O
Grin2c I-GENE
), O
epsilon I-GENE
4 I-GENE
( O
Grin2d I-GENE
) O
and O
zeta I-GENE
1 I-GENE
( O
Grinl I-GENE
) O
subunits O
, O
were O
determined O
using O
an O
interspecific O
backcross O
mapping O
panel O
derived O
from O
crosses O
of O
[( O
C57BL O
/ O
6JxM O
. O
spretus O
) O
F1xC57BL O
/ O
6J O
] O
mice O
. O

CDNA O
cloning O
of O
chick I-GENE
brain I-GENE
alpha I-GENE
- I-GENE
amino I-GENE
- I-GENE
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
5 I-GENE
- I-GENE
methyl I-GENE
- I-GENE
4 I-GENE
- I-GENE
isoxazolepropionic I-GENE
acid I-GENE
receptors I-GENE
reveals O
conservation O
of O
structure O
, O
function O
and O
post O
- O
transcriptional O
processes O
with O
mammalian O
receptors O
. O

Remarkably O
, O
both O
TTD O
- O
A O
and O
XP O
- O
D O
defects O
are O
associated O
with O
subunits O
of O
TFIIH I-GENE
, O
a O
basal O
transcription O
factor O
with O
a O
second O
function O
in O
DNA O
repair O
. O

Adjustment O
for O
age O
, O
total O
cholesterol O
, O
HDL I-GENE
cholesterol I-GENE
, O
triglycerides O
, O
current O
smoking O
, O
and O
systolic O
pressure O
slightly O
reduced O
the O
association O
between O
fibrinogen I-GENE
and O
atherosclerosis O
. O

In O
Experiment O
1 O
, O
pups O
that O
had O
received O
an O
injection O
of O
the O
noncompetitive O
N I-GENE
- I-GENE
methyl I-GENE
- I-GENE
D I-GENE
- I-GENE
aspartate I-GENE
receptor I-GENE
antagonist O
MK O
- O
801 O
( O
0 O
. O
1 O
mg O
/ O
kg O
, O
i O
. O
p O
.) O
either O
30 O
min O
before O
or O
immediately O
after O
conditioning O
spent O
less O
time O
over O
the O
conditioned O
odor O
than O
saline O
- O
treated O
controls O
. O

Cholesterol I-GENE
side I-GENE
- I-GENE
chain I-GENE
cleavage I-GENE
cytochrome I-GENE
P450 I-GENE
( O
CYP11A I-GENE
; O
P450scc I-GENE
) O
gene O
expression O
is O
regulated O
by O
gonadotropins I-GENE
via O
cAMP O
in O
the O
ovary O
and O
by O
ACTH I-GENE
via O
cAMP O
in O
adrenal O
cortical O
cells O
. O

One O
possible O
solution O
is O
a O
thin O
radial O
forearm O
free O
flap O
. O

Structural O
analysis O
and O
characterization O
of O
tissue O
and O
hormonal O
responsive O
expression O
of O
the O
avian I-GENE
bone I-GENE
sialoprotein I-GENE
( O
BSP I-GENE
) O
gene O
. O

Serotonin I-GENE
receptors I-GENE
in O
suicide O
victims O
with O
major O
depression O
. O

The O
Y O
- O
type O
structural O
motif O
is O
also O
conserved O
among O
a O
number O
of O
divergent O
BiP I-GENE
mRNAs I-GENE
. O

A O
false O
positive O
marker O
screen O
was O
associated O
with O
the O
occurrence O
of O
hand O
- O
foot O
syndrome O
even O
when O
the O
effect O
of O
regimen O
was O
accounted O
for O
by O
stratification O
( O
p O
= O
. O
01 O
). O

The O
detection O
of O
ORF I-GENE
- I-GENE
1 I-GENE
sequences O
in O
human O
tumors O
, O
while O
not O
proof O
per O
se O
, O
is O
a O
prerequisite O
for O
establishing O
its O
role O
in O
tumor O
development O
. O

Phylogenetic O
analysis O
gave O
evidence O
for O
a O
close O
evolutionary O
relationship O
between O
PhHV O
- O
1 O
and O
members O
of O
the O
Varicellovirus O
genus O
of O
the O
alpha O
- O
Herpesvirinae O
and O
canid O
herpesvirus O
in O
particular O
. O

In O
this O
method O
, O
PLP O
in O
plasma O
can O
be O
determined O
with O
high O
sensitivity O
using O
derivatization O
with O
sodium O
bisulfite O
in O
the O
mobile O
phase O
. O

Both O
HEF1 I-GENE
and O
Cas I-GENE
were O
found O
to O
complex O
with O
the O
related I-GENE
adhesion I-GENE
focal I-GENE
tyrosine I-GENE
kinase I-GENE
( O
RAFTK I-GENE
), O
and O
when O
tyrosine O
phosphorylated O
, O
with O
the O
adapter O
molecule O
CrkL I-GENE
. O

SIM1 I-GENE
and O
SIM2 I-GENE
do O
not O
form O
homodimers O
, O
and O
they O
do O
not O
interact O
with O
AHR I-GENE
. O

Complexes O
of O
qTBP42 I-GENE
with O
each O
complementary O
strand O
of O
telomeric O
DNA O
and O
with O
quadruplex O
forms O
of O
the O
guanine O
- O
rich O
strand O
had O
3 O
. O
7 O
- O
14 O
. O
6 O
nM O
dissociation O
constants O
, O
Kd O
, O
whereas O
complexes O
with O
double O
- O
stranded O
telomeric O
DNA O
had O
up O
to O
100 O
- O
fold O
higher O
Kd O
values O
. O

Moreover O
, O
the O
effect O
exerted O
by O
TIS1 I-GENE
appeared O
to O
be O
selective O
for O
the O
MCK I-GENE
promoter I-GENE
. O

Experimental O
data O
showed O
that O
these O
abnormal O
proteins O
are O
constitutively O
localized O
in O
the O
nucleus O
, O
have O
lost O
the O
transcriptional O
repressor O
functions O
typical O
of O
normal O
NF I-GENE
- I-GENE
kappa I-GENE
B2p52 I-GENE
and O
may O
be O
capable O
of O
transactivation O
activity O
. O

Because O
L I-GENE
- I-GENE
plastin I-GENE
expression O
in O
tissue O
- O
specifically O
regulated O
in O
both O
humans O
and O
rodents O
, O
it O
is O
likely O
that O
similar O
mechanisms O
regulate O
L I-GENE
- I-GENE
plastin I-GENE
gene I-GENE
expression O
in O
human O
and O
rodent O
cells O
and O
that O
they O
could O
be O
identified O
by O
comparing O
the O
function O
and O
nucleotide O
sequences O
of O
the O
human O
and O
murine O
L I-GENE
- I-GENE
plastin I-GENE
gene O
promoters O
. O

What O
' O
s O
new O
in O
gynecologic O
and O
obstetrical O
surgery O
. O

The O
dnaK I-GENE
operon I-GENE
of I-GENE
Bacillus I-GENE
subtilis I-GENE
is O
heptacistronic O
. O

Moreover O
, O
expression O
of O
CBF1 I-GENE
in O
yeast O
was O
found O
to O
activate O
transcription O
of O
reporter O
genes O
containing O
the O
C O
- O
repeat O
/ O
DRE O
as O
an O
upstream O
activator O
sequence O
but O
not O
mutant O
versions O
of O
the O
DNA O
element O
. O

Forty O
- O
one O
ASA O
physical O
status O
I O
or O
II O
adult O
patients O
undergoing O
a O
variety O
of O
1 O
- O
1 O
. O
5 O
h O
surgical O
procedures O
were O
randomly O
allocated O
to O
receive O
CCA O
with O
desflurane O
or O
isoflurane O
with O
ventilation O
being O
either O
spontaneous O
or O
controlled O
. O

OBJECTIVE O
: O
Our O
goal O
was O
to O
determine O
whether O
chlamydia O
- O
infected O
women O
have O
a O
higher O
rate O
of O
febrile O
complications O
after O
postpartum O
tubal O
ligation O
. O

In O
the O
electrophoresis O
mobility O
shift O
assay O
using O
nuclear O
extracts O
of O
the O
myogenic O
cells O
, O
MyoD I-GENE
and O
myogenin I-GENE
bound O
to O
the O
right O
E O
- O
box O
in O
the O
enhancer O
region O
of O
the O
MCK I-GENE
gene I-GENE
even O
in O
the O
presence O
of O
BMP I-GENE
- I-GENE
2 I-GENE
. O

A O
heterologous O
promoter O
construct O
containing O
three O
repeats O
of O
a O
consensus O
Sp1 I-GENE
site I-GENE
, O
cloned O
upstream O
of O
a O
single O
copy O
of O
the O
ZII I-GENE
( O
CREB I-GENE
/ I-GENE
AP1 I-GENE
) O
element O
from O
the O
BZLF1 I-GENE
promoter I-GENE
linked O
to O
the O
beta I-GENE
- I-GENE
globin I-GENE
TATA O
box O
, O
exhibited O
phorbol O
ester O
inducibility O
. O

Subsequent O
experiments O
showed O
that O
motoric O
tasks O
rather O
than O
cognitive O
aspects O
of O
the O
COWA O
task O
were O
critical O
in O
potentiating O
finger O
- O
tapping O
performance O
. O

How O
does O
a O
nurse O
go O
about O
maintaining O
her O
level O
of O
competence O
when O
she O
is O
one O
of O
the O
few O
local O
practitioners O
in O
her O
field O
? O
Vancouver O
sex O
therapist O
Bianca O
Rucker O
is O
doing O
it O
by O
cultivating O
a O
network O
of O
colleagues O
and O
mentors O
in O
related O
fields O
both O
at O
home O
and O
across O
the O
continent O
. O

Finally O
, O
antibody O
binding O
to O
site O
IIIa O
on O
the O
hCG I-GENE
- I-GENE
ectodomain I-GENE
complex I-GENE
was O
also O
hindered O
by O
an O
anti O
- O
peptide O
mAb O
directed O
against O
a O
peptide O
encoded O
by O
the O
eighth O
exon O
( O
pE O
x O
8 O
) O
of O
the O
LHR I-GENE
. O

cDNA O
cloning O
, O
expression O
analysis O
, O
and O
chromosomal O
localization O
of O
a O
gene O
with O
high O
homology O
to O
wheat I-GENE
eIF I-GENE
-( I-GENE
iso I-GENE
) I-GENE
4F I-GENE
and O
mammalian I-GENE
eIF I-GENE
- I-GENE
4G I-GENE
. O

Therefore O
, O
it O
is O
important O
to O
control O
hypertension O
and O
keep O
appropriate O
renal O
blood O
flow O
during O
living O
renal O
transplantation O
surgery O
. O

The O
initial O
patients O
treated O
with O
AZQ O
and O
mitroxantrone O
experienced O
prolonged O
bone O
marrow O
suppression O
and O
, O
therefore O
, O
subsequent O
cohorts O
were O
treated O
with O
G I-GENE
- I-GENE
CSF I-GENE
, O
5 O
micrograms O
/ O
kg O
, O
beginning O
the O
day O
after O
completion O
of O
the O
third O
cycle O
of O
chemotherapy O
. O

Human I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
hGM I-GENE
- I-GENE
CSF I-GENE
) O
activates O
a O
set O
of O
genes O
such O
as O
c I-GENE
- I-GENE
fos I-GENE
, O
jun I-GENE
, O
myc I-GENE
, O
and O
early I-GENE
growth I-GENE
response I-GENE
gene I-GENE
1 I-GENE
( O
egr I-GENE
- I-GENE
1 I-GENE
). O

In O
order O
to O
provide O
adequate O
local O
control O
without O
compromising O
cosmetic O
outcome O
, O
the O
amount O
of O
breast O
tissue O
that O
must O
be O
excised O
in O
BCT O
needs O
to O
be O
individualized O
. O

Surprisingly O
, O
however O
, O
TCR I-GENE
- O
mediated O
tyrosine O
phosphorylation O
of O
phospholipase I-GENE
C I-GENE
gamma I-GENE
1 I-GENE
remains O
intact O
in O
the O
Jurkat O
cells O
expressing O
the O
A2 I-GENE
/ O
HCP I-GENE
chimera O
. O

The O
14 I-GENE
. I-GENE
1 I-GENE
( I-GENE
IGLL1 I-GENE
) I-GENE
gene I-GENE
is O
expressed O
in O
a O
lineage O
- O
and O
stage O
- O
restricted O
manner O
. O

The O
interferon I-GENE
( O
IFN I-GENE
)- O
induced O
double I-GENE
- I-GENE
stranded I-GENE
RNA I-GENE
( I-GENE
dsRNA I-GENE
)- I-GENE
activated I-GENE
Ser I-GENE
/ I-GENE
Thr I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
plays O
a O
role O
in O
the O
antiviral O
and O
antiproliferative O
effects O
of O
IFN I-GENE
. O

Together O
, O
the O
data O
suggest O
that O
cAMP O
- O
dependent O
control O
of O
the O
amounts O
of O
the O
activator O
SF I-GENE
- I-GENE
1 I-GENE
vs O
. O
the O
repressor O
COUP I-GENE
- I-GENE
TF I-GENE
could O
influence O
CRS2 O
- O
dependent O
transcription O
. O

Object O
relations O
, O
affect O
management O
, O
and O
psychic O
structure O
formation O
. O

When O
expressed O
in O
COS O
- O
7 O
cells O
, O
MKP I-GENE
- I-GENE
4 I-GENE
blocks O
activation O
of O
MAP I-GENE
kinases I-GENE
with O
the O
selectivity O
ERK I-GENE
> O
p38 I-GENE
= O
JNK I-GENE
/ O
SAPK I-GENE
. O

In O
rlf2 I-GENE
mutants I-GENE
, O
telomeric O
chromatin O
is O
perturbed O
: O
Telomeric O
silencing O
is O
reduced O
and O
Rap1p I-GENE
localization O
is O
altered O
. O

Most O
kinases O
are O
not O
significantly O
inhibited O
by O
roscovitine O
. O
cdc2 I-GENE
/ O
cyclin I-GENE
B I-GENE
, O
cdk2 I-GENE
/ O
cyclin I-GENE
A I-GENE
, O
cdk2 I-GENE
/ O
cyclin I-GENE
E I-GENE
and O
cdk5 I-GENE
/ O
p35 I-GENE
only O
are O
substantially O
inhibited O
( O
IC50 O
values O
of O
0 O
. O
65 O
, O
0 O
. O
7 O
, O
0 O
. O
7 O
and O
0 O
. O
2 O
microM O
, O
respectively O
). O
cdk4 I-GENE
/ O
cyclin I-GENE
D1 I-GENE
and O
cdk6 I-GENE
/ O
cyclin I-GENE
D2 I-GENE
are O
very O
poorly O
inhibited O
by O
roscovitine O
( O
IC50 O
> O
100 O
microM O
). O

This O
0 O
. O
74 O
kb O
cDNA O
contains O
an O
open O
reading O
frame O
( O
ORF O
) O
of O
477 O
bp O
encoding O
a O
polypeptide O
of O
159 O
amino O
acids O
( O
aa O
) O
which O
differs O
at O
only O
one O
position O
( O
position O
65 O
) O
from O
the O
human I-GENE
U1 I-GENE
- I-GENE
C I-GENE
protein I-GENE
. O

Interaction O
of O
Ets I-GENE
- I-GENE
1 I-GENE
and O
the O
POU I-GENE
- I-GENE
homeodomain I-GENE
protein I-GENE
GHF I-GENE
- I-GENE
1 I-GENE
/ O
Pit I-GENE
- I-GENE
1 I-GENE
reconstitutes O
pituitary O
- O
specific O
gene O
expression O
. O

Although O
Pho85 I-GENE
is O
not O
essential O
for O
viability O
, O
Pcl1 I-GENE
, I-GENE
2 I-GENE
- O
Pho85 I-GENE
kinase O
complexes O
become O
essential O
for O
Start O
in O
the O
absence O
of O
Cln1 I-GENE
, I-GENE
2 I-GENE
- O
Cdc28 I-GENE
kinases O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 I-GENE
, O
we O
isolated O
the O
B O
subunit O
of O
the O
CCAAT O
binding O
protein O
NF I-GENE
- I-GENE
Y I-GENE
from O
a O
HeLa O
cDNA O
library O
. O

Enhancer O
activity O
requires O
both O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
these O
adjacent O
sequences O
. O

Studies O
using O
HLA I-GENE
- I-GENE
DR I-GENE
- O
B7 I-GENE
- I-GENE
1 I-GENE
- O
LFA I-GENE
- I-GENE
3 I-GENE
triple O
transfectants O
showed O
that O
the O
LFA I-GENE
- I-GENE
3 I-GENE
- O
induced O
NF I-GENE
- I-GENE
AT I-GENE
DNA O
binding O
activity O
was O
negatively O
regulated O
by O
B7 I-GENE
- I-GENE
1 I-GENE
costimulation O
. O

Constitutive O
activation O
of O
Rac1 I-GENE
and O
RhoA I-GENE
causes O
tumorigenic O
transformation O
of O
NIH O
3T3 O
cells O
, O
and O
their O
functions O
may O
be O
required O
for O
full O
Ras I-GENE
transformation O
. O

Furthermore O
, O
Rac1 I-GENE
activation O
of O
JNK I-GENE
or O
SRF I-GENE
, O
or O
induction O
of O
lamellipodia O
, O
was O
neither O
necessary O
nor O
sufficient O
for O
Rac1 I-GENE
transforming O
activity O
. O

Overexpression O
of O
the O
bZip O
interaction O
domain O
of O
CBP I-GENE
specifically O
abolishes O
the O
positive O
cross O
talk O
between O
TR I-GENE
and O
p45 I-GENE
/ O
NF I-GENE
- I-GENE
E2 I-GENE
. O

This O
inhibitory O
domain O
has O
been O
deleted O
in O
all O
naturally O
occurring O
AHC I-GENE
deletion I-GENE
mutants I-GENE
described O
to O
date O
. O

Identification O
of O
a O
promoter O
- O
specific O
transactivation O
domain O
in O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
regulatory I-GENE
protein I-GENE
ICP4 I-GENE
. O

DNA O
sequencing O
of O
a O
17 O
- O
kb O
segment O
encompassing O
a O
gammaherpesvirus O
divergent O
locus O
( O
DL O
- O
B O
) O
between O
ORF11 O
and O
ORF17 O
revealed O
the O
presence O
of O
nine O
viral O
ORFs O
with O
predicted O
gene O
products O
related O
to O
cellular O
proteins O
. O

Studies O
in O
mammalian O
cells O
have O
correlated O
induction O
of O
inhibitory O
tyrosine O
15 O
( O
Y15 O
) O
phosphorylation O
on O
p34cdc2 I-GENE
with O
the O
response O
to O
DNA O
damage O
. O

We O
report O
herein O
the O
case O
of O
a O
30 O
- O
year O
- O
old O
man O
in O
whom O
ectopic O
mediastinal O
parathyroid O
adenoma O
was O
detected O
by O
99mTc O
- O
methoxyisobutylisonitrile O
scintigraphy O
( O
99mTc O
- O
MIBI O
). O

Cardiac I-GENE
endothelin I-GENE
release O
and O
infarct O
size O
, O
myocardial O
blood O
flow O
, O
and O
ventricular O
function O
in O
canine O
infarction O
and O
reperfusion O
. O

The O
workup O
included O
skin O
tests O
( O
up O
to O
1 O
microgram O
/ O
ml O
, O
Pharmacia O
), O
measurement O
of O
specific O
serum O
IgE I-GENE
with O
RAST O
- O
CAP O
( O
Pharmacia O
), O
and O
CAST O
with O
three O
concentrations O
of O
bee O
( O
Apis O
mellifera O
) O
and O
wasp O
( O
Vespula O
spec O
.) O
venom O
( O
Aquagen O
ALK O
). O

The O
proliferation I-GENE
potential I-GENE
protein I-GENE
- I-GENE
related I-GENE
( O
P2P I-GENE
- I-GENE
R I-GENE
) O
gene O
with O
domains O
encoding O
heterogeneous O
nuclear O
ribonucleoprotein O
association O
and O
Rb1 I-GENE
binding O
shows O
repressed O
expression O
during O
terminal O
differentiation O
. O

Recent O
application O
of O
recombinant O
canarypox O
ALVAC O
/ O
HIV O
- O
1 O
vectors O
as O
vaccine O
immunogens O
in O
HIV O
- O
1 O
,- O
noninfected O
volunteers O
has O
produced O
CTL O
responses O
in O
a O
significant O
number O
of O
vaccinees O
. O

The O
relevance O
of O
these O
elements O
in O
conferring O
anaerobic O
induction O
of O
gpc4 I-GENE
gene I-GENE
expression O
is O
discussed O
. O

Exons O
A1a O
and O
A1b O
are O
separated O
from O
each O
other O
by O
a O
124 O
- O
nucleotide O
intron O
. O

A O
MEK I-GENE
- O
specific O
inhibitor O
( O
PD098059 O
) O
( O
Dudley O
, O
D O
. O

These O
data O
support O
the O
idea O
that O
the O
repression O
activity O
of O
NRSF I-GENE
/ O
REST I-GENE
depends O
upon O
the O
species O
of O
promoter O
to O
which O
it O
is O
linked O
and O
upon O
the O
proteins O
that O
bind O
to O
those O
promoters O
. O

Enhanced O
period O
- O
peak O
analysis O
of O
electro O
- O
encephalograms O
using O
a O
fast O
sinc O
function O
. O

In O
summary O
, O
p56 I-GENE
( O
lck I-GENE
) O
activity O
stimulates O
G1 O
/ O
S O
transition O
in O
immature O
thymoblasts O
and O
maintains O
cell O
viability O
via O
transduction O
of O
constitutive O
activation O
signals O
downstream O
to O
components O
of O
the O
Ras I-GENE
/ O
Raf I-GENE
/ O
MAPK I-GENE
pathway O
. O

However O
, O
the O
action O
of O
each O
cognate O
ligand O
and O
the O
accessory O
cellular O
factors O
that O
can O
differentially O
regulate O
the O
transcriptional O
responses O
of O
a O
heterodimer O
- O
DNA O
complex O
are O
not O
well O
understood O
. O

We O
have O
measured O
the O
MBF O
on O
incisors O
and O
its O
direction O
in O
three O
dimensions O
for O
different O
jaw O
openings O
in O
ten O
subjects O
. O

These O
findings O
suggest O
that O
intraarterial O
neoadjuvant O
chemotherapy O
should O
be O
effective O
on O
advanced O
cervical O
cancer O
. O

The O
FBF O
questionnaire O
did O
not O
highlight O
a O
characteristic O
basic O
symptoms O
profile O
of O
schizoaffective O
disorder O
, O
when O
compared O
with O
bipolar O
affective O
disorder O
and O
schizophrenia O
. O

The O
alternative O
sigma I-GENE
factor I-GENE
sigmaB I-GENE
in I-GENE
Staphylococcus I-GENE
aureus I-GENE
: O
regulation O
of O
the O
sigB I-GENE
operon I-GENE
in O
response O
to O
growth O
phase O
and O
heat O
shock O

Cognate O
promoter O
elements O
implicated O
in O
glucocorticoid O
- O
and O
cAMP O
- O
mediated O
regulation O
as O
well O
as O
in O
liver O
-, O
myeloid O
-, O
and O
lymphocyte O
- O
specific O
expression O
are O
located O
within O
the O
5 O
' O
flanking O
sequence O
. O

Clinically O
meaningful O
decreases O
due O
to O
alkalinization O
alone O
within O
30 O
minutes O
are O
unlikely O
. O

We O
have O
studied O
the O
biokinetics O
of O
BLM O
labeled O
with O
indium O
- O
111 O
( O
In O
- O
111 O
). O

CD3 I-GENE
cross O
- O
linking O
induced O
tyrosine O
phosphorylation O
of O
Sam68 I-GENE
in O
uninfected O
T O
cells O
. O

Acetoin O
- O
dependent O
expression O
of O
the O
acoABCD I-GENE
operon I-GENE
could O
be O
restored O
in O
the O
E I-GENE
. I-GENE
coli I-GENE
acoK I-GENE
mutants I-GENE
by O
supplying O
a O
plasmid O
carrying O
an O
intact O
acoK I-GENE
, O
suggesting O
a O
transactivating O
function O
of O
the O
gene O
product O
. O

Mutations O
in O
the O
alpha I-GENE
and I-GENE
sigma I-GENE
- I-GENE
70 I-GENE
subunits I-GENE
of I-GENE
RNA I-GENE
polymerase I-GENE
affect O
expression O
of O
the O
mer I-GENE
operon I-GENE
. O

Taken O
together O
, O
we O
provide O
evidence O
for O
the O
existence O
of O
an O
activator O
, O
NFE I-GENE
, O
which O
in O
combination O
with O
the O
p50 I-GENE
and O
c I-GENE
- I-GENE
Rel I-GENE
proteins I-GENE
, O
are O
part O
of O
the O
transcription O
factor O
machinery O
that O
regulates O
3 O
' O
enhancer O
activity O
, O
and O
thus O
the O
control O
of O
the O
IgH I-GENE
locus I-GENE
in O
late O
B O
lymphocyte O
development O
. O

The O
neuroprotective O
efficacy O
of O
the O
selective O
N O
- O
type O
voltage O
- O
sensitive O
calcium O
channel O
blocker O
, O
SNX O
- O
111 O
, O
was O
evaluated O
in O
spontaneously O
hypertensive O
rats O
subjected O
to O
60 O
min O
of O
focal O
cerebral O
ischemia O
by O
permanent O
ligation O
of O
the O
right O
common O
carotid O
artery O
and O
temporary O
occlusion O
of O
the O
right O
middle O
cerebral O
artery O
. O

The O
genes O
encoding O
the O
transcription I-GENE
factor I-GENE
yTAFII60 I-GENE
, O
the O
G4p1 I-GENE
protein I-GENE
and O
a O
putative O
glucose O
transporter O
are O
contained O
in O
a O
12 O
. O
3 O
kb O
DNA O
fragment O
on O
the O
left O
arm O
of O
Saccharomyces O
cerevisiae O
chromosome O
VII O
. O

The O
protector O
doubled O
the O
estimated O
fall O
distance O
for O
fracture O
of O
the O
trochanter O
. O

Marinol O
/ O
marijuana O
usage O
was O
associated O
with O
depressed O
CD4 I-GENE
+ I-GENE
counts O
and O
elevated O
amylase I-GENE
levels O
within O
the O
DDI O
subgroup O
. O

METHODS O
: O
Fifty O
- O
eight O
patients O
who O
underwent O
a O
curative O
hepatic O
resection O
for O
HCC O
and O
whose O
preoperative O
AFP I-GENE
levels O
were O
> O
100 O
ng O
/ O
ml O
, O
were O
selected O
for O
this O
study O
. O

Calmodulin I-GENE
- I-GENE
binding I-GENE
peptide I-GENE
( O
CBP I-GENE
), O
a O
peptide O
of O
26 O
amino O
acids O
derived O
from O
muscle I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
( O
MLCK I-GENE
), O
binds O
to O
calmodulin I-GENE
with O
nanomolar O
affinity O
. O

Here O
we O
show O
that O
the O
type O
of O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
stimulated O
also O
participates O
in O
the O
nature O
of O
the O
cAMP O
effect O
. O

To O
gain O
insight O
into O
the O
possible O
involvement O
of O
p21 I-GENE
in O
liver O
cell O
growth O
, O
the O
expression O
and O
regulation O
of O
the O
p21 I-GENE
gene I-GENE
was O
evaluated O
in O
rodent O
models O
of O
liver O
regeneration O
and O
specimens O
of O
human O
liver O
diseases O
. O

Northern O
blot O
analysis O
of O
LeMT I-GENE
( I-GENE
A I-GENE
) I-GENE
and O
LeMT I-GENE
( I-GENE
B I-GENE
) I-GENE
showed O
that O
transcripts O
of O
both O
MT I-GENE
- I-GENE
like I-GENE
genes I-GENE
were O
more O
abundant O
in O
leaves O
than O
roots O
in O
tomato O
plants O
grown O
without O
addition O
of O
extra O
metal O
ions O
, O
a O
characteristic O
of O
type I-GENE
II I-GENE
MTs I-GENE
. O

In O
co O
- O
transfection O
studies O
, O
an O
AP I-GENE
- I-GENE
2 I-GENE
but O
not O
an O
Egr I-GENE
- I-GENE
1 I-GENE
expression O
vector O
activated O
VPF I-GENE
/ O
VEGF I-GENE
transcription O
, O
thus O
indicating O
that O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
functionally O
important O
in O
TGF I-GENE
alpha I-GENE
- O
induced O
VPF I-GENE
/ O
VEGF I-GENE
gene O
expression O
. O

The O
HBP I-GENE
gene I-GENE
is O
composed O
of O
eight O
exons O
covering O
19 O
. O
5 O
kb O
on O
the O
short O
arm O
of O
chromosome O
4 O
. O

In O
some O
instances O
, O
this O
is O
partly O
mediated O
by O
the O
expression O
of O
virally O
encoded O
proteases O
which O
lead O
to O
the O
cleavage O
of O
initiation I-GENE
factor I-GENE
eIF4G I-GENE
. O

The O
best O
endometrial O
ablation O
was O
seen O
when O
SnET2 O
was O
given O
by O
intrauterine O
administration O
with O
light O
treatment O
at O
150 O
J O
/ O
cm O
24 O
hours O
later O
. O

Unlike O
class O
II O
- O
and O
III O
- O
specific O
TBP I-GENE
- O
TAF I-GENE
complexes O
, O
the O
corresponding O
murine O
and O
human O
class O
I O
- O
specific O
transcription O
initiation O
factor O
TIF I-GENE
- I-GENE
IB I-GENE
/ O
SL1 I-GENE
exhibits O
a O
pronounced O
selectivity O
for O
its O
homologous O
promoter O
. O

Cytohesin I-GENE
- I-GENE
1 I-GENE
, O
a O
protein O
abundant O
in O
cells O
of O
the O
immune O
system O
, O
has O
been O
proposed O
to O
be O
a O
human O
homolog O
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
Sec7 I-GENE
gene I-GENE
product I-GENE
, O
which O
is O
crucial O
in O
protein O
transport O
. O

In O
this O
regard O
, O
it O
differs O
from O
a O
recently O
reported O
BFA O
- O
sensitive O
ARF I-GENE
- O
GEP I-GENE
that O
contains O
a O
Sec7 I-GENE
domain I-GENE
. O

We O
now O
describe O
the O
identification O
of O
DEK I-GENE
as O
this O
43 I-GENE
- I-GENE
kDa I-GENE
pets I-GENE
factor I-GENE
. O

These O
elements O
comprise O
a O
binding O
site O
for O
Krox I-GENE
proteins I-GENE
, O
one O
for O
nuclear I-GENE
factor I-GENE
1 I-GENE
, O
an O
octamer O
motif O
that O
binds O
POU I-GENE
- I-GENE
homeodomain I-GENE
proteins I-GENE
, O
and O
a O
novel O
TN I-GENE
control I-GENE
element I-GENE
. O

Tissue O
samples O
were O
obtained O
either O
from O
rats O
that O
had O
been O
exposed O
to O
opiate O
withdrawal O
following O
a O
seven O
day O
morphine O
infusion O
or O
sham O
treated O
control O
subjects O
. O

Therefore O
, O
the O
impaired O
floor O
plate O
development O
in O
oep I-GENE
mutants I-GENE
is O
not O
caused O
by O
the O
absence O
of O
the O
floor I-GENE
plate I-GENE
inducer I-GENE
shh I-GENE
. O

RESULTS O
: O
The O
medians O
of O
average O
daily O
CD34 I-GENE
+ I-GENE
cell O
yields O
for O
patients O
who O
received O
paclitaxel O
plus O
CY O
, O
CE O
, O
and O
CEP O
with O
G I-GENE
- I-GENE
CSF I-GENE
were O
12 O
. O
9 O
, O
11 O
. O
03 O
, O
and O
5 O
. O
37 O
x O
10 O
( O
6 O
)/ O
kg O
, O
respectively O
, O
compared O
with O
2 O
. O
02 O
x O
10 O
( O
6 O
)/ O
kg O
in O
the O
reference O
group O
that O
received O
CY O
with O
G I-GENE
- I-GENE
CSF I-GENE
( O
P O
= O
< O
. O
0001 O
, O
. O
002 O
, O
and O
. O
09 O
, O
respectively O
). O

Increased O
p53 I-GENE
activity O
induced O
by O
OP O
is O
not O
due O
to O
elevated O
p53 I-GENE
mRNA I-GENE
nor O
to O
protein O
levels O
. O

CONCLUSION O
: O
Chronic O
administration O
of O
misoprostol O
may O
have O
caused O
a O
negative O
natriuretic O
effect O
in O
cirrhotic O
patients O
with O
ascites O
. O

The O
intensity O
of O
the O
SSTEs O
is O
an O
order O
of O
magnitude O
larger O
than O
that O
of O
the O
MSEs O
and O
determines O
the O
signal O
contrast O
if O
both O
effects O
are O
selected O
simultaneously O
. O

In O
eukaryotic O
cells O
, O
premature O
termination O
of O
translation O
at O
nonsense O
codons O
has O
been O
implicated O
as O
the O
cause O
of O
a O
variety O
of O
posttranscriptional O
events O
, O
including O
rapid O
mRNA O
decay O
in O
the O
cytoplasm O
or O
the O
nucleus O
, O
altered O
splice O
site O
selection O
, O
and O
exon O
skipping O
. O

The O
region O
of O
plasmid O
pCM2 O
encoding O
the O
pathogenicity I-GENE
locus I-GENE
pat I-GENE
- I-GENE
1 I-GENE
was O
mapped O
by O
deletion O
analysis O
and O
complementation O
studies O
to O
a O
1 O
. O
5 O
- O
kb O
Bg I-GENE
/ I-GENE
II I-GENE
/ O
SmaI I-GENE
DNA O
fragment O
. O

Transient O
cotransfection O
of O
tat I-GENE
cDNA I-GENE
in O
sense O
orientation O
( O
tat I-GENE
/ I-GENE
S I-GENE
), O
together O
with O
a O
plasmid O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
( O
FC3 I-GENE
, O
from O
- O
711 O
to O
+ O
42 O
) O
in O
front O
of O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
significantly O
enhanced O
CAT I-GENE
activity O
in O
Jurkat O
cells O
activated O
by O
the O
addition O
of O
15 O
% O
fetal O
calf O
serum O
( O
FCS O
) O
or O
5 O
micrograms O
/ O
mL O
phytohemagglutinin I-GENE
plus O
10 O
(- O
7 O
) O
mol O
/ O
L O
phorbol O
myristate O
acetate O
( O
PMA O
) O
and O
U937 O
cells O
activated O
by O
15 O
% O
FCS O
or O
10 O
(- O
7 O
) O
mol O
/ O
L O
PMA O
. O

Snail O
mortality O
did O
not O
differ O
among O
the O
various O
treatment O
conditions O
. O

The O
recombinant O
protein O
was O
purified O
to O
homogeneity O
by O
( O
NH4 O
) O
2SO4 O
- O
precipitation O
and O
affinity O
chromatography O
on O
5 O
' O
AMP O
- O
Sepharose O
. O

Derepression O
of O
gene O
expression O
mediated O
by O
the O
5 O
' O
upstream O
region O
of O
the O
isocitrate I-GENE
lyase I-GENE
gene I-GENE
of I-GENE
Candida I-GENE
tropicalis I-GENE
is O
controlled O
by O
two O
distinct O
regulatory O
pathways O
in O
Saccharomyces O
cerevisiae O
. O

Exploratory O
- O
motor O
task O
to O
evaluate O
right O
frontal O
lobe O
damage O
. O

To O
avoid O
complications O
, O
accurate O
quantitative O
analysis O
of O
NO O
and O
NO2 O
is O
necessary O
during O
this O
therapy O
. O

Our O
results O
demonstrate O
that O
cis O
elements O
positioned O
between O
the O
alpha I-GENE
3 I-GENE
and O
beta I-GENE
4 I-GENE
coding O
regions O
are O
important O
for O
establishing O
part O
of O
the O
restricted O
CNS O
patterns O
of O
beta I-GENE
4 I-GENE
, O
alpha I-GENE
3 I-GENE
, O
and O
alpha I-GENE
5 I-GENE
gene I-GENE
transcription O
. O

RNase I-GENE
protection O
experiments O
confirmed O
the O
presence O
of O
the O
GHR1 I-GENE
- I-GENE
279 I-GENE
variant I-GENE
in O
IM O
- O
9 O
cells O
and O
human O
liver O
. O

Functional O
tests O
using O
a O
reporter O
gene O
, O
containing O
Stat5 I-GENE
- I-GENE
binding I-GENE
elements I-GENE
, O
confirmed O
that O
while O
the O
variant O
form O
was O
inactive O
by O
itself O
, O
it O
could O
inhibit O
the O
function O
of O
the O
full O
- O
length O
receptor O
. O

Conversely O
, O
activated O
glucocorticoid I-GENE
receptors I-GENE
suppressed O
the O
transactivation O
function O
of O
p53 I-GENE
, O
while O
transrepression O
by O
p53 I-GENE
was O
largely O
unaffected O
. O

99mTc O
- O
HMPAO O
was O
distributed O
in O
the O
territories O
of O
the O
ACA O
and O
MCA O
in O
the O
two O
patients O
who O
were O
treated O
with O
intraarterial O
infusion O
of O
papaverine O
from O
the O
C4 O
segment O
, O
but O
was O
distributed O
only O
to O
the O
territory O
of O
the O
ACA O
in O
four O
patients O
who O
were O
treated O
with O
intraarterial O
infusion O
of O
papaverine O
from O
the O
C1 O
segment O
at O
1 O
ml O
/ O
min O
. O

This O
brief O
review O
analyses O
these O
interactions O
and O
defines O
clinical O
settings O
where O
antibiotic O
- O
induced O
endotoxin O
release O
may O
prove O
to O
be O
clinically O
relevant O
. O

This O
promoter O
segment O
could O
drive O
expression O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
, O
could O
confer O
correct O
transcriptional O
initiation O
to O
the O
reporter O
and O
could O
confer O
the O
EGF I-GENE
- O
responsiveness O
previously O
observed O
in O
the O
native O
gene O
. O

This O
is O
the O
first O
report O
that O
an O
in O
vitro O
- O
synthesized O
alphavirus O
RNA O
lacking O
a O
poly O
( O
A O
) O
tail O
can O
initiate O
infection O
and O
produce O
3 O
' O
polyadenylated O
viral O
genome O
in O
vivo O
. O

The O
human O
coreceptor O
was O
as O
active O
as O
the O
simian O
for O
SIV O
entry O
. O

These O
changes O
in O
virus O
entry O
features O
may O
result O
in O
coronaviruses O
with O
novel O
pathogenic O
properties O
. O

RESULTS O
: O
Among O
women O
, O
the O
age O
- O
related O
decline O
in O
BMD O
at O
all O
non O
- O
spine O
skeletal O
sites O
was O
significantly O
different O
from O
zero O
, O
with O
the O
largest O
decline O
seen O
at O
the O
femoral O
neck O
(-. O
0038 O
g O
/ O
cm2 O
/ O
y O
, O
p O
< O
. O
001 O
) O
and O
the O
smallest O
at O
the O
trochanter O
of O
the O
hip O
(-. O
0023 O
g O
/ O
cm2 O
/ O
y O
, O
p O
= O
. O
03 O
). O

Sixty O
- O
nine O
( O
44 O
%) O
patients O
were O
administered O
250 O
MBq O
( O
7 O
mCi O
) O
99Tcm O
- O
tetrofosmin O
at O
rest O
followed O
4 O
h O
later O
by O
750 O
MBq O
( O
21 O
mCi O
) O
during O
stress O
( O
the O
1 O
day O
protocol O
), O
whereas O
88 O
( O
56 O
%) O
patients O
had O
rest O
and O
stress O
imaging O
studies O
on O
two O
separate O
days O
, O
receiving O
a O
500 O
MBq O
( O
14 O
mCi O
) O
dose O
of O
99Tcm O
- O
tetrofosmin O
on O
each O
occasion O
( O
the O
2 O
day O
protocol O
). O

Myocardial O
SPET O
imaging O
with O
99Tcm O
- O
tetrofosmin O
in O
clinical O
practice O
: O
comparison O
of O
a O
1 O
day O
and O
a O
2 O
day O
imaging O
protocol O
. O

99Tcm O
- O
DMP O
- O
HSA O
showed O
an O
almost O
identical O
behaviour O
to O
in O
vitro O
labelled O
red O
blood O
cells O
( O
RBCs O
), O
which O
are O
generally O
considered O
the O
reference O
standard O
for O
blood O
pool O
agents O
. O

Relief O
from O
autoinhibition O
and O
a O
subsequent O
10 O
- O
60 O
- O
fold O
increase O
in O
V O
( O
max O
) O
have O
been O
observed O
upon O
N I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
engagement O
by O
a O
specific O
phosphotyrosyl O
ligand O
or O
upon O
deletion O
of O
the O
SH2 I-GENE
domains I-GENE
to O
yield O
the O
catalytic O
PTPase I-GENE
domain I-GENE
. O

We O
have O
thus O
identified O
the O
first O
mammalian I-GENE
homolog I-GENE
of I-GENE
yeast I-GENE
UPF1 I-GENE
, O
a O
protein O
that O
regulates O
levels O
of O
nonsense O
mRNA O
, O
and O
we O
tentatively O
name O
this O
protein O
human I-GENE
HUPF1 I-GENE
( O
for O
human I-GENE
homolog I-GENE
of I-GENE
UPF1 I-GENE
). O

A O
miracle O
cure O
and O
its O
solution O

The O
addition O
of O
zidovudine O
did O
not O
influence O
this O
transfer O
. O

DNA O
strand O
exchange O
catalyzed O
by O
Rad51 I-GENE
protein I-GENE
is O
also O
greatly O
stimulated O
by O
RPA I-GENE
. O

Ume6p I-GENE
, O
which O
also O
controls O
the O
expression O
of O
early O
meiotic O
genes O
, O
represses O
CAR1 I-GENE
expression O
through O
a O
sequence O
called O
URS O
, O
as O
a O
function O
of O
nitrogen O
availability O
. O

The O
second O
class O
of O
cDNA O
hybridized O
to O
a O
13 O
kb O
transcript O
, O
which O
was O
approximately O
twice O
as O
large O
as O
the O
mammalian I-GENE
lactase I-GENE
mRNA I-GENE
. O

In O
cell O
lines O
transformed O
by O
BCR I-GENE
/ O
ABL I-GENE
, O
CRKL I-GENE
was O
tyrosine O
phosphorylated O
, O
while O
CRK I-GENE
was O
not O
. O

In O
untransformed O
cells O
, O
three O
major O
proteins O
coprecipitated O
with O
CRKL I-GENE
, O
identified O
as O
C3G I-GENE
, O
SOS I-GENE
and O
c I-GENE
- I-GENE
ABL I-GENE
. O

Effect O
of O
Azadirachta O
indica O
hydroalcoholic O
leaf O
extract O
on O
the O
cardiovascular O
system O
. O

RESULTS O
: O
Nodular O
opacities O
, O
mainly O
centrilobular O
in O
distribution O
, O
were O
the O
most O
common O
finding O
, O
seen O
in O
21 O
( O
72 O
%) O
and O
15 O
( O
65 O
%) O
of O
patients O
with O
MTB O
and O
NTMB O
, O
respectively O
. O

Circulating O
oxytocin I-GENE
in O
male O
guinea O
pigs O
affected O
by O
the O
female O
cohabitation O
and O
reproductive O
condition O
. O

In O
cellular O
supernatant O
fraction O
, O
SHRSP O
showed O
a O
decrease O
of O
magnesium O
in O
many O
tissues O
and O
an O
elevation O
of O
the O
calcium O
to O
magnesium O
ratio O
when O
compared O
to O
age O
- O
matched O
WKY O
and O
SHRSR O
. O

Antisense O
transcription O
of O
a O
murine I-GENE
FGFR I-GENE
- I-GENE
3 I-GENE
psuedogene I-GENE
during O
fetal O
developement O
. O

A O
previous O
report O
described O
that O
a O
548 O
- O
bp O
BglII I-GENE
- O
SmaI I-GENE
fragment O
has O
an O
SSO O
activity O
( O
ori2 O
; O
Kataoka O
et O
al O
., O
Mol O
. O

The O
human I-GENE
CD38 I-GENE
gene I-GENE
consists O
of O
8 O
exons O
that O
extend O
more O
than O
77 O
kb O
on O
the O
human O
genome O
. O

Type O
IV O
splice O
pattern O
, O
containing O
exon O
U3 O
and O
S O
was O
found O
both O
in O
kidney O
and O
ovary O
. O

GH I-GENE
deficiency O
may O
be O
absolute O
, O
but O
often O
is O
not O
and O
the O
diagnosis O
may O
be O
complicated O
by O
a O
constellation O
of O
physical O
and O
hormonal O
findings O
that O
are O
along O
a O
spectrum O
from O
low O
normal O
GH I-GENE
sufficiency O
to O
absent O
GH I-GENE
secretion O
. O

Positive O
CRP I-GENE
test O
were O
seen O
. O

During O
the O
febrile O
period O
, O
pleocytosis O
was O
associated O
with O
high O
levels O
of O
IgG I-GENE
, O
IL I-GENE
- I-GENE
6 I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
and O
PGE2 O
in O
the O
cerebrospinal O
fluid O
. O

Recognition O
mechanisms O
of O
the O
minus O
- O
strand O
origin O
of O
phage O
f1 O
by O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

The O
minimum O
and O
essential O
subunits O
for O
RNA O
synthesis O
have O
not O
yet O
been O
identified O
. O

Syndecan I-GENE
- I-GENE
4 I-GENE
is O
a O
focal O
adhesion O
component O
, O
and O
this O
interaction O
may O
both O
localize O
PKC I-GENE
and O
amplify O
its O
activity O
at O
sites O
of O
forming O
adhesions O
. O

The O
3ASubE O
cells O
expressing O
CXCR2 I-GENE
with O
mutation O
of O
Ser O
- O
346 O
, O
- O
347 O
, O
and O
- O
348 O
to O
alanine O
, O
or O
with O
mutation O
of O
only O
one O
serine O
in O
this O
domain O
, O
continue O
to O
be O
phosphorylated O
in O
response O
to O
ligand O
and O
are O
60 O
- O
70 O
% O
desensitized O
following O
the O
initial O
ligand O
challenge O
. O

Members O
of O
the O
MAPK I-GENE
family I-GENE
include O
the O
extracellular I-GENE
response I-GENE
kinases I-GENE
( O
ERKs I-GENE
or O
p42 I-GENE
/ I-GENE
44 I-GENE
( O
MAPK I-GENE
)), O
the O
c I-GENE
- I-GENE
Jun I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
JNKs I-GENE
), O
and O
the O
p38 I-GENE
/ O
Hog I-GENE
1 I-GENE
protein O
kinases O
. O

MOP5 I-GENE
contained O
the O
characteristic O
PAS I-GENE
domain O
and O
a O
variable O
C O
terminus O
; O
it O
is O
possible O
that O
the O
cDNA O
contains O
a O
bHLH O
domain O
, O
but O
the O
entire O
open O
reading O
frame O
has O
yet O
to O
be O
completed O
. O

The O
reduced O
NO O
production O
in O
these O
cells O
was O
associated O
with O
low O
levels O
of O
mRNA O
of O
inducible I-GENE
NO I-GENE
synthetase I-GENE
. O

Some O
8 O
. O
8 O
kb O
of O
the O
Lactobacillus O
sake O
plasmid O
pCIM1 O
was O
sequenced O
, O
revealing O
eight O
tightly O
clustered O
open O
reading O
frames O
( O
ORFs O
) O
downstream O
from O
lasA I-GENE
, O
which O
encodes O
pre I-GENE
- I-GENE
lactocin I-GENE
S I-GENE
. O

Purified I-GENE
Pra I-GENE
was O
also O
shown O
to O
physically O
interact O
with O
pyruvate I-GENE
kinase I-GENE
( O
Pk I-GENE
); O
Pk I-GENE
and O
Pra I-GENE
can O
form O
a O
complex O
, O
but O
when O
the O
12 I-GENE
- I-GENE
kDa I-GENE
Ndk I-GENE
, O
Pk I-GENE
, O
and O
Pra I-GENE
are O
all O
present O
, O
Pk I-GENE
has O
a O
higher O
affinity O
than O
Pra I-GENE
for O
forming O
a O
complex O
with O
the O
12 I-GENE
- I-GENE
kDa I-GENE
Ndk I-GENE
. O

Apart O
from O
iron O
regulation O
, O
sodA I-GENE
expression O
was O
affected O
by O
changes O
in O
DNA O
topology O
induced O
by O
coumermycin O
A O
but O
not O
by O
the O
global O
virulence O
regulatory O
Bvg I-GENE
system I-GENE
. O

Molecular O
characterization O
of O
a O
large O
Borrelia O
burgdorferi O
motility O
operon O
which O
is O
initiated O
by O
a O
consensus O
sigma70 I-GENE
promoter I-GENE
. O

M I-GENE
. I-GENE
leprae I-GENE
OxyR I-GENE
was O
overproduced O
and O
purified O
, O
and O
its O
binding O
to O
the O
oxyR I-GENE
- O
ahpC I-GENE
intergenic O
region O
of O
M O
. O
leprae O
was O
demonstrated O
. O

The O
binding O
site O
for O
OxyR I-GENE
overlapped O
P1oxyR I-GENE
, O
reminiscent O
of O
the O
autoregulatory O
loops O
controlling O
expression O
of O
oxyR I-GENE
in O
enteric O
bacteria O
and O
characteristic O
of O
the O
LysR I-GENE
superfamily I-GENE
in O
general O
. O

In O
the O
present O
study O
, O
we O
have O
isolated O
and O
sequenced O
several O
p15E I-GENE
cDNA I-GENE
gene I-GENE
fragments I-GENE
amplified O
by O
means O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
from O
parental O
( O
P815 O
) O
and O
xenogenized O
( O
P815 O
/ O
DTIC O
) O
tumour O
cells O
. O

Thirty O
- O
five O
patients O
were O
included O
. O

Grade O
3 O
- O
4 O
mucositis O
was O
present O
in O
13 O
% O
of O
the O
cycles O
. O

Therefore O
more O
active O
and O
tolerable O
salvage O
regimens O
are O
needed O
. O

None O
of O
these O
organic O
manifestations O
was O
discovered O
by O
scintigraphic O
means O
. O

While O
TGF I-GENE
- I-GENE
beta1 I-GENE
does O
not O
alter O
the O
mitogen O
- O
induced O
expression O
and O
abundance O
of O
G1 O
phase O
cyclin I-GENE
D1 I-GENE
and O
cdks I-GENE
4 I-GENE
and I-GENE
2 I-GENE
in O
MCs O
, O
it O
inhibits O
cyclin I-GENE
E I-GENE
- O
cdk I-GENE
2 I-GENE
activity O
, O
thus O
preventing O
mitogen O
- O
elicited O
phosphorylation O
and O
inactivation O
of O
pRb I-GENE
in O
G1 O
phase O
and O
transition O
to O
S O
phase O
. O

However O
, O
the O
range O
of O
values O
observed O
is O
suggestive O
of O
the O
need O
to O
investigate O
districts O
with O
contrasting O
values O
of O
SYPLR O
with O
respect O
to O
the O
inter O
- O
relationships O
between O
sociodemographic O
characteristics O
, O
duration O
of O
symptoms O
, O
clinical O
presentation O
and O
treatment O
efficacy O
. O

The O
prominent O
lesions O
were O
confined O
to O
the O
cerebral O
surface O
layer O
and O
leptomeningeal O
tissue O
including O
the O
arachnoid O
vessels O
, O
which O
were O
all O
bathed O
in O
the O
cerebrospinal O
fluid O
, O
suggesting O
that O
some O
necrotizing O
toxins O
had O
been O
secreted O
into O
the O
fluid O
by O
the O
B O
. O
cereus O
. O

This O
fragment O
contained O
the O
C O
- O
terminal O
47 O
nucleotides O
of O
leuB I-GENE
, O
encoding O
3 I-GENE
- I-GENE
isopropylmalate I-GENE
dehydrogenase I-GENE
; O
asd I-GENE
, O
encoding O
aspartate I-GENE
- I-GENE
beta I-GENE
- I-GENE
semialdehyde I-GENE
dehydrogenase I-GENE
( O
Asd I-GENE
); O
and O
orfA O
, O
whose O
product O
showed O
similarity O
to O
the O
Asd I-GENE
proteins I-GENE
from I-GENE
Vibrio I-GENE
spp I-GENE
. O

Transcriptional O
activity O
was O
measured O
by O
slot O
- O
blot O
hybridization O
with O
steady O
- O
state O
RNA O
isolated O
from O
lacZ I-GENE
+ I-GENE
M I-GENE
. I-GENE
smegmatis I-GENE
clones O
. O

Hovenitin O
I O
and O
(+)- O
ampelopsin O
, O
both O
of O
which O
were O
principal O
ingredients O
of O
the O
active O
fractions O
from O
this O
natural O
medicine O
, O
were O
found O
to O
show O
an O
inhibitory O
activity O
on O
the O
ethanol O
- O
induced O
muscle O
relaxation O
in O
rats O
. O

Movement O
time O
and O
kinematic O
characteristics O
were O
analyzed O
together O
with O
the O
magnitude O
of O
cerebral O
blood O
flow O
to O
identify O
areas O
of O
brain O
activity O
proportionate O
to O
task O
and O
movement O
variables O
. O

Areas O
with O
significantly O
greater O
rCBF O
for O
targeting O
were O
the O
left O
motor O
cortex O
, O
left O
intraparietal O
sulcus O
, O
and O
left O
caudate O
. O

Recent O
studies O
have O
demonstrated O
that O
the O
U1 I-GENE
snRNP I-GENE
is O
recruited O
to O
the O
5 O
' O
splice O
site O
by O
protein O
/ O
protein O
interactions O
involving O
the O
SR I-GENE
domains O
of O
the O
U1 I-GENE
- I-GENE
70K I-GENE
protein I-GENE
and O
SF2 I-GENE
/ O
ASF I-GENE
. O

Thus O
, O
the O
tri O
- O
snRNP O
- O
specific O
27K O
protein O
could O
potentially O
be O
involved O
in O
SR I-GENE
protein O
- O
mediated O
protein O
/ O
protein O
interactions O
and O
, O
additionally O
, O
its O
phosphorylation O
state O
could O
modulate O
pre O
- O
mRNA O
splicing O
. O

Purified I-GENE
P7 I-GENE
could O
be O
assembled O
onto O
particles O
lacking O
P7 I-GENE
and O
particles O
lacking O
both O
P2 I-GENE
( O
RNA I-GENE
polymerase I-GENE
) O
and O
P7 I-GENE
. O

However O
, O
the O
same O
U1A I-GENE
peptide I-GENE
, O
when O
conjugated O
to O
BSA I-GENE
, O
inhibits O
vertebrate I-GENE
PAP I-GENE
. O

Plasma O
levels O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
and O
antithrombin I-GENE
III I-GENE
in O
patients O
with O
subarachnoid O
haemorrhage O
. O

Idiopathic O
bilateral O
recurrent O
branch O
retinal O
arterial O
occlusion O
( O
IBRBRAO O
) O
is O
a O
rare O
syndrome O
characterized O
by O
migraine O
headaches O
, O
tinnitus O
, O
vertigo O
, O
hearing O
loss O
, O
and O
recurrent O
branch O
retinal O
artery O
occlusion O
of O
unknown O
etiology O
. O

Epithelial O
and O
corneal O
thickness O
measurements O
by O
in O
vivo O
confocal O
microscopy O
through O
focusing O
( O
CMTF O
). O

Sequences O
downstream O
of O
the O
two O
human I-GENE
CA I-GENE
genes I-GENE
, O
possibly O
containing O
homologous O
enhancer O
elements O
, O
have O
not O
yet O
been O
reported O
. O

Recombinant O
plasmids O
containing O
the O
entire O
322 O
nt O
5 O
' O
UTR O
of O
exon O
1 O
and O
a O
1630 O
nt O
segment O
of O
5 O
' O
flanking O
sequence O
stimulated O
luciferase I-GENE
activity O
nearly O
70 O
times O
higher O
than O
a O
promoterless O
control O
plasmid O
. O

Analysis O
for O
DNA O
- O
protein O
interactions O
by O
in O
vitro O
DNase I-GENE
- I-GENE
I I-GENE
footprinting O
identified O
a O
broad O
region O
of O
protection O
extending O
from O
nt O
- O
12 O
to O
+ O
38 O
. O

It O
is O
also O
homologous O
to O
other O
sugar O
carriers O
from O
human O
, O
mouse O
and O
Escherichia O
coli O
. O

Until O
now O
, O
each O
of O
these O
loci O
was O
considered O
to O
contain O
three O
genes O
( O
for O
regulator I-GENE
, O
permease I-GENE
and O
alpha I-GENE
- I-GENE
glucosidase I-GENE
), O
but O
a O
fourth O
gene O
, O
presumably O
an O
extra O
alpha I-GENE
- I-GENE
glucosidase I-GENE
gene I-GENE
, O
was O
found O
at O
MAL1 I-GENE
adjacent O
to O
the O
usual O
cluster O
of O
three O
genes O
. O

Although O
methods O
to O
align O
the O
control O
and O
activation O
fMR O
images O
may O
correct O
for O
some O
of O
this O
motional O
error O
, O
they O
will O
be O
incomplete O
in O
correcting O
for O
those O
that O
depend O
on O
spatial O
orientation O
. O

Three O
women O
have O
had O
abnormal O
endocervical O
follow O
up O
cytology O
suggestive O
of O
residual O
disease O
. O

Autorosette O
- O
forming O
cells O
are O
characterized O
by O
a O
high O
activity O
of O
alkaline I-GENE
and I-GENE
acid I-GENE
phosphatases I-GENE
and O
low O
NBT O
- O
test O
values O
. O

Analysis O
of O
homologous O
DNA O
sequences O
within O
the O
first O
intron O
of O
the O
mouse I-GENE
and I-GENE
human I-GENE
mts1 I-GENE
genes I-GENE
: O
kB I-GENE
- I-GENE
like I-GENE
site I-GENE
and O
microsatellite O
DNA O

The O
integration O
at O
the O
VIP I-GENE
CyRE I-GENE
of O
the O
Jak I-GENE
- O
Stat I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
signaling O
pathways O
with O
other O
pre O
- O
existing O
proteins O
provides O
a O
cellular O
mechanism O
for O
cell O
- O
and O
cytokine O
- O
specific O
signaling O
. O

These O
studies O
point O
to O
the O
involvement O
of O
the O
MAP I-GENE
kinase I-GENE
pathway O
in O
the O
activation O
of O
monocytic O
cells O
during O
transmigration O
to O
inflammatory O
sites O
. O

Our O
results O
show O
that O
the O
temperature I-GENE
- I-GENE
sensitive I-GENE
rad54 I-GENE
- I-GENE
3 I-GENE
allele I-GENE
blocks O
mitotic O
recombination O
between O
tandemly O
repeated O
DYZ3 I-GENE
satellite I-GENE
sequences I-GENE
and O
significantly O
stabilizes O
a O
human I-GENE
DYZ5 I-GENE
satellite O
- O
containing O
YAC O
clone O
. O

A O
P22 O
R17 O
derivative O
with O
an O
OcRNA O
site O
( O
P22 O
R17 O
[ O
A O
(- O
10 O
) O
U O
]) O
develops O
lytically O
following O
infection O
of O
these O
strains O
. O

Circularized O
Ac I-GENE
/ O
Ds I-GENE
transposons O
: O
formation O
, O
structure O
and O
fate O
. O

This O
site O
is O
upstream O
from O
the O
TATA O
box O
used O
in O
somatic O
cells O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
regulation O
of O
B I-GENE
- I-GENE
Myb I-GENE
activity O
by O
cyclin I-GENE
- O
Cdks I-GENE
. O

Candidate O
tumor O
suppressor O
genes O
, O
Mts1 I-GENE
( O
p16INK4a I-GENE
) O
and O
Mts2 I-GENE
( O
p15INK4b I-GENE
), O
have O
been O
mapped O
to O
this O
region O
, O
but O
by O
Southern O
blot O
analysis O
, O
no O
homozygous O
deletions O
were O
detected O
in O
either O
gene O
. O

Excision O
repair O
at O
the O
level O
of O
the O
nucleotide O
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
MFA2 I-GENE
gene I-GENE
: O
mapping O
of O
where O
enhanced O
repair O
in O
the O
transcribed O
strand O
begins O
or O
ends O
and O
identification O
of O
only O
a O
partial O
rad16 I-GENE
requisite O
for O
repairing O
upstream O
control O
sequences O
. O

An O
aromatic O
stacking O
interaction O
between O
subunits O
helps O
mediate O
DNA O
sequence O
specificity O
: O
operator O
site O
discrimination O
by O
phage I-GENE
lambda I-GENE
cI I-GENE
repressor I-GENE
. O

We O
have O
characterized O
a O
panel O
of O
6 O
monoclonal O
antibodies O
raised O
against O
human I-GENE
platelet I-GENE
talin I-GENE
by O
Western O
blotting O
, O
immune O
precipitation O
, O
and O
immunofluorescence O
, O
and O
shown O
that O
antibodies I-GENE
TA205 I-GENE
and O
TD77 I-GENE
disrupt O
actin I-GENE
stress O
fibers O
and O
focal O
adhesions O
, O
and O
inhibit O
cell O
motility O
when O
microinjected O
into O
human O
fibroblasts O
. O

This O
locus O
maps O
approximately O
160 O
kbp O
from O
the O
genes O
encoding O
cytadherence O
- O
associated O
proteins O
HMW1 I-GENE
and O
HMW3 I-GENE
, O
and O
yet O
insertions O
therein O
result O
in O
loss O
of O
these O
proteins O
and O
a O
hemadsorption O
- O
negative O
( O
HA O
-) O
phenotype O
, O
prompting O
the O
designation O
cytadherence I-GENE
- I-GENE
regulatory I-GENE
locus I-GENE
( O
crl I-GENE
). O

Coliphage I-GENE
186 I-GENE
B I-GENE
is O
a O
72 O
- O
amino O
acid O
protein O
belonging O
to O
the O
Ogr I-GENE
family O
of O
analogous O
transcription O
factors O
present O
in O
P2 O
- O
like O
phage O
, O
which O
contain O
a O
Cys O
- O
X2 O
- O
Cys O
- O
X22 O
- O
Cys O
- O
X4 O
- O
Cys O
presumptive O
zinc O
- O
finger O
motif O
. O

The O
UV O
absorption O
spectrum O
revealed O
a O
shoulder O
at O
250 O
nm O
, O
characteristic O
of O
CysS O
- O
Cd O
( O
II O
) O
ligand O
- O
to O
- O
metal O
charge O
- O
transfer O
transitions O
, O
and O
the O
difference O
absorption O
coefficient O
after O
acidification O
( O
delta O
epsilon O
248 O
, O
24 O
mM O
- O
1 O
cm O
- O
1 O
) O
indicated O
the O
presence O
of O
a O
Cd O
( O
Cys O
- O
S O
) O
4 O
center O
. O

Diacylglycerol I-GENE
kinase I-GENE
( O
DGK I-GENE
) O
attenuates O
levels O
of O
second O
messenger O
diacylglycerol O
in O
cells O
and O
produces O
another O
( O
putative O
) O
messenger O
, O
phosphatidic O
acid O
. O

Recently O
, O
we O
have O
reported O
the O
cloning O
of O
the O
germ O
cell O
- O
specific O
, O
nuclear O
orphan O
receptor O
germ I-GENE
cell I-GENE
nuclear I-GENE
factor I-GENE
( O
GCNF I-GENE
)/ O
RTR I-GENE
. O

Based O
on O
the O
sequence O
of O
the O
conRTRE I-GENE
, O
we O
located O
a O
putative O
RTRE I-GENE
, O
referred O
to O
as O
P2 I-GENE
- I-GENE
RE I-GENE
, O
in O
the O
5 O
' O
promoter O
- O
flanking O
region O
of O
the O
mouse I-GENE
protamine I-GENE
2 I-GENE
gene I-GENE
, O
which O
is O
induced O
during O
the O
same O
stage O
of O
spermatogenesis O
as O
RTR I-GENE
. O

Here O
we O
report O
the O
purification O
of O
this O
larger O
form O
as O
an O
approximately O
320 O
- O
kDa O
particle O
that O
contains O
mRNP3 I-GENE
+ I-GENE
4 I-GENE
and O
nine O
additional O
polypeptides O
, O
including O
mRNA O
- O
binding O
polypeptides O
of O
34 O
and O
36 O
kDa O
and O
a O
doublet O
of O
110 O
/ O
105 O
kDa O
that O
proved O
to O
be O
nucleolin I-GENE
. O

Active O
complexes O
eluted O
at O
a O
higher O
molecular O
weight O
than O
inactive O
complexes O
, O
were O
relatively O
deficient O
in O
both O
p21 I-GENE
and O
p27 I-GENE
, O
and O
contained O
Cdk2 I-GENE
with O
increased O
threonine O
160 O
phosphorylation O
, O
consistent O
with O
a O
mechanism O
of O
activation O
of O
cyclin I-GENE
E I-GENE
- O
Cdk2 I-GENE
involving O
both O
reduced O
CDK I-GENE
inhibitor O
association O
and O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
- O
mediated O
phosphorylation O
of O
Cdk2 I-GENE
. O

Thirty O
Class O
I O
and O
Class O
II O
recessions O
in O
30 O
patients O
were O
treated O
with O
a O
modified O
subepithelial O
connective O
tissue O
graft O
procedure O
. O

The O
derivatives O
of O
the O
latter O
two O
cell O
lines O
showed O
increased O
expression O
of O
the O
p27Kip1 I-GENE
protein I-GENE
and O
inhibition O
of O
cell O
growth O
. O

The O
perioperative O
mortality O
of O
all O
patients O
was O
1 O
. O
9 O
%, O
the O
mortality O
of O
patients O
older O
than O
70 O
years O
was O
4 O
. O
3 O
%. O

Chronic O
renal O
failure O
patients O
essentially O
die O
from O
cardiovascular O
causes O
, O
and O
the O
frequency O
of O
malignant O
disease O
responsible O
for O
death O
is O
estimated O
to O
be O
10 O
%. O

The O
new O
FIGO O
definition O
of O
cervical O
cancer O
stage O
IA O
: O
a O
critique O
. O

The O
effect O
of O
Vpu I-GENE
on O
class O
I O
biogenesis O
was O
analyzed O
in O
more O
detail O
using O
a O
Vpu I-GENE
- O
expressing O
recombinant O
vaccinia O
virus O
( O
VV O
). O

This O
study O
indicates O
that O
the O
phenotype O
of O
myofibrillar O
disarray O
seen O
in O
HCM O
patients O
which O
harbor O
either O
of O
these O
two O
mutations O
may O
not O
be O
directly O
due O
to O
the O
failure O
of O
the O
mutant I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
protein I-GENE
to O
assemble O
and O
form O
normal O
sarcomeres O
, O
but O
may O
rather O
be O
a O
secondary O
effect O
possibly O
resulting O
from O
the O
chronic O
stress O
of O
decreased O
beta I-GENE
MHC I-GENE
function O
. O

Inductively O
coupled O
plasma O
atomic O
emission O
spectroscopy O
was O
employed O
to O
obtain O
the O
tissue O
silicon O
measurements O
. O

An O
egg O
protein O
, O
lysozyme I-GENE
, O
is O
a O
still O
unlabeled O
additive O
currently O
used O
in O
cheese O
preparation O
. O

A O
method O
for O
the O
simultaneous O
determination O
of O
de O
( O
N O
- O
methyl O
)- O
N O
- O
ethyl O
- O
8 O
, O
9 O
- O
anhydroerythromycin O
A O
6 O
, O
9 O
- O
hemiacetal O
( O
EM523 O
, O
I O
) O
and O
its O
three O
metabolites O
in O
human O
plasma O
and O
urine O
has O
been O
developed O
using O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
chemiluminescence O
( O
CL O
) O
detection O
. O

Similarly O
, O
the O
DNA O
- O
binding O
activity O
of O
activator I-GENE
protein I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
is O
modified O
by O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
redox I-GENE
factor I-GENE
1 I-GENE
( O
Ref I-GENE
- I-GENE
1 I-GENE
), O
which O
is O
identical O
to O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
AP I-GENE
endonuclease I-GENE
. O

Having O
an O
LRR I-GENE
domain I-GENE
and O
an O
SH3 I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
Acan125 I-GENE
and O
the O
C O
. O
elegans O
homologue O
define O
a O
novel O
family O
of O
bifunctional O
binding O
proteins O
. O

However O
, O
its O
participation O
in O
gagging O
induced O
by O
oropharyngeal O
irritation O
is O
unclear O
. O

The O
capacity O
to O
repair O
8 O
- O
OxoG O
has O
been O
measured O
in O
cell O
- O
free O
extracts O
of O
wild O
- O
type O
and O
ogg1 I-GENE
strains O
using O
a O
34mer O
DNA O
fragment O
containing O
a O
single O
8 O
- O
OxoG O
residue O
paired O
with O
a O
cytosine O
( O
8 O
- O
OxoG O
/ O
C O
) O
as O
a O
substrate O
. O

Results O
from O
our O
and O
other O
laboratories O
have O
suggested O
that O
UCN O
- O
01 O
induces O
preferential O
G1 O
- O
phase O
accumulation O
in O
several O
human O
tumor O
cell O
lines O
tested O
. O

Northern O
and O
RT O
- O
PCR O
analysis O
of O
Ube3a I-GENE
expression O
in O
mouse O
tissues O
from O
animals O
with O
segmental O
, O
paternal O
uniparental O
disomy O
failed O
to O
detect O
substantially O
reduced O
or O
absent O
expression O
compared O
to O
control O
animals O
, O
failing O
to O
provide O
any O
evidence O
for O
maternal O
- O
specific O
expression O
from O
this O
locus O
. O

Two O
predominant O
effects O
were O
noted O
: O
( O
i O
) O
the O
Xaa O
residue O
in O
the O
dual O
phosphorylation O
motif O
Thr O
- O
Xaa O
- O
Tyr O
as O
well O
as O
the O
length O
of O
L12 O
influence O
p38 I-GENE
substrate O
specificity O
, O
and O
( O
ii O
) O
the O
length O
of O
L12 O
plays O
a O
major O
role O
in O
controlling O
autophosphorylation O
. O

A O
novel O
, O
testis I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcript I-GENE
encoding O
an O
NH2 I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
nitric I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
. O
mRNA O
diversity O
represents O
a O
major O
theme O
of O
neuronal I-GENE
nitric I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
( O
nNOS I-GENE
) O
gene O
expression O
in O
somatic O
cells O
/ O
tissues O
. O

Unlike O
the O
MAR O
- O
binding O
domain O
, O
the O
homeodomain I-GENE
when O
isolated O
binds O
poorly O
and O
with O
low O
specificity O
to O
DNA O
. O

Cotransfection O
of O
Ets I-GENE
- I-GENE
2 I-GENE
and O
p44 I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
expression O
vectors O
strongly O
potentiated O
HB I-GENE
- O
EGF I-GENE
promoter O
activation O
in O
response O
to O
deltaRaf I-GENE
- I-GENE
1 I-GENE
: O
ER I-GENE
. O

Cyclin I-GENE
D1 I-GENE
could O
not O
be O
displaced O
from O
cdk4 I-GENE
in O
the O
resistant O
184A1L5R O
cell O
lysates O
. O

The O
importance O
of O
posttranslational O
regulation O
of O
p15INK4B I-GENE
by O
TGF I-GENE
- I-GENE
beta I-GENE
is O
underlined O
by O
the O
observation O
that O
in O
TGF I-GENE
- I-GENE
beta I-GENE
- O
resistant O
184A1L5R O
, O
although O
the O
p15 I-GENE
transcript I-GENE
increased O
, O
p15INK4B I-GENE
protein I-GENE
was O
not O
stabilized O
and O
did O
not O
accumulate O
, O
and O
cyclin I-GENE
D1 I-GENE
- O
cdk I-GENE
association O
and O
kinase O
activation O
were O
not O
inhibited O
. O

The O
Rlm1 I-GENE
protein I-GENE
, O
a O
member O
of O
the O
MADS I-GENE
box I-GENE
family I-GENE
of O
transcription O
factors O
, O
functions O
downstream O
of O
Mpk1 I-GENE
in O
the O
pathway O
. O

To O
identify O
cis O
- O
acting O
elements O
that O
target O
c I-GENE
- I-GENE
myc I-GENE
mRNA I-GENE
for O
downregulation O
during O
myogenesis O
, O
we O
stably O
transfected O
C2C12 O
cells O
with O
mutant I-GENE
myc I-GENE
genes I-GENE
or O
chimeric O
genes O
in O
which O
various O
myc I-GENE
sequences I-GENE
were O
fused O
to O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
or O
to O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene O
. O

Furthermore O
, O
experiments O
with O
32D O
temperature O
- O
sensitive O
p53 I-GENE
cells O
indicate O
that O
aberrant O
tal I-GENE
- I-GENE
1 I-GENE
expression O
at O
the O
permissive O
temperature O
does O
not O
exert O
a O
proliferative O
effect O
but O
causes O
p53 I-GENE
- O
mediated O
apoptosis O
, O
i O
. O
e O
., O
the O
tal I-GENE
- I-GENE
1 I-GENE
proliferative O
effect O
depends O
on O
the O
integrity O
of O
the O
cell O
cycle O
checkpoints O
of O
the O
host O
cell O
, O
as O
observed O
for O
c I-GENE
- I-GENE
myc I-GENE
and O
other O
oncogenes O
. O
tal I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
experiments O
indicate O
that O
ectopic O
tal I-GENE
- I-GENE
1 I-GENE
effects O
are O
mediated O
by O
both O
the O
DNA O
- O
binding O
and O
the O
heterodimerization O
domains O
, O
while O
the O
N I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
tal I-GENE
- I-GENE
1 I-GENE
variant I-GENE
( O
M3 I-GENE
) O
expressed O
in O
T O
- O
ALL O
malignant O
cells O
mimics O
the O
effects O
of O
the O
wild O
- O
type O
protein O
. O

The O
likelihood O
that O
a O
common O
region O
of O
deletions O
would O
contain O
a O
tumor O
suppressor O
is O
strongly O
enhanced O
by O
coincidence O
of O
that O
region O
with O
a O
chromosome O
fragment O
suppressing O
tumorigenicity O
upon O
introduction O
in O
tumor O
cells O
. O

DNA O
- O
binding O
activity O
was O
not O
increased O
by O
the O
addition O
of O
forskolin O
to O
thecal O
or O
luteal O
cells O
. O

However O
, O
in O
some O
of O
them O
either O
pattern O
may O
predominate O
or O
be O
exclusively O
present O
. O

Upon O
induction O
of O
SOS O
, O
viability O
increased O
2 O
- O
6 O
- O
fold O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
binding O
site O
between O
- O
2010 O
and O
- O
1954 O
in O
regulating O
transcription O
of O
collagenase I-GENE
- I-GENE
1 I-GENE
in O
monocytic O
cells O
. O

11 O
- O
Aminoundecanoyl O
- O
SK O
- O
NH2 O
and O
11 O
- O
aminoundecanoyl O
- O
SH O
- O
NH2 O
establish O
that O
a O
simple O
alkyl O
backbone O
can O
maintain O
an O
appropriate O
distance O
between O
three O
elements O
critical O
for O
recognition O
by O
the O
fungal O
enzyme O
' O
s O
peptide O
- O
binding O
site O
: O
a O
simple O
omega O
- O
terminal O
amino O
group O
, O
a O
beta O
- O
hydroxyl O
, O
and O
an O
epsilon O
- O
amino O
group O
or O
an O
imidazole O
. O

The O
carboxyl O
- O
terminal O
CCCC O
module O
is O
structurally O
related O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
erythroid I-GENE
transcription I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
. O

Cdc2 I-GENE
co O
- O
precipitates O
with O
Pch1 I-GENE
in O
S O
. O
pombe O
cell O
lysates O
, O
although O
Cdc2 I-GENE
may O
not O
be O
the O
major O
catalytic O
partner O
of O
a O
Pch1 I-GENE
kinase I-GENE
in O
vivo O
. O

Little O
is O
known O
about O
the O
mechanism O
, O
but O
the O
availability O
of O
rapid O
facile O
assays O
for O
monitoring O
immunoglobulin I-GENE
hypermutation O
would O
greatly O
aid O
the O
development O
of O
culture O
systems O
for O
hypermutating O
B O
cells O
as O
well O
as O
the O
screening O
for O
individuals O
deficient O
in O
the O
process O
. O

Expression O
of O
the O
human I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
gene I-GENE
( O
hsp70 I-GENE
) O
is O
induced O
by O
various O
kinds O
of O
stress O
and O
by O
oncogenes O
. O

Of O
these O
proteins O
, O
five O
have O
previously O
been O
shown O
to O
be O
phosphorylated O
during O
mitosis O
( O
epithelial I-GENE
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
115 I-GENE
, O
Oct91 I-GENE
, O
Elongation I-GENE
factor I-GENE
1gamma I-GENE
, O
BRG1 I-GENE
and O
Ribosomal I-GENE
protein I-GENE
L18A I-GENE
), O
five O
are O
related O
to O
proteins O
postulated O
to O
have O
roles O
in O
mitosis O
( O
epithelial I-GENE
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
115 I-GENE
, O
Schizosaccharomyces I-GENE
pombe I-GENE
Cdc5 I-GENE
, O
innercentrosome I-GENE
protein I-GENE
, O
BRG1 I-GENE
and O
the O
RNA I-GENE
helicase I-GENE
WM6 I-GENE
), O
and O
nine O
are O
related O
to O
transcription O
factors O
( O
BRG1 I-GENE
, O
negative I-GENE
co I-GENE
- I-GENE
factor I-GENE
2alpha I-GENE
, O
Oct91 I-GENE
, O
S O
. O
pombe O
Cdc5 I-GENE
, O
HoxD1 I-GENE
, O
Sox3 I-GENE
, O
Vent2 I-GENE
, O
and O
two O
isoforms O
of O
Xbr1b I-GENE
). O

Thus O
, O
depending O
on O
their O
location O
, O
psoralen O
cross O
- O
links O
affected O
different O
steps O
in O
the O
initiation O
process O
. O

Activation O
of O
alpha I-GENE
4 I-GENE
beta I-GENE
1 I-GENE
with O
TS2 I-GENE
/ I-GENE
16 I-GENE
inhibited O
the O
cytoplasmic O
protrusions O
and O
cell O
migration O
but O
did O
not O
affect O
the O
pattern O
of O
phosphorylation O
. O

Performance O
on O
two O
verbal O
measures O
- O
the O
National O
Adult O
Reading O
Test O
- O
Revised O
( O
NART O
- O
R O
) O
and O
the O
Vocabulary O
subtest O
from O
the O
Wechsler O
Adult O
Intelligence O
Scale O
- O
Revised O
( O
WAIS O
- O
R O
)- O
showed O
strong O
correlations O
with O
level O
of O
education O
. O

L O
- O
canavanine O
, O
a O
selective O
inhibitor O
of O
the O
inducible O
nitric I-GENE
oxide I-GENE
synthase I-GENE
, O
increases O
the O
mean O
systemic O
filling O
pressure O
, O
thereby O
improving O
venous O
return O
, O
under O
these O
conditions O
. O

RESULTS O
: O
Of O
the O
29 O
patients O
who O
received O
concurrent O
chemotherapy O
and O
G I-GENE
- I-GENE
CSF I-GENE
, O
ten O
( O
34 O
%; O
95 O
% O
confidence O
interval O
[ O
CI O
], O
17 O
. O
9 O
to O
54 O
. O
3 O
%) O
were O
believed O
to O
have O
clinically O
significant O
bleomycin O
toxicity O
. O

The O
different O
holoenzyme I-GENE
RNA I-GENE
polymerases I-GENE
generated O
upon O
reconstituting O
these O
mutants O
independently O
with O
core I-GENE
RNA I-GENE
polymerase I-GENE
( O
alpha2beta O
beta O
') O
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild I-GENE
- I-GENE
type I-GENE
sigma I-GENE
factor I-GENE
. O

These O
data O
are O
consistent O
with O
a O
model O
in O
which O
GATA I-GENE
- I-GENE
5 I-GENE
performs O
a O
unique O
temporally O
and O
spatially O
restricted O
function O
in O
the O
embryonic O
heart O
and O
lung O
. O

The O
exonic O
sequence O
encodes O
a O
protein O
of O
495 O
amino O
acids O
that O
is O
nearly O
identical O
to O
the O
previously O
reported O
protein O
sequence O
of O
human I-GENE
GPT I-GENE
- I-GENE
1 I-GENE
. O

Here O
we O
characterize O
an O
S I-GENE
. I-GENE
cerevisiae I-GENE
Swi3 I-GENE
homolog I-GENE
( O
Swh3 I-GENE
) O
and O
present O
evidence O
that O
it O
associates O
in O
a O
complex O
with O
a O
Snf2 I-GENE
homolog I-GENE
, O
Sthl I-GENE
. O

Shc I-GENE
stimulates O
Ras I-GENE
/ O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
through O
forming O
a O
complex O
with O
Grb2 I-GENE
at O
the O
phosphorylated O
tyrosine O
( O
Y O
) O
residue O
317 O
. O

In O
contrast O
, O
Y239 I-GENE
/ I-GENE
240F I-GENE
Shc I-GENE
, O
but O
not O
Y317F I-GENE
Shc I-GENE
, O
reduced O
the O
EGF I-GENE
- O
induced O
c I-GENE
- I-GENE
myc I-GENE
message O
. O

The O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
protein I-GENE
functions O
as O
a O
molecular O
switch O
in O
signalling O
downstream O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
. O

We O
show O
that O
Rlm1 I-GENE
and O
Smp1 I-GENE
have O
MEF2 I-GENE
- O
related O
DNA O
- O
binding O
specificities O
: O
Rlm1 I-GENE
binds O
with O
the O
same O
specificity O
as O
MEF2 I-GENE
, O
CTA I-GENE
( I-GENE
T I-GENE
/ I-GENE
A I-GENE
) I-GENE
4TAG I-GENE
, O
while O
SMP1 I-GENE
binds O
a O
more O
extended O
consensus O
sequence O
, O
ACTACTA O
( O
T O
/ O
A O
) O
4TAG O
. O

Domains O
I O
and O
II O
of O
B I-GENE
" I-GENE
are O
buried O
upon O
assembly O
of O
the O
TFIIIB I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
, O
as O
determined O
by O
protein O
footprinting O
. O

Domain O
switch O
experiments O
reveal O
that O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
proteins I-GENE
containing O
either O
the O
leucine O
zipper O
or O
the O
activation O
domain O
of O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
are O
unable O
to O
stimulate O
the O
2D5 I-GENE
promoter I-GENE
yet O
are O
fully O
capable O
of O
transactivating O
an O
artificial O
promoter O
bearing O
a O
high O
- O
affinity O
C I-GENE
/ I-GENE
EBP I-GENE
site I-GENE
. O

The O
similar O
phenotypes O
of O
bur6 I-GENE
and O
bur3 I-GENE
( O
mot1 I-GENE
) O
mutations O
suggest O
that O
Bur6p I-GENE
and O
Mot1p I-GENE
have O
related O
, O
but O
not O
identical O
, O
functions O
in O
modulating O
the O
activity O
of O
the O
general O
transcription O
machinery O
in O
vivo O
. O

PRH75 I-GENE
, O
a O
new O
nucleus O
- O
localized O
member O
of O
the O
DEAD I-GENE
- I-GENE
box I-GENE
protein I-GENE
family I-GENE
from O
higher O
plants O
. O

These O
activities O
are O
all O
required O
for O
stimulation O
of O
cell O
growth O
by O
middle I-GENE
- I-GENE
T I-GENE
and O
activate O
members O
of O
the O
MAP I-GENE
kinase I-GENE
family I-GENE
. O

A O
role O
for O
the O
small I-GENE
GTPase I-GENE
Rac I-GENE
in O
polyomavirus I-GENE
middle I-GENE
- I-GENE
T I-GENE
antigen I-GENE
- O
mediated O
activation O
of O
the O
serum O
response O
element O
and O
in O
cell O
transformation O
. O

Time O
- O
activity O
curves O
from O
the O
gastric O
region O
of O
interest O
were O
used O
, O
after O
subjection O
to O
appropriate O
corrective O
procedures O
, O
to O
calculate O
the O
mean O
gastric O
transit O
time O
( O
MTT O
90 O
) O
and O
the O
fraction O
of O
the O
test O
meal O
retained O
in O
the O
stomach O
after O
90 O
min O
( O
F90 O
). O

This O
study O
provides O
a O
direct O
demonstration O
of O
a O
role O
for O
G I-GENE
betagamma I-GENE
in O
mediating O
the O
agonist O
- O
stimulated O
translocation O
of O
GRK2 I-GENE
and O
GRK3 I-GENE
in O
an O
intact O
cellular O
system O
and O
demonstrates O
isoform O
specificity O
in O
the O
interaction O
of O
these O
components O
. O

Our O
results O
indicate O
that O
RA O
- O
mediated O
repression O
of O
the O
hMGP I-GENE
gene I-GENE
is O
due O
to O
binding O
of O
liganded O
RAR I-GENE
/ O
RXR I-GENE
to O
a O
novel O
negative O
RA O
response O
element O
. O

Point O
mutations O
of O
the O
five O
tyrosine O
residues O
in O
the O
cytoplasmic O
domain O
of O
the O
receptor O
were O
subsequently O
used O
to O
confirm O
our O
conclusions O
. O

We O
describe O
a O
novel O
method O
using O
Saccharomyces O
cerevisiae O
for O
detecting O
protein O
- O
truncating O
mutations O
in O
any O
gene O
of O
interest O
. O

Hepatocellular O
injury O
during O
preservation O
of O
human O
livers O
with O
UW O
and O
HTK O
solution O
. O

The O
electromyographically O
recorded O
responses O
consisted O
of O
an O
early O
R1 O
response O
in O
the O
orbicularis O
oculi O
muscle O
ipsilateral O
to O
the O
side O
of O
stimulation O
, O
a O
bilateral O
late O
response O
( O
ipsilateral O
R2 O
and O
contralateral O
Rc O
) O
and O
a O
third O
, O
R3 O
response O
, O
in O
the O
ipsilateral O
orbicularis O
oculi O
muscle O
. O

The O
prognosis O
of O
seven O
patients O
who O
received O
ABSCT O
was O
significantly O
better O
than O
that O
of O
13 O
patients O
who O
received O
conventional O
therapy O
alone O
. O

( O
1994 O
, O
Hum O
. O

The O
pigment O
intensity O
of O
both O
melanized O
colonies O
and O
appressoria O
of O
CAL O
transformants O
was O
weaker O
than O
that O
of O
the O
wild O
type O
. O

Malonate O
decarboxylation O
in O
Malonomonas O
rubra O
involves O
the O
formation O
of O
malonyl I-GENE
- I-GENE
S I-GENE
-[ I-GENE
acyl I-GENE
- I-GENE
carrier I-GENE
protein I-GENE
] I-GENE
from O
acetyl I-GENE
- I-GENE
S I-GENE
-[ I-GENE
acyl I-GENE
- I-GENE
carrier I-GENE
protein I-GENE
] I-GENE
and O
malonate O
, O
carboxyltransfer O
to O
a O
biotin I-GENE
protein I-GENE
and O
its O
decarboxylation O
that O
is O
coupled O
to O
delta O
mu O
Na O
+ O
generation O
. O

The O
Jem I-GENE
peptide O
sequence O
shows O
a O
' O
leucine O
- O
zipper O
' O
dimerisation O
motif O
with O
limited O
homology O
to O
Fos I-GENE
/ O
Jun I-GENE
and O
ATF I-GENE
/ O
CREB I-GENE
proteins O
and O
several O
putative O
phosphorylation O
sites O
. O

Here O
we O
report O
the O
cloning O
of O
the O
protein O
that O
binds O
to O
enhancer O
site O
III O
. O

Further O
support O
for O
a O
direct O
interaction O
of O
Tub4p I-GENE
, O
Spc98p I-GENE
and O
Spc97p I-GENE
comes O
from O
the O
toxicity O
of O
strong O
SPC97 I-GENE
overexpression O
which O
is O
suppressed O
by O
co O
- O
overexpression O
of O
TUB4 I-GENE
or O
SPC98 I-GENE
. O

Sequences O
needed O
for O
iron O
- O
regulated O
expression O
of O
sid1 I-GENE
were O
localized O
to O
a O
306 O
bp O
region O
mapping O
2 O
. O
3 O
and O
2 O
. O
6 O
kb O
upstream O
of O
the O
ATG O
. O

A O
genetic O
screen O
applied O
to O
mutants O
in O
the O
branch O
site O
region O
shows O
that O
all O
positions O
in O
the O
conserved O
TACTAAC O
sequence O
are O
important O
for O
intron O
recognition O
. O

Implication O
of O
PAF I-GENE
and O
acetylhydrolase I-GENE
( O
PAF I-GENE
- I-GENE
AH I-GENE
) O
activity O
in O
periodontal O
disease O
. O

Comparison O
of O
the O
p50 I-GENE
sequence I-GENE
to O
other O
cloned O
proteins O
revealed O
89 O
% O
homology O
with O
a O
glycosaminoglycan O
- O
binding O
protein O
and O
54 O
% O
homology O
with O
Drosophila I-GENE
cell I-GENE
cycle I-GENE
control I-GENE
protein I-GENE
( I-GENE
cdc I-GENE
) I-GENE
37 O
. O

A O
polypeptide O
encoded O
by O
the O
NTS O
16 O
open O
reading O
frame O
has O
sequence O
similarity O
to O
the O
catalytic O
domain O
of O
several O
receptor I-GENE
protein I-GENE
kinases I-GENE
from I-GENE
plants I-GENE
including O
the O
S I-GENE
- I-GENE
receptor I-GENE
kinases I-GENE
implicated O
in O
the O
rejection O
of O
self O
- O
pollen O
in O
Brassica O
species O
and O
the O
Pto I-GENE
gene I-GENE
product I-GENE
of I-GENE
tomato I-GENE
which O
confers O
resistance O
to O
a O
bacterial O
pathogen O
. O

The O
atp I-GENE
1 I-GENE
and O
atp I-GENE
2 I-GENE
types O
of O
cDNA O
sequences O
were O
the O
most O
redundant O
among O
the O
28 O
different O
isoperoxidases I-GENE
identified O
among O
about O
200 O
peroxidase I-GENE
encoding I-GENE
ESTs I-GENE
. O

Additional O
information O
including O
echocardiographic O
sequences O
, O
perioperative O
video O
sequences O
, O
x O
- O
ray O
analysis O
, O
angiograms O
, O
etc O
. O
is O
represented O
in O
the O
program O
. O

We O
report O
here O
that O
constitutively O
active O
Mek1 I-GENE
could O
activate O
p96h2bk I-GENE
in O
the O
absence O
of O
oncogenic I-GENE
Ras I-GENE
. O

In O
Schizosaccharomyces O
pombe O
, O
the O
activity O
of O
the O
M O
- O
phase O
- O
inducing O
Cdc2 I-GENE
/ O
Cdc13 I-GENE
cyclin O
- O
dependent O
kinase O
is O
inhibited O
by O
Wee1 I-GENE
and O
Mik1 I-GENE
tyrosine I-GENE
kinases I-GENE
, O
and O
activated O
by O
Cdc25 I-GENE
and O
Pyp3 I-GENE
tyrosine I-GENE
phosphatases I-GENE
. O

Glycemic O
response O
to O
malted O
, O
popped O
and O
roller O
dried O
wheat O
- O
legume O
based O
foods O
in O
normal O
subjects O
. O

4 O
. O
26 O
+/- O
1 O
. O
54 O
mmol O
/ O
l O
, O
P O
< O
0 O
. O
01 O
), O
and O
systolic O
BP O
responses O
to O
intravenous O
norepinephrine O
and O
angiotensin I-GENE
II I-GENE
were O
significantly O
higher O
on O
glibenclamide O
than O
on O
metformin O
( O
P O
< O
0 O
. O
02 O
and O
P O
< O
0 O
. O
05 O
, O
respectively O
). O

The O
sequencing O
of O
Stellate I-GENE
copies O
located O
along O
the O
discontinuous O
cluster O
revealed O
a O
complex O
pattern O
of O
diversification O
. O

The O
results O
indicate O
that O
DNA O
methylation O
, O
chromatin O
structure O
, O
and O
transactivation O
at O
an O
Sp1 I-GENE
site I-GENE
contribute O
to O
the O
highly O
restricted O
expression O
of O
this O
myelomonocytic O
lineage O
specific O
gene O
. O

In O
gel O
mobility O
shift O
assays O
, O
factors O
present O
in O
nuclear O
extracts O
derived O
from O
differentiated O
osteoblast O
bound O
to O
oligonucleotide O
probes O
containing O
the O
E O
- O
box O
1 O
and O
E O
- O
box O
2 O
elements O
. O

Laboratory O
exam O
: O
IDR O
of O
the O
tuberculin I-GENE
was O
high O
positive O
, O
chest O
radiography O
shows O
hilar O
bilateral O
calcifications O
, O
ORL O
exam O
shows O
a O
tumor O
at O
the O
foot O
of O
the O
epiglottis O
and O
anatomopathological O
exam O
shows O
low O
differentiated O
epidermoid O
carcinoma O
. O

Finally O
, O
we O
show O
that O
PhLP I-GENE
complexes O
, O
at O
least O
partially O
, O
with O
Gbetagamma I-GENE
in O
vivo O
. O

CTF1alpha I-GENE
, O
expressed O
in O
Escherichia O
coli O
, O
showed O
specific O
binding O
to O
the O
palindrome O
2 O
DNA O
fragment O
but O
not O
to O
palindrome O
1 O
or O
mutant O
palindrome O
2 O
DNA O
fragments O
, O
suggesting O
specific O
binding O
of O
CTF1alpha I-GENE
to O
palindrome O
2 O
. O

Cyclin I-GENE
G2 I-GENE
is O
highly O
expressed O
in O
the O
immune O
system O
where O
immunologic O
tolerance O
subjects O
self O
- O
reactive O
lymphocytes O
to O
negative O
selection O
and O
clonal O
deletion O
via O
apoptosis O
. O

A O
sterol O
- O
regulated O
protease O
initiates O
release O
of O
the O
NH2 O
- O
terminal O
segments O
of O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
SREBPs I-GENE
) O
from O
cell O
membranes O
, O
thereby O
allowing O
them O
to O
enter O
the O
nucleus O
and O
to O
stimulate O
transcription O
of O
genes O
involved O
in O
the O
uptake O
and O
synthesis O
of O
cholesterol O
and O
fatty O
acids O
. O

Thus O
, O
the O
P O
. O
aeruginosa O
orfX O
and O
vfr I-GENE
promoters I-GENE
are O
arranged O
in O
a O
back O
- O
to O
- O
back O
orientation O
rather O
than O
the O
face O
- O
to O
- O
face O
orientation O
of O
the O
dorf O
and O
crp I-GENE
promoters I-GENE
. O

Sequence O
analysis O
of O
cloned O
PCR O
products O
confirmed O
the O
presence O
of O
two O
different O
nifV I-GENE
- I-GENE
like I-GENE
DNA I-GENE
fragments I-GENE
, O
which O
were O
subsequently O
used O
as O
nifV I-GENE
- O
and O
leuA I-GENE
- I-GENE
specific I-GENE
probes I-GENE
, O
respectively O
, O
to O
clone O
XbaI I-GENE
fragments I-GENE
of O
2 O
. O
1 O
kbp O
( O
pOST4 O
) O
and O
2 O
. O
6 O
kbp O
( O
pOST2 O
). O

In O
contrast O
, O
the O
Anabaena O
strain O
7120 O
leuA I-GENE
gene O
did O
not O
complement O
the O
nifV I-GENE
mutation I-GENE
of O
R229I O
efficiently O
. O

( O
3 O
) O
This O
effect O
occurs O
without O
removing O
TRs I-GENE
from O
the O
TRE O
. O

Is O
leishmaniasis O
endemic O
on O
the O
island O
of O
Minorca O
( O
Spain O
)? O
A O
human O
visceral O
case O
after O
living O
13 O
years O
in O
Minorca O
. O

RESULTS O
: O
Surprisingly O
, O
PAF I-GENE
blockade O
increased O
mortality O
after O
trauma O
( O
5 O
of O
11 O
WEB O
- O
2086 O
animals O
versus O
1 O
of O
9 O
vehicle O
animals O
; O
p O
= O
0 O
. O
15 O
) O
and O
depressed O
cardiac O
index O
and O
O2 O
delivery O
at O
72 O
hours O
( O
p O
< O
0 O
. O
05 O
). O

This O
finding O
is O
the O
first O
example O
of O
utilization O
of O
noncomplementary O
dinucleotide O
primer O
by O
an O
RNA I-GENE
polymerase I-GENE
. O

Pure O
T1 O
and O
dual O
- O
T1 O
images O
were O
visually O
evaluated O
for O
image O
quality O
( O
IQ O
) O
on O
a O
five O
- O
point O
scale O
( O
0 O
= O
unacceptable O
to O
4 O
= O
excellent O
). O

In O
a O
model O
of O
the O
ternary O
complex O
, O
the O
segment O
of O
NFAT I-GENE
nearest O
AP I-GENE
- I-GENE
1 I-GENE
is O
the O
Rel I-GENE
insert O
region O
( O
RIR O
), O
a O
feature O
that O
is O
notable O
for O
its O
hypervariability O
in O
size O
and O
in O
sequence O
amongst O
members O
of O
the O
Rel I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

We O
thus O
conclude O
that O
the O
NFAT I-GENE
RIR I-GENE
plays O
an O
essential O
dual O
role O
in O
DNA O
recognition O
and O
cooperative O
binding O
to O
AP I-GENE
- I-GENE
1 I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

Thus O
, O
the O
association O
of O
PS1 I-GENE
fragments I-GENE
may O
be O
maintained O
during O
cycles O
of O
phosphorylation O
/ O
dephosphorylation O
of O
the O
PS1 I-GENE
CTF I-GENE
. O

This O
conformer O
features O
a O
Type O
I O
beta O
- O
turn O
and O
has O
extensive O
hydrophobic O
contacts O
with O
the O
FKBP12 I-GENE
binding O
surface O
. O

This O
protein O
can O
bind O
to O
a O
region O
of O
the O
promoter O
of O
an O
Arabidopsis I-GENE
light I-GENE
- I-GENE
harvesting I-GENE
chlorophyll I-GENE
a I-GENE
/ I-GENE
b I-GENE
protein I-GENE
gene I-GENE
, O
Lhcb1 I-GENE
* I-GENE
3 I-GENE
, O
which O
is O
necessary O
for O
its O
regulation O
by O
phytochrome I-GENE
. O

A O
patient O
of O
Group O
B O
had O
severe O
athetoid O
CP O
with O
spasticity O
, O
being O
unable O
to O
right O
his O
trunk O
and O
neck O
. O

Dystonic O
movement O
of O
the O
left O
upper O
limb O
in O
a O
case O
of O
the O
right O
pontine O
hemorrhage O

It O
has O
repeatedly O
been O
shown O
that O
HCMV O
IE1 I-GENE
/ O
IE2 I-GENE
can O
independently O
transactivate O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

TAR I-GENE
and O
Sp1 I-GENE
- O
independent O
transactivation O
of O
HIV I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
by O
the O
Tat I-GENE
protein I-GENE
in O
the O
presence O
of O
human O
cytomegalovirus O
IE1 I-GENE
/ O
IE2 I-GENE
. O

Respiratory O
chain O
enzyme O
activity O
was O
normal O
. O

Children O
' O
s O
temperament O
and O
maternal O
socialization O
at O
Time O
1 O
( O
n O
= O
103 O
, O
aged O
2 O
- O
3 O
years O
) O
were O
considered O
predictors O
of O
future O
conscience O
, O
assessed O
using O
new O
observational O
and O
narrative O
measures O
. O

Cellular I-GENE
Csk I-GENE
was O
associated O
with O
several O
phosphoproteins O
, O
some O
of O
which O
were O
interacting O
with O
the O
Csk I-GENE
SH2 I-GENE
domain I-GENE
. O

Thus O
, O
our O
studies O
suggest O
that O
pV O
- O
mediated O
activation O
of O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
activity O
is O
controlled O
by O
the O
nuclear O
translocation O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
transcription I-GENE
factor I-GENE
, O
which O
is O
mediated O
by O
IkappaBalpha I-GENE
serine O
phosphorylation O
and O
degradation O
, O
but O
also O
by O
a O
still O
undefined O
NF I-GENE
- I-GENE
kappaB I-GENE
- O
independent O
pathway O
. O

One O
P1 O
genomic O
clone O
and O
six O
subsequent O
plasmid O
subclones O
were O
isolated O
and O
analyzed O
for O
the O
exon O
- O
intron O
organization O
of O
the O
Ctpct I-GENE
gene I-GENE
. O

FN I-GENE
- O
stimulated O
c I-GENE
- I-GENE
Src I-GENE
PTK I-GENE
activity O
was O
enhanced O
by O
wild O
type O
FAK I-GENE
expression O
, O
whereas O
FN I-GENE
- O
stimulated O
activation O
of O
ERK2 I-GENE
was O
blocked O
by O
expression O
of O
the O
c I-GENE
- I-GENE
Src I-GENE
binding I-GENE
site I-GENE
Phe I-GENE
- I-GENE
397 I-GENE
mutant I-GENE
of O
FAK I-GENE
. O

A O
promising O
new O
cement O
, O
4 O
- O
META O
/ O
MMA O
- O
TBB O
opaque O
resin O
, O
has O
shown O
remarkable O
adhesive O
properties O
as O
a O
bone O
cement O
in O
vivo O
. O

Congruent O
with O
empirical O
predictions O
, O
the O
most O
homesick O
children O
perceived O
low O
control O
over O
homesickness O
and O
separation O
, O
and O
coped O
by O
relinquishing O
control O
. O

Each O
sample O
was O
analysed O
as O
soon O
as O
possible O
, O
and O
repeated O
15 O
, O
30 O
, O
60 O
and O
120 O
min O
after O
sampling O
. O

We O
also O
review O
the O
role O
of O
grains O
in O
the O
formation O
of O
complex O
molecules O
in O
interstellar O
molecular O
clouds O
. O

Like O
the O
elicitors O
of O
the O
hypersensitive O
reaction O
( O
HR O
) O
produced O
by O
E O
. O
chrysanthemi O
( O
HarpinEch O
) O
and O
E O
. O
amylovora O
( O
HarpinEa O
), O
the O
deduced O
36 O
- O
kDa O
protein O
does O
not O
possess O
a O
typical O
signal O
sequence O
, O
but O
it O
contains O
a O
putative O
membrane O
- O
spanning O
domain O
. O

Molecular O
characterization O
and O
expression O
of O
the O
Erwinia I-GENE
carotovora I-GENE
hrpNEcc I-GENE
gene I-GENE
, O
which O
encodes O
an O
elicitor O
of O
the O
hypersensitive O
reaction O
. O

The O
mRNA O
from O
this O
gene O
, O
termed O
HES1 I-GENE
, O
is O
ubiquitously O
expressed O
, O
but O
strongly O
so O
in O
heart O
and O
skeletal O
muscle O
. O

Anesthesia O
was O
maintained O
with O
isoflurane O
( O
ISO O
)/ O
N2O O
/ O
O2 O
inhalation O
. O

They O
observed O
depressed O
protein I-GENE
C I-GENE
activity O
that O
significantly O
( O
p O
< O
0 O
. O
005 O
) O
increased O
and O
became O
normal O
immediately O
after O
hemodialysis O
while O
factor I-GENE
X I-GENE
and O
factor I-GENE
VII I-GENE
increased O
( O
p O
< O
0 O
. O
01 O
; O
p O
< O
0 O
. O
05 O
) O
despite O
heparinization O
together O
with O
amount O
of O
serum O
lipoprotein O
( O
a O
). O

We O
present O
a O
case O
of O
type O
II O
hyperbetalipoproteinemia O
in O
a O
patient O
whose O
diagnosis O
had O
been O
previously O
unrecognized O
, O
and O
who O
had O
previously O
been O
misdiagnosed O
with O
rheumatoid O
arthritis O
and O
later O
gout O
. O

These O
data O
provide O
evidence O
that O
the O
2 I-GENE
. I-GENE
0 I-GENE
- I-GENE
kb I-GENE
LAT I-GENE
is O
an O
intron O
of O
the O
mLAT I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
with O
a O
unique O
branch O
point O
. O

The O
altered O
amino O
acid O
residues O
of O
the O
seven O
mutant I-GENE
9ORF1 I-GENE
polypeptides I-GENE
clustered O
within O
three O
separate O
regions O
referred O
to O
as O
region O
I O
( O
residues O
34 O
to O
41 O
), O
region O
II O
( O
residues O
89 O
to O
91 O
), O
and O
C O
- O
terminal O
region O
III O
( O
residues O
122 O
to O
125 O
). O

Rep I-GENE
- O
Rep I-GENE
protein O
interaction O
was O
confirmed O
in O
vitro O
through O
coimmunoprecipitation O
experiments O
with O
a O
bacterially O
expressed O
maltose I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- O
Rep78 I-GENE
fusion O
protein O
in O
combination O
with O
[ O
35S O
] O
methionine O
- O
labeled O
Rep78 I-GENE
synthesized O
in O
a O
coupled O
in O
vitro O
transcription O
- O
translation O
system O
. O

The O
C O
- O
LIP O
also O
was O
compared O
with O
transcather O
arterial O
embolization O
( O
TAE O
; O
C O
- O
LIP O
followed O
by O
gelatin O
sponge O
) O
and O
percutaneous O
ethanol O
injection O
therapy O
( O
PEIT O
). O

Fourteen O
patients O
with O
New O
York O
Heart O
Association O
class O
II O
congestive O
heart O
failure O
were O
enrolled O
in O
a O
double O
- O
blind O
, O
cross O
- O
over O
study O
. O

The O
main O
advantages O
of O
Multi O
- O
MUP O
analysis O
are O
: O
( O
1 O
) O
quick O
acquisition O
of O
many O
MUPs O
; O
( O
2 O
) O
simultaneous O
collection O
of O
several O
MUPs O
at O
one O
recording O
site O
; O
( O
3 O
) O
possibility O
to O
analyze O
not O
only O
low O
threshold O
MUPs O
; O
( O
4 O
) O
less O
bias O
in O
the O
selection O
of O
MUPs O
and O
( O
5 O
) O
the O
reproducibility O
of O
the O
results O
that O
allow O
the O
same O
reference O
values O
to O
be O
used O
in O
different O
laboratories O
. O

We O
also O
demonstrate O
that O
preformed O
triplexes O
are O
quite O
stable O
when O
precipitated O
with O
ethanol O
and O
resuspended O
in O
water O
. O

Transfection O
experiments O
using O
preformed O
triplexes O
with O
a O
reporter O
plasmid O
containing O
the O
collagen I-GENE
promoter I-GENE
sequence I-GENE
showed O
significant O
inhibition O
of O
transcription O
when O
compared O
with O
a O
control O
phosphorothioate O
ODN O
. O

Thus O
, O
an O
increase O
in O
plasma I-GENE
TBG I-GENE
and O
a O
shift O
from O
adrenal O
androgen O
and O
mineralocorticoid O
steroid O
secretion O
towards O
cortisol O
secretion O
may O
be O
endocrine O
markers O
for O
progression O
of O
the O
disease O
in O
patients O
with O
HIV O
- O
infection O
. O

In O
several O
studies O
the O
RDFS O
has O
shown O
evidence O
of O
reliability O
and O
validity O
. O

Latanoprost O
produces O
an O
additional O
reduction O
of O
intraocular O
pressure O
( O
IOP O
) O
when O
used O
in O
combination O
with O
timolol O
, O
pilocarpine O
, O
acetazolamide O
and O
dipivefrin O
. O

These O
results O
suggest O
that O
dietary O
safflower O
phospholipids O
may O
be O
a O
valuable O
ingredient O
to O
layers O
for O
reducing O
liver O
triglycerides O
and O
serum O
cholesterol O
without O
any O
adverse O
effects O
. O

Using O
various O
techniques O
, O
we O
have O
undertaken O
a O
systematic O
analysis O
of O
the O
natural O
TATA O
- O
less O
human I-GENE
DNA I-GENE
polymerase I-GENE
beta I-GENE
( O
beta I-GENE
- I-GENE
pol I-GENE
) O
gene O
promoter O
. O

Saturable O
spermidine O
transport O
in O
stk2 I-GENE
:: O
lacZ I-GENE
mutants I-GENE
had O
an O
approximately O
fivefold O
- O
lower O
affinity O
and O
twofold O
- O
lower O
Vmax O
than O
in O
the O
parental O
strain O
. O

Transient O
overexpression O
of O
c I-GENE
- I-GENE
Jun I-GENE
induced O
tenascin I-GENE
- I-GENE
C I-GENE
expression O
in O
primary O
REF O
and O
in O
FR3T3 O
, O
an O
established O
fibroblast O
cell O
line O
. O

Inhibition O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
cyclic O
AMP O
agonists O
causes O
apoptosis O
of O
v I-GENE
- I-GENE
abl I-GENE
- O
transformed O
cells O
. O

Previous O
studies O
have O
indicated O
that O
a O
hamster O
cell O
line O
( O
ts13 O
) O
with O
a O
point O
mutation O
in O
the O
TAF I-GENE
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
/ O
CCG1 I-GENE
( O
TAF I-GENE
( I-GENE
II I-GENE
) I-GENE
250 I-GENE
) O
gene O
shows O
temperature O
- O
sensitive O
expression O
of O
a O
subset O
of O
genes O
and O
arrests O
in O
late O
G1 O
at O
39 O
. O
5 O
degrees O
C O
. O

We O
show O
here O
that O
the O
protein O
kinase O
MEKK1 I-GENE
can O
induce O
reporter O
gene O
expression O
from O
the O
atrial I-GENE
natriuretic I-GENE
factor I-GENE
( O
ANF I-GENE
) O
promoter O
, O
a O
genetic O
marker O
that O
is O
activated O
during O
in O
vivo O
hypertrophy O
. O

Overexpression O
of O
EFG1 I-GENE
in O
C O
. O
albicans O
leads O
to O
enhanced O
filamentous O
growth O
in O
the O
form O
of O
extended O
pseudohyphae O
in O
liquid O
and O
on O
solid O
media O
. O

Selected O
parameters O
: O
heart O
rate O
( O
HR O
), O
arterial O
blood O
pressure O
( O
ABP O
) O
and O
arterial O
O2 O
saturation O
( O
SaO2 O
) O
monitored O
by O
pulsoximetry O
were O
measured O
during O
the O
procedure O
. O

To O
determine O
if O
signing O
, O
when O
established O
, O
would O
compete O
with O
SIB O
when O
both O
were O
reinforced O
, O
extinction O
was O
then O
withdrawn O
. O

The O
husband O
in O
one O
of O
the O
married O
couples O
was O
treated O
for O
hepatitis O
of O
unidentified O
etiology O
in O
an O
Infectology O
Department O
four O
years O
ago O
. O

Both O
quantitative O
and O
qualitative O
analysis O
of O
individual O
cytoarchitectonic O
peculiarities O
of O
Meynart O
' O
s O
nucleus O
as O
well O
as O
of O
external O
part O
of O
dorsomedial O
nucleus O
of O
thalamus O
was O
performed O
in O
mentally O
normal O
individuals O
. O

We O
have O
tested O
this O
proposal O
by O
carrying O
out O
circular O
dichroism O
( O
CD O
) O
and O
NMR O
experiments O
on O
the O
Skn I-GENE
domain I-GENE
and O
five O
truncated O
proteins O
. O

Positional O
cloning O
has O
already O
produced O
the O
sequences O
of O
more O
than O
70 O
human O
genes O
associated O
with O
specific O
diseases O
. O

Genes O
for O
ocs I-GENE
element I-GENE
binding I-GENE
factors I-GENE
( O
OBFs I-GENE
), O
belonging O
to O
a O
specific O
class O
of O
basic I-GENE
- I-GENE
region I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bZIP I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
, O
have O
been O
isolated O
in O
a O
number O
of O
plants O
. O

The O
30 O
- O
day O
mortality O
in O
the O
CPB O
group O
and O
the O
non O
- O
CPB O
group O
were O
20 O
% O
and O
4 O
. O
6 O
%, O
respectively O
which O
was O
not O
statistically O
significant O
( O
p O
= O
0 O
. O
06 O
). O

As O
opposed O
to O
in O
vitro O
co O
- O
precipitation O
studies O
, O
the O
yeast O
two O
- O
hybrid O
screen O
reveals O
in O
vivo O
protein O
- O
protein O
interactions O
. O

This O
association O
appears O
to O
be O
mediated O
by O
Src I-GENE
- O
SH2 I-GENE
domain O
, O
because O
PECAM I-GENE
- I-GENE
1 I-GENE
can O
be O
precipitated O
by O
a O
GST I-GENE
- O
Src I-GENE
- O
SH2 I-GENE
affinity O
matrix O
. O

MKK3 I-GENE
autophosphorylation O
and O
activation O
of O
p38 I-GENE
was O
also O
observed O
following O
coexpression O
of O
MKK3 I-GENE
with O
MEKK3 I-GENE
, O
but O
not O
with O
MEKK2 I-GENE
. O

An O
alternatively O
spliced O
MAdCAM I-GENE
- I-GENE
1 I-GENE
variant O
was O
identified O
that O
lacks O
exon O
4 O
encoding O
the O
mucin I-GENE
domain O
, O
and O
may O
mediate O
leukocyte O
adhesion O
to O
LPAM I-GENE
- I-GENE
1 I-GENE
without O
adhesion O
to O
the O
alternate O
receptor O
, O
L I-GENE
- I-GENE
selectin I-GENE
. O

In O
summary O
, O
the O
data O
establish O
that O
the O
previously O
reported O
human I-GENE
MAdCAM I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
does O
indeed O
encode O
the O
human O
homologue O
of O
mouse I-GENE
MAdCAM I-GENE
- I-GENE
1 I-GENE
, O
despite O
gross O
dissimilarities O
in O
the O
MAdCAM I-GENE
- I-GENE
1 I-GENE
C O
- O
terminal O
structures O
. O

We O
have O
used O
a O
site O
- O
directed O
mutagenesis O
approach O
to O
examine O
how O
the O
Xaa O
and O
hydroxy O
( O
Ser O
/ O
Thr O
) O
amino O
acid O
residues O
in O
sequons O
influence O
core O
- O
glycosylation O
efficiency O
. O

MATERIAL O
AND O
METHODS O
: O
The O
authors O
analyzed O
41 O
persons O
formerly O
submitted O
to O
surgery O
( O
after O
8 O
years O
and O
4 O
months O
, O
as O
a O
mean O
), O
31 O
to O
highly O
selective O
vagotomy O
, O
and O
10 O
to O
truncal O
or O
selective O
vagotomy O
plus O
gastroduodenal O
drainage O
. O

This O
region O
does O
not O
contain O
an O
identifiable O
TATA O
element O
, O
indicating O
that O
transcription O
of O
the O
glutaminase I-GENE
gene I-GENE
is O
driven O
by O
a O
TATA O
- O
less O
promoter O
. O

SRE O
activity O
is O
dependent O
upon O
the O
activation O
by O
phosphorylation O
of O
a O
ternary O
complex O
factor O
; O
included O
among O
the O
ternary O
complex O
factors O
is O
Elk I-GENE
- I-GENE
1 I-GENE
. O

Serum I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
, O
bone O
mass O
measurements O
, O
dual O
energy O
x O
- O
ray O
absortiometric O
analysis O
of O
mineral O
density O
, O
and O
mechanical O
testing O
values O
in O
vertebrae O
and O
femora O
of O
the O
- O
D O
Sal O
animals O
did O
not O
significantly O
differ O
from O
those O
in O
+ O
D O
Sal O
animals O
. O

The O
monkey I-GENE
LHR I-GENE
cDNA I-GENE
displayed O
83 O
- O
94 O
% O
overall O
sequence O
homology O
with O
the O
other O
mammalian I-GENE
LHR I-GENE
cDNAs I-GENE
. O

In O
conclusion O
, O
marmoset I-GENE
monkey I-GENE
LHR I-GENE
seems O
to O
lack O
the O
sequence O
corresponding O
to O
exon O
10 O
of O
the O
LHR I-GENE
gene I-GENE
in O
other O
mammalian O
species O
. O

In O
unc I-GENE
- I-GENE
4 I-GENE
mutants I-GENE
, O
VA O
motor O
neurons O
assume O
the O
pattern O
of O
synaptic O
input O
normally O
reserved O
for O
their O
lineal O
sister O
cells O
, O
the O
VB O
motor O
neurons O
; O
the O
loss O
of O
normal O
input O
to O
the O
VAs O
produces O
a O
distinctive O
backward O
movement O
defect O
. O

Intracavitary O
irradiation O
was O
carried O
out O
with O
a O
microSelectron O
HDR O
afterloading O
device O
and O
usually O
22 O
. O
5 O
Gy O
was O
given O
in O
three O
fractions O
repeated O
weekly O
. O

No O
patient O
in O
group O
2 O
developed O
HAT O
( O
P O
= O
0 O
. O
006 O
versus O
group O
1 O
). O

Sequence O
comparison O
of O
the O
0 O
. O
38 O
kb O
promoter O
sequence O
with O
the O
promoters O
of O
the O
Sm I-GENE
- I-GENE
E I-GENE
gene O
and O
U1 I-GENE
snRNA I-GENE
genes I-GENE
revealed O
several O
homologous O
motifs O
, O
suggesting O
that O
genes O
encoding O
the O
snRNP O
components O
may O
be O
coordinately O
regulated O
. O

METHODS O
: O
The O
responses O
of O
a O
31 O
- O
year O
- O
old O
woman O
with O
complex O
regional O
pain O
syndrome O
type O
I O
( O
reflex O
sympathetic O
dystrophy O
) O
to O
a O
thermal O
grill O
were O
evaluated O
before O
and O
after O
stellate O
ganglion O
block O
. O

More O
recently O
, O
however O
, O
a O
number O
of O
developments O
such O
as O
the O
successful O
use O
of O
the O
inhaled O
steroid O
budesonide O
and O
oral O
dexamethasone O
have O
reinforced O
the O
argument O
for O
using O
steroids O
. O

A O
xylE I-GENE
transcriptional I-GENE
fusion I-GENE
to O
the O
putative O
mxbD I-GENE
promoter I-GENE
showed O
low O
- O
level O
expression O
in O
wild O
- O
type O
cells O
grown O
on O
one O
- O
carbon O
( O
C1 O
) O
compounds O
and O
no O
detectable O
expression O
in O
cells O
grown O
on O
succinate O
. O

In O
AcMNPV O
- O
infected O
Sf9 O
cells O
, O
late O
transcription O
initiation O
is O
detected O
from O
only O
two O
upstream O
TAAG O
sites O
and O
not O
from O
three O
downstream O
TAAG O
sites O
. O

Mutation O
of O
nucleotides O
adjacent O
to O
the O
AP I-GENE
- I-GENE
1 I-GENE
cis I-GENE
- I-GENE
response I-GENE
elements I-GENE
had O
no O
effect O
on O
trans O
- O
activation O
. O

The O
close O
proximity O
of O
the O
two O
neuropeptide I-GENE
Y I-GENE
receptor I-GENE
genes I-GENE
suggests O
that O
they O
have O
evolved O
from O
a O
gene O
duplication O
event O
with O
the O
small O
intron O
interrupting O
the O
coding O
sequence O
of O
the O
y1 I-GENE
gene I-GENE
being O
converted O
into O
a O
functional O
sequence O
within O
the O
y5 I-GENE
gene I-GENE
, O
while O
the O
reverse O
complementary O
sequence O
was O
utilized O
as O
an O
alternatively O
spliced O
5 O
' O
exon O
for O
the O
y1 I-GENE
gene I-GENE
. O

The O
mammalian I-GENE
phosphoinositide I-GENE
3 I-GENE
- I-GENE
kinases I-GENE
( O
PI3Ks I-GENE
) O
p110alpha I-GENE
, I-GENE
beta I-GENE
, I-GENE
and I-GENE
delta I-GENE
form O
heterodimers O
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domain O
- O
containing O
adaptors O
such O
as O
p85alpha I-GENE
or O
p55 I-GENE
( O
PIK I-GENE
). O

In O
the O
studies O
reported O
here O
, O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
gp130 I-GENE
gene I-GENE
was O
isolated O
and O
the O
transcription O
initiation O
sites O
were O
mapped O
. O

Localization O
of O
the O
cytokine O
response O
element O
by O
5 O
'- O
deletion O
analysis O
and O
site O
- O
directed O
mutagenesis O
revealed O
a O
cis O
- O
acting O
binding O
site O
for O
activated O
STAT I-GENE
complexes O
. O

Insulin I-GENE
regulation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
), O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
and O
casein I-GENE
kinase I-GENE
in O
the O
cell O
nucleus O
: O
a O
possible O
role O
in O
the O
regulation O
of O
gene O
expression O
. O

Sequencing O
of O
the O
three O
pag I-GENE
- I-GENE
3 I-GENE
alleles I-GENE
showed O
that O
two O
apparent O
null O
alleles O
encode O
a O
nonsense O
mutation O
before O
the O
zinc O
fingers O
and O
a O
missense O
mutation O
in O
the O
fourth O
zinc O
finger O
that O
changes O
a O
coordinating O
histidine O
to O
a O
tyrosine O
. O

Pax I-GENE
- I-GENE
3 I-GENE
is O
a O
paired I-GENE
- I-GENE
type I-GENE
homeobox I-GENE
gene I-GENE
that O
is O
specifically O
expressed O
in O
the O
dorsal O
and O
posterior O
neural O
tube O
. O

Instead O
, O
they O
contained O
dendritic O
cells O
that O
express O
melanogenic O
marker O
proteins O
such O
as O
tyrosinase I-GENE
and O
tyrosinase I-GENE
- I-GENE
related I-GENE
protein I-GENE
1 I-GENE
. O

These O
mutations O
create O
stop O
codons O
in O
exon O
7 O
and O
8 O
, O
respectively O
, O
and O
probably O
result O
in O
truncated O
proteins O
lacking O
HLH O
- O
Zip O
or O
Zip O
structure O
. O

Here O
, O
a O
case O
of O
Sjogren O
' O
s O
syndrome O
is O
presented O
that O
was O
initially O
diagnosed O
because O
of O
dental O
complaints O
, O
and O
long O
- O
term O
treatment O
of O
Sjogren O
' O
s O
patients O
is O
discussed O
. O

Cloning O
and O
characterization O
of O
a O
cDNA O
encoding O
a O
bacteriophage I-GENE
- I-GENE
type I-GENE
RNA I-GENE
polymerase I-GENE
from O
the O
higher O
plant O
Chenopodium O
album O
. O

Similarly O
, O
overexpression O
of O
increasing O
concentration O
of O
COUP I-GENE
- I-GENE
TFI I-GENE
, O
but O
not O
COUP I-GENE
- I-GENE
TFI I-GENE
delta35 I-GENE
, O
can O
squelch O
the O
silencing O
activity O
of O
the O
unliganded O
TRbeta I-GENE
. O

These O
six O
amino O
acids O
are O
part O
of O
an O
amphipathic O
helix O
that O
is O
highly O
conserved O
among O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
and O
contains O
the O
core O
domain O
of O
the O
ligand O
- O
dependent O
transactivation O
function O
, O
AF O
- O
2 O
. O

Surprisingly O
, O
the O
RXR I-GENE
- O
specific O
ligand O
9 O
- O
cis O
- O
retinoic O
acid O
induced O
binding O
of O
SRC I-GENE
- I-GENE
1 I-GENE
to O
the O
RXR I-GENE
component I-GENE
of O
the O
TRE O
- O
bound O
heterodimer O
. O

In O
ciliates O
, O
both O
mechanisms O
are O
readily O
observed O
. O

Based O
on O
the O
occurrence O
of O
several O
transcription O
signals O
in O
the O
Thermus I-GENE
pyr I-GENE
promoter I-GENE
region I-GENE
and O
strong O
amino O
acid O
sequence O
identities O
( O
about O
60 O
%) O
between O
Thermus I-GENE
PyrR I-GENE
and O
the O
PyrR I-GENE
attenuation I-GENE
proteins I-GENE
of O
two O
Bacillus O
sp O
., O
we O
propose O
a O
regulatory O
mechanism O
involving O
transcriptional O
attenuation O
to O
control O
pyr I-GENE
gene I-GENE
expression O
in O
Thermus O
. O

Diver O
respiratory O
responses O
to O
a O
tunable O
closed O
- O
circuit O
breathing O
apparatus O
. O

Measurement O
of O
the O
time O
constant O
of O
VO2 O
and O
oxygen O
pulse O
during O
constant O
work O
rate O
exercise O
are O
useful O
for O
the O
objective O
evaluation O
of O
the O
training O
effect O
of O
patients O
with O
COPD O
. O

Characterization O
of O
CR1 I-GENE
repeat O
random O
PCR O
markers O
for O
mapping O
the O
chicken O
genome O
. O

A O
reversed O
- O
phase O
high O
- O
performance O
liquid O
chromatographic O
( O
HPLC O
) O
method O
for O
the O
determination O
of O
cocaine O
metabolites O
produced O
in O
vitro O
by O
serum I-GENE
and I-GENE
liver I-GENE
esterases I-GENE
is O
described O
. O

Mutational O
studies O
provide O
evidence O
to O
this O
end O
and O
indicate O
that O
the O
side O
chains O
of O
subdomain O
4 O
. O
2 O
make O
specific O
contacts O
with O
the O
nucleotides O
at O
- O
35 O
. O

It O
is O
concluded O
that O
fludarabine O
is O
a O
highly O
useful O
agent O
in O
CLL O
. O

Three O
different O
techniques O
of O
EA O
analysis O
were O
used O
in O
the O
study O
: O
1 O
) O
fast O
Fourier O
transformation O
( O
FFT O
) O
of O
EA O
in O
a O
broad O
band O
, O
2 O
) O
developed O
by O
us O
alternative O
method O
of O
non O
- O
harmonic O
expansion O
of O
the O
EEG O
curves O
taking O
into O
account O
their O
shape O
, O
3 O
) O
factor O
analysis O
of O
the O
EA O
spectral O
densities O
. O

Concomitantly O
, O
p34CDC2 I-GENE
histone I-GENE
H1 I-GENE
kinase O
activity O
increases O
in O
the O
former O
, O
but O
not O
in O
the O
latter O
cell O
lines O
, O
hence O
suggesting O
a O
role O
for O
this O
protein O
in O
radiation O
- O
induced O
cell O
death O
. O

Using O
PRL I-GENE
- I-GENE
R I-GENE
tagged O
both O
in O
the O
N O
- O
terminal O
or O
C O
- O
terminal O
regions O
of O
the O
mature O
receptor O
excludes O
the O
possibility O
of O
a O
cleaved O
fragment O
which O
could O
have O
been O
subsequently O
imported O
into O
the O
nucleus O
. O

Thus O
, O
the O
B O
- O
S O
mutant O
does O
not O
mimic O
efficiently O
the O
chloroplastic I-GENE
GAPDHs I-GENE
, O
and O
long O
- O
range O
and O
/ O
or O
second O
- O
layer O
effects O
, O
not O
easily O
predictable O
from O
visual O
inspection O
of O
three O
- O
dimensional O
structures O
, O
need O
to O
be O
taken O
into O
account O
for O
designing O
a O
true O
" O
chloroplastic O
- O
like O
" O
mutant O
of O
cytosolic I-GENE
GAPDH I-GENE
. O

Transcription O
of O
these O
genes O
was O
also O
elevated O
in O
gut O
and O
lung O
during O
freezing O
, O
but O
mRNA O
levels O
in O
these O
tissues O
were O
lower O
than O
in O
liver O
. O

Computer O
software O
assisted O
ordering O
( O
CSAO O
) O
was O
developed O
to O
integrate O
PN O
Ca O
: O
P O
solubility O
with O
clinical O
data O
to O
improve O
parenteral O
Ca O
and O
P O
administration O
. O

A O
similar O
chimera O
was O
assembled O
from O
the O
two O
halves O
of O
the O
molecule O
expressed O
separately O
in O
different O
bacteria O
and O
refolded O
together O
. O

The O
conditions O
for O
obtaining O
titanium O
dioxide O
from O
the O
substrates O
titanium O
tetrachloride O
and O
oxygen O
and O
applying O
this O
to O
a O
surgical O
stainless O
steel O
of O
the O
type O
316L O
by O
the O
plasma O
assisted O
chemical O
vapour O
deposition O
method O
have O
been O
determined O
. O

All O
six O
genes O
were O
cloned O
and O
characterised O
. O

We O
analysed O
two O
regions O
involved O
in O
preS2 I-GENE
/ O
S I-GENE
gene I-GENE
transcription O
of O
the O
HBV O
adw O
subtype O
: O
the O
diverged O
TATA O
box O
and O
a O
putative O
initiator O
element O
. O

Indeed O
the O
predicted O
folding O
of O
the O
5 O
' O
and O
3 O
'- O
untranslated O
regions O
revealed O
patterns O
of O
stem O
and O
loop O
structures O
conserved O
for O
all O
tick O
- O
borne O
flaviviruses O
suggesting O
a O
purifying O
selection O
for O
preservation O
of O
essential O
RNA O
secondary O
structures O
which O
could O
be O
involved O
in O
translational O
control O
and O
replication O
. O

EGF I-GENE
acts O
primarily O
by O
means O
of O
transactivation O
domain O
AF O
- O
1 O
, O
whereas O
cAMP O
acts O
via O
transactivation O
domain O
AF O
- O
2 O
of O
the O
ER I-GENE
. O

To O
determine O
which O
region O
of O
SulA I-GENE
is O
essential O
for O
the O
inhibition O
of O
cell O
division O
, O
we O
constructed O
a O
series O
of O
N O
- O
terminal O
and O
C O
- O
terminal O
deletions O
of O
SulA I-GENE
and O
a O
series O
of O
alanine O
substitution O
mutants O
. O

We O
have O
inactivated O
Krox I-GENE
- I-GENE
20 I-GENE
by O
homologous O
recombination O
in O
ES O
cells O
and O
demonstrated O
that O
the O
mutation O
leads O
to O
the O
deletion O
of O
r3 O
and O
r5 O
. O

Recently O
we O
have O
performed O
a O
detailed O
analysis O
of O
specific O
neuronal O
populations O
affected O
by O
the O
mutation O
which O
shed O
new O
light O
on O
the O
role O
of O
Krox I-GENE
- I-GENE
20 I-GENE
in O
the O
segmentation O
and O
on O
the O
physiological O
consequences O
of O
its O
inactivation O
. O

The O
most O
important O
one O
among O
them O
is O
Cyclosporin O
A O
, O
which O
is O
a O
selective O
immunosuppressive O
drug O
. O

Consistent O
with O
its O
role O
in O
p53 I-GENE
ubiquitination O
, O
mE6 I-GENE
- I-GENE
AP I-GENE
was O
found O
both O
in O
the O
nucleus O
and O
cytosol O
, O
while O
Nedd I-GENE
- I-GENE
4 I-GENE
was O
found O
only O
in O
the O
cytosol O
. O

SPP I-GENE
also O
induced O
transient O
tyrosine O
phosphorylation O
of O
focal I-GENE
adhesion I-GENE
kinase I-GENE
( O
p125 I-GENE
( O
FAK I-GENE
)), O
a O
cytosolic I-GENE
tyrosine I-GENE
kinase I-GENE
that O
localizes O
in O
focal O
adhesions O
, O
and O
of O
the O
cytoskeleton I-GENE
- I-GENE
associated I-GENE
protein I-GENE
paxillin I-GENE
. O

Using O
a O
conditional O
- O
lethal O
mutant O
allele O
of O
SUP45 I-GENE
( O
sup45 I-GENE
- I-GENE
2 I-GENE
) O
and O
a O
combination O
of O
in O
vivo O
and O
in O
vitro O
approaches O
, O
we O
demonstrate O
that O
the O
product O
of O
the O
SUP45 I-GENE
gene I-GENE
( O
Sup45p I-GENE
or O
eRF1 I-GENE
) O
is O
a O
factor O
required O
for O
translation O
termination O
in O
yeast O
. O

Evaluation O
of O
myocardial O
perfusion O
by O
99mTc O
- O
tetrofosmin O
SPECT O
before O
and O
after O
emergent O
percutaneous O
transluminal O
coronary O
angioplasty O
for O
acute O
myocardial O
infarction O

A O
neonatal O
alloimmune O
thrombocytopenia O
with O
an O
HPA I-GENE
- I-GENE
3a I-GENE
( O
Baka O
) O
incompatibility O
was O
confirmed O
. O

She O
was O
able O
to O
stand O
unaided O
by O
3 O
years O
of O
age O
with O
then O
progressive O
worsening O
of O
motor O
abilities O
. O

Merosin I-GENE
positive O
congenital O
muscular O
dystrophy O
with O
mental O
deficiency O
, O
epilepsy O
and O
MRI O
changes O
in O
the O
cerebral O
white O
matter O
. O

Most O
eukaryotic O
mRNAs O
are O
translated O
by O
a O
" O
scanning O
ribosome O
" O
mechanism O
. O

Comparison O
of O
Tc O
- O
99m O
sestamibi O
perfusion O
imaging O
and O
echocardiography O
using O
an O
arbutamine O
infusion O
for O
the O
detection O
of O
coronary O
artery O
disease O
. O

Also O
, O
transient O
overexpression O
of O
this O
protein O
in O
C2C12 O
cells O
reduced O
the O
transcription O
of O
a O
CAT I-GENE
- O
reporter O
regulated O
by O
an O
E12 I-GENE
/ O
MyoD I-GENE
driven O
enhancer O
. O

Five O
of O
these O
have O
ocular O
or O
oculocutaneous O
albinism O
. O

Comprising O
a O
126 O
- O
nucleotide O
5 O
' O
untranscribed O
genomic O
sequence O
and O
a O
466 O
- O
nucleotide O
5 O
' O
noncoding O
cDNA O
sequence O
, O
the O
592 O
- O
nucleotide O
5 O
' O
CpG O
island O
lacked O
TATA O
and O
CAAT O
boxes O
but O
displayed O
a O
high O
G O
+ O
C O
content O
, O
was O
enriched O
for O
CpG O
dinucleotides O
, O
and O
contained O
a O
potential O
Sp1 I-GENE
- I-GENE
binding I-GENE
site I-GENE
, O
i O
. O
e O
., O
features O
compatible O
with O
a O
housekeeping O
gene O
. O

SSeCKS I-GENE
( O
pronounced O
essex O
) O
encodes O
a O
major O
protein I-GENE
kinase I-GENE
C I-GENE
substrate O
, O
the O
expression O
of O
which O
is O
down O
- O
regulated O
in O
src I-GENE
- O
and O
ras I-GENE
- O
transformed O
rodent O
fibroblasts O
but O
not O
in O
raf O
- O
transformed O
rodent O
fibroblasts O
( O
X O
. O

Type O
I O
position O
- O
vestibular O
- O
pause O
( O
PVP O
I O
) O
and O
vestibular O
- O
only O
( O
V O
I O
) O
neurons O
, O
as O
well O
as O
a O
smaller O
number O
of O
other O
type O
I O
and O
type O
II O
eye O
- O
plus O
- O
vestibular O
neurons O
were O
studied O
. O

The O
1 O
. O
1 O
- O
and O
1 O
. O
3 O
- O
kb O
mRNA O
species O
were O
found O
only O
in O
the O
heart O
, O
and O
the O
2 O
. O
6 O
- O
kb O
species O
was O
found O
in O
the O
heart O
, O
kidney O
and O
brain O
, O
but O
not O
in O
skeletal O
muscle O
or O
liver O
. O

Taurine O
deficiency O
significantly O
depressed O
the O
amplitude O
of O
OP1 O
and O
OP4 O
. O

We O
have O
found O
that O
mcs4 I-GENE
- O
cells O
are O
defective O
at O
activation O
of O
Spc1 I-GENE
in O
response O
to O
various O
forms O
of O
stress O
. O

The O
extended O
rat I-GENE
SP I-GENE
- I-GENE
A I-GENE
isoforms I-GENE
were O
enriched O
in O
the O
more O
fully O
glycosylated O
and O
multimeric O
SP I-GENE
- I-GENE
A I-GENE
species O
separated O
on O
SDS O
- O
PAGE O
gels O
. O

Alternative O
splicing O
of O
CDC25B I-GENE
may O
therefore O
contribute O
to O
the O
control O
of O
cell O
proliferation O
. O

This O
investigation O
was O
undertaken O
to O
determine O
whether O
consuming O
several O
small O
feedings O
of O
preexercise O
carbohydrate O
( O
CHO O
), O
rather O
than O
a O
single O
bolus O
, O
would O
affect O
blood O
glucose O
and O
insulin I-GENE
responses O
during O
rest O
and O
exercise O
. O

The O
findings O
suggest O
that O
ERP O
effects O
of O
distinct O
memory O
processes O
are O
differentially O
influenced O
by O
the O
encoding O
instructions O
. O

This O
coat I-GENE
protein I-GENE
consists O
of O
Sar1p I-GENE
, O
the O
Sec23p I-GENE
protein I-GENE
complex I-GENE
containing O
Sec23p I-GENE
and O
Sec24p I-GENE
, O
and O
the O
Sec13p I-GENE
protein I-GENE
complex I-GENE
containing O
Sec13p I-GENE
and O
a O
novel O
150 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
, I-GENE
p150 I-GENE
. O

The O
second O
primary O
mutant O
contained O
a O
proline O
- O
to O
- O
leucine O
change O
at O
position O
243 O
( O
P243L O
). O

Induction O
of O
correctly O
spliced O
germline O
transcripts O
is O
necessary O
to O
target O
a O
switch O
region O
for O
recombination O
and O
switching O
. O

Thus O
, O
the O
PCE I-GENE
binds O
a O
Pbx I-GENE
dimer I-GENE
partner I-GENE
that O
behaves O
unlike O
Class I-GENE
I I-GENE
Hox I-GENE
proteins I-GENE
. O

Furthermore O
, O
the O
NH2 O
- O
terminal O
portion O
of O
the O
homologue O
was O
not O
translocated O
into O
the O
outer O
membrane O
without O
its O
COOH O
- O
terminal O
part O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA O
, O
CHEMR1 I-GENE
, O
encoding O
a O
chemokine O
receptor O
with O
a O
homology O
to O
the O
human I-GENE
C I-GENE
- I-GENE
C I-GENE
chemokine I-GENE
receptor I-GENE
, O
CCR I-GENE
- I-GENE
4 I-GENE
. O

Organization O
of O
the O
human I-GENE
LU I-GENE
gene I-GENE
and O
molecular O
basis O
of O
the O
Lu O
( O
a O
)/ O
Lu I-GENE
( I-GENE
b I-GENE
) I-GENE
blood O
group O
polymorphism O
. O

Using O
mouse O
- O
human O
somatic O
hybrids O
and O
FISH O
analysis O
, O
the O
PE I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
localized O
to O
human O
chromosome O
19q13 O
. O
2 O
, O
a O
region O
involved O
in O
translocations O
and O
deletions O
in O
leukemias O
and O
several O
solid O
tumors O
, O
suggesting O
that O
this O
novel O
ETS I-GENE
factor I-GENE
may O
play O
a O
role O
in O
carcinogenesis O
. O

Whereas O
the O
mutant O
enzymes O
terminate O
normally O
at O
the O
late O
terminator O
in O
T7 O
DNA O
( O
T O
( O
phi O
)) O
and O
rrnB I-GENE
T2 O
, O
they O
fail O
to O
terminate O
at O
one O
of O
the O
termination O
sites O
of O
rrnB I-GENE
T1 O
, O
and O
also O
fail O
to O
recognize O
the O
PTH I-GENE
and O
CJ O
signals O
. O

Cytological O
data O
suggest O
that O
the O
transgenes O
associate O
with O
a O
nucleolus O
. O

Light I-GENE
regulatory I-GENE
unit I-GENE
1 I-GENE
( O
LRU1 I-GENE
) O
is O
necessary O
for O
and O
sufficient O
to O
mediate O
light O
- O
dependent O
activation O
of O
the O
chalcone I-GENE
synthase I-GENE
( I-GENE
CHS I-GENE
) I-GENE
minimal I-GENE
promoter I-GENE
in O
Petroselinum O
crispum O
. O

Sequence O
divergence O
is O
observed O
in O
untranslated O
regions O
which O
allows O
the O
definition O
of O
gene O
- O
specific O
probes O
. O

The O
active O
state O
is O
terminated O
by O
hydrolysis O
of O
bound O
GTP O
, O
producing O
inactive O
ARF I-GENE
- I-GENE
GDP I-GENE
. O

We O
suggest O
that O
apart O
from O
the O
World O
Summit O
for O
Children O
' O
s O
under O
- O
five O
mortality O
target O
for O
the O
year O
2000 O
, O
intraregional O
targets O
to O
reduce O
geographical O
inequalities O
in O
under O
- O
five O
mortality O
should O
be O
specified O
. O

The O
immunophilin I-GENE
, O
which O
can O
be O
of O
the O
FK506 O
- O
or O
cyclosporin O
A O
- O
binding O
class O
, O
binds O
to O
hsp90 I-GENE
via O
its O
tetratricopeptide O
repeat O
( O
TPR O
) O
domain O
, O
and O
different O
receptor O
heterocomplexes O
exist O
depending O
upon O
which O
immunophilin I-GENE
occupies O
the O
TPR O
- O
binding O
region O
of O
hsp90 I-GENE
. O

In O
adherent O
macrophages O
, O
absence O
of O
CD45 I-GENE
led O
to O
the O
hyperphosphorylation O
and O
hyperactivation O
of O
p56 I-GENE
/ I-GENE
59 I-GENE
( O
hck I-GENE
) O
and O
p53 I-GENE
/ I-GENE
56 I-GENE
( O
lyn I-GENE
), O
but O
not O
of O
p58 I-GENE
( O
c I-GENE
- I-GENE
fgr I-GENE
). O

Secretion O
in O
milk O
and O
transplacental O
transfer O
of O
two O
iodized O
oils O
, O
Lipiodol O
UF O
and O
Oriodol O
, O
in O
rabbits O
. O

Sequencing O
of O
the O
facB I-GENE
gene I-GENE
revealed O
that O
it O
encodes O
a O
protein O
that O
contains O
an O
N O
- O
terminal O
GAL4 I-GENE
- O
like O
Zn O
( O
II O
) O
2Cys6 O
( O
or O
C6 O
zinc O
) O
binuclear O
cluster O
for O
DNA O
binding O
, O
leucine O
zipper O
- O
like O
heptad O
repeat O
motifs O
and O
central O
and O
C O
- O
terminal O
acidic O
alpha O
- O
helical O
regions O
, O
consistent O
with O
a O
function O
as O
a O
DNA O
- O
binding O
transcriptional O
activator O
. O

Overexpression O
of O
Sed5p I-GENE
allowed O
growth O
in O
the O
absence O
of O
Vti1p I-GENE
. O

The O
coding O
region O
of O
mkh1 I-GENE
is O
contained O
within O
a O
single O
exon O
encoding O
a O
1 O
, O
116 O
- O
amino O
- O
acid O
protein O
. O

Strikingly O
, O
stoichiometric O
association O
of O
p107 I-GENE
or O
p130 I-GENE
with O
either O
cyclin I-GENE
E I-GENE
- O
cdk2 I-GENE
or O
cyclin I-GENE
A I-GENE
- O
cdk2 I-GENE
negated O
the O
activities O
of O
these O
kinases O
. O

Furthermore O
, O
p150 I-GENE
suppresses O
actin I-GENE
gelation O
, O
which O
is O
induced O
by O
smooth I-GENE
muscle I-GENE
alpha I-GENE
- I-GENE
actinin I-GENE
. O

Denaturation O
of O
the O
simian O
virus O
40 O
origin O
of O
replication O
mediated O
by O
human I-GENE
replication I-GENE
protein I-GENE
A I-GENE
. O

This O
effect O
was O
abolished O
once O
the O
EM O
motif O
in O
the O
promoter O
- O
reporter O
construct O
was O
mutated O
, O
thus O
suggesting O
that O
the O
synergistic O
transactivation O
function O
of O
the O
TEF I-GENE
- I-GENE
1 I-GENE
- O
Max I-GENE
heterotypic O
complex O
is O
mediated O
through O
binding O
of O
the O
complex O
to O
the O
EM O
motif O
. O

Interdigitated O
residues O
within O
a O
small O
region O
of O
VP16 I-GENE
interact O
with O
Oct I-GENE
- I-GENE
1 I-GENE
, O
HCF I-GENE
, O
and O
DNA O
. O

With O
a O
view O
to O
identifying O
other O
important O
U14 I-GENE
interactions O
, O
a O
stem O
- O
loop O
domain O
required O
for O
activity O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
U14 I-GENE
RNAs I-GENE
( O
the O
Y O
domain O
) O
was O
first O
subjected O
to O
detailed O
mutational O
analysis O
. O

Based O
on O
these O
results O
and O
because O
Cdc68 I-GENE
has O
been O
implicated O
as O
a O
regulator O
of O
chromatin O
structure O
, O
we O
postulate O
that O
polymerase I-GENE
alpha I-GENE
may O
interact O
with O
these O
proteins O
to O
gain O
access O
to O
its O
template O
or O
to O
origins O
of O
replication O
in O
vivo O
. O

Even O
when O
the O
inoculum O
size O
was O
reduced O
sixfold O
( O
i O
. O
e O
., O
6 O
x O
10 O
( O
6 O
) O
CFU O
/ O
mouse O
), O
50 O
% O
of O
the O
RB6 I-GENE
- I-GENE
8C5 I-GENE
- O
treated O
animals O
died O
within O
6 O
days O
. O

In O
12 O
cases O
( O
3 O
. O
1 O
%), O
a O
change O
in O
stage O
resulted O
. O

Promoter O
recognition O
algorithms O
identified O
divergent O
promoter O
elements O
within O
the O
CpG O
island O
, O
which O
lies O
between O
the O
ATM I-GENE
and O
E14 I-GENE
/ O
NPAT I-GENE
genes O
, O
and O
provide O
evidence O
for O
a O
putative O
second O
ATM I-GENE
promoter I-GENE
located O
within O
intron O
3 O
, O
immediately O
upstream O
of O
the O
first O
coding O
exon O
. O

Recombinant I-GENE
soluble I-GENE
pMCP I-GENE
that O
lacked O
transmembrane O
and O
cytoplasmic O
domains O
had O
factor I-GENE
I I-GENE
cofactor I-GENE
activity O
in O
C3b I-GENE
cleavage O
, O
indicating O
that O
it O
is O
functionally O
, O
as O
well O
as O
structurally O
homologous O
to O
MCP I-GENE
. O

Clinical O
and O
haematological O
signs O
are O
not O
specific O
in O
this O
setting O
, O
and O
the O
diagnosis O
relies O
on O
histological O
features O
, O
mainly O
bone O
marrow O
examination O
. O

Spatial O
zones O
for O
muscle O
coactivation O
and O
the O
control O
of O
postural O
stability O
. O

Liquid O
chromatographic O
separation O
was O
achieved O
on O
a O
Zorbax O
RX O
C8 O
analytical O
column O
using O
gradient O
elution O
. O

The O
linear O
plasmid O
pDHL1 O
from O
Debaryomyces O
hansenii O
encodes O
a O
protein O
highly O
homologous O
to O
the O
pGKL1 I-GENE
- I-GENE
plasmid I-GENE
DNA I-GENE
polymerase I-GENE
. O

The O
RNA O
- O
binding O
and O
RNA I-GENE
- I-GENE
DNA I-GENE
helicase I-GENE
activities O
of O
the O
Escherichia I-GENE
coli I-GENE
transcription I-GENE
termination I-GENE
factor I-GENE
rho I-GENE
have O
been O
investigated O
using O
natural O
RNA O
molecules O
that O
are O
255 O
and O
391 O
nucleotide O
residues O
in O
length O
and O
that O
contain O
the O
trp I-GENE
t I-GENE
' I-GENE
rho I-GENE
- I-GENE
dependent I-GENE
termination I-GENE
sequence I-GENE
of O
E O
. O
coli O
. O

The O
p20 I-GENE
- I-GENE
CGGBP I-GENE
gene I-GENE
is O
conserved O
among O
mammals O
but O
shows O
no O
homology O
to O
non O
- O
vertebrate O
species O
. O

The O
data O
suggest O
that O
like O
in O
yeast O
, O
in O
plants O
a O
certain O
subfamily O
of O
UBC I-GENE
is O
specifically O
involved O
in O
the O
proteolytic O
degradation O
of O
abnormal O
proteins O
as O
result O
of O
stress O
. O

The O
pWP I-GENE
- I-GENE
19 I-GENE
also O
encodes O
the O
AAV O
inverted O
terminal O
repeats O
for O
integration O
and O
replication O
and O
the O
herpes O
virus O
thymidine I-GENE
kinase I-GENE
promoter O
- O
driven O
gene O
for O
neomycin O
resistance O
( O
neoR I-GENE
). O

We O
have O
developed O
a O
rAAV O
- O
mediated O
gene O
transfer O
system O
for O
the O
rat I-GENE
preproinsulin I-GENE
II I-GENE
gene I-GENE
. O

The O
serum O
levels O
of O
beta I-GENE
- I-GENE
human I-GENE
chorionic I-GENE
gonadotropin I-GENE
( O
HCG I-GENE
) O
and O
placental I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
PLAP I-GENE
) O
were O
not O
elevated O
. O

A O
striking O
feature O
of O
the O
recombinant I-GENE
H19 I-GENE
allele I-GENE
is O
the O
occurrence O
of O
a O
parental O
imprint O
set O
on O
the O
neo I-GENE
replacement I-GENE
cassette I-GENE
. O

This O
indicates O
that O
recruitment O
of O
large I-GENE
T I-GENE
antigen I-GENE
to O
the O
rRNA O
promoter O
by O
SL1 I-GENE
constitutes O
a O
crucial O
step O
in O
the O
activation O
process O
. O

In O
1990 O
, O
an O
International O
Commission O
for O
the O
Certification O
of O
Eradication O
of O
Poliomyelitis O
Eradication O
( O
ICCPE O
) O
was O
established O
by O
the O
Pan O
American O
Health O
Organization O
to O
eventually O
determine O
if O
transmission O
was O
interrupted O
. O

Functional O
and O
regulatory O
analysis O
of O
the O
two O
copies O
of O
the O
fixNOQP I-GENE
operon I-GENE
of O
Rhizobium O
leguminosarum O
strain O
VF39 O
. O

This O
study O
describes O
a O
new O
MADS I-GENE
box I-GENE
gene I-GENE
, O
nmhC5 I-GENE
, O
which O
along O
with O
nmh7 I-GENE
( O
J O
. O

Thus O
E14 O
. O
1TG3B1 O
is O
a O
useful O
ES O
cell O
line O
for O
modifying O
the O
mouse O
genome O
using O
the O
HPRT I-GENE
gene I-GENE
as O
a O
selection O
marker O
and O
for O
transmission O
at O
a O
high O
frequency O
into O
the O
mouse O
germ O
line O
. O

Lung O
and O
multi O
- O
system O
damage O
were O
early O
indicators O
of O
poor O
outcome O
in O
severe O
non O
- O
fatal O
disease O
. O

The O
results O
suggest O
that O
the O
bulbospinal O
micturition O
reflex O
evoked O
by O
bladder O
filling O
and O
L O
- O
dopa O
involves O
a O
descending O
pathway O
where O
transmission O
is O
partly O
mediated O
by O
spinal I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
adrenoceptors I-GENE
. O

OBJECTIVE O
: O
This O
study O
was O
designed O
to O
analyze O
the O
common O
cause O
of O
asthenopia O
, O
mixed O
astigmatism O
. O

Disturbance O
of O
regeneration O
in O
the O
above O
pathological O
condition O
results O
from O
the O
damage O
to O
tunica O
propria O
and O
loss O
of O
its O
function O
for O
the O
support O
of O
structural O
homeostasis O
. O

Sternocleidomastoid O
, O
neck O
or O
facial O
muscles O
wasting O
were O
also O
found O
in O
three O
cases O
. O

Identification O
of O
five O
new O
genes O
, O
closely O
related O
to O
the O
interleukin I-GENE
- I-GENE
1beta I-GENE
converting I-GENE
enzyme I-GENE
gene I-GENE
, O
that O
do O
not O
encode O
functional O
proteases O
. O

The O
C O
- O
terminal O
mature O
region O
is O
highly O
conserved O
in O
other O
serine I-GENE
carboxypeptidases I-GENE
. O

One O
RNA O
construct O
which O
consisted O
of O
112 O
nucleotides O
( O
nt O
) O
from O
nt O
639 O
to O
nt O
750 O
formed O
a O
heterodimeric O
complex O
with O
the O
RNA O
which O
consisted O
of O
200 O
nucleotides O
from O
nt O
551 O
to O
nt O
750 O
. O

Here O
we O
demonstrate O
that O
AML1a I-GENE
, O
which O
solely O
has O
no O
effects O
as O
a O
transcriptional O
regulator O
, O
dominantly O
suppresses O
transcriptional O
activation O
by O
AML1b I-GENE
, O
and O
that O
AML1a I-GENE
exhibits O
the O
higher O
affinity O
for O
DNA O
- O
binding O
than O
AML1b I-GENE
. O

However O
, O
we O
could O
not O
find O
the O
homologous O
regions O
with O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
or O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
in O
the O
c I-GENE
- I-GENE
cbl I-GENE
gene I-GENE
. O

However O
, O
using O
ATL O
- O
16T O
nuclear O
extract O
, O
we O
demonstrated O
that O
GATA I-GENE
- I-GENE
4 I-GENE
is O
the O
only O
GATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
forms O
specific O
DNA O
- O
protein O
complex O
with O
the O
- O
70 O
GATA O
site O
. O

The O
impact O
of O
social O
support O
on O
the O
relationships O
of O
gay O
male O
couples O
is O
examined O
. O

The O
ubiquitously O
expressed O
hypoxia I-GENE
- I-GENE
inducible I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HIF I-GENE
- I-GENE
1 I-GENE
) O
is O
involved O
in O
expression O
of O
a O
large O
number O
of O
oxygen O
- O
regulated O
genes O
. O

Stromelysin I-GENE
- I-GENE
1 I-GENE
, O
matrix I-GENE
metalloproteinase I-GENE
- I-GENE
3 I-GENE
( O
MMP I-GENE
- I-GENE
3 I-GENE
), O
is O
an O
important O
endopeptidase O
selectively O
expressed O
by O
somatic O
cells O
in O
organ O
tissues O
. O

Tendon O
also O
shows O
a O
degree O
of O
extensibility O
. O

Surveillance O
for O
preeclampsia O
was O
conducted O
by O
personnel O
unaware O
of O
treatment O
- O
group O
assignments O
, O
using O
standardized O
measurements O
of O
blood O
pressure O
and O
urinary O
protein O
excretion O
at O
uniformly O
scheduled O
prenatal O
visits O
, O
protocols O
for O
monitoring O
these O
measurements O
during O
the O
hospitalization O
for O
delivery O
, O
and O
reviews O
of O
medical O
records O
of O
unscheduled O
outpatient O
visits O
and O
all O
hospitalizations O
. O

Aryl I-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
translocator I-GENE
( O
ARNT I-GENE
) O
is O
a O
component O
of O
the O
transcription O
factors O
, O
aryl I-GENE
hydrocarbon I-GENE
receptor I-GENE
( O
AhR I-GENE
) O
and O
hypoxia I-GENE
- I-GENE
inducible I-GENE
factor I-GENE
1 I-GENE
, O
which O
transactivate O
their O
target O
genes O
, O
such O
as O
CYP1A1 I-GENE
and O
erythropoietin I-GENE
, O
in O
response O
to O
xenobiotic O
aromatic O
hydrocarbons O
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

DNase I-GENE
I I-GENE
footprint O
analysis O
identified O
a O
protected O
region O
from O
- O
37 O
to O
- O
53 O
. O

We O
also O
provide O
evidence O
that O
gar2 I-GENE
is O
phosphorylated O
in O
vitro O
by O
a O
p13 I-GENE
( O
suc1 I-GENE
)- O
Sepharose O
- O
bound O
kinase O
from O
Schizosaccharomyces O
pombe O
extracts O
that O
displays O
cell O
cycle O
- O
regulated O
activity O
similar O
to O
that O
of O
the O
p34 I-GENE
( O
cdc2 I-GENE
( O
kinase O
. O

However O
, O
by O
immobilized O
metal O
affinity O
chromatography O
assay O
, O
self O
- O
association O
of O
PR I-GENE
- I-GENE
A I-GENE
was O
3 O
. O
5 O
- O
fold O
more O
efficient O
than O
that O
of O
either O
the O
DhLBD O
or O
hLBD O
constructs O
. O

The O
overall O
results O
of O
this O
paper O
are O
consistent O
with O
the O
conclusion O
that O
the O
carboxyl O
- O
terminal O
LBD O
is O
not O
sufficient O
for O
mediating O
PR I-GENE
dimerization O
and O
that O
multiple O
regions O
, O
including O
the O
hinge O
and O
amino O
- O
terminal O
sequences O
, O
contribute O
either O
directly O
or O
indirectly O
to O
homodimerization O
of O
PR I-GENE
. O

We O
isolated O
several O
overlapping O
A O
- O
phage O
and O
cosmid O
clones O
that O
cover O
more O
than O
100 O
kb O
of O
human O
DNA O
and O
contained O
the O
entire O
VDR I-GENE
gene I-GENE
. O

Colorectal O
carcinoma O
: O
therapeutic O
approach O
in O
patients O
already O
treated O
with O
metastasis O
resection O

Here O
, O
we O
correlate O
Dox O
effects O
on O
cell O
cycle O
with O
changes O
of O
E2F I-GENE
/ O
DP I-GENE
complexes O
and O
activity O
in O
differentiating O
C2C12 O
myocytes O
. O

The O
products O
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
CIN1 I-GENE
, O
CIN2 I-GENE
and O
CIN4 I-GENE
genes I-GENE
participate O
in O
a O
nonessential O
pathway O
required O
for O
normal O
microtubule O
function O
. O

Vitrectomy O
was O
still O
a O
significant O
risk O
factor O
when O
macular O
holes O
were O
excluded O
. O

Invited O
editorial O
on O
" O
Acute O
and O
chronic O
effects O
of O
exercise O
on O
leptin I-GENE
levels O
in O
humans O
". O

Both O
promoters O
lack O
a O
TATA O
box O
, O
and O
Pint I-GENE
belongs O
to O
the O
MED I-GENE
- I-GENE
1 I-GENE
class O
of O
promoters O
, O
which O
initiate O
transcription O
at O
multiple O
sites O
. O

Serum I-GENE
response I-GENE
factor I-GENE
( O
SRF I-GENE
), O
a O
member O
of O
an O
ancient O
family O
of O
DNA O
- O
binding O
proteins O
, O
is O
generally O
assumed O
to O
be O
a O
ubiquitous O
transcription O
factor O
involved O
in O
regulating O
growth O
factor O
- O
responsive O
genes O
. O

We O
have O
initiated O
studies O
to O
identify O
candidate O
signal O
transducers O
that O
associate O
with O
the O
cytosolic O
domain O
( O
cd O
) O
of O
the O
IL I-GENE
- I-GENE
1R I-GENE
. O

In O
this O
study O
, O
we O
sought O
to O
identify O
mechanisms O
that O
could O
account O
for O
the O
antimitogenic O
effects O
of O
IL I-GENE
- I-GENE
4 I-GENE
. O

Pseudomonas O
aeruginosa O
strains O
infecting O
patients O
with O
cystic O
fibrosis O
( O
CF O
) O
acquire O
a O
mucoid O
phenotype O
due O
to O
overproduction O
of O
alginate O
. O

Activity O
of O
palgD I-GENE
in O
the O
cysB I-GENE
mutant I-GENE
, O
in O
CHA O
and O
in O
the O
non O
- O
mucoid O
strain O
PAO O
was O
assessed O
by O
the O
use O
of O
a O
transcriptional O
algD I-GENE
- O
xylE I-GENE
fusion O
. O

The O
Man9 I-GENE
- I-GENE
mannosidase I-GENE
specificity O
of O
the O
cDNA O
construct O
was O
verified O
by O
the O
observation O
that O
all O
peptide O
sequences O
derived O
from O
a O
previously O
purified O
, O
catalytically O
active O
49 O
- O
kDa O
fragment O
were O
found O
within O
the O
coding O
region O
. O

A O
soluble O
62 O
- O
kDa O
protein O
was O
produced O
without O
the O
proteolytic O
processing O
by O
inserting O
the O
coding O
sequence O
of O
amino O
acids O
112 O
to O
660 O
of O
ORF O
- O
2 O
in O
a O
baculovirus O
expression O
vector O
and O
using O
the O
corresponding O
virus O
to O
infect O
Sf9 O
cells O
. O

The O
CPK I-GENE
- I-GENE
MB I-GENE
isoenzyme O
showed O
no O
percentage O
increase O
of O
total O
CPK I-GENE
higher O
than O
5 O
%, O
measured O
at O
6 O
, O
12 O
, O
and O
24 O
h O
after O
the O
shock O
, O
independent O
of O
the O
number O
of O
attempts O
of O
cardioversion O
. O

Serum O
and O
peritoneal O
dialysis O
fluid O
( O
PDF O
) O
were O
collected O
for O
assay O
throughout O
the O
course O
of O
the O
study O
and O
for O
5 O
days O
thereafter O
. O

Results O
support O
the O
hypothesis O
that O
endogenous I-GENE
corticotropin I-GENE
- I-GENE
releasing I-GENE
factor I-GENE
, O
perhaps O
acting O
at O
a O
peripheral O
binding O
site O
, O
suppresses O
the O
active O
behavioral O
response O
characteristic O
of O
pups O
during O
the O
early O
phase O
of O
isolation O
in O
novel O
surroundings O
. O

Liver O
regional O
blood O
volume O
( O
LRBV O
) O
is O
altered O
by O
several O
disease O
states O
and O
various O
drugs O
. O

The O
gray O
matter O
NAA O
/ O
mI O
ratio O
clearly O
separated O
the O
two O
groups O
. O

As O
with O
the O
murine I-GENE
and I-GENE
human I-GENE
mb I-GENE
- I-GENE
1 I-GENE
genes I-GENE
, O
the O
5 O
' O
region O
of O
the O
bovine I-GENE
mb I-GENE
- I-GENE
1 I-GENE
gene I-GENE
lacked O
a O
TATA O
box O
. O

Chloramphenicol I-GENE
acetyltransferase I-GENE
assays O
examining O
the O
ability O
of O
IE86 I-GENE
to O
repress O
activity O
from O
the O
HCMV O
major O
IE I-GENE
promoter I-GENE
or O
activate O
the O
HCMV I-GENE
early I-GENE
promoter I-GENE
for O
the O
2 O
. O
2 O
- O
kb O
class O
of O
RNAs O
demonstrated O
the O
functional O
integrity O
of O
the O
IE86 I-GENE
protein I-GENE
. O

ORF O
M1 O
has O
striking O
homology O
to O
poxvirus O
serpins I-GENE
, O
while O
ORF O
M11 O
encodes O
a O
potential O
homolog O
of O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
like I-GENE
molecules I-GENE
encoded O
by O
other O
gammaherpesviruses O
( O
gene I-GENE
16 I-GENE
of O
HVS O
and O
KSHV O
and O
the O
BHRF1 I-GENE
gene I-GENE
of O
EBV O
). O

Transcription O
factor O
binding O
sites O
downstream O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
start O
site O
are O
important O
for O
virus O
infectivity O
. O

Crystal O
structure O
of O
an O
oligomer O
of O
proteolytic O
zymogens O
: O
detailed O
conformational O
analysis O
of O
the O
bovine O
ternary O
complex O
and O
implications O
for O
their O
activation O
. O

Through O
transient O
transfection O
of O
NIH3T3 O
fibroblast O
cells O
and O
gel O
mobility O
shift O
assays O
, O
the O
functional O
binding O
site O
was O
localized O
to O
a O
short O
region O
(- O
318 O
to O
- O
303 O
bp O
from O
the O
transcription O
start O
site O
) O
which O
has O
a O
CTCCC O
sequence O
. O

We O
suppose O
that O
this O
injection O
speed O
( O
0 O
. O
1 O
- O
0 O
. O
2 O
ml O
. O
s O
- O
1 O
) O
is O
suitable O
for O
spinal O
anesthesia O
. O

Alternative O
splicing O
of O
ClC I-GENE
- I-GENE
6 I-GENE
( O
a O
member O
of O
the O
CIC I-GENE
chloride I-GENE
- I-GENE
channel I-GENE
family I-GENE
) O
transcripts O
generates O
three O
truncated O
isoforms O
one O
of O
which O
, O
ClC I-GENE
- I-GENE
6c I-GENE
, O
is O
kidney O
- O
specific O
. O

The O
current O
study O
demonstrates O
that O
T3 O
- O
activated O
transcription O
of O
the O
NADPH I-GENE
: I-GENE
cytochrome I-GENE
P450 I-GENE
oxidoreductase I-GENE
( O
P450R I-GENE
) O
gene O
is O
dependent O
on O
the O
thyroid O
hormonal O
status O
of O
the O
animal O
, O
with O
both O
transcriptional O
and O
post O
- O
transcriptional O
pathways O
being O
important O
in O
regulating O
the O
cellular O
P450R I-GENE
mRNA O
level O
. O

The O
behavior O
of O
different O
types O
of O
polytetrafluoroethylene O
( O
PTFE O
) O
prostheses O
in O
the O
reparative O
scarring O
process O
of O
abdominal O
wall O
defects O
. O

The O
control O
group O
revealed O
significantly O
higher O
levels O
of O
coagulation I-GENE
factors I-GENE
II I-GENE
, I-GENE
V I-GENE
and I-GENE
VIII I-GENE
, O
compared O
to O
the O
index O
group O
. O

The O
frequency O
of O
positive O
anti I-GENE
- I-GENE
GM1 I-GENE
antibody I-GENE
titers O
in O
the O
Guillain O
- O
Barre O
syndrome O
patients O
with O
PEN O
19 O
isolates O
was O
higher O
than O
that O
in O
the O
Guillain O
- O
Barre O
syndrome O
and O
Fisher O
' O
s O
syndrome O
patients O
without O
PEN O
19 O
isolates O
. O

Stereotactic O
radiofrequency O
lesioning O
of O
the O
hamartoma O
resulted O
in O
seizure O
remission O
without O
complications O
20 O
months O
after O
surgery O
. O

NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ O
Rel I-GENE
transcription O
factors O
participate O
in O
the O
activation O
of O
numerous O
genes O
involved O
in O
immune O
regulation O
/ O
inflammation O
including O
cytokines O
, O
cell O
surface O
receptors O
, O
adhesion O
molecules O
, O
and O
acute O
phase O
proteins O
. O

If O
E O
. O
coli O
is O
present O
in O
any O
source O
water O
sample O
, O
the O
borehole O
and O
any O
directly O
connected O
borehole O
should O
be O
embargoed O
. O

However O
, O
mean O
food O
intake O
in O
the O
40 O
% O
group O
was O
half O
that O
of O
the O
ACT O
group O
( O
p O
< O
0 O
. O
001 O
) O
and O
significantly O
less O
( O
p O
< O
0 O
. O
01 O
) O
than O
the O
SEP O
group O
, O
which O
consumed O
amounts O
equivalent O
to O
65 O
% O
of O
daily O
requirement O
. O

The O
following O
technique O
describes O
a O
modification O
to O
a O
bar O
superstructure O
that O
provided O
the O
advantages O
of O
convenience O
, O
security O
, O
and O
consistent O
positioning O
even O
though O
one O
implant O
was O
lost O
and O
the O
angulation O
of O
implants O
limited O
accuracy O
. O

In O
summary O
, O
DDC O
express O
receptors O
for O
a O
broad O
panel O
of O
cytokines O
, O
even O
receptors O
for O
cytokines O
whose O
effects O
on O
DC O
are O
still O
unknown O
( O
i O
. O
e O
. O

Its O
potential O
as O
a O
diagnostic O
tool O
for O
epidemiological O
surveillance O
was O
assessed O
in O
comparison O
with O
three O
other O
diagnostic O
tests O
: O
stool O
examination O
, O
ELISA O
with O
soluble I-GENE
egg I-GENE
antigen I-GENE
( O
SEA I-GENE
) O
and O
the O
circumoval O
precipitin I-GENE
test O
( O
COPT O
). O

We O
have O
separated O
a O
dermatan O
sulfate O
proteoglycan O
, O
epiphycan O
, O
from O
decorin I-GENE
and O
biglycan O
by O
using O
dissociative O
extraction O
of O
bovine O
fetal O
epiphyseal O
cartilage O
, O
followed O
by O
sequential O
ion O
- O
exchange O
, O
gel O
permeation O
, O
hydrophobic O
, O
and O
Zn2 O
+ O
chelate O
chromatographic O
steps O
. O

These O
analyses O
demonstrate O
that O
the O
dUTPase I-GENE
isoforms O
are O
encoded O
by O
the O
same O
gene O
with O
isoform O
- O
specific O
transcripts O
arising O
through O
the O
use O
of O
alternative O
5 O
' O
exons O
. O

The O
selective O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
ramosetron O
( O
YM060 O
), O
YM114 O
( O
KAE O
- O
393 O
), O
granisetron O
and O
ondansetron O
, O
and O
the O
substituted O
benzamides O
( O
5 I-GENE
- I-GENE
HT4 I-GENE
receptor I-GENE
agonist O
/ O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
) O
cisapride O
mosapride O
and O
SC O
- O
53116 O
dose O
- O
dependently O
enhanced O
gastric O
emptying O
in O
normal O
rats O
. O

Re O
- O
evaluation O
of O
the O
biopsy O
specimen O
from O
the O
right O
hip O
taken O
at O
the O
time O
of O
the O
initial O
operation O
showed O
areas O
of O
chondrosarcoma O
arising O
in O
the O
background O
of O
synovial O
chondromatosis O
. O

All O
corneal O
buttons O
were O
processed O
for O
histopathologic O
and O
electron O
microscopic O
studies O
. O

3600 O
- O
fold O
to O
apparent O
homogeneity O
with O
a O
41 O
% O
yield O
by O
affinity O
chromatography O
utilizing O
DNA O
- O
cellulose O
; O
the O
purity O
of O
the O
final O
preparation O
was O
assessed O
by O
SDS O
/ O
PAGE O
, O
lack O
of O
contamination O
by O
other O
nucleases O
and O
production O
of O
a O
monospecific O
antibody O
against O
the O
enzyme O
. O

Human I-GENE
thymine I-GENE
- I-GENE
DNA I-GENE
glycosylase I-GENE
maps O
at O
chromosome O
12q22 O
- O
q24 O
. O
1 O
: O
a O
region O
of O
high O
loss O
of O
heterozygosity O
in O
gastric O
cancer O
. O

FOG I-GENE
is O
coexpressed O
with O
GATA I-GENE
- I-GENE
1 I-GENE
during O
embryonic O
development O
and O
in O
erythroid O
and O
megakaryocytic O
cells O
. O

The O
mean O
times O
to O
detection O
of O
all O
mycobacteria O
with O
BACTEC O
9000 O
MB O
and O
BACTEC O
460 O
TB O
were O
similar O
( O
10 O
. O
3 O
and O
10 O
. O
0 O
days O
, O
respectively O
). O

Though O
the O
BACTEC O
9000 O
MB O
system O
is O
recommended O
for O
respiratory O
specimens O
, O
we O
demonstrated O
that O
it O
can O
be O
successfully O
used O
also O
for O
recovery O
of O
mycobacteria O
from O
clinical O
specimens O
from O
various O
extrapulmonary O
sites O
. O

We O
further O
found O
that O
KmMig1p I-GENE
is O
fully O
functional O
when O
expressed O
in O
S O
. O
cerevisiae O
. O

A O
pre O
- O
boutonniere O
deformity O
was O
simulated O
by O
dividing O
the O
central O
slip O
. O

Autoimmune O
neutropenia O
( O
AIN O
) O
is O
a O
frequent O
cause O
of O
chronic O
neutropenia O
especially O
in O
youngest O
children O
. O

With O
regard O
to O
the O
characteristic O
expression O
pattern O
of O
DJ I-GENE
protein I-GENE
and O
its O
conspicuous O
repeat O
units O
possible O
functional O
roles O
are O
discussed O
. O

Future O
analysis O
of O
long O
- O
term O
outcome O
measures O
of O
performance O
with O
the O
implant O
will O
confirm O
or O
dispute O
the O
benefit O
of O
ear O
selection O
using O
the O
Prom O
- O
EABR O
. O

This O
protein O
, O
designated O
p532 I-GENE
based O
on O
its O
predicted O
molecular O
weight O
( O
EMBO O
J O
15 O
: O
5738 O
, O
1996 O
), O
contains O
multiple O
structural O
domains O
including O
two O
regions O
of O
seven O
internal O
repeats O
highly O
related O
to O
the O
cell O
cycle O
regulator O
RCC1 I-GENE
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
for O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
Ran I-GENE
, O
seven O
beta O
- O
repeat O
domains O
characteristic O
of O
the O
beta O
subunit O
of O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
, O
three O
putative O
SH3 I-GENE
binding I-GENE
sites I-GENE
, O
a O
putative O
leucine O
- O
zipper O
and O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
HECT I-GENE
domain I-GENE
characteristic O
of O
E3 I-GENE
ubiquitin I-GENE
- I-GENE
protein I-GENE
ligases I-GENE
. O

Thus O
, O
the O
L45 O
sequence O
between O
kinase O
subdomains O
IV O
and O
V O
specifies O
TGF I-GENE
- I-GENE
beta I-GENE
responsiveness O
of O
the O
type I-GENE
I I-GENE
receptor I-GENE
. O

The O
two O
mouse O
lines O
carrying O
the O
unfragmented O
Hnf3g I-GENE
- O
lacZ I-GENE
YAC O
showed O
tissue O
- O
specific O
, O
copy O
number O
- O
dependent O
and O
position O
- O
independent O
expression O
, O
proving O
that O
170 O
kb O
of O
the O
Hnf3g I-GENE
locus O
contain O
all O
elements O
important O
in O
the O
regulation O
of O
Hnf3g I-GENE
. O

Second O
, O
plasmid O
- O
derived O
transgenes O
and O
gene O
targeting O
of O
the O
endogenous I-GENE
Hnf3g I-GENE
gene I-GENE
locus I-GENE
were O
used O
to O
demonstrate O
that O
the O
3 O
'- O
flanking O
region O
of O
the O
gene O
is O
necessary O
and O
sufficient O
to O
direct O
reporter O
gene O
expression O
in O
liver O
, O
pancreas O
, O
stomach O
and O
small O
intestine O
. O

This O
regulation O
requires O
two O
HMG I-GENE
- I-GENE
box I-GENE
proteins I-GENE
: O
the O
ubiquitous O
Ste11 I-GENE
transcription I-GENE
factor I-GENE
and O
the O
M O
cell O
- O
controlling O
protein O
Mat1 I-GENE
- I-GENE
Mc I-GENE
. O

Here O
we O
have O
tested O
the O
hypothesis O
that O
the O
short O
transcripts O
, O
or O
proteins O
translated O
from O
the O
short O
transcripts O
, O
are O
also O
required O
for O
respiration O
. O

Upstream O
activating O
sequences O
( O
UASs O
) O
derived O
from O
known O
Ste12p I-GENE
- O
dependent O
genes O
have O
previously O
been O
characterized O
to O
require O
either O
multiple O
PREs O
or O
a O
single O
PRE O
coupled O
to O
a O
binding O
site O
for O
a O
second O
protein O
. O

Prominent O
protein O
kinase O
cascades O
are O
those O
that O
activate O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinases I-GENE
. O

JNK I-GENE
is O
additionally O
regulated O
by O
the O
Ras I-GENE
- O
related O
G I-GENE
proteins I-GENE
Rac I-GENE
and O
Cdc42 I-GENE
. O

In O
this O
study O
, O
we O
tested O
this O
notion O
by O
using O
ligation O
- O
mediated O
PCR O
to O
assess O
the O
formation O
of O
recombination I-GENE
- I-GENE
activating I-GENE
gene I-GENE
( O
RAG I-GENE
)- O
dependent O
double O
- O
strand O
breaks O
( O
DSBs O
) O
at O
RSSs O
3 O
' O
of O
Ddelta3 I-GENE
and O
5 O
' O
of O
Jdelta1 I-GENE
. O

Recent O
studies O
have O
demonstrated O
that O
Cbl I-GENE
, O
the O
120 O
- O
kDa O
protein O
product O
of O
the O
c I-GENE
- I-GENE
cbl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
, O
serves O
as O
a O
substrate O
of O
a O
number O
of O
receptor I-GENE
- I-GENE
coupled I-GENE
tyrosine I-GENE
kinases I-GENE
and O
forms O
complexes O
with O
SH3 I-GENE
and O
SH2 I-GENE
domain O
- O
containing O
proteins O
, O
pointing O
to O
its O
role O
in O
signal O
transduction O
. O

Although O
neither O
constitutively O
activated O
MEK I-GENE
( O
MEK I-GENE
- I-GENE
2E I-GENE
) O
nor O
v I-GENE
- I-GENE
Src I-GENE
was O
sufficient O
individually O
to O
differentiate O
the O
H19 O
- O
7 O
cells O
, O
coexpression O
of O
constitutively O
activated O
MEK I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
induced O
neurite O
outgrowth O
. O

This O
mechanism O
is O
in O
contrast O
to O
other O
cases O
of O
splicing O
regulation O
by O
PTB I-GENE
, O
in O
which O
the O
protein O
represses O
the O
splice O
site O
to O
which O
it O
binds O
. O

While O
important O
for O
ligand O
- O
dependent O
transactivation O
, O
this O
interaction O
surface O
is O
not O
directly O
involved O
in O
transrepression O
of O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

Gal4 I-GENE
- O
Eed I-GENE
fusion O
protein O
represses O
transcription O
of O
a O
reporter O
gene O
driven O
by O
a O
promoter O
that O
contains O
Gal4 I-GENE
- I-GENE
binding I-GENE
DNA I-GENE
elements I-GENE
. O

In O
situ O
hybridization O
analysis O
in O
adult O
rat O
tissue O
reveals O
good O
correlation O
with O
this O
pattern O
and O
indicates O
that O
drm I-GENE
mRNA I-GENE
is O
most O
highly O
expressed O
in O
nondividing O
and O
terminally O
differentiated O
cells O
, O
such O
as O
neurons O
, O
type O
1 O
lung O
cells O
, O
and O
goblet O
cells O
. O

Neither O
of O
these O
proteins O
, O
individually O
or O
as O
a O
pair O
, O
can O
bind O
the O
alpha I-GENE
- I-GENE
globin I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
unless O
they O
are O
complexed O
with O
the O
remaining O
non O
- O
poly O
( O
C O
) O
binding O
proteins O
of O
the O
alpha I-GENE
- I-GENE
complex I-GENE
. O

A O
2 O
years O
and O
9 O
months O
old O
female O
patient O
, O
with O
the O
diagnosis O
of O
Weaver O
syndrome O
is O
reported O
. O

Confirming O
measures O
made O
by O
nurses O
and O
additionally O
, O
ABPM O
for O
women O
, O
seem O
to O
lessen O
this O
effect O
. O

In O
a O
series O
of O
patients O
with O
neuroinfection O
, O
Lyme O
disease O
, O
Guillain O
Barre O
syndrome O
, O
demyelinization O
, O
partial O
or O
generalized O
, O
epilepsy O
, O
we O
have O
investigated O
antiphospholipid O
antibodies O
of O
IgG I-GENE
and O
IgM I-GENE
subtypes O
, O
together O
with O
anticoagulant O
factors O
, O
member O
of O
thrombocytes O
, O
sedimentation O
rate O
of O
erythrocytes O
. O

( O
1996a O
) O
Biochemistry O
35 O
, O
1589 O
- O
1598 O
]. O

Second O
, O
the O
membrane O
expression O
of O
alpha O
and O
beta O
subunits O
was O
mimicked O
by O
cholesterol O
and O
17 O
- O
ketocholesterol O
, O
both O
of O
which O
inhibit O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
. O

Our O
results O
suggest O
that O
Lrp I-GENE
binds O
a O
central O
palindromic O
site O
, O
interacting O
predominantly O
with O
the O
major O
groove O
of O
its O
DNA O
target O
, O
and O
that O
additional O
dimers O
bind O
to O
flanking O
sites O
to O
form O
a O
nucleoprotein O
activation O
complex O
. O

Sustained O
activation O
of O
p21 I-GENE
expression O
is O
proposed O
to O
be O
a O
distinguishing O
feature O
of O
the O
activity O
of O
NGF I-GENE
that O
contributes O
to O
PC12 O
growth O
arrest O
during O
differentiation O

The O
remaining O
80 O
patients O
underwent O
recordings O
of O
ECG O
, O
beat O
- O
to O
- O
beat O
arterial O
oxygen O
saturation O
( O
SaO2 O
), O
and O
respiration O
during O
both O
spontaneous O
and O
controlled O
breathing O
. O

The O
mean O
total O
white O
cell O
count O
increased O
from O
a O
baseline O
of O
11 O
. O
3 O
x O
10 O
( O
9 O
)/ O
L O
( O
SD O
2 O
. O
3 O
) O
to O
16 O
. O
2 O
x O
10 O
( O
9 O
)/ O
L O
( O
SD O
4 O
. O
6 O
) O
on O
day O
1 O
, O
normalising O
thereafter O
. O

A O
prospective O
observational O
study O
was O
conducted O
to O
identify O
early O
indicators O
of O
acute O
dengue O
virus O
infection O
. O

In O
all O
experimental O
eyes O
, O
there O
was O
a O
marked O
reduction O
, O
but O
never O
a O
complete O
absence O
of O
adrenergic O
nerves O
in O
the O
iris O
. O

These O
lesions O
may O
be O
treated O
by O
propranolol O
or O
phentolamine O
. O

Furthermore O
, O
ICER I-GENE
negatively O
autoregulates O
the O
alternative O
promoter O
, O
thus O
generating O
a O
feedback O
loop O
. O

This O
night O
- O
day O
oscillation O
is O
driven O
by O
the O
endogenous O
clock O
( O
located O
in O
the O
suprachiasmatic O
nucleus O
, O
SCN O
). O

It O
is O
present O
in O
the O
nucleus O
of O
the O
cells O
in O
which O
it O
is O
expressed O
and O
can O
phosphorylate O
and O
activate O
the O
cyclic I-GENE
AMP I-GENE
response I-GENE
element I-GENE
binding I-GENE
proteins I-GENE
CREB I-GENE
and O
CREM I-GENE
tau I-GENE
in O
a O
manner O
analogous O
to O
protein I-GENE
kinase I-GENE
A I-GENE
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB I-GENE
and O
produce O
significantly O
less O
of O
the O
cytokine O
Interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
in O
response O
to O
agents O
that O
either O
increase O
intracellular O
Ca2 O
+ O
and O
/ O
or O
activate O
protein I-GENE
kinase I-GENE
C I-GENE
. O

Both O
of O
these O
dogs O
had O
low O
serum O
IgG I-GENE
( O
3 O
. O
5 O
to O
7 O
. O
2 O
mg O
/ O
ml O
) O
and O
the O
second O
littermate O
also O
had O
reduced O
serum O
IgA I-GENE
(< O
0 O
. O
1 O
to O
0 O
. O
15 O
mg O
/ O
ml O
). O

CONCLUSIONS O
: O
Valproate O
appears O
to O
inhibit O
the O
glucuronidation O
of O
carbamazepine O
- O
10 O
, O
11 O
- O
trans O
- O
diol O
, O
and O
probably O
also O
inhibits O
the O
conversion O
of O
carbamazepine O
- O
10 O
, O
11 O
- O
epoxide O
to O
this O
trans O
- O
diol O
derivative O
, O
rather O
than O
simply O
inhibiting O
the O
latter O
reaction O
only O
. O

The O
Ogg1 I-GENE
protein I-GENE
efficiently O
cleaves O
a O
DNA O
duplex O
where O
a O
preformed O
AP I-GENE
site I-GENE
is O
placed O
opposite O
a O
cytosine O
( O
AP O
/ O
C O
). O

A O
consensus O
sequence O
indicates O
a O
highly O
conserved O
lysine O
residue O
, O
K120 O
of O
endonuclease I-GENE
III I-GENE
or O
K241 O
of O
Ogg1 I-GENE
, O
respectively O
. O

Overall O
, O
these O
findings O
demonstrate O
that O
mutations O
E768D O
and O
V804L O
are O
gain O
- O
of O
- O
function O
mutations O
that O
confer O
to O
the O
long I-GENE
RET I-GENE
isoform I-GENE
the O
capacity O
to O
exert O
a O
biological O
effect O
, O
although O
these O
mutations O
are O
more O
weakly O
activating O
than O
the O
MEN2A I-GENE
and O
MEN2B I-GENE
mutations O
. O

Volunteers O
were O
irradiated O
on O
their O
backs O
with O
suberythemal O
UV O
daily O
for O
5 O
d O
after O
application O
of O
the O
sunscreens O
and O
their O
base O
lotion O
to O
different O
sites O
. O

E2F I-GENE
is O
a O
heterodimeric O
complex O
consisting O
of O
E2F I-GENE
family I-GENE
members I-GENE
( I-GENE
1 I-GENE
- I-GENE
5 I-GENE
) I-GENE
and O
DP O
proteins O
( O
1 O
- O
3 O
). O

EBER1 I-GENE
mRNA I-GENE
, O
a O
consistent O
marker O
of O
viral O
latency O
, O
was O
positive O
in O
all O
PEL O
cases O
, O
although O
at O
lower O
levels O
than O
in O
the O
non O
- O
PEL O
controls O
due O
to O
EBER1 I-GENE
expression O
by O
only O
a O
variable O
subset O
of O
lymphoma O
cells O
. O

METHODS O
: O
Four O
hundred O
fifty O
patients O
with O
the O
diagnosis O
of O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
received O
their O
primary O
treatment O
at O
Roswell O
Park O
Cancer O
Center O
( O
RPCI O
) O
from O
1971 O
to O
1991 O
. O

Therefore O
, O
use O
of O
presaturation O
is O
recommended O
for O
myocardial O
motion O
studies O
using O
cine O
PC O
velocity O
data O
. O

In O
addition O
, O
the O
DNA O
- O
binding O
experiments O
show O
that O
either O
one O
of O
the O
two O
MADS I-GENE
domains I-GENE
of O
a O
dimer O
can O
be O
sufficient O
to O
confer O
a O
particular O
DNA O
- O
binding O
specificity O
to O
the O
complex O
and O
that O
sequences O
outside O
the O
amino O
- O
terminal O
basic O
region O
of O
the O
MADS I-GENE
domain O
can O
, O
in O
some O
cases O
, O
contribute O
to O
the O
DNA O
- O
binding O
specificity O
of O
the O
proteins O
. O

PURPOSE O
/ O
OBJECTIVES O
: O
To O
examine O
the O
question O
of O
whether O
an O
early O
first O
full O
- O
term O
pregnancy O
( O
FFTP O
) O
protects O
against O
breast O
cancer O
and O
whether O
interruption O
of O
the O
pregnancy O
with O
an O
induced O
abortion O
increases O
breast O
cancer O
risk O
. O

Two O
related O
studies O
conducted O
over O
a O
five O
week O
period O
measured O
and O
typed O
HLA I-GENE
- I-GENE
DQA1 I-GENE
from O
accumulated O
DNA O
on O
autopsy O
room O
and O
Forensic O
DNA O
Laboratory O
structures O
. O

Thirty O
- O
two O
rats O
were O
divided O
into O
four O
groups O
. O

Mutagenesis O
of O
the O
pecT I-GENE
regulatory O
region O
revealed O
the O
presence O
of O
two O
sites O
in O
which O
insertions O
reproduced O
the O
pec I-GENE
- I-GENE
1 I-GENE
phenotype O
. O

BRCA1 I-GENE
, O
a O
familial O
breast O
and O
ovarian O
cancer O
susceptibility O
gene O
encodes O
nuclear O
phosphoproteins O
that O
function O
as O
tumor O
suppressors O
in O
human O
breast O
cancer O
cells O
. O

The O
alternative O
splice O
sites O
for O
the O
smallest O
adducin I-GENE
isoform O
, O
beta I-GENE
- I-GENE
3 I-GENE
, O
are O
alternative O
donor O
and O
acceptor O
sites O
within O
exons O
7 O
and O
12 O
. O

Proteinuria O
in O
a O
young O
man O
. O

Neural O
blockade O
in O
chronic O
and O
cancer O
pain O
. O

Two O
new O
temperature O
- O
sensitive O
alleles O
of O
SEC3 I-GENE
, O
1 O
of O
10 O
late O
- O
acting O
SEC I-GENE
genes I-GENE
required O
for O
targeting O
or O
fusion O
of O
post O
- O
Golgi O
secretory O
vesicles O
to O
the O
plasma O
membrane O
in O
Saccharomyces O
cerevisiae O
, O
were O
isolated O
in O
a O
screen O
for O
temperature O
- O
sensitive O
secretory O
mutants O
that O
are O
synthetically O
lethal O
with O
sec4 I-GENE
- I-GENE
8 I-GENE
. O

Five O
cell O
strains O
of O
human O
dermal O
fibroblasts O
were O
each O
treated O
with O
three O
samples O
of O
burn O
blister O
fluid O
and O
the O
effect O
compared O
with O
the O
rate O
of O
contraction O
of O
free O
floating O
fibroblast O
populated O
collagen I-GENE
lattices O
( O
FPCL O
). O

It O
is O
thus O
one O
of O
the O
key O
enzymes O
involved O
in O
the O
triiodothyronine O
- O
mediated O
control O
of O
growth O
, O
differentiation O
and O
basal O
metabolism O
in O
vertebrates O
. O

Cell O
49 O
, O
753 O
- O
761 O
]. O

Twenty O
- O
one O
ELISA O
- O
positive O
sera O
were O
tested O
and O
confirmed O
positive O
by O
plaque O
reduction O
neutralization O
testing O
. O

Patients O
received O
either O
diltiazem O
CD O
180 O
mg O
or O
placebo O
once O
/ O
day O
in O
combination O
with O
existing O
antianginal O
therapy O
. O

Reactive O
lymphoid O
hyperplasia O
was O
found O
in O
15 O
cases O
, O
2 O
cases O
had O
angiofollicular O
lymphoid O
hyperplasia O
or O
Castleman O
' O
s O
disease O
, O
atypical O
lymphoid O
hyperplasia O
suggestive O
of O
malignant O
lymphoma O
was O
observed O
in O
3 O
cases O
, O
and O
malignant O
lymphoma O
was O
diagnosed O
in O
the O
remaining O
4 O
cases O
. O

We O
had O
previously O
analyzed O
repair O
rates O
of O
cyclobutane O
pyrimidine O
dimers O
at O
nucleotide O
resolution O
along O
the O
human I-GENE
JUN I-GENE
gene I-GENE
in O
normal O
fibroblasts O
and O
found O
very O
efficient O
repair O
of O
sequences O
near O
the O
transcription O
initiation O
site O
but O
slow O
repair O
along O
the O
promoter O
. O

Tyrosine O
1356 O
forms O
a O
multisubstrate O
binding O
site O
for O
the O
Grb2 I-GENE
and O
Shc I-GENE
adaptor I-GENE
proteins I-GENE
, O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
, O
phospholipase I-GENE
Cgamma I-GENE
, O
and O
a O
phosphatase O
, O
SHP2 I-GENE
. O

Then O
we O
correlated O
HRCT O
findings O
with O
the O
clinical O
features O
, O
pulmonary O
functions O
and O
methacholine O
PC20 O
( O
PC20M O
) O
and O
studied O
their O
clinical O
significance O
. O

Gtx I-GENE
mRNA I-GENE
accumulates O
in O
parallel O
with O
the O
RNAs O
encoding O
the O
major O
structural O
proteins O
of O
myelin O
, O
myelin I-GENE
basic I-GENE
protein I-GENE
( O
MBP I-GENE
), O
and O
proteolipid I-GENE
protein I-GENE
( O
PLP I-GENE
) O
during O
postnatal O
brain O
development O
; O
Gtx I-GENE
mRNA I-GENE
decreases O
in O
parallel O
with O
MBP I-GENE
and O
PLP I-GENE
mRNAs I-GENE
in O
the O
brains O
of O
myelin O
- O
deficient O
rats O
, O
which O
have O
a O
point O
mutation O
in O
the O
PLP I-GENE
gene I-GENE
. O

Contacts O
between O
Bacillus O
subtilis O
catabolite O
regulatory O
protein O
CcpA I-GENE
and O
amyO I-GENE
target O
site O
. O

They O
also O
interact O
with O
GTPase I-GENE
activating I-GENE
proteins I-GENE
encoded O
by O
IRA1 I-GENE
and O
IRA2 I-GENE
. O

For O
E2 O
, O
each O
cat O
was O
given O
either O
5 O
( O
group O
[ O
G O
] O
1 O
) O
or O
10 O
( O
G2 O
) O
mg O
of O
itraconazole O
/ O
kg O
( O
capsules O
) O
twice O
daily O
for O
6 O
weeks O
. O

RESULTS O
: O
For O
E1 O
, O
itraconazole O
plasma O
drug O
concentration O
extrapolated O
to O
time O
zero O
( O
IV O
dose O
) O
was O
5 O
. O
2 O
+/- O
1 O
. O
4 O
micrograms O
/ O
ml O
, O
and O
mean O
residence O
time O
( O
MRT O
) O
was O
37 O
+/- O
16 O
hours O
. O

The O
human O
U4 I-GENE
/ O
U6 I-GENE
snRNP O
contains O
60 O
and O
90kD O
proteins O
that O
are O
structurally O
homologous O
to O
the O
yeast O
splicing O
factors O
Prp4p I-GENE
and O
Prp3p I-GENE
. O

G I-GENE
- I-GENE
CSF I-GENE
was O
started O
on O
day O
3 O
of O
each O
cycle O
( O
5 O
microg O
/ O
kg O
/ O
day O
) O
and O
was O
stopped O
the O
day O
before O
the O
last O
apheresis O
or O
when O
absolute O
neutrophil O
count O
was O
above O
0 O
. O
5 O
x O
10 O
( O
9 O
)/ O
l O
. O

The O
used O
expression O
system O
could O
allow O
to O
produce O
mutated O
forms O
of O
SsEF I-GENE
- I-GENE
2 I-GENE
obtained O
by O
mutagenesis O
of O
the O
corresponding O
gene O
. O

Crosstalk O
among O
the O
pathways O
may O
explain O
how O
some O
forms O
of O
stress O
can O
contribute O
to O
the O
development O
of O
a O
malignancy O
. O

Supershift O
assays O
, O
using O
Jun I-GENE
and I-GENE
Fos I-GENE
family I-GENE
member I-GENE
- I-GENE
specific I-GENE
antibodies I-GENE
, O
showed O
that O
protein O
complexes O
formed O
by O
AtT O
- O
20 O
cell O
nuclear O
extracts O
bound O
to O
the O
c I-GENE
- I-GENE
jun I-GENE
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
were O
comprised O
of O
Jun I-GENE
family O
members O
, O
JunD I-GENE
, O
JunB I-GENE
, O
and O
cJun I-GENE
. O

The O
majority O
of O
PI I-GENE
kinase I-GENE
activity O
appeared O
to O
be O
cbl I-GENE
- O
associated O
after O
PRL I-GENE
stimulation O
. O

Mutation O
of O
Enh4 I-GENE
, O
an O
essential O
GT I-GENE
- I-GENE
IIC I-GENE
- I-GENE
like I-GENE
enhanson I-GENE
in O
the O
context O
of O
the O
intact O
enhancer O
, O
abolishes O
silencer O
activity O
, O
and O
multimerized O
GT I-GENE
- I-GENE
IIC I-GENE
enhansons I-GENE
mimic O
the O
intact O
CSEn I-GENE
enhancer I-GENE
/ I-GENE
silencer I-GENE
activities O
in O
BeWo O
and O
GC O
cells O
, O
respectively O
. O

Using O
lectin I-GENE
- O
affinity O
chromatography O
, O
discordance O
between O
the O
pattern O
of O
O O
- O
glycosylation O
of O
SSBP I-GENE
and O
DSBP I-GENE
was O
demonstrated O
. O

Deletion O
mapping O
experiments O
determined O
that O
the O
sequences O
required O
for O
full O
activity O
in O
MSC O
- O
1 O
cells O
were O
included O
within O
619 O
bp O
of O
the O
start O
site O
and O
identified O
several O
regions O
that O
demonstrated O
increased O
luciferase I-GENE
activity O
: O
the O
- O
583 O
bp O
to O
- O
564 O
bp O
, O
- O
503 O
bp O
to O
- O
484 O
bp O
, O
and O
- O
114 O
bp O
to O
- O
65 O
regions O
. O

Furthermore O
, O
the O
PH I-GENE
and O
PTB O
domains O
are O
highly O
homologous O
( O
at O
least O
40 O
% O
identical O
) O
to O
those O
found O
in O
insulin I-GENE
receptor I-GENE
substrates I-GENE
1 I-GENE
, I-GENE
2 I-GENE
, I-GENE
and I-GENE
3 I-GENE
( O
IRS I-GENE
- I-GENE
1 I-GENE
, O
IRS I-GENE
- I-GENE
2 I-GENE
, O
and O
IRS I-GENE
- I-GENE
3 I-GENE
). O

The O
mouse O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
2 I-GENE
gene I-GENE
. O

As O
demonstrated O
by O
gel O
mobility O
shift O
analysis O
and O
supershift O
experiments O
, O
FIRE1 I-GENE
, O
located O
between O
- O
516 O
and O
- O
498 O
, O
is O
responsible O
for O
binding O
NF I-GENE
- I-GENE
Y I-GENE
. O

MR O
imaging O
of O
traumatic O
head O
injuries O
using O
FLAIR O
technique O

Gag I-GENE
protein O
sequence O
motifs O
of O
the O
NC I-GENE
domain I-GENE
of O
primate O
foamy O
viruses O
assumed O
to O
be O
involved O
in O
genome O
encapsidation O
are O
not O
conserved O
in O
FeFV O
. O

Induction O
of O
B O
cell O
apoptosis O
by O
co O
- O
cross O
- O
linking O
CD23 I-GENE
and O
sIg I-GENE
involves O
aberrant O
regulation O
of O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
inhibited O
by O
bcl I-GENE
- I-GENE
2 I-GENE
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
Lung O
elastance O
( O
EL O
) O
and O
resistance O
( O
RL O
) O
were O
calculated O
from O
measurements O
of O
airway O
pressure O
, O
esophageal O
pressure O
, O
and O
airway O
flow O
in O
five O
anesthetized O
, O
paralyzed O
dogs O
during O
sinusoidal O
forcing O
at O
a O
constant O
mean O
airway O
pressure O
of O
10 O
cmH2O O
in O
a O
wide O
range O
of O
breathing O
frequencies O
( O
0 O
. O
2 O
to O
1 O
. O
0 O
Hz O
in O
intervals O
of O
0 O
. O
2 O
) O
and O
tidal O
volumes O
( O
50 O
, O
100 O
, O
200 O
, O
and O
to O
300 O
mL O
). O

Here O
, O
we O
report O
theoretical O
models O
for O
the O
Gla O
and O
EGF I-GENE
- I-GENE
1 I-GENE
modules I-GENE
of O
human I-GENE
PS I-GENE
constructed O
using O
prothrombin I-GENE
and O
factor I-GENE
X I-GENE
experimental O
structures O
. O

The O
Cut9 I-GENE
subunit I-GENE
is O
likely O
to O
be O
a O
target O
for O
regulating O
APC I-GENE
/ I-GENE
cyclosome I-GENE
function O
through O
protein O
- O
protein O
interactions O
and O
phosphorylation O
. O

The O
dose O
was O
50 O
Gy O
/ O
20 O
fractions O
/ O
5 O
weeks O
. O

Because O
the O
biosynthetic O
pathway O
to O
the O
vacuole O
intersects O
with O
the O
endocytic O
pathway O
, O
internalization O
of O
a O
bulk O
membrane O
endocytic O
marker O
FM O
4 O
- O
64 O
was O
assayed O
in O
the O
sop I-GENE
mutants I-GENE
. O

All O
the O
women O
received O
13 O
. O
5 O
mg O
plain O
bupivacaine O
via O
subarachnoid O
injection O
at O
the O
L2 O
- O
3 O
interspace O
. O

Far O
from O
this O
being O
the O
case O
, O
however O
, O
the O
measurement O
of O
apo I-GENE
B I-GENE
has O
met O
every O
reasonable O
standard O
of O
laboratory O
precision O
and O
reliability O
to O
allow O
its O
widespread O
introduction O
in O
clinical O
laboratories O
. O

Two O
soybean O
cDNA O
clones O
, O
SPK I-GENE
- I-GENE
3 I-GENE
and O
SPK I-GENE
- I-GENE
4 I-GENE
, O
encoding O
putative O
protein O
kinases O
were O
isolated O
and O
characterized O
. O

Genes O
belonging O
to O
the O
ras I-GENE
superfamily I-GENE
encode O
low I-GENE
- I-GENE
molecular I-GENE
- I-GENE
weight I-GENE
GTP I-GENE
/ I-GENE
GDP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
highly O
conserved O
in O
wide O
variety O
of O
organisms O
. O

Naltrexone O
has O
been O
recently O
approved O
by O
the O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
alcohol O
dependence O
. O

Ent I-GENE
- I-GENE
kaurene I-GENE
synthase I-GENE
from I-GENE
the I-GENE
fungus I-GENE
Phaeosphaeria I-GENE
sp O
. O

In O
this O
report O
, O
we O
identify O
and O
characterize O
two O
overlapping O
ELL I-GENE
functional I-GENE
domains I-GENE
that O
govern O
its O
interaction O
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
the O
ternary O
elongation O
complex O
. O

Eight O
induced O
cDNA O
sequences O
were O
identified O
and O
designated O
message I-GENE
up I-GENE
- I-GENE
regulated I-GENE
during I-GENE
death I-GENE
( I-GENE
mud I-GENE
)- I-GENE
1 I-GENE
- I-GENE
8 I-GENE
. O

The O
position O
, O
transcription O
orientation O
, O
and O
imprinted O
status O
of O
the O
genes O
immediately O
flanking O
Igf2r I-GENE
have O
been O
assessed O
. O

Here O
, O
we O
describe O
directional O
chromosome O
walking O
studies O
starting O
from O
D8S260 I-GENE
as O
well O
as O
D8S285 I-GENE
. O

We O
describe O
a O
novel O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
dsRBP I-GENE
- I-GENE
ZFa I-GENE
, O
isolated O
by O
screening O
an O
expression O
library O
with O
dsRNA O
. O

Our O
results O
indicate O
that O
the O
retroplasmid O
reverse I-GENE
transcriptase I-GENE
is O
uniquely O
adapted O
to O
initiate O
cDNA O
synthesis O
by O
recognizing O
a O
3 O
' O
CCA O
sequence O
. O

Nasal O
absorption O
was O
rapid O
, O
nasal O
bioavailability O
was O
43 O
%, O
and O
the O
iv O
and O
nasal O
elimination O
profiles O
were O
similar O
. O

Together O
, O
these O
results O
suggest O
that O
EGF I-GENE
/ O
Ras I-GENE
/ O
Raf I-GENE
induces O
transcription O
via O
combined O
activation O
of O
ATF3 I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
and O
a O
52 O
- O
kDa O
nuclear O
factor O
, O
whereas O
JunD I-GENE
acts O
as O
a O
repressor O
of O
this O
response O
. O

Together O
, O
these O
data O
support O
a O
model O
in O
which O
Tax I-GENE
anchors O
CBP I-GENE
to O
the O
HTLV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
, O
with O
strong O
transcriptional O
activation O
resulting O
from O
the O
CBP I-GENE
- O
associated O
activities O
of O
nucleosome O
remodeling O
and O
recruitment O
of O
the O
general O
transcription O
machinery O
. O

DNase I-GENE
I I-GENE
and O
1 O
, O
10 O
- O
phenanthroline O
- O
copper O
footprinting O
of O
MURA I-GENE
- O
Mu1 I-GENE
TIR O
complexes O
indicate O
that O
MURA I-GENE
binds O
to O
a O
conserved O
approximately O
32 O
- O
bp O
region O
in O
the O
TIR O
of O
Mu1 I-GENE
. O

Consistent O
with O
this O
model O
, O
a O
synthetic O
construct O
containing O
three O
tandem O
copies O
of O
the O
native O
LDL I-GENE
receptor I-GENE
SREBP I-GENE
site O
linked O
to O
a O
single O
Sp1 I-GENE
site I-GENE
was O
also O
significantly O
activated O
in O
a O
buttonhead I-GENE
- O
independent O
fashion O
. O

Various O
assays O
demonstrate O
promoter O
activity O
in O
this O
sequence O
that O
reproduces O
the O
normal O
control O
of O
E2F2 I-GENE
expression O
during O
a O
growth O
stimulation O
. O

In O
the O
adult O
mouse O
, O
ERR I-GENE
alpha I-GENE
is O
most O
highly O
expressed O
in O
kidney O
, O
heart O
, O
and O
brown O
adipocytes O
, O
tissues O
which O
preferentially O
metabolize O
fatty O
acids O
. O

The O
MCAD I-GENE
nuclear I-GENE
receptor I-GENE
response I-GENE
element I-GENE
1 I-GENE
( O
NRRE I-GENE
- I-GENE
1 I-GENE
) O
interacts O
in O
vitro O
with O
ERR I-GENE
alpha I-GENE
expressed O
in O
COS O
- O
7 O
cells O
. O

Mapping O
features O
of O
HIV I-GENE
- I-GENE
1 I-GENE
integrase I-GENE
near O
selected O
sites O
on O
viral O
and O
target O
DNA O
molecules O
in O
an O
active O
enzyme O
- O
DNA O
complex O
by O
photo O
- O
cross O
- O
linking O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

Analysis O
of O
the O
5 O
' O
flanking O
region O
of O
the O
gene O
also O
revealed O
the O
presence O
of O
multiple O
TATA O
and O
CAAT O
sequences O
. O

The O
complete O
response O
( O
CR O
) O
rate O
was O
34 O
% O
in O
the O
CODE O
with O
rhG I-GENE
- I-GENE
CSF I-GENE
group O
and O
23 O
% O
in O
the O
CODE O
alone O
group O
; O
the O
median O
survival O
was O
59 O
and O
32 O
weeks O
, O
respectively O
, O
in O
these O
groups O
( O
P O
= O
0 O
. O
004 O
). O

Heterogeneous I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
binds O
to O
the O
transcription O
- O
regulatory O
region O
of O
mouse O
hepatitis O
virus O
RNA O
. O

The O
m7GpppN O
cap O
structure O
of O
eukaryotic O
mRNA O
is O
formed O
cotranscriptionally O
by O
the O
sequential O
action O
of O
three O
enzymes O
: O
RNA I-GENE
triphosphatase I-GENE
, O
RNA I-GENE
guanylyltransferase I-GENE
, O
and O
RNA I-GENE
( I-GENE
guanine I-GENE
- I-GENE
7 I-GENE
)- I-GENE
methyltransferase I-GENE
. O

In O
the O
first O
part O
of O
our O
study O
, O
the O
highest O
mutagenicity O
was O
revealed O
by O
TA98 O
strain O
without O
enzymatic O
activation O
, O
suggesting O
a O
direct O
- O
acting O
mutagenicity O
prevalence O
in O
diesel O
particulate O
. O

The O
addition O
of O
culture O
to O
the O
CC O
and O
CC O
: O
SW O
by O
- O
products O
resulted O
in O
pH O
values O
lower O
( O
P O
< O
0 O
. O
05 O
) O
than O
those O
without O
culture O
on O
Day O
21 O
, O
and O
the O
15 O
% O
carbohydrate O
treatment O
significantly O
reduced O
pH O
beyond O
the O
5 O
% O
carbohydrate O
. O

Myocardial O
interstitial O
edema O
is O
more O
likely O
a O
potential O
mechanism O
of O
diastolic O
dysfunction O
after O
DC O
shocks O
. O

Two O
experiments O
( O
N O
= O
20 O
each O
) O
were O
carried O
out O
to O
explore O
the O
nature O
of O
ERP O
negativities O
in O
a O
visuospatial O
memory O
task O
and O
in O
an O
auditory O
spatial O
memory O
task O
, O
respectively O
. O

Biol O
. O

The O
pattern O
and O
timing O
of O
CARP I-GENE
mRNA I-GENE
expression O
, O
including O
transient O
expression O
in O
the O
tongue O
at O
14 O
. O
5 O
days O
p O
. O
c O
., O
coincides O
with O
that O
of O
Nkx2 I-GENE
. I-GENE
5 I-GENE
/ O
Csx I-GENE
( O
a O
putative O
homolog O
of O
tinman I-GENE
, O
the O
Drosophila O
melanogaster O
gene O
responsible O
for O
cardiac O
development O
). O

Overexpression O
of O
CARP I-GENE
in O
cardiomyocytes O
suppresses O
cardiac I-GENE
troponin I-GENE
C I-GENE
and O
atrial I-GENE
natriuretic I-GENE
factor I-GENE
transcription O
. O

Substrate O
specificity O
of O
the O
RNase I-GENE
activity O
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
. O

Electrophoretic O
mobility O
shift O
assays O
and O
competition O
experiments O
showed O
that O
site O
A O
is O
recognized O
by O
an O
NF1 I-GENE
protein I-GENE
. O

Examination O
of O
the O
MMP I-GENE
- I-GENE
2 I-GENE
RE1 I-GENE
sequence I-GENE
revealed O
an O
incomplete O
Y O
- O
box O
sequence O
( O
CTGCTGGGCAAG O
), O
which O
specifically O
interacted O
with O
recombinant I-GENE
YB I-GENE
- I-GENE
1 I-GENE
on O
DMS O
protection O
footprinting O
analysis O
. O

Hence O
, O
scs32 I-GENE
only O
partially O
suppressed O
the O
ts O
phenotype O
and O
was O
unable O
to O
suppress O
the O
Ino O
- O
phenotype O
of O
rpo26 I-GENE
- I-GENE
31 I-GENE
. O

In O
contrast O
, O
both O
Sp1 I-GENE
and O
ETS I-GENE
proteins I-GENE
are O
required O
to O
bring O
about O
full O
promoter O
activity O
in O
the O
Surf I-GENE
- I-GENE
1 I-GENE
direction O
. O

CONCLUSION O
: O
Patients O
wit O
clinically O
palpable O
neck O
disease O
( O
N1 O
- O
3 O
), O
histological O
evidence O
of O
metastatic O
nodal O
disease O
, O
extracapsular O
spread O
, O
and O
three O
or O
more O
positive O
lymph O
nodes O
are O
at O
greater O
risk O
of O
developing O
failure O
at O
distant O
sites O
. O

We O
have O
subcloned O
into O
pBR322 O
deoxyribonucleic O
acid O
( O
DNA O
) O
sequences O
mapping O
either O
in O
the O
coding O
region O
, O
the O
5 O
' O
spacer O
, O
or O
the O
3 O
' O
spacer O
of O
the O
H2B I-GENE
histone I-GENE
gene I-GENE
. O

4 O
. O

Area O
under O
the O
drug O
concentration O
- O
time O
curves O
( O
AUC0 O
- O
24 O
hr O
) O
for O
MTX O
were O
2379 O
and O
3534 O
ng O
* O
hr O
/ O
ml O
from O
PG O
- O
2 O
. O
5 O
% O
Azone O
and O
PG O
- O
7 O
. O
5 O
% O
Azone O
systems O
respectively O
. O

The O
combination O
of O
hydralazine O
hydrochloride O
and O
isosorbide O
dinitrate O
also O
improves O
survival O
, O
but O
direct O
comparison O
of O
both O
regimens O
provided O
evidence O
for O
a O
less O
favourable O
effect O
than O
that O
of O
the O
ACE I-GENE
inhibitors O
. O

To O
address O
mechanisms O
that O
define O
interactions O
of O
Site I-GENE
II I-GENE
regulatory I-GENE
factors I-GENE
with O
this O
cell O
cycle O
control O
element O
, O
we O
have O
investigated O
these O
determinants O
of O
transcriptional O
regulation O
at O
the O
G1 O
/ O
S O
phase O
transition O
in O
FDC O
- O
P1 O
hematopoietic O
progenitor O
cells O
. O

The O
goal O
of O
this O
study O
was O
to O
identify O
neuronal O
cell O
cultures O
that O
express O
RC3 I-GENE
/ O
neurogranin I-GENE
, O
to O
check O
whether O
they O
are O
sensitive O
to O
T3 O
, O
and O
to O
examine O
the O
mechanism O
of O
regulation O
. O

There O
were O
differences O
between O
males O
( O
p O
< O
0 O
. O
05 O
) O
for O
most O
of O
the O
characteristics O
studied O
. O

Their O
circadian O
responses O
to O
both O
photic O
and O
non O
- O
photic O
cues O
were O
then O
tested O
. O

Although O
previous O
data O
have O
suggested O
that O
Rev I-GENE
uses O
the O
same O
export O
pathway O
as O
uracil O
- O
rich O
small O
nuclear O
RNAs O
and O
5S I-GENE
ribosomal I-GENE
RNA I-GENE
, O
the O
CTE O
seems O
to O
interact O
with O
evolutionarily O
conserved O
factors O
that O
are O
essential O
for O
cellular O
mRNA O
export O
. O

Human I-GENE
Duo I-GENE
contains O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
GEF I-GENE
) O
domain O
that O
is O
likely O
to O
be O
rac1 I-GENE
- O
specific O
, O
a O
pleckstrin I-GENE
homology I-GENE
( O
PH I-GENE
) O
domain O
and O
spectrin I-GENE
- I-GENE
like I-GENE
repeat I-GENE
units I-GENE
. O

S2F I-GENE
, O
a O
leaf O
- O
specific O
trans O
- O
acting O
factor O
, O
binds O
to O
a O
novel O
cis O
- O
acting O
element O
and O
differentially O
activates O
the O
RPL21 I-GENE
gene I-GENE
. O

ArgR I-GENE
was O
shown O
to O
be O
a O
dimer O
of O
two O
equal O
subunits O
, O
each O
with O
a O
molecular O
mass O
of O
37 O
, O
000 O
Da O
. O

Plasma I-GENE
leptin I-GENE
concentrations O
were O
higher O
in O
women O
than O
men O
, O
even O
after O
the O
adjustment O
for O
differences O
in O
fat O
mass O
( O
28 O
+/- O
3 O
ng O
/ O
ml O
for O
women O
vs O
. O

Consistent O
with O
effects O
on O
STAT I-GENE
activation O
, O
altered O
SHP I-GENE
- I-GENE
1 I-GENE
expression O
also O
affected O
EGF I-GENE
- O
induced O
activation O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
; O
expression O
of O
SHP I-GENE
- I-GENE
1 I-GENE
-( I-GENE
Cys I-GENE
--> I-GENE
Ser I-GENE
) I-GENE
inhibited O
activity O
of O
MEK I-GENE
by O
approximately O
25 O
%, O
whereas O
expression O
of O
SHP I-GENE
- I-GENE
1 I-GENE
resulted O
in O
a O
approximately O
25 O
% O
increase O
. O

This O
interaction O
involved O
the O
SH3 I-GENE
region I-GENE
of O
p50 I-GENE
( O
csk I-GENE
) O
and O
a O
proline O
- O
rich O
region O
( O
PPPLPERTPESFVLADM O
) O
outside O
the O
catalytic O
region O
of O
PTP I-GENE
- O
PEST O
. O

Following O
2 O
. O
5 O
Gy O
, O
HbO2 I-GENE
changes O
were O
minimal O
. O

Polarised O
expression O
of O
human O
intestinal O
N I-GENE
- I-GENE
benzoyl I-GENE
- I-GENE
L I-GENE
- I-GENE
tyrosyl I-GENE
- I-GENE
p I-GENE
- I-GENE
aminobenzoic I-GENE
acid I-GENE
hydrolase I-GENE
( O
human I-GENE
meprin I-GENE
) O
alpha O
and O
beta O
subunits O
in O
Madin O
- O
Darby O
canine O
kidney O
cells O
. O

Neither O
mutant O
exhibited O
derepression O
of O
the O
silent I-GENE
mating I-GENE
type I-GENE
loci I-GENE
. O

Among O
38 O
patients O
with O
inducible O
reentrant O
VTs O
who O
underwent O
electrophysiologic O
study O
( O
EPS O
), O
10 O
VTs O
of O
six O
patients O
were O
selected O
. O

The O
cycle O
length O
of O
induced O
VT O
( O
n O
= O
10 O
VTs O
) O
was O
380 O
+/- O
41 O
msec O
. O

Transient O
hyperammonaemia O
in O
an O
adult O
German O
shepherd O
dog O
. O

We O
established O
that O
the O
2 O
. O
6 O
kb O
mRNA O
V O
- O
1 O
and O
the O
2 O
. O
3 O
kb O
GGT I-GENE
mRNA O
V O
- O
2 O
derive O
, O
by O
alternate O
splicing O
, O
from O
a O
primary O
transcript O
initiated O
on O
a O
distal O
promoter O
on O
the O
rat I-GENE
GGT I-GENE
gene I-GENE
. O

A O
specific O
distal O
promoter O
controls O
gamma I-GENE
- I-GENE
glutamyl I-GENE
transpeptidase I-GENE
gene I-GENE
expression O
in O
undifferentiated O
rat O
transformed O
liver O
cells O
. O

These O
repressor O
sites O
are O
pyrimidine O
rich O
and O
bind O
avidly O
to O
the O
polypyrimidine I-GENE
tract I-GENE
binding I-GENE
protein I-GENE
( O
PTB I-GENE
) O
in O
HeLa O
nuclear O
extracts O
as O
determined O
by O
UV O
crosslinking O
/ O
competition O
assays O
. O

For O
higher O
expression O
of O
lipA I-GENE
in O
S O
. O
lividans O
, O
the O
gene O
was O
cloned O
next O
to O
the O
strong O
aphII I-GENE
promoter I-GENE
. O

Within O
a O
135 O
- O
bp O
core O
homology O
region O
, O
the O
human I-GENE
HS12 I-GENE
enhancers I-GENE
are O
approximately O
90 O
% O
identical O
to O
the O
murine O
homolog O
and O
include O
several O
motifs O
previously O
demonstrated O
to O
be O
important O
for O
function O
of O
the O
murine O
enhancer O
; O
additional O
segments O
of O
high O
sequence O
conservation O
suggest O
the O
possibility O
of O
previously O
unrecognized O
functional O
motifs O
. O

In O
contrast O
to O
the O
wild O
- O
type O
protein O
, O
expression O
of O
p45 I-GENE
NF I-GENE
- I-GENE
E2 I-GENE
lacking O
this O
activation O
domain O
in O
an O
NF I-GENE
- I-GENE
E2 I-GENE
null O
cell O
line O
fails O
to O
support O
enhancer O
- O
dependent O
transcription O
in O
transient O
assays O
. O

These O
findings O
suggest O
one O
potential O
mechanism O
for O
direct O
recruitment O
of O
distal O
regulatory O
regions O
of O
the O
globin I-GENE
loci I-GENE
to O
the O
individual O
promoters O
. O

The O
promoter O
region O
showed O
no O
consensus O
TATA O
box O
but O
it O
contains O
CCAAT O
and O
CreA I-GENE
boxes O
known O
to O
be O
involved O
in O
both O
stress O
and O
carbon O
- O
catabolite O
regulation O
of O
fungal O
promoters O
. O

The O
two O
cysteine O
residues O
located O
in O
this O
additional O
region O
may O
be O
involved O
in O
the O
formation O
of O
a O
disulfide O
bridge O
associated O
with O
the O
activation O
process O
of O
the O
catalytic O
activity O
. O

The O
por I-GENE
gene I-GENE
has O
been O
expressed O
, O
for O
the O
first O
time O
, O
in O
anaerobically O
grown O
Escherichia O
coli O
behind O
the O
isopropyl O
- O
beta O
- O
D O
- O
thiogalactopyranoside O
- O
inducible O
tac I-GENE
promoter I-GENE
, O
resulting O
in O
the O
production O
of O
POR I-GENE
in O
its O
active O
form O
. O

When O
the O
downstream O
operator O
was O
altered O
, O
there O
was O
a O
fourfold O
reduction O
in O
reporter O
enzyme O
levels O
. O

The O
ORF3 O
mutant O
produced O
reduced O
levels O
of O
tabtoxin I-GENE
, O
indicating O
that O
ORF3 O
may O
have O
a O
role O
in O
T I-GENE
beta I-GENE
L I-GENE
biosynthesis O
. O

Refined O
Cox O
models O
using O
a O
CD4 I-GENE
count O
of O
150 O
/ O
microL O
rather O
than O
200 O
/ O
microL O
to O
distinguish O
I0 O
and O
I1 O
yielded O
a O
simplified O
model O
with O
better O
fit O
to O
the O
observed O
data O
. O

However O
, O
the O
published O
reports O
consist O
of O
a O
small O
number O
of O
patients O
and O
limited O
data O
. O

These O
transcripts O
contain O
the O
5 O
' O
ends O
of O
mature O
UbCRBP I-GENE
mRNAs I-GENE
; O
extend O
through O
UbCRBP I-GENE
, O
across O
the O
intergenic O
region O
, O
and O
a O
significant O
distance O
3 O
' O
into O
the O
enolase I-GENE
gene I-GENE
. O

The O
distribution O
of O
cryptosporidia O
in O
the O
intestine O
and O
number O
of O
cryptosporidia O
per O
ileal O
villus O
on O
different O
DPI O
were O
also O
estimated O
for O
detailed O
characterization O
of O
the O
infection O
in O
kids O
as O
a O
model O
for O
experimental O
cryptosporidiosis O
. O

As O
a O
result O
, O
the O
subendocardial O
/ O
subepicardial O
blood O
flow O
ratio O
( O
ENDO O
/ O
EPI O
) O
increased O
from O
0 O
. O
44 O
+/- O
0 O
. O
09 O
during O
control O
stenosis O
to O
0 O
. O
85 O
+/- O
0 O
. O
13 O
after O
ITF O
1129 O
( O
10 O
micrograms O
/ O
kg O
/ O
min O
i O
. O
v O
.) O
and O
to O
0 O
. O
81 O
+/- O
0 O
. O
12 O
after O
NTG O
. O

Proteasomes O
are O
the O
multisubunit O
protease O
involved O
in O
the O
generation O
of O
peptides O
presented O
by O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
. O

In O
support O
of O
this O
interpretation O
we O
demonstrate O
that O
MQ9b I-GENE
binds O
strongly O
5 O
of O
17 O
motif O
- O
positive O
, O
pathogen O
- O
derived O
synthetic O
peptides O
. O

Takahashi O
, O
H O
. O

For O
sputum I-GENE
interleukin I-GENE
- I-GENE
8 I-GENE
there O
was O
an O
estimated O
true O
treatment O
median O
difference O
of O
142 O
pg O
/ O
ml O
( O
95 O
% O
confidence O
interval O
( O
CI O
) O
8 O
to O
2866 O
pg O
/ O
ml O
) O
in O
favour O
of O
placebo O
; O
while O
for O
maximal O
expiratory O
flow O
at O
25 O
% O
( O
MEF25 O
%) O
remaining O
forced O
vital O
capacity O
predicted O
for O
sex O
and O
height O
there O
was O
a O
15 O
percentage O
points O
( O
pp O
) O
( O
95 O
% O
CI O
4 O
to O
26 O
pp O
) O
mean O
treatment O
difference O
in O
favour O
of O
placebo O
. O

However O
, O
although O
deletion O
of O
Fp1 I-GENE
in O
the O
hCRBP1 I-GENE
gene I-GENE
yielded O
increased O
CAT I-GENE
activity O
, O
pointing O
toward O
a O
negative O
regulatory O
function O
exerted O
by O
this O
element O
, O
its O
insertion O
upstream O
of O
the O
p12 I-GENE
basal I-GENE
promoter I-GENE
results O
in O
an O
impressive O
positive O
stimulation O
of O
CAT I-GENE
gene I-GENE
expression O
. O

Gaucher O
' O
s O
disease O
is O
a O
rare O
metabolic O
disorder O
characterized O
by O
the O
lack O
of O
beta I-GENE
- I-GENE
glucocerebrosidase I-GENE
enzyme I-GENE
. O

These O
discoloration O
' O
s O
can O
be O
treated O
in O
several O
ways O
but O
up O
to O
lately O
tooth O
structure O
had O
to O
be O
removed O
in O
an O
irreversible O
manner O
in O
order O
to O
provide O
sufficient O
bulk O
for O
the O
new O
restorative O
material O
. O

The O
9 O
; O
22 O
chromosomal O
translocation O
characteristic O
of O
CML O
results O
in O
a O
fused O
bcr I-GENE
/ O
abl I-GENE
gene O
and O
an O
abnormal O
fusion O
protein O
, O
p210bcr I-GENE
/ O
abl I-GENE
. O

Overexpression O
of O
BAG I-GENE
- I-GENE
1 I-GENE
also O
protected O
certain O
cell O
lines O
from O
heat O
shock O
- O
induced O
cell O
death O
. O

The O
5 O
' O
flanking O
region O
contains O
potential O
binding O
sites O
for O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
Sp1 I-GENE
, O
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
NF1 I-GENE
), O
CAAT I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
), O
hepatocyte I-GENE
nuclear I-GENE
factors I-GENE
1 I-GENE
and I-GENE
5 I-GENE
( O
HNF1 I-GENE
, O
HNF5 I-GENE
) O
and O
activator I-GENE
proteins I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
AP1 I-GENE
, O
AP2 I-GENE
). O

The O
recognition O
specificity O
of O
the O
p55 I-GENE
PDZ I-GENE
domain I-GENE
appears O
to O
be O
unique O
, O
since O
the O
three O
PDZ I-GENE
domains I-GENE
of O
hDlg I-GENE
( O
human O
lymphocyte O
homologue O
of O
the O
Drosophila I-GENE
discs I-GENE
large I-GENE
tumor I-GENE
suppressor I-GENE
) O
do O
not O
bind O
the O
cytoplasmic O
domain O
of O
glycophorin I-GENE
C I-GENE
. O

By O
analyzing O
the O
RanGAP I-GENE
activity O
of O
a O
series O
of O
recombinantly O
expressed O
rna1p I-GENE
mutant I-GENE
derivatives O
, O
we O
show O
that O
the O
highly O
acidic O
sequence O
in O
the O
C O
- O
terminal O
domain O
of O
both O
yeast O
proteins O
is O
indispensable O
for O
activating O
Ran I-GENE
- O
mediated O
GTP O
hydrolysis O
. O

In O
the O
absence O
of O
MHC I-GENE
class I-GENE
II I-GENE
, O
purified I-GENE
soluble I-GENE
D10 I-GENE
TCR I-GENE
bound O
to O
Staphylococcus I-GENE
aureus I-GENE
enterotoxin I-GENE
C2 I-GENE
with O
an O
association O
rate O
of O
1 O
. O
69 O
+/- O
0 O
. O
12 O
x O
10 O
( O
4 O
) O
M O
(- O
1 O
) O
sec O
(- O
1 O
) O
and O
a O
dissociation O
rate O
of O
1 O
. O
9 O
+/- O
0 O
. O
47 O
x O
10 O
(- O
2 O
) O
sec O
(- O
1 O
), O
giving O
a O
dissociation O
constant O
of O
1 O
. O
1 O
microM O
. O

Evidence O
for O
such O
peak O
shifts O
has O
been O
found O
in O
the O
responses O
of O
auditory O
nerve O
fibers O
, O
cochlear O
microphonics O
, O
and O
the O
responses O
of O
outer O
hair O
cells O
and O
supporting O
cells O
in O
the O
cochlea O
, O
as O
well O
as O
in O
basilar O
membrane O
vibration O
measurements O
, O
and O
indirectly O
, O
in O
psychophysical O
data O
. O

Mnt I-GENE
: O
Max I-GENE
complexes O
also O
efficiently O
suppress O
Myc I-GENE
- O
dependent O
activation O
from O
the O
same O
promoter O
. O

In O
the O
United O
States O
high O
- O
MW O
HES O
480 O
which O
is O
difficult O
to O
degrade O
is O
most O
frequently O
used O
and O
results O
in O
a O
larger O
in O
vivo O
MW O
and O
subsequent O
decrease O
in O
factor I-GENE
VIII I-GENE
/ O
von I-GENE
Willebrand I-GENE
factor I-GENE
levels O
. O

Assays O
of O
total O
cholesterol O
as O
well O
as O
the O
HDL I-GENE
, O
HDL2 I-GENE
, O
LDL I-GENE
, O
triglycerides O
, O
endothelin I-GENE
- I-GENE
1 I-GENE
, O
lipoprotein O
( O
a O
), O
estradiol O
and O
FSH I-GENE
were O
also O
obtained O
at O
baseline O
before O
receiving O
ERT O
and O
after O
3 O
months O
of O
ERT O
. O

Six O
tandem O
repeats O
of O
the O
P I-GENE
element I-GENE
linked O
to O
the O
SV40 I-GENE
promoter I-GENE
responded O
to O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
, O
while O
that O
of O
other O
elements O
did O
not O
. O

The O
distributed O
current O
density O
J O
is O
calculated O
within O
the O
volume O
defined O
by O
the O
motor O
unit O
. O

The O
cleavage O
dipeptides O
of O
C1YVV I-GENE
NIa I-GENE
protease I-GENE
are O
Q O
( O
E O
)/ O
S O
( O
A O
, O
G O
). O

In O
our O
previous O
studies O
, O
transcriptional O
activation O
was O
shown O
to O
correlate O
with O
IEP86 I-GENE
binding O
to O
both O
the O
TATA I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
the O
transcription O
factor O
bound O
upstream O
. O

However O
, O
we O
were O
unable O
to O
identify O
a O
p4 I-GENE
molecule O
. O

( O
iv O
) O
The O
accumulation O
of O
cyclin I-GENE
D3 I-GENE
protein I-GENE
in O
Vero O
cells O
infected O
with O
an O
alpha0 I-GENE
deletion I-GENE
mutant I-GENE
was O
reduced O
relative O
to O
that O
of O
cells O
infected O
with O
wild O
- O
type O
virus O
or O
a O
recombinant O
virus O
in O
which O
the O
deleted O
alpha0 I-GENE
sequences I-GENE
were O
restored O
. O

We O
report O
the O
preliminary O
biochemical O
characterization O
of O
the O
T I-GENE
antigens I-GENE
encoded O
by O
three O
SV40 O
mutants O
, O
5030 O
, O
5031 O
, O
and O
5061 O
, O
each O
of O
which O
have O
altered O
residues O
within O
or O
near O
the O
ATP O
binding O
pocket O
. O

These O
effects O
were O
abrogated O
by O
co O
- O
expression O
of O
kinase I-GENE
- I-GENE
deficient I-GENE
PKC I-GENE
zeta I-GENE
and O
inhibition O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
p85alpha I-GENE
- O
p110 I-GENE
by O
wortmannin O
, O
LY294002 O
and O
a O
dominant O
- O
negative O
mutant O
of O
p85alpha I-GENE
. O

Protein I-GENE
phosphatase I-GENE
2A I-GENE
is O
a O
critical O
regulator O
of O
protein I-GENE
kinase I-GENE
C I-GENE
zeta I-GENE
signaling O
targeted O
by O
SV40 I-GENE
small I-GENE
t I-GENE
to O
promote O
cell O
growth O
and O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

Interestingly O
, O
the O
RXRalphaF318A I-GENE
constitutive O
activity O
generated O
within O
heterodimers O
in O
the O
presence O
of O
BMS614 O
requires O
the O
integrity O
of O
both O
RXR I-GENE
and O
RAR I-GENE
AF O
- O
2 O
domains O
. O

These O
introns O
contain O
only O
single O
snoRNA I-GENE
genes I-GENE
and O
their O
processing O
involves O
exonucleolytic O
release O
of O
the O
snoRNA O
from O
debranched O
intron O
lariats O
. O

Recent O
studies O
have O
shown O
that O
the O
Src I-GENE
homology I-GENE
- I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domain O
- O
containing O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
SHP I-GENE
- I-GENE
2 I-GENE
, O
associates O
with O
the O
cytoplasmic O
domain O
of O
PECAM I-GENE
- I-GENE
1 I-GENE
as O
it O
becomes O
tyrosine O
- O
phosphorylated O
during O
platelet O
aggregation O
: O
a O
process O
that O
can O
be O
mimicked O
in O
part O
by O
small O
synthetic O
phosphopeptides O
corresponding O
to O
the O
cytoplasmic O
domain O
of O
PECAM I-GENE
- I-GENE
1 I-GENE
encompassing O
tyrosine O
residues O
Tyr O
- O
663 O
or O
Tyr O
- O
686 O
. O

Underlying O
the O
clustering O
of O
these O
risk O
variables O
were O
three O
factors O
. O

Supplementation O
was O
stopped O
when O
pl I-GENE
- I-GENE
ALB I-GENE
reached O
2 O
. O
0 O
g O
/ O
dL O
. O

Detection O
of O
airborne O
Mycobacterium O
tuberculosis O
by O
air O
filtration O
and O
polymerase O
chain O
reaction O
. O

These O
findings O
show O
that O
EBP50 I-GENE
is O
a O
physiologically O
relevant O
ezrin I-GENE
binding I-GENE
protein I-GENE
. O

Previously O
, O
we O
reported O
that O
scanthrough O
translation O
, O
where O
the O
initiating O
AUG O
of O
a O
primary O
open O
reading O
frame O
is O
bypassed O
, O
is O
most O
likely O
to O
account O
for O
the O
presentation O
of O
cryptic O
epitopes O
from O
alternative O
reading O
frames O
within O
the O
influenza I-GENE
A I-GENE
PR I-GENE
/ I-GENE
8 I-GENE
/ I-GENE
34 I-GENE
nucleoprotein I-GENE
gene I-GENE
. O

This O
family O
of O
proteins O
binds O
GC O
- O
rich O
motifs O
widely O
distributed O
in O
gene O
promoters O
, O
resulting O
in O
distinct O
activation O
or O
repression O
of O
transcriptional O
activities O
. O

Deletion O
of O
the O
POR2 I-GENE
gene I-GENE
alone O
had O
no O
detectable O
phenotype O
, O
while O
yeasts O
with O
deletions O
of O
both O
the O
POR1 I-GENE
and O
POR2 I-GENE
genes I-GENE
were O
viable O
and O
able O
to O
grow O
on O
glycerol O
at O
30 O
degrees O
C O
, O
albeit O
more O
slowly O
than O
delta I-GENE
por1 I-GENE
single I-GENE
mutants I-GENE
. O

Furthermore O
, O
our O
novel O
observation O
that O
expression O
of O
a O
highly O
activated O
FGFR3 I-GENE
kinase I-GENE
domain I-GENE
is O
able O
to O
morphologically O
transform O
fibroblasts O
suggests O
that O
dysregulation O
of O
FGFR3 I-GENE
has O
the O
potential O
to O
play O
a O
role O
in O
human O
neoplasia O
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
gene O
has O
significant O
homology O
to O
the O
interferon I-GENE
regulatory I-GENE
factors I-GENE
( O
IRFs I-GENE
). O

Involvement O
of O
AP I-GENE
- I-GENE
2 I-GENE
in O
regulation O
of O
the O
R I-GENE
- I-GENE
FABP I-GENE
gene I-GENE
in O
the O
developing O
chick O
retina O
. O

However O
, O
Cbf5p I-GENE
was O
found O
to O
be O
nucleolar O
and O
is O
highly O
homologous O
to O
the O
rat I-GENE
nucleolar I-GENE
protein I-GENE
NAP57 I-GENE
, O
which O
coimmunoprecipitates O
with O
Nopp140 I-GENE
and O
which O
is O
postulated O
to O
be O
involved O
in O
nucleolar O
- O
cytoplasmic O
shuttling O
( O
U O
. O

This O
newly O
described O
organism O
was O
difficult O
to O
identify O
due O
to O
discrepancies O
between O
the O
Vitek O
and O
API O
20E O
identification O
systems O
. O

Ig I-GENE
heavy I-GENE
chain I-GENE
class O
switching O
is O
directed O
by O
cytokines O
inducing O
transcription O
from O
unrearranged O
CH I-GENE
genes I-GENE
. O

The O
available O
data O
suggest O
that O
the O
NF I-GENE
kappa I-GENE
B2 I-GENE
nucleoprotein I-GENE
complex I-GENE
may O
cooperate O
with O
DNA O
- O
bound O
STAT6 I-GENE
to O
achieve O
IL I-GENE
- I-GENE
4 I-GENE
- O
dependent O
activation O
of O
the O
human I-GENE
IgE I-GENE
germline I-GENE
gene I-GENE
. O

EXERCISE O
IN O
THE O
TERRESTRIAL O
CHRISTMAS O
ISLAND O
RED O
CRAB O
GECARCOIDEA O
NATALIS O
- O
ENERGETICS O
OF O
LOCOMOTION O

THE O
SCALING O
OF O
SONG O
FREQUENCY O
IN O
CICADAS O

The O
pheromone O
response O
pathway O
activates O
transcription O
of O
Ty5 I-GENE
retrotransposons I-GENE
located O
within O
silent O
chromatin O
of O
Saccharomyces O
cerevisiae O
. O

In O
this O
study O
we O
have O
introduced O
mutations O
into O
the O
corresponding O
elements O
of O
two O
cox3 I-GENE
promoters I-GENE
and O
show O
that O
while O
the O
core O
element O
is O
essential O
for O
cox3 I-GENE
promoter I-GENE
activity O
, O
upstream O
element O
mutations O
have O
little O
or O
no O
effect O
. O

We O
found O
that O
multiple O
tumor O
suppressor O
genes O
( O
e O
. O
g O
., O
p53 I-GENE
, O
DCC I-GENE
, O
APC I-GENE
, O
MCC I-GENE
, O
BRCA1 I-GENE
, O
and O
WAF1 I-GENE
/ O
CIP1 I-GENE
) O
were O
inactivated O
at O
different O
frequencies O
via O
various O
mechanisms O
[ O
e O
. O
g O
., O
loss O
of O
heterozygosity O
( O
LOH O
), O
loss O
of O
expression O
( O
LOE O
), O
mutation O
, O
and O
inactivation O
by O
cellular O
binding O
protein O
]. O

The O
histidine O
- O
tagged O
gene O
, O
rpoCHIS I-GENE
, O
was O
used O
to O
replace O
the O
wild O
- O
type O
allele O
in O
the O
chromosome O
of O
S O
. O
coelicolor O
and O
S O
. O
lividans O
. O

Because O
the O
deletion O
included O
the O
TK I-GENE
gene I-GENE
, O
selection O
with O
gancyclovir O
against O
cells O
not O
having O
undergone O
recombination O
was O
possible O
. O

The O
malate I-GENE
synthase I-GENE
gene I-GENE
, O
MLS1 I-GENE
, O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
is O
transcriptionally O
regulated O
by O
the O
carbon O
source O
in O
the O
growth O
medium O
. O

By O
deletion O
analysis O
of O
the O
MLS1 I-GENE
control O
region O
, O
we O
identified O
two O
sites O
, O
UAS1 O
and O
UAS2 O
, O
as O
important O
for O
efficient O
derepression O
of O
the O
gene O
. O

Lack O
of O
controlled O
prospective O
studies O
of O
sleep O
electroencephalograms O
( O
EEG O
), O
and O
the O
use O
of O
medication O
, O
in O
children O
with O
developmental O
dysphasia O
, O
may O
deny O
appropriate O
treatment O
strategies O
to O
children O
with O
severe O
developmental O
speech O
and O
language O
disorders O
. O

Prior O
to O
meals O
2 O
to O
3 O
times O
daily O
, O
1 O
- O
2 O
tablespoons O
of O
Alzoon O
are O
recommended O
. O

Widening O
of O
the O
abdominal O
aortic O
wall O
on O
an O
ultrasound O
examination O
was O
the O
key O
to O
the O
incidental O
diagnosis O
of O
a O
clinically O
unsuspected O
type O
B O
dissection O
. O

Fermentation O
process O
after O
supplementation O
of O
nitrate O
, O
nitrite O
, O
lactic O
acid O
bacteria O
and O
formic O
acid O

Substrates O
include O
the O
p21 I-GENE
( O
ras I-GENE
) O
proteins O
, O
nuclear I-GENE
lamins I-GENE
, O
and O
a O
series O
of O
retinal O
proteins O
. O

Ovaries O
of O
10 O
animals O
per O
group O
from O
16 O
studies O
in O
CD O
- O
1 O
mice O
and O
1 O
study O
each O
in O
C3H O
and O
C57BL O
/ O
6 O
mice O
were O
sectioned O
serially O
at O
6 O
microm O
. O

The O
Trx I-GENE
- O
CT I-GENE
fusion O
protein O
was O
produced O
less O
efficiently O
( O
20 O
% O
of O
total O
soluble O
cellular O
protein O
). O

These O
results O
suggest O
that O
UBP41 I-GENE
may O
play O
an O
important O
role O
in O
the O
recycling O
of O
ubiquitin I-GENE
by O
hydrolysis O
of O
branched I-GENE
poly I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
generated O
by O
the O
action O
of O
26 I-GENE
S I-GENE
proteasome I-GENE
on O
poly O
- O
ubiquitinated O
protein O
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin I-GENE
from O
linear I-GENE
poly I-GENE
- I-GENE
ubiquitin I-GENE
chains I-GENE
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin I-GENE
fusion I-GENE
proteins I-GENE
. O

A O
data O
base O
homology O
search O
revealed O
that O
the O
predicted O
ER1 I-GENE
amino O
acid O
sequence O
contains O
three O
regions O
of O
similarity O
to O
the O
rat O
and O
human O
proteins O
encoded O
by O
the O
metastasis O
- O
associated O
gene O
, O
mta1 I-GENE
, O
and O
two O
regions O
of O
similarity O
to O
the O
Caenorhabditis O
elegans O
sequence O
that O
is O
similar O
to O
mta1 I-GENE
. O

The O
sequenced O
cDNA O
predicts O
a O
704 O
- O
amino O
acid O
protein O
80 O
% O
identical O
to O
human I-GENE
progelatinase I-GENE
B I-GENE
. O

The O
inhibition O
by O
cytosolic O
Ca2 O
+ O
was O
caused O
by O
a O
decrease O
in O
cooperativity O
and O
by O
a O
shift O
in O
EC50 O
toward O
higher O
InsP3 O
concentrations O
. O

RESULTS O
: O
The O
standardised O
mortality O
ratio O
( O
SMR O
) O
for O
all O
malignant O
neoplasms O
was O
94 O
( O
95 O
% O
CI O
74 O
to O
118 O
). O

Sequence O
analysis O
of O
this O
region O
revealed O
three O
eight O
- O
bp O
repetitive O
elements O
, O
the O
deletion O
of O
which O
restored O
wild O
- O
type O
levels O
of O
luciferase I-GENE
activity O
to O
the O
- O
916 O
- O
bp O
reporter O
plasmid O
. O

Using O
5 O
' O
RACE O
and O
reverse O
transcription O
- O
PCR O
( O
RT O
- O
PCR O
) O
methodologies O
, O
we O
cloned O
these O
sequences O
from O
brain O
and O
placenta O
and O
found O
this O
material O
to O
be O
composed O
of O
alternatively O
spliced O
exons O
using O
a O
previously O
reported O
noncoding O
exon O
( O
1A O
) O
and O
a O
novel O
97 O
- O
bp O
noncoding O
exon O
( O
1B O
). O

This O
is O
the O
first O
study O
in O
which O
mutation O
screening O
has O
been O
performed O
for O
both O
the O
EXT1 I-GENE
and O
EXT2 I-GENE
genes I-GENE
prior O
to O
any O
linkage O
analysis O
. O

The O
regurgitation O
of O
large O
vitreous O
injections O
. O

Positron O
emission O
tomography O
radioligands O
for O
dopamine I-GENE
transporters I-GENE
and O
studies O
in O
human O
and O
nonhuman O
primates O
. O

Attenuation O
from O
the O
vit I-GENE
A2 I-GENE
consensus O
ERE O
is O
not O
necessarily O
dependent O
on O
DNA O
binding O
as O
the O
TR I-GENE
alpha I-GENE
DNA O
binding O
mutant O
was O
still O
able O
to O
inhibit O
E O
- O
dependent O
transactivation O
. O

Expression O
from O
this O
element O
is O
regulated O
by O
a O
heteromeric O
protein O
complex O
containing O
ubiquitous O
( O
i O
. O
e O
. O
the O
E2A I-GENE
- O
and O
HEB I-GENE
- I-GENE
encoded I-GENE
proteins I-GENE
) O
and O
islet O
- O
enriched O
members O
of O
the O
bHLH I-GENE
family I-GENE
. O

Thus O
, O
the O
CCAAT O
box O
also O
has O
tissue O
- O
specific O
characteristics O
that O
assist O
in O
targeting O
expression O
of O
the O
alpha I-GENE
- I-GENE
subunit I-GENE
gene I-GENE
to O
trophoblasts O
. O

U4 I-GENE
/ O
U6 I-GENE
snRNP O
is O
one O
of O
four O
essential O
small O
nuclear O
ribonucleoprotein O
( O
snRNP O
) O
particles O
( O
U1 I-GENE
, O
U2 I-GENE
, O
U5 I-GENE
and O
U4 I-GENE
/ O
U6 I-GENE
) O
present O
in O
the O
spliceosome O
. O

Hprp3p I-GENE
is O
a O
77 O
kDa O
protein O
, O
which O
is O
homologous O
to O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
splicing I-GENE
factor I-GENE
Prp3p I-GENE
. O

The O
growth O
- O
promoting O
properties O
of O
the O
retroviral I-GENE
v I-GENE
- I-GENE
erbA I-GENE
oncogene I-GENE
, O
a O
highly O
mutated O
version O
of O
the O
chicken I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( I-GENE
TR I-GENE
) I-GENE
alpha I-GENE
, O
have O
so O
far O
exclusively O
been O
linked O
to O
dominant O
repression O
of O
the O
antimitogenic O
roles O
of O
TR I-GENE
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
. O

We O
cloned O
a O
complete O
cDNA O
( O
2 O
. O
9 O
kb O
) O
for O
HET I-GENE
from O
an O
MCF O
- O
7 O
cDNA O
library O
. O

The O
most O
common O
grade O
3 O
toxicity O
was O
neutropenia O
, O
thrombocytopenia O
, O
and O
parasthesias O
( O
observed O
in O
< O
10 O
% O
of O
cycles O
). O

Serum O
concentrations O
of O
E2 O
and O
TBOH O
were O
measured O
on O
d O
0 O
, O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
13 O
, O
21 O
, O
28 O
, O
42 O
, O
56 O
, O
84 O
, O
112 O
, O
and O
140 O
in O
finishing O
heifers O
administered O
the O
following O
treatments O
: O
1 O
) O
control O
; O
2 O
) O
MGA O
, O
. O
5 O
mg O
per O
heifer O
daily O
; O
3 O
) O
Revalor O
- O
H O
( O
140 O
mg O
TBA O
+ O
14 O
mg O
E2 O
); O
4 O
) O
Revalor O
- O
H O
+ O
MGA O
; O
5 O
) O
Finaplix O
- O
H O
( O
200 O
mg O
TBA O
); O
and O
6 O
) O
Finaplix O
- O
H O
+ O
MGA O
. O

Serum O
E2 O
concentrations O
increased O
numerically O
two O
- O
to O
threefold O
from O
d O
56 O
to O
140 O
in O
controls O
fed O
MGA O
, O
compared O
with O
controls O
not O
fed O
MGA O
. O

Interferon I-GENE
Regulatory I-GENE
Factor I-GENE
( I-GENE
IRF I-GENE
)- I-GENE
1 I-GENE
has O
been O
characterized O
as O
an O
important O
growth O
regulatory O
and O
immunomodulatory O
transcription O
factor O
. O

The O
genomic O
structure O
of O
brk I-GENE
consists O
of O
8 O
exons O
, O
whose O
boundaries O
are O
distinct O
from O
other O
non O
- O
receptor O
PTK I-GENE
family I-GENE
members O
, O
again O
indicating O
a O
structural O
and O
functional O
divergence O
. O

We O
have O
previously O
reported O
that O
expression O
of O
a O
tumour O
derived O
brk I-GENE
cDNA I-GENE
in O
mouse O
embryonic O
fibroblasts O
and O
human O
mammary O
epithelial O
cells O
supports O
anchorage O
independent O
growth O
, O
and O
in O
the O
latter O
potentiates O
the O
mitogenic O
response O
to O
epidermal I-GENE
growth I-GENE
factor I-GENE
. O

Anti I-GENE
- I-GENE
hepatitis I-GENE
A I-GENE
virus O
( O
HAV O
) O
titer O
after O
vaccination O
was O
measured O
in O
83 O
HIV O
- O
positive O
and O
39 O
HIV O
- O
negative O
men O
. O

One O
skull O
does O
not O
a O
species O
make O
. O

Surprisingly O
, O
calf I-GENE
thymus I-GENE
CstF I-GENE
contained O
an O
additional O
, O
novel O
form O
of O
the O
64 O
- O
kDa O
subunit O
with O
a O
molecular O
mass O
of O
70 O
kDa O
. O

Null O
mutations O
in O
daf I-GENE
- I-GENE
3 I-GENE
suppress O
mutations O
in O
genes O
encoding O
this O
TGF I-GENE
- I-GENE
beta I-GENE
signal O
, O
its O
receptors O
, O
and O
associated O
Smad I-GENE
signal I-GENE
transduction I-GENE
proteins I-GENE
. O
daf I-GENE
- I-GENE
3 I-GENE
encodes O
a O
Smad I-GENE
protein I-GENE
that O
is O
most O
closely O
related O
to O
mammalian I-GENE
DPC4 I-GENE
, O
and O
is O
expressed O
throughout O
development O
in O
many O
of O
the O
tissues O
that O
are O
remodeled O
during O
dauer O
development O
. O

Our O
results O
favor O
the O
possibility O
that O
the O
Drosophila I-GENE
EGF I-GENE
receptor I-GENE
DER I-GENE
/ O
Egfr I-GENE
expressed O
by O
the O
EMA O
cells O
functions O
as O
a O
receptor O
for O
Vein I-GENE
. O

PATIENTS O
AND O
METHODS O
: O
In O
807 O
consecutive O
patients O
from O
the O
Chilean O
National O
Registry O
of O
Acute O
Myocardial O
Infarction O
we O
analyzed O
the O
resolution O
of O
chest O
pain O
and O
ST O
segment O
elevation O
over O
50 O
% O
within O
the O
first O
90 O
min O
, O
abrupt O
CK I-GENE
rise O
within O
8 O
h O
and O
T O
wave O
inversion O
in O
infarct O
related O
EKG O
leads O
within O
the O
first O
24 O
h O
after O
thrombolysis O
. O

Because O
of O
the O
operon O
structure O
of O
this O
organism O
, O
traditional O
methods O
such O
as O
insertional O
mutagenesis O
run O
the O
risk O
of O
introducing O
polar O
effects O
on O
downstream O
genes O
or O
creating O
secondary O
mutations O
elsewhere O
in O
the O
genome O
. O

It O
has O
been O
proposed O
that O
the O
parCBA I-GENE
operon I-GENE
encodes O
a O
plasmid O
partitioning O
system O
( O
M O
. O

Furthermore O
, O
the O
insertion O
of O
the O
ColE1 I-GENE
cer I-GENE
site I-GENE
into O
the O
RK2 O
plasmid O
deleted O
for O
the O
par O
region O
failed O
to O
stabilize O
the O
plasmid O
in O
the O
MC1061K O
strain O
, O
indicating O
that O
the O
multimer O
resolution O
activity O
encoded O
by O
parCBA I-GENE
is O
not O
by O
itself O
responsible O
for O
the O
stabilization O
activity O
observed O
for O
this O
operon O
. O

To O
examine O
the O
basis O
for O
the O
apparent O
differences O
in O
postsegregational O
killing O
between O
the O
two O
E O
. O
coli O
strains O
, O
transformation O
assays O
were O
carried O
out O
to O
determine O
the O
relative O
sensitivities O
of O
the O
strains O
to O
the O
ParE I-GENE
toxin I-GENE
protein I-GENE
. O

Splice O
- O
junction O
elements O
and O
intronic O
sequences O
regulate O
alternative O
splicing O
of O
the O
Drosophila O
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
transcript O
. O

Nucleotide O
sequence O
analysis O
of O
R O
has O
revealed O
similarities O
to O
the O
R1 O
plasmid O
found O
in O
some O
South O
American O
maize O
races O
with O
RU O
cytoplasm O
, O
to O
the O
M1 O
plasmid O
found O
in O
one O
source O
of O
Zea O
luxurians O
teosinte O
, O
to O
the O
atp9 I-GENE
mitochondrial I-GENE
gene I-GENE
and O
its O
3 O
' O
flanking O
sequence O
, O
and O
also O
to O
a O
region O
3 O
' O
to O
the O
orf221 I-GENE
gene I-GENE
. O

We O
have O
measured O
the O
kinetics O
of O
the O
recovery O
of O
mRNA O
synthesis O
in O
the O
inducible O
GAL10 I-GENE
and O
RNR3 I-GENE
genes I-GENE
after O
exposure O
of O
yeast O
cells O
to O
ultraviolet O
( O
UV O
) O
radiation O
. O

Cloning O
of O
a O
human I-GENE
phosphoinositide I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
with O
a O
C2 I-GENE
domain O
that O
displays O
reduced O
sensitivity O
to O
the O
inhibitor O
wortmannin O
. O

Ea O
value O
was O
calculated O
as O
the O
ratio O
of O
the O
steady O
- O
state O
end O
- O
systolic O
aortic O
pressure O
( O
ESAP O
) O
to O
stroke O
volume O
( O
thermodilution O
). O

Functional O
analysis O
of O
promoter O
activity O
of O
the O
5 O
'- O
flanking O
region O
of O
cyclin I-GENE
D2 I-GENE
suggested O
that O
the O
region O
- O
1 O
, O
100 O
to O
- O
805 O
including O
C I-GENE
/ I-GENE
EBP I-GENE
, O
PEA3 I-GENE
, O
AP2 I-GENE
, O
NF I-GENE
- I-GENE
Y I-GENE
, O
c I-GENE
- I-GENE
Myc I-GENE
, O
and O
Sp1 I-GENE
may O
have O
a O
major O
positive O
regulatory O
activity O
for O
expression O
of O
cyclin I-GENE
D2 I-GENE
. O

Effect O
of O
alcohol O
on O
minimal O
effective O
nCPAP O
pressure O

In O
contrast O
, O
resensitization O
of O
a O
sequestration O
- O
impaired O
beta2AR I-GENE
mutant O
( O
Y326A O
) O
was O
reestablished O
following O
the O
overexpression O
of O
either O
GRK2 I-GENE
or O
beta I-GENE
- I-GENE
arrestin I-GENE
1 I-GENE
. O

The O
medium O
chains O
of O
these O
complexes O
, O
mu1 I-GENE
and O
mu2 I-GENE
, O
have O
been O
implicated O
in O
two O
types O
of O
interaction O
: O
assembly O
with O
the O
beta1 I-GENE
and I-GENE
beta2 I-GENE
chains I-GENE
of O
the O
corresponding O
complexes O
and O
recognition O
of O
tyrosine O
- O
based O
sorting O
signals O
. O

We O
have O
overexpressed O
, O
purified O
, O
characterized O
, O
and O
crystallized O
the O
BTB I-GENE
/ O
POZ O
domain O
from O
PLZF I-GENE
( O
PLZF I-GENE
- O
BTB I-GENE
/ O
POZ O
). O

Osmotic O
shock O
stimulates O
GLUT4 I-GENE
translocation O
in O
3T3L1 O
adipocytes O
by O
a O
novel O
tyrosine I-GENE
kinase I-GENE
pathway O
. O

We O
also O
identified O
Sp1 I-GENE
, O
Sp3 I-GENE
, O
and O
NGFI I-GENE
- I-GENE
A I-GENE
/ O
Egr I-GENE
- I-GENE
1 I-GENE
as O
the O
primary O
nuclear O
transcription O
factors O
binding O
to O
TRE1 I-GENE
which O
mediate O
Tax I-GENE
responsiveness O
. O

Interestingly O
, O
segment O
nesting O
differentially O
increases O
the O
copy O
number O
of O
genes O
encoded O
by O
segment O
W O
, O
suggesting O
that O
the O
unusual O
genomic O
organization O
of O
PDVs O
may O
be O
directly O
linked O
to O
the O
unique O
functions O
of O
this O
virus O
in O
its O
obligate O
mutualistic O
association O
with O
parasitic O
wasps O
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
performed O
with O
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs I-GENE
revealed O
that O
Tax I-GENE
was O
trans O
activating O
the O
VCAM I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
via O
two O
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM I-GENE
- I-GENE
1 I-GENE
gene I-GENE
promoter I-GENE
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax I-GENE
- O
induced O
expression O
of O
this O
adhesion O
molecule O
. O

The O
AGM I-GENE
and I-GENE
NIH I-GENE
/ I-GENE
Swiss I-GENE
mouse I-GENE
CCR5 I-GENE
proteins I-GENE
are O
97 O
. O
7 O
to O
98 O
. O
3 O
% O
and O
79 O
. O
8 O
% O
identical O
to O
the O
human O
protein O
, O
respectively O
. O

Processivity O
of O
DNA O
synthesis O
by O
the O
mutant O
holoenzyme O
containing O
pcna I-GENE
- I-GENE
79 I-GENE
was O
unaffected O
on O
poly O
( O
dA O
) O
x O
oligo O
( O
dT O
) O
but O
was O
dramatically O
reduced O
on O
a O
natural O
template O
with O
secondary O
structure O
. O

Alanine O
substitution O
mutations O
in O
the O
Zta I-GENE
activation I-GENE
domain I-GENE
which O
eliminate O
the O
ability O
of O
Zta I-GENE
to O
stimulate O
the O
D I-GENE
- I-GENE
A I-GENE
complex I-GENE
were O
examined O
. O

The O
Scm I-GENE
and O
ph I-GENE
proteins O
share O
a O
homology O
domain O
with O
38 O
% O
identity O
over O
a O
length O
of O
65 O
amino O
acids O
, O
termed O
the O
SPM O
domain O
, O
that O
is O
located O
at O
their O
respective O
C O
termini O
. O

It O
has O
been O
previously O
shown O
that O
genes O
transcribed O
by O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
RNAP I-GENE
II I-GENE
) O
are O
subject O
to O
position O
effect O
variegation O
when O
located O
near O
yeast O
telomeres O
. O

Likewise O
, O
rad6 I-GENE
- I-GENE
delta I-GENE
reduces O
silencing O
of O
the O
telomere I-GENE
- I-GENE
located I-GENE
RNAP I-GENE
II I-GENE
- I-GENE
transcribed I-GENE
genes I-GENE
URA3 I-GENE
and O
ADE2 I-GENE
. O

The O
amplitude O
of O
detrusor O
contractions O
at O
6 O
, O
12 O
, O
and O
24 O
hours O
showed O
no O
significant O
difference O
from O
that O
in O
the O
controls O
. O

In O
the O
predicted O
transmembrane O
domain O
, O
Casr I-GENE
- I-GENE
rs2 I-GENE
and O
Casr I-GENE
- I-GENE
rs3 I-GENE
are O
95 O
% O
identical O
to O
Casr I-GENE
- I-GENE
rs1 I-GENE
. O

Recently O
, O
roles O
also O
have O
been O
suggested O
for O
the O
nuclear O
trans O
- O
factor O
GATA I-GENE
- I-GENE
1 I-GENE
in O
regulating O
progenitor O
cell O
proliferation O
. O

PET O
activation O
studies O
are O
performed O
widely O
to O
study O
human O
brain O
function O
. O

F I-GENE
- I-GENE
box I-GENE
proteins I-GENE
are O
receptors O
that O
recruit O
phosphorylated O
substrates O
to O
the O
SCF I-GENE
ubiquitin I-GENE
- O
ligase I-GENE
complex O
. O

In O
the O
context O
of O
liver O
allograft O
shortage O
, O
our O
results O
suggest O
that O
an O
ELT O
should O
not O
be O
performed O
in O
patients O
with O
cardiac O
failure O
, O
more O
than O
two O
OSF O
, O
or O
an O
APACHE O
II O
score O
higher O
than O
30 O
. O

The O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
bound O
in O
vitro O
to O
specific O
proline O
- O
rich O
motifs O
in O
the O
HPK1 I-GENE
tail O
and O
functioned O
synergistically O
to O
direct O
the O
stable O
binding O
of O
Grb2 I-GENE
to O
HPK1 I-GENE
in O
transfected O
Cos1 O
cells O
. O

By O
far O
- O
Western O
analysis O
and O
coimmunoprecipitation O
studies O
, O
we O
demonstrate O
that O
ZNF74 I-GENE
interacts O
, O
via O
its O
zinc O
finger O
domain O
, O
with O
the O
hyperphosphorylated O
largest O
subunit O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
pol I-GENE
IIo I-GENE
) O
but O
not O
with O
the O
hypophosphorylated O
form O
. O

Thus O
, O
ZNF74 I-GENE
sublocalization O
in O
nuclear O
domains O
enriched O
in O
pre O
- O
mRNA O
maturating O
factors O
, O
its O
RNA O
binding O
activity O
, O
and O
its O
direct O
phosphodependent O
interaction O
with O
the O
pol I-GENE
IIo I-GENE
, O
a O
form O
of O
the O
RNA I-GENE
polymerase I-GENE
functionally O
associated O
with O
pre O
- O
mRNA O
processing O
, O
suggest O
a O
role O
for O
this O
member O
of O
the O
KRAB I-GENE
multifinger I-GENE
protein I-GENE
family I-GENE
in O
RNA O
processing O
. O

Ki I-GENE
- I-GENE
ras4BVal I-GENE
- I-GENE
12 I-GENE
transfectant O
cells O
expressed O
2 O
- O
fold O
elevated O
protein O
levels O
of O
the O
lysosomal I-GENE
cysteine I-GENE
protease I-GENE
cathepsin I-GENE
B I-GENE
but O
did O
not O
up O
- O
regulate O
cathepsin I-GENE
B I-GENE
mRNA I-GENE
expression O
. O

The O
cellular O
rate O
of O
anticoagulant I-GENE
heparan I-GENE
sulfate I-GENE
proteoglycan I-GENE
( O
HSPGact I-GENE
) O
generation O
is O
determined O
by O
the O
level O
of O
a O
kinetically O
limiting O
microsomal O
activity O
, O
HSact O
conversion O
activity O
, O
which O
is O
predominantly O
composed O
of O
the O
long O
sought O
heparan I-GENE
sulfate I-GENE
D I-GENE
- I-GENE
glucosaminyl I-GENE
3 I-GENE
- I-GENE
O I-GENE
- I-GENE
sulfotransferase I-GENE
( O
3 I-GENE
- I-GENE
OST I-GENE
) O
( O
Shworak O
, O
N O
. O

Interestingly O
, O
EGF I-GENE
, O
but O
not O
insulin I-GENE
, O
stimulated O
tyrosine O
phosphorylation O
of O
c I-GENE
- I-GENE
cbl I-GENE
and O
its O
association O
with O
Crk I-GENE
- I-GENE
II I-GENE
. O

An O
end O
to O
the O
lottery O
. O

We O
previously O
showed O
that O
the O
N O
- O
terminal O
portion O
common O
to O
various O
chimeric I-GENE
MLL I-GENE
products I-GENE
, O
as O
well O
as O
to O
MLL I-GENE
- I-GENE
LTG9 I-GENE
and O
MLL I-GENE
- I-GENE
LTG19 I-GENE
, O
localizes O
in O
the O
nuclei O
, O
and O
therefore O
suggested O
that O
it O
might O
play O
an O
important O
role O
in O
leukemogenesis O
. O

Our O
results O
suggest O
that O
the O
pattern O
of O
blood O
supply O
is O
relevant O
to O
the O
structural O
organisation O
of O
mature O
lamellar O
bone O
around O
the O
implant O
. O

Induction O
of O
AtP5CS1 I-GENE
mRNA I-GENE
accumulation O
in O
salt O
- O
treated O
seedlings O
involves O
an O
immediate O
early O
transcriptional O
response O
regulated O
by O
ABA O
signalling O
that O
is O
not O
inhibited O
by O
cycloheximide O
, O
but O
abolished O
by O
the O
deficiency O
of O
ABA O
biosynthesis O
in O
the O
aba1 I-GENE
Arabidopsis I-GENE
mutant I-GENE
. O

It O
thus O
appears O
that O
MAPK I-GENE
functions O
in O
meiotic O
maturation O
by O
preventing O
unfertilized O
eggs O
from O
proceeding O
into O
parthenogenetic O
development O
. O

( O
ii O
) O
An O
AF O
G I-GENE
- I-GENE
CSF I-GENE
level O
> O
2000 O
pg O
/ O
ml O
is O
a O
strong O
positive O
predictor O
of O
CAM O
. O

A O
positive O
correlation O
between O
serum I-GENE
myoglobin I-GENE
and O
CA I-GENE
III I-GENE
concentrations O
( O
rs O
= O
0 O
. O
933 O
, O
P O
< O
0 O
. O
001 O
) O
was O
observed O
in O
hemodialyzed O
patients O
with O
chronic O
renal O
failure O
. O

Furthermore O
, O
the O
over O
- O
replication O
phenotype O
produced O
by O
this O
mutant I-GENE
p65cdc18 I-GENE
is O
resistant O
to O
increased O
mitotic O
cyclin I-GENE
/ O
CDK I-GENE
activity O
, O
a O
known O
inhibitor O
of O
over O
- O
replication O
. O

Rip1p I-GENE
is O
inessential O
, O
associated O
with O
nuclear O
pore O
complexes O
, O
and O
structurally O
related O
to O
the O
FG I-GENE
- I-GENE
nucleoporin I-GENE
family I-GENE
of O
pore O
proteins O
. O

The O
CNXA O
domain O
is O
similar O
at O
the O
amino O
acid O
level O
to O
the O
Escherichia I-GENE
coli I-GENE
moaA I-GENE
gene I-GENE
product I-GENE
, O
while O
CNXC O
is O
similar O
to O
the O
E I-GENE
. I-GENE
coli I-GENE
moaC I-GENE
product I-GENE
, O
with O
both O
E O
. O
coli O
products O
encoded O
by O
different O
cistrons O
. O

Deletions O
in O
each O
of O
these O
regions O
abolish O
membrane O
localization O
of O
Tiam1 I-GENE
and O
membrane O
ruffling O
, O
suggesting O
that O
they O
function O
cooperatively O
. O

However O
, O
besides O
the O
kinase O
catalytic O
domain O
and O
double O
leucine O
/ O
isoleucine O
zippers O
, O
there O
was O
no O
significant O
homology O
with O
known O
proteins O
. O

RNA I-GENE
polymerase I-GENE
II I-GENE
inhibition O
increased O
the O
binding O
of O
ARE O
( O
AUBP O
activity O
) O
and O
poly O
( O
U O
)- O
Sepharose O
by O
cytoplasmic I-GENE
hnRNP I-GENE
A1 I-GENE
, O
while O
nuclear I-GENE
hnRNP I-GENE
A1 I-GENE
binding O
was O
unaffected O
. O

Modulation O
of O
AUUUA O
response O
element O
binding O
by O
heterogeneous I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
in O
human O
T O
lymphocytes O
. O

Histological O
slides O
of O
one O
biopsy O
of O
each O
patient O
( O
formalin O
- O
fixed O
and O
paraffin O
- O
embedded O
) O
were O
stained O
with O
a O
Modified O
Giemsa O
( O
MG O
), O
the O
Warthin O
- O
Starry O
( O
WS O
), O
and O
an O
immunohistochemical O
method O
( O
IMM O
) O
using O
purified O
polyclonal O
H O
. O
pylori O
antiserum O
( O
DAKO O
B471 O
). O

Their O
biosynthesis O
proceeds O
via O
linear O
precursors O
that O
become O
branched O
by O
beta1 I-GENE
, I-GENE
6 I-GENE
- I-GENE
GlcNAc I-GENE
transferases I-GENE
( O
IGnT6 O
, O
GlcNAc O
to O
Gal O
). O

These O
findings O
indicate O
that O
the O
t O
( O
4 O
; O
14 O
)( O
p16 O
. O
3 O
; O
q32 O
) O
represents O
a O
novel O
, O
recurrent O
chromosomal O
translocation O
in O
MM O
, O
and O
suggest O
that O
the O
FGFR3 I-GENE
gene I-GENE
may O
be O
the O
target O
of O
this O
abnormality O
and O
thus O
contribute O
to O
tumorigenesis O
in O
MM O
. O

In O
addition O
, O
mutation O
of O
the O
Sp1 I-GENE
site I-GENE
also O
significantly O
reduced O
promoter O
activity O
. O

Amino O
acid O
residues O
of O
beta O
1 O
', O
alpha O
A O
', O
alpha O
B O
', O
and O
the O
loop O
containing O
His539 O
of O
the O
RNase I-GENE
H I-GENE
domain I-GENE
interact O
with O
the O
primer O
strand O
of O
the O
dsDNA O
. O

Moreover O
, O
in O
one O
patient O
with O
a O
sarcoma O
who O
underwent O
a O
leg O
- O
sparing O
procedure O
, O
no O
sciatic O
nerve O
enlargement O
was O
seen O
postoperatively O
. O

The O
full O
length O
cDNA O
sequence O
of O
a O
Type I-GENE
I I-GENE
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
( I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
) I-GENE
receptor I-GENE
has O
been O
isolated O
from O
the O
filarial O
parasitic O
nematode O
Brugia O
pahangi O
. O

This O
sequence O
possessed O
homology O
with O
a O
methylation O
- O
sensitive O
promoter O
element O
, O
Enh2 O
, O
present O
in O
the O
LTR O
of O
mouse O
intractisternal O
A O
- O
particles O
. O

Codon O
optimization O
for O
high O
- O
level O
expression O
of O
human I-GENE
erythropoietin I-GENE
( O
EPO I-GENE
) O
in O
mammalian O
cells O
. O

Parodoxical O
rise O
in O
urinary I-GENE
albumin I-GENE
levels O
after O
treatment O
of O
essential O
hypertension O
. O

20 O
% O
of O
total O
HSL I-GENE
transcripts I-GENE
in O
human O
subcutaneous O
adipocytes O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
Rat7p I-GENE
/ O
Nup159p I-GENE
is O
anchored O
within O
the O
NPC O
through O
its O
coiled O
- O
coil O
region O
and O
adjacent O
sequences O
. O

In O
a O
group O
of O
13 O
patients O
with O
obliterative O
arteriopathies O
of O
the O
lower O
limbs O
the O
plasma O
levels O
of O
thrombomodulin I-GENE
( O
TM I-GENE
), O
betathromboglobulin I-GENE
( O
beta I-GENE
- I-GENE
TG I-GENE
), O
D O
- O
dimer O
( O
DD O
) O
and O
plasminogen I-GENE
activator I-GENE
- I-GENE
inhibitor I-GENE
( O
pAI I-GENE
- I-GENE
1 I-GENE
) O
were O
measured O
, O
and O
compared O
to O
the O
values O
obtained O
from O
10 O
healthy O
volunteers O
. O

These O
residues O
, O
Ile244 O
at O
the O
extracellular O
end O
of O
transmembrane O
helix O
3 O
, O
and O
Tyr318 O
at O
the O
COOH O
- O
terminal O
portion O
of O
extracellular O
loop O
2 O
, O
are O
replaced O
by O
Leu O
and O
Ile O
in O
the O
PTH I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
respectively O
. O

We O
have O
now O
shown O
that O
in O
vivo O
phosphorylation O
of O
14 I-GENE
- I-GENE
3 I-GENE
- I-GENE
3 I-GENE
zeta I-GENE
at O
the O
CKIalpha I-GENE
site I-GENE
( I-GENE
Thr I-GENE
- I-GENE
233 I-GENE
) I-GENE
negatively O
regulates O
its O
binding O
to O
c I-GENE
- I-GENE
Raf I-GENE
, O
and O
may O
be O
important O
in O
Raf I-GENE
- O
mediated O
signal O
transduction O
. O

Mouse I-GENE
mast I-GENE
cell I-GENE
protease I-GENE
9 I-GENE
, O
a O
novel O
member O
of O
the O
chromosome O
14 O
family O
of O
serine I-GENE
proteases I-GENE
that O
is O
selectively O
expressed O
in O
uterine O
mast O
cells O
. O

A O
DNase I-GENE
I I-GENE
- I-GENE
hypersensitive I-GENE
site I-GENE
has O
also O
been O
mapped O
in O
the O
258 O
- O
base O
pair O
enhancer O
region O
. O

[ O
Pulmonary O
vascular O
resistance O
( O
PVR O
) O
during O
10 O
% O
O2 O
- O
PVR O
during O
21 O
% O
O2 O
/ O
PVR O
during O
21 O
% O
O2 O
] O
x O
100 O
was O
termed O
as O
hypoxic O
pulmonary O
vasoconstriction O
( O
HPV O
). O

Together O
, O
our O
results O
show O
that O
tinman I-GENE
is O
controlled O
by O
an O
array O
of O
discrete O
enhancer O
elements O
that O
are O
activated O
successively O
by O
differential O
genetic O
inputs O
, O
as O
well O
as O
by O
closely O
linked O
activator O
and O
repressor O
binding O
sites O
within O
an O
early O
- O
acting O
enhancer O
, O
which O
restrict O
twist I-GENE
activity O
to O
specific O
areas O
within O
the O
twist I-GENE
expression I-GENE
domain I-GENE
. O

An O
unusual O
cysteine O
triplet O
conserved O
in O
the O
sequences O
of O
TB I-GENE
domains I-GENE
is O
localized O
to O
the O
hydrophobic O
core O
, O
at O
the O
C O
- O
terminus O
of O
an O
alpha O
- O
helix O
. O

The O
Fis I-GENE
protein I-GENE
regulates O
site O
- O
specific O
DNA O
inversion O
catalyzed O
by O
a O
family O
of O
DNA I-GENE
invertases I-GENE
when O
bound O
to O
a O
cis O
- O
acting O
recombinational O
enhancer O
. O

Protein O
phosphatases O
play O
a O
critical O
role O
in O
the O
regulation O
of O
the O
eukaryotic O
cell O
cycle O
and O
signal O
transduction O
. O

The O
cell O
cycle O
- O
regulated O
transcription O
factor O
E2F I-GENE
is O
also O
known O
to O
bend O
DNA O
upon O
binding O
. O

Our O
study O
reveals O
that O
the O
modular O
structure O
of O
the O
FSH I-GENE
receptor I-GENE
gene O
generates O
motifs O
that O
allows O
coupling O
to O
different O
effectors O
. O

Transcriptional O
regulation O
of O
SUP35 I-GENE
and O
SUP45 I-GENE
in I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

These O
studies O
serve O
as O
the O
basis O
for O
the O
further O
characterization O
of O
the O
regulatory O
mechanism O
of O
aromatase I-GENE
expression O
in O
human O
breast O
cancer O
and O
ASCs O
. O

Xenopus I-GENE
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
: O
molecular O
interactions O
and O
effects O
on O
nuclear O
assembly O
in O
Xenopus O
egg O
extracts O
. O

She O
improved O
with O
a O
combination O
of O
benzodiazepines O
and O
the O
acetylcholinesterase I-GENE
inhibitor O
physostigmine O
. O

METHODS O
: O
Total O
muscle O
paralysis O
was O
induced O
under O
general O
anesthesia O
in O
a O
group O
of O
obese O
persons O
( O
n O
= O
9 O
; O
body O
mass O
index O
, O
32 O
+/- O
3 O
kg O
[- O
2 O
]) O
and O
in O
a O
group O
of O
nonobese O
persons O
( O
n O
= O
9 O
; O
body O
mas O
index O
, O
21 O
+/- O
2 O
kg O
[- O
2 O
]). O

PKA I-GENE
phosphorylated O
WT1 I-GENE
at O
Ser O
- O
365 O
and O
Ser O
- O
393 O
in O
vitro O
, O
as O
well O
as O
at O
additional O
sites O
, O
and O
this O
phosphorylation O
abolished O
the O
DNA O
- O
binding O
activity O
of O
WT1 I-GENE
in O
vitro O
. O

Our O
findings O
provide O
the O
first O
evidence O
that O
the O
function O
of O
WT1 I-GENE
can O
be O
modulated O
by O
its O
phosphorylation O
in O
vivo O
. O

Re O
: O
" O
Assessing O
the O
direction O
of O
causality O
in O
cross O
- O
sectional O
studies O
". O

A O
second O
aim O
was O
to O
determine O
whether O
the O
decrease O
in O
muscle O
- O
tendon O
unit O
rest O
length O
produced O
by O
prolonged O
immobilisation O
in O
a O
shortened O
position O
is O
mediated O
primarily O
by O
adaptations O
of O
the O
muscle O
or O
tendon O
. O

The O
presence O
of O
an O
additional O
sequence O
of O
nucleotides O
145 O
- O
165 O
from O
the O
3 O
' O
end O
of O
RNA3 I-GENE
enhanced O
template O
recognition O
by O
RdRp I-GENE
in O
vitro O
and O
accumulation O
of O
RNA3 I-GENE
in O
vivo O
to O
wild O
- O
type O
levels O
. O

We O
argue O
that O
the O
primary O
role O
of O
hh I-GENE
in O
controlling O
polarity O
is O
to O
cause O
anterior O
compartment O
cells O
to O
reverse O
their O
interpretation O
of O
an O
underlying O
symmetric O
polarization O
. O

Restriction O
enzyme O
mapping O
, O
subcloning O
, O
and O
DNA O
sequencing O
analysis O
of O
recombinant O
phage O
lambda O
and O
P1 O
clones O
revealed O
that O
exons O
encoding O
the O
1 O
. O
9 O
- O
kb O
mouse I-GENE
TS I-GENE
mRNA I-GENE
are O
dispersed O
over O
> O
150 O
kb O
genomic O
DNA O
. O

Transfection O
analyses O
indicated O
that O
the O
expression O
of O
Tbxas1 I-GENE
is O
controlled O
by O
a O
short O
( O
70 O
- O
bp O
) O
positive O
regulatory O
sequence O
and O
several O
upstream O
repressive O
elements O
. O

The O
results O
of O
this O
study O
suggest O
that O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
may O
be O
regulated O
by O
its O
interaction O
with O
the O
cell O
cycle O
regulatory O
protein O
, O
E2F I-GENE
- I-GENE
1 I-GENE
. O

The O
lysozyme I-GENE
FEF I-GENE
site O
is O
immediately O
5 O
' O
to O
a O
PU I-GENE
. O

Osteocalcin I-GENE
( O
OC I-GENE
) O
is O
a O
matrix I-GENE
calcium I-GENE
- I-GENE
binding I-GENE
protein I-GENE
expressed O
in O
osteoblasts O
and O
odontoblasts O
undergoing O
mineralization O
. O

In O
this O
study O
, O
we O
examine O
the O
effects O
of O
Msx2 I-GENE
expression O
on O
OC I-GENE
promoter I-GENE
activation O
( O
luciferase I-GENE
reporter I-GENE
) O
by O
FGF2 I-GENE
/ O
FSK I-GENE
and O
calcitriol O
in O
MC3T3 O
- O
E1 O
osteoblasts O
. O

Thus O
, O
unlike O
other O
proteins O
reported O
to O
inhibit O
SRF I-GENE
activity O
, O
the O
repressor O
activity O
associated O
with O
the O
GC O
- O
rich O
element O
does O
not O
appear O
to O
function O
through O
direct O
inhibition O
of O
SRF I-GENE
binding O
. O

However O
, O
one O
CAK I-GENE
- O
phosphorylated O
phosphopeptide O
comigrates O
with O
a O
Cdc2 I-GENE
- O
phosphorylated O
phosphopeptide O
previously O
shown O
to O
be O
mitosis O
- O
specific O
, O
suggesting O
that O
, O
in O
vitro O
, O
CAK I-GENE
is O
able O
to O
phosphorylate O
at O
least O
one O
site O
that O
is O
also O
phosphorylated O
in O
vivo O
. O

The O
pen O
can O
heal O
. O

The O
mHIF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
structural I-GENE
gene I-GENE
is O
composed O
of O
15 O
exons O
. O

However O
, O
when O
a O
second O
, O
upstream I-GENE
IRE I-GENE
- I-GENE
like I-GENE
sequence I-GENE
was O
evaluated O
by O
EMSA O
, O
a O
DNA O
binding O
pattern O
distinct O
from O
that O
seen O
following O
exposure O
to O
IFN I-GENE
- I-GENE
gamma I-GENE
alone O
was O
observed O
after O
prolonged O
stimulation O
with O
both O
IFN I-GENE
- I-GENE
alpha I-GENE
and O
IFN I-GENE
- I-GENE
gamma I-GENE
. O

In O
Arabidopsis O
, O
the O
induction O
of O
a O
dehydration O
- O
responsive O
gene O
, O
rd22 I-GENE
, O
is O
mediated O
by O
abscisic O
acid O
( O
ABA O
) O
and O
requires O
protein O
biosynthesis O
for O
ABA O
- O
dependent O
gene O
expression O
. O

A O
cDNA O
encoding O
a O
MYC I-GENE
- I-GENE
related I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
was O
isolated O
by O
DNA O
- O
ligand O
binding O
screening O
, O
using O
the O
67 O
- O
bp O
region O
as O
a O
probe O
, O
and O
designated O
rd22BP1 I-GENE
. O

Human I-GENE
PDK1 I-GENE
is O
homologous O
to O
the O
Drosophila I-GENE
protein I-GENE
kinase I-GENE
DSTPK61 I-GENE
, O
which O
has O
been O
implicated O
in O
the O
regulation O
of O
sex O
differentiation O
, O
oogenesis O
and O
spermatogenesis O
. O

Thus O
, O
the O
synergistic O
effects O
of O
HNF I-GENE
- I-GENE
1beta I-GENE
and O
the O
GR I-GENE
on O
dexamethasone O
- O
stimulated O
promoter O
activity O
require O
that O
they O
are O
bound O
to O
the O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
the O
GRE O
, O
respectively O
, O
and O
may O
involve O
protein O
- O
protein O
interactions O
between O
the O
transcription O
factors O
, O
or O
between O
them O
and O
the O
basal O
transcription O
machinery O
or O
a O
steroid I-GENE
receptor I-GENE
coactivator I-GENE
. O

Mutational O
analysis O
shows O
that O
both O
an O
AP I-GENE
- I-GENE
1 I-GENE
like I-GENE
sequence I-GENE
(- O
294 O
/- O
285 O
, O
TGAATCATCA O
) O
and O
an O
A O
/ O
T O
- O
rich O
myocyte I-GENE
enhancer I-GENE
factor I-GENE
( I-GENE
MEF I-GENE
)- I-GENE
2 I-GENE
like I-GENE
sequence I-GENE
(- O
310 O
/- O
298 O
, O
TTAAAAATAAAAA O
) O
in O
the O
33 O
- O
bp O
region O
are O
necessary O
for O
the O
OP I-GENE
- I-GENE
1 I-GENE
effect O
. O

Unlike O
most O
other O
members O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
family I-GENE
, O
BAD I-GENE
( O
Bcl I-GENE
- I-GENE
xL I-GENE
/ I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
associated I-GENE
death I-GENE
promoter I-GENE
), O
a O
death I-GENE
enhancer I-GENE
, O
has O
no O
C O
- O
terminal O
transmembrane O
domain O
for O
targeting O
to O
the O
outer O
mitochondrial O
membrane O
and O
nuclear O
envelope O
. O

Electromobility O
shift O
and O
cotransfection O
assays O
demonstrated O
that O
HNF1alpha I-GENE
, O
but O
not O
HNF4 I-GENE
, O
bound O
to O
its O
cognate O
site O
and O
transactivated O
G6Pase I-GENE
gene I-GENE
expression O
. O

An O
open O
reading O
frame O
of O
2862 O
bp O
encoding O
a O
954 O
amino O
acid O
protein O
was O
identified O
. O

One O
of O
these O
, O
an O
AACA O
motif O
, O
has O
been O
shown O
to O
be O
a O
negative O
regulator O
in O
non O
- O
seed O
tissues O
and O
has O
a O
similarity O
to O
the O
barley O
gibberellin O
responsive O
element O
recognized O
by O
MYB I-GENE
- I-GENE
like I-GENE
DNA I-GENE
binding I-GENE
proteins I-GENE
. O

Strain O
CFN037 O
is O
an O
R O
. O
etli O
mutant O
induced O
by O
a O
single O
Tn5mob I-GENE
insertion O
in O
the O
promoter O
region O
of O
the O
thiCOGE I-GENE
gene I-GENE
cluster I-GENE
. O

Expression O
of O
thiamin O
biosynthetic O
genes O
( O
thiCOGE I-GENE
) O
and O
production O
of O
symbiotic I-GENE
terminal I-GENE
oxidase I-GENE
cbb3 I-GENE
in O
Rhizobium O
etli O
. O

We O
have O
cloned O
and O
sequenced O
a O
region O
encoding O
a O
lipase I-GENE
operon I-GENE
and O
a O
putative O
, O
previously O
uncharacterized O
metalloprotease I-GENE
of I-GENE
Vibrio I-GENE
cholerae I-GENE
O1 I-GENE
. O

Furthermore O
, O
the O
amount O
of O
tRNA I-GENE
( I-GENE
3Lys I-GENE
) I-GENE
that O
was O
placed O
onto O
viral O
RNA O
in O
mutated O
viruses O
was O
significantly O
less O
than O
that O
placed O
in O
the O
wild O
- O
type O
virus O
. O

This O
protein O
is O
present O
in O
both O
HeLa O
nuclear O
extracts O
and O
S100 I-GENE
extracts O
but O
absent O
from O
SR I-GENE
protein I-GENE
preparations O
, O
suggesting O
that O
it O
is O
not O
a O
classical O
SR I-GENE
protein I-GENE
. O

Differential O
regulation O
of O
the O
pre I-GENE
- I-GENE
C I-GENE
and O
pregenomic O
promoters O
of O
human O
hepatitis O
B O
virus O
by O
members O
of O
the O
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

Acad O
. O

Chimeras O
containing O
IE1 I-GENE
peptides I-GENE
dramatically O
activated O
transcription O
of O
the O
basal O
promoter O
only O
when O
lac I-GENE
operator I-GENE
sequences I-GENE
were O
present O
. O

The O
results O
of O
replicase I-GENE
assays O
performed O
with O
mutant I-GENE
VP2 I-GENE
containing O
a O
deletion O
in O
its O
RNA O
- O
binding O
domain O
suggests O
that O
the O
essential O
role O
for O
VP2 I-GENE
in O
replication O
is O
linked O
to O
the O
protein O
' O
s O
ability O
to O
bind O
the O
mRNA O
template O
for O
minus O
- O
strand O
synthesis O
. O

We O
previously O
described O
two O
alanine O
cluster O
mutations O
, O
R77 O
to O
A O
( O
R77A O
)- O
K79A O
and O
E192A O
- O
E194A O
, O
which O
selectively O
inactivated O
the O
triphosphatase O
component O
. O

Transfection O
of O
HepG2 O
and O
SK O
- O
N O
- O
MC O
cells O
with O
constructs O
deleted O
of O
additional O
5 O
'- O
flanking O
fragments O
permitted O
the O
definition O
of O
a O
minimal O
200 O
bp O
promoter O
fragment O
containing O
the O
pseudo O
- O
TATA O
box O
and O
two O
putative O
SP1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Both O
inserts O
are O
larger O
than O
their O
homologues O
in O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinases I-GENE
. O

Three O
monopolar O
electrodes O
were O
inserted O
into O
the O
left O
and O
right O
lateral O
vestibulospinal O
tract O
( O
LVST O
) O
and O
medial O
vestibulospinal O
tract O
( O
MVST O
) O
of O
the O
C1 O
segment O
, O
to O
determine O
the O
pathway O
of O
axons O
. O

Epitopes O
of O
adhesion O
- O
perturbing O
monoclonal O
antibodies O
map O
within O
a O
predicted O
alpha O
- O
helical O
domain O
of O
the O
integrin I-GENE
beta I-GENE
1 I-GENE
subunit I-GENE
. O

Polyhomeotic I-GENE
and I-GENE
Posterior I-GENE
Sex I-GENE
Combs I-GENE
may O
participate O
in O
a O
more O
general O
transcriptional O
mechanism O
that O
causes O
modulated O
gene O
repression O
, O
whereas O
the O
inclusion O
of O
Polycomb I-GENE
protein I-GENE
in O
the O
complex O
at O
PREs I-GENE
leads O
to O
stable O
silencing O
. O

Furthermore O
, O
both O
rhHR23 I-GENE
proteins I-GENE
function O
in O
a O
defined O
NER O
system O
reconstituted O
with O
purified O
proteins O
, O
indicating O
direct O
involvement O
of O
hHR23 I-GENE
proteins I-GENE
in O
the O
DNA O
repair O
reaction O
via O
interaction O
with O
XPC I-GENE
. O

The O
yeast O
silent I-GENE
information I-GENE
regulator I-GENE
Sir4p I-GENE
anchors O
and O
partitions O
plasmids O
. O

These O
results O
implicate O
a O
precursor O
- O
specific O
base O
- O
paired O
structure O
involving O
sequences O
on O
both O
sides O
of O
the O
mature O
cleavage O
site O
in O
the O
3 O
' O
processing O
of O
human I-GENE
U2 I-GENE
RNA I-GENE
. O

Polysome O
analyses O
in O
a O
temperature O
- O
sensitive O
fal1 I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
and O
a O
Fal1p I-GENE
- O
depleted O
strain O
reveal O
a O
decrease O
in O
the O
number O
of O
40S I-GENE
ribosomal I-GENE
subunits I-GENE
. O

Sequence O
analysis O
identified O
some O
of O
these O
cDNA O
clones O
as O
Dlc I-GENE
- I-GENE
1 I-GENE
, O
a O
sequence O
encoding O
a O
small O
, O
9 I-GENE
- I-GENE
kDa I-GENE
human I-GENE
homolog I-GENE
of I-GENE
the I-GENE
outer I-GENE
- I-GENE
arm I-GENE
dynein I-GENE
light I-GENE
- I-GENE
chain I-GENE
protein O
. O

Importantly O
, O
in O
HeLa O
and O
293 O
cells O
, O
endogenous O
and O
transfected O
I I-GENE
kappaB I-GENE
alpha I-GENE
coimmunoprecipitated O
with O
Myc I-GENE
- O
tagged O
or O
endogenous O
Dlc I-GENE
- I-GENE
1 I-GENE
. O

The O
mouse I-GENE
M I-GENE
- I-GENE
lysozyme I-GENE
downstream I-GENE
enhancer I-GENE
has O
been O
previously O
characterized O
on O
several O
levels O
of O
gene O
regulation O
. O

Identification O
of O
dynein I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
expressed O
in O
human O
and O
mouse O
testis O
: O
chromosomal O
localization O
of O
an O
axonemal I-GENE
dynein I-GENE
gene I-GENE
. O

Bitter O
cassava O
contains O
cyanogenic O
glycosides O
; O
processing O
breaks O
them O
down O
to O
acetone O
cyanohydrin O
and O
hydrogen O
cyanide O
. O

The O
proposed O
mechanism O
of O
effect O
states O
that O
mono O
( O
2 O
- O
ethylhexyl O
) O
phthalate O
( O
MEHP O
), O
the O
primary O
hydrolysis O
product O
of O
DEHP O
, O
mimics O
the O
inducing O
prostaglandins O
( O
PG O
) O
PGD O
( O
2 O
), O
9alpha O
, O
11betaPGF2 O
, O
and O
PGF2alpha O
, O
and O
thromboxanes O
in O
the O
lungs O
, O
thereby O
increasing O
the O
risk O
of O
inducing O
inflammation O
in O
the O
airways O
, O
which O
is O
a O
characteristic O
of O
asthma O
. O

We O
found O
14 O
protein O
binding O
sites O
that O
were O
occupied O
in O
vivo O
. O

Constitutive O
protection O
of O
E2F I-GENE
recognition I-GENE
sequences I-GENE
in O
the O
human I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
during O
cell O
cycle O
progression O
. O

Comparison O
of O
genomic O
sequence O
shows O
that O
the O
ph I-GENE
locus I-GENE
has O
been O
duplicated O
, O
and O
that O
it O
contains O
proximal O
and O
distal O
transcription O
units O
. O

Radiation O
decreased O
the O
levels O
of O
T4 O
and O
T3 O
6 O
h O
and O
72 O
h O
in O
group O
C O
, O
in O
group O
A O
at O
72 O
h O
, O
in O
group O
B O
at O
24 O
h O
postexposure O
. O

We O
have O
reviewed O
the O
experience O
of O
a O
major O
MMT O
general O
practice O
with O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
from O
1991 O
to O
1995 O
. O

The O
author O
analyzes O
extensive O
own O
data O
based O
on O
study O
into O
particular O
features O
of O
cardiovascular O
disorders O
in O
chronic O
renal O
impairement O
with O
making O
use O
of O
modern O
diagnostic O
tools O
. O

In O
this O
paper O
, O
characterization O
is O
given O
of O
clinical O
and O
biochemical O
features O
of O
VH O
B O
course O
against O
the O
background O
of O
narcomania O
. O

447 O
microns O
for O
A O
. O
microcephalum O
and O
350 O
microns O
for O
A O
. O
wedli O
), O
and O
fewer O
testes O
per O
proglottis O
( O
44 O
- O
73 O
vs O
. O

The O
ZnF20 I-GENE
cDNA I-GENE
hybridized O
to O
multiple O
transcripts O
in O
a O
thyroid O
cancer O
cell O
line O
( O
8 O
. O
0 O
, O
4 O
. O
5 O
and O
2 O
kb O
) O
that O
increased O
after O
cycloheximide O
treatment O
and O
decayed O
< O
2 O
h O
after O
addition O
of O
actinomycin O
D O
. O

Glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- O
E2F I-GENE
and O
GST I-GENE
- O
DP I-GENE
fusion O
proteins O
were O
found O
to O
cooperate O
in O
binding O
to O
the O
three O
E2F I-GENE
sites I-GENE
in O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
promoter I-GENE
in O
vitro O
. O

Two O
sterol O
regulatory O
element O
- O
like O
sequences O
mediate O
up O
- O
regulation O
of O
caveolin I-GENE
gene I-GENE
transcription O
in O
response O
to O
low I-GENE
density I-GENE
lipoprotein I-GENE
free O
cholesterol O
. O

Furthermore O
, O
DNA O
- O
bound O
LAZ3 I-GENE
/ O
BCL6 I-GENE
recruits O
SMRT I-GENE
in O
vivo O
, O
and O
both O
overexpressed O
proteins O
completely O
colocalize O
in O
nuclear O
dots O
. O

CONCLUSIONS O
: O
We O
obtained O
normal O
EPO I-GENE
levels O
for O
mothers O
and O
newborns O
for O
our O
area O
, O
similarly O
to O
the O
previously O
described O
ones O
. O

Ischaemia O
was O
induced O
by O
a O
low O
flow O
rate O
of O
0 O
. O
8 O
mL O
min O
- O
1 O
for O
30 O
min O
, O
and O
was O
followed O
by O
a O
40 O
- O
minute O
reperfusion O
. O

First O
, O
two O
MCTs O
using O
a O
long O
electrode O
, O
3 O
cm O
in O
size O
, O
were O
performed O
in O
the O
central O
area O
of O
the O
tumor O
, O
and O
eight O
MCTs O
by O
a O
short O
electrode O
, O
2 O
cm O
in O
size O
, O
were O
done O
in O
the O
peripheral O
and O
surrounding O
area O
of O
the O
tumor O
. O

BACKGROUND O
: O
Checkpoint O
pathways O
prevent O
cell O
- O
cycle O
progression O
in O
the O
event O
of O
DNA O
lesions O
. O

Direct O
proof O
that O
the O
heightened O
renal O
cellular O
apoptosis O
in O
PKD O
is O
not O
occurring O
through O
p53 I-GENE
was O
obtained O
by O
successive O
matings O
between O
SBM O
and O
p53 I-GENE
(-/-) O
mice O
. O

Accumulated O
evidence O
indicates O
that O
, O
upon O
stimulation O
with O
interferon I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
), O
three O
beta O
- O
type O
subunits O
, O
designated O
LMP2 I-GENE
, O
LMP7 I-GENE
, O
and O
PSMB10 I-GENE
, O
are O
incorporated O
into O
the O
20S I-GENE
proteasome I-GENE
by O
displacing O
the O
housekeeping O
beta O
- O
type O
subunits O
designated O
PSMB6 I-GENE
, O
PSMB5 I-GENE
, O
and O
PSMB7 I-GENE
, O
respectively O
. O

The O
major O
RNase I-GENE
E I-GENE
cleavage O
product O
( O
denoted O
pSok I-GENE
- I-GENE
6 I-GENE
) O
is O
rapidly O
degraded O
by O
polynucleotide I-GENE
phosphorylase I-GENE
( O
PNPase I-GENE
). O

This O
difference O
may O
result O
from O
the O
lower O
match O
to O
the O
ARG O
box O
consensus O
of O
the O
O I-GENE
( I-GENE
rocD I-GENE
) I-GENE
site I-GENE
. O

Ask O
AONE O
' O
s O
experts O
... O
about O
productivity O
indicators O
. O

All O
pigs O
had O
significant O
regional O
LV O
dysfunction O
and O
reduced O
LV O
ejection O
fraction O
( O
41 O
+/- O
11 O
%). O

The O
progress O
of O
morphological O
research O
on O
the O
parabrachial O
nucleus O

The O
amplitudes O
of O
DPOAE O
also O
recovered O
to O
a O
greater O
extent O
and O
outer O
hair O
cell O
losses O
were O
less O
severe O
in O
the O
R O
- O
PIA O
- O
treated O
ears O
. O

The O
data O
provide O
evidence O
both O
for O
a O
signal O
transduction O
pathway O
independent O
of O
JNK I-GENE
, O
ERK I-GENE
, O
and O
p38 I-GENE
MAP I-GENE
kinase I-GENE
to O
be O
involved O
in O
the O
induction O
of O
rhoB I-GENE
by O
genotoxic O
stress O
, O
and O
furthermore O
, O
indicate O
autoregulation O
of O
rhoB I-GENE
. O

In O
an O
effort O
to O
separate O
domains O
of O
FadR I-GENE
required O
for O
DNA O
binding O
, O
dimerization O
, O
and O
ligand O
binding O
, O
chimeric O
protein O
fusions O
between O
the O
DNA O
binding O
domain O
of O
LexA I-GENE
and O
different O
regions O
of O
FadR I-GENE
were O
constructed O
. O

Inhibition O
appears O
to O
result O
from O
titration O
of O
general O
transcription O
factors O
because O
MDM2 I-GENE
overexpression O
inhibits O
c I-GENE
- I-GENE
fos I-GENE
as O
well O
as O
other O
promoters O
in O
vivo O
and O
basal O
transcription O
in O
vitro O
. O

4 O
) O
PU I-GENE
and O
PD I-GENE
lacked O
the O
canonical O
TATA O
or O
CAAT O
motifs O
, O
and O
are O
AT O
- O
rich O
. O

We O
also O
show O
by O
immunogold O
electron O
microscopy O
immunocytochemistry O
that O
amphiphysin I-GENE
I I-GENE
is O
localized O
in O
the O
nerve O
terminal O
cytomatrix O
and O
is O
partially O
associated O
with O
endocytic O
intermediates O
. O

The O
mobility O
shift O
of O
both O
of O
these O
proteins O
is O
abolished O
by O
treatment O
with O
inhibitors O
of O
PKC I-GENE
or O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ O
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
kinase I-GENE
. O

The O
prescription O
for O
apoplexy O
includes O
C1 O
- O
7 O
, O
T1 O
- O
9 O
and O
L2 O
- O
4 O
. O

During O
the O
aftermath O
of O
excitation O
of O
the O
skin O
sympathetic O
nerve O
by O
mental O
arithmetics O
, O
3 O
/ O
12 O
A O
delta O
units O
were O
turned O
to O
the O
active O
state O
with O
decreased O
mechanical O
threshold O
. O

In O
a O
similar O
fashion O
to O
adipose O
stromal O
cells O
, O
serum O
potentiated O
the O
response O
to O
dexamethasone O
but O
had O
no O
effect O
on O
phorbol O
ester O
- O
stimulated O
activity O
. O

Thus O
, O
Hex I-GENE
expression O
marks O
the O
earliest O
unequivocal O
molecular O
anteroposterior O
asymmetry O
in O
the O
mouse O
embryo O
and O
indicates O
that O
the O
anteroposterior O
axis O
of O
the O
embryo O
develops O
from O
conversion O
of O
a O
proximodistal O
asymmetry O
established O
in O
the O
primitive O
endoderm O
lineage O
. O

Thus O
, O
dpp I-GENE
and O
omb I-GENE
promote O
both O
dorsal O
leg O
cell O
fate O
as O
well O
as O
transdetermination O
- O
competent O
leg O
disc O
cells O
. O

CONCLUSIONS O
: O
While O
INR O
correction O
may O
be O
achieved O
by O
all O
the O
above O
methods O
, O
that O
relating O
log O
reference O
INR O
to O
log O
local O
prothrombin I-GENE
time O
by O
linear O
regression O
analysis O
is O
the O
simplest O
to O
perform O
. O

RESULTS O
: O
The O
overall O
FNF O
for O
1992 O
was O
12 O
. O
3 O
% O
and O
was O
19 O
. O
1 O
%, O
22 O
. O
2 O
%, O
3 O
. O
8 O
% O
and O
6 O
. O
1 O
% O
per O
successive O
quarters O
in O
1992 O
. O

Western O
blot O
analysis O
of O
various O
bovine O
tissues O
with O
human O
NMT I-GENE
peptide I-GENE
antibody I-GENE
indicated O
a O
common O
prominent O
immunoreactive O
band O
with O
an O
apparent O
molecular O
mass O
of O
48 O
. O
5 O
- O
50 O
kDa O
in O
all O
tissues O
. O

Transcription O
start O
sites O
of O
the O
plastid O
ACCase I-GENE
genes I-GENE
were O
estimated O
from O
the O
longest O
cDNA O
clones O
obtained O
by O
5 O
'- O
RACE O
( O
rapid O
amplification O
of O
cDNA O
ends O
). O

AIDS O
- O
related O
disseminated O
histoplasmosis O
in O
San O
Francisco O
, O
California O
. O

Thus O
, O
Fis I-GENE
acts O
as O
an O
accessory O
transcriptional O
activator O
at O
the O
mar I-GENE
promoter I-GENE
. O

These O
observations O
provide O
strong O
support O
for O
the O
idea O
that O
expression O
of O
mutant O
tRNA O
can O
confer O
a O
mutator O
phenotype O
, O
including O
the O
UVM O
- O
constitutive O
phenotype O
observed O
in O
mutA I-GENE
and O
mutC I-GENE
cells O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
exposure O
markedly O
increased O
activity O
of O
several O
RNA O
- O
binding O
proteins O
, O
especially O
a O
novel O
Mr O
50 O
, O
000 O
- O
55 O
, O
000 O
RNA O
- O
binding O
protein O
. O

We O
speculate O
that O
the O
human O
papillomavirus O
late O
mRNAs O
, O
produced O
from O
several O
hundred O
copies O
of O
the O
virus O
genome O
present O
in O
infected O
cells O
, O
compete O
with O
the O
c I-GENE
- I-GENE
fos I-GENE
mRNAs I-GENE
for O
destabilizing O
cellular O
factors O
and O
that O
this O
may O
lead O
to O
elevated O
Fos I-GENE
protein I-GENE
levels O
in O
human O
papillomavirus O
infected O
cells O
. O

Two O
closely O
related O
IgH I-GENE
constant O
region O
genes O
, O
CHA I-GENE
and O
CHB I-GENE
, O
have O
been O
sequenced O
completely O
. O

The O
aim O
of O
this O
study O
was O
to O
find O
out O
whether O
it O
was O
possible O
to O
detect O
normal O
lymph O
nodes O
by O
high O
- O
resolution O
mediastinal O
US O
. O

To O
study O
the O
role O
of O
heavy O
chain O
motifs O
in O
substrate O
recognition O
, O
secreted O
variants O
of O
recombinant I-GENE
bovine I-GENE
proenteropeptidase I-GENE
were O
constructed O
by O
replacing O
the O
transmembrane O
domain O
with O
a O
signal O
peptide O
. O

CKbeta4GT I-GENE
- I-GENE
II I-GENE
is O
predicted O
to O
encode O
a O
type I-GENE
II I-GENE
transmembrane I-GENE
glycoprotein I-GENE
of O
43 O
kDa O
with O
five O
potential O
N O
- O
linked O
glycosylation O
sites O
. O

We O
now O
demonstrate O
that O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
delta I-GENE
is O
a O
major O
component O
of O
a O
PGE2 O
- O
stimulated O
DNA O
- O
protein O
complex O
involving O
HS3D I-GENE
and O
find O
that O
C I-GENE
/ I-GENE
EBPdelta I-GENE
transactivates O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
through O
this O
site O
. O

PATIENTS O
AND O
METHODS O
: O
Semen O
analyses O
were O
performed O
on O
58 O
patients O
with O
stages O
I O
- O
III O
HD O
before O
, O
during O
, O
and O
after O
chemotherapy O
and O
after O
the O
sperm O
count O
recovered O
from O
the O
effects O
of O
abdominal O
radiotherapy O
that O
was O
given O
after O
chemotherapy O
. O

Thus O
, O
the O
absence O
of O
residual O
infarct O
- O
zone O
viability O
discriminates O
patients O
who O
develop O
progressive O
left O
ventricular O
dilation O
after O
reperfused O
AMI O
from O
those O
who O
maintain O
normal O
left O
ventricular O
geometry O
. O

With O
a O
BMI O
cutoff O
of O
27 O
, O
mean O
cardiac O
NE O
spillover O
was O
46 O
% O
lower O
in O
the O
obese O
subjects O
when O
compared O
with O
the O
lean O
subjects O
( O
P O
=. O
017 O
). O

The O
gene O
( O
ApxII I-GENE
) O
encoding O
both O
chloroplastic I-GENE
ascorbate I-GENE
peroxidase I-GENE
isoenzymes I-GENE
was O
isolated O
and O
the O
organization O
of O
the O
gene O
was O
determined O
. O

This O
emphasizes O
the O
conclusion O
that O
CDF I-GENE
- I-GENE
1 I-GENE
is O
not O
an O
E2F I-GENE
family I-GENE
member I-GENE
and O
points O
to O
profound O
differences O
in O
the O
cell O
cycle O
regulation O
of O
CDF I-GENE
- I-GENE
1 I-GENE
and O
E2F I-GENE
. O

The O
proofreading O
domain O
of O
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
other O
DNA I-GENE
and I-GENE
/ I-GENE
or I-GENE
RNA I-GENE
exonuclease I-GENE
domains I-GENE
. O

Interleukin I-GENE
- I-GENE
1 I-GENE
levels O
remained O
low O
throughout O
the O
course O
. O

Responsibility O
matters O
-- O
this O
is O
a O
scientific O
council O

Southern O
blot O
analysis O
of O
endonuclease O
- O
digested O
genomic O
DNA O
from O
primary O
chick O
embryo O
fibroblasts O
( O
CEF O
) O
suggested O
that O
MEK2 I-GENE
is O
a O
single O
- O
copy O
gene O
in O
this O
vertebrate O
species O
. O

Sequences O
required O
for O
interaction O
of O
mu2 I-GENE
and O
CTLA I-GENE
- I-GENE
4 I-GENE
were O
localized O
to O
residues O
, O
161TTGVY O
in O
CTLA I-GENE
- I-GENE
4 I-GENE
; O
this O
sequence O
is O
N O
- O
terminal O
to O
, O
but O
overlaps O
with O
, O
a O
previously O
identified O
SH2 I-GENE
binding I-GENE
motif I-GENE
, O
165YVKM O
, O
involved O
in O
CTLA I-GENE
- I-GENE
4 I-GENE
signaling O
. O

Here O
, O
we O
report O
that O
a O
transfected O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cell O
line O
expressing O
a O
murine I-GENE
CD4 I-GENE
fragment I-GENE
containing O
the O
first O
two O
N O
- O
terminal O
domains O
secretes O
both O
monomeric O
molecules O
and O
disulfide O
- O
linked O
multimers O
. O

SCID O
V I-GENE
( O
D I-GENE
) O
J I-GENE
recombination O
can O
be O
partly O
rescued O
in O
T O
- O
lymphocytes O
by O
either O
DNA O
- O
damaging O
agents O
( O
gamma O
- O
irradiation O
and O
bieomycin O
) O
or O
a O
null O
mutation O
of O
the O
p53 I-GENE
gene I-GENE
, O
possibly O
because O
of O
transiently O
elevated O
DNA O
repair O
activity O
in O
response O
to O
DNA O
damage O
or O
to O
delayed O
apoptosis O
in O
the O
absence O
of O
p53 I-GENE
. O

Coexpression O
of O
mouse O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
515 I-GENE
) I-GENE
WT I-GENE
as O
a O
Gal4 I-GENE
DNA O
- O
binding O
domain O
fusion O
with O
either O
the O
catalytic O
- O
deficient O
human O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
551 I-GENE
) I-GENE
K296R O
mutant O
, O
the O
RNA O
- O
binding O
- O
deficient O
human O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
551 I-GENE
) I-GENE
K64E I-GENE
/ I-GENE
K296R I-GENE
double O
mutant O
, O
or O
wild O
- O
type O
mouse O
PKR I-GENE
( I-GENE
1 I-GENE
- I-GENE
515 I-GENE
) I-GENE
WT I-GENE
as O
full O
- O
length O
PKR I-GENE
- O
Gal4 I-GENE
activation O
domain O
fusions O
resulted O
in O
activation O
of O
the O
HIS3 I-GENE
and O
lacZ I-GENE
reporters O
. O

Using O
GST I-GENE
- O
PKR I-GENE
fusion O
chromatography O
, O
direct O
physical O
interaction O
between O
the O
mouse O
and O
human I-GENE
PKR I-GENE
homologs I-GENE
was O
established O
. O

An O
even O
greater O
inflammatory O
response O
was O
observed O
after O
intratracheal O
instillation O
of O
ufCB O
, O
but O
not O
after O
CB O
instillation O
. O

Interestingly O
, O
the O
avirulent O
strain O
H37Ra O
showed O
weak O
hybridization O
with O
these O
two O
probes O
, O
suggesting O
that O
these O
genes O
might O
have O
been O
deleted O
in O
the O
avirulent O
strain O
or O
are O
present O
in O
limited O
copy O
numbers O
as O
opposed O
to O
those O
in O
the O
virulent O
strain O
H37Rv O
. O

These O
defects O
no O
doubt O
impair O
the O
folding O
and O
configuration O
necessary O
for O
normal O
processing O
of O
the O
AVP I-GENE
gene I-GENE
precursor I-GENE
. O

Similarities O
between O
the O
hIGFBP I-GENE
- I-GENE
1 I-GENE
and O
phosphoenolpyruvate I-GENE
kinase I-GENE
( O
PEPCK I-GENE
) O
promoters O
, O
including O
regions O
conferring O
insulin I-GENE
, O
glucocorticoid O
, O
and O
cyclic O
adenosine O
- O
monophosphate O
responses O
, O
are O
consistent O
with O
our O
previous O
hypothesis O
that O
IGFBP I-GENE
- I-GENE
1 I-GENE
is O
involved O
in O
regulation O
of O
glucose O
metabolism O
. O

This O
binary O
repeat O
contains O
repetitive O
DNA O
elements O
that O
include O
LINES O
, O
SINES O
, O
medium O
reiteration O
frequency O
repeats O
, O
and O
a O
transposon O
- O
like O
element O
. O

At O
60 O
days O
the O
amount O
of O
gangliosides O
was O
on O
average O
lower O
in O
females O
than O
in O
males O
, O
even O
if O
with O
some O
exception O
. O

Large O
genomic O
constructs O
integrate O
at O
the O
endogenous O
locus O
by O
homologous O
recombination O
, O
but O
cDNA O
- O
derived O
sequences O
lacking O
long O
stretches O
of O
contiguous O
genomic O
DNA O
( O
due O
to O
intron O
excision O
) O
typically O
integrate O
into O
chromosomal O
DNA O
by O
nonhomologous O
recombination O
. O

The O
existence O
of O
these O
two O
categories O
of O
strains O
offers O
a O
new O
genetic O
system O
in O
which O
the O
properties O
of O
a O
potential O
invertebrate O
retrovirus O
can O
be O
tested O
. O

During O
the O
conditioning O
procedure O
, O
the O
C O
- O
fiber O
reflex O
was O
facilitated O
( O
wind O
- O
up O
) O
in O
a O
stimulus O
- O
dependent O
fashion O
in O
intact O
, O
anesthetized O
animals O
during O
the O
application O
of O
the O
first O
seven O
conditioning O
stimuli O
; O
thereafter O
, O
the O
magnitude O
of O
the O
responses O
reached O
a O
plateau O
and O
then O
decreased O
. O

As O
a O
sequence O
- O
specific O
DNA O
binding O
transcription O
factor O
, O
p53 I-GENE
specifically O
binds O
to O
a O
20 O
- O
bp O
consensus O
motif O
5 O
'- O
PuPuPuC O
( O
A O
/ O
T O
) O
( O
T O
/ O
A O
) O
GPyPyPyPuPuPuC O
( O
A O
/ O
T O
)( O
T O
/ O
A O
) O
GPyPyPy O
- O
3 O
'. O

TSA O
treatment O
, O
however O
, O
did O
not O
detectably O
alter O
enhancer O
factor O
binding O
or O
the O
positioning O
of O
nuc I-GENE
- I-GENE
1 I-GENE
on O
the O
majority O
of O
the O
chromatin O
templates O
indicating O
that O
protein O
acetylation O
and O
chromatin O
remodeling O
may O
be O
limiting O
steps O
that O
occur O
only O
on O
transcriptionally O
competent O
templates O
, O
or O
that O
remodeling O
of O
nuc I-GENE
- I-GENE
1 I-GENE
requires O
additional O
factors O
. O

Upon O
UV O
damage O
, O
Crb2 I-GENE
is O
transiently O
modified O
, O
probably O
phosphorylated O
, O
with O
a O
similar O
timing O
of O
phosphorylation O
in O
Chk1 I-GENE
kinase I-GENE
, O
which O
is O
reported O
to O
restrain O
Cdc2 I-GENE
activation O
. O

Moreover O
, O
moderate O
overexpression O
of O
Chk1 I-GENE
suppresses O
the O
phenotypes O
of O
cut5 I-GENE
and O
crb2 I-GENE
mutants I-GENE
. O

Tcn1p I-GENE
/ O
Crz1p I-GENE
, O
a O
calcineurin O
- O
dependent O
transcription O
factor O
that O
differentially O
regulates O
gene O
expression O
in O
Saccharomyces O
cerevisiae O
. O

Structure O
and O
localization O
of O
the O
human O
gene O
encoding O
SR I-GENE
- I-GENE
BI I-GENE
/ O
CLA I-GENE
- I-GENE
1 I-GENE
. O

We O
introduced O
the O
gel O
technique O
as O
a O
routine O
assay O
for O
antibody O
detection O
and O
identification O
in O
1993 O
. O

Stability O
of O
pyrimethamine O
in O
a O
liquid O
dosage O
formulation O
stored O
for O
three O
months O
. O

Multiple O
regression O
analyses O
revealed O
that O
WAIS O
- O
R O
factor O
scores O
Verbal O
Comprehension O
and O
Freedom O
from O
Distractibility O
accounted O
for O
up O
to O
42 O
% O
of O
the O
variance O
in O
WMS O
- O
R O
and O
CVLT O
indices O
. O

Bilateral O
basal O
arteries O
were O
measured O
by O
the O
transtemporal O
approach O
with O
a O
2 O
MHz O
pulsed O
Doppler O
instrument O
( O
TC O
- O
2 O
64B O
EME O
). O

At O
the O
genomic O
level O
, O
the O
sequences O
of O
two O
members O
of O
this O
family O
are O
known O
in O
the O
rat O
Rattus O
norvegicus O
: O
the O
VCSA1 I-GENE
gene I-GENE
, O
encoding O
the O
prohormone I-GENE
- I-GENE
like I-GENE
polypeptide I-GENE
SMR1 I-GENE
, O
and O
the O
VCSB1 I-GENE
gene I-GENE
, O
encoding O
a O
salivary O
Pro O
- O
rich O
polypeptide O
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
RAD30 I-GENE
gene I-GENE
, O
a O
homologue I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
dinB I-GENE
and O
umuC I-GENE
, O
is O
DNA O
damage O
inducible O
and O
functions O
in O
a O
novel O
error O
- O
free O
postreplication O
repair O
mechanism O
. O

However O
, O
in O
a O
new O
experiment O
in O
which O
the O
deletion O
task O
was O
presented O
as O
a O
puppet O
game O
, O
and O
with O
pretraining O
and O
selection O
on O
vowel O
deletion O
, O
a O
significantly O
higher O
level O
of O
success O
was O
achieved O
by O
the O
children O
working O
with O
the O
CVCC O
material O
. O

Diet O
therapy O
with O
soy O
proteins O
for O
chronic O
stomach O
ulcers O

In O
ICU O
patients O
, O
the O
LIS O
related O
to O
the O
postoperative O
rise O
in O
IL I-GENE
- I-GENE
6 I-GENE
level O
only O
, O
even O
though O
the O
rise O
in O
plasma O
concentrations O
of O
cytokines O
interrelated O
. O

Resistance O
training O
shifts O
the O
power O
curve O
in O
a O
positive O
direction O
when O
the O
measurements O
are O
determined O
with O
absolute O
loads O
, O
but O
the O
increased O
power O
may O
not O
be O
transferred O
to O
an O
absolute O
performance O
task O
like O
the O
SSP O
. O

Gel O
- O
shift O
assays O
identified O
two O
Sp1 I-GENE
binding I-GENE
sites I-GENE
within O
this O
element O
. O

Y15170 I-GENE
( O
Surf I-GENE
- I-GENE
2 I-GENE
, O
Surf I-GENE
- I-GENE
4 I-GENE
), O
Y15171 I-GENE
( O
Surf I-GENE
- I-GENE
3 I-GENE
, O
Surf I-GENE
- I-GENE
1 I-GENE
, O
Surf I-GENE
- I-GENE
6 I-GENE
), O
and O
Y15172 I-GENE
( O
Surf I-GENE
- I-GENE
5 I-GENE
.)] O

Gel O
mobility O
shift O
and O
super O
- O
shift O
assays O
using O
liver O
nuclear O
extracts O
from O
either O
rat O
liver O
or O
DDT1MF O
- O
2 O
cells O
demonstrated O
that O
the O
CRE O
in O
the O
alpha I-GENE
1B I-GENE
- I-GENE
AR I-GENE
gene I-GENE
bound O
CRE I-GENE
binding I-GENE
protein I-GENE
. O

These O
results O
suggest O
that O
, O
in O
this O
experimental O
model O
, O
ACE I-GENE
inhibitors O
limit O
the O
arrhythmias O
following O
ischemia O
- O
reperfusion O
and O
free O
radical O
scavenging O
action O
of O
these O
drugs O
does O
not O
have O
a O
major O
contributory O
role O
in O
their O
protective O
effect O
. O

The O
mean O
values O
of O
the O
first O
three O
components O
were O
not O
significantly O
different O
in O
ARVD O
patients O
and O
control O
subjects O
. O

However O
, O
the O
signaling O
cascade O
utilized O
by O
the O
urokinase I-GENE
receptor I-GENE
is O
only O
incompletely O
understood O
. O

The O
murine O
Htf9 I-GENE
- I-GENE
a I-GENE
/ O
RanBP1 I-GENE
and O
Htf9 I-GENE
- I-GENE
c I-GENE
genes I-GENE
are O
divergently O
transcribed O
from O
a O
shared O
TATA O
- O
less O
promoter O
. O

In O
accordance O
with O
clinical O
improvement O
we O
found O
a O
decrease O
of O
laboratory O
indicators O
of O
inflammation O
( O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
, O
alpha I-GENE
2 I-GENE
- I-GENE
globuline I-GENE
, O
prostaglandin O
E2 O
). O

We O
have O
previously O
reported O
that O
depletion O
of O
protein I-GENE
kinase I-GENE
C I-GENE
by O
long O
- O
term O
treatment O
of O
B16 O
mouse O
melanoma O
cells O
with O
phorbol O
dibutyrate O
( O
PDBu O
) O
prevented O
cell O
density O
- O
dependent O
melanogenesis O
. O

Replacement O
of O
residues O
in O
positions O
+ O
3 O
( O
His128Asn O
) O
and O
+ O
2 O
( O
Gln155Lys O
) O
of O
the O
reading O
helices O
of O
fingers O
2 O
and O
3 O
, O
respectively O
, O
prevented O
binding O
. O

Two O
disulphide O
bridges O
, O
which O
are O
conserved O
in O
all O
spermadhesin O
molecules O
and O
many O
CUB O
domains O
, O
crosslink O
loop O
LA O
and O
strand O
beta O
4 O
and O
loops O
LE O
and O
LG O
, O
respectively O
, O
at O
opposite O
edges O
of O
the O
same O
face O
of O
the O
domain O
. O

Mg I-GENE
- I-GENE
chelatase I-GENE
of O
tobacco O
: O
identification O
of O
a O
Chl I-GENE
D I-GENE
cDNA I-GENE
sequence I-GENE
encoding O
a O
third O
subunit O
, O
analysis O
of O
the O
interaction O
of O
the O
three O
subunits O
with O
the O
yeast O
two O
- O
hybrid O
system O
, O
and O
reconstitution O
of O
the O
enzyme O
activity O
by O
co O
- O
expression O
of O
recombinant I-GENE
CHL I-GENE
D I-GENE
, O
CHL I-GENE
H I-GENE
and O
CHL I-GENE
I I-GENE
. O

One O
R O
- O
EST O
and O
one O
Pto I-GENE
- I-GENE
like I-GENE
sequence I-GENE
each O
mapped O
to O
two O
locations O
. O

The O
multidomain O
structure O
includes O
a O
cysteine O
- O
rich O
motif O
resembling O
those O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
n I-GENE
- I-GENE
chimaerin I-GENE
and O
a O
putative O
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

The O
interaction O
between O
DDB I-GENE
and O
E2F1 I-GENE
can O
also O
be O
detected O
by O
coimmunoprecipitation O
experiments O
. O

271 O
: O
31290 O
- O
31295 O
, O
1996 O
). O

Nevertheless O
, O
antibodies O
directed O
against O
an O
epitope O
- O
tagged O
version O
of O
Prp42p I-GENE
specifically O
precipitate O
U1 I-GENE
snRNA I-GENE
from O
yeast O
extracts O
. O

These O
results O
indicate O
that O
in O
addition O
to O
Grb2 I-GENE
- O
mediated O
activation O
of O
Ras I-GENE
, O
PLC I-GENE
- I-GENE
gamma1 I-GENE
- O
mediated O
DAG O
production O
is O
required O
for O
EGF I-GENE
- O
and O
PDGF I-GENE
- O
induced O
S O
- O
phase O
entry O
and O
gene O
expression O
, O
possibly O
through O
activation O
of O
PKC I-GENE
. O

In O
this O
study O
, O
we O
investigated O
STAT I-GENE
activation O
in O
a O
panel O
of O
rodent O
fibroblast O
cell O
lines O
stably O
transformed O
by O
diverse O
viral O
oncoproteins O
. O

In O
serum O
- O
stimulated O
cells O
, O
the O
binding O
of O
NF I-GENE
- I-GENE
Y I-GENE
/ O
CBF I-GENE
to O
TKC1 I-GENE
increased O
gradually O
, O
reaching O
a O
plateau O
at O
the O
S O
phase O
. O

CONCLUSION O
: O
In O
our O
animal O
model O
, O
blood O
- O
brain O
barrier O
disruption O
was O
a O
reproducible O
, O
integral O
finding O
of O
single O
- O
fraction O
, O
high O
- O
dose O
irradiation O
injury O
. O

To O
facilitate O
the O
investigation O
of O
parameters O
that O
govern O
selective O
export O
in O
adenovirus O
- O
infected O
cells O
, O
we O
constructed O
a O
marked O
human O
beta I-GENE
- I-GENE
actin I-GENE
minigene I-GENE
under O
the O
control O
of O
the O
glucocorticoid I-GENE
- I-GENE
inducible I-GENE
enhancer I-GENE
- I-GENE
promoter I-GENE
of O
mouse O
mammary O
tumor O
virus O
and O
introduced O
it O
into O
the O
left O
end O
of O
the O
adenovirus O
type O
5 O
( O
Ad5 O
) O
genome O
. O

Cell O
factor O
- O
mediated O
regulatory O
interactions O
are O
involved O
in O
regulating O
the O
restricted O
expression O
of O
the O
HCMV I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
( I-GENE
IE I-GENE
) I-GENE
gene I-GENE
( O
J O
. O

MpB I-GENE
GroEL I-GENE
has O
extensive O
sequence O
similarity O
( O
92 O
%) O
with O
Escherichia I-GENE
coli I-GENE
GroEL I-GENE
and O
other O
members O
of O
the O
chaperonin I-GENE
- I-GENE
60 I-GENE
family I-GENE
. O

The O
critical O
mutations O
were O
likely O
to O
have O
been O
multiple O
and O
dispersed O
, O
including O
elongation O
of O
the O
TM O
and O
Nef I-GENE
coding I-GENE
sequences I-GENE
; O
changes O
in O
RNA O
splice O
donor O
and O
acceptor O
sites O
, O
TATA O
box O
sites O
, O
and O
Sp1 I-GENE
sites I-GENE
; O
multiple O
changes O
in O
the O
V2 I-GENE
region O
of O
SU I-GENE
, O
including O
a O
consensus O
neutralization O
epitope O
; O
and O
five O
new O
N O
- O
linked O
glycosylation O
sites O
in O
SU I-GENE
. O

C O
. O

These O
are O
the O
long O
terminal O
repeat O
( O
LTR O
) O
promoter O
, O
which O
regulates O
expression O
of O
the O
viral O
structural O
proteins O
, O
and O
a O
second O
internal O
promoter O
, O
located O
towards O
the O
3 O
' O
end O
of O
the O
env I-GENE
gene I-GENE
, O
that O
directs O
expression O
of O
the O
viral O
auxiliary O
proteins O
. O

The O
5 O
' O
end O
of O
the O
genomic O
RNA O
of O
rubella O
virus O
( O
RUB O
) O
contains O
a O
14 O
- O
nucleotide O
( O
nt O
) O
single O
- O
stranded O
leader O
( O
ss O
- O
leader O
) O
followed O
by O
a O
stem O
- O
and O
- O
loop O
structure O
[ O
5 O
'(+) O
SL O
] O
( O
nt O
15 O
to O
65 O
), O
the O
complement O
of O
which O
at O
the O
3 O
' O
end O
of O
the O
minus O
- O
strand O
RNA O
[ O
3 O
'(-) O
SL O
] O
has O
been O
proposed O
to O
function O
as O
a O
promoter O
for O
synthesis O
of O
genomic O
plus O
strands O
. O

To O
investigate O
the O
requirements O
for O
CBF2 I-GENE
binding O
, O
we O
synthesized O
a O
series O
of O
oligonucleotides O
carrying O
double O
transversion O
mutations O
spanning O
both O
the O
conserved O
core O
sequence O
and O
outside O
flanking O
sequences O
. O

In O
addition O
, O
the O
affinities O
of O
CBF2 I-GENE
for O
binding O
to O
the O
LMP I-GENE
- I-GENE
1 I-GENE
, O
LMP I-GENE
- I-GENE
2 I-GENE
, O
and O
CD23 I-GENE
promoters I-GENE
were O
also O
measured O
. O

CONCLUSIONS O
: O
The O
myocardial O
uptake O
of O
99mTc O
sestamibi O
in O
normal O
subjects O
and O
patients O
with O
coronary O
artery O
disease O
is O
comparable O
after O
exercise O
, O
dipyridamole O
, O
and O
adenosine O
stress O
. O

The O
SR I-GENE
protein I-GENE
family I-GENE
is O
involved O
in O
constitutive O
and O
regulated O
pre O
- O
mRNA O
splicing O
and O
has O
been O
found O
to O
be O
evolutionarily O
conserved O
in O
metazoan O
organisms O
. O

To O
investigate O
the O
activity O
of O
TCF11 I-GENE
through O
this O
selected O
site O
, O
both O
alone O
and O
in O
the O
presence O
of O
MafG I-GENE
, O
we O
have O
used O
a O
transient O
transfection O
assay O
. O

These O
and O
other O
comparisons O
suggest O
that O
, O
during O
evolution O
, O
both O
the O
RNA I-GENE
- I-GENE
polymerase I-GENE
specificity O
of O
telomerase I-GENE
RNA I-GENE
- I-GENE
gene I-GENE
promoters I-GENE
and O
, O
more O
recently O
, O
the O
position O
of O
the O
template O
sequence O
in O
the O
telomerase I-GENE
RNA I-GENE
changed O
. O

Deadenylation O
and O
decay O
of O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
extraordinarily O
slow O
compared O
with O
NIH O
3T3 O
cells O
, O
suggesting O
that O
the O
increased O
stability O
gained O
by O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
mainly O
controlled O
at O
the O
deadenylation O
step O
. O

Holliday I-GENE
junction I-GENE
resolvase I-GENE
in O
Schizosaccharomyces O
pombe O
has O
identical O
endonuclease O
activity O
to O
the O
CCE1 I-GENE
homologue O
YDC2 I-GENE
. O

Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
II I-GENE
( O
CaMK I-GENE
II I-GENE
) O
is O
a O
multifunctional O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
that O
regulates O
ion O
channels O
, O
metabolic O
enzymes O
, O
cytoskeletal O
proteins O
, O
and O
possibly O
transcription O
factors O
. O

A O
cAMP O
- O
responsive O
element O
- O
like O
( O
CRE O
- O
like O
, O
TGACGTGA O
) O
promoter O
sequence O
and O
a O
protein I-GENE
kinase I-GENE
A I-GENE
signaling O
pathway O
are O
involved O
in O
this O
induction O
, O
and O
activation O
of O
both O
CRE I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
activating I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
2 I-GENE
( O
ATF I-GENE
- I-GENE
2 I-GENE
) O
is O
required O
in O
the O
above O
process O
. O

IVOX O
was O
named O
as O
an O
acronym O
for O
intravascular O
oxygenator O
. O

Histopathologically O
, O
a O
cystic O
lymphangioma O
was O
diagnosed O
because O
of O
the O
morphological O
features O
and O
the O
immunohistochemical O
stainings O
of O
CD34 I-GENE
and O
Factor I-GENE
VIII I-GENE
related I-GENE
antigen I-GENE
which O
were O
observed O
positive O
reactions O
in O
endothelial O
cells O
of O
the O
cysts O
. O

Protease O
activities O
in O
cultures O
of O
the O
streptococcal O
strains O
were O
associated O
with O
species O
of O
different O
molecular O
masses O
ranging O
from O
130 O
to O
200 O
kDa O
, O
suggesting O
posttranslational O
processing O
possibly O
as O
a O
result O
of O
autoproteolysis O
at O
post O
- O
proline O
peptide O
bonds O
in O
the O
N O
- O
terminal O
parts O
of O
the O
molecules O
. O

The O
mechanism O
underlying O
such O
analgesia O
has O
been O
suggested O
to O
involve O
the O
interaction O
between O
the O
two O
separate O
but O
interconnected O
motivational O
systems O
" O
defense O
" O
and O
" O
pain O
." O
To O
determine O
the O
developmental O
course O
of O
defense O
and O
nociception O
, O
these O
processes O
were O
analyzed O
during O
early O
ontogeny O
in O
rats O
. O

Three O
large O
field O
placement O
errors O
( O
two O
patients O
with O
11 O
. O
5 O
and O
16 O
. O
0 O
mm O
distances O
of O
the O
planned O
versus O
simulated O
isocenter O
, O
respectively O
and O
one O
patient O
with O
a O
7 O
degree O
rotational O
error O
) O
were O
detected O
and O
, O
as O
with O
the O
smaller O
errors O
, O
were O
immediately O
corrected O
. O

In O
addition O
, O
a O
catalytically O
inactive O
version O
of O
the O
Src I-GENE
family I-GENE
member O
, O
Lck I-GENE
( O
lymphoid I-GENE
cell I-GENE
kinase I-GENE
), O
was O
expressed O
, O
purified O
, O
and O
evaluated O
as O
a O
Csk I-GENE
substrate O
. O

A O
., O
Swift O
, O
A O
. O

Neuronal O
mechanisms O
underlying O
stimulus O
- O
response O
( O
S O
- O
R O
) O
associations O
in O
S O
- O
R O
compatibility O
tasks O
were O
identified O
in O
2 O
experiments O
with O
monkeys O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
/ O
TGF I-GENE
- I-GENE
alpha I-GENE
HCCs O
were O
also O
characterized O
by O
a O
particularly O
strong O
expression O
of O
TGF I-GENE
- I-GENE
alpha I-GENE
and O
very O
low O
apoptotic O
index O
in O
contrast O
to O
high O
levels O
of O
apoptosis O
in O
peritumorous O
tissues O
and O
c I-GENE
- I-GENE
myc I-GENE
HCCs O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
the O
antagonistic O
effects O
of O
CRP I-GENE
and O
KdgR I-GENE
on O
the O
expression O
of O
the O
pectinolysis I-GENE
genes I-GENE
occur O
by O
different O
mechanisms O
, O
including O
direct O
competition O
between O
the O
two O
regulators O
or O
between O
the O
repressor O
and O
RNA I-GENE
polymerase I-GENE
for O
the O
occupation O
of O
a O
common O
DNA O
region O
on O
the O
target O
genes O
. O

The O
well O
- O
known O
Rel I-GENE
/ O
NF I-GENE
- I-GENE
kappaB I-GENE
family O
of O
vertebrate O
transcription O
factors O
comprises O
a O
number O
of O
structurally O
related O
, O
interacting O
proteins O
that O
bind O
DNA O
as O
dimers O
and O
whose O
activity O
is O
regulated O
by O
subcellular O
location O
. O

The O
cglIM I-GENE
gene I-GENE
is O
organized O
in O
an O
unusual O
operon O
which O
contains O
, O
in O
addition O
, O
two O
genes O
encoding O
stress O
- O
sensitive O
restriction O
enzymes O
. O

Lysine I-GENE
- I-GENE
ketoglutarate I-GENE
reductase I-GENE
and O
saccharopine I-GENE
dehydrogenase I-GENE
from O
Arabidopsis O
thaliana O
: O
nucleotide O
sequence O
and O
characterization O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
describe O
a O
new O
formulation O
of O
silver O
sulfadiazine O
in O
a O
water O
soluble O
gel O
, O
poloxamer O
188 O
. O

The O
study O
goals O
were O
to O
isolate O
a O
full O
- O
length O
clone O
encoding O
CO I-GENE
- I-GENE
Ag I-GENE
from O
a O
bovine O
corneal O
cDNA O
library O
and O
to O
express O
this O
clone O
in O
Escherichia O
coli O
( O
E O
. O
coli O
). O

The O
pel I-GENE
gene I-GENE
from O
an O
Amycolata O
sp O
. O
encoding O
a O
pectate I-GENE
lyase I-GENE
( O
EC I-GENE
4 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
. I-GENE
2 I-GENE
) O
was O
isolated O
by O
activity O
screening O
a O
genomic O
DNA O
library O
in O
Streptomyces O
lividans O
TK24 O
. O

The O
gene O
contains O
six O
exons O
separated O
by O
1 O
. O
1 O
- O
5 O
. O
8 O
kb O
introns O
and O
has O
been O
localized O
to O
the O
murine O
chromosome O
2 O
by O
linkage O
analysis O
. O

In O
Xenopus O
embryos O
, O
the O
engineered I-GENE
PDGF I-GENE
receptor I-GENE
protein I-GENE
induced O
the O
formation O
of O
mesoderm O
from O
animal O
- O
pole O
explants O
in O
an O
FK1012 O
- O
dependent O
manner O
. O

A O
cytosolic O
variant O
of O
the O
protein O
underwent O
efficient O
transphosphorylation O
, O
yet O
failed O
to O
activate O
appreciably O
either O
p70 I-GENE
( O
S6k I-GENE
) O
or O
MAP I-GENE
kinase I-GENE
following O
treatment O
with O
FK1012 O
. O

Small O
- O
molecule O
control O
of O
insulin I-GENE
and O
PDGF I-GENE
receptor I-GENE
signaling O
and O
the O
role O
of O
membrane O
attachment O
. O

Conversely O
, O
the O
inactive O
dAK I-GENE
subunit I-GENE
is O
progressively O
activated O
by O
1 O
) O
association O
with O
a O
dGK I-GENE
or O
dCK I-GENE
subunit I-GENE
and O
2 O
) O
the O
conformationally O
driven O
heterotropic O
affect O
of O
dGuo I-GENE
or O
dCyd I-GENE
bound O
to O
the O
opposing O
subunit O
. O

CONCLUSIONS O
: O
A O
50 O
- O
mg O
daily O
dose O
of O
bicalutamide O
is O
sufficient O
when O
given O
in O
combination O
with O
an O
agent O
, O
such O
as O
a O
LHRH I-GENE
- O
A O
, O
that O
lowers O
serum O
testosterone O
, O
but O
higher O
doses O
of O
bicalutamide O
may O
be O
needed O
when O
the O
drug O
is O
given O
as O
monotherapy O
. O

A O
genomic O
clone O
was O
isolated O
that O
contained O
12 O
. O
5 O
kb O
of O
the O
5 O
'- O
flanking O
region O
and O
the O
first O
exon O
of O
the O
p69 I-GENE
/ I-GENE
71 I-GENE
2 I-GENE
- I-GENE
5A I-GENE
synthetase I-GENE
gene I-GENE
. O

Although O
the O
gene O
is O
substantially O
smaller O
than O
the O
human O
genes O
for O
other O
mitochondrial O
enzymes O
, O
its O
intron O
/ O
exon O
organization O
is O
very O
similar O
, O
especially O
to O
that O
of O
P450scc I-GENE
. O

RESULTS O
: O
Looking O
at O
the O
question O
of O
its O
benefits O
, O
we O
were O
unable O
to O
find O
any O
methodologically O
sound O
studies O
that O
have O
shown O
efficacy O
for O
EMDR O
in O
eating O
disorders O
, O
or O
, O
indeed O
, O
any O
psychiatric O
disorder O
. O

In O
the O
clinical O
study O
, O
the O
defect O
size O
shown O
by O
BMIPP O
imaging O
was O
greater O
in O
anterior O
than O
in O
inferior O
infarcts O
( O
p O
< O
0 O
. O
001 O
) O
and O
correlated O
well O
with O
the O
risk O
area O
revealed O
by O
contrast O
ventriculography O
( O
r O
= O
0 O
. O
80 O
, O
p O
< O
0 O
. O
0001 O
) O
CONCLUSION O
: O
The O
above O
preliminary O
data O
, O
admittedly O
from O
a O
small O
group O
of O
patients O
, O
suggest O
that O
tomographic O
BMIPP O
imaging O
provides O
an O
accurate O
quantification O
of O
defect O
size O
by O
means O
of O
a O
simple O
threshold O
technique O
and O
, O
in O
the O
subacute O
phase O
, O
permits O
determination O
of O
the O
amount O
of O
myocardium O
at O
risk O
after O
acute O
myocardial O
infarction O
. O

Transient O
overexpression O
of O
mutant I-GENE
EphB1 I-GENE
receptors I-GENE
( O
Y594F O
) O
blocked O
Nck I-GENE
recruitment O
to O
EphB1 I-GENE
, O
attenuated O
downstream O
JNK I-GENE
activation O
, O
and O
blocked O
cell O
attachment O
responses O
. O

The O
promoter O
for O
HMG I-GENE
- I-GENE
CoA I-GENE
synthase I-GENE
contains O
two O
binding O
sites O
for O
the O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
SREBPs I-GENE
). O

S O
., O
and O
Walter O
, O
P O
. O

Here O
we O
demonstrate O
that O
Hh I-GENE
and O
Patched I-GENE
( O
Ptc I-GENE
) O
act O
through O
those O
Ci I-GENE
binding O
sites O
to O
modulate O
the O
level O
of O
Ci I-GENE
- O
dependent O
transcriptional O
activation O
in O
S2 O
cells O
. O

Furthermore O
the O
median O
increase O
in O
cyclosporine O
DR O
/ O
C O
( O
SS O
trough O
) O
was O
18 O
l O
h O
- O
1 O
(- O
3 O
. O
1 O
to O
42 O
. O
1 O
l O
h O
- O
1 O
, O
interquartile O
range O
). O

Patients O
and O
their O
relatives O
must O
be O
informed O
about O
the O
available O
effective O
treatment O
possibilities O
and O
about O
the O
right O
moment O
for O
their O
application O
in O
an O
individual O
patient O
. O

Several O
PTPases I-GENE
were O
expressed O
abundantly O
in O
the O
5 O
- O
FU O
- O
treated O
bone O
marrow O
stem O
cells O
. O

Expression O
of O
PTPRO I-GENE
was O
also O
observed O
in O
human I-GENE
CD34 I-GENE
+ I-GENE
bone O
marrow O
cells O
and O
5 O
- O
FU O
- O
treated O
murine O
primitive O
stem O
cells O
. O

The O
organization O
of O
SPP1 I-GENE
genes I-GENE
involved O
in O
the O
replication O
, O
DNA O
packaging O
and O
phage O
assembly O
proteins O
resembles O
the O
organization O
of O
genes O
of O
equivalent O
regions O
of O
different O
E O
. O
coli O
double O
- O
stranded O
DNA O
phages O
. O

Our O
results O
showed O
that O
compared O
to O
the O
primary O
photon O
fluence O
, O
the O
extra O
- O
focal O
photon O
fluence O
from O
the O
primary O
collimator O
and O
the O
flattening O
filter O
was O
11 O
%- O
16 O
% O
at O
the O
isocenter O
, O
among O
which O
70 O
% O
was O
contributed O
by O
the O
flattening O
filter O
. O

The O
functional O
mature O
domain O
of O
pediocin I-GENE
AcH I-GENE
( I-GENE
Lys I-GENE
+ I-GENE
1 I-GENE
to I-GENE
Cys I-GENE
+ I-GENE
44 I-GENE
) I-GENE
is O
targeted O
into O
the O
E O
. O
coli O
sec O
machinery O
and O
secreted O
to O
the O
periplasm O
in O
active O
form O
when O
fused O
in O
frame O
to O
the O
COOH O
terminus O
of O
the O
secretory I-GENE
protein I-GENE
maltose I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
MBP I-GENE
). O

Isomers O
were O
differentiated O
based O
on O
the O
MS O
- O
MS O
data O
of O
the O
trofluoroacetyl O
- O
biphenylol O
derivatives O
. O

Although O
RAD17 I-GENE
, O
RAD24 I-GENE
and O
MEC3 I-GENE
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S O
phase O
is O
inhibited O
by O
hydroxyurea O
( O
HU O
), O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
HU O
, O
possibly O
because O
they O
are O
required O
for O
the O
repair O
of O
HU O
- O
induced O
DNA O
damage O
. O

Clinical O
value O
of O
the O
estimation O
of O
growth O
kinetics O
of O
primary O
ovarian O
cancer O
recurrences O
by O
CA125 I-GENE
doubling O
time O

This O
review O
seeks O
to O
summarize O
the O
disease O
, O
to O
propose O
pathways O
of O
carcinogenesis O
and O
to O
suggest O
ways O
in O
which O
the O
" O
traditional O
" O
risk O
factors O
may O
be O
interpreted O
on O
the O
basis O
of O
evolving O
knowledge O
. O

The O
patient O
underwent O
two O
intracytoplasmic O
sperm O
injection O
cycles O
with O
thawed O
epididymal O
spermatozoa O
, O
in O
which O
, O
due O
to O
a O
pharmacist O
' O
s O
mistake O
, O
ovarian O
stimulation O
was O
carried O
out O
by O
a O
combination O
of O
long O
- O
acting O
gonadotrophin I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
agonist O
( O
leuprolide O
depot O
) O
and O
gonadotrophins I-GENE
. O

Protein I-GENE
C I-GENE
deficiency O
or O
protein I-GENE
S I-GENE
deficiency O
was O
the O
only O
identified O
risk O
factor O
for O
5 O
. O
4 O
% O
( O
2 O
patients O
) O
and O
13 O
. O
5 O
% O
( O
5 O
patients O
), O
respectively O
, O
of O
these O
37 O
children O
. O

Perhaps O
in O
addition O
to O
, O
or O
as O
part O
of O
, O
its O
essential O
function O
in O
late O
mitosis O
, O
MOB1 I-GENE
is O
required O
for O
a O
cell O
cycle O
reset O
function O
necessary O
for O
the O
initiation O
of O
the O
spindle O
pole O
body O
duplication O
. O

In O
contrast O
, O
overproduction O
of O
Der3p I-GENE
is O
lethal O
in O
a O
sec61 I-GENE
- I-GENE
2 I-GENE
strain O
at O
the O
permissive O
temperature O
of O
25 O
degrees O
C O
. O

Normal O
baseline O
( O
day O
- O
8 O
) O
PC O
levels O
( O
86 O
and O
89 O
%) O
were O
markedly O
reduced O
in O
both O
patients O
at O
the O
time O
of O
VOD O
manifestation O
on O
day O
20 O
and O
40 O
, O
respectively O
( O
26 O
and O
31 O
%). O

To O
examine O
the O
role O
of O
this O
CE2 O
element O
in O
regulating O
Hoxa1 I-GENE
expression O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
which O
express O
a O
Hoxa1 I-GENE
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter O
gene O
that O
contains O
a O
mutation O
in O
the O
CE2 O
element O
. O

An O
evolutionary O
conserved O
element O
is O
essential O
for O
somite O
and O
adjacent O
mesenchymal O
expression O
of O
the O
Hoxa1 I-GENE
gene I-GENE
. O

RESULTS O
: O
The O
bovine O
cDNA O
insert O
sequence O
was O
273 O
nucleotides O
in O
length O
for O
the O
entire O
mRNA O
coding O
region O
, O
212 O
nucleotides O
in O
the O
5 O
' O
untranslated O
region O
, O
83 O
nucleotides O
in O
the O
3 O
' O
untranslated O
region O
and O
a O
poly O
( O
A O
) O
tail O
. O

Altogether O
46 O
phase O
III O
activities O
were O
recorded O
. O

We O
have O
previously O
identified O
a O
liver O
- O
enriched O
transcription O
factor O
, O
HNF I-GENE
- I-GENE
6 I-GENE
, O
which O
is O
required O
for O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
activity O
and O
also O
recognizes O
the O
regulatory O
region O
of O
numerous O
hepatocyte O
- O
specific O
genes O
. O

A O
cDNA O
clone O
was O
identified O
encoding O
a O
second O
GHS I-GENE
- I-GENE
R I-GENE
- I-GENE
related I-GENE
gene I-GENE
( O
GPR39 I-GENE
). O

( O
1997 O
) O
Science O
275 O
, O
1927 O
- O
1930 O
). O

P O
., O
Peyron O
, O
J O
. O

A O
hybridoma O
clone O
( O
7H1 O
) O
resulting O
from O
the O
fusion O
between O
CEMLAI O
/ O
NP O
and O
human O
embryonic O
fibroblasts O
MRC5 O
cells O
produced O
very O
large O
amounts O
of O
P47 I-GENE
that O
was O
purified O
using O
Jacalin I-GENE
lectin I-GENE
( O
specific O
for O
O O
- O
glycans O
) O
and O
microsequenced O
. O

This O
information O
, O
together O
with O
estimation O
of O
the O
size O
of O
the O
deglycosylated O
A O
subunit O
relative O
to O
a O
series O
of O
C I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
TSHR I-GENE
ectodomain I-GENE
variants I-GENE
, O
places O
cleavage O
Site O
1 O
in O
the O
vicinity O
of O
, O
or O
closely O
upstream O
to O
, O
residue O
317 O
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
of O
the O
200 O
- O
bp O
proximal O
region O
of O
the O
promoter O
with O
a O
murine O
Hepa O
1 O
- O
6 O
cell O
nuclear O
extract O
revealed O
a O
clear O
footprint O
of O
a O
region O
corresponding O
to O
- O
80 O
to O
- O
28 O
bp O
of O
the O
murine I-GENE
fVII I-GENE
gene I-GENE
, O
suggesting O
that O
liver O
factors O
interact O
with O
this O
region O
of O
the O
DNA O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP I-GENE
- I-GENE
1 I-GENE
and O
SHP I-GENE
- I-GENE
2 I-GENE
revealed O
specific O
association O
of O
SHP I-GENE
- I-GENE
2 I-GENE
( O
but O
not O
SHP I-GENE
- I-GENE
1 I-GENE
) O
with O
a O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
incorporating O
GHR I-GENE
cytoplasmic I-GENE
domain I-GENE
residues I-GENE
485 I-GENE
- I-GENE
620 I-GENE
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered O
tyrosine O
- O
phosphorylated O
. O

Both O
increasing O
basal O
FSH I-GENE
and O
age O
were O
associated O
significantly O
with O
increased O
total O
gonadotrophin I-GENE
dose O
, O
and O
reduced O
number O
of O
oocytes O
collected O
and O
pregnancy O
rate O
. O

A O
comparative O
study O
was O
undertaken O
between O
an O
enzymatic O
immunohistochemical O
technique O
( O
EIT O
) O
developed O
for O
the O
diagnosis O
of O
human O
trichinellosis O
and O
the O
indirect O
immunofluorescence O
test O
( O
IIF O
), O
analysing O
sera O
from O
outbreaks O
of O
human O
trichinellosis O
in O
Argentina O
. O

Our O
results O
establish O
GKLF I-GENE
as O
a O
sequence O
- O
specific O
transcription O
factor O
likely O
involved O
in O
regulation O
of O
expression O
of O
endogenous O
genes O
. O

CES4 I-GENE
on O
a O
multicopy O
plasmid O
was O
unable O
to O
suppress O
tif1 I-GENE
- I-GENE
A79V I-GENE
. O

Here O
we O
report O
that O
in O
cultured O
cells O
from O
Drosophila O
melanogaster O
human I-GENE
Sp1 I-GENE
efficiently O
activates O
transcription O
from O
synthetic O
promoters O
containing O
TATA O
boxes O
, O
but O
not O
from O
promoters O
that O
contain O
an O
initiator O
instead O
of O
a O
TATA O
box O
. O

No O
apparent O
clinical O
signs O
indicative O
of O
systemic O
toxicity O
were O
observed O
in O
the O
F0 O
and O
F1 O
animals O
of O
either O
sex O
. O

We O
have O
used O
mutation O
- O
directed O
chemical O
cross O
- O
linking O
with O
bis O
( O
sulfosuccinimidyl O
) O
suberate O
( O
BS3 O
) O
to O
investigate O
the O
architecture O
of O
the O
gp41 I-GENE
oligomer I-GENE
. O

In O
an O
effort O
to O
identify O
the O
USH1C I-GENE
disease I-GENE
gene I-GENE
we O
have O
isolated O
the O
region O
between O
these O
markers O
in O
yeast O
artificial O
chromosomes O
( O
YACs O
) O
using O
a O
combination O
of O
STS O
content O
mapping O
and O
Alu I-GENE
- O
PCR O
hybridization O
. O

PowerBLAST O
analysis O
identified O
six O
clusters O
of O
expressed O
sequence O
tags O
( O
ESTs O
), O
two O
known O
genes O
( O
BIR I-GENE
, O
SUR1 I-GENE
) O
mapped O
previously O
to O
this O
region O
, O
and O
a O
previously O
characterized O
but O
unmapped O
gene I-GENE
NEFA I-GENE
( O
DNA I-GENE
binding I-GENE
/ I-GENE
EF I-GENE
hand I-GENE
/ I-GENE
acidic I-GENE
amino I-GENE
- I-GENE
acid I-GENE
- I-GENE
rich I-GENE
). O

A O
fusion O
protein O
composed O
of O
beta I-GENE
- I-GENE
galactosidase I-GENE
and O
full I-GENE
- I-GENE
length I-GENE
Ahr I-GENE
translocates O
from O
the O
cytoplasm O
to O
the O
nucleus O
in O
a O
ligand O
- O
dependent O
manner O
. O

Reconstitution O
of O
Raf I-GENE
- I-GENE
1 I-GENE
activity O
was O
observed O
only O
with O
kinase O
active O
Jak1 I-GENE
in O
both O
cell O
lines O
. O

In O
addition O
, O
negatively O
regulatory O
region O
may O
exist O
from O
- O
1782 O
to O
- O
1295 O
bp O
. O

The O
hypothesis O
of O
Geisler O
( O
Brain O
Res O
. O

The O
second O
transcript O
, O
rhis4l I-GENE
, O
is O
bicistronic O
. O

Consistent O
with O
this O
interpretation O
, O
a O
mutant O
form O
of O
XRN1 I-GENE
, O
which O
encodes O
a O
5 O
'- O
3 O
' O
exonuclease O
, O
was O
identified O
as O
an O
extragenic O
suppressor O
that O
increases O
the O
half O
- O
life O
of O
rhis4 I-GENE
mRNA I-GENE
, O
leading O
to O
a O
10 O
- O
fold O
increase O
in O
steady O
- O
state O
mRNA O
levels O
compared O
to O
the O
wild I-GENE
- I-GENE
type I-GENE
HIS4 I-GENE
mRNA I-GENE
level O
. O

Sip1 I-GENE
was O
initially O
identified O
by O
virtue O
of O
its O
interaction O
with O
SC35 I-GENE
, O
a O
splicing O
factor O
of O
the O
SR I-GENE
family I-GENE
. O

Consistent O
with O
previous O
reports O
, O
addition O
of O
a O
myristoylation O
signal O
to O
mSos1 I-GENE
( O
MyrSos1 I-GENE
) O
rendered O
it O
transforming O
for O
NIH O
3T3 O
cells O
and O
deletion O
of O
the O
mSos I-GENE
C I-GENE
terminus I-GENE
( O
MyrSos1 I-GENE
- I-GENE
deltaC I-GENE
) O
did O
not O
interfere O
with O
this O
activity O
. O

Such O
mutations O
are O
thought O
to O
exert O
their O
dominant O
phenotype O
by O
sequestration O
of O
the O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
GNEF I-GENE
). O

Several O
studies O
have O
characterized O
the O
upstream O
regulatory O
region O
of O
c I-GENE
- I-GENE
fos I-GENE
, O
and O
identified O
cis O
- O
acting O
elements O
termed O
the O
cyclic O
AMP O
( O
cAMP O
) O
response O
elements O
( O
CREs O
) O
that O
are O
critical O
for O
c I-GENE
- I-GENE
fos I-GENE
transcription O
in O
response O
to O
a O
variety O
of O
extracellular O
stimuli O
. O

We O
have O
cloned O
a O
kinase O
, O
Nlk I-GENE
, O
that O
is O
a O
murine I-GENE
homolog I-GENE
of I-GENE
the I-GENE
Drosophila I-GENE
nemo I-GENE
( O
nmo I-GENE
) O
gene O
. O

Our O
findings O
suggest O
that O
striatal O
FDG O
and O
particularly O
RACLO O
are O
sensitive O
and O
effective O
measures O
of O
striatal O
function O
and O
may O
help O
characterizing O
patients O
with O
multiple O
system O
atrophy O
. O

Childhood O
misbehavior O
and O
the O
risk O
of O
injecting O
drug O
use O
. O

Genetic O
analysis O
has O
subsequently O
identified O
subpathways O
of O
the O
DNA O
structure O
checkpoints O
, O
including O
the O
reversible O
arrest O
of O
DNA O
synthesis O
. O

Thus O
, O
Esigma54 I-GENE
promoters I-GENE
are O
responsive O
to O
CRP I-GENE
, O
a O
protein O
unrelated O
to O
sigma54 I-GENE
activators I-GENE
, O
and O
the O
repression O
exerted O
is O
the O
direct O
result O
of O
an O
interaction O
between O
Esigma54 I-GENE
and O
the O
CRP I-GENE
- I-GENE
cAMP I-GENE
complex I-GENE
. O

GlcNAc O
- O
and O
GlcNAc2 O
- O
PP O
- O
Dolichol O
biosynthesis O
could O
be O
shown O
with O
isolated O
S O
. O
cerevisiae O
membranes O
from O
cells O
harboring O
the O
recombinant O
plasmid O
and O
grown O
on O
glucose O
thus O
suppressing O
transcription O
of O
the O
endogenous O
gene O
. O

Demonstration O
of O
tissue O
lesions O
after O
intramuscular O
injection O
by O
determination O
of O
creatine I-GENE
kinase I-GENE
in O
blood O

Antibodies O
raised O
against O
GST I-GENE
mSH2 I-GENE
- I-GENE
B I-GENE
identified O
a O
cellular O
protein O
of O
92 O
kDa O
that O
was O
not O
found O
to O
be O
phosphorylated O
on O
Tyr O
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
is O
a O
pleiotropic O
cytokine O
, O
which O
is O
involved O
in O
inflammatory O
and O
immune O
responses O
, O
acute O
phase O
reactions O
, O
and O
hematopoiesis O
. O

Upon O
analysis O
of O
various O
deletion O
and O
point O
- O
mutated O
variants O
of O
the O
human I-GENE
IL I-GENE
- I-GENE
6 I-GENE
gene I-GENE
promoter I-GENE
coupled O
to O
a O
reporter O
gene O
, O
we O
screened O
for O
possible O
cooperating O
transcription O
factors O
. O

This O
region O
, O
however O
, O
contains O
a O
CCAATC O
box O
in O
the O
reverse O
complement O
and O
several O
GC O
boxes O
that O
are O
recognition O
sites O
for O
SP1 I-GENE
. O

Our O
purpose O
was O
to O
determine O
if O
intact O
perianal O
( O
S4 O
- O
5 O
) O
pin O
sensation O
( O
PPS O
) O
and O
bulbocavernosus O
( O
S2 O
- O
4 O
) O
reflex O
( O
BCR O
) O
shortly O
after O
spinal O
cord O
injury O
( O
SCI O
) O
are O
predictive O
of O
bladder O
function O
recovery O
. O

The O
correct O
termination O
of O
retroviral O
transcripts O
at O
the O
3 O
' O
LTR O
R O
/ O
U5 O
junction O
is O
primarily O
dependent O
on O
the O
canonical O
AAUAAA O
polyadenylation O
signal O
, O
so O
we O
have O
analyzed O
the O
effect O
of O
mutating O
the O
polyadenylation O
signal O
sequences O
on O
the O
properties O
of O
a O
selectable O
murine O
retroviral O
vector O
. O

Levels O
of O
the O
MEK I-GENE
inhibitor O
PD98059 O
that O
block O
EGF I-GENE
- O
induced O
mitogenesis O
and O
MAP I-GENE
kinase I-GENE
phosphorylation O
also O
abrogate O
EGF I-GENE
- O
induced O
focal O
adhesion O
disassembly O
and O
cell O
motility O
. O

ALT I-GENE
levels O
in O
responders O
were O
lowered O
by O
46 O
% O
and O
AST I-GENE
levels O
were O
lowered O
by O
35 O
% O
after O
12 O
weeks O
of O
vitamin O
E O
treatment O
. O

Surprisingly O
, O
the O
COOH O
- O
terminal O
domain O
of O
RanGAP1 I-GENE
was O
also O
found O
to O
harbor O
a O
nuclear O
localization O
signal O
. O

51 O
. O
9 O
% O
( O
P O
= O
0 O
. O
0006 O
) O
in O
the O
MMF O
versus O
the O
AZA O
groups O
, O
respectively O
. O

Our O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
MMF O
on O
in O
vivo O
bone O
mineral O
metabolism O
. O

Pao2 O
increased O
from O
15 O
. O
5 O
+/- O
5 O
. O
6 O
kPa O
( O
116 O
+/- O
42 O
mm O
Hg O
) O
to O
17 O
. O
3 O
+/- O
6 O
. O
3 O
kPa O
( O
130 O
+/- O
47 O
mm O
Hg O
) O
( O
P O
< O
0 O
. O
05 O
). O

Typical O
configurations O
of O
psychosocial O
stress O
factors O
of O
psychiatrically O
conspicuous O
children O
and O
adolescents O

Nine O
cats O
received O
PMEA O
at O
a O
dosage O
of O
10 O
mg O
/ O
kg O
body O
weight O
, O
nine O
cats O
received O
FPMPA O
at O
a O
dosage O
of O
25 O
mg O
/ O
kg O
body O
weight O
. O

Resistance O
to O
thyroid O
hormone O
: O
implications O
for O
neurodevelopmental O
research O
on O
the O
effects O
of O
thyroid O
hormone O
disruptors O
. O

Here O
, O
we O
present O
evidence O
that O
exposure O
of O
DT40 O
lymphoma O
B O
cells O
to O
low O
energy O
electromagnetic O
field O
( O
EMF O
) O
results O
in O
a O
tyrosine I-GENE
kinase I-GENE
- O
dependent O
activation O
of O
phospholipase I-GENE
Cgamma2 I-GENE
( O
PLC I-GENE
- I-GENE
gamma2 I-GENE
) O
leading O
to O
increased O
inositol O
phospholipid O
turnover O
. O

We O
present O
the O
preliminary O
results O
obtained O
on O
36 O
patients O
which O
were O
followed O
for O
a O
mean O
period O
of O
12 O
months O
. O

Moreover O
, O
xTAK1KN I-GENE
could O
block O
the O
expression O
of O
ventral O
mesoderm O
marker O
genes O
induced O
by O
Smad1 I-GENE
or I-GENE
5 I-GENE
. O

PATIENTS O
AND O
METHOD O
: O
Since O
1986 O
, O
62 O
patients O
were O
irradiated O
stereotactically O
. O

The O
assay O
exhibits O
a O
dynamic O
range O
of O
0 O
. O
1 O
- O
100 O
micrograms O
l O
- O
1 O
using O
a O
monoclonal O
antibody O
or O
alternatively O
10 O
micrograms O
l O
- O
1 O
to O
10 O
mg O
l O
- O
1 O
using O
commercially O
available O
antiserum O
. O

Training O
for O
audit O
. O

A O
canonical O
TATA O
box O
was O
not O
detected O
. O

Expression O
and O
characterization O
of O
recombinant I-GENE
single I-GENE
- I-GENE
chain I-GENE
Fv I-GENE
and O
Fv I-GENE
fragments I-GENE
derived O
from O
a O
set O
of O
catalytic O
antibodies O
. O

A O
putative O
inhibitor O
( O
s O
) O
appears O
to O
co O
- O
elute O
in O
the O
inactive O
fraction O
that O
blocked O
the O
L I-GENE
( I-GENE
alpha I-GENE
) I-GENE
activity O
. O

Platelet O
aggregation O
in O
response O
to O
10 O
micrograms O
collagen I-GENE
/ O
ml O
was O
decreased O
in O
parallel O
after O
treatment O
with O
ASA O
. O

Using O
himA I-GENE
mutants I-GENE
, O
we O
confirmed O
that O
IHF I-GENE
plays O
a O
role O
in O
the O
molybdate O
- O
dependent O
regulation O
of O
dmsA I-GENE
- O
lacZ I-GENE
expression O
in O
vivo O
. O

Cross O
- O
talking O
among O
Drosophila O
nuclear O
receptors O
at O
the O
promiscuous O
response O
element O
of O
the O
ng I-GENE
- I-GENE
1 I-GENE
and O
ng I-GENE
- I-GENE
2 I-GENE
intermolt I-GENE
genes I-GENE
. O

The O
ipsilateral O
breast O
tumor O
relapse O
rate O
was O
similar O
between O
the O
PALP O
and O
MGDET O
groups O
. O

Sibling O
aggregation O
of O
low I-GENE
- I-GENE
and I-GENE
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
cholesterol I-GENE
and O
apolipoproteins I-GENE
B I-GENE
and I-GENE
A I-GENE
- I-GENE
I I-GENE
levels O
in O
black O
and O
white O
children O
: O
the O
Bogalusa O
Heart O
Study O
. O

The O
CAPLC1 I-GENE
protein I-GENE
also O
exhibited O
several O
unique O
features O
, O
including O
a O
novel O
stretch O
of O
18 O
- O
19 O
amino O
acid O
residues O
within O
the O
X O
domain O
and O
an O
unusually O
long O
N O
- O
terminus O
which O
did O
not O
contain O
a O
recognizable O
EF O
- O
hand O
Ca O
( O
2 O
+)- O
binding O
domain O
. O

This O
hypothesis O
is O
consistent O
with O
the O
occurrence O
of O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
PEA3 I-GENE
promoter I-GENE
and O
with O
the O
ability O
of O
PEA3 I-GENE
to O
transactivate O
this O
promoter O
. O

Pet I-GENE
- I-GENE
1 I-GENE
can O
bind O
specifically O
to O
a O
PEA3 I-GENE
ETS I-GENE
DNA O
- O
binding O
motif O
and O
can O
modulate O
transcription O
of O
synthetic O
promoter O
constructs O
in O
a O
sequence O
- O
specific O
manner O
. O

The O
protein O
expressed O
by O
F2771 I-GENE
cDNA I-GENE
in O
transfected O
COS O
cells O
is O
localized O
in O
the O
cytoplasm O
. O

Northern O
analysis O
indicated O
differential O
expression O
by O
tissue O
with O
highest O
expression O
in O
the O
heart O
. O

As O
well O
, O
further O
deletion O
of O
the O
promoter O
region O
to O
nucleotide O
- O
110 O
, O
which O
contains O
only O
one O
SF I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
still O
retained O
the O
ability O
to O
respond O
to O
exogenous O
SF I-GENE
- I-GENE
1 I-GENE
. O

The O
observation O
that O
beta I-GENE
2m I-GENE
with O
covalently O
attached O
peptide O
can O
effectively O
create O
CTL O
target O
structures O
in O
vitro O
offers O
new O
possibilities O
for O
the O
in O
vivo O
induction O
of O
epitope O
- O
specific O
CTL O
responses O
by O
either O
DNA O
immunization O
or O
injection O
of O
the O
purified O
epitope O
- O
linked O
beta I-GENE
2m I-GENE
. O

The O
mRNAs O
of O
these O
genes O
contain O
respectively O
one O
( O
YAP1 I-GENE
uORF I-GENE
) O
and O
two O
( O
YAP2 I-GENE
uORF1 I-GENE
and O
uORF2 O
) O
upstream O
open O
reading O
frames O
. O
uORF O
- O
mediated O
modulation O
of O
post O
- O
termination O
events O
on O
the O
5 O
'- O
untranslated O
region O
( O
5 O
'- O
UTR O
) O
directs O
differential O
control O
not O
only O
of O
translation O
but O
also O
of O
mRNA O
decay O
. O

To O
further O
investigate O
the O
nature O
of O
the O
site O
specificity O
a O
set O
of O
deletion O
mutants O
of O
the O
160 O
bp O
sequence O
were O
analysed O
. O

In O
the O
tissues O
tested O
, O
except O
brain O
, O
the O
message O
for O
CLIP I-GENE
- I-GENE
170 I-GENE
was O
more O
abundant O
than O
that O
for O
Restin I-GENE
. O

BACKGROUND O
: O
Chemicals O
vary O
considerably O
in O
their O
intrinsic O
ability O
to O
cause O
allergic O
contact O
dermatitis O
. O

Cytoskeletal O
polarization O
of O
T O
cells O
is O
regulated O
by O
an O
immunoreceptor O
tyrosine O
- O
based O
activation O
motif O
- O
dependent O
mechanism O
. O

Here O
we O
have O
examined O
the O
ability O
of O
the O
cellular O
protein O
YB I-GENE
- I-GENE
1 I-GENE
to O
modulate O
transcription O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
in O
a O
human O
astrocytic O
cell O
line O
( O
U O
- O
87MG O
), O
a O
neuronal O
cell O
line O
( O
SK O
- O
N O
- O
MC O
) O
and O
lymphoid O
cells O
( O
Jurkat O
) O
by O
transfection O
assay O
. O

Also O
, O
the O
deduced O
amino O
acids O
of O
the O
antigenic I-GENE
regions I-GENE
A I-GENE
, I-GENE
B I-GENE
and I-GENE
C I-GENE
of I-GENE
VP7 I-GENE
were O
nearly O
conserved O
within O
the O
phylogenetic O
lineages O
. O

The O
cloned O
alcR I-GENE
gene I-GENE
provided O
in O
trans O
restored O
these O
siderophore O
system O
activities O
to O
the O
mutants O
. O

The O
cloned O
alcR I-GENE
gene I-GENE
provided O
in O
trans O
restored O
these O
siderophore O
system O
activities O
to O
the O
mutants O
. O

Copyright O
1998 O
Academic O
Press O
. O

It O
may O
also O
be O
suggested O
that O
particular O
care O
should O
be O
taken O
when O
such O
a O
trans O
- O
dominant O
Rev I-GENE
mutant I-GENE
is O
considered O
to O
be O
used O
as O
a O
genetic O
therapy O
against O
HIV O
- O
I O
infection O
, O
in O
individuals O
infected O
with O
both O
HIV O
- O
I O
and O
HTLV O
- O
1 O
. O

PATIENTS O
AND O
METHODS O
: O
Between O
January O
1992 O
and O
June O
1994 O
at O
St O
. O

The O
frequency O
of O
SPs O
for O
both O
the O
moderate O
and O
severe O
groups O
was O
significantly O
higher O
than O
that O
in O
patients O
with O
a O
normal O
MMFCV O
( O
p O
< O
. O
01 O
); O
of O
154 O
arms O
with O
a O
normal O
MMFCV O
, O
only O
9 O
( O
6 O
%) O
had O
an O
SP O
. O

We O
analyzed O
the O
P O
- O
SAECG O
in O
the O
time O
and O
frequency O
domain O
in O
23 O
patients O
with O
Paf O
and O
19 O
controls O
. O

Competitive O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
HPLC O
analysis O
showed O
that O
RUSH I-GENE
- I-GENE
1alpha I-GENE
is O
the O
progesterone O
- O
dependent O
splice O
variant O
. O

TOR2 I-GENE
is O
part O
of O
two O
related O
signaling O
pathways O
coordinating O
cell O
growth O
in O
Saccharomyces O
cerevisiae O
. O

Transcervical O
amnioinfusion O
. O

SETTING O
: O
A O
division O
of O
a O
large O
tea O
plantation O
in O
Kandy O
. O

Simple O
models O
of O
bimolecular O
interaction O
did O
not O
fully O
account O
for O
the O
kinetic O
profiles O
obtained O
with O
the O
parental O
antibodies O
and O
the O
hybrids O
, O
and O
this O
complexity O
suggested O
the O
existence O
of O
a O
conformational O
heterogeneity O
in O
these O
molecules O
. O

In O
order O
to O
decipher O
the O
pathway O
that O
leads O
to O
Hox I-GENE
gene I-GENE
induction O
, O
we O
have O
investigated O
whether O
a O
Hox I-GENE
gene I-GENE
regulator O
, O
the O
leucine O
zipper O
transcription O
factor O
MafB I-GENE
/ O
Kr I-GENE
, O
is O
itself O
transcriptionally O
regulated O
by O
the O
environmental O
signals O
. O

Substrates O
for O
p210 I-GENE
( O
bcr I-GENE
- O
abl I-GENE
) O
are O
likely O
to O
be O
involved O
in O
the O
pathogenesis O
of O
CML O
. O

Reporter O
constructs O
function O
in O
a O
parallel O
manner O
, O
demonstrating O
the O
key O
role O
of O
the O
AhR I-GENE
in O
constitutive O
as O
well O
as O
TCDD O
- O
induced O
expression O
of O
Cyp1B1 I-GENE
in O
mouse O
embryo O
fibroblasts O
. O

Transfection O
studies O
also O
showed O
that O
3 O
'- O
deletion O
of O
sequences O
downstream O
of O
the O
transcriptional O
start O
site O
(+ O
1 O
/+ O
47 O
) O
markedly O
reduced O
OSM I-GENE
- O
fold O
induction O
. O

Oncostatin I-GENE
M I-GENE
stimulates O
c I-GENE
- I-GENE
Fos I-GENE
to O
bind O
a O
transcriptionally O
responsive O
AP I-GENE
- I-GENE
1 I-GENE
element I-GENE
within O
the O
tissue I-GENE
inhibitor I-GENE
of I-GENE
metalloproteinase I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
. O

We O
have O
isolated O
a O
new O
human I-GENE
RING I-GENE
- I-GENE
finger I-GENE
gene I-GENE
( O
RNF4 I-GENE
) O
that O
encodes O
a O
190 O
- O
amino O
- O
acid O
protein O
. O

To O
elucidate O
the O
regulatory O
mechanism O
of O
human I-GENE
AM I-GENE
gene I-GENE
expression O
, O
functional O
elements O
of O
5 O
'- O
flanking O
region O
of O
AM I-GENE
gene I-GENE
were O
studied O
in O
human O
aortic O
endothelial O
cells O
( O
HAEC O
). O

The O
COOH O
- O
terminal O
region O
of O
the O
transcripts O
contained O
fifteen O
triplet O
repeats O
( O
GCT O
; O
alanine O
) O
at O
nucleotide O
465 O
to O
509 O
, O
which O
is O
significantly O
expanded O
compared O
to O
the O
rat I-GENE
RL14 I-GENE
. O

Soluble O
FasR I-GENE
ligand O
- O
binding O
domain O
: O
high O
- O
yield O
production O
of O
active O
fusion O
and O
non O
- O
fusion O
recombinant O
proteins O
using O
the O
baculovirus O
/ O
insect O
cell O
system O
. O

Control O
of O
fatty O
liver O
syndrome O
in O
a O
Jersey O
herd O
by O
a O
change O
of O
diet O
and O
the O
use O
of O
recombinant O
bovine O
somatotrophin I-GENE
. O

The O
inhibition O
of O
focus O
formation O
observed O
in O
the O
presence O
of O
C3G I-GENE
was O
not O
due O
to O
toxic O
effects O
on O
cell O
viability O
, O
since O
transfected O
C3G I-GENE
cells O
exhibited O
the O
same O
survival O
and O
growth O
rates O
as O
untransfected O
NIH3T3 O
cells O
or O
cells O
transfected O
with O
plasmid O
vector O
alone O
. O

C O
. O
D2 O
- O
Chr O
4 O
congenic O
strains O
harboring O
DBA O
/ O
2 O
alleles O
associated O
with O
the O
Pctr1 I-GENE
locus I-GENE
contained O
DBA O
/ O
2 O
" O
resistant O
" O
alleles O
of O
the O
CDK4 I-GENE
/ O
CDK6 I-GENE
inhibitors O
p16 I-GENE
and O
p15 I-GENE
. O

When O
tested O
with O
wild O
- O
type O
( O
DBA O
/ O
2 O
) O
p16 I-GENE
, O
both O
A134C O
and O
G232A O
BALB O
/ O
c O
- O
specific O
variants O
of O
p16 I-GENE
were O
inefficient O
in O
their O
ability O
to O
inhibit O
the O
activity O
of O
cyclin I-GENE
D2 I-GENE
/ O
CDK4 I-GENE
in O
kinase O
assays O
with O
retinoblastoma I-GENE
protein I-GENE
, O
suggesting O
this O
defective O
, O
inherited O
allele O
plays O
an O
important O
role O
in O
the O
genetic O
susceptibility O
of O
BALB O
/ O
c O
mice O
for O
plasmacytoma O
induction O
and O
that O
p16 I-GENE
( O
INK4a I-GENE
) O
is O
a O
strong O
candidate O
for O
the O
Pctr1 I-GENE
locus I-GENE
. O

Despite O
this O
there O
was O
no O
difference O
in O
the O
intubating O
conditions O
at O
one O
minute O
with O
25 O
excellent O
/ O
5 O
good O
in O
the O
suxamethonium O
group O
and O
27 O
excellent O
/ O
3 O
good O
in O
the O
rocuronium O
group O
. O

Cloning O
and O
expression O
of O
two O
genes O
encoding O
auxin I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
from O
tobacco O
. O

Furthermore O
, O
direct O
association O
with O
D3 O
phosphatidylinositides O
seems O
to O
be O
essential O
for O
activation O
of O
PKB I-GENE
/ O
Akt I-GENE
. O

The O
FMN O
moiety O
but O
not O
the O
[ O
3Fe O
- O
4S O
] O
cluster O
of O
the O
subunit O
appears O
to O
participate O
in O
this O
reaction O
. O

Alison O
Bell O
Memorial O
Award O
. O

METHODS O
: O
A O
population O
survey O
was O
undertaken O
in O
10 O
, O
148 O
individuals O
to O
measure O
the O
prevalence O
and O
identify O
the O
causes O
of O
blindness O
in O
Lebanon O
. O

During O
organogenesis O
, O
HFH I-GENE
- I-GENE
8 I-GENE
expression O
is O
found O
in O
the O
splanchnic O
mesoderm O
in O
close O
apposition O
of O
the O
gut O
endoderm O
, O
suggesting O
a O
role O
in O
mesenchymal O
- O
epithelial O
induction O
of O
lung O
and O
gut O
morphogenesis O
. O

However O
, O
laparoscopy O
failed O
to O
establish O
inoperability O
in O
any O
cases O
of O
carcinoma O
spread O
to O
areas O
not O
accessible O
to O
laparoscopic O
visualization O
. O

No O
difference O
in O
telomere O
length O
was O
seen O
in O
mutants O
affected O
in O
the O
regulation O
of O
Cdc2 I-GENE
, O
whereas O
some O
of O
the O
DNA O
repair O
mutants O
examined O
had O
slightly O
longer O
telomeres O
than O
did O
the O
wild O
type O
. O

The O
mean O
duration O
of O
pain O
relief O
was O
4 O
- O
6 O
weeks O
. O

The O
ESEM O
differs O
from O
conventional O
SEM O
in O
that O
no O
sample O
preparation O
is O
needed O
, O
eliminating O
artifactual O
changes O
. O

Sp1 I-GENE
can O
activate O
transcription O
through O
immunoglobulin I-GENE
kappa I-GENE
- I-GENE
chain I-GENE
enhancer I-GENE
or O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
. O
p50 I-GENE
homodimers I-GENE
replace O
Sp1 I-GENE
from O
the O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
by O
binding O
site O
competition O
and O
thereby O
either O
inhibit O
basal O
Sp1 I-GENE
- O
driven O
expression O
or O
, O
in O
concert O
with O
Bcl I-GENE
- I-GENE
3 I-GENE
, O
stimulate O
expression O
. O

The O
3 O
' O
fragment O
was O
shown O
to O
accumulate O
as O
full O
- O
length O
mRNA O
disappeared O
in O
actinomycin O
D O
- O
treated O
cells O
, O
indicating O
a O
precursor O
- O
product O
relationship O
. O

The O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
plays O
an O
essential O
role O
in O
transcription O
by O
all O
three O
eukaryotic O
nuclear I-GENE
RNA I-GENE
polymerases I-GENE
, O
polymerases I-GENE
( I-GENE
Pol I-GENE
) I-GENE
I I-GENE
, I-GENE
II I-GENE
, I-GENE
and I-GENE
III I-GENE
. O

A O
triple I-GENE
- I-GENE
mutant I-GENE
TBP I-GENE
( O
R231E O
+ O
R235E O
+ O
R239S O
) O
had O
greatly O
reduced O
activity O
for O
yeast I-GENE
U6 I-GENE
snRNA I-GENE
gene I-GENE
transcription O
while O
remaining O
active O
for O
Pol I-GENE
II I-GENE
basal O
transcription O
. O

E2F I-GENE
activity O
is O
regulated O
in O
part O
by O
the O
retinoblastoma I-GENE
family I-GENE
of I-GENE
tumor I-GENE
suppressor I-GENE
proteins I-GENE
. O

This O
resulted O
in O
a O
complete O
inhibition O
of O
Site O
- O
1 O
cleavage O
that O
was O
restored O
by O
concomitant O
overexpression O
of O
full O
- O
length O
SCAP I-GENE
. O

To O
determine O
the O
true O
molecular O
identity O
of O
SFD I-GENE
, O
both O
the O
50 O
- O
and O
57 O
- O
kDa O
polypeptides O
were O
directly O
sequenced O
. O

Molecular O
characterization O
of O
the O
50 O
- O
and O
57 O
- O
kDa O
subunits O
of O
the O
bovine I-GENE
vacuolar I-GENE
proton I-GENE
pump I-GENE
. O

In O
C O
. O
albicans O
, O
HST6 I-GENE
is O
expressed O
constitutively O
at O
high O
levels O
in O
the O
different O
cell O
types O
analysed O
( O
yeast O
, O
hyphae O
, O
white O
and O
opaque O
), O
demonstrating O
that O
HST6 I-GENE
transcription O
is O
not O
repressed O
in O
this O
diploid O
yeast O
, O
unlike O
in O
diploid O
S O
. O
cerevisiae O
, O
and O
suggesting O
a O
basic O
biological O
function O
for O
the O
Hst6p I-GENE
transporter O
in O
C O
. O
albicans O
. O

Furthermore O
, O
binding O
of O
recombinant I-GENE
Myb I-GENE
and O
Ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
to O
these O
fragments O
could O
be O
competed O
with O
an O
excess O
of O
double O
stranded O
oligodeoxynucleotides O
containing O
canonical O
, O
but O
not O
mutated O
, O
Myb I-GENE
- O
or O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

This O
structure O
interconnects O
specific O
triplets O
of O
the O
basal O
bodies O
with O
the O
microtubular O
bundles O
that O
emerge O
from O
the O
basal O
apparatus O
. O

To O
understand O
the O
regulatory O
mechanism O
controlling O
its O
expression O
at O
low O
temperature O
, O
the O
promoter O
region O
has O
been O
characterized O
. O

In O
the O
current O
study O
, O
the O
roles O
of O
two O
putative O
cis O
- O
acting O
elements O
within O
the O
- O
73 O
to O
+ O
44 O
region O
in O
basal O
exon O
2 O
promoter O
activity O
were O
evaluated O
using O
mutagenesis O
and O
nuclear O
protein O
- O
DNA O
binding O
assays O
. O

For O
the O
5HT5A I-GENE
receptor I-GENE
the O
addition O
of O
yohimbine O
resulted O
in O
a O
similar O
but O
smaller O
effect O
. O

We O
have O
examined O
reporter O
gene O
( O
beta I-GENE
- I-GENE
gal I-GENE
) O
expression O
directed O
by O
human I-GENE
heat I-GENE
shock I-GENE
transcription I-GENE
factors I-GENE
1 I-GENE
and I-GENE
2 I-GENE
( O
HSF1 I-GENE
and O
HSF2 I-GENE
) O
in O
HeLa O
cells O
and O
in O
yeast O
( O
Saccharomyces O
cerevisiae O
). O

Localized O
fluorescence O
was O
detectable O
only O
in O
cells O
containing O
a O
visible O
midcell O
constriction O
, O
suggesting O
that O
FtsK I-GENE
targeting O
normally O
occurs O
only O
at O
a O
late O
stage O
of O
septation O
. O

No O
TATA O
box O
was O
found O
in O
the O
putative O
promoter O
region O
, O
but O
multiple O
GC O
boxes O
were O
found O
around O
the O
cap O
sites O
, O
supporting O
the O
previously O
inferred O
housekeeping O
nature O
of O
CYP51 I-GENE
gene I-GENE
and O
the O
existence O
of O
the O
multiple O
transcription O
initiation O
sites O
. O

Structural O
and O
evolutionary O
studies O
on O
sterol I-GENE
14 I-GENE
- I-GENE
demethylase I-GENE
P450 I-GENE
( O
CYP51 I-GENE
), O
the O
most O
conserved O
P450 I-GENE
monooxygenase I-GENE
: O
I O
. O

Its O
expression O
pattern O
is O
representative O
of O
many O
B O
cell O
- O
specific O
proteins O
, O
which O
are O
essential O
for O
B O
cell O
development O
and O
activation O
but O
are O
down O
- O
regulated O
after O
B O
cells O
become O
terminally O
differentiated O
plasma O
cells O
. O

The O
intercistronic O
gene O
junctions O
of O
vesicular O
stomatitis O
virus O
( O
VSV O
) O
contain O
conserved O
sequence O
elements O
that O
are O
important O
for O
polyadenylation O
and O
transcription O
termination O
of O
upstream O
transcript O
as O
well O
as O
reinitiation O
of O
transcription O
of O
downstream O
transcript O
. O

Infectious O
mutant O
virus O
progeny O
was O
obtained O
only O
on O
complementing O
gK I-GENE
- O
expressing O
cells O
, O
suggesting O
that O
gK I-GENE
has O
an O
important O
function O
in O
the O
replication O
cycle O
. O

Cleavage O
and O
DNA O
joining O
reactions O
, O
carried O
out O
by O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
integrase I-GENE
, O
are O
necessary O
to O
effect O
the O
covalent O
insertion O
of O
HIV O
- O
1 O
DNA O
into O
the O
host O
genome O
. O

The O
DSF O
regimen O
appears O
to O
have O
significant O
activity O
in O
patients O
who O
have O
metastatic O
pancreatic O
islet O
- O
cell O
carcinoma O
, O
and O
patient O
tolerance O
of O
the O
regimen O
is O
excellent O
, O
thus O
warranting O
further O
investigation O
. O

Activation O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
is O
a O
primary O
consequence O
of O
Ras I-GENE
activation O
and O
plays O
a O
key O
role O
in O
mediating O
Ras I-GENE
signal O
transduction O
. O

Histone I-GENE
acetylation O
levels O
in O
cells O
result O
from O
a O
dynamic O
equilibrium O
between O
competing O
histone I-GENE
acetylases I-GENE
and I-GENE
deacetylases I-GENE
. O

CONCLUSIONS O
: O
XCoe2 I-GENE
may O
play O
a O
pivotal O
role O
in O
the O
transcriptional O
cascade O
that O
specifies O
primary O
neurons O
in O
Xenopus O
embryos O
: O
by O
maintaining O
Delta I-GENE
- O
Notch I-GENE
signalling O
, O
XCoe2 I-GENE
stabilises O
the O
higher O
neural O
potential O
of O
selected O
progenitor O
cells O
that O
express O
X I-GENE
- I-GENE
ngnr I-GENE
- I-GENE
1 I-GENE
, O
ensuring O
the O
transition O
between O
neural O
competence O
and O
irreversible O
commitment O
to O
a O
neural O
fate O
; O
and O
it O
promotes O
neuronal O
differentiation O
by O
activating O
XNeuroD I-GENE
expression O
, O
directly O
or O
indirectly O
. O

RESULTS O
: O
Patients O
in O
Group O
A O
had O
a O
higher O
incidence O
of O
posterolateral O
wall O
motion O
abnormalities O
( O
p O
< O
0 O
. O
001 O
) O
on O
radionuclide O
ventriculography O
, O
a O
larger O
infarct O
area O
( O
as O
evidenced O
by O
higher O
peak O
creatine I-GENE
kinase I-GENE
levels O
) O
( O
p O
< O
0 O
. O
02 O
) O
and O
a O
lower O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
at O
hospital O
discharge O
( O
p O
< O
0 O
. O
008 O
) O
than O
those O
in O
Group O
B O
. O

CyIIa I-GENE
transcription O
follows O
, O
and O
is O
therefore O
downstream O
of O
, O
the O
initial O
specification O
of O
these O
embryonic O
domains O
. O

Cis O
- O
regulation O
downstream O
of O
cell O
type O
specification O
: O
a O
single O
compact O
element O
controls O
the O
complex O
expression O
of O
the O
CyIIa I-GENE
gene I-GENE
in O
sea O
urchin O
embryos O
. O

We O
also O
present O
evidence O
that O
human I-GENE
HYAL1 I-GENE
is O
identical O
to O
an O
uncharacterized O
gene O
positionally O
cloned O
by O
others O
from O
chromosome O
3p21 O
. O
3 O
that O
is O
homozygously O
deleted O
in O
several O
small O
- O
cell O
lung O
carcinoma O
cell O
lines O
. O

In O
patients O
with O
myalgia O
, O
Raynaud O
' O
s O
syndrome O
, O
skin O
vasculitis O
and O
vascular O
diseases O
WFAg I-GENE
concentrations O
were O
higher O
than O
in O
patients O
without O
them O
. O

Although O
the O
expression O
of O
the O
4E I-GENE
- I-GENE
BP1 I-GENE
gene I-GENE
alone O
has O
not O
yet O
been O
accomplished O
, O
the O
gene O
was O
expressed O
in O
Escherichia O
coli O
[ O
BL21 O
( O
DE3 O
)] O
as O
a O
fusion O
gene O
with O
the O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
gene O
using O
a O
prokaryotic O
gene O
fusion O
vector O
( O
pGEX O
- O
4T O
- O
2 O
), O
which O
contains O
a O
gene O
sequence O
coding O
the O
cleavage O
site O
for O
a O
specific O
protease O
, O
alpha I-GENE
- I-GENE
thrombin I-GENE
. O

Randomised O
comparison O
of O
addition O
of O
autologous O
bone O
- O
marrow O
transplantation O
to O
intensive O
chemotherapy O
for O
acute O
myeloid O
leukaemia O
in O
first O
remission O
: O
results O
of O
MRC O
AML O
10 O
trial O
. O

Therapeutic O
use O
of O
cannabis O
. O

Analysis O
of O
intragenic O
revertants O
shows O
that O
this O
function O
depends O
on O
the O
amino O
acid O
preceding O
the O
first O
cysteine O
residue O
of O
the O
DNA O
- O
binding O
domain O
of O
Hap1p I-GENE
. O

Peripheral O
visual O
stimuli O
and O
monoaural O
auditory O
stimuli O
were O
used O
as O
targets O
. O

A O
review O
of O
studies O
published O
between O
1983 O
and O
1995 O
shows O
that O
there O
are O
some O
common O
factors O
as O
regards O
the O
psychological O
distress O
and O
social O
and O
functional O
limitations O
this O
group O
of O
patients O
has O
to O
deal O
with O
. O

PKC I-GENE
- I-GENE
gamma I-GENE
, O
which O
is O
not O
present O
in O
keratinocytes O
, O
also O
induces O
involucrin I-GENE
gene I-GENE
expression O
in O
a O
TPA O
- O
independent O
manner O
, O
when O
introduced O
into O
SVHK O
cells O
. O

Identification O
and O
characterization O
of O
specific O
DNA O
- O
binding O
complexes O
containing O
members O
of O
the O
Myc I-GENE
/ O
Max I-GENE
/ O
Mad I-GENE
network O
of O
transcriptional O
regulators O
. O

We O
further O
show O
that O
proteolytic O
targeting O
by O
calpain I-GENE
II I-GENE
and O
the O
proteasome O
involves O
different O
structural O
elements O
of O
YY1 I-GENE
. O

Primers O
for O
subsequent O
rounds O
of O
RACE O
were O
designed O
from O
the O
5 O
'- O
ends O
of O
amplified O
RACE O
products O
. O

Human O
ZFM1 I-GENE
protein I-GENE
is O
a O
transcriptional O
repressor O
that O
interacts O
with O
the O
transcription I-GENE
activation I-GENE
domain I-GENE
of I-GENE
stage I-GENE
- I-GENE
specific I-GENE
activator I-GENE
protein I-GENE
. O

Surprisingly O
, O
the O
CSF1R I-GENE
/ O
IRDelta960 I-GENE
was O
as O
effective O
as O
the O
CSF1R I-GENE
/ O
IR I-GENE
in O
mediating O
CSF I-GENE
- I-GENE
1 I-GENE
protection O
of O
cells O
from O
staurosporine O
- O
induced O
apoptosis O
. O

CONCLUSIONS O
: O
The O
special O
clinical O
presentation O
of O
our O
case O
of O
possible O
Gardner O
' O
s O
syndrome O
is O
discussed O
. O

These O
results O
would O
suggest O
that O
a O
high O
UV O
sensitivity O
is O
associated O
with O
high O
phaeomelanin O
and O
low O
eumelanin O
levels O
, O
and O
point O
to O
the O
eumelanin O
/ O
phaeomelanin O
ratio O
as O
a O
novel O
chemical O
parameter O
that O
could O
be O
used O
for O
predicting O
individuals O
at O
high O
risk O
for O
skin O
cancer O
and O
melanoma O
. O

In O
ferrets O
naturally O
infected O
with O
H O
. O
mustelae O
, O
a O
single O
dose O
( O
50 O
mg O
/ O
kg O
, O
per O
os O
) O
of O
fluorofamide O
completely O
inhibited O
bacterial I-GENE
urease I-GENE
. O

The O
cAMP O
- O
dependent O
mitogenic O
pathway O
is O
unique O
as O
it O
is O
independent O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
and O
differs O
from O
growth O
factor O
- O
dependent O
pathways O
at O
the O
level O
of O
the O
expression O
of O
several O
protooncogenes O
/ O
transcription O
factors O
. O

CONCLUSIONS O
: O
Use O
of O
the O
first O
method O
was O
associated O
with O
a O
reduction O
in O
the O
time O
patients O
remained O
in O
the O
ICU O
before O
transfer O
to O
another O
unit O
and O
savings O
in O
nursing O
time O
, O
but O
the O
two O
methods O
did O
not O
differ O
according O
to O
clinical O
outcomes O
. O

We O
have O
elucidated O
the O
exon O
- O
intron O
organization O
of O
the O
entire O
human O
CD58 I-GENE
gene I-GENE
, O
including O
approximately O
2 O
. O
5 O
kilobases O
( O
kb O
) O
of O
5 O
'- O
flanking O
DNA O
. O

The O
risk O
factors O
for O
hematuria O
in O
patients O
with O
renal O
hypouricemia O
are O
the O
elevation O
of O
urinary O
urate O
concentration O
and O
the O
subtypes O
of O
Post O
and O
Secretion O
. O

Two O
hundred O
sixty O
- O
four O
patients O
scheduled O
for O
DCBM O
were O
randomized O
to O
receive O
intravenously O
geG O
0 O
. O
25 O
mg O
( O
geG O
- O
25 O
), O
or O
geG O
0 O
. O
5 O
mg O
( O
geG O
- O
50 O
), O
or O
HBB O
20 O
mg O
as O
hypotonic O
agent O
. O

If O
the O
haemoglobin I-GENE
concentration O
( O
Hb I-GENE
) O
was O
less O
than O
12 O
g O
dL O
- O
1 O
they O
were O
given O
a O
four O
week O
course O
of O
ferrous O
sulphate O
. O

In O
all O
cells O
, O
the O
accumulation O
of O
high O
Dsg I-GENE
protein I-GENE
levels O
required O
calcium O
and O
was O
not O
observed O
in O
low O
calcium O
( O
0 O
. O
05 O
- O
0 O
. O
07 O
mM O
) O
media O
. O

Based O
on O
restriction O
enzyme O
analysis O
, O
Southern O
blots O
, O
polymerase O
chain O
reaction O
analysis O
and O
DNA O
sequencing O
, O
it O
was O
confirmed O
that O
the O
three O
overlapping O
clones O
isolated O
cover O
the O
entire O
cHO I-GENE
- I-GENE
1 I-GENE
gene I-GENE
, O
as O
well O
as O
approximately O
10 O
kb O
of O
the O
flanking O
regions O
on O
both O
ends O
. O

RESULTS O
: O
Using O
information O
in O
the O
dbEST O
database O
of O
expressed O
sequence O
tags O
, O
we O
isolated O
an O
Arabidopsis O
thaliana O
gene O
( O
GCR1 I-GENE
) O
that O
encodes O
a O
protein O
with O
seven O
predicted O
membrane O
- O
spanning O
domains O
and O
other O
features O
characteristic O
of O
7TM I-GENE
receptors I-GENE
. O

E1A I-GENE
represses O
apolipoprotein I-GENE
AI I-GENE
enhancer I-GENE
activity O
in O
liver O
cells O
through O
a O
pRb I-GENE
- O
and O
CBP I-GENE
- O
independent O
pathway O
. O

Position O
- O
independent O
expression O
of O
a O
human O
nerve I-GENE
growth I-GENE
factor I-GENE
- O
luciferase I-GENE
reporter O
gene O
cloned O
on O
a O
yeast O
artificial O
chromosome O
vector O
. O

Calcitriol O
therapy O
was O
associated O
with O
a O
decrease O
in O
serum O
iPTH I-GENE
levels O
( O
701 O
+/- O
103 O
. O
9 O
vs O
. O

Alterations O
in O
DNase I-GENE
I I-GENE
reactivity O
of O
the O
GC O
- O
response O
element O
region O
suggest O
that O
GC I-GENE
receptor I-GENE
- I-GENE
GC I-GENE
complexes I-GENE
may O
associate O
, O
in O
a O
transient O
manner O
, O
with O
the O
promoter O
in O
the O
actively O
transcribing O
control O
state O
. O

Most O
pituitary O
hormone O
- O
coding O
gene O
promoters O
are O
activated O
by O
Ptx1 I-GENE
. O

One O
of O
these O
small I-GENE
inteins I-GENE
might O
be O
inactive O
or O
a O
" I-GENE
pseudo I-GENE
intein I-GENE
." I-GENE
The O
results O
suggest O
a O
modular O
architecture O
for O
inteins I-GENE
, O
clarify O
their O
origin O
and O
relationship O
to O
other O
protein O
families O
, O
and O
extend O
recent O
experimental O
findings O
on O
the O
functional O
roles O
of O
intein I-GENE
N I-GENE
, I-GENE
C I-GENE
, I-GENE
and I-GENE
EN I-GENE
motifs I-GENE
. O

Purification O
of O
MvaT I-GENE
enriched O
for O
two O
polypeptides O
of O
approximate O
molecular O
mass O
15 O
kDa O
and O
16 O
kDa O
, O
designated O
P15 I-GENE
and O
P16 I-GENE
. O

M I-GENE
- I-GENE
66 I-GENE
identified O
the O
14 O
- O
kDa O
protein O
in O
another O
MMTV O
bearing O
T O
- O
cell O
lymphoma O
, O
EL O
- O
4 O
. O

These O
results O
indicate O
that O
TGF I-GENE
- I-GENE
betaf I-GENE
potentiates O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
activated O
by O
PKC I-GENE
through O
the O
SRF I-GENE
binding I-GENE
site I-GENE
. O

RT O
- O
PCR O
indicated O
that O
p21 I-GENE
mRNA I-GENE
was O
induced O
1 O
. O
4 O
-, O
2 O
. O
0 O
-, O
and O
3 O
. O
1 O
- O
fold O
in O
the O
2 O
- O
day O
neonatal O
, O
7 O
- O
day O
neonatal O
, O
and O
adult O
stages O
, O
respectively O
, O
compared O
to O
the O
17 O
- O
day O
fetal O
stage O
. O

Ganciclovir O
and O
foscarnet O
efficacy O
in O
AIDS O
- O
related O
CMV O
polyradiculopathy O
. O

BACKGROUND O
: O
Defensins I-GENE
, O
also O
known O
as O
human I-GENE
neutrophil I-GENE
peptides I-GENE
, O
are O
antimicrobial O
peptides O
present O
in O
the O
azurophil O
granules O
of O
neutrophils O
. O

The O
spontaneous O
mutation O
blocking O
pca I-GENE
gene I-GENE
expression O
was O
located O
in O
the O
promoter O
for O
the O
pca I-GENE
operon I-GENE
. O

From O
250 O
g O
of O
cells O
, O
we O
isolated O
1 O
mg O
of O
PDH I-GENE
complex I-GENE
with O
a O
specific O
activity O
of O
12 O
. O
6 O
U O
/ O
mg O
of O
protein O
. O

The O
PDH I-GENE
complex I-GENE
- I-GENE
encoding I-GENE
genes I-GENE
were O
identified O
by O
hybridization O
experiments O
and O
sequence O
analysis O
in O
two O
separate O
gene O
regions O
in O
the O
genome O
of O
Z O
. O
mobilis O
. O

We O
have O
identified O
two O
functional O
elements O
, O
both O
located O
downstream O
from O
the O
TATA O
motif O
, O
that O
control O
Id4 I-GENE
promoter I-GENE
activity O
. O

Azithromycin O
is O
a O
new O
generation O
macrolide O
antibiotic O
with O
unusual O
and O
favorable O
pharmacokinetics O
, O
and O
seems O
to O
be O
a O
very O
promising O
agent O
for O
innovative O
anti O
- O
H O
. O
pylori O
regimens O
. O

The O
study O
enrolled O
994 O
people O
co O
- O
infected O
with O
CMV O
and O
HIV O
, O
with O
at O
least O
one O
CD4 I-GENE
count O
recorded O
< O
100 O
x O
10 O
( O
6 O
) O
cells O
/ O
l O
. O

BACKGROUND O
AND O
OBJECTIVES O
: O
The O
sexually O
transmitted O
diseases O
( O
STD O
) O
control O
program O
for O
female O
sex O
workers O
( O
FSW O
) O
in O
Lima O
, O
Peru O
, O
provided O
periodic O
serological O
tests O
for O
syphilis O
and O
cervical O
smears O
for O
gonococci O
, O
but O
not O
medication O
for O
STD O
or O
condoms O
. O

National O
certification O
: O
a O
vital O
component O
of O
quality O
assurance O
. O

Two O
rare O
novel O
mutations O
, O
D811N O
in O
exon O
20 O
and O
R835C O
in O
exon O
21 O
, O
were O
identified O
in O
the O
first O
nucleotide O
- O
binding O
fold O
( O
NBF O
), O
a O
functionally O
important O
region O
of O
SUR1 I-GENE
, O
in O
one O
patient O
each O
, O
both O
heterozygotes O
. O

Chimaeric O
VP16 I-GENE
- O
E2 I-GENE
molecules O
suggest O
that O
the O
epithelial O
specific O
transcriptional O
activation O
of O
the O
BPV I-GENE
- I-GENE
4 I-GENE
LCR I-GENE
promoter I-GENE
is O
mediated O
by O
the O
E2 I-GENE
transactivation I-GENE
domain I-GENE
. O

In O
order O
to O
examine O
the O
potential O
role O
of O
transcriptional O
silencing O
during O
productive O
HSV O
- O
1 O
infection O
, O
recombinant O
viruses O
were O
generated O
in O
which O
wild I-GENE
- I-GENE
type I-GENE
or I-GENE
mutant I-GENE
ICP34 I-GENE
. I-GENE
5 I-GENE
promoters I-GENE
controlling O
the O
expression O
of O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
gene I-GENE
were O
inserted O
into O
the O
thymidine I-GENE
kinase I-GENE
gene I-GENE
of O
the O
viral O
genome O
. O

These O
changes O
correlate O
directly O
with O
an O
increase O
in O
the O
acetylation O
levels O
of O
all O
four O
core I-GENE
histones I-GENE
in O
vivo O
. O

Drosophila I-GENE
orthodenticle I-GENE
( O
otd I-GENE
) O
and O
murine I-GENE
Otx I-GENE
genes I-GENE
exemplify O
this O
, O
both O
in O
terms O
of O
expression O
patterns O
and O
mutant O
phenotypes O
. O

APETALA3 I-GENE
transcripts I-GENE
are O
first O
detected O
in O
a O
meristematic O
region O
that O
will O
give O
rise O
to O
the O
petal O
and O
stamen O
primordia O
, O
and O
expression O
is O
maintained O
in O
this O
region O
during O
subsequent O
development O
of O
these O
organs O
. O

We O
also O
recovered O
mutations O
in O
the O
60A I-GENE
gene I-GENE
which O
encodes O
another O
TGF I-GENE
- I-GENE
beta I-GENE
- I-GENE
related I-GENE
factor I-GENE
in O
Drosophila O
. O

Cell O
lines O
are O
checked O
to O
find O
out O
whether O
they O
develop O
tumors O
in O
nude O
mice O
followed O
by O
an O
analysis O
of O
the O
karyotype O
. O

Cervicovaginal O
foetal I-GENE
fibronectin I-GENE
in O
the O
prediction O
of O
preterm O
labour O
in O
a O
low O
- O
risk O
population O
. O

In O
addition O
, O
IgM I-GENE
can O
be O
absent O
in O
children O
with O
congenital O
toxoplasmosis O
or O
subjects O
with O
secondary O
reactivation O
. O

Both O
variants O
display O
the O
seven O
- O
transmembrane O
topology O
that O
is O
typical O
for O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptors I-GENE
. O

A O
constitutive O
allele O
of O
GPA2 I-GENE
could O
stimulate O
growth O
of O
a O
strain O
lacking O
both O
RAS I-GENE
genes I-GENE
. O

The O
COOH O
- O
terminus O
of O
this O
new O
isoform O
, O
which O
we O
designate O
beta I-GENE
4 I-GENE
, O
lacks O
a O
22 O
amino O
acid O
lysine O
- O
rich O
sequence O
common O
to O
both O
the O
human I-GENE
red I-GENE
cell I-GENE
alpha I-GENE
- I-GENE
and I-GENE
beta I-GENE
- I-GENE
adducin I-GENE
subunits I-GENE
and O
homologous O
to O
a O
highly O
conserved O
region O
in O
MARCKS I-GENE
, O
a O
filamentous O
actin I-GENE
- O
cross O
linking O
protein O
regulated O
by O
protein I-GENE
kinase I-GENE
C I-GENE
and O
calcium O
/ O
calmodulin I-GENE
. O
beta I-GENE
4 I-GENE
- I-GENE
adducin I-GENE
preserves O
a O
previously O
identified O
calmodulin I-GENE
binding I-GENE
domain I-GENE
. O

PCR O
analysis O
indicates O
that O
this O
new O
beta I-GENE
- I-GENE
adducin I-GENE
isoform I-GENE
is O
expressed O
in O
fetal O
brain O
and O
liver O
, O
bone O
marrow O
, O
and O
NT O
- O
2 O
( O
neuroepithelial O
) O
cells O
, O
but O
is O
not O
detected O
in O
several O
other O
tissues O
. O

The O
gene I-GENE
lac I-GENE
- I-GENE
1 I-GENE
, O
encoding O
the O
enzyme O
laccase I-GENE
, O
is O
the O
best O
characterized O
of O
a O
number O
of O
genes O
in O
the O
chestnut O
blight O
fungus O
, O
Cryphonectria O
parasitica O
, O
that O
are O
repressed O
by O
hypoviruses O
, O
a O
group O
of O
virulence O
- O
attenuating O
mycoviruses O
. O
lac I-GENE
- I-GENE
1 I-GENE
has O
also O
been O
shown O
to O
be O
transcriptionally O
activated O
by O
low O
concentrations O
of O
the O
translational O
inhibitor O
cycloheximide O
( O
CHX O
) O
and O
by O
the O
immunosuppressant O
cyclosporin O
A O
. O

Both O
TRE O
- O
like O
elements O
were O
capable O
of O
binding O
AP1 I-GENE
. O

The O
hp55 I-GENE
gamma I-GENE
protein I-GENE
interacts O
strongly O
with O
the O
activated O
IGFIR I-GENE
but O
not O
with O
the O
kinase O
- O
negative O
mutant O
receptor O
. O
hp55 I-GENE
gamma I-GENE
also O
interacts O
with O
the O
insulin I-GENE
receptor I-GENE
( O
IR I-GENE
) O
in O
the O
yeast O
two O
- O
hybrid O
system O
. O

The O
plant O
protein O
maintains O
all O
the O
functional O
domains O
found O
in O
the O
other O
proteins O
, O
including O
nuclear O
localization O
signal O
, O
DNA O
- O
binding O
domain O
and O
helicase I-GENE
motifs I-GENE
, O
suggesting O
that O
it O
might O
also O
act O
as O
part O
of O
the O
RNA O
transcription O
apparatus O
, O
as O
well O
as O
nucleotide O
excision O
repair O
in O
plant O
cells O
. O

This O
paper O
describes O
the O
genomic O
organization O
of O
mouse O
gC1qBP I-GENE
and O
the O
characterization O
of O
its O
5 O
' O
flanking O
region O
. O

LysR I-GENE
proteins I-GENE
have O
been O
shown O
to O
regulate O
urease I-GENE
in I-GENE
Klebsiella I-GENE
aerogenes I-GENE
( O
NAC I-GENE
), O
and O
catalase I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
( O
OxyR I-GENE
), O
which O
offers O
the O
intracellular O
bacterium O
protection O
from O
phagolysosome O
damage O
. O

Also O
, O
the O
anti O
- O
inflammatory O
activities O
of O
an O
aqueous O
extract O
of O
Buddleia O
cordata O
and O
its O
principal O
glycoside O
linarin O
were O
evaluated O
. O

Regulation O
of O
the O
Raf I-GENE
kinase I-GENE
in O
T O
cells O
differs O
from O
findings O
with O
a O
variety O
of O
cell O
lines O
that O
the O
catalytic I-GENE
domain I-GENE
of I-GENE
Raf I-GENE
( O
Raf I-GENE
( O
delta26 O
- O
303 O
)) O
shows O
no O
activity O
. O

Full I-GENE
- I-GENE
length I-GENE
FLAP I-GENE
clones O
were O
isolated O
from O
a O
mouse O
skeletal O
muscle O
cDNA O
library O
. O

Members O
of O
the O
meis1 I-GENE
and O
pbx I-GENE
homeodomain I-GENE
protein I-GENE
families I-GENE
cooperatively O
bind O
a O
cAMP O
- O
responsive O
sequence O
( O
CRS1 O
) O
from O
bovine I-GENE
CYP17 I-GENE
. O

We O
have O
visualized O
DNA O
- O
protein O
complexes O
by O
electron O
microscopy O
and O
a O
high O
- O
affinity O
binding O
site O
of O
WDV I-GENE
Rep I-GENE
protein I-GENE
within O
the O
core O
element O
has O
been O
mapped O
to O
approximately O
144 O
+/- O
18 O
bp O
upstream O
from O
the O
initiation O
site O
, O
between O
the O
start O
site O
for O
complementary O
- O
sense O
transcription O
and O
the O
TATA O
box O
. O

Rex I-GENE
- I-GENE
1 I-GENE
, O
a O
gene O
encoding O
a O
transcription O
factor O
expressed O
in O
the O
early O
embryo O
, O
is O
regulated O
via O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
and O
Oct I-GENE
- I-GENE
6 I-GENE
binding O
to O
an O
octamer O
site O
and O
a O
novel O
protein O
, O
Rox I-GENE
- I-GENE
1 I-GENE
, O
binding O
to O
an O
adjacent O
site O
. O

However O
, O
inhibition O
of O
both O
the O
ERK I-GENE
/ O
RSK I-GENE
and O
the O
p38 I-GENE
/ O
MAPKAP I-GENE
kinase I-GENE
2 I-GENE
pathways O
completely O
abolished O
NGF I-GENE
- O
induced O
CREB I-GENE
Ser O
- O
133 O
phosphorylation O
. O

Cells O
respond O
to O
the O
accumulation O
of O
unfolded O
proteins O
in O
the O
endoplasmic O
reticulum O
( O
ER O
) O
by O
increasing O
the O
transcription O
of O
the O
genes O
encoding O
ER I-GENE
- I-GENE
resident I-GENE
chaperone I-GENE
proteins I-GENE
. O

The O
RAS I-GENE
- O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
cAPK I-GENE
pathway O
prevents O
the O
UAS O
activity O
of O
IREu I-GENE
in O
the O
presence O
of O
glucose O
as O
the O
sole O
carbon O
source O
, O
while O
the O
transcriptional O
activators O
Msn2p I-GENE
and O
Msn4p I-GENE
promote O
the O
UAS O
activity O
of O
this O
repeat O
in O
the O
presence O
of O
acetate O
. O

The O
mei4 I-GENE
+ I-GENE
gene I-GENE
of O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
was O
cloned O
by O
functional O
complementation O
. O

Alternative O
splicing O
of O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
( O
FGF I-GENE
- I-GENE
R2 I-GENE
) O
is O
an O
example O
of O
highly O
regulated O
alternative O
splicing O
in O
which O
exons O
IIIb O
and O
IIIc O
are O
utilized O
in O
a O
mutually O
exclusive O
manner O
in O
different O
cell O
types O
. O

In O
some O
cases O
, O
the O
aberrant O
methylation O
of O
CpGs O
within O
5 O
' O
regulatory O
regions O
has O
led O
to O
suppression O
of O
gene O
activity O
. O

The O
genomic O
fragments O
were O
fused O
upstream O
of O
the O
luciferase I-GENE
reporter I-GENE
gene I-GENE
. O

Cotransfection O
analyses O
of O
the O
T I-GENE
/ I-GENE
EBP I-GENE
promoter I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
with O
a O
T I-GENE
/ I-GENE
EBP I-GENE
expression O
vector O
into O
human O
HepG2 O
cells O
, O
which O
do O
not O
express O
T I-GENE
/ I-GENE
EBP I-GENE
, O
suggested O
that O
autoregulation O
may O
be O
involved O
in O
controlling O
both O
rat O
and O
human I-GENE
T I-GENE
/ I-GENE
EBP I-GENE
gene I-GENE
expression O
. O

Deletion O
of O
the O
last O
two O
Ser O
residues O
, O
including O
one O
PKC I-GENE
consensus O
site O
in O
the O
receptor O
tail O
, O
prevented O
only O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
- O
induced O
desensitization O
by O
30 O
%. O

Flap O
survival O
depends O
on O
the O
development O
of O
a O
small O
number O
of O
vascular O
connections O
between O
vessels O
arising O
from O
the O
pedicle O
and O
preexisting O
dermal O
vessels O
. O

Jean O
Klig O
reviews O
recent O
literature O
about O
lower O
respiratory O
tract O
infection O
in O
children O
. O

Potential O
indicators O
were O
assessed O
for O
the O
two O
classifications O
of O
protein O
- O
energy O
malnutrition O
in O
the O
guidelines O
for O
integrated O
management O
of O
childhood O
illness O
: O
severe O
malnutrition O
, O
which O
requires O
immediate O
referral O
to O
hospital O
, O
and O
very O
low O
weight O
, O
which O
calls O
for O
feeding O
assessment O
, O
nutritional O
counselling O
and O
follow O
- O
up O
. O

SNAC O
or O
PBS O
was O
infused O
for O
6 O
. O
5 O
h O
, O
beginning O
30 O
min O
before O
ischemia O
and O
continuing O
throughout O
the O
duration O
of O
reperfusion O
. O

Despite O
its O
requirement O
for O
enhancer O
- O
dependent O
splicing O
activity O
in O
vitro O
, O
the O
dU2AF38 I-GENE
RS I-GENE
domain I-GENE
was O
also O
inessential O
in O
vivo O
. O

In O
vitro O
binding O
studies O
using O
GST I-GENE
fusion O
proteins O
and O
yeast O
extracts O
defined O
distinct O
binding O
sites O
on O
yAP180A I-GENE
for O
Pan1p I-GENE
and O
clathrin I-GENE
. O
yAP180 I-GENE
proteins I-GENE
and O
Pan1p I-GENE
, O
like O
actin I-GENE
, O
localize O
to O
peripheral O
patches O
along O
the O
plasma O
membrane O
. O

In O
vitro O
affinity O
analyses O
demonstrated O
that O
recombinant O
130 O
- O
kD O
protein O
directly O
interacts O
with O
ZO I-GENE
- I-GENE
1 I-GENE
and O
the O
cytoplasmic O
domain O
of O
occludin I-GENE
, O
but O
not O
with O
ZO I-GENE
- I-GENE
2 I-GENE
. O

Cytochrome I-GENE
b I-GENE
in O
human I-GENE
complex I-GENE
II I-GENE
( O
succinate I-GENE
- I-GENE
ubiquinone I-GENE
oxidoreductase I-GENE
): O
cDNA O
cloning O
of O
the O
components O
in O
liver O
mitochondria O
and O
chromosome O
assignment O
of O
the O
genes O
for O
the O
large O
( O
SDHC I-GENE
) O
and O
small O
( O
SDHD I-GENE
) O
subunits O
to O
1q21 O
and O
11q23 O
. O

A O
possible O
decrease O
in O
theophylline O
' O
s O
volume O
of O
distribution O
at O
4 O
days O
, O
but O
not O
immediately O
, O
after O
administration O
of O
chloroquine O
was O
suggested O
, O
although O
this O
just O
failed O
to O
achieve O
statistical O
significance O
( O
p O
= O
0 O
. O
055 O
). O

The O
addition O
of O
a O
Paf I-GENE
- O
containing O
extract O
does O
not O
lead O
to O
significant O
protein O
binding O
to O
these O
two O
hly I-GENE
target I-GENE
sequences I-GENE
in O
the O
absence O
of O
PrfA I-GENE
but O
converts O
the O
complex O
( O
CIII O
) O
consisting O
of O
PrfA I-GENE
and O
the O
109 I-GENE
bp I-GENE
hly I-GENE
DNA I-GENE
fragment I-GENE
to O
a O
slower O
migrating O
PrfA I-GENE
- O
Paf I-GENE
- O
DNA O
complex O
( O
CI O
). O

Moreover O
, O
it O
is O
the O
assumptions O
behind O
steady O
- O
state O
O2 O
uptake O
that O
do O
not O
permit O
proper O
interpretation O
of O
energy O
expenditure O
during O
EPOC O
; O
1 O
l O
O2 O
not O
= O
20 O
. O
9 O
kJ O
. O

The O
predicted O
amino O
acid O
sequence O
of O
m I-GENE
- I-GENE
Staf I-GENE
is O
highly O
homologous O
to O
that O
of O
Staf I-GENE
, O
another O
selenocysteine I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
of O
Xenopus O
laevis O
. O

ROCK I-GENE
- I-GENE
I I-GENE
, O
Kinectin I-GENE
, O
and O
mDia2 I-GENE
can O
bind O
the O
wild O
type O
forms O
of O
both O
RhoA I-GENE
and O
Cdc42 I-GENE
in O
a O
GTP O
- O
dependent O
manner O
in O
vitro O
. O

Among O
three O
isoforms O
, O
the O
beta O
isoform O
has O
the O
greatest O
Vmax O
value O
for O
the O
PtdIns I-GENE
( I-GENE
4 I-GENE
) I-GENE
P I-GENE
kinase I-GENE
activity O
and O
the O
gamma O
isoform O
is O
most O
markedly O
stimulated O
by O
phosphatidic O
acid O
. O

The O
beta O
subunit O
of O
the O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
that O
transduce O
signals O
across O
the O
plasma O
membrane O
is O
made O
up O
of O
an O
amino O
- O
terminal O
alpha O
- O
helical O
segment O
followed O
by O
seven O
repeating O
units O
called O
WD O
( O
Trp O
- O
Asp O
) O
repeats O
that O
occur O
in O
about O
140 O
different O
proteins O
. O

Two O
differentially O
expressed O
LNX I-GENE
messages I-GENE
encode O
overlapping O
proteins O
with O
predicted O
molecular O
masses O
of O
80 I-GENE
kDa I-GENE
( I-GENE
LNX I-GENE
) I-GENE
and O
70 O
kDa O
( O
LNX O
- O
b O
). O

In O
contrast O
, O
the O
contractile O
action O
of O
arachidonic O
acid O
, O
via O
a O
presumed O
cyclooxygenase I-GENE
product O
that O
mediated O
the O
contractions O
caused O
by O
both O
TF I-GENE
and O
EGF I-GENE
, O
was O
not O
blocked O
by O
any O
of O
the O
signal O
pathway O
probe O
inhibitors O
. O

Recent O
studies O
have O
revealed O
unconventional O
myosin I-GENE
V I-GENE
to O
be O
an O
important O
actin I-GENE
- O
based O
molecular O
motor O
involved O
in O
vesicular O
movement O
. O

On O
a O
separate O
occasion O
the O
T1 O
weighted O
and O
T2 O
weighted O
sagittal O
and O
T2 O
weighted O
axial O
sequences O
were O
reported O
blind O
in O
relation O
to O
the O
initial O
assessment O
. O

Furthermore O
, O
a O
minor O
start O
site O
was O
localized O
179 O
bp O
upstream O
of O
the O
major O
site O
using O
reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
with O
various O
P1 O
primers O
( O
primer O
walking O
), O
primer O
extension O
, O
and O
cDNA O
cloning O
. O

Analysis O
of O
promoter O
and O
androgen O
regulatory O
sequences O
required O
for O
optimal O
transcription O
of O
the O
rat O
androgen I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene O
. O

The O
iron O
dependence O
of O
transcription O
and O
expression O
of O
cvaA I-GENE
, O
which O
encodes O
a O
transporter O
accessory O
protein O
, O
and O
cvi I-GENE
, O
encoding O
the O
colicin I-GENE
V I-GENE
immunity I-GENE
protein I-GENE
, O
was O
assessed O
under O
conditions O
of O
iron O
excess O
or O
depletion O
. O

In O
a O
gntR I-GENE
deletion I-GENE
mutant I-GENE
, O
the O
expression O
of O
a O
chromosomal O
gntT I-GENE
:: O
lacZ I-GENE
fusion O
is O
both O
high O
and O
constitutive O
, O
confirming O
that O
GntR I-GENE
is O
the O
negative O
regulator O
of O
gntT I-GENE
. O

Furthermore O
, O
the O
deletion O
of O
bcp I-GENE
from O
the O
chromosome O
had O
no O
effect O
on O
gcv I-GENE
- O
lacZ I-GENE
expression O
. O

Of O
these O
sites O
, O
PEA3 I-GENE
and O
STAT I-GENE
contributed O
specifically O
to O
induction O
by O
v I-GENE
- I-GENE
src I-GENE
, O
whereas O
the O
remaining O
elements O
were O
also O
involved O
in O
induction O
by O
the O
phorbol O
ester O
phorbol O
myristate O
acetate O
( O
PMA O
). O

BRCA1 I-GENE
protein I-GENE
contains O
an O
amino O
- O
terminal O
zinc O
finger O
motif O
and O
a O
carboxy O
- O
terminal O
acidic O
region O
. O

The O
mitochondrial I-GENE
regulatory I-GENE
region I-GENE
( O
mrr I-GENE
) O
located O
between O
the O
tRNAPhe I-GENE
and O
tRNAPro I-GENE
genes I-GENE
of O
mitochondrial O
DNA O
( O
mtDNA O
) O
is O
essential O
for O
regulation O
of O
replication O
and O
transcription O
of O
the O
mitochondrial O
genome O
. O

In O
this O
report O
, O
we O
investigate O
the O
mechanism O
underlying O
Ras I-GENE
activation O
upon O
stimulation O
of O
these O
two O
types O
of O
receptors O
in O
hematopoietic O
cells O
. O

Thus O
, O
Sir I-GENE
proteins I-GENE
from O
K O
. O
lactis O
have O
roles O
in O
both O
silencing O
and O
telomere O
length O
maintenance O
, O
reflecting O
conserved O
functional O
themes O
. O

Therefore O
, O
we O
conclude O
that O
DnaA I-GENE
may O
contact O
the O
beta O
subunit O
of O
RNA I-GENE
polymerase I-GENE
during O
activation O
of O
the O
pR I-GENE
promoter I-GENE
. O

Expression O
of O
Bcl I-GENE
- I-GENE
XL I-GENE
inhibited O
the O
association O
of O
Apaf I-GENE
- I-GENE
1 I-GENE
with O
caspase I-GENE
- I-GENE
9 I-GENE
in O
mammalian O
cells O
. O

Whole O
- O
mount O
in O
situ O
hybridization O
to O
early O
mouse O
embryos O
of O
9 O
. O
5 O
- O
10 O
. O
5 O
days O
indicated O
a O
complex O
pattern O
of O
Arp1 I-GENE
expression O
spatially O
overlapping O
with O
the O
expression O
of O
All1 I-GENE
. O

These O
mutants O
were O
tested O
for O
ability O
to O
bind O
each O
of O
the O
Site I-GENE
II I-GENE
cognate I-GENE
proteins I-GENE
, O
and O
subsequently O
evaluated O
for O
ability O
to O
confer O
H4 I-GENE
transcriptional O
activity O
using O
chimeric O
H4 I-GENE
promoter O
/ O
CAT I-GENE
fusion O
constructs O
in O
different O
cell O
types O
. O

Increased O
plasma O
IgE I-GENE
was O
also O
confirmed O
in O
the O
NC O
mice O
, O
and O
treatment O
with O
FK506 O
ointment O
reduced O
the O
plasma O
IgE I-GENE
level O
. O

Creatine I-GENE
kinase I-GENE
release O
after O
hepatic O
artery O
embolization O
in O
patients O
with O
carcinoid O
tumors O
. O

Furthermore O
, O
in O
the O
ischemia O
/ O
angiotension I-GENE
II I-GENE
- O
induced O
AHF O
model O
, O
NIC O
decreased O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
LVEDP O
). O

Group O
A O
( O
68 O
. O
7 O
+/- O
2 O
. O
7 O
years O
) O
consisted O
of O
patients O
with O
0 O
or O
1 O
risk O
factors O
; O
B O
( O
68 O
. O
3 O
+/- O
4 O
. O
2 O
years O
) O
those O
with O
2 O
risk O
factors O
; O
and O
C O
( O
69 O
. O
2 O
+/- O
3 O
. O
6 O
years O
) O
those O
with O
3 O
or O
more O
risk O
factors O
. O

We O
further O
demonstrate O
that O
RU486 O
- O
PR I-GENE
- I-GENE
B I-GENE
interacts O
physically O
with O
NCoR I-GENE
in O
vitro O
. O

PRL I-GENE
receptor I-GENE
also O
activates O
SHP I-GENE
- I-GENE
2 I-GENE
, O
a O
cytosolic I-GENE
tyrosine I-GENE
phosphatase I-GENE
. O

The O
dominant O
negative O
mutant O
of O
SHP I-GENE
- I-GENE
2 I-GENE
was O
found O
to O
inhibit O
the O
induction O
of O
tyrosine O
phosphorylation O
and O
DNA O
- O
binding O
activity O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
, O
m I-GENE
- I-GENE
Stat5b I-GENE
, O
and O
the O
carboxyl O
- O
terminal O
deletion O
variant O
m I-GENE
- I-GENE
Stat5adelta749 I-GENE
, O
as O
well O
as O
the O
transactivation O
potential O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
and O
m I-GENE
- I-GENE
Stat5b I-GENE
. O

CONCLUSIONS O
: O
These O
routinely O
collected O
data O
provided O
quantitative O
estimates O
of O
changes O
in O
CBZ O
Cl O
/ O
F O
due O
to O
comedication O
and O
an O
age O
- O
related O
decrease O
in O
Cl O
/ O
F O
The O
derived O
regression O
equations O
reasonably O
predicted O
concentrations O
in O
a O
separate O
validation O
set O
. O

Sites O
1 O
and O
4 O
in O
lumican I-GENE
and O
keratocan I-GENE
are O
in O
a O
homologous O
location O
. O

Our O
observations O
suggest O
that O
members O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
family I-GENE
play O
an O
important O
role O
in O
SRF I-GENE
- O
dependent O
transcription O
and O
that O
their O
effect O
is O
mediated O
primarily O
by O
a O
protein O
- O
protein O
interaction O
. O

ATP O
- O
dependent O
assembly O
of O
a O
ternary O
complex O
consisting O
of O
a O
DNA O
mismatch O
and O
the O
yeast O
MSH2 I-GENE
- O
MSH6 I-GENE
and O
MLH1 I-GENE
- O
PMS1 I-GENE
protein O
complexes O
. O

Mutation O
of O
the O
central O
Tyr497 O
to O
Phe O
blocks O
the O
tyrosine O
phosphorylation O
of O
the O
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
( O
IRS1 I-GENE
) O
and O
diminishes O
proliferation O
in O
response O
to O
IL I-GENE
- I-GENE
4 I-GENE
. O

Instead O
, O
it O
contained O
two O
tandem O
kappaB I-GENE
elements I-GENE
and O
a O
variant O
activating I-GENE
transcription I-GENE
factor I-GENE
/ I-GENE
cAMP I-GENE
response I-GENE
element I-GENE
site O
, O
which O
closely O
resembled O
sites O
in O
the O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
that O
are O
required O
for O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
or O
LPS O
- O
inducible O
expression O
. O

We O
recently O
characterized O
a O
single O
yeast I-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
HMT1 I-GENE
). O

We O
recently O
characterized O
a O
single O
yeast I-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
HMT1 I-GENE
). O

Recombinant I-GENE
HRMT1L2 I-GENE
protein I-GENE
encoded O
by O
the O
most O
common O
5 O
'- O
variant O
exhibited O
methyltransferase O
activity O
in O
vitro O
. O

The O
possible O
roles O
of O
HRMT1L1 I-GENE
and O
HRMT1L2 I-GENE
in O
human O
disease O
are O
currently O
unknown O
. O

Identification O
and O
characterization O
of O
two O
putative O
human I-GENE
arginine I-GENE
methyltransferases I-GENE
( O
HRMT1L1 I-GENE
and O
HRMT1L2 I-GENE
). O

Interestingly O
, O
the O
activated O
PDGF I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
was O
found O
not O
to O
bind O
Crk I-GENE
proteins I-GENE
. O

Furthermore O
, O
interactions O
were O
identified O
between O
endogenous I-GENE
E I-GENE
- I-GENE
cadherin I-GENE
and O
the O
chimera O
containing O
the O
E I-GENE
- I-GENE
cadherin I-GENE
extracellular I-GENE
domain I-GENE
and O
the O
desmoglein I-GENE
1 I-GENE
intracellular I-GENE
domain I-GENE
providing O
in O
vivo O
evidence O
for O
previously O
predicted O
lateral O
interactions O
of O
E I-GENE
- I-GENE
cadherin I-GENE
extracellular I-GENE
domains I-GENE
. O

The O
ether O
phospholipid O
1 O
- O
O O
- O
octadecyl O
- O
2 O
- O
O O
- O
methyl O
- O
rac O
- O
glycero O
- O
3 O
- O
phosphocholine O
( O
ET O
- O
18 O
- O
OCH3 O
; O
edelfosine O
) O
is O
a O
potent O
inducer O
of O
apoptosis O
in O
human O
tumor O
cells O
. O

In O
addition O
to O
a O
previously O
characterized O
promoter O
( O
P1 O
), O
we O
now O
show O
the O
existence O
of O
a O
second O
promoter O
for O
the O
human I-GENE
IL I-GENE
- I-GENE
5Ralpha I-GENE
gene I-GENE
. O

Serum O
levels O
of O
testosterone O
also O
showed O
no O
significant O
changes O
by O
exposure O
to O
p O
, O
p O
'- O
DDE O
under O
the O
conditions O
of O
this O
study O
. O

Overall O
agreement O
between O
rest O
/ O
postnitroglycerin O
technetium O
- O
99m O
tetrofosmin O
SPET O
studies O
and O
rest O
/ O
redistribution O
or O
rest O
/ O
reinjection O
thallium O
- O
201 O
SPET O
studies O
, O
regarding O
the O
presence O
of O
myocardial O
viability O
, O
was O
87 O
% O
and O
90 O
%, O
respectively O
. O

Their O
use O
resulted O
in O
a O
sensitivity O
of O
73 O
% O
and O
a O
specificity O
of O
74 O
% O
with O
regard O
to O
predictability O
of O
ALT I-GENE
levels O
increasing O
during O
the O
trial O
. O

One O
hundred O
replicate O
data O
sets O
of O
100 O
subjects O
each O
were O
simulated O
for O
each O
missing O
data O
scenario O
. O

Spatial O
accuracy O
of O
primary O
and O
secondary O
memory O
- O
guided O
saccades O
in O
schizophrenic O
patients O
. O

Successful O
treatment O
with O
nasal O
continuous O
positive O
airway O
pressure O
( O
8 O
. O
3 O
+/- O
1 O
. O
5 O
cmH2O O
) O
for O
3 O
days O
caused O
a O
significant O
decrease O
in O
mean O
blood O
pressure O
in O
OSAS O
. O

When O
data O
were O
expressed O
in O
a O
cumulative O
manner O
, O
the O
response O
to O
intravenous O
adenosine O
3 O
mg O
, O
6 O
mg O
, O
9 O
mg O
and O
12 O
mg O
in O
the O
24 O
episodes O
of O
PSVT O
were O
5 O
episodes O
( O
21 O
%), O
16 O
episodes O
( O
67 O
%), O
20 O
episodes O
( O
83 O
%) O
and O
20 O
episodes O
( O
83 O
%) O
respectively O
. O

RNAs O
are O
not O
only O
essential O
components O
of O
both O
ribosomal O
subunits O
but O
also O
transiently O
interacting O
factors O
during O
particle O
formation O
. O

To O
study O
retinoid O
signalling O
in O
zebrafish O
embryos O
, O
we O
developed O
a O
novel O
method O
to O
detect O
endogenous O
retinoids O
in O
situ O
in O
embryos O
, O
using O
a O
fusion O
protein O
of O
the O
ligand O
inducible O
transactivation O
domain O
of O
a O
retinoic I-GENE
acid I-GENE
receptor I-GENE
and O
a O
heterologous O
DNA O
binding O
domain O
. O

To O
identify O
nuclear O
regulatory O
factors O
, O
we O
have O
located O
and O
functionally O
characterized O
the O
CCR5 I-GENE
gene I-GENE
promoter I-GENE
. O

Fluorescence O
in O
situ O
hybridization O
of O
metaphase O
spreads O
of O
chromosome O
8 O
, O
containing O
hybrid O
cell O
line O
706 O
- O
B6 O
clone O
17 O
( O
CL O
- O
17 O
) O
with O
cosmid O
c101F1 O
, O
placed O
the O
9804 I-GENE
gene I-GENE
close O
to O
the O
telomere O
at O
8q24 O
. O
3 O
. O

The O
interaction O
between O
piroxicam O
and O
poloxamer O
was O
studied O
by O
x O
- O
ray O
diffractometry O
( O
XRD O
), O
infrared O
( O
IR O
) O
spectroscopy O
and O
differential O
thermal O
analysis O
( O
DTA O
) O
with O
a O
solid O
dispersion O
, O
coprecipitate O
, O
or O
physical O
mixture O
. O

Cell O
survival O
by O
Epo I-GENE
did O
not O
require O
activation O
of O
other O
known O
signaling O
pathways O
including O
PI I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
, O
PLC I-GENE
- I-GENE
gamma I-GENE
, O
Ras I-GENE
or O
Stats I-GENE
. O

The O
N O
- O
syndecan O
- O
dependent O
neurite O
outgrowth O
is O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
inhibitors O
herbimycin O
A O
and O
PP1 I-GENE
. O

An O
in O
vivo O
ZAP I-GENE
- I-GENE
70 I-GENE
substrate O
, O
SLP I-GENE
- I-GENE
76 I-GENE
, O
implicated O
in O
Erk I-GENE
activation O
, O
also O
became O
rapidly O
tyrosine O
- O
phosphorylated O
in O
Jurkat O
cells O
, O
but O
not O
in O
P116 O
cells O
, O
upon O
treatment O
with O
H2O2 O
. O

The O
pharmacokinetic O
patterns O
of O
estradiol O
( O
CAS O
50 O
- O
28 O
- O
2 O
) O
and O
of O
estrone O
( O
CAS O
53 O
- O
16 O
- O
7 O
) O
were O
investigated O
in O
18 O
women O
in O
natural O
or O
surgical O
menopause O
during O
the O
application O
of O
a O
new O
estradiol O
transdermal O
patch O
with O
active O
matrix O
and O
without O
absorption O
enhancers O
designed O
for O
epicutaneous O
applications O
of O
7 O
days O
( O
hereinafter O
called O
" O
patch O
7D O
"). O

The O
results O
confirm O
that O
a O
single O
base O
change O
in O
the O
branchpoint O
consensus O
sequence O
of O
an O
intron O
can O
cause O
human O
disease O
although O
this O
sequence O
is O
poorly O
conserved O
in O
mammals O
. O

Conversely O
, O
the O
central O
regions O
are O
highly O
variable O
. O

Among O
the O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNAs I-GENE
associated O
with O
Gar1p I-GENE
, O
one O
can O
distinguish O
a O
large O
group O
of O
snoRNAs O
that O
are O
not O
essential O
in O
yeast O
and O
serve O
as O
guides O
for O
pseudouridine O
synthesis O
onto O
the O
pre O
- O
rRNA O
molecule O
. O

It O
bound O
to O
vitamin I-GENE
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
but O
not O
retinoic I-GENE
acid I-GENE
Xalpha I-GENE
receptor I-GENE
( O
RXRalpha I-GENE
) O
in O
the O
human O
T O
cell O
line O
MT2 O
cells O
. O

Further O
studies O
demonstrated O
that O
the O
PPARalpha I-GENE
ligand O
8 O
( O
S O
)- O
hydroxyeicosatetraenoic O
acid O
strongly O
promotes O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
co O
- O
activator O
RIP I-GENE
- I-GENE
140 I-GENE
but O
decreases O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
co O
- O
repressor O
SMRT I-GENE
. O

Based O
on O
the O
current O
literature O
, O
the O
mechanisms O
involved O
in O
the O
toxicity O
of O
OA I-GENE
indicate O
three O
major O
effects O
: O
( O
1 O
) O
inhibition O
of O
mitochondrial O
respiration O
correlated O
with O
a O
depletion O
of O
ATP O
; O
( O
2 O
) O
inhibition O
of O
tRNA I-GENE
- I-GENE
synthetase I-GENE
accompanied O
by O
a O
reduced O
protein O
synthesis O
; O
and O
( O
3 O
) O
enhanced O
lipid O
peroxidation O
. O

We O
previously O
demonstrated O
that O
acute O
expression O
of O
the O
bovine O
papillomavirus O
type O
1 O
( O
BPV1 O
) O
E2 I-GENE
protein I-GENE
in O
HeLa O
and O
HT O
- O
3 O
cervical O
carcinoma O
cell O
lines O
greatly O
reduced O
cellular O
proliferation O
by O
imposing O
a O
specific O
G1 O
/ O
S O
phase O
growth O
arrest O
. O

Four O
possible O
isoforms O
( O
hGli2 I-GENE
alpha I-GENE
, I-GENE
beta I-GENE
, I-GENE
gamma I-GENE
, I-GENE
and I-GENE
delta I-GENE
) O
are O
formed O
by O
combinations O
of O
two O
independent O
alternative O
splicings O
, O
and O
all O
the O
isoforms O
could O
bind O
to O
a O
DNA O
motif O
, O
TRE2S O
, O
in O
the O
LTR O
. O

Specialized O
actin I-GENE
tails O
that O
propel O
IEV O
particles O
to O
the O
periphery O
and O
virus O
- O
tipped O
microvilli O
( O
both O
common O
in O
wild O
- O
type O
- O
infected O
cells O
) O
were O
absent O
in O
cells O
infected O
with O
vA33delta O
. O

Their O
mean O
IOP O
was O
15 O
. O
3 O
( O
SD O
3 O
. O
7 O
) O
mmHg O
prior O
to O
induction O
of O
anesthesia O
, O
13 O
. O
5 O
( O
SD O
3 O
. O
5 O
) O
mmHg O
after O
loss O
of O
eyelash O
reflex O
following O
injection O
of O
methohexitone O
, O
16 O
. O
1 O
( O
SD O
2 O
. O
4 O
) O
mmHg O
after O
cessation O
of O
muscle O
fasciculations O
induced O
by O
suxamethonium O
, O
19 O
. O
2 O
( O
SD O
5 O
. O
6 O
) O
mmHg O
after O
cessation O
of O
convulsion O
and O
15 O
. O
5 O
( O
SD O
4 O
. O
4 O
) O
mmHg O
following O
resumption O
of O
regular O
spontaneous O
respiration O
. O

A O
cDNA O
, O
cak1At I-GENE
, O
was O
isolated O
that O
suppressed O
the O
CAK I-GENE
mutation I-GENE
in O
budding O
yeast O
, O
and O
it O
also O
complemented O
a O
fission I-GENE
yeast I-GENE
CAK I-GENE
mutant I-GENE
. O
cak1At I-GENE
encodes O
a O
protein O
related O
to O
animal I-GENE
CAKs I-GENE
. O

Post O
- O
translational O
modifications O
such O
as O
glycosylation O
and O
phosphorylation O
could O
be O
excluded O
as O
potential O
explanations O
for O
the O
protein O
heterogeneity O
. O

In O
addition O
to O
restoring O
checkpoint O
control O
, O
overexpression O
of O
sum1 I-GENE
+ I-GENE
inhibits O
the O
normal O
cell O
cycle O
response O
to O
osmotic O
stress O
. O

Ime1 I-GENE
plays O
a O
pivotal O
role O
in O
the O
initiation O
of O
meiosis O
in O
a O
/ O
alpha O
diploid O
cells O
of O
Saccharomyces O
cerevisiae O
. O

Rhesus O
macaques O
and O
BALB O
/ O
c O
mice O
inoculated O
with O
the O
Mengo O
virus O
SIV O
recombinants O
failed O
to O
develop O
CTL O
responses O
against O
the O
SIV O
gene O
products O
, O
while O
one O
of O
the O
HIV I-GENE
- I-GENE
Nef I-GENE
recombinants I-GENE
induced O
a O
weak O
CTL O
response O
in O
mice O
directed O
to O
an O
HIV1 I-GENE
Nef I-GENE
peptide I-GENE
spanning O
positions O
182 O
- O
198 O
. O

Deltamethrin O
was O
most O
effective O
on O
the O
thatched O
surface O
and O
produced O
100 O
% O
mortality O
of O
An O
. O
culicifacies O
adults O
up O
to O
12 O
weeks O
, O
even O
when O
exposed O
at O
the O
lowest O
dose O
/ O
12 O
. O
5 O
mg O
/ O
m2 O
. O

Trichloroethylene O
, O
in O
turn O
, O
increased O
the O
AUC O
5 O
. O
0 O
( O
1 O
. O
9 O
- O
13 O
. O
4 O
), O
25 O
. O
8 O
( O
8 O
. O
2 O
- O
80 O
. O
8 O
) O
and O
2 O
. O
9 O
( O
1 O
. O
6 O
- O
5 O
. O
4 O
), O
respectively O
, O
whereas O
the O
corresponding O
values O
for O
n O
- O
hexane O
were O
1 O
. O
9 O
( O
0 O
. O
7 O
- O
5 O
. O
1 O
), O
1 O
. O
5 O
( O
0 O
. O
5 O
- O
4 O
. O
6 O
), O
and O
3 O
. O
2 O
( O
1 O
. O
8 O
- O
5 O
. O
9 O
). O

Solution O
structure O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
: O
a O
novel O
subgroup O
of O
the O
winged I-GENE
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
family I-GENE
. O

In O
contrast O
, O
receptor I-GENE
/ I-GENE
G I-GENE
protein I-GENE
coupling O
appeared O
unaffected O
by O
expression O
of O
loop O
3i O
domains O
derived O
from O
two O
receptors O
coupled O
to O
G I-GENE
( I-GENE
i I-GENE
/ I-GENE
o I-GENE
) I-GENE
proteins I-GENE
( O
M2Ach I-GENE
- I-GENE
muscarinic I-GENE
and I-GENE
alpha2A I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
). O

These O
data O
indicate O
that O
the O
third O
intracellular O
loop O
of O
the O
rat I-GENE
GnRH I-GENE
- I-GENE
R I-GENE
is O
involved O
in O
receptor I-GENE
G I-GENE
( I-GENE
q I-GENE
/ I-GENE
11 I-GENE
) I-GENE
protein I-GENE
coupling O
and O
/ O
or O
selectivity O
, O
and O
in O
the O
GGH O
( O
3 O
) O
1 O
' O
cell O
line O
, O
this O
loop O
is O
also O
involved O
in O
signal O
transduction O
mediated O
through O
the O
Gs I-GENE
protein O
pathway O
. O

Decreased O
levels O
of O
alpha2 I-GENE
- I-GENE
antiplasmin I-GENE
were O
also O
observed O
in O
the O
mediastinum O
( O
0 O
. O
50 O
versus O
0 O
. O
61 O
U O
/ O
mL O
; O
p O
< O
0 O
. O
05 O
). O

A O
catalytic O
domain O
of O
eukaryotic I-GENE
DNA I-GENE
topoisomerase I-GENE
I I-GENE
. O

A O
cluster O
of O
basic O
amino O
acids O
, O
KKKR O
, O
generated O
by O
joining O
of O
the O
sequences O
encoded O
by O
the O
constitutive O
exon O
13 O
and O
the O
alternative O
exon O
16 O
, O
is O
necessary O
for O
the O
nuclear O
targeting O
of O
4 I-GENE
. I-GENE
1H I-GENE
, O
as O
demonstrated O
by O
site O
- O
directed O
mutagenesis O
analysis O
. O

Another O
stem O
- O
loop O
called O
structure O
III O
near O
the O
3 O
'- O
end O
of O
repY I-GENE
sequesters O
both O
the O
5 O
'- O
rCGCC O
- O
3 O
' O
sequence O
and O
the O
repZ I-GENE
ribosome I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

All O
three O
genes O
have O
been O
mapped O
precisely O
to O
a O
small O
region O
on O
human O
chromosome O
16p12 O
. O
1 O
- O
p11 O
. O
2 O
( O
homologous O
to O
mouse O
chromosome O
7 O
), O
using O
somatic O
cell O
hybrids O
and O
cosmid O
clones O
. O

In O
fus3 I-GENE
mutants I-GENE
, O
the O
levels O
of O
Ty1 I-GENE
RNA I-GENE
, O
protein O
synthesis O
, O
and O
proteolytic O
processing O
were O
not O
altered O
relative O
to O
those O
in O
FUS3 I-GENE
strains O
but O
steady O
- O
state O
levels O
of O
TyA I-GENE
, O
integrase I-GENE
, O
and O
reverse I-GENE
transcriptase I-GENE
proteins O
and O
Ty1 I-GENE
cDNA I-GENE
were O
all O
increased O
. O

Posttranslational O
regulation O
of O
Ty1 I-GENE
retrotransposition O
by O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
Fus3 I-GENE
. O

The O
general O
transcription I-GENE
factor I-GENE
IIA I-GENE
( O
TFIIA I-GENE
) O
interacts O
with O
the O
TATA I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
promoter O
DNA O
to O
mediate O
transcription O
activation O
in O
vitro O
. O

Their O
function O
is O
not O
only O
to O
recruit O
Pho2 I-GENE
to O
the O
promoter O
but O
to O
allow O
cooperative O
binding O
of O
Pho4 I-GENE
together O
with O
Pho2 I-GENE
. O

Substitution O
of O
the O
Ser O
- O
Thr O
sites O
with O
the O
phosphomimetic O
Asp O
generated O
a O
constitutively O
active O
form O
of O
IRF I-GENE
- I-GENE
3 I-GENE
that O
functioned O
as O
a O
very O
strong O
activator O
of O
promoters O
containing O
PRDI I-GENE
- O
PRDIII I-GENE
or O
ISRE I-GENE
regulatory I-GENE
elements I-GENE
. O

New O
- O
onset O
angina O
preceding O
acute O
myocardial O
infarction O
is O
associated O
with O
improved O
contractile O
recovery O
after O
thrombolysis O
. O

In O
this O
study O
, O
the O
effect O
of O
acute O
administration O
of O
various O
doses O
of O
malathion O
via O
oral O
and O
dermal O
routes O
to O
mice O
and O
rats O
on O
serum O
levels O
of O
histamine O
was O
evaluated O
. O

Fetal O
growth O
retardation O
as O
a O
cause O
of O
impaired O
ovarian O
development O
. O

Similarly O
, O
PCDFs O
/ O
PCDDs O
ratio O
in O
ESP O
ash O
was O
lower O
than O
that O
in O
boiler O
ash O
. O

In O
addition O
to O
DNA O
- O
protein O
interactions O
, O
protein O
- O
protein O
interactions O
with O
partner O
proteins O
often O
play O
major O
roles O
in O
targeting O
ETS I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
to O
specific O
promoters O
. O

Localization O
of O
67 O
exons O
on O
a O
YAC O
contig O
spanning O
1 O
. O
5 O
Mb O
around O
the O
multidrug I-GENE
resistance I-GENE
gene I-GENE
region I-GENE
of O
human O
chromosome O
7q21 O
. O
1 O
. O

The O
complete O
exon O
- O
intron O
organization O
of O
the O
murine O
gene O
encoding O
M I-GENE
- I-GENE
protein I-GENE
, O
a O
structural O
protein O
of O
sarcomeric O
myofibrils O
, O
was O
determined O
. O

PURPOSE O
: O
To O
introduce O
an O
image O
analysis O
of O
the O
cornea O
in O
photorefractive O
keratectomy O
( O
PRK O
) O
for O
preoperative O
and O
early O
postoperative O
determination O
of O
changes O
in O
the O
condition O
of O
the O
cornea O
. O

Mean O
+/- O
SD O
serum I-GENE
VEGF I-GENE
concentrations O
were O
significantly O
higher O
( O
P O
< O
0 O
. O
001 O
) O
in O
women O
with O
PCO O
and O
PCOS O
( O
3 O
. O
4 O
+/- O
0 O
. O
7 O
and O
3 O
. O
2 O
+/- O
0 O
. O
66 O
ng O
/ O
ml O
respectively O
) O
compared O
with O
women O
with O
normal O
ovaries O
( O
2 O
. O
3 O
+/- O
0 O
. O
5 O
ng O
/ O
ml O
). O

Strikingly O
, O
these O
cells O
contain O
a O
missense O
mutation O
of O
the O
p53 I-GENE
gene I-GENE
at O
codon O
242 O
( O
p53 I-GENE
( O
242 O
)), O
which O
substitutes O
alanine O
for O
glycine O
. O

The O
new O
algorithm O
, O
called O
RBI O
- O
MAP O
, O
is O
based O
on O
the O
rescaled O
block O
iterative O
EM O
( O
RBI O
- O
EM O
) O
algorithm O
. O

A O
third O
ORF O
, O
ORF5 O
, O
shows O
homology O
with O
gene I-GENE
agrB I-GENE
from O
Staphylococcus O
aureus O
, O
which O
is O
involved O
in O
the O
mechanism O
of O
regulation O
of O
the O
virulence O
phenotype O
in O
this O
species O
. O

An O
association O
between O
hSIE I-GENE
and O
Stat I-GENE
- I-GENE
3 I-GENE
after O
MHC I-GENE
- I-GENE
I I-GENE
ligation O
was O
directly O
demonstrated O
by O
precipitating O
Stat I-GENE
- I-GENE
3 I-GENE
from O
nuclear O
extracts O
with O
biotinylated O
hSIE I-GENE
probe O
and O
avidin I-GENE
- O
coupled O
agarose O
. O

Transcriptional O
repression O
mediated O
by O
LysR I-GENE
- I-GENE
type I-GENE
regulator I-GENE
CatR I-GENE
bound O
at O
multiple O
binding O
sites O
. O

Two O
of O
these O
resulted O
in O
increased O
levels O
of O
the O
alpha O
subunit O
, O
and O
one O
caused O
a O
substitution O
of O
glycine O
for O
the O
aspartic O
acid O
residue O
at O
position O
171 O
, O
in O
the O
N O
- O
terminal O
domain O
. O

These O
two O
mRNA O
species O
are O
produced O
by O
differential O
polyadenylation O
site O
usage O
. O

Using O
Southern O
blot O
analysis O
and O
restriction O
mapping O
of O
genomic O
YAC O
( O
yeast O
artificial O
chromosome O
) O
and O
cosmid O
clones O
, O
we O
located O
the O
human I-GENE
RIL I-GENE
gene I-GENE
240 O
- O
260 O
kb O
telomeric O
to O
the O
IRF1 I-GENE
gene I-GENE
and O
characterized O
its O
genomic O
structure O
. O

U73 I-GENE
contains O
C O
, O
D O
and O
D O
' O
boxes O
and O
a O
12 O
- O
nucleotide O
antisense O
complementarity O
to O
the O
28S I-GENE
ribosomal I-GENE
RNA I-GENE
. O

However O
, O
mandibular O
position O
( O
S O
- O
N O
- O
B O
and O
S O
- O
N O
- O
Pog O
) O
was O
found O
to O
be O
significantly O
more O
retrusive O
in O
Class O
II O
when O
compared O
with O
Class O
I O
subjects O
. O

Echinostomiasis O
is O
aggravated O
by O
socioeconomic O
factors O
such O
as O
poverty O
, O
malnutrition O
, O
an O
explosively O
growing O
free O
- O
food O
market O
, O
a O
lack O
of O
supervised O
food O
inspection O
, O
poor O
or O
insufficient O
sanitation O
, O
other O
helminthiases O
, O
and O
declining O
economic O
conditions O
. O

The O
localization O
of O
ZAP I-GENE
- I-GENE
70 I-GENE
to O
the O
cell O
cortex O
is O
, O
therefore O
, O
regulated O
by O
the O
activity O
of O
SRC I-GENE
- I-GENE
family I-GENE
kinases I-GENE
, O
independently O
of O
their O
ability O
to O
phosphorylate O
immunoreceptor O
tyrosine O
- O
based O
activation O
motifs O
of O
the O
TCR I-GENE
. O

Finally O
, O
a O
role O
for O
NF I-GENE
- I-GENE
kappaB I-GENE
in O
preventing O
apoptosis O
induced O
by O
ER O
calcium O
release O
was O
demonstrated O
by O
data O
showing O
that O
sAPPalpha I-GENE
prevents O
thapsigargin O
- O
induced O
apoptosis O
, O
an O
effect O
blocked O
by O
kappaB I-GENE
decoy O
DNA O
. O

Many O
cytokine O
receptors O
employ O
Janus I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
Jaks I-GENE
) O
and O
signal I-GENE
transducers I-GENE
and I-GENE
activators I-GENE
of I-GENE
transcription I-GENE
( O
Stats I-GENE
) O
for O
nuclear O
signaling O
. O

A O
site O
- O
directed O
R618K O
mutation O
in O
the O
Stat5 I-GENE
SH2 I-GENE
domain I-GENE
abolished O
the O
phosphorylation O
by O
Jak2 I-GENE
, O
while O
deletion O
of O
the O
C O
terminus O
led O
to O
Stat5 I-GENE
hyperphosphorylation O
. O

The O
effect O
of O
nitric I-GENE
oxide I-GENE
synthase I-GENE
inhibitor O
on O
reperfusion O
injury O
of O
the O
brain O
under O
hypothermic O
circulatory O
arrest O
. O

Specifically O
, O
recombination O
at O
HMR I-GENE
was O
used O
to O
produce O
rings O
that O
lacked O
the O
E O
and O
I O
silencers O
. O

In O
angiodysplasia O
, O
ectatic O
vessels O
in O
the O
mucosa O
appeared O
to O
contain O
less O
collagen I-GENE
type I-GENE
IV I-GENE
than O
similarly O
sized O
vessels O
in O
the O
submucosa O
, O
and O
perforating O
vessels O
appeared O
in O
many O
cases O
to O
lose O
staining O
at O
the O
level O
of O
the O
muscularis O
mucosae O
. O

We O
studied O
the O
human O
vestibulo O
- O
ocular O
reflex O
( O
VOR O
) O
in O
response O
to O
head O
' O
impulses O
': O
brief O
, O
unpredictable O
, O
passive O
, O
high O
- O
acceleration O
( O
up O
to O
4000 O
degrees O
/ O
s2 O
), O
low O
- O
amplitude O
( O
20 O
- O
30 O
degrees O
) O
head O
rotations O
. O

To O
clarify O
whether O
seizure O
- O
offset O
patterns O
are O
reliable O
in O
predicting O
seizure O
outcome O
, O
we O
studied O
SEEG O
/ O
ECoG O
in O
a O
similar O
group O
of O
patients O
with O
temporal O
lobe O
epilepsy O
( O
TLE O
). O

In O
this O
study O
, O
to O
characterize O
the O
gene O
for O
protein I-GENE
Z I-GENE
, O
its O
organization O
and O
structure O
were O
determined O
by O
a O
combination O
of O
PCR O
amplification O
of O
leukocyte O
DNA O
and O
isolation O
of O
phage O
clones O
from O
a O
human O
genomic O
library O
. O

These O
modifications O
may O
improve O
the O
interlaboratory O
reproducibility O
of O
CD34 I-GENE
determinations O
due O
to O
the O
reduction O
in O
sample O
handling O
and O
calculation O
of O
results O
. O

The O
present O
results O
demonstrate O
that O
rats O
with O
relatively O
small O
remnants O
of O
one O
olfactory O
bulb O
can O
perform O
a O
variety O
of O
odor O
detection O
and O
discrimination O
tasks O
as O
well O
or O
nearly O
as O
well O
as O
controls O
. O

UDP I-GENE
- I-GENE
GlcNAc I-GENE
: O
alpha I-GENE
- I-GENE
6 I-GENE
- I-GENE
D I-GENE
- I-GENE
mannoside I-GENE
beta I-GENE
- I-GENE
1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
N I-GENE
- I-GENE
acetylglucosaminyltransferase I-GENE
II I-GENE
( O
GnT I-GENE
II I-GENE
; O
EC I-GENE
2 I-GENE
. I-GENE
4 I-GENE
. I-GENE
1 I-GENE
. I-GENE
143 I-GENE
) O
is O
essential O
for O
the O
normal O
assembly O
of O
complex O
Asn O
- O
linked O
glycans O
. O

These O
patients O
failed O
to O
respond O
to O
intravenous O
cyclophosphamide O
and O
steroids O
and O
were O
then O
changed O
to O
receive O
oral O
cyclosporine O
A O
, O
at O
a O
dose O
of O
5 O
mg O
/ O
kg O
/ O
day O
. O

The O
predicted O
amino O
acid O
sequence O
is O
78 O
. O
0 O
% O
identical O
to O
the O
cytoplasmic I-GENE
dynein I-GENE
heavy I-GENE
chain I-GENE
of I-GENE
Neurospora I-GENE
crassa I-GENE
, O
70 O
. O
2 O
% O
identical O
to O
that O
of O
Aspergillus O
nidulans O
and O
24 O
. O
8 O
% O
identical O
to O
that O
of O
Saccharomyces O
cerevisiae O
. O

The O
DNA O
binding O
activities O
of O
the O
three O
repressor O
preparations O
were O
studied O
using O
fragments O
containing O
CIRs O
( O
CIR3 O
- O
CIR6 O
) O
from O
the O
essential O
early O
region O
as O
templates O
for O
DNase I-GENE
I I-GENE
footprinting O
. O

Molecular O
modelling O
suggested O
that O
the O
tetramerization O
domain O
was O
a O
four O
- O
helix O
bundle O
, O
stabilized O
by O
interactions O
of O
seven O
conserved O
aromatic O
amino O
acids O
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
in O
chronically O
HIV O
- O
1 O
- O
infected O
promonocytic O
U937 O
( O
U9 O
- O
IIIB O
) O
and O
myeloblastic O
PLB O
- O
985 O
( O
PLB O
- O
IIIB O
) O
cells O
affects O
apoptotic O
signaling O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
silymarin O
may O
exert O
a O
strong O
anticarcinogenic O
effect O
against O
PCA O
and O
that O
this O
effect O
is O
likely O
to O
involve O
impairment O
of O
erbB1 I-GENE
- O
SHC I-GENE
- O
mediated O
signaling O
pathway O
, O
induction O
of O
CDKIs I-GENE
, O
and O
a O
resultant O
G1 O
arrest O
. O

In O
connective O
tissue O
, O
cell O
structure O
contributes O
to O
type I-GENE
I I-GENE
collagen I-GENE
expression O
. O

To O
explore O
the O
function O
of O
human O
SINA I-GENE
- I-GENE
homologous I-GENE
( I-GENE
Siah I-GENE
) I-GENE
proteins I-GENE
, O
expression O
plasmids O
encoding O
Siah I-GENE
- I-GENE
1A I-GENE
were O
transiently O
transfected O
into O
293 O
epithelial O
cells O
and O
GM701 O
fibroblast O
cells O
, O
resulting O
in O
growth O
arrest O
without O
induction O
of O
apoptosis O
. O

A O
point O
mutation O
in O
Galphao I-GENE
and O
Galphai1 I-GENE
blocks O
interaction O
with O
regulator O
of O
G I-GENE
protein I-GENE
signaling O
proteins O
. O

Indeed O
, O
it O
is O
shown O
that O
it O
mediates O
the O
formation O
of O
disulfide O
- O
linked O
homodimers O
and O
that O
the O
formation O
of O
homo O
- O
and O
heterodimers O
are O
mutually O
excluded O
. O

N O
., O
and O
Fanning O
, O
E O
. O

We O
have O
shown O
previously O
that O
GH3 O
cells O
transfected O
with O
the O
rat I-GENE
GnRH I-GENE
receptor I-GENE
cDNA I-GENE
( O
GGH3 O
- O
1 O
' O
cells O
) O
support O
the O
expression O
of O
a O
cotransfected O
fusion O
gene O
composed O
of O
797 O
base O
pairs O
of O
rat I-GENE
LHbeta I-GENE
gene I-GENE
5 I-GENE
'- I-GENE
flanking I-GENE
sequence I-GENE
and O
the O
first O
5 O
base O
pairs O
of O
the O
5 O
'- O
untranslated O
region O
fused O
to O
a O
luciferase I-GENE
reporter I-GENE
(- I-GENE
797 I-GENE
/+ I-GENE
5LHbetaLUC I-GENE
) I-GENE
and O
respond O
to O
a O
GnRH I-GENE
agonist O
with O
a O
10 O
- O
fold O
stimulation O
of O
activity O
. O

The O
5 O
'- O
flanking O
region O
, O
from O
nucleotide O
- O
837 O
to O
- O
336 O
, O
contains O
TATA O
and O
inverted O
CAAT O
boxes O
as O
well O
as O
GATA I-GENE
- I-GENE
1 I-GENE
/ O
SP1 I-GENE
erythroid O
- O
specific O
cis O
- O
acting O
regulatory O
elements O
. O

We O
established O
the O
radiosensitive O
cell O
line O
SX9 O
from O
mammary O
carcinoma O
cell O
line O
FM3A O
. O

In O
patients O
with O
type O
IA O
maple O
syrup O
urine O
disease O
, O
the O
E1alpha I-GENE
subunit I-GENE
is O
affected O
, O
resulting O
in O
the O
loss O
of O
E1 I-GENE
and O
branched I-GENE
- I-GENE
chain I-GENE
ketoacid I-GENE
dehydrogenase I-GENE
catalytic O
activities O
. O

Results O
showed O
that O
the O
mean O
bond O
strength O
of O
H O
. O
T O
. O
V O
. O
specimens O
ranged O
from O
9 O
. O
6 O
to O
13 O
. O
12 O
kg O
/ O
cm2 O
, O
while O
the O
mean O
bond O
strength O
of O
R O
. O
T O
. O
V O
. O
specimens O
ranged O
from O
0 O
. O
36 O
to O
1 O
. O
75 O
kg O
/ O
cm2 O
. O

OBJECTIVES O
: O
To O
measure O
coagulation I-GENE
factor I-GENE
VIII I-GENE
: I-GENE
coagulant I-GENE
( O
F I-GENE
. I-GENE
VIII I-GENE
: I-GENE
C I-GENE
) O
and O
C1 I-GENE
- I-GENE
esterase I-GENE
inhibitor I-GENE
( O
C1 I-GENE
- I-GENE
INH I-GENE
), O
hemostasis O
- O
associated O
acute O
- O
phase O
reactant O
proteins O
and O
coagulation I-GENE
factors I-GENE
VII I-GENE
( O
F I-GENE
. I-GENE
VII I-GENE
), O
IX O
( O
F I-GENE
. I-GENE
IX I-GENE
), O
and O
X O
( O
F I-GENE
. I-GENE
X I-GENE
), O
hemostasis O
proteins O
not O
associated O
with O
an O
acute O
- O
phase O
response O
, O
in O
a O
select O
population O
of O
horses O
with O
colic O
and O
hemostasis O
abnormalities O
, O
and O
presumed O
to O
have O
acute O
- O
phase O
changes O
. O

RESULTS O
: O
Horses O
with O
colic O
had O
significantly O
higher O
fibrinogen I-GENE
concentration O
, O
greater O
alpha I-GENE
2AP I-GENE
and O
protein I-GENE
C I-GENE
activities O
, O
and O
longer O
PT O
and O
APTT O
than O
did O
healthy O
horses O
. O

The O
data O
suggest O
that O
plasminogen I-GENE
, O
alpha I-GENE
2AP I-GENE
, O
and O
C1 I-GENE
- I-GENE
INH I-GENE
, O
should O
be O
considered O
equine O
acute O
- O
phase O
proteins O
. O

None O
of O
the O
patients O
was O
obese O
. O

Marked O
elevation O
of O
creatine I-GENE
kinase I-GENE
was O
observed O
while O
serum O
albumin I-GENE
, O
immunoglobulin I-GENE
, O
and O
complement O
were O
decreased O
. O

DESIGN O
AND O
METHODS O
: O
Case O
study O
. O

METHODS O
: O
A O
total O
of O
15 O
pigs O
were O
randomised O
to O
ligation O
of O
left O
marginal O
arteries O
( O
infarction O
group O
, O
n O
= O
5 O
), O
to O
TMLR O
of O
the O
left O
lateral O
wall O
using O
a O
holmium O
: O
yttrium O
- O
aluminium O
garnet O
( O
Ho O
: O
YAG O
) O
laser O
( O
laser O
group O
, O
n O
= O
5 O
), O
and O
to O
both O
( O
laser O
- O
infarction O
group O
, O
n O
= O
5 O
). O

RACK1 I-GENE
, O
a O
receptor O
for O
activated I-GENE
C I-GENE
kinase I-GENE
and O
a O
homolog O
of O
the O
beta O
subunit O
of O
G I-GENE
proteins I-GENE
, O
inhibits O
activity O
of O
src I-GENE
tyrosine I-GENE
kinases I-GENE
and O
growth O
of O
NIH O
3T3 O
cells O
. O

Peptide O
sequences O
of O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
Ttk I-GENE
and O
the O
transcription I-GENE
factor I-GENE
Adf I-GENE
- I-GENE
1 I-GENE
were O
obtained O
. O

The O
same O
IL I-GENE
- I-GENE
4 I-GENE
- O
inducible O
reporter O
gene O
is O
also O
synergistically O
activated O
by O
the O
endogenous I-GENE
Stat6 I-GENE
and O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
in O
IL I-GENE
- I-GENE
4 I-GENE
- O
stimulated O
I O
. O
29mu O
B O
lymphoma O
cells O
. O

HEF1 I-GENE
, O
p130 I-GENE
( O
Cas I-GENE
), O
and O
Efs I-GENE
/ O
Sin I-GENE
constitute O
a O
family O
of O
multidomain O
docking O
proteins O
that O
have O
been O
implicated O
in O
coordinating O
the O
regulation O
of O
cell O
adhesion O
. O

In O
support O
of O
a O
role O
at O
the O
spindle O
, O
two O
- O
hybrid O
library O
screening O
with O
HEF1 I-GENE
identifies O
the O
human O
homolog O
of O
the O
G2 I-GENE
/ I-GENE
M I-GENE
spindle I-GENE
- I-GENE
regulatory I-GENE
protein I-GENE
Dim1p I-GENE
as O
a O
specific O
interactor O
with O
a O
region O
of O
HEF1 I-GENE
encompassed O
in O
p55 I-GENE
( O
HEF1 I-GENE
). O

Our O
data O
showed O
that O
activation O
of O
the O
raf I-GENE
- O
ERK I-GENE
pathway O
led O
to O
activation O
of O
TF I-GENE
expression O
in O
breast O
carcinoma O
cells O
and O
suggested O
that O
constitutive O
activation O
of O
this O
pathway O
leads O
to O
high O
TF I-GENE
expression O
in O
MDA O
- O
MB O
- O
231 O
cells O
. O

However O
, O
a O
zinc O
- O
depleted O
enzyme O
was O
obtained O
after O
prolonged O
dialysis O
against O
the O
specific O
chelating O
agent O
1 O
, O
10 O
- O
phenanthroline O
. O

All O
patients O
diagnosed O
of O
H O
. O
influenza O
type O
b O
meningitis O
were O
less O
than O
3 O
years O
old O
. O

The O
lines O
also O
differed O
in O
postsynaptic O
, O
but O
not O
presynaptic O
, O
5 I-GENE
- I-GENE
HT1A I-GENE
receptors I-GENE
. O

Convulsive O
seizure O
during O
a O
treatment O
with O
interferon I-GENE
alpha I-GENE
for O
chronic O
viral O
hepatitis O
C O

Immunohistochemically O
, O
anticytokeratin I-GENE
19 I-GENE
antibody I-GENE
revealed O
strong O
staining O
in O
both O
epithelial O
and O
sarcomatous O
MPM O
tissues O
. O

Genetic O
studies O
in O
Drosophila O
have O
led O
to O
the O
identification O
of O
several O
components O
of O
the O
Notch I-GENE
pathway O
. O

The O
bZP2 O
cDNA O
( O
115 O
- O
1914 O
nt O
, O
1 O
. O
8 O
kb O
), O
excluding O
sequences O
coding O
for O
N O
- O
terminal O
signal O
sequence O
and O
C O
- O
terminal O
transmembranelike O
domain O
, O
was O
PCR O
amplified O
and O
Sac1 I-GENE
- O
Sal1 I-GENE
restricted O
fragment O
cloned O
in O
frame O
downstream O
of O
the O
T5 O
promoter O
under O
the O
lac I-GENE
operator I-GENE
control O
in O
a O
pQE O
- O
30 O
vector O
. O

Control O
subjects O
' O
evoked O
potentials O
( O
EPs O
) O
were O
characterized O
by O
an O
initial O
positivity O
in O
the O
90 O
- O
140 O
ms O
range O
( O
P1 O
) O
at O
the O
temporo O
- O
occipital O
site O
. O

Class I-GENE
I I-GENE
alpha1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
mannosidases I-GENE
play O
an O
essential O
role O
in O
the O
elaboration O
of O
complex O
and O
hybrid O
N O
- O
glycans O
in O
mammalian O
cells O
. O

Structural O
features O
of O
the O
minimal O
DNA O
binding O
domain O
( O
M98 O
- O
F219 O
) O
of O
human I-GENE
nucleotide I-GENE
excision I-GENE
repair I-GENE
protein I-GENE
XPA I-GENE
. O

Amongst O
other O
qualities O
, O
the O
book O
' O
s O
importance O
lies O
in O
the O
fact O
that O
it O
associates O
an O
elaborate O
theoretical O
construction O
with O
the O
empirical O
data O
, O
working O
within O
the O
possibilities O
provided O
by O
late O
19th O
- O
century O
moral O
statistics O
. O

The O
results O
point O
to O
the O
effectiveness O
of O
the O
educational O
intervention O
. O

The O
mechanistic O
implications O
of O
aromatic O
non O
- O
responsiveness O
of O
autonomously O
expressed O
A O
- O
domain O
, O
despite O
its O
demonstrated O
ability O
to O
bind O
phenol O
, O
are O
discussed O
. O

RESULTS O
: O
Acetabular O
index O
returned O
to O
normal O
gradually O
as O
the O
time O
went O
by O
and O
significantly O
within O
one O
year O
after O
the O
reduction O
of O
developmental O
dislocation O
of O
the O
hip O
. O

Recently O
, O
extremely O
high O
levels O
of O
endothelin I-GENE
- I-GENE
1 I-GENE
( O
ET I-GENE
- I-GENE
1 I-GENE
) O
were O
detected O
in O
the O
pericardial O
fluid O
of O
patients O
undergoing O
cardiac O
surgery O
. O

Consequently O
, O
it O
is O
not O
known O
how O
knee O
loading O
changes O
following O
ACL O
transection O
, O
and O
how O
it O
contributes O
to O
cartilage O
degeneration O
. O

We O
show O
that O
the O
surfaces O
of O
tracheal O
cartilage O
matrix O
are O
collagen I-GENE
- O
rich O
and O
surround O
a O
proteoglycan O
- O
rich O
core O
. O

Comparative O
mapping O
of O
the O
Brassica I-GENE
S I-GENE
locus I-GENE
region I-GENE
and O
its O
homeolog O
in O
Arabidopsis O
. O

Roles O
of O
the O
Candida I-GENE
albicans I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
homolog I-GENE
, O
Cek1p I-GENE
, O
in O
hyphal O
development O
and O
systemic O
candidiasis O
. O

Neither O
the O
reaction O
of O
monosaccharides O
nor O
the O
disaccharides O
with O
beta O
- O
alanine O
resulted O
in O
the O
formation O
of O
maltol O
. O

In O
most O
subjects O
, O
markers O
of O
bone O
formation O
and O
resorption O
were O
normal O
. O

Analysis O
of O
a O
Mac1p I-GENE
mutant I-GENE
, O
refractile O
for O
copper O
- O
dependent O
repression O
of O
the O
Cu I-GENE
( I-GENE
I I-GENE
) I-GENE
transport I-GENE
genes I-GENE
, O
showed O
an O
aberrant O
pattern O
of O
CUP1 I-GENE
expression O
and O
copper O
sensitivity O
. O

The O
DNA O
sequencing O
of O
the O
recombinant O
clones O
revealed O
the O
expression O
of O
RXR I-GENE
alpha I-GENE
and O
RXR I-GENE
beta I-GENE
. O

A O
stratified O
random O
sample O
of O
20 O
active O
employees O
from O
a O
cohort O
of O
phenoxy O
herbicide O
workers O
was O
selected O
in O
1995 O
for O
determining O
PCDD O
and O
PCDF O
congeners O
in O
blood O
lipids O
to O
assess O
the O
extent O
of O
past O
PCDD O
and O
PCDF O
exposure O
in O
this O
cohort O
and O
whether O
that O
exposure O
might O
explain O
site O
- O
specific O
cancer O
findings O
in O
the O
total O
cohort O
. O

The O
clinical O
and O
laboratory O
features O
of O
72 O
children O
with O
Henoch O
- O
Schonlein O
purpura O
( O
HSP O
) O
were O
examined O
to O
determine O
if O
there O
were O
associations O
between O
the O
laboratory O
indices O
-- O
including O
white O
blood O
cell O
( O
WBC O
) O
counts O
, O
serum I-GENE
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
( O
CRP I-GENE
) O
levels O
, O
platelet O
( O
PLT O
) O
counts O
-- O
and O
the O
clinical O
manifestations O
of O
acute O
HSP O
. O

We O
provide O
community O
metabolic O
data O
that O
indicate O
that O
large O
changes O
in O
CO2 O
concentration O
can O
occur O
in O
coral O
reef O
waters O
via O
biogeochemical O
processes O
not O
directly O
associated O
with O
photosynthesis O
, O
respiration O
, O
calcification O
, O
and O
CaCO3 O
dissolution O
. O

In O
contrast O
to O
other O
known O
retroviruses O
, O
the O
FV I-GENE
pol I-GENE
genes I-GENE
are O
expressed O
via O
spliced O
transcripts O
. O

Substitution O
of O
bulky O
hydrophobic O
residues O
with O
charged O
residues O
within O
PEP1 I-GENE
affects O
the O
fusion O
activity O
of O
the O
S I-GENE
protein I-GENE
without O
affecting O
processing O
and O
surface O
expression O
. O

Tributyltin O
and O
its O
breakdown O
products O
, O
mono O
- O
and O
di O
- O
butyltin O
, O
were O
determined O
in O
water O
birds O
collected O
from O
Lake O
Huron O
( O
the O
Great O
Lakes O
), O
marine O
coastal O
United O
States O
, O
and O
the O
west O
coast O
of O
British O
Columbia O
, O
Canada O
. O

The O
5 O
' O
flanking O
region O
of O
the O
CD1 I-GENE
gene I-GENE
contained O
the O
binding O
motifs O
for O
two O
cytokine O
- O
inducible O
transcription O
factors O
, O
NF I-GENE
- I-GENE
IL2 I-GENE
- I-GENE
A I-GENE
and O
NF I-GENE
- I-GENE
IL6 I-GENE
. O

Fregnac O
, O
M O
. O

GLRaV O
- O
2 O
is O
the O
only O
closterovirus O
, O
so O
far O
, O
that O
matches O
the O
genome O
organization O
of O
the O
type O
member O
of O
the O
group O
, O
BYV O
, O
and O
thus O
can O
be O
unambiguously O
classified O
as O
a O
definitive O
member O
of O
the O
genus O
Closterovirus O
. O

Demographic O
and O
clinical O
data O
were O
compared O
with O
a O
control O
group O
of O
339 O
healthy O
age O
- O
matched O
women O
and O
with O
a O
sample O
of O
224 O
women O
with O
wrist O
fracture O
. O

Combined O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
p65 I-GENE
induced O
vigorous O
transcription O
of O
IL I-GENE
- I-GENE
2 I-GENE
promoter O
- O
and O
CD28RE I-GENE
- I-GENE
driven I-GENE
reporter I-GENE
constructs I-GENE
in O
both O
LFA I-GENE
- I-GENE
3 I-GENE
- O
and O
B7 I-GENE
- I-GENE
1 I-GENE
- O
costimulated O
Jurkat O
cells O
. O

Identical O
results O
were O
obtained O
when O
transfections O
and O
mobility O
shift O
assays O
were O
performed O
in O
primary O
rat O
hepatocytes O
in O
which O
the O
endogenous O
ALS I-GENE
gene I-GENE
is O
expressed O
. O

This O
E O
box O
sequence O
( O
CACGTG O
) O
is O
identical O
to O
the O
binding O
element O
for O
USF I-GENE
( O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
), O
a O
member O
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
family I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
. O

Interferon I-GENE
beta I-GENE
therapy O
was O
discontinued O
for O
4 O
weeks O
. O

Liquid O
chromatographic O
method O
for O
analysis O
of O
all O
- O
rac O
- O
alpha O
- O
tocopheryl O
acetate O
and O
retinyl O
palmitate O
in O
milk O
- O
based O
infant O
formula O
using O
matrix O
solid O
- O
phase O
dispersion O
. O

We O
specially O
devised O
3 O
types O
of O
turbo O
pumps O
, O
a O
centrifugal O
pump O
( O
CFP O
), O
a O
mixed O
flow O
pump O
( O
MFP O
), O
and O
an O
axial O
flow O
pump O
( O
AFP O
), O
and O
analyzed O
their O
in O
vitro O
performance O
. O

Examination O
of O
the O
mitochondrial I-GENE
bc1 I-GENE
complex I-GENE
crystal I-GENE
structure I-GENE
[ O
Zhang O
, O
Z O
., O
Huang O
, O
L O
., O
Shulmeister O
, O
V O
. O

Two O
protease O
- O
resistant O
fragments O
spanning O
the O
N O
- O
and O
C O
- O
terminal O
halves O
of O
the O
nuclease O
were O
identified O
using O
different O
proteases O
which O
cleave O
the O
protein O
in O
the O
same O
region O
. O

The O
side O
- O
to O
- O
side O
difference O
was O
statistically O
significant O
at O
EXT O
30 O
degrees O
/ O
s O
and O
60 O
degrees O
/ O
s O
( O
p O
< O
0 O
. O
05 O
). O

CONCLUSION O
: O
In O
women O
who O
want O
or O
require O
conservative O
management O
of O
grade O
4 O
prolapse O
and O
are O
unable O
to O
retain O
a O
single O
pessary O
, O
the O
placement O
of O
two O
pessaries O
often O
will O
be O
successful O
. O

The O
ability O
to O
maintain O
expression O
of O
FAS1 I-GENE
in O
nmt1 I-GENE
- O
451Dino2 I-GENE
Delta O
cells O
suggests O
the O
existence O
of O
another O
transcription O
factor O
, O
or O
factors O
, O
whose O
expression O
/ O
activity O
is O
inversely O
related O
to O
overall O
levels O
of O
cellular O
protein O
N O
- O
myristoy O
- O
lation O
. O

Rev I-GENE
- O
erbAalpha I-GENE
/ I-GENE
beta I-GENE
), O
Mxi I-GENE
- I-GENE
1 I-GENE
and O
Mad I-GENE
bHLH O
- O
zip O
proteins O
and O
the O
oncoproteins O
PLZF I-GENE
and O
LAZ3 I-GENE
/ O
BCL6 I-GENE
is O
mediated O
by O
the O
corepressors O
N I-GENE
- I-GENE
CoR I-GENE
and O
SMRT I-GENE
. O

The O
identified O
isolates O
of O
CSF O
( O
20 O
of O
29 O
) O
were O
: O
ECHO O
30 O
( O
9 O
), O
ECHO O
11 O
( O
7 O
), O
ECHO O
9 O
( O
3 O
) O
and O
ECHO O
7 O
( O
1 O
). O

There O
was O
no O
evidence O
of O
any O
persistent O
oscillation O
within O
the O
ULF O
band O
. O

The O
ParaSight O
- O
F O
test O
alone O
was O
used O
to O
monitor O
serum O
antigen O
levels O
after O
treatment O
in O
24 O
patients O
. O

The O
purified O
recombinant O
protein O
was O
assayed O
for O
its O
enzyme O
activity O
by O
monitoring O
transfer O
of O
[ O
3H O
] O
methyl O
groups O
from O
the O
substrate O
DNA O
to O
the O
MGMT I-GENE
protein I-GENE
; O
the O
activity O
was O
found O
to O
be O
stable O
at O
90 O
degrees O
C O
for O
at O
least O
30 O
min O
. O

A O
deproteinization O
procedure O
was O
coupled O
with O
a O
reversed O
- O
phase O
HPLC O
separation O
using O
a O
250x4 O
. O
6 O
mm O
I O
. O
D O
. O

Elimination O
of O
the O
inducible O
response O
requires O
simultaneous O
mutation O
of O
both O
sequences O
, O
however O
, O
in O
the O
presence O
of O
an O
intact O
EpRE O
the O
upstream O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
irrelevant O
to O
induction O
. O

Three O
high I-GENE
mobility I-GENE
group I-GENE
- I-GENE
like I-GENE
sequences I-GENE
within O
a O
48 O
- O
base O
pair O
enhancer O
of O
the O
Col2a1 I-GENE
gene I-GENE
are O
required O
for O
cartilage O
- O
specific O
expression O
in O
vivo O
. O

The O
sequence O
contains O
an O
open O
reading O
frame O
of O
1744 O
nt O
in O
the O
virus O
- O
sense O
strand O
, O
a O
3 O
' O
untranslated O
region O
of O
1360 O
nt O
and O
a O
3 O
' O
poly O
( O
A O
) O
tail O
. O

A O
phylogenetic O
analysis O
of O
the O
reverse I-GENE
transcriptase I-GENE
domain I-GENE
confirms O
our O
differential O
genetic O
assessment O
that O
Cyclops I-GENE
from O
pea O
is O
a O
novel O
element O
with O
no O
specific O
relationship O
to O
the O
previously O
described O
Gypsy I-GENE
- I-GENE
like I-GENE
elements I-GENE
from O
plants O
. O

At O
physiological O
doses O
, O
either O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
or O
insulin I-GENE
turned O
out O
to O
be O
as O
potent O
as O
dibutyryl O
cAMP O
( O
dbcAMP O
) O
in O
increasing O
UCP1 I-GENE
gene I-GENE
transcription O
rate O
( O
1 O
h O
) O
and O
also O
UCP1 I-GENE
mRNA I-GENE
accumulation O
( O
3 O
h O
), O
their O
maximal O
effect O
( O
15 O
- O
fold O
increase O
) O
reached O
upon O
treatment O
for O
24 O
h O
. O

In O
addition O
, O
insulin I-GENE
induced O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activity O
, O
this O
effect O
being O
totally O
prevented O
in O
the O
presence O
of O
MEK I-GENE
- I-GENE
1 I-GENE
inhibitor O
. O

Essentially O
, O
2 O
'- O
O O
- O
methyl O
oligoribonucleotides O
( O
2 O
' O
OMeRNA O
) O
were O
delivered O
to O
the O
nuclei O
of O
primary O
mdx O
myoblasts O
in O
culture O
. O

A O
large O
deletion O
in O
the O
CTD I-GENE
- I-GENE
binding I-GENE
motif I-GENE
blocks O
down O
- O
regulation O
but O
does O
not O
affect O
the O
essential O
function O
of O
Nrd1 I-GENE
. O

Regulation O
of O
the O
human O
p21 I-GENE
/ O
WAF1 I-GENE
/ O
Cip1 I-GENE
promoter O
in O
hepatic O
cells O
by O
functional O
interactions O
between O
Sp1 I-GENE
and O
Smad I-GENE
family I-GENE
members I-GENE
. O

RESULTS O
: O
We O
isolated O
a O
C O
. O
elegans O
cDNA O
that O
encoded O
a O
protein O
which O
was O
similar O
to O
, O
but O
not O
exactly O
homologous O
with O
mammalian O
p120 I-GENE
Ras I-GENE
- O
GAP I-GENE
. O

The O
weak O
base O
ketoconazole O
showed O
complete O
dissolution O
from O
a O
tablet O
formulation O
in O
Simulated O
Gastric O
Fluid O
without O
pepsin I-GENE
( O
SGFsp O
) O
within O
30 O
minutes O
, O
70 O
% O
dissolution O
in O
2 O
hours O
under O
fed O
state O
simulated O
upper O
jejunal O
conditions O
but O
only O
6 O
% O
dissolution O
in O
2 O
hours O
under O
fasted O
state O
conditions O
. O

In O
mammals O
, O
the O
Rb I-GENE
protein I-GENE
interacts O
specifically O
with O
D I-GENE
- I-GENE
type I-GENE
cyclins I-GENE
and O
regulates O
cell O
proliferation O
by O
binding O
and O
inhibiting O
E2F I-GENE
transcription I-GENE
factors I-GENE
. O

In O
addition O
to O
the O
signals O
obtained O
by O
ligation O
of O
the O
TCR I-GENE
, O
T O
cells O
need O
additional O
, O
co O
- O
stimulatory O
signals O
to O
be O
activated O
. O

Moreover O
, O
the O
observation O
of O
enhanced O
luteal I-GENE
HSP I-GENE
- I-GENE
27 I-GENE
phosphorylation O
in O
vivo O
, O
in O
late O
pregnancy O
, O
when O
PKC I-GENE
- I-GENE
delta I-GENE
is O
abundant O
and O
active O
, O
suggests O
that O
select O
PKC I-GENE
family I-GENE
members I-GENE
contribute O
to O
sHSP I-GENE
phosphorylation O
events O
in O
vivo O
. O

We O
characterized O
the O
structure O
of O
this O
leader O
mRNA O
by O
using O
the O
program O
Mfold O
and O
a O
combination O
of O
nested O
and O
internal O
deletions O
transcriptionally O
fused O
to O
a O
promoterless O
lac I-GENE
operon I-GENE
. O

The O
importance O
of O
these O
sites O
for O
transcriptional O
activation O
was O
studied O
by O
site O
- O
directed O
mutagenesis O
followed O
by O
promoter O
function O
analysis O
of O
the O
mutants O
with O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
system O
. O

Routine O
blood O
examination O
showed O
leukocytosis O
, O
thrombocytopenia O
, O
positive O
CRP I-GENE
, O
and O
elevated O
myocardial O
enzymes O
. O

Previous O
studies O
have O
suggested O
that O
moderate O
cooling O
increases O
the O
responsiveness O
of O
vascular I-GENE
alpha2 I-GENE
- I-GENE
adrenoceptors I-GENE
. O

Two O
members O
of O
the O
Cbl I-GENE
family I-GENE
have O
since O
been O
defined O
in O
mammals O
( O
c I-GENE
- I-GENE
Cbl I-GENE
and O
Cbl I-GENE
- I-GENE
b I-GENE
), O
one O
in O
C O
. O
elegans O
( O
Sli I-GENE
- I-GENE
1 I-GENE
) O
and O
one O
in O
Drosophila O
( O
D I-GENE
- I-GENE
Cbl I-GENE
). O

Anti I-GENE
- I-GENE
PTB I-GENE
antibodies I-GENE
did O
not O
inhibit O
the O
binding O
of O
PTB I-GENE
to O
RNA O
because O
they O
were O
able O
to O
supershift O
RNA I-GENE
- I-GENE
PTB I-GENE
complexes I-GENE
. O

The O
use O
of O
antibodies O
to O
the O
polypyrimidine I-GENE
tract I-GENE
binding I-GENE
protein I-GENE
( O
PTB I-GENE
) O
to O
analyze O
the O
protein O
components O
that O
assemble O
on O
alternatively O
spliced O
pre O
- O
mRNAs O
that O
use O
distant O
branch O
points O
. O

The O
therapeutic O
use O
of O
botulinum I-GENE
toxin I-GENE
( O
Botox I-GENE
) O
is O
increasing O
in O
popularity O
. O

The O
viral I-GENE
oncoprotein I-GENE
E1A I-GENE
inhibits O
NFAT I-GENE
- O
dependent O
transactivation O
in O
a O
p300 I-GENE
- O
dependent O
manner O
. O

We O
have O
applied O
the O
mRNA O
differential O
display O
method O
to O
compare O
and O
analyze O
mRNAs O
prepared O
from O
five O
normal O
nasopharyngeal O
epithelial O
cell O
cultures O
and O
five O
nasopharyngeal O
carcinoma O
cell O
lines O
. O

Similar O
experiments O
with O
TR I-GENE
support O
the O
high O
affinity O
of O
RIP140 I-GENE
to O
the O
RXR I-GENE
subunit I-GENE
and O
also O
suggest O
that O
either O
partner O
in O
the O
TR I-GENE
/ O
RXR I-GENE
heterodimer O
can O
independently O
respond O
to O
ligand O
. O

SETTING O
: O
University O
hospital O
- O
based O
, O
tertiary O
care O
infertility O
center O
. O

RESULT O
( O
S O
): O
In O
patients O
with O
elevated O
FSH I-GENE
levels O
on O
cycle O
day O
3 O
, O
a O
low O
oocyte O
yield O
was O
achieved O
( O
7 O
versus O
11 O
) O
and O
a O
high O
number O
of O
ampules O
of O
hMG I-GENE
was O
necessary O
( O
56 O
versus O
33 O
). O

RESULTS O
: O
Of O
the O
patients O
with O
IS O
, O
67 O
% O
had O
significantly O
greater O
values O
of O
directional O
preponderance O
on O
the O
OVAR O
test O
( O
a O
measure O
of O
otolith O
system O
imbalance O
) O
compared O
with O
control O
subjects O
. O

In O
the O
ePTFE O
specimens O
, O
tissue O
coverage O
had O
increased O
. O

As O
predicted O
by O
the O
Wing O
and O
Kristofferson O
model O
, O
the O
durations O
of O
successive O
ISIs O
tended O
to O
be O
negatively O
correlated O
. O

Thus O
, O
included O
in O
the O
KG1a O
EST O
dataset O
are O
candidates O
for O
new O
human O
genes O
that O
may O
play O
roles O
in O
hematopoietic O
differentiative O
progression O
and O
lineage O
commitment O
. O

We O
found O
the O
following O
: O
Specific O
mutations O
affected O
the O
precise O
carbohydrate O
structure O
and O
folding O
of O
the O
HA I-GENE
trimer I-GENE
. O

The O
results O
show O
that O
ROS O
production O
by O
viable O
spermatozoa O
is O
highly O
correlated O
with O
the O
concentration O
of O
PMN I-GENE
elastase I-GENE
and O
the O
number O
of O
both O
peroxidase I-GENE
- O
positive O
and O
round O
cells O
. O

Yeast I-GENE
U1 I-GENE
snRNP I-GENE
is O
considerably O
more O
complex O
than O
its O
metazoan O
counterpart O
, O
which O
suggests O
possible O
differences O
between O
yeast O
and O
metazoa O
in O
early O
splicing O
events O
. O

Yeast I-GENE
U1 I-GENE
snRNP I-GENE
therefore O
contains O
16 O
different O
proteins O
, O
including O
seven O
snRNP I-GENE
core I-GENE
proteins I-GENE
, O
three O
homologues O
of O
the O
metazoan I-GENE
U1 I-GENE
snRNP I-GENE
- I-GENE
specific I-GENE
proteins I-GENE
, O
and O
six O
yeast I-GENE
- I-GENE
specific I-GENE
U1 I-GENE
snRNP I-GENE
proteins I-GENE
. O

After O
the O
first O
cycle O
, O
18 O
cases O
were O
treated O
at O
dose O
level O
1 O
, O
after O
a O
second O
cycle O
, O
13 O
cases O
were O
treated O
at O
dose O
level O
2 O
. O

The O
opioid O
antagonist O
naltrexone O
( O
0 O
. O
01 O
- O
1 O
. O
0 O
mg O
/ O
kg O
) O
antagonized O
the O
discriminative O
stimulus O
effects O
of O
heroin O
, O
but O
naltrexone O
at O
doses O
up O
to O
10 O
mg O
/ O
kg O
had O
no O
effect O
on O
the O
discriminative O
stimulus O
effects O
of O
cocaine O
. O

In O
this O
study O
we O
examined O
hepatic O
stellate O
cell O
regulation O
of O
M6P I-GENE
/ O
IGFIIR I-GENE
expression O
and O
found O
that O
M6P I-GENE
/ O
IGFIIR I-GENE
mRNA O
transcript O
levels O
increased O
in O
stellate O
cells O
from O
rats O
exposed O
to O
carbon O
tetrachloride O
( O
CCl4 O
), O
a O
potent O
fibrogenic O
stimulant O
. O

One O
cDNA O
clone O
designated O
NCoA O
- O
62 O
, O
encoded O
a O
62 O
, O
000 O
- O
Da O
protein O
that O
is O
highly O
related O
to O
BX42 I-GENE
, O
a O
Drosophila O
melanogaster O
nuclear O
protein O
involved O
in O
ecdysone O
- O
stimulated O
gene O
expression O
. O

These O
widely O
expressed O
proteins O
share O
a O
C O
- O
terminal O
region O
that O
bears O
significant O
sequence O
homology O
to O
a O
group O
of O
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
proteins I-GENE
for O
the O
Rab3 I-GENE
family I-GENE
of O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
. O

Whereas O
p82 I-GENE
expression O
had O
no O
effect O
on O
ERK2 I-GENE
activation O
by O
p126 I-GENE
, O
p70 I-GENE
completely O
abrogated O
this O
activity O
. O

The O
pre O
- O
mRNA O
splicing O
factor O
U2AF I-GENE
( O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
particle I-GENE
[ I-GENE
snRNP I-GENE
] I-GENE
auxiliary I-GENE
factor I-GENE
) O
plays O
a O
critical O
role O
in O
3 O
' O
splice O
site O
selection O
. O

The O
brackets O
were O
bonded O
to O
100 O
freshly O
extracted O
bovine O
incisors O
, O
and O
, O
after O
storage O
in O
tap O
water O
at O
room O
temperature O
for O
24 O
hours O
, O
they O
were O
subsequently O
tested O
in O
a O
shear O
mode O
using O
a O
universal O
testing O
machine O
. O

Exercise O
training O
has O
become O
increasingly O
important O
in O
the O
treatment O
of O
heart O
failure O
patients O
. O

The O
growth O
of O
Aer O
. O
hydrophila O
in O
filter O
- O
sterilized O
lettuce O
extract O
was O
completely O
inhibited O
by O
0 O
. O
1 O
% O
( O
v O
/ O
v O
) O
BMC O
whereas O
that O
of O
Ps O
. O
fluorescens O
was O
not O
significantly O
affected O
by O
1 O
% O
( O
v O
/ O
v O
) O
BMC O
. O

Despite O
continuous O
compliance O
, O
unexplained O
resurgence O
of O
serum O
ferritin I-GENE
levels O
occurred O
in O
4 O
/ O
7 O
patients O
of O
the O
' O
veteran O
' O
group O
after O
4 O
- O
5 O
years O
on O
L1 O
. O

Hematocrit O
and O
PaO2 O
did O
not O
change O
. O

Regulation O
of O
myosin I-GENE
phosphatase I-GENE
activity O
involves O
changes O
in O
subunit O
interactions O
, O
although O
molecular O
mechanisms O
are O
not O
defined O
. O

Commutative O
saccadic O
generator O
is O
sufficient O
to O
control O
a O
3 O
- O
D O
ocular O
plant O
with O
pulleys O
. O

The O
virus O
- O
associated O
VAI I-GENE
RNA O
of O
adenovirus O
is O
a O
small O
highly O
structured O
RNA O
that O
is O
required O
for O
the O
efficient O
translation O
of O
cellular O
and O
viral O
mRNAs O
at O
late O
times O
after O
infection O
. O

Structure O
of O
the O
gene O
encoding O
the O
human O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p18 I-GENE
and O
mutational O
analysis O
in O
breast O
cancer O
. O

The O
YccA I-GENE
protein I-GENE
was O
found O
to O
be O
degraded O
in O
an O
FtsH I-GENE
- O
dependent O
manner O
in O
vivo O
and O
in O
vitro O
, O
whereas O
the O
YccA11 I-GENE
mutant I-GENE
protein I-GENE
, O
lacking O
eight O
amino O
acid O
residues O
within O
the O
amino O
- O
terminal O
cytoplasmic O
domain O
, O
was O
refractory O
to O
the O
degradation O
. O

The O
major O
type O
involves O
activator O
proteins O
that O
bind O
to O
DNA O
adjacent O
to O
where O
the O
RNA I-GENE
polymerase I-GENE
( O
RNAP I-GENE
) O
holoenzyme O
binds O
, O
usually O
assisting O
in O
recruitment O
of O
the O
RNAP I-GENE
to O
the O
promoter O
. O

A O
conserved O
role O
for O
L1 I-GENE
as O
a O
transmembrane O
link O
between O
neuronal O
adhesion O
and O
membrane O
cytoskeleton O
assembly O
. O

Atmospheric O
benzene O
, O
urinary O
muconic O
acid O
( O
tt O
- O
MA O
) O
and O
leukocyte I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
( O
LAPA O
) O
were O
evaluated O
among O
66 O
car O
mechanics O
, O
34 O
road O
tanker O
drivers O
, O
and O
28 O
nonexposed O
workers O
. O

It O
contains O
a O
5 O
'- O
noncoding O
region O
( O
NCR O
) O
of O
73 O
nucleotides O
, O
five O
open O
reading O
frames O
( O
ORFs O
1 O
to O
5 O
) O
which O
encode O
proteins O
with O
M O
( O
r O
) O
160 O
kDa O
RNA O
- O
dependent O
RNA O
polymerase O
( O
ORF1 O
), O
26 O
kDa O
movement O
protein O
1 O
( O
ORF2 O
), O
13 O
kDa O
movement O
protein O
2 O
( O
ORF3 O
), O
10 O
kDa O
movement O
protein O
3 O
( O
ORF4 O
), O
24 O
kDa O
coat O
protein O
( O
OFR5 O
), O
and O
a O
3 O
' O
NCR O
of O
76 O
nucleotides O
. O

After O
profound O
normovolemic O
hemodilution O
( O
Hct O
9 O
%) O
superiority O
of O
LV O
MC O
and O
LV O
diastolic O
properties O
was O
found O
, O
when O
myocardial O
oxygenation O
was O
supported O
by O
i O
. O
v O
. O
perflubron O
emulsion O
, O
a O
temporary O
O2 O
carrier O
. O

Sp1 I-GENE
and O
two O
Sp3 I-GENE
isoforms I-GENE
were O
detected O
as O
the O
primary O
cellular O
constituents O
of O
DNA O
- O
protein O
complexes O
formed O
with O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
proximal I-GENE
site I-GENE
. O

These O
genes O
may O
represent O
interesting O
targets O
for O
new O
therapeutic O
strategies O
. O

It O
could O
also O
inhibit O
C1q I-GENE
- O
dependent O
haemolysis O
of O
both O
IgG I-GENE
- O
and O
IgM I-GENE
- O
sensitized O
erythrocytes O
. O

3 O
) O
and O
one O
distal O
(- O
11 O
. O
8 O
/- O
10 O
. O
9 O
), O
presented O
an O
enhancer O
activity O
in O
pituitary O
cells O
when O
placed O
upstream O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

The O
second O
patient O
had O
received O
pituitary I-GENE
- I-GENE
derived I-GENE
growth I-GENE
hormone I-GENE
for O
treatment O
of O
growth I-GENE
hormone I-GENE
deficiency O
, O
secondary O
to O
a O
third O
ventricle O
teratoma O
, O
exised O
13 O
yr O
earlier O
. O

3 O
-- O
It O
is O
necessary O
to O
think O
about O
cosmetic O
consequences O
of O
the O
chinese O
flap O
and O
consider O
other O
possibilities O
of O
the O
flap O
choice O
. O

CONCLUSION O
: O
TNF I-GENE
alpha I-GENE
, O
TGF I-GENE
beta I-GENE
, O
PDGF I-GENE
and O
IL I-GENE
- I-GENE
1beta I-GENE
increased O
LDLr I-GENE
gene I-GENE
expression O
by O
increasing O
sterol O
- O
independent O
and O
mitogenesis O
- O
independent O
gene O
transcription O
. O

Binding O
affinities O
of O
different O
nucleotide O
mono O
-, O
di O
- O
and O
triphosphates O
and O
non O
- O
hydrolyzable O
analogs O
indicate O
that O
the O
beta O
- O
phosphate O
moiety O
is O
required O
for O
substrate O
binding O
. O

However O
, O
it O
is O
only O
one O
- O
half O
and O
one O
- O
third O
the O
size O
of O
the O
proteolipids O
from O
M O
. O
thermoautotrophicum O
and O
M O
. O
jannaschii O
, O
respectively O
. O
ahaK I-GENE
is O
expressed O
in O
Escherichia O
coli O
, O
and O
it O
is O
incorporated O
into O
the O
cytoplasmic O
membrane O
despite O
the O
different O
chemical O
natures O
of O
lipids O
from O
archaea O
and O
bacteria O
. O

In O
this O
report O
we O
studied O
the O
role O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
in O
ErbB I-GENE
- O
mediated O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
by O
overexpressing O
SHP I-GENE
- I-GENE
2 I-GENE
mutants I-GENE
in O
COS O
- O
7 O
cells O
. O

Osteoadherin I-GENE
is O
a O
recently O
described O
bone O
proteoglycan O
containing O
keratan O
sulfate O
. O

Intron O
8 O
harbored O
a O
strong O
erythroid O
- O
specific O
enhancer O
activity O
which O
was O
orientation O
- O
dependent O
. O

The O
intron O
8 O
enhancer O
region O
was O
not O
activated O
by O
GATA I-GENE
- I-GENE
1 I-GENE
together O
with O
Sp1 I-GENE
in O
transactivation O
experiments O
in O
COS O
- O
1 O
cells O
indicating O
the O
involvement O
of O
a O
related O
Sp1 I-GENE
protein I-GENE
or O
of O
another O
unidentified O
erythroid O
factor O
. O

The O
cleavage O
of O
Fak I-GENE
by O
caspases I-GENE
may O
thus O
play O
an O
important O
role O
in O
the O
execution O
of O
the O
suicide O
program O
by O
disabling O
the O
anti O
- O
apoptotic O
function O
of O
Fak I-GENE
. O

Moreover O
, O
the O
mass O
estimated O
with O
the O
QCM O
response O
through O
the O
Sauerbrey O
equation O
and O
the O
mass O
which O
can O
be O
measured O
thanks O
to O
other O
analytical O
techniques O
, O
in O
our O
case O
an O
enzymatic O
assay O
, O
are O
different O
: O
the O
deposited O
mass O
is O
generally O
overestimated O
by O
the O
QCM O
. O

[ O
Treatment O
of O
early O
T1 O
small O
T2N O
breast O
cancers O
. O

Transcription O
initiation O
occurred O
predominantly O
at O
the O
putative O
sigmaA I-GENE
- I-GENE
dependent I-GENE
promoter I-GENE
in O
exponentially O
growing O
cells O
and O
was O
induced O
under O
stress O
conditions O
. O

The O
genes O
encoding O
( I-GENE
2Fe I-GENE
- I-GENE
2S I-GENE
) I-GENE
plant I-GENE
- I-GENE
like I-GENE
ferredoxins I-GENE
were O
studied O
in O
the O
widely O
used O
cyanobacterium O
Synechocystis O
PCC6803 O
. O

RNA O
of O
GBV O
- O
C O
was O
detected O
in O
14 O
( O
18 O
%) O
patients O
before O
BMT O
. O

A O
major O
pool O
of O
Dsg I-GENE
- O
plakoglobin I-GENE
complexes O
sedimented O
at O
8S O
and O
exhibited O
a O
1 O
: O
1 O
stoichiometry O
. O

Our O
results O
indicate O
that O
the O
binding O
of O
CBF I-GENE
/ O
NF I-GENE
- I-GENE
Y I-GENE
to O
the O
inverted O
CCAAT O
box O
is O
responsible O
for O
transcriptional O
activation O
of O
the O
nTPH I-GENE
gene I-GENE
. O

In O
macrophages O
, O
LPS O
- O
inducible O
HIV O
- O
1 O
gene O
expression O
is O
mediated O
in O
part O
by O
binding O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
to O
identical O
tandem O
binding O
sites O
located O
within O
the O
long O
terminal O
repeat O
( O
LTR O
). O

The O
influence O
of O
p53 I-GENE
on O
cytokine O
- O
triggered O
Janus I-GENE
kinase I-GENE
- O
STAT I-GENE
signaling O
was O
investigated O
in O
human O
hepatoma O
Hep3B O
cell O
lines O
engineered O
to O
constitutively O
express O
the O
temperature O
- O
sensitive O
Val135 I-GENE
mutant I-GENE
of I-GENE
p53 I-GENE
. O

It O
can O
also O
be O
used O
to O
examine O
various O
laryngeal O
parameters O
obtained O
from O
videotaped O
endoscopic O
and O
stroboscopic O
examinations O
. O

CONCLUSIONS O
: O
Two O
consecutive O
sets O
of O
transrectal O
ultrasound O
guided O
sextant O
biopsies O
of O
the O
prostate O
performed O
in O
a O
single O
office O
visit O
represent O
a O
cost O
- O
effective O
biopsy O
strategy O
for O
men O
presenting O
with O
an O
abnormal O
digital O
rectal O
examination O
and O
/ O
or O
elevated O
serum I-GENE
PSA I-GENE
. O

Examination O
of O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectra O
of O
a O
series O
of O
N I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
MIP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
variants I-GENE
reveals O
that O
these O
proteins O
possess O
a O
range O
of O
ability O
to O
dimerize O
. O

Interestingly O
, O
PKA I-GENE
activity O
is O
dispensable O
in O
a O
strain O
lacking O
Msn2p I-GENE
and O
Msn4p I-GENE
activity O
. O

They O
also O
indicate O
that O
direct O
interactions O
between O
C I-GENE
/ I-GENE
EBPs I-GENE
and O
specific O
Ets I-GENE
family O
members O
, O
together O
with O
GATA I-GENE
- I-GENE
1 I-GENE
, O
are O
important O
for O
eosinophil O
lineage O
determination O
. O

Recently O
, O
a O
human I-GENE
transcription I-GENE
elongation I-GENE
factor I-GENE
P I-GENE
- I-GENE
TEFb I-GENE
, O
consisting O
of O
CDK9 I-GENE
kinase I-GENE
, O
cyclin I-GENE
T I-GENE
and O
other O
associated O
factors O
, O
has O
been O
shown O
to O
interact O
with O
Tat I-GENE
to O
restore O
Tat I-GENE
activation O
in O
HeLa O
nuclear O
extract O
depleted O
of O
P I-GENE
- I-GENE
TEFb I-GENE
. O

We O
have O
used O
the O
hydrophobic O
repeats O
of O
the O
HSF1 I-GENE
trimerization I-GENE
domain I-GENE
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat I-GENE
shock I-GENE
factor I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
HSBP1 I-GENE
), O
a O
novel O
, O
conserved O
, O
76 O
- O
amino O
- O
acid O
protein O
that O
contains O
two O
extended O
arrays O
of O
hydrophobic O
repeats O
that O
interact O
with O
the O
HSF1 I-GENE
heptad I-GENE
repeats I-GENE
. O

Genomic O
and O
cDNA O
clones O
homologous O
to O
the O
yeast O
GCN2 I-GENE
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase O
( O
yGCN2 O
) O
were O
isolated O
from O
Drosophila O
melanogaster O
. O

The O
general O
recombination O
at O
a O
polarizing O
voltage O
of O
300 O
V O
is O
less O
than O
2 O
% O
for O
dose O
- O
rates O
up O
to O
about O
100 O
mGy O
min O
- O
1 O
. O

The O
low O
number O
of O
false O
positives O
indicates O
that O
our O
scheme O
would O
not O
confuse O
the O
radiologist O
by O
suggesting O
normal O
regions O
as O
suspicious O
. O

Strengthening O
the O
biological O
weapons O
convention O
and O
implications O
on O
the O
pharmaceutical O
and O
biotechnology O
industry O
. O

VirD2 I-GENE
is O
one O
of O
the O
key O
Agrobacterium O
tumefaciens O
proteins O
involved O
in O
T O
- O
DNA O
processing O
and O
transfer O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
VirD2 I-GENE
omega I-GENE
domain I-GENE
is O
important O
for O
efficient O
T O
- O
DNA O
integration O
. O

The O
DHEAS O
levels O
in O
all O
stages O
of O
decreased O
BMD O
were O
significantly O
lower O
than O
those O
in O
the O
group O
with O
normal O
BMD O
. O

Orientation O
of O
the O
nuclear O
spin O
system O
by O
optical O
pumping O
causes O
an O
Overhauser O
shift O
of O
the O
excitonic O
energy O
levels O
proportional O
to O
the O
degree O
of O
nuclear O
orientation O
. O

Cystatin I-GENE
A I-GENE
, O
a O
cysteine I-GENE
proteinase I-GENE
inhibitor O
, O
is O
one O
of O
the O
precursor O
proteins O
of O
cornified I-GENE
cell I-GENE
envelope I-GENE
of O
keratinocytes O
and O
is O
expressed O
during O
the O
late O
stage O
of O
keratinocyte O
differentiation O
. O

A O
role O
for O
RalGDS I-GENE
and O
a O
novel O
Ras I-GENE
effector O
in O
the O
Ras I-GENE
- O
mediated O
inhibition O
of O
skeletal O
myogenesis O
. O

GTPase I-GENE
activating O
specificity O
of O
RGS12 I-GENE
and O
binding O
specificity O
of O
an O
alternatively O
spliced O
PDZ I-GENE
( O
PSD I-GENE
- I-GENE
95 I-GENE
/ O
Dlg I-GENE
/ O
ZO I-GENE
- I-GENE
1 I-GENE
) O
domain O
. O

However O
, O
mutations O
in O
the O
HNF I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
on O
element I-GENE
CIIB I-GENE
and O
inhibition O
of O
HNF I-GENE
- I-GENE
4 I-GENE
synthesis O
in O
HepG2 O
cells O
by O
antisense O
HNF I-GENE
- I-GENE
4 I-GENE
constructs I-GENE
decreased O
the O
apoCII I-GENE
promoter I-GENE
activity O
to O
25 O
- O
40 O
% O
of O
the O
control O
, O
indicating O
that O
HNF I-GENE
- I-GENE
4 I-GENE
is O
a O
positive O
regulator O
of O
the O
apoCII I-GENE
gene I-GENE
. O

272 O
, O
19107 O
- O
19110 O
). O

In O
addition O
, O
we O
find O
that O
E2F I-GENE
- I-GENE
1 I-GENE
can O
cause O
apoptosis O
in O
p53 I-GENE
-/- I-GENE
tumour O
cells O
and O
further O
p300 I-GENE
, O
which O
also O
functions O
as O
a O
co O
- O
activator O
for O
the O
E2F I-GENE
/ O
DP I-GENE
heterodimer O
, O
enhances O
the O
apoptotic O
activity O
of O
E2F I-GENE
- I-GENE
1 I-GENE
. O

Blocked O
shift O
/ O
supershift O
analysis O
indicates O
that O
Fos I-GENE
family I-GENE
member O
proteins O
especially O
Fra I-GENE
- I-GENE
1 I-GENE
and O
Fra I-GENE
- I-GENE
2 I-GENE
are O
related O
to O
progression O
and O
no O
changes O
found O
in O
the O
Jun I-GENE
family I-GENE
member O
proteins O
although O
they O
are O
present O
in O
the O
AP I-GENE
- I-GENE
1 I-GENE
/ I-GENE
DNA I-GENE
binding I-GENE
complex I-GENE
. O

Initially O
, O
we O
observed O
that O
unmutated O
p53 I-GENE
is O
strongly O
expressed O
in O
premalignant O
mammary O
glands O
and O
in O
mammary O
tumors O
derived O
from O
the O
MMTV O
- O
c I-GENE
- I-GENE
myc I-GENE
strain O
. O

These O
data O
show O
that O
heterologous O
virus O
RNAs O
( O
BSMV O
) O
can O
serve O
as O
primer O
donors O
for O
MStV O
mRNA O
capped O
RNA O
- O
primed O
transcription O
in O
doubly O
infected O
plants O
. O

Human O
isoforms O
, O
designated O
1 O
to O
4 O
, O
differ O
from O
each O
other O
by O
the O
start O
codon O
used O
. O

Comparison O
of O
cDNA O
and O
genomic O
sequences O
shows O
that O
the O
ZNF189 I-GENE
gene I-GENE
spans O
approximately O
11 O
kb O
and O
is O
organized O
into O
at O
least O
four O
exons O
, O
the O
large O
3 O
'- O
end O
exon O
coding O
for O
the O
complete O
zinc O
finger O
domain O
and O
the O
3 O
' O
untranslated O
region O
. O

Malaria O
had O
diminished O
significantly O
by O
the O
early O
1940s O
, O
and O
this O
paper O
queries O
whether O
that O
reduction O
was O
due O
to O
the O
control O
projects O
of O
the O
thirties O
, O
and O
, O
if O
so O
, O
whether O
such O
projects O
should O
be O
a O
model O
for O
the O
current O
developing O
world O
, O
where O
malaria O
is O
a O
growing O
problem O
today O
. O

The O
gp330 I-GENE
/ O
Megalin I-GENE
/ O
LRP I-GENE
- I-GENE
2 I-GENE
protein O
belongs O
to O
the O
low I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
family I-GENE
and O
is O
believed O
to O
function O
as O
an O
endocytic O
receptor O
for O
the O
uptake O
of O
lipoproteins O
and O
many O
other O
ligands O
. O

In O
the O
DNA O
recognition O
helix O
of O
finger O
II O
, O
the O
conserved O
Arg O
at O
position O
62 O
( O
N O
- O
terminal O
side O
of O
the O
first O
zinc O
- O
coordinating O
histidine O
) O
was O
changed O
to O
a O
Leu O
or O
Gln O
. O

Dosage O
in O
both O
cases O
was O
0 O
. O
2 O
g O
/ O
m2 O
. O

Five O
additional O
copies O
of O
Lian I-GENE
elements I-GENE
were O
isolated O
, O
mapped O
by O
restriction O
digestion O
, O
and O
partially O
sequenced O
. O

Evolutionary O
relationships O
among O
putative O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerases I-GENE
encoded O
by O
a O
mitochondrial O
virus O
- O
like O
RNA O
in O
the O
Dutch O
elm O
disease O
fungus O
, O
Ophiostoma O
novo O
- O
ulmi O
, O
by O
other O
viruses O
and O
virus O
- O
like O
RNAs O
and O
by O
the O
Arabidopsis O
mitochondrial O
genome O
. O

Role O
of O
the O
transcription O
start O
site O
core O
region O
and O
transcription I-GENE
factor I-GENE
YY1 I-GENE
in O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
long I-GENE
terminal I-GENE
repeat I-GENE
promoter I-GENE
activity O
. O

Fowlpox O
virus O
encodes O
nonessential O
homologs O
of O
cellular I-GENE
alpha I-GENE
- I-GENE
SNAP I-GENE
, O
PC I-GENE
- I-GENE
1 I-GENE
, O
and O
an O
orphan O
human O
homolog O
of O
a O
secreted O
nematode O
protein O
. O

Addition O
of O
Rap O
or O
KN62 O
after O
exposure O
of O
cells O
to O
progesterone O
agonist O
Org O
2058 O
had O
no O
effect O
on O
induction O
of O
CAT I-GENE
activity O
. O

The O
Dax I-GENE
- I-GENE
1 I-GENE
gene I-GENE
encodes O
a O
protein O
that O
is O
structurally O
related O
to O
members O
of O
the O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

He O
was O
administered O
recombinant I-GENE
IFN I-GENE
alpha I-GENE
- I-GENE
2b I-GENE
under O
the O
diagnosis O
of O
chronic O
hepatitis O
C O
. O

Further O
, O
Ser O
/ O
Thr O
phosphorylation O
of O
downstream O
molecules O
Akt I-GENE
and O
p70 I-GENE
S6 I-GENE
kinase I-GENE
was O
inhibited O
. O

Quantitative O
evaluation O
of O
the O
steady O
state O
kinetics O
of O
MEK I-GENE
inhibition O
by O
these O
compounds O
reveals O
that O
U0126 O
has O
approximately O
100 O
- O
fold O
higher O
affinity O
for O
deltaN3 I-GENE
- I-GENE
S218E I-GENE
/ I-GENE
S222D I-GENE
MEK I-GENE
than O
does O
PD098059 O
. O

Regulation O
at O
37 O
degrees O
C O
, O
therefore O
, O
involves O
the O
action O
of O
three O
protein O
kinase O
cascades O
that O
repress O
HSF1 I-GENE
through O
phosphorylation O
of O
serine O
residues O
303 O
, O
307 O
, O
and O
363 O
and O
may O
promote O
growth O
by O
suppressing O
the O
heat O
shock O
response O
. O

Clinical O
implication O
of O
protein O
levels O
of O
IL I-GENE
- I-GENE
5 I-GENE
in O
induced O
sputum O
in O
asthmatic O
patients O
. O

In O
these O
cells O
, O
ras I-GENE
- O
induced O
transition O
is O
accompanied O
by O
a O
strong O
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
- O
binding O
activity O
along O
with O
increased O
expression O
of O
CD44 I-GENE
mRNA I-GENE
and O
protein O
. O

However O
, O
little O
is O
known O
regarding O
the O
genomic O
organization O
and O
developmental O
expression O
of O
the O
caveolin I-GENE
gene I-GENE
family I-GENE
. O

Tensile O
bond O
strengths O
between O
resin O
composite O
and O
bovine O
dentin O
using O
dentin O
adhesive O
systems O
( O
Clearfil O
Liner O
Bond O
II O
: O
LB O
II O
; O
Scotchbond O
Multi O
- O
Purpose O
: O
MP O
) O
bonding O
systems O
showed O
a O
large O
scatter O
among O
students O
and O
dentists O
. O

This O
distribution O
implies O
that O
the O
polycistronic O
precursor O
is O
imported O
into O
the O
nucleolus O
for O
processing O
to O
the O
mature O
snoRNAs O
, O
and O
that O
the O
import O
or O
processing O
pathway O
involves O
coiled O
bodies O
. O

Suppressive O
therapy O
for O
thyroid O
nodules O
. O

Fourteen O
healthy O
male O
volunteers O
completed O
the O
study O
. O

In O
the O
absence O
of O
Mg2 O
+, O
a O
hydrophobic O
exonuclease O
site O
dominates O
over O
the O
polymerase O
site O
for O
possession O
of O
the O
primer O
terminus O
. O

As O
the O
high O
- O
affinity O
Mg2 O
+ O
binding O
sites O
are O
filled O
, O
the O
primer O
terminus O
migrates O
from O
the O
exonuclease O
site O
to O
a O
highly O
based O
stacked O
polymerase O
active O
site O
. O

One O
missense O
allele O
( O
P236S O
) O
with O
complete O
loss O
of O
function O
at O
30 O
degreesC O
and O
four O
missense O
alleles O
( O
L173F O
, O
E225K O
, O
S269L O
and O
E274K O
) O
that O
conferred O
a O
temperature O
sensitive O
phenotype O
were O
identified O
. O

Structural O
analysis O
of O
the O
5 O
'- O
regulatory O
region O
reveals O
that O
the O
c I-GENE
- I-GENE
met I-GENE
promoter I-GENE
lacks O
TATA O
or O
CAAT O
elements O
but O
has O
an O
extremely O
high O
G O
- O
C O
content O
and O
multiple O
Sp1 I-GENE
binding I-GENE
sites I-GENE
. O

The O
report O
highlights O
the O
possible O
contribution O
of O
stress O
factors O
in O
the O
context O
of O
therapy O
resistant O
periodontal O
disease O
, O
and O
the O
results O
seem O
to O
be O
understandable O
within O
the O
context O
of O
a O
stress O
system O
disorder O
perspective O
. O

Acute O
pancreatitis O
is O
a O
rather O
common O
abdominal O
disorder O
. O

To O
better O
understand O
the O
role O
of O
Ets I-GENE
proteins I-GENE
in O
Ras I-GENE
transformation O
, O
we O
have O
now O
analyzed O
the O
effects O
of O
stably O
expressing O
a O
variety O
of O
Ets2 I-GENE
constructs I-GENE
in O
Ras I-GENE
- O
transformed O
NIH3T3 O
( O
DT O
) O
cells O
. O

Each O
binding O
site O
, O
however O
, O
was O
different O
in O
its O
preference O
for O
binding O
partners O
. O

We O
isolated O
the O
human I-GENE
FGF I-GENE
- I-GENE
BP I-GENE
promoter I-GENE
and O
determined O
by O
deletion O
analysis O
that O
TPA O
regulatory O
elements O
were O
all O
contained O
in O
the O
first O
118 O
base O
pairs O
upstream O
of O
the O
transcription O
start O
site O
. O

Manipulation O
of O
the O
checkpoint O
regulators O
involved O
in O
cell O
cycle O
arrest O
and O
apoptosis O
may O
thus O
provide O
a O
novel O
strategy O
to O
cancer O
therapy O
. O

Electrophoretic O
mobility O
shift O
assays O
demonstrated O
specific O
nuclear O
protein O
binding O
to O
- O
85 O
/- O
64 O
, O
and O
single O
point O
mutations O
suggested O
important O
binding O
nucleotides O
between O
- O
79 O
/- O
68 O
with O
five O
critical O
bases O
between O
- O
74 O
/- O
70 O
( O
5 O
'- O
CTCCT O
- O
3 O
'). O

The O
diagnostic O
accuracy O
of O
serum O
PE I-GENE
- I-GENE
1 I-GENE
was O
0 O
. O
80 O
, O
and O
that O
of O
amylase I-GENE
0 O
. O
97 O
. O

We O
demonstrate O
that O
Ddc1p I-GENE
interacts O
physically O
in O
vivo O
with O
Mec3p I-GENE
, O
and O
this O
interaction O
requires O
Rad17p I-GENE
. O

" O
Complex O
partial O
" O
seizures O
. O

B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
( O
BCR I-GENE
)- O
mediated O
formation O
of O
a O
SHP I-GENE
- I-GENE
2 I-GENE
- O
pp120 I-GENE
complex O
and O
its O
inhibition O
by O
Fc I-GENE
gamma I-GENE
RIIB1 I-GENE
- O
BCR I-GENE
coligation O
. O

Chem O
., O
270 O
: O
7117 O
- O
7124 O
, O
1995 O
; O
and O
MT O
Hartsough O
et O
al O
., O
J O
. O

Deleting O
SNF1 I-GENE
repressed O
meiosis O
at O
the O
same O
three O
steps O
that O
were O
inhibited O
by O
glucose O
, O
suggesting O
that O
glucose O
blocks O
meiosis O
by O
inhibiting O
Snf1 I-GENE
. O

Here O
we O
investigate O
the O
role O
of O
c I-GENE
- I-GENE
Cbl I-GENE
in O
development O
and O
homeostasis O
in O
mice O
by O
targeted O
disruption O
of O
the O
c I-GENE
- I-GENE
Cbl I-GENE
locus I-GENE
. O
c I-GENE
- I-GENE
Cbl I-GENE
- O
deficient O
mice O
were O
viable O
, O
fertile O
, O
and O
outwardly O
normal O
in O
appearance O
. O

One O
is O
to O
act O
within O
the O
visceral O
endoderm O
to O
promote O
proper O
streak O
morphogenesis O
. O

We O
propose O
that O
noi I-GENE
/ O
pax2 I-GENE
. I-GENE
1 I-GENE
participates O
in O
sequential O
signaling O
processes O
as O
a O
key O
integrator O
of O
midbrain O
- O
hindbrain O
boundary O
development O
. O

Ligand O
- O
independent O
activation O
of O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
is O
a O
necessary O
intermediate O
in O
lysophosphatidic O
, O
acid O
- O
stimulated O
mitogenic O
activity O
in O
L O
cells O
. O

METHODS O
: O
Fibrotic O
changes O
involving O
bone O
marrow O
were O
evaluated O
histologically O
semiquantitatively O
using O
reticulin I-GENE
fiber O
impregnation O
( O
method O
of O
Gomori O
). O

In O
canrenoate O
- O
treated O
rats O
, O
ANP I-GENE
infusion O
caused O
greater O
increases O
in O
sodium O
excretion O
( O
FENA O
from O
3 O
. O
05 O
+/- O
0 O
. O
71 O
to O
7 O
. O
21 O
+/- O
0 O
. O
45 O
%; O
P O
< O
0 O
. O
05 O
; O
n O
= O
8 O
) O
than O
saline O
infusion O
( O
FENA O
from O
4 O
. O
16 O
+/- O
1 O
. O
11 O
to O
5 O
. O
47 O
+/- O
0 O
. O
66 O
%; O
n O
= O
6 O
), O
despite O
the O
hypocapnia O
. O

We O
then O
studied O
four O
unrelated O
Japanese O
families O
with O
GSD O
- O
Ib O
, O
and O
found O
three O
novel O
mutations O
: O
a O
four O
- O
base O
deletion O
/ O
two O
- O
base O
insertion O
, O
a O
point O
mutation O
within O
a O
consensus O
splicing O
donor O
site O
, O
and O
a O
missense O
mutation O
( O
W118R O
). O

Removal O
of O
the O
carboxyl O
region O
severely O
reduced O
transcriptional O
activation O
. O

A O
" O
Level O
A O
" O
in O
vitro O
/ O
in O
vivo O
correlation O
was O
established O
for O
a O
sustained O
release O
theophylline O
( O
CAS O
58 O
- O
55 O
- O
9 O
) O
preparation O
( O
Bronchoretard O
) O
under O
investigation O
. O

METHOD O
: O
50 O
consecutive O
children O
aged O
from O
6 O
months O
to O
17 O
years O
were O
included O
into O
the O
study O
which O
comprised O
questionnaires O
of O
patient O
and O
family O
histories O
, O
serological O
screening O
tests O
for O
common O
inhalational O
allergens O
( O
CAP O
SX1 O
), O
and O
determination O
of O
total O
serum I-GENE
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
and O
of O
latex O
- O
specific O
serum I-GENE
IgE I-GENE
by O
solid O
- O
phase O
immunoassays O
. O

The O
PDE4A I-GENE
- I-GENE
subfamily I-GENE
- I-GENE
specific I-GENE
linker I-GENE
region I-GENE
LR1 O
, O
which O
joins O
UCR1 O
and O
UCR2 O
, O
is O
encoded O
by O
two O
exons O
, O
whereas O
LR2 O
, O
which O
joins O
UCR2 O
to O
the O
catalytic O
unit O
, O
is O
encoded O
by O
a O
single O
exon O
. O

Pol32Delta I-GENE
strains O
are O
weak O
antimutators O
and O
are O
defective O
for O
damage O
- O
induced O
mutagenesis O
. O

At O
the O
same O
time O
, O
the O
results O
indicate O
that O
p53 I-GENE
plays O
a O
defensive O
role O
against O
HBV O
by O
transcriptionally O
repressing O
the O
HBV I-GENE
core I-GENE
promoter I-GENE
through O
liver I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
II I-GENE
and O
HBx I-GENE
is O
required O
to O
counteract O
this O
inhibitory O
function O
of O
p53 I-GENE
. O

To O
gain O
insight O
into O
the O
expression O
of O
the O
AtCP1 I-GENE
gene I-GENE
, O
northern O
blot O
analysis O
was O
carried O
out O
. O

The O
aim O
of O
the O
study O
was O
to O
correlate O
the O
responsiveness O
to O
bronchoprovocation O
with O
methacholine O
in O
subjects O
a O
with O
allergic O
rhinitis O
during O
and O
out O
of O
the O
pollen O
season O
with O
total O
serum O
IgE I-GENE
and O
blood O
eosinophils O
. O

These O
results O
provide O
the O
first O
demonstration O
that O
an O
SR I-GENE
protein I-GENE
can O
influence O
splicing O
of O
specific O
pre O
- O
mRNAs O
in O
vivo O
. O

In O
particular O
, O
the O
potential O
for O
prostate O
cancer O
chemoprevention O
using O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
cyclo I-GENE
- I-GENE
oxygenase I-GENE
inhibitors O
; O
NSAIDs O
) O
has O
received O
little O
attention O
. O

This O
study O
reports O
the O
isolation O
of O
a O
P O
. O
hybrida O
gene O
, O
jaf13 I-GENE
, O
encoding O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
that O
, O
on O
the O
basis O
of O
sequence O
homology O
and O
intron O
/ O
exon O
structure O
, O
represents O
the O
P O
. O
hybrida O
orthologue O
of O
the O
Z I-GENE
. I-GENE
mays I-GENE
r I-GENE
genes I-GENE
. O

Identical O
c I-GENE
- I-GENE
erbB3 I-GENE
transcripts I-GENE
are O
expressed O
in O
normal O
human O
placental O
tissues O
. O

During O
the O
past O
4 O
years O
, O
a O
purposeful O
search O
was O
made O
for O
electrocardiograms O
with O
documented O
reversible O
QRS O
changes O
associated O
with O
all O
acute O
injury O
pattern O
. O

Mutating O
a O
potential O
cleavage O
site O
located O
N O
- O
terminal O
to O
the O
protease O
domain O
, O
Gln2526 O
- O
Asp2527 O
, O
diminished O
processing O
. O

METHODS O
: O
Millipore O
ultrafiltration O
membranes O
of O
three O
different O
pore O
sizes O
were O
used O
as O
model O
lenticule O
materials O
. O
The O
nominal O
membrane O
pore O
sizes O
were O
0 O
. O
1 O
microm O
, O
0 O
. O
45 O
microm O
, O
and O
3 O
microm O
; O
the O
surface O
roughness O
increased O
in O
the O
same O
order O
The O
membranes O
were O
coated O
with O
a O
thin O
layer O
of O
collagen I-GENE
I I-GENE
and O
implanted O
in O
a O
circular O
pocket O
of O
the O
anterior O
cornea O
of O
adult O
cats O
, O
and O
were O
clinically O
evaluated O
for O
the O
extent O
of O
epithelialization O
and O
the O
persistence O
of O
epithelial O
attachment O
. O

The O
role O
of O
calcitonin I-GENE
, O
and O
other O
agonists O
which O
activate O
the O
cAMP O
pathway O
, O
in O
regulating O
transcription O
of O
the O
human I-GENE
parathyroid I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
PTHrP I-GENE
) O
gene O
was O
investigated O
in O
a O
human O
lung O
cancer O
cell O
line O
( O
BEN O
). O

The O
combination O
of O
Pitx2 I-GENE
and O
another O
homeodomain I-GENE
protein I-GENE
, O
Pit I-GENE
- I-GENE
1 I-GENE
, O
yielded O
a O
synergistic O
55 O
- O
fold O
activation O
of O
the O
prolactin I-GENE
promoter I-GENE
in O
transfection O
assays O
. O

The O
biochemical O
and O
molecular O
spectrum O
of O
ornithine I-GENE
transcarbamylase I-GENE
deficiency O
. O

To O
further O
understand O
the O
role O
of O
cis O
- O
acting O
elements O
in O
these O
regulatory O
mechanisms O
, O
we O
have O
characterized O
a O
transcriptional O
promoter O
that O
drives O
germline O
expression O
of O
TCR I-GENE
beta I-GENE
gene I-GENE
segments I-GENE
in O
vivo O
. O

Our O
results O
suggest O
that O
the O
crucial O
role O
of O
the O
mutations O
activating O
v I-GENE
- I-GENE
erbA I-GENE
as O
an O
oncogene O
is O
to O
' O
freeze O
' O
c I-GENE
- I-GENE
ErbA I-GENE
/ O
TRalpha I-GENE
in O
its O
non O
- O
liganded O
, O
repressive O
conformation O
and O
to O
facilitate O
its O
overexpression O
. O

Downregulation O
of O
FUS I-GENE
expression O
in O
BCR I-GENE
/ O
ABL I-GENE
- O
expressing O
32Dcl3 O
cells O
was O
associated O
with O
suppression O
of O
growth O
factor O
- O
independent O
colony O
formation O
, O
restoration O
of O
G I-GENE
- I-GENE
CSF I-GENE
- O
induced O
granulocytic O
differentiation O
and O
reduced O
tumorigenic O
potential O
in O
vivo O
. O

In O
this O
study O
, O
we O
describe O
a O
mammalian O
cell O
- O
free O
transcription O
system O
reconstituted O
with O
only O
recombinant O
proteins O
and O
epitope O
- O
tagged O
multiprotein O
complexes O
. O

This O
repressor O
is O
however O
unlikely O
to O
mediate O
spi I-GENE
2 I-GENE
. I-GENE
3 I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
silencer I-GENE
action O
since O
it O
was O
not O
detected O
in O
rat O
hepatocytes O
. O

A O
prerequisite O
for O
the O
synthesis O
of O
sialylated O
glycoconjugates O
is O
the O
activated O
sugar O
- O
nucleotide O
cytidine O
5 O
'- O
monophosphate O
N O
- O
acetylneuraminic O
acid O
( O
CMP O
- O
Neu5Ac O
), O
which O
provides O
a O
substrate O
for O
Golgi I-GENE
sialyltransferases I-GENE
. O

Thus O
, O
the O
bovine I-GENE
PEDF I-GENE
cDNA I-GENE
isolated O
here O
codes O
for O
a O
functional O
soluble O
secreted I-GENE
PEDF I-GENE
glycoprotein I-GENE
. O

We O
propose O
a O
model O
in O
which O
Sro7 I-GENE
function O
is O
involved O
in O
the O
targeting O
of O
the O
myosin I-GENE
proteins I-GENE
to O
their O
intrinsic O
pathways O
. O

We O
found O
sequences O
related O
to O
this O
insertion O
in O
wild O
- O
type O
strains O
of O
N O
. O
crassa O
and O
other O
Neurospora O
species O
. O

When O
cysteine O
is O
scanned O
through O
the O
helices O
, O
characteristic O
repeating O
patterns O
of O
solvent O
exposure O
and O
burial O
are O
observed O
. O

Human I-GENE
ULK1 I-GENE
, O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
related O
to O
UNC I-GENE
- I-GENE
51 I-GENE
kinase I-GENE
of O
Caenorhabditis O
elegans O
: O
cDNA O
cloning O
, O
expression O
, O
and O
chromosomal O
assignment O
. O

Specifically O
, O
I O
use O
molecular O
markers O
that O
identify O
particular O
neuroectodermal O
domains O
, O
all O
neuroblasts O
or O
individual O
neuroblasts O
, O
to O
show O
that O
in O
DER I-GENE
mutant I-GENE
embryos O
( O
1 O
) O
intermediate O
column O
neuroblasts O
do O
not O
form O
, O
( O
2 O
) O
medial O
column O
neuroblasts O
often O
acquire O
identities O
inappropriate O
for O
their O
position O
, O
while O
( O
3 O
) O
lateral O
neuroblasts O
develop O
normally O
. O

Cochlear O
microphonic O
potentials O
in O
patients O
with O
vestibular O
schwannomas O
. O

These O
results O
with O
clozapine O
illustrate O
that O
LI O
is O
sensitive O
to O
antipsychotics O
which O
differ O
in O
their O
mode O
of O
action O
and O
furthermore O
emphasize O
the O
value O
of O
LI O
as O
a O
test O
model O
for O
detecting O
the O
antipsychotic O
potential O
of O
novel O
drugs O
. O

The O
complement I-GENE
C3a I-GENE
anaphylatoxin I-GENE
receptor I-GENE
( O
C3aR I-GENE
) O
is O
a O
seven I-GENE
- I-GENE
transmembrane I-GENE
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
chemoattractant I-GENE
receptor I-GENE
that O
on O
binding O
the O
C3a I-GENE
peptide I-GENE
ligand I-GENE
mediates O
numerous O
cellular O
responses O
, O
including O
histamine O
release O
from O
mast O
cells O
. O
smooth O
muscle O
contraction O
, O
and O
the O
directed O
migration O
of O
eosinophils O
. O

CONCLUSIONS O
: O
Significant O
elevations O
of O
IL I-GENE
- I-GENE
1alpha I-GENE
and O
IL I-GENE
- I-GENE
1beta I-GENE
occur O
in O
patients O
with O
bacterial O
cystitis O
and O
microscopic O
hematuria O
. O

Band O
- O
shift O
assays O
were O
performed O
using O
the O
LPS I-GENE
- I-GENE
and I-GENE
IL I-GENE
- I-GENE
1 I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
LILRE I-GENE
) O
oligonucleotide O
, O
a O
gamma I-GENE
interferon I-GENE
activation I-GENE
site I-GENE
- I-GENE
like I-GENE
site I-GENE
that O
is O
present O
in O
the O
human I-GENE
IL I-GENE
- I-GENE
1beta I-GENE
promoter I-GENE
. O

The O
C O
- O
terminal O
region O
contains O
the O
PTP I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
whereas O
the O
N O
- O
terminal O
region O
shows O
no O
homology O
to O
any O
known O
mammalian O
protein O
. O

In O
addition O
, O
and O
in O
support O
of O
a O
mediating O
role O
of O
STATs I-GENE
in O
the O
activation O
of O
the O
p21 I-GENE
promoter I-GENE
, O
overexpression O
of O
Stat3 I-GENE
potentiated O
the O
cytokine O
effect O
on O
the O
p21 I-GENE
promoter I-GENE
; O
whereas O
a O
dominant I-GENE
negative I-GENE
Stat3 I-GENE
, O
or O
a O
mutation O
of O
the O
STAT I-GENE
response I-GENE
element I-GENE
on O
the O
promoter O
, O
significantly O
reduced O
the O
cytokine O
effect O
. O

The O
heterogeneous O
nuclear I-GENE
ribonucleoprotein I-GENE
C I-GENE
protein I-GENE
tetramer I-GENE
binds O
U1 I-GENE
, O
U2 I-GENE
, O
and O
U6 I-GENE
snRNAs I-GENE
through O
its O
high O
affinity O
RNA O
binding O
domain O
( O
the O
bZIP O
- O
like O
motif O
). O

On O
the O
comparison O
of O
correlated O
proportions O
for O
clustered O
data O
. O

A O
safe O
and O
simple O
system O
for O
the O
detection O
of O
sudden O
infant O
death O
syndrome O
( O
SIDS O
) O
is O
proposed O
. O

The O
resulting O
mutants O
were O
coexpressed O
with O
gE I-GENE
in O
the O
vaccinia O
virus O
- O
based O
vTF7 O
- O
3 O
system O
, O
and O
the O
formation O
and O
endoplasmic O
reticulum O
( O
ER O
)- O
to O
- O
Golgi O
transport O
of O
the O
hetero O
- O
oligomeric O
complex O
were O
monitored O
. O

Homozygous O
mutant O
mice O
, O
designated O
Cux I-GENE
/ O
CDPDeltaCR1 I-GENE
, O
display O
a O
phenotype O
characterized O
by O
curly O
vibrissae O
and O
wavy O
hair O
. O

The O
mutant O
protein O
is O
present O
at O
levels O
slightly O
greater O
than O
wild O
- O
type O
, O
but O
exhibits O
the O
same O
tissue O
distribution O
as O
wild O
- O
type O
protein O
, O
and O
has O
approximately O
normal O
affinity O
for O
known O
target O
sequences O
( O
though O
no O
DNA O
targets O
identified O
to O
date O
require O
the O
first O
cut O
repeat O
for O
binding O
). O

METHODS O
: O
We O
retrospectively O
reviewed O
242 O
adult O
cadaveric O
renal O
transplant O
recipients O
treated O
between O
11 O
/ O
91 O
and O
5 O
/ O
97 O
. O

The O
spectrum O
of O
age O
- O
associated O
brain O
abnormalities O
: O
their O
measurement O
and O
histopathological O
correlates O
. O

Our O
laboratory O
has O
recently O
identified O
two O
phosducin I-GENE
- I-GENE
like I-GENE
orphan I-GENE
proteins I-GENE
( O
PhLOP1 I-GENE
and O
PhLOP2 I-GENE
) O
that O
lack O
the O
ability O
to O
interact O
with O
Gbetagamma I-GENE
. O

Reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
( O
RT I-GENE
- O
PCR O
) O
was O
performed O
using O
eyestalk O
complementary O
DNA O
of O
the O
sand O
shrimp O
Metapenaeus O
ensis O
. O

In O
contrast O
, O
transcription O
initiating O
from O
opuE I-GENE
P I-GENE
- I-GENE
1 I-GENE
( O
sigma I-GENE
A I-GENE
) O
rose O
in O
proportion O
to O
the O
external O
osmolarity O
and O
was O
maintained O
at O
high O
levels O
. O

Randomly O
selected O
300 O
children O
aged O
3 O
months O
- O
3 O
yr O
were O
analysed O
over O
a O
period O
of O
one O
year O
for O
estimating O
prevalence O
of O
nutritional O
anaemia O
. O

In O
insects O
, O
arylalkylamine I-GENE
N I-GENE
- I-GENE
acetyltransferases I-GENE
( O
AANATs I-GENE
) O
have O
been O
implicated O
in O
several O
physiological O
processes O
, O
including O
sclerotization O
, O
inactivation O
of O
certain O
neurotransmitters O
, O
and O
, O
similar O
to O
the O
function O
in O
vertebrates O
, O
catalysis O
of O
the O
rate O
- O
limiting O
step O
in O
melatonin O
biosynthesis O
. O

In O
experiments O
with O
the O
D1 O
antagonist O
SCH O
23390 O
, O
buprenorphine O
- O
induced O
depression O
was O
consistently O
blocked O
, O
but O
facilitation O
was O
unaffected O
. O

These O
results O
establish O
that O
hydroquinones O
lead O
to O
mutagenicity O
and O
carcinogenicity O
. O

IA O
- O
CT O
with O
cisplatin O
50 O
mg O
and O
doxorubicin O
30 O
mg O
was O
administered O
by O
one O
shot O
method O
in O
bilateral O
internal O
iliac O
arteries O
. O

Arnt3 I-GENE
mRNA I-GENE
was O
expressed O
in O
brain O
, O
skeletal O
muscle O
, O
13 O
. O
5 O
- O
day O
embryos O
, O
and O
P19 O
cells O
treated O
with O
retinoic O
acid O
. O

Acute O
idiopathic O
thrombocytopenic O
purpura O
presenting O
a O
high O
serum O
level O
of O
immunoglobulin I-GENE
E I-GENE
and O
eosinophilia O
in O
an O
elderly O
patient O
. O

The O
genomic O
structure O
and O
chromosomal O
location O
of O
the O
human I-GENE
TR2 I-GENE
orphan I-GENE
receptor I-GENE
, O
a O
member O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

Correlation O
of O
skin O
disorders O
with O
CD4 I-GENE
lymphocyte O
counts O
in O
patients O
with O
HIV O
/ O
AIDS O
. O

E2F I-GENE
- I-GENE
6 I-GENE
shares O
significant O
homology O
with O
E2Fs I-GENE
1 I-GENE
- I-GENE
5 I-GENE
, O
especially O
within O
the O
DNA O
binding O
, O
heterodimerization O
and O
marked O
box O
domains O
. O

The O
IE13 O
. O
1 O
cell O
line O
was O
able O
to O
complement O
a O
recombinant O
virus O
in O
which O
both O
copies O
of O
the O
IE I-GENE
gene I-GENE
were O
replaced O
by O
insertion O
of O
the O
Escherichia I-GENE
coli I-GENE
lacZ I-GENE
gene I-GENE
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility O
shift O
analyses O
revealed O
two O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HNF1 I-GENE
), O
three O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
), O
and O
one O
consensus O
palindromic O
thyroid O
hormone O
response O
elements O
within O
the O
first O
215 O
base O
pairs O
( O
bp O
) O
of O
the O
promoter O
sequence O
of O
rat I-GENE
Std I-GENE
. O

Thus O
, O
these O
studies O
on O
rat I-GENE
Std I-GENE
promoter I-GENE
function O
indicate O
that O
( O
i O
) O
HNF1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
are O
responsible O
for O
liver O
specificity O
of O
the O
rat I-GENE
Std I-GENE
gene I-GENE
; O
( O
ii O
) O
androgenic O
repression O
of O
the O
gene O
requires O
the O
presence O
of O
all O
of O
the O
OCT I-GENE
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
elements I-GENE
between O
positions O
- O
231 O
and O
- O
292 O
; O
and O
( O
iii O
) O
AR I-GENE
may O
exert O
its O
negative O
regulatory O
effect O
indirectly O
through O
transcriptional O
interference O
of O
OCT I-GENE
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
rather O
than O
through O
a O
direct O
DNA I-GENE
- I-GENE
AR I-GENE
interaction O
. O

Purified O
Hsk1 I-GENE
phosphorylates O
the O
Cdc19 I-GENE
( O
Mcm2 I-GENE
) O
subunit O
of O
the O
six I-GENE
- I-GENE
member I-GENE
minichromosome I-GENE
maintenance I-GENE
protein I-GENE
complex I-GENE
purified O
from O
fission O
yeast O
. O

The O
yeast I-GENE
MMS2 I-GENE
gene I-GENE
was O
cloned O
by O
its O
ability O
to O
complement O
the O
methyl O
methanesulfonate O
sensitivity O
of O
the O
mms2 I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
and O
was O
later O
shown O
to O
be O
involved O
in O
DNA O
post O
- O
replication O
repair O
. O

Expression O
of O
the O
human I-GENE
papillomavirus I-GENE
type I-GENE
11 I-GENE
E5A I-GENE
protein I-GENE
from O
the O
E1E4 I-GENE
, I-GENE
E5 I-GENE
transcript I-GENE
. O

Anesthesia O
with O
M O
/ O
K O
was O
reversed O
after O
41 O
. O
6 O
min O
of O
immobilization O
with O
atipamezole O
. O

There O
was O
no O
evident O
inciting O
agent O
of O
the O
disease O
. O

MK O
- O
801 O
administration O
resulted O
in O
a O
biphasic O
response O
in O
seizure O
latency O
. O

In O
contrast O
, O
the O
distribution O
of O
endocytic O
markers O
is O
not O
affected O
. O

Toxicity O
during O
the O
therapeutic O
period O
was O
not O
significant O
in O
the O
study O
group O
compared O
with O
the O
historical O
control O
, O
treated O
with O
the O
same O
regimen O
without O
G I-GENE
- I-GENE
CSF I-GENE
. O

The O
purpose O
of O
this O
article O
is O
to O
discuss O
the O
factors O
involved O
in O
the O
selection O
of O
antibodies O
, O
radionuclides O
and O
labeling O
methods O
in O
the O
development O
of O
radioimmunotherapy O
( O
RIT O
) O
for O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
NHL O
) O
from O
a O
single O
clinical O
study O
site O
through O
multicenter O
trials O
and O
commercialization O
. O

Both O
methods O
were O
employed O
for O
various O
focal O
- O
film O
distances O
, O
image O
intensifier O
tube O
modes O
and O
laser O
printer O
formats O
. O

The O
effect O
of O
Rho I-GENE
on O
AP I-GENE
- I-GENE
1 I-GENE
is O
independent O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
, O
as O
a O
dominant I-GENE
- I-GENE
negative I-GENE
MEK I-GENE
and O
a O
MEK I-GENE
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho I-GENE
- O
induced O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

Site O
- O
directed O
mutagenesis O
of O
residues O
in O
this O
domain O
( O
R82A O
, O
K85A O
, O
K88A O
, O
and O
V89A O
) O
resulted O
in O
proteins O
which O
failed O
to O
transactivate O
from O
the O
HTLV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
in O
vivo O
. O

Mutations O
within O
the O
C O
terminus O
of O
c I-GENE
- I-GENE
fos I-GENE
at O
serine O
residues O
that O
are O
phosphorylation O
targets O
for O
growth O
factors O
and O
MAP I-GENE
kinase I-GENE
completely O
abrogate O
transactivation O
and O
block O
potentiation O
by O
MAP I-GENE
kinase I-GENE
. O

In O
the O
former O
cells O
, O
ets I-GENE
- I-GENE
2 I-GENE
was O
a O
CSF I-GENE
- I-GENE
1 I-GENE
immediate O
- O
early O
response O
gene O
, O
and O
phosphorylated O
ets I-GENE
- I-GENE
2 I-GENE
was O
detected O
after O
2 O
to O
4 O
h O
, O
coincident O
with O
expression O
of O
ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
. O

Persistent O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
p42 I-GENE
and O
p44 I-GENE
and O
ets I-GENE
- I-GENE
2 I-GENE
phosphorylation O
in O
response O
to O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
/ O
c I-GENE
- I-GENE
fms I-GENE
signaling O
. O

Identification O
of O
a O
proline O
- O
rich O
sequence O
in O
the O
CD2 I-GENE
cytoplasmic I-GENE
domain I-GENE
critical O
for O
regulation O
of O
integrin I-GENE
- O
mediated O
adhesion O
and O
activation O
of O
phosphoinositide I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Vam7p I-GENE
, O
a O
SNAP I-GENE
- I-GENE
25 I-GENE
- I-GENE
like I-GENE
molecule I-GENE
, O
and O
Vam3p I-GENE
, O
a O
syntaxin I-GENE
homolog I-GENE
, O
function O
together O
in O
yeast O
vacuolar O
protein O
trafficking O
. O

We O
have O
tested O
this O
possibility O
by O
constructing O
a O
consecutive O
series O
of O
cysteine O
substitutions O
in O
the O
Neu I-GENE
juxtamembrane I-GENE
domain I-GENE
in O
order O
to O
force O
dimerization O
along O
a O
series O
of O
interreceptor O
faces O
. O

It O
has O
been O
demonstrated O
previously O
that O
Pax I-GENE
- I-GENE
6 I-GENE
, O
a O
paired I-GENE
domain I-GENE
( O
PD I-GENE
)/ O
homeodomain I-GENE
( O
HD I-GENE
) O
transcription O
factor O
critical O
for O
eye O
development O
, O
contributes O
to O
the O
activation O
of O
the O
alphaB I-GENE
-, I-GENE
alphaA I-GENE
-, I-GENE
delta1 I-GENE
-, I-GENE
and I-GENE
zeta I-GENE
- I-GENE
crystallin I-GENE
genes O
in O
the O
lens O
. O

Tctex I-GENE
- I-GENE
1 I-GENE
binding O
required O
the O
first O
19 O
amino O
acids O
of O
Fyn I-GENE
and O
integrity O
of O
two O
lysine O
residues O
within O
this O
sequence O
that O
were O
previously O
shown O
to O
be O
important O
for O
Fyn I-GENE
interactions O
with O
the O
immunoreceptor O
tyrosine O
- O
based O
activation O
motifs O
( O
ITAMs O
) O
of O
lymphocyte I-GENE
Ag I-GENE
receptors I-GENE
. O

The O
prothrombin I-GENE
gene I-GENE
G20210A I-GENE
mutation I-GENE
is O
not O
found O
among O
Japanese O
patients O
with O
deep O
vein O
thrombosis O
and O
healthy O
individuals O
. O

Transcriptional O
regulation O
of O
the O
GluR2 I-GENE
gene I-GENE
: O
neural O
- O
specific O
expression O
, O
multiple O
promoters O
, O
and O
regulatory O
elements O
. O

The O
binding O
of O
NF I-GENE
- I-GENE
ATp I-GENE
, O
although O
not O
NF I-GENE
- I-GENE
AT4 I-GENE
, O
to O
this O
enhancer O
also O
occurs O
along O
with O
HTLV O
- O
I O
- O
mediated O
infection O
of O
human O
peripheral O
blood O
T O
- O
cells O
. O

Thus O
, O
TRAF2 I-GENE
initiates O
SAPK I-GENE
and O
p38 I-GENE
activation O
by O
binding O
two O
proximal O
protein O
kinases O
: O
GCK I-GENE
and O
RIP I-GENE
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
signaling O
to O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
)/ O
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
and O
p38 I-GENE
. O

The O
activity O
of O
the O
minimal O
promoter O
was O
found O
to O
be O
controlled O
by O
a O
combination O
of O
the O
activities O
of O
the O
transcription O
factors O
Sp1 I-GENE
, O
Sp3 I-GENE
, O
and O
NF I-GENE
- I-GENE
Y I-GENE
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
investigated O
the O
signaling O
pathway O
( O
s O
) O
that O
are O
responsible O
for O
CREB I-GENE
activation O
in O
normal O
T O
cells O
. O

Respondents O
who O
lived O
with O
a O
spouse O
/ O
partner O
only O
were O
less O
likely O
to O
have O
an O
unfavorable O
BMI O
status O
than O
people O
in O
the O
other O
two O
groups O
. O

Isolation O
of O
a O
novel O
TP53 I-GENE
target I-GENE
gene I-GENE
from O
a O
colon O
cancer O
cell O
line O
carrying O
a O
highly O
regulated O
wild I-GENE
- I-GENE
type I-GENE
TP53 I-GENE
expression O
system O
. O

Overexpression O
of O
MDR1 I-GENE
has O
been O
demonstrated O
in O
many O
cancers O
, O
both O
in O
patient O
tumors O
and O
in O
cell O
lines O
selected O
with O
a O
variety O
of O
chemotherapeutic O
agents O
. O

Cytogenetic O
and O
molecular O
characterization O
of O
random O
chromosomal O
rearrangements O
activating O
the O
drug O
resistance O
gene O
, O
MDR1 I-GENE
/ O
P I-GENE
- I-GENE
glycoprotein I-GENE
, O
in O
drug O
- O
selected O
cell O
lines O
and O
patients O
with O
drug O
refractory O
ALL O
. O

BACKGROUND O
: O
It O
is O
generally O
accepted O
that O
smoking O
increases O
blood O
pressure O
and O
inhibits O
muscle O
sympathetic O
nerve O
activity O
( O
SNA O
). O

When O
the O
blood O
pressure O
increase O
in O
response O
to O
smoking O
was O
blunted O
by O
nitroprusside O
infusion O
, O
there O
was O
a O
striking O
increase O
in O
muscle O
SNA O
. O

After O
that O
report O
, O
carboxypeptidase I-GENE
D I-GENE
( O
CPD I-GENE
) O
was O
subsequently O
purified O
from O
bovine O
pituitary O
and O
characterized O
as O
a O
novel O
carboxypeptidase I-GENE
E I-GENE
( O
CPE I-GENE
)- O
like O
enzyme O
, O
with O
many O
characteristics O
in O
common O
with O
duck O
gp180 I-GENE
( O
Song O
, O
L O
., O
Fricker O
, O
L O
. O
D O
., O
1995 O
. O

RA O
- O
treatment O
of O
these O
transfectants O
induced O
morphologic O
and O
immunophenotypic O
maturation O
, O
changes O
in O
RA O
- O
regulated O
genes O
, O
and O
a O
G1 O
cell O
cycle O
arrest O
in O
a O
manner O
similar O
to O
parental O
NT2 O
/ O
D1 O
cells O
. O

The O
histopathology O
and O
neovascularization O
did O
not O
appreciably O
differ O
between O
xenograft O
tumors O
derived O
from O
FGF4 I-GENE
over O
- O
expressing O
versus O
control O
transfectants O
. O

For O
smaller O
vessels O
up O
to O
a O
diameter O
of O
0 O
. O
5 O
mm O
, O
treatments O
at O
16 O
and O
18 O
J O
/ O
cm2 O
showed O
good O
results O
in O
60 O
and O
82 O
% O
respectively O
; O
for O
vessels O
up O
to O
1 O
mm O
in O
27 O
and O
33 O
%. O

Pressure O
ulcers O
. O

RXR I-GENE
- I-GENE
gamma I-GENE
expression O
produced O
significant O
reduction O
in O
levels O
of O
RA O
- O
responsive O
genes O
including O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitors O
p21Cip1 I-GENE
/ O
WAF1 I-GENE
and O
p27Kip1 I-GENE
, O
resulting O
in O
increased O
cdc2 I-GENE
and O
cdk2 I-GENE
kinase I-GENE
activity O
and O
RB I-GENE
phosphorylation O
. O

TBP I-GENE
can O
be O
phosphorylated O
in O
vitro O
by O
extracts O
of O
U937 O
cells O
or O
by O
bacterially O
expressed O
activated O
ERK2 I-GENE
; O
the O
phosphorylation O
sites O
were O
mapped O
to O
ERK I-GENE
kinase I-GENE
consensus I-GENE
sites I-GENE
in O
the O
TBP I-GENE
amino I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
. O

During O
the O
CR O
/ O
PP O
diet O
only O
the O
HS O
subjects O
did O
not O
show O
the O
stress O
- O
induced O
rise O
in O
depression O
, O
decline O
in O
vigour O
and O
cortisol O
elevation O
that O
they O
showed O
after O
the O
PR O
/ O
CP O
diet O
. O

Generally O
ILC O
and O
ILVF O
values O
decreased O
with O
increasing O
exposure O
time O
with O
rate O
constants O
ranging O
from O
0 O
. O
03 O
to O
0 O
. O
33 O
day O
- O
1 O
( O
wet O
and O
lipid O
weight O
) O
for O
ILC O
and O
0 O
. O
03 O
to O
0 O
. O
31 O
day O
- O
1 O
for O
ILVF O
. O

These O
sequence O
analyses O
suggest O
that O
xIRS I-GENE
- I-GENE
u I-GENE
is O
a O
novel O
member O
of O
the O
IRS I-GENE
family I-GENE
rather O
than O
a O
Xenopus O
homolog O
of O
an O
existing O
member O
. O

The O
present O
study O
sought O
to O
develop O
an O
equation O
to O
estimate O
VO2peak O
in O
peripheral O
arterial O
occlusive O
disease O
( O
PAOD O
) O
patients O
with O
intermittent O
claudication O
and O
to O
determine O
independent O
predictors O
of O
VO2peak O
in O
this O
population O
. O

Evidence O
for O
a O
novel O
MAPKKK I-GENE
- O
independent O
pathway O
controlling O
the O
stress O
activated O
Sty1 I-GENE
/ O
Spc1 I-GENE
MAP O
kinase O
in O
fission O
yeast O
. O

The O
Abbreviated O
Injury O
Scale O
( O
AIS O
), O
Injury O
Severity O
Scale O
and O
TRISS O
methodology O
comprise O
a O
mathematically O
sound O
system O
for O
the O
analysis O
of O
injuries O
and O
injured O
patients O
. O

This O
hypothesis O
was O
tested O
by O
introducing O
mutations O
at O
each O
of O
the O
three O
histidine O
pairs O
, O
the O
H382 O
- O
X2 O
- O
H385 O
pair O
, O
the O
H411 O
- O
X2 O
- O
H414 O
pair O
and O
the O
H430 O
- O
X5 O
- O
H436 O
pair O
, O
which O
constitute O
the O
histidine O
- O
rich O
region O
near O
the O
C O
terminus O
of O
gp17 I-GENE
. O

Using O
backcross O
analysis O
, O
both O
exons O
1 O
and O
4 O
mapped O
to O
a O
proximal O
region O
of O
murine O
Chromosome O
4 O
indistinguishable O
from O
the O
vacillans I-GENE
gene I-GENE
. O

Seventy O
- O
five O
percent O
of O
children O
who O
received O
a O
second O
transplant O
for O
HCV O
hepatitis O
had O
early O
histologic O
recurrence O
that O
led O
to O
liver O
failure O
and O
death O
. O

However O
, O
both O
TPN O
groups O
showed O
a O
marked O
increase O
in O
activities O
of O
liver O
lysosomal I-GENE
enzymes I-GENE
. O

Regulation O
of O
embryonic O
growth O
and O
lysosomal O
targeting O
by O
the O
imprinted O
Igf2 I-GENE
/ O
Mpr I-GENE
gene O
. O

Furthermore O
, O
we O
demonstrated O
that O
Galpha11 I-GENE
Q209L I-GENE
stimulated O
Src I-GENE
family I-GENE
kinase O
activity O
and O
induced O
tyrosine O
phosphorylation O
of O
several O
proteins O
in O
HEK O
- O
293 O
cells O
. O

The O
micturition O
pressure O
was O
significantly O
decreased O
only O
after O
injection O
with O
BUP O
- O
4 O
in O
both O
normal O
and O
obstructed O
rats O
. O

Peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPAR I-GENE
) O
modulate O
transcription O
by O
binding O
to O
specific O
peroxisome O
proliferator O
- O
response O
elements O
( O
PPRE O
) O
through O
heterodimerization O
with O
the O
9 I-GENE
- I-GENE
cis I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RXR I-GENE
). O

Furthermore O
, O
early O
- O
and O
late O
- O
firing O
origins O
differ O
not O
in O
the O
timing O
of O
their O
recruitment O
of O
an O
Mcm I-GENE
protein I-GENE
, O
but O
in O
the O
timing O
of O
RPA I-GENE
' I-GENE
s I-GENE
recruitment O
. O

Thus O
, O
in O
the O
presence O
of O
active I-GENE
S I-GENE
- I-GENE
CDKs I-GENE
and O
Dbf4 I-GENE
/ O
Cdc7 I-GENE
, O
Mcms I-GENE
may O
open O
origins O
and O
thereby O
facilitate O
the O
loading O
of O
RPA I-GENE
. O

Tyrosine O
phosphorylated O
STATs I-GENE
dimerize O
and O
translocate O
into O
the O
nucleus O
to O
activate O
specific O
genes O
. O

Nonsynonymous O
substitution O
in O
abalone O
sperm O
fertilization O
genes O
exceeds O
substitution O
in O
introns O
and O
mitochondrial O
DNA O
. O

Gel O
retardation O
assays O
detected O
ZiaR I-GENE
- O
dependent O
complexes O
forming O
with O
the O
zia I-GENE
operator I-GENE
- I-GENE
promoter I-GENE
and O
ZiaR I-GENE
- O
DNA O
binding O
was O
enhanced O
by O
treatment O
with O
a O
metal O
- O
chelator O
in O
vitro O
. O

CONCLUSION O
: O
Although O
quantitative O
and O
qualitative O
criteria O
for O
diagnosing O
fatty O
liver O
on O
helical O
CT O
can O
be O
determined O
, O
they O
are O
protocol O
- O
specific O
. O

The O
PC O
- O
based O
RTPS O
is O
designed O
to O
run O
in O
the O
Microsoft O
Windows O
3 O
. O
11 O
environment O
( O
and O
later O
versions O
), O
for O
computers O
equipped O
with O
486 O
or O
Pentium O
processors O
. O

Alternatively O
, O
the O
similarity O
in O
apparent O
regulatory O
action O
of O
the O
genes O
may O
indicate O
allelic O
differences O
wherein O
the O
IS1112C I-GENE
Rf3 I-GENE
allele I-GENE
may O
differ O
from O
alleles O
of O
maintainer O
lines O
by O
the O
capability O
to O
regulate O
both O
orf107 I-GENE
and O
urf209 I-GENE
processing O
activities O
. O

JCAHO O
revised O
interpretation O

Molecular O
cloning O
and O
functional O
characterization O
of O
murine I-GENE
sphingosine I-GENE
kinase I-GENE
. O

A O
human O
SPT3 I-GENE
- O
TAFII31 I-GENE
- O
GCN5 I-GENE
- O
L I-GENE
acetylase I-GENE
complex O
distinct O
from O
transcription I-GENE
factor I-GENE
IID I-GENE
. O

Oleate O
induced O
steady O
- O
state O
levels O
of O
M I-GENE
- I-GENE
CPT I-GENE
I I-GENE
mRNA I-GENE
4 O
. O
5 O
- O
fold O
. O

Mapping O
of O
the O
DNA O
binding O
domain O
of O
the O
copper O
- O
responsive O
transcription O
factor O
Mac1 I-GENE
from I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

A O
further O
mechanism O
increasing O
specific O
activation O
was O
cooperation O
of O
receptors O
at O
multiple O
and O
weak O
HREs O
, O
which O
was O
accentuated O
in O
the O
presence O
of O
both O
the O
AR I-GENE
N O
terminus O
and O
ligand O
binding O
domain O
. O

Previously O
, O
we O
characterized O
a O
DNA O
- O
binding O
protein O
, O
HS2NF5 I-GENE
, O
that O
bound O
tightly O
to O
a O
conserved O
region O
within O
hypersensitive O
site O
2 O
( O
HS2 O
) O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
control I-GENE
region I-GENE
( O
LCR O
) O
( O
Lam O
, O
L O
. O

The O
CBF1 I-GENE
site I-GENE
within O
HS2 O
resides O
near O
sites O
for O
hematopoietic O
regulators O
such O
as O
GATA I-GENE
- I-GENE
1 I-GENE
, O
NF I-GENE
- I-GENE
E2 I-GENE
, O
and O
TAL1 I-GENE
. O

The O
rat I-GENE
branched I-GENE
- I-GENE
chain I-GENE
- I-GENE
2 I-GENE
- I-GENE
oxo I-GENE
- I-GENE
acid I-GENE
dehydrogenase I-GENE
( I-GENE
BCOD I-GENE
) I-GENE
kinase I-GENE
mRNA I-GENE
is O
transcribed O
from O
a O
TATA O
- O
less O
promoter O
that O
has O
GC O
- O
rich O
sequences O
and O
two O
putative O
Sp1 I-GENE
binding I-GENE
sites I-GENE
near O
the O
transcription O
start O
site O
. O

Co O
- O
transfection O
of O
the O
Sp1 I-GENE
expression O
plasmid O
and O
the O
- O
58 O
promoter O
construct O
into O
Drosophila O
Schneider O
cells O
revealed O
that O
Sp1 I-GENE
contributed O
to O
the O
kinase O
basal O
promoter O
activity O
by O
binding O
to O
the O
non O
- O
consensus O
site O
in O
the O
- O
58 O
region O
. O

Until O
such O
investigations O
are O
performed O
, O
we O
conclude O
that O
the O
role O
for O
adjuvant O
treatment O
is O
questionable O
and O
that O
TME O
surgery O
is O
preferred O
as O
the O
treatment O
option O
for O
Stage O
T1 O
- O
T3 O
rectal O
cancers O
. O

Likewise O
, O
at O
150 O
degrees O
C O
with O
2 O
% O
APS O
the O
surface O
density O
of O
NH2 O
groups O
reached O
a O
maximum O
at O
24 O
hr O
and O
remained O
relatively O
constant O
up O
to O
96 O
hr O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
cooperation O
of O
transcription I-GENE
factors I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
is O
essential O
for O
transactivation O
of O
IL I-GENE
- I-GENE
8 I-GENE
gene I-GENE
by O
HTLV I-GENE
- I-GENE
I I-GENE
Tax I-GENE
. O

This O
study O
examines O
the O
cooperative O
effects O
of O
a O
human O
estrogen I-GENE
receptor I-GENE
- I-GENE
alpha I-GENE
( O
ERalpha I-GENE
) O
isoform O
on O
estrogen O
( O
E2 O
)- O
mediated O
gene O
activation O
in O
U2 O
- O
OS O
osteosarcoma O
cells O
. O

Transfection O
of O
increasing O
amounts O
of O
delta5ERalpha I-GENE
expression O
vector O
into O
[ O
ERalpha I-GENE
+] O
OS O
cells O
resulted O
in O
potentiation O
of O
E2 O
- O
stimulated O
ERELuc I-GENE
activity O
in O
a O
synergistic O
, O
dose O
- O
dependent O
manner O
. O

Studies O
using O
the O
yeast O
two O
- O
hybrid O
system O
also O
did O
not O
provide O
evidence O
for O
the O
formation O
of O
a O
VDR I-GENE
- O
TR I-GENE
protein O
- O
protein O
interaction O
. O

Our O
results O
show O
that O
, O
from O
a O
thermodynamical O
standpoint O
, O
melatonin O
may O
directly O
scavenge O
hydroxyl O
radicals O
both O
in O
vacuum O
and O
in O
aqueous O
solution O
. O

This O
sequence O
, O
Thr O
- O
Gly O
- O
X O
- O
X O
- O
Gly O
- O
Asp O
- O
Gly O
- O
Lys O
- O
Ile O
- O
Phe O
, O
forms O
part O
of O
the O
B O
- O
loop O
and O
is O
conserved O
in O
a O
wide O
variety O
of O
organisms O
that O
include O
bacteria O
, O
algae O
and O
archeabacteria O
. O

We O
did O
not O
observe O
any O
changes O
in O
Bcl I-GENE
- I-GENE
2 I-GENE
or O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
proteins I-GENE
( O
Bcl I-GENE
- I-GENE
x I-GENE
, O
Bax I-GENE
, O
and O
Bad I-GENE
) O
in O
control O
or O
KCREB I-GENE
- O
transfected O
cells O
before O
or O
after O
treatment O
with O
Tg O
. O

Tyrosine O
112 O
of O
latent I-GENE
membrane I-GENE
protein I-GENE
2A I-GENE
is O
essential O
for O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
loading O
and O
regulation O
of O
Epstein O
- O
Barr O
virus O
latency O
. O

The O
only O
abundant O
viral O
transcript O
expressed O
during O
latency O
is O
the O
latency I-GENE
- I-GENE
related I-GENE
( O
LR I-GENE
) O
RNA O
. O

To O
improve O
test O
efficiency O
, O
we O
modified O
our O
previously O
introduced O
contrast O
/ O
color O
card O
test O
by O
including O
a O
patterned O
test O
stimulus O
and O
reducing O
the O
number O
of O
stimuli O
in O
both O
experimental O
phases O
. O

The O
defect O
in O
these O
proteins O
was O
also O
uniformly O
suppressed O
by O
either O
Mn2 O
+, O
or O
the O
Mu I-GENE
B I-GENE
protein I-GENE
in O
the O
presence O
of O
ATP O
and O
target O
DNA O
. O

Using O
homology O
cloning O
techniques O
, O
we O
identified O
a O
mouse O
homologue O
of O
E O
( O
Pc O
), O
termed O
Epc1 I-GENE
, O
a O
yeast O
protein O
that O
we O
name O
EPL1 I-GENE
, O
and O
as O
well O
as O
additional O
ESTs O
from O
Caenorhabditis O
elegans O
, O
mice O
and O
humans O
. O

Second O
, O
the O
wild I-GENE
- I-GENE
type I-GENE
m8 I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
strongly O
reduces O
accumulation O
of O
heterologous O
transcripts O
in O
vivo O
, O
an O
activity O
that O
requires O
its O
K O
box O
sequences O
. O

In O
particular O
, O
unc I-GENE
- I-GENE
86 I-GENE
encodes O
a O
POU I-GENE
- I-GENE
type I-GENE
homeodomain I-GENE
protein I-GENE
needed O
for O
the O
production O
of O
the O
touch O
cells O
, O
while O
mec I-GENE
- I-GENE
3 I-GENE
encodes O
a O
LIM I-GENE
- I-GENE
type I-GENE
homeodomain I-GENE
protein I-GENE
needed O
for O
the O
differentiation O
of O
the O
touch O
cells O
. O

During O
the O
2h O
resuscitation O
period O
, O
extracellular O
aspartate O
and O
glutamate O
concentrations O
in O
the O
cerebral O
striatum O
were O
higher O
during O
hypoxaemic O
resuscitation O
( O
p O
= O
0 O
. O
044 O
and O
p O
= O
0 O
. O
055 O
, O
respectively O
) O
than O
during O
resuscitation O
with O
21 O
% O
O2 O
or O
100 O
% O
O2 O
, O
suggesting O
an O
unfavourable O
accumulation O
of O
potent O
excitotoxins O
during O
hypoxaemic O
resuscitation O
. O

Expression O
of O
constitutively O
active O
MEK1 I-GENE
, O
the O
kinase O
that O
activates O
ERKs I-GENE
, O
or O
overexpression O
of O
ERK2 I-GENE
, O
but O
not O
JNK1 I-GENE
, O
inhibited O
Stat3 I-GENE
activation O
. O

MEKs I-GENE
and O
ERKs I-GENE
inhibited O
IL I-GENE
- I-GENE
6 I-GENE
activation O
of O
Stat3 I-GENE
harboring O
a O
mutation O
at O
serine O
- O
727 O
, O
the O
major O
site O
for O
serine O
phosphorylation O
, O
similar O
to O
inhibition O
of O
wild I-GENE
- I-GENE
type I-GENE
Stat3 I-GENE
, O
and O
inhibited O
Janus I-GENE
kinases I-GENE
Jak1 I-GENE
and O
Jak2 I-GENE
upstream O
of O
Stat3 I-GENE
in O
the O
Jak I-GENE
- O
STAT I-GENE
- O
signaling O
pathway O
. O

Furthermore O
, O
phosphatidylinositol O
( O
3 O
, O
4 O
, O
5 O
) O
trisphosphate O
specifically O
stimulates O
the O
activity O
of O
ILK I-GENE
in O
vitro O
, O
and O
in O
addition O
, O
membrane O
targetted O
constitutively O
active O
Pi I-GENE
( I-GENE
3 I-GENE
) I-GENE
K I-GENE
activates O
ILK I-GENE
in O
vivo O
. O

Transfection O
and O
in O
vitro O
binding O
studies O
identified O
within O
HEFT1 I-GENE
a I-GENE
promoter I-GENE
whose O
basal O
activity O
required O
a O
GC O
box O
activated O
by O
Sp1 I-GENE
or O
Sp3 I-GENE
. O

Plasma O
was O
tested O
before O
and O
after O
( O
14 O
+/- O
7 O
. O
5 O
[ O
SD O
] O
days O
) O
surgery O
for O
IgG I-GENE
antibodies I-GENE
to O
the O
complex O
of O
heparin I-GENE
/ I-GENE
platelet I-GENE
factor I-GENE
4 I-GENE
, O
using O
a O
standardized O
, O
validated O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
). O

Genome O
plasticity O
in O
the O
distal O
tail O
fiber O
locus O
of O
the O
T O
- O
even O
bacteriophage O
: O
recombination O
between O
conserved O
motifs O
swaps O
adhesin I-GENE
specificity O
. O

The O
FAS I-GENE
promoter I-GENE
was O
up O
- O
regulated O
by O
insulin I-GENE
through O
the O
proximal O
insulin I-GENE
response I-GENE
sequence I-GENE
containing O
an O
E O
- O
box O
motif O
at O
the O
- O
65 O
- O
base O
pair O
position O
. O

The O
effect O
of O
independent O
predictors O
on O
survival O
was O
examined O
in O
a O
Cox O
regression O
model O
with O
adjustment O
for O
existing O
illnesses O
. O

Effects O
of O
rhG I-GENE
- I-GENE
CSF I-GENE
on O
neutrophil O
functions O
and O
survival O
in O
sepsis O
induced O
diabetic O
rats O
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
article O
is O
to O
review O
balance O
instruments O
developed O
within O
the O
past O
10 O
years O
that O
can O
be O
used O
in O
the O
clinic O
or O
home O
environment O
. O

CASE O
REPORT O
: O
We O
observed O
a O
congenital O
skin O
defect O
located O
exclusively O
on O
the O
trunk O
. O

Whereas O
, O
in O
the O
single O
- O
chambered O
body O
box O
, O
PenH O
units O
( O
Enhanced O
Pause O
) O
reflect O
" O
effort O
of O
breathing O
." O
This O
is O
measured O
as O
the O
pause O
between O
inspiration O
and O
expiration O
. O

Anastrozole O
is O
the O
first O
aromatase I-GENE
inhibitor O
to O
show O
a O
significant O
survival O
advantage O
over O
megestrol O
acetate O
in O
post O
- O
menopausal O
women O
with O
advanced O
breast O
cancer O
. O

W O
. O

Moritta O
) O
and O
contains O
Bis O
- O
GMA O
. O

Mutation O
of O
either O
the O
AP I-GENE
- I-GENE
1 I-GENE
or O
the O
ets I-GENE
component O
of O
this O
site O
also O
prevented O
promoter O
activity O
in O
SMCs O
. O

ANIMALS O
: O
Fifty O
dogs O
with O
naturally O
developing O
DM O
. O

Surprisingly O
, O
double O
mutants O
of O
the O
shy2 I-GENE
- I-GENE
1D I-GENE
mutant I-GENE
with O
the O
phytochrome I-GENE
- O
deficient O
mutants O
hy2 I-GENE
, O
hy3 I-GENE
( O
phyB I-GENE
- I-GENE
1 I-GENE
) O
and O
fre1 I-GENE
- I-GENE
1 I-GENE
( O
phyA I-GENE
- I-GENE
201 I-GENE
) O
showed O
reduced O
photomorphogenic O
response O
in O
darkness O
with O
a O
longer O
hypocotyl O
, O
a O
longer O
inflorescence O
stem O
, O
and O
a O
lower O
level O
expression O
of O
the O
CAB I-GENE
gene I-GENE
than O
the O
shy2 I-GENE
- I-GENE
1D I-GENE
single I-GENE
mutant I-GENE
. O

This O
suggests O
that O
while O
underpredictions O
of O
pain O
do O
not O
hurt O
more O
, O
disruption O
on O
primary O
tasks O
and O
physiological O
impact O
are O
higher O
. O

Laser O
ablation O
has O
been O
employed O
as O
a O
therapeutic O
measure O
for O
chronic O
pulmonary O
emphysema O
. O

The O
SH2 O
- O
containing O
adapter O
protein O
GRB10 I-GENE
interacts O
with O
BCR I-GENE
- O
ABL I-GENE
. O

Saccharomyces O
cerevisiae O
contains O
four O
known O
acyl I-GENE
- I-GENE
CoA I-GENE
synthetases I-GENE
( O
fatty I-GENE
acid I-GENE
activation I-GENE
proteins I-GENE
, O
Faaps I-GENE
). O

We O
recently O
reported O
a O
placenta O
- O
specific O
enhancer O
in O
the O
human I-GENE
leukemia I-GENE
inhibitory I-GENE
factor I-GENE
receptor I-GENE
( O
LIFR I-GENE
) O
gene O
and O
now O
show O
detailed O
characterization O
of O
the O
226 O
- O
base O
pair O
enhancer O
(- O
4625 O
/- O
4400 O
nucleotides O
). O

Copyright O
1998 O
Elsevier O
Science O
B O
. O
V O
. O

It O
may O
be O
time O
to O
reevaluate O
the O
dichotomy O
between O
AD O
and O
VaD O
. O

Clone O
39 O
was O
a O
homolog O
of O
CONSTANS I-GENE
, O
which O
is O
a O
gene O
involved O
in O
controlling O
the O
flowering O
time O
in O
Arabidopsis O
. O

Badcock O
and O
Westheimer O
( O
Spatial O
Vision O
1 O
( O
1 O
), O
3 O
- O
11 O
, O
1985 O
) O
showed O
that O
a O
thin O
vertical O
line O
induces O
nearby O
zones O
of O
attraction O
and O
repulsion O
; O
this O
study O
extends O
those O
results O
by O
more O
closely O
examining O
the O
horizontal O
and O
vertical O
extents O
of O
the O
repulsion O
zone O
and O
by O
using O
an O
illusory O
contour O
to O
induce O
repulsion O
. O

The O
effects O
of O
high O
intensity O
light O
emissions O
, O
produced O
by O
a O
novel O
pulsed O
power O
energization O
technique O
( O
PPET O
), O
on O
the O
survival O
of O
bacterial O
populations O
of O
verocytotoxigenic O
Escherichia O
coli O
( O
serotype O
0157 O
: O
H7 O
) O
and O
Listeria O
monocytogenes O
( O
serotype O
4b O
) O
were O
investigated O
. O

Multiple O
chemical O
sensitivity O
( O
MCS O
) O
is O
a O
syndrome O
in O
which O
multiple O
symptoms O
reportedly O
occur O
with O
low O
- O
level O
chemical O
exposure O
. O

POU I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
, O
such O
as O
the O
pituitary I-GENE
- I-GENE
specific I-GENE
factor I-GENE
Pit I-GENE
- I-GENE
1 I-GENE
, O
are O
members O
of O
the O
homeodomain I-GENE
family I-GENE
of O
proteins O
which O
are O
important O
in O
development O
and O
homeostasis O
, O
acting O
constitutively O
or O
in O
response O
to O
signal O
- O
transduction O
pathways O
to O
either O
repress O
or O
activate O
the O
expression O
of O
specific O
genes O
. O

Wild O
- O
type O
and O
mutant O
MyoD I-GENE
were O
introduced O
into O
cells O
using O
an O
E1 I-GENE
, O
E3 I-GENE
- O
deleted O
adenoviral O
vector O
. O

These O
results O
suggest O
that O
Thr115 O
may O
play O
an O
important O
role O
in O
the O
regulation O
of O
MyoD I-GENE
function O
under O
conditions O
of O
high O
mitogenesis O
. O

This O
and O
previous O
results O
suggest O
that O
the O
CRE O
and O
Sp1 I-GENE
site I-GENE
may O
synergistically O
activate O
TH I-GENE
transcription O
in O
a O
promoter O
context O
- O
dependent O
manner O
. O

desmethyltrimebutine O
was O
inactive O
. O

Endoscopic O
examinations O
, O
peripheral O
white O
blood O
cell O
( O
WBC O
) O
counts O
, O
and O
assays O
of O
myeloperoxidase I-GENE
activity O
( O
MPO I-GENE
) O
in O
homogenates O
of O
colon O
mucosa O
were O
performed O
after O
one O
week O
( O
4 O
% O
DSS O
model O
) O
and O
eight O
weeks O
( O
1 O
% O
DSS O
model O
). O

T7 O
transcription O
could O
be O
manipulated O
to O
achieve O
different O
levels O
of O
constitutive O
expression O
, O
through O
the O
use O
of O
promoter O
mutations O
. O

The O
primers O
were O
degenerate O
sets O
of O
oligonucleotides O
derived O
from O
known O
amino O
acid O
sequences O
of O
the O
PBAN I-GENE
precursor I-GENE
. O

Plants O
transformed O
with O
the O
35S I-GENE
- O
1 I-GENE
- I-GENE
sst I-GENE
construct O
accumulated O
the O
oligofructans O
1 O
- O
kestose O
( O
GF2 O
), O
1 O
, O
1 O
- O
nystose O
( O
GF3 O
) O
and O
1 O
, O
1 O
, O
1 O
- O
fructosylnystose O
( O
GF4 O
). O

Based O
on O
the O
comparison O
of O
the O
predicted O
amino O
acid O
sequences O
of O
1 I-GENE
- I-GENE
sst I-GENE
and O
1 I-GENE
- I-GENE
fft I-GENE
with O
those O
of O
other O
plant O
fructosyl I-GENE
transferase I-GENE
genes I-GENE
, O
we O
postulate O
that O
both O
plant O
fructan I-GENE
genes I-GENE
have O
evolved O
from O
plant O
invertase I-GENE
genes O
. O

However O
, O
ICK1 I-GENE
was O
induced O
by O
ABA O
, O
and O
along O
with O
ICK1 I-GENE
induction O
there O
was O
a O
decrease O
in O
Cdc2 I-GENE
- I-GENE
like I-GENE
histone I-GENE
H1 I-GENE
kinase I-GENE
activity O
. O

A O
5 O
. O
0 O
- O
kb O
transcript O
detected O
by O
the O
differential O
display O
amplicon O
3G1 O
was O
found O
to O
correlate O
strongly O
with O
RAG1 I-GENE
mRNA I-GENE
expression O
in O
various O
human O
cell O
lines O
. O

The O
hBRAG I-GENE
gene I-GENE
was O
localized O
to O
the O
long O
arm O
of O
chromosome O
10 O
( O
10q26 O
). O

Here O
, O
we O
report O
that O
swa5 I-GENE
- I-GENE
1 I-GENE
is O
a O
new O
temperature O
- O
sensitive O
allele O
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
( O
chc1 I-GENE
- I-GENE
5 I-GENE
), O
which O
carries O
a O
frameshift O
mutation O
near O
the O
3 O
' O
end O
of O
the O
CHC1 I-GENE
open O
reading O
frame O
. O

We O
have O
determined O
the O
molecular O
lesions O
of O
nine O
Scm I-GENE
mutant I-GENE
alleles I-GENE
, O
which O
identify O
functional O
requirements O
for O
specific O
domains O
. O

Intriguingly O
, O
three O
hypomorphic O
Scm I-GENE
mutations O
, O
which O
map O
within O
an O
mbt I-GENE
repeat I-GENE
, O
interact O
with O
PcG I-GENE
mutations I-GENE
more O
strongly O
than O
do O
Scm I-GENE
null O
alleles O
. O

Northern O
analysis O
revealed O
no O
detectable O
expression O
of O
the O
transcript O
in O
diapause O
- O
or O
nondiapause O
- O
programmed O
wandering O
larvae O
, O
and O
only O
trace O
expression O
in O
nondiapausing O
pupae O
. O

Besides O
the O
characterization O
and O
discussion O
of O
the O
experimental O
setup O
used O
, O
the O
rate O
constants O
obtained O
are O
discussed O
and O
compared O
with O
estimated O
values O
. O

Genomic O
locus O
of O
chCTCF I-GENE
contains O
a O
GC O
- O
rich O
untranslated O
exon O
separated O
from O
seven O
coding O
exons O
by O
a O
long O
intron O
. O

The O
presence O
of O
PDZ I-GENE
and O
SAM O
domains O
in O
the O
KS5 I-GENE
protein I-GENE
suggests O
that O
it O
may O
act O
as O
a O
molecular O
adaptor O
, O
promoting O
and O
relaying O
information O
in O
a O
signal O
transduction O
pathway O
. O

BACKGROUND O
: O
Fluoroquinolones O
( O
FQ O
) O
are O
contraindicated O
in O
children O
because O
of O
the O
risk O
of O
cartilage O
damage O
. O

In O
analyses O
with O
control O
for O
multiple O
variables O
, O
relative O
risk O
for O
microalbuminuria O
( O
urinary O
albumin I-GENE
excretion O
, O
20 O
- O
199 O
microg O
/ O
min O
) O
in O
men O
and O
women O
was O
2 O
. O
51 O
and O
1 O
. O
62 O
, O
respectively O
, O
with O
18 O
mm O
Hg O
higher O
( O
1 O
SD O
) O
systolic O
blood O
pressure O
; O
2 O
. O
25 O
and O
2 O
. O
10 O
, O
respectively O
, O
with O
1 O
. O
0 O
- O
mmol O
/ O
L O
( O
40 O
mg O
/ O
dL O
) O
higher O
plasma O
cholesterol O
level O
; O
1 O
. O
99 O
and O
1 O
. O
91 O
, O
respectively O
, O
for O
smokers O
vs O
nonsmokers O
; O
and O
1 O
. O
83 O
and O
1 O
. O
33 O
, O
respectively O
, O
with O
4 O
kg O
/ O
m2 O
higher O
body O
mass O
index O
. O

However O
, O
while O
IL I-GENE
- I-GENE
1beta I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
both O
induced O
nuclear O
binding O
of O
the O
Rel I-GENE
proteins I-GENE
p50 I-GENE
and O
p65 I-GENE
to O
an O
NF I-GENE
- I-GENE
kappaB I-GENE
consensus I-GENE
oligonucleotide I-GENE
in O
gel O
shift O
assays O
and O
caused O
transient O
degradation O
of O
inhibitor I-GENE
of I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
alpha I-GENE
( O
IkappaB I-GENE
- I-GENE
alpha I-GENE
) O
in O
the O
cytoplasm O
of O
myofibroblasts O
, O
only O
IL I-GENE
- I-GENE
1beta I-GENE
upregulated O
PDGF I-GENE
- I-GENE
Ralpha I-GENE
. O

Cotransfections O
with O
ATF I-GENE
- I-GENE
2 I-GENE
and O
HNF I-GENE
- I-GENE
4 I-GENE
expression O
plasmids O
resulted O
in O
additive O
transactivation O
of O
the O
apoCIII I-GENE
promoter I-GENE
. O

Phosphocreatine O
hydrolysis O
during O
submaximal O
exercise O
: O
the O
effect O
of O
FIO2 O
. O

Pseudocontact O
shifts O
arise O
from O
the O
isotropic O
reorientational O
average O
of O
the O
dipolar O
coupling O
between O
unpaired O
electron O
and O
nuclei O
, O
in O
the O
presence O
of O
magnetic O
susceptibility O
anisotropy O
. O

GETS I-GENE
- I-GENE
1 I-GENE
is O
expressed O
in O
many O
tissues O
, O
but O
is O
enriched O
in O
retina O
and O
brain O
. O

The O
interaction O
of O
U1 I-GENE
- I-GENE
70K I-GENE
with O
the O
SRZ I-GENE
proteins I-GENE
is O
confirmed O
further O
in O
vitro O
using O
a O
blot O
overlay O
assay O
. O

The O
major O
phenotypes O
resulting O
from O
Fab1p I-GENE
kinase I-GENE
inactivation O
include O
temperature O
- O
sensitive O
growth O
, O
vacuolar O
acidification O
defects O
, O
and O
dramatic O
increases O
in O
vacuolar O
size O
. O

Small I-GENE
GTPases I-GENE
of O
the O
Ypt I-GENE
/ O
Rab I-GENE
family O
are O
involved O
in O
the O
regulation O
of O
vesicular O
transport O
. O

The O
GEF I-GENE
and O
GAP I-GENE
activities O
for O
Ypt1p I-GENE
localize O
to O
particulate O
cellular O
fractions O
. O

Dopamine I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
( O
DBH I-GENE
) O
catalyzes O
the O
conversion O
of O
dopamine O
to O
noradrenaline O
and O
is O
selectively O
expressed O
in O
noradrenergic O
and O
adrenergic O
neurons O
and O
neuroendocrine O
cells O
. O

Collectively O
, O
this O
study O
emphasizes O
a O
critical O
role O
of O
Phox2a I-GENE
as O
well O
as O
its O
functional O
synergism O
with O
other O
transcription O
factors O
( O
e O
. O
g O
., O
CREB I-GENE
, O
AP2 I-GENE
, O
and O
Sp1 I-GENE
) O
in O
transcriptional O
activation O
of O
the O
DBH I-GENE
gene I-GENE
. O

Interestingly O
, O
an O
antibody O
against O
N I-GENE
- I-GENE
SMase I-GENE
can O
abrogate O
Ox I-GENE
- I-GENE
LDL I-GENE
- O
and O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
induced O
apoptosis O
and O
therefore O
may O
be O
useful O
for O
in O
vivo O
studies O
of O
apoptosis O
in O
experimental O
animals O
. O

We O
found O
that O
virulent O
Ngo O
strains O
induce O
phosphorylation O
and O
activation O
of O
JNK I-GENE
but O
not O
of O
p38 I-GENE
kinase O
. O

Focused O
beams O
of O
classical O
light O
ablate O
elements O
of O
the O
cell O
division O
machinery O
and O
switch O
the O
beating O
of O
hearts O
on O
a O
cellular O
basis O
. O

The O
human O
T O
cell O
lymphotropic O
retrovirus O
type O
I O
( O
HTLV O
- O
I O
) O
trans O
- O
activator O
, O
Tax I-GENE
, O
interacts O
specifically O
with O
the O
basic I-GENE
- I-GENE
domain I-GENE
/ I-GENE
leucine I-GENE
- I-GENE
zipper I-GENE
( I-GENE
bZip I-GENE
) I-GENE
protein I-GENE
, O
cAMP I-GENE
response I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
), O
bound O
to O
the O
viral I-GENE
Tax I-GENE
- I-GENE
responsive I-GENE
element I-GENE
consisting O
of O
three O
imperfect O
21 O
- O
base O
pair O
repeats O
, O
each O
with O
a O
cAMP O
response O
element O
core O
flanked O
by O
G O
/ O
C O
- O
rich O
sequences O
. O

This O
sequence O
is O
very O
similar O
to O
the O
insulin I-GENE
response I-GENE
sequence I-GENE
found O
in O
the O
regulatory O
region O
of O
other O
genes O
negatively O
regulated O
by O
insulin I-GENE
such O
as O
those O
encoding O
phosphoenolpyruvate I-GENE
carboxykinase I-GENE
, O
tyrosine I-GENE
aminotransferase I-GENE
, O
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
. O

The O
murine I-GENE
facilitative I-GENE
glucose I-GENE
transporter I-GENE
isoform I-GENE
3 I-GENE
( O
Glut I-GENE
3 I-GENE
) O
is O
developmentally O
regulated O
and O
is O
predominantly O
expressed O
in O
neurons O
and O
trophoblasts O
. O

However O
, O
changing O
the O
half O
- O
site O
to O
the O
consensus O
sequence O
AGGTCA O
( O
IRper O
- O
1 O
) O
increased O
binding O
of O
AaEcR I-GENE
. I-GENE
AaUSP I-GENE
10 O
- O
fold O
over O
IRhsp O
- O
1 O
and O
, O
at O
the O
same O
time O
, O
reduced O
the O
stringency O
of O
the O
spacer O
length O
requirement O
, O
with O
IRper O
- O
0 O
to O
IRper O
- O
5 O
showing O
detectable O
binding O
. O

The O
levels O
of O
transactivation O
are O
correlated O
with O
the O
respective O
binding O
affinities O
of O
the O
response O
elements O
( O
IRper O
- O
1 O
> O
DR O
- O
4 O
> O
IRhsp O
- O
1 O
). O

The O
high O
density O
of O
tegumental O
spines O
on O
posterior O
half O
of O
the O
body O
and O
the O
distribution O
of O
type O
II O
papillae O
on O
dorsal O
surface O
are O
considered O
to O
be O
characteristic O
of O
C O
. O
armatus O
. O

Inactivation O
of O
p53 I-GENE
but O
not O
p73 I-GENE
by O
adenovirus I-GENE
type I-GENE
5 I-GENE
E1B I-GENE
55 I-GENE
- I-GENE
kilodalton I-GENE
and I-GENE
E4 I-GENE
34 I-GENE
- I-GENE
kilodalton I-GENE
oncoproteins I-GENE
. O

The O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
transactivator I-GENE
Zta I-GENE
triggers O
lytic O
gene O
expression O
and O
is O
essential O
for O
replication O
of O
the O
lytic O
origin O
, O
oriLyt O
. O

Cotransfection O
of O
the O
helicase I-GENE
- O
primase I-GENE
proteins O
, O
one O
of O
which O
was O
fused O
to O
a O
heterologous O
activation O
domain O
, O
led O
to O
Zta I-GENE
- O
dependent O
superactivation O
of O
CAT I-GENE
expression O
. O

Sequence O
comparisons O
strongly O
suggest O
that O
the O
S27a I-GENE
and O
the O
ubiquitin I-GENE
coding O
sequences O
found O
in O
the O
genome O
of O
CP O
Rit O
were O
both O
derived O
from O
a O
bovine O
mRNA O
encoding O
a O
hybrid O
protein O
with O
the O
structure O
NH2 O
- O
ubiquitin I-GENE
- O
S27a I-GENE
- O
COOH O
. O

J O
. O

There O
was O
a O
trend O
in O
all O
studies O
favouring O
PVI O
. O

A O
single O
rectal O
dose O
of O
25 O
mg O
/ O
kg O
will O
obtain O
this O
lower O
concentration O
within O
1 O
h O
of O
administration O
and O
maintain O
it O
for O
up O
to O
6 O
h O
. O

This O
domain O
, O
although O
adjacent O
to O
the O
5 O
' O
edge O
of O
the O
SD O
sequence O
, O
does O
not O
inhibit O
ribosome O
binding O
as O
long O
as O
the O
single O
- O
stranded O
region O
of O
domain O
3 O
is O
present O
. O

Although O
YopH I-GENE
is O
a O
highly O
active O
PTP I-GENE
, O
it O
preferentially O
targets O
a O
subset O
of O
tyrosine O
- O
phosphorylated O
proteins O
in O
host O
cells O
, O
including O
p130Cas I-GENE
. O

Phylogenetic O
position O
of O
the O
Phacotaceae O
within O
the O
Chlamydophyceaeas O
revealed O
by O
analysis O
of O
18S I-GENE
rDNA I-GENE
and O
rbcL I-GENE
sequences I-GENE
. O

Previous O
genetic O
studies O
led O
to O
the O
conclusion O
that O
nitrate O
and O
nitrite O
induction O
of O
nasF I-GENE
operon I-GENE
expression O
is O
determined O
by O
a O
transcriptional O
antitermination O
mechanism O
. O

The O
activation O
and O
injury O
of O
endothelial O
cells O
induced O
by O
TNF I-GENE
and O
other O
proinflammatory O
cytokines O
may O
underlie O
the O
local O
effects O
of O
these O
mediators O
in O
vivo O
. O

A O
technique O
for O
thermal O
imaging O
of O
the O
animal O
and O
human O
brain O
cortex O
using O
an O
infrared O
optical O
system O
is O
described O
. O

EGFR I-GENE
levels O
were O
found O
to O
be O
elevated O
5 O
-, O
3 O
. O

Here O
we O
demonstrate O
that O
THOV I-GENE
NP I-GENE
contains O
a O
motif O
( O
KRxxxxxxxxxKTKK O
) O
at O
amino O
acid O
positions O
179 O
- O
193 O
that O
represents O
a O
classical O
bipartite O
nuclear O
localization O
signal O
( O
NLS O
). O

As O
PP2A I-GENE
exerts O
a O
range O
of O
cellular O
functions O
including O
cell O
cycle O
regulation O
and O
cell O
fate O
determination O
, O
we O
were O
surprised O
to O
find O
that O
these O
embryos O
develop O
normally O
until O
postimplantation O
, O
around O
embryonic O
day O
5 O
. O
5 O
/ O
6 O
. O
0 O
. O

The O
most O
frequent O
risk O
factor O
for O
ischaemic O
was O
hypertension O
. O

The O
results O
indicate O
that O
anthraquinone O
sennoside O
B O
and O
rhein O
are O
weakly O
genotoxic O
. O

Furthermore O
, O
LB1 I-GENE
gene I-GENE
mapped O
to O
chromosome O
13q14 O
, O
a O
region O
that O
has O
been O
involved O
as O
a O
chromosomal O
breakpoint O
in O
DLBL O
. O

16 O
subjects O
were O
repatch O
tested O
to O
ethylmercury O
chloride O
( O
EtHgCl O
) O
and O
to O
solutions O
containing O
EtHgCl O
mixed O
with O
L O
- O
cysteine O
and O
glutathione O
, O
respectively O
. O

Wild I-GENE
- I-GENE
type I-GENE
AT1A I-GENE
receptors I-GENE
, O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
, O
rapidly O
internalized O
after O
Ang I-GENE
II I-GENE
stimulation O
[ O
t1 O
/ O
2 O
2 O
. O
3 O
min O
; O
maximal O
level O
of O
internalization O
( O
Ymax O
) O
78 O
. O
2 O
%], O
as O
did O
mutant O
receptors O
carrying O
single O
acidic O
substitutions O
( O
T332E O
, O
t1 O
/ O
2 O
2 O
. O
7 O
min O
, O
Ymax O
76 O
. O
3 O
%; O
S335D O
, O
t1 O
/ O
2 O
2 O
. O
4 O
min O
, O
Ymax O
76 O
. O
7 O
%; O
T336E O
, O
t1 O
/ O
2 O
2 O
. O
5 O
min O
, O
Ymax O
78 O
. O
2 O
%; O
S338D O
, O
t1 O
/ O
2 O
2 O
. O
6 O
min O
, O
Ymax O
78 O
. O
4 O
%). O

The O
activated O
glucocorticoid I-GENE
receptor I-GENE
forms O
a O
complex O
with O
Stat5 I-GENE
and O
enhances O
Stat5 I-GENE
- O
mediated O
transcriptional O
induction O
. O

T O
., O
Mahasneh O
, O
A O
., O
and O
Cote O
, O
G O
. O

The O
carboxyl O
- O
terminal O
portion O
of O
UKLF I-GENE
contains O
three O
zinc O
fingers O
of O
the O
Cys2 O
- O
His2 O
type O
and O
binds O
in O
vitro O
to O
the O
CACCC O
motif O
of O
the O
beta I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
and O
to O
the O
Sp1 I-GENE
recognition I-GENE
sequence I-GENE
. O

We O
have O
recently O
identified O
a O
mouse O
enzyme O
termed O
gamma I-GENE
- I-GENE
glutamyl I-GENE
leukotrienase I-GENE
( O
GGL I-GENE
) O
that O
converts O
leukotriene O
C4 O
( O
LTC4 O
) O
to O
leukotriene O
D4 O
( O
LTD4 O
). O

UGA O
codon O
position O
affects O
the O
efficiency O
of O
selenocysteine O
incorporation O
into O
glutathione I-GENE
peroxidase I-GENE
- I-GENE
1 I-GENE
. O

Forskolin O
significantly O
enhanced O
heregulin I-GENE
- O
stimulated O
expression O
of O
cyclin I-GENE
D I-GENE
and O
phosphorylation O
of O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
. O

The O
ARF I-GENE
promoter I-GENE
was O
also O
found O
to O
be O
highly O
responsive O
to O
E2F1 I-GENE
expression O
, O
in O
keeping O
with O
previous O
results O
at O
the O
RNA O
level O
. O

RESULTS O
: O
The O
binding O
of O
99mTc O
d O
, O
1 O
- O
HMPAO O
to O
human O
placenta O
ranged O
from O
2 O
. O
95 O
% O
+/- O
1 O
. O
5 O
% O
to O
5 O
. O
82 O
% O
+/- O
0 O
. O
3 O
% O
per O
1 O
ml O
standard O
solution O
. O

CM O
reduced O
the O
nuclear O
binding O
activity O
of O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
. O

NF I-GENE
- I-GENE
kappaB I-GENE
, O
which O
is O
probably O
important O
for O
basal O
activity O
of O
the O
human I-GENE
NOS I-GENE
II I-GENE
promoter I-GENE
, O
is O
unlikely O
to O
function O
as O
a O
major O
effector O
of O
CM O
in O
DLD O
- O
1 O
cells O
. O

Observers O
with O
brain O
injury O
and O
control O
participants O
performed O
a O
vigilance O
task O
during O
which O
they O
received O
periodic O
whiffs O
of O
unscented O
air O
or O
air O
scented O
with O
peppermint O
. O

A O
simple O
analytical O
method O
for O
l O
- O
menthol O
by O
high O
- O
performance O
liquid O
chromatography O
with O
a O
polarized O
photometric O
detector O
was O
established O
. O

RESULTS O
: O
The O
cardiac O
index O
significantly O
changed O
with O
varying O
PaCO2 O
levels O
( O
hypocapnia O
, O
- O
9 O
%; O
hypercapnia O
, O
13 O
%). O

After O
measuring O
baseline O
Vmca O
at O
a O
partial O
pressure O
of O
carbon O
dioxide O
in O
arterial O
blood O
( O
PaCO2 O
) O
of O
37 O
. O
7 O
+/- O
4 O
. O
5 O
mmHg O
( O
mean O
+/- O
SD O
), O
measurements O
were O
repeated O
at O
a O
PaCO O
of O
44 O
. O
2 O
+/- O
3 O
. O
8 O
mmHg O
, O
and O
the O
carbon O
dioxide O
reactivity O
( O
absolute O
value O
: O
cm O
x O
s O
(- O
1 O
) O
x O
mmHg O
(- O
1 O
); O
relative O
value O
: O
percentage O
of O
baseline O
Vmca O
/ O
mmHg O
) O
was O
calculated O
. O

Multivariate O
Cox O
survival O
analysis O
identified O
baseline O
EF O
< O
or O
= O
30 O
%, O
presence O
of O
significant O
mitral O
regurgitation O
(> O
2 O
+) O
before O
ablation O
, O
and O
failure O
to O
exhibit O
improved O
cardiac O
performance O
by O
1 O
month O
after O
ablation O
as O
the O
only O
independent O
predictors O
of O
death O
. O

We O
have O
developed O
a O
new O
method O
for O
estimation O
of O
regional O
CBF O
( O
rCBF O
) O
and O
cerebrovascular O
reserve O
capacity O
on O
a O
pixel O
- O
by O
- O
pixel O
basis O
by O
means O
of O
dynamic O
magnetic O
resonance O
imaging O
( O
MRI O
). O

Cost O
- O
effectiveness O
analysis O
provides O
a O
rational O
means O
of O
allocating O
limited O
health O
care O
resources O
by O
allowing O
the O
comparison O
of O
the O
costs O
of O
lipid O
- O
lowering O
therapy O
, O
in O
particular O
, O
therapy O
with O
beta I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
beta I-GENE
- I-GENE
methylglutaryl I-GENE
- I-GENE
CoA I-GENE
( I-GENE
coenzyme I-GENE
A I-GENE
) I-GENE
reductase I-GENE
inhibitors O
( O
statins O
), O
with O
the O
costs O
of O
atherosclerosis O
that O
could O
be O
prevented O
by O
lowering O
cholesterol O
. O

Although O
E2FBP1 I-GENE
lacks O
the O
transactivation O
domain O
, O
it O
stimulates O
E2F I-GENE
site O
- O
dependent O
transcription O
in O
cooperation O
with O
E2F I-GENE
- I-GENE
1 I-GENE
. O

Sequencing O
of O
a O
40 O
- O
kb O
DNA O
segment O
of O
the O
FK506 O
gene O
cluster O
from O
Streptomyces O
sp O
. O

The O
predicted O
domain O
structures O
of O
FkbB I-GENE
and O
FkbC I-GENE
are O
analogous O
to O
that O
of O
FkbA I-GENE
and O
comprise O
30 O
fatty I-GENE
- I-GENE
acid I-GENE
- I-GENE
synthase I-GENE
( O
FAS I-GENE
)- O
like O
domains O
arranged O
in O
6 O
modules O
. O

Analysis O
of O
Msy2 I-GENE
mRNA I-GENE
expression O
in O
prepubertal O
and O
adult O
mouse O
testes O
, O
and O
in O
isolated O
populations O
of O
germ O
cells O
, O
reveals O
maximal O
expression O
in O
postmeiotic O
round O
spermatids O
, O
a O
cell O
type O
with O
abundant O
amounts O
of O
stored O
messenger O
ribonucleoproteins O
. O

1 O
in O
Ho O
Chi O
Minh O
City O
was O
studied O
by O
culture O
and O
latex O
agglutination O
of O
blood O
, O
cerebrospinal O
fluid O
, O
urine O
and O
pleural O
fluid O
. O

Glycogen O
synthesis O
and O
catabolism O
, O
gluconeogenesis O
, O
glycolysis O
, O
motility O
, O
cell O
surface O
properties O
and O
adherence O
are O
modulated O
by O
csrA I-GENE
in I-GENE
Escherichia I-GENE
coli I-GENE
, O
while O
the O
production O
of O
several O
secreted O
virulence O
factors O
, O
the O
plant O
hypersensitive O
response O
elicitor O
HrpN I-GENE
( O
Ecc I-GENE
) O
and O
, O
potentially O
, O
other O
secondary O
metabolites O
are O
regulated O
by O
rsmA I-GENE
in I-GENE
Erwinia I-GENE
carotovora I-GENE
. O

The O
cwg2 I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
was O
identified O
as O
a O
guanine O
to O
adenine O
substitution O
at O
nucleotide O
604 O
of O
the O
coding O
region O
, O
originating O
the O
change O
A202T O
in O
the O
cwg2p I-GENE
. O

Deletion O
analysis O
revealed O
that O
the O
essential O
domain O
of O
this O
promoter O
, O
termed O
the O
ORF5 I-GENE
/ I-GENE
deltaX I-GENE
transcript I-GENE
promoter I-GENE
, O
mapped O
to O
nucleotides O
1525 O
- O
1625 O
. O

Some O
of O
the O
peptide I-GENE
: I-GENE
MBP I-GENE
fusions I-GENE
were O
also O
analyzed O
using O
surface O
plasmon O
resonance O
. O

Cardiac I-GENE
myosin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
C I-GENE
( O
MyBP I-GENE
- I-GENE
C I-GENE
): O
identification O
of O
protein I-GENE
kinase I-GENE
A I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
phosphorylation O
sites O
. O

Handling O
on O
PND O
9 O
did O
not O
result O
in O
elevated O
CORT O
levels O
in O
any O
of O
the O
groups O
. O

Analysis O
of O
chromosomal O
DNA O
sequence O
immediately O
downstream O
of O
the O
transposon O
insertion O
identified O
two O
open O
reading O
frames O
, O
designated O
csrR I-GENE
and O
csrS I-GENE
, O
which O
exhibited O
sequence O
similarity O
to O
bacterial O
two O
- O
component O
regulatory O
systems O
. O

633 O
+/- O
258 O
aggregates O
/ O
ml O
at O
0 O
rpm O
; O
P O
< O
0 O
. O
001 O
). O

We O
previously O
delineated O
a O
region O
in O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
promoter I-GENE
, O
which O
was O
responsible O
for O
obesity O
- O
related O
overexpression O
of O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
( O
FAS I-GENE
) O
gene O
, O
by O
negatively O
regulating O
the O
activity O
of O
the O
downstream O
promoter O
in O
lean O
but O
not O
obese O
rat O
fat O
cells O
. O

Finally O
, O
using O
in O
vitro O
binding O
studies O
, O
we O
showed O
that O
SREBP2 I-GENE
was O
able O
to O
displace O
ADD1 I-GENE
/ O
SREBP1 I-GENE
binding O
from O
the O
sterol O
regulatory O
element O
( O
SRE O
) O
site O
. O

Thus O
, O
IRF I-GENE
- I-GENE
7 I-GENE
exhibits O
functional O
similarity O
to O
IRF I-GENE
- I-GENE
3 I-GENE
; O
however O
, O
the O
preferential O
expression O
of O
IRF I-GENE
- I-GENE
7 I-GENE
in O
lymphoid O
cells O
( O
the O
cell O
type O
that O
expresses O
IFNA I-GENE
) O
suggests O
that O
IRF I-GENE
- I-GENE
7 I-GENE
may O
play O
a O
critical O
role O
in O
regulating O
the O
IFNA I-GENE
gene I-GENE
expression O
. O

J O
. O

PURPOSE O
: O
The O
role O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
in O
the O
treatment O
of O
congenital O
thrombocytopenias O
is O
unknown O
. O

CKII I-GENE
as O
a O
CD44 I-GENE
- I-GENE
associated I-GENE
serine I-GENE
kinase I-GENE
therefore O
may O
serve O
as O
an O
important O
molecule O
in O
a O
signaling O
cascade O
that O
produces O
a O
variety O
of O
cellular O
responses O
in O
MDA231 O
breast O
cancer O
cells O
. O

Galphaq I-GENE
, O
Galpha12 I-GENE
, O
and O
Galpha13 I-GENE
, O
but O
not O
Galphai I-GENE
, O
activate O
SRF I-GENE
through O
RhoA I-GENE
. O

Additionally O
in O
seven O
subjects O
adrenaline O
( O
A O
) O
and O
noradrenaline O
( O
NA O
) O
concentrations O
were O
determined O
. O

Northern O
blot O
analyses O
show O
that O
the O
hBub1 I-GENE
mRNA I-GENE
level O
is O
abundantly O
expressed O
in O
tissues O
or O
cells O
with O
a O
high O
mitotic O
index O
. O

We O
mapped O
two O
overlapping O
expressed O
sequence O
tag O
clones O
within O
a O
genomic O
contig O
on O
human O
chromosome O
5 O
, O
band O
q31 O
. O

Htra2 I-GENE
- I-GENE
beta3 I-GENE
is O
developmentally O
regulated O
and O
expressed O
predominantly O
in O
brain O
, O
liver O
testis O
, O
and O
weakly O
in O
kidney O
. O

Gng3lg I-GENE
transcripts I-GENE
are O
expressed O
in O
a O
variety O
of O
tissues O
including O
both O
brain O
and O
testes O
. O

Using O
an O
interspecific O
backcross O
panel O
, O
we O
localized O
both O
Gng3 I-GENE
and O
Gng3lg I-GENE
to O
the O
same O
locus O
on O
chromosome O
19 O
. O

We O
also O
raised O
a O
polyclonal O
antibody O
against O
the O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
NH2 O
- O
terminal O
86 O
amino O
acids O
of O
human I-GENE
NRAMP2 I-GENE
. O

Inhibition O
of O
the O
apolipoprotein I-GENE
B I-GENE
mRNA I-GENE
editing O
enzyme O
- O
complex O
by O
hnRNP I-GENE
C1 I-GENE
protein I-GENE
and O
40S I-GENE
hnRNP I-GENE
complexes I-GENE
. O

SRC I-GENE
- I-GENE
1 I-GENE
can O
relieve O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
- O
mediated O
repression O
of O
GR I-GENE
activity O
. O

However O
the O
sequence O
surrounding O
the O
transcription O
start O
site O
CTCA O
(+ O
1 O
) O
TTCC O
was O
similar O
to O
the O
consensus O
CTCA O
(+ O
1 O
) O
NTCT O
( O
N O
is O
any O
nucleoside O
) O
for O
an O
initiator O
element O
found O
in O
terminal I-GENE
deoxynucleotidyltransferase I-GENE
and O
a O
number O
of O
other O
highly O
regulated O
genes O
. O

These O
results O
indicate O
that O
the O
total O
number O
of O
subunit O
c O
in O
F0 I-GENE
should O
be O
a O
multiple O
of O
2 O
and O
3 O
. O

Expression O
of O
a O
dominant O
- O
negative O
mutant O
of O
JNK1 I-GENE
also O
suppressed O
glucose O
deprivation O
- O
induced O
JNK1 I-GENE
activation O
as O
well O
as O
HSP70 I-GENE
gene I-GENE
expression O
. O

The O
interaction O
of O
AF O
- O
1 O
with O
proteins O
that O
regulate O
distinct O
steps O
of O
transcription O
may O
provide O
a O
mechanism O
for O
synergistic O
activation O
of O
gene O
expression O
by O
AF O
- O
1 O
. O

The O
role O
of O
protein I-GENE
kinase I-GENE
C I-GENE
signaling O
in O
activated O
DRA I-GENE
transcription O
. O

Ligand O
binding O
to O
the O
receptor O
complex O
leads O
to O
tyrosine O
phosphorylation O
and O
activation O
of O
Janus I-GENE
kinases I-GENE
( O
Jak I-GENE
), O
phosphorylation O
of O
the O
signal I-GENE
transducing I-GENE
subunit I-GENE
gp130 I-GENE
, O
followed O
by O
recruitment O
and O
phosphorylation O
of O
the O
signal I-GENE
transducer I-GENE
and I-GENE
activator I-GENE
of I-GENE
transcription I-GENE
factors I-GENE
STAT3 I-GENE
and O
STAT1 I-GENE
and O
the O
src I-GENE
homology I-GENE
domain I-GENE
( O
SH2 I-GENE
)- O
containing O
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
( O
SHP2 I-GENE
). O

Interestingly O
, O
an O
increase O
of O
distance O
per O
se O
did O
not O
have O
a O
deleterious O
effect O
on O
translation O
efficiency O
. O

We O
also O
mapped O
a O
3 O
'- O
polyadenylation O
site O
504bp O
downstream O
of O
the O
TGA O
stop O
codon O
, O
consistent O
with O
the O
2 O
. O
5kb O
transcript O
size O
. O

RBP56 I-GENE
protein I-GENE
turned O
out O
to O
be O
hTAFII68 I-GENE
which O
was O
isolated O
as O
a O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
associated I-GENE
factor I-GENE
( O
TAF I-GENE
) O
from O
a O
sub O
- O
population O
of O
TFIID I-GENE
complexes I-GENE
( O
Bertolotti O
A O
., O
Lutz O
, O
Y O
., O
Heard O
, O
D O
. O
J O
., O
Chambon O
, O
P O
., O
Tora O
, O
L O
., O
1996 O
. O
hTAFII68 I-GENE
, O
a O
novel O
RNA O
/ O
ssDNA O
- O
binding O
protein O
with O
homology O
to O
the O
proto O
- O
oncoproteins O
TLS I-GENE
/ O
FUS I-GENE
and O
EWS I-GENE
is O
associated O
with O
both O
TFIID I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

An O
electrophoretic O
mobility O
shift O
assay O
was O
performed O
to O
characterize O
the O
binding O
property O
of O
TR2 I-GENE
and O
its O
truncated O
isoform O
. O

Gel O
- O
mobility O
shift O
analysis O
was O
also O
performed O
for O
the O
CCAAT O
motif O
at O
- O
67 O
. O

BACKGROUND O
: O
The O
c I-GENE
- I-GENE
myc I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
has O
been O
suggested O
to O
play O
key O
roles O
in O
cell O
proliferation O
, O
differentiation O
, O
transformation O
and O
apoptosis O
. O

AMY I-GENE
- I-GENE
1 I-GENE
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c I-GENE
- I-GENE
myc I-GENE
at O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c I-GENE
- I-GENE
myc I-GENE
expression O
in O
transiently O
transfected O
cells O
. O

RESULTS O
: O
We O
identified O
a O
full O
- O
length O
cDNA O
with O
an O
open O
reading O
frame O
of O
2883 O
bp O
corresponding O
to O
a O
predicted O
protein O
of O
961 O
amino O
acids O
that O
shares O
greater O
than O
95 O
% O
homology O
with O
the O
rat I-GENE
gamma I-GENE
- I-GENE
aminobutyric I-GENE
acid I-GENE
B I-GENE
( I-GENE
GABAB I-GENE
) I-GENE
receptor I-GENE
. O

On O
Day O
8 O
, O
the O
CIDR O
- O
B O
was O
removed O
and O
500 O
micrograms O
cloprostenol O
injected O
, O
IM O
. O

Antidepressant O
- O
like O
properties O
of O
some O
serotonin I-GENE
receptor I-GENE
ligands O
and O
calcium O
channel O
antagonists O
measured O
with O
the O
forced O
swimming O
test O
in O
mice O
. O

Another O
tentative O
hotspot O
mutation O
in O
the O
third O
patient O
, O
a O
frame O
shift O
caused O
by O
a O
G O
nucleotide O
insertion O
in O
a O
monotonous O
repeat O
of O
six O
Gs O
in O
HPRT I-GENE
exon I-GENE
3 I-GENE
, O
has O
been O
reported O
previously O
in O
three O
other O
LN O
patients O
. O

SRF I-GENE
- O
deficient O
embryos O
( O
Srf I-GENE
-/-) O
have O
a O
severe O
gastrulation O
defect O
and O
do O
not O
develop O
to O
term O
. O

These O
characteristic O
structural O
features O
were O
used O
to O
create O
the O
abbreviation O
AZF1 I-GENE
( O
Asparagine I-GENE
- I-GENE
rich I-GENE
Zinc I-GENE
Finger I-GENE
protein I-GENE
). O

Over O
- O
expression O
of O
Azf1p I-GENE
in O
the O
yeast O
cell O
does O
not O
influence O
the O
expression O
level O
of O
the O
mitochondrial I-GENE
transcription I-GENE
factor I-GENE
Mtf1p I-GENE
, O
indicating O
that O
the O
influence O
of O
Azf1p I-GENE
on O
the O
suppression O
of O
the O
special O
mitochondrial I-GENE
RNA I-GENE
polymerase I-GENE
mutant I-GENE
is O
an O
indirect O
one O
. O

We O
have O
generated O
a O
computer O
model O
of O
the O
C O
- O
terminal O
domain O
of O
the O
434 O
repressor O
based O
on O
the O
crystal O
structure O
of O
the O
homologous I-GENE
UmuD I-GENE
' I-GENE
protein I-GENE
. O

Large O
- O
scale O
sequencing O
of O
two O
regions O
in O
human O
chromosome O
7q22 O
: O
analysis O
of O
650 O
kb O
of O
genomic O
sequence O
around O
the O
EPO I-GENE
and O
CUTL1 I-GENE
loci I-GENE
reveals O
17 O
genes O
. O

Because O
Trp53 I-GENE
( O
the O
mouse I-GENE
homolog I-GENE
of I-GENE
human I-GENE
TP53 I-GENE
) O
is O
located O
with O
Tk1 I-GENE
on O
chromosome O
11 O
and O
is O
critical O
in O
regulating O
cellular O
responses O
following O
exposure O
to O
DNA O
damaging O
agents O
, O
we O
wanted O
to O
determine O
if O
these O
mouse O
lymphoma O
cells O
harbor O
mutations O
in O
Trp53 I-GENE
. O

One O
of O
these O
fragments O
shows O
the O
highest O
amino O
acid O
sequence O
homology O
to O
the O
insect O
ecdysone O
inducible O
gene I-GENE
E75 I-GENE
. O

The O
full O
- O
length O
N I-GENE
gene I-GENE
, O
encoded O
by O
open O
reading O
frame O
7 O
, O
was O
cloned O
from O
the O
Canadian O
PRRS O
virus O
, O
PA O
- O
8 O
. O

Based O
on O
sequence O
homology O
, O
the O
genes O
were O
identified O
as O
TEF I-GENE
, O
encoding O
translation I-GENE
elongation I-GENE
factor I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
and O
RPS7 I-GENE
, O
encoding O
ribosomal O
protein O
S7 I-GENE
. O

We O
have O
previously O
shown O
that O
ARNO I-GENE
localizes O
to O
the O
plasma O
membrane O
in O
vivo O
and O
efficiently O
catalyzes O
ARF6 I-GENE
nucleotide O
exchange O
in O
vitro O
. O

Renal O
pathology O
and O
long O
- O
term O
outcome O
in O
childhood O
SLE O
. O

Transcription O
factors O
of O
the O
Stat I-GENE
family I-GENE
are O
controlled O
by O
protein O
kinases O
. O

We O
propose O
that O
two O
pathways O
regulate O
Stat5 I-GENE
serine O
phosphorylation O
, O
one O
that O
is O
prolactin I-GENE
- O
activated O
and O
PD98059 O
- O
resistant O
and O
one O
that O
is O
constitutively O
active O
and O
PD98059 O
- O
sensitive O
and O
preferentially O
targets O
Stat5a I-GENE
. O

An O
approximately O
37 O
- O
kDa O
cytoplasmic O
protein O
is O
rapidly O
tyrosine O
- O
phosphorylated O
in O
the O
response O
of O
mouse O
BAC1 O
. O
2F5 O
macrophages O
to O
colony I-GENE
stimulating I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
). O
pp37 I-GENE
was O
purified O
from O
the O
cytosolic O
fraction O
by O
anti I-GENE
- I-GENE
Tyr I-GENE
( I-GENE
P I-GENE
) I-GENE
affinity O
chromatography O
, O
size O
exclusion O
chromatography O
, O
and O
C4 O
reverse O
phase O
high O
pressure O
liquid O
chromatography O
. O

Dose O
of O
20 O
ig O
were O
administered O
within O
a O
scheme O
from O
0 O
. O
1 O
to O
6 O
months O
in O
order O
to O
study O
its O
immunogenicity O
, O
which O
was O
evaluated O
at O
2 O
, O
7 O
, O
and O
12 O
months O
after O
the O
first O
dose O
. O

The O
various O
available O
data O
strongly O
suggesting O
an O
environmental O
toxic O
origin O
for O
the O
" O
sperm O
fall O
" O
will O
be O
presented O
as O
well O
as O
the O
most O
frequently O
suspected O
class O
of O
substances O
, O
the O
xenoestrogens O
. O

This O
association O
was O
independently O
significant O
for O
patients O
treated O
primarily O
( O
not O
for O
recurrence O
). O

CONCLUSION O
: O
Local O
control O
was O
highest O
with O
Preop O
in O
patients O
presenting O
primarily O
with O
gross O
disease O
, O
and O
with O
Postop O
in O
patients O
presenting O
primarily O
following O
gross O
total O
excision O
. O

Its O
interaction O
with O
RFX5 I-GENE
and O
RFXAP I-GENE
is O
essential O
for O
binding O
of O
the O
RFX I-GENE
complex I-GENE
to O
MHC I-GENE
- I-GENE
II I-GENE
promoters I-GENE
. O

We O
have O
previously O
mapped O
the O
defect O
in O
RIIIS O
/ O
J O
to O
distal O
mouse O
Chr O
11 O
, O
distinct O
from O
the O
Vwf I-GENE
locus I-GENE
on O
Chr O
6 O
. O

These O
data O
may O
also O
aid O
in O
the O
localization O
of O
other O
disease O
loci O
mapped O
to O
this O
region O
, O
including O
the O
gene O
for O
tricho O
- O
dento O
- O
osseous O
syndrome O
and O
a O
murine O
locus O
for O
susceptibility O
to O
ozone O
- O
induced O
acute O
lung O
injury O
. O

Copyright O
1998 O
Academic O
Press O
. O

An O
open O
reading O
frame O
encoding O
a O
protein O
which O
shows O
significant O
similarity O
to O
invertases I-GENE
and O
resolvases I-GENE
was O
located O
immediately O
upstream O
of O
the O
Pac25I I-GENE
R I-GENE
- I-GENE
M I-GENE
operon I-GENE
. O

Identification O
of O
a O
new O
gene O
in O
the O
streptococcal O
plasmid O
pLS1 O
: O
the O
rnaI I-GENE
gene I-GENE
. O

Rather O
, O
usp I-GENE
is O
required O
in O
late O
third O
instar O
larvae O
for O
appropriate O
developmental O
and O
transcriptional O
responses O
to O
the O
ecdysone O
pulse O
that O
triggers O
puparium O
formation O
. O

An O
intact O
neurovascular O
supply O
is O
essential O
for O
the O
viability O
of O
a O
muscle O
flap O
. O

Examination O
of O
DNA O
: O
protein O
binding O
complexes O
by O
gel O
- O
shift O
analysis O
indicated O
that O
nuclear O
factors O
from O
both O
proliferative O
and O
growth O
- O
arrested O
cells O
bound O
to O
the O
DNA O
fragment O
spanning O
- O
949 O
- O
- O
722 O
bp O
. O

BACKGROUND O
: O
Studies O
in O
lean O
men O
show O
poor O
regulation O
of O
energy O
( O
EB O
) O
and O
fat O
balance O
( O
FB O
) O
during O
manipulation O
of O
dietary O
ratios O
of O
fat O
to O
carbohydrate O
. O

Fatal O
apneusis O
was O
observed O
under O
following O
conditions O
: O
( O
1 O
) O
Persistent O
apnea O
was O
produced O
after O
a O
single O
KA O
microinjection O
in O
one O
side O
of O
the O
VRG O
- O
Apa O
( O
5 O
animals O
). O

A O
comparative O
analysis O
of O
the O
reported O
MOCT O
- O
associated O
malignant O
melanomas O
emphasizes O
the O
singularity O
of O
our O
case O
in O
the O
amelanotic O
character O
of O
the O
melanoma O
, O
its O
lymphotropism O
and O
the O
coexistence O
of O
invasive O
squamous O
cell O
carcinoma O
. O

RESULTS O
: O
An O
herpetic O
seroconversion O
is O
observed O
with O
presence O
of O
type O
I O
herpes O
simplex O
virus O
( O
HSV O
I O
) O
nucleic O
acids O
in O
the O
recipient O
' O
s O
aqueous O
humor O
. O

These O
results O
indicate O
that O
HIV O
- O
1 O
Gag I-GENE
sequences I-GENE
can O
influence O
the O
viral I-GENE
PR I-GENE
- O
mediated O
processing O
of O
the O
MuLV O
TM I-GENE
Env I-GENE
protein I-GENE
p15 O
( O
E O
). O

These O
results O
demonstrate O
a O
specific O
association O
of O
SIV O
and O
HIV I-GENE
- I-GENE
2 I-GENE
nef I-GENE
, O
but O
not O
HIV I-GENE
- I-GENE
1 I-GENE
nef I-GENE
, O
with O
TCRzeta I-GENE
. O

Competition O
EMSA O
established O
that O
constitutively O
expressed O
nuclear O
proteins O
bound O
the O
KCS I-GENE
element I-GENE
selectively O
; O
KCS I-GENE
protein I-GENE
binding O
activity O
correlated O
with O
promoter O
activity O
in O
the O
transient O
transfection O
reporter O
assay O
. O

Mechanism O
of O
interferon I-GENE
action O
: O
identification O
of O
essential O
positions O
within O
the O
novel O
15 I-GENE
- I-GENE
base I-GENE
- I-GENE
pair I-GENE
KCS I-GENE
element I-GENE
required O
for O
transcriptional O
activation O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
pkr I-GENE
gene I-GENE
. O

GH I-GENE
failed O
to O
stimulate O
phosphorylation O
or O
activation O
of O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
under O
the O
conditions O
used O
. O

Expression O
of O
a O
novel O
murine I-GENE
phospholipase I-GENE
D I-GENE
homolog I-GENE
coincides O
with O
late O
neuronal O
development O
in O
the O
forebrain O
. O

We O
detected O
no O
effect O
of O
deleting O
YCL024W I-GENE
, O
either O
alone O
or O
in O
combination O
with O
deletion O
of O
GIN4 I-GENE
. O

Paralemmin I-GENE
is O
also O
phosphorylated O
, O
and O
its O
mRNA O
is O
differentially O
spliced O
in O
a O
tissue O
- O
specific O
and O
developmentally O
regulated O
manner O
. O

The O
deduced O
amino O
acid O
sequence O
of O
CBP90 I-GENE
had O
no O
significant O
similarity O
to O
any O
other O
protein O
, O
but O
it O
had O
a O
proline O
- O
rich O
domain O
at O
the O
C O
- O
terminal O
region O
. O

The O
effect O
of O
low O
- O
profile O
serine O
substitutions O
in O
the O
V3 I-GENE
loop O
of O
HIV O
- O
1 O
gp120 I-GENE
IIIB I-GENE
/ O
LAI I-GENE
on O
the O
immunogenicity O
of O
the O
envelope I-GENE
protein O
. O

Transcription O
start O
site O
mapping O
identified O
the O
presence O
of O
an O
aphidicolin O
- O
sensitive O
late O
transcript O
arising O
from O
a O
TAAG O
motif O
located O
at O
- O
352 O
nucleotides O
and O
an O
aphidicolin O
- O
insensitive O
early O
transcript O
originating O
from O
a O
TTGT O
motif O
located O
35 O
nucleotides O
downstream O
to O
a O
TATA O
box O
at O
- O
312 O
nucleotides O
, O
with O
respect O
to O
the O
+ O
1 O
ATG O
of O
lef2 I-GENE
. O

The O
human I-GENE
2 I-GENE
', I-GENE
5 I-GENE
'- I-GENE
oligoadenylate I-GENE
( I-GENE
2 I-GENE
- I-GENE
5A I-GENE
) I-GENE
synthetases I-GENE
are O
members O
of O
a O
family O
interferon I-GENE
( O
IFN I-GENE
)- O
inducible O
anti I-GENE
- I-GENE
viral I-GENE
proteins I-GENE
. O

Our O
findings O
demonstrate O
a O
dose O
- O
dependent O
blockade O
of O
the O
mechanical O
sensitivity O
caused O
by O
a O
mild O
thermal O
injury O
by O
both O
GBP O
and O
IBG O
. O

These O
striations O
were O
caused O
by O
contact O
between O
the O
sharp O
edge O
of O
the O
upper O
canine O
and O
the O
P3 O
during O
honing O
( O
canine O
/ O
premolar O
complex O
). O

Low O
PbrO2 O
readings O
, O
however O
, O
could O
be O
caused O
by O
local O
microhemorrhages O
, O
undetectable O
on O
CT O
or O
MRI O
. O

The O
consequences O
of O
intensive O
swine O
production O
on O
the O
environment O
and O
possible O
solutions O
by O
means O
of O
nutrition O
are O
outlined O
. O

This O
study O
demonstrates O
that O
alteration O
of O
CDKN2 I-GENE
is O
one O
of O
the O
most O
frequent O
genetic O
abnormalities O
in O
prostate O
cancer O
and O
may O
contribute O
to O
prostate O
carcinogenesis O
. O

The O
pharmacokinetic O
parameters O
which O
helped O
predict O
these O
toxicities O
included O
area O
under O
the O
curve O
and O
peak O
plasma O
level O
. O

A O
Chinese O
( O
HK O
) O
SF O
- O
36 O
survey O
form O
was O
developed O
by O
an O
iterative O
translation O
process O
. O

However O
, O
the O
use O
of O
cyclosporin O
A O
is O
associated O
with O
an O
increased O
prevalence O
of O
hypertension O
in O
kidney O
transplant O
recipients O
. O

PURPOSE O
: O
To O
determine O
the O
effects O
of O
hypercholesterolemia O
and O
atherosclerosis O
- O
induced O
chronic O
cavernosal O
arterial O
insufficiency O
on O
cavernosal O
smooth O
muscle O
tone O
, O
nitric I-GENE
oxide I-GENE
synthase I-GENE
( O
NOS I-GENE
) O
activity O
and O
cavernosal O
tissue O
synthesis O
of O
constrictor O
eicosanoids O
. O

Characterization O
of O
the O
regulatory O
regions O
of O
the O
human I-GENE
aromatase I-GENE
( O
P450arom I-GENE
) O
gene O
involved O
in O
placenta O
- O
specific O
expression O
. O

Recombinant I-GENE
FVIIa I-GENE
was O
stable O
in O
the O
infusion O
pump O
for O
several O
days O
at O
room O
temperature O
and O
for O
24 O
h O
at O
body O
temperature O
. O

CD4 I-GENE
lymphocyte O
and O
viral O
load O
levels O
suggested O
an O
optimal O
response O
to O
ARV O
therapy O
at O
the O
time O
LD O
developed O
. O

( O
1992 O
) O
Biochemistry O
31 O
, O
3351 O
- O
3358 O
]. O

Levels O
of O
serum O
IgE I-GENE
were O
measured O
monthly O
, O
and O
nasal O
IgE I-GENE
was O
measured O
at O
the O
height O
and O
end O
of O
the O
season O
. O

A O
mutation O
in O
the O
5 O
' O
C2U4 O
repeat O
causes O
underaccumulation O
of O
snR13F I-GENE
, O
whereas O
mutations O
in O
the O
3 O
' O
C2U4 O
repeat O
cause O
the O
accumulation O
of O
two O
novel O
RNAs O
that O
migrate O
in O
the O
500 O
- O
nt O
range O
. O

By O
directly O
interacting O
with O
both O
Arfs I-GENE
and O
tyrosine I-GENE
kinases I-GENE
involved O
in O
regulating O
cell O
growth O
and O
cytoskeletal O
organization O
, O
ASAP1 I-GENE
could O
coordinate O
membrane O
remodeling O
events O
with O
these O
processes O
. O

By O
DNase I-GENE
I I-GENE
footprint O
analysis O
of O
the O
PNR O
element O
, O
a O
palindrome O
of O
two O
high O
- O
affinity O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( O
CTTCCCTGGAAG O
) O
was O
identified O
. O

These O
sorting I-GENE
nexins I-GENE
also O
associated O
with O
the O
long O
isoform O
of O
the O
leptin I-GENE
receptor I-GENE
but O
not O
with O
the O
short O
and O
medium O
isoforms O
. O

Cyclophilins I-GENE
are O
cis I-GENE
- I-GENE
trans I-GENE
- I-GENE
peptidyl I-GENE
- I-GENE
prolyl I-GENE
isomerases I-GENE
that O
bind O
to O
and O
are O
inhibited O
by O
the O
immunosuppressant O
cyclosporin O
A O
( O
CsA O
). O

In O
vitro O
protein O
retention O
experiments O
in O
which O
Hsp90 I-GENE
heterocomplexes I-GENE
were O
precipitated O
resulted O
in O
coprecipitation O
of O
Cns1 I-GENE
. O

The O
Ras I-GENE
- I-GENE
related I-GENE
GTPases I-GENE
are O
small O
, O
20 O
- O
to O
25 O
- O
kDa O
proteins O
which O
cycle O
between O
an O
inactive O
GDP O
- O
bound O
form O
and O
an O
active O
GTP O
- O
bound O
state O
. O

To O
modulate O
transcription O
, O
regulatory O
factors O
communicate O
with O
basal O
transcription O
factors O
and O
/ O
or O
RNA I-GENE
polymerases I-GENE
in O
a O
variety O
of O
ways O
. O

Endogenous O
RMP I-GENE
was O
immunologically O
detected O
interacting O
with O
assembled O
RPB5 I-GENE
in O
RNA I-GENE
polymerase I-GENE
in O
mammalian O
cells O
. O

In O
this O
study O
, O
rabbits O
were O
used O
to O
evaluate O
the O
sutured O
wound O
reaction O
with O
Dexon O
or O
nylon O
in O
the O
conjunctival O
flap O
1 O
, O
4 O
, O
7 O
, O
14 O
and O
28 O
days O
after O
trabeculectomy O
surgery O
with O
or O
without O
the O
use O
of O
mitomycin O
- O
C O
. O

The O
mapping O
was O
completed O
with O
Southern O
blotting O
and O
restriction O
analysis O
. O

The O
zona O
pellucida O
( O
ZP O
), O
the O
extracellular O
glycocalyx O
that O
surrounds O
the O
oocyte O
, O
is O
well O
known O
to O
mediate O
homologous O
gamete O
interaction O
. O

Therapeutic O
use O
of O
continuous O
subcutaneous O
infusion O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
in O
malnourished O
predialysis O
anemic O
patients O
with O
diabetic O
nephropathy O
. O

Although O
pathological O
thyroid O
function O
is O
related O
to O
changes O
in O
energy O
expenditure O
and O
body O
composition O
, O
its O
possible O
influence O
on O
leptin I-GENE
levels O
remains O
to O
be O
determined O
. O

These O
cognitive O
deficits O
were O
prevented O
in O
animals O
treated O
with O
MK O
- O
801 O
during O
SE O
. O

Here O
we O
demonstrate O
that O
the O
mechanism O
of O
activation O
of O
HIF I-GENE
- I-GENE
1alpha I-GENE
is O
a O
multi O
- O
step O
process O
which O
includes O
hypoxia O
- O
dependent O
nuclear O
import O
and O
activation O
( O
derepression O
) O
of O
the O
transactivation O
domain O
, O
resulting O
in O
recruitment O
of O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
)/ O
p300 I-GENE
coactivator I-GENE
. O

Thus O
, O
hypoxia O
- O
inducible O
nuclear O
import O
and O
transactivation O
by O
recruitment O
of O
CBP I-GENE
can O
be O
functionally O
separated O
from O
one O
another O
and O
play O
critical O
roles O
in O
signal O
transduction O
by O
HIF I-GENE
- I-GENE
1alpha I-GENE
. O

The O
rat I-GENE
aldolase I-GENE
C I-GENE
gene I-GENE
encodes O
a O
glycolytic O
enzyme O
strongly O
expressed O
in O
adult O
brain O
. O

A O
synergistic O
effect O
on O
HCK I-GENE
promoter I-GENE
activity O
was O
observed O
at O
high O
concentrations O
of O
Sp1 I-GENE
. O

Quinone O
- O
binding O
domain O
and O
amino O
acid O
residues O
involved O
in O
quinone O
binding O
. O

Western O
analyses O
with O
antisera O
raised O
against O
Lu I-GENE
- I-GENE
ECAM I-GENE
- I-GENE
1 I-GENE
peptides I-GENE
show O
that O
the O
N O
- O
terminal O
region O
of O
the O
predicted O
open O
reading O
frame O
is O
present O
only O
in O
the O
larger O
size O
proteins O
( O
i O
. O
e O
. O

Mammalian O
sperm O
motility O
is O
regulated O
by O
a O
cascade O
of O
cAMP O
- O
dependent O
protein O
phosphorylation O
events O
mediated O
by O
protein I-GENE
kinase I-GENE
A I-GENE
. O

In O
this O
paper O
, O
we O
show O
that O
, O
like O
BAP2 I-GENE
, O
the O
expression O
of O
the O
BAP3 I-GENE
gene I-GENE
in O
S O
. O
cerevisiae O
is O
induced O
by O
the O
addition O
of O
branched O
- O
chain O
amino O
acids O
to O
the O
medium O
. O

Effect O
of O
enteral O
nutritional O
products O
differing O
in O
carbohydrate O
and O
fat O
on O
indices O
of O
carbohydrate O
and O
lipid O
metabolism O
in O
patients O
with O
NIDDM O
. O

Low O
- O
grade O
gastric O
MALT O
lymphoma O
and O
helicobacter O
heilmannii O
( O
Gastrospirillum O
hominis O

These O
studies O
support O
the O
view O
that O
HMG I-GENE
I I-GENE
( I-GENE
Y I-GENE
) I-GENE
is O
an O
important O
cofactor O
for O
HLA I-GENE
- I-GENE
DRA I-GENE
gene I-GENE
activation O
by O
Oct I-GENE
- I-GENE
2A I-GENE
and O
provide O
insights O
into O
its O
mechanism O
of O
action O
. O

In O
contrast O
to O
hemodynamic O
and O
histopathological O
predictors O
of O
survival O
, O
vWF I-GENE
: O
Ag O
does O
not O
require O
invasive O
techniques O
to O
be O
determined O
. O

CONCLUSION O
: O
We O
were O
unable O
to O
identify O
features O
of O
disease O
likely O
to O
be O
associated O
with O
a O
clinically O
useful O
response O
to O
inhaled O
NO O
therapy O
using O
the O
parameters O
studied O
. O

We O
find O
that O
BCL I-GENE
- I-GENE
6 I-GENE
POZ O
domain O
mutations O
that O
disrupt O
the O
interaction O
with O
N I-GENE
- I-GENE
CoR I-GENE
and O
SMRT I-GENE
no O
longer O
repress O
transcription O
. O

Partial O
characterization O
of O
the O
active O
site O
human I-GENE
platelet I-GENE
cAMP I-GENE
phosphodiesterase I-GENE
, O
PDE3A I-GENE
, O
by O
site O
- O
directed O
mutagenesis O
. O

This O
core O
sequence O
, O
along O
with O
additional O
nonspecific O
downstream O
nucleotides O
, O
is O
sufficient O
for O
partial O
suppression O
of O
spliceosome O
assembly O
and O
splicing O
of O
BPV O
- O
1 O
pre O
- O
mRNAs O
. O

Over O
- O
expression O
of O
the O
cofactor O
p300 I-GENE
, O
which O
functions O
as O
a O
coactivator O
of O
myoD I-GENE
- O
mediated O
transcription O
, O
alleviated O
repression O
by O
COUP I-GENE
- I-GENE
TF I-GENE
II I-GENE
. O

Familial O
autoimmune O
hepatitis O
and O
C4 I-GENE
deficiency O

No O
mutations O
were O
found O
in O
follicular O
adenomas O
. O

Since O
glutathione I-GENE
peroxidase I-GENE
( O
GPX I-GENE
) O
and O
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
play O
a O
significant O
role O
in O
erythrocyte O
antioxidative O
defence O
, O
it O
is O
very O
important O
to O
determine O
their O
activity O
in O
occupationally O
exposed O
workers O
. O

Retroviral I-GENE
nucleocapsid I-GENE
proteins I-GENE
( O
NCPs I-GENE
) O
are O
CCHC I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
that O
mediate O
virion O
RNA O
binding O
activities O
associated O
with O
retrovirus O
assembly O
and O
genomic O
RNA O
encapsidation O
. O

The O
Schizosaccharomyces I-GENE
pombe I-GENE
rad1 I-GENE
+ I-GENE
cell I-GENE
cycle I-GENE
checkpoint I-GENE
control I-GENE
gene I-GENE
is O
required O
for O
S O
- O
phase O
and O
G2 O
/ O
M O
arrest O
in O
response O
to O
both O
DNA O
damage O
and O
incomplete O
DNA O
replication O
. O

It O
is O
now O
well O
established O
that O
progression O
through O
the O
eukaryotic O
cell O
cycle O
is O
controlled O
by O
oscillations O
in O
the O
activity O
of O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
CDKs I-GENE
). O

Positive O
genetic O
selections O
for O
inhibition O
of O
cyclin I-GENE
/ O
CDK I-GENE
function O
were O
characterized O
using O
the O
E I-GENE
. I-GENE
coli I-GENE
neo I-GENE
and O
yeast I-GENE
LEU2 I-GENE
genes I-GENE
. O

The O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
CSF I-GENE
) O
have O
been O
introduced O
into O
clinical O
practice O
as O
additional O
supportive O
measures O
that O
can O
reduce O
the O
incidence O
of O
infectious O
complications O
in O
patients O
with O
cancer O
and O
neutropenia O
. O

All O
injections O
of O
CSF I-GENE
were O
given O
after O
the O
initiation O
of O
neutropenia O
and O
continued O
until O
the O
occurrence O
of O
an O
absolute O
neutrophil O
recovery O
. O
rHu I-GENE
GM I-GENE
- I-GENE
CSF I-GENE
and O
rHu I-GENE
G I-GENE
- I-GENE
CSF I-GENE
, O
administered O
once O
daily O
at O
the O
250 O
microg O
m O
(- O
2 O
) O
day O
(- O
1 O
) O
and O
5 O
microg O
kg O
(- O
1 O
) O
day O
(- O
1 O
) O
level O
, O
were O
effective O
in O
increasing O
the O
absolute O
neutrophil O
count O
and O
neutrophil O
function O
, O
as O
measured O
by O
an O
automated O
chemiluminescence O
system O
. O

Expression O
of O
lacZ I-GENE
from O
the O
promoter O
of O
the O
Escherichia I-GENE
coli I-GENE
spc I-GENE
operon I-GENE
cloned O
into O
vectors O
carrying O
the O
W205 O
trp I-GENE
- O
lac I-GENE
fusion O
. O

We O
evaluated O
regional O
right O
ventricular O
wall O
motion O
during O
systole O
in O
patients O
with O
surgically O
repaired O
tetralogy O
of O
Fallot O
( O
TOF O
) O
using O
color O
kinesis O
imaging O
. O

RT O
- O
PCR O
analysis O
showed O
that O
PLP I-GENE
- I-GENE
H I-GENE
as O
well O
as O
PLP I-GENE
- I-GENE
C I-GENE
and O
PLP I-GENE
- I-GENE
D I-GENE
are O
expressed O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
PLP I-GENE
diversity O
is O
not O
due O
to O
strain O
differences O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
new O
member O
of O
the O
rat I-GENE
placental I-GENE
prolactin I-GENE
( O
PRL I-GENE
) O
family O
, O
PRL I-GENE
- O
like O
protein I-GENE
H I-GENE
. O

Interestingly O
, O
we O
find O
that O
the O
interaction O
between O
Tat I-GENE
and O
hCycT1 I-GENE
requires O
zinc O
as O
well O
as O
essential O
cysteine O
residues O
in O
both O
proteins O
. O

Thus O
, O
we O
have O
identified O
an O
activation O
target O
of O
a O
human O
activator O
, O
Oct I-GENE
- I-GENE
1 I-GENE
, O
within O
its O
cognate O
basal O
transcription O
complex O
. O

During O
early O
neurogenesis O
, O
Vnd I-GENE
protein I-GENE
is O
restricted O
to O
ventral O
column O
neuroectoderm O
and O
neuroblasts O
; O
later O
it O
is O
detected O
in O
a O
complex O
pattern O
of O
neurons O
. O

The O
repression O
domain O
, O
and O
indeed O
the O
entire O
Cdc68 I-GENE
protein I-GENE
, O
is O
highly O
conserved O
, O
as O
shown O
by O
the O
sequence O
of O
the O
Cdc68 I-GENE
functional I-GENE
homolog I-GENE
from O
the O
yeast O
Kluyveromyces O
lactis O
and O
by O
database O
searches O
. O

The O
exodomain O
alone O
has O
the O
high O
affinity O
hormone O
binding O
site O
but O
is O
not O
capable O
of O
generating O
hormonal O
signal O
. O

Pyrrolidine O
dithiocarbamate O
, O
a O
potent O
transcriptional O
inhibitor O
of O
the O
viral I-GENE
LTR I-GENE
, O
abrogated O
the O
cytokine O
responses O
in O
both O
U1 O
and O
ACH O
- O
2 O
cells O
, O
suggesting O
a O
common O
TNF I-GENE
- I-GENE
alpha I-GENE
- O
mediated O
transcriptional O
mechanism O
in O
these O
cell O
types O
despite O
their O
different O
modes O
of O
provirus O
latency O
. O

Furthermore O
, O
synergistic O
activation O
of O
ERK2 I-GENE
occurred O
in O
the O
absence O
of O
changes O
in O
intracellular O
Ca2 O
+, O
and O
was O
not O
blocked O
by O
inhibition O
of O
protein I-GENE
kinase I-GENE
C I-GENE
activity O
and O
represents O
a O
separate O
pathway O
by O
which O
CD19 I-GENE
regulates O
B O
cell O
function O
. O

The O
retrovesical O
hydatid O
cyst O
is O
a O
very O
rare O
site O
. O

Biochemical O
analysis O
reveals O
that O
KS1 I-GENE
is O
a O
nuclear O
protein O
containing O
two O
transcriptional O
repressor O
domains O
, O
R1 O
and O
R2 O
. O

However O
, O
the O
BCH O
group O
showed O
inferior O
gross O
motor O
performance O
on O
the O
Bruininks O
- O
Oseretsky O
Test O
of O
Motor O
Proficiency O
( O
Bruininks O
1978 O
). O

The O
results O
raise O
the O
possibility O
that O
pH O
induced O
post O
- O
translational O
modifications O
of O
DdRPA I-GENE
are O
involved O
in O
events O
that O
halt O
cell O
proliferation O
and O
induce O
differentiation O
in O
Dictyostelium O
. O

We O
report O
here O
that O
, O
for O
a O
constant O
amount O
of O
transfected O
DNA O
, O
the O
level O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
mRNA O
is O
increased O
in O
Vpr I-GENE
- O
expressing O
cells O
using O
either O
HIV O
- O
1 O
or O
a O
murine O
leukemia I-GENE
virus I-GENE
( I-GENE
MLV I-GENE
) I-GENE
SL3 I-GENE
- I-GENE
3 I-GENE
LTR I-GENE
- O
CAT I-GENE
reporter O
construct O
. O

We O
identified O
telSMN I-GENE
mutations O
in O
11 O
of O
these O
unrelated O
SMA O
- O
like O
individuals O
who O
carry O
a O
single O
copy O
of O
telSMN I-GENE
: O
these O
include O
two O
frameshift O
mutations O
( O
800ins11 O
and O
542delGT O
) O
and O
three O
missense O
mutations O
( O
A2G O
, O
S262I O
, O
and O
T274I O
). O

The O
decrease O
of O
TNF I-GENE
receptors I-GENE
by O
IL I-GENE
- I-GENE
4 I-GENE
was O
accompanied O
by O
down O
- O
regulation O
of O
TNF I-GENE
- O
induced O
activities O
, O
including O
cytotoxicity O
, O
caspase I-GENE
- I-GENE
3 I-GENE
activation O
, O
NF I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
activation O
, O
and O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
induction O
. O

Type I-GENE
2 I-GENE
deiodinase I-GENE
( O
D2 I-GENE
) O
catalyzes O
the O
5 O
'- O
deiodination O
of O
thyroxine O
to O
form O
3 O
, O
5 O
, O
3 O
'- O
triiodothyronine O
. O

We O
have O
identified O
two O
overlapping O
expressed O
sequence O
tag O
clones O
, O
which O
contain O
the O
missing O
4 O
. O
4 O
- O
kb O
3 O
'- O
UTR O
of O
the O
human I-GENE
D2 I-GENE
( O
hD2 I-GENE
) O
cDNA O
. O

Biol O
. O

Here O
we O
have O
investigated O
the O
structural O
requirements O
and O
consequences O
of O
regulatory O
phosphorylation O
for O
the O
interaction O
between O
c I-GENE
- I-GENE
Jun I-GENE
and O
JNK I-GENE
in O
vivo O
. O

P I-GENE
- I-GENE
CIP1 I-GENE
, O
a O
novel O
protein O
that O
interacts O
with O
the O
cytosolic O
domain O
of O
peptidylglycine I-GENE
alpha I-GENE
- I-GENE
amidating I-GENE
monooxygenase I-GENE
, O
is O
associated O
with O
endosomes O
. O

Immunolocalization O
of O
Sop1p I-GENE
revealed O
a O
cytoplasmic O
distribution O
and O
cell O
fractionation O
studies O
showed O
that O
a O
significant O
fraction O
of O
Sop1p I-GENE
was O
recovered O
in O
a O
sedimentable O
fraction O
of O
the O
cytosolic O
material O
. O

Resultant O
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ O
SAPK I-GENE
). O

Here O
we O
report O
the O
full O
- O
length O
coding O
cDNA O
sequence O
of O
the O
mouse I-GENE
homologue I-GENE
of I-GENE
MPP3 I-GENE
. O

The O
method O
also O
eliminates O
tagging O
of O
venous O
spins O
and O
concern O
about O
asymmetric O
magnetization O
transfer O
effects O
. O

Consistent O
with O
this O
, O
purified O
Dlk I-GENE
phosphorylated O
core O
histones I-GENE
H3 I-GENE
, O
H2A I-GENE
and O
H4 I-GENE
as O
exogenous O
substrates O
and O
endogenous O
histone I-GENE
H3 I-GENE
in O
kinase O
assays O
with O
nuclear O
extracts O
. O

In O
this O
study O
we O
provide O
evidence O
that O
B I-GENE
- I-GENE
Myb I-GENE
is O
a O
direct O
physiological O
target O
for O
cyclin I-GENE
A I-GENE
/ O
Cdk2 I-GENE
. O

Neither O
Ha I-GENE
- I-GENE
Ras I-GENE
( O
G12V O
, O
T35S O
) O
( O
Ha I-GENE
- I-GENE
RasV12S35 I-GENE
), O
which O
activates O
the O
Rafl I-GENE
signaling O
pathway O
, O
nor O
Ha I-GENE
- I-GENE
Ras I-GENE
( I-GENE
G12V I-GENE
, I-GENE
E37G I-GENE
) I-GENE
( O
Ha I-GENE
- I-GENE
RasV12G37 I-GENE
), O
which O
stimulates O
the O
RalGDS I-GENE
pathway O
, O
did O
not O
have O
significant O
effects O
on O
factor O
- O
withdrawal O
apoptosis O
of O
myeloid O
cells O
. O

We O
have O
isolated O
a O
novel O
human I-GENE
cyclin I-GENE
, O
cyclin I-GENE
E2 I-GENE
, O
that O
contains O
significant O
homology O
to O
cyclin I-GENE
E I-GENE
. O

Initial O
experience O
with O
the O
new O
technology O
indicates O
that O
SieScape O
is O
an O
alternative O
to O
other O
methods O
such O
as O
CT O
and O
MRI O
. O

The O
dopamine I-GENE
D4 I-GENE
receptor I-GENE
as O
well O
as O
many O
other O
catecholaminergic I-GENE
receptors I-GENE
contain O
several O
putative O
SH3 I-GENE
binding I-GENE
domains I-GENE
. O

The O
highly O
amyloidogenic O
42 O
- O
residue O
form O
of O
Abeta I-GENE
( O
Abeta42 I-GENE
) O
is O
the O
first O
species O
to O
be O
deposited O
in O
both O
sporadic O
and O
familial O
AD O
. O

This O
model O
is O
supported O
by O
experiments O
showing O
that O
Cdr2 I-GENE
associates O
with O
the O
N I-GENE
- I-GENE
terminal I-GENE
regulatory I-GENE
domain I-GENE
of I-GENE
Wee1 I-GENE
in O
cell O
lysates O
and O
phosphorylates O
Wee1 I-GENE
in O
vitro O
. O

Schizosaccharomyces O
pombe O
cells O
respond O
to O
nutrient O
deprivation O
by O
altering O
G2 O
/ O
M O
cell O
size O
control O
. O

A O
- O
tracts O
functioned O
best O
when O
positioned O
close O
to O
the O
- O
35 O
hexamer O
rather O
than O
one O
helical O
turn O
farther O
upstream O
, O
similar O
to O
the O
positioning O
optimal O
for O
UP O
element O
function O
. O

Pyk2 I-GENE
phosphorylation O
increased O
upon O
adherence O
of O
FLG O
29 O
. O
1 O
cells O
to O
fibronectin I-GENE
and O
to O
ST2 O
stromal O
cells O
. O

Raf I-GENE
is O
a O
key O
serine I-GENE
- I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
which O
participates O
in O
the O
transmission O
of O
growth O
, O
anti O
- O
apoptotic O
and O
differentiation O
messages O
. O

The O
US O
National O
Institute O
on O
Alcohol O
Abuse O
and O
Alcoholism O
( O
NIAAA O
) O
recognizes O
two O
forms O
of O
problematic O
drinking O
: O
' O
willful O
alcohol O
abuse O
', O
a O
behavioural O
problem O
, O
and O
' O
alcohol O
dependence O
', O
a O
true O
medical O
disorder O
, O
which O
includes O
a O
genetic O
component O
, O
that O
can O
be O
scientifically O
understood O
and O
medically O
treated O
. O

Collagen I-GENE
was O
extracted O
from O
the O
skin O
, O
and O
the O
lack O
of O
type I-GENE
III I-GENE
collagen I-GENE
was O
determined O
by O
means O
of O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- O
PAGE O
). O

RESULTS O
: O
During O
the O
7 O
- O
year O
period O
, O
10 O
, O
331 O
symptomatic O
duodenal O
ulcer O
diseases O
were O
diagnosed O
. O

RESULTS O
: O
Significant O
changes O
from O
pretreatment O
to O
posttreatment O
were O
observed O
( O
p O
< O
0 O
. O
001 O
). O

In O
turn O
, O
assembly O
of O
this O
complex O
mediates O
the O
enzymatic O
activation O
of O
the O
p21 I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
and O
facilitates O
actin I-GENE
polymerization O
. O

The O
tip O
of O
the O
button O
caused O
a O
perforation O
of O
the O
posterior O
stomach O
wall O
, O
leading O
to O
death O
. O

Jembrana O
disease O
virus O
( O
JDV O
) O
is O
a O
newly O
identified O
bovine O
lentivirus O
that O
is O
closely O
related O
to O
the O
bovine O
immunodeficiency O
virus O
( O
BIV O
). O

Approximately O
50 O
% O
of O
the O
residues O
are O
conserved O
among O
all O
three O
sequences O
, O
yet O
all O
three O
viruses O
have O
retained O
response O
elements O
for O
glucocorticoids O
, O
two O
positionally O
conserved O
CCAAT O
boxes O
, O
and O
positionally O
conserved O
TATA O
boxes O
. O

Nhp2p I-GENE
is O
a O
highly O
basic O
protein O
that O
belongs O
to O
a O
family O
of O
putative O
RNA O
- O
binding O
proteins O
. O

This O
survey O
included O
3000 O
randomly O
selected O
Norwegians O
above O
18 O
years O
of O
age O
who O
received O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
( O
EORTC O
QLQ O
- O
C30 O
(+ O
3 O
) O
by O
mail O
. O

During O
presentation O
of O
happy O
facial O
expressions O
, O
we O
detected O
a O
signal O
increase O
predominantly O
in O
the O
left O
anterior O
cingulate O
gyrus O
, O
bilateral O
posterior O
cingulate O
gyri O
, O
medial O
frontal O
cortex O
and O
right O
supramarginal O
gyrus O
, O
brain O
regions O
previously O
implicated O
in O
visuospatial O
and O
emotion O
processing O
tasks O
. O

Down O
- O
regulation O
of O
IRS I-GENE
- I-GENE
1 I-GENE
is O
linked O
to O
its O
serine O
phosphorylation O
dependent O
on O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
activity O
and O
appears O
required O
for O
differentiation O
to O
occur O
, O
as O
IRS I-GENE
- I-GENE
1 I-GENE
is O
not O
modified O
and O
continues O
to O
accumulate O
in O
a O
nondifferentiating O
myoblast O
cell O
line O
. O

This O
study O
utilizes O
the O
mammalian O
two O
- O
hybrid O
system O
to O
examine O
the O
role O
of O
ligand O
in O
the O
dimerization O
of O
human I-GENE
progesterone I-GENE
receptor I-GENE
( O
hPR I-GENE
). O

One O
of O
its O
unique O
features O
appears O
to O
be O
the O
unusually O
short O
5 O
'- O
untranslated O
regions O
( O
UTR O
) O
( O
1 O
- O
6 O
nucleotides O
( O
nts O
)) O
and O
the O
apparent O
absence O
of O
5 O
'- O
cap O
structures O
from O
its O
mRNAs O
. O

The O
gene I-GENE
encoding I-GENE
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
. O

Both O
the O
presence O
of O
arginine O
and O
anaerobiosis O
are O
needed O
to O
trigger O
induction O
of O
the O
pathway O
. O

Competition O
with O
a O
putative O
MADS I-GENE
box I-GENE
consensus O
binding O
site O
from O
the O
promoter O
of O
the O
coordinately O
regulated O
opaque I-GENE
- I-GENE
phase I-GENE
- I-GENE
specific I-GENE
gene I-GENE
PEP1 I-GENE
( O
SAP1 I-GENE
) O
and O
the O
human I-GENE
MADS I-GENE
box I-GENE
consensus I-GENE
binding I-GENE
site I-GENE
for O
serum I-GENE
response I-GENE
factor I-GENE
demonstrated O
that O
one O
of O
the O
three O
complexes O
formed O
was O
specific O
to O
the O
OP4 I-GENE
sequence I-GENE
. O

The O
human I-GENE
SHBG I-GENE
proximal I-GENE
promoter I-GENE
was O
analyzed O
by O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
the O
functional O
significance O
of O
6 O
footprinted O
regions O
( O
FP1 O
- O
FP6 O
) O
within O
the O
proximal O
promoter O
was O
studied O
in O
human O
HepG2 O
hepatoblastoma O
cells O
. O

In O
vitro O
translation O
and O
in O
vivo O
polysome O
profile O
analysis O
indicated O
that O
transcripts I-GENE
C I-GENE
and I-GENE
E I-GENE
were O
translated O
with O
similar O
translational O
efficiencies O
that O
are O
substantially O
greater O
than O
that O
of O
transcript I-GENE
D I-GENE
, O
suggesting O
that O
5 O
'- O
untranslated O
regions O
play O
a O
role O
in O
translational O
control O
. O

We O
have O
introduced O
a O
mutation O
( O
Ser36 O
--> O
Asn O
) O
into O
this O
domain O
of O
p190 I-GENE
that O
decreased O
its O
ability O
to O
bind O
guanine O
nucleotide O
when O
expressed O
as O
a O
hemagglutinin I-GENE
( O
HA I-GENE
)- O
tagged O
protein O
in O
COS O
cells O
. O

Wild O
type O
HA I-GENE
- O
p190 I-GENE
induced O
a O
phenotype O
of O
rounded O
cells O
with O
long O
, O
beaded O
extensions O
similar O
to O
that O
seen O
when O
Rho I-GENE
function O
is O
disrupted O
by O
ADP O
- O
ribosylation O
. O

We O
emphasize O
that O
ANCA I-GENE
- O
associated O
vasculitis O
is O
another O
important O
complication O
of O
RA O
. O

The O
downstream O
, O
TATA O
- O
less O
promoter O
has O
high O
G O
+ O
C O
content O
, O
and O
exon O
1b O
predominates O
among O
abundantly O
expressed O
mRNA O
species O
. O

Although O
we O
predicted O
that O
overexpression O
of O
the O
COOH O
- O
terminal O
domains O
, O
which O
were O
thought O
to O
be O
involved O
in O
the O
regulation O
of O
SREBP I-GENE
processing O
, O
would O
result O
in O
disruption O
of O
the O
SREBP I-GENE
- O
dependent O
transcriptional O
regulation O
of O
several O
genes O
, O
the O
mRNA O
levels O
for O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylglutaryl I-GENE
coenzyme I-GENE
A I-GENE
( I-GENE
HMG I-GENE
CoA I-GENE
) I-GENE
synthase I-GENE
in O
these O
two O
cell O
lines O
were O
regulated O
in O
a O
sterol O
- O
dependent O
manner O
. O

Dry O
matter O
intake O
, O
apparent O
nutrient O
digestibilities O
, O
serum O
chemistry O
profiles O
, O
sphingolipid O
concentrations O
, O
and O
persistency O
of O
FB1 O
in O
tissues O
were O
evaluated O
. O

However O
, O
no O
studies O
have O
been O
conducted O
to O
further O
investigate O
this O
potentially O
hazardous O
effect O
of O
lidocaine O
. O

E O
., O
Scott O
, O
J O
. O

Yap1p I-GENE
is O
constitutively O
nuclear O
in O
a O
crm1 I-GENE
mutant I-GENE
, O
and O
Crm1p I-GENE
binds O
to O
a O
nuclear O
export O
sequence O
( O
NES O
)- O
like O
sequence O
in O
Yap1p I-GENE
in O
the O
presence O
of O
RanGTP I-GENE
. O

Mean O
intake O
of O
vitamin O
A O
amounted O
to O
1 O
. O
1 O
and O
0 O
. O
9 O
mg O
RE O
/ O
day O
for O
men O
and O
women O
, O
respectively O
; O
the O
contributions O
of O
meat O
, O
fats O
and O
oils O
, O
vegetables O
and O
dairy O
products O
to O
total O
intake O
were O
35 O
%, O
24 O
%, O
16 O
%, O
and O
16 O
%, O
respectively O
. O

Also O
, O
the O
amplitude O
of O
the O
oscillatory O
potentials O
( O
O1 O
+ O
O2 O
+ O
O3 O
+ O
O4 O
) O
was O
significantly O
reduced O
in O
the O
early O
postoperative O
period O
. O

Furthermore O
, O
RING1 I-GENE
overexpression O
results O
in O
enhanced O
expression O
of O
the O
proto O
- O
oncogenes O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
. O

The O
yeast I-GENE
RER2 I-GENE
gene I-GENE
, O
identified O
by O
endoplasmic O
reticulum O
protein O
localization O
mutations O
, O
encodes O
cis I-GENE
- I-GENE
prenyltransferase I-GENE
, O
a O
key O
enzyme O
in O
dolichol O
synthesis O
. O

The O
yeast O
retrotransposon I-GENE
Ty5 I-GENE
preferentially O
integrates O
into O
regions O
of O
silent O
chromatin O
. O

The O
loss O
of O
SKO1 I-GENE
completely O
restored O
ENA1 I-GENE
expression O
in O
a O
hog1 I-GENE
mutant I-GENE
and O
partially O
suppressed O
the O
osmotic O
stress O
sensitivity O
, O
qualifying O
Sko1p I-GENE
as O
a O
downstream O
effector O
of O
the O
HOG I-GENE
pathway O
. O

Elevated O
expression O
of O
a O
previously O
uncharacterized O
gene O
, O
SPP381 I-GENE
, O
efficiently O
suppresses O
the O
growth O
and O
splicing O
defects O
of O
a O
temperature O
- O
sensitive O
( O
Ts O
) O
mutant I-GENE
prp38 I-GENE
- I-GENE
1 I-GENE
. O

The O
slower O
- O
electrophoretic O
- O
mobility O
form O
of O
p68 I-GENE
was O
absent O
in O
human O
cells O
in O
G1 O
/ O
S O
and O
appeared O
as O
the O
cells O
entered O
G2 O
/ O
M O
. O

We O
have O
identified O
amino O
acid O
sequences O
in O
mammalian O
and O
Xenopus O
NeuroD1 I-GENE
/ O
BETA2 I-GENE
that O
are O
necessary O
for O
insulin I-GENE
gene I-GENE
expression O
and O
ectopic O
neurogenesis O
. O

Both O
NUP98 I-GENE
- O
HOXA9 I-GENE
chimeras O
transformed O
NIH O
3T3 O
fibroblasts O
, O
and O
this O
transformation O
required O
the O
HOXA9 I-GENE
domains I-GENE
for O
DNA O
binding O
and O
PBX I-GENE
interaction O
. O

Recent O
studies O
have O
suggested O
that O
Y319 O
also O
positively O
regulate O
ZAP I-GENE
- I-GENE
70 I-GENE
function O
. O

Genetic O
and O
molecular O
data O
indicate O
that O
wild I-GENE
- I-GENE
type I-GENE
Pan I-GENE
and O
CiD I-GENE
compete O
for O
binding O
to O
Arm I-GENE
, O
leading O
to O
a O
compromised O
transduction O
of O
the O
Wg I-GENE
signal O
in O
heterozygous O
ciD I-GENE
/+ I-GENE
animals O
and O
to O
a O
dramatic O
enhancement O
of O
the O
gain O
- O
of O
- O
function O
activity O
of O
CiD I-GENE
in O
homozygous O
mutants O
. O

Another O
ORF O
, O
dda I-GENE
. I-GENE
2 I-GENE
located O
between O
modA I-GENE
and O
dda I-GENE
, O
shares O
sequence O
similarity O
with O
sigma70 I-GENE
, O
and O
we O
call O
it O
srd I-GENE
. O

The O
location O
of O
the O
IBS O
within O
the O
catB I-GENE
structural I-GENE
gene I-GENE
, O
the O
cooperativity O
observed O
in O
footprinting O
studies O
and O
phasing O
studies O
suggest O
that O
the O
IBS O
participates O
in O
the O
interaction O
of O
CatR I-GENE
with O
the O
upstream O
binding O
sites O
by O
looping O
out O
the O
intervening O
DNA O
. O

In O
vitro O
transcription O
assays O
demonstrate O
that O
the O
TCA O
- O
cycle O
intermediate O
, O
fumarate O
, O
directly O
and O
specifically O
inhibits O
the O
formation O
of O
the O
clcA I-GENE
transcript I-GENE
. O

BIAcore O
analysis O
gave O
a O
Kaff O
of O
4 O
. O
4 O
x O
10 O
( O
10 O
) O
M O
- O
1 O
for O
the O
binding O
of O
N I-GENE
- I-GENE
A3 I-GENE
to O
T84 I-GENE
. I-GENE
1 I-GENE
and O
2 O
. O
2 O
x O
10 O
( O
10 O
) O
M O
- O
1 O
for O
the O
binding O
of O
N I-GENE
- I-GENE
A3 I-GENE
to O
T84 I-GENE
. I-GENE
66 I-GENE
. O

Expression O
of O
p130 I-GENE
( O
Cas I-GENE
) O
( O
Cas I-GENE
), O
a O
major O
binding O
protein O
for O
the O
Crk I-GENE
SH2 I-GENE
- I-GENE
domain I-GENE
, O
also O
induced O
JNK I-GENE
activation O
, O
which O
was O
blocked O
by O
the O
SH2 I-GENE
- I-GENE
mutant I-GENE
of O
Crk I-GENE
. O

Positive O
correlations O
were O
seen O
between O
the O
measurements O
for O
protein O
intake O
( O
r O
=. O
58 O
, O
P O
=. O
0026 O
) O
energy O
intake O
( O
r O
=. O
78 O
, O
P O
<. O
00001 O
), O
with O
mean O
differences O
of O
. O
066 O
g O
/ O
kg O
/ O
d O
( O
SD O
. O
38 O
) O
2 O
. O
04 O
kcal O
/ O
kg O
/ O
day O
( O
SD O
6 O
. O
67 O
), O
respectively O
. O

The O
Og4C3 I-GENE
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
to O
detect O
circulating O
Wuchereria I-GENE
bancrofti I-GENE
antigen I-GENE
uses O
50 O
microL O
of O
serum O
. O

We O
now O
show O
that O
gp200 I-GENE
- O
MR6 I-GENE
ligation O
can O
also O
mimic O
IL I-GENE
- I-GENE
4 I-GENE
and O
have O
an O
anti O
- O
proliferative O
pro O
- O
maturational O
influence O
within O
the O
immune O
system O
, O
causing O
up O
- O
regulation O
of O
co O
- O
stimulatory O
molecules O
on O
B O
lymphocytes O
. O

The O
Mig1 I-GENE
repressor I-GENE
is O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
that O
mediates O
glucose O
repression O
in O
yeast O
. O

Ethylene O
is O
involved O
in O
endosperm O
rupture O
and O
high O
- O
level O
betaGLU I-GENE
I I-GENE
expression O
; O
but O
, O
it O
does O
not O
affect O
the O
spatial O
and O
temporal O
pattern O
of O
betaGLU I-GENE
I I-GENE
expression O
. O

The O
divergence O
in O
primary O
structure O
between O
the O
sheep O
CRF1 I-GENE
and O
the O
other O
mammalian I-GENE
CRF1s I-GENE
is O
primarily O
localized O
to O
the O
extracellular O
amino O
terminal O
domain O
of O
the O
receptor O
( O
18 O
of O
22 O
divergent O
residues O
, O
ovine O
vs O
human I-GENE
CRF1 I-GENE
). O

Agonist O
- O
induced O
receptor O
internalization O
, O
determined O
as O
the O
percent O
of O
total O
[ O
125I O
] O
Tyr0 I-GENE
- I-GENE
oCRF I-GENE
bound O
located O
in O
the O
acid O
- O
resistant O
fraction O
of O
transfected O
Cos O
7 O
cells O
, O
increased O
with O
time O
( O
0 O
- O
60 O
min O
at O
37 O
degrees O
C O
) O
for O
both O
wild O
- O
type O
and O
variant O
oCRF1 I-GENE
. O

Recurrent O
arterial O
thrombotic O
disease O
on O
young O
onset O
and O
protein I-GENE
S I-GENE
deficiency O
. O

We O
showed O
that O
Stat3 I-GENE
and O
Stat3beta I-GENE
were O
affinity O
purified O
using O
phosphopeptides O
containing O
Y704 O
and O
Y744 O
but O
not O
by O
nonphosphorylated O
peptide O
analogues O
or O
by O
phosphopeptides O
containing O
Y729 O
and O
Y764 O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
the O
FCR1 I-GENE
gene I-GENE
behaves O
as O
a O
negative O
regulator O
of O
drug O
resistance O
in O
C O
. O
albicans O
and O
constitute O
the O
first O
evidence O
that O
FCZ O
resistance O
can O
result O
from O
the O
inactivation O
of O
a O
regulatory O
factor O
such O
as O
Fcr1p I-GENE
. O

These O
findings O
suggest O
that O
late O
MYO O
/ O
M O
is O
more O
useful O
than O
washout O
rate O
to O
assess O
the O
effect O
of O
treatment O
on O
heart O
failure O
due O
to O
DCM O
. O

This O
study O
was O
undertaken O
to O
evaluate O
how O
couplers O
and O
their O
placement O
affect O
the O
ALGO2 O
click O
spectral O
properties O
. O

CONCLUSIONS O
: O
Pretreatment O
with O
OCs O
prior O
to O
pituitary O
suppression O
in O
the O
early O
follicular O
phase O
decreases O
ovarian O
cyst O
formation O
, O
without O
an O
apparent O
effect O
on O
subsequent O
follicular O
recruitment O
or O
pregnancy O
rates O
. O

With O
regard O
to O
the O
optimal O
threshold O
values O
, O
sensitivity O
and O
specificity O
were O
100 O
%/ O
97 O
% O
and O
95 O
%/ O
95 O
% O
with O
FDG O
PET O
, O
compared O
to O
86 O
%/ O
92 O
% O
and O
77 O
%/ O
82 O
% O
with O
IS O
, O
respectively O
. O

This O
c I-GENE
- I-GENE
Jun I-GENE
activity O
is O
inhibited O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
another O
protooncoprotein O
that O
can O
dimerize O
with O
c I-GENE
- I-GENE
Jun I-GENE
to O
form O
the O
transcription O
factor O
AP I-GENE
- I-GENE
1 I-GENE
. O

Dorsal O
root O
ganglia O
neuron O
- O
specific O
promoter O
activity O
of O
the O
rabbit I-GENE
beta I-GENE
- I-GENE
galactoside I-GENE
alpha1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
fucosyltransferase I-GENE
gene I-GENE
. O

CONCLUSION O
: O
Our O
study O
shows O
that O
( O
1 O
) O
total O
body O
BMD O
and O
femoral O
neck O
BMD O
were O
significantly O
higher O
in O
the O
study O
group O
that O
performed O
weight O
- O
bearing O
exercises O
than O
in O
control O
subjects O
, O
( O
2 O
) O
swimming O
exercise O
had O
no O
effect O
on O
BMD O
, O
and O
( O
3 O
) O
although O
swimming O
is O
not O
a O
bone O
- O
building O
exercise O
, O
it O
can O
significantly O
improve O
shoulder O
, O
back O
, O
and O
grip O
muscle O
strength O
. O

This O
suggests O
roles O
for O
both O
the O
CE1 O
and O
CE2 O
elements O
in O
regulating O
Hoxb1 I-GENE
gene I-GENE
expression O
during O
development O
. O

CAL O
gain O
amounted O
to O
4 O
. O
2 O
+/- O
1 O
. O
3 O
mm O
, O
60 O
% O
of O
the O
defects O
showing O
CAL O
gain O
> O
or O
= O
4 O
mm O
. O

Comparisons O
with O
other O
known O
germins I-GENE
and O
germin I-GENE
- I-GENE
like I-GENE
proteins I-GENE
indicate O
that O
these O
Arabidopsis O
GLP I-GENE
subfamilies O
are O
unique O
from O
wheat O
germin I-GENE
. O

Lead O
fixation O
in O
dogs O
achieved O
with O
RF O
energy O
. O

However O
, O
there O
has O
not O
been O
any O
evidence O
of O
A O
. O
salmonicida O
infections O
, O
specifically O
furunculosis O
, O
associated O
with O
the O
fish O
in O
this O
loch O
. O

Further O
, O
we O
show O
that O
this O
EIA I-GENE
- O
inducible O
CBF O
/ O
cdc2 I-GENE
is O
related O
to O
the O
CBF I-GENE
which O
was O
shown O
to O
activate O
the O
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
promoter I-GENE
. O

The O
percutaneous O
absorption O
of O
clindamycin O
was O
studied O
in O
healthy O
male O
volunteers O
, O
comparing O
two O
investigative O
clindamycin O
(% O
w O
/ O
v O
)/ O
tretinoin O
( O
0 O
. O
025 O
% O
w O
/ O
v O
) O
gels O
, O
containing O
clindamycin O
phosphate O
ester O
and O
clindamycin O
HCl O
, O
respectively O
, O
relative O
to O
a O
clindamycin O
phosphate O
lotion O
( O
1 O
% O
clindamycin O
; O
Dalacin O
T O
). O

The O
BAL O
concentrations O
of O
the O
nine O
cytokines O
evaluated O
for O
the O
more O
and O
less O
affected O
lungs O
were O
compared O
: O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
), O
IL I-GENE
- I-GENE
8 I-GENE
, O
IL I-GENE
- I-GENE
12 I-GENE
, O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
), O
and O
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
showed O
significant O
differences O
( O
p O
ranged O
between O
0 O
. O

Phosphorylation O
analyses O
indicated O
that O
inhibition O
of O
ERK I-GENE
- I-GENE
1 I-GENE
/ I-GENE
2 I-GENE
decreased O
okadaic O
acid O
- O
elevated O
phosphorylation O
of O
JunD I-GENE
and O
FosB I-GENE
. O

Two O
- O
way O
analysis O
of O
variance O
was O
used O
to O
determine O
whether O
composite O
knowledge O
score O
differed O
among O
patient O
groups O
. O

The O
human O
pathogenic O
bacterium O
group O
A O
Streptococcus O
produces O
an O
extracellular O
cysteine I-GENE
protease I-GENE
[ O
streptococcal I-GENE
pyrogenic I-GENE
exotoxin I-GENE
B I-GENE
( O
SpeB I-GENE
)] O
that O
is O
a O
critical O
virulence O
factor O
for O
invasive O
disease O
episodes O
. O

The O
orbitofrontal O
, O
cingulate O
, O
and O
anteromedial O
part O
of O
the O
dorsal O
premotor O
areas O
were O
preferentially O
activated O
by O
the O
self O
- O
initiated O
hand O
movement O
task O
( O
SELF O
). O

Improving O
the O
evidence O
base O
for O
anaesthesia O
. O

Plasma O
CCK I-GENE
levels O
were O
determined O
at O
regular O
intervals O
. O

The O
peroxisome O
biogenesis O
disorders O
( O
PBDs O
) O
are O
a O
set O
of O
lethal O
genetic O
diseases O
characterized O
by O
peroxisomal O
metabolic O
deficiencies O
, O
multisystem O
abnormalities O
, O
mental O
retardation O
, O
and O
premature O
death O
. O

The O
active O
site O
includes O
the O
acidic O
triad O
Asp53 O
( O
the O
site O
of O
phosphorylation O
), O
Asp10 O
and O
Glu9 O
. O

Consistent O
with O
these O
findings O
, O
relatively O
weak O
transcriptional O
silencing O
by O
the O
native O
VDR I-GENE
was O
observed O
using O
the O
osteopontin I-GENE
VDRE O
. O

In O
PAV O
- O
3 O
, O
the O
E1A I-GENE
region I-GENE
is O
located O
between O
1 O
. O
5 O
and O
3 O
. O
8 O
map O
units O
. O

Six O
putative O
MDV O
genome O
products O
, O
including O
one O
Rep I-GENE
and O
five O
non O
- O
Rep I-GENE
proteins O
, O
show O
high O
( O
70 O
. O
4 O
- O
90 O
. O
9 O
%) O
amino O
acid O
identity O
to O
the O
corresponding O
six O
FBNYV I-GENE
proteins I-GENE
, O
whereas O
two O
other O
Rep I-GENE
proteins I-GENE
encoded O
by O
MDV I-GENE
- I-GENE
C2 I-GENE
and O
C3 I-GENE
are O
82 O
. O
3 O
% O
and O
73 O
. O
0 O
% O
identical O
to O
those O
encoded O
by O
SCSV I-GENE
- I-GENE
C2 I-GENE
and O
C6 I-GENE
, O
respectively O
. O

MPO I-GENE
was O
labeled O
with O
1 O
mCi O
125I O
by O
a O
technique O
of O
self O
- O
labeling O
in O
the O
presence O
of O
10 O
(- O
4 O
) O
M O
hydrogen O
peroxide O
. O

It O
is O
related O
to O
a O
variety O
of O
mammalian O
Golgi O
- O
associated O
proteins O
and O
to O
the O
yeast O
Uso1p I-GENE
, O
an O
essential O
protein O
involved O
in O
docking O
of O
endoplasmic O
reticulum O
- O
derived O
vesicles O
to O
the O
cis O
- O
Golgi O
. O

The O
data O
indicate O
that O
Bmp2 I-GENE
is O
directly O
regulated O
by O
retinoic O
acid O
- O
bound O
receptors O
and O
Sp1 I-GENE
. O

Both O
proteins O
were O
shown O
to O
be O
constitutively O
associated O
with O
tubulin I-GENE
. O

HEED I-GENE
was O
found O
to O
bind O
to O
MA I-GENE
protein I-GENE
in O
vitro O
, O
as O
efficiently O
as O
in O
vivo O
in O
yeast O
cells O
. O

Fas I-GENE
- O
resistant O
DT O
- O
40 O
lymphoma O
B O
- O
cells O
rendered O
BTK I-GENE
- O
deficient O
through O
targeted O
disruption O
of O
the O
btk I-GENE
gene I-GENE
by O
homologous O
recombination O
knockout O
underwent O
apoptosis O
after O
Fas I-GENE
ligation O
, O
but O
wild O
- O
type O
DT O
- O
40 O
cells O
or O
BTK I-GENE
- O
deficient O
DT O
- O
40 O
cells O
reconstituted O
with O
wild I-GENE
- I-GENE
type I-GENE
human I-GENE
btk I-GENE
gene I-GENE
did O
not O
. O

A O
motif O
( O
TGATGTCA O
) O
which O
matches O
a O
CREB I-GENE
site I-GENE
and O
is O
similar O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
embedded O
within O
ER2 I-GENE
. O

Conventionally O
, O
four O
nominal O
allotypic O
variants O
, O
b4 O
, O
b5 O
, O
b6 O
and O
b9 O
have O
been O
shown O
to O
be O
co O
- O
dominantly O
expressed O
at O
the O
Ckappa1 I-GENE
gene I-GENE
locus I-GENE
. O

Therefore O
, O
in O
order O
to O
search O
for O
the O
latent O
genes O
, O
we O
used O
allotype O
- O
specific O
oligonucleotides O
for O
b5 O
, O
b6 O
and O
b9 O
to O
probe O
DNAs O
from O
both O
normal O
and O
T O
. O
brucei O
- O
infected O
rabbits O
by O
Southern O
blotting O
. O

TRAF2 I-GENE
is O
known O
to O
associate O
with O
TRADD I-GENE
, O
and O
expression O
of O
a O
dominant O
- O
negative O
N O
- O
terminal O
deletion O
TRAF2 I-GENE
mutant I-GENE
was O
found O
to O
partially O
inhibit O
LMP1 I-GENE
- O
induced O
JNK I-GENE
activation O
in O
293 O
cells O
. O

These O
data O
further O
define O
a O
role O
for O
TRADD I-GENE
and O
TRAF2 I-GENE
in O
JNK I-GENE
activation O
and O
confirm O
that O
LMP1 I-GENE
utilizes O
signalling O
mechanisms O
used O
by O
the O
TNF I-GENE
receptor I-GENE
/ O
CD40 I-GENE
family O
to O
elicit O
its O
pleiotropic O
activities O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
- I-GENE
encoded I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
activates O
the O
JNK I-GENE
pathway O
through O
its O
extreme O
C O
terminus O
via O
a O
mechanism O
involving O
TRADD I-GENE
and O
TRAF2 I-GENE
. O

In O
contrast O
, O
transiently O
transfected O
cells O
expressing O
EBNA I-GENE
- I-GENE
3 I-GENE
revealed O
a O
sixfold O
increase O
in O
EBNA I-GENE
- I-GENE
3 I-GENE
protein I-GENE
expression O
from O
the O
genomic O
EBNA I-GENE
- I-GENE
3 I-GENE
gene I-GENE
compared O
to O
EBNA I-GENE
- I-GENE
3 I-GENE
cDNA I-GENE
. O

However O
, O
serial O
passages O
of O
fetal O
lamb O
kidney O
( O
FLK O
) O
cells O
, O
which O
are O
sensitive O
to O
infection O
with O
BLV O
, O
after O
transient O
transfection O
revealed O
that O
mutation O
of O
a O
second O
tyrosine O
residue O
in O
the O
N O
- O
terminal O
motif O
completely O
prevented O
the O
propagation O
of O
the O
virus O
. O

Varicella I-GENE
- I-GENE
zoster I-GENE
virus I-GENE
( I-GENE
VZV I-GENE
) I-GENE
glycoprotein I-GENE
gI I-GENE
is O
a O
type I-GENE
1 I-GENE
transmembrane I-GENE
glycoprotein I-GENE
which O
is O
one O
component O
of O
the O
heterodimeric O
gE I-GENE
: O
gI I-GENE
Fc I-GENE
receptor I-GENE
complex O
. O

To O
this O
end O
, O
we O
analyzed O
the O
phosphorylation O
status O
of O
a O
universal O
tyrosine I-GENE
kinase I-GENE
substrate O
, O
the O
transforming O
Shc I-GENE
adapter I-GENE
protein I-GENE
, O
in O
fibroblasts O
expressing O
the O
viral O
oncogene O
. O

These O
genes O
were O
expressed O
in O
a O
Saccharomyces O
cerevisiae O
mutant O
in O
which O
the O
endogenous I-GENE
ferrochelatase I-GENE
gene I-GENE
( O
HEM15 I-GENE
) O
had O
been O
deleted O
, O
and O
the O
phenotypes O
of O
the O
transformants O
were O
characterized O
. O

In O
this O
study O
, O
evidence O
is O
presented O
that O
temporally O
and O
spatially O
specific O
mef2 I-GENE
expression O
is O
controlled O
by O
a O
complex O
array O
of O
cis O
- O
acting O
regulatory O
modules O
that O
are O
responsive O
to O
different O
genetic O
signals O
. O

Furthermore O
, O
using O
transgenic O
mouse O
technology O
we O
localized O
independent O
cis O
- O
regulatory O
elements O
controlling O
the O
tissue O
- O
specific O
expression O
of O
Pax6 I-GENE
. O

In O
the O
second O
experiment O
, O
a O
stable O
nickel O
isotope O
, O
61Ni O
, O
was O
given O
in O
drinking O
water O
to O
20 O
nickel O
- O
sensitized O
women O
and O
20 O
age O
- O
matched O
controls O
, O
both O
groups O
having O
vesicular O
hand O
eczema O
of O
the O
pompholyx O
type O
. O

Folded O
tissue O
and O
crimped O
collagen I-GENE
fibers O
in O
the O
tunica O
albuginea O
permit O
its O
expansion O
during O
erection O
. O

Number O
of O
patients O
infected O
with O
nontuberculous O
mycobacteria O
( O
NTM O
) O
is O
increasing O
world O
- O
wide O
in O
recent O
years O
. O

Comparison O
of O
the O
sequences O
of O
attP I-GENE
, O
attB I-GENE
and O
bacteria O
- O
prophage O
junctions O
attL I-GENE
and O
attR I-GENE
showed O
a O
26 O
bp O
common O
core O
sequence O
, O
where O
recombination O
takes O
place O
, O
near O
the O
5 O
' O
end O
of O
the O
integrase I-GENE
gene I-GENE
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
treatment O
of O
posttransplant O
lymphoproliferative O
disorder O
in O
recipients O
of O
solid O
organ O
transplants O
. O

Immunological O
testing O
was O
performed O
on O
all O
brewery O
workers O
and O
some O
control O
volunteers O
using O
skin O
prick O
testing O
with O
hops O
, O
barley O
, O
and O
yeast O
antigens O
as O
well O
as O
other O
nonoccupational O
allergens O
, O
and O
by O
determining O
total O
serum I-GENE
IgE I-GENE
levels O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
accuracy O
of O
working O
casts O
for O
crown O
and O
bridge O
restorations O
made O
from O
twin O
mix O
putty O
/ O
wash O
silicone O
elastomeric O
impression O
materials O
using O
different O
types O
of O
stock O
tray O
. O

OBJECTIVES O
: O
To O
assess O
the O
ability O
of O
pretreatment O
and O
post O
- O
treatment O
prostate I-GENE
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
measurements O
, O
clinical O
tumor O
stage O
, O
tumor O
grade O
, O
Gleason O
sum O
, O
race O
, O
age O
, O
and O
radiation O
dose O
to O
predict O
the O
recurrence O
of O
prostate O
cancer O
following O
external O
beam O
radiation O
therapy O
( O
XRT O
) O
since O
the O
introduction O
of O
PSA I-GENE
as O
a O
tumor O
marker O
at O
one O
tertiary O
care O
center O
. O

To O
evaluate O
whether O
the O
human O
gene O
is O
also O
a O
target O
of O
thyroid O
hormone O
we O
have O
searched O
for O
T3 O
- O
responsive O
elements O
in O
NRGN I-GENE
cloned O
genomic O
fragments O
spanning O
the O
whole O
gene O
. O

The O
transcriptional O
activity O
of O
PPARgamma I-GENE
is O
positively O
modulated O
by O
ligand O
binding O
and O
negatively O
regulated O
by O
phosphorylation O
mediated O
by O
the O
MEK I-GENE
/ O
ERK I-GENE
signaling O
pathway O
. O

BACKGROUND O
: O
Diazepam O
, O
one O
of O
the O
benzodiazepine O
group O
of O
tranquilizers O
, O
is O
used O
as O
an O
adjunctive O
drug O
for O
sedation O
and O
for O
relief O
of O
anxiety O
in O
the O
treatment O
of O
epilepsy O
. O

Bioplastique O
granuloma O
presents O
with O
irregularly O
shaped O
cystic O
spaces O
of O
varying O
size O
containing O
jagged O
, O
translucent O
, O
nonbirefringent O
foreign O
bodies O
whereas O
Artecoll O
granuloma O
shows O
numerous O
round O
vacuoles O
nearly O
identical O
in O
size O
and O
shape O
enclosing O
round O
and O
sharply O
circumscribed O
, O
translucent O
, O
nonbirefringent O
foreign O
bodies O
. O

This O
Tbx6 I-GENE
- I-GENE
subfamily I-GENE
gene I-GENE
is O
likely O
to O
participate O
in O
paraxial O
mesoderm O
formation O
and O
somitogenesis O
in O
human O
embryo O
. O

Structure O
- O
function O
analysis O
of O
the O
Z O
- O
DNA O
- O
binding O
domain O
Zalpha O
of O
dsRNA I-GENE
adenosine I-GENE
deaminase I-GENE
type I-GENE
I I-GENE
reveals O
similarity O
to O
the O
( I-GENE
alpha I-GENE
+ I-GENE
beta I-GENE
) I-GENE
family I-GENE
of O
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
proteins I-GENE
. O

In O
addition O
, O
the O
regulation O
of O
Glvr I-GENE
- I-GENE
1 I-GENE
gene I-GENE
expression O
also O
has O
potential O
applications O
to O
gene O
therapy O
, O
since O
retroviral O
vectors O
carrying O
gibbon I-GENE
ape I-GENE
leukemia I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
are O
used O
for O
gene O
delivery O
into O
different O
cell O
types O
. O

Carbohydrates O
and O
glycoconjugates O
biophysical O
methods O
. O

Molecular O
cloning O
of O
mouse I-GENE
glycolate I-GENE
oxidase I-GENE
. O

In O
such O
a O
manner O
, O
activated O
PKR I-GENE
inhibits O
cell O
growth O
and O
induces O
apoptosis O
, O
whereas O
disruption O
of O
normal O
PKR I-GENE
signaling O
results O
in O
unregulated O
cell O
growth O
. O

We O
isolated O
a O
ribosomal I-GENE
protein I-GENE
L18 I-GENE
by O
interaction O
with O
PKR I-GENE
. O

Processing O
of O
the O
polycistronic O
precursor O
requires O
nucleases O
also O
involved O
in O
rRNA O
processing O
, O
i O
. O
e O
., O
Rnt1p I-GENE
and O
Rat1p I-GENE
. O

To O
search O
for O
transcriptional O
regulators O
, O
we O
used O
a O
fragment O
of O
the O
SpHE I-GENE
promoter I-GENE
containing O
several O
individual O
elements O
instead O
of O
the O
conventional O
bait O
that O
contains O
a O
multimerized O
cis O
element O
. O

As O
expected O
for O
a O
positive O
SpHE I-GENE
transcriptional I-GENE
regulator I-GENE
, O
the O
timing O
of O
SpEts4 I-GENE
gene I-GENE
expression O
precedes O
the O
transient O
expression O
of O
SpHE I-GENE
in O
the O
very O
early O
sea O
urchin O
blastula O
. O

Furthermore O
, O
rhoA I-GENE
- O
mediated O
SRE O
activation O
was O
blocked O
by O
dominant O
negative O
mutants O
of O
PKC I-GENE
- I-GENE
alpha I-GENE
or O
PKC I-GENE
- I-GENE
epsilon I-GENE
. O

Nip7p I-GENE
- O
depleted O
cells O
exhibited O
the O
same O
defects O
as O
Nop8p I-GENE
- O
depleted O
cells O
, O
except O
that O
they O
accumulated O
27S I-GENE
precursors I-GENE
. O

We O
show O
that O
the O
Sm I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
stem O
- O
loop O
III O
structures O
are O
necessary O
for O
correct O
3 O
'- O
end O
formation O
. O

Five O
different O
subtypes O
of O
spondyloarthropathy O
( O
SpA O
) O
are O
now O
recognized O
. O

Further O
experiments O
will O
be O
required O
to O
highlight O
the O
in O
vivo O
role O
of O
ELE1 I-GENE
in O
nuclear O
receptor O
functioning O
. O

Overexpression O
of O
PTTG I-GENE
in O
transfected O
NIH O
3T3 O
cells O
also O
stimulated O
expression O
and O
secretion O
of O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
, O
a O
human I-GENE
pituitary I-GENE
tumor I-GENE
growth I-GENE
- I-GENE
regulating I-GENE
factor I-GENE
. O

The O
perifascicular O
connective O
tissue O
sheath O
is O
important O
in O
organising O
the O
contraction O
of O
the O
myocardium O
by O
preventing O
lateral O
spread O
of O
conduction O
and O
by O
permitting O
transmission O
of O
the O
impulse O
only O
at O
the O
termination O
of O
the O
purkinje O
fibre O
. O

E1 I-GENE
, O
a O
DNA I-GENE
helicase I-GENE
, O
collaborates O
with O
the O
HPV I-GENE
E2 I-GENE
protein I-GENE
in O
ori O
- O
dependent O
replication O
. O

Here O
we O
describe O
a O
mutant O
alpha O
subunit O
designed O
to O
inhibit O
receptor O
- O
mediated O
hormonal O
activation O
of O
Gs I-GENE
, O
the O
stimulatory O
regulator O
of O
adenylyl I-GENE
cyclase I-GENE
. O

A O
gapped O
search O
with O
the O
C O
- O
terminal O
region O
of O
CDED I-GENE
/ O
LIOR I-GENE
revealed O
a O
36 O
- O
41 O
% O
similarity O
to O
several O
proteins O
related O
to O
signal O
transduction O
and O
cell O
replication O
, O
such O
as O
ORC1 I-GENE
and O
KSR I-GENE
. O

Northern O
blot O
analysis O
demonstrated O
the O
ubiquitous O
expression O
of O
2 O
. O
9 O
kb O
and O
3 O
. O

Additionally O
, O
a O
variety O
of O
regulatory O
schemes O
contribute O
temporal O
and O
/ O
or O
spatial O
restriction O
to O
TGF I-GENE
- I-GENE
beta I-GENE
responses O
. O

Induction O
of O
anaesthesia O
was O
standardised O
: O
fentanyl O
( O
3 O
micrograms O
/ O
kg O
), O
thiopentone O
( O
5 O
mg O
/ O
kg O
), O
atracurium O
( O
0 O
. O
4 O
mg O
/ O
kg O
). O

A O
comparison O
of O
the O
clinical O
profile O
of O
cavernous O
malformations O
with O
and O
without O
associated O
venous O
malformations O
. O

Conserved O
and O
distinct O
roles O
of O
kreisler I-GENE
in O
regulation O
of O
the O
paralogous O
Hoxa3 I-GENE
and O
Hoxb3 I-GENE
genes I-GENE
. O

Magnetically O
induced O
optical O
self O
- O
pulsing O
in O
a O
nonlinear O
resonator O
. O

Wave O
cybernetics O
: O
A O
simple O
model O
of O
wave O
- O
controlled O
nonlinear O
and O
nonlocal O
cooperative O
phenomena O
. O

Autoionization O
rates O
and O
energy O
levels O
of O
triplet O
nf O
, O
v O
= O
1 O
Rydberg O
states O
of O
H2 O
. O

Unitary O
- O
group O
approach O
to O
spin O
- O
dependent O
operators O
. O

Nonlocal O
approach O
to O
scattering O
in O
a O
one O
- O
dimensional O
problem O
. O

Soft O
- O
x O
- O
ray O
lasing O
at O
32 O
. O
6 O
nm O
in O
Ne O
- O
like O
Ti O
ions O
driven O
by O
40 O
J O
of O
energy O
from O
two O
650 O
- O
ps O
laser O
pulses O
. O

Next O
, O
to O
identify O
regions O
of O
the O
promoter O
involved O
, O
we O
examined O
a O
series O
of O
tenascin I-GENE
- I-GENE
C I-GENE
promoter I-GENE
constructs I-GENE
with O
5 O
' O
deletions O
and O
showed O
that O
denatured O
collagen I-GENE
- I-GENE
dependent I-GENE
promoter I-GENE
activity O
was O
retained O
by O
a O
122 O
- O
base O
pair O
element O
, O
located O
- O
43 O
to O
- O
165 O
bp O
upstream O
of O
the O
RNA O
start O
site O
. O

Nuclear I-GENE
factor I-GENE
kappa I-GENE
B I-GENE
( O
NF I-GENE
- I-GENE
kappaB I-GENE
) O
is O
an O
important O
transcription O
factor O
for O
the O
genes O
of O
many O
pro O
- O
inflammatory O
proteins O
and O
is O
strongly O
activated O
by O
the O
cytokines O
interleukin I-GENE
- I-GENE
1 I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( I-GENE
TNF I-GENE
) I-GENE
alpha I-GENE
under O
various O
pathological O
conditions O
. O

Moreover O
, O
this O
enhancement O
of O
transcriptional O
activation O
by O
COUP I-GENE
- I-GENE
TFI I-GENE
requires O
specifically O
the O
AF O
- O
1 O
transactivation O
function O
of O
ER I-GENE
and O
can O
be O
observed O
in O
the O
presence O
of O
E2 O
or O
4 O
- O
hydroxytamoxifen O
but O
not O
ICI O
164384 O
. O

Recombinant I-GENE
Ffh I-GENE
has O
a O
melting O
point O
of O
tm O
= O
89 O
degreesC O
. O

Unilateral O
naris O
occlusion O
and O
the O
rat O
accessory O
olfactory O
bulb O
. O

This O
region O
of O
hsp90 I-GENE
mediates O
ATP O
- O
independent O
chaperone O
activity O
, O
overlaps O
the O
hsp90 I-GENE
dimerization I-GENE
domain I-GENE
, O
and O
includes O
structural O
elements O
important O
for O
steroid I-GENE
receptor I-GENE
interaction O
. O

The O
promoter O
of O
the O
rat O
pgp2 I-GENE
/ O
mdr1b I-GENE
gene O
has O
a O
GC O
- O
rich O
region O
( O
pgp2GC I-GENE
) O
that O
is O
highly O
conserved O
in O
mdr I-GENE
genes I-GENE
and O
contains O
an O
consensus O
Sp1 I-GENE
site I-GENE
. O

Sp1 I-GENE
' O
s O
role O
in O
transactivation O
of O
the O
pgp2 I-GENE
/ O
mdr1b I-GENE
promoter O
was O
tested O
in O
Drosophila O
Schneider O
cells O
. O

Measurements O
included O
bone O
mineral O
density O
of O
the O
lumbar O
spine O
and O
proximal O
femur O
( O
by O
dual O
- O
energy O
X O
- O
ray O
absorptiometry O
) O
and O
biochemical O
markers O
of O
bone O
remodeling O
( O
serum O
bone O
- O
specific O
alkaline I-GENE
phosphatase I-GENE
by O
immunoassay O
and O
urine O
deoxypyridinoline O
by O
high O
- O
pressure O
liquid O
chromatography O
). O

Human I-GENE
MGP I-GENE
is O
a O
10 I-GENE
- I-GENE
kD I-GENE
skeletal I-GENE
extracellular I-GENE
matrix I-GENE
( I-GENE
ECM I-GENE
) I-GENE
protein I-GENE
that O
consists O
of O
an O
84 O
- O
aa O
mature O
protein O
and O
a O
19 O
- O
aa O
transmembrane O
signal O
peptide O
. O

Dual O
roles O
of O
p82 I-GENE
, O
the O
clam O
CPEB I-GENE
homolog I-GENE
, O
in O
cytoplasmic O
polyadenylation O
and O
translational O
masking O
. O

The O
RNA I-GENE
polymerase I-GENE
III I-GENE
- I-GENE
recruiting I-GENE
factor I-GENE
TFIIIB I-GENE
induces O
a O
DNA O
bend O
between O
the O
TATA O
box O
and O
the O
transcriptional O
start O
site O
. O

The O
pattern O
of O
RNase I-GENE
E I-GENE
digestion O
of O
finP305 I-GENE
RNA I-GENE
differed O
from O
FinP I-GENE
, O
and O
GST I-GENE
- O
FinO I-GENE
did O
not O
protect O
finP305 I-GENE
RNA I-GENE
from O
cleavage O
in O
vitro O
. O

Transcription O
readthrough O
into O
the O
inverted O
repeats O
has O
little O
effect O
on O
this O
event O
. O

Analysis O
of O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
prescriptions O
in O
19 O
french O
cancer O
centers O

In O
the O
second O
case O
, O
an O
epidermal O
cyst O
was O
diagnosed O
. O

MotA I-GENE
also O
binds O
a O
DNA O
sequence O
( O
a O
MotA I-GENE
box I-GENE
), O
centered O
at O
position O
- O
30 O
. O

We O
suggest O
that O
MotA I-GENE
and O
AsiA I-GENE
may O
function O
like O
certain O
eukaryotic I-GENE
TAFs I-GENE
( O
TATA I-GENE
binding I-GENE
protein I-GENE
( I-GENE
TBP I-GENE
) I-GENE
associated I-GENE
factors I-GENE
) O
whose O
binding O
to O
TBP I-GENE
results O
in O
transcription O
from O
new O
core O
promoter O
sequences O
. O

The O
S229A O
variant O
can O
better O
flip O
modified O
bases O
but O
does O
not O
tightly O
lock O
the O
flipped O
base O
into O
the O
adenine O
- O
binding O
pocket O
, O
suggesting O
that O
Ser229 O
could O
form O
a O
contact O
to O
the O
flipped O
adenine O
. O

The O
high O
conservation O
of O
the O
3 O
' O
terminus O
suggests O
that O
this O
region O
directs O
the O
assembly O
of O
proteins O
required O
for O
the O
initiation O
of O
RNA O
replication O
. O

All O
stimulations O
were O
down O
- O
regulated O
with O
GnRH I-GENE
- I-GENE
a I-GENE
commenced O
on O
day O
21 O
in O
a O
long O
protocol O
before O
gonadotropin I-GENE
stimulation O
. O

The O
sequence O
up O
to O
- O
267 O
bp O
relative O
to O
the O
transcription O
start O
site O
was O
sufficient O
to O
enhance O
reporter O
gene O
expression O
depending O
on O
the O
mesodermal O
differentiation O
of O
P19 O
cells O
. O

Chem O
. O

No O
significant O
differences O
between O
the O
substituted O
and O
wild O
type O
peptides O
were O
observed O
, O
suggesting O
that O
this O
substitution O
in O
the O
intact O
protein O
may O
cause O
disruption O
of O
global O
rather O
than O
local O
structures O
. O

These O
results O
suggest O
that O
the O
c I-GENE
- I-GENE
met I-GENE
gene I-GENE
is O
also O
a O
target O
of O
p53 I-GENE
gene I-GENE
regulation O
. O

C3 I-GENE
toxin I-GENE
completely O
inhibited O
RhoA I-GENE
function O
, O
partially O
inhibited O
SRE O
: O
Luc I-GENE
activity O
, O
but O
had O
no O
effect O
on O
LPA O
- O
stimulated O
c I-GENE
- I-GENE
Fos I-GENE
expression O
. O

However O
, O
C3 I-GENE
toxin I-GENE
alone O
or O
in O
combination O
with O
growth O
factors O
did O
not O
stimulate O
AP I-GENE
- I-GENE
1 I-GENE
: O
Luc I-GENE
activity O
and O
actually O
antagonized O
the O
synergistic O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
: O
Luc I-GENE
observed O
in O
response O
to O
co O
- O
stimulation O
with O
growth O
factors O
and O
Ro O
- O
31 O
- O
8220 O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
antimicrobial O
susceptibility O
to O
10 O
currently O
used O
antimicrobial O
agents O
of O
50 O
strains O
of O
P O
. O
acnes O
isolated O
from O
acne O
lesions O
and O
identified O
using O
a O
Rap O
ID O
ANA O
II O
panel O
. O

The O
role O
of O
intraoperative O
echocardiography O
in O
surgery O
of O
the O
heart O
and O
large O
vessels O

Taken O
together O
, O
our O
results O
demonstrate O
that O
CAP1 I-GENE
is O
involved O
in O
multidrug O
resistance O
and O
oxidative O
stress O
response O
in O
C O
. O
albicans O
. O

Trinipatch O
is O
a O
small O
, O
transparent O
, O
matricial O
, O
monolayer O
patch O
with O
an O
absorption O
promoter O
, O
marketed O
in O
two O
dose O
- O
strengths O
( O
5 O
mg O
/ O
24 O
h O
and O
10 O
mg O
/ O
24 O
h O
) O
by O
Laboratoires O
Synthelabo O
. O

The O
RMRI O
was O
tested O
for O
interrater O
reliability O
using O
three O
simulated O
and O
10 O
actual O
patients O
. O

The O
starting O
point O
is O
the O
consideration O
that O
the O
conceptions O
underlying O
the O
ICIDH O
are O
not O
suitable O
to O
serve O
as O
a O
mainstay O
of O
a O
model O
for O
diagnostics O
in O
rehabilitation O
because O
they O
do O
not O
reflect O
essential O
characteristics O
of O
the O
diagnostic O
process O
which O
is O
the O
basis O
for O
intervention O
. O

Pokeweed I-GENE
antiviral I-GENE
protein I-GENE
( O
PAP I-GENE
) O
from O
Phytolacca O
americana O
is O
a O
highly O
specific O
N I-GENE
- I-GENE
glycosidase I-GENE
removing O
adenine O
residues O
( O
A4324 O
in O
28S I-GENE
rRNA I-GENE
and O
A2660 O
in O
23S I-GENE
rRNA I-GENE
) O
from O
intact O
ribosomes O
of O
both O
eukaryotes O
and O
prokaryotes O
. O

OBJECTIVE O
: O
This O
meta O
- O
analysis O
of O
67 O
controlled O
trials O
was O
performed O
to O
quantify O
the O
cholesterol O
- O
lowering O
effect O
of O
major O
dietary O
fibers O
. O

Among O
these O
360 O
ZFPs I-GENE
, O
a O
novel O
ZFP I-GENE
cDNA I-GENE
named O
HFHZ I-GENE
( O
human I-GENE
fetal I-GENE
heart I-GENE
ZFP I-GENE
) O
with O
sequence O
homology O
to O
a O
Kruppel I-GENE
- I-GENE
associated I-GENE
box I-GENE
( O
KRAB I-GENE
) O
was O
identified O
. O

The O
3 O
. O
3 O
- O
fold O
higher O
expression O
in O
the O
fetal O
heart O
than O
in O
the O
adult O
heart O
suggests O
that O
HFHZ I-GENE
mRNA I-GENE
is O
downregulated O
in O
the O
process O
of O
development O
. O

When O
the O
high O
affinity O
hnRNP I-GENE
A1 I-GENE
binding I-GENE
site I-GENE
was O
inserted O
into O
the O
beta I-GENE
- I-GENE
globin I-GENE
reporter I-GENE
, O
Rev I-GENE
was O
able O
to O
increase O
the O
cytoplasmic O
levels O
of O
unspliced O
mRNAs O
to O
14 O
%. O

To O
date O
, O
two O
such O
proteins O
, O
PLZF I-GENE
and O
LAZ I-GENE
- I-GENE
3 I-GENE
/ O
BCL I-GENE
- I-GENE
6 I-GENE
, O
have O
been O
implicated O
in O
oncogenesis O
. O

Overexpression O
of O
POG1 I-GENE
inhibits O
alpha I-GENE
- I-GENE
factor I-GENE
- O
induced O
G1 O
arrest O
and O
transcriptional O
repression O
of O
the O
CLN1 I-GENE
and O
CLN2 I-GENE
genes I-GENE
. O

We O
now O
show O
that O
RNU2 I-GENE
fragility O
can O
be O
induced O
by O
transfection O
with O
an O
expression O
vector O
encoding O
Ad12 I-GENE
E1B I-GENE
55 O
kDa O
alone O
but O
not O
by O
an O
E1 I-GENE
vector O
encoding O
all O
E1 I-GENE
products I-GENE
( O
3 O
E1A I-GENE
proteins I-GENE
, O
as O
well O
as O
the O
E1B I-GENE
19 O
kDa O
and O
55 O
kDa O
proteins O
). O

Competitionsupershift O
EMSA O
assays O
revealed O
that O
multiple O
proteins O
were O
involved O
in O
bandshift O
complex O
formation O
with O
KCS I-GENE
, O
one O
of O
which O
was O
identified O
as O
factor O
Sp1 O
. O

Similarity O
of O
DNA O
binding O
and O
transcriptional O
regulation O
by O
Caenorhabditis I-GENE
elegans I-GENE
MAB I-GENE
- I-GENE
3 I-GENE
and O
Drosophila I-GENE
melanogaster I-GENE
DSX I-GENE
suggests O
conservation O
of O
sex O
determining O
mechanisms O
. O

CONTEXT O
: O
ThinPrep O
, O
AutoPap O
, O
and O
Papnet O
are O
3 O
new O
technologies O
that O
increase O
the O
sensitivity O
and O
cost O
of O
cervical O
cancer O
screening O
. O

Experiments O
on O
narcotized O
cats O
demonstrated O
that O
the O
derivatives O
of O
2 O
- O
mercaptobenzimidazole O
possessing O
the O
properties O
of O
specific O
bradycardic O
agents O
and O
coded O
as O
CM O
- O
251 O
, O
CM O
- O
266 O
, O
and O
CM O
- O
345 O
, O
reduce O
the O
mean O
rise O
of O
segment O
ST O
on O
numerous O
leads O
of O
the O
epicardial O
electrogram O
during O
5 O
- O
min O
occlusion O
of O
the O
anterior O
descending O
branch O
of O
the O
left O
coronary O
artery O
. O

Neither O
the O
p42 I-GENE
/ I-GENE
44 I-GENE
nor O
the O
JNK I-GENE
pathway O
was O
involved O
in O
the O
action O
of O
IL I-GENE
- I-GENE
1beta I-GENE
. O

In O
protocol O
2 O
, O
eight O
different O
subjects O
performed O
Con O
and O
Ecc O
arm O
curls O
to O
fatigue O
, O
followed O
by O
postexercise O
muscle O
ischemia O
, O
by O
using O
the O
same O
resistance O
as O
in O
protocol O
1 O
. O

Airflow O
was O
measured O
with O
a O
custom O
- O
designed O
turbine O
and O
a O
45 O
- O
ft O
.- O
long O
cable O
to O
reach O
the O
volume O
- O
measuring O
module O
. O

Both O
mutations O
confer O
amino O
acid O
substitutions O
in O
the O
viral I-GENE
coat I-GENE
protein I-GENE
but O
differ O
in O
their O
relative O
abilities O
to O
utilize O
the O
foreign O
scaffolding I-GENE
protein I-GENE
. O

Complete O
recovery O
of O
liver O
function O
after O
this O
surgery O
tended O
to O
be O
slow O
. O

Although O
both O
transcripts O
share O
the O
first O
nine O
exons O
, O
exon O
10 O
of O
ZIS I-GENE
- I-GENE
2 I-GENE
is O
lacking O
in O
ZIS I-GENE
- I-GENE
1 I-GENE
, O
and O
instead O
, O
exon O
11 O
( O
10th O
exon O
) O
of O
ZIS I-GENE
- I-GENE
1 I-GENE
is O
larger O
in O
size O
, O
leading O
to O
the O
longer O
3 O
'- O
UTR O
. O

Expression O
of O
the O
second O
gene O
( O
XT3 I-GENE
) O
was O
found O
to O
be O
conserved O
in O
human O
kidney O
, O
and O
partial O
sequence O
was O
obtained O
from O
a O
human O
cDNA O
library O
. O

IFN I-GENE
- I-GENE
gamma I-GENE
was O
elevated O
during O
active O
TB O
when O
compared O
with O
healthy O
controls O
, O
declining O
during O
and O
after O
treatment O
. O

The O
missing O
5 O
' O
sequences O
were O
obtained O
by O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
and O
by O
analysis O
of O
an O
NHE5 I-GENE
genomic I-GENE
clone I-GENE
, O
and O
the O
missing O
3 O
' O
sequences O
were O
obtained O
by O
3 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
. O

If O
no O
alloantibodies O
are O
detected O
, O
further O
analysis O
to O
define O
a O
role O
of O
drug O
- O
related O
or O
autoantibodies O
is O
required O
. O

This O
dependence O
, O
however O
, O
can O
be O
overcome O
to O
a O
large O
extent O
by O
dividing O
min O
LVdP O
/ O
dt O
by O
mean O
aortic O
pressure O
. O

Genoa O
, O
Italy O
, O
24 O
- O
28 O
August O
1997 O
. O

Electronic O
structure O
of O
delta O
- O
plutonium O
and O
of O
single O
Al O
, O
Ga O
, O
and O
Sc O
impurities O
in O
delta O
- O
plutonium O
. O

Bound O
- O
exciton O
transfer O
and O
photoluminescence O
undulation O
spectra O
for O
acceptors O
in O
ZnTe O
. O

Unified O
theory O
of O
segregated O
- O
stack O
organic O
charge O
- O
transfer O
solids O
: O
Magnetic O
properties O
. O

Internal O
modes O
of O
a O
soliton O
. O

II O
. O

Envelope O
- O
function O
matching O
conditions O
for O
GaAs O
/( O
Al O
, O
Ga O
) O
As O
heterojunctions O
. O

Neutron O
scattering O
measurements O
of O
critical O
exponents O
in O
CsMnBr3 O
: O
A O
Z2 O
& O
gt O
;= O
1 O
antiferromagnet O
. O

( O
2 O
) O
Erythroid O
32D O
Epo1 I-GENE
cells O
showed O
a O
lower O
level O
of O
bulk O
PKC I-GENE
catalytic O
activity O
, O
lacked O
the O
expression O
of O
epsilon I-GENE
and I-GENE
eta I-GENE
PKC I-GENE
isoforms I-GENE
, O
and O
showed O
a O
weak O
or O
absent O
upregulation O
of O
the O
remaining O
isoforms O
, O
except O
betaI I-GENE
, O
upon O
readdition O
of O
Epo I-GENE
to O
growth O
factor O
- O
starved O
cells O
. O

We O
used O
expression O
cloning O
to O
identify O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
as O
one O
factor O
that O
suppressed O
growth O
of O
a O
pre O
- O
B O
- O
cell O
variant O
line O
, O
1A9 O
- O
M O
. O

Airflow O
through O
the O
dust O
trap O
was O
controlled O
with O
a O
vacuum O
pump O
. O

Thus O
, O
in O
normal O
intestinal O
epithelial O
goblet O
cells O
, O
TbetaRI I-GENE
and O
TbetaRII I-GENE
can O
respond O
to O
autocrine O
but O
not O
exogenous O
TGF I-GENE
- I-GENE
beta I-GENE
without O
the O
participation O
of O
TbetaRIII I-GENE
. O

The O
history O
of O
exposure O
and O
carboxyhemoglobin I-GENE
levels O
should O
alert O
the O
physician O
to O
this O
diagnosis O
. O

The O
odds O
ratio O
for O
CHD O
was O
1 O
. O
21 O
( O
95 O
% O
confidence O
interval O
, O
0 O
. O
84 O
- O
1 O
. O
75 O
) O
given O
a O
positive O
serostatus O
of O
specific O
IgG I-GENE
antibodies O
after O
adjustment O
for O
covariates O
. O

Another O
group O
of O
HIPP O
- O
and O
HCX O
- O
lesioned O
animals O
trained O
on O
the O
tasks O
after O
the O
lesion O
showed O
reduced O
impairments O
of O
the O
type O
described O
above O
, O
suggesting O
that O
extrahippocampal O
structures O
trained O
after O
the O
lesion O
can O
assume O
the O
role O
of O
the O
hippocampus O
to O
some O
degree O
. O

The O
case O
for O
neutrinos O
from O
SN O
1987A O
. O

Scaling O
of O
fluctuations O
in O
one O
- O
dimensional O
interface O
and O
hopping O
models O
. O

Model O
of O
spatiotemporal O
dynamics O
of O
stick O
- O
slip O
motion O
. O

NMR O
of O
diffusing O
atoms O
in O
a O
periodic O
porous O
medium O
in O
the O
presence O
of O
a O
nonuniform O
magnetic O
field O
. O

Microstructure O
and O
conductivity O
of O
hierarchical O
laminate O
composites O
. O

Anisotropic O
heat O
transport O
in O
the O
octylcyanobiphenyl O
( O
8CB O
) O
liquid O
crystal O
. O

Direct O
approach O
to O
the O
study O
of O
soliton O
perturbations O
. O

Mutations O
affecting O
only O
CD4 I-GENE
regulation O
mapped O
to O
residues O
previously O
shown O
to O
mediate O
the O
binding O
of O
Nef I-GENE
to O
this O
receptor O
, O
such O
as O
W57 O
and O
L58 O
, O
as O
well O
as O
to O
an O
AP I-GENE
- I-GENE
recruiting I-GENE
dileucine I-GENE
motif I-GENE
and O
to O
an O
acidic O
dipeptide O
in O
the O
C O
- O
terminal O
region O
of O
the O
protein O
. O

Several O
mutations O
disrupted O
the O
endonuclease O
and O
helicase I-GENE
activities O
; O
however O
, O
only O
one O
amino I-GENE
- I-GENE
terminal I-GENE
- I-GENE
charge I-GENE
cluster I-GENE
mutant I-GENE
protein I-GENE
( O
D40A O
- O
D42A O
- O
D44A O
) O
completely O
lost O
AAV O
hairpin O
DNA O
binding O
activity O
. O

The O
lytic O
cycle O
of O
KSHV O
, O
probably O
under O
the O
initial O
control O
of O
the O
KSHV I-GENE
/ I-GENE
Rta I-GENE
gene I-GENE
, O
may O
directly O
contribute O
to O
tumor O
pathogenesis O
. O

We O
conclude O
that O
( O
i O
) O
we O
have O
identified O
several O
candidate O
latency O
genes O
of O
murine O
gammaHV68 O
, O
( O
ii O
) O
expression O
of O
genes O
during O
latency O
may O
be O
different O
in O
different O
organs O
, O
consistent O
with O
multiple O
latency O
programs O
and O
/ O
or O
multiple O
cellular O
sites O
of O
latency O
, O
and O
( O
iii O
) O
regions O
of O
the O
viral O
genome O
( O
v I-GENE
- I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
v I-GENE
- I-GENE
GCR I-GENE
gene I-GENE
, O
and O
gene I-GENE
73 I-GENE
) O
are O
transcribed O
during O
latency O
with O
both O
gammaHV68 O
and O
primate O
gammaherpesviruses O
. O

These O
data O
indicate O
a O
functional O
role O
for O
U1 I-GENE
in O
NRS I-GENE
- O
mediated O
splicing O
inhibition O
. O

This O
suggests O
that O
the O
DcuS I-GENE
- O
DcuR I-GENE
system O
responds O
to O
external O
substrates O
. O

Here O
we O
describe O
the O
identification O
and O
characterization O
of O
several O
Sp100 I-GENE
splice I-GENE
variant I-GENE
proteins I-GENE
and O
support O
their O
existence O
by O
elucidation O
of O
the O
3 O
'- O
end O
of O
the O
Sp100 I-GENE
gene I-GENE
. O

Crossover O
in O
the O
specific O
heat O
of O
dilute O
magnets O
induced O
by O
critical O
spin O
- O
wave O
dynamics O
. O

Erratum O
: O
Absence O
of O
precursor O
effects O
above O
the O
martensitic O
transformation O
in O
a O
virgin O
crystal O
of O
Li O
metal O

Interplane O
coupling O
in O
the O
superconductor O
Y2Ba4Cu7O15 O
as O
revealed O
by O
NQR O
spin O
- O
echo O
double O
resonance O
. O

Electronic O
structure O
of O
a O
buried O
NiSi2 O
or O
CoSi2 O
layer O
in O
bulk O
Si O
. O

Raman O
investigation O
of O
YBa2 O
- O
xLaxCu3O7 O
ceramics O
. O

Effects O
of O
point O
defects O
on O
lattice O
parameters O
of O
semiconductors O
. O

Chaotic O
electron O
dynamics O
around O
a O
single O
elliptically O
shaped O
antidot O
. O

However O
, O
deletions O
of O
the O
C O
terminal O
11 O
or O
14 O
amino O
acids O
had O
more O
substantial O
effects O
. O

Sixty O
months O
after O
the O
initial O
vaccination O
, O
all O
vaccinees O
who O
received O
annual O
follow O
- O
up O
still O
had O
protective O
levels O
of O
anti I-GENE
- I-GENE
HAV I-GENE
. O

However O
, O
after O
PRK O
at O
5 O
weeks O
of O
age O
, O
partial O
retreatment O
may O
be O
necessary O
due O
to O
regression O
of O
the O
PRK O
effect O
. O

Its O
early O
lesions O
were O
characterized O
by O
angiomatosis O
, O
vasculopathy O
, O
and O
proliferation O
of O
synoviocytes O
and O
fibroblasts O
. O

Molecular O
cloning O
of O
human O
cDNA O
encoding O
a O
novel O
beta1 I-GENE
, I-GENE
6 I-GENE
- I-GENE
N I-GENE
- I-GENE
acetylglucosaminyltransferase I-GENE
forming O
core O
2 O
and O
core O
4 O
. O

Interspecific O
mouse O
back O
- O
cross O
analysis O
identified O
the O
loci O
for O
mouse I-GENE
3Ost I-GENE
genes I-GENE
and O
syntenic O
assignments O
of O
corresponding O
human O
isologs O
were O
confirmed O
by O
the O
identification O
of O
mapped O
sequence O
- O
tagged O
site O
markers O
. O

The O
Scales O
of O
Cognitive O
Impairment O
Rated O
From O
Institutional O
Records O
( O
SCIRFIR O
), O
a O
battery O
based O
on O
commonly O
used O
dementia O
rating O
instruments O
, O
was O
tested O
on O
the O
records O
of O
26 O
chronically O
institutionalized O
, O
elderly O
schizophrenia O
patients O
, O
for O
the O
purpose O
of O
retrospectively O
evaluating O
the O
long O
- O
term O
course O
of O
cognitive O
change O
in O
schizophrenia O
and O
relating O
it O
to O
available O
autopsy O
materials O
. O

It O
was O
demonstrated O
that O
the O
processing O
signals O
in O
the O
transcript O
, O
i O
. O
e O
. O
both O
donor O
splice O
sites O
and O
the O
polyadenylation O
site O
located O
in O
the O
muscle O
- O
specific O
intron O
, O
have O
to O
be O
weak O
. O

Most O
recently O
, O
the O
use O
of O
the O
product O
of O
brain O
weight O
and O
clearance O
has O
been O
proposed O
. O

Recombination O
and O
transcription O
of O
the O
endogenous I-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
locus I-GENE
is O
effected O
by O
the O
Ig I-GENE
heavy I-GENE
chain I-GENE
intronic I-GENE
enhancer I-GENE
core I-GENE
region I-GENE
in O
the O
absence O
of O
the O
matrix O
attachment O
regions O
. O

Two O
of O
these O
motifs O
are O
part O
of O
a O
highly O
conserved O
and O
inducible O
dyad O
symmetry O
element O
shown O
previously O
to O
control O
a O
remote O
IL I-GENE
- I-GENE
2 I-GENE
enhancer I-GENE
and O
the O
CD18 I-GENE
promoter I-GENE
. O

In O
concert O
with O
the O
coactivator O
CREB I-GENE
binding I-GENE
protein I-GENE
/ O
p300 I-GENE
, O
which O
interacts O
with O
GABPalpha I-GENE
, O
the O
binding O
of O
GABPalpha I-GENE
and I-GENE
- I-GENE
beta I-GENE
to O
the O
dyad O
symmetry O
element O
controls O
the O
induction O
of O
IL I-GENE
- I-GENE
16 I-GENE
promoter I-GENE
in O
T O
cells O
. O

TPO I-GENE
by O
itself O
did O
not O
activate O
ERK1 I-GENE
, O
ERK2 I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
), O
whereas O
TPO I-GENE
directly O
enhanced O
the O
PKC I-GENE
- O
dependent O
activation O
of O
ERKs I-GENE
induced O
by O
other O
agonists O
including O
thrombin I-GENE
and O
phorbol O
esters O
, O
without O
affecting O
the O
PKC I-GENE
activation O
by O
those O
agonists O
. O

BACKGROUND O
: O
In O
the O
ubiquitin I-GENE
- O
dependent O
proteolysis O
pathway O
, O
a O
ubiquitin I-GENE
ligase I-GENE
( O
E3 I-GENE
) O
is O
responsible O
for O
substrate O
selectivity O
and O
timing O
of O
degradation O
. O

CONCLUSIONS O
: O
Fission I-GENE
yeast I-GENE
SCF I-GENE
is O
composed O
of O
Pop1 I-GENE
and O
Pop2 I-GENE
, O
two O
structurally O
related O
but O
functionally O
independent O
F I-GENE
- I-GENE
box I-GENE
/ I-GENE
WD I-GENE
- I-GENE
repeat I-GENE
proteins I-GENE
. O

19F O
NMR O
studies O
in O
ABF4 O
- O
type O
layered O
antiferromagnets O
. O

Optical O
- O
absorption O
spectra O
, O
crystal O
- O
field O
energy O
levels O
, O
and O
transition O
line O
strengths O
of O
holmium O
in O
trigonal O
Na3 O

Observation O
of O
dipolar O
interactions O
between O
Pb0 O
defects O
at O
the O
( O
111 O
) O
Si O
/ O
SiO2 O
interface O
. O

Quantum O
- O
statistical O
theory O
of O
high O
- O
field O
transport O
phenomena O
. O

NH3 O
and O
NO O
interaction O
with O
Si O
( O
100 O
)-( O
2 O
x O
1 O
) O
surfaces O
. O

Chirality O
- O
glass O
and O
spin O
- O
glass O
correlations O
in O
the O
two O
- O
dimensional O
random O
- O
bond O
XY O
model O
. O

Echo O
modulation O
in O
Pr3 O
+: O
YAlO3 O
. O

Mechanisms O
of O
visible O
- O
light O
emission O
from O
electro O
- O
oxidized O
porous O
silicon O
. O

Far O
- O
infrared O
hopping O
conductivity O
in O
the O
CuO O
chains O
of O
a O
single O
- O
domain O
YBa2Cu3O7 O
- O
delta O
crystal O
. O

Surface O
spin O
waves O
in O
a O
Heisenberg O
ferrimagnet O
with O
a O
single O
- O
ion O
anisotropy O
( O
uniaxial O
and O
nonuniaxial O
). O

Optically O
detected O
librons O
and O
phonons O
in O
crystalline O
C60 O
. O

Multilayer O
- O
relaxation O
geometry O
and O
electronic O
structure O
of O
a O
W O
( O
111 O
) O
surface O
. O

Temperature O
dependence O
of O
the O
sublattice O
spontaneous O
magnetization O
of O
YBa2Cu3O6 O
. O

GW O
Gamma O
approximation O
for O
electron O
self O
- O
energies O
in O
semiconductors O
and O
insulators O
. O

Precision O
measurement O
of O
the O
pion O
mass O
difference O
m O
pi O
-- O
m O
pi O
0 O
. O

Testing O
gravity O
to O
second O
post O
- O
Newtonian O
order O
: O
A O
field O
- O
theory O
approach O
. O

Genetic O
experiments O
using O
mutants O
defective O
in O
apontic I-GENE
and O
bruno I-GENE
reveal O
a O
functional O
interaction O
between O
these O
genes O
. O

In O
the O
current O
model O
, O
Wingless I-GENE
/ O
Wnt I-GENE
signal O
stabilizes O
Armadillo I-GENE
/ O
beta I-GENE
- I-GENE
catenin I-GENE
, O
which O
then O
accumulates O
in O
nuclei O
and O
binds O
TCF I-GENE
/ O
LEF I-GENE
family O
proteins O
, O
forming O
bipartite O
transcription O
factors O
which O
activate O
transcription O
of O
Wingless I-GENE
/ O
Wnt I-GENE
responsive O
genes O
. O

In O
support O
of O
clinical O
antianginal O
studies O
, O
the O
vasodilator O
nicorandil O
( O
NIC O
) O
was O
combined O
with O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
antagonists O
propranolol O
( O
PRO O
) O
and O
atenolol O
( O
ATN O
) O
and O
with O
the O
calcium O
channel O
blocker O
diltiazem O
( O
DTZ O
) O
to O
determine O
their O
cardiovascular O
and O
pharmacokinetic O
interactions O
. O

Factors O
influencing O
direct O
- O
immersion O
( O
DI O
)- O
SPME O
process O
were O
also O
checked O
and O
chosen O
experimentally O
. O

In O
contrast O
, O
an O
amino O
- O
terminal O
fragment O
containing O
the O
C O
/ O
H1 O
domain O
was O
sufficient O
for O
coactivation O
of O
Zta I-GENE
transcription O
and O
viral O
reactivation O
function O
. O

In O
addition O
, O
a O
potent O
splicing O
enhancer O
sequence O
isolated O
in O
the O
selection O
specifically O
binds O
a O
20 I-GENE
- I-GENE
kDa I-GENE
SR I-GENE
protein I-GENE
. O

Elimination O
of O
ETH1 I-GENE
in O
apn1 I-GENE
strains O
also O
increased O
spontaneous O
mutation O
rates O
9 O
- O
or O
31 O
- O
fold O
compared O
to O
the O
wild O
type O
as O
determined O
by O
reversion O
to O
adenine O
or O
lysine O
prototrophy O
, O
respectively O
. O

Elimination O
of O
ETH1 I-GENE
in O
apn1 I-GENE
strains O
also O
increased O
spontaneous O
mutation O
rates O
9 O
- O
or O
31 O
- O
fold O
compared O
to O
the O
wild O
type O
as O
determined O
by O
reversion O
to O
adenine O
or O
lysine O
prototrophy O
, O
respectively O
. O

These O
data O
suggest O
that O
other O
Ras I-GENE
effectors I-GENE
can O
collaborate O
with O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
with O
each O
other O
to O
activate O
Pak I-GENE
. O

Mammalian O
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
GAP I-GENE
), O
p120 I-GENE
Ras I-GENE
- O
GAP I-GENE
, O
has O
been O
implicated O
as O
both O
a O
downregulator O
and O
effector O
of O
Ras I-GENE
proteins I-GENE
, O
but O
its O
precise O
role O
in O
Ras I-GENE
- O
mediated O
signal O
transduction O
pathways O
is O
unclear O
. O

Three O
mog I-GENE
- I-GENE
1 I-GENE
alleles I-GENE
possess O
premature O
stop O
codons O
and O
are O
likely O
to O
be O
null O
alleles O
, O
and O
one O
is O
a O
missense O
mutation O
and O
is O
likely O
to O
retain O
residual O
activity O
. O
mog I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
is O
expressed O
in O
both O
germ O
line O
and O
somatic O
tissues O
and O
appears O
to O
be O
ubiquitous O
. O

However O
, O
unlike O
the O
SIN3 I-GENE
gene I-GENE
of O
Saccharomyces O
cerevisiae O
, O
pst1 I-GENE
(+) I-GENE
is O
essential O
for O
cell O
viability O
. O

The O
Nmd3 I-GENE
protein I-GENE
sequence I-GENE
does O
not O
contain O
readily O
recognizable O
motifs O
of O
known O
function O
. O

The O
distribution O
of O
the O
various O
repeats O
suggests O
its O
organization O
is O
similar O
to O
the O
beta O
- O
heterochromatic O
regions O
near O
the O
base O
of O
the O
major O
chromosome O
arms O
. O

Calcitonin I-GENE
simultaneously O
regulates O
both O
periosteal O
hyperostosis O
and O
trabecular O
osteopenia O
in O
the O
spinal O
hyperostotic O
mouse O
( O
twy I-GENE
/ O
twy I-GENE
) O
in O
vivo O
. O

Electrophoretic O
mobility O
- O
shift O
assays O
performed O
with O
the O
HNF I-GENE
- I-GENE
3 I-GENE
X O
and O
Y O
sites O
demonstrated O
that O
both O
sites O
are O
capable O
of O
binding O
HNF I-GENE
- I-GENE
3alpha I-GENE
and O
HNF I-GENE
- I-GENE
3beta I-GENE
. O

In O
addition O
, O
we O
also O
show O
that O
cdk7 I-GENE
may O
phosphorylate O
the O
carboxy O
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA I-GENE
pol I-GENE
II I-GENE
in O
the O
absence O
of O
promoter O
opening O
. O

The O
therapy O
with O
a O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
is O
less O
effective O
than O
the O
triple O
therapies O
with O
omeprazole O
or O
lansoprazole O
. O

In O
humans O
, O
three O
tissue I-GENE
- I-GENE
specific I-GENE
plastin I-GENE
isoforms I-GENE
have O
been O
identified O
. O

No O
TATA O
or O
Inr O
sequence O
was O
found O
. O

The O
inhibition O
by O
the O
RIalpha I-GENE
subunit I-GENE
is O
reversed O
by O
addition O
of O
nanomolar O
concentrations O
of O
cAMP O
( O
Ka O
= O
40 O
nM O
), O
thus O
demonstrating O
that O
PrKX I-GENE
is O
a O
novel O
, O
type I-GENE
I I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
that O
is O
activated O
at O
lower O
cAMP O
concentrations O
than O
the O
holoenzyme O
with O
the O
Calpha I-GENE
subunit I-GENE
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

Proteins O
known O
to O
bind O
the O
PEPCK I-GENE
CRE O
include O
the O
CRE I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
members O
of O
the O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
family O
. O

This O
construct O
, O
termed O
pDeltaCREC I-GENE
/ O
EBP I-GENE
, O
binds O
C I-GENE
/ I-GENE
EBPalpha I-GENE
and I-GENE
beta I-GENE
but O
not O
CREB I-GENE
, O
yet O
it O
confers O
a O
nearly O
complete O
glucocorticoid O
response O
when O
transiently O
transfected O
into O
H4IIE O
rat O
hepatoma O
cells O
. O

In O
addition O
, O
in O
vitro O
mutagenesis O
of O
both O
Engrailed I-GENE
and O
Pbx1 I-GENE
sites I-GENE
indicated O
that O
other O
unidentified O
sites O
are O
responsible O
for O
the O
transcriptional O
enhancement O
observed O
with O
the O
intronic O
fragment O
. O

Several O
secondary O
structure O
elements O
were O
identified O
. O

Here O
, O
we O
evidence O
that O
the O
developmental O
functions O
of O
the O
family O
of O
transcription O
factors O
characterized O
by O
the O
POU I-GENE
DNA I-GENE
binding I-GENE
motif I-GENE
exerts O
roles O
in O
mammalian O
development O
. O

High O
- O
affinity O
site O
- O
specific O
DNA O
binding O
by O
POU I-GENE
domain I-GENE
transcription I-GENE
factors I-GENE
requires O
both O
the O
POU I-GENE
- I-GENE
specific I-GENE
and O
the O
POU I-GENE
- I-GENE
homeodomain I-GENE
. O

In O
the O
Oct I-GENE
- I-GENE
1 I-GENE
crystal O
, O
the O
POU I-GENE
- I-GENE
specific I-GENE
domain I-GENE
recognizes O
a O
GCAT O
half O
- O
site O
, O
while O
the O
corresponding O
sequence O
recognized O
by O
the O
Pit I-GENE
- I-GENE
1 I-GENE
POU I-GENE
- O
specific O
domain O
, O
GTAT O
, O
is O
on O
the O
opposing O
strand O
. O

Systematic O
functional O
analysis O
of O
V1a I-GENE
/ I-GENE
V2 I-GENE
hybrid I-GENE
receptors I-GENE
showed O
that O
the O
second O
intracellular O
loop O
of O
the O
V1a I-GENE
receptor I-GENE
is O
required O
and O
sufficient O
for O
efficient O
coupling O
to O
Gq I-GENE
/ I-GENE
11 I-GENE
, O
whereas O
the O
third O
intracellular O
loop O
of O
the O
V2 I-GENE
receptor I-GENE
is O
required O
and O
sufficient O
for O
coupling O
to O
Gs I-GENE
. O

Most O
other O
end O
points O
were O
highly O
significant O
, O
and O
death O
, O
which O
was O
monitored O
across O
the O
U O
. O
S O
. O
program O
, O
was O
different O
with O
p O
< O
0 O
. O
0001 O
. O

The O
other O
is O
located O
at O
- O
1335 O
, O
outside O
this O
highly O
conserved O
region O
. O

The O
fatigue O
exercise O
showed O
relatively O
high O
blood O
lactate O
concentration O
[ O
12 O
. O
5 O
( O
SD O
2 O
. O
6 O
) O
mmol O
x O
l O
(- O
1 O
)] O
and O
an O
increase O
of O
serum I-GENE
creatine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
activity O
delayed O
by O
2 O
days O
[ O
540 O
( O
SD O
407 O
) O
U O
x O
l O
(- O
1 O
)]. O

Those O
radiological O
aspects O
were O
distributed O
in O
two O
categories O
: O
1 O
) O
type O
I O
- O
presenting O
variable O
sinusoidal O
filling O
. O

Results O
demonstrated O
that O
the O
presence O
of O
myofibroblasts O
varied O
considerably O
from O
case O
to O
case O
and O
was O
always O
related O
to O
smooth O
muscle O
cell O
dispersion O
, O
which O
occurred O
around O
medium O
- O
sized O
damaged O
portal O
vein O
branches O
. O

New O
Langevin O
equations O
for O
a O
translating O
and O
simultaneously O
rotating O
asymmetric O
top O
. O

Radiative O
corrections O
to O
beta O
decay O
and O
the O
possibility O
of O
a O
fourth O
generation O
. O

Depth O
- O
controlled O
grazing O
- O
incidence O
diffraction O
of O
synchrotron O
x O
radiation O
. O

Oscillatory O
exchange O
of O
atoms O
between O
traps O
containing O
Bose O
condensates O
. O

Structure O
determination O
of O
an O
adsorbate O
- O
induced O
multilayer O
reconstruction O
: O
( O
1 O
x O
2 O
)- O
H O
/ O
Ni O
( O
110 O
). O

Magnetic O
trapping O
of O
spin O
- O
polarized O
atomic O
hydrogen O
. O

Northern O
blot O
and O
in O
situ O
hybridization O
analyses O
revealed O
GPR34 I-GENE
mRNA I-GENE
transcripts I-GENE
in O
several O
human O
and O
rat O
brain O
regions O
. O

The O
microphthalmia I-GENE
- I-GENE
TFE I-GENE
( O
MiT I-GENE
) O
subfamily O
of O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bHLH I-GENE
- I-GENE
ZIP I-GENE
) I-GENE
transcription I-GENE
factors I-GENE
, O
including O
TFE3 I-GENE
, O
TFEB I-GENE
, O
TFEC I-GENE
, O
and O
Mitf I-GENE
, O
has O
been O
implicated O
in O
the O
regulation O
of O
tissue O
- O
specific O
gene O
expression O
in O
several O
cell O
lineages O
. O

Fifty O
- O
seven O
patients O
aged O
< O
55 O
years O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
in O
second O
or O
third O
bone O
marrow O
( O
BM O
) O
relapse O
or O
refractory O
to O
first O
- O
line O
therapy O
were O
enrolled O
in O
an O
Italian O
cooperative O
study O
. O

The O
dorsal O
nerves O
of O
the O
penis O
were O
anesthetized O
bilaterally O
with O
lidocaine O
. O

In O
the O
brain O
, O
muscarinic I-GENE
receptors I-GENE
mediate O
motor O
and O
memory O
function O
by O
interaction O
with O
their O
ligand O
acetylcholine O
. O

Early O
- O
onset O
scleral O
necrosis O
after O
iodine O
I O
125 O
plaque O
radiotherapy O
for O
ciliochoroidal O
melanoma O
. O

Successful O
interaction O
of O
ARF I-GENE
and O
PKC I-GENE
- I-GENE
alpha I-GENE
with O
PLD1 I-GENE
was O
not O
achieved O
, O
but O
a O
C O
- O
terminal O
fragment O
of O
human I-GENE
PLD1 I-GENE
( O
denoted O
" O
D4 O
") O
interacted O
with O
the O
active O
mutant O
of O
RhoA I-GENE
, O
RhoAVal I-GENE
- I-GENE
14 I-GENE
. O

In O
this O
study O
, O
we O
investigated O
the O
signal O
transduction O
pathways O
that O
are O
involved O
in O
OM I-GENE
- O
induced O
LDLR I-GENE
transcription O
. O

Vacuum O
Rabi O
splitting O
as O
a O
feature O
of O
linear O
- O
dispersion O
theory O
: O
Analysis O
and O
experimental O
observations O
. O

High O
- O
pressure O
effects O
on O
ultrafast O
- O
relaxation O
kinetics O
of O
excitons O
in O
polydiacetylene O
4BCMU O
. O

Drag O
reduction O
in O
turbulent O
flows O
by O
polymers O
. O

Large O
scale O
electronic O
structure O
calculations O
. O

Current O
world O
literature O
. O

These O
results O
show O
that O
Ski I-GENE
is O
a O
component O
of O
the O
HDAC I-GENE
complex I-GENE
and O
that O
Ski I-GENE
is O
required O
for O
the O
transcriptional O
repression O
mediated O
by O
this O
complex O
. O

Recombinant O
unr I-GENE
acts O
synergistically O
with O
recombinant O
PTB I-GENE
to O
stimulate O
translation O
dependent O
on O
the O
rhinovirus O
IRES O
. O

Analysis O
of O
the O
consensus O
binding O
sequence O
and O
the O
DNA O
- O
binding O
domain O
of O
ZF5 I-GENE
. O

Mapping O
of O
the O
human I-GENE
Voltage I-GENE
- I-GENE
Dependent I-GENE
Anion I-GENE
Channel I-GENE
isoforms I-GENE
1 I-GENE
and I-GENE
2 I-GENE
reconsidered O
. O

Identification O
of O
RNase I-GENE
T I-GENE
as O
a O
high O
- O
copy O
suppressor O
of O
the O
UV O
sensitivity O
associated O
with O
single I-GENE
- I-GENE
strand I-GENE
DNA I-GENE
exonuclease I-GENE
deficiency O
in O
Escherichia O
coli O
. O

Inhibition O
of O
phosphatidylinositol I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
did O
not O
have O
a O
significant O
effect O
on O
p53 I-GENE
conformation O
but O
did O
have O
a O
weak O
but O
significant O
effect O
on O
Tpo I-GENE
- O
enhanced O
viability O
. O

No O
difference O
in O
percentage O
of O
males O
in O
semen O
production O
was O
noted O
between O
strains O
, O
CP O
levels O
, O
or O
feeding O
regimens O
. O

The O
Lp I-GENE
mouse I-GENE
mutant I-GENE
provides O
a O
model O
for O
the O
severe O
human O
neural O
tube O
defect O
( O
NTD O
), O
cranio O
- O
rachischisis O
. O

Further O
analysis O
of O
AP I-GENE
- I-GENE
1 I-GENE
DNA O
binding O
activities O
in O
7 O
- O
to O
14 O
- O
day O
culture O
activated O
HSCs O
led O
to O
the O
discovery O
of O
high I-GENE
mobility I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complexes I-GENE
( O
HMAP I-GENE
- I-GENE
1 I-GENE
). O

Mutations O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
of O
the O
TIMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
that O
prevented O
formation O
of O
HMAP I-GENE
- I-GENE
1 I-GENE
caused O
a O
70 O
% O
loss O
of O
activity O
in O
transfected O
activated O
HSCs O
. O

STUDY O
DESIGN O
: O
Salivary I-GENE
immunoglobulin I-GENE
A I-GENE
levels O
of O
each O
of O
20 O
subjects O
were O
determined O
on O
3 O
occasions O
: O
first O
, O
while O
the O
subject O
was O
still O
smoking O
; O
second O
, O
7 O
days O
after O
cessation O
of O
smoking O
; O
third O
, O
on O
the O
14th O
day O
after O
cessation O
. O

Therefore O
, O
high O
set O
- O
up O
accuracy O
and O
reproducibility O
are O
mandatory O
. O

Role O
of O
g2 O
in O
relating O
the O
Schwinger O
and O
Gerasimov O
- O
Drell O
- O
Hearn O
sum O
rules O
. O

Spectroscopy O
of O
negative O
ions O
utilizing O
multiphoton O
detachment O
in O
a O
Raman O
coupling O
regime O
. O

Band O
structure O
effects O
of O
transport O
properties O
in O
icosahedral O
quasicrystals O
. O

Acoustic O
transmission O
spectra O
in O
the O
Penrose O
lattice O
. O

Two O
- O
Channel O
Kondo O
Lattice O
: O
An O
Incoherent O
Metal O
. O

Basal O
midexpiratory O
lower O
esophageal O
sphincter O
pressure O
was O
similar O
in O
the O
study O
group O
( O
mean O
[ O
SD O
] O
20 O
. O
1 O
[ O
9 O
. O
1 O
] O
mmHg O
) O
and O
controls O
( O
17 O
. O
6 O
[ O
6 O
. O
0 O
] O
mmHg O
); O
the O
pressure O
did O
not O
change O
following O
EVS O
or O
EVL O
. O

CPDs O
at O
these O
three O
sites O
may O
partially O
displace O
TFIIIA I-GENE
, O
thereby O
enabling O
rapid O
repair O
. O

There O
was O
no O
difference O
in O
the O
hormone O
receptor O
status O
between O
the O
cases O
without O
lymph O
node O
metastases O
and O
with O
lymph O
node O
metastases O
, O
' O
clandestine O
' O
or O
macrometastases O
. O

On O
the O
other O
hand O
, O
subjects O
with O
air O
trapping O
( O
residual O
volume O
( O
RV O
)/ O
total O
lung O
capacity O
( O
TLC O
) O
> O
37 O
%) O
disclosed O
not O
only O
a O
higher O
n O
( O
mit O
) O
( O
0 O
. O
63 O
+/- O
0 O
. O
17 O
versus O
0 O
. O
43 O
+/- O
0 O
. O
07 O
mt O
x O
microm O
(- O
2 O
), O
p O
< O
0 O
. O
05 O
) O
but O
shorter O
sarcomeres O
( O
L O
( O
sar O
)) O
than O
subjects O
without O
this O
functional O
abnormality O
( O
2 O
. O
08 O
+/- O
0 O
. O
16 O
to O
2 O
. O
27 O
+/- O
0 O
. O
15 O
microm O
, O
p O
< O
0 O
. O
05 O
). O

Gel O
filtration O
, O
sedimentation O
velocity O
, O
and O
immunoprecipitation O
experiments O
revealed O
that O
beta4 O
is O
a O
component O
of O
a O
multisubunit O
complex O
( O
AP I-GENE
- I-GENE
4 I-GENE
) O
that O
also O
contains O
the O
sigma4 O
polypeptide O
and O
two O
additional O
adaptor O
subunit O
homologs O
named O
mu4 O
( O
mu O
- O
ARP2 O
) O
and O
epsilon O
. O

Cyclin I-GENE
D1 I-GENE
- I-GENE
associated I-GENE
kinase I-GENE
activity O
and O
protein O
levels O
were O
increased O
in O
mammary O
tumors O
from O
murine O
mammary O
tumor O
virus O
- O
pp60 I-GENE
( O
c I-GENE
- I-GENE
src527F I-GENE
) O
transgenic O
mice O
. O

The O
SH2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
inositol I-GENE
5 I-GENE
'- I-GENE
phosphatase I-GENE
( O
SHIP I-GENE
) O
recruits O
the O
p85 I-GENE
subunit I-GENE
of O
phosphoinositide I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
during O
FcgammaRIIb1 I-GENE
- O
mediated O
inhibition O
of O
B I-GENE
cell I-GENE
receptor I-GENE
signaling O
. O

We O
show O
that O
the O
mouse O
genome O
contains O
four O
copies O
of O
the O
ubc I-GENE
- I-GENE
9 I-GENE
gene I-GENE
. O

An O
increase O
in O
bone O
mineral O
density O
at O
the O
spine O
, O
total O
hip O
, O
and O
total O
body O
has O
been O
reported O
with O
raloxifene O
but O
seems O
to O
be O
less O
than O
that O
seen O
with O
estrogen O
or O
alendronate O
therapy O
. O

However O
, O
in O
those O
studies O
due O
to O
the O
presence O
of O
thiol O
agents O
in O
the O
PKC I-GENE
preparations O
, O
the O
sensitive O
reaction O
of O
BPO O
with O
redox O
- O
active O
cysteine O
residues O
in O
PKC I-GENE
was O
not O
observed O
. O

Interestingly O
, O
Csx I-GENE
/ O
Nkx2 I-GENE
. O

We O
also O
identified O
an O
alternative O
spliced O
form O
of O
Lyp I-GENE
RNA I-GENE
, O
Lyp2 I-GENE
. O

The O
costs O
were O
DM O
11 O
, O
562 O
for O
a O
PE O
, O
DM O
12 O
, O
477 O
for O
a O
VR O
and O
DM O
7 O
, O
532 O
for O
a O
MR O
. O

We O
now O
provide O
evidence O
for O
physical O
and O
functional O
interaction O
between O
Doa4 I-GENE
and O
the O
proteasome O
. O

Independent O
splicing O
events O
involve O
three O
previously O
described O
cassette O
exons O
, O
which O
are O
predicted O
to O
encode O
most O
of O
the O
second O
transmembrane O
domain O
. O

Each O
of O
these O
genes O
contains O
a O
putative O
upstream O
ORF O
, O
while O
STA2 I-GENE
has O
two O
additional O
in O
- O
frame O
AUG O
codons O
5 O
' O
to O
the O
major O
cistron O
. O

Nipponbare O
as O
well O
as O
O O
. O
australiensis O
. O

In O
addition O
, O
mapping O
of O
the O
promoter O
region O
and O
the O
identification O
of O
putative O
promoter O
regulatory O
sequences O
should O
give O
insight O
into O
the O
transcriptional O
regulation O
of O
UCP2 I-GENE
expression O
-- O
in O
particular O
by O
anyone O
of O
the O
above O
mentioned O
factors O
-- O
in O
vitro O
and O
in O
vivo O
. O

The O
rate O
of O
resectability O
is O
low O
and O
5 O
- O
year O
survival O
is O
very O
poor O
. O

In O
order O
to O
better O
characterize O
the O
distribution O
of O
ML O
and O
MAP O
estimates O
under O
these O
conditions O
, O
we O
derive O
a O
point O
approximation O
to O
density O
values O
of O
the O
conditional O
distribution O
of O
such O
estimates O
. O

RT O
- O
PCR O
was O
performed O
using O
previously O
reported O
degenerate O
oligonucleotide O
primers O
to O
the O
ligand O
binding O
domain O
( O
LBD O
) O
of O
known O
beta I-GENE
integrin I-GENE
subunits I-GENE
and O
Bge I-GENE
cDNA I-GENE
. O

The O
lowest O
culture O
failure O
rate O
of O
0 O
. O
2 O
per O
cent O
was O
found O
after O
EAF O
compared O
with O
0 O
. O
9 O
per O
cent O
among O
CVS O
. O

Ectopic O
expression O
of O
d I-GENE
- I-GENE
axin I-GENE
inhibited O
Wingless I-GENE
signaling O
. O

The O
corresponding O
differences O
in O
FVIIa I-GENE
and O
PAI I-GENE
- I-GENE
1 I-GENE
were O
not O
statistically O
significant O
. O

Primary O
and O
secondary O
structural O
elements O
required O
for O
synthesis O
of O
barley O
yellow O
dwarf O
virus O
subgenomic O
RNA1 O
. O

On O
the O
other O
side O
, O
when O
the O
aortic O
ring O
was O
perfused O
with O
L O
- O
NNA O
( O
NO O
- O
synthesis O
inhibitor O
) O
or O
methylene O
blue O
( O
soluble O
cGMPase I-GENE
inhibitor O
), O
the O
changes O
could O
be O
attenuated O
. O

Nevertheless O
, O
inactivation O
of O
the O
cyclin I-GENE
E I-GENE
- O
Cdk2 I-GENE
complex O
in O
response O
to O
mitogen O
starvation O
occurs O
normally O
in O
MEFs O
that O
have O
a O
homozygous O
deletion O
of O
the O
p27 I-GENE
gene I-GENE
. O

Identification O
and O
characterization O
of O
IS2404 I-GENE
and O
IS2606 I-GENE
: O
two O
distinct O
repeated O
sequences O
for O
detection O
of O
Mycobacterium O
ulcerans O
by O
PCR O
. O

Taken O
together O
, O
these O
results O
are O
consistent O
with O
the O
possibility O
that O
p202 I-GENE
protein I-GENE
contributes O
to O
the O
cell O
growth O
retardation O
activity O
of O
the O
IFNs I-GENE
, O
at O
least O
in O
part O
, O
by O
modulating O
p21 I-GENE
protein I-GENE
levels O
. O

Similar O
results O
were O
also O
obtained O
with O
a O
HepG2 O
hepatoblastoma O
cell O
line O
carrying O
wt I-GENE
p53 I-GENE
. O

Partial O
sequencing O
of O
the O
region O
downstream O
of O
ORF I-GENE
- I-GENE
Pto I-GENE
revealed O
homology O
to O
the O
ru I-GENE
/ I-GENE
AB I-GENE
genes I-GENE
, O
involved O
in O
UV O
resistance O
, O
from O
plasmid O
pPSR1 O
. O

The O
MSY2 I-GENE
associated O
kinase O
is O
not O
casein I-GENE
kinase I-GENE
2 I-GENE
, O
the O
kinase O
believed O
to O
phosphorylate O
mRNP3 I-GENE
+ I-GENE
4 I-GENE
in O
oocytes O
, O
but O
a O
yet O
unidentified O
kinase O
. O

This O
suggests O
that O
helicase I-GENE
- I-GENE
like I-GENE
genes I-GENE
may O
be O
involved O
in O
the O
biosynthesis O
of O
nucleic O
acids O
and O
proteins O
, O
and O
that O
the O
genes O
can O
be O
transcriptionally O
activated O
by O
heat O
shock O
to O
compensate O
for O
the O
repressed O
synthesis O
of O
mRNA O
and O
protein O
. O

These O
data O
provide O
the O
molecular O
tools O
for O
the O
final O
identification O
of O
the O
MKS I-GENE
and O
the O
MUL I-GENE
genes I-GENE
. O

The O
H O
- O
reflex O
recovery O
curve O
was O
obtained O
after O
stimulation O
of O
the O
median O
nerve O
at O
the O
elbow O
and O
recording O
from O
the O
flexor O
carpi O
radialis O
. O

The O
origins O
of O
reflected O
light O
changes O
associated O
with O
neuronal O
activity O
( O
optical O
signals O
) O
were O
investigated O
in O
rat O
somatosensory O
cortex O
with O
optical O
imaging O
, O
microspectrophotometry O
, O
and O
laser O
- O
Doppler O
flowmetry O
, O
and O
dynamic O
changes O
in O
local O
hemoglobin I-GENE
concentration O
and O
oxygenation O
were O
focused O
on O
. O

Human I-GENE
neuronal I-GENE
Elav I-GENE
- I-GENE
like I-GENE
proteins I-GENE
contain O
three O
RNP O
- O
type O
RNA O
recognition O
motifs O
( O
RRMs O
). O

Comparison O
of O
frequencies O
of O
atrial O
fibrillation O
after O
coronary O
artery O
bypass O
grafting O
with O
and O
without O
the O
use O
of O
cardiopulmonary O
bypass O
. O

The O
results O
of O
supershift O
analysis O
using O
specific O
antibodies O
against O
transcription O
factors O
suggested O
that O
both O
binding O
complexes O
contained O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
components O
p50 I-GENE
and O
p65 I-GENE
, O
and O
did O
not O
contain O
other O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
( O
p52 I-GENE
, O
c I-GENE
- I-GENE
Rel I-GENE
, O
Rel I-GENE
B I-GENE
), O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
( O
c I-GENE
- I-GENE
Fos I-GENE
, O
C I-GENE
- I-GENE
Jun I-GENE
), O
CREB I-GENE
or O
C I-GENE
/ I-GENE
EBPbeta I-GENE
( O
NF I-GENE
- I-GENE
IL6 I-GENE
). O

A O
set O
of O
peptides O
corresponding O
to O
the O
individual O
elements O
of O
secondary O
structure O
derived O
from O
the O
N O
- O
terminal O
domain O
of O
the O
ribosomal I-GENE
protein I-GENE
L9 I-GENE
have O
been O
synthesized O
. O

The O
results O
showed O
that O
IFN I-GENE
- I-GENE
gamma I-GENE
stimulated O
the O
rapid O
accumulation O
of O
interferon I-GENE
regulated I-GENE
factor I-GENE
( I-GENE
IRF I-GENE
)- I-GENE
1 I-GENE
mRNA I-GENE
, O
followed O
by O
a O
delayed O
and O
dose O
- O
dependent O
inhibition O
of O
alpha1 I-GENE
( I-GENE
I I-GENE
) I-GENE
procollagen I-GENE
mRNA I-GENE
expression O
in O
skin O
fibroblasts O
from O
several O
different O
donors O
. O

Functional O
domains O
of O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
involved O
in O
transcriptional O
repression O
and O
cell O
growth O
regulation O
. O

Therefore O
, O
we O
have O
named O
this O
gene O
UBP43 I-GENE
. O

These O
results O
continue O
to O
support O
the O
hypothesis O
that O
HS2 O
, O
HS3 O
, O
and O
HS4 O
act O
as O
a O
single O
, O
integral O
unit O
to O
regulate O
human I-GENE
globin I-GENE
gene I-GENE
transcription O
as O
a O
holocomplex O
, O
but O
they O
can O
also O
be O
interpreted O
to O
say O
that O
formation O
of O
a O
DNase I-GENE
I I-GENE
hypersensitive O
holocomplex O
alone O
is O
not O
sufficient O
for O
mediating O
high O
- O
level O
globin I-GENE
gene I-GENE
transcription O
. O

To O
identify O
additional O
non O
- O
Sir I-GENE
factors I-GENE
that O
affect O
rDNA O
silencing O
, O
we O
performed O
a O
genetic O
screen O
designed O
to O
isolate O
mutations O
which O
alter O
the O
expression O
of O
reporter O
genes O
integrated O
within O
the O
rDNA O
. O

Because O
there O
is O
great O
need O
for O
iron O
in O
the O
EPO I-GENE
- O
stimulated O
erythroid O
progenitors O
, O
it O
is O
essential O
that O
serum I-GENE
ferritin I-GENE
and O
transferrin I-GENE
saturation O
levels O
should O
be O
maintained O
over O
300 O
microg O
/ O
liter O
and O
30 O
%, O
respectively O
. O

These O
results O
indicate O
that O
the O
p33 I-GENE
subunit I-GENE
of O
eIF3 I-GENE
plays O
an O
important O
role O
in O
the O
initiation O
phase O
of O
protein O
synthesis O
and O
that O
its O
RNA O
- O
binding O
domain O
is O
required O
for O
optimal O
activity O
. O

In O
this O
study O
, O
we O
elucidate O
signaling O
pathways O
induced O
by O
photodynamic O
therapy O
( O
PDT O
) O
with O
hypericin O
. O

These O
results O
indicate O
that O
ATF I-GENE
- I-GENE
2 I-GENE
plays O
a O
central O
role O
in O
TGF I-GENE
- I-GENE
beta I-GENE
signaling O
by O
acting O
as O
a O
common O
nuclear O
target O
of O
both O
Smad I-GENE
and O
TAK1 I-GENE
pathways O
. O

KEY O
WORDS O
: O
Melaleuca O
; O
Lake O
Okeechobee O
; O
Littoral O
zone O
; O
Water O
level O
; O
Regulation O
schedule O

The O
systolic O
peak O
of O
pulmonary O
vein O
was O
higher O
than O
the O
diastolic O
peak O
in O
45 O
out O
of O
56 O
cases O
. O

Specimens O
were O
assayed O
for O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
, O
unconjugated O
estriol O
, O
free O
alpha I-GENE
hCG I-GENE
, O
and O
total O
hCG I-GENE
. O

FASEB O
Federal O
Funding O
Consensus O
Conference O
FY O
2000 O
. O

The O
following O
data O
were O
recorded O
at O
arrival O
in O
the O
intensive O
care O
unit O
6 O
, O
12 O
, O
24 O
, O
and O
48 O
hours O
after O
termination O
of O
CPB O
: O
heart O
rate O
, O
blood O
pressure O
, O
left O
atrial O
pressure O
, O
central O
- O
peripheral O
temperature O
difference O
, O
arterial O
- O
central O
venous O
oxygen O
saturation O
difference O
, O
urine O
output O
, O
serum O
creatinine O
, O
lactate O
and O
neutrophil I-GENE
elastase I-GENE
levels O
, O
the O
Doppler O
echocardiographic O
factors O
shortening O
fraction O
and O
preejection O
period O
/ O
left O
- O
ventricular O
ejection O
time O
, O
and O
cumulative O
doses O
of O
catecholamines O
( O
epinephrine O
), O
enoximone O
, O
and O
furosemide O
. O

MDS1 I-GENE
/ O
EVI1 I-GENE
, O
located O
on O
chromosome O
3 O
band O
q26 O
, O
encodes O
a O
zinc I-GENE
- I-GENE
finger I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
activator I-GENE
not O
detected O
in O
normal O
hematopoietic O
cells O
but O
expressed O
in O
several O
normal O
tissues O
. O

Analysis O
of O
the O
protein O
sequences O
of O
these O
two O
replicases I-GENE
, O
together O
with O
previously O
characterized O
H I-GENE
. I-GENE
pylori I-GENE
plasmid I-GENE
replication I-GENE
proteins I-GENE
, O
supports O
the O
formation O
of O
a O
distinct O
class O
of O
H I-GENE
. I-GENE
pylori I-GENE
plasmid I-GENE
proteins I-GENE
. O

The O
JTc O
delta O
among O
the O
three O
groups O
did O
not O
differ O
as O
well O
: O
JTc O
delta O
of O
the O
VT O
group O
was O
70 O
ms O
+/- O
30 O
ms O
, O
the O
JTc O
delta O
of O
the O
PVC O
group O
was O
60 O
msec O
+/- O
25 O
msec O
, O
and O
the O
JTc O
delta O
of O
the O
control O
group O
was O
70 O
ms O
+/- O
30 O
ms O
. O

In O
contrast O
, O
deletion O
of O
the O
upstream O
portion O
of O
the O
delta O
promoter O
led O
to O
a O
10 O
fold O
decrease O
in O
expression O
. O

Site O
- O
directed O
mutagenesis O
of O
binding O
sites O
for O
the O
repressor I-GENE
proteins I-GENE
BP1 I-GENE
and O
BP2 I-GENE
in O
the O
upstream O
portion O
of O
the O
beta I-GENE
globin I-GENE
gene I-GENE
flanking I-GENE
region I-GENE
led O
to O
a O
4 O
- O
6 O
fold O
increase O
in O
promoter O
activity O
. O

However O
, O
with O
the O
alpha1 O
antagonist O
prazosin O
( O
5 O
x O
10 O
(- O
8 O
)- O
5 O
x O
10 O
(- O
7 O
) O
M O
), O
no O
relaxation O
occurred O
. O

Differential O
expression O
of O
AP I-GENE
- I-GENE
2alpha I-GENE
and O
AP I-GENE
- I-GENE
2beta I-GENE
in O
the O
developing O
chick O
retina O
: O
repression O
of O
R I-GENE
- I-GENE
FABP I-GENE
promoter I-GENE
activity O
by O
AP I-GENE
- I-GENE
2 I-GENE
. O

The O
algorithm O
also O
limited O
TG O
to O
20 O
and O
64 O
%, O
apoB I-GENE
to O
6 O
and O
20 O
%, O
and O
Lp I-GENE
( I-GENE
a I-GENE
) I-GENE
to O
15 O
and O
56 O
%, O
of O
low O
- O
and O
high O
- O
risk O
groups O
, O
respectively O
. O

The O
mean O
value O
of O
the O
CD79b I-GENE
to O
the O
CD79b I-GENE
internally O
deleted O
ratio O
was O
0 O
. O
64 O
+/- O
0 O
. O
20 O
SD O
in O
normal O
donors O
and O
0 O
. O
44 O
+/- O
0 O
. O
27 O
SD O
in O
B O
- O
CLL O
( O
P O
=. O
01 O
). O

As O
normal O
B O
cells O
also O
present O
this O
variant O
, O
the O
mechanism O
of O
CD79b I-GENE
posttranscriptional O
regulation O
might O
reflect O
the O
activation O
stage O
of O
the O
normal O
B O
cell O
from O
which O
B O
- O
CLL O
derives O
. O

Conformational O
studies O
combining O
secondary O
structure O
predictions O
, O
CD O
and O
NMR O
spectroscopy O
together O
with O
ELISA O
assays O
, O
showed O
that O
the O
greater O
is O
the O
propensity O
of O
the O
epitope O
for O
helix O
formation O
the O
higher O
is O
the O
recognition O
by O
anti I-GENE
- I-GENE
K159 I-GENE
. O

Schwab O
and O
England O
ADL O
scores O
in O
the O
" O
off O
" O
state O
were O
improved O
by O
18 O
% O
and O
in O
the O
" O
on O
" O
state O
the O
scores O
declined O
by O
2 O
%. O

High O
- O
level O
gains O
( O
HLGs O
) O
indicative O
of O
gene O
amplifications O
were O
identified O
at O
11q13 O
in O
two O
cases O
, O
and O
in O
one O
case O
each O
at O
2q33 O
- O
34 O
, O
3q25 O
- O
29 O
, O
5p15 O
. O
1 O
- O
15 O
. O
2 O
, O
7q21 O
- O
22 O
, O
11p11 O
. O
2 O
, O
12p11 O
. O
2 O
- O
12 O
, O
and O
13q34 O
. O

With O
respect O
to O
the O
distribution O
of O
active O
MREs O
over O
the O
promoter O
region O
, O
the O
hMT I-GENE
- I-GENE
IIA I-GENE
gene I-GENE
is O
largely O
different O
from O
the O
mouse O
metallothionein I-GENE
- I-GENE
I I-GENE
gene I-GENE
, O
suggesting O
that O
MRE O
arrangement O
is O
not O
an O
important O
factor O
for O
metal O
regulation O
. O

The O
cDNA O
was O
expressed O
in O
Saccharomyces O
cerevisiae O
under O
the O
control O
of O
the O
yeast I-GENE
triose I-GENE
phosphate I-GENE
isomerase I-GENE
promoter I-GENE
. O

Interestingly O
, O
the O
RNA O
sequences O
selected O
by O
the O
mutated O
zinc I-GENE
knuckle I-GENE
9G8 I-GENE
variant I-GENE
are O
efficiently O
recognized O
by O
SRp20 I-GENE
, O
in O
agreement O
with O
the O
fact O
that O
the O
RBD O
of O
9G8 I-GENE
and O
SRp20 I-GENE
are O
similar O
. O

Topoisomerase I-GENE
II I-GENE
is O
a O
major O
target O
of O
the O
protein I-GENE
kinase I-GENE
casein I-GENE
kinase I-GENE
2 I-GENE
( O
PK I-GENE
CK2 I-GENE
) O
in O
vivo O
. O

Recent O
work O
in O
this O
laboratory O
has O
shown O
that O
the O
gene O
coding O
for O
acetate I-GENE
kinase I-GENE
( O
ackA I-GENE
) O
in O
Sinorhizobium O
meliloti O
is O
up O
- O
regulated O
in O
response O
to O
phosphate O
limitation O
. O

All O
numbers O
refer O
to O
nucleotide O
positions O
on O
the O
wild O
- O
type O
HIV O
- O
1 O
transcript O
. O

Sequence O
analysis O
revealed O
that O
the O
MEMA I-GENE
protein I-GENE
is O
identical O
with O
a O
160 I-GENE
kDa I-GENE
nuclear I-GENE
' I-GENE
domain I-GENE
rich I-GENE
in I-GENE
serines I-GENE
' I-GENE
( I-GENE
DRS I-GENE
) I-GENE
protein I-GENE
occurring O
free O
in O
the O
nucleoplasm O
and O
in O
U2 I-GENE
- I-GENE
ribonucleoprotein I-GENE
structures I-GENE
. O

Here O
, O
we O
report O
the O
complete O
structure O
of O
the O
human I-GENE
topoisomerase I-GENE
IIalpha I-GENE
gene I-GENE
, O
which O
consists O
of O
35 O
exons O
spanning O
27 O
. O
5 O
kb O
. O

Dopaminergic O
modulation O
of O
transcallosal O
activity O
of O
cat O
motor O
cortical O
neurons O
. O

Previous O
studies O
characterized O
a O
cytokine O
- O
inducible O
, O
functional O
nuclear I-GENE
factor I-GENE
( I-GENE
NF I-GENE
)- I-GENE
kappaB I-GENE
consensus I-GENE
element I-GENE
in O
the O
immediate O
5 O
' O
regulatory O
region O
of O
the O
MGSA I-GENE
/ O
GRO I-GENE
- I-GENE
alpha I-GENE
gene O
at O
- O
78 O
bp O
. O

An O
exon O
that O
prevents O
transport O
of O
a O
mature O
mRNA O
. O

Four O
CsA O
- O
treated O
patients O
developed O
persistently O
elevated O
UAER O
> O
30 O
mg O
/ O
24 O
h O
( O
n O
= O
3 O
with O
microalbuminuria O
), O
whereas O
all O
the O
17 O
placebo O
- O
treated O
patients O
had O
normal O
UAER O
(< O
30 O
mg O
/ O
24 O
h O
) O
after O
7 O
years O
of O
follow O
- O
up O
. O

Mutational O
analysis O
of O
the O
- O
84 O
/- O
55 O
DNA O
showed O
that O
JEG O
- O
3 O
nuclear O
proteins O
bound O
to O
a O
site O
containing O
, O
but O
not O
identical O
to O
, O
the O
SF I-GENE
- I-GENE
1 I-GENE
sequence I-GENE
. O

In O
contrast O
, O
no O
change O
was O
detected O
in O
the O
phenotype O
of O
' O
unstressed O
' O
clones O
, O
with O
respect O
to O
any O
of O
the O
following O
parameters O
: O
proliferation O
rate O
in O
monolayer O
, O
serum O
- O
dependence O
for O
proliferation O
or O
survival O
, O
tumorigenicity O
, O
cellular O
morphology O
, O
or O
tissue O
- O
specific O
differentiation O
markers O
. O

A O
high O
reactor O
pH O
(+/- O
8 O
), O
a O
short O
solid O
retention O
time O
(< O
150 O
days O
), O
and O
the O
presence O
of O
a O
substantial O
SRB O
population O
in O
the O
inoculum O
may O
considerably O
reduce O
the O
time O
required O
for O
acetate O
- O
utilising O
SRB O
to O
outcompete O
MB O
. O

In O
throttling O
valves O
, O
the O
aim O
is O
to O
correlate O
the O
effect O
of O
shear O
to O
a O
parameter O
related O
to O
the O
inner O
geometry O
of O
the O
valve O
and O
to O
operating O
conditions O
. O

The O
induced O
respiratory O
burst O
was O
investigated O
by O
the O
intracellular O
oxidative O
transformation O
of O
dihydrorhodamine O
123 O
to O
the O
fluorescent O
dye O
rhodamine O
123 O
via O
flow O
cytometry O
. O

A O
mutation O
linked O
to O
the O
SOC1 I-GENE
gene I-GENE
, O
previously O
defined O
by O
recessive O
mutations O
that O
suppress O
cbp1 I-GENE
ts I-GENE
alleles I-GENE
and O
stabilize O
many O
mitochondrial O
mRNAs O
, O
was O
also O
isolated O
. O

A O
deletion O
mutation O
analysis O
of O
the O
recombinant O
protein O
has O
shown O
that O
the O
N O
- O
terminal O
region O
and O
the O
two O
leucine O
zippers O
are O
necessary O
for O
the O
binding O
. O

A O
database O
search O
has O
revealed O
as O
the O
most O
significative O
homology O
a O
match O
with O
the O
human I-GENE
mitochondrial I-GENE
transcription I-GENE
termination I-GENE
factor I-GENE
( O
mTERF I-GENE
), O
a O
protein O
that O
also O
binds O
DNA O
as O
a O
monomer O
and O
contains O
three O
leucine O
zippers O
forming O
intramolecular O
interactions O
. O

In O
all O
trials O
, O
antigen O
challenge O
followed O
1 O
h O
after O
the O
last O
treatment O
. O

31 O
, O
1997 O
, O
40 O
patients O
had O
died O
( O
35 O
in O
the O
ERA O
- O
II O
group O
and O
5 O
in O
the O
ERA O
- O
III O
group O
), O
for O
a O
crude O
mortality O
rate O
of O
8 O
. O
0 O
%. O

We O
found O
that O
total O
PSA I-GENE
can O
be O
detected O
in O
all O
cyst O
fluids O
and O
in O
about O
75 O
% O
of O
female O
sera O
. O

Type O
I O
cysts O
( O
with O
a O
high O
K O
+/ O
Na O
+ O
ratio O
) O
tend O
to O
have O
higher O
total O
PSA I-GENE
than O
Type O
II O
cysts O
. O

Despite O
this O
DNA O
binding O
activity O
, O
AP I-GENE
- I-GENE
1 I-GENE
reporter I-GENE
activity O
was O
suppressed O
in O
these O
cells O
. O

A O
single O
N O
- O
glycosylation O
site O
present O
in O
chicken I-GENE
gp42 I-GENE
is O
conserved O
among O
all O
five O
of O
these O
proteins O
: O
carbohydrate O
analysis O
of O
gp42 I-GENE
revealed O
the O
presence O
of O
a O
complex O
type O
glycan O
chain O
at O
this O
site O
. O

Here O
we O
describe O
the O
optimization O
and O
characterization O
of O
a O
140 O
- O
residue O
fragment O
, O
containing O
the O
Runt I-GENE
domain I-GENE
of O
AML1 I-GENE
, O
which O
is O
suitable O
for O
structural O
studies O
. O

Judge O
OKs O
docs O
' O
bid O
for O
Chicago O
hospital O
. O

HANYS O
criticizes O
laparoscopic O
gall O
bladder O
guidelines O
. O

Groups O
dicker O
for O
price O
breaks O
as O
anesthetic O
gas O
goes O
multi O
- O
source O
. O

Troubled O
CareNetwork O
gets O
pact O
from O
largest O
teacher O
union O
in O
Wis O
. O

JCAHO O
asks O
for O
hospitals O
' O
patience O
. O

Ultrasonography O
provides O
excellent O
intraoperative O
evaluation O
of O
spinal O
cord O
injury O
. O

UPMC O
is O
not O
the O
only O
organization O
pursuing O
controlled O
NHBC O
organ O
procurement O
, O
however O
. O

Because O
of O
concerns O
regarding O
blood O
transfusion O
- O
related O
communicable O
disease O
( O
eg O
, O
acquired O
immune O
deficiency O
syndrome O
and O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
), O
there O
has O
been O
increasing O
research O
effort O
into O
postoperative O
hemorrhage O
related O
to O
cardiopulmonary O
bypass O
with O
extracorporeal O
circulation O
. O

They O
contrast O
trends O
in O
fertility O
, O
life O
expectancy O
ratios O
, O
and O
gender O
differences O
in O
these O
countries O
with O
the O
Hispanic O
population O
of O
the O
United O
States O
. O

Holger O
v O
. O

Hospital O
hit O
for O
hiring O
AHERF O
physicians O
. O

Overexpression O
of O
either O
DAP I-GENE
- I-GENE
1 I-GENE
or O
sentrin I-GENE
causes O
apoptosis O
of O
TNF I-GENE
- O
sensitive O
L929 O
fibroblast O
cell O
line O
, O
as O
well O
as O
TNF I-GENE
- O
resistant O
osteosarcoma O
cell O
line O
, O
U2OS O
. O

This O
is O
in O
contrast O
to O
PPARgamma2 I-GENE
, O
which O
was O
previously O
shown O
to O
be O
phosphorylated O
at O
a O
single O
site O
in O
a O
motif O
that O
is O
not O
homologous O
to O
the O
sites O
now O
described O
in O
PPARalpha I-GENE
. O

These O
results O
suggest O
KCC3 I-GENE
is O
a O
new O
member O
of O
the O
KCC I-GENE
family I-GENE
that O
is O
under O
distinct O
regulation O
from O
KCC1 I-GENE
. O

We O
have O
screened O
the O
elastin I-GENE
gene I-GENE
for O
mutations O
responsible O
for O
supravalvular O
aortic O
stenosis O
( O
SVAS O
) O
in O
two O
large O
, O
independently O
collected O
families O
with O
isolated O
( O
nonsyndromic O
) O
SVAS O
. O

Spatiotemporal O
expression O
of O
the O
PAX3 I-GENE
gene I-GENE
is O
tightly O
regulated O
during O
development O
. O

25 O
- O
OH O
- O
D3 O
did O
not O
adversely O
affect O
animal O
health O
at O
the O
proposed O
use O
level O
of O
99 O
micrograms O
/ O
kg O
feed O
when O
replacing O
vitamin O
D3 O
in O
turkey O
rations O
. O

A O
list O
of O
12 O
names O
for O
the O
disease O
and O
37 O
diagnostic O
criteria O
were O
proposed O
to O
a O
Consensus O
Panel O
of O
12 O
Italian O
experts O
who O
ranked O
them O
in O
order O
so O
as O
to O
identify O
a O
core O
set O
of O
criteria O
. O

Methanesulfonyl O
fluoride O
( O
MSF O
): O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
of O
safety O
and O
efficacy O
in O
the O
treatment O
of O
senile O
dementia O
of O
the O
Alzheimer O
type O
. O

METHODS O
: O
Between O
August O
1991 O
and O
June O
1994 O
, O
198 O
men O
with O
clinical O
T2 O
or O
T3 O
classified O
( O
TNM O
) O
prostate O
carcinoma O
( O
bone O
scan O
negative O
) O
who O
were O
at O
high O
risk O
of O
lymph O
node O
involvement O
underwent O
a O
111In O
- O
capromab O
pendetide O
scan O
prior O
to O
staging O
lymphadenectomy O
. O

Voluntary O
wheel O
running O
did O
not O
significantly O
increase O
estimated O
alanine O
or O
pyruvate O
Gneo O
or O
absolute O
glycerol O
Ra O
. O

Immediately O
after O
surgery O
, O
dialysate O
PGE2 O
and O
adenosine O
concentrations O
were O
3 O
. O
7 O
+/- O
0 O
. O
7 O
and O
296 O
+/- O
127 O
nM O
, O
respectively O
. O

Because O
of O
the O
probable O
causal O
relationship O
between O
constitutive O
p210 I-GENE
( O
bcr I-GENE
/ O
abl I-GENE
) O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
and O
manifestations O
of O
chronic O
- O
phase O
chronic O
myelogenous O
leukemia O
( O
CML O
; O
myeloid O
expansion O
), O
a O
key O
goal O
is O
to O
identify O
relevant O
p210 I-GENE
substrates O
in O
primary O
chronic O
- O
phase O
CML O
hematopoietic O
progenitor O
cells O
. O

In O
vitro O
precipitation O
with O
a O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
C O
- O
terminal O
transactivation O
domain O
of O
STAT5a I-GENE
showed O
GH I-GENE
- O
regulated O
association O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
with O
the O
fusion O
protein O
, O
while O
this O
was O
not O
seen O
when O
serine O
780 O
in O
STAT5a I-GENE
was O
changed O
to O
alanine O
. O

One O
such O
element O
, O
1P O
, O
was O
employed O
to O
clone O
from O
a O
rat O
pituitary O
cDNA O
expression O
library O
a O
novel O
417 I-GENE
- I-GENE
amino I-GENE
acid I-GENE
WD I-GENE
protein I-GENE
, O
designated O
PREB I-GENE
( I-GENE
PRL I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
) I-GENE
protein I-GENE
. O

Characterization O
of O
the O
transcription I-GENE
factor I-GENE
MTF I-GENE
- I-GENE
1 I-GENE
from O
the O
Japanese O
pufferfish O
( O
Fugu O
rubripes O
) O
reveals O
evolutionary O
conservation O
of O
heavy O
metal O
stress O
response O
. O

The O
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
PPARs I-GENE
) O
are O
members O
of O
the O
nuclear I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

However O
, O
F I-GENE
- I-GENE
SRC I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
lacking O
CBP I-GENE
- I-GENE
interacting I-GENE
domain I-GENE
still O
preserved O
enhancing O
activity O
. O

The O
catalytic O
site O
has O
an O
S1 O
pocket O
lined O
with O
conserved O
hydrophobic O
residues O
to O
accommodate O
the O
pyroglutamyl O
residue O
. O

The O
complete O
circular O
TTV O
genome O
contained O
a O
novel O
sequence O
of O
113 O
nt O
( O
nt O
3740 O
to O
3852 O
[= O
0 O
]) O
in O
between O
the O
known O
3 O
'- O
and O
5 O
'- O
end O
arms O
, O
forming O
a O
117 O
- O
nt O
GC O
- O
rich O
stretch O
( O
GC O
content O
, O
90 O
. O
6 O
% O
at O
nt O
3736 O
to O
3852 O
). O

The O
Asian O
mouse O
Mus O
castaneus O
is O
resistant O
to O
infection O
by O
the O
polytropic O
mink O
cell O
focus O
- O
inducing O
( O
MCF O
) O
subgroup O
of O
murine O
leukemia O
viruses O
( O
MuLVs O
). O

To O
determine O
the O
function O
of O
VZV I-GENE
gK I-GENE
in O
virus O
growth O
, O
a O
series O
of O
gK I-GENE
deletion I-GENE
mutants I-GENE
were O
constructed O
with O
VZV O
cosmid O
DNA O
derived O
from O
the O
Oka O
strain O
. O

CCAAT I-GENE
displacement I-GENE
protein I-GENE
binds O
to O
and O
negatively O
regulates O
human O
papillomavirus O
type O
6 O
E6 I-GENE
, O
E7 I-GENE
, O
and O
E1 I-GENE
promoters O
. O

As O
such O
the O
findings O
support O
existing O
studies O
that O
have O
identified O
given O
social O
characteristics O
of O
drink O
drivers O
. O

Three O
different O
site O
- O
directed O
mutations O
of O
the O
cyclic O
AMP O
response O
element O
each O
reduced O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
effect O
by O
> O
90 O
%. O

Using O
an O
RNase I-GENE
H I-GENE
protection O
assay O
and O
specific O
blocking O
oligonucleotides O
, O
we O
find O
that O
recognition O
of O
the O
5 O
' O
splice O
- O
site O
( O
5 O
' O
ss O
) O
and O
branchpoint O
sequence O
( O
BPS O
) O
elements O
by O
U11 I-GENE
and O
U12 I-GENE
snRNPs I-GENE
, O
respectively O
, O
displays O
strong O
cooperativity O
, O
requiring O
both O
sites O
in O
the O
pre O
- O
mRNA O
substrate O
for O
efficient O
complex O
formation O
. O

Analysis O
of O
lacZ I-GENE
transcriptional I-GENE
fusions I-GENE
shows O
that O
the O
KdgR I-GENE
- I-GENE
binding I-GENE
sites I-GENE
negatively O
affect O
the O
expression O
of O
rsmB I-GENE
. O

Many O
eukaryotic O
cell O
surface O
proteins O
are O
anchored O
in O
the O
lipid O
bilayer O
through O
glycosylphosphatidylinositol O
( O
GPI O
). O

In O
the O
cell O
- O
free O
import O
assay O
, O
beta I-GENE
- I-GENE
catenin I-GENE
rapidly O
migrates O
into O
the O
nucleus O
without O
the O
exogenous O
addition O
of O
cytosol O
, O
Ran I-GENE
, O
or O
ATP O
/ O
GTP O
. O

In O
ischemic O
and O
hypoxic O
hypoxia O
, O
a O
strong O
correlation O
was O
found O
between O
cyt O
a O
, O
a3 O
oxidation O
level O
and O
VO2 O
in O
both O
ischemic O
and O
hypoxic O
hypoxia O
( O
r2 O
=. O
90 O
and O
. O
87 O
, O
respectively O
). O

An O
endogenous O
mammalian O
regulator O
of O
this O
process O
, O
named O
Usurpin I-GENE
, O
has O
been O
identified O
( O
aliases O
for O
Usurpin I-GENE
include O
CASH I-GENE
, O
Casper I-GENE
, O
CLARP I-GENE
, O
FLAME I-GENE
- I-GENE
1 I-GENE
, O
FLIP I-GENE
, O
I I-GENE
- I-GENE
FLICE I-GENE
and O
MRIT I-GENE
). O

Plasma O
glucose O
, O
immunoreactive I-GENE
insulin I-GENE
( O
IRI I-GENE
), O
C I-GENE
- I-GENE
peptide I-GENE
, O
glucagon I-GENE
, O
and O
GLP I-GENE
- I-GENE
1 I-GENE
levels O
at O
each O
time O
point O
during O
OGTT O
were O
measured O
. O

Each O
recombinant O
product O
was O
a O
fusion O
protein O
with O
a O
B O
domain O
of O
Staphylococcal I-GENE
protein I-GENE
A I-GENE
( O
SPA I-GENE
). O

Polypyrimidine O
and O
ssDNA O
binding O
by O
the O
isolated O
VH I-GENE
domain I-GENE
of O
immunization O
- O
induced O
anti O
- O
Z O
- O
DNA O
Ab O
resembles O
the O
activity O
of O
natural O
autoantibodies O
and O
suggests O
that O
VH I-GENE
- O
dependent O
binding O
to O
a O
ligand O
mimicked O
by O
polypyrimidines O
may O
play O
a O
role O
in O
B O
cell O
selection O
before O
immunization O
with O
Z O
- O
DNA O
. O

Technetium O
- O
99m O
methylene O
diphosphonate O
scintimammography O
for O
evaluation O
of O
palpable O
breast O
masses O
. O

INTERVENTIONS O
: O
Study O
patients O
were O
randomly O
divided O
into O
four O
parallel O
groups O
to O
receive O
either O
terbinafine O
250 O
mg O
a O
day O
for O
12 O
or O
16 O
weeks O
( O
groups O
T12 O
and O
T16 O
) O
or O
itraconazole O
400 O
mg O
a O
day O
for O
1 O
week O
in O
every O
4 O
weeks O
for O
12 O
or O
16 O
weeks O
( O
groups O
I3 O
and O
I4 O
). O

Nuclear O
receptors O
( O
NRs O
) O
can O
function O
as O
ligandinducible O
transregulators O
in O
both O
mammalian O
and O
yeast O
cells O
, O
indicating O
that O
important O
features O
of O
transcriptional O
control O
have O
been O
conserved O
throughout O
evolution O
. O

When O
tethered O
to O
a O
heterologous O
DNA O
- O
binding O
domain O
, O
PSU1 I-GENE
can O
activate O
transcription O
on O
its O
own O
. O

OBJECTIVE O
: O
To O
follow O
- O
up O
prospectively O
patients O
with O
arthritis O
after O
infection O
with O
beta O
- O
haemolytic O
streptococci O
of O
Lancefield O
group O
A O
( O
beta O
HSA O
), O
with O
emphasis O
on O
clinical O
characteristics O
and O
serological O
features O
. O

Bacteria O
can O
also O
cause O
a O
labyrinthitis O
acting O
directly O
on O
the O
inner O
ear O
: O
among O
these O
, O
Treponemas O
Pallidum O
, O
a O
spirochaete O
which O
causes O
syphilis O
and O
Borrelia O
Burgdorferi O
, O
a O
spirochaete O
that O
causes O
Lyme O
Disease O
, O
must O
be O
mentioned O
. O

We O
found O
that O
the O
expression O
of O
the O
protein O
was O
maximum O
in O
mitosis O
and O
minimum O
in O
G1 O
, O
which O
correlated O
with O
the O
expression O
of O
its O
messenger O
RNA O
. O

These O
findings O
demonstrate O
that O
signature O
- O
tagged O
mutagenesis O
is O
a O
viable O
approach O
to O
identify O
bacterial O
genes O
associated O
with O
the O
ability O
to O
infect O
the O
urinary O
tract O
. O

Pathol O
. O

The O
eukaryotic O
cell O
cycle O
is O
governed O
in O
part O
by O
the O
periodic O
transcription O
of O
cyclin I-GENE
genes I-GENE
, O
whose O
protein O
products O
associate O
with O
and O
positively O
regulate O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

The O
GAC1 I-GENE
gene I-GENE
encodes O
the O
regulatory O
subunit O
for O
a O
type I-GENE
1 I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
phosphoprotein I-GENE
phosphatase I-GENE
, O
Glc7 I-GENE
. O

The O
results O
demonstrate O
that O
the O
Glc7 I-GENE
phosphatase I-GENE
and O
its O
Gac1 I-GENE
regulatory O
subunit O
play O
positive O
roles O
in O
HSF I-GENE
activation O
of O
CUP1 I-GENE
transcription O
. O

MEF I-GENE
and O
AML1B I-GENE
synergistically O
transactivated O
an O
interleukin I-GENE
3 I-GENE
promoter I-GENE
reporter I-GENE
gene I-GENE
construct I-GENE
, O
yet O
the O
activating O
activity O
of O
MEF I-GENE
was O
abolished O
when O
MEF I-GENE
was O
coexpressed O
with O
AML1 I-GENE
/ O
ETO I-GENE
. O

Mechanistically O
, O
the O
presence O
of O
the O
GRR O
appears O
to O
stop O
further O
degradation O
of O
p50 I-GENE
and O
to O
stabilize O
the O
molecule O
. O

This O
phosphorylation O
can O
be O
catalyzed O
by O
a O
break O
- O
ended O
double O
- O
stranded O
DNA O
- O
activated O
protein O
kinase O
activity O
from O
the O
sea O
urchin O
nucleus O
in O
vitro O
. O

Concomitantly O
, O
the O
total O
cellular O
level O
of O
p21 I-GENE
increased O
severalfold O
via O
a O
posttranscriptional O
mechanism O
. O

Moreover O
, O
when O
added O
to O
the O
osteoclast O
cultures O
, O
mrIhh I-GENE
- I-GENE
N I-GENE
markedly O
stimulated O
the O
formation O
of O
resorption O
pits O
on O
dentine O
slices O
. O

Overall O
, O
our O
results O
suggest O
that O
resistant O
genotypes O
exist O
among O
the O
WAD O
goat O
population O
. O

The O
molecular O
mechanism O
by O
which O
Gle2p I-GENE
and O
the O
Gle2p I-GENE
- O
Nup116p I-GENE
interaction O
function O
in O
mRNA O
export O
is O
unknown O
. O

The O
Fyn I-GENE
NH2 I-GENE
terminus I-GENE
was O
necessary O
but O
not O
sufficient O
for O
interaction O
with O
zeta O
and O
both O
Fyn I-GENE
kinase I-GENE
and O
SH2 I-GENE
domains I-GENE
were O
required O
, O
directing O
phosphorylation O
of O
zeta I-GENE
ITAM I-GENE
tyrosines O
and O
binding O
to O
zeta I-GENE
ITAM I-GENE
phosphotyrosines O
. O

In O
budding O
yeast O
, O
the O
protein O
Skp1p I-GENE
, O
the O
cullin I-GENE
- I-GENE
family I-GENE
member I-GENE
Cdc53p I-GENE
, O
and O
the O
F O
- O
box O
/ O
WD O
- O
repeat O
protein O
Cdc4p I-GENE
form O
the O
SCFCdc4p I-GENE
ubiquitin I-GENE
ligase I-GENE
complex O
, O
which O
targets O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
inhibitor O
Sic1p I-GENE
for O
proteolysis O
[ O
3 O
] O
[ O
4 O
] O
[ O
5 O
] O
[ O
6 O
] O
[ O
7 O
] O
[ O
8 O
]. O

We O
show O
here O
that O
, O
despite O
their O
structural O
and O
functional O
similarities O
, O
the O
pop1 I-GENE
and O
pop2 I-GENE
genes I-GENE
fail O
to O
complement O
each O
other O
' O
s O
deletion O
phenotypes O
, O
indicating O
that O
they O
perform O
non O
- O
redundant O
, O
but O
potentially O
interdependent O
, O
functions O
in O
proteolysis O
. O

Antithrombin I-GENE
III I-GENE
prevents O
60 O
min O
warm O
intestinal O
ischemia O
reperfusion O
injury O
in O
rats O
. O

In O
retrospect O
, O
the O
diagnoses O
were O
reconsidered O
applying O
strict O
criteria O
. O

These O
observations O
of O
elevated O
serum I-GENE
lipase I-GENE
and O
serum O
CA I-GENE
19 I-GENE
- I-GENE
9 I-GENE
in O
Sjogren O
' O
s O
syndrome O
without O
evidence O
of O
malignancy O
may O
reflect O
pancreatic O
involvement O
in O
this O
disorder O
. O

Acute O
pancreatitis O
as O
a O
complication O
of O
polyarteritis O
nodosa O
. O

Significantly O
greater O
improvement O
( O
p O
< O
0 O
. O
05 O
) O
in O
the O
sertraline O
group O
first O
became O
apparent O
by O
the O
end O
of O
week O
3 O
on O
the O
Y O
- O
BOCS O
and O
the O
CGI O
Improvement O
scale O
, O
and O
by O
the O
end O
of O
weeks O
6 O
and O
8 O
, O
respectively O
, O
on O
the O
NIMH O
and O
CGI O
Severity O
scale O
. O

Stress I-GENE
- I-GENE
inducible I-GENE
protein I-GENE
kinases I-GENE
capable O
of O
activating O
c I-GENE
- I-GENE
jun I-GENE
expression O
include O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
/ O
JNK I-GENE
) O
and O
p38 I-GENE
members O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
superfamily O
of O
signaling O
molecules O
. O

Transforming I-GENE
growth I-GENE
factor I-GENE
( I-GENE
TGF I-GENE
)- I-GENE
beta1 I-GENE
induces O
extracellular O
matrix O
deposition O
and O
proliferation O
of O
mesenchymal O
cells O
. O

Chronotherapeutics O
in O
cardiovascular O
disease O
. O

Group O
psychometric O
functions O
for O
listeners O
with O
hearing O
loss O
do O
not O
show O
a O
decrease O
in O
performance O
at O
the O
largest O
values O
of O
delta O
f O
included O
in O
this O
study O
. O

Uroflowmetry O
can O
detect O
dysuria O
, O
which O
may O
be O
poorly O
perceived O
or O
even O
unknown O
to O
the O
subjects O
themselves O
. O

Marked O
racial O
variation O
in O
birthweight O
percentiles O
by O
gestational O
age O
was O
evident O
. O

Significant O
correlations O
between O
mental O
status O
as O
measured O
by O
the O
Mini O
- O
Mental O
State O
Examination O
and O
NA O
/ O
mI O
, O
mI O
/ O
Cr O
and O
NA O
were O
found O
. O

Glucagon I-GENE
also O
induced O
LUC I-GENE
activity O
very O
strongly O
when O
the O
CRE1 O
and O
CRE2 O
sites O
were O
combined O
; O
induction O
of O
the O
( O
CRE1 O
) O
3 O
( O
CRE2 O
) O
2SV40 O
- O
LUC I-GENE
constructs O
was O
positively O
modulated O
by O
the O
pO2 O
. O

In O
this O
study O
, O
we O
report O
the O
isolation O
and O
characterization O
of O
the O
entire O
rat I-GENE
GSTA3 I-GENE
( O
rGST I-GENE
Yc1 I-GENE
) O
subunit O
gene O
. O

Calcinosis O
cutis O
following O
intravenous O
infusion O
of O
calcium O
gluconate O
. O

Initial O
control O
of O
bleeding O
is O
similar O
, O
but O
eradication O
is O
achieved O
in O
fewer O
sessions O
with O
EVL O
. O

Finally O
, O
we O
determined O
the O
genomic O
organization O
of O
the O
human I-GENE
TrxR2 I-GENE
gene I-GENE
, O
which O
consists O
of O
18 O
exons O
spanning O
about O
67 O
kb O
, O
and O
its O
chromosomal O
localization O
at O
position O
22q11 O
. O
2 O
. O

The O
aims O
of O
this O
study O
were O
to O
determine O
and O
rank O
the O
frequency O
of O
self O
reported O
visual O
disability O
in O
daily O
tasks O
performed O
by O
glaucoma O
patients O
; O
to O
examine O
the O
interrelation O
between O
disabilities O
using O
factor O
analysis O
; O
to O
study O
the O
relation O
between O
perceived O
visual O
difficulty O
and O
a O
measure O
of O
the O
severity O
of O
visual O
field O
loss O
; O
to O
develop O
a O
glaucoma O
specific O
subgroup O
of O
questions O
; O
and O
examine O
the O
validity O
and O
reliability O
of O
this O
subgroup O
of O
questions O
. O

Furthermore O
, O
the O
validity O
of O
this O
new O
subset O
of O
questions O
was O
shown O
to O
be O
significant O
( O
r O
= O
0 O
. O
037 O
, O
p O
< O
0 O
. O
05 O
) O
for O
the O
correlation O
between O
a O
measure O
of O
the O
severity O
of O
binocular O
visual O
field O
loss O
and O
the O
mean O
score O
of O
the O
variables O
used O
in O
the O
glaucoma O
specific O
subgroup O
of O
questions O
. O

Sequence O
comparison O
of O
cytochromes I-GENE
bd I-GENE
and O
their O
homologs O
from O
various O
organisms O
demonstrates O
that O
the O
proteins O
can O
be O
classified O
into O
two O
subfamilies O
, O
a O
proteobacterial O
type O
including O
E I-GENE
. I-GENE
coli I-GENE
bd I-GENE
and O
a O
more O
widely O
distributed O
type O
including O
the O
B O
. O
stearothermophilus O
enzyme O
, O
suggesting O
that O
the O
latter O
type O
is O
evolutionarily O
older O
. O

Canalith O
repositioning O
is O
the O
mainstay O
of O
treatment O
. O

Solution O
structure O
and O
mechanism O
of O
the O
MutT I-GENE
pyrophosphohydrolase I-GENE
. O

In O
11 O
eyes O
that O
had O
been O
selected O
at O
random O
10 O
micrograms O
of O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
were O
injected O
midvitreally O
24 O
hrs O
later O
. O

RESULTS O
AND O
CONCLUSIONS O
: O
Brandt O
' O
s O
double O
cuff O
- O
tubes O
( O
G2 O
) O
succeed O
in O
avoiding O
uncontrolled O
increase O
of O
cuff O
- O
pressure O
during O
anaesthesia O
with O
N2O O
. O

Accordingly O
, O
we O
designated O
this O
gene I-GENE
CTL1 I-GENE
( O
capping I-GENE
enzyme I-GENE
RNAtriphosphatase I-GENE
- I-GENE
like I-GENE
1 I-GENE
). O

The O
binding O
of O
PH I-GENE
domains I-GENE
to O
Gbetagamma I-GENE
was O
inhibited O
by O
preincubation O
of O
Gbetagamma I-GENE
with O
the O
GDP O
- O
bound O
but O
not O
the O
GTP O
- O
bound O
form O
of O
Gialpha I-GENE
. O

Their O
afterglows O
are O
brighter O
than O
supernovae O
and O
therefore O
are O
called O
hypernovae O
. O

Constrictive O
pericarditis O
and O
pleuropulmonary O
disease O
linked O
to O
ergot O
dopamine O
agonist O
therapy O
( O
cabergoline O
) O
for O
Parkinson O
' O
s O
disease O
. O

An O
undilated O
type O
of O
APBD O
is O
frequently O
associated O
with O
AMT O
and O
we O
believe O
, O
therefore O
, O
that O
clinicians O
should O
be O
aware O
of O
a O
possible O
coexistence O
of O
APBD O
and O
AMT O
. O

In O
addition O
, O
we O
also O
constructed O
and O
expressed O
chimeric O
fusion O
protein O
that O
contains O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
with O
V3 I-GENE
domains O
of O
HIV O
- O
1IIIB O
, O
HIV O
- O
1MN O
, O
HIV O
- O
1SF2 O
and O
HIV O
- O
1RF O
. O

Our O
results O
indicate O
that O
V3 I-GENE
peptides O
from O
all O
major O
clades O
of O
HIV O
- O
1 O
carried O
by O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
can O
be O
used O
as O
a O
potential O
HIV O
/ O
AIDS O
vaccine O
. O

Efficacy O
was O
determined O
by O
responses O
to O
question O
3 O
( O
ability O
to O
achieve O
an O
erection O
) O
and O
question O
4 O
( O
ability O
to O
maintain O
an O
erection O
) O
of O
the O
15 O
- O
item O
International O
Index O
of O
Erectile O
Function O
( O
IIEF O
). O

Evidence O
for O
the O
involvement O
of O
the O
Glc7 I-GENE
- O
Reg1 I-GENE
phosphatase O
and O
the O
Snf1 I-GENE
- O
Snf4 I-GENE
kinase O
in O
the O
regulation O
of O
INO1 I-GENE
transcription O
in O
Saccharomyces O
cerevisiae O
. O

In O
XO O
males O
, O
two O
her I-GENE
- I-GENE
1 I-GENE
mRNAs I-GENE
, O
her I-GENE
- I-GENE
1a I-GENE
and O
her I-GENE
- I-GENE
1b I-GENE
, O
are O
transcribed O
from O
two O
separate O
promoters O
: O
P1 O
, O
located O
in O
the O
5 O
'- O
flanking O
region O
, O
and O
P2 O
, O
located O
in O
the O
large O
second O
intron O
. O

Induction O
of O
Fas I-GENE
ligand I-GENE
expression O
by O
HIV O
involves O
the O
interaction O
of O
Nef I-GENE
with O
the O
T I-GENE
cell I-GENE
receptor I-GENE
zeta I-GENE
chain I-GENE
. O

Receptor I-GENE
protein I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
RPTPs I-GENE
) O
comprise O
a O
family O
of O
proteins O
that O
feature O
intracellular O
phosphatase O
domains O
and O
an O
ectodomain O
with O
putative O
ligand O
- O
binding O
motifs O
. O

These O
well O
- O
characterized O
brain O
regions O
may O
provide O
a O
basis O
for O
future O
studies O
of O
RPTP I-GENE
- I-GENE
kappa I-GENE
function O
. O

Commonly O
used O
stressors O
are O
mental O
arithmetics O
, O
speech O
tasks O
, O
the O
Stroop O
test O
, O
videogame O
playing O
, O
films O
or O
videotapes O
and O
interviews O
. O

The O
control O
group O
included O
8 O
afterbirth O
samples O
from O
physiological O
full O
- O
term O
pregnancies O
. O

However O
, O
we O
identified O
a O
gene O
between O
the O
MDV2 I-GENE
UL54 I-GENE
and O
UL55 I-GENE
genes I-GENE
with O
homology O
to O
the O
first I-GENE
ORF I-GENE
( I-GENE
ORF I-GENE
- I-GENE
1 I-GENE
) I-GENE
of I-GENE
equine I-GENE
herpesvirus I-GENE
type I-GENE
1 I-GENE
and O
corresponding O
gene O
identified O
in O
pseudorabies O
virus O
. O

In O
contrast O
, O
the O
loss O
of O
MAD2 I-GENE
staining O
in O
meiosis O
was O
not O
correlated O
with O
initial O
microtubule O
attachment O
but O
was O
correlated O
with O
a O
measure O
of O
tension O
: O
the O
distance O
between O
homologous O
or O
sister O
kinetochores O
( O
in O
meiosis O
I O
and O
II O
, O
respectively O
). O

In O
epithelial O
cells O
, O
the O
PH I-GENE
domain I-GENE
of O
Akt I-GENE
/ O
PKB I-GENE
localised O
to O
sites O
of O
cell O
- O
cell O
and O
cell O
- O
matrix O
contact O
, O
distinct O
from O
focal O
contacts O
, O
even O
in O
the O
absence O
of O
serum O
. O

The O
5 O
' O
untranslated O
and O
coding O
regions O
are O
contained O
within O
12 O
exons O
, O
with O
the O
translation O
start O
site O
located O
within O
the O
first O
exon O
. O

The O
motility O
of O
sperm O
, O
except O
for O
those O
adjacent O
to O
both O
electrodes O
, O
did O
not O
change O
after O
stimulation O
for O
60s O
, O
despite O
a O
high O
electrical O
energy O
. O

Induction O
of O
the O
CINC I-GENE
promoter I-GENE
by O
IL I-GENE
- I-GENE
17 I-GENE
in O
IEC O
- O
6 O
cells O
was O
TNF I-GENE
receptor I-GENE
- I-GENE
associated I-GENE
factor I-GENE
- I-GENE
6 I-GENE
( O
TRAF6 I-GENE
), O
but O
not O
TRAF2 I-GENE
, O
dependent O
. O

SCFFWD1 I-GENE
may O
be O
critical O
for O
tumor O
development O
and O
suppression O
through O
regulation O
of O
beta I-GENE
- I-GENE
catenin I-GENE
protein I-GENE
stability O
. O

A O
Bub2p I-GENE
- O
dependent O
spindle O
checkpoint O
pathway O
regulates O
the O
Dbf2p I-GENE
kinase I-GENE
in I-GENE
budding I-GENE
yeast I-GENE
. O

We O
analyzed O
the O
modular O
organization O
of O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
found O
that O
residues O
making O
contact O
with O
DNA O
phosphates O
were O
localized O
to O
five O
modules O
. O

RESULTS O
: O
Cholinergic O
nerves O
are O
mainly O
involved O
in O
the O
regulation O
of O
enteric O
nerve O
responses O
to O
EFS O
in O
the O
normal O
IAS O
. O

Two O
- O
dimensional O
gel O
electrophoresis O
of O
anti I-GENE
- I-GENE
p59fyn I-GENE
immunoprecipitates O
obtained O
from O
non O
- O
transformed O
resting O
human O
T O
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
oligomeric O
protein O
complex O
which O
is O
constitutively O
formed O
between O
Fyn I-GENE
and O
several O
additional O
phosphoproteins O
( O
pp43 I-GENE
, O
pp72 I-GENE
, O
pp85 I-GENE
, O
the O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
Pyk2 I-GENE
, O
as O
well O
as O
the O
two O
recently O
cloned O
adaptor O
proteins O
, O
SKAP55 I-GENE
and O
SLAP I-GENE
- I-GENE
130 I-GENE
). O

We O
show O
that O
other O
cdc33 I-GENE
mutants I-GENE
also O
arrest O
in O
G1 O
. O

A O
cdc33 I-GENE
- I-GENE
1 I-GENE
strain O
expressing O
either O
stable O
Cln3p I-GENE
( O
Cln3 I-GENE
- I-GENE
1p I-GENE
) O
or O
a O
hybrid O
UBI4 I-GENE
5 I-GENE
'- I-GENE
CLN3 I-GENE
mRNA O
, O
whose O
translation O
displays O
decreased O
dependence O
on O
eIF4E I-GENE
, O
arrested O
randomly O
in O
the O
cell O
cycle O
. O

Regulatory O
motifs O
for O
gene O
expression O
such O
as O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
kappaB I-GENE
site I-GENE
) O
and O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
interleukin I-GENE
- I-GENE
6 I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
site I-GENE
) O
were O
found O
in O
the O
5 O
'- O
upstream O
regulatory O
region O
. O

The O
gene O
structure O
of O
Elk1 I-GENE
spans O
15 O
. O
2 O
kb O
and O
consists O
of O
seven O
exons O
and O
six O
introns O
. O

Total O
serum O
calcium O
was O
7 O
. O
8 O
+/- O
0 O
. O
8 O
mg O
/ O
dl O
, O
whereas O
ionized O
calcium O
was O
5 O
. O
7 O
+/- O
0 O
. O
7 O
mg O
/ O
dl O
, O
phosphorus O
3 O
. O
2 O
+/- O
1 O
. O
2 O
mg O
/ O
dl O
, O
and O
alkaline I-GENE
phosphatase I-GENE
149 O
+/- O
48 O
. O
6 O
U O
/ O
liter O
. O

Sequence O
analysis O
suggests O
that O
TtrA I-GENE
contains O
a O
molybdopterin O
guanine O
dinucleotide O
cofactor O
and O
a O
[ O
4Fe O
- O
4S O
] O
cluster O
, O
that O
TtrB I-GENE
binds O
four O
[ O
4Fe O
- O
4S O
] O
clusters O
, O
and O
that O
TtrC I-GENE
is O
an O
integral O
membrane O
protein O
containing O
a O
quinol O
oxidation O
site O
. O

Cranio O
- O
caudal O
differences O
in O
granulation O
tissue O
formation O
: O
an O
experimental O
study O
in O
the O
rat O
. O

Site O
- O
directed O
mutagenesis O
showed O
that O
two O
adjacent O
SP1 I-GENE
sites I-GENE
proximal O
to O
exon O
1 O
were O
equally O
important O
in O
sustaining O
basal O
promoter O
activity O
. O

Breast O
- O
fed O
newborn O
infants O
synthesize O
n O
- O
6 O
long O
- O
chain O
polyunsaturated O
fatty O
acids O
already O
during O
the O
first O
week O
of O
life O
, O
but O
the O
contribution O
of O
endogenous O
synthesis O
to O
the O
total O
plasma O
long O
- O
chain O
polyunsaturated O
pool O
is O
small O
. O

Ischemia O
and O
reperfusion O
markedly O
increased O
the O
release O
of O
6 O
- O
keto O
- O
PGF1 O
alpha O
and O
TXB2 O
. O

Prostate I-GENE
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
promoter O
- O
driven O
androgen O
- O
inducible O
expression O
of O
sodium I-GENE
iodide I-GENE
symporter I-GENE
in O
prostate O
cancer O
cell O
lines O
. O

It O
is O
clear O
that O
subclinical O
and O
silent O
CD O
exist O
in O
a O
large O
subgroup O
of O
the O
celiac O
population O
. O

Ras2p I-GENE
activates O
invasive O
growth O
using O
either O
of O
two O
downstream O
signaling O
pathways O
, O
the O
filamentation O
MAPK I-GENE
( O
Cdc42p I-GENE
/ O
Ste20p I-GENE
/ O
MAPK I-GENE
) O
cascade O
or O
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
Cyr1p I-GENE
/ O
cAMP O
/ O
PKA I-GENE
) O
pathway O
. O

Consistent O
with O
this O
prediction O
, O
transfections O
into O
the O
hematopoietic O
cell O
line O
Jurkat O
showed O
a O
9 O
. O
0 O
- O
and O
2 O
. O
5 O
- O
fold O
activation O
of O
the O
mim I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
p32 I-GENE
and O
p30 I-GENE
isoforms I-GENE
, O
respectively O
. O

Previous O
work O
has O
shown O
that O
spleen I-GENE
necrosis I-GENE
virus I-GENE
( I-GENE
SNV I-GENE
) I-GENE
long I-GENE
terminal I-GENE
repeats I-GENE
( O
LTRs O
) O
are O
associated O
with O
Rex I-GENE
/ O
Rex I-GENE
- O
responsive O
element O
- O
independent O
expression O
of O
bovine O
leukemia O
virus O
RNA O
and O
supports O
the O
hypothesis O
that O
SNV O
RNA O
contains O
a O
cis O
- O
acting O
element O
that O
interacts O
with O
cellular I-GENE
Rex I-GENE
- I-GENE
like I-GENE
proteins I-GENE
. O

Despite O
the O
reported O
detrimental O
effects O
on O
CNS O
development O
, O
a O
number O
of O
animal O
studies O
have O
shown O
that O
pretreatment O
with O
corticosteroids O
nevertheless O
protect O
the O
brain O
from O
hypoxia O
- O
ischemic O
injury O
; O
however O
, O
clinically O
such O
treatment O
is O
no O
longer O
favored O
. O

In O
one O
mechanism O
, O
a O
specialized O
ubiquitin I-GENE
- O
dependent O
proteolytic O
system O
( O
called O
the O
APC O
- O
dependent O
proteolysis O
machinery O
) O
degrades O
the O
mitotic O
( O
Clb I-GENE
) O
cyclin I-GENE
subunit I-GENE
. O

Predictors O
of O
success O
in O
pharmacy O
school O
: O
PCAT O
vs O
. O
other O
admission O
criteria O
. O

Canadian O
survey O
reveals O
widespread O
dissatisfaction O
among O
physicians O
. O

In O
a O
series O
of O
16 O
full O
- O
scale O
fire O
tests O
, O
investigators O
at O
the O
IIT O
Research O
Institute O
have O
concluded O
that O
automatic O
door O
control O
in O
the O
room O
of O
fire O
origin O
can O
significantly O
reduce O
the O
spread O
of O
toxic O
smoke O
and O
gases O
. O

Online O
LATCH O
demonstrates O
a O
shift O
in O
identification O
of O
the O
library O
as O
an O
isolated O
unit O
to O
an O
interactive O
resource O
center O
. O

Reporting O
of O
adverse O
events O
occurring O
during O
clinical O
trials O
of O
investigational O
drugs O
is O
a O
complex O
and O
controversial O
issue O
. O

Medicare O
SNF O
benefits O
revised O
-- O
again O
. O

In O
this O
paper O
, O
the O
current O
status O
of O
the O
understanding O
of O
the O
interaction O
mechanisms O
of O
ultrasound O
with O
biological O
media O
and O
the O
factors O
that O
govern O
different O
biological O
effects O
are O
surveyed O
. O

Members O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
family I-GENE
, O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
, O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
/ O
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
, O
and O
p38 I-GENE
, O
are O
central O
elements O
that O
transduce O
the O
signal O
generated O
by O
growth O
factors O
, O
cytokines O
, O
and O
stressing O
agents O
. O

In O
the O
present O
study O
, O
we O
have O
investigated O
the O
functional O
role O
of O
the O
other O
MAP I-GENE
kinases I-GENE
in O
PDGF I-GENE
- O
mediated O
cellular O
responses O
. O

Analyses O
of O
tyrosine O
residue O
- O
mutated O
PDGF I-GENE
receptors I-GENE
show O
that O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
proteins I-GENE
including O
Src I-GENE
family I-GENE
kinases I-GENE
, O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
of O
Ras I-GENE
, O
the O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing I-GENE
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
, O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
, O
and O
Crk I-GENE
do O
not O
play O
a O
major O
role O
in O
mediating O
the O
PDGF I-GENE
- O
induced O
activation O
of O
p38 I-GENE
. O

Here O
we O
show O
that O
calpeptin I-GENE
inhibits O
tyrosine I-GENE
phosphatases I-GENE
, O
enhancing O
tyrosine O
phosphorylation O
particularly O
of O
paxillin I-GENE
. O

Three O
- O
dimensional O
structural O
studies O
using O
electron O
cryomicroscopy O
showed O
that O
the O
binding O
of O
one O
Fab I-GENE
( O
8H2 O
/ O
G5 O
) O
does O
not O
affect O
the O
conformation O
of O
the O
capsid O
, O
and O
the O
efficiency O
of O
mRNA O
production O
is O
similar O
to O
that O
of O
the O
native O
subviral O
particle O
. O

Further O
, O
mutational O
analysis O
of O
NS5A I-GENE
assigned O
the O
SH3 I-GENE
- I-GENE
binding I-GENE
region I-GENE
to O
a O
proline O
- O
rich O
motif O
that O
is O
highly O
conserved O
among O
HCV O
genotypes O
. O

Taken O
together O
, O
these O
findings O
show O
that O
16K I-GENE
hPRL I-GENE
inhibits O
the O
VEGF I-GENE
- O
induced O
Ras I-GENE
activation O
; O
this O
antagonism O
represents O
a O
novel O
and O
potentially O
important O
mechanism O
for O
the O
control O
of O
angiogenesis O
. O

Analysis O
of O
SRE O
oligonucleotide O
gel O
mobility O
shift O
assays O
with O
nuclear O
extracts O
from O
Sertoli O
cells O
demonstrated O
the O
presence O
of O
both O
the O
SRF I-GENE
and O
the O
ubiquitously O
expressed O
bHLH O
protein O
E12 I-GENE
/ O
E47 I-GENE
. O

We O
calculated O
differences O
in O
late O
occlusion O
rates O
by O
the O
chi2 O
( O
chi O
- O
square O
) O
test O
, O
and O
found O
these O
differences O
were O
significant O
( O
P O
=. O
04 O
). O

Baseline O
electrocorticography O
over O
the O
surface O
of O
the O
temporal O
lobe O
and O
depth O
electrode O
recordings O
in O
the O
amygdala O
and O
hippocampus O
were O
obtained O
, O
followed O
by O
10 O
min O
of O
recording O
before O
and O
after O
the O
i O
. O
v O
. O
administration O
of O
both O
alfentanil O
50 O
microg O
/ O
kg O
and O
fentanyl O
10 O
microg O
/ O
kg O
. O

We O
describe O
a O
genetic O
system O
for O
further O
characterizing O
the O
role O
of O
the O
extreme O
C O
- O
terminus O
of O
the O
beta O
subunit O
of O
E I-GENE
. I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

We O
suggest O
that O
FlgN I-GENE
and O
FliT I-GENE
are O
substrate O
- O
specific O
flagellar O
chaperones O
that O
prevent O
oligomerization O
of O
the O
HAPs I-GENE
by O
binding O
to O
their O
helical O
domains O
before O
export O
. O

Post O
and O
core O
fabrication O
for O
divergent O
canals O
with O
a O
cast O
post O
and O
core O
and O
a O
prefabricated O
dowel O
. O

Rep63A O
( O
513 O
amino O
acids O
[ O
aa O
]), O
encoded O
by O
the O
largest O
ORF O
, O
displayed O
strong O
similarity O
( O
40 O
% O
identity O
) O
to O
the O
replication O
proteins O
from O
plasmids O
pAMbeta1 O
, O
pIP501 O
, O
and O
pSM19035 O
, O
indicating O
that O
the O
pAW63 O
replicon O
belongs O
to O
the O
pAMbeta1 O
family O
of O
gram O
- O
positive O
theta O
- O
replicating O
plasmids O
. O

Here O
we O
report O
the O
cloning O
and O
characterization O
of O
Xenopus I-GENE
Pax I-GENE
- I-GENE
5 I-GENE
and O
Pax I-GENE
- I-GENE
8 I-GENE
, O
two O
orthologues O
of O
the O
Pax I-GENE
- I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
/ I-GENE
8 I-GENE
gene I-GENE
family I-GENE
. O

Km O
values O
for O
ammonium O
, O
2 O
- O
oxoglutarate O
, O
NADH O
, O
glutamate O
and O
NAD O
+ O
were O
6 O
. O
5 O
, O
3 O
. O
5 O
, O
0 O
. O
06 O
, O
37 O
. O
1 O
and O
0 O
. O
046 O
mM O
, O
respectively O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
exacerbate O
cryoblobulinemia O
- O
related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti O
- O
angiogenic O
activity O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
exacerbate O
cryoblobulinemia O
- O
related O
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related O
to O
its O
anti O
- O
angiogenic O
activity O
. O

In O
addition O
, O
we O
demonstrate O
that O
the O
production O
of O
active I-GENE
recombinant I-GENE
telomerase I-GENE
requires O
a O
factor O
in O
rabbit O
reticulocyte O
lysate O
that O
promotes O
ribonucleoprotein O
assembly O
. O

The O
enhanced O
binding O
of O
c I-GENE
- I-GENE
Abl I-GENE
to O
DNA O
containing O
5 O
- O
methylcytosine O
residues O
may O
result O
from O
an O
increased O
propensity O
of O
the O
double O
helix O
to O
denature O
locally O
coupled O
with O
a O
protein O
- O
induced O
reduction O
in O
the O
base O
stacking O
interaction O
. O

Homozygous O
mutation O
in O
two O
children O
led O
to O
amputation O
of O
legs O
due O
to O
purpura O
fulminans O
. O

According O
to O
pilot O
experiments O
which O
considered O
various O
durations O
of O
global O
no O
- O
flow O
ischemia O
ranging O
from O
10 O
to O
20 O
minutes O
, O
two O
durations O
were O
chosen O
for O
the O
present O
study O
: O
20 O
minutes O
( O
group O
20 O
) O
in O
which O
ventricular O
fibrillation O
( O
VF O
) O
was O
the O
predominant O
form O
of O
arrhythmias O
, O
and O
18 O
minutes O
( O
group O
18 O
) O
in O
which O
the O
prevalence O
of O
VF O
was O
markedly O
lower O
despite O
the O
small O
difference O
in O
the O
duration O
of O
ischemia O
. O

An O
end O
- O
to O
- O
end O
pancreaticojejunostomy O
using O
a O
mechanical O
purse O
- O
string O
device O
. O

We O
further O
demonstrate O
that O
the O
Stress I-GENE
- I-GENE
Activated I-GENE
- I-GENE
Protein I-GENE
- I-GENE
Kinase I-GENE
( O
SAPK I-GENE
) O
target O
sites O
of O
ATF2 I-GENE
, O
Thr69 O
and O
Thr71 O
are O
not O
required O
for O
the O
formation O
of O
the O
p300 I-GENE
/ O
CBP I-GENE
- O
ATF2 I-GENE
multiprotein O
complex O
. O

Blood O
samples O
were O
obtained O
daily O
during O
this O
supplementation O
period O
and O
5 O
d O
thereafter O
( O
d O
11 O
to O
15 O
). O

These O
results O
suggest O
that O
mitochondrial O
presequences O
interact O
with O
the O
mt I-GENE
- I-GENE
hsp70 I-GENE
during O
or O
after O
mitochondrial O
protein O
import O
. O

The O
3 O
' O
terminus O
of O
the O
genome O
can O
be O
folded O
into O
a O
tRNA O
- O
like O
secondary O
structure O
that O
has O
a O
valine O
anticodon O
; O
the O
tRNA O
- O
like O
structure O
lacks O
a O
pseudoknot O
in O
the O
aminoacyl O
stem O
, O
a O
feature O
common O
to O
both O
genera O
of O
tetraviruses O
. O

O I-GENE
. I-GENE
novo I-GENE
- I-GENE
ulmi I-GENE
RNA I-GENE
- I-GENE
7 I-GENE
, O
previously O
believed O
to O
be O
a O
satellite O
- O
like O
RNA O
, O
is O
shown O
to O
be O
a O
defective O
RNA O
, O
derived O
from O
OnuMV4 I-GENE
- I-GENE
Ld I-GENE
RNA I-GENE
by O
multiple O
internal O
deletions O
. O

Only O
one O
gene O
, O
fibronectin I-GENE
( O
FN I-GENE
), O
was O
highly O
overexpressed O
(> O
60 O
- O
fold O
) O
in O
LNCaP O
- O
r O
cells O
, O
consistent O
with O
previously O
reported O
overexpression O
of O
FN I-GENE
in O
prostate O
cancer O
. O

We O
also O
observed O
that O
cell O
surface O
CD4 I-GENE
(-) O
CD8 I-GENE
(-) O
CD3 I-GENE
(-) O
cells O
with O
rearranged I-GENE
TCR I-GENE
genes I-GENE
developed O
from O
Id3 I-GENE
- O
transduced O
but O
not O
from O
control O
- O
transduced O
pre O
- O
T O
cells O
in O
an O
FTOC O
. O

As O
determined O
in O
a O
modified O
yeast O
two O
- O
hybrid O
system O
, O
mIRS3 I-GENE
bound O
strongly O
to O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Insulin I-GENE
stimulation O
promoted O
the O
association O
of O
mIRS3 I-GENE
with O
p85 I-GENE
, O
SHP2 I-GENE
, O
Nck I-GENE
, O
and O
Shc I-GENE
. O

The O
mRNA O
expression O
of O
RFX1 I-GENE
, O
RFX2 I-GENE
, O
and O
RFX3 I-GENE
was O
detected O
ubiquitously O
, O
but O
in O
transient O
- O
transfection O
assays O
, O
multimerized I-GENE
RFX I-GENE
binding I-GENE
sites I-GENE
in O
front O
of O
a O
basal O
promoter O
efficiently O
functioned O
in O
a O
tissue O
- O
and O
lineage O
- O
specific O
manner O
. O

In O
the O
case O
of O
the O
unspliceable O
intron O
, O
repression O
of O
luciferase I-GENE
expression O
likely O
involved O
two O
AUF1 I-GENE
- I-GENE
binding I-GENE
sequences I-GENE
, O
since O
luciferase I-GENE
expression O
was O
increased O
by O
deletion O
of O
these O
sites O
. O

Thus O
, O
VDR I-GENE
acts O
selectively O
on O
the O
two O
components O
required O
for O
activation O
of O
this O
promoter O
/ O
enhancer O
: O
it O
competes O
with O
NFAT1 I-GENE
for O
binding O
to O
the O
composite O
site O
, O
positioning O
itself O
adjacent O
to O
Jun I-GENE
- O
Fos I-GENE
on O
the O
DNA O
. O

Two O
evolutionarily O
conserved O
kinases O
, O
the O
cyclin I-GENE
B I-GENE
( O
Clb I-GENE
)/ O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
/ O
Cdc28p I-GENE
) O
and O
Cdc7p I-GENE
along O
with O
its O
interacting O
factor O
Dbf4p I-GENE
, O
are O
required O
late O
in O
G1 O
to O
initiate O
DNA O
replication O
. O

The O
RanQ69L I-GENE
preincubation O
leads O
to O
accumulation O
of O
CRM1 I-GENE
at O
the O
cytoplasmic O
periphery O
of O
the O
nuclear O
pore O
complex O
( O
NPC O
) O
in O
association O
with O
the O
p62 I-GENE
complex I-GENE
and O
Can I-GENE
/ O
Nup214 I-GENE
. O

All O
of O
the O
elements O
exhibited O
a O
uniform O
structure O
. O

In O
contrast O
, O
the O
deduced O
amino O
acid O
sequence O
of O
a O
second O
family O
( O
ART5 I-GENE
) O
of O
transferases O
, O
cloned O
from O
murine O
lymphoma O
cells O
and O
expressed O
in O
high O
abundance O
in O
testis O
, O
displays O
a O
hydrophobic O
amino O
terminus O
, O
consistent O
with O
a O
signal O
sequence O
, O
but O
lacks O
a O
hydrophobic O
signal O
sequence O
at O
its O
carboxyl O
terminus O
, O
suggesting O
that O
the O
protein O
is O
destined O
for O
export O
. O

RESULTS O
: O
Each O
year O
, O
on O
average O
39 O
% O
of O
cases O
seen O
in O
Sardinia O
are O
notified O
; O
646 O
( O
40 O
%) O
of O
the O
1591 O
patients O
notified O
during O
the O
study O
period O
were O
never O
seen O
by O
regional O
medical O
centres O
. O

This O
dimer O
interface O
is O
likely O
important O
for O
increasing O
the O
DNA O
- O
binding O
specificity O
and O
affinity O
of O
the O
trimeric O
form O
of O
HSF I-GENE
, O
as O
well O
as O
for O
increasing O
cooperativity O
between O
adjacent O
trimers O
. O

The O
paramyxovirus I-GENE
fusion I-GENE
( I-GENE
F I-GENE
) I-GENE
protein I-GENE
mediates O
membrane O
fusion O
. O

Additionally O
, O
deletion O
analysis O
of O
the O
UCP2 I-GENE
promoter O
- O
PLAP I-GENE
constructs O
indicated O
that O
the O
minimal O
region O
exhibiting O
the O
promoter O
activity O
was O
located O
between O
nt O
- O
33 O
and O
+ O
100 O
, O
and O
that O
a O
strong O
enhancer O
was O
present O
within O
601 O
bp O
of O
the O
5 O
'- O
promoter O
region O
. O

The O
hTERT I-GENE
gene I-GENE
encompasses O
more O
than O
37kb O
and O
consists O
of O
16 O
exons O
. O

Both O
betaAPP I-GENE
mRNA I-GENE
and O
Abeta I-GENE
levels O
are O
increased O
in O
trisomy O
21 O
. O

In O
reperfusion O
B O
, O
only O
the O
diabetic O
group O
demonstrated O
a O
significant O
increase O
in O
IL I-GENE
- I-GENE
8 I-GENE
concentrations O
at O
1 O
and O
15 O
min O
compared O
to O
nondiabetics O
. O

This O
repression O
was O
reversed O
agonists O
of O
either O
receptor O
demonstrating O
a O
functional O
interaction O
between O
NCoR I-GENE
and O
PPARalpha I-GENE
. O
RXRalpha I-GENE
heterodimeric O
complexes O
in O
mammalian O
cells O
. O

In O
the O
present O
study O
, O
we O
show O
that O
SRm160 I-GENE
/ I-GENE
300 I-GENE
is O
required O
for O
a O
purine O
- O
rich O
ESE I-GENE
to O
promote O
the O
splicing O
of O
a O
pre O
- O
mRNA O
derived O
from O
the O
Drosophila I-GENE
doublesex I-GENE
gene I-GENE
. O

Spc42p I-GENE
also O
was O
identified O
as O
a O
component O
of O
a O
cytoplasmic O
SPB O
subcomplex O
containing O
Spc94p I-GENE
/ O
Nud1p I-GENE
, O
Cnm67p I-GENE
, O
and O
Spc42p I-GENE
. O

The O
average O
coefficients O
of O
correlation O
were O
0 O
. O
9998 O
and O
0 O
. O
9993 O
for O
the O
QMF O
and O
the O
QIT O
system O
, O
respectively O
. O

The O
5 O
- O
year O
OS O
for O
stage O
IIIB O
was O
30 O
. O
9 O
%, O
compared O
to O
7 O
. O
8 O
% O
for O
stage O
IV O
. O

Furthermore O
, O
heparin I-GENE
lyase I-GENE
treatment O
of O
extracts O
of O
cells O
expressing O
recombinant I-GENE
YD I-GENE
- I-GENE
repeat I-GENE
protein I-GENE
releases O
this O
protein O
from O
high O
molecular O
mass O
aggregates O
. O

The O
coefficient O
of O
determination O
, O
r2 O
, O
of O
the O
other O
scores O
ranged O
from O
0 O
. O
56 O
to O
0 O
. O
61 O
. O

While O
determination O
of O
the O
protein O
content O
of O
the O
formulae O
gave O
no O
valid O
information O
, O
RAST O
/ O
EAST O
inhibition O
was O
highest O
for O
cow O
' O
s O
milk O
, O
followed O
by O
the O
partially O
hydrolysed O
whey O
formula O
, O
partially O
hydrolysed O
whey O
/ O
casein I-GENE
formula O
, O
soy I-GENE
/ I-GENE
pork I-GENE
collagen I-GENE
formula O
, O
and O
the O
amino O
acid O
formula O
. O

In O
light O
of O
the O
importance O
of O
GnRHR I-GENE
, O
the O
molecular O
mechanisms O
underlying O
the O
transcriptional O
regulation O
of O
the O
human I-GENE
GnRHR I-GENE
( O
hGnRHR I-GENE
) O
gene O
become O
a O
key O
issue O
in O
understanding O
human O
reproduction O
. O

Competitive O
mobility O
shift O
assays O
using O
either O
alphaT3 O
- O
1 O
nuclear O
extract O
or O
recombinant I-GENE
SF I-GENE
- I-GENE
1 I-GENE
protein I-GENE
clearly O
indicated O
that O
SF I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
interact O
specifically O
with O
this O
GSE I-GENE
element I-GENE
positioned O
at O
- O
134 O
. O

Grade O
3 O
mucositis O
was O
reported O
in O
1 O
patient O
. O

CDK4 I-GENE
kinase I-GENE
activities O
were O
unaffected O
, O
as O
were O
the O
levels O
of O
the O
CDK I-GENE
inhibitor O
p21Cip1 I-GENE
present O
in O
cyclin I-GENE
E I-GENE
immunocomplexes I-GENE
. O

The O
recombinant O
purified O
protein O
expressed O
in O
the O
baculovirus O
system O
had O
an O
approximate O
molecular O
size O
20 O
kDa O
with O
amino O
- O
terminal O
sequence O
of O
AVQGP O
. O

Induction O
of O
the O
urokinase I-GENE
promoter I-GENE
by O
HGF I-GENE
/ O
SF I-GENE
via O
the O
Met I-GENE
receptor I-GENE
was O
blocked O
by O
co O
- O
expression O
of O
a O
dominant O
- O
negative O
Grb2 I-GENE
and O
Sos1 I-GENE
expression O
construct O
. O

Serine O
phosphorylation O
of O
STAT3 I-GENE
was O
only O
apparent O
after O
somatostatin I-GENE
treatment O
and O
was O
abolished O
by O
pertussis I-GENE
toxin I-GENE
or O
PD O
98059 O
, O
together O
with O
the O
associated O
increases O
in O
proliferation O
. O

Nevertheless O
, O
we O
demonstrate O
that O
the O
entire O
three O
- O
component O
yeast O
capping O
apparatus O
, O
consisting O
of O
RNA I-GENE
5 I-GENE
'- I-GENE
triphosphatase I-GENE
( O
Cet1p I-GENE
), O
RNA I-GENE
guanylyltransferase I-GENE
( O
Ceg1p I-GENE
), O
and O
Abd1p I-GENE
could O
be O
replaced O
in O
vivo O
by O
the O
two O
- O
component O
mammalian O
apparatus O
consisting O
of O
a O
bifunctional O
triphosphatase I-GENE
- I-GENE
guanylyltransferase I-GENE
Mce1p I-GENE
and O
the O
methyltransferase I-GENE
Hcm1 I-GENE
( I-GENE
121 I-GENE
- I-GENE
476 I-GENE
) I-GENE
p I-GENE
. O

The O
IC50 O
values O
for O
rat O
and O
dog O
urinary O
bladder O
were O
3 O
. O
9 O
x O
10 O
(- O
6 O
) O
M O
and O
3 O
. O
8 O
x O
10 O
(- O
6 O
) O
M O
, O
respectively O
. O

Although O
it O
has O
two O
potential O
binding O
sites O
, O
the O
purified O
MerR I-GENE
homodimer I-GENE
binds O
only O
one O
Hg O
( O
II O
) O
ion O
, O
employing O
Cys82 O
from O
one O
monomer O
and O
Cys117 O
and O
Cys126 O
from O
the O
other O
. O

The O
influence O
of O
Epstein O
- O
Barr O
virus O
seropositivity O
on O
the O
efficacy O
of O
intravenous O
immune I-GENE
globulin I-GENE
in O
children O
with O
immune O
thrombocytopenic O
purpura O
. O

The O
results O
of O
the O
lab O
and O
field O
tests O
yielded O
high O
levels O
of O
infestation O
in O
larvae O
with O
values O
ranging O
from O
90 O
to O
100 O
% O
and O
from O
85 O
to O
95 O
%, O
respectively O
. O

Amisulpride O
400 O
mg O
had O
several O
adverse O
effects O
on O
psychomotor O
and O
, O
although O
less O
severe O
, O
on O
cognitive O
performance O
on O
the O
fifth O
day O
only O
. O

MutY I-GENE
is O
an O
adenine I-GENE
- I-GENE
DNA I-GENE
glycosylase I-GENE
with O
specificity O
for O
mismatches O
involving O
8 O
- O
oxoguanine O
( O
oG O
. O
A O
) O
or O
guanine O
( O
G O
. O
A O
). O

The O
kinetics O
of O
kinase O
activity O
within O
these O
complexes O
compared O
to O
CheA I-GENE
alone O
indicate O
approximately O
a O
50 O
% O
decrease O
in O
the O
KM O
for O
ATP O
and O
a O
100 O
- O
fold O
increase O
in O
the O
Vmax O
. O

Latexin I-GENE
, O
a O
carboxypeptidase I-GENE
A I-GENE
inhibitor O
, O
is O
expressed O
in O
a O
cell O
type O
- O
specific O
manner O
in O
both O
central O
and O
peripheral O
nervous O
systems O
in O
the O
rat O
. O

Regression O
analyses O
identified O
7 O
risk O
and O
7 O
protective O
factors O
with O
minimal O
overlap O
. O

During O
1985 O
, O
1990 O
, O
and O
1995 O
, O
respectively O
, O
11 O
. O
7 O
, O
11 O
. O
3 O
, O
and O
11 O
. O
4 O
infants O
per O
100 O
, O
000 O
live O
births O
had O
a O
diagnosis O
of O
HSV O
( O
P O
=. O
98 O
). O

Subsets O
of O
patients O
were O
performed O
according O
to O
the O
severity O
of O
trauma O
( O
ISS O
< O
9 O
; O
9 O
- O
17 O
; O
18 O
- O
31 O
; O
> O
32 O
), O
based O
on O
the O
different O
injury O
pattern O
, O
and O
survivors O
versus O
nonsurvivors O
as O
well O
. O

The O
median O
age O
was O
33 O
years O
( O
range O
17 O
- O
56 O
years O
). O

Developmental O
follow O
- O
up O
at O
age O
2 O
years O
was O
performed O
. O

In O
the O
whole O
group O
of O
infected O
children O
, O
an O
age O
- O
specific O
z O
score O
< O
- O
2 O
for O
weight O
and O
for O
FFM O
was O
significantly O
associated O
with O
an O
increased O
risk O
of O
death O
[ O
relative O
risk O
( O
95 O
% O
CI O
) O
= O
11 O
. O
4 O
( O
3 O
. O
1 O
, O
41 O
. O
0 O
) O
and O
5 O
. O
1 O
( O
1 O
. O
5 O
, O
18 O
. O
2 O
), O
respectively O
]; O
when O
only O
children O
with O
more O
severe O
disease O
were O
considered O
, O
only O
z O
score O
for O
weight O
was O
significantly O
associated O
with O
an O
increased O
risk O
[ O
4 O
. O
6 O
( O
1 O
. O
4 O
, O
14 O
. O
9 O
)]. O

In O
addition O
, O
these O
cells O
contained O
one O
, O
two O
, O
or O
multiple O
nuclei O
indicative O
of O
a O
G2 O
/ O
M O
delay O
in O
nuclear O
division O
and O
also O
a O
defect O
in O
cytokinesis O
and O
/ O
or O
cell O
separation O
. O

DAF16 I-GENE
is O
known O
to O
be O
a O
component O
of O
a O
signaling O
pathway O
that O
has O
been O
partially O
dissected O
genetically O
and O
includes O
homologues O
of O
the O
insulin I-GENE
/ O
IGF I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
PtdIns I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
PKB I-GENE
. O

However O
, O
neu I-GENE
differentiation O
factor O
- O
induced O
heterodimers O
of O
ErbB2 I-GENE
and O
ErbB4 I-GENE
activated O
Stat5 I-GENE
. O

Although O
linker O
regions O
in O
transcription O
factors O
are O
known O
to O
modulate O
DNA O
binding O
specificity O
, O
our O
studies O
suggest O
that O
the O
human I-GENE
HSF1 I-GENE
linker O
plays O
no O
role O
in O
determining O
HSF1 I-GENE
binding O
preferences O
in O
vivo O
but O
is O
a O
critical O
determinant O
in O
regulating O
the O
HSF1 I-GENE
monomer I-GENE
- I-GENE
trimer I-GENE
equilibrium O
. O

Modulation O
of O
human I-GENE
heat I-GENE
shock I-GENE
factor I-GENE
trimerization O
by O
the O
linker O
domain O
. O

Both O
functional O
analyses O
in O
undifferentiated O
and O
differentiated O
F9 O
cells O
and O
characterization O
of O
DNA O
- O
protein O
complexes O
in O
vitro O
have O
identified O
the O
sequence O
motifs O
GTGACT O
( O
C O
), O
ATTGT O
, O
and O
GATA O
as O
the O
key O
transcription O
factor O
binding O
sites O
. O

These O
results O
suggest O
that O
the O
phenotype O
of O
XLP O
may O
result O
from O
perturbed O
signaling O
not O
only O
through O
SLAM I-GENE
, O
but O
also O
other O
cell O
surface O
molecules O
that O
utilize O
SAP I-GENE
as O
a O
signaling O
adaptor O
protein O
. O

We O
also O
localized O
the O
Fra I-GENE
- I-GENE
2 I-GENE
phosphorylation I-GENE
sites I-GENE
by O
MAPK I-GENE
to O
three O
threonine O
and O
three O
serine O
residues O
in O
the O
COOH O
- O
terminal O
region O
by O
means O
of O
site O
- O
directed O
mutagenesis O
and O
showed O
that O
the O
threonine O
residues O
were O
more O
susceptible O
to O
MAPK I-GENE
. O

Nevertheless O
, O
they O
are O
functionally O
distinct O
in O
that O
FcalphaRI I-GENE
binds O
human I-GENE
IgA I-GENE
( O
hIgA I-GENE
) O
but O
not O
bovine I-GENE
IgG2 I-GENE
( O
bIgG2 I-GENE
), O
whereas O
bFcgamma2R I-GENE
binds O
bIgG2 I-GENE
but O
not O
hIgA I-GENE
. O

Vac1p I-GENE
was O
found O
to O
bind O
the O
Sec1p I-GENE
homologue I-GENE
Vps45p I-GENE
. O

In O
a O
heterologous O
transcriptional O
system O
in O
which O
the O
upstream O
regions O
of O
oIFNtau I-GENE
were O
inserted O
in O
front O
of O
simian I-GENE
virus I-GENE
40 I-GENE
( I-GENE
SV40 I-GENE
) I-GENE
promoter I-GENE
, O
the O
regions O
between O
bases O
- O
654 O
and O
- O
555 O
were O
determined O
as O
being O
the O
enhancer O
region O
required O
for O
oIFNtau I-GENE
- O
SV40 O
- O
CAT I-GENE
transactivation O
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
plus O
c I-GENE
- I-GENE
Fos I-GENE
enhanced O
the O
transactivation O
of O
oIFNtau I-GENE
- O
CAT I-GENE
but O
the O
expression O
of O
GATA I-GENE
- I-GENE
1 I-GENE
, O
GATA I-GENE
- I-GENE
2 I-GENE
or O
GATA I-GENE
- I-GENE
3 I-GENE
did O
not O
. O

To O
identify O
these O
sites O
, O
Cdk2 I-GENE
- O
phosphorylated O
MARCKS I-GENE
was O
digested O
with O
lysyl I-GENE
endoprotease I-GENE
and O
analysed O
by O
electrospray O
MS O
. O

The O
yeast I-GENE
LPD1 I-GENE
gene I-GENE
encoding O
lipoamide I-GENE
dehydrogenase I-GENE
is O
subject O
to O
the O
general O
control O
of O
amino O
acid O
biosynthesis O
mediated O
by O
the O
GCN4 I-GENE
transcription I-GENE
factor I-GENE
. O

The O
relatively O
mild O
defects O
observed O
in O
Rpd3 I-GENE
mutants I-GENE
suggest O
that O
the O
recently O
identified O
Groucho I-GENE
and O
dCtBP I-GENE
corepressor I-GENE
proteins I-GENE
do O
not O
function O
solely O
through O
the O
recruitment O
of O
histone I-GENE
deacetylases I-GENE
. O

However O
, O
the O
serum I-GENE
TNF I-GENE
- I-GENE
a I-GENE
concentration O
decreased O
significantly O
in O
patients O
receiving O
pentoxifylline O
( O
basal O
623 O
+/- O
366 O
pg O
/ O
ml O
; O
6th O
month O
562 O
+/- O
358 O
pg O
/ O
ml O
, O
p O
< O
0 O
. O
01 O
), O
but O
not O
in O
the O
control O
group O
. O

In O
addition O
, O
we O
show O
that O
the O
expression O
of O
individual O
members O
of O
one O
subfamily O
of O
KRAB I-GENE
zinc I-GENE
finger I-GENE
genes I-GENE
is O
restricted O
to O
specific O
hematopoietic O
cell O
lineages O
. O

Employing O
fluorescence O
spectroscopy O
and O
circular O
dichroism O
, O
we O
showed O
that O
the O
binding O
of O
Ca2 O
+ O
to O
ALG I-GENE
- I-GENE
2 I-GENE
induced O
significant O
conformational O
changes O
in O
both O
the O
N O
- O
terminal O
and O
C O
- O
terminal O
domains O
of O
the O
protein O
. O

They O
also O
occur O
in O
similar O
locations O
in O
the O
promoters O
of O
several O
other O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Both O
carbachol O
( O
100 O
microM O
) O
and O
EGF I-GENE
( O
10 O
nM O
) O
induced O
Ras I-GENE
activation O
. O

Dominant O
negative O
Sos I-GENE
did O
not O
affect O
carbachol O
stimulation O
of O
HA I-GENE
- O
ERK2 I-GENE
but O
inhibited O
the O
stimulatory O
effect O
of O
EGF I-GENE
by O
60 O
%. O

RESULTS O
: O
Transpulmonary O
passage O
of O
contrast O
occurred O
in O
sufficient O
amounts O
to O
enhance O
the O
intensity O
of O
the O
Doppler O
signal O
significantly O
, O
but O
the O
duration O
of O
this O
effect O
was O
short O
. O

In O
this O
paper O
, O
such O
lesions O
in O
two O
cases O
were O
evaluated O
by O
ultrasonography O
. O

These O
regions O
contain O
inverted O
E O
- O
box O
palindromic O
or O
direct O
repeat O
motifs O
and O
bind O
SREBP I-GENE
- I-GENE
1 I-GENE
with O
different O
affinities O
. O

To O
address O
these O
questions O
, O
a O
recombinant O
FRAP I-GENE
/ O
mTOR I-GENE
protein O
and O
a O
FRAP I-GENE
/ O
mTOR I-GENE
immunoprecipitate O
were O
utilized O
in O
in O
vitro O
kinase O
assays O
to O
phosphorylate O
4E I-GENE
- I-GENE
BP1 I-GENE
. O

Hrs I-GENE
has O
a O
FYVE O
double O
zinc O
finger O
domain O
, O
which O
specifically O
binds O
phosphatidylinositol O
( O
3 O
)- O
phosphate O
and O
is O
conserved O
in O
several O
proteins O
involved O
in O
vesicular O
traffic O
. O

The O
coexpression O
of O
full O
- O
length O
expression O
constructs O
for O
both O
DBP I-GENE
and O
hepatic I-GENE
leukemia I-GENE
factor I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
activation O
mediated O
by O
the O
GAL4 I-GENE
- O
DBP I-GENE
fusion O
proteins O
, O
suggesting O
the O
involvement O
of O
a O
regulated O
coactivator O
in O
this O
process O
. O

Three O
subgenomes O
also O
comprised O
15 O
to O
75 O
nucleotides O
derived O
from O
the O
5 O
' O
part O
of O
the O
NS2 I-GENE
gene I-GENE
. O

Cp I-GENE
is O
normally O
the O
main O
promoter O
for O
EBNA I-GENE
mRNA I-GENE
initiation O
, O
so O
it O
appears O
that O
EBNA3C I-GENE
contributes O
to O
a O
negative O
autoregulatory O
control O
loop O
. O

These O
indications O
of O
deregulated O
signalling O
in O
the O
absence O
of O
tyrosine O
118 O
were O
substantiated O
by O
sustained O
activation O
of O
STAT3 I-GENE
. O

With O
exon O
trapping O
, O
we O
could O
isolate O
five O
potential O
exons O
from O
the O
YAC O
946E12 O
that O
spans O
the O
region O
, O
four O
of O
which O
could O
be O
placed O
in O
the O
contig O
in O
the O
vicinity O
of O
the O
breakpoints O
. O

Campomelic O
dysplasia O
translocation O
breakpoints O
are O
scattered O
over O
1 O
Mb O
proximal O
to O
SOX9 I-GENE
: O
evidence O
for O
an O
extended O
control O
region O
. O

The O
most O
common O
characteristics O
of O
VRE O
patients O
were O
recent O
prior O
vancomycin O
use O
, O
recent O
prior O
susceptible O
enterococcal O
infection O
, O
coinfection O
with O
other O
microbial O
pathogens O
, O
and O
concurrent O
fungal O
infection O
. O

A O
coiled O
- O
coil O
domain O
, O
conserved O
within O
each O
encoded O
protein O
, O
serves O
as O
a O
potential O
interaction O
motif O
for O
FLI I-GENE
LRR I-GENE
. O

Binding O
affinities O
of O
these O
recombinant O
phages O
as O
determined O
by O
the O
retention O
of O
these O
phages O
by O
a O
His O
- O
tag O
immobilized O
gp17 I-GENE
column O
, O
and O
by O
co O
- O
immunoprecipitation O
with O
purified O
terminase I-GENE
supported O
the O
specific O
nature O
of O
the O
portal I-GENE
protein I-GENE
and O
terminase I-GENE
interaction I-GENE
sites I-GENE
. O

Although O
the O
terminase I-GENE
apparently O
interacts O
with O
this O
gp20 I-GENE
portal I-GENE
peptide I-GENE
, O
polyclonal O
antibody O
against O
the O
portal O
peptide O
appears O
unable O
to O
access O
it O
in O
the O
native O
structure O
, O
suggesting O
intimate O
association O
of O
gp20 I-GENE
and O
gp17 I-GENE
possibly O
internalizes O
terminase I-GENE
regions I-GENE
within O
the O
portal O
in O
the O
packasome O
complex O
. O

The O
hybrid O
viruses O
were O
found O
to O
accumulate O
to O
high O
levels O
in O
infected O
plants O
, O
to O
form O
stable O
virions O
, O
and O
to O
be O
mechanically O
transmissible O
. O

cDNA O
and O
structural O
organization O
of O
the O
gene I-GENE
Pole1 I-GENE
for O
the O
mouse I-GENE
DNA I-GENE
polymerase I-GENE
epsilon I-GENE
catalytic I-GENE
subunit I-GENE
. O

Nevertheless O
cryopreservation O
of O
spermatozoa O
in O
a O
medium O
containing O
neither O
SP O
nor O
biological O
substances O
could O
offer O
an O
acceptable O
cryoprotection O
of O
spermatozoa O
to O
be O
used O
in O
assisted O
fertilization O
procedures O
, O
especially O
for O
intracytoplasmic O
sperm O
injection O
. O

A O
liquid O
chromatographic O
method O
is O
described O
for O
analysis O
of O
beta O
- O
carotene O
in O
medical O
food O
. O

The O
FCMS O
conditions O
were O
as O
follows O
: O
2 O
kW O
maximum O
electrical O
power O
consumption O
, O
800 O
V O
maximum O
capacitor O
voltage O
, O
720 O
microseconds O
pulsewidth O
( O
180 O
microseconds O
rise O
time O
), O
and O
5 O
- O
30 O
Hz O
frequency O
. O

Severe O
hemolysis O
resulted O
in O
statistically O
significant O
changes O
in O
the O
mean O
values O
of O
the O
above O
analytes O
in O
addition O
to O
the O
following O
increases O
: O
alanine I-GENE
aminotransferase I-GENE
, O
calcium O
, O
and O
serum I-GENE
globulins I-GENE
( O
P O
< O
0 O
. O
001 O
) O
and O
albumin I-GENE
and O
total O
protein O
( O
P O
< O
0 O
. O
01 O
). O

EMSA O
with O
crude O
nuclear O
extracts O
demonstrated O
that O
stimulation O
with O
CD40L I-GENE
results O
in O
the O
induction O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
complexes I-GENE
that O
bind O
to O
each O
of O
the O
three O
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
and O
are O
composed O
mainly O
of O
p50 I-GENE
and O
RelB I-GENE
, O
but O
also O
include O
c I-GENE
- I-GENE
Rel I-GENE
and O
p65 I-GENE
. O

Optimal O
monitoring O
of O
ODA O
remains O
undefined O
. O

The O
major O
transcription O
factors O
controlling O
arginine O
metabolism O
in O
Escherichia O
coli O
and O
Bacillus O
subtilis O
, O
ArgR I-GENE
and O
AhrC I-GENE
, O
respectively O
, O
are O
homologous O
multimeric O
proteins O
that O
form O
l O
- O
arginine O
- O
dependent O
DNA O
- O
binding O
complexes O
capable O
of O
repressing O
transcription O
of O
the O
biosynthetic O
genes O
( O
both O
), O
activating O
transcription O
of O
catabolic O
genes O
( O
AhrC I-GENE
only O
) O
or O
facilitating O
plasmid O
dimer O
resolution O
( O
both O
). O

The O
studied O
protein O
fragments O
consist O
of O
residues O
Arg183 O
- O
His267 O
of O
the O
human I-GENE
ER I-GENE
and O
residues O
Lys438 O
- O
Gln520 O
of O
the O
rat O
GR I-GENE
. O

The O
exon O
: O
intron O
structure O
of O
chicken I-GENE
IL8 I-GENE
corresponds O
almost O
exactly O
to O
that O
of O
human I-GENE
IL8 I-GENE
and O
differs O
from O
those O
of O
other O
known O
mammalian I-GENE
CXC I-GENE
chemokine I-GENE
genes I-GENE
. O

The O
Aa I-GENE
- I-GENE
Pri2 I-GENE
gene I-GENE
, O
specifically O
expressed O
during O
basidiocarp O
differentiation O
of O
the O
mushroom O
Agrocybe O
aegerita O
, O
was O
cloned O
. O

The O
main O
causes O
of O
liver O
disease O
in O
the O
patients O
with O
HCC O
were O
hepatitis O
C O
virus O
( O
HCV O
) O
( O
77 O
%), O
alcohol O
abuse O
( O
73 O
%), O
and O
the O
combination O
of O
HCV O
and O
alcohol O
abuse O
( O
50 O
%). O

Three O
new O
aromatase I-GENE
inhibitors O
have O
recently O
completed O
phase O
III O
evaluation O
as O
treatment O
of O
metastatic O
breast O
cancer O
in O
post O
- O
menopausal O
women O
whose O
disease O
has O
progressed O
despite O
tamoxifen O
therapy O
: O
anastrozole O
( O
ARIMIDEX O
, O
Zeneca O
), O
letrozole O
( O
FEMARA O
, O
Novartis O
) O
and O
vorozole O
( O
RIVIZOR O
, O
Janssen O
). O

CONCLUSIONS O
: O
Turbutest O
is O
a O
valuable O
tool O
in O
asthmatic O
patients O
' O
training O
, O
allowing O
identification O
and O
improvement O
of O
an O
inadequate O
inhalation O
technique O
with O
Turbuhaler O
. O

Of O
those O
injuries O
, O
143 O
cases O
were O
snowboard O
related O
and O
158 O
cases O
were O
ski O
related O
. O

The O
femoral O
artery O
/ O
vein O
and O
the O
soleus O
and O
gastrocnemius O
muscles O
were O
examined O
in O
healthy O
human O
male O
volunteers O
. O

SRFDelta5 I-GENE
acts O
as O
a O
naturally O
occurring O
dominant O
negative O
regulatory O
mutant O
that O
blocks O
SRF I-GENE
- O
dependent O
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
cardiac I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
smooth I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
SM22alpha I-GENE
, O
and O
SRF I-GENE
promoter O
- O
luciferase I-GENE
reporter O
activities O
. O

In O
serum O
- O
free O
media O
, O
p50E4F I-GENE
accelerated O
E1A I-GENE
- O
induced O
apoptosis O
. O

The O
potency O
of O
the O
effect O
of O
Nim O
( O
0 O
. O
5 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
.) O
was O
similar O
to O
that O
of O
NBP O
( O
10 O
mg O
. O
kg O
- O
1 O
i O
. O
p O
.). O

CONCLUSION O
: O
NBP O
pre O
- O
treatment O
or O
post O
- O
treatment O
markedly O
enhanced O
the O
rCBF O
to O
striatum O
in O
RMCAO O
rats O
. O

Progression O
after O
first O
- O
line O
chemotherapy O
was O
associated O
with O
significantly O
worse O
survival O
for O
patients O
with O
metastasis O
. O

Mutations O
within O
human O
UTR1 O
modulate O
NRF I-GENE
- I-GENE
1 I-GENE
expression O
by O
interfering O
with O
mRNA O
translational O
efficiency O
in O
transfected O
cells O
and O
in O
an O
in O
vitro O
translation O
system O
. O

As O
is O
deduced O
from O
the O
nucleotide O
sequence O
of O
the O
cDNA O
, O
CBS I-GENE
- I-GENE
1 I-GENE
contains O
an O
open O
reading O
frame O
consisting O
of O
182 O
amino O
acids O
, O
with O
a O
molecular O
weight O
of O
19 O
. O
5kDa O
. O

Corticostriatal O
and O
corticosubthalamic O
input O
zones O
from O
the O
presupplementary O
motor O
area O
in O
the O
macaque O
monkey O
: O
comparison O
with O
the O
input O
zones O
from O
the O
supplementary O
motor O
area O
. O

Basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
( O
bFGF I-GENE
) O
has O
been O
shown O
to O
induce O
angiogenesis O
in O
various O
animal O
models O
, O
but O
the O
methods O
of O
administration O
used O
experimentally O
are O
not O
clinically O
feasible O
. O

Both O
filters O
equally O
contributed O
to O
elevation O
of O
iliac O
venous O
pressure O
( O
median O
, O
9 O
. O
3 O
and O
7 O
. O
2 O
mm O
Hg O
[ O
n O
= O
9 O
] O
with O
the O
spring O
filter O
and O
RF02 O
filter O
, O
respectively O
). O

12 O
healthy O
women O
( O
age O
18 O
- O
38 O
years O
) O
were O
examined O
using O
the O
2 O
- O
hour O
' O
s O
method O
of O
passive O
leg O
rising O
( O
PLR O
) O
in O
follicular O
( O
FP O
) O
and O
luteal O
( O
LP O
) O
phases O
of O
normal O
ovulatory O
cycle O
. O

Thus O
, O
sgRNA2 I-GENE
has O
the O
3 O
' O
TE O
in O
its O
5 O
' O
UTR O
. O

These O
single O
mutational O
defects O
in O
the O
eRF1 I-GENE
- O
eRF3 I-GENE
interaction O
became O
evident O
when O
either O
truncated O
protein O
eRF3C I-GENE
or O
C O
- O
terminally O
altered O
eRF1 I-GENE
proteins O
were O
used O
for O
the O
authentic O
protein O
, O
providing O
further O
support O
for O
the O
presence O
of O
a O
C O
- O
terminal O
interaction O
. O

Removal O
of O
each O
of O
three O
contiguous O
segments O
from O
the O
N O
- O
terminal O
half O
specifically O
inhibits O
the O
formation O
of O
5 I-GENE
. I-GENE
8Ss I-GENE
rRNA I-GENE
, O
whereas O
deleting O
part O
of O
the O
C O
- O
terminal O
region O
of O
the O
protein O
only O
blocks O
the O
production O
of O
18S I-GENE
rRNA I-GENE
. O

Ras I-GENE
is O
not O
associated O
with O
the O
tegument O
. O

Green O
fluorescent O
protein O
- O
tagged O
UNC I-GENE
- I-GENE
49B I-GENE
and O
UNC I-GENE
- I-GENE
49C I-GENE
subunits I-GENE
are O
coexpressed O
in O
muscle O
cells O
and O
are O
colocalized O
to O
synaptic O
regions O
. O

We O
show O
that O
a O
protein O
, O
UBC9 I-GENE
, O
interacts O
specifically O
with O
TEL I-GENE
in O
vitro O
and O
in O
vivo O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
spontaneous O
reports O
of O
suspected O
adverse O
drug O
reactions O
, O
observed O
in O
elderly O
patients O
( O
over O
65 O
years O
of O
age O
) O
in O
Sicily O
( O
Italy O
) O
during O
the O
period O
from O
1 O
January O
1995 O
to O
31 O
December O
1997 O
. O

Molecules O
of O
NH3 O
are O
capable O
of O
emitting O
stimulated O
radiation O
( O
MASER O
). O

The O
major O
findings O
of O
our O
studies O
are O
as O
follows O
: O
1 O
) O
There O
are O
no O
detectable O
signals O
around O
GDF I-GENE
- I-GENE
9 I-GENE
- O
deficient O
follicles O
for O
several O
theca O
cell O
layer O
markers O
[ O
i O
. O
e O
. O

Interestingly O
, O
highly O
charged O
residues O
were O
abundantly O
possessed O
in O
the O
carboxy O
- O
terminal O
part O
of O
the O
MDV2 I-GENE
UL10 I-GENE
protein I-GENE
. O

Identification O
and O
structure O
of O
the O
Marek I-GENE
' I-GENE
s I-GENE
disease I-GENE
virus I-GENE
serotype I-GENE
2 I-GENE
glycoprotein I-GENE
M I-GENE
gene I-GENE
: O
comparison O
with O
glycoprotein I-GENE
M I-GENE
genes I-GENE
of O
Herpesviridae O
family O
. O

OBJECTIVE O
: O
To O
perform O
a O
cost O
- O
effectiveness O
analysis O
( O
CEA O
) O
between O
a O
standard O
antiemetic O
regimen O
- O
chlorpromazine O
+ O
dexamethasone O
( O
CPM O
- O
DEX O
)- O
and O
a O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
- O
tropisetron O
( O
TROP O
)-- O
in O
the O
control O
of O
acute O
emesis O
induced O
by O
highly O
emetogenic O
chemotherapy O
in O
children O
, O
considering O
two O
analytic O
perspectives O
: O
hospital O
and O
patients O
. O

Baseline O
data O
were O
obtained O
from O
10 O
adults O
. O

A O
comparison O
of O
the O
nucleotide O
and O
deduced O
amino O
acid O
sequences O
of O
the O
core O
regions O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
domains I-GENE
found O
in O
these O
three O
dsRNAs O
suggested O
that O
these O
dsRNAs O
probably O
evolved O
independently O
within O
each O
host O
plant O
from O
a O
common O
ancestor O
. O

Consistent O
with O
this O
possibility O
, O
a O
non O
- O
MBD I-GENE
region O
of O
Bin1 I-GENE
was O
sufficient O
to O
recruit O
a O
repression O
function O
to O
DNA O
that O
was O
unrelated O
to O
histone I-GENE
deacetylase I-GENE
. O

Forty O
- O
eight O
sequences O
, O
30 O
not O
previously O
identified O
as O
IR O
- O
responsive O
, O
were O
significantly O
regulated O
by O
IR O
. O

A O
recently O
described O
protein O
, O
metaxin I-GENE
1 I-GENE
, O
serves O
as O
a O
component O
of O
a O
preprotein O
import O
complex O
in O
the O
outer O
membrane O
of O
the O
mammalian O
mitochondrion O
. O

Molecular O
cloning O
of O
rat I-GENE
SH2 I-GENE
- I-GENE
containing I-GENE
inositol I-GENE
phosphatase I-GENE
2 I-GENE
( O
SHIP2 I-GENE
) O
and O
its O
role O
in O
the O
regulation O
of O
insulin I-GENE
signaling O
. O

Slp1 I-GENE
represses O
transcription O
via O
this O
binding O
site O
in O
yeast O
cells O
, O
consistent O
with O
its O
role O
as O
a O
direct O
repressor O
of O
ftz I-GENE
stripes O
in O
interstripe O
regions O
during O
late O
stages O
of O
embryogenesis O
. O

The O
results O
of O
these O
studies O
support O
a O
model O
in O
which O
VirB4 I-GENE
dimers I-GENE
or O
homomultimers O
contribute O
structural O
information O
for O
the O
assembly O
of O
a O
transenvelope O
channel O
competent O
for O
bidirectional O
DNA O
transfer O
, O
whereas O
an O
ATP O
- O
dependent O
activity O
is O
required O
for O
configuring O
this O
channel O
as O
a O
dedicated O
export O
machine O
. O

The O
penicillin I-GENE
binding I-GENE
proteins I-GENE
( O
PBPs I-GENE
) O
synthesize O
and O
remodel O
peptidoglycan O
, O
the O
structural O
component O
of O
the O
bacterial O
cell O
wall O
. O

TCR I-GENE
alpha I-GENE
( O
TCRA I-GENE
) O
expression O
was O
examined O
in O
RNA O
samples O
from O
PBMC O
and O
isolated O
populations O
of O
CD4 O
+, O
CD8 O
+, O
and O
DN O
T O
cells O
from O
15 O
healthy O
individuals O
. O

Similar O
results O
were O
obtained O
with O
xylitol O
, O
an O
activator O
of O
the O
pentose O
phosphate O
pathway O
. O

The O
high I-GENE
density I-GENE
lipoprotein I-GENE
( I-GENE
HDL I-GENE
) I-GENE
receptor I-GENE
mediates O
the O
uptake O
of O
cholesterol O
and O
cholesteryl O
esters O
, O
substrates O
for O
steroidogenesis O
, O
from O
an O
HDL I-GENE
particle O
in O
the O
adrenal O
gland O
and O
gonads O
. O

D3S1261 I-GENE
is O
physically O
located O
at O
or O
near O
the O
MITF I-GENE
locus I-GENE
, O
while O
D3S2465 I-GENE
and O
D3S1766 I-GENE
are O
flanking O
the O
locus O
at O
about O
17 O
. O
5 O
cM O
genetic O
distance O
each O
side O
. O

The O
percentages O
of O
recovery O
decreased O
with O
storage O
time O
, O
although O
the O
addition O
of O
dispersant O
( O
Tris O
- O
Tween O
80 O
) O
before O
storage O
appeared O
to O
partially O
prevent O
adhesion O
. O

Point O
mutations O
of O
the O
site O
that O
suppressed O
Pit I-GENE
- I-GENE
1 I-GENE
binding O
in O
vitro O
restored O
full O
tiGH I-GENE
promoter I-GENE
activity O
. O

A O
human I-GENE
Raf I-GENE
- I-GENE
responsive I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
that O
binds O
to O
divergent O
sequences O
. O

We O
are O
reporting O
an O
autopsy O
case O
of O
so O
- O
called O
" O
acute O
multiple O
sclerosis O
" O
that O
was O
difficult O
to O
differentiate O
from O
a O
brain O
tumor O
on O
MRI O
findings O
. O

Furthermore O
, O
MOM I-GENE
- I-GENE
4 I-GENE
and O
TAK1 I-GENE
bind O
related O
proteins O
that O
promote O
their O
kinase O
activities O
. O

BACKGROUND O
: O
The O
MAZE O
- O
III O
is O
the O
surgical O
treatment O
of O
choice O
for O
medically O
refractory O
atrial O
fibrillation O
. O

Gab2 I-GENE
, O
a O
new O
pleckstrin I-GENE
homology O
domain O
- O
containing O
adapter O
protein O
, O
acts O
to O
uncouple O
signaling O
from O
ERK I-GENE
kinase I-GENE
to O
Elk I-GENE
- I-GENE
1 I-GENE
. O

The O
presence O
of O
cutaneous O
xanthomas O
with O
normal O
serum O
lipid O
levels O
is O
due O
to O
the O
antibetalipoproteic O
activity O
of O
the O
monoclonal I-GENE
immunoglobulin I-GENE
. O

In O
an O
attempt O
to O
reduce O
the O
incidence O
of O
NSAID O
- O
induced O
gastrointestinal O
lesions O
, O
the O
following O
approaches O
have O
been O
proposed O
: O
( O
i O
) O
use O
of O
the O
prostaglandin O
analogue O
misoprostol O
, O
which O
is O
an O
antiulcer O
drug O
which O
has O
been O
proven O
to O
be O
as O
effective O
in O
the O
prevention O
of O
NSAID O
- O
induced O
gastric O
and O
duodenal O
ulcers O
as O
in O
the O
reduction O
of O
serious O
upper O
gastrointestinal O
complications O
; O
( O
ii O
) O
histamine I-GENE
H2 I-GENE
receptor I-GENE
antagonists O
( O
H2 O
antagonists O
), O
e O
. O
g O
. O
ranitidine O
, O
cimetidine O
and O
famotidine O
, O
which O
are O
useful O
in O
the O
prevention O
of O
NSAID O
- O
induced O
duodenal O
ulcers O
during O
long O
term O
treatment O
, O
but O
not O
in O
the O
prevention O
of O
NSAID O
- O
induced O
gastric O
ulcers O
; O
( O
iii O
) O
proton O
pump O
inhibitors O
, O
e O
. O
g O
omeprazole O
, O
and O
pantoprazole O
, O
whose O
efficacy O
in O
preventing O
NSAID O
- O
associated O
ulcers O
has O
been O
recently O
demonstrated O
; O
and O
( O
iv O
) O
barrier O
agents O
, O
e O
. O
g O
. O
sucralfate O
, O
which O
cannot O
be O
recommended O
as O
prophylactic O
agents O
to O
prevent O
NSAID O
- O
induced O
gastropathy O
. O

Lung O
mesenchyme O
serves O
as O
a O
' O
compleat O
' O
inducer O
of O
lung O
morphogenesis O
by O
secreting O
soluble O
peptide O
growth O
factors O
. O

The O
activation O
of O
the O
HIV O
promoter O
required O
the O
nuclear O
localization O
of O
c I-GENE
- I-GENE
Abl I-GENE
and O
could O
be O
correlated O
with O
increased O
tyrosine O
phosphorylation O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

The O
bovine I-GENE
papillomavirus I-GENE
E2 I-GENE
protein I-GENE
can O
inhibit O
the O
proliferation O
of O
HT O
- O
3 O
cells O
, O
a O
p53 I-GENE
- O
negative O
cervical O
carcinoma O
cell O
line O
containing O
integrated O
human O
papillomavirus O
type O
30 O
DNA O
. O

E2 I-GENE
point O
mutants O
unable O
to O
inhibit O
cell O
growth O
did O
not O
repress O
cdc25A I-GENE
and O
cdc25B I-GENE
expression O
, O
nor O
did O
the O
cell O
cycle O
inhibitors O
hydroxyurea O
and O
mimosine O
. O

BACKGROUND O
/ O
PURPOSE O
: O
Anomalous O
arrangement O
of O
the O
pancreaticobiliary O
duct O
( O
AAPBD O
) O
is O
closely O
related O
to O
congenital O
biliary O
dilatation O
and O
frequently O
associated O
with O
biliary O
tract O
malignancy O
. O

Neurospora O
crassa O
CYT I-GENE
- I-GENE
18 I-GENE
, O
can O
rescue O
the O
exonic O
trap O
and O
intron O
mutants O
which O
cause O
a O
structural O
defect O
. O

DDP1 I-GENE
also O
localizes O
to O
heterochromatin O
in O
interphase O
nuclei O
of O
larval O
neuroblasts O
. O

In O
a O
reconstituted O
human O
DNA O
repair O
system O
containing O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
DNA I-GENE
ligase I-GENE
III I-GENE
- O
XRCC1 I-GENE
, O
accurate O
rejoining O
of O
a O
3 O
' O
mismatched O
base O
residue O
at O
a O
single O
- O
strand O
break O
is O
dependent O
on O
addition O
of O
the O
exonuclease O
. O

The O
PAC O
clone O
with O
an O
insert O
size O
of O
120kb O
was O
isolated O
and O
mapped O
by O
restriction O
analysis O
. O

Sequence O
of O
10q24 I-GENE
locus I-GENE
surrounding O
the O
HOX11 I-GENE
oncogene I-GENE
reveals O
a O
new O
gene O
HUG1 I-GENE
expressed O
in O
a O
T O
- O
ALL O
cell O
line O
. O

About O
20 O
kb O
upstream O
of O
LAMB2 I-GENE
we O
found O
a O
gene O
encoding O
a O
transcribed O
, O
non O
- O
processed O
LAMB2 I-GENE
- I-GENE
like I-GENE
pseudogene I-GENE
( O
LAMB2L I-GENE
). O

Site O
- O
directed O
mutagenesis O
of O
the O
R2 I-GENE
protein I-GENE
was O
used O
to O
provide O
evidence O
that O
this O
motif O
is O
also O
part O
of O
the O
active O
site O
of O
the O
endonuclease O
encoded O
by O
this O
element O
. O

The O
infected I-GENE
cell I-GENE
protein I-GENE
no I-GENE
. I-GENE
0 I-GENE
( O
ICP0 I-GENE
) O
of O
herpes O
simplex O
virus O
1 O
is O
a O
promiscuous O
transactivator O
shown O
to O
enhance O
the O
expression O
of O
genes O
introducted O
into O
cells O
by O
infection O
or O
transfection O
. O

Wrist O
measurement O
of O
blood O
pressure O
: O
some O
critical O
remarks O
to O
oscillometry O
. O

G O
- O
box O
- O
directed O
expression O
in O
leaves O
required O
the O
presence O
of O
an O
enhancer O
region O
from O
the O
cauliflower O
mosaic O
virus O
( O
CaMV O
) O
35S I-GENE
promoter I-GENE
. O

Another O
element O
necessary O
for O
augmenting O
the O
amplitude O
of O
the O
oscillation O
lies O
between O
- O
178 O
and O
- O
264 O
. O

This O
scFv O
was O
therefore O
used O
as O
control O
in O
experiments O
where O
another O
anti I-GENE
- I-GENE
Ras I-GENE
scFv I-GENE
( O
Y259 I-GENE
scFv I-GENE
, O
derived O
from O
the O
neutralizing O
anti I-GENE
- I-GENE
Ras I-GENE
mAb I-GENE
Y13 I-GENE
- I-GENE
259 I-GENE
) O
blocked O
the O
Ras I-GENE
pathway O
in O
vitro O
and O
led O
to O
tumor O
regression O
in O
a O
nude O
mouse O
model O
[ O
Cochet O
, O
O O
., O
Kenigsberg O
, O
M O
., O
Delumeau O
, O
I O
., O
Virone O
- O
Oddos O
, O
A O
., O
Multon O
, O
M O
. O
C O
., O
Fridman O
, O
W O
. O
H O
., O
Schweighoffer O
, O
F O
., O
Teillaud O
, O
J O
. O
L O
., O
Tocque O
, O
B O
., O
1998 O
. O

There O
was O
no O
competition O
between O
activin I-GENE
A I-GENE
and O
OP I-GENE
- I-GENE
1 I-GENE
for O
availability O
of O
Smad4 I-GENE
, O
indicating O
that O
the O
concentration O
of O
this O
common O
signal O
transducer O
is O
not O
limiting O
for O
generating O
the O
observed O
biological O
responses O
. O

Our O
data O
therefore O
indicate O
that O
it O
is O
possible O
to O
engineer O
the O
HA I-GENE
envelope I-GENE
glycoprotein I-GENE
by O
fusing O
ligands O
to O
its O
amino O
- O
terminal O
end O
without O
affecting O
its O
fusion O
activity O
. O

However O
, O
the O
favored O
, O
parallel O
beta O
helix O
model O
is O
a O
compact O
coil O
of O
ten O
helically O
arranged O
beta O
strands O
forming O
two O
parallel O
beta O
sheet O
faces O
. O

This O
is O
predicted O
to O
encode O
a O
315 O
- O
residue O
protein O
containing O
seven O
hydrophobic O
helical O
regions O
and O
a O
17 O
amino O
acid O
motif O
characteristic O
of O
the O
R7G I-GENE
family I-GENE
of O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
membrane I-GENE
- I-GENE
bound I-GENE
receptors I-GENE
. O

Characterisation O
of O
the O
chicken I-GENE
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
gene I-GENE
5 O
'- O
flanking O
region O
. O

These O
results O
suggest O
that O
members O
of O
the O
ATF I-GENE
family I-GENE
are O
involved O
in O
mediating O
the O
transcriptional O
regulation O
of O
the O
KGF I-GENE
gene I-GENE
in O
response O
to O
extracellular O
stimuli O
via O
a O
novel O
CRE O
regulatory O
element O
. O

Moreover O
, O
a O
high O
proportion O
of O
blood O
samples O
from O
a O
random O
sample O
of O
the O
rest O
of O
the O
suspects O
tested O
positive O
for O
trypanosome O
- O
specific O
DNA O
by O
PCR O
( O
79 O
. O
9 O
% O
for O
T O
. O
b O
. O
gambiense O
and O
13 O
. O
9 O
% O
for O
T O
. O
b O
. O
rhodesiense O
). O

A O
multi O
- O
centre O
evaluation O
of O
the O
card O
indirect O
agglutination O
test O
for O
trypanosomiasis O
( O
TrypTect O
CIATT O
). O

Results O
for O
men O
who O
drank O
up O
to O
two O
drinks O
per O
day O
suggest O
that O
if O
the O
dependence O
criteria O
were O
invalid O
, O
reductions O
in O
the O
prevalence O
of O
specific O
indicators O
of O
alcohol O
dependence O
would O
range O
from O
0 O
. O
3 O
% O
to O
5 O
. O
2 O
%. O

Mutagenesis O
of O
the O
CDE O
/ O
CHR O
elements O
and O
Sp1 I-GENE
sites I-GENE
in O
this O
region O
, O
alone O
or O
in O
combination O
, O
reduced O
transcriptional O
activity O
by O
40 O
- O
60 O
% O
in O
asynchronously O
growing O
cells O
and O
abolished O
cell O
cycle O
periodicity O
in O
G2 O
- O
M O
- O
synchronized O
cells O
. O

Using O
Scheffe O
' O
s O
procedure O
as O
an O
illustration O
, O
comparisons O
are O
made O
to O
usual O
sample O
size O
methods O
that O
incorrectly O
ignore O
the O
stochastic O
nature O
of O
S2p O
. O

The O
crystal O
structure O
of O
the O
VP16 I-GENE
core I-GENE
has O
been O
determined O
at O
2 O
. O
1 O
A O
resolution O
. O

Ozagrel O
, O
ifenprodil O
, O
cinnarizine O
and O
dilazep O
were O
more O
effective O
than O
pentoxifylline O
in O
increasing O
rCBF O
at O
the O
HPC O
. O

The O
latter O
method O
adds O
clamping O
of O
the O
inferior O
vena O
cava O
, O
which O
results O
in O
hypotension O
, O
requiring O
invasive O
anesthetic O
management O
. O

By O
contrast O
, O
PvirE I-GENE
or O
Plac I-GENE
promoter I-GENE
constructs I-GENE
yielded O
functional O
VirE2 I-GENE
only O
if O
virE1 I-GENE
was O
coexpressed O
with O
virE2 I-GENE
. O

Simian O
parainfluenza O
virus O
5 O
( O
SV5 O
) O
is O
a O
prototype O
of O
the O
Paramyxoviridae O
family O
of O
nonsegmented O
negative O
- O
sense O
RNA O
viruses O
. O

To O
investigate O
the O
functions O
of O
GE O
, O
IG O
, O
and O
GS O
sequences O
in O
transcription O
, O
we O
constructed O
plasmids O
containing O
cDNAs O
of O
the O
full O
- O
length O
SV5 O
genome O
in O
which O
the O
gene O
junction O
sequences O
( O
GE O
, O
IG O
, O
and O
GS O
sequences O
) O
located O
between O
the O
hemagglutinin I-GENE
- I-GENE
neuraminidase I-GENE
( O
HN I-GENE
) O
and O
the O
polymerase I-GENE
( I-GENE
L I-GENE
) I-GENE
genes I-GENE
were O
replaced O
with O
the O
counterpart O
sequences O
from O
other O
gene O
junctions O
. O

CXCR4 I-GENE
is O
a O
chemokine O
receptor O
and O
a O
coreceptor O
for O
T O
- O
cell O
- O
line O
- O
tropic O
( O
X4 O
) O
and O
dual O
- O
tropic O
( O
R5X4 O
) O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
isolates O
. O

These O
data O
will O
help O
us O
to O
better O
detail O
the O
CXCR4 I-GENE
structural O
requirements O
exhibited O
by O
different O
HIV O
- O
1 O
strains O
and O
will O
direct O
further O
mutagenesis O
efforts O
aimed O
at O
better O
defining O
the O
domains O
in O
CXCR4 I-GENE
involved O
in O
the O
HIV O
- O
1 O
Env I-GENE
- O
mediated O
fusion O
process O
. O

The O
results O
of O
these O
analyses O
indicate O
that O
the O
proteinase O
cleaves O
at O
amino O
acid O
residues O
E960 O
- O
A961 O
, O
E1071 O
- O
S1072 O
, O
E1345 O
- O
T1346 O
, O
and O
E1419 O
- O
G1420 O
; O
however O
, O
the O
cleavage O
efficiency O
is O
varied O
. O

y O
. O

SM I-GENE
is O
also O
shown O
to O
be O
associated O
in O
vivo O
with O
other O
components O
of O
the O
CRM I-GENE
1 I-GENE
export O
pathway O
, O
including O
the O
small I-GENE
GTPase I-GENE
Ran I-GENE
and O
the O
nucleoporin O
CAN I-GENE
/ O
Nup214 I-GENE
. O

Identification O
of O
a O
spliced O
gene O
from O
Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
encoding O
a O
protein O
with O
similarities O
to O
latent I-GENE
membrane I-GENE
proteins I-GENE
1 I-GENE
and I-GENE
2A I-GENE
of I-GENE
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
. O

Auditory O
clicks O
were O
given O
at O
a O
rate O
of O
20 O
s O
(- O
1 O
). O

Myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
functions O
downstream O
of O
Ras I-GENE
/ O
ERK I-GENE
to O
promote O
migration O
of O
urokinase I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
- O
stimulated O
cells O
in O
an O
integrin I-GENE
- O
selective O
manner O
. O

The O
inhibition O
of O
StAR I-GENE
gene I-GENE
transcription O
by O
DAX I-GENE
- I-GENE
1 I-GENE
was O
dose O
- O
dependent O
reducing O
transcription O
to O
6 O
% O
of O
control O
levels O
. O

In O
a O
prospective O
randomized O
study O
, O
287 O
patients O
with O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
NSCLC O
) O
stage O
IIIb O
or O
IV O
with O
ECOG O
performance O
status O
( O
PS O
) O
0 O
- O
1 O
or O
2 O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive O
care O
( O
BSC O
) O
or O
supportive O
care O
plus O
combination O
chemotherapy O
( O
IEP O
regimen O
: O
ifosfamide O
3 O
gm O
/ O
m2 O
IV O
with O
mesna O
uroprotection O
, O
epirubicin O
60 O
mg O
/ O
m2 O
IV O
on O
day O
1 O
and O
cisplatin O
60 O
mg O
/ O
m2 O
IV O
on O
day O
2 O
; O
or O
MVP O
regimen O
: O
mitomycin O
- O
C O
8 O
mg O
/ O
m2 O
, O
cisplatin O
100 O
mg O
/ O
m2 O
IV O
on O
day O
1 O
, O
vinblastine O
4 O
mg O
/ O
m2 O
IV O
on O
days O
1 O
and O
15 O
). O

Using O
sequence O
information O
from O
human I-GENE
BMAL1 I-GENE
( O
hBMAL1 I-GENE
) O
cDNAs O
previously O
reported O
by O
our O
laboratory O
, O
we O
have O
isolated O
and O
characterized O
cDNAs O
encoding O
three O
splice O
variants O
of O
the O
mouse I-GENE
BMAL1 I-GENE
( O
mBMAL1 I-GENE
) O
gene O
. O

Comparison O
with O
the O
bHLH I-GENE
/ O
PAS I-GENE
family O
genes O
revealed O
that O
the O
intron O
/ O
exon O
splice O
pattern O
of O
mBMAL1 I-GENE
most O
closely O
matches O
that O
of O
the O
mAhr I-GENE
, O
which O
suggests O
that O
BMAL1 I-GENE
and O
Ahr I-GENE
belong O
to O
the O
same O
subclass O
and O
may O
be O
derived O
from O
a O
common O
primordial O
gene O
. O

The O
transcriptional O
activities O
of O
the O
full O
- O
length O
promoter O
(- O
295 O
to O
+ O
85 O
) O
and O
of O
three O
deletion O
constructs O
(- O
197 O
, O
- O
154 O
and O
- O
74 O
to O
+ O
85 O
) O
were O
significantly O
down O
- O
regulated O
in O
resistant O
cells O
. O

We O
were O
able O
to O
detect O
significant O
differences O
in O
functional O
residual O
capacity O
adjusted O
for O
weight O
or O
height O
, O
and O
compliance O
of O
the O
respiratory O
system O
adjusted O
for O
weight O
or O
lung O
volume O
in O
the O
ILD O
infants O
compared O
to O
the O
healthy O
controls O
or O
infants O
who O
had O
PPHN O
, O
indicating O
that O
these O
PFTs O
were O
sensitive O
enough O
to O
determine O
abnormal O
lung O
function O
in O
this O
age O
group O
. O

A O
13 O
- O
bp O
cis O
- O
regulatory O
element O
in O
the O
LTR O
promoter O
of O
the O
tobacco I-GENE
retrotransposon I-GENE
Tto1 I-GENE
is O
involved O
in O
responsiveness O
to O
tissue O
culture O
, O
wounding O
, O
methyl O
jasmonate O
and O
fungal O
elicitors O
. O

In O
this O
study O
we O
describe O
that O
platelet I-GENE
- I-GENE
derived I-GENE
growth I-GENE
factor I-GENE
( O
PDGF I-GENE
), O
12 O
- O
O O
- O
tetradecanoyl O
- O
phorbol O
- O
acetate O
( O
TPA O
), O
and O
forskolin O
induced O
CREB I-GENE
( O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
Ser O
- O
133 O
phosphorylation O
with O
comparable O
magnitude O
and O
kinetics O
in O
NIH O
3T3 O
cells O
. O

This O
constitutes O
evidence O
for O
an O
in O
vivo O
role O
of O
SRC I-GENE
- I-GENE
1 I-GENE
in O
dimerization O
- O
induced O
activation O
by O
OR1 I-GENE
/ O
RXRalpha I-GENE
. O

By O
contrast O
, O
mTRAP100 I-GENE
coprecipitates O
in O
vivo O
with O
another O
component O
of O
the O
TRAP I-GENE
complex I-GENE
( O
TRAP220 I-GENE
), O
which O
directly O
contacts O
TR I-GENE
and O
the O
vitamin I-GENE
D I-GENE
receptor I-GENE
in O
a O
ligand O
- O
dependent O
manner O
. O

This O
sequence O
also O
confers O
VDR I-GENE
and O
vitamin O
D O
responsiveness O
to O
a O
heterologous O
promoter O
. O

Classical O
ligand O
- O
activated O
nuclear O
receptors O
( O
e O
. O
g O
. O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
, O
retinoic I-GENE
acid I-GENE
receptor I-GENE
), O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
( O
e O
. O
g O
. O

Expression O
of O
GlcNAc I-GENE
- I-GENE
TI I-GENE
mRNA I-GENE
in O
tobacco O
leaves O
was O
detected O
using O
RT O
- O
PCR O
. O

Chemical O
stability O
tests O
and O
site O
- O
specific O
mutagenesis O
identified O
amino O
acids O
H219 O
and O
D63 O
of O
RegS I-GENE
and O
RegR I-GENE
, O
respectively O
, O
as O
the O
phosphorylated O
residues O
. O

An O
overexpression O
of O
the O
betaAPP I-GENE
gene I-GENE
in O
certain O
areas O
of O
the O
AD O
brain O
has O
been O
suggested O
to O
be O
an O
important O
factor O
in O
the O
neuropathology O
of O
AD O
. O

For O
functional O
studies O
, O
two O
promoter O
regions O
were O
cloned O
upstream O
of O
the O
reporter O
gene O
, O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
): O
( O
i O
) O
phbetaE O
- O
B O
- O
the O
plasmid O
that O
contains O
the O
human O
( O
h O
) O
promoter O
region O
(- O
2832 O
to O
+ O
101 O
) O
including O
URE O
, O
and O
( O
ii O
) O
prhbetaE O
- O
B O
- O
the O
plasmid O
that O
contains O
the O
rhesus O
( O
rh O
) O
promoter O
region O
excluding O
URE O
as O
it O
lacks O
a O
270 O
bp O
region O
of O
the O
hbetaAPP I-GENE
promoter I-GENE
(- O
2435 O
to O
- O
2165 O
). O

67 O
393 O
bp O
of O
contiguous O
DNA O
located O
between O
markers O
cdc18 I-GENE
and O
cdc14 I-GENE
on O
the O
right O
arm O
of O
fission O
yeast O
chromosome O
II O
has O
been O
sequenced O
as O
part O
of O
the O
European O
Union O
Schizosaccharomyces O
pombe O
genome O
sequencing O
project O
. O

67 O
393 O
bp O
of O
contiguous O
DNA O
located O
between O
markers O
cdc18 I-GENE
and O
cdc14 I-GENE
on O
the O
right O
arm O
of O
fission O
yeast O
chromosome O
II O
has O
been O
sequenced O
as O
part O
of O
the O
European O
Union O
Schizosaccharomyces O
pombe O
genome O
sequencing O
project O
. O

G I-GENE
- I-GENE
CSF I-GENE
( O
480 O
micrograms O
subcutaneously O
( O
s O
. O
c O
.)) O
were O
used O
in O
55 O
and O
GM I-GENE
- I-GENE
CSF I-GENE
( O
400 O
micrograms O
s O
. O
c O
.) O
in O
28 O
chemotherapeutic O
cycles O
. O

Overexpression O
of O
H411 I-GENE
cDNA I-GENE
in O
the O
RAW O
264 O
. O
7 O
macrophage O
cell O
line O
promoted O
an O
increased O
growth O
rate O
, O
suggesting O
that O
expression O
of O
H411 I-GENE
is O
part O
of O
the O
proliferative O
cell O
response O
to O
LPS O
. O

Human O
expressed O
sequence O
tag O
clones O
were O
identified O
by O
sequence O
similarity O
to O
mammalian I-GENE
and I-GENE
yeast I-GENE
oligosaccharide I-GENE
- I-GENE
processing I-GENE
mannosidases I-GENE
, O
and O
the O
full O
- O
length O
coding O
region O
of O
the O
putative O
mannosidase I-GENE
homolog I-GENE
was O
isolated O
by O
a O
combination O
of O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
and O
direct O
polymerase O
chain O
reaction O
from O
human O
placental O
cDNA O
. O

Activation O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
is O
correlated O
with O
induction O
of O
the O
immediate I-GENE
- I-GENE
early I-GENE
response I-GENE
genes I-GENE
. O

The O
transcription O
of O
most O
RP I-GENE
genes I-GENE
is O
activated O
by O
two O
Rap1p I-GENE
binding I-GENE
sites I-GENE
, O
250 O
to O
400 O
bp O
upstream O
from O
the O
initiation O
of O
transcription O
. O

We O
have O
isolated O
three O
mutant O
alleles O
of O
CDC4 I-GENE
( O
cdc4 I-GENE
- I-GENE
10 I-GENE
, O
cdc4 I-GENE
- I-GENE
11 I-GENE
, O
and O
cdc4 I-GENE
- I-GENE
16 I-GENE
) O
which O
suppress O
the O
nuclear O
division O
defect O
of O
cdc20 I-GENE
- I-GENE
1 I-GENE
cells O
. O

Role O
of O
secondary O
structure O
in O
discrimination O
between O
constitutive O
and O
inducible O
activators O
. O

In O
summary O
, O
Ca O
( O
2 O
+)- O
dependent O
activation O
of O
NO O
production O
mediates O
apoptosis O
after O
TG I-GENE
exposure O
in O
JT O
/ O
Neo O
cells O
. O

Accumulation O
of O
the O
U4 I-GENE
/ O
U6 I-GENE
duplex O
was O
relieved O
by O
overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
Prp44p I-GENE
. O

Our O
results O
, O
when O
combined O
with O
previously O
published O
in O
vitro O
results O
, O
support O
a O
direct O
role O
for O
Prp44p I-GENE
in O
unwinding O
of O
the O
U4 I-GENE
/ O
U6 I-GENE
helix O
. O

This O
approximately O
125 O
- O
nt O
RNA O
proved O
to O
arise O
via O
RNase I-GENE
E I-GENE
cleavage O
from O
the O
3 O
'- O
terminal O
region O
of O
the O
mRNAs O
bearing O
the O
terminator O
. O

The O
mysteries O
of O
geographic O
variability O
in O
nonmelanoma O
skin O
cancer O
incidence O
. O

In O
Saccharomyces O
cerevisiae O
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
PKAs I-GENE
) O
promote O
cytoplasmic O
growth O
and O
modulate O
the O
growth O
- O
regulated O
mechanism O
triggering O
the O
begin O
of O
DNA O
synthesis O
. O

We O
have O
shown O
previously O
that O
in O
contrast O
to O
other O
extracellular O
matrix O
molecules O
pepsin I-GENE
- O
solubilized O
collagen I-GENE
VI I-GENE
( O
CVI I-GENE
) O
can O
stimulate O
DNA O
synthesis O
of O
various O
mesenchymal O
cell O
types O
, O
apparently O
independent O
of O
integrin I-GENE
- O
mediated O
signal O
transduction O
. O

A O
recombinant O
derivative O
harboring O
the O
pMJ101 O
replication O
region O
proved O
to O
be O
compatible O
with O
pJM1 O
, O
a O
plasmid O
containing O
the O
iron O
acquisition O
system O
required O
for O
the O
virulence O
of O
V O
. O
anguillarum O
775 O
, O
another O
important O
pathogen O
that O
causes O
vibriosis O
. O

FAK I-GENE
localizes O
to O
sites O
of O
transmembrane I-GENE
integrin I-GENE
receptor I-GENE
clustering O
and O
facilitates O
intracellular O
signaling O
events O
. O

Expression O
of O
various O
FAK I-GENE
mutants I-GENE
in O
the O
FAK I-GENE
- O
cells O
showed O
that O
FAK I-GENE
kinase I-GENE
activity O
, O
the O
Tyr I-GENE
- I-GENE
397 I-GENE
/ I-GENE
SH2 I-GENE
domain I-GENE
binding I-GENE
site I-GENE
, O
and O
the O
first O
proline O
- O
rich O
SH3 I-GENE
binding I-GENE
region I-GENE
in O
the O
FAK I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
were O
individually O
needed O
to O
promote O
full O
FAK I-GENE
- O
mediated O
FAK I-GENE
- O
cell O
migration O
to O
FN I-GENE
whereas O
direct O
paxillin I-GENE
binding O
to O
FAK I-GENE
was O
not O
required O
. O

This O
dominant O
- O
negative O
effect O
of O
FRNK I-GENE
was O
reversed O
by O
a O
point O
mutation O
( O
Leu O
- O
1034 O
to O
Ser O
) O
which O
prevented O
FRNK I-GENE
localization O
to O
focal O
contact O
sites O
. O

Fifty O
six O
young O
patients O
( O
age O
< O
45 O
yr O
) O
with O
doppler O
- O
proven O
DVT O
were O
investigated O
for O
the O
presence O
of O
resistance O
to O
activated I-GENE
protein I-GENE
C I-GENE
( O
APC I-GENE
- I-GENE
R I-GENE
), O
lupus O
anticoagulant O
( O
LA O
), O
anticardiolipin I-GENE
antibodies I-GENE
and O
deficiencies O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
ATIII I-GENE
activities O
. O

DESIGN O
: O
Comparison O
of O
number O
of O
women O
with O
PKU O
aged O
15 O
- O
44 O
years O
on O
the O
NSW O
PKU O
database O
( O
observed O
number O
) O
with O
expected O
number O
derived O
from O
population O
data O
. O

PURPOSE O
: O
The O
purposes O
of O
the O
present O
study O
were O
to O
assess O
the O
effects O
of O
a O
12 O
- O
wk O
laboratory O
based O
aerobic O
exercise O
program O
on O
cardiopulmonary O
function O
, O
CD4 I-GENE
cell O
count O
, O
and O
physician O
- O
assessed O
health O
status O
among O
symptomatic O
pre O
- O
AIDS O
HIV O
- O
infected O
individuals O
( O
N O
= O
28 O
) O
and O
to O
assess O
the O
degree O
to O
which O
ill O
health O
was O
associated O
with O
exercise O
relapse O
. O

The O
enzyme O
displays O
optimal O
activity O
at O
about O
0 O
. O
5 O
mM O
pantoate O
( O
k O
( O
cat O
) O
0 O
. O
63 O
s O
(- O
1 O
)) O
and O
at O
pH O
7 O
. O
8 O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
the O
RP I-GENE
, O
like O
the O
20S I-GENE
proteasome I-GENE
, O
is O
functionally O
and O
structurally O
conserved O
among O
eukaryotes O
and O
indicate O
that O
the O
plant I-GENE
RPT I-GENE
subunits I-GENE
, O
like O
their O
yeast O
counterparts O
, O
have O
non O
- O
redundant O
functions O
. O

Epidemiologic O
evidence O
indicates O
that O
estrogen O
replacement O
therapy O
after O
menopause O
increases O
breast O
cancer O
risk O
. O

In O
addition O
to O
its O
elongation O
activity O
, O
ELL I-GENE
contains O
a O
novel O
type O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
interaction I-GENE
domain I-GENE
that O
is O
capable O
of O
repressing O
polymerase O
activity O
in O
promoter O
- O
specific O
transcription O
. O

A O
diagnosis O
of O
IgA I-GENE
lambda I-GENE
multiple O
myeloma O
with O
peritoneal O
involvement O
was O
made O
. O

The O
radiation O
burden O
associated O
with O
the O
majority O
of O
examinations O
in O
nuclear O
medicine O
expressed O
as O
the O
effective O
dose O
is O
comparable O
with O
the O
radiation O
burden O
of O
radiodiagnostic O
examinations O
, O
only O
after O
administration O
of O
preparations O
with O
131I O
, O
201Tl O
, O
67Ga O
and O
111In O
it O
is O
markedly O
higher O
. O

Although O
the O
risk O
of O
malformation O
in O
children O
born O
after O
ICSI O
is O
not O
increased O
there O
is O
an O
increased O
risk O
to O
transmit O
genetic O
abnormalities O
in O
case O
of O
NOA O
( O
such O
as O
the O
rate O
of O
sex O
chromosome O
, O
or O
microdeletions O
of O
the O
Y O
chromosome O
) O
and O
in O
case O
of O
congenital O
OA O
( O
mutations O
of O
the O
cystic I-GENE
fibrosis I-GENE
gene I-GENE
). O

TaV O
particles O
have O
a O
buoyant O
density O
of O
1 O
. O
296 O
g O
/ O
cm3 O
in O
CsCl O
and O
consist O
of O
two O
capsid I-GENE
proteins I-GENE
of O
56 O
and O
6 O
kDa O
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
vibration O
- O
induced O
neural O
involvement O
can O
be O
considered O
neither O
pure O
digital O
neuropathy O
, O
nor O
definite O
CTS O
, O
as O
previously O
described O
. O

In O
about O
770 O
bp O
upstream O
region O
of O
Spam1 I-GENE
that O
has O
been O
cloned O
and O
sequenced O
, O
multiple O
transcription O
factor O
binding O
sites O
including O
a O
CRE O
( O
cAMP O
- O
responsive O
element O
) O
were O
found O
. O

The O
in O
vitro O
relaxivity O
of O
the O
complex O
is O
16 O
. O
24 O
s O
(- O
1 O
) O
mM O
(- O
1 O
). O

Structure O
and O
expression O
of O
the O
mouse I-GENE
growth I-GENE
hormone I-GENE
receptor I-GENE
/ O
growth I-GENE
hormone I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
. O

Bacterial O
recovery O
of O
SA O
from O
the O
liver O
/ O
spleen O
and O
the O
cecal O
tonsil O
in O
contact O
poults O
and O
SG O
from O
contact O
chicks O
treated O
with O
ILK I-GENE
was O
dramatically O
reduced O
when O
compared O
to O
non O
- O
treated O
contact O
poults O
and O
chicks O
. O

The O
results O
of O
the O
ISIS O
- O
2 O
trial O
and O
the O
data O
from O
the O
Antiplatelet O
Trialists O
' O
Collaboration O
indicated O
that O
aspirin O
is O
mandatory O
in O
patients O
with O
acute O
myocardial O
infarction O
and O
for O
secondary O
prevention O
. O

This O
study O
was O
performed O
to O
assess O
the O
role O
of O
additional O
diagnostic O
laparoscopy O
in O
the O
preoperative O
staging O
of O
patients O
with O
adenocarcinoma O
of O
the O
esophagus O
, O
gastric O
cancer O
and O
pancreatic O
cancer O
prior O
to O
intended O
curative O
surgery O
. O

This O
report O
presents O
state O
- O
specific O
MMRs O
for O
1987 O
- O
1996 O
, O
focusing O
on O
persistent O
disparities O
in O
maternal O
mortality O
between O
black O
and O
white O
women O
. O

Preheparin O
LPL I-GENE
mass O
level O
did O
not O
significantly O
differ O
in O
individuals O
from O
19 O
to O
70 O
years O
old O
, O
for O
both O
men O
and O
women O
. O

A O
decrease O
in O
insulin I-GENE
- O
induced O
receptor O
kinase O
activity O
was O
observed O
for O
solubilized O
chimeric O
receptors O
. O

Cat I-GENE
- I-GENE
1 I-GENE
is O
identical O
to O
the O
recently O
identified O
binding O
partner O
for O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
kinase I-GENE
( O
betaARK I-GENE
or O
GRK I-GENE
- I-GENE
2 I-GENE
), O
which O
was O
shown O
to O
have O
Arf I-GENE
- O
GAP I-GENE
activity O
. O

Cat I-GENE
proteins I-GENE
are O
tyrosine O
- O
phosphorylated O
when O
co O
- O
expressed O
in O
cells O
with O
the O
focal I-GENE
adhesion I-GENE
kinase I-GENE
Fak I-GENE
and O
Src I-GENE
. O

Immunoprecipitation O
experiments O
using O
DokR I-GENE
- I-GENE
specific I-GENE
antibodies I-GENE
revealed O
an O
interaction O
between O
endogenous I-GENE
DokR I-GENE
and O
a O
150 O
- O
kDa O
protein O
that O
is O
tyrosine O
- O
phosphorylated O
in O
EGF I-GENE
- O
stimulated O
BaF O
/ O
3 O
cells O
. O

Expansins I-GENE
are O
a O
family O
of O
proteins O
that O
catalyse O
long O
- O
term O
extension O
of O
isolated O
plant O
cell O
walls O
due O
to O
an O
as O
yet O
unknown O
biochemical O
mechanism O
. O

This O
review O
summarizes O
the O
clinical O
evidence O
to O
support O
current O
therapies O
in O
irritable O
bowel O
syndrome O
( O
IBS O
). O

The O
responsive O
region O
of O
the O
alpha I-GENE
2 I-GENE
( I-GENE
V I-GENE
) I-GENE
collagen I-GENE
gene I-GENE
was O
localized O
to O
a O
fragment O
including O
100 O
bp O
of O
basal O
promoter O
and O
150 O
bp O
of O
exon O
1 O
sequences O
, O
which O
contained O
two O
CRE O
- O
like O
elements O
. O

Furthermore O
, O
addition O
of O
B I-GENE
- I-GENE
Myb I-GENE
- O
glutathionine I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion O
protein O
inhibited O
complex O
formation O
. O

APOE I-GENE
- O
epsilon4 O
count O
predicts O
age O
when O
prevalence O
of O
AD O
increases O
, O
then O
declines O
: O
the O
Cache O
County O
Study O
. O

Repair O
of O
double O
- O
strand O
breaks O
( O
DSBs O
) O
in O
chromosomal O
DNA O
by O
nonhomologous O
end O
- O
joining O
( O
NHEJ O
) O
is O
not O
well O
characterized O
in O
the O
yeast O
Saccharomyces O
cerevisiae O
. O

A O
new O
DNA I-GENE
repair I-GENE
gene I-GENE
from O
Schizosaccharomyces O
pombe O
with O
homology O
to O
RecA I-GENE
was O
identified O
and O
characterized O
. O

Among O
mucus O
- O
secreting O
cells O
, O
the O
gastric O
gland O
mucous O
cells O
, O
Brunner O
' O
s O
glands O
, O
accessory O
glands O
of O
pancreaticobiliary O
tract O
, O
and O
pancreatic O
ducts O
exhibiting O
gastric O
metaplasia O
are O
unique O
in O
that O
they O
express O
class I-GENE
III I-GENE
mucin I-GENE
identified O
by O
paradoxical O
Con I-GENE
A I-GENE
staining O
composed O
of O
periodate O
oxidation O
, O
sodium O
borohydride O
reduction O
, O
Con I-GENE
A I-GENE
, O
and O
horseradish I-GENE
peroxidase I-GENE
reaction O
. O

The O
C O
- O
terminal O
mutants O
were O
strongly O
dominant O
over O
TraR I-GENE
, O
suggesting O
that O
they O
can O
form O
heteromultimers O
with O
the O
wild O
- O
type O
activator O
. O

Thus O
, O
elongin I-GENE
C I-GENE
is O
found O
to O
oligomerize O
in O
solution O
and O
to O
undergo O
significant O
structural O
rearrangements O
upon O
binding O
of O
two O
different O
partner O
proteins O
. O

The O
data O
imply O
that O
JAK I-GENE
/ O
STAT I-GENE
signaling O
has O
a O
role O
in O
EBV O
- O
associated O
malignancies O
. O

There O
were O
27 O
men O
and O
156 O
women O
. O

A O
., O
Bowers O
, O
K O
. O
E O
, O
and O
Matthews O
, O
C O
. O

Spfkh1 I-GENE
is O
transcribed O
in O
one O
open O
reading O
frame O
that O
contains O
the O
DNA O
binding O
domain O
, O
nuclear O
localization O
signal O
and O
transactivation O
domain O
. O

The O
molecular O
mechanism O
of O
Tax I-GENE
- O
mediated O
trans O
- O
activation O
has O
been O
well O
investigated O
. O

Gel O
filtration O
and O
co O
- O
immunoprecipitation O
analyses O
reveal O
that O
Mad2p I-GENE
tightly O
associates O
with O
another O
spindle O
checkpoint O
component O
, O
Mad1p I-GENE
. O

METHODS O
: O
109 O
suspected O
cases O
with O
SS O
underwent O
the O
biopsies O
. O

We O
also O
identify O
several O
regulatory O
domain O
mutants O
in O
which O
Cd O
( O
2 O
+) O
tolerance O
of O
the O
mutant O
strain O
and O
transport O
activity O
of O
the O
protein O
are O
dissociated O
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
- I-GENE
1 I-GENE
( I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
) I-GENE
Tat I-GENE
protein I-GENE
regulates O
transcription O
by O
stimulating O
RNA I-GENE
polymerase I-GENE
processivity O
. O

One O
of O
these O
SEBPs I-GENE
, O
SEBP2 I-GENE
, O
was O
shown O
to O
be O
the O
product O
of O
the O
homeotic I-GENE
gene I-GENE
fork I-GENE
head I-GENE
. O

Identity O
elements O
in O
tRNA O
for O
mono O
- O
and O
dimethylation O
reactions O
by O
the O
recombinant I-GENE
pfTrm1p I-GENE
were O
identified O
using O
in O
vitro O
T7 O
transcripts O
of O
33 O
variants O
of O
tRNA I-GENE
( I-GENE
Asp I-GENE
) I-GENE
and O
tRNA I-GENE
( I-GENE
Phe I-GENE
) I-GENE
from O
yeast O
. O

In O
insulin I-GENE
- O
responsive O
cells O
, O
Akt I-GENE
phosphorylates O
and O
inactivates O
the O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
( O
GSK I-GENE
- I-GENE
3 I-GENE
). O

The O
B I-GENE
cell I-GENE
antigen I-GENE
receptor I-GENE
activates O
the O
Akt I-GENE
( O
protein I-GENE
kinase I-GENE
B I-GENE
)/ O
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
signaling O
pathway O
via O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Fewer O
recombination O
events O
are O
detected O
in O
four O
different O
B O
and O
T O
cell O
lines O
that O
do O
not O
undergo O
switch O
recombination O
of O
their O
endogenous O
genes O
. O

IL I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
increase O
AND I-GENE
- I-GENE
34 I-GENE
transcript I-GENE
levels O
in O
thymic O
cortical O
reticular O
, O
thymic O
nurse O
, O
and O
fibroblast O
cell O
lines O
. O

To O
determine O
what O
role O
eIF4E I-GENE
might O
play O
in O
c I-GENE
- I-GENE
myc I-GENE
expression O
, O
the O
c I-GENE
- I-GENE
myc I-GENE
5 I-GENE
' I-GENE
untranslated I-GENE
region I-GENE
( I-GENE
UTR I-GENE
) I-GENE
was O
fused O
in O
- O
frame O
to O
CAT I-GENE
reporters I-GENE
, O
and O
several O
more O
derivative O
constructs O
were O
made O
. O

Analysis O
of O
cell O
cycle O
proteins O
showed O
that O
24 O
h O
of O
lovastatin O
treatment O
in O
the O
control O
cells O
caused O
an O
elevation O
in O
the O
levels O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p27 I-GENE
( O
kip1 I-GENE
), O
inhibition O
of O
both O
cyclin I-GENE
E I-GENE
- I-GENE
and I-GENE
cyclin I-GENE
A I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
activity O
, O
and O
decreased O
levels O
of O
hyperphosphorylated O
retinoblastoma I-GENE
protein I-GENE
( O
pRb I-GENE
). O

RESULTS O
: O
Circulating O
leptin I-GENE
concentrations O
in O
AN O
were O
3 O
. O
5 O
+/- O
0 O
. O
5 O
versus O
7 O
. O
6 O
+/- O
1 O
. O
2 O
ng O
/ O
ml O
in O
control O
subjects O
. O

Copyright O
1999 O
Academic O
Press O
. O

Oligonucleotide O
probes O
corresponding O
to O
wild O
- O
type O
and O
mutant O
EpRE O
sequences O
were O
used O
in O
gel O
- O
shift O
and O
super O
- O
shift O
analyses O
to O
identify O
proteins O
binding O
. O

PKNbeta I-GENE
had O
high O
sequence O
homology O
with O
PKNalpha I-GENE
, O
originally O
isolated O
PKN I-GENE
, O
especially O
in O
the O
repeats O
of O
charged O
amino O
acid O
- O
rich O
region O
with O
leucine O
- O
zipper O
like O
sequences O
( O
CZ O
region O
/ O
HR1 O
), O
in O
the O
carboxyl O
- O
terminal O
catalytic O
domain O
, O
and O
in O
approximately O
130 O
amino O
acid O
stretch O
( O
D O
region O
/ O
HR2 O
), O
located O
between O
CZ O
region O
/ O
HR1 O
and O
the O
catalytic O
domain O
. O

At O
baseline O
, O
serum O
levels O
of O
lycopene O
and O
FLOP O
were O
abnormally O
high O
and O
serum O
FLOP O
was O
correlated O
significantly O
with O
plasma O
cyclosporine O
levels O
( O
r O
= O
0 O
. O
646 O
, O
p O
= O
0 O
. O
016 O
). O

BACKGROUND O
: O
Chronic O
alcohol O
consumption O
has O
been O
demonstrated O
to O
be O
deleterious O
to O
bone O
health O
. O

Interestingly O
, O
following O
induction O
of O
stress O
by O
heat O
shock O
, O
high O
salt O
, O
or O
ethanol O
, O
conditions O
under O
which O
most O
mRNA O
export O
is O
blocked O
, O
Npl3p I-GENE
is O
still O
exported O
from O
the O
nucleus O
. O

For O
symptomatic O
relief O
and O
inhibition O
of O
the O
growth O
of O
the O
metastases O
interferon I-GENE
- I-GENE
a I-GENE
and O
somatostatin I-GENE
analogues O
can O
be O
employed O
. O

In O
summary O
, O
the O
no O
- O
adverse O
- O
effect O
- O
level O
for O
this O
study O
was O
determined O
to O
be O
1000 O
ppm O
, O
based O
on O
decreased O
weight O
gain O
in O
female O
rats O
, O
and O
on O
slight O
organ O
weight O
changes O
in O
both O
sexes O
at O
3000 O
ppm O
. O

Some O
of O
them O
produce O
gigantic O
sperm O
several O
times O
the O
total O
male O
body O
length O
. O

John O
leonard O
dawson O

PDGF I-GENE
A I-GENE
- I-GENE
chain I-GENE
levels O
increase O
in O
cultured O
vascular O
smooth O
muscle O
cells O
( O
SMCs O
) O
exposed O
to O
ATII I-GENE
. O

M I-GENE
- I-GENE
Ras I-GENE
interacted O
poorly O
in O
a O
yeast O
two O
- O
hybrid O
assay O
with O
multiple O
Ras I-GENE
effectors O
, O
including O
c I-GENE
- I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
, O
A I-GENE
- I-GENE
Raf I-GENE
, O
B I-GENE
- I-GENE
Raf I-GENE
, O
phosphoinositol I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
delta I-GENE
, O
RalGDS I-GENE
, O
and O
Rin1 I-GENE
. O

Deletion O
mapping O
of O
the O
human I-GENE
presenilin I-GENE
- I-GENE
1 I-GENE
( O
PS1 I-GENE
) O
promoter O
delineated O
the O
most O
active O
fragment O
from O
- O
118 O
to O
+ O
178 O
in O
relation O
to O
the O
transcription O
start O
site O
mapped O
in O
this O
study O
, O
in O
both O
human O
neuroblastoma O
SK O
- O
N O
- O
SH O
and O
hepatoma O
HepG2 O
cells O
. O

Microcirculatory O
oxygenation O
and O
shunting O
in O
sepsis O
and O
shock O
. O

Analysis O
of O
the O
E2F1 I-GENE
gene I-GENE
promoter I-GENE
showed O
that O
the O
- O
146 O
to O
- O
54 O
region O
was O
required O
for O
E2 I-GENE
- O
responsiveness O
in O
transient O
transfection O
assays O
, O
and O
subsequent O
deletion O
/ O
mutation O
analysis O
showed O
that O
a O
single O
upstream O
GC O
- O
rich O
and O
two O
downstream O
CCAAT O
- O
binding O
sites O
were O
required O
for O
transactivation O
by O
E2 I-GENE
. O

In O
the O
course O
of O
investigating O
the O
mechanisms O
by O
which O
OF5 I-GENE
and O
OF3 I-GENE
regulated O
CYP11A1 I-GENE
transcription O
, O
we O
found O
that O
OF5 I-GENE
and O
OF3 I-GENE
bound O
Sp1 I-GENE
and O
Sp3 I-GENE
in O
JEG O
- O
3 O
cells O
. O

In O
contrast O
, O
the O
differentiation O
of O
neoplastically O
transformed O
cells O
does O
not O
repress O
mitogenic O
responsiveness O
or O
junB I-GENE
or O
c I-GENE
- I-GENE
fos I-GENE
inducibility O
. O

Adipocyte O
differentiation O
of O
nontransformed O
cells O
also O
markedly O
represses O
the O
ability O
of O
SRF I-GENE
to O
bind O
to O
the O
junB I-GENE
SRE O
, O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
, O
and O
other O
SREs O
, O
as O
determined O
by O
mobility O
shift O
and O
gel O
supershift O
assays O
, O
without O
affecting O
the O
DNA O
binding O
characteristics O
of O
the O
nuclear O
protein O
SP O
- O
1 O
. O

Transformation O
blocks O
differentiation O
- O
induced O
inhibition O
of O
serum I-GENE
response I-GENE
factor I-GENE
interactions O
with O
serum O
response O
elements O
. O

The O
core I-GENE
enzyme I-GENE
is O
homologous O
to O
those O
of O
bacteriophages O
T3 O
, O
T7 O
and O
SP6 O
whereas O
the O
specificity O
factor O
shows O
similarities O
with O
bacterial I-GENE
sigma I-GENE
factors I-GENE
. O

The O
Cr I-GENE
. I-GENE
psbA I-GENE
- I-GENE
4 I-GENE
ORF I-GENE
contains O
an O
H O
- O
N O
- O
H O
motif O
, O
and O
possibly O
a O
GIY O
- O
YIG O
motif O
. O

The O
interaction O
of O
zf4 I-GENE
- I-GENE
6 I-GENE
with O
full I-GENE
- I-GENE
length I-GENE
5 I-GENE
S I-GENE
RNA I-GENE
was O
far O
more O
sensitive O
to O
non O
- O
specific O
competitor O
concentration O
than O
was O
the O
zf4 I-GENE
- I-GENE
7 I-GENE
: O
5 I-GENE
S I-GENE
RNA I-GENE
interaction O
, O
suggesting O
that O
finger O
seven O
contributes O
to O
both O
affinity O
and O
specificity O
in O
this O
protein O
: O
RNA O
interaction O
. O

The O
STAT I-GENE
protein I-GENE
accumulation O
resulting O
from O
C I-GENE
/ I-GENE
EBP I-GENE
expression O
was O
tightly O
coupled O
to O
the O
morphological O
conversion O
of O
fibroblasts O
to O
adipocytes O
and O
represents O
an O
expression O
profile O
identical O
to O
that O
reported O
for O
mature O
adipocytes O
in O
vivo O
. O

The O
median O
durations O
for O
response O
and O
survival O
time O
in O
the O
late O
phase O
II O
trial O
were O
2 O
. O
3 O
months O
and O
5 O
. O
8 O
months O
, O
respectively O
. O

The O
role O
of O
' O
scientific O
psychiatry O
' O
in O
understanding O
patients O
with O
chronic O
schizophrenia O
or O
severe O
personality O
disorder O
. O

Myocardial O
antioxidant O
enzymes O
, O
catalase I-GENE
, O
glutathione I-GENE
peroxidase I-GENE
and O
superoxide I-GENE
dismutase I-GENE
, O
in O
the O
MCT O
- O
treated O
rats O
were O
not O
different O
compared O
to O
control O
rats O
. O

The O
second O
goal O
was O
to O
ascertain O
the O
somatotopic O
arrangement O
of O
the O
GPi O
in O
PD O
. O

These O
overall O
results O
indicate O
that O
there O
is O
generally O
one O
PERV O
copy O
per O
integration O
site O
. O

The O
present O
investigation O
conducted O
in O
a O
population O
of O
258 O
dentally O
aware O
individuals O
in O
the O
age O
range O
20 O
- O
69 O
years O
, O
was O
initiated O
to O
elucidate O
the O
relationship O
between O
tobacco O
smoking O
and O
supragingival O
calculus O
, O
taking O
into O
account O
possible O
confounding O
factors O
such O
as O
age O
, O
gender O
, O
oral O
hygiene O
and O
gingival O
inflammation O
. O

OBJECTIVE O
: O
To O
determine O
whether O
administration O
of O
misoprostol O
prevents O
gastric O
hemorrhage O
in O
healthy O
dogs O
treated O
with O
high O
doses O
of O
methylprednisolone O
sodium O
succinate O
( O
MPSS O
). O

Patients O
were O
assessed O
for O
cardiac O
MIBG O
uptake O
, O
circulating O
norepinephrine O
concentration O
, O
LVEF O
, O
peak O
Vo2 O
, O
x O
- O
ray O
cardiothoracic O
ratio O
, O
M O
- O
mode O
echographic O
end O
- O
diastolic O
diameter O
and O
right O
- O
sided O
heart O
catheterization O
parameters O
. O

Nuclear O
hormone O
receptors O
( O
NRs O
) O
are O
ligand O
- O
inducible O
transcription O
factors O
that O
mediate O
critical O
functions O
in O
many O
species O
. O

These O
cells O
were O
able O
to O
present O
influenza O
virus O
particles O
to O
HLA I-GENE
- I-GENE
DR1 I-GENE
- O
restricted O
T O
cell O
clones O
. O

Sequencing O
of O
zebrafish O
( O
Danio O
rerio O
) O
bacterial O
artificial O
chromosome O
and O
P1 O
artificial O
chromosome O
genomic O
clone O
fragments O
and O
of O
cDNA O
clones O
has O
led O
to O
the O
identification O
of O
five O
new O
loci O
coding O
for O
beta O
subunits O
of O
proteasomes O
( O
PSMB I-GENE
). O

In O
addition O
to O
homologues O
of O
the O
human I-GENE
genes I-GENE
PSMB5 I-GENE
through O
PSMB9 I-GENE
, O
two O
new O
genes O
, O
PSMB11 I-GENE
and O
PSMB12 I-GENE
, O
have O
been O
found O
for O
which O
there O
are O
no O
known O
corresponding O
genes O
in O
humans O
. O

It O
applies O
Udry O
' O
s O
biosocial O
perspective O
, O
which O
attempts O
to O
reconcile O
the O
biological O
and O
sociological O
models O
of O
premarital O
sexual O
and O
reproductive O
behaviour O
. O

Weight O
and O
height O
z O
- O
scores O
were O
significantly O
associated O
with O
BMD O
z O
- O
scores O
. O

A O
limited O
sampling O
strategy O
was O
used O
based O
on O
a O
bayesian O
parameter O
estimation O
algorithm O
that O
is O
part O
of O
the O
ADAPT O
II O
software O
package O
. O

Interaction O
of O
HRI I-GENE
with O
Hsc70 I-GENE
was O
required O
for O
the O
transformation O
of O
HRI I-GENE
, O
as O
the O
Hsc70 I-GENE
antagonist O
clofibric O
acid O
inhibited O
the O
folding O
of O
HRI I-GENE
into O
a O
mature O
- O
competent O
conformation O
. O

The O
amino O
acid O
changes O
D206A O
and O
D208A O
abolish O
singly O
or O
in O
combination O
the O
exonuclease O
activity O
in O
vivo O
. O

Previous O
experimental O
evidence O
had O
indicated O
that O
Reg1 I-GENE
might O
target O
Glc7 I-GENE
to O
nuclear O
substrates O
such O
as O
the O
Snf1 I-GENE
kinase I-GENE
complex I-GENE
. O

In O
the O
budding O
yeast O
, O
Saccharomyces O
cerevisiae O
, O
replicators O
can O
function O
outside O
the O
chromosome O
as O
autonomously O
replicating O
sequence O
( O
ARS O
) O
elements O
; O
however O
, O
within O
chromosome O
III O
, O
certain O
ARSs O
near O
the O
transcriptionally O
silent O
HML I-GENE
locus I-GENE
show O
no O
replication O
origin O
activity O
. O

These O
results O
suggest O
that O
, O
for O
the O
HML I-GENE
ARS O
cluster O
( O
ARS303 I-GENE
, O
ARS320 I-GENE
, O
and O
ARS302 I-GENE
), O
inactivity O
of O
origins O
is O
independent O
of O
local O
transcriptional O
silencing O
, O
even O
though O
origins O
and O
silencers O
share O
key O
cis O
- O
and O
trans O
- O
acting O
components O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
expression O
of O
TD I-GENE
- I-GENE
IkappaBalpha I-GENE
blocked O
phorbol O
myristate O
acetate I-GENE
- I-GENE
phytohemagglutinin I-GENE
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
- O
induced O
IkappaBalpha I-GENE
gene I-GENE
transcription O
and O
abolished O
NF I-GENE
- I-GENE
kappaB I-GENE
DNA O
binding O
activity O
, O
due O
to O
the O
continued O
cytoplasmic O
sequestration O
of O
RelA I-GENE
( O
p65 I-GENE
) O
by O
TD I-GENE
- I-GENE
IkappaBalpha I-GENE
. O

( O
i O
) O
Complete O
Grb10 I-GENE
expression O
from O
cDNA O
with O
an O
ecdysone O
- O
regulated O
transient O
expression O
system O
stimulated O
PDGF I-GENE
- I-GENE
BB I-GENE
-, O
IGF I-GENE
- I-GENE
I I-GENE
, O
and O
insulin I-GENE
- O
but O
not O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
)- O
induced O
DNA O
synthesis O
in O
an O
ecdysone O
dose O
- O
responsive O
fashion O
. O

The O
analysis O
of O
two O
distinct O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathways O
shows O
that O
stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation O
, O
resulting O
in O
the O
phosphorylation O
of O
ATF I-GENE
- I-GENE
2 I-GENE
, O
c I-GENE
- I-GENE
Jun I-GENE
, O
and O
JunD I-GENE
, O
is O
required O
not O
only O
for O
the O
IL I-GENE
- I-GENE
1 I-GENE
- O
but O
also O
for O
the O
TPA O
- O
dependent O
induction O
, O
while O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
1 I-GENE
( O
ERK I-GENE
- I-GENE
1 I-GENE
) O
and O
ERK I-GENE
- I-GENE
2 I-GENE
activation O
is O
involved O
in O
the O
TPA O
- O
but O
not O
in O
the O
IL I-GENE
- I-GENE
1 I-GENE
- O
dependent O
stimulation O
of O
the O
uPA I-GENE
enhancer I-GENE
. O

CONCLUSIONS O
: O
In O
healthy O
individuals O
, O
whole O
body O
insulin I-GENE
sensitivity O
is O
related O
, O
or O
" O
coupled O
, O
" O
to O
the O
anaerobic O
threshold O
. O

Interdomain O
signaling O
in O
a O
two O
- O
domain O
fragment O
of O
the O
human I-GENE
glucocorticoid I-GENE
receptor I-GENE
. O

In O
contrast O
, O
the O
xtRNA I-GENE
( O
Sec I-GENE
) O
gene O
needs O
the O
binding O
of O
the O
seven O
Staf I-GENE
zinc I-GENE
fingers I-GENE
, O
but O
not O
Oct I-GENE
- I-GENE
1 I-GENE
, O
for O
optimal O
transcriptional O
capacity O
. O

Collectively O
, O
these O
results O
show O
that O
the O
differential O
utilization O
of O
Staf I-GENE
zinc I-GENE
finger I-GENE
1 I-GENE
represents O
a O
new O
, O
critical O
determinant O
of O
the O
transcriptional O
activation O
mechanism O
for O
the O
Xenopus I-GENE
tRNA I-GENE
( O
Sec I-GENE
) O
and O
human I-GENE
U6 I-GENE
snRNA I-GENE
genes I-GENE
. O

In O
B O
cells O
, O
HEF1 I-GENE
is O
phosphorylated O
by O
a O
cytoskeleton O
- O
dependent O
mechanism O
that O
is O
triggered O
by O
integrin I-GENE
ligation O
. O

The O
calcitonin I-GENE
- O
induced O
tyrosine O
phosphorylation O
of O
HEF1 I-GENE
increased O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

Independent O
protrudor O
muscle O
stimulation O
increased O
VI O
, O
max O
( O
peak O
increase O
61 O
%, O
P O
< O
0 O
. O
05 O
), O
did O
not O
change O
Pcrit O
, O
and O
decreased O
Rn O
( O
peak O
decrease O
of O
41 O
%, O
P O
< O
0 O
. O
05 O
). O

We O
report O
the O
construction O
of O
an O
approximately O
1 O
. O
7 O
- O
Mb O
sequence O
- O
ready O
YAC O
/ O
BAC O
clone O
contig O
of O
8p22 O
- O
p23 O
. O

The O
human I-GENE
RAD30B I-GENE
and O
mouse I-GENE
Rad30b I-GENE
mRNA I-GENE
transcripts I-GENE
, O
like O
many O
repair O
proteins O
, O
are O
highly O
expressed O
in O
the O
testis O
. O

Analysis O
of O
the O
mouse I-GENE
STAP I-GENE
gene I-GENE
isolated O
from O
the O
genomic O
library O
revealed O
that O
the O
STAP I-GENE
gene I-GENE
spans O
a O
region O
of O
over O
11 O
kb O
and O
comprises O
eight O
exons O
. O

A O
reduced O
matrix O
distribution O
and O
enhanced O
cell O
density O
were O
observed O
as O
the O
biofilm O
aged O
. O

After O
10 O
months O
of O
treatment O
with O
the O
conjugated O
estrogen O
, O
both O
his O
height O
and O
weight O
showed O
improvement O
, O
while O
his O
bone O
mineral O
density O
and O
bone O
age O
were O
increased O
. O

Viscosity O
experiments O
on O
the O
catalytic O
fragment O
kinase O
reaction O
demonstrated O
that O
the O
chemical O
( O
phosphoryl O
transfer O
) O
step O
had O
a O
reduced O
rate O
. O

Velocity O
sedimentation O
, O
cross O
- O
linking O
, O
and O
immunoprecipitation O
analyses O
of O
detergent O
- O
solubilized O
rat O
brain O
revealed O
that O
the O
32 O
and O
34 O
kDa O
polypeptides O
reside O
within O
heterotetramers O
. O

In O
vitro O
expression O
levels O
of O
the O
different O
plasmids O
differed O
by O
as O
much O
as O
tenfold O
. O

In O
EEG O
only O
single O
slow O
waves O
above O
left O
temporal O
region O
were O
revealed O
. O

Molecular O
characterization O
of O
type O
- O
specific O
capsular O
polysaccharide O
biosynthesis O
genes O
of O
Streptococcus O
agalactiae O
type O
Ia O
. O

( O
1998 O
) O
FASEB O
J O
. O

IL I-GENE
- I-GENE
1beta I-GENE
( O
10 O
ng O
/ O
ml O
) O
drastically O
increased O
both O
PDGFalphaR I-GENE
and O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
delta I-GENE
( O
C I-GENE
/ I-GENE
EBPdelta I-GENE
) O
mRNA O
levels O
in O
a O
time O
dependent O
manner O
. O

The O
recruitment O
of O
constitutively O
phosphorylated O
p185 I-GENE
( O
neu I-GENE
) O
and O
the O
activated O
mitogenic O
pathway O
proteins O
to O
this O
membrane O
- O
microfilament O
interaction O
site O
provides O
a O
physical O
model O
for O
integrating O
the O
assembly O
of O
the O
mitogenic O
pathway O
with O
the O
transmission O
of O
growth O
factor O
signal O
to O
the O
cytoskeleton O
. O

Transient O
tyrosine O
phosphorylation O
of O
Crk I-GENE
in O
fibroblast I-GENE
growth I-GENE
factor I-GENE
- I-GENE
2 I-GENE
- O
stimulated O
endothelial O
cells O
was O
dependent O
on O
the O
juxtamembrane O
tyrosine O
residue O
463 O
in O
FGFR I-GENE
- I-GENE
1 I-GENE
, O
and O
a O
Crk I-GENE
SH2 I-GENE
domain I-GENE
precipitated O
FGFR I-GENE
- I-GENE
1 I-GENE
via O
phosphorylated O
Tyr O
- O
463 O
, O
indicating O
direct O
complex O
formation O
between O
Crk I-GENE
and O
FGFR I-GENE
- I-GENE
1 I-GENE
. O

ECG O
- O
gated O
myocardial O
Technetium O
- O
99m O
sestamibi O
SPECT O
is O
a O
useful O
technique O
to O
measure O
myocardial O
perfusion O
and O
function O
simultaneously O
. O

Role O
of O
the O
3 O
' O
untranslated O
region O
of O
baculovirus I-GENE
p10 I-GENE
mRNA I-GENE
in O
high O
- O
level O
expression O
of O
foreign O
genes O
. O

The O
intron O
RNA O
consists O
of O
2492 O
nucleotides O
which O
can O
be O
folded O
into O
a O
secondary O
structure O
with O
all O
the O
expected O
sequence O
motifs O
of O
subgroup O
- O
IIA1 O
introns O
( O
Michel O
et O
al O
. O

The O
intron O
is O
capable O
of O
splicing O
despite O
the O
fact O
that O
both O
the O
EBS1 I-GENE
/ O
IBS1 I-GENE
and O
the O
EBS2 I-GENE
/ O
IBS2 I-GENE
sequence O
motifs O
, O
thought O
to O
be O
necessary O
for O
correct O
splicing O
, O
extend O
over O
5 O
instead O
of O
6 O
bp O
. O

The O
Trk I-GENE
/ I-GENE
Nerve I-GENE
Growth I-GENE
Factor I-GENE
receptor I-GENE
mediates O
the O
rapid O
activation O
of O
a O
number O
of O
intracellular O
signaling O
proteins O
, O
including O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
). O

The O
controversy O
of O
significance O
testing O
: O
misconceptions O
and O
alternatives O
. O

Chemical O
uptake O
into O
human O
stratum O
corneum O
in O
vivo O
from O
volatile O
and O
non O
- O
volatile O
solvents O
. O

Like O
DNA O
binding O
, O
transcriptional O
enhancement O
required O
amino O
- O
terminally O
located O
basic O
amino O
acid O
residues O
but O
not O
the O
carboxyl O
- O
terminal O
portion O
of O
Hap46 I-GENE
known O
to O
participate O
in O
hsp70 I-GENE
interaction O
. O

We O
have O
tested O
the O
function O
of O
two O
potential O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
like I-GENE
sites I-GENE
present O
in O
the O
PAI I-GENE
- I-GENE
2 I-GENE
proximal I-GENE
promoter I-GENE
for O
responsiveness O
to O
TNFalpha I-GENE
using O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
reporter I-GENE
gene I-GENE
deletion O
and O
mutation O
analyses O
. O

N O
- O
terminal O
sequence O
analysis O
and O
NMR O
measurements O
revealed O
that O
this O
fragment O
originates O
from O
the O
C O
- O
terminal O
80 O
residues O
of O
MBF1 I-GENE
and O
form O
a O
well O
structured O
C O
- O
terminal O
domain O
of O
MBF1 I-GENE
, O
MBF1CTD I-GENE
. O

The O
nucleosomal O
response O
associated O
with O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
is O
mediated O
via O
alternative O
MAP I-GENE
kinase I-GENE
cascades I-GENE
: O
MSK1 I-GENE
as O
a O
potential O
histone I-GENE
H3 I-GENE
/ O
HMG I-GENE
- I-GENE
14 I-GENE
kinase O
. O

The O
arrangement O
of O
these O
cutoff O
- O
levels O
leads O
to O
a O
sensitivity O
of O
85 O
% O
at O
a O
specificity O
of O
55 O
% O
for O
Protein I-GENE
S100 I-GENE
when O
measured O
by O
RIA O
, O
and O
to O
a O
sensitivity O
of O
77 O
% O
at O
a O
specificity O
of O
61 O
% O
when O
measured O
by O
LIA O
. O

272 O
, O
1904 O
]. O

Using O
16 O
strains O
of O
C O
. O
trachomatis O
in O
triplicate O
assays O
, O
we O
found O
the O
RT O
- O
PCR O
method O
consistently O
more O
sensitive O
than O
the O
conventional O
technique O
for O
all O
eight O
antimicrobials O
tested O
, O
with O
resultant O
MICs O
determined O
by O
RT O
- O
PCR O
ranging O
from O
1 O
. O
6 O
- O
fold O
higher O
( O
erythromycin O
) O
to O
>/= O
195 O
- O
fold O
higher O
( O
amoxicillin O
). O

Null O
alleles O
of O
SAS4 I-GENE
and O
SAS5 I-GENE
bypassed O
the O
role O
of O
the O
Abf1p I-GENE
binding I-GENE
site I-GENE
of O
the O
HMR I-GENE
- I-GENE
E I-GENE
silencer I-GENE
but O
not O
the O
role O
of O
the O
ACS I-GENE
or O
Rap1p I-GENE
binding I-GENE
site I-GENE
. O

Recent O
molecular O
analysis O
has O
revealed O
that O
the O
S I-GENE
locus I-GENE
is O
highly O
polymorphic O
and O
contains O
several O
genes O
, O
i O
. O
e O
., O
SLG I-GENE
, O
SRK I-GENE
, O
the O
as O
- O
yet O
- O
unidentified O
pollen O
S O
gene O
( O
s O
), O
and O
other O
linked O
genes O
. O

A O
cDNA O
encoding O
a O
putative O
RNA I-GENE
and I-GENE
/ I-GENE
or I-GENE
DNA I-GENE
helicase I-GENE
has O
been O
isolated O
from O
Arabidopsis O
thaliana O
cDNA O
libraries O
. O

In O
vivo O
, O
MyoD I-GENE
requires O
this O
tryptophan O
motif O
to O
evoke O
chromatin O
remodeling O
in O
the O
Myogenin I-GENE
promoter I-GENE
and O
to O
activate O
Myogenin I-GENE
transcription O
. O

RESULTS O
: O
256 O
Periods O
of O
TTP O
or O
PUNP O
were O
reported O
by O
men O
and O
174 O
by O
women O
. O

Feed O
intake O
and O
BW O
gains O
were O
decreased O
( O
P O
< O
0 O
. O
05 O
) O
by O
dietary O
treatments O
containing O
M O
. O

The O
N O
terminus O
of O
beta O
( O
95 O
kDa O
) O
corresponds O
to O
alpha O
with O
the O
integrase I-GENE
domain I-GENE
attached O
to O
the O
C O
terminus O
( O
32 O
kDa O
). O

Skn I-GENE
- I-GENE
1a I-GENE
lacking O
the O
C O
- O
terminal O
region O
completely O
lost O
transactivation O
ability O
, O
irrespective O
of O
the O
promoter O
tested O
, O
and O
was O
able O
to O
block O
transactivation O
by O
normal O
Skn I-GENE
- I-GENE
1a I-GENE
in O
competition O
assays O
. O

In O
early O
Xenopus O
embryos O
, O
the O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
member O
activin I-GENE
induces O
the O
gene I-GENE
Mix I-GENE
. I-GENE
2 I-GENE
by O
stimulating O
the O
formation O
of O
a O
multiprotein O
complex O
, O
activin I-GENE
- I-GENE
responsive I-GENE
factor I-GENE
( O
ARF I-GENE
). O

To O
further O
characterize O
the O
structure O
and O
evolutionary O
synthesis O
of O
the O
CMT1A O
- O
REP O
repeat O
, O
fluorescent O
in O
situ O
hybridization O
( O
FISH O
) O
analysis O
and O
heterologous O
PCR O
- O
based O
assays O
were O
carried O
out O
for O
a O
series O
of O
primates O
. O

Natl O
. O

In O
the O
face O
of O
the O
outbreak O
, O
there O
was O
a O
delay O
before O
vaccination O
was O
able O
to O
stop O
deaths O
. O

Here O
we O
show O
that O
a O
novel O
isoform O
of O
Rapl I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
called O
rap1GAPII I-GENE
, O
binds O
specifically O
to O
the O
alpha O
- O
subunits O
of O
the O
G I-GENE
( I-GENE
i I-GENE
) I-GENE
family I-GENE
of O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
. O

The O
B O
- O
oligomer O
of O
pertussis I-GENE
toxin I-GENE
deactivates O
CC I-GENE
chemokine I-GENE
receptor I-GENE
5 I-GENE
and O
blocks O
entry O
of O
M O
- O
tropic O
HIV O
- O
1 O
strains O
. O

Cross O
- O
linking O
the O
B I-GENE
cell I-GENE
Ag I-GENE
receptor I-GENE
( O
BCR I-GENE
) O
to O
surface I-GENE
Fc I-GENE
receptors I-GENE
for O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 O
- O
to O
- O
S O
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

Cross O
- O
linking O
the O
B I-GENE
cell I-GENE
Ag I-GENE
receptor I-GENE
( O
BCR I-GENE
) O
to O
surface I-GENE
Fc I-GENE
receptors I-GENE
for O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 O
- O
to O
- O
S O
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

TRAF2 I-GENE
is O
a O
potent O
activator O
of O
a O
95 I-GENE
- I-GENE
kDa I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
termed O
germinal I-GENE
center I-GENE
kinase I-GENE
related I-GENE
( O
GCKR I-GENE
, O
also O
referred O
to O
as O
KHS1 I-GENE
), O
which O
signals O
activation O
of O
the O
SAPK I-GENE
pathway O
. O

An O
activation O
- O
responsive O
element O
in O
single I-GENE
C I-GENE
motif I-GENE
- I-GENE
1 I-GENE
/ O
lymphotactin I-GENE
promoter O
is O
a O
site O
of O
constitutive O
and O
inducible O
DNA O
- O
protein O
interactions O
involving O
nuclear O
factor O
of O
activated O
T O
cell O
. O

Cytokine O
- O
induced O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
DNA O
binding O
activity O
, O
RelA I-GENE
nuclear O
translocation O
, O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
degradation O
, O
I I-GENE
kappa I-GENE
B I-GENE
serine O
32 O
phosphorylation O
, O
and O
I I-GENE
kappa I-GENE
B I-GENE
kinase I-GENE
( O
IKK I-GENE
) O
activity O
were O
blocked O
by O
curcumin O
treatment O
. O

A O
portion O
of O
p193 I-GENE
is O
nuclear O
and O
localizes O
to O
the O
mitotic O
spindle O
. O

The O
main O
issues O
are O
the O
need O
to O
explain O
a O
number O
of O
still O
unknown O
mechanisms O
, O
to O
determine O
which O
" O
natural O
diet O
" O
carries O
the O
minimum O
coronary O
risk O
and O
whether O
" O
new O
" O
foods O
produced O
by O
modern O
technology O
are O
really O
needed O
to O
contrast O
this O
epidemic O
. O

Cotransfection O
of O
the O
coactivator O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
relieved O
the O
transcriptional O
repression O
of O
PPARalphawt I-GENE
by O
PPARalphatr I-GENE
, O
suggesting O
that O
the O
dominant O
negative O
effect O
of O
PPARalphatr I-GENE
might O
occur O
through O
competition O
for O
essential O
coactivators O
. O

SF I-GENE
- I-GENE
1 I-GENE
does O
not O
have O
an O
N O
- O
terminal O
AF1 O
domain O
. O

To O
estimate O
the O
locations O
of O
sources O
with O
the O
TF O
- O
MUSIC O
algorithm O
, O
we O
first O
set O
the O
target O
region O
on O
the O
spectrogram O
of O
the O
somatosensory O
responses O
. O

We O
discuss O
these O
results O
in O
terms O
of O
the O
influence O
that O
time O
and O
nutritional O
constraints O
have O
on O
odonate O
development O
patterns O
and O
fitness O
. O

OBJECTIVE O
: O
1998 O
Surveillance O
, O
Epidemiology O
, O
and O
End O
Results O
( O
SEER O
) O
data O
estimate O
an O
83 O
. O
1 O
% O
5 O
- O
year O
survival O
rate O
for O
corpus O
uteri O
adenocarcinoma O
FIGO O
stage O
II O
. O

A O
novel O
Drosophila I-GENE
A I-GENE
kinase I-GENE
anchor I-GENE
protein I-GENE
, O
Drosophila I-GENE
A I-GENE
kinase I-GENE
anchor I-GENE
protein I-GENE
200 I-GENE
( O
DAKAP200 I-GENE
), O
is O
predicted O
to O
be O
involved O
in O
routing O
, O
mediating O
, O
and O
integrating O
signals O
carried O
by O
cAMP O
, O
Ca O
( O
2 O
+), O
and O
diacylglycerol O
( O
Li O
, O
Z O
., O
Rossi O
, O
E O
. O

In O
vitro O
transcription O
results O
indicate O
that O
this O
5 O
' O
structure O
functions O
in O
the O
attenuation O
mechanism O
, O
since O
deletion O
of O
the O
stem O
- O
loop O
caused O
an O
increase O
in O
transcription O
readthrough O
. O

A O
5 O
' O
RNA O
stem O
- O
loop O
participates O
in O
the O
transcription O
attenuation O
mechanism O
that O
controls O
expression O
of O
the O
Bacillus I-GENE
subtilis I-GENE
trpEDCFBA I-GENE
operon I-GENE
. O

Single O
- O
alanine O
- O
substitution O
mutations O
had O
minimal O
, O
if O
any O
, O
effects O
on O
S O
- O
induced O
cell O
- O
to O
- O
cell O
fusion O
. O

Furthermore O
, O
we O
demonstrate O
that O
transcription O
from O
the O
MMTV I-GENE
5 I-GENE
' I-GENE
LTR I-GENE
is O
highly O
active O
in O
the O
absence O
of O
Stat5a I-GENE
, O
a O
transcription O
factor O
that O
had O
been O
shown O
previously O
to O
be O
required O
for O
transcription O
from O
the O
MMTV I-GENE
LTR I-GENE
. O

Regional O
insertional O
mutagenesis O
of O
specific O
genes O
on O
the O
CIC5F11 I-GENE
/ O
CIC2B9 I-GENE
locus O
of O
Arabidopsis O
thaliana O
chromosome O
5 O
using O
the O
Ac I-GENE
/ O
Ds I-GENE
transposon O
in O
combination O
with O
the O
cDNA O
scanning O
method O
. O

RESULTS O
: O
CK I-GENE
- O
MB I-GENE
elevation O
was O
detected O
in O
313 O
patients O
( O
18 O
. O
7 O
%), O
with O
1 O
- O
3x O
in O
12 O
. O
8 O
%, O
3 O
- O
5x O
in O
3 O
. O
5 O
% O
and O
> O
5x O
normal O
in O
2 O
. O
4 O
% O
of O
patients O
. O

Thus O
, O
NART O
- O
R O
performance O
may O
not O
be O
a O
valid O
estimate O
of O
baseline O
IQ O
for O
patients O
with O
neurologic O
disorders O
with O
suspected O
language O
impairment O
. O

Activated O
areas O
have O
been O
identified O
by O
means O
of O
cross O
- O
correlation O
analysis O
. O

Natural O
Haemophilus O
influenzae O
type O
b O
capsular O
polysaccharide O
antibodies O
in O
412 O
infants O
and O
children O
from O
West O
Africa O
( O
Burkina O
- O
Faso O
) O
and O
France O
: O
a O
cross O
- O
sectional O
serosurvey O
. O

In O
this O
study O
, O
we O
identified O
Sp1 I-GENE
and O
Sp3 I-GENE
as O
major O
factors O
binding O
to O
the O
Sp1 I-GENE
sites I-GENE
of O
the O
p21 I-GENE
/ O
WAF1 I-GENE
/ O
Cip1 I-GENE
promoter O
in O
MG63 O
cells O
through O
electrophoretic O
mobility O
shift O
assays O
and O
showed O
that O
TSA O
treatment O
did O
not O
change O
their O
binding O
activities O
. O

Galoyan O
has O
summarized O
the O
results O
of O
his O
discovery O
of O
cardioactive O
neurohormones O
. O

To O
study O
the O
regulation O
of O
its O
expression O
, O
the O
human I-GENE
aldehyde I-GENE
reductase I-GENE
gene I-GENE
and O
promoter O
were O
cloned O
and O
characterized O
. O

Immunohistochemical O
staining O
with O
MIB I-GENE
- I-GENE
1 I-GENE
and O
p53 I-GENE
antibodies I-GENE
showed O
low O
(< O
1 O
%) O
and O
negative O
reaction O
. O

The O
C2C I-GENE
- O
Prx I-GENE
is O
encoded O
as O
a O
preprotein O
of O
273 O
amino O
acids O
containing O
a O
putative O
chloroplast O
- O
targeting O
signal O
of O
65 O
amino O
acids O
at O
its O
N O
- O
terminus O
. O

Immediately O
before O
surgery O
patients O
received O
either O
intravenous O
hydrocortisone O
100 O
mg O
or O
placebo O
in O
random O
, O
double O
- O
blind O
order O
. O

A O
tyrosine O
- O
based O
sorting O
signal O
in O
the O
beta2 I-GENE
integrin I-GENE
cytoplasmic I-GENE
domain I-GENE
mediates O
its O
recycling O
to O
the O
plasma O
membrane O
and O
is O
required O
for O
ligand O
- O
supported O
migration O
. O

The O
injection O
of O
XDRP1 I-GENE
protein I-GENE
into O
fertilized O
Xenopus O
eggs O
blocked O
embryonic O
cell O
division O
. O

Using O
transgenic O
Xenopus O
embryos O
, O
we O
demonstrate O
that O
the O
integrity O
of O
these O
two O
sequences O
is O
necessary O
for O
correct O
spatial O
expression O
of O
a O
Xbra2 I-GENE
promoter I-GENE
- I-GENE
driven I-GENE
reporter I-GENE
gene I-GENE
. O

In O
order O
to O
screen O
for O
such O
cofactors O
, O
we O
have O
used O
a O
transcriptionally O
inactive O
mutant O
of O
Xenopus I-GENE
MEF2D I-GENE
in O
a O
yeast O
two O
- O
hybrid O
screen O
. O

NuA4 I-GENE
has O
an O
apparent O
molecular O
mass O
of O
1 O
. O
3 O
MDa O
. O

ATF1 I-GENE
transcription O
is O
negatively O
regulated O
by O
unsaturated O
fatty O
acids O
and O
oxygen O
. O

Two O
patients O
with O
recurrent O
tumors O
had O
high O
S O
- O
phase O
fractions O
both O
on O
the O
first O
resected O
specimens O
and O
at O
the O
time O
of O
the O
second O
operation O
. O

Mutation O
of O
TTF I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( I-GENE
TBE I-GENE
) I-GENE
1 I-GENE
, I-GENE
3 I-GENE
, I-GENE
and I-GENE
4 I-GENE
in O
combination O
markedly O
decreased O
transcriptional O
activity O
of O
SP I-GENE
- I-GENE
A I-GENE
promoter O
- O
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs O
containing O
SP I-GENE
- I-GENE
A I-GENE
gene I-GENE
sequences O
from O
- O
256 O
to O
+ O
45 O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
induces O
bcl I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
through O
the O
transcription O
factor O
cAMP I-GENE
- I-GENE
response I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Synthesis O
of O
antisense O
RNA O
and O
S O
phase O
- O
dependent O
binding O
of O
E2F I-GENE
complexes I-GENE
in O
intron O
1 O
. O

Identification O
of O
eotaxin I-GENE
- I-GENE
3 I-GENE
will O
further O
promote O
our O
understanding O
of O
the O
control O
of O
eosinophil O
trafficking O
and O
other O
CCR3 I-GENE
- O
mediated O
biological O
phenomena O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
plays O
a O
critical O
role O
in O
activation O
of O
HIV O
- O
1 O
gene O
expression O
by O
cytokines O
and O
other O
stimuli O
, O
but O
the O
signal O
transduction O
pathways O
that O
regulate O
the O
switch O
from O
latent O
to O
productive O
infection O
have O
not O
been O
defined O
. O

These O
studies O
suggest O
that O
MAPK I-GENE
acts O
by O
stimulating O
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
subsequent O
physical O
and O
functional O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
with O
NF I-GENE
- I-GENE
kappaB I-GENE
, O
resulting O
in O
a O
complex O
that O
synergistically O
transactivates O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

ERK I-GENE
MAP I-GENE
kinase I-GENE
links O
cytokine O
signals O
to O
activation O
of O
latent O
HIV O
- O
1 O
infection O
by O
stimulating O
a O
cooperative O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
and O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

A O
human O
nuclear O
- O
localized O
chaperone O
that O
regulates O
dimerization O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
bZIP I-GENE
proteins I-GENE
. O

Clinical O
differentiation O
of O
patients O
with O
mild O
diplegic O
cerebral O
palsy O
( O
CP O
) O
and O
idiopathic O
toe O
walking O
( O
ITW O
) O
can O
be O
difficult O
. O

Sputum I-GENE
IL I-GENE
- I-GENE
8 I-GENE
and O
MPO I-GENE
were O
significantly O
increased O
after O
BPT O
in O
both O
TDI O
- O
and O
grain O
dust O
- O
asthma O
( O
P O
< O
0 O
. O
05 O
). O

Montelukast O
reduces O
airway O
eosinophilic O
inflammation O
in O
asthma O
: O
a O
randomized O
, O
controlled O
trial O
. O

Treatment O
of O
unstable O
angina O
: O
role O
of O
antithrombotic O
therapy O
. O

Here O
, O
we O
demonstrate O
that O
kinase O
- O
dead O
but O
not O
wild O
- O
type O
forms O
of O
Fyn I-GENE
, O
Lck I-GENE
, O
and O
ZAP I-GENE
- I-GENE
70 I-GENE
block O
70Z O
Cbl I-GENE
- O
mediated O
NFAT I-GENE
activation O
. O

Substitutions O
of O
region O
I O
with O
synthetic O
sequences O
showed O
that O
no O
specific O
sequence O
but O
rather O
repeats O
of O
three O
or O
more O
consecutive O
adenines O
or O
thymines O
, O
without O
interruption O
by O
guanine O
or O
cytosine O
, O
are O
required O
for O
the O
ARS O
activity O
. O

In O
Saccharomyces O
cerevisiae O
, O
PHO85 I-GENE
encodes O
a O
cyclin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
catalytic O
subunit O
with O
multiple O
regulatory O
roles O
thought O
to O
be O
specified O
by O
association O
with O
different O
cyclin I-GENE
partners O
( O
Pcls I-GENE
). O

Mutants O
with O
mild O
lace I-GENE
alleles I-GENE
grow O
to O
become O
adults O
with O
multiple O
aberrant O
morphologies O
in O
the O
appendages O
, O
compound O
eye O
, O
and O
bristles O
. O

In O
fact O
, O
SPT I-GENE
activity O
in O
the O
fly O
expressing O
epitope O
- O
tagged O
Lace I-GENE
was O
absorbed O
by O
epitope O
- O
specific O
antibody O
. O

Mutations O
of O
the O
RET I-GENE
gene I-GENE
, O
encoding O
a O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
, O
have O
been O
associated O
with O
the O
inherited O
cancer O
syndromes O
MEN O
2A O
and O
MEN O
2B O
. O

These O
results O
show O
that O
targeting O
of O
Ras I-GENE
- O
GAP I-GENE
could O
represent O
a O
novel O
anticancer O
approach O
. O

EB I-GENE
- I-GENE
1 I-GENE
, O
a O
tyrosine I-GENE
kinase I-GENE
signal I-GENE
transduction I-GENE
gene I-GENE
, O
is O
transcriptionally O
activated O
in O
the O
t O
( O
1 O
; O
19 O
) O
subset O
of O
pre O
- O
B O
ALL O
, O
which O
express O
oncoprotein O
E2a I-GENE
- O
Pbx1 I-GENE
. O

Protein I-GENE
kinase I-GENE
A I-GENE
- I-GENE
Ialpha I-GENE
subunit O
- O
directed O
antisense O
inhibition O
of O
ovarian O
cancer O
cell O
growth O
: O
crosstalk O
with O
tyrosine I-GENE
kinase I-GENE
signaling O
pathway O
. O

BCL6 I-GENE
encodes O
a O
POZ I-GENE
/ I-GENE
Zn I-GENE
finger I-GENE
protein I-GENE
, O
a O
structure O
similar O
to O
that O
of O
many O
Drosophila O
developmental O
regulators O
and O
to O
another O
protein O
involved O
in O
a O
human O
hematopoietic O
malignancy O
, O
PLZF I-GENE
. O

Beta I-GENE
1 I-GENE
integrin I-GENE
- O
and O
proteoglycan O
- O
mediated O
stimulation O
of O
T O
lymphoma O
cell O
adhesion O
and O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
by O
thrombospondin I-GENE
- I-GENE
1 I-GENE
and O
thrombospondin I-GENE
- I-GENE
1 I-GENE
peptides I-GENE
. O

Optical O
CD O
, O
and O
spectral O
and O
activity O
analyses O
were O
used O
to O
examine O
reactivity O
of O
HO I-GENE
isozymes I-GENE
with O
NO O
species O
produced O
by O
NO O
donors O
. O

The O
phosphotransferase O
system O
( O
PTS O
) O
of O
Streptomyces O
coelicolor O
identification O
and O
biochemical O
analysis O
of O
a O
histidine I-GENE
phosphocarrier I-GENE
protein I-GENE
HPr I-GENE
encoded O
by O
the O
gene O
ptsH I-GENE
. O

Serum O
concentrations O
of O
bone I-GENE
specific I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
BALP I-GENE
) O
and O
osteocalcin I-GENE
( O
bone I-GENE
Gla I-GENE
protein I-GENE
, O
BGP I-GENE
), O
urinary O
levels O
of O
pyridinoline O
( O
Pyr O
) O
and O
deoxypyridinoline O
( O
Dpyr O
) O
and O
computed O
tomography O
( O
CT O
) O
measurements O
of O
the O
cross O
- O
sectional O
areas O
of O
the O
vertebrae O
and O
the O
femurs O
, O
the O
apparent O
density O
of O
cancellous O
bone O
in O
the O
vertebrae O
, O
and O
the O
volume O
and O
the O
material O
density O
of O
cortical O
bone O
in O
the O
femurs O
were O
determined O
in O
126 O
boys O
and O
143 O
girls O
, O
ages O
7 O
- O
18 O
years O
. O

In O
another O
study O
, O
intravenous O
administration O
of O
devazepide O
, O
a O
specific O
cholecystokinin I-GENE
- I-GENE
A I-GENE
receptor I-GENE
antagonist O
, O
at O
a O
dose O
of O
0 O
. O
1 O
mg O
/ O
kg O
/ O
hr O
was O
begun O
15 O
min O
before O
postprandial O
saline O
intake O
and O
continued O
for O
1 O
hr O
. O

This O
cluster O
consisted O
of O
four O
apparently O
unrelated O
ESTs O
and O
two O
genes O
, O
pregnancy I-GENE
- I-GENE
associated I-GENE
plasma I-GENE
protein I-GENE
- I-GENE
A I-GENE
( O
PAPP I-GENE
- I-GENE
A I-GENE
) O
and O
a O
novel O
gene O
( O
tentatively O
named O
EST I-GENE
- I-GENE
YD1 I-GENE
). O

Prognostic O
value O
of O
a O
treadmill O
exercise O
score O
in O
symptomatic O
patients O
with O
nonspecific O
ST O
- O
T O
abnormalities O
on O
resting O
ECG O
. O

Structural O
changes O
in O
the O
C O
- O
terminus O
of O
Ca2 O
+- O
bound O
rat I-GENE
S100B I-GENE
( O
beta I-GENE
beta I-GENE
) O
upon O
binding O
to O
a O
peptide O
derived O
from O
the O
C O
- O
terminal O
regulatory O
domain O
of O
p53 I-GENE
. O

We O
propose O
that O
Gly84 O
is O
part O
of O
a O
putative O
" O
oxyanion O
hole O
" O
involved O
in O
the O
stabilization O
of O
the O
transition O
state O
similar O
to O
the O
C I-GENE
group I-GENE
of O
the O
esterase I-GENE
/ O
lipase I-GENE
family O
. O

The O
solution O
structure O
of O
the O
adduct O
derived O
from O
the O
covalent O
bonding O
of O
the O
fjord O
region O
(+)-( O
11S O
, O
12R O
, O
13R O
, O
14S O
) O
stereoisomer O
of O
anti O
- O
11 O
, O
12 O
- O
dihydroxy O
- O
13 O
, O
14 O
- O
epoxy O
- O
11 O
, O
12 O
, O
13 O
, O
14 O
- O
tetrahydrobenzo O
[ O
g O
] O
chrysene O
, O
(+)- O
anti O
- O
B O
[ O
g O
] O
CDE O
, O
to O
the O
exocyclic O
N O
( O
6 O
) O
amino O
group O
of O
the O
adenine O
residue O
dA6 O
, O
( O
designated O
(+)- O
trans O
- O
anti O
-( O
B O
[ O
g O
] O
C O
) O
dA6 O
), O
positioned O
opposite O
a O
thymine O
residue O
dT17 O
in O
the O
DNA O
sequence O
context O
d O
( O
C1 O
- O
T2 O
- O
C3 O
- O
T4 O
- O
C5 O
-( O
B O
[ O
g O
] O
C O
) O
A6 O
- O
C7 O
- O
T8 O
- O
T9 O
- O
C10 O
- O
C11 O
). O
d O
( O
G12 O
- O
G13 O
- O
A14 O
- O
A15 O
- O
G16 O
- O
T17 O
- O
G18 O
- O
A19 O
- O
G20 O
++ O
+- O
A21 O
- O
G22 O
) O
( O
designated O
( O
B O
[ O
g O
] O
C O
) O
dA O
. O
dT O
11 O
- O
mer O
duplex O
), O
has O
been O
studied O
using O
structural O
information O
derived O
from O
NMR O
data O
in O
combination O
with O
molecular O
dynamics O
( O
MD O
) O
calculations O
. O

Since O
sildenafil O
came O
on O
the O
market O
, O
it O
seems O
that O
the O
place O
of O
MUSE O
is O
reduced O
because O
comparative O
studies O
give O
better O
results O
for O
sildenafil O
than O
MUSE O
( O
70 O
% O
vs O
40 O
%) O
and O
of O
course O
with O
a O
better O
acceptance O
. O

Serum O
antibodies O
were O
detected O
in O
at O
least O
95 O
% O
of O
the O
infected O
guinea O
pigs O
between O
4 O
- O
30 O
WPI O
and O
rats O
between O
3 O
- O
16 O
WPI O
. O

During O
both O
encephalopathy O
episodes O
, O
CSF O
protein O
and O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
levels O
were O
elevated O
without O
an O
increased O
IgG I-GENE
index O
or O
IgG I-GENE
synthesis O
rate O
. O

CONCLUSIONS O
: O
These O
results O
show O
that O
once O
daily O
oral O
valganciclovir O
can O
produce O
exposures O
of O
ganciclovir O
( O
AUC24 O
) O
exceeding O
those O
attained O
using O
intravenous O
ganciclovir O
10 O
mg O
/ O
kg O
. O

Except O
for O
nonperfusion O
of O
neurosensory O
retinal O
vessels O
at O
a O
light O
dose O
of O
150 O
J O
/ O
cm2 O
, O
no O
other O
adverse O
events O
were O
of O
concern O
. O

Except O
for O
nonperfusion O
of O
neurosensory O
retinal O
vessels O
at O
a O
light O
dose O
of O
150 O
J O
/ O
cm2 O
, O
no O
other O
adverse O
events O
were O
of O
concern O
. O

The O
healing O
rate O
in O
HIV O
- O
positive O
patients O
was O
66 O
percent O
after O
14 O
weeks O
and O
100 O
percent O
after O
32 O
weeks O
; O
the O
corresponding O
figures O
for O
patients O
with O
acquired O
immunodeficiency O
syndrome O
were O
0 O
and O
50 O
percent O
. O

The O
P I-GENE
mRNA I-GENE
also O
contains O
a O
third O
ORF O
for O
the O
V I-GENE
protein I-GENE
, O
although O
it O
is O
unclear O
how O
or O
whether O
this O
ORF O
is O
accessed O
. O

A O
genetic O
screen O
in O
yeast O
has O
allowed O
us O
to O
identify O
a O
novel O
transcriptional O
factor O
binding O
to O
the O
GlRE O
, O
i O
. O
e O
. O
the O
chicken I-GENE
ovalbumin I-GENE
upstream I-GENE
promoter I-GENE
- I-GENE
transcription I-GENE
factor I-GENE
II I-GENE
( O
COUP I-GENE
- I-GENE
TFII I-GENE
). O

We O
have O
cloned O
the O
single O
- O
copy O
gene O
for O
the O
trans I-GENE
- I-GENE
spliceosomal I-GENE
U5 I-GENE
snRNA I-GENE
from O
the O
trypanosomatid O
species O
Leptomonas O
seymouri O
, O
using O
U5 I-GENE
RNA I-GENE
affinity O
selection O
and O
cDNA O
cloning O
. O

The O
MMPI O
- O
A O
( O
Butcher O
et O
al O
., O
1992 O
), O
like O
the O
older O
MMPI O
( O
Hathaway O
& O
McKinley O
, O
1983 O
), O
distinguishes O
between O
anorexia O
and O
bulimia O
. O

On O
the O
other O
hand O
, O
phosphatidyl O
inositol O
4 O
, O
5 O
bisphosphate O
( O
PIP2 O
) O
hydrolysis O
requires O
direct O
phosphorylation O
at O
tyrosine O
residue O
of O
the O
PLC I-GENE
- I-GENE
gamma1 I-GENE
isozyme I-GENE
. O

A O
G22V I-GENE
mutant I-GENE
of O
M I-GENE
- I-GENE
Ras I-GENE
was O
constitutively O
active O
and O
its O
expression O
in O
an O
interleukin I-GENE
- I-GENE
3 I-GENE
( O
IL I-GENE
- I-GENE
3 I-GENE
)- O
dependent O
mast O
cell O
/ O
megakaryocyte O
cell O
line O
resulted O
in O
increased O
survival O
in O
the O
absence O
of O
IL I-GENE
- I-GENE
3 I-GENE
, O
increased O
growth O
in O
IL I-GENE
- I-GENE
4 I-GENE
, O
and O
, O
at O
high O
expression O
levels O
, O
in O
factor O
- O
independent O
growth O
. O

Mammalian I-GENE
M I-GENE
- I-GENE
Ras I-GENE
and O
a O
Caenorhabditis O
elegans O
orthologue O
exhibit O
conserved O
structural O
features O
, O
and O
these O
are O
likely O
to O
mediate O
activation O
of O
distinctive O
signaling O
paths O
that O
function O
in O
parallel O
to O
those O
downstream O
of O
p21 I-GENE
Ras I-GENE
. O

Taken O
together O
, O
our O
data O
suggest O
that O
PecS I-GENE
attenuates O
pelD I-GENE
and O
pelE I-GENE
expression O
rather O
than O
acting O
as O
a O
true O
repressor O
like O
KdgR I-GENE
. O

These O
observations O
establish O
that O
RsmC I-GENE
negatively O
regulates O
rsmB I-GENE
transcription O
but O
positively O
affects O
RsmA I-GENE
production O
. O

All O
were O
experienced O
hearing O
aid O
users O
who O
wore O
linear O
Class O
D O
instruments O
with O
input O
compression O
limiting O
at O
the O
time O
of O
their O
enrollment O
in O
this O
study O
. O

SCOB O
testing O
of O
food O
- O
restricted O
animals O
, O
using O
a O
multiple O
fixed O
ratio O
( O
FR O
)/ O
fixed O
interval O
( O
FI O
) O
schedule O
( O
FR20 O
: O
FI120 O
), O
was O
conducted O
prior O
to O
each O
exposure O
to O
maintain O
the O
operant O
behavior O
; O
the O
data O
from O
Weeks O
- O
1 O
, O
4 O
, O
8 O
, O
and O
13 O
were O
evaluated O
for O
evidence O
of O
neurotoxicity O
. O

Ribonuclease O
protection O
assays O
revealed O
that O
hmg1 I-GENE
and O
hmg2 I-GENE
are O
differentially O
expressed O
in O
a O
developmentally O
- O
and O
spatially O
- O
modulated O
manner O
during O
morphogenesis O
of O
specialized O
terpenoid O
- O
containing O
pigment O
glands O
in O
embryos O
. O

Differential O
expression O
was O
confirmed O
by O
Northern O
blot O
analysis O
employing O
multiple O
normal O
and O
tumor O
cell O
lines O
. O

Inactivation O
of O
the O
Neurospora I-GENE
crassa I-GENE
mitochondrial I-GENE
outer I-GENE
membrane I-GENE
protein I-GENE
TOM70 I-GENE
by O
repeat O
- O
induced O
point O
mutation O
( O
RIP O
) O
causes O
defects O
in O
mitochondrial O
protein O
import O
and O
morphology O
. O

Several O
genes O
or O
transcriptional O
units O
were O
identified O
, O
including O
the O
3 O
' O
end O
of O
ribosomal I-GENE
s6 I-GENE
kinase I-GENE
( O
Rsk3 I-GENE
); O
two O
apparently O
intronless O
and O
ORF O
- O
less O
genes O
; O
and O
Gpr31 I-GENE
, O
an O
intronless O
, O
putative O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
receptor I-GENE
. O

The O
results O
suggest O
that O
GATA I-GENE
- I-GENE
5 I-GENE
may O
have O
specific O
downstream O
targets O
and O
that O
GATA I-GENE
- I-GENE
4 I-GENE
, I-GENE
- I-GENE
5 I-GENE
, I-GENE
and I-GENE
- I-GENE
6 I-GENE
can O
only O
partially O
substitute O
for O
each O
other O
in O
cardiogenesis O
. O

This O
study O
was O
designed O
to O
compare O
the O
efficacy O
of O
efegatran O
plus O
streptokinase I-GENE
versus O
heparin O
plus O
accelerated O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
TPA I-GENE
) O
in O
coronary O
reperfusion O
in O
acute O
MI O
. O

Recently O
, O
cell O
- O
surface O
TRAIL I-GENE
has O
been O
shown O
to O
be O
expressed O
by O
activated O
human O
and O
mouse O
T O
lymphocytes O
, O
raising O
the O
possibility O
that O
TRAIL I-GENE
might O
be O
involved O
in O
T O
cell O
- O
mediated O
cytotoxicity O
and O
/ O
or O
immune O
regulation O
. O

A O
panel O
of O
pharmacologic O
inhibitors O
was O
used O
to O
investigate O
the O
signal O
transduction O
pathways O
involved O
in O
TRAIL I-GENE
gene I-GENE
induction O
following O
T O
lymphocyte O
activation O
. O

From O
February O
1991 O
to O
August O
1997 O
, O
124 O
patients O
with O
endometrial O
carcinoma O
were O
treated O
postoperatively O
with O
high O
- O
dose O
- O
rate O
vaginal O
vault O
brachytherapy O
as O
the O
only O
adjuvant O
treatment O
. O

Twelve O
patients O
had O
stage O
IBG3 O
, O
14 O
had O
ICG1 O
, O
9 O
had O
ICG2 O
, O
and O
3 O
had O
ICG3 O
disease O
. O

Defective O
provirus O
genomes O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
are O
frequently O
detected O
in O
lymphocytes O
from O
infected O
individuals O
and O
in O
infected O
cell O
lines O
. O

A O
total O
of O
174 O
primer O
pairs O
gave O
interpretable O
banding O
patterns O
, O
137 O
( O
79 O
%) O
of O
which O
revealed O
at O
least O
two O
alleles O
on O
native O
polyacrylamide O
gels O
. O

A O
population O
pharmacokinetic O
study O
of O
cyclosporin O
in O
organ O
transplant O
patients O
, O
including O
elderly O
allograft O
recipients O
up O
to O
75 O
years O
of O
age O
, O
did O
not O
identify O
age O
as O
a O
covariable O
influencing O
cyclosporin O
pharmacokinetics O
. O

Immunofluoresence O
data O
indicated O
that O
once O
bound O
to O
the O
mutant O
receptor O
, O
fluorescent O
- O
labeled O
RAP I-GENE
co O
- O
localized O
with O
markers O
of O
the O
endosomal O
pathway O
, O
whereas O
, O
in O
cells O
expressing O
the O
wild O
- O
type O
receptor O
, O
RAP I-GENE
fluorescence O
co O
- O
localized O
with O
lysosomal O
markers O
. O

Interleukin I-GENE
- I-GENE
12 I-GENE
( O
IL I-GENE
- I-GENE
12 I-GENE
) O
is O
a O
cytokine O
produced O
by O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
that O
causes O
interferon I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
production O
and O
enhancement O
of O
cell O
- O
mediated O
cytotoxicity O
. O

IL I-GENE
- I-GENE
12 I-GENE
production O
was O
correlated O
with O
C3a O
concentration O
measured O
at O
the O
outlet O
of O
hemodialyzer O
after O
15 O
min O
of O
dialysis O
( O
r O
= O
0 O
. O
69 O
, O
P O
< O
0 O
. O
01 O
). O

In O
HeLa O
cells O
, O
the O
JNKK2 I-GENE
- O
JNK1 I-GENE
fusion O
protein O
showed O
significant O
JNK I-GENE
activity O
, O
which O
was O
comparable O
with O
that O
of O
JNK1 I-GENE
activated O
by O
many O
stimuli O
and O
activators O
, O
including O
EGF I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
anisomycin O
, O
UV O
irradiation O
, O
MEKK1 I-GENE
, O
and O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
Cdc42Hs I-GENE
. O

J O
. O

Our O
results O
implicate O
TGF I-GENE
- I-GENE
beta I-GENE
RII I-GENE
as O
a O
direct O
target O
of O
EWS I-GENE
- O
FLI1 I-GENE
. O

The O
reduction O
in O
saturated O
fatty O
acids O
intake O
led O
to O
modest O
( O
but O
in O
group O
1 O
significant O
) O
0 O
. O
15 O
mmol O
/ O
l O
( O
2 O
. O
5 O
%) O
reduction O
in O
total O
serum O
cholesterol O
level O
. O

Secondly O
, O
an O
ethanol O
repression O
autoregulation O
( O
ERA O
)/ O
twelve O
- O
fold O
TA O
repeat O
( O
TAB O
) O
repressor O
element O
was O
identified O
within O
the O
promoter O
region O
of O
the O
GLK1 I-GENE
gene I-GENE
. O

A O
crucial O
transcription O
factor O
in O
this O
process O
is O
STAT6 I-GENE
, O
which O
binds O
to O
a O
specific O
DNA O
element O
upon O
cytokine O
activation O
. O

CONCLUSIONS O
: O
Congenital O
horizontal O
tarsal O
kink O
is O
rare O
and O
its O
cause O
is O
unknown O
. O

A O
local O
, O
high O
- O
density O
, O
single O
- O
nucleotide O
polymorphism O
map O
used O
to O
clone O
Caenorhabditis I-GENE
elegans I-GENE
cdf I-GENE
- I-GENE
1 I-GENE
. O

This O
machinery O
involves O
a O
secondary O
structure O
, O
SECIS O
element O
, O
in O
the O
selenoprotein I-GENE
- O
encoding O
mRNA O
, O
directing O
selenocysteine O
insertion O
at O
the O
position O
of O
an O
opal O
( O
UGA O
) O
codon O
, O
normally O
conferring O
termination O
of O
translation O
. O

High O
- O
level O
expression O
in O
Escherichia O
coli O
of O
selenocysteine O
- O
containing O
rat I-GENE
thioredoxin I-GENE
reductase I-GENE
utilizing O
gene O
fusions O
with O
engineered O
bacterial O
- O
type O
SECIS O
elements O
and O
co O
- O
expression O
with O
the O
selA I-GENE
, O
selB I-GENE
and O
selC I-GENE
genes I-GENE
. O

In O
Wnt I-GENE
signaling O
, O
beta I-GENE
- I-GENE
catenin I-GENE
and O
plakoglobin I-GENE
transduce O
signals O
to O
the O
nucleus O
through O
interactions O
with O
TCF I-GENE
- I-GENE
type I-GENE
transcription I-GENE
factors I-GENE
. O

Assembly O
of O
a O
complex O
between O
FAK I-GENE
and O
Src I-GENE
kinases I-GENE
may O
serve O
to O
regulate O
the O
subcellular O
localization O
and O
the O
enzymatic O
activity O
of O
members O
of O
the O
Src I-GENE
family I-GENE
of O
kinases O
. O

For O
EPV O
3 O
, O
10 O
, O
or O
40 O
, O
the O
bias O
exceeded O
25 O
% O
for O
7 O
, O
3 O
, O
and O
1 O
in O
the O
8 O
- O
predictor O
model O
respectively O
, O
when O
a O
conventional O
selection O
criterion O
was O
used O
( O
alpha O
= O
0 O
. O
05 O
). O

Our O
study O
also O
demonstrated O
significant O
increases O
in O
the O
number O
of O
larger O
myelinated O
fibers O
crossing O
the O
repair O
site O
in O
comparison O
with O
the O
neonatal O
and O
adult O
groups O
( O
p O
< O
0 O
. O
04 O
). O

Me O
( O
2 O
) O
SO O
- O
induced O
neuronal O
differentiation O
of O
N1E O
- O
115 O
neuroblastoma O
cells O
increased O
both O
the O
expression O
of O
the O
endogenous I-GENE
Ntr I-GENE
- I-GENE
1 I-GENE
gene I-GENE
and O
reporter O
genes O
driven O
by O
NTR I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sequences I-GENE
by O
3 O
- O
4 O
- O
fold O
. O

Cortical O
dysplasias O
, O
genetics O
, O
and O
epileptogenesis O
. O

In O
the O
work O
reported O
here O
, O
we O
used O
peptide O
mapping O
, O
mass O
spectrometry O
, O
and O
site O
- O
directed O
mutagenesis O
to O
identify O
two O
sets O
of O
pAP I-GENE
phosphorylation O
sites O
. O

Both O
HERV O
- O
K O
type O
1 O
and O
2 O
clones O
were O
isolated O
. O

Duch O
, O
and O
F O
. O

At O
all O
time O
- O
points O
, O
most O
patients O
(>/= O
87 O
%) O
were O
receiving O
irbesartan O
/ O
HCTZ O
alone O
. O

Modification O
of O
dopamine I-GENE
D2 I-GENE
receptor I-GENE
activity O
by O
pergolide O
in O
Parkinson O
' O
s O
disease O
: O
an O
in O
vivo O
study O
by O
PET O
. O

High O
- O
affinity O
binding O
sites O
for O
both O
GR I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
nucleoproteins I-GENE
were O
identified O
at O
adjacent O
elements O
within O
the O
nGRE O
. O

When O
the O
73 O
- O
bp O
fragment O
was O
fused O
to O
an O
alpha1 I-GENE
- I-GENE
globin I-GENE
promoter O
- O
CAT I-GENE
construct O
and O
cotransfected O
with O
CCAAT I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
CTF1 I-GENE
)/ O
NF1 I-GENE
into O
Drosophila O
Schneider O
SL2 O
insect O
cells O
( O
which O
lack O
NF1 I-GENE
- I-GENE
like I-GENE
proteins I-GENE
) O
trans O
- O
activation O
of O
CAT I-GENE
activity O
was O
observed O
. O

Western O
blot O
analysis O
showed O
a O
rapid O
corresponding O
increase O
in O
p21WAF1 I-GENE
/ O
CIP1 I-GENE
protein O
, O
whereas O
protein O
levels O
of O
another O
member O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor I-GENE
family I-GENE
, O
p27kip1 I-GENE
, O
were O
unchanged O
. O

Aggregation O
of O
vHnf1 I-GENE
- O
deficient O
embryonic O
stem O
cells O
with O
wild O
- O
type O
tetraploid O
embryos O
, O
which O
contribute O
exclusively O
to O
extraembryonic O
tissues O
, O
rescues O
periimplantation O
lethality O
and O
allows O
development O
to O
progress O
to O
early O
organogenesis O
. O

nos I-GENE
- I-GENE
1 I-GENE
and O
nos I-GENE
- I-GENE
2 I-GENE
, O
two O
genes O
related O
to O
Drosophila I-GENE
nanos I-GENE
, O
regulate O
primordial O
germ O
cell O
development O
and O
survival O
in O
Caenorhabditis O
elegans O
. O

Although O
upstream O
regulators O
of O
Tec I-GENE
family I-GENE
kinases I-GENE
are O
relatively O
well O
characterized O
, O
little O
is O
known O
of O
the O
downstream O
effectors O
of O
these O
enzymes O
. O

Efficient O
phosphorylation O
of O
BRDG1 I-GENE
by O
Tec I-GENE
required O
the O
PH I-GENE
and O
SH2 I-GENE
domains I-GENE
as O
well O
as O
the O
kinase O
domain O
of O
the O
latter O
. O

CONCLUSION O
: O
These O
findings O
imply O
that O
eotaxin O
either O
is O
mechanistically O
involved O
in O
acute O
asthma O
or O
serves O
as O
a O
biomarker O
for O
activity O
of O
the O
CCR3 I-GENE
receptor I-GENE
ligand I-GENE
system O
, O
which O
is O
functionally O
linked O
to O
asthma O
. O

The O
expression O
analysis O
of O
the O
KlHIS4 I-GENE
gene I-GENE
under O
phosphate O
starvation O
or O
high O
adenine O
supply O
shows O
that O
factors O
, O
such O
as O
Bas1 I-GENE
or O
Bas2 I-GENE
, O
involved O
in O
the O
basal O
control O
may O
also O
operate O
in O
a O
different O
way O
in O
K O
. O
lactis O
. O

These O
thyroid O
hormone O
changes O
may O
be O
mediated O
in O
part O
by O
cytokines O
or O
other O
inflammatory O
mediators O
, O
acting O
at O
the O
level O
of O
the O
hypothalamus O
and O
pituitary O
gland O
, O
the O
thyroid O
gland O
, O
and O
the O
hepatic I-GENE
deiodinase I-GENE
system O
. O

ESS O
type O
1 O
, O
with O
FT3 O
low O
and O
FT4 O
and O
TSH I-GENE
normal O
, O
is O
the O
most O
frequent O
form O
. O

METHODS O
: O
We O
studied O
20 O
symptomatic O
patients O
with O
HOCM O
( O
12 O
men O
), O
mean O
age O
52 O
+/- O
17 O
years O
, O
before O
and O
after O
septal O
reduction O
using O
echocardiography O
and O
electrocardiogram O
( O
ECG O
). O

Paleoceanographic O
data O
from O
the O
Laurentian O
Fan O
, O
used O
as O
a O
proxy O
for O
sea O
surface O
temperature O
, O
reveal O
that O
surface O
slope O
waters O
north O
of O
the O
Gulf O
Stream O
experienced O
warming O
during O
the O
Little O
Ice O
Age O
of O
the O
16th O
to O
19th O
centuries O
and O
support O
the O
notion O
of O
an O
NAO O
- O
driven O
coupled O
system O
. O

This O
effect O
required O
( O
i O
) O
IR I-GENE
activation O
since O
it O
was O
abrogated O
by O
IR I-GENE
mutation O
at O
tyrosines O
1162 O
and O
1163 O
and O
( O
ii O
) O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
since O
it O
was O
abolished O
by O
overexpression O
of O
dominant I-GENE
- I-GENE
negative I-GENE
IkappaB I-GENE
- I-GENE
alpha I-GENE
( I-GENE
A32 I-GENE
/ I-GENE
36 I-GENE
) I-GENE
and O
mimicked O
by O
overexpression O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
c I-GENE
- I-GENE
Rel I-GENE
subunit I-GENE
. O

The O
factor O
designated O
B O
formed O
a O
complex O
centered O
on O
the O
sequence O
TGTGGT O
, O
a O
core O
motif O
recognized O
by O
members O
of O
the O
AML I-GENE
/ I-GENE
CBFalpha I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Furthermore O
, O
overexpression O
of O
AML3 I-GENE
/ O
CBFalpha1 I-GENE
could O
rescue O
the O
AML1 I-GENE
- O
ETO I-GENE
repression O
. O

We O
examined O
Akt I-GENE
activation O
in O
Lyn I-GENE
-, O
Syk I-GENE
- O
and O
Btk I-GENE
- O
deficient O
DT40 O
cells O
and O
B O
cells O
from O
Lyn I-GENE
(-/-) I-GENE
mice O
. O

Regulators O
of O
G I-GENE
protein I-GENE
signaling I-GENE
( I-GENE
RGS I-GENE
) I-GENE
proteins I-GENE
that O
contain O
DEP I-GENE
( O
disheveled I-GENE
, O
EGL I-GENE
- I-GENE
10 I-GENE
, O
pleckstrin I-GENE
) O
and O
GGL I-GENE
( O
G I-GENE
protein I-GENE
gamma I-GENE
subunit I-GENE
- I-GENE
like I-GENE
) O
domains O
form O
a O
subfamily O
that O
includes O
the O
mammalian I-GENE
RGS I-GENE
proteins I-GENE
RGS6 I-GENE
, O
RGS7 I-GENE
, O
RGS9 I-GENE
, O
and O
RGS11 I-GENE
. O

Cloning O
and O
expression O
of O
a O
specific O
human I-GENE
alpha I-GENE
1 I-GENE
, I-GENE
2 I-GENE
- I-GENE
mannosidase I-GENE
that O
trims O
Man9GlcNAc2 O
to O
Man8GlcNAc2 O
isomer O
B O
during O
N O
- O
glycan O
biosynthesis O
. O

The O
ORs O
of O
GC O
, O
adjusted O
for O
age O
and O
sex O
, O
varied O
from O
17 O
. O
1 O
, O
for O
those O
with O
baseline O
diagnoses O
of O
superficial O
intestinal O
metaplasia O
( O
IM O
), O
to O
29 O
. O
3 O
, O
for O
those O
with O
deep O
IM O
or O
mild O
dysplasia O
( O
DYS O
) O
or O
IM O
with O
glandular O
atrophy O
and O
neck O
hyperplasia O
, O
to O
104 O
. O
2 O
, O
for O
those O
with O
moderate O
or O
severe O
DYS O
, O
as O
compared O
with O
subjects O
with O
superficial O
gastritis O
( O
SG O
) O
or O
chronic O
atrophic O
gastritis O
( O
CAG O
) O
at O
baseline O
. O

Here O
we O
report O
that O
Dbp5p I-GENE
and O
Rat7p I-GENE
interact O
through O
their O
Nterminal O
domains O
. O

Thus O
, O
the O
nematode O
genes O
could O
be O
the O
homologs I-GENE
of I-GENE
Hh I-GENE
molecules I-GENE
in O
other O
phyla O
. O

A O
subset O
of O
mutations O
in O
the O
Psi I-GENE
synthase I-GENE
domain I-GENE
impairs O
association O
of O
the O
altered O
Cbf5p I-GENE
proteins I-GENE
with O
selected O
box O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNAs I-GENE
, O
suggesting O
that O
the O
functional O
catalytic O
domain O
is O
essential O
for O
that O
interaction O
. O

Although O
the O
Src I-GENE
tyrosine I-GENE
kinase I-GENE
induces O
constitutive O
Stat3 I-GENE
phosphorylation O
on O
tyrosine O
, O
activation O
of O
Stat3 I-GENE
- O
mediated O
gene O
regulation O
requires O
both O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 I-GENE
. O

The O
transcription I-GENE
factor I-GENE
CHOP I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
homologous I-GENE
protein I-GENE
10 I-GENE
) O
is O
a O
bZIP I-GENE
protein I-GENE
induced O
by O
a O
variety O
of O
stimuli O
that O
evoke O
cellular O
stress O
responses O
and O
has O
been O
shown O
to O
arrest O
cell O
growth O
and O
to O
promote O
programmed O
cell O
death O
. O

Thus O
, O
CHOP I-GENE
not O
only O
is O
a O
negative O
or O
a O
positive O
regulator O
of O
C I-GENE
/ I-GENE
EBP I-GENE
target O
genes O
but O
also O
, O
when O
tethered O
to O
AP I-GENE
- I-GENE
1 I-GENE
factors I-GENE
, O
can O
activate O
AP I-GENE
- I-GENE
1 I-GENE
target O
genes O
. O

This O
motif O
, O
first O
described O
for O
the O
Drosophila I-GENE
homeobox I-GENE
activator I-GENE
DEAF I-GENE
- I-GENE
1 I-GENE
, O
identifies O
an O
emerging O
group O
of O
metazoan O
transcriptional O
modulators O
. O

RNase I-GENE
MRP I-GENE
is O
a O
ribonucleoprotein O
endoribonuclease O
that O
has O
been O
shown O
to O
have O
roles O
in O
both O
mitochondrial O
DNA O
replication O
and O
nuclear I-GENE
5 I-GENE
. I-GENE
8S I-GENE
rRNA I-GENE
processing O
. O

We O
have O
examined O
the O
regulation O
of O
the O
FGFR I-GENE
- I-GENE
1 I-GENE
gene I-GENE
( O
cek I-GENE
- I-GENE
1 I-GENE
) O
in O
avian O
myogenic O
cultures O
by O
immunocytochemistry O
and O
Northern O
blot O
analysis O
. O

Regulation O
of O
avian I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
1 I-GENE
( O
FGFR I-GENE
- I-GENE
1 I-GENE
) O
gene O
expression O
during O
skeletal O
muscle O
differentiation O
. O

The O
backbone O
dynamics O
of O
residues O
located O
in O
the O
folded O
part O
of O
CRP2 I-GENE
( O
LIM2 I-GENE
) O
R122A I-GENE
have O
been O
characterized O
by O
proton O
- O
detected O
( O
15 O
) O
N O
NMR O
spectroscopy O
. O

Rac I-GENE
causes O
uncapping O
of O
actin I-GENE
filaments I-GENE
( O
F I-GENE
- I-GENE
actin I-GENE
) O
at O
the O
plus O
- O
ends O
, O
through O
phosphatidylinositol O
4 O
, O
5 O
bisphosphate O
( O
PIP2 O
), O
and O
eventually O
induces O
membrane O
ruffling O
. O

However O
, O
a O
specific O
ICE I-GENE
/ O
caspase I-GENE
- I-GENE
1 I-GENE
inhibitor O
called O
N1445 O
completely O
abolished O
the O
CK I-GENE
- O
induced O
apoptosis O
by O
reactivating O
PKB I-GENE
, O
but O
without O
affecting O
the O
CK I-GENE
- O
induced O
suppression O
of O
Ras I-GENE
transformation O
. O

OBJECTIVE O
: O
Although O
the O
preponderance O
of O
findings O
offer O
support O
for O
transient O
( O
where O
is O
it O
?) O
as O
opposed O
to O
sustained O
( O
what O
is O
it O
?) O
deficit O
, O
a O
need O
remains O
for O
specific O
depiction O
of O
the O
deficit O
. O

The O
AL O
- O
R8 O
SI O
: O
the O
next O
generation O
staging O
container O
for O
plutonium O
pits O
at O
the O
USDOE O
Pantex O
Plant O
. O

RESULTS O
: O
Factors O
associated O
with O
significantly O
( O
P O
<. O
05 O
) O
increased O
risk O
of O
treatment O
failure O
in O
a O
Cox O
multivariate O
analysis O
included O
age O
older O
than O
45 O
years O
( O
relative O
hazard O
, O
1 O
. O
17 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
], O
1 O
. O
02 O
- O
1 O
. O
33 O
), O
Karnofsky O
performance O
score O
less O
than O
90 O
% O
( O
1 O
. O
27 O
; O
95 O
% O
CI O
, O
1 O
. O
07 O
- O
1 O
. O
51 O
), O
absence O
of O
hormone O
receptors O
( O
1 O
. O
31 O
; O
95 O
% O
CI O
, O
1 O
. O
15 O
- O
1 O
. O
51 O
), O
prior O
use O
of O
adjuvant O
chemotherapy O
( O
1 O
. O
31 O
; O
95 O
% O
CI O
, O
1 O
. O
10 O
- O
1 O
. O
56 O
), O
initial O
disease O
- O
free O
survival O
interval O
after O
adjuvant O
treatment O
of O
no O
more O
than O
18 O
months O
( O
1 O
. O
99 O
; O
95 O
% O
CI O
, O
1 O
. O
62 O
- O
2 O
. O
43 O
), O
metastases O
in O
the O
liver O
( O
1 O
. O
47 O
; O
95 O
% O
CI O
, O
1 O
. O
20 O
- O
1 O
. O
80 O
) O
or O
central O
nervous O
system O
( O
1 O
. O
56 O
; O
95 O
% O
CI O
, O
0 O
. O
99 O
- O
2 O
. O
46 O
[ O
approaches O
significance O
]) O
vs O
soft O
tissue O
, O
bone O
, O
or O
lung O
, O
3 O
or O
more O
sites O
of O
metastatic O
disease O
( O
1 O
. O
32 O
; O
95 O
% O
CI O
, O
1 O
. O
13 O
- O
1 O
. O
54 O
), O
and O
incomplete O
response O
vs O
complete O
response O
to O
standard O
- O
dose O
chemotherapy O
( O
1 O
. O
65 O
; O
95 O
% O
CI O
, O
1 O
. O
36 O
- O
1 O
. O
99 O
). O

One O
form O
of O
the O
SBEI I-GENE
gene I-GENE
transcript I-GENE
in O
12 O
- O
day O
old O
kernels O
contained O
the O
exon O
I O
+ O
II O
+ O
III O
combination O
at O
the O
5 O
' O
end O
, O
whereas O
other O
forms O
differed O
by O
inclusion O
of O
intron O
1 O
or O
exclusion O
of O
exon O
II O
sequences O
. O

In O
PC O
, O
rare O
MNGCs O
had O
intranuclear O
inclusions O
and O
grooves O
. O

16 O
percent O
, O
P O
< O
0 O
. O
001 O
), O
and O
sustained O
normalization O
of O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
levels O
( O
41 O
percent O
vs O
. O

Its O
C O
- O
terminal O
catalytic O
domain O
was O
found O
to O
be O
highly O
conserved O
in O
the O
homologues O
p140 I-GENE
( O
ras I-GENE
- O
GRF I-GENE
) O
and O
Sos I-GENE
. O

356 O
, O
93 O
- O
98 O
]. O

The O
proteasome O
is O
a O
large O
complex O
consisting O
of O
two O
multisubunit O
structures O
, O
the O
20S I-GENE
and O
19S I-GENE
( O
PA700 I-GENE
) O
or O
P28 I-GENE
complexes I-GENE
, O
that O
combine O
to O
form O
the O
26S I-GENE
particles I-GENE
. O

In O
assays O
with O
purified O
enzymes O
, O
wild O
- O
type O
but O
not O
PTPS I-GENE
- O
S19A I-GENE
was O
a O
specific O
substrate O
for O
the O
cGMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( I-GENE
cGK I-GENE
) I-GENE
type I-GENE
I I-GENE
and I-GENE
II I-GENE
. O

R O
., O
Fleischmann O
, O
R O
., O
Venter O
, O
J O
. O

The O
N O
- O
terminal O
domain O
of O
approximately O
70 O
kDa O
exhibits O
11 O
imperfect O
amino O
acid O
repeats O
that O
show O
some O
homology O
to O
promastigote O
surface O
glycoproteins O
of O
the O
psa2 I-GENE
/ O
gp46 I-GENE
complex O
. O

In O
contrast O
to O
previously O
characterized O
proteophosphoglycans O
, O
the O
ppg1 I-GENE
gene O
product O
is O
predominantly O
membrane O
- O
associated O
and O
it O
is O
expressed O
on O
the O
promastigote O
cell O
surface O
. O

Most O
important O
, O
infection O
of O
the O
cells O
with O
an O
adenoviral O
construct O
expressing O
this O
mutant O
inhibited O
the O
induction O
of O
VEGF I-GENE
mRNA I-GENE
under O
conditions O
that O
mimic O
hypoxia O
. O

Neuregulin I-GENE
stimulates O
ErbB2 I-GENE
, O
ErbB3 I-GENE
, O
and O
ErbB4 I-GENE
, O
members O
of O
the O
ErbB I-GENE
family I-GENE
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
. O

Our O
results O
suggest O
that O
Anu2p I-GENE
is O
the O
yeast I-GENE
homologue I-GENE
of I-GENE
mammalian I-GENE
epsilon I-GENE
- I-GENE
COP I-GENE
and O
the O
abrupt O
accumulation O
of O
the O
ER O
membrane O
caused O
by O
a O
blockage O
of O
the O
early O
protein O
transport O
pathway O
leads O
to O
alteration O
of O
nuclear O
morphology O
of O
the O
budding O
yeast O
cells O
. O

In O
PC12 O
cells O
, O
nerve I-GENE
growth I-GENE
factor I-GENE
induces O
neuronal O
differentiation O
and O
repressed O
expression O
of O
nrg I-GENE
- I-GENE
1 I-GENE
. O

In O
a O
PC12 O
cell O
mutant O
that O
is O
deficient O
in O
protein I-GENE
kinase I-GENE
A I-GENE
activity O
( O
AB O
. O
11 O
), O
all O
three O
differentiating O
agents O
were O
unable O
to O
down O
- O
regulate O
nrg I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
. O

TSC1 I-GENE
mutations I-GENE
include O
two O
nonsense O
mutations O
, O
four O
insertions O
, O
and O
three O
splice O
mutations O
. O

Twelve O
patients O
without O
abnormalities O
in O
the O
PTT O
are O
assumed O
to O
harbor O
missense O
mutations O
, O
probably O
in O
TSC2 I-GENE
. O

The O
first O
algorithm O
, O
FOREPROJ O
, O
is O
a O
fast O
- O
forward O
projection O
algorithm O
that O
allows O
calculation O
of O
the O
3 O
- O
D O
attenuation O
correction O
factors O
( O
ACF O
' O
s O
) O
directly O
from O
a O
two O
- O
dimensional O
( O
2 O
- O
D O
) O
transmission O
scan O
, O
without O
first O
reconstructing O
the O
attenuation O
map O
and O
then O
performing O
a O
3 O
- O
D O
forward O
projection O
. O

We O
have O
cloned O
cDNA O
and O
genomic O
DNA O
for O
a O
mouse O
gene O
encoding O
a O
protein O
with O
significant O
sequence O
similarity O
to O
conserved O
domains O
found O
in O
proteins O
of O
the O
Spo11p I-GENE
family I-GENE
. O

RT O
- O
PCR O
and O
in O
situ O
hybridization O
analyses O
of O
a O
time O
course O
of O
juvenile O
testis O
development O
indicate O
that O
Spo11 I-GENE
expression O
begins O
in O
early O
meiotic O
Prophase O
I O
, O
prior O
to O
the O
pachytene O
stage O
, O
with O
increasing O
accumulation O
of O
mRNA O
through O
the O
pachytene O
stage O
. O

Animals O
were O
put O
to O
death O
8 O
weeks O
later O
and O
the O
grafts O
were O
sterilely O
explanted O
and O
analyzed O
via O
microbiologic O
culture O
and O
standard O
histologic O
procedures O
for O
evidence O
of O
infection O
. O

The O
RMR O
was O
measured O
twice O
in O
each O
phase O
and O
found O
to O
be O
similar O
( O
F O
( O
1 O
, O
18 O
) O
= O
0 O
. O
863 O
) O
across O
the O
follicular O
( O
5018 O
kJ O
/ O
24 O
h O
) O
and O
the O
luteal O
( O
5098 O
kJ O
/ O
24 O
h O
) O
phases O
. O

Oseltamivir O
( O
GS4104 O
), O
which O
can O
be O
administered O
orally O
, O
is O
the O
prodrug O
of O
GS4071 O
, O
a O
potent O
and O
selective O
inhibitor O
of O
influenzavirus I-GENE
neuraminidases I-GENE
. O

In O
gel O
mobility O
shift O
assays O
, O
we O
found O
no O
evidence O
for O
VDR I-GENE
- O
TR I-GENE
heterodimer O
interaction O
with O
any O
tested O
element O
. O

The O
relative O
importance O
of O
these O
two O
mechanisms O
differed O
in O
a O
response O
element O
- O
specific O
manner O
. O

After O
14 O
d O
of O
overfeeding O
, O
hepatic O
PL O
profiles O
were O
identical O
in O
the O
two O
breeds O
and O
similar O
to O
that O
in O
control O
livers O
; O
choline O
- O
containing O
PL O
accounted O
for O
95 O
% O
of O
total O
PL O
. O

C O
- O
SP O
duration O
was O
significantly O
reduced O
in O
ALS O
patients O
compared O
to O
controls O
at O
low O
stimulation O
intensity O
corresponding O
to O
an O
MEP O
threshold O
increased O
by O
15 O
%. O

These O
data O
show O
that O
the O
spv I-GENE
virulence I-GENE
genes I-GENE
belong O
simultaneously O
to O
several O
regulons O
in O
the O
cell O
, O
raising O
the O
possibility O
that O
spv I-GENE
expression O
can O
be O
fine O
- O
tuned O
in O
response O
to O
multiple O
environmental O
inputs O
. O

Intensive O
synthesis O
of O
PNA I-GENE
in O
the O
cells O
of O
microvascular O
wall O
evidenced O
of O
their O
high O
functional O
activity O
, O
and O
the O
synthesis O
of O
DNA O
in O
them O
showed O
their O
ability O
for O
proliferation O
, O
i O
. O
g O
.-- O
for O
growth O
. O

Tracheal O
transsection O
combined O
with O
hilar O
ligation O
( O
TL O
& O
PL O
) O
effected O
a O
reduction O
of O
19 O
. O
9 O
% O
( O
n O
. O
s O
.). O

Kinase O
- O
deficient O
erbB I-GENE
proteins I-GENE
reduced O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
)- O
induced O
tyrosine O
phosphorylation O
of O
endogenous O
Shc I-GENE
proteins I-GENE
and O
also O
reduced O
immediate O
and O
sustained O
EGF I-GENE
- I-GENE
induced I-GENE
ERK I-GENE
MAPK I-GENE
activities O
in O
human O
glioblastoma O
cells O
, O
although O
basal O
ERK I-GENE
MAPK I-GENE
activities O
were O
unaffected O
. O

Using O
immunolocalization O
, O
we O
observe O
that O
ACE3 I-GENE
, O
a O
440 O
- O
bp O
chorion O
element O
that O
contains O
information O
sufficient O
to O
drive O
amplification O
, O
directs O
DmORC I-GENE
localization O
in O
follicle O
cells O
. O

Therefore O
, O
homozygous O
co O
- O
deletions O
of O
CDKN2A I-GENE
and O
CDKN2B I-GENE
rather O
than O
mutations O
targeting O
individual O
transcripts O
are O
frequently O
selected O
for O
in O
these O
tumors O
. O

Here O
, O
we O
show O
that O
aortic O
explants O
isolated O
from O
PPARalpha I-GENE
- O
null O
mice O
display O
an O
exacerbated O
response O
to O
inflammatory O
stimuli O
, O
such O
as O
lipopolysaccharide O
( O
LPS O
), O
as O
demonstrated O
by O
increased O
IL I-GENE
- I-GENE
6 I-GENE
secretion O
. O

Albumin O
expression O
is O
maintained O
in O
the O
liver O
by O
a O
combination O
of O
liver O
- O
enriched O
transcription O
factors O
such O
as O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
) I-GENE
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
. O

The O
requirement O
for O
proteolytic O
activity O
of O
both O
FVIIa I-GENE
and O
FXa I-GENE
suggests O
that O
protease O
- O
activated O
receptors O
may O
be O
involved O
. O

Amyloid I-GENE
beta I-GENE
- I-GENE
protein I-GENE
( O
Abeta I-GENE
) O
is O
the O
main O
constituent O
of O
amyloid O
fibrils O
found O
in O
senile O
plaques O
and O
cerebral O
vessels O
in O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
and O
is O
derived O
by O
proteolysis O
from O
the O
beta I-GENE
- I-GENE
amyloid I-GENE
precursor I-GENE
protein I-GENE
( O
APP I-GENE
). O

We O
also O
show O
that O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
) O
signaling O
is O
sufficient O
to O
down O
- O
regulate O
caveolin I-GENE
- I-GENE
1 I-GENE
protein I-GENE
expression O
and O
promoter O
activity O
. O

The O
importin I-GENE
alpha I-GENE
. I-GENE
beta I-GENE
heterodimer I-GENE
mediates O
nuclear O
import O
of O
proteins O
containing O
classical O
nuclear O
localization O
signals O
. O

The O
expressed O
G1 I-GENE
- O
G2 I-GENE
bound O
to O
both O
hyaluronan O
and O
link I-GENE
protein I-GENE
indicating O
that O
the O
immunoglobulin I-GENE
- I-GENE
fold I-GENE
motif I-GENE
and O
proteoglycan O
tandem O
repeat O
loops O
of O
the O
G1 I-GENE
domain I-GENE
were O
correctly O
folded O
. O

The O
results O
suggest O
that O
the O
presence O
or O
absence O
per O
se O
of O
keratan O
sulfate O
on O
native O
G1 O
- O
G2 O
does O
not O
affect O
the O
activity O
of O
atrolysin O
C O
toward O
the O
two O
sites O
. O

Despite O
i O
. O
v O
. O
steroid O
therapy O
, O
[ O
NOexh O
] O
remained O
elevated O
throughout O
recovery O
( O
37 O
. O
9 O
+/- O
4 O
. O
8 O
ppb O
, O
p O
< O
0 O
. O
001 O
) O
until O
discharge O
( O
40 O
. O
9 O
+/- O
4 O
. O
3 O
ppb O
, O
p O
< O
0 O
. O
001 O
). O

It O
contains O
binding O
sites O
for O
several O
transcription O
factors O
, O
for O
example O
: O
( O
i O
) O
a O
well O
- O
characterized O
binding O
site O
for O
rel I-GENE
/ O
NF I-GENE
- I-GENE
kappaB I-GENE
transcription O
factors O
in O
its O
3 O
'- O
end O
( O
the O
H2TF1 I-GENE
or O
kappaB1 I-GENE
element I-GENE
), O
( O
ii O
) O
a O
second O
kappaB I-GENE
site I-GENE
( O
the O
kappaB2 I-GENE
element I-GENE
), O
which O
is O
located O
immediately O
adjacent O
5 O
' O
to O
the O
H2TF1 I-GENE
element I-GENE
and O
which O
is O
recognized O
by O
p65 I-GENE
/ O
relA I-GENE
in O
the O
human I-GENE
HLA I-GENE
system O
, O
and O
( O
iii O
) O
an O
AP I-GENE
- I-GENE
1 I-GENE
/ O
ATF I-GENE
recognition O
sequence O
in O
the O
5 O
' O
end O
( O
EnA I-GENE
- I-GENE
TRE I-GENE
). O

The O
tumorigenic O
E1A I-GENE
+ O
cHa I-GENE
- I-GENE
ras I-GENE
cells O
are O
characterized O
by O
high O
and O
constitutive O
DNA O
binding O
activities O
of O
AP I-GENE
- I-GENE
1 I-GENE
, O
in O
contrast O
to O
nontransformed O
cells O
and O
the O
E1A I-GENE
cells O
. O

The O
yeast O
C I-GENE
- I-GENE
type I-GENE
cyclin I-GENE
Ume3p I-GENE
/ O
Srb11p I-GENE
and O
its O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
Ume5p I-GENE
are O
required O
for O
the O
full O
repression O
of O
genes O
involved O
in O
the O
stress O
response O
or O
meiosis O
. O

In O
particular O
, O
the O
S1 I-GENE
' I-GENE
specificity I-GENE
site I-GENE
is O
a O
deep O
and O
highly O
hydrophobic O
cavity O
. O

FZD4 I-GENE
is O
homologous O
to O
FZD9 I-GENE
and O
FZD10 I-GENE
, O
and O
overall O
amino O
acid O
identity O
is O
as O
follows O
: O
FZD4 I-GENE
vs O
FZD9 I-GENE
, O
51 O
. O
6 O
%; O
FZD4 I-GENE
vs O
FZD10 I-GENE
, O
51 O
. O
2 O
%; O
FZD9 I-GENE
vs O
FZD10 I-GENE
, O
65 O
. O
7 O
%. O

The O
NF I-GENE
- I-GENE
kappaB I-GENE
responsive O
reporter O
construct O
, O
( O
PRDII O
)( O
4 O
)- O
CAT I-GENE
, O
was O
used O
to O
explore O
transcription O
resulting O
from O
NF I-GENE
- I-GENE
kappaB I-GENE
activated O
by O
Tat I-GENE
. O

The O
RNA O
transcripts O
structurally O
equivalent O
to O
I I-GENE
( I-GENE
2 I-GENE
) I-GENE
sgRNAs I-GENE
of O
TMV I-GENE
U1 I-GENE
and O
crTMV O
, O
but O
containing O
a O
hairpin O
structure O
( O
H O
) O
immediately O
upstream O
of O
IRES I-GENE
( I-GENE
MP I-GENE
, I-GENE
75 I-GENE
) I-GENE
( I-GENE
HIRES I-GENE
( I-GENE
MP I-GENE
), I-GENE
( I-GENE
75 I-GENE
)( I-GENE
CR I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
; O
HIRES I-GENE
( I-GENE
MP I-GENE
, I-GENE
75 I-GENE
)( I-GENE
U1 I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' I-GENE
UTR I-GENE
), O
were O
able O
to O
express O
the O
MP I-GENE
gene I-GENE
in O
vitro O
. O

EIAV I-GENE
LTR I-GENE
sequence I-GENE
variability O
is O
confined O
mostly O
to O
a O
small O
portion O
of O
the O
enhancer O
within O
the O
U3 O
segment O
of O
the O
LTR O
. O

Phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
requirement O
in O
activation O
of O
the O
ras I-GENE
/ O
C I-GENE
- I-GENE
raf I-GENE
- I-GENE
1 I-GENE
/ O
MEK I-GENE
/ O
ERK I-GENE
and O
p70 I-GENE
( O
s6k I-GENE
) O
signaling O
cascade O
by O
the O
insulinomimetic O
agent O
vanadyl O
sulfate O
. O

The O
core O
of O
this O
enhancer O
contains O
two O
evolutionarily O
conserved O
binding O
sites O
for O
the O
homeodomain I-GENE
protein I-GENE
Tinman I-GENE
( O
Tin I-GENE
), O
expressed O
in O
developing O
cardiac O
, O
somatic O
, O
and O
visceral O
muscle O
lineages O
. O

For O
example O
, O
introduction O
of O
immunogenic O
and O
purification O
tag O
sequences O
into O
the O
C O
- O
terminal O
coding O
region O
significantly O
decreased O
bop I-GENE
gene I-GENE
mRNA I-GENE
and O
protein O
accumulation O
. O

Furthermore O
, O
the O
striking O
ability O
of O
polyoma I-GENE
middle I-GENE
T I-GENE
antigens I-GENE
to O
promote O
retinoic O
acid O
- O
induced O
differentiation O
appears O
to O
utilize O
ERK I-GENE
, O
but O
not O
JNK I-GENE
/ O
SPK I-GENE
or O
p38 I-GENE
signaling O
. O

We O
recommend O
that O
paracervical O
block O
with O
lignocaine O
should O
be O
used O
in O
conjunction O
with O
i O
. O
v O
. O
sedation O
/ O
analgesia O
during O
egg O
collection O
performed O
through O
the O
transvaginal O
route O
under O
ultrasound O
guidance O
( O
TUGOR O
) O
to O
reduce O
the O
pain O
of O
the O
procedure O
. O

All O
loci O
have O
a O
similar O
organization O
, O
except O
for O
H1 I-GENE
. I-GENE
8 I-GENE
that O
harbors O
two O
TcP2beta I-GENE
genes I-GENE
arranged O
in O
tandem O
and O
separated O
by O
a O
short O
repetitive O
sequence O
, O
named O
SIRE O
( O
short O
interspersed O
repetitive O
element O
), O
which O
is O
also O
found O
upstream O
of O
the O
first O
gene O
of O
the O
tandem O
and O
downstream O
of O
the O
second O
. O

A O
proportion O
of O
APC I-GENE
wild O
- O
type O
colon O
carcinomas O
and O
melanomas O
also O
contains O
constitutive O
nuclear O
Tcf I-GENE
- I-GENE
4 I-GENE
/ O
beta I-GENE
- I-GENE
catenin I-GENE
complexes O
as O
a O
result O
of O
dominant O
mutations O
in O
the O
N O
terminus O
of O
beta I-GENE
- I-GENE
catenin I-GENE
that O
render O
it O
insensitive O
to O
downregulation O
by O
APC I-GENE
, O
GSK3 I-GENE
beta I-GENE
, O
and O
Axin I-GENE
/ O
Conductin I-GENE
. O

Similar O
mechanisms O
leading O
to O
deregulation O
of O
Tcf I-GENE
target I-GENE
gene I-GENE
activity O
are O
likely O
to O
be O
involved O
in O
melanoma O
and O
other O
forms O
of O
cancer O
. O

This O
report O
describes O
a O
patient O
with O
a O
previous O
inferior O
acute O
myocardial O
infarction O
who O
developed O
right O
ventricular O
infarction O
with O
significant O
anterior O
lead O
ST O
segment O
elevation O
( O
V1 O
- O
V4 O
) O
caused O
by O
the O
loss O
of O
two O
large O
right O
ventricular O
branches O
during O
a O
coronary O
angioplasty O
of O
the O
right O
coronary O
artery O
. O

PATIENTS O
AND O
METHODS O
: O
Immediately O
before O
radical O
prostatectomy O
, O
bone O
marrow O
aspirates O
from O
both O
sides O
of O
the O
iliac O
crest O
were O
taken O
from O
287 O
patients O
. O

PURPOSE O
: O
Previous O
WR O
- O
2721 O
human O
pharmacokinetic O
studies O
were O
limited O
to O
plasma O
levels O
in O
patients O
receiving O
platinum O
- O
based O
compounds O
, O
and O
none O
includes O
the O
effects O
of O
WR O
- O
2721 O
on O
endogenous O
thiols O
. O

With O
regard O
to O
nonhematologic O
toxicities O
, O
diarrhea O
, O
infection O
and O
elevated O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
of O
grade O
3 O
or O
over O
were O
observed O
in O
2 O
% O
of O
cycles O
, O
but O
were O
tolerable O
and O
reversible O
. O

LHbeta I-GENE
is O
expressed O
in O
pituitary O
gonadotrope O
cells O
and O
CGbeta I-GENE
is O
expressed O
in O
placental O
trophoblast O
cells O
. O

Regulation O
of O
HIV O
- O
1 O
transcription O
. O

Human I-GENE
LTBP I-GENE
- I-GENE
1 I-GENE
is O
known O
to O
exist O
in O
different O
forms O
. O

In O
an O
earlier O
study O
( O
Kimura O
, O
Y O
., O
Kurzydlowski O
, O
K O
., O
Tada O
, O
M O
., O
and O
MacLennan O
, O
D O
. O

It O
consists O
of O
2185 O
amino O
acid O
residues O
encoded O
by O
a O
9 O
- O
kilobase O
pair O
mRNA O
; O
several O
splice O
variants O
have O
been O
detected O
in O
human O
and O
rat O
cDNA O
libraries O
. O

Cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
binding O
to O
A I-GENE
- I-GENE
kinase I-GENE
anchoring O
proteins O
in O
living O
cells O
by O
fluorescence O
resonance O
energy O
transfer O
of O
green I-GENE
fluorescent I-GENE
protein I-GENE
fusion O
proteins O
. O

CONCLUSIONS O
: O
In O
addition O
to O
the O
superiority O
of O
octafluoropropane O
- O
filled O
microspheres O
to O
air O
- O
filled O
microspheres O
for O
LV O
opacification O
, O
the O
efficacy O
of O
OCTA O
is O
relatively O
unaffected O
by O
impaired O
LV O
function O
and O
is O
less O
susceptible O
to O
the O
effects O
of O
poor O
echogenicity O
than O
AIR O
. O

Factor I-GENE
XI I-GENE
deficiency O
is O
a O
rare O
hereditary O
bleeding O
disorder O
affecting O
the O
intrinsic O
pathway O
. O

The O
Ishasha O
samples O
show O
a O
range O
encompassing O
three O
trophic O
levels O
. O

The O
more O
traditional O
SERMS O
, O
clomiphene O
citrate O
and O
tamoxifen O
, O
will O
be O
reviewed O
along O
with O
such O
modern O
drugs O
as O
raloxifene O
and O
faslodex O
, O
with O
emphasis O
upon O
their O
actions O
on O
breast O
, O
uterus O
, O
bone O
and O
lipids O
. O

Ti O
exhibited O
a O
feather O
- O
like O
morphology O
. O

This O
organization O
suggests O
that O
duplication O
events O
that O
have O
generated O
the O
primate O
FUT3 I-GENE
- O
FUT5 I-GENE
- O
FUT6 I-GENE
cluster O
might O
have O
occurred O
through O
a O
long O
- O
interspersed O
- O
nuclear O
- O
element O
- O
based O
mechanism O
of O
unequal O
crossing O
over O
, O
as O
described O
for O
the O
globin I-GENE
cluster I-GENE
. O

S O
., O
Kim O
, O
S O
. O

The O
cop I-GENE
region I-GENE
also O
harbors O
a O
region O
of O
plasmid O
incompatibility O
, O
inc I-GENE
, O
encompassing O
a O
stem O
- O
loop O
structure O
, O
the O
repA I-GENE
promoter I-GENE
, O
Prep I-GENE
, O
as O
well O
as O
two O
distinct O
RepA I-GENE
binding I-GENE
sites I-GENE
, O
BD O
- O
1 O
and O
BD O
- O
2 O
. O

WA O
constructs O
afforded O
relaxed O
and O
positive O
topoisomers O
, O
and O
cyclization O
kinetics O
indicated O
slow O
interconversion O
of O
precursors O
to O
the O
two O
topoisomers O
. O

The O
RFX I-GENE
protein I-GENE
family I-GENE
includes O
members O
from O
yeast O
to O
humans O
, O
which O
function O
in O
various O
biological O
systems O
, O
and O
share O
a O
DNA O
- O
binding O
domain O
and O
a O
conserved O
C O
- O
terminal O
region O
. O

Binding O
to O
sulphatides O
and O
the O
alpha I-GENE
- I-GENE
dystroglycan I-GENE
receptor I-GENE
was O
much O
stronger O
and O
required O
at O
least O
two O
LG I-GENE
modules I-GENE
. O

Here O
, O
we O
propose O
that O
an O
antagonistic O
, O
BMP I-GENE
/ O
ALK2 I-GENE
/ O
Smad I-GENE
- O
mediated O
signaling O
pathway O
is O
active O
on O
the O
right O
side O
of O
the O
Xenopus O
embryo O
. O

These O
kinases O
belong O
to O
a O
new O
subfamily O
related O
to O
the O
Trk I-GENE
subfamily I-GENE
. O

The O
data O
indicate O
that O
etr I-GENE
- I-GENE
1 I-GENE
is O
essential O
for O
muscle O
development O
in O
C O
. O
elegans O
, O
perhaps O
by O
playing O
a O
role O
in O
post O
- O
transcriptional O
processing O
of O
some O
muscle O
component O
, O
and O
thus O
suggesting O
a O
possible O
conservation O
of O
gene O
function O
with O
human I-GENE
CUG I-GENE
- I-GENE
bp I-GENE
. O

Gentamicin O
given O
by O
DPI O
and O
SVN O
significantly O
decreased O
the O
sputum O
Psa O
density O
( O
p O
< O
0 O
. O
05 O
), O
by O
almost O
one O
order O
of O
magnitude O
. O

CONCLUSIONS O
: O
The O
largest O
value O
of O
the O
joint O
space O
may O
be O
used O
when O
evaluating O
rheumatoid O
AC O
joint O
space O
. O

An O
analysis O
of O
sequence O
of O
the O
mutant I-GENE
recN I-GENE
gene I-GENE
revealed O
a O
G O
: O
C O
to O
T O
: O
A O
transversion O
near O
the O
3 O
' O
end O
of O
the O
coding O
region O
. O

Nevertheless O
, O
in O
view O
of O
the O
potential O
transmission O
rates O
of O
HGV O
and O
the O
lack O
of O
effective O
immunization O
, O
HGV O
should O
be O
regarded O
as O
a O
potential O
occupational O
hazard O
for O
medical O
and O
dental O
staff O
. O

Detection O
of O
poisoning O
by O
Impila O
( O
Callilepis O
laureola O
) O
in O
a O
mother O
and O
child O
. O

We O
have O
previously O
identified O
mouse I-GENE
and I-GENE
human I-GENE
cDNAs I-GENE
encoding I-GENE
UNC I-GENE
- I-GENE
51 I-GENE
- I-GENE
like I-GENE
kinase I-GENE
( O
ULK1 I-GENE
). O

ULKs I-GENE
and O
UNC I-GENE
- I-GENE
51 I-GENE
share O
a O
typical O
domain O
structure O
of O
an O
amino O
- O
terminal O
kinase O
domain O
, O
a O
central O
proline O
/ O
serine O
rich O
( O
PS O
) O
domain O
, O
and O
a O
carboxy O
- O
terminal O
( O
C O
) O
domain O
. O

These O
results O
suggest O
that O
ULK2 I-GENE
is O
involved O
in O
a O
previously O
uncharacterized O
signaling O
pathway O
in O
mammalian O
cells O
. O

Connector I-GENE
enhancer I-GENE
of I-GENE
KSR I-GENE
( O
CNK I-GENE
) O
is O
a O
multidomain O
protein O
required O
for O
RAS I-GENE
signaling O
. O

In O
simpler O
organisms O
, O
the O
ATP I-GENE
sulfurylase I-GENE
and O
APS I-GENE
kinase I-GENE
reactions O
are O
catalyzed O
by O
separate O
enzymes O
encoded O
by O
two O
or O
three O
genes O
, O
suggesting O
that O
a O
fusion O
of O
separate O
genes O
during O
the O
course O
of O
evolution O
generated O
the O
bifunctional O
enzyme O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
( I-GENE
EBV I-GENE
) I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
( O
LMP1 I-GENE
) O
is O
essential O
for O
EBV O
- O
mediated O
transformation O
of O
primary O
B O
lymphocytes O
. O

The O
amino O
- O
terminal O
half O
of O
1a I-GENE
is O
a O
distant O
homolog I-GENE
of I-GENE
alphavirus I-GENE
nonstructural I-GENE
protein I-GENE
nsP1 I-GENE
, O
which O
has O
been O
implicated O
in O
capping O
viral O
RNAs O
. O

Moreover O
, O
a O
recombinant O
Ad O
expressing O
Ad5 I-GENE
E4orf6 I-GENE
/ I-GENE
7 I-GENE
induced O
apoptosis O
in O
rat O
cells O
when O
coinfected O
with O
wild O
- O
type O
p53 I-GENE
- O
expressing O
Ad O
. O

In O
HCMV O
( O
Towne O
)- O
infected O
HF O
cells O
at O
24 O
to O
48 O
h O
, O
IE2 I-GENE
also O
accumulated O
in O
newly O
formed O
viral O
DNA O
replication O
compartments O
containing O
the O
polymerase I-GENE
processivity I-GENE
factor I-GENE
( O
UL44 I-GENE
), O
the O
single I-GENE
- I-GENE
stranded I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
( O
SSB I-GENE
; O
UL57 I-GENE
), O
the O
UL112 I-GENE
- I-GENE
113 I-GENE
accessory I-GENE
protein I-GENE
, O
and O
newly O
incorporated O
bromodeoxyuridine O
( O
BrdU O
). O

Macroscopic O
researches O
on O
heart O
vascularization O
have O
indicated O
that O
the O
angioarchitecture O
of O
the O
conducting O
system O
differs O
from O
that O
of O
the O
normal O
myocardium O
. O

CONCLUSION O
( O
S O
): O
Measuring O
urinary O
LH I-GENE
levels O
is O
an O
excellent O
method O
for O
determining O
ovulation O
. O

However O
, O
reoperation O
for O
bulky O
cervical O
disease O
( O
group O
3 O
) O
rarely O
results O
in O
normal O
calcitonin I-GENE
levels O
and O
is O
associated O
with O
a O
high O
incidence O
of O
permanent O
hypoparathyroidism O
. O

We O
present O
a O
case O
of O
carcinoma O
of O
the O
breast O
presenting O
concurrently O
with O
SSc O
that O
subsequently O
progressed O
to O
dialysis O
- O
dependent O
renal O
failure O
in O
just O
1 O
month O
. O

PURPOSE O
: O
To O
evaluate O
the O
disease O
- O
free O
survival O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
), O
prognostic O
factors O
, O
and O
treatment O
- O
related O
mortality O
of O
women O
with O
stage O
IIIB O
inflammatory O
breast O
cancer O
( O
IBC O
) O
treated O
with O
combined O
modality O
therapy O
( O
CMT O
) O
and O
high O
- O
dose O
chemotherapy O
( O
HDCT O
) O
with O
autologous O
stem O
- O
cell O
transplantation O
. O

The O
GPI O
anchor O
moiety O
is O
either O
absent O
or O
present O
at O
a O
very O
low O
level O
in O
the O
polypeptide O
expressed O
from O
the O
cDNA O
that O
contained O
both O
the O
signal O
peptide O
and O
GPI O
signal O
sequences O
. O

We O
have O
cloned O
a O
novel O
100 O
- O
kDa O
mammalian O
protein O
, O
which O
was O
recognized O
by O
an O
anti O
- O
peptide O
antibody O
against O
an O
epitope O
- O
containing O
nuclear O
localization O
signal O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
p65 I-GENE
subunit I-GENE
. O

Insulin I-GENE
- O
regulated O
events O
, O
however O
, O
occur O
in O
all O
cells O
. O

Regulatory O
regions O
in O
the O
promoter O
and O
third O
intron O
of O
the O
growth I-GENE
hormone I-GENE
gene I-GENE
in I-GENE
rainbow I-GENE
trout I-GENE
, O
Oncorhynchus O
mykiss O
walbaum O
. O

Although O
most O
SFV O
genes O
have O
homologs O
encoded O
by O
other O
Chordopoxvirinae O
, O
the O
SFV O
genome O
lacks O
a O
key O
gene O
required O
for O
the O
production O
of O
extracellular O
enveloped O
virus O
. O

They O
self O
- O
completed O
the O
SF O
- O
36 O
questionnaire O
and O
their O
QoL O
was O
described O
and O
retrospectively O
compared O
to O
that O
of O
historical O
controls O
. O

There O
was O
a O
trend O
toward O
an O
association O
between O
IENF O
and O
sural O
nerve O
unmyelinated O
fiber O
densities O
( O
r O
= O
0 O
. O
32 O
, O
p O
= O
0 O
. O
054 O
). O

In O
addition O
, O
media O
containing O
F I-GENE
beta I-GENE
alpha I-GENE
/ O
CG I-GENE
beta I-GENE
displayed O
high O
- O
affinity O
binding O
to O
both O
CG I-GENE
and I-GENE
FSH I-GENE
receptors I-GENE
. O

In O
contrast O
, O
AP I-GENE
- I-GENE
2 I-GENE
binding O
activity O
was O
significantly O
greater O
in O
T47D O
cells O
, O
and O
Western O
blots O
confirmed O
increased O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
levels O
in O
these O
cells O
. O

N O
. O
van O
Hoek O
, O
and O
M O
. O

Here O
, O
we O
describe O
a O
tyrosine O
- O
phosphorylated O
nuclear O
protein O
, O
YT521 I-GENE
- I-GENE
B I-GENE
, O
and O
show O
that O
it O
interacts O
with O
the O
nuclear I-GENE
transcriptosomal I-GENE
component I-GENE
scaffold I-GENE
attachment I-GENE
factor I-GENE
B I-GENE
, O
and O
the O
68 I-GENE
- I-GENE
kDa I-GENE
Src I-GENE
substrate O
associated O
during O
mitosis O
, O
Sam68 I-GENE
. O

These O
mutants O
all O
failed O
to O
interact O
with O
the O
TraR I-GENE
fusion I-GENE
in O
the O
two O
- O
hybrid O
system O
. O

PhoP I-GENE
- O
PhoQ I-GENE
homologues O
in O
Pseudomonas O
aeruginosa O
regulate O
expression O
of O
the O
outer I-GENE
- I-GENE
membrane I-GENE
protein I-GENE
OprH I-GENE
and O
polymyxin O
B O
resistance O
. O

Deletion O
of O
fdsR I-GENE
revealed O
a O
dual O
regulatory O
effect O
of O
FdsR I-GENE
on O
the O
fds I-GENE
operon I-GENE
by O
acting O
as O
transcriptional O
activator O
in O
the O
presence O
of O
formate O
or O
as O
repressor O
in O
the O
absence O
of O
formate O
. O

With O
constructs O
containing O
the O
binding O
site O
of O
one O
gene O
fused O
to O
the O
promoter O
of O
the O
other O
, O
we O
demonstrated O
that O
the O
positional O
requirements O
are O
a O
function O
of O
the O
specific O
binding O
site O
, O
not O
the O
promoter O
. O

In O
addition O
, O
all O
three O
Opa I-GENE
proteins I-GENE
of O
C751 O
bind O
equally O
well O
to O
HeLa O
cells O
transfected O
with O
cDNA O
encoding O
the O
carcinoembryonic I-GENE
antigen I-GENE
[ O
CEA I-GENE
( O
CD66e I-GENE
)] O
subgroup O
of O
the O
CD66 I-GENE
family I-GENE
, O
but O
show O
distinct O
tropism O
for O
CGM1 I-GENE
- O
( O
CD66d I-GENE
) O
and O
NCA I-GENE
( O
CD66c I-GENE
)- O
expressing O
cells O
. O

FISH O
using O
a O
whole O
chromosome O
4 O
paint O
demonstrated O
multiple O
rearrangements O
involving O
chromosome O
4 O
in O
MCF O
- O
7 O
AdVp3000 O
and O
MCF O
- O
7 O
MX O
, O
while O
S1 O
- O
M1 O
- O
80 O
contained O
only O
a O
simple O
reciprocal O
translocation O
. O

The O
MXR I-GENE
gene I-GENE
encodes O
a O
half O
- O
transporter O
and O
the O
absence O
of O
cytogenetic O
evidence O
of O
coamplification O
of O
other O
regions O
suggests O
that O
a O
partner O
may O
not O
be O
overexpressed O
, O
and O
instead O
the O
MXR I-GENE
half I-GENE
- I-GENE
transporter I-GENE
homodimerizes O
to O
mediate O
drug O
transport O
. O

The O
effect O
of O
smoking O
was O
not O
examined O
in O
this O
study O
, O
as O
such O
data O
were O
not O
available O
. O

Serum I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
SD O
score O
increased O
from O
- O
2 O
. O
2 O
and O
- O
4 O
. O
2 O
in O
men O
and O
women O
, O
respectively O
, O
to O
1 O
. O
8 O
and O
- O
0 O
. O
9 O
at O
6 O
months O
and O
0 O
. O
8 O
and O
- O
0 O
. O
7 O
at O
12 O
months O
. O

BACKGROUND O
: O
Measurement O
of O
stereoacuity O
at O
varying O
distances O
, O
by O
real O
or O
simulated O
depth O
stereoacuity O
tests O
, O
is O
helpful O
in O
the O
evaluation O
of O
patients O
with O
binocular O
imbalance O
or O
strabismus O
. O

Additional O
studies O
revealed O
that O
bovine I-GENE
brain I-GENE
Galpha I-GENE
( I-GENE
q I-GENE
/ I-GENE
11 I-GENE
) I-GENE
could O
also O
bind O
to O
an O
N O
- O
terminal O
construct O
of O
GRK2 I-GENE
, O
while O
no O
binding O
of O
Galpha O
( O
q O
/ O
11 O
), O
Galpha O
( O
s O
), O
Galpha O
( O
i O
), O
or O
Galpha I-GENE
( I-GENE
12 I-GENE
/ I-GENE
13 I-GENE
) I-GENE
to O
comparable O
constructs O
of O
GRK5 I-GENE
or O
GRK6 I-GENE
was O
observed O
. O

The O
elm1 I-GENE
kinase I-GENE
functions O
in O
a O
mitotic O
signaling O
network O
in O
budding O
yeast O
. O

Reverse O
transcription O
( O
RT O
)- O
PCR O
products O
were O
synthesized O
with O
two O
degenerate O
primers O
derived O
from O
the O
conserved O
motifs O
of O
various O
tyrosine I-GENE
kinases I-GENE
. O

In O
addition O
, O
the O
acetyltransferase O
activity O
of O
p300 I-GENE
was O
observed O
to O
be O
distinct O
from O
the O
broadly O
essential O
activation O
function O
of O
the O
CH3 I-GENE
domain I-GENE
/ O
E1A I-GENE
- O
binding O
region O
. O

The O
proliferation O
- O
specific O
HNF I-GENE
- I-GENE
3 I-GENE
/ O
fork I-GENE
head I-GENE
homolog I-GENE
- I-GENE
11B I-GENE
protein O
( O
HFH I-GENE
- I-GENE
11B I-GENE
; O
also O
known O
as O
Trident I-GENE
and O
Win I-GENE
) O
is O
a O
family O
member O
of O
the O
winged I-GENE
helix I-GENE
/ O
fork I-GENE
head I-GENE
transcription O
factors O
and O
in O
regenerating O
liver O
its O
expression O
is O
reactivated O
prior O
to O
hepatocyte O
entry O
into O
DNA O
replication O
( O
S O
phase O
). O

In O
the O
mouse O
, O
CtBP1 I-GENE
is O
expressed O
from O
embryo O
to O
adult O
, O
but O
CtBP2 I-GENE
is O
mainly O
expressed O
during O
embryogenesis O
. O

The O
multiple O
functions O
of O
Pmt3p I-GENE
described O
here O
suggest O
that O
several O
nuclear O
proteins O
are O
regulated O
by O
Pmt3p I-GENE
conjugation O
. O

The O
role O
of O
transport O
by O
sea O
ice O
from O
the O
Kara O
Sea O
into O
the O
Arctic O
Ocean O
was O
assessed O
by O
a O
small O
subgroup O
at O
GEOMAR O
. O

We O
determined O
whether O
a O
single O
injection O
of O
slow O
- O
release O
estradiol O
- O
17beta O
( O
SRE2 O
) O
would O
induce O
pseudopregnancy O
in O
gilts O
and O
whether O
PGF2alpha O
would O
regress O
the O
corpora O
lutea O
( O
CL O
) O
of O
pseudopregnancy O
. O

The O
level O
of O
serum I-GENE
creatine I-GENE
kinase I-GENE
was O
significantly O
high O
2 O
days O
after O
ESWIB O
, O
but O
it O
recovered O
in O
a O
week O
. O

Among O
the O
remaining O
22 O
sites O
, O
six O
are O
in O
the O
promoters O
of O
known O
alpha O
- O
specific O
genes O
and O
two O
other O
sites O
have O
an O
alpha2 I-GENE
- O
Mcm1 I-GENE
- O
dependent O
role O
in O
determining O
the O
direction O
of O
mating O
type O
switching O
. O

Activation O
of O
T O
cells O
via O
the O
TCR I-GENE
and O
other O
costimulatory O
receptors O
triggers O
a O
number O
of O
signaling O
cascades O
. O

A O
phylogenetic O
analysis O
with O
the O
TK I-GENE
domains I-GENE
from O
these O
sequences O
and O
a O
fourth O
, O
from O
a O
novel O
scavenger I-GENE
RTK I-GENE
( O
all O
domains O
comprise O
the O
signature O
for O
the O
TK I-GENE
class I-GENE
II I-GENE
receptors I-GENE
), O
showed O
that O
they O
are O
distantly O
related O
to O
the O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
receptors I-GENE
. O

Several O
7SL I-GENE
RNA I-GENE
- I-GENE
encoding I-GENE
sequences I-GENE
and O
various O
intergenic O
spacers O
were O
amplified O
from O
the O
individual O
HindIII I-GENE
fragments I-GENE
of O
about O
1 O
. O
3 O
and O
2 O
. O
8 O
kb O
. O

Results O
confirmed O
that O
stress O
produced O
CA3 O
dendritic O
atrophy O
and O
tianeptine O
prevented O
it O
. O

We O
have O
isolated O
a O
binding O
partner O
for O
the O
Fanconi I-GENE
anemia I-GENE
group I-GENE
C I-GENE
protein I-GENE
( O
FANCC I-GENE
) O
by O
yeast O
two O
- O
hybrid O
screening O
. O

These O
results O
suggest O
that O
both O
transcription O
activators O
depend O
on O
or O
interact O
with O
different O
subunits O
of O
RNA I-GENE
polymerase I-GENE
, O
although O
their O
role O
in O
formation O
of O
proper O
DNA O
geometry O
may O
also O
be O
crucial O
. O

Klebsiella O
oxytoca O
can O
assimilate O
nitrate O
and O
nitrite O
by O
using O
enzymes O
encoded O
by O
the O
nasFEDCBA I-GENE
operon I-GENE
. O

Marked O
hemolysis O
significantly O
increased O
plasma O
values O
of O
potassium O
, O
phosphorus O
, O
total O
protein O
, O
and O
aspartate I-GENE
aminotransferase I-GENE
. O

Studies O
have O
substantiated O
the O
involvement O
of O
numerous O
loci O
on O
certain O
chromosomes O
; O
in O
excess O
of O
10 O
chromosomes O
are O
thought O
to O
be O
involved O
. O

By O
negatively O
regulating O
GRK I-GENE
- O
mediated O
receptor O
phosphorylation O
, O
beta I-GENE
- I-GENE
arrestin I-GENE
- O
mediated O
processes O
such O
as O
Src I-GENE
recruitment O
and O
clathrin I-GENE
- O
mediated O
internalization O
, O
which O
are O
required O
for O
GPCR I-GENE
- O
mediated O
ERK I-GENE
activation O
, O
are O
inhibited O
, O
thus O
dampening O
further O
ERK I-GENE
activation O
. O

Based O
on O
subcellular O
fractionation O
, O
the O
47 I-GENE
- I-GENE
kDa I-GENE
P I-GENE
- I-GENE
CIP2 I-GENE
protein I-GENE
is O
mostly O
cytosolic O
. O

Supershift O
EMSAs O
identified O
that O
upstream I-GENE
stimulatory I-GENE
factor I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
( O
USF I-GENE
- I-GENE
1 I-GENE
and I-GENE
- I-GENE
2 I-GENE
) O
were O
part O
of O
these O
complexes O
. O

Conversely O
, O
E1A I-GENE
binding O
to O
only O
p300 I-GENE
/ O
CBP I-GENE
results O
in O
an O
increase O
in O
PARP I-GENE
enzyme I-GENE
activity O
and O
consequently O
in O
cell O
death O
susceptibility O
to O
irradiation O
, O
which O
is O
effectively O
counteracted O
by O
the O
PARP I-GENE
chemical O
inhibitor O
3 O
- O
aminobenzamide O
. O

Analysis O
of O
its O
genomic O
region O
revealed O
that O
the O
13 O
- O
kb O
Cdc6 I-GENE
gene I-GENE
is O
divided O
into O
12 O
exons O
by O
11 O
introns O
. O

These O
include O
the O
CACCC O
and O
CAAT O
motifs O
. O

Skin O
pH O
changes O
associated O
with O
iontophoresis O
. O

This O
distinction O
was O
based O
upon O
whether O
the O
diagnosis O
provided O
a O
straightforward O
range O
of O
prognoses O
or O
an O
ambiguous O
clinical O
implication O
. O

The O
availability O
of O
potent O
regulatory O
DNA O
cassettes O
harboring O
the O
murine I-GENE
D1A I-GENE
gene I-GENE
promoter I-GENE
could O
aid O
testing O
the O
neuronal O
- O
specific O
expression O
of O
transgenes O
in O
vivo O
. O

It O
may O
be O
dependent O
on O
location O
of O
a O
focus O
( O
according O
to O
EEG O
) O
as O
well O
as O
on O
the O
character O
and O
manifestation O
of O
the O
accompanying O
neuropsychologic O
symptomatology O
. O

The O
results O
of O
these O
studies O
demonstrate O
that O
the O
rat O
HDL O
receptor O
SR I-GENE
- I-GENE
BI I-GENE
promoter O
contains O
two O
sterol O
response O
elements O
( O
pSRE O
and O
dSRE O
) O
through O
which O
SREBP I-GENE
- I-GENE
1a I-GENE
can O
bind O
and O
activate O
transcription O
of O
this O
gene O
. O

Phosphorylation O
of O
myosin I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
( O
MBS I-GENE
) O
of O
myosin I-GENE
phosphatase I-GENE
by O
Rho I-GENE
- I-GENE
kinase I-GENE
in O
vivo O
. O

Of O
these O
patients O
, O
46 O
, O
164 O
were O
placed O
on O
a O
waiting O
list O
for O
transplantation O
, O
23 O
, O
275 O
of O
whom O
received O
a O
first O
cadaveric O
transplant O
between O
1991 O
and O
1997 O
. O

In O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
), O
this O
GLUT4 I-GENE
repressor I-GENE
element I-GENE
( O
G4RE I-GENE
) O
generated O
specific O
bands O
with O
nuclear O
extracts O
from O
preadipocytes O
, O
but O
not O
from O
adipocytes O
. O

Syndromes O
of O
abnormal O
fat O
redistribution O
and O
metabolic O
complications O
in O
HIV O
- O
infected O
patients O
. O

Cytoprotection O
with O
amifostine O
in O
radiotherapy O
or O
radio O
- O
chemotherapy O
of O
head O
and O
neck O
tumors O

Immunohistochemical O
staining O
was O
positive O
for O
S I-GENE
- I-GENE
100 I-GENE
in O
all O
9 O
cases O
stained O
, O
positive O
for O
HMB I-GENE
- I-GENE
45 I-GENE
in O
9 O
( O
90 O
%) O
of O
10 O
, O
and O
negative O
for O
cytokeratin I-GENE
in O
all O
9 O
cases O
in O
which O
myxoid O
melanoma O
remained O
in O
the O
block O
after O
previous O
sections O
. O

Patients O
with O
types O
I O
and O
III O
MPGN O
did O
not O
differ O
in O
age O
at O
apparent O
onset O
, O
age O
at O
diagnosis O
, O
or O
interval O
from O
apparent O
onset O
of O
symptoms O
to O
diagnosis O
( O
biopsy O
). O

Residual O
urinary O
abnormalities O
were O
significantly O
more O
frequent O
in O
patients O
with O
type O
III O
than O
type O
I O
MPGN O
. O

Taken O
together O
, O
differences O
in O
signaling O
and O
tissue O
expression O
suggest O
that O
the O
human I-GENE
intermediate I-GENE
PRLr I-GENE
differs O
from O
the O
long I-GENE
PRLr I-GENE
in O
physiological O
function O
. O

We O
describe O
here O
a O
Drosophila I-GENE
melanogaster I-GENE
FAK I-GENE
homologue I-GENE
, O
DFak56 I-GENE
, O
which O
maps O
to O
band O
56D O
on O
the O
right O
arm O
of O
the O
second O
chromosome O
. O

Because O
the O
Pit I-GENE
- I-GENE
1 I-GENE
sites I-GENE
in O
the O
hGH I-GENE
- I-GENE
N I-GENE
gene I-GENE
promoter I-GENE
are O
insufficient O
for O
such O
gene O
activation O
in O
vivo O
, O
these O
data O
suggested O
a O
unique O
chromatin O
- O
mediated O
developmental O
role O
for O
Pit I-GENE
- I-GENE
1 I-GENE
in O
the O
hGH I-GENE
LCR I-GENE
. O

Recombinant I-GENE
prenylcysteine I-GENE
lyase I-GENE
was O
produced O
in O
a O
baculovirus O
- O
Sf9 O
expression O
system O
. O

We O
show O
here O
that O
the O
third O
SH3 I-GENE
domain I-GENE
binds O
to O
Sos I-GENE
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
for O
Ras I-GENE
and O
Rac I-GENE
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Point O
mutations O
in O
the O
third O
SH3 I-GENE
domain I-GENE
abolished O
the O
vinexin I-GENE
- O
Sos I-GENE
interaction O
. O

In O
gel O
mobility O
shift O
assays O
, O
low O
binding O
activity O
of O
CBF I-GENE
to O
the O
wild I-GENE
- I-GENE
type I-GENE
AtpC I-GENE
promoter I-GENE
sequence I-GENE
was O
observed O
with O
nuclear O
extracts O
from O
tissue O
with O
low O
AtpC I-GENE
expression O
levels O
, O
i O
. O
e O
. O
extracts O
from O
etiolated O
and O
photobleached O
seedlings O
, O
whereas O
high O
binding O
activity O
was O
detectable O
with O
extracts O
from O
tissues O
with O
high O
AtpC I-GENE
expression O
levels O
, O
i O
. O
e O
. O
extracts O
from O
light O
- O
grown O
seedlings O
and O
etiolated O
seedlings O
treated O
with O
cytokinin I-GENE
. O

Mycoplasma O
hominis O
infections O
are O
easily O
missed O
because O
conventional O
methods O
for O
bacterial O
detection O
may O
fail O
. O

For O
this O
purpose O
, O
we O
used O
a O
series O
of O
plasmid O
constructs O
encoding O
different O
forms O
of O
the O
envelope I-GENE
glycoprotein I-GENE
E I-GENE
of I-GENE
the I-GENE
flavivirus I-GENE
tick I-GENE
- I-GENE
borne I-GENE
encephalitis I-GENE
virus I-GENE
. O

They O
are O
subdivided O
into O
two O
types O
that O
activate O
transduction O
pathways O
via O
different O
cell O
surface O
receptors O
. O

We O
report O
here O
that O
out O
of O
the O
major O
pro O
- O
inflammatory O
cytokines O
examined O
, O
IL I-GENE
- I-GENE
1alpha I-GENE
, O
IL I-GENE
- I-GENE
1beta I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
, O
only O
IL I-GENE
- I-GENE
6 I-GENE
was O
generated O
and O
secreted O
in O
PKCeta I-GENE
- O
expressing O
cells O
without O
any O
additional O
inducer O
in O
serum O
- O
supplemented O
cultures O
( O
10 O
% O
FCS O
). O

Demyelinating O
diseases O
involving O
the O
grey O
matter O
were O
very O
rare O
, O
but O
we O
must O
consider O
the O
presence O
of O
symmetrical O
thalamic O
involvement O
in O
patients O
with O
ADEM O
. O

To O
define O
the O
minimal O
VDRE O
binding O
domain O
for O
human I-GENE
VDR I-GENE
( O
hVDR I-GENE
), O
a O
series O
of O
C O
- O
terminally O
truncated O
hVDR I-GENE
mutants I-GENE
( O
Delta134 O
, O
Delta113 O
, O
Delta102 O
, O
Delta90 O
, O
Delta84 O
, O
Delta80 O
, O
and O
Delta60 O
) O
was O
generated O
and O
expressed O
in O
bacteria O
. O

By O
an O
induced O
- O
fit O
mechanism O
, O
contacts O
with O
the O
anticodon O
can O
activate O
formation O
of O
a O
robust O
transition O
state O
at O
a O
site O
over O
70 O
A O
away O
. O

These O
REPs O
, O
or O
clusters O
of O
paralogous O
loci O
, O
are O
15 O
- O
100 O
kb O
and O
harbor O
at O
least O
four O
ESTs O
and O
an O
expressed O
SH3GL I-GENE
pseudogene I-GENE
. O

This O
revealed O
a O
minimum O
of O
six O
novel O
OSBP I-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
designated O
ORP I-GENE
- I-GENE
1 I-GENE
to O
ORP I-GENE
- I-GENE
6 I-GENE
. O

In O
part O
as O
a O
result O
of O
its O
inability O
to O
sustain O
radiative O
loses O
, O
the O
BB O
resonator O
has O
extremely O
low O
RF O
power O
requirements O
. O

In O
addition O
, O
narZ I-GENE
expression O
was O
induced O
approximately O
20 O
- O
fold O
intracellularly O
in O
Madin O
- O
Darby O
canine O
kidney O
epithelial O
cells O
and O
16 O
- O
fold O
in O
intracellular O
salts O
medium O
, O
which O
is O
believed O
to O
mimic O
the O
intracellular O
milieu O
. O

However O
, O
mechanisms O
underlying O
HIV O
- O
1 O
gene O
expression O
in O
the O
CNS O
are O
poorly O
understood O
. O

Is O
radical O
trachelectomy O
a O
safe O
alternative O
to O
radical O
hysterectomy O
for O
patients O
with O
stage O
IA O
- O
B O
carcinoma O
of O
the O
cervix O
? O
BACKGROUND O
: O
The O
prognosis O
associated O
with O
lymph O
node O
negative O
, O
early O
stage O
carcinoma O
of O
the O
cervix O
is O
excellent O
, O
with O
5 O
- O
year O
survival O
rates O
greater O
than O
90 O
%. O

A O
key O
event O
in O
this O
process O
is O
the O
selective O
recognition O
of O
the O
target O
membrane O
by O
the O
vesicle O
and O
the O
current O
view O
is O
that O
SNARE I-GENE
protein I-GENE
interactions O
likely O
play O
a O
central O
role O
in O
vesicle O
- O
target O
recognition O
and O
or O
membrane O
fusion O
. O

Scapulae O
with O
a O
Type O
I O
configuration O
were O
found O
to O
have O
low O
values O
for O
the O
coraco O
- O
glenoid O
angle O
and O
coracoid O
overlap O
, O
which O
are O
known O
to O
be O
associated O
with O
a O
short O
coraco O
- O
humeral O
distance O
. O

Measurements O
in O
the O
LWS O
p O
. O
a O
. O
, O
LWS O
lat O
. O
and O
at O
Ward O
' O
s O
triangle O
were O
made O
in O
a O
total O
of O
100 O
patients O
. O

A O
group O
of O
66 O
DSM O
- O
IV O
paranoid O
schizophrenic O
in O
- O
patients O
were O
assessed O
three O
times O
using O
the O
SAPS O
, O
SANS O
, O
BPRS O
and O
PAS O
. O

In O
conclusion O
: O
( O
i O
) O
TECRA O
kit O
is O
suggested O
to O
be O
used O
for O
screening O
SE O
producing O
strains O
; O
( O
ii O
) O
SET O
- O
RPLA O
and O
RIDASCREEN O
kits O
are O
suitable O
for O
epidemiological O
investigation O
of O
SE O
types O
, O
but O
the O
lack O
of O
ability O
for O
detecting O
SEE O
, O
long O
time O
required O
for O
testing O
with O
SET O
- O
RPLA O
kit O
and O
high O
background O
when O
using O
RIDASCREEN O
kit O
must O
be O
overcome O
; O
and O
( O
iii O
) O
because O
of O
the O
complicated O
test O
procedures O
and O
the O
lack O
of O
ability O
for O
detecting O
SEE O
, O
the O
practicality O
of O
SET O
- O
EIA O
kit O
in O
screening O
and O
epidemiological O
research O
purposes O
is O
low O
. O

Comparison O
of O
immunoassay O
kits O
for O
detection O
of O
staphylococcal I-GENE
enterotoxins I-GENE
produced O
by O
Staphylococcus O
aureus O

Despite O
the O
high O
frequency O
of O
natural O
infection O
, O
the O
seropositive O
rates O
of O
JEV O
antibody O
still O
correlated O
well O
with O
the O
dose O
of O
vaccine O
received O
, O
i O
. O
e O
., O
67 O
% O
( O
1122 O
/ O
1664 O
), O
66 O
% O
( O
65 O
/ O
97 O
), O
33 O
% O
( O
4 O
/ O
12 O
) O
and O
40 O
% O
( O
19 O
/ O
47 O
) O
for O
children O
receiving O
3 O
, O
2 O
, O
1 O
, O
and O
0 O
dose O
of O
JE O
vaccines O
, O
respectively O
( O
P O
< O
0 O
. O
0001 O
Chi O
- O
square O
for O
trend O
test O
). O

Furthermore O
, O
in O
vivo O
and O
in O
vitro O
protein O
- O
protein O
interaction O
experiments O
have O
shown O
that O
SR33 I-GENE
protein I-GENE
interacts O
with O
itself O
and O
with O
SR45 I-GENE
protein I-GENE
but O
not O
with O
two O
other O
members O
( O
SRZ21 I-GENE
and O
SRZ22 I-GENE
) O
of O
the O
SR I-GENE
family I-GENE
that O
are O
known O
to O
interact O
with O
the O
Arabidopsis O
full O
- O
length O
U I-GENE
- I-GENE
70K I-GENE
only O
. O

In O
summary O
, O
WT1 I-GENE
is O
enriched O
by O
oligo O
( O
dT O
) O
chromatography O
, O
as O
are O
U2AF65 I-GENE
, O
the O
U5 I-GENE
small I-GENE
nuclear I-GENE
RNP I-GENE
- I-GENE
associated I-GENE
protein I-GENE
p116 I-GENE
and O
hnRNP O
A1 I-GENE
. O

Six O
out O
of O
ten O
hearts O
from O
macerated O
stillborn O
infants O
showed O
varying O
degrees O
of O
positive O
staining O
. O

Tih1 I-GENE
maps O
to O
distal O
mouse O
Chr O
1 O
and O
human O
Chr O
1q31 O
, O
chromosomal O
regions O
that O
have O
not O
shown O
evidence O
for O
imprinting O
and O
, O
in O
contrast O
to O
Ipl I-GENE
, O
Tih1 I-GENE
is O
expressed O
equally O
from O
both O
parental O
alleles O
. O

A O
novel O
pleckstrin I-GENE
homology I-GENE
- I-GENE
related I-GENE
gene I-GENE
family I-GENE
defined O
by O
Ipl I-GENE
/ O
Tssc3 I-GENE
, O
TDAG51 I-GENE
, O
and O
Tih1 I-GENE
: O
tissue O
- O
specific O
expression O
, O
chromosomal O
location O
, O
and O
parental O
imprinting O
. O

The O
potential O
for O
highly O
reactive O
nanoparticles O
( O
RNP O
) O
to O
absorb O
destructively O
, O
i O
. O
e O
. O
to O
neutralize O
highly O
toxic O
substances O
such O
as O
the O
warfare O
agents O
GA O
, O
GB O
, O
HD O
and O
VX O
, O
has O
been O
demonstrated O
in O
the O
laboratory O
. O

There O
were O
minimal O
negative O
effects O
on O
hematological O
parameters O
, O
acid O
- O
base O
status O
, O
and O
blood O
gases O
. O

Twelve O
out O
of O
43 O
renal O
failure O
patients O
had O
troponin I-GENE
I I-GENE
0 O
. O
13 O
- O
0 O
. O
9 O
microg O
/ O
l O
using O
Axsym O
method O
and O
4 O
had O
levels O
of O
0 O
. O
07 O
- O
0 O
. O
13 O
microg O
/ O
l O
using O
Immuno O
1 O
. O

Therefore O
, O
we O
propose O
that O
p27 I-GENE
represents O
a O
crucial O
molecule O
in O
HMBA O
signaling O
that O
cannot O
be O
replaced O
by O
p21 I-GENE
. O

Transient O
, O
high O
- O
level O
Ras I-GENE
- O
expression O
induces O
transcriptional O
activation O
of O
p21 I-GENE
mediated O
by O
a O
GC O
- O
rich O
region O
in O
p21 I-GENE
promoter I-GENE
- O
83 O
- O
54 O
bp O
relative O
to O
the O
transcription O
initiation O
site O
containing O
binding O
sites O
for O
Sp1 I-GENE
- I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

The O
RET I-GENE
/ O
PTC3 I-GENE
rearrangement O
is O
formed O
by O
fusion O
of O
the O
ELE1 I-GENE
and O
RET I-GENE
genes I-GENE
, O
and O
is O
highly O
prevalent O
in O
radiation O
- O
induced O
post O
- O
Chernobyl O
papillary O
thyroid O
carcinomas O
. O

Apoptosis O
of O
small O
cells O
is O
still O
observed O
after O
co O
- O
transfection O
of O
JBD I-GENE
and O
LMP1 I-GENE
but O
in O
addition O
a O
few O
apoptotic O
HD O
- O
MyZ O
cells O
with O
large O
fused O
nuclear O
masses O
are O
identified O
suggesting O
that O
specific O
inhibition O
of O
JNK I-GENE
leads O
also O
to O
apoptosis O
of O
LMP1 I-GENE
induced O
RS O
cells O
. O

In O
addition O
to O
the O
bZIP I-GENE
protein I-GENE
Opaque2 I-GENE
( O
O2 I-GENE
), O
there O
are O
other O
maize O
endosperm O
nuclear O
proteins O
that O
recognize O
the O
O2 I-GENE
box I-GENE
in O
22 O
kDa O
zein I-GENE
gene O
promoters O
. O

The O
mEmBP I-GENE
- I-GENE
1 I-GENE
protein I-GENE
can O
activate O
transcription O
from O
a O
truncated O
promoter O
containing O
a O
pentamer O
of O
the O
O2 I-GENE
site I-GENE
in O
yeast O
cells O
; O
however O
, O
it O
inhibited O
regulated O
transcription O
of O
a O
22 I-GENE
kDa I-GENE
zein I-GENE
promoter I-GENE
in O
a O
transient O
expression O
assay O
using O
cultured O
maize O
endosperm O
cells O
. O

GHB O
, O
2 O
CB O
, O
HMB O
, O
are O
some O
of O
these O
recent O
substances O
. O

There O
were O
15 O
deaths O
, O
seven O
of O
which O
were O
felt O
to O
be O
avoidable O
. O

With O
this O
GH I-GENE
and O
estrogen O
treatment O
regimen O
, O
most O
girls O
with O
TS O
can O
grow O
and O
develop O
much O
more O
in O
conformity O
with O
their O
healthy O
peers O
. O

We O
propose O
that O
the O
reduced O
responsiveness O
of O
CYP3A2 I-GENE
is O
the O
result O
of O
preferential O
binding O
of O
COUP I-GENE
- I-GENE
TF I-GENE
at O
the O
CYP3A2 I-GENE
DexRE I-GENE
- I-GENE
1 I-GENE
site I-GENE
. O

Higher O
CYP3A23 I-GENE
basal O
activity O
appears O
to O
be O
due O
to O
an O
E O
- O
box O
in O
3A23SiteA I-GENE
that O
interacts O
with O
USF1 I-GENE
, O
a O
ubiquitous O
bHLH I-GENE
/ I-GENE
leucine I-GENE
zipper I-GENE
transcription I-GENE
factor I-GENE
. O

The O
first O
one O
is O
a O
TPA O
- O
responsive O
element O
that O
controls O
the O
base O
- O
line O
ST3 I-GENE
promoter I-GENE
activity O
but O
is O
not O
required O
for O
its O
activation O
. O

To O
understand O
the O
basis O
for O
the O
increased O
cell O
surface O
stability O
compared O
with O
wild O
- O
type O
peptide O
and O
to O
understand O
the O
differences O
in O
T O
cell O
recognition O
between O
I1Y I-GENE
and O
I1F I-GENE
, O
we O
determined O
the O
x O
- O
ray O
crystal O
structures O
of O
the O
two O
class I-GENE
I I-GENE
MHC I-GENE
- I-GENE
peptide I-GENE
complexes I-GENE
. O

Redistribution O
of O
mannosidase I-GENE
I I-GENE
was O
also O
observed O
in O
cells O
incubated O
at O
15 O
degrees O
C O
. O

In O
addition O
, O
using O
biochemical O
activity O
assays O
for O
Rho I-GENE
- O
like O
GTPases I-GENE
, O
we O
show O
that O
the O
expression O
of O
beta1A I-GENE
, O
beta1D I-GENE
, O
or O
IL2R I-GENE
- O
beta1A I-GENE
in O
GE11 O
or O
GD25 O
cells O
triggers O
activation O
of O
both O
RhoA I-GENE
and O
Rac1 I-GENE
, O
but O
not O
of O
Cdc42 I-GENE
. O

In O
conclusion O
, O
our O
data O
do O
not O
support O
a O
role O
for O
IVIg I-GENE
in O
the O
remyelination O
of O
stable O
multiple O
sclerosis O
lesions O
as O
measured O
by O
central O
conduction O
time O
. O

The O
rhabdomyosarcoma O
R1H O
growing O
on O
the O
right O
flank O
of O
male O
WAG O
/ O
Rij O
rats O
was O
clamped O
for O
2 O
or O
4 O
h O
at O
20 O
degrees O
C O
or O
37 O
degrees O
C O
. O

Relative O
to O
coherent O
control O
words O
( O
e O
. O
g O
., O
quick O
), O
these O
discourse O
- O
dependent O
semantic O
anomalies O
elicited O
a O
large O
N400 O
effect O
that O
began O
at O
about O
200 O
to O
250 O
msec O
after O
word O
onset O
. O

These O
synergistic O
effects O
were O
strongly O
Jem I-GENE
- I-GENE
1 I-GENE
dose O
- O
dependent O
. O

Like O
the O
Tob I-GENE
protein I-GENE
, O
Tob2 I-GENE
inhibited O
cell O
cycle O
progression O
from O
the O
G0 O
/ O
G1 O
to O
S O
phases O
. O

The O
coordinate O
increase O
in O
cyclin I-GENE
D1 I-GENE
and O
p21 I-GENE
had O
the O
effect O
of O
decreasing O
the O
specific O
but O
not O
absolute O
activity O
of O
cyclin I-GENE
D1 I-GENE
/ O
cdk4 I-GENE
. O
p53 I-GENE
was O
not O
involved O
since O
CSF I-GENE
- I-GENE
1 I-GENE
induction O
of O
p21 I-GENE
was O
unaffected O
by O
dominant I-GENE
- I-GENE
negative I-GENE
p53 I-GENE
expression O
. O

In O
addition O
, O
SLK I-GENE
displays O
high O
homology O
to O
microtubule I-GENE
and I-GENE
nuclear I-GENE
associated I-GENE
protein I-GENE
( O
M I-GENE
- I-GENE
NAP I-GENE
) O
and O
AT1 I-GENE
- I-GENE
46 I-GENE
, O
both O
of O
unknown O
function O
. O

In O
this O
study O
26 O
patients O
( O
20 O
females O
and O
6 O
males O
) O
were O
evaluated O
. O

The O
signalling O
molecules O
Wnt1 I-GENE
and O
Sonic I-GENE
hedgehog I-GENE
, O
implicated O
in O
the O
activation O
of O
Myf5 I-GENE
in O
myogenic O
progenitor O
cells O
in O
the O
somite O
, O
are O
also O
produced O
in O
the O
viscinity O
of O
the O
Myf5 I-GENE
expression I-GENE
domain I-GENE
in O
the O
mesencephalon O
. O

STUDY O
DESIGN O
AND O
METHODS O
: O
A O
study O
was O
initiated O
to O
compare O
the O
collection O
of O
PBPCs O
with O
the O
new O
device O
, O
the O
AutoPBSC O
( O
version O
[ O
V O
] O
6 O
. O
0 O
with O
AutoPBSC O
tubing O
set O
), O
and O
that O
with O
the O
MNC O
( O
mononuclear O
cell O
) O
procedure O
( O
V4 O
. O
7 O
with O
white O
cell O
tubing O
set O
), O
for O
patients O
and O
healthy O
donors O
. O

Albumin I-GENE
dialysis O
: O
effective O
removal O
of O
copper O
in O
a O
patient O
with O
fulminant O
Wilson O
disease O
and O
successful O
bridging O
to O
liver O
transplantation O
: O
a O
new O
possibility O
for O
the O
elimination O
of O
protein O
- O
bound O
toxins O
. O

Some O
artificial O
promoter O
constructs O
containing O
multiple O
Sp1 I-GENE
sites I-GENE
were O
highly O
responsive O
to O
ethanol O
, O
but O
others O
were O
not O
, O
suggesting O
that O
the O
organization O
of O
the O
proximal O
promoter O
region O
was O
an O
additional O
factor O
that O
affected O
the O
ethanol O
response O
. O

Overexpression O
of O
CDP I-GENE
/ O
cut I-GENE
in O
ROS O
17 O
/ O
2 O
. O
8 O
osteosarcoma O
cells O
results O
in O
repression O
of O
OC I-GENE
promoter I-GENE
activity O
; O
this O
repression O
is O
abrogated O
by O
mutating O
OC I-GENE
box I-GENE
I I-GENE
. O

Injection O
of O
double O
- O
stranded O
RNA O
into O
C O
. O
elegans O
results O
in O
embryonic O
lethality O
; O
thus O
, O
the O
SF1 I-GENE
gene I-GENE
is O
essential O
not O
only O
in O
yeast O
but O
also O
in O
at O
least O
one O
metazoan O
. O

Both O
domains O
were O
required O
for O
specific O
DNA O
binding O
to O
the O
beta I-GENE
- I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
element I-GENE
, O
producing O
a O
DNase I-GENE
I I-GENE
footprint O
covering O
predominantly O
one O
strand O
. O

Snail I-GENE
family I-GENE
proteins I-GENE
are O
zinc O
finger O
transcriptional O
regulators O
first O
identified O
in O
Drosophila O
which O
play O
critical O
roles O
in O
cell O
fate O
determination O
. O

Consistent O
with O
this O
finding O
, O
beta I-GENE
- I-GENE
catenin I-GENE
interacted O
directly O
with O
the O
RA I-GENE
receptor I-GENE
( O
RAR I-GENE
) O
in O
a O
retinoid O
- O
dependent O
manner O
, O
but O
not O
with O
the O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
), O
and O
RAR I-GENE
competed O
with O
TCF I-GENE
for O
beta I-GENE
- I-GENE
catenin I-GENE
binding O
. O

Sequence O
analysis O
of O
the O
promoter O
region O
showed O
no O
TATA O
box O
but O
identified O
consensus O
binding O
motifs O
for O
Sp1 I-GENE
, O
CREB I-GENE
, O
and O
half O
sites O
of O
the O
estrogen I-GENE
receptor I-GENE
binding I-GENE
site I-GENE
. O

Sak I-GENE
kinase I-GENE
gene O
structure O
and O
transcriptional O
regulation O
. O

Thrombolysis O
was O
followed O
by O
a O
similar O
increase O
of O
platelet O
activity O
with O
maximal O
values O
reached O
at O
the O
3rd O
hour O
in O
both O
groups O
( O
196 O
+/- O
43 O
IU O
/ O
ml O
in O
Group O
1 O
and O
192 O
+/- O
39 O
in O
Group O
2 O
: O
p O
& O
lt O
; O
001versus O
baseline O
and O
p O
NS O
between O
the O
groups O
). O

Similar O
to O
Hp140 I-GENE
, O
isolated O
Hp55 I-GENE
binds O
DNA O
with O
moderate O
strength O
and O
was O
a O
specificity O
for O
double O
- O
stranded O
primer O
- O
template O
DNA O
. O

Finally O
, O
three O
new O
missense O
mutations O
, O
E138V O
, O
R254G O
, O
and O
P362R O
, O
were O
identified O
in O
the O
human I-GENE
AC I-GENE
gene I-GENE
from O
FD O
patients O
. O

These O
data O
indicate O
that O
the O
interaction O
of O
eIF4A I-GENE
with O
the O
middle O
region O
of O
eIF4GI I-GENE
is O
necessary O
for O
translation O
, O
whereas O
the O
interaction O
of O
eIF4A I-GENE
with O
the O
C O
- O
terminal O
region O
plays O
a O
modulatory O
role O
. O

The O
DAP5 I-GENE
/ O
p86 I-GENE
apoptotic O
form O
was O
more O
potent O
than O
DAP5 I-GENE
/ O
p97 I-GENE
in O
these O
functional O
assays O
. O

12 O
: O
2684 O
- O
2697 O
, O
1998 O
): O
a O
key O
step O
of O
this O
model O
is O
the O
activation O
of O
the O
MAPK I-GENE
Fus3p I-GENE
through O
the O
G O
( O
betagamma O
)- O
dependent O
relocalization O
of O
the O
Ste5p I-GENE
- O
MAPK I-GENE
cascade O
to O
the O
plasma O
membrane O
. O

Consistent O
with O
this O
finding O
, O
wild I-GENE
- I-GENE
type I-GENE
SAGA I-GENE
inhibits O
TBP I-GENE
binding O
to O
the O
HIS3 I-GENE
promoter I-GENE
in O
vitro O
, O
while O
SAGA I-GENE
lacking O
Spt3 I-GENE
or O
Spt8 I-GENE
is O
not O
inhibitory O
. O

Saccharomyces O
cerevisiae O
contains O
a O
genetically O
and O
biochemically O
proven O
CAK I-GENE
gene I-GENE
, O
CAK1 I-GENE
, O
that O
encodes O
a O
monomeric O
44 I-GENE
- I-GENE
kDa I-GENE
Cak1p I-GENE
protein I-GENE
unrelated O
to O
Cdk7 I-GENE
. O

Northern O
blot O
and O
reverse O
transcription O
- O
PCR O
analyses O
of O
human O
mRNA O
samples O
demonstrate O
that O
RNR I-GENE
is O
expressed O
exclusively O
in O
the O
retina O
, O
with O
transcripts O
of O
approximately O
7 O
. O
5 O
kb O
, O
approximately O
3 O
. O
0 O
kb O
, O
and O
approximately O
2 O
. O
3 O
kb O
by O
Northern O
blot O
analysis O
. O

Particularly O
striking O
was O
the O
conservation O
of O
an O
AP I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
within O
100 O
nucleotides O
upstream O
of O
the O
transcription O
initiation O
site O
in O
both O
Aal I-GENE
- O
rpL34 I-GENE
and O
Aal I-GENE
- O
rpL8 I-GENE
genes O
. O

Based O
on O
a O
type O
I O
error O
of O
0 O
. O
05 O
, O
our O
study O
had O
a O
power O
greater O
than O
or O
equal O
to O
75 O
% O
to O
detect O
group O
differences O
in O
treatment O
effect O
of O
greater O
than O
or O
equal O
to O
15 O
% O
to O
20 O
%. O

CONCLUSIONS O
: O
Serum O
levels O
of O
S I-GENE
- I-GENE
100beta I-GENE
are O
reliable O
markers O
for O
adverse O
neurologic O
outcomes O
after O
cardiac O
surgery O
. O

However O
, O
no O
genetic O
alteration O
was O
detected O
in O
any O
of O
the O
cancers O
examined O
. O

All O
problems O
were O
associated O
with O
fractured O
or O
lost O
screws O
. O

Statins I-GENE
: O
lower O
lipids O
and O
better O
bones O
? O
Although O
statins O
are O
widely O
used O
as O
cholesterol O
- O
lowering O
drugs O
, O
a O
recent O
study O
suggests O
that O
these O
compounds O
have O
anabolic O
effects O
on O
bone O
and O
could O
be O
developed O
into O
new O
treatments O
for O
common O
metabolic O
bone O
diseases O
such O
as O
osteoporosis O

The O
accumulated O
products O
of O
ancient O
duplication O
events O
can O
be O
readily O
observed O
among O
the O
genes O
encoding O
voltage O
- O
dependent O
Ca O
( O
2 O
+) O
ion O
channels O
. O

The O
VirR I-GENE
response I-GENE
regulator I-GENE
from O
Clostridium O
perfringens O
binds O
independently O
to O
two O
imperfect O
direct O
repeats O
located O
upstream O
of O
the O
pfoA I-GENE
promoter I-GENE
. O

Cloning O
and O
sequencing O
of O
the O
upstream O
region O
of O
pepX I-GENE
revealed O
the O
presence O
of O
two O
ORFs O
of O
360 O
and O
1 O
, O
338 O
bp O
that O
were O
shown O
to O
be O
able O
to O
encode O
proteins O
with O
high O
homology O
to O
GlnR I-GENE
and O
GlnA I-GENE
proteins I-GENE
, O
respectively O
. O

Objective O
: O
To O
evaluate O
endometrial O
thickness O
and O
the O
incidence O
of O
uterine O
bleeding O
in O
postmenopausal O
women O
using O
either O
tibolone O
2 O
. O
5 O
mg O
or O
continuous O
combined O
2 O
mg O
estradiol O
and O
1 O
mg O
norethisterone O
acetate O
( O
E O
+ O
NETA O
) O
daily O
as O
hormone O
replacement O
therapy O
. O

Leukocyte O
cultures O
, O
prepared O
from O
blood O
drawn O
from O
these O
18 O
children O
at O
6 O
months O
of O
age O
, O
produced O
lower O
yields O
of O
IFN I-GENE
than O
those O
of O
the O
remaining O
53 O
children O
, O
when O
stimulated O
with O
adenovirus O
( O
P O
< O
0 O
. O
001 O
), O
coronavirus O
( O
P O
< O
0 O
. O
001 O
) O
or O
rhinovirus O
( O
P O
= O
0 O
. O
002 O
). O

In O
the O
BF O
ECT O
group O
the O
- O
age O
based O
dose O
would O
have O
been O
similarly O
dependent O
on O
the O
initial O
seizure O
threshold O
level O
. O

Histological O
analysis O
showed O
that O
the O
neuronal O
loss O
in O
the O
DHED O
- O
treated O
group O
was O
notably O
reduced O
in O
the O
hippocampal O
area O
( O
CA1 O
) O
of O
ischemic O
rats O
and O
in O
the O
dentate O
gyrus O
and O
hippocampal O
area O
( O
CA1 O
and O
CA3 O
) O
of O
EC O
- O
lesioned O
rats O
compared O
with O
the O
nontreated O
group O
. O

The O
extents O
of O
phosphorylation O
of O
Ser44 O
and O
Ser64 O
were O
1 O
: O
1 O
, O
whereas O
those O
of O
the O
four O
minor O
sites O
all O
together O
were O
< O
30 O
% O
of O
the O
major O
one O
. O

Serum O
HBV O
- O
DNA O
, O
viral O
serology O
, O
and O
liver O
enzymes O
were O
measured O
sequentially O
; O
liver O
histology O
was O
taken O
before O
and O
during O
treatment O
in O
12 O
patients O
. O

Chem O
. O

Maximum O
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
was O
reached O
at O
a O
concentration O
of O
250 O
nmol O
/ O
L O
of O
CalC O
. O

Haycocknema O
perplexum O
n O
. O
g O
., O
n O
. O
sp O
. O

Rams O
were O
weighed O
and O
testis O
size O
was O
estimated O
by O
orchimetry O
at O
each O
time O
period O
. O

Animal O
studies O
showed O
that O
beam O
equalization O
significantly O
improved O
fluoroscopic O
and O
angiographic O
image O
quality O
. O

Role O
of O
estrogen I-GENE
receptor I-GENE
ligand O
and O
estrogen O
response O
element O
sequence O
on O
interaction O
with O
chicken I-GENE
ovalbumin I-GENE
upstream I-GENE
promoter I-GENE
transcription I-GENE
factor I-GENE
( O
COUP I-GENE
- I-GENE
TF I-GENE
). O

CONCLUSION O
: O
In O
Cdks I-GENE
functioning O
throughout O
the O
cell O
cycle O
, O
tyrosine O
phosphorylation O
is O
inhibitory O
to O
the O
activation O
of O
kinase O
, O
whereas O
the O
phosphorylation O
of O
threonine O
in O
the O
T O
- O
loop O
is O
essential O
for O
activation O
. O

We O
also O
report O
that O
AHR I-GENE
interacts O
with O
COUP I-GENE
- I-GENE
TF I-GENE
in O
transfected O
CV O
- O
1 O
cells O
. O

AB004534 I-GENE
. O

The O
prevalence O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
infection O
is O
relatively O
low O
in O
childhood O
, O
with O
anti I-GENE
- I-GENE
HCV I-GENE
prevalence O
rates O
of O
0 O
. O
1 O
- O
0 O
. O
4 O
% O
in O
the O
Western O
world O
. O

Clear O
and O
evidenced O
- O
based O
information O
should O
be O
provided O
to O
patients O
as O
to O
the O
means O
of O
prevention O
with O
special O
attention O
to O
individual O
risk O
groups O
such O
as O
IV O
drug O
abusers O
. O

During O
latency O
, O
more O
than O
1 O
% O
of O
neurons O
in O
ganglia O
that O
innervate O
the O
footpad O
expressed O
beta I-GENE
- I-GENE
galactosidase I-GENE
, O
with O
the O
number O
of O
positive O
cells O
remaining O
constant O
for O
at O
least O
5 O
months O
. O

As O
an O
alternative O
approach O
to O
this O
question O
, O
we O
have O
studied O
the O
effects O
of O
ectopically O
expressed O
SHIP I-GENE
, O
SHP I-GENE
- I-GENE
1 I-GENE
, O
or O
SHP I-GENE
- I-GENE
2 I-GENE
SH2 O
- O
containing O
decoy O
proteins O
on O
Fc I-GENE
gamma I-GENE
RIIB1 I-GENE
signaling O
. O

Compared O
to O
those O
with O
normal O
renal O
functions O
, O
these O
patients O
were O
older O
( O
P O
< O
or O
= O
0 O
. O
01 O
), O
had O
significantly O
elevated O
blood O
pressures O
( O
P O
< O
0 O
. O
01 O
or O
P O
= O
0 O
. O
0001 O
), O
and O
in O
the O
case O
of O
Type O
1 O
DM O
, O
with O
a O
higher O
body O
mass O
index O
( O
P O
= O
0 O
. O
0001 O
) O
and O
waist O
- O
hip O
ratio O
( O
P O
< O
0 O
. O
01 O
). O

In O
all O
tissues O
examined O
only O
transcripts O
positive O
for O
insert O
3 O
, O
an O
18 O
bp O
insertion O
in O
repeat O
21 O
, O
were O
amplified O
, O
even O
under O
conditions O
in O
which O
a O
30 O
% O
level O
of O
insert O
3 O
negative O
transcript O
could O
be O
easily O
detected O
in O
artificially O
prepared O
control O
samples O
. O

These O
results O
show O
that O
the O
CAAT O
- O
region O
is O
involved O
in O
upregulating O
the O
MDR1 I-GENE
promoter I-GENE
in O
HL60 O
/ O
VCR O
cells O
. O

Both O
receptors O
utilize O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
PTKs I-GENE
) O
for O
the O
phosphorylation O
of O
various O
signaling O
molecules O
, O
a O
process O
that O
is O
critical O
for O
the O
function O
of O
both O
receptors O
. O

Hypothermia O
After O
Cardiac O
Arrest O
( O
HACA O
) O
Study O
Group O
. O

The O
synergistic O
effect O
due O
to O
the O
5 O
'- O
3 O
' O
cooperation O
was O
at O
least O
fourfold O
greater O
than O
the O
sum O
of O
the O
contributions O
of O
the O
individual O
UTRs O
. O

We O
demonstrate O
that O
both O
R I-GENE
and O
Z I-GENE
activate O
the O
cellular O
stress O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinases I-GENE
, O
p38 I-GENE
and O
JNK I-GENE
, O
resulting O
in O
phosphorylation O
( O
and O
activation O
) O
of O
the O
cellular I-GENE
transcription I-GENE
factor I-GENE
ATF2 I-GENE
. O

Two O
US O
commercial O
cultivars O
( O
Tehama O
and O
Vina O
), O
three O
European O
commercial O
cultivars O
( O
Esterhazy O
, O
139 O
, O
G120 O
) O
and O
five O
New O
Zealand O
selections O
( O
Rex O
, O
Dublin O
' O
s O
Glory O
, O
Meyric O
, O
McKinster O
, O
Stanley O
) O
were O
evaluated O
. O

Anatomy O
of O
the O
uterine O
artery O
. O

However O
, O
activation O
of O
the O
cAMP O
pathway O
, O
which O
is O
known O
to O
regulate O
inhibin I-GENE
alpha I-GENE
expression O
, O
greatly O
enhanced O
the O
actions O
of O
SF I-GENE
- I-GENE
1 I-GENE
. O

Deletion O
and O
site O
- O
directed O
mutagenesis O
localized O
a O
novel O
SF I-GENE
- I-GENE
1 I-GENE
regulatory I-GENE
element I-GENE
( O
TCA O
GGGCCA O
; O
- O
137 O
to O
- O
129 O
) O
adjacent O
to O
a O
variant O
cAMP O
- O
response O
element O
( O
CRE O
; O
- O
120 O
to O
- O
114 O
). O

Previously O
, O
we O
showed O
that O
the O
APRE O
is O
a O
cytokine O
[ O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNFalpha I-GENE
)]- O
inducible O
enhancer O
by O
binding O
the O
heterodimeric I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
( O
NF I-GENE
- I-GENE
kappaB I-GENE
) O
complex O
Rel I-GENE
A I-GENE
x O
NF I-GENE
- I-GENE
kappaB1 I-GENE
. O

Angiotensin I-GENE
II I-GENE
induces O
nuclear I-GENE
factor I-GENE
( I-GENE
NF I-GENE
)- I-GENE
kappaB1 I-GENE
isoforms I-GENE
to O
bind O
the O
angiotensinogen I-GENE
gene I-GENE
acute O
- O
phase O
response O
element O
: O
a O
stimulus O
- O
specific O
pathway O
for O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

Synthetic O
ligands O
have O
been O
identified O
that O
reset O
and O
amplify O
the O
cycle O
of O
pulsatile O
GH I-GENE
secretion O
by O
interacting O
with O
the O
orphan I-GENE
GH I-GENE
- I-GENE
secretagogue I-GENE
receptor I-GENE
( O
GHS I-GENE
- I-GENE
R I-GENE
). O

The O
collection O
of O
mutants O
displaying O
TGN O
sorting O
defects O
includes O
members O
with O
mutations O
in O
previously O
identified O
vacuolar I-GENE
protein I-GENE
sorting I-GENE
genes I-GENE
( O
VPS I-GENE
), O
including O
the O
dynamin I-GENE
family O
member O
VPS1 I-GENE
. O

Also O
in O
the O
spectrum O
of O
mutants O
with O
TGN O
sorting O
defects O
are O
isolates O
with O
mutations O
in O
the O
following O
: O
RIC1 I-GENE
, O
encoding O
a O
product O
originally O
proposed O
to O
participate O
in O
ribosome O
biogenesis O
; O
LUV1 I-GENE
, O
encoding O
a O
product O
potentially O
involved O
in O
vacuole O
and O
microtubule O
organization O
; O
and O
INP53 I-GENE
, O
encoding O
a O
synaptojanin I-GENE
- I-GENE
like I-GENE
inositol I-GENE
polyphosphate I-GENE
5 I-GENE
- I-GENE
phosphatase I-GENE
. O

The O
single O
strandedness O
is O
manifested O
as O
a O
terminal O
extension O
of O
the O
G O
- O
rich O
strand O
( O
G O
tails O
) O
that O
can O
occur O
independently O
of O
telomerase I-GENE
, O
suggesting O
that O
cdc17 I-GENE
/ O
pol1 I-GENE
mutants O
exhibit O
defects O
in O
telomeric O
lagging O
- O
strand O
synthesis O
. O

In O
addition O
, O
CaMig1 I-GENE
formed O
specific O
complexes O
with O
the O
URS1 O
region O
of O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
FBP1 I-GENE
gene I-GENE
. O

Furthermore O
, O
the O
wide O
distribution O
of O
the O
GFP I-GENE
- O
POLO I-GENE
protein O
to O
all O
compartments O
of O
the O
mitotic O
apparatus O
provides O
a O
valuable O
tool O
for O
future O
studies O
on O
cell O
cycle O
during O
development O
. O

An O
ASIC O
- O
chip O
for O
stereoscopic O
depth O
analysis O
in O
video O
- O
real O
- O
time O
based O
on O
visual O
cortical O
cell O
behavior O
. O

However O
, O
calphostin O
C O
, O
a O
specific O
inhibitor O
of O
PKC I-GENE
, O
abolished O
the O
TPA O
- O
induced O
increase O
in O
CFI I-GENE
mRNA I-GENE
levels O
. O

Preimmune I-GENE
IgG I-GENE
, O
anti I-GENE
- I-GENE
GalT I-GENE
Fab I-GENE
fragments I-GENE
, O
irrelevant O
polymers O
and O
monomeric O
N O
- O
acetylglucosamine O
had O
no O
effect O
. O

Arhythmacanthus O
Yamaguti O
, O
1935 O
is O
maintained O
as O
a O
synonym O
of O
Heterosentis O
because O
the O
distinction O
between O
two O
and O
three O
hook O
types O
is O
made O
equivocal O
when O
the O
transition O
between O
the O
apical O
and O
subapical O
hooks O
is O
gradual O
. O

We O
describe O
a O
case O
of O
acetaminophen O
overdose O
that O
was O
treated O
with O
both O
hemodialysis O
( O
HD O
) O
and O
NAC O
due O
to O
severe O
intoxication O
and O
slow O
drug O
clearance O
. O

Following O
conditioning O
, O
a O
single O
coat O
of O
adhesive O
was O
applied O
and O
light O
- O
cured O
. O

Downstream O
of O
the O
G O
- O
A O
anastomosis O
, O
the O
RD O
, O
CC O
, O
E O
( O
p O
) O
and O
loop O
areas O
were O
significantly O
different O
from O
REF O
, O
but O
significantly O
different O
from O
A O
- O
A O
. O

Induced O
expression O
of O
c I-GENE
- I-GENE
myc I-GENE
is O
likely O
to O
contribute O
to O
the O
proliferation O
of O
Stat1 I-GENE
- O
null O
cells O
in O
response O
to O
IFNs I-GENE
. O

Eastern O
Cooperative O
Oncology O
Group O
trial O
E3186 O
was O
initiated O
to O
explore O
this O
question O
. O

We O
determined O
how O
DNA O
repair O
is O
affected O
by O
TFA1 I-GENE
conditional O
mutations O
. O

These O
articles O
both O
report O
the O
results O
of O
multi O
- O
institutional O
, O
randomized O
, O
phase O
3 O
trials O
for O
the O
treatment O
of O
patients O
with O
localized O
( O
T1 O
- O
3 O
N0 O
- O
1 O
M0 O
) O
esophageal O
squamous O
cell O
carcinoma O
( O
SCC O
) O
or O
esophageal O
adenocarcinoma O
. O

Studies O
of O
MPO I-GENE
gene I-GENE
regulation O
can O
help O
to O
elucidate O
the O
mechanism O
of O
normal O
and O
abnormal O
myeloid O
differentiation O
. O

NDRF I-GENE
/ O
NeuroD2 I-GENE
was O
co O
- O
precipitated O
with O
PKN I-GENE
from O
the O
lysate O
of O
COS O
- O
7 O
cells O
transfected O
with O
both O
expression O
constructs O
for O
NDRF I-GENE
/ O
NeuroD2 I-GENE
and O
PKN I-GENE
. O

Transient O
transfection O
assays O
using O
P19 O
cells O
revealed O
that O
expression O
of O
NDRF I-GENE
/ O
NeuroD2 I-GENE
increased O
the O
transactivation O
of O
the O
rat I-GENE
insulin I-GENE
promoter I-GENE
element I-GENE
3 I-GENE
( O
RIPE3 I-GENE
) O
enhancer O
up O
to O
approximately O
12 O
- O
fold O
and O
that O
co O
- O
expression O
of O
catalytically O
active O
form O
of O
PKN I-GENE
, O
but O
not O
kinase O
- O
deficient O
derivative O
, O
resulted O
in O
a O
further O
threefold O
increase O
of O
NDRF I-GENE
/ O
NeuroD2 I-GENE
- O
mediated O
transcription O
. O

Two O
Pax2 I-GENE
/ I-GENE
5 I-GENE
/ I-GENE
8 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
in O
Engrailed2 I-GENE
are O
required O
for O
proper O
initiation O
of O
endogenous O
mid O
- O
hindbrain O
expression O
. O

Upon O
tyrosine O
phosphorylation O
at O
the O
ITIMs O
, O
these O
molecules O
recruit O
SH2 I-GENE
domain O
- O
containing O
phosphatases O
such O
as O
SH2 I-GENE
- O
containing O
tyrosine I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
and O
negatively O
regulate O
cell O
activity O
. O

AF154055 I-GENE
. O

Alignment O
of O
the O
cervical O
spine O
, O
vertebral O
abnormalities O
, O
and O
disc O
changes O
also O
were O
evaluated O
. O

The O
concomitant O
interaction O
of O
mSTI1 I-GENE
with O
hsp70 I-GENE
and O
hsp90 I-GENE
at O
its O
N O
- O
and O
C O
- O
termini O
respectively O
is O
mediated O
by O
the O
tetratricopeptide O
repeat O
( O
TPR O
) O
motifs O
in O
these O
regions O
. O

Competition O
experiments O
demonstrate O
a O
negative O
allosteric O
relationship O
between O
these O
RGD O
recognition O
sites O
. O

Sequence O
analysis O
showed O
that O
the O
5 O
'- O
flanking O
region O
upstream O
to O
the O
ATG O
codon O
did O
not O
contain O
a O
conventional O
TATA O
box O
. O

After O
i O
. O
v O
. O
administration O
of O
500 O
mg O
acetazolamide O
and O
disinfection O
of O
the O
conjunctiva O
, O
50 O
micrograms O
rt I-GENE
- I-GENE
PA I-GENE
in O
0 O
. O
1 O
ml O
( O
BSS O
) O
and O
0 O
. O
5 O
ml O
SF6 O
were O
injected O
intravitreally O
. O

These O
results O
suggest O
that O
VP1 I-GENE
was O
efficiently O
transported O
to O
the O
nucleus O
and O
localized O
in O
the O
discrete O
subnuclear O
regions O
, O
possibly O
with O
VP2 I-GENE
and O
VP3 I-GENE
. O

Differential O
expression O
and O
regulation O
by O
20 O
- O
hydroxyecdysone O
of O
mosquito O
ultraspiracle O
isoforms O
. O

The O
three O
isoforms O
purified O
with O
anti I-GENE
- I-GENE
FLAG I-GENE
antibody I-GENE
affinity O
column O
transferred O
sulfate O
to O
heparan O
sulfate O
and O
heparin O
but O
not O
to O
other O
glycosaminoglycans O
. O

The O
differentiation O
and O
maintenance O
of O
a O
neurotransmitter O
phenotype O
is O
guided O
by O
the O
interaction O
of O
exogenous O
cues O
with O
intrinsic O
genetic O
machinery O
. O

Analysis O
of O
functional O
domains O
of O
Arix I-GENE
reveals O
an O
N O
- O
terminal O
activation O
domain O
and O
a O
C O
- O
terminal O
repression O
domain O
. O

BACKGROUND O
: O
Left O
ventricular O
hypertrophy O
is O
a O
heterogeneous O
disorder O
with O
distinct O
morphologies O
. O

Multivariate O
predictors O
were O
concentric O
remodeling O
( O
P O
< O
0 O
. O
0001 O
; O
odds O
ratio O
, O
13 O
. O
5 O
), O
left O
ventricular O
ejection O
fraction O
> O
2 O
SD O
above O
normal O
( O
P O
< O
0 O
. O
0001 O
), O
and O
single O
- O
vessel O
left O
circumflex O
disease O
( O
P O
< O
0 O
. O
0007 O
; O
odds O
ratio O
, O
7 O
. O
6 O
). O

The O
case O
for O
completing O
the O
lymphadenectomy O
when O
positive O
lymph O
nodes O
are O
found O
during O
radical O
hysterectomy O
for O
cervical O
carcinoma O
. O

Overexpression O
of O
ICBP90 I-GENE
in O
COS O
- O
1 O
- O
transfected O
cells O
induced O
an O
enhanced O
expression O
of O
endogenous I-GENE
topoisomerase I-GENE
IIalpha I-GENE
. O

The O
RNA O
aptamer O
contains O
three O
stems O
separated O
by O
a O
pair O
of O
two O
- O
base O
bulges O
, O
and O
adopts O
an O
unanticipated O
fold O
in O
which O
both O
junctional O
sites O
are O
anchored O
through O
base O
triple O
formation O
. O

The O
study O
suggests O
the O
presence O
of O
an O
anatomical O
sphincter O
at O
the O
RSJ O
which O
seems O
to O
regulate O
the O
passage O
of O
stools O
from O
the O
sigmoid O
colon O
to O
the O
rectum O
. O

Isolation O
of O
cDNAs I-GENE
encoding I-GENE
gibbon I-GENE
and I-GENE
monkey I-GENE
platelet I-GENE
and I-GENE
T I-GENE
cell I-GENE
activation I-GENE
antigen I-GENE
1 I-GENE
( O
PTA1 I-GENE
). O

To O
quantify O
any O
mechanical O
inhibitory O
effect O
of O
nasal O
intermittent O
positive O
pressure O
ventilation O
( O
IPPV O
) O
on O
inspiratory O
activity O
of O
the O
diaphragm O
we O
ventilated O
five O
conscious O
relaxed O
subjects O
on O
two O
occasions O
at O
respiratory O
rates O
similar O
to O
quiet O
breathing O
( O
QB O
) O
and O
at O
three O
levels O
of O
applied O
pressure O
( O
Pappl O
)-- O
6 O
, O
9 O
and O
12 O
cmH2O O
, O
each O
during O
hypocapnia O
( O
P O
( O
CO2 O
) O
allowed O
to O
decrease O
) O
and O
eucapnia O
( O
CO2 O
added O
to O
inspired O
gas O
). O

METHODS O
: O
Von I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
and O
the O
fibrinolytic O
factors O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
tPA I-GENE
), O
measured O
as O
tPA I-GENE
capacity O
, O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
1 I-GENE
( O
PAI I-GENE
- I-GENE
1 I-GENE
), O
platelets O
, O
fibrinogen I-GENE
, O
and O
inflammatory O
markers O
were O
measured O
in O
74 O
patients O
with O
active O
seropositive O
RA O
. O

Neuronal O
signaling O
properties O
are O
largely O
determined O
by O
the O
quantity O
and O
combination O
of O
ion O
channels O
expressed O
. O

Treatment O
also O
led O
to O
a O
significant O
dose O
dependent O
reduction O
in O
the O
sum O
of O
ST O
segment O
depression O
at O
both O
trough O
and O
peak O
concentrations O
. O

We O
have O
investigated O
the O
contribution O
of O
specific O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
)- O
TATA O
interactions O
to O
the O
promoter O
activity O
of O
a O
constitutively O
expressed O
silkworm I-GENE
tRNA I-GENE
( I-GENE
C I-GENE
)( I-GENE
Ala I-GENE
) I-GENE
gene I-GENE
and O
have O
also O
asked O
whether O
the O
lack O
of O
similar O
interactions O
accounts O
for O
the O
low O
promoter O
activity O
of O
a O
silk I-GENE
gland I-GENE
- I-GENE
specific I-GENE
tRNA I-GENE
( I-GENE
SG I-GENE
)( I-GENE
Ala I-GENE
) I-GENE
gene I-GENE
. O

The O
sequences O
showed O
extensive O
homologies O
with O
squalene I-GENE
synthase I-GENE
genes I-GENE
and O
enzymes O
from O
a O
number O
of O
other O
organisms O
and O
extreme O
amino O
acid O
conservation O
within O
the O
binding O
and O
catalytic O
domains O
. O

All O
clones O
and O
strains O
produced O
have O
been O
deposited O
in O
the O
EUROFAN O
genetic O
stock O
centre O
( O
EUROSCARF O
, O
Frankfurt O
). O

Two O
episodes O
of O
peritonitis O
occurred O
while O
the O
patient O
received O
CAPD O
( O
1 O
episode O
/ O
3 O
. O
5 O
patient O
- O
months O
). O

Copyright O
2000 O
The O
Royal O
College O
of O
Radiologists O
. O

Two O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
) O
isoforms O
with O
different O
estrogen O
dependencies O
are O
generated O
from O
the O
trout I-GENE
ER I-GENE
gene I-GENE
. O

Induction O
was O
reversed O
by O
coexpression O
of O
A I-GENE
- I-GENE
Fos I-GENE
, O
a O
dominant O
negative O
to O
AP I-GENE
- I-GENE
1 I-GENE
. O

In O
myometrial O
SMC O
, O
both O
isoforms O
of O
the O
progesterone I-GENE
receptor I-GENE
, O
PR I-GENE
- I-GENE
B I-GENE
and O
PR I-GENE
- I-GENE
A I-GENE
, O
caused O
a O
ligand O
- O
dependent O
activation O
of O
PGDH I-GENE
- I-GENE
2368 I-GENE
/ O
luc3 I-GENE
. O

Element O
B O
(- O
249 O
/- O
229 O
) O
shows O
more O
than O
80 O
% O
homology O
to O
a O
consensus I-GENE
c I-GENE
- I-GENE
myb I-GENE
element I-GENE
, O
but O
formed O
two O
specific O
complexes O
that O
differed O
from O
that O
of O
c I-GENE
- I-GENE
myb I-GENE
in O
the O
electrophoretic O
mobility O
shift O
assay O
. O

High O
resolution O
computed O
tomography O
of O
the O
lungs O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Stable O
transfection O
of O
the O
truncated O
reduced I-GENE
folate I-GENE
carrier I-GENE
cDNA I-GENE
into O
mouse O
L1210 O
leukemia O
cells O
: O
increased O
folate O
accumulation O
, O
decreased O
their O
leucovorin O
and O
folic O
acid O
growth O
requirements O
, O
and O
increased O
their O
sensitivity O
to O
methotrexate O
. O

Characterization O
of O
a O
human I-GENE
alternatively I-GENE
spliced I-GENE
truncated I-GENE
reduced I-GENE
folate I-GENE
carrier I-GENE
increasing O
folate O
accumulation O
in O
parental O
leukemia O
cells O
. O

Electron O
microscopic O
and O
enzymatic O
analyses O
revealed O
that O
the O
A118 O
genome O
is O
a O
linear O
, O
circularly O
permuted O
, O
terminally O
redundant O
collection O
of O
double O
- O
stranded O
DNA O
molecules O
. O

Moreover O
, O
increasing O
the O
dosage O
of O
wild I-GENE
- I-GENE
type I-GENE
Fus3 I-GENE
intensifies O
the O
inhibition O
of O
both O
Ty1 I-GENE
transposition O
and O
invasive O
growth O
. O

Consistently O
, O
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
downstream O
of O
Rho I-GENE
family I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
was O
also O
enhanced O
when O
Dbl I-GENE
was O
tyrosine O
- O
phosphorylated O
. O

However O
, O
its O
participation O
in O
collagen I-GENE
binding O
has O
not O
been O
shown O
. O

Together O
, O
these O
data O
suggest O
that O
the O
carboxyl O
terminus O
of O
CFTR I-GENE
contains O
a O
tyrosine O
- O
based O
internalization O
signal O
that O
interacts O
with O
the O
endocytic O
adaptor O
complex O
AP I-GENE
- I-GENE
2 I-GENE
to O
facilitate O
efficient O
entry O
of O
CFTR I-GENE
into O
clathrin I-GENE
- O
coated O
vesicles O
. O

The O
insulin I-GENE
therapy O
regimen O
did O
not O
affect O
the O
evolution O
of O
the O
patients O
and O
no O
significant O
relationship O
existed O
between O
the O
age O
at O
diagnosis O
, O
duration O
of O
diabetes O
, O
daily O
insulin I-GENE
dosage O
or O
metabolic O
control O
and O
height O
or O
BMI O
. O

Scmh1 I-GENE
maps O
to O
4D1 O
- O
D2 O
. O
1 O
in O
mice O
. O

The O
applicability O
of O
laparoscopic O
donor O
nephrectomy O
( O
LDN O
) O
has O
not O
been O
assessed O
in O
the O
obese O
donor O
. O

Hyaluronan O
treatment O
stimulated O
collagen I-GENE
remodeling O
in O
the O
peripheral O
region O
and O
inhibited O
swelling O
of O
the O
meniscus O
repaired O
in O
the O
inner O
region O
. O

We O
have O
addressed O
these O
issues O
by O
reconstituting O
and O
characterizing O
the O
KRAB I-GENE
: O
KAP I-GENE
- I-GENE
1 I-GENE
- O
RBCC I-GENE
interaction O
using O
purified O
components O
. O

The O
RING O
finger O
, O
B2 O
box O
, O
and O
coiled O
- O
coil O
region O
are O
required O
for O
oligomerization O
of O
KAP I-GENE
- I-GENE
1 I-GENE
- O
RBCC I-GENE
and O
KRAB I-GENE
binding O
, O
as O
mutations O
in O
these O
domains O
concomitantly O
abolished O
these O
functions O
. O

Actins I-GENE
show O
two O
different O
forms O
of O
N O
- O
terminal O
processing O
dependent O
on O
their O
N O
- O
terminal O
sequence O
. O

All O
four O
domains O
were O
linked O
via O
proline O
- O
threonine O
- O
rich O
peptides O
. O

JPEG O
53 O
, O
resulting O
in O
a O
compression O
ratio O
of O
1 O
: O
21 O
, O
does O
not O
compromise O
the O
diagnostic O
performance O
in O
general O
. O

We O
critically O
assess O
current O
systematic O
uncertainties O
and O
determine O
the O
primordial O
Li O
abundance O
within O
new O
, O
much O
tighter O
limits O
: O
& O
amp O
; O
parl0 O
; O
Li O
& O
amp O
; O
solm0 O
; O
H O
& O
amp O
; O
parr0 O
; O
p O
= O
1 O
. O
23 O
+ O
0 O
. O
68 O
- O
0 O
. O
32x10 O
- O
10 O
. O

Like O
their O
yeast O
counterpart O
, O
the O
mouse O
GCN2 I-GENE
isoforms O
contain O
HisRS I-GENE
- I-GENE
related I-GENE
sequences I-GENE
juxtaposed O
to O
the O
kinase O
catalytic O
domain O
. O

Five O
women O
( O
15 O
. O
6 O
%) O
met O
criteria O
for O
PMS O
. O

MBI O
and O
MMBI O
showed O
similar O
Cmax O
values O
, O
but O
the O
former O
disappeared O
slower O
in O
the O
serum O
than O
the O
latter O
and O
resulted O
in O
its O
larger O
AUC O
values O
. O

Another O
long O
insertion O
in O
the O
cathepsin I-GENE
X I-GENE
amino I-GENE
acid I-GENE
sequence I-GENE
forms O
a O
beta O
- O
hairpin O
pointing O
away O
from O
the O
active O
site O
. O

Transfection O
experiments O
demonstrated O
that O
the O
5 O
'- O
flanking O
region O
(- O
1894 O
to O
+ O
37 O
) O
of O
the O
mStaf I-GENE
gene I-GENE
drives O
transcription O
in O
mouse O
NMuMG O
cells O
and O
that O
a O
construct O
containing O
a O
fragment O
from O
- O
387 O
to O
+ O
37 O
showed O
the O
highest O
transcriptional O
activity O
. O

Further O
studies O
in O
T O
- O
24 O
cells O
demonstrated O
that O
HA O
fragments O
also O
induced O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
phosphorylation O
and O
degradation O
, O
kappa I-GENE
B I-GENE
- I-GENE
linked I-GENE
reporter I-GENE
gene I-GENE
expression O
, O
and O
ICAM I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
an O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- O
dependent O
manner O
. O

Pretreatment O
of O
cells O
or O
mouse O
skin O
with O
antisense O
oligonucleotides O
of O
PKCzeta I-GENE
impaired O
UV O
- O
induced O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
in O
JB6 O
cells O
as O
well O
as O
in O
AP I-GENE
- I-GENE
1 I-GENE
- O
luciferase I-GENE
transgenic O
mice O
. O

The O
level O
of O
subclinical O
infection O
was O
75 O
% O
among O
seropositive O
dogs O
. O

METHODS O
: O
The O
former O
group O
included O
patients O
who O
had O
been O
treated O
with O
at O
least O
four O
PGE1 O
alpha O
- O
ciclodestrina O
, O
short O
- O
term O
treatment O
cycles O
per O
year O
while O
the O
latter O
was O
a O
historical O
reference O
group O
managed O
without O
prostaglandins O
. O

Desmethylferrochloroquine O
1a O
and O
didesmethylferrochloroquine O
2 O
would O
be O
more O
potent O
against O
schizontocides O
than O
CQ O
in O
vitro O
against O
two O
strains O
( O
HB3 O
and O
Dd2 O
) O
of O
Plasmodium O
falciparum O
. O

The O
rrd1 I-GENE
, I-GENE
2delta I-GENE
mutant I-GENE
was O
partially O
rescued O
by O
inactivation O
of O
HOG1 I-GENE
or O
PBS2 I-GENE
, O
suggesting O
an O
interaction O
between O
the O
RRD I-GENE
genes I-GENE
and O
the O
Hog1p I-GENE
signal I-GENE
transduction I-GENE
pathway I-GENE
. O

Members O
of O
the O
JAK I-GENE
/ O
Tyk I-GENE
family O
of O
tyrosine I-GENE
kinases I-GENE
mediate O
phosphorylation O
of O
STAT3 I-GENE
at O
Tyr705 O
during O
CNTF I-GENE
signaling O
; O
however O
, O
the O
kinase O
responsible O
for O
phosphorylation O
at O
STAT3 I-GENE
Tyr727 O
appears O
to O
depend O
on O
both O
the O
extracellular O
stimulus O
and O
the O
cellular O
context O
. O

In O
vivo O
, O
CARbeta I-GENE
/ O
RXRalpha I-GENE
activated O
transcription O
from O
an O
HD I-GENE
- O
PPRE O
luciferase I-GENE
reporter I-GENE
construct I-GENE
. O

Zebrafish O
cyclops I-GENE
( O
cyc I-GENE
) O
encodes O
a O
Transforming I-GENE
Growth I-GENE
Factor I-GENE
beta I-GENE
( O
TGFbeta I-GENE
) O
signaling O
factor O
closely O
related O
to O
mouse O
Nodal I-GENE
. O

Thus O
, O
SOX8 I-GENE
is O
a O
good O
candidate O
gene O
contributing O
to O
the O
mental O
retardation O
phenotype O
seen O
in O
ATR O
- O
16 O
patients O
. O

The O
genome O
organization O
of O
the O
mite O
- O
transmitted O
wheat O
streak O
mosaic O
virus O
( O
WSMV O
) O
appears O
to O
parallel O
that O
of O
members O
of O
the O
Potyviridae O
with O
monopartite O
genomes O
, O
but O
there O
are O
substantial O
amino O
acid O
dissimilarities O
with O
other O
potyviral O
polyproteins O
. O

The O
two O
- O
hybrid O
assay O
was O
then O
performed O
using O
full O
- O
length O
genes O
of O
CI I-GENE
, O
HC I-GENE
- I-GENE
Pro I-GENE
, O
P1 I-GENE
, O
P3 I-GENE
, O
and O
CP I-GENE
, O
but O
no O
heterologous O
interactions O
were O
detected O
. O

Diverse O
endogenous O
light O
chains O
contribute O
to O
basement O
membrane O
reactivity O
in O
nonautoimmune O
mice O
transgenic O
for O
an O
anti I-GENE
- I-GENE
laminin I-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
. O

Patch O
test O
results O
obtained O
with O
corticosteroid O
allergic O
patients O
tested O
with O
a O
large O
corticosteroid O
series O
validated O
the O
earlier O
classification O
of O
corticosteroid O
molecules O
in O
four O
groups O
of O
cross O
- O
reacting O
molecules O
: O
i O
. O
e O
., O
group O
A O
( O
hydrocortisone O
type O
), O
group O
B O
( O
acetonides O
), O
group O
C O
( O
betamethasone O
type O
- O
non O
esterified O
) O
and O
group O
D O
( O
esters O
). O

Mechanisms O
of O
tachyphylaxis O
in O
regional O
anesthesia O
of O
long O
duration O

An O
increase O
in O
the O
level O
of O
serum O
enzymes O
, O
such O
as O
aspartate I-GENE
transaminase I-GENE
, O
alkaline I-GENE
phosphatase I-GENE
, O
creatine I-GENE
phosphokinase I-GENE
, O
lactate I-GENE
dehydrogenase I-GENE
after O
D O
. O
russelli O
venom O
injection O
in O
albino O
rats O
is O
indicative O
of O
cell O
or O
tissue O
damage O
. O

The O
partial O
farm O
budget O
highlighted O
the O
importance O
of O
reducing O
sub O
- O
clinical O
lesions O
in O
a O
feedlot O
. O

Surprisingly O
, O
3 O
full I-GENE
- I-GENE
length I-GENE
murine I-GENE
survivin I-GENE
cDNA I-GENE
clones O
were O
isolated O
, O
predicting O
the O
existence O
of O
3 O
distinct O
survivin I-GENE
proteins I-GENE
. O

Thus O
, O
the O
induction O
of O
E2F I-GENE
binding O
to O
the O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
E4 I-GENE
- I-GENE
6 I-GENE
/ I-GENE
7 I-GENE
protein I-GENE
observed O
in O
vitro O
correlates O
with O
transactivation O
of O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
vivo O
. O

We O
show O
that O
stabilization O
of O
the O
hairpin O
reduced O
the O
amount O
of O
tRNA O
primer O
that O
is O
annealed O
to O
the O
PBS O
. O

Ischemia O
- O
induced O
biphasic O
arrhythmias O
were O
suppressed O
in O
both O
zatebradine O
and O
propranolol O
groups O
. O

ZK7 I-GENE
and O
HZF16 I-GENE
genes I-GENE
appear O
to O
be O
the O
splice O
variants O
transcribed O
from O
the O
same O
gene O
. O

CONCLUSION O
: O
Presence O
of O
APOE I-GENE
epsilon4 I-GENE
/* I-GENE
seems O
to O
increase O
the O
risk O
for O
dementia O
and O
AD O
independently O
of O
its O
effect O
on O
dyslipidemia O
and O
atherogenesis O
. O

No O
definite O
conclusions O
are O
possible O
because O
of O
the O
small O
number O
of O
patients O
involved O
in O
this O
phase O
II O
trial O
. O

Two O
distinct O
Salmonella I-GENE
fimbrins I-GENE
, O
AgfA I-GENE
and O
SefA I-GENE
, O
comprising O
thin O
aggregative O
fimbriae O
SEF17 I-GENE
and O
SEF14 I-GENE
, O
respectively O
, O
were O
each O
genetically O
engineered O
to O
carry O
PT3 I-GENE
, O
an O
alpha O
- O
helical O
16 O
- O
amino O
acid O
Leishmania O
T O
- O
cell O
epitope O
derived O
from O
the O
metalloprotease I-GENE
gp63 I-GENE
. O

In O
marked O
contrast O
to O
AgfA I-GENE
, O
none O
of O
the O
chimeric I-GENE
SefA I-GENE
proteins I-GENE
were O
expressed O
or O
assembled O
into O
fimbriae O
. O

Productive O
growth O
of O
phage O
P22 O
in O
wild O
- O
type O
Salmonella O
typhimurium O
correlates O
with O
the O
presence O
of O
Abc2 I-GENE
, O
but O
is O
independent O
of O
the O
absolute O
level O
of O
ATP I-GENE
- I-GENE
dependent I-GENE
nuclease I-GENE
activity O
, O
suggesting O
a O
qualitative O
change O
in O
the O
nature O
of O
Abc2 I-GENE
- O
modified O
RecBCD I-GENE
nuclease I-GENE
activity O
relative O
to O
the O
native O
enzyme O
. O

In O
this O
study O
, O
we O
investigated O
the O
molecular O
mechanisms O
underlying O
the O
inducible O
expression O
of O
the O
flt I-GENE
- I-GENE
1 I-GENE
gene I-GENE
during O
the O
activation O
of O
THP O
- O
1 O
cells O
. O

There O
was O
a O
2 O
. O
4 O
- O
fold O
difference O
in O
CAT I-GENE
produced O
from O
these O
transcripts O
in O
HeLa O
cells O
, O
which O
contain O
a O
greater O
natural O
abundance O
of O
PTB I-GENE
. O

Multiple O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
pathways O
connect O
the O
cot I-GENE
oncoprotein I-GENE
to O
the O
c I-GENE
- I-GENE
jun I-GENE
promoter I-GENE
and O
to O
cellular O
transformation O
. O

Dermatology O
is O
no O
exception O
. O

4 O
. O

In O
the O
present O
study O
we O
have O
investigated O
the O
regulatory O
mechanism O
for O
CD95L I-GENE
expression O
. O

Protein O
sequence O
analysis O
reveals O
that O
MAN1 I-GENE
shares O
a O
conserved O
globular O
domain O
of O
approximately O
40 O
amino O
acids O
, O
which O
we O
term O
the O
LEM I-GENE
module I-GENE
, O
with O
inner O
nuclear O
membrane O
proteins O
lamina I-GENE
- I-GENE
associated I-GENE
polypeptide I-GENE
2 I-GENE
and O
emerin I-GENE
. O

Molecular O
cloning O
of O
a O
novel O
human I-GENE
I I-GENE
- I-GENE
mfa I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
that O
differently O
regulates O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
and O
HIV O
- O
1 O
expression O
. O

The O
encoded O
amino O
acid O
sequences O
in O
the O
full O
- O
length O
bovine O
and O
porcine O
cDNAs O
were O
identical O
, O
consisting O
of O
209 O
amino O
acid O
residues O
, O
and O
were O
nearly O
the O
same O
as O
the O
published O
sequence O
determined O
by O
Edman O
degradation O
. O

With O
chemical O
shift O
imaging O
, O
the O
signal O
intensity O
decreased O
on O
the O
out O
- O
of O
- O
phase O
images O
in O
six O
of O
seven O
( O
86 O
%) O
patients O
with O
APA O
and O
in O
eight O
of O
nine O
( O
89 O
%) O
patients O
with O
BAH O
. O

For O
each O
night O
, O
the O
diary O
allowed O
the O
subjective O
measurement O
of O
bedtime O
, O
wake O
time O
, O
time O
in O
bed O
( O
TIB O
), O
sleep O
efficiency O
, O
number O
of O
minutes O
of O
wake O
after O
sleep O
onset O
( O
WASO O
), O
alertness O
on O
awakening O
, O
and O
percentage O
of O
morning O
needing O
an O
alarm O
( O
or O
a O
person O
functioning O
as O
one O
). O

Acad O
. O

Copyright O
2000 O
Academic O
Press O
. O

The O
central O
( O
R O
) O
domain O
is O
responsible O
for O
receptor O
- O
binding O
activity O
whereas O
the O
N O
- O
terminal O
( O
T O
) O
domain O
mediates O
translocation O
, O
the O
process O
by O
which O
the O
C O
- O
terminal O
cytotoxic O
domain O
is O
transported O
from O
the O
receptor O
to O
the O
site O
of O
its O
cytotoxicity O
. O

We O
have O
previously O
demonstrated O
that O
expression O
of O
the O
gene O
for O
the O
reproductive O
neuropeptide O
, O
GnRH I-GENE
, O
is O
repressed O
by O
the O
glutamate O
/ O
NO O
/ O
cyclic O
GMP O
( O
cGMP O
) O
signal O
transduction O
pathway O
through O
cGMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
in O
the O
hypothalamic O
GnRH I-GENE
- O
secreting O
neuronal O
cell O
line O
GT1 O
- O
7 O
. O

These O
data O
suggest O
that O
combined O
lesions O
of O
cholinergic O
and O
serotonergic O
neurons O
in O
the O
rat O
brain O
do O
not O
alter O
olfactory O
perception O
or O
olfactory O
short O
- O
term O
memory O
. O

Extreme O
potency O
of O
botulinum I-GENE
toxin I-GENE
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
activated O
by O
isoproterenol O
led O
to O
tyrosine O
phosphorylation O
of O
Shc I-GENE
and O
subsequent O
Erk I-GENE
activation O
, O
but O
not O
tyrosine O
phosphorylation O
of O
cortactin I-GENE
or O
Stat3 I-GENE
. O

MSSPs I-GENE
are O
believed O
to O
regulate O
DNA O
replication O
, O
transcription O
, O
apopotosis O
and O
cell O
cycle O
progression O
by O
interacting O
with O
the O
C I-GENE
- I-GENE
MYC I-GENE
protein I-GENE
. O

For O
wild O
type O
MutT I-GENE
and O
its O
E53D I-GENE
and O
E44D I-GENE
mutants I-GENE
, O
plots O
of O
log O
( O
k O
( O
cat O
)) O
versus O
pH O
exhibited O
a O
limiting O
slope O
of O
1 O
on O
the O
ascending O
limb O
and O
then O
a O
hump O
, O
i O
. O
e O
., O
a O
sharply O
defined O
maximum O
near O
pH O
8 O
followed O
by O
a O
plateau O
, O
yielding O
apparent O
pK O
( O
a O
) O
values O
of O
7 O
. O
6 O
+/- O
0 O
. O
3 O
and O
8 O
. O
4 O
+/- O
0 O
. O
4 O
for O
an O
essential O
base O
and O
a O
nonessential O
acid O
catalyst O
, O
respectively O
, O
in O
the O
active O
quaternary O
MutT I-GENE
- O
Mg O
( O
2 O
+)- O
dGTP O
- O
Mg O
( O
2 O
+) O
complex O
. O

Structural O
changes O
in O
the O
kinetically O
more O
damaged O
E44D O
mutant O
detected O
in O
( O
1 O
) O
H O
-( O
15 O
) O
N O
HSQC O
spectra O
were O
largely O
limited O
to O
the O
loop O
I O
- O
helix O
I O
motif O
, O
suggesting O
that O
Glu O
- O
44 O
stabilizes O
the O
active O
site O
region O
. O

In O
vitro O
expression O
of O
four O
different O
naturally O
occurring O
nonsense O
and O
missense O
mutations O
revealed O
a O
dramatically O
altered O
subcellular O
location O
of O
the O
protein O
in O
cultured O
cells O
. O

After O
i O
. O
v O
. O

Immunity O
acquired O
by O
mice O
during O
I O
. O
scapularis O
nymphal O
activity O
in O
early O
summer O
may O
exclude O
a O
large O
proportion O
of O
the O
mouse O
population O
from O
maintaining O
E O
. O
phagocytophila O
during O
the O
period O
of O
larval O
activity O
later O
in O
the O
season O
. O

The O
emerging O
view O
based O
on O
studies O
in O
yeast O
is O
that O
each O
class O
of O
snoRNPs O
is O
composed O
of O
a O
unique O
set O
of O
proteins O
. O

BCR I-GENE
cross O
- O
linking O
also O
led O
to O
increased O
MAPK I-GENE
- O
activated O
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
activity O
, O
an O
enzyme O
that O
lies O
immediately O
downstream O
from O
p38 I-GENE
MAPK I-GENE
; O
MAPK I-GENE
- O
activated O
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
immune O
complexes O
phosphorylated O
a O
peptide O
substrate O
containing O
the O
CREB I-GENE
serine I-GENE
133 I-GENE
phosphoacceptor I-GENE
motif I-GENE
. O

Activation O
of O
a O
CRE O
- O
dependent O
junB I-GENE
promoter I-GENE
/ O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
reporter O
gene O
by O
the O
BCR I-GENE
was O
also O
blocked O
by O
SB203580 O
. O

We O
present O
evidence O
that O
the O
upstream O
open O
reading O
frame O
( O
uORF O
) O
represses O
the O
translation O
of O
the O
downstream O
major O
open O
reading O
frame O
( O
mORF O
). O

METHODS O
: O
TBN O
measurements O
were O
performed O
in O
31 O
female O
outpatients O
with O
breast O
carcinoma O
who O
were O
undergoing O
standard O
cyclophosphamide O
, O
methotrexate O
, O
and O
5 O
- O
fluorouracil O
( O
CMF O
)- O
based O
chemotherapy O
( O
median O
age O
, O
48 O
years O
; O
range O
, O
26 O
- O
77 O
years O
). O

A O
385 O
bp O
Glucocorticoid O
Response O
Unit O
( O
GRU O
) O
was O
identified O
whose O
glucocorticoid O
induction O
was O
enhanced O
by O
dibutyryl O
- O
cAMP O
and O
reduced O
by O
phorbol O
esters O
. O

No O
somatic O
mutations O
were O
found O
in O
any O
of O
the O
samples O
, O
suggesting O
that O
ING1 I-GENE
is O
not O
a O
tumor O
suppressor O
gene O
target O
in O
head O
and O
neck O
cancer O
. O

Ras I-GENE
- O
GRF1 I-GENE
transiently O
expressed O
with O
v I-GENE
- I-GENE
Src I-GENE
was O
tyrosine O
- O
phosphorylated O
and O
showed O
significant O
GEF I-GENE
activity O
toward O
Rac I-GENE
, O
but O
not O
Rho I-GENE
and O
Cdc42 I-GENE
, O
which O
was O
comparable O
with O
that O
induced O
by O
Gbetagamma I-GENE
. O

As O
no O
complete O
PPARgamma I-GENE
antagonists O
have O
been O
described O
hitherto O
, O
we O
have O
constructed O
a O
dominant O
- O
negative O
mutant O
receptor O
to O
inhibit O
wild O
- O
type O
PPARgamma I-GENE
action O
. O

EMSA O
showed O
that O
nuclear O
proteins O
from O
PC12 O
but O
not O
C6 O
or O
Rat2 O
cells O
bind O
the O
CRE O
as O
a O
complex O
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( I-GENE
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
C6 O
cell O
nuclear O
extracts O
were O
recruited O
by O
the O
CCAAT O
- O
box O
as O
a O
complex O
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

EMSA O
showed O
that O
nuclear O
proteins O
from O
PC12 O
but O
not O
C6 O
or O
Rat2 O
cells O
bind O
the O
CRE O
as O
a O
complex O
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( I-GENE
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
C6 O
cell O
nuclear O
extracts O
were O
recruited O
by O
the O
CCAAT O
- O
box O
as O
a O
complex O
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

Despite O
resolution O
of O
the O
solid O
portion O
of O
the O
tumor O
, O
serial O
MRI O
showed O
enlargement O
of O
a O
bilobar O
tumor O
cyst O
3 O
years O
after O
the O
original O
diagnosis O
. O

LPO O
and O
SOD I-GENE
levels O
were O
measured O
at O
five O
points O
before O
and O
during O
the O
operation O
. O

Sustained O
ventricular O
tachycardia O
and O
its O
successful O
prophylaxis O
during O
high O
- O
dose O
bolus O
interleukin I-GENE
- I-GENE
2 I-GENE
therapy O
for O
metastatic O
renal O
cell O
carcinoma O
. O

Second O
, O
when O
the O
NBF1 I-GENE
+ I-GENE
R I-GENE
protein I-GENE
, O
the O
NBF2 I-GENE
protein I-GENE
, O
and O
a O
mixture O
of O
the O
two O
proteins O
were O
folded O
separately O
and O
analyzed O
by O
molecular O
sieve O
chomatography O
, O
the O
mixture O
was O
found O
to O
elute O
prior O
to O
either O
NBF1 I-GENE
+ I-GENE
R I-GENE
or O
NBF2 I-GENE
. O

Collectively O
, O
these O
experiments O
demonstrate O
that O
CFTR I-GENE
' I-GENE
s I-GENE
NBF1 I-GENE
+ I-GENE
R I-GENE
region I-GENE
and O
its O
NBF2 I-GENE
domain I-GENE
, O
after O
folding O
separately O
as O
distinct O
units O
, O
have O
a O
strong O
propensity O
to O
interact O
and O
that O
this O
interaction O
is O
stable O
in O
the O
absence O
of O
added O
nucleotides O
or O
exogenously O
induced O
phosphorylation O
. O

Copyright O
2000 O
Academic O
Press O
. O

Sulfhydryl O
titration O
with O
iodoacetamide O
, O
monitored O
by O
quantitating O
the O
residual O
thiols O
after O
reaction O
with O
a O
maleimide O
derivative O
of O
biotin O
, O
revealed O
a O
striking O
difference O
in O
the O
apparent O
pK O
( O
a O
) O
values O
of O
the O
cysteines O
at O
the O
two O
splice O
junctions O
. O

After O
nitric O
oxide O
inhalation O
, O
the O
results O
showed O
moderate O
increases O
in O
PaO2 O
and O
SaO2 O
( O
P O
> O
0 O
. O
05 O
) O
and O
a O
significant O
decrease O
in O
Qs O
/ O
Q O
tau O
ratio O
( O
P O
< O
0 O
. O
01 O
). O

The O
results O
showed O
that O
MIP O
, O
MMIF O
, O
FIC O
, O
Wimax O
, O
P0 O
. O
1 O
and O
minute O
ventilation O
( O
Vr O
) O
were O
significantly O
increased O
after O
administration O
of O
methylphenidatum O
and O
aminophylline O
. O

Forty O
4 O
- O
month O
old O
SD O
female O
rats O
were O
randomly O
divided O
into O
four O
groups O
, O
namely O
sham O
operation O
, O
bilateral O
ovariectomy O
, O
ovariectomy O
plus O
supplementary O
ethinyl O
estradiol O
( O
0 O
. O
2 O
microgram O
/ O
100 O
g O
B O
. O

It O
has O
also O
been O
shown O
that O
a O
variety O
of O
extracellular O
factors O
stimulate O
a O
pair O
of O
MAPK O
p44 I-GENE
and O
MAPK O
p42 I-GENE
of O
MAPK I-GENE
family I-GENE
members I-GENE
. O

Covalent O
modification O
of O
the O
transactivator O
protein O
IE2 I-GENE
- O
p86 I-GENE
of O
human O
cytomegalovirus O
by O
conjugation O
to O
the O
ubiquitin I-GENE
- I-GENE
homologous I-GENE
proteins I-GENE
SUMO I-GENE
- I-GENE
1 I-GENE
and O
hSMT3b I-GENE
. O

73 O
: O
658 O
- O
666 O
, O
1999 O
). O

The O
interaction O
between O
U O
( O
L O
) O
3 O
. O

Protamine I-GENE
and O
heparin O
doses O
, O
their O
sum O
( O
Sigma O
- O
dose O
) O
and O
differential O
( O
Delta O
- O
dose O
) O
doses O
, O
and O
activated O
clotting O
times O
were O
tabulated O
. O

In O
this O
study O
, O
a O
common O
mechanism O
has O
been O
identified O
to O
coordinate O
the O
growth O
- O
and O
FC O
- O
dependent O
expression O
of O
caveolin I-GENE
. O

Comparison O
of O
the O
plant O
nuclear O
tRNA O
3 O
' O
processing O
enzyme O
with O
the O
plant O
mitochondrial O
one O
suggests O
that O
both O
activities O
are O
different O
enzymes O
. O

The O
requirement O
of O
3 O
' O
complementarity O
for O
a O
ligation O
reaction O
is O
reaffirmed O
by O
results O
from O
1 O
nt O
insertions O
on O
either O
the O
3 O
'- O
or O
5 O
'- O
side O
of O
the O
nick O
. O

NKX2 I-GENE
. I-GENE
1 I-GENE
is O
a O
member O
of O
the O
NK2 I-GENE
family I-GENE
of O
homeodomain I-GENE
- I-GENE
containing I-GENE
transcription I-GENE
factors I-GENE
whose O
targeted O
disruption O
in O
mouse O
results O
in O
the O
absence O
of O
thyroid O
tissue O
and O
a O
severely O
abnormal O
lung O
phenotype O
. O

National O
abortion O
laws O
usually O
do O
not O
allow O
abortion O
when O
a O
foetus O
is O
independently O
viable O
, O
i O
. O
e O
. O
from O
a O
gestational O
age O
of O
about O
24 O
weeks O
. O

Expression O
in O
early O
postnatal O
pituitary O
and O
in O
pre O
- O
somatotrophic O
cells O
suggests O
that O
Zn I-GENE
- I-GENE
16 I-GENE
could O
play O
a O
role O
in O
pituitary O
development O
prior O
to O
somatotroph O
differentiation O
. O

Mouse I-GENE
growth I-GENE
hormone I-GENE
transcription I-GENE
factor I-GENE
Zn I-GENE
- I-GENE
16 I-GENE
: O
unique O
bipartite O
structure O
containing O
tandemly O
repeated O
zinc O
finger O
domains O
not O
reported O
in O
rat I-GENE
Zn I-GENE
- I-GENE
15 I-GENE
. O

The O
CCAAT O
core O
sequence O
mutants O
in O
which O
both O
CIII O
and O
CI O
/ O
CII O
were O
abolished O
, O
also O
increased O
the O
promoter O
activity O
. O

Deglutition O
is O
considered O
to O
be O
immature O
in O
infants O
and O
to O
mature O
postnatally O
. O

This O
repression O
does O
not O
require O
the O
PU I-GENE
. I-GENE
1 I-GENE
transactivation O
or O
PEST O
domains O
and O
cannot O
be O
reversed O
by O
p300 I-GENE
expression O
. O

First O
, O
human O
erythroid O
K562 O
cells O
stably O
integrated O
with O
various O
HS I-GENE
- I-GENE
40 I-GENE
mutants I-GENE
cis O
linked O
to O
a O
human I-GENE
alpha I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
- O
growth I-GENE
hormone I-GENE
hybrid O
gene O
were O
analyzed O
by O
genomic O
footprinting O
and O
expression O
analysis O
. O

Interestingly O
, O
addition O
of O
purified O
CBP I-GENE
to O
the O
nuclear O
extracts O
of O
T47D O
cells O
markedly O
stimulated O
progesterone O
- O
and O
PR I-GENE
- O
dependent O
transcription O
from O
a O
nucleosome O
- O
free O
, O
progesterone O
response O
element O
( O
PRE O
)- O
linked O
reporter O
DNA O
template O
. O

Its O
cognate O
binding O
protein O
, O
REST I-GENE
/ O
NRSF I-GENE
, O
is O
an O
essential O
transcription O
factor O
; O
its O
null O
mutations O
result O
in O
embryonic O
lethality O
, O
and O
its O
dominant O
negative O
mutants O
produce O
aberrant O
expression O
of O
neuron O
- O
specific O
genes O
. O

Removal O
of O
all O
core I-GENE
histone I-GENE
tail O
domains O
by O
limited O
trypsin I-GENE
proteolysis O
or O
acetylation O
of O
the O
core I-GENE
histone I-GENE
tails O
significantly O
relieves O
this O
inhibition O
and O
allows O
TFIIIA I-GENE
to O
exhibit O
high O
- O
affinity O
binding O
to O
nucleosomal O
DNA O
. O

Finally O
, O
the O
mechanism O
of O
ASK1 I-GENE
activation O
involves O
, O
in O
part O
, O
homo O
- O
oligomerization O
. O

OUTCOME O
: O
Acetylcholine I-GENE
receptor I-GENE
antibodies I-GENE
and O
single O
- O
fibre O
electromyogram O
were O
useful O
in O
the O
diagnosis O
of O
myasthenia O
gravis O
. O

Two O
other O
patients O
underwent O
PRFR O
. O

The O
variations O
were O
caused O
by O
opposite O
shifts O
in O
TSH I-GENE
frequency O
distribution O
in O
mothers O
and O
neonates O
. O

Characterization O
of O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
multidrug I-GENE
resistance I-GENE
protein I-GENE
2 I-GENE
( O
MRP2 I-GENE
) O
gene O
and O
its O
regulation O
in O
comparison O
withthe O
multidrug I-GENE
resistance I-GENE
protein I-GENE
3 I-GENE
( O
MRP3 I-GENE
) O
gene O
. O

However O
, O
such O
a O
mechanism O
was O
not O
detected O
in O
preliminary O
observations O
on O
M O
. O
synoviae O
. O

These O
results O
suggest O
that O
the O
M O
. O
jannaschii O
as O
well O
as O
related O
archaeal I-GENE
20S I-GENE
proteasomes I-GENE
require O
a O
nucleotidase O
complex O
such O
as O
PAN I-GENE
to O
mediate O
the O
energy O
- O
dependent O
hydrolysis O
of O
folded O
- O
substrate O
proteins O
and O
that O
the O
N O
- O
terminal O
73 O
amino O
acid O
residues O
of O
PAN I-GENE
are O
not O
absolutely O
required O
for O
this O
reaction O
. O

The O
transcription O
factor O
E2F I-GENE
plays O
an O
important O
role O
in O
G O
( O
1 O
) O
to O
S O
phase O
transition O
in O
the O
higher O
eukaryotic O
cell O
cycle O
. O

In O
two O
- O
field O
nodal O
dissection O
, O
two O
components O
are O
included O
with O
( O
modern O
two O
- O
field O
) O
or O
without O
( O
traditional O
two O
- O
field O
) O
nodal O
dissection O
around O
both O
recurrent O
laryngeal O
nerve O
chains O
in O
the O
upper O
mediastinum O
. O

Of O
the O
153 O
patients O
studied O
, O
CK I-GENE
- I-GENE
MB I-GENE
results O
were O
positive O
in O
91 O
( O
59 O
%) O
patients O
; O
ECG O
revealed O
AMI O
in O
72 O
( O
47 O
%) O
patients O
. O

The O
effect O
of O
MIB O
on O
the O
dose O
- O
response O
curve O
of O
externally O
applied O
noradrenaline O
was O
also O
studied O
. O

The O
regional O
blockade O
of O
H1R I-GENE
was O
observed O
mainly O
in O
the O
frontal O
, O
temporal O
and O
anterior O
cingulate O
cortices O
, O
and O
the O
intravenous O
administration O
of O
d O
- O
chlorpheniramine O
as O
a O
therapeutic O
dose O
( O
2 O
mg O
) O
blocked O
over O
60 O
% O
of O
H1R I-GENE
in O
the O
frontal O
cortices O
. O

The O
expression O
of O
the O
yam8 I-GENE
(+) I-GENE
cDNA I-GENE
in O
the O
mid1 I-GENE
mutant I-GENE
cells O
partially O
remediated O
the O
mid O
phenotype O
and O
resulted O
in O
a O
slight O
increase O
in O
Ca O
( O
2 O
+) O
uptake O
activity O
. O

Linearized O
overall O
infection O
rates O
( O
events O
/ O
100 O
patient O
- O
days O
) O
were O
2 O
. O
05 O
+/- O
0 O
. O
33 O
( O
heart O
- O
lung O
) O
and O
2 O
. O
34 O
+/- O
0 O
. O
34 O
( O
double O
- O
lung O
; O
P O
= O
NS O
) O
at O
3 O
months O
. O

Static O
and O
dynamic O
compliance O
was O
measured O
after O
induction O
of O
anesthesia O
, O
before O
and O
immediately O
after O
filtration O
in O
the O
operating O
theater O
, O
1 O
hour O
after O
return O
to O
the O
pediatric O
intensive O
care O
unit O
, O
and O
24 O
hours O
after O
the O
operation O
. O

Antipyretic O
therapy O
: O
physiologic O
rationale O
, O
diagnostic O
implications O
, O
and O
clinical O
consequences O
. O

There O
is O
no O
correlation O
between O
C2 O
- O
C3 O
disk O
morphology O
and O
the O
diskographically O
provoked O
response O
. O

KFC I-GENE
, O
a O
Ste20 I-GENE
- I-GENE
like I-GENE
kinase I-GENE
with O
mitogenic O
potential O
and O
capability O
to O
activate O
the O
SAPK I-GENE
/ O
JNK I-GENE
pathway O
. O

TIP30 I-GENE
has O
an O
intrinsic O
kinase O
activity O
required O
for O
up O
- O
regulation O
of O
a O
subset O
of O
apoptotic O
genes O
. O

We O
have O
mapped O
the O
human I-GENE
STAG3 I-GENE
gene I-GENE
to O
the O
7q22 O
region O
of O
chromosome O
7 O
; O
six O
human I-GENE
STAG3 I-GENE
- I-GENE
related I-GENE
genes I-GENE
have O
also O
been O
mapped O
: O
two O
at O
7q22 O
near O
the O
functional O
gene O
, O
one O
at O
7q11 O
. O
22 O
, O
and O
three O
at O
7q11 O
. O
23 O
, O
two O
of O
them O
flanking O
the O
breakpoints O
commonly O
associated O
with O
the O
Williams I-GENE
- I-GENE
Beuren I-GENE
syndrome I-GENE
( I-GENE
WBS I-GENE
) I-GENE
deletion I-GENE
. O

Reaction O
time O
( O
RT O
) O
and O
P300 O
were O
collected O
simultaneously O
. O

In O
experiment O
2 O
the O
rats O
had O
free O
access O
to O
two O
bottles O
, O
one O
of O
which O
contained O
tap O
water O
, O
and O
the O
other O
contained O
either O
an O
ethanol O
( O
6 O
%) O
or O
a O
sucrose O
( O
5 O
%) O
solution O
. O

Furthermore O
, O
Zelen O
' O
s O
method O
is O
used O
to O
balance O
the O
number O
of O
patients O
allocated O
to O
the O
two O
groups O
within O
each O
institution O
( O
M O
. O

RESULTS O
: O
In O
this O
group O
of O
patients O
, O
male O
gender O
( O
P O
= O
0 O
. O

Selective O
visual O
attention O
involves O
dynamic O
interplay O
between O
attentional O
control O
systems O
and O
sensory O
brain O
structures O
. O

The O
patient O
had O
developed O
left O
- O
sided O
low O
- O
frequency O
tremor O
and O
hemidystonia O
after O
a O
severe O
head O
trauma O
sustained O
at O
15 O
years O
of O
age O
. O

However O
, O
the O
a1 O
isoform O
is O
expressed O
most O
heavily O
in O
brain O
and O
heart O
, O
a2 O
in O
liver O
and O
kidney O
, O
and O
a3 O
in O
liver O
, O
lung O
, O
heart O
, O
brain O
, O
spleen O
, O
and O
kidney O
. O

During O
the O
cloning O
by O
reverse I-GENE
transcriptase I-GENE
- O
polymerase O
chain O
reaction O
of O
the O
human I-GENE
HIF I-GENE
- I-GENE
1alpha I-GENE
subunit I-GENE
, O
we O
isolated O
two O
cDNA O
clones O
which O
corresponded O
to O
alternative O
splicing O
of O
the O
HIF I-GENE
- I-GENE
1alpha I-GENE
gene I-GENE
. O

To O
assess O
the O
relationship O
between O
G O
( O
q O
)/ O
G I-GENE
( I-GENE
11 I-GENE
) I-GENE
function O
with O
the O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
dependent O
pathway O
, O
expression O
of O
a O
dominant O
- O
interfering O
p85 I-GENE
regulatory I-GENE
subunit I-GENE
, O
as O
well O
as O
wortmannin O
treatment O
inhibited O
insulin I-GENE
- O
stimulated O
but O
not O
G I-GENE
( I-GENE
q I-GENE
)/ I-GENE
Q209L I-GENE
- O
stimulated O
GLUT4 I-GENE
- O
EGFP I-GENE
translocation O
. O

In O
endemic O
BL O
, O
the O
RB2 I-GENE
/ O
p130 I-GENE
gene O
is O
mutated O
in O
most O
of O
the O
cases O
, O
and O
the O
protein O
is O
restricted O
to O
the O
cytoplasm O
. O

Together O
, O
these O
data O
identify O
ERK2 I-GENE
as O
a O
specific O
and O
direct O
target O
of O
HePTP I-GENE
and O
are O
consistent O
with O
a O
model O
in O
which O
HePTP I-GENE
negatively O
regulates O
ERK2 I-GENE
activity O
as O
part O
of O
a O
feedback O
mechanism O
. O

Cross O
- O
reaction O
between O
a O
monoclonal O
antibody O
and O
two O
alpha I-GENE
beta I-GENE
T I-GENE
cell I-GENE
receptors I-GENE
. O

Strontium O
nitrate O
mixed O
with O
glycolic O
acid O
, O
in O
comparison O
with O
glycolic O
acid O
alone O
, O
markedly O
( O
p O
< O
0 O
. O
01 O
) O
shortened O
the O
duration O
of O
the O
irritation O
sensation O
from O
24 O
. O
4 O
+/- O
4 O
. O
1 O
( O
mean O
+/- O
SEM O
) O
min O
to O
8 O
. O
9 O
+/- O
3 O
. O
7 O
( O
mean O
+/- O
SEM O
) O
min O
, O
and O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
reduced O
the O
mean O
magnitude O
of O
the O
irritation O
sensation O
at O
all O
time O
points O
( O
overall O
). O

The O
pCMBS O
- O
reactive O
sulfhydryl O
groups O
were O
located O
exclusively O
in O
the O
exofacial O
half O
of O
the O
plasma O
membrane O
and O
, O
when O
presented O
in O
a O
helical O
model O
, O
lie O
along O
one O
side O
of O
the O
helices O
. O

Analysis O
of O
1 O
Mb O
of O
published O
sequence O
from O
the O
region O
of O
conserved O
synteny O
on O
human O
chromosome O
5q31 O
- O
q33 O
identified O
45 O
gene O
candidates O
, O
including O
35 O
expressed O
genes O
in O
the O
human I-GENE
IL I-GENE
- I-GENE
4 I-GENE
cytokine I-GENE
gene I-GENE
cluster I-GENE
. O

Human I-GENE
AP I-GENE
- I-GENE
2rep I-GENE
repressed O
both O
reporter O
expression O
from O
a O
transiently O
transfected O
AP I-GENE
- I-GENE
2alpha I-GENE
promoter I-GENE
and O
the O
endogenous O
AP I-GENE
- I-GENE
2alpha I-GENE
gene I-GENE
and O
inversely O
was O
negatively O
regulated O
by O
AP I-GENE
- I-GENE
2alpha I-GENE
. O

In O
order O
to O
gain O
deeper O
insight O
into O
the O
role O
of O
the O
amino O
- O
terminal O
domain O
of O
the O
p24 I-GENE
( O
CA I-GENE
) O
protein O
during O
viral O
replication O
, O
eight O
highly O
conserved O
proline O
residues O
known O
to O
promote O
turns O
and O
to O
terminate O
alpha O
- O
helices O
within O
the O
p24 I-GENE
tertiary O
structure O
were O
replaced O
by O
a O
leucine O
residue O
( O
P O
- O
position O
- O
L O
). O

Clb I-GENE
/ O
Cdc28 I-GENE
kinases O
promote O
nuclear O
export O
of O
the O
replication I-GENE
initiator I-GENE
proteins I-GENE
Mcm2 I-GENE
- I-GENE
7 I-GENE
. O

Alternatively O
, O
PC12 O
- O
E2 O
cells O
were O
submitted O
to O
treatment O
with O
antibodies O
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
( I-GENE
FGF I-GENE
) I-GENE
receptor I-GENE
, O
inhibitors O
of O
the O
nonreceptor I-GENE
tyrosine I-GENE
kinase I-GENE
p59 I-GENE
( O
fyn I-GENE
), O
PLC I-GENE
, O
PKC I-GENE
and O
MEK I-GENE
and O
an O
activator O
of O
PKC I-GENE
, O
phorbol O
- O
12 O
- O
myristate O
- O
13 O
- O
acetate O
( O
PMA O
). O

Cooperative O
roles O
of O
Bozozok I-GENE
/ O
Dharma I-GENE
and O
Nodal I-GENE
- I-GENE
related I-GENE
proteins I-GENE
in O
the O
formation O
of O
the O
dorsal O
organizer O
in O
zebrafish O
. O

Thiopentone O
sodium O
administered O
at O
30 O
and O
10 O
min O
before O
or O
5 O
, O
10 O
and O
15 O
min O
after O
exposure O
to O
NOC O
- O
5 O
, O
but O
not O
thereafter O
, O
significantly O
attenuated O
NO O
- O
induced O
neurotoxicity O
compared O
with O
controls O
. O

We O
also O
show O
that O
zygotically O
activated O
Xretpos O
transcripts O
are O
restricted O
to O
ventro O
- O
posterior O
specific O
regions O
and O
induced O
by O
UV O
- O
irradiation O
and O
BMP I-GENE
- I-GENE
4 I-GENE
overexpression O
in O
cycloheximide O
- O
dependent O
way O
. O
genesis O
26 O
: O
198 O
- O
207 O
, O
2000 O
. O

In O
all O
other O
cases O
, O
vestibular O
neurectomy O
or O
chemical O
vestibular O
labyrinthectomy O
, O
by O
means O
of O
intratympanic O
low O
concentration O
gentamicin O
( O
20 O
mg O
/ O
mL O
), O
are O
indicated O
. O

However O
, O
when O
, O
where O
and O
how O
the O
DSPP I-GENE
is O
cleaved O
into O
DSP I-GENE
and O
DPP I-GENE
is O
not O
clear O
. O

It O
has O
a O
grave O
prognosis O
with O
> O
70 O
% O
mortality O
in O
3 O
months O
, O
despite O
mechanical O
ventilation O
. O

We O
found O
that O
TCR I-GENE
signaling O
induces O
AP I-GENE
- I-GENE
1 I-GENE
binding O
to O
this O
site O
and O
regulates O
the O
fasl I-GENE
promoter I-GENE
function O
in O
a O
fashion O
dependent O
on O
NF I-GENE
- I-GENE
kappaB I-GENE
binding O
. O

Thus O
, O
patients O
with O
metastatic O
melanoma O
are O
not O
tolerant O
to O
gp100 I-GENE
Ag I-GENE
based O
on O
the O
detection O
of O
CD8 I-GENE
+ I-GENE
T O
cells O
specific O
for O
multiple O
HLA I-GENE
- I-GENE
A I-GENE
* I-GENE
0201 I-GENE
- O
restricted O
, O
gp100 I-GENE
- O
derived O
epitopes O
. O

Approximately O
20 O
% O
of O
ALCLs O
that O
express O
ALK I-GENE
do O
not O
contain O
the O
t O
( O
2 O
; O
5 O
), O
suggesting O
that O
other O
genetic O
abnormalities O
can O
result O
in O
aberrant O
ALK I-GENE
expression O
. O

In O
addition O
, O
expected O
decreases O
in O
ATIC I-GENE
enzymatic O
function O
in O
ATIC I-GENE
- O
ALK I-GENE
- O
containing O
lymphomas O
may O
render O
these O
tumors O
more O
sensitive O
to O
antifolate O
drugs O
such O
as O
methotrexate O
. O

Following O
the O
observation O
that O
non O
- O
organ O
- O
specific O
antibodies O
are O
related O
with O
pregnancy O
loss O
and O
preeclampsia O
, O
the O
role O
of O
organ O
- O
specific O
antibodies O
is O
currently O
being O
extensively O
investigated O
. O

Manganese O
ions O
were O
found O
to O
be O
essential O
for O
autophosphorylation O
of O
BGLF4 I-GENE
, O
and O
magnesium O
can O
stimulate O
the O
activity O
. O

The O
Mif1 I-GENE
5 I-GENE
' I-GENE
flanking I-GENE
region I-GENE
contains O
a O
functional O
ER O
stress O
- O
responsive O
element O
which O
is O
sufficient O
for O
induction O
by O
tunicamycin O
. O

Rigid O
point O
feature O
registration O
using O
mutual O
information O
. O

Methysergide O
is O
a O
serotonin O
antagonist O
and O
has O
been O
demonstrated O
to O
reduce O
wound O
blood O
flow O
and O
edema O
formation O
. O

Serum O
leptin I-GENE
concentrations O
in O
women O
during O
gonadotropin I-GENE
stimulation O
cycles O
. O

Valuing O
families O
: O
social O
work O
practice O
with O
families O
from O
a O
strengths O
perspective O
. O

PURPOSE O
: O
A O
two O
- O
generation O
consanguineous O
Pakistani O
family O
with O
autosomal O
recessive O
Leber O
congenital O
amaurosis O
( O
LCA O
, O
MIM O
204 O
, O
000 O
) O
and O
keratoconus O
was O
identified O
. O

Ste18p I-GENE
was O
targeted O
to O
the O
plasma O
membrane O
even O
in O
the O
absence O
of O
prenylation O
or O
thioacylation O
. O

Here O
, O
we O
show O
that O
IRF I-GENE
- I-GENE
1 I-GENE
is O
degraded O
via O
the O
ubiquitin I-GENE
- O
proteasome O
pathway O
. O

An O
amino O
- O
acid O
sequence O
comparison O
revealed O
that O
Bacillus I-GENE
YM55 I-GENE
- I-GENE
1 I-GENE
aspartase I-GENE
shared O
71 O
% O
homology O
with O
Bacillus I-GENE
subtilis I-GENE
aspartase I-GENE
and O
49 O
% O
with O
Escherichia O
coli O
and O
Pseudomonas I-GENE
fluorescens I-GENE
aspartases I-GENE
. O

Unique O
to O
this O
system O
, O
the O
activity O
of O
TraR I-GENE
is O
negatively O
modulated O
by O
an O
antiactivator O
called O
TraM I-GENE
. O

As O
assessed O
by O
a O
genetic O
assay O
that O
measures O
AAI O
- O
dependent O
DNA O
binding O
, O
TraM I-GENE
inhibited O
TraR I-GENE
function O
before O
and O
after O
the O
transcription O
factor O
had O
bound O
to O
its O
DNA O
recognition O
site O
. O

Here O
we O
show O
that O
IIIa O
pre O
- O
mRNA O
splicing O
is O
activated O
more O
than O
200 O
- O
fold O
in O
nuclear O
extracts O
prepared O
from O
late O
adenovirus O
- O
infected O
cells O
( O
Ad O
- O
NE O
) O
compared O
to O
uninfected O
HeLa O
cell O
nuclear O
extracts O
( O
HeLa O
- O
NE O
). O

Inactivation O
of O
Ulp2 I-GENE
also O
suppresses O
several O
ulp1 I-GENE
( I-GENE
ts I-GENE
) I-GENE
defects O
, O
and O
the O
double O
mutant O
accumulates O
far O
fewer O
Smt3 I-GENE
- I-GENE
protein I-GENE
conjugates O
than O
either O
single O
mutant O
. O

Collectively O
, O
the O
results O
suggest O
that O
ARF I-GENE
binding O
to O
Mdm2 I-GENE
induces O
a O
conformational O
change O
that O
facilitates O
nucleolar O
import O
of O
the O
ARF I-GENE
- O
Mdm2 I-GENE
complex O
and O
p53 I-GENE
- O
dependent O
cell O
cycle O
arrest O
. O

Cyclin I-GENE
A I-GENE
expression O
is O
repressed O
in O
quiescent O
cells O
by O
E2F I-GENE
acting O
in O
conjunction O
with O
its O
pocket O
protein O
partners O
Rb I-GENE
, O
p107 I-GENE
, O
and O
p130 I-GENE
; O
however O
, O
v I-GENE
- I-GENE
Jun I-GENE
overrides O
this O
control O
, O
causing O
phosphorylated O
Rb I-GENE
and O
proliferation O
- O
specific O
E2F I-GENE
- O
p107 I-GENE
complexes O
to O
persist O
after O
mitogen O
withdrawal O
. O

D I-GENE
- I-GENE
cyclin I-GENE
- O
cdk I-GENE
activity O
is O
required O
for O
Rb I-GENE
phosphorylation O
in O
v I-GENE
- I-GENE
Jun I-GENE
- O
transformed O
cells O
, O
since O
ectopic O
expression O
of O
the O
cdk4 I-GENE
- O
and O
cdk6 I-GENE
- O
specific O
inhibitor O
p16 I-GENE
( O
INK4A I-GENE
) O
inhibits O
both O
DNA O
synthesis O
and O
cell O
proliferation O
. O

CONCLUSION O
: O
A O
valve O
- O
like O
mechanism O
formed O
by O
the O
capsulorhexis O
rim O
partially O
adhered O
to O
the O
IOL O
optic O
can O
occur O
postoperatively O
. O

The O
protein O
first O
identified O
by O
the O
monoclonal I-GENE
antibody I-GENE
Q18 I-GENE
is O
encoded O
by O
a O
gene O
located O
in O
57A O
on O
polytene O
chromosomes O
and O
has O
been O
consequently O
named O
Hrb57A I-GENE
. O

3 O
' O
RNA O
boundary O
experiments O
indicate O
that O
the O
5 O
' O
structure O
reduces O
the O
number O
of O
( O
G O
/ O
U O
) O
AG O
repeats O
required O
for O
stable O
TRAP I-GENE
- O
trp I-GENE
leader O
RNA O
association O
. O

Gene O
silencing O
associated O
with O
repeated O
DNA O
sequences O
has O
been O
reported O
for O
many O
eukaryotes O
, O
including O
plants O
. O

The O
AtERF I-GENE
genes I-GENE
were O
differentially O
regulated O
by O
ethylene O
and O
by O
abiotic O
stress O
conditions O
, O
such O
as O
wounding O
, O
cold O
, O
high O
salinity O
, O
or O
drought O
, O
via O
ETHYLENE I-GENE
- I-GENE
INSENSITIVE2 I-GENE
( O
EIN2 I-GENE
)- O
dependent O
or O
- O
independent O
pathways O
. O

Animals O
received O
a O
dose O
of O
dexamethasone O
( O
10 O
mg O
/ O
kg O
i O
. O
p O
.) O
prior O
to O
the O
protein O
- O
free O
surfactant O
preparation O
Exosurf O
( O
pure O
phospholipids O
containing O
surfactant O
, O
Wellcome O
GmbH O
, O
Burgwedel O
, O
Germany O
) O
and O
a O
rSP O
- O
C O
based O
surfactant O
, O
respectively O
. O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
response O
rates O
and O
toxicity O
of O
two O
regimens O
containing O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
GM I-GENE
- I-GENE
CSF I-GENE
) O
in O
combination O
with O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
in O
the O
treatment O
of O
patients O
with O
metastatic O
renal O
cell O
carcinoma O
. O

We O
show O
, O
by O
injection O
of O
synthetic O
mRNAs O
, O
that O
the O
cis O
- O
acting O
sequences O
responsible O
for O
repression O
of O
cyclin I-GENE
B1 I-GENE
mRNA I-GENE
reside O
within O
its O
3 O
' O
UTR O
. O

These O
data O
indicate O
that O
expansion O
of O
the O
dodecamer O
repeat O
located O
in O
the O
proximal O
promoter O
of O
CSTB I-GENE
severely O
disrupts O
the O
function O
of O
the O
promoter O
and O
thereby O
reduces O
transcription O
of O
CSTB I-GENE
. O

Thus O
, O
while O
the O
genomic O
organization O
of O
mHuA I-GENE
is O
similar O
to O
the O
neural O
- O
restricted O
members O
of O
the O
Elav I-GENE
family I-GENE
, O
the O
promoter O
element O
differs O
substantially O
both O
by O
sequence O
analysis O
and O
transcriptional O
activity O
in O
non O
- O
neural O
cell O
types O
. O

Analysis O
of O
the O
5 O
' O
end O
of O
the O
mouse I-GENE
Elavl1 I-GENE
( O
mHuA I-GENE
) O
gene O
reveals O
a O
transcriptional O
regulatory O
element O
and O
evidence O
for O
conserved O
genomic O
organization O
. O
mHuA I-GENE
( O
Elavl1 I-GENE
) O
belongs O
to O
a O
highly O
conserved O
family O
of O
genes O
encoding O
RNA O
- O
binding O
proteins O
and O
has O
been O
linked O
to O
cell O
growth O
and O
proliferation O
through O
its O
regulation O
of O
mRNA O
stability O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
that O
Sp1 I-GENE
binds O
to O
two O
different O
regions O
in O
the O
proximal O
promoter O
, O
a O
typical O
Sp1 I-GENE
site I-GENE
located O
at O
(- O
38 O
; O
- O
33 O
) O
and O
a O
G O
/ O
C O
- O
rich O
region O
between O
(- O
67 O
; O
- O
62 O
). O

Fgd3 I-GENE
and O
FGD1 I-GENE
share O
a O
high O
degree O
of O
sequence O
identity O
that O
spans O
> O
560 O
contiguous O
amino O
acid O
residues O
. O

Molecular O
cloning O
of O
mouse I-GENE
thioredoxin I-GENE
reductases I-GENE
. O

The O
HPLC O
method O
involves O
an O
octadecylsilane O
column O
at O
55 O
degrees O
C O
, O
a O
mixture O
of O
water O
- O
acetonitrile O
- O
orthophosphoric O
acid O
( O
779 O
: O
220 O
: O
1 O
, O
v O
/ O
v O
) O
as O
mobile O
phase O
and O
detection O
at O
226 O
nm O
. O

Eight O
patients O
received O
1 O
. O
5 O
mg O
of O
adefovir O
dipivoxil O
per O
kg O
of O
body O
weight O
, O
and O
six O
patients O
received O
3 O
. O
0 O
mg O
of O
adefovir O
dipivoxil O
per O
kg O
. O

CYC2 I-GENE
encodes O
a O
24 O
- O
kDa O
protein O
that O
has O
sequence O
identity O
to O
the O
Neurospora I-GENE
crassa I-GENE
PREG1 I-GENE
and O
the O
S I-GENE
. I-GENE
cerevisiae I-GENE
PHO80 I-GENE
cyclin I-GENE
. O

To O
determine O
if O
CYC2 I-GENE
is O
found O
in O
a O
complex O
with O
previously O
identified O
trypanosome I-GENE
cdc2 I-GENE
- I-GENE
related I-GENE
kinases I-GENE
( O
CRKs I-GENE
), O
the O
CYC2 I-GENE
gene I-GENE
was O
fused O
to O
the O
TY I-GENE
epitope I-GENE
tag O
, O
integrated O
into O
the O
trypanosome O
genome O
, O
and O
expressed O
under O
inducible O
control O
. O

These O
findings O
indicate O
the O
involvement O
of O
Sp1 I-GENE
and O
an O
Inr O
in O
non O
- O
cell O
- O
specific O
regulation O
and O
a O
Kruppel I-GENE
- I-GENE
like I-GENE
transcription I-GENE
factor I-GENE
and O
Sp1 I-GENE
in O
the O
cell O
- O
specific O
regulation O
of O
the O
LTC I-GENE
( I-GENE
4 I-GENE
) I-GENE
S I-GENE
gene I-GENE
. O

Here O
we O
review O
progress O
to O
date O
in O
this O
area O
. O

Additionally O
, O
the O
mouse O
promoter O
contains O
22 O
copies O
of O
a O
CT O
dinucleotide O
repeat O
sequence O
located O
approximately O
155 O
bp O
5 O
' O
to O
exon O
1 O
. O

The O
newly O
defined O
region O
contains O
an O
intron O
that O
may O
be O
alternatively O
spliced O
and O
seven O
polyadenylation O
signal O
sequences O
. O

Depleted O
and O
enriched O
U3O8 O
standard O
reference O
materials O
were O
used O
to O
calibrate O
the O
system O
. O

Therefore O
, O
the O
positive O
cAMP O
control O
of O
the O
hypoxic O
SRP1 I-GENE
and O
HEM13 I-GENE
genes I-GENE
was O
uncoupled O
from O
the O
HOG I-GENE
pathway O
. O

Most O
likely O
they O
might O
represent O
regulatory O
RNAs O
or O
transcribed O
transposable O
elements O
. O

This O
paper O
reviews O
the O
middleware O
- O
based O
approach O
adopted O
by O
CEN O
ENV O
12967 O
- O
1 O
and O
the O
specialisation O
necessary O
for O
the O
healthcare O
record O
based O
on O
CEN O
ENV O
12265 O
' O
Electronic O
Healthcare O
Record O
Architecture O
'. O

Sequence O
analyses O
of O
sos2 I-GENE
mutant I-GENE
alleles I-GENE
reveal O
that O
both O
the O
N O
- O
terminal O
catalytic O
domain O
and O
the O
C O
- O
terminal O
regulatory O
domain O
of O
SOS2 I-GENE
are O
functionally O
essential O
. O

A O
mutation O
which O
abrogates O
the O
binding O
of O
these O
factors O
reduces O
Wp I-GENE
reporter I-GENE
activity O
specifically O
in O
B O
cell O
lines O
, O
whereas O
a O
mutation O
which O
converts O
the O
site O
to O
a O
consensus O
CREB I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
maintains O
wild O
- O
type O
promoter O
function O
. O

Here O
we O
describe O
the O
cloning O
, O
tissue O
- O
specific O
expression O
pattern O
, O
and O
functional O
characterization O
of O
two O
novel O
TEF I-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
, O
TEF I-GENE
- I-GENE
1beta I-GENE
and O
TEF I-GENE
- I-GENE
1gamma I-GENE
. O

Therefore O
the O
binding O
sites O
for O
liver O
- O
enriched O
factors O
, O
present O
in O
the O
hamster I-GENE
CYP7A1 I-GENE
proximal I-GENE
promoter I-GENE
in O
close O
vicinity O
and O
conserved O
between O
species O
, O
constitute O
a O
regulatory O
unit O
important O
for O
basal O
hepatic O
expression O
and O
tissue O
restriction O
of O
the O
action O
of O
hormones O
such O
as O
insulin I-GENE
. O

The O
kinase O
activity O
of O
PfPK6 I-GENE
is O
sensitive O
to O
CDK I-GENE
inhibitors O
such O
as O
olomoucine O
and O
roscovitine O
. O

Although O
MAP I-GENE
( I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
) I-GENE
kinases I-GENE
are O
implicated O
in O
cell O
proliferation O
and O
differentiation O
in O
many O
cell O
types O
, O
the O
role O
of O
MAP I-GENE
kinases I-GENE
in O
cardiac O
hypertrophy O
remains O
unclear O
. O

Transfection O
with O
a O
CSF I-GENE
- I-GENE
1R I-GENE
expression O
plasmid O
permitted O
CSF I-GENE
- I-GENE
1 I-GENE
- O
dependent O
activation O
of O
the O
signalling O
pathway O
targeting O
an O
Ets I-GENE
/ O
AP1 I-GENE
( O
activator I-GENE
protein I-GENE
1 I-GENE
) O
element O
in O
the O
uPA I-GENE
promoter I-GENE
that O
has O
been O
shown O
previously O
to O
be O
a O
target O
of O
oncogenic I-GENE
ras I-GENE
and O
protein O
kinase O
C O
pathways O
. O

Regulation O
of O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
transcription O
in O
the O
RAW264 O
murine O
macrophage O
cell O
line O
by O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
) O
is O
dependent O
upon O
the O
level O
of O
cell O
- O
surface O
receptor O
. O

Molecule O
( O
s O
) O
secreted O
by O
neuronal O
cultures O
contribute O
to O
this O
induction O
of O
GLT I-GENE
- I-GENE
1 I-GENE
, O
but O
little O
is O
known O
about O
the O
signaling O
pathways O
mediating O
this O
regulation O
. O

Coactivation O
of O
endogenous O
or O
exogenous O
G I-GENE
( I-GENE
q I-GENE
)- I-GENE
coupled I-GENE
receptors I-GENE
with O
the O
delta I-GENE
- I-GENE
opioid I-GENE
receptor I-GENE
produced O
strong O
stimulations O
of O
PLCbeta I-GENE
and O
such O
responses O
could O
be O
partially O
blocked O
by O
pertussis I-GENE
toxin I-GENE
. O

Patients O
enrolled O
in O
the O
Integrilin O
to O
Minimize O
Platelet O
Aggregation O
and O
Coronary O
Thrombosis O
- O
II O
( O
IMPACT O
- O
II O
) O
trial O
were O
analyzed O
. O

The O
Wnt I-GENE
signaling O
pathway O
functions O
reiteratively O
during O
animal O
development O
to O
control O
cell O
fate O
decisions O
. O

This O
mutation O
no O
longer O
repressed O
the O
HPV O
- O
11 O
upstream O
regulatory O
region O
- O
controlled O
reporter O
expression O
. O

In O
the O
icosahaedral O
MVMi O
capsid O
, O
this O
sequence O
forms O
the O
carboxy O
end O
of O
the O
amphipathic O
beta O
- O
strand O
I O
( O
betaI O
), O
and O
all O
its O
basic O
residues O
are O
contiguously O
positioned O
at O
the O
face O
that O
in O
the O
unassembled O
subunit O
would O
be O
exposed O
to O
solvent O
. O

The O
two O
contiguous O
IGF2 I-GENE
( O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
) O
and O
H19 I-GENE
genes I-GENE
are O
reciprocally O
imprinted O
in O
both O
human O
and O
mouse O
. O

The O
asymmetric O
methylation O
was O
associated O
with O
tissue O
- O
specific O
disruption O
of O
H19 I-GENE
genomic O
imprinting O
in O
fetal O
brain O
. O

The O
comparison O
of O
the O
expression O
patterns O
of O
the O
known O
Kv4 I-GENE
family I-GENE
members I-GENE
shows O
subtype O
specificity O
with O
significant O
overlaps O
. O

Early O
treatment O
mechanics O
of O
the O
Class O
II O
division O
2 O
malocclusion O
. O

Preliminary O
use O
of O
the O
Nottingham O
Eczema O
Severity O
Score O
would O
support O
further O
development O
as O
a O
research O
tool O
for O
a O
simple O
assessment O
of O
disease O
severity O
that O
could O
be O
used O
in O
epidemiological O
studies O
. O

The O
consensus O
highlights O
the O
importance O
of O
residues O
other O
than O
the O
eight O
motifs O
that O
are O
often O
associated O
with O
DEAD I-GENE
- I-GENE
box I-GENE
RNA I-GENE
helicases I-GENE
, O
as O
well O
as O
de O
- O
emphasising O
the O
importance O
of O
the O
" O
A O
" O
residue O
within O
the O
" O
DEAD O
" O
motif O
. O

Advanced O
adenoma O
was O
defined O
as O
an O
adenoma O
larger O
than O
10 O
mm O
or O
an O
adenoma O
of O
any O
size O
with O
villous O
component O
, O
high O
- O
grade O
dysplasia O
or O
invasive O
carcinoma O
. O

In O
transient O
assays O
, O
using O
rice O
suspension O
- O
cultured O
cells O
transformed O
by O
particle O
bombardment O
, O
we O
showed O
previously O
that O
Oshox1 I-GENE
can O
transcriptionally O
repress O
the O
activity O
of O
reporter O
gene O
constructs O
with O
upstream O
HD I-GENE
- I-GENE
Zip I-GENE
binding O
sites O
. O

Results O
of O
two O
- O
hybrid O
assays O
and O
electrophoretic O
mobility O
shift O
assays O
strongly O
suggest O
that O
all O
HD I-GENE
- I-GENE
Zip I-GENE
proteins I-GENE
of O
families O
I O
and O
II O
can O
form O
homodimers O
and O
also O
heterodimers O
with O
all O
HD I-GENE
- I-GENE
Zip I-GENE
proteins I-GENE
of O
the O
same O
family O
. O

Among O
mammalian I-GENE
HSFs I-GENE
, O
HSF1 I-GENE
has O
been O
shown O
to O
be O
important O
for O
regulation O
of O
the O
heat O
- O
induced O
stress O
gene O
expression O
, O
whereas O
the O
function O
of O
HSF2 I-GENE
in O
stress O
response O
is O
unclear O
. O

Importantly O
, O
concomitant O
expression O
of O
constitutive O
activated O
Raf I-GENE
and O
V12N38 I-GENE
Ras I-GENE
results O
in O
almost O
complete O
loss O
of O
TTF I-GENE
- I-GENE
1 I-GENE
activity O
. O

They O
share O
many O
downstream O
targets O
, O
including O
remodeling O
of O
the O
actin I-GENE
cytoskeleton O
, O
activation O
of O
p70 I-GENE
( I-GENE
S6 I-GENE
) I-GENE
kinase I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
), O
and O
regulation O
of O
transcription O
and O
cell O
proliferation O
. O

Expression O
of O
activated O
Cdc42 I-GENE
results O
in O
the O
translocation O
of O
PKClambda I-GENE
from O
the O
nucleus O
into O
the O
cytosol O
, O
and O
Cdc42 I-GENE
and O
PKClambda I-GENE
colocalize O
at O
the O
plasma O
membrane O
and O
in O
the O
cytoplasm O
. O

Copyright O
2000 O
Academic O
Press O
. O

To O
understand O
whether O
Shc I-GENE
localization O
in O
membrane O
rafts O
is O
sufficient O
to O
regulate O
Shc I-GENE
function O
, O
we O
constructed O
a O
Shc I-GENE
chimera I-GENE
containing O
the O
Ras I-GENE
membrane I-GENE
localization I-GENE
motif I-GENE
at O
the O
C O
- O
terminus O
. O

Southern O
blotting O
and O
single O
strand O
conformation O
polymorphism O
analyses O
did O
not O
show O
tumor O
- O
specific O
alterations O
of O
this O
gene O
in O
gliomas O
and O
RT O
- O
PCR O
studies O
showed O
expression O
in O
glioma O
cell O
lines O
, O
suggesting O
that O
ANOVA I-GENE
is O
not O
the O
chromosome O
19q O
glioma O
tumor O
suppressor O
gene O
. O

RegA I-GENE
is O
a O
positive O
yet O
nonessential O
regulator O
of O
tol I-GENE
- O
oprL I-GENE
expression O
. O

Enzyme I-GENE
I I-GENE
of O
the O
phosphoenolpyruvate I-GENE
: I-GENE
sugar I-GENE
phosphotransferase I-GENE
system O
. O

Based O
on O
these O
data O
, O
we O
conclude O
that O
transcription O
of O
prgX I-GENE
is O
initiated O
from O
the O
Qa I-GENE
promoter I-GENE
in O
prgQ I-GENE
, O
and O
PrgX I-GENE
autoregulates O
its O
transcription O
either O
by O
mediating O
transcriptional O
readthrough O
or O
increasing O
mRNA O
stability O
. O

It O
was O
established O
that O
intrathecal O
or O
intraperitoneal O
PTFL O
, O
elevated O
the O
nociceptive O
threshold O
for O
mechanical O
stimuli O
in O
the O
formalin O
test O
in O
rats O
. O

Molecular O
mimicry O
of O
human O
cytokine O
and O
cytokine O
response O
pathway O
genes O
by O
KSHV O
. O

Family O
environment O
was O
an O
important O
influence O
on O
interpersonal O
relationships O
, O
substance O
use O
, O
and O
social O
support O
. O

By O
electrophoresis O
mobility O
shift O
assays O
using O
probes O
corresponding O
to O
different O
segments O
of O
the O
putative O
human I-GENE
c I-GENE
- I-GENE
myb I-GENE
intron I-GENE
1 I-GENE
transcription I-GENE
pause I-GENE
region I-GENE
and O
nuclear O
extracts O
from O
myeloid O
leukemia O
HL O
60 O
and O
fibroblast O
WI O
38 O
cells O
, O
we O
detected O
a O
HL O
- O
60 O
- O
specific O
DNA O
- O
protein O
complex O
with O
a O
123 O
- O
bp O
fragment O
containing O
binding O
sites O
for O
the O
interferon I-GENE
regulatory I-GENE
factors I-GENE
( O
IRFs I-GENE
) O
nuclear O
proteins O
. O

STUDY O
DESIGN O
: O
Fine O
needle O
aspiration O
cytologic O
smears O
from O
21 O
cases O
of O
invasive O
lobular O
carcinoma O
( O
ILC O
) O
of O
breast O
were O
subjected O
to O
detailed O
cytomorphologic O
analysis O
. O

Electrophile O
Response O
Elements O
( O
EpREs O
), O
located O
in O
5 O
'- O
flanking O
sequences O
of O
both O
the O
GCSh I-GENE
and O
GCSl I-GENE
subunit I-GENE
genes I-GENE
, O
are O
hypothesized O
to O
at O
least O
partially O
mediate O
gene O
induction O
following O
xenobiotic O
exposure O
. O

A O
new O
technique O
to O
create O
an O
artificial O
stenosis O
in O
the O
native O
LAD O
using O
a O
hemoclip O
. O

Dll3 I-GENE
is O
mutated O
in O
the O
X O
- O
ray O
- O
induced O
mouse I-GENE
mutant I-GENE
pudgy I-GENE
( O
pu I-GENE
), O
causing O
a O
variety O
of O
vertebrocostal O
defects O
similar O
to O
SD O
phenotypes O
. O

Schlegel O
, O
J O
. O

TbRAB31 I-GENE
behaviour O
was O
also O
studied O
during O
the O
cell O
cycle O
; O
TbRAB31 I-GENE
always O
localised O
to O
a O
discrete O
structure O
that O
duplicated O
very O
early O
in O
mitosis O
and O
relocated O
to O
daughter O
cells O
in O
a O
coordinate O
manner O
with O
the O
basal O
body O
and O
kinetoplast O
, O
suggesting O
the O
involvement O
of O
microtubules O
. O

The O
early O
dg O
. O
of O
rejection O
and O
especially O
acute O
rejection O
, O
it O
' O
s O
adequate O
management O
, O
decreased O
risk O
for O
the O
future O
chronic O
rejection O
nephropathy O
. O

Invertases I-GENE
are O
responsible O
for O
the O
breakdown O
of O
sucrose O
to O
fructose O
and O
glucose O
. O

To O
investigate O
the O
molecular O
mechanisms O
of O
this O
Tax I-GENE
- O
mediated O
inhibition O
, O
we O
analyzed O
its O
effect O
on O
the O
transcriptional O
activity O
of O
the O
myogenic O
MyoD I-GENE
protein I-GENE
, O
which O
was O
used O
as O
a O
paradigm O
of O
bHLH I-GENE
factors I-GENE
. O

The O
human I-GENE
T I-GENE
cell I-GENE
leukemia I-GENE
/ I-GENE
lymphotropic I-GENE
virus I-GENE
type I-GENE
1 I-GENE
Tax I-GENE
protein I-GENE
represses O
MyoD I-GENE
- O
dependent O
transcription O
by O
inhibiting O
MyoD I-GENE
- O
binding O
to O
the O
KIX I-GENE
domain I-GENE
of O
p300 I-GENE
. O

Phosphorylation O
and O
spindle O
pole O
body O
localization O
of O
the O
Cdc15p I-GENE
mitotic I-GENE
regulatory I-GENE
protein I-GENE
kinase I-GENE
in I-GENE
budding I-GENE
yeast I-GENE
. O

Thus O
, O
both O
the O
hyperplasia O
and O
thrombotic O
complications O
which O
often O
follow O
stenting O
might O
be O
minimized O
by O
employing O
gold O
stents O
, O
which O
have O
a O
greater O
capacity O
than O
steel O
in O
supporting O
a O
functional O
neo O
- O
endothelium O
. O

The O
cell O
cycle O
and O
transcriptional O
defects O
caused O
by O
taf17 I-GENE
( O
slm7 I-GENE
- I-GENE
1 I-GENE
) O
are O
consistent O
with O
the O
role O
of O
TAF I-GENE
( I-GENE
II I-GENE
) I-GENE
s I-GENE
as O
modulators O
of O
transcriptional O
activation O
and O
may O
reflect O
a O
role O
for O
TAF17 I-GENE
in O
regulating O
activation O
by O
SBF I-GENE
and O
MBF I-GENE
. O

Extracellular I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
activation O
and O
molecular O
coupling O
of O
the O
adaptor O
proteins O
p130 I-GENE
Crk I-GENE
- I-GENE
associated I-GENE
substrate I-GENE
( O
CAS I-GENE
) O
and O
c I-GENE
- I-GENE
CrkII I-GENE
( O
Crk I-GENE
) O
represent O
two O
distinct O
pathways O
that O
induce O
cell O
invasion O
and O
protect O
cells O
from O
apoptosis O
in O
a O
three O
- O
dimensional O
collagen I-GENE
matrix O
. O

Proteolysis O
of O
Mbp1 I-GENE
and O
Swi4 I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
has O
revealed O
the O
extent O
of O
these O
sequences O
, O
and O
C O
- O
terminally O
extended O
molecules O
with O
substantially O
enhanced O
DNA O
binding O
activity O
compared O
to O
the O
core O
domains O
alone O
have O
been O
produced O
. O

The O
evolution O
of O
the O
CCR5 I-GENE
cis I-GENE
- I-GENE
regulatory I-GENE
region I-GENE
versus O
the O
open O
reading O
frame O
as O
well O
as O
among O
different O
domains O
of O
the O
open O
reading O
frame O
differed O
from O
one O
another O
. O

These O
results O
indicate O
that O
residue O
266 O
serves O
as O
a O
" O
protein O
sensor O
" O
of O
altered O
minor O
groove O
interactions O
and O
identifies O
which O
base O
pair O
interactions O
are O
altered O
by O
these O
lesions O
. O

The O
recombinant O
enzymes O
exist O
as O
monomers O
. O

A O
pathway O
for O
regulation O
of O
B I-GENE
lymphocyte I-GENE
antigen I-GENE
receptor I-GENE
- O
induced O
calcium O
flux O
. O

We O
now O
describe O
a O
second O
RIM I-GENE
protein I-GENE
, O
called O
RIM2 I-GENE
, O
that O
is O
highly O
homologous O
to O
RIM1 I-GENE
and O
also O
expressed O
primarily O
in O
brain O
. O

Inhibitor I-GENE
- I-GENE
1 I-GENE
( O
I I-GENE
- I-GENE
1 I-GENE
) O
and O
inhibitor I-GENE
- I-GENE
2 I-GENE
( O
I I-GENE
- I-GENE
2 I-GENE
) O
selectively O
inhibit O
type I-GENE
1 I-GENE
protein I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
phosphatases I-GENE
( O
PP1 I-GENE
). O

Scanning O
mutations O
throughout O
the O
AC O
element O
interfered O
with O
induction O
but O
allowed O
us O
to O
define O
five O
overlapping O
sites O
for O
regulatory O
factors O
in O
AC O
and O
to O
design O
probes O
binding O
just O
one O
or O
two O
factors O
. O

The O
substrates O
for O
glycan O
synthesis O
in O
the O
lumen O
of O
the O
Golgi O
are O
nucleotide O
sugars O
that O
must O
be O
transported O
from O
the O
cytosol O
by O
specific O
membrane O
- O
bound O
transporters O
. O

Synaptic O
targeting O
of O
the O
postsynaptic I-GENE
density I-GENE
protein I-GENE
PSD I-GENE
- I-GENE
95 I-GENE
mediated O
by O
a O
tyrosine O
- O
based O
trafficking O
signal O
. O

( O
1998 O
) O
J O
. O

Bites O
by O
two O
species O
of O
adders O
( O
Vipera O
aspis O
and O
Vipera O
berus O
) O
can O
lead O
to O
extensive O
swelling O
with O
multiorgan O
failure O
. O

Both O
normal O
and O
transforming O
PCPH I-GENE
proteins I-GENE
have O
guanosine I-GENE
diphosphatase I-GENE
activity O
but O
only O
the O
oncoprotein O
cooperates O
with O
Ras I-GENE
in O
activating O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
ERK1 I-GENE
. O

These O
results O
indicate O
that O
virulence O
- O
associated O
genes O
and O
their O
overall O
chromosomal O
arrangement O
are O
relatively O
well O
conserved O
between O
B O
. O
henselae O
and O
other O
gram O
- O
negative O
bacteria O
such O
as O
A O
. O
tumefaciens O
. O

An O
important O
mechanism O
by O
which O
the O
tumor O
suppressor O
p53 I-GENE
maintains O
genomic O
stability O
is O
to O
induce O
cell O
cycle O
arrest O
through O
activation O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor O
p21 I-GENE
( O
WAF1 I-GENE
/ O
Cip1 I-GENE
) O
gene O
. O

Paxillin I-GENE
acts O
as O
an O
adaptor O
molecule O
in O
integrin I-GENE
signaling O
. O

Thus O
, O
growth O
factor O
activation O
of O
ER I-GENE
can O
mediate O
transactivation O
vs O
ER I-GENE
/ O
Sp1 I-GENE
binding O
to O
GC O
- O
rich O
sites O
and O
represents O
a O
novel O
pathway O
for O
ligand O
- O
independent O
ER I-GENE
action O
. O

Furthermore O
, O
analysis O
of O
deletion O
promoter O
- O
reporter O
constructs O
found O
that O
the O
basal O
activity O
of O
P2 O
resided O
in O
the O
proximal O
region O
of O
P2 O
. O

RESULTS O
: O
Auditory O
thresholds O
collected O
during O
audiometric O
tests O
increased O
gradually O
in O
proportion O
with O
age O
, O
especially O
in O
the O
hypertensive O
group O
( O
p O
< O
0 O
. O
05 O
). O

In O
addition O
, O
the O
transcription O
of O
c I-GENE
- I-GENE
IAP2 I-GENE
promoter I-GENE
was O
strongly O
up O
- O
regulated O
when O
CD40 I-GENE
or O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
was O
overexpressed O
. O

A O
variety O
of O
professional O
and O
self O
- O
applied O
fluoride O
products O
are O
available O
and O
new O
fluoride O
delivery O
systems O
have O
recently O
entered O
the O
market O
. O

These O
studies O
identify O
several O
of O
the O
signal O
- O
transduction O
events O
involved O
in O
the O
apoptosis O
of O
malignant O
B O
cells O
that O
transpire O
following O
ligation O
of O
CD20 I-GENE
by O
anti I-GENE
- I-GENE
CD20 I-GENE
antibodies I-GENE
in O
the O
presence O
of O
Fc I-GENE
- I-GENE
receptor I-GENE
- O
expressing O
cells O
or O
secondary O
goat O
anti I-GENE
-( I-GENE
mouse I-GENE
Ig I-GENE
) I-GENE
antibodies I-GENE
and O
which O
may O
contribute O
to O
the O
tumor O
regressions O
observed O
in O
mouse O
models O
and O
clinical O
trials O
. O

CONCLUSION O
: O
Treatment O
of O
sepsis O
with O
the O
platelet I-GENE
- I-GENE
activating I-GENE
factor I-GENE
antagonist O
BB O
- O
882 O
offers O
no O
advantage O
over O
placebo O
on O
survival O
, O
hemodynamic O
status O
, O
respiratory O
function O
, O
or O
organ O
failure O
scores O
. O

Phenazone O
potentiates O
the O
local O
anaesthetic O
effect O
of O
lidocaine O
in O
mice O
. O

The O
solubility O
of O
all O
the O
mutated O
proteins O
was O
remarkably O
reduced O
. O

Recently O
, O
identical O
RBE I-GENE
sequences I-GENE
have O
been O
identified O
at O
other O
locations O
in O
the O
human O
genome O
. O

EM O
analysis O
demonstrated O
that O
only O
one O
Rep I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
was O
formed O
on O
ch O
- O
19 O
target O
DNA O
. O

The O
protein O
was O
associated O
with O
purified O
vaccinia O
virus O
particles O
and O
with O
membranes O
of O
immature O
and O
mature O
virions O
that O
were O
visualized O
by O
electron O
microscopy O
of O
infected O
cells O
. O

In O
vivo O
dimethyl O
sulfate O
footprinting O
of O
the O
cyclin I-GENE
E I-GENE
promoter I-GENE
revealed O
several O
regions O
of O
protection O
and O
hypersensitivity O
that O
were O
unique O
to O
infected O
cells O
. O

A O
total O
of O
194 O
STSs O
map O
to O
this O
interval O
of O
3 O
Mb O
, O
giving O
an O
average O
marker O
resolution O
of O
approximately O
one O
per O
15 O
kb O
. O

Recently O
, O
a O
mutation O
in O
the O
amino O
- O
terminus O
of O
IB1 I-GENE
was O
associated O
with O
diabetes O
. O

CONCLUSION O
: O
More O
than O
50 O
% O
of O
patients O
with O
perennial O
rhinitis O
and O
CRS O
do O
not O
improve O
after O
surgery O
, O
a O
response O
that O
may O
be O
predicted O
by O
more O
cells O
expressing O
IL I-GENE
- I-GENE
5 I-GENE
mRNA I-GENE
in O
the O
ethmoid O
sinuses O
. O

Biol O
. O

On O
the O
basis O
of O
size O
, O
the O
CRS O
sequence O
to O
which O
it O
binds O
, O
and O
its O
tentative O
identification O
as O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
Adx I-GENE
factor I-GENE
has O
been O
identified O
as O
a O
Kruppel I-GENE
- I-GENE
like I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
( O
a O
mouse I-GENE
ZBP I-GENE
- I-GENE
89 I-GENE
homologue I-GENE
). O

METHODS O
: O
The O
most O
distal O
muscle O
fibres O
from O
the O
deep O
and O
superficial O
finger O
flexors O
were O
measured O
relative O
to O
the O
pisiform O
bone O
in O
18 O
cadaveric O
specimens O
. O

Here O
we O
report O
on O
the O
isolation O
of O
ICK2 I-GENE
, O
and O
show O
that O
it O
interacts O
with O
Cdc2aAt I-GENE
, O
but O
not O
with O
a O
second O
CDK I-GENE
from I-GENE
Arabidopsis I-GENE
, O
Cdc2bAt I-GENE
. O

Systemic O
impact O
of O
risk O
- O
sharing O
arrangements O
. O

METHODS O
: O
We O
determined O
an O
odds O
ratio O
( O
OR O
), O
as O
a O
measure O
of O
the O
relative O
risk O
of O
being O
exposed O
to O
a O
potential O
interaction O
, O
comparing O
the O
use O
of O
the O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
, O
cimetidine O
, O
with O
that O
of O
the O
noninteracting O
agents O
ranitidine O
, O
famotidine O
and O
nizatidine O
in O
users O
and O
nonusers O
of O
warfarin O
, O
phenytoin O
and O
theophylline O
. O

The O
prevalence O
of O
malnutrition O
was O
30 O
% O
in O
the O
47 O
patients O
without O
CVD O
and O
was O
significantly O
higher O
( O
70 O
%, O
P O
< O
0 O
. O
001 O
) O
in O
the O
70 O
patients O
with O
CVD O
, O
who O
also O
had O
lower O
tHcy O
, O
SAlb O
, O
plasma I-GENE
IGF I-GENE
- I-GENE
1 I-GENE
, O
serum O
creatinine O
( O
SCr O
), O
and O
blood I-GENE
hemoglobin I-GENE
. O

Our O
data O
suggest O
that O
, O
at O
least O
at O
high O
temperature O
, O
a O
critical O
minimal O
level O
of O
Ypt I-GENE
protein I-GENE
prenylation O
is O
required O
for O
maintaining O
vesicle O
polarization O
. O

The O
second O
functional O
pair O
of O
CreA I-GENE
sites I-GENE
is O
located O
between O
the O
two O
transcription O
initiation O
sites O
. O

A O
distinct O
staining O
pattern O
for O
the O
N I-GENE
- I-GENE
utrophin I-GENE
was O
not O
detectable O
, O
although O
it O
was O
expected O
to O
localise O
at O
the O
actin I-GENE
stress O
fibers O
. O

The O
' O
Newcastle O
' O
model O
, O
which O
is O
based O
on O
Hotelling O
' O
s O
T2 O
statistic O
, O
proved O
to O
be O
more O
sensitive O
and O
diagnosed O
a O
systematic O
displacement O
for O
three O
prostate O
patients O
. O

The O
MMA I-GENE
, I-GENE
DMA I-GENE
, I-GENE
and I-GENE
TMA I-GENE
methyltransferases I-GENE
are O
not O
homologs O
; O
however O
, O
like O
the O
MMA I-GENE
methyltransferase I-GENE
gene I-GENE
, O
the O
genes O
encoding O
the O
DMA I-GENE
and I-GENE
TMA I-GENE
methyltransferases I-GENE
each O
contain O
a O
single O
in O
- O
frame O
amber O
codon O
. O

After O
phosphorylation O
, O
STAT I-GENE
proteins I-GENE
are O
transported O
into O
the O
nucleus O
and O
exhibit O
transcriptional O
activity O
. O

Overexpression O
of O
mcl I-GENE
- I-GENE
1 I-GENE
is O
sufficient O
to O
protect O
against O
apoptosis O
, O
while O
transfection O
of O
a O
mcl I-GENE
- I-GENE
1 I-GENE
antisense O
plasmid O
causes O
cell O
death O
. O

Thus O
, O
although O
multiple O
senescence O
pathways O
are O
activated O
in O
response O
to O
a O
ras I-GENE
oncogene I-GENE
, O
inactivation O
of O
TGFbeta1 I-GENE
secretion O
or O
response O
is O
sufficient O
to O
block O
the O
senescence O
program O
. O

In O
this O
study O
, O
the O
abilities O
of O
constitutive O
and O
conditional O
forms O
of O
the O
three O
Raf I-GENE
kinases I-GENE
to O
abrogate O
the O
cytokine O
dependency O
of O
FDC O
- O
P1 O
cells O
were O
examined O
. O

Application O
of O
the O
method O
to O
a O
representative O
set O
of O
50 O
known O
genes O
from O
Arabidopsis O
thaliana O
showed O
significant O
improvement O
in O
prediction O
accuracy O
compared O
to O
previous O
spliced O
alignment O
methods O
. O

The O
complete O
cDNA O
sequence O
of O
human I-GENE
betaV I-GENE
spectrin I-GENE
is O
available O
from O
GenBank O
( O
TM O
) O
as O
accession O
number O
. O

Transactivation O
of O
naturally O
occurring O
HIV I-GENE
- I-GENE
1 I-GENE
long I-GENE
terminal I-GENE
repeats I-GENE
by O
the O
JNK I-GENE
signaling O
pathway O
. O

These O
data O
show O
that O
the O
alpha O
- O
helix O
domain O
of O
p57 I-GENE
( O
Kip2 I-GENE
), O
which O
is O
conserved O
in O
the O
Cip I-GENE
/ O
Kip I-GENE
proteins O
, O
is O
implicated O
in O
protein O
- O
protein O
interaction O
and O
confers O
a O
specific O
regulatory O
mechanism O
, O
outside O
of O
their O
Cdk I-GENE
- O
inhibitory O
activity O
, O
by O
which O
the O
p57 I-GENE
( O
Kip2 I-GENE
) O
family O
members O
positively O
act O
on O
myogenic O
differentiation O
. O

The O
mode O
of O
resistance O
to O
quinupristin O
/ O
dalfopristin O
was O
not O
evident O
( O
sat O
A O
- O
negative O
by O
PCR O
); O
and O
these O
cases O
illustrate O
the O
existence O
of O
streptogramin O
- O
resistant O
isolates O
before O
the O
introduction O
of O
this O
antimicrobial O
class O
into O
human O
clinical O
practice O
. O

This O
study O
was O
carried O
out O
to O
analyze O
PRL I-GENE
secretion O
in O
metastatic O
prostate O
cancer O
patients O
both O
at O
basal O
conditions O
and O
in O
response O
to O
L O
- O
Dopa O
and O
metoclopramide O
, O
which O
represents O
the O
most O
classical O
inhibitory O
and O
stimulatory O
tests O
for O
PRL I-GENE
secretion O
, O
respectively O
. O

Integrin I-GENE
adhesion I-GENE
receptors I-GENE
transduce O
signals O
that O
control O
complex O
cell O
functions O
which O
require O
the O
regulation O
of O
gene O
expression O
, O
such O
as O
proliferation O
, O
differentiation O
and O
survival O
. O

Recombination O
, O
replication O
, O
repair O
: O
from O
complexity O
to O
harmony O
. O

The O
somatoform O
conundrum O
: O
a O
question O
of O
nosological O
valves O
. O

Intra O
- O
operative O
ultrasound O
( O
IOUS O
) O
has O
been O
widely O
used O
in O
an O
attempt O
to O
overcome O
these O
difficulties O
, O
but O
is O
limited O
by O
its O
two O
- O
dimensional O
nature O
, O
inter O
- O
user O
variability O
, O
and O
image O
obliteration O
with O
ablative O
or O
resectional O
techniques O
. O

CONCLUSIONS O
: O
This O
randomized O
study O
shows O
that O
Vivostat O
fibrin I-GENE
sealant O
is O
effective O
in O
preventing O
air O
leakage O
after O
small O
lung O
resections O
in O
pigs O
, O
even O
at O
high O
inspiratory O
pressures O
. O

Hailey O
- O
Hailey O
disease O
is O
caused O
by O
mutations O
in O
ATP2C1 I-GENE
encoding O
a O
novel O
Ca O
( O
2 O
+) O
pump O
. O

Hex I-GENE
is O
expressed O
in O
the O
developing O
liver O
coincident O
with O
the O
forkhead I-GENE
/ O
winged I-GENE
helix I-GENE
transcription O
factor O
, O
Hepatocyte I-GENE
Nuclear I-GENE
Factor I-GENE
3beta I-GENE
( O
HNF3beta I-GENE
). O

As O
an O
extension O
of O
our O
structural O
characterization O
of O
the O
exon O
- O
intron O
organization O
of O
the O
mouse I-GENE
Pkr I-GENE
gene I-GENE
, O
we O
now O
have O
isolated O
and O
characterized O
the O
mouse I-GENE
Pkr I-GENE
promoter I-GENE
region I-GENE
required O
for O
IFN I-GENE
- O
inducible O
transcription O
. O

The O
CRE O
, O
5 O
'- O
TGACGTCA O
- O
3 O
', O
has O
been O
described O
as O
the O
consensus O
sequence O
for O
the O
cis O
- O
element O
that O
directs O
cAMP O
- O
regulated O
gene O
expression O
. O

Kidney O
length O
did O
not O
significantly O
differ O
between O
right O
and O
left O
, O
however O
, O
kidney O
width O
, O
cortical O
thickness O
and O
size O
did O
( O
p O
< O
0 O
. O
05 O
). O

The O
clinical O
stage O
was O
I O
( O
T1N0M0 O
), O
and O
S2 O
sleeve O
segmentectomy O
with O
lymph O
node O
dissection O
( O
R O
2 O
b O
) O
was O
performed O
. O

Benztropine O
for O
venlafaxine O
- O
induced O
night O
sweats O
. O

A O
cause O
of O
increase O
of O
alkaline I-GENE
phosphatase I-GENE
in O
children O

The O
physicians O
in O
charge O
of O
all O
patients O
with O
evidence O
of O
acute O
Q O
fever O
( O
seroconversion O
and O
/ O
or O
presence O
of O
IgM I-GENE
) O
or O
chronic O
Q O
fever O
( O
prolonged O
disease O
and O
/ O
or O
IgG I-GENE
antibody I-GENE
titer O
to O
phase O
I O
of O
Coxiella O
burnetii O
> O
or O
= O
800 O
) O
were O
asked O
to O
complete O
a O
questionnaire O
, O
which O
was O
computerized O
. O

Copyright O
2000 O
Academic O
Press O
. O

Viral O
cell O
- O
to O
- O
cell O
movement O
of O
PVX I-GENE
CP I-GENE
mutant I-GENE
was O
complemented O
in O
Nicotiana O
tabacum O
cv O
. O

Induction O
of O
CD86 I-GENE
expression O
by O
stimulation O
of O
U937 O
cells O
with O
IFN I-GENE
- I-GENE
gamma I-GENE
revealed O
the O
presence O
of O
two O
functional O
GAS I-GENE
( O
gamma I-GENE
- I-GENE
interferon I-GENE
activation I-GENE
site I-GENE
) O
elements O
. O

Significantly O
, O
two O
proximal O
GATA I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
(- O
118 O
/- O
113 O
and O
- O
98 O
/- O
93 O
) O
and O
a O
region O
located O
within O
- O
518 O
to O
- O
315bp O
of O
the O
mouse I-GENE
ALAS2 I-GENE
promoter I-GENE
were O
essential O
for O
transcriptional O
activation O
during O
chemically O
induced O
differentiation O
of O
MEL O
cells O
, O
implying O
their O
importance O
in O
conferring O
erythroid O
specificity O
to O
the O
ALAS2 I-GENE
transcriptional O
activation O
. O

SNAP I-GENE
- I-GENE
23 I-GENE
plays O
an O
important O
role O
in O
the O
regulation O
of O
vesicle O
trafficking O
in O
mammalian O
cells O
. O

The O
HMG I-GENE
domain I-GENE
of O
both O
HMG20 I-GENE
proteins I-GENE
is O
most O
similar O
to O
that O
of O
yeast I-GENE
NHP6A I-GENE
( O
38 O
% O
to O
42 O
%). O

IgM I-GENE
and O
IgG I-GENE
anti I-GENE
A I-GENE
and O
anti I-GENE
B I-GENE
antibody I-GENE
status O
of O
100 O
antenatal O
O O
group O
mothers O
( O
who O
had O
non O
O O
group O
husbands O
) O
were O
studied O
. O

In O
an O
attempt O
to O
understand O
Wee1 I-GENE
regulation O
during O
cell O
cycle O
, O
yeast O
two O
- O
hybrid O
screening O
was O
used O
to O
identify O
Wee1 O
- O
binding O
protein O
( O
s O
). O

Retroviral O
transduction O
of O
T I-GENE
/ I-GENE
T I-GENE
( I-GENE
L I-GENE
) I-GENE
causes O
a O
rapidly O
fatal O
myeloproliferative O
disease O
in O
a O
murine O
bone O
marrow O
transplant O
( O
BMT O
) O
model O
, O
whereas O
T I-GENE
/ I-GENE
T I-GENE
( I-GENE
F I-GENE
) I-GENE
causes O
a O
long O
- O
latency O
, O
pre O
- O
B O
- O
cell O
lymphoblastic O
lymphoma O
. O

Ab O
- O
MLV O
strains O
expressing O
P70 I-GENE
/ O
S2 I-GENE
failed O
to O
transform O
NIH O
3T3 O
cells O
and O
demonstrated O
a O
greatly O
reduced O
capacity O
to O
mediate O
signaling O
events O
associated O
with O
the O
Ras I-GENE
- O
dependent O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
pathway O
. O

The O
codon O
usage O
is O
particularly O
marked O
for O
the O
gag I-GENE
, O
pol I-GENE
, O
and O
env I-GENE
genes I-GENE
. O

The O
p53 I-GENE
- I-GENE
homolog I-GENE
p73beta I-GENE
also O
activated O
the O
PIG3 I-GENE
promoter I-GENE
, O
but O
in O
contrast O
to O
p53 I-GENE
, O
the O
proline O
- O
rich O
domain O
of O
p73beta I-GENE
( I-GENE
residues I-GENE
81 I-GENE
- I-GENE
113 I-GENE
) I-GENE
was O
dispensable O
to O
induce O
the O
PIG3 I-GENE
promoter I-GENE
. O

Results O
from O
transient O
assays O
using O
these O
mutants O
showed O
that O
the O
DE1 O
received O
signals O
from O
phytochromes I-GENE
A I-GENE
and I-GENE
B I-GENE
, O
demonstrating O
that O
this O
element O
is O
indeed O
a O
light O
- O
responsive O
element O
. O

Co O
- O
immunoprecipitation O
and O
DNA O
affinity O
chromatography O
prove O
that O
Sp1 I-GENE
heterodimerizes O
with O
ZBP I-GENE
- I-GENE
89 I-GENE
when O
bound O
to O
the O
silencer O
element O
to O
yield O
a O
DNA O
- O
protein O
complex O
whose O
mobility O
is O
indistinguishable O
from O
that O
displayed O
by O
HeLa O
nuclear O
extract O
in O
band O
shift O
assays O
. O

The O
ZNF274 I-GENE
gene I-GENE
is O
mapped O
distal O
to O
marker O
RP O
S28 O
1 O
in O
the O
human O
chromosome O
19qter O
region O
, O
by O
RH O
mapping O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
Cdk2 I-GENE
truncations O
, O
however O
, O
were O
non O
- O
functional O
in O
these O
strains O
and O
thus O
dependent O
for O
activity O
on O
the O
pho85 I-GENE
coding I-GENE
region I-GENE
which O
remained O
in O
the O
mutant I-GENE
pho85 I-GENE
:: O
HIS3 I-GENE
chromosomal I-GENE
locus I-GENE
. O

We O
report O
here O
on O
the O
molecular O
nature O
of O
an O
EMS O
- O
induced O
mutant O
, O
mn1 I-GENE
- I-GENE
89 I-GENE
, O
a O
leaky O
semidominant O
allele O
of O
the O
Miniature1 I-GENE
( O
Mn1 I-GENE
) O
seed O
locus O
that O
encodes O
a O
seed I-GENE
- I-GENE
specific I-GENE
cell I-GENE
wall I-GENE
invertase I-GENE
, O
INCW2 I-GENE
. O

We O
conclude O
that O
, O
both O
in O
atrial O
myocytes O
and O
in O
Xenopus O
oocytes O
, O
beta O
- O
adrenergic O
stimulation O
potentiates O
the O
ACh O
- O
evoked O
GIRK I-GENE
channels I-GENE
via O
a O
pathway O
that O
involves O
PKA I-GENE
- O
catalyzed O
phosphorylation O
downstream O
from O
beta I-GENE
( I-GENE
2 I-GENE
) I-GENE
AR I-GENE
. O

Slap I-GENE
negatively O
regulates O
Src I-GENE
mitogenic O
function O
but O
does O
not O
revert O
Src I-GENE
- O
induced O
cell O
morphology O
changes O
. O

Identification O
of O
a O
novel O
E2F3 I-GENE
product I-GENE
suggests O
a O
mechanism O
for O
determining O
specificity O
of O
repression O
by O
Rb I-GENE
proteins I-GENE
. O

In O
DNase I-GENE
I I-GENE
footprinting O
protection O
analysis O
, O
both O
SFRE I-GENE
and O
ERE O
regions O
were O
protected O
by O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- O
ERRalpha1 I-GENE
fusion O
protein O
. O

Overexpressing O
the O
coactivator O
, O
SRC1a I-GENE
or O
GRIP1 I-GENE
, O
further O
enhances O
ERRalpha1 I-GENE
- O
induced O
transcriptional O
activity O
. O

Estrogen I-GENE
receptor I-GENE
- I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
1 I-GENE
interacts O
with O
coactivator O
and O
constitutively O
activates O
the O
estrogen O
response O
elements O
of O
the O
human I-GENE
lactoferrin I-GENE
gene I-GENE
. O

We O
examine O
current O
models O
of O
the O
effects O
of O
aging O
on O
mean O
response O
time O
and O
show O
how O
they O
might O
be O
reinterpreted O
. O

The O
effects O
of O
these O
mutations O
on O
protein O
function O
require O
further O
examination O
. O

The O
median O
levels O
of O
particles O
with O
50 O
% O
cut O
- O
off O
aerodynamic O
diameters O
of O
10 O
( O
PM10 O
) O
and O
2 O
. O
5 O
microm O
( O
PM2 O
. O
5 O
) O
were O
170 O
( O
range O
103 O
- O
613 O
) O
and O
95 O
( O
range O
61 O
- O
218 O
) O
micro O
x O
m O
- O
3 O
, O
respectively O
. O

Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
viral I-GENE
interferon I-GENE
regulatory I-GENE
factor I-GENE
confers O
resistance O
to O
the O
antiproliferative O
effect O
of O
interferon I-GENE
- I-GENE
alpha I-GENE
. O

Specific O
and O
heritable O
genetic O
interference O
by O
double O
- O
stranded O
RNA O
in O
Arabidopsis O
thaliana O
. O

Comparison O
of O
sequences O
from O
- O
215 O
to O
+ O
1 O
bp O
identified O
consensus O
binding O
sites O
for O
the O
homeodomain I-GENE
transcription I-GENE
factor I-GENE
thyroid I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
). O

Two O
additional O
cis O
- O
acting O
sequences O
, O
conserved O
in O
both O
the O
region O
1 O
and O
3 O
promoters O
, O
were O
identified O
, O
suggesting O
a O
role O
for O
these O
sequences O
in O
the O
coordinate O
regulation O
of O
transcription O
from O
these O
promoters O
. O

Purple O
photosynthetic O
bacteria O
are O
capable O
of O
generating O
cellular O
energy O
from O
several O
sources O
, O
including O
photosynthesis O
, O
respiration O
, O
and O
H O
( O
2 O
) O
oxidation O
. O

An O
analysis O
of O
synthetic O
peptides O
revealed O
a O
minimal O
CTD O
sequence O
that O
is O
sufficient O
to O
bind O
to O
the O
second O
Rsp5 I-GENE
WW I-GENE
domain I-GENE
( O
Rsp5 I-GENE
WW2 I-GENE
) O
in O
vitro O
and O
in O
yeast O
two O
- O
hybrid O
assays O
. O

Furthermore O
, O
bone O
marrow O
- O
derived O
macrophages O
from O
LAT I-GENE
- O
deficient O
mice O
displayed O
reduced O
phagocytic O
efficiency O
in O
comparison O
to O
the O
macrophages O
from O
wild O
- O
type O
mice O
. O

T1 O
- O
weighted O
MRI O
on O
the O
49th O
postoperative O
day O
demonstrated O
bilateral O
and O
symmetrical O
hyperintense O
lesions O
in O
the O
globus O
pallidus O
. O

The O
method O
is O
applied O
to O
determine O
aberration O
constants O
of O
a O
CM300 O
FEG O
/ O
UT O
microscope O
with O
correction O
of O
the O
three O
- O
fold O
astigmatism O
. O

The O
interaction O
does O
not O
depend O
on O
the O
presence O
of O
the O
correct O
amino O
- O
terminal O
DNA O
binding O
domain O
or O
the O
amino O
acid O
sequences O
between O
the O
DNA O
binding O
domain O
and O
the O
last O
ten O
amino O
acids O
. O

METHOD O
: O
The O
sample O
of O
subjects O
was O
drawn O
from O
the O
Suffolk O
County O
Mental O
Health O
Project O
, O
a O
longitudinal O
epidemiologic O
study O
of O
first O
- O
hospitalized O
subjects O
with O
psychotic O
disorders O
; O
the O
present O
study O
focused O
on O
patients O
with O
schizophrenic O
disorders O
. O

Marrow O
dysplasia O
is O
a O
major O
characteristic O
of O
patients O
with O
myelodysplastic O
syndrome O
( O
MDS O
), O
along O
with O
marrow O
blastosis O
, O
cytopenia O
and O
cytogenetic O
anomalies O
. O

Eight O
of O
the O
non O
- O
acceptable O
inlays O
/ O
onlays O
and O
five O
of O
the O
direct O
restorations O
were O
replaced O
, O
while O
the O
other O
ones O
were O
repaired O
with O
resin O
composite O
. O

How O
plants O
respond O
to O
attack O
by O
the O
range O
of O
herbivores O
and O
pathogens O
that O
confront O
them O
in O
the O
field O
is O
the O
subject O
of O
considerable O
research O
by O
both O
molecular O
biologists O
and O
ecologists O
. O

CONCLUSION O
: O
The O
probability O
of O
cardiopulmonary O
complications O
increases O
significantly O
when O
patients O
develop O
class O
1 O
HELLP O
syndrome O
. O

The O
rate O
- O
limiting O
step O
for O
telomerase I-GENE
activity O
seems O
to O
be O
the O
expression O
of O
the O
catalytic O
subunit O
of O
the O
enzyme O
, O
encoded O
by O
the O
human I-GENE
telomerase I-GENE
reverse I-GENE
transcriptase I-GENE
( O
hTERT I-GENE
) O
gene O
. O

In O
the O
control O
group O
, O
platelet O
markers O
increased O
1 O
h O
after O
surgery O
. O

However O
, O
the O
element O
proximal O
to O
the O
transcription O
start O
site O
is O
dependent O
on O
the O
SRE O
- O
1 O
. O

AMDA O
white O
paper O
identifies O
ways O
to O
improve O
pharmaceutical O
care O
in O
SNFs O
. O

Since O
proteins O
containing O
TPR O
elements O
are O
typically O
involved O
in O
multiple O
protein O
- O
protein O
interactions O
, O
we O
suggest O
that O
the O
102kD O
protein O
interacts O
within O
the O
tri O
- O
snRNP O
with O
both O
the O
U5 I-GENE
and O
U4 I-GENE
/ O
U6 I-GENE
snRNPs O
, O
thus O
bridging O
the O
two O
particles O
. O

Antibodies O
raised O
against O
a O
C O
- O
terminal O
portion O
of O
Sec31A I-GENE
co O
- O
precipitate O
Sec13 I-GENE
and O
inhibit O
ER O
- O
Golgi O
transport O
of O
temperature O
- O
arrested O
vesicular O
stomatitis I-GENE
G I-GENE
protein I-GENE
in O
a O
semi O
- O
intact O
cell O
assay O
. O

Regulation O
of O
mitochondrial O
single O
- O
stranded O
DNA O
- O
binding O
protein O
gene O
expression O
links O
nuclear O
and O
mitochondrial O
DNA O
replication O
in O
drosophila O
. O

Genetic O
and O
molecular O
complexity O
of O
the O
position O
effect O
variegation O
modifier O
mod I-GENE
( O
mdg4 I-GENE
) O
in O
Drosophila O
. O
mod I-GENE
( O
mdg4 I-GENE
), O
also O
known O
as O
E I-GENE
( I-GENE
var I-GENE
) I-GENE
3 I-GENE
- I-GENE
93D I-GENE
, O
is O
involved O
in O
a O
variety O
of O
processes O
, O
such O
as O
gene O
silencing O
in O
position O
effect O
variegation O
( O
PEV O
), O
the O
control O
of O
gypsy I-GENE
insulator I-GENE
sequences I-GENE
, O
regulation O
of O
homeotic I-GENE
gene I-GENE
expression O
, O
and O
programmed O
cell O
death O
. O

They O
are O
present O
in O
many O
kinds O
of O
living O
things O
, O
but O
their O
functions O
, O
especially O
those O
in O
humans O
, O
are O
unclear O
. O

This O
tendency O
is O
likely O
due O
to O
the O
biased O
nucleotide O
composition O
of O
the O
asparagus O
genome O
, O
rather O
than O
to O
the O
translational O
selection O
for O
specific O
codons O
. O

Transduction O
of O
the O
human O
leukemic O
cell O
line O
K562 O
showed O
that O
viral O
MRP1 I-GENE
- O
PG13 O
supernatants O
routinely O
transfer O
the O
MRP1 I-GENE
gene I-GENE
to O
approximately O
35 O
% O
of O
target O
K562 O
cells O
, O
of O
which O
at O
least O
one O
third O
are O
capable O
of O
proliferating O
in O
the O
presence O
of O
otherwise O
toxic O
concentrations O
of O
etoposide O
. O

Regulation O
of O
pituitary O
vasopressin I-GENE
V1b I-GENE
receptors I-GENE
plays O
a O
critical O
role O
in O
regulating O
pituitary I-GENE
adrenocorticotropic I-GENE
hormone I-GENE
( O
ACTH I-GENE
) O
secretion O
during O
adaptation O
to O
stress O
. O

Identification O
of O
an O
AfsA I-GENE
homologue I-GENE
( O
BarX I-GENE
) O
from O
Streptomyces O
virginiae O
as O
a O
pleiotropic O
regulator O
controlling O
autoregulator O
biosynthesis O
, O
virginiamycin O
biosynthesis O
and O
virginiamycin O
M1 O
resistance O
. O

Because O
the O
mutant O
defective O
in O
DNA O
binding O
also O
fails O
to O
stimulate O
Abf1 I-GENE
ARS1 O
DNA O
- O
binding O
activity O
, O
our O
results O
suggest O
that O
Cdc6 I-GENE
DNA O
- O
binding O
activity O
may O
play O
a O
pivotal O
role O
in O
the O
initiation O
of O
DNA O
replication O
. O

Given O
its O
relative O
longevity O
on O
the O
Web O
, O
TIE O
researchers O
have O
been O
in O
a O
unique O
position O
to O
observe O
trends O
in O
telemedicine O
. O

The O
structural O
study O
of O
peptides O
belonging O
to O
the O
terminal O
domains O
of O
histone I-GENE
H1 I-GENE
can O
be O
considered O
as O
a O
step O
toward O
the O
understanding O
of O
the O
function O
of O
H1 I-GENE
in O
chromatin O
. O

The O
recovery O
rates O
for O
the O
MB O
/ O
BacT O
, O
MGIT O
960 O
, O
and O
solid O
media O
were O
91 O
. O
6 O
, O
87 O
. O
4 O
, O
and O
54 O
. O
7 O
%, O
respectively O
, O
for O
all O
mycobacteria O
; O
the O
recovery O
rates O
were O
93 O
. O
6 O
, O
88 O
. O
9 O
, O
and O
63 O
. O
4 O
%, O
respectively O
, O
for O
M O
. O
tuberculosis O
complex O
alone O
, O
and O
87 O
. O
5 O
, O
84 O
. O
4 O
, O
and O
37 O
. O
5 O
%, O
respectively O
, O
for O
all O
nontuberculous O
mycobacteria O
. O

Cerebral O
vasculitis O
secondary O
to O
Crohn O
' O
s O
disease O
seems O
to O
be O
a O
very O
rare O
phenomenon O
. O

SELECTION O
CRITERIA O
: O
Randomised O
and O
possibly O
randomised O
trials O
using O
acupuncture O
to O
treat O
asthma O
and O
asthma O
- O
like O
symptoms O
. O

SELECTION O
CRITERIA O
: O
Randomised O
trials O
comparing O
children O
undergoing O
systematic O
therapy O
focusing O
on O
the O
family O
in O
conjunction O
with O
asthma O
medication O
, O
with O
children O
taking O
asthma O
medication O
only O
. O

To O
test O
the O
hypothesis O
that O
progestin O
- O
mediated O
increases O
in O
resting O
core O
temperature O
and O
the O
core O
temperature O
threshold O
for O
sweating O
onset O
are O
counteracted O
by O
estrogen O
, O
we O
studied O
eight O
women O
( O
24 O
+/- O
2 O
yr O
) O
at O
27 O
degrees O
C O
rest O
, O
during O
20 O
min O
of O
passive O
heating O
( O
35 O
degrees O
C O
), O
and O
during O
40 O
min O
of O
exercise O
at O
35 O
degrees O
C O
. O

The O
models O
were O
tested O
by O
studying O
their O
response O
to O
disturbances O
of O
the O
afferent O
signal O
from O
the O
bladder O
. O

Our O
data O
show O
also O
that O
phagocytic O
killing O
of O
meningococci O
is O
probably O
a O
more O
consistent O
assay O
than O
antibody O
titer O
levels O
for O
antimeningococcal O
immunity O
, O
especially O
in O
LCC O
- O
deficient O
patients O
. O

These O
studies O
suggest O
an O
additional O
component O
or O
cellular O
environment O
is O
required O
for O
SPRK I-GENE
activation O
by O
Cdc42 I-GENE
. O

M O
. O

Jkappa I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
sites I-GENE
were O
not O
required O
for O
this O
activation O
, O
and O
a O
mutant I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
protein I-GENE
unable O
to O
bind O
Jkappa I-GENE
activated O
transcription O
as O
efficiently O
as O
wild I-GENE
- I-GENE
type I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
, O
indicating O
that O
EBNA I-GENE
- I-GENE
3C I-GENE
can O
regulate O
transcription O
through O
a O
mechanism O
that O
is O
independent O
of O
Jkappa I-GENE
. O

Thus O
, O
both O
YY1 I-GENE
and O
CDP I-GENE
appear O
to O
be O
negative O
regulators O
of O
the O
differentiation O
- O
induced O
HPV I-GENE
- I-GENE
6 I-GENE
E1 I-GENE
promoter I-GENE
and O
thereby O
the O
HPV O
life O
cycle O
. O

Sequential O
cleavage O
by O
metallopeptidases I-GENE
and O
proteasomes O
is O
involved O
in O
processing O
HIV I-GENE
- I-GENE
1 I-GENE
ENV I-GENE
epitope I-GENE
for O
endogenous O
MHC I-GENE
class I-GENE
I I-GENE
antigen I-GENE
presentation O
. O

Cloning O
and O
characterization O
of O
human I-GENE
Lnk I-GENE
, O
an O
adaptor O
protein O
with O
pleckstrin I-GENE
homology O
and O
Src I-GENE
homology I-GENE
2 I-GENE
domains I-GENE
that O
can O
inhibit O
T O
cell O
activation O
. O

Vancomycin O
data O
were O
analyzed O
according O
to O
a O
one O
- O
compartment O
open O
model O
with O
use O
of O
NONMEM O
population O
pharmacokinetic O
software O
. O

Finally O
, O
Cas I-GENE
existed O
mainly O
in O
cytosol O
and O
membrane O
cytoskeleton O
fractions O
in O
the O
resting O
state O
, O
and O
remained O
unchanged O
during O
platelet O
aggregation O
, O
when O
FAK I-GENE
translocated O
to O
the O
cytoskeletal O
fraction O
. O

We O
also O
show O
that O
p65 I-GENE
binds O
to O
these O
targets O
with O
almost O
equal O
affinity O
and O
that O
different O
residues O
have O
variable O
roles O
in O
binding O
different O
kappaB I-GENE
targets I-GENE
. O

Transcriptional O
regulation O
of O
the O
yeast I-GENE
PHO8 I-GENE
promoter I-GENE
in O
comparison O
to O
the O
coregulated O
PHO5 I-GENE
promoter I-GENE
. O

The O
Siglecs I-GENE
are O
a O
subfamily O
of O
I I-GENE
- I-GENE
type I-GENE
lectins I-GENE
( O
immunoglobulin I-GENE
superfamily I-GENE
proteins I-GENE
that O
bind O
sugars O
) O
that O
specifically O
recognize O
sialic O
acids O
. O

Our O
data O
provide O
a O
biochemical O
explanation O
for O
the O
similarity O
in O
phenotype O
between O
A O
- O
T O
and O
NBS O
. O

PATIENTS O
OR O
OTHER O
PARTICIPANTS O
: O
Twenty O
children O
met O
the O
criteria O
for O
being O
learning O
disabled O
. O

Update O
on O
maternal O
- O
fetal O
infections O
by O
hepatitis O
C O
, O
HIV O
and O
cytomegalovirus O

In O
the O
present O
study O
, O
we O
characterized O
cis O
- O
elements O
of O
the O
human I-GENE
PCI I-GENE
gene I-GENE
required O
for O
expression O
in O
the O
hepatoma O
- O
derived O
cell O
line O
, O
HepG2 O
cells O
, O
and O
also O
evaluated O
rat I-GENE
PCI I-GENE
mRNA I-GENE
expression O
, O
particularly O
on O
the O
effect O
of O
androgen O
in O
rat O
reproductive O
tissues O
. O

In O
the O
study O
on O
PCI I-GENE
mRNA I-GENE
expression O
in O
the O
reproductive O
organs O
, O
we O
first O
cloned O
rat I-GENE
PCI I-GENE
cDNA I-GENE
and O
then O
evaluated O
the O
effect O
of O
androgen O
on O
the O
PCI I-GENE
mRNA I-GENE
expression O
. O

To O
illustrate O
its O
performance O
, O
measurements O
of O
photoluminescence O
in O
GaAs O
/ O
AlGaAs O
heterostructures O
are O
presented O
. O

The O
stoichiometry O
of O
the O
complexes O
formed O
with O
the O
dodeca O
- O
satellite O
C O
strand O
suggests O
that O
, O
in O
DDP1 I-GENE
, O
the O
15 O
consecutive O
KH O
domains O
are O
organized O
such O
that O
they O
define O
two O
nucleic O
acid O
binding O
surfaces O
. O

Mutational O
analysis O
of O
mammalian I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
5 I-GENE
( O
eIF5 I-GENE
): O
role O
of O
interaction O
between O
the O
beta O
subunit O
of O
eIF2 I-GENE
and O
eIF5 I-GENE
in O
eIF5 I-GENE
function O
in O
vitro O
and O
in O
vivo O
. O

Much O
evidence O
indicates O
that O
p38 I-GENE
is O
an O
activator O
of O
MyoD I-GENE
: O
( O
i O
) O
p38 I-GENE
kinase I-GENE
activity O
is O
required O
for O
the O
expression O
of O
MyoD I-GENE
- O
responsive O
genes O
, O
( O
ii O
) O
enforced O
induction O
of O
p38 I-GENE
stimulates O
the O
transcriptional O
activity O
of O
a O
Gal4 I-GENE
- O
MyoD I-GENE
fusion O
protein O
and O
allows O
efficient O
activation O
of O
chromatin O
- O
integrated O
reporters O
by O
MyoD I-GENE
, O
and O
( O
iii O
) O
MyoD I-GENE
- O
dependent O
myogenic O
conversion O
is O
reduced O
in O
mouse O
embryonic O
fibroblasts O
derived O
from O
p38alpha I-GENE
(-/-) I-GENE
embryos O
. O

This O
activity O
is O
stimulated O
by O
complex O
formation O
with O
the O
other O
eIF2B I-GENE
subunits I-GENE
. O

Our O
analysis O
of O
nonsense O
mutations O
indicates O
that O
the O
C O
terminus O
of O
eIF2Bepsilon I-GENE
( I-GENE
residues I-GENE
518 I-GENE
to I-GENE
712 I-GENE
) I-GENE
is O
required O
for O
both O
catalytic O
activity O
and O
interaction O
with O
eIF2 I-GENE
. O

In O
contrast O
, O
mutations O
affecting O
the O
other O
two O
Nim1p I-GENE
- I-GENE
related I-GENE
kinases I-GENE
in O
S O
. O
cerevisiae O
, O
Hsl1p I-GENE
and O
Kcc4p I-GENE
, O
produce O
no O
detectable O
effect O
on O
septin I-GENE
organization O
. O

CONCLUSIONS O
: O
Physiologic O
pacing O
provides O
little O
benefit O
over O
ventricular O
pacing O
for O
the O
prevention O
of O
stroke O
or O
death O
due O
to O
cardiovascular O
causes O
. O

Among O
non O
- O
cirrhotics O
, O
lack O
of O
portal O
vein O
visualisation O
had O
a O
90 O
% O
sensitivity O
, O
88 O
% O
specificity O
, O
94 O
% O
negative O
predictive O
value O
, O
and O
83 O
% O
positive O
predictive O
value O
in O
the O
diagnosis O
of O
pre O
- O
sinusoidal O
portal O
hypertension O
. O

D5 I-GENE
/ I-GENE
D1 I-GENE
( I-GENE
CT I-GENE
) I-GENE
or O
D5 I-GENE
/ I-GENE
D1D I-GENE
( I-GENE
CT I-GENE
) I-GENE
tail O
substitution O
mutants O
displayed O
a O
rank O
order O
of O
potency O
and O
agonist O
affinities O
virtually O
mimicking O
wild I-GENE
- I-GENE
type I-GENE
( I-GENE
wt I-GENE
) I-GENE
D1 I-GENE
receptors I-GENE
, O
as O
indexed O
by O
both O
ligand O
binding O
and O
dopamine O
- O
stimulated O
cAMP O
accumulation O
assays O
, O
and O
, O
similar O
to O
wt O
D1 I-GENE
receptors I-GENE
, O
did O
not O
exhibit O
receptor O
constitutive O
activity O
or O
responsiveness O
to O
inverse O
agonists O
. O

Modeling O
also O
revealed O
a O
very O
hydrophobic O
surface O
due O
to O
the O
absence O
of O
H12 O
, O
exposing O
residues O
from O
H3 O
, O
loop O
3 O
- O
4 O
, O
H4 O
, O
and O
H11 O
. O

The O
serine I-GENE
- I-GENE
threonine I-GENE
kinase I-GENE
gene I-GENE
is O
likely O
functional O
, O
whereas O
the O
zinc O
finger O
motif O
is O
likely O
nonfunctional O
. O

Stat I-GENE
activation O
in O
response O
to O
GH I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
was O
determined O
by O
reporter O
gene O
induction O
. O

HFA O
134a O
had O
a O
greater O
tendency O
to O
take O
up O
moisture O
from O
the O
environment O
than O
did O
HFA O
227 O
. O

RESULTS O
: O
Abnormal O
color O
perception O
was O
found O
in O
32 O
% O
of O
the O
epilepsy O
patients O
treated O
with O
vigabatrin O
monotherapy O
and O
28 O
% O
of O
the O
epilepsy O
patients O
treated O
with O
carbamazepine O
monotherapy O
. O

In O
the O
SPP2 O
screening O
test O
, O
a O
few O
plates O
were O
not O
seen O
in O
both O
groups O
. O

Mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
3 I-GENE
( O
MKP I-GENE
- I-GENE
3 I-GENE
) O
is O
a O
dual O
specificity O
phosphatase O
that O
inactivates O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
( O
ERK I-GENE
) O
MAP I-GENE
kinases I-GENE
. O

Consistent O
with O
this O
, O
we O
show O
that O
peptides O
representing O
docking O
sites O
within O
the O
target O
substrates O
Elk I-GENE
- I-GENE
1 I-GENE
and O
p90 I-GENE
( O
rsk I-GENE
) O
inhibit O
ERK I-GENE
- O
dependent O
activation O
of O
MKP I-GENE
- I-GENE
3 I-GENE
. O

HPLC O
phosphopeptide O
mapping O
, O
amino O
acid O
sequencing O
, O
and O
site O
- O
directed O
mutagenesis O
determined O
that O
NCLK I-GENE
phosphorylates O
Ser O
( O
67 O
) O
of O
I I-GENE
- I-GENE
1 I-GENE
. O

When O
the O
entire O
diet O
consisted O
of O
SBF O
, O
voluntary O
feed O
intake O
was O
reduced O
, O
indicating O
that O
SBF O
should O
not O
be O
fed O
to O
ponies O
as O
the O
sole O
dietary O
ingredient O
. O

Hepatitis O
C O
virus O
infection O
and O
lymphoproliferative O
diseases O
in O
France O
: O
a O
national O
study O
. O

The O
immune O
system O
is O
closely O
integrated O
with O
the O
neuroendocrine O
system O
, O
and O
infection O
- O
induced O
increases O
in O
cytokines O
such O
as O
IL I-GENE
- I-GENE
1 I-GENE
, O
IL I-GENE
- I-GENE
6 I-GENE
and O
TNF I-GENE
have O
numerous O
effects O
on O
the O
central O
nervous O
system O
. O

Interestingly O
, O
a O
decreased O
transcription O
from O
the O
endogenous O
c I-GENE
- I-GENE
Myb I-GENE
promoter I-GENE
was O
observed O
in O
several O
HTLV O
- O
I O
transformed O
T O
- O
cell O
lines O
. O

H19 I-GENE
and O
Igf2 I-GENE
monoallelic O
expression O
is O
regulated O
in O
two O
distinct O
ways O
by O
a O
shared O
cis O
acting O
regulatory O
region O
upstream O
of O
H19 I-GENE
. O

C O
. O
elegans O
KLP I-GENE
- I-GENE
11 I-GENE
/ O
OSM I-GENE
- I-GENE
3 I-GENE
/ O
KAP I-GENE
- I-GENE
1 I-GENE
: O
orthologs O
of O
the O
sea I-GENE
urchin I-GENE
kinesin I-GENE
- I-GENE
II I-GENE
, O
and O
mouse O
KIF3A I-GENE
/ O
KIFB I-GENE
/ O
KAP3 I-GENE
kinesin I-GENE
complexes O
. O

Flavonoids O
from O
Brosimum O
acutifolium O
. O

BACKGROUND O
: O
Hepatic O
encephalopathy O
is O
a O
neuropsychiatric O
syndrome O
associated O
with O
acute O
liver O
failure O
, O
chronic O
parenchymal O
liver O
disease O
or O
portal O
systemic O
anastomosis O
. O

These O
natural O
antisense O
S I-GENE
transcripts I-GENE
co O
- O
exist O
with O
several O
less O
abundant O
sense O
S I-GENE
transcripts I-GENE
. O

Nor O
is O
such O
adjustment O
possible O
unless O
one O
posits O
a O
model O
that O
relates O
the O
missing O
observations O
to O
other O
observed O
information O
for O
each O
subject O
- O
models O
that O
are O
inherently O
untestable O
. O

However O
, O
the O
presence O
of O
effacement O
seems O
to O
be O
a O
more O
reliable O
and O
practical O
parameter O
that O
will O
be O
preferred O
in O
that O
prediction O
. O

The O
data O
are O
compatible O
with O
the O
idea O
that O
YLL031c I-GENE
transfers O
the O
ethanolaminephosphate O
to O
the O
inner O
alpha1 O
- O
2 O
- O
linked O
mannose O
, O
i O
. O
e O
. O
the O
group O
that O
links O
the O
GPI O
lipid O
anchor O
to O
proteins O
, O
whereas O
Mcd4p I-GENE
and O
Gpi7p I-GENE
transfer O
ethanolaminephosphate O
onto O
the O
alpha1 O
- O
4 O
- O
and O
alpha1 O
- O
6 O
- O
linked O
mannoses O
of O
the O
GPI O
anchor O
, O
respectively O
. O

The O
C O
terminus O
of O
TRBP I-GENE
binds O
to O
CBP I-GENE
/ O
p300 I-GENE
and O
DRIP130 I-GENE
, O
a O
component O
of O
the O
DRIP I-GENE
/ O
TRAP I-GENE
/ O
ARC I-GENE
complex O
, O
which O
suggests O
that O
TRBP I-GENE
may O
activate O
transcription O
by O
means O
of O
such O
interactions O
. O

The O
patients O
who O
presented O
with O
mucocutaneous O
disease O
also O
had O
low O
CD4 I-GENE
+ I-GENE
T O
lymphocyte O
counts O
, O
and O
most O
of O
them O
had O
AIDS O
defining O
illnesses O
. O

Increased O
dietary O
energy O
decreased O
PAB O
and O
the O
use O
of O
added O
dietary O
CO O
rather O
than O
PF O
decreased O
PSHL O
in O
broiler O
breeders O
between O
26 O
and O
47 O
wk O
of O
age O
. O

The O
gene O
amplification O
model O
of O
Coquelle O
et O
al O
. O

Hierarchy O
of O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
in O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
signaling O
: O
activation O
of O
syk I-GENE
depends O
on O
Jak3 I-GENE
; O
however O
, O
neither O
Syk I-GENE
nor O
Lck I-GENE
is O
required O
for O
IL I-GENE
- I-GENE
2 I-GENE
- O
mediated O
STAT I-GENE
activation O
. O

Immobilized O
dimers O
of O
N I-GENE
- I-GENE
cadherin I-GENE
- O
Fc I-GENE
chimera O
mimic O
cadherin O
- O
mediated O
cell O
contact O
formation O
: O
contribution O
of O
both O
outside O
- O
in O
and O
inside O
- O
out O
signals O
. O

Although O
the O
OC I-GENE
promoter I-GENE
is O
activated O
in O
a O
C O
terminus O
dependent O
manner O
, O
the O
MDR I-GENE
, O
LTR O
and O
BSP I-GENE
promoters I-GENE
are O
repressed O
by O
three O
distinct O
mechanisms O
, O
either O
independent O
of O
or O
involving O
the O
AML I-GENE
C I-GENE
terminus I-GENE
, O
or O
requiring O
only O
the O
conserved O
C O
- O
terminal O
pentapeptide O
VWRPY O
. O

The O
monoclonal O
immunoglobulin I-GENE
products O
of O
plasma O
cell O
neoplasm O
can O
give O
rise O
to O
a O
variety O
of O
manifestations O
including O
hyperviscosity O
, O
amyloidosis O
, O
cryoglobulinemia O
, O
neuropathy O
, O
and O
renal O
failure O
. O

Investigation O
of O
the O
structural O
basis O
of O
the O
interaction O
between O
human I-GENE
Igs I-GENE
and O
gp120 I-GENE
shows O
that O
the O
viral I-GENE
gp120 I-GENE
SAg I-GENE
can O
interact O
only O
with O
a O
subset O
of O
human I-GENE
V I-GENE
( I-GENE
H I-GENE
) I-GENE
3 I-GENE
+ I-GENE
Igs I-GENE
. O

Double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O

Here O
, O
it O
is O
shown O
that O
TAFII250 I-GENE
, O
the O
largest O
subunit O
of O
TFIID I-GENE
, O
contains O
two O
tandem O
bromodomain O
modules O
that O
bind O
selectively O
to O
multiply O
acetylated O
histone I-GENE
H4 I-GENE
peptides I-GENE
. O

Endostatin O
treatment O
for O
10 O
minutes O
or O
24 O
hours O
induced O
tyrosine O
phosphorylation O
of O
Shb I-GENE
and O
formation O
of O
multiprotein O
complexes O
. O

Therefore O
, O
analogs O
of O
vitamin O
D3 O
have O
been O
investigated O
in O
a O
number O
of O
trials O
showing O
improvement O
of O
psoriasis O
. O

The O
transcript O
was O
initially O
identified O
as O
a O
partial O
cDNA O
sequence O
in O
the O
course O
of O
constructing O
a O
transcript O
map O
of O
the O
region O
between O
markers O
D11S1765 I-GENE
and O
uteroglobin I-GENE
known O
to O
encompass O
the O
gene O
causing O
Best O
disease O
. O

The O
real O
challenge O
for O
the O
future O
will O
be O
the O
management O
of O
patients O
who O
do O
not O
respond O
to O
first O
- O
line O
treatment O
. O

Iodine O
deficiency O
disorders O
in O
Bangladesh O
. O

The O
network O
evolution O
was O
interpreted O
by O
an O
approach O
based O
on O
the O
Flory O
model O
. O

RESULTS O
: O
Soluble O
CD23 I-GENE
levels O
were O
significantly O
higher O
in O
women O
with O
endometriosis O
before O
treatment O
than O
in O
ten O
normal O
controls O
. O

CONCLUSION O
: O
Our O
findings O
suggest O
that O
endometriosis O
increases O
soluble O
CD23 I-GENE
levels O
, O
which O
can O
be O
suppressed O
with O
either O
danazol O
or O
leuprolide O
acetate O
injection O
. O

To O
isolate O
this O
gene O
, O
a O
P O
- O
1 O
artificial O
chromosome O
( O
PAC O
) O
library O
was O
screened O
with O
a O
full I-GENE
length I-GENE
UGT2B7 I-GENE
probe O
and O
a O
clone O
of O
approximately O
100 O
kb O
in O
length O
was O
isolated O
. O

Age O
>/= O
50 O
years O
( O
odds O
ratio O
[ O
OR O
], O
14 O
. O
1 O
), O
BMI O
>/= O
28 O
kg O
/ O
m O
( O
2 O
) O
( O
OR O
, O
5 O
. O
7 O
), O
triglycerides O
>/= O
1 O
. O
7 O
mmol O
/ O
L O
( O
OR O
, O
5 O
), O
and O
alanine I-GENE
aminotransferase I-GENE
( O
ALT I-GENE
) O
>/= O
2N O
( O
OR O
, O
4 O
. O
6 O
) O
were O
independently O
associated O
with O
septal O
fibrosis O
. O

Biologically O
significant O
amounts O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
were O
eluted O
from O
the O
sorbent O
during O
the O
entire O
treatment O
time O
. O

However O
, O
the O
elderly O
group O
showed O
significantly O
longer O
mean O
residence O
times O
( O
MRTs O
) O
and O
lower O
plasma O
clearance O
of O
lidocaine O
during O
the O
period O
compared O
with O
the O
adult O
group O
( O
P O
< O
. O
05 O
). O

Here O
, O
we O
show O
that O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
Gis1 I-GENE
acts O
as O
a O
dosage O
- O
dependent O
suppressor O
of O
the O
rim15Delta I-GENE
defect O
in O
nutrient O
limitation O
- O
induced O
transcriptional O
derepression O
of O
SSA3 I-GENE
. O

The O
so O
- O
called O
" I-GENE
SH3 I-GENE
" I-GENE
segment I-GENE
of O
the O
linker O
domain O
, O
in O
contrast O
, O
shows O
species O
- O
specific O
sequence O
identity O
in O
all O
but O
one O
amino O
acid O
residues O
in O
both O
factors O
, O
in O
cattle O
, O
human O
, O
and O
mouse O
. O

No O
differences O
in O
total O
cholesterol O
levels O
were O
observed O
between O
mapuches O
and O
aymaras O
. O

Up O
to O
95 O
% O
of O
the O
total O
UV O
exposure O
received O
is O
in O
the O
UV O
- O
A O
waveband O
( O
320 O
- O
400 O
nm O
). O

To O
begin O
to O
characterize O
the O
role O
of O
the O
RNA O
subunits O
in O
enzyme O
function O
and O
substrate O
specificity O
, O
we O
swapped O
two O
hairpin O
structures O
( O
MRP3 O
and O
P3 O
) O
between O
RNase I-GENE
MRP I-GENE
RNA I-GENE
and O
RNase I-GENE
P I-GENE
RNA I-GENE
of I-GENE
S I-GENE
. I-GENE
cerevisiae I-GENE
. O

Among O
genes O
induced O
by O
added O
pMesogenin1 I-GENE
is O
Xwnt I-GENE
- I-GENE
8 I-GENE
, O
a O
signaling O
factor O
that O
induces O
a O
similar O
repertoire O
of O
marker O
genes O
and O
a O
similar O
cellular O
phenotype O
. O

Accordingly O
, O
no O
Ha I-GENE
- I-GENE
ras I-GENE
codon I-GENE
12 I-GENE
mutations O
are O
found O
in O
the O
EtNU O
- O
induced O
mammary O
tumors O
. O

False O
positive O
PET O
FDG O
corresponded O
to O
lung O
infection O
, O
degenerative O
bone O
disease O
, O
and O
reconstruction O
artifact O
. O

Tumor O
stages O
were O
IIB O
( O
T3 O
N0 O
) O
in O
52 O
%, O
IIIA O
in O
15 O
%, O
and O
IIIB O
in O
27 O
% O
of O
patients O
. O

Similarly O
, O
comparison O
of O
percentage O
reductions O
of O
heart O
rate O
at O
supine O
, O
sitting O
and O
exercise O
by O
repeated O
measure O
analysis O
showed O
the O
Malays O
to O
have O
significantly O
higher O
change O
compared O
to O
the O
Chinese O
( O
p O
= O
0 O
. O
040 O
). O

Consistent O
with O
our O
model O
, O
CTCF I-GENE
binding O
is O
abolished O
by O
DNA O
methylation O
. O

OBJECTIVE O
: O
To O
determine O
the O
efficacy O
and O
safety O
of O
amphotericin O
B O
oral O
suspension O
( O
ABOS O
) O
for O
the O
treatment O
of O
fluconazole O
refractory O
oral O
candidiasis O
in O
persons O
with O
HIV O
infection O
. O

Mucin I-GENE
gene I-GENE
expression O
has O
been O
shown O
to O
be O
altered O
in O
many O
intestinal O
diseases O
and O
especially O
cancers O
of O
the O
gastrointestinal O
tract O
. O

The O
experimentally O
mapped O
regions O
of O
RPB5 I-GENE
involved O
in O
these O
interactions O
correspond O
to O
distinct O
and O
surface O
- O
exposed O
alpha O
- O
helical O
structures O
. O

The O
model O
indicates O
that O
a O
0 O
. O
076 O
% O
reduction O
in O
cigarette O
consumption O
is O
associated O
with O
the O
availability O
of O
nicotine O
patches O
after O
1992 O
. O

Paper O
alert O
. O

The O
tryptase I-GENE
locus I-GENE
also O
contains O
at O
least O
four O
tryptase I-GENE
- I-GENE
like I-GENE
pseudogenes I-GENE
, O
including O
mastin I-GENE
, O
a O
gene O
expressed O
in O
dogs O
but O
not O
in O
humans O
. O

The O
cellular O
part O
of O
the O
third O
chimeric O
clone O
shows O
significant O
homology O
to O
an O
exon O
of O
the O
human I-GENE
tyrosine I-GENE
phosphatase I-GENE
1 I-GENE
gene I-GENE
, O
although O
oriented O
in O
the O
antisense O
direction O
compared O
to O
the O
adjacent O
LTR O
. O

OBJECTIVE O
: O
This O
study O
was O
conducted O
to O
assess O
the O
relative O
roles O
of O
99mTc O
- O
sestamibi O
scintimammography O
and O
sonography O
in O
the O
evaluation O
of O
breast O
lesions O
that O
are O
indeterminate O
or O
suspicious O
on O
mammography O
or O
clinical O
examination O
. O

Mutational O
analyses O
showed O
that O
in O
- O
frame O
stop O
codons O
introduced O
into O
five O
of O
seven O
RNA I-GENE
2 I-GENE
ORFs I-GENE
did O
not O
affect O
accumulation O
of O
progeny O
LIYV I-GENE
RNA I-GENE
1 I-GENE
or O
RNA I-GENE
2 I-GENE
, O
confirming O
that O
RNA I-GENE
2 I-GENE
does O
not O
encode O
proteins O
necessary O
for O
LIYV O
RNA O
replication O
. O

Role O
of O
NH O
( O
2 O
)- O
and O
COOH O
- O
terminal O
domains O
of O
the O
P I-GENE
protein I-GENE
of O
human O
parainfluenza O
virus O
type O
3 O
in O
transcription O
and O
replication O
. O

Phosphorylation O
of O
tyrosine O
residues O
in O
the O
kinase O
domain O
and O
juxtamembrane O
region O
regulates O
the O
biological O
and O
catalytic O
activities O
of O
Eph I-GENE
receptors I-GENE
. O

RESULTS O
: O
Fournier O
' O
s O
gangrene O
occurs O
worldwide O
. O

Genomic O
DNA O
sequencing O
in O
the O
vicinity O
of O
methylmalonyl I-GENE
- I-GENE
CoA I-GENE
mutase I-GENE
gene I-GENE
( O
mutAB I-GENE
) O
from O
a O
rifamycin O
SV O
- O
producing O
Amycolatopsis O
mediterranei O
U32 O
allowed O
us O
to O
clone O
, O
sequence O
, O
and O
identify O
a O
gene O
encoding O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
( O
amk I-GENE
). O

IL I-GENE
- I-GENE
2 I-GENE
is O
accepted O
as O
a O
standard O
treatment O
used O
alone O
, O
or O
in O
combination O
with O
chemotherapy O
or O
biotherapy O
in O
the O
management O
of O
metastatic O
melanoma O
and O
metastatic O
renal O
cell O
carcinoma O
. O

Moreover O
, O
expression O
of O
antisense I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
or O
dominant I-GENE
negative I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
abrogated O
the O
mitogenic O
effect O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
in O
TSU O
- O
Pr1 O
, O
and O
the O
TGF I-GENE
- I-GENE
beta1 I-GENE
inhibition O
of O
DU145 O
was O
switched O
to O
stimulation O
by O
V12Ha I-GENE
- I-GENE
Ras I-GENE
transfection O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
prostate O
carcinomas O
with O
the O
Ras I-GENE
/ O
MAPK I-GENE
pathway O
activation O
might O
have O
a O
selective O
growth O
advantage O
by O
autocrine O
TGF I-GENE
- I-GENE
beta1 I-GENE
production O
. O

Vbeta I-GENE
segments O
are O
appended O
to O
DJbeta I-GENE
rearrangements O
, O
with O
little O
or O
no O
direct O
Vbeta I-GENE
to O
Jbeta I-GENE
joining O
, O
despite O
12 O
/ O
23 O
compatibility O
of O
Vbeta I-GENE
23 I-GENE
- I-GENE
RSSs I-GENE
and O
Jbeta12 I-GENE
- I-GENE
RSSs I-GENE
. O

For O
oral O
administration O
, O
AUC0 O
- O
infinity O
was O
58 O
. O
47 O
+/- O
16 O
. O
37 O
microg O
x O
h O
/ O
ml O
, O
t1 O
/ O
2beta O
was O
18 O
. O
39 O
+/- O
0 O
. O
06 O
hours O
, O
maximum O
concentration O
( O
Cmax O
) O
was O
2 O
. O
12 O
+/- O
00 O
. O
51 O
microg O
/ O
ml O
, O
time O
to O
Cmax O
was O
2 O
. O
20 O
+/- O
2 O
. O
17 O
hours O
, O
mean O
absorption O
time O
was O
2 O
. O
09 O
+/- O
0 O
. O
51 O
hours O
, O
and O
bioavailability O
was O
42 O
+/- O
0 O
. O
42 O
%. O

In O
experiment O
2 O
, O
no O
difference O
in O
gastric O
emptying O
of O
40 O
% O
peptone O
or O
25 O
% O
glucose O
was O
found O
between O
rats O
receiving O
TPN O
and O
those O
receiving O
intragastric O
nutrition O
for O
10 O
to O
12 O
days O
. O

In O
contrast O
, O
H I-GENE
- I-GENE
NS I-GENE
negative O
regulation O
operated O
only O
in O
the O
absence O
of O
Fur I-GENE
. O

Thus O
, O
SAG I-GENE
appears O
to O
control O
cell O
cycle O
progression O
in O
yeast O
by O
promoting O
ubiquitination O
and O
degradation O
of O
cell O
cycle O
regulatory O
proteins O
. O

E2F I-GENE
- I-GENE
1 I-GENE
is O
a O
transcription O
factor O
that O
regulates O
cell O
cycle O
progression O
into O
S O
- O
phase O
. O

It O
brings O
about O
fatigue O
, O
negative O
moods O
, O
and O
impaired O
health O
, O
sleep O
, O
safety O
, O
and O
working O
capacity O
. O

This O
demonstrates O
that O
treatment O
of O
the O
graft O
recipient O
for O
a O
relatively O
short O
period O
during O
and O
after O
surgery O
has O
a O
favorable O
effect O
on O
the O
survival O
of O
grafted O
dopaminergic O
neurons O
. O

The O
relationships O
among O
blood O
concentrations O
of O
thyroid O
hormones O
and O
selenium O
, O
zinc O
, O
retinol O
, O
and O
alpha O
- O
tocopherol O
were O
studied O
in O
44 O
healthy O
Northern O
Italian O
oldest O
- O
old O
subjects O
( O
age O
range O
, O
90 O
- O
107 O
yr O
), O
selected O
by O
the O
criteria O
of O
the O
SENIEUR O
protocol O
. O

Chinese O
Spring O
( O
CS O
) O
carrying O
the O
Q I-GENE
gene I-GENE
to O
those O
of O
a O
chromosome O
deletion O
line O
of O
CS O
, O
namely O
, O
q5 O
, O
which O
lacks O
15 O
% O
of O
5AL O
including O
the O
Q I-GENE
gene I-GENE
. O

Investigations O
using O
hippocampal O
slices O
maintained O
in O
vitro O
have O
demonstrated O
that O
bursts O
of O
oscillatory O
field O
potentials O
in O
the O
gamma O
frequency O
range O
( O
30 O
- O
80 O
Hz O
) O
are O
followed O
by O
a O
slower O
oscillation O
in O
the O
beta O
1 O
range O
( O
12 O
- O
20 O
Hz O
). O

Karger O
AG O
, O
Basel O

During O
surgery O
bone O
cysts O
were O
excised O
and O
filled O
by O
bone O
grafts O
. O

Urinary O
LTE4 O
increased O
after O
both O
challenges O
the O
rise O
being O
higher O
following O
oral O
as O
compared O
to O
inhalation O
provocation O
( O
p O
= O
0 O
. O
0001 O
). O

Basal O
FVR O
was O
reduced O
by O
approximately O
18 O
% O
by O
ERT O
and O
HRT O
, O
but O
FVR O
responses O
to O
noradrenaline O
, O
angiotensin I-GENE
II I-GENE
, O
acetylcholine O
and O
nitroprusside O
were O
unaffected O
. O

Three O
FGF I-GENE
- I-GENE
AS I-GENE
cDNAs I-GENE
were O
isolated O
; O
the O
full I-GENE
- I-GENE
length I-GENE
FGF I-GENE
- I-GENE
AS I-GENE
mRNA I-GENE
and O
two O
alternative O
splice O
variants O
lacking O
exon O
2 O
or O
exons O
2 O
and O
3 O
of O
the O
FGF I-GENE
- I-GENE
AS I-GENE
sequence I-GENE
. O

Taken O
together O
, O
these O
results O
indicate O
that O
MAP I-GENE
kinase I-GENE
stimulates O
the O
hPL I-GENE
- I-GENE
B I-GENE
enhancer I-GENE
by O
an O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
- O
dependent O
pathway O
. O

Characterization O
of O
polymorphic O
TNRs O
in O
novel O
and O
even O
known O
genes O
expressed O
in O
human O
spinal O
cord O
is O
likely O
to O
help O
in O
the O
identification O
of O
new O
candidates O
for O
genes O
involved O
in O
neurodegenerative O
disorders O
. O

Finally O
, O
in O
situ O
RNA O
hybridization O
studies O
revealed O
a O
very O
specific O
pattern O
of O
EphA8 I-GENE
gene I-GENE
expression O
restricted O
to O
the O
rostral O
region O
of O
midbrain O
tectum O
during O
embryonic O
development O
. O

Transfection O
of O
cDNAs O
for O
three O
mutant O
enzymes O
into O
FPGS I-GENE
- O
null O
Chinese O
hamster O
ovary O
cells O
restored O
a O
reduced O
level O
of O
clonal O
growth O
, O
whereas O
a O
T339I O
mutant O
supported O
growth O
at O
a O
level O
comparable O
to O
that O
of O
the O
wild O
- O
type O
enzyme O
. O

SETTING O
: O
University O
of O
Paris O
VII O
hospital O
. O
Patient O
( O
s O
): O
Nine O
women O
had O
embolization O
for O
symptomatic O
myoma O
, O
with O
12 O
pregnancies O
observed O
. O

Improving O
fissure O
sealant O
quality O
: O
mechanical O
preparation O
and O
filling O
level O
. O

The O
Menopause O
- O
Rating O
- O
Scale O
( O
MRS O
I O
) O
was O
used O
in O
clinical O
practice O
since O
1992 O
. O

The O
MRS O
II O
meets O
a O
high O
methodological O
standard O
as O
an O
instrument O
standardized O
in O
the O
population O
. O

The O
protein O
encoded O
by O
the O
fruA I-GENE
transcript I-GENE
is O
well O
conserved O
with O
the O
D I-GENE
. I-GENE
melanogaster I-GENE
type I-GENE
A I-GENE
protein I-GENE
, O
particularly O
the O
BTB I-GENE
protein I-GENE
- O
protein O
- O
binding O
domain O
, O
which O
is O
encoded O
by O
exons O
I O
and O
II O
and O
is O
100 O
% O
conserved O
. O

In O
addition O
, O
the O
mouse O
ortholog O
( O
Mharp I-GENE
/ O
Smarcal1 I-GENE
) O
was O
cloned O
, O
and O
the O
Caenorhabditis O
elegans O
ortholog O
( O
CEHARP I-GENE
) O
was O
identified O
in O
the O
GenBank O
database O
. O

Sparfloxacin O
and O
clinafloxacin O
were O
evaluated O
against O
Enterococcus O
faecium O
SF2149 O
and O
Enterococcus O
faecalis O
WH245 O
, O
respectively O
. O

ECP I-GENE
and O
tryptase I-GENE
levels O
in O
serum O
were O
measured O
before O
and O
after O
the O
last O
oral O
challenge O
. O

Tolterodine O
users O
were O
7 O
. O
5 O
times O
more O
likely O
to O
have O
received O
another O
spasmolytic O
drug O
( O
RR O
7 O
. O
5 O
, O
95 O
% O
CI O
4 O
. O
8 O
to O
11 O
. O
9 O
). O

For O
an O
unsupervised O
program O
, O
the O
costs O
were O
estimated O
at O
$ O
311 O
for O
the O
first O
year O
and O
$ O
73 O
for O
all O
additional O
years O
. O

The O
presence O
of O
such O
a O
putative O
RNA O
- O
binding O
domain O
suggests O
a O
mechanism O
for O
the O
observed O
autoregulation O
of O
bacteriophage O
T4 I-GENE
DNA I-GENE
polymerase I-GENE
synthesis O
by O
binding O
to O
its O
own O
mRNA O
. O

Deletion O
and O
mutational O
analyses O
revealed O
two O
positive O
cis O
- O
regulatory O
elements O
in O
this O
region O
that O
are O
essential O
for O
CSX1 I-GENE
expression O
in O
cardiomyocytes O
. O

Functional O
studies O
which O
introduced O
a O
mutation O
in O
the O
AP2 I-GENE
core I-GENE
binding I-GENE
region I-GENE
as O
well O
as O
cotransfection O
experiments O
using O
an O
AP2 I-GENE
expression O
vector O
revealed O
that O
AP2 I-GENE
exerts O
a O
repressive O
role O
on O
the O
HGF I-GENE
gene I-GENE
promoter I-GENE
activity O
. O

Using O
adenoviral O
transfer O
of O
IkappaBalpha I-GENE
( O
IkappaBalpha I-GENE
overexpression O
), O
the O
production O
of O
TNF I-GENE
- I-GENE
alpha I-GENE
induced O
by O
whole O
GBS O
was O
inhibited O
by O
only O
20 O
%. O

In O
reconstitution O
experiments O
, O
we O
first O
showed O
that O
expression O
in O
the O
RAW O
264 O
. O
7 O
cell O
line O
of O
C I-GENE
- I-GENE
terminal I-GENE
Src I-GENE
kinase I-GENE
( O
Csk I-GENE
) O
inhibited O
and O
that O
of O
a O
membrane O
- O
anchored O
, O
gain O
- O
of O
- O
function O
Csk I-GENE
abolished O
the O
Fc I-GENE
gamma I-GENE
R I-GENE
- O
mediated O
signaling O
that O
leads O
to O
phagocytosis O
in O
a O
kinase O
- O
dependent O
manner O
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
- I-GENE
derived I-GENE
construct I-GENE
( O
a I-GENE
- I-GENE
Src I-GENE
), O
that O
was O
excluded O
from O
detergent O
- O
resistant O
membranes O
, O
could O
not O
restore O
the O
series O
of O
phagocytosis O
signaling O
. O

The O
delta I-GENE
srb10 I-GENE
mutation I-GENE
also O
influenced O
on O
the O
transcript O
levels O
of O
meiosis O
- O
inducing O
genes O
called O
IME1 I-GENE
and O
IME2 I-GENE
: O
the O
mutation O
elevated O
the O
transcript O
level O
of O
IME1 I-GENE
but O
reduced O
that O
of O
IME2 I-GENE
, O
resulting O
in O
partial O
defects O
in O
premeiotic O
DNA O
synthesis O
and O
meiosis O
. O

We O
also O
found O
that O
environmental O
conditions O
for O
meiosis O
finely O
regulate O
the O
transcript O
levels O
of O
KIN28 I-GENE
and O
CCL1 I-GENE
, O
such O
that O
nitrogen O
starvation O
first O
elevates O
them O
but O
subsequent O
alkalization O
of O
medium O
decreases O
them O
. O

The O
pJR O
vectors O
differ O
among O
them O
in O
: O
( O
a O
) O
the O
selectable O
marker O
( O
Saccharomyces O
cerevisiae O
LEU I-GENE
2 I-GENE
gene I-GENE
, O
which O
complements O
S I-GENE
. I-GENE
pombe I-GENE
leu1 I-GENE
- I-GENE
gene I-GENE
and O
S O
. O
pombe O
ura4 I-GENE
+ I-GENE
and O
his3 I-GENE
+ I-GENE
genes I-GENE
); O
( O
b O
) O
the O
thiamine O
- O
repressible O
nmt1 I-GENE
promoter I-GENE
( O
3X O
, O
41X O
and O
81X O
with O
extremely O
high O
, O
moderate O
or O
low O
transcription O
efficiency O
, O
respectively O
); O
and O
( O
c O
) O
the O
multiple O
cloning O
site O
( O
two O
multiple O
cloning O
sites O
, O
with O
12 O
restriction O
sites O
each O
). O

( O
GUT O
) O
Sera O
of O
30 O
montoux O
negative O
healthy O
adults O
( O
age O
/ O
sex O
matched O
) O
were O
taken O
as O
control O
by O
detecting O
IgG I-GENE
anti I-GENE
bodies I-GENE
to O
A60 I-GENE
antigen I-GENE
. O

The O
effect O
of O
acute O
, O
mid O
- O
cervical O
spinal O
cord O
lesions O
on O
neuronal O
and O
reflex O
activity O
evoked O
by O
the O
noxious O
visceral O
stimulus O
, O
colorectal O
distension O
( O
CRD O
; O
80 O
mmHg O
, O
20 O
s O
), O
was O
determined O
in O
halothane O
- O
anesthetized O
rats O
. O

Franz O
Schubert O
-- O
his O
life O
, O
music O
and O
diseases O

The O
results O
suggest O
that O
the O
role O
of O
S O
. O
argyrostoma O
in O
the O
dissemination O
of O
Trichinella O
larvae O
in O
nature O
is O
limited O
in O
comparison O
to O
the O
role O
played O
by O
mammals O
with O
scavenger O
and O
cannibalistic O
behavior O
. O

The O
equilibrium O
dissociation O
binding O
constant O
for O
the O
interaction O
of O
TnrA I-GENE
with O
the O
nrgAB I-GENE
promoter I-GENE
fragment I-GENE
was O
7 O
. O
7 O
nM O
under O
the O
conditions O
used O
here O
. O

These O
results O
demonstrate O
that O
N O
- O
glycans O
flanking O
the O
receptor O
- O
binding O
site O
of O
the O
HA I-GENE
molecule I-GENE
are O
potent O
regulators O
of O
influenza O
virus O
growth O
, O
with O
the O
glycan O
at O
Asn149 O
being O
dominant O
and O
that O
at O
Asn123 O
being O
less O
effective O
. O

RESULTS O
: O
The O
introduction O
of O
the O
PAIP O
resulted O
in O
a O
significant O
( O
p O
< O
0 O
. O
001 O
) O
reduction O
in O
contaminating O
WBCs O
( O
median O
, O
30 O
, O
000 O
) O
from O
the O
numbers O
seen O
with O
FIP O
( O
median O
, O
2 O
, O
300 O
, O
000 O
) O
while O
maintaining O
the O
separation O
efficacy O
( O
47 O
%) O
and O
separation O
time O
. O

All O
were O
tested O
for O
serum O
ferritin I-GENE
( O
SF I-GENE
), O
hemoglobin I-GENE
( O
Hb I-GENE
) O
level O
and O
asked O
for O
detailed O
histories O
of O
donations O
and O
iron O
supplementation O
. O

Vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
), O
a O
potent O
agonist O
secreted O
by O
virtually O
all O
cells O
, O
controls O
migration O
and O
division O
of O
vascular O
endothelial O
cells O
. O

The O
antioxidant O
agent O
pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
has O
been O
shown O
to O
protect O
endothelial O
cells O
( O
EC O
) O
from O
pro O
- O
inflammatory O
- O
induced O
and O
pro O
- O
oxidant O
- O
induced O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

We O
further O
studied O
the O
effects O
of O
SIE I-GENE
- I-GENE
1 I-GENE
hypermethylation O
on O
p21WAF1 I-GENE
induction O
by O
STAT I-GENE
activation O
. O

Phd I-GENE
antibody O
- O
immunoreactive O
peptides O
are O
seen O
in O
light O
- O
adapted O
mouse O
retinal O
cytosolic O
and O
nuclear O
extracts O
. O

In O
the O
pRb I-GENE
(-) I-GENE
SAOS O
- O
2 O
cell O
line O
transiently O
transfected O
with O
a O
reporter O
plasmid O
containing O
six O
tal I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
pRb I-GENE
enhances O
the O
transcriptional O
activity O
of O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
- O
Lmo2 I-GENE
and O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
- O
Lmo2 I-GENE
- O
Ldb1 I-GENE
complexes O
but O
not O
that O
of O
a O
tal I-GENE
- I-GENE
1 I-GENE
- O
E12 I-GENE
heterodimer O
. O

This O
effect O
was O
not O
seen O
in O
conjunction O
with O
oxycodone O
, O
a O
morphine I-GENE
- I-GENE
like I-GENE
mu I-GENE
- I-GENE
receptor I-GENE
agonist O
. O

In O
contrast O
to O
the O
morphological O
criteria O
, O
the O
few O
data O
available O
from O
recent O
studies O
at O
the O
genetic O
level O
have O
suggested O
that O
EPVs O
infecting O
different O
insect O
orders O
are O
phylogenetically O
distant O
. O

Neurofibromatosis O
of O
the O
breast O
in O
a O
patient O
with O
Morbus O
von O
Recklinghausen O

In O
the O
premating O
period O
male O
rate O
of O
aggression O
was O
not O
significantly O
correlated O
with O
testosterone O
level O
. O

These O
results O
support O
the O
hypothesis O
that O
in O
the O
presence O
of O
tryptophan O
the O
ribosome O
translating O
tnaC I-GENE
blocks O
Rho I-GENE
' O
s O
access O
to O
the O
boxA I-GENE
and O
rut I-GENE
sites I-GENE
, O
thereby O
preventing O
transcription O
termination O
. O

In O
situ O
hybridization O
with O
the O
antisense O
RNA O
probes O
further O
supported O
the O
expression O
changes O
of O
these O
six O
clones O
and O
localized O
the O
changes O
in O
multiple O
germ O
cell O
stages O
as O
well O
as O
other O
cell O
types O
( O
Sertoli O
, O
interstitial O
and O
peritubular O
cells O
). O

The O
administration O
of O
the O
GnRH I-GENE
agonist O
reduced O
the O
bone O
mineral O
density O
in O
the O
whole O
femur O
to O
91 O
. O
0 O
% O
of O
that O
in O
the O
control O
group O
. O

Prevention O
, O
differential O
diagnosis O
and O
therapy O
of O
travel O
diarrhea O

This O
study O
shows O
that O
C I-GENE
/ I-GENE
EBPbeta I-GENE
is O
the O
predominant O
C I-GENE
/ I-GENE
EBP I-GENE
isoform I-GENE
found O
in O
activated O
stellate O
cells O
and O
that O
increased O
C I-GENE
/ I-GENE
EBPbeta I-GENE
protein I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
binding O
to O
a O
proximal O
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
site I-GENE
in O
the O
promoter O
mediates O
the O
activating O
effect O
of O
acetaldehyde O
. O

Mutation O
analysis O
demonstrates O
that O
the O
motif O
TCCCCT O
is O
critical O
for O
PyRo1 I-GENE
interaction O
. O

As O
with O
VP16 I-GENE
, O
the O
transactivation O
function O
of O
Luman I-GENE
is O
also O
regulated O
by O
HCF I-GENE
. O

After O
two O
successive O
rounds O
of O
selection O
by O
focus O
formation O
assay O
, O
a O
transforming O
ribozyme O
( O
Rz007 I-GENE
) O
was O
identified O
. O

G O
., O
and O
Hyde O
, O
C O
. O

Our O
results O
suggest O
that O
proteasome O
inhibition O
leads O
to O
upregulation O
of O
specific O
members O
of O
transcription O
factor O
families O
controlling O
cellular O
stress O
response O
and O
proliferation O
. O

The O
ATR O
- O
X O
syndrome O
results O
from O
mutations O
of O
the O
XH2 I-GENE
gene I-GENE
, O
located O
on O
the O
X O
chromosome O
( O
Xq13 O
. O
3 O
) O
and O
coding O
for O
a O
transacting O
factor O
which O
regulates O
gene O
expression O
. O

AIMS O
: O
To O
evaluate O
the O
role O
of O
environmental O
intra O
- O
uterine O
factors O
in O
determining O
the O
birthweights O
of O
twins O
with O
increased O
susceptibility O
to O
diabetes O
and O
discordant O
for O
abnormal O
responses O
to O
the O
oral O
glucose O
tolerance O
test O
( O
OGTT O
) O
and O
verify O
the O
possible O
association O
of O
within O
- O
pair O
birthweight O
differences O
and O
metabolic O
abnormalities O
in O
adult O
life O
. O

In O
NASCIS O
III O
, O
a O
randomization O
imbalance O
occurred O
that O
allocated O
a O
disproportionate O
number O
of O
patients O
with O
no O
motor O
deficit O
( O
and O
therefore O
no O
chance O
for O
recovery O
) O
to O
the O
lower O
dose O
control O
group O
. O

Penicillin I-GENE
acylase I-GENE
( O
PA I-GENE
) O
from O
Escherichia O
coli O
ATCC11105 O
is O
a O
periplasmic O
heterodimer O
consisting O
of O
a O
24 O
kDa O
small O
subunit O
and O
a O
65 O
kDa O
large O
subunit O
. O

A O
murine O
expressed O
sequence O
tag O
( O
EST O
) O
showing O
homology O
with O
erythropoietin I-GENE
receptor I-GENE
( O
EPOR I-GENE
) O
was O
identified O
in O
the O
EST O
database O
. O

When O
the O
LCx O
was O
partially O
occluded O
, O
mild O
PM O
- O
induced O
tachycardia O
resulted O
in O
decreased O
AoP O
( O
P O
= O
0 O
. O
045 O
) O
as O
well O
as O
in O
decreased O
SV O
( O
P O
= O
0 O
. O
048 O
); O
the O
LVEDP O
remained O
high O
( O
P O
= O
0 O
. O
002 O
). O

Activation O
of O
nuclear I-GENE
factor I-GENE
( I-GENE
NF I-GENE
)- I-GENE
kappaB I-GENE
and O
subsequent O
proinflammatory O
gene O
expression O
in O
human O
airway O
epithelial O
cells O
can O
be O
evoked O
by O
oxidative O
stress O
. O

GAP O
JUNCTIONS O
IN O
THE O
BRAIN O
: O
PREFACE O
. O

We O
have O
isolated O
and O
functionally O
characterized O
the O
mouse O
gene O
for O
the O
C2 O
subunit O
of O
the O
20S I-GENE
proteasome I-GENE
. O

Furthermore O
, O
as O
in O
the O
human O
gene O
, O
the O
3 O
' O
end O
of O
the O
Cacna1f I-GENE
gene I-GENE
maps O
within O
5 O
kb O
of O
the O
5 O
' O
end O
of O
the O
mouse I-GENE
synaptophysin I-GENE
gene I-GENE
in O
a O
region O
orthologous O
to O
Xp11 O
. O
23 O
. O

With O
the O
human I-GENE
Rhotekin I-GENE
cDNA I-GENE
as O
a O
probe O
, O
Northern O
hybridization O
revealed O
that O
a O
4 O
. O
0 O
- O
kb O
transcript O
was O
expressed O
at O
a O
high O
level O
in O
prostate O
and O
at O
a O
middle O
level O
in O
13 O
of O
16 O
tissues O
examined O
, O
but O
it O
cannot O
be O
detected O
in O
liver O
and O
lung O
tissues O
. O

Similarly O
, O
co O
- O
expression O
of O
a O
dominant O
- O
negative O
mutant O
of O
p38alpha I-GENE
, O
but O
not O
of O
ERK1 I-GENE
, O
ERK2 I-GENE
, O
JNK1 I-GENE
, O
or O
JNK2 I-GENE
, O
reduces O
basal O
and O
cadmium O
- O
induced O
pE1 I-GENE
- I-GENE
luc I-GENE
activity O
. O

BACKGROUND O
: O
Gamma O
knife O
radiosurgery O
( O
GKR O
) O
is O
a O
safe O
and O
effective O
alternative O
to O
surgery O
for O
intracranial O
lesions O
. O

In O
hemodialyzed O
patients O
( O
Epo I-GENE
and O
Non O
- O
Epo I-GENE
group O
) O
leptin I-GENE
levels O
were O
significantly O
higher O
when O
compared O
to O
CAPD O
patients O
( O
Epo I-GENE
and O
Non O
- O
Epo I-GENE
group O
, O
respectively O
). O

It O
is O
mainly O
transcribed O
in O
neural O
structures O
and O
in O
developing O
organs O
characterized O
by O
epithelial O
- O
mesenchymal O
interactions O
. O

CONCLUSION O
: O
The O
alpha2 O
- O
adrenergic O
antagonist O
idazoxan O
increases O
glucose O
- O
induced O
sympathetic O
activity O
but O
not O
energy O
expenditure O
in O
obese O
subjects O
. O

ID O
- O
PaGIA O
diphtheria I-GENE
toxin I-GENE
polymer O
particle O
diagnostic O
agent O
manufactured O
by O
DiaMed O
AG O
, O
Switzerland O
, O
was O
tried O
at O
bacteriological O
laboratory O
of O
Institute O
of O
Childhood O
Infections O
in O
St O
. O

Next O
, O
we O
show O
that O
two O
EMS O
- O
induced O
mutations O
, O
previously O
shown O
to O
interact O
genetically O
with O
zipper O
( O
Ebr I-GENE
), O
disrupt O
the O
RhoA I-GENE
locus I-GENE
. O

Therefore O
, O
the O
results O
indicate O
that O
repeated O
exposure O
to O
amphetamine O
or O
apomorphine O
overcomes O
the O
context O
- O
dependent O
component O
of O
sensitization O
of O
amphetamine O
- O
or O
apomorphine O
- O
induced O
stereotyped O
behavior O
. O

Testing O
for O
serum I-GENE
IgM I-GENE
binding O
to O
GM1 O
ganglioside O
in O
clinical O
practice O
. O

Objective O
responses O
also O
occurred O
in O
studies O
that O
explored O
sequential O
use O
of O
exemestane O
after O
failure O
of O
aminoglutethimide O
( O
26 O
% O
with O
exemestane O
200 O
mg O
/ O
day O
) O
or O
other O
nonsteroidal O
aromatase I-GENE
inhibitors O
( O
6 O
. O
6 O
% O
with O
exemestane O
25 O
mg O
/ O
day O
). O

Topics O
reviewed O
here O
include O
: O
data O
supporting O
the O
association O
of O
myositis O
with O
cancer O
and O
the O
appropriate O
evaluations O
for O
malignancy O
in O
a O
myositis O
patient O
; O
an O
approach O
to O
the O
assessment O
of O
patients O
with O
dermatomyositis O
sine O
myositis O
; O
the O
usefulness O
of O
the O
clinicopathological O
and O
serological O
classifications O
; O
a O
discussion O
of O
whether O
childhood O
and O
adult O
myositis O
are O
the O
same O
or O
different O
entities O
; O
a O
review O
of O
those O
prognostic O
factors O
to O
consider O
in O
the O
clinical O
management O
of O
myositis O
patients O
; O
current O
approaches O
and O
their O
limitations O
for O
assessing O
disease O
activity O
and O
damage O
. O

The O
science O
of O
tissue O
engineering O
. O

Endonuclease I-GENE
III I-GENE
( O
Nth I-GENE
) O
of O
Escherichia O
coli O
is O
a O
DNA I-GENE
glycosylase I-GENE
essential O
for O
the O
removal O
of O
oxidised O
pyrimidine O
base O
residues O
from O
DNA O
. O

The O
duration O
of O
reactive O
hyperemia O
decreased O
with O
aging O
, O
but O
the O
difference O
between O
males O
and O
females O
was O
not O
significant O
at O
any O
age O
. O

Acquired O
bile O
duct O
blockage O
: O
entry O
of O
hepatobiliary O
agent O
into O
an O
intrahepatic O
abscess O
. O

Furthermore O
, O
this O
study O
looks O
at O
the O
impact O
of O
synthesis O
conditions O
on O
block O
length O
and O
crystallinity O
, O
and O
the O
impact O
of O
the O
blocking O
on O
both O
, O
crystallinity O
and O
solubility O
of O
the O
polymers O
. O

However O
, O
little O
was O
understood O
about O
the O
normal O
function O
of O
CREB I-GENE
- I-GENE
2 I-GENE
in O
mammalian O
development O
or O
organ O
physiology O
. O

The O
outer O
diameter O
and O
the O
thickness O
of O
the O
rotor O
are O
60 O
mm O
and O
8 O
mm O
, O
respectively O
. O

Both O
the O
MVBF O
and O
the O
maximum O
EMG O
activity O
in O
the O
right O
masseter O
and O
the O
left O
anterior O
temporalis O
muscles O
were O
significantly O
decreased O
during O
muscle O
pain O
when O
the O
subjects O
bit O
on O
the O
painful O
side O
. O

CONCLUSIONS O
: O
There O
is O
a O
relation O
in O
the O
topography O
of O
some O
visual O
field O
areas O
assessed O
by O
SWAP O
and O
the O
inferotemporal O
neuroretinal O
rim O
area O
, O
which O
may O
play O
a O
role O
in O
the O
diagnosis O
and O
follow O
- O
up O
of O
suspected O
glaucoma O
. O

The O
total O
alkaloids O
contained O
in O
the O
peel O
of O
Atzimba O
, O
Lopez O
, O
Marciana O
, O
Montsama O
, O
Murca O
, O
and O
Puebla O
was O
lower O
than O
the O
limits O
recommended O
for O
food O
safety O
. O

The O
detection O
success O
rate O
was O
determined O
for O
different O
markers O
using O
this O
MEK I-GENE
. O

Herein O
, O
we O
show O
that O
Smad3 I-GENE
physically O
interacts O
with O
the O
HMG I-GENE
box O
domain O
of O
LEF1 I-GENE
and O
that O
TGFbeta I-GENE
and O
Wnt I-GENE
pathways O
synergize O
to O
activate O
transcription O
of O
the O
Xenopus O
homeobox O
gene O
twin I-GENE
( O
Xtwn I-GENE
). O

The O
transmembrane O
topology O
of O
Na O
(+)/ O
H O
(+) O
exchanger O
NHE3 I-GENE
has O
been O
studied O
using O
in O
vitro O
transcription O
/ O
translation O
of O
two O
types O
of O
fusion O
vectors O
designed O
to O
test O
membrane O
insertion O
properties O
of O
cDNA O
sequences O
encoding O
putative O
NHE3 I-GENE
membrane O
spanning O
domains O
( O
msds O
). O

ACE I-GENE
- I-GENE
2 I-GENE
has O
a O
hydrophobic O
C O
terminus O
of O
H O
type O
. O

Members O
of O
the O
titin I-GENE
/ O
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
family O
play O
an O
essential O
role O
in O
the O
organization O
of O
the O
actin I-GENE
/ O
myosin I-GENE
cytoskeleton O
, O
especially O
in O
sarcomere O
assembly O
and O
function O
. O

We O
concluded O
that O
activation O
of O
c I-GENE
- I-GENE
fosER I-GENE
mediated O
transcriptional O
inhibition O
of O
p21 I-GENE
( O
Cip1 I-GENE
/ O
WAF1 I-GENE
) O
through O
a O
previously O
uncharacterized O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
revealing O
an O
important O
role O
for O
c I-GENE
- I-GENE
fos I-GENE
in O
negative O
control O
of O
cell O
cycle O
regulatory O
genes O
. O

Furthermore O
, O
a O
pTyr317 I-GENE
Shc I-GENE
phosphopeptide I-GENE
selectively O
recognized O
Grb2 I-GENE
, O
Sos1 I-GENE
, O
SHIP I-GENE
, O
and O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
' I-GENE
kinase I-GENE
from O
mast O
cells O
, O
as O
characterized O
by O
mass O
spectrometry O
. O

Although O
increased O
expression O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
/ I-GENE
Y I-GENE
proteins I-GENE
is O
associated O
with O
cellular O
proliferation O
, O
neoplastic O
transformation O
, O
and O
several O
human O
cancers O
, O
the O
role O
of O
these O
proteins O
in O
the O
pathogenesis O
of O
malignancy O
remains O
unclear O
. O

The O
naltrexone O
/ O
lofexidine O
combination O
was O
associated O
with O
a O
more O
rapid O
resolution O
of O
the O
opiate O
withdrawal O
syndrome O
than O
a O
7 O
- O
day O
lofexidine O
- O
only O
treatment O
schedule O
, O
without O
substantial O
increases O
in O
withdrawal O
symptoms O
or O
hypotensive O
side O
- O
effects O
. O

The O
first O
symptoms O
of O
enzootic O
calcinosis O
were O
noted O
in O
March O
1998 O
, O
when O
some O
of O
the O
cows O
developed O
locomotor O
abnormalities O
. O

Screening O
, O
counseling O
, O
and O
treatment O
for O
alcohol O
and O
illicit O
drug O
use O
should O
be O
essential O
components O
in O
comprehensive O
HBP O
care O
. O

Transcriptional O
regulation O
of O
the O
mouse I-GENE
cytosolic I-GENE
chaperonin I-GENE
subunit I-GENE
gene I-GENE
Ccta I-GENE
/ I-GENE
t I-GENE
- I-GENE
complex I-GENE
polypeptide I-GENE
1 I-GENE
by O
selenocysteine I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
family I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

The O
unfolded O
protein O
response O
regulates O
multiple O
aspects O
of O
secretory O
and O
membrane O
protein O
biogenesis O
and O
endoplasmic O
reticulum O
quality O
control O
. O

PNRC I-GENE
: O
a O
proline O
- O
rich O
nuclear O
receptor O
coregulatory O
protein O
that O
modulates O
transcriptional O
activation O
of O
multiple O
nuclear O
receptors O
including O
orphan O
receptors O
SF1 I-GENE
( O
steroidogenic I-GENE
factor I-GENE
1 I-GENE
) O
and O
ERRalpha1 I-GENE
( O
estrogen I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
1 I-GENE
). O

Studies O
using O
a O
reporter O
plasmid O
with O
a O
functionally O
disrupted O
sterol O
- O
responsive O
element O
( O
SRE O
)- O
1 O
revealed O
a O
reduced O
stimulatory O
response O
to O
IL I-GENE
- I-GENE
6 I-GENE
. O

However O
, O
there O
is O
still O
a O
subset O
of O
tumors O
that O
displayed O
no O
changes O
in O
these O
genes O
. O

We O
have O
shown O
that O
the O
epidural O
( O
EPI O
) O
delivery O
of O
morphine O
encapsulated O
in O
multivesicular O
liposomes O
( O
DepoFoam O
drug O
delivery O
system O
) O
produces O
a O
sustained O
clearance O
of O
morphine O
and O
a O
prolonged O
analgesia O
. O

Following O
EPI O
- O
C0401 O
, O
but O
not O
saline O
or O
DepoFoam O
vehicle O
, O
there O
were O
transient O
(< O
72 O
hr O
) O
decreases O
in O
food O
consumption O
, O
arousal O
, O
hindlimb O
muscle O
tone O
, O
and O
body O
temperature O
. O

Bailey O
Instruments O
and O
Owen O
Mumford O
filaments O
were O
the O
most O
accurate O
with O
100 O
% O
buckling O
within O
+/- O
1 O
. O
0 O
g O
of O
10 O
g O
. O

PARTICIPANTS O
: O
Convenience O
sample O
of O
ambulatory O
outpatients O
with O
hereditary O
motor O
and O
sensory O
neuropathy O
, O
type O
I O
( O
n O
= O
9 O
), O
myotonic O
muscular O
dystrophy O
( O
n O
= O
10 O
), O
and O
able O
- O
bodied O
controls O
( O
n O
= O
11 O
). O

The O
effect O
of O
water O
deprivation O
for O
19 O
h O
on O
renal O
Na O
excretion O
of O
conscious O
adrenalectomized O
( O
ADX O
) O
sheep O
maintained O
on O
a O
constant O
intravenous O
infusion O
of O
aldosterone O
and O
cortisol O
( O
ADX O
- O
constant O
steroid O
sheep O
) O
was O
investigated O
. O

Neither O
is O
it O
a O
major O
cause O
of O
rehydration O
- O
induced O
renal O
Na O
retention O
. O

CONCLUSION O
: O
Rheumatic O
fever O
in O
the O
Nazareth O
area O
is O
still O
manifest O
. O

Antithrombin I-GENE
III I-GENE
deficiency O
: O
when O
substitute O
, O
when O
heparin O
? O
Thrombosis O
ABC O
, O
3 O
: O
The O
role O
of O
antithrombin I-GENE
III I-GENE

Specific O
class I-GENE
I I-GENE
and I-GENE
II I-GENE
histone I-GENE
deacetylases I-GENE
( O
HDACs I-GENE
) O
interact O
in O
vivo O
with O
BCoR I-GENE
, O
suggesting O
that O
BCoR I-GENE
may O
functionally O
link O
these O
two O
classes O
of O
HDACs I-GENE
. O

This O
is O
the O
first O
example O
of O
a O
eukaryotic O
transcription O
factor O
complex O
containing O
both O
a O
MADS I-GENE
- I-GENE
box I-GENE
and O
a O
forkhead I-GENE
protein I-GENE
, O
and O
it O
has O
important O
implications O
for O
the O
regulation O
of O
mammalian O
gene O
expression O
. O

After O
screening O
the O
Berkeley O
Drosophila O
Genome O
Project O
database O
with O
sequences O
from O
a O
recently O
characterized O
Leu I-GENE
- I-GENE
rich I-GENE
repeats I-GENE
- I-GENE
containing I-GENE
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
LGR I-GENE
) O
from O
Drosophila O
( O
DLGR I-GENE
- I-GENE
1 I-GENE
), O
we O
identified O
a O
second O
gene O
for O
a O
different O
LGR I-GENE
( O
DLGR I-GENE
- I-GENE
2 I-GENE
) O
and O
cloned O
its O
cDNA O
. O

Degenerate O
primers O
homologous O
to O
highly O
conserved O
regions O
of O
known O
CYP3A I-GENE
sequences I-GENE
were O
used O
for O
initial O
RT O
- O
PCRs O
. O

When O
cells O
were O
microinjected O
with O
TFOs O
designed O
to O
bind O
to O
a O
30 O
- O
bp O
polypurine O
site O
situated O
between O
the O
two O
TK I-GENE
genes I-GENE
, O
recombination O
was O
observed O
at O
frequencies O
in O
the O
range O
of O
1 O
%, O
2 O
, O
500 O
- O
fold O
above O
the O
background O
. O

Methyllevamisole O
was O
used O
as O
the O
internal O
standard O
. O

Resistance O
ratios O
for O
the O
other O
field O
strains O
obtained O
by O
comparison O
with O
the O
R5 O
strain O
ranged O
from O
24 O
. O
5 O
to O
239 O
for O
topical O
application O
and O
from O
1 O
. O
2 O
to O
9 O
. O
8 O
for O
the O
glass O
jar O
method O
. O

Only O
transcripts O
specific O
for O
TSGF I-GENE
- I-GENE
2 I-GENE
are O
detected O
in O
ovary O
and O
testes O
tissues O
of O
adults O
as O
well O
as O
in O
puparia O
, O
while O
neither O
gene O
is O
expressed O
during O
the O
larval O
developmental O
stages O
. O

In O
a O
gel O
retardation O
assay O
using O
HepG2 O
nuclear O
extracts O
, O
the O
5 O
' O
flanking O
sequence O
from O
- O
74 O
to O
- O
46 O
showed O
a O
shifted O
band O
. O

Reliability O
of O
cervical O
range O
of O
motion O
using O
the O
OSI O
CA O
6000 O
spine O
motion O
analyser O
on O
asymptomatic O
and O
symptomatic O
subjects O
. O

Coimmunoprecipitation O
experiments O
performed O
in O
transfected O
cells O
showed O
that O
BCMA I-GENE
associates O
with O
TNFR I-GENE
- I-GENE
associated I-GENE
factor I-GENE
( I-GENE
TRAF I-GENE
) I-GENE
1 I-GENE
, O
TRAF2 I-GENE
, O
and O
TRAF3 I-GENE
adaptor I-GENE
proteins I-GENE
. O

Since O
the O
RINX I-GENE
gene I-GENE
is O
likely O
an O
ortholog O
of O
the O
goldfish I-GENE
Vsx1 I-GENE
gene I-GENE
, O
it O
has O
been O
named O
VSX1 I-GENE
by O
the O
Human O
Gene O
Nomenclature O
Committee O
. O

The O
chromosomal O
localization O
on O
distal O
chromosome O
7 O
places O
it O
in O
a O
cluster O
of O
imprinted O
genes O
, O
flanked O
by O
the O
previously O
described O
Tapa1 I-GENE
and O
Kcnq1 I-GENE
genes I-GENE
. O

Activation O
of O
PKA I-GENE
by O
8 O
- O
bromo O
- O
cyclic O
AMP O
or O
forskolin O
, O
and O
inhibition O
of O
PKC I-GENE
by O
calphostin O
C O
, O
resulted O
in O
a O
significant O
decrease O
in O
3TP I-GENE
activity O
as O
well O
as O
in O
vitro O
ERK I-GENE
kinase I-GENE
activity O
in O
CRAC O
. O

The O
present O
study O
was O
designed O
to O
evaluate O
the O
sensitivity O
and O
specificity O
of O
AMP O
CT O
( O
Gen O
- O
Probe O
Incorporated O
, O
San O
Diego O
, O
CA O
, O
USA O
) O
on O
urogenital O
specimens O
taken O
from O
symptomatic O
patients O
and O
on O
first O
void O
urine O
( O
FVU O
) O
specimens O
from O
asymptomatic O
patients O
. O

Mus81p I-GENE
also O
shares O
homology O
with O
motifs O
found O
in O
the O
XPF I-GENE
endonuclease I-GENE
superfamily I-GENE
. O

Double O
mutant O
analysis O
suggests O
that O
Rad54p I-GENE
and O
Mus81p I-GENE
act O
in O
one O
pathway O
for O
the O
repair O
of O
, O
or O
tolerance O
to O
, O
UV O
- O
induced O
DNA O
damage O
. O

The O
linear O
plasmid O
pCLU1 O
from O
the O
yeast O
Kluyveromyces O
lactis O
normally O
replicates O
in O
the O
cytoplasm O
, O
with O
the O
aid O
of O
the O
helper O
linear O
plasmid O
pGKL2 O
, O
using O
terminal I-GENE
protein I-GENE
( O
TP I-GENE
) O
as O
a O
primer O
. O

The O
repetitive O
ETn I-GENE
( O
early I-GENE
transposon I-GENE
) O
family O
of O
sequences O
represents O
an O
active O
" O
mobile O
mutagen O
" O
in O
the O
mouse O
genome O
. O

The O
two O
main O
experimental O
variables O
were O
the O
attended O
hemifield O
( O
left O
or O
right O
) O
and O
the O
proportion O
of O
trials O
requiring O
a O
shift O
within O
that O
hemifield O
( O
20 O
% O
or O
80 O
%). O

The O
measurement O
of O
NO O
in O
biological O
systems O
using O
chemiluminescence O
. O

Biochemical O
examinations O
of O
calcium O
- O
phosphorus O
metabolism O
included O
ions O
and O
PTH I-GENE
concentrations O
in O
blood O
serum O
, O
and O
the O
activity O
of O
bone O
isoenzyme O
of O
AP I-GENE
. O

Atorvastatin O
was O
the O
most O
cost O
- O
effective O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor O
. O

Pharmacoeconomic O
assessment O
of O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor O
therapy O
: O
an O
analysis O
based O
on O
the O
CURVES O
study O
. O

Interestingly O
, O
although O
E O
domains O
of O
these O
two O
receptors O
are O
much O
less O
conserved O
, O
replacement O
of O
this O
domain O
in O
rtER I-GENE
by O
its O
human O
counterpart O
resulted O
in O
higher O
estradiol O
sensitivity O
but O
no O
increase O
in O
the O
magnitude O
of O
transactivation O
. O

G O
- O
DNA O
is O
a O
four O
- O
stranded O
DNA O
structure O
with O
diverse O
putative O
biological O
roles O
. O

The O
effectiveness O
of O
NRT O
appears O
to O
be O
largely O
independent O
of O
the O
intensity O
of O
additional O
support O
provided O
to O
the O
smoker O
. O

SELECTION O
CRITERIA O
: O
All O
controlled O
trials O
where O
adults O
with O
schizophrenia O
or O
similar O
illnesses O
were O
randomised O
to O
quetiapine O
, O
placebo O
or O
other O
neuroleptic O
drugs O
and O
where O
clinically O
relevant O
outcomes O
were O
reported O
. O

8 O
% O
( O
95 O
% O
CI O
, O
21 O
. O
3 O
- O
44 O
. O
3 O
%). O

In O
contrast O
, O
the O
action O
of O
GLP I-GENE
- I-GENE
1 I-GENE
at O
the O
CRE O
was O
not O
blocked O
by O
cotransfection O
with O
M1 I-GENE
- I-GENE
CREB I-GENE
, O
an O
isoform O
that O
lacks O
a O
consensus O
serine O
residue O
serving O
as O
substrate O
for O
PKA I-GENE
- O
mediated O
phosphorylation O
. O

Because O
all O
PDGFbetaR I-GENE
fusions I-GENE
described O
thus O
far O
result O
in O
splicing O
to O
a O
common O
exon O
of O
this O
gene O
, O
we O
performed O
5 O
'- O
rapid O
amplification O
of O
cDNA O
ends O
PCR O
on O
patient O
RNA O
. O

CONCLUSIONS O
: O
In O
essential O
hypertension O
an O
acute O
protein O
load O
induces O
a O
decrease O
in O
GFR O
that O
may O
normalize O
under O
antihypertensive O
treatment O
. O

This O
finding O
suggested O
that O
the O
PI3K I-GENE
- O
Akt I-GENE
activation O
pathway O
plays O
some O
role O
in O
the O
antiapoptotic O
effect O
of O
EPO I-GENE
. O

Nine O
DNA O
fragments O
that O
were O
specifically O
recognized O
and O
bound O
by O
histidine O
- O
tagged O
AdpA I-GENE
were O
isolated O
by O
cycles O
of O
a O
gel O
mobility O
shift O
- O
PCR O
method O
. O

To O
determine O
whether O
the O
NTP O
- O
binding O
motif O
is O
important O
for O
Rad24 I-GENE
function O
, O
we O
mutated O
the O
conserved O
lysine O
( O
115 O
) O
residue O
in O
this O
motif O
. O

The O
carboxyl O
- O
terminal O
proline O
- O
rich O
domain O
of O
SOS1 I-GENE
is O
involved O
in O
the O
interaction O
with O
the O
PLC I-GENE
- I-GENE
gamma1 I-GENE
SH3 I-GENE
domain I-GENE
. O

From O
transient O
expression O
studies O
, O
we O
could O
demonstrate O
that O
the O
SH3 I-GENE
domain I-GENE
of O
PLC I-GENE
- I-GENE
gamma1 I-GENE
is O
necessary O
for O
the O
association O
with O
SOS1 I-GENE
in O
vivo O
. O

Six O
distinct O
Ets I-GENE
mRNAs I-GENE
were O
identified O
: O
Ets2 I-GENE
, O
Fli1 I-GENE
, O
GABPalpha I-GENE
, O
SAP1 I-GENE
, O
Elk1 I-GENE
, O
and O
PE1 I-GENE
. O

A O
2 O
kb O
transcript O
was O
isolated O
from O
brain O
that O
encodes O
a O
approximately O
57 O
kDa O
protein O
; O
the O
predicted O
protein O
contains O
the O
known O
N I-GENE
- I-GENE
terminal I-GENE
Ets I-GENE
domain I-GENE
of O
PE1 I-GENE
and O
a O
novel O
C O
- O
terminal O
domain O
with O
signficant O
homology O
to O
murine I-GENE
ERF I-GENE
. O

Twenty O
eligible O
patients O
with O
cirrhosis O
were O
randomized O
into O
two O
groups O
: O
10 O
patients O
treated O
with O
6 O
million O
units O
of O
natural O
IFN I-GENE
- I-GENE
beta I-GENE
twice O
a O
week O
for O
36 O
months O
and O
10 O
patients O
without O
IFN I-GENE
therapy O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
overexpression O
in O
mammary O
epithelial O
cells O
induced O
cyclin I-GENE
D1 I-GENE
mRNA I-GENE
and O
targeted O
overexpression O
of O
Wnt I-GENE
- I-GENE
1 I-GENE
in O
the O
mammary O
gland O
of O
transgenic O
mice O
increased O
both O
ILK I-GENE
activity O
and O
cyclin I-GENE
D1 I-GENE
levels O
. O

Intravenous O
versus O
oral O
administration O
of O
amitriptyline O
in O
patients O
with O
major O
depression O
. O

Deletion O
of O
the O
RVH I-GENE
domain I-GENE
resulted O
in O
loss O
of O
Ca O
( O
2 O
+)- O
dependent O
activation O
. O

Logistic O
regression O
analysis O
revealed O
that O
physicians O
were O
3 O
. O
6 O
times O
more O
likely O
to O
detect O
thin O
lesions O
(</= O
0 O
. O
75 O
mm O
) O
compared O
with O
nonphysician O
detectors O
( O
95 O
% O
confidence O
interval O
[ O
95 O
% O
CI O
], O
2 O
. O
1 O
, O
6 O
. O
5 O
; O
P O
= O
0 O
. O
0001 O
). O

Erythema O
exsudativum O
multiforme O
induced O
by O
granulocyte I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
in O
an O
allogeneic O
peripheral O
blood O
stem O
cell O
donor O
. O

VaI O
and O
VaII O
co O
- O
immunoprecipitated O
with O
ErbB2 I-GENE
, O
but O
not O
with O
ErbB1 I-GENE
, O
ErbB3 I-GENE
, O
or O
ErbB4 I-GENE
. O

While O
interactions O
of O
WT O
and O
variant O
TGF I-GENE
- I-GENE
alpha I-GENE
with O
the O
ErbBs I-GENE
all O
result O
in O
ErbB2 I-GENE
activation O
, O
they O
produce O
different O
biological O
consequences O
, O
suggesting O
that O
the O
various O
TGF I-GENE
- I-GENE
alpha I-GENE
precursors I-GENE
differentially O
modulate O
ErbB I-GENE
signaling O
. O

It O
is O
now O
well O
accepted O
that O
the O
p53 I-GENE
C I-GENE
- I-GENE
terminus I-GENE
plays O
a O
central O
role O
in O
controlling O
the O
activity O
of O
the O
wild O
- O
type O
molecule O
. O

In O
contrast O
to O
full I-GENE
- I-GENE
length I-GENE
E2F I-GENE
- I-GENE
3 I-GENE
, O
which O
is O
expressed O
only O
at O
the O
G1 O
/ O
S O
boundary O
, O
E2F I-GENE
- I-GENE
3B I-GENE
is O
detected O
throughout O
the O
cell O
cycle O
with O
peak O
levels O
in O
GO O
where O
it O
is O
associated O
with O
Rb I-GENE
. O

The O
transcription O
factor O
Jun I-GENE
( O
c I-GENE
- I-GENE
Jun I-GENE
) O
functions O
as O
a O
recipient O
of O
extracellular O
growth O
signals O
and O
converts O
them O
into O
patterns O
of O
gene O
expression O
. O

Developmental O
toxicity O
of O
the O
class O
III O
antiarrhythmic O
agent O
almokalant O
in O
mice O
. O

This O
compound O
is O
the O
main O
bioactive O
metabolite O
of O
trimebutine O
II O
( O
Debridat O
, O
CAS O
39133 O
- O
31 O
- O
8 O
), O
an O
antispasmodic O
widely O
used O
for O
intestinal O
diseases O
since O
1969 O
. O

In O
addition O
to O
its O
effect O
in O
augmenting O
the O
neutrophil O
response O
to O
eccentric O
exercise O
, O
vitamin O
E O
causes O
a O
greater O
increase O
in O
circulating O
creatine I-GENE
kinase I-GENE
activity O
, O
perhaps O
indicating O
increased O
skeletal O
muscle O
repair O
. O

This O
enabled O
the O
formation O
of O
stem O
- O
loop O
templates O
with O
the O
fusion O
point O
of O
the O
chimeric O
transcript O
in O
the O
loop O
and O
the O
use O
of O
MLL I-GENE
primers O
in O
two O
- O
sided O
PCR O
. O

CONCLUSION O
: O
The O
authors O
emphasize O
that O
the O
initial O
management O
of O
primary O
STS O
should O
be O
adequate O
and O
suggest O
that O
safty O
margin O
of O
> O
or O
= O
2 O
cm O
should O
be O
adhered O
to O
. O

Measurements O
were O
compared O
with O
two O
computerised O
treatment O
planning O
systems O
-- O
Theraplan O
VO5B O
and O
ADAC O
Pinnacle3 O
V4 O
. O
0b O
. O

Activation O
was O
biphasic O
; O
peaking O
at O
5 O
- O
10 O
min O
and O
24 O
h O
after O
treatment O
. O

Whereas O
MARTA1 I-GENE
is O
clearly O
detectable O
in O
crude O
lysates O
, O
cytosolic O
and O
ribosomal O
salt O
- O
wash O
fractions O
, O
and O
in O
nuclear O
extracts O
, O
MARTA2 I-GENE
is O
preferentially O
found O
in O
the O
ribosomal O
salt O
- O
wash O
preparation O
. O

It O
contains O
25 O
exons O
coding O
for O
a O
4 O
. O
7kb O
transcript O
including O
large O
5 O
'- O
and O
3 O
'- O
( O
1218bp O
and O
701bp O
, O
respectively O
) O
untranslated O
regions O
( O
UTRs O
). O

Five O
of O
the O
PDP1 I-GENE
isoforms I-GENE
differ O
by O
the O
substitution O
or O
insertion O
of O
amino O
acids O
at O
or O
near O
the O
N O
- O
terminal O
of O
the O
protein O
. O

The O
optimum O
technique O
for O
the O
pathological O
examination O
of O
sentinel O
lymph O
nodes O
( O
SLNs O
) O
is O
still O
under O
debate O
. O

Partial O
correction O
of O
anemia O
with O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
likely O
reduces O
left O
ventricular O
mass O
and O
volume O
. O

This O
study O
demonstrated O
that O
the O
PFA O
- O
100 O
analyzer O
can O
accurately O
assess O
vWF I-GENE
- O
dependent O
platelet O
function O
and O
detect O
other O
platelet O
defects O
under O
high O
shear O
stress O
in O
complex O
patient O
populations O
. O

We O
recently O
reported O
the O
molecular O
cloning O
of O
a O
PL I-GENE
scramblase I-GENE
of O
human O
( O
HuPLSCR1 I-GENE
) O
and O
mouse O
origin O
, O
respectively O
. O

To O
analyze O
the O
regulatory O
activity O
of O
Gtx I-GENE
, O
we O
first O
identified O
the O
optimal O
Gtx I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
using O
an O
in O
vitro O
DNA O
- O
binding O
assay O
. O

Using O
an O
oligomer O
duplex O
5 O
'- O
A O
( O
GGGTTA O
)( O
5 O
)- O
3 O
'/ O
5 O
'-( O
TAACCC O
)( O
5 O
) O
T O
- O
3 O
' O
as O
a O
template O
- O
primer O
, O
we O
show O
that O
both O
the O
Klenow I-GENE
fragment I-GENE
of I-GENE
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
HIV I-GENE
reverse I-GENE
transcriptase I-GENE
could O
expand O
telomere O
DNA O
sequences O
as O
well O
, O
giving O
products O
greater O
than O
the O
size O
of O
the O
template O
DNA O
. O

Cdk2 I-GENE
and O
MAPK I-GENE
precipitates O
from O
untreated O
tumor O
lysates O
phosphorylated O
recombinant I-GENE
wild I-GENE
- I-GENE
type I-GENE
p27 I-GENE
but O
not O
the O
T187A O
mutant O
in O
vitro O
. O

The O
loss O
of O
avirulence O
activity O
because O
of O
mutations O
in O
the O
acidic O
transcriptional O
activation O
domain O
was O
restored O
by O
addition O
of O
the O
activation O
domain O
from O
the O
herpes I-GENE
simplex I-GENE
viral I-GENE
protein I-GENE
VP16 I-GENE
. O

Mutations O
in O
the O
RP2 I-GENE
locus I-GENE
at I-GENE
Xp11 I-GENE
. I-GENE
3 I-GENE
were O
found O
in O
a O
further O
10 O
- O
20 O
% O
of O
XLRP O
patients O
, O
as O
predicted O
from O
linkage O
studies O
. O

The O
limit O
between O
the O
cecum O
and O
the O
ascending O
colon O
was O
externally O
marked O
by O
the O
sulcus O
cecocolicus O
dorsalis O
and O
ventralis O
. O

Subsequently O
, O
HD O
inhibited O
healing O
because O
it O
significantly O
delayed O
epithelialization O
and O
caused O
protracted O
inflammation O
. O

The O
effectiveness O
of O
the O
haemodialysate O
Solcoseryl O
for O
second O
- O
intention O
wound O
healing O
in O
horses O
and O
ponies O
. O

Although O
there O
is O
little O
evidence O
that O
diet O
composition O
plays O
a O
clinically O
important O
role O
in O
the O
absorption O
or O
expenditure O
of O
energy O
, O
it O
does O
appear O
to O
play O
a O
role O
in O
food O
intake O
. O

These O
findings O
were O
reinforced O
by O
an O
analysis O
that O
was O
restricted O
to O
living O
donor O
transplants O
without O
acute O
rejection O
. O

These O
results O
further O
support O
an O
important O
role O
for O
CBF2 I-GENE
in O
mediating O
EBNA2 I-GENE
transactivation O
; O
they O
identify O
the O
hnRNP I-GENE
protein I-GENE
AUF1 I-GENE
as O
a O
major O
component O
of O
CBF2 I-GENE
and O
are O
also O
the O
first O
evidence O
of O
a O
cis O
- O
acting O
sequence O
other O
than O
a O
CBF1 I-GENE
binding I-GENE
element I-GENE
that O
is O
able O
to O
confer O
responsiveness O
to O
EBNA2 I-GENE
. O

The O
genome O
of O
the O
human O
herpesvirus O
8 O
( O
HHV O
- O
8 O
) O
contains O
a O
cluster O
of O
open O
reading O
frames O
( O
ORFs O
) O
encoding O
proteins O
with O
homology O
to O
the O
cellular O
transcription O
factors O
of O
the O
interferon I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family O
. O

Despite O
these O
limitations O
the O
CHIME O
monitor O
provides O
an O
opportunity O
to O
record O
physiological O
data O
previously O
unavailable O
in O
the O
home O
. O

DATA O
SYNTHESIS O
: O
Intracoronary O
ultrasound O
has O
been O
shown O
to O
improve O
upon O
demonstrated O
weaknesses O
of O
coronary O
angiography O
. O

TB O
bone O
area O
( O
p O
< O
0 O
. O
001 O
), O
height O
( O
p O
< O
0 O
. O
01 O
), O
years O
in O
present O
colony O
( O
p O
= O
0 O
. O
03 O
), O
and O
menses O
( O
p O
< O
0 O
. O
01 O
) O
predicted O
TB O
BMC O
. O

CREST O
syndrome O
; O
a O
changing O
clinical O
significance O

Troglitazone O
also O
induced O
an O
endogenous I-GENE
PPARgamma I-GENE
target I-GENE
gene I-GENE
in O
T24 O
cells O
, O
adipocyte I-GENE
- I-GENE
type I-GENE
fatty I-GENE
acid I-GENE
binding I-GENE
protein I-GENE
( O
A I-GENE
- I-GENE
FABP I-GENE
), O
the O
expression O
of O
which O
correlates O
with O
bladder O
cancer O
differentiation O
. O

Viruses O
were O
isolated O
from O
9 O
lungs O
: O
7 O
with O
PI O
- O
3V O
, O
1 O
with O
NCP O
BVDV O
type O
1 O
, O
and O
1 O
with O
both O
BVHV O
- O
1 O
and O
BVDV O
. O

The O
RS447 I-GENE
human I-GENE
megasatellite I-GENE
tandem I-GENE
repetitive I-GENE
sequence I-GENE
encodes O
a O
novel O
deubiquitinating O
enzyme O
with O
a O
functional O
promoter O
. O

Previous O
experience O
and O
contextual O
cues O
are O
essential O
elements O
in O
the O
generation O
of O
a O
subjective O
prediction O
. O

To O
characterize O
this O
effect O
, O
we O
looked O
for O
targets O
of O
NS1 I-GENE
influenza I-GENE
virus I-GENE
protein I-GENE
among O
cellular O
translation O
factors O
. O

Collectively O
, O
these O
and O
previously O
published O
data O
suggest O
a O
model O
where O
NS1 I-GENE
recruits O
eIF4GI I-GENE
specifically O
to O
the O
5 O
' O
untranslated O
region O
( O
5 O
' O
UTR O
) O
of O
the O
viral O
mRNA O
, O
allowing O
for O
the O
preferential O
translation O
of O
the O
influenza O
virus O
messengers O
. O

Eukaryotic I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
4GI I-GENE
is O
a O
cellular O
target O
for O
NS1 I-GENE
protein I-GENE
, O
a O
translational O
activator O
of O
influenza O
virus O
. O

Splicing O
of O
the O
K I-GENE
- I-GENE
SAM I-GENE
alternative O
exon O
of O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
gene I-GENE
is O
heavily O
dependent O
on O
the O
U O
- O
rich O
sequence O
IAS1 I-GENE
lying O
immediately O
downstream O
from O
its O
5 O
' O
splice O
site O
. O

( O
iii O
) O
In O
these O
cells O
, O
PKCbeta I-GENE
plays O
a O
unique O
Ras I-GENE
- O
independent O
role O
in O
mediating O
insulin I-GENE
but O
not O
EGF I-GENE
or O
other O
growth O
factor O
mitogenic O
signals O
. O

However O
, O
it O
is O
not O
known O
whether O
the O
recently O
identified O
isoforms O
Vav2 I-GENE
and O
Vav3 I-GENE
, O
which O
are O
broadly O
expressed O
, O
can O
couple O
with O
similar O
classes O
of O
receptors O
, O
nor O
is O
it O
known O
whether O
all O
Vav I-GENE
isoforms I-GENE
possess O
identical O
functional O
activities O
. O

Transcriptional O
regulation O
of O
fbp1 I-GENE
promoter I-GENE
constructs I-GENE
containing O
only O
UAS1 O
or O
UAS2 O
confirms O
that O
the O
PKA I-GENE
and O
MAPK I-GENE
regulation O
is O
targeted O
to O
both O
sites O
. O

X O
- O
ray O
crystallographic O
data O
show O
that O
the O
PLZF I-GENE
BTB I-GENE
/ O
POZ O
domain O
forms O
an O
obligate O
homodimer O
via O
an O
extensive O
interface O
. O

The O
ability O
of O
SMRT I-GENE
to O
associate O
with O
these O
transcription O
factors O
and O
thereby O
to O
mediate O
repression O
is O
strongly O
inhibited O
by O
activation O
of O
tyrosine I-GENE
kinase I-GENE
signaling O
pathways O
, O
such O
as O
that O
represented O
by O
the O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

In O
addition O
, O
the O
ketamine O
- O
treated O
rats O
had O
more O
neurons O
and O
glial O
cells O
surrounding O
the O
ventricles O
. O

The O
differences O
were O
as O
follows O
: O
for O
overall O
response O
rate O
p O
= O
0 O
. O
004 O
; O
power O
( O
for O
p O
= O
0 O
. O
05 O
) O
85 O
%; O
for O
survival O
p O
= O
0 O
. O
09 O
; O
for O
grade O
IV O
granulocytopenia O
p O
= O
0 O
. O
3 O
; O
and O
for O
febrile O
neutropenia O
p O
= O
0 O
. O
61 O
. O

Patients O
were O
randomly O
assigned O
to O
treatment O
with O
the O
ACE I-GENE
inhibitor O
perindopril O
( O
and O
the O
diuretic O
indapamide O
for O
those O
with O
no O
definite O
indication O
for O
or O
contraindication O
to O
treatment O
with O
a O
diuretic O
) O
or O
matching O
placebo O
( O
s O
). O

The O
results O
indicate O
that O
the O
open O
- O
section O
effect O
decreases O
the O
torsional O
stiffness O
and O
stress O
concentration O
effects O
decrease O
the O
torsional O
strength O
of O
a O
long O
bone O
with O
a O
longitudinal O
defect O
. O

These O
regions O
may O
be O
differentially O
involved O
in O
tissue O
- O
specificity O
, O
and O
/ O
or O
circadian O
regulation O
, O
of O
the O
human I-GENE
hPer1 I-GENE
gene I-GENE
transcription O
. O

Additionally O
, O
putative O
CF1 I-GENE
/ O
USP I-GENE
and O
Broad I-GENE
Complex I-GENE
Z2 I-GENE
transcription O
factor O
elements O
were O
found O
in O
the O
upstream O
regions O
of O
MIH I-GENE
and O
MO I-GENE
- I-GENE
IH I-GENE
genes O
respectively O
. O

Sequence O
analysis O
reveals O
that O
the O
newly O
discovered O
oasA2 I-GENE
gene I-GENE
represents O
a O
pseudogene O
that O
is O
still O
transcribed O
, O
but O
is O
not O
functionally O
translated O
. O

Genomic O
and O
functional O
characterization O
of O
the O
oas I-GENE
gene I-GENE
family I-GENE
encoding O
O I-GENE
- I-GENE
acetylserine I-GENE
( I-GENE
thiol I-GENE
) I-GENE
lyases I-GENE
, O
enzymes O
catalyzing O
the O
final O
step O
in O
cysteine O
biosynthesis O
in O
Arabidopsis O
thaliana O
. O

Two O
distinct O
recessive O
susceptibility O
loci O
for O
vasculitis O
were O
mapped O
on O
chromosome O
( O
Chr O
) O
4 O
at O
D4Mit89 I-GENE
and O
D4Mit147 I-GENE
in O
both O
progenies O
. O

During O
treatment O
, O
the O
phosphorylation O
state O
of O
Rb I-GENE
shifted O
to O
a O
hypophosphorylated O
form O
. O
mRNA O
for O
the O
HPV O
E6 I-GENE
/ O
E7 I-GENE
genes O
decreased O
; O
however O
, O
significant O
changes O
in O
the O
E7 I-GENE
protein I-GENE
were O
not O
observed O
, O
while O
increased O
levels O
of O
Rb I-GENE
immunoprecipitated O
with O
anti I-GENE
- I-GENE
E7 I-GENE
antibodies I-GENE
were O
observed O
. O

Further O
characterization O
of O
these O
putative O
Hoxa I-GENE
- I-GENE
1 I-GENE
target I-GENE
genes I-GENE
will O
aid O
in O
delineating O
the O
functions O
of O
the O
Hoxa I-GENE
- I-GENE
1 I-GENE
protein I-GENE
in O
the O
differentiation O
processes O
which O
occur O
during O
embryogenesis O
. O

The O
ability O
of O
U6 I-GENE
- O
U57 I-GENE
mutants O
to O
influence O
the O
fidelity O
of O
both O
branch O
site O
and O
3 O
' O
splice O
site O
recognition O
suggests O
that O
this O
nucleotide O
may O
participate O
in O
the O
formation O
of O
the O
active O
site O
( O
s O
) O
of O
the O
spliceosome O
. O

We O
have O
determined O
the O
structure O
of O
the O
WNT I-GENE
- I-GENE
2B I-GENE
gene I-GENE
. O

The O
role O
of O
daunorubicin O
in O
induction O
therapy O
for O
adult O
acute O
myeloid O
leukemia O

Five O
of O
the O
Aeromonas O
strains O
and O
one O
of O
V O
cholerae O
non O
- O
O1 O
were O
positive O
for O
enterotoxin O
activity O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
induced O
a O
dose O
- O
and O
time O
- O
dependent O
increase O
in O
cyclooxygenase I-GENE
- I-GENE
2 I-GENE
( O
COX I-GENE
- I-GENE
2 I-GENE
) O
expression O
and O
PGE2 O
formation O
in O
human O
NCI O
- O
H292 O
epithelial O
cells O
. O

The O
therapy O
time O
to O
deliver O
the O
NCS O
therapeutic O
dose O
of O
10000 O
RBE O
- O
cGy O
, O
is O
27 O
times O
longer O
when O
157Gd O
is O
used O
instead O
of O
10B O
. O

Mis3 I-GENE
is O
needed O
for O
the O
formation O
of O
18S I-GENE
ribosome I-GENE
RNA I-GENE
, O
and O
may O
hence O
direct O
the O
level O
of O
proteins O
required O
for O
the O
coupling O
. O

Losartan O
Intervention O
For O
Endpoint O
. O

CONCLUSION O
: O
Vitrectomy O
for O
vitreous O
hemorrhage O
in O
Terson O
syndrome O
is O
a O
safe O
and O
effective O
procedure O
, O
offering O
a O
rapid O
and O
prolonged O
improvement O
in O
vision O
. O

RNA O
in O
situ O
hybridization O
on O
brain O
sections O
of O
normal O
human O
embryos O
revealed O
a O
strong O
labeling O
in O
restricted O
areas O
of O
the O
cerebral O
cortex O
. O

To O
facilitate O
manipulation O
of O
large O
genomic O
sequences O
, O
we O
developed O
a O
method O
of O
converting O
Escherichia O
coli O
P1 O
artificial O
chromosomes O
( O
PACs O
) O
into O
yeast O
artificial O
chromosomes O
( O
YACs O
). O

After O
gamma O
- O
irradiation O
, O
the O
majority O
of O
F9 O
cells O
undergo O
apoptosis O
implying O
that O
wt I-GENE
- I-GENE
p53 I-GENE
likely O
triggers O
pro O
- O
apoptotic O
gene O
expression O
in O
DNA O
damaged O
cells O
. O

Mobilization O
with O
cyclophosphamide O
and O
granulocyte I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
was O
effective O
in O
terms O
of O
CD34 I-GENE
+ I-GENE
cell O
shift O
to O
peripheral O
blood O
and O
the O
good O
quality O
autograft O
reliably O
led O
to O
haematopoetic O
recovery O
after O
megachemotherapy O
. O

This O
suggests O
that O
cardiovascular O
magnetic O
resonance O
is O
the O
preferred O
technique O
for O
volume O
and O
ejection O
fraction O
estimation O
in O
heart O
failure O
patients O
, O
because O
of O
its O
3D O
approach O
for O
non O
- O
symmetric O
ventricles O
and O
superior O
image O
quality O
. O

A O
degenerate O
DNA O
transposon O
, O
Pat I-GENE
, O
was O
identified O
in O
the O
genomes O
of O
various O
wild O
- O
type O
strains O
of O
the O
filamentous O
fungus O
Podospora O
anserina O
. O

However O
, O
the O
presence O
of O
Tax I-GENE
I I-GENE
increased O
the O
extent O
and O
altered O
the O
profile O
of O
proteins O
binding O
TRE I-GENE
- I-GENE
2 I-GENE
in O
vivo O
. O

We O
have O
also O
identified O
a O
functional O
domain O
in O
the O
ORF O
50 O
protein O
, O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
product I-GENE
that O
is O
mainly O
encoded O
by O
ORF O
50 O
. O

A O
2 O
. O
3 O
- O
kb O
full O
- O
length O
cDNA O
clone O
of O
an O
Atlantic I-GENE
halibut I-GENE
Mx I-GENE
gene I-GENE
was O
isolated O
from O
a O
liver O
cDNA O
library O
. O

PLUS O
- O
3 O
is O
a O
new O
Swedish O
protocol O
of O
natural O
speech O
in O
3 O
- O
year O
- O
old O
children O
. O

Once O
HIT O
II O
is O
suspected O
, O
heparin O
( O
and O
low O
- O
molecular O
- O
weight O
heparins O
) O
should O
be O
stopped O
immediately O
. O

The O
reduced O
efficiency O
in O
the O
glycosylase I-GENE
activity O
is O
also O
reflected O
in O
a O
reduced O
ability O
of O
S120K I-GENE
MutY I-GENE
to O
prevent O
DNA O
mutations O
in O
vivo O
. O

METHODS O
AND O
RESULTS O
: O
We O
prospectively O
compared O
the O
automated O
measurements O
of O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
and O
volumes O
from O
rest O
- O
injected O
gated O
Technetium O
99m O
( O
Tc99m O
) O
perfusion O
SPECT O
with O
equilibrium O
radionuclide O
angiocardiography O
( O
ERNA O
) O
in O
62 O
patients O
and O
the O
assessment O
of O
regional O
function O
with O
echocardiography O
in O
22 O
patients O
. O

The O
2 O
cDNAs O
differed O
in O
the O
length O
of O
their O
respective O
3 O
' O
untranslated O
regions O
, O
of O
577 O
bp O
in O
Cp I-GENE
. I-GENE
F6 I-GENE
and O
72 O
bp O
in O
Cp I-GENE
. I-GENE
F10 I-GENE
, O
in O
both O
of O
which O
a O
putative O
polyadenylation O
signal O
was O
identified O
. O

This O
intracellular O
signaling O
, O
known O
as O
the O
unfolded O
protein O
response O
( O
UPR O
), O
is O
mediated O
by O
the O
cis O
- O
acting O
ER O
stress O
response O
element O
( O
ERSE O
) O
in O
mammals O
. O

A O
Y I-GENE
. I-GENE
lipolytica I-GENE
Kar2p I-GENE
mutant I-GENE
was O
isolated O
that O
restored O
interaction O
with O
an O
Sls1p I-GENE
mutant I-GENE
, O
suggesting O
that O
the O
interaction O
with O
Sls1p I-GENE
could O
be O
nucleotide O
and O
/ O
or O
conformation O
dependent O
. O

We O
have O
carried O
out O
a O
comprehensive O
and O
systematic O
mutagenesis O
of O
the O
Cse4p I-GENE
N I-GENE
terminus I-GENE
to O
analyze O
its O
function O
. O

The O
spacing O
of O
the O
essential O
N O
- O
terminal O
domain O
( O
END O
) O
relative O
to O
the O
HFD I-GENE
can O
be O
changed O
significantly O
without O
an O
apparent O
effect O
on O
Cse4p I-GENE
function O
. O

The O
bases O
of O
this O
comparison O
are O
reviewed O
and O
discussed O
. O

In O
invertebrates O
, O
Fhit I-GENE
is O
encoded O
as O
a O
fusion O
protein O
with O
Nit I-GENE
, O
a O
member O
of O
the O
nitrilase I-GENE
superfamily I-GENE
. O

Platelet O
counts O
and O
function O
as O
well O
as O
fibrinogen I-GENE
and O
von I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
levels O
were O
determined O
in O
each O
sample O
. O

The O
manifestations O
often O
include O
a O
moderate O
thrombocytopenia O
and O
, O
less O
commonly O
, O
hemolysis O
. O

A O
beta2 I-GENE
RARE I-GENE
reporter I-GENE
construct I-GENE
in O
which O
the O
methylation O
- O
susceptible O
cytosines O
in O
the O
sense O
strand O
were O
replaced O
by O
thymine O
displayed O
marked O
loss O
of O
activity O
in O
a O
replicated O
chromatin O
- O
dependent O
manner O
. O

Non O
- O
poliomyelitis O
AFP O
rate O
had O
increased O
from O
0 O
. O
9 O
in O
1997 O
to O
2 O
. O
8 O
in O
1998 O
. O

Consciousness O
is O
connected O
with O
attention O
, O
working O
memory O
and O
perception O
. O

Multiparity O
had O
a O
protective O
effect O
with O
0 O
. O
66 O
less O
risk O
( O
95 O
% O
CI O
0 O
. O
44 O
- O
0 O
. O
99 O
). O

Picture O
the O
smell O
. O

The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
level O
of O
oxidative O
stress O
in O
healthy O
controls O
( O
CTL O
) O
compared O
with O
CRF O
and O
HD O
patients O
before O
( O
pre O
- O
HD O
) O
and O
after O
( O
post O
- O
HD O
) O
the O
dialysis O
session O
, O
carried O
out O
on O
a O
high O
biocompatible O
polyacrylonitrile O
membrane O
AN69 O
. O

Indirect O
plasma O
parameters O
such O
as O
vitamin O
E O
, O
thiol O
and O
uric O
acid O
levels O
were O
also O
quantified O
. O

Only O
two O
of O
27 O
participants O
( O
7 O
. O
4 O
%) O
with O
definite O
POAG O
had O
been O
previously O
diagnosed O
and O
treated O
, O
and O
66 O
. O
7 O
% O
of O
the O
previously O
undiagnosed O
had O
IOP O
less O
than O
22 O
mmHg O
. O

Taken O
together O
, O
they O
uphold O
the O
emerging O
concern O
that O
women O
with O
ER I-GENE
(+) I-GENE
cancers O
may O
not O
benefit O
significantly O
from O
endocrine O
treatment O
if O
the O
tumors O
also O
overexpress O
HER I-GENE
- I-GENE
2 I-GENE
. O

Promoter O
activity O
was O
dose O
- O
dependently O
inhibited O
by O
cotransfection O
with O
either O
ras I-GENE
or O
mos I-GENE
oncogenes I-GENE
, O
but O
oncogene O
inhibition O
was O
reversed O
and O
the O
overall O
activity O
increased O
when O
cells O
were O
treated O
with O
the O
MAP I-GENE
kinase I-GENE
kinase I-GENE
( O
MKK I-GENE
) O
inhibitor O
PD98059 O
. O

Our O
results O
indicate O
that O
the O
expression O
of O
Cktsf1b1 I-GENE
, O
a O
gene O
associated O
with O
early O
development O
and O
cell O
transformation O
, O
is O
sensitive O
to O
MKK I-GENE
levels O
and O
may O
be O
regulated O
via O
multiple O
transcription O
factor O
complexes O
. O

INTERVENTIONS O
: O
Subcutaneous O
tissue O
PO2 O
and O
PCO2 O
tensions O
were O
measured O
directly O
in O
patients O
with O
necrotising O
fasciitis O
and O
in O
healthy O
volunteers O
during O
normobaric O
and O
hyperbaric O
conditions O
. O

Because O
GH I-GENE
- O
induced O
Akt I-GENE
activation O
was O
completely O
inhibited O
in O
both O
cells O
by O
the O
same O
concentration O
of O
LY294002 O
, O
these O
findings O
indicate O
that O
the O
wortmannin O
sensitivity O
of O
both O
the O
IRS I-GENE
- I-GENE
1 I-GENE
- O
independent O
and O
- O
dependent O
GH I-GENE
- O
induced O
MAP I-GENE
kinase I-GENE
activation O
may O
reflect O
the O
activity O
of O
another O
wortmannin O
- O
sensitive O
target O
( O
s O
) O
in O
addition O
to O
PI3K I-GENE
in O
mediation O
of O
GH I-GENE
- O
induced O
MAP I-GENE
kinase I-GENE
activation O
in O
these O
cells O
. O

Insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
- O
mediated O
enhancement O
of O
growth I-GENE
hormone I-GENE
- O
induced O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
. O

Functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
has O
been O
increasingly O
used O
in O
studying O
human O
brain O
function O
given O
its O
non O
- O
invasive O
feature O
and O
good O
spatial O
resolution O
. O

After O
declamping O
of O
the O
aorta O
, O
there O
were O
also O
severe O
edema O
, O
local O
fibre O
necrosis O
, O
and O
adhesion O
of O
leucocytes O
, O
whereas O
muscle O
fibre O
areas O
became O
3 O
, O
935 O
. O
18 O
micro O
531 O
microm O
( O
2 O
) O
for O
type O
I O
and O
5 O
, O
804 O
+/- O
1 O
, O
075 O
microm O
( O
2 O
) O
for O
type O
II O
. O

The O
results O
indicate O
that O
the O
relationship O
between O
comprehension O
and O
production O
is O
different O
at O
different O
stages O
in O
development O
. O

It O
was O
found O
that O
increase O
in O
the O
RH O
level O
boosts O
the O
current O
values O
by O
2 O
- O
3 O
orders O
of O
magnitude O
; O
contrariwise O
, O
the O
voltage O
values O
rise O
by O
about O
three O
times O
with O
drop O
in O
the O
RH O
. O

On O
long O
- O
term O
follow O
- O
up O
, O
there O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
hospitalizations O
( O
1 O
per O
2 O
. O
1 O
vs O
. O

Genomic O
libraries O
were O
stored O
as O
frozen O
cultures O
in O
a O
96 O
- O
well O
format O
, O
each O
well O
containing O
approximately O
300 O
- O
600 O
colonies O
( O
12 O
plates O
for O
small O
library O
, O
four O
for O
medium O
- O
size O
library O
and O
four O
for O
large O
library O
). O

In O
several O
cell O
lines O
, O
mTOR I-GENE
or O
its O
downstream O
targets O
can O
be O
regulated O
by O
phosphatidylinositol I-GENE
( I-GENE
PI I-GENE
) I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
; O
protein I-GENE
kinases I-GENE
A I-GENE
, I-GENE
B I-GENE
, I-GENE
and I-GENE
C I-GENE
; O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
; O
a O
PD98059 O
- O
sensitive O
kinase O
or O
calcium O
; O
as O
well O
as O
by O
amino O
acids O
. O

The O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
is O
involved O
in O
maintaining O
genomic O
stability O
. O

Abrogation O
of O
p53 I-GENE
function O
by O
E6 I-GENE
resulted O
in O
an O
increase O
in O
the O
spontaneous O
mutation O
frequencies O
at O
the O
heterozygous O
thymidine I-GENE
kinase I-GENE
( O
TK I-GENE
) O
locus O
but O
not O
at O
the O
hemizygous O
hypoxanthine I-GENE
phosphoribosyl I-GENE
transferase I-GENE
( O
HPRT I-GENE
) O
locus O
. O

Cytogenetic O
analysis O
of O
LOH O
mutants O
by O
chromosome O
painting O
indicated O
a O
mosaic O
of O
chromosomal O
aberrations O
involving O
chromosome O
17 O
, O
in O
which O
partial O
chromosome O
deletions O
, O
amplifications O
, O
and O
multiple O
translocations O
appeared O
heterogeneously O
in O
a O
single O
mutant O
. O

These O
results O
support O
a O
model O
in O
which O
p53 I-GENE
protein I-GENE
contributes O
to O
the O
maintenance O
of O
genomic O
integrity O
through O
recombinational O
repair O
. O

The O
importance O
of O
this O
new O
epidemiological O
profile O
of O
schistosomiasis O
in O
the O
State O
of O
Pernambuco O
relies O
on O
the O
fact O
that O
it O
can O
be O
related O
with O
the O
drastic O
human O
interference O
on O
the O
environment O
. O

In O
patients O
with O
type O
II O
tumors O
, O
the O
pattern O
of O
lymphatic O
spread O
was O
primarily O
directed O
toward O
the O
paracardial O
, O
lesser O
curvature O
, O
and O
left O
gastric O
artery O
nodes O
; O
esophagectomy O
offered O
no O
survival O
benefit O
over O
extended O
gastrectomy O
in O
these O
patients O
. O

RESULTS O
: O
No O
significant O
deformation O
in O
vertebral O
artery O
flow O
was O
noted O
in O
the O
flexion O
- O
distraction O
Stage O
I O
injuries O
within O
the O
physiologic O
range O
of O
cervical O
flexion O
. O

We O
screened O
a O
K562 O
cDNA O
library O
and O
identified O
novel O
transcripts O
, O
MZF1B I-GENE
and O
MZF1C I-GENE
. O

The O
human O
cDNA O
clone O
NFBD1 O
( O
previously O
designated O
KIAA0170 O
) O
encodes O
a O
novel O
protein O
( O
2089 O
amino O
acids O
in O
length O
; O
calculated O
molecular O
mass O
226 O
, O
440 O
D O
) O
with O
possible O
BRCT I-GENE
domains I-GENE
at O
its O
carboxy O
terminus O
( O
amino O
acid O
residues O
1894 O
- O
2089 O
). O

RESULTS O
: O
Neither O
basal O
FSH I-GENE
level O
nor O
stimulated O
FSH I-GENE
level O
alone O
were O
statistically O
significant O
predictors O
of O
IVF O
success O
; O
however O
, O
no O
patient O
with O
a O
day O
3 O
FSH I-GENE
level O
> O
11 O
. O
1 O
mIU O
/ O
ml O
or O
a O
stimulated O
day O
10 O
FSH I-GENE
level O
> O
13 O
. O
5 O
mIU O
/ O
ml O
conceived O
and O
carried O
a O
pregnancy O
. O

Parathyroid I-GENE
hormone I-GENE
regulation O
of O
bone I-GENE
sialoprotein I-GENE
( O
BSP I-GENE
) O
gene O
transcription O
is O
mediated O
through O
a O
pituitary I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
Pit I-GENE
- I-GENE
1 I-GENE
) O
motif O
in O
the O
rat I-GENE
BSP I-GENE
gene I-GENE
promoter I-GENE
. O

Recent O
target O
BP O
goals O
promulgated O
by O
the O
Sixth O
Report O
from O
the O
Joint O
National O
Committee O
( O
JNC O
VI O
) O
are O
based O
on O
the O
premise O
that O
the O
intensity O
of O
treatment O
directly O
corresponds O
to O
the O
magnitude O
of O
pretreatment O
risk O
. O

Linking O
continuous O
community O
- O
based O
morbidity O
recording O
of O
influenza O
- O
like O
illness O
( O
ILI O
) O
with O
virological O
sampling O
has O
consistently O
proved O
its O
value O
as O
one O
of O
the O
earliest O
indicators O
of O
circulating O
influenza O
activity O
. O

The O
muskox O
is O
a O
new O
host O
record O
for O
T O
. O
gondii O
. O

These O
include O
NPF O
repeats O
, O
a O
leucine O
heptad O
repeat O
enriched O
in O
charged O
residues O
, O
and O
a O
proline O
- O
rich O
SH3 I-GENE
- I-GENE
like I-GENE
and O
/ O
or O
WW O
domain O
- O
binding O
site O
in O
the O
N O
- O
terminal O
domain O
, O
which O
is O
followed O
by O
a O
membrane O
core O
containing O
four O
putative O
transmembrane O
spans O
and O
three O
amphiphilic O
segments O
that O
are O
the O
most O
highly O
conserved O
structural O
elements O
. O

We O
show O
here O
that O
this O
difference O
is O
due O
to O
the O
presence O
of O
a O
Mot3 I-GENE
binding I-GENE
site I-GENE
in O
OpA I-GENE
. O

The O
article O
deals O
with O
the O
diagnosing O
and O
correction O
of O
reversible O
ischemia O
of O
the O
intestine O
. O

Mucosal O
application O
of O
NCX O
- O
4016 O
, O
however O
, O
did O
not O
cause O
PD O
reduction O
and O
luminal O
H O
+ O
loss O
, O
but O
produced O
a O
marked O
hyperemia O
, O
resulting O
in O
no O
damage O
in O
the O
stomach O
of O
both O
normal O
and O
STZ O
- O
diabetic O
rats O
. O

Functional O
recognition O
of O
5 O
' O
splice O
site O
by O
U4 I-GENE
/ O
U6 I-GENE
. O
U5 I-GENE
tri O
- O
snRNP O
defines O
a O
novel O
ATP O
- O
dependent O
step O
in O
early O
spliceosome O
assembly O
. O

As O
control O
, O
the O
cells O
were O
transfected O
with O
DNA O
mixtures O
containing O
vector O
mU6 O
- O
C1 O
or O
mU6 O
- O
C2 O
. O

The O
amino O
acid O
sequence O
of O
matrilysin I-GENE
- I-GENE
2 I-GENE
also O
contains O
a O
threonine O
residue O
adjacent O
to O
the O
Zn O
- O
binding O
site O
that O
has O
been O
defined O
as O
a O
specific O
feature O
of O
matrilysin I-GENE
. O

In O
this O
regard O
, O
we O
have O
recently O
observed O
that O
a O
constitutively O
active O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
GPCR I-GENE
) O
encoded O
by O
the O
Kaposi O
' O
s O
sarcoma O
- O
associated O
herpes O
virus O
( O
KSHV O
)/ O
human O
herpes O
virus O
8 O
is O
oncogenic O
and O
stimulates O
angiogenesis O
by O
increasing O
the O
secretion O
of O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
), O
which O
is O
a O
key O
angiogenic O
stimulator O
and O
a O
critical O
mitogen O
for O
the O
development O
of O
Kaposi O
' O
s O
sarcoma O
. O

No O
specific O
subgroup O
of O
clients O
benefited O
more O
from O
URD O
, O
although O
a O
prospective O
study O
employing O
random O
assignment O
might O
be O
more O
successful O
in O
identifying O
such O
a O
group O
. O

In O
the O
lattice O
, O
23 O
% O
of O
the O
sites O
are O
occupied O
, O
95 O
% O
of O
the O
atoms O
are O
in O
the O
lowest O
energy O
magnetic O
sublevel O
, O
and O
37 O
% O
are O
in O
the O
lowest O
3D O
vibrational O
state O
. O

Coexisting O
vertical O
and O
horizontal O
one O
and O
a O
half O
syndromes O
. O

As O
in O
the O
other O
three O
members O
whose O
gene O
expression O
is O
altered O
during O
tumorigenesis O
, O
PI12 I-GENE
expression O
was O
found O
to O
be O
down O
- O
regulated O
in O
tumor O
brain O
tissues O
and O
in O
two O
brain O
cancer O
cell O
lines O
: O
U O
- O
87 O
MG O
and O
H4 O
. O

Regarding O
" O
the O
relation O
between O
sexual O
orientation O
and O
penile O
size O
," O
by O
A O
. O

This O
slope O
was O
further O
significantly O
decreased O
at O
5 O
min O
ischemia O
(- O
26 O
. O
5 O
+/- O
8 O
. O
8 O
microm O
/ O
mmHg O
) O
but O
returned O
toward O
control O
values O
in O
short O
- O
term O
hibernating O
myocardium O
at O
90 O
min O
ischemia O
(- O
17 O
. O
2 O
+/- O
6 O
. O
6 O
microm O
/ O
mmHg O
). O

Whereas O
both O
MAP O
and O
MSNA O
increase O
during O
SHG O
, O
the O
transition O
from O
SHG O
to O
PHI O
is O
characterized O
by O
a O
transient O
reduction O
in O
MAP O
but O
sustained O
elevation O
in O
MSNA O
, O
facilitating O
separation O
of O
these O
factors O
in O
vivo O
. O

Analysis O
of O
Standard O
Reference O
Material O
1846 O
, O
Infant O
Formula O
, O
gave O
a O
mean O
value O
of O
0 O
. O
95 O
+/- O
0 O
. O
088 O
mg O
vitamin O
K O
/ O
kg O
( O
K O
or O
K1 O
?) O
( O
n O
= O
31 O
) O
with O
a O
coefficient O
of O
variation O
of O
9 O
. O
26 O
. O

We O
have O
recently O
discovered O
that O
CCAAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
induces O
gene O
transcription O
through O
a O
novel O
IFN I-GENE
response I-GENE
element I-GENE
called O
the O
gamma I-GENE
- I-GENE
IFN I-GENE
- I-GENE
activated I-GENE
transcriptional I-GENE
element I-GENE

Northern O
blot O
analysis O
demonstrated O
that O
the O
STORP I-GENE
gene I-GENE
has O
a O
ubiquitous O
pattern O
of O
expression O
similar O
to O
that O
of O
the O
PML I-GENE
gene I-GENE
. O

In O
the O
TLE O
patients O
the O
NAA O
: O
Cr O
ratios O
were O
reduced O
in O
the O
seizure O
focus O
, O
while O
in O
the O
FLE O
patients O
they O
were O
not O
always O
reduced O
in O
the O
seizure O
focus O
. O

The O
Spo0F I-GENE
residues I-GENE
making O
up O
the O
hydrophobic O
patch O
are O
very O
similar O
in O
all O
response O
regulators O
suggesting O
that O
the O
binding O
is O
initiated O
through O
the O
same O
residues O
in O
all O
interacting O
response O
regulator O
- O
kinase O
pairs O
. O

The O
psychologic O
factors O
associated O
wth O
serious O
illness O
, O
terminal O
prognoses O
, O
and O
dying O
complicate O
the O
scenario O
even O
more O
as O
compared O
with O
that O
of O
nonmalignant O
pain O
. O

However O
, O
if O
the O
spatial O
resolution O
is O
not O
critical O
and O
interest O
is O
to O
compare O
a O
pathologic O
area O
with O
a O
contralateral O
VOI O
, O
then O
the O
acquisition O
of O
two O
single O
- O
voxel O
spectra O
may O
be O
preferred O
. O

Quantitative O
evaluation O
of O
magneto O
- O
optical O
parameters O
is O
necessary O
in O
order O
to O
apply O
scanning O
near O
- O
field O
optical O
microscope O
( O
SNOM O
) O
technology O
to O
the O
study O
of O
magnetism O
on O
the O
mesoscopic O
scale O
. O

We O
found O
that O
the O
amplitude O
of O
the O
cortical O
evoked O
potentials O
( O
amplitude O
of O
the O
N2 O
/ O
P2 O
peak O
) O
increased O
from O
5 O
. O
1 O
+/- O
0 O
. O
7 O
microV O
at O
5 O
mA O
to O
16 O
. O
3 O
+/- O
1 O
. O
1 O
microV O
at O
20 O
mA O
. O

While O
mutations O
in O
K I-GENE
- I-GENE
Rev I-GENE
that O
inactivate O
any O
one O
of O
these O
properties O
also O
blocked O
K I-GENE
- I-GENE
Rev I-GENE
- O
dependent O
nuclear O
RNA O
export O
, O
several O
K I-GENE
- I-GENE
Rev I-GENE
mutants I-GENE
were O
comparable O
to O
wild O
type O
when O
assayed O
for O
any O
of O
these O
individual O
activities O
yet O
nevertheless O
defective O
for O
RNA O
export O
. O

LMP I-GENE
- I-GENE
1 I-GENE
is O
targeted O
to O
the O
plasma O
membrane O
, O
where O
it O
binds O
TRAF I-GENE
, O
TRADD I-GENE
, O
and O
JAK I-GENE
molecules I-GENE
to O
activate O
NF I-GENE
- I-GENE
kappaB I-GENE
-, O
AP I-GENE
- I-GENE
1 I-GENE
-, O
and O
STAT I-GENE
- O
dependent O
pathways O
as O
does O
CD40 I-GENE
. O

Identification O
of O
an O
enhancer O
and O
an O
alternative O
promoter O
in O
the O
first O
intron O
of O
the O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
. O

Studying O
intracellular O
signaling O
pathways O
, O
which O
may O
be O
involved O
in O
malignant O
transformation O
of O
Ret I-GENE
- I-GENE
9bp I-GENE
expressing O
NIH3T3 O
cells O
, O
we O
could O
demonstrate O
Ret I-GENE
- I-GENE
9bp I-GENE
dependent O
phosphorylation O
of O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
2 I-GENE
( O
IRS I-GENE
- I-GENE
2 I-GENE
) O
with O
consecutive O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
and O
protein I-GENE
kinase I-GENE
B I-GENE
( O
PKB I-GENE
/ O
AKT I-GENE
). O

METHODS O
: O
In O
the O
current O
study O
the O
authors O
reported O
on O
PPB O
cases O
from O
a O
national O
retrospective O
search O
performed O
in O
18 O
Italian O
Associations O
for O
Pediatric O
Hematology O
and O
Oncology O
centers O
. O

Phylogenetic O
analysis O
showed O
that O
the O
ToLCV O
isolates O
from O
Bangalore O
constitute O
a O
group O
of O
viruses O
separated O
from O
those O
of O
Northern O
India O
. O

Mutating O
the O
Fcp1p I-GENE
- O
binding O
motif O
KEFGK O
in O
the O
RAP74 I-GENE
( O
Tfg1p I-GENE
) O
subunit O
of O
TFIIF I-GENE
to O
EEFGE O
led O
to O
both O
synthetic O
phenotypes O
in O
certain O
fcp1 I-GENE
tfg1 I-GENE
double O
mutants O
and O
a O
reduced O
ability O
of O
Fcp1p I-GENE
to O
activate O
transcription O
when O
it O
is O
artificially O
tethered O
to O
a O
promoter O
. O

These O
results O
suggest O
that O
Cdc42p I-GENE
is O
in O
fact O
required O
for O
pheromone O
response O
and O
that O
interaction O
with O
the O
PAK I-GENE
Ste20p I-GENE
is O
critical O
for O
that O
role O
. O

Deletion O
of O
an O
intergenic O
DNA O
- O
binding O
site O
for O
this O
complex O
from O
a O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
construct I-GENE
results O
in O
delayed O
human I-GENE
gamma I-GENE
- I-GENE
to I-GENE
beta I-GENE
- I-GENE
globin I-GENE
switching O
in O
transgenic O
mice O
, O
suggesting O
that O
the O
PYR I-GENE
complex I-GENE
acts O
to O
facilitate O
the O
switch O
. O

The O
product O
of O
rat I-GENE
gene I-GENE
33 I-GENE
was O
identified O
as O
an O
ErbB I-GENE
- I-GENE
2 I-GENE
- I-GENE
interacting I-GENE
protein I-GENE
in O
a O
two O
- O
hybrid O
screen O
employing O
the O
ErbB I-GENE
- I-GENE
2 I-GENE
juxtamembrane I-GENE
and I-GENE
kinase I-GENE
domains I-GENE
as O
bait O
. O

Studies O
suggest O
that O
the O
DGOR O
without O
acid O
reflux O
may O
result O
in O
symptoms O
but O
unless O
acid O
reflux O
is O
present O
simultaneously O
, O
it O
does O
not O
cause O
oesophagitis O
. O

Symptoms O
, O
however O
, O
appear O
to O
correlate O
poorly O
with O
oesophagitis O
; O
hence O
, O
severe O
symptoms O
do O
not O
indicate O
there O
is O
greater O
oesophageal O
damage O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
relationship O
between O
blood O
flow O
in O
the O
tumor O
assessed O
by O
color O
Doppler O
ultrasound O
, O
microvessel O
density O
, O
and O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
levels O
in O
endometrial O
carcinoma O
. O

These O
results O
demonstrate O
Ras I-GENE
- O
and O
Raf I-GENE
- O
independent O
ERK I-GENE
MAPK O
activation O
maintains O
cell O
viability O
following O
heat O
shock O
. O

Three O
cDNAs O
encoding O
basic I-GENE
leucine I-GENE
zipper I-GENE
( I-GENE
bZIP I-GENE
)- I-GENE
type I-GENE
ABRE I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
were O
isolated O
by O
using O
the O
yeast O
one O
- O
hybrid O
system O
and O
were O
designated O
AREB1 I-GENE
, O
AREB2 I-GENE
, O
and O
AREB3 I-GENE
( O
ABA I-GENE
- I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
). O

Recombinant O
AROM I-GENE
- O
p64 I-GENE
displayed O
high O
binding O
to O
single O
- O
stranded O
DNA O
and O
poly O
( O
A O
) O
homopolymers O
suggesting O
that O
this O
protein O
could O
play O
a O
role O
in O
mRNA O
maturation O
/ O
metabolism O
. O

The O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
fer I-GENE
associates O
with O
signaling O
complexes O
containing O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
and O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

The O
variable O
phenotype O
of O
the O
allotetraploids O
could O
not O
be O
explained O
by O
cytological O
abnormalities O
. O

In O
the O
PMR O
target O
area O
but O
not O
in O
the O
nontreated O
area O
an O
improvement O
in O
regional O
myocardial O
flow O
reserve O
occurs O
in O
wall O
segments O
with O
initially O
severely O
or O
moderately O
reduced O
stress O
perfusion O
. O

Analysis O
of O
intron O
/ O
exon O
boundaries O
of O
the O
genomic O
BAC O
clones O
demonstrate O
that O
junctin I-GENE
, O
junctate I-GENE
, O
and O
aspartyl I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
result O
from O
alternative O
splicing O
of O
the O
same O
gene O
. O

It O
is O
now O
estimated O
that O
inactivation O
mutants O
of O
PTEN I-GENE
exist O
in O
60 O
% O
of O
all O
forms O
of O
solid O
tumors O
. O

We O
have O
demonstrated O
that O
the O
activity O
of O
ILK I-GENE
is O
constitutively O
elevated O
in O
PTEN I-GENE
mutant I-GENE
cells O
. O

The O
growth I-GENE
factor I-GENE
receptor I-GENE
- I-GENE
bound I-GENE
protein I-GENE
2 I-GENE
( O
Grb2 I-GENE
) O
adaptor O
when O
complexed O
with O
Sos I-GENE
( O
Son I-GENE
of I-GENE
sevenless I-GENE
), O
the O
exchange O
factor O
of O
Ras I-GENE
, O
conveys O
the O
signal O
induced O
by O
tyrosine I-GENE
kinase I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
to O
Ras I-GENE
by O
recruiting O
Sos I-GENE
to O
the O
membrane O
, O
allowing O
activation O
of O
Ras I-GENE
. O

Mutations O
in O
genes O
encoding O
PR65 I-GENE
/ I-GENE
A I-GENE
subunits I-GENE
have O
been O
identified O
in O
several O
different O
human O
cancers O
and O
the O
PP2A I-GENE
inhibitor O
, O
termed O
fostriecin O
, O
is O
being O
tested O
as O
an O
anticancer O
drug O
. O

For O
this O
purpose O
, O
a O
segment O
of O
dxr I-GENE
was O
amplified O
from O
Synechococcus O
leopoliensis O
SAUG O
1402 O
- O
1 O
DNA O
via O
PCR O
using O
oligonucleotides O
for O
conserved O
regions O
. O

Perceptual O
learning O
for O
a O
pattern O
discrimination O
task O
. O

The O
detector O
has O
the O
advantage O
of O
finding O
both O
ST O
segment O
deviations O
and O
entire O
ST O
- O
T O
complex O
changes O
thereby O
providing O
a O
wider O
characterization O
of O
the O
potential O
ischemic O
events O
. O

While O
this O
Saccharomyces O
cerevisiae O
SIN4 I-GENE
gene I-GENE
product I-GENE
is O
a O
component O
of O
a O
mediator O
complex O
associated O
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
various O
studies O
suggest O
the O
involvement O
of O
Sin4 I-GENE
in O
the O
alteration O
of O
higher O
- O
order O
chromatin O
structure O
. O

Primary O
adrenal O
hypersensitivity O
to O
ACTH I-GENE
drive O
in O
obesity O
has O
also O
been O
suggested O
. O

In O
addition O
, O
a O
noncanonical O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
within O
the O
Gadd45gamma I-GENE
promoter I-GENE
where O
C I-GENE
/ I-GENE
EBPbeta I-GENE
and O
C I-GENE
/ I-GENE
EBPdelta I-GENE
could O
bind O
, O
was O
identified O
by O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
and O
reporter O
gene O
analysis O
. O

Src I-GENE
activation O
induced O
by O
FGF1 I-GENE
was O
blocked O
by O
the O
SH2 I-GENE
domain I-GENE
of O
Src I-GENE
and O
PP2 I-GENE
, O
a O
specific O
inhibitor O
of O
Src I-GENE
. O

The O
use O
of O
the O
PLCgamma I-GENE
inhibitory I-GENE
peptide I-GENE
, O
neomycin O
and O
the O
calcium O
chelator O
BAPTA O
- O
AM O
on O
oocytes O
expressing O
FGFR1 I-GENE
or O
the O
stimulation O
by O
PDGF I-GENE
- I-GENE
BB I-GENE
of O
oocytes O
expressing O
PDGFR I-GENE
- O
FGFR1 I-GENE
mutated O
on O
the O
PLCgamma I-GENE
binding I-GENE
site I-GENE
, O
prevented O
GVBD O
and O
ERK2 I-GENE
phosphorylation O
. O

Multiple O
transcription O
start O
sites O
were O
revealed O
by O
primer O
extension O
analysis O
of O
the O
mouse O
gene O
, O
and O
transfection O
constructs O
containing O
the O
prospective O
promoter O
generated O
transcriptional O
activity O
comparable O
to O
that O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

From O
two O
inhibitor O
scaffolds O
, O
we O
have O
identified O
potent O
and O
selective O
inhibitors O
for O
sensitized O
kinases O
from O
five O
distinct O
subfamilies O
. O

To O
determine O
whether O
interaction O
of O
arsenite O
with O
the O
hormone O
- O
binding O
domain O
results O
in O
receptor O
activation O
, O
COS O
- O
1 O
cells O
were O
transiently O
cotransfected O
with O
the O
chimeric I-GENE
receptors I-GENE
GAL I-GENE
- I-GENE
ER I-GENE
, O
which O
contains O
the O
hormone O
- O
binding O
domain O
of O
ERalpha I-GENE
and O
the O
DNA O
- O
binding O
domain O
of O
the O
transcription O
factor O
GAL4 I-GENE
, O
and O
a O
GAL4 I-GENE
- O
responsive O
CAT I-GENE
reporter I-GENE
gene I-GENE
. O

By O
progressive O
5 O
'- O
deletion O
studies O
, O
we O
have O
identified O
a O
248 O
- O
bp O
DNA O
fragment O
(- O
1018 O
to O
- O
771 O
, O
relative O
to O
the O
translation O
start O
site O
) O
at O
the O
5 O
'- O
flanking O
region O
of O
the O
human I-GENE
GnRHR I-GENE
gene I-GENE
that O
is O
responsible O
for O
the O
GnRHa O
- O
mediated O
down O
- O
regulation O
of O
human I-GENE
GnRHR I-GENE
promoter I-GENE
activity O
. O

The O
mean O
day O
of O
diagnosis O
of O
periventricular O
echodensities O
was O
3 O
+/- O
2 O
days O
( O
range O
1 O
- O
11 O
days O
), O
and O
of O
cystic O
PVL O
21 O
+/- O
8 O
days O
( O
range O
2 O
- O
47 O
days O
). O

The O
LAMMER I-GENE
protein O
kinase O
encoded O
by O
the O
Doa I-GENE
locus I-GENE
of O
Drosophila O
is O
required O
in O
both O
somatic O
and O
germline O
cells O
and O
is O
expressed O
as O
both O
nuclear O
and O
cytoplasmic O
isoforms O
throughout O
development O
. O

We O
have O
mutated O
to O
cysteine O
, O
one O
at O
a O
time O
, O
21 O
consecutive O
residues O
in O
the O
fourth O
TMS O
( O
TM4 O
). O

( O
1995 O
) O
J O
. O

HYPOTHESIS O
: O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
oxidative O
susceptibility O
of O
apolipoprotein I-GENE
B I-GENE
- I-GENE
containing I-GENE
lipoproteins I-GENE
and O
antioxidant O
status O
in O
patients O
with O
acute O
coronary O
syndromes O
and O
chronic O
stable O
angina O
pectoris O
. O

In O
group O
B O
37 O
MBq O
in O
150 O
microL O
of O
99mTc O
- O
HSA O
nanocolloid O
was O
additionally O
injected O
intradermally O
18 O
h O
before O
surgery O
( O
3 O
- O
6 O
aliquots O
injected O
perilesionally O
). O

Post O
- O
operative O
functional O
outcome O
is O
related O
to O
pre O
- O
operative O
functional O
status O
. O

We O
cloned O
a O
DNA O
fragment O
encoding O
the O
N O
- O
terminal O
part O
of O
a O
protein O
with O
significant O
similarity O
to O
members O
of O
the O
LysR I-GENE
family I-GENE
of I-GENE
transcriptional I-GENE
regulators I-GENE
( O
LTTRs I-GENE
). O

AGO1 I-GENE
is O
similar O
to O
QDE I-GENE
- I-GENE
2 I-GENE
required O
for O
quelling O
and O
RDE I-GENE
- I-GENE
1 I-GENE
required O
for O
RNAi O
. O

Intracellular O
localization O
studies O
using O
the O
mDAP I-GENE
- I-GENE
3 I-GENE
/ O
EGFP I-GENE
fusion O
protein O
, O
cell O
fractionation O
and O
protease O
protection O
experiments O
localized O
mDAP I-GENE
- I-GENE
3 I-GENE
to O
the O
mitochondrial O
matrix O
. O

We O
could O
demonstrate O
the O
involvement O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
in O
the O
phosphorylation O
of O
CDC25Mm I-GENE
in O
fibroblasts O
overexpressing O
this O
RasGEF I-GENE
as O
well O
as O
in O
mouse O
brain O
synaptosomal O
membranes O
. O

Reporter O
gene O
expression O
analyses O
indicate O
that O
both O
WASP I-GENE
promoters I-GENE
show O
high O
levels O
of O
expression O
in O
different O
hematopoietic O
cell O
lines O
. O

We O
find O
that O
3T1 O
- O
3T2 O
mixing O
has O
a O
pronounced O
effect O
on O
the O
line O
shape O
and O
radiative O
decay O
rate O
of O
emission O
from O
the O
3T2 O
state O
and O
that O
the O
extent O
of O
mixing O
depends O
critically O
on O
the O
magnitude O
of O
nontetrahedral O
distortions O
. O

A O
total O
of O
576 O
1 O
- O
day O
- O
old O
Ross O
broiler O
chicks O
were O
housed O
in O
six O
treatment O
groups O
[ O
six O
replicates O
of O
16 O
each O
; O
control O
, O
CLI O
( O
15 O
g O
kg O
(- O
1 O
) O
diet O
), O
50 O
parts O
per O
billion O
( O
ppb O
) O
AF I-GENE
, O
50 O
ppb O
AF I-GENE
plus O
CLI O
, O
100 O
ppb O
AF I-GENE
, O
100 O
ppb O
AF I-GENE
plus O
CLI O
] O
for O
42 O
days O
. O

The O
cost O
per O
test O
is O
less O
than O
those O
for O
CC O
, O
kEIA O
and O
PACE2 O
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
KG1a O
cells O
, O
TNFalpha I-GENE
can O
stimulate O
in O
parallel O
PC I-GENE
- I-GENE
PLC I-GENE
and O
PLD I-GENE
, O
whose O
lipid O
products O
activate O
in O
turn O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAP I-GENE
kinase I-GENE
) O
and O
NF I-GENE
- I-GENE
kappaB I-GENE
signalling O
respectively O
. O

Concurrently O
, O
we O
monitored O
weather O
conditions O
and O
used O
time O
- O
activity O
budget O
data O
of O
free O
- O
living O
birds O
and O
laboratory O
data O
on O
resting O
metabolic O
rate O
to O
construct O
time O
- O
activity O
laboratory O
( O
TAL O
) O
estimates O
of O
daily O
energy O
expenditure O
( O
DEE O
) O
and O
to O
partition O
the O
verdins O
' O
energy O
budget O
into O
thermoregulatory O
, O
activity O
and O
basal O
components O
. O

L O
/ O
H O
> O
0 O
. O
61 O
( O
chi O
( O
2 O
)= O
10 O
. O
8 O
; O
P O
:< O
0 O
. O
001 O
) O
and O
a O
restrictive O
filling O
pattern O
( O
chi O
( O
2 O
)= O
3 O
. O
6 O
; O
P O
:< O
0 O
. O
05 O
) O
were O
independent O
predictors O
of O
events O
. O

The O
high O
selectivity O
of O
arrestins I-GENE
for O
this O
particular O
functional O
form O
of O
receptor O
ensures O
their O
timely O
binding O
and O
dissociation O
. O

When O
cotransfected O
in O
fibroblasts O
with O
a O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
expression O
vector O
, O
reporter O
gene O
expression O
increased O
3 O
- O
fold O
only O
in O
the O
wild O
- O
type O
constructs O
. O

Expression O
of O
a O
dominant I-GENE
negative I-GENE
Smad2 I-GENE
significantly O
reduces O
the O
level O
of O
luciferase I-GENE
reporter I-GENE
activity O
induced O
by O
nodal O
treatment O
. O

Normal O
alpha1 I-GENE
( I-GENE
I I-GENE
) I-GENE
collagen I-GENE
mRNA I-GENE
showed O
no O
significant O
reduction O
when O
AR O
or O
IR O
was O
expressed O
from O
the O
pHbetaAPr O
- O
1 O
- O
neo O
vector O
and O
a O
small O
( O
10 O
- O
20 O
%) O
but O
significant O
reduction O
when O
either O
ribozyme O
was O
expressed O
from O
the O
pCI O
. O
neo O
vector O
. O

Nature O
398 O
, O
828 O
- O
830 O
) O
that O
the O
amino O
acid O
sequences O
of O
peptide O
fragments O
obtained O
from O
a O
polypeptide O
found O
in O
a O
complex O
of O
proteins O
that O
alters O
chromatin O
structure O
( O
ARC I-GENE
) O
are O
identical O
to O
portions O
of O
the O
deduced O
open O
reading O
frame O
of O
TIG I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
. O

Abnormalities O
of O
plasma I-GENE
cholecystokinin I-GENE
were O
observed O
only O
in O
patients O
with O
delayed O
gastric O
emptying O
. O

5 O
( O
Sunset O
Yellow O
FCF O
) O
were O
determined O
using O
liquid O
chromatography O
/ O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
with O
electrospray O
ionization O
. O

Polysome O
and O
40S I-GENE
ribosome I-GENE
fractions O
were O
severely O
decreased O
in O
the O
krr1 I-GENE
mutant I-GENE
and O
Kri1p I-GENE
- O
depleted O
cells O
. O

They O
also O
negatively O
modulate O
the O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic O
activity O
but O
to O
different O
extents O
, O
dependent O
on O
the O
unique O
N O
- O
terminal O
structure O
of O
each O
isoform O
. O

Cam I-GENE
kinase I-GENE
II I-GENE
induces O
in O
vivo O
phosphorylation O
of O
Smad2 I-GENE
and O
Smad4 I-GENE
and O
, O
to O
a O
lesser O
extent O
, O
Smad3 I-GENE
. O

The O
Drosophila I-GENE
melanogaster I-GENE
suppressor I-GENE
of I-GENE
sable I-GENE
gene I-GENE
, O
su O
( O
s O
), O
encodes O
a O
novel O
, O
150 O
- O
kDa O
nuclear O
RNA O
binding O
protein O
, O
SU O
( O
S O
), O
that O
negatively O
regulates O
RNA O
accumulation O
from O
mutant O
alleles O
of O
other O
genes O
that O
have O
transposon O
insertions O
in O
the O
5 O
' O
transcribed O
region O
. O

As O
a O
result O
, O
we O
have O
defined O
two O
arginine O
- O
rich O
motifs O
( O
ARM1 O
and O
ARM2 O
) O
that O
mediate O
the O
RNA O
binding O
activity O
of O
SU O
( O
S O
). O

This O
interaction O
inhibits O
the O
histone I-GENE
acetyltransferase I-GENE
activity O
of O
p300 I-GENE
, O
resulting O
in O
drastic O
reduction O
of O
nucleosomal O
histone I-GENE
acetylation O
and O
alteration O
of O
chromatin O
structure O
. O

Recombinant I-GENE
BRI1 I-GENE
- I-GENE
KD I-GENE
autophosphorylated O
on O
serine O
( O
Ser O
) O
and O
threonine O
( O
Thr O
) O
residues O
with O
p O
- O
Ser O
predominating O
. O

Flow O
cytomery O
was O
used O
for O
cell O
cycle O
analysis O
. O

Further O
research O
is O
required O
to O
better O
measure O
treatment O
effects O
, O
modification O
of O
MS O
natural O
history O
, O
and O
net O
societal O
costs O
of O
IFN I-GENE
beta I-GENE
- I-GENE
1b I-GENE
in O
RRMS O
. O

Cost O
- O
effectiveness O
of O
interferon I-GENE
beta I-GENE
- I-GENE
1b I-GENE
in O
slowing O
multiple O
sclerosis O
disability O
progression O
. O

Both O
the O
Cmax O
and O
AUC O
values O
were O
almost O
doubled O
with O
doubling O
the O
dose O
. O

Hyperactivation O
of O
Cdc2 I-GENE
in O
fission O
yeast O
causes O
cells O
to O
undergo O
a O
lethal O
premature O
mitosis O
called O
mitotic O
catastrophe O
. O

Diary O
. O

Cells O
differentiate O
in O
response O
to O
various O
extracellular O
stimuli O
. O

Transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
) O
can O
act O
as O
a O
tumor O
suppressor O
or O
a O
tumor O
promoter O
depending O
on O
the O
characteristics O
of O
the O
malignant O
cell O
. O

Vasoactive I-GENE
intestinal I-GENE
peptide I-GENE
and O
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
inhibit O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
activation O
at O
multiple O
levels O
in O
the O
human O
monocytic O
cell O
line O
THP O
- O
1 O
. O

Mn2 O
+ O
increased O
both O
the O
junction O
binding O
and O
cleaving O
activities O
of O
the O
mutant O
proteins O
. O

While O
Pt I-GENE
; I-GENE
cycH I-GENE
; I-GENE
1 I-GENE
and O
Os I-GENE
; I-GENE
cycH I-GENE
; I-GENE
1 I-GENE
were O
expressed O
in O
all O
tissues O
examined O
, O
the O
transcripts O
accumulated O
abundantly O
in O
dividing O
cells O
. O

Moreover O
, O
an O
in O
vitro O
pull O
- O
down O
assay O
showed O
that O
Os I-GENE
; I-GENE
CycH I-GENE
; I-GENE
1 I-GENE
specifically O
bound O
to O
R2 I-GENE
but O
not O
to O
other O
rice I-GENE
CDKs I-GENE
. O

In O
transient O
analysis O
using O
particle O
bombardment O
of O
tobacco O
leaf O
sections O
, O
a O
tetramer O
of O
the O
distB O
ABRE O
( O
abscisic O
acid O
- O
responsive O
element O
) O
mediated O
transactivation O
by O
ABI3 I-GENE
and O
ABI3 I-GENE
- O
dependent O
response O
to O
ABA O
, O
whereas O
a O
tetramer O
of O
the O
composite O
RY O
/ O
G O
complex O
, O
containing O
RY O
repeats O
and O
a O
G O
- O
box O
, O
mediated O
only O
ABA O
- O
independent O
transactivation O
by O
ABI3 I-GENE
. O

The O
major O
neurological O
manifestations O
of O
brain O
injury O
in O
these O
babies O
are O
spastic O
motor O
deficits O
. O

Spores O
from O
Rhizopus O
stolonifer O
were O
suspended O
in O
distilled O
water O
( O
1 O
x O
10 O
( O
6 O
) O
spores O
/ O
mL O
) O
and O
used O
as O
starter O
. O

Overexpression O
of O
Trdpm1 I-GENE
in O
a O
dpm1 O
(+):: O
his7 I-GENE
/ I-GENE
dpm1 I-GENE
(+) I-GENE
S O
. O
pombe O
diploid O
resulted O
in O
a O
4 O
- O
fold O
increase O
in O
specific O
DPM I-GENE
synthase I-GENE
activity O
. O

The O
LMW I-GENE
FGF I-GENE
- I-GENE
2 I-GENE
up O
- O
regulated O
the O
PKC I-GENE
epsilon I-GENE
levels O
by O
1 O
. O
6 O
- O
fold O
; O
by O
contrast O
the O
HMW I-GENE
isoform I-GENE
down O
- O
regulated O
the O
level O
of O
this O
PKC I-GENE
isotype I-GENE
by O
about O
3 O
- O
fold O
and O
increased O
the O
amount O
of O
PKC I-GENE
delta I-GENE
by O
1 O
. O
7 O
- O
fold O
. O

Helicobacter O
pylori O
and O
stomach O
diseases O
: O
from O
clinical O
point O
of O
view O

For O
this O
purpose O
, O
the O
writhing O
test O
, O
capsaicin O
and O
formalin O
induced O
- O
pain O
in O
mice O
were O
used O
. O

2000 O
update O
of O
recommendations O
for O
the O
use O
of O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
: O
evidence O
- O
based O
, O
clinical O
practice O
guidelines O
. O

Prominent O
findings O
were O
chronic O
pancreatitis O
with O
acinar O
and O
ductal O
plugs O
, O
granulomatous O
and O
necrotizing O
peripancreatic O
steatitis O
, O
degenerative O
myopathy O
, O
testicular O
atrophy O
, O
candidiasis O
and O
bacterial O
necrotizing O
glossitis O
. O

Taken O
together O
, O
our O
data O
indicate O
that O
multiple O
survival O
pathways O
are O
triggered O
via O
this O
receptor O
, O
whereas O
NF I-GENE
- I-GENE
kappaB I-GENE
/ O
Rel I-GENE
and O
PI I-GENE
- I-GENE
3K I-GENE
are O
crucial O
for O
CD40 I-GENE
- O
induced O
proliferation O
. O

In O
vitro O
, O
Arix I-GENE
and O
NBPhox I-GENE
form O
DNA O
- O
independent O
multimers O
and O
exhibit O
cooperative O
binding O
to O
the O
DB1 I-GENE
regulatory I-GENE
element I-GENE
, O
which O
contains O
two O
homeodomain I-GENE
recognition I-GENE
sites I-GENE
. O

We O
conclude O
from O
this O
study O
that O
Arix I-GENE
and O
NBPhox I-GENE
exhibit O
indistinguishable O
and O
independent O
transcriptional O
regulatory O
properties O
on O
the O
DBH I-GENE
promoter I-GENE
. O

METHODS O
AND O
RESULTS O
: O
Studies O
were O
undertaken O
in O
9 O
isolated O
guinea O
pig O
hearts O
, O
which O
demonstrated O
reverse O
use O
- O
dependent O
prolongation O
of O
cardiac O
repolarization O
by O
100 O
nmol O
/ O
L O
domperidone O
. O

The O
N O
- O
terminal O
small O
segment O
of O
yeast I-GENE
TAF145 I-GENE
( O
yTAF145 I-GENE
) O
binds O
to O
TBP I-GENE
and O
thereby O
inhibits O
TBP I-GENE
function O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
overall O
performance O
of O
a O
new O
oscillometric O
wrist O
blood O
pressure O
monitor O
( O
Braun O
PrecisionSensor O
, O
Braun O
GmbH O
, O
Kronberg O
, O
Germany O
) O
as O
defined O
by O
the O
ANSI O
/ O
AAMI O
SP10 O
- O
1992 O
guidelines O
, O
and O
to O
analyze O
the O
data O
for O
the O
optimized O
selection O
of O
the O
algorithm O
that O
derives O
the O
blood O
pressure O
values O
from O
the O
oscillometric O
blood O
pressure O
curves O
. O

Following O
the O
results O
of O
toxicological O
experiments O
in O
the O
target O
animals O
" O
Toxicological O
Drinking O
Water O
Standards O
for O
Animals O
" O
can O
be O
established O
. O

An O
increase O
in O
hypothalamic O
expression O
of O
at O
least O
two O
of O
the O
erbB I-GENE
receptors I-GENE
is O
initiated O
before O
the O
pubertal O
augmentation O
of O
gonadal O
steroid O
secretion O
and O
is O
completed O
on O
the O
day O
of O
the O
first O
preovulatory O
surge O
of O
gonadotropins I-GENE
. O

Dsh I-GENE
is O
required O
for O
two O
different O
pathways O
, O
the O
Wnt I-GENE
pathway O
and O
planar O
polarity O
pathway O
in O
Drosophila O
. O

Catch O
- O
up O
growth O
and O
craniofacial O
dimensions O
following O
administration O
of O
the O
antineoplastic O
agent O
vincristine O
to O
young O
rats O
. O

CONCLUSIONS O
: O
LSCC O
malformation O
, O
like O
other O
inner O
ear O
malformations O
such O
as O
large O
vestibular O
aqueduct O
and O
X O
- O
linked O
mixed O
deafness O
with O
perilymph O
gusher O
, O
can O
be O
associated O
with O
CHL O
, O
SNHL O
, O
or O
normal O
hearing O
. O

Escalation O
to O
180 O
mg O
/ O
m2 O
was O
to O
be O
carried O
out O
if O
white O
blood O
cell O
nadir O
count O
was O
> O
2 O
. O
0 O
x O
10 O
( O
9 O
)/ O
l O
and O
platelet O
nadir O
count O
was O
> O
75 O
x O
10 O
( O
9 O
)/ O
l O
. O

Methyl O
formate O
was O
used O
as O
the O
solvent O
of O
biodegradable O
oligoesters O
for O
the O
fabrication O
of O
microspheres O
with O
encapsulated O
bovine I-GENE
serum I-GENE
albumin I-GENE
( O
BSA I-GENE
). O

The O
small I-GENE
monomeric I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
of O
the O
RAB I-GENE
subfamily I-GENE
are O
key O
regulatory O
elements O
of O
the O
machinery O
that O
controls O
membrane O
traffic O
in O
eukaryotic O
cells O
. O

Furthermore O
, O
loss O
of O
methylation O
also O
greatly O
reduced O
the O
association O
of O
another O
yeast O
B O
- O
type O
subunit O
, O
Rts1p I-GENE
. O

Thus O
, O
methylation O
of O
Pph21p I-GENE
is O
important O
for O
formation O
of O
PP2A I-GENE
trimeric I-GENE
and I-GENE
dimeric I-GENE
complexes I-GENE
, O
and O
consequently O
, O
for O
PP2A I-GENE
function O
. O

The O
purpose O
of O
this O
study O
was O
to O
analyze O
the O
temporal O
characteristics O
and O
the O
spatial O
mapping O
of O
the O
independent O
components O
identified O
by O
ICA O
when O
the O
subject O
performs O
a O
finger O
- O
tapping O
task O
. O

The O
authors O
present O
the O
only O
two O
studies O
that O
have O
proved O
successful O
in O
treating O
animal O
models O
of O
osteoarthritis O
using O
gene O
therapy O
, O
and O
propose O
an O
overview O
of O
several O
strategies O
for O
the O
development O
of O
gene O
therapy O
in O
osteoarthritis O
treatment O
in O
the O
future O
. O

Together O
, O
these O
results O
indicate O
that O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
induces O
VEGF I-GENE
gene I-GENE
expression O
at O
both O
transcriptional O
and O
post O
- O
transcriptional O
levels O
, O
and O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
evokes O
p38 I-GENE
MAPK O
and O
JNK I-GENE
signalings O
, O
which O
in O
turn O
stimulate O
the O
transcription O
of O
the O
VEGF I-GENE
gene I-GENE
through O
Sp1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Binding O
of O
NusA I-GENE
to O
RNA O
in O
the O
presence O
of O
alpha O
or O
N O
involves O
an O
amino I-GENE
- I-GENE
terminal I-GENE
S1 I-GENE
homology I-GENE
region I-GENE
that O
is O
otherwise O
inactive O
in O
full I-GENE
- I-GENE
length I-GENE
NusA I-GENE
. O

The O
subjects O
were O
diagnosed O
on O
the O
basis O
of O
DSM O
- O
IV O
pathological O
gambling O
criteria O
and O
completed O
the O
Turkish O
Version O
of O
South O
Oaks O
Gambling O
Screen O
( O
SOGS O
). O

Lys O
( O
193 O
) O
and O
Arg O
( O
194 O
), O
located O
at O
the O
COOH O
- O
terminal O
end O
of O
HD I-GENE
, O
are O
essential O
for O
dimerization O
. O

Elevation O
of O
intracellular O
Ca O
( O
2 O
+) O
levels O
are O
also O
involved O
because O
treatment O
with O
receptor O
- O
associated O
protein O
, O
nifedipine O
, O
MK801 O
, O
removal O
of O
Ca O
( O
2 O
+) O
from O
the O
medium O
and O
dantrolene O
all O
served O
to O
inhibit O
calcium O
elevation O
and O
attenuate O
the O
activation O
of O
CREB I-GENE
. O

The O
present O
study O
shows O
that O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
- O
dependent O
p38 I-GENE
kinase I-GENE
activation O
regulates O
Akt I-GENE
phosphorylation O
and O
activity O
in O
human O
neutrophils O
. O

When O
BFDS O
was O
taken O
as O
the O
reference O
, O
W O
/ O
A O
Z O
scores O
showed O
consistent O
positive O
increments O
, O
from O
birth O
in O
girls O
and O
1 O
mo O
in O
boys O
. O

These O
probable O
border O
sequences O
are O
closely O
related O
to O
those O
of O
other O
known O
T O
- O
regions O
and O
define O
a O
second O
T O
- O
region O
of O
pTiChry5 O
, O
called O
T O
- O
right O
( O
TR O
), O
that O
confers O
production O
of O
the O
Amadoriopines O
. O

Using O
purified O
recombinant I-GENE
HMG I-GENE
I I-GENE
, O
we O
have O
identified O
several O
high O
- O
affinity O
binding O
sites O
which O
overlap O
important O
transcription O
factor O
binding O
sites O
. O

High I-GENE
- I-GENE
mobility I-GENE
- I-GENE
group I-GENE
protein I-GENE
I I-GENE
can O
modulate O
binding O
of O
transcription O
factors O
to O
the O
U5 I-GENE
region I-GENE
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
proviral I-GENE
promoter I-GENE
. O

Another O
cis O
- O
acting O
element O
, O
exonic O
splicing O
suppressor O
1 O
( O
ESS1 O
), O
represses O
use O
of O
the O
nt O
3225 O
3 O
' O
splice O
site O
. O

Leptinaemia O
does O
not O
correlate O
with O
the O
actual O
or O
mean O
blood O
pressure O
reading O
nor O
with O
stage O
of O
hypertension O
according O
to O
the O
WHO O
classification O
. O

5 O
'- O
RACE O
analysis O
suggested O
a O
single O
transcription O
initiation O
site O
187 O
bp O
upstream O
from O
the O
translational O
start O
site O
. O

Thus O
, O
diamide O
treatment O
of O
nuclear O
extracts O
strongly O
reduces O
the O
binding O
of O
NFI I-GENE
proteins I-GENE
, O
and O
the O
addition O
of O
higher O
concentrations O
of O
dithiothreitol O
to O
nuclear O
extracts O
from O
TG I-GENE
- O
treated O
cells O
restores O
NFI I-GENE
- I-GENE
DNA I-GENE
binding O
to O
levels O
in O
extracts O
from O
untreated O
cells O
. O

LMP2A I-GENE
enhances O
Lyn I-GENE
and O
Syk I-GENE
ubiquitination O
in O
vivo O
in O
a O
fashion O
that O
depends O
on O
the O
activity O
of O
Nedd4 I-GENE
family O
members O
and O
correlates O
with O
destabilization O
of O
the O
Lyn I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Further O
, O
Tax I-GENE
- O
mediated O
apoptosis O
was O
effectively O
prevented O
by O
ectopic O
expression O
of O
the O
p300 I-GENE
coactivator I-GENE
. O

Our O
results O
, O
however O
, O
were O
obtained O
for O
Z O
itself O
and O
not O
for O
[ O
Z O
]. O

Fisher O
' O
s O
exact O
test O
or O
Pearson O
' O
s O
chi2 O
test O
were O
used O
for O
statistical O
analysis O
. O

RESULTS O
: O
In O
the O
pregnant O
group O
, O
serum O
PP14 I-GENE
concentrations O
were O
markedly O
increased O
after O
ET O
, O
and O
a O
significant O
difference O
between O
the O
pregnant O
group O
and O
the O
nonpregnant O
group O
was O
observed O
8 O
days O
following O
ET O
( O
p O
< O
0 O
. O
01 O
). O

Thromboelastography O
is O
a O
test O
that O
could O
potentially O
correlate O
with O
the O
degree O
of O
anticoagulation O
produced O
by O
low O
molecular O
weight O
heparin O
. O

High O
expression O
of O
the O
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
alpha I-GENE
( O
PPARalpha I-GENE
) O
differentiates O
brown O
fat O
from O
white O
, O
and O
is O
related O
to O
its O
high O
capacity O
of O
lipid O
oxidation O
. O

This O
- O
2485 O
/- O
2458 O
element O
bound O
PPARalpha I-GENE
and O
PPARgamma I-GENE
from O
brown O
fat O
nuclei O
. O

These O
results O
provide O
direct O
evidence O
for O
differential O
susceptibility O
to O
endonuclease O
- O
mediated O
mRNA O
decay O
resulting O
from O
the O
differential O
affinity O
of O
a O
RNA O
- O
binding O
protein O
for O
cis O
- O
acting O
stability O
determinants O
. O

RESULTS O
: O
Twenty O
- O
two O
( O
26 O
%) O
patients O
had O
PHG O
before O
( O
group O
A O
) O
and O
64 O
( O
74 O
%) O
developed O
PHG O
after O
variceal O
eradication O
( O
group O
B O
). O

Response O
was O
extremely O
poor O
in O
African O
Americans O
and O
those O
with O
HCV O
genotype O
1 O
. O

Aspirin O
causes O
peptic O
ulcers O
predominately O
by O
reducing O
gastric I-GENE
mucosal I-GENE
cyclooxygenase I-GENE
( O
COX I-GENE
) O
activity O
and O
prostaglandin O
synthesis O
. O

A O
total O
of O
1060 O
clones O
were O
randomly O
selected O
for O
sequencing O
of O
one O
end O
. O

Expression O
of O
a O
hybrid O
protein O
containing O
the O
cytoplasmic O
C O
- O
terminal O
half O
of O
UhpB I-GENE
fused O
to O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
also O
interfered O
with O
Uhp I-GENE
signaling O
. O

CONCLUSIONS O
: O
The O
surgical O
or O
multimodality O
treatment O
of O
MSGT O
has O
provided O
a O
good O
locoregional O
control O
( O
78 O
%) O
and O
68 O
% O
10 O
- O
year O
survival O
in O
a O
series O
of O
patients O
treated O
at O
the O
oncology O
department O
of O
a O
general O
hospital O
in O
Quito O
, O
Ecuador O
. O

RESULTS O
: O
Glaucoma O
suspects O
were O
divided O
into O
two O
groups O
according O
to O
their O
SWAP O
results O
: O
high O
risk O
( O
with O
SWAP O
abnormalities O
) O
and O
low O
risk O
( O
with O
normal O
SWAP O
result O
). O

The O
gene O
is O
separated O
into O
four O
exons O
by O
three O
short O
introns O
, O
and O
the O
open O
reading O
frame O
consists O
of O
6660 O
base O
pairs O
( O
bp O
) O
capable O
of O
encoding O
a O
polypeptide O
of O
2220 O
amino O
acid O
residues O
. O

Like O
the O
p190 I-GENE
- I-GENE
B I-GENE
exon O
, O
the O
first O
exon O
of O
p190 I-GENE
- I-GENE
A I-GENE
is O
extremely O
large O
( O
3 O
. O
7 O
kb O
in O
length O
), O
encoding O
both O
the O
GTPase I-GENE
and O
middle O
domains O
( O
residues O
1 O
- O
1228 O
), O
but O
not O
the O
remaining O
GAP I-GENE
domain I-GENE
, O
suggesting O
a O
high O
conservation O
of O
genomic O
structure O
between O
two O
p190 I-GENE
genes I-GENE
. O

The O
entire O
human I-GENE
teneurin I-GENE
- I-GENE
1 I-GENE
( O
TEN1 I-GENE
) O
gene O
is O
contained O
in O
eight O
PAC O
clones O
representing O
part O
of O
the O
chromosomal O
locus O
Xq25 O
. O

The O
plexiform O
neurofibroma O
and O
multiple O
localized O
neurofibromas O
are O
characteristic O
of O
NF1 I-GENE
. O

In O
general O
lookback O
, O
all O
patients O
who O
received O
blood O
before O
being O
tested O
for O
hepatitis O
C O
are O
advised O
to O
undergo O
testing O
. O

The O
proposed O
algorithm O
consists O
of O
several O
steps O
. O

It O
contained O
seven O
extra O
amino O
acids O
of O
FVVLNLQ O
; O
this O
short O
stretch O
of O
extra O
sequence O
was O
found O
between O
Gln O
( O
421 O
) O
and O
Phe O
( O
422 O
) O
within O
the O
SET I-GENE
( O
Suvar3 I-GENE
- I-GENE
9 I-GENE
, O
Enhancer I-GENE
- I-GENE
of I-GENE
- I-GENE
zeste I-GENE
, O
Trithorax I-GENE
) O
interacting O
domain O
( O
SID O
) O
of O
rMTM I-GENE
. O

MED1 I-GENE
has O
a O
weak O
glycosylase I-GENE
activity O
on O
the O
mutagenic O
adduct O
3 O
, O
N O
( O
4 O
)- O
ethenocytosine O
, O
a O
metabolite O
of O
vinyl O
chloride O
and O
ethyl O
carbamate O
. O

There O
were O
no O
instances O
of O
major O
flap O
necrosis O
although O
two O
flaps O
showed O
tip O
ischaemia O
. O

These O
results O
suggest O
that O
XAB1 I-GENE
is O
a O
novel O
cytoplasmic I-GENE
GTPase I-GENE
involved O
in O
nuclear O
localization O
of O
XPA I-GENE
. O

One O
of O
these O
factors O
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
was O
initially O
cloned O
as O
an O
antagonistic O
counterpart O
to O
IRF I-GENE
- I-GENE
1 I-GENE
with O
oncogenic O
potential O
. O

Among O
the O
total O
CDSs O
, O
8 O
. O
8 O
% O
match O
sequences O
of O
proteins O
found O
only O
in O
Bacillus O
subtilis O
and O
66 O
. O
7 O
% O
are O
widely O
conserved O
in O
comparison O
with O
the O
proteins O
of O
various O
organisms O
, O
including O
B O
. O
subtilis O
. O

Tobramycin O
- O
loaded O
SLN O
administered O
i O
. O
v O
. O
showed O
a O
prolonged O
circulation O
time O
compared O
to O
the O
i O
. O
v O
. O
administered O
tobramycin O
solution O
. O

Bacteriol O
. O

Terminal I-GENE
deoxynucleotidyl I-GENE
transferase I-GENE
- O
mediated O
nick O
end O
labeling O
assays O
revealed O
that O
hormonal O
activation O
of O
the O
PAX3 I-GENE
repressors I-GENE
induced O
extensive O
apoptosis O
that O
correlated O
with O
down O
- O
regulation O
of O
BCL I-GENE
- I-GENE
X I-GENE
( I-GENE
L I-GENE
) I-GENE
expression O
. O

VEGF I-GENE
promoter I-GENE
activity O
in O
transient O
transfections O
was O
decreased O
by O
either O
pharmacological O
or O
genetic O
inhibition O
of O
EGFR I-GENE
, O
Ras I-GENE
, O
or O
phosphatidylinositol I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
[ O
PI O
( O
3 O
) O
kinase O
]. O

Epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
transcriptionally O
up O
- O
regulates O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
expression O
in O
human O
glioblastoma O
cells O
via O
a O
pathway O
involving O
phosphatidylinositol I-GENE
3 I-GENE
'- I-GENE
kinase I-GENE
and O
distinct O
from O
that O
induced O
by O
hypoxia O
. O

Thus O
, O
IHHNV O
is O
closely O
related O
to O
densoviruses O
of O
the O
genus O
Brevidensovirus O
in O
the O
family O
Parvoviridae O
, O
and O
we O
therefore O
propose O
to O
rename O
this O
virus O
Penaeus O
stylirostris O
densovirus O
( O
PstDNV O
). O

Stress I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
( O
SAPK1 I-GENE
), O
also O
called O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
), O
becomes O
activated O
in O
vivo O
in O
response O
to O
pro O
- O
inflammatory O
cytokines O
or O
cellular O
stresses O
. O

Catalytic O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( I-GENE
MAP I-GENE
) I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
by O
binding O
to O
p38 I-GENE
MAP I-GENE
kinase I-GENE
: O
critical O
role O
of O
the O
p38 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
in O
its O
negative O
regulation O
. O

Thus O
, O
the O
class I-GENE
C I-GENE
- O
Vps I-GENE
complex O
directs O
multiple O
reactions O
during O
the O
docking O
and O
fusion O
of O
vesicles O
with O
the O
vacuole O
, O
each O
of O
which O
contributes O
to O
the O
overall O
specificity O
and O
efficiency O
of O
this O
transport O
process O
. O

Combined O
intravenous O
and O
intra O
- O
arterial O
recombinant O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
acute O
ischemic O
stroke O
. O

To O
begin O
to O
understand O
this O
role O
, O
we O
overexpressed O
ATF I-GENE
- I-GENE
2 I-GENE
in O
a O
human O
cancer O
cell O
line O
. O

Signal O
transduction O
via O
modulation O
of O
phosphorylation O
after O
selective O
inhibition O
of O
protein I-GENE
phosphatase I-GENE
( I-GENE
PP I-GENE
) I-GENE
1 I-GENE
and O
/ O
or O
PP2A I-GENE
appears O
to O
play O
a O
role O
in O
okadaic O
acid O
( O
OA O
)- O
mediated O
effects O
. O

Botulinum I-GENE
toxin I-GENE
A I-GENE
in O
the O
treatment O
of O
hemiplegic O
spastic O
foot O
drop O
-- O
clinical O
and O
functional O
outcomes O
. O

Exon O
A O
is O
located O
approximately O
7 O
kb O
5 O
' O
to O
the O
HSL I-GENE
translation I-GENE
start I-GENE
site I-GENE
. O

NF I-GENE
- I-GENE
kappaB I-GENE
is O
a O
redox O
- O
sensitive O
transcription O
factor O
known O
to O
be O
activated O
by O
oxidative O
stress O
as O
well O
as O
chemical O
and O
biological O
reductants O
. O

Cardiovascular O
risk O
factors O
and O
antihypertensive O
treatment O
. O

What O
to O
look O
for O
during O
a O
compliance O
review O
: O
10 O
common O
mistakes O
made O
by O
SNFs O
. O

CONCLUSIONS O
: O
EBCT O
technology O
allows O
minimally O
invasive O
evaluation O
of O
intramyocardial O
microcirculatory O
function O
and O
permits O
assessment O
of O
microvascular O
BV O
distribution O
in O
different O
functional O
components O
. O

These O
two O
mAbs O
used O
the O
same O
V O
( O
H O
) O
and O
J O
( O
H O
) O
gene O
segments O
, O
but O
different O
D O
, O
Vkappa O
, O
and O
Jkappa O
genes O
. O

SSF O
experiments O
were O
carried O
out O
in O
bench O
- O
scale O
bioreactors O
( O
equipped O
with O
CO2 O
and O
volatile O
organic O
traps O
) O
containing O
a O
mixture O
of O
lignocellulosic O
materials O
and O
a O
radiolabeled O
pesticide O
. O

Characterization O
of O
a O
Xenopus I-GENE
laevis I-GENE
CXC I-GENE
chemokine I-GENE
receptor I-GENE
4 I-GENE
: O
implications O
for O
hematopoietic O
cell O
development O
in O
the O
vertebrate O
embryo O
. O

Patients O
had O
to O
have O
adequate O
liver O
, O
renal O
, O
and O
marrow O
functions O
. O

Inhibition O
of O
RNA2 I-GENE
translation O
was O
selective O
, O
with O
no O
effect O
on O
general O
cellular O
translation O
or O
translation O
of O
BMV O
RNA1 I-GENE
- O
encoded O
replication I-GENE
factor I-GENE
1a I-GENE
, O
and O
was O
independent O
of O
p20 I-GENE
, O
a O
cellular O
antagonist O
of O
DED1 I-GENE
function O
in O
translation O
. O

Abbreviations O
: O
CAS I-GENE
, O
CRK I-GENE
- I-GENE
associated I-GENE
substrate I-GENE
; O
CH I-GENE
, O
calponin I-GENE
- I-GENE
homology I-GENE
domain I-GENE
; O
CSK I-GENE
, O
C I-GENE
- I-GENE
terminal I-GENE
SRC I-GENE
kinase I-GENE
; O
E6 I-GENE
, O
Papillomavirus I-GENE
E6 I-GENE
protein I-GENE
; O
FAK I-GENE
, O
focal I-GENE
adhesion I-GENE
kinase I-GENE
; O
GIT I-GENE
, O
GRK I-GENE
interacter I-GENE
; O
GPCR I-GENE
, O
heterotrimeric I-GENE
- I-GENE
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
; O
GRK I-GENE
, O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
; O
MAPK I-GENE
, O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ERK I-GENE
, O
p38 I-GENE
, O
JNK I-GENE
); O
PAK I-GENE
, O
p21 I-GENE
- I-GENE
activated I-GENE
kinase I-GENE
; O
PBS I-GENE
, O
paxillin I-GENE
- I-GENE
binding I-GENE
subdomain I-GENE
; O
PIX I-GENE
, O
PAK I-GENE
- I-GENE
interacting I-GENE
exchange I-GENE
factor I-GENE
; O
PKL I-GENE
, O
paxillin I-GENE
kinase I-GENE
linker I-GENE
; O
POR1 I-GENE
, O
partner I-GENE
of I-GENE
Rac I-GENE
; O
PS O
, O
phosphoserine O
; O
PT O
, O
phosphothreonine O
; O
PY O
, O
phosphotyrosine O
; O
RTK I-GENE
, O
growth I-GENE
factor I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
; O
SH I-GENE
, O
SRC I-GENE
- I-GENE
homology I-GENE
domain I-GENE
. O

In O
15 O
ventilator O
- O
dependent O
, O
SB O
, O
and O
actively O
expiring O
patients O
, O
we O
found O
that O
the O
difference O
PEEP O
( O
i O
), O
dyn O
- O
Pga O
, O
total O
decay O
( O
mean O
+/- O
SD O
, O
5 O
. O
7 O
+/- O
1 O
. O
9 O
cm O
H O
( O
2 O
) O
O O
) O
was O
quite O
similar O
to O
PEEP O
( O
i O
), O
dyn O
ref O
( O
5 O
. O
3 O
+/- O
1 O
. O
9 O
cm O
H O
( O
2 O
) O
O O
). O

Of O
208 O
eligible O
subjects O
, O
82 O
received O
supervised O
IPT O
at O
a O
dose O
of O
900 O
mg O
twice O
weekly O
for O
6 O
mo O
( O
Regimen O
A O
), O
73 O
received O
unsupervised O
IPT O
900 O
mg O
twice O
weekly O
for O
6 O
mo O
( O
Regimen O
B O
), O
and O
53 O
received O
unsupervised O
IPT O
300 O
mg O
daily O
for O
6 O
mo O
( O
Regimen O
C O
). O

There O
were O
122 O
cases O
of O
tuberculosis O
over O
an O
average O
10 O
. O
3 O
yr O
of O
follow O
- O
up O
( O
crude O
annual O
incidence O
, O
76 O
. O
2 O
/ O
100 O
, O
000 O
). O

These O
results O
suggested O
that O
BACH1t I-GENE
recruits O
BACH1 I-GENE
to O
the O
nucleus O
through O
BTB I-GENE
domain O
- O
mediated O
interaction O
. O

The O
U17 I-GENE
/ O
U16 I-GENE
and O
the O
U16 I-GENE
+ I-GENE
gene I-GENE
products I-GENE
transactivated O
the O
HIV I-GENE
LTR I-GENE
. O

Transcription O
of O
the O
six O
EBNA I-GENE
genes I-GENE
, O
which O
are O
expressed O
in O
EBV O
- O
immortalized O
primary O
B O
cells O
, O
arises O
from O
one O
of O
two O
promoters O
, O
Cp I-GENE
and O
Wp I-GENE
, O
located O
near O
the O
left O
end O
of O
the O
viral O
genome O
. O

The O
Cili I-GENE
- I-GENE
2 I-GENE
sequences I-GENE
possess O
similarity O
to O
the O
RNaseH I-GENE
domain I-GENE
of O
Lian I-GENE
- O
Aa1 I-GENE
, O
a O
mosquito I-GENE
non I-GENE
- I-GENE
LTR I-GENE
retrotransposon I-GENE
. O

This O
dynamic O
response O
strongly O
suggests O
that O
the O
p53 I-GENE
and O
Rb I-GENE
tumor O
suppressor O
pathways O
are O
intact O
in O
HeLa O
cells O
and O
that O
repression O
of O
HPV I-GENE
E6 I-GENE
and O
E7 I-GENE
mobilizes O
these O
pathways O
in O
an O
orderly O
fashion O
to O
deliver O
growth O
inhibitory O
signals O
to O
the O
cells O
. O

Thus O
, O
blocks O
in O
the O
RARalpha I-GENE
- O
specific O
pathway O
of O
retinoid O
- O
induced O
differentiation O
may O
be O
bypassed O
during O
retinoid O
induction O
of O
FR I-GENE
- I-GENE
beta I-GENE
expression O
. O

Is O
more O
better O
? O
About O
dose O
levels O
of O
ACE I-GENE
inhibitors O
in O
chronic O
heart O
failure O
. O

To O
test O
whether O
or O
not O
SOCS I-GENE
- I-GENE
3 I-GENE
also O
binds O
to O
the O
IGFIR I-GENE
, O
we O
cloned O
human I-GENE
SOCS I-GENE
- I-GENE
3 I-GENE
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
from O
human O
skeletal O
muscle O
mRNA O
. O

A O
protein O
lacking O
the O
SH2 I-GENE
and O
RING O
finger O
domains O
has O
no O
activity O
, O
but O
a O
chimeric O
protein O
with O
the O
SH2 I-GENE
and O
RING O
finger O
domains O
of O
SLI I-GENE
- I-GENE
1 I-GENE
replaced O
by O
the O
equivalent O
domains O
of O
c I-GENE
- I-GENE
Cbl I-GENE
has O
activity O
. O

To O
evaluate O
the O
effects O
of O
HRT O
on O
those O
factors O
in O
end O
- O
stage O
renal O
disease O
( O
ESRD O
) O
patients O
, O
we O
evaluated O
the O
changes O
of O
lipid O
profile O
, O
coagulation O
and O
fibrinolysis O
markers O
, O
and O
plasma O
homocysteine O
levels O
after O
treatment O
. O

There O
was O
a O
weak O
significant O
correlation O
between O
TGF I-GENE
beta I-GENE
1 I-GENE
levels O
and O
normal O
cell O
radiosensitivity O
( O
lymphocyte O
SF2 O
). O

Acute O
feasibility O
and O
safety O
of O
a O
smoking O
reduction O
strategy O
for O
smokers O
with O
schizophrenia O
. O

Tightly O
ordered O
proteasomal O
degradation O
of O
proteins O
critical O
for O
cell O
cycle O
control O
implies O
a O
role O
of O
the O
proteasome O
in O
maintaining O
cell O
proliferation O
and O
cell O
survival O
. O

The O
sixth O
nucleotide O
was O
bulged O
out O
to O
allow O
stacking O
of O
this O
U O
. O
G O
pair O
on O
the O
adjacent O
helical O
region O
. O

Functional O
analysis O
of O
the O
mutant I-GENE
desmin I-GENE
in O
SW13 O
( O
vim I-GENE
-) O
cells O
showed O
aggregation O
of O
abnormal O
coarse O
clumps O
of O
desmin I-GENE
positive O
material O
dispersed O
throughout O
the O
cytoplasm O
. O

Patients O
with O
lesions O
affecting O
the O
PRC O
but O
sparing O
the O
PHC O
, O
and O
patients O
with O
lesions O
affecting O
both O
PRC O
and O
PHC O
, O
performed O
an O
oculomotor O
delayed O
response O
task O
with O
unpredictably O
varied O
memory O
delays O
of O
up O
to O
30 O
s O
. O

In O
addition O
, O
26 O
amino O
acid O
residues O
, O
K69 O
, O
D88 O
, O
E94 O
, O
D134 O
, O
R154 O
, O
K169 O
, O
H197 O
, O
D233 O
, O
G235 O
, O
G236 O
, O
G237 O
, O
F238 O
, O
E274 O
, O
G276 O
, O
R277 O
, O
Y278 O
, O
K294 O
, O
Y323 O
, O
Y331 O
, O
D332 O
, O
C360 O
, O
D361 O
, O
D364 O
, O
G387 O
, O
Y389 O
, O
and O
F397 O
( O
mouse O
ODC I-GENE
numbering O
), O
all O
of O
which O
are O
implicated O
in O
the O
formation O
of O
the O
pyridoxal O
phosphate O
- O
binding O
domain O
and O
the O
substrate O
- O
binding O
domain O
and O
in O
dimer O
stabilization O
with O
the O
eukaryotic O
ODCs I-GENE
, O
were O
also O
conserved O
in O
S O
. O
ruminantium O
LDC I-GENE
. O

The O
Psc2 I-GENE
cDNA I-GENE
contained O
an O
open O
reading O
frame O
homologous O
to O
CP2 I-GENE
family I-GENE
proteins I-GENE
. O

Our O
results O
indicate O
that O
Shh I-GENE
can O
drive O
continued O
cycling O
in O
immature O
, O
proliferating O
CGNPs O
. O

The O
QT O
interval O
was O
related O
to O
various O
components O
of O
the O
insulin I-GENE
resistance O
syndrome O
, O
including O
BP O
and O
insulin I-GENE
sensitivity O
. O

The O
wavenumbers O
corresponding O
to O
the O
normal O
modes O
of O
vibration O
were O
calculated O
using O
the O
DFT O
( O
B3LYP O
/ O
6 O
- O
31G O
**) O
approximation O
and O
their O
agreement O
with O
the O
measured O
values O
improved O
after O
scaling O
of O
the O
associated O
force O
field O
. O

The O
data O
provide O
strong O
evidence O
that O
ThlA I-GENE
is O
involved O
in O
the O
metabolism O
of O
both O
acid O
and O
solvent O
formation O
, O
whereas O
the O
physiological O
function O
of O
ThlB I-GENE
has O
yet O
to O
be O
elucidated O
. O

In O
addition O
, O
npm3 I-GENE
, O
which O
is O
usually O
coactivated O
with O
fgf8 I-GENE
by O
MMTV O
insertion O
, O
was O
not O
up O
- O
regulated O
by O
androgens O
in O
SC O
- O
3 O
cells O
. O

Experiments O
with O
epitope O
- O
tagged O
proteins O
show O
that O
UEV1A I-GENE
is O
a O
nuclear O
protein O
, O
whereas O
both O
Kua I-GENE
and O
Kua I-GENE
- O
UEV I-GENE
localize O
to O
cytoplasmic O
structures O
, O
indicating O
that O
the O
Kua I-GENE
domain I-GENE
determines O
the O
cytoplasmic O
localization O
of O
Kua I-GENE
- O
UEV I-GENE
. O

Stoichiometric O
phosphorylation O
of O
human I-GENE
p53 I-GENE
at O
Ser315 O
stimulates O
p53 I-GENE
- O
dependent O
transcription O
. O
p53 I-GENE
protein I-GENE
activity O
as O
a O
transcription O
factor O
can O
be O
activated O
in O
vivo O
by O
antibodies O
that O
target O
its O
C O
- O
terminal O
negative O
regulatory O
domain O
suggesting O
that O
cellular O
enzymes O
that O
target O
this O
domain O
may O
play O
a O
role O
in O
stimulating O
p53 I-GENE
- O
dependent O
gene O
expression O
. O

Interestingly O
, O
this O
mutant O
cell O
line O
lacks O
expression O
of O
the O
IKK I-GENE
regulatory I-GENE
protein I-GENE
, O
IKKgamma I-GENE
. O

The O
Tax I-GENE
/ O
IKKgamma I-GENE
interaction O
serves O
to O
recruit O
Tax I-GENE
to O
the O
IKK I-GENE
catalytic I-GENE
subunits I-GENE
, O
IKKalpha I-GENE
and O
IKKbeta I-GENE
, O
and O
this O
recruitment O
appears O
to O
be O
an O
essential O
mechanism O
by O
which O
Tax I-GENE
stimulates O
the O
activity O
of O
IKK I-GENE
. O

An O
anchored O
AFLP O
- O
and O
retrotransposon O
- O
based O
map O
of O
diploid O
Avena O
. O

In O
addition O
, O
we O
identified O
a O
novel O
type O
of O
inhibitory O
domain O
in O
the O
N O
- O
terminal O
60 O
amino O
acids O
of O
IRF I-GENE
- I-GENE
1 I-GENE
which O
strongly O
inhibits O
its O
transcriptional O
activity O
. O

Effects O
of O
spatial O
and O
temporal O
smoothing O
on O
stimulated O
brillouin O
scattering O
in O
the O
independent O
- O
hot O
- O
spot O
model O
limit O
The O
influence O
of O
laser O
beam O
smoothing O
on O
stimulated O
Brillouin O
backscattering O
( O
SBBS O
) O
is O
studied O
analytically O
in O
the O
limit O
of O
the O
independent O
hot O
spot O
model O
. O

Simultaneous O
determination O
of O
theophylline O
and O
its O
metabolites O
by O
HPLC O
] O
A O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
method O
has O
been O
developed O
for O
the O
simultaneous O
determination O
of O
theophylline O
and O
its O
metabolites O
, O
with O
caffeine O
and O
its O
metabolites O
. O

Ten O
males O
performed O
both O
test O
conditions O
and O
oxygen O
uptake O
VO2 O
, O
heart O
rate O
, O
minute O
ventilation O
VE O
, O
perceived O
exertion O
and O
spinal O
shrinkage O
were O
recorded O
. O

CONCLUSION O
: O
SPT O
is O
more O
useful O
than O
WST O
in O
differentiating O
patients O
predisposed O
to O
aspiration O
. O

Studied O
groups O
were O
( O
1 O
) O
untreated O
control O
, O
n O
= O
12 O
; O
( O
2 O
) O
FK O
- O
1 O
, O
n O
= O
8 O
; O
( O
3 O
) O
FK O
- O
3 O
, O
n O
= O
8 O
. O

DNA O
binding O
and O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
pull O
- O
down O
assays O
demonstrate O
that O
binding O
requires O
Elk I-GENE
- I-GENE
1 I-GENE
( I-GENE
1 I-GENE
- I-GENE
212 I-GENE
) I-GENE
but O
not O
the O
C O
- O
terminal O
transactivation O
domain O
. O

Unexpectedly O
, O
ALK7 I-GENE
signaling O
produced O
a O
remarkable O
change O
in O
cell O
morphology O
characterized O
by O
cell O
flattening O
and O
elaboration O
of O
blunt O
, O
short O
cell O
processes O
. O

The O
swa2 I-GENE
- I-GENE
1 I-GENE
allele I-GENE
recovered O
from O
the O
original O
screen O
carries O
a O
point O
mutation O
in O
its O
tetratricopeptide O
repeat O
( O
TPR O
) O
domain O
, O
a O
motif O
not O
found O
in O
auxilin I-GENE
but O
known O
in O
other O
proteins O
to O
mediate O
interaction O
with O
heat I-GENE
- I-GENE
shock I-GENE
proteins I-GENE
. O

Association O
of O
stress O
during O
delivery O
with O
increased O
numbers O
of O
nucleated O
cells O
and O
hematopoietic O
progenitor O
cells O
in O
umbilical O
cord O
blood O
. O

In O
slightly O
older O
embryos O
, O
the O
expression O
was O
skewed O
to O
one O
side O
of O
the O
embryo O
and O
by O
E6 O
. O
5 O
, O
at O
the O
onset O
of O
gastrulation O
, O
expression O
was O
seen O
in O
the O
epiblast O
, O
visceral O
endoderm O
, O
nascent O
mesoderm O
, O
and O
the O
primitive O
streak O
. O

Transformation O
of O
the O
sconC3 I-GENE
mutant I-GENE
with O
sconB I-GENE
+ I-GENE
restores O
the O
wild O
- O
type O
phenotype O
. O

The O
authors O
proposed O
that O
the O
highly O
convergent O
inputs O
to O
the O
entorhinal O
cortex O
indicate O
this O
region O
may O
be O
particularly O
important O
for O
selecting O
or O
compressing O
information O
. O

Influence O
of O
oil O
emulsions O
and O
diphenyl O
on O
post O
- O
harvest O
physiconutritional O
changes O
in O
Kagzi O
limes O
( O
Citrus O
aurantifolia O
) O
was O
studied O
. O

Detailed O
analysis O
of O
alpha1 I-GENE
, I-GENE
3GT I-GENE
transcripts I-GENE
revealed O
two O
major O
alternative O
splicing O
patterns O
in O
the O
5 O
'- O
untranslated O
region O
( O
5 O
'- O
UTR O
) O
and O
evidence O
for O
minor O
splicing O
activity O
that O
occurs O
in O
a O
tissue O
- O
specific O
manner O
. O

A O
thermal O
Kubo O
- O
Martin O
- O
Schwinger O
condition O
arises O
due O
to O
the O
coupling O
of O
a O
computer O
to O
a O
strong O
periodic O
source O
, O
namely O
, O
the O
daily O
and O
weekly O
usage O
patterns O
of O
the O
system O
. O

The O
non O
- O
homologous O
sequences O
in O
the O
5 O
' O
untranslated O
regions O
might O
be O
acquired O
at O
or O
after O
transcription O
during O
retrotransposition O
of O
the O
ATLN O
elements O
. O

The O
time O
course O
of O
RNA1 I-GENE
replication O
and O
RNA3 I-GENE
synthesis O
in O
induced O
yeast O
paralleled O
that O
in O
yeast O
transfected O
with O
natural O
FHV O
virion O
RNA O
. O

The O
transcription O
and O
alternative O
splicing O
of O
human I-GENE
ORL1 I-GENE
and O
GAIP I-GENE
are O
cell O
- O
type O
specific O
. O

RESULTS O
: O
The O
main O
effect O
of O
muscle O
pain O
, O
compared O
to O
non O
- O
painful O
stimulation O
, O
was O
a O
significant O
and O
long O
- O
lasting O
increase O
of O
delta O
( O
1 O
- O
3 O
Hz O
) O
power O
and O
an O
alpha O
- O
1 O
( O
9 O
- O
11 O
Hz O
) O
power O
increase O
over O
the O
contralateral O
parietal O
locus O
. O

The O
extraction O
was O
subsequently O
rated O
as O
' O
easy O
' O
or O
' O
difficult O
'. O
Taking O
Pell O
- O
Gregory O
class O
C O
as O
a O
predictor O
of O
a O
' O
difficult O
' O
extraction O
, O
specificity O
was O
88 O
% O
but O
sensitivity O
was O
low O
at O
15 O
%. O

In O
addition O
, O
our O
results O
show O
that O
ERKs I-GENE
and O
PI3Ks I-GENE
can O
synergise O
to O
convert O
ectoderm O
into O
mesoderm O
. O

Based O
on O
16S I-GENE
rRNA I-GENE
gene I-GENE
sequence I-GENE
analysis O
, O
the O
11 O
species O
having O
two O
tuf I-GENE
genes I-GENE
all O
have O
a O
common O
ancestor O
, O
while O
the O
six O
species O
having O
only O
one O
copy O
diverged O
from O
the O
enterococcal O
lineage O
before O
that O
common O
ancestor O
. O

Nevertheless O
, O
protein I-GENE
kinase I-GENE
A I-GENE
stimulation O
induces O
CREMalpha I-GENE
to O
activate O
the O
complex O
native O
promoter O
in O
the O
phosphoenolpyruvate I-GENE
carboxykinase I-GENE
( O
PEPCK I-GENE
) O
gene O
. O

Another O
putative O
HNF3 I-GENE
site I-GENE
in O
close O
apposition O
to O
a O
NF1 I-GENE
/ O
CTF I-GENE
site O
was O
localized O
upstream O
of O
the O
silencer O
- O
like O
element O
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
forkhead I-GENE
transcription I-GENE
factor I-GENE
FKHR I-GENE
- I-GENE
L1 I-GENE
, O
and O
IL I-GENE
- I-GENE
3 I-GENE
inhibited O
FKHR I-GENE
- I-GENE
L1 I-GENE
activity O
in O
a O
PI3K I-GENE
- O
dependent O
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
inhibition O
of O
p27 I-GENE
( O
KIP1 I-GENE
) O
transcription O
through O
PI3K I-GENE
- O
induced O
FKHR I-GENE
- I-GENE
L1 I-GENE
phosphorylation O
provides O
a O
novel O
mechanism O
of O
regulating O
cytokine O
- O
mediated O
survival O
and O
proliferation O
. O

DNase I-GENE
I I-GENE
genomic O
footprinting O
revealed O
that O
the O
c I-GENE
- I-GENE
Myb I-GENE
site I-GENE
is O
occupied O
in O
a O
tissue O
- O
specific O
fashion O
in O
vivo O
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Myb I-GENE
regulates O
the O
RAG I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
in O
T O
cells O
by O
binding O
to O
this O
consensus I-GENE
c I-GENE
- I-GENE
Myb I-GENE
binding I-GENE
site I-GENE
. O

A O
recently O
reported O
new O
member O
of O
the O
Vav I-GENE
family I-GENE
proteins I-GENE
, O
Vav3 I-GENE
has O
been O
identified O
as O
a O
Ros I-GENE
receptor I-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
( O
RPTK I-GENE
) O
interacting O
protein O
by O
yeast O
two O
- O
hybrid O
screening O
. O

Subsequently O
, O
we O
show O
that O
the O
reexpression O
of O
the O
r I-GENE
- I-GENE
PTPeta I-GENE
gene I-GENE
in O
highly O
malignant O
rat O
thyroid O
cells O
transformed O
by O
retroviruses O
carrying O
the O
v I-GENE
- I-GENE
mos I-GENE
and O
v I-GENE
- I-GENE
ras I-GENE
- I-GENE
Ki I-GENE
oncogenes I-GENE
suppresses O
their O
malignant O
phenotype O
. O

Induced O
expression O
of O
Rnd3 I-GENE
is O
associated O
with O
transformation O
of O
polarized O
epithelial O
cells O
by O
the O
Raf I-GENE
- O
MEK I-GENE
- O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

The O
activity O
of O
the O
transcription I-GENE
factor I-GENE
CREB I-GENE
is O
regulated O
by O
extracellular O
stimuli O
that O
result O
in O
its O
phosphorylation O
at O
a O
critical O
serine O
residue O
, O
Ser133 O
. O

RESULTS O
: O
Average O
age O
at O
symptom O
onset O
was O
41 O
. O
2 O
years O
. O

When O
10 O
fields O
were O
analysed O
, O
a O
strong O
relationship O
was O
found O
between O
the O
presence O
of O
bacteria O
on O
Gram O
staining O
and O
the O
final O
diagnosis O
of O
VAP O
( O
for O
PSB O
and O
PTC O
respectively O
: O
sensitivity O
74 O
and O
81 O
%, O
specificity O
94 O
and O
100 O
%, O
positive O
predictive O
value O
91 O
and O
100 O
%, O
negative O
predictive O
value O
82 O
and O
88 O
%). O

Unlike O
the O
mammalian O
proteins O
, O
XFGF3 I-GENE
is O
efficiently O
secreted O
as O
a O
Mr O
31 O
, O
000 O
glycoprotein O
, O
gp31 I-GENE
, O
which O
undergoes O
proteolytic O
cleavage O
to O
produce O
an O
NH2 O
- O
terminally O
truncated O
product O
, O
gp27 I-GENE
. O

NH2 O
- O
terminal O
trimming O
of O
Xenopus O
and O
mammalian I-GENE
FGF3s I-GENE
may O
therefore O
be O
a O
prerequisite O
of O
optimal O
biological O
activity O
. O

Here O
, O
we O
identified O
three O
cis O
- O
elements O
required O
for O
replication O
within O
the O
200 O
bp O
promoter O
, O
using O
autonomously O
replicating O
plasmids O
carrying O
various O
mutations O
and O
deletions O
. O

Tranilast O
in O
the O
Therapy O
of O
Coronary O
Artery O
Disease O
. O

The O
objectives O
of O
the O
present O
study O
were O
to O
evaluate O
the O
effects O
of O
adding O
Equex O
to O
a O
TRIS O
- O
extender O
, O
diluting O
the O
semen O
in O
1 O
or O
2 O
steps O
, O
freezing O
according O
to O
2 O
methods O
, O
thawing O
at O
2 O
rates O
, O
and O
the O
interactions O
between O
these O
treatments O
, O
on O
the O
post O
- O
thaw O
survival O
of O
dog O
spermatozoa O
at O
38 O
degrees O
C O
. O

This O
study O
is O
a O
further O
and O
more O
extensive O
validation O
of O
the O
clinician O
rated O
NIMH O
- O
LCM O
- O
p O
. O

The O
Aie1 I-GENE
locus I-GENE
was O
mapped O
to O
mouse O
chromosome O
7A2 O
- O
A3 O
by O
fluorescent O
in O
situ O
hybridization O
. O

Psychiatric O
disorders O
in O
children O
and O
adolescents O
carry O
considerable O
morbidity O
, O
impede O
development O
, O
and O
carry O
a O
significant O
mortality O
by O
suicide O
. O

Molecular O
cloning O
and O
expression O
of O
human I-GENE
UDP I-GENE
- I-GENE
d I-GENE
- I-GENE
Xylose I-GENE
: I-GENE
proteoglycan I-GENE
core I-GENE
protein I-GENE
beta I-GENE
- I-GENE
d I-GENE
- I-GENE
xylosyltransferase I-GENE
and O
its O
first O
isoform I-GENE
XT I-GENE
- I-GENE
II I-GENE
. O

Thyrotoxicosis O
due O
to O
amiodarone O
is O
difficult O
to O
treat O
and O
is O
further O
complicated O
by O
the O
pro O
- O
arrhythmic O
potential O
of O
thyrotoxicosis O
and O
the O
fading O
antiarrhythmic O
effect O
after O
amiodarone O
withdrawal O
. O

Chaperones O
/ O
HSPs I-GENE
thus O
play O
important O
roles O
within O
cell O
cycle O
processes O
. O

Oncogenic O
signalling O
by O
E2F1 I-GENE
has O
recently O
been O
linked O
to O
stabilization O
and O
activation O
of O
the O
tumour O
suppressor O
p53 I-GENE
( O
refs O
1 O
, O
3 O
, O
4 O
). O

This O
study O
allows O
us O
to O
draw O
conclusions O
about O
the O
identity O
of O
proteins O
required O
for O
the O
development O
of O
the O
nervous O
system O
in O
Drosophila O
and O
provides O
an O
example O
of O
a O
molecular O
approach O
to O
characterize O
en O
masse O
transposon O
- O
tagged O
mutations O
identified O
in O
genetic O
screens O
. O

We O
describe O
the O
identification O
and O
initial O
characterization O
of O
neurobeachin I-GENE
, O
a O
neuron O
- O
specific O
multidomain O
protein O
of O
327 O
kDa O
with O
a O
high O
- O
affinity O
binding O
site O
( O
K O
( O
d O
), O
10 O
nm O
) O
for O
the O
type I-GENE
II I-GENE
regulatory I-GENE
subunit I-GENE
of I-GENE
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
RII I-GENE
). O

Children O
with O
ADD O
showed O
an O
attenuated O
frontal O
CNV O
- O
1 O
amplitude O
and O
a O
trend O
towards O
increased O
CNV O
- O
1 O
and O
CNV O
- O
2 O
occipital O
amplitudes O
. O

Where O
UMDNJ O
is O
headed O
. O

Overexpression O
of O
c I-GENE
- I-GENE
Myc I-GENE
in O
serum O
- O
starved O
human O
or O
mouse O
embryonic O
cells O
leads O
to O
apoptosis O
which O
is O
significantly O
reduced O
in O
the O
presence O
of O
growth O
factor O
- O
containing O
serum O
. O
c I-GENE
- I-GENE
Myc I-GENE
- O
induced O
apoptosis O
appears O
to O
be O
deficient O
in O
bax I-GENE
- O
null O
as O
compared O
with O
bax I-GENE
- O
wild O
- O
type O
mouse O
embryonic O
fibroblasts O
. O

Antimicrobial O
Susceptibility O
of O
Klebsiella O
pneumoniae O
Producing O
Extended I-GENE
- I-GENE
Spectrum I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
( O
ESBL I-GENE
) O
Isolated O
in O
Hospitals O
in O
Brazil O
. O

CONCLUSION O
: O
Our O
results O
suggest O
that O
AIF O
peak O
saturation O
leads O
to O
a O
significant O
systematic O
error O
in O
the O
determination O
of O
CBV O
and O
CBF O
values O
and O
has O
necessarily O
to O
be O
taken O
into O
account O
for O
dynamic O
contrast O
- O
enhanced O
MR O
perfusion O
studies O
. O

METHODS O
: O
T2 O
*- O
weighted O
, O
three O
- O
dimensional O
gradient O
- O
echo O
images O
were O
acquired O
by O
exploiting O
the O
magnetic O
susceptibility O
difference O
between O
oxygenated O
and O
deoxygenated O
hemoglobin I-GENE
in O
the O
vasculature O
and O
microvasculature O
. O

In O
the O
COPD O
patients O
, O
the O
variability O
of O
Delta O
- O
inst O
Rrs O
( O
30 O
%) O
was O
greater O
than O
that O
of O
FOT O
Rrs O
( O
21 O
%). O

Toward O
this O
end O
, O
we O
prepared O
synthetic O
proteins O
with O
either O
the O
catalytic O
domain O
of O
FAP I-GENE
- I-GENE
1 I-GENE
( I-GENE
C I-GENE
- I-GENE
terminal I-GENE
399 I-GENE
amino I-GENE
acids I-GENE
) I-GENE
or O
its O
inactive O
form O
( O
Cys2408 O
--> O
Ser O
) O
fused O
to O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

Thus O
, O
Pet111p I-GENE
could O
play O
dual O
roles O
in O
both O
membrane O
localization O
and O
regulation O
of O
Cox2p I-GENE
synthesis O
within O
mitochondria O
. O

Furthermore O
, O
transfection O
of O
cells O
with O
the O
spacer O
- O
RING O
domain O
alone O
suppressed O
the O
antiapoptotic O
function O
of O
the O
N O
- O
terminal O
BIR I-GENE
domain O
of O
c I-GENE
- I-GENE
IAP1 I-GENE
and O
induced O
apoptosis O
. O

The O
determination O
of O
the O
double O
bounds O
in O
blood O
serum O
lipids O
by O
titration O
with O
ozone O
: O
the O
pathophysiology O
and O
diagnostic O
significance O
] O
In O
this O
article O
the O
method O
of O
definition O
of O
double O
binders O
in O
lipids O
of O
blood O
serum O
in O
patients O
with O
different O
diseases O
basically O
atherosclerosis O
and O
ischemic O
heart O
disease O
, O
with O
use O
titration O
by O
ozone O
is O
given O
. O

Ang I-GENE
II I-GENE
- O
induced O
fibronectin I-GENE
mRNA O
was O
not O
affected O
by O
PKC I-GENE
inhibitors O
or O
PKC I-GENE
depletion O
, O
whereas O
specific O
inhibition O
of O
EGF I-GENE
- I-GENE
R I-GENE
function O
by O
a O
dominant I-GENE
negative I-GENE
EGF I-GENE
- I-GENE
R I-GENE
mutant I-GENE
and O
tyrphostin O
AG1478 O
abolished O
induction O
of O
fibronectin I-GENE
mRNA I-GENE
. O

Acoust O
. O

Video O
images O
of O
the O
nostrils O
were O
captured O
and O
then O
analyzed O
for O
area O
, O
perimeter O
, O
centroid O
, O
principal O
axis O
, O
moments O
about O
the O
major O
and O
minor O
axes O
( O
I11 O
, O
I22 O
), O
anisometry O
, O
bulkiness O
, O
lateral O
offset O
, O
internostril O
angle O
, O
and O
rotational O
angle O
. O

MS O
characteristics O
of O
coumarins O
, O
psoralens O
and O
polymethoxylated O
flavones O
with O
different O
substitution O
patterns O
were O
determined O
on O
the O
basis O
of O
the O
response O
obtained O
with O
the O
APcI O
interface O
. O

Young O
fish O
( O
Oreochromis O
mossambicus O
) O
were O
exposed O
to O
microgravity O
( O
micro O
g O
) O
for O
9 O
to O
10 O
days O
during O
space O
missions O
STS O
- O
55 O
and O
STS O
- O
84 O
, O
or O
to O
hypergravity O
( O
hg O
) O
for O
9 O
days O
. O

S6K2 I-GENE
is O
highly O
homologous O
to O
S6K1 I-GENE
in O
the O
core O
kinase O
and O
linker O
regulatory O
domains O
but O
differs O
from O
S6K1 I-GENE
in O
the O
N O
- O
and O
C O
- O
terminal O
regions O
and O
is O
differently O
localized O
primarily O
to O
the O
nucleus O
because O
of O
a O
C O
- O
terminal O
nuclear O
localization O
signal O
unique O
to O
S6K2 I-GENE
. O

Pretreatment O
of O
cells O
with O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
) O
inhibitor O
U0126 O
inhibited O
S6K2 I-GENE
activation O
to O
a O
greater O
extent O
than O
S6K1 I-GENE
. O

T O
cells O
express O
two O
isoforms O
of O
S6k1 I-GENE
: O
a O
70 O
kDa O
cytoplasmic O
kinase O
and O
an O
85 O
kDa O
isoform O
that O
has O
a O
classic O
nuclear O
localisation O
. O

Ketanserin O
, O
a O
hypotensive O
drug O
with O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
antagonism O
, O
when O
administered O
by O
topical O
infusion O
of O
a O
0 O
. O
25 O
% O
w O
/ O
v O
solution O
by O
corneal O
and O
scleral O
applications O
, O
was O
found O
to O
lower O
intraocular O
pressure O
with O
four O
times O
more O
activity O
than O
its O
metabolite O
, O
ketanserinol O
. O

A O
prospectively O
gated O
2D O
axial O
sequence O
with O
velocity O
encoding O
in O
the O
craniocaudal O
direction O
in O
the O
cervical O
region O
was O
set O
at O
a O
velocity O
of O
+/- O
10 O
cm O
/ O
s O
. O

It O
was O
subsequently O
shown O
that O
Tip60 I-GENE
had O
histone I-GENE
acetyltransferase I-GENE
( O
HAT I-GENE
) O
activity O
. O

Our O
data O
show O
that O
multiple O
MLSN1 I-GENE
transcripts I-GENE
, O
both O
constitutively O
expressed O
and O
inducible O
, O
are O
present O
in O
cultured O
pigmented O
melanoma O
cells O
, O
and O
suggest O
that O
MLSN1 I-GENE
expression O
can O
be O
regulated O
at O
the O
level O
of O
both O
transcription O
and O
mRNA O
processing O
. O

Copyright O
2000 O
Academic O
Press O
. O

Plectin I-GENE
and O
desmoplakin I-GENE
have O
GSR O
- O
containing O
domains O
at O
their O
C O
- O
termini O
and O
we O
further O
demonstrate O
that O
the O
GSR O
- O
containing O
domain O
of O
plectin I-GENE
, O
but O
not O
desmoplakin I-GENE
, O
can O
bind O
to O
MTs O
in O
vivo O
. O

Characterization O
of O
the O
microtubule O
binding O
domain O
of O
microtubule I-GENE
actin I-GENE
crosslinking I-GENE
factor I-GENE
( O
MACF I-GENE
): O
identification O
of O
a O
novel O
group O
of O
microtubule I-GENE
associated I-GENE
proteins I-GENE
. O

These O
results O
also O
suggest O
the O
involvement O
of O
additional O
elements O
in O
the O
UPR O
. O

We O
show O
that O
in O
contrast O
to O
SRC1 I-GENE
, O
direct O
binding O
of O
CBP I-GENE
to O
the O
estrogen I-GENE
receptor I-GENE
is O
weak O
, O
suggesting O
that O
SRC1 I-GENE
functions O
primarily O
as O
an O
adaptor O
to O
recruit O
CBP I-GENE
and O
p300 I-GENE
. O

Remarkably O
, O
a O
construct O
corresponding O
to O
residues O
631 O
to O
970 O
, O
which O
contains O
only O
the O
LXXLL O
motifs O
and O
the O
AD1 O
region O
of O
SRC1 I-GENE
, O
retained O
strong O
coactivator O
activity O
in O
our O
assays O
. O

Since O
MEK I-GENE
acts O
as O
a O
cytoplasmic O
anchor O
for O
the O
ERKs I-GENE
, O
the O
lack O
of O
a O
MEK I-GENE
interaction O
resulted O
in O
the O
aberrant O
nuclear O
localization O
of O
ERK2 I-GENE
- O
Delta19 I-GENE
- I-GENE
25 I-GENE
mutants O
in O
serum O
- O
starved O
cells O
. O

Pmt2 I-GENE
is O
a O
member O
of O
a O
six O
- O
protein O
family O
in O
yeast O
that O
catalyzes O
the O
first O
step O
in O
O O
mannosylation O
of O
target O
proteins O
. O

Fecal O
samples O
were O
collected O
at O
the O
beginning O
and O
end O
of O
each O
trial O
period O
and O
were O
analyzed O
for O
gastrointestinal O
nematode O
eggs O
and O
Giardia O
cyst O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
risk O
factors O
for O
background O
diabetic O
retinopathy O
( O
BDR O
) O
and O
PDR O
by O
following O
394 O
Japanese O
patients O
with O
early O
- O
onset O
type O
2 O
diabetes O
diagnosed O
before O
30 O
years O
of O
age O
( O
mean O
age O
27 O
, O
mean O
blood O
pressure O
at O
entry O
116 O
/ O
73 O
mm O
Hg O
). O

Of O
the O
21 O
quadrants O
positive O
in O
the O
controls O
, O
17 O
were O
correlated O
with O
previously O
detected O
jaw O
pathoses O
. O

Four O
cases O
of O
synovial O
chondromatosis O
are O
presented O
. O

Previous O
studies O
have O
shown O
that O
the O
pro O
- O
inflammatory O
cytokines O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
and O
interferon I-GENE
gamma I-GENE
reduce O
the O
expression O
of O
the O
cystic I-GENE
fibrosis I-GENE
transmembrane I-GENE
conductance I-GENE
regulator I-GENE
( O
CFTR I-GENE
) O
gene O
( O
CFTR I-GENE
) O
in O
HT O
- O
29 O
and O
T84 O
cells O
by O
acting O
post O
- O
transcriptionally O
. O

Regulation O
of O
RhoA I-GENE
is O
required O
to O
maintain O
adhesion O
in O
stationary O
cells O
, O
but O
is O
also O
critical O
for O
cell O
spreading O
and O
migration O
[ O
3 O
]. O

Here O
we O
show O
in O
mouse O
fibroblasts O
stably O
transformed O
by O
v I-GENE
- I-GENE
Src I-GENE
that O
mRNA O
and O
protein O
levels O
of O
p21 I-GENE
( O
WAF1 I-GENE
/ O
CIP1 I-GENE
), O
cyclin I-GENE
D1 I-GENE
, O
and O
cyclin I-GENE
E I-GENE
are O
elevated O
. O

ORFA O
and O
ccdA I-GENE
were O
constitutively O
cotranscribed O
as O
determined O
by O
primer O
extension O
analysis O
. O

Mouse I-GENE
Impact I-GENE
is O
a O
paternally O
expressed O
gene O
encoding O
an O
evolutionarily O
conserved O
protein O
of O
unknown O
function O
. O

These O
cells O
produced O
P2Y I-GENE
( I-GENE
11 I-GENE
) I-GENE
mRNA I-GENE
during O
culture O
. O

Coexpression O
studies O
indicate O
that O
insulin I-GENE
and O
PKB I-GENE
suppress O
transactivation O
by O
C I-GENE
/ I-GENE
EBPbeta I-GENE
, O
but O
not O
C I-GENE
/ I-GENE
EBPalpha I-GENE
, O
and O
that O
N O
- O
terminal O
transactivation O
domains O
in O
C I-GENE
/ I-GENE
EBPbeta I-GENE
are O
required O
. O

Among O
eight O
graminaceous O
species O
tested O
, O
Ids3 I-GENE
expression O
was O
observed O
only O
in O
Fe O
- O
deficient O
roots O
of O
H O
. O
vulgare O
and O
Secale O
cereale O
. O
which O
not O
only O
secrete O
2 O
'- O
deoxymugineic O
acid O
( O
DMA O
), O
but O
also O
mugineic O
acid O
( O
MA O
) O
and O
3 O
- O
epihydroxymugineic O
acid O
( O
epiHMA O
, O
H O
. O
vulgare O
), O
and O
3 O
- O
hydroxymugineic O
acid O
( O
HMA O
, O
S O
. O
cereale O
). O

In O
contrast O
, O
high O
COUP I-GENE
- I-GENE
TFI I-GENE
expression O
impeded O
the O
neuronal O
differentiation O
of O
P19 O
cells O
induced O
with O
RA O
, O
resulting O
in O
cell O
cultures O
lacking O
neurons O
. O

Because O
PET O
is O
also O
useful O
for O
the O
pretreatment O
and O
follow O
- O
up O
evaluation O
, O
the O
use O
of O
stereotactic O
PET O
in O
these O
patients O
can O
enable O
an O
accurate O
comparison O
of O
PET O
- O
based O
metabolic O
data O
with O
MR O
- O
based O
anatomical O
data O
. O

Therefore O
, O
in O
our O
in O
vitro O
model O
, O
the O
localization O
of O
the O
mutation O
in O
the O
K I-GENE
- I-GENE
ras I-GENE
gene I-GENE
predisposes O
to O
a O
different O
level O
of O
aggressiveness O
in O
the O
transforming O
phenotype O
. O

Here O
, O
we O
describe O
the O
isolation O
of O
MdPin1 I-GENE
, O
a O
Pin1 I-GENE
homologue O
from O
the O
plant O
species O
apple O
( O
Malus O
domestica O
) O
and O
show O
that O
it O
has O
the O
same O
phosphorylation O
- O
specific O
substrate O
specificity O
and O
can O
be O
inhibited O
by O
juglone O
in O
vitro O
, O
as O
is O
the O
case O
for O
Pin1 I-GENE
. O

Differential O
association O
of O
products O
of O
alternative O
transcripts O
of O
the O
candidate O
tumor I-GENE
suppressor I-GENE
ING1 I-GENE
with O
the O
mSin3 I-GENE
/ O
HDAC1 I-GENE
transcriptional O
corepressor O
complex O
. O

These O
and O
other O
data O
presented O
suggest O
that O
TAg I-GENE
' O
re O
- O
models O
' O
host O
cell O
transcription O
factors O
that O
are O
used O
early O
in O
viral O
infection O
, O
and O
thereby O
mimics O
an O
event O
that O
naturally O
occurs O
during O
transformation O
. O

This O
sensitivity O
analysis O
showed O
that O
the O
practical O
limits O
of O
the O
accuracy O
of O
the O
used O
screening O
test O
jeopardize O
the O
estimation O
of O
the O
true O
herd O
prevalence O
within O
reasonable O
confidence O
limits O
, O
because O
the O
within O
- O
herd O
PTB O
true O
prevalence O
was O
low O
. O
For O
this O
reason O
we O
augmented O
the O
herd O
specificity O
for O
herds O
with O
larger O
adult O
herd O
size O
(> O
5 O
). O

ORFK10 I-GENE
. I-GENE
5 I-GENE
encodes O
a O
protein O
, O
latency I-GENE
- I-GENE
associated I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
( O
LANA2 I-GENE
), O
which O
is O
expressed O
in O
KSHV O
- O
infected O
hematopoietic O
tissues O
, O
including O
PEL O
and O
CD O
but O
not O
KS O
lesions O
. O

As O
hypothesized O
, O
believers O
showed O
relatively O
higher O
right O
hemispheric O
activation O
and O
reduced O
hemispheric O
asymmetry O
of O
functional O
complexity O
. O

In O
Xenopus O
, O
BMPs I-GENE
act O
as O
epidermal O
inducers O
and O
also O
as O
negative O
regulators O
of O
neurogenesis O
. O

Presently O
four O
unique O
variants O
carrying O
distinct O
GAF I-GENE
sequences I-GENE
in O
the O
N O
- O
terminal O
region O
have O
been O
identified O
. O

Genomic O
organization O
of O
the O
human O
phosphodiesterase I-GENE
PDE11A I-GENE
gene I-GENE
. O

The O
present O
findings O
revealed O
that O
the O
rib I-GENE
- I-GENE
2 I-GENE
protein I-GENE
was O
a O
unique O
alpha1 I-GENE
, I-GENE
4 I-GENE
- I-GENE
N I-GENE
- I-GENE
acetylglucosaminyltransferase I-GENE
involved O
in O
the O
biosynthetic O
initiation O
and O
elongation O
of O
heparan O
sulfate O
. O

Inhibition O
of O
the O
Mek I-GENE
/ O
Erk I-GENE
pathway O
in O
Rat1 O
/ O
ras I-GENE
cells O
, O
using O
the O
Mek I-GENE
inhibitor O
, O
PD98059 O
, O
resulted O
in O
complete O
cytoskeletal O
recovery O
, O
indistinguishable O
from O
that O
induced O
by O
HR12 O
. O

The O
transcription O
factor O
CHOP I-GENE
/ O
GADD153 I-GENE
gene O
is O
induced O
by O
cellular O
stress O
and O
is O
involved O
in O
mediating O
apoptosis O
. O

Addition O
of O
synthetic O
tyrosine O
- O
phosphorylated O
peptides O
derived O
from O
betac O
cytoplasmic O
tyrosines O
prior O
to O
GM I-GENE
- I-GENE
CSF I-GENE
stimulation O
inhibited O
the O
in O
vitro O
activation O
of O
STAT5 I-GENE
. O

MAIN O
OUTCOME O
MEASURES O
: O
Percentage O
change O
in O
the O
apnea O
- O
hypopnea O
index O
( O
AHI O
; O
apnea O
events O
+ O
hypopnea O
events O
per O
hour O
of O
sleep O
) O
and O
odds O
of O
developing O
moderate O
- O
to O
- O
severe O
SDB O
( O
defined O
by O
an O
AHI O
> O
or O
= O
15 O
events O
per O
hour O
of O
sleep O
), O
with O
respect O
to O
change O
in O
weight O
. O

Paraneoplastic O
rheumatic O
syndromes O
. O

This O
article O
reviews O
recent O
information O
on O
the O
frequency O
, O
characteristics O
, O
and O
possible O
pathogenic O
mechanisms O
of O
the O
vasculitides O
occurring O
in O
patients O
with O
the O
main O
connective O
tissue O
diseases O
. O

Tec I-GENE
kinase I-GENE
signaling O
in O
T O
cells O
is O
regulated O
by O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
the O
Tec I-GENE
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

Current O
evidence O
for O
this O
type O
of O
DNA O
supercoiling O
- O
dependent O
transcriptional O
coupling O
, O
based O
largely O
on O
the O
in O
vivo O
activities O
of O
promoters O
contained O
in O
engineered O
DNA O
constructs O
, O
suggests O
that O
the O
transcription O
complex O
must O
be O
physically O
hindered O
to O
generate O
DNA O
supercoils O
and O
to O
prevent O
their O
diffusion O
throughout O
the O
DNA O
duplex O
. O

The O
structure O
of O
the O
free O
SH2 I-GENE
domain I-GENE
has O
been O
compared O
to O
that O
of O
the O
SH2 I-GENE
complexed O
with O
a O
doubly O
phosphorylated O
peptide O
derived O
from O
polyomavirus I-GENE
middle I-GENE
T I-GENE
antigen I-GENE
( O
MT I-GENE
). O

We O
have O
identified O
three O
binding O
sites O
for O
protein O
complexes O
: O
a O
palindrome O
, O
a O
direct O
repeat O
, O
and O
a O
C O
+ O
T O
sequence O
that O
corresponds O
to O
seven O
GAGA O
motifs O
on O
the O
transcribed O
strand O
. O

Copyright O
2000 O
Academic O
Press O
. O

Nucleotide O
sequence O
, O
genome O
organization O
and O
phylogenetic O
analysis O
of O
pineapple O
mealybug O
wilt O
- O
associated O
virus O
- O
2 O
. O

Patients O
underwent O
pretreatment O
cystoscopy O
and O
detailed O
tumor O
mapping O
, O
and O
were O
treated O
with O
75 O
mg O
. O
/ O
m O
. O
2 O
cisplatin O
on O
day O
1 O
and O
1 O
gm O
./ O
m O
. O
2 O
daily O
, O
5 O
- O
fluorouracil O
on O
days O
1 O
to O
4 O
and O
definitive O
radiotherapy O
. O

All O
9 O
untreated O
patients O
underwent O
laparoscopy O
, O
which O
identified O
3 O
intra O
- O
abdominal O
, O
3 O
vanished O
and O
2 O
peeping O
testes O
, O
and O
1 O
atrophic O
testis O
in O
the O
inguinal O
canal O
. O

This O
philosophy O
was O
instituted O
for O
the O
compound O
RP O
73401 O
, O
a O
specific O
phosphodiesterase I-GENE
IV I-GENE
inhibitor O
, O
that O
was O
being O
developed O
simultaneously O
for O
delivery O
by O
both O
oral O
and O
pulmonary O
routes O
of O
administration O
. O

Increased O
levels O
of O
anticardiolipin I-GENE
immunoglobulin I-GENE
G I-GENE
may O
also O
cause O
bleeding O
. O

RESULTS O
: O
Prevalence O
of O
obesity O
( O
BMI O
SDS O
> O
2 O
. O
0 O
) O
was O
< O
2 O
% O
at O
diagnosis O
, O
but O
increased O
to O
16 O
% O
at O
3y O
. O

One O
of O
the O
sequelae O
of O
the O
antiphospholipid O
- O
antibodies O
is O
an O
impaired O
uteroplacental O
circulation O
. O

Bupropion O
to O
aid O
smoking O
cessation O
. O

Using O
a O
natural O
dominant O
negative O
for O
AP I-GENE
- I-GENE
1 I-GENE
transcriptional O
activity O
in O
ROS O
17 O
/ O
2 O
. O
8 O
cells O
, O
we O
then O
showed O
that O
AP I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
mediated O
TGF I-GENE
- I-GENE
beta1 I-GENE
- O
and O
BMP I-GENE
- I-GENE
2 I-GENE
- O
regulated O
expression O
of O
the O
( I-GENE
alpha1 I-GENE
) I-GENE
collagen I-GENE
I I-GENE
gene I-GENE
as O
well O
as O
TGF I-GENE
- I-GENE
beta1 I-GENE
- O
regulated O
expression O
of O
the O
parathyroid I-GENE
hormone I-GENE
( O
PTH I-GENE
)/ O
PTH I-GENE
- I-GENE
related I-GENE
peptide I-GENE
( I-GENE
PTHrP I-GENE
) I-GENE
receptor I-GENE
. O

PM O
12 O
or O
18 O
mg O
/ O
kg O
daily O
plus O
a O
standard O
dose O
of O
SB O
for O
21 O
days O
was O
statistically O
more O
effective O
than O
SB O
in O
producing O
a O
final O
cure O
for O
patients O
with O
VL O
in O
Bihar O
, O
India O
. O

Adjuvant O
therapy O
for O
colon O
cancer O
] O
Surgery O
alone O
may O
fail O
to O
cure O
a O
considerable O
number O
of O
locally O
advanced O
colon O
cancers O
. O

There O
were O
significant O
differences O
( O
p O
< O
0 O
. O
05 O
) O
between O
the O
fracture O
and O
nonfracture O
groups O
in O
the O
total O
femur O
BMD O
( O
13 O
%), O
trabecular O
BMD O
in O
the O
distal O
radius O
( O
4 O
%), O
and O
the O
fractal O
dimension O
in O
the O
radiographs O
( O
FD2 O
) O
( O
3 O
%). O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
and O
compare O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
levels O
in O
gingival O
crevicular O
fluid O
( O
GCF O
) O
and O
clinical O
periodontal O
findings O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
and O
adult O
periodontitis O
( O
AP O
). O

In O
a O
prospective O
, O
multicentre O
trial O
the O
efficacy O
of O
an O
Vitex O
agnus O
castus O
L O
extract O
Ze O
440 O
was O
investigated O
in O
50 O
patients O
with O
pre O
- O
menstrual O
syndrome O
( O
PMS O
). O

Studies O
are O
necessary O
to O
assess O
the O
source O
of O
contamination O
and O
potential O
role O
of O
MRSA O
- O
contaminated O
milk O
in O
the O
transmission O
of O
MRSA O
to O
neonates O
. O

Effects O
of O
Trypanosoma O
vivax O
on O
pregnancy O
of O
Yankasa O
sheep O
and O
the O
results O
of O
homidum O
chloride O
chemotherapy O
. O

NF I-GENE
kappa I-GENE
B I-GENE
was O
activated O
to O
a O
much O
greater O
extent O
by O
roscovitine O
in O
the O
WT O
cells O
than O
in O
Y8 O
cells O
. O

Depending O
on O
treatment O
exposures O
, O
this O
at O
- O
risk O
population O
may O
experience O
life O
- O
threatening O
late O
effects O
, O
such O
as O
cirrhosis O
secondary O
to O
hepatitis O
C O
or O
late O
- O
onset O
anthracycline O
- O
induced O
cardiomyopathy O
, O
or O
life O
- O
changing O
late O
effects O
, O
such O
as O
cognitive O
dysfunction O
. O

The O
presence O
of O
locus O
- O
specific O
residues O
throughout O
the O
entire O
promoter O
region O
strongly O
suggests O
that O
the O
various O
HLA I-GENE
class I-GENE
I I-GENE
loci I-GENE
are O
differentially O
regulated O
. O

Because O
the O
number O
of O
parameters O
required O
by O
a O
Volterra O
series O
grows O
rapidly O
with O
both O
the O
length O
of O
its O
memory O
and O
the O
order O
of O
its O
nonlinearity O
, O
methods O
for O
identifying O
these O
models O
from O
measurements O
of O
input O
/ O
output O
data O
are O
limited O
to O
low O
- O
order O
systems O
with O
relatively O
short O
memories O
. O

The O
standard O
method O
for O
calculating O
the O
composite O
score O
on O
the O
S O
- O
B O
IV O
excludes O
subtests O
with O
a O
raw O
score O
of O
0 O
, O
which O
overestimates O
cognitive O
functioning O
in O
young O
biologically O
high O
risk O
children O
. O

NiCl O
( O
2 O
)- O
induced O
MCP I-GENE
- I-GENE
1 I-GENE
synthesis O
required O
activation O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
since O
mutation O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
sites I-GENE
in O
the O
promoter O
resulted O
in O
complete O
loss O
of O
inducible O
promoter O
activity O
. O

Engagement O
of O
human I-GENE
CD2 I-GENE
by O
mitogenic O
pairs O
of O
anti I-GENE
- I-GENE
CD2 I-GENE
mAb I-GENE
induces O
tyrosine O
phosphorylation O
of O
a O
number O
of O
intracellular O
proteins O
including O
a O
120 O
kDa O
phosphoprotein O
that O
we O
identify O
as O
the O
proto I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
Cbl I-GENE
. O

Validity O
of O
NIR O
spectroscopy O
for O
quantitatively O
measuring O
muscle O
oxidative O
metabolic O
rate O
in O
exercise O
. O

Previous O
studies O
have O
demonstrated O
that O
tissue O
- O
restricted O
transcription O
factors O
including O
PU I-GENE
. I-GENE
1 I-GENE
and O
PU I-GENE
. I-GENE
1 I-GENE
interaction I-GENE
partner I-GENE
( O
PIP I-GENE
) O
function O
synergistically O
with O
c I-GENE
- I-GENE
Fos I-GENE
plus O
c I-GENE
- I-GENE
Jun I-GENE
to O
stimulate O
the O
kappaE3 I-GENE
'- I-GENE
enhancer I-GENE
in O
3T3 O
cells O
. O

The O
murine I-GENE
int I-GENE
- I-GENE
6 I-GENE
locus I-GENE
, O
identified O
as O
a O
frequent O
integration O
site O
of O
mouse O
mammary O
tumor O
viruses O
, O
encodes O
the O
48 I-GENE
- I-GENE
kDa I-GENE
eIF3e I-GENE
subunit I-GENE
of I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
eIF3 I-GENE
. O

An O
int6 I-GENE
deletion I-GENE
( O
int6Delta I-GENE
) O
mutant O
was O
viable O
but O
grew O
slowly O
in O
minimal O
medium O
. O

Additionally O
, O
MIP I-GENE
- I-GENE
2A I-GENE
antagonizes O
cell O
growth O
regulatory O
role O
of O
MBP I-GENE
- I-GENE
1 I-GENE
. O

We O
produced O
transgenic O
plants O
expressing O
the O
antisense I-GENE
Arabidopsis I-GENE
HD I-GENE
( O
AtHD1 I-GENE
) O
gene O
. O

3 O
. O
04 O
+/- O
1 O
. O
2 O
, O
P O
< O
0 O
. O
0001 O
), O
large O
accelerations O
/ O
30 O
min O
( O
1 O
. O
46 O
+/- O
1 O
. O
96 O
vs O
. O

Four O
transcription O
initiation O
sites O
have O
been O
identified O
by O
full O
- O
length O
RNA I-GENE
ligase I-GENE
- O
mediated O
rapid O
amplification O
of O
cDNA O
ends O
( O
RLM O
- O
RACE O
) O
between O
- O
61 O
and O
- O
32 O
bp O
from O
the O
translation O
initiation O
codon O
. O
Reverse O
transcription O
- O
PCR O
analysis O
revealed O
that O
PFK I-GENE
- I-GENE
A I-GENE
, O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
were O
expressed O
, O
in O
all O
mouse O
tissues O
tested O
, O
at O
varying O
levels O
. O

PFK I-GENE
- I-GENE
A I-GENE
mRNA O
was O
more O
abundantly O
expressed O
in O
all O
tissues O
than O
were O
the O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
. O

We O
used O
the O
Toshiba O
IIDR O
system O
, O
which O
is O
composed O
of O
an O
X O
- O
ray O
TV O
system O
and O
a O
digital O
image O
managing O
circuit O
. O

In O
whole O
sardine O
, O
domoic O
acid O
was O
detected O
in O
levels O
exceeding O
sometimes O
the O
regulatory O
limit O
. O

In O
addition O
, O
we O
identified O
two O
mutations O
, O
Delta O
M1281 O
and O
IVS51 O
+ O
5G O
--> O
A O
, O
in O
a O
German O
USH1 I-GENE
patient O
. O

Closeup O
: O
a O
resource O
for O
nurses O
who O
smoke O
. O

[ O
18F O
](+)- O
4 O
- O
fluorobenzyltrozamicol O
( O
FBT O
), O
which O
selectively O
binds O
to O
the O
vesicular O
acetylcholine I-GENE
transporter I-GENE
in O
the O
presynaptic O
cholinergic O
neuron O
, O
has O
previously O
been O
shown O
to O
be O
a O
useful O
ligand O
for O
the O
study O
of O
cholinergic O
terminal O
density O
in O
the O
basal O
ganglia O
with O
PET O
. O

We O
demonstrate O
that O
the O
protein O
is O
a O
murine I-GENE
homologue I-GENE
of I-GENE
SAF I-GENE
- I-GENE
A I-GENE
which O
has O
been O
shown O
to O
bind O
selectively O
to O
MARs O
and O
is O
responsible O
for O
the O
satMa I-GENE
- O
binding O
activity O
in O
the O
chromatographic O
fractions O
. O

The O
molecular O
associations O
dictating O
INCENP I-GENE
behavior O
during O
mitosis O
are O
currently O
unknown O
. O

Ang I-GENE
II I-GENE
significantly O
induced O
Ang2 I-GENE
mRNA I-GENE
accumulations O
without O
affecting O
Ang1 I-GENE
or O
Tie2 I-GENE
expression O
, O
which O
was O
inhibited O
by O
protein I-GENE
kinase I-GENE
C I-GENE
inhibitors O
and O
by O
intracellular O
Ca O
( O
2 O
+) O
chelating O
agents O
. O

Promoter O
analysis O
demonstrated O
that O
the O
sequence O
identical O
to O
consensus O
cAMP O
- O
responsive O
element O
( O
CRE O
) O
located O
at O
- O
481 O
of O
the O
SMemb I-GENE
promoter I-GENE
was O
critical O
for O
Hex I-GENE
responsiveness O
. O

LH I-GENE
/ I-GENE
CG I-GENE
receptor I-GENE
activation O
of O
ARNO I-GENE
is O
not O
mediated O
by O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
or O
by O
G I-GENE
protein I-GENE
beta I-GENE
gamma I-GENE
subunits I-GENE
. O

Deletion O
analysis O
showed O
that O
the O
- O
321 O
/+ O
41 O
sequence O
was O
sufficient O
for O
both O
the O
constitutive O
promoter O
activity O
and O
auto O
- O
activation O
and O
electrophoretic O
mobility O
shift O
assays O
identified O
the O
interaction O
of O
C I-GENE
/ I-GENE
EBPs I-GENE
and O
Sp1 I-GENE
to O
this O
region O
. O

Termination O
of O
induced O
VT O
on O
the O
first O
attempt O
was O
comparable O
with O
BV O
pacing O
( O
87 O
. O
4 O
%) O
versus O
RV O
pacing O
( O
89 O
. O
6 O
%). O

We O
compare O
the O
results O
of O
this O
algorithm O
with O
the O
results O
obtained O
with O
two O
other O
algorithms O
, O
the O
optimal O
algorithm O
for O
monochannel O
nonoverlapping O
noise O
and O
the O
optimal O
algorithm O
for O
multichannel O
additive O
noise O
, O
and O
we O
show O
that O
in O
both O
cases O
improvement O
can O
be O
obtained O
. O

Changes O
in O
stimulation O
levels O
over O
time O
in O
nucleus O
22 O
cochlear O
implant O
users O
. O

Nuclease O
probing O
and O
structure O
- O
directed O
mutagenesis O
revealed O
that O
the O
105 O
- O
nt O
TE O
( O
TE105 O
) O
forms O
a O
cruciform O
secondary O
structure O
containing O
four O
helices O
connected O
by O
single O
- O
stranded O
regions O
. O

Tele O
- O
Talk O
has O
the O
extra O
capability O
of O
operating O
in O
live O
conference O
situations O
using O
microphone O
input O
. O

A O
marked O
decrease O
in O
the O
type I-GENE
1 I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( I-GENE
IGF I-GENE
) I-GENE
receptor I-GENE
( O
IGF I-GENE
- I-GENE
IR I-GENE
) O
occurs O
in O
prostate O
epithelial O
cells O
during O
transformation O
from O
the O
benign O
to O
the O
metastatic O
state O
. O

The O
P69 O
cell O
line O
was O
derived O
by O
immortalization O
of O
human O
primary O
prostate O
epithelial O
cells O
with O
simian I-GENE
virus I-GENE
- I-GENE
40 I-GENE
T I-GENE
antigen I-GENE
and O
is O
rarely O
tumorigenic O
. O

We O
determined O
whether O
the O
human I-GENE
StAR I-GENE
promoter I-GENE
is O
responsive O
to O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
SREBPs I-GENE
). O

Expression O
of O
SREBP I-GENE
- I-GENE
1a I-GENE
stimulated O
StAR I-GENE
promoter I-GENE
activity O
in O
the O
context O
of O
COS O
- O
1 O
cells O
and O
human O
granulosa O
- O
lutein O
cells O
. O

Because O
the O
high I-GENE
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
( O
HDL I-GENE
- I-GENE
R I-GENE
) O
is O
a O
key O
element O
in O
cholesterol O
homeostasis O
and O
a O
potential O
therapeutic O
target O
for O
hypercholesterolemic O
drugs O
, O
an O
understanding O
of O
HDL I-GENE
- I-GENE
R I-GENE
regulation O
is O
essential O
. O

IFN I-GENE
- I-GENE
stimulated I-GENE
gene I-GENE
factor I-GENE
- I-GENE
3 I-GENE
and O
STAT1 I-GENE
homodimers I-GENE
formed O
and O
bound O
an O
IFN I-GENE
- I-GENE
stimulated I-GENE
response I-GENE
element I-GENE
( O
ISRE I-GENE
) O
and O
gamma I-GENE
- I-GENE
activated I-GENE
sequence I-GENE
( O
GAS I-GENE
) O
element O
, O
respectively O
. O

We O
have O
therefore O
studied O
the O
molecular O
mechanisms O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
action O
on O
thyroglobulin I-GENE
( O
TG I-GENE
) O
gene O
expression O
by O
focusing O
our O
attention O
on O
TGF I-GENE
- I-GENE
beta1 I-GENE
regulation O
of O
thyroid O
- O
specific O
transcription O
factors O
. O

The O
epitope O
- O
protected O
lysine O
( O
K O
) O
was O
present O
in O
a O
30 I-GENE
- I-GENE
aa I-GENE
TPO I-GENE
fragment I-GENE
that O
, O
by O
N O
- O
terminal O
sequencing O
, O
was O
found O
to O
be O
K713 O
. O

To O
understand O
the O
molecular O
regulation O
of O
these O
genes O
in O
thyroid O
cells O
, O
the O
effect O
of O
thyroid I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
) O
and O
the O
paired I-GENE
domain I-GENE
- I-GENE
containing I-GENE
protein I-GENE
8 I-GENE
( O
Pax I-GENE
- I-GENE
8 I-GENE
) O
on O
the O
transcriptional O
activity O
of O
the O
deiodinase I-GENE
promoters I-GENE
were O
studied O
. O
